<SEC-DOCUMENT>0001178913-23-001272.txt : 20230331
<SEC-HEADER>0001178913-23-001272.hdr.sgml : 20230331
<ACCEPTANCE-DATETIME>20230331160218
ACCESSION NUMBER:		0001178913-23-001272
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		80
CONFORMED PERIOD OF REPORT:	20221231
FILED AS OF DATE:		20230331
DATE AS OF CHANGE:		20230331

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Entera Bio Ltd.
		CENTRAL INDEX KEY:			0001638097
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			L3
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38556
		FILM NUMBER:		23787421

	BUSINESS ADDRESS:	
		STREET 1:		KIRYAT HADASSAH, MINRAV BUILDING
		STREET 2:		FIFTH FLOOR
		CITY:			JERUSALEM
		STATE:			L3
		ZIP:			9112002
		BUSINESS PHONE:		972-2-532-7151

	MAIL ADDRESS:	
		STREET 1:		KIRYAT HADASSAH, MINRAV BUILDING
		STREET 2:		FIFTH FLOOR
		CITY:			JERUSALEM
		STATE:			L3
		ZIP:			9112002
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>zk2329447.htm
<DESCRIPTION>10-K
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>
<!--INTEGIX by Ez-XBRL-->
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2022-02-16" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:us-types="http://fasb.org/us-types/2021-01-31" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:country="http://xbrl.sec.gov/country/2022" xmlns:currency="http://xbrl.sec.gov/currency/2022" xmlns:exch="http://xbrl.sec.gov/exch/2022" xmlns:naics="http://xbrl.sec.gov/naics/2022" xmlns:sic="http://xbrl.sec.gov/sic/2022" xmlns:stpr="http://xbrl.sec.gov/stpr/2022" xmlns:srt="http://fasb.org/srt/2022" xmlns:srt-types="http://fasb.org/srt-types/2022" xmlns:us-gaap="http://fasb.org/us-gaap/2022" xmlns:entx="http://www.enterabio.com/20221231"  >
<head>
  <meta http-equiv="Content-Type" content="text/html; charset=UTF-8"/>
  <title>Entera Bio Ltd. - 1638097 - 2023</title>
</head>
<body><div style="font-size: 10pt;"><div style="font-size: 10pt;">

<div style="display:none">
<ix:header>
  <ix:hidden>
    <ix:nonNumeric name="dei:EntityCentralIndexKey" contextRef="C_20220101to20221231" id="Fdei_EntityCentralIndexKey20220219150840900" >0001638097</ix:nonNumeric>
    <ix:nonNumeric name="dei:AmendmentFlag" contextRef="C_20220101to20221231" id="Fdei_AmendmentFlag20220219150858854" >false</ix:nonNumeric>
    <ix:nonNumeric name="dei:DocumentFiscalPeriodFocus" contextRef="C_20220101to20221231" id="Fdei_DocumentFiscalPeriodFocus20220219151109286" >FY</ix:nonNumeric>
    <ix:nonFraction name="us-gaap:CommonStockValue" contextRef="C_20221231" id="Fxbrl_20220808213249447" unitRef="USD" xsi:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:CommonStockValue" contextRef="C_20211231" id="Fxbrl_20220808214617486" unitRef="USD" xsi:nil="true"></ix:nonFraction>
    <ix:nonNumeric name="dei:EntityTaxIdentificationNumber" contextRef="C_20220101to20221231" id="Fxbrl_20220429111918108" >00-0000000</ix:nonNumeric>
    <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition" contextRef="C_20210101to20211231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" id="Fxbrl_20220808213010825_xbrl_20220802040425347_20220801223211777_38" unitRef="USD" xsi:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="C_20201231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" id="Fxbrl_20220808214821452" unitRef="USD" xsi:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" contextRef="C_20210101to20211231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" id="Fxbrl_20220808214839417" unitRef="USD" xsi:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="C_20210101to20211231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" id="Fxbrl_20220808214942722" unitRef="USD" xsi:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="C_20211231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" id="Fxbrl_20220808220722541" unitRef="USD" xsi:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="C_20220101to20221231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" id="Fxbrl_20220808220938448" unitRef="USD" xsi:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="C_20221231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" id="Fxbrl_20220808221051935" unitRef="USD" xsi:nil="true"></ix:nonFraction>
    <ix:nonFraction name="entx:ExerciseOfWarrantsValue" contextRef="C_20210101to20211231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" id="Fxbrl_20230227104430880" unitRef="USD" xsi:nil="true"></ix:nonFraction>
    <ix:nonNumeric name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" contextRef="C_20220601to20220615_srtTitleOfIndividualAxis_entxFormerChiefExecutiveOfficerMember" id="Fxbrl_20230228114443567" >P2Y</ix:nonNumeric>
    </ix:hidden>
  <ix:references> <link:schemaRef xlink:type="simple" xlink:href="entx-20221231.xsd"/>
    </ix:references>
  <ix:resources>
    <xbrli:context id="C_20220101to20221231">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001638097</xbrli:identifier>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20211231">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001638097</xbrli:identifier>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20221231">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001638097</xbrli:identifier>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20210101to20211231">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001638097</xbrli:identifier>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20201231">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001638097</xbrli:identifier>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20220101to20221231_srtRangeAxis_srtMinimumMember_usgaapPropertyPlantAndEquipmentByTypeAxis_usgaapComputerEquipmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001638097</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20220101to20221231_srtRangeAxis_srtMaximumMember_usgaapPropertyPlantAndEquipmentByTypeAxis_usgaapComputerEquipmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001638097</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20220101to20221231_srtRangeAxis_srtMinimumMember_usgaapPropertyPlantAndEquipmentByTypeAxis_entxLaboratoryEquipmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001638097</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">entx:LaboratoryEquipmentMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20220101to20221231_srtRangeAxis_srtMaximumMember_usgaapPropertyPlantAndEquipmentByTypeAxis_entxLaboratoryEquipmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001638097</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">entx:LaboratoryEquipmentMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20220101to20221231_usgaapPropertyPlantAndEquipmentByTypeAxis_usgaapOfficeEquipmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001638097</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20190101to20190131_usgaapRelatedPartyTransactionsByRelatedPartyAxis_entxAmgenIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001638097</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">entx:AmgenIncMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-01-31</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20191231_usgaapRelatedPartyTransactionsByRelatedPartyAxis_entxAmgenIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001638097</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">entx:AmgenIncMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2019-12-31</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20230101to20230102_srtTitleOfIndividualAxis_entxNonExecutiveBoardMember_usgaapSubsequentEventTypeAxis_usgaapSubsequentEventMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001638097</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">entx:NonExecutiveBoardMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-01-02</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20220101to20221231_entxLeaseArrangementAxis_entxOperatingLeaseAgreementsForVehiclesForEmployeesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001638097</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="entx:LeaseArrangementAxis">entx:OperatingLeaseAgreementsForVehiclesForEmployeesMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20221231_entxLeaseArrangementAxis_entxOperatingLeaseAgreementsForOfficeAndResearchAndDevelopmentSpaceMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001638097</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="entx:LeaseArrangementAxis">entx:OperatingLeaseAgreementsForOfficeAndResearchAndDevelopmentSpaceMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20220101to20221231_entxLeaseArrangementAxis_entxOperatingLeaseAgreementsForOfficeAndResearchAndDevelopmentSpaceMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001638097</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="entx:LeaseArrangementAxis">entx:OperatingLeaseAgreementsForOfficeAndResearchAndDevelopmentSpaceMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20220101to20221231_usgaapAccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis_usgaapGovernmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001638097</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis">us-gaap:GovernmentMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20220101to20221231_entxAgreementAxis_entxJointVentureAgreementMember_usgaapRelatedPartyTransactionsByRelatedPartyAxis_entxDnaBiomedicalSolutionsLtdAndOramedLtdMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001638097</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="entx:AgreementAxis">entx:JointVentureAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">entx:DnaBiomedicalSolutionsLtdAndOramedLtdMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20220101to20221231_entxAgreementAxis_entxPatentTransferAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001638097</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="entx:AgreementAxis">entx:PatentTransferAgreementMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20221231_usgaapAccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis_usgaapGovernmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001638097</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis">us-gaap:GovernmentMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20220101to20221231_entxAgreementAxis_entxJointVentureAgreementMember_usgaapRelatedPartyTransactionsByRelatedPartyAxis_entxDnaBiomedicalSolutionsLtdMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001638097</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="entx:AgreementAxis">entx:JointVentureAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">entx:DnaBiomedicalSolutionsLtdMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20220101to20221231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001638097</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20180731_usgaapClassOfWarrantOrRightAxis_usgaapWarrantMember_usgaapSubsidiarySaleOfStockAxis_usgaapIPOMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001638097</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2018-07-31</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20180701to20180731_usgaapClassOfWarrantOrRightAxis_usgaapWarrantMember_usgaapSubsidiarySaleOfStockAxis_usgaapIPOMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001638097</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-07-01</xbrli:startDate>
        <xbrli:endDate>2018-07-31</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20210331_usgaapClassOfWarrantOrRightAxis_usgaapWarrantMember_usgaapSubsidiarySaleOfStockAxis_usgaapIPOMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001638097</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2021-03-31</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20210301to20210331_usgaapClassOfWarrantOrRightAxis_usgaapWarrantMember_usgaapSubsidiarySaleOfStockAxis_usgaapIPOMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001638097</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-03-01</xbrli:startDate>
        <xbrli:endDate>2021-03-31</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20191231_usgaapRelatedPartyTransactionsByRelatedPartyAxis_entxAccreditedInvestorsIncludingCertainBoardMembersAndTheirAffiliatesMember_usgaapSubsidiarySaleOfStockAxis_usgaapPrivatePlacementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001638097</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">entx:AccreditedInvestorsIncludingCertainBoardMembersAndTheirAffiliatesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2019-12-31</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20200229_usgaapRelatedPartyTransactionsByRelatedPartyAxis_entxAccreditedInvestorsIncludingCertainBoardMembersAndTheirAffiliatesMember_usgaapSubsidiarySaleOfStockAxis_usgaapPrivatePlacementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001638097</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">entx:AccreditedInvestorsIncludingCertainBoardMembersAndTheirAffiliatesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2020-02-29</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20190101to20191231_usgaapRelatedPartyTransactionsByRelatedPartyAxis_entxAccreditedInvestorsIncludingCertainBoardMembersAndTheirAffiliatesMember_usgaapSubsidiarySaleOfStockAxis_usgaapPrivatePlacementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001638097</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">entx:AccreditedInvestorsIncludingCertainBoardMembersAndTheirAffiliatesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-12-31</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20200201to20200229_usgaapRelatedPartyTransactionsByRelatedPartyAxis_entxAccreditedInvestorsIncludingCertainBoardMembersAndTheirAffiliatesMember_usgaapSubsidiarySaleOfStockAxis_usgaapPrivatePlacementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001638097</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">entx:AccreditedInvestorsIncludingCertainBoardMembersAndTheirAffiliatesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-02-01</xbrli:startDate>
        <xbrli:endDate>2020-02-29</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20191231_usgaapClassOfWarrantOrRightAxis_entxBrokerWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001638097</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">entx:BrokerWarrantsMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2019-12-31</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20200229_usgaapClassOfWarrantOrRightAxis_entxBrokerWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001638097</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">entx:BrokerWarrantsMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2020-02-29</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20210623_usgaapClassOfWarrantOrRightAxis_usgaapWarrantMember_usgaapRelatedPartyTransactionsByRelatedPartyAxis_entxChairmanOfBoardAndDnaMember_usgaapSubsidiarySaleOfStockAxis_usgaapPrivatePlacementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001638097</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">entx:ChairmanOfBoardAndDnaMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2021-06-23</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20210623_usgaapRelatedPartyTransactionsByRelatedPartyAxis_entxChairmanOfBoardAndDnaMember_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember_usgaapSubsidiarySaleOfStockAxis_usgaapPrivatePlacementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001638097</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">entx:ChairmanOfBoardAndDnaMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2021-06-23</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20210601to20210623_usgaapClassOfWarrantOrRightAxis_usgaapWarrantMember_usgaapRelatedPartyTransactionsByRelatedPartyAxis_entxChairmanOfBoardAndDnaMember_usgaapSubsidiarySaleOfStockAxis_usgaapPrivatePlacementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001638097</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">entx:ChairmanOfBoardAndDnaMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-06-01</xbrli:startDate>
        <xbrli:endDate>2021-06-23</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20200704_entxEquityProgramAxis_entxAtmEquityProgram2020Member_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001638097</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="entx:EquityProgramAxis">entx:AtmEquityProgram2020Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2020-07-04</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20201231_entxEquityProgramAxis_entxAtmEquityProgram2020Member_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001638097</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="entx:EquityProgramAxis">entx:AtmEquityProgram2020Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20211231_entxEquityProgramAxis_entxAtmEquityProgram2020Member_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001638097</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="entx:EquityProgramAxis">entx:AtmEquityProgram2020Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20210101to20211231_entxEquityProgramAxis_entxAtmEquityProgram2020Member_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001638097</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="entx:EquityProgramAxis">entx:AtmEquityProgram2020Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20210731_entxEquityProgramAxis_entxAtmEquityProgram2021Member_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001638097</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="entx:EquityProgramAxis">entx:AtmEquityProgram2021Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2021-07-31</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20210601to20210731_entxEquityProgramAxis_entxAtmEquityProgram2021Member_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001638097</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="entx:EquityProgramAxis">entx:AtmEquityProgram2021Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-06-01</xbrli:startDate>
        <xbrli:endDate>2021-07-31</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20210101to20211231_usgaapRelatedPartyTransactionsByRelatedPartyAxis_entxSeveralEmployeesAndServiceProvidersMember_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001638097</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">entx:SeveralEmployeesAndServiceProvidersMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20221231_usgaapClassOfWarrantOrRightAxis_usgaapWarrantMember_usgaapSubsidiarySaleOfStockAxis_usgaapIPOMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001638097</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20201231_entxEquityProgramAxis_entxAtmEquityProgram2020Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001638097</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="entx:EquityProgramAxis">entx:AtmEquityProgram2020Member</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20210507_entxEquityProgramAxis_entxAtmEquityProgram2021Member_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001638097</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="entx:EquityProgramAxis">entx:AtmEquityProgram2021Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2021-05-07</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20191231_usgaapClassOfWarrantOrRightAxis_entxBrokerDealerMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001638097</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">entx:BrokerDealerMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2019-12-31</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20200229_usgaapClassOfWarrantOrRightAxis_entxBrokerDealerMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001638097</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">entx:BrokerDealerMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2020-02-29</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20191231_usgaapClassOfWarrantOrRightAxis_entxBrokerDealerOneMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001638097</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">entx:BrokerDealerOneMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2019-12-31</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20200229_usgaapClassOfWarrantOrRightAxis_entxBrokerDealerOneMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001638097</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">entx:BrokerDealerOneMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2020-02-29</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20191231_usgaapClassOfWarrantOrRightAxis_entxBrokerWarrantsType1Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001638097</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">entx:BrokerWarrantsType1Member</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2019-12-31</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20200229_usgaapClassOfWarrantOrRightAxis_entxBrokerWarrantsType1Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001638097</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">entx:BrokerWarrantsType1Member</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2020-02-29</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20220101to20221231_usgaapRelatedPartyTransactionsByRelatedPartyAxis_entxSeveralEmployeesAndServiceProvidersMember_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001638097</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">entx:SeveralEmployeesAndServiceProvidersMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20200101to20201231_entxEquityProgramAxis_entxAtmEquityProgram2020Member_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001638097</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="entx:EquityProgramAxis">entx:AtmEquityProgram2020Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20230327">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001638097</xbrli:identifier>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2023-03-27</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20220630">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001638097</xbrli:identifier>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2022-06-30</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20220101to20221231_deiLegalEntityAxis_entxEnteraBioLtdMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001638097</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">entx:EnteraBioLtdMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20210101to20211231_deiLegalEntityAxis_entxEnteraBioLtdMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001638097</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">entx:EnteraBioLtdMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20210101to20211231_srtConsolidatedEntitiesAxis_srtSubsidiariesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001638097</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:SubsidiariesMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20220101to20221231_srtConsolidatedEntitiesAxis_srtSubsidiariesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001638097</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:SubsidiariesMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20220101to20221231_usgaapIncomeTaxAuthorityAxis_usgaapDomesticCountryMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001638097</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20220101to20221231_usgaapIncomeTaxAuthorityAxis_usgaapForeignCountryMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001638097</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20210101to20211231_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001638097</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20210101to20211231_usgaapStatementEquityComponentsAxis_usgaapAccumulatedOtherComprehensiveIncomeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001638097</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20210101to20211231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001638097</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20210101to20211231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001638097</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20211231_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001638097</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20211231_usgaapStatementEquityComponentsAxis_usgaapAccumulatedOtherComprehensiveIncomeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001638097</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20211231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001638097</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20211231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001638097</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20220101to20221231_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001638097</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20220101to20221231_usgaapStatementEquityComponentsAxis_usgaapAccumulatedOtherComprehensiveIncomeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001638097</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20220101to20221231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001638097</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20221231_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001638097</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20221231_usgaapStatementEquityComponentsAxis_usgaapAccumulatedOtherComprehensiveIncomeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001638097</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20221231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001638097</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20221231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001638097</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20201231_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001638097</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20201231_usgaapStatementEquityComponentsAxis_usgaapAccumulatedOtherComprehensiveIncomeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001638097</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20201231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001638097</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20201231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001638097</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20220101to20221231_srtRangeAxis_srtMinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001638097</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20221231_srtRangeAxis_srtMaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001638097</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20211231_srtRangeAxis_srtMaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001638097</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20220101to20221231_srtRangeAxis_srtMaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001638097</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20210101to20211231_srtRangeAxis_srtMaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001638097</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20210101to20211231_srtRangeAxis_srtMinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001638097</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20220101to20221231_usgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_entxExercisePricePerShareZeroMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001638097</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">entx:ExercisePricePerShareZeroMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20221231_usgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_entxExercisePricePerShareZeroMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001638097</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">entx:ExercisePricePerShareZeroMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20221231_usgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_entxExercisePricePerShareOnePointTwoFourMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001638097</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">entx:ExercisePricePerShareOnePointTwoFourMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20220101to20221231_usgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_entxExercisePricePerShareOnePointTwoFourMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001638097</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">entx:ExercisePricePerShareOnePointTwoFourMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20221231_usgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_entxExercisePricePerShareTwoPointZeroTwoMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001638097</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">entx:ExercisePricePerShareTwoPointZeroTwoMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20220101to20221231_usgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_entxExercisePricePerShareTwoPointZeroTwoMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001638097</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">entx:ExercisePricePerShareTwoPointZeroTwoMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20221231_usgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_entxExercisePricePerShareTwoPointOneFourMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001638097</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">entx:ExercisePricePerShareTwoPointOneFourMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20220101to20221231_usgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_entxExercisePricePerShareTwoPointOneFourMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001638097</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">entx:ExercisePricePerShareTwoPointOneFourMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20221231_usgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_entxExercisePricePerShareTwoPointFiveSevenMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001638097</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">entx:ExercisePricePerShareTwoPointFiveSevenMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20220101to20221231_usgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_entxExercisePricePerShareTwoPointFiveSevenMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001638097</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">entx:ExercisePricePerShareTwoPointFiveSevenMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20221231_usgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_entxExercisePricePerShareTwoPointEightOneFiveMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001638097</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">entx:ExercisePricePerShareTwoPointEightOneFiveMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20220101to20221231_usgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_entxExercisePricePerShareTwoPointEightOneFiveMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001638097</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">entx:ExercisePricePerShareTwoPointEightOneFiveMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20221231_usgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_entxExercisePricePerShareTwoPointEightSixMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001638097</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">entx:ExercisePricePerShareTwoPointEightSixMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20220101to20221231_usgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_entxExercisePricePerShareTwoPointEightSixMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001638097</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">entx:ExercisePricePerShareTwoPointEightSixMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20221231_usgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_entxExercisePricePerShareThreePointOneFiveMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001638097</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">entx:ExercisePricePerShareThreePointOneFiveMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20220101to20221231_usgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_entxExercisePricePerShareThreePointOneFiveMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001638097</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">entx:ExercisePricePerShareThreePointOneFiveMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20221231_usgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_entxExercisePricePerShareThreePointSixOneMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001638097</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">entx:ExercisePricePerShareThreePointSixOneMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20220101to20221231_usgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_entxExercisePricePerShareThreePointSixOneMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001638097</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">entx:ExercisePricePerShareThreePointSixOneMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20221231_usgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_entxExercisePricePerShareOnePointFourMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001638097</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">entx:ExercisePricePerShareOnePointFourMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20221231_usgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_entxExercisePricePerShareTwoPointFiveThreeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001638097</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">entx:ExercisePricePerShareTwoPointFiveThreeMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20220101to20221231_usgaapIncomeStatementLocationAxis_usgaapResearchAndDevelopmentExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001638097</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20210101to20211231_usgaapIncomeStatementLocationAxis_usgaapResearchAndDevelopmentExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001638097</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20220101to20221231_usgaapIncomeStatementLocationAxis_usgaapGeneralAndAdministrativeExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001638097</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20210101to20211231_usgaapIncomeStatementLocationAxis_usgaapGeneralAndAdministrativeExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001638097</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20221231_usgaapPlanNameAxis_entxShareIncentivePlan2018Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001638097</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">entx:ShareIncentivePlan2018Member</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20180702_usgaapPlanNameAxis_entxShareIncentivePlan2018Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001638097</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">entx:ShareIncentivePlan2018Member</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2018-07-02</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20220101to20221231_usgaapPlanNameAxis_entxShareIncentivePlan2018Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001638097</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">entx:ShareIncentivePlan2018Member</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20210401to20210407_srtTitleOfIndividualAxis_entxEmployeesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001638097</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">entx:EmployeesMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-04-01</xbrli:startDate>
        <xbrli:endDate>2021-04-07</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20210401to20210407_srtTitleOfIndividualAxis_entxNonExecutiveDirectorMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001638097</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">entx:NonExecutiveDirectorMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-04-01</xbrli:startDate>
        <xbrli:endDate>2021-04-07</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20210401to20210421_srtTitleOfIndividualAxis_srtExecutiveOfficerMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001638097</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ExecutiveOfficerMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-04-01</xbrli:startDate>
        <xbrli:endDate>2021-04-21</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20210801to20210823_srtTitleOfIndividualAxis_entxNonExecutiveDirectorMember_usgaapVestingAxis_entxShareBasedPaymentArrangementTrancheSixMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001638097</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">entx:NonExecutiveDirectorMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:VestingAxis">entx:ShareBasedPaymentArrangementTrancheSixMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-08-01</xbrli:startDate>
        <xbrli:endDate>2021-08-23</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20210801to20210823_srtTitleOfIndividualAxis_entxNonExecutiveDirectorMember_usgaapVestingAxis_entxShareBasedPaymentArrangementTrancheFiveMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001638097</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">entx:NonExecutiveDirectorMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:VestingAxis">entx:ShareBasedPaymentArrangementTrancheFiveMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-08-01</xbrli:startDate>
        <xbrli:endDate>2021-08-23</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20210401to20210421_srtTitleOfIndividualAxis_srtExecutiveOfficerMember_usgaapVestingAxis_usgaapShareBasedCompensationAwardTrancheOneMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001638097</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ExecutiveOfficerMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-04-01</xbrli:startDate>
        <xbrli:endDate>2021-04-21</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20210401to20210421_srtTitleOfIndividualAxis_srtExecutiveOfficerMember_usgaapVestingAxis_usgaapShareBasedCompensationAwardTrancheTwoMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001638097</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ExecutiveOfficerMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-04-01</xbrli:startDate>
        <xbrli:endDate>2021-04-21</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20210401to20210407_srtTitleOfIndividualAxis_entxServiceProviderMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001638097</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">entx:ServiceProviderMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-04-01</xbrli:startDate>
        <xbrli:endDate>2021-04-07</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20210401to20210407_srtTitleOfIndividualAxis_entxEmployeesMember_usgaapVestingAxis_usgaapShareBasedCompensationAwardTrancheTwoMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001638097</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">entx:EmployeesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-04-01</xbrli:startDate>
        <xbrli:endDate>2021-04-07</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20210401to20210407_srtTitleOfIndividualAxis_entxServiceProviderMember_usgaapVestingAxis_usgaapShareBasedCompensationAwardTrancheTwoMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001638097</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">entx:ServiceProviderMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-04-01</xbrli:startDate>
        <xbrli:endDate>2021-04-07</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20210401to20210407_srtTitleOfIndividualAxis_entxEmployeesMember_usgaapVestingAxis_usgaapShareBasedCompensationAwardTrancheOneMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001638097</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">entx:EmployeesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-04-01</xbrli:startDate>
        <xbrli:endDate>2021-04-07</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20210401to20210407_srtTitleOfIndividualAxis_entxServiceProviderMember_usgaapVestingAxis_usgaapShareBasedCompensationAwardTrancheOneMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001638097</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">entx:ServiceProviderMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-04-01</xbrli:startDate>
        <xbrli:endDate>2021-04-07</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20220101to20221231_usgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_entxExercisePricePerShareTwoPointFiveThreeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001638097</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">entx:ExercisePricePerShareTwoPointFiveThreeMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20220101to20221231_usgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_entxExercisePricePerShareOnePointFourMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001638097</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">entx:ExercisePricePerShareOnePointFourMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20220101to20221231_usgaapIncomeStatementLocationAxis_usgaapCostOfSalesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001638097</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20210101to20211231_usgaapIncomeStatementLocationAxis_usgaapCostOfSalesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001638097</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20210101to20210104_srtTitleOfIndividualAxis_srtChiefExecutiveOfficerMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001638097</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-01-04</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20210101to20210104_srtTitleOfIndividualAxis_srtChiefExecutiveOfficerMember_usgaapVestingAxis_usgaapShareBasedCompensationAwardTrancheOneMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001638097</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-01-04</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20210101to20210104_srtTitleOfIndividualAxis_srtChiefExecutiveOfficerMember_usgaapVestingAxis_usgaapShareBasedCompensationAwardTrancheTwoMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001638097</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-01-04</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20220601to20220615_srtTitleOfIndividualAxis_entxFormerChiefExecutiveOfficerMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001638097</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">entx:FormerChiefExecutiveOfficerMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-06-01</xbrli:startDate>
        <xbrli:endDate>2022-06-15</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20220331_srtTitleOfIndividualAxis_entxExecutiveOfficerAndServiceProviderMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001638097</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">entx:ExecutiveOfficerAndServiceProviderMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2022-03-31</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20220101to20220331_srtTitleOfIndividualAxis_entxExecutiveOfficerAndServiceProviderMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001638097</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">entx:ExecutiveOfficerAndServiceProviderMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-03-31</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20220101to20220331_srtTitleOfIndividualAxis_entxServiceProviderMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001638097</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">entx:ServiceProviderMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-03-31</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20220331_srtTitleOfIndividualAxis_srtExecutiveOfficerMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001638097</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ExecutiveOfficerMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2022-03-31</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20220101to20220331_srtTitleOfIndividualAxis_srtExecutiveOfficerMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001638097</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ExecutiveOfficerMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-03-31</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20220101to20220331">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001638097</xbrli:identifier>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-03-31</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20220401to20220428_srtTitleOfIndividualAxis_entxEmployeeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001638097</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">entx:EmployeeMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-04-01</xbrli:startDate>
        <xbrli:endDate>2022-04-28</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20220501to20220511_srtTitleOfIndividualAxis_srtChiefFinancialOfficerMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001638097</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefFinancialOfficerMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-05-01</xbrli:startDate>
        <xbrli:endDate>2022-05-11</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20220701to20220715_srtTitleOfIndividualAxis_srtChiefExecutiveOfficerMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001638097</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-07-01</xbrli:startDate>
        <xbrli:endDate>2022-07-15</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20220701to20220715_srtTitleOfIndividualAxis_srtChiefExecutiveOfficerMember_usgaapTypeOfArrangementAxis_entxTriggeringEventMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001638097</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">entx:TriggeringEventMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-07-01</xbrli:startDate>
        <xbrli:endDate>2022-07-15</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20210401to20210430_srtTitleOfIndividualAxis_entxPresidentOfResearchAndDevelopmentMember_usgaapAwardTypeAxis_entxTwentySeventeenMemberMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001638097</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">entx:PresidentOfResearchAndDevelopmentMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">entx:TwentySeventeenMemberMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-04-01</xbrli:startDate>
        <xbrli:endDate>2021-04-30</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20210430_srtTitleOfIndividualAxis_entxPresidentOfResearchAndDevelopmentMember_usgaapAwardTypeAxis_entxTwentySeventeenMemberMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001638097</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">entx:PresidentOfResearchAndDevelopmentMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">entx:TwentySeventeenMemberMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2021-04-30</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20220601to20220615_srtTitleOfIndividualAxis_entxPresidentOfResearchAndDevelopmentMember_usgaapAwardTypeAxis_entxTwentySeventeenMemberMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001638097</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">entx:PresidentOfResearchAndDevelopmentMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">entx:TwentySeventeenMemberMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-06-01</xbrli:startDate>
        <xbrli:endDate>2022-06-15</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20220601to20220615_srtTitleOfIndividualAxis_entxPresidentOfResearchAndDevelopmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001638097</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">entx:PresidentOfResearchAndDevelopmentMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-06-01</xbrli:startDate>
        <xbrli:endDate>2022-06-15</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20220101to20221231_usgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_entxExercisePricePerShareThreePointSixEightMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001638097</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">entx:ExercisePricePerShareThreePointSixEightMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20221231_usgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_entxExercisePricePerShareThreePointSixEightMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001638097</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">entx:ExercisePricePerShareThreePointSixEightMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20220101to20221231_usgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_entxExercisePricePerShareThreePointNineSevenMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001638097</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">entx:ExercisePricePerShareThreePointNineSevenMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20221231_usgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_entxExercisePricePerShareThreePointNineSevenMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001638097</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">entx:ExercisePricePerShareThreePointNineSevenMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20220101to20221231_usgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_entxExercisePricePerShareSixPointThreeOneMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001638097</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">entx:ExercisePricePerShareSixPointThreeOneMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20221231_usgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_entxExercisePricePerShareSixPointThreeOneMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001638097</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">entx:ExercisePricePerShareSixPointThreeOneMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20221231_srtRangeAxis_srtMinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001638097</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20211231_srtRangeAxis_srtMinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001638097</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:unit id="NIS">
      <xbrli:measure>iso4217:ILS</xbrli:measure>
      </xbrli:unit>
    <xbrli:unit id="NIS_per_Share"><xbrli:divide>
      <xbrli:unitNumerator>
      <xbrli:measure>iso4217:ILS</xbrli:measure></xbrli:unitNumerator>
      <xbrli:unitDenominator>
      <xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide>
      </xbrli:unit>
    <xbrli:unit id="Percent">
      <xbrli:measure>xbrli:pure</xbrli:measure>
      </xbrli:unit>
    <xbrli:unit id="USD">
      <xbrli:measure>iso4217:USD</xbrli:measure>
      </xbrli:unit>
    <xbrli:unit id="USD_per_Share"><xbrli:divide>
      <xbrli:unitNumerator>
      <xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator>
      <xbrli:unitDenominator>
      <xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide>
      </xbrli:unit>
    <xbrli:unit id="shares">
      <xbrli:measure>xbrli:shares</xbrli:measure>
      </xbrli:unit>
    <ix:relationship fromRefs="Fxbrl_20220808213249447" toRefs="FN20220808221358290"/>
    <ix:relationship fromRefs="Fxbrl_20220808214617486" toRefs="FN20220808221358290"/>
    <ix:relationship fromRefs="Fxbrl_20220808213010825_xbrl_20220802040425347_20220801223211777_38" toRefs="FN20220808221358290"/>
    <ix:relationship fromRefs="Fxbrl_20220808214821452" toRefs="FN20220808221358290"/>
    <ix:relationship fromRefs="Fxbrl_20220808214839417" toRefs="FN20220808221358290"/>
    <ix:relationship fromRefs="Fxbrl_20220808214942722" toRefs="FN20220808221358290"/>
    <ix:relationship fromRefs="Fxbrl_20220808220722541" toRefs="FN20220808221358290"/>
    <ix:relationship fromRefs="Fxbrl_20220808220938448" toRefs="FN20220808221358290"/>
    <ix:relationship fromRefs="Fxbrl_20220808221051935" toRefs="FN20220808221358290"/>
    <ix:relationship fromRefs="Fxbrl_20230227104430880" toRefs="FN20220808221358290"/>
    </ix:resources>
  </ix:header></div>

<div>

<div>

<div> <hr style="border:none;border-bottom:1px solid black;border-top:4px solid black;height:10px;color:#ffffff;background-color:#ffffff;text-align:center;margin-left:auto;margin-right:auto;text-align:center" />

<div>

<div>

<div style="line-height:1.25">&#160;</div> </div>

<div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-size:14pt;font-weight:bold;background-color:rgb(255, 255, 255);color:rgb(0, 0, 0);font-style:normal;font-variant:normal;text-transform:none"><span style="font-size:14pt"><span style="font-family:Times New Roman,Times,serif">UNITED
STATES</span></span></div>

<div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-size:14pt;font-weight:bold;background-color:rgb(255, 255, 255);color:rgb(0, 0, 0);font-style:normal;font-variant:normal;text-transform:none"><span style="font-size:14pt"><span style="font-family:Times New Roman,Times,serif">SECURITIES
AND EXCHANGE COMMISSION</span></span></div>

<div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">WASHINGTON,
DC 20549</span></span></div>

<div style="line-height:1.25">&#160;</div>

<div style="text-align:center;line-height:1.25"> <hr style="height:1px;width:15%;color:#000000;background-color:#000000;margin-left:auto;margin-right:auto;border:none;text-align:center" />
</div>

<div style="line-height:1.25">&#160;</div>

<div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-size:14pt;font-weight:bold;background-color:rgb(255, 255, 255);color:rgb(0, 0, 0);font-style:normal;font-variant:normal;text-transform:none"><span style="font-size:14pt"><span style="font-family:Times New Roman,Times,serif">FORM
<ix:nonNumeric id="Fxbrl_20220219045605798" name="dei:DocumentType" contextRef="C_20220101to20221231">10-K</ix:nonNumeric>&#160;</span></span></div>

<div style="text-align:center;line-height:1.25;font-weight:bold">&#160;</div>

<div style="line-height:1.25"> <hr style="height:1px;width:15%;color:#000000;background-color:#000000;text-align:center;margin-left:auto;margin-right:auto;border:none;text-align:center" />
</div>

<div style="line-height:1.25;font-weight:bold">&#160;</div>

<div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(Mark
One)</span></span></div>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">
  <tr>
    <td style="width:4%;vertical-align:top">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonNumeric id="Fxbrl_20230330095848199" name="dei:DocumentAnnualReport" contextRef="C_20220101to20221231" format="ixt:fixed-true">&#9746;</ix:nonNumeric></span></span></div>
        </td>
    <td style="width:96%;vertical-align:top">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">ANNUAL
        REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></span></div> </td> </tr>
  </table>

<div style="line-height:1.25">&#160;</div>

<div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">For
the fiscal year ended <ix:nonNumeric id="Fxbrl_20221031100209631" name="dei:DocumentPeriodEndDate" contextRef="C_20220101to20221231" format="ixt:date-monthname-day-year-en"><ix:nonNumeric id="Fxbrl_20230228180646841" name="dei:CurrentFiscalYearEndDate" contextRef="C_20220101to20221231" format="ixt:date-monthname-day-en">December
31</ix:nonNumeric>, <ix:nonNumeric id="Fxbrl_20221031100232614" name="dei:DocumentFiscalYearFocus" contextRef="C_20220101to20221231">2022</ix:nonNumeric></ix:nonNumeric></span></span></div>

<div style="text-align:center;line-height:1.25;font-weight:bold">&#160;</div>

<div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">OR</span></span></div>

<div style="text-align:center;line-height:1.25;font-weight:bold">&#160;</div>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">
  <tr>
    <td style="width:4%;vertical-align:top">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonNumeric id="Fxbrl_20220219045840097" name="dei:DocumentTransitionReport" contextRef="C_20220101to20221231" format="ixt:fixed-false">&#9744;</ix:nonNumeric></span></span></div>
        </td>
    <td style="width:96%;vertical-align:top">
        <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">TRANSITION
        REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></span></div> </td> </tr>
  </table>

<div style="line-height:1.25">&#160;</div>

<div style="text-align:center;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">For
the transition period from </span><span style="text-decoration:underline">&#160;</span><span style="font-weight:bold"><span style="text-decoration:underline">&#160;</span>
to </span><span style="text-decoration:underline">&#160;</span><span style="font-weight:bold"><span style="text-decoration:underline">&#160;</span>.</span></span></span></div>

<div style="line-height:1.25">&#160;</div>

<div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Commission
file number <ix:nonNumeric id="Fxbrl_20220219045917301" name="dei:EntityFileNumber" contextRef="C_20220101to20221231">001-38556</ix:nonNumeric></span></span></div>

<div style="line-height:1.25">&#160;</div>

<div style="line-height:1.25;text-align:center"> <hr style="height:1px;width:15%;color:#000000;background-color:#000000;margin-left:auto;margin-right:auto;border:none;text-align:center" />
</div>

<div style="text-align:center;line-height:1.25;font-family:Times New Roman, Times, serif;font-size:16pt;font-weight:bold;background-color:rgb(255, 255, 255);color:rgb(0, 0, 0);font-style:normal;font-variant:normal;text-transform:none;margin-top:18pt"><span style="font-size:16pt"><span><span style="font-family:Times New Roman,Times,serif"><span><ix:nonNumeric id="Fxbrl_20230330185621996" name="dei:EntityRegistrantName" contextRef="C_20220101to20221231">Entera
Bio Ltd.</ix:nonNumeric></span></span></span></span></div>

<div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>(Exact
Name of Registrant as Specified in Its Charter)</span></span></span></span></div>

<div style="text-align:center;margin-right:195pt;margin-left:195pt;line-height:1.25">&#160;</div>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">
  <tr>
    <td style="width:50%;vertical-align:top">
        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonNumeric id="Fxbrl_20220307234631165" name="dei:EntityIncorporationStateCountryCode" contextRef="C_20220101to20221231" format="ixt-sec:edgarprovcountryen">Israel</ix:nonNumeric></span></span></div>
        </td>
    <td style="width:50%;vertical-align:top">
        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="-sec-ix-hidden:Fxbrl_20220429111918108">00-0000000</span></span></span></div>
        </td> </tr>
  <tr>
    <td style="width:50%;vertical-align:bottom">
        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(State
        or Other Jurisdiction of<br />Incorporation or Organization)</span></span></div> </td>
    <td style="width:50%;vertical-align:bottom">
        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(I.R.S.
        Employer<br />Identification No.)</span></span></div> </td> </tr>
  </table>

<div style="text-align:center;line-height:1.25">&#160;</div>

<div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonNumeric id="Fxbrl_20220219050047075" name="dei:EntityAddressAddressLine1" contextRef="C_20220101to20221231">Kiryat
Hadassah</ix:nonNumeric></span></span></div>

<div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonNumeric id="Fxbrl_20220219050132138" name="dei:EntityAddressAddressLine2" contextRef="C_20220101to20221231">Minrav
Building - Fifth Floor</ix:nonNumeric></span></span></div>

<div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonNumeric id="Fxbrl_20220219050215039" name="dei:EntityAddressCityOrTown" contextRef="C_20220101to20221231">Jerusalem</ix:nonNumeric>,
<ix:nonNumeric id="Fxbrl_20220307234619822" name="dei:EntityAddressCountry" contextRef="C_20220101to20221231" format="ixt-sec:countrynameen">Israel</ix:nonNumeric>&#160;<ix:nonNumeric id="Fxbrl_20220219050350418" name="dei:EntityAddressPostalZipCode" contextRef="C_20220101to20221231">9112002</ix:nonNumeric></span></span></div>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">
  <tr>
    <td colspan="5" style="vertical-align:bottom">
        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(Address
        of Principal Executive Offices) (Zip Code)</span></span></div>
        <div style="text-align:center;line-height:1.25;font-weight:bold">&#160;</div> </td> </tr>
  <tr>
    <td colspan="5" style="vertical-align:middle">
        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonNumeric id="Fxbrl_20220219050426334" name="dei:CityAreaCode" contextRef="C_20220101to20221231">972</ix:nonNumeric>-<ix:nonNumeric id="Fxbrl_20220219050441325" name="dei:LocalPhoneNumber" contextRef="C_20220101to20221231">2-532-7151</ix:nonNumeric></span></span></div>
        </td> </tr>
  <tr>
    <td colspan="5" style="vertical-align:bottom">
        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(Registrant&#8217;s
        Telephone Number, Including Area Code)</span></span></div>
        <div style="text-align:center;line-height:1.25;font-weight:bold">&#160;</div> </td> </tr>
  <tr>
    <td colspan="5" style="vertical-align:top">
        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Securities
        registered pursuant to Section 12(b) of the Act:</span></span></div> </td> </tr>
  <tr>
    <td style="width:35%;vertical-align:bottom">
        <div style="line-height:1.25">&#160;</div> </td>
    <td style="width:2.46%;vertical-align:top">
        <div style="line-height:1.25">&#160;</div> </td>
    <td style="width:26%;vertical-align:bottom">
        <div style="line-height:1.25">&#160;</div> </td>
    <td style="width:2%;vertical-align:top">
        <div style="line-height:1.25">&#160;</div> </td>
    <td style="width:35%;vertical-align:bottom">
        <div style="line-height:1.25">&#160;</div> </td> </tr>
  <tr>
    <td style="width:35%;vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0)">
        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Title
        of Each Class</span></span></div> </td>
    <td style="width:2.46%;vertical-align:top">
        <div style="text-align:center;line-height:1.25">&#160;</div> </td>
    <td style="width:26%;vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0)">
        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Trading
        Symbol</span></span></div> </td>
    <td style="width:2%;vertical-align:top">
        <div style="text-align:center;line-height:1.25">&#160;</div> </td>
    <td style="width:35%;vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0)">
        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Name
        of Each Exchange on Which Registered</span></span></div> </td> </tr>
  <tr>
    <td style="width:35%;vertical-align:middle">
        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonNumeric id="Fxbrl_20220219050502450" name="dei:Security12bTitle" contextRef="C_20220101to20221231">Ordinary
        shares</ix:nonNumeric>, par value NIS 0.0000769 per share</span></span></div> </td>
    <td style="width:2.46%;vertical-align:top">
        <div style="text-align:center;margin-right:4.5pt;margin-left:4.5pt;line-height:1.25">&#160;</div> </td>
    <td style="width:26%;vertical-align:middle">
        <div style="text-align:center;margin-right:4.5pt;margin-left:4.5pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonNumeric id="Fxbrl_20220219050516845" name="dei:TradingSymbol" contextRef="C_20220101to20221231">ENTX</ix:nonNumeric></span></span></div>
        </td>
    <td style="width:2%;vertical-align:top">
        <div style="text-align:center;line-height:1.25">&#160;</div> </td>
    <td style="width:35%;vertical-align:middle">
        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonNumeric id="Fxbrl_20220219115247109" name="dei:SecurityExchangeName" contextRef="C_20220101to20221231" format="ixt-sec:exchnameen">Nasdaq</ix:nonNumeric>
        Capital Market</span></span></div> </td> </tr>
  <tr>
    <td style="width:35%;vertical-align:middle">
        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Warrants
        to purchase ordinary shares</span></span></div> </td>
    <td style="width:2.46%;vertical-align:top">
        <div style="text-align:center;margin-right:4.5pt;margin-left:4.5pt;line-height:1.25">&#160;</div> </td>
    <td style="width:26%;vertical-align:middle">
        <div style="text-align:center;margin-right:4.5pt;margin-left:4.5pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">ENTXW</span></span></div>
        </td>
    <td style="width:2%;vertical-align:top">
        <div style="text-align:center;line-height:1.25">&#160;</div> </td>
    <td style="width:35%;vertical-align:middle">
        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Nasdaq
        Capital Market</span></span></div> </td> </tr>
  </table>

<div style="line-height:1.25">&#160;</div>

<div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Securities
registered pursuant to Section 12(g) of the Act:</span></span></div>

<div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">None</span></span></div>

<div style="line-height:1.25">&#160;</div>

<div style="clear:both;margin-top:10pt;margin-bottom:10pt">

<div style="page-break-after:always"> <hr style="border-width:0px;clear:both;margin:4px 0px;width:100%;height:2px;color:#000000;background-color:#000000" />
</div> </div>

<div style="text-align:center;line-height:1.25">&#160;</div>

<div style="text-align:justify;text-indent:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Indicate
by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.</span></span></div>

<div style="text-align:justify;text-indent:36pt;line-height:1.25">&#160;</div>

<div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Yes&#160;&#9744;
<ix:nonNumeric id="Fxbrl_20230330100604736" name="dei:EntityWellKnownSeasonedIssuer" contextRef="C_20220101to20221231">No</ix:nonNumeric>
&#9746;</span></span></div>

<div style="text-align:justify;line-height:1.25">&#160;</div>

<div style="text-align:justify;text-indent:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Indicate
by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. </span></span></div>

<div style="text-align:justify;text-indent:36pt;line-height:1.25">&#160;</div>

<div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Yes&#160;<span>&#9744;</span>
<ix:nonNumeric id="Fxbrl_20230330190924391" name="dei:EntityVoluntaryFilers" contextRef="C_20220101to20221231">No</ix:nonNumeric> <span>&#9746;</span></span></span></div>

<div style="line-height:1.25">&#160;</div>

<div style="text-align:justify;text-indent:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Indicate
by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange
Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2)
has been subject to such filing requirements for the past 90 days.</span></span></div>

<div style="text-align:justify;text-indent:36pt;line-height:1.25">&#160;</div>

<div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonNumeric id="Fxbrl_20230330191005268" name="dei:EntityCurrentReportingStatus" contextRef="C_20220101to20221231">Yes</ix:nonNumeric>
<span>&#9746;</span> No <span>&#9744;</span></span></span></div>

<div style="line-height:1.25">&#160;</div>

<div style="text-align:justify;text-indent:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Indicate
by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted and posted pursuant
to Rule 405 of Regulation S-T (&#167; 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant
was required to submit and post such files). </span></span></div>

<div style="text-align:justify;text-indent:36pt;line-height:1.25">&#160;</div>

<div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonNumeric id="Fxbrl_20230330100012579" name="dei:EntityInteractiveDataCurrent" contextRef="C_20220101to20221231">Yes</ix:nonNumeric>
<span>&#9746;</span> No <span>&#9744;</span></span></span></div>

<div style="line-height:1.25">&#160;</div>

<div style="text-align:justify;text-indent:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Indicate
by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company
or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller
reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</span></span></div>

<div style="line-height:1.25">&#160;</div>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%">
  <tr>
    <td style="vertical-align:bottom;width:15%">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Large accelerated filer</span></span></div>
        </td>
    <td style="vertical-align:bottom;width:35%">
        <div style="line-height:1.25;font-family:'Segoe UI Symbol', sans-serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">&#9744;</span></span></div>
        </td>
    <td style="vertical-align:bottom;width:15%">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Accelerated filer</span></span></div>
        </td>
    <td style="vertical-align:bottom;width:35%">
        <div style="line-height:1.25;font-family:'Segoe UI Symbol',sans-serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">&#9744;</span></span></div>
        </td> </tr>
  <tr>
    <td style="vertical-align:bottom;width:15%">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonNumeric id="Fxbrl_20230330100029951" name="dei:EntityFilerCategory" contextRef="C_20220101to20221231" format="ixt-sec:entityfilercategoryen">Non-accelerated
        filer</ix:nonNumeric></span></span></div> </td>
    <td style="vertical-align:bottom;width:35%">
        <div style="line-height:1.25;font-family:'Segoe UI Symbol', sans-serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">&#9746;</span></span></div>
        </td>
    <td style="vertical-align:bottom;width:15%">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Smaller reporting company</span></span></div>
        </td>
    <td style="vertical-align:bottom;width:35%">
        <div style="line-height:1.25;font-family:'Segoe UI Symbol',sans-serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonNumeric id="Fxbrl_20230330100052190" name="dei:EntitySmallBusiness" contextRef="C_20220101to20221231" format="ixt:fixed-true">&#9746;</ix:nonNumeric></span></span></div>
        </td> </tr>
  <tr>
    <td style="vertical-align:bottom;width:15%">
        <div style="line-height:1.25">&#160;</div> </td>
    <td style="vertical-align:bottom;width:35%">
        <div style="line-height:1.25">&#160;</div> </td>
    <td style="vertical-align:bottom;width:15%">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Emerging growth company</span></span></div>
        </td>
    <td style="vertical-align:bottom;width:35%">
        <div style="line-height:1.25;font-family:'Segoe UI Symbol',sans-serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonNumeric id="Fxbrl_20230330100105872" name="dei:EntityEmergingGrowthCompany" contextRef="C_20220101to20221231" format="ixt:fixed-true">&#9746;</ix:nonNumeric></span></span></div>
        </td> </tr>
  </table>

<div style="line-height:1.25">&#160;</div>

<div style="text-align:justify;text-indent:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. <span><ix:nonNumeric id="Fxbrl_20230330100135414" name="dei:EntityExTransitionPeriod" contextRef="C_20220101to20221231" format="ixt:fixed-false">&#9744;</ix:nonNumeric></span></span></span></div>

<div style="line-height:1.25">&#160;</div>

<div style="text-align:justify;text-indent:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Indicate
by check mark whether the registrant has filed a report on and attestation to its management&#8217;s assessment of the effectiveness of
its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public
accounting fi rm that prepared or issued its audit report. <span>&#9744;</span></span></span></div>

<div style="line-height:1.25">&#160;</div>

<div style="text-align:justify;text-indent:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">If
securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant
included in the filing reflect the correction of an error to previously issued financial statements. <span>&#9744;</span></span></span></div>

<div style="line-height:1.25">&#160;</div>

<div style="text-align:justify;text-indent:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Indicate
by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation
received by any of the registrant&#8217;s executive officers during the relevant recovery period pursuant to &#167;240.10D-1(b). <span>&#9744;</span></span></span></div>

<div style="line-height:1.25">&#160;</div>

<div style="text-align:justify;text-indent:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Indicate
by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act).</span></span></div>

<div style="text-align:justify;text-indent:36pt;line-height:1.25">&#160;</div>

<div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Yes
<span>&#9744;</span> No <span><ix:nonNumeric id="Fxbrl_20230330100211917" name="dei:EntityShellCompany" contextRef="C_20220101to20221231" format="ixt:fixed-false">&#9746;</ix:nonNumeric></span></span></span></div>

<div style="line-height:1.25">&#160;</div>

<div style="text-align:justify;text-indent:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The
aggregate market value of the voting stock held by non-affiliates of the registrant was approximately $<ix:nonFraction id="Fxbrl_20230330100309896" name="dei:EntityPublicFloat" contextRef="C_20220630" unitRef="USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">32.9</ix:nonFraction>
million as of June 30, 2022.</span></span></div>

<div style="line-height:1.25">&#160;</div>

<div style="text-align:justify;text-indent:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">As
of March 27, 2023, the registrant had <ix:nonFraction id="Fxbrl_20220219151943625" name="dei:EntityCommonStockSharesOutstanding" contextRef="C_20230327" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">28,809,922</ix:nonFraction>
ordinary shares, par value NIS 0.0000769 per share (&#8220;Ordinary Shares&#8221;) outstanding.</span></span></div>

<div style="line-height:1.25">&#160;</div>

<div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Documents
Incorporated by Reference</span></span></div>

<div style="line-height:1.25">&#160;</div>

<div style="text-align:justify;text-indent:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">None.</span></span></div>

<div style="line-height:1.25">&#160;</div>

<div style="clear:both;margin-top:10pt;margin-bottom:10pt">

<div style="text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:normal;font-style:normal">2</span></span></span></div>

<div style="page-break-after:always"> <hr style="border-width:0px;clear:both;margin:4px 0px;width:100%;height:2px;color:#000000;background-color:#000000" />
</div> </div> </div> </div> <!-- Field: Include-Text; File: PF\body.htm; Date: 2023%2D03%2D31T12:01:10; Size: 0x000C3E30; Options: XMLPreprocess -->
<div>

<div style="text-align: center; line-height: 1.25; font-weight: bold">Table of Contents</div>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" border="0" style="font: 10pt Times New Roman,Times,serif; width: 100%; text-align: left; color: rgb(0, 0, 0)">
  <tr>
    <td style="width: 10%; vertical-align: middle; padding-bottom: 2px">
        <div style="line-height: 1.25; font-family: Times New Roman, Times, serif">&#160;</div> </td>
    <td style="width: 86%; vertical-align: bottom; padding-bottom: 2px">
        <div style="line-height: 1.25; font-family: Times New Roman, Times, serif">&#160;</div> </td>
    <td style="border-bottom: rgb(0, 0, 0) 2px solid; width: 4.4%; vertical-align: bottom">
        <div style="text-align: center; line-height: 1.25; font-family: Times New Roman, Times, serif; font-weight: bold">Page</div> </td> </tr>
  <tr>
    <td style="width: 10%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman, Times, serif; font-weight: bold"><a href="#PARTI">PART I</a></div> </td>
    <td style="width: 86%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman, Times, serif">&#160;</div> </td>
    <td style="width: 4.4%; vertical-align: bottom; text-align: right">7 <br /> </td> </tr>
  <tr>
    <td style="width: 10%; vertical-align: top">
        <div style="margin-left: 6.85pt; line-height: 1.25; font-family: Times New Roman, Times, serif"><a href="#ITEM1">Item 1.</a></div> </td>
    <td style="width: 86%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman, Times, serif"><a href="#ITEM1">Business</a></div> </td>
    <td style="width: 4.4%; vertical-align: bottom; text-align: right">&#160;7</td> </tr>
  <tr>
    <td style="width: 10%; vertical-align: top">
        <div style="margin-left: 6.85pt; line-height: 1.25; font-family: Times New Roman, Times, serif"><a href="#ITEM1A">Item 1A.</a></div> </td>
    <td style="width: 86%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman, Times, serif"><a href="#ITEM1A">Risk Factors</a></div> </td>
    <td style="width: 4.4%; vertical-align: bottom; text-align: right">&#160;37</td> </tr>
  <tr>
    <td style="width: 10%; vertical-align: top">
        <div style="margin-left: 6.85pt; line-height: 1.25; font-family: Times New Roman, Times, serif"><a href="#ITEM1B">Item 1B.</a></div> </td>
    <td style="width: 86%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman, Times, serif"><a href="#ITEM1B">Unresolved Staff Comments</a></div> </td>
    <td style="width: 4.4%; vertical-align: bottom; text-align: right">&#160;76</td> </tr>
  <tr>
    <td style="width: 10%; vertical-align: top">
        <div style="margin-left: 6.85pt; line-height: 1.25; font-family: Times New Roman, Times, serif"><a href="#ITEM2">Item 2.</a></div> </td>
    <td style="width: 86%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman, Times, serif"><a href="#ITEM2">Properties</a></div> </td>
    <td style="width: 4.4%; vertical-align: bottom; text-align: right">&#160;77</td> </tr>
  <tr>
    <td style="width: 10%; vertical-align: top">
        <div style="margin-left: 6.85pt; line-height: 1.25; font-family: Times New Roman, Times, serif"><a href="#ITEM3">Item 3.</a></div> </td>
    <td style="width: 86%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman, Times, serif"><a href="#ITEM3">Legal Proceedings</a></div> </td>
    <td style="width: 4.4%; vertical-align: bottom; text-align: right">&#160;77</td> </tr>
  <tr>
    <td style="width: 10%; vertical-align: top">
        <div style="margin-left: 6.85pt; line-height: 1.25; font-family: Times New Roman, Times, serif"><a href="#ITEM4">Item 4.</a></div> </td>
    <td style="width: 86%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman, Times, serif"><a href="#ITEM4">Mine Safety Disclosures</a></div> </td>
    <td style="width: 4.4%; vertical-align: bottom; text-align: right">&#160;77</td> </tr>
  <tr>
    <td style="width: 10%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman, Times, serif">&#160;</div> </td>
    <td style="width: 86%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman, Times, serif">&#160;</div> </td>
    <td style="width: 4.4%; vertical-align: bottom; text-align: right">&#160;</td> </tr>
  <tr>
    <td style="width: 10%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman, Times, serif; font-weight: bold"><a href="#PARTII">PART II</a></div> </td>
    <td style="width: 86%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman, Times, serif">&#160;</div> </td>
    <td style="width: 4.4%; vertical-align: bottom; text-align: right">&#160;78</td> </tr>
  <tr>
    <td style="width: 10%; vertical-align: top">
        <div style="margin-left: 6.85pt; line-height: 1.25; font-family: Times New Roman, Times, serif"><a href="#ITEM5">Item 5.</a></div> </td>
    <td style="width: 86%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman, Times, serif"><a href="#ITEM5">Market for Registrant&#8217;s Common Equity,
        Related Stockholder Matters and Issuer Purchases of Equity Securities</a></div> </td>
    <td style="width: 4.4%; vertical-align: bottom; text-align: right">&#160;78</td> </tr>
  <tr>
    <td style="width: 10%; vertical-align: top">
        <div style="margin-left: 6.85pt; line-height: 1.25; font-family: Times New Roman, Times, serif"><a href="#ITEM6">Item 6.</a></div> </td>
    <td style="width: 86%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman, Times, serif"><a href="#ITEM6">[Reserved]</a></div> </td>
    <td style="width: 4.4%; vertical-align: bottom; text-align: right">&#160;78</td> </tr>
  <tr>
    <td style="width: 10%; vertical-align: top">
        <div style="margin-left: 6.85pt; line-height: 1.25; font-family: Times New Roman, Times, serif"><a href="#ITEM7">Item 7.</a></div> </td>
    <td style="width: 86%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman, Times, serif"><a href="#ITEM7">Management&#8217;s Discussion and Analysis
        of Financial Condition and Results of Operations</a></div> </td>
    <td style="width: 4.4%; vertical-align: bottom; text-align: right">&#160;78</td> </tr>
  <tr>
    <td style="width: 10%; vertical-align: top">
        <div style="margin-left: 6.85pt; line-height: 1.25; font-family: Times New Roman, Times, serif"><a href="#Item7A">Item 7A.</a></div> </td>
    <td style="width: 86%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman, Times, serif"><a href="#Item7A">Quantitative and Qualitative Disclosures
        About Market Risk</a></div> </td>
    <td style="width: 4.4%; vertical-align: bottom; text-align: right">88 <br /> </td> </tr>
  <tr>
    <td style="width: 10%; vertical-align: top">
        <div style="margin-left: 6.85pt; line-height: 1.25; font-family: Times New Roman, Times, serif"><a href="#ITEM8_integixAnchor">Item 8.</a></div> </td>
    <td style="width: 86%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman, Times, serif"><a href="#ITEM8_integixAnchor">Financial Statements and Supplementary Data</a></div> </td>
    <td style="width: 4.4%; vertical-align: bottom; text-align: right">89 <br /> </td> </tr>
  <tr>
    <td style="width: 10%; vertical-align: top">
        <div style="margin-left: 6.85pt; line-height: 1.25; font-family: Times New Roman, Times, serif"><a href="#ITEM9_integixAnchor">Item 9.</a></div> </td>
    <td style="width: 86%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman, Times, serif"><a href="#ITEM9_integixAnchor">Changes in and Disagreements With Accountants on Accounting and Financial Disclosure</a></div> </td>
    <td style="width: 4.4%; vertical-align: bottom; text-align: right">119 <br /> </td> </tr>
  <tr>
    <td style="width: 10%; vertical-align: top">
        <div style="margin-left: 6.85pt; line-height: 1.25; font-family: Times New Roman, Times, serif"><a href="#ITEM9A_integixAnchor">Item 9A.</a></div> </td>
    <td style="width: 86%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman, Times, serif"><a href="#ITEM9A_integixAnchor">Controls and Procedures</a></div> </td>
    <td style="width: 4.4%; vertical-align: bottom; text-align: right">119 <br /> </td> </tr>
  <tr>
    <td style="width: 10%; vertical-align: top">
        <div style="margin-left: 6.85pt; line-height: 1.25; font-family: Times New Roman, Times, serif"><a href="#ITEM9B_integixAnchor">Item 9B.</a></div> </td>
    <td style="width: 86%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman, Times, serif"><a href="#ITEM9B_integixAnchor">Other Information</a></div> </td>
    <td style="width: 4.4%; vertical-align: bottom; text-align: right">119 <br /> </td> </tr>
  <tr>
    <td style="width: 10%; vertical-align: top">
        <div style="margin-left: 6.85pt; line-height: 1.25; font-family: Times New Roman, Times, serif"><a href="#ITEM9C_integixAnchor">Item 9C</a></div> </td>
    <td style="width: 86%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman, Times, serif"><a href="#ITEM9C_integixAnchor">Disclosure Regarding Foreign Jurisdictions that Prevent Inspections</a></div>
        </td>
    <td style="width: 4.4%; vertical-align: bottom; text-align: right">119 <br /> </td> </tr>
  <tr>
    <td style="width: 10%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman, Times, serif">&#160;</div> </td>
    <td style="width: 86%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman, Times, serif">&#160;</div> </td>
    <td style="width: 4.4%; vertical-align: bottom; text-align: right">&#160;</td> </tr>
  <tr>
    <td style="width: 10%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman, Times, serif; font-weight: bold"><a href="#PARTIII_integixAnchor">PART III</a></div> </td>
    <td style="width: 86%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman, Times, serif">&#160;</div> </td>
    <td style="width: 4.4%; vertical-align: bottom; text-align: right">120 <br /> </td> </tr>
  <tr>
    <td style="width: 10%; vertical-align: top">
        <div style="margin-left: 6.85pt; line-height: 1.25; font-family: Times New Roman, Times, serif"><a href="#ITEM10_integixAnchor">Item 10.</a></div> </td>
    <td style="width: 86%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman, Times, serif"><a href="#ITEM10_integixAnchor">Directors, Executive Officers and Corporate Governance</a></div>
        </td>
    <td style="width: 4.4%; vertical-align: bottom; text-align: right">120 <br /> </td> </tr>
  <tr>
    <td style="width: 10%; vertical-align: top">
        <div style="margin-left: 6.85pt; line-height: 1.25; font-family: Times New Roman, Times, serif"><a href="#ITEM11_integixAnchor">Item 11.</a></div> </td>
    <td style="width: 86%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman, Times, serif"><a href="#ITEM11_integixAnchor">Executive Compensation</a></div> </td>
    <td style="width: 4.4%; vertical-align: bottom; text-align: right">129 <br /> </td> </tr>
  <tr>
    <td style="width: 10%; vertical-align: top">
        <div style="margin-left: 6.85pt; line-height: 1.25; font-family: Times New Roman, Times, serif"><a href="#Item12">Item 12.</a></div> </td>
    <td style="width: 86%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman, Times, serif"><a href="#Item12">Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</a></div> </td>
    <td style="width: 4.4%; vertical-align: bottom; text-align: right">139 <br /> </td> </tr>
  <tr>
    <td style="width: 10%; vertical-align: top">
        <div style="margin-left: 6.85pt; line-height: 1.25; font-family: Times New Roman, Times, serif"><a href="#ITEM13_integixAnchor">Item 13.</a></div> </td>
    <td style="width: 86%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman, Times, serif"><a href="#ITEM13_integixAnchor">Certain Relationships and Related Transactions, and Director Independence</a></div> </td>
    <td style="width: 4.4%; vertical-align: bottom; text-align: right">142 <br /> </td> </tr>
  <tr>
    <td style="width: 10%; vertical-align: top">
        <div style="margin-left: 6.85pt; line-height: 1.25; font-family: Times New Roman, Times, serif"><a href="#ITEM14_integixAnchor">Item 14.</a></div> </td>
    <td style="width: 86%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman, Times, serif"><a href="#ITEM14_integixAnchor">Principal Accounting Fees and Services</a></div> </td>
    <td style="width: 4.4%; vertical-align: bottom; text-align: right">143 <br /> </td> </tr>
  <tr>
    <td style="width: 10%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman, Times, serif">&#160;</div> </td>
    <td style="width: 86%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman, Times, serif">&#160;</div> </td>
    <td style="width: 4.4%; vertical-align: bottom; text-align: right">&#160;</td> </tr>
  <tr>
    <td style="width: 10%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman, Times, serif; font-weight: bold"><a href="#PARTIV_integixAnchor">PART IV</a></div> </td>
    <td style="width: 86%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman, Times, serif">&#160;</div> </td>
    <td style="width: 4.4%; vertical-align: bottom; text-align: right">144 <br /> </td> </tr>
  <tr>
    <td style="width: 10%; vertical-align: top">
        <div style="margin-left: 6.85pt; line-height: 1.25; font-family: Times New Roman, Times, serif"><a href="#Item15_integixAnchor">Item 15.</a></div> </td>
    <td style="width: 86%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman, Times, serif"><a href="#Item15_integixAnchor">Exhibits, Financial Statement Schedules</a></div> </td>
    <td style="width: 4.4%; vertical-align: bottom; text-align: right">144 <br /> </td> </tr>
  <tr>
    <td style="width: 10%; vertical-align: top">
        <div style="margin-left: 6.85pt; line-height: 1.25; font-family: Times New Roman, Times, serif"><a href="#ITEM16_integixAnchor">Item 16</a></div> </td>
    <td style="width: 86%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman, Times, serif"><a href="#ITEM16_integixAnchor">Form 10-K Summary</a></div> </td>
    <td style="width: 4.4%; vertical-align: bottom; text-align: right">146 <br /> </td> </tr>
  </table>

<div class="BRPFPageHeader">

<div style="line-height: 1.25"><br /> </div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal">3</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000" /></div>
</div> </div>

<div style="line-height: 1.25">

<div style="line-height: 1.25"><br /> </div> </div>

<div style="text-align: center; line-height: 1.25; font-weight: bold">CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">This Annual Report on Form 10-K (this &#8220;Annual Report&#8221;) contains &#8220;forward-looking
statements,&#8221; as that term is defined under the Private Securities Litigation Reform Act of 1995 (&#8220;PSLRA&#8221;), Section 27A
of the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;), and Section 21E of the Securities Exchange Act of 1934,
as amended (the &#8220;Exchange Act&#8221;). Various statements in this report are &#8220;forward-looking statements&#8221; within the
meaning of the PSLRA and other U.S. Federal securities laws. In addition, historic results of scientific research and clinical and preclinical
trials do not guarantee that the conclusions of future research or trials would not be different, and historic results referred to in
this Annual Report may be interpreted differently in light of additional research and clinical and preclinical trial results. Forward-looking
statements include all statements that are not historical facts. We have based these forward-looking statements largely on our management&#8217;s
current expectations and future events and financial trends that we believe may affect our financial condition, results of operations,
business strategy and financial needs. Forward-looking statements involve substantial risks and uncertainties. All statements, other than
statements of historical facts, included in this report regarding our strategy, future operations, future financial position, projected
costs, prospects, plans and objectives of management are forward-looking statements. These statements are subject to risks and uncertainties
and are based on information currently available to our management. Words such as, but not limited to, &#8220;anticipate,&#8221; &#8220;believe,&#8221;
&#8220;contemplates,&#8221; &#8220;continue,&#8221; &#8220;could,&#8221; &#8220;design,&#8221; &#8220;estimate,&#8221; &#8220;expect,&#8221;
&#8220;intend,&#8221; &#8220;likely,&#8221; &#8220;may,&#8221; &#8220;ongoing,&#8221; &#8220;plan,&#8221; &#8220;potential,&#8221; &#8220;predict,&#8221;
&#8220;project,&#8221; &#8220;will,&#8221; &#8220;would,&#8221; &#8220;seek,&#8221; &#8220;should,&#8221; &#8220;target,&#8221; or the
negative of these terms and similar expressions or words, identify forward-looking statements. The events and circumstances reflected
in our forward-looking statements may not occur and actual results could differ materially from those projected in our forward-looking
statements. These factors include those described in &#8220;Item 1A-Risk Factors&#8221; of this Annual Report on Form 10-K. Meaningful
factors which could cause actual results to differ include, but are not limited to:</div>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 18pt"><br /> </td>
    <td style="width: 18pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>Clinical development involves a lengthy and expensive process with uncertain outcomes. We may incur additional costs and experience
        delays in developing and commercializing or be unable to develop or commercialize our current and future product candidates;</div> </td>
        </tr>
  </table>

<div style="line-height: 1.25"><br /> </div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 18pt"><br /> </td>
    <td style="width: 18pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>The regulatory approval processes of the U.S. Food and Drug Administration (&#8220;FDA&#8221;) and comparable foreign authorities
        are lengthy, time-consuming and inherently unpredictable, and if we are ultimately unable to obtain regulatory approval for our product
        candidates, our business will be materially harmed;</div> </td> </tr>
  </table>

<div style="line-height: 1.25"><br /> </div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 18pt"><br /> </td>
    <td style="width: 18pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>Preclinical development is uncertain. Our preclinical programs may experience delays or may never advance to clinical trials, which
        would adversely affect our ability to obtain regulatory approvals or commercialize these programs on a timely basis or at all;</div> </td>
        </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 18pt"><br /> </td>
    <td style="width: 18pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>Positive results from preclinical studies and early-stage clinical trials may not be predictive of future results. Initial positive
        results in any of our clinical trials may not be indicative of results obtained when the trial is completed or in later stage trials;<br />
        </div> </td> </tr>
  </table>

<div><br /> </div> </div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 18pt"><br /> </td>
    <td style="width: 18pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>The scope, progress and costs of developing our product candidates such as EB613 for Osteoporosis and EB612 for Hypoparathyroidism
        may alter over time based on various factors such as regulatory requirements, the competitive environment and new data from pre-clinical
        and clinical studies;</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 18pt"><br /> </td>
    <td style="width: 18pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>The accuracy of our estimates regarding expenses, capital requirements, the sufficiency of our cash resources and the need for additional
        financing;</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 18pt"><br /> </td>
    <td style="width: 18pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>our ability to continue as a going concern absent access to sources of liquidity;<br /> </div> </td> </tr>
  </table> <br /> </div>

<div style="text-align: justify; line-height: 1.25">

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 18pt"><br /> </td>
    <td style="width: 18pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>Our ability to raise additional funds or consummate strategic partnerships to offset additional required capital to pursue our business
        objectives, which may not be available on acceptable terms or at all. A failure to obtain this additional capital when needed, or failure
        to consummate strategic partnerships, could delay, limit or reduce our product development, and other operations;<br /> </div> </td> </tr>
  </table> <br /> </div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal">4</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000" /></div>
</div>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 18pt"><br /> </td>
    <td style="width: 18pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>Even if a current or future product candidate receives marketing approval, it may fail to achieve the degree of market acceptance
        by physicians, patients, third-party payors and others in the medical community necessary for commercial success;</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 18pt"><br /> </td>
    <td style="width: 18pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>The successful commercialization of our product candidates, if approved, will depend in part on the extent to which governmental
        authorities and third-party payors establish adequate coverage and reimbursement levels and pricing policies;</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 18pt"><br /> </td>
    <td style="width: 18pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>Failure to obtain or maintain coverage and adequate reimbursement for our product candidates, if approved, could limit our ability
        to market those products and decrease our ability to generate revenue;</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 18pt"><br /> </td>
    <td style="width: 18pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>If we are unable to obtain and maintain patent protection for our product candidates, or if the scope of the patent protection obtained
        is not sufficiently broad or robust, our competitors could develop and commercialize products similar or identical to ours, and our ability
        to successfully commercialize our product candidates may be adversely affected;</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 18pt"><br /> </td>
    <td style="width: 18pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>We are an emerging growth company, and we cannot be certain if the reduced reporting requirements applicable to emerging growth companies
        will make our common stock less attractive to investors;</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 18pt"><br /> </td>
    <td style="width: 18pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>Because we do not anticipate paying any cash dividends on our capital stock in the foreseeable future, capital appreciation, if any,
        will be your sole source of gain;</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 18pt"><br /> </td>
    <td style="width: 18pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>Our reliance on third parties to conduct our clinical trials and on third-party suppliers to supply or produce our product candidates;<br />
        </div> </td> </tr>
  </table> <br /> </div>

<div style="text-align: justify; line-height: 1.25">

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 18pt"><br /> </td>
    <td style="width: 18pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>our interpretation of FDA feedback and guidance and how such guidance may impact our clinical development plan;<br /> </div> </td>
        </tr>
  </table> <br /> </div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 18pt"><br /> </td>
    <td style="width: 18pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>our ability to use and expand our drug delivery technology to additional product candidates;</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 18pt"><br /> </td>
    <td style="width: 18pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>our operation as a development stage company with limited operating history and a history of operating losses and our ability to
        fund our operations going forward;<br /> </div> </td> </tr>
  </table> <br /> </div>

<div style="text-align: justify; line-height: 1.25">

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 18pt"><br /> </td>
    <td style="width: 18pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>our competitive position with respect to other products on the market or in development for the treatment of osteoporosis and hypoparathyroidism
        and other disease categories we pursue;<br /> </div> </td> </tr>
  </table> <br /> </div>

<div style="text-align: justify; line-height: 1.25">

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 18pt"><br /> </td>
    <td style="width: 18pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>our ability to establish and maintain development and commercialization collaborations;<br /> </div> </td> </tr>
  </table> <br /> </div>

<div style="text-align: justify; line-height: 1.25">

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 18pt"><br /> </td>
    <td style="width: 18pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>our ability to manufacture and supply enough material to support our clinical trials and any potential future commercial requirements;<br />
        </div> </td> </tr>
  </table> <br /> </div>

<div style="text-align: justify; line-height: 1.25">

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 18pt"><br /> </td>
    <td style="width: 18pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>the size of any market we may target and the adoption of our product candidates, if approved, by physicians and patients;<br /> </div>
        </td> </tr>
  </table> <br /> </div>

<div style="text-align: justify; line-height: 1.25">

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 18pt"><br /> </td>
    <td style="width: 18pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>our ability to obtain, maintain and protect our intellectual property and operate our business without infringing misappropriating
        or otherwise violating any intellectual property rights of others;<br /> </div> </td> </tr>
  </table> <br /> </div>

<div style="text-align: justify; line-height: 1.25">

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 18pt"><br /> </td>
    <td style="width: 18pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>our ability to retain key personnel and recruit additional qualified personnel;<br /> </div> </td> </tr>
  </table> <br /> </div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal">5</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000" /></div>
</div>

<div style="text-align: justify; line-height: 1.25">

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 18pt"><br /> </td>
    <td style="width: 18pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>the possibility that competing products or technologies may make any product candidates we may develop and commercialize or our oral
        delivery technology obsolete;<br /> </div> </td> </tr>
  </table> <br /> </div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 18pt"><br /> </td>
    <td style="width: 18pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>our ability to comply with laws and regulations that currently apply or become applicable to our business in Israel, the United States
        and internationally; and</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 18pt"><br /> </td>
    <td style="width: 18pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>our ability to manage growth.<br /> </div> </td> </tr>
  </table> <br /> </div>

<div style="text-align: justify; line-height: 1.25">All forward-looking statements contained in this Annual Report are expressly qualified
in their entirety by the cautionary statements contained or referred to in this section. We caution investors not to rely too heavily
on the forward-looking statements we make or that are made on our behalf. Except as required by applicable law, we are under no duty,
and expressly disclaim any obligation, to update or revise publicly any forward-looking statements, whether as a result of new information,
future events or otherwise. You are advised, however, to consult any further disclosures we make on related subjects in any annual, quarterly
or current reports that we may file with the Securities and Exchange Commission (&#8220;SEC&#8221;).</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">We encourage you to read the discussion and analysis of our financial condition and
our consolidated financial statements contained in this Annual Report. We also encourage you to read Item 1A of this Annual Report, entitled
&#8220;Risk Factors,&#8221; and Part II, Item 7 &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of
Operation-Liquidity and Capital Resources&#8221; of this Annual Report for additional discussion of the risks and uncertainties associated
with our business. There can be no assurance that the actual results or developments anticipated by us will be realized or, even if substantially
realized, that they will have the expected consequences to, or effects on, us. Therefore, no assurance can be given that the outcomes
stated in such forward-looking statements and estimates will be achieved.</div>

<div style="line-height: 1.25">&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal">6</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000" /></div>
</div>

<div class="BRPFPageHeader">

<div style="line-height: 1.25"><br /> </div> </div>

<div style="text-align: center; line-height: 1.25; font-weight: bold"><span id="PARTI"><!--Anchor--></span>PART I</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Unless the context otherwise requires, all references in this Annual Report on Form
10-K to the &#8220;Company,&#8221; &#8220;Entera,&#8221; &#8220;we,&#8221; &#8220;our,&#8221; and &#8220;us&#8221; refer to Entera Bio
Ltd., an Israeli company, including its consolidated subsidiary.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif; font-weight: bold">ITEM 1<span id="ITEM1"><!--Anchor--></span>.
&#160; &#160; &#160; &#160; &#160; &#160; &#160; BUSINESS</div>

<div style="line-height: 1.25">&#160;</div>

<div style="line-height: 1.25; font-weight: bold">Overview</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Entera is a clinical stage biopharmaceutical company and a leader in the development
of orally delivered macromolecule therapeutics, including peptides and therapeutic proteins. Currently, most protein therapies are administered
via frequent intravenous, subcutaneous, or intramuscular injections. In chronic diseases where patients require persistent management,
these cumbersome, often painful and high-priced injections can create a major treatment gap. Furthermore, from a technical standpoint,
oral delivery of therapeutic proteins has historically been challenging due to enzymatic degradation within the gastrointestinal tract,
poor absorption into the blood stream and variable drug exposures. Entera&#8217;s proprietary technology is designed to deliver orally
administered proteins with sufficient bioavailability to meet treatment goals, using white mini tablets (around 6mm in diameter) of the
desired protein.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">We strategically focus on underserved, chronic medical conditions where oral administration
of a mini tablet peptide or peptide replacement therapy has the potential to significantly shift a treatment paradigm.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">We currently have two product candidates in the clinical stage of development: EB613
and EB612. Both candidates are first-in-class daily mini tablets of human parathyroid hormone (hPTH (1-34), teriparatide). To date, Entera&#8217;s
proprietary PTH tablets have been safely administered to a total of 72 healthy subjects in Phase 1 studies and 153 patients across Phase
2 studies in osteoporosis and hypoparathyroidism, two diseases that remain underserved with the current standard of care and which disproportionately
affect women. In addition to these product candidates, we have various internal early stage research programs in other approved peptides
such as GLP-2 and hGH, as well as outside early stage collaborations to potentially diversify our revenue stream.</div>

<div style="line-height: 1.25"><br /> </div>

<div style="text-align: justify; line-height: 1.25; font-weight: bold">Pipeline</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">The following chart summarizes the current
stage of development of each of our current product candidates and their potential indications.</div>

<div style="line-height: 1.25; text-align: center"><br />

<div><img src="image00015.jpg" alt="" /></div> <br /> </div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal">7</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000" /></div>
</div>

<div style="line-height: 1.25"> <br /> </div>

<div style="text-align: center; text-indent: 14.2pt; line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-weight: bold">Our Product Candidates</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">The following table summarizes our clinical stage product candidates. We retain global
rights to both EB613 and EB612.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="line-height: 1.25">

<table cellspacing="0" cellpadding="0" border="0" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="border-top: rgb(0, 0, 0) 2px solid; width: 22%; vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid">
        <div style="line-height: 1.25; font-weight: bold">Program</div> </td>
    <td style="border-top: rgb(0, 0, 0) 2px solid; width: 1.14%; vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="border-top: rgb(0, 0, 0) 2px solid; width: 20%; vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid">
        <div style="text-align: center; line-height: 1.25; font-weight: bold">Indication</div> </td>
    <td style="border-top: rgb(0, 0, 0) 2px solid; width: 1.14%; vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="border-top: rgb(0, 0, 0) 2px solid; width: 20%; vertical-align: middle; border-bottom: rgb(0, 0, 0) 2px solid; text-align: center">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif; font-weight: bold">Stage</div> </td>
    <td style="border-top: rgb(0, 0, 0) 2px solid; width: 1.14%; vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="border-top: rgb(0, 0, 0) 2px solid; width: 35%; vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif; font-weight: bold">Status</div> </td> </tr>
  <tr>
    <td style="width: 22%; vertical-align: bottom">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 1.14%; vertical-align: bottom">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 20%; vertical-align: bottom">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 1.14%; vertical-align: bottom">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 20%; vertical-align: bottom">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 1.14%; vertical-align: bottom">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 35%; vertical-align: bottom">
        <div style="line-height: 1.25">&#160;</div> </td> </tr>
  <tr>
    <td style="width: 22%; vertical-align: middle; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif; font-weight: bold">EB613</div>
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif; font-weight: bold">Oral PTH Tablets</div> </td>
    <td style="width: 1.14%; vertical-align: bottom; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 20%; vertical-align: middle; background-color: rgb(204, 238, 255); text-align: center">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif; font-weight: bold">Osteoporosis</div> </td>
    <td style="width: 1.14%; vertical-align: bottom; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 20%; vertical-align: middle; background-color: rgb(204, 238, 255); text-align: center">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif; font-weight: bold">Phase 3</div> </td>
    <td style="width: 1.14%; vertical-align: bottom; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 35%; vertical-align: bottom; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25">Phase 2 Trial Completed (Q2 2021)</div>
        <div style="line-height: 1.25">End-of-Phase 2 Meeting with FDA (December 2021)</div>
        <div style="line-height: 1.25">Type C Meeting with FDA (October 2022)</div>
        <div style="line-height: 1.25">Type D Meeting with FDA (March 2023E)</div>
        <div style="line-height: 1.25">Phase 3 Registrational Study Initiation (H2&#8217;2023E)</div> </td> </tr>
  <tr>
    <td style="border-top: rgb(0, 0, 0) 2px solid; width: 22%; vertical-align: bottom">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="border-top: rgb(0, 0, 0) 2px solid; width: 1.14%; vertical-align: bottom">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="border-top: rgb(0, 0, 0) 2px solid; width: 20%; vertical-align: bottom">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="border-top: rgb(0, 0, 0) 2px solid; width: 1.14%; vertical-align: bottom">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="border-top: rgb(0, 0, 0) 2px solid; width: 20%; vertical-align: bottom">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="border-top: rgb(0, 0, 0) 2px solid; width: 1.14%; vertical-align: bottom">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="border-top: rgb(0, 0, 0) 2px solid; width: 35%; vertical-align: bottom">
        <div style="line-height: 1.25">&#160;</div> </td> </tr>
  <tr>
    <td style="border-bottom: rgb(0, 0, 0) 2px solid; width: 22%; vertical-align: middle">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif; font-weight: bold">EB612</div>
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif; font-weight: bold">Oral PTH Tablets</div> </td>
    <td style="border-bottom: rgb(0, 0, 0) 2px solid; width: 1.14%; vertical-align: bottom">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="border-bottom: rgb(0, 0, 0) 2px solid; width: 20%; vertical-align: middle; text-align: center">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif; font-weight: bold">Hypoparathyroidism</div> </td>
    <td style="border-bottom: rgb(0, 0, 0) 2px solid; width: 1.14%; vertical-align: bottom">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="border-bottom: rgb(0, 0, 0) 2px solid; width: 20%; vertical-align: middle; text-align: center">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif; font-weight: bold">Phase 1</div> </td>
    <td style="border-bottom: rgb(0, 0, 0) 2px solid; width: 1.14%; vertical-align: bottom">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="border-bottom: rgb(0, 0, 0) 2px solid; width: 35%; vertical-align: bottom">
        <div style="line-height: 1.25">Phase 2A Old Formulation (2015)</div>
        <div style="line-height: 1.25">Phase 2b Old Formulation PK/PD vs. Natpara (2019)</div>
        <div style="line-height: 1.25">Phase 1 PK Study of New Formulation Initiation H1&#8217;2023E</div> </td> </tr>
  </table> </div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Our lead product candidates, EB613 for the treatment of osteoporosis and EB612 for
the treatment of hypoparathyroidism are first-in-class mini tablet formulations of synthetic human PTH (1-34) (teriparatide), designed
to have differing pharmacokinetic, or PK, profiles. We believe these product candidates, if approved, have the potential to become standards
of care for patients with osteoporosis and hypoparathyroidism.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Additionally, given our expertise in oral PTH, we may investigate the efficacy of
alternative oral PTH tablets for the treatment of delayed-union or non-union fractures independently or in collaboration with a strategic
partner. Currently, no pharmacological treatments are approved to stimulate bone healing, treat delayed union fractures or treat patients
with non-union following a fracture. A number of studies suggest that PTH could be beneficial in the treatment of such fractures by potentially
accelerating union and/or reduce the risk of non-union.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-weight: bold">Our Strategy</div>

<div style="line-height: 1.25">

<div style="line-height: 1.25"><br /> </div>

<div style="text-align: justify; line-height: 1.25">Our goal is to develop first-in-class orally delivered therapies for underserved,
chronic medical conditions where a mini tablet peptide or peptide replacement therapy has the potential to significantly shift a treatment
paradigm. We are developing our product candidates to potentially become the first oral, daily mini tablet peptide or peptide replacement
therapies designed for patients to live injection-free as they actively manage their chronic diseases. We aspire to continue to validate
our platform across a variety of additional high value therapeutic proteins. Our strategy to achieve these goals includes:</div>

<div style="line-height: 1.25">&#160;</div> </div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 18pt"><br /> </td>
    <td style="width: 18pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div><span style="font-weight: bold">Advancing EB613, Potentially the First Daily Anabolic PTH Mini Tablet into Phase 3 for the Treatment
        of Post-Menopausal Women with Low Bone Mass and Osteoporosis:</span> Our six-month placebo-controlled Phase 2 double-blind, dose-ranging
        trial of EB613 in 118 patients with low bone mass and osteoporosis met both primary and secondary endpoints and was selected for oral
        presentation at the American Society of Bone Mineral Research (ASBMR) annual conference in 2021. Based on the outcome of our October 2022
        Type C meeting with the FDA, we believe that EB613 may be the first osteoporosis program to be permitted by FDA to pursue a placebo controlled,
        bone mineral density (&#8220;BMD&#8221;) endpoint registrational Phase 3 study to support a potential new drug application (&#8220;NDA&#8221;)
        pursuant to the FDA&#8217;s pathway under section 505(b)2 of the U.S. Federal Food, Drug, and Cosmetic Act. We view this outcome as testament
        to the treatment gap and unmet need for a viable alternative to treat the millions of osteoporosis patients who, despite current guidelines
        and availability of highly efficacious anabolic agents, are unwilling to take daily or monthly injections.&#160;We are planning to enable
        Phase 3 study initiation in the second half of 2023.</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 18pt"><br /> </td>
    <td style="width: 18pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div><span style="font-weight: bold">Advancing the New Formulation of EB612 Through Clinical Development as the First Daily PTH Mini Tablet
        for the Treatment of Hypoparathyroidism:</span> In 2015, we successfully completed a Phase 2a four-month trial in 19 patients with hypoparathyroidism
        which demonstrated clinical benefit, including a statistically significant reduction in calcium supplementation, maintenance of calcium
        levels above the lower target level for Hypoparathyroidism patients (&gt;7.5 mg/dL) throughout the study and statistically significant
        rapid decline of in median serum phosphate levels two hours following the first dose, which was maintained for the duration of the study.
        We expect to carry out a PK Phase 1 study for the new formulation of EB612 in the first half of 2023. The FDA and the European Medicines
        Agency, or EMA, have granted EB612 orphan drug designation for the treatment of hypoparathyroidism.</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 18pt"><br /> </td>
    <td style="width: 18pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div><span style="font-weight: bold">Establishing Select Global and Regional Development and Commercial Partnerships: </span>Our technology
        platform and intellectual property are designed to generate a pipeline of product candidates across various therapeutic indications. We
        intend to explore opportunities to diversify and shorten the preclinical and clinical development of these candidates in a capital-efficient
        manner, including selectively pursuing research and clinical development partnerships with biopharmaceutical companies with specific domain
        expertise as well as with biopharmaceutical companies with proven commercial footprints to de-risk our late-stage programs.</div> </td>
        </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal">8</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000" /></div>
</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 18pt"><br /> </td>
    <td style="width: 18pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div><span style="font-weight: bold">Identifying and Developing Additional Products Internally based on FDA-Approved Injectable Protein
        Therapeutics:</span><span style="font-weight: bold; font-style: italic">&#160;</span>We intend to leverage our technology platform by
        applying it to the development of additional approved injectable peptides and therapeutic proteins with known mechanisms of action and
        established safety profiles. We believe this will allow us to advance our product candidates more efficiently and predictably through
        the research and clinical development cycle.</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<div style="line-height: 1.25; font-weight: bold">PTH</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Parathyroid hormone (PTH) is an 84-amino acid hormone that regulates calcium and phosphate
homeostasis and bone metabolism in the body. In healthy individuals, PTH is generally produced at very low basal levels, at a blood concentration
of 15&#8201;-&#8201;25 pg/mL. On top of the basal PTH levels, there are physiological pulses two to three times per day that result in
transient increases in PTH levels reaching up to 65 pg/mL. The changes in PTH secretion are in response to ionized calcium concentrations
in the blood resulting from the entry of calcium from nutrients in the intestine and resorption of calcium from bone.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-weight: bold">PTH in Osteoporosis</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">The effects of PTH on bone depends on the duration of exposure.&#160; The physiological
pulses help encourage bone turnover through activation of both osteoblasts and osteoclasts, the two main types of cells responsible for
bone remodeling. In the absence of adequate parathyroid function producing these pulses, it is difficult for the body to regulate homeostatic
processes, and osteoporosis may ensue. The synthetic analog of PTH, human parathyroid hormone (1-34) peptide, Forteo<sup style="font-family: Symbol, serif; vertical-align: text-top; line-height: 1; font-size: smaller">&#226;</sup>
(teriparatide), has been approved in the United States and the EU (Forsteo<sup style="vertical-align: text-top; line-height: 1; font-size: smaller">&#174;</sup>)
and has been a mainstay anabolic (bone forming) therapy for the treatment of osteoporosis patients since 2002 and 2003, respectively.
Forteo&#174; requires a daily subcutaneous injection.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-weight: bold">EB613: First Daily Osteoanabolic Mini Tablets for the Treatment
of Osteoporosis</div>

<div style="line-height: 1.25">&#160;</div>

<div style="line-height: 1.25">

<div style="text-align: justify; line-height: 1.25">EB613 is the first once daily mini tablet formulation of hPTH (1-34), (teriparatide)
and has the same amino acid sequence as Forteo<sup style="font-family: Symbol, serif; vertical-align: text-top; line-height: 1; font-size: smaller">&#226;</sup>
(teriparatide daily subcutaneous injection), a leading anabolic agent which achieved peak annual sales of $1.7 billion prior to patent
expiration.</div> </div>

<div style="line-height: 1.25"> <br /> </div>

<div style="line-height: 1.25"><img src="image00016.jpg" alt="" /></div>

<div style="line-height: 1.25"><br /> </div>

<div style="text-align: justify; line-height: 1.25">Osteoporosis is a disease characterized by low bone mass and structural deterioration
of bone tissue, which leads to greater fragility of bones and an increase in fracture risk. Osteoporosis is most frequently associated
with menopause in women, aging in both women and men and glucocorticoid steroid use (greater than three months). The bone remodeling cycle
can be separated into two distinct processes: (i) bone resorption, where cells called osteoclasts function in the resorption of mineralized
tissue; and (ii) bone formation, where cells called osteoblasts are responsible for bone matrix synthesis and subsequent mineralization
of the bone. In healthy individuals, bone resorption is matched by new bone formation. Osteoporosis develops as the balance between bone
resorption by osteoclasts and bone formation by osteoblasts is not maintained, and not enough bone tissue is formed, leading to frail
and fracture-prone bones.</div>

<div style="line-height: 1.25">&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal">9</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000" /></div>
</div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">Prevalence</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">The Bone Health &amp; Osteoporosis Foundation (formerly named the National Osteoporosis
Foundation) estimates that 10.2 million Americans have osteoporosis and that an additional 40 million have low bone mass.&#160;More than
two million osteoporosis-related fractures occur annually in the United States and more than 70% of these occur in women. In U.S. women
55 years of age and older, the hospitalization burden, including hospital costs of osteoporotic fractures is greater than that of myocardial
infarction, stroke, or breast cancer. Furthermore, it&#160; estimated that the number of fractures in the United States due to osteoporosis
will rise to three million by 2025, resulting in an estimated $25.3 billion in costs each year. Worldwide, osteoporosis affects an estimated
200 million women, according to the International Osteoporosis Foundation, or IOF, and causes more than 8.9 million fractures annually,
which is equivalent to an osteoporotic fracture occurring approximately every three seconds. The IOF has estimated that 1.6 million hip
fractures occur worldwide each year, and by 2050 this number could reach between 4 to 6 million. The IOF estimates that, in Europe alone,
the annual cost of osteoporotic fractures could surpass &#8364;76 billion by 2050.&#160;</div>

<div style="line-height: 1.25"><br /> </div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">Current Osteoporosis Treatment Paradigm</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25"><img src="image00017.jpg" alt="" /></div>

<div style="line-height: 1.25">&#160;</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">The goal of pharmacological treatment of osteoporosis is to maintain or increase bone
mass and strength and to prevent fractures throughout a patient&#8217;s life. Ensuring that nutrients important to bone health is vital
to the prevention and treatment of osteoporosis, and calcium and vitamin D<sub style="vertical-align: bottom; line-height: 1; font-size: smaller">3</sub>
supplements are often required to achieve that goal. However, many patients with osteoporosis require prescription drug therapy to reduce
their risks of fractures. It is critical to identify patients who have significant bone loss. Pharmacologic therapy is strongly recommended
for patients with a T-score of -2.5 or lower in the spine, femoral neck, total hip, or 1/3 radius.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Osteoporosis drugs may be divided into two categories: antiresorptive and anabolic.
Drugs that inhibit bone resorption include oral and injectable options such as estrogen (for postmenopausal women), oral and intravenous
bisphosphonates, selective estrogen receptor modulators (SERMs), the RANK-ligand inhibitor (denosumab) and (salmon) calcitonin. The three
currently approved osteoanabolic drugs that stimulate bone formation all require daily or monthly subcutaneous injections: teriparatide
(hPTH[1-34]); abaloparatide (a PTH-related protein analog); and romosozumab (an antibody that inhibits sclerostin and also inhibits bone
resorption).&#160; There are currently no FDA-approved oral anabolic treatments for osteoporosis.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">One substantial limitation of currently approved anabolic therapies is that osteoporotic
patients often report that the injections are inconvenient and occasionally painful. Many are unwilling to use injections even when their
physicians recommend it.&#160; In a recent review of bone anabolic drugs, the need for subcutaneous administration was cited as a major
reason for why anabolic medications are not a first-line treatment choice for osteoporosis. Thus, we believe that there is a substantial
need for a more generally acceptable oral anabolic alternative with bioavailability adequate to produce therapeutic effects.</div>

<div style="line-height: 1.25">&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal">10</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000" /></div>
</div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">Classification and Guidelines</div>

<div style="line-height: 1.25">&#160;</div>

<div style="line-height: 1.25"><img src="image00018.jpg" alt="" /></div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">According to the AACE 2020 Guidelines, injectable anabolic agents, such as teriparatide,
abaloparatide or romosozumab, can be considered as initial therapy for patients who are at very high fracture risk (which include women
who have had multiple vertebral fractures or hip fractures and high risk patients who have very low T-scores), and who have had an inadequate
response to antiresorptive therapies. For patients undergoing treatment, stable or increasing BMD at the spine and hip indicates a satisfactory
response. If BMD decreases significantly, patients should be evaluated for noncompliance, among other factors.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25"><img src="image00020.jpg" alt="" /></div>

<div style="line-height: 1.25"><br /> </div>

<div style="text-align: justify; line-height: 1.25">In July 2022, we engaged a third-party firm to conduct primary market research with
endocrinologist and general practice clinicians who treat osteoporosis patients and to analyze prescription and sales data for osteoporosis
treatments. According to IQVIA, reported sales and qualitative surveys, it is estimated that less than 10% of osteoporosis patients use
current anabolic drugs (including the injectable PTH receptor activators currently available).</div>

<div style="line-height: 1.25">&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal">11</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000" /></div>
</div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">Phase 1 Safety, PK and PD Data for Entera Oral
PTH Tablet Programs</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Our Oral PTH formulations, including EB613 and EB612, have been administered collectively
to a total of 72 healthy subjects in two Phase 1 studies. In the first Phase 1a study of 42 healthy subjects, escalating single doses
of oral PTH tablets containing up to 1.8&#160;mg of hPTH(1-34) were well tolerated. There were no serious adverse events (SAEs) reported.
In the subsequent Phase 1b study of 30 healthy subjects, single doses of five formulations of oral PTH tablets containing up to 3&#160;mg
of hPTH(1-34), administered collectively a total of 280 times (up to 14 times per person) were well tolerated, with no SAEs reported.
Adverse events considered by the investigator as possibly or probably drug-related were all transient and mild and included mild hypercalcemia
(calcium of 2.56, 2.62 mmol/L, both levels went back to normal within one hour) (N=2), mild tachycardia (N=3), headache (N=2), nausea
(N=1), anemia (N=1), and mild knee cramp (N=1).</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">In the Phase 1 studies in healthy subjects, the PK profile of EB613 daily tablets
was characterized by a rapid increase in plasma hPTH(1-34) levels, with peak concentrations of the drug observed within 30 minutes after
dose, with a rapid decline thereafter. The blood half-life of hPTH(1-34) in humans is less than five minutes (see Forteo&#174; USPI).
Due to this very short elimination time and a short absorption phase, hPTH(1&#8209;34) levels decrease below limit of quantitation within
two hours after the 0.5 mg x3 dose (1.5 mg hPTH[1&#8209;34]) thus no drug accumulation is expected with once daily tablet dosing. Total
systemic exposure (AUC) following the administration of three 0.5 mg EB613 daily tablets (as were tested in Phase 2) was similar to that
of a 0.02 mg subcutaneous injection of Forteo&#174;.</div>

<div style="line-height: 1.25"><br /> </div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">EB613 Phase 2 Study in Post-Menopausal Women
with Low Bone Mass and Osteoporosis</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25"><img src="image00021.jpg" alt="" /></div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">The Phase 2 clinical trial of EB613 was a dose-ranging, placebo-controlled, double-blind
study in 161 postmenopausal women with osteoporosis or low BMD conducted at four leading medical centers in Israel. The trial evaluated
0.5 mg to 2.5 mg daily tablets on BMD, pharmacodynamic bone markers, including P1NP and Osteocalcin - bone formation markers, CTX - a
bone resorption marker, and various safety&#160;endpoints.&#160;The initial treatment regimen included a top dose of 1.5 mg.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">A planned limited interim analysis of the first 80 patients indicated that a dose
higher than 1.5 mg could produce greater effects on bone formation.&#160; A 2.5 mg dose was added, and enrollment of new patients in the
0.5 and 1.0 mg groups was ended. After orthostasis, an adverse event (AE), typical across PTH receptor activating agents, was observed
in patients initiating the constant 2.5 mg dose, the protocol was subsequently amended to introduce a titration regimen whereby patients
received 1.5 mg for one month, 2.0 mg for the next month and 2.5 mg during the remaining four months.&#160; There were no reported drug-related
SAEs. All adverse events were mild or moderate in intensity.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-style: italic">Safety</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">The most common drug-related adverse events associated with the discontinuation of
the Phase 2 clinical study&#8217;s medication were headache, nausea, dizziness and presyncope. There were no treatment emergent hypercalcemia
adverse events, and serial serum chemistry evaluations found no increase in group mean calcium or changes in calcium exceeding predefined
limits in patients treated with EB613 2.5 mg daily tablets. Only one subject in the EB613 2.5 mg titrated group did not tolerate 2.5 mg
but continued in the study and was asymptomatic with a reduced 1.5 mg dose.</div>

<div style="line-height: 1.25">&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal">12</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000" /></div>
</div>

<div style="line-height: 1.25"><br /> </div>

<div style="text-align: justify; line-height: 1.25; font-style: italic">Bone Biomarkers (PD Effect)</div>

<div style="line-height: 1.25">&#160;</div>

<div style="line-height: 1.25">

<div style="text-align: justify; line-height: 1.25">The primary bone biomarker endpoint of the Phase 2 clinical study&#8212;change in
P1NP at Month 3&#8212;was met. Statistically significant increases were observed in P1NP (key anabolic marker) at Month 1 (p&lt;0.001),
Month 2 (p&lt;0.005) and Month 3 (p&lt;0.05) for the 2.5 mg EB613 dose group. Similar to the increase in P1NP, a significant increase
in Osteocalcin was also observed in the 2.5 mg group after 3 months (P &lt;0.01). A statistically significant decrease also occurred in
Serum CTX (marker of resorption) from baseline to Month 6 (p&lt;0.01).</div> </div>

<div style="line-height: 1.25"> <br /> </div>

<div style="line-height: 1.25"><img src="image00022.jpg" alt="" />

<div><br /> </div> </div>

<div style="text-align: justify; line-height: 1.25">The decrease in bone resorption (CTX) resulting from EB613 daily tablets was unanticipated
based on historical results from subcutaneously daily injectable PTH, Forteo&#174;; however, we believe that this was a potentially positive
development, reflecting a lower rate of bone turnover. The finding of no increase in P1NP after three months and decreased bone resorption
that persists through six months may indicate that the &#8220;anabolic window&#8221; remains open after six months of treatment with EB613.
Clinical trials have shown that early changes in biomarkers of bone formation and resorption are associated with long-term BMD changes
in women taking antiresorptive or anabolic drugs. Furthermore, significant dose response was observed for 0.5, 1.0, 1.5 and 2.5 mg of
EB613 on P1NP, Osteocalcin.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-style: italic">Bone Mineral Density</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Dose-related changes in BMD were also observed at the total hip (TH), femoral neck
(FN) and lumbar spine (LS) locations with a linear regression showing a statistically significant dose response at all sites; TH (p=0.008),
FN (p=0.001), and LS (p&lt;0.0001).</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">The placebo-adjusted increases in TH BMD (1.84%) and FN BMD (2.76%) for the pooled
(titrated and non-titrated) 2.5 mg EB613 daily tablets were both statistically significant (P&lt;0.02 and P&lt;0.002, respectively). The
increases in proximal femoral BMD (TH and FN) after six months of EB613 daily tablet treatment were unanticipated given that the reported
subcutaneous Forteo&#174; injection increases are typically small and not significant (TH 0.1% and FN 0.3% p=NS (Leder, 2015) at six months.
The placebo-adjusted increase in LS BMD was 3.78% in the EB613 2.5 mg non-titrated dose group. This increase compares to the 3.9% placebo-adjusted
increase versus placebo seen in a previously reported study (Leder, 2015). Increases in TH (2.07%) and FN (2.92%) BMD in the 2.5 mg EB613
daily tablet titrated group were greater than those previously reported with Forteo&#174;&#65039; at six months (0.1% and 0.3%) (Leder,
2015).</div>

<div style="line-height: 1.25">&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal">13</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000" /></div>
</div>

<div style="line-height: 1.25"><br /> </div>

<div style="line-height: 1.25"><img src="image00023.jpg" alt="" /></div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">The results of the Phase 2 study supported the selection of the 2.5 mg dose with a
titration regimen to be used in the proposed pivotal Phase 3 study of EB613.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">FDA End of Phase 2 Meeting (EOP2) and Phase
3 Plans</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">After successful completion of the Phase 2 dose ranging study of EB613, we held an
end-of-Phase 2 meeting at the end of 2021 with the FDA to discuss various aspects of our nonclinical and clinical development plan. The
meeting focused on the potential use of BMD, rather than fracture incidence, as the primary endpoint, and a 12-month non-inferiority head-to-head
study versus Forteo&#174; phase 3 study design to support an NDA under the 505(b)2 regulatory pathway.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Early in the first quarter of 2022, Entera received EOP2 minutes from the FDA, suggesting
that a non-inferiority head-to-head study versus Forteo&#174; Phase 3 design may not be favorable to the success of the study and potential
approvability of EB613 oral PTH tablets. The agency also commented on a possible exploration of a placebo controlled phase 3 study and
a potential Total Hip (TH) BMD endpoint given recently published 24-month Surrogate Threshold Effects (STEs) that are considered associated
with fracture risk reduction .</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">We subsequently requested an additional EOP2 to the FDA to seek agreement on the specifications
and control of the drug substance, drug product and excipients to support the Phase 3 study and eventual product registration. The meeting
request was granted, and we received a written response from the FDA towards the end of the first quarter of 2022, confirming that the
specifications for the drug substance, excipients and drug product appear reasonable and that final determination on the adequacy of the
proposed excipients and drug product specification will be made during the NDA review. The FDA also provided guidance regarding the proposed
process scale-up, process qualification approach and stability plan for EB613.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">FDA Type C Meeting</div>

<div style="line-height: 1.25">

<div style="line-height: 1.25"><br /> </div>

<div style="text-align: justify; line-height: 1.25">In July 2022, we announced that the FDA had granted our request for a Type C meeting
based on the revised phase 3 registrational study plan for EB613. In October 2022, we announced the successful conclusion of our Type
C meeting and the FDA&#8217;s agreement that a single Phase 3 placebo-controlled study could support a NDA submission of EB613 oral PTH
tablets under the 505(b)(2) regulatory pathway.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">The FDA also agreed (i) that TH BMD could serve as the primary endpoint for the registrational
study of EB613 in post-menopausal women patients diagnosed with osteoporosis, (ii) with the proposed 2:1 randomization (EB613 vs. placebo)
design and (iii) that 400 patients exposed to EB613 would be sufficient to support both the safety and efficacy assessments for the NDA.
Furthermore, the FDA agreed with our proposed enrollment of post-menopausal women diagnosed with osteoporosis based on a BMD T-score of
&#8804;-2.5 to -3.0 and no major fracture history. This patient population is consistent with that studied during our Phase 2 six-month
dose ranging study of EB613, which met all primary and key secondary endpoints of biochemistry and BMD. Finally, we agreed to submit relative
PK data, comparing EB613 versus the subcutaneous injection of teriparatide, Forteo&#174; to support a NDA under the 505(b)2 regulatory
pathway.</div>

<div style="line-height: 1.25">&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal">14</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000" /></div>
</div>

<div style="line-height: 1.25"> <br /> </div> </div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">FDA Type D Meeting</div>

<div style="line-height: 1.25">&#160;</div>

<div style="line-height: 1.25">

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif; font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none">In
February 2023, we announced that a Type D meeting protocol review had been accepted by the FDA to provide responses by&#160;March 30th,
2023. The pivotal, Phase 3 study protocol is entitled &#8220;A 24-Month Phase 3, Randomized, Double-Blind, Global Multicenter Study Comparing
the Effects of Oral hPTH(1-34) (EBP05[EB613]) Daily Tablets vs. Placebo on Bone Mineral Density (BMD) in Postmenopausal Women with Osteoporosis.&#8221;
The objective of the Type D meeting review is to confirm that the protocol fully meets FDA&#8217;s expectations, including the analysis
of the primary endpoint and the population PK evaluations, ahead of potential initiation of the Phase 3 study in the second half of 2023.
<br /> </div>

<div style="line-height: 1.25">&#160;</div> </div>

<div style="line-height: 1.25; font-weight: bold">EB612: First Daily PTH Replacement Therapy Tablets for the Treatment of Hypoparathyroidism</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Hypoparathyroidism is a rare condition in which the body either fails to produce sufficient
amounts of PTH or the PTH produced lacks normal biologic activity. Individuals with a deficiency of parathyroid hormone may exhibit hypocalcemia
and hyperphosphatemia. Hypocalcemia can cause weakness, muscle cramps, excessive nervousness, headaches and uncontrollable twitching and
tetany. Hyperphosphatemia can result in soft tissue calcium deposition, which may lead to severe issues, including damage to the circulatory
and central nervous systems. The most common cause of hypoparathyroidism is damage to, or removal of, the parathyroid glands due to surgery
for another condition.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">PTH in Hypoparathyroidism</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">In contrast to osteoporosis, longer persistence of PTH in plasma is a desirable property
for the treatment of hypoparathyroidism. Here hormone replacement therapy is warranted.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">Prevalence</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25"><img src="image00024.jpg" alt="" /></div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">It is estimated that hypoparathyroidism affects approximately 200,000 people across
the United States, the European Union and Japan, with approximately 43% of cases characterized as mild, 39% characterized as moderate,
and 18% characterized as severe.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">Limitations of current treatments for hypoparathyroidism</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Historically, the treatments for hypoparathyroidism have been calcium supplements,
vitamin D supplements and phosphate binders. Although calcium and vitamin D can help alleviate hypocalcemia, their chronic use can result
in many serious side effects. Hypoparathyroid patients often need to take large doses of calcium throughout the day in order to maintain
serum calcium near the lower limit of the normal range. Moreover, ordinary vitamin D is generally insufficient, as the body cannot produce
adequate quantities of 1,25-dihydroxy vitamin D, the active hormone derived from vitamin D. Drugs like calcitriol and alfacalcitol must
often be prescribed to stimulate calcium absorption. If excess calcium is absorbed, it then falls upon the kidneys to dispose of excess
calcium. Endogenous PTH normally regulates renal calcium excretion, but this regulation is defective in patients with hypoparathyroidism.
Over many years of treatment, kidney stones may develop, and kidney failure may ultimately occur due to either kidney stones or deposition
of calcium phosphate in kidney tissue (called nephrocalcinosis). Despite the use of calcium and vitamin D supplements and other medications,
many patients with hypoparathyroidism continue to experience physical and cognitive symptoms.</div>

<div style="line-height: 1.25">&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal">15</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000" /></div>
</div>

<div style="text-align: justify; line-height: 1.25">An injectable form of full length human PTH (1-84) marketed under the name Natpara&#174;,
was approved for the treatment of hypoparathyroidism in 2015. However, it was recalled in 2019 due to a plastic particulate and will be
permanently phased out globally by the end of 2024. There are two injectable PTH candidates for hypoparathyroidism undergoing clinical
development: TransCon&#8482; PTH developed by Ascendis Pharma (PDUFA date of&#160;April 30, 2023, for adults with hypoparathyroidism;
European MAA decision expected in the fourth quarter of 2023) and Eneboparatide, a parathyroid hormone receptor 1 (PTHR1) agonist developed
by Amolyt Pharma (Phase 3 initiation expected in the first half of 2023). Both TransCon&#8482; PTH and Eneboparatide require a daily subcutaneous
injection.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">EB612</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Our product candidate for hypoparathyroidism, EB612, is the first oral formulation
of PTH (1-34, teriparatide) hormone replacement treatment developed in a mini tablet form. The FDA and the EMA have granted EB612 orphan
drug designation for the treatment of hypoparathyroidism. We believe that EB612 may have inherent advantages compared to injectable forms,
including convenience of administration without any special preparation of the medication, as well as convenience of storage (room temperature
or refrigeration for long term storage).</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">Phase 2a Clinical Trial</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">In 2015, we successfully completed a multicenter Phase 2a clinical trial of EB612
in hypoparathyroidism patients. This study demonstrated the safety and tolerability of EB612 administered four times daily for 16 weeks
to patients with hypoparathyroidism. In this study, patients were titrated up to a maximum of 12 EB612 0.75 mg tablets a day (total daily
dose of 9 mg) according to each subject&#8217;s albumin-adjusted serum calcium (ACa), and supplement treatment regimen. Of the 19 enrolled
patients, 17 completed the trial. No drug-related serious adverse events were reported and most of the adverse events were not considered
study drug-related. The study achieved its primary and secondary endpoints, including a reduction in calcium supplements, reductions in
serum phosphate and 24-hour urine calcium excretion, maintenance of ACa within the reference range, and an improvement in quality of life.
Specific results of this trial included:</div>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 18pt"><br /> </td>
    <td style="width: 18pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>A significant reduction of 42% (p=0.001) from baseline in median calcium supplement use;</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 18pt"><br /> </td>
    <td style="width: 18pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>Maintenance of median ACa levels above the lower target level for HypoPT patients (&gt;7.5 mg/dL) throughout the study;</div> </td>
        </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 18pt"><br /> </td>
    <td style="width: 18pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>A rapid decline of 23% (p=0.0003) in median serum phosphate levels 2 hours following the first dose that was maintained within the
        normal range for the duration of the study;</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 18pt"><br /> </td>
    <td style="width: 18pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>A notable median decrease of 21% (p=0.07) in 24-hour urine calcium excretion between the first and last treatment days; and</div>
        </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 18pt"><br /> </td>
    <td style="width: 18pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>An increase in quality of life score of 5% (p=0.03) from baseline by the end of the treatment period.</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">Phase 2 PK/PD Clinical Trial</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">We initiated a two-part Phase 2 PK/PD trial in 2014. This trial was designed to provide
a bridge from one of our completed Phase 2a trials, which was conducted prior to the marketing approval of Natpara, and our planned future
clinical trials, and to also allow us to better understand the relative strength and dose of our product as compared to the then marketed
product, Natpara. The relevant endpoints for the PK/PD trial included an examination of levels of PTH (1-34), PTH (1-84) (Natpara), serum
calcium, serum phosphate, urinary calcium and urinary phosphate.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">In November 2018, we announced the completion of part I of this Phase 2 PK/PD trial
which showed (i) an increase in the serum calcium by an average of approximately 0.3 mg/dL over baseline, with such increase maintained
over a 24-hour period; (ii) a decrease in serum phosphate by an average of 0.5 mg/dL below baseline with such decrease maintained over
a 24-hour period; (iii) an increase in average levels of serum active vitamin D of approximately 90% on the day of treatment as compared
to baseline; and (iv) a decrease in average levels of 24-hour urinary calcium of approximately 30% on the day of treatment as compared
to baseline. The concentration of PTH (1-34) in blood after administration of Oral PTH (1-34) in the trial was sufficient to produce the
observed pharmacodynamic effects and did not induce hypercalcemia. No serious adverse events were reported.</div>

<div style="line-height: 1.25">&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal">16</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000" /></div>
</div>

<div style="text-align: justify; line-height: 1.25">The second part of the PK/PD trial evaluated a variety of dosing treatment regimens
with a high and low dose of EB612 as well as Natpara with patients also receiving calcium supplements and either alfacalcidol or calcitriol.
There were no treatment-emergent adverse events of hypercalcemia, as well as no treatment-emergent serious adverse events reported in
the trial. In September 2019, we presented the results of Part 2 at the American Society for Bone and Mineral Research (ASBMR) Annual
Meeting.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">Planned Additional Clinical Development and
Regulatory Pathway</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">We have since developed an improved formulation of EB612 based on new intellectual
property, which we have designed to optimize its PK profile and the potential for reduced daily dosing. We expect to carry out a PK study
for the new formulation of EB612 in the first half of 2023. We anticipate that the outcome of the PK study will help determine the design
of a Phase 2/3 trial of EB612 in patients with hypoparathyroidism. If successful, the phase 2/3 clinical trial of EB612 in hypoparathyroidism
may potentially support a submission for regulatory approval of EB612.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-weight: bold">Our Technology</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25"><img src="image00025.jpg" alt="" /></div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">We are focused on the development and commercialization of product candidates that
leverage our proprietary platform technology for the oral delivery of large molecule therapeutics, including peptides and therapeutic
proteins. Historically, peptides, proteins and other large molecule therapeutics have typically been delivered via frequent and often
painful injections because oral administration leads to poor absorption into the blood stream (bioavailability) due to enzymatic degradation
within the gastrointestinal tract and poor permeability though the intestinal wall.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Our proprietary technology is designed to address both issues by utilizing a combination
of a synthetic absorption enhancer, or carrier molecule, to facilitate the enhanced absorption of large molecules, and protease inhibitors
to prevent enzymatic degradation. By designing our product candidates to address both the issues of absorption and degradation, we have
been able to significantly increase bioavailability and decrease the variability of the PTH dose delivered in our clinical trials to date.
The carrier molecule enables transport across the intestinal membrane via transcellular absorption without compromising the integrity
of the intestinal wall. Because of the weak association between the carrier molecule and the therapeutic agent, the interaction is designed
to be reversible and occurs spontaneously by simple dilution on entering the blood. We select protease inhibitors and other excipients
that act by specifically inhibiting several gastrointestinal enzymes designed to assist in the degradation and digestion of proteins without
interfering with normal gastrointestinal activity.</div>

<div style="line-height: 1.25">&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal">17</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000" /></div>
</div>

<div style="text-align: justify; line-height: 1.25; font-weight: bold">Development and License Agreements</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">In addition to the development of our product candidates, we have an early stage research
collaboration and license agreement with Amgen, Inc. (&#8220;Amgen&#8221;) centered on combining our proprietary drug delivery platform
with drugs selected by Amgen to create new products. In January 2019, we received a non-refundable and non-creditable initial technology
access fee of $725,000 from Amgen, of which $500,000 was attributed to the right to use our intellectual property, and $225,000 was attributed
to the pre-clinical R&amp;D services that we are obligated to perform under the agreement. We are eligible to receive from Amgen aggregate
payments of up to $270 million upon achievement of various clinical and commercial milestones or at Amgen&#8217;s exercise of options
to select up to two additional programs to include in the collaboration, as well as tiered royalty payments. Through December 31, 2022,
we had received an aggregate of $968,000 from Amgen for research and development services.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-weight: bold">Intellectual Property</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Our success depends in part on our ability to protect the proprietary nature of our
product candidates, technology, and know-how; operate without infringing on the proprietary rights of others and preventing others from
infringing on our proprietary rights. We seek to protect our proprietary position by, among other methods, seeking patent protection in
the United States and in certain other jurisdictions for our product candidates and other technology that we consider important to the
development of our business, where such protection is available. We believe that our success will depend in part on our ability to obtain
patent protection for our intellectual property. We also intend to rely on trade secret protection, know-how and the exploitation of in-licensing
opportunities to develop our proprietary position.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">Patent Rights</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">As of March 27, 2023, our global patent portfolio included the following patents and
patent applications:</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Patents claiming compositions comprising a protein, an absorption enhancer and a protease
inhibitor as well as methods for oral administration of a protein with an enzymatic activity, which compositions cover EB612 and EB613,
have been issued in the United States, Australia, Japan, China, Hong Kong, Israel, Canada, New Zealand and Russia and have been granted
by the European Patent Office (EPO) and validated accordingly in Belgium, France, Germany, Great Britain, Ireland, Italy, Liechtenstein,
Luxembourg, Netherlands, Spain, Sweden, and Switzerland. Related patent applications are pending before the European Patent Office (EPO)
and in the United States, Hong Kong, Brazil, China and India. Patents specifically covering PTH have already been granted in the United
States, Hong Kong, Israel, Russia and Japan, and have been granted by the EPO and validated in Belgium, France, Germany, Great Britain,
Ireland, Italy, Liechtenstein, Luxembourg, Netherlands, Spain, Sweden, and Switzerland. In addition, patent applications which specifically
cover PTH are currently pending in Hong Kong, Brazil, China and India. The current issued patent in China is limited to insulin. This
issued patent and any patent that may issue from the pending patent applications are currently expected to expire in August 2029, assuming
all annuity and maintenance payments are paid thereon. Rights to these patents and patent applications were assigned to us pursuant to
the Patent Transfer Agreement with Oramed.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Three patent families filed in various jurisdictions, which we believe, if issued
as patents containing substantially the same claims as those in the applications, would cover certain oral administration technologies.
The mentioned technologies include compositions and drug delivery devices which utilize an absorption enhancer to enable the absorption
of a therapeutically active agent in a controlled manner. We believe that certain of the pending claims contained in these patent applications,
if issued in substantially the same form, would cover the formulations of EB612 and EB613. Patent applications covering certain formulations
with a controlled absorption profile were filed with the EPO and in the United States, Canada, Hong Kong, Israel and Mexico (the application
filed in Israel has matured into a patent and a divisional application has been filed therein). Other patent applications covering certain
formulations for co-administration with an antacid or protease inhibitor were filed with the EPO and in the United States, Canada and
Hong Kong (the application in the United States has matured into a patent, and a divisional application has been filed therein). Any patents
that issue from these patent applications are expected to expire in February 2036, assuming all annuity and maintenance payments are paid
thereon. Patent applications covering certain formulations and regimens were filed with the EPO and in the United States, Australia, Brazil,
Canada, China, Hong Kong, India, Israel, Japan, Mexico, New Zealand, Singapore, South Africa and South Korea (the application filed in
New Zealand has matured into a patent). Any patents that issue from this patent application are expected to expire in August 2037, assuming
all annuity and maintenance payments are paid thereon.</div>

<div style="line-height: 1.25">&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal">18</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000" /></div>
</div>

<div style="text-align: justify; line-height: 1.25">Three patent families were filed in various jurisdictions, which we believe, if issued
as patents containing substantially the same claims as those in the applications, would contain method of treatment claims covering the
use of orally administered PTH for the treatment of osteoporosis (filed with the EPO and in the United States, Canada, China, Hong Kong,
Israel and Japan; the applications in Japan and Israel have matured into patents, and a divisional applications has been filed therein),
hypoparathyroidism (filed with the EPO and in the United States, Brazil, Canada, Hong Kong, Israel and Japan; the applications in Japan
and Israel have matured into patents, and divisional applications have been filed therein) and bone fractures and related conditions (filed
with the EPO and in the United States, Canada and Hong Kong). Any patents that issue from these patent applications are expected to expire
in February 2036, assuming all annuity and maintenance payments are paid thereon, and while not considering patent term extension when
applicable.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Seven international PCT patent applications have been filed in 2023, which we believe,
if issued as patents containing substantially the same claims as those in the applications, would cover new discoveries for the oral delivery
of large molecules. Any patents that issue from these patent applications are expected to expire in February 2043, assuming all annuity
and maintenance payments are paid thereon and while not considering patent term extension when applicable.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">The term of individual patents depends upon the legal term for patents in the countries
in which they are granted. In most countries, including the United States, the patent term is generally 20 years from the earliest claimed
filing date of a non-provisional patent application in the applicable country. In the United States, a patent&#8217;s term may, in certain
cases, be lengthened by patent term adjustment, which compensates a patentee for administrative delays by the USPTO in examining and granting
a patent or may be shortened if a patent is terminally disclaimed over a commonly owned patent or a patent naming a common inventor and
having an earlier expiration date. The Hatch-Waxman Act, permits a patent term extension of up to five years beyond the expiration date
of a U.S. patent as partial compensation for the useful patent term lost, if any, during the FDA regulatory review process. However, a
patent term extension cannot extend the remaining term of a patent beyond a total of 14 years from the date of the product&#8217;s approval
by the FDA. The patent term extension period is generally one-half the time between the effective date of the IND and the submission date
of the NDA for the product, plus the time between the submission date of the NDA and the approval of the application. Only one patent
applicable to an approved drug is eligible for the extension and the application for the extension must be submitted prior to the expiration
of the patent. Only those claims covering the approved drug, a method for using it or a method for manufacturing it may be extended. Moreover,
we may not receive an extension because of, for example, failing to apply within applicable deadlines, failing to apply prior to expiration
of relevant patents or otherwise failing to satisfy applicable requirements. Similar provisions are available in the EU and certain other
foreign jurisdictions to extend the term of a patent that covers an approved drug. However, the length of any extension, if granted, could
be less than we request.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">Trade Secrets</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">In addition to patent rights, we also rely on unpatented trade secrets and know-how
to protect our proprietary technology. However, trade secrets can be difficult to protect. We seek to protect our proprietary technology,
in part, by entering into confidentiality agreements with our employees, consultants, contractors, manufacturers, outside scientific collaborators
and sponsored researchers, members of our board of directors, technical review board and other advisors upon their engagement. These agreements
generally provide that all confidential information developed or made known to the individual during the individual&#8217;s relationship
with us is to be kept confidential and not to be disclosed to third parties except in specific limited circumstances. We also generally
require signed confidentiality or material transfer agreements from any company that is to receive our confidential information. In the
case of employees, consultants, and contractors, the agreements also generally provide that all inventions conceived by the individual
while rendering services to us shall be assigned to us as our exclusive property. There can be no assurance, however, that we have entered
into agreements with all applicable parties, that all persons who we desire to sign such agreements will sign, or if they do, that such
agreements will not be breached, that we would have adequate remedies for any breach, or that our unpatented trade secrets or know-how
will not otherwise become known or be independently developed by competitors. Additionally, to the extent that our commercial partners,
collaborators, employees, and consultants use intellectual property owned by others in their work for us, disputes may arise as to the
rights in related or resulting know-how and inventions. For this and a more comprehensive discussion of risks related to our intellectual
property, see &#8220;Item 1A.-Risk Factors-Risks Related to Our Intellectual Property.&#8221;</div>

<div style="line-height: 1.25">&#160;</div>

<div style="line-height: 1.25; font-weight: bold">Commercialization Strategy</div>

<div style="line-height: 1.25">

<div style="line-height: 1.25"><br /> </div>

<div style="text-align: justify; line-height: 1.25">We hold global rights to all of our internally developed product candidates (including
EB613 and EB612), which provide us the optionality to grow our internal pipeline independently or license selected rights to our product
candidates in different geographies or throughout the world. We aim to maximize the value of our product candidates by either independently
commercializing our products in one or more major geographies by building an internal sales and marketing organization, or by seeking
collaborations with third parties with commercialization infrastructure, in either case subject to applicable regulatory approval.</div>

<div style="line-height: 1.25">&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal">19</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000" /></div>
</div>

<div style="line-height: 1.25"><br /> </div> </div>

<div style="text-align: justify; line-height: 1.25; font-weight: bold">Competition</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">The medical and pharmaceutical industries in which we operate are highly competitive
and subject to rapid and significant technological change and changes in practice. While we believe that our technology, knowledge, experience
and scientific resources provide us with competitive advantages, we face competition from many different sources, including large pharmaceutical,
specialty pharmaceutical, biotechnology, and generic drug companies and academic and government institutions. We believe that the key
competitive factors that will affect the development and commercial success of our oral PTH product candidates for osteoporosis, hypoparathyroidism,
non-union fractures, and any other product candidates that we develop, are the efficacy, safety and tolerability profile, convenience
in dosing, product labeling, price and availability of reimbursement from the government and other third-parties. Our commercial opportunity
could be reduced or eliminated if our competitors have products that are better in one or more of these categories.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">We expect that, if approved, our oral PTH product candidates for osteoporosis, hypoparathyroidism,
non-union fractures, and other product candidates that we develop, would compete with a number of existing products. Furthermore, we believe
that we face competition in relation to our oral drug delivery platform, as we believe that other non-invasive medical drug delivery technologies,
including alternative oral delivery systems as well as transdermal patches, are being developed by other parties. Many of our potential
competitors have substantially greater financial, technical, commercial and human resources than we do and significantly more experience
in the discovery, development and regulatory approvals of product candidates, and the commercialization of those products. Accordingly,
our competitors may be more successful than us in obtaining FDA approval for product candidates and achieving widespread market acceptance.
See &#8220;Item 1A.-Risk Factors-Risks Related to Commercialization of Our Product Candidates.&#8221;</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-weight: bold">The Israeli Innovation Authority (IIA) Grants</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">We have received grants of approximately $0.5 million from the IIA to partially fund
our research and development. The grants are subject to certain requirements and restrictions under the Israeli research law, which we
refer to as the Research Law. In general, until the grants are repaid with interest, royalties are payable to the Israeli government in
the amount of 3% on revenues derived from sales of products or services developed in whole or in part using the IIA grants, including
EB613, EB612 and any other oral PTH product candidates we may develop. The royalty rate may increase to 5%, with respect to approved applications
filed following any year in which we achieve sales of over $70 million.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">

<div style="line-height: 1.25">The amount that must be repaid may be increased up to six times the amount of the grant received plus interest.
The rate of royalties may be accelerated, and the royalty liability may increase (up to three times the amount of the grant amount and
the interest) if manufacturing of the products developed with the grant money is transferred outside of the State of Israel. As of December
31, 2022, the total royalty amount that would be payable by the Company to the IIA, before interest and payments as described above, is
approximately $460 thousand. Through December 31, 2022, we had paid royalties in the amount of $83 thousand to the IIA.</div>

<div style="line-height: 1.25">&#160;</div> </div>

<div style="text-align: justify; line-height: 1.25">In addition to paying any royalties due, we must abide by other restrictions associated
with receiving such grants under the Research Law that continue to apply even following repayment to the IIA. These restrictions may impair
our ability to outsource manufacturing, engage in change of control transactions or otherwise transfer our &#8220;know-how&#8221; (in
its meaning under the Research Law) in or outside of Israel, and may require us to obtain the approval of the IIA for certain actions
and transactions and pay additional royalties and other amounts to the IIA. We may not receive the required approvals for any proposed
transfer and, even if received, we may be required to pay the IIA a portion of the consideration that we receive upon any transfer of
such technology to a non-Israeli entity up to 600% of the grant amounts and the interest. The IIA approved the Company&#8217;s Research
Collaboration and License Agreement with Amgen Inc. as of December 2018, subject to payments to the IIA in the rate of 5.38% out of any
payment received from Amgen for the license and up to a total amount of six times the amount of the IIA funding and the interest. In addition,
as disclosed under &#8220;Manufacturing&#8221;, we have signed a contract with a U.K.-based contract manufacturing organization to produce
and supply tablets for trials performed worldwide. We believe that, because production is not being done for commercial purposes, the
entry into the production agreement in the U.K. will not affect the royalty rates to be paid to the IIA. Should it turn out that this
position is not acceptable to the IIA, the maximum royalties to be paid to the IIA will be three times the amount of the grants and the
interest. In addition, any change of control and any change of ownership of our Ordinary Shares that would cause a non-Israeli citizen
or resident to become an interested party as defined in the Research Law (which includes any person who holds 5% or more of our outstanding
shares) requires written notice to the IIA. Such a non-Israeli interested party is required to sign an undertaking towards the IIA in
which it undertakes to comply with the Research Law. If we fail to comply with the Research Law, we may be forced to return the grants
and/or be subject to other payments to the IIA, monetary fines and/or criminal charges.</div>

<div style="line-height: 1.25"><br /> </div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal">20</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000" /></div>
</div>

<div style="line-height: 1.25"> <br /> </div>

<div style="text-align: justify; line-height: 1.25; font-weight: bold">Oramed Patent Transfer Agreement</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">In 2010, in connection with our establishment as a joint venture between D.N.A Biomedical
Solutions Ltd. (&#8220;D.N.A Biomedical&#8221;) and Oramed Ltd. (&#8220;Oramed&#8221;), a subsidiary of Oramed Pharmaceuticals, Inc.,
we entered into a patent license agreement with Oramed pursuant to which Oramed granted us a worldwide, royalty-bearing, exclusive, irrevocable,
perpetual and sub-licensable license under certain Oramed patent rights, to develop, manufacture and commercialize products for certain
indications to be specified by us and Oramed, other than diabetes, obesity and influenza. In February 2011, D.N.A Biomedical and Oramed
entered into a share purchase agreement for the sale by Oramed to D.N.A Biomedical of 47% of our Ordinary Shares at the time of the transaction
in February 2011. In connection with this transaction, in February 2011 we entered into a Patent Transfer Agreement with Oramed to replace
the original 2010 license agreement.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Pursuant to the terms of the Patent Transfer Agreement, Oramed assigned to us all
of its right, title and interest in the previously licensed patent rights, and, in return, we granted to Oramed a worldwide, royalty-free,
exclusive, irrevocable, perpetual and sublicensable license under the assigned patent rights to develop, manufacture and commercialize
products or otherwise exploit such patent rights in the fields of diabetes and influenza. Additionally, we agreed not to engage, directly
or indirectly, in any activities in the fields of diabetes and influenza. In consideration for such assignment, we agreed to pay Oramed
royalties equal to 3% of our net revenues generated, directly or indirectly, from exploitation of the assigned patent rights, including
the sale, lease or transfer of the assigned patent rights or sales of products or services covered by the assigned patent rights. Either
party may terminate the Patent Transfer Agreement for the other party&#8217;s uncured material breach upon 45 days&#8217; written notice
(and immediately upon written notice in the event of an incurable breach), or if the other party undergoes certain insolvency-related
events. The royalty obligations imposed on us will survive termination of the Patent Transfer Agreement.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-weight: bold">Manufacturing</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">We do not own or operate facilities for large scale product manufacturing, storage
and distribution, or testing, nor do we expect to in the future. Our current facility is limited to small-mid scale manufacturing, storage
and distribution of materials and oral drug formulations for clinical studies. Our facility has ISO:9001:2015 quality management systems
accreditation from The Standards Institution of Israel for the production and development of functional excipients for oral drug formulations
to be used in clinical trials. The facility includes a dedicated Class D clean room for tablet production and a dedicated chemical synthesis
room designed to meet ISO 8 specifications.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Our manufacturing activities include the chemical synthesis of one of our non-active
but functional drug components in our facility. In addition, we have a contract with a contract manufacturing organization, to produce
and supply tablets for trials performed worldwide, including formulation and production of the final drug, packaging, storage and distribution.
The manufacturer&#8217;s facility is an FDA/EMA inspected-GMP site and we expect future clinical studies with our oral PTH (1-34) tablets,
as well as the potential commercial supply, if approved, will be provided by the same subcontractor. This contract is not exclusive and
we may enter into additional contracts. Our QA/QC analytical laboratory performs part of the release and stability testing for PTH tablets
manufactured by the contract manufacturing facility. In addition, our research and development team supports the manufacturing activities
and develops/optimizes analytical methods used by the contract manufacturer in order to meet regulatory requirements for our clinical
trials. Various materials included in the drug formulation and materials procured for the chemical synthesis are commercially available
from various accredited suppliers. We do not have supply contracts with all such vendors and are not bound to any specific vendor at this
point in time. However, it is our intention to complete such contracts in anticipation of commercial manufacturing activities, so that
if approved, we will have such contracts in place.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-weight: bold">Government Regulation and Product Approval</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Government authorities in the United States, at the federal, state and local level,
and in other countries and jurisdictions, including the EU, extensively regulate, among other things, the research, development, testing,
manufacture, pricing, quality control, approval, packaging, storage, recordkeeping, labeling, advertising, promotion, distribution, marketing,
post-approval monitoring and reporting, and import and export of pharmaceutical products. The processes for obtaining regulatory approvals
in the United States and in other countries and jurisdictions, along with subsequent compliance with applicable statutes and regulations
and other regulatory authorities, require the expenditure of substantial time and financial resources.</div>

<div style="line-height: 1.25">&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal">21</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000" /></div>
</div>

<div style="text-align: justify; line-height: 1.25; font-weight: bold">Review and Approval of Drugs in the United States</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">In the United States, our product candidates are regulated by the FDA as drugs under
the Federal Food, Drug, and Cosmetic Act, or the FDCA, the Public Health Service Act, or the PHSA, and regulations implemented by the
FDA. The failure to comply with the applicable requirements at any time during the product development process, including preclinical
testing, clinical testing, the approval process or post-approval process, may subject an applicant to delays in the conduct of clinical
trials, regulatory review and approval, and/or administrative or judicial sanctions. These sanctions may include, but are not limited
to, the FDA&#8217;s refusal to allow an applicant to proceed with clinical testing, refusal to approve pending applications, license suspension
or revocation, withdrawal of an approval, warning letters, adverse publicity, customer notifications, product recalls, product seizures,
refusal to grant export or import approval total or partial suspension of production or distribution, consent decrees, injunctions, fines,
and civil or criminal investigations and penalties brought by the FDA or Department of Justice, or other governmental entities.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">The process required by the FDA before a new drug or biologic may be marketed in the
United States generally involves satisfactorily completing each of the following steps:</div>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 18pt"><br /> </td>
    <td style="width: 18pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>preclinical laboratory tests, animal studies and formulation studies all performed in accordance with the FDA&#8217;s Good Laboratory
        Practice regulations;</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 18pt"><br /> </td>
    <td style="width: 18pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>submission to the FDA of an initial new drug, or IND, application for human clinical testing, which must become effective before
        human clinical trials may begin;</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 18pt"><br /> </td>
    <td style="width: 18pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>approval by an independent review board, or IRB, representing each clinical site before each clinical trial may be initiated;</div>
        </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 18pt"><br /> </td>
    <td style="width: 18pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>performance of adequate and well-controlled clinical trials to establish the safety and efficacy of the product candidate for each
        proposed indication for use and conducted in accordance with Good Clinical Practice, or GCP, requirements;</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 18pt"><br /> </td>
    <td style="width: 18pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>submission of data supporting safety and efficacy as well as detailed information on the manufacture and composition of the product
        in clinical development and proposed labeling;</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 18pt"><br /> </td>
    <td style="width: 18pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>preparation and submission to the FDA of a New Drug Application, or an NDA, or Biologics License Application, or BLA;</div> </td>
        </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 18pt"><br /> </td>
    <td style="width: 18pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>review of the product by an FDA advisory committee, where appropriate or if applicable;</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 18pt"><br /> </td>
    <td style="width: 18pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>satisfactory completion of one or more FDA inspections of the manufacturing facility or facilities, including those of third parties,
        at which the product, or components thereof, are produced to assess compliance with current Good Manufacturing Practice, or cGMP, standards
        and to assure that the facilities, methods and controls are adequate to preserve the product&#8217;s identity, strength, quality and purity;</div>
        </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 18pt"><br /> </td>
    <td style="width: 18pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>satisfactory completion of any FDA audits of the non-clinical and clinical trial sites to assure compliance with GCP requirements
        and the integrity of clinical data in support of the NDA or BLA;</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 18pt"><br /> </td>
    <td style="width: 18pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>payment of user fees and securing FDA approval of the NDA or BLA for the proposed indication; and</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 18pt"><br /> </td>
    <td style="width: 18pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>compliance with any post-approval requirements, including risk evaluation and mitigation strategies, or REMS, and any post-approval
        studies required by the FDA.</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-weight: bold">Preclinical Studies and Investigational New Drug Application</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Preclinical tests include laboratory evaluations of product chemistry, formulation
and stability, as well as animal studies to evaluate the potential for efficacy and toxicity. The conduct of the preclinical tests and
formulation of the compounds for testing must comply with federal regulations and requirements. The results of the preclinical tests,
together with manufacturing information and analytical data, are submitted to the FDA as part of an IND application. Some preclinical
tests may continue even after submission of the IND application. The IND automatically becomes effective 30 days after receipt by the
FDA, unless before that time the FDA raises concerns or questions about the product or conduct of the proposed clinical trial, including
concerns that human research volunteers will be exposed to unreasonable health risks. In that case, the IND sponsor and the FDA must resolve
any outstanding FDA concerns before the clinical trial can begin.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">As a result, submission of the IND may result in the FDA not allowing the clinical
trials to commence or allowing the clinical trial to commence on the terms originally specified by the sponsor in the IND. If the FDA
raises concerns or questions either during this initial 30-day period, or at any time during the IND process, it may choose to impose
a partial or complete clinical hold. This order issued by the FDA would delay a proposed clinical trial until all outstanding concerns
have been adequately addressed and the FDA has notified the company that investigations may proceed. This could cause significant delays
or difficulties in completing planned clinical trials in a timely manner.</div>

<div style="line-height: 1.25">&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal">22</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000" /></div>
</div>

<div style="text-align: justify; line-height: 1.25; font-weight: bold">Clinical Trials</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Clinical trials involve the administration of the investigational product candidate
to healthy volunteers or patients with the disease to be treated under the supervision of a qualified principal investigator in accordance
with GCP requirements. Clinical trials are conducted under trial protocols detailing, among other things, the objectives of the clinical
trial, inclusion and exclusion criteria, the parameters to be used in monitoring safety and the effectiveness criteria to be evaluated.
A protocol for each clinical trial and any subsequent protocol amendments must be submitted to the FDA as part of the IND.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">A sponsor who wishes to conduct a clinical trial outside the United States may, but
need not, obtain FDA authorization to conduct the clinical trial under an IND. If a clinical trial outside the United States is not conducted
under an IND, the sponsor may submit data from the clinical trial to the FDA in support of a NDA so long as the clinical trial is conducted
in consistent with GCP and in compliance with an international guideline for the ethical conduct of clinical research known as the Declaration
of Helsinki and/or the laws and regulations of the country or countries in which the clinical trial is performed, whichever provides the
greater protection to the participants in the clinical trial.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Further, each clinical trial must be reviewed and approved by an IRB either centrally
or individually at each institution at which the clinical trial will be conducted. The IRB will consider, among other things, clinical
trial design, patient informed consent, ethical factors, the safety of human subjects and, where appropriate, the protection of privacy
of the human subjects. An IRB must operate in compliance with the FDA regulations. The FDA, IRB, the clinical trial sponsor, or the principal
investigator may suspend or discontinue a clinical trial at any time for various reasons, including a finding that the clinical trial
is not being conducted in accordance with FDA requirements or the subjects or patients are being exposed to an unacceptable health risk.
Clinical testing also must satisfy extensive GCP rules and the requirements for informed consent. Additionally, some clinical trials are
overseen by an independent group of qualified experts organized by the clinical trial sponsor, known as a data and safety monitoring board
or committee. This group may recommend continuing the clinical trial as planned, make changes in clinical trial conduct, or cessation
of the clinical trial at designated check points based on access to certain data from the clinical trial.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Clinical trials typically are conducted in three sequential phases, but the phases
may overlap or be combined. Annual progress reports detailing the results of the clinical trials must be submitted to the FDA. Additional
studies may be required after approval.</div>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 18pt"><br /> </td>
    <td style="width: 18pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div><span style="font-style: italic">Phase 1</span> clinical trials are initially conducted in a limited population to test the product
        candidate for safety, including adverse effects, dose tolerance, absorption, metabolism, distribution, excretion and pharmacodynamics
        in healthy humans. For some products for severe or life-threatening diseases, especially if the product may be too toxic to administer
        to healthy humans, the initial clinical trials may be conducted in individuals having a specific disease for which use the tested product
        is indicated.</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 18pt"><br /> </td>
    <td style="width: 18pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div><span style="font-style: italic">Phase 2</span> clinical trials are generally conducted in a limited patient population to identify
        possible adverse effects and safety risks, evaluate the efficacy of the product candidate for specific targeted indications and determine
        dose tolerance and optimal dosage. Multiple Phase 2 clinical trials may be conducted by the sponsor to obtain information prior to beginning
        larger and more costly Phase 3 clinical trials.</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 18pt"><br /> </td>
    <td style="width: 18pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div><span style="font-style: italic">Phase 3</span> clinical trials proceed if the Phase 2 clinical trials demonstrate that a dose range
        of the product candidate is potentially effective and has an acceptable safety profile. Phase 3 clinical trials are undertaken to further
        evaluate, in a larger number of patients, dosage, provide substantial evidence of clinical efficacy and further test for safety in an
        expanded and diverse patient population at multiple, geographically dispersed clinical trial sites. A well-controlled, statistically robust
        Phase 3 trial may be designed to deliver the data that regulatory authorities will use to decide whether or not to approve, and, if approved,
        how to appropriately label a drug: such Phase 3 studies are referred to as &#8220;pivotal.&#8221;</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">In some cases, the FDA may approve a NDA or BLA for a product candidate but require
the sponsor to conduct additional clinical trials to further assess the drug&#8217;s safety and effectiveness after NDA or BLA approval.
Such post-approval trials are typically referred to as Phase 4 clinical trials. These studies are used to gain additional data from the
treatment of patients in the intended therapeutic indication and to document a clinical benefit in the case of drugs approved under accelerated
approval regulations. If the FDA approves a product while a company has ongoing clinical trials that were not necessary for approval,
a company may be able to use the data from these clinical trials to meet all or part of any Phase 4 clinical trial requirement or to request
a change in the product labeling. Failure to exhibit due diligence with regard to conducting Phase 4 clinical trials could result in withdrawal
of approval for products.</div>

<div style="line-height: 1.25">&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal">23</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000" /></div>
</div>

<div style="text-align: justify; line-height: 1.25; font-weight: bold">Compliance with Current Good Manufacturing Practice Requirements</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Before approving a NDA or BLA, the FDA typically will inspect the facility or facilities
where the product is manufactured. The FDA will not approve an application unless it determines that the manufacturing processes and facilities
are in full compliance with cGMP requirements and able to assure consistent production of the product within required specifications.
The PHSA emphasizes the importance of manufacturing control for products like biologics whose attributes cannot be precisely defined.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Manufacturers and others involved in the manufacture and distribution of products
must also register their establishments with the FDA and certain state regulatory bodies. Both U.S. and non-U.S. manufacturing establishments
must register and provide additional information to the FDA upon their initial participation in the manufacturing process. Any product
manufactured by or imported from a facility that has not registered, whether U.S. or non-U.S., is deemed misbranded under the FDCA. Establishments
may be subject to periodic unannounced inspections by government authorities to ensure compliance with cGMPs and other laws. Inspections
must follow a &#8220;risk-based schedule&#8221; that may result in certain establishments being inspected more frequently. Manufacturers
may also have to provide, on request, electronic or physical records regarding their establishments. Delaying, denying, limiting, or refusing
inspection by the FDA may lead to a product being deemed to be adulterated.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-weight: bold">Review and Approval of a New Drug Application and Biologics License
Application</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">The results of product candidate development, preclinical testing and clinical trials,
including negative or ambiguous results as well as positive findings, are submitted to the FDA as part of a NDA or BLA requesting approval
to market the product. The NDA or BLA also must contain extensive manufacturing information and detailed information on the composition
of the product and proposed labeling as well as payment of a user fee.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Under the Prescription Drug User Fee Act, or PDUFA, as amended, each NDA or BLA must
be accompanied by a user fee, which the FDA adjusts on an annual basis. Fee waivers or reductions are available in certain instances,
such as a waiver of the application fee for an initial application filed by a small business. Moreover, no user fees are assessed on NDAs
or BLAs for products designated as orphan drugs, unless the product has a non-orphan indication for use.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">The FDA has 60 days after submission of the application to conduct an initial review
to determine whether it is sufficient to accept for filing based on the agency&#8217;s threshold determination that it is sufficiently
complete to permit substantive review. Once the submission has been accepted for filing, the FDA begins an in-depth review of the application.
Under the goals and policies under the PDUFA, the FDA has ten months from the filing date in which to complete its initial review of a
standard application and respond to the applicant, and six months for a priority review of the application. The FDA does not always meet
its PDUFA goal dates for standard and priority applications. The review process may often be significantly extended by FDA requests for
additional information or clarification. The review process and the PDUFA goal date may be extended by three months if the FDA requests,
or the applicant otherwise provides additional information or clarification regarding information already provided in the submission within
the last three months before the PDUFA goal date.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Under the FDCA and the PHSA, the FDA may approve a NDA or BLA if it determines that
the product is safe, pure and potent and the facility where the product will be manufactured meets standards designed to ensure that it
continues to be safe, pure and potent.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">On the basis of the FDA&#8217;s evaluation of the application and accompanying information,
including the results of the inspection of the manufacturing facilities, the FDA may issue an approval letter or a complete response letter.
An approval letter authorizes commercial marketing of the product with specific prescribing information for specific indications. If the
application is not approved, the FDA will issue a complete response letter, which will contain the conditions that must be met in order
to secure final approval of the application, and, when possible, will outline recommended actions the sponsor might take to obtain approval
of the application. Sponsors that receive a complete response letter may submit to the FDA information that represents a complete response
to the issues identified by the FDA. Such resubmissions are classified under PDUFA as either Class 1 or Class 2. The classification of
a resubmission is based on the information submitted by an applicant in response to an action letter. Under the goals and policies agreed
to by the FDA under PDUFA, the FDA has two months to review a Class 1 resubmission and six months to review a Class 2 resubmission from
the date of receipt. The FDA will not approve an application until issues identified in the complete response letter have been addressed.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">The FDA may also refer the application to an advisory committee for review, evaluation
and recommendation as to whether the application should be approved. Typically, an advisory committee is a panel of independent experts,
including clinicians and other scientific experts, that reviews, evaluates and provides a recommendation as to whether the application
should be approved and under what conditions. The FDA is not bound by the recommendations of an advisory committee, but it considers such
recommendations carefully when making decisions.</div>

<div style="line-height: 1.25">&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal">24</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000" /></div>
</div>

<div style="text-align: justify; line-height: 1.25">If the FDA approves a new product, it may limit the approved indications for use of
the product. It may also require that contraindications, warnings or precautions be included in the product labeling. In addition, the
FDA may call for post-approval studies, including Phase 4 clinical trials, to further assess the product&#8217;s safety after approval.
The agency may also require testing and surveillance programs to monitor the product after commercialization, or impose other conditions,
including distribution restrictions or other risk management mechanisms, including a REMS, to help ensure that the benefits of the product
outweigh the potential risks. A REMS can include medication guides, communication plans for healthcare professionals, and elements to
assure safe use, or ETASU. ETASU can include, but are not limited to, special training or certification for prescribing or dispensing,
dispensing only under certain circumstances, special monitoring, and the use of patent registries. The FDA may prevent or limit further
marketing of a product based on the results of post-market studies or surveillance programs. After approval, many types of changes to
the approved product, such as adding new indications, manufacturing changes and additional labeling claims, are subject to further testing
requirements and FDA review and approval.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">The Drug Price Competition and Patent Term Restoration Act, or the Hatch-Waxman Act,
added Section 505(b)(2) to the FDCA, allowing a company to submit an NDA application that relies on clinical trial data not conducted
by or for the application, such as published scientific literature and prior FDA findings of safety and efficacy of another company&#8217;s
drug. An NDA application under Section 505(b)(2) is typically used when the applicant product modifies or improves a predicate drug leading
to a new drug product. Because an application under Section 505(b)(2) can rely on prior clinical trial data and published scientific literature,
FDA approval is generally quicker than a normal NDA application. However, an application under Section 505(b)(2) can also be delayed if
the predicate drug is still under patent or exclusivity protections.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-weight: bold">Fast Track, Breakthrough Therapy and Priority Review Designations</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">The FDA is authorized to designate certain products for expedited review if they are
intended to address an unmet medical need in the treatment of a serious or life-threatening disease or condition, or in the event of an
emergency. These programs are fast track designation, breakthrough therapy designation and priority review designation.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Specifically, the FDA may designate a product for fast track review if it is intended,
whether alone or in combination with one or more other products, for the treatment of a serious or life-threatening disease or condition,
and it demonstrates the potential to address unmet medical needs for such a disease or condition. For fast track products, sponsors may
have greater interactions with the FDA and the FDA may initiate review of sections of a fast track product&#8217;s application before
the application is complete. This rolling review may be available if the FDA determines, after preliminary evaluation of clinical data
submitted by the sponsor, that a fast track product may be effective. The sponsor must also provide, and the FDA must approve, a schedule
for the submission of the remaining information and the sponsor must pay applicable user fees. However, the FDA&#8217;s time period goal
for reviewing a fast track application does not begin until the last section of the application is submitted. In addition, the fast track
designation may be withdrawn by the FDA if the FDA believes that the designation is no longer supported by data emerging in the clinical
trial process.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Second, in 2012, Congress enacted the Food and Drug Administration Safety and Innovation
Act, or FDASIA. This law established a new regulatory scheme allowing for expedited review of products designated as &#8220;breakthrough
therapies.&#8221; A product may be designated as a breakthrough therapy if it is intended, either alone or in combination with one or
more other products, to treat a serious or life-threatening disease or condition and preliminary clinical evidence indicates that the
product may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints, such as substantial
treatment effects observed early in clinical development. The FDA may take certain actions with respect to breakthrough therapies, including
holding meetings with the sponsor throughout the development process; providing timely advice to the product sponsor regarding development
and approval; involving more senior staff in the review process; assigning a cross-disciplinary project lead for the review team; and
taking other steps to design the clinical trials in an efficient manner.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Third, the FDA may designate a product for priority review if it is a product that
treats a serious condition and, if approved, would provide a significant improvement in safety or effectiveness. The FDA determines, on
a case-by-case basis, whether the proposed product represents a significant improvement when compared with other available therapies.
Significant improvement may be illustrated by evidence of increased effectiveness in the treatment of a condition, elimination or substantial
reduction of a treatment-limiting product reaction, documented enhancement of patient compliance that may lead to improvement in serious
outcomes, and evidence of safety and effectiveness in a new subpopulation. A priority designation is intended to direct overall attention
and resources to the evaluation of such applications, and to shorten the FDA&#8217;s goal for taking action on a marketing application
from ten months to six months.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Fourth, the Secretary of Health and Human Services may authorize unapproved drugs
and biologics to be marketed in the event an actual or potential emergency has been designated by the U.S. government. After an emergency
has been designated, the FDA may issue an Emergency Use Authorization, or EUA, for the use of a specific product based on criteria established
by the FDCA. An EUA is product specific and is subject to specific conditions and restrictions. Once the emergency underlying the EUA
ends, then the EUA terminates.</div>

<div style="line-height: 1.25">&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal">25</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000" /></div>
</div>

<div style="text-align: justify; line-height: 1.25; font-weight: bold">Accelerated Approval Pathway</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">The FDA may grant accelerated approval to a product for a serious or life-threatening
condition that provides meaningful therapeutic advantage to patients over existing treatments based upon a determination that the product
has an effect on a surrogate endpoint that is reasonably likely to predict clinical benefit. The FDA may also grant accelerated approval
for such a condition when the product has an effect on an intermediate clinical endpoint that can be measured earlier than an effect on
irreversible morbidity or mortality, or IMM, and that is reasonably likely to predict an effect on irreversible morbidity or mortality
or other clinical benefit, taking into account the severity, rarity, or prevalence of the condition and the availability or lack of alternative
treatments. Products granted accelerated approval must meet the same statutory standards for safety and effectiveness as those granted
traditional approval.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">For the purposes of accelerated approval, a surrogate endpoint is a marker, such as
a laboratory measurement, radiographic image, physical sign, or other measure that is thought to predict clinical benefit but is not itself
a measure of clinical benefit. Surrogate endpoints can often be measured more easily or more rapidly than clinical endpoints. An intermediate
clinical endpoint is a measurement of a therapeutic effect that is considered reasonably likely to predict the clinical benefit of a product,
such as an effect on IMM. The FDA has indicated that intermediate clinical endpoints generally may support accelerated approval where
the therapeutic effect measured by the endpoint is not itself a clinical benefit and basis for traditional approval, if there is a basis
for concluding that the therapeutic effect is reasonably likely to predict the ultimate clinical benefit of a product.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">The accelerated approval pathway is most often used in settings in which the course
of a disease is long and an extended period of time is required to measure the intended clinical benefit of a product, even if the effect
on the surrogate or intermediate clinical endpoint occurs rapidly.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">The accelerated approval pathway is usually contingent on a sponsor&#8217;s agreement
to conduct, in a diligent manner, additional post-approval confirmatory studies to verify and describe the product&#8217;s clinical benefit.
As a result, a product candidate approved on this basis is subject to rigorous post-marketing compliance requirements, including the completion
of Phase 4 or post-approval clinical trials to confirm the effect on the clinical endpoint. Failure to conduct required post-approval
studies, or confirm a clinical benefit during post-marketing studies, would allow the FDA to withdraw the product from the market on an
expedited basis. All promotional materials for product candidates approved under accelerated regulations are subject to prior review by
the FDA.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-weight: bold">Post-Approval Regulation</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Once regulatory approval for marketing of a product or new indication for an existing
product is obtained, the sponsor will be required to comply with post-approval regulatory requirements, including any post-approval requirements
that the FDA may have imposed as a condition of approval. The sponsor will be required to report certain adverse reactions and production
problems to the FDA, provide updated safety and efficacy information and comply with requirements concerning advertising and promotional
labeling requirements. Drug manufacturers and certain of their subcontractors are required to register their establishments with the FDA
and certain state agencies and are subject to periodic unannounced inspections by the FDA and certain state agencies for compliance with
ongoing regulatory requirements, including cGMP regulations, which impose certain procedural and documentation requirements upon drug
manufacturers. Accordingly, the sponsor and its third-party manufacturers must continue to spend time, money and effort in the areas of
production and quality control to maintain compliance with cGMP regulations and other regulatory requirements.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">A product may also be subject to official lot release, meaning that the manufacturer
is required to perform certain tests on each lot of the product before it is released for distribution. If the product is subject to official
release, the manufacturer must submit samples of each lot, together with a release protocol showing a summary of the history of manufacture
of the lot and the results of all of the manufacturer&#8217;s tests performed on the lot, to the FDA. The FDA may in addition perform
certain confirmatory tests on lots of some products before releasing the lots for distribution. Finally, the FDA will conduct laboratory
research related to the safety, purity, potency, and effectiveness of pharmaceutical products.</div>

<div style="line-height: 1.25">&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal">26</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000" /></div>
</div>

<div style="text-align: justify; line-height: 1.25">After an approval is granted, the FDA may withdraw the approval if compliance with
regulatory requirements and standards is not maintained or if problems occur after the product reaches the market. Later discovery of
previously unknown problems with a product, including adverse events of unanticipated severity or frequency, or with manufacturing processes,
or failure to comply with regulatory requirements, may result in revisions to the approved labeling to add new safety information; imposition
of post-market studies or clinical trials to assess new safety risks; or imposition of distribution or other restrictions under a REMS
program. Other potential consequences include, among other things:</div>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 18pt"><br /> </td>
    <td style="width: 18pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>restrictions on the marketing or manufacturing of the product, complete withdrawal of the product from the market or product recalls;</div>
        </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 18pt"><br /> </td>
    <td style="width: 18pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>fines, warning letters or holds on post-approval clinical trials;</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 18pt"><br /> </td>
    <td style="width: 18pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>refusal of the FDA to approve pending NDAs or supplements to approved NDAs, or suspension or revocation of product license approvals;</div>
        </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 18pt"><br /> </td>
    <td style="width: 18pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>product seizure or detention, or refusal to permit the import or export of products; or</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 18pt"><br /> </td>
    <td style="width: 18pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>injunctions or the imposition of civil or criminal penalties.</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">The FDA strictly regulates marketing, labeling, advertising and promotion of products
that are placed on the market. Drugs and biologics may be promoted only for the approved indications and in accordance with the provisions
of the approved label. The FDA and other agencies actively enforce the laws and regulations prohibiting the promotion of off-label uses,
and a company that is found to have improperly promoted off-label uses may be subject to significant liability.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-weight: bold">Orphan Drug Designation</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Orphan drug designation in the United States is designed to encourage sponsors to
develop drugs intended for rare diseases or conditions. In the United States, a rare disease or condition is statutorily defined as a
condition that affects fewer than 200,000 individuals in the United States, or that affects more than 200,000 individuals in the United
States and for which there is no reasonable expectation that the cost of developing and making available the drug for the disease or condition
will be recovered from sales of the drug in the United States.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Orphan drug designation qualifies a company for tax credits, waiver of the NDA user
fee and may confer market exclusivity for seven years following the date of the drug&#8217;s marketing approval, if granted by the FDA,
if a product that has orphan designation subsequently receives the first FDA approval of that drug for the disease for which it has such
designation. This means that the FDA may not approve any other applications, including an NDA to market the same drugs or even in a different
formulation for the same indication for seven years, except in limited circumstances such as a showing of clinical superiority over the
product with orphan drug exclusivity or where the manufacturer is unable to assure sufficient product quantity. An application for designation
as an orphan product can be made any time prior to the filing of an application for approval to market the product. A product becomes
an orphan product when it receives orphan drug designation from the Office of Orphan Products Development, or OOPD, at the FDA based on
acceptable confidential requests made under the regulatory provisions. The product must then go through the review and approval process
like any other product.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">A sponsor may request orphan drug designation of a previously unapproved product or
new orphan indication for an already marketed product. In addition, a sponsor of a product that is otherwise the same product as an already
approved orphan drug may seek and obtain orphan drug designation for the subsequent product for the same rare disease or condition if
it can present a plausible hypothesis that its product may be clinically superior to the first, approved product. More than one sponsor
may receive orphan drug designation for the same product for the same rare disease or condition, but each sponsor seeking orphan drug
designation must file a complete request for designation, and only the first sponsor that obtains approval for that drug for the orphan
indication will obtain market exclusivity, effectively preventing the FDA from approving products under development by competitors for
the same drug and same indication, unless the competitor is able to demonstrate that the product under development is clinically superior
to the approved product or the approved product is not available in sufficient quantities. To permit the FDA to end another manufacturer&#8217;s
orphan exclusivity period, the FDA must determine that the manufacturer has demonstrated clinical superiority by showing the later drug
is safer, more effective, or otherwise makes a major contribution to patient care.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">The period of exclusivity begins on the date that the marketing application is approved
by the FDA and applies only to the indication for which the product has been designated. The FDA may approve a second application for
the same product for a different use or a subsequent application for a different drug for the same indication. Orphan drug designation
neither shortens the development time or regulatory review time of a drug nor gives the drug any advantage in the regulatory review or
approval process.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-weight: bold">Biosimilars and Exclusivity</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">The ACA, which was signed into law on March 23, 2010, included a subtitle called the
Biologics Price Competition and Innovation Act of 2009 or BPCIA. The BPCIA established a regulatory scheme authorizing the FDA to approve
biosimilars and interchangeable biosimilars. The FDA has issued several draft guidance documents outlining an approach to review and approval
of biosimilars. Complexities associated with the larger, and often more complex, structures of biological products, as well as the processes
by which such products are manufactured, pose significant hurdles to implementation, which are still being worked out by the FDA.</div>

<div style="line-height: 1.25">&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal">27</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000" /></div>
</div>

<div style="text-align: justify; line-height: 1.25">Under the BPCIA, a manufacturer may submit an application for licensure of a biologic
product that is &#8220;biosimilar to&#8221; or &#8220;interchangeable with&#8221; a previously approved biological product or &#8220;reference
product.&#8221; In order for the FDA to approve a biosimilar product, it must find that there are no clinically meaningful differences
between the reference product and proposed biosimilar product in terms of safety, purity, and potency. For the FDA to approve a biosimilar
product as interchangeable with a reference product, the agency must find that the biosimilar product can be expected to produce the same
clinical results as the reference product, and (for products administered multiple times) that the biologic and the reference biologic
may be switched after one has been previously administered without increasing safety risks or risks of diminished efficacy relative to
exclusive use of the reference biologic.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Under the BPCIA, an application for a biosimilar product may not be submitted to the
FDA until four years following the date of approval of the reference product. The FDA may not approve a biosimilar product until 12 years
from the date on which the reference product was approved. Even if a product is considered to be a reference product eligible for exclusivity,
another company could market a competing version of that product if the FDA approves a full BLA for such product containing the sponsor&#8217;s
own preclinical data and data from adequate and well-controlled clinical trials to demonstrate the safety, purity and potency of their
product. The BPCIA also created certain exclusivity periods for biosimilars approved as interchangeable products.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-weight: bold">Patent Term Extension</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">A patent claiming a new drug or biologic product may be eligible for a limited patent
term extension under the Hatch-Waxman Act, which permits a patent extension of up to five years beyond the expiration date of a U.S. patent
as partial compensation for the useful patent term lost, if any, during the FDA regulatory review process. However, a patent term extension
cannot extend the remaining term of a patent beyond a total of 14 years from the date of the product&#8217;s approval by the FDA. The
patent term extension period granted is typically one-half the time between the effective date of the first IND and the submission date
of the NDA for the product, plus the time between the submission date of the NDA and the approval of that application. Only one patent
applicable to an approved product is eligible for the extension, and the application for the extension must be submitted prior to the
expiration of the patent in question. A patent that covers multiple products for which approval is sought can only be extended in connection
with one of the products. The USPTO reviews and approves the application for any patent term extension or restoration in consultation
with the FDA.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-weight: bold">Regulation Outside the United States</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">In order to market any product outside of the United States, a company must also comply
with numerous and varying regulatory requirements of other countries and jurisdictions regarding quality, safety and efficacy that govern,
among other things, clinical trials, marketing authorization, commercial sales and distribution of drug products. Whether or not it obtains
FDA approval for a product, the company would need to obtain the necessary approvals by the comparable non-U.S. regulatory authorities
before it can commence clinical trials or marketing of the product in those countries or jurisdictions. The approval process ultimately
varies between countries and jurisdictions and can involve additional product testing and additional administrative review periods. The
time required to obtain approval in other countries and jurisdictions might differ from and be longer than that required to obtain FDA
approval. Regulatory approval in one country or jurisdiction does not ensure regulatory approval in another, but a failure or delay in
obtaining regulatory approval in one country or jurisdiction may negatively impact the regulatory process in others.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-weight: bold">Regulation and Marketing Authorization in the European Union</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">The European Medicines Agency, or EMA, is the scientific agency of the European Union,
or EU, that coordinates the evaluation and monitoring of new and approved medicinal products such as drugs and biologics. It is responsible
for the scientific evaluation of applications for EU marketing authorizations, as well as the development of technical guidance and the
provision of scientific advice to sponsors.</div>

<div style="line-height: 1.25">&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal">28</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000" /></div>
</div>

<div style="text-align: justify; line-height: 1.25">The process regarding approval of medicinal products in the EU follows roughly the
same lines as in the United States and likewise generally involves satisfactorily completing each of the following:</div>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 18pt"><br /> </td>
    <td style="width: 18pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>preclinical laboratory tests, animal studies and formulation studies all performed in accordance with the applicable EU Good Laboratory
        Practice regulations;</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 18pt"><br /> </td>
    <td style="width: 18pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>submission to the relevant regulatory agencies in EU member states, or national authorities, of a clinical trial application, or
        CTA, for each clinical trial, which must be approved before human clinical trials may begin;</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 18pt"><br /> </td>
    <td style="width: 18pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>performance of adequate and well-controlled clinical trials to establish the safety and efficacy of the product for each proposed
        indication;</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 18pt"><br /> </td>
    <td style="width: 18pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>submission to the relevant national authorities of a Marketing Authorisation Application, or MAA, which includes the data supporting
        safety and efficacy as well as detailed information on the manufacture and composition of the product in clinical development and proposed
        labeling;</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 18pt"><br /> </td>
    <td style="width: 18pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>satisfactory completion of an inspection by the relevant national authorities of the manufacturing facility or facilities, including
        those of third parties, at which the product is produced to assess compliance with cGMP;</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 18pt"><br /> </td>
    <td style="width: 18pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>potential audits of the non-clinical and clinical trial sites that generated the data in support of the MAA; and</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 18pt"><br /> </td>
    <td style="width: 18pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>review and approval by the relevant national authority of the MAA before any commercial marketing, sale or shipment of the product.</div>
        </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-weight: bold">Preclinical Studies</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Preclinical tests include laboratory evaluations of product chemistry, formulation
and stability, as well as studies to evaluate the potential efficacy and toxicity in animals. The conduct of the preclinical tests and
formulation of the compounds for testing must comply with the relevant EU regulations and requirements. The results of the preclinical
tests, together with relevant manufacturing information and analytical data, are submitted as part of the CTA when seeking approval to
start a clinical trial, and with the MAA when seeking marketing authorization.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-weight: bold">Clinical Trial Approval</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Requirements for the conduct of clinical trials in the EU including cGCP, are implemented
in the currently Clinical Trials Directive 2001/20/EC and the GCP Directive 2005/28/EC. Pursuant to Directive 2001/20/EC and Directive
2005/28/EC, as amended, a system for the approval of clinical trials in the EU has been implemented through national legislation of the
EU member states. Under this system, approval must be obtained from the competent national authority in which a trial is planned to be
conducted, or in multiple member states if the clinical trial is to be conducted in a number of member states. To this end, a CTA is submitted,
which must be supported by an investigational medicinal product dossier, or IMPD, and further supporting information prescribed by Directive
2001/20/EC and Directive 2005/28/EC and other applicable guidance documents. Furthermore, a clinical trial may only be started after a
competent ethics committee has issued a favorable opinion on the clinical trial application in that country.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">On January 31, 2022, the Clinical Trials Regulation (EU) No. 536/2014 replaced the
current Clinical Trials Directive 2001/20/EC. To ensure that the rules for clinical trials are identical throughout the EU, the Clinical
Trials Regulation (EU) No. 536/2014 was passed as a regulation which is directly applicable in all EU member states. The Clinical Trials
Directive 2001/20/EC will, however, still apply three years from the date of entry into application of the Clinical Trials Regulation
to (i) clinical trials applications submitted before the entry into application and (ii) clinical trials applications submitted within
one year after the entry into application if the sponsor opts for the old system.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Regulation (EU) No 536/2014 aims to simplify and streamline the approval of clinical
trial in the EU. The main characteristics of the regulation include:</div>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 18pt"><br /> </td>
    <td style="width: 18pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>A streamlined application procedure via a single entry point, known as the Clinical Trials Information System;</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 18pt"><br /> </td>
    <td style="width: 18pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>A single set of documents to be prepared and submitted for the application as well as simplified reporting procedures which will
        spare sponsors from submitting broadly identical information separately to various and different national authorities;</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 18pt"><br /> </td>
    <td style="width: 18pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>A harmonized procedure for the assessment of applications for clinical trials, which is divided in two parts;</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 18pt"><br /> </td>
    <td style="width: 18pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>Strictly defined deadlines for the assessment of clinical trial application; and</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 18pt"><br /> </td>
    <td style="width: 18pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>The involvement of the ethics committees in the assessment procedure in accordance with the national law of the member state concerned
        but within the overall timelines defined by the Regulation (EU) No 536/2014.</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-weight: bold">Marketing Authorization</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Authorization to market a product in the member states of the EU proceeds under one
of four procedures: a centralized procedure, a mutual recognition procedure, a decentralized procedure or a national procedure.</div>

<div style="line-height: 1.25">&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal">29</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000" /></div>
</div>

<div style="text-align: justify; line-height: 1.25; font-weight: bold">Centralized Procedure</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">The centralized procedure enables applicants to obtain a marketing authorization that
is valid in all EU member states based on a single application. Certain medicinal products, including products developed by means of biotechnological
processes must undergo the centralized authorization procedure for marketing authorization, which, if granted by the European Commission,
based on the opinion of the EMA, is automatically valid in all EU member states. Sponsors may elect to file an MAA through the centralized
procedures for other classes of products.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">The centralized procedure is mandatory for certain types of products such as, medicines
derived from biotechnology processes such as genetic engineering, advanced-therapy medicines such as gene-therapy or tissue engineered
medicine, orphan medicines, and medicinal products containing a new active substance indicated for the treatment of HIV, AIDS, cancer,
diabetes, neurodegenerative disorders, autoimmune and other immune dysfunctions, and viral diseases. The centralized authorization procedure
is optional for other medicinal products if they contain a new active substance, if the applicant shows that the medicinal product concerned
constitutes a significant therapeutic, scientific or technical innovation, or that the granting of authorization is in the public interest
of the EU.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-weight: bold">Administrative Procedure</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Under the centralized procedure, the EMA&#8217;s Committee for Human Medicinal Products,
or CHMP serves as the scientific committee that renders opinions about the safety, efficacy and quality of medicinal products for human
use on behalf of the EMA. The CHMP is composed of experts nominated by each member state&#8217;s national authority for medicinal products,
with one of them appointed to act as Rapporteur for the coordination of the evaluation with the possible assistance of a further member
of the Committee acting as a Co-Rapporteur. After approval, the Rapporteur(s) continue to monitor the product throughout its life cycle.
The CHMP has 210 active days to adopt an opinion as to whether a marketing authorization should be granted. The process usually takes
longer in case additional information is requested, which triggers clock-stops in the procedural timelines. The process is complex and
involves extensive consultation with the regulatory authorities of member states and a number of experts. When an application is submitted
for a marketing authorization in respect of a drug which is of major interest from the point of view of public health and in particular
from the viewpoint of therapeutic innovation, the applicant may, pursuant to Article 14(9) Regulation (EC) No 726/2004, request an accelerated
assessment procedure. If the CHMP accepts such request, the time-limit of 210 days will be reduced to 150 days but it is possible that
the CHMP can revert to the standard time-limit for the centralized procedure if it considers that it is no longer appropriate to conduct
an accelerated assessment. Once the procedure is completed, a European Public Assessment Report, or EPAR, is produced. If the opinion
is negative, information is given as to the grounds on which this conclusion was reached. After the adoption of the CHMP opinion, a decision
on the MAA must be adopted by the European Commission, after consulting the EU member states, which in total can take more than 60 days.
After a drug has been authorized and launched, it is a condition of maintaining the marketing authorization that all aspects relating
to its quality, safety and efficacy must be kept under review.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-weight: bold">Conditional Approval</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">In specific circumstances, EU legislation (Article 14(7) Regulation (EC) No 726/2004
and Regulation (EC) No 507/2006 on Conditional Marketing Authorisations for Medicinal Products for Human Use) enables applicants to obtain
a conditional marketing authorization prior to obtaining the comprehensive clinical data required for an application for a full marketing
authorization. Such conditional approvals may be granted for products (including medicines designated as orphan medicinal products), if&#8201;
(1) the risk-benefit balance of the product is positive, (2) it is likely that the applicant will be in a position to provide the required
comprehensive clinical trial data, (3) the product fulfills unmet medical needs, and (4) the benefit to public health of the immediate
availability on the market of the medicinal product concerned outweighs the risk inherent in the fact that additional data are still required.
A conditional marketing authorization may contain specific obligations to be fulfilled by the marketing authorization holder, including
obligations with respect to the completion of ongoing or new studies, and with respect to the collection of pharmacovigilance data. Conditional
marketing authorizations are valid for one year, and may be renewed annually, if the risk-benefit balance remains positive, and after
an assessment of the need for additional or modified conditions and/or specific obligations. The timelines for the centralized procedure
described above also apply with respect to the review by the CHMP of applications for a conditional marketing authorization.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-weight: bold">Marketing Authorization Under Exceptional Circumstances</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">As per Article 14(8) Regulation (EC) No 726/2004, products for which the applicant
can demonstrate that comprehensive data (in line with the requirements laid down in Annex I of Directive 2001/83/EC, as amended) cannot
be provided (due to specific reasons foreseen in the legislation) might be eligible for marketing authorization under exceptional circumstances.
This type of authorization is reviewed annually to reassess the risk-benefit balance. The fulfillment of any specific procedures/obligations
imposed as part of the marketing authorization under exceptional circumstances is aimed at the provision of information on the safe and
effective use of the product and will normally not lead to the completion of a full dossier/approval.</div>

<div style="line-height: 1.25">&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal">30</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000" /></div>
</div>

<div style="text-align: justify; line-height: 1.25; font-weight: bold">Period of Authorization and Renewals</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">A marketing authorization will be valid for five years in principle, and the marketing
authorization may be renewed after five years on the basis of a re-evaluation of the risk-benefit balance by the EMA or by a national
authority. To this end, the marketing authorization holder must provide the EMA or the competent authority with a consolidated version
of the file in respect of quality, safety and efficacy, including all variations introduced since the marketing authorization was granted,
at least nine months before the marketing authorization ceases to be valid. Once renewed, the marketing authorization will be valid for
an unlimited period, unless the European Commission or the national authority decides, on justified grounds relating to pharmacovigilance,
to proceed with one additional five-year renewal. Any authorization that is not followed by the actual placing of the drug on the EU market
(in case of centralized procedure) or on the market of the authorizing member state within three years after authorization will cease
to be valid, the so-called &#8220;sunset clause.&#8221;</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-weight: bold">Orphan Drug Designation and Exclusivity</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">The European Commission can grant orphan medicinal product designation to products
for which the sponsor can establish that it is intended for the diagnosis, prevention, or treatment of&#8201; (1) a life-threatening or
chronically debilitating condition affecting not more than five in 10,000 people in the EU, or (2) a life threatening, seriously debilitating
or serious and chronic condition in the EU and that without incentives it is unlikely that sales of the drug in the EU would generate
a sufficient return to justify the necessary investment. In addition, the sponsor must establish that there is no other satisfactory method
approved in the EU of diagnosing, preventing or treating the condition, or if such a method exists, the proposed orphan drug will be of
significant benefit to patients.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Orphan drug designation provides a number of benefits, including fee reductions, regulatory
assistance, and the possibility to apply for a centralized EU marketing authorization (see &#8220;Government Regulation and Product Approval-Regulation
Outside the United States-Centralized Authorization Procedure&#8221;), as well as 10 years of market exclusivity following a marketing
authorization. During this market exclusivity period, neither the EMA, nor the European Commission nor the Member States can accept an
application or grant a marketing authorization for a medicinal product containing a similar active substance or substances as contained
in an authorized orphan medicinal product, and which is intended for the same therapeutic indication. The market exclusivity period for
the authorized therapeutic indication may be reduced to six years if, at the end of the fifth year, it is established that the orphan
drug designation criteria are no longer met, including where it is shown that the product is sufficiently profitable not to justify maintenance
of market exclusivity. In addition, a competing similar medicinal product may be authorized prior to the expiration of the market exclusivity
period, including if it is shown to be safer, more effective or otherwise clinically superior to the already approved orphan drug or if
the holder of the marketing authorization for the already approved orphan drug is unable to supply sufficient quantities of the product.&#160;</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">If the MAA of a medicinal product designated as an orphan drug includes the results
of all studies conducted in compliance with an agreed PIP, and a corresponding statement is subsequently included in the marketing authorization
granted, the ten-year period of market exclusivity will be extended to twelve years.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-weight: bold">Regulatory Data Protection</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">EU legislation also provides for a system of regulatory data and market exclusivity.
Upon receiving marketing authorization, new chemical entities approved on the basis of complete independent data package benefit from
eight years of data exclusivity and an additional two years of market exclusivity. Data exclusivity prevents regulatory authorities in
the EU from referencing the innovator&#8217;s data to assess a generic or biosimilar (abbreviated) application. During the additional
two-year period of market exclusivity, a generic or biosimilar marketing authorization can be submitted, and the innovator&#8217;s data
may be referenced, but no generic or biosimilar medicinal product can be marketed until the expiration of the market exclusivity. The
overall ten-year period will be extended to a maximum of eleven years if, during the first eight years of those 10 years, the marketing
authorization holder, or MAH, obtains an authorization for one or more new therapeutic indications which, during the scientific evaluation
prior to their authorization, are held to bring a significant clinical benefit in comparison with existing therapies. Even if a compound
is considered to be a new chemical entity and the innovator is able to gain the period of data exclusivity, another company nevertheless
could also market another version of the drug if such company obtained marketing authorization based on an MAA with a complete independent
data package of pharmaceutical test, pre-clinical tests and clinical trials. However, products designated as orphan medicinal products
enjoy, upon receiving marketing authorization, a period of 10 years of orphan market exclusivity (see also &#8220;Government Regulation
and Product Approval-Regulation and Marketing Authorization in the European Union-Orphan Drug Designation and Exclusivity&#8221;). Depending
upon the timing and duration of the EU marketing authorization process, products may be eligible for up to five years&#8217; supplementary
protection certificates, or SPCs. Such SPCs extend the rights under the basic patent for the drug.</div>

<div style="line-height: 1.25">&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal">31</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000" /></div>
</div>

<div style="text-align: justify; line-height: 1.25; font-weight: bold">Regulatory Requirements After a Marketing Authorization Has Been
Obtained</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">If we obtain authorization for a medicinal product in the EU, we will be required
to comply with a range of requirements applicable to the manufacturing, marketing, promotion and sale of medicinal products:</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-weight: bold">Pharmacovigilance and Other Requirements</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">We will, for example, have to comply with the EU&#8217;s stringent pharmacovigilance
or safety reporting rules, pursuant to which post-authorization studies and additional monitoring obligations can be imposed.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Other requirements relate to, for example, the manufacturing of products and APIs
in accordance with good manufacturing practice standards. EU regulators may conduct inspections to verify our compliance with applicable
requirements, and we will have to continue to expend time, money and effort to remain compliant. Non-compliance with EU requirements regarding
safety monitoring or pharmacovigilance, and with requirements related to the development of products for the pediatric population, can
also result in significant financial penalties in the EU. Similarly, failure to comply with the EU&#8217;s requirements regarding the
protection of individual personal data can also lead to significant penalties and sanctions. Individual EU member states may also impose
various sanctions and penalties in case we do not comply with locally applicable requirements.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-weight: bold">Manufacturing</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">The manufacturing of authorized drugs, for which a separate manufacturer&#8217;s license
is mandatory, must be conducted in compliance with the EMA&#8217;s cGMP requirements and comparable requirements of other national authorities,
which mandate the methods, facilities and controls used in manufacturing, processing and packing of drugs to assure their safety and identity.
The EMA enforces its cGMP requirements through mandatory registration of facilities and inspections of those facilities. The EMA may have
a coordinating role for these inspections while the responsibility for carrying them out rests with the member states competent authority
under whose responsibility the manufacturer falls. Failure to comply with these requirements could interrupt supply and result in delays,
unanticipated costs and lost revenues, and could subject the applicant to potential legal or regulatory action, including but not limited
to warning letters, suspension of manufacturing, seizure of product, injunctive action or possible civil and criminal penalties.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-weight: bold">Marketing and Promotion</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">The marketing and promotion of authorized drugs, including industry-sponsored continuing
medical education and advertising directed toward the prescribers of drugs and/or the general public, are strictly regulated in the EU.
The applicable regulations aim to ensure that information provided by holders of marketing authorizations regarding their products is
truthful, balanced and accurately reflects the safety and efficacy claims authorized by the EMA or by the national authority of the authorizing
member state. Failure to comply with these requirements can result in adverse publicity, warning letters, corrective advertising and potential
civil and criminal penalties.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-weight: bold">Clinical Testing in Israel</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">In order to conduct clinical trials on humans in Israel, prior authorization must
be obtained from the medical director of the institution (i.e., the Director of Hospital - DOH) in which the clinical trials are scheduled
to be conducted. All clinical trials must first be approved by the Institutional Review Board (IRB) / Independent Ethics Committee (IEC)
which may request additional prior approval from the Israeli Ministry of Health (IMOH), as required under the Guidelines for Clinical
Trials in Human Subjects implemented pursuant to the Israeli Public Health Regulations (Clinical Trials in Human Subjects), 5740-1980,
as amended from time to time. Pursuant to the Israeli Public Health Regulations, such authorization generally cannot be granted unless,
among other things, the relevant institutions ethics committee has provided its prior approval of the testing and that the trial complies
with the standards set forth by the Declaration of Helsinki.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">The IRB/IEC and IMOH prioritizes the safety, rights and the wellbeing of the participants
are addressed, as well as among other things, evaluating the anticipated benefits that are likely to be derived from the project to determine
if it justifies the risks and inconvenience to be inflicted on the participating human subjects. The institution may also conduct audits
to insure that all international GCP and IMOH guidelines are being adhered to in order to maintain the proper conduct and accuracy of
the information gathered in the course of the clinical testing.</div>

<div style="line-height: 1.25">&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal">32</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000" /></div>
</div>

<div style="text-align: justify; line-height: 1.25; font-weight: bold">Other Healthcare Laws</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Health care providers, physicians and third-party payers play a primary role in the
recommendation and prescription of drug products that are granted marketing approval. Arrangements with third-party payers and customers
are subject to broadly applicable fraud and abuse and other health care laws and regulations. In the United States, such restrictions
under applicable federal and state healthcare laws and regulations, include the following:</div>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 18pt"><br /> </td>
    <td style="width: 18pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>the federal Anti-Kickback Statute prohibits, among other things, the knowing and willful offer, payment, solicitation or receipt
        of any form of remuneration in return for, or to induce, (i) the referral of a person, (ii) the furnishing or arranging for the furnishing
        of items or services reimbursable under the Medicare, Medicaid or other governmental programs, or (iii) the purchase, lease or order or
        arranging or recommending purchasing, leasing or ordering of any item or service reimbursable under the Medicare, Medicaid or other governmental
        programs. A person or entity does not need to have actual knowledge of the federal Anti-Kickback Statute or specific intent to violate
        it to have committed a violation; in addition, items or services resulting from a violation of the federal Anti-Kickback Statute may constitute
        a false or fraudulent claim for purposes of the False Claims Act;</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 18pt"><br /> </td>
    <td style="width: 18pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>the federal False Claims Act imposes civil penalties, and provides for civil whistleblower or qui tam actions, against individuals
        or entities for knowingly presenting, or causing to be presented, to the federal government, claims for payment that are false or fraudulent
        or making a false statement to avoid, decrease or conceal an obligation to pay money to the federal government;</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 18pt"><br /> </td>
    <td style="width: 18pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>the Health Insurance Portability and Accountability Act of 1996, or HIPAA, imposes criminal and civil liability for executing a scheme
        to defraud any health care benefit program or making false statements relating to health care matters. Similar to the federal Anti-Kickback
        Statute, a person or entity does not need to have actual knowledge of the statute or specific intent to violate it to have committed a
        violation;</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 18pt"><br /> </td>
    <td style="width: 18pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>the federal false statements statute prohibits knowingly and willfully falsifying, concealing or covering up a material fact or making
        any materially false statement in connection with the delivery of or payment for health care benefits, items or services;</div> </td>
        </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 18pt"><br /> </td>
    <td style="width: 18pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act, which governs the conduct of certain
        electronic healthcare transactions and protects the security and privacy of protected health information that is stored or transmitted
        electronically;</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 18pt"><br /> </td>
    <td style="width: 18pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>the Physician Payments Sunshine Act, created under the ACA, and its implementing regulations, which requires specified manufacturers
        of drugs, devices, biologics and medical supplies for which payment is available under Medicare, Medicaid or the Children&#8217;s Health
        Insurance Program, with specific exceptions, to report annually to the Centers for Medicare &amp; Medicaid Services, or CMS, information
        related to payments or other &#8220;transfers of value&#8221; made to physicians. All such reported information is publicly available;</div>
        </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 18pt"><br /> </td>
    <td style="width: 18pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>analogous state and non-U.S. laws and regulations, such as state anti-kickback and false claims laws which may apply to items or
        services reimbursed by any payer, including commercial insurers; state laws that require pharmaceutical companies to comply with the industry&#8217;s
        voluntary compliance guidelines and the applicable compliance guidance promulgated by the federal government or otherwise restrict payments
        that may be made to healthcare providers and other potential referral sources; state laws that require pharmaceutical manufacturers to
        report information related to payments and other transfers of value to physicians and other healthcare providers or marketing expenditures;
        and state laws governing the privacy and security of health information in certain circumstances, many of which differ from each other
        in significant ways and may not have the same effect, thus complicating compliance efforts; and</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 18pt"><br /> </td>
    <td style="width: 18pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>regulation by the Centers for Medicare and Medicaid Services and enforcement by the U.S. Department of Health and Human Services
        Office of Inspector General or the U.S. Department of Justice.</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Because of the breadth of these laws and the narrowness of the statutory exceptions
and safe harbors available, it is possible that some of our future business activities could be subject to challenge under one or more
of such laws. Efforts to ensure that our business arrangements with third parties will comply with applicable laws and regulations will
involve substantial costs. It is possible that governmental authorities will conclude that our business practices may not comply with
current or future statutes, regulations or case law involving applicable fraud and abuse or other health care laws and regulations. If
our operations are found to be in violation of any of these laws or any other governmental regulations that may apply to us, we may be
subject to significant civil, criminal and administrative penalties, damages, fines, exclusion from government funded health care programs,
such as Medicare and Medicaid, and the curtailment or restructuring of our operations. If any of the physicians or other providers or
entities with whom we expect to do business are found to be not in compliance with applicable laws, they may be subject to criminal, civil
or administrative sanctions, including exclusions from government funded health care programs.</div>

<div style="line-height: 1.25">&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal">33</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000" /></div>
</div>

<div style="text-align: justify; line-height: 1.25; font-weight: bold">Environmental, Health and Safety</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">We are further subject to various foreign, national, federal, state and local laws
and regulations relating to environmental, health and safety matters, in a number of jurisdictions, governing, inter alia, (i) the use,
storage, registration, handling, emission and disposal of chemicals, waste materials and sewage; and (ii) chemical, air, water and ground
contamination, air emissions and the cleanup of contaminated sites, including any contamination that results from spills due to our failure
to properly dispose of chemicals, waste materials and sewage. Our operations at our Jerusalem research and development facility use chemicals
and produce waste materials and sewage. Our activities require permits from various governmental authorities including, local municipal
authorities, the Ministry of Environmental Protection and the Ministry of Health. The Ministry of Environmental Protection and the Ministry
of Health, local authorities and the municipal water and sewage company may conduct periodic inspections in order to review and ensure
our compliance with the various regulations.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Although we do not believe that we will be required to make material operating or
capital expenditures in connection with such laws and regulations, we may be required to incur significant costs to comply with these
laws and regulations in the future, and complying with these laws and regulations may result in a material adverse effect upon our business,
financial condition and results of operations. Further, our failure to comply with such laws and regulations could have a material adverse
effect on our business and reputation, result in an interruption or delay in the development or manufacture of our products, or increase
the costs for the development or manufacture of our products.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">In addition, laws and regulations relating to environmental, health and safety matters
are often subject to change. In the event of any changes or new laws or regulations, we could be subject to new compliance measures or
to penalties for activities which were previously permitted. For instance, Israeli regulations were promulgated in 2011 relating to the
discharge of industrial sewage into the sewer system. These regulations establish new and potentially significant fees for discharging
forbidden or irregular sewage into the sewage system.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-weight: bold">Pharmaceutical Pricing and Reimbursement</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Significant uncertainty exists as to the coverage and reimbursement status of any
drug products for which we plan to seek regulatory approval. Sales of any of our product candidates, if approved, will depend, in part,
on the extent to which the costs of the products will be covered by third-party payors, including government health programs such as Medicare
and Medicaid, commercial health insurers and managed care organizations. Concerns about drug pricing have been expressed by both members
of the United States Congress and the administration. The process for determining whether a payer will provide coverage for a drug product
may be separate from the process for setting the price or reimbursement rate that the payer will pay for the drug product once coverage
is approved. Third-party payers may limit coverage to specific drug products on an approved list, or formulary, which might not include
all of the approved drugs for a particular indication.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">In order to secure coverage and reimbursement for any product that might be approved
for sale, we may need to conduct expensive pharmacoeconomic studies in order to demonstrate the medical necessity and cost-effectiveness
of the product, in addition to the costs required to obtain FDA, EMA or other comparable regulatory approvals. Our product candidates
may not be considered medically necessary or cost-effective. A payer&#8217;s decision to provide coverage for a drug product does not
imply that an adequate reimbursement rate will be approved. Third-party reimbursement may not be sufficient to enable us to maintain price
levels high enough to realize an appropriate return on our investment in product development.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">The containment of healthcare costs has become a priority of governments, and the
prices of drugs have been a focus in this effort. Third-party payers are increasingly challenging the prices charged for medical products
and services and examining the medical necessity and cost effectiveness of medical products in addition to their safety and efficacy.
If these third-party payors do not consider our products to be cost-effective compared to other available therapies, they may not cover
our products if approved under their plans or, if they do, the level of payment may not be sufficient to allow us to sell our products
at a profit. The U.S. government, state legislatures and non-U.S. governments have shown significant interest in implementing cost containment
programs to limit the growth of government-paid health care costs, including price controls, restrictions on reimbursement and requirements
for substitution of generic products for branded prescription drugs. Adoption of such controls and measures, and tightening of restrictive
policies in jurisdictions with existing controls and measures, could limit payments for pharmaceuticals such as the product candidates
that we are developing and could adversely affect our net revenue and results.</div>

<div style="line-height: 1.25">&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal">34</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000" /></div>
</div>

<div style="text-align: justify; line-height: 1.25">Pricing and reimbursement schemes vary widely from country to country. Some countries
provide that drug products may be marketed only after a reimbursement price has been agreed. Some countries may require the completion
of additional studies that compare the cost-effectiveness of a particular product candidate to currently available therapies. The conduct
of such studies could be expensive and result in delays in our commercializing efforts. The EU provides options for its member states
to restrict the range of drug products for which their national health insurance systems provide reimbursement and to control the prices
of medicinal products for human use. EU member states may approve a specific price for a drug product or may instead adopt a system of
direct or indirect controls on the profitability of the company placing the drug product on the market. Other member states allow companies
to fix their own prices for drug products, but monitor and control company profits. The downward pressure on health care costs in general,
particularly prescription drugs, has become very intense. As a result, increasingly high barriers are being erected to the entry of new
products. In addition, in some countries, cross-border imports from low-priced markets exert competitive pressure that may reduce pricing
within a country. There can be no assurance that any country that has price controls or reimbursement limitations for drug products will
allow favorable reimbursement and pricing arrangements for any of our products.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">The marketability of any products for which we receive regulatory approval for commercial
sale may suffer if the government and third-party payors fail to provide adequate coverage and reimbursement. In addition, emphasis on
managed care in the United States has increased and we expect will continue to increase the pressure on drug pricing. Coverage policies,
third-party reimbursement rates and drug pricing regulation may change at any time. Even if favorable coverage and reimbursement status
is attained for one or more products for which we receive regulatory approval, less favorable coverage policies and reimbursement rates
may be implemented in the future.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-weight: bold">Health Care Reform</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">In the United States, there have been and continue to be a number of significant legislative
initiatives to contain healthcare costs. The ACA was enacted in the United States in March 2010 and contains provisions that may reduce
the profitability of drug products, including, for example, increased rebates for drugs subject to the Medicaid Drug Rebate Program, extension
of Medicaid rebates to Medicaid managed care plans, mandatory discounts for certain Medicare Part D beneficiaries and annual fees based
on pharmaceutical companies&#8217; share of sales to federal health care programs.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">In addition, other legislative changes have been proposed and adopted since the ACA
was enacted. These changes included aggregate reductions to Medicare payments to providers of 2% per fiscal year, effective April 1, 2013
and, due to subsequent legislative amendments to the statute, will stay in effect through 2027, unless additional Congressional action
is taken; however, pursuant to the CARES Act, and subsequent legislation, these reductions are suspended from May 1, 2020 through March
31, 2022 due to the COVID-19 pandemic. In January 2013, the American Taxpayer Relief Act of 2012 was signed into law, which, among other
things, reduced Medicare payments to several providers, and increased the statute of limitations period for the government to recover
overpayments to providers from three to five years. These laws may result in additional reductions in Medicare and other healthcare funding,
which could have a material adverse effect on customers for our drugs, if approved, and, accordingly, our financial operations.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Moreover, recently there has been heightened governmental scrutiny over the manner
in which manufacturers set prices for their commercial products. There have been several recent U.S. Congressional inquiries and proposed
and enacted federal and state legislation designed to, among other things, bring more transparency to drug pricing, review the relationship
between pricing and manufacturer patient programs, reduce the cost of drugs under Medicare, and reform government program reimbursement
methodologies for drugs. The FDA released a final rule on September 24, 2020, effective November 30, 2020, providing guidance for states
to build and submit importation plans for drugs from Canada. Further, on November 20, 2020, the U.S. Department of Health and Human Services,
or HHS, finalized a regulation removing safe harbor protection for price reductions from pharmaceutical manufacturers to plan sponsors
under Part D, either directly or through pharmacy benefit managers, unless the price reduction is required by law. The rule also creates
a new safe harbor for price reductions reflected at the point-of-sale, as well as a safe harbor for certain fixed fee arrangements between
pharmacy benefit managers and manufacturers. At the state level, legislatures have increasingly passed legislation and implemented regulations
designed to control pharmaceutical and biological product pricing, including price or patient reimbursement constraints, discounts, restrictions
on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation
from other countries and bulk purchasing. Although a number of these, and other proposed measures may require authorization through additional
legislation to become effective, Congress has indicated that it will continue to seek new legislative measures to control drug costs.</div>

<div style="line-height: 1.25">&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal">35</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000" /></div>
</div>

<div style="text-align: justify; line-height: 1.25">Additionally, CMS issued a final rule, effective on July 9, 2019, that requires direct-to-consumer
advertisements of prescription drugs and biological products, for which payment is available through or under Medicare or Medicaid, to
include in the advertisement the Wholesale Acquisition Cost, or list price, of that drug or biological product if it is equal to or greater
than $35 for a monthly supply or usual course of treatment. Prescription drugs and biological products advertisements that are in violation
of these requirements will be included on a public list.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Any adopted health reform measure could reduce the ultimate demand for our products,
if approved, or put pressure on our product pricing. Individual states in the United States have also become increasingly active in passing
legislation and implementing regulations designed to control pharmaceutical product pricing, including price or patient reimbursement
constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases,
designed to encourage importation from other countries and bulk purchasing. In addition, regional healthcare authorities and individual
hospitals are increasingly using bidding procedures to determine what pharmaceutical products and which suppliers will be included in
their prescription drug and other healthcare programs. We expect that additional state and federal healthcare reform measures will be
adopted in the future.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">We expect that additional state and federal healthcare reform measures, as well as
legal changes by foreign governments, will be adopted in the future, any of which could limit the amounts that governments will pay for
healthcare products and services, which could result in reduced demand for our product candidates or additional pricing pressures.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-weight: bold">Employees</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">As of December 31, 2022, we had 20 employees and consultants based in Israel, including
our Chief Executive Officer and Chief Operating Officer, as well as 15 other full-time employees, two part time employees, and one part-time
consultant who serves as our Chief Financial Officer. In addition, we employ a number of specialized outside advisors and expert consultants
based in the United States, United Kingdom and Europe, including our Chief Medical Officer. The distribution of our full-time employees
according to main areas of activity is set forth in the following table:</div>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" class="cfttable" style="font: 10pt Times New Roman, Times, serif; text-align: left; color: #000000; width: 100%">
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid; vertical-align: bottom">
        <div style="text-align: center; line-height: 1.25; font-weight: bold">Employees</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; background-color: #CCEEFF">
        <div style="text-align: justify; line-height: 1.25">Area of Activity:</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; vertical-align: bottom; background-color: #CCEEFF">&#160;</td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: #CCEEFF; vertical-align: bottom">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; width: 88%">
        <div style="text-align: justify; line-height: 1.25">Research and development</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25">15</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">&#160;</td> </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; background-color: #CCEEFF; width: 88%; padding-bottom: 2px">
        <div style="text-align: justify; line-height: 1.25">General and administrative</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; border-bottom: #000000 2px solid; background-color: #CCEEFF; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; border-bottom: #000000 2px solid; background-color: #CCEEFF; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25">2</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: #CCEEFF; vertical-align: bottom; width: 1%; padding-bottom: 2px">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; width: 88%; padding-bottom: 4px">
        <div style="text-align: justify; line-height: 1.25">Total</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 4px">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 4px double; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 4px double; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25">17</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 4px">&#160;</td>
        </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Israeli labor laws govern the length of the workday and workweek, minimum wages for
employees, procedures for hiring and dismissing employees, determination of severance pay, annual leave, sick days, advance notice of
termination, payments to the National Insurance Institute, and other conditions of employment and include equal opportunity and anti-discrimination
laws. While we are not, and none of our employees is, party to any collective bargaining agreements, certain provisions of the collective
bargaining agreements between the Histadrut (General Federation of Labor in Israel) and the Coordination Bureau of Economic Organizations
(including the Industrialists&#8217; Associations) are applicable to our employees in Israel by order of the Israeli Ministry of the Economy.
These provisions primarily concern pension fund benefits for all employees, insurance for work-related accidents, recuperation pay and
travel expenses. We generally provide our employees with benefits and working conditions beyond the required minimums. We have never experienced
any employment-related work stoppages and believe our relationships with our employees are good.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-weight: bold">Facilities</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">For more information regarding our facilities, see &#8220;Item 2&#8212;Properties&#8221;
contained in this Annual Report on Form 10-K.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-weight: bold">Legal Proceedings</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">For more information regarding legal proceedings, see &#8216;Item 3&#8212;Legal Proceedings&#8221;
contained in this Annual Report on Form 10-K.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="line-height: 1.25; font-weight: bold">Additional Information</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Our website is at <span style="text-decoration: underline">www.enterabio.com</span>.
We make available, free of charge, on our investor relations section under the heading &#8220;SEC Filings&#8221; our annual reports on
Form 10-K, quarterly reports on Form 10-Q, current reports on Form 8-K, and any amendments to those reports filed with or furnished to
the SEC pursuant to Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended, as soon as reasonably practicable after
we electronically file such material with, or furnish it to, the SEC. Our website address is included in this report only as an inactive
textual reference. Information contained on, or available through, our website is not incorporated by reference in, or made a part of,
this report.</div>

<div style="line-height: 1.25">&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal">36</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000" /></div>
</div> <br />

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif; font-weight: bold">ITEM 1A<span id="ITEM1A"><!--Anchor--></span>.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
RISK FACTORS</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-style: italic">You should carefully consider the risks described
below, as well as other information contained in this Annual Report, including the consolidated financial statements and the notes thereto
and &#8220;Item 7-Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations.&#8221; The occurrence of
any of the events discussed below could significantly and adversely affect our business, prospects, results of operations, financial condition,
and cash flows.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-style: italic">Any investment in our securities involves a
high degree of risk. You should consider carefully the following factors and all other information contained in this Annual Report before
you make a decision to invest in our Ordinary Shares and publicly traded warrants to purchase our Ordinary Shares listed on the Nasdaq
under the symbol ENTXW (the &#8220;IPO Warrants&#8221;). If any of the negative events referred to below occur, our business, prospects,
financial condition and results of operations could be materially and adversely affected. In any such case, the trading price of our Ordinary
Shares could decline, and you could lose all or part of your investment.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-weight: bold">Risk Factor Summary</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Our business is subject to a number of risks, including risks that may prevent us
from achieving our business objectives or may adversely affect our business, financial condition, results of operations, cash flows and
prospects. These risks are discussed more fully later in this Item 1A, and include, but are not limited to, the following:</div>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 18pt"><br /> </td>
    <td style="width: 18pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>We have incurred significant losses since our inception and anticipate that we will continue to incur substantial losses for the
        next several years;</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 18pt"><br /> </td>
    <td style="width: 18pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>Management has performed an analysis of our ability to continue as a going concern and our independent registered public accounting
        firm has raised substantial doubt as to our ability to continue as a going concern;</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 18pt"><br /> </td>
    <td style="width: 18pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>All of our product candidates, including EB613 and EB612, are in preclinical or clinical development and we have not yet successfully
        completed the development of any product candidates;</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 18pt"><br /> </td>
    <td style="width: 18pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>If serious adverse, undesirable or unacceptable side effects are identified during the development of our product candidates, marketing
        approval may be delayed or we may need to abandon our development of such product candidates, and if such side effects are identified
        following regulatory approval, any approved product label may be limited or we may be subject to other significant negative consequences;</div>
        </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 18pt"><br /> </td>
    <td style="width: 18pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>The commencement and completion of clinical trials can be delayed or prevented for a number of reasons;</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 18pt"><br /> </td>
    <td style="width: 18pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>The results of previous clinical trials may not be predictive of future results, our progress in trials for one product candidate
        may not be indicative of progress in trials for other product candidates, and our trials may not be designed so as to support regulatory
        approval;</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 18pt"><br /> </td>
    <td style="width: 18pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>Even if regulatory approvals are obtained for our product candidates, we will be subject to ongoing government regulation. If we
        fail to comply with applicable current and future laws and government regulations, it could delay or prevent the promotion, marketing
        or sale of our products;</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 18pt"><br /> </td>
    <td style="width: 18pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>Healthcare legislative changes may harm our business and future prospects;</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 18pt"><br /> </td>
    <td style="width: 18pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>We are subject to manufacturing risks that could substantially increase our costs and limit supply of our products;</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 18pt"><br /> </td>
    <td style="width: 18pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>We are highly dependent upon our ability to raise additional capital or enter into agreements with collaborators to develop, commercialize
        and market our products;</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 18pt"><br /> </td>
    <td style="width: 18pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>We may fail to establish, maintain, defend and enforce intellectual property rights with respect to our technology;</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 18pt"><br /> </td>
    <td style="width: 18pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>The price of our Ordinary Shares and IPO Warrants may be volatile, and holders of our Ordinary Shares and IPO Warrants could lose
        all or part of their investment;</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 18pt"><br /> </td>
    <td style="width: 18pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>Your rights and responsibilities as our shareholder will be governed by Israeli law, which may differ in some respects from the rights
        and responsibilities of shareholders of U.S. corporations; and</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 18pt"><br /> </td>
    <td style="width: 18pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>Security, political and economic instability in the Middle East may harm our business.</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal">37</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000" /></div>
</div>

<div style="text-align: justify; line-height: 1.25; font-weight: bold">Risks Related to Our Financial Position</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">We have incurred significant losses since our
inception and anticipate that we will continue to incur substantial losses for the next several years.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">We have incurred net losses in each year since our inception, including net losses
of $13.1 million in 2022 and $12.2 million in 2021. As of December 31, 2022 we had an accumulated deficit of $95.5 million. We expect
to continue to incur substantial losses for the next several years, and we expect these losses to increase as we continue our development
of and potentially seek regulatory approval for, EB613 and EB612 and potentially develop future product candidates, including an additional
oral PTH formulation for non-union fractures. We anticipate that our net losses and accumulated deficit for the next several years will
be significant as we conduct our planned operations. Given our current plans, we anticipate that our existing cash and cash equivalents
will be sufficient to fund our operations into the third quarter of 2024. This assumes capital required to fund our ongoing operations,
including R&amp;D and completion of the Phase 1 PK study related to the new formulation of EB612. This does not include the capital required
to fund our proposed Phase 3 pivotal study for EB613 in osteoporosis and comparative PK study of EB613 and Forteo&#174;. Delays in securing
additional capital or entering into strategic collaborations to capitalize the EB613 Phase 3 program will result in delays in this program.
Accordingly, these factors, among others, raise substantial doubt about our ability to continue as a going concern. Our expectations are
based on management&#8217;s current assumptions, clinical development plans and regulatory submission timelines, which may prove to be
wrong, and we could spend our available financial resources much faster than we currently expect. Because of the numerous risks and uncertainties
associated with the development and commercialization of our product candidates, we are unable to accurately predict the timing or amount
of the development and clinical expenses or when, or if we will be able to achieve, or maintain, profitability. In addition, our expenses
could increase if we are required by the FDA or comparable foreign regulatory authorities to perform preclinical or clinical studies or
trials in addition to those currently expected, or if there are any delays in completing our clinical trials or the development and potential
commercialization of EB613 or any other product candidates. The amount of our future net losses will depend, in part, on the amount and
timing of our expenses, our ability to generate revenue and our ability to raise additional capital. These net losses have had, and will
continue to have, an adverse effect on our stockholders&#8217; equity and working capital.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">Management has performed an analysis of our
ability to continue as a going concern. In addition, our independent registered public accounting firm has raised substantial doubt as
to our ability to continue as a going concern.&#160;</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Based on its assessment, management has raised substantial doubt about our ability
to continue as a going concern. In addition, our independent registered public accounting firm expressed substantial doubt as to our ability
to continue as a going concern in their report accompanying our audited consolidated financial statements. As of March 27, 2023, we had
cash and cash equivalents of approximately $11.0 million. Given our current plans, we anticipate that our existing cash and cash equivalents
will be sufficient to fund our operations into the third quarter of 2024. This assumes capital required to fund our ongoing operations,
including R&amp;D and completion of the Phase 1 PK study related to the new formulation EB612. This does not include the capital required
to fund our proposed Phase 3 pivotal study for EB613 in osteoporosis and comparative PK study of EB613 and Forteo&#174;. Our expectations
are based on management&#8217;s current assumptions, clinical development plans and regulatory submission timelines, which may prove to
be wrong, and we could spend our available financial resources much faster than we currently expect. Our ability to continue as a going
concern will depend on our ability to obtain additional financing. The Company constantly evaluates options with respect to various financing
alternatives including public or private equity offerings, debt financings and strategic collaborations to finance future clinical trials,
including the Phase 3 pivotal study for EB613 in osteoporosis and comparative PK study of EB613 and Forteo&#174;, research and development
activities and general and administrative expenses. A going concern opinion could impair our ability to finance our operations through
public or private equity offerings, or debt financings, or a combination of one or more of these funding sources. Any additional equity
or debt financing could be extremely dilutive to our current shareholders. Additional capital may not be available on reasonable terms,
or at all, and we may be required to delay, terminate or significantly curtail our operations, or enter into arrangements with collaborative
partners or others that may require us to relinquish rights to certain aspects of our product candidates, or potential markets that we
would not otherwise relinquish. If we are unable to obtain capital, our business, including our ability to conduct studies and develop
our product candidates, would be jeopardized and we may not be able to continue operations.</div>

<div style="line-height: 1.25">&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal">38</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000" /></div>
</div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">Due to our limited resources and access to
capital, we must and have in the past decided to prioritize development of certain product candidates; these decisions may prove to have
been wrong and may adversely affect our current and any potential future revenues.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Because we have limited resources and access to capital to fund our operations, we
must decide which product candidates to pursue and the amount of resources to allocate to each product candidate. As such, we are currently
primarily focused on the development of EB613 and EB612 for the treatment of osteoporosis and hypoparathyroidism, respectively. Our decisions
concerning the allocation of research, collaboration, management and financial resources toward particular compounds, product candidates
or therapeutic areas may not lead to the development of viable commercial products and may divert resources away from better opportunities.
Similarly, our current or potential decisions to delay, terminate or collaborate with third parties with respect to certain product development
programs may also be sub-optimal and could cause us to miss valuable opportunities. If we make incorrect determinations regarding the
market potential of our product candidates or misread trends in the biopharmaceutical industry, our business, financial condition and
results of operations could be materially adversely affected.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">We will require substantial additional funding,
which may not be available to us on acceptable terms, or at all, and, if not available, may require us to delay, reduce or cease our product
development activities and operations.&#160;</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">We are currently advancing our lead product candidate EB613 through clinical development.
Developing therapeutics, including conducting preclinical studies and clinical trials, is expensive. We will require substantial additional
capital in order to complete research and development, clinical trials, file with the regulatory agencies, including the FDA and EMA,
secure commercial manufacturing supply for and commercialize our product candidates. If the FDA or comparable foreign regulatory authorities
require that we perform additional preclinical studies or clinical trials at any point, our expenses would further increase beyond what
we currently expect, and the anticipated timing of any future clinical development activities and potential regulatory approvals may be
delayed depending upon our allocation of resources and available funding. Additional funds may not be available when we need them on terms
that are acceptable to us, or at all. If adequate funds are not available to us on a timely basis, or on acceptable terms, we may be required
to delay, limit, reduce or terminate preclinical studies, clinical trials or other development activities for one or more of our product
candidates or delay, limit, reduce or terminate our establishment of manufacturing, sales and marketing capabilities or other activities
that may be necessary to commercialize our product candidates.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">We expect that we would need to raise additional funds to support the execution of
our long-term growth strategy, including for a potential Phase 3 trial of EB613 and a comparative PK trial of EB613 with Forteo&#174;,
additional non-clinical and clinical studies for EB612, and further development of our technology platform and pre-clinical product candidates.
We can provide no assurance that additional funding will be available on a timely basis, on terms acceptable to us, or at all. Because
successful development of our product candidates is uncertain, we are unable to estimate the actual amount of financing we will require
to complete research and development and to commercialize our product candidates. The amount and timing of our funding requirements will
depend on many factors, including but not limited to:</div>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 18pt"><br /> </td>
    <td style="width: 18pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>the scope, progress, timing, cost and results of research, preclinical development, and clinical trials;</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 18pt"><br /> </td>
    <td style="width: 18pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>the costs, timing and outcome of seeking and obtaining approvals from the FDA, EMA or other regulatory agencies in relation to registrational
        strategies and potential NDA or BLA approvals for our product candidates;</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 18pt"><br /> </td>
    <td style="width: 18pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>the costs associated with manufacturing our product candidates and potentially establishing sales, marketing, and distribution capabilities
        in the absence of commercial partnerships;</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 18pt"><br /> </td>
    <td style="width: 18pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>the costs associated with obtaining, maintaining, expanding, defending and enforcing the scope of our intellectual property portfolio,
        including the amount and timing of any payments we may be required to make in connection with the licensing, filing, defense and enforcement
        of any patents or other intellectual property rights;</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 18pt"><br /> </td>
    <td style="width: 18pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>the extent to which we acquire or in-license other products or technologies;</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 18pt"><br /> </td>
    <td style="width: 18pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>the economic and other terms, timing of and success of any collaboration, licensing, or other arrangements into which we entered
        or may enter in the future, including the timing of achievement of milestones and receipt of any milestone or royalty payments under these
        agreements;</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 18pt"><br /> </td>
    <td style="width: 18pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>our need and ability to hire additional management, scientific, and medical personnel;</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal">39</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000" /></div>
</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 18pt"><br /> </td>
    <td style="width: 18pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>the effect of competing products that may limit market penetration of our product candidates;</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 18pt"><br /> </td>
    <td style="width: 18pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>the amount and timing of revenues, if any, we receive from commercial sales of any product candidates for which we receive marketing
        approval in the future;</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 18pt"><br /> </td>
    <td style="width: 18pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>our need to implement additional internal systems and infrastructure, including financial and reporting systems to support our current
        operations as a public company; and</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 18pt"><br /> </td>
    <td style="width: 18pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>the residual impact of COVID-19 on our clinical trials, regulatory timelines, business operations and financial stability.</div>
        </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Many of these factors are outside of our control. Based upon our currently expected
level of operating expenditures, we believe that we will be able to fund our operations into the third quarter of 2024. This assumes capital
required to fund our ongoing operations, including R&amp;D and completion of the Phase 1 PK study related to the new formulation EB612.
This does not include the capital required to fund our proposed Phase 3 pivotal study for EB613 in osteoporosis and comparative PK study
of EB613 and Forteo&#174;. Delays in securing additional capital or entering into strategic collaborations to capitalize the EB613 Phase
3 program will result in delays in this program. Our expectations are based on management&#8217;s current assumptions, clinical development
plans and regulatory submission timelines, which may prove to be wrong, and we could spend our available financial resources much faster
than we currently expect. This period could be shortened if there are any unanticipated increases in spending on development programs
or other unanticipated increases in spending related to circumstances outside of our control, including, without limitation, costs associated
with litigation or other legal proceedings, hiring of additional consultants and personnel or procurement of additional raw materials.
Our existing cash and cash equivalents will not be sufficient to obtain regulatory approval for any of our product candidates. Accordingly,
we continue to require substantial additional capital. In order to fund our future capital needs, we may seek additional funding through
equity or debt financings, development partnering arrangements, lines of credit or other sources. These conditions raise substantial doubt
about our ability to continue as a going concern, and we will be required to raise additional funds, seek alternative means of financial
support, including strategic partnerships, or both, in order to continue operations. The accompanying financial statements have been prepared
assuming that we will continue as a going concern and do not include adjustments that might result from the outcome of this uncertainty.
If we are unable to raise the requisite funds, we will need to delay the initiation of core activities, curtail or cease operations.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Our fundraising efforts in the future to secure additional financing will divert our
management from our day-to-day activities, which may adversely affect our ability to develop and commercialize our product candidates.
In addition, we cannot guarantee that future financing will be available in sufficient amounts or on terms acceptable to us, if at all.
If we are unable to raise additional capital when required or on acceptable terms, we may be required to significantly delay, reduce or
discontinue the development or commercialization of one or more of our product candidates or curtail our operations, which will have an
adverse effect on our business, operating results and prospects.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">We have a limited operating history and no
history of late stage clinical studies and commercializing pharmaceutical products, which may make it difficult to evaluate the prospects
for our future viability and making an investment in our Ordinary Shares unsuitable for many investors.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">We began operations in 2010. Our operations to date have been limited to financing
and staffing our company, developing our drug delivery technology and early clinical development of our product candidates. We have not
yet demonstrated an ability successfully to complete a large-scale, pivotal clinical trial, obtain marketing approval, manufacture a commercial
scale product or conduct sales and marketing activities necessary for successful product commercialization. Consequently, predictions
about our future success or viability may not be as accurate as they could be if we had a history of successfully developing and commercializing
pharmaceutical products.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">Raising additional capital may cause dilution
to our shareholders, and these financings, or disputes with shareholders in connection therewith, may restrict our operations or require
us to relinquish substantial rights or result in unanticipated legal or other costs.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Until such time, if ever, as we can generate substantial product revenue, we expect
to finance our cash needs through a combination of public or private equity offerings, debt financings and strategic collaborations. We
do not have any committed external sources of funds and we will need to raise additional capital. To the extent that we raise additional
capital through the sale of equity or convertible debt securities, your ownership interest will be diluted, and the terms of these new
securities may include liquidation or other preferences that adversely affect the rights of a holder of our Ordinary Shares. Debt financing,
if available at all, may involve agreements that include covenants limiting or restricting our ability to take specific actions such as
incurring additional debt, making capital expenditures, or declaring dividends, and may be secured by all or a portion of our assets.
Further, we may incur substantial costs in pursuing future capital and/or financing, including investment banking fees, legal fees, accounting
fees, printing and distribution expenses and other costs and such efforts may divert our management from their day-to-day activities,
which may compromise our ability to develop and market our product candidates. We may also be required to recognize non-cash expenses
in connection with certain securities we may issue, such as convertible notes and warrants, which could cause our operating results to
fluctuate on a quarterly basis.</div>

<div style="line-height: 1.25">&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal">40</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000" /></div>
</div>

<div style="text-align: justify; line-height: 1.25">If we raise additional funds through collaborations, strategic alliances, or licensing
arrangements with third parties, we may have to relinquish valuable rights to our technologies, product candidates, or future revenue
streams, or grant licenses on terms that are not favorable to us. We cannot assure you that we will be able to obtain additional funding
if and when necessary. If we are unable to obtain adequate financing on a timely basis, we could be required to delay, scale back or eliminate
one or more of our development programs or grant rights to develop and market product candidates that we would otherwise prefer to develop
and market ourselves.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">The requirements of being a public company
may strain our resources and distract our management, which could make it difficult to manage our business, particularly after we are
no longer an Emerging Growth Company.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">As a public company, we are required to comply with various regulatory and reporting
requirements, including those required by the SEC. Complying with these reporting and regulatory requirements are time consuming, result
in increased costs to us and could have a negative effect on our business, results of operations and financial condition.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">We are subject to the reporting requirements of the Exchange Act, and the requirements
of the Sarbanes-Oxley Act of 2002, as amended, or the Sarbanes-Oxley Act. These requirements may place a strain on our systems and resources.
The Exchange Act requires that we file annual and current reports with respect to our business and financial condition. The Sarbanes-Oxley
Act requires that we maintain effective disclosure controls and procedures and internal control over financial reporting. We are implementing
procedures and processes for the purpose of addressing the standards and requirements applicable to public companies. Complying with these
requirements is costly and time consuming. In the event that we are unable to demonstrate compliance with our obligations as a public
company in a timely manner, or are unable to produce timely or accurate financial statements, we may be subject to sanctions or investigations
by regulatory authorities, such as the SEC or Nasdaq, investors may lose confidence in our operating results and the price of our Ordinary
Shares could decline. These activities may divert management&#8217;s attention from other business concerns, which could have a material
adverse effect on our business, financial condition, results of operations and cash flows.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">As an emerging growth company, we may take advantage of certain temporary exemptions
from various reporting requirements including, but not limited to, not being required to comply with the auditor attestation requirements
of Section 404 of the Sarbanes-Oxley Act and the rules and regulations of the SEC thereunder. We plan to take advantage of these exemptions
but we cannot guarantee that we will not be required to implement these requirements sooner than budgeted or planned and thereby incur
unexpected expenses. We will remain an emerging growth company until the earliest of: (a) the last day of our fiscal year during which
we have total annual gross revenues of at least $1.07 billion; (b) the last day of our fiscal year following the fifth anniversary of
the completion of our IPO, specifically, December 31, 2023; (c) the date on which we have, during the previous three-year period, issued
more than $1.0 billion in non-convertible debt; or (d) the date on which we are deemed to be a large accelerated filer, or Large Accelerated
Filer, under the Exchange Act with at least $700 million of equity securities held by non-affiliates. We cannot predict or estimate the
amount of additional costs we may incur as a result of no longer being an Emerging Growth Company or the timing of such costs.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Our Ordinary Shares and IPO Warrants are listed on Nasdaq. As a public company listed
on Nasdaq, we incur significant legal, accounting and other expenses. In addition, changing laws, regulations and standards, in the United
States or Israel, relating to corporate governance and public disclosure and other matters, may be implemented in the future, which may
increase our legal and financial compliance costs, make some activities more time consuming and divert management&#8217;s time and attention
from revenue-generating activities to compliance activities. If our efforts to comply with new laws, regulations and standards differ
from the activities intended by regulatory or governing bodies due to ambiguities related to practice, regulatory authorities may initiate
legal proceedings against us and our business may be harmed. Furthermore, because we are a publicly traded company in the United States
and subject to U.S. rules and regulations, it is more expensive for us to obtain director and officer liability insurance, and we may
be required to accept reduced coverage or incur substantially higher costs to obtain coverage. These factors may also make it more difficult
for us to attract and retain qualified members of our board of directors, particularly to serve on our audit committee, and qualified
executive officers.</div>

<div style="line-height: 1.25">&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal">41</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000" /></div>
</div>

<div style="text-align: justify; line-height: 1.25; font-weight: bold">Risks Related to Our Business and the Development of Our Product
Candidates</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">All of our product candidates are in preclinical
or clinical development and we have not yet successfully completed the development of any product candidates.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">We are a clinical-stage company focused on the development of orally delivered peptide
and protein therapeutics to treat unmet medical needs. We commenced operations in 2010 and have a limited operating history. Since inception,
we have devoted substantially all of our resources to the development of our technology platform, the clinical and preclinical advancement
of our product candidates, the creation, licensing and protection of related intellectual property rights and the provision of general
and administrative support for these operations. We have not yet obtained regulatory approval for any product candidates in any jurisdiction
or generated any revenues from any product sales. If any of our current or future product candidates fails in clinical trials or preclinical
development, or does not gain regulatory approval, or if our product candidates following regulatory approval, if any, do not achieve
market acceptance, we may never become profitable or sustain profitability.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">We commenced our first clinical trials with our oral PTH candidates in osteoporosis
and hypoparathyroidism, and we have a limited operating history of developing products upon which our business and prospects can be evaluated.
In addition, our Phase 2 clinical trial for EB613 for osteoporosis was the largest clinical trial we have conducted to date, and we have
never conducted clinical trials of a size required for regulatory approvals. Furthermore, we have not yet demonstrated an ability to successfully
overcome many of the risks and uncertainties frequently encountered by companies in rapidly evolving fields, such as the oral delivery
of protein therapeutics.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">To become and remain profitable, we must succeed in developing and commercializing
products that generate significant revenues. This will require us to be successful in a range of challenging activities for which we are
only in the preliminary stages, including developing product candidates, completing pre-clinical and clinical trials for such product
candidates, obtaining regulatory approval for them, and manufacturing, marketing and selling those products for which we may obtain regulatory
approval. We may never succeed in these activities and, even if we do, we may never generate revenue from product sales that is significant
enough to achieve profitability. Our ability to generate future revenue from product sales depends heavily on our success in many areas,
including but not limited to:</div>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 18pt"><br /> </td>
    <td style="width: 18pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>the completion of future development efforts for EB613, EB612 or other product candidates;</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 18pt"><br /> </td>
    <td style="width: 18pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>securing additional funding as may be needed to continue the development of EB613 or any other product candidates;</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 18pt"><br /> </td>
    <td style="width: 18pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>obtaining required regulatory and marketing approvals for the clinical development, manufacturing and commercialization of EB613,
        EB612 and any other product candidates we may develop;</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 18pt"><br /> </td>
    <td style="width: 18pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>obtaining adequate reimbursement from third-party payors for any product that may be commercialized, if approved;</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 18pt"><br /> </td>
    <td style="width: 18pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>managing our spending as costs and expenses increase due to the preparation of regulatory filings, potential regulatory approvals,
        manufacturing scale-up and potential commercialization;</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 18pt"><br /> </td>
    <td style="width: 18pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>continuing to build and maintain our intellectual property portfolio;</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 18pt"><br /> </td>
    <td style="width: 18pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>recruiting and retaining qualified executive management and other personnel;</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 18pt"><br /> </td>
    <td style="width: 18pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>building and maintaining appropriate research and development, clinical, regulatory, sales, manufacturing, financial reporting, distribution
        and marketing capabilities on our own or through third parties;</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 18pt"><br /> </td>
    <td style="width: 18pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>gaining market acceptance for our product candidates;</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 18pt"><br /> </td>
    <td style="width: 18pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>developing and maintaining successful strategic relationships and collaborations;</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 18pt"><br /> </td>
    <td style="width: 18pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>developing a sustainable and scalable manufacturing process for any approved product candidates and maintaining supply and manufacturing
        relationships with third parties that can support clinical development and market demand for our product candidates, if approved;</div>
        </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 18pt"><br /> </td>
    <td style="width: 18pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>establishing sales, marketing, and distribution capabilities in the United States and the EU independently or in collaboration with
        strategic partners;</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal">42</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000" /></div>
</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 18pt"><br /> </td>
    <td style="width: 18pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>obtaining market acceptance for any of our product candidates that receive marketing approval, if any, as viable treatment options;</div>
        </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 18pt"><br /> </td>
    <td style="width: 18pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>addressing any competing technological and market developments;</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 18pt"><br /> </td>
    <td style="width: 18pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>negotiating favorable terms in any collaboration, licensing, or other arrangements into which we may enter; and</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 18pt"><br /> </td>
    <td style="width: 18pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>attracting, hiring and retaining qualified personnel.</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">If we are unsuccessful in accomplishing any of these objectives, we may not be able
to develop product candidates, raise capital, expand our business or continue our operations. Even if one or more of the product candidates
that we develop is approved for commercial sale, we anticipate incurring significant costs associated with commercializing any approved
product candidate. Because of the numerous risks and uncertainties with pharmaceutical product development, we are unable to accurately
predict the timing or amount of increased expenses or when, or if, we will be able to achieve profitability. Even if we achieve profitability
in the future, we may not be able to sustain profitability in subsequent periods. Our failure to become or remain profitable would depress
our market value and could impair our ability to raise capital, expand our business, develop other product candidates, or continue our
operations. A decline in the value of our company could also cause you to lose all or part of your investment.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">We depend on enrollment of patients in our
clinical trials for our product candidates. If we are unable to enroll an adequate number of volunteers or patients in our clinical trials,
our research and development efforts could be materially adversely affected.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Successful and timely completion of clinical trials will require that we enroll enough
volunteers in early studies, or patients with a specific disease in later trials. Trials may be subject to delays as a result of enrollment
taking longer than anticipated or subject withdrawal. Enrollment depends on many factors, including the size and nature of the patient
population, eligibility criteria for the trial, the proximity of patients to clinical sites, the design of the clinical protocol, the
number of competing clinical trials, the availability of drugs approved for the indication the clinical trial is investigating, and clinicians&#8217;
and patients&#8217; perceptions as to the potential advantages of the product being studied in relation to other available therapies.
Our most advanced programs, EB613 and EB612 may compete with marketed drugs, such as Forteo&#174;, Tymlos&#174;, Evenity&#174;, and osteoanabolic
drugs in clinical development for osteoporosis and drugs in clinical development for hypoparathyroidism such as TransCon&#8482; PTH or
Eneboparatide. Furthermore, EB612 has orphan drug designation in the United States and in the EU, which means that the potential patient
population is limited. These factors may make it difficult for us to enroll enough subjects to complete our clinical trials in a timely
and cost-effective manner. Delays in the completion of any clinical trial of our product candidates will increase our costs, slow down
development of our product candidates and any potential approvals and delay or potentially jeopardize our ability to commence product
sales and generate revenue. In addition, some of the factors that cause, or lead to, a delay in the commencement or completion of clinical
trials may also ultimately lead to the denial of regulatory approval of our product candidates.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">We may not be successful in our efforts to
use and expand our drug delivery technology to other product candidates.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">An element of our strategy is to combine our oral drug delivery technology platform
with a variety of peptides and therapeutic proteins and large molecule active pharmaceutical ingredients, or APIs, to build a pipeline
of product candidates and progress these product candidates through clinical development for the treatment of a variety of different types
of diseases. We intend to use our technology in combination with known APIs, to validate our platform and potentially minimize risk and
development timelines.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Our initial product candidates combine our oral drug delivery technology with PTH,
a hormone that has been used in injectable form for many years for the treatment of osteoporosis and hypoparathyroidism. Our business
is substantially dependent on our ability to complete the development of, obtain regulatory approval for, and successfully commercialize
our oral PTH product candidates in a timely manner. If we are unable to validate our oral drug delivery technology with our PTH product
candidates, in particular our lead candidate EB613, we may be unsuccessful in leveraging our oral drug delivery technology for use with
other APIs. In addition, we have modified the formulation of oral PTH to develop new formulations for applications in hypoparathyroidism
and other indications. If we are not successful in optimizing the formation of our PTH product candidates for additional indications,
or if we are not otherwise able to obtain regulatory approval for them or successfully commercialize them, our business and prospects
may be severely limited.</div>

<div style="line-height: 1.25">&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal">43</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000" /></div>
</div>

<div style="text-align: justify; line-height: 1.25">In addition, our technology makes use of synthetically bioengineered ingredients.
Although our product candidates utilize a synthesized PTH molecule with a known mechanism of action, they may cause patients to exhibit
safety or immune responses that do not match the biological effect of a human protein produced by the parathyroid gland. Such responses
could result in increased regulatory scrutiny, delays or other impediments to our planned development or the public acceptance and commercialization
of our products. Even if we are successful in expanding our drug delivery technology to other APIs for other indications, the potential
product candidates that we identify may not be suitable for clinical development, to the extent they are shown to have harmful side effects
or other characteristics that indicate that they are unlikely to be products that will receive marketing approval and achieve market acceptance.
We may never successfully develop or commercialize our technology with other APIs, which could limit our business and prospects.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">If serious adverse, undesirable or unacceptable
side effects are identified during the development of our product candidates, marketing approval may be delayed or we may need to abandon
our development of such product candidates, and if such side effects are identified following regulatory approval, any approved product
label may be limited or we may be subject to other significant negative consequences.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">All of our product candidates are still in clinical or non-clinical development and
although our product candidates have undergone or will undergo safety testing, not all adverse effects of drugs can be predicted or anticipated.
Unforeseen side effects from any of our product candidates could be recognized either during clinical development or, if such side effects
are rare, after our product candidates have been approved by regulatory authorities and the approved product has been marketed, resulting
in the exposure of additional patients. While our oral PTH programs have exhibited no serious drug related adverse events in our clinical
trials to date, the results of future clinical trials may show that our product candidates cause undesirable or unacceptable side effects,
which could interrupt, delay or halt clinical trials, and result in delay of, or failure to obtain, marketing approval from the FDA, the
EMA and other regulatory authorities, or result in marketing approval from the FDA, the EMA and other regulatory authorities with restrictive
label warnings or potential product liability claims. For instance, other PTH products have historically been issued with labels that
disclose a potential risk of osteosarcoma based on non-clinical studies.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Additionally, the FDA and foreign regulatory agency regulations require that we report
certain information about adverse medical events if our products may have caused or contributed to those adverse events. The timing of
our obligation to report would be triggered by the date on which we become aware of the adverse event as well as the nature of the event.
We may fail to report adverse events we become aware of within the prescribed timeframe. We may also fail to appreciate that we have become
aware of a reportable adverse event, especially if it is not reported to us as an adverse event or if it is an adverse event that is unexpected
or removed in time from the use of our products. If we fail to comply with our reporting obligations, the FDA or a foreign regulatory
agency could take action including criminal prosecution, the imposition of civil monetary penalties or seizure of our products.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">If any of our product candidates receives marketing approval and we or others later
identify undesirable or unacceptable side effects caused by such products:</div>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 18pt"><br /> </td>
    <td style="width: 18pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>regulatory authorities may require us to take these products off the market;</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 18pt"><br /> </td>
    <td style="width: 18pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>regulatory authorities may require the addition of labeling statements, specific warnings, a contraindication or field alerts to
        physicians and pharmacies;</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 18pt"><br /> </td>
    <td style="width: 18pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>we may be required to change the way the product is administered, conduct additional clinical trials or change the labeling of the
        product;</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 18pt"><br /> </td>
    <td style="width: 18pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>we may be subject to limitations on how we may promote the product;</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 18pt"><br /> </td>
    <td style="width: 18pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>sales of the product may decrease significantly;</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 18pt"><br /> </td>
    <td style="width: 18pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>we may be subject to litigation or product liability claims; and</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 18pt"><br /> </td>
    <td style="width: 18pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>our reputation may suffer.</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Any of these events could prevent us or any potential collaborators from achieving
or maintaining market acceptance of the affected product or could substantially increase commercialization costs and expenses, which in
turn could delay or prevent us from generating significant revenue from the sale of our products.</div>

<div style="line-height: 1.25">&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal">44</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000" /></div>
</div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">We manage our business and develop our technology
with a small number of employees and key advisors with deep functional domain expertise, and, in the event of their loss or unavailability,
we may not be able to grow our business or develop and commercialize our products.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">

<div style="line-height: 1.25">We are highly dependent on the biopharmaceutical research and development, clinical, regulatory, CMC and
strategic expertise of our core executive team and key advisors across these domains, including Miranda Toledano, our Chief Executive
Officer. Our success depends upon the continued contributions of these senior executives, employees and advisors, many of whom have substantial
scientific and technical experience with, and have been instrumental to our regulatory, clinical development and technology platform.
Furthermore, recruiting and retaining new executive talent and qualified scientific personnel to perform future research and clinical
development work will be critical to our success. Competition for skilled personnel is intense and turnover rates are high, and our ability
to attract and retain qualified personnel may be limited. The loss or unavailability of the services of any of our key employees and consultants
for any significant period of time or our inability to attract and retain qualified skilled personnel could have a material adverse effect
on our business, technology, prospects, financial condition and results of operations. We do not maintain &#8220;key man&#8221; life insurance
policies for any of our employees.</div>

<div style="line-height: 1.25">&#160;</div> </div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">We expect to grow our organization, particularly
in the United States, specifically to supplement and expand our senior management, clinical development and regulatory capabilities and
marketing infrastructure, and we may experience difficulties in managing these changes and this growth, which could disrupt our operations.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">As our clinical development and commercialization plans and strategies develop, we
expect to supplement and expand our employee base, particularly in the United States, for clinical development, regulatory, operational,
sales, marketing, financial and other capabilities and with senior managers who are either based in the United States or who have significant
U.S. public company experience. These changes may result in significant shifting of responsibilities or replacement of key personnel.
The need to identify, recruit, maintain, motivate and integrate additional employees and senior members of management, including senior
executives, is expected to impose significant responsibilities on our senior executives and may divert a disproportionate amount of their
attention away from our day-to-day activities. The addition of such employees and managers may have an impact on the decisions that we
make over time.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">In conjunction with the addition of these employees and senior members of management,
we intend to grow our company. Due to our limited financial resources and the limited size of our management team, it is possible that
our management, finance, development personnel, systems and facilities currently in place may not be adequate to support this future growth.
We may not be able to effectively manage the expansion of our operations, which may result in weaknesses in our infrastructure, give rise
to operational errors, loss of business opportunities, loss of employees and reduced productivity among remaining employees. Our expected
growth could require significant expenditures and may divert financial resources from other projects, such as the development of existing
and additional product candidates. If we are unable to effectively manage our expected growth, our expenses may increase more than expected,
our ability to generate or grow revenue could be reduced and we may not be able to implement our strategy. Our future financial performance
and our ability to develop our product candidates and compete effectively with others in our industry will depend, in part, on our ability
to effectively manage any future growth. In addition, pursuant to both Israeli law and Nasdaq rules, we have appointed independent directors,
which may result in a change in the company&#8217;s direction over time.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">We are increasingly dependent on information
technology systems, infrastructure and data, and our internal computer systems, or those of our collaborators, third-party clinical research
organizations or other contractors or consultants, may fail or suffer security breaches, which could result in a material disruption of
our product development programs.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">We are increasingly dependent upon information technology systems, infrastructure
and data. Despite the implementation of security measures, our internal computer systems and those of our development partners, third-party
clinical research organizations, data management organizations and other contractors and consultants are vulnerable to damage from service
interruption or destruction, computer viruses, unauthorized access, natural disasters, terrorism, war and telecommunication and electrical
failures. In addition, such systems are subject to compromise from internal threats, such as theft, misuse, unauthorized access or other
improper actions by employees, third-party service providers and other third parties with otherwise legitimate access to our systems.
Cyber-attacks are increasing in their frequency, sophistication and intensity, and have become increasingly difficult to detect. Cyber-attacks
could include the deployment of harmful malware, denial-of service, social engineering and other means to affect service reliability and
threaten data confidentiality, integrity and availability. It is possible that we may not be able to anticipate, detect, appropriately
react and respond to, or implement effective preventative measures against all cybersecurity incidents. Our key business partners face
similar risks, and a security breach of their systems could adversely affect our security posture.</div>

<div style="line-height: 1.25">&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal">45</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000" /></div>
</div>

<div style="text-align: justify; line-height: 1.25">While we have not experienced any such system failure, accident or security breach
to date, if such an event were to occur and cause interruptions in our operations, it could cause damage or destroy assets, compromise
business systems, or otherwise result in a material disruption of our programs and business operations. Security breaches further pose
a risk that sensitive data, including intellectual property, clinical data, trade secrets or personal information may be exposed to unauthorized
persons or to the public, altered or lost. For example, the loss of clinical trial data for any of our product candidates could delay
our ability to report such data, result in delays in our regulatory approval efforts and significantly increase our costs to recover or
reproduce the data. To the extent that any disruption or security breach results in a loss of or damage to our data or applications or
other data or applications relating to our technology or product candidates, or inappropriate disclosure of confidential or proprietary
information, we could incur liabilities, damages or damage to our reputation and the further development of our product candidates could
be delayed. We do not currently maintain a cyber insurance policy and therefore the successful assertion of one or more large claims against
us in connection with a breach or other cybersecurity-related matter could materially adversely affect our business, financial condition
and operating results.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">We rely on email and other messaging services in connection with our operations. We
may be targeted by parties using fraudulent spoofing and phishing emails to misappropriate passwords, payment information or other personal
information or to introduce viruses through Trojan horse programs or otherwise through our networks, computers, smartphones, tablets or
other devices. Despite our efforts to mitigate the effectiveness of such malicious email campaigns through a variety of control and non-electronic
checks, spoofing and phishing may damage our business and increase our costs. Any of these events or circumstances could materially adversely
affect our business, financial condition and operating results.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">We may be required to expend significant capital and other resources to protect against,
respond to, and recover from any potential, attempted, or existing cybersecurity incidents. As cybersecurity incidents continue to evolve,
we may be required to expend significant additional resources to continue to modify or enhance our protective measures or to investigate
and remediate any information security vulnerabilities. In addition, our remediation efforts may not be successful. Moreover, there could
be public announcements regarding any cybersecurity incidents and any steps we take to respond to or remediate such incidents, and if
securities analysts or investors perceive these announcements to be negative, it could, among other things, have a substantial adverse
effect on the price of our Ordinary Shares. There can be no assurance that our efforts will prevent service interruptions, or identify
breaches in our systems, that could adversely affect our business and operations and/or result in the loss of critical or sensitive information
or the illegal transfer of funds to unknown persons, which could result in financial, legal, business or reputational harm, and may harm
our relationships with third parties.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">Our employees may engage in misconduct or other
improper activities, including noncompliance with regulatory standards and requirements and insider trading.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">We are exposed to the risk of employee fraud or other misconduct. Misconduct by employees
could include intentional failures to comply with the regulations of the FDA or foreign regulators, failure to provide accurate information
to regulatory authorities, failure to comply with manufacturing standards we have established, failure to comply with federal and state
health care fraud and abuse laws and regulations in the United States and abroad, failure to report financial information or data accurately,
disclose unauthorized activities to us or failure to comply with our own internal company policies. In particular, sales, marketing and
business arrangements in the healthcare industry are subject to extensive laws and regulations intended to prevent fraud, misconduct,
kickbacks, self-dealing and other abusive practices. These laws and regulations may restrict or prohibit a wide range of pricing, discounting,
marketing and promotion, sales commission, customer incentive programs and other business arrangements. Employee misconduct could also
involve the improper use of information obtained in the course of clinical trials, which could result in regulatory sanctions and cause
harm to our reputation. We have adopted a code of business conduct and ethics, but it is not always possible to identify and deter employee
misconduct, and the precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks
or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to comply with these
laws or regulations. If any such actions are instituted against us, and we are not successful in defending ourselves or asserting our
rights, those actions could have a significant impact on our business, including the imposition of significant fines or other sanctions.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">In addition, during the course of our operations, our directors, executives and employees
may have access to material, nonpublic information regarding our business, our results of operations or potential transactions we are
considering. We may not be able to prevent a director, executive or employee from trading in our Ordinary Shares on the basis of, or while
having access to, material, nonpublic information. If a director, executive or employee was to be investigated or an action was to be
brought against a director, executive or employee for insider trading, it could have a negative impact on our reputation and our stock
price. Such a claim, with or without merit, could also result in substantial expenditures of time and money and divert attention of our
management team from other tasks important to the success of our business.</div>

<div style="line-height: 1.25">&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal">46</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000" /></div>
</div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">We are subject to risks related to restrictive
data privacy regulations governing the collection, use, processing and cross-border transfer of personal information.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">In the ordinary course of our business, we may collect, process, use, store or transfer
sensitive data in our data centers and on our networks, including intellectual property, proprietary business information (both ours and
that of our customers, suppliers and business partners) and personally identifiable information, including in connection with conducting
clinical trials. We are subject to strict data privacy laws and regulations in the United States, United Kingdom, EU, Israel and other
jurisdictions in which we operate, as well as contractual obligations, governing the collection, transmission, storage and use of personal
information. The legislative and regulatory landscape for data privacy and protection continues to evolve around the world and are increasingly
rigorous, with new and constantly changing requirements applicable to our business, including the U.S.&#8217;s federal Health Insurance
Portability and Accountability Act of 1996, as amended, or HIPAA, the EU General Data Protection Regulation ((EU) 2016/679), or the GDPR,
the Israeli Privacy Protection Law, 5741-1981, and other laws and regulations governing the collection, use, disclosure and transmission
of data. The enforcement practices of these laws and regulations are likely to remain uncertain for the foreseeable future. These laws
and regulations may be interpreted and applied differently over time and from jurisdiction to jurisdiction, and it is possible that they
will be interpreted and applied in ways that may have a material adverse effect on our results of operations, financial condition and
cash flows.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">For example, in the United States, various federal and state regulators have adopted,
or are considering adopting, laws and regulations concerning personal information and data security. Certain state laws may be more stringent
or broader in scope, or offer greater individual rights, with respect to personal information than federal, international or other state
laws, and such laws may differ from each other, all of which may complicate compliance efforts. For example, the California Consumer Privacy
Act, or the CCPA, which increases privacy rights for California residents and imposes obligations on companies that process their personal
information, came into effect on January 1, 2020. Among other things, the CCPA requires covered companies to provide new disclosures to
California consumers and provide such consumers new data protection and privacy rights, including the ability to opt-out of certain sales
of personal information. On November 3, 2020, California voters approved a new privacy law, the California Privacy Rights Act, or CPRA,
which significantly modifies the CCPA, including by expanding consumers&#8217; rights with respect to certain personal information and
creating a new state agency to oversee implementation and enforcement efforts. Many of the CPRA&#8217;s provisions have become effective
on January 1, 2023. The CCPA provides for civil penalties for violations, as well as a private right of action for certain data breaches
that result in the loss of personal information. This private right of action may increase the likelihood of, and risks associated with,
data breach litigation. In addition, laws in all 50 U.S. states require businesses to provide notice to consumers whose personal information
has been disclosed as a result of a data breach. State laws are changing rapidly and there is discussion in Congress of a new comprehensive
federal data privacy law to which we would become subject if it is enacted.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">In addition, outside the United States, laws, regulations and standards in many jurisdictions
apply broadly to the collection, use, retention, security, disclosure, transfer and other processing of personal information. For example,
the GDPR greatly increased the European Commission&#8217;s jurisdictional reach of its laws and adds a broad array of requirements for
handling personal data. EU member states are tasked under the GDPR to enact, and have enacted, certain implementing legislation that adds
to and/or further interprets the GDPR requirements and potentially extends our obligations and potential liability for failing to meet
such obligations. The GDPR, together with national legislation, regulations and guidelines of the EU member states governing the processing
of personal data, impose strict obligations and restrictions on the ability to collect, use, retain, protect, disclose, transfer and otherwise
process personal data. Specifically, the GDPR&#8217;s requirements including having legal bases for processing personal information relating
to identifiable individuals and transferring such information outside of the European Economic Area, including to the United States, and
other countries providing details to those individuals regarding the processing of their personal information, keeping personal information
secure, having data processing agreements with third parties who process personal information, responding to individuals&#8217; requests
to exercise their rights in respect of their personal information, reporting security breaches involving personal data to the competent
national data protection authority and affected individuals, appointing data protection officers, conducting data protection impact assessments
and record-keeping. The GDPR imposes additional responsibilities and liabilities in relation to personal data that we process and authorizes
fines for certain violations of up to 4% of global annual revenue or &#8364;20 million, whichever is greater. The U.K. has transposed
the GDPR into domestic law, with its version of the GDPR that took effect on January 1, 2021, which could expose us to two parallel regimes,
each of which potentially authorizes similar fines for certain violations. As such, we may be required to put in place additional mechanisms
ensuring compliance with the new data protection rules.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">All of these evolving compliance and operational requirements impose significant costs,
such as costs related to organizational changes, implementing additional protection technologies, training associates and engaging consultants,
which are likely to increase over time. In addition, such requirements may require us to modify our data processing practices and policies,
distract management or divert resources from other initiatives and projects. Any failure or perceived failure to comply with the requirements
of privacy laws and regulations, including the CCPA, GDPR and related national data protection laws of the member states of the EU and
the U.K., may result in damage to our reputation and our relationship with our customers, as well as proceedings or litigation by governmental
agencies or customers, including class action privacy litigation in certain jurisdictions, which would subject us to significant fines,
sanctions, awards, penalties or judgments, which could have a material adverse effect on our business, prospects, financial condition
and results of operations.</div>

<div style="line-height: 1.25">&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal">47</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000" /></div>
</div>

<div style="line-height: 1.25">&#160;</div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold">Global economic conditions may negatively affect us and may magnify
certain risks that affect our business.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">In recent months, record levels of inflation have resulted in significant volatility
and disruptions in the global economy. In response to rising inflation, central banks in the markets in which we operate, including the
United States Federal Reserve, have tightened their monetary policies and raised interest rates, and such measures may continue if there
is a period of sustained heightened inflation. Higher interest rates and volatility in financial markets could lead to additional economic
uncertainty or recession. Increased inflation rates have increased our and our suppliers&#8217; operating costs, including labor costs,
raw materials costs, manufacturing costs, freight costs and R&amp;D costs. In addition to rising inflation, the global economy has also
been impacted by fluctuating foreign exchange rates and geopolitical tensions, such as the ongoing conflict between Russia and Ukraine,
which has spurred rising energy costs and exacerbated disruptions to the global supply chain caused by the&#160;COVID-19&#160;pandemic
and the government and societal responses to the pandemic. Supply chain disruptions could continue to result in delays in our R&amp;D
and clinical initiatives. As we have substantial international operations, fluctuations in exchange rates between the currencies in which
we operate, which could increase our operating costs and adversely affect our results of operations, and cash flows. The duration and
extent of such macroeconomic developments are uncertain and we cannot accurately predict whether we will be able to effectively and timely
mitigate their impact on our business.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-weight: bold">Risks Related to Regulatory Approval of Our Product Candidates</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif; font-style: italic; font-weight: bold">Clinical
drug development is expensive, time consuming and uncertain. Development programs are subject to regulatory requirements, unanticipated
delays and we may ultimately not be able to obtain regulatory approvals for the commercialization of our product candidates.&#160;</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Our lead product candidates are orally delivered tablet formulations of the synthetic
form of the first 34 amino acids of human PTH, teriparatide. We are developing EB613 to treat osteoporosis and EB612 to treat hypoparathyroidism.
These product candidates have not yet reached late-stage clinical development and are subject to the risks of failure inherent in regulatory
assessments and drug development. The clinical development, manufacturing, quality assurance, labeling, storage, record-keeping, advertising,
promotion, pharmacovigilance, import, export, marketing and distribution of our product candidates is subject to extensive regulation
by the FDA in the United States and by comparable authorities in foreign markets. We are not permitted to market our product candidates
in the United States until we receive approval of a new drug application, or NDA, or biologics license application, or BLA, from the FDA
or in any other country until we receive marketing approval from the applicable regulatory authorities in such countries. We have not
yet submitted a marketing application, or received marketing approval, for any of our product candidates and have limited experience in
conducting and managing the clinical trials necessary to obtain regulatory approvals. The process of obtaining regulatory approvals is
expensive, often takes many years, and can vary substantially based upon the type, complexity, and novelty of the products involved, as
well as the target indications. Approval policies or regulations may change and the regulatory agencies have substantial discretion in
the approval process for products, including the ability to delay, limit or deny approval of a product candidate for many reasons. Obtaining
approval of an NDA, BLA, or other marketing application can be a lengthy, expensive and uncertain process. Despite the time and expense
invested in clinical development of product candidates, regulatory approval is never guaranteed.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">The FDA or comparable foreign regulatory authorities can delay, limit or deny approval
of a product candidate for many reasons, including:</div>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 18pt"><br /> </td>
    <td style="width: 18pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>such authorities may disagree with the number, design, size, conduct or implementation of our clinical trials or any of our collaborators&#8217;
        clinical trials;</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 18pt"><br /> </td>
    <td style="width: 18pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>we or any of our development partners may be unable to demonstrate to the satisfaction of the FDA or other regulatory authorities
        that a product candidate is safe and effective for any indication;</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 18pt"><br /> </td>
    <td style="width: 18pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>the results of clinical trials may not meet the level of statistical significance or clinical significance required by the FDA, EMA
        or other regulatory agencies for approval;</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal">48</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000" /></div>
</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 18pt"><br /> </td>
    <td style="width: 18pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>such authorities may not accept clinical data from trials which are conducted at clinical facilities or in countries where the standard
        of care is potentially different from that authority&#8217;s jurisdiction;</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 18pt"><br /> </td>
    <td style="width: 18pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>the data collected from non-clinical studies and clinical trials of our product candidates may not be sufficient to support the submission
        of an application for regulatory approval;</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 18pt"><br /> </td>
    <td style="width: 18pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>the results of clinical trials may not demonstrate the safety or efficacy required by such authorities for approval;</div> </td>
        </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 18pt"><br /> </td>
    <td style="width: 18pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>we or any of our future development partners may be unable to demonstrate that a product candidate&#8217;s clinical and other benefits
        outweigh its safety risks;</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 18pt"><br /> </td>
    <td style="width: 18pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>such authorities may disagree with our interpretation of data from preclinical studies or clinical trials or the use of results from
        studies that served as precursors to our current or future product candidates;</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 18pt"><br /> </td>
    <td style="width: 18pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>such authorities may find deficiencies in our manufacturing processes or facilities or those of third-party manufacturers with which
        we or any of our future development partners contract for clinical and commercial supplies;</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 18pt"><br /> </td>
    <td style="width: 18pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>the FDA may require development of a Risk Evaluation and Mitigation Strategy, or REMS, as a condition of approval; and</div> </td>
        </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 18pt"><br /> </td>
    <td style="width: 18pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>the approval policies or regulations of such authorities may significantly change in a manner rendering our or any of our future
        development partners&#8217; clinical data insufficient for approval.</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">Each of our oral PTH product candidates, including EB613 and EB612,
are still in clinical development and face a variety of risks and uncertainties, including the following:</div>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 18pt"><br /> </td>
    <td style="width: 18pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>future clinical trial results may show that our oral PTH is not effective, including if our drug delivery technology is not effective,
        our product candidates are not effective, our clinical trial designs are flawed, or clinical trial investigators or subjects do not comply
        with trial protocols;</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 18pt"><br /> </td>
    <td style="width: 18pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>our product candidates may not be well tolerated or may cause negative side effects;</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 18pt"><br /> </td>
    <td style="width: 18pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>our ability to complete the development and commercialization of our oral PTH for our intended uses may be significantly dependent
        upon our ability to obtain and maintain experienced and committed collaborators to assist us with obtaining clinical and regulatory approvals
        for, and the manufacturing, marketing and distribution of, our oral PTH;</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 18pt"><br /> </td>
    <td style="width: 18pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>even if our oral PTH is shown to be safe and effective for its intended purposes, we may face significant or unforeseen difficulties
        in obtaining or manufacturing sufficient quantities at reasonable prices, or at all;</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 18pt"><br /> </td>
    <td style="width: 18pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>even if our oral PTH is successfully developed, commercially produced and receives all necessary regulatory approvals, there is no
        guarantee that there will be market acceptance;</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 18pt"><br /> </td>
    <td style="width: 18pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>even if our oral PTH is successfully developed, commercially produced and receives all necessary regulatory approvals for the treatment
        of Osteoporosis, there is no guarantee that we will successfully develop and commercialize it for other indications, including hypoparathyroidism
        and delayed union fractures; and</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 18pt"><br /> </td>
    <td style="width: 18pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>our competitors may develop therapeutics or other treatments that are superior to or less costly than our own with the result that
        our products, even if they are successfully developed, manufactured and approved, may not generate significant revenues.</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">If we are unsuccessful in dealing with any of these risks, or if we or a potential
partner are unable to successfully commercialize our oral PTH or any other product candidates we may develop in the future, it would likely
have a material adverse effect on our business, prospects, financial condition and results of operations. \</div>

<div style="line-height: 1.25">&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal">49</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000" /></div>
</div>

<div style="text-align: justify; line-height: 1.25">In addition, before we can submit an application for regulatory approval in the United
States, we must conduct a pivotal trial that will be substantially broader than our completed Phase 2 trials in osteoporosis and hypoparathyroidism
(with the earlier formulation of EB612). We will also need to agree on a protocol with the FDA for a Phase 3 clinical trial before commencing
the trial. Phase 3 clinical trials frequently produce unsatisfactory results even when prior clinical trials were successful. Therefore,
even if the results of our Phase 2 trials are successful, the results of the additional trials that we conduct may or may not be successful.
Further, our product candidates may not be approved even if they achieve their primary endpoints in Phase 3 clinical trials. The FDA,
EMA or other regulatory agencies may require that we conduct additional clinical, nonclinical, manufacturing validation or drug product
quality studies beyond those planned and submit data from such trials before considering or reconsidering the application. Depending on
the extent of these or any other studies, approval of any applications that we submit may be delayed by several years or may require us
to expend more resources than we have available. It is also possible that additional studies, if performed and completed, may not be considered
sufficient by the FDA, EMA or other regulatory agencies. If any of these outcomes occur, we would not receive approval for our oral PTH
tablet or other product candidates we may develop in the future.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">In addition, the FDA, EMA or other regulatory agencies may also approve a product
candidate for fewer or more limited indications than we request, may impose significant limitations related to use restrictions for certain
age groups, warnings, precautions or contraindications or may grant approval contingent on the performance of costly post-marketing clinical
trials or risk mitigation requirements. The FDA, EMA or other regulatory agencies may also not accept the labeling claims that we believe
would be necessary or desirable for the successful commercialization of our product candidates.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">The commencement and completion of clinical
trials can be delayed or prevented for a number of reasons.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif; font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none">EB613
completed a six-month placebo-controlled Phase 2 double-blind, dose-ranging trial. In November 2018, we had a Pre-Investigational New
Drug (&#8220;Pre-IND&#8221;) meeting with the FDA to discuss our EB613 program for the treatment of osteoporosis. In December 2020, we
announced that the FDA had reviewed our October 2020 IND Application and informed us that we may proceed with our U.S. clinical pharmacology
study. In December 2021, we held an end-of-Phase 2 meeting with the FDA to review the six-month phase 2 results and a proposed Head-to-Head
Non-Inferiority Phase 3 study protocol vs. Forteo&#174;, our nonclinical and clinical development plan and the use of BMD, rather than
fracture incidence, as the primary endpoint to support an NDA. Following our End of Phase 2 Meeting with the FDA and pursuant to the FDA&#8217;s
concern that a Head-to-Head study phase 3 design may not be favorable to support an NDA for EB613, we redesigned the pivotal phase 3 study
for EB613 based on the FDA&#8217;s suggestion to explore a placebo-controlled trial. A Type C meeting with the FDA in relation to Entera&#8217;s
proposed Phase 3 registrational study was held in the second half of 2022 and in October 2022, the Company concluded its Type C meeting
and the FDA agreed that a single Phase 3 placebo-controlled study could support an NDA submission of EB613 (oral hPTH (1-34), teriparatide
tablets) under the 505(b)(2) regulatory pathway. The FDA also agreed that Total BMD could serve as the primary endpoint of the registrational
study in post-menopausal osteoporosis patients.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">In addition, we expect to carry out a PK study for the new formulation of EB612 in
the first half of 2023. We anticipate that the outcome of the PK study will help determine the dosing and design of a Phase 2 or Phase
3 trial of EB612 in patients with hypoparathyroidism. If successful, the phase 2/3 clinical trial of EB612 in hypoparathyroidism may potentially
support a submission for regulatory approval of EB612. Drug development is a long, expensive and uncertain process, and delay or failure
can occur at any stage of any of our clinical trials for a number of reasons including:</div>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 18pt"><br /> </td>
    <td style="width: 18pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>difficulties obtaining regulatory approval to commence a clinical trial or complying with conditions imposed by a regulatory authority
        regarding the scope or term of a clinical trial;</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 18pt"><br /> </td>
    <td style="width: 18pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>delays in reaching or failing to reach agreement on acceptable terms with prospective contract research organizations, or CROs, contract
        manufacturing organizations, and trial sites, the terms of which can be subject to extensive negotiation and may vary significantly;</div>
        </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 18pt"><br /> </td>
    <td style="width: 18pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>failure of our third-party contractors, such as CROs and contract manufacturing organizations, or our investigators to comply with
        regulatory requirements or otherwise meet their contractual obligations in a timely manner;</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 18pt"><br /> </td>
    <td style="width: 18pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>insufficient or inadequate supply or quality of a product candidate or other materials necessary to conduct our clinical trials;</div>
        </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 18pt"><br /> </td>
    <td style="width: 18pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>difficulties obtaining institutional review board, or IRB, or ethics committee approval to conduct a clinical trial at a prospective
        site;</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal">50</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000" /></div>
</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 18pt"><br /> </td>
    <td style="width: 18pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>the FDA, EMA or other regulatory authority may require changes to any of our trial designs, our pre-clinical strategy or our manufacturing
        plans;</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 18pt"><br /> </td>
    <td style="width: 18pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>various challenges recruiting and enrolling subjects to participate in clinical trials, including size and nature of subject population,
        proximity of subjects to clinical sites, eligibility criteria for the trial, budgetary limitations, nature of trial protocol, the patient
        referral practices of physicians, changes in the readiness of subjects to volunteer for a trial, the availability of approved effective
        treatments for the relevant disease and competition from other clinical trial programs for similar indications;</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 18pt"><br /> </td>
    <td style="width: 18pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>difficulties in maintaining contact with subjects who withdraw from the trial, resulting in incomplete data;</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 18pt"><br /> </td>
    <td style="width: 18pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>governmental or regulatory delays and changes in regulatory requirements, policy and guidelines;</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 18pt"><br /> </td>
    <td style="width: 18pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>the FDA or other regulatory authorities may impose a clinical hold, or we or our investigators, IRBs, or ethics committees may elect
        to suspend or terminate clinical research or trials;</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 18pt"><br /> </td>
    <td style="width: 18pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>varying interpretations of data by the FDA and foreign regulatory agencies; and</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 18pt"><br /> </td>
    <td style="width: 18pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>inaccurate interpretations by us of the FDA&#8217;s guidance for the clinical and regulatory path for our product candidates.</div>
        </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">If changes in regulatory requirements and guidance occur, we may need to significantly
amend clinical trial protocols or submit new clinical trial protocols with appropriate regulatory authorities to reflect these changes.
Amendments may require us to renegotiate terms with CROs or investigators, or resubmit clinical trial protocols to IRBs or ethics committees
for re-examination, which may impact the costs, timing or successful completion of a clinical trial. Our clinical trials may be suspended
or terminated at any time by the FDA (for trials in the United States), other regulatory authorities (for trials conducted outside the
United States), the IRB /ethics committee overseeing any given clinical trial, any of our clinical trial sites with respect to that site,
or us, due to a number of factors, including:</div>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 18pt"><br /> </td>
    <td style="width: 18pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>failure to conduct the clinical trial in accordance with regulatory requirements or our clinical protocols;</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 18pt"><br /> </td>
    <td style="width: 18pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>failing to establish clinical endpoints acceptable to the FDA and other regulatory authorities;</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 18pt"><br /> </td>
    <td style="width: 18pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>findings of an inspection of the clinical trial operations or trial sites by the FDA or other regulatory authorities;</div> </td>
        </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 18pt"><br /> </td>
    <td style="width: 18pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>unforeseen issues, including serious adverse events associated with a product candidate, or lack of effectiveness or any determination
        that a clinical trial presents unacceptable health risks;</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 18pt"><br /> </td>
    <td style="width: 18pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>lack of adequate funding to continue the clinical trial due to unforeseen costs or other business decisions; and</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 18pt"><br /> </td>
    <td style="width: 18pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>upon a breach or pursuant to the terms of any agreement with, or for any other reason by, current or future collaborators that have
        responsibility for the clinical development of any of our product candidates.</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Moreover, principal investigators for our clinical trials may serve as scientific
advisors or consultants to us from time to time and receive compensation in connection with such services. Under certain circumstances,
we are required to report some of these relationships to the FDA. The FDA may conclude that a financial relationship between us and a
principal investigator has created a conflict of interest or otherwise affected the investigator&#8217;s conduct of the trial. The FDA
may therefore question the integrity of the data generated at the applicable clinical trial site and the utility of the clinical trial
itself may be jeopardized. This could result in a delay in approval, or rejection, of our marketing applications by the FDA and may ultimately
lead to the denial of marketing approval of one or more of our product candidates.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">If we do not succeed in conducting and managing our non-clinical development activities
or clinical trials, or in obtaining regulatory approvals, we might not be able to commercialize our product candidates, or might be significantly
delayed in doing so, which could have a material adverse effect on our business, prospects, financial condition and results of operations.</div>

<div style="line-height: 1.25">&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal">51</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000" /></div>
</div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">The results of previous clinical trials may
not be predictive of future results, our progress in trials for one product candidate may not be indicative of progress in trials for
other product candidates, and our trials may not be designed so as to support regulatory approval.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">We currently have no products approved for sale and we cannot guarantee that we will
ever have marketable products. Clinical failure can occur at any stage of clinical development. Clinical trials may produce negative or
inconclusive results, and we or any of our current and future collaborators may decide, or regulators may require us, to conduct additional
clinical or non-clinical testing. We will be required to demonstrate with substantial evidence through well-controlled clinical trials
that our product candidates are safe and effective for use in a diverse population before we can obtain regulatory approvals for their
commercial sale. Success in early clinical trials does not mean that future clinical trials will be successful because product candidates
in later-stage clinical trials may fail to demonstrate sufficient safety and efficacy to the satisfaction of the FDA and other regulatory
authorities despite having progressed through initial clinical trials. Product candidates that have shown promising results in early clinical
trials may still suffer significant setbacks in subsequent clinical trials. Similarly, the outcome of non-clinical testing and early clinical
trials may not be predictive of the success of later clinical trials, and interim results of a clinical trial do not necessarily predict
final results. Progress in trials of one product candidate does not indicate that we will make similar progress in additional trials for
that product candidate or in trials for our other product candidates. A number of companies in the pharmaceutical industry, including
those with greater resources and experience than us, have suffered significant setbacks in advanced clinical trials, even after obtaining
promising results in earlier clinical trials.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">The design of a clinical trial can determine whether its results will support approval
of a product. We may be unable to design and/or execute a clinical trial to support regulatory approval. Flaws in the design of a clinical
trial may not become apparent until the clinical trial is well advanced or completed. In addition, we or our investigators may have little
control over whether subjects comply with important aspects of clinical trial protocols. In particular, in trials of our oral PTH, if
subjects do not comply with restrictions on eating and drinking before and after administration of our product candidates, interaction
between the drug and food in the gastrointestinal tract, or a &#8220;food effect,&#8221; may decrease the bioavailability and increase
the variability of drug delivered to the subject, which may negatively impact efficacy.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">In some instances, there can be significant variability in safety and/or efficacy
results between different trials of the same product candidate due to numerous factors, including changes in trial protocols, differences
in size and type of the patient populations, adherence to the dosing regimen and other trial protocols, modifications in the formulation
throughout the course of development and the rate of dropout among clinical trial participants. While we have not had any serious adverse
events in our clinical trials to date that are believed to be related to our oral PTH product candidates, we may need to change future
trial designs in response to adverse events that occur during future clinical development. We do not know whether any Phase 2, Phase 3
or other clinical trials we or any of our collaborators may conduct will demonstrate consistent or adequate efficacy and safety to obtain
regulatory approval to market our product candidates.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">Even if regulatory approvals are obtained for
our product candidates, we will be subject to ongoing government regulation. If we fail to comply with applicable current and future laws
and government regulations, it could delay or prevent the promotion, marketing or sale of our products.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Even if marketing approval is obtained for our product candidates, a regulatory authority
may still impose significant restrictions on a product&#8217;s indications, conditions for use, distribution or marketing or impose ongoing
requirements for potentially costly post-market surveillance, post-approval studies or clinical trials, all of which may result in significant
expense and limit our ability to commercialize our products. Our products will also be subject to ongoing requirements governing the labeling,
packaging, storage, advertising, distribution, promotion, recordkeeping and submission of safety and other post-market information, including
adverse events, and any changes to the approved product, product labeling or manufacturing process. In addition, manufacturers of drug
products and their facilities are subject to continual review and periodic inspections by the FDA and other regulatory authorities for
compliance with cGMP, requirements and other regulations.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">If we, our drug products or the manufacturing
facilities for our drug products, fail to comply with applicable regulatory requirements, a regulatory agency may:</div>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 18pt"><br /> </td>
    <td style="width: 18pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>issue warning letters or untitled letters or take similar enforcement actions;</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 18pt"><br /> </td>
    <td style="width: 18pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>seek an injunction or impose civil or criminal penalties or monetary fines;</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 18pt"><br /> </td>
    <td style="width: 18pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>suspend or withdraw marketing approval;</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 18pt"><br /> </td>
    <td style="width: 18pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>suspend any ongoing clinical trials;</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 18pt"><br /> </td>
    <td style="width: 18pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>refuse to approve pending applications or supplements to applications;</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal">52</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000" /></div>
</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 18pt"><br /> </td>
    <td style="width: 18pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>suspend or impose restrictions on operations, including costly new manufacturing requirements;</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 18pt"><br /> </td>
    <td style="width: 18pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>seize or detain products, refuse to permit the import or export of products, exclude products from federal healthcare programs, or
        request that we initiate a product recall; or</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 18pt"><br /> </td>
    <td style="width: 18pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>refuse to allow us to enter into supply contracts, including government contracts.</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">We cannot predict the likelihood, nature or extent of government regulation that may
arise from future legislation or administrative action, either in the United States or abroad, and compliance with such regulation may
be expensive and consume substantial financial and management resources. If we or any future marketing collaborators or contract manufacturers
are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies or are not able to maintain
regulatory compliance, it could delay or prevent the promotion, marketing or sale of our products, which would adversely affect our business
and results of operations.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25"><span style="font-weight: bold; font-style: italic">Healthcare legislative changes
may harm our business and future prospects.</span>&#160;</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Healthcare costs have risen significantly over the past decade. Globally, governments
are becoming increasingly aggressive in imposing health care cost-containment measures. Certain proposals, if passed, would impose limitations
on the prices we will be able to charge for the products that we are developing, or the amounts of reimbursement available for these products
from governmental agencies or third-party payors. These limitations could in turn reduce the amount of revenues that we will be able to
generate in the future from sales of our products and licenses of our technology.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">In the United States, the Medicare Prescription Drug, Improvement, and Modernization
Act of 2003, or MMA, changed the way Medicare covers and pays for pharmaceutical products. The MMA expanded Medicare coverage for outpatient
drug purchases by those covered by Medicare under a new Part D and introduced a new reimbursement methodology based on average sales prices
for Medicare Part B physician-administered drugs. In addition, the MMA authorized Medicare Part D prescription drug plans to limit the
number of drugs that will be covered in any therapeutic class. As a result of this legislation and the expansion of federal coverage of
drug products, we expect that there will be additional pressure to contain and reduce costs. These cost reduction initiatives and other
provisions of the MMA could decrease the coverage and price that we receive for any approved products and could seriously harm our future
business prospects. While this law applies only to drug benefits for Medicare beneficiaries, private payors often follow Medicare coverage
policy and payment limitations in setting their own reimbursement rates, and any reduction in reimbursement that results from this law
may result in a similar reduction in payments from private payors.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">In March 2010, President Obama signed into law the Patient Protection and Affordable
Care Act, as amended by the Health Care and Education Reconciliation Act, or collectively, the ACA, a sweeping law intended to broaden
access to health insurance, reduce or constrain the growth of healthcare spending, enhance remedies against fraud and abuse, add new transparency
requirements for health care and health insurance industries, impose new taxes and fees on the health industry and impose additional health
policy reforms. The ACA, among other things, increased rebates a manufacturer must pay to the Medicaid program, addressed a new methodology
by which rebates owed by manufacturers under the Medicaid Drug Rebate Program are calculated for drugs that are inhaled, infused, instilled,
implanted or injected, established a new Medicare Part D coverage gap discount program, in which manufacturers must provide 75% point-of-sale
discounts on products covered under Part D and implemented payment system reforms including a national pilot program on payment bundling
to encourage hospitals, physicians and other providers to improve the coordination, quality and efficiency of certain healthcare services
through bundled payment models. Further, ACA imposed a significant annual fee on companies that manufacture or import branded prescription
drug products. Substantial new provisions affecting compliance were enacted, which may affect our business practices with health care
practitioners. The ACA appears likely to continue the pressure on pharmaceutical pricing and may also increase our regulatory burdens
and operating costs.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">In addition, other legislative changes have been proposed and adopted in the United
States since the ACA was enacted. In 2011, the U.S. Congress enacted the Budget Control Act of 2011, or the Budget Control Act, which
included provisions intended to reduce the federal deficit. The Budget Control Act resulted in the imposition of 2% reductions in Medicare
payments to providers beginning in 2013 and, due to subsequent legislative amendments to the statute, will remain in effect through 2027
absent additional congressional action. However, pursuant to the CARES Act, and subsequent legislation, these reductions are suspended
from May 1, 2020 through March 31, 2022 due to the COVID-19 pandemic. In January 2013, the American Taxpayer Relief Act of 2012 was signed
into law, which, among other things, reduced Medicare payments to several providers, and increased the statute of limitations period for
the government to recover overpayments to providers from three to five years. These new laws may result in additional reductions in Medicare
and other healthcare funding, which could have a material adverse effect on customers for our drugs, if approved, and accordingly, our
financial operations. If government spending is further reduced, anticipated budgetary shortfalls may also impact the ability of relevant
agencies, such as the FDA, to continue to function at current levels, which may impact the ability of relevant agencies to timely review
and approve research and development, manufacturing and marketing activities, which may delay our ability to develop, market and sell
any product candidates we may develop. In addition, any significant spending reductions affecting Medicare, Medicaid or other publicly
funded or subsidized health programs that may be implemented, or any significant taxes or fees that may be imposed on us, as part of any
broader deficit reduction effort or legislative replacement to the Budget Control Act, could have an adverse impact on our anticipated
product revenues.</div>

<div style="line-height: 1.25">&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal">53</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000" /></div>
</div>

<div style="text-align: justify; line-height: 1.25">There have been changes and modifications to certain aspects of the ACA, and we expect
such changes and modifications to continue. In 2017, the U.S. Congress enacted the Tax Cuts and Jobs Act, or the 2017 Tax Act, which eliminated
the tax-based shared responsibility payment imposed by the ACA on certain individuals who fail to maintain qualifying health coverage
for all or part of a year that is commonly referred to as the &#8220;individual mandate.&#8221; On January 22, 2018, President Trump signed
a continuing resolution on appropriations for fiscal year 2018 that delayed the implementation of certain fees mandated by the ACA, including
the so-called &#8220;Cadillac&#8221; tax on certain high cost employer-sponsored insurance plans and the annual fee imposed on certain
health insurance providers based on market share. The Bipartisan Budget Act of 2018, or the BBA, among other things, amended the ACA,
effective January 1, 2019, to close the coverage gap in most Medicare drug plans. In July 2018, CMS, published a final rule permitting
further collections and payments to and from certain ACA qualified health plans and health insurance issuers under the ACA risk adjustment
program in response to the outcome of federal district court litigation, regarding the method CMS uses to determine this risk adjustment.
On January 28, 2021, President Biden issued an executive order to initiate a special enrollment period from February 15, 2021 through
May 15, 2021 for purposes of obtaining health insurance coverage through the ACA marketplace. The executive order also instructs certain
governmental agencies to review and reconsider their existing policies and rules that limit access to healthcare, including among others,
reexamining Medicaid demonstration projects and waiver programs that include work requirements, and policies that create unnecessary barriers
to obtaining access to health insurance coverage through Medicaid or the ACA. Changes and modifications to the ACA are likely to continue,
with unpredictable and uncertain results.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Recently, there has been heightened governmental scrutiny over the manner in which
manufacturers set prices for their commercial products. There have been several recent U.S. Congressional inquiries and proposed and enacted
federal and state legislation designed to, among other things, bring more transparency to drug pricing, review the relationship between
pricing and manufacturer patient programs, reduce the cost of drugs under Medicare, and reform government program reimbursement methodologies
for drugs. On September 24, 2020, the FDA released a final rule providing guidance for states to build and submit importation plans for
drugs from Canada. Further, on November 20, 2020, the U.S. Department of Health and Human Services, or HHS, finalized a regulation removing
safe harbor protection for price reductions from pharmaceutical manufacturers to plan sponsors under Part D, either directly or through
pharmacy benefit managers, unless the price reduction is required by law. The rule also creates a new safe harbor for price reductions
reflected at the point-of-sale, as well as a safe harbor for certain fixed fee arrangements between pharmacy benefit managers and manufacturers.
At the state level, legislatures have increasingly passed legislation and implemented regulations designed to control pharmaceutical and
biological product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and
marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk
purchasing.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">On November 20, 2020, the HHS Office of Inspector General finalized further modifications
to the federal Anti-Kickback Statute. Under the final rules, the HHS Office of Inspector General added safe harbor protections under the
Anti-Kickback Statute for certain coordinated care and value-based arrangements among clinicians, providers, and others, yet removed safe
harbor protection for price reductions from pharmaceutical manufacturers to plan sponsors under Part D, either directly or through pharmacy
benefit managers, unless the price reduction is required by law. The rule also creates a new safe harbor for price reductions reflected
at the point-of-sale, as well as a safe harbor for certain fixed fee arrangements between pharmacy benefit managers and manufacturers.
This rule (with exceptions) became effective January 19, 2021. We continue to evaluate what effect, if any, these rules will have on our
business. CMS issued a final rule, effective on July 9, 2019, that requires direct-to-consumer advertisements of prescription drugs and
biological products, for which payment is available through or under Medicare or Medicaid, to include in the advertisement the Wholesale
Acquisition Cost, or list price, of that drug or biological product if it is equal to or greater than $35 for a monthly supply or usual
course of treatment. Prescription drugs and biological products that are in violation of these requirements will be included on a public
list. Any adopted health reform measure could reduce the ultimate demand for our products, if approved, or put pressure on our product
pricing. Individual states in the United States have also become increasingly active in passing legislation and implementing regulations
designed to control pharmaceutical product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain
product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other
countries and bulk purchasing. In addition, regional healthcare authorities and individual hospitals are increasingly using bidding procedures
to determine what pharmaceutical products and which suppliers will be included in their prescription drug and other healthcare programs.
We expect that additional state and federal healthcare reform measures will be adopted in the future.</div>

<div style="line-height: 1.25">&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal">54</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000" /></div>
</div>

<div style="text-align: justify; line-height: 1.25">The delivery of healthcare in the EU, including the establishment and operation of
health services and the pricing and reimbursement of medicines, is almost exclusively a matter for national, rather than EU, law and policy.
National governments and health service providers have different priorities and approaches to the delivery of health care and the pricing
and reimbursement of products in that context. In general, however, the healthcare budgetary constraints in most EU member states have
resulted in restrictions on the pricing and reimbursement of medicines by relevant health service providers. Coupled with ever-increasing
EU and national regulatory burdens on those wishing to develop and market products, this could prevent or delay marketing approval of
our product candidates, restrict or regulate post-approval activities and affect our ability to commercialize any products for which we
obtain marketing approval. Both in the United States and in the EU, legislative and regulatory proposals have been made to expand post-approval
requirements and restrict sales and promotional activities for pharmaceutical products. We do not know whether additional legislative
changes will be enacted, or whether the regulations, guidance or interpretations will be changed, or what the impact of such changes on
the marketing approvals of our product candidates, if any, may be.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">Our relationships with customers and payors
are subject to applicable anti-kickback, fraud and abuse and other healthcare laws and regulations, which, if violated, could expose us
to criminal sanctions, civil penalties, exclusion from government healthcare programs, contractual damages, reputational harm and diminished
profits and future earnings.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Healthcare providers, physicians and others will play a primary role in the recommendation
and prescription of any products for which we obtain marketing approval. Our future arrangements with third-party payors and customers
may expose us to broadly applicable fraud and abuse and other healthcare laws and regulations, primarily in the United States, that may
constrain the business or financial arrangements and relationships through which we market, sell and distribute our products for which
we obtain marketing approval. Restrictions under applicable healthcare laws and regulations, include the following:</div>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 18pt"><br /> </td>
    <td style="width: 18pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>the federal Anti-Kickback Statute prohibits, among other things, the knowing and willful offer, payment, solicitation or receipt
        of any form of remuneration in return for, or to induce, (i) the referral of a person, (ii) the furnishing or arranging for the furnishing
        of items or services reimbursable under the Medicare, Medicaid or other governmental programs, or (iii) the purchase, lease or order or
        arranging or recommending purchasing, leasing or ordering of any item or service reimbursable under the Medicare, Medicaid or other governmental
        programs. A person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed
        a violation. In addition, the government may assert that a claim including items or services resulting from a violation of the federal
        Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the False Claims Act;</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 18pt"><br /> </td>
    <td style="width: 18pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>the federal False Claims Act imposes civil penalties, and provides for civil whistleblower or qui tam actions, against individuals
        or entities for knowingly presenting, or causing to be presented, to the federal government, claims for payment that are false or fraudulent
        or making a false statement to avoid, decrease or conceal an obligation to pay money to the federal government;</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 18pt"><br /> </td>
    <td style="width: 18pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>HIPAA imposes criminal and civil liability for executing a scheme to defraud any health care benefit program or making false statements
        relating to health care matters. Similar to the federal Anti-Kickback Statute, a person or entity does not need to have actual knowledge
        of the statute or specific intent to violate it in order to have committed a violation;</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 18pt"><br /> </td>
    <td style="width: 18pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>the federal false statements statute prohibits knowingly and willfully falsifying, concealing or covering up a material fact or making
        any materially false statement in connection with the delivery of or payment for health care benefits, items or services;</div> </td>
        </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 18pt"><br /> </td>
    <td style="width: 18pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>the Physician Payments Sunshine Act, created under the ACA, and its implementing regulations, which requires specified manufacturers
        of drugs, devices, biologics and medical supplies for which payment is available under Medicare, Medicaid or the Children&#8217;s Health
        Insurance Program, with specific exceptions, to report annually to CMS information related to payments or other &#8220;transfers of value&#8221;
        made to physicians. All such reported information is publicly available;</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 18pt"><br /> </td>
    <td style="width: 18pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>analogous state and non-U.S. laws and regulations, such as certain state anti-kickback and false claims laws which may apply to items
        or services reimbursed by any third-party payor, including commercial insurers; state laws that require pharmaceutical companies to comply
        with the industry&#8217;s voluntary compliance guidelines and the applicable compliance guidance promulgated by the federal government
        or otherwise restrict payments that may be made to healthcare providers and other potential referral sources; state laws that require
        drug manufacturers to report information related to payments and other transfers of value to physicians and other healthcare providers
        or marketing expenditures; and state laws governing the privacy and security of health information in certain circumstances, many of which
        differ from each other in significant ways and may not have the same effect, thus complicating compliance efforts; and</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 18pt"><br /> </td>
    <td style="width: 18pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>regulation by the CMS and enforcement by the HHS Office of Inspector General or the U.S. Department of Justice.</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal">55</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000" /></div>
</div>

<div style="text-align: justify; line-height: 1.25">Because of the breadth of these laws and the narrowness of the statutory exceptions
and safe harbors available, it is possible that some of our future business activities could be subject to challenge under one or more
of such laws.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Efforts to ensure that our business arrangements with third parties will comply with
applicable healthcare laws and regulations will involve substantial costs. It is possible that governmental authorities will conclude
that our business practices may not comply with current or future statutes, regulations or case law involving applicable fraud and abuse
or other healthcare laws and regulations. If our operations are found to be in violation of any of these laws or any other governmental
regulations that may apply to us, we may be subject to significant civil, criminal and administrative penalties, damages, fines, exclusion
from U.S. government funded healthcare programs, such as Medicare and Medicaid, and the curtailment or restructuring of our operations.
If any of the physicians or other providers or entities with whom we expect to do business with are found to be not in compliance with
applicable laws, they may be subject to criminal, civil or administrative sanctions, including exclusions from government funded healthcare
programs.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-weight: bold">Risks Related to Commercialization of Our Product Candidates</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">We are likely to face significant competition,
and if our competitors&#8217; products are more effective, safer or less expensive than ours, our commercial opportunities will be negatively
affected. Our lead product candidates, if approved, would compete with existing products.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Our industry is highly competitive and subject to rapid and significant technological
change. While we believe that our technology, drug candidates, knowledge, experience and scientific resources provide us with competitive
advantages, we face competition from many different sources, including large pharmaceutical, specialty pharmaceutical, biotechnology and
generic drug companies and academic and government institutions. These organizations may have significantly greater resources than we
do and conduct similar research, seek and obtain patent protection that may impact our freedom to operate and establish collaborative
arrangements for research, development, manufacturing and marketing of products that compete with our product candidates. We believe that
the key competitive factors that will affect the development and commercial success of our oral PTH product candidates, and any other
product candidates that we develop, are efficacy, safety and tolerability profile, convenience in dosing, product labeling, price and
availability of reimbursement from the government and other third-parties. Our commercial opportunity could be reduced or eliminated if
our competitors have products that are better in one or more of these categories. Furthermore, our competitors may, among other things,
develop and commercialize products that are safer, more effective, less expensive, or more convenient or easier to administer, obtain
quicker regulatory approval, establish superior proprietary positions, have access to more manufacturing capacity, implement more effective
approaches to sales and marketing, or form more advantageous strategic alliances.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Our primary innovation is our development of an oral drug delivery technology for
peptides, therapeutic protein and other large molecules in small tablet form. If another company develops an alternative technology for
oral delivery of such molecules in small tablet form that is equal to or better than our technology, we may be unable to compete.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">The osteoporosis market is already served by a variety of competing products based
on a number of APIs. Many of these existing products have achieved widespread acceptance among physicians, patients and payors for the
treatment of osteoporosis. We anticipate that our product candidate EB613, if approved, will compete with other osteoanabolic drugs such
as daily subcutaneous Forteo&#174;, generic teriparatide daily subcutaneous injections, daily subcutaneous injectable Tymlos&#174; and&#160;
EVENITY&#174; which requires monthly injections, and the rest of the pharmacological treatments for osteoporosis which include anti-resorptive
agents such as the bisphosphonates and Prolia&#174;. Many of these products are available on a generic basis, and EB613 may not demonstrate
sufficient additional clinical benefits to physicians and patients or be priced adequately to support reimbursement. In many cases, insurers
or other third-party payors, particularly Medicare, seek to encourage the use of generic products. Furthermore, our competitors in this
market are large pharmaceutical companies and the alternatives have been on the market for many years and have widespread market acceptance.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Ascendis Pharma has reported that it is developing a long-acting, oral prodrug formulation
of PTH for the treatment of hypoparathyroidism. In 2022, Ascendis reported top-line results from its Phase 3 trial. In addition, Ascendis
submitted an NDA to the FDA and&#160;a Marketing Authorisation Application (&#8220;MAA&#8221;) to the EMA. We believe that our key competitor
in hypoparathyroidism treatment, if approved, could be TransCon&#8482; PTH which requires daily subcutaneous injections.&#160; If we obtain
regulatory approval for EB612, it may compete with TransCon(TM PTH which by that time will have been marketed for several years and may
have wide-spread market acceptance that may be difficult to overcome. &#8201; Moreover, although we have obtained orphan drug designation
for EB612 for the treatment of hypoparathyroidism, we may be unable to maintain the benefits associated with orphan drug designation,
including the potential for market exclusivity.</div>

<div style="line-height: 1.25">&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal">56</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000" /></div>
</div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">We are subject to manufacturing risks that
could substantially increase our costs and limit supply of our products.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">The process of manufacturing our products is complex, highly regulated and subject
to several risks, including:</div>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 18pt"><br /> </td>
    <td style="width: 18pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>We do not have experience in manufacturing our product candidates at commercial scale. We may not succeed in the scaling up of our
        final manufacturing process. We may need a larger-scale manufacturing process for our oral PTH than what we have planned, depending on
        the dose and regimen that will be determined in future studies. Any changes in our manufacturing processes as a result of scaling up may
        result in the need to obtain additional regulatory approvals. Difficulties in achieving commercial-scale production or the need for additional
        regulatory approvals as a result of scaling up could delay the development and regulatory approval of our product candidates and ultimately
        affect our success. Contract manufacturers may not have sufficient expertise to manufacture a dry oral formulation with a large molecule
        API, in which case we may have to establish our own commercial manufacturing capabilities, which could be expensive and delay launch of
        product candidates.</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 18pt"><br /> </td>
    <td style="width: 18pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>The manufacturing process for large molecules is more complex and subject to greater regulation than that of other drugs. The process
        of manufacturing large molecules, such as our product candidates, is extremely susceptible to product loss due to contamination, equipment
        failure or improper installation or operation of equipment, vendor or operator error, inconsistency in yields, variability in product
        characteristics and difficulties in scaling the production process. Even minor deviations from normal manufacturing processes could result
        in reduced production yields, product defects and other supply disruptions. If microbial, viral or other contaminations are discovered
        in our product candidates or in the manufacturing facilities in which our product candidates are made, such manufacturing facilities may
        need to be closed for an extended period of time to investigate and remedy the contamination.</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 18pt"><br /> </td>
    <td style="width: 18pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>The manufacturing facilities in which our product candidates are made could be adversely affected by equipment failures, labor shortages,
        natural disasters, power failures, outbreaks of an infectious disease such as COVID-19, geopolitical tensions such as the ongoing conflict
        between Russia and Ukraine and numerous other factors.</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 18pt"><br /> </td>
    <td style="width: 18pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>We and our contract manufacturing organizations, or CMOs, must comply with applicable current cGMP regulations and guidelines. We
        and our CMOs may encounter difficulties in achieving quality control and quality assurance and may experience shortages in qualified personnel.
        We and our CMOs are subject to inspections by the FDA and comparable agencies in other jurisdictions to confirm compliance with applicable
        regulatory requirements. Any failure to follow cGMP or other regulatory requirements or delay, interruption or other issues that arise
        in the manufacture, fill-finish, packaging, or storage of our product candidates as a result of a failure of our facilities or the facilities
        or operations of third parties to comply with regulatory requirements or pass any regulatory authority inspection could significantly
        impair our ability to develop and commercialize our product candidates, including leading to significant delays in the availability of
        drug product for our clinical trials or the termination or hold on a clinical trial, or the delay or prevention of a filing or approval
        of marketing applications for our product candidates. Significant noncompliance could also result in the imposition of sanctions, including
        fines, injunctions, civil penalties, failure of regulatory authorities to grant marketing approvals for our product candidates, delays,
        suspension or withdrawal of approvals, license revocation, seizures or recalls of products, operating restrictions and criminal prosecutions,
        any of which could damage our reputation. If we are not able to maintain regulatory compliance, we may not be permitted to market our
        product candidates and/or may be subject to product recalls, seizures, injunctions, or criminal prosecution.</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 18pt"><br /> </td>
    <td style="width: 18pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>Any adverse developments affecting manufacturing operations for our product candidates, if any are approved, may result in shipment
        delays, inventory shortages, lot failures, product withdrawals or recalls, or other interruptions in the supply of our products. We may
        also have to take inventory write-offs and incur other charges and expenses for products that fail to meet specifications, undertake costly
        remediation efforts or seek more costly manufacturing alternatives.</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 18pt"><br /> </td>
    <td style="width: 18pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>Our product candidates that have been produced and are stored for later use may degrade, become contaminated or suffer other quality
        defects, which may cause the affected product candidates to no longer be suitable for their intended use in clinical trials or other development
        activities. If the defective product candidates cannot be replaced in a timely fashion, we may incur significant delays in our development
        programs that could adversely affect the value of such product candidates.</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal">57</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000" /></div>
</div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">We currently have no sales, marketing or distribution
infrastructure. Any failure or delay in the development of our internal sales, marketing and distribution capabilities would adversely
affect the commercialization of our products. If we enter into collaborations to market and sell any approved products, our revenue may
be lower and we will be dependent on the efforts of a third party.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">We have no established sales, marketing or distribution operations. If our product
candidates are approved and we were to commercialize these products, such activities would be expensive and time consuming. If we elect
to fund and undertake commercialization activities on our own, we may need to obtain additional expertise and additional capital, which
may not be available to us on acceptable terms or at all. In addition, the costs of establishing sales and marketing operations may be
incurred in advance of any approval of our product candidates. Moreover, we may not be able to hire a sales force that is sufficient in
size or has adequate expertise in the medical markets that we intend to target. Any failure or delay in the development of our internal
sales, marketing and distribution capabilities would adversely affect the commercialization of our products.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Alternatively, we may consider entering into a collaboration to commercialize our
oral PTH candidates globally or in selected regions. Any such collaborator would be responsible for, or substantially support, late stage
clinical trials of our oral PTH product candidates, as well as regulatory approvals and registrations. These arrangements are typically
complex and time consuming to negotiate. To the extent that we enter into collaboration agreements with respect to marketing, sales or
distribution, our product revenue may be lower than if we directly marketed and sold any approved products. In addition, any revenue we
receive will depend in whole or in part upon the efforts of these third-party collaborators, which may not be successful and are generally
not within our control. If we are unable to enter into these arrangements on acceptable terms or at all, we may not be able to successfully
commercialize any approved products. If we are not successful in commercializing any approved products, either on our own or through collaborations
with one or more third parties, our future product revenue will suffer and we may incur significant additional losses.</div>

<div style="line-height: 1.25"><br /> </div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">Even if approved, if any of our product candidates
do not achieve broad market acceptance among physicians, patients, the medical community and third-party payors, our revenue generated
from their sales will be limited.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">The commercial success of our product candidates will depend upon their acceptance
among physicians, patients and the medical community. The degree of market acceptance of our product candidates will depend on a number
of factors, including:</div>

<div style="line-height: 1.25"><br /> </div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 18pt"><br /> </td>
    <td style="width: 18pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>limitations or warnings contained in the approved labeling for a product candidate;</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 18pt"><br /> </td>
    <td style="width: 18pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>changes in the standard of care for the targeted indications for any of our product candidates;</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 18pt"><br /> </td>
    <td style="width: 18pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>limitations in the approved clinical indications for our product candidates;</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 18pt"><br /> </td>
    <td style="width: 18pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>demonstrated clinical safety and efficacy compared to other products;</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 18pt"><br /> </td>
    <td style="width: 18pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>lack of significant adverse side effects;</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 18pt"><br /> </td>
    <td style="width: 18pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>sales, marketing and distribution support;</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 18pt"><br /> </td>
    <td style="width: 18pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>availability and extent of coverage and reimbursement from managed care plans and other third-party payors;</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 18pt"><br /> </td>
    <td style="width: 18pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>timing of market introduction and perceived effectiveness of competitive products;</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 18pt"><br /> </td>
    <td style="width: 18pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>the degree of cost-effectiveness of our product candidates;</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 18pt"><br /> </td>
    <td style="width: 18pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>availability of alternative therapies at similar or lower cost, including generic and over-the-counter products;</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 18pt"><br /> </td>
    <td style="width: 18pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>the extent to which the product candidate is approved for inclusion on formularies of hospitals and third-party payors, including
        managed care organizations;</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 18pt"><br /> </td>
    <td style="width: 18pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>whether the product is designated under physician treatment guidelines as a first-line therapy or as a second- or third-line therapy
        for particular diseases;</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 18pt"><br /> </td>
    <td style="width: 18pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>adverse publicity about our product candidates or favorable publicity about competitive products;</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 18pt"><br /> </td>
    <td style="width: 18pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>convenience and ease of administration of our products; and</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 18pt"><br /> </td>
    <td style="width: 18pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>potential product liability claims.</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">If any of our product candidates are approved, but do not achieve an adequate level
of acceptance by physicians, patients and the medical community, we may not generate sufficient revenue from these products, and we may
not become or remain profitable. In addition, efforts to educate the medical community and third-party payors on the benefits of our product
candidates may require significant resources and may never be successful.</div>

<div style="line-height: 1.25">&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal">58</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000" /></div>
</div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">Even if we obtain regulatory approval of any
of our product candidates in a major pharmaceutical market such as the United States or the EU, we may never obtain approval or commercialize
our products in other major markets, which would limit our ability to realize their full market potential.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">In order to market any products in a country or territory, we must establish and comply
with numerous and varying regulatory requirements of such countries or territories regarding safety and efficacy. Clinical trials conducted
in one country may not be accepted by regulatory authorities in other countries, and regulatory approval in one country does not mean
that regulatory approval will be obtained in any other country. Approval procedures vary among countries and can involve additional product
testing and validation and additional administrative review periods. Seeking regulatory approvals in all major markets could result in
significant delays, difficulties and costs for us and may require additional preclinical studies or clinical trials which would be costly
and time consuming. Regulatory requirements can vary widely from country to country and could delay or prevent the introduction of our
products in those countries. Satisfying these and other regulatory requirements is costly, time consuming, uncertain and subject to unanticipated
delays. In addition, our failure to obtain regulatory approval in any country may delay or have negative effects on the process for regulatory
approval in other countries. We do not have any product candidates approved for sale in any jurisdiction, including international markets,
and we do not have experience in obtaining regulatory approval in international markets. If we fail to comply with regulatory requirements
in international markets or to obtain and maintain required approvals, our target market will be reduced and our ability to realize the
full market potential of our products will be harmed.</div>

<div style="line-height: 1.25"><br /> </div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">The successful commercialization of our product
candidates, if approved, will depend in part on the extent to which governmental authorities and third-party payors establish adequate
coverage and reimbursement levels and pricing policies.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">The successful commercialization of our product candidates, if approved, will depend,
in part, on the extent to which coverage and reimbursement for our products will be available from government and health administration
authorities, private health insurers and other third-party payors. To manage healthcare costs, many governments and third-party payors
increasingly scrutinize the pricing of new technologies and require greater levels of evidence of favorable clinical outcomes and cost-effectiveness
before extending coverage. In light of such challenges to prices and increasing levels of evidence of the benefits and clinical outcomes
required of new technologies, we cannot be sure that coverage will be available for our oral PTH product candidates, if approved, or any
other product candidate that we commercialize and, if available, that the reimbursement rates will be adequate. If we are unable to obtain
adequate levels of coverage and reimbursement for our product candidates, their marketability will be negatively and materially impacted.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Reimbursement may impact the demand for, or the price of, any product for which we
obtain marketing approval. In addition, third-party payors are likely to impose strict requirements for reimbursement in order to limit
off-label use of a higher priced drug. Reimbursement by a third-party payor may depend upon a number of factors, including the third-party
payor&#8217;s determination that use of a product is:</div>

<div style="line-height: 1.25"><br /> </div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 54pt"><br /> </td>
    <td style="width: 18pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>a covered benefit under its health plan;</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 54pt"><br /> </td>
    <td style="width: 18pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>safe, effective and medically necessary;</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 54pt"><br /> </td>
    <td style="width: 18pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>appropriate for the specific patent;</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 54pt"><br /> </td>
    <td style="width: 18pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>cost-effective; and</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 54pt"><br /> </td>
    <td style="width: 18pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>neither experimental nor investigational. &#160;</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Third party payors may deny coverage and reimbursement status altogether of a given
drug product, or cover the product but establish prices at levels that are too low to enable us to realize an appropriate return on our
investment in product development. Because the coverage and reimbursement policies may change frequently, in some cases at short notice,
even when there is favorable coverage and reimbursement, future changes may occur that adversely impact the favorable status. Further,
the net reimbursement for drug products may be subject to additional reductions if there are changes to laws that presently restrict imports
of drugs from countries where they may be sold at lower prices than in the United States.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">The unavailability or inadequacy of third-party coverage and reimbursement could have
a material adverse effect on the market acceptance of our product candidates and the future revenues we may expect to receive from those
product candidates. In addition, we are unable to predict what additional legislation or regulation relating to the healthcare industry
or third-party coverage and reimbursement may be enacted in the future, or what effect such legislation or regulation would have on our
business.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Obtaining coverage and reimbursement approval for a product from a government or other
third-party payors is a time-consuming and costly process that could require us to provide supporting scientific, clinical and cost effectiveness
data for the use of our products to the payor. We may not be able to provide data sufficient to gain acceptance with respect to coverage
and reimbursement. We cannot be sure that coverage or adequate reimbursement will be available for our product candidates, if approved.
Also, we cannot be sure that reimbursement amounts will not reduce the demand for, or the price of, our future products. If reimbursement
is not available, or is available only to limited levels, we may not be able to commercialize our product candidates, profitably or at
all, even if approved.</div>

<div style="line-height: 1.25">&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal">59</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000" /></div>
</div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">We may become exposed to costly and damaging
liability claims, either when testing our product candidates in the clinic or at the commercial stage; and our product liability insurance
may not cover all damages from such claims.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">We are exposed to potential product liability and professional indemnity risks that
are inherent in the research, development, manufacturing, marketing and use of pharmaceutical products. Currently we have no products
that have been approved for commercial sale; however, the current and future use of product candidates by us in clinical trials, and the
sale of any approved products in the future, may expose us to liability claims. These claims might be made by patients that use the product,
healthcare providers, pharmaceutical companies, our collaborators or others selling such products. Any claims against us, regardless of
their merit, could be difficult and costly to defend and could materially adversely affect the market for our product candidates or any
prospects for commercialization of our product candidates. Regardless of the merits or eventual outcome, liability claims may result in:</div>

<div style="line-height: 1.25"><br /> </div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 18pt"><br /> </td>
    <td style="width: 18pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>decreased demand for any of our product candidates or products we develop;</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 18pt"><br /> </td>
    <td style="width: 18pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>injury to our reputation and significant negative media attention;</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 18pt"><br /> </td>
    <td style="width: 18pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>withdrawal of clinical trial participants or cancellation of clinical trials;</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 18pt"><br /> </td>
    <td style="width: 18pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>costs to defend the related litigation, which may be only partially recoverable even in the event of successful defense;</div> </td>
        </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 18pt"><br /> </td>
    <td style="width: 18pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>a diversion of management&#8217;s time and our resources;</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 18pt"><br /> </td>
    <td style="width: 18pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>substantial monetary awards to trial participants or patients;</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 18pt"><br /> </td>
    <td style="width: 18pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>regulatory investigations, product recalls, withdrawals or labeling, marketing or promotional restrictions;</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 18pt"><br /> </td>
    <td style="width: 18pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>loss of revenue; and</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 18pt"><br /> </td>
    <td style="width: 18pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>the inability to commercialize any products we develop.&#160;</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Although the clinical trial process is designed to identify and assess potential side
effects, it is always possible that a drug, even after regulatory approval, may exhibit unforeseen side effects. If any of our product
candidates were to cause adverse side effects during clinical trials or after approval of the product candidate, we may be exposed to
substantial liabilities. Physicians and patients may not comply with any warnings that identify known potential adverse effects and patients
who should not use our product candidates.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Although we maintain limited product liability insurance for our product candidates,
it is possible that our liabilities could exceed our insurance coverage. We intend to expand our insurance coverage to include the sale
of commercial products if we obtain marketing approval for any of our product candidates. However, we may not be able to maintain insurance
coverage at a reasonable cost or obtain insurance coverage that will be adequate to satisfy any liability that may arise. If a successful
product liability claim or series of claims is brought against us for uninsured liabilities or in excess of insured liabilities, our assets
may not be sufficient to cover such claims and our business operations could be impaired.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Should any of the events described above occur, this could have a material adverse
effect on our business, financial condition and results of operations.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-weight: bold">Risks Related to Our Dependence on Third Parties</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">We are highly dependent upon our ability to
enter into agreements with collaborators to develop, commercialize and market our products.</div>

<div style="line-height: 1.25"><br /> </div>

<div style="text-align: justify; line-height: 1.25">We may enter into collaborations with third parties that we believe could provide
us with funding, research support, and other milestone payments. We face significant competition in seeking appropriate collaborators.
Our ability to reach a definitive agreement for a collaboration will depend upon, among other things, our assessment of the collaborator&#8217;s
resources and expertise, the terms and conditions of the proposed collaboration and the proposed collaborator&#8217;s evaluation of a
number of factors. These factors may include the design or results of clinical trials, the likelihood of approval by the FDA, the EMA
or similar regulatory authorities, the potential market for the subject product candidate, the costs and complexities of manufacturing
and delivering such product candidate to patients, the potential of competing products, the existence of uncertainty with respect to our
ownership of technology, which can exist if there is a challenge to such ownership without regard to the merits of the challenge and industry
and market conditions generally. The collaborator may also consider alternative product candidates or technologies for similar indications
that may be available for collaboration and whether such a collaboration could be more attractive than the one with us for our product
candidate.</div>

<div style="line-height: 1.25">&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal">60</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000" /></div>
</div>

<div style="text-align: justify; line-height: 1.25">Collaborations are complex and time-consuming to negotiate and document. If we are
unable to reach agreements with suitable collaborators on a timely basis, on acceptable terms, or at all, and are unable to raise supplemental
capital otherwise, we may have to delay, curtail the development of a product candidate, reduce or delay one or more of our other development
programs, delay potential commercialization of a product candidate or reduce the scope of any sales or marketing activities, or increase
our expenditures and undertake development or commercialization activities at our own expense. If we fail to enter into collaborations
and do not have sufficient funds or expertise to undertake the necessary development or commercialization activities ourselves, we may
not be able to further develop our product candidates or bring them to market or continue to develop our technology platforms and our
business may be materially and adversely affected.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Any collaboration we enter into may pose a number of risks, including the following:</div>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 18pt"><br /> </td>
    <td style="width: 18pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>Collaborators may have significant discretion in determining the efforts and resources that they will apply to these collaborations;</div>
        </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 18pt"><br /> </td>
    <td style="width: 18pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>Collaborators may not perform their obligations as expected;</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 18pt"><br /> </td>
    <td style="width: 18pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>Collaborators may not pursue development and commercialization of any product candidates that achieve regulatory approval or may
        elect not to continue or renew development or commercialization programs based on clinical trial results, changes in the collaborators&#8217;
        strategic focus or available funding, or external factors, such as an acquisition, that divert resources or create competing priorities;</div>
        </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 18pt"><br /> </td>
    <td style="width: 18pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>Collaborators may delay clinical trials, provide insufficient funding for a clinical trial program, stop a clinical trial or abandon
        a product candidate, repeat or conduct new clinical trials or require a new formulation of a product candidate for clinical testing;</div>
        </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 18pt"><br /> </td>
    <td style="width: 18pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>Collaborators could independently develop, or develop with third parties, products that compete directly or indirectly with our products
        or product candidates if the collaborators believe that competitive products are more likely to be successfully developed or can be commercialized
        under terms that are more economically attractive than ours;</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 18pt"><br /> </td>
    <td style="width: 18pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>Product candidates discovered in collaboration with us may be viewed by our collaborators as competitive with their own product candidates
        or products, which may cause collaborators to cease to devote resources to the commercialization of our product candidates;</div> </td>
        </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 18pt"><br /> </td>
    <td style="width: 18pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>A collaborator with marketing and distribution rights to one or more of our product candidates that achieve regulatory approval may
        not commit sufficient resources to the marketing and distribution of such product or products;</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 18pt"><br /> </td>
    <td style="width: 18pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>Disagreements with collaborators, including disagreements over proprietary rights, contract interpretation or the preferred course
        of development, might cause delays or termination of the research, development or commercialization of product candidates, might lead
        to additional responsibilities for us with respect to product candidates, or might result in litigation or arbitration, any of which would
        be time-consuming and expensive;</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 18pt"><br /> </td>
    <td style="width: 18pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>Collaborators may not properly obtain, maintain, defend or enforce our intellectual property rights or may use our proprietary information
        in such a way as to invite litigation that could jeopardize or invalidate our intellectual property or proprietary information or expose
        us to potential litigation or other intellectual property-related proceedings, including proceedings challenging the scope, ownership,
        validity and enforceability of our intellectual property.</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 18pt"><br /> </td>
    <td style="width: 18pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>Collaborators may own or co-own intellectual property covering our product candidates or research programs that results from our
        collaboration with them, and in such cases, we may not have the exclusive right to commercialize such intellectual property or such product
        candidates or research programs;</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 18pt"><br /> </td>
    <td style="width: 18pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>Collaborators may infringe, misappropriate or otherwise violate the intellectual property rights of third parties, which may expose
        us to litigation and potential liability;</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 18pt"><br /> </td>
    <td style="width: 18pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>Collaborators may fail to comply with applicable laws, rules or regulations when performing services for us, which may expose us
        to legal proceedings and potential liability; and</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 18pt"><br /> </td>
    <td style="width: 18pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>Collaborations may be terminated for convenience by the collaborator and, if terminated, we may suffer from negative publicity and
        we may find it more difficult to attract new collaborators.</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">If we enter into collaborations to develop and potentially commercialize any product
candidates, we may not be able to realize the benefit of such transactions if we or our collaborator elects not to exercise the rights
granted under the agreement or if we or our collaborator are unable to successfully integrate a product candidate into existing operations
and company culture. In addition, if our agreement with any of our collaborators terminates, our access to technology and intellectual
property licensed to us by that collaborator may be restricted or terminate entirely, which may delay our continued development of our
product candidates utilizing the collaborator&#8217;s technology or intellectual property or require us to stop development of such product
candidates completely. We may also find it more difficult to find a suitable replacement collaborator or attract new collaborators, and
our development programs may be delayed or the perception of us in the business and financial communities could be adversely affected.
All of the risks relating to product development, regulatory approval and commercialization described in this Annual Report also apply
to the activities of any of our future program collaborators.</div>

<div style="line-height: 1.25"><br /> </div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal">61</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000" /></div>
</div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">We may not be able to secure and maintain research
institutions to conduct our clinical trials.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">We rely on research institutions to conduct our clinical trials. Specifically, the
limited number of centers experienced with pharmaceutical product candidates heightens our dependence on such research institutions. Our
reliance upon research institutions, including hospitals and clinics, provides us with less control over the timing and cost of clinical
trials and the ability to recruit subjects. If we are unable to reach agreements with suitable research institutions on acceptable terms,
if any resulting agreement is terminated, if research institutions are closed down by public authorities for reasons outside of our control,
or if we cannot fulfill contractual commitments, we may be unable to quickly replace the research institution with another qualified institution
on acceptable terms. Furthermore, we may not be able to secure and maintain suitable research institutions to conduct our clinical trials.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">Independent clinical investigators and CROs
that we engage to conduct our clinical trials may not devote sufficient time or attention to our clinical trials or be able to repeat
their past success.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">We expect to continue to depend on independent clinical investigators and CROs to
conduct our clinical trials. CROs may also assist us in the collection and analysis of data. There is a limited number of third-party
service providers that specialize or have the expertise required to achieve our business objectives. Identifying, qualifying and managing
performance of third-party service providers can be difficult, time consuming and cause delays in our development programs. These investigators
and CROs will not be our employees and we will not be able to control, other than by contract, the amount of resources, including time,
which they devote to our product candidates and clinical trials. If independent investigators or CROs fail to devote sufficient resources
to the development of our product candidates, or if their performance is substandard, it may delay or compromise the prospects for approval
and commercialization of any product candidates that we develop. In addition, the use of third-party service providers requires us to
disclose our proprietary information to these parties, which could increase the risk that this information will be misappropriated. Further,
the FDA and other regulatory authorities require that we comply with standards and GCP requirements for conducting, recording and reporting
clinical trials to assure that data and reported results are credible and accurate and that the rights, integrity and confidentiality
of trial subjects are protected. Regulatory authorities enforce these GCPs through periodic inspections of trial sponsors, principal investigators
and trial sites. If we or any of our CROs fail to comply with applicable GCPs, the clinical data generated in our clinical trials may
be deemed unreliable and the FDA, EMA or comparable regulatory authorities may require us to perform additional clinical trials before
approving our marketing applications. We cannot assure you that upon inspection by a given regulatory authority, such regulatory authority
will determine that any of our clinical trials comply with GCP regulations. In addition, our clinical trials must be conducted with product
produced under cGMP regulations. Our failure to comply with these regulations may require us to repeat clinical trials, which would delay
the regulatory approval process. Failure of clinical investigators or CROs to meet their obligations to us or comply with GCP procedures
could adversely affect the clinical development of our product candidates and harm our business.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">If the third parties or consultants that assist us in conducting our clinical trials
do not perform their contractual duties or obligations, experience work stoppages, do not meet expected deadlines, terminate their agreements
with us or need to be replaced, or if the quality or accuracy of the clinical data they obtain is compromised due to the failure to adhere
to our clinical trial protocols or GCPs, or for any other reason, we may need to conduct additional clinical trials or enter into new
arrangements with alternative third parties, which could be difficult, costly or impossible, and our clinical trials may be extended,
delayed or terminated or may need to be repeated. If any of the foregoing were to occur, we may not be able to obtain, or may be delayed
in obtaining, regulatory approval for the product candidates being tested in such trials, and will not be able to, or may be delayed in
our efforts to, successfully commercialize these product candidates.</div>

<div style="line-height: 1.25"><br /> </div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal">62</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000" /></div>
</div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">We contract with third parties for the supply
of materials used in drug formulation for clinical testing and expect to contract with third parties for the manufacturing of our product
candidates for large-scale testing. This reliance on third parties increases the risk that we will not have sufficient quantities of our
product candidates or products or such quantities at an acceptable cost, which could delay, prevent or impair our development or commercialization
efforts.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">We anticipate continuing our engagement of third parties to provide our clinical supply
as we advance our product candidates into and through clinical development. We expect in the future to use third parties for the manufacture
of our product candidates for clinical testing, as well as for commercial manufacture. We plan to enter into long-term supply agreements
with several manufacturers for commercial supplies. We may be unable to reach agreement on satisfactory terms with contract manufacturers
to manufacture our product candidates. Additionally, the facilities to manufacture our product candidates must be the subject of a satisfactory
inspection before the FDA, the EMA or other regulatory authorities approve an NDA or grant a marketing authorization for the product candidate
manufactured at that facility. We will depend on these third-party manufacturers for compliance with the FDA&#8217;s and EMA&#8217;s requirements
for the manufacture of our finished products. We do not control the manufacturing process of, and are completely dependent on, our contract
manufacturers for compliance with cGMPs. If our manufacturers cannot successfully manufacture material that conforms to our specifications
and the FDA, European Commission and other regulatory authorities&#8217; cGMP requirements, they will not be able to secure and/or maintain
regulatory approval for their manufacturing facilities. In addition, we have no control over the ability of our contract manufacturers
to maintain adequate quality control, quality assurance and qualified personnel. If the FDA or a comparable foreign regulatory authority
does not approve these facilities for the manufacture of our product candidates or if it withdraws any such approval in the future, we
may need to find alternative manufacturing facilities, which would significantly impact our ability to develop, obtain regulatory approval
for or market our product candidates, if approved, and may subject us to recalls or enforcement action for products already on the market.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Our failure or the failure of our third party subcontractors and suppliers to comply
with applicable regulations could result in sanctions being imposed on us, including fines, injunctions, civil penalties, delays, suspension
or withdrawal of approvals, license revocation, seizures or recalls of products, operating restrictions and criminal prosecutions, any
of which could significantly and adversely affect supplies of our product candidates that we may develop.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Reliance on third-party manufacturers entails risks to which we would not be subject
if we manufactured the product candidates ourselves, including:</div>

<div style="line-height: 1.25"><br /> </div>

<div style="line-height: 1.25">

<div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 18pt">&#160;</td>
    <td style="vertical-align: top; width: 18pt">
        <div style="text-align: justify; line-height: 1.25"><span style="font-family: Times New Roman,Times,serif">&#8226;</span></div> </td>
    <td style="vertical-align: top; width: auto">
        <div style="text-align: justify; line-height: 1.25"><span style="font-family: Times New Roman,Times,serif">the possibility of a breach
        of the manufacturing agreements by the third parties because of factors beyond our control;</span></div>
        <div style="text-align: justify; line-height: 1.25"><span style="font-family: Times New Roman,Times,serif"> <br /> </span></div> </td>
        </tr>
  </table> </div>

<div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 18pt">&#160;</td>
    <td style="vertical-align: top; width: 18pt">
        <div style="text-align: justify; line-height: 1.25"><span style="font-family: Times New Roman,Times,serif">&#8226;</span></div> </td>
    <td style="vertical-align: top; width: auto">
        <div style="text-align: justify; line-height: 1.25"><span style="font-family: Times New Roman,Times,serif">the possibility that the supply
        is inadequate or delayed;</span></div>
        <div style="text-align: justify; line-height: 1.25"><span style="font-family: Times New Roman,Times,serif"> <br /> </span></div> </td>
        </tr>
  </table> </div>

<div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 18pt">&#160;</td>
    <td style="vertical-align: top; width: 18pt">
        <div style="text-align: justify; line-height: 1.25"><span style="font-family: Times New Roman,Times,serif">&#8226;</span></div> </td>
    <td style="vertical-align: top; width: auto">
        <div style="text-align: justify; line-height: 1.25"><span style="font-family: Times New Roman,Times,serif">the risk that the third party
        may enter the field and seek to compete and may no longer be willing to continue supplying;</span></div>
        <div style="text-align: justify; line-height: 1.25"><span style="font-family: Times New Roman,Times,serif"> <br /> </span></div> </td>
        </tr>
  </table> </div>

<div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 18pt">&#160;</td>
    <td style="vertical-align: top; width: 18pt">
        <div style="text-align: justify; line-height: 1.25"><span style="font-family: Times New Roman,Times,serif">&#8226;</span></div> </td>
    <td style="vertical-align: top; width: auto">
        <div style="text-align: justify; line-height: 1.25"><span style="font-family: Times New Roman,Times,serif">the possibility of termination
        or nonrenewal of the agreements by the third parties before we are able to arrange for a qualified replacement third-party manufacturer;
        and</span></div>
        <div style="text-align: justify; line-height: 1.25"><span style="font-family: Times New Roman,Times,serif"> <br /> </span></div> </td>
        </tr>
  </table> </div>

<div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 18pt">&#160;</td>
    <td style="vertical-align: top; width: 18pt">
        <div style="text-align: justify; line-height: 1.25"><span style="font-family: Times New Roman,Times,serif">&#8226;</span></div> </td>
    <td style="vertical-align: top; width: auto">
        <div style="text-align: justify; line-height: 1.25"><span style="font-family: Times New Roman,Times,serif">the possibility that we may
        not be able to secure a manufacturer or manufacturing capacity in a timely manner and on satisfactory terms in order to meet our manufacturing
        needs.</span></div> </td> </tr>
  </table> </div> </div>

<div style="line-height: 1.25"><br /> </div>

<div style="text-align: justify; line-height: 1.25">Any of these factors could cause the delay of approval or commercialization of our
product candidates, cause us to incur higher costs or prevent us from commercializing our product candidates successfully. Furthermore,
if any of our product candidates are approved and contract manufacturers fail to deliver the required commercial quantities of finished
product on a timely basis and at commercially reasonable prices, and we are unable to find one or more replacement manufacturers capable
of production at a substantially equivalent cost, in substantially equivalent volumes and quality and on a timely basis, we would likely
be unable to meet demand for our products and could lose potential revenue. It may take several years to establish an alternative source
of supply for our product candidates and to have any such new source approved by the FDA, the EMA or any other relevant regulatory authorities.</div>

<div style="line-height: 1.25"><br /> </div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">We maintain our cash at financial institutions,
often in balances that exceed federally insured limits.</div>

<div style="line-height: 1.25"><br /> </div>

<div style="text-align: justify; line-height: 1.25">A portion of our cash may be held in accounts at U.S. banking institutions. Cash held
in non-interest-bearing and interest-bearing operating accounts may exceed the Federal Deposit Insurance Corporation (&#8220;FDIC&#8221;)
insurance limits. If such banking institutions were to fail, we could lose all or a portion of those amounts held in excess of such insurance
limitations. The FDIC took control of Silicon Valley Bank (&#8220;SVB&#8221;), on March 10, 2023. We maintained certain operating accounts
with SVB prior to its closure and have since transferred all of our deposits previously held with the bank to other banking institutions.
The FDIC also took control of Signature Bank (&#8220;Signature Bank&#8221;) on March 12, 2023. We did not maintain any accounts with Signature
Bank. The Federal Reserve announced that account holders with Signature Bank would be made whole. However, as the FDIC continues to address
the situation with SVB, Signature Bank and other banking institutions, the risk of loss in excess of insurance limitations and otherwise
has increased across financial institutions. Any loss that we may experience in the future could have a material and adverse effect on
our ability to pay our operational expenses or make other payments and may require us to move our accounts to other banks, which could
cause delays in making payments to our vendors and employees, among other counterparties, and cause other business and operational disruptions.</div>

<div style="line-height: 1.25"><br /> </div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal">63</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000" /></div>
</div>

<div style="line-height: 1.25"><br /> </div>

<div style="text-align: justify; line-height: 1.25"><span style="font-weight: bold">Risks Related to Our Intellectual Property</span>&#160;</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">If we fail to establish, maintain, defend and
enforce intellectual property rights with respect to our technology, our business, prospects, financial condition and results of operations
may be materially adversely affected.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Our success depends in large part on our ability to obtain and maintain protection
with respect to our intellectual property and proprietary technology. Our product candidates utilize our proprietary technology and know-how
relating to the oral delivery of large molecules for the treatment of certain conditions with oral PTH. We seek to protect our proprietary
position by filing patent applications in the United States and certain foreign jurisdictions relating to our product candidates and technologies
that are important to our business. This process is expensive, complex and time-consuming, and we may not be able to file and prosecute
all necessary or desirable patent applications at a reasonable cost or in a timely manner. It is also possible that we will fail to identify
patentable aspects of our research and development output before it is too late to obtain patent protection. If we do not adequately obtain,
maintain, protect and enforce our proprietary rights in our technologies, competitors may be able to use our technologies and erode or
negate any competitive advantage we may have, which could have a material adverse effect on our business and our ability to achieve profitability.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">We have limited patent protection with respect to our product candidates and technologies.
We have been issued a patent with claims generally directed to compositions comprising a protein, an absorption enhancer and a protease
inhibitor, as well as methods for oral administration of a protein with an enzymatic activity in each of the United States, Australia,
Canada, Japan, New Zealand, China, Israel and Russia. Related patent applications are pending in the United States, the EU, Hong Kong,
Brazil, China and India. We have also filed patent applications derived from seven patent families in various jurisdictions that currently
contain claims directed to oral administration technologies, including compositions and drug delivery devices utilizing an absorption
enhancer and methods of treating osteoporosis, hypoparathyroidism and bone fractures and related conditions with orally administered parathyroid
hormone. Certain of these patent applications have already matured into patents in the United States, Israel and Japan.&#160; Other applications
are in prosecution.&#160; We have also recently filed additional seven international patent applications (patent families) with claims
pertaining to a novel oral delivery platform, with claims directed at compositions comprising a protein, an absorption enhancer and an
alkaline polymer, and methods of oral administration these compositions.&#160; We cannot be certain that patents will be issued or granted
with respect to any of our pending or future patent applications, or that issued or granted patents will not later be found to be invalid
or unenforceable. The patent position of pharmaceutical companies is generally uncertain because it involves complex legal and factual
considerations. The standards applied by the United States Patent and Trademark Office, or USPTO, and foreign patent offices in granting
patents are not always applied uniformly or predictably, and can change. For example, there is no uniform worldwide policy regarding patentable
subject matter or the scope of claims allowable in pharmaceutical or biotechnology patents. Even if our pending patent applications issue
as patents, such patents may not cover our product candidates in the United States or in other countries. Accordingly, we cannot predict
whether additional patents protecting our technology will issue in the United States or in non-U.S. jurisdictions, or whether any patents
that do issue will have claims of adequate scope to provide us with a competitive advantage.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">The issuance of a patent is not conclusive as to its inventorship, scope, validity
or enforceability, and our patents may be challenged in the courts or patent offices in the United States and abroad. Such challenges
may result in loss of exclusivity or in patent claims being narrowed, invalidated or held unenforceable, which could limit our ability
to stop others from using or commercializing technology and products similar or identical to ours, or limit the duration of the patent
protection covering our technology and product candidates. In addition, patents have a limited lifespan. In the United States and most
foreign jurisdictions, the natural expiration of a patent is generally 20 years after its effective filing date. Various extensions may
be available; however, the life of a patent and the protection it affords is limited. For example, the Drug Price Competition and Patent
Term Restoration Act of 1984, or the Hatch-Waxman Act, permits a patent term extension of up to five years beyond the expiration date
of a U.S. patent as partial compensation for the useful patent term lost, if any, during the FDA regulatory review process. However, a
patent term extension cannot extend the remaining term of a patent beyond a total of 14 years from the date of the product&#8217;s approval
by the FDA, only one patent applicable to an approved drug is eligible for the extension, and only those claims covering the approved
drug, a method for using it or a method for manufacturing it may be extended. We may not be granted an extension because we may fail to
satisfy applicable requirements and even if we are granted an extension, the applicable time period or the scope of patent protection
afforded could be less than we request. In addition, if we encounter delays in obtaining regulatory approvals, the period of time during
which we could market a product under patent protection could be reduced. Even if patents covering our product candidates are obtained,
once such patents expire, we may be vulnerable to competition from similar or generic products. Given the amount of time required for
the development, testing and regulatory review of new product candidates, patents protecting such candidates might expire before or shortly
after such candidates are commercialized. As a result, we cannot provide any assurance that any of our issued patents or any patents that
may be issued to us in the future will provide sufficient protections for our technology or product candidates, in whole or in part, or
will effectively prevent competitors from commercializing similar or identical technologies and products.</div>

<div style="line-height: 1.25">&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal">64</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000" /></div>
</div>

<div style="text-align: justify; line-height: 1.25">Our issued patents may not be sufficient to provide us with a competitive advantage.
For example, competitors and other third parties may be able to circumvent our patents by developing similar or alternative technologies
or products in a non-infringing manner. We may also grant licenses under our intellectual property that may limit our ability to exploit
such intellectual property. For example, we are party to a patent transfer agreement, or the Patent Transfer Agreement, with Oramed Ltd.,
or Oramed, pursuant to which we have granted Oramed an exclusive, worldwide, royalty-free, irrevocable and perpetual license, with the
right to sublicense, under certain of our patent rights to develop, manufacture and commercialize covered products or otherwise exploit
such patent rights in the fields of diabetes and influenza and we have agreed not to, directly or indirectly, engage in any activities
within the fields of diabetes and influenza. Even if such agreement were to be terminated, Oramed would retain its exclusive license under
such patent rights.</div>

<div style="line-height: 1.25"><br /> </div>

<div style="text-align: justify; line-height: 1.25">In the future, we may enter into additional collaborative agreements or license agreements
with third parties which may subject us to obligations that must be fulfilled and require us to manage complex relationships with third
parties. If we are unable to meet our obligations or manage our relationships with our collaborators under these agreements, our revenue
may decrease. From the standpoint of our future strategic collaborators, the strength of the intellectual property under which we may
grant licenses can be a determinant of the value of these relationships. If we are unable to secure, protect and enforce our intellectual
property, it may become more difficult for us to attract strategic collaborators. The loss or diminution of our intellectual property
rights could also result in a decision by future third-party collaborators to terminate their agreements with us. In addition, these agreements
may be complex and may contain provisions that could give rise to legal disputes, including potential disputes concerning financial obligations
or ownership of intellectual property and data under such agreements. Such disputes can lead to lengthy, expensive litigation or arbitration,
requiring us to divert management time and resources to such dispute. Any such development could have a material adverse effect on our
business, prospects, financial condition and results of operations.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">We may become involved in proceedings to protect
or enforce our proprietary rights, which could be expensive and time consuming, and may ultimately be unsuccessful.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Competitors or other third parties may infringe or otherwise violate our patents,
trademarks, copyrights or other intellectual property rights. To counter infringement or other violations, we may be required to file
claims, which can be expensive and time consuming. Any such claims could provoke these parties to assert counterclaims against us, including
claims alleging that we infringe their patents or other intellectual property rights. In addition, in a patent infringement proceeding,
a court may decide that one or more of the patents we assert is invalid or unenforceable, in whole or in part, construe the patent&#8217;s
claims narrowly or refuse to prevent the other party from using the technology at issue on the grounds that our patents do not cover the
technology. In any intellectual property litigation, even if we are successful, any award of monetary damages or other remedy we receive
may not be commercially valuable. Furthermore, because of the substantial amount of discovery required in connection with intellectual
property litigation, there is a risk that some of our confidential information could be compromised by disclosure during this type of
litigation. Third parties may also raise challenges to the validity of our patent claims before administrative bodies in the United States
or abroad, even outside the context of litigation. Such mechanisms include re-examination, post-grant review and<span style="font-style: italic">
inter partes</span> review proceedings and equivalent proceedings in foreign jurisdictions such as opposition proceedings. If third parties
have prepared and filed patent applications in the United States that also claim technology to which we have rights, we may have to participate
in interference proceedings in the USPTO, to determine priority of invention for patent applications filed before March 16, 2013, or in
derivation proceedings to determine inventorship for patent applications filed after such date. Such proceedings could result in the revocation
of, cancellation of, or amendment to our patents in such a way that they no longer cover our product candidates or provide us with any
competitive advantage.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">In addition, we may be subject to third-party challenges regarding our exclusive ownership
of our intellectual property. If a third party were successful in challenging our exclusive ownership of any of our intellectual property,
we may lose our right to use such intellectual property, such third party may be able to license such intellectual property to other third
parties, including our competitors, and third parties could market competing products and technology.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">In addition, during the course of this kind of litigation or proceedings, there could
be public announcements of the results of hearings, motions or other interim proceedings or developments or public access to related documents.
If investors perceive these results to be negative, the market price for our Ordinary Shares could be significantly harmed. Any of the
foregoing could have a material adverse effect on our competitive position, business, financial conditions, results of operations, and
prospects.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">Our commercial success depends significantly
on our ability to operate without infringing the patents and other proprietary rights of third parties. We may face claims that we are
violating the intellectual property rights of others.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Our success will depend in part on our ability to operate without infringing the proprietary
rights of third parties. Other entities may have or obtain patents or other proprietary rights that could limit our ability to make, use,
sell, offer for sale or import our product candidates and future approved products or impair our competitive position. We may face claims,
including from direct competitors, asserting that the commercial use of our technology infringes or otherwise violates the intellectual
property rights of others. We cannot be certain that our technologies and processes do not violate the intellectual property rights of
others. Third parties may assert infringement claims against us based on existing or future intellectual property rights. We expect that
we may increasingly be subject to such claims as our product candidates approach commercialization, and as we gain greater visibility
as a public company. We may not be aware of all such intellectual property rights potentially relating to our product candidates and their
uses. Thus, we do not know with certainty that our oral PTH (1-34) tablet or any other product candidate, or our commercialization thereof,
does not and will not infringe or otherwise violate any third party&#8217;s intellectual property.</div>

<div style="line-height: 1.25">&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal">65</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000" /></div>
</div>

<div style="text-align: justify; line-height: 1.25">If we were found to infringe or otherwise violate the intellectual property rights
of others, we could face significant costs to implement work-arounds, and we cannot provide any assurance that any such work-around would
be available or technically equivalent to our current technology. In such cases, we might need to license a third party&#8217;s intellectual
property, and such required licenses might not be available on acceptable terms, or at all. Even if we were able to obtain a license,
it could be non-exclusive, thereby giving our competitors access to the same technologies licensed to us and could require us to make
substantial licensing and royalty payments. We could be forced, including by court order, to cease commercializing the infringing technology
or product. In addition, we could be found liable for monetary damages, including treble damages and attorneys&#8217; fees if we are found
to have willfully infringed a patent or other intellectual property right. A finding of infringement could prevent us from commercializing
our product candidates or force us to cease some of our business operations, which could materially harm our business. Claims that we
have misappropriated the confidential information or trade secrets of third parties could expose us to similar liabilities and have a
similar negative impact on our business.</div>

<div style="line-height: 1.25"><br /> </div>

<div style="text-align: justify; line-height: 1.25">The pharmaceutical and biotechnology industries have produced a significant number
of patents, and it may not always be clear to industry participants, including us, which patents cover various types of products or methods
of use. The coverage of patents is subject to interpretation by the courts, and the interpretation is not always uniform or predictable.
There is a substantial amount of litigation involving patent and other intellectual property rights in the biotechnology and pharmaceutical
industries generally, and these lawsuits can be very time consuming and costly. If we are sued for patent infringement, we would need
to demonstrate that our products or methods either do not infringe the patent claims of the relevant patent or that the patent claims
are invalid, and we may not be successful in doing so. Proving invalidity is difficult. For example, in the United States, proving invalidity
requires a showing of clear and convincing evidence to overcome the presumption of validity enjoyed by issued patents. Even if we are
successful in these proceedings, we may incur substantial costs and divert management&#8217;s time and attention in defending these proceedings,
which could have a material adverse effect on our business.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Also, to the extent that our agreements provide that we will defend and indemnify
our suppliers, service providers, future strategic collaborators or any other party for claims against them relating to any alleged infringement
of the intellectual property rights of third parties in connection with such suppliers&#8217;, service providers&#8217;, strategic collaborators&#8217;
or other parties&#8217; use of our technologies, we may incur substantial costs defending and indemnifying such parties to the extent
they are subject to these types of claims. Any claims brought against us, any suppliers, service providers, future strategic collaborators
or any other party indemnified by us alleging that we have violated the intellectual property of others could have a material adverse
effect on our business, prospects, financial condition and results of operations.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">We may not be able to protect and enforce our
intellectual property rights throughout the world.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">We currently have limited patent protection for our product candidates and technologies,
and filing, prosecuting, maintaining and defending patents on product candidates in all countries throughout the world would be prohibitively
expensive. In addition, we may not pursue or obtain patent protection in all major markets. In addition, the legal systems of some countries,
particularly developing countries, do not favor the enforcement of patents and other intellectual property protection, especially those
relating to life sciences. This could make it difficult for us to stop the infringement of our other intellectual property rights. For
example, many foreign countries have compulsory licensing laws under which a patent owner must grant licenses to certain third parties.
Furthermore, many countries limit the enforceability of patents against third parties, including government agencies or government contractors.
In these countries, patents may provide limited or no benefit.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Competitors may use our technologies in jurisdictions where we have not obtained or
are unable to adequately enforce patent protection to develop or commercialize their own products. These products may compete with our
future products, and our patents or other intellectual property rights may not be effective or sufficient to prevent them from competing.
Proceedings to enforce our patent rights in such jurisdictions, whether or not successful, could result in substantial costs and divert
our efforts and attention from other aspects of our business, could put our patents at risk of being invalidated or interpreted narrowly,
put our patent applications at risk of not issuing and provoke third parties to assert claims against us. We may not prevail in any lawsuits
that we initiate and the damages or other remedies awarded, if any, may not be commercially meaningful. Accordingly, our efforts to enforce
our intellectual property rights around the world may be inadequate to obtain a significant commercial advantage from the intellectual
property that we develop or license.</div>

<div style="line-height: 1.25">&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal">66</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000" /></div>
</div>

<div style="text-align: justify; line-height: 1.25">In addition, changes in the law and legal decisions by courts in the United States
and foreign countries may affect our ability to obtain adequate protection for our technology and to enforce our intellectual property.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">Changes in U.S. patent law could diminish the
value of our future patents, if issued, thereby impairing our ability to protect our product candidates.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">As is the case with other pharmaceutical companies, our success is heavily dependent
on intellectual property, particularly patents. Obtaining and enforcing patents in the pharmaceutical industry involve both technological
and legal complexity. Therefore, obtaining and enforcing pharmaceutical patents is costly, time-consuming and inherently uncertain. In
addition, the United States has recently enacted wide-ranging patent reform legislation, which includes provisions that affect the way
patent applications are prosecuted, redefine prior art, may affect patent litigation, and switch the U.S. patent system from a &#8220;first
to invent&#8221; system to a &#8220;first inventor to file&#8221; system. It is not clear what, if any, impact such legislation will have
on the operation of our business. Additionally, the United States Supreme Court has ruled on several patent cases in recent years, either
narrowing the scope of patent protection available in certain circumstances or weakening the rights of patent owners in certain situations.
In addition to increasing uncertainty with regard to our ability to obtain patents in the future, this combination of events has created
uncertainty with respect to the value of patents, once obtained. Depending on decisions by the U.S. Congress, the federal courts, and
the USPTO, the laws and regulations governing patents could change in unpredictable ways that could increase the uncertainties and costs
surrounding the prosecution of our patent applications and the enforcement or defense of any U.S. patents that may issue to us in the
future, all of which could have a material adverse effect on our business and financial condition.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">Intellectual property litigation may lead to
unfavorable publicity that harms our reputation and causes the market price of our Ordinary Shares to decline.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">During the course of any intellectual property litigation, there could be public announcements
of the results of hearings, rulings on motions, and other interim proceedings. If securities analysts or investors regard these announcements
as negative, the perceived value of our product candidates or future products, services or intellectual property could be diminished and
the market price of our Ordinary Shares may decline as a result. Furthermore, such negative publicity could severely impair our capability
to enter into future agreements with key commercial collaborators.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25"><span style="font-weight: bold; font-style: italic">Obtaining and maintaining our
patent protection depends on compliance with various procedural, document submission, fee payment and other requirements imposed by government
patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements.</span>&#160;</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Periodic maintenance fees, renewal fees, annuity fees and various other government
fees on patents and/or applications will be due to be paid to the USPTO and various government patent agencies outside of the United States
over the lifetime of our owned patents and/or applications and any patent rights we may own or license in the future. The USPTO and various
non-U.S. government patent agencies require compliance with several procedural, documentary, fee payment and other similar provisions
during the patent application process. In many cases, an inadvertent lapse can be cured by payment of a late fee or by other means in
accordance with the applicable rules. There are situations, however, in which non-compliance can result in abandonment or lapse of the
patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. In such an event, potential
competitors might be able to enter the market and this circumstance could have a material adverse effect on our business.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">Under applicable employment laws, we may not
be able to enforce covenants not to compete and therefore may be unable to prevent our competitors from benefiting from the expertise
of some of our former employees. In addition, our Israeli employees may be entitled to seek compensation for their inventions irrespective
of their contractual agreements with us.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Our agreements with our employees and key consultants generally include non-competition
provisions. These provisions prohibit such employees and key consultants, if they cease working for us, from competing directly with us
or working for our competitors or clients for a limited period of time. We may be unable to enforce these provisions under the laws of
the jurisdictions in which our employees and consultants work and it may be difficult for us to restrict our competitors from benefitting
from the expertise our former employees or consultants developed while working for us. For example, Israeli courts have required employers
seeking to enforce non-compete undertakings of a former employee to demonstrate that the competitive activities of the former employee
will harm one of a limited number of material interests of the employer which have been recognized by the courts, such as the secrecy
of a company&#8217;s confidential commercial information or the protection of its intellectual property. If we cannot demonstrate that
such interests will be harmed, we may be unable to prevent our competitors from benefiting from the expertise of our former employees
or consultants and our ability to remain competitive may be diminished. In addition, a significant portion of our intellectual property
has been developed by our employees and consultants in the course of their employment or consulting relationship with us. Under the Israeli
Patent Law, 5727-1967, inventions conceived by an employee or consultant during the scope of his or her employment or consulting relationship
with a company are regarded as &#8220;service inventions.&#8221; Even when our agreements with our employees and consultants include provisions
regarding the assignment and waiver of rights to additional compensation in respect of inventions created within the course of their employment
or consulting relationship with us, including in respect of service inventions, we cannot guarantee that such provisions will be upheld
by Israeli courts, as a result of uncertainty under Israeli law with respect to the efficacy of such provisions. If we are required to
pay additional compensation or face disputes relating to service inventions, our results of operations could be adversely affected.</div>

<div style="line-height: 1.25">&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal">67</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000" /></div>
</div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">We may not be able to protect the confidentiality
of our technology, which, if disseminated, could negatively impact our plan of operations.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">In addition to seeking patent protection, we also rely on trade secret protection
and confidentiality agreements to protect proprietary know-how that may not be patentable, processes for which patents may be difficult
to obtain and/or enforce, and other elements of our technology. Any disclosure to or misappropriation by third parties of our confidential
proprietary information could enable competitors to quickly duplicate or surpass our technological achievements, which would harm our
competitive position. While we strive to maintain systems and procedures to protect the confidentiality of our trade secrets and technical
know-how, these systems and procedures may fail to provide an adequate degree of protection. For example, although we generally enter
into agreements with our employees, consultants, advisors, and other collaborators restricting the disclosure and use of trade secrets,
technical know-how and confidential information, we cannot provide any assurance that these agreements will be sufficient to prevent unauthorized
use or disclosure of our trade secrets and technical know-how, that these agreements will not be breached or that we have executed agreements
with all parties who may have had access to our proprietary information. We may not have adequate remedies in the case of a breach of
any such agreements, and our competitors or others may independently develop substantially equivalent or superior proprietary information
and techniques or otherwise gain access to our trade secrets or know-how. Monitoring and policing unauthorized use and disclosure of intellectual
property is difficult. Further, the laws of certain foreign countries do not protect proprietary rights to the same extent or in the same
manner as the laws of the United States. As a result, we may encounter significant problems in protecting and defending our intellectual
property both in the United States and abroad. If we are unable to prevent material disclosure of the intellectual property related to
our technologies to third parties, or if our competitors or other third parties independently develop any of our trade secrets, we will
not be able to establish or maintain a competitive advantage in our market, which could materially adversely affect our business, results
of operations and financial condition.</div>

<div style="line-height: 1.25"><br /> </div>

<div style="text-align: justify; line-height: 1.25">We currently have relationships with different consultants who perform research and
development activities for us and who are not employed by us, and we may enter into additional relationships of such nature in the future.
We have limited control over the activities of these consultants and can expect only limited amounts of their time to be dedicated to
our activities. These persons may have consulting, employment or advisory arrangements with other entities that may conflict with or compete
with their obligations to us. We typically require our consultants to sign agreements that require such consultants to treat our proprietary
information and results of studies as confidential. However, in connection with each such relationship, we may not be able to maintain
the confidentiality of our technology, the dissemination of which could hurt our competitive position and results of operations. To the
extent that our scientific consultants develop inventions or processes independently that may be applicable to our product candidates,
disputes may arise as to the ownership of the proprietary rights to such information, and we may expend significant resources in such
disputes and we may not win those disputes.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">We may be subject to claims by third parties
asserting that we or our employees, consultants or contractors have misappropriated their intellectual property, or claiming ownership
of what we regard as our own intellectual property.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Certain of our employees, consultants and contractors were previously employed at
other biotechnology or pharmaceutical companies, including our competitors or potential competitors. Although we try to ensure that our
employees, consultants and contractors do not use the proprietary information or know-how of others in their work for us, we may be subject
to claims that we or these employees, consultants or contractors have used or disclosed intellectual property, including trade secrets
or other proprietary information, of any such employee&#8217;s, consultant&#8217;s or contractor&#8217;s former employer. Litigation may
be necessary to defend against these claims and, even if we are successful in defending ourselves, could result in substantial costs to
us or be distracting to our management. If we do not succeed with respect to any such claims, in addition to paying monetary damages and
possible ongoing royalties, we may lose valuable intellectual property rights or personnel. Any of the foregoing could have a material
adverse effect on our competitive position, business, financial conditions, results of operations, and prospects.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">In addition, while we typically require our employees, consultants and contractors
who may be involved in the development of intellectual property to execute agreements assigning such intellectual property to us, we may
be unsuccessful in executing such an agreement with each party who in fact develops intellectual property that we regard as our own. Further,
such assignment agreements may not be self-executing, may be insufficient in scope or may be breached, and we may be forced to bring claims
against third parties, or defend claims they may bring against us, to determine the ownership of what we regard as our intellectual property.</div>

<div style="line-height: 1.25">&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal">68</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000" /></div>
</div>

<div style="text-align: justify; line-height: 1.25">If we fail in prosecuting or defending any such claims, in addition to paying monetary
damages, we may lose valuable intellectual property rights or personnel. Even if we are successful in prosecuting or defending against
such claims, litigation could result in substantial costs and be a distraction to management.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">If trademarks and trade names related to our
product candidates are not adequately protected, then we may not be able to build name recognition in our markets of interest and our
business may be adversely affected.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">We do not currently own or use any registered trademarks for our product candidates.
In the future, our registered or unregistered trademarks or trade names may be challenged, infringed, circumvented or declared generic
or determined to be infringing on other marks. We may not be able to protect our rights to these trademarks and trade names, which we
need to build name recognition by potential collaborators or customers in our markets of interest. Any unauthorized use of these trademarks
could harm our reputation or commercial interests. In addition, our enforcement against third-party infringers or violators may be unduly
expensive and time-consuming, and the outcome may be an inadequate remedy. Over the long term, if we are unable to establish name recognition
based on our trademarks and trade names, then we may not be able to compete effectively and our business may be adversely affected.</div>

<div style="line-height: 1.25"><br /> </div>

<div style="text-align: justify; line-height: 1.25; font-weight: bold">Risks Related to Our Ordinary Shares and IPO Warrants</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">The price of our Ordinary Shares and IPO Warrants
may be volatile, and holders of our Ordinary Shares and IPO Warrants could lose all or part of their investment.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">The price of securities for publicly traded emerging biopharmaceutical and drug discovery
and development companies has been highly volatile and is likely to remain highly volatile in the future. The market price of our Ordinary
Shares and IPO Warrants on Nasdaq may fluctuate as a result of a number of factors, some of which are beyond our control, including, but
not limited to:</div>

<div style="line-height: 1.25"><br /> </div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 36pt"><br /> </td>
    <td style="width: 36pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>our clinical trial results and the timing of the release of such results;</div> </td> </tr>
  </table>

<div> <br /> </div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 36pt"><br /> </td>
    <td style="width: 36pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>the amount of our cash resources and our ability to obtain additional funding;</div> </td> </tr>
  </table>

<div> <br /> </div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 36pt"><br /> </td>
    <td style="width: 36pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>the announcement of research activities, business developments, technological innovations or new products, or acquisitions or expansion
        plans by us or our competitors;</div>
        <div> <br /> </div> </td> </tr>
  </table>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 36pt"><br /> </td>
    <td style="width: 36pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>the success or failure of our research and development projects or those of our competitors;</div>
        <div> <br /> </div> </td> </tr>
  </table>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 36pt"><br /> </td>
    <td style="width: 36pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>our entering into or terminating strategic relationships;<br /> <br /> </div> </td> </tr>
  </table>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 36pt"><br /> </td>
    <td style="width: 36pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>changes in laws or government regulation;</div>
        <div> <br /> </div> </td> </tr>
  </table>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 36pt"><br /> </td>
    <td style="width: 36pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>actual or anticipated fluctuations in our and our competitors&#8217; results of operations and financial condition;</div>
        <div> <br /> </div> </td> </tr>
  </table>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 36pt"><br /> </td>
    <td style="width: 36pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>regulatory developments and the decisions of regulatory authorities as to the approval or rejection of new or modified products and
        plans for clinical development;</div>
        <div> <br /> </div> </td> </tr>
  </table>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 36pt"><br /> </td>
    <td style="width: 36pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>the departure of our key personnel;</div>
        <div> <br /> </div> </td> </tr>
  </table>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 36pt"><br /> </td>
    <td style="width: 36pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>disputes related to intellectual property and proprietary rights, including patents, litigation matters and our ability to obtain
        intellectual property protection for our technologies;</div>
        <div> <br /> </div> </td> </tr>
  </table>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 36pt"><br /> </td>
    <td style="width: 36pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>our sale, or the sale by our significant shareholders, of Ordinary Shares, IPO Warrants or other securities in the future;</div>
        <div> <br /> </div> </td> </tr>
  </table>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 36pt"><br /> </td>
    <td style="width: 36pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>public concern regarding the safety, efficacy or other aspects of the products or methodologies we are developing;</div>
        <div> <br /> </div> </td> </tr>
  </table>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 36pt"><br /> </td>
    <td style="width: 36pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>market conditions in our industry and changes in estimates of the future size and growth rate of our markets;</div>
        <div> <br /> </div> </td> </tr>
  </table>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 36pt"><br /> </td>
    <td style="width: 36pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>market acceptance of our products;</div>
        <div> <br /> </div> </td> </tr>
  </table>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 36pt"><br /> </td>
    <td style="width: 36pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>the mix of products that we sell and related services that we provide;</div>
        <div> <br /> </div> </td> </tr>
  </table>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 36pt"><br /> </td>
    <td style="width: 36pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>the success or failure of our licensees to develop, obtain approval for and commercialize our licensed products, for which we are
        entitled to contingent payments and royalties;</div>
        <div> <br /> </div> </td> </tr>
  </table>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 36pt"><br /> </td>
    <td style="width: 36pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>the publication of the results of preclinical or clinical trials for EB613, EB612 or any other product candidates we may develop,
        including a new Oral GLP-2 analog research program;</div>
        <div> <br /> </div> </td> </tr>
  </table>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 36pt"><br /> </td>
    <td style="width: 36pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>the failure by us to achieve a publicly announced milestone;</div>
        <div> <br /> </div> </td> </tr>
  </table>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 36pt"><br /> </td>
    <td style="width: 36pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>delays between our expenditures to develop and market new or enhanced products and the generation of sales from those products;</div>
        <div> <br /> </div> </td> </tr>
  </table>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 36pt"><br /> </td>
    <td style="width: 36pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>changes in the amounts that we spend to develop, acquire or license new products, technologies or businesses;</div>
        <div> <br /> </div> </td> </tr>
  </table>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 36pt"><br /> </td>
    <td style="width: 36pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>changes in our expenditures to promote our products;</div> </td> </tr>
  </table>

<div> <br /> </div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal">69</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000" /></div>
</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 36pt"><br /> </td>
    <td style="width: 36pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>variances in our financial performance from the expectations of market analysts;</div>
        <div> <br /> </div> </td> </tr>
  </table>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 36pt"><br /> </td>
    <td style="width: 36pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>the limited trading volume of our Ordinary Shares and IPO Warrants; and</div>
        <div> <br /> </div> </td> </tr>
  </table>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 36pt"><br /> </td>
    <td style="width: 36pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>general economic and market conditions, including factors unrelated to our industry or operating performance, such as geopolitical
        tensions.</div> </td> </tr>
  </table>

<div style="text-align: justify; margin-left: 72pt; line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">In addition, the stock market in general has recently experienced extreme price and
volume fluctuations that have often been unrelated or disproportionate to the operating performance of individual companies. Broad market
and industry factors may materially affect the market price of companies&#8217; stock, including ours, regardless of actual operating
performance.</div>

<div style="line-height: 1.25"><br /> </div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">We do not know whether a market for our Ordinary
Shares or IPO Warrants will be sustained and as a result, it may be difficult for holders of our Ordinary Shares or IPO Warrants to sell
their securities.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Although our Ordinary Shares and IPO Warrants are listed on Nasdaq, an active trading
market for our Ordinary Shares and IPO Warrants may not be sustained. The lack of an active market may impair the ability of holders of
our Ordinary Shares or IPO Warrants to sell their Ordinary Shares or IPO Warrants at the time they wish to sell them or at a price that
they consider reasonable. The lack of an active market may also reduce the value of our Ordinary Shares or IPO Warrants, and may cause
the trading price of our Ordinary Shares or IPO Warrants to be more volatile. An inactive market may also impair our ability to raise
capital by selling Ordinary Shares and may impair our ability to acquire other companies by using our Ordinary Shares or IPO Warrants
as consideration<span style="font-weight: bold">.</span></div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">Our stock price may continue to be volatile,
and securities class action litigation has often been instituted against companies following periods of volatility of their stock price.
Any such litigation, if instituted against us, could result in substantial costs and a diversion of our management&#8217;s attention and
resources.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">In the past, following periods of volatility in the overall market and the market
price of a particular company&#8217;s securities, securities class action litigation has often been instituted against these companies.
Although there is no such shareholder litigation currently pending or threatened against the Company, such litigation, if instituted against
us, could result in substantial costs and a diversion of our management&#8217;s attention and resources.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25"><span style="font-weight: bold; font-style: italic">The IPO Warrants are speculative
in nature and are a risky investment. You may not be able to recover your investment in the IPO Warrants, and the IPO Warrants may expire
worthless.</span>&#160;</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">The value of the IPO Warrants will depend on the value of our Ordinary Shares, which
will depend on factors related and unrelated to the success of our clinical development program or other factors as detailed above and
cannot be predicted at this time.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">If the price per share of our Ordinary Shares does not increase to an amount sufficiently
above the applicable exercise price of the IPO Warrants during the period the IPO Warrants are exercisable, and if a public market for
our IPO Warrants does not develop, the IPO Warrants may not have any value, and you may be unable to recover any or all of your investment
in the IPO Warrants. There can be no assurance that the market price of the Ordinary Shares will ever equal or exceed the exercise price
of the IPO Warrants, and consequently, whether it will ever be profitable for holders of the IPO Warrants to exercise the IPO Warrants.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">Holders of the IPO Warrants will have no rights
as shareholders until they acquire our Ordinary Shares.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Until a holder of an IPO Warrant acquires our Ordinary Shares upon exercise of the
IPO Warrants, the holder will have no rights with respect to our Ordinary Shares issuable upon exercise of the IPO Warrants, except as
set forth in the IPO Warrants. Upon exercise of your IPO Warrants, the holder will be entitled to exercise the rights of a shareholder
only as to matters for which the record date occurs on or after the exercise date, unless the IPO Warrants are settled via &#8220;cashless
exercise&#8221; in which case you will be entitled to exercise such rights only after the end of the relevant calculation period as defined
in our Registration Statement on Form F-1 (File No. 333-221472) filed with the SEC on June 27, 2018, under &#8220;Description of IPO Warrants&#8201;-&#8201;Exercisability,
Exercise Price and Term.&#8221;</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">Future sales by our shareholders may adversely
affect our stock price and our ability to raise funds in new stock offerings.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Sales of our Ordinary Shares or IPO Warrants in the public market could lower the
market price of our Ordinary Shares or IPO Warrants. Sales may also make it more difficult for us to sell equity securities or equity-related
securities in the future at a time and price that our management deems acceptable or at all. Most of our outstanding Ordinary Shares and
IPO Warrants are not restricted from resale. In the event of a sale of Ordinary Shares or IPO Warrants offered by selling shareholders,
the price of our Ordinary Shares or IPO Warrants could decline, and such decline could be material.</div>

<div style="line-height: 1.25">&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal">70</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000" /></div>
</div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">The market price of our Ordinary Shares and
IPO Warrants could be negatively affected by future sales of our securities.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">If our shareholders, particularly our directors or our executive officers and their
affiliates,&#160; sell substantial amounts of our Ordinary Shares or IPO Warrants in the public market, or if there is a public perception
that these sales may occur in the future, the market price of our Ordinary Shares or IPO Warrants may decline. The perception in the public
market that our shareholders might sell our Ordinary Shares or IPO Warrants could also depress the market price of our Ordinary Shares
or IPO Warrants and could impair our future ability to obtain capital, especially through an offering of equity securities. In addition,
our sale of additional Ordinary Shares or other similar securities in order to raise capital might have a similar negative impact on the
share price of our Ordinary Shares or IPO Warrants. A decline in the price of our Ordinary Shares may impede our ability to raise capital
through the issuance of additional Ordinary Shares, IPO Warrants or other equity securities, and may cause holders of our Ordinary Shares
or IPO Warrants to lose part or all of their investment.</div>

<div style="line-height: 1.25"><br /> </div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">We have never paid, and we currently do not
intend to pay dividends.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">We have never declared or paid any cash dividends on our Ordinary Shares. We currently
intend to retain any future earnings to finance operations and to expand our business and, therefore, do not expect to pay any cash dividends
in the foreseeable future. As a result, capital appreciation, if any, of our Ordinary Shares will be investors&#8217; sole source of gain
for the foreseeable future. In addition, Israeli law may limit our declaration or payment of dividends, and may subject our dividends
to Israeli withholding taxes.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">We may not have sufficient insurance to cover
our liability in any current or future litigation claims either due to coverage limits or as a result of insurance carriers seeking to
deny coverage of such claims.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">We may face a variety of litigation-related liability risks. Our amended Articles
of Association, or Articles, other applicable agreements and/or Israeli law may require us to indemnify (and advance expenses to) our
current and past directors and officers and employees from reasonable expenses related to the defense of any action arising from their
service to us, including circumstances under which indemnification is otherwise discretionary. While our directors and officers are included
in a director and officer liability insurance policy, which covers all our directors and officers in some circumstances, our insurance
coverage does not cover all of our indemnification obligations and may not be adequate to cover any indemnification or other claims against
us. In addition, the underwriters of our present coverage may seek to avoid coverage in certain circumstances based upon the terms of
the respective policies. If we incur liabilities that exceed our coverage under our directors and officers insurance policy or incur liabilities
not covered by our insurance, we would have to self-fund any indemnification amounts owed to our directors and officers and employees
in which case our results of operations and financial condition could be materially adversely affected. Further, if D&amp;O insurance
becomes prohibitively expensive to maintain in the future, we may be unable to renew such insurance on economic terms or unable renew
such insurance at all. The lack of D&amp;O insurance may make it difficult for us to retain and attract talented and skilled directors
and officers to serve our company, which could adversely affect our business.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">There is a risk that we may be a passive foreign
investment company, for U.S. federal income tax purposes for any taxable year, which generally would result in certain adverse U.S. federal
income tax consequences to our U.S. investors.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">There is a risk that we may be treated as a passive foreign investment company, or
PFIC, for any taxable year. The application of the PFIC rules to a company like us is subject to uncertainties, and for the reasons described
below, we cannot express a view as to whether we will be a PFIC for the current or any future taxable year. In general, a non-U.S. corporation
is a PFIC for any taxable year in which (i) 75% or more of its gross income consists of passive income, or the income test, or (ii) 50%
or more of the average value of its assets consists of assets (generally determined on a quarterly basis) that produce, or are held for
the production of, passive income, or the assets test. Generally, passive income includes interest, dividends, rents, royalties and certain
gains, and cash is generally treated as a passive asset that produces passive income for PFIC purposes. The assets shown on our balance
sheet consist, and are expected to continue to consist, primarily of cash and cash equivalents for the foreseeable future. Therefore,
whether we will satisfy the assets test for the current or any future taxable year will depend largely on the quarterly value of our goodwill
and on how quickly we utilize our cash in our business. Because (i) the value of our goodwill may be determined by reference to the market
price of our Ordinary Shares, which has been, and may continue to be volatile given the nature and early stage of our business, (ii) we
hold, and expect to continue to hold, a significant amount of cash, and (iii) a company&#8217;s annual PFIC status can be determined only
after the end of each taxable year, we cannot express a view as to whether we will be a PFIC for the current or any future taxable year.
In addition, it is not clear how to apply the income test to a company like us, which is still developing its key intangible assets and
whose overall losses from research activities significantly exceed the amount of its income (including passive income). If our losses
from research and development activities are disregarded for purposes of the income test, we may be a PFIC for any taxable year if 75%
or more of our gross income (as determined for U.S. federal income tax purposes) for the relevant year is from interest and financial
investments. Because the revenue shown on our financial statements is not calculated based on U.S. tax principles, and because for any
taxable year we may not have sufficient (or any) non-passive revenue, there is a risk that we may be or become a PFIC under the income
test for any taxable year. If we were a PFIC for any taxable year during which a U.S. investor owned our Ordinary Shares (or under proposed
Treasury regulations, IPO Warrants), such U.S. shareholder generally will be subject to certain adverse U.S. federal income tax consequences,
including increased tax liability on gains from dispositions of the Ordinary Shares (or IPO Warrants) and certain distributions and a
requirement to file annual reports with the Internal Revenue Service. U.S. investors should consult with their tax advisers regarding
the application of the PFIC rules as they may relate to an investment in our company.</div>

<div style="line-height: 1.25">&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal">71</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000" /></div>
</div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">We are an emerging growth company and a smaller
reporting company, and our compliance with the reduced reporting and disclosure requirements applicable to emerging growth companies and
smaller reporting companies could make our Ordinary Shares less attractive to investors and may make it more difficult to raise capital
as and when we need it.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">We are an emerging growth company, as defined in the Jumpstart our Business Startups
Act of 2012, referred to as the JOBS Act, and we expect to take advantage of certain exemptions from various reporting requirements that
are applicable to other public companies that are not emerging growth companies, including the auditor attestation requirements of Section
404, reduced disclosure obligations regarding executive compensation in our periodic reports and proxy statements, exemptions from the
requirements of holding a nonbinding advisory vote on executive compensation and shareholder approval of any golden parachute payments
not previously approved and extended adoption period for accounting pronouncements.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Even after we no longer qualify as an emerging growth company, we may still qualify
as a &#8220;smaller reporting company,&#8221; which would allow us to continue to take advantage of many of the same exemptions from disclosure
requirements, including not being required to comply with the auditor attestation requirements of Section 404 of the Sarbanes-Oxley Act
and reduced disclosure obligations regarding executive compensation in this prospectus and our periodic reports and proxy statements.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">We cannot predict whether investors will find our Ordinary Shares less attractive
as a result of our reliance on these exemptions. If some investors find our ordinary shares less attractive as a result, there may be
a less active trading market for our ordinary shares and our stock price may be more volatile.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Additionally, because of the exemptions from various reporting requirements provided
to us as an emerging growth company, we may be less attractive to investors and it may be difficult for us to raise additional capital
as and when we need it. Investors may be unable to compare our business with other companies in our industry if they believe that our
reporting is not as transparent as the reporting of other companies in our industry. If we are unable to raise additional capital as and
when we need it, our financial condition and results of operations may be materially and adversely affected.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">Our Ordinary Shares may be delisted from the
Nasdaq Capital Market if we are unable to maintain compliance with Nasdaq&#8217;s continued listing standards.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Nasdaq imposes, among other requirements, continued listing standards, including a
minimum bid requirement. The price of our Ordinary Shares must trade at or above $1.00 to comply with the minimum bid requirement for
continued listing on the Nasdaq Capital Market. On November 21, 2022, the Company received a notice (the &#8220;Notice&#8221;) from the
Nasdaq Stock Market LLC (&#8220;Nasdaq&#8221;), stating that the Company&#8217;s Ordinary Shares fail to comply with the $1.00 minimum
bid price requirement for continued listing on Nasdaq in accordance with Nasdaq Listing Rule 5550(a)(2) based upon the closing bid price
of the ordinary shares for the 30 consecutive business days prior to the date of the Notice. Pursuant to Nasdaq Listing Rule 5810(c)(3)(A),
the Company was provided an initial compliance period of 180 calendar days, or until May 22, 2023, to regain compliance with the minimum
bid price requirement.</div>

<div style="line-height: 1.25"><br /> </div>

<div style="text-align: justify; line-height: 1.25">On March 23, 2023, Nasdaq notified us that we had regained compliance with the minimum
bid price requirement given that the closing bid price for our Ordinary Shares had been at or above $1.00 for 14 consecutive trading days,
from March 3<sup style="vertical-align: text-top; line-height: 1; font-size: smaller">rd</sup> through March 22, 2023.</div>

<div style="line-height: 1.25"><br /> </div>

<div style="text-align: justify; line-height: 1.25">There can be no assurance that we will maintain compliance with the $1.00 minimum
bid price&#160;requirement or comply with Nasdaq&#8217;s other continued listing standards in the future.</div>

<div style="line-height: 1.25"><br /> </div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal">72</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000" /></div>
</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">If we fail to maintain an effective system
of internal control over financial reporting, we may not be able to accurately report our financial results or prevent fraud. As a result,
shareholders could lose confidence in our financial and other public reporting, which would harm our business and the trading price of
our Ordinary Shares.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Effective internal controls over financial reporting are necessary for us to provide
reliable financial reports and, together with adequate disclosure controls and procedures, are designed to prevent fraud among other objectives.
Any failure to implement required new or improved controls, or difficulties encountered in their implementation could cause us to fail
to meet our reporting obligations. In addition, any testing by us conducted in connection with Section 404 of the Sarbanes-Oxley Act of
2002, or any subsequent testing by our independent registered public accounting firm, may reveal deficiencies in our internal controls
over financial reporting that are deemed to be material weaknesses or that may require prospective or retroactive changes to our financial
statements or identify other areas for further attention or improvement. Inferior internal controls could also subject us to regulatory
scrutiny and sanctions, impair our ability to raise revenue and cause investors to lose confidence in our reported financial information,
which could have a negative effect on the trading price of our Ordinary Shares.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">We are required to disclose changes made in our internal controls and procedures and
our management is required to assess the effectiveness of these controls annually. However, for as long as we are an &#8220;emerging growth
company&#8221; under the JOBS Act, our independent registered public accounting firm will not be required to attest to the effectiveness
of our internal controls over financial reporting pursuant to Section 404. An independent assessment of the effectiveness of our internal
controls could detect problems that our management&#8217;s assessment might not. Undetected material weaknesses in our internal controls
could lead to financial statement restatements and require us to incur the expense of remediation.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">If securities or industry analysts do not publish
research or reports or publish unfavorable research about our business, our share price and trading volume could decline.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">The trading market for our Ordinary Shares depends in part on the research and reports
that securities or industry analysts publish about us or our business. We do not have control over these analysts and we do not have commitments
from them to write research reports about us. If securities or industry analysts do not commence coverage of our company, the trading
price for our shares may be negatively affected. In the event we obtain securities or industry analyst coverage, if one or more of the
analysts who covers us downgrades our shares, our shares price would likely decline. If one or more of these analysts ceases to cover
us or fails to publish regular reports on us, interest in the purchase of our shares could decrease, which could cause our share price
or trading volume to decline.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-weight: bold">Risks Relating to Our Incorporation and Location in Israel</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">The Israeli government grants we have received
for research and development expenditures restrict our ability to manufacture products and transfer technologies outside of Israel and
require us to satisfy specified conditions. If we fail to satisfy these conditions, we may be required to refund grants previously received
together with interest and penalties or to pay other amounts according to the formulas set out in the relevant laws.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Our research and development efforts have been financed, in part, through the grants
that we have received from the Israeli Innovation Authority (formerly known as the Office of Chief Scientist of the Israeli Ministry of
Economy), or the IIA. Pursuant to these grants, we must comply with the requirements of the Encouragement of Industrial Research, Development
and Technological Innovation in Industry Law 5744-1984 and the IIA regulations, or the Research Law. Until the grants are repaid with
interest, royalties are payable to the IIA in the amount of 3% on revenues derived from sales of products or services developed in whole
or in part using the IIA grants, including EB612, EB613 and any other oral PTH product candidates we may develop. The royalty rate may
increase to 5%, with respect to approved applications filed following any year in which we achieve sales of over $70 million.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Under the Research Law, we are prohibited from manufacturing products developed using
these grants outside of the State of Israel without special approvals. We may not receive the required approvals for any proposed transfer
of manufacturing activities. Even if we do receive approval to manufacture products developed with government grants outside of Israel,
the royalty rate may be increased and we may be required to pay up to three times the grant amounts and the interest, depending on the
manufacturing volume that is performed outside of Israel. This restriction may impair our ability to outsource manufacturing or engage
in our own manufacturing operations for those products or technologies. For additional information, see &#8220;Item 1-Business-The Israeli
Innovation Authority (IIA) Grant.&#8221;</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Additionally, under the Research Law, we are prohibited from transferring in any manner
(including by way of license), the IIA-financed technologies and related rights (including know-how and other intellectual property rights)
in or outside of the State of Israel, except under limited circumstances and only with the approval of the IIA. We may not receive the
required approvals for any proposed transfer and, even if received, we may be required to pay the IIA a portion of the consideration that
we receive upon any transfer of such technology to a non-Israeli entity up to 600% of the grant amounts and the interest. The scope of
the IIA support received, the royalties that we have already paid to the IIA, the amount of time that has elapsed between the date on
which the know-how or other intellectual property rights were transferred and the date on which the IIA grants were received and the sale
price and the form of transaction will be taken into account in order to calculate the amount of the payment to the IIA. Approval to transfer
the technology to residents of the State of Israel is also required, and may be granted in specific circumstances only if the recipient
abides by the provisions of applicable laws, including the restrictions on the transfer of know-how and the obligation to pay royalties.
No assurance can be made that approval to any such transfer, if requested, will be granted. Transfer of know-how or rights outside of
the state of Israel without IIA approval is a criminal offense.</div>

<div style="line-height: 1.25">&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal">73</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000" /></div>
</div>

<div style="text-align: justify; line-height: 1.25">These restrictions may impair our ability to sell our technology assets or to perform
or outsource manufacturing outside of Israel, engage in change of control transactions or otherwise transfer our know-how outside of Israel
and may require us to obtain the approval of the IIA for certain actions and transactions and pay additional royalties and other amounts
to the IIA. In addition, any change of control and any change of ownership of our Ordinary Shares that would make a non-Israeli citizen
or resident an interested party, as defined in the Israeli Securities Law, 5728-1968, as amended, requires written notice to the IIA,
and our failure to comply with this requirement could result in monetary fines. Such non-Israeli interested parties, which include 5%
shareholders and shareholders who have the right to appoint a director to our board of directors, are required to sign an undertaking
towards the IIA in which they would undertake to comply with the Research Law. Shareholders that purchased Ordinary Shares in our IPO
would not be required to sign such an undertaking.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">These restrictions will continue to apply even after we have repaid the full amount
of the grants and the interest. If we fail to satisfy the conditions of the Research Law, we may be required to refund grants previously
received together with interest and penalties, to make other payments to the IIA or become subject to criminal charges.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25"><span style="font-weight: bold; font-style: italic">Legislative developments in Israel
may have an adverse effect on the Company&#8217;s business.</span><sup style="vertical-align: text-top; line-height: 1; font-size: smaller">&#160;</sup>&#160;</div>

<div style="line-height: 1.25"><br /> </div>

<div style="text-align: justify; line-height: 1.25">The Israeli government is currently pursuing extensive changes to Israel&#8217;s judicial
system. In response to the foregoing developments, certain leading international financial institutions, including investment banks, investors
and key economists, have indicated several causes for concern, including that such proposed changes, if adopted, may cause a downgrade
to Israel&#8217;s sovereign credit rating and Israel&#8217;s international standing, which would adversely affect the macroeconomic condition
in which we operate, and also potentially deter foreign investment into Israel or Israeli companies, which may hinder our ability to raise
additional funds, if deemed necessary by our management and board of directors.</div>

<div style="line-height: 1.25"><br /> </div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">Security, political and economic instability
in the Middle East may harm our business.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Our principal research and development facilities are located in Israel. In addition,
part of our key employees, officers and directors are residents of Israel. Accordingly, political, economic and military conditions in
the Middle East may affect our business directly. Since the establishment of the State of Israel in 1948, a number of armed conflicts
have occurred between Israel and its neighboring countries, Hamas (an Islamist militia and political group in the Gaza Strip) and Hezbollah
(an Islamist militia and political group in Lebanon). Recent political uprisings, social unrest and violence in various countries in the
Middle East, including Israel&#8217;s neighbor Syria, are affecting the political stability of those countries. This instability may lead
to deterioration of the political relationships that exist between Israel and certain countries and have raised concerns regarding security
in the region and the potential for armed conflict. In addition, Iran has threatened to attack Israel. Iran is also believed to have a
strong influence among the Syrian government, Hamas and Hezbollah. These situations may potentially escalate in the future into more violent
events which may affect Israel and us. These situations, including conflicts which involved missile strikes against civilian targets in
various parts of Israel have in the past negatively affected business conditions in Israel.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Any hostilities involving Israel or the interruption or curtailment of trade between
Israel and its present trading partners could have a material adverse effect on our business. Although such hostilities did not have a
material adverse impact on our business in the past, we cannot guarantee that hostilities will not be renewed and have such an effect
in the future. The political and security situation in Israel may result in parties with whom we have contracts claiming that they are
not obligated to perform their commitments under those agreements pursuant to force majeure provisions. These or other Israeli political
or economic factors could harm our operations and product development. Any hostilities involving Israel or the interruption or curtailment
of trade between Israel and its present trading partners could adversely affect our operations and could make it more difficult for us
to raise capital. We could experience disruptions if acts associated with this conflict result in any serious damage to our facilities.
Furthermore, several countries, as well as certain companies and organizations, continue to restrict business with Israel and Israeli
companies, which could have an adverse effect on our business and financial condition in the future. Our business interruption insurance
may not adequately compensate us for losses, if at all, that may occur as a result of an event associated with a security situation in
the Middle East, and any losses or damages incurred by us could have a material adverse effect on our business.</div>

<div style="line-height: 1.25"><br /> </div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal">74</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000" /></div>
</div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">Our operations may be disrupted by the obligations
of personnel to perform military service.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Our employees in Israel, including executive officers, generally, may be called upon
to perform up to 42 days (and in some cases more) of annual military reserve duty until they generally reach the age of 45 (or older in
some cases) and, in emergency circumstances, could be called to active duty. In response to increased tension and hostilities, since September
2000 there have been occasional call-ups of military reservists, including in connection with the mid-2006 war in Lebanon and the December
2008, November 2012 and July 2014 conflicts with Hamas, and it is possible that there will be additional call-ups in the future. Our operations
could be disrupted by the absence of a significant number of our employees related to military service or the absence for extended periods
of one or more of our key employees for military service. Such disruption could materially adversely affect our operations, business and
results of operations.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">Our business is subject to currency exchange
risk and fluctuations between the U.S. dollar and other currencies may negatively affect our earnings and results of operations.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">The U.S. dollar is both our functional and reporting currency. As a result, our results
of operations may be adversely affected by exchange rate fluctuations between the U.S. dollar and the NIS. A significant portion of the
expenses associated with our Israeli operations, including personnel and facilities related expenses, are incurred in NIS. Consequently,
inflation in Israel will have the effect of increasing the cost of our operations in Israel unless it is offset on a timely basis by a
devaluation of the NIS relative to the U.S. dollar. In addition, if the value of the U.S. dollar decreases against the NIS, our earnings
may be negatively impacted. Moreover, exchange rate fluctuations in currency exchange rates in countries other than Israel where we operate,
perform our clinical trials or conduct business may also negatively affect our earnings and results of operations. We cannot predict any
future trends in the rate of inflation or deflation in Israel or the rate of devaluation or appreciation of the NIS against the U.S. dollar.
If the dollar cost of our operations in Israel increases, our dollar-measured results of operations will be adversely affected. For example,
in 2021, the value of the NIS appreciated against the U.S. dollar by 3.27%, which appreciation was partially offset by inflation in Israel
of 02.8%. In 2020, the value of the NIS appreciated against the U.S. dollar by 6.97%, the effect of which was partially offset by inflation
in Israel at a rate of approximately 0.7%. As a result of these fluctuations, our NIS denominated expenses were affected.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Potential future revenue may be derived from abroad, including outside of the United
States. As a result, our business and share price may be affected by fluctuations in foreign exchange rates with these other currencies,
which may also have a significant impact on our reported results of operations and cash flows from period to period. Currently, we do
not have any exchange rate hedging arrangements in place. Foreign currency fluctuations could materially adversely affect our results
of operations or could positively affect our results of operations in ways that may not necessarily be repeated in future periods.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">It may be difficult to enforce a U.S. judgment
against us or our officers and directors, to assert U.S. securities laws claims in Israel or to serve process on our officers and directors.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">We are incorporated under the laws of the State of Israel. Service of process upon
us, our directors and officers and the Israeli experts, if any, a significant number of whom reside outside the United States, may be
difficult to obtain within the United States. Furthermore, because the majority of our assets and investments, and several of our directors,
officers and such Israeli experts, if any, are located outside the United States, any judgment obtained in the United States against us
or any of them may be difficult to collect within the United States. In addition, such judgment may not be enforced by an Israeli court.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">In addition, it may also be difficult for an investor to effect service of process
on these persons in the U.S. or to assert U.S. securities law claims in original actions instituted in Israel. Israeli courts may refuse
to hear a claim based on an alleged violation of U.S. securities laws reasoning that Israel is not the most appropriate forum to bring
such a claim. In addition, even if an Israeli court agrees to hear a claim, it may determine that Israeli law and not U.S. law is applicable
to the claim. If U.S. law is found to be applicable, the content of applicable U.S. law must be proved as a fact, which can be a time-consuming
and costly process. Certain matters of procedure will also be governed by Israeli law. There is little binding case law in Israel addressing
the matters described above. See the section in our Registration Statement on Form F-1 filed under the Securities Act with the SEC on
June 27, 2018, entitled &#8220;Enforceability of Civil Liabilities.&#8221; As a result of the difficulty associated with enforcing a judgment
against us in Israel, holders of our Ordinary Shares may not be able to collect any damages awarded by either a U.S. or foreign court.</div>

<div style="line-height: 1.25"><br /> </div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal">75</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000" /></div>
</div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">Provisions of Israeli law and our Articles
may give rise to withholding obligations or delay, prevent or make difficult a change of control and therefore depress the price of our
shares.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Israeli corporate law regulates mergers, requires tender offers for acquisitions of
shares above specified thresholds, requires special approvals for transactions involving directors, officers or significant shareholders
and regulates other matters that may be relevant to these types of transactions. For example, under Israel&#8217;s Companies Law, 5759-1999,
as currently amended or the Companies Law, upon the request of a creditor of either party to a proposed merger, the court may delay or
prevent the merger if it concludes that there exists a reasonable concern that as a result of the merger the surviving company will be
unable to satisfy the obligations of any of the parties to the merger. Additionally, a tender offer for all of a company&#8217;s issued
and outstanding shares can only be completed if the acquirer receives positive responses from the holders of at least 95% of the issued
share capital. Completion of the tender offer also requires approval of a majority of the offerees that do not have a personal interest
in the tender offer unless, following consummation of the tender offer, the acquirer would hold more than 98% of the company&#8217;s outstanding
shares. Furthermore, the shareholders, including those who indicated their acceptance of the tender offer, may, at any time within six
months following the completion of the tender offer, petition an Israeli court to alter the consideration for the acquisition, unless
the acquirer stipulated in its tender offer that a shareholder that accepts the offer may not seek such appraisal rights.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Furthermore, Israeli tax considerations may make potential transactions unappealing
to us or to our shareholders whose country of residence does not have a tax treaty with Israel exempting such shareholders from Israeli
tax. For example, Israeli tax law does not recognize tax-free share exchanges to the same extent as U.S. tax law. With respect to mergers,
Israeli tax law allows for tax deferral in certain circumstances that makes the deferral contingent on the fulfillment of numerous conditions,
including a holding period of two years from the date of the transaction during which sales and dispositions of shares of the participating
companies are, subject to certain exceptions, restricted. Moreover, with respect to certain share swap transactions, the tax deferral
is limited in time, and when the time expires, tax then becomes payable even if no actual disposition of the shares has occurred.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Our Articles provide that our directors are elected on a staggered basis such that
a potential acquirer cannot readily replace our entire board of directors at a single general shareholders meeting.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">These provisions could cause our Ordinary Shares to trade at prices below the price
for which third parties might be willing to pay to gain control of us. Third parties who are otherwise willing to pay a premium over prevailing
market prices to gain control of us may be unable or unwilling to do so because of these provisions of Israeli law and our amended Articles.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">Your rights and responsibilities as a shareholder
are governed by Israeli law, which may differ in some respects from the rights and responsibilities of shareholders of U.S. companies.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">We are incorporated under Israeli law. The rights and responsibilities of the holders
of our Ordinary Shares are governed by our Articles and Israeli law. These rights and responsibilities differ in some respects from the
rights and responsibilities of shareholders in typical U.S.-based corporations. In particular, a shareholder of an Israeli company has
a duty to act in good faith and in a customary manner in exercising its rights and performing its obligations towards the company and
other shareholders and to refrain from abusing its power in the company, including, among other things, in voting at the general meeting
of shareholders on matters such as amendments to a company&#8217;s articles of association, increases in a company&#8217;s authorized
share capital, mergers and acquisitions and interested party transactions requiring shareholder approval. In addition, a shareholder who
knows that it possesses the power to determine the outcome of a shareholder vote or to appoint or prevent the appointment of a director
or executive officer in the company has a duty of fairness toward the company with regard to such vote or appointment. There is limited
case law available to assist us in understanding the implications of these provisions that govern shareholders&#8217; actions, and these
provisions may be interpreted to impose additional obligations and liabilities on holders of our Ordinary Shares that are not typically
imposed on shareholders of U.S. corporations.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">Our business could be negatively affected as
a result of actions of activist shareholders, and such activism could impact the trading value of our securities.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">In recent years, certain Israeli issuers listed on United States exchanges have been
faced with governance-related demands from activist shareholders, unsolicited tender offers and proxy contests. Responding to these types
of actions by activist shareholders could be costly and time-consuming, disrupting our operations and diverting the attention of management
and our employees. Such activities could interfere with our ability to execute our strategic plan. In addition, a proxy contest for the
election of directors at our annual meeting would require us to incur significant legal fees and proxy solicitation expenses and require
significant time and attention by management and our board of directors. The perceived uncertainties as to our future direction also could
affect the market price and volatility of our securities.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="line-height: 1.25">

<table cellspacing="0" cellpadding="0" border="0" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 6%; vertical-align: top">
        <div style="line-height: 1.25; font-weight: bold">
        <div style="line-height: 1.25"><span style="font-weight: bold">ITEM 1B<span id="ITEM1B"><!--Anchor--></span>.</span> <br /> </div> </div>
        </td>
    <td style="width: 94%; vertical-align: top">
        <div style="line-height: 1.25; font-weight: bold"><span style="font-weight: bold">UNRESOLVED STAFF COMMENTS.</span></div> </td> </tr>
  </table> </div>

<div style="line-height: 1.25"><br /> </div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">None.</div>

<div style="line-height: 1.25"><br /> </div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal">76</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000" /></div>
</div>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 6%; vertical-align: top">
        <div style="line-height: 1.25; font-weight: bold">ITEM 2<span id="ITEM2"><!--Anchor--></span>.</div> </td>
    <td style="width: 94%; vertical-align: top">
        <div style="line-height: 1.25; font-weight: bold">PROPERTIES.</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Our facilities in Israel, which house our research and development and certain production
and management functions, are located in Jerusalem, Israel. Most of our clinical development, clinical operations and regulatory functions
are located in the United States. Under a Lease Agreement with Unihead Biopark Ltd. as of December 31, 2022, we are leasing approximately
622 square meters of office and laboratory space pursuant to a lease agreement that will expire on June 30, 2023. Of the 622 square meters
leased, we utilize approximately 527 square meters for our operations and have agreed to sublease the remaining approximately 95 square
meters to a third-party until June 2023.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">We believe that our current office and laboratory space in Israel is sufficient to
meet our anticipated needs for the foreseeable future and is suitable for the conduct of our business. We believe that suitable additional
space would be available if required in the future on commercially reasonable terms.</div>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 6%; vertical-align: top">
        <div style="line-height: 1.25; font-weight: bold">ITEM 3<span id="ITEM3"><!--Anchor--></span>.</div> </td>
    <td style="width: 94%; vertical-align: top">
        <div style="line-height: 1.25; font-weight: bold">LEGAL PROCEEDINGS.</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">We are not currently a party to any material legal proceedings.</div>

<div style="line-height: 1.25"><br /> </div>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 6%; vertical-align: top">
        <div style="line-height: 1.25; font-weight: bold">ITEM 4<span id="ITEM4"><!--Anchor--></span>.</div> </td>
    <td style="width: 94%; vertical-align: top">
        <div style="line-height: 1.25; font-weight: bold">MINE SAFETY DISCLOSURES.</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<div style="line-height: 1.25">Not applicable.</div>

<div style="line-height: 1.25"><br /> </div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal">77</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000" /></div>
</div>

<div style="line-height: 1.25"><br /> </div>

<div style="text-align: center; line-height: 1.25; font-weight: bold">PART II<span id="PARTII"><!--Anchor--></span></div>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 6%; vertical-align: top">
        <div style="line-height: 1.25; font-weight: bold">ITEM 5<span id="ITEM5"><!--Anchor--></span>.</div> </td>
    <td style="width: 94%; vertical-align: top">
        <div style="line-height: 1.25; font-weight: bold">MARKET FOR REGISTRANT&#8217;S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER
        PURCHASES OF EQUITY SECURITIES.</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold">Market for our Ordinary Shares and IPO Warrants</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Our Ordinary Shares and IPO Warrants are listed on the Nasdaq Capital Market under
the symbols &#8220;ENTX&#8221; and &#8220;ENTXW,&#8221; respectively.</div>

<div style="text-align: justify; line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">As of March 27, 2023, there were approximately 44 holders of record of our Ordinary
Shares. This number does not include the number of persons whose shares are in nominee or in &#8220;street name&#8221; accounts through
brokers.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">Dividends</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">If the Company decides to distribute a cash dividend, Israeli residents who are individuals
are generally subject to Israeli income tax at a rate of either 25% or 30%, if the recipient of such dividend is a &#8220;substantial
shareholder&#8221; at the time of distribution or at any time during the preceding 12-month period, unless the cash dividend is paid out
of income that has been tax exempt due to an &#8220;approved enterprise&#8221; status under the Law for the Encouragement of Capital Investments,
5719-1959, in which case the Company will be subject to corporate tax at a rate then in effect under Israeli law on the amount of cash
dividend and in addition, an Israeli shareholder, corporation or individual, will be subject to a tax rate of 20% on such cash dividend
distribution. In addition, Israeli resident corporations are generally exempt from Israeli corporate tax for dividends paid on our Ordinary
Shares. Pursuant to the Convention Between the Government of the United States of America and the Government of Israel with Respect to
Taxes on Income, as amended (the &#8220;U.S.-Israel Tax Treaty&#8221;), the maximum tax on dividends paid to a holder of our Ordinary
Shares who qualifies as a resident of the United States within the meaning of the U.S.-Israel Tax Treaty is 25% or 15% in case of dividends
paid out of the profits of an &#8220;approved enterprise&#8221;, subject to certain conditions. Furthermore, dividends not generated by
an &#8220;approved enterprise&#8221; paid to a U.S. corporation holding at least 10% of our issued voting power during the part of the
tax year which precedes the date of payment of the dividend and during the whole of its prior tax year (if any), are generally taxed at
a rate of 12.5%, subject to certain conditions. The Company has never declared or paid cash dividends on its Ordinary Shares.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">The actual amount, timing, and frequency of future dividends, if any, will be at the
sole discretion of the board of directors and will be declared based upon various factors, many of which are beyond our control. The Company&#8217;s
current plans are to retain future earnings primarily to finance the development of its business and for other corporate purposes.</div>

<div style="line-height: 1.25"><br /> </div>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 6%; vertical-align: top">
        <div style="line-height: 1.25; font-weight: bold">ITEM 6<span id="ITEM6"><!--Anchor--></span>.</div> </td>
    <td style="width: 94%; vertical-align: top">
        <div style="line-height: 1.25; font-weight: bold">[Reserved]</div> </td> </tr>
  </table>

<div style="line-height: 1.25"><br /> </div>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 6%; vertical-align: top">
        <div style="line-height: 1.25; font-weight: bold">ITEM 7<span id="ITEM7"><!--Anchor--></span>.</div> </td>
    <td style="width: 94%; vertical-align: top">
        <div style="line-height: 1.25; font-weight: bold">MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</div>
        </td> </tr>
  </table>

<div style="line-height: 1.25"><br /> </div>

<div style="text-align: justify; line-height: 1.25; font-style: italic">This Annual Report on Form 10-K contains forward-looking statements
within the meaning of the Private Securities Litigation Reform Act of 1995 (&#8220;PSLRA&#8221;), Section 27A of the Securities Act of
1933, as amended, (the &#8220;Securities Act&#8221;), and Section 21E of the Securities Exchange Act of 1934, as amended, (the &#8220;Exchange
Act&#8221;), about our expectations, beliefs or intentions regarding our product development efforts, business, financial condition, results
of operations, strategies and prospects. You can identify forward-looking statements by the fact that these statements do not relate to
historical or current matters. Rather, forward-looking statements relate to anticipated or expected events, activities, trends or results
as of the date they are made. Because forward-looking statements relate to matters that have not yet occurred, these statements are inherently
subject to risks and uncertainties that could cause our actual results to differ materially from any future results expressed or implied
by the forward-looking statements. Many factors could cause our actual activities or results to differ materially from the activities
and results anticipated in forward-looking statements. These factors include those contained in &#8220;Item 1A - Risk Factors&#8221; and
&#8220;Cautionary Statement Regarding Forward-Looking Statements&#8221; of this Annual Report on Form 10-K. We do not undertake any obligation
to update forward-looking statements except as required by applicable law. We intend that all forward-looking statements be subject to
the safe harbor provisions of PSLRA. These forward-looking statements reflect our views only as of the date they are made.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">For purposes of this Item 7, references to the &#8220;Company,&#8221; &#8220;we,&#8221;
&#8220;us&#8221; and &#8220;our&#8221; refer to Entera Bio Ltd. and its consolidated subsidiary.</div>

<div style="line-height: 1.25">&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal">78</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000" /></div>
</div>

<div style="line-height: 1.25; font-weight: bold">Overview</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Entera is a clinical stage biopharmaceutical company and a leader in the development
of orally delivered macromolecule therapeutics, including peptides and therapeutic proteins. Currently, most protein therapies are administered
via frequent intravenous, subcutaneous, or intramuscular injections. In chronic diseases where patients require persistent management,
these cumbersome, often painful and high-priced injections can create a major treatment gap. Furthermore, from a technical standpoint,
oral delivery of therapeutic proteins has historically been challenging due to enzymatic degradation within the gastrointestinal tract,
poor absorption into the blood stream and variable drug exposures. Entera&#8217;s proprietary technology is designed to deliver orally
administered proteins with sufficient bioavailability to meet treatment goals, using white mini tablets (around 6mm in diameter) of the
desired protein.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">We strategically focus on underserved, chronic medical conditions where oral administration
of a mini tablet peptide or peptide replacement therapy has the potential to significantly shift a treatment paradigm.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">We currently have two product candidates in the clinical stage of development: EB613
and EB612. Both candidates are first-in-class daily mini tablets of human parathyroid hormone (hPTH (1-34), teriparatide). To date, Entera&#8217;s
proprietary PTH tablets have been safely administered to a total of 72 healthy subjects in Phase 1 studies and 153 patients across Phase
2 studies in osteoporosis and hypoparathyroidism, two diseases that remain underserved with the current standard of care and which disproportionately
affect women. In addition to these product candidates, we have various internal early stage research programs in other approved peptides
such as GLP-2 and hGH, as well as outside early stage collaborations to potentially diversify our revenue stream.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Since our inception, we have raised a total of $84.7 million from a combination of
public and private equity offerings, grants and the exercise of options and warrants. Since inception, we have incurred significant losses.
For the years ended December 31, 2022 and 2021, our operating losses were $13.0 million and $12.2 million, respectively, and we expect
to continue to incur significant expenses and losses for the foreseeable future. As of December 31, 2022, we had an accumulated deficit
of $95.5 million. Our losses may fluctuate significantly from quarter to quarter and year to year, depending on the timing of our clinical
trials, our expenditures on research and development activities, and payments under any future collaborations into which we may enter.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">As a result of our recurring losses from operations, negative cash flows and lack
of liquidity, management is of the opinion that there is substantial doubt as to the Company's ability to continue as a going concern.
Our independent registered public accounting firm included an explanatory paragraph in its report on our financial statements as of, and
for the year ended, December 31, 2022, expressing the existence of substantial doubt about our ability to continue as a going concern.&#160;
The audited consolidated financial statements included herein have been prepared assuming that we will continue as a going concern and
do not include adjustments that might result from the outcome of this uncertainty. If we are unable to raise the requisite funds, we will
need to delay certain program initiation, curtail or cease operations. See &#8220;Item 1A-Risk Factors-Risks Related to Our Financial
Position and Need for Additional Capital.&#8221;</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">As of December 31, 2022, we had cash and cash equivalents of&#8201;$12.3 million.
We believe that our existing cash resources will be sufficient to meet our projected operating requirements into the third quarter of
2024, which include the capital required to fund our ongoing operations, including R&amp;D and the completion of the Phase 1 PK study
related to the new formulation EB612. However, this does not include the capital required to fund our proposed Phase 3 pivotal study for
EB613 in osteoporosis and comparative PK study of EB613 and Forteo&#174;. We currently do not have funding sufficient for such Phase 3
or PK studies, and our ability to commence such studies requires additional funding, which may not be available on reasonable terms, or
at all.&#160; Any delay or our inability to secure such funding will delay or prevent the commencement of these studies.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">In order to fund further operations, we will need to raise additional capital. We
may raise these funds through a variety of means, including private or public equity offerings, debt financings, strategic collaborations
and licensing arrangements. Additional financing may not be available when we need it or may not be available on terms that are favorable
to us.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="line-height: 1.25; font-weight: bold">Patent Transfer, Licensing Agreements and Grant Funding</div>

<div style="line-height: 1.25">&#160;</div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold">Oramed Patent Transfer Agreement</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">In 2011, we entered into a patent transfer agreement with Oramed, or the Patent Transfer
Agreement, pursuant to which Oramed assigned to us all of its rights, title and interest in the patent rights Oramed licensed to us when
we were originally organized, subject to a worldwide, royalty-free, exclusive, irrevocable, perpetual and sub-licensable license granted
to Oramed under the assigned patent rights to develop, manufacture and commercialize products or otherwise exploit such patent rights
in the fields of diabetes and influenza. Additionally, we agreed not to engage, directly or indirectly, in any activities in the fields
of diabetes and influenza. Under the terms of the Patent Transfer Agreement, we agreed to pay Oramed royalties equal to 3% of our net
revenues generated, directly or indirectly, from exploitation of the assigned patent rights, including the sale, lease or transfer of
the assigned patent rights or sales of products or services covered by the assigned patent rights.</div>

<div style="line-height: 1.25"><br /> </div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal">79</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000" /></div>
</div>

<div style="line-height: 1.25"><span style="font-weight: bold; font-style: italic">Amgen Research Collaboration and License Agreement</span><br />
&#160;</div>

<div style="text-align: justify; line-height: 1.25">On December 10, 2018, we entered into a research collaboration and license agreement
with Amgen, which we refer to as the Amgen Agreement, with respect to inflammatory disease and other serious illnesses. Pursuant to the
Amgen Agreement, we and Amgen have agreed to use our proprietary drug delivery platform to develop oral formulations for one preclinical
large molecule program that Amgen has selected. In exchange for entering into the agreement, Amgen paid us a non-refundable and non-creditable
initial access fee of $725,000 in the first quarter of 2019, of which $500,000 was attributed to the right to use the intellectual property
and $225,000 was attributed to the pre-clinical R&amp;D services that we are obligated to perform under the Amgen Agreement. In addition,
under the Amgen Agreement, Amgen reimburses us for additional expenses that we incur for any work we do under the collaboration. Thus
far during our collaboration, Amgen has paid $968,000 for pre-clinical R&amp;D services by the end of 2022.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Amgen is responsible for the clinical development, regulatory approval, manufacturing
and worldwide commercialization of the programs. Pursuant to the terms of the Amgen Agreement, Amgen is required to make aggregate payments
of up to $270 million upon achievement of various clinical and commercial milestones or its exercise of options to select the additional
two programs to include in the collaboration. In addition, Amgen is required to make tiered royalty payments ranging from the low to mid-single
digits as a percentage of Amgen&#8217;s net sales of the applicable products covered by the Amgen Agreement. Amgen&#8217;s obligation
to pay royalties with respect to a product in a particular country commences upon the first commercial sale of such product in such country
and expires on a country-by-country and product-by-product basis on the later of (a) the date on which the sale of the product is no longer
covered by a valid claim of a patent licensed to Amgen under the Amgen Agreement, and (b) the tenth anniversary of the first commercial
sale of such product in such country.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Under the Amgen Agreement, we granted Amgen an exclusive, worldwide, sub-licensable
license to certain of our intellectual property relating to our drug delivery technology to develop, manufacture and commercialize the
applicable products. We have retained all intellectual property rights to our drug delivery technology, Amgen will retain all rights to
its large molecules and any subsequent improvements, and ownership of certain intellectual property developed through the performance
of the collaboration is to be determined by U.S. patent law. Each party is responsible for the filing and prosecution of patents relating
to its owned developments and, with respect to any jointly-owned developments, we are responsible for the filing and prosecution of patents
solely claiming improvements to our drug delivery technology and Amgen is responsible for the filing and prosecution of any other jointly-owned
developments. Amgen has the primary right to enforce any such patents against third-party infringement with respect to a product that
has the same mechanism of action as one of the collaboration programs, subject to involvement by us in certain circumstances.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">During certain periods covered by the Amgen Agreement, we may not alone, or with a
third party, research, develop, manufacture or commercialize certain products that interact with the targets of the applicable collaboration
programs. The collaboration is governed by a joint research committee, or JRC, made up of equal representatives of us and Amgen. The JRC
may establish additional subcommittees to oversee particular projects or activities. Subject to certain limitations, if the JRC is unable
to make a decision by consensus, the disagreement is to be resolved through escalation to specified senior executive officers of the parties,
although Amgen has the final decision-making ability with respect to certain pre-defined issues.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">The term of the Amgen Agreement commenced on December 10, 2018, and unless earlier
terminated, continues in full force and effect, on a product-by-product basis, until expiration of the last-to-expire royalty term with
respect to such product. At any point in the research, development or commercialization process, subject to certain conditions, Amgen
can terminate the Amgen Agreement in its entirety or with respect to a specific development program. Both parties can terminate the agreement
for a material breach by the other party that goes uncured, subject to a 90-day notice period.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold">Israeli Innovation Authority Grants</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">We have received grants of approximately $0.5 million from the IIA to partially fund
our research and development. The grants are subject to certain requirements and restrictions under the Israeli Encouragement of Research,
Development and Technological Innovation in Industry Law 5477-1984, or the Research Law. In general, until the grants are repaid with
interest, royalties are payable to the Israeli government in the amount of 3% on revenues derived from sales of products or services developed
in whole or in part using the IIA grants, including EB613, EB612 and any other oral PTH product candidates we may develop. The royalty
rate may increase to 5%, with respect to approved applications filed following any year in which we achieve sales of over $70 million.</div>

<div style="line-height: 1.25"><br /> </div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal">80</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000" /></div>
</div>

<div style="text-align: justify; line-height: 1.25">The amount that must be repaid may be increased up to six times the amount of the
grant received and the interest. The rate of royalties may be accelerated and the royalty liability may increase (up to three times the
amount of the grant amount and the interest), if manufacturing of the products developed with the grant money is transferred outside of
the State of Israel. Moreover, a payment of up to 600% of the grant received may be required upon the transfer of any IIA-funded know-how
to a non-Israeli entity. We signed a contract with a U.K.-based contract manufacturing organization to produce and supply pills for trials
performed worldwide. We believe that, because this production is not for commercial purposes, it will not affect the royalty rates to
be paid to the IIA. Should the IIA successfully take a contrary position, the maximum royalties to be paid to the IIA will be approximately
$1.5 million, which is three times the amount of the original grant (three times of the interest will also be added). Following the signing
of the Amgen Agreement, we have been required to pay 5.38% of each payment by Amgen and up to 600% of the grant received and the interest.
As of December 31, 2022, we had paid royalties to the IIA in the amount of $83,000 related to the Amgen Agreement.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">In addition to paying any royalties due, we must abide by other restrictions associated
with receiving such grants under the Research Law that continue to apply following repayment to the IIA.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="line-height: 1.25; font-weight: bold">Financial Overview</div>

<div style="line-height: 1.25">&#160;</div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold">Revenue</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">To date, we have not generated any revenue from sales of our products, and we do not
expect to receive any revenue from any product candidates that we develop unless and until we obtain regulatory approval and successfully
commercialize our products.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Under the Amgen Agreement, through December 31, 2022, we had received an additional
aggregate amount of $968,000 for research and development services.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Revenues, including revenues under the Amgen Agreement, are recognized according to
ASC 606, "Revenues from Contracts with Customers&#8221;.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">According to ASC 606, a performance obligation is a promise to provide a distinct
good or service or a series of distinct goods or services. Goods and services that are not distinct are bundled with other goods or services
in the contract until a bundle of goods or services that is distinct is created. A good or service promised to a customer is distinct
if the customer can benefit from the good or service either on its own or together with other resources that are readily available to
the customer and the entity&#8217;s promise to transfer the good or service to the customer is separately identifiable from other promises
in the contract. Options granted to the customer that do not provide a material right to the customer that it would not receive without
entering into the contract do not give rise to performance obligations. We identified two performance obligations in the agreement: the
license to use the Company's proprietary drug delivery platform and pre-clinical research and development services (&#8220;pre-clinical
R&amp;D services&#8221;). The license to our intellectual property has significant standalone functionality, since we are not required
to continue to support, develop or maintain the intellectual property transferred and will not undertake any activities to change the
standalone functionality of the intellectual property. Therefore, we recognized the revenues related to this performance obligation in
December 2018 at the point in time that control of the license was transferred to Amgen. The preclinical R&amp;D services include discovery,
research and design preclinical activities relating to the programs selected by Amgen. Revenues attributed to the preclinical R&amp;D
services are recognized during the period the pre-clinical R&amp;D services are provided according to the input model method on a cost-to-cost
basis. Each of these items met the definition of distinct performance obligation. The Company evaluated the standalone selling price of
the pre-clinical R&amp;D services at $225,000 and the right to use the intellectual property at $500,000.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Under ASC 606, the consideration that we would be entitled to upon the achievement
of contractual milestones, which are contingent upon the occurrence of future events of development and commercial progress, are a form
of variable consideration. When assessing the portion, if any, of such milestone-related consideration to be included in the transaction
price, we first assess the most likely outcome for each milestone, and exclude the consideration related to milestones of which the occurrence
is not considered the most likely outcome. We then evaluate if any of the variable consideration determined in the first step is constrained.
Variable consideration is included in the transaction price if, in our judgment, it is probable that a significant future reversal of
cumulative revenue under the contract will not occur. Estimates of variable consideration and determination of whether to include estimated
amounts in the transaction price are based largely on an assessment of our anticipated performance and all information (historical, current
and forecasted) that is reasonably available. We did not recognize any revenues from milestone payments.</div>

<div style="line-height: 1.25"><br /> </div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal">81</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000" /></div>
</div>

<div style="text-align: justify; line-height: 1.25">An entity should recognize revenue for a sales-based or usage-based royalty promised
in exchange for a license of intellectual property only when (or as) the later of the following events occurs:</div>

<div style="line-height: 1.25"><br /> </div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 36pt"><br /> </td>
    <td style="width: 36pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>The subsequent sale or usage occurs; and</div>
        <div> <br /> </div> </td> </tr>
  </table>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 36pt"><br /> </td>
    <td style="width: 36pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>The performance obligation to which some or all of the sales-based or usage-based royalty has been allocated has been satisfied (or
        partially satisfied).</div> </td> </tr>
  </table>

<div style="text-align: justify; line-height: 1.25">&#160;&#160;</div>

<div style="text-align: justify; line-height: 1.25">We did not recognize any revenues from royalties because royalties are payable based
on future commercial sales, as defined in the Amgen Agreement, and there have been no commercial sales.</div>

<div style="text-align: justify; line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">For the years ended December 31, 2022 and 2021, we recognized revenues from the Amgen
Agreement and other material transfer agreements (&#8220;MTA&#8221;) in the total amounts of $134 thousand and $571 thousand, respectively.</div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold"> <br /> </div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">Research and Development Expenses</div>

<div style="text-align: justify; line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Research and development expenses consist of costs incurred for the development of
our drug delivery technology and our product candidates. Those expenses include:</div>

<div style="line-height: 1.25"><br /> </div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 36pt"><br /> </td>
    <td style="width: 36pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>employee-related expenses, including salaries, bonuses and share-based compensation expenses for employees and service providers
        in the research and development function;</div>
        <div> <br /> </div> </td> </tr>
  </table>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 36pt"><br /> </td>
    <td style="width: 36pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>expenses incurred in operating our laboratories including our small-scale manufacturing facility;</div>
        <div> <br /> </div> </td> </tr>
  </table>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 36pt"><br /> </td>
    <td style="width: 36pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>expenses incurred under agreements with CROs, and investigative sites that conduct our clinical trials;</div>
        <div> <br /> </div> </td> </tr>
  </table>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 36pt"><br /> </td>
    <td style="width: 36pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>expenses related to outsourced and contracted services, such as external laboratories, consulting and advisory services;<br /> <br />
        </div> </td> </tr>
  </table>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 36pt"><br /> </td>
    <td style="width: 36pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>supply, development and manufacturing costs relating to clinical trial materials; and</div>
        <div> <br /> </div> </td> </tr>
  </table>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 36pt"><br /> </td>
    <td style="width: 36pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>other costs associated with pre-clinical and clinical activities.</div> </td> </tr>
  </table>

<div style="text-align: justify; margin-left: 36pt; line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Research and development activities are the primary focus of our business. Product
candidates in later stages of clinical development generally have higher development costs than those in earlier stages of clinical development,
primarily due to the increased size and duration of later-stage clinical trials. We expect that our research and development expenses
will increase significantly in future periods as we advance EB613 and EB612 into later stages of clinical development and invest in additional
preclinical candidates.</div>

<div style="text-align: justify; text-indent: 14.2pt; line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Our research and development expenses may vary substantially from period to period
based on the timing of our research and development activities, including due to the timing of initiation of clinical trials and the enrollment
of patients in clinical trials. For the years ended December 31, 2022 and 2021, our research and development expenses were $5.8 million
and $6.8 million, respectively. Research and development expenses for the years ended December 31, 2022 and 2021 were primarily for the
development of EB613 and EB612. The successful development of our product candidates is highly uncertain. At this time, we cannot reasonably
estimate the nature, timing and estimated costs of the efforts that will be necessary to complete the development of, or the period, if
any, in which material net cash inflows may commence from, any of our product candidates. This is due to numerous risks and uncertainties
associated with developing drugs, including:</div>

<div style="line-height: 1.25"><br /> </div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 36pt"><br /> </td>
    <td style="width: 36pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>the uncertainty of the scope, rate of progress, results and cost of our clinical trials, nonclinical testing and other related activities;</div>
        <div> <br /> </div> </td> </tr>
  </table>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 36pt"><br /> </td>
    <td style="width: 36pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>the cost of manufacturing clinical supplies and establishing commercial supplies of our product candidates and any products that
        we may develop;</div>
        <div> <br /> </div> </td> </tr>
  </table>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 36pt"><br /> </td>
    <td style="width: 36pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>the number and characteristics of product candidates that we pursue;</div>
        <div> <br /> </div> </td> </tr>
  </table>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 36pt"><br /> </td>
    <td style="width: 36pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>the cost, timing and outcomes of regulatory approvals;</div>
        <div> <br /> </div> </td> </tr>
  </table>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 36pt"><br /> </td>
    <td style="width: 36pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>the cost and timing of establishing any sales, marketing, and distribution capabilities; and</div>
        <div> <br /> </div> </td> </tr>
  </table>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 36pt"><br /> </td>
    <td style="width: 36pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>the terms and timing of any collaborative, licensing and other arrangements that we may establish, including any milestone and royalty
        payments thereunder.</div> </td> </tr>
  </table>

<div style="text-align: justify; margin-left: 72pt; line-height: 1.25">&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal">82</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000" /></div>
</div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold">

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif; font-weight: normal; font-style: normal">A
change in the outcome of any of these variables with respect to the development of EB613, EB612 or any other product candidate that we
may develop could mean a significant change in the costs and timing associated with the development of such product candidate. For example,
if the FDA or other regulatory authority were to require us to conduct preclinical and/or clinical studies beyond those which we currently
anticipate will be required for the completion of clinical development, if we experience significant delays in enrollment in any clinical
trials or if we encounter difficulties in manufacturing our clinical supplies, then we could be required to expend significant additional
financial resources and time on the completion of the clinical development.</div> </div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold"> <br /> </div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold">General and Administrative Expenses</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">General and administrative expenses consist principally of salaries, benefits, share-based
compensation and related costs for directors and personnel in executive and finance functions. Other general and administrative expenses
include D&amp;O insurance and other insurance, communication expenses, professional fees for legal and accounting services, patent counseling
and portfolio maintenance and business development expenses.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">We expect that our general and administrative expenses will increase in the future
as we increase our headcount and expand our administrative function to support our operations.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold">Financial Expenses (Income), Net</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Financial expenses (income), net are composed primarily of interest income and exchange
rate differences of certain currencies against our functional currency.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold">Income Tax Expenses (Benefit)</div>

<div style="text-align: justify; text-indent: 14.2pt; line-height: 1.25">&#160;</div>

<div style="line-height: 1.25">We have not generated taxable income since our inception, and as of December 31, 2022, we had carry-forward
tax losses of $67.1 million. We anticipate that we will be able to carry forward these tax losses indefinitely to future tax years. Accordingly,
we do not expect to pay taxes in Israel until we have taxable income after the full utilization of our carryforward tax losses. We provided
a full valuation allowance with respect to the deferred tax assets related to these carry forward losses of the Company.<br /> <br />
The Company&#8217;s subsidiary, Entera Bio, Inc., is taxed separately under the U.S. tax laws. As of December 31, 2022, Entera Bio Inc.
has tax loss carry-forwards of $98 thousand.<br /> &#160;</div>

<div style="line-height: 1.25; font-weight: bold">Results of Operations</div>

<div style="line-height: 1.25">&#160;</div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold">Comparison of Years Ended December 31, 2022 and 2021</div>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" class="cfttable" style="font: 10pt Times New Roman, Times, serif; text-align: left; color: #000000; width: 100%">
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px">
        <div style="line-height: 1.25; font-weight: bold">&#8203;</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
    <td colspan="6" style="vertical-align: bottom; border-bottom: #000000 2px solid; vertical-align: bottom">
        <div style="text-align: center; line-height: 1.25; font-weight: bold">Year Ended<br /> December 31,</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
    <td colspan="6" style="vertical-align: bottom; border-bottom: #000000 2px solid; vertical-align: bottom">
        <div style="text-align: center; line-height: 1.25; font-weight: bold">Increase (Decrease)</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px">
        <div style="line-height: 1.25; font-weight: bold">&#8203;</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid; vertical-align: bottom">
        <div style="text-align: center; line-height: 1.25; font-weight: bold"> 2022</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid; vertical-align: bottom">
        <div style="text-align: center; line-height: 1.25; font-weight: bold">2021</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid; vertical-align: bottom">
        <div style="text-align: center; line-height: 1.25; font-weight: bold"> $</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid; vertical-align: bottom">
        <div style="text-align: center; line-height: 1.25; font-weight: bold">%</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom">
        <div style="line-height: 1.25">&#8203;</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom">&#160;</td>
    <td colspan="14" style="vertical-align: bottom; vertical-align: bottom">
        <div style="text-align: center; line-height: 1.25">(In thousands, except for percentage information)</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom">&#160;</td> </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; background-color: rgb(204, 238, 255); width: 52%">
        <div style="line-height: 1.25">Revenues</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25">$</div> </td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25">134</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25">$</div> </td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25">571</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25">$</div> </td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25">(437</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25">)</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25">(77</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25">)%</div> </td> </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; width: 52%">
        <div style="line-height: 1.25">Cost of revenues</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; text-align: right; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25">$</div> </td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25">101</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; text-align: right; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25">$</div> </td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25">373</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; text-align: right; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25">(272</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25">)</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; text-align: right; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25">(73</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25">)%</div> </td> </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; background-color: #CCEEFF">
        <div style="line-height: 1.25">Operating expenses:</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; text-align: right; vertical-align: bottom; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: #CCEEFF; vertical-align: bottom">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: #CCEEFF; vertical-align: bottom; text-align: right">&#160;</td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: #CCEEFF; vertical-align: bottom">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; vertical-align: bottom; background-color: #CCEEFF">
        <div style="text-align: center; line-height: 1.25">&#8203;</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: #CCEEFF; vertical-align: bottom">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; text-align: right; vertical-align: bottom; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: #CCEEFF; vertical-align: bottom">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: #CCEEFF; vertical-align: bottom; text-align: right">&#160;</td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: #CCEEFF; vertical-align: bottom">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; text-align: right; vertical-align: bottom; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: #CCEEFF; vertical-align: bottom">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: #CCEEFF; vertical-align: bottom; text-align: right">&#160;</td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: #CCEEFF; vertical-align: bottom">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; width: 52%">
        <div style="margin-left: 10pt; line-height: 1.25">Research and development expenses</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; text-align: right; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25">$</div> </td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25">5,848</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; text-align: right; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25">$</div> </td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25">6,771</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; text-align: right; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25">$</div> </td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25">(923</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25">)</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; text-align: right; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25">(14</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25">)%</div> </td> </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; background-color: rgb(204, 238, 255); width: 52%">
        <div style="margin-left: 10pt; line-height: 1.25">General and administrative expenses</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25">$</div> </td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25">7,253</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25">$</div> </td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25">5,690</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25">$</div> </td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25">1,563</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25">27</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25">%</div> </td> </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; width: 52%; padding-bottom: 2px">
        <div style="margin-left: 10pt; line-height: 1.25">Other income</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25">$</div> </td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25">(51</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 2px">
        <div style="line-height: 1.25">)</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25">$</div> </td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25">(46</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 2px">
        <div style="line-height: 1.25">)</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25">$</div> </td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25">(5</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 2px">
        <div style="line-height: 1.25">)</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25">11</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 2px">
        <div style="line-height: 1.25">%</div> </td> </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; background-color: rgb(204, 238, 255); width: 52%">
        <div style="margin-left: 10pt; line-height: 1.25">Operating loss</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25">$</div> </td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25">13,017</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25">$</div> </td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25">12,217</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25">$</div> </td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25">800</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25">7</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25">%</div> </td> </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; width: 52%">
        <div style="line-height: 1.25">Financial expenses (income), net</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; text-align: right; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25">$</div> </td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25">(83</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25">)</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; text-align: right; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25">$</div> </td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25">29</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; text-align: right; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25">$</div> </td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25">(112</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25">)</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; text-align: right; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25">(386</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25">)%</div> </td> </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; background-color: rgb(204, 238, 255); width: 52%; padding-bottom: 4px">
        <div style="line-height: 1.25">Income tax expenses (benefit)</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 4px double; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25">$</div> </td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 4px double; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25">137</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; padding-bottom: 4px">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 4px double; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25">$</div> </td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 4px double; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25">(59</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; padding-bottom: 4px">
        <div style="line-height: 1.25">)</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 4px double; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25">$</div> </td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 4px double; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25">196</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; padding-bottom: 4px">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 4px double; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 4px double; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25">(332</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; padding-bottom: 4px">
        <div style="line-height: 1.25">)%</div> </td> </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; width: 52%; padding-bottom: 4px">
        <div style="margin-left: 10pt; line-height: 1.25">Net loss</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 4px double; vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25">$</div> </td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 4px double; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25">13,071</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 4px">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 4px double; vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25">$</div> </td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 4px double; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25">12,187</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 4px">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 4px double; vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25">$</div> </td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 4px double; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25">884</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 4px">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 4px double; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 4px double; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25">7</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 4px">
        <div style="line-height: 1.25">%</div> </td> </tr>
  </table>

<div style="line-height: 1.25"><br /> </div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">Revenue</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Revenues for the years ended December 31, 2022 and 2021 were $134,000 and $571,000,
respectively. For 2022 and 2021, the majority of our revenues were attributable to research and development, or R&amp;D, services provided
to Amgen under the Amgen Agreement and other MTA agreements. The decrease in revenue for the year ended December 31, 2022 as compared
to the prior year period was primarily due to finalization of third year pre-clinical R&amp;D services. We did not generate any revenues
prior to entering into the Amgen Agreement.</div>

<div style="line-height: 1.25">&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal">83</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000" /></div>
</div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">Cost of Revenues</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Cost of revenues for the year ended December 31, 2022 were $101,000 compared to $373,000
for the year ended December 31, 2021 and were primarily attributed to salaries and related expenses in connection with the R&amp;D services
provided under the Amgen Agreement and other MTA agreements. The decrease in cost of revenues for the year ended December 31, 2022 was
primarily due to decreased revenues under the Amgen Agreement, as described above.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="line-height: 1.25"><span style="font-weight: bold; font-style: italic">Research and Development Expenses</span><br /> &#160;</div>

<div style="text-align: justify; line-height: 1.25">Research and development expenses for the year ended December 31, 2022 were $5.8 million,
as compared to $6.8 million for the year ended December 31, 2021. The decrease of $1.0 million was primarily attributed to a decrease
of $0.6 million related to the completion of our Phase 2 trial for EB613 in September 2021, and a decrease of $0.9 million in pre-clinical
activities related to our planned Phase 3 clinical trial for EB613, which were partially offset by an increase of $0.3 million in continued
materials and production costs, strengthening the R&amp;D organization in preparation for &#160;EB613&#8217;s proposed phase 3 study and
EB612&#8217;s proposed new formulation PK study and an increase of $0.2 million in employee compensation, primarily related to a one-time
payment to our former President of R&amp;D.</div>

<div style="line-height: 1.25"><br /> </div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold">General and Administrative Expenses</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">General and administrative expenses for the year ended December 31, 2022 were $7.3
million, compared to $5.7 million for the year ended December 31, 2021. The increase of $1.6 million was primarily attributable to an
increase of $0.4 million in non-cash share-based compensation granted to directors and executive officers and an increase of $0.4 with
respect to a one-time payment to our former Chief Executive Officer. Additionally, there was an increase of $0.5 million in professional
fees and an increase of $0.3 million in D&amp;O insurance costs. &#160;<br /> <br /> </div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">Financial Expenses (Income), Net</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Financial income, net for the year ended December 31, 2022 was $83,000, compared to
$29,000 financial expenses, net for the year ended December 31, 2021. Our financial expenses (income) is composed primarily of exchange
rate differences of certain currencies against our functional currency, which is the U.S. Dollar.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="line-height: 1.25; font-weight: bold">Liquidity and Capital Resources</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Since inception, we have incurred significant losses. As a result of our recurring
losses from operations, negative cash flows from operating activities and lack of liquidity, our independent registered public accounting
firm included an explanatory paragraph in its report on our financial statements as of, and for the year ended, December 31, 2022, expressing
the existence of substantial doubt about our ability to continue as a going concern. For the years ended December 31, 2022 and 2021, our
operating losses were $13.0 million and $12.2 million, respectively. We expect to continue to incur significant expenses and losses for
the next several years as we advance our products through development and provide administrative support for our operations. As of December
31, 2022, we had an accumulated deficit of&#8201;$95.5 million. Since our inception, we have raised a total of $84.7 million, including
$25.3 million through at-the-market-offering (&#8220;ATM&#8221;) programs, $14.3 million in our December 2019 private placement, $11.2
million in our IPO in 2018 and $33.9 million in aggregate funding from a combination of grants, exercise of options and warrants and private
placements of Ordinary Shares, preferred shares and debt prior to our IPO. In addition, as of December 31, 2022, we had received approximately
$1.4 million under the Amgen Agreement.</div>

<div style="line-height: 1.25"><br /> </div>

<div style="text-align: justify; line-height: 1.25">As of December 31, 2022, we had cash and cash equivalents of&#8201;$12.3 million.
Our primary uses of cash have been to fund research and development, general and administrative and working capital requirements, and
we expect these will continue to be our primary uses of cash.</div>

<div style="line-height: 1.25"><br /> </div>

<div style="text-align: justify; line-height: 1.25">

<div style="line-height: 1.25">In July 2020, we entered into an equity distribution agreement with Canaccord Genuity LLC, as sales agent,
to implement an at-the-market offering program under which we, from time to time, were able to offer and sell our Ordinary Shares, having
an aggregate offering amount of up to $13.9 million.&#160; This ATM program terminated in accordance with its terms following our sale
of the full dollar amount of ordinary shares permitted thereunder. On May 7, 2021 we entered into an At Market Issuance Sales Agreement
with B. Riley Securities, Inc., as sales agent, under which we, from time to time, had been able to offer and sell up to 5,000,000 Ordinary
Shares . For the year ended December 31, 2021, we sold an aggregate of 4,386,728 ordinary shares under the foregoing ATM programs for
aggregate proceeds of $21.8 million, net of issuance costs.</div> </div>

<div style="text-align: justify; line-height: 1.25">&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal">84</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000" /></div>
</div>

<div style="text-align: justify; line-height: 1.25">Following our loss of foreign private issuer status on January 1, 2022, we were no
longer able to use our then-current ATM program, as offers and sales under which had been registered on our registration statement on
Form F-3, which may be used only by a foreign private issuer; therefore, we filed a new shelf registration statement on Form S-3 (file
no. 333-365286) on May 27, 2022 to, among other things, facilitate our use of the Amended B. Riley ATM Program and SVB ATM Program (each
as defined below). On May 27,2022 we entered into an Amended and Restated at Market Issuance Sales Agreement with B. Riley Securities,
Inc., as sales agent, under which we were able, from time to time, to offer and sell up to 5,000,000 Ordinary Shares (the &#8220;Amended
B. Riley ATM Program&#8221;). Effective August 30, 2022, we terminated the Amended B. Riley ATM Program, and we had not sold any shares
under such agreement.</div>

<div style="text-align: justify; line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">On September 2, 2022, we entered into a Sales Agreement with SVB Securities LLC, as
sales agent, to implement an ATM program under which we may from time to time offer and sell up to 5,000,000 Ordinary Shares (the &#8220;SVB
ATM Program&#8221;) under our currently effective Registration Statement on Form S-3 and a related prospectus supplement forming a part
thereof. The sales agent is entitled to a fixed commission of 3% of the aggregate gross proceeds as well as and reimbursement of expenses.
As of December 31, 2022, we had not sold any shares under the SVB ATM Program.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">Funding Requirements</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">We&#160;believe that our existing cash resources will be sufficient to meet our projected
operating requirements into the third quarter of 2024, which include the capital required to fund our ongoing operations, including R&amp;D
and the completion of the Phase 1 PK study related to the new formulation EB612. However, this does not include the capital required to
fund our proposed Phase 3 pivotal study for EB613 in osteoporosis and comparative PK study of EB613 and Forteo&#174;. We currently do
not have funding sufficient for such Phase 3 or PK studies, and our ability to commence such studies requires additional funding, which
may not be available on reasonable terms, or at all.&#160; Any delay or our inability to secure such funding will delay or prevent the
commencement of these studies.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">We have based these estimates on assumptions that may prove to be wrong, and we may
use our available capital resources sooner than we currently expect. Because of the numerous risks and uncertainties associated with the
development of our product candidates, and the extent to which we may enter into collaborations with third parties for development of
these or other product candidates, we are unable to estimate the amounts of increased capital outlays and operating expenses associated
with completing the development of our current and future product candidates. Our future capital requirements will depend on many factors,
including:</div>

<div style="line-height: 1.25"><br /> </div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 36pt"><br /> </td>
    <td style="width: 36pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>the costs, timing and outcome of clinical trials for, and regulatory review of, EB613, EB612 and any other product candidates we
        may develop;<br /> <br /> </div> </td> </tr>
  </table>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 36pt"><br /> </td>
    <td style="width: 36pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>the costs of development activities for any other product candidates we may pursue;</div>
        <div> <br /> </div> </td> </tr>
  </table>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 36pt"><br /> </td>
    <td style="width: 36pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>the costs of preparing, filing and prosecuting patent applications, maintaining and enforcing our intellectual property rights and
        defending intellectual property-related claims; and</div>
        <div> <br /> </div> </td> </tr>
  </table>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 36pt"><br /> </td>
    <td style="width: 36pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>our ability to establish collaborations on favorable terms, if at all.</div> </td> </tr>
  </table>

<div style="text-align: justify; margin-left: 72pt; line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">We are in the process of evaluating various financing alternatives in the public or
private equity markets or through license of our technology to additional external parties through partnerships or research collaborations
as we will need to finance future research and development activities, general and administrative expenses and working capital through
fund raising. However, there is no certainty about our ability to obtain such funding.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Other than the SVB ATM Program, we do not have any committed external sources of funds.
To the extent that we raise additional capital through the sale of equity or convertible debt securities, the ownership interest of our
then-existing shareholders will be diluted, and the terms of these securities may include liquidation or other preferences that may adversely
affect our existing shareholders&#8217; rights as shareholders. Debt financing, if available, may involve agreements that include covenants
limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring
dividends and may include requirements to hold minimum levels of funding. If we raise additional funds through collaborations, strategic
alliances or licensing arrangements with third parties, we may have to relinquish valuable rights to our technologies, future revenue
streams or research programs or grant licenses on terms that may not be favorable to us. If we are unable to raise additional funds through
equity or debt financings or collaborations, when needed, we may be required to delay, limit, reduce or terminate our product development
or future commercialization efforts or grant rights to develop and market our oral PTH product candidates and any other product candidates
that we would otherwise prefer to develop and market ourselves.</div>

<div style="line-height: 1.25"><br /> </div>

<div style="text-align: justify; line-height: 1.25">Our audited consolidated financial statements for the year ended December 31, 2022,
included elsewhere in this Annual Report on Form 10-K, note that there is substantial doubt about our ability to continue as a going concern
as of such date; and in its report accompanying our audited consolidated financial statements included herein, our independent registered
public accounting firm included an explanatory paragraph stating that our recurring losses from operations and our cash outflows from
operating activities raise substantial doubt as to our ability to continue as a going concern. This means that our management and our
independent registered public accounting firm have expressed substantial doubt about our ability to continue our operations without an
additional infusion of capital from external sources. The audited consolidated financial statements have been prepared on a going concern
basis and do not include any adjustments that may be necessary should we be unable to continue as a going concern. If we are unable to
finance our operations, our business would be in jeopardy and we might not be able to continue operations and might have to liquidate
our assets. In that case, investors might receive less than the value at which those assets are carried on our financial statements, and
it is likely that investors would lose all or a part of their investment.</div>

<div style="line-height: 1.25">&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal">85</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000" /></div>
</div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold">Cash Flows</div>

<div style="line-height: 1.25">&#160;</div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold">Year Ended December 31, 2022 Compared to Year Ended December 31,
2021</div>

<div style="line-height: 1.25">&#160;</div>

<div style="line-height: 1.25">The following table sets forth the primary sources and uses of cash for each of the periods set forth below:</div>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" class="cfttable" style="font: 10pt Times New Roman, Times, serif; text-align: left; color: #000000; width: 100%">
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px">
        <div style="line-height: 1.25; font-weight: bold">&#8203;</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
    <td colspan="6" style="vertical-align: bottom; border-bottom: #000000 2px solid; vertical-align: bottom">
        <div style="text-align: center; line-height: 1.25; font-weight: bold">(audited)<br /> Year ended December 31,</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px">
        <div style="line-height: 1.25; font-weight: bold">&#8203;</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid; vertical-align: bottom">
        <div style="text-align: center; line-height: 1.25; font-weight: bold">2022</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid; vertical-align: bottom">
        <div style="text-align: center; line-height: 1.25; font-weight: bold">2021</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom">
        <div style="line-height: 1.25">&#8203;</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom">&#160;</td>
    <td colspan="6" style="vertical-align: bottom; vertical-align: bottom">
        <div style="text-align: center; line-height: 1.25">(in thousands)</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom">&#160;</td> </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; background-color: #CCEEFF; width: 76%">
        <div style="line-height: 1.25">Net Cash used in operating activities</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: #CCEEFF; vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25">$</div> </td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: #CCEEFF; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25">(12,499</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: #CCEEFF; vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25">)</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: #CCEEFF; vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25">$</div> </td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: #CCEEFF; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25">(9,063</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: #CCEEFF; vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25">)</div> </td> </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; width: 76%">
        <div style="line-height: 1.25">Net Cash used in investing activities</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25">(102</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25">)</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25">(17</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25">)</div> </td> </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; background-color: #CCEEFF; width: 76%; padding-bottom: 2px">
        <div style="line-height: 1.25">Net Cash provided by financing activities</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; border-bottom: #000000 2px solid; background-color: #CCEEFF; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; border-bottom: #000000 2px solid; background-color: #CCEEFF; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25">13</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: #CCEEFF; vertical-align: bottom; width: 1%; padding-bottom: 2px">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; border-bottom: #000000 2px solid; background-color: #CCEEFF; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; border-bottom: #000000 2px solid; background-color: #CCEEFF; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25">25,381</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: #CCEEFF; vertical-align: bottom; width: 1%; padding-bottom: 2px">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; width: 76%; padding-bottom: 4px">
        <div style="line-height: 1.25">Net increase (decrease) in cash and cash equivalents</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 4px">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 4px double; vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25">$</div> </td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 4px double; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25">(12,588</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 4px">
        <div style="line-height: 1.25">)</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 4px">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 4px double; vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25">$</div> </td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 4px double; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25">16,301</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 4px">&#160;</td>
        </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold">Net Cash Used in Operating Activities</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Net Cash used in operating activities for the year ended December 31, 2022 was $12.5
million, consisting primarily of our operating loss of&#8201;$13.0 million and an increase of $1.8 million in our working capital, which
was partially offset by approximately $2.3 million of share-based compensation and depreciation expenses.</div>

<div style="line-height: 1.25"><br /> </div>

<div style="text-align: justify; line-height: 1.25">

<div style="line-height: 1.25">Net Cash used in operating activities for the year ended December 31, 2021 was $9.1 million, consisting
primarily of our operating loss of&#8201;$12.2 million, which was partially offset by $1.7 million of share-based compensation,&#160;depreciation
and deferred income taxes, and a decrease of $1.4 million in our working capital.</div> </div>

<div style="line-height: 1.25">&#160;&#160;</div>

<div style="text-align: justify; line-height: 1.25">

<div style="line-height: 1.25">The increase of $3.4 million in cash used in operating activities for the year ended December 31, 2022
compared to the same period in 2021 was mainly attributed to an increase of $0.8 million in our operating loss, and an increase of $3.2
million in working capital primarily due to payments to suppliers and services providers, which was partially offset by an increase of
$0.4 million in share-based compensation and depreciation expenses.</div> </div>

<div style="line-height: 1.25"><br /> </div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">Net Cash Used in Investing Activities</div>

<div style="text-align: justify; line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Net Cash used in investing activities for the year ended December 31, 2022 and 2021
consisted primarily of the purchase of property and equipment and withdrawal of funds in connection with the retirement of certain employees.<br />
<br /> </div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">Net Cash Provided by Financing Activities</div>

<div style="text-align: justify; line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Net Cash provided by financing activities for the year ended December 31, 2022 primarily
derived from net proceeds of $13 thousand from the exercise of options to purchase Ordinary Shares.</div>

<div style="line-height: 1.25"><br /> </div>

<div style="text-align: justify; line-height: 1.25">Net Cash provided by financing activities for the year ended December 31, 2021 primarily
derived from net proceeds of $21.8 million from the issuance of Ordinary Shares under our ATM and $3.6 million from the exercise of warrants
and options.</div>

<div style="line-height: 1.25">&#160;&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal">86</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000" /></div>
</div>

<div style="line-height: 1.25; font-weight: bold">Contractual Obligations</div>

<div style="line-height: 1.25">&#160;</div>

<div style="line-height: 1.25">The following tables summarize our contractual obligations and commitments as of December 31, 2022 that
will affect our future liquidity:</div>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" class="cfttable" style="font: 10pt Times New Roman, Times, serif; text-align: left; color: #000000; width: 100%">
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px">
        <div style="line-height: 1.25; font-weight: bold">&#8203;</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
    <td colspan="18" style="vertical-align: bottom; border-bottom: #000000 2px solid; vertical-align: bottom">
        <div style="text-align: center; line-height: 1.25; font-weight: bold">Payments due by period</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom">
        <div style="line-height: 1.25; font-weight: bold">Contractual Obligations</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom">
        <div style="text-align: center; line-height: 1.25; font-weight: bold">Total</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom">
        <div style="text-align: center; line-height: 1.25; font-weight: bold">Less than<br /> 1 year</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom">
        <div style="text-align: center; line-height: 1.25; font-weight: bold">1&#8201;-&#8201;3 years</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom">
        <div style="text-align: center; line-height: 1.25; font-weight: bold">3&#8201;-&#8201;5 years</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom">
        <div style="text-align: center; line-height: 1.25; font-weight: bold">More than<br /> 5 years</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom">
        <div style="line-height: 1.25">&#8203;</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom">&#160;</td>
    <td colspan="18" style="vertical-align: bottom; vertical-align: bottom">
        <div style="text-align: center; line-height: 1.25">(In thousands)</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom">&#160;</td> </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; background-color: #CCEEFF; width: 40%">
        <div style="line-height: 1.25">Operating leases for facility</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: #CCEEFF; vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25">$</div> </td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: #CCEEFF; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25">96</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: #CCEEFF; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: #CCEEFF; vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25">$</div> </td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: #CCEEFF; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25">96</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: #CCEEFF; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: #CCEEFF; vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25">$</div> </td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: #CCEEFF; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25">-</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: #CCEEFF; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: #CCEEFF; vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25">$</div> </td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: #CCEEFF; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25">-</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: #CCEEFF; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: #CCEEFF; vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25">$</div> </td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: #CCEEFF; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25">-</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: #CCEEFF; vertical-align: bottom; width: 1%">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; width: 40%; padding-bottom: 4px">
        <div style="line-height: 1.25">Total</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 4px">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 4px double; vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25">$</div> </td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 4px double; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25">96</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 4px">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 4px">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 4px double; vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25">$</div> </td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 4px double; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25">96</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 4px">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 4px">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 4px double; vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25">$</div> </td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 4px double; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25">-</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 4px">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 4px">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 4px double; vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25">$</div> </td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 4px double; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25">-</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 4px">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 4px">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 4px double; vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25">$</div> </td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 4px double; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25">-</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 4px">&#160;</td>
        </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold">Severance Obligations</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">We have long-term liabilities for severance pay that are calculated pursuant to Israeli
law generally based on the most recent salary of the relevant employees multiplied by the number of years of employment to the extent
not covered by our regular deposits with defined contribution plans. As of December 31, 2022, our severance pay liability, net was immaterial.
Because the timing of any such payments is not fixed and determinable, we have not included these liabilities in the table above.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold">Contingencies</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">We also have obligations to make future payments to third parties that become due
and payable on the achievement of certain milestones, such as royalties upon sale of products or revenues from the Amgen Agreement. We
have not included these commitments in our statements of financial position or in the table above because the achievement and timing of
these milestones is not fixed and determinable. These potential future commitments include a commitment to pay Oramed royalties equal
to 3% of our net revenues pursuant to the terms of the Patent Transfer Agreement between us and Oramed and a commitment to pay royalties
to the IIA<span style="font-weight: bold">.</span></div>

<div style="line-height: 1.25">&#160;</div>

<div style="line-height: 1.25; font-weight: bold">Critical Accounting Policies and Estimates</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">We prepare our consolidated financial statements in accordance with U.S. generally
accepted accounting principles, or GAAP. The preparation of consolidated financial statements also requires us to make estimates and assumptions
that affect the reported amounts of assets, liabilities, revenue, expenses and related disclosures. We base our estimates on historical
experience and on various other assumptions that we believe to be reasonable under the circumstances. Actual results could differ significantly
from the estimates made by our management. To the extent that there are differences between our estimates and actual results, our future
financial statement presentation, financial condition, results of operations and cash flows will be affected.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">While our significant accounting policies are more fully described in Note 2 to the
consolidated financial statements included elsewhere in this Annual Report on Form 10-K, we believe that the following accounting policies
are the most critical to assist shareholders and investors reading the consolidated financial statements in fully understanding and evaluating
our financial condition and results of operations. These policies relate to the more significant areas involving management&#8217;s judgments
and estimates and they require our most difficult, subjective or complex judgments, often as a result of the need to make estimates about
the effect of the matters that are inherently uncertain.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold">Revenue Recognition</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">With respect to the Amgen Agreement, we used our judgement to identify our deliverables
in the agreement and whether the deliverables are distinct performance obligation. In addition, we use our judgement to determine the
allocation of the transaction price between our identified distinct performance obligations. We also used significant judgment in order
to determine the R&amp;D services period. For a description of our revenue recognition policy see &#8220;Note 2-Summary of Significant
Accounting Policies-Revenue Recognition&#8221; of our audited consolidated financial statements for the year ended December 31, 2022,
included elsewhere in this Annual Report.</div>

<div style="line-height: 1.25"><br /> </div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold">Share-Based Compensation</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">In 2013 and in 2018, we adopted share-based compensation plans for employees, directors
and service providers. Our share-based compensation plan adopted in 2013 governs the issuance of equity incentive awards prior to our
initial public offering, and the share-based compensation plan adopted in 2018 governs the issuance of equity incentive awards from and
after the closing of our initial public offering. As part of the plans, we grant employees, directors and service providers, from time
to time and at our discretion, options to purchase our Ordinary Shares and restricted share units. The fair value of the services received
in exchange for the grant of the options is recognized as an expense in our statements of comprehensive loss with a corresponding adjustment
to equity in our statements of financial position. The total amount is recognized as an expense ratably over the service period of the
options, which is the period during which all vesting conditions are expected to be met.</div>

<div style="line-height: 1.25">&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal">87</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000" /></div>
</div>

<div style="text-align: justify; line-height: 1.25">We estimate the fair value of our share-based compensation to employees, directors
and service providers using the Black-Scholes option pricing model, which requires the input of highly subjective assumptions, including
(a) the expected volatility of our shares, (b) the expected term of the award, (c) the risk-free interest rate, (d) expected dividends
and (e) the fair value of our Ordinary Shares at the date of grant.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">The following table summarizes the allocation of our share-based compensation expense:</div>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" class="cfttable" style="font: 10pt Times New Roman, Times, serif; text-align: left; color: #000000; width: 100%">
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px">
        <div style="line-height: 1.25; font-weight: bold">&#8203;</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
    <td colspan="6" style="vertical-align: bottom; border-bottom: #000000 2px solid; vertical-align: bottom">
        <div style="text-align: center; line-height: 1.25; font-weight: bold">Year ended<br /> December 31,</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px">
        <div style="line-height: 1.25; font-weight: bold">&#8203;</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid; vertical-align: bottom">
        <div style="text-align: center; line-height: 1.25; font-weight: bold"> 2022</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid; vertical-align: bottom">
        <div style="text-align: center; line-height: 1.25; font-weight: bold">2021</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom">
        <div style="line-height: 1.25; font-weight: bold">&#8203;</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom">&#160;</td>
    <td colspan="6" style="vertical-align: bottom; vertical-align: bottom">
        <div style="text-align: center; line-height: 1.25; font-weight: bold">(in thousands)</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom">&#160;</td> </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; background-color: #CCEEFF; width: 76%">
        <div style="line-height: 1.25">Cost of revenues</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: #CCEEFF; vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25">$</div> </td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: #CCEEFF; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25">14</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: #CCEEFF; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: #CCEEFF; vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25">$</div> </td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: #CCEEFF; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25">102</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: #CCEEFF; vertical-align: bottom; width: 1%">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; width: 76%">
        <div style="line-height: 1.25">Research and development</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25">708</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25">661</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">&#160;</td> </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; background-color: #CCEEFF; width: 76%; padding-bottom: 2px">
        <div style="line-height: 1.25">General and administrative</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; border-bottom: #000000 2px solid; background-color: #CCEEFF; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; border-bottom: #000000 2px solid; background-color: #CCEEFF; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25">1,525</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: #CCEEFF; vertical-align: bottom; width: 1%; padding-bottom: 2px">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; border-bottom: #000000 2px solid; background-color: #CCEEFF; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; border-bottom: #000000 2px solid; background-color: #CCEEFF; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25">1,098</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: #CCEEFF; vertical-align: bottom; width: 1%; padding-bottom: 2px">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; width: 76%; padding-bottom: 4px">
        <div style="line-height: 1.25">Total</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 4px">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 4px double; vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25">$</div> </td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 4px double; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25">2,247</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 4px">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 4px">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 4px double; vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25">$</div> </td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 4px double; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25">1,861</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 4px">&#160;</td>
        </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-weight: bold">Recently Issued Accounting Pronouncements</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Certain recently issued accounting pronouncements are discussed in Note 2 to the consolidated
financial statements included elsewhere in this Annual Report on Form 10-K.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-weight: bold">Item 7A<span id="Item7A"><!--Anchor--></span>. &#160; &#160; &#160;
&#160; &#160; &#160; Quantitative and Qualitative Disclosures about Market Risk</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">&#160;</div>

<div style="line-height: 1.25">Not required for smaller reporting companies.</div>

<div style="line-height: 1.25"><br /> </div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal">88</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000" /></div>
</div>

<div style="line-height: 1.25"><br /> </div> </div>
<!-- Field: /Include-Text -->
</div>

<div>

<div>

<div style="font-family:'Times New Roman',Times,serif">

<div style="line-height:1.25">

<div style="line-height:1.25;text-align:center;margin-top:0px;margin-bottom:0px">&#160;</div> </div> </div>

<div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>

<div>

<div>

<table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">
  <tr>
    <td style="width:6%;vertical-align:top">
        <div style="line-height:1.25;font-weight:bold"><span id="ITEM8_integixAnchor"></span> <span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">ITEM
        8.</span></span></div> </td>
    <td style="width:94%;vertical-align:top">
        <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">FINANCIAL
        STATEMENTS AND SUPPLEMENTARY DATA</span></span></div> </td> </tr>
  </table>

<div style="text-align:center;line-height:1.25">&#160;</div>

<div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">ENTERA
BIO LTD.</span></span></div>

<div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">CONSOLIDATED
FINANCIAL STATEMENTS</span></span></div>

<div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">AS
OF DECEMBER 31, 2022</span></span></div>

<div style="line-height:1.25">&#160;</div>

<div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">TABLE
OF CONTENTS</span></span></div>

<div style="line-height:1.25">&#160;</div>

<table border="0" cellpadding="2" cellspacing="0" style="font-family:'Times New Roman',Times,serif;font-size:10pt;width:100%;text-align:left;color:rgb(0, 0, 0)">
  <tr>
    <td style="width:95.54%;vertical-align:top;padding-bottom:2px">
        <div style="line-height:1.25;font-family:'Times New Roman', Times, serif">&#160;</div> </td>
    <td style="width:4.46%;vertical-align:top;border-bottom:2px solid rgb(0, 0, 0)">
        <div style="text-align:center;line-height:1.25;font-family:'Times New Roman', Times, serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Page</span></span></div>
        </td> </tr>
  <tr>
    <td style="width:95.54%;vertical-align:top">
        <div style="line-height:1.25;font-family:'Times New Roman', Times, serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="#Report_integixAnchor">REPORT
        OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</a><span style="font-weight:normal"> (PCAOB ID No. <ix:nonNumeric id="Fxbrl_20230228173924484" name="dei:AuditorFirmId" contextRef="C_20220101to20221231">1309</ix:nonNumeric>)</span></span></span></div>
        </td>
    <td style="width:4.46%;vertical-align:top;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">90</span></span></td>
        </tr>
  <tr>
    <td style="width:95.54%;vertical-align:top">
        <div style="line-height:1.25;font-family:'Times New Roman', Times, serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">CONSOLIDATED
        FINANCIAL STATEMENTS:</span></span></div> </td>
    <td style="width:4.46%;vertical-align:top;text-align:right">&#160;</td> </tr>
  <tr>
    <td style="width:95.54%;vertical-align:top">
        <div style="margin-left:15.95pt;line-height:1.25;font-family:'Times New Roman', Times, serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="#BALANCESHEETS_integixAnchor">Consolidated
        Balance Sheets</a></span></span></div> </td>
    <td style="width:4.46%;vertical-align:top;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">91
        </span></span></td> </tr>
  <tr>
    <td style="width:95.54%;vertical-align:top">
        <div style="margin-left:15.95pt;line-height:1.25;font-family:'Times New Roman', Times, serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="#OPERATIONS_integixAnchor">Consolidated
        Statements of Operations</a></span></span></div> </td>
    <td style="width:4.46%;vertical-align:top;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">92</span></span></td>
        </tr>
  <tr>
    <td style="width:95.54%;vertical-align:top">
        <div style="margin-left:15.95pt;line-height:1.25;font-family:'Times New Roman', Times, serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="#HAREHOLDERSEQUITY_integixAnchor">Consolidated
        Statements of Changes in Shareholders' Equity</a></span></span></div> </td>
    <td style="width:4.46%;vertical-align:top;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">93</span></span></td>
        </tr>
  <tr>
    <td style="width:95.54%;vertical-align:top">
        <div style="margin-left:15.95pt;line-height:1.25;font-family:'Times New Roman', Times, serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="#CASH_integixAnchor">Consolidated
        Statements of Cash Flows</a></span></span></div> </td>
    <td style="width:4.46%;vertical-align:top;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">94</span></span></td>
        </tr>
  <tr>
    <td style="width:95.54%;vertical-align:top">
        <div style="margin-left:15.95pt;line-height:1.25;font-family:'Times New Roman', Times, serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="#NOTES_integixAnchor">Notes
        to the Consolidated Financial Statements</a></span></span></div> </td>
    <td style="width:4.46%;vertical-align:top;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">95</span></span></td>
        </tr>
  </table> </div> </div>

<div style="text-align:center;line-height:1.25;font-family:Times New Roman, Times, serif;margin-top:0px;margin-bottom:0px">&#160;</div>

<div style="text-align:center;line-height:1.25;font-family:Times New Roman, Times, serif;margin-top:10pt;margin-bottom:0px"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">89</span></span></div>

<div style="clear:both;margin-top:0pt;margin-bottom:0pt">

<div style="page-break-after:always;margin-bottom:0px"> <hr style="border-width:0px;clear:both;margin:4px 0px;width:100%;height:2px;color:#000000;margin-bottom:0px;background-color:#000000" />
</div> </div> </div> </div>

<p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman,Times,serif">&#160;</p>

<h3 style="text-align:center;margin-top:10pt;margin-bottom:0pt;text-align:center"><span id="Report_integixAnchor"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="line-height:normal;color:rgb(31, 55, 99);font-weight:normal"><strong><span><span>Report
of Independent Registered Public Accounting Firm</span></span></strong></span></span></span></span></h3>

<p style="margin-top:0pt;margin-bottom:0px;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>

<p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="line-height:normal"><span><span><span style="color:black">To
the</span></span></span><strong>&#160;</strong><span><span>Board of Directors and Shareholders of Entera Bio Ltd.</span></span></span></span></span></p>

<p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>

<p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="line-height:normal"><strong><i><span><span>Opinion
on the Financial Statements</span></span></i></strong></span></span></span></p>

<p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>

<p style="margin-top:0pt;margin-bottom:0pt;text-align:justify;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="line-height:normal"><span><span><span style="color:black">We
have audited the accompanying </span></span></span><span><span><span style="color:black">consolidated</span></span></span><strong>&#160;</strong><span><span><span style="color:black">balance
sheets</span></span></span><strong>&#160;</strong><span><span><span style="color:black">of </span></span></span><span><span><span style="color:black">Entera
Bio Ltd.</span></span></span>&#160;<span><span><span style="color:black">and its subsidiary</span></span></span><strong>&#160;</strong><span><span>(the
&#8220;Company&#8221;) as of <span style="color:black">December 31, 2022</span><span style="color:black"> and </span></span></span><span><span style="color:black">2021</span></span><span><span>,<strong>&#160;</strong><span style="color:black">and
the related </span><span style="color:black">consolidated</span><strong>&#160;</strong><span style="color:black">statements of operations,
changes in shareholders'&#160;equity and cash flows for the years then ended</span>,<strong>&#160;</strong><span style="color:black">including
the related notes (collectively referred to as the &#8220;</span><span style="color:black">consolidated</span><span style="color:black">
financial statements&#8221;). In our opinion, the </span><span style="color:black">consolidated</span><span style="color:black"> financial
statements present fairly, in all material respects, the financial position of the Company as of </span><span style="color:black">December</span><strong>&#160;</strong><span style="color:black">31,
2022</span><strong>&#160;</strong><span style="color:black">and </span><span style="color:black">2021</span><span style="color:black">,
and the results of</span><strong>&#160;</strong>its<strong>&#160;</strong><span style="color:black">operations and </span>its<strong>&#160;</strong><span style="color:black">cash
flows for the years then ended in conformity with accounting principles generally accepted in the United States of America. </span></span></span></span></span></span></p>

<p style="margin-top:0pt;margin-bottom:0pt;text-align:justify;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>

<p style="margin-top:0pt;margin-bottom:0pt;text-align:justify;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="line-height:normal"><i><span><span><span style="color:black">Substantial
Doubt About the Company&#8217;s Ability to Continue as a Going Concern</span></span></span></i></span></span></span></p>

<p style="margin-top:0pt;margin-bottom:0pt;text-align:justify;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>

<p style="margin-top:0pt;margin-bottom:0pt;text-align:justify;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="line-height:normal"><span><span><span style="color:black">The
accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern. As discussed
in note 1d to the consolidated financial statements, the Company has suffered recurring losses from operations and has cash outflows from
operating activities that raise substantial doubt about its ability to continue as a going concern. Management&#8217;s plans regarding
these matters are also described in note 1d. The consolidated financial statements do not include any adjustments that might result from
the outcome of this uncertainty.</span></span></span></span></span></span></p>

<p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>

<p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="line-height:normal"><strong><i><span><span><span style="color:black">Basis
for Opinion</span></span></span></i></strong></span></span></span></p>

<p style="margin-top:0pt;margin-bottom:0pt;text-align:justify;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>

<p style="margin-top:0pt;margin-bottom:0pt;text-align:justify;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="line-height:normal"><span><span><span style="color:black">These
</span></span></span><span><span><span style="color:black">consolidated</span></span></span>&#160;<span><span><span style="color:black">financial
statements are the responsibility of the Company's management. Our responsibility is to express an opinion on the Company&#8217;s </span></span></span><span><span><span style="color:black">consolidated</span></span></span><strong>&#160;</strong><span><span><span style="color:black">financial
statements based on our audits. </span></span></span><span><span><span style="color:black">We are a public accounting firm registered
with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company
in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission
and the PCAOB. </span></span></span></span></span></span></p>

<p style="margin-top:0pt;margin-bottom:0pt;text-align:justify;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>

<p style="margin-top:0pt;margin-bottom:0pt;text-align:justify;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="line-height:normal"><span><span><span style="color:black">We
conducted our audits of these </span></span></span><span><span><span style="color:black">consolidated</span></span></span><strong>&#160;</strong><span><span><span style="color:black">financial
statements in accordance with the standards </span></span></span><span><span><span style="color:black">of the PCAOB. Those standards require
that we plan and perform the audit to obtain reasonable assurance about whether the </span></span></span><span><span><span style="color:black">consolidated</span></span></span><span><span><span style="color:black">
financial statements are free of material misstatement, whether due to error or fraud.</span></span></span><i>&#160;</i><span><span><span style="color:black">The
Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of
our audits we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing
an opinion on the effectiveness of the Company's internal control over financial reporting. Accordingly, we express no such opinion</span></span></span><span><span>.</span></span></span></span></span></p>

<p style="margin-top:0pt;margin-bottom:0pt;text-align:justify;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>

<p style="margin-top:0pt;margin-bottom:11px;text-align:justify;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="line-height:107%"><span><span style="line-height:107%"><span><span style="color:black">Our
audits included performing </span></span></span></span><span><span style="line-height:107%"><span><span style="color:black">procedures
to assess the risks of material misstatement of the </span></span></span></span><span><span style="line-height:107%"><span><span style="color:black">consolidated</span></span></span></span><strong>&#160;</strong><span><span style="line-height:107%"><span><span style="color:black">financial
statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining,
on a test basis, evidence regarding the amounts and disclosures in the </span></span></span></span><span><span style="line-height:107%"><span><span style="color:black">consolidated</span></span></span></span><strong>&#160;</strong><span><span style="line-height:107%"><span><span style="color:black">financial
statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as
evaluating the overall presentation of the </span></span></span></span><span><span style="line-height:107%"><span><span style="color:black">consolidated</span></span></span></span><span><span style="line-height:107%"><span><span style="color:black">
financial statements. We believe that our audits provide a reasonable basis for our opinion.</span></span></span></span></span></span></span></p>

<table style="width:100%;border-collapse:collapse;border:0px">
  <tr>
    <td style="width:407px;padding:0in 0px 0in 0px;height:15px" valign="top">
        <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="line-height:115%"><span><span style="line-height:115%"><span>/s/<ix:nonNumeric id="Fxbrl_20230228173707325" name="dei:AuditorName" contextRef="C_20220101to20221231">Kesselman
        &#38; Kesselman</ix:nonNumeric></span></span></span></span></span></span></p> </td> </tr>
  <tr>
    <td style="width:407px;padding:0in 0px 0in 0px" valign="top">
        <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="line-height:12pt">Certified
        Public Accountants (lsr.)</span></span></span></p> </td> </tr>
  <tr>
    <td style="width:407px;padding:0in 0px 0in 0px" valign="top">
        <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="line-height:12pt">A
        member firm of PricewaterhouseCoopers International Limited</span></span></span></p> </td> </tr>
  </table>

<p style="margin-top:0pt;margin-right:6px;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>

<table style="width:100%;border-collapse:collapse;border:0px">
  <tr>
    <td style="width:406px;padding:0in 0px 0in 0px" valign="top">
        <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="line-height:12pt"><span><span><ix:nonNumeric id="Fxbrl_20230228173736195" name="dei:AuditorLocation" contextRef="C_20220101to20221231">Tel-Aviv,
        Israel</ix:nonNumeric></span></span></span></span></span></p> </td> </tr>
  <tr>
    <td style="width:406px;padding:0in 0px 0in 0px" valign="top">
        <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="line-height:12pt">March
        31, 2023</span></span></span></p> </td> </tr>
  <tr>
    <td style="width:406px;padding:0in 0px 0in 0px;height:4px" valign="top">
        <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p> </td> </tr>
  <tr>
    <td style="width:406px;padding:0in 0px 0in 0px" valign="top">
        <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="line-height:12pt"><span><span><span style="color:black">We
        have served as the Company&#8217;s auditor since 2010.</span></span></span></span></span></span></p> </td> </tr>
  </table>

<p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman, Times, serif;text-align:center">&#160;</p>

<p style="margin-top:10pt;margin-bottom:0pt;font-family:Times New Roman, Times, serif;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">90</span></span></p>

<div style="page-break-after:always"> <hr style="background:rgb(0, 0, 0);width:100%;border-top:2px solid black;margin-top:4pt;margin-bottom:10pt" />
</div>

<p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman,Times,serif">&#160;</p>

<div style="text-align:center;margin-top:0px"><span style="font-size:10pt;margin-bottom:0px"><span style="font-family:Times New Roman,Times,serif"><span><span><span style="line-height:normal"><strong><span><span>ENTERA
BIO LTD.</span></span></strong></span></span></span></span></span></div>

<div style="text-align:center;margin-top:0px;margin-bottom:0px"><span id="BALANCESHEETS_integixAnchor"></span>&#160;<span style="font-size:10pt;margin-bottom:0px"><span style="font-family:Times New Roman,Times,serif"><span><span><span style="line-height:normal"><strong><span><span>CONSOLIDATED
BALANCE SHEETS</span></span></strong></span></span></span></span></span></div>

<div style="text-align:center;margin-top:0px"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span style="line-height:normal;color:black">&#160;
&#160; &#160; (U.S. dollars in thousands, except share data)</span></span></span></span></span></div>

<div style="text-align:center;margin-top:0px">&#160;</div>

<div>

<div>

<div>

<div>

<table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left;color:#000000;width:100%">
  <tr>
    <td style="vertical-align:top;padding-bottom:2px" valign="bottom">
        <div style="text-align:center;line-height:1.25;font-weight:bold">&#160;</div> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td>
    <td colspan="6" style="vertical-align:top;border-bottom:#000000 solid 2px" valign="bottom">
        <div style="line-height:1.25">
        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">December
        31</span></span></div> </div> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td> </tr>
  <tr>
    <td style="vertical-align:top;padding-bottom:2px" valign="bottom">
        <div style="line-height:1.25;font-weight:bold">&#160;</div> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px" valign="bottom">
        <div style="line-height:1.25">
        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2022</span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px" valign="bottom">
        <div style="line-height:1.25">
        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2021</span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td> </tr>
  <tr>
    <td rowspan="1" style="vertical-align:top;width:76%;background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">A
        s s e t s</span></span></div> </td>
    <td colspan="1" rowspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" rowspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" rowspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" rowspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
    <td colspan="1" rowspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" rowspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" rowspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" rowspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
        </tr>
  <tr>
    <td rowspan="1" style="vertical-align:top;width:76%" valign="bottom">
        <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">CURRENT
        ASSETS:</span></span></div> </td>
    <td colspan="1" rowspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" rowspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" rowspan="1" style="vertical-align:bottom;text-align:right;width:9%" valign="bottom">&#160;</td>
    <td colspan="1" rowspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
    <td colspan="1" rowspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" rowspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" rowspan="1" style="vertical-align:bottom;text-align:right;width:9%" valign="bottom">&#160;</td>
    <td colspan="1" rowspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td> </tr>
  <tr>
    <td style="vertical-align:top;width:76%;background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="text-align:justify;text-indent:14.2pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Cash
        and cash equivalents</span></span></div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20220808213205256_xbrl_20220802012333935_xbrl_20220505162133424_xbrl_20220219060830028_33" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="C_20221231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">12,309</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20220808213205256_xbrl_20220802012333935_xbrl_20220505162133424_xbrl_20220219060830028_37" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="C_20211231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">24,892</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align:top;width:76%" valign="bottom">
        <div style="text-align:justify;text-indent:14.2pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Accounts
        receivable</span></span></div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20220808213205260_xbrl_20220802012333942_xbrl_20220505162133429_xbrl_20220219060830028_43" name="us-gaap:AccountsReceivableNetCurrent" contextRef="C_20221231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">246</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20220808213205260_xbrl_20220802012333942_xbrl_20220505162133429_xbrl_20220219060830028_47" name="us-gaap:AccountsReceivableNetCurrent" contextRef="C_20211231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">183</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td> </tr>
  <tr>
    <td style="vertical-align:top;width:76%;padding-bottom:2px;background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Other
        current assets</span></span></div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20220808213205265_xbrl_20220802012333948_xbrl_20220505162133433_xbrl_20220219060830028_53" name="us-gaap:OtherAssetsCurrent" contextRef="C_20221231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">294</ix:nonFraction></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20220808213205265_xbrl_20220802012333948_xbrl_20220505162133433_xbrl_20220219060830028_57" name="us-gaap:OtherAssetsCurrent" contextRef="C_20211231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">254</ix:nonFraction></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align:top;width:76%;padding-bottom:2px" valign="bottom">
        <div style="text-align:justify;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">TOTAL
        CURRENT ASSETS</span></span></div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0)" valign="bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20220808213205268_xbrl_20220802012333953_xbrl_20220505162133436_xbrl_20220219060830028_63" name="us-gaap:AssetsCurrent" contextRef="C_20221231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">12,849</ix:nonFraction></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0)" valign="bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20220808213205268_xbrl_20220802012333953_xbrl_20220505162133436_xbrl_20220219060830028_67" name="us-gaap:AssetsCurrent" contextRef="C_20211231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">25,329</ix:nonFraction></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td> </tr>
  <tr>
    <td style="vertical-align:top;width:76%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align:top;width:76%" valign="bottom">
        <div style="text-align:justify;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">NON-CURRENT
        ASSETS:</span></span></div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td> </tr>
  <tr>
    <td style="vertical-align:top;width:76%;background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="text-align:justify;text-indent:14.2pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Property
        and equipment, net</span></span></div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20220808213205274_xbrl_20220802012333958_xbrl_20220505162133439_xbrl_20220219060830028_83" name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="C_20221231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">139</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20220808213205274_xbrl_20220802012333958_xbrl_20220505162133439_xbrl_20220219060830028_87" name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="C_20211231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">156</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align:bottom;width:76%" valign="bottom">
        <div style="text-align:justify;text-indent:14.2pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Operating
        lease right-of-use assets</span></span></div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20220808213205277_xbrl_20220802012333963_xbrl_20220505162133441_xbrl_20220219060830028_93" name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="C_20221231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">90</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20220808213205277_xbrl_20220802012333963_xbrl_20220505162133441_xbrl_20220219060830028_97" name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="C_20211231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">239</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td> </tr>
  <tr>
    <td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Deferred income taxes</span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20220808213205281_xbrl_20220802012333968_xbrl_20220505162133444_xbrl_20220305102200651_xbrl_20220219060830028_93" name="us-gaap:DeferredIncomeTaxAssetsNet" contextRef="C_20221231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">43</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20220808213205281_xbrl_20220802012333968_xbrl_20220505162133444_xbrl_20220305102200651_xbrl_20220219060830028_97" name="us-gaap:DeferredIncomeTaxAssetsNet" contextRef="C_20211231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">217</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align:top;width:76%;padding-bottom:2px" valign="bottom">
        <div style="text-align:justify;text-indent:14.2pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Funds
        in respect of employee rights upon retirement</span></span></div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0)" valign="bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20220808213205284_xbrl_20220802012333974_xbrl_20220505162133446_xbrl_20220219060830028_103" name="us-gaap:DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent" contextRef="C_20221231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6</ix:nonFraction></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0)" valign="bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20220808213205284_xbrl_20220802012333974_xbrl_20220505162133446_xbrl_20220219060830028_107" name="us-gaap:DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent" contextRef="C_20211231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">46</ix:nonFraction></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td> </tr>
  <tr>
    <td style="vertical-align:top;width:76%;padding-bottom:2px;background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="text-align:justify;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">TOTAL
        NON-CURRENT ASSETS</span></span></div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20220808213205287_xbrl_20220802012333980_xbrl_20220505162133448_xbrl_20220219060830028_113" name="us-gaap:AssetsNoncurrent" contextRef="C_20221231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">278</ix:nonFraction></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20220808213205287_xbrl_20220802012333980_xbrl_20220505162133448_xbrl_20220219060830028_117" name="us-gaap:AssetsNoncurrent" contextRef="C_20211231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">658</ix:nonFraction></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align:top;width:76%;padding-bottom:4px" valign="bottom">
        <div style="text-align:justify;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">TOTAL
        ASSETS</span></span></div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0)" valign="bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20220808213205289_xbrl_20220802012333985_xbrl_20220505162133450_xbrl_20220219060830028_123" name="us-gaap:Assets" contextRef="C_20221231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">13,127</ix:nonFraction></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;white-space:nowrap" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0)" valign="bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20220808213205289_xbrl_20220802012333985_xbrl_20220505162133450_xbrl_20220219060830028_127" name="us-gaap:Assets" contextRef="C_20211231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">25,987</ix:nonFraction></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;white-space:nowrap" valign="bottom">&#160;</td> </tr>
  <tr>
    <td style="vertical-align:top;width:76%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align:top;width:76%" valign="bottom">
        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">L
        i a b i l i t i e s and shareholders' equity</span></span></div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td> </tr>
  <tr>
    <td style="vertical-align:top;width:76%;background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="text-align:justify;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">CURRENT
        LIABILITIES:</span></span></div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align:bottom;width:76%" valign="bottom">
        <div style="text-align:justify;margin-left:15.65pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Accounts
        payable</span></span></div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20220808213205292_xbrl_20220802012333989_xbrl_20220505162133452_xbrl_20220219060830028_153" name="us-gaap:AccountsPayableCurrent" contextRef="C_20221231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">17</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20220808213205292_xbrl_20220802012333989_xbrl_20220505162133452_xbrl_20220219060830028_157" name="us-gaap:AccountsPayableCurrent" contextRef="C_20211231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">166</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td> </tr>
  <tr>
    <td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="text-align:justify;margin-left:15.65pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Accrued
        expenses and other payables</span></span></div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20220808213205294_xbrl_20220802012333994_xbrl_20220505162133454_xbrl_20220219060830028_163" name="us-gaap:AccruedLiabilitiesAndOtherLiabilities" contextRef="C_20221231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,233</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20220808213205294_xbrl_20220802012333994_xbrl_20220505162133454_xbrl_20220219060830028_167" name="us-gaap:AccruedLiabilitiesAndOtherLiabilities" contextRef="C_20211231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,801</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align:bottom;width:76%" valign="bottom">
        <div style="text-align:justify;margin-left:1.9pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Current
        maturities of operating lease</span></span></div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20220808213205297_xbrl_20220802012333998_xbrl_20220505162133457_xbrl_20220219060830028_173" name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="C_20221231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">91</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20220808213205297_xbrl_20220802012333998_xbrl_20220505162133457_xbrl_20220219060830028_177" name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="C_20211231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">179</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td> </tr>
  <tr>
    <td style="vertical-align:bottom;width:76%;padding-bottom:2px;background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="text-align:justify;margin-left:15.65pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Contract
        liabilities</span></span></div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20220808213205299_xbrl_20220802012334004_xbrl_20220505162133458_xbrl_20220219060830028_183" name="us-gaap:ContractWithCustomerLiabilityCurrent" contextRef="C_20221231" unitRef="USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20220808213205299_xbrl_20220802012334004_xbrl_20220505162133458_xbrl_20220219060830028_187" name="us-gaap:ContractWithCustomerLiabilityCurrent" contextRef="C_20211231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">15</ix:nonFraction></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align:top;width:76%;padding-bottom:2px" valign="bottom">
        <div style="text-align:justify;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">TOTAL
        CURRENT LIABILITIES</span></span></div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0)" valign="bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20220808213205301_xbrl_20220802012334009_xbrl_20220505162133460_xbrl_20220219060830028_193" name="us-gaap:LiabilitiesCurrent" contextRef="C_20221231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,341</ix:nonFraction></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0)" valign="bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20220808213205301_xbrl_20220802012334009_xbrl_20220505162133460_xbrl_20220219060830028_197" name="us-gaap:LiabilitiesCurrent" contextRef="C_20211231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,161</ix:nonFraction></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td> </tr>
  <tr>
    <td style="vertical-align:top;width:76%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align:top;width:76%" valign="bottom">
        <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">NON-CURRENT
        LIABILITIES</span>:</span></span></div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td> </tr>
  <tr>
    <td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="text-align:justify;margin-left:15.55pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Operating
        lease liabilities</span></span></div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20220808213205304_xbrl_20220802012334015_xbrl_20220505162133462_xbrl_20220219060830028_213" name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="C_20221231" unitRef="USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20220808213205304_xbrl_20220802012334015_xbrl_20220505162133462_xbrl_20220219060830028_217" name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="C_20211231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">123</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align:bottom;width:76%;padding-bottom:2px" valign="bottom">
        <div style="text-align:justify;margin-left:15.55pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Liability
        for employee rights upon retirement</span></span></div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0)" valign="bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20220808213205306_xbrl_20220802012334021_xbrl_20220505162133465_xbrl_20220219060830028_223" name="us-gaap:PostemploymentBenefitsLiabilityNoncurrent" contextRef="C_20221231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">32</ix:nonFraction></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0)" valign="bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20220808213205306_xbrl_20220802012334021_xbrl_20220505162133465_xbrl_20220219060830028_227" name="us-gaap:PostemploymentBenefitsLiabilityNoncurrent" contextRef="C_20211231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">138</ix:nonFraction></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td> </tr>
  <tr>
    <td style="vertical-align:bottom;width:76%;padding-bottom:4px;background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="text-align:justify;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">TOTAL
        NON-CURRENT LIABILITIES</span></span></div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20220808213205308_xbrl_20220802012334025_xbrl_20220505162133467_xbrl_20220219060830028_233" name="us-gaap:LiabilitiesNoncurrent" contextRef="C_20221231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">32</ix:nonFraction></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20220808213205308_xbrl_20220802012334025_xbrl_20220505162133467_xbrl_20220219060830028_237" name="us-gaap:LiabilitiesNoncurrent" contextRef="C_20211231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">261</ix:nonFraction></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align:bottom;width:76%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td> </tr>
  <tr>
    <td style="vertical-align:top;width:76%;padding-bottom:2px;background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="text-align:justify;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">TOTAL
        LIABILITIES</span></span></div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20220808213205310_xbrl_20220802012334031_xbrl_20220505162133469_xbrl_20220219060830028_243" name="us-gaap:Liabilities" contextRef="C_20221231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,373</ix:nonFraction></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20220808213205310_xbrl_20220802012334031_xbrl_20220505162133469_xbrl_20220219060830028_247" name="us-gaap:Liabilities" contextRef="C_20211231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,422</ix:nonFraction></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align:top;width:76%" valign="bottom">
        <div style="text-align:justify;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">COMMITMENTS
        AND CONTINGENCIES</span></span></div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%" valign="bottom"><ix:nonFraction id="Fxbrl_20230330102150177" name="us-gaap:CommitmentsAndContingencies" contextRef="C_20221231" unitRef="USD" xsi:nil="true"></ix:nonFraction></td>
    <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%" valign="bottom"><ix:nonFraction id="Fxbrl_20230330102202454" name="us-gaap:CommitmentsAndContingencies" contextRef="C_20211231" unitRef="USD" xsi:nil="true"></ix:nonFraction></td>
    <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td> </tr>
  <tr>
    <td style="vertical-align:top;width:76%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align:top;width:76%" valign="bottom">
        <div style="text-align:justify;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">SHAREHOLDERS'
        EQUITY:</span></span></div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td> </tr>
  <tr>
    <td style="vertical-align:top;width:76%;background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="text-align:justify;margin-left:15.55pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Ordinary
        Shares, NIS <ix:nonFraction id="Fxbrl_20220809034950441" name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="C_20211231" unitRef="NIS_per_Share" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="Fxbrl_20220808214817829" name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="C_20221231" unitRef="NIS_per_Share" decimals="INF" format="ixt:num-dot-decimal">0.0000769</ix:nonFraction></ix:nonFraction>
        par value: Authorized - as of December 31, 2022 and December 31, 2021, <ix:nonFraction id="Fxbrl_20220809035007189" name="us-gaap:CommonStockSharesAuthorized" contextRef="C_20211231" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="Fxbrl_20220808214936276" name="us-gaap:CommonStockSharesAuthorized" contextRef="C_20221231" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">140,010,000</ix:nonFraction></ix:nonFraction>
        shares; issued and outstanding as of December 31, 2022, and December 31, 2021 <ix:nonFraction id="Fxbrl_20220809035046498" name="us-gaap:CommonStockSharesOutstanding" contextRef="C_20221231" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="Fxbrl_20220808215259598" name="us-gaap:CommonStockSharesIssued" contextRef="C_20221231" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">28,809,922</ix:nonFraction></ix:nonFraction>
        and <ix:nonFraction id="Fxbrl_20220809035103868" name="us-gaap:CommonStockSharesOutstanding" contextRef="C_20211231" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="Fxbrl_20220808215224028" name="us-gaap:CommonStockSharesIssued" contextRef="C_20211231" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">28,804,411</ix:nonFraction></ix:nonFraction>
        shares, respectively</span></span></div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="-sec-ix-hidden:Fxbrl_20220808213249447">*</span></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="-sec-ix-hidden:Fxbrl_20220808214617486">*</span></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align:top;width:76%" valign="bottom">
        <div style="text-align:justify;margin-left:15.55pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Additional
        paid-in capital</span></span></div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20220808213205314_xbrl_20220802012334039_xbrl_20220505162133472_xbrl_20220219060830028_283" name="us-gaap:AdditionalPaidInCapitalCommonStock" contextRef="C_20221231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">107,210</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20220808213205314_xbrl_20220802012334039_xbrl_20220505162133472_xbrl_20220219060830028_287" name="us-gaap:AdditionalPaidInCapitalCommonStock" contextRef="C_20211231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">104,950</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td> </tr>
  <tr>
    <td style="vertical-align:top;width:76%;background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="text-align:justify;margin-left:15.55pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Accumulated
        other comprehensive income</span></span></div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20220808213205316_xbrl_20220802012334043_xbrl_20220505162133474_xbrl_20220219060830028_293" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" contextRef="C_20221231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">41</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20220808213205316_xbrl_20220802012334043_xbrl_20220505162133474_xbrl_20220219060830028_297" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" contextRef="C_20211231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">41</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align:top;width:76%;padding-bottom:2px" valign="bottom">
        <div style="text-align:justify;margin-left:15.55pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Accumulated
        deficit</span></span></div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0)" valign="bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="Fxbrl_20220808213205318_xbrl_20220802012334047_xbrl_20220505162133476_xbrl_20220219060830028_303" name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="C_20221231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">95,497</ix:nonFraction></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;white-space:nowrap" valign="bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0)" valign="bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="Fxbrl_20220808213205318_xbrl_20220802012334047_xbrl_20220505162133476_xbrl_20220219060830028_307" name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="C_20211231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">82,426</ix:nonFraction></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;white-space:nowrap" valign="bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
        </div> </td> </tr>
  <tr>
    <td style="vertical-align:top;width:76%;padding-bottom:2px;background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="text-align:justify;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">TOTAL
        SHAREHOLDERS' EQUITY</span></span></div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20220808213205320_xbrl_20220802012334050_xbrl_20220505162133478_xbrl_20220219060830028_313" name="us-gaap:StockholdersEquity" contextRef="C_20221231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">11,754</ix:nonFraction></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20220808213205320_xbrl_20220802012334050_xbrl_20220505162133478_xbrl_20220219060830028_317" name="us-gaap:StockholdersEquity" contextRef="C_20211231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">22,565</ix:nonFraction></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align:top;width:76%;padding-bottom:2px" valign="bottom">
        <div style="text-align:justify;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">TOTAL
        LIABILITIES AND SHAREHOLDERS&#8217; EQUITY</span></span></div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0)" valign="bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20220808213205323_xbrl_20220802012334055_xbrl_20220505162133480_xbrl_20220219060830028_323" name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="C_20221231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">13,127</ix:nonFraction></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0)" valign="bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20220808213205323_xbrl_20220802012334055_xbrl_20220505162133480_xbrl_20220219060830028_327" name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="C_20211231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">25,987</ix:nonFraction></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td> </tr>
  </table> </div> </div>

<div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><br /><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">*
Represents an amount less than one thousand US dollars</span></span></div>

<div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>

<div style="line-height:1.25;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">The
accompanying notes are an integral part of the</span><span>&#160;</span><span style="font-weight:bold">unaudited condensed consolidated
financial statements.</span></span></span></div>

<div style="line-height:1.25;text-align:center">&#160;</div> </div> </div>

<div style="clear:both;margin-top:10pt;margin-bottom:0pt">

<div style="text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="color:#000000;font-weight:normal;font-style:normal">91</span></span></span></div>

<div style="page-break-after:always"><hr style="border-width:0px;clear:both;margin:4px 0px;width:100%;height:2px;color:#000000;background-color:#000000" /></div></div>

<p style="margin-top:0pt;margin-bottom:10pt;font-family:Times New Roman,Times,serif">&#160;</p>

<div style="margin-top:0pt">

<div>

<div style="text-align:center;line-height:1.25;font-family:Times New Roman, Times, serif">

<div style="margin-top:0pt;margin-bottom:0pt;text-align:center;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:center"><strong><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">ENTERA
BIO LTD.</span></span></strong></div>

<div>

<div>

<div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span id="OPERATIONS_integixAnchor"></span><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">CONSOLIDATED
STATEMENTS OF OPERATIONS</span></span></div>

<div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">&#160;
&#160; &#160;(U.S. dollars in thousands, except share and per share data)</span></span></div>

<div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>

<div>

<div>

<table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left;color:#000000;width:100%">
  <tr>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td>
    <td colspan="6" style="vertical-align:bottom;border-bottom:#000000 solid 2px" valign="bottom">
        <div style="line-height:1.25">
        <div style="text-align:center;line-height:1.25;font-weight:bold;text-indent:1pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Year
        ended December 31</span></span></div> </div> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td> </tr>
  <tr>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px" valign="bottom">
        <div style="line-height:1.25">
        <div style="text-align:center;line-height:1.25;font-weight:bold;text-indent:1pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2022</span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px" valign="bottom">
        <div style="line-height:1.25">
        <div style="text-align:center;line-height:1.25;font-weight:bold;text-indent:1pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2021</span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td> </tr>
  <tr>
    <td style="vertical-align:bottom" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align:bottom" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;white-space:nowrap" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align:bottom" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;white-space:nowrap" valign="bottom">&#160;</td> </tr>
  <tr>
    <td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="text-align:justify;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">REVENUES</span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20220218235908029_33" name="us-gaap:Revenues" contextRef="C_20220101to20221231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">134</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20220218235908029_37" name="us-gaap:Revenues" contextRef="C_20210101to20211231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">571</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align:bottom;width:76%;padding-bottom:2px" valign="bottom">
        <div style="text-align:justify;text-indent:-14.2pt;margin-left:15.9pt;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">COST
        OF REVENUES</span></span></div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0)" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20220218235908029_43" name="us-gaap:CostOfRevenue" contextRef="C_20220101to20221231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">101</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0)" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20220218235908029_47" name="us-gaap:CostOfRevenue" contextRef="C_20210101to20211231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">373</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td> </tr>
  <tr>
    <td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255);padding-bottom:2px" valign="bottom">
        <div style="text-align:justify;text-indent:-14.2pt;margin-left:15.9pt;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">GROSS
        PROFIT</span></span></div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);padding-bottom:2px" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);border-bottom:2px solid rgb(0, 0, 0)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);border-bottom:2px solid rgb(0, 0, 0)" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20220218235908029_53" name="us-gaap:GrossProfit" contextRef="C_20220101to20221231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">33</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);padding-bottom:2px" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);border-bottom:2px solid rgb(0, 0, 0)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);border-bottom:2px solid rgb(0, 0, 0)" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20220218235908029_57" name="us-gaap:GrossProfit" contextRef="C_20210101to20211231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">198</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align:bottom;width:76%" valign="bottom">
        <div style="text-align:justify;text-indent:-14.2pt;margin-left:15.9pt;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">OPERATING
        EXPENSES:</span></span></div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td> </tr>
  <tr>
    <td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="text-align:justify;margin-left:15.9pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Research
        and development</span></span></div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20220218235908029_73" name="us-gaap:ResearchAndDevelopmentExpense" contextRef="C_20220101to20221231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,848</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20220218235908029_77" name="us-gaap:ResearchAndDevelopmentExpense" contextRef="C_20210101to20211231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,771</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align:bottom;width:76%" valign="bottom">
        <div style="text-align:justify;margin-left:15.9pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">General
        and administrative</span></span></div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20220218235908029_83" name="us-gaap:GeneralAndAdministrativeExpense" contextRef="C_20220101to20221231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,253</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20220218235908029_87" name="us-gaap:GeneralAndAdministrativeExpense" contextRef="C_20210101to20211231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,690</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td> </tr>
  <tr>
    <td style="vertical-align:bottom;width:76%;padding-bottom:2px;background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="text-align:justify;margin-left:15.9pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Other
        income</span></span></div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="Fxbrl_20220218235908029_93" name="us-gaap:OtherNonrecurringIncome" contextRef="C_20220101to20221231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">51</ix:nonFraction></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="Fxbrl_20220218235908029_97" name="us-gaap:OtherNonrecurringIncome" contextRef="C_20210101to20211231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">46</ix:nonFraction></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
        </div> </td> </tr>
  <tr>
    <td style="vertical-align:bottom;width:76%;padding-bottom:2px" valign="bottom">
        <div style="text-align:justify;text-indent:-14.2pt;margin-left:15.9pt;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">TOTAL
        OPERATING EXPENSES</span></span></div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0)" valign="bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20220218235908029_103" name="us-gaap:OperatingExpenses" contextRef="C_20220101to20221231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">13,050</ix:nonFraction></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0)" valign="bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20220218235908029_107" name="us-gaap:OperatingExpenses" contextRef="C_20210101to20211231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">12,415</ix:nonFraction></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td> </tr>
  <tr>
    <td style="vertical-align:bottom;width:76%;padding-bottom:2px;background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="text-align:justify;text-indent:-14.2pt;margin-left:15.9pt;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">OPERATING
        LOSS</span></span></div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20220218235908029_113" name="us-gaap:OperatingIncomeLoss" contextRef="C_20220101to20221231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">13,017</ix:nonFraction></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20220218235908029_117" name="us-gaap:OperatingIncomeLoss" contextRef="C_20210101to20211231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">12,217</ix:nonFraction></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align:bottom;width:76%;padding-bottom:2px" valign="bottom">
        <div style="text-align:justify;text-indent:-14.2pt;margin-left:15.9pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">FINANCIAL
        EXPENSES (INCOME), </span>net</span></span></div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0)" valign="bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="Fxbrl_20230227103207504" name="us-gaap:NonoperatingIncomeExpense" contextRef="C_20220101to20221231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">83</ix:nonFraction></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;white-space:nowrap" valign="bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0)" valign="bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20220505170041902" name="us-gaap:NonoperatingIncomeExpense" contextRef="C_20210101to20211231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">29</ix:nonFraction></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td> </tr>
  <tr>
    <td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="text-align:justify;text-indent:-14.2pt;margin-left:15.9pt;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">LOSS
        BEFORE INCOME TAX</span></span></div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20220218235908029_143" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="C_20220101to20221231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">12,934</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20220218235908029_147" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="C_20210101to20211231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">12,246</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align:bottom;width:76%;padding-bottom:2px" valign="bottom">
        <div style="text-align:justify;text-indent:-14.2pt;margin-left:15.9pt;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">INCOME
        TAX EXPENSE (BENEFIT)</span></span></div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0)" valign="bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20220305103516954" name="us-gaap:IncomeTaxExpenseBenefit" contextRef="C_20220101to20221231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">137</ix:nonFraction></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0)" valign="bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="Fxbrl_20220218235908029_157" name="us-gaap:IncomeTaxExpenseBenefit" contextRef="C_20210101to20211231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">59</ix:nonFraction></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;white-space:nowrap" valign="bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
        </div> </td> </tr>
  <tr>
    <td style="vertical-align:bottom;width:76%;padding-bottom:4px;background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="text-align:justify;text-indent:-14.2pt;margin-left:15.9pt;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">NET
        LOSS</span></span></div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20220218235908029_163" name="us-gaap:NetIncomeLoss" contextRef="C_20220101to20221231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">13,071</ix:nonFraction></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20220218235908029_167" name="us-gaap:NetIncomeLoss" contextRef="C_20210101to20211231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">12,187</ix:nonFraction></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align:bottom;width:76%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td> </tr>
  <tr>
    <td style="vertical-align:bottom;width:76%;padding-bottom:4px;background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="text-align:justify;text-indent:-14.2pt;margin-left:15.9pt;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">LOSS
        PER SHARE BASIC AND DILUTED</span></span></div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20220809001710649" name="us-gaap:EarningsPerShareDiluted" contextRef="C_20220101to20221231" unitRef="USD_per_Share" scale="0" decimals="2" format="ixt:num-dot-decimal"><ix:nonFraction id="Fxbrl_20220218235908029_183" name="us-gaap:EarningsPerShareBasic" contextRef="C_20220101to20221231" unitRef="USD_per_Share" scale="0" decimals="2" format="ixt:num-dot-decimal">0.45</ix:nonFraction></ix:nonFraction></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20220809001731689" name="us-gaap:EarningsPerShareDiluted" contextRef="C_20210101to20211231" unitRef="USD_per_Share" scale="0" decimals="2" format="ixt:num-dot-decimal"><ix:nonFraction id="Fxbrl_20220218235908029_187" name="us-gaap:EarningsPerShareBasic" contextRef="C_20210101to20211231" unitRef="USD_per_Share" scale="0" decimals="2" format="ixt:num-dot-decimal">0.47</ix:nonFraction></ix:nonFraction></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align:bottom;width:76%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td> </tr>
  <tr>
    <td style="vertical-align:bottom;width:76%;padding-bottom:4px;background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="text-indent:-14.2pt;margin-left:15.9pt;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">WEIGHTED-AVERAGE
        NUMBER OF SHARES OUTSTANDING USED IN COMPUTATION OF BASIC AND DILUTED LOSS PER SHARE</span></span></div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20220809035336353" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="C_20220101to20221231" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="Fxbrl_20220218235908029_203" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="C_20220101to20221231" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">28,808,090</ix:nonFraction></ix:nonFraction></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20220809035344893" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="C_20210101to20211231" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="Fxbrl_20220218235908029_207" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="C_20210101to20211231" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">26,133,770</ix:nonFraction></ix:nonFraction></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
        </tr>
  </table> </div> </div>

<div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>

<div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">The
accompanying notes are an integral part of the</span><span>&#160;</span><span style="font-weight:bold">unaudited condensed consolidated
financial statements.</span></span></span></div>

<div style="line-height:1.25">&#160;</div> </div> </div>

<div>

<div style="margin-top:0pt;margin-bottom:0px;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:left">

<div style="clear:both;margin-top:10pt;margin-bottom:0pt">

<div style="text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="color:#000000;font-weight:normal;font-style:normal">92</span></span></span></div>

<div style="page-break-after:always"><hr style="border-width:0px;clear:both;margin:4px 0px;width:100%;height:2px;color:#000000;background-color:#000000" /></div></div>

<p style="margin-top:0pt;margin-bottom:10pt;font-family:Times New Roman,Times,serif">&#160;</p> </div> </div> </div> </div> </div>

<div style="text-align:center;font-size:10pt;margin-top:0pt;font-family:Times New Roman, Times, serif;text-align:center">

<p style="margin:0px 0pt 0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><strong style="font-size:10pt"><span style="line-height:107%">ENTERA
BIO LTD</span></strong></span></span></span></span></span></span></p> </div>

<div style="margin-top:0pt;margin-bottom:11px;text-align:center;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:center">
<div style="display:inline"> <div style="line-height:107%;display:inline"> <div style="display:inline"> <div style="display:inline"> <div style="font-size:10pt;font-family:Times New Roman, Times, serif;line-height:107%;display:inline">
<div style="display:inline"> <div style="display:inline"> <div style="font-weight:bold;display:inline"><span id="HAREHOLDERSEQUITY_integixAnchor"></span><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">&#160;<span><span><span><span>CONSOLIDATED
STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY</span></span></span></span></span></span></div>

<div>

<p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt">&#160; &#160; &#160; (U.S. dollars
in thousands, except share and per share data)</p> </div> </div> </div> </div> </div> </div> </div> </div> </div>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-top:0pt;text-align:left;color:#000000;width:100%" width="100%">
  <tr>
    <td style="vertical-align:bottom;padding-bottom:2px;font-family:'Times New Roman',Times,serif;white-space:nowrap" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-family:'Times New Roman',Times,serif;white-space:nowrap" valign="bottom">&#160;</td>
    <td colspan="6" rowspan="1" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);font-family:'Times New Roman',Times,serif" valign="bottom">
        <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><strong><span>Ordinary
        shares</span></strong></span></span></span></span></p> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-family:Times New Roman, Times, serif;white-space:nowrap;text-align:center" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-family:Times New Roman, Times, serif;white-space:nowrap;text-align:center" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align:bottom" valign="bottom">
        <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:center">&#160;</p> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-family:Times New Roman, Times, serif;white-space:nowrap;text-align:center" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-family:Times New Roman, Times, serif;white-space:nowrap;text-align:center" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align:bottom;font-family:Times New Roman, Times, serif" valign="bottom">
        <div style="line-height:1.25;font-weight:bold;text-align:center">&#160;</div> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-family:Times New Roman, Times, serif;white-space:nowrap;text-align:center" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-family:Times New Roman, Times, serif;text-align:center" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align:bottom;font-family:Times New Roman, Times, serif;text-align:center" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-family:Times New Roman, Times, serif;white-space:nowrap;text-align:center" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-family:Times New Roman, Times, serif;white-space:nowrap;text-align:center" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align:bottom;font-family:Times New Roman, Times, serif;text-align:center" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-family:'Times New Roman',Times,serif;white-space:nowrap" valign="bottom">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align:bottom;padding-bottom:2px;font-family:'Times New Roman',Times,serif;white-space:nowrap" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-family:'Times New Roman',Times,serif;white-space:nowrap" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);font-family:'Times New Roman',Times,serif" valign="bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25;font-weight:bold;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>Number
        of</span></span></span></span></span></span></div>
        <div style="line-height:1.25;font-weight:bold;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>shares&#160;issued</span></span></span></span></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-family:Times New Roman, Times, serif;white-space:nowrap;text-align:center" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-family:Times New Roman, Times, serif;text-align:center" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);font-family:'Times New Roman',Times,serif" valign="bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25;font-weight:bold;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>Amounts</span></span></span></span></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-family:Times New Roman, Times, serif;white-space:nowrap;text-align:center" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-family:Times New Roman, Times, serif;white-space:nowrap;text-align:center" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0)" valign="bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25;font-family:Georgia, serif;font-size:8pt;text-align:center"><span style="font-size:10pt;font-weight:bold;font-family:Times New Roman, Times, serif">Additional</span></div>
        <div style="line-height:1.25;font-family:Georgia, serif;font-size:8pt;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><span style="font-weight:bold">paid-in</span><span>&#160;</span></span></span></span></span></span></span></div>
        <div style="line-height:1.25;font-family:Georgia, serif;font-size:8pt;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><span><span style="font-weight:bold">capital</span></span></span></span></span></span></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-family:Times New Roman, Times, serif;white-space:nowrap;text-align:center" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-family:Times New Roman, Times, serif;white-space:nowrap;text-align:center" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);font-family:'Times New Roman',Times,serif" valign="bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25;font-weight:bold;text-align:center">
        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">Accumulated</span></div>
        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">other<br /><span style="font-size:10pt">Comprehensive</span></span></div>
        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>income</span></span></span></span></span></span></div>
        </div> </div> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-family:Times New Roman, Times, serif;white-space:nowrap;text-align:center" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-family:Times New Roman, Times, serif;text-align:center" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);font-family:'Times New Roman',Times,serif" valign="bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25;font-weight:bold;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>Accumulated</span></span></span></span></span></span></div>
        <div style="line-height:1.25;font-weight:bold;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>deficit</span></span></span></span></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-family:Times New Roman, Times, serif;white-space:nowrap;text-align:center" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-family:Times New Roman, Times, serif;white-space:nowrap;text-align:center" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);font-family:'Times New Roman',Times,serif" valign="bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25;font-weight:bold;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>Total</span></span></span></span></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-family:'Times New Roman',Times,serif;white-space:nowrap" valign="bottom">&#160;</td>
        </tr>
  <tr style="background-color:rgb(204, 238, 255)">
    <td style="vertical-align:bottom;font-family:Times New Roman, Times, serif;white-space:nowrap;width:28%;background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">BALANCE
        AT JANUARY 1, 2021</span></span></div> </td>
    <td colspan="1" style="vertical-align:bottom;font-family:Times New Roman, Times, serif;white-space:nowrap;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;font-family:Times New Roman, Times, serif;white-space:nowrap;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;font-family:Times New Roman, Times, serif;white-space:nowrap;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20220808214750699_xbrl_20220802040425371_20220801223211790_50" name="us-gaap:SharesOutstanding" contextRef="C_20201231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">21,057,922</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;font-family:Times New Roman, Times, serif;white-space:nowrap;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;font-family:Times New Roman, Times, serif;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;font-family:Times New Roman, Times, serif;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;font-family:Times New Roman, Times, serif;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="-sec-ix-hidden:Fxbrl_20220808214821452">*</span></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;font-family:Times New Roman, Times, serif;white-space:nowrap;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;font-family:Times New Roman, Times, serif;white-space:nowrap;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;font-family:Times New Roman, Times, serif;white-space:nowrap;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;font-family:Times New Roman, Times, serif;white-space:nowrap;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20220808214750699_xbrl_20220802040425371_20220801223211790_49" name="us-gaap:StockholdersEquity" contextRef="C_20201231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">77,708</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;font-family:Times New Roman, Times, serif;white-space:nowrap;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;font-family:Times New Roman, Times, serif;white-space:nowrap;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;font-family:Times New Roman, Times, serif;white-space:nowrap;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;font-family:Times New Roman, Times, serif;white-space:nowrap;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20220808214750699_xbrl_20220802040425371_20220801223211789_48" name="us-gaap:StockholdersEquity" contextRef="C_20201231_usgaapStatementEquityComponentsAxis_usgaapAccumulatedOtherComprehensiveIncomeMember" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">41</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;font-family:Times New Roman, Times, serif;white-space:nowrap;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;font-family:Times New Roman, Times, serif;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;font-family:Times New Roman, Times, serif;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;font-family:Times New Roman, Times, serif;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="Fxbrl_20220808214750699_xbrl_20220802040425371_20220801223211789_47" name="us-gaap:StockholdersEquity" contextRef="C_20201231_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">70,239</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;font-family:Times New Roman, Times, serif;white-space:nowrap;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;font-family:Times New Roman, Times, serif;white-space:nowrap;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;font-family:Times New Roman, Times, serif;white-space:nowrap;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;font-family:Times New Roman, Times, serif;white-space:nowrap;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20220808214750699_xbrl_20220802040425371_20220801223211788_46" name="us-gaap:StockholdersEquity" contextRef="C_20201231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,510</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;font-family:Times New Roman, Times, serif;white-space:nowrap;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
        </tr>
  <tr style="background-color:rgb(255, 255, 255)">
    <td style="vertical-align:bottom;font-family:Times New Roman, Times, serif;white-space:nowrap;width:28%;background-color:rgb(255, 255, 255)" valign="bottom">
        <div style="line-height:1.25;margin-left:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">&#160;
        Net loss</span></span></div> </td>
    <td colspan="1" style="vertical-align:bottom;font-family:Times New Roman, Times, serif;white-space:nowrap;width:1%;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;font-family:Times New Roman, Times, serif;white-space:nowrap;width:1%;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;font-family:Times New Roman, Times, serif;white-space:nowrap;width:9%;background-color:rgb(255, 255, 255)" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;font-family:Times New Roman, Times, serif;white-space:nowrap;width:1%;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;font-family:Times New Roman, Times, serif;width:1%;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;font-family:Times New Roman, Times, serif;width:1%;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;font-family:Times New Roman, Times, serif;width:9%;background-color:rgb(255, 255, 255)" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20220808213010731_xbrl_20220802040425275_20220801223211740_10" name="us-gaap:NetIncomeLoss" contextRef="C_20210101to20211231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;font-family:Times New Roman, Times, serif;white-space:nowrap;width:1%;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;font-family:Times New Roman, Times, serif;white-space:nowrap;width:1%;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;font-family:Times New Roman, Times, serif;white-space:nowrap;width:1%;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;font-family:Times New Roman, Times, serif;white-space:nowrap;width:9%;background-color:rgb(255, 255, 255)" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20220808213010731_xbrl_20220802040425275_20220801223211740_9" name="us-gaap:NetIncomeLoss" contextRef="C_20210101to20211231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember" unitRef="USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;font-family:Times New Roman, Times, serif;white-space:nowrap;width:1%;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;font-family:Times New Roman, Times, serif;white-space:nowrap;width:1%;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;font-family:Times New Roman, Times, serif;white-space:nowrap;width:1%;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;font-family:Times New Roman, Times, serif;white-space:nowrap;width:9%;background-color:rgb(255, 255, 255)" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20220808213010731_xbrl_20220802040425275_20220801223211739_8" name="us-gaap:NetIncomeLoss" contextRef="C_20210101to20211231_usgaapStatementEquityComponentsAxis_usgaapAccumulatedOtherComprehensiveIncomeMember" unitRef="USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;font-family:Times New Roman, Times, serif;white-space:nowrap;width:1%;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;font-family:Times New Roman, Times, serif;width:1%;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;font-family:Times New Roman, Times, serif;width:1%;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;font-family:Times New Roman, Times, serif;width:9%;background-color:rgb(255, 255, 255)" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="Fxbrl_20220808213010731_xbrl_20220802040425275_20220801223211739_7" name="us-gaap:NetIncomeLoss" contextRef="C_20210101to20211231_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">12,187</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;font-family:Times New Roman, Times, serif;white-space:nowrap;width:1%;background-color:rgb(255, 255, 255)" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;font-family:Times New Roman, Times, serif;white-space:nowrap;width:1%;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;font-family:Times New Roman, Times, serif;white-space:nowrap;width:1%;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;font-family:Times New Roman, Times, serif;white-space:nowrap;width:9%;background-color:rgb(255, 255, 255)" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="Fxbrl_20220808213010731_xbrl_20220802040425275_20220801223211738_6" name="us-gaap:NetIncomeLoss" contextRef="C_20210101to20211231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">12,187</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;font-family:Times New Roman, Times, serif;white-space:nowrap;width:1%;background-color:rgb(255, 255, 255)" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
        </td> </tr>
  <tr style="background-color:rgb(204, 238, 255)">
    <td style="vertical-align:bottom;font-family:Times New Roman, Times, serif;white-space:nowrap;width:28%;background-color:rgb(204, 238, 255)" valign="bottom">
        <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;margin-left:10pt"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">&#160;
        Exercise of warrants to ordinary shares</span></p> </td>
    <td colspan="1" style="vertical-align:bottom;font-family:Times New Roman, Times, serif;white-space:nowrap;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;font-family:Times New Roman, Times, serif;white-space:nowrap;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;font-family:Times New Roman, Times, serif;white-space:nowrap;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">
        <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><ix:nonFraction id="Fxbrl_20230227104420960" name="entx:ExerciseOfWarrantsShares" contextRef="C_20210101to20211231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">3,175,050</ix:nonFraction></p>
        </td>
    <td colspan="1" style="vertical-align:bottom;font-family:Times New Roman, Times, serif;white-space:nowrap;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;font-family:Times New Roman, Times, serif;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;font-family:Times New Roman, Times, serif;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;font-family:Times New Roman, Times, serif;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">
        <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt;line-height:107%;font-family:Georgia, serif"><span style="-sec-ix-hidden:Fxbrl_20230227104430880">*</span></span></p>
        </td>
    <td colspan="1" style="vertical-align:bottom;font-family:Times New Roman, Times, serif;white-space:nowrap;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;font-family:Times New Roman, Times, serif;white-space:nowrap;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;font-family:Times New Roman, Times, serif;white-space:nowrap;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;font-family:Times New Roman, Times, serif;white-space:nowrap;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">
        <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><ix:nonFraction id="Fxbrl_20230227104452135" name="entx:ExerciseOfWarrantsValue" contextRef="C_20210101to20211231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,158</ix:nonFraction></p>
        </td>
    <td colspan="1" style="vertical-align:bottom;font-family:Times New Roman, Times, serif;white-space:nowrap;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">
        <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt">&#160;</p> </td>
    <td colspan="1" style="vertical-align:bottom;font-family:Times New Roman, Times, serif;white-space:nowrap;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;font-family:Times New Roman, Times, serif;white-space:nowrap;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;font-family:Times New Roman, Times, serif;white-space:nowrap;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">
        <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><ix:nonFraction id="Fxbrl_20230227104616769" name="entx:ExerciseOfWarrantsValue" contextRef="C_20210101to20211231_usgaapStatementEquityComponentsAxis_usgaapAccumulatedOtherComprehensiveIncomeMember" unitRef="USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></p>
        </td>
    <td colspan="1" style="vertical-align:bottom;font-family:Times New Roman, Times, serif;white-space:nowrap;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;font-family:Times New Roman, Times, serif;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;font-family:Times New Roman, Times, serif;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;font-family:Times New Roman, Times, serif;width:9%;background-color:rgb(204, 238, 255)" valign="bottom"><ix:nonFraction id="Fxbrl_20230227104624778" name="entx:ExerciseOfWarrantsValue" contextRef="C_20210101to20211231_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember" unitRef="USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></td>
    <td colspan="1" style="vertical-align:bottom;font-family:Times New Roman, Times, serif;white-space:nowrap;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;font-family:Times New Roman, Times, serif;white-space:nowrap;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;font-family:Times New Roman, Times, serif;white-space:nowrap;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;font-family:Times New Roman, Times, serif;white-space:nowrap;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">
        <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><ix:nonFraction id="Fxbrl_20230227104635185" name="entx:ExerciseOfWarrantsValue" contextRef="C_20210101to20211231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,158</ix:nonFraction></p>
        </td>
    <td colspan="1" style="vertical-align:bottom;font-family:Times New Roman, Times, serif;white-space:nowrap;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
        </tr>
  <tr style="background-color:rgb(255, 255, 255)">
    <td style="vertical-align:bottom;font-family:Times New Roman, Times, serif;white-space:nowrap;width:28%;background-color:rgb(255, 255, 255)" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">&#160; &#160; &#160;
        Issuance of shares due to the ATM program, net of issuance costs</span></span></div> </td>
    <td colspan="1" style="vertical-align:bottom;font-family:Times New Roman, Times, serif;white-space:nowrap;width:1%;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;font-family:Times New Roman, Times, serif;white-space:nowrap;width:1%;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;font-family:Times New Roman, Times, serif;white-space:nowrap;width:9%;background-color:rgb(255, 255, 255)" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20220808213010746_xbrl_20220802040425293_20220801223211742_15" name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" contextRef="C_20210101to20211231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">4,386,728</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;font-family:Times New Roman, Times, serif;white-space:nowrap;width:1%;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;font-family:Times New Roman, Times, serif;width:1%;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;font-family:Times New Roman, Times, serif;width:1%;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;font-family:Times New Roman, Times, serif;width:9%;background-color:rgb(255, 255, 255)" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="-sec-ix-hidden:Fxbrl_20220808214839417">*</span></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;font-family:Times New Roman, Times, serif;white-space:nowrap;width:1%;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;font-family:Times New Roman, Times, serif;white-space:nowrap;width:1%;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;font-family:Times New Roman, Times, serif;white-space:nowrap;width:1%;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;font-family:Times New Roman, Times, serif;white-space:nowrap;width:9%;background-color:rgb(255, 255, 255)" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20220808213010746_xbrl_20220802040425293_20220801223211742_14" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" contextRef="C_20210101to20211231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">21,805</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;font-family:Times New Roman, Times, serif;white-space:nowrap;width:1%;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;font-family:Times New Roman, Times, serif;white-space:nowrap;width:1%;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;font-family:Times New Roman, Times, serif;white-space:nowrap;width:1%;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;font-family:Times New Roman, Times, serif;white-space:nowrap;width:9%;background-color:rgb(255, 255, 255)" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20220808213010746_xbrl_20220802040425293_20220801223211741_13" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" contextRef="C_20210101to20211231_usgaapStatementEquityComponentsAxis_usgaapAccumulatedOtherComprehensiveIncomeMember" unitRef="USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;font-family:Times New Roman, Times, serif;white-space:nowrap;width:1%;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;font-family:Times New Roman, Times, serif;width:1%;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;font-family:Times New Roman, Times, serif;width:1%;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;font-family:Times New Roman, Times, serif;width:9%;background-color:rgb(255, 255, 255)" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20220808213010746_xbrl_20220802040425293_20220801223211741_12" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" contextRef="C_20210101to20211231_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember" unitRef="USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;font-family:Times New Roman, Times, serif;white-space:nowrap;width:1%;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;font-family:Times New Roman, Times, serif;white-space:nowrap;width:1%;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;font-family:Times New Roman, Times, serif;white-space:nowrap;width:1%;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;font-family:Times New Roman, Times, serif;white-space:nowrap;width:9%;background-color:rgb(255, 255, 255)" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20220808213010746_xbrl_20220802040425293_20220801223211741_11" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" contextRef="C_20210101to20211231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">21,805</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;font-family:Times New Roman, Times, serif;white-space:nowrap;width:1%;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
        </tr>
  <tr style="background-color:rgb(204, 238, 255)">
    <td style="vertical-align:bottom;font-family:Times New Roman, Times, serif;white-space:nowrap;width:28%;background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="line-height:1.25;margin-left:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">&#160;
        Exercise of options to ordinary shares</span></span></div> </td>
    <td colspan="1" style="vertical-align:bottom;font-family:Times New Roman, Times, serif;white-space:nowrap;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;font-family:Times New Roman, Times, serif;white-space:nowrap;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;font-family:Times New Roman, Times, serif;white-space:nowrap;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20220808213010768_xbrl_20220802040425307_20220801223211753_21" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="C_20210101to20211231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">177,711</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;font-family:Times New Roman, Times, serif;white-space:nowrap;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;font-family:Times New Roman, Times, serif;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;font-family:Times New Roman, Times, serif;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;font-family:Times New Roman, Times, serif;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="-sec-ix-hidden:Fxbrl_20220808214942722">*</span></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;font-family:Times New Roman, Times, serif;white-space:nowrap;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;font-family:Times New Roman, Times, serif;white-space:nowrap;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;font-family:Times New Roman, Times, serif;white-space:nowrap;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;font-family:Times New Roman, Times, serif;white-space:nowrap;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20220808213010768_xbrl_20220802040425307_20220801223211752_20" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="C_20210101to20211231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">418</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;font-family:Times New Roman, Times, serif;white-space:nowrap;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;font-family:Times New Roman, Times, serif;white-space:nowrap;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;font-family:Times New Roman, Times, serif;white-space:nowrap;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;font-family:Times New Roman, Times, serif;white-space:nowrap;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20220808213010768_xbrl_20220802040425307_20220801223211752_19" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="C_20210101to20211231_usgaapStatementEquityComponentsAxis_usgaapAccumulatedOtherComprehensiveIncomeMember" unitRef="USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;font-family:Times New Roman, Times, serif;white-space:nowrap;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;font-family:Times New Roman, Times, serif;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;font-family:Times New Roman, Times, serif;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;font-family:Times New Roman, Times, serif;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20220808213010768_xbrl_20220802040425307_20220801223211743_18" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="C_20210101to20211231_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember" unitRef="USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;font-family:Times New Roman, Times, serif;white-space:nowrap;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;font-family:Times New Roman, Times, serif;white-space:nowrap;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;font-family:Times New Roman, Times, serif;white-space:nowrap;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;font-family:Times New Roman, Times, serif;white-space:nowrap;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20220808213010768_xbrl_20220802040425307_20220801223211743_17" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="C_20210101to20211231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">418</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;font-family:Times New Roman, Times, serif;white-space:nowrap;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
        </tr>
  <tr style="background-color:rgb(255, 255, 255)">
    <td style="vertical-align:bottom;font-family:Times New Roman, Times, serif;white-space:nowrap;width:28%;background-color:rgb(255, 255, 255)" valign="bottom">
        <div style="line-height:1.25;margin-left:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">&#160;
        Share-based compensation</span></span></div> </td>
    <td colspan="1" style="vertical-align:bottom;font-family:Times New Roman, Times, serif;white-space:nowrap;width:1%;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;font-family:Times New Roman, Times, serif;white-space:nowrap;width:1%;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;font-family:Times New Roman, Times, serif;white-space:nowrap;width:9%;background-color:rgb(255, 255, 255)" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;font-family:Times New Roman, Times, serif;white-space:nowrap;width:1%;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;font-family:Times New Roman, Times, serif;width:1%;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;font-family:Times New Roman, Times, serif;width:1%;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;font-family:Times New Roman, Times, serif;width:9%;background-color:rgb(255, 255, 255)" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20220808213010808_xbrl_20220802040425336_20220801223211758_33" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="C_20210101to20211231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;font-family:Times New Roman, Times, serif;white-space:nowrap;width:1%;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;font-family:Times New Roman, Times, serif;white-space:nowrap;width:1%;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;font-family:Times New Roman, Times, serif;white-space:nowrap;width:1%;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;font-family:Times New Roman, Times, serif;white-space:nowrap;width:9%;background-color:rgb(255, 255, 255)" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20220808213010808_xbrl_20220802040425336_20220801223211758_32" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="C_20210101to20211231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,861</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;font-family:Times New Roman, Times, serif;white-space:nowrap;width:1%;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;font-family:Times New Roman, Times, serif;white-space:nowrap;width:1%;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;font-family:Times New Roman, Times, serif;white-space:nowrap;width:1%;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;font-family:Times New Roman, Times, serif;white-space:nowrap;width:9%;background-color:rgb(255, 255, 255)" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20220808213010808_xbrl_20220802040425336_20220801223211757_31" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="C_20210101to20211231_usgaapStatementEquityComponentsAxis_usgaapAccumulatedOtherComprehensiveIncomeMember" unitRef="USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;font-family:Times New Roman, Times, serif;white-space:nowrap;width:1%;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;font-family:Times New Roman, Times, serif;width:1%;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;font-family:Times New Roman, Times, serif;width:1%;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;font-family:Times New Roman, Times, serif;width:9%;background-color:rgb(255, 255, 255)" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20220808213010808_xbrl_20220802040425336_20220801223211757_30" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="C_20210101to20211231_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember" unitRef="USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;font-family:Times New Roman, Times, serif;white-space:nowrap;width:1%;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;font-family:Times New Roman, Times, serif;white-space:nowrap;width:1%;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;font-family:Times New Roman, Times, serif;white-space:nowrap;width:1%;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;font-family:Times New Roman, Times, serif;white-space:nowrap;width:9%;background-color:rgb(255, 255, 255)" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20220808213010808_xbrl_20220802040425336_20220801223211756_29" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="C_20210101to20211231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,861</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;font-family:Times New Roman, Times, serif;white-space:nowrap;width:1%;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
        </tr>
  <tr style="background-color:rgb(204, 238, 255)">
    <td style="vertical-align:bottom;padding-bottom:2px;font-family:Times New Roman, Times, serif;white-space:nowrap;width:28%;background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="line-height:1.25;margin-left:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">&#160;
        Vested restricted share units</span></span></div> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-family:Times New Roman, Times, serif;white-space:nowrap;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);font-family:Times New Roman, Times, serif;white-space:nowrap;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;border-bottom:2px solid rgb(0, 0, 0);font-family:Times New Roman, Times, serif;white-space:nowrap;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20220808213010825_xbrl_20220802040425347_20220801223211778_39" name="entx:VestedRestrictedShareUnitsShares" contextRef="C_20210101to20211231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">7,000</ix:nonFraction></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-family:Times New Roman, Times, serif;white-space:nowrap;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-family:Times New Roman, Times, serif;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);font-family:Times New Roman, Times, serif;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;border-bottom:2px solid rgb(0, 0, 0);font-family:Times New Roman, Times, serif;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="-sec-ix-hidden:Fxbrl_20220808213010825_xbrl_20220802040425347_20220801223211777_38"><span>*</span></span></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-family:Times New Roman, Times, serif;white-space:nowrap;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-family:Times New Roman, Times, serif;white-space:nowrap;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);font-family:Times New Roman, Times, serif;white-space:nowrap;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;border-bottom:2px solid rgb(0, 0, 0);font-family:Times New Roman, Times, serif;white-space:nowrap;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20220808213010825_xbrl_20220802040425347_20220801223211777_37" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition" contextRef="C_20210101to20211231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember" unitRef="USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-family:Times New Roman, Times, serif;white-space:nowrap;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-family:Times New Roman, Times, serif;white-space:nowrap;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);font-family:Times New Roman, Times, serif;white-space:nowrap;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;border-bottom:2px solid rgb(0, 0, 0);font-family:Times New Roman, Times, serif;white-space:nowrap;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20220808213010825_xbrl_20220802040425347_20220801223211777_36" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition" contextRef="C_20210101to20211231_usgaapStatementEquityComponentsAxis_usgaapAccumulatedOtherComprehensiveIncomeMember" unitRef="USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-family:Times New Roman, Times, serif;white-space:nowrap;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-family:Times New Roman, Times, serif;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);font-family:Times New Roman, Times, serif;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;border-bottom:2px solid rgb(0, 0, 0);font-family:Times New Roman, Times, serif;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20220808213010825_xbrl_20220802040425347_20220801223211776_35" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition" contextRef="C_20210101to20211231_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember" unitRef="USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-family:Times New Roman, Times, serif;white-space:nowrap;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-family:Times New Roman, Times, serif;white-space:nowrap;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);font-family:Times New Roman, Times, serif;white-space:nowrap;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;border-bottom:2px solid rgb(0, 0, 0);font-family:Times New Roman, Times, serif;white-space:nowrap;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20220808213010825_xbrl_20220802040425347_20220801223211776_34" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition" contextRef="C_20210101to20211231" unitRef="USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-family:Times New Roman, Times, serif;white-space:nowrap;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
        </tr>
  <tr style="background-color:rgb(255, 255, 255)">
    <td style="vertical-align:bottom;padding-bottom:2px;font-family:Times New Roman, Times, serif;white-space:nowrap;width:28%;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-family:Times New Roman, Times, serif;white-space:nowrap;width:1%;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;font-family:Times New Roman, Times, serif;white-space:nowrap;width:1%;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;font-family:Times New Roman, Times, serif;white-space:nowrap;width:9%;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-family:Times New Roman, Times, serif;white-space:nowrap;width:1%;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-family:Times New Roman, Times, serif;width:1%;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;font-family:Times New Roman, Times, serif;width:1%;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;font-family:Times New Roman, Times, serif;width:9%;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-family:Times New Roman, Times, serif;white-space:nowrap;width:1%;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-family:Times New Roman, Times, serif;white-space:nowrap;width:1%;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;font-family:Times New Roman, Times, serif;white-space:nowrap;width:1%;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;font-family:Times New Roman, Times, serif;white-space:nowrap;width:9%;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-family:Times New Roman, Times, serif;white-space:nowrap;width:1%;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-family:Times New Roman, Times, serif;white-space:nowrap;width:1%;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;font-family:Times New Roman, Times, serif;white-space:nowrap;width:1%;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;font-family:Times New Roman, Times, serif;white-space:nowrap;width:9%;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-family:Times New Roman, Times, serif;white-space:nowrap;width:1%;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-family:Times New Roman, Times, serif;width:1%;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;font-family:Times New Roman, Times, serif;width:1%;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;font-family:Times New Roman, Times, serif;width:9%;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-family:Times New Roman, Times, serif;white-space:nowrap;width:1%;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-family:Times New Roman, Times, serif;white-space:nowrap;width:1%;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;font-family:Times New Roman, Times, serif;white-space:nowrap;width:1%;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;font-family:Times New Roman, Times, serif;white-space:nowrap;width:9%;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-family:Times New Roman, Times, serif;white-space:nowrap;width:1%;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
        </tr>
  <tr style="background-color:rgb(204, 238, 255)">
    <td style="vertical-align:bottom;padding-bottom:2px;font-family:Times New Roman, Times, serif;white-space:nowrap;width:28%;background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">BALANCE
        AT DECEMBER 31, 2021</span></span></div> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-family:Times New Roman, Times, serif;white-space:nowrap;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;font-family:Times New Roman, Times, serif;white-space:nowrap;width:1%;border-bottom:4px double black;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;font-family:Times New Roman, Times, serif;white-space:nowrap;width:9%;border-bottom:4px double black;background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20220808213010846_xbrl_20220802040425360_20220801223211788_44" name="us-gaap:SharesOutstanding" contextRef="C_20211231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">28,804,411</ix:nonFraction></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-family:Times New Roman, Times, serif;white-space:nowrap;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-family:Times New Roman, Times, serif;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;font-family:Times New Roman, Times, serif;width:1%;border-bottom:4px double black;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;font-family:Times New Roman, Times, serif;width:9%;border-bottom:4px double black;background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="-sec-ix-hidden:Fxbrl_20220808220722541">*</span></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-family:Times New Roman, Times, serif;white-space:nowrap;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-family:Times New Roman, Times, serif;white-space:nowrap;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;font-family:Times New Roman, Times, serif;white-space:nowrap;width:1%;border-bottom:4px double black;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;font-family:Times New Roman, Times, serif;white-space:nowrap;width:9%;border-bottom:4px double black;background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20220808213010846_xbrl_20220802040425360_20220801223211779_43" name="us-gaap:StockholdersEquity" contextRef="C_20211231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">104,950</ix:nonFraction></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-family:Times New Roman, Times, serif;white-space:nowrap;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-family:Times New Roman, Times, serif;white-space:nowrap;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;font-family:Times New Roman, Times, serif;white-space:nowrap;width:1%;border-bottom:4px double black;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;font-family:Times New Roman, Times, serif;white-space:nowrap;width:9%;border-bottom:4px double black;background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20220808213010846_xbrl_20220802040425360_20220801223211779_42" name="us-gaap:StockholdersEquity" contextRef="C_20211231_usgaapStatementEquityComponentsAxis_usgaapAccumulatedOtherComprehensiveIncomeMember" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">41</ix:nonFraction></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-family:Times New Roman, Times, serif;white-space:nowrap;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-family:Times New Roman, Times, serif;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;font-family:Times New Roman, Times, serif;width:1%;border-bottom:4px double black;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;font-family:Times New Roman, Times, serif;width:9%;border-bottom:4px double black;background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="Fxbrl_20220808213010846_xbrl_20220802040425360_20220801223211779_41" name="us-gaap:StockholdersEquity" contextRef="C_20211231_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">82,426</ix:nonFraction></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2.5pt;font-family:Times New Roman, Times, serif;white-space:nowrap;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-family:Times New Roman, Times, serif;white-space:nowrap;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;font-family:Times New Roman, Times, serif;white-space:nowrap;width:1%;border-bottom:4px double black;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;font-family:Times New Roman, Times, serif;white-space:nowrap;width:9%;border-bottom:4px double black;background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20220808213010846_xbrl_20220802040425360_20220801223211778_40" name="us-gaap:StockholdersEquity" contextRef="C_20211231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">22,565</ix:nonFraction></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-family:Times New Roman, Times, serif;white-space:nowrap;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
        </tr>
  <tr style="background-color:rgb(255, 255, 255)">
    <td style="vertical-align:bottom;font-family:Times New Roman, Times, serif;white-space:nowrap;width:28%;background-color:rgb(255, 255, 255)" valign="bottom">
        <div style="line-height:1.25;margin-left:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">&#160;
        Net loss</span></span></div> </td>
    <td colspan="1" style="vertical-align:bottom;font-family:Times New Roman, Times, serif;white-space:nowrap;width:1%;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;font-family:Times New Roman, Times, serif;white-space:nowrap;width:1%;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;font-family:Times New Roman, Times, serif;white-space:nowrap;width:9%;background-color:rgb(255, 255, 255)" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;font-family:Times New Roman, Times, serif;white-space:nowrap;width:1%;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;font-family:Times New Roman, Times, serif;width:1%;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;font-family:Times New Roman, Times, serif;width:1%;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;font-family:Times New Roman, Times, serif;width:9%;background-color:rgb(255, 255, 255)" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20220808213010872_xbrl_20220802040425392_20220801223211805_56" name="us-gaap:NetIncomeLoss" contextRef="C_20220101to20221231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;font-family:Times New Roman, Times, serif;white-space:nowrap;width:1%;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;font-family:Times New Roman, Times, serif;white-space:nowrap;width:1%;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;font-family:Times New Roman, Times, serif;white-space:nowrap;width:1%;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;font-family:Times New Roman, Times, serif;white-space:nowrap;width:9%;background-color:rgb(255, 255, 255)" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20220808213010872_xbrl_20220802040425392_20220801223211798_55" name="us-gaap:NetIncomeLoss" contextRef="C_20220101to20221231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember" unitRef="USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;font-family:Times New Roman, Times, serif;white-space:nowrap;width:1%;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;font-family:Times New Roman, Times, serif;white-space:nowrap;width:1%;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;font-family:Times New Roman, Times, serif;white-space:nowrap;width:1%;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;font-family:Times New Roman, Times, serif;white-space:nowrap;width:9%;background-color:rgb(255, 255, 255)" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20220808213010872_xbrl_20220802040425392_20220801223211791_54" name="us-gaap:NetIncomeLoss" contextRef="C_20220101to20221231_usgaapStatementEquityComponentsAxis_usgaapAccumulatedOtherComprehensiveIncomeMember" unitRef="USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;font-family:Times New Roman, Times, serif;white-space:nowrap;width:1%;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;font-family:Times New Roman, Times, serif;width:1%;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;font-family:Times New Roman, Times, serif;width:1%;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;font-family:Times New Roman, Times, serif;width:9%;background-color:rgb(255, 255, 255)" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="Fxbrl_20220808213010872_xbrl_20220802040425392_20220801223211791_53" name="us-gaap:NetIncomeLoss" contextRef="C_20220101to20221231_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">13,071</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;font-family:Times New Roman, Times, serif;white-space:nowrap;width:1%;background-color:rgb(255, 255, 255)" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;font-family:Times New Roman, Times, serif;white-space:nowrap;width:1%;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;font-family:Times New Roman, Times, serif;white-space:nowrap;width:1%;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;font-family:Times New Roman, Times, serif;white-space:nowrap;width:9%;background-color:rgb(255, 255, 255)" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="Fxbrl_20220808213010872_xbrl_20220802040425392_20220801223211791_52" name="us-gaap:NetIncomeLoss" contextRef="C_20220101to20221231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">13,071</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;font-family:Times New Roman, Times, serif;white-space:nowrap;width:1%;background-color:rgb(255, 255, 255)" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
        </td> </tr>
  <tr style="background-color:rgb(204, 238, 255)">
    <td style="vertical-align:bottom;font-family:Times New Roman, Times, serif;white-space:nowrap;width:28%;background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="line-height:1.25;margin-left:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">&#160;
        Exercise of options to ordinary shares</span></span></div> </td>
    <td colspan="1" style="vertical-align:bottom;font-family:Times New Roman, Times, serif;white-space:nowrap;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;font-family:Times New Roman, Times, serif;white-space:nowrap;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;font-family:Times New Roman, Times, serif;white-space:nowrap;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20220808213010900_xbrl_20220802045916318_xbrl_20220802040425307_20220801223211753_21" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="C_20220101to20221231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">5,511</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;font-family:Times New Roman, Times, serif;white-space:nowrap;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;font-family:Times New Roman, Times, serif;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;font-family:Times New Roman, Times, serif;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;font-family:Times New Roman, Times, serif;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="-sec-ix-hidden:Fxbrl_20220808220938448">*</span></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;font-family:Times New Roman, Times, serif;white-space:nowrap;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;font-family:Times New Roman, Times, serif;white-space:nowrap;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;font-family:Times New Roman, Times, serif;white-space:nowrap;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;font-family:Times New Roman, Times, serif;white-space:nowrap;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20220808213010900_xbrl_20220802045916318_xbrl_20220802040425307_20220801223211752_20" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="C_20220101to20221231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">13</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;font-family:Times New Roman, Times, serif;white-space:nowrap;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;font-family:Times New Roman, Times, serif;white-space:nowrap;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;font-family:Times New Roman, Times, serif;white-space:nowrap;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;font-family:Times New Roman, Times, serif;white-space:nowrap;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20220808213010900_xbrl_20220802045916318_xbrl_20220802040425307_20220801223211752_19" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="C_20220101to20221231_usgaapStatementEquityComponentsAxis_usgaapAccumulatedOtherComprehensiveIncomeMember" unitRef="USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;font-family:Times New Roman, Times, serif;white-space:nowrap;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;font-family:Times New Roman, Times, serif;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;font-family:Times New Roman, Times, serif;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;font-family:Times New Roman, Times, serif;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20220808213010900_xbrl_20220802045916318_xbrl_20220802040425307_20220801223211743_18" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="C_20220101to20221231_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember" unitRef="USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;font-family:Times New Roman, Times, serif;white-space:nowrap;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;font-family:Times New Roman, Times, serif;white-space:nowrap;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;font-family:Times New Roman, Times, serif;white-space:nowrap;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;font-family:Times New Roman, Times, serif;white-space:nowrap;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20220808213010900_xbrl_20220802045916318_xbrl_20220802040425307_20220801223211743_17" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="C_20220101to20221231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">13</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;font-family:Times New Roman, Times, serif;white-space:nowrap;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
        </tr>
  <tr style="background-color:rgb(255, 255, 255)">
    <td style="vertical-align:bottom;padding-bottom:2px;font-family:Times New Roman, Times, serif;white-space:nowrap;width:28%;background-color:rgb(255, 255, 255)" valign="bottom">
        <div style="line-height:1.25;margin-left:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">&#160;
        Share-based compensation</span></span></div> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-family:Times New Roman, Times, serif;white-space:nowrap;width:1%;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);font-family:Times New Roman, Times, serif;white-space:nowrap;width:1%;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;border-bottom:2px solid rgb(0, 0, 0);font-family:Times New Roman, Times, serif;white-space:nowrap;width:9%;background-color:rgb(255, 255, 255)" valign="bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-family:Times New Roman, Times, serif;white-space:nowrap;width:1%;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-family:Times New Roman, Times, serif;width:1%;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);font-family:Times New Roman, Times, serif;width:1%;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;border-bottom:2px solid rgb(0, 0, 0);font-family:Times New Roman, Times, serif;width:9%;background-color:rgb(255, 255, 255)" valign="bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20220808213010926_xbrl_20220802040425404_20220801223211821_61" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="C_20220101to20221231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-family:Times New Roman, Times, serif;white-space:nowrap;width:1%;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-family:Times New Roman, Times, serif;white-space:nowrap;width:1%;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);font-family:Times New Roman, Times, serif;white-space:nowrap;width:1%;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;border-bottom:2px solid rgb(0, 0, 0);font-family:Times New Roman, Times, serif;white-space:nowrap;width:9%;background-color:rgb(255, 255, 255)" valign="bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20220808213010926_xbrl_20220802040425404_20220801223211820_60" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="C_20220101to20221231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,247</ix:nonFraction></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-family:Times New Roman, Times, serif;white-space:nowrap;width:1%;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-family:Times New Roman, Times, serif;white-space:nowrap;width:1%;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);font-family:Times New Roman, Times, serif;white-space:nowrap;width:1%;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;border-bottom:2px solid rgb(0, 0, 0);font-family:Times New Roman, Times, serif;white-space:nowrap;width:9%;background-color:rgb(255, 255, 255)" valign="bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20220808213010926_xbrl_20220802040425404_20220801223211820_59" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="C_20220101to20221231_usgaapStatementEquityComponentsAxis_usgaapAccumulatedOtherComprehensiveIncomeMember" unitRef="USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-family:Times New Roman, Times, serif;white-space:nowrap;width:1%;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-family:Times New Roman, Times, serif;width:1%;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);font-family:Times New Roman, Times, serif;width:1%;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;border-bottom:2px solid rgb(0, 0, 0);font-family:Times New Roman, Times, serif;width:9%;background-color:rgb(255, 255, 255)" valign="bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20220808213010926_xbrl_20220802040425404_20220801223211806_58" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="C_20220101to20221231_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember" unitRef="USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-family:Times New Roman, Times, serif;white-space:nowrap;width:1%;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-family:Times New Roman, Times, serif;white-space:nowrap;width:1%;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);font-family:Times New Roman, Times, serif;white-space:nowrap;width:1%;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;border-bottom:2px solid rgb(0, 0, 0);font-family:Times New Roman, Times, serif;white-space:nowrap;width:9%;background-color:rgb(255, 255, 255)" valign="bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20220808213010926_xbrl_20220802040425404_20220801223211806_57" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="C_20220101to20221231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,247</ix:nonFraction></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-family:Times New Roman, Times, serif;white-space:nowrap;width:1%;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
        </tr>
  <tr style="background-color:rgb(204, 238, 255)">
    <td style="vertical-align:bottom;padding-bottom:2px;font-family:Times New Roman, Times, serif;white-space:nowrap;width:28%;background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">BALANCE
        AT DECEMBER 31, 2022</span></span></div> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-family:Times New Roman, Times, serif;white-space:nowrap;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;font-family:Times New Roman, Times, serif;white-space:nowrap;width:1%;border-bottom:4px double black;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;font-family:Times New Roman, Times, serif;white-space:nowrap;width:9%;border-bottom:4px double black;background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20220808213010940_xbrl_20220802040425417_20220801223211822_66" name="us-gaap:SharesOutstanding" contextRef="C_20221231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">28,809,922</ix:nonFraction></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-family:Times New Roman, Times, serif;white-space:nowrap;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-family:Times New Roman, Times, serif;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;font-family:Times New Roman, Times, serif;width:1%;border-bottom:4px double black;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;font-family:Times New Roman, Times, serif;width:9%;border-bottom:4px double black;background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="-sec-ix-hidden:Fxbrl_20220808221051935">*</span></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-family:Times New Roman, Times, serif;white-space:nowrap;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-family:Times New Roman, Times, serif;white-space:nowrap;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;font-family:Times New Roman, Times, serif;white-space:nowrap;width:1%;border-bottom:4px double black;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;font-family:Times New Roman, Times, serif;white-space:nowrap;width:9%;border-bottom:4px double black;background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20220808213010940_xbrl_20220802040425417_20220801223211822_65" name="us-gaap:StockholdersEquity" contextRef="C_20221231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">107,210</ix:nonFraction></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-family:Times New Roman, Times, serif;white-space:nowrap;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-family:Times New Roman, Times, serif;white-space:nowrap;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;font-family:Times New Roman, Times, serif;white-space:nowrap;width:1%;border-bottom:4px double black;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;font-family:Times New Roman, Times, serif;white-space:nowrap;width:9%;border-bottom:4px double black;background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20220808213010940_xbrl_20220802040425417_20220801223211822_64" name="us-gaap:StockholdersEquity" contextRef="C_20221231_usgaapStatementEquityComponentsAxis_usgaapAccumulatedOtherComprehensiveIncomeMember" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">41</ix:nonFraction></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-family:Times New Roman, Times, serif;white-space:nowrap;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-family:Times New Roman, Times, serif;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;font-family:Times New Roman, Times, serif;width:1%;border-bottom:4px double black;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;font-family:Times New Roman, Times, serif;width:9%;border-bottom:4px double black;background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="Fxbrl_20220808213010940_xbrl_20220802040425417_20220801223211821_63" name="us-gaap:StockholdersEquity" contextRef="C_20221231_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">95,497</ix:nonFraction></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2.5pt;font-family:Times New Roman, Times, serif;white-space:nowrap;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-family:Times New Roman, Times, serif;white-space:nowrap;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;font-family:Times New Roman, Times, serif;white-space:nowrap;width:1%;border-bottom:4px double black;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;font-family:Times New Roman, Times, serif;white-space:nowrap;width:9%;border-bottom:4px double black;background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20220808213010940_xbrl_20220802040425417_20220801223211821_62" name="us-gaap:StockholdersEquity" contextRef="C_20221231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">11,754</ix:nonFraction></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-family:Times New Roman, Times, serif;white-space:nowrap;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
        </tr>
  </table>

<div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>

<div style="line-height:1.25;font-family:Georgia, serif;font-size:9pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>*

    <ix:footnote id="FN20220808221358290" xml:lang="en-US">Represents an amount less than one thousand US dollars.</ix:footnote></span></span></span></div>

                    <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>

                    <div style="line-height:1.25;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">The
                    accompanying notes are an integral part of the</span><span>&#160;</span><span style="font-weight:bold">unaudited condensed consolidated
                    financial statements.</span></span></span></div>

                    <div style="line-height:1.25;text-align:center">&#160;</div>

                    <div style="margin-top:0pt;margin-bottom:0px;font-size:10pt;font-family:Times New Roman, Times, serif">

                    <div style="clear:both;margin-top:10pt;margin-bottom:0pt">

                    <div style="text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="color:#000000;font-weight:normal;font-style:normal">93</span></span></span></div>

                    <div style="page-break-after:always"><hr style="border-width:0px;clear:both;margin:4px 0px;width:100%;height:2px;color:#000000;background-color:#000000" /></div></div>
                    </div>

<p style="margin-top:0pt;margin-bottom:10pt;font-family:Times New Roman,Times,serif">&#160;</p>

                    <div style="text-align:center;font-size:10pt;font-family:Times New Roman, Times, serif"><strong><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">ENTERA
                    BIO LTD.</span></span></strong></div>

                    <div>

                    <div>

                    <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span id="CASH_integixAnchor"></span><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">CONSOLIDATED
                    STATEMENTS OF CASH FLOWS</span></span></div>

                    <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(U.S.
                    dollars in thousands)</span></span></div>

                    <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>

                    <div>

                    <div>

                    <table cellpadding="0" cellspacing="0" style="width:100%">
  <tr>
    <td style="vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td>
    <td colspan="6" style="vertical-align:top;border-bottom:#000000 solid 2px" valign="bottom">
        <div style="line-height:1.25">
        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Year
        ended December 31</span></span></div> </div> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td> </tr>
  <tr>
    <td style="vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px" valign="bottom">
        <div style="line-height:1.25">
        <div style="text-align:center;line-height:1.25;font-weight:bold;text-indent:1pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2022</span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px" valign="bottom">
        <div style="line-height:1.25">
        <div style="text-align:center;line-height:1.25;font-weight:bold;text-indent:1pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2021</span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td> </tr>
  <tr>
    <td style="vertical-align:top;background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="text-indent:-15.95pt;margin-left:15.95pt;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">CASH
        FLOWS FROM OPERATING ACTIVITIES:</span></span></div> </td>
    <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td> </tr>
  <tr>
    <td style="vertical-align:top;width:76%" valign="bottom">
        <div style="text-indent:-14.2pt;margin-left:30.15pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Net
        loss</span></span></div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="Fxbrl_20220219041121835_33" name="us-gaap:NetIncomeLoss" contextRef="C_20220101to20221231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">13,071</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;white-space:nowrap;width:1%" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="Fxbrl_20220219041121835_37" name="us-gaap:NetIncomeLoss" contextRef="C_20210101to20211231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">12,187</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;white-space:nowrap;width:1%" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
        </td> </tr>
  <tr>
    <td style="vertical-align:top;background-color:rgb(204, 238, 255);width:76%" valign="bottom">
        <div style="text-indent:-14.2pt;margin-left:30.15pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Adjustments
        required to reconcile net loss to net cash used in operating activities:</span></span></div> </td>
    <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;background-color:rgb(204, 238, 255);width:9%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);white-space:nowrap;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;background-color:rgb(204, 238, 255);width:9%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);white-space:nowrap;width:1%" valign="bottom">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align:top;width:76%" valign="bottom">
        <div style="text-indent:0.4pt;margin-left:30.15pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Depreciation</span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20220219041121835_63" name="us-gaap:Depreciation" contextRef="C_20220101to20221231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">64</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;white-space:nowrap;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20220219041121835_67" name="us-gaap:Depreciation" contextRef="C_20210101to20211231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">53</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;white-space:nowrap;width:1%" valign="bottom">&#160;</td> </tr>
  <tr>
    <td style="vertical-align:top;background-color:rgb(204, 238, 255);width:76%" valign="bottom">
        <div style="text-indent:0.4pt;margin-left:30.15pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Deferred
        income taxes</span></span></div> </td>
    <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;background-color:rgb(204, 238, 255);width:9%" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20220305111909474_xbrl_20220219041121835_63" name="us-gaap:DeferredIncomeTaxExpenseBenefit" contextRef="C_20220101to20221231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">174</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);white-space:nowrap;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;background-color:rgb(204, 238, 255);width:9%" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="Fxbrl_20220305111909474_xbrl_20220219041121835_67" name="us-gaap:DeferredIncomeTaxExpenseBenefit" contextRef="C_20210101to20211231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">217</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);white-space:nowrap;width:1%" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
        </td> </tr>
  <tr>
    <td style="vertical-align:top;width:76%" valign="bottom">
        <div style="text-indent:0.4pt;margin-left:30.15pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Share-based
        compensation</span></span></div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20220219041121835_83" name="us-gaap:ShareBasedCompensation" contextRef="C_20220101to20221231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,247</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;white-space:nowrap;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20220219041121835_87" name="us-gaap:ShareBasedCompensation" contextRef="C_20210101to20211231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,861</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;white-space:nowrap;width:1%" valign="bottom">&#160;</td> </tr>
  <tr>
    <td style="vertical-align:top;background-color:rgb(204, 238, 255);width:76%" valign="bottom">
        <div style="text-align:justify;text-indent:0.4pt;margin-left:30.15pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Finance
        expenses (income), net</span></span></div> </td>
    <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;background-color:rgb(204, 238, 255);width:9%" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="Fxbrl_20220219041121835_103" name="entx:FinanceExpensesNet" contextRef="C_20220101to20221231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">78</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);white-space:nowrap;width:1%" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;background-color:rgb(204, 238, 255);width:9%" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20220219041121835_107" name="entx:FinanceExpensesNet" contextRef="C_20210101to20211231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">18</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);white-space:nowrap;width:1%" valign="bottom">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align:top;width:76%" valign="bottom">
        <div style="text-indent:0.4pt;margin-left:15.95pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Changes
        in operating asset and liabilities:</span></span></div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;white-space:nowrap;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;white-space:nowrap;width:1%" valign="bottom">&#160;</td> </tr>
  <tr>
    <td style="vertical-align:top;background-color:rgb(204, 238, 255);width:76%" valign="bottom">
        <div style="text-indent:0.4pt;margin-left:30.1pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Decrease
        (increase) in accounts receivable</span></span></div> </td>
    <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;background-color:rgb(204, 238, 255);width:9%" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="Fxbrl_20220219041121835_123" name="us-gaap:IncreaseDecreaseInAccountsReceivable" contextRef="C_20220101to20221231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">63</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);white-space:nowrap;width:1%" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;background-color:rgb(204, 238, 255);width:9%" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20220219041121835_127" name="us-gaap:IncreaseDecreaseInAccountsReceivable" contextRef="C_20210101to20211231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">72</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);white-space:nowrap;width:1%" valign="bottom">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align:top;width:76%" valign="bottom">
        <div style="text-indent:0.4pt;margin-left:30.1pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Decrease
        (increase) in other current assets</span></span></div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="Fxbrl_20220219041121835_133" name="us-gaap:IncreaseDecreaseInOtherCurrentAssets" contextRef="C_20220101to20221231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">40</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;white-space:nowrap;width:1%" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20220219041121835_137" name="us-gaap:IncreaseDecreaseInOtherCurrentAssets" contextRef="C_20210101to20211231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">7</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;white-space:nowrap;width:1%" valign="bottom">&#160;</td> </tr>
  <tr>
    <td style="vertical-align:top;background-color:rgb(204, 238, 255);width:76%" valign="bottom">
        <div style="text-indent:0.4pt;margin-left:30.1pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Increase
        (decrease) in accounts payable</span></span></div> </td>
    <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;background-color:rgb(204, 238, 255);width:9%" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="Fxbrl_20230227113240554" name="us-gaap:IncreaseDecreaseInAccountsPayable" contextRef="C_20220101to20221231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">149</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);white-space:nowrap;width:1%" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;background-color:rgb(204, 238, 255);width:9%" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20220219041121835_147" name="us-gaap:IncreaseDecreaseInAccountsPayable" contextRef="C_20210101to20211231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);white-space:nowrap;width:1%" valign="bottom">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align:top;width:76%" valign="bottom">
        <div style="text-indent:-8.3pt;margin-left:38.8pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Increase
        (decrease) in accrued expenses and other payables</span></span></div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="Fxbrl_20220219041121835_153" name="us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" contextRef="C_20220101to20221231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">1,568</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;white-space:nowrap;width:1%" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20220219041121835_157" name="us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" contextRef="C_20210101to20211231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,471</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;white-space:nowrap;width:1%" valign="bottom">&#160;</td> </tr>
  <tr>
    <td style="vertical-align:top;padding-bottom:2px;background-color:rgb(204, 238, 255);width:76%" valign="bottom">
        <div style="text-indent:0.4pt;margin-left:30.1pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Decrease
        in contract liabilities</span></span></div> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);width:9%" valign="bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="Fxbrl_20220219041121835_163" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" contextRef="C_20220101to20221231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">15</ix:nonFraction></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;background-color:rgb(204, 238, 255);white-space:nowrap;width:1%" valign="bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);width:9%" valign="bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="Fxbrl_20220219041121835_167" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" contextRef="C_20210101to20211231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">143</ix:nonFraction></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;background-color:rgb(204, 238, 255);white-space:nowrap;width:1%" valign="bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
        </div> </td> </tr>
  <tr>
    <td style="vertical-align:bottom;padding-bottom:2px;width:76%" valign="bottom">
        <div style="text-indent:-14.2pt;margin-left:30.15pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Net
        cash used in operating activities</span></span></div> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;border-bottom:2px solid rgb(0, 0, 0);width:9%" valign="bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="Fxbrl_20220219041121835_173" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="C_20220101to20221231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">12,499</ix:nonFraction></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;white-space:nowrap;width:1%" valign="bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;border-bottom:2px solid rgb(0, 0, 0);width:9%" valign="bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="Fxbrl_20220305111416980" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="C_20210101to20211231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">9,063</ix:nonFraction></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;white-space:nowrap;width:1%" valign="bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
        </div> </td> </tr>
  <tr>
    <td rowspan="1" style="vertical-align:top;background-color:rgb(204, 238, 255);width:76%" valign="bottom">&#160;</td>
    <td colspan="1" rowspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
    <td colspan="1" rowspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
    <td colspan="1" rowspan="1" style="vertical-align:bottom;text-align:right;background-color:rgb(204, 238, 255);width:9%" valign="bottom">&#160;</td>
    <td colspan="1" rowspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);white-space:nowrap;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" rowspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
    <td colspan="1" rowspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
    <td colspan="1" rowspan="1" style="vertical-align:bottom;text-align:right;background-color:rgb(204, 238, 255);width:9%" valign="bottom">&#160;</td>
    <td colspan="1" rowspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);white-space:nowrap;width:1%" valign="bottom">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align:top;width:76%" valign="bottom">
        <div style="text-indent:-15.95pt;margin-left:15.95pt;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">CASH
        FLOWS FROM INVESTING ACTIVITIES:</span></span></div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;white-space:nowrap;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;white-space:nowrap;width:1%" valign="bottom">&#160;</td> </tr>
  <tr>
    <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:76%" valign="bottom">
        <div style="text-indent:-14.2pt;margin-left:30.15pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Funds
        with respect to employee rights upon retirement</span></span></div> </td>
    <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;background-color:rgb(204, 238, 255);width:9%" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="Fxbrl_20221030215603518_xbrl_20220219041121835_203" name="entx:FundsInRespectOfEmployeeRightsUponRetirement" contextRef="C_20220101to20221231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">55</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);white-space:nowrap;width:1%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></td>
    <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;background-color:rgb(204, 238, 255);width:9%" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20221030215603518_xbrl_20220219041121835_207" name="entx:FundsInRespectOfEmployeeRightsUponRetirement" contextRef="C_20210101to20211231" unitRef="USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);white-space:nowrap;width:1%" valign="bottom">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align:bottom;padding-bottom:2px;width:76%" valign="bottom">
        <div style="text-indent:-14.2pt;margin-left:30.15pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Purchase
        of property and equipment</span></span></div> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;border-bottom:2px solid rgb(0, 0, 0);width:9%" valign="bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="Fxbrl_20221030215719839_xbrl_20220219041121835_203" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" contextRef="C_20220101to20221231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">47</ix:nonFraction></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;white-space:nowrap;width:1%" valign="bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;border-bottom:2px solid rgb(0, 0, 0);width:9%" valign="bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="Fxbrl_20221030215719839_xbrl_20220219041121835_207" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" contextRef="C_20210101to20211231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">17</ix:nonFraction></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;white-space:nowrap;width:1%" valign="bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
        </div> </td> </tr>
  <tr>
    <td style="vertical-align:bottom;padding-bottom:2px;background-color:rgb(204, 238, 255);width:76%" valign="bottom">
        <div style="text-indent:-14.2pt;margin-left:30.15pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Net
        cash used in investing activities</span></span></div> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);width:9%" valign="bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="Fxbrl_20221030215741538" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="C_20220101to20221231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">102</ix:nonFraction></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;background-color:rgb(204, 238, 255);white-space:nowrap;width:1%" valign="bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);width:9%" valign="bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="Fxbrl_20221030215753542" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="C_20210101to20211231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">17</ix:nonFraction></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;background-color:rgb(204, 238, 255);white-space:nowrap;width:1%" valign="bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
        </div> </td> </tr>
  <tr>
    <td rowspan="1" style="vertical-align:top;width:76%" valign="bottom">&#160;</td>
    <td colspan="1" rowspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" rowspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" rowspan="1" style="vertical-align:bottom;text-align:right;width:9%" valign="bottom">&#160;</td>
    <td colspan="1" rowspan="1" style="vertical-align:bottom;white-space:nowrap;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" rowspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" rowspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" rowspan="1" style="vertical-align:bottom;text-align:right;width:9%" valign="bottom">&#160;</td>
    <td colspan="1" rowspan="1" style="vertical-align:bottom;white-space:nowrap;width:1%" valign="bottom">&#160;</td> </tr>
  <tr>
    <td style="vertical-align:top;background-color:rgb(204, 238, 255);width:76%" valign="bottom">
        <div style="text-indent:-15.95pt;margin-left:15.95pt;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">CASH
        FLOWS FROM FINANCING ACTIVITIES:</span></span></div> </td>
    <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;background-color:rgb(204, 238, 255);width:9%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);white-space:nowrap;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;background-color:rgb(204, 238, 255);width:9%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);white-space:nowrap;width:1%" valign="bottom">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align:bottom;width:76%" valign="bottom">
        <div style="text-indent:-14.2pt;margin-left:30.15pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Proceeds
        from issuance of shares through ATM programs, net of issuance costs</span></span></div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20220219041121835_283" name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="C_20220101to20221231" unitRef="USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;white-space:nowrap;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20220219041121835_287" name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="C_20210101to20211231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">21,805</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;white-space:nowrap;width:1%" valign="bottom">&#160;</td> </tr>
  <tr>
    <td style="vertical-align:bottom;padding-bottom:2px;background-color:rgb(204, 238, 255);width:76%" valign="bottom">
        <div style="text-indent:-14.2pt;margin-left:30.15pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Exercise
        of options and warrants into shares</span></span></div> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);width:9%" valign="bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20220219041121835_293" name="entx:ProceedsFromOptionsAndWarrantExercises" contextRef="C_20220101to20221231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">13</ix:nonFraction></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;background-color:rgb(204, 238, 255);white-space:nowrap;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);width:9%" valign="bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20220219041121835_297" name="entx:ProceedsFromOptionsAndWarrantExercises" contextRef="C_20210101to20211231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,576</ix:nonFraction></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;background-color:rgb(204, 238, 255);white-space:nowrap;width:1%" valign="bottom">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align:bottom;padding-bottom:2px;width:76%" valign="bottom">
        <div style="text-indent:-14.2pt;margin-left:30.15pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Net
        cash provided by financing activities</span></span></div> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;border-bottom:2px solid rgb(0, 0, 0);width:9%" valign="bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20220219041121835_303" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="C_20220101to20221231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">13</ix:nonFraction></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;white-space:nowrap;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;border-bottom:2px solid rgb(0, 0, 0);width:9%" valign="bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20220219041121835_307" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="C_20210101to20211231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">25,381</ix:nonFraction></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;white-space:nowrap;width:1%" valign="bottom">&#160;</td> </tr>
  <tr>
    <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:76%" valign="bottom">
        <div style="text-indent:-15.95pt;margin-left:15.95pt;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">INCREASE
        (DECREASE) IN CASH, CASH EQUIVALENTS AND RESTRICTED DEPOSITS</span></span></div> </td>
    <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;background-color:rgb(204, 238, 255);width:9%" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="Fxbrl_20220219041121835_313" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" contextRef="C_20220101to20221231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">12,588</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);white-space:nowrap;width:1%" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;background-color:rgb(204, 238, 255);width:9%" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20220219041121835_317" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" contextRef="C_20210101to20211231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">16,301</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);white-space:nowrap;width:1%" valign="bottom">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align:bottom;padding-bottom:2px;width:76%" valign="bottom">
        <div style="text-indent:-15.95pt;margin-left:15.95pt;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">CASH,
        CASH EQUIVALENTS AND RESTRICTED DEPOSITS AT BEGINNING OF THE YEAR</span></span></div> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;border-bottom:2px solid rgb(0, 0, 0);width:9%" valign="bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20220219041121835_323" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="C_20211231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">24,964</ix:nonFraction></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;white-space:nowrap;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;border-bottom:2px solid rgb(0, 0, 0);width:9%" valign="bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20230227113922248" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="C_20201231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,663</ix:nonFraction></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;white-space:nowrap;width:1%" valign="bottom">&#160;</td> </tr>
  <tr>
    <td style="vertical-align:bottom;padding-bottom:4px;background-color:rgb(204, 238, 255);width:76%" valign="bottom">
        <div style="text-indent:-15.95pt;margin-left:15.95pt;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">CASH,
        CASH EQUIVALENTS AND RESTRICTED DEPOSITS AT END OF THE YEAR</span></span></div> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:4px;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);width:9%" valign="bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20220809005417307" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="C_20221231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">12,376</ix:nonFraction></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:4px;background-color:rgb(204, 238, 255);white-space:nowrap;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:4px;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);width:9%" valign="bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20220809005506769" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="C_20211231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">24,964</ix:nonFraction></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:4px;background-color:rgb(204, 238, 255);white-space:nowrap;width:1%" valign="bottom">&#160;</td>
        </tr>
  <tr>
    <td rowspan="1" style="vertical-align:top;width:76%" valign="bottom">&#160;</td>
    <td colspan="1" rowspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" rowspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" rowspan="1" style="vertical-align:bottom;text-align:right;width:9%" valign="bottom">&#160;</td>
    <td colspan="1" rowspan="1" style="vertical-align:bottom;white-space:nowrap;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" rowspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" rowspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" rowspan="1" style="vertical-align:bottom;text-align:right;width:9%" valign="bottom">&#160;</td>
    <td colspan="1" rowspan="1" style="vertical-align:bottom;white-space:nowrap;width:1%" valign="bottom">&#160;</td> </tr>
  <tr>
    <td style="vertical-align:top;background-color:rgb(204, 238, 255);width:76%" valign="bottom">
        <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Reconciliation
        in amounts on consolidated balance sheets:</span></span></div> </td>
    <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;background-color:rgb(204, 238, 255);width:9%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);white-space:nowrap;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;background-color:rgb(204, 238, 255);width:9%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);white-space:nowrap;width:1%" valign="bottom">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align:bottom;width:76%" valign="bottom">
        <div style="text-indent:-15.95pt;margin-left:15.95pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Cash
        and cash equivalents</span></span></div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20220505171612811" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="C_20221231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">12,309</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;white-space:nowrap;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20220505171631694" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="C_20211231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">24,892</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;white-space:nowrap;width:1%" valign="bottom">&#160;</td> </tr>
  <tr>
    <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:76%" valign="bottom">
        <div style="text-indent:-15.95pt;margin-left:15.95pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Restricted
        deposits included in other current assets</span></span></div> </td>
    <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;background-color:rgb(204, 238, 255);width:9%" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20220505171702884" name="us-gaap:RestrictedCashAndCashEquivalents" contextRef="C_20221231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">67</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);white-space:nowrap;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;background-color:rgb(204, 238, 255);width:9%" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20220505171713125" name="us-gaap:RestrictedCashAndCashEquivalents" contextRef="C_20211231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">72</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);white-space:nowrap;width:1%" valign="bottom">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align:bottom;padding-bottom:4px;width:76%" valign="bottom">
        <div style="text-indent:-15.95pt;margin-left:15.95pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Total
        cash and cash equivalents and restricted deposits</span></span></div> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:4px;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;border-bottom:4px double rgb(0, 0, 0);width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;border-bottom:4px double rgb(0, 0, 0);width:9%" valign="bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20220809005613001" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="C_20221231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">12,376</ix:nonFraction></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:4px;white-space:nowrap;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:4px;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;border-bottom:4px double rgb(0, 0, 0);width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;border-bottom:4px double rgb(0, 0, 0);width:9%" valign="bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20220809005750289" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="C_20211231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">24,964</ix:nonFraction></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:4px;white-space:nowrap;width:1%" valign="bottom">&#160;</td> </tr>
  <tr>
    <td rowspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:76%" valign="bottom">&#160;</td>
    <td colspan="1" rowspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
    <td colspan="1" rowspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
    <td colspan="1" rowspan="1" style="vertical-align:bottom;text-align:right;background-color:rgb(204, 238, 255);width:9%" valign="bottom">&#160;</td>
    <td colspan="1" rowspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);white-space:nowrap;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" rowspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
    <td colspan="1" rowspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
    <td colspan="1" rowspan="1" style="vertical-align:bottom;text-align:right;background-color:rgb(204, 238, 255);width:9%" valign="bottom">&#160;</td>
    <td colspan="1" rowspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);white-space:nowrap;width:1%" valign="bottom">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align:bottom;width:76%" valign="bottom">
        <div style="text-indent:-15.95pt;margin-left:15.95pt;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">SUPPLEMENTAL
        DISCLOSURE OF CASH FLOW TRANSACTIONS:</span></span></div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;white-space:nowrap;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;white-space:nowrap;width:1%" valign="bottom">&#160;</td> </tr>
  <tr>
    <td style="vertical-align:top;padding-bottom:4px;background-color:rgb(204, 238, 255);width:76%" valign="bottom">
        <div style="text-indent:-15.95pt;margin-left:15.95pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Income
        taxes paid in cash during the year</span></span></div> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:4px;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);width:9%" valign="bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20220505172109460" name="us-gaap:IncomeTaxesPaidNet" contextRef="C_20220101to20221231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">165</ix:nonFraction></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:4px;background-color:rgb(204, 238, 255);white-space:nowrap;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:4px;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);width:9%" valign="bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20220505172119135" name="us-gaap:IncomeTaxesPaidNet" contextRef="C_20210101to20211231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2</ix:nonFraction></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:4px;background-color:rgb(204, 238, 255);white-space:nowrap;width:1%" valign="bottom">&#160;</td>
        </tr>
  <tr>
    <td rowspan="1" style="vertical-align:bottom;width:76%" valign="bottom">&#160;</td>
    <td colspan="1" rowspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" rowspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" rowspan="1" style="vertical-align:bottom;text-align:right;width:9%" valign="bottom">&#160;</td>
    <td colspan="1" rowspan="1" style="vertical-align:bottom;white-space:nowrap;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" rowspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" rowspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" rowspan="1" style="vertical-align:bottom;text-align:right;width:9%" valign="bottom">&#160;</td>
    <td colspan="1" rowspan="1" style="vertical-align:bottom;white-space:nowrap;width:1%" valign="bottom">&#160;</td> </tr>
  <tr>
    <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:76%" valign="bottom">
        <div style="text-indent:-15.95pt;margin-left:15.95pt;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">SUPPLEMENTARY
        INFORMATION ON INVESTING AND FINANCING ACTIVITIES NOT INVOLVING CASH FLOWS:</span></span></div> </td>
    <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;background-color:rgb(204, 238, 255);width:9%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);white-space:nowrap;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;background-color:rgb(204, 238, 255);width:9%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);white-space:nowrap;width:1%" valign="bottom">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align:bottom;padding-bottom:4px;width:76%" valign="bottom">
        <div style="text-indent:-15.95pt;margin-left:15.95pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Operating
        lease right of use assets obtained in exchange for new operating lease liabilities</span></span></div> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:4px;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;border-bottom:4px double rgb(0, 0, 0);width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;border-bottom:4px double rgb(0, 0, 0);width:9%" valign="bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20221030215529370_xbrl_20220505172109460" name="entx:RightOfUseAssetsObtainedInExchangeForNewOperatingLeaseLiabilities" contextRef="C_20220101to20221231" unitRef="USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:4px;white-space:nowrap;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:4px;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;border-bottom:4px double rgb(0, 0, 0);width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;border-bottom:4px double rgb(0, 0, 0);width:9%" valign="bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20221030215529370_xbrl_20220505172119135" name="entx:RightOfUseAssetsObtainedInExchangeForNewOperatingLeaseLiabilities" contextRef="C_20210101to20211231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">31</ix:nonFraction></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:4px;white-space:nowrap;width:1%" valign="bottom">&#160;</td> </tr>
  </table> </div> </div>

<div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>

<div style="line-height:1.25">

<div style="line-height:1.25;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">The
accompanying notes are an integral part of the</span><span>&#160;</span><span style="font-weight:bold">unaudited condensed consolidated
financial statements.</span></span></span></div>

<div style="line-height:1.25;text-align:center">&#160;</div> </div> </div> </div>

<div style="clear:both;margin-top:10pt;margin-bottom:0pt">

<div style="text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="color:#000000;font-weight:normal;font-style:normal">94</span></span></span></div>

<div style="page-break-after:always"><hr style="border-width:0px;clear:both;margin:4px 0px;width:100%;height:2px;color:#000000;background-color:#000000" /></div></div>

<p style="margin-top:0pt;margin-bottom:10pt;font-family:Times New Roman,Times,serif">&#160;</p>

<div>

<div>

<div>

<div>

<div>

<div>

<div style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0px;margin-bottom:0pt">

<div>

<div style="margin-top:0px;margin-bottom:0pt;text-align:center;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span style="line-height:107%"><strong><span style="line-height:107%">ENTERA
BIO LTD</span><span style="line-height:107%">.</span></strong></span></span></span></span></span></div>

<div style="margin-top:0pt;margin-bottom:0pt;text-align:center;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:center">
<div style="display:inline"> <div style="display:inline"> <div style="display:inline"> <div style="font-size:10pt;font-family:Times New Roman, Times, serif;line-height:normal;display:inline">
<div style="display:inline"> <div style="display:inline"> <div style="font-family:Times New Roman, Times, serif;display:inline"> <div style="font-weight:bold;display:inline"><span id="NOTES_integixAnchor"></span></div>

<div style="font-size:10pt">

<div>

<div>

<div>

<div style="line-height:normal">

<div><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><strong><strong>NOTES TO THE CONSOLIDATED
FINANCIAL STATEMENTS</strong></strong></span></span></span></span></div> </div> </div> </div> </div> </div> </div> </div> </div> </div>
</div> </div> </div> </div>

<div style="margin-top:0pt;margin-bottom:0pt;text-align:center;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span style="margin-bottom:0px;line-height:normal;color:black">(U.S.
dollars in thousands, except share and per share amounts)</span></span></span></span></span></div>

<div style="margin-top:0pt;margin-bottom:0pt;text-align:center;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:center">

<div style="margin:0pt">&#160;</div> </div>

<div> <ix:nonNumeric id="Fxbrl_20220510153034567" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" contextRef="C_20220101to20221231" escape="true">

<div>

<div>

<div>

<div style="line-height:1.25;font-family:Times New Roman, Times, serif"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><strong><span>NOTE
1 - GENERAL</span></strong></span></span></span></span></div>

<div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>

<div>

<table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">
  <tr>
    <td style="vertical-align:top;font-family:Times New Roman, Times, serif;width:47px">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><span>a.</span></span></span></span></span></span></span></div>
        </td>
    <td style="vertical-align:top;font-family:Times New Roman, Times, serif;width:auto">
        <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><span><span><span><span><span><span style="line-height:107%">Entera
        Bio Ltd. (collectively with its subsidiary, the "Company") was incorporated on September 30, 2009 and commenced operation on June 1, 2010.
        On January 8, 2018, the Company incorporated Entera Bio Inc., a wholly owned subsidiary incorporated in Delaware United States. The Company
        is a leader in the development and commercialization of orally delivered large molecule therapeutics for use in areas with significant
        unmet medical need where adoption of injectable therapies is limited due to cost, convenience and compliance challenges for patients.
        The Company&#8217;s most advanced product candidates, EB613 for the treatment of osteoporosis and EB612 for the treatment of hypoparathyroidism,
        are based on its proprietary technology platform and are both in clinical development. Additionally, the Company intends to license its
        oral delivery technology to biopharmaceutical companies for use with their proprietary compounds.</span></span></span></span></span></span></span></span></span></span></span></span></div>
        </td> </tr>
  <tr>
    <td style="vertical-align:top;font-family:Times New Roman, Times, serif;width:47px">&#160;</td>
    <td style="vertical-align:top;font-family:Times New Roman, Times, serif;width:auto">&#160;</td> </tr>
  <tr>
    <td style="vertical-align:top;font-family:Times New Roman, Times, serif;width:47px">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><span>b.</span></span></span></span></span></span></span></div>
        </td>
    <td style="vertical-align:top;font-family:Times New Roman, Times, serif;width:auto">
        <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><span><span style="line-height:107%">The
        Company's ordinary shares, NIS <ix:nonFraction id="Fxbrl_20221030152157060" name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="C_20221231" unitRef="NIS_per_Share" scale="0" decimals="7" format="ixt:num-dot-decimal">0.0000769</ix:nonFraction>
        par value per share (&#8220;ordinary shares&#8221;), are listed on the Nasdaq Capital Market since July 2018 under the symbol &#8220;ENTX&#8221;.</span></span></span></span></span></span></span></span></div>
        </td> </tr>
  <tr>
    <td style="vertical-align:top;font-family:Times New Roman, Times, serif;width:47px">&#160;</td>
    <td style="vertical-align:top;font-family:Times New Roman, Times, serif;width:auto">&#160;</td> </tr>
  <tr>
    <td style="vertical-align:top;font-family:Times New Roman, Times, serif;width:47px">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><span><span><span>c.</span></span></span></span></span></span></span></span></span></div>
        </td>
    <td style="vertical-align:top;font-family:Times New Roman, Times, serif;width:auto">
        <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><span><span><span><span><span><span style="line-height:107%">On
        December 10, 2018, the Company entered into a research collaboration and license agreement with Amgen (the &#8220;Amgen Agreement&#8221;)
        &#160;for the use of the Company&#8217;s oral delivery platform in the field of inflammatory disease and other serious illnesses. Pursuant
        to the Amgen Agreement, the Company and Amgen have agreed to use the Company&#8217;s proprietary drug delivery platform to develop oral
        formulations for one preclinical large molecule program that Amgen has selected. Amgen is responsible for the clinical development, regulatory
        approval, manufacturing and worldwide commercialization of the programs.<br /><br />The Company granted Amgen an exclusive, worldwide,
        sublicensable license under certain of its intellectual property relating to its drug delivery technology to develop, manufacture and
        commercialize the applicable products. The Company will retain all intellectual property rights to its drug delivery technology, and Amgen
        will retain all rights to its large molecules and any subsequent improvements, and ownership of certain intellectual property developed
        through the performance of the agreement is to be determined by U.S. patent law.</span></span></span></span></span></span></span></span></span></span></span></span></div>
        </td> </tr>
  <tr>
    <td style="vertical-align:top;font-family:Times New Roman, Times, serif;width:47px">&#160;</td>
    <td style="vertical-align:top;font-family:Times New Roman, Times, serif;width:auto">&#160;</td> </tr>
  <tr>
    <td style="vertical-align:top;font-family:Times New Roman, Times, serif;width:47px">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><span>d.</span></span></span></span></span></span></span></div>
        </td>
    <td style="vertical-align:top;font-family:Times New Roman, Times, serif;width:auto">
        <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><span><span><span><span><span><span style="line-height:115%"><span style="line-height:115%">Because
        </span></span></span></span></span></span></span></span></span>the Company is engaged in research and development activities, it has not
        derived significant income from its activities and has incurred accumulated deficit in the amount of $<ix:nonFraction id="Fxbrl_20230330101925263" name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="C_20221231" unitRef="USD" scale="6" decimals="-5" format="ixt:num-dot-decimal" sign="-">95.5</ix:nonFraction>
        million through December 31, 2022 and negative cash flows from operating activities. The Company's management is of the opinion that its
        available funds as of December 31, 2022 will allow the Company to operate under its current plans into the third quarter of 2024. This
        assumes the use of the Company&#8217;s capital to fund its ongoing operations, including R&#38;D and the completion of the Phase 1 study
        related to the new formulation EB612. This does not include the capital required to fund the Company's proposed Phase 3 study for EB613
        in osteoporosis and comparative study. These factors raise substantial doubt as to the Company's ability to continue as a going concern.
        Management is in the process of evaluating various financing alternatives in the public or private equity markets, debt financing and
        strategic collaborations, as the Company will need to finance future research and development activities, general and administrative expenses
        and working capital through fund raising. However, there is no certainty about the Company's ability to obtain such funding. The financial
        statements do not include any adjustments that may be necessary should the Company be unable to continue as a going concern.<span><span><span><span><span><span><span style="line-height:107%">
        </span></span></span></span></span></span></span></span></span></span></span></div> </td> </tr>
  </table> </div> </div> </div> </div> </ix:nonNumeric> </div> </div>

<p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman,Times,serif">&#160;</p>

<div style="margin:0pt">

<div style="clear:both;margin-top:0pt;margin-bottom:0pt">

<div style="text-align:center;margin-top:10pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span><span><span><span><span style="color:#000000;font-weight:normal;font-style:normal">95</span></span></span></span></span></span></span></span></span></div>

<div style="page-break-after:always"><hr style="border-width:0px;clear:both;margin:4px 0px;width:100%;height:2px;color:#000000;background-color:#000000" /></div></div>

<p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:center">&#160;</p>

<p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:10pt;margin-bottom:0pt;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span><span><strong>ENTERA
BIO LTD.<br />NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS</strong></span></span></span></span></span></span></p>

<div style="text-align:center;line-height:1.25">

<div style="margin-top:0pt;margin-bottom:0pt;text-align:center;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span><span><span><span><span style="line-height:normal">(U.S.
dollars in thousands, except share and per share </span></span></span></span></span><span style="line-height:107%">amounts</span><span><span><span><span><span style="line-height:normal">)</span></span></span></span></span></span></span></span></span></div></div>

<p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman,Times,serif">&#160;</p> </div> </div> </div> </div> </div> </div>
</div> </div>

<div>

<div> <ix:nonNumeric id="F20230227081832010_0" name="us-gaap:SignificantAccountingPoliciesTextBlock" contextRef="C_20220101to20221231" escape="true">

<div>

<div>

<div style="line-height:1.25;font-family:Times New Roman, Times, serif;font-weight:bold;text-align:justify"> <div style="font-size:10pt;display:inline">
<div style="font-family:Times New Roman,Times,serif;display:inline"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>NOTE
2 - SIGNIFICANT ACCOUNTING POLICIES</span></span></span></span></div> </div> </div>

<div style="line-height:1.25;text-align:justify">&#160;</div>

<div> <ix:nonNumeric id="F20230227081832012_1" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" contextRef="C_20220101to20221231" escape="true">

<div>

<table cellpadding="0" cellspacing="0" style="color:#000000;font-family:'Times New Roman',Times,serif;font-size:10pt;text-align:left;width:100%">
  <tr>
    <td style="width:47px;vertical-align:top;font-family:Times New Roman, Times, serif;font-weight:bold;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">a.</span></span></td>
    <td style="width:auto;vertical-align:top">
        <div style="font-weight:bold;text-align:justify"> <div style="font-size:10pt;display:inline"> <div style="font-family:Times New Roman, Times, serif;display:inline;text-align:left"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>Basis
        of presentation of the financial statements</span></span></span></span></span></span></div> </div> </div> </td> </tr>
  </table>

<div style="line-height:1.25;text-align:justify">&#160;</div>

<div style="margin-left:47px;line-height:1.25;text-align:justify"> <div style="font-size:10pt;display:inline"> <div style="font-family:Times New Roman,Times,serif;display:inline">
<div style="display:inline;text-align:left"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><span><span><span><span><span style="line-height:normal">The
consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States
(&#8220;U.S. GAAP&#8221;). Prior to 2021, the Company prepared its financial statements in accordance with International Financial Reporting
Standards (&#8220;IFRS&#8221;), as issued by the International Accounting Standards Board (&#8220;IASB&#8221;), as permitted in the United
States (&#8220;U.S.&#8221;) based on the Company&#8217;s status as a foreign private issuer as defined in the rules promulgated by the
U.S. Securities and Exchange Commission (the &#8220;SEC&#8221;). During 2021, the Company determined that it is no longer qualified as
a foreign private issuer under the SEC rules. As a result, since January 1, 2022, the Company has been required to comply with all of
the disclosure and reporting requirements applicable to U.S. domestic issuers, including preparing its financial statement in accordance
with U.S. GAAP.</span></span></span></span></span></span></span></span></span></span></span></div> </div> </div> </div> </div> </ix:nonNumeric>
</div>

<div style="line-height:1.25;text-align:justify">&#160;</div>

<div> <ix:nonNumeric id="F20230227081832012_2" name="us-gaap:UseOfEstimates" contextRef="C_20220101to20221231" escape="true">

<div>

<table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">
  <tr>
    <td style="width:47px;vertical-align:top;font-family:Times New Roman, Times, serif;font-weight:bold;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">b.</span></span></td>
    <td style="width:auto;vertical-align:top">
        <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><strong><span style="line-height:107%">Use
        of estimates in the preparation of financial statements</span></strong></span></span></span></span></span></span></p> </td> </tr>
  </table>

<div style="line-height:1.25;text-align:justify">&#160;</div>

<div style="margin-left:47px;line-height:1.25;font-family:Times New Roman, Times, serif;text-align:justify"> <div style="font-size:10pt;display:inline">
<div style="font-family:Times New Roman,Times,serif;display:inline">

<p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><span style="line-height:normal">The
preparation of the consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions
that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial
statements and the reported amounts of revenues and expenses during the reporting period. Actual results may differ from those estimates.</span></span></span></span></span></span></span></p>
</div> </div> </div> </div> </ix:nonNumeric>

<p style="margin:0pt">&#160;</p> </div> </div> <ix:nonNumeric id="F20230227081832013_3" name="us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" contextRef="C_20220101to20221231" escape="true">

<div>

<div>

<div>

<div style="line-height:1.25;text-align:justify">

<table cellpadding="0" cellspacing="0" style="font-family:Times New Roman, Times, serif;font-size:10pt;width:100%;text-align:left;color:rgb(0, 0, 0);border:0px">
  <tr>
    <td style="width:47px;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>c.</strong></span></span></td>
    <td style="width:auto;vertical-align:top">
        <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><strong><span style="line-height:107%">Functional
        currency </span></strong></span></span></span></span></span></span></p> </td> </tr>
  </table> </div>

<p style="margin:0pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">
  <tr>
    <td style="width:47px;text-align:justify">&#160;</td>
    <td style="width:37.25px;vertical-align:top;font-family:Times New Roman, Times, serif;text-align:justify"> <div style="font-size:10pt;display:inline">
        <div style="font-family:Times New Roman,Times,serif;display:inline"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>1)</span></span></span></span></span></span></div>
        </div> </td>
    <td style="width:auto;vertical-align:top">
        <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><span style="line-height:107%">Functional
        and presentation currency</span></span></span></span></span></span></span></p>
        <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt">&#160;</p>
        <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span>Items
        included in the financial statements of the Company are measured using the currency of the primary economic environment in which the entity
        operates (the &#8220;functional currency&#8221;). The U.S. dollar is the currency of the primary economic environment in which the operations
        of the Company are conducted. The consolidated financial statements are presented in U.S. dollars.</span></span></span></span></span></p>
        <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify">&#160;</p>
        <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span>The
        functional currency of the subsidiary is the U.S. dollar.</span></span></span></span></span></p> </td> </tr>
  </table>

<div style="line-height:1.25;text-align:justify">&#160;</div> </div> </div> <div style="font-family:Times New Roman, Times, serif;display:inline;text-align:left">

<table cellpadding="0" cellspacing="0" style="font-family:Times New Roman, Times, serif;font-size:10pt;width:100%;text-align:left;color:rgb(0, 0, 0);border:0px">
  <tr>
    <td style="width:47px;text-align:justify">&#160;</td>
    <td style="width:37.25px;vertical-align:top;font-family:Times New Roman, Times, serif;text-align:justify">
        <div style="font-size:10pt">
        <div style="font-family:Times New Roman, Times, serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><span><span>2)</span></span></span></span></span></span></span></span></div>
        </div> </td>
    <td style="width:auto;vertical-align:top">
        <div style="text-align:justify">
        <div style="font-size:10pt">
        <div style="font-family:Times New Roman, Times, serif;text-align:left"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><span><span>Transactions
        and balances</span></span></span></span></span></span></span></span></div>
        <div style="font-family:Times New Roman, Times, serif">&#160;</div>
        <div style="font-family:Times New Roman, Times, serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span style="line-height:107%">Transactions
        and balances originally denominated in U.S. dollars are presented at their original amounts. Balances in non- U.S. dollar currencies are
        translated into U.S. dollars using historical and current exchange rates for non-monetary and monetary balances, respectively. For non-U.S.
        dollar transactions and other items in the statements of income (indicated below), the following exchange rates are used: (i) for transactions
        &#8211; exchange rates at transaction dates or average exchange rates; and (ii) for other items (derived from non-monetary balance sheet
        items such as depreciation and amortization) &#8211; historical exchange rates. &#160;Currency transaction gains and losses are presented
        in financial income (expenses), as appropriate.</span></span></span></span></span></div> </div> </div> </td> </tr>
  </table> </div> </div> </ix:nonNumeric>

<p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman,Times,serif">&#160;</p>

<div style="line-height:1.25;font-family:Times New Roman, Times, serif;text-align:justify">

<div><ix:exclude>

<div style="clear:both;margin-top:0pt;margin-bottom:0pt">

<div style="text-align:center;margin-top:10pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span><span><span><span><span style="color:#000000;font-weight:normal;font-style:normal">96</span></span></span></span></span></span></span></span></span></div>

<div style="page-break-after:always"><hr style="border-width:0px;clear:both;margin:4px 0px;width:100%;height:2px;color:#000000;background-color:#000000" /></div></div>

<p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:center">&#160;</p>

<p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:10pt;margin-bottom:0pt;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span><span><strong>ENTERA
BIO LTD.<br />NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS</strong></span></span></span></span></span></span></p>

<div style="text-align:center;line-height:1.25">

<div style="margin-top:0pt;margin-bottom:0pt;text-align:center;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span><span><span><span><span style="line-height:normal">(U.S.
dollars in thousands, except share and per share </span></span></span></span></span><span style="line-height:107%">amounts</span><span><span><span><span><span style="line-height:normal">)</span></span></span></span></span></span></span></span></span></div></div>

<p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman,Times,serif">&#160;</p>

<p style="margin:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><strong>NOTE 2 -
SIGNIFICANT ACCOUNTING POLICIES</strong>&#160;</span></span><strong><span><span>(continued)</span></span></strong></span></span></p>

<p style="margin:0pt">&#160;</p> </ix:exclude></div> </div>

<div>

<div>

<div>

<div>

<div>

<div style="line-height:1.25">

<div style="line-height:1.25"> <ix:nonNumeric id="F20230227081832013_4" name="us-gaap:ConsolidationPolicyTextBlock" contextRef="C_20220101to20221231" escape="true">

<table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">
  <tr>
    <td style="width:47px;text-align:justify;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>d.</strong></span></span></td>
    <td style="vertical-align:top;text-align:justify">
        <div> <div style="font-size:10pt;display:inline"> <div style="font-family:Times New Roman,Times,serif;display:inline"> <div style="font-weight:bold;display:inline;text-align:left"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><span style="line-height:107%">Principles
        of consolidation</span></span></span></span></span></span></span></div> </div> </div>
        <div style="margin:0pt">&#160;</div> </div>
        <div>
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">
        <div style="line-height:1.25"> <div style="font-size:10pt;display:inline"> <div style="font-family:Times New Roman, Times, serif;display:inline;text-align:left"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><span style="line-height:normal">The
        consolidated financial statements include the accounts of the Company and its subsidiary Entera Bio Inc. All inter-company transactions
        and balances have been eliminated in consolidation.</span></span></span></span></span></span></span></div> </div> </div> </div> </div>
        </td> </tr>
  </table> </ix:nonNumeric> </div> </div> </div>

<div style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</div>

<div style="line-height:1.25">

<div style="line-height:1.25">

<div> <ix:nonNumeric id="F20230227081832013_5" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" contextRef="C_20220101to20221231" escape="true">

<table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">
  <tr>
    <td style="width:47px;text-align:justify;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>e.</strong></span></span></td>
    <td style="vertical-align:top;text-align:justify">
        <div style="font-weight:bold"> <div style="font-size:10pt;display:inline"> <div style="font-family:Times New Roman, Times, serif;display:inline;text-align:left"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><strong><span style="line-height:107%">Cash
        and cash equivalents</span></strong></span></span></span></span></span></span></div> </div>
        <div style="margin:0pt">&#160;</div> </div>
        <div>
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">
        <div style="line-height:1.25">
        <div style="line-height:1.25"> <div style="font-size:10pt;display:inline"> <div style="font-family:Times New Roman, Times, serif;display:inline;text-align:left"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><span style="line-height:normal">The
        Company considers as cash equivalents all short-term, highly liquid investments, which include short-term bank deposits with original
        maturities of three months or less from the date of purchase that are not restricted as to withdrawal or use and are readily convertible
        to known amounts of cash.</span></span></span></span></span></span></span></div> </div> </div> </div> </div> </div> </td> </tr>
  </table> </ix:nonNumeric> </div>

<div style="margin-left:70.9pt;line-height:1.25;font-family:Times New Roman, Times, serif;text-align:justify">&#160;</div> </div> </div>

<div>

<div style="line-height:1.25">

<div style="line-height:1.25"> <ix:nonNumeric id="F20230227081832014_6" name="us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" contextRef="C_20220101to20221231" escape="true">

<table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">
  <tr>
    <td style="width:47px;text-align:justify;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>f.</strong></span></span></td>
    <td style="vertical-align:top;text-align:justify">
        <div style="font-weight:bold">
        <div style="font-weight:bold"> <div style="font-size:10pt;display:inline"> <div style="font-family:Times New Roman, Times, serif;display:inline;text-align:left"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong><span style="line-height:107%">Restricted
        cash</span></strong></span></span></div> </div>
        <div style="margin:0pt">&#160;</div> </div> </div>
        <div>
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">
        <div style="line-height:1.25">
        <div style="text-align:left;line-height:1.25">
        <div style="line-height:1.25;text-align:justify"> <div style="font-size:10pt;display:inline"> <div style="font-family:Times New Roman, Times, serif;display:inline;text-align:left"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><span style="line-height:normal;color:black">Restricted
        cash deposited in an interest-bearing saving account which is used as a security for the Company's office rent&#160;and credit card.</span></span></span></span></span></span></span></div>
        </div> </div> </div> </div> </div> </div> </td> </tr>
  </table> </ix:nonNumeric>

<div style="margin-left:70.9pt;line-height:1.25;font-family:Times New Roman, Times, serif;text-align:justify">&#160;</div>

<div style="line-height:1.25;font-family:Times New Roman, Times, serif;text-align:justify"> <ix:nonNumeric id="Fxbrl_20230330110451620" name="us-gaap:ConcentrationRiskCreditRisk" contextRef="C_20220101to20221231" escape="true">

<div>

<table cellpadding="0" cellspacing="0" style="border:0px;width:100%">
  <tr>
    <td style="width:47px"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>g.</strong></span></span></td>
    <td>
        <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>Concentrations
        of credit risk</strong></span></span></p> </td> </tr>
  </table>

<p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>

<p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;margin-left:47px"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Financial
instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash and cash equivalents.
The Company maintains cash held in checking accounts and deposits at financial institutions in major Israeli and U.S. banks. Management
believes the Company is not exposed to significant credit risk to its current financial institution, but will continue to monitor regularly
and adjust, if needed, to mitigate risk. The Company has established guidelines regarding diversification of its investments and their
maturities, which are designed to maintain principal and maximize liquidity. To date, the Company has not experienced any losses associated
with this credit risk and continues to believe that this exposure is not significant.</span></span></p> </div> </ix:nonNumeric> </div>

<div style="margin-left:70.9pt;line-height:1.25;font-family:Times New Roman, Times, serif;text-align:justify">&#160;</div> </div> </div>
</div> <ix:nonNumeric id="F20230227081832014_7" name="us-gaap:FairValueMeasurementPolicyPolicyTextBlock" contextRef="C_20220101to20221231" escape="true">

<div>

<div style="line-height:1.25">

<div>

<div style="line-height:1.25">

<div style="line-height:1.25">

<table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">
  <tr>
    <td style="width:47px;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>h.</strong></span></span></td>
    <td style="vertical-align:top;text-align:justify">
        <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>Fair
        value measurement</strong></span></span></p> </td> </tr>
  </table> </div> </div> </div> </div>

<div>

<p style="margin:0pt">&#160;</p>

<p style="margin-left:47px;margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><span style="line-height:normal">The
</span></span></span></span></span>Company measures fair value and discloses fair value measurements for financial assets and liabilities.
Fair value is based on the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between
market participants at the measurement date. The accounting standard establishes a fair value hierarchy that prioritizes observable and
unobservable inputs used to measure fair value into three broad levels, which are described below:</span></span></p>

<p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>

<p style="margin-left:47px;margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><span style="line-height:normal">Level
</span></span></span></span></span>1: Quoted prices (unadjusted) in active markets that are accessible at the measurement date for assets
or liabilities. The fair value hierarchy gives the highest priority to Level 1 inputs.</span></span></p>

<p style="margin-left:50pt;margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>

<p style="margin-left:47px;margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><span style="color:black">Level
</span></span></span></span></span>2: Observable inputs that are based on inputs not quoted on active markets but corroborated by market
data.</span></span></p>

<p style="margin-left:50pt;margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>

<p style="margin-left:47px;margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><span style="color:black">Level
</span></span></span></span></span>3: Unobservable inputs are used when little or no market data is available. The fair value hierarchy
gives the lowest priority to Level 3 inputs.</span></span></p>

<p style="margin-left:47px;margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p> </div>
</div> </ix:nonNumeric>

<div><ix:exclude>

<div style="clear:both;margin-top:0pt;margin-bottom:0pt">

<div style="text-align:center;margin-top:10pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span><span><span><span><span style="color:#000000;font-weight:normal;font-style:normal">97</span></span></span></span></span></span></span></span></span></div>

<div style="page-break-after:always"><hr style="border-width:0px;clear:both;margin:4px 0px;width:100%;height:2px;color:#000000;background-color:#000000" /></div></div>

<p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:center">&#160;</p>

<p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:10pt;margin-bottom:0pt;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span><span><strong>ENTERA
BIO LTD.<br />NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS</strong></span></span></span></span></span></span></p>

<div style="text-align:center;line-height:1.25">

<div style="margin-top:0pt;margin-bottom:0pt;text-align:center;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span><span><span><span><span style="line-height:normal">(U.S.
dollars in thousands, except share and per share </span></span></span></span></span><span style="line-height:107%">amounts</span><span><span><span><span><span style="line-height:normal">)</span></span></span></span></span></span></span></span></span></div></div>

<p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman,Times,serif">&#160;</p>

<p style="margin:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-size:10pt;font-family:Times New Roman, Times, serif"><span><strong>NOTE
2 - SIGNIFICANT ACCOUNTING POLICIES</strong>&#160;</span><strong><span>(continued)</span></strong></span></p>

<p style="margin:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p> </ix:exclude></div> <ix:nonNumeric id="F20230227081832050_33" name="entx:EmployeeSeveranceBenefitsPolicyPolicyTextBlock" contextRef="C_20220101to20221231" escape="true">

<div>

<div style="line-height:1.25">

<div>

<div style="line-height:1.25">

<div style="line-height:1.25">

<table cellpadding="0" cellspacing="0" style="border:0px;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:left;width:100%">
  <tr>
    <td style="width:47px;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>i.</strong></span></span></td>
    <td style="vertical-align:top;text-align:justify">
        <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><strong><span><span>Employee
        severance benefits</span></span></strong></span></span></span></span></p> </td> </tr>
  </table> </div> </div> </div> </div>

<div>

<p style="margin:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>

<p style="margin-top:0pt;margin-left:47px;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span style="line-height:normal">Under
</span>the Israeli Severance Pay Law, 1963, the Company is required to make severance payments upon dismissal of an Israeli employee or
upon termination of employment in certain other circumstances. The severance payment liability to the employees located in Israel (based
upon length of service and the latest monthly salary - one month&#8217;s salary for each year employed) is recorded on the Company&#8217;s
balance sheet under &#8220;Liability for employee rights upon retirement.&#8221; The liability is recorded as if it was payable at each
balance sheet date on an undiscounted basis.</span></span></span></span></p>

<p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>

<p style="margin-top:0pt;margin-left:47px;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span style="line-height:normal">In
</span>accordance with Section 14 of the Israeli Severance Pay Law, 1963, the Company makes regular deposits with certain insurance companies
for accounts controlled by each applicable employee in order to secure the employee&#8217;s retirement benefit obligation. The Company
is fully relieved from any severance pay liability with respect to each such employee after it makes the payments on behalf of the employee.
The liability accrued in respect of these employees and the amounts funded, as of the respective agreement dates, are not reflected in
the Company balance sheet, as the amounts funded are not under the control and management of the Company and the pension or severance
pay risks have been irrevocably transferred to the applicable insurance companies (the &#8220;Contribution Plan&#8221;).</span></span></span></span></p>

<p style="margin-top:0pt;margin-left:50pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>

<p style="margin-top:0pt;margin-left:47px;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span style="line-height:normal">With
regard to the period before December 2013, the liability is funded in part from the purchase of insurance policies or by the establishment
of pension funds with dedicated deposits in the funds. The amounts used to fund these liabilities are included in the balance sheets under
&#8220;Funds in respect of employee rights upon retirement&#8221;. These policies are the Company&#8217;s assets. </span></span></span></span></span></p>

<p style="margin-top:0pt;margin-left:50pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>

<p style="margin-top:0pt;margin-left:47px;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span style="color:black">The
</span>amounts of severance payment expenses were $<ix:nonFraction id="F20230227081832049_28" name="us-gaap:SeveranceCosts1" contextRef="C_20220101to20221231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">132</ix:nonFraction>&#160;and
$<ix:nonFraction id="F20230227081832049_29" name="us-gaap:SeveranceCosts1" contextRef="C_20210101to20211231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">137</ix:nonFraction>
for the years ended December 31, 2022&#160;and 2021, respectively.</span></span></span></span><br />&#160;</p>

<p style="margin-top:0pt;margin-left:47px;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><span style="color:black">The
</span>Company expects to contribute to insurance companies approximately $<ix:nonFraction id="F20230227081832049_30" name="entx:SeveranceExpenses" contextRef="C_20220101to20221231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">132</ix:nonFraction>
for the year ending December 31, 2023 in connection with its expected severance liabilities for that year.</span></span></span></span></span></span></p>

<p style="margin-top:0pt;margin-left:47px;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p> </div>
</div> </ix:nonNumeric>

<div><ix:exclude>

<div style="clear:both;margin-top:0pt;margin-bottom:0pt">

<div style="text-align:center;margin-top:10pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span><span><span><span><span style="color:#000000;font-weight:normal;font-style:normal">98</span></span></span></span></span></span></span></span></span></div>

<div style="page-break-after:always"><hr style="border-width:0px;clear:both;margin:4px 0px;width:100%;height:2px;color:#000000;background-color:#000000" /></div></div>

<p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:center">&#160;</p>

<p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:10pt;margin-bottom:0pt;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span><span><strong>ENTERA
BIO LTD.<br />NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS</strong></span></span></span></span></span></span></p>

<div style="text-align:center;line-height:1.25">

<div style="margin-top:0pt;margin-bottom:0pt;text-align:center;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span><span><span><span><span style="line-height:normal">(U.S.
dollars in thousands, except share and per share </span></span></span></span></span><span style="line-height:107%">amounts</span><span><span><span><span><span style="line-height:normal">)</span></span></span></span></span></span></span></span></span></div></div>

<p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman,Times,serif">&#160;</p>

<p style="margin:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span style="line-height:normal"><strong><span><span>NOTE
2 - SIGNIFICANT ACCOUNTING POLICIES (continued)</span></span></strong></span></span></span></span></span></p>

<p style="margin:0pt">&#160;</p> </ix:exclude></div> </div>

<div> <ix:nonNumeric id="F20230227081832014_8" name="us-gaap:LesseeLeasesPolicyTextBlock" contextRef="C_20220101to20221231" escape="true">

<div>

<div style="line-height:1.25">

<div>

<div style="line-height:1.25">

<div style="line-height:1.25">

<table cellpadding="0" cellspacing="0" style="font-family:Times New Roman, Times, serif;font-size:10pt;width:100%;text-align:left;color:rgb(0, 0, 0);border:0px">
  <tr>
    <td style="width:47px;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>j.</strong></span></span></td>
    <td style="width:auto;vertical-align:top;text-align:justify">
        <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:left"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><strong><span style="line-height:107%">Leases</span></strong></span></span></span></span></span></span></p>
        </td> </tr>
  </table> </div> </div> </div> </div>

<div>

<p style="margin:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>

<p style="margin-top:0pt;margin-left:47px;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The
Company determines if an arrangement is a lease at inception. Balances related to operating leases are included in operating lease right-of-use
(&#8220;ROU&#8221;) assets and current and non-current operating lease liabilities in the consolidated balance sheets.</span></span></p>

<p style="margin:0pt">&#160;</p>

<p style="margin-top:0pt;margin-left:47px;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><span style="line-height:107%">ROU
</span></span></span></span></span>assets represent the Company&#8217;s right to use an underlying asset for the lease term and lease
liabilities represent the Company&#8217;s obligation to make lease payments arising from the lease. Operating lease ROU assets and liabilities
are recognized as of the commencement date based on the present value of lease payments over the lease term. Lease terms will include
options to extend or terminate the lease when it is reasonably certain that the Company will either exercise or not exercise the option
to renew or terminate the lease.</span></span></p>

<p style="margin:0pt">&#160;</p>

<p style="margin-top:0pt;margin-left:47px;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><span style="line-height:107%">The
</span></span></span></span></span>discount rate for the lease is the rate implicit in the lease unless that rate cannot be readily determined.
As the Company&#8217;s leases do not provide an implicit rate, the Company&#8217;s uses its estimated incremental borrowing rate based
on the information available at the commencement date in determining the present value of lease payments. Lease expense for lease payments
is recognized on a straight-line basis over the lease term.</span></span></p>

<p style="margin-top:0pt;margin-left:90px;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>

<p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;margin-left:47px;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Sublease
income is recognized on a straight-line basis over the expected lease term and is included in other income in our consolidated statements
of operations<span style="line-height:107%">.</span></span></span></p> </div> </div> </ix:nonNumeric>

<p style="margin:0pt">&#160;</p> <ix:nonNumeric id="F20230227081832031_9" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" contextRef="C_20220101to20221231" escape="true">

<div>

<table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">
  <tr>
    <td style="width:47px;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><strong>k.</strong></span></span></span></span></td>
    <td style="width:auto;vertical-align:top">
        <div style="font-weight:bold;text-align:justify"> <div style="font-size:10pt;display:inline"> <div style="font-family:Times New Roman, Times, serif;display:inline;text-align:left"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><span><span>Property
        and equipment</span></span></span></span></span></span></span></span></div> </div> </div> </td> </tr>
  </table>

<div style="line-height:1.25;text-align:justify">&#160;</div>

<table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">
  <tr>
    <td style="text-align:justify;width:36pt">&#160;</td>
    <td style="vertical-align:top;font-family:Times New Roman, Times, serif;text-align:justify;width:27pt"> <div style="font-size:10pt;display:inline">
        <div style="font-family:Times New Roman,Times,serif;display:inline"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong><span><span><span><span>1)</span></span></span></span></strong></span></span></div>
        </div> </td>
    <td style="vertical-align:top;width:auto">
        <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><span style="line-height:107%">Property
        and equipment are stated at cost, net of accumulated depreciation and amortization.</span></span></span></span></span></span></span></p>
        </td> </tr>
  </table>

<div style="line-height:1.25;text-align:justify">&#160;</div>

<table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">
  <tr>
    <td style="text-align:justify;width:36pt">&#160;</td>
    <td style="vertical-align:top;font-family:Times New Roman, Times, serif;text-align:justify;width:27pt"> <div style="font-size:10pt;display:inline">
        <div style="font-family:Times New Roman,Times,serif;display:inline"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><strong><span><span><span><span>2)</span></span></span></span></strong></span></span></span></span></div>
        </div> </td>
    <td style="vertical-align:top;width:auto">
        <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><span><span><span style="line-height:normal">The
        </span></span></span></span></span>Company&#8217;s property and equipment are depreciated using the straight-line method, which approximates
        the pattern of usage, over the term of the estimated useful life, as follows<span><span><span><span><span style="line-height:normal">:</span></span></span></span></span></span></span></span></span></p>
        </td> </tr>
  </table>

<div> <ix:nonNumeric id="F20230227081832031_10" name="entx:ScheduleOfEstimatedUsefulLifeTableTextBlock" contextRef="C_20220101to20221231" escape="true">

<div>

<div>

<div>

<div>

<div style="line-height:1.25">&#160;</div>

<div style="margin-left:126pt">

<table border="0" cellpadding="0" cellspacing="0" style="width:70%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left">
  <tr>
    <td style="width:50.94%;vertical-align:top">&#160;</td>
    <td style="width:24.55%;vertical-align:top">&#160;</td>
    <td style="width:24.51%;vertical-align:top;border-bottom:2px solid #000000">
        <div style="line-height:1.25">
        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Years</span></span></div>
        </div> </td> </tr>
  <tr>
    <td style="width:50.94%;vertical-align:bottom">&#160;</td>
    <td style="width:24.55%;vertical-align:bottom">&#160;</td>
    <td style="width:24.51%;vertical-align:bottom">&#160;</td> </tr>
  <tr>
    <td style="width:50.94%;vertical-align:bottom;background-color:rgb(204, 238, 255)">
        <div style="text-align:justify;text-indent:-10.7pt;margin-left:12.6pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Computer
        equipment</span></span></div> </td>
    <td style="width:24.55%;vertical-align:bottom;background-color:rgb(204, 238, 255)">&#160;</td>
    <td style="width:24.51%;vertical-align:bottom;background-color:rgb(204, 238, 255)">
        <div style="text-align:right;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonNumeric id="F20230227081832033_17" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" contextRef="C_20220101to20221231_srtRangeAxis_srtMinimumMember_usgaapPropertyPlantAndEquipmentByTypeAxis_usgaapComputerEquipmentMember" format="ixt-sec:duryear">3</ix:nonNumeric>-<ix:nonNumeric id="F20230227081832034_18" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" contextRef="C_20220101to20221231_srtRangeAxis_srtMaximumMember_usgaapPropertyPlantAndEquipmentByTypeAxis_usgaapComputerEquipmentMember" format="ixt-sec:duryear">5</ix:nonNumeric></span></span></div>
        </td> </tr>
  <tr>
    <td style="width:50.94%;vertical-align:bottom">
        <div style="text-align:justify;text-indent:-10.7pt;margin-left:12.6pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Office
        furniture</span></span></div> </td>
    <td style="width:24.55%;vertical-align:bottom">&#160;</td>
    <td style="width:24.51%;vertical-align:bottom">
        <div style="text-align:right;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonNumeric id="F20230227081832047_21" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" contextRef="C_20220101to20221231_usgaapPropertyPlantAndEquipmentByTypeAxis_usgaapOfficeEquipmentMember" format="ixt-sec:duryear">10</ix:nonNumeric></span></span></div>
        </td> </tr>
  <tr>
    <td style="width:50.94%;vertical-align:bottom;background-color:rgb(204, 238, 255)">
        <div style="text-align:justify;text-indent:-10.7pt;margin-left:12.6pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Laboratory
        equipment</span></span></div> </td>
    <td style="width:24.55%;vertical-align:bottom;background-color:rgb(204, 238, 255)">&#160;</td>
    <td style="width:24.51%;vertical-align:bottom;background-color:rgb(204, 238, 255)">
        <div style="text-align:right;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonNumeric id="F20230227081832034_19" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" contextRef="C_20220101to20221231_srtRangeAxis_srtMinimumMember_usgaapPropertyPlantAndEquipmentByTypeAxis_entxLaboratoryEquipmentMember" format="ixt-sec:duryear">7</ix:nonNumeric>-<ix:nonNumeric id="F20230227081832034_20" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" contextRef="C_20220101to20221231_srtRangeAxis_srtMaximumMember_usgaapPropertyPlantAndEquipmentByTypeAxis_entxLaboratoryEquipmentMember" format="ixt-sec:duryear">10</ix:nonNumeric></span></span></div>
        </td> </tr>
  </table> </div> </div> </div>

<div style="margin-left:36pt;line-height:1.25">&#160;</div> </div> </div> </ix:nonNumeric> </div>

<div style="margin-left:47px;line-height:1.25;text-align:justify"> <div style="font-size:10pt;display:inline"> <div style="font-family:Times New Roman,Times,serif;display:inline">
<div style="display:inline;text-align:left;margin-bottom:0pt;margin-top:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><span style="line-height:107%">Leasehold
improvements are amortized by the straight-line method over the shorter of (i) the expected lease term and (ii) the estimated useful life
of the improvements.</span></span></span></span></span></span></span></div>

<p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman,Times,serif">&#160;</p> </div> </div> </div> </div> </ix:nonNumeric>
</div> </div> </div> </div> </div>

<div><ix:exclude>

<div>

<div>

<div>

<div>

<div>

<div>

<div>

<div> <div style="display:inline">

<div style="clear:both;margin-top:0pt;margin-bottom:0pt">

<div style="text-align:center;margin-top:10pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span><span><span><span><span style="color:#000000;font-weight:normal;font-style:normal">99</span></span></span></span></span></span></span></span></span></div>

<div style="page-break-after:always"><hr style="border-width:0px;clear:both;margin:4px 0px;width:100%;height:2px;color:#000000;background-color:#000000" /></div></div>

<p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:center">&#160;</p>

<p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:10pt;margin-bottom:0pt;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span><span><strong>ENTERA
BIO LTD.<br />NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS</strong></span></span></span></span></span></span></p>

<div style="text-align:center;line-height:1.25">

<div style="margin-top:0pt;margin-bottom:0pt;text-align:center;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span><span><span><span><span style="line-height:normal">(U.S.
dollars in thousands, except share and per share </span></span></span></span></span><span style="line-height:107%">amounts</span><span><span><span><span><span style="line-height:normal">)</span></span></span></span></span></span></span></span></span></div></div>

<p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman,Times,serif">&#160;</p>

<p style="margin:0pt;font-weight:400"><strong><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>NOTE
2 - SIGNIFICANT ACCOUNTING POLICIES (continued)</span></span></span></span></strong></p>

<p style="margin:0pt">&#160;</p> </div> </div> </div> </div> </div> </div> </div> </div> </div> </ix:exclude></div>

<div>

<div>

<div>

<div>

<div>

<div style="line-height:1.25;text-align:justify"> <ix:nonNumeric id="F20230227081832032_11" name="us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" contextRef="C_20220101to20221231" escape="true">

<div>

<div style="line-height:1.25">

<div>

<div style="line-height:1.25">

<div style="line-height:1.25">

<table cellpadding="0" cellspacing="0" style="font-family:Times New Roman, Times, serif;font-size:10pt;width:100%;text-align:left;color:rgb(0, 0, 0);border:0px">
  <tr>
    <td style="width:47px;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>l.</strong></span></span></td>
    <td style="vertical-align:top;text-align:justify">
        <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:left"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><strong><span style="line-height:107%">Impairment&#160;of
        long-lived assets</span></strong></span></span></span></span></span></span></p> </td> </tr>
  </table> </div> </div> </div> </div>

<div>

<p style="margin:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>

<p style="margin-top:0pt;margin-left:47px;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><span><span><span style="line-height:normal">The
</span></span></span></span></span>Company tests long-lived assets for impairment whenever events or changes in circumstances indicate
that the carrying amount of an asset may no longer be recoverable. Recoverability of long-lived assets is measured by comparing the carrying
amount of the long-lived asset to the estimated undiscounted future cash flows expected to be generated by the asset. If the sum of the
expected undiscounted cash flow is less than the carrying amount of the asset, the Company recognizes an impairment loss, which is the
excess of the carrying amount over the fair value of the asset, using the expected future discounted cash flows.</span></span></span></span></p>

<p style="margin-top:0pt;margin-left:47px;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>

<p style="margin-top:0pt;margin-left:47px;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span style="line-height:107%">As
of December 31, 2022 and 2021, the Company did not recognize an impairment loss on its long-lived assets.</span></span></span></span></span></p>
</div> </div> </ix:nonNumeric>

<p style="margin:0pt">&#160;</p> <ix:nonNumeric id="F20230227081832032_12" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" contextRef="C_20220101to20221231" escape="true">

<div>

<div style="line-height:1.25">

<div>

<div style="line-height:1.25">

<div style="line-height:1.25">

<table cellpadding="0" cellspacing="0" style="font-family:Times New Roman, Times, serif;font-size:10pt;width:100%;text-align:left;color:rgb(0, 0, 0);border:0px">
  <tr>
    <td style="width:47px;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>m.</strong></span></span></td>
    <td style="width:auto;vertical-align:top;text-align:justify">
        <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:left"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><strong><span style="line-height:107%">Share-based
        compensation </span></strong></span></span></span></span></span></span></p> </td> </tr>
  </table> </div> </div> </div> </div>

<div>

<p style="margin:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>

<p style="margin-top:0pt;margin-left:47px;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><span><span><span style="line-height:normal"><span><span>The
</span></span></span></span></span></span></span>Company grants share options and restricted share units (&#8220;RSU&#8221;) (together
&#8220;Share-Based Compensation&#8221;) to its employees, directors and non-employees in consideration for services rendered<span><span><span><span><span style="line-height:normal"><span><span>.</span></span></span></span></span></span></span></span></span></span></span></p>

<p style="margin:0pt">&#160;</p>

<p style="margin-top:0pt;margin-left:47px;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><span style="line-height:normal"><span><span>The
Company accounts for Share-Based Compensation awards classified as equity awards, including share-based option awards and RSUs, using
grant-date fair value. The Company recognize the value of the award as an expense over the requisite service period</span></span></span><span><span><span><span><span><span><span style="line-height:normal">.</span></span></span></span></span></span></span></span></span></span></span></span></span></p>

<p style="margin-top:0pt;margin-left:47px;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>

<p style="margin-top:0pt;margin-left:47px;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><span><span><span><span><span><span><span style="line-height:normal">The
Company applies ASU 2018-07 (Topic 718) that expands the scope of Topic 718 to include Share-Based Compensation transactions for acquiring
goods and services from non-employees. Under the provision of the amendment, the Company measures share-based compensation to non-employees
in the same manner as share-based compensation to employees.</span></span></span></span></span></span></span></span></span></span></span></span></span></p>

<p style="margin-top:0pt;margin-left:90px;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:left">&#160;</p>

<p style="margin-top:0pt;margin-left:47px;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><span style="line-height:107%">The
Company calculates the fair value of stock-based option awards on the date of grant using the Black-Scholes option pricing model. The
option-pricing model requires a number of assumptions, of which the most significant are the expected share price volatility and the expected
option term. The computation of expected volatility is based on the historical volatility of the Company&#8217;s ordinary shares. The
expected option term is calculated using the simplified method, as the Company has concluded that its historical share option exercise
experience does not provide a reasonable basis to estimate expected option terms. The interest rate for periods within the expected term
of an award is based on the U.S. Treasury yield curve in effect at the time of grant. The Company&#8217;s expected dividend rate is zero
because the Company does not currently pay cash dividends on its shares and does not anticipate doing so in the foreseeable future</span></span></span><span><span><span style="line-height:107%">.</span></span></span></span></span></span></span></p>

<p style="margin-top:0pt;margin-left:90px;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:left">&#160;</p>

<p style="margin-top:0pt;margin-left:47px;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><span style="line-height:107%">The
</span>Company elected to recognize compensation costs for awards granted to employees and directors conditioned only on continued service
that have a graded vesting schedule using the accelerated method based on the multiple-option award approach. The Company has elected
to account for forfeitures as they occur<span style="line-height:107%">.</span></span></span></span></span></span></span></p>

<p style="margin-top:0pt;margin-left:47px;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p> </div>
</div> </ix:nonNumeric>

<div>

<div><ix:exclude>

<div style="clear:both;margin-top:0pt;margin-bottom:0pt">

<div style="text-align:center;margin-top:10pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span><span><span><span><span style="color:#000000;font-weight:normal;font-style:normal">100</span></span></span></span></span></span></span></span></span></div>

<div style="page-break-after:always"><hr style="border-width:0px;clear:both;margin:4px 0px;width:100%;height:2px;color:#000000;background-color:#000000" /></div></div>

<p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:center">&#160;</p>

<p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:10pt;margin-bottom:0pt;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span><span><strong>ENTERA
BIO LTD.<br />NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS</strong></span></span></span></span></span></span></p>

<div style="text-align:center;line-height:1.25">

<div style="margin-top:0pt;margin-bottom:0pt;text-align:center;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span><span><span><span><span style="line-height:normal">(U.S.
dollars in thousands, except share and per share </span></span></span></span></span><span style="line-height:107%">amounts</span><span><span><span><span><span style="line-height:normal">)</span></span></span></span></span></span></span></span></span></div></div>

<p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman,Times,serif">&#160;</p>

<p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-size:10pt;font-family:Times New Roman, Times, serif;line-height:normal"><strong>NOTE
2 - SIGNIFICANT ACCOUNTING POLICIES (continued)</strong></span></p>

<p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p> </ix:exclude></div> <ix:nonNumeric id="F20230227081832032_13" name="us-gaap:ResearchAndDevelopmentExpensePolicy" contextRef="C_20220101to20221231" escape="true">

<div>

<div style="line-height:1.25">

<div>

<div style="line-height:1.25">

<div style="line-height:1.25">

<table cellpadding="0" cellspacing="0" style="font-family:Times New Roman, Times, serif;font-size:10pt;width:100%;text-align:left;color:rgb(0, 0, 0);border:0px">
  <tr>
    <td style="width:47px;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>n.</strong></span></span></td>
    <td style="width:auto;vertical-align:top;text-align:justify">
        <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:left"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><strong><span style="line-height:107%">Research
        and development expenses</span></strong></span></span></span></span></span></span></p> </td> </tr>
  </table> </div> </div> </div> </div>

<div>

<p style="margin:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:left">&#160;</p>

<p style="margin-top:0pt;margin-left:47px;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><span style="line-height:normal">Research
</span></span></span></span></span>and development expenses include costs directly attributable to the conduct of research and development
programs, including the cost of salaries, share-based compensation expenses, payroll taxes and other employee benefits, lab expenses,
consumable equipment and consulting fees. All costs associated with research and developments are expensed as incurred<span><span><span><span><span style="line-height:normal">.</span></span></span></span></span></span></span></p>

<p style="margin:0pt;text-align:left">&#160;</p>

<p style="margin-top:0pt;margin-left:48px;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><span style="line-height:normal">Grants
received from the Israel Innovation Authority (the &#160;&#8220;IIA&#8221;) are recognized when the grant becomes receivable, provided
there is reasonable assurance that the Company will comply with the conditions attached to the grant and there is reasonable assurance
the grant will be received. At the time grants are received, successful development of the related projects is not assured, therefore,
grants are deducted from the research and development expenses as the applicable costs are incurred, and presented in R&#38;D expenses,
net</span></span></span></span></span><span><span><span><span><span style="line-height:107%"><span>.</span></span></span></span></span></span></span></span></p>
</div> </div> </ix:nonNumeric> </div> <ix:nonNumeric id="F20230227081832033_14" name="us-gaap:RevenueRecognitionPolicyTextBlock" contextRef="C_20220101to20221231" escape="true">

<div>

<div>

<div style="line-height:1.25">

<div>

<div style="line-height:1.25">

<div style="line-height:1.25">

<table cellpadding="0" cellspacing="0" style="font-family:Times New Roman, Times, serif;font-size:10pt;width:100%;text-align:left;color:rgb(0, 0, 0);border:0px">
  <tr>
    <td style="width:47px;text-align:justify">&#160;</td>
    <td style="width:auto;vertical-align:top;text-align:justify">&#160;</td> </tr>
  <tr>
    <td style="width:47px;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><strong>o.</strong></span></span></span></span></td>
    <td style="width:auto;vertical-align:top;text-align:justify">
        <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:left"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><span><strong><span style="line-height:107%">Revenue
        recognition </span></strong></span></span></span></span></span></span></span></p> </td> </tr>
  </table> </div> </div> </div> </div>

<div>

<p style="margin:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>

<p style="margin-top:0pt;margin-left:47px;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><span><span><span><span><span style="line-height:normal">The
Company recognized revenue from the Amgen Agreement according to ASC 606, "Revenues from Contracts with Customers&#8221;. Prior to the
signing of the Amgen Agreement in 2018, the Company did not have revenue transactions.</span></span></span></span></span></span></span></span></span></span></span></p>

<p style="margin:0pt;text-align:left">&#160;</p>

<p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;margin-left:47px"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>ASC
606 Revenue from Contracts with Customer introduces a five-step model for recognizing revenue from contracts with customers, as follows:</span></span></span></span></p>

<p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;margin-left:47px"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>1.&#160;
Identify the contract with a customer.</span></span></span></span></p>

<p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;margin-left:47px"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>2.&#160;
Identify the performance obligations in the contract.</span></span></span></span></p>

<p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;margin-left:47px"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>3.&#160;
Determine the transaction price.</span></span></span></span></p>

<p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;margin-left:47px"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>4.&#160;
Allocate the transaction price to the performance obligations in the contract.</span></span></span></span></p>

<p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;margin-left:47px"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>5.&#160;
Recognize revenue when (or as) the entity satisfies a performance obligation.</span></span></span></span></p>

<p style="margin:0pt;text-align:left">&#160;</p>

<p style="margin-top:0pt;margin-left:47px;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><span><span><span style="line-height:normal">According
to ASC 606, a performance obligation is a promise to provide a distinct good or service or a series of distinct goods or services. Goods
and services that are not distinct are bundled with other goods or services in the contract until a bundle of goods or services that is
distinct is created. A good or service promised to a customer is distinct if the customer can benefit from the good or service either
on its own or together with other resources that are readily available to the customer and the entity&#8217;s promise to transfer the
good or service to the customer is separately identifiable from other promises in the contract.</span></span></span></span></span></span></span></span></span></p>

<p style="margin:0pt;text-align:left">&#160;</p>

<p style="margin-top:0pt;margin-left:47px;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><span><span><span style="line-height:107%">Options
granted to the customer that do not provide a material right to the customer that it would not receive without entering into the contract
do not give rise to performance obligations.</span></span></span></span></span></span></span></span></span></p>

<p style="margin:0pt">&#160;</p>

<p style="margin-top:0pt;margin-left:47px;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><span><span><span><span><span style="line-height:normal">On
December 10, 2018, the Company entered into the Amgen Agreement for the use of the Company&#8217;s oral delivery platform in the field
of inflammatory diseases and other serious illnesses. As part of the agreement, the Company received non-refundable and non-creditable
initial access payment of $<ix:nonFraction id="F20230227081832047_22" name="entx:NonRefundableAndNonCreditableInitialTechnologyAccessFeePayment" contextRef="C_20190101to20190131_usgaapRelatedPartyTransactionsByRelatedPartyAxis_entxAmgenIncMember" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">725</ix:nonFraction>&#160;from
Amgen in January 2019.</span></span></span></span></span></span></span></span></span></span></span></p>

<p style="margin:0pt">&#160;</p>

<p style="margin-top:0pt;margin-left:47px;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><span><span><span style="line-height:normal">The
Company identified two performance obligations in the agreement: 1) License to use the Company's proprietary drug delivery platform and
2) pre-clinical research and development services (&#8220;pre-clinical R&#38;D services&#8221;). The preclinical R&#38;D services include
discovery, research and design preclinical activities relating to the programs selected by Amgen.</span></span></span></span></span></span></span></span></span></p>

<p style="margin-top:0pt;margin-left:47px;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>

<div><ix:exclude>

<div>

<div>

<div style="clear:both;margin-top:0pt;margin-bottom:0pt">

<div style="text-align:center;margin-top:10pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span><span><span><span><span style="color:#000000;font-weight:normal;font-style:normal">101</span></span></span></span></span></span></span></span></span></div>

<div style="page-break-after:always"><hr style="border-width:0px;clear:both;margin:4px 0px;width:100%;height:2px;color:#000000;background-color:#000000" /></div></div>

<p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:center">&#160;</p>

<p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:10pt;margin-bottom:0pt;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span><span><strong>ENTERA
BIO LTD.<br />NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS</strong></span></span></span></span></span></span></p>

<div style="text-align:center;line-height:1.25">

<div style="margin-top:0pt;margin-bottom:0pt;text-align:center;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span><span><span><span><span style="line-height:normal">(U.S.
dollars in thousands, except share and per share </span></span></span></span></span><span style="line-height:107%">amounts</span><span><span><span><span><span style="line-height:normal">)</span></span></span></span></span></span></span></span></span></div></div>

<p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman,Times,serif">&#160;</p>

<p style="margin:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="line-height:normal"><strong>NOTE
2 - SIGNIFICANT ACCOUNTING POLICIES (continued)</strong></span></span></span></p> </div> </div>

<p style="margin:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>

<div style="line-height:1.25">

<div>

<div style="line-height:1.25">

<div style="line-height:1.25">

<table cellpadding="0" cellspacing="0" style="font-family:Times New Roman, Times, serif;font-size:10pt;width:100%;text-align:left;color:rgb(0, 0, 0);border:0px">
  <tr>
    <td style="width:47px;text-align:justify;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>o.</strong></span></span></td>
    <td style="width:auto;vertical-align:top;text-align:justify">
        <p style="margin-top:0pt;margin-bottom:0pt;text-align:left;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><strong><span style="line-height:107%">Revenue
        recognition </span></strong><span style="line-height:107%"> (continued)</span></span></span></span></p> </td> </tr>
  </table>

<p style="margin:0pt">&#160;</p> </div> </div> </div> </div> </ix:exclude></div>

<p style="margin-top:0pt;margin-left:47px;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The
Company determined the license to the intellectual property to be a right to use that has significant standalone functionality separately
from the pre-clinical R&#38;D services since the Company is not required to continue to support, develop or maintain the intellectual
property transferred and will not undertake any activities to change the standalone functionality of the intellectual property. Therefore,
the license to the intellectual property is a distinct performance obligation and as such revenue is recognized at the point in time that
control of the license was transferred to Amgen on December 10, 2018.</span></span></p>

<p style="margin-top:0pt;margin-left:47px;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>

<p style="margin-top:0pt;margin-left:47px;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><span><span><span style="line-height:normal">Revenues
attributed to the preclinical R&#38;Ds services are recognized during the period of the pre-clinical R&#38;D services, over time according
to the input model method on a cost-to-cost basis, since the customer benefits from the research and development services as the entity
performs the service.</span></span></span></span></span></span></span></span></span><br />&#160;</p>

<p style="margin-top:0pt;margin-left:47px;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><span><span><span style="line-height:normal">The
Company evaluated the standalone selling price of the pre-clinical R&#38;D services at $<ix:nonFraction id="F20230227081832048_23" name="entx:AdditionalAmountPaidForServicesToBeRecognized" contextRef="C_20191231_usgaapRelatedPartyTransactionsByRelatedPartyAxis_entxAmgenIncMember" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">225</ix:nonFraction>&#160;and
the right to use the intellectual property at $<ix:nonFraction id="F20230227081832048_24" name="entx:RightToUseIntellectualProperty" contextRef="C_20191231_usgaapRelatedPartyTransactionsByRelatedPartyAxis_entxAmgenIncMember" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">500</ix:nonFraction>.</span></span></span></span></span></span></span></span></span></p>
</div> </div>

<div style="line-height:1.25">

<div>

<div style="line-height:1.25">&#160;</div> </div> </div>

<div>

<p style="margin-top:0pt;margin-left:47px;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><span><span><span style="line-height:normal"><span><span>The
</span></span>transaction price was comprised of fixed consideration and variable consideration (capped research and development reimbursements).
Under ASC 606, the consideration that the Company would be entitled to upon the achievement of contractual milestones, which are contingent
upon the occurrence of future events of development and commercial progress, are a form of variable consideration. Variable consideration
is included in the transaction price if, in the Company&#8217;s judgment, it is highly probable that a significant future reversal of
cumulative revenue under the contract will not occur. Estimates of variable consideration and determination of whether to include estimated
amounts in the transaction price are based largely on an assessment of the Company&#8217;s anticipated performance and all information
(historical, current and forecasted) that is reasonably available. As of December 31, 2022, the Company did not recognize any revenues
from any potential milestone payments<span><span>.</span></span></span></span></span></span></span></span></span></span></span></p>

<p style="margin:0pt;text-align:left">&#160;</p>

<p style="margin-top:0pt;margin-left:47px;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><span style="line-height:107%">An
entity should recognize revenue for a sales-based or usage-based royalty promised in exchange for a license of intellectual property only
when (or as) the later of the following events occurs:</span></span></span></span></span></span></span></p>

<div style="line-height:1.25">

<div style="line-height:1.25">

<div style="line-height:1.25;text-align:left">&#160;</div> </div> </div>

<div style="line-height:1.25">

<div style="line-height:1.25">

<table cellpadding="0" cellspacing="0" style="font-family:Times New Roman, Times, serif;font-size:10pt;width:100%;text-align:left;color:rgb(0, 0, 0);border:0px">
  <tr>
    <td style="width:47px">&#160;</td>
    <td style="width:45px;vertical-align:top;font-family:Times New Roman, Times, serif;text-align:justify">
        <div style="font-size:10pt">
        <div style="font-family:Times New Roman, Times, serif;text-align:left"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>a)</span></span></span></span></div>
        </div> </td>
    <td style="width:auto;vertical-align:top">
        <div>
        <div style="text-align:justify">
        <div style="font-size:10pt">
        <div style="font-family:Times New Roman, Times, serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>The
        subsequent sale or usage occurs; and</span></span></span></span></div> </div> </div> </div> </td> </tr>
  </table>

<table cellpadding="0" cellspacing="0" style="font-family:Times New Roman, Times, serif;font-size:10pt;width:100%;text-align:left;color:rgb(0, 0, 0);border:0px">
  <tr>
    <td style="width:47px;text-align:justify">&#160;</td>
    <td style="width:45px;vertical-align:top;font-family:Times New Roman, Times, serif;text-align:justify">
        <div style="font-size:10pt">
        <div style="font-family:Times New Roman, Times, serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>b)</span></span></span></span></div>
        </div> </td>
    <td style="width:auto;vertical-align:top">
        <div>
        <div style="text-align:justify">
        <div style="font-size:10pt">
        <div style="font-family:Times New Roman, Times, serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>The
        performance obligation to which some or all of the sales based or usage-based royalty has been allocated has been satisfied (or partially
        satisfied).</span></span></span></span></div> </div> </div> </div> </td> </tr>
  </table> </div> </div> </div>

<p style="margin:0pt;text-align:left">&#160;</p>

<p style="margin-top:0pt;margin-left:47px;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><span><span><span style="line-height:normal">As
</span></span></span></span></span>royalties are payable based on future commercial sales, as defined in the agreement, which did not
occur as of the financial statements date, the Company did not recognize any revenues from royalties.&#160;</span></span></span></span></p>

<p style="margin-top:0pt;margin-left:47px;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>

<p style="margin-top:0pt;margin-left:47px;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span style="font-weight:bold"><span><span><span style="font-weight:normal">Revenues
attributed to preclinical R&#38;D services are recognized during the period of the pre-clinical R&#38;D services according to the input
model method on a cost-to-cost basis</span></span></span><span><span><span style="font-weight:normal">.</span></span></span></span></span></span></span></span></span></p>

<p style="margin-top:0pt;margin-left:47px;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>

<p style="margin-top:0pt;margin-left:47px;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span style="line-height:107%">In
2022 and 2021, the Company recorded revenues of $<ix:nonFraction id="Fxbrl_20230228150010939" name="us-gaap:DeferredRevenueRevenueRecognized1" contextRef="C_20220101to20221231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">89</ix:nonFraction>
and $<ix:nonFraction id="Fxbrl_20230228150015534" name="us-gaap:DeferredRevenueRevenueRecognized1" contextRef="C_20210101to20211231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">502</ix:nonFraction>,
respectively, related to services provided under the Amgen Agreement.</span></span></span></span></span></p>

<p style="margin-top:0pt;margin-left:47px;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p> </div>
</ix:nonNumeric>

<div><ix:exclude>

<div style="clear:both;margin-top:0pt;margin-bottom:0pt">

<div style="text-align:center;margin-top:10pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span><span><span><span><span style="color:#000000;font-weight:normal;font-style:normal">102</span></span></span></span></span></span></span></span></span></div>

<div style="page-break-after:always"><hr style="border-width:0px;clear:both;margin:4px 0px;width:100%;height:2px;color:#000000;background-color:#000000" /></div></div>

<p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:center">&#160;</p>

<p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:10pt;margin-bottom:0pt;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span><span><strong>ENTERA
BIO LTD.<br />NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS</strong></span></span></span></span></span></span></p>

<div style="text-align:center;line-height:1.25">

<div style="margin-top:0pt;margin-bottom:0pt;text-align:center;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span><span><span><span><span style="line-height:normal">(U.S.
dollars in thousands, except share and per share </span></span></span></span></span><span style="line-height:107%">amounts</span><span><span><span><span><span style="line-height:normal">)</span></span></span></span></span></span></span></span></span></div></div>

<p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman,Times,serif">&#160;</p>

<div style="text-align:justify;line-height:1.25;font-family:Times New Roman, Times, serif">

<div style="font-size:10pt">

<div style="font-family:Times New Roman, Times, serif"><span style="font-size:10pt;font-family:Times New Roman, Times, serif;line-height:normal"><strong><span>NOTE
2 - SIGNIFICANT ACCOUNTING POLICIES (continued)</span></strong></span></div>

<div style="font-family:Times New Roman, Times, serif">&#160;</div> </div> </div> </ix:exclude></div> <ix:nonNumeric id="F20230227081832033_15" name="us-gaap:IncomeTaxPolicyTextBlock" contextRef="C_20220101to20221231" escape="true">

<div>

<div style="text-align:justify;line-height:1.25">

<table cellpadding="0" cellspacing="0" style="font-family:Times New Roman, Times, serif;font-size:10pt;width:100%;text-align:left;color:rgb(0, 0, 0);border:0px">
  <tr>
    <td style="width:47px;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><strong>p.</strong></span></span></span></span></td>
    <td style="width:auto;vertical-align:top">
        <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><span><span><strong><span style="line-height:107%">Income
        taxes </span></strong></span></span></span></span></span></span></span></span></p> </td> </tr>
  </table> </div>

<p style="margin:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font-family:Times New Roman, Times, serif;font-size:10pt;width:100%;text-align:left;color:rgb(0, 0, 0);border:0px">
  <tr>
    <td style="width:47px;text-align:justify">&#160;</td>
    <td style="width:40px;vertical-align:top;font-family:Times New Roman, Times, serif;text-align:justify">
        <div style="font-size:10pt">
        <div style="font-family:Times New Roman, Times, serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><span>1)</span></span></span></span></span></span></span></div>
        </div> </td>
    <td style="width:auto;vertical-align:top">
        <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><span style="line-height:normal">Deferred
        taxes</span></span></span></span></span></span></span></p> </td> </tr>
  </table>

<div style="line-height:1.25;text-align:left">&#160;</div>

<div style="margin-left:47px;text-align:justify;line-height:1.25;font-family:Times New Roman, Times, serif">

<div style="font-size:10pt">

<div style="font-family:Times New Roman, Times, serif;margin-left:40px"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><span style="line-height:107%">Deferred&#160;</span></span></span></span></span>income
taxes are computed using the asset and liability method. Under the asset and liability method, deferred income tax assets and liabilities
are determined based on the differences between the financial reporting and tax bases of assets and liabilities and are measured using
the currently enacted tax rates and laws. A valuation allowance is recognized to the extent that it is more likely than not that the deferred
taxes will not be realized in the foreseeable future<span><span><span><span><span style="line-height:107%">.</span></span></span></span></span></span></span></div>
</div> </div>

<p style="margin:0pt;text-align:left">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font-family:Times New Roman, Times, serif;font-size:10pt;width:100%;text-align:left;color:rgb(0, 0, 0);border:0px">
  <tr>
    <td style="width:47px">&#160;</td>
    <td style="width:40px;vertical-align:top;font-family:Times New Roman, Times, serif;text-align:justify">
        <div style="font-size:10pt">
        <div style="font-family:Times New Roman, Times, serif;text-align:left"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><span>2)</span></span></span></span></span></span></span></div>
        </div> </td>
    <td style="width:auto;vertical-align:top">
        <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><span style="line-height:107%">Uncertainty
        in income taxes</span></span></span></span></span></span></span></p> </td> </tr>
  </table>

<div style="line-height:1.25;text-align:left">&#160;</div>

<div style="margin-left:47px;text-align:justify;line-height:1.25;font-family:Times New Roman, Times, serif">

<div style="font-size:10pt">

<div style="font-family:Times New Roman, Times, serif;margin-left:40px"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><span style="line-height:107%">The
Company follows a two-step approach in recognizing and measuring uncertain tax positions. The first step is to evaluate the tax position
for recognition by determining if the available evidence indicates that it is more likely than not that the position will be sustained
based on technical merits. If this threshold is met, the second step is to measure the tax position as the largest amount that has more
than a 50% likelihood of being realized upon ultimate settlement.</span></span></span></span></span></span></span></div> </div> </div>
</div> </ix:nonNumeric>

<div style="text-align:justify;line-height:1.25;font-family:Times New Roman, Times, serif">

<div style="font-size:10pt">

<div style="font-family:Times New Roman, Times, serif">

<p style="margin:0pt">&#160;</p> </div> </div> </div> <ix:nonNumeric id="F20230227081832033_16" name="us-gaap:EarningsPerSharePolicyTextBlock" contextRef="C_20220101to20221231" escape="true">

<div>

<div style="line-height:1.25">

<div>

<div style="line-height:1.25">

<div style="line-height:1.25">

<table cellpadding="0" cellspacing="0" style="font-family:Times New Roman, Times, serif;font-size:10pt;width:100%;text-align:left;color:rgb(0, 0, 0);border:0px">
  <tr>
    <td style="width:47px;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><strong>q.</strong></span></span></span></span></td>
    <td style="width:auto;vertical-align:top;text-align:justify">
        <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:left"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><span><span><strong><span style="line-height:107%">Loss
        per share </span></strong></span></span></span></span></span></span></span></span></p> </td> </tr>
  </table> </div> </div> </div> </div>

<div>

<p style="margin:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>

<p style="margin-top:0pt;margin-left:47px;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><span style="line-height:107%">Basic
loss per share is computed on the basis of the net loss, adjusted to recognize the effect of a down-round feature when it is triggered,
for the period, divided by the weighted average number of outstanding ordinary shares during the period.</span></span></span></span></span></span></span></p>

<p style="margin:0pt">&#160;</p>

<p style="margin-top:0pt;margin-left:47px;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><span><span><span><span><span style="line-height:107%">Diluted
</span></span></span></span></span>loss per share is based upon the weighted average number of ordinary shares and of ordinary shares
equivalents outstanding when dilutive. Ordinary share equivalents include outstanding stock options and warrants, which are included under
the treasury stock method when dilutive. The calculation of diluted loss per share does not include options, RSUs and warrants, exercisable
into an aggregate of<span><span><span><span><span style="line-height:107%">&#160;<ix:nonFraction id="Fxbrl_20230227154246022" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="C_20220101to20221231" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">6,255,235</ix:nonFraction>
shares and&#160;</span><span style="line-height:107%"><ix:nonFraction id="F20230227081832048_26" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="C_20210101to20211231" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">6,517,102</ix:nonFraction></span><strong>&#160;</strong></span></span></span></span>shares
for the years ended December&#160;31, 2022&#160;and 2021, respectively, because the effect would have been anti-dilutive.</span></span></span></span></span></span></p>
</div> </div> </ix:nonNumeric>

<p style="margin:0pt">&#160;</p> <ix:nonNumeric id="F20230227081832050_31" name="us-gaap:CommitmentsAndContingenciesPolicyTextBlock" contextRef="C_20220101to20221231" escape="true">

<div>

<div style="line-height:1.25">

<div>

<div style="line-height:1.25">

<div style="line-height:1.25">

<table cellpadding="0" cellspacing="0" style="font-family:Times New Roman, Times, serif;font-size:10pt;width:100%;text-align:left;color:rgb(0, 0, 0);border:0px">
  <tr>
    <td style="width:47px;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong><span><span><span>r.</span></span></span></strong></span></span></td>
    <td style="width:auto;vertical-align:top;text-align:justify">
        <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong><span><span>Legal
        and other contingencies</span></span></strong></span></span></p> </td> </tr>
  </table> </div> </div> </div> </div>

<div>

<p style="margin:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>

<p style="margin-top:0pt;margin-left:47px;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><span style="line-height:107%">Management&#160;</span></span></span></span></span>applies
the guidance in ASC 450-20, &#8220;Loss Contingencies&#8221; when assessing losses resulting from contingencies. If the assessment of
a contingency indicates that it is probable that a material loss has been incurred and the amount of the liability can be estimated, then
the estimated liability is recorded as accrued expenses in the Company&#8217;s consolidated financial statements<span>.</span></span></span></p>

<p style="margin:0pt">&#160;</p>

<p style="margin-top:0pt;margin-left:47px;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Legal
costs incurred in connection with loss contingencies are expensed as incurred<span style="line-height:107%">.</span></span></span></p>

<p style="margin-top:0pt;margin-left:47px;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p> </div>
</div> </ix:nonNumeric>

<div>

<div><ix:exclude>

<div>

<div>

<div>

<div style="clear:both;margin-top:0pt;margin-bottom:0pt">

<div style="text-align:center;margin-top:10pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span><span><span><span><span style="color:#000000;font-weight:normal;font-style:normal">103</span></span></span></span></span></span></span></span></span></div>

<div style="page-break-after:always"><hr style="border-width:0px;clear:both;margin:4px 0px;width:100%;height:2px;color:#000000;background-color:#000000" /></div></div>

<p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:center">&#160;</p>

<p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:10pt;margin-bottom:0pt;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span><span><strong>ENTERA
BIO LTD.<br />NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS</strong></span></span></span></span></span></span></p>

<div style="text-align:center;line-height:1.25">

<div style="margin-top:0pt;margin-bottom:0pt;text-align:center;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span><span><span><span><span style="line-height:normal">(U.S.
dollars in thousands, except share and per share </span></span></span></span></span><span style="line-height:107%">amounts</span><span><span><span><span><span style="line-height:normal">)</span></span></span></span></span></span></span></span></span></div></div>

<p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman,Times,serif">&#160;</p>

<p style="margin:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="line-height:normal"><strong><span>NOTE
2 - SIGNIFICANT ACCOUNTING POLICIES (continued)</span></strong></span></span></span></p>

<p style="margin:0pt">&#160;</p> </div> </div> </div> </ix:exclude></div> </div> <ix:nonNumeric id="F20230227081832049_27" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" contextRef="C_20220101to20221231" escape="true">

<div>

<div style="line-height:1.25">

<div>

<div style="line-height:1.25">

<div style="line-height:1.25">

<table cellpadding="0" cellspacing="0" style="font-family:Times New Roman, Times, serif;font-size:10pt;width:100%;text-align:left;color:rgb(0, 0, 0);border:0px">
  <tr>
    <td style="width:47px;vertical-align:top;font-family:Times New Roman, Times, serif;font-weight:bold;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>s.</span></span></span></span></td>
    <td style="width:auto;vertical-align:top;text-align:justify">
        <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:left"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><span><span><strong><span style="line-height:107%">Newly
        issued and recently adopted accounting pronouncements:</span></strong></span></span></span></span></span></span></span></span></p> </td>
        </tr>
  </table> </div> </div> </div> </div>

<div>

<p style="margin:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>

<p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;margin-left:38pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><em><strong><span><span>Recently
issued accounting pronouncements adopted</span></span></strong></em></span></span></span></span></p>

<p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>

<div style="margin-left:47px">

<table cellpadding="0" cellspacing="0" style="border:0px;width:100%">
  <tr>
    <td style="vertical-align:top;width:20pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>1)</span></span></span></span></td>
    <td style="width:auto">
        <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>In&#160;</span></span><span style="line-height:107%">November
        2021, the FASB issued ASU 2021-10 &#8220;Government Assistance (Topic 832)&#8221;, which requires annual disclosures that increase the
        transparency of transactions involving government grants, including (1) the types of transactions, (2) the accounting for those transactions,
        and (3) the effect of those transactions on an entity&#8217;s financial statements. The amendments in this update are effective for financial
        statements issued for annual periods beginning after December 15, 2021.</span>&#160;<span style="line-height:107%">The adoption of this
        guidance did not have material impact on the Company&#8217;s consolidated financial statements.</span></span></span></span></span></p>
        </td> </tr>
  </table> </div>

<p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>

<div style="margin-left:47px">

<table cellpadding="0" cellspacing="0" style="border:0px;width:100%">
  <tr>
    <td style="vertical-align:top;width:20pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>2)</span></span></span></span></td>
    <td style="width:auto">
        <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>In
        </span></span><span style="line-height:107%">August 2020, the FASB issued ASU 2020-06 &#8220;Debt &#8211; Debt with Conversion and Other
        Options (Subtopic 470-20) and Derivatives and Hedging &#8211; Contracts in Entity&#8217;s Own Equity (Subtopic 815 &#8211; 40).&#8221;
        This guidance simplifies the accounting for certain financial instruments with characteristics of liabilities and equity, including convertible
        instruments and contracts on an entity&#8217;s own equity. The amendments to this guidance are effective for fiscal years beginning after
        December&#160;15, 2021, and interim periods within those fiscal years. The Company early adopted this guidance effective January 1, 2022
        and the impact of the adoption on the Consolidated financial statements was immaterial.</span></span></span></span></span></p> </td> </tr>
  </table> </div>

<p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt">&#160;</p>

<p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;margin-left:38pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><em><strong>Recently
issued accounting pronouncements, not yet adopted</strong></em></span></span></p>

<p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt">&#160;</p>

<div style="margin-left:47px">

<table cellpadding="0" cellspacing="0" style="border:0px;width:100%">
  <tr>
    <td style="vertical-align:top;width:20pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>1)</span></span></span></span></td>
    <td style="width:auto">
        <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>I</span></span></span></span></span><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><span>n
        </span></span><span style="line-height:107%">June 2016, the FASB issued ASU 2016-13 &#8220;Financial Instruments&#8212;Credit Losses&#8212;Measurement
        of Credit Losses on Financial Instruments.&#8221; This guidance replaces the current incurred loss impairment methodology with a methodology
        that reflects expected credit losses and requires consideration of a broader range of reasonable and supportable information to inform
        credit loss estimates. </span></span></span></span></span></span><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="line-height:107%">The
        guidance will be effective for Smaller Reporting Companies (SRCs, as defined by the SEC) for the fiscal year beginning on January 1, 2023,
        including interim periods within that year. The adoption of this guidance will not have material impact on the Company&#8217;s consolidated
        financial statements.</span></span></span></p> </td> </tr>
  </table> </div> </div> </div> </ix:nonNumeric> </div> </div> </div> </div> </div> </div> </ix:nonNumeric> </div> </div>

<p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman,Times,serif">&#160;</p>

<div style="clear:both;margin-top:0pt;margin-bottom:0pt">

<div style="text-align:center;margin-top:10pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span><span><span><span><span style="color:#000000;font-weight:normal;font-style:normal">104</span></span></span></span></span></span></span></span></span></div>

<div style="page-break-after:always"><hr style="border-width:0px;clear:both;margin:4px 0px;width:100%;height:2px;color:#000000;background-color:#000000" /></div></div>

<p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:center">&#160;</p>

<p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:10pt;margin-bottom:0pt;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span><span><strong>ENTERA
BIO LTD.<br />NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS</strong></span></span></span></span></span></span></p>

<div style="text-align:center;line-height:1.25">

<div style="margin-top:0pt;margin-bottom:0pt;text-align:center;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span><span><span><span><span style="line-height:normal">(U.S.
dollars in thousands, except share and per share </span></span></span></span></span><span style="line-height:107%">amounts</span><span><span><span><span><span style="line-height:normal">)</span></span></span></span></span></span></span></span></span></div></div>

<p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman,Times,serif">&#160;</p> <ix:nonNumeric id="F20230227081114746_0" name="us-gaap:LesseeOperatingLeasesTextBlock" contextRef="C_20220101to20221231" escape="true">

<div>

<div>

<div>

<div>

<div>

<div style="font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">NOTE 3 - OPERATING LEASES</span></span></div>

<div style="line-height:1.25;font-weight:bold">&#160;</div>

<table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">
  <tr>
    <td style="width:35.45pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">1)</span></span></td>
    <td style="width:auto;vertical-align:top;text-align:justify">
        <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The Company leases office and research and development
        space under several agreements. The annual lease consideration is a total of $<ix:nonFraction id="F20230227081114758_22" name="us-gaap:PaymentForContingentConsiderationLiabilityOperatingActivities" contextRef="C_20220101to20221231_entxLeaseArrangementAxis_entxOperatingLeaseAgreementsForOfficeAndResearchAndDevelopmentSpaceMember" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">166</ix:nonFraction>
        and is linked to the Israeli CPI. The lease agreement expires on June 30, 2023.</span></span></div> </td> </tr>
  </table>

<div style="line-height:1.25">&#160;</div>

<div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">As
of December 31, 2022, the Company provided bank guarantees of approximately $<ix:nonFraction id="F20230227081114758_21" name="entx:BankGuarantees" contextRef="C_20221231_entxLeaseArrangementAxis_entxOperatingLeaseAgreementsForOfficeAndResearchAndDevelopmentSpaceMember" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">37</ix:nonFraction>,
in the aggregate, to secure the fulfillment of its obligations under the lease agreements. </span></span></div>

<div style="line-height:1.25">&#160;</div>

<div>

<table cellpadding="0" cellspacing="0" style="width:100%;font-family:'Times New Roman', Times, serif;font-size:10pt">
  <tr style="vertical-align:top">
    <td style="vertical-align:top;width:35.45pt">
        <div style="text-align:justify;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2)</span></span></div>
        </td>
    <td style="align:left;vertical-align:top;width:auto">
        <div style="text-align:justify;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The
        Company has entered into operating lease agreements for vehicles used by its employees. The lease periods are generally for three years
        and the payments are linked to the Israeli CPI. To secure the terms of the lease agreements, the Company has made certain deposits to
        the leasing company, representing approximately three months of lease payments. The annual lease consideration is a total of $<ix:nonFraction id="F20230227081114758_20" name="us-gaap:PaymentForContingentConsiderationLiabilityOperatingActivities" contextRef="C_20220101to20221231_entxLeaseArrangementAxis_entxOperatingLeaseAgreementsForVehiclesForEmployeesMember" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">21</ix:nonFraction>.</span></span></div>
        </td> </tr>
  </table> </div>

<div style="margin-left:70.4pt;line-height:1.25">&#160;</div>

<div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The
lease cost was as follows:</span></span></div> </div> </div>

<div> <ix:nonNumeric id="F20230227081114760_27" name="us-gaap:LeaseCostTableTextBlock" contextRef="C_20220101to20221231" escape="true">

<div>

<div>

<div style="text-align:justify;margin-left:36pt;line-height:1.25">&#160;</div>

<div style="margin-left:45pt">

<table border="0" cellpadding="0" cellspacing="0" style="width:92%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left">
  <tr>
    <td style="vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px" valign="bottom">
        <div style="line-height:1.25">
        <div style="text-align:center;line-height:1.25;font-weight:bold;text-indent:1pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Year
        ended</span></span></div>
        <div style="text-align:center;line-height:1.25;font-weight:bold;text-indent:1pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">December&#160;31,<br />2022</span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px" valign="bottom">
        <div style="line-height:1.25">
        <div style="text-align:center;line-height:1.25;font-weight:bold;text-indent:1pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Year
        ended</span></span></div>
        <div style="text-align:center;line-height:1.25;font-weight:bold;text-indent:1pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">December&#160;31,<br />2021</span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td> </tr>
  <tr>
    <td style="vertical-align:bottom;width:76%;padding-bottom:4px;background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Operating
        lease cost</span></span></div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="F20230227081114758_23" name="us-gaap:OperatingLeaseCost" contextRef="C_20220101to20221231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">197</ix:nonFraction></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="F20230227081114758_24" name="us-gaap:OperatingLeaseCost" contextRef="C_20210101to20211231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">216</ix:nonFraction></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
        </tr>
  </table> </div> </div> </div> </ix:nonNumeric> </div>

<div style="margin-left:36pt">

<p style="margin:0pt">&#160;</p>

<p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Supplemental
cash flow information related to leases was as follows:</span></span></span></span><br />&#160;</p> </div>

<div style="line-height:1.25">

<div style="margin-left:45pt"> <ix:nonNumeric id="F20230227081114760_28" name="entx:OperatingLeaseSupplementalCashFlowInformationTableTextBlock" contextRef="C_20220101to20221231" escape="true">

<div>

<div>

<table border="0" cellpadding="0" cellspacing="0" style="width:92%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left">
  <tr>
    <td style="vertical-align:top;padding-bottom:2px" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px" valign="bottom">
        <div style="line-height:1.25">
        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Year
        ended</span></span></div>
        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">December&#160;31,<br />2022</span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px" valign="bottom">
        <div style="line-height:1.25">
        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Year
        ended</span></span></div>
        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">December&#160;31,<br />2021</span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td> </tr>
  <tr>
    <td style="vertical-align:top;width:76%;background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:normal"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Operating
        cash flows from operating leases</span></span></div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-weight:normal;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-weight:normal;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:normal"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="F20230227081114759_25" name="us-gaap:OperatingLeasePayments" contextRef="C_20220101to20221231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">197</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-weight:normal;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-weight:normal;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-weight:normal;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:normal"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="F20230227081114760_26" name="us-gaap:OperatingLeasePayments" contextRef="C_20210101to20211231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">216</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
        </tr>
  </table> </div> </div> </ix:nonNumeric>

<p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt">&#160;</p> </div> </div> </div>

<p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;margin-left:47px"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span>Supplemental
balance sheet information related to operating leases was as follows:</span></span></span></span></span></p>

<p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt">&#160;</p>

<div style="text-align:center">

<div style="clear:both;margin-top:00pt;margin-bottom:00pt">

<div style="text-align:center"> <div style="font-size:10pt;display:inline"> <div style="font-family:Times New Roman,Times,serif;display:inline">
<div style="color:#000000;font-weight:normal;font-style:normal;display:inline">

<div> <ix:nonNumeric id="F20230227081114748_1" name="entx:OperatingLeaseLiabilityAndOperatingLeaseRightOfUseAssetTableTextBlock" contextRef="C_20220101to20221231" escape="true">

<div>

<div>

<div style="line-height:1.25">

<div style="line-height:1.25">&#160;</div> </div>

<div style="margin-left:45pt">

<table border="0" cellpadding="0" cellspacing="0" style="width:92%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left">
  <tr>
    <td style="vertical-align:top;padding-bottom:2px" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px" valign="bottom">
        <div style="line-height:1.25">
        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">December&#160;31,<br />2022</span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px" valign="bottom">
        <div style="line-height:1.25">
        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">December&#160;31,<br />2021</span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td> </tr>
  <tr>
    <td style="vertical-align:bottom;font-weight:bold;background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="margin-right:36pt;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Operating
        Leases</span></span></div> </td>
    <td colspan="1" style="vertical-align:bottom;font-weight:normal;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align:top;font-weight:normal;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;font-weight:normal;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;font-weight:normal;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align:top;font-weight:normal;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;font-weight:normal;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align:bottom;width:76%" valign="bottom">
        <div style="margin-right:36pt;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:normal"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Operating
        lease right-of-use assets</span></span></div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-weight:normal" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-weight:normal" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%" valign="bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:normal"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="F20230227081114748_3" name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="C_20221231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">90</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-weight:normal;white-space:nowrap" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-weight:normal" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-weight:normal" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%" valign="bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:normal"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="F20230227081114749_4" name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="C_20211231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">239</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-weight:normal;white-space:nowrap" valign="bottom">&#160;</td> </tr>
  <tr>
    <td style="vertical-align:top;width:76%;font-weight:normal;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-weight:normal;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-weight:normal;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;font-weight:normal;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-weight:normal;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-weight:normal;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-weight:normal;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;font-weight:normal;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-weight:normal;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align:bottom;width:76%" valign="bottom">
        <div style="margin-right:36pt;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:normal"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Current
        lease liabilities</span></span></div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-weight:normal" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-weight:normal" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%" valign="bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:normal"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="F20230227081114749_5" name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="C_20221231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">91</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-weight:normal;white-space:nowrap" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-weight:normal" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-weight:normal" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%" valign="bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:normal"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="F20230227081114749_6" name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="C_20211231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">179</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-weight:normal;white-space:nowrap" valign="bottom">&#160;</td> </tr>
  <tr>
    <td style="vertical-align:bottom;width:76%;padding-bottom:2px;background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="margin-right:36pt;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:normal"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Non-current
        lease liabilities</span></span></div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;font-weight:normal;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);font-weight:normal;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:normal"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="F20230227081114749_7" name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="C_20221231" unitRef="USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;font-weight:normal;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;font-weight:normal;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);font-weight:normal;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:normal"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="F20230227081114749_8" name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="C_20211231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">123</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;font-weight:normal;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align:bottom;width:76%;font-weight:bold" valign="bottom">
        <div style="margin-right:36pt;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Total
        lease liabilities</span></span></div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-weight:normal" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-weight:normal" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%" valign="bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:normal"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="F20230227081114749_9" name="us-gaap:OperatingLeaseLiability" contextRef="C_20221231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">91</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-weight:normal;white-space:nowrap" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-weight:normal" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-weight:normal" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%" valign="bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:normal"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="F20230227081114750_10" name="us-gaap:OperatingLeaseLiability" contextRef="C_20211231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">302</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-weight:normal;white-space:nowrap" valign="bottom">&#160;</td> </tr>
  <tr>
    <td style="vertical-align:bottom;width:76%;font-weight:normal;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-weight:normal;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-weight:normal;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;font-weight:normal;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-weight:normal;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-weight:normal;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-weight:normal;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;font-weight:normal;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-weight:normal;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align:top;width:76%" valign="bottom">
        <div style="margin-right:36pt;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:normal"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Weighted-average
        remaining lease term (in years)</span></span></div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-weight:normal" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-weight:normal" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%" valign="bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:normal"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><ix:nonNumeric id="F20230227081114750_11" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" contextRef="C_20221231" format="ixt-sec:duryear">0.52</ix:nonNumeric></span></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-weight:normal;white-space:nowrap" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-weight:normal" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-weight:normal" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%" valign="bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:normal"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonNumeric id="F20230227081114750_12" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" contextRef="C_20211231" format="ixt-sec:duryear">1.53</ix:nonNumeric></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-weight:normal;white-space:nowrap" valign="bottom">&#160;</td> </tr>
  <tr>
    <td style="vertical-align:top;width:76%;background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="margin-right:36pt;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:normal"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Weighted-average
        discount rate</span></span></div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-weight:normal;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-weight:normal;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:normal"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="F20230227081114750_13" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" contextRef="C_20221231" unitRef="Percent" scale="-2" decimals="2" format="ixt:num-dot-decimal">16</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:normal"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">%</span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-weight:normal;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-weight:normal;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:normal"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="F20230227081114750_14" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" contextRef="C_20211231" unitRef="Percent" scale="-2" decimals="2" format="ixt:num-dot-decimal">16</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:normal"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">%</span></span></div>
        </td> </tr>
  </table> </div> </div> </div> </ix:nonNumeric> </div>

<div style="margin-left:96pt;line-height:1.25">&#160;</div>

<p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:left;margin-left:36pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><span>As
of December 31, 2022, the maturity of lease liabilities under our non-cancelable operating leases </span></span></span><span style="line-height:107%">are
$<ix:nonFraction id="Fxbrl_20230227144319586" name="us-gaap:OperatingLeaseLiability" contextRef="C_20221231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">91</ix:nonFraction>
to be paid in 2023.</span></span></span></span></span></p> </div> </div> </div> </div> </div> </div> </div> </div> </ix:nonNumeric>

<p style="margin:0pt">&#160;</p>

<div style="clear:both;margin-top:0pt;margin-bottom:0pt">

<div style="text-align:center;margin-top:10pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span><span><span><span><span style="color:#000000;font-weight:normal;font-style:normal">105</span></span></span></span></span></span></span></span></span></div>

<div style="page-break-after:always"><hr style="border-width:0px;clear:both;margin:4px 0px;width:100%;height:2px;color:#000000;background-color:#000000" /></div></div>

<p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:center">&#160;</p>

<p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:10pt;margin-bottom:0pt;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span><span><strong>ENTERA
BIO LTD.<br />NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS</strong></span></span></span></span></span></span></p>

<div style="text-align:center;line-height:1.25">

<div style="margin-top:0pt;margin-bottom:0pt;text-align:center;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span><span><span><span><span style="line-height:normal">(U.S.
dollars in thousands, except share and per share </span></span></span></span></span><span style="line-height:107%">amounts</span><span><span><span><span><span style="line-height:normal">)</span></span></span></span></span></span></span></span></span></div></div>

<p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman,Times,serif">&#160;</p>

<div>

<div> <ix:nonNumeric id="F20230227081114771_0" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" contextRef="C_20220101to20221231" escape="true">

<div>

<div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">NOTE
4 - COMMITMENTS</span>&#160;<span style="font-weight:bold">AND CONTINGENCIES</span></span></span></div>

<div style="text-indent:-36pt;margin-left:36pt;line-height:1.25;font-weight:bold">&#160;</div>

<table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">
  <tr>
    <td style="width:35.45pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">a<span style="font-weight:bold">.</span></span></span></td>
    <td style="width:auto;vertical-align:top;text-align:justify">
        <div style="font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Commitment to pay royalties
        to the government of Israel</span></span></div> </td> </tr>
  </table>

<div style="text-indent:-36pt;margin-left:72pt;line-height:1.25">&#160;</div>

<div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The
Company is committed to pay royalties to the IIA on proceeds from sales of products in the research and development of which the Government
participates by way of grants. At the time the grants were received, successful development of the related project was not assumed. In
the case of failure of the project that was partly financed by the IIA, the Company is not obligated to pay any such royalties.</span></span></div>

<div style="line-height:1.25">&#160;</div>

<div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Under
the terms of the Company&#8217;s funding from the IIA, royalties are payable on sales of products developed from IIA funded projects of
<ix:nonFraction id="F20230227081114771_1" name="entx:RoyaltyGuaranteesCommitmentsPercentageSalesOfProductsDevelopedFromProjectsInFirstThreeYearsFromCommencementOfRevenues" contextRef="C_20220101to20221231_usgaapAccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis_usgaapGovernmentMember" unitRef="Percent" scale="-2" decimals="2" format="ixt:num-dot-decimal">3</ix:nonFraction>%
during the first three years from commencement of revenues, <ix:nonFraction id="F20230227081114772_2" name="entx:RoyaltyGuaranteesCommitmentsPercentageSalesOfProductsDevelopedFromProjectsSubsequentThreeYears" contextRef="C_20220101to20221231_usgaapAccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis_usgaapGovernmentMember" unitRef="Percent" scale="-2" decimals="2" format="ixt:num-dot-decimal">4</ix:nonFraction>%
during the subsequent three years and <ix:nonFraction id="F20230227081114772_3" name="entx:RoyaltyGuaranteesCommitmentsPercentageSalesOfProductsDevelopedFromProjectsCommencingSeventhYear" contextRef="C_20220101to20221231_usgaapAccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis_usgaapGovernmentMember" unitRef="Percent" scale="-2" decimals="2" format="ixt:num-dot-decimal">5</ix:nonFraction>%
commencing the seventh year up to 100% of the amount of the grant received by the Company (dollar linked) plus annual interest based on
LIBOR. The amount that must be repaid may be increased to three times the amount of the grant received, and the rate of royalties may
be accelerated, if manufacturing of the products developed with the grant money is transferred outside of the State of Israel. In addition,
if the Company undergoes a change of control or otherwise transfers the technology &#8220;know-how&#8221; (as defined under the Research
Law) in or outside of Israel, the amount that must be repaid will be increased up to six times.</span></span></div>

<div style="line-height:1.25">&#160;</div>

<div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The
IIA has not yet declared the alternative benchmark rate to replace LIBOR. However, the Company does not believe it will have significant
impact on the Company&#8217;s financial position or results of operations.</span></span></div>

<div style="line-height:1.25">&#160;</div>

<div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">As
of December 31, 2022, the total royalty amount that would be payable by the Company to the IIA, before the interest and payments as described
above, was approximately $<ix:nonFraction id="F20230227081114772_7" name="us-gaap:RoyaltyGuaranteesCommitmentsAmount" contextRef="C_20221231_usgaapAccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis_usgaapGovernmentMember" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">460</ix:nonFraction>.
These grants were allocated to research and development.</span></span></div>

<div style="line-height:1.25">&#160;</div>

<div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Following
the signing of the Amgen Agreement, the IIA determined that the Company should pay <ix:nonFraction id="F20230227081114772_4" name="entx:RoyaltyGuaranteesCommitmentsPercentageOfEachPaymentReceivedFromAmgen" contextRef="C_20220101to20221231_usgaapAccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis_usgaapGovernmentMember" unitRef="Percent" scale="-2" decimals="4" format="ixt:num-dot-decimal">5.38</ix:nonFraction>%
of each payment received by the Company from Amgen on the license of Intellectual Property up to six times the grant received. As of December
31, 2022, the Company had paid a total amount of $<ix:nonFraction id="F20230227081114772_8" name="entx:PaymentOfRoyaltyGuaranteesCommitments" contextRef="C_20220101to20221231_usgaapAccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis_usgaapGovernmentMember" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">83</ix:nonFraction>
to the IIA.</span></span></div>

<div style="text-indent:-36pt;margin-left:36pt;line-height:1.25;font-weight:bold">&#160;</div>

<table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">
  <tr>
    <td style="width:35.45pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">b.</span></span></td>
    <td style="width:auto;vertical-align:top;text-align:justify">
        <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">On June 1, 2010, D.N.A. Biomedical Solutions Ltd.
        ("D.N.A.") and Oramed Ltd., ("Oramed") entered into a joint venture agreement, (the "Joint Venture Agreement") for the establishment of
        Entera Bio Ltd. According to the Joint Venture Agreement each of D.N.A. and Oramed acquired <ix:nonFraction id="F20230227081114772_5" name="entx:SaleOfStockPercentageOfOwnershipOfEntityAcquired" contextRef="C_20220101to20221231_entxAgreementAxis_entxJointVentureAgreementMember_usgaapRelatedPartyTransactionsByRelatedPartyAxis_entxDnaBiomedicalSolutionsLtdAndOramedLtdMember" unitRef="Percent" scale="-2" decimals="2" format="ixt:num-dot-decimal">50</ix:nonFraction>%
        of the Company's ordinary shares. D.N.A invested $<ix:nonFraction id="F20230227081114772_9" name="entx:SaleOfStockAmountOfInvestment" contextRef="C_20220101to20221231_entxAgreementAxis_entxJointVentureAgreementMember_usgaapRelatedPartyTransactionsByRelatedPartyAxis_entxDnaBiomedicalSolutionsLtdMember" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">600</ix:nonFraction>
        in the Company, and Oramed and the Company entered into a Patent License Agreement pursuant to which Oramed licensed to the Company one
        of Oramed&#8217;s patents (the &#8220;IPR&#38;D&#8221;).</span></span></div> </td> </tr>
  </table>

<div style="line-height:1.25">&#160;</div>

<div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">On
February 22, 2011, Oramed and the Company entered into a patent transfer agreement, (the "Patent Transfer Agreement") that superseded
the Patent License Agreement, whereby Oramed assigned to the Company all of its rights, title and interest to its patent that Oramed licensed
to the Company in 2010, under certain conditions. Under this agreement, the Company is obligated to pay Oramed royalties equal to <ix:nonFraction id="F20230227081114772_6" name="entx:RoyaltyGuaranteesCommitmentsPercentageOfNetRevenues" contextRef="C_20220101to20221231_entxAgreementAxis_entxPatentTransferAgreementMember" unitRef="Percent" scale="-2" decimals="2" format="ixt:num-dot-decimal">3</ix:nonFraction>%
of its net revenues (as defined in the Patent Transfer Agreement).</span></span></div> </div> </ix:nonNumeric>

<p style="margin:0pt">&#160;</p>

<div style="clear:both;margin-top:0pt;margin-bottom:0pt">

<div style="text-align:center;margin-top:10pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span><span><span><span><span style="color:#000000;font-weight:normal;font-style:normal">106</span></span></span></span></span></span></span></span></span></div>

<div style="page-break-after:always"><hr style="border-width:0px;clear:both;margin:4px 0px;width:100%;height:2px;color:#000000;background-color:#000000" /></div></div>

<p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:center">&#160;</p>

<p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:10pt;margin-bottom:0pt;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span><span><strong>ENTERA
BIO LTD.<br />NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS</strong></span></span></span></span></span></span></p>

<div style="text-align:center;line-height:1.25">

<div style="margin-top:0pt;margin-bottom:0pt;text-align:center;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span><span><span><span><span style="line-height:normal">(U.S.
dollars in thousands, except share and per share </span></span></span></span></span><span style="line-height:107%">amounts</span><span><span><span><span><span style="line-height:normal">)</span></span></span></span></span></span></span></span></span></div></div>

<p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman,Times,serif">&#160;</p> </div> </div>

<div>

<div style="line-height:1.25"> <ix:nonNumeric id="Fxbrl_20230330110216722" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" contextRef="C_20220101to20221231" escape="true">

<div>

<div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>NOTE
5 - SHARE CAPITAL</span></span></span></span></div>

<div style="line-height:1.25">&#160;</div>

<table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">
  <tr>
    <td style="width:35.45pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>1)</span></span></span></span></td>
    <td style="width:auto;vertical-align:top;text-align:justify">
        <div style="font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Rights of
        the Company&#8217;s ordinary shares</span></span></span></span></div> </td> </tr>
  </table>

<div style="margin-left:72pt;line-height:1.25;font-weight:bold">&#160;</div>

<div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Each
ordinary share is entitled to <ix:nonNumeric id="F20230227081114811_0" name="us-gaap:CommonStockVotingRights" contextRef="C_20220101to20221231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember">one
vote</ix:nonNumeric>. The holder of an ordinary shares is also entitled to receive dividends whenever funds are legally available, when
and if declared by the Board of Directors.<br />&#160;</span></span></span></span></div>

<div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>A
holder of an ordinary share also has the right to receive upon liquidation of the Company, a sum equal to the nominal value of such share,
and if a surplus per share remains, to receive such surplus, subject to the rights conferred on any class of shares which may be issued
in the future. Since its inception, the Company has not declared any dividends.</span></span></span></span></div>

<div style="text-align:justify;margin-left:70.9pt;line-height:1.25">&#160;</div>

<table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">
  <tr>
    <td style="width:35.45pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>2)</span></span></span></span></td>
    <td style="width:auto;vertical-align:top;text-align:justify">
        <div style="font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Changes in
        share capital:</span></span></span></span></div> </td> </tr>
  </table>

<div style="line-height:1.25">&#160;</div>

<table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">
  <tr>
    <td style="width:35.45pt">&#160;</td>
    <td style="width:21.25pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>a.</span></span></span></span></td>
    <td style="width:auto;vertical-align:top">
        <div style="font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>IPO warrants</span></span></span></span></div>
        </td> </tr>
  </table>

<div style="line-height:1.25">&#160;</div>

<div style="text-align:justify;margin-left:56.7pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>In
connection with the Company&#8217;s initial public offering (&#8220;IPO&#8221;) in July 2018, the Company issued <ix:nonFraction id="F20230227081114812_1" name="entx:ClassOfWarrantOrRightIssued" contextRef="C_20180731_usgaapClassOfWarrantOrRightAxis_usgaapWarrantMember_usgaapSubsidiarySaleOfStockAxis_usgaapIPOMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">1,400,000</ix:nonFraction>
IPO warrants to purchase <ix:nonFraction id="F20230227081114812_2" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="C_20180731_usgaapClassOfWarrantOrRightAxis_usgaapWarrantMember_usgaapSubsidiarySaleOfStockAxis_usgaapIPOMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">700,000</ix:nonFraction>
ordinary shares, and these warrants have been listed for trading on the Nasdaq Capital Market since August 12, 2018. The IPO warrants
were immediately exercisable at an initial exercise price of $<ix:nonFraction id="F20230227081114812_3" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="C_20180731_usgaapClassOfWarrantOrRightAxis_usgaapWarrantMember_usgaapSubsidiarySaleOfStockAxis_usgaapIPOMember" unitRef="USD_per_Share" scale="0" decimals="2" format="ixt:num-dot-decimal">8.40</ix:nonFraction>
per ordinary share for a period of <ix:nonNumeric id="F20230227081114813_4" name="entx:ClassOfWarrantOrRightExerciseTerm" contextRef="C_20180701to20180731_usgaapClassOfWarrantOrRightAxis_usgaapWarrantMember_usgaapSubsidiarySaleOfStockAxis_usgaapIPOMember" format="ixt-sec:durwordsen">five
years</ix:nonNumeric>, unless earlier repurchased by the Company under "Fundamental Transactions&#8221; as described in the warrant agreement
or earlier expired as described in the warrant agreement.</span></span></span></span></div>

<div style="text-align:justify;margin-left:56.7pt;line-height:1.25"><br /><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>The
exercise price and number of ordinary shares issuable upon exercise of each warrant are subject to standard adjustments. In addition,
subject to certain exceptions, the exercise price was subject to reduction if, within <ix:nonNumeric id="F20230227081114813_5" name="entx:ClassOfWarrantOrRightThresholdLimitOfPeriodForReductionInExercisePrice" contextRef="C_20180701to20180731_usgaapClassOfWarrantOrRightAxis_usgaapWarrantMember_usgaapSubsidiarySaleOfStockAxis_usgaapIPOMember" format="ixt-sec:durwordsen">two
years</ix:nonNumeric> following the date of original issuance of the warrants, which ended in July 2020, the Company sold or granted any
warrant or option at an effective price per share of less than $<ix:nonFraction id="F20230227081114813_6" name="entx:ClassOfWarrantOrRightThresholdLimitOfReductionInExercisePrice" contextRef="C_20180701to20180731_usgaapClassOfWarrantOrRightAxis_usgaapWarrantMember_usgaapSubsidiarySaleOfStockAxis_usgaapIPOMember" unitRef="USD_per_Share" scale="0" decimals="2" format="ixt:num-dot-decimal">8.00</ix:nonFraction>
(as adjusted in proportion with any adjustments made from time to time), based on a weighted average, as described in the warrant agreement.
As described in note 5b below, the Company completed a financing round during such two-year period at a price per share lower than the
$8.00, therefore, the exercise price of these warrants adjusted to $<ix:nonFraction id="F20230227081114813_7" name="entx:ClassOfWarrantOrRightReducedExercisePrice" contextRef="C_20180701to20180731_usgaapClassOfWarrantOrRightAxis_usgaapWarrantMember_usgaapSubsidiarySaleOfStockAxis_usgaapIPOMember" unitRef="USD_per_Share" scale="0" decimals="2" format="ixt:num-dot-decimal">5.85</ix:nonFraction>
per share.</span></span></span></span></div>

<div style="text-align:justify;margin-left:56.7pt;line-height:1.25">&#160;</div>

<div style="text-align:justify;margin-left:56.7pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>At
the IPO completion date, both of the instruments (warrants and shares) were classified as equity instruments as the warrants are considered
indexed to the entity's own stock based on the provision of ASC 815.<br />&#160;<br />In March 2021, <ix:nonFraction id="F20230227081114814_8" name="entx:ClassOfWarrantOrRightIssued" contextRef="C_20210331_usgaapClassOfWarrantOrRightAxis_usgaapWarrantMember_usgaapSubsidiarySaleOfStockAxis_usgaapIPOMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">4,500</ix:nonFraction>
IPO warrants were exercised into <ix:nonFraction id="F20230227081114814_9" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="C_20210331_usgaapClassOfWarrantOrRightAxis_usgaapWarrantMember_usgaapSubsidiarySaleOfStockAxis_usgaapIPOMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">2,250</ix:nonFraction>
ordinary shares for total consideration of $<ix:nonFraction id="F20230227081114814_10" name="entx:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsTotalConsideration" contextRef="C_20210301to20210331_usgaapClassOfWarrantOrRightAxis_usgaapWarrantMember_usgaapSubsidiarySaleOfStockAxis_usgaapIPOMember" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">13</ix:nonFraction>
at an exercise price of $<ix:nonFraction id="F20230227081114815_11" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="C_20210331_usgaapClassOfWarrantOrRightAxis_usgaapWarrantMember_usgaapSubsidiarySaleOfStockAxis_usgaapIPOMember" unitRef="USD_per_Share" scale="0" decimals="2" format="ixt:num-dot-decimal">5.85</ix:nonFraction>
per ordinary share.</span></span></span></span></div>

<div style="text-align:justify;margin-left:56.7pt;line-height:1.25">&#160;</div>

<div style="text-align:justify;margin-left:56.7pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>As
of the December 31, 2022 there were <ix:nonFraction id="F20230227081114832_56" name="entx:ClassOfWarrantOrRightIssued" contextRef="C_20221231_usgaapClassOfWarrantOrRightAxis_usgaapWarrantMember_usgaapSubsidiarySaleOfStockAxis_usgaapIPOMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">1,395,500</ix:nonFraction>
traded warrants to purchase <ix:nonFraction id="F20230227081114833_57" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="C_20221231_usgaapClassOfWarrantOrRightAxis_usgaapWarrantMember_usgaapSubsidiarySaleOfStockAxis_usgaapIPOMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">697,750</ix:nonFraction>
ordinary shares outstanding with an exercise price of $<ix:nonFraction id="F20230227081114833_58" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="C_20221231_usgaapClassOfWarrantOrRightAxis_usgaapWarrantMember_usgaapSubsidiarySaleOfStockAxis_usgaapIPOMember" unitRef="USD_per_Share" scale="0" decimals="2" format="ixt:num-dot-decimal">5.85</ix:nonFraction>.</span></span></span></span></div>

<div style="text-align:justify;margin-left:56.7pt;line-height:1.25">&#160;</div>

<div><ix:exclude>

<div>

<div style="clear:both;margin-top:0pt;margin-bottom:0pt">

<div style="text-align:center;margin-top:10pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span><span><span><span><span style="color:#000000;font-weight:normal;font-style:normal">107</span></span></span></span></span></span></span></span></span></div>

<div style="page-break-after:always"><hr style="border-width:0px;clear:both;margin:4px 0px;width:100%;height:2px;color:#000000;background-color:#000000" /></div></div>

<p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:center">&#160;</p>

<p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:10pt;margin-bottom:0pt;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span><span><strong>ENTERA
BIO LTD.<br />NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS</strong></span></span></span></span></span></span></p>

<div style="text-align:center;line-height:1.25">

<div style="margin-top:0pt;margin-bottom:0pt;text-align:center;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span><span><span><span><span style="line-height:normal">(U.S.
dollars in thousands, except share and per share </span></span></span></span></span><span style="line-height:107%">amounts</span><span><span><span><span><span style="line-height:normal">)</span></span></span></span></span></span></span></span></span></div></div>

<p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman,Times,serif">&#160;</p>

<p style="margin:0pt"><strong><span style="font-family:Times New Roman, Times, serif;font-size:10pt">NOTE 5 - SHARE CAPITAL (continued)</span></strong></p>

<p style="margin:0pt">&#160;</p> </div> </ix:exclude></div>

<div style="text-align:justify;line-height:1.25">

<table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">
  <tr>
    <td style="width:35.45pt">&#160;</td>
    <td style="width:21.25pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>b.</span></span></span></span></td>
    <td style="width:auto;vertical-align:top;text-align:justify">
        <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>In December 2019 and February 2020,
        the Company entered into subscription agreement with a selected group of accredited investors for the private placement of <ix:nonFraction id="Fxbrl_20230228132916187" name="entx:NumberOfSharesIssuedUnderPrivatePlacement" contextRef="C_20200229_usgaapRelatedPartyTransactionsByRelatedPartyAxis_entxAccreditedInvestorsIncludingCertainBoardMembersAndTheirAffiliatesMember_usgaapSubsidiarySaleOfStockAxis_usgaapPrivatePlacementMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="F20230227081114820_12" name="entx:NumberOfSharesIssuedUnderPrivatePlacement" contextRef="C_20191231_usgaapRelatedPartyTransactionsByRelatedPartyAxis_entxAccreditedInvestorsIncludingCertainBoardMembersAndTheirAffiliatesMember_usgaapSubsidiarySaleOfStockAxis_usgaapPrivatePlacementMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">6,047,706</ix:nonFraction></ix:nonFraction>
        ordinary shares for aggregate subscription proceeds to the Company of $<ix:nonFraction id="Fxbrl_20230228133001926" name="us-gaap:ProceedsFromIssuanceOfPrivatePlacement" contextRef="C_20200201to20200229_usgaapRelatedPartyTransactionsByRelatedPartyAxis_entxAccreditedInvestorsIncludingCertainBoardMembersAndTheirAffiliatesMember_usgaapSubsidiarySaleOfStockAxis_usgaapPrivatePlacementMember" unitRef="USD" scale="6" decimals="-5" format="ixt:num-dot-decimal"><ix:nonFraction id="F20230227081114820_13" name="us-gaap:ProceedsFromIssuanceOfPrivatePlacement" contextRef="C_20190101to20191231_usgaapRelatedPartyTransactionsByRelatedPartyAxis_entxAccreditedInvestorsIncludingCertainBoardMembersAndTheirAffiliatesMember_usgaapSubsidiarySaleOfStockAxis_usgaapPrivatePlacementMember" unitRef="USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">14.3</ix:nonFraction></ix:nonFraction>
        million at a price of $<ix:nonFraction id="Fxbrl_20230228132938100" name="us-gaap:SharePrice" contextRef="C_20200229_usgaapRelatedPartyTransactionsByRelatedPartyAxis_entxAccreditedInvestorsIncludingCertainBoardMembersAndTheirAffiliatesMember_usgaapSubsidiarySaleOfStockAxis_usgaapPrivatePlacementMember" unitRef="USD_per_Share" scale="0" decimals="2" format="ixt:num-dot-decimal"><ix:nonFraction id="F20230227081114820_14" name="us-gaap:SharePrice" contextRef="C_20191231_usgaapRelatedPartyTransactionsByRelatedPartyAxis_entxAccreditedInvestorsIncludingCertainBoardMembersAndTheirAffiliatesMember_usgaapSubsidiarySaleOfStockAxis_usgaapPrivatePlacementMember" unitRef="USD_per_Share" scale="0" decimals="2" format="ixt:num-dot-decimal">2.37</ix:nonFraction></ix:nonFraction>
        per share. In addition, the Company granted <ix:nonFraction id="Fxbrl_20230228132950878" name="entx:ClassOfWarrantOrRightIssued" contextRef="C_20200229_usgaapRelatedPartyTransactionsByRelatedPartyAxis_entxAccreditedInvestorsIncludingCertainBoardMembersAndTheirAffiliatesMember_usgaapSubsidiarySaleOfStockAxis_usgaapPrivatePlacementMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="F20230227081114821_15" name="entx:ClassOfWarrantOrRightIssued" contextRef="C_20191231_usgaapRelatedPartyTransactionsByRelatedPartyAxis_entxAccreditedInvestorsIncludingCertainBoardMembersAndTheirAffiliatesMember_usgaapSubsidiarySaleOfStockAxis_usgaapPrivatePlacementMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">3,023,871</ix:nonFraction></ix:nonFraction>
        warrants, exercisable over a <ix:nonNumeric id="Fxbrl_20230228133032196" name="entx:ClassOfWarrantOrRightExerciseTerm" contextRef="C_20200201to20200229_usgaapRelatedPartyTransactionsByRelatedPartyAxis_entxAccreditedInvestorsIncludingCertainBoardMembersAndTheirAffiliatesMember_usgaapSubsidiarySaleOfStockAxis_usgaapPrivatePlacementMember" format="ixt-sec:durwordsen"><ix:nonNumeric id="F20230227081114821_16" name="entx:ClassOfWarrantOrRightExerciseTerm" contextRef="C_20190101to20191231_usgaapRelatedPartyTransactionsByRelatedPartyAxis_entxAccreditedInvestorsIncludingCertainBoardMembersAndTheirAffiliatesMember_usgaapSubsidiarySaleOfStockAxis_usgaapPrivatePlacementMember" format="ixt-sec:durwordsen">three-year</ix:nonNumeric></ix:nonNumeric>
        period from the date of issuance to purchase up to <ix:nonFraction id="Fxbrl_20230228133118411" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="C_20200229_usgaapRelatedPartyTransactionsByRelatedPartyAxis_entxAccreditedInvestorsIncludingCertainBoardMembersAndTheirAffiliatesMember_usgaapSubsidiarySaleOfStockAxis_usgaapPrivatePlacementMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="F20230227081114821_17" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="C_20191231_usgaapRelatedPartyTransactionsByRelatedPartyAxis_entxAccreditedInvestorsIncludingCertainBoardMembersAndTheirAffiliatesMember_usgaapSubsidiarySaleOfStockAxis_usgaapPrivatePlacementMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">3,023,871</ix:nonFraction></ix:nonFraction>
        ordinary shares at a per share exercise price of $<ix:nonFraction id="Fxbrl_20230228133128455" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="C_20200229_usgaapRelatedPartyTransactionsByRelatedPartyAxis_entxAccreditedInvestorsIncludingCertainBoardMembersAndTheirAffiliatesMember_usgaapSubsidiarySaleOfStockAxis_usgaapPrivatePlacementMember" unitRef="USD_per_Share" scale="0" decimals="2" format="ixt:num-dot-decimal"><ix:nonFraction id="F20230227081114821_18" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="C_20191231_usgaapRelatedPartyTransactionsByRelatedPartyAxis_entxAccreditedInvestorsIncludingCertainBoardMembersAndTheirAffiliatesMember_usgaapSubsidiarySaleOfStockAxis_usgaapPrivatePlacementMember" unitRef="USD_per_Share" scale="0" decimals="2" format="ixt:num-dot-decimal">2.96</ix:nonFraction></ix:nonFraction>
        (&#8220;Investors Warrants&#8221;). In addition, the exercise price was subject to reduction if, within one year of the date of original
        issuance of the warrants which ended in December 2020, the Company issued ordinary shares at an effective price per share less than $<ix:nonFraction id="Fxbrl_20230228133138472" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="C_20200229_usgaapRelatedPartyTransactionsByRelatedPartyAxis_entxAccreditedInvestorsIncludingCertainBoardMembersAndTheirAffiliatesMember_usgaapSubsidiarySaleOfStockAxis_usgaapPrivatePlacementMember" unitRef="USD_per_Share" scale="0" decimals="2" format="ixt:num-dot-decimal"><ix:nonFraction id="Fxbrl_20230228100113652" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="C_20191231_usgaapRelatedPartyTransactionsByRelatedPartyAxis_entxAccreditedInvestorsIncludingCertainBoardMembersAndTheirAffiliatesMember_usgaapSubsidiarySaleOfStockAxis_usgaapPrivatePlacementMember" unitRef="USD_per_Share" scale="0" decimals="2" format="ixt:num-dot-decimal">2.96</ix:nonFraction></ix:nonFraction>.<br />&#160;<br />Following
        the closing of the offering, the Company issued to a broker-dealer <ix:nonFraction id="Fxbrl_20230228133157525" name="us-gaap:SharesIssued" contextRef="C_20200229_usgaapClassOfWarrantOrRightAxis_entxBrokerDealerMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="Fxbrl_20230228101446660" name="us-gaap:SharesIssued" contextRef="C_20191231_usgaapClassOfWarrantOrRightAxis_entxBrokerDealerMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">184,515</ix:nonFraction></ix:nonFraction>
        warrants and <ix:nonFraction id="Fxbrl_20230228133202830" name="us-gaap:SharesIssued" contextRef="C_20200229_usgaapClassOfWarrantOrRightAxis_entxBrokerDealerOneMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="Fxbrl_20230228101451219" name="us-gaap:SharesIssued" contextRef="C_20191231_usgaapClassOfWarrantOrRightAxis_entxBrokerDealerOneMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">92,257</ix:nonFraction></ix:nonFraction>
        warrants with per share exercise prices of $<ix:nonFraction id="Fxbrl_20230228133226908" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="C_20200229_usgaapClassOfWarrantOrRightAxis_entxBrokerWarrantsMember" unitRef="USD_per_Share" scale="0" decimals="2" format="ixt:num-dot-decimal"><ix:nonFraction id="F20230227081114825_26" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="C_20191231_usgaapClassOfWarrantOrRightAxis_entxBrokerWarrantsMember" unitRef="USD_per_Share" scale="0" decimals="2" format="ixt:num-dot-decimal">2.37</ix:nonFraction></ix:nonFraction>
        to $<ix:nonFraction id="Fxbrl_20230228133248658" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="C_20200229_usgaapClassOfWarrantOrRightAxis_entxBrokerWarrantsType1Member" unitRef="USD_per_Share" scale="0" decimals="2" format="ixt:num-dot-decimal"><ix:nonFraction id="Fxbrl_20230228101543156" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="C_20191231_usgaapClassOfWarrantOrRightAxis_entxBrokerWarrantsType1Member" unitRef="USD_per_Share" scale="0" decimals="2" format="ixt:num-dot-decimal">2.96</ix:nonFraction></ix:nonFraction>,
        respectively (&#8220;Broker Warrants&#8221;).</span></span></span></span></div> </td> </tr>
  </table> </div>

<div style="text-align:justify;margin-left:56.7pt;line-height:1.25">&#160;</div>

<div style="text-align:justify;margin-left:56.7pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>During
2020, upon issuance of shares through the Company&#8217;s At-the-market equity program at a price per share lower than the exercise price,
the exercise price of the Investors Warrants and the Broker Warrants adjusted to $<ix:nonFraction id="F20230227081114834_62" name="entx:AdjustedExercisePriceUnderAtMarketEquityProgram" contextRef="C_20201231_entxEquityProgramAxis_entxAtmEquityProgram2020Member" unitRef="USD_per_Share" scale="0" decimals="2" format="ixt:num-dot-decimal">1.05</ix:nonFraction>.
See note 5c.<br />&#160;<br />On April 21, 2021, upon satisfaction of the sale price condition pursuant to the subscription agreement,
the Company&#8217;s Board of Directors elected to accelerate the termination date of the Investors Warrants and Broker Warrants. In accordance
with the terms of the applicable agreements, the holders had the opportunity to exercise their warrants until June 23, 2021, following
which any unexercised warrants would terminate.<br />&#160;</span></span></span></span></div>

<div style="text-align:justify;margin-left:56.7pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Through
June 23, 2021, all warrants holders exercised <ix:nonFraction id="F20230227081114826_32" name="entx:ClassOfWarrantOrRightIssued" contextRef="C_20210623_usgaapClassOfWarrantOrRightAxis_usgaapWarrantMember_usgaapRelatedPartyTransactionsByRelatedPartyAxis_entxChairmanOfBoardAndDnaMember_usgaapSubsidiarySaleOfStockAxis_usgaapPrivatePlacementMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">3,300,645</ix:nonFraction>
warrants into <ix:nonFraction id="F20230227081114826_33" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="C_20210623_usgaapRelatedPartyTransactionsByRelatedPartyAxis_entxChairmanOfBoardAndDnaMember_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember_usgaapSubsidiarySaleOfStockAxis_usgaapPrivatePlacementMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">3,172,800</ix:nonFraction>
ordinary shares, either through purchase or a cashless exercise. The total consideration from the exercise of these warrants was $<ix:nonFraction id="F20230227081114827_34" name="us-gaap:ProceedsFromWarrantExercises" contextRef="C_20210601to20210623_usgaapClassOfWarrantOrRightAxis_usgaapWarrantMember_usgaapRelatedPartyTransactionsByRelatedPartyAxis_entxChairmanOfBoardAndDnaMember_usgaapSubsidiarySaleOfStockAxis_usgaapPrivatePlacementMember" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,145</ix:nonFraction>
at an exercise price of $<ix:nonFraction id="F20230227081114827_35" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="C_20210623_usgaapClassOfWarrantOrRightAxis_usgaapWarrantMember_usgaapRelatedPartyTransactionsByRelatedPartyAxis_entxChairmanOfBoardAndDnaMember_usgaapSubsidiarySaleOfStockAxis_usgaapPrivatePlacementMember" unitRef="USD_per_Share" scale="0" decimals="2" format="ixt:num-dot-decimal">1.05</ix:nonFraction>
per share.</span></span></span></span></div>

<div style="line-height:1.25">&#160;</div>

<div style="text-align:justify;margin-left:56.7pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>As
of December 31, 2021, all Investors Warrants and Broker Warrants had been exercised and none remain outstanding.<br />&#160;</span></span></span></span></div>

<div style="text-align:justify;line-height:1.25">

<table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">
  <tr>
    <td style="width:35.45pt">&#160;</td>
    <td style="width:21.25pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>c.</span></span></span></span></td>
    <td style="width:auto;vertical-align:top;text-align:justify">
        <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>On July 4, 2020, the Company filed
        a primary registration statement on form F-3 and established an at-the-market equity program (the " 2020 ATM Program") that allowed the
        Company to issue up to $<ix:nonFraction id="F20230227081114830_42" name="us-gaap:CommonStockValue" contextRef="C_20200704_entxEquityProgramAxis_entxAtmEquityProgram2020Member_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">13.9</ix:nonFraction>
        million of ordinary shares, at the Company&#8217;s discretion. Distributions of the ordinary shares through 2020 ATM Program were made
        pursuant to the terms of an equity distribution agreement dated July 13, 2020, among the Company and Canaccord Genuity LLC (the "Agent").</span></span></span></span></div>
        </td> </tr>
  </table> </div>

<div style="text-align:justify;margin-left:56.7pt;line-height:1.25">&#160;</div>

<div style="text-align:justify;margin-left:56.7pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>In
2020, the Company issued <ix:nonFraction id="F20230227081114830_43" name="us-gaap:SharesIssued" contextRef="C_20201231_entxEquityProgramAxis_entxAtmEquityProgram2020Member_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">2,802,731</ix:nonFraction>
ordinary shares pursuant to the 2020 ATM Program for net proceeds of $<ix:nonFraction id="Fxbrl_20230228102503264" name="entx:NetProceedsFromIssuanceOfCommonStock" contextRef="C_20200101to20201231_entxEquityProgramAxis_entxAtmEquityProgram2020Member_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">3.2</ix:nonFraction>
million at a weighted average price of $<ix:nonFraction id="F20230227081114831_46" name="entx:SharesIssuedWeightedAveragePricePerShare" contextRef="C_20201231_entxEquityProgramAxis_entxAtmEquityProgram2020Member_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="USD_per_Share" scale="0" decimals="2" format="ixt:num-dot-decimal">1.27</ix:nonFraction>
per ordinary share.<br />&#160;<br />In 2021, the Company issued an additional <ix:nonFraction id="F20230227081114831_47" name="us-gaap:SharesIssued" contextRef="C_20211231_entxEquityProgramAxis_entxAtmEquityProgram2020Member_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">2,546,265</ix:nonFraction>
ordinary shares pursuant to the 2020 ATM Program for net proceeds of $<ix:nonFraction id="F20230227081114831_48" name="entx:NetProceedsFromIssuanceOfCommonStock" contextRef="C_20210101to20211231_entxEquityProgramAxis_entxAtmEquityProgram2020Member_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">9.9</ix:nonFraction>
million at a weighted average price of $<ix:nonFraction id="F20230227081114831_49" name="entx:SharesIssuedWeightedAveragePricePerShare" contextRef="C_20211231_entxEquityProgramAxis_entxAtmEquityProgram2020Member_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="USD_per_Share" scale="0" decimals="2" format="ixt:num-dot-decimal">3.99</ix:nonFraction>
per ordinary share.<br />&#160;</span></span></span></span></div>

<div style="text-align:justify;line-height:1.25">

<table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">
  <tr>
    <td style="width:35.45pt">&#160;</td>
    <td style="width:21.25pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>d.</span></span></span></span></td>
    <td style="width:auto;vertical-align:top;text-align:justify">
        <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>On May 7, 2021, the Company entered
        into a new at-the-market equity program (the "2021 ATM Program") that allowed the Company to issue up to additional <ix:nonFraction id="F20230227081114834_63" name="us-gaap:SharesIssued" contextRef="C_20210507_entxEquityProgramAxis_entxAtmEquityProgram2021Member_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="shares" scale="6" decimals="-6" format="ixt-sec:numwordsen">five</ix:nonFraction>
        million ordinary shares, at the Company's discretion.</span></span></span></span></div> </td> </tr>
  </table> </div>

<div style="line-height:1.25">&#160;</div>

<div>

<div><ix:exclude>

<div style="clear:both;margin-top:0pt;margin-bottom:0pt">

<div style="text-align:center;margin-top:10pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span><span><span><span><span style="color:#000000;font-weight:normal;font-style:normal">108</span></span></span></span></span></span></span></span></span></div>

<div style="page-break-after:always"><hr style="border-width:0px;clear:both;margin:4px 0px;width:100%;height:2px;color:#000000;background-color:#000000" /></div></div>

<p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:center">&#160;</p>

<p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:10pt;margin-bottom:0pt;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span><span><strong>ENTERA
BIO LTD.<br />NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS</strong></span></span></span></span></span></span></p>

<div style="text-align:center;line-height:1.25">

<div style="margin-top:0pt;margin-bottom:0pt;text-align:center;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span><span><span><span><span style="line-height:normal">(U.S.
dollars in thousands, except share and per share </span></span></span></span></span><span style="line-height:107%">amounts</span><span><span><span><span><span style="line-height:normal">)</span></span></span></span></span></span></span></span></span></div></div>

<p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman,Times,serif">&#160;</p>

<p style="margin:0pt"><strong><span style="font-family:Times New Roman, Times, serif;font-size:10pt">NOTE 5 - SHARE CAPITAL (continued)</span></strong></p>

<p style="margin:0pt">&#160;</p> </ix:exclude></div> </div>

<div style="text-align:justify;margin-left:56.7pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Distributions
of the ordinary shares through the 2021 ATM Program were made pursuant to the terms of an equity distribution agreement dated May 7, 2021
among the Company and B. Riley Securities, Inc.</span></span></span></span></div>

<div style="line-height:1.25">&#160;</div>

<table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">
  <tr>
    <td style="width:35.45pt">&#160;</td>
    <td style="width:21.25pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>e.</span></span></span></span></td>
    <td style="width:auto;vertical-align:top;text-align:justify">
        <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>In June and July 2021, the Company
        issued an aggregate of <ix:nonFraction id="F20230227081114831_50" name="us-gaap:SharesIssued" contextRef="C_20210731_entxEquityProgramAxis_entxAtmEquityProgram2021Member_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">1,840,463</ix:nonFraction>
        ordinary shares pursuant to the 2021 ATM Program for net proceeds of $<ix:nonFraction id="F20230227081114832_52" name="entx:NetProceedsFromIssuanceOfCommonStock" contextRef="C_20210601to20210731_entxEquityProgramAxis_entxAtmEquityProgram2021Member_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">12.1</ix:nonFraction>
        million at a weighted average price of $<ix:nonFraction id="F20230227081114831_51" name="entx:SharesIssuedWeightedAveragePricePerShare" contextRef="C_20210731_entxEquityProgramAxis_entxAtmEquityProgram2021Member_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="USD_per_Share" scale="0" decimals="2" format="ixt:num-dot-decimal">6.74</ix:nonFraction>
        per ordinary share.</span></span></span></span></div> </td> </tr>
  </table>

<div style="line-height:1.25">&#160;</div>

<table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">
  <tr>
    <td style="width:35.45pt">&#160;</td>
    <td style="width:21.25pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>f.</span></span></span></span></td>
    <td style="width:auto;vertical-align:top;text-align:justify">
        <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>During the year ended December 31,
        2021, several employees and service providers exercised <ix:nonFraction id="F20230227081114832_53" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="C_20210101to20211231_usgaapRelatedPartyTransactionsByRelatedPartyAxis_entxSeveralEmployeesAndServiceProvidersMember_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">177,711</ix:nonFraction>
        options into <ix:nonFraction id="F20230227081114832_54" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" contextRef="C_20210101to20211231_usgaapRelatedPartyTransactionsByRelatedPartyAxis_entxSeveralEmployeesAndServiceProvidersMember_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">177,711</ix:nonFraction>
        ordinary shares for a total consideration of $<ix:nonFraction id="Fxbrl_20230228102140874" name="entx:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsTotalConsideration" contextRef="C_20210101to20211231_usgaapRelatedPartyTransactionsByRelatedPartyAxis_entxSeveralEmployeesAndServiceProvidersMember_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">418</ix:nonFraction>
        at a weighted average price of $<ix:nonFraction id="F20230227081114832_55" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" contextRef="C_20210101to20211231_usgaapRelatedPartyTransactionsByRelatedPartyAxis_entxSeveralEmployeesAndServiceProvidersMember_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="USD_per_Share" scale="0" decimals="2" format="ixt:num-dot-decimal">2.54</ix:nonFraction>
        per ordinary share.</span></span></span></span></div> </td> </tr>
  </table>

<div style="line-height:1.25">&#160;</div>

<table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">
  <tr>
    <td style="width:35.45pt">&#160;</td>
    <td style="width:21.25pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>g.</span></span></span></span></td>
    <td style="width:auto;vertical-align:top;text-align:justify">
        <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>During the year ended December 31,
        2022, one employee exercised <ix:nonFraction id="Fxbrl_20230228102310848" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="C_20220101to20221231_usgaapRelatedPartyTransactionsByRelatedPartyAxis_entxSeveralEmployeesAndServiceProvidersMember_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">5,511</ix:nonFraction>
        options into <ix:nonFraction id="Fxbrl_20230228102316321" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" contextRef="C_20220101to20221231_usgaapRelatedPartyTransactionsByRelatedPartyAxis_entxSeveralEmployeesAndServiceProvidersMember_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">5,511</ix:nonFraction>
        ordinary shares for a total consideration of $<ix:nonFraction id="Fxbrl_20230228102335627" name="entx:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsTotalConsideration" contextRef="C_20220101to20221231_usgaapRelatedPartyTransactionsByRelatedPartyAxis_entxSeveralEmployeesAndServiceProvidersMember_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">13</ix:nonFraction>
        at a price of $<ix:nonFraction id="Fxbrl_20230228102249646" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" contextRef="C_20220101to20221231_usgaapRelatedPartyTransactionsByRelatedPartyAxis_entxSeveralEmployeesAndServiceProvidersMember_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="USD_per_Share" scale="0" decimals="2" format="ixt:num-dot-decimal">2.14</ix:nonFraction>
        per ordinary share.</span></span></span></span></div> </td> </tr>
  </table> </div> </ix:nonNumeric>

<p style="margin:0pt">&#160;</p>

<div style="clear:both;margin-top:0pt;margin-bottom:0pt">

<div style="text-align:center;margin-top:10pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span><span><span><span><span style="color:#000000;font-weight:normal;font-style:normal">109</span></span></span></span></span></span></span></span></span></div>

<div style="page-break-after:always"><hr style="border-width:0px;clear:both;margin:4px 0px;width:100%;height:2px;color:#000000;background-color:#000000" /></div></div>

<p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:center">&#160;</p>

<p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:10pt;margin-bottom:0pt;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span><span><strong>ENTERA
BIO LTD.<br />NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS</strong></span></span></span></span></span></span></p>

<div style="text-align:center;line-height:1.25">

<div style="margin-top:0pt;margin-bottom:0pt;text-align:center;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span><span><span><span><span style="line-height:normal">(U.S.
dollars in thousands, except share and per share </span></span></span></span></span><span style="line-height:107%">amounts</span><span><span><span><span><span style="line-height:normal">)</span></span></span></span></span></span></span></span></span></div></div>

<p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman,Times,serif">&#160;</p> </div> </div> <ix:nonNumeric id="F20230227081114939_166" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" contextRef="C_20220101to20221231" escape="true">

<div>

<div>

<div>

<div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">NOTE
6 - SHARE-BASED COMPENSATION</span></span></div>

<div style="line-height:1.25">&#160;</div>

<table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">
  <tr>
    <td style="width:35.45pt;vertical-align:top;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">1)</span></span></td>
    <td style="width:auto;vertical-align:top;text-align:justify">
        <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Share-based compensation plan</span></span></div>
        </td> </tr>
  </table>

<div style="line-height:1.25">&#160;</div>

<div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">On
March 17, 2013, the Company's Board of Directors approved a Share Incentive Plan (the &#8220;2013 Plan&#8221;). Under the 2013 Plan, the
Company reserves specified number of ordinary shares for allocation to stock options (each, an &#8220;Option&#8221;), restricted share
units, restricted share awards and performance-based awards, that had been awarded to employees and non-employees under the 2013 Plan.
Each Option is exercisable for one ordinary share.</span></span></div>

<div style="line-height:1.25">&#160;</div>

<div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Any
Option granted under the 2013 Plan that is not exercised within six years from the date upon which it becomes exercisable will expire.
Since adopting the 2018 Plan (as defined below), the Company has not granted any awards under the 2013 Plan.</span></span></div>

<div style="line-height:1.25">&#160;</div>

<div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">On
July 2, 2018, the Company's Board of Directors and shareholders of the Company approved a new Share Incentive Plan (the &#8220;2018 Plan&#8221;)
and reserved <ix:nonFraction id="F20230227081114909_108" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" contextRef="C_20180702_usgaapPlanNameAxis_entxShareIncentivePlan2018Member" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">1,371,398</ix:nonFraction>
ordinary shares for allocation to stock options (each, a "2018 Plan Option"), restricted share units, restricted share awards and performance-based
awards, to employees and non-employees for issuance under the 2018 Plan. Each 2018 Plan Option is exercisable for one ordinary share.<br />&#160;</span></span></div>

<div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Any
2018 Plan Option that is not exercised within 10 years from the date of grant will expire.<br />&#160;</span></span></div>

<div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The
2018 Plan Options granted to employees are subject to the terms stipulated by section 102(b)(2) of the Israeli Income Tax Ordinance (the
&#8220;Ordinance&#8221;). According to these provisions, the Company will not be allowed to claim as an expense for tax purposes the amounts
credited to the employees as a capital gain benefit in respect of the options granted.</span></span></div>

<div style="line-height:1.25">&#160;</div>

<div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2018
Plan Options granted to related parties or non-employees of the Company are governed by Section 3(i) of the Ordinance or Non-Qualified
Share Options ("NSO"). The Company will be allowed to claim as an expense for tax purposes in the year in which the related parties or
non-employees exercised the options into shares.</span></span></div>

<div style="text-align:justify;margin-left:36pt;line-height:1.25">&#160;</div>

<div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">As
of December 31, 2022, <ix:nonFraction id="F20230227081114909_107" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" contextRef="C_20221231_usgaapPlanNameAxis_entxShareIncentivePlan2018Member" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">922,080</ix:nonFraction>
ordinary shares remain available for future grants under the 2018 Plan.</span></span></div>

<div style="text-align:justify;margin-left:36pt;line-height:1.25">&#160;</div>

<div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">On
January 2, 2023, the Company&#8217;s Board of Directors approved an increase of <ix:nonFraction id="F20230227081114910_109" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" contextRef="C_20220101to20221231_usgaapPlanNameAxis_entxShareIncentivePlan2018Member" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">1,440,496</ix:nonFraction>
ordinary shares that may be issued under the Company&#8217;s 2018 Plan pursuant of the terms of the 2018 Plan,</span></span></div>

<div style="text-align:center;line-height:1.25">&#160;</div>

<div>

<div><ix:exclude>

<div style="clear:both;margin-top:0pt;margin-bottom:0pt">

<div style="text-align:center;margin-top:10pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span><span><span><span><span style="color:#000000;font-weight:normal;font-style:normal">110</span></span></span></span></span></span></span></span></span></div>

<div style="page-break-after:always"><hr style="border-width:0px;clear:both;margin:4px 0px;width:100%;height:2px;color:#000000;background-color:#000000" /></div></div>

<p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:center">&#160;</p>

<p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:10pt;margin-bottom:0pt;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span><span><strong>ENTERA
BIO LTD.<br />NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS</strong></span></span></span></span></span></span></p>

<div style="text-align:center;line-height:1.25">

<div style="margin-top:0pt;margin-bottom:0pt;text-align:center;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span><span><span><span><span style="line-height:normal">(U.S.
dollars in thousands, except share and per share </span></span></span></span></span><span style="line-height:107%">amounts</span><span><span><span><span><span style="line-height:normal">)</span></span></span></span></span></span></span></span></span></div></div>

<p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman,Times,serif">&#160;</p>

<p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman,Times,serif"><strong><span style="font-family:Times New Roman, Times, serif;font-size:10pt">NOTE
6 - SHARE-BASED COMPENSATION (continued)</span></strong></p>

<p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman,Times,serif">&#160;</p> </ix:exclude></div> </div>

<div style="text-align:justify;line-height:1.25">

<table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">
  <tr>
    <td style="width:35.45pt;vertical-align:top;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2)</span></span></td>
    <td style="width:auto;vertical-align:top;text-align:justify">
        <div style="font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">share-based compensation
        grants to employees and directors:</span></span></div> </td> </tr>
  </table>

<p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman,Times,serif">&#160;</p> </div>

<div style="text-align:justify;line-height:1.25">

<table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">
  <tr>
    <td style="width:35.45pt">&#160;</td>
    <td style="width:21.25pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">a)</span></span></td>
    <td style="width:auto;vertical-align:top;text-align:justify">
        <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">On January 4, 2021, options to purchase <ix:nonFraction id="Fxbrl_20230228105542355" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="C_20210101to20210104_srtTitleOfIndividualAxis_srtChiefExecutiveOfficerMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">1,314,218</ix:nonFraction>
        ordinary shares were granted to the Company&#8217;s former Chief Executive Officer, Dr. Spiros Jamas with an exercise price of $<ix:nonFraction id="Fxbrl_20230228105553803" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" contextRef="C_20210101to20210104_srtTitleOfIndividualAxis_srtChiefExecutiveOfficerMember" unitRef="USD_per_Share" scale="0" decimals="2" format="ixt:num-dot-decimal">1.24</ix:nonFraction>
        per share. Prior to the terms of Dr. Jamas&#8217; separation agreement (as described below), the options were to vest over four years
        from the date of grant; <ix:nonFraction id="Fxbrl_20230228105603802" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" contextRef="C_20210101to20210104_srtTitleOfIndividualAxis_srtChiefExecutiveOfficerMember_usgaapVestingAxis_usgaapShareBasedCompensationAwardTrancheOneMember" unitRef="Percent" scale="-2" decimals="2" format="ixt:num-dot-decimal">25</ix:nonFraction>%
        vest on the first anniversary of the date of grant and the remaining <ix:nonFraction id="Fxbrl_20230228105614228" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" contextRef="C_20210101to20210104_srtTitleOfIndividualAxis_srtChiefExecutiveOfficerMember_usgaapVestingAxis_usgaapShareBasedCompensationAwardTrancheTwoMember" unitRef="Percent" scale="-2" decimals="2" format="ixt:num-dot-decimal">75</ix:nonFraction>%
        of the option to vest in twelve equal quarterly installments following the first anniversary of the grant date.</span> The grant was subject
        to the approval by the Company&#8217;s shareholders, which approved the grant in March 2021. The fair value of the options at the date
        of grant was $<ix:nonFraction id="Fxbrl_20230228105624538" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" contextRef="C_20210101to20210104_srtTitleOfIndividualAxis_srtChiefExecutiveOfficerMember" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,320</ix:nonFraction>.</span></div>
        </td> </tr>
  </table> </div>

<div style="text-align:justify;margin-left:56.7pt;line-height:1.25">&#160;</div>

<div style="text-align:justify;margin-left:56.7pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">On
July 15, 2022, the Company entered into a mutual separation agreement with Dr. Jamas. Pursuant to the separation agreement, Dr. Jamas
received the following benefits: <ix:nonNumeric id="Fxbrl_20230228114535533" name="us-gaap:DescriptionOfPostemploymentBenefits" contextRef="C_20220601to20220615_srtTitleOfIndividualAxis_entxFormerChiefExecutiveOfficerMember">(i)
a one-time lump sum payment of his annual base salary for a period of 13 months, for a total gross amount equal to $<ix:nonFraction id="Fxbrl_20230228114513250" name="us-gaap:OfficersCompensation" contextRef="C_20220601to20220615_srtTitleOfIndividualAxis_entxFormerChiefExecutiveOfficerMember" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">412</ix:nonFraction>;
and (ii) an extension of the exercise period for the vested portion of the options granted on January 4, 2021, based on the award original
terms, representing an aggregate of <ix:nonFraction id="Fxbrl_20230228114504037" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="C_20220601to20220615_srtTitleOfIndividualAxis_entxFormerChiefExecutiveOfficerMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">492,832</ix:nonFraction>
ordinary shares, through the end of a <span style="-sec-ix-hidden:Fxbrl_20230228114443567">two-year</span> period commencing on July 15,
2022.</ix:nonNumeric> Effective July 15, 2022, upon termination of the employment agreement with Dr. Jamas, the remaining <ix:nonFraction id="Fxbrl_20230228114427110" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares" contextRef="C_20220601to20220615_srtTitleOfIndividualAxis_entxFormerChiefExecutiveOfficerMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">821,386</ix:nonFraction>
unvested options were forfeited and recognized as a reverse of expense of $<ix:nonFraction id="Fxbrl_20230228114415665" name="us-gaap:GeneralAndAdministrativeExpense" contextRef="C_20220601to20220615_srtTitleOfIndividualAxis_entxFormerChiefExecutiveOfficerMember" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">457</ix:nonFraction>
in general and administrative expenses.</span></span></div>

<div style="line-height:1.25">&#160;</div>

<div style="text-align:justify;line-height:1.25">

<table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">
  <tr>
    <td style="width:35.45pt">&#160;</td>
    <td style="width:21.25pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">b)</span></span></td>
    <td style="width:auto;vertical-align:top;text-align:justify">
        <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">On April 7, 2021, the Company&#8217;s Board of
        Directors approved the following option grants:</span></span></div> </td> </tr>
  </table>

<p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman,Times,serif">&#160;</p> </div>

<div style="line-height:1.25">

<table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">
  <tr>
    <td style="width:59.5pt">&#160;</td>
    <td style="width:18pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">i.</span></span></td>
    <td style="width:auto;vertical-align:top">
        <div style="font-family:'Times New Roman',Times,serif;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Option
        grants to purchase <ix:nonFraction id="F20230227081114919_126" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="C_20210401to20210407_srtTitleOfIndividualAxis_entxEmployeesMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">213,000</ix:nonFraction>
        ordinary shares to certain employees and <ix:nonFraction id="F20230227081114927_142" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="C_20210401to20210407_srtTitleOfIndividualAxis_entxServiceProviderMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">70,000</ix:nonFraction>
        options granted to service providers, with an exercise price of&#8201;$<ix:nonFraction id="F20230227081114950_186" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" contextRef="C_20210401to20210407_srtTitleOfIndividualAxis_entxServiceProviderMember" unitRef="USD_per_Share" scale="0" decimals="2" format="ixt:num-dot-decimal"><ix:nonFraction id="F20230227081114928_143" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" contextRef="C_20210401to20210407_srtTitleOfIndividualAxis_entxEmployeesMember" unitRef="USD_per_Share" scale="0" decimals="2" format="ixt:num-dot-decimal">3.61</ix:nonFraction></ix:nonFraction>
        per share. The options vest over <ix:nonNumeric id="Fxbrl_s_20230330125251734" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" contextRef="C_20210401to20210407_srtTitleOfIndividualAxis_entxServiceProviderMember" format="ixt-sec:durwordsen"><ix:nonNumeric id="Fxbrl_20230330125251734" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" contextRef="C_20210401to20210407_srtTitleOfIndividualAxis_entxEmployeesMember" format="ixt-sec:durwordsen">four
        years</ix:nonNumeric></ix:nonNumeric> from the date of grant; <ix:nonFraction id="F20230227081114952_190" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" contextRef="C_20210401to20210407_srtTitleOfIndividualAxis_entxServiceProviderMember_usgaapVestingAxis_usgaapShareBasedCompensationAwardTrancheOneMember" unitRef="Percent" scale="-2" decimals="2" format="ixt:num-dot-decimal"><ix:nonFraction id="F20230227081114930_147" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" contextRef="C_20210401to20210407_srtTitleOfIndividualAxis_entxEmployeesMember_usgaapVestingAxis_usgaapShareBasedCompensationAwardTrancheOneMember" unitRef="Percent" scale="-2" decimals="2" format="ixt:num-dot-decimal">25</ix:nonFraction></ix:nonFraction>%
        vest on the first anniversary of the date of grant and the remaining <ix:nonFraction id="F20230227081114951_188" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" contextRef="C_20210401to20210407_srtTitleOfIndividualAxis_entxServiceProviderMember_usgaapVestingAxis_usgaapShareBasedCompensationAwardTrancheTwoMember" unitRef="Percent" scale="-2" decimals="2" format="ixt:num-dot-decimal"><ix:nonFraction id="F20230227081114929_145" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" contextRef="C_20210401to20210407_srtTitleOfIndividualAxis_entxEmployeesMember_usgaapVestingAxis_usgaapShareBasedCompensationAwardTrancheTwoMember" unitRef="Percent" scale="-2" decimals="2" format="ixt:num-dot-decimal">75</ix:nonFraction></ix:nonFraction>%
        of the option will vest in twelve equal quarterly installments following the first anniversary of the grant date. The fair value of the
        options at the date of grant was $<ix:nonFraction id="F20230227081114952_189" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" contextRef="C_20210401to20210407_srtTitleOfIndividualAxis_entxServiceProviderMember" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal"><ix:nonFraction id="F20230227081114929_146" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" contextRef="C_20210401to20210407_srtTitleOfIndividualAxis_entxEmployeesMember" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">646</ix:nonFraction></ix:nonFraction>.</span></span></div>
        </td> </tr>
  </table> </div>

<div style="line-height:1.25">

<p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman,Times,serif">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">
  <tr>
    <td style="width:59.5pt">&#160;</td>
    <td style="width:18pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">ii.</span></span></td>
    <td style="width:auto;vertical-align:top">
        <div style="font-family:'Times New Roman',Times,serif;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Options
        grant to purchase <ix:nonFraction id="F20230227081114920_127" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="C_20210401to20210407_srtTitleOfIndividualAxis_entxNonExecutiveDirectorMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">33,368</ix:nonFraction>
        ordinary shares to a non-executive director of the Company, with an exercise price of $<ix:nonFraction id="F20230227081114922_131" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" contextRef="C_20210401to20210407_srtTitleOfIndividualAxis_entxNonExecutiveDirectorMember" unitRef="USD_per_Share" scale="0" decimals="2" format="ixt:num-dot-decimal">3.61</ix:nonFraction>.
        The options will vest over <ix:nonNumeric id="Fxbrl_20230330125307484" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" contextRef="C_20210401to20210407_srtTitleOfIndividualAxis_entxNonExecutiveDirectorMember" format="ixt-sec:durwordsen">three
        years</ix:nonNumeric> in twelve equal quarterly instalments starting on the vesting commencement date. These options were subject to the
        approval of the shareholders of the Company, which was approved on October 4, 2021. The fair value of the options at the shareholders'
        approval date was $<ix:nonFraction id="F20230227081114927_140" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" contextRef="C_20210401to20210407_srtTitleOfIndividualAxis_entxNonExecutiveDirectorMember" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">104</ix:nonFraction>.</span></span></div>
        </td> </tr>
  </table> </div>

<p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman,Times,serif">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">
  <tr>
    <td style="width:35.45pt">&#160;</td>
    <td style="width:21.25pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">c)</span></span></td>
    <td style="width:auto;vertical-align:top;text-align:justify">
        <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">On April 21, 2021, options to purchase <ix:nonFraction id="F20230227081114920_128" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="C_20210401to20210421_srtTitleOfIndividualAxis_srtExecutiveOfficerMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">345,000</ix:nonFraction>
        ordinary shares were granted to several executive officers of the Company, with an exercise price of $<ix:nonFraction id="F20230227081114922_132" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" contextRef="C_20210401to20210421_srtTitleOfIndividualAxis_srtExecutiveOfficerMember" unitRef="USD_per_Share" scale="0" decimals="2" format="ixt:num-dot-decimal">3.15</ix:nonFraction>.
        The options vest over <ix:nonNumeric id="Fxbrl_20230330125322325" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" contextRef="C_20210401to20210421_srtTitleOfIndividualAxis_srtExecutiveOfficerMember" format="ixt-sec:durwordsen">four
        years</ix:nonNumeric> from the date of grant; <ix:nonFraction id="F20230227081114924_136" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" contextRef="C_20210401to20210421_srtTitleOfIndividualAxis_srtExecutiveOfficerMember_usgaapVestingAxis_usgaapShareBasedCompensationAwardTrancheOneMember" unitRef="Percent" scale="-2" decimals="2" format="ixt:num-dot-decimal">25</ix:nonFraction>%
        vest on the first anniversary of the date of grant and the remaining <ix:nonFraction id="F20230227081114924_137" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" contextRef="C_20210401to20210421_srtTitleOfIndividualAxis_srtExecutiveOfficerMember_usgaapVestingAxis_usgaapShareBasedCompensationAwardTrancheTwoMember" unitRef="Percent" scale="-2" decimals="2" format="ixt:num-dot-decimal">75</ix:nonFraction>%
        of the option will vest in twelve equal quarterly installments following the first anniversary of the grant date. These options were subject
        to the approval of the shareholders of the Company, which was approved on October 4, 2021. The fair value of the options at the shareholders'
        approval date was $<ix:nonFraction id="F20230227081114927_141" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" contextRef="C_20210401to20210421_srtTitleOfIndividualAxis_srtExecutiveOfficerMember" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,140</ix:nonFraction>.</span></span></div>
        </td> </tr>
  </table>

<div style="text-align:center;line-height:1.25">&#160;</div>

<div>

<div><ix:exclude>

<div style="clear:both;margin-top:0pt;margin-bottom:0pt">

<div style="text-align:center;margin-top:10pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span><span><span><span><span style="color:#000000;font-weight:normal;font-style:normal">111</span></span></span></span></span></span></span></span></span></div>

<div style="page-break-after:always"><hr style="border-width:0px;clear:both;margin:4px 0px;width:100%;height:2px;color:#000000;background-color:#000000" /></div></div>

<p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:center">&#160;</p>

<p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:10pt;margin-bottom:0pt;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span><span><strong>ENTERA
BIO LTD.<br />NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS</strong></span></span></span></span></span></span></p>

<div style="text-align:center;line-height:1.25">

<div style="margin-top:0pt;margin-bottom:0pt;text-align:center;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span><span><span><span><span style="line-height:normal">(U.S.
dollars in thousands, except share and per share </span></span></span></span></span><span style="line-height:107%">amounts</span><span><span><span><span><span style="line-height:normal">)</span></span></span></span></span></span></span></span></span></div></div>

<p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman,Times,serif">&#160;</p>

<p style="margin:0pt"><strong><span style="font-family:Times New Roman, Times, serif;font-size:10pt">NOTE 6 - SHARE-BASED COMPENSATION
(continued)</span></strong></p>

<p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman,Times,serif">&#160;</p> </ix:exclude></div> </div>

<table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">
  <tr>
    <td style="width:35.45pt">&#160;</td>
    <td style="width:21.25pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">d)</span></span></td>
    <td style="width:auto;vertical-align:top;text-align:justify">
        <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">On August 23, 2021, the Company&#8217;s Board
        of Directors approved the following option grants which were approved by the shareholders of the Company on October 4, 2021.</span></span></div>
        </td> </tr>
  </table>

<p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman,Times,serif">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">
  <tr>
    <td style="width:59.5pt">&#160;</td>
    <td style="width:18pt;vertical-align:top;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">i.</span></span></td>
    <td style="width:auto;vertical-align:top;text-align:justify">
        <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Grants of options to purchase ordinary shares
        with a total fair value 0f $<ix:nonFraction id="F20230227081114936_158" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" contextRef="C_20210801to20210823_srtTitleOfIndividualAxis_entxNonExecutiveDirectorMember_usgaapVestingAxis_entxShareBasedPaymentArrangementTrancheFiveMember" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">195</ix:nonFraction>
        for each of the seven non-executive board members on January 1, 2022. The options will vest over <ix:nonNumeric id="Fxbrl_20230330125332741" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" contextRef="C_20210801to20210823_srtTitleOfIndividualAxis_entxNonExecutiveDirectorMember_usgaapVestingAxis_entxShareBasedPaymentArrangementTrancheFiveMember" format="ixt-sec:durwordsen">three
        years</ix:nonNumeric> in twelve equal quarterly instalments starting on January 1, 2022 the vesting commencement date. On January 1, 2022,
        which is considered the awards grant date, the Company granted <ix:nonFraction id="F20230227081114935_157" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="C_20210801to20210823_srtTitleOfIndividualAxis_entxNonExecutiveDirectorMember_usgaapVestingAxis_entxShareBasedPaymentArrangementTrancheFiveMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">752,899</ix:nonFraction>
        ordinary shares to non-executive directors with an exercise price of&#8201;$<ix:nonFraction id="F20230227081114922_133" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" contextRef="C_20210801to20210823_srtTitleOfIndividualAxis_entxNonExecutiveDirectorMember_usgaapVestingAxis_entxShareBasedPaymentArrangementTrancheFiveMember" unitRef="USD_per_Share" scale="0" decimals="3" format="ixt:num-dot-decimal">2.815</ix:nonFraction>
        per share.</span></span></div> </td> </tr>
  </table>

<div style="line-height:1.25">&#160;</div>

<table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">
  <tr>
    <td style="width:59.5pt">&#160;</td>
    <td style="width:18pt;vertical-align:top;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">ii.</span></span></td>
    <td style="width:auto;vertical-align:top;text-align:justify">
        <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Grants of options to purchase ordinary shares
        with a total fair value 0f $<ix:nonFraction id="F20230227081114936_160" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" contextRef="C_20210801to20210823_srtTitleOfIndividualAxis_entxNonExecutiveDirectorMember_usgaapVestingAxis_entxShareBasedPaymentArrangementTrancheSixMember" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">65</ix:nonFraction>
        for each of the seven non-executive board members on January 1, 2022. The options will vest over <ix:nonNumeric id="Fxbrl_20230330125342141" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" contextRef="C_20210801to20210823_srtTitleOfIndividualAxis_entxNonExecutiveDirectorMember_usgaapVestingAxis_entxShareBasedPaymentArrangementTrancheSixMember" format="ixt-sec:durwordsen">one
        year</ix:nonNumeric> in four equal quarterly instalments starting on January 1, 2022 the vesting commencement date. On January 1, 2022,
        which is considered the awards grant date, the Company granted <ix:nonFraction id="F20230227081114921_129" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="C_20210801to20210823_srtTitleOfIndividualAxis_entxNonExecutiveDirectorMember_usgaapVestingAxis_entxShareBasedPaymentArrangementTrancheSixMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">250,964</ix:nonFraction>
        ordinary shares to non-executive directors with an exercise price of&#8201;$<ix:nonFraction id="F20230227081114923_134" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" contextRef="C_20210801to20210823_srtTitleOfIndividualAxis_entxNonExecutiveDirectorMember_usgaapVestingAxis_entxShareBasedPaymentArrangementTrancheSixMember" unitRef="USD_per_Share" scale="0" decimals="3" format="ixt:num-dot-decimal">2.815</ix:nonFraction>
        per share.</span></span></div> </td> </tr>
  </table>

<div style="line-height:1.25">&#160;</div>

<div style="text-align:justify;line-height:1.25">

<table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">
  <tr>
    <td style="width:35.45pt">&#160;</td>
    <td style="width:21.25pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">e)</span></span></td>
    <td style="width:auto;vertical-align:top;text-align:justify">
        <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">On March 31, 2022, the Company&#8217;s Board of
        Directors approved the following option grants:</span></span></div> </td> </tr>
  </table>

<p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman,Times,serif">&#160;</p> </div>

<div style="line-height:1.25">

<table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">
  <tr>
    <td style="width:59.5pt">&#160;</td>
    <td style="width:18pt;vertical-align:top;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">i.</span></span></td>
    <td style="width:auto;vertical-align:top">
        <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Options to purchase <ix:nonFraction id="Fxbrl_20230228114600349" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" contextRef="C_20220331_srtTitleOfIndividualAxis_entxExecutiveOfficerAndServiceProviderMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">80,000</ix:nonFraction>
        ordinary shares to an executive officer and a service provider, in each case, with an exercise price of&#8201;$<ix:nonFraction id="Fxbrl_s_20221030170139370" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" contextRef="C_20220101to20220331_srtTitleOfIndividualAxis_entxServiceProviderMember" unitRef="USD_per_Share" scale="0" decimals="2" format="ixt:num-dot-decimal"><ix:nonFraction id="Fxbrl_20230228114906381" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" contextRef="C_20220101to20220331_srtTitleOfIndividualAxis_entxExecutiveOfficerAndServiceProviderMember" unitRef="USD_per_Share" scale="0" decimals="2" format="ixt:num-dot-decimal">2.86</ix:nonFraction></ix:nonFraction>
        per share. The fair value of the options was $<ix:nonFraction id="Fxbrl_20230228115152783" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" contextRef="C_20220101to20220331_srtTitleOfIndividualAxis_entxExecutiveOfficerAndServiceProviderMember" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">147</ix:nonFraction>.</span></span></div>
        </td> </tr>
  </table>

<p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman,Times,serif">&#160;</p> </div>

<div style="line-height:1.25">

<table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">
  <tr>
    <td style="width:59.5pt">&#160;</td>
    <td style="width:18pt;vertical-align:top;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">ii.</span></span></td>
    <td style="width:auto;vertical-align:top">
        <div style="text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Options to purchase
        <ix:nonFraction id="Fxbrl_20230228115200286" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" contextRef="C_20220331_srtTitleOfIndividualAxis_srtExecutiveOfficerMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">55,000</ix:nonFraction>
        ordinary shares to certain executive officers with an exercise price of&#8201;$<ix:nonFraction id="Fxbrl_s_20221030172710053" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" contextRef="C_20220101to20220331_srtTitleOfIndividualAxis_entxServiceProviderMember" unitRef="USD_per_Share" scale="0" decimals="2" format="ixt:num-dot-decimal"><ix:nonFraction id="Fxbrl_20230228115207754" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" contextRef="C_20220101to20220331_srtTitleOfIndividualAxis_srtExecutiveOfficerMember" unitRef="USD_per_Share" scale="0" decimals="2" format="ixt:num-dot-decimal">2.86</ix:nonFraction></ix:nonFraction>
        per share. This grant was subject to shareholders' approval, which was obtained at a meeting of the Company&#8217;s shareholders held
        on September 7, 2022. The fair value of the options was $<ix:nonFraction id="Fxbrl_20230228115213430" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" contextRef="C_20220101to20220331_srtTitleOfIndividualAxis_srtExecutiveOfficerMember" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">37</ix:nonFraction>.</span></span></div>
        <div>&#160;</div>
        <div>
        <div style="text-align:justify;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonNumeric id="Fxbrl_20230228115233528" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription" contextRef="C_20220101to20220331">The
        options vest over <ix:nonNumeric id="Fxbrl_20230228115221470" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" contextRef="C_20220101to20220331" format="ixt-sec:durwordsen">four
        years</ix:nonNumeric> from the date of grant; 25% vest on the first anniversary of the date of grant and the remaining 75% of the option
        will vest in twelve equal quarterly installments following the first anniversary of the grant date.</ix:nonNumeric></span></span></div>
        </div> </td> </tr>
  </table> </div>

<p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman,Times,serif">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">
  <tr>
    <td style="width:35.45pt">&#160;</td>
    <td style="width:21.25pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">f)</span></span></td>
    <td style="width:auto;vertical-align:top;text-align:justify">
        <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">On April 28, 2022, the Company&#8217;s Board of
        Directors approved option grants to purchase <ix:nonFraction id="Fxbrl_20230228115246112" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="C_20220401to20220428_srtTitleOfIndividualAxis_entxEmployeeMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">220,000</ix:nonFraction>
        ordinary shares to employees with an exercise price of&#8201;$<ix:nonFraction id="Fxbrl_20230228115252271" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" contextRef="C_20220401to20220428_srtTitleOfIndividualAxis_entxEmployeeMember" unitRef="USD_per_Share" scale="0" decimals="2" format="ixt:num-dot-decimal">2.57</ix:nonFraction>
        per share. <ix:nonNumeric id="Fxbrl_20230228115314000" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription" contextRef="C_20220401to20220428_srtTitleOfIndividualAxis_entxEmployeeMember">The
        options vest over <ix:nonNumeric id="Fxbrl_20230228115303854" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" contextRef="C_20220401to20220428_srtTitleOfIndividualAxis_entxEmployeeMember" format="ixt-sec:durwordsen">four
        years</ix:nonNumeric> from the date of grant; 25% vest on the first anniversary of the date of grant and the remaining 75% of the option
        will vest in twelve equal quarterly installments following the first anniversary of the grant date.</ix:nonNumeric> The fair value of
        the options was $<ix:nonFraction id="Fxbrl_20230228115321149" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" contextRef="C_20220401to20220428_srtTitleOfIndividualAxis_entxEmployeeMember" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">364</ix:nonFraction>.</span></span></div>
        </td> </tr>
  </table>

<div style="line-height:1.25">&#160;</div>

<table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">
  <tr>
    <td style="width:35.45pt">&#160;</td>
    <td style="width:21.25pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">g)</span></span></td>
    <td style="width:auto;vertical-align:top;text-align:justify">
        <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">On May 11, 2022, the Company&#8217;s Board of
        Directors approved a grant of options to purchase <ix:nonFraction id="Fxbrl_20230228115329584" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="C_20220501to20220511_srtTitleOfIndividualAxis_srtChiefFinancialOfficerMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">500,000</ix:nonFraction>
        ordinary shares to Ms. Miranda Toledano, who was serving as the Company&#8217;s Chief Financial Officer at the time of the grant. Ms.
        Toledano has since been appointed the Company&#8217;s Chief Executive Officer (as described in Note 6(2)l below). <ix:nonNumeric id="Fxbrl_20230228115512200" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription" contextRef="C_20220501to20220511_srtTitleOfIndividualAxis_srtChiefFinancialOfficerMember">This
        grant was subject to shareholders' approval, which was obtained at a meeting of the Company&#8217;s shareholders held on September 7,
        2022. These options have an exercise price of&#8201;$<ix:nonFraction id="Fxbrl_20230228115349904" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" contextRef="C_20220501to20220511_srtTitleOfIndividualAxis_srtChiefFinancialOfficerMember" unitRef="USD_per_Share" scale="0" decimals="2" format="ixt:num-dot-decimal">2.00</ix:nonFraction>
        per share and vest over <ix:nonNumeric id="Fxbrl_20230228115401506" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" contextRef="C_20220501to20220511_srtTitleOfIndividualAxis_srtChiefFinancialOfficerMember" format="ixt-sec:durwordsen">four
        years</ix:nonNumeric> from the date of grant; 25% vest on the first anniversary of the date of grant and the remaining 75% of the option
        will vest in twelve equal quarterly installments following the first anniversary of the grant date.</ix:nonNumeric> The fair value of
        the options was $<ix:nonFraction id="Fxbrl_20230228115412102" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" contextRef="C_20220501to20220511_srtTitleOfIndividualAxis_srtChiefFinancialOfficerMember" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">390</ix:nonFraction>.</span></span></div>
        </td> </tr>
  </table>

<div style="text-align:center;line-height:1.25">&#160;</div>

<div>

<div><ix:exclude>

<div style="clear:both;margin-top:0pt;margin-bottom:0pt">

<div style="text-align:center;margin-top:10pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span><span><span><span><span style="color:#000000;font-weight:normal;font-style:normal">112</span></span></span></span></span></span></span></span></span></div>

<div style="page-break-after:always"><hr style="border-width:0px;clear:both;margin:4px 0px;width:100%;height:2px;color:#000000;background-color:#000000" /></div></div>

<p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:center">&#160;</p>

<p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:10pt;margin-bottom:0pt;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span><span><strong>ENTERA
BIO LTD.<br />NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS</strong></span></span></span></span></span></span></p>

<div style="text-align:center;line-height:1.25">

<div style="margin-top:0pt;margin-bottom:0pt;text-align:center;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span><span><span><span><span style="line-height:normal">(U.S.
dollars in thousands, except share and per share </span></span></span></span></span><span style="line-height:107%">amounts</span><span><span><span><span><span style="line-height:normal">)</span></span></span></span></span></span></span></span></span></div></div>

<p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman,Times,serif">&#160;</p>

<p style="margin:0pt"><strong><span style="font-family:Times New Roman, Times, serif;font-size:10pt">NOTE 6 - SHARE-BASED COMPENSATION
(continued)</span></strong></p>

<p style="margin:0pt">&#160;</p> </ix:exclude></div> </div>

<table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">
  <tr>
    <td style="width:35.45pt">&#160;</td>
    <td style="width:21.25pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">h)</span></span></td>
    <td style="width:auto;vertical-align:top;text-align:justify">
        <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">On July 15, 2022, the Company&#8217;s Board of
        Directors appointed Ms. Miranda Toledano as the Company&#8217;s Chief Executive Officer and approved a grant of options to purchase <ix:nonFraction id="Fxbrl_20230228115520463" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="C_20220701to20220715_srtTitleOfIndividualAxis_srtChiefExecutiveOfficerMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">600,000</ix:nonFraction>
        ordinary shares at an exercise price of&#8201;$<ix:nonFraction id="Fxbrl_20230228115538118" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" contextRef="C_20220701to20220715_srtTitleOfIndividualAxis_srtChiefExecutiveOfficerMember" unitRef="USD_per_Share" scale="0" decimals="2" format="ixt:num-dot-decimal">1.40</ix:nonFraction>
        per share, which are in addition to the options described in note 6(2)k above. <ix:nonNumeric id="Fxbrl_20230228115602861" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription" contextRef="C_20220701to20220715_srtTitleOfIndividualAxis_srtChiefExecutiveOfficerMember">This
        grant was subject to shareholders' approval, which was obtained at a meeting of the Company&#8217;s shareholders held on September 7,
        2022. The options vest over <ix:nonNumeric id="Fxbrl_20230228115550920" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" contextRef="C_20220701to20220715_srtTitleOfIndividualAxis_srtChiefExecutiveOfficerMember" format="ixt-sec:durwordsen">four
        years</ix:nonNumeric> from the date of grant; 25% vest on the first anniversary of the date of grant and the remaining 75% of the option
        will vest in twelve equal quarterly installments following the first anniversary of the applicable grant date.</ix:nonNumeric> The fair
        value of the options was $<ix:nonFraction id="Fxbrl_20230228115608325" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" contextRef="C_20220701to20220715_srtTitleOfIndividualAxis_srtChiefExecutiveOfficerMember" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">524</ix:nonFraction>.</span></span></div>
        </td> </tr>
  </table>

<div style="line-height:1.25">&#160;</div>

<div style="text-align:justify;margin-left:56.7pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">In
addition, upon the occurrence of a Triggering Event (as defined below) and subject to the approval of the Board of Directors, Ms. Toledano
will be granted additional options to purchases <ix:nonFraction id="Fxbrl_20230228115624800" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="C_20220701to20220715_srtTitleOfIndividualAxis_srtChiefExecutiveOfficerMember_usgaapTypeOfArrangementAxis_entxTriggeringEventMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">200,000</ix:nonFraction>
ordinary shares. The exercise price will be determined at the time of the Board of Directors&#8217; approval.</span></span></div>

<div style="line-height:1.25">&#160;</div>

<div style="text-align:justify;margin-left:56.7pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">"Triggering
Event" means the earlier of the following events: (i) the execution by the Company of a binding strategic or partnership agreement with
a strategic partner to fund the Company's Phase III FDA Trial; or (b) raising sufficient funding to complete the Company's Phase III FDA
Trial, in each case as such event is approved by the Board of Directors.</span></span></div>

<div style="line-height:1.25">&#160;</div>

<table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">
  <tr>
    <td style="width:35.45pt">&#160;</td>
    <td style="width:21.25pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">i)</span></span></td>
    <td style="width:auto;vertical-align:top;text-align:justify">
        <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">On June 15, 2022, the Company entered into a separation
        agreement with Dr. Phillip Schwartz, the Company&#8217;s former President of R&#38;D, under which Dr. Schwartz agreed to continue to provide
        services to the Company until July 21, 2022 (the &#8220;Separation Date&#8221;). Pursuant to the terms of the separation agreement, which
        were approved by the Company&#8217;s shareholders on September 7, 2022, Dr. Schwartz received a full acceleration of his unvested options,
        as of the Separation Date, to purchase <ix:nonFraction id="Fxbrl_20230228115646297" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="C_20210401to20210430_srtTitleOfIndividualAxis_entxPresidentOfResearchAndDevelopmentMember_usgaapAwardTypeAxis_entxTwentySeventeenMemberMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">68,750</ix:nonFraction>
        ordinary shares granted in April 2021 that otherwise would have been forfeited. These options, together with <ix:nonFraction id="Fxbrl_20230228115655873" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" contextRef="C_20210430_srtTitleOfIndividualAxis_entxPresidentOfResearchAndDevelopmentMember_usgaapAwardTypeAxis_entxTwentySeventeenMemberMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">31,250</ix:nonFraction>
        already vested options granted in April 2021 and <ix:nonFraction id="Fxbrl_20230228115701279" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="C_20220601to20220615_srtTitleOfIndividualAxis_entxPresidentOfResearchAndDevelopmentMember_usgaapAwardTypeAxis_entxTwentySeventeenMemberMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">357,500</ix:nonFraction>
        already vested options to purchase ordinary shares granted in 2017, will be exercisable for a period of <ix:nonNumeric id="Fxbrl_20230228115706687" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" contextRef="C_20220601to20220615_srtTitleOfIndividualAxis_entxPresidentOfResearchAndDevelopmentMember_usgaapAwardTypeAxis_entxTwentySeventeenMemberMember" format="ixt-sec:duryear">10</ix:nonNumeric>
        years from their respective initial grant dates<span style="font-weight:bold">.</span></span></span></div> </td> </tr>
  </table>

<div style="text-align:justify;margin-left:56.7pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">&#160;<br />The
acceleration described above was recognized as a "Type III" modification; therefore, on the shareholder approval date, the Company recognized
the incremental costs of unvested options based on the fair value of the options on such date. In addition, the extension of the exercise
period for the vested awards was recognized as a "Type I" modification. The total expense amount was $<ix:nonFraction id="Fxbrl_20230228115714373" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="C_20220601to20220615_srtTitleOfIndividualAxis_entxPresidentOfResearchAndDevelopmentMember" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">112</ix:nonFraction>
thousand, which was classified as additional share-based compensation costs in the research and development expenses.<br />&#160;<br />In
addition, the separation agreement provides for the following payments to Dr. Schwartz, all of which would have otherwise been payable
in accordance with either Israeli law or pursuant to his existing employment agreement: a one-time cash separation payment in an amount
equal to NIS <ix:nonFraction id="Fxbrl_20230228130502260" name="entx:CashSeparationPayment" contextRef="C_20220601to20220615_srtTitleOfIndividualAxis_entxPresidentOfResearchAndDevelopmentMember" unitRef="NIS" scale="3" decimals="-3" format="ixt:num-dot-decimal">537,600</ix:nonFraction>
(approximately $<ix:nonFraction id="Fxbrl_20230228130507093" name="entx:CashSeparationPayment" contextRef="C_20220601to20220615_srtTitleOfIndividualAxis_entxPresidentOfResearchAndDevelopmentMember" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">156</ix:nonFraction>)
and additional payments of NIS <ix:nonFraction id="Fxbrl_20230228130514055" name="entx:AdditionalCashSeparationPayment" contextRef="C_20220601to20220615_srtTitleOfIndividualAxis_entxPresidentOfResearchAndDevelopmentMember" unitRef="NIS" scale="3" decimals="-3" format="ixt:num-dot-decimal">737,771</ix:nonFraction>
(approximately $<ix:nonFraction id="Fxbrl_20230228130518598" name="entx:AdditionalCashSeparationPayment" contextRef="C_20220601to20220615_srtTitleOfIndividualAxis_entxPresidentOfResearchAndDevelopmentMember" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">214</ix:nonFraction>)
in respect of all other ongoing accrued benefits, subject to any mandatory deductions. The foregoing payments were recognized in the research
and development expenses.</span></span></div>

<div style="text-align:justify;margin-left:56.7pt;line-height:1.25">&#160;</div> </div> </div>

<div><ix:exclude>

<div>

<div>

<div style="line-height:1.25">

<div style="clear:both;margin-top:0pt;margin-bottom:0pt">

<div style="text-align:center;margin-top:10pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span><span><span><span><span style="color:#000000;font-weight:normal;font-style:normal">113</span></span></span></span></span></span></span></span></span></div>

<div style="page-break-after:always"><hr style="border-width:0px;clear:both;margin:4px 0px;width:100%;height:2px;color:#000000;background-color:#000000" /></div></div>

<p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:center">&#160;</p>

<p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:10pt;margin-bottom:0pt;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span><span><strong>ENTERA
BIO LTD.<br />NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS</strong></span></span></span></span></span></span></p>

<div style="text-align:center;line-height:1.25">

<div style="margin-top:0pt;margin-bottom:0pt;text-align:center;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span><span><span><span><span style="line-height:normal">(U.S.
dollars in thousands, except share and per share </span></span></span></span></span><span style="line-height:107%">amounts</span><span><span><span><span><span style="line-height:normal">)</span></span></span></span></span></span></span></span></span></div></div>

<p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman,Times,serif">&#160;</p> </div> </div> </div>

<div style="line-height:1.25"> <div style="font-size:10pt;display:inline"> <div style="font-family:Times New Roman,Times,serif;display:inline">
<div style="display:inline"> <div style="font-weight:bold;display:inline"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><span><span><span><span><span><span><span><span><span><span><span><span><span><span><span><span><span><span><span>NOTE
6 - S</span></span><span><span style="line-height:normal"><strong>HARE-BASED COMPENSATION </strong></span>(continued)</span></span></span></span></span></span></span></span></span></span></span></span></span></span></span></span></span></span></span></span></span></span></span></span></div>
</div> </div> </div> </div>

<div style="line-height:1.25">&#160;</div> </ix:exclude></div>

<div>

<div>

<div style="line-height:1.25">

<div>

<div>

<div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><span>The
fair value of each option granted is estimated at the date of grant using the Black-Scholes option-pricing model, with the following weighted
average assumptions:</span></span></span></span></span></span></span></div> </div> </div>

<p style="margin:0pt">&#160;</p> </div> <ix:nonNumeric id="F20230227081114851_0" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" contextRef="C_20220101to20221231" escape="true">

<div>

<div>

<div>

<div style="margin-left:54pt">

<table border="0" cellpadding="0" cellspacing="0" style="width:85%">
  <tr>
    <td style="vertical-align:top;padding-bottom:2px" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px" valign="bottom">
        <div style="line-height:1.25">
        <div style="text-align:center;text-indent:0.05pt;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span>2022</span></span></span></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px" valign="bottom">
        <div style="line-height:1.25">
        <div style="text-align:center;text-indent:0.05pt;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span>2021</span></span></span></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td> </tr>
  <tr>
    <td style="vertical-align:top;padding-bottom:4px;background-color:rgb(204, 238, 255);width:70%" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span>Exercise
        price</span></span></span></span></span></div> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:4px;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);width:1%" valign="bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25">&#160;</div> </div> </td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);width:12%" valign="bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span>$<ix:nonFraction id="Fxbrl_20230330184810532" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" contextRef="C_20221231_srtRangeAxis_srtMinimumMember" unitRef="USD_per_Share" scale="0" decimals="2" format="ixt:num-dot-decimal">1.40</ix:nonFraction>-$<ix:nonFraction id="F20230227081114857_8" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" contextRef="C_20221231_srtRangeAxis_srtMaximumMember" unitRef="USD_per_Share" scale="0" decimals="2" format="ixt:num-dot-decimal">2.86</ix:nonFraction></span></span></span></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:4px;background-color:rgb(204, 238, 255);white-space:nowrap;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:4px;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);width:1%" valign="bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25">&#160;</div> </div> </td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);width:12%" valign="bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span>$<ix:nonFraction id="Fxbrl_20230330184828074" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" contextRef="C_20211231_srtRangeAxis_srtMinimumMember" unitRef="USD_per_Share" scale="0" decimals="2" format="ixt:num-dot-decimal">1.24</ix:nonFraction>-$<ix:nonFraction id="F20230227081114858_10" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" contextRef="C_20211231_srtRangeAxis_srtMaximumMember" unitRef="USD_per_Share" scale="0" decimals="2" format="ixt:num-dot-decimal">3.61</ix:nonFraction></span></span></span></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:4px;background-color:rgb(204, 238, 255);white-space:nowrap;width:1%" valign="bottom">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align:top;padding-bottom:4px;width:70%" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span>Dividend
        yield</span></span></span></span></span></div> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:4px;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;border-bottom:4px double rgb(0, 0, 0);width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;border-bottom:4px double rgb(0, 0, 0);width:12%" valign="bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><ix:nonFraction id="F20230227081114853_4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="C_20220101to20221231" unitRef="Percent" scale="-2" decimals="2" format="ixt:fixed-zero">-</ix:nonFraction></span></span></span></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:4px;white-space:nowrap;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:4px;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;border-bottom:4px double rgb(0, 0, 0);width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;border-bottom:4px double rgb(0, 0, 0);width:12%" valign="bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><ix:nonFraction id="F20230227081114856_5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="C_20210101to20211231" unitRef="Percent" scale="-2" decimals="2" format="ixt:fixed-zero">-</ix:nonFraction></span></span></span></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:4px;white-space:nowrap;width:1%" valign="bottom">&#160;</td> </tr>
  <tr>
    <td style="vertical-align:top;padding-bottom:4px;background-color:rgb(204, 238, 255);width:70%" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span>Expected
        volatility</span></span></span></span></span></div> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:4px;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);width:12%" valign="bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><ix:nonFraction id="F20230227081114858_11" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="C_20220101to20221231_srtRangeAxis_srtMinimumMember" unitRef="Percent" scale="-2" decimals="2" format="ixt:num-dot-decimal">69</ix:nonFraction>%-<ix:nonFraction id="F20230227081114860_13" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="C_20220101to20221231_srtRangeAxis_srtMaximumMember" unitRef="Percent" scale="-2" decimals="3" format="ixt:num-dot-decimal">70.2</ix:nonFraction>%</span></span></span></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:4px;background-color:rgb(204, 238, 255);white-space:nowrap;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:4px;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);width:12%" valign="bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><ix:nonFraction id="F20230227081114862_18" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="C_20210101to20211231_srtRangeAxis_srtMinimumMember" unitRef="Percent" scale="-2" decimals="2" format="ixt:num-dot-decimal">68</ix:nonFraction>%-<ix:nonFraction id="F20230227081114860_14" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="C_20210101to20211231_srtRangeAxis_srtMaximumMember" unitRef="Percent" scale="-2" decimals="2" format="ixt:num-dot-decimal">71</ix:nonFraction>%</span></span></span></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:4px;background-color:rgb(204, 238, 255);white-space:nowrap;width:1%" valign="bottom">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align:top;padding-bottom:4px;width:70%" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span>Risk-free
        interest rate</span></span></span></span></span></div> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:4px;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;border-bottom:4px double rgb(0, 0, 0);width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;border-bottom:4px double rgb(0, 0, 0);width:12%" valign="bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><ix:nonFraction id="F20230227081114859_12" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="C_20220101to20221231_srtRangeAxis_srtMinimumMember" unitRef="Percent" scale="-2" decimals="4" format="ixt:num-dot-decimal">1.35</ix:nonFraction>%-<ix:nonFraction id="F20230227081114861_15" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="C_20220101to20221231_srtRangeAxis_srtMaximumMember" unitRef="Percent" scale="-2" decimals="4" format="ixt:num-dot-decimal">3.36</ix:nonFraction>%</span></span></span></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:4px;white-space:nowrap;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:4px;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;border-bottom:4px double rgb(0, 0, 0);width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;border-bottom:4px double rgb(0, 0, 0);width:12%" valign="bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><ix:nonFraction id="F20230227081114863_19" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="C_20210101to20211231_srtRangeAxis_srtMinimumMember" unitRef="Percent" scale="-2" decimals="4" format="ixt:num-dot-decimal">1.11</ix:nonFraction>%-<ix:nonFraction id="F20230227081114861_16" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="C_20210101to20211231_srtRangeAxis_srtMaximumMember" unitRef="Percent" scale="-2" decimals="4" format="ixt:num-dot-decimal">0.94</ix:nonFraction>%</span></span></span></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:4px;white-space:nowrap;width:1%" valign="bottom">&#160;</td> </tr>
  <tr>
    <td style="vertical-align:top;padding-bottom:4px;background-color:rgb(204, 238, 255);width:70%" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span>Expected
        life - in years</span></span></span></span></span></div> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:4px;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);width:12%" valign="bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><ix:nonNumeric id="F20230227081114856_6" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" contextRef="C_20220101to20221231_srtRangeAxis_srtMinimumMember" format="ixt-sec:duryear">5.5</ix:nonNumeric>-<ix:nonNumeric id="F20230227081114942_170" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" contextRef="C_20220101to20221231_srtRangeAxis_srtMaximumMember" format="ixt-sec:duryear">6.5</ix:nonNumeric></span></span></span></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:4px;background-color:rgb(204, 238, 255);white-space:nowrap;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:4px;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);width:12%" valign="bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><ix:nonNumeric id="F20230227081114865_20" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" contextRef="C_20210101to20211231_srtRangeAxis_srtMinimumMember" format="ixt-sec:duryear">6.1</ix:nonNumeric>-<ix:nonNumeric id="F20230227081114862_17" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" contextRef="C_20210101to20211231_srtRangeAxis_srtMaximumMember" format="ixt-sec:duryear">5.8</ix:nonNumeric></span></span></span></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:4px;background-color:rgb(204, 238, 255);white-space:nowrap;width:1%" valign="bottom">&#160;</td>
        </tr>
  </table> </div> </div> </div> </div> </ix:nonNumeric> <ix:nonNumeric id="F20230227081114852_1" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" contextRef="C_20220101to20221231" escape="true">

<div>

<div style="line-height:1.25">

<div style="margin:0pt">&#160;</div> </div>

<div>

<div style="margin-left:54pt">

<table cellpadding="0" cellspacing="0" style="color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:left;width:92%">
  <tr>
    <td style="vertical-align:top;padding-bottom:2px" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td>
    <td colspan="6" style="vertical-align:top;border-bottom:#000000 solid 2px" valign="bottom">
        <div style="line-height:1.25">
        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span>2022</span></span></span></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td>
    <td colspan="6" style="vertical-align:top;border-bottom:#000000 solid 2px" valign="bottom">
        <div style="line-height:1.25">
        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span>2021</span></span></span></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td> </tr>
  <tr>
    <td style="vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px" valign="bottom">
        <div style="line-height:1.25">
        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span>Number
        of</span></span></span></span></span></div>
        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span>options</span></span></span></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px" valign="bottom">
        <div style="line-height:1.25">
        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span>Weighted</span></span></span></span></span></div>
        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span>average</span></span></span></span></span></div>
        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span>exercise</span></span></span></span></span></div>
        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span>price</span></span></span></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px" valign="bottom">
        <div style="line-height:1.25">
        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span>Number
        of</span></span></span></span></span></div>
        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span>options</span></span></span></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px" valign="bottom">
        <div style="line-height:1.25">
        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span>Weighted</span></span></span></span></span></div>
        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span>average</span></span></span></span></span></div>
        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span>exercise</span></span></span></span></span></div>
        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span>price</span></span></span></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td> </tr>
  <tr>
    <td style="vertical-align:middle;width:52%;background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="text-indent:-1.3pt;margin-left:1.3pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span>Outstanding
        at beginning of the year</span></span></span></span></span></div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><ix:nonFraction id="F20230227081114865_21" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="C_20211231" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">4,316,859</ix:nonFraction></span></span></span></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span>$</span></span></span></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><ix:nonFraction id="F20230227081114866_22" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="C_20211231" unitRef="USD_per_Share" scale="0" decimals="2" format="ixt:num-dot-decimal">3.63</ix:nonFraction></span></span></span></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><ix:nonFraction id="F20230227081114866_23" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="C_20201231" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">2,570,109</ix:nonFraction></span></span></span></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span>$</span></span></span></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><ix:nonFraction id="F20230227081114867_24" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="C_20201231" unitRef="USD_per_Share" scale="0" decimals="2" format="ixt:num-dot-decimal">4.85</ix:nonFraction></span></span></span></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align:middle;width:52%" valign="bottom">
        <div style="text-indent:-1.3pt;margin-left:1.3pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span>Granted</span></span></span></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><ix:nonFraction id="F20230227081114868_26" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="C_20220101to20221231" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">2,458,863</ix:nonFraction></span></span></span></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><ix:nonFraction id="F20230227081114868_27" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" contextRef="C_20220101to20221231" unitRef="USD_per_Share" scale="0" decimals="2" format="ixt:num-dot-decimal">2.29</ix:nonFraction></span></span></span></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><ix:nonFraction id="F20230227081114868_28" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="C_20210101to20211231" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">1,975,586</ix:nonFraction></span></span></span></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">
        <div style="line-height:1.25">&#160;</div> </td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><ix:nonFraction id="F20230227081114869_29" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" contextRef="C_20210101to20211231" unitRef="USD_per_Share" scale="0" decimals="2" format="ixt:num-dot-decimal">1.95</ix:nonFraction></span></span></span></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td> </tr>
  <tr>
    <td style="vertical-align:middle;width:52%;background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="text-indent:-1.3pt;margin-left:1.3pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span>Exercised</span></span></span></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span>(<ix:nonFraction id="F20230227081114869_30" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="C_20220101to20221231" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">5,511</ix:nonFraction></span></span></span></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span>)</span></span></span></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><ix:nonFraction id="F20230227081114867_25" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" contextRef="C_20220101to20221231" unitRef="USD_per_Share" scale="0" decimals="2" format="ixt:num-dot-decimal">2.14</ix:nonFraction></span></span></span></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span>(<ix:nonFraction id="F20230227081114870_31" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="C_20210101to20211231" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">177,710</ix:nonFraction></span></span></span></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span>)</span></span></span></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><ix:nonFraction id="F20230227081114870_32" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" contextRef="C_20210101to20211231" unitRef="USD_per_Share" scale="0" decimals="2" format="ixt:num-dot-decimal">2.37</ix:nonFraction></span></span></span></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align:middle;width:52%" valign="bottom">
        <div style="text-indent:-1.3pt;margin-left:1.3pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span>Forfeited</span></span></span></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span>(<ix:nonFraction id="F20230227081114871_33" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" contextRef="C_20220101to20221231" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">902,009</ix:nonFraction></span></span></span></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span>)</span></span></span></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><ix:nonFraction id="F20230227081114871_34" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" contextRef="C_20220101to20221231" unitRef="USD_per_Share" scale="0" decimals="2" format="ixt:num-dot-decimal">1.41</ix:nonFraction></span></span></span></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span>(<ix:nonFraction id="F20230227081114873_35" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" contextRef="C_20210101to20211231" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">16,660</ix:nonFraction></span></span></span></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span>)</span></span></span></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><ix:nonFraction id="F20230227081114873_36" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" contextRef="C_20210101to20211231" unitRef="USD_per_Share" scale="0" decimals="2" format="ixt:num-dot-decimal">2.37</ix:nonFraction></span></span></span></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td> </tr>
  <tr>
    <td style="vertical-align:middle;width:52%;padding-bottom:2px;background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="text-indent:-8.4pt;margin-left:8.4pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span>Expired</span></span></span></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span>(<ix:nonFraction id="F20230227081114874_37" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" contextRef="C_20220101to20221231" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">135,115</ix:nonFraction></span></span></span></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span>)</span></span></span></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><ix:nonFraction id="F20230227081114874_38" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" contextRef="C_20220101to20221231" unitRef="USD_per_Share" scale="0" decimals="2" format="ixt:num-dot-decimal">3.80</ix:nonFraction></span></span></span></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span>(<ix:nonFraction id="F20230227081114874_39" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" contextRef="C_20210101to20211231" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">34,466</ix:nonFraction></span></span></span></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span>)</span></span></span></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><ix:nonFraction id="F20230227081114875_40" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" contextRef="C_20210101to20211231" unitRef="USD_per_Share" scale="0" decimals="2" format="ixt:num-dot-decimal">4.00</ix:nonFraction></span></span></span></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align:middle;width:52%;padding-bottom:4px" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span>Outstanding
        at end of the year</span></span></span></span></span></div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0)" valign="bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><ix:nonFraction id="F20230227081114875_41" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="C_20221231" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">5,733,087</ix:nonFraction></span></span></span></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;white-space:nowrap" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0)" valign="bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span>$</span></span></span></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0)" valign="bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><ix:nonFraction id="F20230227081114876_42" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="C_20221231" unitRef="USD_per_Share" scale="0" decimals="2" format="ixt:num-dot-decimal">3.30</ix:nonFraction></span></span></span></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;white-space:nowrap" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0)" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><ix:nonFraction id="F20230227081114876_43" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="C_20211231" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">4,316,859</ix:nonFraction></span></span></span></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;white-space:nowrap" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0)" valign="bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span>$</span></span></span></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0)" valign="bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><ix:nonFraction id="F20230227081114877_44" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="C_20211231" unitRef="USD_per_Share" scale="0" decimals="2" format="ixt:num-dot-decimal">3.63</ix:nonFraction></span></span></span></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;white-space:nowrap" valign="bottom">&#160;</td> </tr>
  <tr>
    <td style="vertical-align:middle;width:52%;padding-bottom:4px;background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span>Exercisable
        at end of the year</span></span></span></span></span></div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><ix:nonFraction id="F20230227081114877_45" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" contextRef="C_20221231" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">3,165,677</ix:nonFraction></span></span></span></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span>$</span></span></span></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><ix:nonFraction id="F20230227081114877_46" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" contextRef="C_20221231" unitRef="USD_per_Share" scale="0" decimals="2" format="ixt:num-dot-decimal">4.06</ix:nonFraction></span></span></span></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><ix:nonFraction id="F20230227081114878_47" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" contextRef="C_20211231" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">2,068,067</ix:nonFraction></span></span></span></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span>$</span></span></span></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><ix:nonFraction id="F20230227081114878_48" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" contextRef="C_20211231" unitRef="USD_per_Share" scale="0" decimals="2" format="ixt:num-dot-decimal">5.39</ix:nonFraction></span></span></span></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
        </tr>
  </table> </div> </div> </div> </ix:nonNumeric> </div> </div>

<p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman,Times,serif">&#160;</p>

<div><ix:exclude>

<div>

<div>

<div style="line-height:1.25;clear:both">

<div style="clear:both;margin-top:0pt;margin-bottom:0pt">

<div style="text-align:center;margin-top:10pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span><span><span><span><span style="color:#000000;font-weight:normal;font-style:normal">114</span></span></span></span></span></span></span></span></span></div>

<div style="page-break-after:always"><hr style="border-width:0px;clear:both;margin:4px 0px;width:100%;height:2px;color:#000000;background-color:#000000" /></div></div>

<p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:center">&#160;</p>

<p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:10pt;margin-bottom:0pt;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span><span><strong>ENTERA
BIO LTD.<br />NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS</strong></span></span></span></span></span></span></p>

<div style="text-align:center;line-height:1.25">

<div style="margin-top:0pt;margin-bottom:0pt;text-align:center;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span><span><span><span><span style="line-height:normal">(U.S.
dollars in thousands, except share and per share </span></span></span></span></span><span style="line-height:107%">amounts</span><span><span><span><span><span style="line-height:normal">)</span></span></span></span></span></span></span></span></span></div></div>

<p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman,Times,serif">&#160;</p>

<p style="margin:0pt"><strong><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><span><span><span><span><span><span><span><span><span><span><span><span><span><span><span><span><span><span><span>NOTE
6 - SHARE-BASED COMPENSATION </span>(continued</span></span></span></span></span></span></span></span></span></span></span><span><span><span><span><span><span><span><span><span><span><span>)</span></span></span></span></span></span></span></span></span></span></span></span></span></span></span></span></span></span></span></span></span></span></span></span></strong></p>

<p style="margin:0pt">&#160;</p> </div> </div> </div> </ix:exclude></div>

<div>

<div>

<p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><span><span><span><span><span><span><span><span style="line-height:107%">The
following tables summarizes information concerning outstanding and exercisable options as of December 31, 2022, in terms of ordinary shares:</span></span></span></span></span></span></span></span></span></span></span></span></span></span></p>

<p style="margin:0pt">&#160;</p>

<div>

<div>

<div>

<div style="margin-left:45pt"> <ix:nonNumeric id="Fxbrl_20230228131212864" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock" contextRef="C_20220101to20221231" escape="true">

<table border="0" cellpadding="0" cellspacing="0" style="color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:left;width:85%">
  <tr>
    <td colspan="18" rowspan="1" style="vertical-align:top;padding-bottom:2px;border-bottom:2px solid black" valign="bottom">
        <div style="line-height:1.25">
        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span>December
        31, 2022</span></span></span></span></span></div> </div> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td> </tr>
  <tr>
    <td colspan="10" style="vertical-align:top;border-bottom:#000000 solid 2px" valign="bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><strong>Options
        outstanding</strong></span></span></span></span></span></div> </div> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;white-space:nowrap;text-align:center" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center" valign="bottom">&#160;</td>
    <td colspan="6" style="vertical-align:top;border-bottom:#000000 solid 2px" valign="bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><strong>Options
        exercisable</strong></span></span></span></span></span></div> </div> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td> </tr>
  <tr>
    <td colspan="2" style="vertical-align:top" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;white-space:nowrap" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align:top" valign="bottom">
        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span>Number
        of</span></span></span></span></span></div> </td>
    <td colspan="1" style="vertical-align:bottom;white-space:nowrap" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align:top" valign="bottom">
        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span>Weighted</span></span></span></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;white-space:nowrap" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align:top" valign="bottom">
        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span>Number
        of</span></span></span></span></span></div> </td>
    <td colspan="1" style="vertical-align:bottom;white-space:nowrap" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align:top" valign="bottom">
        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span>Weighted</span></span></span></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;white-space:nowrap" valign="bottom">&#160;</td> </tr>
  <tr>
    <td colspan="2" style="vertical-align:top" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;white-space:nowrap" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align:top" valign="bottom">
        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span>options</span></span></span></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;white-space:nowrap" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align:top" valign="bottom">
        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span>Average</span></span></span></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;white-space:nowrap" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align:top" valign="bottom">
        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span>options</span></span></span></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;white-space:nowrap" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align:top" valign="bottom">
        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span>Average</span></span></span></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;white-space:nowrap" valign="bottom">&#160;</td> </tr>
  <tr>
    <td colspan="2" style="vertical-align:top" valign="bottom">
        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span>Exercise</span></span></span></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;white-space:nowrap" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align:top" valign="bottom">
        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span>outstanding</span></span></span></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;white-space:nowrap" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align:top" valign="bottom">
        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span>Remaining</span></span></span></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;white-space:nowrap" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align:top" valign="bottom">
        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span>exercisable</span></span></span></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;white-space:nowrap" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align:top" valign="bottom">
        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span>Remaining</span></span></span></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;white-space:nowrap" valign="bottom">&#160;</td> </tr>
  <tr>
    <td colspan="2" style="vertical-align:top" valign="bottom">
        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span>prices
        per</span></span></span></span></span></div> </td>
    <td colspan="1" style="vertical-align:bottom;white-space:nowrap" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align:top" valign="bottom">
        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span>at
        end of</span></span></span></span></span></div> </td>
    <td colspan="1" style="vertical-align:bottom;white-space:nowrap" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align:top" valign="bottom">
        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span>Contractual</span></span></span></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;white-space:nowrap" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align:top" valign="bottom">
        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span>at
        end of</span></span></span></span></span></div> </td>
    <td colspan="1" style="vertical-align:bottom;white-space:nowrap" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align:top" valign="bottom">
        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span>contractual</span></span></span></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;white-space:nowrap" valign="bottom">&#160;</td> </tr>
  <tr>
    <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px" valign="bottom">
        <div style="line-height:1.25">
        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span>share
        (USD)</span></span></span></span></span></div> </div> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px" valign="bottom">
        <div style="line-height:1.25">
        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span>Year</span></span></span></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px" valign="bottom">
        <div style="line-height:1.25">
        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span>Life</span></span></span></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px" valign="bottom">
        <div style="line-height:1.25">
        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span>year</span></span></span></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px" valign="bottom">
        <div style="line-height:1.25">
        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span>Life</span></span></span></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td> </tr>
  <tr style="background-color:rgb(204, 238, 255)">
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><ix:nonFraction id="F20230227081114937_162" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="C_20221231_usgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_entxExercisePricePerShareZeroMember" unitRef="USD_per_Share" scale="0" decimals="0" format="ixt:fixed-zero">-</ix:nonFraction></span></span></span></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><ix:nonFraction id="F20230227081114898_86" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="C_20221231_usgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_entxExercisePricePerShareZeroMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">1,560</ix:nonFraction></span></span></span></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><ix:nonNumeric id="F20230227081114879_49" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" contextRef="C_20220101to20221231_usgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_entxExercisePricePerShareZeroMember" format="ixt-sec:duryear">0.09</ix:nonNumeric></span></span></span></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><ix:nonFraction id="F20230227081114880_50" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" contextRef="C_20221231_usgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_entxExercisePricePerShareZeroMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">1,560</ix:nonFraction></span></span></span></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><ix:nonNumeric id="F20230227081114881_51" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" contextRef="C_20220101to20221231_usgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_entxExercisePricePerShareZeroMember" format="ixt-sec:duryear">0.09</ix:nonNumeric></span></span></span></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
        </tr>
  <tr style="background-color:rgb(255, 255, 255)">
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(255, 255, 255)" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><ix:nonFraction id="F20230227081114899_87" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="C_20221231_usgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_entxExercisePricePerShareOnePointTwoFourMember" unitRef="USD_per_Share" scale="0" decimals="2" format="ixt:num-dot-decimal">1.24</ix:nonFraction></span></span></span></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(255, 255, 255)" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><ix:nonFraction id="F20230227081114881_52" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="C_20221231_usgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_entxExercisePricePerShareOnePointTwoFourMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">492,831</ix:nonFraction></span></span></span></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(255, 255, 255)" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><ix:nonNumeric id="F20230227081114882_53" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" contextRef="C_20220101to20221231_usgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_entxExercisePricePerShareOnePointTwoFourMember" format="ixt-sec:duryear">1.54</ix:nonNumeric></span></span></span></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(255, 255, 255)" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><ix:nonFraction id="F20230227081114882_54" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" contextRef="C_20221231_usgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_entxExercisePricePerShareOnePointTwoFourMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">492,831</ix:nonFraction></span></span></span></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(255, 255, 255)" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><ix:nonNumeric id="F20230227081114883_55" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" contextRef="C_20220101to20221231_usgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_entxExercisePricePerShareOnePointTwoFourMember" format="ixt-sec:duryear">1.54</ix:nonNumeric></span></span></span></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
        </tr>
  <tr style="background-color:rgb(204, 238, 255)">
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><ix:nonFraction id="F20230227081114942_171" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="C_20221231_usgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_entxExercisePricePerShareOnePointFourMember" unitRef="USD_per_Share" scale="0" decimals="2" format="ixt:num-dot-decimal">1.40</ix:nonFraction></span></span></span></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><ix:nonFraction id="F20230227081114899_88" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="C_20221231_usgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_entxExercisePricePerShareOnePointFourMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">600,000
        </ix:nonFraction></span></span></span></span></span></div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><ix:nonNumeric id="F20230227081114939_165" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" contextRef="C_20220101to20221231_usgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_entxExercisePricePerShareOnePointFourMember" format="ixt-sec:duryear">9.54</ix:nonNumeric></span></span></span></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><ix:nonFraction id="F20230227081114940_168" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" contextRef="C_20221231_usgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_entxExercisePricePerShareOnePointFourMember" unitRef="shares" decimals="INF" format="ixt:fixed-zero">-</ix:nonFraction></span></span></span></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span>-</span></span></span></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
        </tr>
  <tr style="background-color:rgb(255, 255, 255)">
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(255, 255, 255)" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><ix:nonFraction id="F20230227081114900_89" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="C_20221231_usgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_entxExercisePricePerShareTwoPointZeroTwoMember" unitRef="USD_per_Share" scale="0" decimals="2" format="ixt:num-dot-decimal">2.02</ix:nonFraction></span></span></span></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(255, 255, 255)" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><ix:nonFraction id="F20230227081114883_56" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="C_20221231_usgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_entxExercisePricePerShareTwoPointZeroTwoMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">500,000</ix:nonFraction></span></span></span></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(255, 255, 255)" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><ix:nonNumeric id="F20230227081114883_57" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" contextRef="C_20220101to20221231_usgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_entxExercisePricePerShareTwoPointZeroTwoMember" format="ixt-sec:duryear">9.37</ix:nonNumeric></span></span></span></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(255, 255, 255)" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><ix:nonFraction id="F20230227081114884_58" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" contextRef="C_20221231_usgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_entxExercisePricePerShareTwoPointZeroTwoMember" unitRef="shares" decimals="INF" format="ixt:fixed-zero">-</ix:nonFraction></span></span></span></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(255, 255, 255)" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span>-</span></span></span></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
        </tr>
  <tr style="background-color:rgb(204, 238, 255)">
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><ix:nonFraction id="F20230227081114900_90" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="C_20221231_usgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_entxExercisePricePerShareTwoPointOneFourMember" unitRef="USD_per_Share" scale="0" decimals="2" format="ixt:num-dot-decimal">2.14</ix:nonFraction></span></span></span></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><ix:nonFraction id="F20230227081114885_60" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="C_20221231_usgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_entxExercisePricePerShareTwoPointOneFourMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">400,775</ix:nonFraction></span></span></span></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><ix:nonNumeric id="F20230227081114885_61" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" contextRef="C_20220101to20221231_usgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_entxExercisePricePerShareTwoPointOneFourMember" format="ixt-sec:duryear">7.26</ix:nonNumeric></span></span></span></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><ix:nonFraction id="F20230227081114886_62" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" contextRef="C_20221231_usgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_entxExercisePricePerShareTwoPointOneFourMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">277,994</ix:nonFraction></span></span></span></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><ix:nonNumeric id="F20230227081114886_63" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" contextRef="C_20220101to20221231_usgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_entxExercisePricePerShareTwoPointOneFourMember" format="ixt-sec:duryear">7.26</ix:nonNumeric></span></span></span></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
        </tr>
  <tr style="background-color:rgb(255, 255, 255)">
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(255, 255, 255)" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><ix:nonFraction id="F20230227081114938_163" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="C_20221231_usgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_entxExercisePricePerShareTwoPointFiveThreeMember" unitRef="USD_per_Share" scale="0" decimals="2" format="ixt:num-dot-decimal">2.53</ix:nonFraction></span></span></span></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(255, 255, 255)" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><ix:nonFraction id="F20230227081114900_91" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="C_20221231_usgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_entxExercisePricePerShareTwoPointFiveThreeMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">33,638</ix:nonFraction></span></span></span></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(255, 255, 255)" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><ix:nonNumeric id="F20230227081114938_164" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" contextRef="C_20220101to20221231_usgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_entxExercisePricePerShareTwoPointFiveThreeMember" format="ixt-sec:duryear">6.89</ix:nonNumeric></span></span></span></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(255, 255, 255)" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><span><span><ix:nonFraction id="F20230227081114941_169" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" contextRef="C_20221231_usgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_entxExercisePricePerShareTwoPointFiveThreeMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">33,638</ix:nonFraction></span></span></span></span></span></span></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(255, 255, 255)" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><ix:nonNumeric id="Fxbrl_20230228123058155" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" contextRef="C_20220101to20221231_usgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_entxExercisePricePerShareTwoPointFiveThreeMember" format="ixt-sec:duryear">6.89</ix:nonNumeric></span></span></span></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
        </tr>
  <tr style="background-color:rgb(204, 238, 255)">
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><ix:nonFraction id="F20230227081114901_92" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="C_20221231_usgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_entxExercisePricePerShareTwoPointFiveSevenMember" unitRef="USD_per_Share" scale="0" decimals="2" format="ixt:num-dot-decimal">2.57</ix:nonFraction></span></span></span></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><ix:nonFraction id="F20230227081114887_64" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="C_20221231_usgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_entxExercisePricePerShareTwoPointFiveSevenMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">205,500</ix:nonFraction></span></span></span></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><ix:nonNumeric id="F20230227081114888_65" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" contextRef="C_20220101to20221231_usgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_entxExercisePricePerShareTwoPointFiveSevenMember" format="ixt-sec:duryear">9.33</ix:nonNumeric></span></span></span></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><ix:nonFraction id="F20230227081114888_66" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" contextRef="C_20221231_usgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_entxExercisePricePerShareTwoPointFiveSevenMember" unitRef="shares" decimals="INF" format="ixt:fixed-zero">-</ix:nonFraction></span></span></span></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span>-</span></span></span></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
        </tr>
  <tr style="background-color:rgb(255, 255, 255)">
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(255, 255, 255)" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><ix:nonFraction id="F20230227081114901_93" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="C_20221231_usgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_entxExercisePricePerShareTwoPointEightOneFiveMember" unitRef="USD_per_Share" scale="0" decimals="3" format="ixt:num-dot-decimal">2.815</ix:nonFraction></span></span></span></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(255, 255, 255)" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><ix:nonFraction id="F20230227081114889_68" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="C_20221231_usgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_entxExercisePricePerShareTwoPointEightOneFiveMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">1,003,863</ix:nonFraction></span></span></span></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(255, 255, 255)" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><ix:nonNumeric id="F20230227081114890_69" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" contextRef="C_20220101to20221231_usgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_entxExercisePricePerShareTwoPointEightOneFiveMember" format="ixt-sec:duryear">9.01</ix:nonNumeric></span></span></span></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(255, 255, 255)" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><ix:nonFraction id="F20230227081114890_70" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" contextRef="C_20221231_usgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_entxExercisePricePerShareTwoPointEightOneFiveMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">376,447</ix:nonFraction></span></span></span></span></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(255, 255, 255)" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><ix:nonNumeric id="F20230227081114891_71" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" contextRef="C_20220101to20221231_usgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_entxExercisePricePerShareTwoPointEightOneFiveMember" format="ixt-sec:duryear">9.01</ix:nonNumeric></span></span></span></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
        </tr>
  <tr style="background-color:rgb(204, 238, 255)">
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><ix:nonFraction id="F20230227081114902_94" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="C_20221231_usgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_entxExercisePricePerShareTwoPointEightSixMember" unitRef="USD_per_Share" scale="0" decimals="2" format="ixt:num-dot-decimal">2.86</ix:nonFraction></span></span></span></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><ix:nonFraction id="F20230227081114891_72" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="C_20221231_usgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_entxExercisePricePerShareTwoPointEightSixMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">135,000</ix:nonFraction></span></span></span></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><ix:nonNumeric id="F20230227081114891_73" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" contextRef="C_20220101to20221231_usgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_entxExercisePricePerShareTwoPointEightSixMember" format="ixt-sec:duryear">9.25</ix:nonNumeric></span></span></span></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><ix:nonFraction id="F20230227081114892_74" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" contextRef="C_20221231_usgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_entxExercisePricePerShareTwoPointEightSixMember" unitRef="shares" decimals="INF" format="ixt:fixed-zero">-</ix:nonFraction></span></span></span></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span>-</span></span></span></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
        </tr>
  <tr style="background-color:rgb(255, 255, 255)">
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(255, 255, 255)" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><ix:nonFraction id="F20230227081114903_95" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="C_20221231_usgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_entxExercisePricePerShareThreePointOneFiveMember" unitRef="USD_per_Share" scale="0" decimals="2" format="ixt:num-dot-decimal">3.15</ix:nonFraction></span></span></span></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(255, 255, 255)" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><ix:nonFraction id="F20230227081114893_76" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="C_20221231_usgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_entxExercisePricePerShareThreePointOneFiveMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">345,000</ix:nonFraction></span></span></span></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(255, 255, 255)" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><ix:nonNumeric id="F20230227081114893_77" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" contextRef="C_20220101to20221231_usgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_entxExercisePricePerShareThreePointOneFiveMember" format="ixt-sec:duryear">8.30</ix:nonNumeric></span></span></span></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(255, 255, 255)" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><ix:nonFraction id="F20230227081114894_78" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" contextRef="C_20221231_usgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_entxExercisePricePerShareThreePointOneFiveMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">123,125</ix:nonFraction></span></span></span></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(255, 255, 255)" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><ix:nonNumeric id="F20230227081114894_79" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" contextRef="C_20220101to20221231_usgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_entxExercisePricePerShareThreePointOneFiveMember" format="ixt-sec:duryear">8.30</ix:nonNumeric></span></span></span></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
        </tr>
  <tr style="background-color:rgb(204, 238, 255)">
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;padding-bottom:2px;background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><ix:nonFraction id="F20230227081114904_96" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="C_20221231_usgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_entxExercisePricePerShareThreePointSixOneMember" unitRef="USD_per_Share" scale="0" decimals="2" format="ixt:num-dot-decimal">3.61</ix:nonFraction></span></span></span></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;white-space:nowrap;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><ix:nonFraction id="F20230227081114896_80" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="C_20221231_usgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_entxExercisePricePerShareThreePointSixOneMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">250,868</ix:nonFraction></span></span></span></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;white-space:nowrap;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;padding-bottom:2px;background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><ix:nonNumeric id="F20230227081114896_81" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" contextRef="C_20220101to20221231_usgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_entxExercisePricePerShareThreePointSixOneMember" format="ixt-sec:duryear">8.27</ix:nonNumeric></span></span></span></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;white-space:nowrap;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><ix:nonFraction id="F20230227081114897_82" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" contextRef="C_20221231_usgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_entxExercisePricePerShareThreePointSixOneMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">101,059</ix:nonFraction></span></span></span></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;white-space:nowrap;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;padding-bottom:2px;background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><ix:nonNumeric id="F20230227081114897_83" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" contextRef="C_20220101to20221231_usgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_entxExercisePricePerShareThreePointSixOneMember" format="ixt-sec:duryear">8.27</ix:nonNumeric></span></span></span></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;white-space:nowrap;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
        </tr>
  <tr style="background-color:rgb(255, 255, 255)">
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;padding-bottom:2px;background-color:rgb(255, 255, 255)" valign="bottom">
        <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span style="line-height:107%"><ix:nonFraction id="Fxbrl_20230228121220208_20230227081114904_96" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="C_20221231_usgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_entxExercisePricePerShareThreePointSixEightMember" unitRef="USD_per_Share" scale="0" decimals="2" format="ixt:num-dot-decimal">3.68</ix:nonFraction></span></span></span></span></span></p>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;white-space:nowrap;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(255, 255, 255)" valign="bottom">
        <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span style="line-height:107%"><ix:nonFraction id="Fxbrl_20230228121220208_20230227081114896_80" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="C_20221231_usgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_entxExercisePricePerShareThreePointSixEightMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">294,580</ix:nonFraction></span></span></span></span></span></p>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;white-space:nowrap;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;padding-bottom:2px;background-color:rgb(255, 255, 255)" valign="bottom">
        <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span style="line-height:107%"><ix:nonNumeric id="Fxbrl_20230228121220208_20230227081114896_81" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" contextRef="C_20220101to20221231_usgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_entxExercisePricePerShareThreePointSixEightMember" format="ixt-sec:duryear">0.26</ix:nonNumeric></span></span></span></span></span></p>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;white-space:nowrap;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(255, 255, 255)" valign="bottom">
        <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span style="line-height:107%"><ix:nonFraction id="Fxbrl_20230228121220208_20230227081114897_82" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" contextRef="C_20221231_usgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_entxExercisePricePerShareThreePointSixEightMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">294,580</ix:nonFraction></span></span></span></span></span></p>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;white-space:nowrap;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;padding-bottom:2px;background-color:rgb(255, 255, 255)" valign="bottom">
        <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span style="line-height:107%"><ix:nonNumeric id="Fxbrl_20230228121220208_20230227081114897_83" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" contextRef="C_20220101to20221231_usgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_entxExercisePricePerShareThreePointSixEightMember" format="ixt-sec:duryear">0.26</ix:nonNumeric></span></span></span></span></span></p>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;white-space:nowrap;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
        </tr>
  <tr style="background-color:rgb(204, 238, 255)">
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;padding-bottom:2px;background-color:rgb(204, 238, 255)" valign="bottom">
        <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span style="line-height:107%"><ix:nonFraction id="Fxbrl_20230228121257544_xbrl_20230228121220208_20230227081114904_96" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="C_20221231_usgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_entxExercisePricePerShareThreePointNineSevenMember" unitRef="USD_per_Share" scale="0" decimals="2" format="ixt:num-dot-decimal">3.97</ix:nonFraction></span></span></span></span></span></p>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;white-space:nowrap;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">
        <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span style="line-height:107%"><ix:nonFraction id="Fxbrl_20230228121257544_xbrl_20230228121220208_20230227081114896_80" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="C_20221231_usgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_entxExercisePricePerShareThreePointNineSevenMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">247,082</ix:nonFraction></span></span></span></span></span></p>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;white-space:nowrap;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;padding-bottom:2px;background-color:rgb(204, 238, 255)" valign="bottom">
        <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span style="line-height:107%"><ix:nonNumeric id="Fxbrl_20230228121257544_xbrl_20230228121220208_20230227081114896_81" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" contextRef="C_20220101to20221231_usgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_entxExercisePricePerShareThreePointNineSevenMember" format="ixt-sec:duryear">6.05</ix:nonNumeric></span></span></span></span></span></p>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;white-space:nowrap;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">
        <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span style="line-height:107%"><ix:nonFraction id="Fxbrl_20230228121257544_xbrl_20230228121220208_20230227081114897_82" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" contextRef="C_20221231_usgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_entxExercisePricePerShareThreePointNineSevenMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">242,053</ix:nonFraction></span></span></span></span></span></p>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;white-space:nowrap;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;padding-bottom:2px;background-color:rgb(204, 238, 255)" valign="bottom">
        <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span style="line-height:107%"><ix:nonNumeric id="Fxbrl_20230228121257544_xbrl_20230228121220208_20230227081114897_83" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" contextRef="C_20220101to20221231_usgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_entxExercisePricePerShareThreePointNineSevenMember" format="ixt-sec:duryear">6.05</ix:nonNumeric></span></span></span></span></span></p>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;white-space:nowrap;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
        </tr>
  <tr style="background-color:rgb(255, 255, 255)">
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;padding-bottom:2px;background-color:rgb(255, 255, 255)" valign="bottom">
        <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span style="line-height:107%"><ix:nonFraction id="Fxbrl_20230228121259249_xbrl_20230228121220208_20230227081114904_96" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="C_20221231_usgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_entxExercisePricePerShareSixPointThreeOneMember" unitRef="USD_per_Share" scale="0" decimals="2" format="ixt:num-dot-decimal">6.31</ix:nonFraction></span></span></span></span></span></p>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;white-space:nowrap;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid black;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid black;background-color:rgb(255, 255, 255)" valign="bottom">
        <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span style="line-height:107%"><ix:nonFraction id="Fxbrl_20230228121259249_xbrl_20230228121220208_20230227081114896_80" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="C_20221231_usgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_entxExercisePricePerShareSixPointThreeOneMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">1,222,390</ix:nonFraction></span></span></span></span></span></p>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;white-space:nowrap;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;padding-bottom:2px;background-color:rgb(255, 255, 255)" valign="bottom">
        <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span style="line-height:107%"><ix:nonNumeric id="Fxbrl_20230228121259249_xbrl_20230228121220208_20230227081114896_81" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" contextRef="C_20220101to20221231_usgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_entxExercisePricePerShareSixPointThreeOneMember" format="ixt-sec:duryear">3.08</ix:nonNumeric></span></span></span></span></span></p>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;white-space:nowrap;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid black;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid black;background-color:rgb(255, 255, 255)" valign="bottom">
        <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span style="line-height:107%"><ix:nonFraction id="Fxbrl_20230228121259249_xbrl_20230228121220208_20230227081114897_82" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" contextRef="C_20221231_usgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_entxExercisePricePerShareSixPointThreeOneMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">1,222,390</ix:nonFraction></span></span></span></span></span></p>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;white-space:nowrap;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;padding-bottom:2px;background-color:rgb(255, 255, 255)" valign="bottom">
        <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span style="line-height:107%"><ix:nonNumeric id="Fxbrl_20230228121259249_xbrl_20230228121220208_20230227081114897_83" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" contextRef="C_20220101to20221231_usgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_entxExercisePricePerShareSixPointThreeOneMember" format="ixt-sec:duryear">3.08</ix:nonNumeric></span></span></span></span></span></p>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;white-space:nowrap;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
        </tr>
  <tr style="background-color:rgb(204, 238, 255)">
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;padding-bottom:4px;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;white-space:nowrap;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><ix:nonFraction id="F20230227081114897_84" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="C_20221231" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">5,733,087</ix:nonFraction></span></span></span></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;white-space:nowrap;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;padding-bottom:4px;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;white-space:nowrap;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><ix:nonFraction id="F20230227081114898_85" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" contextRef="C_20221231" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">3,165,677</ix:nonFraction></span></span></span></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;white-space:nowrap;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;padding-bottom:4px;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;white-space:nowrap;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
        </tr>
  </table> </ix:nonNumeric> </div> </div> </div>

<div>

<div>

<p style="margin-top:0pt;margin-bottom:0pt"><br /><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><span><span><span><span><span><span><span><span><span style="line-height:107%">The
</span><span style="line-height:107%">aggregate intrinsic value of the total of the outstanding and exercisable options as of December
31, 2022, is $<ix:nonFraction id="F20230227081114907_103" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" contextRef="C_20221231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1</ix:nonFraction>.</span></span></span></span></span></span></span></span></span></span></span></span></span></span></span></p>
</div> </div> </div>

<div style="line-height:1.25;clear:both">

<p style="margin:0pt">&#160;</p> </div>

<div>

<p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><span><span><span><span><span><span><span><span><span><span><span><span><span>The
</span></span></span></span></span><span style="line-height:107%">following table illustrates the effect of share-based compensation on
the statements of operations:</span></span></span></span></span></span></span></span></span></span></span></span></span></span></span></p>

<p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt">&#160;</p> </div> </div> </div> <ix:nonNumeric id="F20230227081114852_2" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" contextRef="C_20220101to20221231" escape="true">

<div>

<div style="text-align:center">

<div style="clear:both;margin-top:0pt;margin-bottom:0pt">

<div style="text-align:center"> <div style="font-size:10pt;display:inline"> <div style="font-family:Times New Roman,Times,serif;display:inline">
<div style="color:#000000;font-weight:normal;font-style:normal;display:inline">

<div>

<div>

<div style="margin-left:45pt">

<table border="0" cellpadding="0" cellspacing="0" style="color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:left;width:85%">
  <tr>
    <td style="vertical-align:top;padding-bottom:2px" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px" valign="bottom">
        <div style="line-height:1.25">
        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span>2022</span></span></span></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px" valign="bottom">
        <div style="line-height:1.25">
        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span>2021</span></span></span></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td> </tr>
  <tr>
    <td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="text-align:justify;text-indent:-12.6pt;margin-left:12.6pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span>Cost
        of revenues</span></span></span></span></span></div> </td>
    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><ix:nonFraction id="F20230227081114943_172" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="C_20220101to20221231_usgaapIncomeStatementLocationAxis_usgaapCostOfSalesMember" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">14</ix:nonFraction></span></span></span></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><ix:nonFraction id="F20230227081114943_173" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="C_20210101to20211231_usgaapIncomeStatementLocationAxis_usgaapCostOfSalesMember" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">102</ix:nonFraction></span></span></span></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align:bottom;width:76%" valign="bottom">
        <div style="text-align:justify;text-indent:-12.6pt;margin-left:12.6pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span>Research
        and development expenses</span></span></span></span></span></div> </td>
    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><ix:nonFraction id="F20230227081114904_97" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="C_20220101to20221231_usgaapIncomeStatementLocationAxis_usgaapResearchAndDevelopmentExpenseMember" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">708</ix:nonFraction></span></span></span></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><ix:nonFraction id="F20230227081114905_98" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="C_20210101to20211231_usgaapIncomeStatementLocationAxis_usgaapResearchAndDevelopmentExpenseMember" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">661</ix:nonFraction></span></span></span></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td> </tr>
  <tr>
    <td style="vertical-align:bottom;width:76%;padding-bottom:2px;background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="text-align:justify;text-indent:-12.6pt;margin-left:12.6pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span>General
        and administrative</span></span></span></span></span></div> </td>
    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><ix:nonFraction id="F20230227081114905_99" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="C_20220101to20221231_usgaapIncomeStatementLocationAxis_usgaapGeneralAndAdministrativeExpenseMember" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,525</ix:nonFraction></span></span></span></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><ix:nonFraction id="F20230227081114906_100" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="C_20210101to20211231_usgaapIncomeStatementLocationAxis_usgaapGeneralAndAdministrativeExpenseMember" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,098</ix:nonFraction></span></span></span></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align:bottom;width:76%;padding-bottom:4px" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;padding-bottom:4px" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0)" valign="bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><ix:nonFraction id="F20230227081114906_101" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="C_20220101to20221231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,247</ix:nonFraction></span></span></span></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;white-space:nowrap" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;padding-bottom:4px" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0)" valign="bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><ix:nonFraction id="F20230227081114907_102" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="C_20210101to20211231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,861</ix:nonFraction></span></span></span></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;white-space:nowrap" valign="bottom">&#160;</td> </tr>
  </table> </div> </div> </div> </div> </div> </div> </div> </div> </div> </div> </ix:nonNumeric> </div> </ix:nonNumeric>

<p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman,Times,serif">&#160;</p>

<div style="clear:both;margin-top:0pt;margin-bottom:0pt">

<div style="text-align:center;margin-top:10pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span><span><span><span><span style="color:#000000;font-weight:normal;font-style:normal">115</span></span></span></span></span></span></span></span></span></div>

<div style="page-break-after:always"><hr style="border-width:0px;clear:both;margin:4px 0px;width:100%;height:2px;color:#000000;background-color:#000000" /></div></div>

<p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:center">&#160;</p>

<p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:10pt;margin-bottom:0pt;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span><span><strong>ENTERA
BIO LTD.<br />NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS</strong></span></span></span></span></span></span></p>

<div style="text-align:center;line-height:1.25">

<div style="margin-top:0pt;margin-bottom:0pt;text-align:center;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span><span><span><span><span style="line-height:normal">(U.S.
dollars in thousands, except share and per share </span></span></span></span></span><span style="line-height:107%">amounts</span><span><span><span><span><span style="line-height:normal">)</span></span></span></span></span></span></span></span></span></div></div>

<p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman,Times,serif">&#160;</p> <ix:nonNumeric id="F20230227081114972_14" name="us-gaap:IncomeTaxDisclosureTextBlock" contextRef="C_20220101to20221231" escape="true">

<div>

<div style="line-height:1.25;font-family:Times New Roman, Times, serif"> <div style="font-size:10pt;display:inline"> <div style="font-family:Times New Roman,Times,serif;display:inline"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><span><span><strong>NOTE
7 - <span style="line-height:107%">INCOME TAX</span></strong></span></span></span></span></span></span></span></span>

<div>

<div>

<div style="text-indent:-36pt;margin-left:36pt;line-height:1.25">&#160;</div>

<table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">
  <tr>
    <td style="width:35.45pt;vertical-align:top;font-weight:bold">A.</td>
    <td style="width:auto;vertical-align:top;text-align:justify">
        <div style="font-weight:bold">Corporate tax rate</div> </td> </tr>
  </table>

<div style="line-height:1.25">&#160;</div>

<table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">
  <tr>
    <td style="width:35pt">&#160;</td>
    <td style="vertical-align:top;width:21pt">1)</td>
    <td style="vertical-align:top;text-align:justify;width:auto">
        <div>Ordinary taxable income in Israel is subject to a corporate tax rate of <ix:nonFraction id="Fxbrl_20230330104022412" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" contextRef="C_20220101to20221231_usgaapIncomeTaxAuthorityAxis_usgaapDomesticCountryMember" unitRef="Percent" scale="-2" decimals="2" format="ixt:num-dot-decimal">23</ix:nonFraction>%.</div>
        </td> </tr>
  </table>

<div style="line-height:1.25">&#160;</div>

<table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">
  <tr>
    <td style="width:35.45pt">&#160;</td>
    <td style="width:21.25pt;vertical-align:top">2)</td>
    <td style="width:auto;vertical-align:top;text-align:justify">
        <div>The Company&#8217;s subsidiary Entera Bio, Inc. is taxed separately under the U.S. tax laws at a tax rate of <ix:nonFraction id="Fxbrl_20230330104030550" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" contextRef="C_20220101to20221231_usgaapIncomeTaxAuthorityAxis_usgaapForeignCountryMember" unitRef="Percent" scale="-2" decimals="2" format="ixt:num-dot-decimal">29</ix:nonFraction>%
        (Federal and state tax)</div> </td> </tr>
  </table> </div> </div>

<p style="margin:0pt">&#160;</p> </div> </div> </div>

<table cellpadding="0" cellspacing="0" style="color:#000000;font-family:'Times New Roman',Times,serif;font-size:10pt;text-align:left;width:100%">
  <tr>
    <td style="width:47px"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>B.</strong></span></span></td>
    <td style="width:auto;vertical-align:top">
        <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>Losses
        for tax purposes carried forward to future years</strong></span></span></p> </td> </tr>
  <tr>
    <td style="width:47px">&#160;</td>
    <td style="width:auto;vertical-align:top">&#160;</td> </tr>
  <tr>
    <td style="width:47px">&#160;</td>
    <td style="width:auto;vertical-align:top">
        <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The
        balance of carryforward losses as of December 31, 2022&#160;and 2021&#160;are approximately $<ix:nonFraction id="F20230227081114972_17" name="us-gaap:OperatingLossCarryforwards" contextRef="C_20221231" unitRef="USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">67.1</ix:nonFraction>&#160;million
        and $<ix:nonFraction id="F20230227081114972_18" name="us-gaap:OperatingLossCarryforwards" contextRef="C_20211231" unitRef="USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">56.1</ix:nonFraction>&#160;million,
        respectively.</span></span></p> </td> </tr>
  <tr>
    <td style="width:47px">&#160;</td>
    <td style="width:auto;vertical-align:top">&#160;</td> </tr>
  <tr>
    <td style="width:47px">&#160;</td>
    <td style="width:auto;vertical-align:top">
        <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Under
        Israeli tax law, tax loss carry forward have no expiration date.</span></span></p> </td> </tr>
  <tr>
    <td style="width:47px">&#160;</td>
    <td style="width:auto;vertical-align:top">&#160;</td> </tr>
  <tr>
    <td style="width:47px"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>C.</strong></span></span></td>
    <td style="width:auto;vertical-align:top">
        <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><span><span><strong><span style="line-height:107%">Tax
        assessments</span></strong></span></span></span></span></span></span></span></span></p> </td> </tr>
  <tr>
    <td style="width:47px">&#160;</td>
    <td style="width:auto;vertical-align:top">&#160;</td> </tr>
  <tr>
    <td style="width:47px">&#160;</td>
    <td style="width:auto;vertical-align:top">
        <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><span><span><span style="line-height:107%">The
        Company and its subsidiary have tax assessments that are considered to be final through tax year 2017.</span></span></span></span></span></span></span></span></span></p>
        </td> </tr>
  <tr>
    <td style="width:47px">&#160;</td>
    <td style="width:auto;vertical-align:top">&#160;</td> </tr>
  <tr>
    <td style="width:47px"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>D.</strong></span></span></td>
    <td style="width:auto;vertical-align:top">
        <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>Loss
        (income) before income taxes is composed of the following</strong></span></span></p> </td> </tr>
  </table> <ix:nonNumeric id="Fxbrl_20230228130917561" name="us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" contextRef="C_20220101to20221231" escape="true">

<div>

<p style="margin:0pt;font-size:10pt">&#160;</p>

<div>

<div>

<div style="margin-left:47px">

<table border="0" cellpadding="0" cellspacing="0" style="color:#000000;float:left;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:left;width:85%">
  <tr>
    <td style="vertical-align:top;padding-bottom:2px" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td>
    <td colspan="6" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);font-weight:bold">
        <div style="line-height:1.25">
        <div style="text-align:center;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Year
        ended December 31</span></span></div> </div> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td> </tr>
  <tr>
    <td style="vertical-align:top;padding-bottom:2px" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0)">
        <div style="line-height:1.25">
        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2022</span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px">&#160;</td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0)">
        <div style="line-height:1.25">
        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2021</span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td> </tr>
  <tr>
    <td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="text-indent:-12.6pt;margin-left:12.6pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Entera
        Bio Ltd.</span></span></div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="F20230227081114972_19" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="C_20220101to20221231_deiLegalEntityAxis_entxEnteraBioLtdMember" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">12,997</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="F20230227081114973_20" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="C_20210101to20211231_deiLegalEntityAxis_entxEnteraBioLtdMember" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">12,362</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align:bottom;width:76%;padding-bottom:2px" valign="bottom">
        <div style="text-indent:-12.6pt;margin-left:12.6pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Entera
        Bio Inc.</span></span></div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0)" valign="bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="Fxbrl_20220305152625682_20230227081114972_19" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="C_20220101to20221231_srtConsolidatedEntitiesAxis_srtSubsidiariesMember" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">65</ix:nonFraction></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;white-space:nowrap" valign="bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0)" valign="bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="Fxbrl_20220305152625682_20230227081114973_20" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="C_20210101to20211231_srtConsolidatedEntitiesAxis_srtSubsidiariesMember" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">116</ix:nonFraction></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;white-space:nowrap" valign="bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
        </div> </td> </tr>
  <tr>
    <td style="vertical-align:bottom;width:76%;padding-bottom:2px;background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="text-indent:-12.6pt;margin-left:12.6pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Total
        loss before taxes</span></span></div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20220305152701116_xbrl_20220305152625682_20230227081114972_19" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="C_20220101to20221231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">12,934</ix:nonFraction></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20220305152701116_xbrl_20220305152625682_20230227081114973_20" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="C_20210101to20211231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">12,246</ix:nonFraction></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
        </tr>
  </table> </div>

<div style="line-height:1.25;clear:both">

<div style="line-height:1.25">&#160;</div> </div> </div> </div> </div> </ix:nonNumeric>

<div>

<div>

<div style="line-height:1.25;clear:both">

<div style="line-height:1.25">

<div style="line-height:1.25">

<div>

<div>

<div style="line-height:1.25">

<div style="line-height:1.25">

<div style="line-height:1.25">

<div>

<div>

<div>

<div style="line-height:1.25">

<div>

<div style="line-height:1.25">

<div style="line-height:1.25">

<div style="line-height:1.25">

<div style="line-height:1.25;font-weight:bold">

<div style="line-height:1.25">

<div style="line-height:1.25;font-weight:bold">

<table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">
  <tr>
    <td style="width:35.45pt;vertical-align:top;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">E.</span></span></td>
    <td style="width:auto;vertical-align:top;text-align:justify">
        <div style="font-weight:normal">
        <div style="line-height:1.25">
        <div style="line-height:1.25">
        <div style="line-height:1.25">
        <div style="line-height:1.25">
        <div style="line-height:1.25">
        <div style="line-height:1.25">
        <div style="line-height:1.25">
        <div style="line-height:1.25">
        <div style="line-height:1.25">
        <div style="line-height:1.25">
        <div style="line-height:1.25">
        <div style="line-height:1.25">
        <div style="line-height:1.25">
        <div>
        <div style="line-height:1.25">
        <div style="line-height:1.25">
        <div>
        <div>
        <div>
        <div>
        <div style="line-height:1.25;font-weight:bold">
        <div style="line-height:1.25;font-weight:bold">
        <div>
        <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Income tax expense&#160;(benefit):</span></span></div>
        </div> </div> </div> </div> </div> </div> </div> </div> </div> </div> </div> </div> </div> </div> </div> </div> </div> </div> </div> </div>
        </div> </div> </div> </div> </td> </tr>
  </table> </div> </div> </div> </div> </div> </div> </div> </div> </div> </div> </div> </div> </div> </div> </div> </div> </div>

<div style="margin-left:36pt;line-height:1.25">&#160;</div> </div> </div>

<div style="margin-left:36pt"> <ix:nonNumeric id="F20230227081114976_41" name="us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" contextRef="C_20220101to20221231" escape="true">

<table border="0" cellpadding="0" cellspacing="0" style="color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:left;width:85%">
  <tr>
    <td style="vertical-align:top;padding-bottom:2px" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td>
    <td colspan="6" style="vertical-align:bottom;border-bottom:#000000 solid 2px" valign="bottom">
        <div style="line-height:1.25;font-weight:bold">
        <div style="text-align:center;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Year
        ended December 31</span></span></div> </div> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td> </tr>
  <tr>
    <td style="vertical-align:top;padding-bottom:2px" valign="bottom">
        <div style="line-height:1.25">&#160;</div> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0)" valign="bottom">
        <div style="line-height:1.25;font-weight:bold">
        <div style="text-align:center;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2022</span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-weight:bold;white-space:nowrap" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-weight:bold" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0)" valign="bottom">
        <div style="line-height:1.25;font-weight:bold">
        <div style="text-align:center;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2021</span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td> </tr>
  <tr>
    <td rowspan="1" style="vertical-align:top;background-color:rgb(204, 238, 255);height:15px" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Current:</span></span></div>
        </td>
    <td colspan="1" rowspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);height:15px" valign="bottom">&#160;</td>
    <td colspan="2" rowspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);height:15px" valign="bottom">&#160;</td>
    <td colspan="1" rowspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);white-space:nowrap;height:15px" valign="bottom">&#160;</td>
    <td colspan="1" rowspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);height:15px" valign="bottom">&#160;</td>
    <td colspan="2" rowspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);height:15px" valign="bottom">&#160;</td>
    <td colspan="1" rowspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);white-space:nowrap;height:15px" valign="bottom">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align:bottom;width:76%;padding-bottom:2px;height:15px" valign="bottom">
        <div style="text-indent:-12.6pt;margin-left:12.6pt;line-height:1.25;margin-top:0px;margin-bottom:0px"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Subsidiary:</span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;height:15px" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);height:15px" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);height:15px" valign="bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="Fxbrl_20230228134937123" name="us-gaap:CurrentIncomeTaxExpenseBenefit" contextRef="C_20220101to20221231_srtConsolidatedEntitiesAxis_srtSubsidiariesMember" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">37</ix:nonFraction></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:1pt;white-space:nowrap;height:15px" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;height:15px" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);height:15px" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);height:15px" valign="bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="F20230227081114975_26" name="us-gaap:CurrentIncomeTaxExpenseBenefit" contextRef="C_20210101to20211231_srtConsolidatedEntitiesAxis_srtSubsidiariesMember" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">158</ix:nonFraction></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;white-space:nowrap;height:15px" valign="bottom">&#160;</td> </tr>
  <tr>
    <td style="vertical-align:bottom;width:76%;padding-bottom:2px;background-color:rgb(204, 238, 255);height:15px" valign="bottom">
        <div style="text-indent:-12.6pt;margin-left:12.6pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Total
        current income tax</span></span></div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);height:15px" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);height:15px" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);height:15px" valign="bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="Fxbrl_20230228134908782" name="us-gaap:CurrentIncomeTaxExpenseBenefit" contextRef="C_20220101to20221231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">37</ix:nonFraction></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:1pt;background-color:rgb(204, 238, 255);white-space:nowrap;height:15px" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);height:15px" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);height:15px" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);height:15px" valign="bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20220305155620306_20230227081114975_26" name="us-gaap:CurrentIncomeTaxExpenseBenefit" contextRef="C_20210101to20211231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">158</ix:nonFraction></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);white-space:nowrap;height:15px" valign="bottom">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align:bottom;width:76%;height:15px" valign="bottom">
        <div style="text-indent:-12.6pt;margin-left:12.6pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Deferred
        income&#160;taxes</span></span></div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;height:15px" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;height:15px" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;height:15px" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20230228142546107_xbrl_20220305155912894_xbrl_20220305155728354_xbrl_20220305155620306_20230227081114975_25" name="us-gaap:DeferredFederalStateAndLocalTaxExpenseBenefit" contextRef="C_20220101to20221231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">174</ix:nonFraction></span></span></td>
    <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap;height:15px" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;height:15px" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;height:15px" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;height:15px" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="Fxbrl_20230228142546107_xbrl_20220305155912894_xbrl_20220305155728354_xbrl_20220305155620306_20230227081114975_26" name="us-gaap:DeferredFederalStateAndLocalTaxExpenseBenefit" contextRef="C_20210101to20211231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">217</ix:nonFraction></span></span></td>
    <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap;height:15px" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></td>
        </tr>
  <tr>
    <td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255);padding-bottom:2px;height:15px" valign="bottom">
        <div style="text-indent:-12.6pt;margin-left:12.6pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Total
        deferred income taxes</span></span></div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);padding-bottom:2px;height:15px" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);border-bottom:2px solid rgb(0, 0, 0);height:15px" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);border-bottom:2px solid rgb(0, 0, 0);height:15px" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20230228142548077_xbrl_20220305155912894_xbrl_20220305155728354_xbrl_20220305155620306_20230227081114975_25" name="us-gaap:DeferredIncomeTaxExpenseBenefit" contextRef="C_20220101to20221231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">174</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);padding-bottom:2px;white-space:nowrap;height:15px" valign="bottom">
        <div style="line-height:1.25">&#160;</div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);padding-bottom:2px;height:15px" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);border-bottom:2px solid rgb(0, 0, 0);height:15px" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);border-bottom:2px solid rgb(0, 0, 0);height:15px" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="Fxbrl_20230228142548077_xbrl_20220305155912894_xbrl_20220305155728354_xbrl_20220305155620306_20230227081114975_26" name="us-gaap:DeferredIncomeTaxExpenseBenefit" contextRef="C_20210101to20211231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">217</ix:nonFraction></span></span></td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);padding-bottom:1pt;white-space:nowrap;height:15px" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></td>
        </tr>
  <tr>
    <td style="vertical-align:baseline;width:76%;padding-bottom:4px;height:15px">
        <div style="text-indent:-12.6pt;margin-left:12.6pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Total
        income tax expense (benefit)&#160;</span></span></div> </td>
    <td colspan="1" style="vertical-align:baseline;width:1%;padding-bottom:4px;height:15px">&#160;</td>
    <td colspan="1" style="vertical-align:baseline;width:1%;border-bottom:4px double rgb(0, 0, 0);height:15px">&#160;</td>
    <td colspan="1" style="vertical-align:baseline;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);height:15px">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20230228143853981_xbrl_20230228142548077_xbrl_20220305155912894_xbrl_20220305155728354_xbrl_20220305155620306_20230227081114975_25" name="us-gaap:IncomeTaxExpenseBenefit" contextRef="C_20220101to20221231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">137</ix:nonFraction></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:baseline;width:1%;padding-bottom:4px;white-space:nowrap;height:15px">
        <div style="line-height:1.25">
        <div style="line-height:1.25">&#160;</div> </div> </td>
    <td colspan="1" style="vertical-align:baseline;width:1%;padding-bottom:4px;height:15px">&#160;</td>
    <td colspan="1" style="vertical-align:baseline;width:1%;border-bottom:4px double rgb(0, 0, 0);height:15px">&#160;</td>
    <td colspan="1" style="vertical-align:baseline;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);height:15px">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="Fxbrl_20230228143853981_xbrl_20230228142548077_xbrl_20220305155912894_xbrl_20220305155728354_xbrl_20220305155620306_20230227081114975_26" name="us-gaap:IncomeTaxExpenseBenefit" contextRef="C_20210101to20211231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">59</ix:nonFraction></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:baseline;width:1%;padding-bottom:1pt;white-space:nowrap;height:15px"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></td>
        </tr>
  </table>

<p style="margin:0pt">&#160;</p> </ix:nonNumeric> </div> </div> </div>

<div><ix:exclude>

<div style="clear:both;margin-top:0pt;margin-bottom:0pt">

<div style="text-align:center;margin-top:10pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span><span><span><span><span style="color:#000000;font-weight:normal;font-style:normal">116</span></span></span></span></span></span></span></span></span></div>

<div style="page-break-after:always"><hr style="border-width:0px;clear:both;margin:4px 0px;width:100%;height:2px;color:#000000;background-color:#000000" /></div></div>

<p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:center">&#160;</p>

<p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:10pt;margin-bottom:0pt;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span><span><strong>ENTERA
BIO LTD.<br />NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS</strong></span></span></span></span></span></span></p>

<div style="text-align:center;line-height:1.25">

<div style="margin-top:0pt;margin-bottom:0pt;text-align:center;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span><span><span><span><span style="line-height:normal">(U.S.
dollars in thousands, except share and per share </span></span></span></span></span><span style="line-height:107%">amounts</span><span><span><span><span><span style="line-height:normal">)</span></span></span></span></span></span></span></span></span></div></div>

<p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman,Times,serif">&#160;</p>

<p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><strong>NOTE
7 - <span style="line-height:107%">INCOME TAX&#160;</span></strong></span>&#160;<strong>(continued)</strong></span></span></p>

<p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt">&#160;</p> </ix:exclude></div>

<table cellpadding="0" cellspacing="0" style="color:rgb(0, 0, 0);font-family:Times New Roman, Times, serif;font-size:10pt;width:100%">
  <tr>
    <td style="width:47px"><span style="font-size:10pt"><span><strong>F.</strong></span></span></td>
    <td style="vertical-align:top;width:auto">
        <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span><span><span><span><span><span><span><strong><span style="line-height:107%">Deferred
        income taxes</span></strong></span></span></span></span></span></span></span></span></p> </td> </tr>
  <tr>
    <td style="width:35px">&#160;</td>
    <td style="vertical-align:top">&#160;</td> </tr>
  </table>

<div>

<div>

<div> <ix:nonNumeric id="F20230227081114972_15" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" contextRef="C_20220101to20221231" escape="true">

<div style="margin-left:47px">

<div>

<div>

<div>

<table border="0" cellpadding="0" cellspacing="0" style="color:#000000;float:left;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:left;width:85%">
  <tr>
    <td rowspan="1" style="vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td>
    <td colspan="1" rowspan="1" style="vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td>
    <td colspan="6" rowspan="1" style="vertical-align:bottom;border-bottom:#000000 solid 2px" valign="bottom">
        <div style="text-align:center;line-height:1.25;font-weight:bold;text-indent:1pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>December
        31,</span></span></span></span></div> </td>
    <td colspan="1" rowspan="1" style="vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td> </tr>
  <tr>
    <td rowspan="1" style="vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td>
    <td colspan="1" rowspan="1" style="vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td>
    <td colspan="2" rowspan="1" style="vertical-align:bottom;border-bottom:#000000 solid 2px" valign="bottom">
        <div style="text-align:center;line-height:1.25;font-weight:bold;text-indent:4pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>2022</span></span></span></span></div>
        </td>
    <td colspan="1" rowspan="1" style="vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
    <td colspan="1" rowspan="1" style="text-align:center;font-weight:bold;vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td>
    <td colspan="2" rowspan="1" style="vertical-align:bottom;text-align:center;font-weight:bold;border-bottom:#000000 solid 2px" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>2021</span></span></span></span></td>
    <td colspan="1" rowspan="1" style="font-weight:bold;vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
        </tr>
  <tr>
    <td rowspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Deferred
        tax assets:</span></span></span></span></div> </td>
    <td colspan="1" rowspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="2" rowspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" rowspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap" valign="bottom">&#160;</td>
    <td colspan="1" rowspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="2" rowspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" rowspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap" valign="bottom">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align:bottom;width:76%" valign="bottom">
        <div style="text-indent:-35.1pt;margin-left:35.1pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Net
        operating loss carry forward</span></span></span></span></div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="F20230227081114970_2" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" contextRef="C_20221231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">15,428</ix:nonFraction></span></span></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="F20230227081114970_3" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" contextRef="C_20211231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">12,895</ix:nonFraction></span></span></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td> </tr>
  <tr>
    <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:76%" valign="bottom">
        <div style="text-indent:-35.1pt;margin-left:35.1pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Research
        and development</span></span></span></span></div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:9%" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="F20230227081114970_4" name="us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment" contextRef="C_20221231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,225</ix:nonFraction></span></span></span></span></div>
        </td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:9%" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="F20230227081114970_5" name="us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment" contextRef="C_20211231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,319</ix:nonFraction></span></span></span></span></div>
        </td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align:bottom;width:76%" valign="bottom">
        <div style="text-indent:-35.1pt;margin-left:35.1pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Share-based
        compensation</span></span></span></span></div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20220305162048791_20230227081114970_6" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" contextRef="C_20221231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">877</ix:nonFraction></span></span></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20220305162048791_20230227081114971_7" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" contextRef="C_20211231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">876</ix:nonFraction></span></span></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td> </tr>
  <tr>
    <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:76%" valign="bottom">
        <div style="text-indent:-35.1pt;margin-left:35.1pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Other</span></span></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:9%" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="F20230227081114970_6" name="us-gaap:DeferredTaxAssetsOther" contextRef="C_20221231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">158</ix:nonFraction></span></span></span></span></div>
        </td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:9%" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="F20230227081114971_7" name="us-gaap:DeferredTaxAssetsOther" contextRef="C_20211231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">152</ix:nonFraction></span></span></span></span></div>
        </td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align:bottom;width:76%;padding-bottom:2px" valign="bottom">
        <div style="text-indent:-35.1pt;margin-left:35.1pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Net
        deferred tax assets before valuation allowance</span></span></span></span></div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0)" valign="bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20220305162112863_20230227081114970_6" name="us-gaap:DeferredTaxAssetsGross" contextRef="C_20221231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">17,688</ix:nonFraction></span></span></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0)" valign="bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20220305162112863_20230227081114971_7" name="us-gaap:DeferredTaxAssetsGross" contextRef="C_20211231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">15,242</ix:nonFraction></span></span></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td> </tr>
  <tr>
    <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:76%;padding-bottom:2px" valign="bottom">
        <div style="text-indent:-35.1pt;margin-left:35.1pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Valuation
        allowance</span></span></span></span></div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0)" valign="bottom">&#160;</td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0)" valign="bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>(<ix:nonFraction id="Fxbrl_20220305162203888_xbrl_20220305162112863_20230227081114970_6" name="us-gaap:DeferredTaxAssetsValuationAllowance" contextRef="C_20221231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">17,645</ix:nonFraction></span></span></span></span></div>
        </div> </td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;padding-bottom:2px;white-space:nowrap" valign="bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>)</span></span></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0)" valign="bottom">&#160;</td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0)" valign="bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>(<ix:nonFraction id="Fxbrl_20220305162203888_xbrl_20220305162112863_20230227081114971_7" name="us-gaap:DeferredTaxAssetsValuationAllowance" contextRef="C_20211231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">15,025</ix:nonFraction></span></span></span></span></div>
        </div> </td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;padding-bottom:2px;white-space:nowrap" valign="bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>)</span></span></span></span></div>
        </div> </td> </tr>
  <tr>
    <td style="vertical-align:bottom;width:76%;padding-bottom:4px" valign="bottom">
        <div style="text-indent:-35.1pt;margin-left:35.1pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Net
        deferred tax assets</span></span></span></span></div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0)" valign="bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="F20230227081114971_8" name="us-gaap:DeferredTaxAssetsNet" contextRef="C_20221231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">43</ix:nonFraction></span></span></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;white-space:nowrap" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0)" valign="bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="F20230227081114975_39" name="us-gaap:DeferredTaxAssetsNet" contextRef="C_20211231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">217</ix:nonFraction></span></span></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;white-space:nowrap" valign="bottom">&#160;</td> </tr>
  </table> </div>

<div style="line-height:1.25;clear:both">&#160;</div> </div> </div> </div> </ix:nonNumeric>

<div style="line-height:1.25;clear:both">

<table cellpadding="0" cellspacing="0" style="font-family:Times New Roman, Times, serif;font-size:10pt;width:100%;color:rgb(0, 0, 0);border-width:0px;border-style:initial;border-color:initial">
  <tr>
    <td style="width:47px">&#160;</td>
    <td style="vertical-align:top;width:auto">
        <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;text-align:justify">The Company has classified the net deferred tax assets as
        long-term. In assessing the likelihood of realizing deferred tax assets, management considers whether it is more likely than not that
        some portion or all of the deferred tax assets will not be realized. The ultimate realization of deferred tax assets is dependent upon
        the generation of future taxable income during the periods in which those temporary differences and carry forward losses become deductible.
        Based on the taxable loss in the Israel, management believes it was more likely than not that the deferred tax assets will not be realized
        in the Israel and believes it was more likely than not that deferred tax assets will be realized for the U.S. subsidiary.</p> </td> </tr>
  </table> </div>

<div>

<p style="margin-top:0px;margin-bottom:0px">&#160;</p>

<table cellpadding="0" cellspacing="0" style="border:0px;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:left;width:100%">
  <tr>
    <td style="width:47px"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><strong>G.</strong></span></span></span></span></td>
    <td style="width:auto;vertical-align:top">
        <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><strong><span style="line-height:107%">Rollforward
        of valuation allowance:</span></strong></span></span></span></span></span></span></p> </td> </tr>
  </table> </div>

<p style="margin:0pt">&#160;</p> <ix:nonNumeric id="F20230227081114972_16" name="us-gaap:SummaryOfValuationAllowanceTextBlock" contextRef="C_20220101to20221231" escape="true">

<div style="margin-left:36pt">

<table border="0" cellpadding="0" cellspacing="0" style="color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:left;width:85%">
  <tr style="background-color:rgb(204, 238, 255)">
    <td style="vertical-align:top;background-color:rgb(204, 238, 255);width:89%" valign="bottom">
        <div style="line-height:1.25"> <div style="font-size:10pt;display:inline"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><span style="line-height:107%">Balance
        at January 1, 2021</span></span></span></span></span></span></span></div> </div> </td>
    <td colspan="1" style="vertical-align:bottom;border-bottom:2px solid black;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid black;background-color:rgb(204, 238, 255);width:9%" valign="bottom">
        <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong><span><span><span><span><span style="line-height:107%"><ix:nonFraction id="F20230227081114971_9" name="us-gaap:DeferredTaxAssetsValuationAllowance" contextRef="C_20201231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">12,420</ix:nonFraction></span></span></span></span></span></strong></span></span></p>
        </td>
    <td colspan="1" style="vertical-align:bottom;white-space:nowrap;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
        </tr>
  <tr style="background-color:rgb(255, 255, 255)">
    <td style="vertical-align:top;background-color:rgb(255, 255, 255)" valign="bottom">
        <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><span style="line-height:107%">Additions</span></span></span></span></span></span></span></p>
        </td>
    <td colspan="1" style="vertical-align:bottom;border-bottom:4px double black;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:4px double black;background-color:rgb(255, 255, 255);width:9%" valign="bottom">
        <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><span style="line-height:107%"><ix:nonFraction id="F20230227081114971_12" name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" contextRef="C_20210101to20211231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,605</ix:nonFraction></span></span></span></span></span></span></span></p>
        </td>
    <td colspan="1" style="vertical-align:bottom;white-space:nowrap;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td> </tr>
  <tr style="background-color:rgb(204, 238, 255)">
    <td style="vertical-align:top;background-color:rgb(204, 238, 255)" valign="bottom">
        <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><span style="line-height:107%">Balance
        at January 1, 2022</span></span></span></span></span></span></span></p> </td>
    <td colspan="1" style="vertical-align:bottom;border-bottom:4px double black;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:4px double black;background-color:rgb(204, 238, 255);width:9%" valign="bottom">
        <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong><span><span><span><span><span style="line-height:107%"><ix:nonFraction id="F20230227081114971_10" name="us-gaap:DeferredTaxAssetsValuationAllowance" contextRef="C_20211231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">15,025</ix:nonFraction></span></span></span></span></span></strong></span></span></p>
        </td>
    <td colspan="1" style="vertical-align:bottom;white-space:nowrap;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td> </tr>
  <tr style="background-color:rgb(255, 255, 255)">
    <td style="vertical-align:top;background-color:rgb(255, 255, 255)" valign="bottom">
        <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><span style="line-height:107%">Additions</span></span></span></span></span></span></span></p>
        </td>
    <td colspan="1" style="vertical-align:bottom;border-bottom:4px double black;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:4px double black;background-color:rgb(255, 255, 255);width:9%" valign="bottom">
        <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><span style="line-height:107%"><ix:nonFraction id="F20230227081114971_13" name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" contextRef="C_20220101to20221231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,620</ix:nonFraction></span></span></span></span></span></span></span></p>
        </td>
    <td colspan="1" style="vertical-align:bottom;white-space:nowrap;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td> </tr>
  <tr style="background-color:rgb(204, 238, 255)">
    <td style="vertical-align:top;background-color:rgb(204, 238, 255)" valign="bottom">
        <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><span style="line-height:107%">Balance
        at December 31, 2022</span></span></span></span></span></span></span></p> </td>
    <td colspan="1" style="vertical-align:bottom;border-bottom:4px double black;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:4px double black;background-color:rgb(204, 238, 255);width:9%" valign="bottom">
        <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong><span><span><span><span><span style="line-height:107%"><ix:nonFraction id="F20230227081114971_11" name="us-gaap:DeferredTaxAssetsValuationAllowance" contextRef="C_20221231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">17,645</ix:nonFraction></span></span></span></span></span></strong></span></span></p>
        </td>
    <td colspan="1" style="vertical-align:bottom;white-space:nowrap;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td> </tr>
  </table>

<p style="margin:0pt">&#160;</p> </div> </ix:nonNumeric>

<div><ix:exclude>

<div style="clear:both;margin-top:0pt;margin-bottom:0pt">

<div style="text-align:center;margin-top:10pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span><span><span><span><span style="color:#000000;font-weight:normal;font-style:normal">117</span></span></span></span></span></span></span></span></span></div>

<div style="page-break-after:always"><hr style="border-width:0px;clear:both;margin:4px 0px;width:100%;height:2px;color:#000000;background-color:#000000" /></div></div>

<p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:center">&#160;</p>

<p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:10pt;margin-bottom:0pt;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span><span><strong>ENTERA
BIO LTD.<br />NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS</strong></span></span></span></span></span></span></p>

<div style="text-align:center;line-height:1.25">

<div style="margin-top:0pt;margin-bottom:0pt;text-align:center;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span><span><span><span><span style="line-height:normal">(U.S.
dollars in thousands, except share and per share </span></span></span></span></span><span style="line-height:107%">amounts</span><span><span><span><span><span style="line-height:normal">)</span></span></span></span></span></span></span></span></span></div></div>

<p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman,Times,serif">&#160;</p>

<p style="margin:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>NOTE 7 - INCOME TAX (continued)</strong></span></span></p>

<p style="margin:0pt">&#160;</p> </ix:exclude></div>

<table cellpadding="0" cellspacing="0" style="font-weight:bold;color:rgb(0, 0, 0);font-family:Times New Roman, Times, serif;font-size:10pt;width:100%">
  <tr>
    <td style="vertical-align:top;width:35.45pt"><span style="font-size:10pt"><span>H.</span></span></td>
    <td style="vertical-align:top;text-align:justify;width:auto">
        <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span>Reconciliation of theoretical tax expenses
        to actual expenses</span></span></p> </td> </tr>
  <tr>
    <td style="vertical-align:top;width:35.45pt">&#160;</td>
    <td style="vertical-align:top;text-align:justify;width:auto">&#160;</td> </tr>
  </table>

<p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;margin-left:47px;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The
primary difference between the statutory tax rate of the Company and the effective rate results virtually from the changes in valuation
allowance in respect of carry forward tax losses and research and development expenses due to the uncertainty of the realization of such
tax benefits.</span></span></p>

<p style="margin:0pt">&#160;</p>

<div>

<div>

<div style="line-height:1.25">

<div style="line-height:1.25">

<div style="line-height:1.25">

<div style="line-height:1.25;clear:both">

<div style="line-height:1.25">

<div style="line-height:1.25">

<div>

<div>

<div style="line-height:1.25">

<div style="line-height:1.25">

<div style="line-height:1.25">

<div>

<div>

<div>

<div style="line-height:1.25">

<div>

<div style="line-height:1.25">

<div style="line-height:1.25">

<div style="line-height:1.25">

<div style="line-height:1.25;font-weight:bold">

<div style="line-height:1.25">

<div style="line-height:1.25;font-weight:bold">

<table cellpadding="0" cellspacing="0" style="color:#000000;font-family:'Times New Roman',Times,serif;font-size:10pt;text-align:left;width:100%">
  <tr>
    <td style="width:47px;vertical-align:top;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>I.</span></span></span></span></td>
    <td style="width:auto;vertical-align:top;text-align:justify">
        <div style="font-weight:normal">
        <div style="line-height:1.25">
        <div style="line-height:1.25">
        <div style="line-height:1.25">
        <div style="line-height:1.25">
        <div style="line-height:1.25">
        <div style="line-height:1.25">
        <div style="line-height:1.25">
        <div style="line-height:1.25">
        <div style="line-height:1.25">
        <div style="line-height:1.25">
        <div style="line-height:1.25">
        <div style="line-height:1.25">
        <div style="line-height:1.25">
        <div>
        <div style="line-height:1.25">
        <div style="line-height:1.25">
        <div>
        <div>
        <div>
        <div>
        <div style="line-height:1.25;font-weight:bold">
        <div style="line-height:1.25;font-weight:bold">
        <div>
        <div>
        <div style="line-height:1.25;font-weight:bold">
        <div style="line-height:1.25;font-weight:bold">
        <div style="line-height:1.25;font-weight:bold">
        <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Uncertain
        tax positions</span></span></span></span></div> </div> </div> </div> </div> </div> </div> </div> </div> </div> </div> </div> </div> </div>
        </div> </div> </div> </div> </div> </div> </div> </div> </div> </div> </div> </div> </div> </div> </div> </td> </tr>
  </table> </div> </div> </div> </div> </div> </div> </div> </div> </div> </div> </div> </div> </div> </div> </div> </div> </div> </div>
</div> </div> </div>

<div style="line-height:1.25">&#160;</div> </div>

<div style="margin-left:47px;line-height:1.25;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>As
of December 31, 2022&#160;and 2021, the Company does not have a provision for uncertain tax positions.</span></span></span></span></div>
</div> </div> </div> </div> </div> </div> </ix:nonNumeric>

<p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman,Times,serif">&#160;</p>

<div>

<div> <ix:nonNumeric id="Fxbrl_20230330094603682" name="entx:SupplementaryFinancialStatementInformationTextBlock" contextRef="C_20220101to20221231" escape="true">

<div>

<div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">NOTE
8 - SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION:</span></span></div>

<div style="line-height:1.25">&#160;</div>

<div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Balance
sheets:</span></span></div> <ix:nonNumeric id="Fxbrl_20220808200946504" name="us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" contextRef="C_20220101to20221231" escape="true">

<div>

<div style="line-height:1.25">&#160;</div>

<table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left;color:#000000;width:100%">
  <tr>
    <td style="vertical-align:top;padding-bottom:2px" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td>
    <td colspan="6" style="vertical-align:top;border-bottom:#000000 solid 2px" valign="bottom">
        <div style="line-height:1.25">
        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">December
        31,</span></span></div> </div> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td> </tr>
  <tr>
    <td style="vertical-align:bottom;padding-bottom:2px" valign="bottom">
        <div style="line-height:1.25;font-weight:bold">&#160;</div> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align:top;border-bottom:2px solid rgb(0, 0, 0)" valign="bottom">
        <div style="line-height:1.25">
        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2022</span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align:top;border-bottom:2px solid rgb(0, 0, 0)" valign="bottom">
        <div style="line-height:1.25">
        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2021</span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td> </tr>
  <tr>
    <td rowspan="1" style="vertical-align:top;width:76%;background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Accrued
        expenses and other payables:</span></span></div> </td>
    <td colspan="1" rowspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" rowspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" rowspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" rowspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
    <td colspan="1" rowspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" rowspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" rowspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" rowspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align:top;width:76%" valign="bottom">
        <div style="text-align:justify;text-indent:14.2pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Employees
        and employees related</span></span></div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20220808200953075_xbrl_20220510112546992" name="us-gaap:AccruedEmployeeBenefitsCurrent" contextRef="C_20221231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">154</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20220808200953075_xbrl_20220510112707928" name="us-gaap:AccruedEmployeeBenefitsCurrent" contextRef="C_20211231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">147</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td> </tr>
  <tr>
    <td style="vertical-align:top;width:76%;background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="text-align:justify;text-indent:14.2pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Income
        tax</span></span></div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20220808200953077_xbrl_20220510112605192" name="us-gaap:AccruedIncomeTaxesCurrent" contextRef="C_20221231" unitRef="USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20220808200953077_xbrl_20220510112721383" name="us-gaap:AccruedIncomeTaxesCurrent" contextRef="C_20211231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">134</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align:top;width:76%" valign="bottom">
        <div style="text-align:justify;text-indent:14.2pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Provision
        for vacation</span></span></div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20220808200953079_xbrl_20220510112621448" name="us-gaap:AccruedVacationCurrent" contextRef="C_20221231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">146</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20220808200953079_xbrl_20220510112732615" name="us-gaap:AccruedVacationCurrent" contextRef="C_20211231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">308</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td> </tr>
  <tr>
    <td style="vertical-align:top;width:76%;padding-bottom:2px;background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="text-align:justify;line-height:1.25;margin-left:14.2pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Accrued
        expenses</span></span></div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20220808200953081_xbrl_20220510112644305" name="us-gaap:OtherAccruedLiabilitiesCurrent" contextRef="C_20221231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">933</ix:nonFraction></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20220808200953081_xbrl_20220510112742136" name="us-gaap:OtherAccruedLiabilitiesCurrent" contextRef="C_20211231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,212</ix:nonFraction></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align:top;width:76%;padding-bottom:2px" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0)" valign="bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20220808200953083_xbrl_20220510112657784" name="us-gaap:AccruedLiabilitiesAndOtherLiabilities" contextRef="C_20221231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,233</ix:nonFraction></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0)" valign="bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20220808200953083_xbrl_20220510112751072" name="us-gaap:AccruedLiabilitiesAndOtherLiabilities" contextRef="C_20211231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,801</ix:nonFraction></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td> </tr>
  </table> </div> </ix:nonNumeric> </div> </ix:nonNumeric>

<div style="line-height:1.25;font-weight:bold">&#160;</div> </div> </div> <ix:nonNumeric id="Fxbrl_20230228133032277" name="us-gaap:SubsequentEventsTextBlock" contextRef="C_20220101to20221231" escape="true">

<div>

<div>

<div>

<div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">NOTE
9 - SUBSEQUENT EVENT</span></span></div>

<div style="line-height:1.25;font-weight:bold">&#160;</div>

<table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">
  <tr>
    <td style="width:35.45pt;vertical-align:top;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">a.</span></span></td>
    <td style="width:auto;vertical-align:top;text-align:justify">
        <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">On January 2, 2023, <ix:nonFraction id="Fxbrl_20230228135953818" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="C_20230101to20230102_srtTitleOfIndividualAxis_entxNonExecutiveBoardMember_usgaapSubsequentEventTypeAxis_usgaapSubsequentEventMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">534,246</ix:nonFraction>
        options to purchase ordinary shares were granted to six non-executive board members with an exercise price of&#8201;$<ix:nonFraction id="Fxbrl_20230228140034596" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="C_20230101to20230102_srtTitleOfIndividualAxis_entxNonExecutiveBoardMember_usgaapSubsequentEventTypeAxis_usgaapSubsequentEventMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">0.73</ix:nonFraction>
        per share. The options will vest over <ix:nonNumeric id="Fxbrl_20230330124225419" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" contextRef="C_20230101to20230102_srtTitleOfIndividualAxis_entxNonExecutiveBoardMember_usgaapSubsequentEventTypeAxis_usgaapSubsequentEventMember" format="ixt-sec:durwordsen">one
        year</ix:nonNumeric> in four equal quarterly installments starting on January 1, 2023. This grant was approved by the shareholders of
        the Company on October 4, 2021.</span></span></div> </td> </tr>
  </table> </div> </div> </div> </ix:nonNumeric>

<p style="margin:0pt">&#160;</p>

<div style="clear:both;margin-top:0pt;margin-bottom:0pt">

<div style="text-align:center;margin-top:0px"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span style="color:#000000;font-weight:normal;font-style:normal">118</span></span></span></span></span></div>

<div style="page-break-after:always"> <hr style="border-width:0px;clear:both;margin:4px 0px;width:100%;height:2px;color:#000000;background-color:#000000;margin-bottom:8pt" />
</div> </div>

<p style="margin:0pt">&#160;</p>

<div>

<div>

<div>

<table cellpadding="0" cellspacing="0" style="width:100%">
  <tr>
    <td style="vertical-align:top;width:65pt">
        <div style="line-height:1.25;font-weight:bold"><span id="ITEM9_integixAnchor"></span><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">ITEM
        9.</span></span></div></td>
    <td style="vertical-align:top;width:auto">
        <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">CHANGES
        IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE</span></span></div></td></tr>
  </table>

<div style="line-height:1.25">&#160;</div>

<div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">None.</span></span></div>

<div style="line-height:1.25">&#160;</div>

<table cellpadding="0" cellspacing="0" style="width:100%">
  <tr>
    <td style="vertical-align:top;width:65pt">
        <div style="line-height:1.25;font-weight:bold"><span id="ITEM9A_integixAnchor"></span><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">ITEM
        9A.</span></span></div></td>
    <td style="vertical-align:top;width:auto">
        <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">CONTROLS
        AND PROCEDURES</span></span></div></td></tr>
  </table>

<div style="line-height:1.25">&#160;</div>

<div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Evaluation
of Disclosure Controls and Procedures</span></span></div>

<div style="line-height:1.25">&#160;</div>

<div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Our
management, with the participation of our Chief Executive Officer and Chief Financial Officer, has evaluated the effectiveness of our
disclosure controls and procedures (as such term is defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act and regulations promulgated
thereunder) as of December 31, 2022, which we refer to as the Evaluation Date. Based on such evaluation, those officers have concluded
that, as of the Evaluation Date, our disclosure controls and procedures were effective.</span></span></div>

<div style="line-height:1.25">&#160;</div>

<div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Management&#8217;s
Report on Internal Control over Financial Reporting</span></span></div>

<div style="line-height:1.25">&#160;</div>

<div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Our
management, under the supervision of our Chief Executive Officer and Chief Financial Officer, is responsible for establishing and maintaining
adequate internal control over our financial reporting, as defined in Rules 13a-15(f) and 15d-15(f) of the Exchange Act. The Company&#8217;s
internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial
reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles.
Internal control over financial reporting includes policies and procedures that:</span></span></div>

<div style="line-height:1.25">&#160;</div>

<table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">
  <tr>
    <td style="width:36pt">&#160;</td>
    <td style="width:36pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">&#8226;</span></span></td>
    <td style="width:auto;vertical-align:top;text-align:justify">
        <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">pertain to the maintenance of records that in
        reasonable detail accurately and fairly reflect our transactions and asset dispositions;</span></span></div>
        <div>&#160;</div></td></tr>
  </table>

<table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">
  <tr>
    <td style="width:36pt">&#160;</td>
    <td style="width:36pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">&#8226;</span></span></td>
    <td style="width:auto;vertical-align:top;text-align:justify">
        <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">provide reasonable assurance that transactions
        are recorded as necessary to permit the preparation of our financial statements in accordance with generally accepted accounting principles;</span></span></div>
        <div>&#160;</div></td></tr>
  </table>

<table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">
  <tr>
    <td style="width:36pt">&#160;</td>
    <td style="width:36pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">&#8226;</span></span></td>
    <td style="width:auto;vertical-align:top;text-align:justify">
        <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">provide reasonable assurance that receipts and
        expenditures are made only in accordance with authorizations of our management and board of directors (as appropriate); and</span></span></div>
        <div>&#160;</div></td></tr>
  </table>

<table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">
  <tr>
    <td style="width:36pt">&#160;</td>
    <td style="width:36pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">&#8226;</span></span></td>
    <td style="width:auto;vertical-align:top;text-align:justify">
        <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">provide reasonable assurance regarding the prevention
        or timely detection of unauthorized acquisition, use or disposition of assets that could have a material effect on our financial statements.</span></span></div></td></tr>
  </table>

<div style="line-height:1.25">&#160;</div>

<div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Due
to its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. In addition, projections
of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in
conditions, or that the degree of compliance with the policies or procedures may deteriorate.</span></span></div>

<div style="text-align:justify;text-indent:21.3pt;line-height:1.25">&#160;</div>

<div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Our
management, including our Chief Executive Officer and Chief Financial Officer, assessed the effectiveness of our internal control over
financial reporting as of December 31, 2022 based on criteria established in Internal Control-Integrated Framework (2013) by the Committee
of Sponsoring Organizations of the Treadway Commission (COSO).</span></span></div>

<div style="text-align:justify;text-indent:21.3pt;line-height:1.25">&#160;</div>

<div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Based
on such assessment, our management concluded that the Company&#8217;s internal control over financial reporting was effective as of December
31, 2022.</span></span></div>

<div style="line-height:1.25">&#160;</div>

<div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Changes
in Internal Control over Financial Reporting</span></span></div>

<div style="line-height:1.25">&#160;</div>

<div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">There have been no changes
in our internal control over financial reporting that occurred during the last fiscal quarter that have materially affected, or are reasonably
likely to materially affect, our internal control over financial reporting.</span></span></div>

<div style="line-height:1.25">&#160;</div>

<table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">
  <tr>
    <td style="vertical-align:top;width:65pt">
        <div style="line-height:1.25;font-weight:bold"><span id="ITEM9B_integixAnchor"></span><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">ITEM
        9B.</span></span></div></td>
    <td style="vertical-align:top;width:auto">
        <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">OTHER
        INFORMATION</span></span></div></td></tr>
  </table>

<div style="line-height:1.25">&#160;</div>

<div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">None.</span></span></div>

<div style="line-height:1.25">&#160;</div>

<table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">
  <tr>
    <td style="vertical-align:top;width:65pt">
        <div style="line-height:1.25;font-weight:bold"><span id="ITEM9C_integixAnchor"></span><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">ITEM
        9C.</span></span></div></td>
    <td style="vertical-align:top;width:auto">
        <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">DISCLOSURE
        REGARDING FOREIGN JURISDICTIONS THAT PREVENT INSPECTIONS.</span></span></div></td></tr>
  </table>

<div style="line-height:1.25">&#160;</div>

<div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">None.</span></span></div>

<div>

<div style="line-height:1.25">&#160;</div>

<div style="clear:both;margin-top:10pt;margin-bottom:10pt">

<div style="text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:normal;font-style:normal">119</span></span></span></div>

<div style="page-break-after:always"><hr style="border-width:0px;clear:both;margin:4px 0px;width:100%;height:2px;color:#000000;background-color:#000000" /></div></div></div>

<div style="line-height:1.25">&#160;</div>

<div style="text-align:center;line-height:1.25;font-weight:bold"><span id="PARTIII_integixAnchor"></span><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">PART
III</span></span></div>

<div style="line-height:1.25">&#160;</div>

<div style="line-height:1.25"><span id="ITEM10_integixAnchor"></span><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">I</span></span></span><span style="color:#000000;font-family:Times New Roman, Times, serif;font-size:13.3333px;font-style:normal;font-variant-ligatures:normal;text-align:left;white-space:normal;background-color:#ffffff;text-decoration-thickness:initial;text-decoration-style:initial;text-decoration-color:initial;font-weight:bold">TEM
10.</span>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<span style="color:#000000;font-family:Times New Roman, Times, serif;font-size:13.3333px;font-style:normal;font-variant-ligatures:normal;text-align:left;white-space:normal;background-color:#ffffff;text-decoration-thickness:initial;text-decoration-style:initial;text-decoration-color:initial;font-weight:bold">DIRECTORS,
EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE</span></div>

<div style="line-height:1.25">&#160;</div>

<div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The
names of our directors and executive officers as of the date of this Annual Report and their respective ages, positions and biographies
are set forth below.</span></span></div>

<div style="line-height:1.25">&#160;</div>

<table border="0" cellpadding="3" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">
  <tr>
    <td style="width:29.72%;vertical-align:top">
        <div style="text-align:justify;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="text-decoration:underline">Name</span></span></span></div></td>
    <td style="width:7.78%;vertical-align:top">
        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="text-decoration:underline">Age</span></span></span></div></td>
    <td style="width:62.5%;vertical-align:top">
        <div style="text-align:justify;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="text-decoration:underline">Position</span></span></span></div></td></tr>
  <tr>
    <td style="width:29.72%;vertical-align:top;background-color:#CCEEFF">
        <div style="text-align:justify;line-height:1.25;font-style:italic;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Executive
        Officers</span></span></div></td>
    <td style="width:7.78%;vertical-align:top;background-color:#CCEEFF">&#160;</td>
    <td style="width:62.5%;vertical-align:top;background-color:#CCEEFF">
        <div style="line-height:1.25">&#160;</div></td></tr>
  <tr>
    <td style="width:29.72%;vertical-align:top">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">Miranda
        J. Toledano</span><sup style="font-weight:bold;vertical-align:text-top;line-height:1;font-size:smaller"> (5)</sup>&#160;</span></span></div></td>
    <td style="width:7.78%;vertical-align:top">
        <div style="text-align:center;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">46</span></span></div></td>
    <td style="width:62.5%;vertical-align:top">
        <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Chief
        Executive Officer and Director</span></span></div></td></tr>
  <tr>
    <td style="width:29.72%;vertical-align:top;background-color:rgb(204, 238, 255)">
        <div style="text-align:justify;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Dana
        Yaacov-Garbeli</span></span></div></td>
    <td style="width:7.78%;vertical-align:top;background-color:rgb(204, 238, 255)">
        <div style="text-align:center;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">39</span></span></div></td>
    <td style="width:62.5%;vertical-align:top;background-color:rgb(204, 238, 255)">
        <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Chief
        Financial Officer</span></span></div></td></tr>
  <tr>
    <td style="width:29.72%;vertical-align:top">
        <div style="text-align:justify;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Dr.
        Hillel Galitzer</span></span></div></td>
    <td style="width:7.78%;vertical-align:top">
        <div style="text-align:center;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">44</span></span></div></td>
    <td style="width:62.5%;vertical-align:top">
        <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Chief
        Operating Officer</span></span></div></td></tr>
  <tr>
    <td style="width:29.72%;vertical-align:top;background-color:#CCEEFF">
        <div style="text-align:justify;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Dr.
        Arthur Santora</span></span></div></td>
    <td style="width:7.78%;vertical-align:top;background-color:#CCEEFF">
        <div style="text-align:center;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">72</span></span></div></td>
    <td style="width:62.5%;vertical-align:top;background-color:#CCEEFF">
        <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Chief
        Medical Officer</span></span></div></td></tr>
  <tr>
    <td style="width:29.72%;vertical-align:top">
        <div style="text-align:justify;line-height:1.25;font-style:italic;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Non-Employee
        Directors</span></span></div></td>
    <td style="width:7.78%;vertical-align:top">
        <div style="line-height:1.25">&#160;</div></td>
    <td style="width:62.5%;vertical-align:top">
        <div style="line-height:1.25">&#160;</div></td></tr>
  <tr>
    <td style="width:29.72%;vertical-align:top;background-color:#CCEEFF">
        <div style="text-align:justify;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Gerald
        Lieberman <sup style="vertical-align:text-top;line-height:1;font-size:smaller">(1)</sup></span></span></div></td>
    <td style="width:7.78%;vertical-align:top;background-color:#CCEEFF">
        <div style="text-align:center;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">76</span></span></div></td>
    <td style="width:62.5%;vertical-align:top;background-color:#CCEEFF">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Director, Chairman of
        the Board of Directors</span></span></div></td></tr>
  <tr>
    <td style="width:29.72%;vertical-align:top">
        <div style="text-align:justify;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Dr.
        Roger J. Garceau <sup style="vertical-align:text-top;line-height:1;font-size:smaller">(5)</sup></span></span></div></td>
    <td style="width:7.78%;vertical-align:top">
        <div style="text-align:center;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">69</span></span></div></td>
    <td style="width:62.5%;vertical-align:top">
        <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Director,
        Chairman of the Scientific Advisory Committee</span></span></div></td></tr>
  <tr>
    <td style="width:29.72%;vertical-align:top;background-color:#CCEEFF">
        <div style="text-align:justify;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Ron
        Mayron <sup style="vertical-align:text-top;line-height:1;font-size:smaller">(1) (2)</sup></span></span></div></td>
    <td style="width:7.78%;vertical-align:top;background-color:#CCEEFF">
        <div style="text-align:center;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">59</span></span></div></td>
    <td style="width:62.5%;vertical-align:top;background-color:#CCEEFF">
        <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Director,
        Chairman of the Compensation Committee</span></span></div></td></tr>
  <tr>
    <td style="width:29.72%;vertical-align:top">
        <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Gerald
        M. Ostrov <sup style="vertical-align:text-top;line-height:1;font-size:smaller">(1) (2) (3)</sup></span></span></div></td>
    <td style="width:7.78%;vertical-align:top">
        <div style="text-align:center;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">73</span></span></div></td>
    <td style="width:62.5%;vertical-align:top">
        <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Director,
        Chairman of the Audit Committee</span></span></div></td></tr>
  <tr>
    <td style="width:29.72%;vertical-align:top;background-color:rgb(204, 238, 255)">
        <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Sean
        Ellis<sup style="vertical-align:text-top;line-height:1;font-size:smaller"> (1) (3) (4)</sup></span></span></div></td>
    <td style="width:7.78%;vertical-align:top;background-color:rgb(204, 238, 255)">
        <div style="text-align:center;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">48</span></span></div></td>
    <td style="width:62.5%;vertical-align:top;background-color:rgb(204, 238, 255)">
        <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Director</span></span></div></td></tr>
  <tr>
    <td style="width:29.72%;vertical-align:top">
        <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Yonatan
        Malca<sup style="vertical-align:text-top;line-height:1;font-size:smaller"> (1)(2) (3) (4) (5)</sup></span></span></div></td>
    <td style="width:7.78%;vertical-align:top">
        <div style="text-align:center;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">56</span></span></div></td>
    <td style="width:62.5%;vertical-align:top">
        <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Director,
        Chairman of the Corporate Governance and Nomination Committee</span></span></div></td></tr>
  </table>

<div style="text-align:justify;line-height:1.25">&#160;</div>

<div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(1)
Independent in accordance with SEC regulations and Nasdaq rules requirements applicable to us.</span></span></div>

<div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(2)<span style="font-weight:bold">&#160;</span>Member
of the Compensation Committee.</span></span></div>

<div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(3)<span style="font-weight:bold">&#160;</span>Member
of the Audit Committee.</span></span></div>

<div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(4)<span style="font-weight:bold">&#160;</span>Member
of the Corporate Governance and Nomination Committee.</span></span></div>

<div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(5)<span style="font-weight:bold">&#160;</span>Member
of the Scientific Advisory Committee.<br />&#160;</span></span></div>

<div style="text-align:justify;line-height:1.25;font-style:italic;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Executive
Officers</span></span></div>

<div style="text-align:justify;line-height:1.25">&#160;</div>

<div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">Miranda
J. Toledano</span> has served as the Company's<span style="font-weight:bold">&#160;</span> Chief Executive Officer, or CEO, since July
2022. Prior to her appointment as CEO, Ms. Toledano served as the Company&#8217;s Chief Business Officer, Chief Financial Officer and
Head of Corporate Strategy since May 2022. Ms. Toledano has over 20 years of C-level leadership, principal investment and Wall Street/capital
market experience in the biotech sector. Ms. Toledano has served as a member of our Board of Directors (the &#8220;Board&#8221;) since
2018, and as Member of the Scientific Advisory Committee since February 2022. Previously, Miranda served as Chief Operating Officer, Chief
Financial Officer, and Director of TRIGR Therapeutics, an oncology focused, clinical stage bispecific antibody company, from August 2018
until its acquisition by Compass Therapeutics (Nasdaq: CMPX) in June 2021. At TRIGR, Miranda oversaw the clinical development of lead
asset TR009 (now CTX-009) and led strategic execution, including a $117 million China License Transaction and acquisition by CMPX. Previously,
Ms. Toledano served as Head of Healthcare Investment Banking at MLV &#38; Co. (acquired by B. Riley FBR &#38; Co.), where she completed
biotech equity financings (IPOs, ATMs, and follow-ons) totaling over $4 billion in aggregate value. Earlier in her career, Ms. Toledano
served as vice president in the investment group of Royalty Pharma (Nasdaq: RPRX) from 2004 to 2010. Ms. Toledano is also a member of
the board of directors of Journey Medical (Nasdaq: DERM) and NEXGEL (Nasdaq: NXGL). Ms. Toledano holds a B.A. in Economics from Tufts
University and an MBA in Finance and Entrepreneurship from the NYU Stern School of Business.<br />&#160;</span></span></div>

<div style="clear:both;margin-top:10pt;margin-bottom:10pt">

<div style="text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:normal;font-style:normal">120</span></span></span></div>

<div style="page-break-after:always"><hr style="border-width:0px;clear:both;margin:4px 0px;width:100%;height:2px;color:#000000;background-color:#000000" /></div></div>

<div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">Dana
Yaacov-Garbeli </span>has served as our Chief Financial Officer since July 2022. Prior that, Ms. Yaacov-Garbeli served as our Israel-based
Chief Financial Officer from June 2019 through July 2022. Ms. Yaacov-Garbeli has over 15 years of chief finance and accounting experience.
She previously served as Senior Manager at PwC Israel overseeing audits of public and private companies. She has significant experience
in financial planning, operations management, external and internal audit for public multinational companies under US GAAP, IFRS and PCAOB
standards. Ms. Yaacov-Garbeli is also a partner at A2Z-Finance, a company that provides financial and accounting services. Ms. Yaacov-Garbeli
holds a B.A in accounting and business management and an MBA in financial management from The College of Management and Academic studies.
Ms. Yaacov-Garbeli is a Certified Public Accountant in Israel.</span></span></div>

<div style="line-height:1.25">&#160;</div>

<div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">Dr.
Hillel Galitzer</span><span style="font-weight:bold;font-style:italic">&#160;</span>has served as our Chief Operating Officer since February
2014, prior to which he served as our Director of Scientific Development from July 2012. Dr. Galitzer has more than ten years of experience
in medical research and molecular biology. Between August 2010 and February 2014, Dr. Galitzer was an analyst and the chief operating
officer for Hadasit Bio Holdings Ltd., a publicly traded company on the Tel Aviv Stock Exchange (TASE: HDST) and OTC markets. He is the
co-founder and former chief operating officer of Optivasive Inc. He has written numerous publications in peer-reviewed journals and has
lectured and presented in international conferences and universities. Dr. Galitzer received his Ph.D. from the Hebrew University Medical
School in Jerusalem, where he was mentored by two world renowned researchers in the areas of parathyroid hormone and calcium regulation,
his M.B.A. from Bar Ilan University in Israel and his B.Med.Sc. from the Hebrew University Medical School in Jerusalem.</span></span></div>

<div style="line-height:1.25">&#160;</div>

<div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">Dr.
Arthur Santora </span>has served as our Chief Medical Officer since September 2018. Dr. Santora has more than 30 years of experience in
the biopharmaceutical industry. He spent the majority of his career in the clinical research team at Merck &#38; Co., Inc., from June
1989 to March 2017, where he was the lead clinical research physician responsible for much of the clinical development of Fosamax<sup style="vertical-align:text-top;line-height:1;font-size:smaller">&#174;</sup>
(alendronate sodium), one of the world&#8217;s most prescribed osteoporosis treatments. He was closely involved in the clinical development
of Merck&#8217;s once-weekly Fosamax Plus D (alendronate sodium/ vitamin D3 combination tablets), the first drug/vitamin combination tablet
in the US. His position at Merck immediately prior to his termination of services in 2017 was Scientific Associate Vice President of Clinical
Research, where he was directly responsible for the technical and scientific support for all clinical research of Fosamax/Fosamax plus
D and contributed to the development of many other osteoporosis and endocrine marketed and investigational drugs. Prior to joining Merck,
he served as a Medical Officer at the US FDA and subsequently was a faculty member at Wayne State University Medical School in Detroit.
Dr. Santora is a Clinical Associate Professor at the clinical faculty of Rutgers Robert Wood Johnson Medical School in New Brunswick,
New Jersey. He has graduate training in Internal Medicine at Emory, and its Endocrinology and Metabolism subspecialty at the NIH in Bethesda.
Dr. Santora received his M.D. and Ph.D. in biochemistry from Emory University in Atlanta.</span></span></div>

<div style="line-height:1.25">&#160;</div>

<div style="text-align:justify;line-height:1.25;font-style:italic;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Non-Employee
Directors</span></span></div>

<div style="text-align:justify;line-height:1.25">&#160;</div>

<div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">Gerald
Lieberman</span><span style="font-weight:bold;font-style:italic">&#160;</span>Mr. Lieberman has served as a member of our Board since
April 2014 and became our Chairman in July 2019. Mr. Lieberman is also a member of the board of directors of Teva Pharmaceutical Industries
Ltd. (NYSE and TASE: TEVA), a global leader in pharmaceuticals and the world&#8217;s largest generic drug developer and manufacturer,
where he chairs the Audit Committee and serves on both the Human Resources and Compensation Committee and the Finance Committee. He also
serves as Chairman of the Board of Directors of DosenRx, Ltd., a Digital health company that has developed a personalized, patient-controlled
device for delivering medication. He is also currently a special advisor at Reverence Capital Partners, a private investment firm focused
on the middle-market financial services industry. From 2000 to 2009, Mr. Lieberman was an executive at Alliance Bernstein L.P., where
he served as President and Chief Operating Officer from 2004 to 2009, as Chief Operating Officer from 2003 to 2004 and as Executive Vice
President, Finance and Operations from 2000 to 2003. From 1998 to 2000, he served as Senior Vice President, Finance and Administration
at Sanford C. Bernstein &#38; Co., Inc., until it was acquired by Alliance Capital in 2000, forming Alliance Bernstein L.P. Prior to that,
he served in various executive positions at Fidelity Investments and at Citicorp. Prior to joining Citicorp he was a certified public
accountant with Arthur Andersen. He previously served on the board of directors of Forest Laboratories, LLC from 2011 to 2014, Computershare
Ltd. from 2010 to 2012 and Alliance Bernstein L.P. from 2004 to 2009. Mr. Lieberman received a B.S. Beta Gamma Sigma with honors in business
from the University of Connecticut. Our Board believes that Mr. Lieberman is qualified to serve as director based upon his experience
on boards of other pharmaceutical companies and his years of experience working with healthcare and pharmaceutical companies.<br />&#160;</span></span></div>

<div style="clear:both;margin-top:10pt;margin-bottom:10pt">

<div style="text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:normal;font-style:normal">121</span></span></span></div>

<div style="page-break-after:always"><hr style="border-width:0px;clear:both;margin:4px 0px;width:100%;height:2px;color:#000000;background-color:#000000" /></div></div>

<div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">Dr.
Roger J. Garceau</span><span style="font-weight:bold;font-style:italic">&#160;</span>has served as a member of our Board since March 2016,
and he served as our interim CEO From August 2020 to January 4, 2021. Dr. Garceau served also served as our Chief Development Advisor
from December 2016 to December 2021 (excluding the period he served as our interim CEO). Dr. Garceau has more than 30 years of broad pharmaceutical
industry experience. He has been a director of Enterome SA since December 2016, and a director of ArTara Therapeutics since January 2019.
Prior to joining Entera, Dr. Garceau served as Chief Medical Officer and Executive Vice President of NPS Pharmaceuticals, Inc. from December
2008 and January 2013 respectively, until February 2015, when NPS Pharmaceuticals, Inc., then traded on Nasdaq, was acquired by Shire
plc. (NASDAQ: SHPG). Previously, Dr. Garceau served in several managerial positions with Sanofi-Aventis (NYSE: SNY) from 2002 until 2008,
and Pharmacia Corporation from 1986 until 2002. Dr. Garceau is a board-certified pediatrician and is a Fellow of the American Academy
of Pediatrics. Dr. Garceau holds a B.S. in Biology from Fairfield University in Fairfield, Connecticut and an M.D. from the University
of Massachusetts Medical School. Our Board believes that Dr. Garceau is qualified to serve as director based upon his experience with
the Company and his years of experience working with healthcare and pharmaceutical companies.<br />&#160;</span></span></div>

<div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">Ron
Mayron</span> has served as a member of our Board since April 2021 and is a global healthcare specialist who serves on the boards of numerous
public and privately-held pharma and medical device companies in Israel, including DNA BioMedical Solutions, Innocan Pharma, and IceCure
Medical. His prior executive experience includes several leadership positions culminating in CEO of Teva Israel &#38; Africa from 2009
until 2013 and CEO of S.L.E from 1999 and until 2007. His expertise within healthcare includes M&#38;A, integration and implementation,
global business development, global operations, and supply chain management. He earned a B.Sc. from Ben-Gurion University, and an MBA
from the University of Tel Aviv, and attended several programs at Insead University Fontainebleu, France and the Massachusetts Institute
of Technology, Boston. Our Board believes that Mr. Mayron is qualified to serve as a director based upon his pharmaceutical industry experience
in multiple capacities from operations to chief executive positions as well as his experience on multiple boards of pharmaceutical and
medical device companies in Israel.<br />&#160;</span></span></div>

<div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">Gerald
M. Ostrov</span> has served as a member of our Board since January 2019. Mr. Ostrov consults and invests in new technologies in the medical
device and consumer products fields. Mr. Ostrov currently serves on the board of directors of several privately held companies, including
Mother&#8217;s Choice, a natural products company working with industry giants, Addon Optics, an innovative technology company, and Nuvo
Group Ltd., a developer of next generation baby and mother health monitoring for both hospital and home use. From 2008 to 2010, he served
as Chairman and CEO of Bausch &#38; Lomb. There Mr. Ostrov led the stabilization, streamlining and pipeline building of Bausch &#38; Lomb
following its going-private transaction. From 1998 until 2006, Mr. Ostrov very successfully served as Company Group Chairman for Johnson
&#38; Johnson&#8217;s Worldwide Vision Care businesses. From 1991 to 1998, Mr. Ostrov worked for Johnson &#38; Johnson and quickly rose
to serve as Company Group Chairman of the Consumer and Personal Care businesses in North America. From 1982 to 1991, he served as President
of CIBA Consumer Pharmaceuticals Company. From 1976 to 1982, he worked for the Health Care Division of Johnson &#38; Johnson. From 1973
to 1976, Mr. Ostrov worked at Procter &#38; Gamble. Mr. Ostrov holds a B.S. from Cornell and an M.B.A. from Harvard. Our Board believes
that Mr. Ostrov is qualified to serve as a director based upon his years as an investor in healthcare related companies.<br />&#160;</span></span></div>

<div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">Sean
Ellis </span>has served as a member of our Board since June 2019. Mr. Ellis brings extensive knowledge of both life science industries
and the U.S. financial markets, with a longstanding history in asset management. Mr. Ellis is a fund manager of Centillion Fund, a venture
capital fund dedicated to Israeli investments, with a primary focus on investments in the biotech and healthcare industries. Centillion
is one of Entera Bio&#8217;s earliest investors and largest shareholders. He holds a BA from New York University and MBA from Columbia
University. Our Board believes that Mr. Ellis is qualified to serve as a director based upon his years as an investor in healthcare related
companies.</span></span></div>

<div style="line-height:1.25">&#160;</div>

<div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">Yonatan
Malca</span><span style="font-weight:bold;font-style:italic">&#160;</span>has served as a member of our Board since 2011. Mr. Malca currently
serves as a Chief Executive Officer and director of NanoGohst Ltd. Since 2010 until 2021, he served as a Chief Executive Officer and director
of D.N.A Biomedical Mr. Malca also serves as a director of Nextgen-Biomed LTD. (TASE: NXGN) and Jungo Connectivity Ltd. (TASE: JNGO),
each of which is an Israeli public company. Mr. Malca holds a B.A. in Economics and Statistics from Bar-Ilan University and an M.A. in
Economics and Finance from Bar Ilan University, Israel. Our Board believes that Mr. Malca is qualified to serve as a director based upon
his pharmaceutical industry experience as an executive as well as his experience on boards of multiple pharmaceutical companies.</span></span></div>

<div style="line-height:1.25">&#160;</div>

<div style="clear:both;margin-top:10pt;margin-bottom:10pt">

<div style="text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:normal;font-style:normal">122</span></span></span></div>

<div style="page-break-after:always"><hr style="border-width:0px;clear:both;margin:4px 0px;width:100%;height:2px;color:#000000;background-color:#000000" /></div></div>

<div style="text-align:justify;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Family
Relationships</span></span></div>

<div style="line-height:1.25">&#160;</div>

<div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">There
are no family relationships among any of our directors or executive officers.<br />&#160;</span></span></div>

<div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Involvement
in Certain Legal Proceedings</span></span></div>

<div style="line-height:1.25">&#160;</div>

<div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Our
directors and executive officers are not parties to any material legal proceedings.</span></span></div>

<div style="line-height:1.25">&#160;</div>

<div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Overall
Role of the Board and Board Leadership Structure</span></span></div>

<div style="line-height:1.25">&#160;</div>

<div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Under
the Israeli Companies Law, 1999 and the regulations promulgated thereunder (together, the &#8220;Companies Law&#8221;), our Board is responsible
for setting our general policies and supervising the performance of management. Our Board may exercise all powers and may take all actions
that are not specifically granted by the Companies Law or our Amended and Restated Articles of Association (&#8220;Articles&#8221;) to
our shareholders or to management. Our executive officers are responsible for our day-to-day management and have individual responsibilities
established by our Board. Our chief executive officer is appointed by, and serves at the discretion of, our Board, subject to the terms
of the employment agreement that we have entered into with him. All other executive officers are also appointed by our Board, and are
subject to the terms of any applicable employment agreements that we may enter into with them.</span></span></div>

<div style="line-height:1.25">&#160;</div>

<div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Our
Board currently consists of seven directors. According to our Articles, the number of members of our Board must be at least three and
cannot be more than ten. Our Board is divided into three classes with staggered three-year terms, and one class comes up for election
each year. The Class I directors were re-elected at our 2021 annual meeting of shareholders to serve until our annual meeting of shareholders
in 2024. The Class II director was re-elected at our 2022 annual meeting of shareholders to serve until our annual meeting in 2025. Our
Class III directors have terms expiring at our annual meeting of shareholders in 2023. The members of the classes as of the date hereof
are as follows:</span></span></div>

<div style="line-height:1.25">&#160;</div>

<table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">
  <tr>
    <td style="width:36pt">&#160;</td>
    <td style="width:36pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">&#8226;</span></span></td>
    <td style="width:auto;vertical-align:top;text-align:justify">
        <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">the Class I directors are Miranda J. Toledano,
        Roger Garceau and Ron Mayron;</span></span></div>
        <div>&#160;</div></td></tr>
  </table>

<table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">
  <tr>
    <td style="width:36pt">&#160;</td>
    <td style="width:36pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">&#8226;</span></span></td>
    <td style="width:auto;vertical-align:top;text-align:justify">
        <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">the Class II director is Yonatan Malca; and</span></span></div>
        <div>&#160;</div></td></tr>
  </table>

<table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">
  <tr>
    <td style="width:36pt">&#160;</td>
    <td style="width:36pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">&#8226;</span></span></td>
    <td style="width:auto;vertical-align:top;text-align:justify">
        <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">the Class III directors are Gerald Lieberman,
        Gerald M. Ostrov and Mr. Sean Ellis.</span></span></div></td></tr>
  </table>

<div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">&#8203;</span></span></div>

<div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">At
each annual meeting of shareholders, directors will be elected to succeed the class of directors whose term has expired. This classification
of our Board could have the effect of increasing the length of time necessary to change the composition of a majority of the Board. In
general, at least two annual meetings of shareholders will be necessary for shareholders to effect a change in a majority of the members
of the Board.<br />&#160;</span></span></div>

<div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Under
the Companies Law and our Articles, nominees for directors may also be proposed by any shareholder holding at least one percent (1%) of
our outstanding voting power. However, any such shareholder may propose a nominee only if a written notice of such shareholder&#8217;s
intent to propose a nominee has been given to our Secretary (or, if we have no such Secretary, our Chief Executive Officer). Subject to
any requirements under the Companies Law, to be considered timely and thereby be added to such agenda, such a request must be delivered,
either in person or by certified mail, postage prepaid, and received at the Company's offices, (i) in the case of an annual meeting, no
less than sixty (60) days nor more than one-hundred twenty (120) days prior to the date of the first anniversary of the preceding year&#8217;s
annual meeting, provided, however, that, in the event that the date of the annual meeting is advanced more than thirty (30) days prior
to or delayed by more than thirty (30) days after the anniversary of the preceding year&#8217;s annual meeting, notice by the proposing
shareholder, in order to be timely, must be received no earlier than the close of business one-hundred twenty (120) days prior to such
annual meeting and no later than the close of business on the later of ninety (90) days prior to such annual meeting or the tenth (10th)
day following the day on which public announcement of the date of such meeting is first made, and (ii) in the case of a Company meeting
of shareholders that is an extraordinary meeting, no earlier than one-hundred twenty (120) days prior to such extraordinary meeting and
no later than the close of business on the later of sixty (60) days prior to such extraordinary meeting or the tenth (10th) day following
the day on which public announcement of the date of such meeting is first made, subject to applicable law. Any such notice must include
certain information, including, inter alia, a description of all arrangements between the nominating shareholder and the proposed director
nominee and any other person pursuant to which the nomination is to be made by the nominating shareholder, the consent of the proposed
director nominee to serve as our director if elected and a declaration signed by the nominee declaring that there is no limitation under
the Companies Law preventing his or her election, and that all of the information that is required under the Companies Law to be provided
to us in connection with such election has been provided.</span></span></div>

<div style="line-height:1.25">&#160;</div>

<div style="clear:both;margin-top:10pt;margin-bottom:10pt">

<div style="text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:normal;font-style:normal">123</span></span></span></div>

<div style="page-break-after:always"><hr style="border-width:0px;clear:both;margin:4px 0px;width:100%;height:2px;color:#000000;background-color:#000000" /></div></div>

<div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Our
Board is also authorized to appoint directors in order to fill vacancies, including filling empty board seats if the number of directors
is below the maximum number permitted under our Articles. Each of our directors, other than our external directors, will serve from the
date of election or appointment until the next annual meeting of shareholders for which such director&#8217;s class is due for reelection.
The approval of at least a majority of the voting power in the Company is generally required to remove any of our directors from office
(other than external directors).</span></span></div>

<div style="line-height:1.25">&#160;</div>

<div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Under
the Companies Law, our Board must also determine the minimum number of directors who are required to have accounting and financial expertise.
In determining the number of directors required to have such expertise, our Board must consider, among other things, the type and size
of the company and the scope and complexity of its operations. Our Board has determined that the minimum number of directors of our company
who are required to have accounting and financial expertise is one. Our Board has determined that Mr. Gerald Lieberman and Ms. Miranda
J. Toledano have financial and accounting expertise as defined in the regulations promulgated under the Companies Law, or Financial and
Accounting Expertise.</span></span></div>

<div style="line-height:1.25">&#160;</div>

<div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Other
than with respect to our directors that are also executive officers or employees, there are no arrangements or understandings between
us, on the one hand, and any of our directors, on the other hand, providing for benefits upon termination of their service as directors
of our Company. For information with respect to compensation arrangements with our directors that are also executive officers or employees,
see the sections entitled &#8220;Item 11. Executive Compensation&#8221;&#8221; included in this Annual Report.</span></span></div>

<div style="line-height:1.25">&#160;</div>

<div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Alternate
Directors</span></span></div>

<div style="line-height:1.25">&#160;</div>

<div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Our
Articles provide that, as permitted under the Companies law, any director may appoint another person, who is qualified to be appointed
as a director and who is not a director or an alternate director, to serve as his or her alternate director, subject to the approval of
a majority of the members of the Board, excluding such director. The term of an alternate director could be terminated at any time by
the appointing director or our Board and would terminate under circumstances in which, according to our Articles, the term of any director
shall terminate or automatically terminate upon the termination of the term of the appointing director. The Companies Law stipulates that
an external director may not appoint an alternate director, except under very limited circumstances. An alternate director has the same
rights and responsibilities as a director, except for the right to appoint an alternate director.</span></span></div>

<div style="line-height:1.25">&#160;</div>

<div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Board
Leadership Structure</span></span></div>

<div style="line-height:1.25">&#160;</div>

<div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The
Board currently separates the roles of Board Chairperson and Chief Executive Officer. We believe that separation of the positions of Chairperson
of the Board and Chief Executive Officer reinforces the independence of the Board in its oversight of our business and affairs, is more
conducive to objective evaluation and oversight of management&#8217;s performance, increases management accountability, and improves the
Board&#8217;s ability to monitor whether management&#8217;s actions are in the best interests of the Company and its shareholders. </span></span></div>

<div style="line-height:1.25">&#160;</div>

<div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Role
of the Board in Risk Oversight</span></span></div>

<div style="line-height:1.25">&#160;</div>

<div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Our
Board is responsible for overseeing our risk management process. Our Board focuses on our general risk management strategy, the most significant
risks facing us, and oversees the implementation of risk mitigation strategies by management. Our Board is also apprised by management
of particular risk management matters in connection with its general oversight and approval of corporate matters and significant transactions.
The Board&#8217;s independent oversight function is further enhanced by the fact that all of the Board&#8217;s Committees are composed
entirely of independent directors, the directors have complete access to management and the Board and its committees may retain their
own respective advisors.</span></span></div>

<div style="text-align:justify;line-height:1.25">&#160;</div>

<div style="clear:both;margin-top:10pt;margin-bottom:10pt">

<div style="text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:normal;font-style:normal">124</span></span></span></div>

<div style="page-break-after:always"><hr style="border-width:0px;clear:both;margin:4px 0px;width:100%;height:2px;color:#000000;background-color:#000000" /></div></div>

<div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Corporate
Governance Guidelines</span></span></div>

<div style="line-height:1.25">&#160;</div>

<div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Our
Board strongly supports effective corporate governance and has developed and followed a program of strong corporate governance. Our Nominating
and Corporate Governance Committee is responsible for overseeing our guidelines and reporting and making recommendations to the Board
concerning corporate governance matters. Our guidelines are published on our website at www.enterabio.com and are available in print to
any shareholder who requests them from our Secretary.</span></span></div>

<div style="line-height:1.25">&#160;</div>

<div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">Director
Independence</span>&#160;</span></span></div>

<div style="line-height:1.25">&#160;</div>

<div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Our
Board undertook a review of the independence of each director. Based on information provided by each director concerning his or her background,
employment, and affiliations, our Board has determined that the Board meets independence standards under the applicable rules and regulations
of the SEC and the listing standards of Nasdaq. The Board has affirmatively determined that the following Directors are &#8220;independent&#8221;
as of the date of this Annual Report as defined in the listing standards of Nasdaq: Gerald Lieberman, Ron Mayron, Gerald M. Ostrov, Sean
Ellis and Yonatan Malca. In making these determinations, our Board considered the current and prior relationships that each non-employee
director has with our Company and all other facts and circumstances our Board deemed relevant in determining their independence, including
the beneficial ownership of our capital stock by each non-employee director, and the transactions involving them described in the section
titled Item 13 &#8220;Certain Relationships and Related Party Transactions, and Director Independence&#8221; contained in this Annual
Report on Form 10-K.</span></span></div>

<div style="line-height:1.25">&#160;</div>

<div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Code
of Ethics</span></span></div>

<div style="line-height:1.25">&#160;</div>

<div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">We
have adopted a Code of Business Conduct and Ethics applicable to all of our directors, executive officers and employees, including our
Chief Executive Officer, Chief Financial Officer, controller or principal accounting officer, or other persons performing similar functions.
The full text of the Code of Business Conduct and Ethics can be found on our website at www.enterabio.com. Information contained on, or
that can be accessed through, our website does not constitute a part of this report and is not incorporated by reference herein. If we
make any amendment to the Code of Business Conduct and Ethics or grant any waivers, including any implicit waiver, from a provision of
the code of ethics, we will disclose the nature of such amendment or waiver on our website to the extent required by the rules and regulations
of the SEC.</span></span></div>

<div style="line-height:1.25">&#160;</div>

<div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Board
Committees</span></span></div>

<div style="line-height:1.25">&#160;</div>

<div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Our Board has established
the following committees:</span></span></div>

<div style="line-height:1.25">&#160;</div>

<div style="line-height:1.25;font-style:italic;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Audit
Committee</span></span></div>

<div style="line-height:1.25">&#160;</div>

<div style="line-height:1.25;font-style:italic"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Composition
and Quorum</span></span></div>

<div style="line-height:1.25">&#160;</div>

<div style="line-height:1.25;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Under
the Nasdaq rules and SEC regulations, we are required to maintain an Audit Committee consisting of at least three independent directors,
each of whom is financially literate and one of whom has accounting or related financial management expertise and would qualify as an
&#8220;audit committee financial expert&#8221; as such term is defined in Item 407(d)(5) of Regulation S-K.<br />&#160;</span></span></div>

<div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Our
Audit Committee consists of Gerald M. Ostrov, who also serves as chairman, Yonatan Malca and Sean Ellis. The Board has determined that
each of the members of our Audit Committee is an independent director in accordance with SEC regulations and satisfies the independent
director requirements under the Nasdaq rules. All designated members of our Audit Committee meet the requirements for financial literacy
under the applicable Nasdaq rules and SEC regulations. Our Board has determined that Gerald M. Ostrov is an &#8220;audit committee financial
expert,&#8221; as such term is defined under applicable SEC rules.<br />&#160;</span></span></div>

<div style="clear:both;margin-top:10pt;margin-bottom:10pt">

<div style="text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:normal;font-style:normal">125</span></span></span></div>

<div style="page-break-after:always"><hr style="border-width:0px;clear:both;margin:4px 0px;width:100%;height:2px;color:#000000;background-color:#000000" /></div></div>

<div style="text-align:justify;line-height:1.25;font-style:italic"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Roles,
responsibilities and procedures</span></span></div>

<div style="line-height:1.25">&#160;</div>

<div style="line-height:1.25">

<div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Our
Audit Committee provides assistance to our Board in fulfilling its legal and fiduciary obligations in matters involving our accounting,
auditing, financial reporting, internal control and legal compliance functions by, among other things, pre-approving the services performed
by our independent accountants and reviewing their reports regarding our accounting practices. Our Audit Committee also oversees the audit
efforts of our independent accountants and takes those actions that it deems necessary to satisfy itself that the accountants are independent
of management.</span></span></div></div>

<div style="line-height:1.25">

<div style="line-height:1.25">&#160;</div></div>

<div style="line-height:1.25">

<div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Our
Board has adopted an Audit Committee charter setting forth the responsibilities of the Audit Committee consistent with the applicable
rules and regulations of the SEC and Nasdaq, as well as the requirements for such committee under the Companies Law, including (a) oversight
of our independent registered public accounting firm and recommending the engagement, compensation or termination of engagement of our
independent registered public accounting firm to the Board in accordance with the Companies law; (b) recommending the engagement or termination
of our internal auditor; (c) recommending the terms of audit and non-audit services provided by the independent registered public accounting
firm for pre-approval by our Board; (d) identifying deficiencies in the business management practices of our Company, including, inter
alia, in consultation with our internal auditor or the independent auditor, and making recommendations to the Board as to how to correct
such practices; (e) reviewing and considering the approval of related party transactions; (f) determining whether related party transactions
are extraordinary or material under the Companies Law, including transactions in which an office holder has a &#8220;personal interest&#8221;,
under the Companies Law, and whether to approve such transactions; (g) establishing the approval process for certain transactions with
a controlling shareholder or in which the controlling shareholder has a &#8220;personal interest&#8221;; (h) examining and approving the
working plan of the internal auditor, subject to any modifications in its discretion; (i) examining our internal audit controls and internal
auditor&#8217;s performance, including whether the internal auditor has sufficient resources and tools to fulfill his or her responsibilities;
(j) examining the scope of our auditor&#8217;s work and compensation and submitting its recommendations with respect thereto to our Board
or shareholders, depending on which of them is considering the appointment of our auditor; (k) establishing procedures for the handling
of employees&#8217; complaints as to the management of our business and the protection to be provided to such employees; and (l) reviewing
the our annual audited financial statements and quarterly financial statements with management and the independent auditor, including
a review of our disclosures under &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221;
sections.<br />&#160;</span></span></div></div>

<div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">A
copy of the Audit Committee Charter is available on our website at <span style="text-decoration:underline">www.enterabio.com</span>.</span></span></div>

<div style="line-height:1.25">&#160;</div>

<div style="line-height:1.25">

<div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">A
&#8220;personal interest&#8221; under the Companies Law includes an interest of any person in an action or transaction of a company, excluding
any interest arising solely from holding the Company&#8217;s shares, but including the personal interest of such person&#8217;s spouse,
sibling, parent, grandparent, descendant, spouse&#8217;s descendant, sibling or parent or the spouse of any of such persons, and the personal
interest of any entity in which such person or one of the aforementioned relatives of such person serves as a director or Chief Executive
Officer, owns 5% or more of such entity&#8217;s outstanding shares or voting rights or has the right to appoint one or more directors
or the Chief Executive Officer. Further, in the case of a person voting by proxy, &#8220;personal interest&#8221; includes the personal
interest of either the proxy holder or the shareholder granting the proxy, whether or not the proxy holder has discretion how to vote.</span></span></div></div>

<div style="line-height:1.25">

<div style="line-height:1.25">&#160;</div></div>

<div style="line-height:1.25;font-style:italic;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Compensation
Committee</span></span></div>

<div style="line-height:1.25">&#160;</div>

<div style="line-height:1.25;font-style:italic"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Composition
and quorum</span></span></div>

<div style="line-height:1.25">&#160;</div>

<div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">We have a Compensation
Committee, the members of which are Ron Mayron, who also serves as chairman, Gerald M. Ostrov and Yonatan Malca. Each member of our Compensation
Committee is independent under Nasdaq rules.<br />&#160;</span></span></div>

<div style="text-align:justify;line-height:1.25;font-style:italic"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Roles,
responsibilities and procedures</span></span></div>

<div style="line-height:1.25">&#160;</div>

<div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Our
Board has adopted a charter setting forth the Compensation Committee&#8217;s roles and responsibilities, which include (a) recommending
a compensation policy regarding the terms of engagement of office holders, which is recommended to the Board for approval and subsequently
to shareholders for their approval, in accordance with the Companies Law, and reviewing such policy from time to time, (b) recommending
to the Board periodic updates to the compensation policy and whether the compensation policy should continue in effect every three years;
(c) assessing the implementation of the compensation policy; (d) reviewing and approving the granting of options, restricted share units,
or RSUs, and other incentive awards to the extent such authority is delegated by the Board; (e) reviewing, evaluating and making recommendations
regarding the compensation and benefits for non-executive directors, (f) determining whether to approve and recommend to the Board and
shareholders to approve transactions with office holders relating to their terms of compensation, as required under the Companies Law,
(g) determining whether changes to the compensation terms of the Chief Executive Officer of the Company are material and if the changes
are required to be brought to the shareholders for approval, (h) overseeing compliance reporting requirements of the SEC, (i) determining
whether to recommend to the Board to adopt a share ownership policy for directors and executive officers, and (j) performing such other
activities as may be required.<br />&#160;</span></span></div>

<div style="clear:both;margin-top:10pt;margin-bottom:10pt">

<div style="text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:normal;font-style:normal">126</span></span></span></div>

<div style="page-break-after:always"><hr style="border-width:0px;clear:both;margin:4px 0px;width:100%;height:2px;color:#000000;background-color:#000000" /></div></div>

<div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">A
copy of the Compensation Committee Charter is available on our website at <span style="text-decoration:underline">www.enterabio.com</span>.</span></span></div>

<div style="line-height:1.25">&#160;</div>

<div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Under
the Companies Law, the compensation policy must be adopted by the Board after considering the recommendations of the Compensation Committee
and needs to be further brought before the company&#8217;s shareholders for approval by a special majority, if necessary.</span></span></div>

<div style="line-height:1.25">&#160;</div>

<div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The
compensation policy must serve as the basis for decisions concerning the terms of employment or engagement of office holders, including
exculpation, insurance, indemnification and any monetary payment and obligation of payment in respect of employment or engagement. The
compensation policy must relate to certain factors, including advancement of the Company&#8217;s objectives, the Company&#8217;s business
plan and its long-term strategy, and creation of appropriate incentives for office holders. It must also consider, inter alia, the Company&#8217;s
risk management, size and the nature of its operations.</span></span></div>

<div style="line-height:1.25">&#160;</div>

<div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The
compensation policy must furthermore consider additional factors, as follows: (a) the knowledge, skills, expertise and accomplishments
of the relevant office holder; (b) the office holder&#8217;s roles and responsibilities and prior compensation agreements with him or
her; (c) the ratio between the terms offered and the average compensation of the other employees of the company, including those employed
through manpower companies; (d) the impact of disparities in salary upon work relationships in the company; (e) the possibility of reducing
variable compensation at the discretion of the Board; (f) as to variable compensation, the possibility of setting a limit on the exercise
value of non-cash variable equity-based compensation; and (g) as to severance compensation, the period of service of the office holder,
the terms of his or her compensation during such service period, the company&#8217;s performance during that period of service, the person&#8217;s
contribution towards the company&#8217;s achievement of its goals and the maximization of its profits, and the circumstances of termination
of services.</span></span></div>

<div style="line-height:1.25">&#160;</div>

<div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The
compensation policy must also include the following principles: (a) the link between variable compensation and long-term performance and
measurable criteria; (b) the ratio between variable and fixed compensation, and the ceiling for the value of variable compensation; (c)
the conditions under which an office holder would be required to repay compensation paid to him or her if it was later shown that the
data upon which such compensation was based was inaccurate and was required to be restated in the company&#8217;s financial statements;
(d) the minimum holding or vesting period for variable, equity-based compensation, including bonuses; and (e) maximum limits for severance.</span></span></div>

<div style="line-height:1.25">&#160;</div>

<div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Under
the Companies Law, every three years we are required to re-obtain the approval of our Compensation Committee, Board and shareholders for
either the continuation of our existing compensation policy or adoption of a new compensation policy. Our compensation policy was last
approved by our shareholders on October 4, 2021, after having been recommended by our Compensation Committee and approved by our Board,
and will therefore need to be either re-approved, amended, or replaced by a new policy in 2024.</span></span></div>

<div style="line-height:1.25">&#160;</div>

<div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Our
Compensation Committee may conduct or authorize investigations into, or studies of, matters within its scope of responsibilities, and
may retain or obtain the advice of a compensation consultant, legal counsel or other advisor in its sole discretion. The Compensation
Committee is directly responsible for the appointment, compensation and oversight of the work of any compensation consultant, legal counsel
or other advisor that it retains, at the expense of the Company. The Compensation Committee may select, or receive advice from, a compensation
consultant, legal counsel or other advisor to the Compensation Committee, other than in-house legal counsel, only after conducting an
assessment of, and determining, the advisor&#8217;s independence, including whether the advisor&#8217;s work has raised any questions
of independence or conflicts of interest, taking into consideration the Exchange Act, the factors set forth in Nasdaq rules and any other
factors that the committee deems relevant.<br />&#160;</span></span></div>

<div style="clear:both;margin-top:10pt;margin-bottom:10pt">

<div style="text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:normal;font-style:normal">127</span></span></span></div>

<div style="page-break-after:always"><hr style="border-width:0px;clear:both;margin:4px 0px;width:100%;height:2px;color:#000000;background-color:#000000" /></div></div>

<div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">In
2021, in determining the compensation of certain non-executive directors and in determining our compensation policy, the Compensation
Committee retained the services of a compensation consultant, Brightman Almagor Zohar &#38; co., or Deloitte, to conduct a comparative
survey of the compensation of such office holders. The 2021 comparative study consisted of: (i) an executive compensation benchmark analysis
which included comparative data of the Company&#8217;s executive compensation, relative to the peer-group companies in Israel and (ii)
an executive compensation benchmark analysis which included comparative data of the Company&#8217;s executive compensation, relative to
the peer-group companies in the United States.<sup style="vertical-align:text-top;line-height:1;font-size:smaller">&#160;</sup><br />&#160;</span></span></div>

<div style="line-height:1.25;font-style:italic;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Nominating
and Corporate Governance Committee</span></span></div>

<div style="line-height:1.25">&#160;</div>

<div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Our
Board has adopted a Nominating and Corporate Governance Committee Charter that sets forth the responsibilities of the Nominating and Governance
Committee consistent with the rules and regulations of the SEC and Nasdaq, including (a) assisting in identifying, recruiting and, if
appropriate, interviewing candidates to fill positions on the Board, including persons suggested by shareholders or others, (b) establishing
procedures to be followed by shareholders in submitting recommendations for Board candidates, if appropriate, (c) reviewing the background
and qualifications of individuals being considered as director candidates, while considering the candidate&#8217;s experience, skills,
expertise, diversity, personal and professional integrity, character, business judgment, time availability in light of other commitments,
dedication, conflicts of interest and such other relevant factors that the committee considers appropriate in the context of the needs
of the Board, (d) recommending the Board nominees for election by shareholders or appointment by the Board, as the case may be, in a manner
consistent with the criteria for selecting directors, as established by the Board from time to time, (e) reviewing the suitability for
continued service as a director of each Board member, when the term of service of the director expires, and when the director has a change
in status (including, but not limited to, an employment change) and recommending whether or not the director should be re-nominated, (f)
making recommendations to the Board regarding the size and composition of each committee; and (g) overseeing the performance of the Board
as a whole.</span></span></div>

<div style="line-height:1.25">&#160;</div>

<div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">A
copy of the Nominating and Corporate Governance Committee Charter is available on our website at www.enterabio.com.</span></span></div>

<div style="line-height:1.25">&#160;</div>

<div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Our
Nominating and Corporate Governance Committee consists of Yonatan Malca, who serves as chairman, and Sean Ellis.</span></span></div>

<div style="line-height:1.25;font-style:italic;font-weight:bold"><br /><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Scientific
Advisory Committee</span></span></div>

<div style="line-height:1.25">&#160;</div>

<div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Our
Board has adopted a Scientific Advisory Committee Charter that sets forth the responsibilities of the Scientific Advisory Committee, including
(a) reviewing, evaluating and reporting to the Board regarding strategy, plans and goals, as well as progress and performance, of the
Company&#8217;s clinical programs, licensing activities, and research and development activities, (b) meeting with the Company&#8217;s
R&#38;D and licensing teams to evaluate the plans, goals and performance of the Company&#8217;s clinical programs and research and development
projects, and make recommendations to the Board as appropriate in the opinion of the committee to fulfill the company strategic goals,
(c) identifying and discussing significant emerging regulatory, research and scientific issues and trends and competitive activity, including
their potential impacts on any Company programs, plans, or policies relating to its licensing opportunities, clinical programs and research
and development activities. (d) evaluating the performance of the committee, including a review of the committee&#8217;s compliance with
its charter, and review and reassess the charter and submit any recommended changes to the Board for its consideration and approval, (e)
form external consulting panels to assist the committee in review of specific R&#38;D programs either current or planned and (f) such
other duties and responsibilities as may be assigned to the committee, from time to time, by the Board.</span></span></div>

<div style="line-height:1.25">&#160;</div>

<div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">A
copy of the Scientific Advisory Committee Charter is available on our website at www.enterabio.com.</span></span></div>

<div style="line-height:1.25">&#160;</div>

<div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Our
Scientific Advisory Committee consists of Roger Garceau, who also serves as chairman of the committee, along with Yonatan Malca and Miranda
Toledano.</span></span></div>

<div style="line-height:1.25">&#160;</div>

<div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Section
16(a) Beneficial Ownership Reporting Compliance</span></span></div>

<div style="line-height:1.25">&#160;</div>

<div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Section
16(a) of the Exchange Act and the rules thereunder require our directors and executive officers and persons who beneficially own more
than 10% of a registered class of our equity securities, to file reports with the SEC relating to their share ownership and changes in
such ownership.</span></span></div>

<div style="line-height:1.25">&#160;</div>

<div style="clear:both;margin-top:10pt;margin-bottom:10pt">

<div style="text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:normal;font-style:normal">128</span></span></span></div>

<div style="page-break-after:always"><hr style="border-width:0px;clear:both;margin:4px 0px;width:100%;height:2px;color:#000000;background-color:#000000" /></div></div>

<div style="text-align:justify;line-height:1.25;font-style:italic;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Delinquent
Section 16(a) Reports</span></span></div>

<div style="line-height:1.25">&#160;</div>

<div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Based
solely upon our review of copies of filings or written representations from the reporting persons, we believe that certain reports for
our executive officers and directors that were required to be filed under Section 16(a) of the Exchange Act during the year ended December
31, 2022 were not filed on a timely basis. Specifically, (i) Messrs. Garceau, Mayron, Lieberman, Ostrov, Galitzer, Santora II, Malca,
Ellis, Jamas, Schwartz and Ratan as well as Mses. Toledano and Yaacov-Garbeli each filed a late Form 3 and (ii) Messrs. Garceau, Mayron,
Lieberman, Ostrov, Malca and Ellis as well as Ms. Toledano each filed a late Form 4 disclosing two January 2022 option grants from the
Company in connection with their service as directors of the Company, in each case due to the delay in obtaining EDGAR codes in connection
with our transition from a foreign private issuer to a domestic reporting company. Other than with respect to the aforementioned forms,
we believe that all other reports for our executive officers and directors and persons who beneficially own more than 10% of our common
stock that were required to be filed under Section 16(a) of the Exchange Act during the year ended December 31, 2022 were filed on a timely
basis.</span></span></div>

<div style="line-height:1.25">&#160;</div>

<div style="line-height:1.25"><span id="ITEM11_integixAnchor"></span><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">I</span></span></span><span style="color:#000000;font-family:Times New Roman, Times, serif;font-size:13.3333px;font-style:normal;font-variant-ligatures:normal;text-align:left;white-space:normal;background-color:#ffffff;text-decoration-thickness:initial;text-decoration-style:initial;text-decoration-color:initial;font-weight:bold">TEM
11.</span>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<span style="color:#000000;font-family:Times New Roman, Times, serif;font-size:13.3333px;font-style:normal;font-variant-ligatures:normal;text-align:left;white-space:normal;background-color:#ffffff;text-decoration-thickness:initial;text-decoration-style:initial;text-decoration-color:initial;font-weight:bold">EXECUTIVE
COMPENSATION</span></div>

<div style="line-height:1.25">&#160;</div>

<div style="text-align:justify;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Compensation
Policy</span></span></div>

<div style="line-height:1.25">&#160;</div>

<div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Our
compensation policy was adopted by our shareholders on October 4, 2021, after having been recommended by our Compensation Committee and
approved by our Board, and will therefore, under the Companies Law, need to be either re-approved, amended, or replaced by a new policy
no later than 2024, and every three years thereafter. The compensation policy includes, among other matters prescribed by the Companies
Law, a framework for establishing the terms of office and employment of the directors and officers and guidelines with respect to the
structure of the variable pay of officers.</span></span></div>

<div style="line-height:1.25">&#160;</div>

<div style="text-align:justify;line-height:1.25;font-style:italic;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Objectives</span></span></div>

<div style="line-height:1.25">&#160;</div>

<div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Our
compensation policy is intended to align our objectives and work plans with appropriate goals and objectives of our officers and directors,
and to ensure that the overall financial and strategic objectives of the Company and its shareholders are met. We recognize that strong
and effective leadership is fundamental to our continued growth and success. Therefore, our compensation policy recognizes as a primary
objective the need to attract, retain, reward and motivate highly talented officers and directors in competitive labor markets.</span></span></div>

<div style="line-height:1.25">&#160;</div>

<div style="text-align:justify;line-height:1.25;font-style:italic;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Officer
compensation</span></span></div>

<div style="line-height:1.25">&#160;</div>

<div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">With
regard to our executive officers, or &#8220;Officers,&#8221; (which includes our Named Executive Officers, as defined below) our compensation
policy is designed to provide a mix of compensation to pay Officers for individual and company performance as well as align their interests
with the interests of shareholders. The compensation policy is also designed to provide flexibility in design. It must also take into
consideration the fact that the appropriate mix of compensation may vary from period to period and from Officer to Officer. To achieve
this philosophy, our compensation policy generally includes: (i) short-term incentives such as an annual base salary, benefits and perquisites,
(ii) short to medium-term incentives such as annual bonus based on target and above-target performance, and (iii) medium to long-term
incentives such as equity-based compensation, termination and retirement benefits.</span></span></div>

<div style="line-height:1.25">&#160;</div>

<div style="text-align:justify;line-height:1.25;font-style:italic;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Base
salary</span></span></div>

<div style="line-height:1.25">&#160;</div>

<div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Base
salary for Officers is a fixed compensation element which provides compensation to an Officer for performance of his or her standard duties
and responsibilities that reflects the Officer&#8217;s education, skills, qualifications, expertise, professional experience and accomplishments,
as well as the position, areas and scope of responsibilities of such Officer and his or her prior compensation agreements. Adjustments
to base salary are periodically reviewed by the Compensation Committee and the Board.</span></span></div>

<div style="line-height:1.25">&#160;</div>

<div style="clear:both;margin-top:10pt;margin-bottom:10pt">

<div style="text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:normal;font-style:normal">129</span></span></span></div>

<div style="page-break-after:always"><hr style="border-width:0px;clear:both;margin:4px 0px;width:100%;height:2px;color:#000000;background-color:#000000" /></div></div>

<div style="text-align:justify;line-height:1.25;font-style:italic;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Bonuses</span></span></div>

<div style="line-height:1.25">&#160;</div>

<div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Monetary
bonuses are generally paid annually, and are designed to reward Officers based on the performance of the Company and their individual
results. The target bonus amount and the performance measures and targets for each Officer are provided and calculated in an annual bonus
plan, to the extent it is determined and approved by the Company's Compensation Committee and Board, at the beginning of each calendar
year for which the bonus is paid. However, the CEO has the power to determine the annual bonus's performance measures and targets for
any of the other Officers.</span></span></div>

<div style="line-height:1.25">&#160;</div>

<div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The
performance measures and targets for receiving the annual bonus are intended to be measurable and quantifiable and may include (but are
not limited to) (i) objectives such as capital investment, cash balance relative to equity, obtaining approval from the authorities in
the target markets; and (ii) key performance indicators, determined for each Officer separately, according to the Officer's position.
The annual bonus also includes a non-measurable component of up to 20% of the Officer&#8217;s annual bonus, which is based on the evaluation
of each Officer's, according to qualitative measures provided in the annual bonus plan.</span></span></div>

<div style="line-height:1.25">&#160;</div>

<div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">In
addition to the annual bonus, the Compensation Committee and the Board may elect to pay each Officer a special bonus, based on non-measurable
criteria, in recognition of a significant achievement or for completion of an assignment, such as completion of a major transaction or
achieving a major milestone with material effect over the Company's business. Our compensation policy provides for a maximum cap for bonus
payments made to our Officers. The maximum bonus cap for each of our Officers is six times the monthly base salary and with respect to
the CEO, up to three times the monthly base salary, determined by non-measurable criteria.</span></span></div>

<div style="line-height:1.25">&#160;</div>

<div style="text-align:justify;line-height:1.25;font-style:italic;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Equity-based
compensation</span></span></div>

<div style="line-height:1.25">&#160;</div>

<div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Our
compensation policy also includes an equity incentive component designed, inter alia, to retain Officers, align Officers and shareholders&#8217;
interests and incentivize Officers to attain high level of business achievements without taking unreasonable risk, under which the Company
may grant Officers options to purchase shares, share appreciation rights, restricted shares, restricted share units, performance awards
or other share-based awards (collectively referred to as &#8220;equity awards&#8221;). The equity awards are determined individually and
awarded from time to time, inter alia, according to each Officer&#8217;s (a) contribution to the Company's performance; (b) ability to
influence the Company's future and performance; (c) the desired mix of compensation components and the mix of equity awards; (d) the Officer's
skills, qualifications, experience, roles and personal responsibilities; and (e) the desired competitive levels and dilution or pool limits.</span></span></div>

<div style="line-height:1.25">&#160;</div>

<div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The
compensation policy caps the annual value of the equity awards to be granted to each Officer, measured at the applicable grant date, at
18 times the monthly base salary of each Officer. The equity awards vesting period shall not be less than one year. Options shall expire
up to 10 years from the grant date. For option grants and share appreciation rights, the exercise price shall be no less than the fair
market value of the underlying ordinary shares on the date of grant, and subject to applicable law.</span></span></div>

<div style="line-height:1.25">&#160;</div>

<div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The
compensation policy provides that Officers and directors (to the extent granted equity awards) may be prohibited from hedging their equity
awards and any other Company securities held by them. The no-hedging policy applies to each director and each Officer until one year following
their termination of employment. The compensation policy further provides that Officers and directors are subject to certain restrictions
on pledging or using their equity awards and any other Company securities held by them (whether they are subject to transfer restrictions
or not) as collateral for loans, as the Company's Compensation Committee and Board shall determine.</span></span></div>

<div style="line-height:1.25">&#160;</div>

<div style="text-align:justify;line-height:1.25;font-style:italic;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Benefits
and perquisites</span></span></div>

<div style="line-height:1.25">&#160;</div>

<div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Under
the compensation policy, our Officers are further entitled to certain fringe benefits that we believe are commonly provided to similarly-situated
executives in the market in which we compete for talent and therefore are important to our ability to attract and retain top-level executive
management. This includes vacation days, paid sick leave, as well as additional benefits such as, but not limited to, health insurance,
a company car and cell phone, company-provided health insurance and meals.</span></span></div>

<div style="line-height:1.25">&#160;</div>

<div style="clear:both;margin-top:10pt;margin-bottom:10pt">

<div style="text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:normal;font-style:normal">130</span></span></span></div>

<div style="page-break-after:always"><hr style="border-width:0px;clear:both;margin:4px 0px;width:100%;height:2px;color:#000000;background-color:#000000" /></div></div>

<div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">For
Officers residing in Israel, these benefits may also include contributions to a pension fund, provident fund or insurance policy in accordance
with Israeli law, contributions to an education fund of 7.5% of the Officer&#8217;s monthly salary and recuperation pay as required under
applicable law. An &#8216;education fund&#8217; is a medium-term savings scheme that takes advantage of a unique tax break granted under
Israeli law, whereby a company&#8217;s contributions to such fund (which, despite its misleading name, may be used by the employee for
any purpose), as well as all capital gains accrued on such contributions, are free of tax if (a) the company contributes an amount equal
to 7.5% of the employee&#8217;s salary to such fund, up to a certain limit, and the employee further contributes 2.5% of his salary at
his expense, and (b) the fund remains undrawn for a period of at least six years from the time of the first contribution. While some of
these contributions and benefits are not mandatory under Israeli law, the nature and amount of the benefits provided to our Israeli Officers
are customary and prevalent in the Israeli high-tech and bio-pharma market, especially among executives. Non-Israeli Officers may receive
similar, comparable or customary benefits as applicable in the jurisdiction in which they are employed.</span></span></div>

<div style="line-height:1.25">&#160;</div>

<div style="text-align:justify;line-height:1.25;font-style:italic;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Termination</span></span></div>

<div style="line-height:1.25">&#160;</div>

<div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Our
Officers are further entitled to certain termination payments and benefits. Officers are entitled to an advance notice period, severance
payments and retirement and termination awards. The retirement and termination awards are subject to the Compensation Committee and the
Board's approval, and may be provided only if: (a) certain change of control related cases; (b) the Officer has made a special contribution
to the advancement of the Company&#8217;s business during his employment period as shall be determined by the Compensation Committee;
and (d) in respect of Officers other than the CEO, the CEO has recommended granting a retirement bonus.</span></span></div>

<div style="line-height:1.25">&#160;</div>

<div style="text-align:justify;line-height:1.25;font-style:italic;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Director
compensation</span></span></div>

<div style="line-height:1.25">&#160;</div>

<div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The
compensation policy provides that non-employee and non-executive directors&#8217; compensation packages shall be determined pursuant to
the provisions of the Companies Law in accordance with the Company's objective to attract and retain talented directors with excellent
educational background, qualifications, skills, expertise, professional experience and achievements, by providing a fair and competitive
compensation program. Such non-employee and non-executive directors&#8217; may be eligible to receive an annual Board membership fee,
annual Committee membership fee and equity based compensation. Notwithstanding, non-employee and non-executive directors shall also be
entitled to insurance, indemnification and release arrangements. The chair of the Board and the chair of the Board committees may also
receive additional annual cash payments for their extra service in such capacities, subject to the provisions of applicable law.</span></span></div>

<div style="line-height:1.25">&#160;</div>

<div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">In
May 2021, we elected to be governed by an exemption under the Companies Law regulations that exempts us from appointing external directors
and from complying with the Companies Law requirements related to the composition of the Audit Committee and Compensation Committee of
our Board. Our eligibility for that exemption is conditioned upon: (i) the continued listing of our Ordinary Shares on the Nasdaq Capital
Market (or one of a few select other non-Israeli stock exchanges); (ii) there not being a controlling shareholder of our company under
the Companies Law; and (iii) our compliance with the Nasdaq Listing Rules requirements as to the composition of (a) our Board of Directors-which
requires that we maintain a majority of independent directors (as defined under the Nasdaq Listing Rules) on our Board of Directors (subject
to applicable cure periods under the Nasdaq Listing Rules) and (b) the Audit and Compensation Committees of our Board of Directors, which
rules require that such committees consist solely of independent directors (at least three and two members, respectively). At the time
that it was determined to exempt our Company from the external director requirement, our Board affirmatively determined that we met the
conditions for exemption from the external director requirement. As of the date hereof, we continue to meet the conditions for exemption
from the external director requirement.</span></span></div>

<div style="line-height:1.25">&#160;</div>

<div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">As
a result of our election to be exempt from the external director requirement under the Companies Law, none of our directors are categorized
as external directors and as such the applicable requirements and restrictions relating to external directors (including certain compensation
related provisions) is no longer applicable.</span></span></div>

<div style="line-height:1.25">&#160;</div>

<div style="text-align:justify;line-height:1.25;font-style:italic;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Claw-back</span></span></div>

<div style="line-height:1.25">&#160;</div>

<div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The
compensation packages to Officers and directors are also subject to claw-back provisions, allowing for the Company&#8217;s recovery of
any payment made to an Officer or director if the payment was based on incorrect financial statements that subsequently required restatement.
The Officer or director will be required to repay to the Company the difference between the original payment and any payment due to the
officer or director based on the restatement.</span></span></div>

<div style="line-height:1.25">&#160;</div>

<div style="clear:both;margin-top:10pt;margin-bottom:10pt">

<div style="text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:normal;font-style:normal">131</span></span></span></div>

<div style="page-break-after:always"><hr style="border-width:0px;clear:both;margin:4px 0px;width:100%;height:2px;color:#000000;background-color:#000000" /></div></div>

<div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Our
Compensation Committee periodically reviews the compensation policy, monitors its implementation and recommends to our Board and shareholders
amendments to the compensation policy as it deems necessary from time to time. The term of the compensation policy is for a period of
three years following the date of its adoption, during which, the Board is required to examine the compensation policy and revise it from
time to time if the circumstances under which it had been adopted have materially changed. Following such three-year term, the compensation
policy, including any revisions recommended by our Compensation Committee and approved by our Board, as applicable, will be brought once
again to the shareholders for approval.</span></span></div>

<div style="line-height:1.25">&#160;</div>

<div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Summary
Compensation Table</span></span></div>

<div style="line-height:1.25">&#160;</div>

<div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The
table and summary below outline the compensation granted to our named executive officers (&#8220;Named Executive Officers&#8221;) during
our fiscal years ended December 31, 2022 and December 31, 2021. As a &#8220;smaller reporting company,&#8221; we are required to provide
executive compensation information for the following individuals: (i) all individuals who served as the Company&#8217;s principal executive
officer (&#8220;PEO&#8221;), during the last completed fiscal year, regardless of compensation; (ii) the two most highly compensated executive
officers (other than the PEO) who were serving as executive officers of the Company at the end of the last completed fiscal year and whose
total compensation was greater than $100,000; and (iii) up to two additional persons who served as executive officers (other than as the
PEO) during the last completed fiscal year but who were not serving in that capacity at the end of the fiscal year if their total compensation
is higher than any of the other two Named Executive Officers in the preceding group.</span></span></div>

<div style="line-height:1.25">&#160;</div>

<table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left;color:#000000;width:100%">
  <tr>
    <td style="vertical-align:bottom;width:30%;border-bottom:2px solid rgb(0, 0, 0)" valign="bottom">
        <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Name
        and Principal Position</span></span></div></td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:9%;border-bottom:2px solid rgb(0, 0, 0)" valign="bottom">
        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Year</span></span></div></td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;width:1%" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0)" valign="bottom">
        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Salary
        ($)</span></span></div></td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;width:1%" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0)" valign="bottom">
        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Bonus
        ($)</span></span></div></td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;width:1%" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0)" valign="bottom">
        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Option</span></span></div>
        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Award(s)</span></span></div>
        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">($)(1)</span></span></div></td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;width:1%" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0)" valign="bottom">
        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">All
        Other</span></span></div>
        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Compensation</span></span></div>
        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">($)</span></span></div></td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;width:1%" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0)" valign="bottom">
        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Total
        ($)</span></span></div></td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;width:1%;white-space:nowrap" valign="bottom">&#160;</td></tr>
  <tr>
    <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:30%" valign="bottom">
        <div style="margin-right:2.25pt;margin-left:2.25pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Miranda
        Toledano (2)</span></span></div></td>
    <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
    <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:9%" valign="bottom">
        <div style="text-align:center;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2022</span></span></div></td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="background-color:#CCEEFF;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="background-color:#CCEEFF;vertical-align:bottom;text-align:right;width:9%" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">231</span></span></div></td>
    <td colspan="1" style="background-color:#CCEEFF;vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="background-color:#CCEEFF;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="background-color:#CCEEFF;vertical-align:bottom;text-align:right;width:9%" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></div></td>
    <td colspan="1" style="background-color:#CCEEFF;vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="background-color:#CCEEFF;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="background-color:#CCEEFF;vertical-align:bottom;text-align:right;width:9%" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">382</span></span></div></td>
    <td colspan="1" style="background-color:#CCEEFF;vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="background-color:#CCEEFF;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="background-color:#CCEEFF;vertical-align:bottom;text-align:right;width:9%" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">66</span></span></div></td>
    <td colspan="1" style="background-color:#CCEEFF;vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="background-color:#CCEEFF;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="background-color:#CCEEFF;vertical-align:bottom;text-align:right;width:9%" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">679</span></span></div></td>
    <td colspan="1" style="background-color:#CCEEFF;vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td></tr>
  <tr>
    <td style="vertical-align:bottom;width:30%" valign="bottom">
        <div style="margin-right:2.25pt;margin-left:9pt;line-height:1.25;font-style:italic"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Chief
        Executive Officer and director</span></span></div></td>
    <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
    <td style="vertical-align:bottom;width:9%" valign="bottom">
        <div style="text-align:center;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2021</span></span></div></td>
    <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">17</span></span></div></td>
    <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">65</span></span></div></td>
    <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">82</span></span></div></td>
    <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td></tr>
  <tr>
    <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:30%" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Spiros Jamas (3)</span></span></div></td>
    <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
    <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:9%" valign="bottom">
        <div style="text-align:center;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2022</span></span></div></td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="background-color:#CCEEFF;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="background-color:#CCEEFF;vertical-align:bottom;text-align:right;width:9%" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">255</span></span></div></td>
    <td colspan="1" style="background-color:#CCEEFF;vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="background-color:#CCEEFF;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="background-color:#CCEEFF;vertical-align:bottom;text-align:right;width:9%" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">95</span></span></div></td>
    <td colspan="1" style="background-color:#CCEEFF;vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="background-color:#CCEEFF;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="background-color:#CCEEFF;vertical-align:bottom;text-align:right;width:9%" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(256</span></span></div></td>
    <td colspan="1" style="background-color:#CCEEFF;vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div></td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="background-color:#CCEEFF;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="background-color:#CCEEFF;vertical-align:bottom;text-align:right;width:9%" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">428</span></span></div></td>
    <td colspan="1" style="background-color:#CCEEFF;vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="background-color:#CCEEFF;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="background-color:#CCEEFF;vertical-align:bottom;text-align:right;width:9%" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">522</span></span></div></td>
    <td colspan="1" style="background-color:#CCEEFF;vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td></tr>
  <tr>
    <td style="vertical-align:bottom;width:30%" valign="bottom">
        <div style="margin-right:2pt;margin-left:9pt;line-height:1.25;font-style:italic;margin-top:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Former
        Chief Executive Officer</span></span></div></td>
    <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
    <td style="vertical-align:bottom;width:9%" valign="bottom">
        <div style="text-align:center;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2021</span></span></div></td>
    <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">392</span></span></div></td>
    <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></div></td>
    <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">751</span></span></div></td>
    <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></div></td>
    <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">1,143</span></span></div></td>
    <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td></tr>
  <tr>
    <td style="vertical-align:bottom;width:30%;background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="margin-right:2.25pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Dr.
        Phillip Schwartz (4)</span></span></div></td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td style="vertical-align:bottom;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="text-align:center;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2022</span></span></div></td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">188</span></span></div></td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">27</span></span></div></td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">196</span></span></div></td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">371</span></span></div></td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">782</span></span></div></td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td></tr>
  <tr>
    <td style="vertical-align:bottom;width:30%" valign="bottom">
        <div style="margin-right:2.25pt;margin-left:6.75pt;line-height:1.25;font-style:italic"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Former
        President of R&#38;D</span></span></div></td>
    <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
    <td style="vertical-align:bottom;width:9%" valign="bottom">
        <div style="text-align:center;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2021</span></span></div></td>
    <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">453</span></span></div></td>
    <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></div></td>
    <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">183</span></span></div></td>
    <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">49</span></span></div></td>
    <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">685</span></span></div></td>
    <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td></tr>
  <tr>
    <td style="vertical-align:bottom;width:30%;background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="margin-right:2.25pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Dr.
        Hillel Galitzer</span></span></div></td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td style="vertical-align:bottom;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="text-align:center;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2022</span></span></div></td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">287</span></span></div></td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">63</span></span></div></td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">234</span></span></div></td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">37</span></span></div></td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">621</span></span></div></td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td></tr>
  <tr>
    <td style="vertical-align:bottom;width:30%" valign="bottom">
        <div style="margin-right:2.25pt;margin-left:6.75pt;line-height:1.25;font-style:italic"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Chief
        Operating Officer</span></span></div></td>
    <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
    <td style="vertical-align:bottom;width:9%" valign="bottom">
        <div style="text-align:center;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2021</span></span></div></td>
    <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">319</span></span></div></td>
    <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">260</span></span></div></td>
    <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">61</span></span></div></td>
    <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">640</span></span></div></td>
    <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td></tr>
  </table>

<div style="text-align:justify;line-height:1.25">&#160;</div>

<table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">
  <tr>
    <td style="width:2.5%;vertical-align:top">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(1)</span></span></div></td>
    <td style="width:97.5%;vertical-align:top">
        <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Reflects
        the associated annual expense recorded in our financial statements for the year ended December 31, 2022, based on the grant date fair
        value of the share-based compensation granted in exchange for the directors&#8217; and officers&#8217; services computed in accordance
        with Financial Accounting Standards Board (&#8220;FASB&#8221;) Accounting Standards Codification (&#8220;ASC&#8221;) Topic 718, <span style="font-style:italic">Compensation
        - Stock Compensation</span> (&#8220;ASC Topic 718&#8221;). The assumptions used in calculating the amounts are discussed in the notes
        of the Company&#8217;s audited financial statements for the year ended December 31, 2022 included in this Annual Report. The fair value
        amount is recognized as an expense over the course of the vesting period of the options (subject to any applicable accounting adjustments
        during that period).</span></span></div></td></tr>
  </table>

<div style="line-height:1.25">&#160;</div>

<table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">
  <tr>
    <td style="width:2.5%;vertical-align:top">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(2)</span></span></div></td>
    <td style="width:97.5%;vertical-align:top">
        <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Ms.
        Toledano was appointed as our Chief Business Officer, Chief Financial Officer and Head of Corporate Strategy in May 2022. Ms. Toledano
        was then appointed as our Chief Executive Officer in July 2022. The compensation for fiscal year 2021 and until May 2022 represents her
        compensation as a non-employee board member.</span></span></div></td></tr>
  </table>

<div style="line-height:1.25">&#160;</div>

<table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">
  <tr>
    <td style="width:2.5%;vertical-align:top">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(3)</span></span></div></td>
    <td style="width:97.5%;vertical-align:top">
        <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Mr.
        Jamas served as our Chief Executive Officer from January 4, 2021 until July 13, 2022. Pursuant to the mutual separation agreement entered
        into between us and Mr. Jamas, he was entitled to a one-time lump sum payment of his annual base salary for a period of 13 months which
        is included in the table above.</span></span></div></td></tr>
  </table>

<div style="line-height:1.25">&#160;</div>

<table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">
  <tr>
    <td style="width:2.5%;vertical-align:top">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(4)</span></span></div></td>
    <td style="width:97.5%;vertical-align:top">
        <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Dr.
        Schwartz served as the President of R&#38;D during fiscal years 2021 and 2022 through his resignation on July 21, 2022. On June 15, 2022,
        Dr. Schwartz resigned from his position with the Company, effective July 21, 2022. The compensation for fiscal year 2022 represents his
        compensation received for services rendered through his resignation date.</span></span></div></td></tr>
  </table>

<div style="line-height:1.25">&#160;</div>

<div style="clear:both;margin-top:10pt;margin-bottom:10pt">

<div style="text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:normal;font-style:normal">132</span></span></span></div>

<div style="page-break-after:always"><hr style="border-width:0px;clear:both;margin:4px 0px;width:100%;height:2px;color:#000000;background-color:#000000" /></div></div>

<div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Outstanding
Equity Awards at Fiscal Year End</span></span></div>

<div style="line-height:1.25">&#160;</div>

<div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The
following table sets forth the outstanding equity awards at December 31, 2022 for our Named Executive Officers.</span></span></div>

<div style="text-align:justify;line-height:1.25">&#160;</div>

<table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left;color:#000000;width:100%">
  <tr>
    <td style="vertical-align:bottom;padding-bottom:2px;width:64%" valign="bottom">
        <div style="line-height:1.25">&#160;</div></td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;width:1%" valign="bottom">&#160;</td>
    <td colspan="6" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0)" valign="bottom">
        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Number
        of Securities<br />Underlying<br />Unexercised Options</span></span></div></td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;width:2%" valign="bottom">&#160;</td>
    <td style="vertical-align:bottom;padding-bottom:2px;width:10%;text-align:center" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">Option</span></span></span></td></tr>
  <tr>
    <td style="vertical-align:bottom;width:64%;border-bottom:2px solid rgb(0, 0, 0)" valign="bottom">
        <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Name</span></span></div></td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;width:1%" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0)" valign="bottom">
        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Exercisable</span></span></div></td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;width:1%" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0)" valign="bottom">
        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Unexercisable</span></span></div></td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;width:2%" valign="bottom">&#160;</td>
    <td style="vertical-align:bottom;width:10%;border-bottom:2px solid rgb(0, 0, 0)" valign="bottom">
        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Expiration
        Date</span></span></div></td></tr>
  <tr>
    <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:64%" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Miranda Toledano</span></span></div></td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:9%" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">33,638</span></span></div></td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:top;background-color:rgb(204, 238, 255);width:2%" valign="bottom">&#160;</td>
    <td style="vertical-align:top;background-color:rgb(204, 238, 255);width:10%" valign="bottom">
        <div style="text-align:center;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">17/1/2029</span></span></div></td></tr>
  <tr>
    <td style="vertical-align:bottom;width:64%" valign="bottom">
        <div style="margin-left:9pt;line-height:1.25;font-style:italic"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Chief
        Executive Officer and director</span></span></div></td>
    <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">35,852</span></span></div></td>
    <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align:bottom" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:top;width:2%" valign="bottom">&#160;</td>
    <td style="vertical-align:top;width:10%" valign="bottom">
        <div style="text-align:center;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">1/1/2031</span></span></div></td></tr>
  <tr>
    <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:64%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="background-color:#CCEEFF;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="background-color:#CCEEFF;vertical-align:bottom;text-align:right;width:9%" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">35,852</span></span></div></td>
    <td colspan="1" style="background-color:#CCEEFF;vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="background-color:#CCEEFF;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="background-color:#CCEEFF;vertical-align:bottom;text-align:right;width:9%" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">71,705</span></span></div></td>
    <td colspan="1" style="background-color:#CCEEFF;vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(1)</span></span></div></td>
    <td colspan="1" style="vertical-align:top;background-color:rgb(204, 238, 255);width:2%" valign="bottom">&#160;</td>
    <td style="vertical-align:top;background-color:rgb(204, 238, 255);width:10%" valign="bottom">
        <div style="text-align:center;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">1/1/2031</span></span></div></td></tr>
  <tr>
    <td style="vertical-align:bottom;width:64%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">500,000</span></span></div></td>
    <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(2)</span></span></div></td>
    <td colspan="1" style="vertical-align:top;width:2%" valign="bottom">&#160;</td>
    <td style="vertical-align:top;width:10%" valign="bottom">
        <div style="text-align:center;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">16/05/2032</span></span></div></td></tr>
  <tr>
    <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:64%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="background-color:#CCEEFF;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="background-color:#CCEEFF;vertical-align:bottom;text-align:right;width:9%" valign="bottom">&#160;</td>
    <td colspan="1" style="background-color:#CCEEFF;vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="background-color:#CCEEFF;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="background-color:#CCEEFF;vertical-align:bottom;text-align:right;width:9%" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">600,000</span></span></div></td>
    <td colspan="1" style="background-color:#CCEEFF;vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(3)</span></span></div></td>
    <td colspan="1" style="vertical-align:top;background-color:rgb(204, 238, 255);width:2%" valign="bottom">&#160;</td>
    <td style="vertical-align:top;background-color:rgb(204, 238, 255);width:10%" valign="bottom">
        <div style="text-align:center;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">15/07/2032</span></span></div></td></tr>
  <tr>
    <td style="vertical-align:bottom;width:64%" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Dr. Spiros Jamas</span></span></div>
        <div style="margin-right:2.25pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Former<span style="font-style:italic">
        Chief Executive Officer</span></span></span></div></td>
    <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">492,832</span></span></div></td>
    <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></div></td>
    <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:2%" valign="bottom">&#160;</td>
    <td style="vertical-align:bottom;width:10%" valign="bottom">
        <div style="text-align:center;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">14/7/2023</span></span></div></td></tr>
  <tr>
    <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:64%" valign="bottom">
        <div style="margin-right:2.25pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Dr.
        Phillip Schwartz</span></span></div></td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="background-color:#CCEEFF;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="background-color:#CCEEFF;vertical-align:bottom;text-align:right;width:9%" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">357,500</span></span></div></td>
    <td colspan="1" style="background-color:#CCEEFF;vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="background-color:#CCEEFF;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="background-color:#CCEEFF;vertical-align:bottom;text-align:right;width:9%" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></div></td>
    <td colspan="1" style="background-color:#CCEEFF;vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:2%" valign="bottom">&#160;</td>
    <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:10%" valign="bottom">
        <div style="text-align:center;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">23/11/2027</span></span></div></td></tr>
  <tr>
    <td style="vertical-align:bottom;width:64%" valign="bottom">
        <div style="line-height:1.25;font-style:italic"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Former
        President of R&#38;D</span></span></div></td>
    <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">100,000</span></span></div></td>
    <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></div></td>
    <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:2%" valign="bottom">&#160;</td>
    <td style="vertical-align:bottom;width:10%" valign="bottom">
        <div style="text-align:center;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">21/4/2031</span></span></div></td></tr>
  <tr>
    <td style="vertical-align:top;background-color:rgb(204, 238, 255);width:64%" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Dr. Hillel Galitzer</span></span></div></td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="background-color:#CCEEFF;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="background-color:#CCEEFF;vertical-align:bottom;text-align:right;width:9%" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">143,000</span></span></div></td>
    <td colspan="1" style="background-color:#CCEEFF;vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="background-color:#CCEEFF;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="background-color:#CCEEFF;vertical-align:bottom;text-align:right;width:9%" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></div></td>
    <td colspan="1" style="background-color:#CCEEFF;vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:top;background-color:rgb(204, 238, 255);width:2%" valign="bottom">&#160;</td>
    <td style="vertical-align:top;background-color:rgb(204, 238, 255);width:10%" valign="bottom">
        <div style="text-align:center;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">15/11/2023</span></span></div></td></tr>
  <tr>
    <td style="vertical-align:top;width:64%" valign="bottom">
        <div style="line-height:1.25;font-style:italic"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Chief
        Operating Officer</span></span></div></td>
    <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">120,312</span></span></div></td>
    <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">54,688</span></span></div></td>
    <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(4)</span></span></div></td>
    <td colspan="1" style="vertical-align:top;width:2%" valign="bottom">&#160;</td>
    <td style="vertical-align:top;width:10%" valign="bottom">
        <div style="text-align:center;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">16/3/2030</span></span></div></td></tr>
  <tr>
    <td style="vertical-align:top;background-color:rgb(204, 238, 255);width:64%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="background-color:#CCEEFF;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="background-color:#CCEEFF;vertical-align:bottom;text-align:right;width:9%" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">46,875</span></span></div></td>
    <td colspan="1" style="background-color:#CCEEFF;vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="background-color:#CCEEFF;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="background-color:#CCEEFF;vertical-align:bottom;text-align:right;width:9%" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">78,125</span></span></div></td>
    <td colspan="1" style="background-color:#CCEEFF;vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(5)</span></span></div></td>
    <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:2%" valign="bottom">&#160;</td>
    <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:10%" valign="bottom">
        <div style="text-align:center;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">21/4/2031</span></span></div></td></tr>
  <tr>
    <td style="vertical-align:top;width:64%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">60,000</span></span></div></td>
    <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(6)</span></span></div></td>
    <td colspan="1" style="vertical-align:bottom;width:2%" valign="bottom">&#160;</td>
    <td style="vertical-align:bottom;width:10%" valign="bottom">
        <div style="text-align:center;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">30/3/2032</span></span></div></td></tr>
  </table>

<div style="line-height:1.25">&#160;</div>

<table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">
  <tr>
    <td style="width:2.5%;vertical-align:top">
        <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(1)</span></span></div></td>
    <td style="width:97.5%;vertical-align:top">
        <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The
        71,705 unexercisable options as of December 31, 2022 will vest in eight equal quarterly installments beginning on March 31, 2023.</span></span></div>
        <div style="text-align:justify;line-height:1.25">&#160;</div></td></tr>
  <tr>
    <td style="width:2.5%;vertical-align:top">
        <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(2)</span></span></div></td>
    <td style="width:97.5%;vertical-align:top">
        <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Of
        the 500,000 unexercisable options as of December 31, 2022, 25% vest on May 16, 2023, the first anniversary of the grant date and the remaining
        75% begin vesting in 12 equal quarterly installments over the following three years.<br />&#160;</span></span></div></td></tr>
  <tr>
    <td style="width:2.5%;vertical-align:top">
        <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(3)</span></span></div></td>
    <td style="width:97.5%;vertical-align:top">
        <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Of
        the 600,000 unexercisable options as of December 31, 2022, 25% vest on July 15, 2023, the first anniversary of the grant date and the
        remaining 75% begin vesting in 12 equal quarterly installments over the following three years.</span></span></div>
        <div style="text-align:justify;line-height:1.25">&#160;</div></td></tr>
  <tr>
    <td style="width:2.5%;vertical-align:top">
        <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(4)</span></span></div></td>
    <td style="width:97.5%;vertical-align:top">
        <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The
        54,688 unexercisable options as of December 31, 2022 will vest in five equal quarterly installments beginning on March 16, 2023.</span></span></div>
        <div style="text-align:justify;line-height:1.25">&#160;</div></td></tr>
  </table>

<table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">
  <tr>
    <td style="width:2.5%;vertical-align:top">
        <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(5)</span></span></div></td>
    <td style="width:97.5%;vertical-align:top">
        <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The
        78,125 unexercisable options as of December 31, 2022 will vest in 10 equal quarterly installments from January 21, 2023.</span></span></div>
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="line-height:1.25">&#160;</span></span></span></div></td></tr>
  <tr>
    <td style="width:2.5%;vertical-align:top">
        <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(6)</span></span></div></td>
    <td style="width:97.5%;vertical-align:top">
        <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Of
        the 60,000 unexercisable options as of December 31, 2022, 25% vest on March 31, 2023, the first anniversary of the grant date and the
        remaining 75% will vest in 12 equal quarterly installments over the following three years.</span></span></div></td></tr>
  </table>

<div style="line-height:1.25">&#160;</div>

<div style="clear:both;margin-top:10pt;margin-bottom:10pt">

<div style="text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:normal;font-style:normal">133</span></span></span></div>

<div style="page-break-after:always"><hr style="border-width:0px;clear:both;margin:4px 0px;width:100%;height:2px;color:#000000;background-color:#000000" /></div></div>

<div style="line-height:1.25">&#160;</div>

<div style="text-align:justify;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Director
Compensation Table</span></span></div>

<div style="text-align:justify;line-height:1.25">&#160;</div>

<div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Under
the Companies Law, our directors can be paid for their services as directors to the extent such payments are in accordance with the compensation
policy adopted by the Company after approval by the Compensation Committee, our Board and our shareholders by ordinary majority, or, if
their compensation deviates from our compensation policy, after approval by the Compensation Committee, our Board and our shareholders
by a special majority, if necessary, provided that (i) the majority of the votes includes at least a majority of all the votes of shareholders
who are not controlling shareholders of the Company or who do not have a personal interest in the compensation paid to the directors and
participating in the vote or (ii) the total of opposing votes from among the shareholders described in subsection (i) above does not exceed
2% of all the voting rights in the Company.</span></span></div>

<div style="line-height:1.25">&#160;</div>

<div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The
table below outlines compensation earned by our non-employee directors for the fiscal year ended December 31, 2022, including fees earned
in cash and options awarded for services provided as a director. Ms. Toledano served as a non-employee director in 2022 until her appointment
as an officer in May 2022. Her compensation received in connection with her service as a director is included in her 2022 compensation
described above in &#8220;Summary Compensation Table&#8221;, above.</span></span></div>

<div style="text-align:justify;line-height:1.25">&#160;</div>

<table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left;color:#000000;width:100%">
  <tr>
    <td style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0)" valign="bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Name</span></span></div></td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0)" valign="bottom">
        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Fees</span></span></div>
        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Earned</span></span></div>
        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">or
        Paid</span></span></div>
        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">in
        Cash</span></span></div>
        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">($)</span></span></div></td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0)" valign="bottom">
        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Option</span></span></div>
        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Awards</span></span></div>
        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">($)(1)</span></span></div></td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0)" valign="bottom">
        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">All
        Other</span></span></div>
        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Compensation</span></span></div>
        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">($)</span></span></div></td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0)" valign="bottom">
        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Total</span></span></div>
        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">($)</span></span></div></td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td></tr>
  <tr>
    <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:52%" valign="bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Gerald
        Lieberman</span></span></div></td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="background-color:#CCEEFF;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="background-color:#CCEEFF;vertical-align:bottom;text-align:right;width:9%" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">61,000</span></span></div></td>
    <td colspan="1" style="background-color:#CCEEFF;vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="background-color:#CCEEFF;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="background-color:#CCEEFF;vertical-align:bottom;text-align:right;width:9%" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">196,000</span></span></div></td>
    <td colspan="1" style="background-color:#CCEEFF;vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="background-color:#CCEEFF;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="background-color:#CCEEFF;vertical-align:bottom;text-align:right;width:9%" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></div></td>
    <td colspan="1" style="background-color:#CCEEFF;vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="background-color:#CCEEFF;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="background-color:#CCEEFF;vertical-align:bottom;text-align:right;width:9%" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">257,000</span></span></div></td>
    <td colspan="1" style="background-color:#CCEEFF;vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td></tr>
  <tr>
    <td style="vertical-align:bottom;width:52%" valign="bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Dr.
        Roger J. Garceau</span></span></div></td>
    <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">41,000</span></span></div></td>
    <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">196,000</span></span></div></td>
    <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></div></td>
    <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">237,000</span></span></div></td>
    <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td></tr>
  <tr>
    <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:52%" valign="bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Yonatan
        Malca</span></span></div></td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="background-color:#CCEEFF;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="background-color:#CCEEFF;vertical-align:bottom;text-align:right;width:9%" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">56,000</span></span></div></td>
    <td colspan="1" style="background-color:#CCEEFF;vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="background-color:#CCEEFF;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="background-color:#CCEEFF;vertical-align:bottom;text-align:right;width:9%" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">196,000</span></span></div></td>
    <td colspan="1" style="background-color:#CCEEFF;vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="background-color:#CCEEFF;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="background-color:#CCEEFF;vertical-align:bottom;text-align:right;width:9%" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></div></td>
    <td colspan="1" style="background-color:#CCEEFF;vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="background-color:#CCEEFF;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="background-color:#CCEEFF;vertical-align:bottom;text-align:right;width:9%" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">252,000</span></span></div></td>
    <td colspan="1" style="background-color:#CCEEFF;vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td></tr>
  <tr>
    <td style="vertical-align:bottom;width:52%" valign="bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Ron
        Mayron</span></span></div></td>
    <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">50,000</span></span></div></td>
    <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">229,000</span></span></div></td>
    <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></div></td>
    <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">279,000</span></span></div></td>
    <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td></tr>
  <tr>
    <td style="vertical-align:bottom;width:52%;background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Gerald
        M. Ostrov</span></span></div></td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">56,000</span></span></div></td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">196,000</span></span></div></td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></div></td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">252,000</span></span></div></td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td></tr>
  <tr>
    <td style="vertical-align:bottom;width:52%" valign="bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Sean
        Ellis</span></span></div></td>
    <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">52,000</span></span></div></td>
    <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">196,000</span></span></div></td>
    <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></div></td>
    <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">248,000</span></span></div></td>
    <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td></tr>
  </table>

<div style="line-height:1.25">&#160;</div>

<table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">
  <tr>
    <td style="width:2.53%;vertical-align:top">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(1)</span></span></div></td>
    <td style="width:97.47%;vertical-align:top">
        <div style="text-align:justify;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Reflects
        the associated annual expense recorded in our financial statements for the year ended December 31, 2022, based on the grant date fair
        value of the share-based compensation granted in exchange for the directors&#8217; and officers&#8217; services computed in accordance
        with Financial Accounting Standards Board (&#8220;FASB&#8221;) Accounting Standards Codification (&#8220;ASC&#8221;) Topic 718, <span style="font-style:italic">Compensation
        - Stock Compensation</span> (&#8220;ASC Topic 718&#8221;). The assumptions used in calculating the amounts are discussed in the notes
        of the Company&#8217;s audited financial statements for the year ended December 31, 2022 included in this Annual Report. The fair value
        amount is recognized as an expense over the course of the vesting period of the options (subject to any applicable accounting adjustments
        during that period).</span></span></div></td></tr>
  </table>

<div style="line-height:1.25">&#160;</div>

<div style="text-align:justify;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The
table below sets forth the aggregate number of share options of each non-employee director outstanding as of December 31, 2022:</span></span></div>

<div style="line-height:1.25">&#160;</div>

<table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left;color:#000000;width:100%">
  <tr>
    <td style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0)" valign="bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Name</span></span></div></td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0)" valign="bottom">
        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Share
        Options</span></span></div></td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td></tr>
  <tr>
    <td style="vertical-align:top;background-color:rgb(204, 238, 255);width:88%" valign="bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Gerald
        Lieberman</span></span></div></td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:9%" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">324,337</span></span></div></td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td></tr>
  <tr>
    <td style="vertical-align:top;width:88%" valign="bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Dr.
        Roger J. Garceau</span></span></div></td>
    <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">449,739</span></span></div></td>
    <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td></tr>
  <tr>
    <td style="vertical-align:top;background-color:rgb(204, 238, 255);width:88%" valign="bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Yonatan
        Malca</span></span></div></td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="background-color:#CCEEFF;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="background-color:#CCEEFF;vertical-align:bottom;text-align:right;width:9%" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">177,047</span></span></div></td>
    <td colspan="1" style="background-color:#CCEEFF;vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td></tr>
  <tr>
    <td style="vertical-align:top;width:88%" valign="bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Ron
        Mayron</span></span></div></td>
    <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">177,047</span></span></div></td>
    <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td></tr>
  <tr>
    <td style="vertical-align:top;width:88%;background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Gerald
        M. Ostrov</span></span></div></td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">177,047</span></span></div></td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td></tr>
  <tr>
    <td style="vertical-align:top;width:88%" valign="bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Sean
        Ellis</span></span></div></td>
    <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">177,047</span></span></div></td>
    <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td></tr>
  </table>

<div style="line-height:1.25;font-weight:bold"><br /><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Employment
Agreements</span></span></div>

<div style="line-height:1.25">&#160;</div>

<div style="text-align:justify;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">We
have entered into employment agreements with our Named Executive Officers. A summary of the material terms of these agreements with each
of our Named Executive Officers is set forth below. The below descriptions of employment agreements and separation agreements, as applicable,
are only summaries and are qualified in their entirety by reference to the full text of the applicable agreement, which are filed as exhibits
to this Annual Report on Form 10-K.</span></span></div>

<div style="line-height:1.25">&#160;</div>

<div style="clear:both;margin-top:10pt;margin-bottom:10pt">

<div style="text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:normal;font-style:normal">134</span></span></span></div>

<div style="page-break-after:always"><hr style="border-width:0px;clear:both;margin:4px 0px;width:100%;height:2px;color:#000000;background-color:#000000" /></div></div>

<div style="text-align:justify;line-height:1.25;font-style:italic;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Miranda
J. Toledano</span></span></div>

<div style="line-height:1.25">&#160;</div>

<div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">In
connection with Ms. Toledano&#8217;s appointment as the Company&#8217;s Chief Business Officer, Chief Financial Officer and Head of Corporate
Strategy in May 2022, Ms. Toledano entered into an employment agreement (the &#8220;Original Employment Agreement&#8221;) with the Company,
providing for an annual employer cost of $350,000 inclusive of base salary, pension payments, severance and disability benefits as required
under Israeli law. Additionally, Ms. Toledano was entitled to a grant of options pursuant to the Company&#8217;s 2018 Equity Incentive
Plan to purchase 500,000 Ordinary Shares of the Company&#8217;s Ordinary Shares at an exercise price of $2.02 per share, the closing price
of the Ordinary Shares on the date the option was approved by the Board. The options vest over four years, with 25% of the options vesting
on May 16, 2023 and the remaining 75% vesting in quarterly increments over the remaining three-year period, subject to Ms. Toledano&#8217;s
continued employment. In addition, Ms. Toledano was eligible to receive an annual bonus in an amount equal to 50% of her annual base salary.
Under the Original Employment Agreement, Ms. Toledano also agreed to customary non-disclosure and non-competition covenants,</span></span></div>

<div style="line-height:1.25">&#160;</div>

<div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">In
connection with Ms. Toledano&#8217;s appointment as Chief Executive Officer, on July 15, 2022, Ms. Toledano and the Company entered into
an amended and restated employment agreement (the &#8220;A&#38;R Employment Agreement&#8221;), which amends and restates the Original
Employment Agreement. The material terms of the Original Employment Agreement remain unchanged, except that the A&#38;R Employment Agreement
provides for (i) Ms. Toledano&#8217;s service as Chief Executive Officer, (ii) an annual employer cost of $380,000 inclusive of base salary,
pension payments, severance and disability benefits as required under Israeli law, (iii) eligibility to receive an annual bonus in an
amount equal to 60% of Ms. Toledano&#8217;s annual base salary, (iv) a one-time separation payment in the total amount of 12 months of
salary and an extension of the exercise period with respect to vested options for a period of up to two-years post-termination, in each
case in the event of the termination of Ms. Toledano&#8217;s employment by the Company for any reason other than for Cause (as defined
in the A&#38;R Employment Agreement), (v) an additional grant of options (the &#8220;Options&#8221;) pursuant to the Company&#8217;s 2018
Equity Incentive Plan to purchase 600,000 Ordinary Shares at an exercise price of $1.40, which was the closing price of the Ordinary Shares
on the date the Board approved such option grant and (vi), upon the Company&#8217;s achievement of certain performance or financial milestones,
a grant of options (the &#8220;Additional Options&#8221;) to purchase an additional 200,000 Ordinary Shares pursuant to the Company&#8217;s
2018 Equity Incentive Plan at an exercise price equal to the closing price of the Ordinary Shares on the date the Board approves such
option grant. The Options will vest over four years, with 25% of the Options vesting on July 15, 2023 and the remaining 75% vesting in
quarterly increments over the remaining three-year period, subject to Ms. Toledano&#8217;s continued employment. The Additional Options
will vest over four years, with 25% of the Additional Options vesting on the first anniversary of the grant date and the remaining 75%
vesting in quarterly increments over the remaining three-year period, subject to Ms. Toledano&#8217;s continued employment.</span></span></div>

<div style="line-height:1.25">&#160;</div>

<div style="text-align:justify;line-height:1.25;font-style:italic;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Spiros
Jamas</span></span></div>

<div style="line-height:1.25">&#160;</div>

<div style="text-align:justify;line-height:1.25;font-style:italic"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Employment
Agreement</span></span></div>

<div style="line-height:1.25">&#160;</div>

<div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">We
entered into an employment agreement, effective as of January 2021, with Dr. Spiros Jamas, in connection with his appointment as our Chief
Executive Officer and in light of his previous membership in our Board. Pursuant to the agreement, Dr. Spiros Jamas was entitled to an
annual base salary of $380,000 and an annual bonus of up to 60% of his base salary (up to $228,000). Additionally, Dr. Jamas was eligible
to participate in the Company&#8217;s standard full-time employment benefits that are offered by the Company from time to time, which
currently include medical, short term disability and 401(k) benefits. Mr. Jamas was also generally entitled to reimbursement for travel
and other business expenses and other benefits, including, vacation, holidays and sick leave. Subject to applicable law, Dr. Jamas is
also covered by our D&#38;O insurance policy. Dr. Jamas was also granted options to purchase 1,314,218 Ordinary Shares under the 2018
Plan, effective as of January 2021, at an exercise price of $1.24. Salary and other benefits (including any bonus) shall immediately terminate
upon termination, provided, however, that in case Dr. Jamas&#8217;s employment would have been terminated by the Company without Cause
or if Dr. Jamas resigned for Good Reason ("Cause" and Good Reason" as defined in the proxy statement of the Company&#8217;s extraordinary
general meeting dated March 3, 2021) at any time, he would have been entitled to (i) a one-time lump sum severance payment equal to a
period of twelve (12) months of his then-effective annual base salary and (ii) an extension of the exercise period with respect to his
vested options to purchase ordinary shares as of the date of termination for up to two (2) years post-termination (provided that in no
event shall such extension extend beyond 10 years from the applicable grant date), all subject to his execution and non-revocation of
a customary release of claims against the Company, its subsidiary, Entera Bio, Inc., or any applicable affiliates.</span></span></div>

<div style="line-height:1.25">&#160;</div>

<div style="clear:both;margin-top:10pt;margin-bottom:10pt">

<div style="text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:normal;font-style:normal">135</span></span></span></div>

<div style="page-break-after:always"><hr style="border-width:0px;clear:both;margin:4px 0px;width:100%;height:2px;color:#000000;background-color:#000000" /></div></div>

<div style="text-align:justify;line-height:1.25;font-style:italic"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Separation
Agreement</span></span></div>

<div style="text-align:justify;line-height:1.25">&#160;</div>

<div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">On
July 13, 2022, the Company and Dr. Jamas entered into a mutual separation agreement (the &#8220;Separation Agreement&#8221;), pursuant
to which the parties agreed that Dr. Jamas would resign from his position as the Company&#8217;s Chief Executive Officer, effective July
15, 2022 (the &#8220;Jamas Separation Date&#8221;). Pursuant to the Separation Agreement, Dr. Jamas&#8217; employment agreement, dated
November 30, 2020, terminated, other than with respect to those provisions intended to survive termination, including those with respect
to confidentiality, non-competition, non-solicitation and intellectual property.</span></span></div>

<div style="text-align:justify;text-indent:36pt;line-height:1.25">&#160;</div>

<div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Pursuant
to the terms of the Separation Agreement, Dr. Jamas was entitled to receive payment for all accrued but unpaid base salary through the
Jamas Separation Date, unused paid time off through the Jamas Separation Date, reimbursement for unreimbursed business expenses properly
incurred pursuant to the Company&#8217;s applicable expense reimbursement policy, and benefits provided under the Company&#8217;s employee
benefit plan. In addition, in consideration for Dr. Jamas&#8217; execution of the Separation Agreement and non-revocation of a waiver
and release of claims relating thereto, Dr. Jamas was entitled to the following benefits under the Separation Agreement:</span></span></div>

<div style="text-align:justify;text-indent:36pt;line-height:1.25">&#160;</div>

<table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">
  <tr>
    <td style="width:18pt">&#160;</td>
    <td style="width:18pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">&#8226;</span></span></td>
    <td style="width:auto;vertical-align:top;text-align:justify">
        <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">a one-time lump sum payment of Dr. Jamas&#8217;
        annual base salary for a period of thirteen (13) months, for a total gross amount equal to $411,666.67, after the expiration of the revocation
        period;</span></span></div></td></tr>
  </table>

<div style="line-height:1.25">&#160;</div>

<table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">
  <tr>
    <td style="width:18pt">&#160;</td>
    <td style="width:18pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">&#8226;</span></span></td>
    <td style="width:auto;vertical-align:top;text-align:justify">
        <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">an extension of the exercise period for the vested
        portion of the share option granted to Dr. Jamas on January 4, 2021 pursuant to the terms of the Company&#8217;s 2018 Equity Incentive
        Plan, representing collectively 492,832 ordinary shares, through the end of a two-year period commencing on the Jamas Separation Date.</span></span></div></td></tr>
  </table>

<div style="line-height:1.25">&#160;</div>

<div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Under
the Separation Agreement, Dr. Jamas agreed to cooperate with and assist the Company regarding certain matters and transitioning his employment
duties and responsibilities. Subject to certain exceptions and limitations, the Separation Agreement included a general release of claims
by Dr. Jamas in favor of the Company and certain related persons and parties, and customary non-disparagement provisions. The Separation
Agreement also included certain other customary representations, warranties and covenants of Dr. Jamas. The Separation Agreement superseded
all other agreements or arrangements between Dr. Jamas and the Company regarding the subject matter of the agreement, including those
with respect to severance payments and benefits.</span></span></div>

<div style="line-height:1.25">&#160;</div>

<div style="text-align:justify;line-height:1.25;font-style:italic;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Phillip
Schwartz</span></span></div>

<div style="line-height:1.25">&#160;</div>

<div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Dr.
Phillip Schwartz<span style="font-style:italic">&#160;</span>was appointed as our President of Research and Development in August 2019
and served in this capacity until July 21, 2022, (the &#8220;Schwartz Separation Date&#8221;), and acted as a director from our inception
in 2010 until June 15, 2022, and as Chief Executive Officer from 2010 up until August 2019. We entered into an employment agreement with
Dr. Schwartz as our Chief Executive Officer dated June 8, 2014 which was amended last and approved on April 6, 2021, and on April 21,
2021, by our Compensation Committee and the Board, respectively, and approved accordingly by our shareholders in the last annual meeting
of the shareholders of the Company on October 4, 2021. Pursuant to the agreement as amended, effective as of January 1, 2021, Dr. Schwartz
was entitled to an annual gross base salary of $312,889. Additionally, Dr. Schwartz was eligible to participate in the Company&#8217;s
standard full-time employment benefits that are offered by the Company from time to time, which currently include medical, short term
disability and pension fund benefits. Dr. Schwartz was also generally entitled to reimbursement for travel and other business expenses
and other benefits, including, vacation, holidays and sick leave. Subject to applicable law, Dr. Schwartz was also covered by our D&#38;O
insurance policy. Dr. Schwartz was granted 357,000 Ordinary Shares under our 2013 Equity Incentive Plan, as of November 23, 2017, at an
exercise price of $6.31, which are as of today considered fully vested. In April 2021, he was also granted options to purchase 100,000
Ordinary Shares of the Company under the 2018 Plan, at an exercise price of $3.15. In addition, in case of termination of Dr. Schwartz&#8217;s
employment, the Company agreed to pay Dr. Schwartz an amount equal to six (6) months salaries as a severance payment, as well as all accrued
and unused vacation days and any accrued and unpaid bonuses (to the extent that Dr. Schwartz is entitled to such bonus as of the termination
date).</span></span></div>

<div style="line-height:1.25">&#160;</div>

<div style="clear:both;margin-top:10pt;margin-bottom:10pt">

<div style="text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:normal;font-style:normal">136</span></span></span></div>

<div style="page-break-after:always"><hr style="border-width:0px;clear:both;margin:4px 0px;width:100%;height:2px;color:#000000;background-color:#000000" /></div></div>

<div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">On
June 15, 2022, the Company entered into a separation agreement with Dr. Phillip Schwartz, the Company&#8217;s former President of R&#38;D,
under which Dr. Schwartz agreed to continue to provide services to the Company until July 21, 2022 (the &#8220;Schwartz Separation Date&#8221;).
Pursuant to the terms of the separation agreement, which were approved by the Company&#8217;s shareholders on September 7, 2022, Dr. Schwartz
received a full acceleration of his unvested options, as of the Shwartz Separation Date, to purchase 68,750 ordinary shares granted in
April 2021 that otherwise would have been forfeited. These options, together with 31,250 already vested options granted in April 2021
and 357,500 already vested options to purchase ordinary shares granted in 2017, will be exercisable for a period of 10 years from their
respective initial grant dates. The acceleration described above was recognized as a "Type III" modification; therefore, on the shareholder
approval date, the Company recognized the incremental costs of unvested options based on the fair value of the options on such date. In
addition, the extension of the exercise period for the vested awards was recognized as a "Type I" modification. The total expense amount
was $112 thousand, which was classified as additional share-based compensation costs in the research and development expenses.<br />&#160;<br />In
addition, the separation agreement provides for the following payments to Dr. Schwartz, all of which would have otherwise been payable
in accordance with either Israeli law or pursuant to his existing employment agreement: a one-time cash separation payment in an amount
equal to NIS 537,600 (approximately $155.9) and additional payments of NIS 737,771 (approximately $214.0) in respect of all other ongoing
accrued benefits, subject to any mandatory deductions. The foregoing payments were recognized in the research and development expenses</span></span></div>

<div style="text-align:justify;line-height:1.25">&#160;</div>

<div style="text-align:justify;line-height:1.25;font-style:italic;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Hillel
Galitzer</span></span></div>

<div style="line-height:1.25">&#160;</div>

<div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">We
entered into an employment agreement, effective as of June 8, 2014, with Dr. Hillel Galitzer, in connection with his appointment as our
Chief Operating Officer, who prior to that served as our Director of Scientific Development from July 2012. Pursuant to the agreement
as amended most recently and approved in the Company's annual meeting of shareholders dated October 4, 2021, Dr. Galitzer is entitled
to an annual gross base salary of $246,547. Additionally, Dr. Galitzer is eligible to participate in the Company&#8217;s standard full-time
employment benefits that are offered by the Company from time to time, which currently include medical, short term disability and pension
fund benefits. Dr. Galitzer is also generally entitled to reimbursement for travel and other business expenses and other benefits, including,
vacation, holidays, company car and sick leave. Subject to applicable law, Dr. Galitzer is also covered by our D&#38;O insurance policy.
In November 2017, Dr. Galitzer was granted options to purchase 143,000 Ordinary Shares of the Company, under the Company's 2013 Equity
Incentive Plan, with an exercise price of $6.31, all of which are fully vested.<sup style="vertical-align:text-top;line-height:1;font-size:smaller">&#160;</sup>We
also granted Dr. Galitzer options to purchase 175,000 Ordinary Shares of the Company, under the Company&#8217;s 2018 Plan, as of March
16, 2020, at an exercise price of $2.14. Additionally, Dr. Galitzer received a grant of options to purchase 125,000 Ordinary Shares under
the Company&#8217;s 2018 Plan, as of April 28, 2021, at an exercise price of $3.15, under the 2018 Plan. In addition, Dr. Galitzer received
a grant of options to purchase 60,000 Ordinary Shares of the Company, under the Company&#8217;s 2018 Plan, as of March 31, 2022, at an
exercise price of $2.86.</span></span></div>

<div style="line-height:1.25">&#160;</div>

<div style="text-align:justify;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Employee
Equity Incentive Plan</span></span></div>

<div style="line-height:1.25">&#160;</div>

<div style="line-height:1.25;font-style:italic;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Share
Incentive Plan</span></span></div>

<div style="line-height:1.25">&#160;</div>

<div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">On
March 17, 2013, our Board approved our 2013 Plan for the granting of stock options, restricted share units, restricted share awards and
performance-based awards, in order to provide incentives to our employees, directors, consultants and/or service providers. As of December
31, 2022, 1,518,262 Ordinary Shares were issuable upon the exercise of outstanding awards under the 2013 Plan, at a weighted-average exercise
price of$5.71 per share. As of December 31, 2022, all of the foregoing outstanding options had vested under the 2013 Plan.</span></span></div>

<div style="line-height:1.25">&#160;</div>

<div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Awards
granted under the 2013 Plan are subject to vesting schedules and generally vest over a four-year period commencing from the applicable
grant date, such that 25% of the awards vest on the first anniversary of the applicable grant date and 75% of the awards vest in 12 equal
installments upon the lapse of each three-month period following the first anniversary of the applicable grant date. Subject to the discretion
of the 2013 Plan administrator, if an award has not been exercised within six years after the date of the grant, the award expires. Any
period in which a grantee is not our employee or has taken a leave of absence will not be included in such vesting period.</span></span></div>

<div style="line-height:1.25">&#160;</div>

<div style="clear:both;margin-top:10pt;margin-bottom:10pt">

<div style="text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:normal;font-style:normal">137</span></span></span></div>

<div style="page-break-after:always"><hr style="border-width:0px;clear:both;margin:4px 0px;width:100%;height:2px;color:#000000;background-color:#000000" /></div></div>

<div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The
2013 Plan provides for granting awards in compliance with Section 102 of the Israeli Income Tax Ordinance, 5721-1961, or the Ordinance,
which provides to employees, directors and officers, who are not controlling shareholders (as defined in the Ordinance) and are Israeli
residents, favorable tax treatment for compensation in the form of shares or equity awards issued or granted, as applicable, to a trustee
under the capital gains track, or Capital Gains Track, for the benefit of the relevant employee, director or officer and are, or were,
to be held by the trustee for at least two years after the date of grant or issuance. Under the Capital Gains Track, any accounting expense
with respect to the grant or issuance of such shares or awards which relates to gain taxed as capital gains is not allowed as a deduction
for tax purposes.</span></span></div>

<div style="line-height:1.25">&#160;</div>

<div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The
2013 Plan addresses the treatment of vested and unvested awards upon the cessation of employment or engagement of the award holder as
well as upon consummation of a merger, consolidation or similar transaction, or sale of all or substantially all of our assets or sale
of at least 80% of our outstanding securities. The 2013 Plan also provides for certain lock-up arrangements upon consummation of a public
offering.</span></span></div>

<div style="line-height:1.25">&#160;</div>

<div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The
2013 Plan is administered by our Board or by a committee appointed by our Board. Upon the completion of our initial public offering, the
remaining pool of reserved Ordinary Shares under the 2013 Plan was cancelled, and the only reserved Ordinary Shares available for grants
to our employees, directors, consultants and service providers in the future are those under the 2018 Plan (which is described below).</span></span></div>

<div style="line-height:1.25">&#160;</div>

<div style="line-height:1.25;font-style:italic;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2018
Equity Incentive Plan</span></span></div>

<div style="line-height:1.25">&#160;</div>

<div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">On
July 2, 2018, in connection with the consummation of our initial public offering, our Board approved our 2018 Plan, with the purpose of
advancing the interests of our shareholders by enhancing our ability to attract, retain and motivate individuals to perform at the highest
level. The 2018 Plan governs issuances of equity incentive awards from and after the closing of our initial public offering. The maximum
number of Ordinary Shares initially available for issuance under equity incentive awards granted pursuant to the 2018 Plan could not exceed
12% of the total outstanding Ordinary Shares as of the time of adoption. On January 1, 2019 and on January 1 of each calendar year thereafter,
an additional number of shares equal to 5% of the total outstanding Ordinary Shares on such date (or any lower number of shares as determined
by our Board) have and will become available for issuance under the 2018 Plan. In our shareholders meeting held September 7, 2022, our
shareholders approved an amendment to the 2018 Plan to increase the number of Ordinary Shares issuable under the 2018 Plan by a one-time
additional amount of 576,188 Ordinary Shares. As of December 31, 2022, a total of 922,080 Ordinary Shares representing 3.2% of the total
outstanding shares as of that date remained available for issuance under the 2018 Plan. On January 1, 2023, pursuant to the annual evergreen
provision and following the approval of our Board, an additional 1,440,496 Ordinary Shares, equal to 5% of the total outstanding shares
as of January 1, 2023, became available for issuance under the 2018 Plan.</span></span></div>

<div style="line-height:1.25">&#160;</div>

<div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Equity
incentive awards may be granted to our employees, non-employee directors, consultants or other advisors, as well as holders of equity
compensation awards granted by a company that may be acquired by us in the future. Awards under the 2018 Plan may be granted in the form
of options, share appreciation rights, restricted shares, restricted share units, performance awards or other share-based awards. Options
and share appreciation rights will have an exercise price determined by the administrator but that is no less than fair market value of
the underlying Ordinary Shares on the date of grant.</span></span></div>

<div style="line-height:1.25">&#160;</div>

<div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">As
of December 31, 2022, 4,214,825 Ordinary Shares were issuable upon the exercise of outstanding awards under the 2018 Plan, at a weighted-average
exercise price of&#8201;$2.04 per share. Of the foregoing outstanding awards, as of December 31, 2022, options to purchase 1,653,531 Ordinary
Shares, in the aggregate, had vested under the 2018 Plan, with a weighted-average exercise price of&#8201;$2.47 per share.</span></span></div>

<div style="line-height:1.25">&#160;</div>

<div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The
vesting conditions for grants under the 2018 Plan will be determined by the administrator and, in the case of restricted shares and restricted
share units, will be set forth in the applicable award documentation.</span></span></div>

<div style="line-height:1.25">&#160;</div>

<div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">In
the event of a participant&#8217;s termination of employment, the administrator may, in its discretion, determine the extent to which
an equity incentive award may be exercised, settled, vested, paid or forfeited. In the event of a change in control (as defined in the
2018 Plan) of the Company, the Compensation Committee may, in its discretion, take a number of actions with respect to awards outstanding
under the 2018 Plan, including the following: (i) continuing awards or converting such awards into an award or right with respect to shares
of the successor or surviving corporation; (ii) immediately vesting and settling awards (or in the case of options and share appreciation
rights, providing that such awards will become fully exercisable); (iii) cancelling unvested awards for no consideration; (iv) terminating
or cancelling awards in exchange for a cash payment; and (v) providing that awards may be assumed, exchanged, replaced or continued by
the successor or surviving corporation with cash, securities, rights or other property. In the event of a structural change of the Company
(i.e., a transaction in which the Company&#8217;s shares immediately prior to the transaction are converted into or exchanged for shares
that represent at least a majority of the share capital of the surviving corporation, such as a re-domestication of the Company or a share
flip), outstanding awards will be exchanged or converted into awards to acquire shares of the company (if it is the surviving corporation)
or the successor company in accordance with the applicable exchange ratio.</span></span></div>

<div style="line-height:1.25">&#160;</div>

<div style="clear:both;margin-top:10pt;margin-bottom:10pt">

<div style="text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:normal;font-style:normal">138</span></span></span></div>

<div style="page-break-after:always"><hr style="border-width:0px;clear:both;margin:4px 0px;width:100%;height:2px;color:#000000;background-color:#000000" /></div></div>

<div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The
2018 Plan is administered by the Board, provided that the Board may delegate its authority to the Compensation Committee to administer
the 2018 Plan.</span></span></div>

<div style="line-height:1.25">&#160;</div>

<div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The
2018 Plan provides for granting awards in compliance with Section 102 of the Ordinance, which provides to employees, directors and officers
of the Company, who are not controlling shareholders (as defined in the Ordinance) of the Company and are Israeli residents, potential
favorable tax treatment for compensation in the form of shares or equity awards issued or granted, as applicable, to a trustee under the
Capital Gains Track for the benefit of the relevant employee, director or officer, subject to compliance with the terms and conditions
of such tax track. Under the Capital Gains Track, any accounting expense with respect to the grant or issuance of such shares or awards
which relates to gain taxed as capital gains is not allowed as a deduction for tax purposes.<br />&#160;</span></span></div>

<a id="Item12"></a><div style="line-height:1.25"><span style="color:#000000;font-family:Times New Roman, Times, serif;font-size:13.3333px;font-style:normal;font-variant-ligatures:normal;text-align:left;white-space:normal;background-color:#ffffff;text-decoration-thickness:initial;text-decoration-style:initial;text-decoration-color:initial;font-weight:bold">ITEM
12.</span>&#160;&#160; &#160; &#160; &#160; &#160;&#160;<span style="color:#000000;font-family:Times New Roman, Times, serif;font-size:13.3333px;font-style:normal;font-variant-ligatures:normal;text-align:left;white-space:normal;background-color:#ffffff;text-decoration-thickness:initial;text-decoration-style:initial;text-decoration-color:initial;font-weight:bold">SECURITY
OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED SHAREHOLDER MATTERS</span></div>

<div style="line-height:1.25">&#160;</div>

<div style="text-align:justify;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Security
Ownership of Certain Beneficial Owners and Management</span></span></div>

<div style="line-height:1.25">&#160;</div>

<div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The
following table sets forth information known to us with respect to the beneficial ownership of our Ordinary Shares as of March 27, 2023
by:</span></span></div>

<div style="line-height:1.25">&#160;</div>

<table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">
  <tr>
    <td style="width:36pt">&#160;</td>
    <td style="width:36pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">&#8226;</span></span></td>
    <td style="width:auto;vertical-align:top;text-align:justify">
        <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">each person or entity known by us to own beneficially
        5% or more of our outstanding Ordinary Shares;</span></span></div>
        <div>&#160;</div></td></tr>
  </table>

<table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">
  <tr>
    <td style="width:36pt">&#160;</td>
    <td style="width:36pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">&#8226;</span></span></td>
    <td style="width:auto;vertical-align:top;text-align:justify">
        <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">each of our directors and executive officers individually;
        and<br />&#160;</span></span></div></td></tr>
  </table>

<table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">
  <tr>
    <td style="width:36pt">&#160;</td>
    <td style="width:36pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">&#8226;</span></span></td>
    <td style="width:auto;vertical-align:top;text-align:justify">
        <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">all of our executive officers and directors as
        a group.</span></span></div></td></tr>
  </table>

<div style="line-height:1.25">&#160;</div>

<div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The
beneficial ownership of our Ordinary Shares is determined in accordance with the rules of the SEC, and the information is not necessarily
indicative of beneficial ownership for any other purpose. Under such rules, beneficial ownership, generally, includes any shares over
which a person exercises sole or shared voting or investment power. For purposes of the table and the related footnotes, unless described
otherwise within the footnotes, Ordinary Shares issuable pursuant to options or warrants that are currently exercisable will become exercisable
within 60 following March 27, 2023 to be outstanding and beneficially owned by the person holding the options or warrants for the purposes
of computing the percentage ownership of that person, but we do not treat them as outstanding for the purpose of computing the percentage
ownership of any other person, except with respect to the percentage ownership of all executive officers and directors as a group. The
percentage of Ordinary Shares beneficially owned is based on 28,809,922 Ordinary Shares outstanding as of March 27, 2023. The beneficial
ownership data provided below is based solely on information available to our Company and, in the case of major shareholders who are not
otherwise officers or directors, has not been verified further. Except where otherwise indicated, we believe, based on information furnished
to us by such owners, that the beneficial owners of the Ordinary Shares listed below have sole investment and voting power with respect
to such shares.</span></span></div>

<div style="line-height:1.25">&#160;</div>

<div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Unless
otherwise noted below, each shareholder&#8217;s address is c/o Entera Bio Ltd., Kiryat Hadassah, Minrav Building - Fifth Floor, Jerusalem,
Israel.</span></span></div>

<div style="line-height:1.25">&#160;</div>

<div style="clear:both;margin-top:10pt;margin-bottom:10pt">

<div style="text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:normal;font-style:normal">139</span></span></span></div>

<div style="page-break-after:always"><hr style="border-width:0px;clear:both;margin:4px 0px;width:100%;height:2px;color:#000000;background-color:#000000" /></div></div>

<table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left;color:#000000;width:100%">
  <tr>
    <td style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0)" valign="bottom">
        <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Name</span></span></div></td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td>
    <td colspan="6" style="vertical-align:top;border-bottom:2px solid rgb(0, 0, 0)" valign="bottom">
        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Number
        and Percentage of</span></span></div>
        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Ordinary
        Shares</span></span></div></td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td></tr>
  <tr>
    <td style="vertical-align:top;padding-bottom:2px" valign="bottom">
        <div style="line-height:1.25">&#160;</div></td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align:top;border-bottom:2px solid rgb(0, 0, 0);width:110px" valign="bottom">
        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Number</span></span></div></td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;white-space:nowrap;width:14px" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px" valign="bottom">
        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Percent</span></span></div></td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td></tr>
  <tr>
    <td style="vertical-align:top;background-color:#CCEEFF" valign="bottom">
        <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">5% or
        Greater Shareholders (other than directors and executive officers)</span></span></div></td>
    <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align:top;background-color:rgb(204, 238, 255);width:110px" valign="bottom">&#160;</td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap;width:14px" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align:top;background-color:#CCEEFF" valign="bottom">&#160;</td>
    <td colspan="1" style="background-color:#CCEEFF;vertical-align:bottom;white-space:nowrap" valign="bottom">&#160;</td></tr>
  <tr>
    <td style="vertical-align:bottom;width:76%" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">D.N.A Biomedical Solutions
        Ltd.(1)</span></span></div></td>
    <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:99px" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">3,762,960</span></span></div></td>
    <td colspan="1" style="vertical-align:bottom;width:14px;white-space:nowrap" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">13.1</span></span></div></td>
    <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">%</span></span></div></td></tr>
  <tr>
    <td style="vertical-align:bottom;background-color:#CCEEFF;width:76%" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Gakasa Holdings LLC.(2)</span></span></div></td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="background-color:#CCEEFF;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:99px" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2,484,275</span></span></div></td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:14px;white-space:nowrap" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="background-color:#CCEEFF;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="background-color:#CCEEFF;vertical-align:bottom;text-align:right;width:9%" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">8.6</span></span></div></td>
    <td colspan="1" style="background-color:#CCEEFF;vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">%</span></span></div></td></tr>
  <tr>
    <td style="vertical-align:bottom;width:76%" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Centillion Fund (3)</span></span></div></td>
    <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:99px" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2,396,953</span></span></div></td>
    <td colspan="1" style="vertical-align:bottom;width:14px;white-space:nowrap" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">8.3</span></span></div></td>
    <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">%</span></span></div></td></tr>
  <tr>
    <td style="vertical-align:bottom;background-color:#CCEEFF;width:76%" valign="bottom">
        <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Executive
        Officers and Directors:</span></span></div></td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="background-color:#CCEEFF;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:99px" valign="bottom">&#160;</td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:14px;white-space:nowrap" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="background-color:#CCEEFF;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="background-color:#CCEEFF;vertical-align:bottom;text-align:right;width:9%" valign="bottom">&#160;</td>
    <td colspan="1" style="background-color:#CCEEFF;vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td></tr>
  <tr>
    <td style="vertical-align:bottom;width:76%" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Yonatan Malca(4)</span></span></div></td>
    <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:99px" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">143,798</span></span></div></td>
    <td colspan="1" style="vertical-align:bottom;width:14px;white-space:nowrap" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">*</span></span></div></td>
    <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td></tr>
  <tr>
    <td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Gerald Lieberman(5)</span></span></div></td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:99px;background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">494,515</span></span></div></td>
    <td colspan="1" style="vertical-align:bottom;width:14px;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">1.7</span></span></div></td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">%</span></span></div></td></tr>
  <tr>
    <td style="vertical-align:bottom;width:76%" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Dr. Roger J. Garceau(6)</span></span></div></td>
    <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:99px" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">464,198</span></span></div></td>
    <td colspan="1" style="vertical-align:bottom;width:14px;white-space:nowrap" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">1.6</span></span></div></td>
    <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">%</span></span></div></td></tr>
  <tr>
    <td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Dr. Hillel Galitzer(7)</span></span></div></td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:99px;background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">385,856</span></span></div></td>
    <td colspan="1" style="vertical-align:bottom;width:14px;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">1.3</span></span></div></td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">%</span></span></div></td></tr>
  <tr>
    <td style="vertical-align:bottom;width:76%" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Dr. Arthur Santora(8)</span></span></div></td>
    <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:99px" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">60,000</span></span></div></td>
    <td colspan="1" style="vertical-align:bottom;width:14px;white-space:nowrap" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">*</span></span></div></td>
    <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td></tr>
  <tr>
    <td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Miranda J. Toledano(9)</span></span></div></td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:99px;background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">296,105</span></span></div></td>
    <td colspan="1" style="vertical-align:bottom;width:14px;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">1.0</span></span></div></td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">%</span></span></div></td></tr>
  <tr>
    <td style="vertical-align:bottom;width:76%" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Gerald M. Ostrov(10)</span></span></div></td>
    <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:99px" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">146,566</span></span></div></td>
    <td colspan="1" style="vertical-align:bottom;width:14px;white-space:nowrap" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">*</span></span></div></td>
    <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td></tr>
  <tr>
    <td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Sean Ellis(11)</span></span></div></td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:99px;background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">201,666</span></span></div></td>
    <td colspan="1" style="vertical-align:bottom;width:14px;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">*</span></span></div></td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td></tr>
  <tr>
    <td style="vertical-align:bottom;width:76%" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Dana Yaacov-Garbeli(12)</span></span></div></td>
    <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:99px" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">151,580</span></span></div></td>
    <td colspan="1" style="vertical-align:bottom;width:14px;white-space:nowrap" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">*</span></span></div></td>
    <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td></tr>
  <tr>
    <td style="vertical-align:bottom;background-color:#CCEEFF;width:76%" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Ron Mayron(13)</span></span></div></td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="background-color:#CCEEFF;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:99px" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">132,353</span></span></div></td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:14px;white-space:nowrap" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="background-color:#CCEEFF;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="background-color:#CCEEFF;vertical-align:bottom;text-align:right;width:9%" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">*</span></span></div></td>
    <td colspan="1" style="background-color:#CCEEFF;vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td></tr>
  <tr>
    <td style="vertical-align:bottom;width:76%" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">All Directors and Executive
        Officers as a Group (10 persons)(14)</span></span></div></td>
    <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:99px" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2,476,637</span></span></div></td>
    <td colspan="1" style="vertical-align:bottom;width:14px;white-space:nowrap" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">8.0</span></span></div></td>
    <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">%</span></span></div></td></tr>
  </table>

<div style="text-align:justify;line-height:1.25">&#160;</div>

<div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">*
Less than 1%</span></span></div>

<div style="line-height:1.25">&#160;</div>

<table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">
  <tr>
    <td style="width:3.57%;vertical-align:top">
        <div style="text-indent:-18pt;margin-left:18pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(1)</span></span></div></td>
    <td style="width:96.43%;vertical-align:top">
        <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">D.N.A
        Biomedical Solutions Ltd.&#8217;s holdings consisted of 3,762,960 Ordinary Shares. D.N.A&#8217;s address is at Shimon Hatarsi 43 St.,
        Tel Aviv, Israel.</span></span></div></td></tr>
  <tr>
    <td style="width:3.57%;vertical-align:top">
        <div style="text-indent:-18pt;margin-left:18pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(2)</span></span></div></td>
    <td style="width:96.43%;vertical-align:top">
        <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Based
        on the Schedule 13G/A filed by Gakasa Holdings LLC with the SEC on June 14, 2021 regarding its holdings as of May 19, 2021. Gakasa Holdings
        LLC&#8217;s address is 201 S. Biscayne Blvd., Suite 800, Miami, Florida.</span></span></div></td></tr>
  <tr>
    <td style="width:3.57%;vertical-align:top">
        <div style="text-indent:-18pt;margin-left:18pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(3)</span></span></div></td>
    <td style="width:96.43%;vertical-align:top">
        <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Based
        on the Schedule 13G/A filed by Centillion Fund Inc. with the SEC on November 18, 2022 regarding its holdings as of August 31, 2022. Centillion
        Fund Inc&#8217;s address is 10 Manoel Street, Castries, Saint Lucia LC04 101</span></span></div></td></tr>
  <tr>
    <td style="width:3.57%;vertical-align:top">
        <div style="text-indent:-18pt;margin-left:18pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(4)</span></span></div></td>
    <td style="width:96.43%;vertical-align:top">
        <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Consists
        of (i) 7,232 Ordinary Shares and (ii) 136,566 Ordinary Shares underlying options to acquire Ordinary Shares.</span></span></div></td></tr>
  <tr>
    <td style="width:3.57%;vertical-align:top">
        <div style="text-indent:-18pt;margin-left:18pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(5)</span></span></div></td>
    <td style="width:96.43%;vertical-align:top">
        <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Consists
        of&#8201;(i) 210,659 Ordinary Shares and (ii) 283,856 Ordinary Shares underlying options to acquire Ordinary Shares.</span></span></div></td></tr>
  <tr>
    <td style="width:3.57%;vertical-align:top">
        <div style="text-indent:-18pt;margin-left:18pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(6)</span></span></div></td>
    <td style="width:96.43%;vertical-align:top">
        <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Consists
        of&#8201;(i) 4,940 Ordinary Shares and (ii) 459,258 Ordinary Shares underlying options to acquire Ordinary Shares.</span></span></div></td></tr>
  <tr>
    <td style="width:3.57%;vertical-align:top">
        <div style="text-indent:-18pt;margin-left:18pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(7)</span></span></div></td>
    <td style="width:96.43%;vertical-align:top">
        <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Consists
        of (i) 34,106 Ordinary Shares and (ii) 351,750 Ordinary Shares underlying options to acquire Ordinary Shares.</span></span></div></td></tr>
  <tr>
    <td style="width:3.57%;vertical-align:top">
        <div style="text-indent:-18pt;margin-left:18pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(8)</span></span></div></td>
    <td style="width:96.43%;vertical-align:top">
        <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Consists
        of 60,000 Ordinary Shares underlying options to acquire Ordinary Shares.</span></span></div></td></tr>
  <tr>
    <td style="width:3.57%;vertical-align:top">
        <div style="text-indent:-18pt;margin-left:18pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(9)</span></span></div></td>
    <td style="width:96.43%;vertical-align:top">
        <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Consists
        of (i) 56,800 Ordinary Shares and (ii) 239,305 Ordinary Shares underlying options to acquire Ordinary Shares.</span></span></div></td></tr>
  <tr>
    <td style="width:3.57%;vertical-align:top">
        <div style="text-indent:-18pt;margin-left:18pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(10)</span></span></div></td>
    <td style="width:96.43%;vertical-align:top">
        <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Consists
        of (i) 10,000 Ordinary Shares and (ii) 136,566 Ordinary Shares underlying options to acquire Ordinary Shares.</span></span></div></td></tr>
  <tr>
    <td style="width:3.57%;vertical-align:top">
        <div style="text-indent:-18pt;margin-left:18pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(11)</span></span></div></td>
    <td style="width:96.43%;vertical-align:top">
        <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Consists
        of (i) 62,100 Ordinary Shares (ii) 3,000 Ordinary Shares underlying warrant to acquire Ordinary Shares and (iii) 136,566 Ordinary Shares
        underlying options to acquire Ordinary Shares.</span></span></div></td></tr>
  <tr>
    <td style="width:3.57%;vertical-align:top">
        <div style="text-indent:-18pt;margin-left:18pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(12)</span></span></div></td>
    <td style="width:96.43%;vertical-align:top">
        <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Consists
        of (i) 56,580 Ordinary Shares and (ii) 95,000 Ordinary Shares underlying options to acquire Ordinary Shares.</span></span></div></td></tr>
  <tr>
    <td style="width:3.57%;vertical-align:top">
        <div style="text-indent:-18pt;margin-left:18pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(13)</span></span></div></td>
    <td style="width:96.43%;vertical-align:top">
        <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Consists
        of (i) 7,000 Ordinary Shares and (ii) 125,353 Ordinary Shares underlying options to acquire Ordinary Shares.</span></span></div></td></tr>
  <tr>
    <td style="width:3.57%;vertical-align:top">
        <div style="text-indent:-18pt;margin-left:18pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(14)</span></span></div></td>
    <td style="width:96.43%;vertical-align:top">
        <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Consists
        of (i) 449,417 ordinary Shares (ii) 3,000 Ordinary Shares underlying warrant to acquire Ordinary Shares and (iii) options to acquire 1,899,220
        Ordinary Shares.</span></span></div></td></tr>
  </table>

<div style="line-height:1.25">&#160;</div>

<div style="clear:both;margin-top:10pt;margin-bottom:10pt">

<div style="text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:normal;font-style:normal">140</span></span></span></div>

<div style="page-break-after:always"><hr style="border-width:0px;clear:both;margin:4px 0px;width:100%;height:2px;color:#000000;background-color:#000000" /></div></div>

<div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">Securities
Authorized for Issuance under Equity Compensation Plans</span><br />&#160;</span></span></div>

<div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The
following table provides certain information as of December 31, 2022, with respect to our equity compensation plans under which our equity
securities are authorized for issuance:</span></span></div>

<div style="text-align:justify;line-height:1.25">&#160;</div>

<table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left;color:#000000;width:100%">
  <tr>
    <td style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0)" valign="bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Plan
        Category</span></span></div></td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0)" valign="bottom">
        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Number
        of securities to be issued upon exercise of outstanding options, RSUs, warrants and rights</span></span></div>
        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(#)</span></span></div></td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0)" valign="bottom">
        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Weighted-average
        exercise price of outstanding options, RSUs,</span></span></div>
        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">warrants
        and rights</span></span></div>
        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">($)</span></span></div></td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0)" valign="bottom">
        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Number
        of securities remaining available for future issuance under equity compensation plans (excluding securities reflected in column (a)) (#)</span></span></div></td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td></tr>
  <tr>
    <td style="vertical-align:bottom" valign="bottom">
        <div style="text-align:center;line-height:1.25;font-weight:bold">&#160;</div></td>
    <td colspan="1" style="vertical-align:bottom" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align:bottom" valign="bottom">
        <div style="text-align:right;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(a)</span></span></div></td>
    <td colspan="1" style="vertical-align:bottom;white-space:nowrap" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align:bottom" valign="bottom">
        <div style="text-align:right;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(b)</span></span></div></td>
    <td colspan="1" style="vertical-align:bottom;white-space:nowrap" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align:bottom" valign="bottom">
        <div style="text-align:right;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(c)</span></span></div></td>
    <td colspan="1" style="vertical-align:bottom;white-space:nowrap" valign="bottom">&#160;</td></tr>
  <tr>
    <td style="vertical-align:bottom;background-color:#CCEEFF" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Equity compensation plans
        approved by security holders</span></span></div></td>
    <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align:bottom;background-color:#CCEEFF" valign="bottom">&#160;</td>
    <td colspan="1" style="background-color:#CCEEFF;vertical-align:bottom;white-space:nowrap" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align:bottom;background-color:#CCEEFF" valign="bottom">&#160;</td>
    <td colspan="1" style="background-color:#CCEEFF;vertical-align:bottom;white-space:nowrap" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align:bottom;background-color:#CCEEFF" valign="bottom">&#160;</td>
    <td colspan="1" style="background-color:#CCEEFF;vertical-align:bottom;white-space:nowrap" valign="bottom">&#160;</td></tr>
  <tr>
    <td style="vertical-align:bottom" valign="bottom">
        <div style="line-height:1.25">&#160;</div></td>
    <td colspan="1" style="vertical-align:bottom" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align:bottom" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;white-space:nowrap" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align:bottom" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;white-space:nowrap" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align:bottom" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;white-space:nowrap" valign="bottom">&#160;</td></tr>
  <tr>
    <td style="vertical-align:bottom;background-color:#CCEEFF;width:64%" valign="bottom">
        <div style="line-height:1.25;font-style:italic"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2013
        Plan</span></span></div></td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="background-color:#CCEEFF;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="background-color:#CCEEFF;vertical-align:bottom;text-align:right;width:9%" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">1,518,262</span></span></div></td>
    <td colspan="1" style="background-color:#CCEEFF;vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="background-color:#CCEEFF;vertical-align:bottom;width:1%" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div></td>
    <td colspan="1" style="background-color:#CCEEFF;vertical-align:bottom;text-align:right;width:9%" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">5.71</span></span></div></td>
    <td colspan="1" style="background-color:#CCEEFF;vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="background-color:#CCEEFF;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="background-color:#CCEEFF;vertical-align:bottom;text-align:right;width:9%" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></div></td>
    <td colspan="1" style="background-color:#CCEEFF;vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td></tr>
  <tr>
    <td style="vertical-align:bottom;width:64%" valign="bottom">
        <div style="line-height:1.25;font-style:italic"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2018
        Plan</span></span></div></td>
    <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">4,214,825</span></span></div></td>
    <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div></td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2.04</span></span></div></td>
    <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">922,080</span></span></div></td>
    <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td></tr>
  <tr>
    <td style="vertical-align:bottom;background-color:#CCEEFF;width:64%" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Equity compensation plans
        not approved by security holders</span></span></div></td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="background-color:#CCEEFF;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="background-color:#CCEEFF;vertical-align:bottom;text-align:right;width:9%" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></div></td>
    <td colspan="1" style="background-color:#CCEEFF;vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="background-color:#CCEEFF;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="background-color:#CCEEFF;vertical-align:bottom;text-align:right;width:9%" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></div></td>
    <td colspan="1" style="background-color:#CCEEFF;vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="background-color:#CCEEFF;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="background-color:#CCEEFF;vertical-align:bottom;text-align:right;width:9%" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></div></td>
    <td colspan="1" style="background-color:#CCEEFF;vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td></tr>
  <tr>
    <td style="vertical-align:bottom;width:64%" valign="bottom">
        <div style="line-height:1.25">&#160;</div></td>
    <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td></tr>
  <tr>
    <td style="vertical-align:bottom;background-color:#CCEEFF;width:64%" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Total </span></span></div></td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="background-color:#CCEEFF;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="background-color:#CCEEFF;vertical-align:bottom;text-align:right;width:9%" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">5,733,087</span></span></div>
        <div style="line-height:1.25">&#160;</div></td>
    <td colspan="1" style="background-color:#CCEEFF;vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="background-color:#CCEEFF;vertical-align:bottom;width:1%" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div></td>
    <td colspan="1" style="background-color:#CCEEFF;vertical-align:bottom;text-align:right;width:9%" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">3.30</span></span></div></td>
    <td colspan="1" style="background-color:#CCEEFF;vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="background-color:#CCEEFF;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="background-color:#CCEEFF;vertical-align:bottom;text-align:right;width:9%" valign="bottom">
        <div style="line-height:1.25">&#160;</div>
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">922,080</span></span></div></td>
    <td colspan="1" style="background-color:#CCEEFF;vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td></tr>
  </table>

<div style="line-height:1.25">&#160;</div>

<div style="clear:both;margin-top:10pt;margin-bottom:10pt">

<div style="text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:normal;font-style:normal">141</span></span></span></div>

<div style="page-break-after:always"><hr style="border-width:0px;clear:both;margin:4px 0px;width:100%;height:2px;color:#000000;background-color:#000000" /></div></div>

<table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">
  <tr>
    <td style="vertical-align:top;width:65pt">
        <div style="line-height:1.25;font-weight:bold"><span id="ITEM13_integixAnchor"></span><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">ITEM
        13.</span></span></div></td>
    <td style="vertical-align:top;width:auto">
        <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">CERTAIN
        RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE</span></span></div></td></tr>
  </table>

<div style="text-align:justify;line-height:1.25">&#160;</div>

<div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Described
below are any transactions occurring since January 1, 2021, and any currently proposed transactions to which either the Company was a
party and in which:</span></span></div>

<div style="line-height:1.25">&#160;</div>

<table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">
  <tr>
    <td style="width:36pt">&#160;</td>
    <td style="width:36pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">&#8226;</span></span></td>
    <td style="width:auto;vertical-align:top;text-align:justify">
        <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The amounts involved exceeded or will exceed the
        lesser of&#8201; (i) $120,000 and (ii) one percent of the average of the Company&#8217;s total assets at year-end for the last two completed
        fiscal years; and</span></span></div>
        <div>&#160;</div></td></tr>
  </table>

<table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">
  <tr>
    <td style="width:36pt">&#160;</td>
    <td style="width:36pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">&#8226;</span></span></td>
    <td style="width:auto;vertical-align:top;text-align:justify">
        <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">A director, executive officer, holder of more
        than 5% of the outstanding share capital of the Company, or any member of such person&#8217;s immediate family had or will have a direct
        or indirect material interest.</span></span></div></td></tr>
  </table>

<div style="line-height:1.25">&#160;</div>

<div style="text-align:justify;line-height:1.25;font-style:italic;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Indemnification
Agreements with Directors</span></span></div>

<div style="line-height:1.25">&#160;</div>

<div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Our
Articles provide that we may indemnify each of our directors and officers to the fullest extent permitted by the Companies law. Accordingly,
we have entered into standard indemnification agreements with each of our directors, whereby we have undertaken to indemnify each such
director, in advance, for losses, damages, costs or expenses that such director may suffer or incur as a result of his or her actions
or omissions in such capacity on behalf of the Company in certain circumstances and events, subject to the terms, conditions and limitations
set out in the indemnification agreement.</span></span></div>

<div style="line-height:1.25">&#160;</div>

<div style="text-align:justify;line-height:1.25;font-style:italic;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Approval
of Related Party Transactions</span></span></div>

<div style="line-height:1.25">&#160;</div>

<div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The
Companies Law requires that an &#8220;office holder&#8221; (as defined in the Companies Law) of a company promptly disclose any personal
interest that he or she may have and all related material information known to him or her, in connection with any existing or proposed
transaction of the company.<br />&#160;</span></span></div>

<div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Pursuant
to the Companies Law, any transaction with an office holder or in which the office holder has a personal interest must be brought before
the Audit Committee, in order to determine whether such transaction is an Extraordinary Transaction.</span></span></div>

<div style="line-height:1.25">&#160;</div>

<div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Pursuant
to the Companies Law, our Articles and Entera written policy, in the event that the Audit Committee determines that the transaction is
not an Extraordinary Transaction, the transaction will require only Audit Committee approval; if, however, it is determined to be an Extraordinary
Transaction, Board approval is also required and, in some circumstances, shareholder approval may also be required. Such a transaction
may only be approved if it is determined to be in the best interests of Entera.</span></span></div>

<div style="line-height:1.25">&#160;</div>

<div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">A
person with a personal interest in the matter generally may not be present at meetings of the Board or certain committees where the matter
is being considered and, if a member of the Board or a committee, may generally not vote on the matter.</span></span></div>

<div style="line-height:1.25">&#160;</div>

<div style="text-align:justify;line-height:1.25;font-style:italic;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Transactions
with Controlling Shareholders</span></span></div>

<div style="line-height:1.25">&#160;</div>

<div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Under
the Companies law, Extraordinary Transactions with a controlling shareholder, or in which the controlling shareholder has a personal interest,
and any engagement with a controlling shareholder, or a controlling shareholder&#8217;s relative, with respect to the provision of services
to the company or their Terms of Office and Employment as an office holder or their employment, if they are not an office holder, generally
require the approval of the Audit Committee (or with respect to Terms of Office and Employment, the Compensation Committee), the Board
of Directors and the shareholders. If required, shareholder approval must include (i) at least a majority of the shareholders who do not
have a personal interest in the transaction and are present and voting at the meeting (abstentions are disregarded), or, alternatively,
that (ii) the total shareholdings of the disinterested shareholders who vote against the transaction do not represent more than two percent
of the voting rights in the company. Transactions for a period of more than three years generally need to be brought for approval in accordance
with the above procedures every three years. A shareholder who holds 25% or more of the voting rights in a company is considered a controlling
shareholder for these purposes if no other shareholder holds more than 50% of the voting rights. If two or more shareholders are interested
parties in the same transaction, their shareholdings are combined for the purposes of calculating percentages.</span></span></div>

<div style="line-height:1.25">&#160;</div>

<div style="clear:both;margin-top:10pt;margin-bottom:10pt">

<div style="text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:normal;font-style:normal">142</span></span></span></div>

<div style="page-break-after:always"><hr style="border-width:0px;clear:both;margin:4px 0px;width:100%;height:2px;color:#000000;background-color:#000000" /></div></div>

<div style="text-align:justify;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Independent
Directors</span></span></div>

<div style="line-height:1.25">&#160;</div>

<div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Our
Board undertook a review of the independence of each director. Based on information provided by each director concerning his or her background,
employment, and affiliations, our Board has determined that the Board meets independence standards under the applicable rules and regulations
of the SEC and the listing standards of Nasdaq. The Board has affirmatively determined that the following Directors are &#8220;independent&#8221;
as of the date of this Annual Report as defined in the listing standards of Nasdaq: Gerald Lieberman, Ron Mayron, Gerald M. Ostrov, Sean
Ellis and Yonatan Malca. In making these determinations, our Board considered the current and prior relationships that each non-employee
director has with our Company and all other facts and circumstances our Board deemed relevant in determining their independence, including
the beneficial ownership of our capital stock by each non-employee director, and the transactions involving them described in this Item
13.</span></span></div>

<div style="line-height:1.25">&#160;</div>

<div style="line-height:1.25"><span id="ITEM14_integixAnchor"></span><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">I</span></span></span><span style="color:#000000;font-family:Times New Roman, Times, serif;font-size:13.3333px;font-style:normal;font-variant-ligatures:normal;text-align:left;white-space:normal;background-color:#ffffff;text-decoration-thickness:initial;text-decoration-style:initial;text-decoration-color:initial;font-weight:bold">TEM
14.</span>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<span style="color:#000000;font-family:Times New Roman, Times, serif;font-size:13.3333px;font-style:normal;font-variant-ligatures:normal;text-align:left;white-space:normal;background-color:#ffffff;text-decoration-thickness:initial;text-decoration-style:initial;text-decoration-color:initial;font-weight:bold">PRINCIPAL
ACCOUNTING FEES AND SERVICES</span></div>

<div style="text-align:justify;line-height:1.25"><br /><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Kesselman
&#38; Kesselman (a member firm of PricewaterhouseCoopers International Limited, or PwC) has served as our independent registered public
accounting firm for 2022 and 2021. The following table sets forth fees billed to us by our independent registered public accounting firm
during the fiscal years ended December 31, 2022 and 2021 for (i) services rendered for the audit of our annual financial statements and
the review of our quarterly financial statements; (ii) services by our independent registered public accounting firm that are reasonably
related to the performance of the audit or review of our financial statements and that are not reported as Audit Fees; (iii) services
rendered during the period in connection with tax compliance, tax advice and tax planning; and (iv) all other fees for services rendered.</span></span></div>

<div style="line-height:1.25">&#160;</div>

<table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left;color:#000000;width:100%">
  <tr>
    <td style="vertical-align:bottom;padding-bottom:2px" valign="bottom">
        <div style="line-height:1.25">&#160;</div>
        <div style="line-height:1.25">&#160;</div></td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td>
    <td colspan="6" style="vertical-align:bottom;border-bottom:#000000 solid 2px" valign="bottom">
        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Year
        Ended<br />December 31,</span></span></div></td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td></tr>
  <tr>
    <td style="vertical-align:bottom;padding-bottom:2px" valign="bottom">
        <div style="line-height:1.25">&#160;</div></td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px" valign="bottom">
        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2022</span></span></div></td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px" valign="bottom">
        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2021</span></span></div></td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td></tr>
  <tr>
    <td style="vertical-align:bottom;background-color:#CCEEFF;width:76%" valign="bottom">
        <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Audit
        fees (1)</span></span></div></td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="background-color:#CCEEFF;vertical-align:bottom;width:1%" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div></td>
    <td colspan="1" style="background-color:#CCEEFF;vertical-align:bottom;text-align:right;width:9%" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">194,000</span></span></div></td>
    <td colspan="1" style="background-color:#CCEEFF;vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="background-color:#CCEEFF;vertical-align:bottom;width:1%" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div></td>
    <td colspan="1" style="background-color:#CCEEFF;vertical-align:bottom;text-align:right;width:9%" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">190,000</span></span></div></td>
    <td colspan="1" style="background-color:#CCEEFF;vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td></tr>
  <tr>
    <td style="vertical-align:bottom;width:76%" valign="bottom">
        <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Tax
        fees(2)</span></span></div></td>
    <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">7,500</span></span></div></td>
    <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">6,500</span></span></div></td>
    <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td></tr>
  <tr>
    <td style="vertical-align:bottom;background-color:#CCEEFF;width:76%;padding-bottom:2px" valign="bottom">
        <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Total
        fees</span></span></div></td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="background-color:#CCEEFF;vertical-align:bottom;width:1%;border-bottom:#000000 solid 2px" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div></td>
    <td colspan="1" style="background-color:#CCEEFF;vertical-align:bottom;text-align:right;width:9%;border-bottom:#000000 solid 2px" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">201,500</span></span></div></td>
    <td colspan="1" style="background-color:#CCEEFF;vertical-align:bottom;width:1%;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="background-color:#CCEEFF;vertical-align:bottom;width:1%;border-bottom:#000000 solid 2px" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div></td>
    <td colspan="1" style="background-color:#CCEEFF;vertical-align:bottom;text-align:right;width:9%;border-bottom:#000000 solid 2px" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">196,500</span></span></div></td>
    <td colspan="1" style="background-color:#CCEEFF;vertical-align:bottom;width:1%;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td></tr>
  </table>

<div style="line-height:1.25">&#160;</div>

<table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">
  <tr>
    <td style="width:2.5%;vertical-align:top">
        <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(1)</span></span></div></td>
    <td style="width:97.5%;vertical-align:top">
        <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Includes
        professional services rendered in connection with the audit of our annual financial statements and the review of our interim financial
        statements and services related to certain registration statements.</span></span></div></td></tr>
  <tr>
    <td rowspan="1" style="width:2.5%;vertical-align:top">&#160;</td>
    <td rowspan="1" style="width:97.5%;vertical-align:top">&#160;</td></tr>
  <tr>
    <td style="width:2.5%;vertical-align:top">
        <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(2)</span></span></div></td>
    <td style="width:97.5%;vertical-align:top">
        <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Tax
        consulting services.</span></span></div></td></tr>
  </table>

<div style="text-align:justify;line-height:1.25;font-weight:bold">&#160;</div>

<div style="text-align:justify;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Audit
Committee Pre-approval Policies and Procedures</span></span></div>

<div style="line-height:1.25">&#160;</div>

<div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Our
Audit Committee is responsible for pre-approving audit and non-audit services provided to us by our independent registered public accounting
firm. All of the non-audit services provided to us by the independent auditors following the formation of our Audit Committee were pre-approved
by the Audit Committee.</span></span></div>

<div style="line-height:1.25"><br /><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">&#160;<br />&#160;</span></span></div>

<div style="clear:both;margin-top:10pt;margin-bottom:10pt">

<div style="text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:normal;font-style:normal">143</span></span></span></div>

<div style="page-break-after:always"><hr style="border-width:0px;clear:both;margin:4px 0px;width:100%;height:2px;color:#000000;background-color:#000000" /></div></div>

<div style="text-align:center;line-height:1.25;font-weight:bold"><span id="PARTIV_integixAnchor"></span><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">PART
IV.</span></span></div>

<div style="line-height:1.25">&#160;</div>

<table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">
  <tr>
    <td style="vertical-align:top;width:65pt">
        <div style="line-height:1.25;font-weight:bold"><span id="Item15_integixAnchor"></span><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Item
        15.</span></span></div></td>
    <td style="vertical-align:top;width:auto">
        <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">EXHIBITS,
        FINANCIAL STATEMENT SCHEDULES.</span></span></div></td></tr>
  </table>

<div style="line-height:1.25">&#160;</div>

<table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">
  <tr>
    <td colspan="1" style="width:3%;vertical-align:top">&#160;</td>
    <td style="width:3%;vertical-align:top">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(a)</span></span></div></td>
    <td style="width:94%;vertical-align:top">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Documents filed as part
        of this report:</span></span></div></td></tr>
  </table>

<div style="line-height:1.25">&#160;</div>

<table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">
  <tr>
    <td colspan="1" style="width:6%;vertical-align:top">&#160;</td>
    <td style="width:3%;vertical-align:top">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(1)</span></span></div></td>
    <td style="width:91%;vertical-align:top">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Financial statements</span></span></div>
        <div style="line-height:1.25">&#160;</div>
        <div style="line-height:1.25">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">See Item 8 for Financial
        Statements included with this Annual Report.</span></span></div></div></td></tr>
  </table>

<div style="line-height:1.25">&#160;</div>

<table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">
  <tr>
    <td colspan="1" style="width:6%;vertical-align:top">&#160;</td>
    <td style="width:3%;vertical-align:top">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(2)</span></span></div></td>
    <td style="width:91%;vertical-align:top">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Financial Statement Schedules</span></span></div>
        <div style="line-height:1.25">&#160;</div>
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">None.</span></span></div></div></td></tr>
  </table>

<div style="text-indent:36pt;margin-left:36pt;line-height:1.25">&#160;</div>

<div style="line-height:1.25">

<table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">
  <tr>
    <td colspan="1" style="width:6%;vertical-align:top">&#160;</td>
    <td style="width:3%;vertical-align:top">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(3)</span></span></div></td>
    <td style="width:91%;vertical-align:top">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Exhibits: See below.</span></span></div></td></tr>
  </table>

<div style="text-indent:36pt;margin-left:36pt;line-height:1.25">&#160;</div></div>

<div style="clear:both;margin-top:10pt;margin-bottom:10pt">

<div style="text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:normal;font-style:normal">144</span></span></span></div>

<div style="page-break-after:always"><hr style="border-width:0px;clear:both;margin:4px 0px;width:100%;height:2px;color:#000000;background-color:#000000" /></div></div>

<div style="line-height:1.25">&#160;</div>

<div>

<div>

<table border="0" cellpadding="1" cellspacing="0" style="font-family:'Times New Roman',Times,serif;font-size:10pt;width:100%;text-align:left;color:rgb(0, 0, 0)">
  <tr>
    <td style="width:8%;vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0)">
        <div style="line-height:1.25;font-family:'Times New Roman', Times, serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Exhibit
        No.</span></span></div></td>
    <td colspan="1" style="width:2%;vertical-align:bottom;padding-bottom:2px">&#160;</td>
    <td style="vertical-align:bottom;width:90%;border-bottom:2px solid rgb(0, 0, 0)">
        <div style="text-align:center;line-height:1.25;font-family:'Times New Roman', Times, serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Description</span></span></div></td></tr>
  <tr>
    <td style="width:8%;vertical-align:top">
        <div style="line-height:1.25;font-family:'Times New Roman', Times, serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="https://www.sec.gov/Archives/edgar/data/1638097/000117891321001087/exhibit_1-1.htm">3.1</a></span></span></div></td>
    <td colspan="1" style="width:2%;vertical-align:top">&#160;</td>
    <td style="vertical-align:top;width:90%">
        <div style="text-align:justify;line-height:1.25;font-family:'Times New Roman', Times, serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="https://www.sec.gov/Archives/edgar/data/1638097/000117891321001087/exhibit_1-1.htm">Amended
        and Restated Articles of Association of Entera Bio Ltd. (incorporated by reference to Exhibit 1.1 to the Form 20-F, filed with the SEC
        on March 18, 2021).</a></span></span></div></td></tr>
  <tr>
    <td style="width:8%;vertical-align:top">
        <div style="line-height:1.25;font-family:'Times New Roman', Times, serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="https://www.sec.gov/Archives/edgar/data/1638097/000117891321001087/exhibit_2-2.htm">4.1</a></span></span></div></td>
    <td colspan="1" style="width:2%;vertical-align:top">&#160;</td>
    <td style="vertical-align:top;width:90%">
        <div style="text-align:justify;line-height:1.25;font-family:'Times New Roman', Times, serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="https://www.sec.gov/Archives/edgar/data/1638097/000117891321001087/exhibit_2-2.htm">Description
        of rights of each applicable class of securities registered under Section 12 of the Securities Exchange Act of 1934 (incorporated by reference
        to Exhibit 2.2 to the Form 20-F filed with the SEC on March 18, 2021).</a></span></span></div></td></tr>
  <tr>
    <td style="width:8%;vertical-align:top">
        <div style="line-height:1.25;font-family:'Times New Roman', Times, serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="https://www.sec.gov/Archives/edgar/data/1638097/000095010317011026/dp82654_ex0401.htm">4.2</a></span></span></div></td>
    <td colspan="1" style="width:2%;vertical-align:top">&#160;</td>
    <td style="vertical-align:top;width:90%">
        <div style="text-align:justify;line-height:1.25;font-family:'Times New Roman', Times, serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="https://www.sec.gov/Archives/edgar/data/1638097/000095010317011026/dp82654_ex0401.htm">Specimen
        Form of Ordinary Share Certificate (incorporated by reference to Exhibit 4.1 to the Registration Statement on Form F-1 (File No. 333-221472)
        filed with the SEC on November 9, 2017)</a></span></span></div></td></tr>
  <tr>
    <td style="width:8%;vertical-align:top">
        <div style="line-height:1.25;font-family:'Times New Roman', Times, serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="https://www.sec.gov/Archives/edgar/data/1638097/000095010318006271/dp89252_ex0402.htm">4.3</a></span></span></div></td>
    <td colspan="1" style="width:2%;vertical-align:top">&#160;</td>
    <td style="vertical-align:top;width:90%">
        <div style="text-align:justify;line-height:1.25;font-family:'Times New Roman', Times, serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="https://www.sec.gov/Archives/edgar/data/1638097/000095010318006271/dp89252_ex0402.htm">Form
        of IPO Warrant (incorporated herein by reference to Exhibit 4.2 to the Company&#8217;s Registration Statement on Form F-1 (File No. 333-221472)
        filed with the SEC on May 17, 2018)</a></span></span></div></td></tr>
  <tr>
    <td style="width:8%;vertical-align:top">
        <div style="line-height:1.25;font-family:'Times New Roman', Times, serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="https://www.sec.gov/Archives/edgar/data/1638097/000095010318006271/dp89252_ex0403.htm">4.4</a></span></span></div></td>
    <td colspan="1" style="width:2%;vertical-align:top">&#160;</td>
    <td style="vertical-align:top;width:90%">
        <div style="text-align:justify;line-height:1.25;font-family:'Times New Roman', Times, serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="https://www.sec.gov/Archives/edgar/data/1638097/000095010318006271/dp89252_ex0403.htm">Form
        of Underwriter Warrant issued by the Registrant to Maxim Group LLC (incorporated by reference to Exhibit 4.3 to the Registration Statement
        on Form F-1 (File No. 333-221472) filed with the SEC on May 17, 2018)</a></span></span></div></td></tr>
  <tr>
    <td style="width:8%;vertical-align:top">
        <div style="line-height:1.25;font-family:'Times New Roman', Times, serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="https://www.sec.gov/Archives/edgar/data/1638097/000095010317011026/dp82654_ex0405.htm">4.5</a></span></span></div></td>
    <td colspan="1" style="width:2%;vertical-align:top">&#160;</td>
    <td style="vertical-align:top;width:90%">
        <div style="text-align:justify;line-height:1.25;font-family:'Times New Roman', Times, serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="https://www.sec.gov/Archives/edgar/data/1638097/000095010317011026/dp82654_ex0405.htm">Form
        of Warrant issued by the Registrant to GP Nurmenkari Inc. (incorporated by reference to Exhibit 4.5 to the Registration Statement on Form
        F-1 (File No. 333-221472) filed with the SEC on November 9, 2017)</a></span></span></div></td></tr>
  <tr>
    <td style="width:8%;vertical-align:top">
        <div style="line-height:1.25;font-family:'Times New Roman', Times, serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="https://www.sec.gov/Archives/edgar/data/1638097/000095010317011026/dp82654_ex1010.htm">10.1</a></span></span></div></td>
    <td colspan="1" style="width:2%;vertical-align:top">&#160;</td>
    <td style="vertical-align:top;width:90%">
        <div style="text-align:justify;line-height:1.25;font-family:'Times New Roman', Times, serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="https://www.sec.gov/Archives/edgar/data/1638097/000095010317011026/dp82654_ex1010.htm">Amended
        and Restated Investor&#8217;s Rights Agreement, dated as of October 4, 2017, between the Registrant and the other parties thereto (incorporated
        by reference to Exhibit 10.10 to the Registration Statement on Form F-1 (File No. 333-221472) filed with the SEC on November 9, 2017)</a></span></span></div></td></tr>
  <tr>
    <td style="width:8%;vertical-align:top">
        <div style="line-height:1.25;font-family:'Times New Roman', Times, serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="https://www.sec.gov/Archives/edgar/data/1638097/000095010317011026/dp82654_ex1001.htm">10.2</a></span></span></div></td>
    <td colspan="1" style="width:2%;vertical-align:top">&#160;</td>
    <td style="vertical-align:top;width:90%">
        <div style="text-align:justify;line-height:1.25;font-family:'Times New Roman', Times, serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="https://www.sec.gov/Archives/edgar/data/1638097/000095010317011026/dp82654_ex1001.htm">Patent
        Transfer Agreement, dated as of February 22, 2011, between the Registrant and Oramed Ltd. (incorporated by reference to Exhibit 10.1 to
        the Registration Statement on Form F-1 (File No. 333-221472) filed with the SEC on November 9, 2017)</a></span></span></div></td></tr>
  <tr>
    <td style="width:8%;vertical-align:top">
        <div style="line-height:1.25;font-family:'Times New Roman', Times, serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="https://www.sec.gov/Archives/edgar/data/1638097/000114420418034345/tv496350_ex10-18.htm">10.3</a></span></span></div></td>
    <td colspan="1" style="width:2%;vertical-align:top">&#160;</td>
    <td style="vertical-align:top;width:90%">
        <div style="text-align:justify;line-height:1.25;font-family:'Times New Roman', Times, serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="https://www.sec.gov/Archives/edgar/data/1638097/000114420418034345/tv496350_ex10-18.htm">Form
        of Warrant Agency Agreement (incorporated by reference to Exhibit 10.18 to the Registration Statement on Form F-1 (File No. 333-221472)
        filed with the SEC on June 15, 2018)</a></span></span></div></td></tr>
  <tr>
    <td style="width:8%;vertical-align:top">
        <div style="line-height:1.25;font-family:'Times New Roman', Times, serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="https://www.sec.gov/Archives/edgar/data/1638097/000117891320000939/exhibit_4-25.htm">10.4</a></span></span></div></td>
    <td colspan="1" style="width:2%;vertical-align:top">&#160;</td>
    <td style="vertical-align:top;width:90%">
        <div style="text-align:justify;line-height:1.25;font-family:'Times New Roman', Times, serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="https://www.sec.gov/Archives/edgar/data/1638097/000117891320000939/exhibit_4-25.htm">Form
        of Regulation D Private Placement Subscription Agreement (incorporated by reference to Exhibit 4.25 to the Form 20-F filed with the SEC
        on March 18, 2021).</a></span></span></div></td></tr>
  <tr>
    <td style="width:8%;vertical-align:top">
        <div style="line-height:1.25;font-family:'Times New Roman', Times, serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="https://www.sec.gov/Archives/edgar/data/1638097/000117891320000939/exhibit_4-26.htm">10.5</a></span></span></div></td>
    <td colspan="1" style="width:2%;vertical-align:top">&#160;</td>
    <td style="vertical-align:top;width:90%">
        <div style="text-align:justify;line-height:1.25;font-family:'Times New Roman', Times, serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="https://www.sec.gov/Archives/edgar/data/1638097/000117891320000939/exhibit_4-26.htm">Subscription
        Agreement, dated December 13, 2019, between the Registrant and D.N.A Biomedical Solutions Ltd. (incorporated by reference to Exhibit 4.26
        to the Form 20-F filed with the SEC on March 18, 2021).</a></span></span></div></td></tr>
  <tr>
    <td style="width:8%;vertical-align:top">
        <div style="line-height:1.25;font-family:'Times New Roman', Times, serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="https://www.sec.gov/Archives/edgar/data/1638097/000117891320000939/exhibit_4-28.htm">10.6</a></span></span></div></td>
    <td colspan="1" style="width:2%;vertical-align:top">&#160;</td>
    <td style="vertical-align:top;width:90%">
        <div style="text-align:justify;line-height:1.25;font-family:'Times New Roman', Times, serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="https://www.sec.gov/Archives/edgar/data/1638097/000117891320000939/exhibit_4-28.htm">Registration
        Rights Agreement, dated December 10, 2019, between the Registrant and the other parties thereto (incorporated by reference to Exhibit
        4.28 to the Form 20-F filed with the SEC on March 18, 2021).</a></span></span></div></td></tr>
  <tr>
    <td style="width:8%;vertical-align:top">
        <div style="line-height:1.25;font-family:'Times New Roman', Times, serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="https://www.sec.gov/Archives/edgar/data/1638097/000117891321002124/exhibit_1-1.htm">10.7</a></span></span></div></td>
    <td colspan="1" style="width:2%;vertical-align:top">&#160;</td>
    <td style="vertical-align:top;width:90%">
        <div style="text-align:justify;line-height:1.25;font-family:'Times New Roman', Times, serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="https://www.sec.gov/Archives/edgar/data/1638097/000117891321002124/exhibit_1-1.htm">Sales
        Agreement, dated September 2, 2022, between Entera Bio. Ltd. and SVB Securities LLC (incorporated by reference to Exhibit 10.1 to the
        Form 8-K filed with the SEC on September 2, 2022)</a></span></span></div></td></tr>
  <tr>
    <td style="width:8%;vertical-align:top">
        <div style="line-height:1.25;font-family:'Times New Roman', Times, serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="https://www.sec.gov/Archives/edgar/data/1638097/000095010319004878/dp105233_ex0428.htm">10.8&#8224;&#8224;</a></span></span></div></td>
    <td colspan="1" style="width:2%;vertical-align:top">&#160;</td>
    <td style="vertical-align:top;width:90%">
        <div style="text-align:justify;line-height:1.25;font-family:'Times New Roman', Times, serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="https://www.sec.gov/Archives/edgar/data/1638097/000095010319004878/dp105233_ex0428.htm">Research
        Collaboration and License Agreement, dated as of December 10, 2018, between Amgen Inc. and Entera Bio Ltd. (incorporated by reference
        to Exhibit 4.28 to the Amended Annual Report on Form 20-F/A (File No. 001-38556) filed with the SEC on April 17, 2019)</a></span></span></div></td></tr>
  <tr>
    <td style="width:8%;vertical-align:top">
        <div style="line-height:1.25;font-family:'Times New Roman', Times, serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="https://www.sec.gov/Archives/edgar/data/1638097/000095010317011366/dp82999_ex1012.htm">10.9&#8224;</a></span></span></div></td>
    <td colspan="1" style="width:2%;vertical-align:top">&#160;</td>
    <td style="vertical-align:top;width:90%">
        <div style="text-align:justify;line-height:1.25;font-family:'Times New Roman', Times, serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="https://www.sec.gov/Archives/edgar/data/1638097/000095010317011366/dp82999_ex1012.htm">Form
        of indemnification agreement between the Registrant and its directors and executive officers (incorporated by reference to Exhibit 10.12
        to the Registration Statement on Form F-1 (File No. 333-221472) filed with the SEC on November 20, 2017)</a></span></span></div></td></tr>
  <tr>
    <td style="width:8%;vertical-align:top">
        <div style="line-height:1.25;font-family:'Times New Roman', Times, serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="https://www.sec.gov/Archives/edgar/data/1638097/000095010317011026/dp82654_ex1004.htm">10.10&#8224;</a></span></span></div></td>
    <td colspan="1" style="width:2%;vertical-align:top">&#160;</td>
    <td style="vertical-align:top;width:90%">
        <div style="text-align:justify;line-height:1.25;font-family:'Times New Roman', Times, serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="https://www.sec.gov/Archives/edgar/data/1638097/000095010317011026/dp82654_ex1004.htm">The
        Entera Bio Ltd. Share Incentive Plan (incorporated by reference to Exhibit 10.4 to the Registration Statement on Form F-1 (File No. 333-221472)
        filed with the SEC on November 9, 2017)</a></span></span></div></td></tr>
  <tr>
    <td style="width:8%;vertical-align:top">
        <div style="line-height:1.25;font-family:'Times New Roman', Times, serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="https://www.sec.gov/Archives/edgar/data/1638097/000095010318010965/dp95859_ex99.htm">10.11&#8224;</a></span></span></div></td>
    <td colspan="1" style="width:2%;vertical-align:top">&#160;</td>
    <td style="vertical-align:top;width:90%">
        <div style="text-align:justify;line-height:1.25;font-family:'Times New Roman', Times, serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="https://www.sec.gov/Archives/edgar/data/1638097/000095010318010965/dp95859_ex99.htm">2018
        Equity Incentive Plan (incorporated by reference to Exhibit 99 to the Registration Statement on Form S-8 (File No. 333-227488) filed with
        the SEC on September 24, 2018)</a></span></span></div></td></tr>
  <tr>
    <td style="width:8%;vertical-align:top">
        <div style="line-height:1.25;font-family:'Times New Roman', Times, serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="https://www.sec.gov/Archives/edgar/data/1638097/000117891319000961/exhibit_4-25.htm">10.12&#8224;</a></span></span></div></td>
    <td colspan="1" style="width:2%;vertical-align:top">&#160;</td>
    <td style="vertical-align:top;width:90%">
        <div style="text-align:justify;line-height:1.25;font-family:'Times New Roman', Times, serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="https://www.sec.gov/Archives/edgar/data/1638097/000117891319000961/exhibit_4-25.htm">Form
        of Stock Option Award Agreement under the 2018 Equity Incentive Plan (incorporated by reference to Exhibit 4.25 to the Annual Report on
        Form 20-F (File No. 001-38556) filed with the SEC on March 28, 2019)</a></span></span></div></td></tr>
  <tr>
    <td style="width:8%;vertical-align:top">
        <div style="line-height:1.25;font-family:'Times New Roman', Times, serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="https://www.sec.gov/Archives/edgar/data/1638097/000117891322002674/exhibit_10-1.htm">10.13&#8224;</a></span></span></div></td>
    <td colspan="1" style="width:2%;vertical-align:top">&#160;</td>
    <td style="vertical-align:top;width:90%">
        <div style="text-align:justify;line-height:1.25;font-family:'Times New Roman', Times, serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="https://www.sec.gov/Archives/edgar/data/1638097/000117891322002674/exhibit_10-1.htm">Amended
        and Restated Employment Agreement, dated July 15, 2022, by and between Entera Bio Ltd. and Miranda Toledano (incorporated by reference
        to Exhibit 10.1 to the Form 8-K filed with the SEC on July 18, 2022)</a></span></span></div></td></tr>
  <tr>
    <td style="width:8%;vertical-align:top">
        <div style="line-height:1.25;font-family:'Times New Roman', Times, serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="exhibit_10-14.htm">10.14&#8224;</a></span></span></div></td>
    <td colspan="1" style="width:2%;vertical-align:top">&#160;</td>
    <td style="vertical-align:top;width:90%">
        <div style="text-align:justify;line-height:1.25;font-family:'Times New Roman', Times, serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="exhibit_10-14.htm">Consulting
        agreement, dated June 2, 2019, between Entera Bio Ltd. and Dana Yaacov Garbeli (through A2Z Finance Ltd.), as amended.</a></span></span></div></td></tr>
  </table>

<div>&#160;</div>

<div style="clear:both;margin-top:10pt;margin-bottom:10pt">

<div style="text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:normal;font-style:normal">145</span></span></span></div>

<div style="page-break-after:always"><hr style="border-width:0px;clear:both;margin:4px 0px;width:100%;height:2px;color:#000000;background-color:#000000" /></div></div>

<table border="0" cellpadding="1" cellspacing="0" style="font-family:'Times New Roman',Times,serif;font-size:10pt;width:100%;text-align:left;color:rgb(0, 0, 0)">
  <tr>
    <td style="width:8%;vertical-align:top">
        <div style="line-height:1.25;font-family:'Times New Roman', Times, serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="exhibit_10-15.htm">10.15&#8224;</a></span></span></div></td>
    <td colspan="1" style="width:2%;vertical-align:top">&#160;</td>
    <td style="vertical-align:top;width:90%">
        <div style="text-align:justify;line-height:1.25;font-family:'Times New Roman', Times, serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="exhibit_10-15.htm">Employment
        Agreement, dated as of June 8, 2014, between Entera Bio Ltd. and Dr. Hillel Galitzer, as amended.</a></span></span></div></td></tr>
  <tr>
    <td style="width:8%;vertical-align:top">
        <div style="line-height:1.25;font-family:'Times New Roman', Times, serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="https://www.sec.gov/Archives/edgar/data/1638097/000117891321001087/exhibit_4-30.htm">10.16&#8224;</a></span></span></div></td>
    <td colspan="1" style="width:2%;vertical-align:top">&#160;</td>
    <td style="vertical-align:top;width:90%">
        <div style="text-align:justify;line-height:1.25;font-family:'Times New Roman', Times, serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="https://www.sec.gov/Archives/edgar/data/1638097/000117891321001087/exhibit_4-30.htm">Employment
        Agreement, dated as of January 4, 2021 between Entera Bio Ltd. and Dr. Spiros Jamas (incorporated by reference to Exhibit 4.30 to the
        Form 20-F, filed with the SEC on March 18, 2021).</a></span></span></div></td></tr>
  <tr>
    <td style="width:8%;vertical-align:top">
        <div style="line-height:1.25;font-family:'Times New Roman', Times, serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="https://www.sec.gov/Archives/edgar/data/1638097/000117891322002674/exhibit_10-2.htm">10.17&#8224;</a></span></span></div></td>
    <td colspan="1" style="width:2%;vertical-align:top">&#160;</td>
    <td style="vertical-align:top;width:90%">
        <div style="text-align:justify;line-height:1.25;font-family:'Times New Roman', Times, serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="https://www.sec.gov/Archives/edgar/data/1638097/000117891322002674/exhibit_10-2.htm">Mutual
        Separation Agreement, dated July 13, 2022, by and between Entera Bio Ltd. and Dr. Spiros Jamas (incorporated by reference to Exhibit 10.2
        to the Form 8-K filed with the SEC on July 18, 2022)</a></span></span></div></td></tr>
  <tr>
    <td style="width:8%;vertical-align:top">
        <div style="line-height:1.25;font-family:'Times New Roman', Times, serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="https://www.sec.gov/Archives/edgar/data/1638097/000117891322002398/exhibit_10-1.htm">10.18&#8224;</a></span></span></div></td>
    <td colspan="1" style="width:2%;vertical-align:top">&#160;</td>
    <td style="vertical-align:top;width:90%">
        <div style="text-align:justify;line-height:1.25;font-family:'Times New Roman', Times, serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="https://www.sec.gov/Archives/edgar/data/1638097/000117891322002398/exhibit_10-1.htm">Mutual
        Separation Agreement, dated June 15, 2022, by and between Entera Bio Ltd. and Dr. Phillip Schwartz (incorporated by reference to Exhibit
        10.1 to the Form 8-K filed with the SEC on June 17, 2022)</a></span></span></div></td></tr>
  <tr>
    <td style="width:8%;vertical-align:top">
        <div style="line-height:1.25;font-family:'Times New Roman', Times, serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="exhibit_21-1.htm">21.1*</a></span></span></div></td>
    <td colspan="1" style="width:2%;vertical-align:top">&#160;</td>
    <td style="vertical-align:top;width:90%">
        <div style="text-align:justify;line-height:1.25;font-family:'Times New Roman', Times, serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="exhibit_21-1.htm">List
        of Subsidiaries</a></span></span></div></td></tr>
  <tr>
    <td style="width:8%;vertical-align:top">
        <div style="line-height:1.25;font-family:'Times New Roman', Times, serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="exhibit_23-1.htm">23.1*</a></span></span></div></td>
    <td colspan="1" style="width:2%;vertical-align:top">&#160;</td>
    <td style="vertical-align:top;width:90%">
        <div style="text-align:justify;line-height:1.25;font-family:'Times New Roman', Times, serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="exhibit_23-1.htm">Consent
        of Kesselman &#38; Kesselman, an independent registered public accounting firm in Israel and a member of PricewaterhouseCoopers International
        Limited.</a></span></span></div></td></tr>
  <tr>
    <td style="width:8%;vertical-align:top">
        <div style="line-height:1.25;font-family:'Times New Roman', Times, serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="exhibit_31-1.htm">31.1*</a></span></span></div></td>
    <td colspan="1" style="width:2%;vertical-align:top">&#160;</td>
    <td style="vertical-align:top;width:90%">
        <div style="text-align:justify;line-height:1.25;font-family:'Times New Roman', Times, serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="exhibit_31-1.htm">Certification
        of Principal Executive Officer of Entera Bio Ltd. pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</a></span></span></div></td></tr>
  <tr>
    <td style="width:8%;vertical-align:top">
        <div style="line-height:1.25;font-family:'Times New Roman', Times, serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="exhibit_31-2.htm">31.2*</a></span></span></div></td>
    <td colspan="1" style="width:2%;vertical-align:top">&#160;</td>
    <td style="vertical-align:top;width:90%">
        <div style="text-align:justify;line-height:1.25;font-family:'Times New Roman', Times, serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="exhibit_31-2.htm">Certification
        of Principal Financial and Accounting Officer of Entera Bio Ltd. pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</a></span></span></div></td></tr>
  <tr>
    <td style="width:8%;vertical-align:top">
        <div style="line-height:1.25;font-family:'Times New Roman', Times, serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="exhibit_32-1.htm">32.1**</a></span></span></div></td>
    <td colspan="1" style="width:2%;vertical-align:top">&#160;</td>
    <td style="vertical-align:top;width:90%">
        <div style="text-align:justify;line-height:1.25;font-family:'Times New Roman', Times, serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="exhibit_32-1.htm">Certification
        of Principal Executive Officer of Entera Bio Ltd. pursuant to Section 906 of the Sarbanes-Oxley act of 2002</a></span></span></div></td></tr>
  <tr>
    <td style="width:8%;vertical-align:top">
        <div style="line-height:1.25;font-family:'Times New Roman', Times, serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="exhibit_32-2.htm">32.2**</a></span></span></div></td>
    <td colspan="1" style="width:2%;vertical-align:top">&#160;</td>
    <td style="vertical-align:top;width:90%">
        <div style="text-align:justify;line-height:1.25;font-family:'Times New Roman', Times, serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="exhibit_32-2.htm">Certification
        of Principal Financial and Accounting Officer of Entera Bio Ltd. pursuant to Section 906 of the Sarbanes-Oxley act of 2002</a></span></span></div></td></tr>
  </table>

<div>&#160;</div>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:'Times New Roman',Times,serif;font-size:10pt;width:100%;text-align:left;color:rgb(0, 0, 0)">
  <tr>
    <td style="width:7.98%;vertical-align:top">
        <div style="line-height:1.25;font-family:'Times New Roman', Times, serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">101.INS</span></span></div></td>
    <td style="width:2%;vertical-align:top">
        <div style="line-height:1.25;font-family:'Times New Roman', Times, serif">&#160;</div></td>
    <td style="width:90%;vertical-align:top">
        <div style="line-height:1.25;font-family:'Times New Roman', Times, serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Inline
        XBRL Instance Document</span></span></div></td></tr>
  <tr>
    <td style="width:7.98%;vertical-align:top">
        <div style="line-height:1.25;font-family:'Times New Roman', Times, serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">101.SCH</span></span></div></td>
    <td style="width:2%;vertical-align:top">
        <div style="line-height:1.25;font-family:'Times New Roman', Times, serif">&#160;</div></td>
    <td style="width:90%;vertical-align:top">
        <div style="line-height:1.25;font-family:'Times New Roman', Times, serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Inline
        XBRL Taxonomy Extension Schema Document</span></span></div></td></tr>
  <tr>
    <td style="width:7.98%;vertical-align:top">
        <div style="line-height:1.25;font-family:'Times New Roman', Times, serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">101.CAL</span></span></div></td>
    <td style="width:2%;vertical-align:top">
        <div style="line-height:1.25;font-family:'Times New Roman', Times, serif">&#160;</div></td>
    <td style="width:90%;vertical-align:top">
        <div style="line-height:1.25;font-family:'Times New Roman', Times, serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Inline
        XBRL Taxonomy Extension Calculation Linkbase Document</span></span></div></td></tr>
  <tr>
    <td style="width:7.98%;vertical-align:top">
        <div style="line-height:1.25;font-family:'Times New Roman', Times, serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">101.DEF</span></span></div></td>
    <td style="width:2%;vertical-align:top">
        <div style="line-height:1.25;font-family:'Times New Roman', Times, serif">&#160;</div></td>
    <td style="width:90%;vertical-align:top">
        <div style="line-height:1.25;font-family:'Times New Roman', Times, serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Inline
        XBRL Taxonomy Extension Definition Linkbase Document</span></span></div></td></tr>
  <tr>
    <td style="width:7.98%;vertical-align:top">
        <div style="line-height:1.25;font-family:'Times New Roman', Times, serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">101.LAB</span></span></div></td>
    <td style="width:2%;vertical-align:top">
        <div style="line-height:1.25;font-family:'Times New Roman', Times, serif">&#160;</div></td>
    <td style="width:90%;vertical-align:top">
        <div style="line-height:1.25;font-family:'Times New Roman', Times, serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Inline
        XBRL Taxonomy Extension Label Linkbase Document</span></span></div></td></tr>
  <tr>
    <td style="width:7.98%;vertical-align:top">
        <div style="line-height:1.25;font-family:'Times New Roman', Times, serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">101.PRE</span></span></div></td>
    <td style="width:2%;vertical-align:top">
        <div style="line-height:1.25;font-family:'Times New Roman', Times, serif">&#160;</div></td>
    <td style="width:90%;vertical-align:top">
        <div style="line-height:1.25;font-family:'Times New Roman', Times, serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Inline
        XBRL Taxonomy Extension Presentation Linkbase Document</span></span></div></td></tr>
  <tr>
    <td style="width:7.98%;vertical-align:top">
        <div style="line-height:1.25;font-family:'Times New Roman', Times, serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">104</span></span></div></td>
    <td style="width:2%;vertical-align:top">
        <div style="line-height:1.25;font-family:'Times New Roman', Times, serif">&#160;</div></td>
    <td style="width:90%;vertical-align:top">
        <div style="line-height:1.25;font-family:'Times New Roman', Times, serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Inline
        XBRL for the cover page of this Annual Report on Form 10-K, included in the Exhibit 101 Inline XBRL Document Set.</span></span></div></td></tr>
  </table>

<div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">_____________________</span></span></div>

<div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">&#8224; Management contract
or compensatory plan or arrangement.</span></span></div>

<div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">* Filed herewith.</span></span></div>

<div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">** Furnished herewith.</span></span></div>

<div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">&#8224;&#8224; Confidential
treatment granted as to portions of the exhibit. Confidential materials omitted and filed separately with the Securities and Exchange
Commission.</span></span></div></div></div>

<div style="line-height:1.25">&#160;</div>

<table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">
  <tr>
    <td style="vertical-align:top;width:65pt">
        <div style="line-height:1.25;font-weight:bold"><span id="ITEM16_integixAnchor"></span><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">ITEM
        16.</span></span></div></td>
    <td style="vertical-align:top;width:auto">
        <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">FORM
        10-K SUMMARY</span></span></div></td></tr>
  </table>

<div style="line-height:1.25">&#160;</div>

<div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Not
applicable.</span></span></div>

<div style="line-height:1.25">&#160;</div>

<div style="clear:both;margin-top:10pt;margin-bottom:10pt">

<div style="text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:normal;font-style:normal">146</span></span></span></div>

<div style="page-break-after:always"><hr style="border-width:0px;clear:both;margin:4px 0px;width:100%;height:2px;color:#000000;background-color:#000000" /></div></div>

<div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">SIGNATURES</span></span></div>

<div style="line-height:1.25">&#160;</div>

<div style="text-indent:24.5pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Pursuant
to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed
on its behalf by the undersigned, thereunto duly authorized.</span></span></div>

<div style="line-height:1.25">&#160;</div>

<table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">
  <tr>
    <td style="width:50%;vertical-align:bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Date: March 31, 2023</span></span></div></td>
    <td colspan="2" style="vertical-align:bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">ENTERA BIO LTD.</span></span></div></td>
    <td colspan="1" style="width:20%;vertical-align:bottom">&#160;</td></tr>
  <tr>
    <td style="width:50%;vertical-align:bottom">
        <div style="line-height:1.25">&#160;</div></td>
    <td style="width:3%;vertical-align:bottom">
        <div style="line-height:1.25">&#160;</div></td>
    <td style="width:27%;vertical-align:bottom">
        <div style="line-height:1.25">&#160;</div></td>
    <td colspan="1" style="width:20%;vertical-align:bottom">&#160;</td></tr>
  <tr>
    <td style="width:50%;vertical-align:bottom;padding-bottom:2px">
        <div style="line-height:1.25">&#160;</div></td>
    <td style="width:3%;vertical-align:top;padding-bottom:2px">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">By:</span></span></div></td>
    <td style="width:27%;vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0)">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">/s/ Miranda J. Toledano</span></span></div></td>
    <td colspan="1" style="width:20%;vertical-align:bottom;padding-bottom:2px">&#160;</td></tr>
  <tr>
    <td style="width:50%;vertical-align:bottom">
        <div style="line-height:1.25">&#160;</div></td>
    <td style="width:3%;vertical-align:bottom">
        <div style="line-height:1.25">&#160;</div></td>
    <td style="width:27%;vertical-align:bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Miranda J. Toledano</span></span></div></td>
    <td colspan="1" style="width:20%;vertical-align:bottom">&#160;</td></tr>
  <tr>
    <td style="width:50%;vertical-align:bottom">
        <div style="line-height:1.25">&#160;</div></td>
    <td style="width:3%;vertical-align:bottom">
        <div style="line-height:1.25">&#160;</div></td>
    <td style="width:27%;vertical-align:bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Chief Executive Officer</span></span></div>
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">and Director</span></span></div></td>
    <td colspan="1" style="width:20%;vertical-align:bottom">&#160;</td></tr>
  </table>

<div style="line-height:1.25">&#160;</div>

<div style="text-align:justify;text-indent:24.5pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">KNOW
ALL MEN BY THESE PRESENTS, that each of the undersigned constitutes and appoints each of Miranda J. Toledano and Dana Yaacov-Garbelli,
or any of them, each acting alone, his true and lawful attorney-in-fact and agent, with full power of substitution and resubstituting,
for such person and in his name, place and stead, in any and all capacities, to sign this Annual Report on Form 10-K, and to file the
same, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto
said attorneys-in-fact and agents, each acting alone, full power and authority to do and perform each and every act and thing requisite
and necessary to be done in and about the premises, as fully to all intents and purposes as he might or could do in person, hereby ratifying
and confirming that any such attorney-in-fact and agent, or his substitute or substitutes, may lawfully do or cause to be done by virtue
hereof.</span></span></div>

<div style="line-height:1.25">&#160;</div>

<div style="text-indent:24.5pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Pursuant
to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the
registrant and in the capacities and on the dates indicated.</span></span></div>

<div style="text-indent:24.5pt;line-height:1.25">&#160;</div>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">
  <tr>
    <td style="width:28.57%;vertical-align:bottom;border-bottom:#000000 2px solid">
        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Name</span></span></div></td>
    <td style="width:0.72%;vertical-align:top">
        <div style="text-align:justify;line-height:1.25;font-weight:bold">&#160;</div></td>
    <td style="width:51%;vertical-align:top;border-bottom:2px solid rgb(0, 0, 0)">
        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Title</span></span></div></td>
    <td style="width:0.72%;vertical-align:top">
        <div style="text-align:justify;line-height:1.25;font-weight:bold">&#160;</div></td>
    <td style="width:18.28%;vertical-align:top;border-bottom:#000000 2px solid">
        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Date</span></span></div></td></tr>
  <tr>
    <td style="width:28.57%;vertical-align:bottom">
        <div style="text-align:center;line-height:1.25">&#160;</div></td>
    <td style="width:0.72%;vertical-align:top">
        <div style="line-height:1.25">&#160;</div></td>
    <td style="width:51%;vertical-align:top">
        <div style="line-height:1.25">&#160;</div></td>
    <td style="width:0.72%;vertical-align:top">
        <div style="line-height:1.25">&#160;</div></td>
    <td style="width:18.28%;vertical-align:top">
        <div style="line-height:1.25">&#160;</div></td></tr>
  <tr>
    <td style="width:28.57%;vertical-align:bottom;border-bottom:#000000 2px solid">
        <div style="text-align:center;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">/s/
        Miranda J. Toledano</span></span></div></td>
    <td style="width:0.72%;vertical-align:top">
        <div style="line-height:1.25">&#160;</div></td>
    <td style="width:51%;vertical-align:top">
        <div style="text-align:center;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Chief
        Executive Officer and Director</span></span></div></td>
    <td style="width:0.72%;vertical-align:top">
        <div style="line-height:1.25">&#160;</div></td>
    <td style="width:18.28%;vertical-align:top">
        <div style="text-align:center;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">March
        31, 2023</span></span></div></td></tr>
  <tr>
    <td style="width:28.57%;vertical-align:bottom">
        <div style="text-align:center;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Miranda
        J. Toledano</span></span></div></td>
    <td style="width:0.72%;vertical-align:top">
        <div style="line-height:1.25">&#160;</div></td>
    <td style="width:51%;vertical-align:top">
        <div style="text-align:center;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(Principal
        Executive Officer)</span></span></div></td>
    <td style="width:0.72%;vertical-align:top">
        <div style="line-height:1.25">&#160;</div></td>
    <td style="width:18.28%;vertical-align:top">
        <div style="line-height:1.25">&#160;</div></td></tr>
  <tr>
    <td style="width:28.57%;vertical-align:bottom">
        <div style="text-align:center;line-height:1.25">&#160;</div></td>
    <td style="width:0.72%;vertical-align:top">
        <div style="line-height:1.25">&#160;</div></td>
    <td style="width:51%;vertical-align:top">
        <div style="line-height:1.25">&#160;</div></td>
    <td style="width:0.72%;vertical-align:top">
        <div style="line-height:1.25">&#160;</div></td>
    <td style="width:18.28%;vertical-align:top">
        <div style="line-height:1.25">&#160;</div></td></tr>
  <tr>
    <td style="width:28.57%;vertical-align:bottom;border-bottom:#000000 2px solid">
        <div style="text-align:center;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">/s/
        Dana Yaacov-Garbeli</span></span></div></td>
    <td style="width:0.72%;vertical-align:top">
        <div style="line-height:1.25">&#160;</div></td>
    <td style="width:51%;vertical-align:top">
        <div style="text-align:center;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Chief
        Financial Officer</span></span></div></td>
    <td style="width:0.72%;vertical-align:top">
        <div style="line-height:1.25">&#160;</div></td>
    <td style="width:18.28%;vertical-align:top">
        <div style="text-align:center;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">March
        31, 2023</span></span></div></td></tr>
  <tr>
    <td style="width:28.57%;vertical-align:bottom">
        <div style="text-align:center;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Dana
        Yaacov-Garbeli</span></span></div></td>
    <td style="width:0.72%;vertical-align:top">
        <div style="line-height:1.25">&#160;</div></td>
    <td style="width:51%;vertical-align:top">
        <div style="text-align:center;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(Principal
        Financial and Accounting Officer)</span></span></div></td>
    <td style="width:0.72%;vertical-align:top">
        <div style="line-height:1.25">&#160;</div></td>
    <td style="width:18.28%;vertical-align:top">
        <div style="line-height:1.25">&#160;</div></td></tr>
  <tr>
    <td style="width:28.57%;vertical-align:bottom">
        <div style="text-align:center;line-height:1.25">&#160;</div></td>
    <td style="width:0.72%;vertical-align:top">
        <div style="line-height:1.25">&#160;</div></td>
    <td style="width:51%;vertical-align:top">
        <div style="line-height:1.25">&#160;</div></td>
    <td style="width:0.72%;vertical-align:top">
        <div style="line-height:1.25">&#160;</div></td>
    <td style="width:18.28%;vertical-align:top">
        <div style="line-height:1.25">&#160;</div></td></tr>
  <tr>
    <td style="width:28.57%;vertical-align:bottom;border-bottom:#000000 2px solid">
        <div style="text-align:center;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">/s/
        Gerald Lieberman</span></span></div></td>
    <td style="width:0.72%;vertical-align:top">
        <div style="line-height:1.25">&#160;</div></td>
    <td style="width:51%;vertical-align:top">
        <div style="text-align:center;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Director</span></span></div></td>
    <td style="width:0.72%;vertical-align:top">
        <div style="line-height:1.25">&#160;</div></td>
    <td style="width:18.28%;vertical-align:top">
        <div style="text-align:center;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">March
        31, 2023</span></span></div></td></tr>
  <tr>
    <td style="width:28.57%;vertical-align:bottom">
        <div style="text-align:center;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Gerald
        Lieberman</span></span></div></td>
    <td style="width:0.72%;vertical-align:top">
        <div style="line-height:1.25">&#160;</div></td>
    <td style="width:51%;vertical-align:top">
        <div style="line-height:1.25">&#160;</div></td>
    <td style="width:0.72%;vertical-align:top">
        <div style="line-height:1.25">&#160;</div></td>
    <td style="width:18.28%;vertical-align:top">
        <div style="line-height:1.25">&#160;</div></td></tr>
  <tr>
    <td style="width:28.57%;vertical-align:bottom">
        <div style="text-align:center;line-height:1.25">&#160;</div></td>
    <td style="width:0.72%;vertical-align:top">
        <div style="line-height:1.25">&#160;</div></td>
    <td style="width:51%;vertical-align:top">
        <div style="line-height:1.25">&#160;</div></td>
    <td style="width:0.72%;vertical-align:top">
        <div style="line-height:1.25">&#160;</div></td>
    <td style="width:18.28%;vertical-align:top">
        <div style="line-height:1.25">&#160;</div></td></tr>
  <tr>
    <td style="width:28.57%;vertical-align:bottom;border-bottom:#000000 2px solid">
        <div style="text-align:center;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">/s/
        Roger J. Garceau</span></span></div></td>
    <td style="width:0.72%;vertical-align:top">
        <div style="line-height:1.25">&#160;</div></td>
    <td style="width:51%;vertical-align:top">
        <div style="text-align:center;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Director</span></span></div></td>
    <td style="width:0.72%;vertical-align:top">
        <div style="line-height:1.25">&#160;</div></td>
    <td style="width:18.28%;vertical-align:top">
        <div style="text-align:center;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">March
        31, 2023</span></span></div></td></tr>
  <tr>
    <td style="width:28.57%;vertical-align:bottom">
        <div style="text-align:center;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Roger
        J. Garceau</span></span></div></td>
    <td style="width:0.72%;vertical-align:top">
        <div style="line-height:1.25">&#160;</div></td>
    <td style="width:51%;vertical-align:top">
        <div style="line-height:1.25">&#160;</div></td>
    <td style="width:0.72%;vertical-align:top">
        <div style="line-height:1.25">&#160;</div></td>
    <td style="width:18.28%;vertical-align:top">
        <div style="line-height:1.25">&#160;</div></td></tr>
  <tr>
    <td style="width:28.57%;vertical-align:bottom">
        <div style="text-align:center;line-height:1.25">&#160;</div></td>
    <td style="width:0.72%;vertical-align:top">
        <div style="line-height:1.25">&#160;</div></td>
    <td style="width:51%;vertical-align:top">
        <div style="line-height:1.25">&#160;</div></td>
    <td style="width:0.72%;vertical-align:top">
        <div style="line-height:1.25">&#160;</div></td>
    <td style="width:18.28%;vertical-align:top">
        <div style="line-height:1.25">&#160;</div></td></tr>
  <tr>
    <td style="width:28.57%;vertical-align:bottom;border-bottom:#000000 2px solid">
        <div style="text-align:center;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">/s/
        Ron Mayron</span></span></div></td>
    <td style="width:0.72%;vertical-align:top">
        <div style="line-height:1.25">&#160;</div></td>
    <td style="width:51%;vertical-align:top">
        <div style="text-align:center;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Director</span></span></div></td>
    <td style="width:0.72%;vertical-align:top">
        <div style="line-height:1.25">&#160;</div></td>
    <td style="width:18.28%;vertical-align:top">
        <div style="text-align:center;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">March
        31, 2023</span></span></div></td></tr>
  <tr>
    <td style="width:28.57%;vertical-align:bottom">
        <div style="text-align:center;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Ron
        Mayron</span></span></div></td>
    <td style="width:0.72%;vertical-align:top">
        <div style="line-height:1.25">&#160;</div></td>
    <td style="width:51%;vertical-align:top">
        <div style="line-height:1.25">&#160;</div></td>
    <td style="width:0.72%;vertical-align:top">
        <div style="line-height:1.25">&#160;</div></td>
    <td style="width:18.28%;vertical-align:top">
        <div style="line-height:1.25">&#160;</div></td></tr>
  <tr>
    <td style="width:28.57%;vertical-align:bottom">
        <div style="text-align:center;line-height:1.25">&#160;</div></td>
    <td style="width:0.72%;vertical-align:top">
        <div style="line-height:1.25">&#160;</div></td>
    <td style="width:51%;vertical-align:top">
        <div style="line-height:1.25">&#160;</div></td>
    <td style="width:0.72%;vertical-align:top">
        <div style="line-height:1.25">&#160;</div></td>
    <td style="width:18.28%;vertical-align:top">
        <div style="line-height:1.25">&#160;</div></td></tr>
  <tr>
    <td style="width:28.57%;vertical-align:bottom;border-bottom:#000000 2px solid">
        <div style="text-align:center;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">/s/
        Yonatan Malca</span></span></div></td>
    <td style="width:0.72%;vertical-align:top">
        <div style="line-height:1.25">&#160;</div></td>
    <td style="width:51%;vertical-align:top">
        <div style="text-align:center;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Director</span></span></div></td>
    <td style="width:0.72%;vertical-align:top">
        <div style="line-height:1.25">&#160;</div></td>
    <td style="width:18.28%;vertical-align:top">
        <div style="text-align:center;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">March
        31, 2023</span></span></div></td></tr>
  <tr>
    <td style="width:28.57%;vertical-align:bottom">
        <div style="text-align:center;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Yonatan
        Malca</span></span></div></td>
    <td style="width:0.72%;vertical-align:top">
        <div style="line-height:1.25">&#160;</div></td>
    <td style="width:51%;vertical-align:top">
        <div style="line-height:1.25">&#160;</div></td>
    <td style="width:0.72%;vertical-align:top">
        <div style="line-height:1.25">&#160;</div></td>
    <td style="width:18.28%;vertical-align:top">
        <div style="line-height:1.25">&#160;</div></td></tr>
  <tr>
    <td style="width:28.57%;vertical-align:bottom">
        <div style="text-align:center;line-height:1.25">&#160;</div></td>
    <td style="width:0.72%;vertical-align:top">
        <div style="line-height:1.25">&#160;</div></td>
    <td style="width:51%;vertical-align:top">
        <div style="line-height:1.25">&#160;</div></td>
    <td style="width:0.72%;vertical-align:top">
        <div style="line-height:1.25">&#160;</div></td>
    <td style="width:18.28%;vertical-align:top">
        <div style="line-height:1.25">&#160;</div></td></tr>
  <tr>
    <td style="width:28.57%;vertical-align:bottom;border-bottom:#000000 2px solid">
        <div style="text-align:center;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">/s/
        Sean Ellis</span></span></div></td>
    <td style="width:0.72%;vertical-align:top">
        <div style="line-height:1.25">&#160;</div></td>
    <td style="width:51%;vertical-align:top">
        <div style="text-align:center;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Director</span></span></div></td>
    <td style="width:0.72%;vertical-align:top">
        <div style="line-height:1.25">&#160;</div></td>
    <td style="width:18.28%;vertical-align:top">
        <div style="text-align:center;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">March
        31, 2023</span></span></div></td></tr>
  <tr>
    <td style="width:28.57%;vertical-align:bottom">
        <div style="text-align:center;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Sean
        Ellis</span></span></div></td>
    <td style="width:0.72%;vertical-align:top">
        <div style="line-height:1.25">&#160;</div></td>
    <td style="width:51%;vertical-align:top">
        <div style="line-height:1.25">&#160;</div></td>
    <td style="width:0.72%;vertical-align:top">
        <div style="line-height:1.25">&#160;</div></td>
    <td style="width:18.28%;vertical-align:top">
        <div style="line-height:1.25">&#160;</div></td></tr>
  <tr>
    <td rowspan="1" style="width:28.57%;vertical-align:bottom">&#160;</td>
    <td rowspan="1" style="width:0.72%;vertical-align:top">&#160;</td>
    <td rowspan="1" style="width:51%;vertical-align:top">&#160;</td>
    <td rowspan="1" style="width:0.72%;vertical-align:top">&#160;</td>
    <td rowspan="1" style="width:18.28%;vertical-align:top">&#160;</td></tr>
  <tr>
    <td rowspan="1" style="width:28.57%;vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0)">
        <div style="text-align:center;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">/s/
        Gerald M. Ostrov</span></span></div></td>
    <td rowspan="1" style="width:0.72%;vertical-align:top;padding-bottom:2px">&#160;</td>
    <td rowspan="1" style="width:51%;vertical-align:top;padding-bottom:2px">
        <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Director</span></span></div></td>
    <td rowspan="1" style="width:0.72%;vertical-align:top;padding-bottom:2px">&#160;</td>
    <td rowspan="1" style="width:18.28%;vertical-align:top;padding-bottom:2px">
        <div style="text-align:center;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">March
        31, 2023</span></span></div></td></tr>
  <tr>
    <td rowspan="1" style="width:28.57%;vertical-align:bottom">
        <div style="text-align:center;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Gerald
        M. Ostrov</span></span></div></td>
    <td rowspan="1" style="width:0.72%;vertical-align:top">&#160;</td>
    <td rowspan="1" style="width:51%;vertical-align:top">&#160;</td>
    <td rowspan="1" style="width:0.72%;vertical-align:top">&#160;</td>
    <td rowspan="1" style="width:18.28%;vertical-align:top">&#160;</td></tr>
  </table>

<div style="line-height:1.25;text-align:center">

<div style="margin-top:10pt;margin-bottom:10pt">

<div style="text-align:center"><span style="font-size:10pt;font-family:Times New Roman, Times, serif;font-style:normal;font-weight:normal">147</span><hr style="border:none;border-bottom:4px solid black;border-top:1px solid black;height:10px;width:100%;color:#ffffff;background-color:#ffffff;text-align:center;margin-left:auto;margin-right:auto;margin-top:5pt;text-align:center" /></div></div></div></div></div></div></div>

</div></div></body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.14
<SEQUENCE>2
<FILENAME>exhibit_10-14.htm
<DESCRIPTION>EXHIBIT 10.14
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: Z-K Global
         Document created using Broadridge PROfile 23.3.1.5138
         Copyright 1995 - 2023 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000;">


  <div>
    <hr align="center" style="border: none; border-bottom: 1px solid black; border-top: 4px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;">
    <div style="text-align: right;"><u><font style="font-weight: bold;"> Exhibit 10.14</font></u><br>
    </div>
    <div>
      <div style="text-align: center; line-height: 1.25;"><u> <br>
        </u></div>
      <div style="text-align: center; line-height: 1.25;"><u>CONSULTANCY AGREEMENT</u></div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; line-height: 1.25;">This Consultancy Agreement ("Agreement") is entered into effective as of June 2, 2019, by and between Entera Bio Ltd.,
          an Israeli company I.D. No. 514330604 ("Company"), and A2Z Finance Ltd., a company organized under the laws of the State of Israel ("Consultant").<br>
          <br style="line-height: 1.25;">
      </div>
      <table cellspacing="0" cellpadding="0" id="zbd2491a10a0144f4951c9649a4af5bcc" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 85.05pt; vertical-align: top; font-weight: bold;">WHEREAS,</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>the Consultant agrees to perform the Services for the interim period until the engagement by the Company of a new chief financial officer for the Company on a
                permanent basis; and</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25">&#160;</div>
      <table cellspacing="0" cellpadding="0" id="ze51d8dfd68e7430fb7d89c1a262e03dd" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 85.05pt; vertical-align: top; font-weight: bold;">WHEREAS,</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>the Consultant is ready, qualified, willing and able to carry out her obligations and undertakings towards the Company pursuant hereto; and</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25">&#160;</div>
      <table cellspacing="0" cellpadding="0" id="za8827aefebff4a89bea6a7814c1e7cb5" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 85.05pt; vertical-align: top; font-weight: bold;">WHEREAS,</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>the Services will be provided by the Consultant as an independent contractor, as per the Consultant's and the Designated Service Provider's specific wish and
                requirement, made as a result of considerations and benefits personal to the Consultant and the Designated Service Provider, that the Services shall be provided to the Company by the Consultant on an independent contractor basis, absent an
                employment relationship between the Company and the Consultant or the Designated Service Provider; and</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25">&#160;</div>
      <table cellspacing="0" cellpadding="0" id="z158d539b3e9a4963a009ab53648bd382" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 85.05pt; vertical-align: top; font-weight: bold;">WHEREAS,</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>the parties hereto wish to regulate their relationship in accordance with the terms and conditions set forth herein.</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; line-height: 1.25;"><font style="font-weight: bold;">NOW, THEREFORE</font>, in
        consideration of the foregoing, the parties do mutually agree as follows:</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; line-height: 1.25;">1.&#160;&#160;&#160;&#160;&#160;&#160; &#160; &#160; <u>Engagement of Services</u>.</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 35.5pt; line-height: 1.25;">1.1.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Consultant
          will provide to the Company CFO services, which shall include, without limitation, the list of responsibilities described in <font style="font-weight: bold;"><u>Exhibit A</u></font>
          (the &#8220;<u>Services</u>&#8221;), in a scope and position expressly stated in <font style="font-weight: bold;"><u>Exhibit A</u></font>. Consultant will perform Services faithfully, diligently and to the best of Consultant&#8217;s skill and ability. The engagement hereunder is not exclusive, and shall not limit the Company from engaging a third party to
          provide services which are the same as or similar to the Services.</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 35.5pt; line-height: 1.25;">1.2.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Consultant
          will provide the Services commencing as of June 2, 2019 (the &#8220;<u>Commencement Date</u>&#8221;) until termination of this Agreement in accordance with the terms of this
          Agreement. The provisions of this Section 1.2 and of Sections 2, and 4 through 9 of this Agreement shall survive any termination of this Agreement indefinitely. Upon termination of this Agreement or at such other time as directed by the Company,
          the Consultant shall immediately return to the Company all assets in the Consultant's possession or control which belong to, or have been entrusted to, the Company. The Consultant shall neither have, nor retain, any proprietary interest or lien
          in such assets.</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 35.5pt; line-height: 1.25;">1.3.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;This
          Agreement will be in effect commencing on the Commencement Date, until terminated by either party as provided below.&#160; Either party may terminate this Agreement immediately without cause upon prior written notice of 30 days to the other party.</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 35.5pt; line-height: 1.25;">1.4.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Notwithstanding
          the above, the Company shall be entitled to terminate this Agreement with an immediate effect if: (i) the Consultant act dishonestly, breach its duties (including the duty of loyalty) towards the Company and/or its subsidiaries (the &#8220;<u>Group</u>&#8221;), or breach the terms of this Agreement, or other agreement with the Company relating to confidentiality, ownership or protection of proprietary rights,
          non-solicitation or non-disparagement or in the event of any act or omission of the Consultant which would have entitled the Company legally to dismiss the Consultant without severance pay, in whole or in part, had the Consultant or the
          Designated Service Provider been engaged as an employee of the Company; or (ii) the Company has employed a new Chief Financial Officer (the &#8220;<u>New CFO</u>&#8221;) (for
          the avoidance of doubt, the Company shall be entitled to terminate this Agreement with an immediate effect, at the Company's sole discretion, on the starting date of the New CFO with the Company.</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
        <div style="page-break-after: always;" class="BRPFPageBreak">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <!--PROfilePageNumberReset%Num%2%- % -%-->
      <div style="text-align: justify; text-indent: 35.5pt; line-height: 1.25;">1.5.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u>Designated Service Provider</u>. The Consultant undertakes that all of the Services shall be performed solely and exclusively by Dana Yaacov (the &#8220;<u>Designated Service Provider</u>&#8221;) for the entire term of this Agreement, unless otherwise agreed in writing by the Company.</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 35.5pt; line-height: 1.25;">1.6.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u>Corporate approvals</u>. Notwithstanding anything to the contrary herein, the Consultant agrees and understands that this Agreement is subject to, and shall only
          enter into effect upon the receipt of the approval by all corporate organs of the Company as required according to the applicable law (as determined by the Company on its sole discretion).</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; line-height: 1.25;">2.&#160;&#160;&#160;&#160;&#160;&#160; &#160; &#160; <u>Representations and Obligations</u>. Consultant warrants and undertakes as follows:</div>
      <div style="text-align: justify; line-height: 1.25;"> <br>
        </div>
      <div style="text-align: justify; text-indent: 35.5pt; line-height: 1.25;">2.1.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Consultant
          has the ability, experience, expertise and resources to provide the Services and to perform all of its obligations hereunder. Consultant shall perform all duties and obligations under this Agreement with the highest degree of professionalism,
          loyalty and to the full satisfaction of the Company.&#160; Consultant is free to provide the Company with the Services, upon the terms contained in this Agreement, and there are no legal, commercial or contractual restrictions preventing the
          Consultant from fully performing all duties hereunder. Designated Service Provider is an employee of the Consultant (&#8220;<u>Employer</u>&#8221;). Consultant represents
          warrants and covenants that Consultant's performance of the obligations under this Agreement does not and will not violate the terms of any of Designated Service Provider's agreements with Employer or any other party. Neither Consultant nor the
          Designated Service Provider shall accept any Confidential Information (as defined in Section 5.1 below) if he believes, in her sole discretion, that such acceptance might impair her ability to perform her duties of research and publication under
          her employment agreement with Employer.</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 35.5pt; line-height: 1.25;">2.2.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Consultant
          shall provide the Company with the Services, in accordance with the directions of the Company&#8217;s Chief Executive Officer, or such other person as directed.</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 35.5pt; line-height: 1.25;">2.3. &#160;&#160;&#160;&#160;&#160;&#160;&#160; Consultant
          will notify the Company immediately should anything occur or come to its attention which would or might prevent it from providing the Services at the level required by the Company. In these circumstances, the Company may terminate this Agreement
          immediately, without any advance notice, in respect of which the Consultant will not be entitled to any damages or payment other than the Fee (as defined below) for Services provided to the Company prior to termination. Where the Consultant
          discovers that it has or might have at some point in the future, any personal interest in Company business, or a conflict of interest arising out of or in connection with the Services then, immediately upon discovery, Consultant shall notify the
          same to the Company in writing. Without derogating from any other rights under this Agreement or under law, the Company may require the Consultant to cease to have any such personal interest or conflict of interest, as the case may be or to
          immediately terminate this Agreement as detailed in this Section 1.4.</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 35.5pt; line-height: 1.25;">2.4.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Consultant
          shall be responsible, at its own expense, to obtain all of the equipment necessary for providing the Services, such as car, phone, computer or other communications equipment.</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 35.5pt; line-height: 1.25;">2.5.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Consultant
          shall comply with all of the Company's policies, as effective from time to time, and acknowledges that the Company is a public company and further represents that Consultant shall at all times comply with all applicable laws, including any
          applicable securities laws.</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 35.5pt; line-height: 1.25;">2.6.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The
          Consultant has, and will have throughout the term of this Agreement, all approvals, permits and licenses required pursuant to any law to provide the Services in accordance with this Agreement (if required).</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
        <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-weight: normal; font-style: normal;" class="BRPFPageNumber">- 2 -</font></div>
        <div style="page-break-after: always;" class="BRPFPageBreak">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <div style="text-align: justify; text-indent: 35.5pt; line-height: 1.25;">2.7.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The
          Consultant shall not, directly or indirectly, accept any commission, rebate, discount or gratuity in cash or in kind, from any person who has or is likely to have a business relationship with the Group related in any way to the Services provided
          by the Consultant.</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; line-height: 1.25;">3.&#160;&#160;&#160;&#160;&#160; &#160; &#160;&#160; <u>Consideration</u></div>
      <div style="text-align: justify; line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 35.5pt; line-height: 1.25;">3.1.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Subject
          to the fulfillment of the Consultant's obligations hereunder, and contingent upon the performance of the Services by it, the Company shall pay the Consultant a gross service fee (and expense reimbursement, if applicable) as (and only as)
          expressly stated in <font style="font-weight: bold;"><u>Exhibit A</u></font> (&#8220;<u>Fee</u>&#8221;).
          Payment of the Fee by the Company will be made within 30 days following the receipt by the Company of a valid tax invoice issued by the Consultant.</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 35.5pt; line-height: 1.25;">3.2.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Subject
          to and without derogating from Section 2.4, the Company will reimburse the Consultant for reasonable out of pocket expenses which were pre-approved in writing in connection with its duties hereunder (at the Company's sole discretion), all subject
          to any Company policies as may be in force from time to time and against the provision of proper receipts. For the avoidance of doubt, it is hereby clarified that the Company will not reimburse the Consultant for any car expenses or other similar
          expenses according to this Section 3.2.</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 35.5pt; line-height: 1.25;">3.3.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The
          Consultant shall not be entitled to any further compensation in connection with the Services except as otherwise stated in this Agreement.</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; line-height: 1.25;">4.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u>Taxes</u>. Consultant shall bear any and all taxes and national insurance contributions (as
          applicable) which may be payable in connection with any consideration payable to, or benefit receivable by, Consultant and/or Designated Service Provider pursuant
          to this Agreement. Consultant declares that it maintains financial books in accordance with applicable law and that it is duly registered with the income tax, VAT and national insurance authorities (if and as applicable). Consultant shall bear
          and be responsible for, and shall indemnify and hold the Company harmless from, all payments required to be made to any such applicable national insurance institute, taxation body or other third party in consequence of the provision of the
          Services or the remuneration provided in connection therewith. Notwithstanding the above, the Company shall withhold at source all taxes and compulsory payments on any payment to the Consultant to the extent that such taxes and compulsory
          payments are required by any applicable law to be withheld at source.</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; line-height: 1.25;">5.&#160;&#160;&#160;&#160;&#160; &#160; &#160;&#160; <u>Status of Parties</u></div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 35.5pt; line-height: 1.25;">5.1.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; The
          relationship between the Consultant and the Designated Service Provider and the Company, in compliance with the Consultant's request, is one of principal and independent contractor. The Consultant declares that he maintains financial books in
          accordance with the applicable law and that it is duly registered with the income tax, VAT and National Insurance authorities, and that he must perform and continue to perform all actions legally required to establish and maintain its status as
          an independent contractor with an independent business. The parties expressly declare that no employment relationship exists between the Company and the Consultant and/or the Designated Service Provider.</div>
      <div style="text-align: justify; text-indent: 35.5pt; line-height: 1.25;"> <br>
        </div>
      <div style="text-align: justify; text-indent: 35.5pt; line-height: 1.25;">5.2.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;If,
          notwithstanding anything contained in this Agreement any person shall claim, or a judicial authority shall determine, that the Consultant and/or the Designated Service Provider provided the Services under this Agreement as an employee of the
          Company, then the following provisions shall apply:</div>
      <div style="line-height: 1.25">&#160;</div>
      <table cellspacing="0" cellpadding="0" id="za8c4ac13a9e342ef8db638228af90059" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 74.7pt;"><br>
            </td>
            <td style="width: 35.45pt; vertical-align: top;">(a)</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>For the period as to which it is claimed or determined that an employment relationship existed between the Company and the Consultant (the &#8220;<u>Relevant Period</u>&#8221;), the Consultant shall not be entitled to the Fee, but only 60% thereof (the &#8220;<u>Reduced
                    Fee</u>&#8221;).</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25">&#160;</div>
      <table cellspacing="0" cellpadding="0" id="ze1397c2dd48645a4b4f169d1526045c1" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 74.7pt;"><br>
            </td>
            <td style="width: 35.45pt; vertical-align: top;">(b)</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>The Reduced Fee shall constitute the full Fee payable to the Consultant as salary in connection with said employment relationship, on which basis any social benefits
                will be calculated - to the extent that such social benefits are required to be paid to or in respect of the Consultant pursuant to any third party authority's decision reclassifying the Consultant as an employee.</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25">&#160;</div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
        <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-weight: normal; font-style: normal;" class="BRPFPageNumber">- 3 -</font></div>
        <div style="page-break-after: always;" class="BRPFPageBreak">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <div style="line-height: 1.25">&#160;</div>
      <table cellspacing="0" cellpadding="0" id="z805bdbb62ec54e46a4a264e77536b1b8" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 74.7pt;"><br>
            </td>
            <td style="width: 35.45pt; vertical-align: top;">(c)</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>In view thereof, an accounting shall be conducted between the parties, and the Consultant shall immediately return and pay to the Company all amounts paid to him in
                excess of the Reduced Fee for the Relevant Period, along with linkage differentials and interest from the date of payment of each amount by the Company to the Consultant and up to the date upon which actual return and payment of the funds
                is made by the Consultant, all based on the Consumer Price Indices known at the relevant dates and as provided by the Adjudication of Interest and Linkage Law, 1961.</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 35.5pt; line-height: 1.25;">5.3.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;In
          addition, in the event that the relationship between the Company and the Consultant shall be claimed, regarded or determined by any third party, including any governmental or judicial or tax authority to be an employment relationship, the
          Consultant shall reimburse and indemnify the Company for any expense and payment incurred by or demanded of the Company as a consequence, no later than seven days of its receipt of such demand.</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 35.5pt; line-height: 1.25;">5.4.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The
          Company shall be entitled to offset any amounts due to it under this Section 5 from any amounts payable to the Consultant under this Agreement.</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; line-height: 1.25;">6.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u>Confidentiality and Assignment of IP</u>. Each of Consultant and Designated Service Provider shall sign and comply with the Company's standard Proprietary Information and Inventions
          Agreement attached hereto as <font style="font-weight: bold;"><u>Exhibit B</u></font>, which requires, among other things, the assignment of Consultant and Designated Service
          Provider rights to any intellectual property made during Consultant and Designated Service Provider Services at the Company and the nondisclosure of proprietary information.</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <table cellspacing="0" cellpadding="0" id="z536ca59fc7b4482891cb85caa1db9624" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 36pt; vertical-align: top; font-family: 'Times New Roman',Times,serif;">7.</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div><u>Non-Competition and Non-Solicitation.</u></div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25">&#160;</div>
      <table cellspacing="0" cellpadding="0" id="z7c39e70be67941e4af0f5417d99641a9" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 36pt;"><br>
            </td>
            <td style="width: 21.6pt; vertical-align: top;">7.1.</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>During the term of this Agreement and for a period of twelve (12) months following its termination, the Consultant and the Designated Service Provider shall not:</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25">&#160;</div>
      <table cellspacing="0" cellpadding="0" id="z3dee0d27d9974263be486d569e6a2eb4" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 63pt;"><br>
            </td>
            <td style="width: 36pt; vertical-align: top;">7.1.1.</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>directly or indirectly, in any capacity whatsoever, whether independently or as a shareholder, an employee, consultant, an officer or any managerial capacity, carry
                on, set up, own, manage, control or operate, be employed, engaged or interested in a business, anywhere in the world, which competes with, or proposes to compete with the Group.</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25">&#160;</div>
      <table cellspacing="0" cellpadding="0" id="zfe1947bb0f63420abb0fb8d9e789942c" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 63pt;"><br>
            </td>
            <td style="width: 36pt; vertical-align: top;">7.1.2.</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>directly or indirectly, in any way (i) offer, solicit or attempt to solicit, induce or attempt to induce or endeavor to entice away, any person with whom any member
                of the Group has or had or shall have any contractual or commercial relationship as a consultant, licensor, joint venturer, supplier, customer, distributor, agent or contractor of whatsoever nature, existing or under negotiation on or prior
                to date of termination of this Agreement, to cease his, her or its relationship with that member of the Group, or otherwise interfere in any way with the relationship between that member of the Group and such person or (ii) have any
                business dealings with any such person.</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25">&#160;</div>
      <table cellspacing="0" cellpadding="0" id="z122ca52482a245fbbbc98d6939e668e2" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 63pt;"><br>
            </td>
            <td style="width: 36pt; vertical-align: top;">7.1.3.</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>directly or indirectly, in any way (i) offer, solicit or attempt to solicit for employment or other engagement, or otherwise contract or seek to contract the services
                of, any individual who is, at the effective date of termination of this Agreement, employed or engaged (whether directly or indirectly) by any member of the Group or induce or entice or attempt to induce or entice such individual to leave
                such employment or other engagement or otherwise interfere in its, his or her relationship with any member of the Group.</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25">&#160;</div>
      <table cellspacing="0" cellpadding="0" id="z8cfcb942250e49d3bb27be768d872e8b" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 36pt;"><br>
            </td>
            <td style="width: 21.6pt; vertical-align: top;">7.2.</td>
            <td style="width: auto; vertical-align: top;">
              <div>The Consultant acknowledges that its obligations under this Section are reasonable, in light of knowledge it will gain of the Group&#8217;s Confidential Information and
                that the consideration it receives hereunder is paid, inter alia, as consideration for its undertaking under this Section.</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25">&#160;</div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
        <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-weight: normal; font-style: normal;" class="BRPFPageNumber">- 4 -</font></div>
        <div style="page-break-after: always;" class="BRPFPageBreak">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <table cellspacing="0" cellpadding="0" id="zf424659f5c3e4e919c93e6fd053fcd55" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 36pt; vertical-align: top; font-family: 'Times New Roman',Times,serif;">8.</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div><u>No Conflicting Obligations</u>. The Consultant and the Designated Service
                Provider will not, at any time during the term of the Agreement, use or disclose any trade secrets or proprietary or confidential information in such manner that may breach any confidentiality or other obligation that the Consultant owes to
                any third party (including to any other employer or other clients of the Consultant and the Designated Service Provider), without their prior written consent.</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25">&#160;</div>
      <table cellspacing="0" cellpadding="0" id="z2bbe99df4f8f4e07bf1f90a6269f7cc2" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 36pt; vertical-align: top; font-family: 'Times New Roman',Times,serif;">9.</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div><u>General</u>. This Agreement inures to the benefit of the parties hereto and
                their permitted assigns and successors, and will not inure to the benefit of any third party (such as the Designated Service Provider). The Consultant shall not assign any of its rights and obligations hereunder without the prior written
                consent of the Company, and any attempt to do so shall be null and void. This Agreement shall be interpreted, construed, governed and enforced according to the laws of the State of Israel, regardless of any conflicts of laws provisions. The
                competent courts of Tel-Aviv, Israel shall have exclusive jurisdiction to hear any such dispute and no other courts shall have any jurisdiction whatsoever in respect of such disputes. This Agreement contains the entire agreement and
                understanding between the parties with respect to the subject matter hereof, and supersedes all prior discussions, agreements, representations and understandings in this regard. No amendment or modification of the terms or conditions of
                this Agreement shall be valid unless in writing and signed by the Company and Consultant. Each notice given by one party to the other pursuant to this Agreement shall be given in writing, correctly addressed to the relevant party's address
                as set forth below (unless another address has been notified in accordance with this clause), and will be deemed to have been duly served with immediate effect at the time of hand delivery (or refusal to receive) or email receipt, on the
                next business day (being a day in which the banks are open to the public in Israel) following transmission by facsimile (and electronic confirmation of receipt), three business days after posting for delivery with a first class registered
                or recorded delivery post, or on the second business day after posting with an overnight courier. Without derogating from any relief to which the Company is entitled to pursuant to any law and/or agreement, the Company may set off any
                amount which the Consultant owes it pursuant to this Agreement and/or any other source from any sum that the Consultant is entitled to receive from the Company, from whatever source. No behaviour by either party hereto shall be deemed to
                constitute a waiver of any rights according to this Agreement, and/or a waiver of or consent to any breach or default in respect of any of the terms hereof, or a change, invalidation or addition to any term, unless expressly made in
                writing. The Consultant hereby declares that this Agreement is signed by it upon its request, after it has checked all its rights and obligations deriving from this Agreement, according to any law and after it has investigated all its
                rights pursuant to this Agreement against the Company.</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: center; line-height: 1.25; font-style: italic;">[Signature Page to Follow]</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
        <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-weight: normal; font-style: normal;" class="BRPFPageNumber">- 5 -</font></div>
        <div style="page-break-after: always;" class="BRPFPageBreak">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">IN WITNESS WHEREOF, the parties have executed this Consultancy Agreement effective as of the date first written
        above. This Consultancy Agreement may be executed in any number of counterparts, each of which when so executed and delivered shall be deemed an original, and such counterparts shall together constitute one and the same instrument.</div>
      <div style="line-height: 1.25">&#160;</div>
      <table cellspacing="0" cellpadding="3" border="0" id="z7a9ced07c6344fd889819ae179af51ed" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);">

          <tr>
            <td style="width: 50%; vertical-align: top; border-top: 1px solid rgb(0, 0, 0); border-left: 1px solid rgb(0, 0, 0);">
              <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-weight: bold;"><u>Company:</u></div>
              <div style="line-height: 1.25;"><font style="line-height: 1.25;">&#160;</font></div>
              <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Entera Bio Ltd.</div>
              <div style="line-height: 1.25;"><font style="line-height: 1.25;">&#160;</font></div>
              <div style="text-align: justify; line-height: 1.25;"><font style="font-family: 'Times New Roman', Times, serif;">By:</font>&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman', Times, serif;"><u>/s/_Phillip
                      Schwartz</u> <br>
                </font></div>
              <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-weight: bold;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Phillip Schwartz, CEO</div>
              <div style="line-height: 1.25;"><font style="line-height: 1.25;">&#160;</font></div>
            </td>
            <td style="width: 50%; vertical-align: top; border-top: 1px solid rgb(0, 0, 0); border-left: 1px solid rgb(0, 0, 0); border-right: 1px solid rgb(0, 0, 0);">
              <div style="line-height: 1.25;"><font style="line-height: 1.25;">&#160;</font></div>
              <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman', Times, serif;">Address:</div>
              <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman', Times, serif;">Hadassah Medical Center, Kiryat Hadassa, PO Box 12117, Jerusalem, Israel</div>
              <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman', Times, serif;">Attention: Chief Executive Officer</div>
              <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman', Times, serif;">e-mail: phillip@enterabio.com</div>
              <div style="line-height: 1.25;"><font style="line-height: 1.25;">&#160;</font></div>
            </td>
          </tr>
          <tr>
            <td style="width: 50%; vertical-align: top; border-top: 1px solid rgb(0, 0, 0); border-left: 1px solid rgb(0, 0, 0); border-bottom: 1px solid rgb(0, 0, 0);">
              <div style="line-height: 1.25;"><font style="line-height: 1.25;">&#160;</font></div>
              <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman', Times, serif;"><font style="font-weight: bold;"><u>Consultant</u></font><u>:</u></div>
              <div style="line-height: 1.25;"><font style="line-height: 1.25;">&#160;</font></div>
              <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman', Times, serif;"><u>/s/Dana Yaacov-Garbeli</u></div>
              <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-weight: bold;">A2Z Finance Ltd.</div>
              <div style="line-height: 1.25;"><font style="line-height: 1.25;">&#160;</font></div>
            </td>
            <td style="width: 50%; vertical-align: top; border-width: 1px; border-style: solid; border-color: rgb(0, 0, 0);">
              <div style="line-height: 1.25;"><font style="line-height: 1.25;">&#160;</font></div>
              <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman', Times, serif;"><u>Address</u>:</div>
              <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman', Times, serif;">Haplech 7, Tel Aviv</div>
              <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman', Times, serif;">Israel</div>
              <div style="line-height: 1.25;"><font style="line-height: 1.25;">&#160;</font></div>
              <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman', Times, serif;">e-mail: dana@a2z-finance.co.il</div>
              <div style="line-height: 1.25;"><font style="line-height: 1.25;">&#160;</font></div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: center; line-height: 1.25;">-----------------------</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">In connection with the above Consultancy Agreement, as may be amended from time to time, the undersigned hereby
        irrevocably agrees and undertakes to exclusively perform the Services thereunder on behalf of the Consultant (as defined therein), and to comply with and be bound by the provisions of this Consultancy Agreement, as if a party thereto.</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; line-height: 1.25; font-weight: bold;"><u>Designated Service Provider</u>:</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="line-height: 1.25;">
        <div style="text-align: justify; line-height: 1.25;"><u>/s/Dana Yaacov-Garbeli</u></div>
      </div>
      <div style="line-height: 1.25;">Dana Yaacov-Garbeli</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: center; line-height: 1.25; font-style: italic;">[Signature Page to Consultancy Agreement/ June 2019]</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
        <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-weight: normal; font-style: normal;" class="BRPFPageNumber">- 6 -</font></div>
        <div style="page-break-after: always;" class="BRPFPageBreak">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <div style="text-align: center; text-indent: 28.35pt; line-height: 1.25; font-weight: bold;">AMENDMENT NO. 1 TO CONSULTING AGREEMENT</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-indent: 28.35pt; line-height: 1.25;">This Amendment to the Consulting Agreement (the "<font style="font-weight: bold;">Amendment</font>"), is made as of June 25, 2020 , by and between Entera Bio Ltd. (the "<font style="font-weight: bold;">Company</font>") and A2Z
        Finance Ltd. (the "<font style="font-weight: bold;">Consultant</font>"). Each of the Company and the Consultant shall be referred to as a "<font style="font-weight: bold;">Party</font>" and collectively as the "<font style="font-weight: bold;">Parties</font>". Capitalized terms used but not defined
        herein shall have the meaning assigned to them in the Consulting Agreement (as defined below).</div>
      <div style="line-height: 1.25">&#160;</div>
      <table cellspacing="0" cellpadding="0" id="z6d40e89c34604f2d9410d23eaacb1dd4" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 72pt; vertical-align: top;"><font style="font-weight: bold; font-variant: small-caps;">WHEREAS</font>,</td>
            <td style="width: auto; vertical-align: top;">
              <div>the Company and the Consultant have entered into that certain Consulting Agreement, dated
                June 2, 2019, as amended (the "<font style="font-weight: bold;">Consulting Agreement</font>") pursuant to which the Designated Service Provider is providing the Company with CFO Services;</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25">&#160;</div>
      <div>
        <table cellspacing="0" cellpadding="0" style="width: 100%; font-family: 'Times New Roman', Times, serif; font-size: 10pt;" id="zf8f3857449aa44e59f42498d50d22626" class="DSPFListTable">

            <tr style="vertical-align: top;">
              <td style="vertical-align: top; width: 72pt;">
                <div style="text-align: left; line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><font style="font-weight: bold; font-variant: small-caps;">WHEREAS</font>,</div>
              </td>
              <td style="vertical-align: top; width: auto;">
                <div style="text-align: left; line-height: 1.25; font-family: 'Times New Roman',Times,serif;">the Company has lawfully approved
                    the amendment of the Consulting Agreement according to the terms of this Amendment; and</div>
              </td>
            </tr>

        </table>
      </div>
      <div style="line-height: 1.25">&#160;</div>
      <div>
        <table cellspacing="0" cellpadding="0" style="width: 100%; font-family: 'Times New Roman', Times, serif; font-size: 10pt;" id="z5346c2008e4f4baa8228aa5e3d35eab2" class="DSPFListTable">

            <tr style="vertical-align: top;">
              <td style="vertical-align: top; width: 72pt;">
                <div style="text-align: left; text-indent: -72pt; margin-left: 72pt; line-height: 1.25;"><font style="font-weight: bold; font-variant: small-caps;">WHEREAS</font>,</div>
              </td>
              <td style="vertical-align: top; width: auto;">
                <div style="text-align: left; line-height: 1.25; font-family: 'Times New Roman',Times,serif;">the Parties have mutually agreed
                    to amend the Consulting Agreement in accordance with the provisions of this Amendment, effective as of January 1, 2020 (the &#8220;<font style="font-weight: bold;">Effective Date</font>&#8221;);</div>
              </td>
            </tr>

        </table>
      </div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-indent: -72pt; margin-left: 72pt; line-height: 1.25;"><font style="font-weight: bold; font-variant: small-caps;">NOW THEREFORE,</font> the Parties hereby agree as follows:</div>
      <div style="line-height: 1.25">&#160;</div>
      <table cellspacing="0" cellpadding="0" id="z4642d63e571047239d0626b84824cc66" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 18pt; vertical-align: top;">1.</td>
            <td style="width: auto; vertical-align: top;">
              <div><u>Fee</u>. As of the Effective Date, the Consultant's Fee as mentioned in <font style="font-weight: bold;"><u>Exhibit A</u></font> to the Consulting Agreement shall be amend to $14,000 plus VAT.</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25">&#160;</div>
      <table cellspacing="0" cellpadding="0" id="z4e569526ca284839bdb1037da4e6d1d2" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 18pt; vertical-align: top;">2.</td>
            <td style="width: auto; vertical-align: top;">
              <div>Unless otherwise specifically provided for herein, all other terms and conditions of the Consulting Agreement remain in full force and effect, and this Amendment
                shall be deemed an integral part of the Consulting Agreement for all intents and purposes.</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25">&#160;</div>
      <table cellspacing="0" cellpadding="0" id="z565ce3bdd8c74a8fb7f224eeae0aaa9a" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 18pt; vertical-align: top;">3.</td>
            <td style="width: auto; vertical-align: top;">
              <div>In case of any conflict or inconsistency between the terms of this Amendment and the terms of the Consulting Agreement, this Amendment shall prevail.</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25">&#160;</div>
      <table cellspacing="0" cellpadding="0" id="z49f290bf5450467b9b86cec8bef03813" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 18pt; vertical-align: top;">4.</td>
            <td style="width: auto; vertical-align: top;">
              <div>This Amendment may not be amended, other than by written instrument executed by both Parties.</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><font style="font-weight: bold; font-style: italic;"></font><font style="font-weight: bold;"> </font><font style="font-style: italic;">[Signature Page to Follow]</font></div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
        <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-weight: normal; font-style: normal;" class="BRPFPageNumber">- 7 -</font></div>
        <div style="page-break-after: always;" class="BRPFPageBreak">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <div style="line-height: 1.25;"><font style="font-weight: bold;">IN WITNESS WHEREOF</font>, the Parties
        have caused this Amendment to be executed and delivered by their duly authorized representatives, as of the date hereof.</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><font style="font-weight: bold;">Company</font>:</div>
      <div style="line-height: 1.25;">&#160;</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-style: italic;"><u>/s/ Yonatan Malca</u></div>
      <table cellspacing="0" cellpadding="0" id="z075049a2f2e34ac6bded6e0337678406" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 84.95%; vertical-align: top;">
              <div style="line-height: 1.25; font-weight: bold;">Entera Bio Ltd<font style="font-variant: small-caps;">.</font></div>
            </td>
            <td style="width: 15.05%; vertical-align: top;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 84.95%; vertical-align: top;">
              <div style="line-height: 1.25;">Name: Yonatan Malca</div>
            </td>
            <td style="width: 15.05%; vertical-align: top;" rowspan="2">&#160;</td>
          </tr>
          <tr>
            <td style="width: 84.95%; vertical-align: top;">
              <div style="line-height: 1.25;">Title: Director</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><font style="font-weight: bold;">Consultant</font>:</div>
      <div style="line-height: 1.25;">&#160;</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><u>/s/ Dana Yaacov-Garbeli</u></div>
      <table cellspacing="0" cellpadding="0" id="zfb1c0e9ab633415a8f48acabe7d94e26" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 84.95%; vertical-align: top;">
              <div style="line-height: 1.25; font-weight: bold;">A2Z Finance Ltd.</div>
            </td>
            <td style="width: 15.05%; vertical-align: top;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 84.95%; vertical-align: top;">
              <div style="line-height: 1.25;">Name: Dana Yaacov-Garbeli</div>
            </td>
            <td style="width: 15.05%; vertical-align: top;" rowspan="2">&#160;</td>
          </tr>
          <tr>
            <td style="width: 84.95%; vertical-align: top;">
              <div style="line-height: 1.25;">Title: Partner</div>
              <div style="line-height: 1.25;"><font style="line-height: 1.25;">&#160;</font></div>
              <div style="line-height: 1.25;"><font style="font-weight: bold;">Designated Service Provider</font>:</div>
              <div style="line-height: 1.25;"><font style="line-height: 1.25;">&#160;</font></div>
              <div style="line-height: 1.25;"><u>/s/ Dana Yaacov-Garbeli</u></div>
              <div style="line-height: 1.25;">Dana Yaacov-Garbeli</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
        <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-weight: normal; font-style: normal;" class="BRPFPageNumber">- 8 -</font></div>
        <div style="page-break-after: always;" class="BRPFPageBreak">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <div style="text-align: center; text-indent: 28.35pt; line-height: 1.25; font-weight: bold;">AMENDMENT NO. 2 TO CONSULTING AGREEMENT</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-indent: 28.35pt; line-height: 1.25;">This Amendment to the Consulting Agreement (the "<font style="font-weight: bold;">Amendment</font>"), is made as of October 4, 2021 , by and between Entera Bio Ltd. (the "<font style="font-weight: bold;">Company</font>") and A2Z
        Finance Ltd. (the "<font style="font-weight: bold;">Consultant</font>"). Each of the Company and the Consultant shall be referred to as a "<font style="font-weight: bold;">Party</font>" and collectively as the "<font style="font-weight: bold;">Parties</font>". Capitalized terms used but not defined
        herein shall have the meaning assigned to them in the Consulting Agreement (as defined below).</div>
      <div style="line-height: 1.25">&#160;</div>
      <table cellspacing="0" cellpadding="0" id="z3ac4923191274641901d460f4fef50bb" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 72pt; vertical-align: top;"><font style="font-weight: bold; font-variant: small-caps;">WHEREAS</font>,</td>
            <td style="width: auto; vertical-align: top;">
              <div>the Company and the Consultant have entered into that certain Consulting Agreement, dated
                June 2, 2019, as amended (the "<font style="font-weight: bold;">Consulting Agreement</font>") pursuant to which the Designated Service Provider is providing the Company with CFO Services;</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25">&#160;</div>
      <div>
        <table cellspacing="0" cellpadding="0" style="width: 100%; font-family: 'Times New Roman', Times, serif; font-size: 10pt;" id="z0772618cb78e4878a103e6170691fc96" class="DSPFListTable">

            <tr style="vertical-align: top;">
              <td style="vertical-align: top; width: 72pt;">
                <div style="text-align: left; text-indent: -72pt; margin-left: 72pt; line-height: 1.25;"><font style="font-weight: bold; font-variant: small-caps;">WHEREAS</font>,</div>
              </td>
              <td style="align: left; vertical-align: top; width: auto;">
                <div style="text-align: left; text-indent: -72pt; margin-left: 72pt; line-height: 1.25;">the Company
                    has lawfully approved the amendment of the Consulting Agreement according to the terms of this Amendment; and</div>
              </td>
            </tr>

        </table>
      </div>
      <div style="line-height: 1.25">&#160;</div>
      <div>
        <table cellspacing="0" cellpadding="0" style="width: 100%; font-family: 'Times New Roman', Times, serif; font-size: 10pt;" id="z7c00e62723db4096805cdc9fb8085f76" class="DSPFListTable">

            <tr style="vertical-align: top;">
              <td style="vertical-align: top; width: 72pt;">
                <div style="text-align: left; text-indent: -72pt; margin-left: 72pt; line-height: 1.25;"><font style="font-weight: bold; font-variant: small-caps;">WHEREAS</font>,</div>
              </td>
              <td style="vertical-align: top; width: auto;">
                <div style="text-align: left; line-height: 1.25; font-family: 'Times New Roman',Times,serif;">the Parties have mutually agreed
                    to amend the Consulting Agreement in accordance with the provisions of this Amendment, effective as of January 1, 2021 (the &#8220;<font style="font-weight: bold;">Effective Date</font>&#8221;);</div>
              </td>
            </tr>

        </table>
      </div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-indent: -72pt; margin-left: 72pt; line-height: 1.25;"><font style="font-weight: bold; font-variant: small-caps;">NOW THEREFORE,</font> the Parties hereby agree as follows:</div>
      <div style="line-height: 1.25">&#160;</div>
      <table cellspacing="0" cellpadding="0" id="zbd0889a5c1df4baa815c73560232691c" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 18pt; vertical-align: top;">5.</td>
            <td style="width: auto; vertical-align: top;">
              <div><u>Fee</u>. As of the Effective Date, the Consultant's Fee as mentioned in <font style="font-weight: bold;"><u>Exhibit A</u></font> to the Consulting Agreement shall be amend to $16,100 plus VAT.</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25">&#160;</div>
      <table cellspacing="0" cellpadding="0" id="zf7009c03b4804fdda84fcf9aef8addc0" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 18pt; vertical-align: top;">6.</td>
            <td style="width: auto; vertical-align: top;">
              <div>Unless otherwise specifically provided for herein, all other terms and conditions of the Consulting Agreement remain in full force and effect, and this Amendment
                shall be deemed an integral part of the Consulting Agreement for all intents and purposes.</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25">&#160;</div>
      <table cellspacing="0" cellpadding="0" id="z1d8337a185674a59827f1dc326228ec5" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 18pt; vertical-align: top;">7.</td>
            <td style="width: auto; vertical-align: top;">
              <div>In case of any conflict or inconsistency between the terms of this Amendment and the terms of the Consulting Agreement, this Amendment shall prevail.</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25">&#160;</div>
      <table cellspacing="0" cellpadding="0" id="zb73d6f4d8127488f97958208787acb3f" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 18pt; vertical-align: top;">8.</td>
            <td style="width: auto; vertical-align: top;">
              <div>This Amendment may not be amended, other than by written instrument executed by both Parties.</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><font style="font-style: italic;">[Signature Page to
          Follow]</font></div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
        <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-weight: normal; font-style: normal;" class="BRPFPageNumber">- 9 -</font></div>
        <div style="page-break-after: always;" class="BRPFPageBreak">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="line-height: 1.25;"><font style="font-weight: bold;">IN WITNESS WHEREOF</font>, the Parties
        have caused this Amendment to be executed and delivered by their duly authorized representatives, as of the date hereof.</div>
      <div style="line-height: 1.25">&#160;<br>
        <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><font style="font-weight: bold;">Company</font>:</div>
        <div style="line-height: 1.25;">&#160;</div>
        <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-style: italic;"><u>/s/ Yonatan Malca</u></div>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

            <tr>
              <td style="width: 84.95%; vertical-align: top;">
                <div style="line-height: 1.25; font-weight: bold;">Entera Bio Ltd<font style="font-variant: small-caps;">.</font></div>
              </td>
              <td style="width: 15.05%; vertical-align: top;">&#160;</td>
            </tr>
            <tr>
              <td style="width: 84.95%; vertical-align: top;">
                <div style="line-height: 1.25;">Name: Yonatan Malca</div>
              </td>
              <td style="width: 15.05%; vertical-align: top;" rowspan="2">&#160;</td>
            </tr>
            <tr>
              <td style="width: 84.95%; vertical-align: top;">
                <div style="line-height: 1.25;">Title: Director</div>
              </td>
            </tr>

        </table>
        <div style="line-height: 1.25;"><br style="line-height: 1.25;">
        </div>
        <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><font style="font-weight: bold;">Consultant</font>:</div>
        <div style="line-height: 1.25;">&#160;</div>
        <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><u>/s/ Dana Yaacov-Garbeli</u></div>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

            <tr>
              <td style="width: 84.95%; vertical-align: top;">
                <div style="line-height: 1.25; font-weight: bold;">A2Z Finance Ltd.</div>
              </td>
              <td style="width: 15.05%; vertical-align: top;">&#160;</td>
            </tr>
            <tr>
              <td style="width: 84.95%; vertical-align: top;">
                <div style="line-height: 1.25;">Name: Dana Yaacov-Garbeli</div>
              </td>
              <td style="width: 15.05%; vertical-align: top;" rowspan="2">&#160;</td>
            </tr>
            <tr>
              <td style="width: 84.95%; vertical-align: top;">
                <div style="line-height: 1.25;">Title: Partner</div>
                <div style="line-height: 1.25;"><font style="line-height: 1.25;">&#160;</font></div>
                <div style="line-height: 1.25;"><font style="font-weight: bold;">Designated Service Provider</font>:</div>
                <div style="line-height: 1.25;"><font style="line-height: 1.25;">&#160;</font></div>
                <div style="line-height: 1.25;"><u>/s/ Dana Yaacov-Garbeli</u></div>
                <div style="line-height: 1.25;">Dana Yaacov-Garbeli</div>
              </td>
            </tr>

        </table>
      </div>
      <div><br>
      </div>
      <br>
    </div>
  </div>
  <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-weight: normal; font-style: normal;" class="BRPFPageNumber">- 10 -</font>
    <hr align="center" style="border: none; border-bottom: 4px solid black; border-top: 1px solid black; height: 10px; color: #ffffff; background-color: #ffffff; margin-left: auto; margin-right: auto;"></div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.15
<SEQUENCE>3
<FILENAME>exhibit_10-15.htm
<DESCRIPTION>EXHIBIT 10.15
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: Z-K Global
         Document created using Broadridge PROfile 23.3.1.5138
         Copyright 1995 - 2023 Broadridge -->
  </head>
<body style="font: 10pt Times New Roman, Times, Serif">
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt; margin-right: 0">&#160;</p>
  <!-- Field: Rule-Page -->
  <div align="LEFT" style="margin-top: 12pt; margin-bottom: 3pt; margin-right: 0">
    <div style="font-size: 1pt; border-top: Black 4pt solid; border-bottom: Black 1pt solid; width: 100%; margin-right: 0">&#160;</div>
  </div>
  <!-- Field: /Rule-Page -->
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: right; margin-bottom: 0pt; margin-right: 0"><b><u>Exhibit
        10.15</u></b></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt; margin-right: 0">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt; margin-right: 0"><font style="font-style: normal; font-variant: normal"><b><u>Personal
          Employment Agreement</u></b></font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1pt">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">This Personal
    Employment Agreement (this <font style="font-family: Times New Roman, Times, Serif; background-color: white"><b>&#8220;Agreement&#8221;</b>),
    </font>is entered into at <u>Hadassah, J<font style="font-family: Times New Roman, Times, Serif; background-color: white">-m</font></u>
    on 8 June 2014 &#160;this <u>effective as</u> of March, 2014, by and between:</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1pt; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in"><b>Entera Bio Ltd.</b></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">of Kiryat Hadassah, Minrav Building &#8211; Fifth
    Floor,</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left">POB
    12117, Jerusalem 91220, Israel<br>
    (the <font style="font-family: Times New Roman, Times, Serif; background-color: white"><b>&#8220;Company&#8221;</b>);</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left">and</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left"><font style="font-family: Times New Roman, Times, Serif; background-color: white"><b>Hillel
        Galitzer </b></font>(ID No. 015346109) <br>
    of Slav 43, Yad Binyamin <br>
    (the <font style="font-family: Times New Roman, Times, Serif; background-color: white"><b>&#8220;Executive&#8221;</b>).</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 67pt; text-align: left; text-indent: 0in">&#160;</p>
  <table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%">

      <tr style="vertical-align: top; text-align: justify">
        <td style="width: 1in; text-align: left; padding-right: 0">WHEREAS,</td>
        <td style="padding-right: 0;">the Company and the Employee have entered into a prior
          Employment Agreement, dated July 20, 2012, and a new employment agreement on May 1, 2013 (collectively, the <font style="font-family: Times New Roman, Times, Serif; background-color: white"><b>&#8220;Prior
              Employment Agreement&#8221;</b>); </font>and</td>
      </tr>

  </table>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 67pt; text-align: justify; text-indent: -66pt">&#160;</p>
  <table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%">

      <tr style="vertical-align: top; text-align: justify">
        <td style="width: 1in; padding-right: 0;">WHEREAS,</td>
        <td style="padding-right: 0;">the parties hereto wish to amend the Prior Employment
          Agreement in its entirety and enter into this Agreement to set forth the terms and conditions of Executive&#8217;s employment by the
          Company;</td>
      </tr>

  </table>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 67pt; text-align: left; text-indent: -66pt">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1pt; text-align: justify; text-indent: 0in">NOW,
    THEREFORE, the parties hereto hereby agree as follows:</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1pt; text-align: justify; text-indent: 0in">&#160;</p>
  <table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%">

      <tr style="vertical-align: top; text-align: justify">
        <td style="width: 0.5in; text-align: left; padding-right: 0">1.</td>
        <td style="padding-right: 0;"><font style="font-variant: normal; color: black"><b><u>Recitals, Headings and Interpretation</u></b></font></td>
      </tr>

  </table>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1pt; text-align: justify; text-indent: 0in">&#160;</p>
  <table cellspacing="0" cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: Transparent">

      <tr style="vertical-align: top">
        <td style="width: 0.5in; padding-right: 0"></td>
        <td style="width: 0.5in; padding-right: 0">1.1</td>
        <td style="text-align: justify; padding-right: 0">The recitals to this Agreement constitute an integral part hereof.</td>
      </tr>

  </table>
  <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0">&#160;</p>
  <table cellspacing="0" cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: Transparent">

      <tr style="vertical-align: top">
        <td style="width: 0.5in; text-align: justify; padding-right: 0"></td>
        <td style="width: 0.5in; text-align: justify; padding-right: 0">1.2</td>
        <td style="text-align: justify; padding-right: 0">The division of the terms of this Agreement into clauses and the headings is solely for convenience
          of reference and shall not affect its interpretation.</td>
      </tr>

  </table>
  <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0">&#160;</p>
  <table cellspacing="0" cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: Transparent">

      <tr style="vertical-align: top">
        <td style="width: 0.5in; text-align: justify; padding-right: 0"></td>
        <td style="width: 0.5in; text-align: justify; padding-right: 0">1.3</td>
        <td style="text-align: justify; padding-right: 0">For the purposes of this Agreement, the <font style="font-family: Times New Roman, Times, Serif; background-color: white"><b>&#8220;Effective Date&#8221; </b></font>shall mean February 1, 2014. As of the
          Effective Date, this Agreement shall replace the Prior Employment Agreement in its entirety.</td>
      </tr>

  </table>
  <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; margin-right: 0">&#160;</p>
  <table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%">

      <tr style="vertical-align: top; text-align: justify">
        <td style="width: 0.5in; text-align: left; padding-right: 0">2.</td>
        <td style="padding-right: 0;"><font style="font-variant: normal; color: black"><b><u>Exclusivity of the Agreement</u></b></font></td>
      </tr>

  </table>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1pt; text-align: justify; text-indent: 0in">&#160;</p>
  <table cellspacing="0" cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: Transparent">

      <tr style="vertical-align: top">
        <td style="width: 0.5in; padding-right: 0"></td>
        <td style="width: 0.5in; padding-right: 0">2.1</td>
        <td style="text-align: justify; padding-right: 0">This Agreement is personal and the terms and conditions of the employment of
          the Executive shall be solely as set forth in this Agreement.</td>
      </tr>

  </table>
  <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; margin-right: 0">&#160;</p>
  <table cellspacing="0" cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: Transparent">

      <tr style="vertical-align: top">
        <td style="width: 0.5in; padding-right: 0"></td>
        <td style="width: 0.5in; padding-right: 0">2.2</td>
        <td style="text-align: justify; padding-right: 0">Except as provided in this Agreement, no provisions of any collective bargaining
          agreement (&#8220;Heskem Kibbutzi&#8221;), collective arrangement (&#8220;Hesder Kibutsi&#8221;) or other industry practice or
          custom of any kind shall apply.</td>
      </tr>

  </table>
  <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; margin-right: 0">&#160;</p>
  <table cellspacing="0" cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: Transparent">

      <tr style="vertical-align: top">
        <td style="width: 0.5in; padding-right: 0"></td>
        <td style="width: 0.5in; padding-right: 0">2.3</td>
        <td style="text-align: justify; padding-right: 0">This Agreement constitutes the entire agreement between the parties with respect
          to the subject matter hereof and supersedes all prior understandings, agreements, representations and discussions between them,
          oral or written.</td>
      </tr>

  </table>
  <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; margin-right: 0">&#160;</p>
  <table cellspacing="0" cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: Transparent">

      <tr style="vertical-align: top">
        <td style="width: 0.5in; padding-right: 0"></td>
        <td style="width: 0.5in; padding-right: 0">2.4</td>
        <td style="text-align: justify; padding-right: 0">Except as expressly provided in this Agreement, the Executive shall not be
          entitled to any payments or other benefits in respect of his employment and the termination of his employment with the Company.
          This Agreement may only be modified by an agreement in writing duly signed by both parties hereto.</td>
      </tr>

  </table>
  <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; margin-right: 0">&#160;</p>
  <!-- Field: Page; Sequence: 1 -->
  <div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid; margin-right: 0">
    <p style="margin: 0pt 0 0pt 0pt">&#160;</p>
  </div>
  <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt; margin-right: 0">
    <p style="margin: 0pt 0 0pt 0pt">&#160;</p>
  </div>
  <!-- Field: /Page -->
  <p style="margin-top: 0; margin-bottom: 0; margin-right: 0">&#160;</p>
  <table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%">

      <tr style="vertical-align: top; text-align: justify">
        <td style="width: 0.5in; text-align: left; padding-right: 0">3.</td>
        <td style="padding-right: 0;"><b><u>Absence of Impediment to the Executive&#8217;s Employment</u></b></td>
      </tr>

  </table>
  <p style="margin-top: 0; margin-bottom: 0; margin-right: 0"></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1pt"><font style="font-weight: normal; font-style: normal; font-variant: normal"><u></u></font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1pt">&#160;</p>
  <table cellspacing="0" cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: Transparent">

      <tr style="vertical-align: top">
        <td style="width: 0.5in; padding-right: 0"></td>
        <td style="width: 0.5in; padding-right: 0">3.1</td>
        <td style="text-align: justify; padding-right: 0">The Executive warrants, confirms and undertakes that he is entitled to enter
          into this Agreement and to assume all of the obligations pursuant hereto, that there is no contractual or other impediment to his
          entering into this Agreement, fulfilling his obligations hereunder or to his employment with the Company and that in entering into
          this Agreement he is not in breach of any other agreement or obligation to which he is or was a party.</td>
      </tr>

  </table>
  <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; margin-right: 0">&#160;</p>
  <table cellspacing="0" cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: Transparent">

      <tr style="vertical-align: top">
        <td style="width: 0.5in; padding-right: 0"></td>
        <td style="width: 0.5in; padding-right: 0">3.2</td>
        <td style="text-align: justify; padding-right: 0">The Executive hereby warrants that he has no medical or other problems, which
          might prevent him from performing his obligations to work for the Company. The Executive shall notify the Company of any change
          in his state of health, which has the potential to affect his ability to perform his obligations under this Agreement.</td>
      </tr>

  </table>
  <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; margin-right: 0">&#160;</p>
  <table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%">

      <tr style="vertical-align: top; text-align: justify">
        <td style="width: 0.5in; text-align: left; padding-right: 0">4.</td>
        <td style="padding-right: 0;"><font style="font-variant: normal; color: black"><b><u>Position and Duties</u></b></font></td>
      </tr>

  </table>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <table cellspacing="0" cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: Transparent">

      <tr style="vertical-align: top">
        <td style="width: 0.5in; padding-right: 0"></td>
        <td style="width: 0.5in; padding-right: 0">4.1</td>
        <td style="text-align: justify; padding-right: 0">The Executive shall be employed by the Company in the position of Chief Operating
          Officer. The Executive shall be subject and report to the Company&#8217;s CEO or any other officer as the Company decides and directs
          from time to time. For the avoidance of any doubt, it is hereby expressed that the Company may alter the Executive position and
          subordination, at its discretion.</td>
      </tr>

  </table>
  <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; margin-right: 0">&#160;</p>
  <table cellspacing="0" cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: Transparent">

      <tr style="vertical-align: top">
        <td style="width: 0.5in; padding-right: 0"></td>
        <td style="width: 0.5in; padding-right: 0">4.2</td>
        <td style="text-align: justify; padding-right: 0">During the course of his employment with the Company, the Executive shall honestly,
          diligently, skillfully and faithfully serve the Company. The Executive undertakes to devote all his working time, efforts and the
          best of his qualifications and skills to promoting the business and affairs of the Company, and further undertakes to comply with
          the policies and working arrangements of the Company, to loyally and fully comply with the decisions of the Company, its management
          and his supervisors in Israel and abroad, to follow the Company procedures as established from time to time, to carry out the duties
          imposed upon him, whenever established and whatever they shall be.</td>
      </tr>

  </table>
  <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; margin-right: 0">&#160;</p>
  <table cellspacing="0" cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: Transparent">

      <tr style="vertical-align: top">
        <td style="width: 0.5in; padding-right: 0"></td>
        <td style="width: 0.5in; padding-right: 0">4.3</td>
        <td style="text-align: justify; padding-right: 0">The Executive shall at all times act in a manner suitable for his position
          and status in the Company.</td>
      </tr>

  </table>
  <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; margin-right: 0">&#160;</p>
  <table cellspacing="0" cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: Transparent">

      <tr style="vertical-align: top">
        <td style="width: 0.5in; padding-right: 0"></td>
        <td style="width: 0.5in; padding-right: 0">4.4</td>
        <td style="text-align: justify; padding-right: 0">The Executive shall not, without the prior written authorization of the Company,
          directly or indirectly undertake any other employment, whether as an Executive of another employer or independently as an agent
          or consultant or in any other manner (whether for compensation or otherwise), and shall not assume any position or render services
          in any of the above-stated manners to any other entity.</td>
      </tr>

  </table>
  <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; margin-right: 0">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">Notwithstanding
    the aforesaid, the Company agrees that the Executive is authorized to provide third parties with consulting services of not more
    than 10 hours per calendar month (the <font style="font-family: Times New Roman, Times, Serif; background-color: white"><b>&#8220;Additional
        Engagement&#8221;</b>), </font>provided that such Additional Engagement shall not (a) be likely to create a conflict of interest
    with the Executive position, duties and responsibilities at the Company and (b) derogate from any of his undertaking and obligations
    according to this Agreement (including as described in Section 18 below with respect to confidentiality, non-competition and protection
    of intellectual property).</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 66pt; text-align: justify; text-indent: 0in">&#160;</p>
  <table cellspacing="0" cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: Transparent">

      <tr style="vertical-align: top">
        <td style="width: 0.5in; padding-right: 0"></td>
        <td style="width: 0.5in; padding-right: 0">4.5</td>
        <td style="text-align: justify; padding-right: 0">The Executive undertakes to notify the Company immediately and without delay
          regarding any matter or subject in respect of which he has a personal interest and/or which might create a conflict of interest
          with his position in the Company.</td>
      </tr>

  </table>
  <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; margin-right: 0">&#160;</p>
  <table cellspacing="0" cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: Transparent">

      <tr style="vertical-align: top; text-align: justify">
        <td style="width: 0.5in; padding-right: 0"></td>
        <td style="width: 0.5in; text-align: left; padding-right: 0">4.6</td>
        <td style="padding-right: 0;">The Executive undertakes to fulfill the responsibilities
          described in this Agreement and assist the Company, its affiliates, subsidiaries, related corporations and parent company now
          or hereafter existing (collectively, <font style="font-family: Times New Roman, Times, Serif; background-color: white"><b>&#8220;Affiliates&#8221;</b>)
          </font>and to make himself available to it, even after the termination of his employment relations with the Company, for any
          reason, in any matter which the Company may reasonably request his assistance, including for the purpose of providing any information
          relating to his work or actions taken by him and including in the framework of disputes (including legal or quasi-legal proceedings).
          If the Company requires the Executive&#8217;s services after the termination of the employment relations with him, for any reason, it
          shall reimburse the Executive for his expenses in connection with performing the provisions of this Section 4.6.</td>
      </tr>

  </table>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 66pt; text-align: justify; text-indent: 0in">&#160;</p>
  <!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
  <div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid">
    <p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">-
      <!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --> -&#160;</p>
  </div>
  <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt">
    <p style="margin: 0pt">&#160;</p>
  </div>
  <!-- Field: /Page -->
  <p style="margin-top: 0; margin-bottom: 0; margin-right: 0">&#160;</p>
  <table cellspacing="0" cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: Transparent">

      <tr style="vertical-align: top">
        <td style="width: 0.5in; padding-right: 0"></td>
        <td style="width: 0.5in; padding-right: 0">4.7</td>
        <td style="text-align: justify; padding-right: 0">The Executive shall be based in the Company&#8217;s Israeli offices, but he understands that his
          position involves international and local travel as required to discharge his responsibilities hereunder.</td>
      </tr>

  </table>
  <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; margin-right: 0">&#160;&#160;</p>
  <table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%">

      <tr style="vertical-align: top; text-align: justify">
        <td style="width: 0.5in; text-align: left; padding-right: 0">5.</td>
        <td style="padding-right: 0;"><font style="font-variant: normal; color: black"><b><u>Employment Term and Termination</u></b></font></td>
      </tr>

  </table>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <table cellspacing="0" cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: Transparent">

      <tr style="vertical-align: top">
        <td style="width: 0.5in; padding-right: 0"></td>
        <td style="width: 0.5in; padding-right: 0">5.1</td>
        <td style="text-align: justify; padding-right: 0">The Executive&#8217;s employment by the Company commenced on <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><b>July 20<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">th</sup> 2010.</b></font></td>
      </tr>

  </table>
  <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; margin-right: 0">&#160;</p>
  <table cellspacing="0" cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: Transparent">

      <tr style="vertical-align: top">
        <td style="width: 0.5in; padding-right: 0"></td>
        <td style="width: 0.5in; padding-right: 0">5.2</td>
        <td style="text-align: justify; padding-right: 0">The Executive&#8217;s employment may be terminated by either party subject
          to the delivery of thirty (30) days prior written notice by the terminating party (the <font style="font-family: Times New Roman, Times, Serif; background-color: white"><b>&#8220;Notice
              Period&#8221;</b>).</font></td>
      </tr>

  </table>
  <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; margin-right: 0">&#160;</p>
  <table cellspacing="0" cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: Transparent">

      <tr style="vertical-align: top">
        <td style="width: 0.5in; padding-right: 0"></td>
        <td style="width: 0.5in; padding-right: 0">5.3</td>
        <td style="text-align: justify; padding-right: 0">During the Notice Period the Executive shall continue to perform his duties
          until the conclusion of the Notice Period. Nevertheless, the Company shall have the right not to take advantage of the full Notice
          Period. In the event of such termination, the Company shall pay the Executive his Salary for the remainder of the Notice Period
          (as payment in lieu of prior notice period).</td>
      </tr>

  </table>
  <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; margin-right: 0">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">It
    is hereby expressly stated that the Company reserves the right to terminate the Executive&#8217;s employment at any time during
    the Notice Period, regardless of whether notice of termination of employment was delivered by the Company or whether such notice
    was delivered by the Executive. In the latter case such termination shall not constitute a dismissal of the Executive by the Company.</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 66pt; text-align: justify; text-indent: 0in">&#160;</p>
  <table cellspacing="0" cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: Transparent">

      <tr style="vertical-align: top">
        <td style="width: 0.5in; padding-right: 0"></td>
        <td style="width: 0.5in; padding-right: 0">5.4</td>
        <td style="text-align: justify; padding-right: 0">Notwithstanding the foregoing, the Company may terminate the Executive&#8217;s
          employment without the delivery of prior written notice, in the event of termination under circumstances which deprive the Executive
          of severance pay under Israeli law, and/or a breach of trust, and/or the Executive&#8217;s breach of the terms and conditions of
          Section 18 of this Agreement all at the discretion of the Company.</td>
      </tr>

  </table>
  <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; margin-right: 0">&#160;</p>
  <table cellspacing="0" cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: Transparent">

      <tr style="vertical-align: top">
        <td style="width: 0.5in; padding-right: 0"></td>
        <td style="width: 0.5in; padding-right: 0">5.5</td>
        <td style="text-align: justify; padding-right: 0">In the event that the Executive terminates his employment with the Company,
          for any reason, without the delivery of a written notice in accordance with Section 5.2 above, or without the completion of the
          Notice Period or any part thereof, the Company will be entitled to deduct from any debt which it may owe the Executive an amount
          equal to the salary that would have been paid to the Executive during the Notice Period, had he worked.</td>
      </tr>

  </table>
  <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; margin-right: 0">&#160;</p>
  <table cellspacing="0" cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: Transparent">

      <tr style="vertical-align: top">
        <td style="width: 0.5in; padding-right: 0"></td>
        <td style="width: 0.5in; padding-right: 0">5.6</td>
        <td style="text-align: justify; padding-right: 0">The Executive undertakes that immediately upon the termination of his employment
          with the Company, for any reason, he shall act as follows:</td>
      </tr>

  </table>
  <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; margin-right: 0">&#160;</p>
  <table cellspacing="0" cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: Transparent">

      <tr style="vertical-align: top">
        <td style="width: 1in; padding-right: 0"></td>
        <td style="width: 0.5in; padding-right: 0">5.6.1</td>
        <td style="text-align: justify; padding-right: 0">He shall deliver and/or return to the Company all the documents, diskettes
          or other magnetic media, letters, notes, reports and other papers in his possession and relating to his employment with the Company
          and the fulfillment of his duties, as well as any equipment and/or other property belonging to the Company which was placed at
          his disposal, including any Company car, computer equipment, telephone equipment, Executive ID badge or other equipment;</td>
      </tr>

  </table>
  <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; margin-right: 0">&#160;</p>
  <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; margin-right: 0"></p>
  <!-- Field: Page; Sequence: 3; Value: 2 -->
  <div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid">
    <p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">-
      <!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --> -&#160;</p>
  </div>
  <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt">
    <p style="margin: 0pt">&#160;</p>
  </div>
  <!-- Field: /Page -->
  <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; margin-right: 0">&#160;</p>
  <table cellspacing="0" cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: Transparent">

      <tr style="vertical-align: top">
        <td style="width: 1in; padding-right: 0"></td>
        <td style="width: 0.5in; padding-right: 0">5.6.2</td>
        <td style="text-align: justify; padding-right: 0">He shall delete any information relating to the Company or its business from
          his personal computer, if any; and</td>
      </tr>

  </table>
  <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; margin-right: 0">&#160;</p>
  <table cellspacing="0" cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: Transparent">

      <tr style="vertical-align: top">
        <td style="width: 1in; padding-right: 0"></td>
        <td style="width: 0.5in; padding-right: 0">5.6.3</td>
        <td style="text-align: justify; padding-right: 0">He shall coordinate the termination of his employment with his supervisors,
          and he shall transfer in an orderly fashion and in accordance with Company procedures and in accordance with the timetable determined
          by his supervisors, all documents and information and all matters with which he dealt, to whomever the Company instructs, all in
          a manner satisfactory to the Company.</td>
      </tr>

  </table>
  <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; margin-right: 0">&#160;</p>
  <table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%">

      <tr style="vertical-align: top; text-align: justify">
        <td style="width: 0.5in; text-align: left; padding-right: 0">6.</td>
        <td style="padding-right: 0;"><font style="font-variant: normal; color: black"><b><u>Working Hours</u></b></font></td>
      </tr>

  </table>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">For
    the period of February 2014 and March 2014 your working hours shall be as customary for employees of your position, however no
    less than 25.5 hours per week, reflecting a 60% job basis.</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">Starting
    April 1, 2014 your working hours will reflect a full time (100%) basis and shall be as follows: The working hours of the Executive
    shall be as required by the nature of the Executive&#8217;s position in the Company, however no less than 9 hours per day, 5 days
    per week.</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">The
    weekly day of rest of the Company shall be Saturday. The Executive may be required, from time to time and according to the work
    load demanded of him/her, to work beyond the regular working hours and days in order to fulfill his obligations according to this
    Agreement.</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">The
    position the Executive is to hold within the Company is a management position which requires a special measure of personal trust.
    Therefore, the provisions of the Hours of Work and Rest Law - 1951 <font style="font-family: Times New Roman, Times, Serif; background-color: white">(<b>&#8220;Hours
        of Work Law&#8221;</b>) </font>shall not apply to the Executive. The Executive acknowledges that the consideration set for him
    hereunder nevertheless includes within it consideration that would otherwise have been due to him pursuant to such law</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 33pt; text-align: justify; text-indent: 0in">&#160;</p>
  <table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%">

      <tr style="vertical-align: top; text-align: justify">
        <td style="width: 0.5in; text-align: left; padding-right: 0">7.</td>
        <td style="padding-right: 0;"><font style="font-variant: normal; color: black"><b><u>Salary</u></b></font></td>
      </tr>

  </table>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <table cellspacing="0" cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: Transparent">

      <tr style="vertical-align: top; text-align: justify">
        <td style="width: 0.5in; padding-right: 0"></td>
        <td style="width: 0.5in; text-align: left; padding-right: 0">7.1</td>
        <td style="padding-right: 0;">For the period of February 2014 and March 2014:</td>
      </tr>

  </table>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 33pt; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">As
    compensation for the Executive&#8217;s performance, the Company shall pay the Executive a basic gross monthly salary of NIS 14,000
    (the <font style="font-family: Times New Roman, Times, Serif; background-color: white"><b>&#8220;Base Salary&#8221;</b>). </font>In
    light of the aforesaid, in addition to the Base Salary the Executive shall be entitled to a global monthly consideration for working
    overtime in the gross amount of NIS 6,000 per month <font style="font-family: Times New Roman, Times, Serif; background-color: white"><b>(&#8220;Global
        Overtime Consideration&#8221;</b>).</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 66pt; text-align: justify; text-indent: 0in">&#160;</p>
  <table cellspacing="0" cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: Transparent">

      <tr style="vertical-align: top; text-align: justify">
        <td style="width: 0.5in; padding-right: 0"></td>
        <td style="width: 0.5in; text-align: left; padding-right: 0">7.2</td>
        <td style="padding-right: 0;">Starting April 1, 2014 your gross monthly salary will change as
          follows: Base salary will increase to NIS 24,500 and Global Overtime Consideration will increase to NIS 10,500.</td>
      </tr>

  </table>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 66pt; text-align: justify; text-indent: 0in">&#160;</p>
  <table cellspacing="0" cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: Transparent">

      <tr style="vertical-align: top; text-align: justify">
        <td style="width: 0.5in; padding-right: 0"></td>
        <td style="width: 0.5in; text-align: left; padding-right: 0">7.3</td>
        <td style="padding-right: 0;">In the event that it is claimed or determined that the
          Hours of Work Law is applicabl to the Executive&#8217;s employment under this Agreement despite the specific agreement between
          him and the Company, the Global Overtime Consideration represents any amounts payable under such law. The above-mentioned Salary
          and Global Overtime Consideration are defined together the <font style="font-family: Times New Roman, Times, Serif; background-color: white"><b>&#8220;Salary&#8221;</b>.</font></td>
      </tr>

  </table>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 66pt; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 73pt; text-align: justify; text-indent: 0in">The
    Salary is to be paid to the Executive in accordance with the Company&#8217;s normal and reasonable payroll practices, no later than the
    9th day of each month. For the avoidance of any doubt, it is hereby expressed that the Salary constitutes the overall consideration
    for the Executive&#8217;s work and in view of his position and status.</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 66pt; text-align: justify; text-indent: 0in">&#160;</p>
  <!-- Field: Page; Sequence: 4; Value: 2 -->
  <div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid">
    <p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">-
      <!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --> -&#160;</p>
  </div>
  <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt">
    <p style="margin: 0pt">&#160;</p>
  </div>
  <!-- Field: /Page -->
  <p style="margin-top: 0; margin-bottom: 0; margin-right: 0">&#160;</p>
  <table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%">

      <tr style="vertical-align: top; text-align: justify">
        <td style="width: 0.5in; text-align: left; padding-right: 0">8.</td>
        <td style="padding-right: 0;"><b><u>Manager&#8217;s Insurance/Pension Fund and Severance Pay</u></b></td>
      </tr>

  </table>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-weight: normal; font-style: normal; font-variant: normal"><u></u></font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">The
    Executive shall be entitled to a Managers&#8217; Insurance Policy (the <font style="font-family: Times New Roman, Times, Serif; background-color: white"><b>&#8220;Policy&#8221;</b>)
    </font>and/or Pension Fund (the <font style="font-family: Times New Roman, Times, Serif; background-color: white"><b>&#8220;Pension
        Fund&#8221;</b>), </font>and the Company encourages the Executive to tailor a plan or a combination of plans which best suit the
    Executive&#8217;s anticipated future needs. For the avoidance of doubt, in the event the Executive chooses to combine plans, the
    contributions percentages will relate to such portion of Salary which the Executive has allocated towards each benefit plan as
    follows:</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 26pt; text-align: justify; text-indent: 0in">&#160;</p>
  <table cellspacing="0" cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: Transparent">

      <tr style="vertical-align: top">
        <td style="width: 0.5in; padding-right: 0"></td>
        <td style="width: 0.5in; padding-right: 0">8.1.</td>
        <td style="text-align: justify; padding-right: 0">The Company shall pay into the Policy an aggregate amount representing 13.33%
          of the Salary as follows: 8.33% for severance compensation <font style="font-family: Times New Roman, Times, Serif; background-color: white">(<b>&#8220;Company&#8217;s
              Severance Contribution&#8221;</b>) </font>and 5% for pension compensation (which shall be 6% if made to a Pension Fund) (&#8220;Tagmulim&#8221;).
          In addition, the Company shall deduct 5% (which shall be 5.5% if made to a Pension Fund) of the Salary and transfer that amount
          to the Policy. The Company shall also obtain disability insurance, which may be included within the Policy, for the exclusive benefit
          of the Executive. The Company shall contribute in respect of such disability insurance an amount up to 2.5% of the Salary.</td>
      </tr>

  </table>
  <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; margin-right: 0">&#160;</p>
  <table cellspacing="0" cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: Transparent">

      <tr style="vertical-align: top">
        <td style="width: 0.5in; padding-right: 0"></td>
        <td style="width: 0.5in; padding-right: 0">8.2.</td>
        <td style="text-align: justify; padding-right: 0">The instructions of <font style="font-family: Times New Roman, Times, Serif; background-color: white"><i>&#8220;The General Approval Regarding Employers&#8217; Payments to Pension Fund and Insurance Fund
              Instead of Severance Pay&#8221;</i></font> (the <font style="font-family: Times New Roman, Times, Serif; background-color: white"><b>&#8220;General Approval&#8221; </b></font>a copy of which is attached hereto as <font style="font-family: Times New Roman, Times, Serif; background-color: white"><b><u>Schedule A</u></b>), </font>as amended from time to time, shall apply to the contributions referred to above.</td>
      </tr>

  </table>
  <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; margin-right: 0">&#160;</p>
  <table cellspacing="0" cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: Transparent">

      <tr style="vertical-align: top">
        <td style="width: 0.5in; padding-right: 0"></td>
        <td style="width: 0.5in; padding-right: 0">8.3.</td>
        <td style="text-align: justify; padding-right: 0">The Executive hereby agrees and approves that Company&#8217;s Severance Contribution,
          as detailed and defined in the General Approval, shall come in lieu of the Executive&#8217;s severance pay, and shall therefore
          constitute the full and final severance pay as stated above.</td>
      </tr>

  </table>
  <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; margin-right: 0">&#160;</p>
  <table cellspacing="0" cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: Transparent">

      <tr style="vertical-align: top">
        <td style="width: 0.5in; padding-right: 0"></td>
        <td style="width: 0.5in; padding-right: 0">8.4.</td>
        <td style="text-align: justify; padding-right: 0">The Company hereby waives any of its rights to refund of monies from the payments
          it has transferred according to the General Approval, unless the Executive&#8217;s right to severance pay is denied by virtue of a court
          order, under Sections 16 or 17 of the Severance Pay Law 5723-1963, and in the same amount which was denied, or the Executive had
          withdrawn monies from the Policy and/or the Pension Fund not due to a Granting Event. The term <font style="font-family: Times New Roman, Times, Serif; background-color: white"><i>&#8217;&#8216;Granting
              Event&#8217;&#8217;</i></font> shall mean death, disability or retirement at the age of sixty or more.</td>
      </tr>

  </table>
  <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; margin-right: 0">&#160;</p>
  <table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%">

      <tr style="vertical-align: top; text-align: justify">
        <td style="width: 0.5in; text-align: left; padding-right: 0">9.</td>
        <td style="padding-right: 0;"><font style="font-variant: normal; color: black"><b><u>Advanced Study Fund <i>(Keren Hishtalmut)</i></u></b></font></td>
      </tr>

  </table>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1pt; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0">The
    Company shall make monthly contributions on the Executive&#8217;s behalf to a recognized advanced study fund (the <font style="font-family: Times New Roman, Times, Serif; background-color: white"><b>&#8220;Study
        Fund&#8221; </b></font>(&#8220;Keren Hishtalmut&#8221;)) in an amount equal to 7.5% of the Salary. In addition, the Company shall
    deduct 2.5% from the Salary and transfer those monies to the Study Fund. Said contributions shall not exceed the tax-exempt ceiling
    set by the applicable law for tax purposes.</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 34pt; text-align: justify; text-indent: 0in">&#160;</p>
  <table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%">

      <tr style="vertical-align: top; text-align: justify">
        <td style="width: 0.5in; text-align: left; padding-right: 0">10.</td>
        <td style="padding-right: 0;"><font style="font-variant: normal; color: black"><b><u>Vacation</u></b></font></td>
      </tr>

  </table>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1pt; text-align: justify; text-indent: 0in">&#160;</p>
  <table cellspacing="0" cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: Transparent">

      <tr style="vertical-align: top">
        <td style="width: 0.5in; padding-right: 0"></td>
        <td style="width: 0.5in; padding-right: 0">10.1</td>
        <td style="text-align: justify; padding-right: 0">The Executive shall be entitled to 16 business days of paid vacation each year
          <font style="font-family: Times New Roman, Times, Serif; background-color: white">(<b>&#8220;Annual Vacation&#8221;</b>).</font></td>
      </tr>

  </table>
  <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; margin-right: 0">&#160;</p>
  <table cellspacing="0" cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: Transparent">

      <tr style="vertical-align: top">
        <td style="width: 0.5in; padding-right: 0"></td>
        <td style="width: 0.5in; padding-right: 0">10.2</td>
        <td style="text-align: justify; padding-right: 0">It is hereby expressed that the Executive must make every effort to exercise
          his Annual Vacation; however, if he/she is unable to utilize all the vacation days, the Executive shall be entitled to accumulate
          the unused balance of the vacation days standing to his credit up to a ceiling of double the number of the Annual Vacation (the
          <font style="font-family: Times New Roman, Times, Serif; background-color: white"><b>&#8220;Ceiling&#8221;</b>), </font>provided
          that the Executive takes at least seven consecutive annual working days vacation. If the Executive accumulates vacation days exceeding
          the Ceiling, the balance shall be deleted.</td>
      </tr>

  </table>
  <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; margin-right: 0">&#160;</p>
  <p style="margin: 0"></p>
  <!-- Field: Page; Sequence: 5; Value: 2 -->
  <div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid">
    <p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">-
      <!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --> -&#160;</p>
  </div>
  <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt">
    <p style="margin: 0pt">&#160;</p>
  </div>
  <!-- Field: /Page -->
  <p style="margin: 0">&#160;</p>
  <table width="100%" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: transparent">

      <tr style="vertical-align: top">
        <td style="width: 0.5in; padding-right: 0"></td>
        <td style="width: 0.5in; padding-right: 0">10.3</td>
        <td style="text-align: justify; padding-right: 0">The Company may instruct the Executive to use his Annual Vacation, in the event that Company employees are sent by the Company on an organized vacation.</td>
      </tr>

  </table>
  <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; margin-right: 0">&#160;</p>
  <table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%">

      <tr style="vertical-align: top; text-align: justify">
        <td style="width: 0in; padding-right: 0"></td>
        <td style="width: 0.5in; text-align: left; padding-right: 0">11.</td>
        <td style="padding-right: 0;"><font style="font-variant: normal"><b><u>Convalescence</u></b></font></td>
      </tr>

  </table>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">The
    Executive shall be entitled to convalescence (&#8220;Havra&#8217;ah&#8221;) pay in accordance with Israeli law.</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&#160;</p>
  <table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%">

      <tr style="vertical-align: top; text-align: justify">
        <td style="width: 0in; padding-right: 0"></td>
        <td style="width: 0.5in; text-align: left; padding-right: 0">12.</td>
        <td style="padding-right: 0;"><font style="font-variant: normal"><b><u>Sick Pay</u></b></font></td>
      </tr>

  </table>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">The
    Executive shall be entitled to 18 annual paid sick days according to the Company&#8217;s policy. Sick leave may be accumulated
    up to a ceiling of 90 days, but may not be redeemed on a cash basis under any circumstances.</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&#160;</p>
  <table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%">

      <tr style="vertical-align: top; text-align: justify">
        <td style="width: 0in; padding-right: 0"></td>
        <td style="width: 0.5in; text-align: left; padding-right: 0">13.</td>
        <td style="padding-right: 0;"><font style="font-variant: normal"><b><u>Reserve Duty</u></b></font></td>
      </tr>

  </table>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">The
    Company shall pay the Executive his entire Salary for periods that he performs reserve duty, provided that he delivers to the
    Company all official documents necessary for the Company to obtain reimbursement from the National Insurance Institute.</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&#160;</p>
  <table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%">

      <tr style="vertical-align: top; text-align: justify">
        <td style="width: 0in; padding-right: 0"></td>
        <td style="width: 0.5in; text-align: left; padding-right: 0">14.</td>
        <td style="padding-right: 0;"><font style="font-variant: normal"><b><u>Expenses</u></b></font></td>
      </tr>

  </table>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1pt; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 33pt; text-align: justify; text-indent: 0in">The
    Executive will be reimbursed by the Company for pre-approved business expenses incurred by him in connection with his duties and
    against valid receipts furnished by the Executive to the Company, all in accordance with Company&#8217;s policy, as may be amended
    from time to time.</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 33pt; text-align: justify; text-indent: 0in">&#160;</p>
  <table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%">

      <tr style="vertical-align: top; text-align: justify">
        <td style="width: 0in; padding-right: 0"></td>
        <td style="width: 0.5in; text-align: left; padding-right: 0">15.</td>
        <td style="padding-right: 0;"><font style="font-variant: normal"><b><u>Company Car</u></b></font></td>
      </tr>

  </table>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1pt; text-align: justify; text-indent: 0in">&#160;</p>
  <table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%">

      <tr style="vertical-align: top; text-align: justify">
        <td style="width: 0.5in; padding-right: 0"></td>
        <td style="width: 0.5in; text-align: left; padding-right: 0">15.1</td>
        <td style="padding-right: 0;"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
            February 2014 the Company shall pay the Executive monthly travel expenses of 833 N1S.</font></td>
      </tr>

  </table>
  <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; margin-right: 0">&#160;</p>
  <table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%">

      <tr style="vertical-align: top">
        <td style="width: 0.5in; padding-right: 0"></td>
        <td style="width: 0.5in; padding-right: 0">15.2</td>
        <td style="text-align: justify; padding-right: 0"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Starting March 1, 2014 Company shall provide Executive with a Car from class 2 (i.e, a price of up to NIS135,000) (the <b>&#8220;Company
              Car&#8221;) </b>to be placed at Executive&#8217;s disposal, for his business and personal use, and for the use of his spouse and any children over the age of 24 holding valid driver&#8217;s licenses for at least two years <b>(&#8220;Authorized Drivers&#8221;), provided</b>
            that Company&#8217;s procedures in respect of said use are followed. Company Car may also be used by Company personnel.</font></td>
      </tr>

  </table>
  <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; margin-right: 0">&#160;</p>
  <table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%">

      <tr style="vertical-align: top">
        <td style="width: 0.5in; padding-right: 0"></td>
        <td style="width: 0.5in; padding-right: 0">15.3</td>
        <td style="text-align: justify; padding-right: 0">Executive shall maintain the Company Car in a good state of repair, and take all necessary
          steps so as to ensure that the Company&#8217;s rules relating to Company Car, and the provisions of the insurance policy relating
          to the use of the Company Car, are strictly and carefully observed.</td>
      </tr>

  </table>
  <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; margin-right: 0">&#160;</p>
  <table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%">

      <tr style="vertical-align: top">
        <td style="width: 0.5in; padding-right: 0"></td>
        <td style="width: 0.5in; padding-right: 0">15.4</td>
        <td style="text-align: justify; padding-right: 0">Executive hereby declares that he is aware that in order to provide him with the Company
          Car, Company intends to rent or lease the Company Car, pursuant to a car rent/lease agreement. Executive undertakes to strictly
          comply with all of the provisions of said agreement relating to the use of the Company Car.</td>
      </tr>

  </table>
  <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; margin-right: 0">&#160;</p>
  <table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%">

      <tr style="vertical-align: top">
        <td style="width: 0.5in; padding-right: 0"></td>
        <td style="width: 0.5in; padding-right: 0">15.5</td>
        <td style="text-align: justify; padding-right: 0">Executive shall bear and pay all expenses relating to any violation of law committed in connection with the use of the Company Car, and shall indemnify and/or reimburse Company, upon its first
          demand for all expenses incurred by it as a result of such violations as well as with respect to charges made by the leasing Company with respect to road accidents or other damages to the car. Executive shall sign a declaration allowing the
          Company to endorse any tickets received to his name as described in <b><u>Schedule B</u></b>.</td>
      </tr>

  </table>
  <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; margin-right: 0">&#160;</p>
  <!-- Field: Page; Sequence: 1; Options: NewSection; Value: 6 -->
  <div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid; margin-right: 0">
    <p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: normal 10pt Times New Roman, Times, Serif; margin-right: 0">-
      <!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --> -</p>
  </div>
  <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt; margin-right: 0">
    <p style="margin: 0pt 0 0pt 0pt">&#160;</p>
  </div>
  <!-- Field: /Page -->
  <p style="margin-top: 0; margin-bottom: 0; margin-right: 0">&#160;</p>
  <table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%">

      <tr style="vertical-align: top">
        <td style="width: 0.5in; padding-right: 0"></td>
        <td style="width: 0.5in; padding-right: 0">15.6</td>
        <td style="text-align: justify; padding-right: 0">Executive shall bear and pay all taxes applicable to Executive in connection with the Company Car.</td>
      </tr>

  </table>
  <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; margin-right: 0">&#160;</p>
  <table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%">

      <tr style="vertical-align: top">
        <td style="width: 0.5in; padding-right: 0"></td>
        <td style="width: 0.5in; padding-right: 0">15.7</td>
        <td style="text-align: justify; padding-right: 0">Executive hereby irrevocably authorizes Company to set off all amounts, which the Company may have to pay under this Section (including early return fees which the Company may have to pay according
          the car rent/lease agreement), against any and all amounts due to Executive from Company under this Agreement.</td>
      </tr>

  </table>
  <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; margin-right: 0">&#160;</p>
  <table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%">

      <tr style="vertical-align: top">
        <td style="width: 0.5in; padding-right: 0"></td>
        <td style="width: 0.5in; padding-right: 0">15.8</td>
        <td style="text-align: justify; padding-right: 0">without derogating the above mentioned, Executive hereby irrevocably authorizes Company to set off all excess amounts, which the Company may have to pay according to the terms set forth in <font style="font-family: Times New Roman, Times, Serif"><b><u>Schedule C</u></b>,</font> against any and all amounts due to Executive from Company under this Agreement.</td>
      </tr>

  </table>
  <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; margin-right: 0">&#160;</p>
  <table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%">

      <tr style="vertical-align: top">
        <td style="width: 0.5in; padding-right: 0"></td>
        <td style="width: 0.5in; padding-right: 0">15.9</td>
        <td style="text-align: justify; padding-right: 0">Executive shall return the Company Car (together with its keys and any other equipment supplied and/or installed therein by Company, but free of any of Executive&#8217;s belongings) to Company&#8217;s principal
          office at the earliest of (a) immediately upon termination of Executive&#8217;s employment or (b) within 7 days from the Company&#8217;s demand, in proper working order and in the condition in which he received it, taking into account normal wear and tear
          resulting from reasonable use of the Company Car. Executive shall have no rights of lien with respect to the Company Car and/or any of said other equipment.</td>
      </tr>

  </table>
  <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; margin-right: 0">&#160;</p>
  <table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%">

      <tr style="vertical-align: top">
        <td style="width: 0.5in; padding-right: 0"></td>
        <td style="width: 0.5in; padding-right: 0">15.10</td>
        <td style="text-align: justify; padding-right: 0">To remove any doubt, it is hereby clarified that the Executive shall be liable under the provisions of this Section for any actions of the Authorized Drivers relating to the Company Car and shall
          cause said Authorized Drivers to fulfill all of the provisions of this Section.</td>
      </tr>

  </table>
  <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; margin-right: 0">&#160;</p>
  <table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%">

      <tr style="vertical-align: top">
        <td style="width: 0.5in; padding-right: 0"></td>
        <td style="width: 0.5in; padding-right: 0">15.11</td>
        <td style="text-align: justify; padding-right: 0">For the avoidance of doubt it is hereby clarified that the Car shall come in lieu of any payment in respect of travel expenses in accordance with the Law.</td>
      </tr>

  </table>
  <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; margin-right: 0">&#160;</p>
  <table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%">

      <tr style="vertical-align: top; text-align: justify">
        <td style="width: 0in; padding-right: 0"></td>
        <td style="width: 0.5in; text-align: left; padding-right: 0">16.</td>
        <td style="padding-right: 0;"><font style="font-variant: normal"><b><u>Cellular Phone and Lap </u></b></font><b><u><font style="font-variant: small-caps">Top</font></u></b></td>
      </tr>

  </table>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>
  <table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%">

      <tr style="vertical-align: top">
        <td style="width: 0.5in; padding-right: 0"></td>
        <td style="width: 0.5in; padding-right: 0">16.1</td>
        <td style="text-align: justify; padding-right: 0"><font style="font-size: 10pt">The Company shall provide Executive with a cellular phone (the <font style="font-family: Times New Roman, Times, Serif"><b>&#8220;Cellular Phone&#8221;) </b></font>and a Lap Top
            (the <font style="font-family: Times New Roman, Times, Serif"><b>&#8220;Lap Top&#8221;) </b></font>to be placed at Executive&#8217;s disposal for Executive &#8217;s use in the course of performing Executive&#8217;s obligations under this Agreement, <font style="font-family: Times New Roman, Times, Serif"><i>provided </i></font>that the Company&#8217;s procedures in respect thereof are followed. Executive shall bear all taxes applicable to Executive in connection with the Cellular Phone and the Lap
            Top.</font></td>
      </tr>

  </table>
  <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; margin-right: 0">&#160;</p>
  <table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%">

      <tr style="vertical-align: top">
        <td style="width: 0.5in; padding-right: 0"></td>
        <td style="width: 0.5in; padding-right: 0">16.2</td>
        <td style="text-align: justify; padding-right: 0"><font style="font-size: 10pt">Executive shall return the Cellular Phone and the Lap Top (together with any other equipment supplied) to the Company&#8217;s principal office at the earliest of (a)
            immediately upon termination of Executive&#8217;s employment or (b) within 7 days from the Company&#8217;s demand. Executive shall have no rights of lien with respect to the Cellular Phone, the Lap Top and/or any of said other equipment.</font></td>
      </tr>

  </table>
  <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; margin-right: 0">&#160;</p>
  <table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%">

      <tr style="vertical-align: top">
        <td style="width: 0.5in; padding-right: 0"></td>
        <td style="width: 0.5in; padding-right: 0">16.3</td>
        <td style="text-align: justify; padding-right: 0"><font style="font-size: 10pt">In Case Executive damages or loses the cellular phone than Executive shall bear the cost of a replacement phone or the deductible that the Cellular Company requires
            (Hishtatfut Azmit). In case the Cellular Phone is stolen than the Company shall bear half of the cost and the Executive half of the cost of a replacement phone or the deductible that the Cellular Company requires (Hishtatfut Azmit).</font></td>
      </tr>

  </table>
  <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; margin-right: 0">&#160;</p>
  <table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%">

      <tr style="vertical-align: top; text-align: justify">
        <td style="width: 0in; padding-right: 0"></td>
        <td style="width: 0.5in; text-align: left; padding-right: 0">17.</td>
        <td style="padding-right: 0;"><font style="font-variant: normal"><b><u>Share Options</u></b></font></td>
      </tr>

  </table>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.9in; text-align: justify; text-indent: 0.1in">In
    accordance with the Company&#8217;s policy and subject to prior approval of the Board of Directors of the Company, the Company
    shall consider making a grant of options to Executive to purchase ordinary shares of the Company, all on such amounts and terms
    as to be approved by the Board of Directors of the Company. The grant of options shall be subject to Executive&#8217;s separate
    execution of the Company&#8217;s <font style="font-family: Times New Roman, Times, Serif">standard </font>option agreement.</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.85in; text-align: justify; text-indent: 0in">&#160;</p>
  <!-- Field: Page; Sequence: 2; Value: 6 -->
  <div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid; margin-right: 0">
    <p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: normal 10pt Times New Roman, Times, Serif; margin-right: 0">-
      <!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --> -</p>
  </div>
  <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt; margin-right: 0">
    <p style="margin: 0pt 0 0pt 0pt">&#160;</p>
  </div>
  <!-- Field: /Page -->
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.7in; text-align: justify; text-indent: 9.35pt">&#160;</p>
  <table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%">

      <tr style="vertical-align: top; text-align: justify">
        <td style="width: 0in; padding-right: 0"></td>
        <td style="width: 0.5in; text-align: left; padding-right: 0"><font style="font-style: normal; font-variant: normal">18.</font></td>
        <td style="padding-right: 0;"><font style="font-style: normal; font-variant: normal"><b><u>Confidentiality,
                Non-Competition and Intellectual Property</u></b></font></td>
      </tr>

  </table>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">The
    Executive warrants and undertakes that for as long as he is employed by the Company, and upon termination of employment thereafter,
    for any reason, he shall maintain in complete confidence any matters that relate to the Company, its affairs and/or business,
    including regarding the terms and conditions of his employment pursuant to this Agreement, and that he shall not harm its goodwill
    or reputation, and he agrees to the provisions of the confidentiality, non-competition and intellectual property clauses as specified
    below.</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">The
    Executive&#8217;s obligations pursuant to this Section derive from his status and his position in the Company, along with all matters
    connected therewith, and the terms and conditions of the Executive&#8217;s employment pursuant to this Agreement, including his Salary,
    have been determined in part, inter alia, in consideration of this undertaking and constitute sufficient consideration for his
    obligations hereunder.</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&#160;</p>
  <table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%">

      <tr style="vertical-align: top; text-align: justify">
        <td style="width: 0.5in; padding-right: 0"></td>
        <td style="width: 0.5in; text-align: left; padding-right: 0">18.1</td>
        <td style="padding-right: 0;"><font style="font-variant: normal"><b><u>Confidentiality</u></b></font></td>
      </tr>

  </table>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%">

      <tr style="vertical-align: top">
        <td style="width: 1in; padding-right: 0"></td>
        <td style="width: 0.5in; padding-right: 0">18.1.1</td>
        <td style="text-align: justify; padding-right: 0">The Executive undertakes to maintain the Confidential Information (as defined below) of the Company, including its Affiliates, during the term of his employment with the Company and after the
          termination of such employment, for any reason.</td>
      </tr>

  </table>
  <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; margin-right: 0">&#160;</p>
  <table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%">

      <tr style="vertical-align: top">
        <td style="width: 1in; padding-right: 0"></td>
        <td style="width: 0.5in; padding-right: 0">18.1.2</td>
        <td style="text-align: justify; padding-right: 0">Without derogating from the generality of the foregoing, the Executive hereby agrees that he shall not, directly or indirectly, disclose or transfer to any person or entity, at any time, either
          during or subsequent to his employment period, any trade secrets or other confidential information, whether patentable or not, of the Company and/or its Affiliates, including but not limited to, any (i) processes, formulas, trade secrets,
          innovations, inventions, discoveries, improvements, research or development and test results, survey, specifications, data and know-how; (ii) marketing plans, business plans, strategies, forecasts, unpublished financial information, budgets,
          projections, product plans and pricing; (iii) personnel information, including organizational structure, salary, and qualifications of Executives; (iv) customer and supplier information, including identities, product sales and purchase history or
          forecasts and agreements; and (v) any other information which is not known to the public (collectively, <font style="font-family: Times New Roman, Times, Serif"><b>&#8220;Confidential Information&#8221;), </b></font>of which the Executive is or becomes
          informed or aware during the employment period, whether or not developed by the Executive.</td>
      </tr>

  </table>
  <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; margin-right: 0">&#160;</p>
  <table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%">

      <tr style="vertical-align: top">
        <td style="width: 1in; padding-right: 0"></td>
        <td style="width: 0.5in; padding-right: 0">18.1.3</td>
        <td style="text-align: justify; padding-right: 0">The Executive undertakes not to directly or indirectly give and/or transfer, directly or indirectly, to any person or entity, any material and/or raw material and/or product and/or part of a product
          and/or model and/or document and/or diskette and/or other information storage media and/or photocopied and/or printed and/or duplicated object containing any or all of the Confidential Information.</td>
      </tr>

  </table>
  <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; margin-right: 0">&#160;</p>
  <table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%">

      <tr style="vertical-align: top">
        <td style="width: 1in; padding-right: 0"></td>
        <td style="width: 0.5in; padding-right: 0">18.1.4</td>
        <td style="text-align: justify; padding-right: 0">The Executive undertakes not to make any use, including duplication, production, sale, transfer, imitation and distribution, of all or any of the Confidential Information, without the prior written
          consent of the Company.</td>
      </tr>

  </table>
  <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; margin-right: 0">&#160;</p>
  <table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%">

      <tr style="vertical-align: top">
        <td style="width: 1in; padding-right: 0"></td>
        <td style="width: 0.5in; padding-right: 0">18.1.5</td>
        <td style="text-align: justify; padding-right: 0">In the event the Executive is in breach of any of his above obligations, he shall be liable to compensate the Company in respect of all damages and/or expenses incurred by the Company as a result of
          such breach, including trial costs and legal fees and statutory VAT, and such being without derogating from
          any other relief and/or remedy available to the Company by virtue of any law</td>
      </tr>

  </table>
  <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; margin-right: 0">&#160;</p>
  <!-- Field: Page; Sequence: 3; Value: 6 -->
  <div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid; margin-right: 0">
    <p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: normal 10pt Times New Roman, Times, Serif; margin-right: 0">-
      <!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --> -</p>
  </div>
  <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt; margin-right: 0">
    <p style="margin: 0pt 0 0pt 0pt">&#160;</p>
  </div>
  <!-- Field: /Page -->
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.9in; text-align: justify; text-indent: 0in">&#160;</p>
  <table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%">

      <tr style="vertical-align: top; text-align: justify">
        <td style="width: 0.5in; padding-right: 0"></td>
        <td style="width: 0.5in; text-align: left; padding-right: 0">18.2</td>
        <td style="padding-right: 0;"><b><u>Non-Competition<font style="font-variant: normal">/ Non-Solicitation</font></u></b></td>
      </tr>

  </table>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&#160;</p>
  <table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%">

      <tr style="vertical-align: top">
        <td style="width: 1in; padding-right: 0"></td>
        <td style="width: 0.5in; padding-right: 0">18.2.1</td>
        <td style="text-align: justify; padding-right: 0">The Executive undertakes that during the period of his employment with the Company and <font style="font-family: Times New Roman, Times, Serif">for </font>a period <font style="font-family: Times New Roman, Times, Serif">of </font>(12) months from the termination <font style="font-family: Times New Roman, Times, Serif">of </font>his employment therewith, <font style="font-family: Times New Roman, Times, Serif">for </font>any
          reason, he shall not, anywhere in the world, do business, as an Executive, independent contractor, consultant or otherwise, and shall not directly or indirectly participate in or accept any <font style="font-family: Times New Roman, Times, Serif">Position, </font>proposal or job <font style="font-family: Times New Roman, Times, Serif">offer </font>that may directly or indirectly compete with or harm the Company, or in the field in which the Company engages, is engaged or is
          about to engaged (the <font style="font-family: Times New Roman, Times, Serif">&#8220;<b>Competitive Occupation</b>&#8221;).</font></td>
      </tr>

  </table>
  <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; margin-right: 0">&#160;</p>
  <table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%">

      <tr style="vertical-align: top">
        <td style="width: 1in; padding-right: 0"></td>
        <td style="width: 0.5in; padding-right: 0">18.2.2</td>
        <td style="text-align: justify; padding-right: 0">Without derogating from the generality of the foregoing, the Executive undertakes not to maintain any business relations of any type whatsoever, including a proposal to conduct business relations,
          directly or indirectly, with any of the Company&#8217;s customers and/or suppliers and/or agents, including customers and/or suppliers and/or agents with whom the Company conducted negotiations towards an agreement at the time of the termination of his
          employment with the Company or prior thereto. In addition, the Executive undertakes not to approach and/or solicit and/or recruit any employee of the Company to leave the Company for a period of (12) months from the date of the termination of the
          employment relationship.</td>
      </tr>

  </table>
  <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; margin-right: 0">&#160;</p>
  <table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%">

      <tr style="vertical-align: top">
        <td style="width: 1in; padding-right: 0"></td>
        <td style="width: 0.5in; padding-right: 0">18.2.3</td>
        <td style="text-align: justify; padding-right: 0">The foregoing shall apply irrespective of whether the Competitive Occupation is carried out by the Executive alone or in cooperation with others and shall apply to the participation of the Executive
          in a Competitive Occupation, whether as a Controlling shareholder or as an interested party.</td>
      </tr>

  </table>
  <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; margin-right: 0">&#160;</p>
  <table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%">

      <tr style="vertical-align: top; text-align: justify">
        <td style="width: 0.5in; padding-right: 0"></td>
        <td style="width: 0.5in; text-align: left; padding-right: 0"><font style="font-weight: normal; font-style: normal; font-variant: normal">18.3</font></td>
        <td style="padding-right: 0;"><font style="font-style: normal; font-variant: normal"><b><u>Intellectual Property. Copyright and Patents</u></b></font></td>
      </tr>

  </table>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&#160;</p>
  <table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%">

      <tr style="vertical-align: top">
        <td style="width: 1in; padding-right: 0"></td>
        <td style="width: 0.5in; padding-right: 0">18.3.1</td>
        <td style="text-align: justify; padding-right: 0">The Executive hereby acknowledges and agrees that the Company owns and shall own any and all Intellectual Property Rights created, made or discovered by the Executive or employee (whether solely or
          <font style="font-family: Times New Roman, Times, Serif">jointly </font>with others) related to the <font style="font-family: Times New Roman, Times, Serif">company&#8217;s activity </font>(Drug Development and Manufacturing) either: during the term
          of employment; and/or in connection therewith; and/or in connection with the Company, its business (actual and/ or contemplated), products, technology and/or know how <font style="font-family: Times New Roman, Times, Serif"><b>(&#8220;Company IPR&#8221;).
              Intellectual Property Rights</b> </font>means all worldwide (a) patents, patent applications and patent rights; (b) rights associated with works of authorship, including <font style="font-family: Times New Roman, Times, Serif">Copyrights,
            Copyrights </font>applications, <font style="font-family: Times New Roman, Times, Serif">Copyrights </font>restrictions, mask work rights, mask work applications and mask work registrations; (c) rights relating to the protection of trade
          secrets and confidential information; (d) moral rights; (e) rights analogous to those set forth herein and any other proprietary rights relating to intangible property including ideas; and (f) divisions, continuations, renewals, reissues and
          extensions of the foregoing (as applicable) now existing or hereafter filed, issued, or acquired.</td>
      </tr>

  </table>
  <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; margin-right: 0">&#160;</p>
  <table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%">

      <tr style="vertical-align: top">
        <td style="width: 1in; padding-right: 0"></td>
        <td style="width: 0.5in; padding-right: 0">18.3.2</td>
        <td style="text-align: justify; padding-right: 0">The Executive acknowledges and agrees that all Company IPR belong to, and shall be the sole property of, the Company and shall be Company IPR of the Company upon creation thereof. The Executive
          hereby irrevocably assigns to the Company and/or its designee, all right, title and interest the Executive may have or may acquire in and to Company IPR upon its creation. The Executive acknowledges and agrees that no rights relating to any
          Company IPR are reserved to Executive. The Executive will assist the Company to obtain, and from time to time enforce, any Company IPR worldwide,
          including without limitation, executing, verifying and delivering such documents and performing such other acts as the Company
          may reasonably request for use in applying for, obtaining, perfecting, evidencing, sustaining and enforcing such Company IPR.
          Such Obligation shall remain in effect beyond the termination of the Executive&#8217;s relationship with the Company, all for no additional
          consideration provided that Executive shall not be required to bear any expenses as a result of such assignment. In the event
          the Company is unable for any reason, after reasonable effort, to secure Executive&#8217;s signature on any document required, Executive
          hereby irrevocably designate and appoint the Company and its duly authorized officers and agents as its agent and attorney in fact
          to act for and in its behalf to further the above purposes.</td>
      </tr>

  </table>
  <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; margin-right: 0">&#160;</p>
  <!-- Field: Page; Sequence: 4; Value: 6 -->
  <div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid; margin-right: 0">
    <p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: normal 10pt Times New Roman, Times, Serif; margin-right: 0">-
      <!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --> -</p>
  </div>
  <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt; margin-right: 0">
    <p style="margin: 0pt 0 0pt 0pt">&#160;</p>
  </div>
  <!-- Field: /Page -->
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">&#160;</p>
  <table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%">

      <tr style="vertical-align: top">
        <td style="width: 1in; padding-right: 0"></td>
        <td style="width: 0.5in; padding-right: 0">18.3.3</td>
        <td style="text-align: justify; padding-right: 0">The Executive irrevocably confirms that the consideration explicitly set forth in the employment agreement between the Executive and the Company is inclusive of any and all rights for compensation
          that may arise in connection with the Company IPR under applicable law and the Executive waives any legal right he may have in connection with the Company IPR including without limitation any moral rights and/or right to claim royalties or any
          other additional consideration from the Company with regard to the assigned Company IPR, including without limitation, in respect of Section 134 of the Patent Law 5727-1967 and/or other applicable laws.</td>
      </tr>

  </table>
  <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; margin-right: 0">&#160;</p>
  <table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%">

      <tr style="vertical-align: top">
        <td style="width: 1in; padding-right: 0"></td>
        <td style="width: 0.5in; padding-right: 0">18.3.4</td>
        <td style="text-align: justify; padding-right: 0">The Executive represents and warrants that upon execution hereof it has not created and does not have any right, title or interest in and to any Intellectual Property Rights related and/or similar
          to Company&#8217;s business, products or Intellectual Property Rights, other than those set forth in <font style="font-family: Times New Roman, Times, Serif"><b><u>Schedule A1</u></b></font> hereto <font style="font-family: Times New Roman, Times, Serif"><b>(&#8220;Prior Inventions&#8221;)</b></font>. The Executive undertakes not to incorporate any Prior Inventions in any Company IPR.</td>
      </tr>

  </table>
  <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; margin-right: 0">&#160;</p>
  <table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%">

      <tr style="vertical-align: top">
        <td style="width: 1in; padding-right: 0"></td>
        <td style="width: 0.5in; padding-right: 0">18.3.5</td>
        <td style="text-align: justify; padding-right: 0">The Executive undertakes to immediately inform and deliver IN WRITING to the Company, written notice of any Company IPR conceived/ invented by him and/or personal of the Company and/or its
          successors who are subordinate to him, immediately upon the discovery thereof.</td>
      </tr>

  </table>
  <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; margin-right: 0">&#160;</p>
  <table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%">

      <tr style="vertical-align: top">
        <td style="width: 1in; padding-right: 0"></td>
        <td style="width: 0.5in; padding-right: 0">18.3.6</td>
        <td style="text-align: justify; padding-right: 0">The Executive&#8217;s obligations pursuant to this Section shall survive the termination of his employment with the Company and/or its successors and assigns with respect to inventions conceived by him
          during the term of his employment or as a result of his employment with the Company.</td>
      </tr>

  </table>
  <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; margin-right: 0">&#160;</p>
  <table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%">

      <tr style="vertical-align: top">
        <td style="width: 0.5in; padding-right: 0"></td>
        <td style="width: 0.5in; padding-right: 0">18.4</td>
        <td style="text-align: justify; padding-right: 0">Executive acknowledges that the restricted period of time and geographical area specified hereunder are reasonable, in view of his position and the nature of the business in which the Company is
          engaged, the Executive&#8217;s knowledge of the Company&#8217;s business and the compensation he receives. Notwithstanding anything contained herein to the contrary, if the period of time or the geographical area specified herein should be determined to be
          unreasonable in any judicial proceeding, then the period of time and area of the restriction shall be reduced so that this Agreement may be enforced in such area and during such period of time as shall be determined to be reasonable by such
          judicial proceeding. The Executive acknowledges that the compensation and benefits granted to him by the Company under this Agreement were determined, inter alia, in consideration for his obligations under this Section 18.</td>
      </tr>

  </table>
  <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; margin-right: 0">&#160;</p>
  <!-- Field: Page; Sequence: 5; Value: 6 -->
  <div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid; margin-right: 0">
    <p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: normal 10pt Times New Roman, Times, Serif; margin-right: 0">-
      <!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --> -</p>
  </div>
  <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt; margin-right: 0">
    <p style="margin: 0pt 0 0pt 0pt">&#160;</p>
  </div>
  <!-- Field: /Page -->
  <p style="margin-top: 0; margin-bottom: 0; margin-right: 0">&#160;</p>
  <table cellspacing="0" cellpadding="0" style="font-size: 10pt; margin-top: 0; margin-bottom: 0; width: 100%">

      <tr style="vertical-align: top; text-align: justify">
        <td style="width: 0in; padding-right: 0"></td>
        <td style="width: 0.5in; text-align: left; padding-right: 0">19.</td>
        <td style="padding-right: 0;"><font style="font-family: Times New Roman, Times, Serif; font-style: normal; font-variant: normal;"><b><u>General</u></b></font></td>
      </tr>

  </table>
  <p style="margin-top: 0; margin-bottom: 0; margin-right: 0">&#160;</p>
  <table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%">

      <tr style="vertical-align: top; text-align: justify">
        <td style="width: 0.5in; padding-right: 0"></td>
        <td style="width: 0.5in; text-align: left; padding-right: 0">19.1</td>
        <td style="padding-right: 0;">The Executive shall bear all the taxes deriving from
          the rights and benefits received by him pursuant hereto. It is hereby expressed that all the amounts specified in this Agreement
          are gross, and statutory tax and all the other compulsory payments, including health insurance contributions and national insurance
          contributions, shall be deducted from them and from all the rights and benefits received by the Executive pursuant hereto.</td>
      </tr>

  </table>
  <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; margin-right: 0">&#160;</p>
  <table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%">

      <tr style="vertical-align: top">
        <td style="width: 0.5in; padding-right: 0"></td>
        <td style="width: 0.5in; padding-right: 0">19.2</td>
        <td style="text-align: justify; padding-right: 0">This Agreement and all rights and duties of the parties hereunder shall be exclusively governed by and interpreted in accordance with the laws of the State of Israel. The competent courts of the
          State of Israel, Tel Aviv Jaffa district, shall have the exclusive jurisdiction over the parties with regard to this Agreement, its execution, Interpretation and performance.</td>
      </tr>

  </table>
  <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; margin-right: 0">&#160;</p>
  <table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%">

      <tr style="vertical-align: top">
        <td style="width: 0.5in; padding-right: 0"></td>
        <td style="width: 0.5in; padding-right: 0">19.3</td>
        <td style="text-align: justify; padding-right: 0">Any modification or amendment to the provisions of this Agreement and the appendices hereto shall only be valid if effected in writing and signed by the parties hereto.</td>
      </tr>

  </table>
  <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; margin-right: 0">&#160;</p>
  <table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%">

      <tr style="vertical-align: top">
        <td style="width: 0.5in; padding-right: 0"></td>
        <td style="width: 0.5in; padding-right: 0">19.4</td>
        <td style="text-align: justify; padding-right: 0">This Agreement is subject to all the applicable approvals according to applicable law.</td>
      </tr>

  </table>
  <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; margin-right: 0">&#160;</p>
  <table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%">

      <tr style="vertical-align: top">
        <td style="width: 0.5in; padding-right: 0"></td>
        <td style="width: 0.5in; padding-right: 0">19.5</td>
        <td style="text-align: justify; padding-right: 0">Any notice sent by prepaid registered mail by one party to the other shall be deemed to have been received by the addressee within three business days of its dispatch, and if delivered by hand, at
          the time of its delivery.</td>
      </tr>

  </table>
  <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; margin-right: 0">&#160;</p>
  <table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%">

      <tr style="vertical-align: top">
        <td style="width: 0.5in; padding-right: 0"></td>
        <td style="width: 0.5in; padding-right: 0">19.6</td>
        <td style="text-align: justify; padding-right: 0">This Agreement shall be deemed due notification regarding the Employee&#8217;s employment terms in accordance with the provisions of the Notice of Employment Terms Law (Employment Terms), 2002 and the
          regulations thereunder.</td>
      </tr>

  </table>
  <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; margin-right: 0">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><font style="font-style: normal; font-variant: normal"><b>IN
        WITNESS WHEREOF THE PARTIES HAVE SET THEIR HANDS HERETO AS OF THE DATE FIRST WRITTEN ABOVE:</b></font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>
  <table cellspacing="0" cellpadding="0" style="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">

      <tr style="vertical-align: top; text-align: left">
        <td style="border-bottom: Black 1pt solid; padding-right: 0" colspan="2">Enterabio</td>
        <td style="padding-right: 0">&#160;</td>
      </tr>
      <tr style="vertical-align: top; text-align: left">
        <td style="width: 3%; padding-right: 0">&#160;</td>
        <td style="width: 47%; padding-right: 0">&#160;</td>
        <td style="width: 50%; padding-right: 0">&#160;</td>
      </tr>
      <tr style="vertical-align: top; text-align: left">
        <td style="vertical-align: bottom; padding-right: 0;">By:</td>
        <td style="border-bottom: Black 1pt solid; padding-right: 0"><img alt="" src="ex1015101.jpg"></td>
        <td style="padding-right: 0">&#160;</td>
      </tr>

  </table>
  <table cellspacing="0" cellpadding="0" style="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">

      <tr style="vertical-align: top; text-align: left">
        <td style="width: 5%; vertical-align: bottom; padding-right: 0;">&#160;</td>
        <td style="width: 45%; padding-right: 0">&#160;</td>
        <td style="width: 50%; padding-right: 0">&#160;</td>
      </tr>
      <tr style="vertical-align: top; text-align: left">
        <td style="vertical-align: bottom; padding-right: 0;">Name:</td>
        <td style="border-bottom: Black 1pt solid; vertical-align: bottom; padding-right: 0;">Phillip Schwartz</td>
        <td style="padding-right: 0">&#160;</td>
      </tr>
      <tr style="vertical-align: top; text-align: left">
        <td style="vertical-align: bottom; padding-right: 0;">&#160;</td>
        <td style="padding-right: 0">&#160;</td>
        <td style="padding-right: 0">&#160;</td>
      </tr>
      <tr style="vertical-align: top; text-align: left">
        <td style="vertical-align: bottom; padding-right: 0;">Title:</td>
        <td style="border-bottom: Black 1pt solid; padding-right: 0">CEO</td>
        <td style="padding-right: 0">&#160;</td>
      </tr>
      <tr style="vertical-align: top; text-align: left">
        <td style="vertical-align: bottom; padding-right: 0;">&#160;</td>
        <td style="padding-right: 0">&#160;</td>
        <td style="padding-right: 0">&#160;</td>
      </tr>
      <tr style="vertical-align: top; text-align: left">
        <td style="border-bottom: Black 1pt solid; padding-right: 0" colspan="2"><img alt="" src="ex1015102.jpg"></td>
        <td style="padding-right: 0">&#160;</td>
      </tr>
      <tr style="vertical-align: top; text-align: left">
        <td style="padding-right: 0" colspan="2"><b>The Executive</b></td>
        <td style="padding-right: 0">&#160;</td>
      </tr>

  </table>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>
  <!-- Field: Page; Sequence: 6; Value: 6 -->
  <div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid; margin-right: 0">
    <p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: normal 10pt Times New Roman, Times, Serif; margin-right: 0">-
      <!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --> -</p>
  </div>
  <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt; margin-right: 0">
    <p style="margin: 0pt 0 0pt 0pt">&#160;</p>
  </div>
  <!-- Field: /Page -->
  <p style="margin: 0">&#160;</p>
  <!-- Field: /Page -->
  <p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-right: 0">&#160;</p>
  <table cellspacing="0" cellpadding="0" style="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">

      <tr style="vertical-align: top; text-align: left">
        <td style="width: 25%"><img alt="" src="ex1015103.jpg"></td>
        <td style="width: 75%">Entera Bio Ltd.<br>
          The Jerusalem Bio Park, Hadassah Ein Kerem,<br>
          Minrav Building F. 5,<br>
          P.O. box 12117<br>
          Jerusalem, Israel 9112002</td>
      </tr>

  </table>
  <p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-right: 0">&#160;</p>
  <p style="text-align: right; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-right: 0">June 21, 2016</p>
  <p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-right: 0">&#160;</p>
  <p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-right: 0">Dr. Hillel Galitzer</p>
  <p style="text-align: right; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-right: 0">&#160;</p>
  <p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-right: 0">Re:&#160;&#160;&#160;&#160;&#160;<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal; font-style: normal; font-variant: normal; color: black"><u>Amendment to
        Agreement</u></font></p>
  <p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-right: 0">&#160;</p>
  <p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-right: 0">Dear Hillel,</p>
  <p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-right: 0">&#160;</p>
  <p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-right: 0">Further to that
    certain agreement between Entera Bio Ltd. (the <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; color: black"><b>&#8220;Company&#8221;</b>)
    </font>and you dated June 8, 2014 (the <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; color: black"><b>&#8220;Agreement&#8221;</b>),
    </font>this letter shall confirm our mutual agreement to amend the Agreement as provided herein. Unless otherwise defined
    herein, capitalized terms used herein shall have the meaning ascribed to them in the Agreement.</p>
  <p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-right: 0">&#160;</p>
  <p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-right: 0">Effective as of
    June 1, 2016 you shall be entitled to a gross monthly salary of NIS 48,460, which includes Global Overtime Consideration in the
    gross amount of NIS 14,500.</p>
  <p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-right: 0">&#160;</p>
  <p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-right: 0">Except as set forth
    herein, this letter shall not affect any provisions in the Agreement, which shall remain in full force and effect, with the necessary
    changes. In the event of inconsistency between the provisions of this letter and the Agreement, the provisions of this letter
    shall prevail.</p>
  <p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-right: 0">&#160;</p>
  <p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-right: 0">Please confirm the
    above agreement by signing and dating this amendment and the enclosed duplicate original copy of this amendment, and returning
    one such duplicate original to the undersigned. &#160;</p>
  <p style="text-align: center; font: italic 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-right: 0">&#160;</p>
  <p style="text-align: center; font: italic 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-right: 0">[Signature
    page to follow]</p>
  <p style="text-align: center; font: italic 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-right: 0">&#160;</p>
  <!-- Field: Page; Sequence: 3; Options: NewSection -->
  <div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid; margin-right: 0">
    <p style="margin: 0pt 0 0pt 0pt">&#160;</p>
  </div>
  <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt; margin-right: 0">
    <p style="margin: 0pt 0 0pt 0pt">&#160;</p>
  </div>
  <!-- Field: /Page -->
  <p style="text-align: center; font: italic 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-right: 0">&#160;</p>
  <table cellspacing="0" cellpadding="0" style="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">

      <tr style="vertical-align: top; text-align: left">
        <td style="width: 25%"><img alt="" src="ex1015103.jpg"></td>
        <td style="width: 75%">Entera Bio Ltd.<br>
          The Jerusalem Bio Park, Hadassah Ein Kerem,<br>
          Minrav Building F. 5,<br>
          P.O. box 12117<br>
          Jerusalem, Israel 9112002</td>
      </tr>

  </table>
  <p style="text-align: center; font: italic 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-right: 0">&#160;</p>
  <table cellspacing="0" cellpadding="0" style="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">

      <tr style="vertical-align: top; text-align: left">
        <td>&#160;</td>
        <td colspan="3">Very truly yours,</td>
        <td>&#160;</td>
      </tr>
      <tr style="vertical-align: top; text-align: left">
        <td style="width: 10%">&#160;</td>
        <td style="width: 10%">&#160;</td>
        <td style="width: 3%">&#160;</td>
        <td style="width: 40%">&#160;</td>
        <td style="width: 37%">&#160;</td>
      </tr>
      <tr style="vertical-align: top; text-align: left">
        <td>&#160;</td>
        <td>&#160;</td>
        <td colspan="3">Entera Bio Ltd.</td>
      </tr>
      <tr style="vertical-align: top; text-align: left">
        <td>&#160;</td>
        <td>&#160;</td>
        <td>&#160;</td>
        <td>&#160;</td>
        <td>&#160;</td>
      </tr>
      <tr style="vertical-align: top; text-align: left">
        <td>&#160;</td>
        <td>&#160;</td>
        <td style="vertical-align: bottom;">By:</td>
        <td style="border-bottom: Black 1pt solid"><img style="height: 44px; width: 200px" alt="" src="ex1015104.jpg"></td>
        <td>&#160;</td>
      </tr>
      <tr style="vertical-align: top; text-align: left">
        <td>&#160;</td>
        <td>&#160;</td>
        <td colspan="2">Phillip Schwartz</td>
        <td>&#160;</td>
      </tr>
      <tr style="vertical-align: top; text-align: left">
        <td>&#160;</td>
        <td>&#160;</td>
        <td style="padding-left: 0.25in" colspan="2">CEO</td>
        <td>&#160;</td>
      </tr>

  </table>
  <p style="text-align: center; font: italic 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-right: 0">&#160;</p>
  <table cellspacing="0" cellpadding="0" style="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">

      <tr style="vertical-align: top; text-align: left">
        <td style="width: 30%">Acknowledged and Agreed by:</td>
        <td style="width: 20%">&#160;</td>
        <td style="width: 5%">&#160;</td>
        <td style="width: 30%">&#160;</td>
        <td style="width: 15%">&#160;</td>
      </tr>
      <tr style="vertical-align: top; text-align: left">
        <td>&#160;</td>
        <td>&#160;</td>
        <td>&#160;</td>
        <td>&#160;</td>
        <td>&#160;</td>
      </tr>
      <tr style="vertical-align: top; text-align: left">
        <td style="border-bottom: Black 1pt solid"><img alt="" src="ex1015105.jpg"></td>
        <td>&#160;</td>
        <td style="vertical-align: bottom;">Date:</td>
        <td style="border-bottom: Black 1pt solid; vertical-align: bottom;">30/4/17</td>
        <td>&#160;</td>
      </tr>
      <tr style="vertical-align: top; text-align: left">
        <td>&#160;</td>
        <td>&#160;</td>
        <td>&#160;</td>
        <td>&#160;</td>
        <td>&#160;</td>
      </tr>
      <tr style="vertical-align: top; text-align: left">
        <td>Hillel Galitzer</td>
        <td>&#160;</td>
        <td>&#160;</td>
        <td>&#160;</td>
        <td>&#160;</td>
      </tr>

  </table>
  <p style="text-align: center; font: italic 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-right: 0"><font style="font-family: Times New Roman, Times, Serif; font-style: normal">&#160;</font></p>
  <p style="text-align: center; font: italic 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-right: 0"><font style="font-family: Times New Roman, Times, Serif">[Signature
      page &#8211; Amendment to Agreement]</font></p>
  <p style="margin: 0">&#160;</p>
  <!-- Field: Page; Sequence: 4 -->
  <div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid; margin-right: 0">
    <p style="margin: 0pt 0 0pt 0pt">&#160;</p>
  </div>
  <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt; margin-right: 0">
    <p style="margin: 0pt 0 0pt 0pt">&#160;</p>
  </div>
  <!-- Field: /Page -->
  <p style="margin: 0">&#160;</p>
  <table cellspacing="0" cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">

      <tr style="vertical-align: top">
        <td style="width: 25%; padding-top: 8pt; font-size: 10pt"><img alt="" src="ex1015103.jpg"></td>
        <td style="width: 75%; font-size: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-weight: normal; font-style: normal; font-variant: normal;">Entera Bio Ltd.</font><br>
          <font style="font-family: Times New Roman, Times, Serif; font-weight: normal; font-style: normal; font-variant: normal;">The Jerusalem Bio Park, Hadassah Ein Kerem, </font><br>
          <font style="font-family: Times New Roman, Times, Serif; font-weight: normal; font-style: normal; font-variant: normal;">Minrav Building F. 5,</font><br>
          <font style="font-family: Times New Roman, Times, Serif; font-weight: normal; font-style: normal; font-variant: normal;">P.O. box 12117 </font><br>
          <font style="font-family: Times New Roman, Times, Serif; font-weight: normal; font-style: normal; font-variant: normal;">Jerusalem, Israel 9112002</font></td>
      </tr>

  </table>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><font style="font-weight: normal; font-style: normal; font-variant: normal">March
      2, 2017</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><font style="font-weight: normal; font-style: normal; font-variant: normal">Dr.
      Hillel Galitzer</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal; font-variant: normal">Re: &#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><u>Amendment
      to Agreement</u></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><font style="font-weight: normal; font-style: normal; font-variant: normal">Dear
      Hillel,</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal; font-variant: normal">Further
      to that certain agreement between Entera Bio Ltd. (the </font><b>&#8220;Company&#8221;</b>) <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal; font-variant: normal">and
      you dated June 8, 2014 (the </font><b>&#8220;Agreement&#8221;</b>), <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal; font-variant: normal">this
      letter shall confirm our mutual agreement to amend the Agreement, as provided herein. Unless otherwise defined herein, capitalized
      terms used herein shall have the meaning ascribed to them in the Agreement.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-weight: normal; font-style: normal; font-variant: normal">Effective
      as of March 2,2017 the Notice Period shall be 90 days.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-weight: normal; font-style: normal; font-variant: normal">Except
      as set forth herein, this letter shall not affect any provisions in the Agreement, which shall remain in full force and effect,
      with the necessary changes. In the event of inconsistency between the provisions of this letter and the Agreement, the provisions
      of this letter shall prevail.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-weight: normal; font-style: normal; font-variant: normal">Please
      confirm the above agreement by signing and dating this amendment and the enclosed duplicate original copy of this amendment, and
      returning one such duplicate original to the undersigned.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><font style="font-weight: normal; font-variant: normal"><i>[Signature
        page to follow]</i></font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>
  <!-- Field: Page; Sequence: 5 -->
  <div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid; margin-right: 0">
    <p style="margin: 0pt 0 0pt 0pt">&#160;</p>
  </div>
  <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt; margin-right: 0">
    <p style="margin: 0pt 0 0pt 0pt">&#160;</p>
  </div>
  <!-- Field: /Page -->
  <p style="margin-top: 0; margin-bottom: 0; margin-right: 0">&#160;</p>
  <p style="margin-top: 0; margin-bottom: 0; margin-right: 0">&#160;</p>
  <table cellspacing="0" cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">

      <tr style="vertical-align: top">
        <td style="width: 25%; font-size: 10pt"><img alt="" src="ex1015103.jpg"></td>
        <td style="width: 75%; font-size: 10pt">Entera Bio Ltd.<br>
          <font style="font-family: Times New Roman, Times, Serif; font-weight: normal; font-style: normal; font-variant: normal;">The Jerusalem Bio Park, Hadassah Ein Kerem, </font><br>
          <font style="font-family: Times New Roman, Times, Serif; font-weight: normal; font-style: normal; font-variant: normal;">Minrav Building F. 5,</font><br>
          <font style="font-family: Times New Roman, Times, Serif; font-weight: normal; font-style: normal; font-variant: normal;">P.O. box 12117 </font><br>
          <font style="font-family: Times New Roman, Times, Serif; font-weight: normal; font-style: normal; font-variant: normal;">Jerusalem, Israel 9112002</font></td>
      </tr>

  </table>
  <p style="margin-top: 0; margin-bottom: 0; margin-right: 0">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>
  <table cellspacing="0" cellpadding="0" style="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">

      <tr style="vertical-align: top; text-align: left">
        <td>&#160;</td>
        <td colspan="3">Very truly yours,</td>
        <td>&#160;</td>
      </tr>
      <tr style="vertical-align: top; text-align: left">
        <td style="width: 10%">&#160;</td>
        <td style="width: 10%">&#160;</td>
        <td style="width: 3%">&#160;</td>
        <td style="width: 40%">&#160;</td>
        <td style="width: 37%">&#160;</td>
      </tr>
      <tr style="vertical-align: top; text-align: left">
        <td>&#160;</td>
        <td>&#160;</td>
        <td colspan="3">Entera Bio Ltd.</td>
      </tr>
      <tr style="vertical-align: top; text-align: left">
        <td>&#160;</td>
        <td>&#160;</td>
        <td>&#160;</td>
        <td>&#160;</td>
        <td>&#160;</td>
      </tr>
      <tr style="vertical-align: top; text-align: left">
        <td>&#160;</td>
        <td>&#160;</td>
        <td style="vertical-align: bottom;">By:</td>
        <td style="border-bottom: Black 1pt solid"><img style="height: 44px; width: 200px" alt="" src="ex1015104.jpg"></td>
        <td>&#160;</td>
      </tr>
      <tr style="vertical-align: top; text-align: left">
        <td>&#160;</td>
        <td>&#160;</td>
        <td colspan="2">Phillip Schwartz</td>
        <td>&#160;</td>
      </tr>
      <tr style="vertical-align: top; text-align: left">
        <td>&#160;</td>
        <td>&#160;</td>
        <td style="padding-left: 0.25in" colspan="2">CEO</td>
        <td>&#160;</td>
      </tr>

  </table>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>
  <table cellspacing="0" cellpadding="0" style="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">

      <tr style="vertical-align: top; text-align: left">
        <td style="width: 30%">Acknowledged and Agreed by:</td>
        <td style="width: 20%">&#160;</td>
        <td style="width: 5%">&#160;</td>
        <td style="width: 30%">&#160;</td>
        <td style="width: 15%">&#160;</td>
      </tr>
      <tr style="vertical-align: top; text-align: left">
        <td>&#160;</td>
        <td>&#160;</td>
        <td>&#160;</td>
        <td>&#160;</td>
        <td>&#160;</td>
      </tr>
      <tr style="vertical-align: top; text-align: left">
        <td style="border-bottom: Black 1pt solid"><img alt="" src="ex1015105.jpg"></td>
        <td>&#160;</td>
        <td style="vertical-align: bottom;">Date:</td>
        <td style="border-bottom: Black 1pt solid; vertical-align: bottom;">30/4/17</td>
        <td>&#160;</td>
      </tr>
      <tr style="vertical-align: top; text-align: left">
        <td>&#160;</td>
        <td>&#160;</td>
        <td>&#160;</td>
        <td>&#160;</td>
        <td>&#160;</td>
      </tr>
      <tr style="vertical-align: top; text-align: left">
        <td>Hillel Galitzer</td>
        <td>&#160;</td>
        <td>&#160;</td>
        <td>&#160;</td>
        <td>&#160;</td>
      </tr>

  </table>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><font style="font-weight: normal; font-variant: normal"><i>[Signature
        page &#8211; Amendment to Agreement]</i></font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>
  <!-- Field: Page; Sequence: 6 -->
  <div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid; margin-right: 0">
    <p style="margin: 0pt 0 0pt 0pt">&#160;</p>
  </div>
  <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt; margin-right: 0">
    <p style="margin: 0pt 0 0pt 0pt">&#160;</p>
  </div>
  <!-- Field: /Page -->
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><font style="font-weight: normal; font-style: normal; font-variant: normal"><u>Amendment
        to the Employment Agreement</u></font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">This Amendment (the &#8220;Amendment&#8221;) to the Employment
    Agreement by and between Entera Bio Ltd. (the &#8220;Company&#8221;), and Hillel Galitzer (the &#8220;Employee&#8221;) is entered
    into between the Company and the Employee on June 25, 2020.</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Parties have mutually agreed to amend certain terms of the
    Employment Agreement form June 8 2014, and its amendments, as follows:</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>
  <table width="100%" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">

      <tr style="vertical-align: top">
        <td style="width: 0"></td>
        <td style="width: 0.25in">1.</td>
        <td>This Amendment shall enter into effect as of January 1,2020 (the &#8220;Effective Date&#8221;).</td>
      </tr>

  </table>
  <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; margin-right: 0">&#160;</p>
  <table width="100%" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">

      <tr style="vertical-align: top">
        <td style="width: 0"></td>
        <td style="width: 0.25in">2.</td>
        <td>Section 7.2 of the Employment agreement with the following:</td>
      </tr>

  </table>
  <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; margin-right: 0">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in">The Employee shall be entitled to a gross monthly
    salary of 42,980 NIS (the &#8220;Base Salary&#8221;). In consideration for overtime hours the Employee shall receive a global payment
    of 18,420 NIS per month (the &#8220;Overtime Payment &#8220;, and together with the Base Salary, the &#8220;Salary&#8221;). A total
    increase of 8,470 NIS. The Overtime Payment shall be adjusted simultaneously with the adjustment of the Base Salary and the ratio
    of adjustment as that of the Base Salary, unless specifically stated otherwise.</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in">&#160;</p>
  <table width="100%" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">

      <tr style="vertical-align: top">
        <td style="width: 0"></td>
        <td style="width: 0.25in">3.</td>
        <td>Section 10.1 of the Employment agreement with the following:</td>
      </tr>

  </table>
  <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; margin-right: 0">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in">Subject to the provisions of the Annual Vacation
    Law-1951 (the &#8220;Vacation Law&#8221;), the Employee shall be entitled to 16 vacation days (the &#8220;Vacation Days&#8221;),
    with respect to each twelve (12) months&#8217; period of continuous employment with the Company. These Vacation Days include the
    number of paid vacation days to which the Employee is entitled in accordance with the Vacation Law (the &#8220;Vacation Law Days&#8221;).
    Any Vacation Days shall be first credited on account of Vacation Days which are not Vacation Law Days (if any).</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in">&#160;</p>
  <table width="100%" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">

      <tr style="vertical-align: top">
        <td style="width: 0"></td>
        <td style="width: 0.25in">4.</td>
        <td>All other provisions of the Employment Agreement (including any Appendices or Exhibits thereto) shall remain unchanged.</td>
      </tr>

  </table>
  <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; margin-right: 0">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">The parties have caused this
    Amendment to be executed and delivered by their duly authorized representatives, as of the date hereof.</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">&#160;</p>
  <!-- Field: Rule-Page -->
  <div align="LEFT" style="margin-top: 0pt; margin-bottom: 3pt; margin-right: 0">
    <div style="font-size: 1pt; border-top: Black 1pt solid; width: 20%; margin-right: 0">&#160;</div>
  </div>
  <!-- Field: /Rule-Page -->
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in"><img alt="" src="ex1015107.jpg"></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>
  <!-- Field: Rule-Page -->
  <div align="LEFT" style="margin-top: 3pt; margin-bottom: 3pt">
    <div style="font-size: 1pt; border-top: Black 1pt solid; width: 15%">&#160;</div>
  </div>
  <!-- Field: /Rule-Page -->
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>COMPANY</b></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><font style="font-variant: small-caps"><b>Entera Bio Ltd.</b></font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Name: Adam Gridley</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Title: CEO</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>
  <!-- Field: Page; Sequence: 7 -->
  <div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid; margin-right: 0">
    <p style="margin: 0pt 0 0pt 0pt">&#160;</p>
  </div>
  <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt; margin-right: 0">
    <p style="margin: 0pt 0 0pt 0pt">&#160;</p>
  </div>
  <!-- Field: /Page -->
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>EMPLOYEE</b></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>
  <table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%">

      <tr style="vertical-align: top; text-align: justify">
        <td style="text-align: left">Name: </td>
        <td style="border-bottom: Black 1pt solid;">Hillel Galitzer</td>
        <td>&#160;</td>
      </tr>
      <tr style="vertical-align: top; text-align: justify">
        <td style="text-align: left">&#160;</td>
        <td>&#160;</td>
        <td>&#160;</td>
      </tr>
      <tr style="vertical-align: top; text-align: justify">
        <td style="width: 5%; text-align: left">Title:</td>
        <td style="width: 35%; border-bottom: Black 1pt solid;">COO</td>
        <td style="width: 60%;">&#160;</td>
      </tr>

  </table>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>
  <!-- Field: Page; Sequence: 8 -->
  <div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid; margin-right: 0">
    <p style="margin: 0pt 0 0pt 0pt">&#160;</p>
  </div>
  <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt; margin-right: 0">
    <p style="margin: 0pt 0 0pt 0pt">&#160;</p>
  </div>
  <!-- Field: /Page -->
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><font style="font-style: normal; font-variant: normal">May
      9, 2022</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><font style="font-style: normal; font-variant: normal"><b><u>Amendment
          to the Employment Agreement</u></b></font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><font style="font-weight: normal; font-style: normal; font-variant: normal">Effective
      as of January 1, 2021 Appendix A to the Employment Agreement from June 8, 2014 and its amendments shall be amended as follows:</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>
  <table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%">

      <tr style="vertical-align: top; text-align: justify">
        <td style="width: 0in"></td>
        <td style="width: 0.25in; text-align: left">1.</td>
        <td><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal; font-variant: normal">Item
            1 shall be replaced by the following:</font></td>
      </tr>

  </table>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>
  <table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%">

      <tr style="vertical-align: top; text-align: justify">
        <td style="width: 0.5in"></td>
        <td style="width: 0.25in; text-align: left">1.</td>
        <td><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: normal"><b><u>Salary</u></b></font></td>
      </tr>

  </table>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><font style="font-weight: normal; font-style: normal; font-variant: normal">The
      Employee shall be entitled to a gross monthly salary of 49,420 NIS (the &#8220;Base Salary&#8221;). In consideration for overtime
      hours the Employee shall receive a global payment of 21,180 NIS per month (the &#8220;Overtime Payment &#8220;, and together with
      the Base Salary, the &#8220;Salary&#8221;). A total increase of 9,200 NIS. The Overtime Payment shall be adjusted simultaneously
      with the adjustment of the Base Salary and the ratio of adjustment as that of the Base Salary, unless specifically stated otherwise.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&#160;</p>
  <table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%">

      <tr style="vertical-align: top; text-align: justify">
        <td style="width: 0in"></td>
        <td style="width: 0.25in; text-align: left">2.</td>
        <td><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal; font-variant: normal">All
            other provisions of the Appendix A and of the Employment Agreement (including any Appendices or Exhibits thereto) shall remain
            unchanged.</font></td>
      </tr>

  </table>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>
  <table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse">

      <tr style="vertical-align: top">
        <td style="width: 65%"><img alt="" src="ex1015106.jpg"></td>
        <td style="width: 35%">&#160;</td>
      </tr>
      <tr style="vertical-align: top">
        <td>Entera Bio Ltd.</td>
        <td><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal; font-style: normal; font-variant: normal">Employee: Galitzer Hillel</font></td>
      </tr>
      <tr>
        <td style="vertical-align: bottom"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal; font-style: normal; font-variant: normal">By : Spiros Jamas</font></td>
        <td style="vertical-align: top">&#160;</td>
      </tr>
      <tr>
        <td style="vertical-align: bottom"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal; font-style: normal; font-variant: normal">Title: CEO</font></td>
        <td style="vertical-align: top">&#160;</td>
      </tr>

  </table>
  <p style="margin: 0">&#160;</p>
  <!-- Field: Rule-Page -->
  <div align="LEFT" style="margin-top: 0pt; margin-bottom: 0pt; margin-right: 0">
    <div style="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 4pt solid; width: 100%; margin-right: 0">&#160;</div>
  </div>
  <!-- Field: /Rule-Page -->
  <p style="margin: 0">&#160;</p>
  <!-- Field: Page; Sequence: 9 -->
  <!-- Field: /Page -->
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-21.1
<SEQUENCE>4
<FILENAME>exhibit_21-1.htm
<DESCRIPTION>EXHIBIT 21.1
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: Z-K Global
         Document created using Broadridge PROfile 23.3.1.5138
         Copyright 1995 - 2023 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000;">
  <div>
    <hr align="center" style="border: none; border-bottom: 1px solid black; border-top: 4px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;">
    <div>
      <div style="text-align: right; text-indent: -18pt; margin-left: 18pt; line-height: 1.25; font-weight: bold;"><u>Exhibit 21.1</u></div>
      <div style="text-indent: -18pt; margin-left: 18pt; line-height: 1.25;">&#160;</div>
      <div style="text-align: center; text-indent: -18pt; margin-left: 18pt; line-height: 1.25; font-weight: bold;">Entera Bio Ltd.</div>
      <div style="text-indent: -18pt; margin-left: 18pt; line-height: 1.25;">&#160;</div>
      <div style="text-indent: -18pt; margin-left: 18pt; line-height: 1.25;">The following is a list of subsidiaries of Entera Bio Ltd. as of December 31, 2022:</div>
      <div style="text-indent: -18pt; margin-left: 18pt; line-height: 1.25;">&#160;</div>
      <table cellspacing="0" cellpadding="0" id="za1a38d0006bc49c19a7de89347da03e8" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 26.82%; vertical-align: bottom; border-bottom: #000000 2px solid;">
              <div style="line-height: 1.25; font-weight: bold;">SUBSIDIARY</div>
            </td>
            <td style="width: 2.01%; vertical-align: bottom;">&#160;</td>
            <td style="width: 71.16%; vertical-align: bottom; border-bottom: #000000 2px solid;">
              <div style="line-height: 1.25; font-weight: bold;">STATE OR OTHER JURISDICTION OF INCORPORATION OR ORGANIZATION</div>
            </td>
          </tr>
          <tr>
            <td style="width: 26.82%; vertical-align: top; background-color: #CCEEFF;">
              <div style="line-height: 1.25;">Entera Bio Inc.</div>
            </td>
            <td style="width: 2.01%; vertical-align: top; background-color: #CCEEFF;">&#160;</td>
            <td style="width: 71.16%; vertical-align: top; background-color: #CCEEFF;">
              <div style="line-height: 1.25;">Delaware</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
    </div>
    <hr align="center" style="border: none; border-bottom: 4px solid black; border-top: 1px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;"></div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>5
<FILENAME>exhibit_23-1.htm
<DESCRIPTION>EXHIBIT 23.1
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: Z-K Global
         Document created using Broadridge PROfile 23.3.1.5138
         Copyright 1995 - 2023 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000;">
  <div>
    <hr align="center" style="border: none; border-bottom: 1px solid black; border-top: 4px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;">
    <div>
      <div class="BRPFPageHeader">
        <div style="line-height: 1.25; text-align: right;"><u><font style="font-weight: bold;">Exhibit 23.1</font></u><br style="line-height: 1.25;">
        </div>
      </div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: center; line-height: 1.25;">CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman',Times,serif;">We hereby consent to the incorporation by reference in the Registration Statements on Form S-8 (No. 333-227488) and Form S-3
        (Nos. 333-265291 and 333-265286) of Entera Bio Ltd. of our report dated March 31, 2023 relating to the financial statements, which appears in this Form 10-K.</div>
      <div style="line-height: 1.25">&#160;</div>
      <table cellspacing="0" cellpadding="0" id="z762f219317e74d4794372f050669b3cb" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 100%; vertical-align: top;">
              <div style="line-height: 1.25;">/s/ Kesselman &amp; Kesselman</div>
            </td>
          </tr>
          <tr>
            <td style="width: 100%; vertical-align: top;">
              <div style="line-height: 1.25;">Certified Public Accountants (lsr.)</div>
            </td>
          </tr>
          <tr>
            <td style="width: 100%; vertical-align: top;">
              <div style="line-height: 1.25;">A member firm of PricewaterhouseCoopers International Limited</div>
            </td>
          </tr>
          <tr>
            <td style="width: 100%; vertical-align: top;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 100%; vertical-align: top;">
              <div style="line-height: 1.25;">Tel-Aviv, Israel</div>
            </td>
          </tr>
          <tr>
            <td style="width: 100%; vertical-align: top;">
              <div style="line-height: 1.25;">March 31, 2023</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25">&#160;</div>
      <div style="line-height: 1.25;">
        <hr align="center" style="border: none; border-bottom: 4px solid black; border-top: 1px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;"></div>
      <div class="BRPFPageFooter">
        <div style="line-height: 1.25;"><br style="line-height: 1.25;">
        </div>
      </div>
    </div>
  </div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>6
<FILENAME>exhibit_31-1.htm
<DESCRIPTION>EXHIBIT 31.1
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: Z-K Global
         Document created using Broadridge PROfile 23.3.1.5138
         Copyright 1995 - 2023 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000;">
  <div>
    <hr align="center" style="border: none; border-bottom: 1px solid black; border-top: 4px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;">
    <div>
      <div class="BRPFPageHeader">
        <div style="line-height: 1.25; text-align: right;"><u><font style="font-weight: bold;">Exhibit 31.1</font></u><br style="line-height: 1.25;">
        </div>
        <div style="line-height: 1.25;"><br style="line-height: 1.25;">
        </div>
      </div>
      <div style="text-align: justify; line-height: 1.25; font-weight: bold;">CERTIFICATION PURSUANT TO SECTION 302 OF THE SARBANES OXLEY ACT OF 2002</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; line-height: 1.25;">I, Miranda J. Toledano, certify that:</div>
      <div style="line-height: 1.25">&#160;</div>
      <table cellspacing="0" cellpadding="0" id="ze00a94fb7b7f45e99909672a29bf2056" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 18pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top;">1.</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>I have reviewed this Annual Report on Form 10-K for the year ended December 31, 2022 of Entera Bio Ltd.;</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25">&#160;</div>
      <table cellspacing="0" cellpadding="0" id="zefc898f00b604c8c97a70c1d9a959c99" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 18pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top;">2.</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in
                light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25">&#160;</div>
      <table cellspacing="0" cellpadding="0" id="z0aec34de696d4d34b8e420f0664375c4" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 18pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top;">3.</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial
                condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25">&#160;</div>
      <table cellspacing="0" cellpadding="0" id="z0774e0e9c3c945619d364863ac6df9a1" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 18pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top;">4.</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules
                13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25">&#160;</div>
      <table cellspacing="0" cellpadding="0" id="z46592c4787fc4eb197b8e99b1900e3e8" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 54pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top;">a.</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material
                information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25">&#160;</div>
      <table cellspacing="0" cellpadding="0" id="zc7ecb6fb16c64d569064c7bd41fec970" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 54pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top;">b.</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide
                reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25">&#160;</div>
      <table cellspacing="0" cellpadding="0" id="z6c302b90ace746b48303c768467aeac7" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 54pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top;">c.</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the
                disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25">&#160;</div>
      <table cellspacing="0" cellpadding="0" id="z6c0d498757fc4f538819c175effd4dbf" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 54pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top;">d.</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter
                (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting; and</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25">&#160;</div>
      <table cellspacing="0" cellpadding="0" id="z77f728a180be4beab507c59a4ea58053" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 18pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top;">5.</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s
                auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions):</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25">&#160;</div>
      <table cellspacing="0" cellpadding="0" id="zb53f856b45924a058aae7863060659eb" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 54pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top;">a.</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely
                affect the registrant&#8217;s ability to record, process, summarize and report financial information; and</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25">&#160;</div>
      <table cellspacing="0" cellpadding="0" id="zbabc9144cb674596970138c86797c24f" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 54pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top;">b.</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial
                reporting.</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25">&#160;</div>
      <table cellspacing="0" cellpadding="0" border="0" id="za29fabb2275546dca5041e7e824d1562" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);">

          <tr>
            <td style="width: 50%; vertical-align: top;">
              <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman', Times, serif;">Date: March 31, 2023</div>
            </td>
            <td style="width: 50%; vertical-align: top;">
              <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman', Times, serif;"><u>/s/ Miranda J. Toledano</u> <br>
              </div>
            </td>
          </tr>
          <tr>
            <td style="width: 50%; vertical-align: top;">&#160;</td>
            <td style="width: 50%; vertical-align: top;">
              <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman', Times, serif;">Miranda J. Toledano</div>
            </td>
          </tr>
          <tr>
            <td style="width: 50%; vertical-align: top;">&#160;</td>
            <td style="width: 50%; vertical-align: top;">
              <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman', Times, serif;">Chief Executive Officer</div>
            </td>
          </tr>
          <tr>
            <td style="width: 50%; vertical-align: top;">&#160;</td>
            <td style="width: 50%; vertical-align: top;">
              <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman', Times, serif;">(Principal Executive Officer)</div>
            </td>
          </tr>

      </table>
    </div>
    <div> <br>
    </div>
    <div>
      <hr align="center" style="border: none; border-bottom: 4px solid black; border-top: 1px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;"> </div>
  </div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>7
<FILENAME>exhibit_31-2.htm
<DESCRIPTION>EXHIBIT 31.2
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: Z-K Global
         Document created using Broadridge PROfile 23.3.1.5138
         Copyright 1995 - 2023 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000;">
  <div>
    <hr align="center" style="border: none; border-bottom: 1px solid black; border-top: 4px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;">
    <div> <br>
    </div>
    <div style="text-align: right;"><u><font style="font-weight: bold;">Exhibit 31.2</font></u><br>
    </div>
    <div>
      <div class="BRPFPageHeader">
        <div style="line-height: 1.25;"><br style="line-height: 1.25;">
        </div>
      </div>
      <div style="text-align: justify; line-height: 1.25; font-weight: bold;">CERTIFICATION PURSUANT TO SECTION 302 OF THE SARBANES OXLEY ACT OF 2002</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; line-height: 1.25;">I, Dana Yaacov-Garbeli, certify that:</div>
      <div style="line-height: 1.25">&#160;</div>
      <table cellspacing="0" cellpadding="0" id="z487c2a12496445ad8f4e50828b75215e" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 18pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top;">1.</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>I have reviewed this Annual Report on Form 10-K for the year ended December 31, 2022 of Entera Bio Ltd.;</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25">&#160;</div>
      <table cellspacing="0" cellpadding="0" id="z55ed9d308dc548ed9f106622e64fbb75" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 18pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top;">2.</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in
                light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25">&#160;</div>
      <table cellspacing="0" cellpadding="0" id="z5fce6d53c4344de2a2f6616a06d9ae2b" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 18pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top;">3.</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial
                condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25">&#160;</div>
      <table cellspacing="0" cellpadding="0" id="z87646e115a5748b4ad45c08e0ded2c5b" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 18pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top;">4.</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules
                13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25">&#160;</div>
      <table cellspacing="0" cellpadding="0" id="zb8f759f1f1ba4e46b0d63391e0cd65b4" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 54pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top;">a.</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material
                information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25">&#160;</div>
      <table cellspacing="0" cellpadding="0" id="z83d2111f4ff047bf9245a35cf3277d55" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 54pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top;">b.</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide
                reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25">&#160;</div>
      <table cellspacing="0" cellpadding="0" id="z51376b7908004829bff9e0540468bae8" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 54pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top;">c.</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the
                disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25">&#160;</div>
      <table cellspacing="0" cellpadding="0" id="zaaabd43f4ab240c39c357620229496ab" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 54pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top;">d.</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter
                (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting; and</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25">&#160;</div>
      <table cellspacing="0" cellpadding="0" id="zefee40d567de4d73b8c9bdc6f2cf392b" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 18pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top;">5.</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s
                auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions):</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25">&#160;</div>
      <table cellspacing="0" cellpadding="0" id="zadaa2287740b4064bdf4a3c4b0b3bcd1" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 54pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top;">a.</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely
                affect the registrant&#8217;s ability to record, process, summarize and report financial information; and</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25">&#160;</div>
      <table cellspacing="0" cellpadding="0" id="z313bbcb3246d4168a3942ef92a4eb515" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 54pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top;">b.</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial
                reporting.</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25">&#160;</div>
      <div style="line-height: 1.25">
        <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);">

            <tr>
              <td style="width: 50%; vertical-align: top;">
                <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman', Times, serif;">Date: March 31, 2023</div>
              </td>
              <td style="width: 50%; vertical-align: top;">
                <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman', Times, serif;"><u>/s/ Dana Yaacov Garbeli</u> </div>
              </td>
            </tr>
            <tr>
              <td style="width: 50%; vertical-align: top;">&#160;</td>
              <td style="width: 50%; vertical-align: top;">
                <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman', Times, serif;">Dana Yaacov-Garbeli</div>
              </td>
            </tr>
            <tr>
              <td style="width: 50%; vertical-align: top;">&#160;</td>
              <td style="width: 50%; vertical-align: top;">
                <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman', Times, serif;">Chief Financial Officer</div>
              </td>
            </tr>
            <tr>
              <td style="width: 50%; vertical-align: top;">&#160;</td>
              <td style="width: 50%; vertical-align: top;">
                <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman', Times, serif;">(Principal Financial and Accounting Officer)</div>
              </td>
            </tr>

        </table>
      </div>
      <div style="line-height: 1.25"> <br>
      </div>
      <br>
      <hr align="center" style="border: none; border-bottom: 4px solid black; border-top: 1px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;">
      <div style="line-height: 1.25">&#160;</div>
      <div class="BRPFPageFooter">
        <div style="line-height: 1.25;"><br style="line-height: 1.25;">
        </div>
      </div>
    </div>
  </div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>8
<FILENAME>exhibit_32-1.htm
<DESCRIPTION>EXHIBIT 32.1
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: Z-K Global
         Document created using Broadridge PROfile 23.3.1.5138
         Copyright 1995 - 2023 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000;">
  <div>
    <hr align="center" style="border: none; border-bottom: 1px solid black; border-top: 4px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;">
    <div>
      <div class="BRPFPageHeader">
        <div style="line-height: 1.25; text-align: right;"><u><font style="font-weight: bold;">Exhibit 32.1</font></u><br style="line-height: 1.25;">
        </div>
        <div style="line-height: 1.25;"><br style="line-height: 1.25;">
        </div>
      </div>
      <div style="text-align: justify; line-height: 1.25; font-weight: bold;">CERTIFICATION PURSUANT TO SECTION 906 OF THE SARBANES OXLEY ACT OF 2002</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; line-height: 1.25;">I, Miranda J. Toledano, Chief Executive Officer of Entera Bio Ltd. (the &#8220;Company&#8221;), certify, pursuant to Section 906 of the
        Sarbanes-Oxley Act of 2002, 18 U.S.C. Section 1350 that, to the best of my knowledge:</div>
      <div style="line-height: 1.25">&#160;</div>
      <table cellspacing="0" cellpadding="0" id="z189b6bcc967244dda40dc29ece97d135" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 18pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top;">1.</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>the Annual Report on Form 10-K of the Company for the year ended December 31, 2022 (the &#8220;Report&#8221;) fully complies with the requirements of Section 13(a) or 15(d) of
                the Securities Exchange Act of 1934 (15 U.S.C. 78m or 78o(d)); and</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25">&#160;</div>
      <table cellspacing="0" cellpadding="0" id="za6cfe077cf1c45648c96361871a78b40" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 18pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top;">2.</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25">&#160;</div>
      <table cellspacing="0" cellpadding="0" border="0" id="z6a14cf6e650d48009b6c49313d782c7c" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 50%; vertical-align: top;">
              <div style="text-align: justify; line-height: 1.25;">Date: March 31, 2023</div>
            </td>
            <td style="width: 50%; vertical-align: top;">
              <div style="text-align: justify; line-height: 1.25;"><u>/s/ Miranda J. Toledano</u></div>
            </td>
          </tr>
          <tr>
            <td style="width: 50%; vertical-align: top;">&#160;</td>
            <td style="width: 50%; vertical-align: top;">
              <div style="text-align: justify; line-height: 1.25;">Miranda J. Toledano</div>
            </td>
          </tr>
          <tr>
            <td style="width: 50%; vertical-align: top;">&#160;</td>
            <td style="width: 50%; vertical-align: top;">
              <div style="text-align: justify; line-height: 1.25;">Chief Executive Officer</div>
            </td>
          </tr>
          <tr>
            <td style="width: 50%; vertical-align: top;">&#160;</td>
            <td style="width: 50%; vertical-align: top;">
              <div style="text-align: justify; line-height: 1.25;">(Principal Executive Officer)</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="line-height: 1.25">
        <hr align="center" style="border: none; border-bottom: 4px solid black; border-top: 1px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;"></div>
    </div>
  </div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>9
<FILENAME>exhibit_32-2.htm
<DESCRIPTION>EXHIBIT 32.2
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: Z-K Global
         Document created using Broadridge PROfile 23.3.1.5138
         Copyright 1995 - 2023 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000;">
  <div>
    <hr align="center" style="border: none; border-bottom: 1px solid black; border-top: 4px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;">
    <div>
      <div class="BRPFPageHeader">
        <div style="line-height: 1.25; text-align: right;"><u><font style="font-weight: bold;">Exhibit 32.2</font></u><br style="line-height: 1.25;">
        </div>
        <div style="line-height: 1.25;"><br style="line-height: 1.25;">
        </div>
      </div>
      <div style="text-align: justify; line-height: 1.25; font-weight: bold;">CERTIFICATION PURSUANT TO SECTION 906 OF THE SARBANES OXLEY ACT OF 2002</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; line-height: 1.25;">I, Dana Yaacov-Garbeli, Chief Financial Officer of Entera Bio Ltd. (the &#8220;Company&#8221;), certify, pursuant to Section 906 of the
        Sarbanes-Oxley Act of 2002, 18 U.S.C. Section 1350 that, to the best of my knowledge:</div>
      <div style="line-height: 1.25">&#160;</div>
      <table cellspacing="0" cellpadding="0" id="z0c99bc407c7c4fc38eb6babe788cfe8b" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 18pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top;">1.</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>the Annual Report on Form 10-K of the Company for the year ended December 31, 2022 (the &#8220;Report&#8221;) fully complies with the requirements of Section 13(a) or 15(d) of
                the Securities Exchange Act of 1934 (15 U.S.C. 78m or 78o(d)); and</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25">&#160;</div>
      <table cellspacing="0" cellpadding="0" id="z0bbe703612cd4d88976573441c8bec55" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 18pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top;">2.</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25">&#160;</div>
      <table cellspacing="0" cellpadding="0" border="0" id="za8bc8bad61a945b29df2e74874cd5600" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);">

          <tr>
            <td style="width: 50%; vertical-align: top;">
              <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman', Times, serif;">Date: March 31, 2023</div>
            </td>
            <td style="width: 50%; vertical-align: top;">
              <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman', Times, serif;"><u>/s/ Dana Yaacov-Garbeli</u></div>
            </td>
          </tr>
          <tr>
            <td style="width: 50%; vertical-align: top;">&#160;</td>
            <td style="width: 50%; vertical-align: top;">
              <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman', Times, serif;">Dana Yaacov-Garbeli</div>
            </td>
          </tr>
          <tr>
            <td style="width: 50%; vertical-align: top;">&#160;</td>
            <td style="width: 50%; vertical-align: top;">
              <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman', Times, serif;">Chief Financial Officer</div>
            </td>
          </tr>
          <tr>
            <td style="width: 50%; vertical-align: top;">&#160;</td>
            <td style="width: 50%; vertical-align: top;">
              <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman', Times, serif;">(Principal Financial and Accounting Officer)</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="line-height: 1.25">
        <hr align="center" style="border: none; border-bottom: 4px solid black; border-top: 1px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;"></div>
    </div>
  </div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>10
<FILENAME>entx-20221231.xsd
<DESCRIPTION>XBRL SCHEMA FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<schema xmlns:entx="http://www.enterabio.com/20221231" xmlns="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:negated="http://www.xbrl.org/2009/role/negated" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:deprecated="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:country="http://xbrl.sec.gov/country/2022" xmlns:currency="http://xbrl.sec.gov/currency/2022" xmlns:exch="http://xbrl.sec.gov/exch/2022" xmlns:naics="http://xbrl.sec.gov/naics/2022" xmlns:sic="http://xbrl.sec.gov/sic/2022" xmlns:stpr="http://xbrl.sec.gov/stpr/2022" xmlns:us-types="http://fasb.org/us-types/2022" xmlns:srt="http://fasb.org/srt/2022" xmlns:srt-types="http://fasb.org/srt-types/2022" xmlns:us-gaap="http://fasb.org/us-gaap/2022" targetNamespace="http://www.enterabio.com/20221231" elementFormDefault="qualified">
  <!-- INTEGIX by Ez-XBRL -->
  <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd"/>
  <import namespace="http://www.xbrl.org/2009/role/net" schemaLocation="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd"/>
  <import namespace="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" schemaLocation="http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd"/>
  <import namespace="http://xbrl.sec.gov/dei/2022" schemaLocation="https://xbrl.sec.gov/dei/2022/dei-2022.xsd"/>
  <import namespace="http://xbrl.sec.gov/country/2022" schemaLocation="https://xbrl.sec.gov/country/2022/country-2022.xsd"/>
  <import namespace="http://xbrl.sec.gov/currency/2022" schemaLocation="https://xbrl.sec.gov/currency/2022/currency-2022.xsd"/>
  <import namespace="http://xbrl.sec.gov/exch/2022" schemaLocation="https://xbrl.sec.gov/exch/2022/exch-2022.xsd"/>
  <import namespace="http://xbrl.sec.gov/naics/2022" schemaLocation="https://xbrl.sec.gov/naics/2022/naics-2022.xsd"/>
  <import namespace="http://xbrl.sec.gov/sic/2022" schemaLocation="https://xbrl.sec.gov/sic/2022/sic-2022.xsd"/>
  <import namespace="http://xbrl.sec.gov/stpr/2022" schemaLocation="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd"/>
  <import namespace="http://fasb.org/us-types/2022" schemaLocation="https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd"/>
  <import namespace="http://fasb.org/srt/2022" schemaLocation="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd"/>
  <import namespace="http://fasb.org/srt-types/2022" schemaLocation="https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd"/>
  <import namespace="http://fasb.org/us-gaap/2022" schemaLocation="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd"/>
  <import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"/>
  <annotation>
    <appinfo>
      <link:roleType roleURI="http://www.enterabio.com/role/DocumentAndEntityInformation" id="DocumentAndEntityInformation">
        <link:definition>0001 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.enterabio.com/role/CONSOLIDATEDBALANCESHEETS" id="CONSOLIDATEDBALANCESHEETS">
        <link:definition>0002 - Statement - CONSOLIDATED BALANCE SHEETS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.enterabio.com/role/CONSOLIDATEDBALANCESHEETSParentheticals" id="CONSOLIDATEDBALANCESHEETSParentheticals">
        <link:definition>0003 - Statement - CONSOLIDATED BALANCE SHEETS (Parentheticals)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.enterabio.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS" id="CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS">
        <link:definition>0004 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.enterabio.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY" id="CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY">
        <link:definition>0005 - Statement - CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.enterabio.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" id="CONSOLIDATEDSTATEMENTSOFCASHFLOWS">
        <link:definition>0006 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.enterabio.com/role/GENERAL" id="GENERAL">
        <link:definition>0007 - Disclosure - GENERAL</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.enterabio.com/role/SIGNIFICANTACCOUNTINGPOLICIES" id="SIGNIFICANTACCOUNTINGPOLICIES">
        <link:definition>0008 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.enterabio.com/role/OPERATINGLEASES" id="OPERATINGLEASES">
        <link:definition>0009 - Disclosure - OPERATING LEASES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.enterabio.com/role/COMMITMENTS" id="COMMITMENTS">
        <link:definition>0010 - Disclosure - COMMITMENTS AND CONTINGENCIES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.enterabio.com/role/SHARECAPITAL" id="SHARECAPITAL">
        <link:definition>0011 - Disclosure - SHARE CAPITAL</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.enterabio.com/role/SHAREBASEDCOMPENSATION" id="SHAREBASEDCOMPENSATION">
        <link:definition>0012 - Disclosure - SHARE-BASED COMPENSATION</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.enterabio.com/role/INCOMETAX" id="INCOMETAX">
        <link:definition>0013 - Disclosure - INCOME TAX</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.enterabio.com/role/SUPPLEMENTARYFINANCIALSTATEMENTINFORMATION" id="SUPPLEMENTARYFINANCIALSTATEMENTINFORMATION">
        <link:definition>0014 - Disclosure - SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.enterabio.com/role/SUBSEQUENTEVENT" id="SUBSEQUENTEVENT">
        <link:definition>0015 - Disclosure - SUBSEQUENT EVENTS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.enterabio.com/role/SIGNIFICANTACCOUNTINGPOLICIESPolicies" id="SIGNIFICANTACCOUNTINGPOLICIESPolicies">
        <link:definition>0016 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.enterabio.com/role/SIGNIFICANTACCOUNTINGPOLICIESTables" id="SIGNIFICANTACCOUNTINGPOLICIESTables">
        <link:definition>0017 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.enterabio.com/role/OPERATINGLEASESTables" id="OPERATINGLEASESTables">
        <link:definition>0018 - Disclosure - OPERATING LEASES (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.enterabio.com/role/SHAREBASEDCOMPENSATIONTables" id="SHAREBASEDCOMPENSATIONTables">
        <link:definition>0019 - Disclosure - SHARE-BASED COMPENSATION (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.enterabio.com/role/INCOMETAXTables" id="INCOMETAXTables">
        <link:definition>0020 - Disclosure - INCOME TAX (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.enterabio.com/role/SUPPLEMENTARYFINANCIALSTATEMENTINFORMATIONTable" id="SUPPLEMENTARYFINANCIALSTATEMENTINFORMATIONTable">
        <link:definition>0021 - Disclosure - SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.enterabio.com/role/GENERALDetailTextuals" id="GENERALDetailTextuals">
        <link:definition>0022 - Disclosure - GENERAL (Detail Textuals)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.enterabio.com/role/SIGNIFICANTACCOUNTINGPOLICIESDetails" id="SIGNIFICANTACCOUNTINGPOLICIESDetails">
        <link:definition>0023 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.enterabio.com/role/SIGNIFICANTACCOUNTINGPOLICIESDetailTextuals" id="SIGNIFICANTACCOUNTINGPOLICIESDetailTextuals">
        <link:definition>0024 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Detail Textuals)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.enterabio.com/role/OperatingLeaseDetails" id="OperatingLeaseDetails">
        <link:definition>0025 - Disclosure - OPERATING LEASE (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.enterabio.com/role/OperatingLeaseDetails1" id="OperatingLeaseDetails1">
        <link:definition>0026 - Disclosure - OPERATING LEASE (Details 1)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.enterabio.com/role/OPERATINGLEASESDetails" id="OPERATINGLEASESDetails">
        <link:definition>0027 - Disclosure - OPERATING LEASES (Details 2)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.enterabio.com/role/OPERATINGLEASESDetailTextuals" id="OPERATINGLEASESDetailTextuals">
        <link:definition>0028 - Disclosure - OPERATING LEASES (Detail Textuals)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.enterabio.com/role/COMMITMENTSDetailTextuals" id="COMMITMENTSDetailTextuals">
        <link:definition>0029 - Disclosure - COMMITMENTS AND CONTINGENCIES (Detail Textuals)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.enterabio.com/role/SHARECAPITALDetailTextuals" id="SHARECAPITALDetailTextuals">
        <link:definition>0030 - Disclosure - SHARE CAPITAL (Detail Textuals)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.enterabio.com/role/SHAREBASEDCOMPENSATIONDetails" id="SHAREBASEDCOMPENSATIONDetails">
        <link:definition>0031 - Disclosure - SHARE-BASED COMPENSATION (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.enterabio.com/role/SHAREBASEDCOMPENSATIONDetails1" id="SHAREBASEDCOMPENSATIONDetails1">
        <link:definition>0032 - Disclosure - SHARE-BASED COMPENSATION (Details 1)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.enterabio.com/role/SHAREBASEDCOMPENSATIONDetails2" id="SHAREBASEDCOMPENSATIONDetails2">
        <link:definition>0033 - Disclosure - SHARE-BASED COMPENSATION (Details 2)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.enterabio.com/role/SHAREBASEDCOMPENSATIONDetails3" id="SHAREBASEDCOMPENSATIONDetails3">
        <link:definition>0034 - Disclosure - SHARE-BASED COMPENSATION (Details 3)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.enterabio.com/role/SHAREBASEDCOMPENSATIONDetailTextuals" id="SHAREBASEDCOMPENSATIONDetailTextuals">
        <link:definition>0035 - Disclosure - SHARE-BASED COMPENSATION (Detail Textuals)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.enterabio.com/role/INCOMETAXDetails1" id="INCOMETAXDetails1">
        <link:definition>0036 - Disclosure - INCOME TAX (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.enterabio.com/role/INCOMETAXDetails3" id="INCOMETAXDetails3">
        <link:definition>0037 - Disclosure - INCOME TAX (Details 1)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.enterabio.com/role/INCOMETAXDetails" id="INCOMETAXDetails">
        <link:definition>0038 - Disclosure - INCOME TAX (Details 2)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.enterabio.com/role/INCOMETAXDetails2" id="INCOMETAXDetails2">
        <link:definition>0039 - Disclosure - INCOME TAX (Details 3)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.enterabio.com/role/INCOMETAXDetailTextuals" id="INCOMETAXDetailTextuals">
        <link:definition>0040 - Disclosure - INCOME TAX (Detail Textuals)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.enterabio.com/role/SUPPLEMENTARYFINANCIALSTATEMENTINFORMATIONDetails" id="SUPPLEMENTARYFINANCIALSTATEMENTINFORMATIONDetails">
        <link:definition>0041 - Disclosure - SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.enterabio.com/role/SUBSEQUENTEVENTSNarrative" id="SUBSEQUENTEVENTSNarrative">
        <link:definition>0042 - Disclosure - SUBSEQUENT EVENTS (Detail Textuals)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:linkbaseRef xlink:type="simple" xlink:href="entx-20221231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase"/>
      <link:linkbaseRef xlink:type="simple" xlink:href="entx-20221231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase"/>
      <link:linkbaseRef xlink:type="simple" xlink:href="entx-20221231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase"/>
      <link:linkbaseRef xlink:type="simple" xlink:href="entx-20221231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase"/>
    </appinfo>
  </annotation>
  <element name="AccreditedInvestorsIncludingCertainBoardMembersAndTheirAffiliatesMember" id="entx_AccreditedInvestorsIncludingCertainBoardMembersAndTheirAffiliatesMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="AdditionalAmountPaidForServicesToBeRecognized" id="entx_AdditionalAmountPaidForServicesToBeRecognized" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="AdditionalCashSeparationPayment" id="entx_AdditionalCashSeparationPayment" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="AdjustedExercisePriceUnderAtMarketEquityProgram" id="entx_AdjustedExercisePriceUnderAtMarketEquityProgram" type="dtr-types:perShareItemType" abstract="false" xbrli:periodType="instant" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="AgreementAxis" id="entx_AgreementAxis" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" nillable="true"/>
  <element name="AgreementDomain" id="entx_AgreementDomain" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="AmendmentToBusinessDevelopmentServicesAgreementMember" id="entx_AmendmentToBusinessDevelopmentServicesAgreementMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="AmgenIncMember" id="entx_AmgenIncMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="AtmEquityProgram2020Member" id="entx_AtmEquityProgram2020Member" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="AtmEquityProgram2021Member" id="entx_AtmEquityProgram2021Member" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="BankGuarantees" id="entx_BankGuarantees" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="BoardMembersMember" id="entx_BoardMembersMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="BrokerDealerMember" id="entx_BrokerDealerMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="BrokerDealerOneMember" id="entx_BrokerDealerOneMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="BrokerWarrantsMember" id="entx_BrokerWarrantsMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="BrokerWarrantsType1Member" id="entx_BrokerWarrantsType1Member" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="BrokerWarrantsType2Member" id="entx_BrokerWarrantsType2Member" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="CashFeesInPercentage" id="entx_CashFeesInPercentage" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="CashlessExerciseOfWarrants" id="entx_CashlessExerciseOfWarrants" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="CashSeparationPayment" id="entx_CashSeparationPayment" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="ChairmanOfBoardAndDnaMember" id="entx_ChairmanOfBoardAndDnaMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="ClassOfWarrantOrRightExerciseTerm" id="entx_ClassOfWarrantOrRightExerciseTerm" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="ClassOfWarrantOrRightIssued" id="entx_ClassOfWarrantOrRightIssued" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="instant" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="ClassOfWarrantOrRightPercentageOfIpoPricePerUnit" id="entx_ClassOfWarrantOrRightPercentageOfIpoPricePerUnit" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="ClassOfWarrantOrRightReducedExercisePrice" id="entx_ClassOfWarrantOrRightReducedExercisePrice" type="dtr-types:perShareItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="ClassOfWarrantOrRightThresholdConsecutiveTradingDays" id="entx_ClassOfWarrantOrRightThresholdConsecutiveTradingDays" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="ClassOfWarrantOrRightThresholdLimitOfLastReportedSalePrice" id="entx_ClassOfWarrantOrRightThresholdLimitOfLastReportedSalePrice" type="dtr-types:perShareItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="ClassOfWarrantOrRightThresholdLimitOfPeriodForReductionInExercisePrice" id="entx_ClassOfWarrantOrRightThresholdLimitOfPeriodForReductionInExercisePrice" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="ClassOfWarrantOrRightThresholdLimitOfReductionInExercisePrice" id="entx_ClassOfWarrantOrRightThresholdLimitOfReductionInExercisePrice" type="dtr-types:perShareItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="CommitmentsAndContingenciesTable" id="entx_CommitmentsAndContingenciesTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" nillable="true"/>
  <element name="CommitmentsLineItems" id="entx_CommitmentsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="ConsultantMember" id="entx_ConsultantMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="DecreaseIncreaseInTaxRefundAbstract" id="entx_DecreaseIncreaseInTaxRefundAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="DnaBiomedicalSolutionsLtdAndOramedLtdMember" id="entx_DnaBiomedicalSolutionsLtdAndOramedLtdMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="DnaBiomedicalSolutionsLtdMember" id="entx_DnaBiomedicalSolutionsLtdMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="EffectOfDownRoundTriggerAmount" id="entx_EffectOfDownRoundTriggerAmount" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="EmployeeMember" id="entx_EmployeeMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="EmployeeSeveranceBenefitsPolicyPolicyTextBlock" id="entx_EmployeeSeveranceBenefitsPolicyPolicyTextBlock" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="EmployeesMember" id="entx_EmployeesMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="EnteraBioLtdMember" id="entx_EnteraBioLtdMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="EquityProgramAxis" id="entx_EquityProgramAxis" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" nillable="true"/>
  <element name="EquityProgramDomain" id="entx_EquityProgramDomain" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="ExecutiveOfficerAndServiceProviderMember" id="entx_ExecutiveOfficerAndServiceProviderMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="ExerciseOfWarrantsShares" id="entx_ExerciseOfWarrantsShares" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="ExerciseOfWarrantsValue" id="entx_ExerciseOfWarrantsValue" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="ExercisePricePerShareOnePointFourMember" id="entx_ExercisePricePerShareOnePointFourMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="ExercisePricePerShareOnePointTwoFourMember" id="entx_ExercisePricePerShareOnePointTwoFourMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="ExercisePricePerShareOnePointZeroSixMember" id="entx_ExercisePricePerShareOnePointZeroSixMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="ExercisePricePerShareSevenPointFiveFourMember" id="entx_ExercisePricePerShareSevenPointFiveFourMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="ExercisePricePerShareSixPointThreeOneMember" id="entx_ExercisePricePerShareSixPointThreeOneMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="ExercisePricePerShareThreePointNineSevenMember" id="entx_ExercisePricePerShareThreePointNineSevenMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="ExercisePricePerShareThreePointOneFiveMember" id="entx_ExercisePricePerShareThreePointOneFiveMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="ExercisePricePerShareThreePointSixEightMember" id="entx_ExercisePricePerShareThreePointSixEightMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="ExercisePricePerShareThreePointSixOneMember" id="entx_ExercisePricePerShareThreePointSixOneMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="ExercisePricePerShareTwoPointEightOneFiveMember" id="entx_ExercisePricePerShareTwoPointEightOneFiveMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="ExercisePricePerShareTwoPointEightSixMember" id="entx_ExercisePricePerShareTwoPointEightSixMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="ExercisePricePerShareTwoPointFiveSevenMember" id="entx_ExercisePricePerShareTwoPointFiveSevenMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="ExercisePricePerShareTwoPointFiveThreeMember" id="entx_ExercisePricePerShareTwoPointFiveThreeMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="ExercisePricePerShareTwoPointOneFourMember" id="entx_ExercisePricePerShareTwoPointOneFourMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="ExercisePricePerShareTwoPointZeroTwoMember" id="entx_ExercisePricePerShareTwoPointZeroTwoMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="ExercisePricePerShareZeroMember" id="entx_ExercisePricePerShareZeroMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="FinanceExpensesNet" id="entx_FinanceExpensesNet" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="FormerChiefExecutiveOfficerMember" id="entx_FormerChiefExecutiveOfficerMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="FundsInRespectOfEmployeeRightsUponRetirement" id="entx_FundsInRespectOfEmployeeRightsUponRetirement" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="GeneralLineItems" id="entx_GeneralLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="GeneralTable" id="entx_GeneralTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" nillable="true"/>
  <element name="InvestorRelationsServicesAgreementMember" id="entx_InvestorRelationsServicesAgreementMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="IssuanceOfOrdinarySharesAndWarrantsDueToPrivatePlacementNetOfIssuanceCosts" id="entx_IssuanceOfOrdinarySharesAndWarrantsDueToPrivatePlacementNetOfIssuanceCosts" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="IssuanceOfOrdinarySharesAndWarrantsDueToPrivatePlacementNetOfIssuanceCostsShares" id="entx_IssuanceOfOrdinarySharesAndWarrantsDueToPrivatePlacementNetOfIssuanceCostsShares" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="IssuanceOfSharesDueToAtMarketProgramNetOfIssuanceCostsShares" id="entx_IssuanceOfSharesDueToAtMarketProgramNetOfIssuanceCostsShares" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="IssuanceOfSharesDueToAtMarketProgramNetOfIssuanceCostsValue" id="entx_IssuanceOfSharesDueToAtMarketProgramNetOfIssuanceCostsValue" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="JointVentureAgreementMember" id="entx_JointVentureAgreementMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="LaboratoryEquipmentMember" id="entx_LaboratoryEquipmentMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="LeaseArrangementAxis" id="entx_LeaseArrangementAxis" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" nillable="true"/>
  <element name="LeaseArrangementDomain" id="entx_LeaseArrangementDomain" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="LiabilityForEmployeeRightsUponRetirement" id="entx_LiabilityForEmployeeRightsUponRetirement" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="ManagementAndConsultingFees" id="entx_ManagementAndConsultingFees" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="NetProceedsFromIssuanceOfCommonStock" id="entx_NetProceedsFromIssuanceOfCommonStock" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="NonExecutiveBoardMember" id="entx_NonExecutiveBoardMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="NonExecutiveDirectorMember" id="entx_NonExecutiveDirectorMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="NonExecutiveDirectorsMember" id="entx_NonExecutiveDirectorsMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="NonRefundableAndNonCreditableInitialTechnologyAccessFeePayment" id="entx_NonRefundableAndNonCreditableInitialTechnologyAccessFeePayment" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="NumberOfNonExecutiveBoardMembers" id="entx_NumberOfNonExecutiveBoardMembers" type="xbrli:integerItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="NumberOfSharesIssuedUnderPrivatePlacement" id="entx_NumberOfSharesIssuedUnderPrivatePlacement" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="instant" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="OneTimeTerminationPayment" id="entx_OneTimeTerminationPayment" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="OperatingLeaseAgreementsForOfficeAndResearchAndDevelopmentSpaceMember" id="entx_OperatingLeaseAgreementsForOfficeAndResearchAndDevelopmentSpaceMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="OperatingLeaseAgreementsForVehiclesForEmployeesMember" id="entx_OperatingLeaseAgreementsForVehiclesForEmployeesMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="OperatingLeaseLiabilityAndOperatingLeaseRightOfUseAssetTableTextBlock" id="entx_OperatingLeaseLiabilityAndOperatingLeaseRightOfUseAssetTableTextBlock" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="OperatingLeaseSupplementalCashFlowInformationTableTextBlock" id="entx_OperatingLeaseSupplementalCashFlowInformationTableTextBlock" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="OramedLtdMember" id="entx_OramedLtdMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="PatentCostsPolicyTextBlock" id="entx_PatentCostsPolicyTextBlock" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="PatentTransferAgreementMember" id="entx_PatentTransferAgreementMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="PaymentOfRoyaltyGuaranteesCommitments" id="entx_PaymentOfRoyaltyGuaranteesCommitments" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="PlacementAgencyAgreementWithGpNumenkariIncMember" id="entx_PlacementAgencyAgreementWithGpNumenkariIncMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="PresidentOfResearchAndDevelopmentMember" id="entx_PresidentOfResearchAndDevelopmentMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="ProceedsFromIssuanceOfSharesAndWarrantsNetOfIssuanceCosts" id="entx_ProceedsFromIssuanceOfSharesAndWarrantsNetOfIssuanceCosts" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="ProceedsFromIssuanceOfSharesThroughAtmProgramsNetOfIssuanceCosts" id="entx_ProceedsFromIssuanceOfSharesThroughAtmProgramsNetOfIssuanceCosts" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="ProceedsFromOptionsAndWarrantExercises" id="entx_ProceedsFromOptionsAndWarrantExercises" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="ProceedsFromShortTermBankDeposits" id="entx_ProceedsFromShortTermBankDeposits" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="ReconciliationInAmountsOnConsolidatedBalanceSheetsAbstract" id="entx_ReconciliationInAmountsOnConsolidatedBalanceSheetsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="RelatedPartyTransactionOfCompensationOfExecutiveOfficers" id="entx_RelatedPartyTransactionOfCompensationOfExecutiveOfficers" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="RelatedPartyTransactionOfManagementAndConsultingFeesToBoardMembers" id="entx_RelatedPartyTransactionOfManagementAndConsultingFeesToBoardMembers" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="RelatedPartyTransactionOfStockBasedCompensationExpensesToBoardMembers" id="entx_RelatedPartyTransactionOfStockBasedCompensationExpensesToBoardMembers" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="RelatedPartyTransactionOfStockBasedCompensationExpensesToExecutiveOfficers" id="entx_RelatedPartyTransactionOfStockBasedCompensationExpensesToExecutiveOfficers" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="RelatedPartyTransactionWithExecutiveOfficersPayables" id="entx_RelatedPartyTransactionWithExecutiveOfficersPayables" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="RelatedPartyTransactionWithNonExecutiveDirectorsPayable" id="entx_RelatedPartyTransactionWithNonExecutiveDirectorsPayable" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="ResearchAndDevelopmentServiceExpense" id="entx_ResearchAndDevelopmentServiceExpense" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="ResearchCollaborationAndLicenseAgreementMember" id="entx_ResearchCollaborationAndLicenseAgreementMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="ReversalOfExpensesUponForfeitureOfOptions" id="entx_ReversalOfExpensesUponForfeitureOfOptions" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="RightOfUseAssetsObtainedInExchangeForNewOperatingLeaseLiabilities" id="entx_RightOfUseAssetsObtainedInExchangeForNewOperatingLeaseLiabilities" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="RightToUseIntellectualProperty" id="entx_RightToUseIntellectualProperty" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="RoyaltyGuaranteesCommitmentsPercentageOfEachPaymentReceivedFromAmgen" id="entx_RoyaltyGuaranteesCommitmentsPercentageOfEachPaymentReceivedFromAmgen" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="RoyaltyGuaranteesCommitmentsPercentageOfNetRevenues" id="entx_RoyaltyGuaranteesCommitmentsPercentageOfNetRevenues" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="RoyaltyGuaranteesCommitmentsPercentageSalesOfProductsDevelopedFromProjectsCommencingSeventhYear" id="entx_RoyaltyGuaranteesCommitmentsPercentageSalesOfProductsDevelopedFromProjectsCommencingSeventhYear" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="RoyaltyGuaranteesCommitmentsPercentageSalesOfProductsDevelopedFromProjectsInFirstThreeYearsFromCommencementOfRevenues" id="entx_RoyaltyGuaranteesCommitmentsPercentageSalesOfProductsDevelopedFromProjectsInFirstThreeYearsFromCommencementOfRevenues" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="RoyaltyGuaranteesCommitmentsPercentageSalesOfProductsDevelopedFromProjectsSubsequentThreeYears" id="entx_RoyaltyGuaranteesCommitmentsPercentageSalesOfProductsDevelopedFromProjectsSubsequentThreeYears" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="SaleOfStockAmountOfInvestment" id="entx_SaleOfStockAmountOfInvestment" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="SaleOfStockPercentageOfOwnershipOfEntityAcquired" id="entx_SaleOfStockPercentageOfOwnershipOfEntityAcquired" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="ScheduleOfEstimatedUsefulLifeTableTextBlock" id="entx_ScheduleOfEstimatedUsefulLifeTableTextBlock" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="ScheduleOfRelatedPartyTransactionReportedInConsolidatedStatementsOfComprehensiveLossTableTextBlock" id="entx_ScheduleOfRelatedPartyTransactionReportedInConsolidatedStatementsOfComprehensiveLossTableTextBlock" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="ScheduleOfRelatedPartyTransactionsReportedInConsolidatedBalanceSheetsTableTextBlock" id="entx_ScheduleOfRelatedPartyTransactionsReportedInConsolidatedBalanceSheetsTableTextBlock" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="SellingPriceOfPreclinicalResearchAndDevelopmentServices" id="entx_SellingPriceOfPreclinicalResearchAndDevelopmentServices" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="ServiceProviderMember" id="entx_ServiceProviderMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="SeveralEmployeesAndServiceProvidersMember" id="entx_SeveralEmployeesAndServiceProvidersMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="SeveranceExpenses" id="entx_SeveranceExpenses" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="SeverancePayPolicyTextBlock" id="entx_SeverancePayPolicyTextBlock" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsTotalConsideration" id="entx_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsTotalConsideration" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="ShareBasedPaymentArrangementTrancheFiveMember" id="entx_ShareBasedPaymentArrangementTrancheFiveMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="ShareBasedPaymentArrangementTrancheFourMember" id="entx_ShareBasedPaymentArrangementTrancheFourMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="ShareBasedPaymentArrangementTrancheSevenMember" id="entx_ShareBasedPaymentArrangementTrancheSevenMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="ShareBasedPaymentArrangementTrancheSixMember" id="entx_ShareBasedPaymentArrangementTrancheSixMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="ShareIncentivePlan2013Member" id="entx_ShareIncentivePlan2013Member" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="ShareIncentivePlan2018Member" id="entx_ShareIncentivePlan2018Member" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="SharesGrantedInPercentage" id="entx_SharesGrantedInPercentage" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="SharesIssuedWeightedAveragePricePerShare" id="entx_SharesIssuedWeightedAveragePricePerShare" type="dtr-types:perShareItemType" abstract="false" xbrli:periodType="instant" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="SignificantAccountingPoliciesLineItems" id="entx_SignificantAccountingPoliciesLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="SignificantAccountingPoliciesTable" id="entx_SignificantAccountingPoliciesTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" nillable="true"/>
  <element name="StockholdersEquityNoteLineItems" id="entx_StockholdersEquityNoteLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="StockholdersEquityNoteTable" id="entx_StockholdersEquityNoteTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" nillable="true"/>
  <element name="SupplementaryFinancialStatementInformationAbstract" id="entx_SupplementaryFinancialStatementInformationAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="SupplementaryFinancialStatementInformationTextBlock" id="entx_SupplementaryFinancialStatementInformationTextBlock" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="TransactionCosts" id="entx_TransactionCosts" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="TriggeringEventAxis" id="entx_TriggeringEventAxis" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" nillable="true"/>
  <element name="TriggeringEventDomain" id="entx_TriggeringEventDomain" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="TriggeringEventMember" id="entx_TriggeringEventMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="TwentySeventeenMemberMember" id="entx_TwentySeventeenMemberMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="TwentyTwentyOneGrantMember" id="entx_TwentyTwentyOneGrantMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="VestedRestrictedSharesUnits" id="entx_VestedRestrictedSharesUnits" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="VestedRestrictedShareUnitsShares" id="entx_VestedRestrictedShareUnitsShares" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="WarrantToPurchaseOrdinaryShare" id="entx_WarrantToPurchaseOrdinaryShare" type="dtr-types:perShareItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>11
<FILENAME>entx-20221231_cal.xml
<DESCRIPTION>XBRL CALCULATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <!-- INTEGIX by Ez-XBRL -->
  <roleRef xlink:type="simple" xlink:href="entx-20221231.xsd#CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS" roleURI="http://www.enterabio.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS"/>
  <roleRef xlink:type="simple" xlink:href="entx-20221231.xsd#CONSOLIDATEDBALANCESHEETS" roleURI="http://www.enterabio.com/role/CONSOLIDATEDBALANCESHEETS"/>
  <roleRef xlink:type="simple" xlink:href="entx-20221231.xsd#CONSOLIDATEDSTATEMENTSOFCASHFLOWS" roleURI="http://www.enterabio.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"/>
  <roleRef xlink:type="simple" xlink:href="entx-20221231.xsd#SUPPLEMENTARYFINANCIALSTATEMENTINFORMATIONDetails" roleURI="http://www.enterabio.com/role/SUPPLEMENTARYFINANCIALSTATEMENTINFORMATIONDetails"/>
  <roleRef xlink:type="simple" xlink:href="entx-20221231.xsd#INCOMETAXDetails" roleURI="http://www.enterabio.com/role/INCOMETAXDetails"/>
  <calculationLink xlink:type="extended" xlink:role="http://www.enterabio.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GrossProfit" xlink:label="loc_us-gaap_GrossProfit_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfRevenue" xlink:label="loc_us-gaap_CostOfRevenue_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_5"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonrecurringIncome" xlink:label="loc_us-gaap_OtherNonrecurringIncome_6"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_9"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_11"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_0" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_1" order="0" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_1" xlink:to="loc_us-gaap_OperatingIncomeLoss_1" order="0" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_1" xlink:to="loc_us-gaap_GrossProfit_1" order="0" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_GrossProfit_1" xlink:to="loc_us-gaap_Revenues_1" order="0" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_GrossProfit_1" xlink:to="loc_us-gaap_CostOfRevenue_2" order="10" use="optional" weight="-1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_1" xlink:to="loc_us-gaap_OperatingExpenses_4" order="10" use="optional" weight="-1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_4" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_4" order="0" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_4" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_5" order="10" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_4" xlink:to="loc_us-gaap_OtherNonrecurringIncome_6" order="20" use="optional" weight="-1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_1" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_9" order="10" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_0" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_11" order="10" use="optional" weight="-1"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.enterabio.com/role/CONSOLIDATEDBALANCESHEETS">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsCurrent" xlink:label="loc_us-gaap_OtherAssetsCurrent_3"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsNoncurrent" xlink:label="loc_us-gaap_AssetsNoncurrent_5"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent" xlink:label="loc_us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent_5"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_6"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_7"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxAssetsNet" xlink:label="loc_us-gaap_DeferredIncomeTaxAssetsNet_8"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_10"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities_11"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent_11"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaap_AccountsPayableCurrent_11"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:label="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilities_12"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_13"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_14"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesNoncurrent" xlink:label="loc_us-gaap_LiabilitiesNoncurrent_16"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PostemploymentBenefitsLiabilityNoncurrent" xlink:label="loc_us-gaap_PostemploymentBenefitsLiabilityNoncurrent_16"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_17"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaap_CommitmentsAndContingencies_20"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_21"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_21"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_22"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_23"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_24"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_0" xlink:to="loc_us-gaap_AssetsCurrent_1" order="0" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_1" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_1" order="0" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_1" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_2" order="10" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_1" xlink:to="loc_us-gaap_OtherAssetsCurrent_3" order="20" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_0" xlink:to="loc_us-gaap_AssetsNoncurrent_5" order="10" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsNoncurrent_5" xlink:to="loc_us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent_5" order="0" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsNoncurrent_5" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_6" order="10" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsNoncurrent_5" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_7" order="20" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsNoncurrent_5" xlink:to="loc_us-gaap_DeferredIncomeTaxAssetsNet_8" order="30" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_10" xlink:to="loc_us-gaap_Liabilities_11" order="0" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_11" xlink:to="loc_us-gaap_LiabilitiesCurrent_11" order="0" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_11" xlink:to="loc_us-gaap_AccountsPayableCurrent_11" order="0" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_11" xlink:to="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilities_12" order="10" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_11" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_13" order="20" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_11" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_14" order="30" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_11" xlink:to="loc_us-gaap_LiabilitiesNoncurrent_16" order="10" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesNoncurrent_16" xlink:to="loc_us-gaap_PostemploymentBenefitsLiabilityNoncurrent_16" order="0" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesNoncurrent_16" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_17" order="10" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_10" xlink:to="loc_us-gaap_CommitmentsAndContingencies_20" order="10" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_10" xlink:to="loc_us-gaap_StockholdersEquity_21" order="20" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_21" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_21" order="0" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_21" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_22" order="10" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_21" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_23" order="20" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_21" xlink:to="loc_us-gaap_CommonStockValue_24" order="30" use="optional" weight="1"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.enterabio.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_1"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_FundsInRespectOfEmployeeRightsUponRetirement" xlink:label="loc_entx_FundsInRespectOfEmployeeRightsUponRetirement_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_4"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_FinanceExpensesNet" xlink:label="loc_entx_FinanceExpensesNet_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_5"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_6"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaap_Depreciation_7"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsFinitelived_8"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccretionExpenseIncludingAssetRetirementObligations" xlink:label="loc_us-gaap_AccretionExpenseIncludingAssetRetirementObligations_9"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsFinitelived_10"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_11"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_12"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_13"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherCurrentAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherCurrentAssets_14"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_15"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_16"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_17"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_19"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_19"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_ProceedsFromOptionsAndWarrantExercises" xlink:label="loc_entx_ProceedsFromOptionsAndWarrantExercises_20"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_22"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_23"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalents" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalents_24"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_0" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_1" order="0" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_1" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_1" order="0" use="optional" weight="-1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_1" xlink:to="loc_entx_FundsInRespectOfEmployeeRightsUponRetirement_2" order="10" use="optional" weight="-1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_0" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_4" order="10" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_4" xlink:to="loc_entx_FinanceExpensesNet_4" order="0" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_4" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_5" order="10" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_4" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_6" order="20" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_4" xlink:to="loc_us-gaap_Depreciation_7" order="30" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_4" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsFinitelived_8" order="40" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_4" xlink:to="loc_us-gaap_AccretionExpenseIncludingAssetRetirementObligations_9" order="50" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_4" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsFinitelived_10" order="60" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_4" xlink:to="loc_us-gaap_ShareBasedCompensation_11" order="70" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_4" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_12" order="80" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_4" xlink:to="loc_us-gaap_NetIncomeLoss_13" order="90" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_4" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherCurrentAssets_14" order="100" use="optional" weight="-1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_4" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_15" order="110" use="optional" weight="-1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_4" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_16" order="120" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_4" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_17" order="130" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_0" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_19" order="20" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_19" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_19" order="0" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_19" xlink:to="loc_entx_ProceedsFromOptionsAndWarrantExercises_20" order="10" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_22" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_23" order="0" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_22" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalents_24" order="10" use="optional" weight="1"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.enterabio.com/role/SUPPLEMENTARYFINANCIALSTATEMENTINFORMATIONDetails">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:label="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilities_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedEmployeeBenefitsCurrent" xlink:label="loc_us-gaap_AccruedEmployeeBenefitsCurrent_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedVacationCurrent" xlink:label="loc_us-gaap_AccruedVacationCurrent_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_3"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedIncomeTaxesCurrent" xlink:label="loc_us-gaap_AccruedIncomeTaxesCurrent_4"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilities_0" xlink:to="loc_us-gaap_AccruedEmployeeBenefitsCurrent_1" order="0" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilities_0" xlink:to="loc_us-gaap_AccruedVacationCurrent_2" order="10" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilities_0" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_3" order="20" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilities_0" xlink:to="loc_us-gaap_AccruedIncomeTaxesCurrent_4" order="30" use="optional" weight="1"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.enterabio.com/role/INCOMETAXDetails">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="loc_us-gaap_DeferredTaxAssetsOther_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:label="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_3"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_4"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_0" xlink:to="loc_us-gaap_DeferredTaxAssetsOther_1" order="0" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_0" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_2" order="10" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_0" xlink:to="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_3" order="20" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_0" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_4" order="30" use="optional" weight="1"/>
  </calculationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>12
<FILENAME>entx-20221231_def.xml
<DESCRIPTION>XBRL DEFINITION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:xbrldt="http://xbrl.org/2005/xbrldt">
  <!-- INTEGIX by Ez-XBRL -->
  <roleRef xlink:type="simple" xlink:href="entx-20221231.xsd#SIGNIFICANTACCOUNTINGPOLICIESDetailTextuals" roleURI="http://www.enterabio.com/role/SIGNIFICANTACCOUNTINGPOLICIESDetailTextuals"/>
  <roleRef xlink:type="simple" xlink:href="entx-20221231.xsd#SHAREBASEDCOMPENSATIONDetails" roleURI="http://www.enterabio.com/role/SHAREBASEDCOMPENSATIONDetails"/>
  <roleRef xlink:type="simple" xlink:href="entx-20221231.xsd#SHAREBASEDCOMPENSATIONDetailTextuals" roleURI="http://www.enterabio.com/role/SHAREBASEDCOMPENSATIONDetailTextuals"/>
  <roleRef xlink:type="simple" xlink:href="entx-20221231.xsd#GENERALDetailTextuals" roleURI="http://www.enterabio.com/role/GENERALDetailTextuals"/>
  <roleRef xlink:type="simple" xlink:href="entx-20221231.xsd#CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY" roleURI="http://www.enterabio.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY"/>
  <roleRef xlink:type="simple" xlink:href="entx-20221231.xsd#OPERATINGLEASESDetailTextuals" roleURI="http://www.enterabio.com/role/OPERATINGLEASESDetailTextuals"/>
  <roleRef xlink:type="simple" xlink:href="entx-20221231.xsd#COMMITMENTSDetailTextuals" roleURI="http://www.enterabio.com/role/COMMITMENTSDetailTextuals"/>
  <roleRef xlink:type="simple" xlink:href="entx-20221231.xsd#SHARECAPITALDetailTextuals" roleURI="http://www.enterabio.com/role/SHARECAPITALDetailTextuals"/>
  <roleRef xlink:type="simple" xlink:href="entx-20221231.xsd#INCOMETAXDetails1" roleURI="http://www.enterabio.com/role/INCOMETAXDetails1"/>
  <roleRef xlink:type="simple" xlink:href="entx-20221231.xsd#SHAREBASEDCOMPENSATIONDetails3" roleURI="http://www.enterabio.com/role/SHAREBASEDCOMPENSATIONDetails3"/>
  <roleRef xlink:type="simple" xlink:href="entx-20221231.xsd#INCOMETAXDetails3" roleURI="http://www.enterabio.com/role/INCOMETAXDetails3"/>
  <roleRef xlink:type="simple" xlink:href="entx-20221231.xsd#INCOMETAXDetailTextuals" roleURI="http://www.enterabio.com/role/INCOMETAXDetailTextuals"/>
  <roleRef xlink:type="simple" xlink:href="entx-20221231.xsd#SHAREBASEDCOMPENSATIONDetails2" roleURI="http://www.enterabio.com/role/SHAREBASEDCOMPENSATIONDetails2"/>
  <roleRef xlink:type="simple" xlink:href="entx-20221231.xsd#SIGNIFICANTACCOUNTINGPOLICIESDetails" roleURI="http://www.enterabio.com/role/SIGNIFICANTACCOUNTINGPOLICIESDetails"/>
  <roleRef xlink:type="simple" xlink:href="entx-20221231.xsd#SUBSEQUENTEVENTSNarrative" roleURI="http://www.enterabio.com/role/SUBSEQUENTEVENTSNarrative"/>
  <arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/notAll" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#notAll"/>
  <definitionLink xlink:type="extended" xlink:role="http://www.enterabio.com/role/SIGNIFICANTACCOUNTINGPOLICIESDetailTextuals">
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_SignificantAccountingPoliciesLineItems" xlink:label="loc_entx_SignificantAccountingPoliciesLineItems_0"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_SignificantAccountingPoliciesTable" xlink:label="loc_entx_SignificantAccountingPoliciesTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_1"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_AmgenIncMember" xlink:label="loc_entx_AmgenIncMember_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_Default"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeveranceCosts1" xlink:label="loc_us-gaap_SeveranceCosts1_6"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_SeveranceExpenses" xlink:label="loc_entx_SeveranceExpenses_7"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_NonRefundableAndNonCreditableInitialTechnologyAccessFeePayment" xlink:label="loc_entx_NonRefundableAndNonCreditableInitialTechnologyAccessFeePayment_8"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_AdditionalAmountPaidForServicesToBeRecognized" xlink:label="loc_entx_AdditionalAmountPaidForServicesToBeRecognized_9"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_RightToUseIntellectualProperty" xlink:label="loc_entx_RightToUseIntellectualProperty_10"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_11"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredRevenueRevenueRecognized1" xlink:label="loc_us-gaap_DeferredRevenueRevenueRecognized1_12"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_entx_SignificantAccountingPoliciesLineItems_0" xlink:to="loc_entx_SignificantAccountingPoliciesTable_1" order="0" use="optional" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_entx_SignificantAccountingPoliciesTable_1" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1" xlink:to="loc_us-gaap_RelatedPartyDomain_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_1" xlink:to="loc_entx_AmgenIncMember_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1" xlink:to="loc_us-gaap_RelatedPartyDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_entx_SignificantAccountingPoliciesLineItems_0" xlink:to="loc_us-gaap_SeveranceCosts1_6" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_entx_SignificantAccountingPoliciesLineItems_0" xlink:to="loc_entx_SeveranceExpenses_7" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_entx_SignificantAccountingPoliciesLineItems_0" xlink:to="loc_entx_NonRefundableAndNonCreditableInitialTechnologyAccessFeePayment_8" order="30" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_entx_SignificantAccountingPoliciesLineItems_0" xlink:to="loc_entx_AdditionalAmountPaidForServicesToBeRecognized_9" order="40" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_entx_SignificantAccountingPoliciesLineItems_0" xlink:to="loc_entx_RightToUseIntellectualProperty_10" order="50" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_entx_SignificantAccountingPoliciesLineItems_0" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_11" order="60" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_entx_SignificantAccountingPoliciesLineItems_0" xlink:to="loc_us-gaap_DeferredRevenueRevenueRecognized1_12" order="70" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.enterabio.com/role/SHAREBASEDCOMPENSATIONDetails">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_Default"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_7"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_8"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_9"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_10"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_11"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" order="0" use="optional" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_srt_RangeAxis_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_1" xlink:to="loc_srt_RangeMember_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_1" xlink:to="loc_srt_MinimumMember_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_1" xlink:to="loc_srt_MaximumMember_2" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_1" xlink:to="loc_srt_RangeMember_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_7" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_8" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_9" order="30" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_10" order="40" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_11" order="50" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.enterabio.com/role/SHAREBASEDCOMPENSATIONDetailTextuals">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_1"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_ShareIncentivePlan2013Member" xlink:label="loc_entx_ShareIncentivePlan2013Member_1"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_ShareIncentivePlan2018Member" xlink:label="loc_entx_ShareIncentivePlan2018Member_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_Default"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srt_TitleOfIndividualAxis_6"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_6"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_ExecutiveOfficerAndServiceProviderMember" xlink:label="loc_entx_ExecutiveOfficerAndServiceProviderMember_6"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_EmployeesMember" xlink:label="loc_entx_EmployeesMember_7"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_ServiceProviderMember" xlink:label="loc_entx_ServiceProviderMember_8"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ExecutiveOfficerMember" xlink:label="loc_srt_ExecutiveOfficerMember_9"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_FormerChiefExecutiveOfficerMember" xlink:label="loc_entx_FormerChiefExecutiveOfficerMember_10"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_ConsultantMember" xlink:label="loc_entx_ConsultantMember_11"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_NonExecutiveDirectorMember" xlink:label="loc_entx_NonExecutiveDirectorMember_12"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_DirectorMember" xlink:label="loc_srt_DirectorMember_13"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_EmployeeMember" xlink:label="loc_entx_EmployeeMember_14"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ChiefExecutiveOfficerMember" xlink:label="loc_srt_ChiefExecutiveOfficerMember_15"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ChiefFinancialOfficerMember" xlink:label="loc_srt_ChiefFinancialOfficerMember_16"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_PresidentOfResearchAndDevelopmentMember" xlink:label="loc_entx_PresidentOfResearchAndDevelopmentMember_17"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_Default"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingAxis" xlink:label="loc_us-gaap_VestingAxis_21"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingDomain" xlink:label="loc_us-gaap_VestingDomain_21"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_21"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_22"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationAwardTrancheThreeMember" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheThreeMember_23"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_ShareBasedPaymentArrangementTrancheFourMember" xlink:label="loc_entx_ShareBasedPaymentArrangementTrancheFourMember_24"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_ShareBasedPaymentArrangementTrancheFiveMember" xlink:label="loc_entx_ShareBasedPaymentArrangementTrancheFiveMember_25"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_ShareBasedPaymentArrangementTrancheSixMember" xlink:label="loc_entx_ShareBasedPaymentArrangementTrancheSixMember_26"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingDomain" xlink:label="loc_us-gaap_VestingDomain_Default"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_30"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_30"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_InvestorRelationsServicesAgreementMember" xlink:label="loc_entx_InvestorRelationsServicesAgreementMember_30"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_AmendmentToBusinessDevelopmentServicesAgreementMember" xlink:label="loc_entx_AmendmentToBusinessDevelopmentServicesAgreementMember_31"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_TriggeringEventMember" xlink:label="loc_entx_TriggeringEventMember_32"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_Default"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_36"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_36"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_36"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_TwentyTwentyOneGrantMember" xlink:label="loc_entx_TwentyTwentyOneGrantMember_37"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_TwentySeventeenMemberMember" xlink:label="loc_entx_TwentySeventeenMemberMember_38"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_Default"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_43"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_44"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription_45"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_46"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_47"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_48"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_49"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_50"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_51"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_ReversalOfExpensesUponForfeitureOfOptions" xlink:label="loc_entx_ReversalOfExpensesUponForfeitureOfOptions_52"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_53"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_54"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_55"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_56"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_57"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfessionalFees" xlink:label="loc_us-gaap_ProfessionalFees_58"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_59"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_CashSeparationPayment" xlink:label="loc_entx_CashSeparationPayment_60"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_AdditionalCashSeparationPayment" xlink:label="loc_entx_AdditionalCashSeparationPayment_61"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OfficersCompensation" xlink:label="loc_us-gaap_OfficersCompensation_62"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DescriptionOfPostemploymentBenefits" xlink:label="loc_us-gaap_DescriptionOfPostemploymentBenefits_63"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_64"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares_65"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_66"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" order="0" use="optional" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_us-gaap_PlanNameAxis_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_1" xlink:to="loc_us-gaap_PlanNameDomain_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_1" xlink:to="loc_entx_ShareIncentivePlan2013Member_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_1" xlink:to="loc_entx_ShareIncentivePlan2018Member_2" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_1" xlink:to="loc_us-gaap_PlanNameDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_srt_TitleOfIndividualAxis_6" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_TitleOfIndividualAxis_6" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_6" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_6" xlink:to="loc_entx_ExecutiveOfficerAndServiceProviderMember_6" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_6" xlink:to="loc_entx_EmployeesMember_7" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_6" xlink:to="loc_entx_ServiceProviderMember_8" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_6" xlink:to="loc_srt_ExecutiveOfficerMember_9" order="30" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_6" xlink:to="loc_entx_FormerChiefExecutiveOfficerMember_10" order="40" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_6" xlink:to="loc_entx_ConsultantMember_11" order="50" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_6" xlink:to="loc_entx_NonExecutiveDirectorMember_12" order="60" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_6" xlink:to="loc_srt_DirectorMember_13" order="70" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_6" xlink:to="loc_entx_EmployeeMember_14" order="80" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_6" xlink:to="loc_srt_ChiefExecutiveOfficerMember_15" order="90" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_6" xlink:to="loc_srt_ChiefFinancialOfficerMember_16" order="100" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_6" xlink:to="loc_entx_PresidentOfResearchAndDevelopmentMember_17" order="110" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_TitleOfIndividualAxis_6" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_us-gaap_VestingAxis_21" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_VestingAxis_21" xlink:to="loc_us-gaap_VestingDomain_21" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VestingDomain_21" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_21" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VestingDomain_21" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_22" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VestingDomain_21" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheThreeMember_23" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VestingDomain_21" xlink:to="loc_entx_ShareBasedPaymentArrangementTrancheFourMember_24" order="30" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VestingDomain_21" xlink:to="loc_entx_ShareBasedPaymentArrangementTrancheFiveMember_25" order="40" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VestingDomain_21" xlink:to="loc_entx_ShareBasedPaymentArrangementTrancheSixMember_26" order="50" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_VestingAxis_21" xlink:to="loc_us-gaap_VestingDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_us-gaap_TypeOfArrangementAxis_30" order="30" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_30" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_30" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_30" xlink:to="loc_entx_InvestorRelationsServicesAgreementMember_30" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_30" xlink:to="loc_entx_AmendmentToBusinessDevelopmentServicesAgreementMember_31" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_30" xlink:to="loc_entx_TriggeringEventMember_32" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_30" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_us-gaap_AwardTypeAxis_36" order="40" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_36" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_36" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_36" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_36" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_36" xlink:to="loc_entx_TwentyTwentyOneGrantMember_37" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_36" xlink:to="loc_entx_TwentySeventeenMemberMember_38" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_36" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_43" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_44" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription_45" order="30" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_46" order="40" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_47" order="50" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_48" order="60" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_49" order="70" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_50" order="80" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_51" order="90" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_entx_ReversalOfExpensesUponForfeitureOfOptions_52" order="100" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_53" order="110" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_54" order="120" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_55" order="130" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_56" order="140" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_57" order="150" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_ProfessionalFees_58" order="160" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_59" order="170" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_entx_CashSeparationPayment_60" order="180" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_entx_AdditionalCashSeparationPayment_61" order="190" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_OfficersCompensation_62" order="200" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_DescriptionOfPostemploymentBenefits_63" order="210" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_64" order="220" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares_65" order="230" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_66" order="240" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.enterabio.com/role/GENERALDetailTextuals">
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_GeneralLineItems" xlink:label="loc_entx_GeneralLineItems_0"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_GeneralTable" xlink:label="loc_entx_GeneralTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IPOMember" xlink:label="loc_us-gaap_IPOMember_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_Default"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_5"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_5"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_5"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_Default"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_10"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesIssued" xlink:label="loc_us-gaap_SharesIssued_11"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_ClassOfWarrantOrRightIssued" xlink:label="loc_entx_ClassOfWarrantOrRightIssued_12"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_13"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_NetProceedsFromIssuanceOfCommonStock" xlink:label="loc_entx_NetProceedsFromIssuanceOfCommonStock_14"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_WarrantToPurchaseOrdinaryShare" xlink:label="loc_entx_WarrantToPurchaseOrdinaryShare_15"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaap_SharePrice_16"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_17"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_entx_GeneralLineItems_0" xlink:to="loc_entx_GeneralTable_1" order="0" use="optional" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_entx_GeneralTable_1" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_1" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1" xlink:to="loc_us-gaap_IPOMember_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_1" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_entx_GeneralTable_1" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_5" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_5" xlink:to="loc_us-gaap_EquityComponentDomain_5" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_5" xlink:to="loc_us-gaap_CommonStockMember_5" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_5" xlink:to="loc_us-gaap_EquityComponentDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_entx_GeneralLineItems_0" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_10" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_entx_GeneralLineItems_0" xlink:to="loc_us-gaap_SharesIssued_11" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_entx_GeneralLineItems_0" xlink:to="loc_entx_ClassOfWarrantOrRightIssued_12" order="30" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_entx_GeneralLineItems_0" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_13" order="40" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_entx_GeneralLineItems_0" xlink:to="loc_entx_NetProceedsFromIssuanceOfCommonStock_14" order="50" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_entx_GeneralLineItems_0" xlink:to="loc_entx_WarrantToPurchaseOrdinaryShare_15" order="60" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_entx_GeneralLineItems_0" xlink:to="loc_us-gaap_SharePrice_16" order="70" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_entx_GeneralLineItems_0" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_17" order="80" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.enterabio.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_3"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaap_RetainedEarningsMember_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_Default"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_9"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_9"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaap_SharesOutstanding_10"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_11"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_ExerciseOfWarrantsValue" xlink:label="loc_entx_ExerciseOfWarrantsValue_12"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_ExerciseOfWarrantsShares" xlink:label="loc_entx_ExerciseOfWarrantsShares_13"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_IssuanceOfOrdinarySharesAndWarrantsDueToPrivatePlacementNetOfIssuanceCosts" xlink:label="loc_entx_IssuanceOfOrdinarySharesAndWarrantsDueToPrivatePlacementNetOfIssuanceCosts_14"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_IssuanceOfOrdinarySharesAndWarrantsDueToPrivatePlacementNetOfIssuanceCostsShares" xlink:label="loc_entx_IssuanceOfOrdinarySharesAndWarrantsDueToPrivatePlacementNetOfIssuanceCostsShares_15"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueIssuedForServices_16"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_17"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_18"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_19"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_20"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition_21"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_VestedRestrictedShareUnitsShares" xlink:label="loc_entx_VestedRestrictedShareUnitsShares_22"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_StatementTable_1" order="0" use="optional" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_1" xlink:to="loc_us-gaap_EquityComponentDomain_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_1" xlink:to="loc_us-gaap_CommonStockMember_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_1" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_2" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_1" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_3" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_1" xlink:to="loc_us-gaap_RetainedEarningsMember_4" order="30" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_1" xlink:to="loc_us-gaap_EquityComponentDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_9" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_9" xlink:to="loc_us-gaap_StockholdersEquity_9" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_9" xlink:to="loc_us-gaap_SharesOutstanding_10" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_9" xlink:to="loc_us-gaap_NetIncomeLoss_11" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_9" xlink:to="loc_entx_ExerciseOfWarrantsValue_12" order="30" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_9" xlink:to="loc_entx_ExerciseOfWarrantsShares_13" order="40" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_9" xlink:to="loc_entx_IssuanceOfOrdinarySharesAndWarrantsDueToPrivatePlacementNetOfIssuanceCosts_14" order="50" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_9" xlink:to="loc_entx_IssuanceOfOrdinarySharesAndWarrantsDueToPrivatePlacementNetOfIssuanceCostsShares_15" order="60" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_9" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueIssuedForServices_16" order="70" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_9" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_17" order="80" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_9" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_18" order="90" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_9" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_19" order="100" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_9" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_20" order="110" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_9" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition_21" order="120" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_9" xlink:to="loc_entx_VestedRestrictedShareUnitsShares_22" order="130" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.enterabio.com/role/OPERATINGLEASESDetailTextuals">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_1"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_LeaseArrangementAxis" xlink:label="loc_entx_LeaseArrangementAxis_1"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_LeaseArrangementDomain" xlink:label="loc_entx_LeaseArrangementDomain_1"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_OperatingLeaseAgreementsForOfficeAndResearchAndDevelopmentSpaceMember" xlink:label="loc_entx_OperatingLeaseAgreementsForOfficeAndResearchAndDevelopmentSpaceMember_1"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_OperatingLeaseAgreementsForVehiclesForEmployeesMember" xlink:label="loc_entx_OperatingLeaseAgreementsForVehiclesForEmployeesMember_2"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_LeaseArrangementDomain" xlink:label="loc_entx_LeaseArrangementDomain_Default"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentForContingentConsiderationLiabilityOperatingActivities" xlink:label="loc_us-gaap_PaymentForContingentConsiderationLiabilityOperatingActivities_7"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_BankGuarantees" xlink:label="loc_entx_BankGuarantees_8"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaap_OperatingLeaseLiability_9"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_0" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_1" order="0" use="optional" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_1" xlink:to="loc_entx_LeaseArrangementAxis_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_entx_LeaseArrangementAxis_1" xlink:to="loc_entx_LeaseArrangementDomain_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_entx_LeaseArrangementDomain_1" xlink:to="loc_entx_OperatingLeaseAgreementsForOfficeAndResearchAndDevelopmentSpaceMember_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_entx_LeaseArrangementDomain_1" xlink:to="loc_entx_OperatingLeaseAgreementsForVehiclesForEmployeesMember_2" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_entx_LeaseArrangementAxis_1" xlink:to="loc_entx_LeaseArrangementDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_0" xlink:to="loc_us-gaap_PaymentForContingentConsiderationLiabilityOperatingActivities_7" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_0" xlink:to="loc_entx_BankGuarantees_8" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_0" xlink:to="loc_us-gaap_OperatingLeaseLiability_9" order="30" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.enterabio.com/role/COMMITMENTSDetailTextuals">
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_CommitmentsLineItems" xlink:label="loc_entx_CommitmentsLineItems_0"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_CommitmentsAndContingenciesTable" xlink:label="loc_entx_CommitmentsAndContingenciesTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis" xlink:label="loc_us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LegalEntityTypeOfCounterpartyDomain" xlink:label="loc_us-gaap_LegalEntityTypeOfCounterpartyDomain_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GovernmentMember" xlink:label="loc_us-gaap_GovernmentMember_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LegalEntityTypeOfCounterpartyDomain" xlink:label="loc_us-gaap_LegalEntityTypeOfCounterpartyDomain_Default"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_5"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_5"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_DnaBiomedicalSolutionsLtdMember" xlink:label="loc_entx_DnaBiomedicalSolutionsLtdMember_5"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_DnaBiomedicalSolutionsLtdAndOramedLtdMember" xlink:label="loc_entx_DnaBiomedicalSolutionsLtdAndOramedLtdMember_6"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_Default"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_AgreementAxis" xlink:label="loc_entx_AgreementAxis_10"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_AgreementDomain" xlink:label="loc_entx_AgreementDomain_10"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_JointVentureAgreementMember" xlink:label="loc_entx_JointVentureAgreementMember_10"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_PatentTransferAgreementMember" xlink:label="loc_entx_PatentTransferAgreementMember_11"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_AgreementDomain" xlink:label="loc_entx_AgreementDomain_Default"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_RoyaltyGuaranteesCommitmentsPercentageSalesOfProductsDevelopedFromProjectsInFirstThreeYearsFromCommencementOfRevenues" xlink:label="loc_entx_RoyaltyGuaranteesCommitmentsPercentageSalesOfProductsDevelopedFromProjectsInFirstThreeYearsFromCommencementOfRevenues_16"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_RoyaltyGuaranteesCommitmentsPercentageSalesOfProductsDevelopedFromProjectsSubsequentThreeYears" xlink:label="loc_entx_RoyaltyGuaranteesCommitmentsPercentageSalesOfProductsDevelopedFromProjectsSubsequentThreeYears_17"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_RoyaltyGuaranteesCommitmentsPercentageSalesOfProductsDevelopedFromProjectsCommencingSeventhYear" xlink:label="loc_entx_RoyaltyGuaranteesCommitmentsPercentageSalesOfProductsDevelopedFromProjectsCommencingSeventhYear_18"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RoyaltyGuaranteesCommitmentsAmount" xlink:label="loc_us-gaap_RoyaltyGuaranteesCommitmentsAmount_19"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_RoyaltyGuaranteesCommitmentsPercentageOfEachPaymentReceivedFromAmgen" xlink:label="loc_entx_RoyaltyGuaranteesCommitmentsPercentageOfEachPaymentReceivedFromAmgen_20"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_PaymentOfRoyaltyGuaranteesCommitments" xlink:label="loc_entx_PaymentOfRoyaltyGuaranteesCommitments_21"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_SaleOfStockPercentageOfOwnershipOfEntityAcquired" xlink:label="loc_entx_SaleOfStockPercentageOfOwnershipOfEntityAcquired_22"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_SaleOfStockAmountOfInvestment" xlink:label="loc_entx_SaleOfStockAmountOfInvestment_23"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_RoyaltyGuaranteesCommitmentsPercentageOfNetRevenues" xlink:label="loc_entx_RoyaltyGuaranteesCommitmentsPercentageOfNetRevenues_24"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_entx_CommitmentsLineItems_0" xlink:to="loc_entx_CommitmentsAndContingenciesTable_1" order="0" use="optional" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_entx_CommitmentsAndContingenciesTable_1" xlink:to="loc_us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis_1" xlink:to="loc_us-gaap_LegalEntityTypeOfCounterpartyDomain_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LegalEntityTypeOfCounterpartyDomain_1" xlink:to="loc_us-gaap_GovernmentMember_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis_1" xlink:to="loc_us-gaap_LegalEntityTypeOfCounterpartyDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_entx_CommitmentsAndContingenciesTable_1" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_5" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_5" xlink:to="loc_us-gaap_RelatedPartyDomain_5" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_5" xlink:to="loc_entx_DnaBiomedicalSolutionsLtdMember_5" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_5" xlink:to="loc_entx_DnaBiomedicalSolutionsLtdAndOramedLtdMember_6" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_5" xlink:to="loc_us-gaap_RelatedPartyDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_entx_CommitmentsAndContingenciesTable_1" xlink:to="loc_entx_AgreementAxis_10" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_entx_AgreementAxis_10" xlink:to="loc_entx_AgreementDomain_10" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_entx_AgreementDomain_10" xlink:to="loc_entx_JointVentureAgreementMember_10" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_entx_AgreementDomain_10" xlink:to="loc_entx_PatentTransferAgreementMember_11" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_entx_AgreementAxis_10" xlink:to="loc_entx_AgreementDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_entx_CommitmentsLineItems_0" xlink:to="loc_entx_RoyaltyGuaranteesCommitmentsPercentageSalesOfProductsDevelopedFromProjectsInFirstThreeYearsFromCommencementOfRevenues_16" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_entx_CommitmentsLineItems_0" xlink:to="loc_entx_RoyaltyGuaranteesCommitmentsPercentageSalesOfProductsDevelopedFromProjectsSubsequentThreeYears_17" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_entx_CommitmentsLineItems_0" xlink:to="loc_entx_RoyaltyGuaranteesCommitmentsPercentageSalesOfProductsDevelopedFromProjectsCommencingSeventhYear_18" order="30" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_entx_CommitmentsLineItems_0" xlink:to="loc_us-gaap_RoyaltyGuaranteesCommitmentsAmount_19" order="40" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_entx_CommitmentsLineItems_0" xlink:to="loc_entx_RoyaltyGuaranteesCommitmentsPercentageOfEachPaymentReceivedFromAmgen_20" order="50" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_entx_CommitmentsLineItems_0" xlink:to="loc_entx_PaymentOfRoyaltyGuaranteesCommitments_21" order="60" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_entx_CommitmentsLineItems_0" xlink:to="loc_entx_SaleOfStockPercentageOfOwnershipOfEntityAcquired_22" order="70" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_entx_CommitmentsLineItems_0" xlink:to="loc_entx_SaleOfStockAmountOfInvestment_23" order="80" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_entx_CommitmentsLineItems_0" xlink:to="loc_entx_RoyaltyGuaranteesCommitmentsPercentageOfNetRevenues_24" order="90" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.enterabio.com/role/SHARECAPITALDetailTextuals">
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_StockholdersEquityNoteLineItems" xlink:label="loc_entx_StockholdersEquityNoteLineItems_0"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_StockholdersEquityNoteTable" xlink:label="loc_entx_StockholdersEquityNoteTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IPOMember" xlink:label="loc_us-gaap_IPOMember_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrivatePlacementMember" xlink:label="loc_us-gaap_PrivatePlacementMember_2"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_PlacementAgencyAgreementWithGpNumenkariIncMember" xlink:label="loc_entx_PlacementAgencyAgreementWithGpNumenkariIncMember_3"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_Default"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_7"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_7"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_7"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_Default"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_11"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_11"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaap_WarrantMember_11"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_BrokerWarrantsType1Member" xlink:label="loc_entx_BrokerWarrantsType1Member_12"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_BrokerWarrantsType2Member" xlink:label="loc_entx_BrokerWarrantsType2Member_13"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_BrokerWarrantsMember" xlink:label="loc_entx_BrokerWarrantsMember_14"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_BrokerDealerMember" xlink:label="loc_entx_BrokerDealerMember_15"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_BrokerDealerOneMember" xlink:label="loc_entx_BrokerDealerOneMember_16"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_Default"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_20"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_20"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_AccreditedInvestorsIncludingCertainBoardMembersAndTheirAffiliatesMember" xlink:label="loc_entx_AccreditedInvestorsIncludingCertainBoardMembersAndTheirAffiliatesMember_20"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_DnaBiomedicalSolutionsLtdMember" xlink:label="loc_entx_DnaBiomedicalSolutionsLtdMember_21"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_ChairmanOfBoardAndDnaMember" xlink:label="loc_entx_ChairmanOfBoardAndDnaMember_22"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_SeveralEmployeesAndServiceProvidersMember" xlink:label="loc_entx_SeveralEmployeesAndServiceProvidersMember_23"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_Default"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_27"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_27"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="loc_us-gaap_SeriesBPreferredStockMember_27"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="loc_us-gaap_SeriesAPreferredStockMember_28"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_Default"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_EquityProgramAxis" xlink:label="loc_entx_EquityProgramAxis_32"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_EquityProgramDomain" xlink:label="loc_entx_EquityProgramDomain_32"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_AtmEquityProgram2020Member" xlink:label="loc_entx_AtmEquityProgram2020Member_32"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_AtmEquityProgram2021Member" xlink:label="loc_entx_AtmEquityProgram2021Member_33"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_EquityProgramDomain" xlink:label="loc_entx_EquityProgramDomain_Default"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockVotingRights" xlink:label="loc_us-gaap_CommonStockVotingRights_38"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_ClassOfWarrantOrRightIssued" xlink:label="loc_entx_ClassOfWarrantOrRightIssued_39"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_40"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_41"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_AdjustedExercisePriceUnderAtMarketEquityProgram" xlink:label="loc_entx_AdjustedExercisePriceUnderAtMarketEquityProgram_42"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_ClassOfWarrantOrRightExerciseTerm" xlink:label="loc_entx_ClassOfWarrantOrRightExerciseTerm_43"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_ClassOfWarrantOrRightThresholdLimitOfPeriodForReductionInExercisePrice" xlink:label="loc_entx_ClassOfWarrantOrRightThresholdLimitOfPeriodForReductionInExercisePrice_44"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_ClassOfWarrantOrRightThresholdLimitOfReductionInExercisePrice" xlink:label="loc_entx_ClassOfWarrantOrRightThresholdLimitOfReductionInExercisePrice_45"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_ClassOfWarrantOrRightReducedExercisePrice" xlink:label="loc_entx_ClassOfWarrantOrRightReducedExercisePrice_46"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_ClassOfWarrantOrRightThresholdLimitOfLastReportedSalePrice" xlink:label="loc_entx_ClassOfWarrantOrRightThresholdLimitOfLastReportedSalePrice_47"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_ClassOfWarrantOrRightPercentageOfIpoPricePerUnit" xlink:label="loc_entx_ClassOfWarrantOrRightPercentageOfIpoPricePerUnit_48"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_ClassOfWarrantOrRightThresholdConsecutiveTradingDays" xlink:label="loc_entx_ClassOfWarrantOrRightThresholdConsecutiveTradingDays_49"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="loc_us-gaap_ProceedsFromWarrantExercises_50"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_NumberOfSharesIssuedUnderPrivatePlacement" xlink:label="loc_entx_NumberOfSharesIssuedUnderPrivatePlacement_51"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfPrivatePlacement_52"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaap_SharePrice_53"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_TransactionCosts" xlink:label="loc_entx_TransactionCosts_54"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_CashFeesInPercentage" xlink:label="loc_entx_CashFeesInPercentage_55"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_SharesGrantedInPercentage" xlink:label="loc_entx_SharesGrantedInPercentage_56"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_57"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalOther" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalOther_58"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_59"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_EffectOfDownRoundTriggerAmount" xlink:label="loc_entx_EffectOfDownRoundTriggerAmount_60"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_61"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_SharesIssuedWeightedAveragePricePerShare" xlink:label="loc_entx_SharesIssuedWeightedAveragePricePerShare_62"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_NetProceedsFromIssuanceOfCommonStock" xlink:label="loc_entx_NetProceedsFromIssuanceOfCommonStock_63"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesIssued" xlink:label="loc_us-gaap_SharesIssued_64"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_65"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_66"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_67"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_68"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsTotalConsideration" xlink:label="loc_entx_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsTotalConsideration_69"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_entx_StockholdersEquityNoteLineItems_0" xlink:to="loc_entx_StockholdersEquityNoteTable_1" order="0" use="optional" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_entx_StockholdersEquityNoteTable_1" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_1" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1" xlink:to="loc_us-gaap_IPOMember_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1" xlink:to="loc_us-gaap_PrivatePlacementMember_2" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1" xlink:to="loc_entx_PlacementAgencyAgreementWithGpNumenkariIncMember_3" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_1" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_entx_StockholdersEquityNoteTable_1" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_7" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_7" xlink:to="loc_us-gaap_EquityComponentDomain_7" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_7" xlink:to="loc_us-gaap_CommonStockMember_7" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_7" xlink:to="loc_us-gaap_EquityComponentDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_entx_StockholdersEquityNoteTable_1" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_11" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_11" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_11" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_11" xlink:to="loc_us-gaap_WarrantMember_11" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_11" xlink:to="loc_entx_BrokerWarrantsType1Member_12" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_11" xlink:to="loc_entx_BrokerWarrantsType2Member_13" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_11" xlink:to="loc_entx_BrokerWarrantsMember_14" order="30" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_11" xlink:to="loc_entx_BrokerDealerMember_15" order="40" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_11" xlink:to="loc_entx_BrokerDealerOneMember_16" order="50" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_11" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_entx_StockholdersEquityNoteTable_1" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_20" order="30" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_20" xlink:to="loc_us-gaap_RelatedPartyDomain_20" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_20" xlink:to="loc_entx_AccreditedInvestorsIncludingCertainBoardMembersAndTheirAffiliatesMember_20" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_20" xlink:to="loc_entx_DnaBiomedicalSolutionsLtdMember_21" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_20" xlink:to="loc_entx_ChairmanOfBoardAndDnaMember_22" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_20" xlink:to="loc_entx_SeveralEmployeesAndServiceProvidersMember_23" order="30" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_20" xlink:to="loc_us-gaap_RelatedPartyDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_entx_StockholdersEquityNoteTable_1" xlink:to="loc_us-gaap_StatementClassOfStockAxis_27" order="40" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_27" xlink:to="loc_us-gaap_ClassOfStockDomain_27" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_27" xlink:to="loc_us-gaap_SeriesBPreferredStockMember_27" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_27" xlink:to="loc_us-gaap_SeriesAPreferredStockMember_28" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_27" xlink:to="loc_us-gaap_ClassOfStockDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_entx_StockholdersEquityNoteTable_1" xlink:to="loc_entx_EquityProgramAxis_32" order="50" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_entx_EquityProgramAxis_32" xlink:to="loc_entx_EquityProgramDomain_32" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_entx_EquityProgramDomain_32" xlink:to="loc_entx_AtmEquityProgram2020Member_32" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_entx_EquityProgramDomain_32" xlink:to="loc_entx_AtmEquityProgram2021Member_33" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_entx_EquityProgramAxis_32" xlink:to="loc_entx_EquityProgramDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_entx_StockholdersEquityNoteLineItems_0" xlink:to="loc_us-gaap_CommonStockVotingRights_38" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_entx_StockholdersEquityNoteLineItems_0" xlink:to="loc_entx_ClassOfWarrantOrRightIssued_39" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_entx_StockholdersEquityNoteLineItems_0" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_40" order="30" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_entx_StockholdersEquityNoteLineItems_0" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_41" order="40" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_entx_StockholdersEquityNoteLineItems_0" xlink:to="loc_entx_AdjustedExercisePriceUnderAtMarketEquityProgram_42" order="50" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_entx_StockholdersEquityNoteLineItems_0" xlink:to="loc_entx_ClassOfWarrantOrRightExerciseTerm_43" order="60" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_entx_StockholdersEquityNoteLineItems_0" xlink:to="loc_entx_ClassOfWarrantOrRightThresholdLimitOfPeriodForReductionInExercisePrice_44" order="70" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_entx_StockholdersEquityNoteLineItems_0" xlink:to="loc_entx_ClassOfWarrantOrRightThresholdLimitOfReductionInExercisePrice_45" order="80" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_entx_StockholdersEquityNoteLineItems_0" xlink:to="loc_entx_ClassOfWarrantOrRightReducedExercisePrice_46" order="90" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_entx_StockholdersEquityNoteLineItems_0" xlink:to="loc_entx_ClassOfWarrantOrRightThresholdLimitOfLastReportedSalePrice_47" order="100" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_entx_StockholdersEquityNoteLineItems_0" xlink:to="loc_entx_ClassOfWarrantOrRightPercentageOfIpoPricePerUnit_48" order="110" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_entx_StockholdersEquityNoteLineItems_0" xlink:to="loc_entx_ClassOfWarrantOrRightThresholdConsecutiveTradingDays_49" order="120" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_entx_StockholdersEquityNoteLineItems_0" xlink:to="loc_us-gaap_ProceedsFromWarrantExercises_50" order="130" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_entx_StockholdersEquityNoteLineItems_0" xlink:to="loc_entx_NumberOfSharesIssuedUnderPrivatePlacement_51" order="140" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_entx_StockholdersEquityNoteLineItems_0" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfPrivatePlacement_52" order="150" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_entx_StockholdersEquityNoteLineItems_0" xlink:to="loc_us-gaap_SharePrice_53" order="160" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_entx_StockholdersEquityNoteLineItems_0" xlink:to="loc_entx_TransactionCosts_54" order="170" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_entx_StockholdersEquityNoteLineItems_0" xlink:to="loc_entx_CashFeesInPercentage_55" order="180" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_entx_StockholdersEquityNoteLineItems_0" xlink:to="loc_entx_SharesGrantedInPercentage_56" order="190" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_entx_StockholdersEquityNoteLineItems_0" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_57" order="200" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_entx_StockholdersEquityNoteLineItems_0" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalOther_58" order="210" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_entx_StockholdersEquityNoteLineItems_0" xlink:to="loc_us-gaap_CommonStockValue_59" order="220" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_entx_StockholdersEquityNoteLineItems_0" xlink:to="loc_entx_EffectOfDownRoundTriggerAmount_60" order="230" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_entx_StockholdersEquityNoteLineItems_0" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_61" order="240" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_entx_StockholdersEquityNoteLineItems_0" xlink:to="loc_entx_SharesIssuedWeightedAveragePricePerShare_62" order="250" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_entx_StockholdersEquityNoteLineItems_0" xlink:to="loc_entx_NetProceedsFromIssuanceOfCommonStock_63" order="260" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_entx_StockholdersEquityNoteLineItems_0" xlink:to="loc_us-gaap_SharesIssued_64" order="270" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_entx_StockholdersEquityNoteLineItems_0" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_65" order="280" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_entx_StockholdersEquityNoteLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_66" order="290" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_entx_StockholdersEquityNoteLineItems_0" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_67" order="300" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_entx_StockholdersEquityNoteLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_68" order="310" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_entx_StockholdersEquityNoteLineItems_0" xlink:to="loc_entx_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsTotalConsideration_69" order="320" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.enterabio.com/role/INCOMETAXDetails1">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwardsLineItems" xlink:label="loc_us-gaap_OperatingLossCarryforwardsLineItems_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:label="loc_us-gaap_OperatingLossCarryforwardsTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidatedEntitiesAxis" xlink:label="loc_srt_ConsolidatedEntitiesAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="loc_srt_ConsolidatedEntitiesDomain_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SubsidiariesMember" xlink:label="loc_srt_SubsidiariesMember_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="loc_srt_ConsolidatedEntitiesDomain_Default"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_5"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_5"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_EnteraBioLtdMember" xlink:label="loc_entx_EnteraBioLtdMember_5"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_Default"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_10"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_0" xlink:to="loc_us-gaap_OperatingLossCarryforwardsTable_1" order="0" use="optional" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_1" xlink:to="loc_srt_ConsolidatedEntitiesAxis_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ConsolidatedEntitiesAxis_1" xlink:to="loc_srt_ConsolidatedEntitiesDomain_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidatedEntitiesDomain_1" xlink:to="loc_srt_SubsidiariesMember_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ConsolidatedEntitiesAxis_1" xlink:to="loc_srt_ConsolidatedEntitiesDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_1" xlink:to="loc_dei_LegalEntityAxis_5" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_5" xlink:to="loc_dei_EntityDomain_5" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_5" xlink:to="loc_entx_EnteraBioLtdMember_5" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_5" xlink:to="loc_dei_EntityDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_0" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_10" order="10" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.enterabio.com/role/SHAREBASEDCOMPENSATIONDetails3">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfSalesMember" xlink:label="loc_us-gaap_CostOfSalesMember_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_3"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_Default"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_8"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_0" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_1" order="0" use="optional" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_1" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_1" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_1" xlink:to="loc_us-gaap_CostOfSalesMember_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_1" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_2" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_1" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_3" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_1" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_0" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_8" order="10" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.enterabio.com/role/INCOMETAXDetails3">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwardsLineItems" xlink:label="loc_us-gaap_OperatingLossCarryforwardsLineItems_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:label="loc_us-gaap_OperatingLossCarryforwardsTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidatedEntitiesAxis" xlink:label="loc_srt_ConsolidatedEntitiesAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="loc_srt_ConsolidatedEntitiesDomain_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SubsidiariesMember" xlink:label="loc_srt_SubsidiariesMember_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="loc_srt_ConsolidatedEntitiesDomain_Default"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:label="loc_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract_6"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_6"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:label="loc_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract_8"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit_8"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_9"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_11"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_0" xlink:to="loc_us-gaap_OperatingLossCarryforwardsTable_1" order="0" use="optional" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_1" xlink:to="loc_srt_ConsolidatedEntitiesAxis_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ConsolidatedEntitiesAxis_1" xlink:to="loc_srt_ConsolidatedEntitiesDomain_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidatedEntitiesDomain_1" xlink:to="loc_srt_SubsidiariesMember_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ConsolidatedEntitiesAxis_1" xlink:to="loc_srt_ConsolidatedEntitiesDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_0" xlink:to="loc_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract_6" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract_6" xlink:to="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_6" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_0" xlink:to="loc_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract_8" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract_8" xlink:to="loc_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit_8" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract_8" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_9" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_0" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_11" order="30" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.enterabio.com/role/INCOMETAXDetailTextuals">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwardsLineItems" xlink:label="loc_us-gaap_OperatingLossCarryforwardsLineItems_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:label="loc_us-gaap_OperatingLossCarryforwardsTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DomesticCountryMember" xlink:label="loc_us-gaap_DomesticCountryMember_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCountryMember" xlink:label="loc_us-gaap_ForeignCountryMember_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_Default"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_7"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="loc_us-gaap_OperatingLossCarryforwards_8"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_0" xlink:to="loc_us-gaap_OperatingLossCarryforwardsTable_1" order="0" use="optional" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_1" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_1" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_1" xlink:to="loc_us-gaap_DomesticCountryMember_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_1" xlink:to="loc_us-gaap_ForeignCountryMember_2" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_1" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_0" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_7" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_0" xlink:to="loc_us-gaap_OperatingLossCarryforwards_8" order="20" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.enterabio.com/role/SHAREBASEDCOMPENSATIONDetails2">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_1"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_ExercisePricePerShareZeroMember" xlink:label="loc_entx_ExercisePricePerShareZeroMember_1"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_ExercisePricePerShareOnePointTwoFourMember" xlink:label="loc_entx_ExercisePricePerShareOnePointTwoFourMember_2"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_ExercisePricePerShareOnePointFourMember" xlink:label="loc_entx_ExercisePricePerShareOnePointFourMember_3"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_ExercisePricePerShareTwoPointZeroTwoMember" xlink:label="loc_entx_ExercisePricePerShareTwoPointZeroTwoMember_4"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_ExercisePricePerShareTwoPointOneFourMember" xlink:label="loc_entx_ExercisePricePerShareTwoPointOneFourMember_5"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_ExercisePricePerShareTwoPointFiveThreeMember" xlink:label="loc_entx_ExercisePricePerShareTwoPointFiveThreeMember_6"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_ExercisePricePerShareTwoPointFiveSevenMember" xlink:label="loc_entx_ExercisePricePerShareTwoPointFiveSevenMember_7"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_ExercisePricePerShareTwoPointEightOneFiveMember" xlink:label="loc_entx_ExercisePricePerShareTwoPointEightOneFiveMember_8"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_ExercisePricePerShareTwoPointEightSixMember" xlink:label="loc_entx_ExercisePricePerShareTwoPointEightSixMember_9"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_ExercisePricePerShareThreePointOneFiveMember" xlink:label="loc_entx_ExercisePricePerShareThreePointOneFiveMember_10"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_ExercisePricePerShareOnePointZeroSixMember" xlink:label="loc_entx_ExercisePricePerShareOnePointZeroSixMember_11"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_ExercisePricePerShareThreePointSixOneMember" xlink:label="loc_entx_ExercisePricePerShareThreePointSixOneMember_12"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_ExercisePricePerShareThreePointSixEightMember" xlink:label="loc_entx_ExercisePricePerShareThreePointSixEightMember_13"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_ExercisePricePerShareThreePointNineSevenMember" xlink:label="loc_entx_ExercisePricePerShareThreePointNineSevenMember_14"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_ExercisePricePerShareSixPointThreeOneMember" xlink:label="loc_entx_ExercisePricePerShareSixPointThreeOneMember_15"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_Default"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_20"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_21"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_22"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_23"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_24"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" order="0" use="optional" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_1" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_1" xlink:to="loc_entx_ExercisePricePerShareZeroMember_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_1" xlink:to="loc_entx_ExercisePricePerShareOnePointTwoFourMember_2" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_1" xlink:to="loc_entx_ExercisePricePerShareOnePointFourMember_3" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_1" xlink:to="loc_entx_ExercisePricePerShareTwoPointZeroTwoMember_4" order="30" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_1" xlink:to="loc_entx_ExercisePricePerShareTwoPointOneFourMember_5" order="40" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_1" xlink:to="loc_entx_ExercisePricePerShareTwoPointFiveThreeMember_6" order="50" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_1" xlink:to="loc_entx_ExercisePricePerShareTwoPointFiveSevenMember_7" order="60" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_1" xlink:to="loc_entx_ExercisePricePerShareTwoPointEightOneFiveMember_8" order="70" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_1" xlink:to="loc_entx_ExercisePricePerShareTwoPointEightSixMember_9" order="80" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_1" xlink:to="loc_entx_ExercisePricePerShareThreePointOneFiveMember_10" order="90" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_1" xlink:to="loc_entx_ExercisePricePerShareOnePointZeroSixMember_11" order="100" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_1" xlink:to="loc_entx_ExercisePricePerShareThreePointSixOneMember_12" order="110" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_1" xlink:to="loc_entx_ExercisePricePerShareThreePointSixEightMember_13" order="120" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_1" xlink:to="loc_entx_ExercisePricePerShareThreePointNineSevenMember_14" order="130" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_1" xlink:to="loc_entx_ExercisePricePerShareSixPointThreeOneMember_15" order="140" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_1" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_20" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_21" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_22" order="30" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_23" order="40" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_24" order="50" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.enterabio.com/role/SIGNIFICANTACCOUNTINGPOLICIESDetails">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComputerEquipmentMember" xlink:label="loc_us-gaap_ComputerEquipmentMember_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OfficeEquipmentMember" xlink:label="loc_us-gaap_OfficeEquipmentMember_2"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_LaboratoryEquipmentMember" xlink:label="loc_entx_LaboratoryEquipmentMember_3"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_Default"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_7"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_7"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_7"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_8"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_Default"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_13"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_0" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_1" order="0" use="optional" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_1" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_1" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1" xlink:to="loc_us-gaap_ComputerEquipmentMember_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1" xlink:to="loc_us-gaap_OfficeEquipmentMember_2" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1" xlink:to="loc_entx_LaboratoryEquipmentMember_3" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_1" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_1" xlink:to="loc_srt_RangeAxis_7" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_7" xlink:to="loc_srt_RangeMember_7" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_7" xlink:to="loc_srt_MinimumMember_7" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_7" xlink:to="loc_srt_MaximumMember_8" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_7" xlink:to="loc_srt_RangeMember_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_0" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_13" order="10" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.enterabio.com/role/SUBSEQUENTEVENTSNarrative">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventLineItems" xlink:label="loc_us-gaap_SubsequentEventLineItems_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTable" xlink:label="loc_us-gaap_SubsequentEventTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_Default"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srt_TitleOfIndividualAxis_5"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_5"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_NonExecutiveBoardMember" xlink:label="loc_entx_NonExecutiveBoardMember_5"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_Default"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_10"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_11"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_12"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_NumberOfNonExecutiveBoardMembers" xlink:label="loc_entx_NumberOfNonExecutiveBoardMembers_13"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SubsequentEventLineItems_0" xlink:to="loc_us-gaap_SubsequentEventTable_1" order="0" use="optional" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_1" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_1" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_1" xlink:to="loc_us-gaap_SubsequentEventMember_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_1" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_1" xlink:to="loc_srt_TitleOfIndividualAxis_5" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_TitleOfIndividualAxis_5" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_5" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_5" xlink:to="loc_entx_NonExecutiveBoardMember_5" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_TitleOfIndividualAxis_5" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_10" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_0" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_11" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_12" order="30" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_0" xlink:to="loc_entx_NumberOfNonExecutiveBoardMembers_13" order="40" use="optional"/>
  </definitionLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>13
<FILENAME>entx-20221231_lab.xml
<DESCRIPTION>XBRL LABEL FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <!-- INTEGIX by Ez-XBRL -->
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel"/>
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel"/>
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel"/>
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel"/>
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel"/>
  <labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentDescription" xlink:label="loc_dei_AmendmentDescription_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag" xlink:label="loc_dei_AmendmentFlag_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorFirmId" xlink:label="loc_dei_AuditorFirmId_3"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorLocation" xlink:label="loc_dei_AuditorLocation_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorName" xlink:label="loc_dei_AuditorName_5"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode" xlink:label="loc_dei_CityAreaCode_6"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract" xlink:label="loc_dei_CoverAbstract_7"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract" xlink:label="loc_dei_CoverAbstract_8"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_dei_CurrentFiscalYearEndDate_9"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAnnualReport" xlink:label="loc_dei_DocumentAnnualReport_10"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_dei_DocumentFiscalPeriodFocus_11"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_dei_DocumentFiscalYearFocus_12"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_dei_DocumentPeriodEndDate_13"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_dei_DocumentQuarterlyReport_14"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport" xlink:label="loc_dei_DocumentTransitionReport_15"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType" xlink:label="loc_dei_DocumentType_16"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_dei_EntityAddressAddressLine1_17"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_dei_EntityAddressAddressLine2_18"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine3" xlink:label="loc_dei_EntityAddressAddressLine3_19"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_dei_EntityAddressCityOrTown_20"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCountry" xlink:label="loc_dei_EntityAddressCountry_21"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_dei_EntityAddressPostalZipCode_22"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_dei_EntityAddressStateOrProvince_23"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey" xlink:label="loc_dei_EntityCentralIndexKey_24"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_25"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_dei_EntityCurrentReportingStatus_26"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_27"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_dei_EntityEmergingGrowthCompany_28"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_dei_EntityExTransitionPeriod_29"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber" xlink:label="loc_dei_EntityFileNumber_30"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory" xlink:label="loc_dei_EntityFilerCategory_31"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_dei_EntityIncorporationStateCountryCode_32"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_dei_EntityInteractiveDataCurrent_33"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityPublicFloat" xlink:label="loc_dei_EntityPublicFloat_34"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName" xlink:label="loc_dei_EntityRegistrantName_35"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany" xlink:label="loc_dei_EntityShellCompany_36"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness" xlink:label="loc_dei_EntitySmallBusiness_37"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_dei_EntityTaxIdentificationNumber_38"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_dei_EntityVoluntaryFilers_39"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer_40"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_41"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber" xlink:label="loc_dei_LocalPhoneNumber_42"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle" xlink:label="loc_dei_Security12bTitle_43"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName" xlink:label="loc_dei_SecurityExchangeName_44"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol" xlink:label="loc_dei_TradingSymbol_45"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_AccreditedInvestorsIncludingCertainBoardMembersAndTheirAffiliatesMember" xlink:label="loc_entx_AccreditedInvestorsIncludingCertainBoardMembersAndTheirAffiliatesMember_46"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_AccreditedInvestorsIncludingCertainBoardMembersAndTheirAffiliatesMember" xlink:label="loc_entx_AccreditedInvestorsIncludingCertainBoardMembersAndTheirAffiliatesMember_47"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_AccreditedInvestorsIncludingCertainBoardMembersAndTheirAffiliatesMember" xlink:label="loc_entx_AccreditedInvestorsIncludingCertainBoardMembersAndTheirAffiliatesMember_48"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_AdditionalAmountPaidForServicesToBeRecognized" xlink:label="loc_entx_AdditionalAmountPaidForServicesToBeRecognized_49"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_AdditionalAmountPaidForServicesToBeRecognized" xlink:label="loc_entx_AdditionalAmountPaidForServicesToBeRecognized_50"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_AdditionalAmountPaidForServicesToBeRecognized" xlink:label="loc_entx_AdditionalAmountPaidForServicesToBeRecognized_51"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_AdditionalCashSeparationPayment" xlink:label="loc_entx_AdditionalCashSeparationPayment_52"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_AdditionalCashSeparationPayment" xlink:label="loc_entx_AdditionalCashSeparationPayment_53"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_AdditionalCashSeparationPayment" xlink:label="loc_entx_AdditionalCashSeparationPayment_54"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_AdjustedExercisePriceUnderAtMarketEquityProgram" xlink:label="loc_entx_AdjustedExercisePriceUnderAtMarketEquityProgram_55"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_AdjustedExercisePriceUnderAtMarketEquityProgram" xlink:label="loc_entx_AdjustedExercisePriceUnderAtMarketEquityProgram_56"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_AdjustedExercisePriceUnderAtMarketEquityProgram" xlink:label="loc_entx_AdjustedExercisePriceUnderAtMarketEquityProgram_57"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_AgreementAxis" xlink:label="loc_entx_AgreementAxis_58"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_AgreementAxis" xlink:label="loc_entx_AgreementAxis_59"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_AgreementDomain" xlink:label="loc_entx_AgreementDomain_60"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_AgreementDomain" xlink:label="loc_entx_AgreementDomain_61"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_AmendmentToBusinessDevelopmentServicesAgreementMember" xlink:label="loc_entx_AmendmentToBusinessDevelopmentServicesAgreementMember_62"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_AmendmentToBusinessDevelopmentServicesAgreementMember" xlink:label="loc_entx_AmendmentToBusinessDevelopmentServicesAgreementMember_63"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_AmendmentToBusinessDevelopmentServicesAgreementMember" xlink:label="loc_entx_AmendmentToBusinessDevelopmentServicesAgreementMember_64"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_AmgenIncMember" xlink:label="loc_entx_AmgenIncMember_65"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_AmgenIncMember" xlink:label="loc_entx_AmgenIncMember_66"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_AmgenIncMember" xlink:label="loc_entx_AmgenIncMember_67"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_AmgenIncMember" xlink:label="loc_entx_AmgenIncMember_68"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_AtmEquityProgram2020Member" xlink:label="loc_entx_AtmEquityProgram2020Member_69"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_AtmEquityProgram2020Member" xlink:label="loc_entx_AtmEquityProgram2020Member_70"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_AtmEquityProgram2020Member" xlink:label="loc_entx_AtmEquityProgram2020Member_71"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_AtmEquityProgram2021Member" xlink:label="loc_entx_AtmEquityProgram2021Member_72"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_AtmEquityProgram2021Member" xlink:label="loc_entx_AtmEquityProgram2021Member_73"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_AtmEquityProgram2021Member" xlink:label="loc_entx_AtmEquityProgram2021Member_74"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_BankGuarantees" xlink:label="loc_entx_BankGuarantees_75"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_BankGuarantees" xlink:label="loc_entx_BankGuarantees_76"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_BankGuarantees" xlink:label="loc_entx_BankGuarantees_77"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_BoardMembersMember" xlink:label="loc_entx_BoardMembersMember_78"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_BoardMembersMember" xlink:label="loc_entx_BoardMembersMember_79"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_BrokerDealerMember" xlink:label="loc_entx_BrokerDealerMember_80"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_BrokerDealerMember" xlink:label="loc_entx_BrokerDealerMember_81"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_BrokerDealerOneMember" xlink:label="loc_entx_BrokerDealerOneMember_82"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_BrokerDealerOneMember" xlink:label="loc_entx_BrokerDealerOneMember_83"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_BrokerDealerOneMember" xlink:label="loc_entx_BrokerDealerOneMember_84"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_BrokerWarrantsMember" xlink:label="loc_entx_BrokerWarrantsMember_85"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_BrokerWarrantsMember" xlink:label="loc_entx_BrokerWarrantsMember_86"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_BrokerWarrantsMember" xlink:label="loc_entx_BrokerWarrantsMember_87"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_BrokerWarrantsType1Member" xlink:label="loc_entx_BrokerWarrantsType1Member_88"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_BrokerWarrantsType1Member" xlink:label="loc_entx_BrokerWarrantsType1Member_89"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_BrokerWarrantsType1Member" xlink:label="loc_entx_BrokerWarrantsType1Member_90"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_BrokerWarrantsType2Member" xlink:label="loc_entx_BrokerWarrantsType2Member_91"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_BrokerWarrantsType2Member" xlink:label="loc_entx_BrokerWarrantsType2Member_92"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_BrokerWarrantsType2Member" xlink:label="loc_entx_BrokerWarrantsType2Member_93"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_CashFeesInPercentage" xlink:label="loc_entx_CashFeesInPercentage_94"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_CashFeesInPercentage" xlink:label="loc_entx_CashFeesInPercentage_95"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_CashFeesInPercentage" xlink:label="loc_entx_CashFeesInPercentage_96"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_CashlessExerciseOfWarrants" xlink:label="loc_entx_CashlessExerciseOfWarrants_97"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_CashlessExerciseOfWarrants" xlink:label="loc_entx_CashlessExerciseOfWarrants_98"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_CashlessExerciseOfWarrants" xlink:label="loc_entx_CashlessExerciseOfWarrants_99"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_CashSeparationPayment" xlink:label="loc_entx_CashSeparationPayment_100"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_CashSeparationPayment" xlink:label="loc_entx_CashSeparationPayment_101"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_CashSeparationPayment" xlink:label="loc_entx_CashSeparationPayment_102"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_ChairmanOfBoardAndDnaMember" xlink:label="loc_entx_ChairmanOfBoardAndDnaMember_103"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_ChairmanOfBoardAndDnaMember" xlink:label="loc_entx_ChairmanOfBoardAndDnaMember_104"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_ChairmanOfBoardAndDnaMember" xlink:label="loc_entx_ChairmanOfBoardAndDnaMember_105"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_ClassOfWarrantOrRightExerciseTerm" xlink:label="loc_entx_ClassOfWarrantOrRightExerciseTerm_106"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_ClassOfWarrantOrRightExerciseTerm" xlink:label="loc_entx_ClassOfWarrantOrRightExerciseTerm_107"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_ClassOfWarrantOrRightExerciseTerm" xlink:label="loc_entx_ClassOfWarrantOrRightExerciseTerm_108"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_ClassOfWarrantOrRightIssued" xlink:label="loc_entx_ClassOfWarrantOrRightIssued_109"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_ClassOfWarrantOrRightIssued" xlink:label="loc_entx_ClassOfWarrantOrRightIssued_110"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_ClassOfWarrantOrRightIssued" xlink:label="loc_entx_ClassOfWarrantOrRightIssued_111"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_ClassOfWarrantOrRightPercentageOfIpoPricePerUnit" xlink:label="loc_entx_ClassOfWarrantOrRightPercentageOfIpoPricePerUnit_112"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_ClassOfWarrantOrRightPercentageOfIpoPricePerUnit" xlink:label="loc_entx_ClassOfWarrantOrRightPercentageOfIpoPricePerUnit_113"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_ClassOfWarrantOrRightPercentageOfIpoPricePerUnit" xlink:label="loc_entx_ClassOfWarrantOrRightPercentageOfIpoPricePerUnit_114"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_ClassOfWarrantOrRightReducedExercisePrice" xlink:label="loc_entx_ClassOfWarrantOrRightReducedExercisePrice_115"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_ClassOfWarrantOrRightReducedExercisePrice" xlink:label="loc_entx_ClassOfWarrantOrRightReducedExercisePrice_116"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_ClassOfWarrantOrRightReducedExercisePrice" xlink:label="loc_entx_ClassOfWarrantOrRightReducedExercisePrice_117"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_ClassOfWarrantOrRightThresholdConsecutiveTradingDays" xlink:label="loc_entx_ClassOfWarrantOrRightThresholdConsecutiveTradingDays_118"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_ClassOfWarrantOrRightThresholdConsecutiveTradingDays" xlink:label="loc_entx_ClassOfWarrantOrRightThresholdConsecutiveTradingDays_119"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_ClassOfWarrantOrRightThresholdConsecutiveTradingDays" xlink:label="loc_entx_ClassOfWarrantOrRightThresholdConsecutiveTradingDays_120"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_ClassOfWarrantOrRightThresholdLimitOfLastReportedSalePrice" xlink:label="loc_entx_ClassOfWarrantOrRightThresholdLimitOfLastReportedSalePrice_121"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_ClassOfWarrantOrRightThresholdLimitOfLastReportedSalePrice" xlink:label="loc_entx_ClassOfWarrantOrRightThresholdLimitOfLastReportedSalePrice_122"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_ClassOfWarrantOrRightThresholdLimitOfLastReportedSalePrice" xlink:label="loc_entx_ClassOfWarrantOrRightThresholdLimitOfLastReportedSalePrice_123"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_ClassOfWarrantOrRightThresholdLimitOfPeriodForReductionInExercisePrice" xlink:label="loc_entx_ClassOfWarrantOrRightThresholdLimitOfPeriodForReductionInExercisePrice_124"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_ClassOfWarrantOrRightThresholdLimitOfPeriodForReductionInExercisePrice" xlink:label="loc_entx_ClassOfWarrantOrRightThresholdLimitOfPeriodForReductionInExercisePrice_125"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_ClassOfWarrantOrRightThresholdLimitOfPeriodForReductionInExercisePrice" xlink:label="loc_entx_ClassOfWarrantOrRightThresholdLimitOfPeriodForReductionInExercisePrice_126"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_ClassOfWarrantOrRightThresholdLimitOfReductionInExercisePrice" xlink:label="loc_entx_ClassOfWarrantOrRightThresholdLimitOfReductionInExercisePrice_127"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_ClassOfWarrantOrRightThresholdLimitOfReductionInExercisePrice" xlink:label="loc_entx_ClassOfWarrantOrRightThresholdLimitOfReductionInExercisePrice_128"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_ClassOfWarrantOrRightThresholdLimitOfReductionInExercisePrice" xlink:label="loc_entx_ClassOfWarrantOrRightThresholdLimitOfReductionInExercisePrice_129"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_CommitmentsAndContingenciesTable" xlink:label="loc_entx_CommitmentsAndContingenciesTable_130"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_CommitmentsAndContingenciesTable" xlink:label="loc_entx_CommitmentsAndContingenciesTable_131"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_CommitmentsLineItems" xlink:label="loc_entx_CommitmentsLineItems_132"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_CommitmentsLineItems" xlink:label="loc_entx_CommitmentsLineItems_133"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_ConsultantMember" xlink:label="loc_entx_ConsultantMember_134"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_ConsultantMember" xlink:label="loc_entx_ConsultantMember_135"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_ConsultantMember" xlink:label="loc_entx_ConsultantMember_136"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_DecreaseIncreaseInTaxRefundAbstract" xlink:label="loc_entx_DecreaseIncreaseInTaxRefundAbstract_137"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_DecreaseIncreaseInTaxRefundAbstract" xlink:label="loc_entx_DecreaseIncreaseInTaxRefundAbstract_138"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_DecreaseIncreaseInTaxRefundAbstract" xlink:label="loc_entx_DecreaseIncreaseInTaxRefundAbstract_139"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_DnaBiomedicalSolutionsLtdAndOramedLtdMember" xlink:label="loc_entx_DnaBiomedicalSolutionsLtdAndOramedLtdMember_140"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_DnaBiomedicalSolutionsLtdAndOramedLtdMember" xlink:label="loc_entx_DnaBiomedicalSolutionsLtdAndOramedLtdMember_141"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_DnaBiomedicalSolutionsLtdAndOramedLtdMember" xlink:label="loc_entx_DnaBiomedicalSolutionsLtdAndOramedLtdMember_142"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_DnaBiomedicalSolutionsLtdMember" xlink:label="loc_entx_DnaBiomedicalSolutionsLtdMember_143"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_DnaBiomedicalSolutionsLtdMember" xlink:label="loc_entx_DnaBiomedicalSolutionsLtdMember_144"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_DnaBiomedicalSolutionsLtdMember" xlink:label="loc_entx_DnaBiomedicalSolutionsLtdMember_145"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_EffectOfDownRoundTriggerAmount" xlink:label="loc_entx_EffectOfDownRoundTriggerAmount_146"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_EffectOfDownRoundTriggerAmount" xlink:label="loc_entx_EffectOfDownRoundTriggerAmount_147"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_EffectOfDownRoundTriggerAmount" xlink:label="loc_entx_EffectOfDownRoundTriggerAmount_148"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_EmployeeMember" xlink:label="loc_entx_EmployeeMember_149"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_EmployeeMember" xlink:label="loc_entx_EmployeeMember_150"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_EmployeeMember" xlink:label="loc_entx_EmployeeMember_151"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_EmployeeSeveranceBenefitsPolicyPolicyTextBlock" xlink:label="loc_entx_EmployeeSeveranceBenefitsPolicyPolicyTextBlock_152"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_EmployeeSeveranceBenefitsPolicyPolicyTextBlock" xlink:label="loc_entx_EmployeeSeveranceBenefitsPolicyPolicyTextBlock_153"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_EmployeeSeveranceBenefitsPolicyPolicyTextBlock" xlink:label="loc_entx_EmployeeSeveranceBenefitsPolicyPolicyTextBlock_154"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_EmployeesMember" xlink:label="loc_entx_EmployeesMember_155"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_EmployeesMember" xlink:label="loc_entx_EmployeesMember_156"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_EmployeesMember" xlink:label="loc_entx_EmployeesMember_157"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_EnteraBioLtdMember" xlink:label="loc_entx_EnteraBioLtdMember_158"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_EnteraBioLtdMember" xlink:label="loc_entx_EnteraBioLtdMember_159"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_EnteraBioLtdMember" xlink:label="loc_entx_EnteraBioLtdMember_160"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_EquityProgramAxis" xlink:label="loc_entx_EquityProgramAxis_161"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_EquityProgramAxis" xlink:label="loc_entx_EquityProgramAxis_162"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_EquityProgramDomain" xlink:label="loc_entx_EquityProgramDomain_163"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_EquityProgramDomain" xlink:label="loc_entx_EquityProgramDomain_164"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_ExecutiveOfficerAndServiceProviderMember" xlink:label="loc_entx_ExecutiveOfficerAndServiceProviderMember_165"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_ExecutiveOfficerAndServiceProviderMember" xlink:label="loc_entx_ExecutiveOfficerAndServiceProviderMember_166"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_ExecutiveOfficerAndServiceProviderMember" xlink:label="loc_entx_ExecutiveOfficerAndServiceProviderMember_167"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_ExerciseOfWarrantsShares" xlink:label="loc_entx_ExerciseOfWarrantsShares_168"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_ExerciseOfWarrantsShares" xlink:label="loc_entx_ExerciseOfWarrantsShares_169"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_ExerciseOfWarrantsShares" xlink:label="loc_entx_ExerciseOfWarrantsShares_170"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_ExerciseOfWarrantsValue" xlink:label="loc_entx_ExerciseOfWarrantsValue_171"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_ExerciseOfWarrantsValue" xlink:label="loc_entx_ExerciseOfWarrantsValue_172"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_ExerciseOfWarrantsValue" xlink:label="loc_entx_ExerciseOfWarrantsValue_173"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_ExercisePricePerShareOnePointFourMember" xlink:label="loc_entx_ExercisePricePerShareOnePointFourMember_174"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_ExercisePricePerShareOnePointFourMember" xlink:label="loc_entx_ExercisePricePerShareOnePointFourMember_175"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_ExercisePricePerShareOnePointFourMember" xlink:label="loc_entx_ExercisePricePerShareOnePointFourMember_176"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_ExercisePricePerShareOnePointTwoFourMember" xlink:label="loc_entx_ExercisePricePerShareOnePointTwoFourMember_177"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_ExercisePricePerShareOnePointTwoFourMember" xlink:label="loc_entx_ExercisePricePerShareOnePointTwoFourMember_178"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_ExercisePricePerShareOnePointTwoFourMember" xlink:label="loc_entx_ExercisePricePerShareOnePointTwoFourMember_179"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_ExercisePricePerShareOnePointZeroSixMember" xlink:label="loc_entx_ExercisePricePerShareOnePointZeroSixMember_180"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_ExercisePricePerShareOnePointZeroSixMember" xlink:label="loc_entx_ExercisePricePerShareOnePointZeroSixMember_181"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_ExercisePricePerShareOnePointZeroSixMember" xlink:label="loc_entx_ExercisePricePerShareOnePointZeroSixMember_182"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_ExercisePricePerShareSevenPointFiveFourMember" xlink:label="loc_entx_ExercisePricePerShareSevenPointFiveFourMember_183"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_ExercisePricePerShareSevenPointFiveFourMember" xlink:label="loc_entx_ExercisePricePerShareSevenPointFiveFourMember_184"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_ExercisePricePerShareSevenPointFiveFourMember" xlink:label="loc_entx_ExercisePricePerShareSevenPointFiveFourMember_185"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_ExercisePricePerShareSixPointThreeOneMember" xlink:label="loc_entx_ExercisePricePerShareSixPointThreeOneMember_186"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_ExercisePricePerShareSixPointThreeOneMember" xlink:label="loc_entx_ExercisePricePerShareSixPointThreeOneMember_187"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_ExercisePricePerShareSixPointThreeOneMember" xlink:label="loc_entx_ExercisePricePerShareSixPointThreeOneMember_188"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_ExercisePricePerShareThreePointNineSevenMember" xlink:label="loc_entx_ExercisePricePerShareThreePointNineSevenMember_189"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_ExercisePricePerShareThreePointNineSevenMember" xlink:label="loc_entx_ExercisePricePerShareThreePointNineSevenMember_190"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_ExercisePricePerShareThreePointNineSevenMember" xlink:label="loc_entx_ExercisePricePerShareThreePointNineSevenMember_191"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_ExercisePricePerShareThreePointOneFiveMember" xlink:label="loc_entx_ExercisePricePerShareThreePointOneFiveMember_192"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_ExercisePricePerShareThreePointOneFiveMember" xlink:label="loc_entx_ExercisePricePerShareThreePointOneFiveMember_193"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_ExercisePricePerShareThreePointOneFiveMember" xlink:label="loc_entx_ExercisePricePerShareThreePointOneFiveMember_194"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_ExercisePricePerShareThreePointSixEightMember" xlink:label="loc_entx_ExercisePricePerShareThreePointSixEightMember_195"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_ExercisePricePerShareThreePointSixEightMember" xlink:label="loc_entx_ExercisePricePerShareThreePointSixEightMember_196"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_ExercisePricePerShareThreePointSixEightMember" xlink:label="loc_entx_ExercisePricePerShareThreePointSixEightMember_197"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_ExercisePricePerShareThreePointSixOneMember" xlink:label="loc_entx_ExercisePricePerShareThreePointSixOneMember_198"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_ExercisePricePerShareThreePointSixOneMember" xlink:label="loc_entx_ExercisePricePerShareThreePointSixOneMember_199"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_ExercisePricePerShareThreePointSixOneMember" xlink:label="loc_entx_ExercisePricePerShareThreePointSixOneMember_200"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_ExercisePricePerShareTwoPointEightOneFiveMember" xlink:label="loc_entx_ExercisePricePerShareTwoPointEightOneFiveMember_201"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_ExercisePricePerShareTwoPointEightOneFiveMember" xlink:label="loc_entx_ExercisePricePerShareTwoPointEightOneFiveMember_202"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_ExercisePricePerShareTwoPointEightOneFiveMember" xlink:label="loc_entx_ExercisePricePerShareTwoPointEightOneFiveMember_203"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_ExercisePricePerShareTwoPointEightSixMember" xlink:label="loc_entx_ExercisePricePerShareTwoPointEightSixMember_204"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_ExercisePricePerShareTwoPointEightSixMember" xlink:label="loc_entx_ExercisePricePerShareTwoPointEightSixMember_205"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_ExercisePricePerShareTwoPointEightSixMember" xlink:label="loc_entx_ExercisePricePerShareTwoPointEightSixMember_206"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_ExercisePricePerShareTwoPointFiveSevenMember" xlink:label="loc_entx_ExercisePricePerShareTwoPointFiveSevenMember_207"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_ExercisePricePerShareTwoPointFiveSevenMember" xlink:label="loc_entx_ExercisePricePerShareTwoPointFiveSevenMember_208"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_ExercisePricePerShareTwoPointFiveSevenMember" xlink:label="loc_entx_ExercisePricePerShareTwoPointFiveSevenMember_209"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_ExercisePricePerShareTwoPointFiveThreeMember" xlink:label="loc_entx_ExercisePricePerShareTwoPointFiveThreeMember_210"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_ExercisePricePerShareTwoPointFiveThreeMember" xlink:label="loc_entx_ExercisePricePerShareTwoPointFiveThreeMember_211"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_ExercisePricePerShareTwoPointFiveThreeMember" xlink:label="loc_entx_ExercisePricePerShareTwoPointFiveThreeMember_212"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_ExercisePricePerShareTwoPointOneFourMember" xlink:label="loc_entx_ExercisePricePerShareTwoPointOneFourMember_213"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_ExercisePricePerShareTwoPointOneFourMember" xlink:label="loc_entx_ExercisePricePerShareTwoPointOneFourMember_214"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_ExercisePricePerShareTwoPointOneFourMember" xlink:label="loc_entx_ExercisePricePerShareTwoPointOneFourMember_215"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_ExercisePricePerShareTwoPointZeroTwoMember" xlink:label="loc_entx_ExercisePricePerShareTwoPointZeroTwoMember_216"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_ExercisePricePerShareTwoPointZeroTwoMember" xlink:label="loc_entx_ExercisePricePerShareTwoPointZeroTwoMember_217"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_ExercisePricePerShareTwoPointZeroTwoMember" xlink:label="loc_entx_ExercisePricePerShareTwoPointZeroTwoMember_218"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_ExercisePricePerShareZeroMember" xlink:label="loc_entx_ExercisePricePerShareZeroMember_219"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_ExercisePricePerShareZeroMember" xlink:label="loc_entx_ExercisePricePerShareZeroMember_220"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_ExercisePricePerShareZeroMember" xlink:label="loc_entx_ExercisePricePerShareZeroMember_221"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_FinanceExpensesNet" xlink:label="loc_entx_FinanceExpensesNet_222"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_FinanceExpensesNet" xlink:label="loc_entx_FinanceExpensesNet_223"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_FinanceExpensesNet" xlink:label="loc_entx_FinanceExpensesNet_224"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_FormerChiefExecutiveOfficerMember" xlink:label="loc_entx_FormerChiefExecutiveOfficerMember_225"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_FormerChiefExecutiveOfficerMember" xlink:label="loc_entx_FormerChiefExecutiveOfficerMember_226"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_FormerChiefExecutiveOfficerMember" xlink:label="loc_entx_FormerChiefExecutiveOfficerMember_227"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_FundsInRespectOfEmployeeRightsUponRetirement" xlink:label="loc_entx_FundsInRespectOfEmployeeRightsUponRetirement_228"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_FundsInRespectOfEmployeeRightsUponRetirement" xlink:label="loc_entx_FundsInRespectOfEmployeeRightsUponRetirement_229"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_FundsInRespectOfEmployeeRightsUponRetirement" xlink:label="loc_entx_FundsInRespectOfEmployeeRightsUponRetirement_230"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_FundsInRespectOfEmployeeRightsUponRetirement" xlink:label="loc_entx_FundsInRespectOfEmployeeRightsUponRetirement_231"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_GeneralLineItems" xlink:label="loc_entx_GeneralLineItems_232"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_GeneralLineItems" xlink:label="loc_entx_GeneralLineItems_233"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_GeneralTable" xlink:label="loc_entx_GeneralTable_234"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_GeneralTable" xlink:label="loc_entx_GeneralTable_235"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_InvestorRelationsServicesAgreementMember" xlink:label="loc_entx_InvestorRelationsServicesAgreementMember_236"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_InvestorRelationsServicesAgreementMember" xlink:label="loc_entx_InvestorRelationsServicesAgreementMember_237"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_InvestorRelationsServicesAgreementMember" xlink:label="loc_entx_InvestorRelationsServicesAgreementMember_238"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_IssuanceOfOrdinarySharesAndWarrantsDueToPrivatePlacementNetOfIssuanceCosts" xlink:label="loc_entx_IssuanceOfOrdinarySharesAndWarrantsDueToPrivatePlacementNetOfIssuanceCosts_239"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_IssuanceOfOrdinarySharesAndWarrantsDueToPrivatePlacementNetOfIssuanceCosts" xlink:label="loc_entx_IssuanceOfOrdinarySharesAndWarrantsDueToPrivatePlacementNetOfIssuanceCosts_240"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_IssuanceOfOrdinarySharesAndWarrantsDueToPrivatePlacementNetOfIssuanceCosts" xlink:label="loc_entx_IssuanceOfOrdinarySharesAndWarrantsDueToPrivatePlacementNetOfIssuanceCosts_241"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_IssuanceOfOrdinarySharesAndWarrantsDueToPrivatePlacementNetOfIssuanceCostsShares" xlink:label="loc_entx_IssuanceOfOrdinarySharesAndWarrantsDueToPrivatePlacementNetOfIssuanceCostsShares_242"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_IssuanceOfOrdinarySharesAndWarrantsDueToPrivatePlacementNetOfIssuanceCostsShares" xlink:label="loc_entx_IssuanceOfOrdinarySharesAndWarrantsDueToPrivatePlacementNetOfIssuanceCostsShares_243"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_IssuanceOfOrdinarySharesAndWarrantsDueToPrivatePlacementNetOfIssuanceCostsShares" xlink:label="loc_entx_IssuanceOfOrdinarySharesAndWarrantsDueToPrivatePlacementNetOfIssuanceCostsShares_244"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_IssuanceOfSharesDueToAtMarketProgramNetOfIssuanceCostsShares" xlink:label="loc_entx_IssuanceOfSharesDueToAtMarketProgramNetOfIssuanceCostsShares_245"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_IssuanceOfSharesDueToAtMarketProgramNetOfIssuanceCostsShares" xlink:label="loc_entx_IssuanceOfSharesDueToAtMarketProgramNetOfIssuanceCostsShares_246"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_IssuanceOfSharesDueToAtMarketProgramNetOfIssuanceCostsShares" xlink:label="loc_entx_IssuanceOfSharesDueToAtMarketProgramNetOfIssuanceCostsShares_247"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_IssuanceOfSharesDueToAtMarketProgramNetOfIssuanceCostsValue" xlink:label="loc_entx_IssuanceOfSharesDueToAtMarketProgramNetOfIssuanceCostsValue_248"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_IssuanceOfSharesDueToAtMarketProgramNetOfIssuanceCostsValue" xlink:label="loc_entx_IssuanceOfSharesDueToAtMarketProgramNetOfIssuanceCostsValue_249"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_IssuanceOfSharesDueToAtMarketProgramNetOfIssuanceCostsValue" xlink:label="loc_entx_IssuanceOfSharesDueToAtMarketProgramNetOfIssuanceCostsValue_250"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_JointVentureAgreementMember" xlink:label="loc_entx_JointVentureAgreementMember_251"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_JointVentureAgreementMember" xlink:label="loc_entx_JointVentureAgreementMember_252"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_JointVentureAgreementMember" xlink:label="loc_entx_JointVentureAgreementMember_253"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_LaboratoryEquipmentMember" xlink:label="loc_entx_LaboratoryEquipmentMember_254"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_LaboratoryEquipmentMember" xlink:label="loc_entx_LaboratoryEquipmentMember_255"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_LaboratoryEquipmentMember" xlink:label="loc_entx_LaboratoryEquipmentMember_256"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_LeaseArrangementAxis" xlink:label="loc_entx_LeaseArrangementAxis_257"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_LeaseArrangementAxis" xlink:label="loc_entx_LeaseArrangementAxis_258"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_LeaseArrangementDomain" xlink:label="loc_entx_LeaseArrangementDomain_259"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_LeaseArrangementDomain" xlink:label="loc_entx_LeaseArrangementDomain_260"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_LiabilityForEmployeeRightsUponRetirement" xlink:label="loc_entx_LiabilityForEmployeeRightsUponRetirement_261"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_LiabilityForEmployeeRightsUponRetirement" xlink:label="loc_entx_LiabilityForEmployeeRightsUponRetirement_262"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_LiabilityForEmployeeRightsUponRetirement" xlink:label="loc_entx_LiabilityForEmployeeRightsUponRetirement_263"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_ManagementAndConsultingFees" xlink:label="loc_entx_ManagementAndConsultingFees_264"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_ManagementAndConsultingFees" xlink:label="loc_entx_ManagementAndConsultingFees_265"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_ManagementAndConsultingFees" xlink:label="loc_entx_ManagementAndConsultingFees_266"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_NetProceedsFromIssuanceOfCommonStock" xlink:label="loc_entx_NetProceedsFromIssuanceOfCommonStock_267"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_NetProceedsFromIssuanceOfCommonStock" xlink:label="loc_entx_NetProceedsFromIssuanceOfCommonStock_268"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_NetProceedsFromIssuanceOfCommonStock" xlink:label="loc_entx_NetProceedsFromIssuanceOfCommonStock_269"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_NonExecutiveBoardMember" xlink:label="loc_entx_NonExecutiveBoardMember_270"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_NonExecutiveBoardMember" xlink:label="loc_entx_NonExecutiveBoardMember_271"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_NonExecutiveDirectorMember" xlink:label="loc_entx_NonExecutiveDirectorMember_272"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_NonExecutiveDirectorMember" xlink:label="loc_entx_NonExecutiveDirectorMember_273"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_NonExecutiveDirectorMember" xlink:label="loc_entx_NonExecutiveDirectorMember_274"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_NonExecutiveDirectorsMember" xlink:label="loc_entx_NonExecutiveDirectorsMember_275"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_NonExecutiveDirectorsMember" xlink:label="loc_entx_NonExecutiveDirectorsMember_276"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_NonExecutiveDirectorsMember" xlink:label="loc_entx_NonExecutiveDirectorsMember_277"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_NonRefundableAndNonCreditableInitialTechnologyAccessFeePayment" xlink:label="loc_entx_NonRefundableAndNonCreditableInitialTechnologyAccessFeePayment_278"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_NonRefundableAndNonCreditableInitialTechnologyAccessFeePayment" xlink:label="loc_entx_NonRefundableAndNonCreditableInitialTechnologyAccessFeePayment_279"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_NonRefundableAndNonCreditableInitialTechnologyAccessFeePayment" xlink:label="loc_entx_NonRefundableAndNonCreditableInitialTechnologyAccessFeePayment_280"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_NonRefundableAndNonCreditableInitialTechnologyAccessFeePayment" xlink:label="loc_entx_NonRefundableAndNonCreditableInitialTechnologyAccessFeePayment_281"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_NumberOfNonExecutiveBoardMembers" xlink:label="loc_entx_NumberOfNonExecutiveBoardMembers_282"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_NumberOfNonExecutiveBoardMembers" xlink:label="loc_entx_NumberOfNonExecutiveBoardMembers_283"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_NumberOfNonExecutiveBoardMembers" xlink:label="loc_entx_NumberOfNonExecutiveBoardMembers_284"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_NumberOfSharesIssuedUnderPrivatePlacement" xlink:label="loc_entx_NumberOfSharesIssuedUnderPrivatePlacement_285"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_NumberOfSharesIssuedUnderPrivatePlacement" xlink:label="loc_entx_NumberOfSharesIssuedUnderPrivatePlacement_286"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_NumberOfSharesIssuedUnderPrivatePlacement" xlink:label="loc_entx_NumberOfSharesIssuedUnderPrivatePlacement_287"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_OneTimeTerminationPayment" xlink:label="loc_entx_OneTimeTerminationPayment_288"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_OneTimeTerminationPayment" xlink:label="loc_entx_OneTimeTerminationPayment_289"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_OneTimeTerminationPayment" xlink:label="loc_entx_OneTimeTerminationPayment_290"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_OperatingLeaseAgreementsForOfficeAndResearchAndDevelopmentSpaceMember" xlink:label="loc_entx_OperatingLeaseAgreementsForOfficeAndResearchAndDevelopmentSpaceMember_291"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_OperatingLeaseAgreementsForOfficeAndResearchAndDevelopmentSpaceMember" xlink:label="loc_entx_OperatingLeaseAgreementsForOfficeAndResearchAndDevelopmentSpaceMember_292"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_OperatingLeaseAgreementsForOfficeAndResearchAndDevelopmentSpaceMember" xlink:label="loc_entx_OperatingLeaseAgreementsForOfficeAndResearchAndDevelopmentSpaceMember_293"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_OperatingLeaseAgreementsForVehiclesForEmployeesMember" xlink:label="loc_entx_OperatingLeaseAgreementsForVehiclesForEmployeesMember_294"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_OperatingLeaseAgreementsForVehiclesForEmployeesMember" xlink:label="loc_entx_OperatingLeaseAgreementsForVehiclesForEmployeesMember_295"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_OperatingLeaseAgreementsForVehiclesForEmployeesMember" xlink:label="loc_entx_OperatingLeaseAgreementsForVehiclesForEmployeesMember_296"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_OperatingLeaseLiabilityAndOperatingLeaseRightOfUseAssetTableTextBlock" xlink:label="loc_entx_OperatingLeaseLiabilityAndOperatingLeaseRightOfUseAssetTableTextBlock_297"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_OperatingLeaseLiabilityAndOperatingLeaseRightOfUseAssetTableTextBlock" xlink:label="loc_entx_OperatingLeaseLiabilityAndOperatingLeaseRightOfUseAssetTableTextBlock_298"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_OperatingLeaseLiabilityAndOperatingLeaseRightOfUseAssetTableTextBlock" xlink:label="loc_entx_OperatingLeaseLiabilityAndOperatingLeaseRightOfUseAssetTableTextBlock_299"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_OperatingLeaseSupplementalCashFlowInformationTableTextBlock" xlink:label="loc_entx_OperatingLeaseSupplementalCashFlowInformationTableTextBlock_300"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_OperatingLeaseSupplementalCashFlowInformationTableTextBlock" xlink:label="loc_entx_OperatingLeaseSupplementalCashFlowInformationTableTextBlock_301"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_OperatingLeaseSupplementalCashFlowInformationTableTextBlock" xlink:label="loc_entx_OperatingLeaseSupplementalCashFlowInformationTableTextBlock_302"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_OramedLtdMember" xlink:label="loc_entx_OramedLtdMember_303"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_OramedLtdMember" xlink:label="loc_entx_OramedLtdMember_304"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_OramedLtdMember" xlink:label="loc_entx_OramedLtdMember_305"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_PatentCostsPolicyTextBlock" xlink:label="loc_entx_PatentCostsPolicyTextBlock_306"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_PatentCostsPolicyTextBlock" xlink:label="loc_entx_PatentCostsPolicyTextBlock_307"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_PatentCostsPolicyTextBlock" xlink:label="loc_entx_PatentCostsPolicyTextBlock_308"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_PatentTransferAgreementMember" xlink:label="loc_entx_PatentTransferAgreementMember_309"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_PatentTransferAgreementMember" xlink:label="loc_entx_PatentTransferAgreementMember_310"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_PatentTransferAgreementMember" xlink:label="loc_entx_PatentTransferAgreementMember_311"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_PaymentOfRoyaltyGuaranteesCommitments" xlink:label="loc_entx_PaymentOfRoyaltyGuaranteesCommitments_312"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_PaymentOfRoyaltyGuaranteesCommitments" xlink:label="loc_entx_PaymentOfRoyaltyGuaranteesCommitments_313"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_PaymentOfRoyaltyGuaranteesCommitments" xlink:label="loc_entx_PaymentOfRoyaltyGuaranteesCommitments_314"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_PlacementAgencyAgreementWithGpNumenkariIncMember" xlink:label="loc_entx_PlacementAgencyAgreementWithGpNumenkariIncMember_315"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_PlacementAgencyAgreementWithGpNumenkariIncMember" xlink:label="loc_entx_PlacementAgencyAgreementWithGpNumenkariIncMember_316"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_PlacementAgencyAgreementWithGpNumenkariIncMember" xlink:label="loc_entx_PlacementAgencyAgreementWithGpNumenkariIncMember_317"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_PresidentOfResearchAndDevelopmentMember" xlink:label="loc_entx_PresidentOfResearchAndDevelopmentMember_318"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_PresidentOfResearchAndDevelopmentMember" xlink:label="loc_entx_PresidentOfResearchAndDevelopmentMember_319"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_PresidentOfResearchAndDevelopmentMember" xlink:label="loc_entx_PresidentOfResearchAndDevelopmentMember_320"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_ProceedsFromIssuanceOfSharesAndWarrantsNetOfIssuanceCosts" xlink:label="loc_entx_ProceedsFromIssuanceOfSharesAndWarrantsNetOfIssuanceCosts_321"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_ProceedsFromIssuanceOfSharesAndWarrantsNetOfIssuanceCosts" xlink:label="loc_entx_ProceedsFromIssuanceOfSharesAndWarrantsNetOfIssuanceCosts_322"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_ProceedsFromIssuanceOfSharesAndWarrantsNetOfIssuanceCosts" xlink:label="loc_entx_ProceedsFromIssuanceOfSharesAndWarrantsNetOfIssuanceCosts_323"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_ProceedsFromIssuanceOfSharesThroughAtmProgramsNetOfIssuanceCosts" xlink:label="loc_entx_ProceedsFromIssuanceOfSharesThroughAtmProgramsNetOfIssuanceCosts_324"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_ProceedsFromIssuanceOfSharesThroughAtmProgramsNetOfIssuanceCosts" xlink:label="loc_entx_ProceedsFromIssuanceOfSharesThroughAtmProgramsNetOfIssuanceCosts_325"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_ProceedsFromIssuanceOfSharesThroughAtmProgramsNetOfIssuanceCosts" xlink:label="loc_entx_ProceedsFromIssuanceOfSharesThroughAtmProgramsNetOfIssuanceCosts_326"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_ProceedsFromOptionsAndWarrantExercises" xlink:label="loc_entx_ProceedsFromOptionsAndWarrantExercises_327"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_ProceedsFromOptionsAndWarrantExercises" xlink:label="loc_entx_ProceedsFromOptionsAndWarrantExercises_328"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_ProceedsFromOptionsAndWarrantExercises" xlink:label="loc_entx_ProceedsFromOptionsAndWarrantExercises_329"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_ProceedsFromShortTermBankDeposits" xlink:label="loc_entx_ProceedsFromShortTermBankDeposits_330"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_ProceedsFromShortTermBankDeposits" xlink:label="loc_entx_ProceedsFromShortTermBankDeposits_331"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_ProceedsFromShortTermBankDeposits" xlink:label="loc_entx_ProceedsFromShortTermBankDeposits_332"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_ProceedsFromShortTermBankDeposits" xlink:label="loc_entx_ProceedsFromShortTermBankDeposits_333"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_ProceedsFromShortTermBankDeposits" xlink:label="loc_entx_ProceedsFromShortTermBankDeposits_334"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_ReconciliationInAmountsOnConsolidatedBalanceSheetsAbstract" xlink:label="loc_entx_ReconciliationInAmountsOnConsolidatedBalanceSheetsAbstract_335"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_ReconciliationInAmountsOnConsolidatedBalanceSheetsAbstract" xlink:label="loc_entx_ReconciliationInAmountsOnConsolidatedBalanceSheetsAbstract_336"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_RelatedPartyTransactionOfCompensationOfExecutiveOfficers" xlink:label="loc_entx_RelatedPartyTransactionOfCompensationOfExecutiveOfficers_337"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_RelatedPartyTransactionOfCompensationOfExecutiveOfficers" xlink:label="loc_entx_RelatedPartyTransactionOfCompensationOfExecutiveOfficers_338"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_RelatedPartyTransactionOfCompensationOfExecutiveOfficers" xlink:label="loc_entx_RelatedPartyTransactionOfCompensationOfExecutiveOfficers_339"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_RelatedPartyTransactionOfManagementAndConsultingFeesToBoardMembers" xlink:label="loc_entx_RelatedPartyTransactionOfManagementAndConsultingFeesToBoardMembers_340"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_RelatedPartyTransactionOfManagementAndConsultingFeesToBoardMembers" xlink:label="loc_entx_RelatedPartyTransactionOfManagementAndConsultingFeesToBoardMembers_341"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_RelatedPartyTransactionOfManagementAndConsultingFeesToBoardMembers" xlink:label="loc_entx_RelatedPartyTransactionOfManagementAndConsultingFeesToBoardMembers_342"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_RelatedPartyTransactionOfStockBasedCompensationExpensesToBoardMembers" xlink:label="loc_entx_RelatedPartyTransactionOfStockBasedCompensationExpensesToBoardMembers_343"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_RelatedPartyTransactionOfStockBasedCompensationExpensesToBoardMembers" xlink:label="loc_entx_RelatedPartyTransactionOfStockBasedCompensationExpensesToBoardMembers_344"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_RelatedPartyTransactionOfStockBasedCompensationExpensesToBoardMembers" xlink:label="loc_entx_RelatedPartyTransactionOfStockBasedCompensationExpensesToBoardMembers_345"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_RelatedPartyTransactionOfStockBasedCompensationExpensesToExecutiveOfficers" xlink:label="loc_entx_RelatedPartyTransactionOfStockBasedCompensationExpensesToExecutiveOfficers_346"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_RelatedPartyTransactionOfStockBasedCompensationExpensesToExecutiveOfficers" xlink:label="loc_entx_RelatedPartyTransactionOfStockBasedCompensationExpensesToExecutiveOfficers_347"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_RelatedPartyTransactionOfStockBasedCompensationExpensesToExecutiveOfficers" xlink:label="loc_entx_RelatedPartyTransactionOfStockBasedCompensationExpensesToExecutiveOfficers_348"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_RelatedPartyTransactionWithExecutiveOfficersPayables" xlink:label="loc_entx_RelatedPartyTransactionWithExecutiveOfficersPayables_349"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_RelatedPartyTransactionWithExecutiveOfficersPayables" xlink:label="loc_entx_RelatedPartyTransactionWithExecutiveOfficersPayables_350"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_RelatedPartyTransactionWithExecutiveOfficersPayables" xlink:label="loc_entx_RelatedPartyTransactionWithExecutiveOfficersPayables_351"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_RelatedPartyTransactionWithNonExecutiveDirectorsPayable" xlink:label="loc_entx_RelatedPartyTransactionWithNonExecutiveDirectorsPayable_352"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_RelatedPartyTransactionWithNonExecutiveDirectorsPayable" xlink:label="loc_entx_RelatedPartyTransactionWithNonExecutiveDirectorsPayable_353"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_RelatedPartyTransactionWithNonExecutiveDirectorsPayable" xlink:label="loc_entx_RelatedPartyTransactionWithNonExecutiveDirectorsPayable_354"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_ResearchAndDevelopmentServiceExpense" xlink:label="loc_entx_ResearchAndDevelopmentServiceExpense_355"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_ResearchAndDevelopmentServiceExpense" xlink:label="loc_entx_ResearchAndDevelopmentServiceExpense_356"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_ResearchAndDevelopmentServiceExpense" xlink:label="loc_entx_ResearchAndDevelopmentServiceExpense_357"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_ResearchCollaborationAndLicenseAgreementMember" xlink:label="loc_entx_ResearchCollaborationAndLicenseAgreementMember_358"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_ResearchCollaborationAndLicenseAgreementMember" xlink:label="loc_entx_ResearchCollaborationAndLicenseAgreementMember_359"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_ResearchCollaborationAndLicenseAgreementMember" xlink:label="loc_entx_ResearchCollaborationAndLicenseAgreementMember_360"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_ReversalOfExpensesUponForfeitureOfOptions" xlink:label="loc_entx_ReversalOfExpensesUponForfeitureOfOptions_361"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_ReversalOfExpensesUponForfeitureOfOptions" xlink:label="loc_entx_ReversalOfExpensesUponForfeitureOfOptions_362"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_ReversalOfExpensesUponForfeitureOfOptions" xlink:label="loc_entx_ReversalOfExpensesUponForfeitureOfOptions_363"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_RightOfUseAssetsObtainedInExchangeForNewOperatingLeaseLiabilities" xlink:label="loc_entx_RightOfUseAssetsObtainedInExchangeForNewOperatingLeaseLiabilities_364"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_RightOfUseAssetsObtainedInExchangeForNewOperatingLeaseLiabilities" xlink:label="loc_entx_RightOfUseAssetsObtainedInExchangeForNewOperatingLeaseLiabilities_365"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_RightOfUseAssetsObtainedInExchangeForNewOperatingLeaseLiabilities" xlink:label="loc_entx_RightOfUseAssetsObtainedInExchangeForNewOperatingLeaseLiabilities_366"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_RightToUseIntellectualProperty" xlink:label="loc_entx_RightToUseIntellectualProperty_367"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_RightToUseIntellectualProperty" xlink:label="loc_entx_RightToUseIntellectualProperty_368"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_RightToUseIntellectualProperty" xlink:label="loc_entx_RightToUseIntellectualProperty_369"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_RoyaltyGuaranteesCommitmentsPercentageOfEachPaymentReceivedFromAmgen" xlink:label="loc_entx_RoyaltyGuaranteesCommitmentsPercentageOfEachPaymentReceivedFromAmgen_370"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_RoyaltyGuaranteesCommitmentsPercentageOfEachPaymentReceivedFromAmgen" xlink:label="loc_entx_RoyaltyGuaranteesCommitmentsPercentageOfEachPaymentReceivedFromAmgen_371"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_RoyaltyGuaranteesCommitmentsPercentageOfEachPaymentReceivedFromAmgen" xlink:label="loc_entx_RoyaltyGuaranteesCommitmentsPercentageOfEachPaymentReceivedFromAmgen_372"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_RoyaltyGuaranteesCommitmentsPercentageOfNetRevenues" xlink:label="loc_entx_RoyaltyGuaranteesCommitmentsPercentageOfNetRevenues_373"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_RoyaltyGuaranteesCommitmentsPercentageOfNetRevenues" xlink:label="loc_entx_RoyaltyGuaranteesCommitmentsPercentageOfNetRevenues_374"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_RoyaltyGuaranteesCommitmentsPercentageOfNetRevenues" xlink:label="loc_entx_RoyaltyGuaranteesCommitmentsPercentageOfNetRevenues_375"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_RoyaltyGuaranteesCommitmentsPercentageSalesOfProductsDevelopedFromProjectsCommencingSeventhYear" xlink:label="loc_entx_RoyaltyGuaranteesCommitmentsPercentageSalesOfProductsDevelopedFromProjectsCommencingSeventhYear_376"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_RoyaltyGuaranteesCommitmentsPercentageSalesOfProductsDevelopedFromProjectsCommencingSeventhYear" xlink:label="loc_entx_RoyaltyGuaranteesCommitmentsPercentageSalesOfProductsDevelopedFromProjectsCommencingSeventhYear_377"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_RoyaltyGuaranteesCommitmentsPercentageSalesOfProductsDevelopedFromProjectsCommencingSeventhYear" xlink:label="loc_entx_RoyaltyGuaranteesCommitmentsPercentageSalesOfProductsDevelopedFromProjectsCommencingSeventhYear_378"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_RoyaltyGuaranteesCommitmentsPercentageSalesOfProductsDevelopedFromProjectsInFirstThreeYearsFromCommencementOfRevenues" xlink:label="loc_entx_RoyaltyGuaranteesCommitmentsPercentageSalesOfProductsDevelopedFromProjectsInFirstThreeYearsFromCommencementOfRevenues_379"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_RoyaltyGuaranteesCommitmentsPercentageSalesOfProductsDevelopedFromProjectsInFirstThreeYearsFromCommencementOfRevenues" xlink:label="loc_entx_RoyaltyGuaranteesCommitmentsPercentageSalesOfProductsDevelopedFromProjectsInFirstThreeYearsFromCommencementOfRevenues_380"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_RoyaltyGuaranteesCommitmentsPercentageSalesOfProductsDevelopedFromProjectsInFirstThreeYearsFromCommencementOfRevenues" xlink:label="loc_entx_RoyaltyGuaranteesCommitmentsPercentageSalesOfProductsDevelopedFromProjectsInFirstThreeYearsFromCommencementOfRevenues_381"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_RoyaltyGuaranteesCommitmentsPercentageSalesOfProductsDevelopedFromProjectsSubsequentThreeYears" xlink:label="loc_entx_RoyaltyGuaranteesCommitmentsPercentageSalesOfProductsDevelopedFromProjectsSubsequentThreeYears_382"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_RoyaltyGuaranteesCommitmentsPercentageSalesOfProductsDevelopedFromProjectsSubsequentThreeYears" xlink:label="loc_entx_RoyaltyGuaranteesCommitmentsPercentageSalesOfProductsDevelopedFromProjectsSubsequentThreeYears_383"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_RoyaltyGuaranteesCommitmentsPercentageSalesOfProductsDevelopedFromProjectsSubsequentThreeYears" xlink:label="loc_entx_RoyaltyGuaranteesCommitmentsPercentageSalesOfProductsDevelopedFromProjectsSubsequentThreeYears_384"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_SaleOfStockAmountOfInvestment" xlink:label="loc_entx_SaleOfStockAmountOfInvestment_385"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_SaleOfStockAmountOfInvestment" xlink:label="loc_entx_SaleOfStockAmountOfInvestment_386"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_SaleOfStockAmountOfInvestment" xlink:label="loc_entx_SaleOfStockAmountOfInvestment_387"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_SaleOfStockPercentageOfOwnershipOfEntityAcquired" xlink:label="loc_entx_SaleOfStockPercentageOfOwnershipOfEntityAcquired_388"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_SaleOfStockPercentageOfOwnershipOfEntityAcquired" xlink:label="loc_entx_SaleOfStockPercentageOfOwnershipOfEntityAcquired_389"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_SaleOfStockPercentageOfOwnershipOfEntityAcquired" xlink:label="loc_entx_SaleOfStockPercentageOfOwnershipOfEntityAcquired_390"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_ScheduleOfEstimatedUsefulLifeTableTextBlock" xlink:label="loc_entx_ScheduleOfEstimatedUsefulLifeTableTextBlock_391"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_ScheduleOfEstimatedUsefulLifeTableTextBlock" xlink:label="loc_entx_ScheduleOfEstimatedUsefulLifeTableTextBlock_392"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_ScheduleOfEstimatedUsefulLifeTableTextBlock" xlink:label="loc_entx_ScheduleOfEstimatedUsefulLifeTableTextBlock_393"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_ScheduleOfRelatedPartyTransactionReportedInConsolidatedStatementsOfComprehensiveLossTableTextBlock" xlink:label="loc_entx_ScheduleOfRelatedPartyTransactionReportedInConsolidatedStatementsOfComprehensiveLossTableTextBlock_394"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_ScheduleOfRelatedPartyTransactionReportedInConsolidatedStatementsOfComprehensiveLossTableTextBlock" xlink:label="loc_entx_ScheduleOfRelatedPartyTransactionReportedInConsolidatedStatementsOfComprehensiveLossTableTextBlock_395"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_ScheduleOfRelatedPartyTransactionReportedInConsolidatedStatementsOfComprehensiveLossTableTextBlock" xlink:label="loc_entx_ScheduleOfRelatedPartyTransactionReportedInConsolidatedStatementsOfComprehensiveLossTableTextBlock_396"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_ScheduleOfRelatedPartyTransactionsReportedInConsolidatedBalanceSheetsTableTextBlock" xlink:label="loc_entx_ScheduleOfRelatedPartyTransactionsReportedInConsolidatedBalanceSheetsTableTextBlock_397"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_ScheduleOfRelatedPartyTransactionsReportedInConsolidatedBalanceSheetsTableTextBlock" xlink:label="loc_entx_ScheduleOfRelatedPartyTransactionsReportedInConsolidatedBalanceSheetsTableTextBlock_398"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_ScheduleOfRelatedPartyTransactionsReportedInConsolidatedBalanceSheetsTableTextBlock" xlink:label="loc_entx_ScheduleOfRelatedPartyTransactionsReportedInConsolidatedBalanceSheetsTableTextBlock_399"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_SellingPriceOfPreclinicalResearchAndDevelopmentServices" xlink:label="loc_entx_SellingPriceOfPreclinicalResearchAndDevelopmentServices_400"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_SellingPriceOfPreclinicalResearchAndDevelopmentServices" xlink:label="loc_entx_SellingPriceOfPreclinicalResearchAndDevelopmentServices_401"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_SellingPriceOfPreclinicalResearchAndDevelopmentServices" xlink:label="loc_entx_SellingPriceOfPreclinicalResearchAndDevelopmentServices_402"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_ServiceProviderMember" xlink:label="loc_entx_ServiceProviderMember_403"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_ServiceProviderMember" xlink:label="loc_entx_ServiceProviderMember_404"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_ServiceProviderMember" xlink:label="loc_entx_ServiceProviderMember_405"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_SeveralEmployeesAndServiceProvidersMember" xlink:label="loc_entx_SeveralEmployeesAndServiceProvidersMember_406"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_SeveralEmployeesAndServiceProvidersMember" xlink:label="loc_entx_SeveralEmployeesAndServiceProvidersMember_407"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_SeveralEmployeesAndServiceProvidersMember" xlink:label="loc_entx_SeveralEmployeesAndServiceProvidersMember_408"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_SeveranceExpenses" xlink:label="loc_entx_SeveranceExpenses_409"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_SeveranceExpenses" xlink:label="loc_entx_SeveranceExpenses_410"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_SeveranceExpenses" xlink:label="loc_entx_SeveranceExpenses_411"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_SeverancePayPolicyTextBlock" xlink:label="loc_entx_SeverancePayPolicyTextBlock_412"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_SeverancePayPolicyTextBlock" xlink:label="loc_entx_SeverancePayPolicyTextBlock_413"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_SeverancePayPolicyTextBlock" xlink:label="loc_entx_SeverancePayPolicyTextBlock_414"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsTotalConsideration" xlink:label="loc_entx_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsTotalConsideration_415"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsTotalConsideration" xlink:label="loc_entx_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsTotalConsideration_416"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsTotalConsideration" xlink:label="loc_entx_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsTotalConsideration_417"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_ShareBasedPaymentArrangementTrancheFiveMember" xlink:label="loc_entx_ShareBasedPaymentArrangementTrancheFiveMember_418"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_ShareBasedPaymentArrangementTrancheFiveMember" xlink:label="loc_entx_ShareBasedPaymentArrangementTrancheFiveMember_419"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_ShareBasedPaymentArrangementTrancheFiveMember" xlink:label="loc_entx_ShareBasedPaymentArrangementTrancheFiveMember_420"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_ShareBasedPaymentArrangementTrancheFourMember" xlink:label="loc_entx_ShareBasedPaymentArrangementTrancheFourMember_421"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_ShareBasedPaymentArrangementTrancheFourMember" xlink:label="loc_entx_ShareBasedPaymentArrangementTrancheFourMember_422"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_ShareBasedPaymentArrangementTrancheFourMember" xlink:label="loc_entx_ShareBasedPaymentArrangementTrancheFourMember_423"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_ShareBasedPaymentArrangementTrancheSevenMember" xlink:label="loc_entx_ShareBasedPaymentArrangementTrancheSevenMember_424"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_ShareBasedPaymentArrangementTrancheSevenMember" xlink:label="loc_entx_ShareBasedPaymentArrangementTrancheSevenMember_425"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_ShareBasedPaymentArrangementTrancheSixMember" xlink:label="loc_entx_ShareBasedPaymentArrangementTrancheSixMember_426"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_ShareBasedPaymentArrangementTrancheSixMember" xlink:label="loc_entx_ShareBasedPaymentArrangementTrancheSixMember_427"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_ShareBasedPaymentArrangementTrancheSixMember" xlink:label="loc_entx_ShareBasedPaymentArrangementTrancheSixMember_428"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_ShareIncentivePlan2013Member" xlink:label="loc_entx_ShareIncentivePlan2013Member_429"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_ShareIncentivePlan2013Member" xlink:label="loc_entx_ShareIncentivePlan2013Member_430"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_ShareIncentivePlan2013Member" xlink:label="loc_entx_ShareIncentivePlan2013Member_431"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_ShareIncentivePlan2018Member" xlink:label="loc_entx_ShareIncentivePlan2018Member_432"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_ShareIncentivePlan2018Member" xlink:label="loc_entx_ShareIncentivePlan2018Member_433"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_ShareIncentivePlan2018Member" xlink:label="loc_entx_ShareIncentivePlan2018Member_434"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_SharesGrantedInPercentage" xlink:label="loc_entx_SharesGrantedInPercentage_435"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_SharesGrantedInPercentage" xlink:label="loc_entx_SharesGrantedInPercentage_436"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_SharesGrantedInPercentage" xlink:label="loc_entx_SharesGrantedInPercentage_437"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_SharesIssuedWeightedAveragePricePerShare" xlink:label="loc_entx_SharesIssuedWeightedAveragePricePerShare_438"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_SharesIssuedWeightedAveragePricePerShare" xlink:label="loc_entx_SharesIssuedWeightedAveragePricePerShare_439"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_SharesIssuedWeightedAveragePricePerShare" xlink:label="loc_entx_SharesIssuedWeightedAveragePricePerShare_440"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_SignificantAccountingPoliciesLineItems" xlink:label="loc_entx_SignificantAccountingPoliciesLineItems_441"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_SignificantAccountingPoliciesLineItems" xlink:label="loc_entx_SignificantAccountingPoliciesLineItems_442"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_SignificantAccountingPoliciesTable" xlink:label="loc_entx_SignificantAccountingPoliciesTable_443"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_SignificantAccountingPoliciesTable" xlink:label="loc_entx_SignificantAccountingPoliciesTable_444"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_StockholdersEquityNoteLineItems" xlink:label="loc_entx_StockholdersEquityNoteLineItems_445"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_StockholdersEquityNoteLineItems" xlink:label="loc_entx_StockholdersEquityNoteLineItems_446"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_StockholdersEquityNoteTable" xlink:label="loc_entx_StockholdersEquityNoteTable_447"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_StockholdersEquityNoteTable" xlink:label="loc_entx_StockholdersEquityNoteTable_448"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_SupplementaryFinancialStatementInformationAbstract" xlink:label="loc_entx_SupplementaryFinancialStatementInformationAbstract_449"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_SupplementaryFinancialStatementInformationTextBlock" xlink:label="loc_entx_SupplementaryFinancialStatementInformationTextBlock_450"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_SupplementaryFinancialStatementInformationTextBlock" xlink:label="loc_entx_SupplementaryFinancialStatementInformationTextBlock_451"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_SupplementaryFinancialStatementInformationTextBlock" xlink:label="loc_entx_SupplementaryFinancialStatementInformationTextBlock_452"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_TransactionCosts" xlink:label="loc_entx_TransactionCosts_453"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_TransactionCosts" xlink:label="loc_entx_TransactionCosts_454"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_TransactionCosts" xlink:label="loc_entx_TransactionCosts_455"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_TriggeringEventAxis" xlink:label="loc_entx_TriggeringEventAxis_456"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_TriggeringEventAxis" xlink:label="loc_entx_TriggeringEventAxis_457"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_TriggeringEventDomain" xlink:label="loc_entx_TriggeringEventDomain_458"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_TriggeringEventDomain" xlink:label="loc_entx_TriggeringEventDomain_459"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_TriggeringEventMember" xlink:label="loc_entx_TriggeringEventMember_460"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_TriggeringEventMember" xlink:label="loc_entx_TriggeringEventMember_461"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_TriggeringEventMember" xlink:label="loc_entx_TriggeringEventMember_462"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_TwentySeventeenMemberMember" xlink:label="loc_entx_TwentySeventeenMemberMember_463"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_TwentySeventeenMemberMember" xlink:label="loc_entx_TwentySeventeenMemberMember_464"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_TwentySeventeenMemberMember" xlink:label="loc_entx_TwentySeventeenMemberMember_465"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_TwentyTwentyOneGrantMember" xlink:label="loc_entx_TwentyTwentyOneGrantMember_466"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_TwentyTwentyOneGrantMember" xlink:label="loc_entx_TwentyTwentyOneGrantMember_467"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_TwentyTwentyOneGrantMember" xlink:label="loc_entx_TwentyTwentyOneGrantMember_468"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_VestedRestrictedSharesUnits" xlink:label="loc_entx_VestedRestrictedSharesUnits_469"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_VestedRestrictedSharesUnits" xlink:label="loc_entx_VestedRestrictedSharesUnits_470"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_VestedRestrictedSharesUnits" xlink:label="loc_entx_VestedRestrictedSharesUnits_471"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_VestedRestrictedShareUnitsShares" xlink:label="loc_entx_VestedRestrictedShareUnitsShares_472"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_VestedRestrictedShareUnitsShares" xlink:label="loc_entx_VestedRestrictedShareUnitsShares_473"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_VestedRestrictedShareUnitsShares" xlink:label="loc_entx_VestedRestrictedShareUnitsShares_474"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_WarrantToPurchaseOrdinaryShare" xlink:label="loc_entx_WarrantToPurchaseOrdinaryShare_475"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_WarrantToPurchaseOrdinaryShare" xlink:label="loc_entx_WarrantToPurchaseOrdinaryShare_476"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_WarrantToPurchaseOrdinaryShare" xlink:label="loc_entx_WarrantToPurchaseOrdinaryShare_477"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ChiefExecutiveOfficerMember" xlink:label="loc_srt_ChiefExecutiveOfficerMember_478"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ChiefExecutiveOfficerMember" xlink:label="loc_srt_ChiefExecutiveOfficerMember_479"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ChiefExecutiveOfficerMember" xlink:label="loc_srt_ChiefExecutiveOfficerMember_480"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ChiefFinancialOfficerMember" xlink:label="loc_srt_ChiefFinancialOfficerMember_481"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidatedEntitiesAxis" xlink:label="loc_srt_ConsolidatedEntitiesAxis_482"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="loc_srt_ConsolidatedEntitiesDomain_483"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_DirectorMember" xlink:label="loc_srt_DirectorMember_484"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_DirectorMember" xlink:label="loc_srt_DirectorMember_485"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ExecutiveOfficerMember" xlink:label="loc_srt_ExecutiveOfficerMember_486"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ExecutiveOfficerMember" xlink:label="loc_srt_ExecutiveOfficerMember_487"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ExecutiveOfficerMember" xlink:label="loc_srt_ExecutiveOfficerMember_488"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_489"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_490"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_491"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_492"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_493"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_494"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_495"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_496"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SubsidiariesMember" xlink:label="loc_srt_SubsidiariesMember_497"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SubsidiariesMember" xlink:label="loc_srt_SubsidiariesMember_498"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SubsidiariesMember" xlink:label="loc_srt_SubsidiariesMember_499"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srt_TitleOfIndividualAxis_500"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_501"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_502"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis" xlink:label="loc_us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis_503"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:label="loc_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_504"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:label="loc_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_505"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_506"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_507"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_508"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_509"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_510"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_511"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_512"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaap_AccountsPayableCurrent_513"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaap_AccountsPayableCurrent_514"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_515"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_516"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedEmployeeBenefitsCurrent" xlink:label="loc_us-gaap_AccruedEmployeeBenefitsCurrent_517"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedEmployeeBenefitsCurrent" xlink:label="loc_us-gaap_AccruedEmployeeBenefitsCurrent_518"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedIncomeTaxesCurrent" xlink:label="loc_us-gaap_AccruedIncomeTaxesCurrent_519"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedIncomeTaxesCurrent" xlink:label="loc_us-gaap_AccruedIncomeTaxesCurrent_520"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:label="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilities_521"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:label="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilities_522"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:label="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilities_523"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:label="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilities_524"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_525"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_526"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedVacationCurrent" xlink:label="loc_us-gaap_AccruedVacationCurrent_527"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedVacationCurrent" xlink:label="loc_us-gaap_AccruedVacationCurrent_528"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_529"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_530"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_531"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_532"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalFinancialInformationDisclosureTextBlock" xlink:label="loc_us-gaap_AdditionalFinancialInformationDisclosureTextBlock_533"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalFinancialInformationDisclosureTextBlock" xlink:label="loc_us-gaap_AdditionalFinancialInformationDisclosureTextBlock_534"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_535"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_536"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_537"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_538"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalOther" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalOther_539"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalOther" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalOther_540"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_541"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_542"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition_543"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition_544"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_545"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_546"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_547"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_548"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_549"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_550"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_551"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_552"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_553"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_554"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaap_AssetsAbstract_555"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaap_AssetsAbstract_556"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent_557"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent_558"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaap_AssetsCurrentAbstract_559"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsNoncurrent" xlink:label="loc_us-gaap_AssetsNoncurrent_560"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsNoncurrent" xlink:label="loc_us-gaap_AssetsNoncurrent_561"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsNoncurrentAbstract" xlink:label="loc_us-gaap_AssetsNoncurrentAbstract_562"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_563"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_564"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_565"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_566"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_567"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_568"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_569"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_570"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:label="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_571"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:label="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_572"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_573"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_574"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_575"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_576"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_577"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_578"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_579"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_580"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_581"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_582"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_583"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_584"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_585"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaap_CommitmentsAndContingencies_586"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaap_CommitmentsAndContingencies_587"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_588"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_589"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_590"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesPolicyTextBlock" xlink:label="loc_us-gaap_CommitmentsAndContingenciesPolicyTextBlock_591"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesPolicyTextBlock" xlink:label="loc_us-gaap_CommitmentsAndContingenciesPolicyTextBlock_592"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_593"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_594"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_595"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_596"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_597"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_598"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued_599"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued_600"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_601"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_602"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_603"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_604"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_605"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_606"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_607"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_608"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValueOutstanding" xlink:label="loc_us-gaap_CommonStockValueOutstanding_609"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValueOutstanding" xlink:label="loc_us-gaap_CommonStockValueOutstanding_610"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockVotingRights" xlink:label="loc_us-gaap_CommonStockVotingRights_611"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockVotingRights" xlink:label="loc_us-gaap_CommonStockVotingRights_612"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CompensationExpenseExcludingCostOfGoodAndServiceSold" xlink:label="loc_us-gaap_CompensationExpenseExcludingCostOfGoodAndServiceSold_613"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CompensationExpenseExcludingCostOfGoodAndServiceSold" xlink:label="loc_us-gaap_CompensationExpenseExcludingCostOfGoodAndServiceSold_614"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComputerEquipmentMember" xlink:label="loc_us-gaap_ComputerEquipmentMember_615"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComputerEquipmentMember" xlink:label="loc_us-gaap_ComputerEquipmentMember_616"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk_617"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk_618"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock_619"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock_620"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiability" xlink:label="loc_us-gaap_ContractWithCustomerLiability_621"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiability" xlink:label="loc_us-gaap_ContractWithCustomerLiability_622"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_623"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_624"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_625"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_626"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_627"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfRevenue" xlink:label="loc_us-gaap_CostOfRevenue_628"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfRevenue" xlink:label="loc_us-gaap_CostOfRevenue_629"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfSalesMember" xlink:label="loc_us-gaap_CostOfSalesMember_630"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfSalesMember" xlink:label="loc_us-gaap_CostOfSalesMember_631"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:label="loc_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract_632"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:label="loc_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract_633"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_634"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_635"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit_636"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit_637"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit_638"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:label="loc_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract_639"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:label="loc_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract_640"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxAssetsNet" xlink:label="loc_us-gaap_DeferredIncomeTaxAssetsNet_641"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxAssetsNet" xlink:label="loc_us-gaap_DeferredIncomeTaxAssetsNet_642"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_643"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_644"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_645"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_646"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredRevenueRevenueRecognized1" xlink:label="loc_us-gaap_DeferredRevenueRevenueRecognized1_647"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredRevenueRevenueRecognized1" xlink:label="loc_us-gaap_DeferredRevenueRevenueRecognized1_648"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_649"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_650"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:label="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_651"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:label="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_652"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_653"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_654"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_655"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract" xlink:label="loc_us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract_656"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract" xlink:label="loc_us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract_657"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_658"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_659"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="loc_us-gaap_DeferredTaxAssetsOther_660"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="loc_us-gaap_DeferredTaxAssetsOther_661"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_662"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_663"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_664"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_665"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_666"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_667"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_668"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_669"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_670"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent" xlink:label="loc_us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent_671"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent" xlink:label="loc_us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent_672"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaap_Depreciation_673"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaap_Depreciation_674"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativesPolicyTextBlock" xlink:label="loc_us-gaap_DerivativesPolicyTextBlock_675"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativesPolicyTextBlock" xlink:label="loc_us-gaap_DerivativesPolicyTextBlock_676"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DescriptionOfPostemploymentBenefits" xlink:label="loc_us-gaap_DescriptionOfPostemploymentBenefits_677"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DescriptionOfPostemploymentBenefits" xlink:label="loc_us-gaap_DescriptionOfPostemploymentBenefits_678"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueLineItems" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_679"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTable" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_680"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_681"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_682"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_683"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DomesticCountryMember" xlink:label="loc_us-gaap_DomesticCountryMember_684"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DomesticCountryMember" xlink:label="loc_us-gaap_DomesticCountryMember_685"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DueToRelatedPartiesCurrentAndNoncurrent" xlink:label="loc_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent_686"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaap_EarningsPerShareBasic_687"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaap_EarningsPerShareBasic_688"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="loc_us-gaap_EarningsPerShareDiluted_689"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="loc_us-gaap_EarningsPerShareDiluted_690"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock_691"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock_692"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_693"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_694"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_695"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_696"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_697"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ExtraordinaryAndUnusualItemsAbstract" xlink:label="loc_us-gaap_ExtraordinaryAndUnusualItemsAbstract_698"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_699"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_700"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_701"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_702"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCountryMember" xlink:label="loc_us-gaap_ForeignCountryMember_703"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCountryMember" xlink:label="loc_us-gaap_ForeignCountryMember_704"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:label="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_705"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:label="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_706"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_707"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_708"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_709"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_710"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_711"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GovernmentMember" xlink:label="loc_us-gaap_GovernmentMember_712"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GovernmentMember" xlink:label="loc_us-gaap_GovernmentMember_713"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GrossProfit" xlink:label="loc_us-gaap_GrossProfit_714"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GrossProfit" xlink:label="loc_us-gaap_GrossProfit_715"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_716"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_717"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_718"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_719"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_720"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_721"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_722"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_723"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_724"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_725"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_726"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_727"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_728"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_729"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromSubsidiariesNetOfTax" xlink:label="loc_us-gaap_IncomeLossFromSubsidiariesNetOfTax_730"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromSubsidiariesNetOfTax" xlink:label="loc_us-gaap_IncomeLossFromSubsidiariesNetOfTax_731"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromSubsidiariesNetOfTax" xlink:label="loc_us-gaap_IncomeLossFromSubsidiariesNetOfTax_732"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaap_IncomeStatementAbstract_733"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_734"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_735"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_736"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_737"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_738"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_739"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_740"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_741"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxesPaidNet" xlink:label="loc_us-gaap_IncomeTaxesPaidNet_742"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxesPaidNet" xlink:label="loc_us-gaap_IncomeTaxesPaidNet_743"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_744"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_745"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_746"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_747"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_748"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_749"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock_750"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock_751"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_752"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_753"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_754"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_755"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseAmortization" xlink:label="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseAmortization_756"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseAmortization" xlink:label="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseAmortization_757"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationTaxExemptIncome" xlink:label="loc_us-gaap_IncomeTaxReconciliationTaxExemptIncome_758"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationTaxExemptIncome" xlink:label="loc_us-gaap_IncomeTaxReconciliationTaxExemptIncome_759"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationTaxExemptIncome" xlink:label="loc_us-gaap_IncomeTaxReconciliationTaxExemptIncome_760"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_761"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_762"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_763"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_764"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_765"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_766"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_767"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_768"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_769"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_770"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_771"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_772"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_773"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherCurrentAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherCurrentAssets_774"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherCurrentAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherCurrentAssets_775"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_776"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_777"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntellectualPropertyMember" xlink:label="loc_us-gaap_IntellectualPropertyMember_778"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IPOMember" xlink:label="loc_us-gaap_IPOMember_779"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IPOMember" xlink:label="loc_us-gaap_IPOMember_780"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCostTableTextBlock" xlink:label="loc_us-gaap_LeaseCostTableTextBlock_781"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCostTableTextBlock" xlink:label="loc_us-gaap_LeaseCostTableTextBlock_782"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract" xlink:label="loc_us-gaap_LeasesAbstract_783"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LegalEntityTypeOfCounterpartyDomain" xlink:label="loc_us-gaap_LegalEntityTypeOfCounterpartyDomain_784"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LegalMattersAndContingenciesTextBlock" xlink:label="loc_us-gaap_LegalMattersAndContingenciesTextBlock_785"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_786"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_787"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock_788"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock_789"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_790"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_791"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_792"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_793"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_794"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterRollingYearFive" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterRollingYearFive_795"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_796"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_797"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_798"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_799"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_800"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_801"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_802"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeasesTextBlock" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock_803"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeasesTextBlock" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock_804"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities_805"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities_806"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAbstract" xlink:label="loc_us-gaap_LiabilitiesAbstract_807"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAbstract" xlink:label="loc_us-gaap_LiabilitiesAbstract_808"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_809"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_810"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_811"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_812"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent_813"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent_814"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_815"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_816"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesNoncurrent" xlink:label="loc_us-gaap_LiabilitiesNoncurrent_817"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesNoncurrent" xlink:label="loc_us-gaap_LiabilitiesNoncurrent_818"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesNoncurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesNoncurrentAbstract_819"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesNoncurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesNoncurrentAbstract_820"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_821"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_822"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_823"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_824"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_825"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_826"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_827"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_828"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_829"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_830"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_831"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_832"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_833"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_834"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_835"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_836"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_837"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_838"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_839"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:label="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_840"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:label="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_841"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_842"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_843"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_844"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_845"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OfficeEquipmentMember" xlink:label="loc_us-gaap_OfficeEquipmentMember_846"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OfficeEquipmentMember" xlink:label="loc_us-gaap_OfficeEquipmentMember_847"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OfficersCompensation" xlink:label="loc_us-gaap_OfficersCompensation_848"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OfficersCompensation" xlink:label="loc_us-gaap_OfficersCompensation_849"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses_850"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses_851"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses_852"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaap_OperatingExpensesAbstract_853"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaap_OperatingExpensesAbstract_854"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_855"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_856"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_857"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseCost" xlink:label="loc_us-gaap_OperatingLeaseCost_858"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseCost" xlink:label="loc_us-gaap_OperatingLeaseCost_859"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseCost" xlink:label="loc_us-gaap_OperatingLeaseCost_860"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaap_OperatingLeaseLiability_861"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaap_OperatingLeaseLiability_862"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaap_OperatingLeaseLiability_863"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityAbstract" xlink:label="loc_us-gaap_OperatingLeaseLiabilityAbstract_864"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityAbstract" xlink:label="loc_us-gaap_OperatingLeaseLiabilityAbstract_865"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_866"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_867"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_868"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_869"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_870"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_871"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeasePayments" xlink:label="loc_us-gaap_OperatingLeasePayments_872"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeasePayments" xlink:label="loc_us-gaap_OperatingLeasePayments_873"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeasePayments" xlink:label="loc_us-gaap_OperatingLeasePayments_874"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_875"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_876"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_877"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_878"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_879"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_880"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_881"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_882"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="loc_us-gaap_OperatingLossCarryforwards_883"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="loc_us-gaap_OperatingLossCarryforwards_884"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwardsLineItems" xlink:label="loc_us-gaap_OperatingLossCarryforwardsLineItems_885"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:label="loc_us-gaap_OperatingLossCarryforwardsTable_886"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_887"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_888"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_889"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_890"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_891"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_892"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsCurrent" xlink:label="loc_us-gaap_OtherAssetsCurrent_893"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsCurrent" xlink:label="loc_us-gaap_OtherAssetsCurrent_894"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_895"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_896"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonrecurringIncome" xlink:label="loc_us-gaap_OtherNonrecurringIncome_897"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonrecurringIncome" xlink:label="loc_us-gaap_OtherNonrecurringIncome_898"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonrecurringIncome" xlink:label="loc_us-gaap_OtherNonrecurringIncome_899"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherOperatingIncome" xlink:label="loc_us-gaap_OtherOperatingIncome_900"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherOperatingIncome" xlink:label="loc_us-gaap_OtherOperatingIncome_901"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherOperatingIncome" xlink:label="loc_us-gaap_OtherOperatingIncome_902"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentForContingentConsiderationLiabilityOperatingActivities" xlink:label="loc_us-gaap_PaymentForContingentConsiderationLiabilityOperatingActivities_903"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentForContingentConsiderationLiabilityOperatingActivities" xlink:label="loc_us-gaap_PaymentForContingentConsiderationLiabilityOperatingActivities_904"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForProceedsFromShortTermInvestments" xlink:label="loc_us-gaap_PaymentsForProceedsFromShortTermInvestments_905"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForProceedsFromShortTermInvestments" xlink:label="loc_us-gaap_PaymentsForProceedsFromShortTermInvestments_906"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_907"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_908"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_909"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_910"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PostemploymentBenefitsLiabilityNoncurrent" xlink:label="loc_us-gaap_PostemploymentBenefitsLiabilityNoncurrent_911"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PostemploymentBenefitsLiabilityNoncurrent" xlink:label="loc_us-gaap_PostemploymentBenefitsLiabilityNoncurrent_912"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrivatePlacementMember" xlink:label="loc_us-gaap_PrivatePlacementMember_913"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrivatePlacementMember" xlink:label="loc_us-gaap_PrivatePlacementMember_914"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_915"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_916"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfPrivatePlacement_917"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfPrivatePlacement_918"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="loc_us-gaap_ProceedsFromWarrantExercises_919"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="loc_us-gaap_ProceedsFromWarrantExercises_920"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfessionalAndContractServicesExpense" xlink:label="loc_us-gaap_ProfessionalAndContractServicesExpense_921"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfessionalAndContractServicesExpense" xlink:label="loc_us-gaap_ProfessionalAndContractServicesExpense_922"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfessionalFees" xlink:label="loc_us-gaap_ProfessionalFees_923"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfessionalFees" xlink:label="loc_us-gaap_ProfessionalFees_924"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_925"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_926"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_927"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_928"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_929"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_930"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_931"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_932"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_933"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:label="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_934"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_935"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_936"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_937"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:label="loc_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_938"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:label="loc_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_939"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:label="loc_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_940"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_941"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_942"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_943"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_944"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_945"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_946"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_947"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_948"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_949"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_950"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_951"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalents" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalents_952"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalents" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalents_953"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndInvestments" xlink:label="loc_us-gaap_RestrictedCashAndInvestments_954"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_955"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_956"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_957"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_958"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaap_RetainedEarningsMember_959"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaap_RetainedEarningsMember_960"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_961"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_962"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_963"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized" xlink:label="loc_us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized_964"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized" xlink:label="loc_us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized_965"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="loc_us-gaap_RevenueRecognitionPolicyTextBlock_966"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="loc_us-gaap_RevenueRecognitionPolicyTextBlock_967"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues_968"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues_969"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues_970"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RoyaltyGuaranteesCommitmentsAmount" xlink:label="loc_us-gaap_RoyaltyGuaranteesCommitmentsAmount_971"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RoyaltyGuaranteesCommitmentsAmount" xlink:label="loc_us-gaap_RoyaltyGuaranteesCommitmentsAmount_972"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_973"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_974"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_975"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_976"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_977"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_978"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_979"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_980"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_981"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_982"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_983"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_984"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_985"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_986"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_987"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_988"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_989"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_990"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_991"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_992"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_993"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_994"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="loc_us-gaap_SeriesAPreferredStockMember_995"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="loc_us-gaap_SeriesAPreferredStockMember_996"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="loc_us-gaap_SeriesBPreferredStockMember_997"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="loc_us-gaap_SeriesBPreferredStockMember_998"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ServiceMember" xlink:label="loc_us-gaap_ServiceMember_999"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeveranceCosts1" xlink:label="loc_us-gaap_SeveranceCosts1_1000"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeveranceCosts1" xlink:label="loc_us-gaap_SeveranceCosts1_1001"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_1002"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_1003"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_1004"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_1005"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_1006"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_1007"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription_1008"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription_1009"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_1010"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_1011"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_1012"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_1013"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_1014"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_1015"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_1016"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_1017"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_1018"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_1019"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_1020"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_1021"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_1022"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_1023"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_1024"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_1025"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1026"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_1027"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_1028"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_1029"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_1030"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_1031"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_1032"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_1033"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_1034"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_1035"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_1036"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_1037"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_1038"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_1039"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_1040"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_1041"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_1042"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_1043"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_1044"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_1045"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_1046"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_1047"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_1048"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_1049"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_1050"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_1051"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_1052"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares_1053"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares_1054"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares_1055"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares_1056"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_1057"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_1058"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_1059"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_1060"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_1061"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_1062"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_1063"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_1064"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_1065"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_1066"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_1067"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_1068"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_1069"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_1070"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_1071"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_1072"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock_1073"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock_1074"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_1075"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_1076"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_1077"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_1078"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward_1079"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward_1080"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1081"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_1082"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_1083"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_1084"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_1085"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_1086"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_1087"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_1088"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_1089"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_1090"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_1091"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_1092"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_1093"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationAwardTrancheThreeMember" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheThreeMember_1094"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationAwardTrancheThreeMember" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheThreeMember_1095"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_1096"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_1097"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_1098"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_1099"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_1100"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_1101"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaap_SharePrice_1102"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaap_SharePrice_1103"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesIssued" xlink:label="loc_us-gaap_SharesIssued_1104"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesIssued" xlink:label="loc_us-gaap_SharesIssued_1105"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaap_SharesOutstanding_1106"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaap_SharesOutstanding_1107"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaap_SharesOutstanding_1108"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_1109"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_1110"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_1111"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_1112"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_1113"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_1114"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_1115"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_1116"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1117"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_1118"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_1119"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_1120"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_1121"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_1122"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_1123"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_1124"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_1125"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_1126"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_1127"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:label="loc_us-gaap_StockholdersEquityNumberOfSharesParValueAndOtherDisclosuresAbstract_1128"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:label="loc_us-gaap_StockholdersEquityNumberOfSharesParValueAndOtherDisclosuresAbstract_1129"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_1130"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_1131"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_1132"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_1133"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_1134"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_1135"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_1136"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_1137"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueIssuedForServices_1138"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueIssuedForServices_1139"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_1140"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_1141"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_1142"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_1143"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventLineItems" xlink:label="loc_us-gaap_SubsequentEventLineItems_1144"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember_1145"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember_1146"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaap_SubsequentEventsAbstract_1147"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="loc_us-gaap_SubsequentEventsTextBlock_1148"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="loc_us-gaap_SubsequentEventsTextBlock_1149"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTable" xlink:label="loc_us-gaap_SubsequentEventTable_1150"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_1151"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_1152"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_1153"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SummaryOfValuationAllowanceTextBlock" xlink:label="loc_us-gaap_SummaryOfValuationAllowanceTextBlock_1154"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SummaryOfValuationAllowanceTextBlock" xlink:label="loc_us-gaap_SummaryOfValuationAllowanceTextBlock_1155"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_1156"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_1157"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_1158"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnusualOrInfrequentItemsDisclosureTextBlock" xlink:label="loc_us-gaap_UnusualOrInfrequentItemsDisclosureTextBlock_1159"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnusualOrInfrequentItemsDisclosureTextBlock" xlink:label="loc_us-gaap_UnusualOrInfrequentItemsDisclosureTextBlock_1160"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UseOfEstimates" xlink:label="loc_us-gaap_UseOfEstimates_1161"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UseOfEstimates" xlink:label="loc_us-gaap_UseOfEstimates_1162"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_1163"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_1164"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_1165"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingAxis" xlink:label="loc_us-gaap_VestingAxis_1166"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingDomain" xlink:label="loc_us-gaap_VestingDomain_1167"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaap_WarrantMember_1168"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaap_WarrantMember_1169"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_1170"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_1171"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_1172"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_1173"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_AmendmentDescription_0" xml:lang="en-US">Amendment Description</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_AmendmentFlag_0" xml:lang="en-US">Amendment Flag</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_AuditorFirmId_0" xml:lang="en-US">Auditor Firm ID</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_AuditorLocation_0" xml:lang="en-US">Auditor Location</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_AuditorName_0" xml:lang="en-US">Auditor Name</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_CityAreaCode_0" xml:lang="en-US">City Area Code</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_CoverAbstract_0" xml:lang="en-US">Cover [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_dei_CoverAbstract_1" xml:lang="en-US">CURRENT ASSETS</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_CurrentFiscalYearEndDate_0" xml:lang="en-US">Current Fiscal Year End Date</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_DocumentAnnualReport_0" xml:lang="en-US">Document Annual Report</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_DocumentFiscalPeriodFocus_0" xml:lang="en-US">Document Fiscal Period Focus</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_DocumentFiscalYearFocus_0" xml:lang="en-US">Document Fiscal Year Focus</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_DocumentPeriodEndDate_0" xml:lang="en-US">Document Period End Date</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_DocumentQuarterlyReport_0" xml:lang="en-US">Document Quarterly Report</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_DocumentTransitionReport_0" xml:lang="en-US">Document Transition Report</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_DocumentType_0" xml:lang="en-US">Document Type</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityAddressAddressLine1_0" xml:lang="en-US">Entity Address, Address Line One</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityAddressAddressLine2_0" xml:lang="en-US">Entity Address, Address Line Two</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityAddressAddressLine3_0" xml:lang="en-US">Entity Address, Address Line Three</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityAddressCityOrTown_0" xml:lang="en-US">Entity Address, City or Town</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityAddressCountry_0" xml:lang="en-US">Entity Address, Country</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityAddressPostalZipCode_0" xml:lang="en-US">Entity Address, Postal Zip Code</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityAddressStateOrProvince_0" xml:lang="en-US">Entity Address, State or Province</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityCentralIndexKey_0" xml:lang="en-US">Entity Central Index Key</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityCommonStockSharesOutstanding_0" xml:lang="en-US">Entity Common Stock, Shares Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityCurrentReportingStatus_0" xml:lang="en-US">Entity Current Reporting Status</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityDomain_0" xml:lang="en-US">Entity [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityEmergingGrowthCompany_0" xml:lang="en-US">Entity Emerging Growth Company</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityExTransitionPeriod_0" xml:lang="en-US">Entity Ex Transition Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityFileNumber_0" xml:lang="en-US">Entity File Number</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityFilerCategory_0" xml:lang="en-US">Entity Filer Category</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityIncorporationStateCountryCode_0" xml:lang="en-US">Entity Incorporation, State or Country Code</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityInteractiveDataCurrent_0" xml:lang="en-US">Entity Interactive Data Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityPublicFloat_0" xml:lang="en-US">Entity Public Float</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityRegistrantName_0" xml:lang="en-US">Entity Registrant Name</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityShellCompany_0" xml:lang="en-US">Entity Shell Company</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntitySmallBusiness_0" xml:lang="en-US">Entity Small Business</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityTaxIdentificationNumber_0" xml:lang="en-US">Entity Tax Identification Number</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityVoluntaryFilers_0" xml:lang="en-US">Entity Voluntary Filers</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer_0" xml:lang="en-US">Entity Well-known Seasoned Issuer</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_LegalEntityAxis_0" xml:lang="en-US">Legal Entity [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_LocalPhoneNumber_0" xml:lang="en-US">Local Phone Number</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_Security12bTitle_0" xml:lang="en-US">Title of 12(b) Security</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_SecurityExchangeName_0" xml:lang="en-US">Security Exchange Name</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_TradingSymbol_0" xml:lang="en-US">Trading Symbol</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_entx_AccreditedInvestorsIncludingCertainBoardMembersAndTheirAffiliatesMember_0" xml:lang="en-US">Accredited Investors, Including Certain Board Members And Their Affiliates [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_entx_AccreditedInvestorsIncludingCertainBoardMembersAndTheirAffiliatesMember_1" xml:lang="en-US">Represents the information regarding accredited investors, including certain board members and their affiliates.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_entx_AccreditedInvestorsIncludingCertainBoardMembersAndTheirAffiliatesMember_2" xml:lang="en-US">Accredited investors, including certain board members and their affiliates [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_entx_AdditionalAmountPaidForServicesToBeRecognized_0" xml:lang="en-US">Additional Amount Paid For Services To Be Recognized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_entx_AdditionalAmountPaidForServicesToBeRecognized_1" xml:lang="en-US">Represents the additional amount paid for services to be recognized.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_entx_AdditionalAmountPaidForServicesToBeRecognized_2" xml:lang="en-US">Additional amount paid for services to be recognized upon commencement of the pre-clinical Research and Development services</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_entx_AdditionalCashSeparationPayment_0" xml:lang="en-US">Additional Cash Separation Payment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_entx_AdditionalCashSeparationPayment_1" xml:lang="en-US">Represents about additional cash separation payment.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_entx_AdditionalCashSeparationPayment_2" xml:lang="en-US">Additional cash separation payment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_entx_AdjustedExercisePriceUnderAtMarketEquityProgram_0" xml:lang="en-US">Adjusted Exercise Price Under At Market Equity Program</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_entx_AdjustedExercisePriceUnderAtMarketEquityProgram_1" xml:lang="en-US">Adjusted Exercise Price under At-the-market equity program.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_entx_AdjustedExercisePriceUnderAtMarketEquityProgram_2" xml:lang="en-US">Adjusted exercise price under At-the-market equity program</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_entx_AgreementAxis_0" xml:lang="en-US">Agreement [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_entx_AgreementAxis_1" xml:lang="en-US">Information by the type of agreements.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_entx_AgreementDomain_0" xml:lang="en-US">Agreement [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_entx_AgreementDomain_1" xml:lang="en-US">Name of the agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_entx_AmendmentToBusinessDevelopmentServicesAgreementMember_0" xml:lang="en-US">Amendment To Business Development Services Agreement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_entx_AmendmentToBusinessDevelopmentServicesAgreementMember_1" xml:lang="en-US">Amendment to business development services agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_entx_AmendmentToBusinessDevelopmentServicesAgreementMember_2" xml:lang="en-US">Amendment to business development services agreement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_entx_AmgenIncMember_0" xml:lang="en-US">Amgen Inc [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_entx_AmgenIncMember_1" xml:lang="en-US">Represents one of the related party.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_entx_AmgenIncMember_2" xml:lang="en-US">Amgen Inc [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_entx_AmgenIncMember_3" xml:lang="en-US">From Amgen [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_entx_AtmEquityProgram2020Member_0" xml:lang="en-US">Atm Equity Program 2020 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_entx_AtmEquityProgram2020Member_1" xml:lang="en-US">Represents the information related to at-the-market equity program for 2020.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_entx_AtmEquityProgram2020Member_2" xml:lang="en-US">ATM Equity Program 2020 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_entx_AtmEquityProgram2021Member_0" xml:lang="en-US">Atm Equity Program 2021 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_entx_AtmEquityProgram2021Member_1" xml:lang="en-US">Represents the information related to at-the-market equity program for 2021.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_entx_AtmEquityProgram2021Member_2" xml:lang="en-US">ATM Equity Program 2021 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_entx_BankGuarantees_0" xml:lang="en-US">Bank Guarantees</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_entx_BankGuarantees_1" xml:lang="en-US">Represents the value of bank guarantees.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_entx_BankGuarantees_2" xml:lang="en-US">Value of bank guarantees provided</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_entx_BoardMembersMember_0" xml:lang="en-US">Board Members [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_entx_BoardMembersMember_1" xml:lang="en-US">Board Members</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_entx_BrokerDealerMember_0" xml:lang="en-US">Broker Dealer [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_entx_BrokerDealerMember_1" xml:lang="en-US">This member stand for broker-dealer.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_entx_BrokerDealerOneMember_0" xml:lang="en-US">Broker Dealer One [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_entx_BrokerDealerOneMember_1" xml:lang="en-US">This member stand for broker-dealer one.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_entx_BrokerDealerOneMember_2" xml:lang="en-US">Broker-Dealer 1 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_entx_BrokerWarrantsMember_0" xml:lang="en-US">Broker Warrants [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_entx_BrokerWarrantsMember_1" xml:lang="en-US">Represents the type of warrants as broker warrants.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_entx_BrokerWarrantsMember_2" xml:lang="en-US">Broker Warrants [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_entx_BrokerWarrantsType1Member_0" xml:lang="en-US">Broker Warrants Type 1 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_entx_BrokerWarrantsType1Member_1" xml:lang="en-US">Represents the type of warrant as Broker Warrants Type 1.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_entx_BrokerWarrantsType1Member_2" xml:lang="en-US">Broker Warrants Type 1 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_entx_BrokerWarrantsType2Member_0" xml:lang="en-US">Broker Warrants Type 2 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_entx_BrokerWarrantsType2Member_1" xml:lang="en-US">Represents the type of warrants as Broker Warrants Type 2.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_entx_BrokerWarrantsType2Member_2" xml:lang="en-US">Broker Warrants Type 2 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_entx_CashFeesInPercentage_0" xml:lang="en-US">Cash Fees In Percentage</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_entx_CashFeesInPercentage_1" xml:lang="en-US">Represents the cash fees in percentage.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_entx_CashFeesInPercentage_2" xml:lang="en-US">Cash fees in percentage of total proceeds paid by subscribers invested through the Broker</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_entx_CashlessExerciseOfWarrants_0" xml:lang="en-US">Cashless Exercise Of Warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_entx_CashlessExerciseOfWarrants_1" xml:lang="en-US">Value of exercise of warrants in noncash transactions.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_entx_CashlessExerciseOfWarrants_2" xml:lang="en-US">Cashless exercise of warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_entx_CashSeparationPayment_0" xml:lang="en-US">Cash Separation Payment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_entx_CashSeparationPayment_1" xml:lang="en-US">Represents about cash separation payment.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_entx_CashSeparationPayment_2" xml:lang="en-US">Cash separation payment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_entx_ChairmanOfBoardAndDnaMember_0" xml:lang="en-US">Chairman Of Board And Dna [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_entx_ChairmanOfBoardAndDnaMember_1" xml:lang="en-US">Represents the information regarding two related parties.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_entx_ChairmanOfBoardAndDnaMember_2" xml:lang="en-US">Chairman of the board and DNA [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_entx_ClassOfWarrantOrRightExerciseTerm_0" xml:lang="en-US">Class Of Warrant Or Right, Exercise Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_entx_ClassOfWarrantOrRightExerciseTerm_1" xml:lang="en-US">Represents the exercise period of warrants or rights.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_entx_ClassOfWarrantOrRightExerciseTerm_2" xml:lang="en-US">Term of warrants issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_entx_ClassOfWarrantOrRightIssued_0" xml:lang="en-US">Class Of Warrant Or Right, Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_entx_ClassOfWarrantOrRightIssued_1" xml:lang="en-US">Represents the number of warrants or rights issued.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_entx_ClassOfWarrantOrRightIssued_2" xml:lang="en-US">Number of warrants issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_entx_ClassOfWarrantOrRightPercentageOfIpoPricePerUnit_0" xml:lang="en-US">Class Of Warrant Or Right, Percentage Of Ipo Price Per Unit</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_entx_ClassOfWarrantOrRightPercentageOfIpoPricePerUnit_1" xml:lang="en-US">Represents the percentage of IPO price per unit of warrants or rights.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_entx_ClassOfWarrantOrRightPercentageOfIpoPricePerUnit_2" xml:lang="en-US">Percentage of IPO price per unit</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_entx_ClassOfWarrantOrRightReducedExercisePrice_0" xml:lang="en-US">Class Of Warrant Or Right, Reduced Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_entx_ClassOfWarrantOrRightReducedExercisePrice_1" xml:lang="en-US">Represents the reduced exercise price of warrants or rights.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_entx_ClassOfWarrantOrRightReducedExercisePrice_2" xml:lang="en-US">Reduced exercise price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_entx_ClassOfWarrantOrRightThresholdConsecutiveTradingDays_0" xml:lang="en-US">Class Of Warrant Or Right, Threshold Consecutive Trading Days</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_entx_ClassOfWarrantOrRightThresholdConsecutiveTradingDays_1" xml:lang="en-US">Represents the threshold period of specified consecutive trading days.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_entx_ClassOfWarrantOrRightThresholdConsecutiveTradingDays_2" xml:lang="en-US">Threshold consecutive trading days</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_entx_ClassOfWarrantOrRightThresholdLimitOfLastReportedSalePrice_0" xml:lang="en-US">Class Of Warrant Or Right, Threshold Limit Of Last Reported Sale Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_entx_ClassOfWarrantOrRightThresholdLimitOfLastReportedSalePrice_1" xml:lang="en-US">Represents the threshold limit of last reported sale price of warrants or rights.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_entx_ClassOfWarrantOrRightThresholdLimitOfLastReportedSalePrice_2" xml:lang="en-US">Threshold limit of last reported sale price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_entx_ClassOfWarrantOrRightThresholdLimitOfPeriodForReductionInExercisePrice_0" xml:lang="en-US">Class Of Warrant Or Right, Threshold Limit Of Period For Reduction In Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_entx_ClassOfWarrantOrRightThresholdLimitOfPeriodForReductionInExercisePrice_1" xml:lang="en-US">Represents the threshold limit of period for reduction in exercise price of warrants or rights.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_entx_ClassOfWarrantOrRightThresholdLimitOfPeriodForReductionInExercisePrice_2" xml:lang="en-US">Threshold limit of period for reduction in exercise price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_entx_ClassOfWarrantOrRightThresholdLimitOfReductionInExercisePrice_0" xml:lang="en-US">Class Of Warrant Or Right, Threshold Limit Of Reduction In Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_entx_ClassOfWarrantOrRightThresholdLimitOfReductionInExercisePrice_1" xml:lang="en-US">Represents the threshold limit of reduction in exercise price of warrants or rights.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_entx_ClassOfWarrantOrRightThresholdLimitOfReductionInExercisePrice_2" xml:lang="en-US">Threshold limit of reduction in exercise price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_entx_CommitmentsAndContingenciesTable_0" xml:lang="en-US">Commitments And Contingencies [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_entx_CommitmentsAndContingenciesTable_1" xml:lang="en-US">Information and financial data about the commitments.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_entx_CommitmentsLineItems_0" xml:lang="en-US">Commitments [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_entx_CommitmentsLineItems_1" xml:lang="en-US">Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_entx_ConsultantMember_0" xml:lang="en-US">Consultant [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_entx_ConsultantMember_1" xml:lang="en-US">Information of consultant.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_entx_ConsultantMember_2" xml:lang="en-US">Consultant [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_entx_DecreaseIncreaseInTaxRefundAbstract_0" xml:lang="en-US">Decrease Increase In Tax Refund [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_entx_DecreaseIncreaseInTaxRefundAbstract_1" xml:lang="en-US">Decrease increase in tax refund [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_entx_DecreaseIncreaseInTaxRefundAbstract_2" xml:lang="en-US">Decrease (increase) in tax refund resulting from:</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_entx_DnaBiomedicalSolutionsLtdAndOramedLtdMember_0" xml:lang="en-US">Dna Biomedical Solutions Ltd And Oramed Ltd [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_entx_DnaBiomedicalSolutionsLtdAndOramedLtdMember_1" xml:lang="en-US">Represents the information regarding both of the related parties combined.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_entx_DnaBiomedicalSolutionsLtdAndOramedLtdMember_2" xml:lang="en-US">D. N. A Biomedical Solutions Ltd And Oramed Ltd [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_entx_DnaBiomedicalSolutionsLtdMember_0" xml:lang="en-US">Dna Biomedical Solutions Ltd [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_entx_DnaBiomedicalSolutionsLtdMember_1" xml:lang="en-US">Represents the information regarding one of the related parties.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_entx_DnaBiomedicalSolutionsLtdMember_2" xml:lang="en-US">D.N.A Biomedical Solutions Ltd [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_entx_EffectOfDownRoundTriggerAmount_0" xml:lang="en-US">Effect Of Down Round Trigger Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_entx_EffectOfDownRoundTriggerAmount_1" xml:lang="en-US">It represents effect of down round trigger amount.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_entx_EffectOfDownRoundTriggerAmount_2" xml:lang="en-US">Effect of down round trigger amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_entx_EmployeeMember_0" xml:lang="en-US">Employee [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_entx_EmployeeMember_1" xml:lang="en-US">Employee [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_entx_EmployeeMember_2" xml:lang="en-US">Employee [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_entx_EmployeeSeveranceBenefitsPolicyPolicyTextBlock_0" xml:lang="en-US">Employee Severance Benefits Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_entx_EmployeeSeveranceBenefitsPolicyPolicyTextBlock_1" xml:lang="en-US">Disclosure of accounting policy for employee severance benefits.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_entx_EmployeeSeveranceBenefitsPolicyPolicyTextBlock_2" xml:lang="en-US">Employee severance benefits</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_entx_EmployeesMember_0" xml:lang="en-US">Employees [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_entx_EmployeesMember_1" xml:lang="en-US">Information of employees.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_entx_EmployeesMember_2" xml:lang="en-US">Certain employees [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_entx_EnteraBioLtdMember_0" xml:lang="en-US">Entera Bio Ltd [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_entx_EnteraBioLtdMember_1" xml:lang="en-US">This member stands for Entera Bio Ltd.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_entx_EnteraBioLtdMember_2" xml:lang="en-US">Entera Bio Ltd</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_entx_EquityProgramAxis_0" xml:lang="en-US">Equity Program [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_entx_EquityProgramAxis_1" xml:lang="en-US">Information by equity program.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_entx_EquityProgramDomain_0" xml:lang="en-US">Equity Program [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_entx_EquityProgramDomain_1" xml:lang="en-US">Name of the equity program.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_entx_ExecutiveOfficerAndServiceProviderMember_0" xml:lang="en-US">Executive Officer And Service Provider [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_entx_ExecutiveOfficerAndServiceProviderMember_1" xml:lang="en-US">Represents about executive officer and service provider.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_entx_ExecutiveOfficerAndServiceProviderMember_2" xml:lang="en-US">Executive Officer and Service Provider [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_entx_ExerciseOfWarrantsShares_0" xml:lang="en-US">Exercise Of Warrants Shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_entx_ExerciseOfWarrantsShares_1" xml:lang="en-US">Number of warrants exercise.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_entx_ExerciseOfWarrantsShares_2" xml:lang="en-US">Exercise of warrants to ordinary shares (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_entx_ExerciseOfWarrantsValue_0" xml:lang="en-US">Exercise Of Warrants Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_entx_ExerciseOfWarrantsValue_1" xml:lang="en-US">Represents the exercise of warrants.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_entx_ExerciseOfWarrantsValue_2" xml:lang="en-US">Exercise of warrants to ordinary shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_entx_ExercisePricePerShareOnePointFourMember_0" xml:lang="en-US">Exercise Price Per Share One Point Four [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_entx_ExercisePricePerShareOnePointFourMember_1" xml:lang="en-US">This member is stand for 1.4.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_entx_ExercisePricePerShareOnePointFourMember_2" xml:lang="en-US">Exercise Price Per Share - 1.4</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_entx_ExercisePricePerShareOnePointTwoFourMember_0" xml:lang="en-US">Exercise Price Per Share One Point Two Four [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_entx_ExercisePricePerShareOnePointTwoFourMember_1" xml:lang="en-US">Exercise price per share 1.24.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_entx_ExercisePricePerShareOnePointTwoFourMember_2" xml:lang="en-US">Exercise Price Per Share - 1.24</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_entx_ExercisePricePerShareOnePointZeroSixMember_0" xml:lang="en-US">Exercise Price Per Share One Point Zero Six [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_entx_ExercisePricePerShareOnePointZeroSixMember_1" xml:lang="en-US">Exercise Price Per Share 1.06.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_entx_ExercisePricePerShareOnePointZeroSixMember_2" xml:lang="en-US">Exercise Price Per Share - 1.06</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_entx_ExercisePricePerShareSevenPointFiveFourMember_0" xml:lang="en-US">Exercise Price Per Share Seven Point Five Four [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_entx_ExercisePricePerShareSevenPointFiveFourMember_1" xml:lang="en-US">Exercise Price Per Share 7.54.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_entx_ExercisePricePerShareSevenPointFiveFourMember_2" xml:lang="en-US">Exercise Price Per Share - 7.54</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_entx_ExercisePricePerShareSixPointThreeOneMember_0" xml:lang="en-US">Exercise Price Per Share Six Point Three One [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_entx_ExercisePricePerShareSixPointThreeOneMember_1" xml:lang="en-US">Exercise Price Per Share 6.31.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_entx_ExercisePricePerShareSixPointThreeOneMember_2" xml:lang="en-US">Exercise Price Per Share - 6.31</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_entx_ExercisePricePerShareThreePointNineSevenMember_0" xml:lang="en-US">Exercise Price Per Share Three Point Nine Seven [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_entx_ExercisePricePerShareThreePointNineSevenMember_1" xml:lang="en-US">Exercise Price Per Share 3.97.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_entx_ExercisePricePerShareThreePointNineSevenMember_2" xml:lang="en-US">Exercise Price Per Share - 3.97</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_entx_ExercisePricePerShareThreePointOneFiveMember_0" xml:lang="en-US">Exercise Price Per Share Three Point One Five [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_entx_ExercisePricePerShareThreePointOneFiveMember_1" xml:lang="en-US">Exercise Price Per Share 3.15.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_entx_ExercisePricePerShareThreePointOneFiveMember_2" xml:lang="en-US">Exercise Price Per Share - 3.15</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_entx_ExercisePricePerShareThreePointSixEightMember_0" xml:lang="en-US">Exercise Price Per Share Three Point Six Eight [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_entx_ExercisePricePerShareThreePointSixEightMember_1" xml:lang="en-US">Exercise Price Per Share 3.68.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_entx_ExercisePricePerShareThreePointSixEightMember_2" xml:lang="en-US">Exercise Price Per Share - 3.68</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_entx_ExercisePricePerShareThreePointSixOneMember_0" xml:lang="en-US">Exercise Price Per Share Three Point Six One [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_entx_ExercisePricePerShareThreePointSixOneMember_1" xml:lang="en-US">Exercise Price Per Share 3.61.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_entx_ExercisePricePerShareThreePointSixOneMember_2" xml:lang="en-US">Exercise Price Per Share - 3.61</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_entx_ExercisePricePerShareTwoPointEightOneFiveMember_0" xml:lang="en-US">Exercise Price Per Share Two Point Eight One Five [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_entx_ExercisePricePerShareTwoPointEightOneFiveMember_1" xml:lang="en-US">This member is stand for exercise price per 2.815</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_entx_ExercisePricePerShareTwoPointEightOneFiveMember_2" xml:lang="en-US">Exercise Price Per Share - 2.815</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_entx_ExercisePricePerShareTwoPointEightSixMember_0" xml:lang="en-US">Exercise Price Per Share Two Point Eight Six [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_entx_ExercisePricePerShareTwoPointEightSixMember_1" xml:lang="en-US">This member is stand for exercise price per 2.86.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_entx_ExercisePricePerShareTwoPointEightSixMember_2" xml:lang="en-US">Exercise Price Per Share - 2.86</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_entx_ExercisePricePerShareTwoPointFiveSevenMember_0" xml:lang="en-US">Exercise Price Per Share Two Point Five Seven [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_entx_ExercisePricePerShareTwoPointFiveSevenMember_1" xml:lang="en-US">This member is stand for exercise price per 2.57.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_entx_ExercisePricePerShareTwoPointFiveSevenMember_2" xml:lang="en-US">Exercise Price Per Share - 2.57</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_entx_ExercisePricePerShareTwoPointFiveThreeMember_0" xml:lang="en-US">Exercise Price Per Share Two Point Five Three [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_entx_ExercisePricePerShareTwoPointFiveThreeMember_1" xml:lang="en-US">Exercise Price Per Share 2.53.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_entx_ExercisePricePerShareTwoPointFiveThreeMember_2" xml:lang="en-US">Exercise Price Per Share - 2.53</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_entx_ExercisePricePerShareTwoPointOneFourMember_0" xml:lang="en-US">Exercise Price Per Share Two Point One Four [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_entx_ExercisePricePerShareTwoPointOneFourMember_1" xml:lang="en-US">Exercise Price Per Share 2.14.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_entx_ExercisePricePerShareTwoPointOneFourMember_2" xml:lang="en-US">Exercise Price Per Share - 2.14</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_entx_ExercisePricePerShareTwoPointZeroTwoMember_0" xml:lang="en-US">Exercise Price Per Share Two Point Zero Two [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_entx_ExercisePricePerShareTwoPointZeroTwoMember_1" xml:lang="en-US">This member is stand for 2.02.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_entx_ExercisePricePerShareTwoPointZeroTwoMember_2" xml:lang="en-US">Exercise Price Per Share - 2.02</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_entx_ExercisePricePerShareZeroMember_0" xml:lang="en-US">Exercise Price Per Share Zero [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_entx_ExercisePricePerShareZeroMember_1" xml:lang="en-US">No exercise price per share.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_entx_ExercisePricePerShareZeroMember_2" xml:lang="en-US">Exercise Price Per Share - Zero</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_entx_FinanceExpensesNet_0" xml:lang="en-US">Finance Expenses, Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_entx_FinanceExpensesNet_1" xml:lang="en-US">The amount of finance expenses, net.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_entx_FinanceExpensesNet_2" xml:lang="en-US">Finance expenses (income), net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_entx_FormerChiefExecutiveOfficerMember_0" xml:lang="en-US">Former Chief Executive Officer [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_entx_FormerChiefExecutiveOfficerMember_1" xml:lang="en-US">Former Chief Executive Officer.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_entx_FormerChiefExecutiveOfficerMember_2" xml:lang="en-US">Former CEO [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_entx_FundsInRespectOfEmployeeRightsUponRetirement_0" xml:lang="en-US">Funds In Respect Of Employee Rights Upon Retirement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_entx_FundsInRespectOfEmployeeRightsUponRetirement_1" xml:lang="en-US">Information about funds in respect of employee rights upon retirement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_entx_FundsInRespectOfEmployeeRightsUponRetirement_2" xml:lang="en-US">Funds in respect of employee rights upon retirement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_entx_FundsInRespectOfEmployeeRightsUponRetirement_3" xml:lang="en-US">Funds with respect to employee rights upon retirement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_entx_GeneralLineItems_0" xml:lang="en-US">General [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_entx_GeneralLineItems_1" xml:lang="en-US">Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_entx_GeneralTable_0" xml:lang="en-US">General [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_entx_GeneralTable_1" xml:lang="en-US">Disclosure of information about general information of the entity.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_entx_InvestorRelationsServicesAgreementMember_0" xml:lang="en-US">Investor Relations Services Agreement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_entx_InvestorRelationsServicesAgreementMember_1" xml:lang="en-US">Investor relations services agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_entx_InvestorRelationsServicesAgreementMember_2" xml:lang="en-US">Investor relations services agreement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_entx_IssuanceOfOrdinarySharesAndWarrantsDueToPrivatePlacementNetOfIssuanceCosts_0" xml:lang="en-US">Issuance Of Ordinary Shares And Warrants Due To Private Placement Net Of Issuance Costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_entx_IssuanceOfOrdinarySharesAndWarrantsDueToPrivatePlacementNetOfIssuanceCosts_1" xml:lang="en-US">Value of issuance of ordinary shares and warrants due to a private placement net of issuance costs.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_entx_IssuanceOfOrdinarySharesAndWarrantsDueToPrivatePlacementNetOfIssuanceCosts_2" xml:lang="en-US">Issuance of ordinary shares and warrants due to a private placement net of issuance costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_entx_IssuanceOfOrdinarySharesAndWarrantsDueToPrivatePlacementNetOfIssuanceCostsShares_0" xml:lang="en-US">Issuance Of Ordinary Shares And Warrants Due To Private Placement Net Of Issuance Costs Shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_entx_IssuanceOfOrdinarySharesAndWarrantsDueToPrivatePlacementNetOfIssuanceCostsShares_1" xml:lang="en-US">Number of ordinary shares and warrants issued due to a private placement net of issuance costs.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_entx_IssuanceOfOrdinarySharesAndWarrantsDueToPrivatePlacementNetOfIssuanceCostsShares_2" xml:lang="en-US">Issuance of ordinary shares and warrants due to a private placement net of issuance costs (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_entx_IssuanceOfSharesDueToAtMarketProgramNetOfIssuanceCostsShares_0" xml:lang="en-US">Issuance Of Shares Due To At Market Program, Net Of Issuance Costs, Shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_entx_IssuanceOfSharesDueToAtMarketProgramNetOfIssuanceCostsShares_1" xml:lang="en-US">Number of shares issuued due to the At The Market program, net of issuance costs.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_entx_IssuanceOfSharesDueToAtMarketProgramNetOfIssuanceCostsShares_2" xml:lang="en-US">Issuance of shares due to the ATM program, net of issuance costs (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_entx_IssuanceOfSharesDueToAtMarketProgramNetOfIssuanceCostsValue_0" xml:lang="en-US">Issuance Of Shares Due To At Market Program, Net Of Issuance Costs, Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_entx_IssuanceOfSharesDueToAtMarketProgramNetOfIssuanceCostsValue_1" xml:lang="en-US">Represents the issuance of shares due to at market program, net of issuance costs,.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_entx_IssuanceOfSharesDueToAtMarketProgramNetOfIssuanceCostsValue_2" xml:lang="en-US">Issuance of shares due to the ATM program, net of issuance costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_entx_JointVentureAgreementMember_0" xml:lang="en-US">Joint Venture Agreement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_entx_JointVentureAgreementMember_1" xml:lang="en-US">Represents the information regarding the joint venture agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_entx_JointVentureAgreementMember_2" xml:lang="en-US">Joint Venture Agreement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_entx_LaboratoryEquipmentMember_0" xml:lang="en-US">Laboratory Equipment [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_entx_LaboratoryEquipmentMember_1" xml:lang="en-US">Tangible personal property used in laboratory.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_entx_LaboratoryEquipmentMember_2" xml:lang="en-US">Laboratory equipment [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_entx_LeaseArrangementAxis_0" xml:lang="en-US">Lease Arrangement [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_entx_LeaseArrangementAxis_1" xml:lang="en-US">Information of lease arrangement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_entx_LeaseArrangementDomain_0" xml:lang="en-US">Lease Arrangement [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_entx_LeaseArrangementDomain_1" xml:lang="en-US">Name of the lease arrangement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_entx_LiabilityForEmployeeRightsUponRetirement_0" xml:lang="en-US">Liability For Employee Rights Upon Retirement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_entx_LiabilityForEmployeeRightsUponRetirement_1" xml:lang="en-US">Information about liability for employee rights upon retirement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_entx_LiabilityForEmployeeRightsUponRetirement_2" xml:lang="en-US">Liability for employee rights upon retirement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_entx_ManagementAndConsultingFees_0" xml:lang="en-US">Management And Consulting Fees</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_entx_ManagementAndConsultingFees_1" xml:lang="en-US">The amount of management and consulting fees.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_entx_ManagementAndConsultingFees_2" xml:lang="en-US">Management and consulting fees</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_entx_NetProceedsFromIssuanceOfCommonStock_0" xml:lang="en-US">Net Proceeds From Issuance Of Common Stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_entx_NetProceedsFromIssuanceOfCommonStock_1" xml:lang="en-US">Represents the net cash inflow from the additional capital contribution to the entity.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_entx_NetProceedsFromIssuanceOfCommonStock_2" xml:lang="en-US">Net proceeds from share issuance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_entx_NonExecutiveBoardMember_0" xml:lang="en-US">Non Executive Board [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_entx_NonExecutiveBoardMember_1" xml:lang="en-US">This member is stand for Non Executive Board.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_entx_NonExecutiveDirectorMember_0" xml:lang="en-US">Non Executive Director [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_entx_NonExecutiveDirectorMember_1" xml:lang="en-US">Non-executive director.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_entx_NonExecutiveDirectorMember_2" xml:lang="en-US">Non-executive director [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_entx_NonExecutiveDirectorsMember_0" xml:lang="en-US">Non Executive Directors [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_entx_NonExecutiveDirectorsMember_1" xml:lang="en-US">Non executive directors.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_entx_NonExecutiveDirectorsMember_2" xml:lang="en-US">Non-executive directors [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_entx_NonRefundableAndNonCreditableInitialTechnologyAccessFeePayment_0" xml:lang="en-US">Non Refundable And Non Creditable Initial Technology Access Fee Payment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_entx_NonRefundableAndNonCreditableInitialTechnologyAccessFeePayment_1" xml:lang="en-US">Represents the value of non-refundable and non-creditable initial technology access fee payment.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_entx_NonRefundableAndNonCreditableInitialTechnologyAccessFeePayment_2" xml:lang="en-US">Non-refundable and non-creditable initial technology access fee payment, including payment for the first year of preclinical services</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_entx_NonRefundableAndNonCreditableInitialTechnologyAccessFeePayment_3" xml:lang="en-US">Non-refundable and non-creditable initial technology access fee payment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_entx_NumberOfNonExecutiveBoardMembers_0" xml:lang="en-US">Number Of Non Executive Board Members</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_entx_NumberOfNonExecutiveBoardMembers_1" xml:lang="en-US">Represents the number of non executive board members.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_entx_NumberOfNonExecutiveBoardMembers_2" xml:lang="en-US">Number of non executive board members</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_entx_NumberOfSharesIssuedUnderPrivatePlacement_0" xml:lang="en-US">Number Of Shares Issued Under Private Placement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_entx_NumberOfSharesIssuedUnderPrivatePlacement_1" xml:lang="en-US">Represents the number of shares issued under private placement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_entx_NumberOfSharesIssuedUnderPrivatePlacement_2" xml:lang="en-US">Number of shares issued under private placement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_entx_OneTimeTerminationPayment_0" xml:lang="en-US">One Time Termination Payment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_entx_OneTimeTerminationPayment_1" xml:lang="en-US">Represents a lump sum payment to an involuntarily terminated employee in conjunction with exit or disposal activities.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_entx_OneTimeTerminationPayment_2" xml:lang="en-US">One-time cash termination payment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_entx_OperatingLeaseAgreementsForOfficeAndResearchAndDevelopmentSpaceMember_0" xml:lang="en-US">Operating Lease Agreements For Office And Research And Development Space [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_entx_OperatingLeaseAgreementsForOfficeAndResearchAndDevelopmentSpaceMember_1" xml:lang="en-US">Represents the operating lease agreements for office and research and development space.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_entx_OperatingLeaseAgreementsForOfficeAndResearchAndDevelopmentSpaceMember_2" xml:lang="en-US">Operating lease agreements for office and research and development space [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_entx_OperatingLeaseAgreementsForVehiclesForEmployeesMember_0" xml:lang="en-US">Operating Lease Agreements For Vehicles For Employees [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_entx_OperatingLeaseAgreementsForVehiclesForEmployeesMember_1" xml:lang="en-US">Represents the operating lease agreements for vehicles for employees.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_entx_OperatingLeaseAgreementsForVehiclesForEmployeesMember_2" xml:lang="en-US">Operating lease agreements for vehicles for employees [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_entx_OperatingLeaseLiabilityAndOperatingLeaseRightOfUseAssetTableTextBlock_0" xml:lang="en-US">Operating Lease Liability And Operating Lease Right Of Use Asset [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_entx_OperatingLeaseLiabilityAndOperatingLeaseRightOfUseAssetTableTextBlock_1" xml:lang="en-US">The tabular disclosure of operating lease liability and operating lease right of use asset.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_entx_OperatingLeaseLiabilityAndOperatingLeaseRightOfUseAssetTableTextBlock_2" xml:lang="en-US">Schedule of operating lease liability and operating lease right-of-use asset</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_entx_OperatingLeaseSupplementalCashFlowInformationTableTextBlock_0" xml:lang="en-US">Operating Lease Supplemental Cash Flow Information [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_entx_OperatingLeaseSupplementalCashFlowInformationTableTextBlock_1" xml:lang="en-US">The tabular disclosure of operating lease supplemental cash flow information.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_entx_OperatingLeaseSupplementalCashFlowInformationTableTextBlock_2" xml:lang="en-US">Schedule of operating lease cashflow information</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_entx_OramedLtdMember_0" xml:lang="en-US">Oramed Ltd [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_entx_OramedLtdMember_1" xml:lang="en-US">Represents the information regarding one of the related parties.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_entx_OramedLtdMember_2" xml:lang="en-US">Oramed Ltd [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_entx_PatentCostsPolicyTextBlock_0" xml:lang="en-US">Patent Costs [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_entx_PatentCostsPolicyTextBlock_1" xml:lang="en-US">Disclosure of accounting policy for patent costs.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_entx_PatentCostsPolicyTextBlock_2" xml:lang="en-US">Patent Costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_entx_PatentTransferAgreementMember_0" xml:lang="en-US">Patent Transfer Agreement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_entx_PatentTransferAgreementMember_1" xml:lang="en-US">Represents the information regarding the patent transfer agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_entx_PatentTransferAgreementMember_2" xml:lang="en-US">Patent Transfer Agreement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_entx_PaymentOfRoyaltyGuaranteesCommitments_0" xml:lang="en-US">Payment Of Royalty Guarantees Commitments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_entx_PaymentOfRoyaltyGuaranteesCommitments_1" xml:lang="en-US">Represents the amount paid for royalty to IIA.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_entx_PaymentOfRoyaltyGuaranteesCommitments_2" xml:lang="en-US">Royalty amount paid</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_entx_PlacementAgencyAgreementWithGpNumenkariIncMember_0" xml:lang="en-US">Placement Agency Agreement With Gp Numenkari Inc [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_entx_PlacementAgencyAgreementWithGpNumenkariIncMember_1" xml:lang="en-US">Represents the information regarding Placement Agency Agreement With Gp Numenkari Inc.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_entx_PlacementAgencyAgreementWithGpNumenkariIncMember_2" xml:lang="en-US">Placement Agency agreement with GP Numenkari Inc [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_entx_PresidentOfResearchAndDevelopmentMember_0" xml:lang="en-US">President Of Research And Development [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_entx_PresidentOfResearchAndDevelopmentMember_1" xml:lang="en-US">President Of Research And Development [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_entx_PresidentOfResearchAndDevelopmentMember_2" xml:lang="en-US">President of R&amp;D [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_entx_ProceedsFromIssuanceOfSharesAndWarrantsNetOfIssuanceCosts_0" xml:lang="en-US">Proceeds From Issuance Of Shares And Warrants, Net Of Issuance Costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_entx_ProceedsFromIssuanceOfSharesAndWarrantsNetOfIssuanceCosts_1" xml:lang="en-US">The cash inflow from issuance of shares and warrants, net of issuance costs.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_entx_ProceedsFromIssuanceOfSharesAndWarrantsNetOfIssuanceCosts_2" xml:lang="en-US">Proceeds from issuance of shares and warrants, net of issuance costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_entx_ProceedsFromIssuanceOfSharesThroughAtmProgramsNetOfIssuanceCosts_0" xml:lang="en-US">Proceeds From Issuance Of Shares Through Atm Programs, Net Of Issuance Costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_entx_ProceedsFromIssuanceOfSharesThroughAtmProgramsNetOfIssuanceCosts_1" xml:lang="en-US">The cash inflow from issuance of shares through ATM programs, net of issuance costs.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_entx_ProceedsFromIssuanceOfSharesThroughAtmProgramsNetOfIssuanceCosts_2" xml:lang="en-US">Proceeds from issuance of shares through ATM programs, net of issuance costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_entx_ProceedsFromOptionsAndWarrantExercises_0" xml:lang="en-US">Proceeds From Options And Warrant Exercises</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_entx_ProceedsFromOptionsAndWarrantExercises_1" xml:lang="en-US">The cash inflow from exercise of options and warrants into shares.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_entx_ProceedsFromOptionsAndWarrantExercises_2" xml:lang="en-US">Exercise of options and warrants into shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_entx_ProceedsFromShortTermBankDeposits_0" xml:lang="en-US">Proceeds From Short Term Bank Deposits</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_entx_ProceedsFromShortTermBankDeposits_1" xml:lang="en-US">The amount o f proceeds from short term bank deposits.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_entx_ProceedsFromShortTermBankDeposits_2" xml:lang="en-US">Payments for (Proceeds from) Short-term Investments, Total</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_entx_ProceedsFromShortTermBankDeposits_3" xml:lang="en-US">Short-term bank deposits</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_entx_ProceedsFromShortTermBankDeposits_4" xml:lang="en-US">Short-term bank deposits</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_entx_ReconciliationInAmountsOnConsolidatedBalanceSheetsAbstract_0" xml:lang="en-US">Reconciliation In Amounts On Consolidated Balance Sheets [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_entx_ReconciliationInAmountsOnConsolidatedBalanceSheetsAbstract_1" xml:lang="en-US">Reconciliation in amounts on consolidated balance sheets:</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_entx_RelatedPartyTransactionOfCompensationOfExecutiveOfficers_0" xml:lang="en-US">Related Party Transaction Of Compensation Of Executive Officers</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_entx_RelatedPartyTransactionOfCompensationOfExecutiveOfficers_1" xml:lang="en-US">It represents related party transaction of compensation of executive officers.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_entx_RelatedPartyTransactionOfCompensationOfExecutiveOfficers_2" xml:lang="en-US">Compensation of executive officers</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_entx_RelatedPartyTransactionOfManagementAndConsultingFeesToBoardMembers_0" xml:lang="en-US">Related Party Transaction Of Management And Consulting Fees To Board Members</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_entx_RelatedPartyTransactionOfManagementAndConsultingFeesToBoardMembers_1" xml:lang="en-US">It represents related party transaction of management and consulting fees to Board members.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_entx_RelatedPartyTransactionOfManagementAndConsultingFeesToBoardMembers_2" xml:lang="en-US">Management and consulting fees to Board Members</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_entx_RelatedPartyTransactionOfStockBasedCompensationExpensesToBoardMembers_0" xml:lang="en-US">Related Party Transaction Of Stock Based Compensation Expenses To Board Members</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_entx_RelatedPartyTransactionOfStockBasedCompensationExpensesToBoardMembers_1" xml:lang="en-US">It represents related party transaction of stock-based compensation expenses to board members.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_entx_RelatedPartyTransactionOfStockBasedCompensationExpensesToBoardMembers_2" xml:lang="en-US">Stock-based compensation expenses to Board Members</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_entx_RelatedPartyTransactionOfStockBasedCompensationExpensesToExecutiveOfficers_0" xml:lang="en-US">Related Party Transaction Of Stock Based Compensation Expenses To Executive Officers</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_entx_RelatedPartyTransactionOfStockBasedCompensationExpensesToExecutiveOfficers_1" xml:lang="en-US">It represents related party transaction of stock-based compensation expenses to executive officers.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_entx_RelatedPartyTransactionOfStockBasedCompensationExpensesToExecutiveOfficers_2" xml:lang="en-US">Stock-based compensation expenses to executive officers</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_entx_RelatedPartyTransactionWithExecutiveOfficersPayables_0" xml:lang="en-US">Related Party Transaction With Executive Officers Payables</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_entx_RelatedPartyTransactionWithExecutiveOfficersPayables_1" xml:lang="en-US">It represents related party transaction with executive officers payables.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_entx_RelatedPartyTransactionWithExecutiveOfficersPayables_2" xml:lang="en-US">Executive officers&#8217; payables</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_entx_RelatedPartyTransactionWithNonExecutiveDirectorsPayable_0" xml:lang="en-US">Related Party Transaction With Non Executive Directors Payable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_entx_RelatedPartyTransactionWithNonExecutiveDirectorsPayable_1" xml:lang="en-US">It represents related party transaction with non executive directors payable.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_entx_RelatedPartyTransactionWithNonExecutiveDirectorsPayable_2" xml:lang="en-US">Non-executive directors&#8217; payable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_entx_ResearchAndDevelopmentServiceExpense_0" xml:lang="en-US">Research And Development Service Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_entx_ResearchAndDevelopmentServiceExpense_1" xml:lang="en-US">It represents research and development service expense.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_entx_ResearchAndDevelopmentServiceExpense_2" xml:lang="en-US">Research and development service expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_entx_ResearchCollaborationAndLicenseAgreementMember_0" xml:lang="en-US">Research Collaboration And License Agreement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_entx_ResearchCollaborationAndLicenseAgreementMember_1" xml:lang="en-US">Represents the detail of research collaboration and license agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_entx_ResearchCollaborationAndLicenseAgreementMember_2" xml:lang="en-US">Research Collaboration And License Agreement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_entx_ReversalOfExpensesUponForfeitureOfOptions_0" xml:lang="en-US">Reversal Of Expenses Upon Forfeiture Of Options</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_entx_ReversalOfExpensesUponForfeitureOfOptions_1" xml:lang="en-US">Reversal of expenses upon forfeiture of options.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_entx_ReversalOfExpensesUponForfeitureOfOptions_2" xml:lang="en-US">Reversal of expenses upon forfeiture of options</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_entx_RightOfUseAssetsObtainedInExchangeForNewOperatingLeaseLiabilities_0" xml:lang="en-US">Right Of Use Assets Obtained In Exchange For New Operating Lease Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_entx_RightOfUseAssetsObtainedInExchangeForNewOperatingLeaseLiabilities_1" xml:lang="en-US">Amount of right of use assets obtained in exchange for new operating lease liabilities.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_entx_RightOfUseAssetsObtainedInExchangeForNewOperatingLeaseLiabilities_2" xml:lang="en-US">Operating lease right of use assets obtained in exchange for new operating lease liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_entx_RightToUseIntellectualProperty_0" xml:lang="en-US">Right To Use Intellectual Property</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_entx_RightToUseIntellectualProperty_1" xml:lang="en-US">Represents the value of right to use the intellectual property.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_entx_RightToUseIntellectualProperty_2" xml:lang="en-US">Right to use intellectual property</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_entx_RoyaltyGuaranteesCommitmentsPercentageOfEachPaymentReceivedFromAmgen_0" xml:lang="en-US">Royalty Guarantees Commitments Percentage Of Each Payment Received From Amgen</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_entx_RoyaltyGuaranteesCommitmentsPercentageOfEachPaymentReceivedFromAmgen_1" xml:lang="en-US">Represents the percentage of each payment received from Amgen.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_entx_RoyaltyGuaranteesCommitmentsPercentageOfEachPaymentReceivedFromAmgen_2" xml:lang="en-US">Percentage of each payment received from Amgen</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_entx_RoyaltyGuaranteesCommitmentsPercentageOfNetRevenues_0" xml:lang="en-US">Royalty Guarantees Commitments Percentage Of Net Revenues</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_entx_RoyaltyGuaranteesCommitmentsPercentageOfNetRevenues_1" xml:lang="en-US">Represents the percentage of net revenues.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_entx_RoyaltyGuaranteesCommitmentsPercentageOfNetRevenues_2" xml:lang="en-US">Percentage of net revenues</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_entx_RoyaltyGuaranteesCommitmentsPercentageSalesOfProductsDevelopedFromProjectsCommencingSeventhYear_0" xml:lang="en-US">Royalty Guarantees Commitments Percentage Sales Of Products Developed From Projects Commencing Seventh Year</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_entx_RoyaltyGuaranteesCommitmentsPercentageSalesOfProductsDevelopedFromProjectsCommencingSeventhYear_1" xml:lang="en-US">Represents the percentage sales of products developed from projects commencing the seventh year.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_entx_RoyaltyGuaranteesCommitmentsPercentageSalesOfProductsDevelopedFromProjectsCommencingSeventhYear_2" xml:lang="en-US">Percentage sales of products developed from projects commencing the seventh year up to 100% of amount of grant received</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_entx_RoyaltyGuaranteesCommitmentsPercentageSalesOfProductsDevelopedFromProjectsInFirstThreeYearsFromCommencementOfRevenues_0" xml:lang="en-US">Royalty Guarantees Commitments Percentage Sales Of Products Developed From Projects In First Three Years, From Commencement Of Revenues</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_entx_RoyaltyGuaranteesCommitmentsPercentageSalesOfProductsDevelopedFromProjectsInFirstThreeYearsFromCommencementOfRevenues_1" xml:lang="en-US">Represents the percentage sales of products developed from projects in first three years, from commencement of revenues.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_entx_RoyaltyGuaranteesCommitmentsPercentageSalesOfProductsDevelopedFromProjectsInFirstThreeYearsFromCommencementOfRevenues_2" xml:lang="en-US">Percentage sales of products developed from projects in first three years, from commencement of revenues</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_entx_RoyaltyGuaranteesCommitmentsPercentageSalesOfProductsDevelopedFromProjectsSubsequentThreeYears_0" xml:lang="en-US">Royalty Guarantees Commitments Percentage Sales Of Products Developed From Projects Subsequent Three Years</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_entx_RoyaltyGuaranteesCommitmentsPercentageSalesOfProductsDevelopedFromProjectsSubsequentThreeYears_1" xml:lang="en-US">Represents the percentage sales of products developed from projects subsequent three years.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_entx_RoyaltyGuaranteesCommitmentsPercentageSalesOfProductsDevelopedFromProjectsSubsequentThreeYears_2" xml:lang="en-US">Percentage sales of products developed from projects subsequent three years</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_entx_SaleOfStockAmountOfInvestment_0" xml:lang="en-US">Sale Of Stock, Amount Of Investment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_entx_SaleOfStockAmountOfInvestment_1" xml:lang="en-US">Represents the amount invested in the entity.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_entx_SaleOfStockAmountOfInvestment_2" xml:lang="en-US">Amount of investment in entity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_entx_SaleOfStockPercentageOfOwnershipOfEntityAcquired_0" xml:lang="en-US">Sale Of Stock, Percentage Of Ownership Of Entity Acquired</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_entx_SaleOfStockPercentageOfOwnershipOfEntityAcquired_1" xml:lang="en-US">Represents the percentage of ownership of entity acquired.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_entx_SaleOfStockPercentageOfOwnershipOfEntityAcquired_2" xml:lang="en-US">Percentage of ownership of entity acquired</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_entx_ScheduleOfEstimatedUsefulLifeTableTextBlock_0" xml:lang="en-US">Schedule Of Estimated Useful Life [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_entx_ScheduleOfEstimatedUsefulLifeTableTextBlock_1" xml:lang="en-US">Tabular disclosure of the estimated useful life used to calculate depreciation of assets.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_entx_ScheduleOfEstimatedUsefulLifeTableTextBlock_2" xml:lang="en-US">Schedule of estimated useful life</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_entx_ScheduleOfRelatedPartyTransactionReportedInConsolidatedStatementsOfComprehensiveLossTableTextBlock_0" xml:lang="en-US">Schedule Of Related Party Transaction Reported In Consolidated Statements Of Comprehensive Loss [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_entx_ScheduleOfRelatedPartyTransactionReportedInConsolidatedStatementsOfComprehensiveLossTableTextBlock_1" xml:lang="en-US">Tabular disclosure of related party transaction reported in consolidated statements of comprehensive loss.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_entx_ScheduleOfRelatedPartyTransactionReportedInConsolidatedStatementsOfComprehensiveLossTableTextBlock_2" xml:lang="en-US">Schedule of related parties of consolidated statements of comprehensive loss</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_entx_ScheduleOfRelatedPartyTransactionsReportedInConsolidatedBalanceSheetsTableTextBlock_0" xml:lang="en-US">Schedule Of Related Party Transactions Reported In Consolidated Balance Sheets [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_entx_ScheduleOfRelatedPartyTransactionsReportedInConsolidatedBalanceSheetsTableTextBlock_1" xml:lang="en-US">Tabular disclosure of related party transactions reported in consolidated balance sheets.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_entx_ScheduleOfRelatedPartyTransactionsReportedInConsolidatedBalanceSheetsTableTextBlock_2" xml:lang="en-US">Schedule of related party transaction of consolidated balance sheets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_entx_SellingPriceOfPreclinicalResearchAndDevelopmentServices_0" xml:lang="en-US">Selling Price Of Preclinical Research And Development Services</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_entx_SellingPriceOfPreclinicalResearchAndDevelopmentServices_1" xml:lang="en-US">Selling price of preclinical Research and Development services.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_entx_SellingPriceOfPreclinicalResearchAndDevelopmentServices_2" xml:lang="en-US">Selling price of preclinical R&amp;D services</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_entx_ServiceProviderMember_0" xml:lang="en-US">Service Provider [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_entx_ServiceProviderMember_1" xml:lang="en-US">Information of service provider.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_entx_ServiceProviderMember_2" xml:lang="en-US">Service Provider [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_entx_SeveralEmployeesAndServiceProvidersMember_0" xml:lang="en-US">Several Employees And Service Providers [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_entx_SeveralEmployeesAndServiceProvidersMember_1" xml:lang="en-US">Represents the information regarding two related parties.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_entx_SeveralEmployeesAndServiceProvidersMember_2" xml:lang="en-US">Several employees and service providers [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_entx_SeveranceExpenses_0" xml:lang="en-US">Severance Expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_entx_SeveranceExpenses_1" xml:lang="en-US">It represents severance expenses.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_entx_SeveranceExpenses_2" xml:lang="en-US">Severance expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_entx_SeverancePayPolicyTextBlock_0" xml:lang="en-US">Severance Pay [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_entx_SeverancePayPolicyTextBlock_1" xml:lang="en-US">Disclosure of accounting policy for severance pay.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_entx_SeverancePayPolicyTextBlock_2" xml:lang="en-US">Severance pay</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_entx_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsTotalConsideration_0" xml:lang="en-US">Share Based Compensation Arrangements By Share Based Payment Award Options Total Consideration</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_entx_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsTotalConsideration_1" xml:lang="en-US">Represents the amount of share based compensation arrangements by share based payment award options total consideration.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_entx_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsTotalConsideration_2" xml:lang="en-US">Total Consideration</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_entx_ShareBasedPaymentArrangementTrancheFiveMember_0" xml:lang="en-US">Share Based Payment Arrangement Tranche Five [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_entx_ShareBasedPaymentArrangementTrancheFiveMember_1" xml:lang="en-US">Fifth portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_entx_ShareBasedPaymentArrangementTrancheFiveMember_2" xml:lang="en-US">Vest over twelve equal quarterly instalments starting on January 1, 2022 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_entx_ShareBasedPaymentArrangementTrancheFourMember_0" xml:lang="en-US">Share Based Payment Arrangement Tranche Four [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_entx_ShareBasedPaymentArrangementTrancheFourMember_1" xml:lang="en-US">Forth portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_entx_ShareBasedPaymentArrangementTrancheFourMember_2" xml:lang="en-US">Vest in three equal installments until January 8, 2021 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_entx_ShareBasedPaymentArrangementTrancheSevenMember_0" xml:lang="en-US">Share Based Payment Arrangement Tranche Seven [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_entx_ShareBasedPaymentArrangementTrancheSevenMember_1" xml:lang="en-US">Seventh portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_entx_ShareBasedPaymentArrangementTrancheSixMember_0" xml:lang="en-US">Share Based Payment Arrangement Tranche Six [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_entx_ShareBasedPaymentArrangementTrancheSixMember_1" xml:lang="en-US">Sixth portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_entx_ShareBasedPaymentArrangementTrancheSixMember_2" xml:lang="en-US">Vest over four equal quarterly instalments starting on January 1, 2022 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_entx_ShareIncentivePlan2013Member_0" xml:lang="en-US">Share Incentive Plan 2013 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_entx_ShareIncentivePlan2013Member_1" xml:lang="en-US">Share Incentive Plan 2013.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_entx_ShareIncentivePlan2013Member_2" xml:lang="en-US">2013 Plan [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_entx_ShareIncentivePlan2018Member_0" xml:lang="en-US">Share Incentive Plan 2018 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_entx_ShareIncentivePlan2018Member_1" xml:lang="en-US">Share Incentive Plan 2018.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_entx_ShareIncentivePlan2018Member_2" xml:lang="en-US">2018 Plan [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_entx_SharesGrantedInPercentage_0" xml:lang="en-US">Shares Granted In Percentage</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_entx_SharesGrantedInPercentage_1" xml:lang="en-US">Represents the percentage of he number of shares issued to subscribers invested through the Broker.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_entx_SharesGrantedInPercentage_2" xml:lang="en-US">Shares granted in percentage</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_entx_SharesIssuedWeightedAveragePricePerShare_0" xml:lang="en-US">Shares Issued Weighted Average Price Per Share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_entx_SharesIssuedWeightedAveragePricePerShare_1" xml:lang="en-US">Represents the weighted average price per share or per unit of equity securities issued.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_entx_SharesIssuedWeightedAveragePricePerShare_2" xml:lang="en-US">Weighted average price of share issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_entx_SignificantAccountingPoliciesLineItems_0" xml:lang="en-US">Significant Accounting Policies [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_entx_SignificantAccountingPoliciesLineItems_1" xml:lang="en-US">Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_entx_SignificantAccountingPoliciesTable_0" xml:lang="en-US">Significant Accounting Policies [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_entx_SignificantAccountingPoliciesTable_1" xml:lang="en-US">This table may contain information related to significant accounting policies.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_entx_StockholdersEquityNoteLineItems_0" xml:lang="en-US">Stockholders Equity Note [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_entx_StockholdersEquityNoteLineItems_1" xml:lang="en-US">Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_entx_StockholdersEquityNoteTable_0" xml:lang="en-US">Stockholders Equity Note [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_entx_StockholdersEquityNoteTable_1" xml:lang="en-US">Schedule of information regarding the share capital of the entity.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_entx_SupplementaryFinancialStatementInformationAbstract_0" xml:lang="en-US">Supplementary Financial Statement Information [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_entx_SupplementaryFinancialStatementInformationTextBlock_0" xml:lang="en-US">Supplementary Financial Statement Information [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_entx_SupplementaryFinancialStatementInformationTextBlock_1" xml:lang="en-US">The entire disclosure for supplementary financial statement information.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_entx_SupplementaryFinancialStatementInformationTextBlock_2" xml:lang="en-US">SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_entx_TransactionCosts_0" xml:lang="en-US">Transaction Costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_entx_TransactionCosts_1" xml:lang="en-US">It represents transaction costs.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_entx_TransactionCosts_2" xml:lang="en-US">Transaction costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_entx_TriggeringEventAxis_0" xml:lang="en-US">Triggering Event [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_entx_TriggeringEventAxis_1" xml:lang="en-US">Information by triggering event of options under share-based payment arrangement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_entx_TriggeringEventDomain_0" xml:lang="en-US">Triggering Event [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_entx_TriggeringEventDomain_1" xml:lang="en-US">Triggering event of options under share-based payment arrangement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_entx_TriggeringEventMember_0" xml:lang="en-US">Triggering Event [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_entx_TriggeringEventMember_1" xml:lang="en-US">Represents the information of triggering event.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_entx_TriggeringEventMember_2" xml:lang="en-US">Triggering event [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_entx_TwentySeventeenMemberMember_0" xml:lang="en-US">Twenty Seventeen Member [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_entx_TwentySeventeenMemberMember_1" xml:lang="en-US">Twenty Seventeen Member [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_entx_TwentySeventeenMemberMember_2" xml:lang="en-US">2017 Grant [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_entx_TwentyTwentyOneGrantMember_0" xml:lang="en-US">Twenty Twenty One Grant [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_entx_TwentyTwentyOneGrantMember_1" xml:lang="en-US">Twenty Twenty One Grant [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_entx_TwentyTwentyOneGrantMember_2" xml:lang="en-US">2021 Grant [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_entx_VestedRestrictedSharesUnits_0" xml:lang="en-US">Vested Restricted Shares Units</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_entx_VestedRestrictedSharesUnits_1" xml:lang="en-US">Value of vested restricted shares units in noncash transactions.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_entx_VestedRestrictedSharesUnits_2" xml:lang="en-US">Vested restricted shares units</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_entx_VestedRestrictedShareUnitsShares_0" xml:lang="en-US">Vested Restricted Share Units Shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_entx_VestedRestrictedShareUnitsShares_1" xml:lang="en-US">Number of shares vested restricted share units.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_entx_VestedRestrictedShareUnitsShares_2" xml:lang="en-US">Vested restricted share units (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_entx_WarrantToPurchaseOrdinaryShare_0" xml:lang="en-US">Warrant To Purchase Ordinary Share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_entx_WarrantToPurchaseOrdinaryShare_1" xml:lang="en-US">It represents warrant to purchase ordinary share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_entx_WarrantToPurchaseOrdinaryShare_2" xml:lang="en-US">Warrant to purchase ordinary share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_ChiefExecutiveOfficerMember_0" xml:lang="en-US">Chief Executive Officer [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_srt_ChiefExecutiveOfficerMember_1" xml:lang="en-US">Chief Executive Officer [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_srt_ChiefExecutiveOfficerMember_2" xml:lang="en-US">New CEO [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_ChiefFinancialOfficerMember_0" xml:lang="en-US">Chief Financial Officer [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_ConsolidatedEntitiesAxis_0" xml:lang="en-US">Consolidated Entities [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_ConsolidatedEntitiesDomain_0" xml:lang="en-US">Consolidated Entities [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_DirectorMember_0" xml:lang="en-US">Director [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_srt_DirectorMember_1" xml:lang="en-US">Director [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_ExecutiveOfficerMember_0" xml:lang="en-US">Executive Officer [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_srt_ExecutiveOfficerMember_1" xml:lang="en-US">Executive Officer [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_srt_ExecutiveOfficerMember_2" xml:lang="en-US">Executive officers [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_MaximumMember_0" xml:lang="en-US">Maximum [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_srt_MaximumMember_1" xml:lang="en-US">Maximum [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_MinimumMember_0" xml:lang="en-US">Minimum [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_srt_MinimumMember_1" xml:lang="en-US">Minimum [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_ProductOrServiceAxis_0" xml:lang="en-US">Product and Service [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_ProductsAndServicesDomain_0" xml:lang="en-US">Product and Service [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_RangeAxis_0" xml:lang="en-US">Statistical Measurement [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_RangeMember_0" xml:lang="en-US">Statistical Measurement [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_SubsidiariesMember_0" xml:lang="en-US">Subsidiaries [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_srt_SubsidiariesMember_1" xml:lang="en-US">Entera Bio Inc</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_srt_SubsidiariesMember_2" xml:lang="en-US">Subsidiary</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_TitleOfIndividualAxis_0" xml:lang="en-US">Title of Individual [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain_0" xml:lang="en-US">Title of Individual [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccountingPoliciesAbstract_0" xml:lang="en-US">Accounting Policies [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis_0" xml:lang="en-US">Legal Entity of Counterparty, Type [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_0" xml:lang="en-US">Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Current [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_1" xml:lang="en-US">Schedule of accounts payable - other</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_0" xml:lang="en-US">Accounts Payable and Accrued Liabilities, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_1" xml:lang="en-US">Total Accounts payable and Accrued expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_0" xml:lang="en-US">Accounts Payable and Accrued Liabilities, Current [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_1" xml:lang="en-US">Accounts payable - other:</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_2" xml:lang="en-US">Accrued expenses and other payables:</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_0" xml:lang="en-US">Accounts Payable and Other Accrued Liabilities, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_1" xml:lang="en-US">Accrued expenses and other</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccountsPayableCurrent_0" xml:lang="en-US">Accounts Payable, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AccountsPayableCurrent_1" xml:lang="en-US">Accounts payable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent_0" xml:lang="en-US">Accounts receivable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent_1" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccruedEmployeeBenefitsCurrent_0" xml:lang="en-US">Employees and employees related</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AccruedEmployeeBenefitsCurrent_1" xml:lang="en-US">Employees and employees related</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccruedIncomeTaxesCurrent_0" xml:lang="en-US">Income tax</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AccruedIncomeTaxesCurrent_1" xml:lang="en-US">Income tax</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccruedLiabilitiesAndOtherLiabilities_0" xml:lang="en-US">Accrued Liabilities and Other Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_AccruedLiabilitiesAndOtherLiabilities_1" xml:lang="en-US">Accrued expenses and other payables, total</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AccruedLiabilitiesAndOtherLiabilities_2" xml:lang="en-US">Accrued expenses and other payables</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_AccruedLiabilitiesAndOtherLiabilities_3" xml:lang="en-US">Accrued expenses and other payables</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent_0" xml:lang="en-US">Accrued Liabilities, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent_1" xml:lang="en-US">Accrued liabilities and other</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccruedVacationCurrent_0" xml:lang="en-US">Accrued Vacation, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AccruedVacationCurrent_1" xml:lang="en-US">Provision for vacation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_0" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_1" xml:lang="en-US">Accumulated other comprehensive income</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_0" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_1" xml:lang="en-US">Accumulated other Comprehensive income [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AdditionalFinancialInformationDisclosureTextBlock_0" xml:lang="en-US">Additional Financial Information Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AdditionalFinancialInformationDisclosureTextBlock_1" xml:lang="en-US">SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock_0" xml:lang="en-US">Additional paid-in capital</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock_1" xml:lang="en-US">Additional Paid in Capital, Common Stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember_0" xml:lang="en-US">Additional Paid-in Capital [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember_1" xml:lang="en-US">Additional paid-in capital [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalOther_0" xml:lang="en-US">Adjustments to Additional Paid in Capital, Other</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalOther_1" xml:lang="en-US">Amount transferred from Other Reserves to Additional paid in Capital</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_0" xml:lang="en-US">APIC, Share-based Payment Arrangement, Increase for Cost Recognition</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_1" xml:lang="en-US">Share-based compensation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition_0" xml:lang="en-US">APIC, Share-based Payment Arrangement, Restricted Stock Unit, Increase for Cost Recognition</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition_1" xml:lang="en-US">Vested restricted share units</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_0" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_1" xml:lang="en-US">Adjustments required to reconcile net loss to net cash used in operating activities:</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense_0" xml:lang="en-US">Share-based Payment Arrangement, Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense_1" xml:lang="en-US">Stock-based compensation expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense_2" xml:lang="en-US">Share-based compensation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_0" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_1" xml:lang="en-US">Number of antidilutive securities excluded from computation of earnings per share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_0" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_Assets_0" xml:lang="en-US">TOTAL ASSETS</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_Assets_1" xml:lang="en-US">Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AssetsAbstract_0" xml:lang="en-US">Assets [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AssetsAbstract_1" xml:lang="en-US">ASSETS</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_AssetsCurrent_0" xml:lang="en-US">TOTAL CURRENT ASSETS</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AssetsCurrent_1" xml:lang="en-US">Assets, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AssetsCurrentAbstract_0" xml:lang="en-US">CURRENT ASSETS:</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_AssetsNoncurrent_0" xml:lang="en-US">TOTAL NON-CURRENT ASSETS</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AssetsNoncurrent_1" xml:lang="en-US">Assets, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AssetsNoncurrentAbstract_0" xml:lang="en-US">NON-CURRENT ASSETS:</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AwardTypeAxis_0" xml:lang="en-US">Award Type [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_0" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_1" xml:lang="en-US">Basis of presentation of the financial statements</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_0" xml:lang="en-US">Cash and cash equivalents</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_1" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_2" xml:lang="en-US">Cash and cash equivalents</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_0" xml:lang="en-US">Cash and Cash Equivalents, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_1" xml:lang="en-US">Cash and cash equivalents</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_0" xml:lang="en-US">Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_1" xml:lang="en-US">Restricted cash</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_0" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_1" xml:lang="en-US">CASH, CASH EQUIVALENTS AND RESTRICTED DEPOSITS AT BEGINNING OF THE YEAR</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2" xml:lang="en-US">CASH, CASH EQUIVALENTS AND RESTRICTED DEPOSITS AT END OF THE YEAR</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_3" xml:lang="en-US">Total cash and cash equivalents and restricted deposits</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_0" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_1" xml:lang="en-US">INCREASE (DECREASE) IN CASH, CASH EQUIVALENTS AND RESTRICTED DEPOSITS</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ClassOfStockDomain_0" xml:lang="en-US">Class of Stock [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ClassOfWarrantOrRightAxis_0" xml:lang="en-US">Class of Warrant or Right [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ClassOfWarrantOrRightDomain_0" xml:lang="en-US">Class of Warrant or Right [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_0" xml:lang="en-US">Class of Warrant or Right, Exercise Price of Warrants or Rights</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_1" xml:lang="en-US">Exercise price of warrants issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_0" xml:lang="en-US">Class of Warrant or Right, Number of Securities Called by Warrants or Rights</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_1" xml:lang="en-US">Number of ordinary shares called by warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommitmentsAndContingencies_0" xml:lang="en-US">Commitments and Contingencies</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CommitmentsAndContingencies_1" xml:lang="en-US">COMMITMENTS AND CONTINGENCIES</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_0" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_0" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_1" xml:lang="en-US">COMMITMENTS AND CONTINGENCIES</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommitmentsAndContingenciesPolicyTextBlock_0" xml:lang="en-US">Commitments and Contingencies, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_CommitmentsAndContingenciesPolicyTextBlock_1" xml:lang="en-US">Legal and other contingencies</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockMember_0" xml:lang="en-US">Common Stock [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CommonStockMember_1" xml:lang="en-US">Ordinary shares [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare_0" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare_1" xml:lang="en-US">Ordinary share, par value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockSharesAuthorized_0" xml:lang="en-US">Common Stock, Shares Authorized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CommonStockSharesAuthorized_1" xml:lang="en-US">Ordinary shares, authorized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockSharesIssued_0" xml:lang="en-US">Common Stock, Shares, Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CommonStockSharesIssued_1" xml:lang="en-US">Ordinary shares, issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockSharesOutstanding_0" xml:lang="en-US">Common Stock, Shares, Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CommonStockSharesOutstanding_1" xml:lang="en-US">Ordinary shares, outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockValue_0" xml:lang="en-US">Common Stock, Value, Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_CommonStockValue_1" xml:lang="en-US">Value of shares issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_CommonStockValue_2" xml:lang="en-US">Common Stock, Value, Issued, Total</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_CommonStockValue_3" xml:lang="en-US">Common Stock, Value, Issued, Beginning Balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_CommonStockValue_4" xml:lang="en-US">Common Stock, Value, Issued, Ending Balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CommonStockValue_5" xml:lang="en-US">Ordinary Shares, NIS 0.0000769 par value: Authorized - as of December 31, 2022 and December 31, 2021, 140,010,000 shares; issued and outstanding as of December 31, 2022, and December 31, 2021 28,809,922 and 28,804,411 shares, respectively</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockValueOutstanding_0" xml:lang="en-US">Common Stock, Value, Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CommonStockValueOutstanding_1" xml:lang="en-US">Ordinary Shares, NIS 0.0000769 par value: Authorized - as of December 31, 2021 and December 31, 2020, 140,010,000 shares; issued and outstanding: as of December 31, 2021, and December 31, 2020 28,804,411 and 21,057,922 shares, respectively</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockVotingRights_0" xml:lang="en-US">Common Stock, Voting Rights</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_CommonStockVotingRights_1" xml:lang="en-US">Voting rights of ordinary share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CompensationExpenseExcludingCostOfGoodAndServiceSold_0" xml:lang="en-US">Compensation Expense, Excluding Cost of Good and Service Sold</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_CompensationExpenseExcludingCostOfGoodAndServiceSold_1" xml:lang="en-US">Compensation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ComputerEquipmentMember_0" xml:lang="en-US">Computer Equipment [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ComputerEquipmentMember_1" xml:lang="en-US">Computer equipment [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk_0" xml:lang="en-US">Concentration Risk, Credit Risk, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk_1" xml:lang="en-US">Concentrations of credit risk</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock_0" xml:lang="en-US">Consolidation, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock_1" xml:lang="en-US">Principles of consolidation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ContractWithCustomerLiability_0" xml:lang="en-US">Contract with Customer, Liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ContractWithCustomerLiability_1" xml:lang="en-US">Contract liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent_0" xml:lang="en-US">Contract with Customer, Liability, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent_1" xml:lang="en-US">Other Liabilities, Current, Total</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent_2" xml:lang="en-US">Contract liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_0" xml:lang="en-US">Contract with Customer, Liability, Revenue Recognized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_1" xml:lang="en-US">Milestone payments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CostOfRevenue_0" xml:lang="en-US">Cost of Revenue</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CostOfRevenue_1" xml:lang="en-US">COST OF REVENUES</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CostOfSalesMember_0" xml:lang="en-US">Cost of Sales [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CostOfSalesMember_1" xml:lang="en-US">Cost of revenues</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract_0" xml:lang="en-US">Current Federal, State and Local, Tax Expense (Benefit) [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract_1" xml:lang="en-US">Current:</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefit_0" xml:lang="en-US">Current Income Tax Expense (Benefit)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefit_1" xml:lang="en-US">Total current income tax</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit_0" xml:lang="en-US">Deferred Federal, State and Local, Tax Expense (Benefit)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit_1" xml:lang="en-US">Deferred income taxes</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit_2" xml:lang="en-US">Losses and benefits for tax purposes for the year, for which deferred taxes were recorded</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract_0" xml:lang="en-US">Deferred Federal, State and Local, Tax Expense (Benefit) [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract_1" xml:lang="en-US">Deferred:</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredIncomeTaxAssetsNet_0" xml:lang="en-US">Deferred Income Tax Assets, Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DeferredIncomeTaxAssetsNet_1" xml:lang="en-US">Deferred income taxes</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_0" xml:lang="en-US">Deferred Income Tax Expense (Benefit)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_1" xml:lang="en-US">Deferred income taxes</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_2" xml:lang="en-US">Total deferred income taxes</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_3" xml:lang="en-US">Total deferred income tax</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredRevenueRevenueRecognized1_0" xml:lang="en-US">Deferred Revenue, Revenue Recognized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DeferredRevenueRevenueRecognized1_1" xml:lang="en-US">Revenues recorded in revenue recognition</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredTaxAssetsGross_0" xml:lang="en-US">Deferred Tax Assets, Gross</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_DeferredTaxAssetsGross_1" xml:lang="en-US">Net deferred tax assets before valuation allowance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_0" xml:lang="en-US">Deferred Tax Assets, in Process Research and Development</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_1" xml:lang="en-US">Research and development</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredTaxAssetsNet_0" xml:lang="en-US">Deferred Tax Assets, Net of Valuation Allowance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_DeferredTaxAssetsNet_1" xml:lang="en-US">Net deferred tax assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DeferredTaxAssetsNet_2" xml:lang="en-US">Net deferred tax assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract_0" xml:lang="en-US">Deferred Tax Assets, Net of Valuation Allowance [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract_1" xml:lang="en-US">Deferred tax assets:</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_0" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_1" xml:lang="en-US">Net operating loss carry forward</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredTaxAssetsOther_0" xml:lang="en-US">Deferred Tax Assets, Other</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_DeferredTaxAssetsOther_1" xml:lang="en-US">Other</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_0" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_1" xml:lang="en-US">Share-based compensation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance_0" xml:lang="en-US">Deferred Tax Assets, Valuation Allowance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance_1" xml:lang="en-US">Less - valuation allowance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance_2" xml:lang="en-US">Opening balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance_3" xml:lang="en-US">Closing balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance_4" xml:lang="en-US">Less - valuation allowance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance_5" xml:lang="en-US">valuation allowance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance_6" xml:lang="en-US">valuation allowance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent_0" xml:lang="en-US">Assets for Plan Benefits, Defined Benefit Plan</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent_1" xml:lang="en-US">Funds in respect of employee rights upon retirement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_Depreciation_0" xml:lang="en-US">Depreciation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_Depreciation_1" xml:lang="en-US">Depreciation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DerivativesPolicyTextBlock_0" xml:lang="en-US">Derivatives, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_DerivativesPolicyTextBlock_1" xml:lang="en-US">Derivatives</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DescriptionOfPostemploymentBenefits_0" xml:lang="en-US">Description of Postemployment Benefits</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DescriptionOfPostemploymentBenefits_1" xml:lang="en-US">Description of mutual separation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DisaggregationOfRevenueLineItems_0" xml:lang="en-US">Disaggregation of Revenue [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DisaggregationOfRevenueTable_0" xml:lang="en-US">Disaggregation of Revenue [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0" xml:lang="en-US">Share-based Payment Arrangement [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_0" xml:lang="en-US">Share-based Payment Arrangement [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_1" xml:lang="en-US">SHARE-BASED COMPENSATION</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DomesticCountryMember_0" xml:lang="en-US">Domestic Tax Authority [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_DomesticCountryMember_1" xml:lang="en-US">Israeli tax rate [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent_0" xml:lang="en-US">Due to Related Parties</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EarningsPerShareBasic_0" xml:lang="en-US">Earnings Per Share, Basic and Diluted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EarningsPerShareBasic_1" xml:lang="en-US">LOSS PER SHARE BASIC</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EarningsPerShareDiluted_0" xml:lang="en-US">Earnings Per Share, Diluted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_EarningsPerShareDiluted_1" xml:lang="en-US">LOSS PER SHARE DILUTED</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock_0" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock_1" xml:lang="en-US">Loss per share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_0" xml:lang="en-US">Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_1" xml:lang="en-US">Income tax rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_2" xml:lang="en-US">Statutory tax rate of Entera Bio Ltd.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_0" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EquityComponentDomain_0" xml:lang="en-US">Equity Component [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ExtraordinaryAndUnusualItemsAbstract_0" xml:lang="en-US">Unusual or Infrequent Items, or Both [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_0" xml:lang="en-US">Fair Value Measurement, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_1" xml:lang="en-US">Fair value measurement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_0" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_0" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ForeignCountryMember_0" xml:lang="en-US">Foreign Tax Authority [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ForeignCountryMember_1" xml:lang="en-US">U.S. tax rate [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_0" xml:lang="en-US">Foreign Currency Transactions and Translations Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_1" xml:lang="en-US">Functional currency</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense_0" xml:lang="en-US">General and Administrative Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense_1" xml:lang="en-US">General and administrative</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense_2" xml:lang="en-US">General and administrative expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember_0" xml:lang="en-US">General and Administrative Expense [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember_1" xml:lang="en-US">General and administrative</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_GovernmentMember_0" xml:lang="en-US">Government [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_GovernmentMember_1" xml:lang="en-US">Government of Israel [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_GrossProfit_0" xml:lang="en-US">Gross Profit</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_GrossProfit_1" xml:lang="en-US">GROSS PROFIT</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_0" xml:lang="en-US">Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_1" xml:lang="en-US">Impairment of long-lived assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_0" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_1" xml:lang="en-US">LOSS BEFORE INCOME TAX</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/positiveLabel" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_2" xml:lang="en-US">Net loss for the year</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_3" xml:lang="en-US">Comprehensive loss</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_4" xml:lang="en-US">LOSS BEFORE INCOME TAX</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_5" xml:lang="en-US">Loss (income) before income taxes</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/positiveVerboseLabel" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_6" xml:lang="en-US">Loss before income taxes</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_7" xml:lang="en-US">Loss before income taxes</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_8" xml:lang="en-US">Loss (income) before income taxes</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_0" xml:lang="en-US">Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_1" xml:lang="en-US">LOSS FOR THE YEAR</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_2" xml:lang="en-US">LOSS FOR THE YEAR</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeLossFromSubsidiariesNetOfTax_0" xml:lang="en-US">Income (Loss) from Subsidiaries, Net of Tax</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_IncomeLossFromSubsidiariesNetOfTax_1" xml:lang="en-US">Different tax rate in subsidiary operating outside of Israel</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_IncomeLossFromSubsidiariesNetOfTax_2" xml:lang="en-US">Different tax rate in subsidiary operating outside of Israel</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeStatementAbstract_0" xml:lang="en-US">Income Statement [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeStatementLocationAxis_0" xml:lang="en-US">Income Statement Location [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeStatementLocationDomain_0" xml:lang="en-US">Income Statement Location [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis_0" xml:lang="en-US">Income Tax Authority [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain_0" xml:lang="en-US">Income Tax Authority [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract_0" xml:lang="en-US">Income Tax Disclosure [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract_1" xml:lang="en-US">Rollforward of valuation allowance:</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock_0" xml:lang="en-US">Income Tax Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock_1" xml:lang="en-US">INCOME TAX</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxesPaidNet_0" xml:lang="en-US">Income Taxes Paid, Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncomeTaxesPaidNet_1" xml:lang="en-US">Income taxes paid in cash during the year</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit_0" xml:lang="en-US">Income Tax Expense (Benefit)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit_1" xml:lang="en-US">INCOME TAX EXPENSE (BENEFIT)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit_2" xml:lang="en-US">TAXES ON INCOME</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit_3" xml:lang="en-US">Total income tax expense (benefit)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit_4" xml:lang="en-US">Actual income tax (benefit) expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/positiveTerseLabel" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit_5" xml:lang="en-US">Actual income tax (benefit) expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock_0" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock_1" xml:lang="en-US">Income taxes</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_0" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_1" xml:lang="en-US">Additions</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_2" xml:lang="en-US">Net change in valuation allowance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_3" xml:lang="en-US">Net change in valuation allowance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseAmortization_0" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Amortization, Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseAmortization_1" xml:lang="en-US">Non-deductible expenses and other permanent differences</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxReconciliationTaxExemptIncome_0" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Exempt Income, Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_IncomeTaxReconciliationTaxExemptIncome_1" xml:lang="en-US">Computed &#8220;expected&#8221; tax benefit</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_IncomeTaxReconciliationTaxExemptIncome_2" xml:lang="en-US">Computed &#8220;expected&#8221; tax benefit</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable_0" xml:lang="en-US">Increase (Decrease) in Accounts Payable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable_1" xml:lang="en-US">Increase (decrease) in accounts payable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_0" xml:lang="en-US">Increase (Decrease) in Accounts Payable and Accrued Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_1" xml:lang="en-US">Increase (decrease) in accrued expenses and other payables</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_0" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_1" xml:lang="en-US">Decrease (increase) in accounts receivable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_0" xml:lang="en-US">Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_1" xml:lang="en-US">Increase (Decrease) in Accounts Payable and Accrued Liabilities, Total</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_2" xml:lang="en-US">Increase (decrease) in accrued expenses and other payables</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_0" xml:lang="en-US">Increase (Decrease) in Contract with Customer, Liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_1" xml:lang="en-US">Decrease in contract liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_0" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_1" xml:lang="en-US">Changes in operating asset and liabilities:</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherCurrentAssets_0" xml:lang="en-US">Increase (Decrease) in Other Current Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherCurrentAssets_1" xml:lang="en-US">Decrease (increase) in other current assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_1" xml:lang="en-US">CHANGES DURING THE YEAR ENDED</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IntellectualPropertyMember_0" xml:lang="en-US">Intellectual Property [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IPOMember_0" xml:lang="en-US">IPO [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_IPOMember_1" xml:lang="en-US">IPO [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LeaseCostTableTextBlock_0" xml:lang="en-US">Lease, Cost [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LeaseCostTableTextBlock_1" xml:lang="en-US">Schedule of lease cost</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LeasesAbstract_0" xml:lang="en-US">Leases [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LegalEntityTypeOfCounterpartyDomain_0" xml:lang="en-US">Legal Entity Type of Counterparty [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LegalMattersAndContingenciesTextBlock_0" xml:lang="en-US">Legal Matters and Contingencies [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LesseeLeaseDescriptionLineItems_0" xml:lang="en-US">Lessee, Lease, Description [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LesseeLeaseDescriptionTable_0" xml:lang="en-US">Lessee, Lease, Description [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock_0" xml:lang="en-US">Lessee, Leases [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock_1" xml:lang="en-US">Leases</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_0" xml:lang="en-US">Lessee, Operating Lease, Liability, Maturity [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_1" xml:lang="en-US">Schedule of maturities of undiscounted lease liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_0" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_1" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Total</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_2" xml:lang="en-US">Total future minimum lease payments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterRollingYearFive_0" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due after Rolling Year Five</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_0" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year One</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_1" xml:lang="en-US">2022</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_0" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Two</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_1" xml:lang="en-US">2023</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_0" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_1" xml:lang="en-US">Less: interest</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_2" xml:lang="en-US">Less: interest</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock_0" xml:lang="en-US">Lessee, Operating Leases [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock_1" xml:lang="en-US">OPERATING LEASES</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_Liabilities_0" xml:lang="en-US">Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_Liabilities_1" xml:lang="en-US">TOTAL LIABILITIES</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LiabilitiesAbstract_0" xml:lang="en-US">Liabilities [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LiabilitiesAbstract_1" xml:lang="en-US">LIABILITIES</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity_0" xml:lang="en-US">TOTAL LIABILITIES AND SHAREHOLDERS&#8217; EQUITY</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity_1" xml:lang="en-US">Liabilities and Equity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_0" xml:lang="en-US">Liabilities and Equity [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_1" xml:lang="en-US">Liabilities and shareholders' equity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_LiabilitiesCurrent_0" xml:lang="en-US">TOTAL CURRENT LIABILITIES</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LiabilitiesCurrent_1" xml:lang="en-US">Liabilities, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract_0" xml:lang="en-US">Liabilities, Current [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract_1" xml:lang="en-US">CURRENT LIABILITIES:</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_LiabilitiesNoncurrent_0" xml:lang="en-US">TOTAL NON-CURRENT LIABILITIES</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LiabilitiesNoncurrent_1" xml:lang="en-US">Liabilities, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LiabilitiesNoncurrentAbstract_0" xml:lang="en-US">NON-CURRENT LIABILITIES:</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LiabilitiesNoncurrentAbstract_1" xml:lang="en-US">Liabilities, Noncurrent [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_0" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_1" xml:lang="en-US">Net cash provided by financing activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_0" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_1" xml:lang="en-US">CASH FLOWS FROM FINANCING ACTIVITIES:</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_0" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_1" xml:lang="en-US">Net cash used in investing activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_0" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_1" xml:lang="en-US">CASH FLOWS FROM INVESTING ACTIVITIES:</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_0" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_1" xml:lang="en-US">Net cash used in operating activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_0" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_1" xml:lang="en-US">CASH FLOWS FROM OPERATING ACTIVITIES:</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetIncomeLoss_0" xml:lang="en-US">Net Income (Loss) Attributable to Parent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_NetIncomeLoss_1" xml:lang="en-US">Net Income (Loss) Attributable to Parent, Total</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_NetIncomeLoss_2" xml:lang="en-US">Net loss</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/positiveLabel" xlink:label="lab_us-gaap_NetIncomeLoss_3" xml:lang="en-US">Net loss</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:label="lab_us-gaap_NetIncomeLoss_4" xml:lang="en-US">NET LOSS</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_0" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_1" xml:lang="en-US">Newly issued and recently adopted accounting pronouncements</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract_0" xml:lang="en-US">Noncash Investing and Financing Items [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract_1" xml:lang="en-US">SUPPLEMENTARY INFORMATION ON INVESTING AND FINANCING ACTIVITIES NOT INVOLVING CASH FLOWS:</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NonoperatingIncomeExpense_0" xml:lang="en-US">Nonoperating Income (Expense)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_NonoperatingIncomeExpense_1" xml:lang="en-US">FINANCE EXPENSES (INCOME), net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_NonoperatingIncomeExpense_2" xml:lang="en-US">FINANCIAL EXPENSES (INCOME), net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:label="lab_us-gaap_NonoperatingIncomeExpense_3" xml:lang="en-US">FINANCIAL EXPENSES (INCOME), net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OfficeEquipmentMember_0" xml:lang="en-US">Office Equipment [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_OfficeEquipmentMember_1" xml:lang="en-US">Office furniture [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OfficersCompensation_0" xml:lang="en-US">Salary and Wage, Officer, Excluding Cost of Good and Service Sold</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OfficersCompensation_1" xml:lang="en-US">Annual base salary</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingExpenses_0" xml:lang="en-US">Operating Expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_OperatingExpenses_1" xml:lang="en-US">TOTAL OPERATING EXPENSES</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:label="lab_us-gaap_OperatingExpenses_2" xml:lang="en-US">TOTAL OPERATING EXPENSES</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingExpensesAbstract_0" xml:lang="en-US">Operating Expenses [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OperatingExpensesAbstract_1" xml:lang="en-US">OPERATING EXPENSES:</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingIncomeLoss_0" xml:lang="en-US">Operating Income (Loss)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_OperatingIncomeLoss_1" xml:lang="en-US">OPERATING LOSS</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:label="lab_us-gaap_OperatingIncomeLoss_2" xml:lang="en-US">OPERATING LOSS</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingLeaseCost_0" xml:lang="en-US">Operating Lease, Cost</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_OperatingLeaseCost_1" xml:lang="en-US">Annual lease consideration</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OperatingLeaseCost_2" xml:lang="en-US">Operating lease cost</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingLeaseLiability_0" xml:lang="en-US">Operating Lease, Liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_OperatingLeaseLiability_1" xml:lang="en-US">Total lease liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OperatingLeaseLiability_2" xml:lang="en-US">Maturity of lease liabilities under our non-cancelable operating leases to be paid in 2023</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingLeaseLiabilityAbstract_0" xml:lang="en-US">Operating Lease, Liability [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_OperatingLeaseLiabilityAbstract_1" xml:lang="en-US">Operating Leases</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent_0" xml:lang="en-US">Operating Lease, Liability, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent_1" xml:lang="en-US">Current maturities of operating lease</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent_2" xml:lang="en-US">Current lease liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_0" xml:lang="en-US">Operating Lease, Liability, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_1" xml:lang="en-US">Operating lease liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_2" xml:lang="en-US">Non-current lease liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingLeasePayments_0" xml:lang="en-US">Operating Lease, Payments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_OperatingLeasePayments_1" xml:lang="en-US">Operating cash flows from operating leases</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OperatingLeasePayments_2" xml:lang="en-US">Operating leases cost for rental space and vehicles</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset_0" xml:lang="en-US">Operating Lease, Right-of-Use Asset</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset_1" xml:lang="en-US">Operating lease right-of-use assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_0" xml:lang="en-US">Operating Lease, Right-of-Use Asset, Amortization Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_1" xml:lang="en-US">Net changes in operating leases</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_0" xml:lang="en-US">Operating Lease, Weighted Average Discount Rate, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_1" xml:lang="en-US">Weighted-average discount rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_0" xml:lang="en-US">Operating Lease, Weighted Average Remaining Lease Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_1" xml:lang="en-US">Weighted-average remaining lease term (in years)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingLossCarryforwards_0" xml:lang="en-US">Operating Loss Carryforwards</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_OperatingLossCarryforwards_1" xml:lang="en-US">Carryforward losses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingLossCarryforwardsLineItems_0" xml:lang="en-US">Operating Loss Carryforwards [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingLossCarryforwardsTable_0" xml:lang="en-US">Operating Loss Carryforwards [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_0" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_1" xml:lang="en-US">GENERAL</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_2" xml:lang="en-US">DESCRIPTION OF BUSINESS</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent_0" xml:lang="en-US">Other Accrued Liabilities, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent_1" xml:lang="en-US">Accrued expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OtherAssetsCurrent_0" xml:lang="en-US">Other current assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherAssetsCurrent_1" xml:lang="en-US">Other Assets, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent_0" xml:lang="en-US">Other Liabilities, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent_1" xml:lang="en-US">Contract liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherNonrecurringIncome_0" xml:lang="en-US">Other Nonrecurring Income</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_OtherNonrecurringIncome_1" xml:lang="en-US">Other income</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_OtherNonrecurringIncome_2" xml:lang="en-US">Other income</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherOperatingIncome_0" xml:lang="en-US">Other Operating Income</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_OtherOperatingIncome_1" xml:lang="en-US">Other income</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_OtherOperatingIncome_2" xml:lang="en-US">Other income</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PaymentForContingentConsiderationLiabilityOperatingActivities_0" xml:lang="en-US">Payment for Contingent Consideration Liability, Operating Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_PaymentForContingentConsiderationLiabilityOperatingActivities_1" xml:lang="en-US">Annual lease consideration</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PaymentsForProceedsFromShortTermInvestments_0" xml:lang="en-US">Payments for (Proceeds from) Short-term Investments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_PaymentsForProceedsFromShortTermInvestments_1" xml:lang="en-US">Short-term bank deposits</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_0" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_1" xml:lang="en-US">Purchase of property and equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PlanNameAxis_0" xml:lang="en-US">Plan Name [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PlanNameDomain_0" xml:lang="en-US">Plan Name [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PostemploymentBenefitsLiabilityNoncurrent_0" xml:lang="en-US">Postemployment Benefits Liability, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PostemploymentBenefitsLiabilityNoncurrent_1" xml:lang="en-US">Liability for employee rights upon retirement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PrivatePlacementMember_0" xml:lang="en-US">Private Placement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_PrivatePlacementMember_1" xml:lang="en-US">Private Placement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_0" xml:lang="en-US">Proceeds from Issuance of Common Stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_1" xml:lang="en-US">Proceeds from issuance of shares through ATM programs, net of issuance costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfPrivatePlacement_0" xml:lang="en-US">Proceeds from Issuance of Private Placement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfPrivatePlacement_1" xml:lang="en-US">Proceeds from private placement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProceedsFromWarrantExercises_0" xml:lang="en-US">Proceeds from Warrant Exercises</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ProceedsFromWarrantExercises_1" xml:lang="en-US">Proceeds from exercise of warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProfessionalAndContractServicesExpense_0" xml:lang="en-US">Professional and Contract Services Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ProfessionalAndContractServicesExpense_1" xml:lang="en-US">Amount to be paid for preclinical services</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProfessionalFees_0" xml:lang="en-US">Professional Fees</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ProfessionalFees_1" xml:lang="en-US">Monthly fee</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_0" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems_0" xml:lang="en-US">Property, Plant and Equipment [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet_0" xml:lang="en-US">Property and equipment, net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet_1" xml:lang="en-US">Property, Plant and Equipment, Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_0" xml:lang="en-US">Property, Plant and Equipment, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_1" xml:lang="en-US">Property and equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_0" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_0" xml:lang="en-US">Property, Plant and Equipment, Useful Life</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_1" xml:lang="en-US">Estimated useful life</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_0" xml:lang="en-US">Quarterly Financial Information Disclosure [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RelatedPartyDomain_0" xml:lang="en-US">Related Party [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RelatedPartyTransactionAxis_0" xml:lang="en-US">Related Party Transaction [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RelatedPartyTransactionDomain_0" xml:lang="en-US">Related Party Transaction [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_0" xml:lang="en-US">Related Party Transaction, Expenses from Transactions with Related Party</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_1" xml:lang="en-US">Related party transaction with continuing operations</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_2" xml:lang="en-US">Related party transaction with continuing operations</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RelatedPartyTransactionLineItems_0" xml:lang="en-US">Related Party Transaction [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RelatedPartyTransactionsAbstract_0" xml:lang="en-US">Related Party Transactions [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_0" xml:lang="en-US">Related Party [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_0" xml:lang="en-US">Related Party Transactions Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_1" xml:lang="en-US">RELATED PARTY TRANSACTIONS</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense_0" xml:lang="en-US">Research and Development Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense_1" xml:lang="en-US">Research and development</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember_0" xml:lang="en-US">Research and Development Expense [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember_1" xml:lang="en-US">Research and development expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_0" xml:lang="en-US">Research and Development Expense, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_1" xml:lang="en-US">Research and development expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalents_0" xml:lang="en-US">Restricted Cash and Cash Equivalents</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalents_1" xml:lang="en-US">Restricted deposits included in other current assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RestrictedCashAndInvestments_0" xml:lang="en-US">Restricted Cash and Investments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember_0" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember_1" xml:lang="en-US">Restricted Stock Units (RSUs)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit_0" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit_1" xml:lang="en-US">Accumulated deficit</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RetainedEarningsMember_0" xml:lang="en-US">Accumulated Deficit [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_RetainedEarningsMember_1" xml:lang="en-US">Accumulated deficit [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerAbstract_0" xml:lang="en-US">Revenue from Contract with Customer [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerTextBlock_0" xml:lang="en-US">Revenue from Contract with Customer [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerTextBlock_1" xml:lang="en-US">REVENUE FROM COLLABORATION AND LICENSE AGREEMENT</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized_0" xml:lang="en-US">Revenue Recognition, Milestone Method, Revenue Recognized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized_1" xml:lang="en-US">Milestone payments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RevenueRecognitionPolicyTextBlock_0" xml:lang="en-US">Revenue [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_RevenueRecognitionPolicyTextBlock_1" xml:lang="en-US">Revenue recognition</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_Revenues_0" xml:lang="en-US">Revenues</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_Revenues_1" xml:lang="en-US">Revenues</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/positiveLabel" xlink:label="lab_us-gaap_Revenues_2" xml:lang="en-US">REVENUES</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RoyaltyGuaranteesCommitmentsAmount_0" xml:lang="en-US">Royalty Guarantees, Commitments, Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_RoyaltyGuaranteesCommitmentsAmount_1" xml:lang="en-US">Total royalty amount payable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain_0" xml:lang="en-US">Sale of Stock [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_0" xml:lang="en-US">Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_1" xml:lang="en-US">Schedule of accounts payable and accrued liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_0" xml:lang="en-US">Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_1" xml:lang="en-US">Schedule of tax expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_0" xml:lang="en-US">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_1" xml:lang="en-US">Schedule of deferred income taxes</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_0" xml:lang="en-US">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_1" xml:lang="en-US">Schedule of rconciliation of statutory tax rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_0" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_0" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_1" xml:lang="en-US">Schedule of of share-based compensation on statements of operations</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_0" xml:lang="en-US">Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_1" xml:lang="en-US">Schedule of loss (income) before income taxes</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_0" xml:lang="en-US">Property, Plant and Equipment [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_0" xml:lang="en-US">Schedule of Related Party Transactions, by Related Party [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_0" xml:lang="en-US">Share-based Payment Arrangement, Option, Exercise Price Range [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_0" xml:lang="en-US">Share-based Payment Arrangement, Option, Activity [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_1" xml:lang="en-US">Schedule of option activity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_0" xml:lang="en-US">Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_1" xml:lang="en-US">Schedule of fair value assumptions of option granted using Black-Scholes option-pricing model</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SeriesAPreferredStockMember_0" xml:lang="en-US">Series A Preferred Stock [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_SeriesAPreferredStockMember_1" xml:lang="en-US">Series A Preferred Stock [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SeriesBPreferredStockMember_0" xml:lang="en-US">Series B Preferred Stock [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_SeriesBPreferredStockMember_1" xml:lang="en-US">Series B Preferred Stock [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ServiceMember_0" xml:lang="en-US">Service [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SeveranceCosts1_0" xml:lang="en-US">Severance Costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_SeveranceCosts1_1" xml:lang="en-US">Severance payment expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensation_0" xml:lang="en-US">Share-based Payment Arrangement, Noncash Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ShareBasedCompensation_1" xml:lang="en-US">Share-based compensation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_1" xml:lang="en-US">Vestion period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_0" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_1" xml:lang="en-US">Vesting percentage</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription_0" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Description</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription_1" xml:lang="en-US">Description of terms of share-based payment arrangement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_0" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_1" xml:lang="en-US">Restricted Share Units granted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_0" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_1" xml:lang="en-US">Restricted Share Units vested</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_0" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_1" xml:lang="en-US">Fair value of the RSU at the grant date</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_0" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_1" xml:lang="en-US">Exercise price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_0" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_1" xml:lang="en-US">Dividend yield</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_0" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_1" xml:lang="en-US">Expected life - in years</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_0" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_1" xml:lang="en-US">Expected volatility</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_0" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_1" xml:lang="en-US">Risk-free interest rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_0" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_1" xml:lang="en-US">Number of additional ordinary shares authorized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_0" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_1" xml:lang="en-US">Number of ordinary shares authorized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_0" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_1" xml:lang="en-US">Ordinary shares available for future grant</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_0" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_1" xml:lang="en-US">Aggregate intrinsic value of exercisable options</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_0" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_1" xml:lang="en-US">Exercisable at end of the year</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_2" xml:lang="en-US">Number of options exercisable at end of year</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_0" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_1" xml:lang="en-US">Exercisable at end of the year</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_0" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_1" xml:lang="en-US">Options exercisable, Weighted Average Remaining contractual Life</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_0" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_1" xml:lang="en-US">Expired</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_2" xml:lang="en-US">Expired</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_0" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_1" xml:lang="en-US">Forfeited</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_2" xml:lang="en-US">Forfeited</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_1" xml:lang="en-US">Granted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_2" xml:lang="en-US">Number of options to purchase ordinary shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested, Number of Shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_1" xml:lang="en-US">Number of unvested options</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares_0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested Options Forfeited, Number of Shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares_1" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested, Number of Shares, Beginning Balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares_2" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested, Number of Shares, Ending Balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares_3" xml:lang="en-US">Number of unvested options forfeited</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_0" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_1" xml:lang="en-US">Aggregate intrinsic value of outstanding options</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_0" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_1" xml:lang="en-US">Outstanding at beginning of the year</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2" xml:lang="en-US">Outstanding at end of the year</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_3" xml:lang="en-US">Number of options outstanding at end of year</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_0" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_1" xml:lang="en-US">Number of options</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_0" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_1" xml:lang="en-US">Outstanding at beginning of the year</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2" xml:lang="en-US">Outstanding at end of the year</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_3" xml:lang="en-US">Exercise Price Per Share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_0" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_1" xml:lang="en-US">Weighted Average exercise price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_0" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_1" xml:lang="en-US">Options outstanding, Weighted Average Remaining contractual Life</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock_0" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding and Exercisable [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock_1" xml:lang="en-US">Schedule of outstanding and exercisable options of ordinary shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_0" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_1" xml:lang="en-US">Fair value of options at the date of grant</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_0" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Shares Issued in Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_1" xml:lang="en-US">Number of shares issued on options exercised</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward_0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Shares Purchased for Award</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward_1" xml:lang="en-US">Number of options to purchase ordinary shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0" xml:lang="en-US">Award Type [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_0" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_1" xml:lang="en-US">Weighted average exercise rice of options exercised</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_2" xml:lang="en-US">Exercised</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_0" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_1" xml:lang="en-US">Expired</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_0" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_1" xml:lang="en-US">Forfeited</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_0" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_1" xml:lang="en-US">Granted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_2" xml:lang="en-US">Exercise price of options granted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember_0" xml:lang="en-US">Share-based Payment Arrangement, Tranche One [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember_1" xml:lang="en-US">Vest on the first anniversary of the date of grant [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheThreeMember_0" xml:lang="en-US">Share-based Payment Arrangement, Tranche Three [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheThreeMember_1" xml:lang="en-US">Shares vested on the signing date [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_0" xml:lang="en-US">Share-based Payment Arrangement, Tranche Two [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_1" xml:lang="en-US">Vest in twelve equal quarterly installments following the first anniversary of the applicable grant date [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_0" xml:lang="en-US">Share-based Payment Arrangement [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_1" xml:lang="en-US">Share-based compensation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_0" xml:lang="en-US">Exercise Price Range [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_0" xml:lang="en-US">Exercise Price Range [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharePrice_0" xml:lang="en-US">Share Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_SharePrice_1" xml:lang="en-US">Price of shares issued under private placement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharesIssued_0" xml:lang="en-US">Shares, Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_SharesIssued_1" xml:lang="en-US">Number of shares issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharesOutstanding_0" xml:lang="en-US">Shares, Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_SharesOutstanding_1" xml:lang="en-US">BALANCE (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_SharesOutstanding_2" xml:lang="en-US">BALANCE (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock_0" xml:lang="en-US">Significant Accounting Policies [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock_1" xml:lang="en-US">SIGNIFICANT ACCOUNTING POLICIES</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementClassOfStockAxis_0" xml:lang="en-US">Class of Stock [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementEquityComponentsAxis_0" xml:lang="en-US">Equity Components [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementLineItems_0" xml:lang="en-US">Statement [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract_0" xml:lang="en-US">Statement of Cash Flows [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract_0" xml:lang="en-US">Statement of Financial Position [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract_0" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementTable_0" xml:lang="en-US">Statement [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockholdersEquity_0" xml:lang="en-US">Stockholders' Equity Attributable to Parent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_StockholdersEquity_1" xml:lang="en-US">TOTAL SHAREHOLDERS' EQUITY</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_StockholdersEquity_2" xml:lang="en-US">BALANCE</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_StockholdersEquity_3" xml:lang="en-US">BALANCE</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_0" xml:lang="en-US">Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_1" xml:lang="en-US">BALANCE</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_2" xml:lang="en-US">BALANCE</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockholdersEquityNoteAbstract_0" xml:lang="en-US">Stockholders' Equity Note [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_0" xml:lang="en-US">Stockholders' Equity Note Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_1" xml:lang="en-US">SHARE CAPITAL</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockholdersEquityNumberOfSharesParValueAndOtherDisclosuresAbstract_0" xml:lang="en-US">Stockholders' Equity, Number of Shares, Par Value and Other Disclosures [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StockholdersEquityNumberOfSharesParValueAndOtherDisclosuresAbstract_1" xml:lang="en-US">SHAREHOLDERS' EQUITY:</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_0" xml:lang="en-US">Stock Issued During Period, Shares, Issued for Services</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_1" xml:lang="en-US">Issuance of shares due to the ATM program, net of issuance costs (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_0" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_1" xml:lang="en-US">Issuance of ordinary shares and warrants due to a private placement net of issuance costs (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_1" xml:lang="en-US">Number of options exercised</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_2" xml:lang="en-US">Exercise of options to ordinary shares (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_3" xml:lang="en-US">Exercised</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueIssuedForServices_0" xml:lang="en-US">Stock Issued During Period, Value, Issued for Services</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueIssuedForServices_1" xml:lang="en-US">Issuance of shares due to the ATM program, net of issuance costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_0" xml:lang="en-US">Stock Issued During Period, Value, New Issues</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_1" xml:lang="en-US">Issuance of ordinary shares and warrants due to a private placement net of issuance costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_0" xml:lang="en-US">Stock Issued During Period, Value, Stock Options Exercised</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_1" xml:lang="en-US">Exercise of options to ordinary shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubsequentEventLineItems_0" xml:lang="en-US">Subsequent Event [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SubsequentEventMember_0" xml:lang="en-US">Subsequent Event [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubsequentEventMember_1" xml:lang="en-US">Subsequent Event [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubsequentEventsAbstract_0" xml:lang="en-US">Subsequent Events [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubsequentEventsTextBlock_0" xml:lang="en-US">Subsequent Events [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_SubsequentEventsTextBlock_1" xml:lang="en-US">SUBSEQUENT EVENTS</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubsequentEventTable_0" xml:lang="en-US">Subsequent Event [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubsequentEventTypeAxis_0" xml:lang="en-US">Subsequent Event Type [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubsequentEventTypeDomain_0" xml:lang="en-US">Subsequent Event Type [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis_0" xml:lang="en-US">Sale of Stock [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SummaryOfValuationAllowanceTextBlock_0" xml:lang="en-US">Summary of Valuation Allowance [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_SummaryOfValuationAllowanceTextBlock_1" xml:lang="en-US">Schedule of rollforward of valuation allowance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract_0" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract_1" xml:lang="en-US">SUPPLEMENTAL DISCLOSURE OF CASH FLOW TRANSACTIONS:</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_TypeOfArrangementAxis_0" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_UnusualOrInfrequentItemsDisclosureTextBlock_0" xml:lang="en-US">Unusual or Infrequent Items, or Both, Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_UnusualOrInfrequentItemsDisclosureTextBlock_1" xml:lang="en-US">COVID-19</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_UseOfEstimates_0" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_UseOfEstimates_1" xml:lang="en-US">Use of estimates in the preparation of financial statements</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_0" xml:lang="en-US">Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_1" xml:lang="en-US">Additions</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_2" xml:lang="en-US">Net change in valuation allowance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_VestingAxis_0" xml:lang="en-US">Vesting [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_VestingDomain_0" xml:lang="en-US">Vesting [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_WarrantMember_0" xml:lang="en-US">Warrant [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_WarrantMember_1" xml:lang="en-US">Warrant [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_0" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_1" xml:lang="en-US">WEIGHTED AVERAGE NUMBER OF SHARES OUTSTANDING USED IN COMPUTATION OF DILUTED LOSS PER SHARE</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_0" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic and Diluted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_1" xml:lang="en-US">WEIGHTED AVERAGE NUMBER OF SHARES OUTSTANDING USED IN COMPUTATION OF BASIC LOSS PER SHARE</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentDescription_1" xlink:to="lab_dei_AmendmentDescription_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag_2" xlink:to="lab_dei_AmendmentFlag_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorFirmId_3" xlink:to="lab_dei_AuditorFirmId_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorLocation_4" xlink:to="lab_dei_AuditorLocation_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorName_5" xlink:to="lab_dei_AuditorName_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode_6" xlink:to="lab_dei_CityAreaCode_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract_7" xlink:to="lab_dei_CoverAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract_8" xlink:to="lab_dei_CoverAbstract_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate_9" xlink:to="lab_dei_CurrentFiscalYearEndDate_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentAnnualReport_10" xlink:to="lab_dei_DocumentAnnualReport_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus_11" xlink:to="lab_dei_DocumentFiscalPeriodFocus_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus_12" xlink:to="lab_dei_DocumentFiscalYearFocus_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate_13" xlink:to="lab_dei_DocumentPeriodEndDate_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentQuarterlyReport_14" xlink:to="lab_dei_DocumentQuarterlyReport_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport_15" xlink:to="lab_dei_DocumentTransitionReport_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType_16" xlink:to="lab_dei_DocumentType_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1_17" xlink:to="lab_dei_EntityAddressAddressLine1_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine2_18" xlink:to="lab_dei_EntityAddressAddressLine2_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine3_19" xlink:to="lab_dei_EntityAddressAddressLine3_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown_20" xlink:to="lab_dei_EntityAddressCityOrTown_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCountry_21" xlink:to="lab_dei_EntityAddressCountry_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode_22" xlink:to="lab_dei_EntityAddressPostalZipCode_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince_23" xlink:to="lab_dei_EntityAddressStateOrProvince_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey_24" xlink:to="lab_dei_EntityCentralIndexKey_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding_25" xlink:to="lab_dei_EntityCommonStockSharesOutstanding_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus_26" xlink:to="lab_dei_EntityCurrentReportingStatus_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityDomain_27" xlink:to="lab_dei_EntityDomain_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany_28" xlink:to="lab_dei_EntityEmergingGrowthCompany_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityExTransitionPeriod_29" xlink:to="lab_dei_EntityExTransitionPeriod_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber_30" xlink:to="lab_dei_EntityFileNumber_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory_31" xlink:to="lab_dei_EntityFilerCategory_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode_32" xlink:to="lab_dei_EntityIncorporationStateCountryCode_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent_33" xlink:to="lab_dei_EntityInteractiveDataCurrent_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityPublicFloat_34" xlink:to="lab_dei_EntityPublicFloat_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName_35" xlink:to="lab_dei_EntityRegistrantName_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany_36" xlink:to="lab_dei_EntityShellCompany_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness_37" xlink:to="lab_dei_EntitySmallBusiness_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber_38" xlink:to="lab_dei_EntityTaxIdentificationNumber_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityVoluntaryFilers_39" xlink:to="lab_dei_EntityVoluntaryFilers_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityWellKnownSeasonedIssuer_40" xlink:to="lab_dei_EntityWellKnownSeasonedIssuer_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LegalEntityAxis_41" xlink:to="lab_dei_LegalEntityAxis_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber_42" xlink:to="lab_dei_LocalPhoneNumber_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle_43" xlink:to="lab_dei_Security12bTitle_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName_44" xlink:to="lab_dei_SecurityExchangeName_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol_45" xlink:to="lab_dei_TradingSymbol_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_AccreditedInvestorsIncludingCertainBoardMembersAndTheirAffiliatesMember_46" xlink:to="lab_entx_AccreditedInvestorsIncludingCertainBoardMembersAndTheirAffiliatesMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_AccreditedInvestorsIncludingCertainBoardMembersAndTheirAffiliatesMember_47" xlink:to="lab_entx_AccreditedInvestorsIncludingCertainBoardMembersAndTheirAffiliatesMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_AccreditedInvestorsIncludingCertainBoardMembersAndTheirAffiliatesMember_48" xlink:to="lab_entx_AccreditedInvestorsIncludingCertainBoardMembersAndTheirAffiliatesMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_AdditionalAmountPaidForServicesToBeRecognized_49" xlink:to="lab_entx_AdditionalAmountPaidForServicesToBeRecognized_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_AdditionalAmountPaidForServicesToBeRecognized_50" xlink:to="lab_entx_AdditionalAmountPaidForServicesToBeRecognized_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_AdditionalAmountPaidForServicesToBeRecognized_51" xlink:to="lab_entx_AdditionalAmountPaidForServicesToBeRecognized_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_AdditionalCashSeparationPayment_52" xlink:to="lab_entx_AdditionalCashSeparationPayment_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_AdditionalCashSeparationPayment_53" xlink:to="lab_entx_AdditionalCashSeparationPayment_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_AdditionalCashSeparationPayment_54" xlink:to="lab_entx_AdditionalCashSeparationPayment_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_AdjustedExercisePriceUnderAtMarketEquityProgram_55" xlink:to="lab_entx_AdjustedExercisePriceUnderAtMarketEquityProgram_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_AdjustedExercisePriceUnderAtMarketEquityProgram_56" xlink:to="lab_entx_AdjustedExercisePriceUnderAtMarketEquityProgram_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_AdjustedExercisePriceUnderAtMarketEquityProgram_57" xlink:to="lab_entx_AdjustedExercisePriceUnderAtMarketEquityProgram_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_AgreementAxis_58" xlink:to="lab_entx_AgreementAxis_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_AgreementAxis_59" xlink:to="lab_entx_AgreementAxis_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_AgreementDomain_60" xlink:to="lab_entx_AgreementDomain_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_AgreementDomain_61" xlink:to="lab_entx_AgreementDomain_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_AmendmentToBusinessDevelopmentServicesAgreementMember_62" xlink:to="lab_entx_AmendmentToBusinessDevelopmentServicesAgreementMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_AmendmentToBusinessDevelopmentServicesAgreementMember_63" xlink:to="lab_entx_AmendmentToBusinessDevelopmentServicesAgreementMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_AmendmentToBusinessDevelopmentServicesAgreementMember_64" xlink:to="lab_entx_AmendmentToBusinessDevelopmentServicesAgreementMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_AmgenIncMember_65" xlink:to="lab_entx_AmgenIncMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_AmgenIncMember_66" xlink:to="lab_entx_AmgenIncMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_AmgenIncMember_67" xlink:to="lab_entx_AmgenIncMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_AmgenIncMember_68" xlink:to="lab_entx_AmgenIncMember_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_AtmEquityProgram2020Member_69" xlink:to="lab_entx_AtmEquityProgram2020Member_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_AtmEquityProgram2020Member_70" xlink:to="lab_entx_AtmEquityProgram2020Member_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_AtmEquityProgram2020Member_71" xlink:to="lab_entx_AtmEquityProgram2020Member_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_AtmEquityProgram2021Member_72" xlink:to="lab_entx_AtmEquityProgram2021Member_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_AtmEquityProgram2021Member_73" xlink:to="lab_entx_AtmEquityProgram2021Member_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_AtmEquityProgram2021Member_74" xlink:to="lab_entx_AtmEquityProgram2021Member_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_BankGuarantees_75" xlink:to="lab_entx_BankGuarantees_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_BankGuarantees_76" xlink:to="lab_entx_BankGuarantees_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_BankGuarantees_77" xlink:to="lab_entx_BankGuarantees_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_BoardMembersMember_78" xlink:to="lab_entx_BoardMembersMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_BoardMembersMember_79" xlink:to="lab_entx_BoardMembersMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_BrokerDealerMember_80" xlink:to="lab_entx_BrokerDealerMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_BrokerDealerMember_81" xlink:to="lab_entx_BrokerDealerMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_BrokerDealerOneMember_82" xlink:to="lab_entx_BrokerDealerOneMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_BrokerDealerOneMember_83" xlink:to="lab_entx_BrokerDealerOneMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_BrokerDealerOneMember_84" xlink:to="lab_entx_BrokerDealerOneMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_BrokerWarrantsMember_85" xlink:to="lab_entx_BrokerWarrantsMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_BrokerWarrantsMember_86" xlink:to="lab_entx_BrokerWarrantsMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_BrokerWarrantsMember_87" xlink:to="lab_entx_BrokerWarrantsMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_BrokerWarrantsType1Member_88" xlink:to="lab_entx_BrokerWarrantsType1Member_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_BrokerWarrantsType1Member_89" xlink:to="lab_entx_BrokerWarrantsType1Member_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_BrokerWarrantsType1Member_90" xlink:to="lab_entx_BrokerWarrantsType1Member_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_BrokerWarrantsType2Member_91" xlink:to="lab_entx_BrokerWarrantsType2Member_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_BrokerWarrantsType2Member_92" xlink:to="lab_entx_BrokerWarrantsType2Member_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_BrokerWarrantsType2Member_93" xlink:to="lab_entx_BrokerWarrantsType2Member_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_CashFeesInPercentage_94" xlink:to="lab_entx_CashFeesInPercentage_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_CashFeesInPercentage_95" xlink:to="lab_entx_CashFeesInPercentage_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_CashFeesInPercentage_96" xlink:to="lab_entx_CashFeesInPercentage_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_CashlessExerciseOfWarrants_97" xlink:to="lab_entx_CashlessExerciseOfWarrants_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_CashlessExerciseOfWarrants_98" xlink:to="lab_entx_CashlessExerciseOfWarrants_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_CashlessExerciseOfWarrants_99" xlink:to="lab_entx_CashlessExerciseOfWarrants_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_CashSeparationPayment_100" xlink:to="lab_entx_CashSeparationPayment_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_CashSeparationPayment_101" xlink:to="lab_entx_CashSeparationPayment_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_CashSeparationPayment_102" xlink:to="lab_entx_CashSeparationPayment_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_ChairmanOfBoardAndDnaMember_103" xlink:to="lab_entx_ChairmanOfBoardAndDnaMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_ChairmanOfBoardAndDnaMember_104" xlink:to="lab_entx_ChairmanOfBoardAndDnaMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_ChairmanOfBoardAndDnaMember_105" xlink:to="lab_entx_ChairmanOfBoardAndDnaMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_ClassOfWarrantOrRightExerciseTerm_106" xlink:to="lab_entx_ClassOfWarrantOrRightExerciseTerm_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_ClassOfWarrantOrRightExerciseTerm_107" xlink:to="lab_entx_ClassOfWarrantOrRightExerciseTerm_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_ClassOfWarrantOrRightExerciseTerm_108" xlink:to="lab_entx_ClassOfWarrantOrRightExerciseTerm_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_ClassOfWarrantOrRightIssued_109" xlink:to="lab_entx_ClassOfWarrantOrRightIssued_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_ClassOfWarrantOrRightIssued_110" xlink:to="lab_entx_ClassOfWarrantOrRightIssued_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_ClassOfWarrantOrRightIssued_111" xlink:to="lab_entx_ClassOfWarrantOrRightIssued_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_ClassOfWarrantOrRightPercentageOfIpoPricePerUnit_112" xlink:to="lab_entx_ClassOfWarrantOrRightPercentageOfIpoPricePerUnit_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_ClassOfWarrantOrRightPercentageOfIpoPricePerUnit_113" xlink:to="lab_entx_ClassOfWarrantOrRightPercentageOfIpoPricePerUnit_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_ClassOfWarrantOrRightPercentageOfIpoPricePerUnit_114" xlink:to="lab_entx_ClassOfWarrantOrRightPercentageOfIpoPricePerUnit_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_ClassOfWarrantOrRightReducedExercisePrice_115" xlink:to="lab_entx_ClassOfWarrantOrRightReducedExercisePrice_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_ClassOfWarrantOrRightReducedExercisePrice_116" xlink:to="lab_entx_ClassOfWarrantOrRightReducedExercisePrice_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_ClassOfWarrantOrRightReducedExercisePrice_117" xlink:to="lab_entx_ClassOfWarrantOrRightReducedExercisePrice_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_ClassOfWarrantOrRightThresholdConsecutiveTradingDays_118" xlink:to="lab_entx_ClassOfWarrantOrRightThresholdConsecutiveTradingDays_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_ClassOfWarrantOrRightThresholdConsecutiveTradingDays_119" xlink:to="lab_entx_ClassOfWarrantOrRightThresholdConsecutiveTradingDays_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_ClassOfWarrantOrRightThresholdConsecutiveTradingDays_120" xlink:to="lab_entx_ClassOfWarrantOrRightThresholdConsecutiveTradingDays_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_ClassOfWarrantOrRightThresholdLimitOfLastReportedSalePrice_121" xlink:to="lab_entx_ClassOfWarrantOrRightThresholdLimitOfLastReportedSalePrice_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_ClassOfWarrantOrRightThresholdLimitOfLastReportedSalePrice_122" xlink:to="lab_entx_ClassOfWarrantOrRightThresholdLimitOfLastReportedSalePrice_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_ClassOfWarrantOrRightThresholdLimitOfLastReportedSalePrice_123" xlink:to="lab_entx_ClassOfWarrantOrRightThresholdLimitOfLastReportedSalePrice_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_ClassOfWarrantOrRightThresholdLimitOfPeriodForReductionInExercisePrice_124" xlink:to="lab_entx_ClassOfWarrantOrRightThresholdLimitOfPeriodForReductionInExercisePrice_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_ClassOfWarrantOrRightThresholdLimitOfPeriodForReductionInExercisePrice_125" xlink:to="lab_entx_ClassOfWarrantOrRightThresholdLimitOfPeriodForReductionInExercisePrice_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_ClassOfWarrantOrRightThresholdLimitOfPeriodForReductionInExercisePrice_126" xlink:to="lab_entx_ClassOfWarrantOrRightThresholdLimitOfPeriodForReductionInExercisePrice_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_ClassOfWarrantOrRightThresholdLimitOfReductionInExercisePrice_127" xlink:to="lab_entx_ClassOfWarrantOrRightThresholdLimitOfReductionInExercisePrice_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_ClassOfWarrantOrRightThresholdLimitOfReductionInExercisePrice_128" xlink:to="lab_entx_ClassOfWarrantOrRightThresholdLimitOfReductionInExercisePrice_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_ClassOfWarrantOrRightThresholdLimitOfReductionInExercisePrice_129" xlink:to="lab_entx_ClassOfWarrantOrRightThresholdLimitOfReductionInExercisePrice_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_CommitmentsAndContingenciesTable_130" xlink:to="lab_entx_CommitmentsAndContingenciesTable_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_CommitmentsAndContingenciesTable_131" xlink:to="lab_entx_CommitmentsAndContingenciesTable_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_CommitmentsLineItems_132" xlink:to="lab_entx_CommitmentsLineItems_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_CommitmentsLineItems_133" xlink:to="lab_entx_CommitmentsLineItems_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_ConsultantMember_134" xlink:to="lab_entx_ConsultantMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_ConsultantMember_135" xlink:to="lab_entx_ConsultantMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_ConsultantMember_136" xlink:to="lab_entx_ConsultantMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_DecreaseIncreaseInTaxRefundAbstract_137" xlink:to="lab_entx_DecreaseIncreaseInTaxRefundAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_DecreaseIncreaseInTaxRefundAbstract_138" xlink:to="lab_entx_DecreaseIncreaseInTaxRefundAbstract_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_DecreaseIncreaseInTaxRefundAbstract_139" xlink:to="lab_entx_DecreaseIncreaseInTaxRefundAbstract_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_DnaBiomedicalSolutionsLtdAndOramedLtdMember_140" xlink:to="lab_entx_DnaBiomedicalSolutionsLtdAndOramedLtdMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_DnaBiomedicalSolutionsLtdAndOramedLtdMember_141" xlink:to="lab_entx_DnaBiomedicalSolutionsLtdAndOramedLtdMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_DnaBiomedicalSolutionsLtdAndOramedLtdMember_142" xlink:to="lab_entx_DnaBiomedicalSolutionsLtdAndOramedLtdMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_DnaBiomedicalSolutionsLtdMember_143" xlink:to="lab_entx_DnaBiomedicalSolutionsLtdMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_DnaBiomedicalSolutionsLtdMember_144" xlink:to="lab_entx_DnaBiomedicalSolutionsLtdMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_DnaBiomedicalSolutionsLtdMember_145" xlink:to="lab_entx_DnaBiomedicalSolutionsLtdMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_EffectOfDownRoundTriggerAmount_146" xlink:to="lab_entx_EffectOfDownRoundTriggerAmount_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_EffectOfDownRoundTriggerAmount_147" xlink:to="lab_entx_EffectOfDownRoundTriggerAmount_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_EffectOfDownRoundTriggerAmount_148" xlink:to="lab_entx_EffectOfDownRoundTriggerAmount_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_EmployeeMember_149" xlink:to="lab_entx_EmployeeMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_EmployeeMember_150" xlink:to="lab_entx_EmployeeMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_EmployeeMember_151" xlink:to="lab_entx_EmployeeMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_EmployeeSeveranceBenefitsPolicyPolicyTextBlock_152" xlink:to="lab_entx_EmployeeSeveranceBenefitsPolicyPolicyTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_EmployeeSeveranceBenefitsPolicyPolicyTextBlock_153" xlink:to="lab_entx_EmployeeSeveranceBenefitsPolicyPolicyTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_EmployeeSeveranceBenefitsPolicyPolicyTextBlock_154" xlink:to="lab_entx_EmployeeSeveranceBenefitsPolicyPolicyTextBlock_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_EmployeesMember_155" xlink:to="lab_entx_EmployeesMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_EmployeesMember_156" xlink:to="lab_entx_EmployeesMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_EmployeesMember_157" xlink:to="lab_entx_EmployeesMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_EnteraBioLtdMember_158" xlink:to="lab_entx_EnteraBioLtdMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_EnteraBioLtdMember_159" xlink:to="lab_entx_EnteraBioLtdMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_EnteraBioLtdMember_160" xlink:to="lab_entx_EnteraBioLtdMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_EquityProgramAxis_161" xlink:to="lab_entx_EquityProgramAxis_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_EquityProgramAxis_162" xlink:to="lab_entx_EquityProgramAxis_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_EquityProgramDomain_163" xlink:to="lab_entx_EquityProgramDomain_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_EquityProgramDomain_164" xlink:to="lab_entx_EquityProgramDomain_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_ExecutiveOfficerAndServiceProviderMember_165" xlink:to="lab_entx_ExecutiveOfficerAndServiceProviderMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_ExecutiveOfficerAndServiceProviderMember_166" xlink:to="lab_entx_ExecutiveOfficerAndServiceProviderMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_ExecutiveOfficerAndServiceProviderMember_167" xlink:to="lab_entx_ExecutiveOfficerAndServiceProviderMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_ExerciseOfWarrantsShares_168" xlink:to="lab_entx_ExerciseOfWarrantsShares_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_ExerciseOfWarrantsShares_169" xlink:to="lab_entx_ExerciseOfWarrantsShares_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_ExerciseOfWarrantsShares_170" xlink:to="lab_entx_ExerciseOfWarrantsShares_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_ExerciseOfWarrantsValue_171" xlink:to="lab_entx_ExerciseOfWarrantsValue_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_ExerciseOfWarrantsValue_172" xlink:to="lab_entx_ExerciseOfWarrantsValue_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_ExerciseOfWarrantsValue_173" xlink:to="lab_entx_ExerciseOfWarrantsValue_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_ExercisePricePerShareOnePointFourMember_174" xlink:to="lab_entx_ExercisePricePerShareOnePointFourMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_ExercisePricePerShareOnePointFourMember_175" xlink:to="lab_entx_ExercisePricePerShareOnePointFourMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_ExercisePricePerShareOnePointFourMember_176" xlink:to="lab_entx_ExercisePricePerShareOnePointFourMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_ExercisePricePerShareOnePointTwoFourMember_177" xlink:to="lab_entx_ExercisePricePerShareOnePointTwoFourMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_ExercisePricePerShareOnePointTwoFourMember_178" xlink:to="lab_entx_ExercisePricePerShareOnePointTwoFourMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_ExercisePricePerShareOnePointTwoFourMember_179" xlink:to="lab_entx_ExercisePricePerShareOnePointTwoFourMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_ExercisePricePerShareOnePointZeroSixMember_180" xlink:to="lab_entx_ExercisePricePerShareOnePointZeroSixMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_ExercisePricePerShareOnePointZeroSixMember_181" xlink:to="lab_entx_ExercisePricePerShareOnePointZeroSixMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_ExercisePricePerShareOnePointZeroSixMember_182" xlink:to="lab_entx_ExercisePricePerShareOnePointZeroSixMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_ExercisePricePerShareSevenPointFiveFourMember_183" xlink:to="lab_entx_ExercisePricePerShareSevenPointFiveFourMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_ExercisePricePerShareSevenPointFiveFourMember_184" xlink:to="lab_entx_ExercisePricePerShareSevenPointFiveFourMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_ExercisePricePerShareSevenPointFiveFourMember_185" xlink:to="lab_entx_ExercisePricePerShareSevenPointFiveFourMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_ExercisePricePerShareSixPointThreeOneMember_186" xlink:to="lab_entx_ExercisePricePerShareSixPointThreeOneMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_ExercisePricePerShareSixPointThreeOneMember_187" xlink:to="lab_entx_ExercisePricePerShareSixPointThreeOneMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_ExercisePricePerShareSixPointThreeOneMember_188" xlink:to="lab_entx_ExercisePricePerShareSixPointThreeOneMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_ExercisePricePerShareThreePointNineSevenMember_189" xlink:to="lab_entx_ExercisePricePerShareThreePointNineSevenMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_ExercisePricePerShareThreePointNineSevenMember_190" xlink:to="lab_entx_ExercisePricePerShareThreePointNineSevenMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_ExercisePricePerShareThreePointNineSevenMember_191" xlink:to="lab_entx_ExercisePricePerShareThreePointNineSevenMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_ExercisePricePerShareThreePointOneFiveMember_192" xlink:to="lab_entx_ExercisePricePerShareThreePointOneFiveMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_ExercisePricePerShareThreePointOneFiveMember_193" xlink:to="lab_entx_ExercisePricePerShareThreePointOneFiveMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_ExercisePricePerShareThreePointOneFiveMember_194" xlink:to="lab_entx_ExercisePricePerShareThreePointOneFiveMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_ExercisePricePerShareThreePointSixEightMember_195" xlink:to="lab_entx_ExercisePricePerShareThreePointSixEightMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_ExercisePricePerShareThreePointSixEightMember_196" xlink:to="lab_entx_ExercisePricePerShareThreePointSixEightMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_ExercisePricePerShareThreePointSixEightMember_197" xlink:to="lab_entx_ExercisePricePerShareThreePointSixEightMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_ExercisePricePerShareThreePointSixOneMember_198" xlink:to="lab_entx_ExercisePricePerShareThreePointSixOneMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_ExercisePricePerShareThreePointSixOneMember_199" xlink:to="lab_entx_ExercisePricePerShareThreePointSixOneMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_ExercisePricePerShareThreePointSixOneMember_200" xlink:to="lab_entx_ExercisePricePerShareThreePointSixOneMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_ExercisePricePerShareTwoPointEightOneFiveMember_201" xlink:to="lab_entx_ExercisePricePerShareTwoPointEightOneFiveMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_ExercisePricePerShareTwoPointEightOneFiveMember_202" xlink:to="lab_entx_ExercisePricePerShareTwoPointEightOneFiveMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_ExercisePricePerShareTwoPointEightOneFiveMember_203" xlink:to="lab_entx_ExercisePricePerShareTwoPointEightOneFiveMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_ExercisePricePerShareTwoPointEightSixMember_204" xlink:to="lab_entx_ExercisePricePerShareTwoPointEightSixMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_ExercisePricePerShareTwoPointEightSixMember_205" xlink:to="lab_entx_ExercisePricePerShareTwoPointEightSixMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_ExercisePricePerShareTwoPointEightSixMember_206" xlink:to="lab_entx_ExercisePricePerShareTwoPointEightSixMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_ExercisePricePerShareTwoPointFiveSevenMember_207" xlink:to="lab_entx_ExercisePricePerShareTwoPointFiveSevenMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_ExercisePricePerShareTwoPointFiveSevenMember_208" xlink:to="lab_entx_ExercisePricePerShareTwoPointFiveSevenMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_ExercisePricePerShareTwoPointFiveSevenMember_209" xlink:to="lab_entx_ExercisePricePerShareTwoPointFiveSevenMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_ExercisePricePerShareTwoPointFiveThreeMember_210" xlink:to="lab_entx_ExercisePricePerShareTwoPointFiveThreeMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_ExercisePricePerShareTwoPointFiveThreeMember_211" xlink:to="lab_entx_ExercisePricePerShareTwoPointFiveThreeMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_ExercisePricePerShareTwoPointFiveThreeMember_212" xlink:to="lab_entx_ExercisePricePerShareTwoPointFiveThreeMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_ExercisePricePerShareTwoPointOneFourMember_213" xlink:to="lab_entx_ExercisePricePerShareTwoPointOneFourMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_ExercisePricePerShareTwoPointOneFourMember_214" xlink:to="lab_entx_ExercisePricePerShareTwoPointOneFourMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_ExercisePricePerShareTwoPointOneFourMember_215" xlink:to="lab_entx_ExercisePricePerShareTwoPointOneFourMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_ExercisePricePerShareTwoPointZeroTwoMember_216" xlink:to="lab_entx_ExercisePricePerShareTwoPointZeroTwoMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_ExercisePricePerShareTwoPointZeroTwoMember_217" xlink:to="lab_entx_ExercisePricePerShareTwoPointZeroTwoMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_ExercisePricePerShareTwoPointZeroTwoMember_218" xlink:to="lab_entx_ExercisePricePerShareTwoPointZeroTwoMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_ExercisePricePerShareZeroMember_219" xlink:to="lab_entx_ExercisePricePerShareZeroMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_ExercisePricePerShareZeroMember_220" xlink:to="lab_entx_ExercisePricePerShareZeroMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_ExercisePricePerShareZeroMember_221" xlink:to="lab_entx_ExercisePricePerShareZeroMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_FinanceExpensesNet_222" xlink:to="lab_entx_FinanceExpensesNet_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_FinanceExpensesNet_223" xlink:to="lab_entx_FinanceExpensesNet_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_FinanceExpensesNet_224" xlink:to="lab_entx_FinanceExpensesNet_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_FormerChiefExecutiveOfficerMember_225" xlink:to="lab_entx_FormerChiefExecutiveOfficerMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_FormerChiefExecutiveOfficerMember_226" xlink:to="lab_entx_FormerChiefExecutiveOfficerMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_FormerChiefExecutiveOfficerMember_227" xlink:to="lab_entx_FormerChiefExecutiveOfficerMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_FundsInRespectOfEmployeeRightsUponRetirement_228" xlink:to="lab_entx_FundsInRespectOfEmployeeRightsUponRetirement_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_FundsInRespectOfEmployeeRightsUponRetirement_229" xlink:to="lab_entx_FundsInRespectOfEmployeeRightsUponRetirement_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_FundsInRespectOfEmployeeRightsUponRetirement_230" xlink:to="lab_entx_FundsInRespectOfEmployeeRightsUponRetirement_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_FundsInRespectOfEmployeeRightsUponRetirement_231" xlink:to="lab_entx_FundsInRespectOfEmployeeRightsUponRetirement_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_GeneralLineItems_232" xlink:to="lab_entx_GeneralLineItems_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_GeneralLineItems_233" xlink:to="lab_entx_GeneralLineItems_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_GeneralTable_234" xlink:to="lab_entx_GeneralTable_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_GeneralTable_235" xlink:to="lab_entx_GeneralTable_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_InvestorRelationsServicesAgreementMember_236" xlink:to="lab_entx_InvestorRelationsServicesAgreementMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_InvestorRelationsServicesAgreementMember_237" xlink:to="lab_entx_InvestorRelationsServicesAgreementMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_InvestorRelationsServicesAgreementMember_238" xlink:to="lab_entx_InvestorRelationsServicesAgreementMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_IssuanceOfOrdinarySharesAndWarrantsDueToPrivatePlacementNetOfIssuanceCosts_239" xlink:to="lab_entx_IssuanceOfOrdinarySharesAndWarrantsDueToPrivatePlacementNetOfIssuanceCosts_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_IssuanceOfOrdinarySharesAndWarrantsDueToPrivatePlacementNetOfIssuanceCosts_240" xlink:to="lab_entx_IssuanceOfOrdinarySharesAndWarrantsDueToPrivatePlacementNetOfIssuanceCosts_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_IssuanceOfOrdinarySharesAndWarrantsDueToPrivatePlacementNetOfIssuanceCosts_241" xlink:to="lab_entx_IssuanceOfOrdinarySharesAndWarrantsDueToPrivatePlacementNetOfIssuanceCosts_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_IssuanceOfOrdinarySharesAndWarrantsDueToPrivatePlacementNetOfIssuanceCostsShares_242" xlink:to="lab_entx_IssuanceOfOrdinarySharesAndWarrantsDueToPrivatePlacementNetOfIssuanceCostsShares_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_IssuanceOfOrdinarySharesAndWarrantsDueToPrivatePlacementNetOfIssuanceCostsShares_243" xlink:to="lab_entx_IssuanceOfOrdinarySharesAndWarrantsDueToPrivatePlacementNetOfIssuanceCostsShares_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_IssuanceOfOrdinarySharesAndWarrantsDueToPrivatePlacementNetOfIssuanceCostsShares_244" xlink:to="lab_entx_IssuanceOfOrdinarySharesAndWarrantsDueToPrivatePlacementNetOfIssuanceCostsShares_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_IssuanceOfSharesDueToAtMarketProgramNetOfIssuanceCostsShares_245" xlink:to="lab_entx_IssuanceOfSharesDueToAtMarketProgramNetOfIssuanceCostsShares_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_IssuanceOfSharesDueToAtMarketProgramNetOfIssuanceCostsShares_246" xlink:to="lab_entx_IssuanceOfSharesDueToAtMarketProgramNetOfIssuanceCostsShares_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_IssuanceOfSharesDueToAtMarketProgramNetOfIssuanceCostsShares_247" xlink:to="lab_entx_IssuanceOfSharesDueToAtMarketProgramNetOfIssuanceCostsShares_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_IssuanceOfSharesDueToAtMarketProgramNetOfIssuanceCostsValue_248" xlink:to="lab_entx_IssuanceOfSharesDueToAtMarketProgramNetOfIssuanceCostsValue_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_IssuanceOfSharesDueToAtMarketProgramNetOfIssuanceCostsValue_249" xlink:to="lab_entx_IssuanceOfSharesDueToAtMarketProgramNetOfIssuanceCostsValue_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_IssuanceOfSharesDueToAtMarketProgramNetOfIssuanceCostsValue_250" xlink:to="lab_entx_IssuanceOfSharesDueToAtMarketProgramNetOfIssuanceCostsValue_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_JointVentureAgreementMember_251" xlink:to="lab_entx_JointVentureAgreementMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_JointVentureAgreementMember_252" xlink:to="lab_entx_JointVentureAgreementMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_JointVentureAgreementMember_253" xlink:to="lab_entx_JointVentureAgreementMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_LaboratoryEquipmentMember_254" xlink:to="lab_entx_LaboratoryEquipmentMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_LaboratoryEquipmentMember_255" xlink:to="lab_entx_LaboratoryEquipmentMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_LaboratoryEquipmentMember_256" xlink:to="lab_entx_LaboratoryEquipmentMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_LeaseArrangementAxis_257" xlink:to="lab_entx_LeaseArrangementAxis_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_LeaseArrangementAxis_258" xlink:to="lab_entx_LeaseArrangementAxis_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_LeaseArrangementDomain_259" xlink:to="lab_entx_LeaseArrangementDomain_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_LeaseArrangementDomain_260" xlink:to="lab_entx_LeaseArrangementDomain_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_LiabilityForEmployeeRightsUponRetirement_261" xlink:to="lab_entx_LiabilityForEmployeeRightsUponRetirement_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_LiabilityForEmployeeRightsUponRetirement_262" xlink:to="lab_entx_LiabilityForEmployeeRightsUponRetirement_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_LiabilityForEmployeeRightsUponRetirement_263" xlink:to="lab_entx_LiabilityForEmployeeRightsUponRetirement_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_ManagementAndConsultingFees_264" xlink:to="lab_entx_ManagementAndConsultingFees_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_ManagementAndConsultingFees_265" xlink:to="lab_entx_ManagementAndConsultingFees_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_ManagementAndConsultingFees_266" xlink:to="lab_entx_ManagementAndConsultingFees_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_NetProceedsFromIssuanceOfCommonStock_267" xlink:to="lab_entx_NetProceedsFromIssuanceOfCommonStock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_NetProceedsFromIssuanceOfCommonStock_268" xlink:to="lab_entx_NetProceedsFromIssuanceOfCommonStock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_NetProceedsFromIssuanceOfCommonStock_269" xlink:to="lab_entx_NetProceedsFromIssuanceOfCommonStock_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_NonExecutiveBoardMember_270" xlink:to="lab_entx_NonExecutiveBoardMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_NonExecutiveBoardMember_271" xlink:to="lab_entx_NonExecutiveBoardMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_NonExecutiveDirectorMember_272" xlink:to="lab_entx_NonExecutiveDirectorMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_NonExecutiveDirectorMember_273" xlink:to="lab_entx_NonExecutiveDirectorMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_NonExecutiveDirectorMember_274" xlink:to="lab_entx_NonExecutiveDirectorMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_NonExecutiveDirectorsMember_275" xlink:to="lab_entx_NonExecutiveDirectorsMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_NonExecutiveDirectorsMember_276" xlink:to="lab_entx_NonExecutiveDirectorsMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_NonExecutiveDirectorsMember_277" xlink:to="lab_entx_NonExecutiveDirectorsMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_NonRefundableAndNonCreditableInitialTechnologyAccessFeePayment_278" xlink:to="lab_entx_NonRefundableAndNonCreditableInitialTechnologyAccessFeePayment_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_NonRefundableAndNonCreditableInitialTechnologyAccessFeePayment_279" xlink:to="lab_entx_NonRefundableAndNonCreditableInitialTechnologyAccessFeePayment_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_NonRefundableAndNonCreditableInitialTechnologyAccessFeePayment_280" xlink:to="lab_entx_NonRefundableAndNonCreditableInitialTechnologyAccessFeePayment_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_NonRefundableAndNonCreditableInitialTechnologyAccessFeePayment_281" xlink:to="lab_entx_NonRefundableAndNonCreditableInitialTechnologyAccessFeePayment_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_NumberOfNonExecutiveBoardMembers_282" xlink:to="lab_entx_NumberOfNonExecutiveBoardMembers_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_NumberOfNonExecutiveBoardMembers_283" xlink:to="lab_entx_NumberOfNonExecutiveBoardMembers_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_NumberOfNonExecutiveBoardMembers_284" xlink:to="lab_entx_NumberOfNonExecutiveBoardMembers_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_NumberOfSharesIssuedUnderPrivatePlacement_285" xlink:to="lab_entx_NumberOfSharesIssuedUnderPrivatePlacement_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_NumberOfSharesIssuedUnderPrivatePlacement_286" xlink:to="lab_entx_NumberOfSharesIssuedUnderPrivatePlacement_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_NumberOfSharesIssuedUnderPrivatePlacement_287" xlink:to="lab_entx_NumberOfSharesIssuedUnderPrivatePlacement_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_OneTimeTerminationPayment_288" xlink:to="lab_entx_OneTimeTerminationPayment_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_OneTimeTerminationPayment_289" xlink:to="lab_entx_OneTimeTerminationPayment_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_OneTimeTerminationPayment_290" xlink:to="lab_entx_OneTimeTerminationPayment_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_OperatingLeaseAgreementsForOfficeAndResearchAndDevelopmentSpaceMember_291" xlink:to="lab_entx_OperatingLeaseAgreementsForOfficeAndResearchAndDevelopmentSpaceMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_OperatingLeaseAgreementsForOfficeAndResearchAndDevelopmentSpaceMember_292" xlink:to="lab_entx_OperatingLeaseAgreementsForOfficeAndResearchAndDevelopmentSpaceMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_OperatingLeaseAgreementsForOfficeAndResearchAndDevelopmentSpaceMember_293" xlink:to="lab_entx_OperatingLeaseAgreementsForOfficeAndResearchAndDevelopmentSpaceMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_OperatingLeaseAgreementsForVehiclesForEmployeesMember_294" xlink:to="lab_entx_OperatingLeaseAgreementsForVehiclesForEmployeesMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_OperatingLeaseAgreementsForVehiclesForEmployeesMember_295" xlink:to="lab_entx_OperatingLeaseAgreementsForVehiclesForEmployeesMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_OperatingLeaseAgreementsForVehiclesForEmployeesMember_296" xlink:to="lab_entx_OperatingLeaseAgreementsForVehiclesForEmployeesMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_OperatingLeaseLiabilityAndOperatingLeaseRightOfUseAssetTableTextBlock_297" xlink:to="lab_entx_OperatingLeaseLiabilityAndOperatingLeaseRightOfUseAssetTableTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_OperatingLeaseLiabilityAndOperatingLeaseRightOfUseAssetTableTextBlock_298" xlink:to="lab_entx_OperatingLeaseLiabilityAndOperatingLeaseRightOfUseAssetTableTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_OperatingLeaseLiabilityAndOperatingLeaseRightOfUseAssetTableTextBlock_299" xlink:to="lab_entx_OperatingLeaseLiabilityAndOperatingLeaseRightOfUseAssetTableTextBlock_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_OperatingLeaseSupplementalCashFlowInformationTableTextBlock_300" xlink:to="lab_entx_OperatingLeaseSupplementalCashFlowInformationTableTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_OperatingLeaseSupplementalCashFlowInformationTableTextBlock_301" xlink:to="lab_entx_OperatingLeaseSupplementalCashFlowInformationTableTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_OperatingLeaseSupplementalCashFlowInformationTableTextBlock_302" xlink:to="lab_entx_OperatingLeaseSupplementalCashFlowInformationTableTextBlock_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_OramedLtdMember_303" xlink:to="lab_entx_OramedLtdMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_OramedLtdMember_304" xlink:to="lab_entx_OramedLtdMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_OramedLtdMember_305" xlink:to="lab_entx_OramedLtdMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_PatentCostsPolicyTextBlock_306" xlink:to="lab_entx_PatentCostsPolicyTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_PatentCostsPolicyTextBlock_307" xlink:to="lab_entx_PatentCostsPolicyTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_PatentCostsPolicyTextBlock_308" xlink:to="lab_entx_PatentCostsPolicyTextBlock_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_PatentTransferAgreementMember_309" xlink:to="lab_entx_PatentTransferAgreementMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_PatentTransferAgreementMember_310" xlink:to="lab_entx_PatentTransferAgreementMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_PatentTransferAgreementMember_311" xlink:to="lab_entx_PatentTransferAgreementMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_PaymentOfRoyaltyGuaranteesCommitments_312" xlink:to="lab_entx_PaymentOfRoyaltyGuaranteesCommitments_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_PaymentOfRoyaltyGuaranteesCommitments_313" xlink:to="lab_entx_PaymentOfRoyaltyGuaranteesCommitments_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_PaymentOfRoyaltyGuaranteesCommitments_314" xlink:to="lab_entx_PaymentOfRoyaltyGuaranteesCommitments_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_PlacementAgencyAgreementWithGpNumenkariIncMember_315" xlink:to="lab_entx_PlacementAgencyAgreementWithGpNumenkariIncMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_PlacementAgencyAgreementWithGpNumenkariIncMember_316" xlink:to="lab_entx_PlacementAgencyAgreementWithGpNumenkariIncMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_PlacementAgencyAgreementWithGpNumenkariIncMember_317" xlink:to="lab_entx_PlacementAgencyAgreementWithGpNumenkariIncMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_PresidentOfResearchAndDevelopmentMember_318" xlink:to="lab_entx_PresidentOfResearchAndDevelopmentMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_PresidentOfResearchAndDevelopmentMember_319" xlink:to="lab_entx_PresidentOfResearchAndDevelopmentMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_PresidentOfResearchAndDevelopmentMember_320" xlink:to="lab_entx_PresidentOfResearchAndDevelopmentMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_ProceedsFromIssuanceOfSharesAndWarrantsNetOfIssuanceCosts_321" xlink:to="lab_entx_ProceedsFromIssuanceOfSharesAndWarrantsNetOfIssuanceCosts_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_ProceedsFromIssuanceOfSharesAndWarrantsNetOfIssuanceCosts_322" xlink:to="lab_entx_ProceedsFromIssuanceOfSharesAndWarrantsNetOfIssuanceCosts_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_ProceedsFromIssuanceOfSharesAndWarrantsNetOfIssuanceCosts_323" xlink:to="lab_entx_ProceedsFromIssuanceOfSharesAndWarrantsNetOfIssuanceCosts_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_ProceedsFromIssuanceOfSharesThroughAtmProgramsNetOfIssuanceCosts_324" xlink:to="lab_entx_ProceedsFromIssuanceOfSharesThroughAtmProgramsNetOfIssuanceCosts_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_ProceedsFromIssuanceOfSharesThroughAtmProgramsNetOfIssuanceCosts_325" xlink:to="lab_entx_ProceedsFromIssuanceOfSharesThroughAtmProgramsNetOfIssuanceCosts_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_ProceedsFromIssuanceOfSharesThroughAtmProgramsNetOfIssuanceCosts_326" xlink:to="lab_entx_ProceedsFromIssuanceOfSharesThroughAtmProgramsNetOfIssuanceCosts_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_ProceedsFromOptionsAndWarrantExercises_327" xlink:to="lab_entx_ProceedsFromOptionsAndWarrantExercises_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_ProceedsFromOptionsAndWarrantExercises_328" xlink:to="lab_entx_ProceedsFromOptionsAndWarrantExercises_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_ProceedsFromOptionsAndWarrantExercises_329" xlink:to="lab_entx_ProceedsFromOptionsAndWarrantExercises_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_ProceedsFromShortTermBankDeposits_330" xlink:to="lab_entx_ProceedsFromShortTermBankDeposits_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_ProceedsFromShortTermBankDeposits_331" xlink:to="lab_entx_ProceedsFromShortTermBankDeposits_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_ProceedsFromShortTermBankDeposits_332" xlink:to="lab_entx_ProceedsFromShortTermBankDeposits_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_ProceedsFromShortTermBankDeposits_333" xlink:to="lab_entx_ProceedsFromShortTermBankDeposits_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_ProceedsFromShortTermBankDeposits_334" xlink:to="lab_entx_ProceedsFromShortTermBankDeposits_4"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_ReconciliationInAmountsOnConsolidatedBalanceSheetsAbstract_335" xlink:to="lab_entx_ReconciliationInAmountsOnConsolidatedBalanceSheetsAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_ReconciliationInAmountsOnConsolidatedBalanceSheetsAbstract_336" xlink:to="lab_entx_ReconciliationInAmountsOnConsolidatedBalanceSheetsAbstract_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_RelatedPartyTransactionOfCompensationOfExecutiveOfficers_337" xlink:to="lab_entx_RelatedPartyTransactionOfCompensationOfExecutiveOfficers_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_RelatedPartyTransactionOfCompensationOfExecutiveOfficers_338" xlink:to="lab_entx_RelatedPartyTransactionOfCompensationOfExecutiveOfficers_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_RelatedPartyTransactionOfCompensationOfExecutiveOfficers_339" xlink:to="lab_entx_RelatedPartyTransactionOfCompensationOfExecutiveOfficers_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_RelatedPartyTransactionOfManagementAndConsultingFeesToBoardMembers_340" xlink:to="lab_entx_RelatedPartyTransactionOfManagementAndConsultingFeesToBoardMembers_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_RelatedPartyTransactionOfManagementAndConsultingFeesToBoardMembers_341" xlink:to="lab_entx_RelatedPartyTransactionOfManagementAndConsultingFeesToBoardMembers_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_RelatedPartyTransactionOfManagementAndConsultingFeesToBoardMembers_342" xlink:to="lab_entx_RelatedPartyTransactionOfManagementAndConsultingFeesToBoardMembers_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_RelatedPartyTransactionOfStockBasedCompensationExpensesToBoardMembers_343" xlink:to="lab_entx_RelatedPartyTransactionOfStockBasedCompensationExpensesToBoardMembers_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_RelatedPartyTransactionOfStockBasedCompensationExpensesToBoardMembers_344" xlink:to="lab_entx_RelatedPartyTransactionOfStockBasedCompensationExpensesToBoardMembers_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_RelatedPartyTransactionOfStockBasedCompensationExpensesToBoardMembers_345" xlink:to="lab_entx_RelatedPartyTransactionOfStockBasedCompensationExpensesToBoardMembers_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_RelatedPartyTransactionOfStockBasedCompensationExpensesToExecutiveOfficers_346" xlink:to="lab_entx_RelatedPartyTransactionOfStockBasedCompensationExpensesToExecutiveOfficers_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_RelatedPartyTransactionOfStockBasedCompensationExpensesToExecutiveOfficers_347" xlink:to="lab_entx_RelatedPartyTransactionOfStockBasedCompensationExpensesToExecutiveOfficers_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_RelatedPartyTransactionOfStockBasedCompensationExpensesToExecutiveOfficers_348" xlink:to="lab_entx_RelatedPartyTransactionOfStockBasedCompensationExpensesToExecutiveOfficers_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_RelatedPartyTransactionWithExecutiveOfficersPayables_349" xlink:to="lab_entx_RelatedPartyTransactionWithExecutiveOfficersPayables_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_RelatedPartyTransactionWithExecutiveOfficersPayables_350" xlink:to="lab_entx_RelatedPartyTransactionWithExecutiveOfficersPayables_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_RelatedPartyTransactionWithExecutiveOfficersPayables_351" xlink:to="lab_entx_RelatedPartyTransactionWithExecutiveOfficersPayables_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_RelatedPartyTransactionWithNonExecutiveDirectorsPayable_352" xlink:to="lab_entx_RelatedPartyTransactionWithNonExecutiveDirectorsPayable_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_RelatedPartyTransactionWithNonExecutiveDirectorsPayable_353" xlink:to="lab_entx_RelatedPartyTransactionWithNonExecutiveDirectorsPayable_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_RelatedPartyTransactionWithNonExecutiveDirectorsPayable_354" xlink:to="lab_entx_RelatedPartyTransactionWithNonExecutiveDirectorsPayable_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_ResearchAndDevelopmentServiceExpense_355" xlink:to="lab_entx_ResearchAndDevelopmentServiceExpense_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_ResearchAndDevelopmentServiceExpense_356" xlink:to="lab_entx_ResearchAndDevelopmentServiceExpense_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_ResearchAndDevelopmentServiceExpense_357" xlink:to="lab_entx_ResearchAndDevelopmentServiceExpense_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_ResearchCollaborationAndLicenseAgreementMember_358" xlink:to="lab_entx_ResearchCollaborationAndLicenseAgreementMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_ResearchCollaborationAndLicenseAgreementMember_359" xlink:to="lab_entx_ResearchCollaborationAndLicenseAgreementMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_ResearchCollaborationAndLicenseAgreementMember_360" xlink:to="lab_entx_ResearchCollaborationAndLicenseAgreementMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_ReversalOfExpensesUponForfeitureOfOptions_361" xlink:to="lab_entx_ReversalOfExpensesUponForfeitureOfOptions_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_ReversalOfExpensesUponForfeitureOfOptions_362" xlink:to="lab_entx_ReversalOfExpensesUponForfeitureOfOptions_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_ReversalOfExpensesUponForfeitureOfOptions_363" xlink:to="lab_entx_ReversalOfExpensesUponForfeitureOfOptions_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_RightOfUseAssetsObtainedInExchangeForNewOperatingLeaseLiabilities_364" xlink:to="lab_entx_RightOfUseAssetsObtainedInExchangeForNewOperatingLeaseLiabilities_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_RightOfUseAssetsObtainedInExchangeForNewOperatingLeaseLiabilities_365" xlink:to="lab_entx_RightOfUseAssetsObtainedInExchangeForNewOperatingLeaseLiabilities_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_RightOfUseAssetsObtainedInExchangeForNewOperatingLeaseLiabilities_366" xlink:to="lab_entx_RightOfUseAssetsObtainedInExchangeForNewOperatingLeaseLiabilities_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_RightToUseIntellectualProperty_367" xlink:to="lab_entx_RightToUseIntellectualProperty_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_RightToUseIntellectualProperty_368" xlink:to="lab_entx_RightToUseIntellectualProperty_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_RightToUseIntellectualProperty_369" xlink:to="lab_entx_RightToUseIntellectualProperty_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_RoyaltyGuaranteesCommitmentsPercentageOfEachPaymentReceivedFromAmgen_370" xlink:to="lab_entx_RoyaltyGuaranteesCommitmentsPercentageOfEachPaymentReceivedFromAmgen_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_RoyaltyGuaranteesCommitmentsPercentageOfEachPaymentReceivedFromAmgen_371" xlink:to="lab_entx_RoyaltyGuaranteesCommitmentsPercentageOfEachPaymentReceivedFromAmgen_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_RoyaltyGuaranteesCommitmentsPercentageOfEachPaymentReceivedFromAmgen_372" xlink:to="lab_entx_RoyaltyGuaranteesCommitmentsPercentageOfEachPaymentReceivedFromAmgen_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_RoyaltyGuaranteesCommitmentsPercentageOfNetRevenues_373" xlink:to="lab_entx_RoyaltyGuaranteesCommitmentsPercentageOfNetRevenues_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_RoyaltyGuaranteesCommitmentsPercentageOfNetRevenues_374" xlink:to="lab_entx_RoyaltyGuaranteesCommitmentsPercentageOfNetRevenues_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_RoyaltyGuaranteesCommitmentsPercentageOfNetRevenues_375" xlink:to="lab_entx_RoyaltyGuaranteesCommitmentsPercentageOfNetRevenues_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_RoyaltyGuaranteesCommitmentsPercentageSalesOfProductsDevelopedFromProjectsCommencingSeventhYear_376" xlink:to="lab_entx_RoyaltyGuaranteesCommitmentsPercentageSalesOfProductsDevelopedFromProjectsCommencingSeventhYear_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_RoyaltyGuaranteesCommitmentsPercentageSalesOfProductsDevelopedFromProjectsCommencingSeventhYear_377" xlink:to="lab_entx_RoyaltyGuaranteesCommitmentsPercentageSalesOfProductsDevelopedFromProjectsCommencingSeventhYear_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_RoyaltyGuaranteesCommitmentsPercentageSalesOfProductsDevelopedFromProjectsCommencingSeventhYear_378" xlink:to="lab_entx_RoyaltyGuaranteesCommitmentsPercentageSalesOfProductsDevelopedFromProjectsCommencingSeventhYear_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_RoyaltyGuaranteesCommitmentsPercentageSalesOfProductsDevelopedFromProjectsInFirstThreeYearsFromCommencementOfRevenues_379" xlink:to="lab_entx_RoyaltyGuaranteesCommitmentsPercentageSalesOfProductsDevelopedFromProjectsInFirstThreeYearsFromCommencementOfRevenues_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_RoyaltyGuaranteesCommitmentsPercentageSalesOfProductsDevelopedFromProjectsInFirstThreeYearsFromCommencementOfRevenues_380" xlink:to="lab_entx_RoyaltyGuaranteesCommitmentsPercentageSalesOfProductsDevelopedFromProjectsInFirstThreeYearsFromCommencementOfRevenues_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_RoyaltyGuaranteesCommitmentsPercentageSalesOfProductsDevelopedFromProjectsInFirstThreeYearsFromCommencementOfRevenues_381" xlink:to="lab_entx_RoyaltyGuaranteesCommitmentsPercentageSalesOfProductsDevelopedFromProjectsInFirstThreeYearsFromCommencementOfRevenues_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_RoyaltyGuaranteesCommitmentsPercentageSalesOfProductsDevelopedFromProjectsSubsequentThreeYears_382" xlink:to="lab_entx_RoyaltyGuaranteesCommitmentsPercentageSalesOfProductsDevelopedFromProjectsSubsequentThreeYears_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_RoyaltyGuaranteesCommitmentsPercentageSalesOfProductsDevelopedFromProjectsSubsequentThreeYears_383" xlink:to="lab_entx_RoyaltyGuaranteesCommitmentsPercentageSalesOfProductsDevelopedFromProjectsSubsequentThreeYears_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_RoyaltyGuaranteesCommitmentsPercentageSalesOfProductsDevelopedFromProjectsSubsequentThreeYears_384" xlink:to="lab_entx_RoyaltyGuaranteesCommitmentsPercentageSalesOfProductsDevelopedFromProjectsSubsequentThreeYears_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_SaleOfStockAmountOfInvestment_385" xlink:to="lab_entx_SaleOfStockAmountOfInvestment_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_SaleOfStockAmountOfInvestment_386" xlink:to="lab_entx_SaleOfStockAmountOfInvestment_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_SaleOfStockAmountOfInvestment_387" xlink:to="lab_entx_SaleOfStockAmountOfInvestment_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_SaleOfStockPercentageOfOwnershipOfEntityAcquired_388" xlink:to="lab_entx_SaleOfStockPercentageOfOwnershipOfEntityAcquired_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_SaleOfStockPercentageOfOwnershipOfEntityAcquired_389" xlink:to="lab_entx_SaleOfStockPercentageOfOwnershipOfEntityAcquired_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_SaleOfStockPercentageOfOwnershipOfEntityAcquired_390" xlink:to="lab_entx_SaleOfStockPercentageOfOwnershipOfEntityAcquired_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_ScheduleOfEstimatedUsefulLifeTableTextBlock_391" xlink:to="lab_entx_ScheduleOfEstimatedUsefulLifeTableTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_ScheduleOfEstimatedUsefulLifeTableTextBlock_392" xlink:to="lab_entx_ScheduleOfEstimatedUsefulLifeTableTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_ScheduleOfEstimatedUsefulLifeTableTextBlock_393" xlink:to="lab_entx_ScheduleOfEstimatedUsefulLifeTableTextBlock_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_ScheduleOfRelatedPartyTransactionReportedInConsolidatedStatementsOfComprehensiveLossTableTextBlock_394" xlink:to="lab_entx_ScheduleOfRelatedPartyTransactionReportedInConsolidatedStatementsOfComprehensiveLossTableTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_ScheduleOfRelatedPartyTransactionReportedInConsolidatedStatementsOfComprehensiveLossTableTextBlock_395" xlink:to="lab_entx_ScheduleOfRelatedPartyTransactionReportedInConsolidatedStatementsOfComprehensiveLossTableTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_ScheduleOfRelatedPartyTransactionReportedInConsolidatedStatementsOfComprehensiveLossTableTextBlock_396" xlink:to="lab_entx_ScheduleOfRelatedPartyTransactionReportedInConsolidatedStatementsOfComprehensiveLossTableTextBlock_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_ScheduleOfRelatedPartyTransactionsReportedInConsolidatedBalanceSheetsTableTextBlock_397" xlink:to="lab_entx_ScheduleOfRelatedPartyTransactionsReportedInConsolidatedBalanceSheetsTableTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_ScheduleOfRelatedPartyTransactionsReportedInConsolidatedBalanceSheetsTableTextBlock_398" xlink:to="lab_entx_ScheduleOfRelatedPartyTransactionsReportedInConsolidatedBalanceSheetsTableTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_ScheduleOfRelatedPartyTransactionsReportedInConsolidatedBalanceSheetsTableTextBlock_399" xlink:to="lab_entx_ScheduleOfRelatedPartyTransactionsReportedInConsolidatedBalanceSheetsTableTextBlock_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_SellingPriceOfPreclinicalResearchAndDevelopmentServices_400" xlink:to="lab_entx_SellingPriceOfPreclinicalResearchAndDevelopmentServices_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_SellingPriceOfPreclinicalResearchAndDevelopmentServices_401" xlink:to="lab_entx_SellingPriceOfPreclinicalResearchAndDevelopmentServices_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_SellingPriceOfPreclinicalResearchAndDevelopmentServices_402" xlink:to="lab_entx_SellingPriceOfPreclinicalResearchAndDevelopmentServices_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_ServiceProviderMember_403" xlink:to="lab_entx_ServiceProviderMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_ServiceProviderMember_404" xlink:to="lab_entx_ServiceProviderMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_ServiceProviderMember_405" xlink:to="lab_entx_ServiceProviderMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_SeveralEmployeesAndServiceProvidersMember_406" xlink:to="lab_entx_SeveralEmployeesAndServiceProvidersMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_SeveralEmployeesAndServiceProvidersMember_407" xlink:to="lab_entx_SeveralEmployeesAndServiceProvidersMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_SeveralEmployeesAndServiceProvidersMember_408" xlink:to="lab_entx_SeveralEmployeesAndServiceProvidersMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_SeveranceExpenses_409" xlink:to="lab_entx_SeveranceExpenses_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_SeveranceExpenses_410" xlink:to="lab_entx_SeveranceExpenses_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_SeveranceExpenses_411" xlink:to="lab_entx_SeveranceExpenses_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_SeverancePayPolicyTextBlock_412" xlink:to="lab_entx_SeverancePayPolicyTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_SeverancePayPolicyTextBlock_413" xlink:to="lab_entx_SeverancePayPolicyTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_SeverancePayPolicyTextBlock_414" xlink:to="lab_entx_SeverancePayPolicyTextBlock_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsTotalConsideration_415" xlink:to="lab_entx_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsTotalConsideration_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsTotalConsideration_416" xlink:to="lab_entx_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsTotalConsideration_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsTotalConsideration_417" xlink:to="lab_entx_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsTotalConsideration_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_ShareBasedPaymentArrangementTrancheFiveMember_418" xlink:to="lab_entx_ShareBasedPaymentArrangementTrancheFiveMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_ShareBasedPaymentArrangementTrancheFiveMember_419" xlink:to="lab_entx_ShareBasedPaymentArrangementTrancheFiveMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_ShareBasedPaymentArrangementTrancheFiveMember_420" xlink:to="lab_entx_ShareBasedPaymentArrangementTrancheFiveMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_ShareBasedPaymentArrangementTrancheFourMember_421" xlink:to="lab_entx_ShareBasedPaymentArrangementTrancheFourMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_ShareBasedPaymentArrangementTrancheFourMember_422" xlink:to="lab_entx_ShareBasedPaymentArrangementTrancheFourMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_ShareBasedPaymentArrangementTrancheFourMember_423" xlink:to="lab_entx_ShareBasedPaymentArrangementTrancheFourMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_ShareBasedPaymentArrangementTrancheSevenMember_424" xlink:to="lab_entx_ShareBasedPaymentArrangementTrancheSevenMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_ShareBasedPaymentArrangementTrancheSevenMember_425" xlink:to="lab_entx_ShareBasedPaymentArrangementTrancheSevenMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_ShareBasedPaymentArrangementTrancheSixMember_426" xlink:to="lab_entx_ShareBasedPaymentArrangementTrancheSixMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_ShareBasedPaymentArrangementTrancheSixMember_427" xlink:to="lab_entx_ShareBasedPaymentArrangementTrancheSixMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_ShareBasedPaymentArrangementTrancheSixMember_428" xlink:to="lab_entx_ShareBasedPaymentArrangementTrancheSixMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_ShareIncentivePlan2013Member_429" xlink:to="lab_entx_ShareIncentivePlan2013Member_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_ShareIncentivePlan2013Member_430" xlink:to="lab_entx_ShareIncentivePlan2013Member_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_ShareIncentivePlan2013Member_431" xlink:to="lab_entx_ShareIncentivePlan2013Member_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_ShareIncentivePlan2018Member_432" xlink:to="lab_entx_ShareIncentivePlan2018Member_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_ShareIncentivePlan2018Member_433" xlink:to="lab_entx_ShareIncentivePlan2018Member_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_ShareIncentivePlan2018Member_434" xlink:to="lab_entx_ShareIncentivePlan2018Member_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_SharesGrantedInPercentage_435" xlink:to="lab_entx_SharesGrantedInPercentage_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_SharesGrantedInPercentage_436" xlink:to="lab_entx_SharesGrantedInPercentage_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_SharesGrantedInPercentage_437" xlink:to="lab_entx_SharesGrantedInPercentage_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_SharesIssuedWeightedAveragePricePerShare_438" xlink:to="lab_entx_SharesIssuedWeightedAveragePricePerShare_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_SharesIssuedWeightedAveragePricePerShare_439" xlink:to="lab_entx_SharesIssuedWeightedAveragePricePerShare_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_SharesIssuedWeightedAveragePricePerShare_440" xlink:to="lab_entx_SharesIssuedWeightedAveragePricePerShare_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_SignificantAccountingPoliciesLineItems_441" xlink:to="lab_entx_SignificantAccountingPoliciesLineItems_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_SignificantAccountingPoliciesLineItems_442" xlink:to="lab_entx_SignificantAccountingPoliciesLineItems_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_SignificantAccountingPoliciesTable_443" xlink:to="lab_entx_SignificantAccountingPoliciesTable_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_SignificantAccountingPoliciesTable_444" xlink:to="lab_entx_SignificantAccountingPoliciesTable_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_StockholdersEquityNoteLineItems_445" xlink:to="lab_entx_StockholdersEquityNoteLineItems_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_StockholdersEquityNoteLineItems_446" xlink:to="lab_entx_StockholdersEquityNoteLineItems_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_StockholdersEquityNoteTable_447" xlink:to="lab_entx_StockholdersEquityNoteTable_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_StockholdersEquityNoteTable_448" xlink:to="lab_entx_StockholdersEquityNoteTable_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_SupplementaryFinancialStatementInformationAbstract_449" xlink:to="lab_entx_SupplementaryFinancialStatementInformationAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_SupplementaryFinancialStatementInformationTextBlock_450" xlink:to="lab_entx_SupplementaryFinancialStatementInformationTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_SupplementaryFinancialStatementInformationTextBlock_451" xlink:to="lab_entx_SupplementaryFinancialStatementInformationTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_SupplementaryFinancialStatementInformationTextBlock_452" xlink:to="lab_entx_SupplementaryFinancialStatementInformationTextBlock_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_TransactionCosts_453" xlink:to="lab_entx_TransactionCosts_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_TransactionCosts_454" xlink:to="lab_entx_TransactionCosts_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_TransactionCosts_455" xlink:to="lab_entx_TransactionCosts_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_TriggeringEventAxis_456" xlink:to="lab_entx_TriggeringEventAxis_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_TriggeringEventAxis_457" xlink:to="lab_entx_TriggeringEventAxis_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_TriggeringEventDomain_458" xlink:to="lab_entx_TriggeringEventDomain_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_TriggeringEventDomain_459" xlink:to="lab_entx_TriggeringEventDomain_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_TriggeringEventMember_460" xlink:to="lab_entx_TriggeringEventMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_TriggeringEventMember_461" xlink:to="lab_entx_TriggeringEventMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_TriggeringEventMember_462" xlink:to="lab_entx_TriggeringEventMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_TwentySeventeenMemberMember_463" xlink:to="lab_entx_TwentySeventeenMemberMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_TwentySeventeenMemberMember_464" xlink:to="lab_entx_TwentySeventeenMemberMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_TwentySeventeenMemberMember_465" xlink:to="lab_entx_TwentySeventeenMemberMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_TwentyTwentyOneGrantMember_466" xlink:to="lab_entx_TwentyTwentyOneGrantMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_TwentyTwentyOneGrantMember_467" xlink:to="lab_entx_TwentyTwentyOneGrantMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_TwentyTwentyOneGrantMember_468" xlink:to="lab_entx_TwentyTwentyOneGrantMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_VestedRestrictedSharesUnits_469" xlink:to="lab_entx_VestedRestrictedSharesUnits_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_VestedRestrictedSharesUnits_470" xlink:to="lab_entx_VestedRestrictedSharesUnits_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_VestedRestrictedSharesUnits_471" xlink:to="lab_entx_VestedRestrictedSharesUnits_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_VestedRestrictedShareUnitsShares_472" xlink:to="lab_entx_VestedRestrictedShareUnitsShares_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_VestedRestrictedShareUnitsShares_473" xlink:to="lab_entx_VestedRestrictedShareUnitsShares_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_VestedRestrictedShareUnitsShares_474" xlink:to="lab_entx_VestedRestrictedShareUnitsShares_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_WarrantToPurchaseOrdinaryShare_475" xlink:to="lab_entx_WarrantToPurchaseOrdinaryShare_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_WarrantToPurchaseOrdinaryShare_476" xlink:to="lab_entx_WarrantToPurchaseOrdinaryShare_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_WarrantToPurchaseOrdinaryShare_477" xlink:to="lab_entx_WarrantToPurchaseOrdinaryShare_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ChiefExecutiveOfficerMember_478" xlink:to="lab_srt_ChiefExecutiveOfficerMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ChiefExecutiveOfficerMember_479" xlink:to="lab_srt_ChiefExecutiveOfficerMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ChiefExecutiveOfficerMember_480" xlink:to="lab_srt_ChiefExecutiveOfficerMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ChiefFinancialOfficerMember_481" xlink:to="lab_srt_ChiefFinancialOfficerMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ConsolidatedEntitiesAxis_482" xlink:to="lab_srt_ConsolidatedEntitiesAxis_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ConsolidatedEntitiesDomain_483" xlink:to="lab_srt_ConsolidatedEntitiesDomain_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_DirectorMember_484" xlink:to="lab_srt_DirectorMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_DirectorMember_485" xlink:to="lab_srt_DirectorMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ExecutiveOfficerMember_486" xlink:to="lab_srt_ExecutiveOfficerMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ExecutiveOfficerMember_487" xlink:to="lab_srt_ExecutiveOfficerMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ExecutiveOfficerMember_488" xlink:to="lab_srt_ExecutiveOfficerMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember_489" xlink:to="lab_srt_MaximumMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember_490" xlink:to="lab_srt_MaximumMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember_491" xlink:to="lab_srt_MinimumMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember_492" xlink:to="lab_srt_MinimumMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductOrServiceAxis_493" xlink:to="lab_srt_ProductOrServiceAxis_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductsAndServicesDomain_494" xlink:to="lab_srt_ProductsAndServicesDomain_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis_495" xlink:to="lab_srt_RangeAxis_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember_496" xlink:to="lab_srt_RangeMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_SubsidiariesMember_497" xlink:to="lab_srt_SubsidiariesMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_SubsidiariesMember_498" xlink:to="lab_srt_SubsidiariesMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_SubsidiariesMember_499" xlink:to="lab_srt_SubsidiariesMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_TitleOfIndividualAxis_500" xlink:to="lab_srt_TitleOfIndividualAxis_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_501" xlink:to="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_502" xlink:to="lab_us-gaap_AccountingPoliciesAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis_503" xlink:to="lab_us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_504" xlink:to="lab_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_505" xlink:to="lab_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_506" xlink:to="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_507" xlink:to="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_508" xlink:to="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_509" xlink:to="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_510" xlink:to="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_511" xlink:to="lab_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_512" xlink:to="lab_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent_513" xlink:to="lab_us-gaap_AccountsPayableCurrent_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent_514" xlink:to="lab_us-gaap_AccountsPayableCurrent_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent_515" xlink:to="lab_us-gaap_AccountsReceivableNetCurrent_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent_516" xlink:to="lab_us-gaap_AccountsReceivableNetCurrent_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedEmployeeBenefitsCurrent_517" xlink:to="lab_us-gaap_AccruedEmployeeBenefitsCurrent_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedEmployeeBenefitsCurrent_518" xlink:to="lab_us-gaap_AccruedEmployeeBenefitsCurrent_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedIncomeTaxesCurrent_519" xlink:to="lab_us-gaap_AccruedIncomeTaxesCurrent_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedIncomeTaxesCurrent_520" xlink:to="lab_us-gaap_AccruedIncomeTaxesCurrent_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilities_521" xlink:to="lab_us-gaap_AccruedLiabilitiesAndOtherLiabilities_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilities_522" xlink:to="lab_us-gaap_AccruedLiabilitiesAndOtherLiabilities_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilities_523" xlink:to="lab_us-gaap_AccruedLiabilitiesAndOtherLiabilities_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilities_524" xlink:to="lab_us-gaap_AccruedLiabilitiesAndOtherLiabilities_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_525" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrent_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_526" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrent_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedVacationCurrent_527" xlink:to="lab_us-gaap_AccruedVacationCurrent_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedVacationCurrent_528" xlink:to="lab_us-gaap_AccruedVacationCurrent_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_529" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_530" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_531" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_532" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalFinancialInformationDisclosureTextBlock_533" xlink:to="lab_us-gaap_AdditionalFinancialInformationDisclosureTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalFinancialInformationDisclosureTextBlock_534" xlink:to="lab_us-gaap_AdditionalFinancialInformationDisclosureTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalCommonStock_535" xlink:to="lab_us-gaap_AdditionalPaidInCapitalCommonStock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalCommonStock_536" xlink:to="lab_us-gaap_AdditionalPaidInCapitalCommonStock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember_537" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember_538" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalOther_539" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalOther_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalOther_540" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalOther_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_541" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_542" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition_543" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition_544" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_545" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_546" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense_547" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense_548" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense_549" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_550" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_551" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_552" xlink:to="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets_553" xlink:to="lab_us-gaap_Assets_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets_554" xlink:to="lab_us-gaap_Assets_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract_555" xlink:to="lab_us-gaap_AssetsAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract_556" xlink:to="lab_us-gaap_AssetsAbstract_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent_557" xlink:to="lab_us-gaap_AssetsCurrent_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent_558" xlink:to="lab_us-gaap_AssetsCurrent_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract_559" xlink:to="lab_us-gaap_AssetsCurrentAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsNoncurrent_560" xlink:to="lab_us-gaap_AssetsNoncurrent_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsNoncurrent_561" xlink:to="lab_us-gaap_AssetsNoncurrent_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_562" xlink:to="lab_us-gaap_AssetsNoncurrentAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis_563" xlink:to="lab_us-gaap_AwardTypeAxis_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_564" xlink:to="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_565" xlink:to="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_566" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_567" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_568" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_569" xlink:to="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_570" xlink:to="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_571" xlink:to="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_572" xlink:to="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_573" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_574" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_575" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_576" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_577" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_578" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockDomain_579" xlink:to="lab_us-gaap_ClassOfStockDomain_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_580" xlink:to="lab_us-gaap_ClassOfWarrantOrRightAxis_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_581" xlink:to="lab_us-gaap_ClassOfWarrantOrRightDomain_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_582" xlink:to="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_583" xlink:to="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_584" xlink:to="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_585" xlink:to="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies_586" xlink:to="lab_us-gaap_CommitmentsAndContingencies_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies_587" xlink:to="lab_us-gaap_CommitmentsAndContingencies_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_588" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_589" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_590" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesPolicyTextBlock_591" xlink:to="lab_us-gaap_CommitmentsAndContingenciesPolicyTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesPolicyTextBlock_592" xlink:to="lab_us-gaap_CommitmentsAndContingenciesPolicyTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember_593" xlink:to="lab_us-gaap_CommonStockMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember_594" xlink:to="lab_us-gaap_CommonStockMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare_595" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare_596" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized_597" xlink:to="lab_us-gaap_CommonStockSharesAuthorized_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized_598" xlink:to="lab_us-gaap_CommonStockSharesAuthorized_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued_599" xlink:to="lab_us-gaap_CommonStockSharesIssued_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued_600" xlink:to="lab_us-gaap_CommonStockSharesIssued_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding_601" xlink:to="lab_us-gaap_CommonStockSharesOutstanding_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding_602" xlink:to="lab_us-gaap_CommonStockSharesOutstanding_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue_603" xlink:to="lab_us-gaap_CommonStockValue_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue_604" xlink:to="lab_us-gaap_CommonStockValue_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue_605" xlink:to="lab_us-gaap_CommonStockValue_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue_606" xlink:to="lab_us-gaap_CommonStockValue_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue_607" xlink:to="lab_us-gaap_CommonStockValue_4"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue_608" xlink:to="lab_us-gaap_CommonStockValue_5"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValueOutstanding_609" xlink:to="lab_us-gaap_CommonStockValueOutstanding_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValueOutstanding_610" xlink:to="lab_us-gaap_CommonStockValueOutstanding_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockVotingRights_611" xlink:to="lab_us-gaap_CommonStockVotingRights_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockVotingRights_612" xlink:to="lab_us-gaap_CommonStockVotingRights_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CompensationExpenseExcludingCostOfGoodAndServiceSold_613" xlink:to="lab_us-gaap_CompensationExpenseExcludingCostOfGoodAndServiceSold_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CompensationExpenseExcludingCostOfGoodAndServiceSold_614" xlink:to="lab_us-gaap_CompensationExpenseExcludingCostOfGoodAndServiceSold_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComputerEquipmentMember_615" xlink:to="lab_us-gaap_ComputerEquipmentMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComputerEquipmentMember_616" xlink:to="lab_us-gaap_ComputerEquipmentMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskCreditRisk_617" xlink:to="lab_us-gaap_ConcentrationRiskCreditRisk_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskCreditRisk_618" xlink:to="lab_us-gaap_ConcentrationRiskCreditRisk_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConsolidationPolicyTextBlock_619" xlink:to="lab_us-gaap_ConsolidationPolicyTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConsolidationPolicyTextBlock_620" xlink:to="lab_us-gaap_ConsolidationPolicyTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiability_621" xlink:to="lab_us-gaap_ContractWithCustomerLiability_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiability_622" xlink:to="lab_us-gaap_ContractWithCustomerLiability_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityCurrent_623" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityCurrent_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityCurrent_624" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityCurrent_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityCurrent_625" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityCurrent_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_626" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_627" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfRevenue_628" xlink:to="lab_us-gaap_CostOfRevenue_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfRevenue_629" xlink:to="lab_us-gaap_CostOfRevenue_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfSalesMember_630" xlink:to="lab_us-gaap_CostOfSalesMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfSalesMember_631" xlink:to="lab_us-gaap_CostOfSalesMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract_632" xlink:to="lab_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract_633" xlink:to="lab_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_634" xlink:to="lab_us-gaap_CurrentIncomeTaxExpenseBenefit_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_635" xlink:to="lab_us-gaap_CurrentIncomeTaxExpenseBenefit_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit_636" xlink:to="lab_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit_637" xlink:to="lab_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit_638" xlink:to="lab_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract_639" xlink:to="lab_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract_640" xlink:to="lab_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxAssetsNet_641" xlink:to="lab_us-gaap_DeferredIncomeTaxAssetsNet_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxAssetsNet_642" xlink:to="lab_us-gaap_DeferredIncomeTaxAssetsNet_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_643" xlink:to="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_644" xlink:to="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_645" xlink:to="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_646" xlink:to="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredRevenueRevenueRecognized1_647" xlink:to="lab_us-gaap_DeferredRevenueRevenueRecognized1_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredRevenueRevenueRecognized1_648" xlink:to="lab_us-gaap_DeferredRevenueRevenueRecognized1_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_649" xlink:to="lab_us-gaap_DeferredTaxAssetsGross_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_650" xlink:to="lab_us-gaap_DeferredTaxAssetsGross_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_651" xlink:to="lab_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_652" xlink:to="lab_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsNet_653" xlink:to="lab_us-gaap_DeferredTaxAssetsNet_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsNet_654" xlink:to="lab_us-gaap_DeferredTaxAssetsNet_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsNet_655" xlink:to="lab_us-gaap_DeferredTaxAssetsNet_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract_656" xlink:to="lab_us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract_657" xlink:to="lab_us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_658" xlink:to="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_659" xlink:to="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOther_660" xlink:to="lab_us-gaap_DeferredTaxAssetsOther_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOther_661" xlink:to="lab_us-gaap_DeferredTaxAssetsOther_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_662" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_663" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsValuationAllowance_664" xlink:to="lab_us-gaap_DeferredTaxAssetsValuationAllowance_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsValuationAllowance_665" xlink:to="lab_us-gaap_DeferredTaxAssetsValuationAllowance_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsValuationAllowance_666" xlink:to="lab_us-gaap_DeferredTaxAssetsValuationAllowance_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsValuationAllowance_667" xlink:to="lab_us-gaap_DeferredTaxAssetsValuationAllowance_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsValuationAllowance_668" xlink:to="lab_us-gaap_DeferredTaxAssetsValuationAllowance_4"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsValuationAllowance_669" xlink:to="lab_us-gaap_DeferredTaxAssetsValuationAllowance_5"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsValuationAllowance_670" xlink:to="lab_us-gaap_DeferredTaxAssetsValuationAllowance_6"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent_671" xlink:to="lab_us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent_672" xlink:to="lab_us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Depreciation_673" xlink:to="lab_us-gaap_Depreciation_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Depreciation_674" xlink:to="lab_us-gaap_Depreciation_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativesPolicyTextBlock_675" xlink:to="lab_us-gaap_DerivativesPolicyTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativesPolicyTextBlock_676" xlink:to="lab_us-gaap_DerivativesPolicyTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DescriptionOfPostemploymentBenefits_677" xlink:to="lab_us-gaap_DescriptionOfPostemploymentBenefits_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DescriptionOfPostemploymentBenefits_678" xlink:to="lab_us-gaap_DescriptionOfPostemploymentBenefits_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_679" xlink:to="lab_us-gaap_DisaggregationOfRevenueLineItems_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_680" xlink:to="lab_us-gaap_DisaggregationOfRevenueTable_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_681" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_682" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_683" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DomesticCountryMember_684" xlink:to="lab_us-gaap_DomesticCountryMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DomesticCountryMember_685" xlink:to="lab_us-gaap_DomesticCountryMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent_686" xlink:to="lab_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic_687" xlink:to="lab_us-gaap_EarningsPerShareBasic_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic_688" xlink:to="lab_us-gaap_EarningsPerShareBasic_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted_689" xlink:to="lab_us-gaap_EarningsPerShareDiluted_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted_690" xlink:to="lab_us-gaap_EarningsPerShareDiluted_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerSharePolicyTextBlock_691" xlink:to="lab_us-gaap_EarningsPerSharePolicyTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerSharePolicyTextBlock_692" xlink:to="lab_us-gaap_EarningsPerSharePolicyTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_693" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_694" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_695" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_696" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain_697" xlink:to="lab_us-gaap_EquityComponentDomain_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ExtraordinaryAndUnusualItemsAbstract_698" xlink:to="lab_us-gaap_ExtraordinaryAndUnusualItemsAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_699" xlink:to="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_700" xlink:to="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_701" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_702" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCountryMember_703" xlink:to="lab_us-gaap_ForeignCountryMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCountryMember_704" xlink:to="lab_us-gaap_ForeignCountryMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_705" xlink:to="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_706" xlink:to="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpense_707" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpense_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpense_708" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpense_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpense_709" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpense_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpenseMember_710" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpenseMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpenseMember_711" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpenseMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GovernmentMember_712" xlink:to="lab_us-gaap_GovernmentMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GovernmentMember_713" xlink:to="lab_us-gaap_GovernmentMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GrossProfit_714" xlink:to="lab_us-gaap_GrossProfit_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GrossProfit_715" xlink:to="lab_us-gaap_GrossProfit_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_716" xlink:to="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_717" xlink:to="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_718" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_719" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_720" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_721" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_722" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_4"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_723" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_5"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_724" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_6"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_725" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_7"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_726" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_8"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_727" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_728" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_729" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromSubsidiariesNetOfTax_730" xlink:to="lab_us-gaap_IncomeLossFromSubsidiariesNetOfTax_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromSubsidiariesNetOfTax_731" xlink:to="lab_us-gaap_IncomeLossFromSubsidiariesNetOfTax_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromSubsidiariesNetOfTax_732" xlink:to="lab_us-gaap_IncomeLossFromSubsidiariesNetOfTax_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract_733" xlink:to="lab_us-gaap_IncomeStatementAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_734" xlink:to="lab_us-gaap_IncomeStatementLocationAxis_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_735" xlink:to="lab_us-gaap_IncomeStatementLocationDomain_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_736" xlink:to="lab_us-gaap_IncomeTaxAuthorityAxis_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_737" xlink:to="lab_us-gaap_IncomeTaxAuthorityDomain_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_738" xlink:to="lab_us-gaap_IncomeTaxDisclosureAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_739" xlink:to="lab_us-gaap_IncomeTaxDisclosureAbstract_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock_740" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock_741" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxesPaidNet_742" xlink:to="lab_us-gaap_IncomeTaxesPaidNet_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxesPaidNet_743" xlink:to="lab_us-gaap_IncomeTaxesPaidNet_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_744" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_745" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_746" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_747" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_748" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit_4"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_749" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit_5"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxPolicyTextBlock_750" xlink:to="lab_us-gaap_IncomeTaxPolicyTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxPolicyTextBlock_751" xlink:to="lab_us-gaap_IncomeTaxPolicyTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_752" xlink:to="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_753" xlink:to="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_754" xlink:to="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_755" xlink:to="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseAmortization_756" xlink:to="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseAmortization_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseAmortization_757" xlink:to="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseAmortization_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationTaxExemptIncome_758" xlink:to="lab_us-gaap_IncomeTaxReconciliationTaxExemptIncome_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationTaxExemptIncome_759" xlink:to="lab_us-gaap_IncomeTaxReconciliationTaxExemptIncome_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationTaxExemptIncome_760" xlink:to="lab_us-gaap_IncomeTaxReconciliationTaxExemptIncome_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayable_761" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayable_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayable_762" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayable_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_763" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_764" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_765" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_766" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_767" xlink:to="lab_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_768" xlink:to="lab_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_769" xlink:to="lab_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_770" xlink:to="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_771" xlink:to="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_772" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_773" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherCurrentAssets_774" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherCurrentAssets_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherCurrentAssets_775" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherCurrentAssets_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_776" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_777" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntellectualPropertyMember_778" xlink:to="lab_us-gaap_IntellectualPropertyMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IPOMember_779" xlink:to="lab_us-gaap_IPOMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IPOMember_780" xlink:to="lab_us-gaap_IPOMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCostTableTextBlock_781" xlink:to="lab_us-gaap_LeaseCostTableTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCostTableTextBlock_782" xlink:to="lab_us-gaap_LeaseCostTableTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeasesAbstract_783" xlink:to="lab_us-gaap_LeasesAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LegalEntityTypeOfCounterpartyDomain_784" xlink:to="lab_us-gaap_LegalEntityTypeOfCounterpartyDomain_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LegalMattersAndContingenciesTextBlock_785" xlink:to="lab_us-gaap_LegalMattersAndContingenciesTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_786" xlink:to="lab_us-gaap_LesseeLeaseDescriptionLineItems_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_787" xlink:to="lab_us-gaap_LesseeLeaseDescriptionTable_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeasesPolicyTextBlock_788" xlink:to="lab_us-gaap_LesseeLeasesPolicyTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeasesPolicyTextBlock_789" xlink:to="lab_us-gaap_LesseeLeasesPolicyTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_790" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_791" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_792" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_793" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_794" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterRollingYearFive_795" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterRollingYearFive_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_796" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_797" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_798" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_799" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_800" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_801" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_802" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeasesTextBlock_803" xlink:to="lab_us-gaap_LesseeOperatingLeasesTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeasesTextBlock_804" xlink:to="lab_us-gaap_LesseeOperatingLeasesTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities_805" xlink:to="lab_us-gaap_Liabilities_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities_806" xlink:to="lab_us-gaap_Liabilities_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAbstract_807" xlink:to="lab_us-gaap_LiabilitiesAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAbstract_808" xlink:to="lab_us-gaap_LiabilitiesAbstract_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_809" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_810" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_811" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_812" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent_813" xlink:to="lab_us-gaap_LiabilitiesCurrent_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent_814" xlink:to="lab_us-gaap_LiabilitiesCurrent_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_815" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_816" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesNoncurrent_817" xlink:to="lab_us-gaap_LiabilitiesNoncurrent_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesNoncurrent_818" xlink:to="lab_us-gaap_LiabilitiesNoncurrent_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_819" xlink:to="lab_us-gaap_LiabilitiesNoncurrentAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_820" xlink:to="lab_us-gaap_LiabilitiesNoncurrentAbstract_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_821" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_822" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_823" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_824" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_825" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_826" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_827" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_828" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_829" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_830" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_831" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_832" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss_833" xlink:to="lab_us-gaap_NetIncomeLoss_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss_834" xlink:to="lab_us-gaap_NetIncomeLoss_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss_835" xlink:to="lab_us-gaap_NetIncomeLoss_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss_836" xlink:to="lab_us-gaap_NetIncomeLoss_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss_837" xlink:to="lab_us-gaap_NetIncomeLoss_4"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_838" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_839" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_840" xlink:to="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_841" xlink:to="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_842" xlink:to="lab_us-gaap_NonoperatingIncomeExpense_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_843" xlink:to="lab_us-gaap_NonoperatingIncomeExpense_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_844" xlink:to="lab_us-gaap_NonoperatingIncomeExpense_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_845" xlink:to="lab_us-gaap_NonoperatingIncomeExpense_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OfficeEquipmentMember_846" xlink:to="lab_us-gaap_OfficeEquipmentMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OfficeEquipmentMember_847" xlink:to="lab_us-gaap_OfficeEquipmentMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OfficersCompensation_848" xlink:to="lab_us-gaap_OfficersCompensation_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OfficersCompensation_849" xlink:to="lab_us-gaap_OfficersCompensation_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpenses_850" xlink:to="lab_us-gaap_OperatingExpenses_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpenses_851" xlink:to="lab_us-gaap_OperatingExpenses_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpenses_852" xlink:to="lab_us-gaap_OperatingExpenses_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpensesAbstract_853" xlink:to="lab_us-gaap_OperatingExpensesAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpensesAbstract_854" xlink:to="lab_us-gaap_OperatingExpensesAbstract_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss_855" xlink:to="lab_us-gaap_OperatingIncomeLoss_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss_856" xlink:to="lab_us-gaap_OperatingIncomeLoss_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss_857" xlink:to="lab_us-gaap_OperatingIncomeLoss_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseCost_858" xlink:to="lab_us-gaap_OperatingLeaseCost_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseCost_859" xlink:to="lab_us-gaap_OperatingLeaseCost_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseCost_860" xlink:to="lab_us-gaap_OperatingLeaseCost_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiability_861" xlink:to="lab_us-gaap_OperatingLeaseLiability_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiability_862" xlink:to="lab_us-gaap_OperatingLeaseLiability_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiability_863" xlink:to="lab_us-gaap_OperatingLeaseLiability_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityAbstract_864" xlink:to="lab_us-gaap_OperatingLeaseLiabilityAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityAbstract_865" xlink:to="lab_us-gaap_OperatingLeaseLiabilityAbstract_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent_866" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent_867" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent_868" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_869" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_870" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_871" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasePayments_872" xlink:to="lab_us-gaap_OperatingLeasePayments_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasePayments_873" xlink:to="lab_us-gaap_OperatingLeasePayments_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasePayments_874" xlink:to="lab_us-gaap_OperatingLeasePayments_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset_875" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset_876" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_877" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_878" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_879" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_880" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_881" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_882" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLossCarryforwards_883" xlink:to="lab_us-gaap_OperatingLossCarryforwards_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLossCarryforwards_884" xlink:to="lab_us-gaap_OperatingLossCarryforwards_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_885" xlink:to="lab_us-gaap_OperatingLossCarryforwardsLineItems_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_886" xlink:to="lab_us-gaap_OperatingLossCarryforwardsTable_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_887" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_888" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_889" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_890" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAccruedLiabilitiesCurrent_891" xlink:to="lab_us-gaap_OtherAccruedLiabilitiesCurrent_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAccruedLiabilitiesCurrent_892" xlink:to="lab_us-gaap_OtherAccruedLiabilitiesCurrent_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsCurrent_893" xlink:to="lab_us-gaap_OtherAssetsCurrent_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsCurrent_894" xlink:to="lab_us-gaap_OtherAssetsCurrent_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesCurrent_895" xlink:to="lab_us-gaap_OtherLiabilitiesCurrent_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesCurrent_896" xlink:to="lab_us-gaap_OtherLiabilitiesCurrent_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonrecurringIncome_897" xlink:to="lab_us-gaap_OtherNonrecurringIncome_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonrecurringIncome_898" xlink:to="lab_us-gaap_OtherNonrecurringIncome_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonrecurringIncome_899" xlink:to="lab_us-gaap_OtherNonrecurringIncome_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherOperatingIncome_900" xlink:to="lab_us-gaap_OtherOperatingIncome_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherOperatingIncome_901" xlink:to="lab_us-gaap_OtherOperatingIncome_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherOperatingIncome_902" xlink:to="lab_us-gaap_OtherOperatingIncome_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentForContingentConsiderationLiabilityOperatingActivities_903" xlink:to="lab_us-gaap_PaymentForContingentConsiderationLiabilityOperatingActivities_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentForContingentConsiderationLiabilityOperatingActivities_904" xlink:to="lab_us-gaap_PaymentForContingentConsiderationLiabilityOperatingActivities_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForProceedsFromShortTermInvestments_905" xlink:to="lab_us-gaap_PaymentsForProceedsFromShortTermInvestments_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForProceedsFromShortTermInvestments_906" xlink:to="lab_us-gaap_PaymentsForProceedsFromShortTermInvestments_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_907" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_908" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameAxis_909" xlink:to="lab_us-gaap_PlanNameAxis_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameDomain_910" xlink:to="lab_us-gaap_PlanNameDomain_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PostemploymentBenefitsLiabilityNoncurrent_911" xlink:to="lab_us-gaap_PostemploymentBenefitsLiabilityNoncurrent_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PostemploymentBenefitsLiabilityNoncurrent_912" xlink:to="lab_us-gaap_PostemploymentBenefitsLiabilityNoncurrent_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrivatePlacementMember_913" xlink:to="lab_us-gaap_PrivatePlacementMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrivatePlacementMember_914" xlink:to="lab_us-gaap_PrivatePlacementMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_915" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_916" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfPrivatePlacement_917" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfPrivatePlacement_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfPrivatePlacement_918" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfPrivatePlacement_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromWarrantExercises_919" xlink:to="lab_us-gaap_ProceedsFromWarrantExercises_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromWarrantExercises_920" xlink:to="lab_us-gaap_ProceedsFromWarrantExercises_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProfessionalAndContractServicesExpense_921" xlink:to="lab_us-gaap_ProfessionalAndContractServicesExpense_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProfessionalAndContractServicesExpense_922" xlink:to="lab_us-gaap_ProfessionalAndContractServicesExpense_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProfessionalFees_923" xlink:to="lab_us-gaap_ProfessionalFees_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProfessionalFees_924" xlink:to="lab_us-gaap_ProfessionalFees_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_925" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_926" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentLineItems_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_927" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_928" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_929" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_930" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_931" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_932" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_933" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_934" xlink:to="lab_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyDomain_935" xlink:to="lab_us-gaap_RelatedPartyDomain_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_936" xlink:to="lab_us-gaap_RelatedPartyTransactionAxis_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_937" xlink:to="lab_us-gaap_RelatedPartyTransactionDomain_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_938" xlink:to="lab_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_939" xlink:to="lab_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_940" xlink:to="lab_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_941" xlink:to="lab_us-gaap_RelatedPartyTransactionLineItems_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_942" xlink:to="lab_us-gaap_RelatedPartyTransactionsAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_943" xlink:to="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_944" xlink:to="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_945" xlink:to="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense_946" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense_947" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember_948" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember_949" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_950" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_951" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalents_952" xlink:to="lab_us-gaap_RestrictedCashAndCashEquivalents_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalents_953" xlink:to="lab_us-gaap_RestrictedCashAndCashEquivalents_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashAndInvestments_954" xlink:to="lab_us-gaap_RestrictedCashAndInvestments_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockUnitsRSUMember_955" xlink:to="lab_us-gaap_RestrictedStockUnitsRSUMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockUnitsRSUMember_956" xlink:to="lab_us-gaap_RestrictedStockUnitsRSUMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit_957" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit_958" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember_959" xlink:to="lab_us-gaap_RetainedEarningsMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember_960" xlink:to="lab_us-gaap_RetainedEarningsMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_961" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_962" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_963" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized_964" xlink:to="lab_us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized_965" xlink:to="lab_us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRecognitionPolicyTextBlock_966" xlink:to="lab_us-gaap_RevenueRecognitionPolicyTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRecognitionPolicyTextBlock_967" xlink:to="lab_us-gaap_RevenueRecognitionPolicyTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Revenues_968" xlink:to="lab_us-gaap_Revenues_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Revenues_969" xlink:to="lab_us-gaap_Revenues_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Revenues_970" xlink:to="lab_us-gaap_Revenues_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RoyaltyGuaranteesCommitmentsAmount_971" xlink:to="lab_us-gaap_RoyaltyGuaranteesCommitmentsAmount_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RoyaltyGuaranteesCommitmentsAmount_972" xlink:to="lab_us-gaap_RoyaltyGuaranteesCommitmentsAmount_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_973" xlink:to="lab_us-gaap_SaleOfStockNameOfTransactionDomain_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_974" xlink:to="lab_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_975" xlink:to="lab_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_976" xlink:to="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_977" xlink:to="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_978" xlink:to="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_979" xlink:to="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_980" xlink:to="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_981" xlink:to="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_982" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_983" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_984" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_985" xlink:to="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_986" xlink:to="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_987" xlink:to="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_988" xlink:to="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_989" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_990" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_991" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_992" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_993" xlink:to="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_994" xlink:to="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SeriesAPreferredStockMember_995" xlink:to="lab_us-gaap_SeriesAPreferredStockMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SeriesAPreferredStockMember_996" xlink:to="lab_us-gaap_SeriesAPreferredStockMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SeriesBPreferredStockMember_997" xlink:to="lab_us-gaap_SeriesBPreferredStockMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SeriesBPreferredStockMember_998" xlink:to="lab_us-gaap_SeriesBPreferredStockMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ServiceMember_999" xlink:to="lab_us-gaap_ServiceMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SeveranceCosts1_1000" xlink:to="lab_us-gaap_SeveranceCosts1_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SeveranceCosts1_1001" xlink:to="lab_us-gaap_SeveranceCosts1_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation_1002" xlink:to="lab_us-gaap_ShareBasedCompensation_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation_1003" xlink:to="lab_us-gaap_ShareBasedCompensation_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_1004" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_1005" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_1006" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_1007" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription_1008" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription_1009" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_1010" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_1011" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_1012" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_1013" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_1014" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_1015" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_1016" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_1017" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_1018" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_1019" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_1020" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_1021" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_1022" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_1023" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_1024" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_1025" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1026" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_1027" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_1028" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_1029" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_1030" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_1031" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_1032" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_1033" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_1034" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_1035" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_1036" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_1037" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_1038" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_1039" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_1040" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_1041" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_1042" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_1043" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_1044" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_1045" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_1046" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_1047" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_1048" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_1049" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_1050" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_1051" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_1052" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares_1053" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares_1054" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares_1055" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares_1056" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_1057" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_1058" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_1059" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_1060" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_1061" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_1062" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_1063" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_1064" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_1065" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_1066" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_1067" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_1068" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_1069" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_1070" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_1071" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_1072" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock_1073" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock_1074" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_1075" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_1076" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_1077" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_1078" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward_1079" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward_1080" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1081" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_1082" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_1083" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_1084" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_1085" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_1086" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_1087" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_1088" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_1089" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_1090" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_1091" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_1092" xlink:to="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_1093" xlink:to="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationAwardTrancheThreeMember_1094" xlink:to="lab_us-gaap_ShareBasedCompensationAwardTrancheThreeMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationAwardTrancheThreeMember_1095" xlink:to="lab_us-gaap_ShareBasedCompensationAwardTrancheThreeMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_1096" xlink:to="lab_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_1097" xlink:to="lab_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_1098" xlink:to="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_1099" xlink:to="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_1100" xlink:to="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_1101" xlink:to="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharePrice_1102" xlink:to="lab_us-gaap_SharePrice_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharePrice_1103" xlink:to="lab_us-gaap_SharePrice_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesIssued_1104" xlink:to="lab_us-gaap_SharesIssued_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesIssued_1105" xlink:to="lab_us-gaap_SharesIssued_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesOutstanding_1106" xlink:to="lab_us-gaap_SharesOutstanding_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesOutstanding_1107" xlink:to="lab_us-gaap_SharesOutstanding_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesOutstanding_1108" xlink:to="lab_us-gaap_SharesOutstanding_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SignificantAccountingPoliciesTextBlock_1109" xlink:to="lab_us-gaap_SignificantAccountingPoliciesTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SignificantAccountingPoliciesTextBlock_1110" xlink:to="lab_us-gaap_SignificantAccountingPoliciesTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementClassOfStockAxis_1111" xlink:to="lab_us-gaap_StatementClassOfStockAxis_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_1112" xlink:to="lab_us-gaap_StatementEquityComponentsAxis_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems_1113" xlink:to="lab_us-gaap_StatementLineItems_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_1114" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_1115" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_1116" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable_1117" xlink:to="lab_us-gaap_StatementTable_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity_1118" xlink:to="lab_us-gaap_StockholdersEquity_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity_1119" xlink:to="lab_us-gaap_StockholdersEquity_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity_1120" xlink:to="lab_us-gaap_StockholdersEquity_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity_1121" xlink:to="lab_us-gaap_StockholdersEquity_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_1122" xlink:to="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_1123" xlink:to="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_1124" xlink:to="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_1125" xlink:to="lab_us-gaap_StockholdersEquityNoteAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_1126" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_1127" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNumberOfSharesParValueAndOtherDisclosuresAbstract_1128" xlink:to="lab_us-gaap_StockholdersEquityNumberOfSharesParValueAndOtherDisclosuresAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNumberOfSharesParValueAndOtherDisclosuresAbstract_1129" xlink:to="lab_us-gaap_StockholdersEquityNumberOfSharesParValueAndOtherDisclosuresAbstract_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_1130" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_1131" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_1132" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_1133" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_1134" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_1135" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_1136" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_1137" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueIssuedForServices_1138" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueIssuedForServices_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueIssuedForServices_1139" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueIssuedForServices_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_1140" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_1141" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_1142" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_1143" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventLineItems_1144" xlink:to="lab_us-gaap_SubsequentEventLineItems_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventMember_1145" xlink:to="lab_us-gaap_SubsequentEventMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventMember_1146" xlink:to="lab_us-gaap_SubsequentEventMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsAbstract_1147" xlink:to="lab_us-gaap_SubsequentEventsAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsTextBlock_1148" xlink:to="lab_us-gaap_SubsequentEventsTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsTextBlock_1149" xlink:to="lab_us-gaap_SubsequentEventsTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTable_1150" xlink:to="lab_us-gaap_SubsequentEventTable_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_1151" xlink:to="lab_us-gaap_SubsequentEventTypeAxis_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_1152" xlink:to="lab_us-gaap_SubsequentEventTypeDomain_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_1153" xlink:to="lab_us-gaap_SubsidiarySaleOfStockAxis_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SummaryOfValuationAllowanceTextBlock_1154" xlink:to="lab_us-gaap_SummaryOfValuationAllowanceTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SummaryOfValuationAllowanceTextBlock_1155" xlink:to="lab_us-gaap_SummaryOfValuationAllowanceTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_1156" xlink:to="lab_us-gaap_SupplementalCashFlowInformationAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_1157" xlink:to="lab_us-gaap_SupplementalCashFlowInformationAbstract_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfArrangementAxis_1158" xlink:to="lab_us-gaap_TypeOfArrangementAxis_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnusualOrInfrequentItemsDisclosureTextBlock_1159" xlink:to="lab_us-gaap_UnusualOrInfrequentItemsDisclosureTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnusualOrInfrequentItemsDisclosureTextBlock_1160" xlink:to="lab_us-gaap_UnusualOrInfrequentItemsDisclosureTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates_1161" xlink:to="lab_us-gaap_UseOfEstimates_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates_1162" xlink:to="lab_us-gaap_UseOfEstimates_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_1163" xlink:to="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_1164" xlink:to="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_1165" xlink:to="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VestingAxis_1166" xlink:to="lab_us-gaap_VestingAxis_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VestingDomain_1167" xlink:to="lab_us-gaap_VestingDomain_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantMember_1168" xlink:to="lab_us-gaap_WarrantMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantMember_1169" xlink:to="lab_us-gaap_WarrantMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_1170" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_1171" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_1172" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_1173" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_1"/>
  </labelLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>14
<FILENAME>entx-20221231_pre.xml
<DESCRIPTION>XBRL PRESENTATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <!-- INTEGIX by Ez-XBRL -->
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel"/>
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel"/>
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel"/>
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel"/>
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel"/>
  <roleRef xlink:type="simple" xlink:href="entx-20221231.xsd#SIGNIFICANTACCOUNTINGPOLICIESPolicies" roleURI="http://www.enterabio.com/role/SIGNIFICANTACCOUNTINGPOLICIESPolicies"/>
  <roleRef xlink:type="simple" xlink:href="entx-20221231.xsd#SIGNIFICANTACCOUNTINGPOLICIES" roleURI="http://www.enterabio.com/role/SIGNIFICANTACCOUNTINGPOLICIES"/>
  <roleRef xlink:type="simple" xlink:href="entx-20221231.xsd#SIGNIFICANTACCOUNTINGPOLICIESDetailTextuals" roleURI="http://www.enterabio.com/role/SIGNIFICANTACCOUNTINGPOLICIESDetailTextuals"/>
  <roleRef xlink:type="simple" xlink:href="entx-20221231.xsd#SHAREBASEDCOMPENSATION" roleURI="http://www.enterabio.com/role/SHAREBASEDCOMPENSATION"/>
  <roleRef xlink:type="simple" xlink:href="entx-20221231.xsd#SHAREBASEDCOMPENSATIONTables" roleURI="http://www.enterabio.com/role/SHAREBASEDCOMPENSATIONTables"/>
  <roleRef xlink:type="simple" xlink:href="entx-20221231.xsd#SHAREBASEDCOMPENSATIONDetails" roleURI="http://www.enterabio.com/role/SHAREBASEDCOMPENSATIONDetails"/>
  <roleRef xlink:type="simple" xlink:href="entx-20221231.xsd#SHAREBASEDCOMPENSATIONDetailTextuals" roleURI="http://www.enterabio.com/role/SHAREBASEDCOMPENSATIONDetailTextuals"/>
  <roleRef xlink:type="simple" xlink:href="entx-20221231.xsd#GENERAL" roleURI="http://www.enterabio.com/role/GENERAL"/>
  <roleRef xlink:type="simple" xlink:href="entx-20221231.xsd#GENERALDetailTextuals" roleURI="http://www.enterabio.com/role/GENERALDetailTextuals"/>
  <roleRef xlink:type="simple" xlink:href="entx-20221231.xsd#CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS" roleURI="http://www.enterabio.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS"/>
  <roleRef xlink:type="simple" xlink:href="entx-20221231.xsd#CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY" roleURI="http://www.enterabio.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY"/>
  <roleRef xlink:type="simple" xlink:href="entx-20221231.xsd#CONSOLIDATEDBALANCESHEETS" roleURI="http://www.enterabio.com/role/CONSOLIDATEDBALANCESHEETS"/>
  <roleRef xlink:type="simple" xlink:href="entx-20221231.xsd#CONSOLIDATEDBALANCESHEETSParentheticals" roleURI="http://www.enterabio.com/role/CONSOLIDATEDBALANCESHEETSParentheticals"/>
  <roleRef xlink:type="simple" xlink:href="entx-20221231.xsd#CONSOLIDATEDSTATEMENTSOFCASHFLOWS" roleURI="http://www.enterabio.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"/>
  <roleRef xlink:type="simple" xlink:href="entx-20221231.xsd#DocumentAndEntityInformation" roleURI="http://www.enterabio.com/role/DocumentAndEntityInformation"/>
  <roleRef xlink:type="simple" xlink:href="entx-20221231.xsd#SUBSEQUENTEVENT" roleURI="http://www.enterabio.com/role/SUBSEQUENTEVENT"/>
  <roleRef xlink:type="simple" xlink:href="entx-20221231.xsd#SUPPLEMENTARYFINANCIALSTATEMENTINFORMATION" roleURI="http://www.enterabio.com/role/SUPPLEMENTARYFINANCIALSTATEMENTINFORMATION"/>
  <roleRef xlink:type="simple" xlink:href="entx-20221231.xsd#SUPPLEMENTARYFINANCIALSTATEMENTINFORMATIONDetails" roleURI="http://www.enterabio.com/role/SUPPLEMENTARYFINANCIALSTATEMENTINFORMATIONDetails"/>
  <roleRef xlink:type="simple" xlink:href="entx-20221231.xsd#SUPPLEMENTARYFINANCIALSTATEMENTINFORMATIONTable" roleURI="http://www.enterabio.com/role/SUPPLEMENTARYFINANCIALSTATEMENTINFORMATIONTable"/>
  <roleRef xlink:type="simple" xlink:href="entx-20221231.xsd#OPERATINGLEASES" roleURI="http://www.enterabio.com/role/OPERATINGLEASES"/>
  <roleRef xlink:type="simple" xlink:href="entx-20221231.xsd#OperatingLeaseDetails" roleURI="http://www.enterabio.com/role/OperatingLeaseDetails"/>
  <roleRef xlink:type="simple" xlink:href="entx-20221231.xsd#OperatingLeaseDetails1" roleURI="http://www.enterabio.com/role/OperatingLeaseDetails1"/>
  <roleRef xlink:type="simple" xlink:href="entx-20221231.xsd#OPERATINGLEASESDetails" roleURI="http://www.enterabio.com/role/OPERATINGLEASESDetails"/>
  <roleRef xlink:type="simple" xlink:href="entx-20221231.xsd#OPERATINGLEASESDetailTextuals" roleURI="http://www.enterabio.com/role/OPERATINGLEASESDetailTextuals"/>
  <roleRef xlink:type="simple" xlink:href="entx-20221231.xsd#OPERATINGLEASESTables" roleURI="http://www.enterabio.com/role/OPERATINGLEASESTables"/>
  <roleRef xlink:type="simple" xlink:href="entx-20221231.xsd#COMMITMENTS" roleURI="http://www.enterabio.com/role/COMMITMENTS"/>
  <roleRef xlink:type="simple" xlink:href="entx-20221231.xsd#COMMITMENTSDetailTextuals" roleURI="http://www.enterabio.com/role/COMMITMENTSDetailTextuals"/>
  <roleRef xlink:type="simple" xlink:href="entx-20221231.xsd#SHARECAPITAL" roleURI="http://www.enterabio.com/role/SHARECAPITAL"/>
  <roleRef xlink:type="simple" xlink:href="entx-20221231.xsd#INCOMETAX" roleURI="http://www.enterabio.com/role/INCOMETAX"/>
  <roleRef xlink:type="simple" xlink:href="entx-20221231.xsd#SIGNIFICANTACCOUNTINGPOLICIESTables" roleURI="http://www.enterabio.com/role/SIGNIFICANTACCOUNTINGPOLICIESTables"/>
  <roleRef xlink:type="simple" xlink:href="entx-20221231.xsd#SHARECAPITALDetailTextuals" roleURI="http://www.enterabio.com/role/SHARECAPITALDetailTextuals"/>
  <roleRef xlink:type="simple" xlink:href="entx-20221231.xsd#INCOMETAXDetails2" roleURI="http://www.enterabio.com/role/INCOMETAXDetails2"/>
  <roleRef xlink:type="simple" xlink:href="entx-20221231.xsd#INCOMETAXDetails1" roleURI="http://www.enterabio.com/role/INCOMETAXDetails1"/>
  <roleRef xlink:type="simple" xlink:href="entx-20221231.xsd#INCOMETAXDetails" roleURI="http://www.enterabio.com/role/INCOMETAXDetails"/>
  <roleRef xlink:type="simple" xlink:href="entx-20221231.xsd#SHAREBASEDCOMPENSATIONDetails3" roleURI="http://www.enterabio.com/role/SHAREBASEDCOMPENSATIONDetails3"/>
  <roleRef xlink:type="simple" xlink:href="entx-20221231.xsd#INCOMETAXDetails3" roleURI="http://www.enterabio.com/role/INCOMETAXDetails3"/>
  <roleRef xlink:type="simple" xlink:href="entx-20221231.xsd#SHAREBASEDCOMPENSATIONDetails1" roleURI="http://www.enterabio.com/role/SHAREBASEDCOMPENSATIONDetails1"/>
  <roleRef xlink:type="simple" xlink:href="entx-20221231.xsd#INCOMETAXTables" roleURI="http://www.enterabio.com/role/INCOMETAXTables"/>
  <roleRef xlink:type="simple" xlink:href="entx-20221231.xsd#INCOMETAXDetailTextuals" roleURI="http://www.enterabio.com/role/INCOMETAXDetailTextuals"/>
  <roleRef xlink:type="simple" xlink:href="entx-20221231.xsd#SHAREBASEDCOMPENSATIONDetails2" roleURI="http://www.enterabio.com/role/SHAREBASEDCOMPENSATIONDetails2"/>
  <roleRef xlink:type="simple" xlink:href="entx-20221231.xsd#SIGNIFICANTACCOUNTINGPOLICIESDetails" roleURI="http://www.enterabio.com/role/SIGNIFICANTACCOUNTINGPOLICIESDetails"/>
  <roleRef xlink:type="simple" xlink:href="entx-20221231.xsd#SUBSEQUENTEVENTSNarrative" roleURI="http://www.enterabio.com/role/SUBSEQUENTEVENTSNarrative"/>
  <presentationLink xlink:type="extended" xlink:role="http://www.enterabio.com/role/SIGNIFICANTACCOUNTINGPOLICIESPolicies">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UseOfEstimates" xlink:label="loc_us-gaap_UseOfEstimates_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:label="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_3"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_5"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:label="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_6"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk_7"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_8"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_EmployeeSeveranceBenefitsPolicyPolicyTextBlock" xlink:label="loc_entx_EmployeeSeveranceBenefitsPolicyPolicyTextBlock_9"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock_10"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_11"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_12"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_13"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_14"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="loc_us-gaap_RevenueRecognitionPolicyTextBlock_15"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock_16"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock_17"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesPolicyTextBlock" xlink:label="loc_us-gaap_CommitmentsAndContingenciesPolicyTextBlock_18"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativesPolicyTextBlock" xlink:label="loc_us-gaap_DerivativesPolicyTextBlock_19"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_20"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_UseOfEstimates_2" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_3" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_ConsolidationPolicyTextBlock_4" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_5" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_6" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_ConcentrationRiskCreditRisk_7" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_8" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_entx_EmployeeSeveranceBenefitsPolicyPolicyTextBlock_9" order="80" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_LesseeLeasesPolicyTextBlock_10" order="90" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_11" order="100" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_12" order="110" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_13" order="120" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_14" order="130" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_RevenueRecognitionPolicyTextBlock_15" order="140" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_IncomeTaxPolicyTextBlock_16" order="150" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_EarningsPerSharePolicyTextBlock_17" order="160" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_CommitmentsAndContingenciesPolicyTextBlock_18" order="170" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_DerivativesPolicyTextBlock_19" order="180" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_20" order="190" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.enterabio.com/role/SIGNIFICANTACCOUNTINGPOLICIES">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_SignificantAccountingPoliciesTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.enterabio.com/role/SIGNIFICANTACCOUNTINGPOLICIESDetailTextuals">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_0"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_SignificantAccountingPoliciesTable" xlink:label="loc_entx_SignificantAccountingPoliciesTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_1"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_AmgenIncMember" xlink:label="loc_entx_AmgenIncMember_1"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_SignificantAccountingPoliciesLineItems" xlink:label="loc_entx_SignificantAccountingPoliciesLineItems_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeveranceCosts1" xlink:label="loc_us-gaap_SeveranceCosts1_4"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_SeveranceExpenses" xlink:label="loc_entx_SeveranceExpenses_5"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_NonRefundableAndNonCreditableInitialTechnologyAccessFeePayment" xlink:label="loc_entx_NonRefundableAndNonCreditableInitialTechnologyAccessFeePayment_6"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_AdditionalAmountPaidForServicesToBeRecognized" xlink:label="loc_entx_AdditionalAmountPaidForServicesToBeRecognized_7"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_RightToUseIntellectualProperty" xlink:label="loc_entx_RightToUseIntellectualProperty_8"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_9"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredRevenueRevenueRecognized1" xlink:label="loc_us-gaap_DeferredRevenueRevenueRecognized1_10"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_entx_SignificantAccountingPoliciesTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_entx_SignificantAccountingPoliciesTable_1" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1" xlink:to="loc_us-gaap_RelatedPartyDomain_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_1" xlink:to="loc_entx_AmgenIncMember_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_entx_SignificantAccountingPoliciesTable_1" xlink:to="loc_entx_SignificantAccountingPoliciesLineItems_4" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_entx_SignificantAccountingPoliciesLineItems_4" xlink:to="loc_us-gaap_SeveranceCosts1_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_entx_SignificantAccountingPoliciesLineItems_4" xlink:to="loc_entx_SeveranceExpenses_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_entx_SignificantAccountingPoliciesLineItems_4" xlink:to="loc_entx_NonRefundableAndNonCreditableInitialTechnologyAccessFeePayment_6" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_entx_SignificantAccountingPoliciesLineItems_4" xlink:to="loc_entx_AdditionalAmountPaidForServicesToBeRecognized_7" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_entx_SignificantAccountingPoliciesLineItems_4" xlink:to="loc_entx_RightToUseIntellectualProperty_8" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_entx_SignificantAccountingPoliciesLineItems_4" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_9" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_entx_SignificantAccountingPoliciesLineItems_4" xlink:to="loc_us-gaap_DeferredRevenueRevenueRecognized1_10" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.enterabio.com/role/SHAREBASEDCOMPENSATION">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.enterabio.com/role/SHAREBASEDCOMPENSATIONTables">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock_3"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_4"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0" xlink:to="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_2" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock_3" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_4" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.enterabio.com/role/SHAREBASEDCOMPENSATIONDetails">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_5"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_6"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_7"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_8"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_9"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_srt_RangeAxis_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_1" xlink:to="loc_srt_RangeMember_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_1" xlink:to="loc_srt_MinimumMember_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_1" xlink:to="loc_srt_MaximumMember_2" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_5" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_6" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_7" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_8" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_9" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.enterabio.com/role/SHAREBASEDCOMPENSATIONDetailTextuals">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_1"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_ShareIncentivePlan2013Member" xlink:label="loc_entx_ShareIncentivePlan2013Member_1"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_ShareIncentivePlan2018Member" xlink:label="loc_entx_ShareIncentivePlan2018Member_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srt_TitleOfIndividualAxis_5"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_5"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_ExecutiveOfficerAndServiceProviderMember" xlink:label="loc_entx_ExecutiveOfficerAndServiceProviderMember_5"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_EmployeesMember" xlink:label="loc_entx_EmployeesMember_6"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_ServiceProviderMember" xlink:label="loc_entx_ServiceProviderMember_7"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ExecutiveOfficerMember" xlink:label="loc_srt_ExecutiveOfficerMember_8"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_FormerChiefExecutiveOfficerMember" xlink:label="loc_entx_FormerChiefExecutiveOfficerMember_9"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_ConsultantMember" xlink:label="loc_entx_ConsultantMember_10"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_NonExecutiveDirectorMember" xlink:label="loc_entx_NonExecutiveDirectorMember_11"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_DirectorMember" xlink:label="loc_srt_DirectorMember_12"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_EmployeeMember" xlink:label="loc_entx_EmployeeMember_13"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ChiefExecutiveOfficerMember" xlink:label="loc_srt_ChiefExecutiveOfficerMember_14"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ChiefFinancialOfficerMember" xlink:label="loc_srt_ChiefFinancialOfficerMember_15"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_PresidentOfResearchAndDevelopmentMember" xlink:label="loc_entx_PresidentOfResearchAndDevelopmentMember_16"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingAxis" xlink:label="loc_us-gaap_VestingAxis_19"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingDomain" xlink:label="loc_us-gaap_VestingDomain_19"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_19"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_20"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationAwardTrancheThreeMember" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheThreeMember_21"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_ShareBasedPaymentArrangementTrancheFourMember" xlink:label="loc_entx_ShareBasedPaymentArrangementTrancheFourMember_22"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_ShareBasedPaymentArrangementTrancheFiveMember" xlink:label="loc_entx_ShareBasedPaymentArrangementTrancheFiveMember_23"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_ShareBasedPaymentArrangementTrancheSixMember" xlink:label="loc_entx_ShareBasedPaymentArrangementTrancheSixMember_24"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_27"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_27"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_InvestorRelationsServicesAgreementMember" xlink:label="loc_entx_InvestorRelationsServicesAgreementMember_27"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_AmendmentToBusinessDevelopmentServicesAgreementMember" xlink:label="loc_entx_AmendmentToBusinessDevelopmentServicesAgreementMember_28"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_TriggeringEventMember" xlink:label="loc_entx_TriggeringEventMember_29"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_32"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_32"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_32"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_TwentyTwentyOneGrantMember" xlink:label="loc_entx_TwentyTwentyOneGrantMember_33"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_TwentySeventeenMemberMember" xlink:label="loc_entx_TwentySeventeenMemberMember_34"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_37"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_37"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_38"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription_39"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_40"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_41"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_42"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_43"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_44"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_45"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_ReversalOfExpensesUponForfeitureOfOptions" xlink:label="loc_entx_ReversalOfExpensesUponForfeitureOfOptions_46"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_47"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_48"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_49"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_50"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_51"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfessionalFees" xlink:label="loc_us-gaap_ProfessionalFees_52"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_53"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_CashSeparationPayment" xlink:label="loc_entx_CashSeparationPayment_54"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_AdditionalCashSeparationPayment" xlink:label="loc_entx_AdditionalCashSeparationPayment_55"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OfficersCompensation" xlink:label="loc_us-gaap_OfficersCompensation_56"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DescriptionOfPostemploymentBenefits" xlink:label="loc_us-gaap_DescriptionOfPostemploymentBenefits_57"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_58"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares_59"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_60"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_us-gaap_PlanNameAxis_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_1" xlink:to="loc_us-gaap_PlanNameDomain_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_1" xlink:to="loc_entx_ShareIncentivePlan2013Member_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_1" xlink:to="loc_entx_ShareIncentivePlan2018Member_2" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_srt_TitleOfIndividualAxis_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualAxis_5" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_5" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_5" xlink:to="loc_entx_ExecutiveOfficerAndServiceProviderMember_5" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_5" xlink:to="loc_entx_EmployeesMember_6" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_5" xlink:to="loc_entx_ServiceProviderMember_7" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_5" xlink:to="loc_srt_ExecutiveOfficerMember_8" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_5" xlink:to="loc_entx_FormerChiefExecutiveOfficerMember_9" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_5" xlink:to="loc_entx_ConsultantMember_10" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_5" xlink:to="loc_entx_NonExecutiveDirectorMember_11" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_5" xlink:to="loc_srt_DirectorMember_12" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_5" xlink:to="loc_entx_EmployeeMember_13" order="80" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_5" xlink:to="loc_srt_ChiefExecutiveOfficerMember_14" order="90" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_5" xlink:to="loc_srt_ChiefFinancialOfficerMember_15" order="100" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_5" xlink:to="loc_entx_PresidentOfResearchAndDevelopmentMember_16" order="110" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_us-gaap_VestingAxis_19" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingAxis_19" xlink:to="loc_us-gaap_VestingDomain_19" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingDomain_19" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_19" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingDomain_19" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_20" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingDomain_19" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheThreeMember_21" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingDomain_19" xlink:to="loc_entx_ShareBasedPaymentArrangementTrancheFourMember_22" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingDomain_19" xlink:to="loc_entx_ShareBasedPaymentArrangementTrancheFiveMember_23" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingDomain_19" xlink:to="loc_entx_ShareBasedPaymentArrangementTrancheSixMember_24" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_us-gaap_TypeOfArrangementAxis_27" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_27" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_27" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_27" xlink:to="loc_entx_InvestorRelationsServicesAgreementMember_27" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_27" xlink:to="loc_entx_AmendmentToBusinessDevelopmentServicesAgreementMember_28" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_27" xlink:to="loc_entx_TriggeringEventMember_29" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_us-gaap_AwardTypeAxis_32" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_32" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_32" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_32" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_32" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_32" xlink:to="loc_entx_TwentyTwentyOneGrantMember_33" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_32" xlink:to="loc_entx_TwentySeventeenMemberMember_34" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_37" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_37" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_37" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_37" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_38" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_37" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription_39" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_37" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_40" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_37" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_41" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_37" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_42" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_37" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_43" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_37" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_44" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_37" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_45" order="80" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_37" xlink:to="loc_entx_ReversalOfExpensesUponForfeitureOfOptions_46" order="90" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_37" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_47" order="100" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_37" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_48" order="110" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_37" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_49" order="120" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_37" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_50" order="130" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_37" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_51" order="140" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_37" xlink:to="loc_us-gaap_ProfessionalFees_52" order="150" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_37" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_53" order="160" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_37" xlink:to="loc_entx_CashSeparationPayment_54" order="170" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_37" xlink:to="loc_entx_AdditionalCashSeparationPayment_55" order="180" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_37" xlink:to="loc_us-gaap_OfficersCompensation_56" order="190" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_37" xlink:to="loc_us-gaap_DescriptionOfPostemploymentBenefits_57" order="200" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_37" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_58" order="210" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_37" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares_59" order="220" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_37" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_60" order="230" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.enterabio.com/role/GENERAL">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0" xlink:to="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.enterabio.com/role/GENERALDetailTextuals">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_GeneralTable" xlink:label="loc_entx_GeneralTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IPOMember" xlink:label="loc_us-gaap_IPOMember_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_4"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_GeneralLineItems" xlink:label="loc_entx_GeneralLineItems_7"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_7"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesIssued" xlink:label="loc_us-gaap_SharesIssued_8"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_ClassOfWarrantOrRightIssued" xlink:label="loc_entx_ClassOfWarrantOrRightIssued_9"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_10"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_NetProceedsFromIssuanceOfCommonStock" xlink:label="loc_entx_NetProceedsFromIssuanceOfCommonStock_11"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_WarrantToPurchaseOrdinaryShare" xlink:label="loc_entx_WarrantToPurchaseOrdinaryShare_12"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaap_SharePrice_13"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_14"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0" xlink:to="loc_entx_GeneralTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_entx_GeneralTable_1" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_1" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1" xlink:to="loc_us-gaap_IPOMember_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_entx_GeneralTable_1" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_4" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_4" xlink:to="loc_us-gaap_EquityComponentDomain_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_4" xlink:to="loc_us-gaap_CommonStockMember_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_entx_GeneralTable_1" xlink:to="loc_entx_GeneralLineItems_7" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_entx_GeneralLineItems_7" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_7" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_entx_GeneralLineItems_7" xlink:to="loc_us-gaap_SharesIssued_8" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_entx_GeneralLineItems_7" xlink:to="loc_entx_ClassOfWarrantOrRightIssued_9" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_entx_GeneralLineItems_7" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_10" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_entx_GeneralLineItems_7" xlink:to="loc_entx_NetProceedsFromIssuanceOfCommonStock_11" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_entx_GeneralLineItems_7" xlink:to="loc_entx_WarrantToPurchaseOrdinaryShare_12" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_entx_GeneralLineItems_7" xlink:to="loc_us-gaap_SharePrice_13" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_entx_GeneralLineItems_7" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_14" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.enterabio.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaap_IncomeStatementAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfRevenue" xlink:label="loc_us-gaap_CostOfRevenue_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GrossProfit" xlink:label="loc_us-gaap_GrossProfit_3"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaap_OperatingExpensesAbstract_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_5"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonrecurringIncome" xlink:label="loc_us-gaap_OtherNonrecurringIncome_6"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses_7"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_9"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_10"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_11"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_12"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_13"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaap_EarningsPerShareBasic_14"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="loc_us-gaap_EarningsPerShareDiluted_15"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_16"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_17"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_0" xlink:to="loc_us-gaap_Revenues_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/positiveLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_0" xlink:to="loc_us-gaap_CostOfRevenue_2" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_0" xlink:to="loc_us-gaap_GrossProfit_3" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_0" xlink:to="loc_us-gaap_OperatingExpensesAbstract_4" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_4" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_4" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_4" xlink:to="loc_us-gaap_OtherNonrecurringIncome_6" order="20" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_4" xlink:to="loc_us-gaap_OperatingExpenses_7" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_0" xlink:to="loc_us-gaap_OperatingIncomeLoss_9" order="40" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_0" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_10" order="50" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_0" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_11" order="60" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_0" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_12" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_0" xlink:to="loc_us-gaap_NetIncomeLoss_13" order="80" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_0" xlink:to="loc_us-gaap_EarningsPerShareBasic_14" order="90" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_0" xlink:to="loc_us-gaap_EarningsPerShareDiluted_15" order="100" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_0" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_16" order="110" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_0" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_17" order="120" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.enterabio.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_3"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaap_RetainedEarningsMember_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_5"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_7"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_7"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaap_SharesOutstanding_8"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_9"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_ExerciseOfWarrantsValue" xlink:label="loc_entx_ExerciseOfWarrantsValue_10"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_ExerciseOfWarrantsShares" xlink:label="loc_entx_ExerciseOfWarrantsShares_11"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_IssuanceOfOrdinarySharesAndWarrantsDueToPrivatePlacementNetOfIssuanceCosts" xlink:label="loc_entx_IssuanceOfOrdinarySharesAndWarrantsDueToPrivatePlacementNetOfIssuanceCosts_12"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_IssuanceOfOrdinarySharesAndWarrantsDueToPrivatePlacementNetOfIssuanceCostsShares" xlink:label="loc_entx_IssuanceOfOrdinarySharesAndWarrantsDueToPrivatePlacementNetOfIssuanceCostsShares_13"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueIssuedForServices_14"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_15"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_16"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_17"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_18"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition_19"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_VestedRestrictedShareUnitsShares" xlink:label="loc_entx_VestedRestrictedShareUnitsShares_20"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaap_SharesOutstanding_21"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_22"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_0" xlink:to="loc_us-gaap_StatementTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_1" xlink:to="loc_us-gaap_CommonStockMember_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_1" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_2" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_1" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_3" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_1" xlink:to="loc_us-gaap_RetainedEarningsMember_4" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_1" xlink:to="loc_us-gaap_EquityComponentDomain_5" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_StatementLineItems_7" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_7" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7" xlink:to="loc_us-gaap_StockholdersEquity_7" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7" xlink:to="loc_us-gaap_SharesOutstanding_8" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7" xlink:to="loc_us-gaap_NetIncomeLoss_9" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7" xlink:to="loc_entx_ExerciseOfWarrantsValue_10" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7" xlink:to="loc_entx_ExerciseOfWarrantsShares_11" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7" xlink:to="loc_entx_IssuanceOfOrdinarySharesAndWarrantsDueToPrivatePlacementNetOfIssuanceCosts_12" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7" xlink:to="loc_entx_IssuanceOfOrdinarySharesAndWarrantsDueToPrivatePlacementNetOfIssuanceCostsShares_13" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueIssuedForServices_14" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_15" order="80" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_16" order="90" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_17" order="100" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_18" order="110" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition_19" order="120" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7" xlink:to="loc_entx_VestedRestrictedShareUnitsShares_20" order="130" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7" xlink:to="loc_us-gaap_SharesOutstanding_21" order="140" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7" xlink:to="loc_us-gaap_StockholdersEquity_22" order="150" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.enterabio.com/role/CONSOLIDATEDBALANCESHEETS">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaap_AssetsAbstract_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaap_AssetsCurrentAbstract_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsCurrent" xlink:label="loc_us-gaap_OtherAssetsCurrent_3"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsNoncurrentAbstract" xlink:label="loc_us-gaap_AssetsNoncurrentAbstract_6"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_6"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_7"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxAssetsNet" xlink:label="loc_us-gaap_DeferredIncomeTaxAssetsNet_8"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent" xlink:label="loc_us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent_9"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsNoncurrent" xlink:label="loc_us-gaap_AssetsNoncurrent_10"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_12"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_14"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAbstract" xlink:label="loc_us-gaap_LiabilitiesAbstract_14"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_14"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaap_AccountsPayableCurrent_14"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:label="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilities_15"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_16"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_17"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent_18"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesNoncurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesNoncurrentAbstract_20"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_20"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PostemploymentBenefitsLiabilityNoncurrent" xlink:label="loc_us-gaap_PostemploymentBenefitsLiabilityNoncurrent_21"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesNoncurrent" xlink:label="loc_us-gaap_LiabilitiesNoncurrent_22"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities_24"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaap_CommitmentsAndContingencies_26"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:label="loc_us-gaap_StockholdersEquityNumberOfSharesParValueAndOtherDisclosuresAbstract_27"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_27"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_28"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_29"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_30"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_31"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_33"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_0" xlink:to="loc_us-gaap_AssetsAbstract_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_1" xlink:to="loc_us-gaap_AssetsCurrentAbstract_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_1" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_1" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_2" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_1" xlink:to="loc_us-gaap_OtherAssetsCurrent_3" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_1" xlink:to="loc_us-gaap_AssetsCurrent_4" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_1" xlink:to="loc_us-gaap_AssetsNoncurrentAbstract_6" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_6" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_6" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_6" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_7" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_6" xlink:to="loc_us-gaap_DeferredIncomeTaxAssetsNet_8" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_6" xlink:to="loc_us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent_9" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_6" xlink:to="loc_us-gaap_AssetsNoncurrent_10" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_1" xlink:to="loc_us-gaap_Assets_12" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_0" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_14" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_14" xlink:to="loc_us-gaap_LiabilitiesAbstract_14" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAbstract_14" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_14" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_14" xlink:to="loc_us-gaap_AccountsPayableCurrent_14" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_14" xlink:to="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilities_15" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_14" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_16" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_14" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_17" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_14" xlink:to="loc_us-gaap_LiabilitiesCurrent_18" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAbstract_14" xlink:to="loc_us-gaap_LiabilitiesNoncurrentAbstract_20" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_20" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_20" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_20" xlink:to="loc_us-gaap_PostemploymentBenefitsLiabilityNoncurrent_21" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_20" xlink:to="loc_us-gaap_LiabilitiesNoncurrent_22" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAbstract_14" xlink:to="loc_us-gaap_Liabilities_24" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_14" xlink:to="loc_us-gaap_CommitmentsAndContingencies_26" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_14" xlink:to="loc_us-gaap_StockholdersEquityNumberOfSharesParValueAndOtherDisclosuresAbstract_27" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNumberOfSharesParValueAndOtherDisclosuresAbstract_27" xlink:to="loc_us-gaap_CommonStockValue_27" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNumberOfSharesParValueAndOtherDisclosuresAbstract_27" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_28" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNumberOfSharesParValueAndOtherDisclosuresAbstract_27" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_29" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNumberOfSharesParValueAndOtherDisclosuresAbstract_27" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_30" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNumberOfSharesParValueAndOtherDisclosuresAbstract_27" xlink:to="loc_us-gaap_StockholdersEquity_31" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_14" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_33" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.enterabio.com/role/CONSOLIDATEDBALANCESHEETSParentheticals">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued_3"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_4"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_0" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_0" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_2" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_0" xlink:to="loc_us-gaap_CommonStockSharesIssued_3" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_0" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_4" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.enterabio.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaap_Depreciation_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_3"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_4"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_FinanceExpensesNet" xlink:label="loc_entx_FinanceExpensesNet_5"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_6"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_6"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherCurrentAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherCurrentAssets_7"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_8"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_9"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_10"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_13"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_15"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_FundsInRespectOfEmployeeRightsUponRetirement" xlink:label="loc_entx_FundsInRespectOfEmployeeRightsUponRetirement_15"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_16"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_17"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_19"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_19"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_ProceedsFromOptionsAndWarrantExercises" xlink:label="loc_entx_ProceedsFromOptionsAndWarrantExercises_20"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_21"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_23"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_24"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_25"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_ReconciliationInAmountsOnConsolidatedBalanceSheetsAbstract" xlink:label="loc_entx_ReconciliationInAmountsOnConsolidatedBalanceSheetsAbstract_26"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_26"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalents" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalents_27"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_28"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_30"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxesPaidNet" xlink:label="loc_us-gaap_IncomeTaxesPaidNet_30"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:label="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_32"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_RightOfUseAssetsObtainedInExchangeForNewOperatingLeaseLiabilities" xlink:label="loc_entx_RightOfUseAssetsObtainedInExchangeForNewOperatingLeaseLiabilities_32"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_0" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_1" xlink:to="loc_us-gaap_NetIncomeLoss_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/positiveLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_1" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2" xlink:to="loc_us-gaap_Depreciation_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_3" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2" xlink:to="loc_us-gaap_ShareBasedCompensation_4" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2" xlink:to="loc_entx_FinanceExpensesNet_5" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_6" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_6" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_6" order="0" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_6" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherCurrentAssets_7" order="10" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_6" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_8" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_6" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_9" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_6" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_10" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_1" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_13" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_0" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_15" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_15" xlink:to="loc_entx_FundsInRespectOfEmployeeRightsUponRetirement_15" order="0" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_15" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_16" order="10" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_15" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_17" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_0" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_19" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_19" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_19" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_19" xlink:to="loc_entx_ProceedsFromOptionsAndWarrantExercises_20" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_19" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_21" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_0" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_23" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_0" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_24" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_0" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_25" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_0" xlink:to="loc_entx_ReconciliationInAmountsOnConsolidatedBalanceSheetsAbstract_26" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_entx_ReconciliationInAmountsOnConsolidatedBalanceSheetsAbstract_26" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_26" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_entx_ReconciliationInAmountsOnConsolidatedBalanceSheetsAbstract_26" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalents_27" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_entx_ReconciliationInAmountsOnConsolidatedBalanceSheetsAbstract_26" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_28" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_0" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_30" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_30" xlink:to="loc_us-gaap_IncomeTaxesPaidNet_30" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_0" xlink:to="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_32" order="80" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_32" xlink:to="loc_entx_RightOfUseAssetsObtainedInExchangeForNewOperatingLeaseLiabilities_32" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.enterabio.com/role/DocumentAndEntityInformation">
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract" xlink:label="loc_dei_CoverAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityPublicFloat" xlink:label="loc_dei_EntityPublicFloat_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName" xlink:label="loc_dei_EntityRegistrantName_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType" xlink:label="loc_dei_DocumentType_3"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_dei_DocumentPeriodEndDate_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey" xlink:label="loc_dei_EntityCentralIndexKey_5"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_dei_CurrentFiscalYearEndDate_6"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory" xlink:label="loc_dei_EntityFilerCategory_7"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag" xlink:label="loc_dei_AmendmentFlag_8"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_dei_EntityCurrentReportingStatus_9"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_10"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_dei_DocumentFiscalYearFocus_11"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_dei_DocumentFiscalPeriodFocus_12"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany" xlink:label="loc_dei_EntityShellCompany_13"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness" xlink:label="loc_dei_EntitySmallBusiness_14"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_dei_EntityInteractiveDataCurrent_15"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_dei_EntityEmergingGrowthCompany_16"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_dei_EntityExTransitionPeriod_17"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_dei_EntityIncorporationStateCountryCode_18"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_dei_EntityAddressAddressLine1_19"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_dei_EntityAddressAddressLine2_20"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine3" xlink:label="loc_dei_EntityAddressAddressLine3_21"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_dei_EntityAddressStateOrProvince_22"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_dei_EntityAddressCityOrTown_23"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_dei_EntityAddressPostalZipCode_24"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCountry" xlink:label="loc_dei_EntityAddressCountry_25"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode" xlink:label="loc_dei_CityAreaCode_26"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber" xlink:label="loc_dei_LocalPhoneNumber_27"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_dei_DocumentQuarterlyReport_28"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport" xlink:label="loc_dei_DocumentTransitionReport_29"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber" xlink:label="loc_dei_EntityFileNumber_30"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_dei_EntityTaxIdentificationNumber_31"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol" xlink:label="loc_dei_TradingSymbol_32"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName" xlink:label="loc_dei_SecurityExchangeName_33"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle" xlink:label="loc_dei_Security12bTitle_34"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_dei_EntityVoluntaryFilers_35"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer_36"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAnnualReport" xlink:label="loc_dei_DocumentAnnualReport_37"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentDescription" xlink:label="loc_dei_AmendmentDescription_38"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorName" xlink:label="loc_dei_AuditorName_39"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorLocation" xlink:label="loc_dei_AuditorLocation_40"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorFirmId" xlink:label="loc_dei_AuditorFirmId_41"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0" xlink:to="loc_dei_EntityPublicFloat_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0" xlink:to="loc_dei_EntityRegistrantName_2" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0" xlink:to="loc_dei_DocumentType_3" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0" xlink:to="loc_dei_DocumentPeriodEndDate_4" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0" xlink:to="loc_dei_EntityCentralIndexKey_5" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0" xlink:to="loc_dei_CurrentFiscalYearEndDate_6" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0" xlink:to="loc_dei_EntityFilerCategory_7" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0" xlink:to="loc_dei_AmendmentFlag_8" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0" xlink:to="loc_dei_EntityCurrentReportingStatus_9" order="80" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_10" order="90" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0" xlink:to="loc_dei_DocumentFiscalYearFocus_11" order="100" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0" xlink:to="loc_dei_DocumentFiscalPeriodFocus_12" order="110" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0" xlink:to="loc_dei_EntityShellCompany_13" order="120" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0" xlink:to="loc_dei_EntitySmallBusiness_14" order="130" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0" xlink:to="loc_dei_EntityInteractiveDataCurrent_15" order="140" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0" xlink:to="loc_dei_EntityEmergingGrowthCompany_16" order="150" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0" xlink:to="loc_dei_EntityExTransitionPeriod_17" order="160" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0" xlink:to="loc_dei_EntityIncorporationStateCountryCode_18" order="170" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0" xlink:to="loc_dei_EntityAddressAddressLine1_19" order="180" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0" xlink:to="loc_dei_EntityAddressAddressLine2_20" order="190" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0" xlink:to="loc_dei_EntityAddressAddressLine3_21" order="200" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0" xlink:to="loc_dei_EntityAddressStateOrProvince_22" order="210" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0" xlink:to="loc_dei_EntityAddressCityOrTown_23" order="220" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0" xlink:to="loc_dei_EntityAddressPostalZipCode_24" order="230" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0" xlink:to="loc_dei_EntityAddressCountry_25" order="240" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0" xlink:to="loc_dei_CityAreaCode_26" order="250" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0" xlink:to="loc_dei_LocalPhoneNumber_27" order="260" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0" xlink:to="loc_dei_DocumentQuarterlyReport_28" order="270" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0" xlink:to="loc_dei_DocumentTransitionReport_29" order="280" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0" xlink:to="loc_dei_EntityFileNumber_30" order="290" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0" xlink:to="loc_dei_EntityTaxIdentificationNumber_31" order="300" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0" xlink:to="loc_dei_TradingSymbol_32" order="310" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0" xlink:to="loc_dei_SecurityExchangeName_33" order="320" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0" xlink:to="loc_dei_Security12bTitle_34" order="330" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0" xlink:to="loc_dei_EntityVoluntaryFilers_35" order="340" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0" xlink:to="loc_dei_EntityWellKnownSeasonedIssuer_36" order="350" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0" xlink:to="loc_dei_DocumentAnnualReport_37" order="360" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0" xlink:to="loc_dei_AmendmentDescription_38" order="370" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0" xlink:to="loc_dei_AuditorName_39" order="380" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0" xlink:to="loc_dei_AuditorLocation_40" order="390" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0" xlink:to="loc_dei_AuditorFirmId_41" order="400" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.enterabio.com/role/SUBSEQUENTEVENT">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaap_SubsequentEventsAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="loc_us-gaap_SubsequentEventsTextBlock_1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_0" xlink:to="loc_us-gaap_SubsequentEventsTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.enterabio.com/role/SUPPLEMENTARYFINANCIALSTATEMENTINFORMATION">
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_SupplementaryFinancialStatementInformationAbstract" xlink:label="loc_entx_SupplementaryFinancialStatementInformationAbstract_0"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_SupplementaryFinancialStatementInformationTextBlock" xlink:label="loc_entx_SupplementaryFinancialStatementInformationTextBlock_1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_entx_SupplementaryFinancialStatementInformationAbstract_0" xlink:to="loc_entx_SupplementaryFinancialStatementInformationTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.enterabio.com/role/SUPPLEMENTARYFINANCIALSTATEMENTINFORMATIONDetails">
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_SupplementaryFinancialStatementInformationAbstract" xlink:label="loc_entx_SupplementaryFinancialStatementInformationAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedEmployeeBenefitsCurrent" xlink:label="loc_us-gaap_AccruedEmployeeBenefitsCurrent_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedIncomeTaxesCurrent" xlink:label="loc_us-gaap_AccruedIncomeTaxesCurrent_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedVacationCurrent" xlink:label="loc_us-gaap_AccruedVacationCurrent_3"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:label="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilities_5"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_entx_SupplementaryFinancialStatementInformationAbstract_0" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_1" xlink:to="loc_us-gaap_AccruedEmployeeBenefitsCurrent_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_1" xlink:to="loc_us-gaap_AccruedIncomeTaxesCurrent_2" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_1" xlink:to="loc_us-gaap_AccruedVacationCurrent_3" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_1" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_4" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_1" xlink:to="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilities_5" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.enterabio.com/role/SUPPLEMENTARYFINANCIALSTATEMENTINFORMATIONTable">
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_SupplementaryFinancialStatementInformationAbstract" xlink:label="loc_entx_SupplementaryFinancialStatementInformationAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_entx_SupplementaryFinancialStatementInformationAbstract_0" xlink:to="loc_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.enterabio.com/role/OPERATINGLEASES">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract" xlink:label="loc_us-gaap_LeasesAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeasesTextBlock" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock_1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_0" xlink:to="loc_us-gaap_LesseeOperatingLeasesTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.enterabio.com/role/OperatingLeaseDetails">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract" xlink:label="loc_us-gaap_LeasesAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseCost" xlink:label="loc_us-gaap_OperatingLeaseCost_1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_0" xlink:to="loc_us-gaap_OperatingLeaseCost_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.enterabio.com/role/OperatingLeaseDetails1">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract" xlink:label="loc_us-gaap_LeasesAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeasePayments" xlink:label="loc_us-gaap_OperatingLeasePayments_1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_0" xlink:to="loc_us-gaap_OperatingLeasePayments_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.enterabio.com/role/OPERATINGLEASESDetails">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract" xlink:label="loc_us-gaap_LeasesAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityAbstract" xlink:label="loc_us-gaap_OperatingLeaseLiabilityAbstract_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_3"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaap_OperatingLeaseLiability_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_6"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_7"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_0" xlink:to="loc_us-gaap_OperatingLeaseLiabilityAbstract_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilityAbstract_1" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilityAbstract_1" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_2" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilityAbstract_1" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_3" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilityAbstract_1" xlink:to="loc_us-gaap_OperatingLeaseLiability_4" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_0" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_6" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_0" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_7" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.enterabio.com/role/OPERATINGLEASESDetailTextuals">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract" xlink:label="loc_us-gaap_LeasesAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_1"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_LeaseArrangementAxis" xlink:label="loc_entx_LeaseArrangementAxis_1"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_LeaseArrangementDomain" xlink:label="loc_entx_LeaseArrangementDomain_1"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_OperatingLeaseAgreementsForOfficeAndResearchAndDevelopmentSpaceMember" xlink:label="loc_entx_OperatingLeaseAgreementsForOfficeAndResearchAndDevelopmentSpaceMember_1"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_OperatingLeaseAgreementsForVehiclesForEmployeesMember" xlink:label="loc_entx_OperatingLeaseAgreementsForVehiclesForEmployeesMember_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_5"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentForContingentConsiderationLiabilityOperatingActivities" xlink:label="loc_us-gaap_PaymentForContingentConsiderationLiabilityOperatingActivities_5"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_BankGuarantees" xlink:label="loc_entx_BankGuarantees_6"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaap_OperatingLeaseLiability_7"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_0" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_1" xlink:to="loc_entx_LeaseArrangementAxis_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_entx_LeaseArrangementAxis_1" xlink:to="loc_entx_LeaseArrangementDomain_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_entx_LeaseArrangementDomain_1" xlink:to="loc_entx_OperatingLeaseAgreementsForOfficeAndResearchAndDevelopmentSpaceMember_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_entx_LeaseArrangementDomain_1" xlink:to="loc_entx_OperatingLeaseAgreementsForVehiclesForEmployeesMember_2" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_1" xlink:to="loc_us-gaap_LesseeLeaseDescriptionLineItems_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_5" xlink:to="loc_us-gaap_PaymentForContingentConsiderationLiabilityOperatingActivities_5" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_5" xlink:to="loc_entx_BankGuarantees_6" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_5" xlink:to="loc_us-gaap_OperatingLeaseLiability_7" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.enterabio.com/role/OPERATINGLEASESTables">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract" xlink:label="loc_us-gaap_LeasesAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCostTableTextBlock" xlink:label="loc_us-gaap_LeaseCostTableTextBlock_1"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_OperatingLeaseSupplementalCashFlowInformationTableTextBlock" xlink:label="loc_entx_OperatingLeaseSupplementalCashFlowInformationTableTextBlock_2"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_OperatingLeaseLiabilityAndOperatingLeaseRightOfUseAssetTableTextBlock" xlink:label="loc_entx_OperatingLeaseLiabilityAndOperatingLeaseRightOfUseAssetTableTextBlock_3"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_4"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_0" xlink:to="loc_us-gaap_LeaseCostTableTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_0" xlink:to="loc_entx_OperatingLeaseSupplementalCashFlowInformationTableTextBlock_2" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_0" xlink:to="loc_entx_OperatingLeaseLiabilityAndOperatingLeaseRightOfUseAssetTableTextBlock_3" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_0" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_4" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.enterabio.com/role/COMMITMENTS">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_0" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.enterabio.com/role/COMMITMENTSDetailTextuals">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_0"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_CommitmentsAndContingenciesTable" xlink:label="loc_entx_CommitmentsAndContingenciesTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis" xlink:label="loc_us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LegalEntityTypeOfCounterpartyDomain" xlink:label="loc_us-gaap_LegalEntityTypeOfCounterpartyDomain_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GovernmentMember" xlink:label="loc_us-gaap_GovernmentMember_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_4"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_DnaBiomedicalSolutionsLtdMember" xlink:label="loc_entx_DnaBiomedicalSolutionsLtdMember_4"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_DnaBiomedicalSolutionsLtdAndOramedLtdMember" xlink:label="loc_entx_DnaBiomedicalSolutionsLtdAndOramedLtdMember_5"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_AgreementAxis" xlink:label="loc_entx_AgreementAxis_8"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_AgreementDomain" xlink:label="loc_entx_AgreementDomain_8"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_JointVentureAgreementMember" xlink:label="loc_entx_JointVentureAgreementMember_8"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_PatentTransferAgreementMember" xlink:label="loc_entx_PatentTransferAgreementMember_9"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_CommitmentsLineItems" xlink:label="loc_entx_CommitmentsLineItems_12"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_RoyaltyGuaranteesCommitmentsPercentageSalesOfProductsDevelopedFromProjectsInFirstThreeYearsFromCommencementOfRevenues" xlink:label="loc_entx_RoyaltyGuaranteesCommitmentsPercentageSalesOfProductsDevelopedFromProjectsInFirstThreeYearsFromCommencementOfRevenues_12"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_RoyaltyGuaranteesCommitmentsPercentageSalesOfProductsDevelopedFromProjectsSubsequentThreeYears" xlink:label="loc_entx_RoyaltyGuaranteesCommitmentsPercentageSalesOfProductsDevelopedFromProjectsSubsequentThreeYears_13"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_RoyaltyGuaranteesCommitmentsPercentageSalesOfProductsDevelopedFromProjectsCommencingSeventhYear" xlink:label="loc_entx_RoyaltyGuaranteesCommitmentsPercentageSalesOfProductsDevelopedFromProjectsCommencingSeventhYear_14"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RoyaltyGuaranteesCommitmentsAmount" xlink:label="loc_us-gaap_RoyaltyGuaranteesCommitmentsAmount_15"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_RoyaltyGuaranteesCommitmentsPercentageOfEachPaymentReceivedFromAmgen" xlink:label="loc_entx_RoyaltyGuaranteesCommitmentsPercentageOfEachPaymentReceivedFromAmgen_16"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_PaymentOfRoyaltyGuaranteesCommitments" xlink:label="loc_entx_PaymentOfRoyaltyGuaranteesCommitments_17"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_SaleOfStockPercentageOfOwnershipOfEntityAcquired" xlink:label="loc_entx_SaleOfStockPercentageOfOwnershipOfEntityAcquired_18"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_SaleOfStockAmountOfInvestment" xlink:label="loc_entx_SaleOfStockAmountOfInvestment_19"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_RoyaltyGuaranteesCommitmentsPercentageOfNetRevenues" xlink:label="loc_entx_RoyaltyGuaranteesCommitmentsPercentageOfNetRevenues_20"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_0" xlink:to="loc_entx_CommitmentsAndContingenciesTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_entx_CommitmentsAndContingenciesTable_1" xlink:to="loc_us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis_1" xlink:to="loc_us-gaap_LegalEntityTypeOfCounterpartyDomain_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LegalEntityTypeOfCounterpartyDomain_1" xlink:to="loc_us-gaap_GovernmentMember_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_entx_CommitmentsAndContingenciesTable_1" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_4" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_4" xlink:to="loc_us-gaap_RelatedPartyDomain_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_4" xlink:to="loc_entx_DnaBiomedicalSolutionsLtdMember_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_4" xlink:to="loc_entx_DnaBiomedicalSolutionsLtdAndOramedLtdMember_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_entx_CommitmentsAndContingenciesTable_1" xlink:to="loc_entx_AgreementAxis_8" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_entx_AgreementAxis_8" xlink:to="loc_entx_AgreementDomain_8" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_entx_AgreementDomain_8" xlink:to="loc_entx_JointVentureAgreementMember_8" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_entx_AgreementDomain_8" xlink:to="loc_entx_PatentTransferAgreementMember_9" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_entx_CommitmentsAndContingenciesTable_1" xlink:to="loc_entx_CommitmentsLineItems_12" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_entx_CommitmentsLineItems_12" xlink:to="loc_entx_RoyaltyGuaranteesCommitmentsPercentageSalesOfProductsDevelopedFromProjectsInFirstThreeYearsFromCommencementOfRevenues_12" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_entx_CommitmentsLineItems_12" xlink:to="loc_entx_RoyaltyGuaranteesCommitmentsPercentageSalesOfProductsDevelopedFromProjectsSubsequentThreeYears_13" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_entx_CommitmentsLineItems_12" xlink:to="loc_entx_RoyaltyGuaranteesCommitmentsPercentageSalesOfProductsDevelopedFromProjectsCommencingSeventhYear_14" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_entx_CommitmentsLineItems_12" xlink:to="loc_us-gaap_RoyaltyGuaranteesCommitmentsAmount_15" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_entx_CommitmentsLineItems_12" xlink:to="loc_entx_RoyaltyGuaranteesCommitmentsPercentageOfEachPaymentReceivedFromAmgen_16" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_entx_CommitmentsLineItems_12" xlink:to="loc_entx_PaymentOfRoyaltyGuaranteesCommitments_17" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_entx_CommitmentsLineItems_12" xlink:to="loc_entx_SaleOfStockPercentageOfOwnershipOfEntityAcquired_18" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_entx_CommitmentsLineItems_12" xlink:to="loc_entx_SaleOfStockAmountOfInvestment_19" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_entx_CommitmentsLineItems_12" xlink:to="loc_entx_RoyaltyGuaranteesCommitmentsPercentageOfNetRevenues_20" order="80" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.enterabio.com/role/SHARECAPITAL">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_0" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.enterabio.com/role/INCOMETAX">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_0" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.enterabio.com/role/SIGNIFICANTACCOUNTINGPOLICIESTables">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_0"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_ScheduleOfEstimatedUsefulLifeTableTextBlock" xlink:label="loc_entx_ScheduleOfEstimatedUsefulLifeTableTextBlock_1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_entx_ScheduleOfEstimatedUsefulLifeTableTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.enterabio.com/role/SHARECAPITALDetailTextuals">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_0"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_StockholdersEquityNoteTable" xlink:label="loc_entx_StockholdersEquityNoteTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IPOMember" xlink:label="loc_us-gaap_IPOMember_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrivatePlacementMember" xlink:label="loc_us-gaap_PrivatePlacementMember_2"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_PlacementAgencyAgreementWithGpNumenkariIncMember" xlink:label="loc_entx_PlacementAgencyAgreementWithGpNumenkariIncMember_3"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_6"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_6"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_6"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_9"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_9"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaap_WarrantMember_9"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_BrokerWarrantsType1Member" xlink:label="loc_entx_BrokerWarrantsType1Member_10"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_BrokerWarrantsType2Member" xlink:label="loc_entx_BrokerWarrantsType2Member_11"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_BrokerWarrantsMember" xlink:label="loc_entx_BrokerWarrantsMember_12"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_BrokerDealerMember" xlink:label="loc_entx_BrokerDealerMember_13"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_BrokerDealerOneMember" xlink:label="loc_entx_BrokerDealerOneMember_14"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_17"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_17"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_AccreditedInvestorsIncludingCertainBoardMembersAndTheirAffiliatesMember" xlink:label="loc_entx_AccreditedInvestorsIncludingCertainBoardMembersAndTheirAffiliatesMember_17"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_DnaBiomedicalSolutionsLtdMember" xlink:label="loc_entx_DnaBiomedicalSolutionsLtdMember_18"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_ChairmanOfBoardAndDnaMember" xlink:label="loc_entx_ChairmanOfBoardAndDnaMember_19"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_SeveralEmployeesAndServiceProvidersMember" xlink:label="loc_entx_SeveralEmployeesAndServiceProvidersMember_20"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_23"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_23"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="loc_us-gaap_SeriesBPreferredStockMember_23"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="loc_us-gaap_SeriesAPreferredStockMember_24"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_EquityProgramAxis" xlink:label="loc_entx_EquityProgramAxis_27"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_EquityProgramDomain" xlink:label="loc_entx_EquityProgramDomain_27"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_AtmEquityProgram2020Member" xlink:label="loc_entx_AtmEquityProgram2020Member_27"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_AtmEquityProgram2021Member" xlink:label="loc_entx_AtmEquityProgram2021Member_28"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_StockholdersEquityNoteLineItems" xlink:label="loc_entx_StockholdersEquityNoteLineItems_31"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockVotingRights" xlink:label="loc_us-gaap_CommonStockVotingRights_31"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_ClassOfWarrantOrRightIssued" xlink:label="loc_entx_ClassOfWarrantOrRightIssued_32"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_33"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_34"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_AdjustedExercisePriceUnderAtMarketEquityProgram" xlink:label="loc_entx_AdjustedExercisePriceUnderAtMarketEquityProgram_35"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_ClassOfWarrantOrRightExerciseTerm" xlink:label="loc_entx_ClassOfWarrantOrRightExerciseTerm_36"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_ClassOfWarrantOrRightThresholdLimitOfPeriodForReductionInExercisePrice" xlink:label="loc_entx_ClassOfWarrantOrRightThresholdLimitOfPeriodForReductionInExercisePrice_37"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_ClassOfWarrantOrRightThresholdLimitOfReductionInExercisePrice" xlink:label="loc_entx_ClassOfWarrantOrRightThresholdLimitOfReductionInExercisePrice_38"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_ClassOfWarrantOrRightReducedExercisePrice" xlink:label="loc_entx_ClassOfWarrantOrRightReducedExercisePrice_39"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_ClassOfWarrantOrRightThresholdLimitOfLastReportedSalePrice" xlink:label="loc_entx_ClassOfWarrantOrRightThresholdLimitOfLastReportedSalePrice_40"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_ClassOfWarrantOrRightPercentageOfIpoPricePerUnit" xlink:label="loc_entx_ClassOfWarrantOrRightPercentageOfIpoPricePerUnit_41"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_ClassOfWarrantOrRightThresholdConsecutiveTradingDays" xlink:label="loc_entx_ClassOfWarrantOrRightThresholdConsecutiveTradingDays_42"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="loc_us-gaap_ProceedsFromWarrantExercises_43"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_NumberOfSharesIssuedUnderPrivatePlacement" xlink:label="loc_entx_NumberOfSharesIssuedUnderPrivatePlacement_44"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfPrivatePlacement_45"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaap_SharePrice_46"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_TransactionCosts" xlink:label="loc_entx_TransactionCosts_47"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_CashFeesInPercentage" xlink:label="loc_entx_CashFeesInPercentage_48"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_SharesGrantedInPercentage" xlink:label="loc_entx_SharesGrantedInPercentage_49"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_50"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalOther" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalOther_51"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_52"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_EffectOfDownRoundTriggerAmount" xlink:label="loc_entx_EffectOfDownRoundTriggerAmount_53"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_54"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_SharesIssuedWeightedAveragePricePerShare" xlink:label="loc_entx_SharesIssuedWeightedAveragePricePerShare_55"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_NetProceedsFromIssuanceOfCommonStock" xlink:label="loc_entx_NetProceedsFromIssuanceOfCommonStock_56"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesIssued" xlink:label="loc_us-gaap_SharesIssued_57"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_58"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_59"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_60"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_61"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsTotalConsideration" xlink:label="loc_entx_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsTotalConsideration_62"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_0" xlink:to="loc_entx_StockholdersEquityNoteTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_entx_StockholdersEquityNoteTable_1" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_1" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1" xlink:to="loc_us-gaap_IPOMember_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1" xlink:to="loc_us-gaap_PrivatePlacementMember_2" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1" xlink:to="loc_entx_PlacementAgencyAgreementWithGpNumenkariIncMember_3" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_entx_StockholdersEquityNoteTable_1" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_6" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_6" xlink:to="loc_us-gaap_EquityComponentDomain_6" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_6" xlink:to="loc_us-gaap_CommonStockMember_6" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_entx_StockholdersEquityNoteTable_1" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_9" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_9" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_9" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_9" xlink:to="loc_us-gaap_WarrantMember_9" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_9" xlink:to="loc_entx_BrokerWarrantsType1Member_10" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_9" xlink:to="loc_entx_BrokerWarrantsType2Member_11" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_9" xlink:to="loc_entx_BrokerWarrantsMember_12" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_9" xlink:to="loc_entx_BrokerDealerMember_13" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_9" xlink:to="loc_entx_BrokerDealerOneMember_14" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_entx_StockholdersEquityNoteTable_1" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_17" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_17" xlink:to="loc_us-gaap_RelatedPartyDomain_17" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_17" xlink:to="loc_entx_AccreditedInvestorsIncludingCertainBoardMembersAndTheirAffiliatesMember_17" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_17" xlink:to="loc_entx_DnaBiomedicalSolutionsLtdMember_18" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_17" xlink:to="loc_entx_ChairmanOfBoardAndDnaMember_19" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_17" xlink:to="loc_entx_SeveralEmployeesAndServiceProvidersMember_20" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_entx_StockholdersEquityNoteTable_1" xlink:to="loc_us-gaap_StatementClassOfStockAxis_23" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_23" xlink:to="loc_us-gaap_ClassOfStockDomain_23" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_23" xlink:to="loc_us-gaap_SeriesBPreferredStockMember_23" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_23" xlink:to="loc_us-gaap_SeriesAPreferredStockMember_24" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_entx_StockholdersEquityNoteTable_1" xlink:to="loc_entx_EquityProgramAxis_27" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_entx_EquityProgramAxis_27" xlink:to="loc_entx_EquityProgramDomain_27" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_entx_EquityProgramDomain_27" xlink:to="loc_entx_AtmEquityProgram2020Member_27" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_entx_EquityProgramDomain_27" xlink:to="loc_entx_AtmEquityProgram2021Member_28" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_entx_StockholdersEquityNoteTable_1" xlink:to="loc_entx_StockholdersEquityNoteLineItems_31" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_entx_StockholdersEquityNoteLineItems_31" xlink:to="loc_us-gaap_CommonStockVotingRights_31" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_entx_StockholdersEquityNoteLineItems_31" xlink:to="loc_entx_ClassOfWarrantOrRightIssued_32" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_entx_StockholdersEquityNoteLineItems_31" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_33" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_entx_StockholdersEquityNoteLineItems_31" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_34" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_entx_StockholdersEquityNoteLineItems_31" xlink:to="loc_entx_AdjustedExercisePriceUnderAtMarketEquityProgram_35" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_entx_StockholdersEquityNoteLineItems_31" xlink:to="loc_entx_ClassOfWarrantOrRightExerciseTerm_36" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_entx_StockholdersEquityNoteLineItems_31" xlink:to="loc_entx_ClassOfWarrantOrRightThresholdLimitOfPeriodForReductionInExercisePrice_37" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_entx_StockholdersEquityNoteLineItems_31" xlink:to="loc_entx_ClassOfWarrantOrRightThresholdLimitOfReductionInExercisePrice_38" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_entx_StockholdersEquityNoteLineItems_31" xlink:to="loc_entx_ClassOfWarrantOrRightReducedExercisePrice_39" order="80" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_entx_StockholdersEquityNoteLineItems_31" xlink:to="loc_entx_ClassOfWarrantOrRightThresholdLimitOfLastReportedSalePrice_40" order="90" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_entx_StockholdersEquityNoteLineItems_31" xlink:to="loc_entx_ClassOfWarrantOrRightPercentageOfIpoPricePerUnit_41" order="100" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_entx_StockholdersEquityNoteLineItems_31" xlink:to="loc_entx_ClassOfWarrantOrRightThresholdConsecutiveTradingDays_42" order="110" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_entx_StockholdersEquityNoteLineItems_31" xlink:to="loc_us-gaap_ProceedsFromWarrantExercises_43" order="120" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_entx_StockholdersEquityNoteLineItems_31" xlink:to="loc_entx_NumberOfSharesIssuedUnderPrivatePlacement_44" order="130" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_entx_StockholdersEquityNoteLineItems_31" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfPrivatePlacement_45" order="140" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_entx_StockholdersEquityNoteLineItems_31" xlink:to="loc_us-gaap_SharePrice_46" order="150" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_entx_StockholdersEquityNoteLineItems_31" xlink:to="loc_entx_TransactionCosts_47" order="160" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_entx_StockholdersEquityNoteLineItems_31" xlink:to="loc_entx_CashFeesInPercentage_48" order="170" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_entx_StockholdersEquityNoteLineItems_31" xlink:to="loc_entx_SharesGrantedInPercentage_49" order="180" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_entx_StockholdersEquityNoteLineItems_31" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_50" order="190" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_entx_StockholdersEquityNoteLineItems_31" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalOther_51" order="200" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_entx_StockholdersEquityNoteLineItems_31" xlink:to="loc_us-gaap_CommonStockValue_52" order="210" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_entx_StockholdersEquityNoteLineItems_31" xlink:to="loc_entx_EffectOfDownRoundTriggerAmount_53" order="220" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_entx_StockholdersEquityNoteLineItems_31" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_54" order="230" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_entx_StockholdersEquityNoteLineItems_31" xlink:to="loc_entx_SharesIssuedWeightedAveragePricePerShare_55" order="240" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_entx_StockholdersEquityNoteLineItems_31" xlink:to="loc_entx_NetProceedsFromIssuanceOfCommonStock_56" order="250" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_entx_StockholdersEquityNoteLineItems_31" xlink:to="loc_us-gaap_SharesIssued_57" order="260" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_entx_StockholdersEquityNoteLineItems_31" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_58" order="270" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_entx_StockholdersEquityNoteLineItems_31" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_59" order="280" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_entx_StockholdersEquityNoteLineItems_31" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_60" order="290" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_entx_StockholdersEquityNoteLineItems_31" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_61" order="300" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_entx_StockholdersEquityNoteLineItems_31" xlink:to="loc_entx_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsTotalConsideration_62" order="310" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.enterabio.com/role/INCOMETAXDetails2">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_3"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_0" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_0" xlink:to="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_2" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_0" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_3" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.enterabio.com/role/INCOMETAXDetails1">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:label="loc_us-gaap_OperatingLossCarryforwardsTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidatedEntitiesAxis" xlink:label="loc_srt_ConsolidatedEntitiesAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="loc_srt_ConsolidatedEntitiesDomain_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SubsidiariesMember" xlink:label="loc_srt_SubsidiariesMember_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_4"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_EnteraBioLtdMember" xlink:label="loc_entx_EnteraBioLtdMember_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwardsLineItems" xlink:label="loc_us-gaap_OperatingLossCarryforwardsLineItems_7"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_7"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_0" xlink:to="loc_us-gaap_OperatingLossCarryforwardsTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_1" xlink:to="loc_srt_ConsolidatedEntitiesAxis_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidatedEntitiesAxis_1" xlink:to="loc_srt_ConsolidatedEntitiesDomain_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidatedEntitiesDomain_1" xlink:to="loc_srt_SubsidiariesMember_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_1" xlink:to="loc_dei_LegalEntityAxis_4" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_4" xlink:to="loc_dei_EntityDomain_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_4" xlink:to="loc_entx_EnteraBioLtdMember_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_1" xlink:to="loc_us-gaap_OperatingLossCarryforwardsLineItems_7" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_7" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_7" order="0" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.enterabio.com/role/INCOMETAXDetails">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract" xlink:label="loc_us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:label="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_3"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="loc_us-gaap_DeferredTaxAssetsOther_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_5"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_6"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_7"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_0" xlink:to="loc_us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract_1" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract_1" xlink:to="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_2" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract_1" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_3" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract_1" xlink:to="loc_us-gaap_DeferredTaxAssetsOther_4" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract_1" xlink:to="loc_us-gaap_DeferredTaxAssetsGross_5" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract_1" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_6" order="50" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract_1" xlink:to="loc_us-gaap_DeferredTaxAssetsNet_7" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.enterabio.com/role/SHAREBASEDCOMPENSATIONDetails3">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfSalesMember" xlink:label="loc_us-gaap_CostOfSalesMember_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_3"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_6"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_6"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_1" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_1" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_1" xlink:to="loc_us-gaap_CostOfSalesMember_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_1" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_2" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_1" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_3" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_1" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_6" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_6" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_6" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.enterabio.com/role/INCOMETAXDetails3">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:label="loc_us-gaap_OperatingLossCarryforwardsTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidatedEntitiesAxis" xlink:label="loc_srt_ConsolidatedEntitiesAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="loc_srt_ConsolidatedEntitiesDomain_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SubsidiariesMember" xlink:label="loc_srt_SubsidiariesMember_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwardsLineItems" xlink:label="loc_us-gaap_OperatingLossCarryforwardsLineItems_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:label="loc_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:label="loc_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract_6"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit_6"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_7"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_9"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_0" xlink:to="loc_us-gaap_OperatingLossCarryforwardsTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_1" xlink:to="loc_srt_ConsolidatedEntitiesAxis_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidatedEntitiesAxis_1" xlink:to="loc_srt_ConsolidatedEntitiesDomain_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidatedEntitiesDomain_1" xlink:to="loc_srt_SubsidiariesMember_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_1" xlink:to="loc_us-gaap_OperatingLossCarryforwardsLineItems_4" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_4" xlink:to="loc_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract_4" xlink:to="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_4" xlink:to="loc_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract_6" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract_6" xlink:to="loc_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit_6" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract_6" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_7" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_4" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_9" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.enterabio.com/role/SHAREBASEDCOMPENSATIONDetails1">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_3"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_5"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_6"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_7"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_9"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_9"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_10"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_11"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_12"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_13"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_14"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_15"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_2" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_1" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_3" order="20" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_4" order="30" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_5" order="40" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_6" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_7" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_9" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_9" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_10" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_11" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_12" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_13" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_14" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_15" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.enterabio.com/role/INCOMETAXTables">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_3"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SummaryOfValuationAllowanceTextBlock" xlink:label="loc_us-gaap_SummaryOfValuationAllowanceTextBlock_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_5"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_0" xlink:to="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_0" xlink:to="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_2" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_0" xlink:to="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_3" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_0" xlink:to="loc_us-gaap_SummaryOfValuationAllowanceTextBlock_4" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_0" xlink:to="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_5" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.enterabio.com/role/INCOMETAXDetailTextuals">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:label="loc_us-gaap_OperatingLossCarryforwardsTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DomesticCountryMember" xlink:label="loc_us-gaap_DomesticCountryMember_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCountryMember" xlink:label="loc_us-gaap_ForeignCountryMember_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwardsLineItems" xlink:label="loc_us-gaap_OperatingLossCarryforwardsLineItems_5"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_5"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="loc_us-gaap_OperatingLossCarryforwards_6"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_0" xlink:to="loc_us-gaap_OperatingLossCarryforwardsTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_1" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_1" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_1" xlink:to="loc_us-gaap_DomesticCountryMember_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_1" xlink:to="loc_us-gaap_ForeignCountryMember_2" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_1" xlink:to="loc_us-gaap_OperatingLossCarryforwardsLineItems_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_5" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_5" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_5" xlink:to="loc_us-gaap_OperatingLossCarryforwards_6" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.enterabio.com/role/SHAREBASEDCOMPENSATIONDetails2">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_1"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_ExercisePricePerShareZeroMember" xlink:label="loc_entx_ExercisePricePerShareZeroMember_1"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_ExercisePricePerShareOnePointTwoFourMember" xlink:label="loc_entx_ExercisePricePerShareOnePointTwoFourMember_2"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_ExercisePricePerShareOnePointFourMember" xlink:label="loc_entx_ExercisePricePerShareOnePointFourMember_3"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_ExercisePricePerShareTwoPointZeroTwoMember" xlink:label="loc_entx_ExercisePricePerShareTwoPointZeroTwoMember_4"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_ExercisePricePerShareTwoPointOneFourMember" xlink:label="loc_entx_ExercisePricePerShareTwoPointOneFourMember_5"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_ExercisePricePerShareTwoPointFiveThreeMember" xlink:label="loc_entx_ExercisePricePerShareTwoPointFiveThreeMember_6"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_ExercisePricePerShareTwoPointFiveSevenMember" xlink:label="loc_entx_ExercisePricePerShareTwoPointFiveSevenMember_7"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_ExercisePricePerShareTwoPointEightOneFiveMember" xlink:label="loc_entx_ExercisePricePerShareTwoPointEightOneFiveMember_8"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_ExercisePricePerShareTwoPointEightSixMember" xlink:label="loc_entx_ExercisePricePerShareTwoPointEightSixMember_9"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_ExercisePricePerShareThreePointOneFiveMember" xlink:label="loc_entx_ExercisePricePerShareThreePointOneFiveMember_10"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_ExercisePricePerShareOnePointZeroSixMember" xlink:label="loc_entx_ExercisePricePerShareOnePointZeroSixMember_11"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_ExercisePricePerShareThreePointSixOneMember" xlink:label="loc_entx_ExercisePricePerShareThreePointSixOneMember_12"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_ExercisePricePerShareThreePointSixEightMember" xlink:label="loc_entx_ExercisePricePerShareThreePointSixEightMember_13"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_ExercisePricePerShareThreePointNineSevenMember" xlink:label="loc_entx_ExercisePricePerShareThreePointNineSevenMember_14"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_ExercisePricePerShareSixPointThreeOneMember" xlink:label="loc_entx_ExercisePricePerShareSixPointThreeOneMember_15"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_18"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_18"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_19"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_20"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_21"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_22"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_1" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_1" xlink:to="loc_entx_ExercisePricePerShareZeroMember_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_1" xlink:to="loc_entx_ExercisePricePerShareOnePointTwoFourMember_2" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_1" xlink:to="loc_entx_ExercisePricePerShareOnePointFourMember_3" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_1" xlink:to="loc_entx_ExercisePricePerShareTwoPointZeroTwoMember_4" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_1" xlink:to="loc_entx_ExercisePricePerShareTwoPointOneFourMember_5" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_1" xlink:to="loc_entx_ExercisePricePerShareTwoPointFiveThreeMember_6" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_1" xlink:to="loc_entx_ExercisePricePerShareTwoPointFiveSevenMember_7" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_1" xlink:to="loc_entx_ExercisePricePerShareTwoPointEightOneFiveMember_8" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_1" xlink:to="loc_entx_ExercisePricePerShareTwoPointEightSixMember_9" order="80" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_1" xlink:to="loc_entx_ExercisePricePerShareThreePointOneFiveMember_10" order="90" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_1" xlink:to="loc_entx_ExercisePricePerShareOnePointZeroSixMember_11" order="100" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_1" xlink:to="loc_entx_ExercisePricePerShareThreePointSixOneMember_12" order="110" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_1" xlink:to="loc_entx_ExercisePricePerShareThreePointSixEightMember_13" order="120" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_1" xlink:to="loc_entx_ExercisePricePerShareThreePointNineSevenMember_14" order="130" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_1" xlink:to="loc_entx_ExercisePricePerShareSixPointThreeOneMember_15" order="140" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_18" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_18" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_18" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_18" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_19" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_18" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_20" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_18" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_21" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_18" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_22" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.enterabio.com/role/SIGNIFICANTACCOUNTINGPOLICIESDetails">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComputerEquipmentMember" xlink:label="loc_us-gaap_ComputerEquipmentMember_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OfficeEquipmentMember" xlink:label="loc_us-gaap_OfficeEquipmentMember_2"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_LaboratoryEquipmentMember" xlink:label="loc_entx_LaboratoryEquipmentMember_3"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_6"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_6"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_6"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_7"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_10"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_10"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_1" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_1" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1" xlink:to="loc_us-gaap_ComputerEquipmentMember_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1" xlink:to="loc_us-gaap_OfficeEquipmentMember_2" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1" xlink:to="loc_entx_LaboratoryEquipmentMember_3" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_1" xlink:to="loc_srt_RangeAxis_6" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_6" xlink:to="loc_srt_RangeMember_6" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_6" xlink:to="loc_srt_MinimumMember_6" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_6" xlink:to="loc_srt_MaximumMember_7" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_1" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_10" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_10" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_10" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.enterabio.com/role/SUBSEQUENTEVENTSNarrative">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaap_SubsequentEventsAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTable" xlink:label="loc_us-gaap_SubsequentEventTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srt_TitleOfIndividualAxis_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_4"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_NonExecutiveBoardMember" xlink:label="loc_entx_NonExecutiveBoardMember_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventLineItems" xlink:label="loc_us-gaap_SubsequentEventLineItems_7"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_7"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_8"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_9"/>
    <loc xlink:type="locator" xlink:href="entx-20221231.xsd#entx_NumberOfNonExecutiveBoardMembers" xlink:label="loc_entx_NumberOfNonExecutiveBoardMembers_10"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_0" xlink:to="loc_us-gaap_SubsequentEventTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_1" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_1" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_1" xlink:to="loc_us-gaap_SubsequentEventMember_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_1" xlink:to="loc_srt_TitleOfIndividualAxis_4" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualAxis_4" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_4" xlink:to="loc_entx_NonExecutiveBoardMember_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_1" xlink:to="loc_us-gaap_SubsequentEventLineItems_7" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_7" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_7" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_8" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_9" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_7" xlink:to="loc_entx_NumberOfNonExecutiveBoardMembers_10" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>image00015.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image00015.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  8$!08%! 8&!08'!P8("A *"@D)
M"A0.#PP0%Q08&!<4%A8:'24?&ALC'!86("P@(R8G*2HI&1\M,"TH,"4H*2C_
MVP!# 0<'!PH("A,*"A,H&A8:*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H
M*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"C_P  1" &Q SH# 2(  A$! Q$!_\0
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M?]-1_P!\_P#UZ -'S8_[Z?G1YL?]]/SK._LK_IJ/^^?_ *]']E?]-1_WS_\
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MI7]L*O\ :&L_VMYOD@^7^\1_+QNY^[C/OTKLO[*_Z:C_ +Y_^O1_97_34?\
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MFH_[Y_\ KT?V5_TU'_?/_P!>DJ\ULQNG%[F7X>\-0:+XEUG5(KU7CU"*VB6
MJ!Y0A0J/FSSG/H*Z7S8_[Z?G6=_97_34?]\__7H_LK_IJ/\ OG_Z]1*3D[LI
M)1T1H^;'_?3\Z/-C_OI^=9W]E?\ 34?]\_\ UZ/[*_Z:C_OG_P"O4C-'S8_[
MZ?G1YL?]]/SK._LK_IJ/^^?_ *]']E?]-1_WS_\ 7H T?-C_ +Z?G1YL?]]/
MSK._LK_IJ/\ OG_Z]']E?]-1_P!\_P#UZ -2BBB@ HHHH **** "BBB@!'8(
MI9LX'H,U!]KB_P"FG_?IO\*L44 5_M<7_33_ +]-_A1]KB_Z:?\ ?IO\*L44
M 5_M<7_33_OTW^%'VN+_ *:?]^F_PJQ10!7^UQ?]-/\ OTW^%'VN+_II_P!^
MF_PJQ10!7^UQ?]-/^_3?X4?:XO\ II_WZ;_"K%% %?[7%_TT_P"_3?X4?:XO
M^FG_ 'Z;_"K%% %?[7%_TT_[]-_A1]KB_P"FG_?IO\*L44 5_M<7_33_ +]-
M_A1]KB_Z:?\ ?IO\*L44 5_M<7_33_OTW^%'VN+_ *:?]^F_PJQ10!7^UQ?]
M-/\ OTW^%'VN+_II_P!^F_PJQ10!7^UQ?]-/^_3?X4?:XO\ II_WZ;_"K%%
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M[5&5'0DD@ 54TCQBGDZBGBJUCT"]TV-)KI)KE7A\IL[9$EX#*2&'(!!&,=*
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M_P +]\=?\_&G?^ @_P :\HHH^JT?Y4'UBK_,>K_\+]\=?\_&G?\ @(/\:/\
MA?OCK_GXT[_P$'^->444?5:/\J#ZQ5_F/5_^%^^.O^?C3O\ P$'^-'_"_?'7
M_/QIW_@(/\:\HHH^JT?Y4'UBK_,>K_\ "_?'7_/QIW_@(/\ &C_A?OCK_GXT
M[_P$'^->444?5:/\J#ZQ5_F/H;X2?%[Q9XG\?Z;I.JS636<ZREQ';!6^6-F&
M#GU KZ(^T/[?E7QM^SW_ ,E:T;_=G_\ 13U]B5XV80C3JI15M#TL'.4Z=Y.^
MI+]H?V_*C[0_M^5145PG62_:']ORH^T/[?E45% $OVA_;\J/M#^WY5%10!+]
MH?V_*C[0_M^5144 2_:']ORH^T/[?E45% $OVA_;\J/M#^WY5%10!+]H?V_*
MC[0_M^5144 2_:']ORH^T/[?E45% %JWD9V(;'2IZJVGWF^E6J "BBB@ HHH
MH **** "BBB@ HHHH **** "N?\ B%8W.I^!?$%C8PF>ZN;":**($ NS(0!D
M\<^]=!12:NK#3L[GC'A/P_8V?GQ:7\,;_0;^:PFM_M\CVY4$QG@[96/S$ =*
MH^ ?!K6MUH T[P+<>&KVUC6/4M2GFBQ<1^45D1521BVYL'D#&,^U>ZT55[DV
M/(OA_P"$;S2=8T&W7PW'I+:+')%=ZHDD;#4E*%5 (.]@3ASO VE<#-=9;V>L
MV&L>,K^PLXI9KE[>2R6>3:D^R%589&2O((R1U]J[&BAMA8X'X=:5=6VM:OJ*
M:'-X=TV\52=/FF21Y;G<QDG(1F5<@J.#SC) KOJ**0PHHHH **** "BBB@#D
M?%MKJEEK^G>(M&T\ZH]O;RVES9)*L<CQ.58-&6(4L&0<$C(/7BN9US1=7\36
M>JZSJF@W=O(\-O!9Z=!>QI>(L<OFF7?S&) V"JY(^7D\UZI10!X]H>B^)XVT
M*\U#3KF41:G<8,JVZ7<,,L&P2S^60C,KY)*DL1@\FL/PU\.M<%N=,NT\00W-
MG87-K'>7.HP/9;Y(RF8D1?,(;.2&VX]R*]]HH!,\(\8:=JEWX9U"\N_#":%!
MINBOIS1O+$PNV9XL*OED_NAL."V#\W0<UL:CX?UK6;JZUJ+PTNGK;FR5=(DF
MBS?"WE9VR5)0## )N/..<"O6KJV@N[=X+N&.>!QAHY%#*WU!X-2T[]0Z6/);
M7PYJ>J^(K;6KO0/[.MI]9@NS8R/&SQ+%;2IYT@4E=Q9E& 2< 9]FW'A[6C=7
M6A)H"NL^MC55UWS8PB1^<).1GS/-"CRP ,8QSCBO7**+_P!?=_D']?G_ )GA
MEOX6\1I'KMAI^D:A;:8=.O+=;>_FMIT#R#Y%M)5Q($)ZA\#IWK5N?#^O6_CN
M";1],OX(I;JWN+J2:6WGT^4*JJ\FQOWL<V%P-G<#G!->O44)VL#U"BBBD 44
M44 %%%% !1110 444'I0!\ ?$/\ Y'[Q'_V$)_\ T,UZOX<\6:5X1\ ^!K_4
MAKDEU&+J2VAL;D102D2])@3\PR1^&:\F^(3K_P )]XC^8?\ (0G[_P"V:PO-
MRJJ9,JO0%N!]*^C]DJL(I_UH>,ING.31ZMHWB+5IOA/XSNTU&]A==1M#$([A
MP(5=G)1.?E7M@5Z!X/O]$BU[X86E[HDMSK4VDHUOJ NF181^\X,?1NC<GU]J
M^:UFPA4284\E0W!_"GBX8,I$S!D&%(<Y4>WI1/"J2:3M?_*P+$-6NOZO<ZKP
M-K5YH?CRWGTXQK/-=?9B[QARBO( Q7/1L<9]S70>,;7P_<?$;QH=<U.]L;Y-
M0D^Q+! '21\G[['[HSMY]":\S$@!R' /7.:&E#L6=]S'DDMDFM72O)2OTM^1
MG[5ZJW6Y[WK.GW#>#=.LOB3=MIP77DDN;MYC/_:49BR95/) "@("HV\^M8OQ
M^E@OM/\ !VH07MA,LEE(D45HKJ@B$AVE=RCY0 %YP<CI7C[SEPH>4L%&%#-G
M:/;TH:7<%#29"C"@MG'TK..&Y9*5]G^EC25>\7&VZ_6X44W>O]X?G1O7^\/S
MKJ.6S'44W>O]X?G1O7^\/SH"S'44W>O]X?G1O7^\/SH"S'44W>O]X?G1O7^\
M/SH"S'44W>O]X?G1O7^\/SH"S'44W>O]X?G1O7^\/SH"S'44W>O]X?G1O7^\
M/SH"S'44W>O]X?G1O7^\/SH"S'44W>O]X?G1O7^\/SH"S'44W>O]X?G1O7^\
M/SH"S'44W>O]X?G1O7^\/SH"S'44W>O]X?G1O7^\/SH"S'44W>O]X?G1O7^\
M/SH"S'44W>O]X?G1O7^\/SH"S'44W>O]X?G1O7^\/SH"S/1_V>_^2M:-_NS_
M /HIZ^Q*^.OV>F!^+FB@$$[9^_\ TQ>OL7!]#7A9G_%7I_F>M@?X;]0HHP?0
MT8/H:\X[0HHP?0T8/H: "BC!]#1@^AH **,'T-&#Z&@ HHP?0T8/H: "BC!]
M#1@^AH **,'T-&#Z&@ HHP?0T8/H: )[3[S?2K55K0?,WTJS0 4444 %%%%
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M_P *F^RI_>F_[^M_C1]E3^]-_P!_6_QHYF%D0_V3IW_/A:?]^5_PH_LG3O\
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M!]E3^]-_W];_ !H^RI_>F_[^M_C0!/14'V5/[TW_ '];_&C[*G]Z;_OZW^-
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MYP0!7AFG^&+UO"'V;4=(UB&-="LXREO;":5'2[E?9L?Y9-H*ED.=RGH<U?\
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MM*_W31]I7^Z:JT4 6OM*_P!TT?:5_NFJM% %K[2O]TT?:5_NFJM% %K[2O\
M=-'VE?[IJK10!:^TK_=-'VE?[IJK10!:^TK_ '31]I7^Z:JT4 6OM*_W31]I
M7^Z:JT4 6OM*_P!TT?:5_NFJM% %K[2O]TT?:5_NFJM% %K[2O\ =-'VE?[I
MJK10!:^TK_=-'VE?[IJK10!:^TK_ '31]I7^Z:JT4 6OM*_W31]I7^Z:JT4
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M>E^%M(\-2QZ9<7>NG0$BAN!>E8(U<,N&B'!(R3S[5Y[\6O\ DI&N_P#79?\
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M^^UH L457\Z?_GU;_OM:/.G_ .?5O^^UH L457\Z?_GU;_OM:/.G_P"?5O\
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M 'VM'G3_ //JW_?:T[@6**K^=/\ \^K?]]K1YT__ #ZM_P!]K2 L457\Z?\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MVQ0MM?ZU_P @>^G]:?YFU+\3=)2WM"FG:U+?7,LMN-.CL\W,<L:!V1TSP=K
M@YQCO72Z#KMEKNBVVI6#L(;A2529=CJ02&5E/(((((]17+:%X-U6#Q)9:]J]
M]9S:@TT\]XEO&RQ@O"D2)'G)PH3DMR<U;\.^ =+M(K"XUBPL;W5[&::2WO#'
MEH@\SR*%)Y&-_P">:&!G3>*]53X.V?B(/#_:DL=NS-Y?R9>9$;Y?H36@OQ%T
MD^(&TK['JH"7W]FR7GV4_9H[CC:A?/\ %N ''?G%9$'@CQ$+.#PW/J6EMX1@
MF212L#B\:-)1(L).=@&0%W#D@=,FM1_!UXUG=P_:H,S>($U<'!P(UE1]G^]A
M#[<U6C?]>7_!#I_7G_P"*/X@6EGIMH7AU76;R=YV\JQL<R)%',R%V0-@*"-N
M<Y;' Z@&I?%+0K-QY-OJM_#]DBOY)[*T,D<5O)NQ*YR, ;#D8S['!Q1MO!?B
M/1&MKSP[J&EC4=D]M<+>1.T31/</,C+M((==Y&#P<]L5-8?#ZXT_1];TZWOH
MY%O=%CTV.212#YBB;=(P'0$RYP.E3TO_ %_6P^O]>7_!-GXDZY/HO@'4=7TR
M[AMY(TC:.YDC\Q(U9U!<KQD ,37*>%_'$5KIE_K%_P"-;?Q5I\,D-MY>FZ6(
MGBED<*G1R6R3C%=EXB\/SZIX+71H9HDG"VZ^8P.W]VZ,??G::L>+M&EUO3[6
MWMY(XVBOK:Z8N#@K'*KD<=R%XIZ7^9*O;4QM1^(EEIIMFO\ 1O$$%O(L;7%P
M]B1%9E\865L\'D9V[L9YI]]\0M+M=8N-.2TU2X,,C6_VJ&U+6[7(7<+</G_6
M'ICIGC.>*Y7XA?#36O%&LZC-%>Z5):W/EO!)>K,\MH4V_NXU#>6%)4G=C<"Q
MZX%=#8^&/$6G:[<Q:=JMC!X<N[Y]1G7R"UUN?EX03\NPMD[L;@#@>M+=#V)?
M ?CI/$.CZ;)?65U9ZA<Z>VH/$\6U0BL%)7D\$G(]13X?B-H\US;Q);ZCY<EC
M'J4L_D?NK:W=&8/*V?E^X1CDYK!T[P1XITRUTC[#J>CK=6MC+I,S202,C6Y<
M&.11D'S!CD'Y3DU=TSX>2+H6I:5J=Y&\-[HEKI+O"IW!HDD5GYXP=X('M3?5
MK^M_^ "WL_ZV_P""7K?XDZ.UA?7-W:ZK8?98EG6&[M2DEQ&S!%:-<G<"Q48.
M""1D#-=!X:UM->L&N%L=1T]T<QO;W]N89%. >G((P1R"17GOASX97.F:?JT9
MTWP7;7%Q;_9H_LNF.4G7<"?/#-T;;@JO3KDX%=)\,/"EYX4TV\AO9;5/M$HD
MCLK)I3;6H"@8C\PE@#C)' '84:"U.THHHI#"H;S_ %!J:H;S_4-0!\">)8TF
M^)&HQ2C=')JC(P]09,&O5_'/A;P[H.DZE?7?A:TL([&\B^Q;-29SJ2;OF1DR
M2@V\^HKR3Q;,;;Q_J\Z@,T6HR2 'H2),U3U_59=<UR^U2XC2*6[F:9D0DJI/
M89YKW53E/DL[)?\  /*YXPYKJ[_X<]?U:W\'RR^"+:T\'6UJ_B P3R2K>2L8
MD,VUHP"?FR!UXZU%XF^'5CH/A7QQJ,SZ3<O#=Q+IXL[LRO:(9B"KCL=N!SGH
M:X!O&5VUUX6G-K;[O#R(D RV)0K[QOY]?2E/B^Y-AXHM/LEN$\07"7$[#.8B
MLA<!>>F3CFK5&HK<KZ]_-?H+VM-_$NW3R=_Q-[X9Z)X;U;0O$KZFMQ<ZU;:=
M<W-O#@K#"J*,2$@Y+;CP.G!S6/H.C/I T_7O%.@W5SX>N/EA9G\J*:1@=FYA
MSMR"3CG -9WA?Q%/X=?4VMH(IOM]C+8/YA/R+)C+#'<8J3PYXHO=%NHVD5-1
MLEC:(V-Z6D@*L,$!<_*?0K@BMY1GS2:V?_!V[&,90Y8I[J_Z'IS?#[1KCXFV
M?^CBW\+K:VEU<&%V>&XDE(54@8G<49^.3D -7FOB6SAT[XA:A96D7DV]OJ;1
M11C)VJ)< <\]*V?^%I>(H=<M+W39O[.L[5(88].M798#%$?EC;G)!R<DG/)K
MG]6UN[\1^,'U?4&S<7=VLC#)(0;AA1GL!@#V%9TH58N\WI8N<Z;5H[W1]X2?
MZQOK3:=)_K&^M-KYP]D**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M,_XT?VG3[,7U"?<^(JL:=_R$;3_KLG_H0K[5_P"%6?#[_H7M-_,_XTL?PO\
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MGP_\]8_^^A1Y\/\ SUC_ .^A0!4\M_[C?E1Y;_W&_*K?GP_\]8_^^A1Y\/\
MSUC_ .^A0!4\M_[C?E1Y;_W&_*K?GP_\]8_^^A1Y\/\ SUC_ .^A0!4\M_[C
M?E1Y;_W&_*K?GP_\]8_^^A1Y\/\ SUC_ .^A0!4\M_[C?E1Y;_W&_*K?GP_\
M]8_^^A1Y\/\ SUC_ .^A0!4\M_[C?E1Y;_W&_*K?GP_\]8_^^A1Y\/\ SUC_
M .^A0!4\M_[C?E1Y;_W&_*K?GP_\]8_^^A1Y\/\ SUC_ .^A0!4\M_[C?E1Y
M;_W&_*K?GP_\]8_^^A1Y\/\ SUC_ .^A0!4\M_[C?E1Y;_W&_*K?GP_\]8_^
M^A1Y\/\ SUC_ .^A0!4\M_[C?E1Y;_W&_*K?GP_\]8_^^A1Y\/\ SUC_ .^A
M0!4\M_[C?E1Y;_W&_*K?GP_\]8_^^A1Y\/\ SUC_ .^A0!4\M_[C?E1Y;_W&
M_*K?GP_\]8_^^A1Y\/\ SUC_ .^A0!4\M_[C?E1Y;_W&_*K?GP_\]8_^^A1Y
M\/\ SUC_ .^A0 L((B4'@XI]1^?#_P ]8_\ OH4>?#_SUC_[Z% $E%1^?#_S
MUC_[Z%'GP_\ /6/_ +Z% $E%1^?#_P ]8_\ OH4>?%_SUC_[Z% $E%%% !11
M10 4444 %%%% ", RD, 0>H-,\B'_GE'_P!\BI** (_(A_YY1_\ ?(H\B'_G
ME'_WR*DHH C\B'_GE'_WR*/(A_YY1_\ ?(J2B@"/R(?^>4?_ 'R*/(A_YY1_
M]\BI** (_(A_YY1_]\BCR(?^>4?_ 'R*DHH C\B'_GE'_P!\BCR(?^>4?_?(
MJ2B@"/R(?^>4?_?(H\B'_GE'_P!\BI** (_(A_YY1_\ ?(H\B'_GE'_WR*DH
MH C\B'_GE'_WR*/(A_YY1_\ ?(J2B@"/R(?^>4?_ 'R*/(A_YY1_]\BI** (
M_(A_YY1_]\BCR(?^>4?_ 'R*DHH C\B'_GE'_P!\BCR(?^>4?_?(J2B@"/R(
M?^>4?_?(H\B'_GE'_P!\BI** (_(A_YY1_\ ?(H\B'_GE'_WR*DHH C\B'_G
ME'_WR*/(A_YY1_\ ?(J2B@"/R(?^>4?_ 'R*/(A_YY1_]\BI** (_(A_YY1_
M]\BFO!#L;]U'T_NBIJ",@@]Z /-;6&/C]W'_ -\BMNRABX_=1_\ ?(KY7O/C
M%XMM=0N88I;#9',Z+FU!X#$#O4D/QR\9I]V73?\ P#'^-=BP%5[6.9XNFCZ_
MMH8L#]U'_P!\"KJP0_\ /*/_ +X%?'R?'OQP.DVF?^ 8_P :D'Q]\<_\]]-_
M\!!_C5_V=6\B?KM(^O\ R(?^>4?_ 'R*7R(?^>4?_?(KY _X7]XY_P">^F_^
M G_UZ/\ A?WCG_GOIO\ X"?_ %Z?]FUO(/KM(^O_ "(?^>4?_?(H\B'_ )Y1
M_P#?(KY _P"%_>.?^>^F_P#@)_\ 7K4\+?''QIJ/B?2+&ZFT\V]S>0PR!;7!
M*LX!P<\<&D\NK)7T!8VFW8^J_(A_YY1_]\BCR(?^>4?_ 'R*B:X8,1@=:3[2
MWHM<!UDWD0_\\H_^^11Y$/\ SRC_ .^14/VEO1:/M+>BT 3>1#_SRC_[Y%'D
M0_\ /*/_ +Y%0_:6]%H^TMZ+0!-Y$/\ SRC_ .^11Y$/_/*/_OD5#]I;T6C[
M2WHM $WD0_\ /*/_ +Y%'D0_\\H_^^14/VEO1:/M+>BT 3>1#_SRC_[Y%'D0
M_P#/*/\ [Y%0_:6]%H^TMZ+0!-Y$/_/*/_OD4>1#_P \H_\ OD5#]I;T6C[2
MWHM $WD0_P#/*/\ [Y%'D0_\\H_^^14/VEO1:/M+>BT 3>1#_P \H_\ OD4>
M1#_SRC_[Y%0_:6]%H^TMZ+0!-Y$/_/*/_OD4>1#_ ,\H_P#OD5#]I;T6C[2W
MHM $WD0_\\H_^^11Y$/_ #RC_P"^14/VEO1:/M+>BT 3>1#_ ,\H_P#OD4>1
M#_SRC_[Y%0_:6]%H^TMZ+0!-Y$/_ #RC_P"^11Y$/_/*/_OD5#]I;T6C[2WH
MM $WD0_\\H_^^11Y$/\ SRC_ .^14/VEO1:/M+>BT 3>1#_SRC_[Y%'D0_\
M/*/_ +Y%0_:6]%H^TMZ+0!-Y$/\ SRC_ .^11Y$/_/*/_OD5#]I;T6C[2WHM
M $WD0_\ /*/_ +Y%'D0_\\H_^^14/VEO1:/M+>BT 3>1#_SRC_[Y%'D0_P#/
M*/\ [Y%0_:6]%H^TMZ+0!-Y$/_/*/_OD4>1#_P \H_\ OD5#]I;T6C[2WHM
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MI-YJ-YO^S6D+32;%RVU1DX'<\5%JNM66E:*^JWTC1VB(K9"%F.[ 50HY+$D
M =2:^=O#>GWBZ3K[?;F?4/[%N5U2TCTBZADDF,?'GRR2,KR!LX*CGG'%>W^+
M5C/@91=Z;=:A;A(3-%:LRS1J"I,B8^8LF-P Y^7BAJR_KS!;V_KH6?#'BZQ\
M07$UK':ZEI]]$@E:UU&U:WE,9. X!ZKD8R#]:Z*O']'>X\4QZKI>B:SJ>KZ0
M++S(;_4;5H9;:\1U,:K(40N,C)R#C:.>:I+:KXW.@ZMJEI<_9-8UDAX-S+B"
M&UE0(V.BEPY]#N'K18/Z_ ]MK.\/ZQ:Z]I,6HV'F?9Y6=5\Q=K95RAX^JFO&
M/L.G6*V5CXDM=0?P?8ZCJ%O#"B3R+%*)4^S@A,L5"^8$/(!Q[56\&Z!-J-GI
M[):7?VVRT*ZFT];K<ICNOM<OE,V>/,''7U)HZ7_K:X:[?UO8^@:*^=);?3WT
M/4U\(6FL6\G]BW":Z98YT+7)";-V_P"]/NWG*YXSSC%;'B7P?I]F?&"V5G=A
M;&PM]1L@LLIV7A\W=,O/,AVID_XT6#?^OZ[GN=%?/FM66IS_ !/NI+W419ZL
MU_&VFD:3<W$YMALXBE201*A^8,&''S9S7T'2Z7%?6P4444#/SDU7_D+7_P#U
M\2?^AFH$J?5O^0O??]?$G_H9J%*^EI[(\.>[)!3A313A70C%BT444Q!6YX$_
MY'CP[_V$;?\ ]&+6'6YX$_Y'CP[_ -A&W_\ 1BU$_A94/B1]W/\ >/UI*5_O
M'ZTE?*'T(4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% %FSZ-^%6*KV?1OPJQ0 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M_1_[X%'DS_\ /T?^^!5BB@"OY,__ #]'_O@4>3/_ ,_1_P"^!5BB@"OY,_\
MS]'_ +X%'DS_ //T?^^!5BB@"OY,_P#S]'_O@4>3/_S]'_O@58HH K^3/_S]
M'_O@4>3/_P _1_[X%6** *_DS_\ /T?^^!1Y,_\ S]'_ +X%6** *_DS_P#/
MT?\ O@4>3/\ \_1_[X%6** *_DS_ //T?^^!1Y,__/T?^^!5BB@"OY,__/T?
M^^!1Y,__ #]'_O@58HH K^3/_P _1_[X%'DS_P#/T?\ O@58HH K^3/_ ,_1
M_P"^!1Y,_P#S]'_O@58HH K^3/\ \_1_[X%'DS_\_1_[X%6** *_DS_\_1_[
MX%'DS_\ /T?^^!5BB@"OY,__ #]'_O@4>3/_ ,_1_P"^!5BB@"OY,_\ S]'_
M +X%->&?8W^E'I_SS%6J;,P6)V;@!22: /.;:*;C_2#_ -^Q6W9Q3<?Z2?\
MOVM>;6_Q3\%KC.N1_P#?B7_XFM:T^+?@9/O:_&/^V$O_ ,36OL:G\K^XCVD.
MZ/2X(I\#_2C_ -^EJTL,_P#S]'_OVM>?0_&+P"!SXAB_\!YO_B*L+\9OA_\
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MC_O4>='_ 'J (_)G_P"?H_\ ? H\F?\ Y^C_ -\"I/.C_O4>='_>H C\F?\
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MLN[S1M&UPC;P!N&%()!I+4'H>CT5CZ'K#:K?ZND<2BTLK@6T<H;)E8(K/QV
M+;?P-;% !1110 4444 %%%% !4-[_P ><_\ US;^535#>_\ 'G/_ -<V_E0@
M/S@7I4JU$M2K7T\3P6/6G"FBG"MD9L6BBBF(*[+X-?\ )5/#'_7X/_037&UV
M7P:_Y*IX8_Z_!_Z":RK?PY>C-*7QH^UZ***^6/?"BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH LV?1OPJQ5>SZ-^%6*
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M4?P;\>-]W0C_ .!,7_Q5?1QKTOYE]YXLJ53^5G BEKT-?@MX_/303_X%0_\
MQ5/_ .%*^/\ _H _^34/_P 76BQ%+^9?>9NC4_E9YU17HO\ PI3Q_P#] '_R
M;A_^+H_X4IX__P"@#_Y-P_\ Q=/ZQ2_F7WB]C4_E9YU79?!K_DJGAC_K\'_H
M)K3_ .%*>/\ _H _^3</_P 773?#/X3^--&^(&@ZEJ6C>396UR))9/M,3;5P
M><!B36=6O2=.24EL^II2HU%--Q9]/45)Y$G]W]:/(D_N_K7S9[9'14GD2?W?
MUH\B3^[^M $=%2>1)_=_6CR)/[OZT 1T5)Y$G]W]:/(D_N_K0!'14GD2?W?U
MH\B3^[^M $=%2>1)_=_6CR)/[OZT 1T5)Y$G]W]:/(D_N_K0!'14GD2?W?UH
M\B3^[^M $=%2>1)_=_6CR)/[OZT 1T5)Y$G]W]:/(D_N_K0!'14GD2?W?UH\
MB3^[^M $=%2>1)_=_6CR)/[OZT 1T5)Y$G]W]:/(D_N_K0!'14GD2?W?UH\B
M3^[^M $=%2>1)_=_6CR)/[OZT 1T5)Y$G]W]:/(D_N_K0!'14GD2?W?UH\B3
M^[^M $=%2>1)_=_6CR)/[OZT 1T5)Y$G]W]:/(D_N_K0!'14GD2?W?UH\B3^
M[^M $=%2>1)_=_6CR)/[OZT 1T5)Y$G]W]:/(D_N_K0!'14GD2?W?UH\B3^[
M^M $=%2>1)_=_6CR)/[OZT 2V?1OPJQ4-LC)NW#&:FH **** "BBB@ HHHH
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ME_[]-_A52W4^AK5ME.!P: )XKJ/^[-_WZ;_"IA=1_P!V;_ORW^%/C!]#4HH
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M_A1]KC_NS?\ ?EO\*GHH @^UQ_W9O^_+?X4?:X_[LW_?EO\ "IZ* (/M<?\
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MF=.'*]"H3ES+4^\&=MQ^8]?6D\Q_[S?G2/\ >/UI*^6/?'>8_P#>;\Z/,?\
MO-^=-HH =YC_ -YOSH\Q_P"\WYTVB@!WF/\ WF_.CS'_ +S?G3:* '>8_P#>
M;\Z/,?\ O-^=-HH =YC_ -YOSH\Q_P"\WYTVB@!WF/\ WF_.CS'_ +S?G3:*
M '>8_P#>;\Z/,?\ O-^=-HH =YC_ -YOSH\Q_P"\WYTVB@!WF/\ WF_.CS'_
M +S?G3:* '>8_P#>;\Z/,?\ O-^=-HH =YC_ -YOSH\Q_P"\WYTVB@!WF/\
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MYKGQ&$GATO:=;_@=.%QM/%-^SZ6_$NVK,S-DD\=S5BJMI]YOI5JN4[ HHHH
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M18$UPH+Y/& #EB.3Q5#PD]UXHTFTCOM:U3R;?2=1D7[+?2H7,5WMB)<X=MH
MP6P2.N:--_ZVN*SZ_P!:V/H:BO ]2FO['0)KF'6=4-SJWAE-0N)'NF;;<>9"
M!)&,XCX<C"X'3BK?B+3)=+?QA]EUO7 -%6TO[,/J$C;)I,[RV3\RG;]QLJ,G
M &:KE!:GN-065Y;WT'G6<R31;V3>AR-RL58?@01^%>!Z[XE0_$JT>QU">"]_
MMZ*PFAGU>5I3"7V,/LBKY:1'/RLQR>#G)%-T7^Q-/TC3],U/6[W3O#O]HZDN
MHRC498REVDP\J*27=NC!3+!<@,<'G/,K57_K^OU!Z.W]=?\ (^A:*\2\(V5S
MXLUJVM]5U?66LXM+DDM6%S) \Z?:I4AGD"D%F\O'7KD$BNL^'5_?ZUJ]S+J$
MDV[1K==*G4DA)+H',KXZ'Y1%@_[1IV%<]!HHHI#"BBB@ HHHH **** "BBB@
M#\[=;_Y#FI?]?4O_ *&:J"K>N$?VYJ7(_P"/J7_T,U3!'J*^JALCP)[L>*6F
M@CU%+D>HJS,6BDR/449'J*8"UN>!/^1X\._]A&W_ /1BUA9'J*W/ A'_  G'
MAWD?\A&W_P#1BU$_A94/B1]WO]X_6DI7^\?K25\H?0A1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110!S/Q(&HR>#KZ#1[>:XO+C;"%A&6"D_,?RR/QK
MS;Q!\-;K2]-T:32S?W]R94-Q" "D7&20.W/%>WT5V8?&SP\5&'>_J<.)P%/$
MR<I[VLO+J> W_@[6IO#$Z#2;HW7]K/(J;/F,3)][Z9 K1UWP7K<WBS5-1TJU
MDC:R$$UF67"S%%4%5]3Q^AKVVBM_[4JWNDNOXV_R.;^QZ-K-OI^%_P#,\+UJ
MRU?QSJ<$?_"*MIVH.RB[OY=X4 <=#P![<FJ^C^%]5TS4[JW;PM)=QF5UAO9
MX:-<$!E .#G@\U[YDGK10LSFH\D8VCVN_P#,'E$)3]I*3<N]E_E^)\_2^ M4
M/@_2KB/2[D:K'=O'-#L^8Q'!5B/8@C\:^@%X1?\ ='\J6BN;$XN>(MS]+_B=
M>$P4,*VX=;?@3VGWF^E6JJVGWV^E6JY3L"BBB@ HHHH **** "BBB@ HHHH
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MZW^-'V2+UE_[^M_C4E$NQ?[J_E1L7^ZOY5%]DB]9?^_K?XT?9(O67_OZW^-
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M+UE_[^M_C1]DB]9?^_K?XT 2[%_NK^5&Q?[J_E47V2+UE_[^M_C1]DB]9?\
MOZW^- $NQ?[J_E1L7^ZOY5%]DB]9?^_K?XT?9(O67_OZW^- $NQ?[J_E1L7^
MZOY5%]DB]9?^_K?XT?9(O67_ +^M_C0!+L7^ZOY4;%_NK^51?9(O67_OZW^-
M'V2+UE_[^M_C0!+L7^ZOY4;%_NK^51?9(O67_OZW^-'V2+UE_P"_K?XT 2[%
M_NK^5&Q?[J_E47V2+UE_[^M_C1]DB]9?^_K?XT 3!0.@ ^@I:@^R1>LO_?UO
M\:/LD7K+_P!_6_QH GHJ#[)%ZR_]_6_QH^R1>LO_ '];_&@">BH/LD7K+_W]
M;_&C[)%ZR_\ ?UO\: )Z*** "BBB@ HHHH **** "BBFRR)#$TDSK'&@W,S'
M 4>I- #J*C>>*/R_,E1?,;:F6 W'&<#U/%24 %%03WEM;L1<7$,1"[R'<+A<
M@9Y[9(&?>IZ "BF32QP1F2:1(XUZL[8 _&GT %%%% !13%FC>5XED1I8P"Z!
M@2N>F1VS3Z "BBB@ HIGG1^>8?,3S@N\IN&[;TSCTH26-Y'1'1GCP'4')7/(
MR.U #Z*;-(D,3R3.L<: LSL<!0.I)I5(905(((R".] "T444 %%%% !1110
M4444 %%%% !1110 4444 %-E<1QN[9PH).*=4-Y_QYS_ /7-OY4 >.+^T!X*
M'\.L?^ @_P#BJD7]H3P4/X-7_P# 4?\ Q5?(ZTZO>_LZCYGD_7:A]<C]H;P7
M_P \]7_\!1_\52_\-#^"_P#GGJ__ ("C_P"*KY&HI_V=1\Q?7JA]J>#?C%X9
M\7:_#I&E+J(NY4=U,T 5<*,GG<>U>A>?'_>_2OC;]G#_ )*QI_\ U[7'_HLU
M]>5Y>,HQHU.6/8[\-5=6'-(N^?'_ 'OTH\^/^]^E4J*Y#H+OGQ_WOTH\^/\
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M /7-OY5-4-Y_QYS_ /7-OY4UN!^=(I12"G5]8?.,****8'IO[.'_ "5C3_\
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M8JO9]&_"K%(84444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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1** "BBB@ HHHH **** /_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>image00016.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image00016.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  8$!08%! 8&!08'!P8("A *"@D)
M"A0.#PP0%Q08&!<4%A8:'24?&ALC'!86("P@(R8G*2HI&1\M,"TH,"4H*2C_
MVP!# 0<'!PH("A,*"A,H&A8:*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H
M*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"C_P  1" %K NP# 2(  A$! Q$!_\0
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M_I4_WS_RT/K4?VZ[_P"?J?\ [^&H[G_CXE_WS_.HJ^HLCYJ[+/VZ[_Y^I_\
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M1GCM7E^BZ%I,?[-\NJ)I=@NIMIL^;P6Z"8_.P^_C=TXZ]*<(0<')WTLOOO\
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M&T*5;1V6SM^*3/;:*^;(?B5X]UK[1J^BP:TT'G,+:QM= 6XM74'&'GW;P?7
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ML1@QW/N;;@<9!YQS5*5=^\KD\M%/ET-2U^'>@VVN7NHI%*R7>GKICV;%3 (
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M<:VSOK?\=7]X*5'I;2WX;?B10?"GPY'X/7P[+]LGM([AKJ*>24":&0_Q*R@
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MQTUXGA>-T$C&-2!N)4@]>< 5P_CSPEK$GC:[U31/"VI3"X4+/-IOB)+)+M0
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M-JLL,0C)X\R%7#$@9Z8_X%C)Z;Q7X!U2#4K1K3PC8:O!;VD5O;W.FZG)I]S
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M1#)<Q21NB[P( Y8$ID-*X/)&.!4NG_"V]M8OAS)-;Z)>7?AVTDM+LREANW*
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MBO-T+S.8PK>:8U(3]X,G9D8Z&NMM?"'AJSMY+>T\/:/!!)LWQQ642JVQMRY
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M]?+5RUV_K^OZW//]:^*5[IVL:Y;Q>'HI[#2-1M=.FN#J&R1VG";&6/RR, N
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MT'>E.J>*4.0^BR_['DRIG_@6X_RJS;^,TMB%\0V$VF<X^T!O.M_Q<<K_ ,"
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MYJO_ ,(?X:^SW$'_  CNC>3<RB>>/[#%MED!R'8;<,W)Y/-.ZNG_ %O_ ):
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M GEOYBJ(P 3Q][IQ@FM:;<*B,:J4X,]YHHHKU3S"O%]YOK5@57B^\WUJP*;
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M_$>V-O8VVO0C]_I;[Y,?QP-@2+^ PW_ :QQ$7*FTC6A+EFFSP*ZN%TR&*\N
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M?>1(1)%"G[J3/S%2>A'J!WKJ%&!Q753^ PG\0&N=U>TU-];2YLRWDHB@+YA
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MH[8'%6J9 FQ!GKWIYKN.,J6'^LO/^NY_]!6KE4[#_67G_7<_^@K5R@$%%%%
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M%O&VX/E4&<@Y'Y$<>E:-% !1110 4444 %%%% !1110 4444 %%%% !1110
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MEXRI;/!$\QF9E+*$5 2Q(!P .> .2*+@6_*?^^WYT>4_]]OSKG[;XA>&+AT
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M8E*-F(YPK 9')Z4/:[_KI^@*^_\ 73_-'1:?9VVG6,%G8PI!:VZ".**,85%
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M#110!A7,NLF:006D CW_ "/D$D;OK_=_G3%GUUXW#6,$9*G!1P2IQP>O//\
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M-,F<PJZH5:7Y3B,$L>, Y% '5T5RI^('AP102?;+DK*'+8L;@F *Y1C.-F8
M&# F3:/E/H:L7'C30[?6&TR6YN!<I<):NPLYVACE<*41I@GEJ6WIC+#.X"@#
MHJ*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "@T44
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M_&"2<D?3-7$OKX,LAT(JQQR "P_S]:?97]V5N?M&E[9XXP_[M>6SP!]>O?\
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M2HFDWLYVYZA01\W3+D9X-='1126UOZ[AUO\ UV"BBB@ HHHH **** "BBB@
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$0!__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>image00017.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image00017.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  8$!08%! 8&!08'!P8("A *"@D)
M"A0.#PP0%Q08&!<4%A8:'24?&ALC'!86("P@(R8G*2HI&1\M,"TH,"4H*2C_
MVP!# 0<'!PH("A,*"A,H&A8:*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H
M*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"C_P  1" &G P(# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#R&YOKO[1+
M_I4_WS_RT/K4?VZ[_P"?J?\ [^&H[G_CXE_WS_.HJ^HLCYJ[+/VZ[_Y^I_\
MOX:^R/V?Y'E^$>@O(S.Y^T99CDG_ $B2OBZOL_\ 9Z_Y(_H'_;Q_Z425P9BO
MW2]?\SNR]_O'Z?Y'HM%%%>,>N%%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% 'YX7/_ !\2_P"^?YU%4MS_ ,?$O^^?
MYU%7U)\T%?9_[/7_ "1_0/\ MX_]*)*^,*^S_P!GK_DC^@?]O'_I1)7!F/\
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M 8=#CCG%9>C?$WP?K5_:V6F:U'/<W*NT:"&1<!02Q8E0$P%)^;'%'LYW:L]
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M_,CT>BN1UWXD>$=!U;^S-5UN""]! :,([[">S%5(7\2*U-2\5:+ILFD)=WZ
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M0GI;33LMFWT7G]^HE0::DM]>[W275^7W:%#X9_\ ).O#/_8-M_\ T6M>-_\
M+M\</]__ ..5]"VMO#:6\5O:Q1PP1*$CBC4*J*.  !P /2J7]A:3B^']EV&+
M_F['V=/](_ZZ<?/U/7/6L_;+FG*WQ?YI_H:*D^2$?Y;?DU^IX+XYM8(/@)X#
MD@B2-UN;5PRC!#,CEC]2>:ZGX:WEM9_&/XAV=U<PPW=U<0M;PR.%>7"NQVCJ
M< @\=J]2N-#TFYT^"PN-+L9;&W*F&WDMT:.,J,#:I&!CMBE?1=+?55U-]-LF
MU)1A;LP*9@,8P'QGI[UI+$*2DFM[_CRO]#-8=KEL]N7\+_YGAGP_U?0-!\+^
M.].\93VD&M->7!NX;H@2W*E?EV@\N,[L 9QG/?GH/A;/I.D_#WP5;^,XX?[0
MNIW_ +*%S;&5U+293:=IV'!4@\<$>E>GZAH&C:C>1W>H:3I]U=1_<FGMD=UQ
MZ,1D58O=,L+^:VEOK*UN9;9_,@>:)7:)O[RDCY3P.1Z4G7BUJM[7^2MH5[&2
M>CVO;Y]RW1117*= 4444 %%%% !1110 4444 %%%% !1110 4444 ?GA<_\
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M=?YCG*=M6_M+UL]/P/H&OFJY-_KOQ \7P7GQ-NO"\%E>E((9;UE5U);A 94
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M;:_G;OV*A*<IJ*>C>_R].XRR^,VHW?AM?$,?@B].B1/LN[I;Q#Y7S8RBE09
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MB2N#,?X2]?\ ,[<O_B/T_P CT6BBBO%/8"BBB@ HHHH **** "BBB@ HHHH
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M *425P9C_"7K_F=N7_Q'Z?Y'HM%%%>*>P%%%% !1110 4444 %%%% !1110
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M (&1_P"-'_"5^'?^@]I/_@9'_C7P+11_9L?Y@_M&7\I]]?\ "5^'?^@]I/\
MX&1_XT?\)7X=_P"@]I/_ (&1_P"-? M%']FQ_F#^T9?RGWU_PE?AW_H/:3_X
M&1_XT?\ "5^'?^@]I/\ X&1_XU\"T4?V;'^8/[1E_*??7_"5^'?^@]I/_@9'
M_C1_PE?AW_H/:3_X&1_XU\"T4?V;'^8/[1E_*??7_"5^'?\ H/:3_P"!D?\
MC1_PE?AW_H/:3_X&1_XU\"T4?V;'^8/[1E_*??7_  E?AW_H/:3_ .!D?^-'
M_"5^'?\ H/:3_P"!D?\ C7P+11_9L?Y@_M&7\I]]?\)7X=_Z#VD_^!D?^-'_
M  E?AW_H/:3_ .!D?^-? M%']FQ_F#^T9?RGWY'XHT"618X]<TMW8A55;N,D
MD] !FMBO@'PE_P C5HW_ %^P_P#H8K[^KBQ6'5!I)WN=>&Q#K)MJU@HHHKE.
MH**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MSMK.I--.4,LANG+2%#E-QSD[3R,]#TK#V=2UD[?CV_X/WFZJ4[W:_K7_ #_
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M$;*O'ICD 5F^*M(UVRT>XATV:\N7G$D<"QWMPK1R- BJYD4,PQ(KGG"_/N+
MT<\AJG&]OZ_K_(Z7_A%O^H[KW_@9_P#6JC<64^B^(O#PAU;4[B.[NI()HKF?
MS%91;RN.,<'<BG-==&"(U#<L ,US_B7_ )&'PE_V$)?_ $DGJXR;=GYF;BK)
MKR.BHHHK(U"BBB@#\\+G_CXE_P!\_P ZBJ6Y_P"/B7_?/\ZBKZD^:"OL_P#9
MZ_Y(_H'_ &\?^E$E?&%?9_[/7_)'] _[>/\ THDK@S'^$O7_ #.W+_XC]/\
M(]%HHHKQ3V HHHH AN[:&\MW@N8Q)$^-RGO@Y'ZU0_X1[2_^?;_R(W^-:M%
M&5_PCVE_\^W_ )$;_&C_ (1[2_\ GV_\B-_C6K10!E?\(]I?_/M_Y$;_ !H_
MX1[2_P#GV_\ (C?XUJT4 97_  CVE_\ /M_Y$;_&C_A'],_AMV4]F65U(^A!
MXK5HH RO*U*Q_P!1(-0@'_+.8A)1]'Z-]" ?5JGL]4MKJ;R,M#= 9-O,NR3Z
M@=Q[C(]ZO5!>6=O>P^7=PI*F<@,,X/J/0^XH H^*"?[%E4%AODB0E3@X:10?
MT-'_  CVE_\ /M_Y$;_&J][I%XT4<%M?>9:^=%(R7(+.H216^5^I^[_%GZUN
MT 90\/Z6&4_902I##+L1D'([UJT44 %%%% !115#5[\6,*$/&CR.%!D!( SR
M>/2@"_15$+J) (FM,'G_ %+?_%4NS4?^>UI_WY;_ .*H NT52V:C_P ]K3_O
MRW_Q5&S4?^>UI_WY;_XJ@"[15+9J/_/:T_[\M_\ %4;-1_Y[6G_?EO\ XJ@"
M[15+9J/_ #VM/^_+?_%4;-1_Y[6G_?EO_BJ +M%4MFH_\]K3_ORW_P 51LU'
M_GM:?]^6_P#BJ +M%4MFH_\ /:T_[\M_\51LU'_GM:?]^6_^*H NT52V:C_S
MVM/^_+?_ !5&S4?^>UI_WY;_ .*H X'XF?"6Q\>:]!JEWJ=S:20VRVP2*-6!
M 9FSS_O_ *5R/_#-^D_]!Z__ ._*5[9LU'_GM:?]^6_^*HV:C_SVM/\ ORW_
M ,56\<35BN6+T,)8:E)\S1XG_P ,WZ3_ -!Z_P#^_*4?\,WZ3_T'K_\ [\I7
MMFS4?^>UI_WY;_XJC9J/_/:T_P"_+?\ Q55]<K?S"^J4?Y3Q/_AF_2?^@]?_
M /?E*/\ AF_2?^@]?_\ ?E*]LV:C_P ]K3_ORW_Q5&S4?^>UI_WY;_XJCZY6
M_F#ZI1_E/$_^&;])_P"@]?\ _?E*/^&;])_Z#U__ -^4KVS9J/\ SVM/^_+?
M_%4;-1_Y[6G_ 'Y;_P"*H^N5OY@^J4?Y3Q/_ (9OTG_H/7__ 'Y2C_AF_2?^
M@]?_ /?E*]LV:C_SVM/^_+?_ !5&S4?^>UI_WY;_ .*H^N5OY@^J4?Y3PNX_
M9XTF&XMHO[<OV\YBN?+0;< G^E6/^&;])_Z#U_\ ]^4KV::TOYIH)6GM0T+%
MEQ$V#D8Y^;WJ;9J/_/:T_P"_+?\ Q5'URM_,'U2C_*>)_P##-^D_]!Z__P"_
M*4?\,WZ3_P!!Z_\ ^_*5[9LU'_GM:?\ ?EO_ (JC9J/_ #VM/^_+?_%4?7*W
M\P?5*/\ *>)_\,WZ3_T'K_\ [\I1_P ,WZ3_ -!Z_P#^_*5[9LU'_GM:?]^6
M_P#BJ-FH_P#/:T_[\M_\51]<K?S!]4H_RGB?_#-^D_\ 0>O_ /ORE'_#-^D_
M]!Z__P"_*5[9LU'_ )[6G_?EO_BJ-FH_\]K3_ORW_P 51]<K?S!]4H_RGB?_
M  S?I/\ T'K_ /[\I1_PS?I/_0>O_P#ORE>V;-1_Y[6G_?EO_BJ-FH_\]K3_
M +\M_P#%4?7*W\P?5*/\IX[I?[/6E:?J5I>)KE\[6\R3!3$F"58''Z5[?5+9
MJ/\ SVM/^_+?_%4;-1_Y[6G_ 'Y;_P"*K*I5G4^-W-*=*%/X%8NT52V:C_SV
MM/\ ORW_ ,51LU'_ )[6G_?EO_BJS-"[15+9J/\ SVM/^_+?_%4;-1_Y[6G_
M 'Y;_P"*H NT52V:C_SVM/\ ORW_ ,51LU'_ )[6G_?EO_BJ +M%4MFH_P#/
M:T_[\M_\51LU'_GM:?\ ?EO_ (J@"[15+9J/_/:T_P"_+?\ Q5&S4?\ GM:?
M]^6_^*H NT52V:C_ ,]K3_ORW_Q5&S4?^>UI_P!^6_\ BJ +M%4MFH_\]K3_
M +\M_P#%4;-1_P">UI_WY;_XJ@"[15+9J/\ SVM/^_+?_%4;-1_Y[6G_ 'Y;
M_P"*H NT52V:C_SVM/\ ORW_ ,55:XOI[&XMUO)[79(V"%C93C!YZGOC\Z -
M:BBB@ K#\6_V$UE"GB(Q-'YN^",EC(\@!'[M5^9FP3PH)Y-4_$D?BV^N7M=
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M^0?^ Y_^*H\F_P#^?R#_ ,!S_P#%5F_\)!)_SX/_ -_11_PD$G_/@_\ W]%
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MZ",?_@,/_BJ/LVH_]!&/_P !A_\ %507Q$7&8[%RF3@F0#-+_P )!)_SX/\
M]_10!>^S:C_T$8__  &'_P 51]FU'_H(Q_\ @,/_ (JJ/_"02?\ /@__ ']%
M'_"02?\ /@__ ']% %[[-J/_ $$8_P#P&'_Q50NNHI>0P?;HSYB,V?L_3;CW
M]ZK_ /"02?\ /@__ ']%4+B^:;58+PVDH\M<%/-&&/8_Y]!0!O\ V?4/^?\
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M?_LJ/*O/^?J+_OS_ /95DIXB=T5EL'PPR/WHI?\ A()/^?!_^_HH U?*O/\
MGZB_[\__ &5'E7G_ #]1?]^?_LJRO^$@D_Y\'_[^BC_A()/^?!_^_HH U?*O
M/^?J+_OS_P#94V%YTOA#-(DBF,N"$VX(('J?6LS_ (2"3_GP?_OZ*HM?EM66
M^^QRY";2GFC!/K^5 '6T5@?\)!)_SX/_ -_11_PD$G_/@_\ W]% &_16!_PD
M$G_/@_\ W]%'_"02?\^#_P#?T4 ;]%<])XC:.-G>Q?:H+'$@Z"NA4Y /KS0
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MASM;"'YN.E.'CGP^9HHEO9"\D?F+BUF( PYP3MPK?NW^4X;*D8R*Y/7/A?\
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M$+T)!(S76TEMJ&H4444#$;[I^E=-H?\ R!=/_P"O>/\ ]!%<RWW3]*Z;0_\
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M]>\)6VGDI!IDLY^S"W1].WF&(&(3+(2F'<X<ALMQG!!(%06VJ>#DCMQ+%:-
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M>Z?M2?ZSPO\ 2Z_]HUX759'_ +G'Y_F3FO\ O,OE^0AZ&O5)/B6(Y9+>RO\
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MR_K\2W&M"*CRJ[M^?Z_\#L,U[Q%X=33=6_LV/3+C49(&6W>/3=B!&E!50&C
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M=7/M.I?W;/\ \>H^TZE_=L__ !Z@"G_8-W_S_P '_@,?_BZ/[!N_^?\ @_\
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MH)D)R21GM2?:=2_NV?\ X]0!3_L&[_Y_X/\ P&/_ ,71_8-W_P _\'_@,?\
MXNKGVG4O[MG_ ./4?:=2_NV?_CU %/\ L&[_ .?^#_P&/_Q=']@W?_/_  ?^
M Q_^+J&W\3Q7.KS:5;:GHDNJ0@M+9QW(::,#&2R [AU'4=Q5N^U6YL+.6[OY
MM-MK6%=\DTTA1$7U+'@"CI</(B_L&[_Y_P"#_P !C_\ %T?V#=_\_P#!_P"
MQ_\ BZG74+QK<7 ?3S 4\P2AFVE<9W9Z8QSFF6.K7-]$9+.6PF0'!*EC@T!Y
MD?\ 8-W_ ,_\'_@,?_BZ/[!N_P#G_@_\!C_\75S[3J7]VS_\>H^TZE_=L_\
MQZ@"G_8-W_S_ ,'_ (#'_P"+K4T^P-KI?V1I0YP^7"[?O$GID^OK5?[3J7]V
MS_\ 'JN:7<O=V2RRJJON="%/'RL5_I0!C1^'KI(U07\&%  S;'_XNE_L&[_Y
M_P"#_P !C_\ %UT5% '._P!@W?\ S_P?^ Q_^+H_L&[_ .?^#_P&/_Q==%10
M!SO]@W?_ #_P?^ Q_P#BZ/[!N_\ G_@_\!C_ /%UT5% '._V#=_\_P#!_P"
MQ_\ BZ/[!N_^?^#_ ,!C_P#%UT5% '._V#=_\_\ !_X#'_XNC^P;O_G_ (/_
M  &/_P 77144 <W-X=NI8GC:_AVNI4XMCGG_ ('71J,*!Z#%+10 4444 >8?
M$WX5OXV\10ZHFM+8>7:I;&(VGG9VN[;L[U_OXQCM7)?\,^3?]#5'_P""P_\
MQZO2_$7B+5K;Q)+I>E6]BRPVD-R\ERSY)D>50 %]/*_6J?\ PD'BC_GAHOYR
MUZM#$XV%-1IRLNFQYM:CA)3;J1U^9P'_  SY-_T-4?\ X+#_ /'J/^&?)O\
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MHZ>*8A_W##_\>H_X9\F_Z&J/_P %A_\ CU=__P )!XH_YX:+^<M'_"0>*/\
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M4=U"DRI* '4, 0" 2,\^IJW4-G;I:6D-O",1PHL:CT &!4U5*U]!*]M2K?\
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M/^NA$?=LET_X<H>&?AY?P:_K=SJZ:;;:?J-ND*P:=*24V,I3[T2YV@%1DD
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M4EO)KMZ9$5FS''*Z/A58A'5"KMAU^523\P&,G%!*:9UW]E2?]!.]_P"^8O\
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M>_[XL_\ Y'KLJ*U5>I%63,G1A)W:.-_X0>3_ *&G7O\ OBS_ /D>C_A!Y/\
MH:=>_P"^+/\ ^1Z[*BG]8J=Q?5Z?8XW_ (0>3_H:=>_[XL__ )'H_P"$'D_Z
M&G7O^^+/_P"1Z[*BCZQ4[A]7I]CC?^$'D_Z&G7O^^+/_ .1Z/^$'D_Z&G7O^
M^+/_ .1Z[*BCZQ4[A]7I]CC?^$'D_P"AIU[_ +XL_P#Y'H_X0>3_ *&G7O\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M-BINIMK%$$8W#?@@JJA@<AMJ[LX%;WVZ/_GC>_\ @'+_ /$T?;H_^>-[_P"
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M((K&2=[-[6('[5#'*L&%RYW2--N ' P5K1L_A3I4&I6]]/JNKW=S#):NK3-
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M()"V-SKG/)'W5;.1O6_Q-T8Z3JE]?VNIZ:=.C@EDMKJ ><Z3_P"I**C-G>>
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MW W%<$''KS5JLBW_ .0XG_7L_P#Z$M:] !1110 4444 %%%% !1110 4444
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M\4K?3=).H-:6R6USJATS39[N^%O!<;0=\SR%2(HP4D /S%MH('(K.A^+YO\
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M(I9CV!)+') Z8IV3NGMK^EE^?R\P3<;26^GZW_1^OD<7\,K;6/!VL>%_#EQ
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ME!R<[2>*Q]?^&]A=^'[O3='F-E+=67]ER75VTU\ZVA+$QIYDO!RW#'., 8(
M ZCPWH5CX>\.V.B:=%ML+. 0(K8)8 <EO4GDGU)-4VG=K^M?T5E]Y*35D_Z_
MIW^5CS/5/C2MGJ/EVVC1WUA(KS0W4%S* T"2(KRDM $( ?/[MWZ '&<UT\_Q
M C31+[4X[2$0&^:PTPRW##^T&7AF4)&S ;ED VJY(3.,&IK;X8^$K>*>*/3)
M&BFLY-/9)+V>15MI""T2!G.Q<J,!<8YQC)K3OO!VAWFC:;I<EFT=GII0V0MY
MY('MRJ[04D1@X^4D=><G.:5M/Z[_ .7YOR'U_KM_F<9#\3/[6T/2+A;:XT^>
MYU:6SE\F086.W5GF?][#N*80J08T;)QE3S6)I'Q=OK#PUI-QJEM%JEU<>5)>
M;'=)+?[1)F&+:D!C!$;Q_P"L>//N3D^AQ_#WPQ'86UE'IK+;6T=S%"BW,PV+
M<9\[!WYRV3SU&>,5%=?#7PI<W0GDTV16#PRA(KR>./?"%$;^6KA=ZA0-V,X&
M,XH6_P!W_!_S]1/_ #_X'^3.6\&?$74I[N.;7+>)]%UBYU"73+M)AOB@M\X#
M1J@&TJC,'WDY.",8-8?@?XU/-_9-AK:6T][<W$$,[/=QPW"M=$O$([?8#(B(
M\2L^1U_BP37HNF?#7PGIEK+;66EM'!):O9!#=S.(X7^^L>YSY>[JQ3!8\DD\
MUI6/A+1]/U1-0L+>>UG5$C*07<T<+A5V+OB5@CD*  64G '/ IQLFK[*W]?-
M6_K<=VG;S_K\_P"MN6^,?C35/" T(Z3%9R)/-+-=^=(5?[/!$99 @"L.54C<
M>A(&.<KJ>$O&-[JVMII>L:,NF74^GKJEN([O[0/)9MNV3Y%V2 D<#<O7#'%:
M_B/PIHWB2>TEUFU>>2U$BQ%9Y(AM< .C!& =&  *MD$=12>&_">C>'))Y=)M
MI5GF1(WFN+F6YD**/E3?*S,$'90<#TI1TW_K^M/Q[CETM_6O^7Z'++\2+@ZL
M0=%B_L7^W#H0O5OLR-+C_6"+9C8&RI^?(QG!YQ5A^*ZW.N2V-I86LMK):75W
M9WHN9A'(L R6=F@"!22!F-Y,9&16KX/^&>CZ#%;S7H.I:I'--<O<2-(L332L
MQ:18"[(KX;;NQNQQFKFG_#?PK8>=]FTV3;+9RZ>5DO)Y%6VD(+1*&<A$X& N
M,<XQDTFGRVZV_&W^>OHQJW-?I?\ "_\ D>8Z3\8-5L8-(?Q,EHM]=VL$F#?)
M;V6ZY+R1^<[0EHBD4;9PS=N'+9';:?\ $TZMI?A>XT;24NKK7);F/RFO0J0"
M ,))/,"G<@90-P'(8''8Z]O\-_#%O:RPQ6=V#))'-Y[:C<M.C1J40I,9/,3"
MDJ-K#@D=#6Q)X:TN6ZMKF:&:6YM[22RBEDN97=8I-N\;BV2QVK\Y^;CK52V=
MOE_7KIZ$I/2_]?UN>8K\4/$&J77A^ZT;1;=[*32;K5[VR2X:2XD6-S&J1$1D
M'+$,O +=/EQ\W=_#7Q=_PFGA]]3-K!;%9VA*0W7GC( ZY5&4\X*NBD8Z8()C
MN/AOX5N(;:*339!%;V*Z:D:7DZ*;=<[48!P'VDDAFR0V""" :W=!T.PT&S>V
MTR%XTDD::1I)GFDE<]6=W)9FX'))/ HTU_KK_D#OI;^M/\S2HHHI#"BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH X_QI?746
MOZ+8QH#9W$-S+*^TDJR&((,]!G>_UQ[52J[XTU&XAU_1=.2-#;74-S-(Y4[E
M:,Q!0#G&#YC9X["J5>MAOX2/*Q/\5A1116YB9GB:4P>']0G%Y/8^1"TQN(%0
MN@4;C@.K+T&.0>M>:V/B_6+-KC3[[7+=IXEB\V\OX(5^S2Y3S$81NN4(W[0R
MQMTPS9!KUVBLY0;=TRU))6L>1V?C?6VMV@\NQL)9;9[DO,L0\HR,2LFPRJY4
M,RJ?D()))?((/9>$=6GUUM8@OY]/O+>&7R5%M 0NTY!63<[?/Q\R%5*Y[@@U
MU5%-1:=VQ2DFM@HHHJR2**V@AFFEAABCEG8-*ZH TA  !8]R  .>PJ_X7T^8
M^*)M1\Q?(6S^SF/)SN+[L^G055JSX7L)SXJEU'>GV9;+[.4R=V\ONSC&,8![
MUCB/X;-:'\1':4445Y!ZP4444 %%%% 'YX7/_'Q+_OG^=15+<_\ 'Q+_ +Y_
MG45?4GS05]G_ +/7_)'] _[>/_2B2OC"OL_]GK_DC^@?]O'_ *425P9C_"7K
M_F=N7_Q'Z?Y'HM%%%>*>P%%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% '%^.M9^Q:]H6FR&%(+Y+AM
M[M@^8AB"*O.,GS&XZ\<5EW.I6-K=+;7-[;0W#8VQ22JKG/3@G/->ASVT$[1F
M>&.4QL'0NH;8P[C/0^]13Z=97%P)Y[.VEG7&)'B5F&.G)&:ZZ6)5.*C8Y*N&
M=23E<X&]U.PL9EBO;VUMI6&X)-*J,1TS@GIP:+[4K'3W5+^\MK9V&56:54)'
MJ,FN^NM-L;N427=G;3R ;0TL2L0/3)%%WIUE>.K7EG;7#*, RQ*Y _$5I]=7
M8CZF^YP5[J%E8",WUW;VPD&4\Z54W?3)YZBB[U"RLXHI+N[MX(Y1F-I954/]
M"3SU%=]=:?9WFS[7:6\^P83S8E;;],CBBYT^SNHXTN;2WF2,819(E8+] 1Q1
M]=78/J;[G W&H65M;Q7%S=V\,$P!CEDE55?(R,$G!XYHEU"RALX[N6[MTM9#
MA)FE4(WT;.#T-=]/I]G/!'#/:6\L,8 2-XE94P,< CCBB33[.6U2VDM+=[=#
ME8FB4HOT&,"CZZNP?4WW.!;4+);%;UKNW%FQPLYE41GG'#9QUH_M"R^P_;?M
M=O\ 8\X\_P U?+ZX^]G'7BN\DL;+[&+9[6V^RKR(C&NP=^F,51EN-$AM_L4B
MV:VY/^I,8V9Z],8]Z:Q=]HB^I_WCD8]1LI+)[R.\MFM$.&G652BGW;.!U'YU
M<\%XO_$L^I6-Y!<:>EI]G;RI@X$N\-T''3^==7:0Z7-9O;VD-F]LW+11HNT_
M5>G:K-G:6UG&4L[>&!"=Q6) @)]<"LZF*YHN-BZ>%Y9*5R>BBBN,[ HHHH *
M*** /SPN?^/B7_?/\ZBJ6Y_X^)?]\_SJ*OJ3YH*^S_V>O^2/Z!_V\?\ I1)7
MQA7V?^SU_P D?T#_ +>/_2B2N#,?X2]?\SMR_P#B/T_R/1:***\4]@**** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***BN9TMXF
MDD.%'- $M%<+JWQ'T^PE,:0/,P]' JO9_%'2Y6Q<VEU#[KAZW^K5;7Y2/:1[
MGH5(6 ZD#ZFN97QMH4T.8;]=Y4G:RE3].1UKR7QIXR\W4 MK<ETY.X-P:NCA
M9U'9Z"E445='OZN&SM(.#@X[4ZOF/3_%5];R;[?4+B-NO$A'Z5VFC?$W4HMJ
MW?V>\3_:&Q_S''Z5K/+ZB^'4E5X]3VBBN-TGX@Z3>X6Y$MF__33YE_,5U=K=
M07<8DMIHY4]48&N.=.</B5C124MB>BC-%04%%%% !1110!5O@K;5?[I!XKF-
M3L \O R">#Z5T^HPO-#^ZQYB\CW]JYUKC),;\.IY4]1730;2T(DEU.1U*W>V
MF+VS/'-C[\9P1BGZ/XUUFQN(X;V'[;;LP0,QVN,^_?\ &NBFM%F&16=<:6&'
M"C(.>E=EHS5I(R:<=CKM#\1:;K.19W \]>'@?Y9%_#_"MBO*/^$?4733HFV5
MFW;AP0?8UU.E7NI6L82>47"#IY@^;\ZY:F&MK!E1J]&==16"WB)(C^^MV^JL
M#5JSU[3KM@B7"I(?X)/E-<[IRCNC123-2BBBH*/SPN?^/B7_ 'S_ #J*I;G_
M (^)?]\_SJ*OJ3YH*^S_ -GK_DC^@?\ ;Q_Z425\85]G_L]?\D?T#_MX_P#2
MB2N#,?X2]?\ ,[<O_B/T_P CT6BBBO%/8"BBB@ HHHH **** "BBB@ HHHH
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M<Y#8V\^QJBNHJIQ*K)[XS5ZWO=R_NW#*>HSG]*VN18S9-+ YL[A6'79,,?\
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D(]^\-6TUGX=TJVN4V3PVD4<BY!VL$ (R..HHHHKE;N[FA__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>image00018.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image00018.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  8$!08%! 8&!08'!P8("A *"@D)
M"A0.#PP0%Q08&!<4%A8:'24?&ALC'!86("P@(R8G*2HI&1\M,"TH,"4H*2C_
MVP!# 0<'!PH("A,*"A,H&A8:*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H
M*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"C_P  1" &G N\# 2(  A$! Q$!_\0
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M_I4_WS_RT/K4?VZ[_P"?J?\ [^&H[G_CXE_WS_.HJ^HLCYJ[+/VZ[_Y^I_\
MOX:^W?A&[/\ #/PVSL68V2$DG)-?#-?<OP@_Y)CX:_Z\DKS\Q^!>IWY?\;]#
MKZ***\<]8**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M\&6L[6"W:XNX99C%&$,KD199L=3[GFO:_P#A"O#^W7%^P<:V<ZA^^D_?=?\
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M5N#F1_O2,3EF/U)_ 8%;E%%$I.3<I;A&*BE&.P4445)04444 %%%% !1110
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M9C;1QI>QLSRC&8P V2PR/EZ\U/;^(M$N=3N=-MM8TV;4;8$SVL=TC2Q =2R
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M5<Z7%J-UK5SJ]S/ECSY<BVB [,L%S%G.,8;&>Y+1:?UM_P '[O,<==_ZT?\
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MP[+IZO9I=_+>3O$%EEA,22 K&^=@=SM(&<CFB5TO/_@+\W<$DW;I_P /_P
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M@HWLK[A1112&%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M9_Y,2_\ Q5=510!RO_"O?#'_ $#/_)B7_P"*KJ(8UAB2.,81%"J,YP!TIU%
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M\.7$]EI-[)I]W::>U^&:6&,71)($<8DAE,A7:2P4+@'E@.1[%13LK<JV_P"
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ML-*^VS7;FWM_[0DY7;&C0R;\%22J!, C+CK7M]%#U_KR_P ]?N70:T?]=_\
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M)':%GMQ(74Q@XVY(RN37M5%5?M_6O^2MZ$[[_P!:?YZGS[\7=>NX/#/@A_\
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M<<C1?9W?<,JVU1(H(7)^:O8]0U&RTX0'4+RVM1<3+;P^?*L?F2-]U%R>6..
M.34,.MZ5/>7MI#J=C)=62[KJ%+A"\ ]77.5'UQ22]VW]:6_R_$KK?^NMOS_
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MTDWL?.Q:6YA9K[D^$'_),?#7_7DE?#5?<OP@_P"28^&O^O)*X<R^!>IV9?\
M&_0Z^BBBO'/6"N$^(/BW5/#NI*NG1:=):P:;<:G<K=LR,ZQ-&"B.#A20_!((
MR!7=UFZIH.CZM=VEUJFE:?>W-HVZWFN;9)'A.0<HS E3D \>@HZK^N@=#D+#
MXI:?>:7J>HKHVMI96<#7"2O;!5N%5]A"$D+G/(#$<'/'(%?6/B>EM;1JFEWU
MG<223V_G7,<<D,4T3E6C.)1N8@$@*V<<]CCM4\.Z*DE\Z:/IRO??\?;"U0&X
MY)_><?-R2><\DTVX\-:%<7*7%QHNF2W"%V65[2-F4N<N02,Y8\GU[T+=7%9V
M9S.F?$*+R=.CUBSGAOM1N)H+6.)5(F9+DQ;5^<G*KM=NVT,1TJI\2O'][X1\
M5:!806D,]G?*\EP[HV459(U)W@X7Y78C(.XJ%'+"NU;1+ WUA<K L9L3*\$:
M*%17D^\^ /O<MS_MMZU->:787TJ27MC:W$B *KS0JY4!E< $C^\BM]5!Z@4M
M=!]SBX?B;!)X;N=8/A[7HX8&BW)+;A#Y<G(DW%MNU0#N.?E[\<TSQ'\28;*Z
MMK/3;.::YEOY+(EU4I^[6-F((<=1*H!]<YKJ5\)^'5T^6P70-)%C-()I+<6<
M?EO(,8<KC!88')YX%32>'=%DU)]1DT?3FU"0*KW36J&5@N-H+XR<8&.>U$M=
MOZV_X/W@M/Z]3#\)>,SK-YIUA>:=<VMW<Z7%J/FN%6&3<JEEC^8EMI89ZXR,
M]1GL*S[71=*M+X7MKIEC!>"!;83QVZ+((E^['N SM&!A>E:%5)IO0F*:5F%<
M]-H4S^*;_58)8;<W&GQVL<RH&EC=7D);!&",,OKTZ5N75Q%:6TMQ<N(X8E+N
M[=%4<DU@?\)SX9_Z#-K^9_PJ6TGJR:E>G2TG)*_=G,77@_Q,;K76CU(36UW<
M6T\<4VISHTZIGS$9T0?9T;CA _0@G:<";Q!X4\17T.E#3KI;+R;;RF0:O<G[
M'+O#><K[<W)P"H60*,<="170_P#"<^&?^@S:_F?\*/\ A.?#/_09M?S/^%)3
MBK:_U:W]?@9/%X=W_>+[U_7]:G(W_@3Q+*FAB'7;D&V5OM1CU*2-O-:0,9@6
MC?S#MX"L% Q@'#&O4JYO_A.?#/\ T&;7\S_A6GH^MZ;K(E.EWD5T(L;_ "S]
MW.<?R-$9*W*F5'$4:DK0FF_)HT:***HW"BBB@ HHHH **** "BBB@!&.%).>
M!G@9KY]5/&&HZ=KFHWO_  EL7E:7=WD%I"]S"\ES/._D1*%PV8XXX^%Z;^0,
MG/T'12:O_7<:?Z?@>0:/'KJ^*XK7Q'+XMDNK5K1;.;3PXM&A2!6F>=O]4^^3
M>K*VZ0?+L ZUBWFG^+X/ ^CZRS>(;C4-2U!I]4M3>WD;VUH[NZ0I'$'>/!\M
M24C,@!(R!T]YHJF[Z_U_3Z_/N2E96_K^M?R['BFK3>+K3P7X<TN_34KN:9+B
M6:_LUOI9%VL3!"_E>3-N*L 6<QC*G=63\(QXX?Q?HTOB-_$LL;6N;J.\6>WC
MMOW(*@[MT,RDGJ-LP8'=P#GZ!HH3LV^_]?U_PX-75CQOP>OC6X^)L\FJO=V]
MO#>W1N$EFNC;S6A!$"Q(8?LX(^1MRRESEMWH-:4ZI=?$N[BU/_A*8UCO(/[,
M.G!DLEMA$&D:9C^Z?<^]2K;I!\NP#K7IU%):6\OZ_KY]QO6_G_7]?(^?_%6K
M>-'\5O?Z=I^OV[VUY<J]K%;WTD3010R&+D-]G?S2JX"1E@6&7!QF;Q'H?BW0
M]'\+V\%YXAOQ<6;?VI<_VE?&07?EJ(R?(25T0%G.%0*Q4;V/?WJBDE96_K^N
MOJ#U=_Z_KIZ'E'Q/TG4-0^&WAC3=>BO=1G:]L1JLNFI<.=J?-*^R)=Y4E2!\
MO!93@$ C-TN/Q+_PE=O$'\3?VI'K;+(TQG_L^/2DR%&7_=2,R[?F^:7>3DC!
MKVFBJ3]YOSO^7^7W-H37N\OE;\_\_O2/$?'.E:[J7B#Q3JFEIK=I?>?IVC:9
M+:B6(!-X>6<[0-T8,K@YRGRG/;$&M7NO)XKO=0U]O%$'A-KV[W)9+<QLJP0Q
MK"<QX:.-V\Y]WRH2!N) %>ZUDZUX9T+79H9M;T73-1EA&(GO+2.9HQU^4L#C
M\*BUE;^M;:_?K\RFTW=_U_6GW>9\PZ)I?Q#U?PW)X@L;G6?[9OKBRLX;FY:X
M606\C-,94*  HIF .[,856X)QCU'4+3Q&_A_QMKRR>(FU>>\FL]'LXY9T6"/
MY8%E6 '!!.Z3<PP/O#'6O8E 50J@  8 ':EJW;5+;_.W^7XBUT?7_A_Z^1X5
MX/F\6:1?^+;JXC\3ZE#;Z?.]JMXMP&,RL0D(A<LDC8'RR0-AE/S98\:?P+\/
M^)O#KWVF>*9+N62SLK;["R,ZV860,TB[>%:42 [F.6Y&, XKV*BET^5OS_S%
M;^ON_P CP"QD\8&QCFC?QBNL?8+PZ[(]O(\:2L-L0M89"L;,C?,/(ZJO))(%
M6S9>(;KX!>)K+4+;6[J_GD>"#?)=22RQLR+YB)(/M"I]YC&^X\,.5(%>Z44=
M_/\ SN5?5-='<\%^%=CXLM_%%O#G4[73;26X!CU">_9);(J1;(D<L/E(R_(?
M];YG+!@,;1S7B;4_&-GH.G&";Q=%KEZS6FM2R^=%$)9956-+56PFY?F*F#C:
M/F)R*^GZKWEC:7IMS>VL%P;>43PF6,/Y4@SAUST89/(YYIWNU?\ KO\ ?U\R
M4DDTOZ_K\CQ:X'B(+?2V$GBR+PC<:M:J_FK<OJ MA$WGM&K W"(TOEC@!@-Q
M7"U8TNQ\4ZO/H6FS3>([+1I-0OKT22S317"V2H%@@FFSO!9G+88^9A>H*Y'M
M-%+^OR_R_%]QVT27];_Y_@NQ\]Z0OBZWTBV%O)XT_M2+3KM=;EGCFF592-L(
MMDF8+(R-\P,)^95.2S,,Z>FGQ='\,XK(Q>(6U&[UI(1<*]PTWV565GD7S]LL
M2L$90LK<%OO8(%>XT4/O_6]_^ #_ *^ZW_!/*_@6GB!(=9_X2"36;A"\1@N=
M2\^(RDJ2V()\M$P) ;8QC)QLQ@YYKQ-J.N:SXJ\8)H3^)FU&VO+2RTA+.29;
M-)(PK3M(1^Z ^<AA)U & 3T]YJO96-I8B865K!;":5IY1#&$\R1OO.V.K'N3
MR:?6_P#5]/\ @BMHT>#Z3=>,-1UR[OI[+7X89=(OY[RP*WT:_:, 1V\;2/LW
M_-E6A1.G#-SCGM&TWQ7I.AV$.@VWB2/0[..QM;VWD;4+5I6*227#Q 1M,BF7
MRT)BC) SC )-?4-%+;;R_!O\-;#>O]>GXZ'D%G9^*9K3P=I^KW>L/';PWE_J
M%S9/<(98URL%N[E$=G*R#(*AR8R<9Y'G.D:-XC6+4M0U)?&%KXBDTVQ@@O!#
M?7!6-F,DH<H02 '2-E4F12K.%SN:OJ6BA[W_ *Z_II_PX+^OS_/^M#E/AG_:
M:> =,.LPWD>H^6Q>.\G::4?,VW+L V,8QO&X# 8D@FO#].3QOJ%OIMWIS7,$
MNLVOVY+V"6[CB6_DG;>9Q!#*'"1K%&%E*H%''(X^FZBM+:"S@$-I!%!"I)$<
M2!5!)))P/4DGZFG?WN;^OZ_5(25H\O\ 7]?HSRFP_P"$DD^-LLDG]NOHXWHT
M;B:"W@"P@ C[T$R.W(*[958G=P,4_P"!<8TG3&LI=)\0V^HZC/=W]Y)>Q7 A
MA?S?E0M,>7*.OS("'V,2217K%%):?=8&CQ;QSX>\7:M\6/#UU-86-WIEM=-/
M9.L\FRUCCCY,@\DJ)7=E(.[GRPHQ\S&AX!\)7>KV]O!KMEJ=E9VF@7-AJ+RV
M[0RW%Y<RAYRF1F0#9G> RL6&">17O%%$?=5E_6EOR?WV8WJ[_P!:._\ 7S/*
MO"5OKGA[QEINE0Z9-+IES;M-<7MS$SO$K&5]OFKB-7W[6=-OS&;Y<+&*T_B=
M)?KK&@K)_;O_  C>+AKY=$2<SR2A5\E"8/WJH?GY4@9 #'%>A442U_K^O^'!
M:.YXYX.T#7M0\8^$KWQ4FJ&XTG1Y9I)9II AGDE*QHVUO+:18MV_ ).1NSQ6
M3X<U#7/$&O)?Z7-XD-U+XCFD#2/.-.338R8RO/[EMQ3A1\X8Y&!DGWFJ^GV-
MIIMG'::=:P6EK$,1PP1B-$YSPHX')-'6_P#6KO\ \#T$U=6_K:W_  ?4^:/$
MVI^,;/0=.,$WBZ+7+UFM-:EE\Z*(2RRJL:6JMA-R_,5,'&T?,3D5U6I+J5W8
M:IIMFVN?8]8U?3X]&BU5IOM \ITEN9@)?WJ1#83\V ".  5%>VWEC:7IMS>V
ML%P;>43PF6,/Y4@SAUST89/(YYIYMH#=K=&"(W*H8UF*#>%)!*ANN"0#CV%-
M.VOG_D[?>.2N[K^OZT):***0!1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 ?GA<_\?$O^^?YUI:9H5SJ%F;F.:UBBRX'G2[2=@4L<>@##\ZS;G_C
MXE_WS_.NP\%WMI!I4RW]YIH"._E6MS&^YRZJ&)<*<)A5X')P?N]:^FFVHW1\
M[!*4DF<C>VTEG>3VLX EAD:)P#D!E.#S^%?;WP@_Y)CX:_Z\DKXGUN2:;6K^
M6Z""X>XD:0(I50Q8YP#R!GL>:^V/A!_R3'PU_P!>25P8]MTHMG;@4E4DD=?1
M117D'JA1110 4444 %%%% !1110 445R_CN:Y"Z%96MW/:)J&I+:S2V[!9/+
M\J5R%;!VDE!R.<9H N^-_P#D3M;_ .O*7_T U\N5]">(O"EAIGAS5[R&[UN:
M=+*;_CYUB[GC.4(YC>0H?^^>.U?/3#<I4YP1C@X/YUQXG='Q?$_\:GZ?J5;S
M4K.SLY[JXN(U@A)$C YVGTX[^U11ZM;-H8U5MZ6IA\[YA\P7&>@[U6L="BLH
M;Q5DEF,[LZ^;([A<].&8\@_Q=:J3Z)>2>$[;1UDMPWDB*=SN(&%X*_\  @O7
MMFL4HGBQIX9V7-U6OE;70V--U!+]9ML<L,L+^7+%*!N0X![$CH0>#7MW[/\
M_J=<_P!Z'_V>O"=%L9[:2^N;SRA<7<HD9(F+*H"A0 2!GIGH.M>[?L__ .IU
MS_>A_P#9ZTI6]HK?UH=^3J*S&"AMK_Z2[_B>N4445W'WX4444 %%%% !1110
M 5X?\1/CG/X0\9:CH::#'=K:% )C=%"VZ-7Z;#C[V.O:O<*^*?V@_P#DL'B#
M_>A_]$1UVX"E"K4<9J^ARXNI*G!.+ZGH7_#2]S_T*\/_ (&G_P"(H_X:7N?^
MA7A_\#3_ /$5\\T5ZWU&A_+^9YWUNM_,?0W_  TO<_\ 0KP_^!I_^(H_X:7N
M?^A7A_\  T__ !%?/-%'U&A_+^8?6ZW\Q]#?\-+W/_0KP_\ @:?_ (BC_AI>
MY_Z%>'_P-/\ \17SS11]1H?R_F'UNM_,?0W_  TO<_\ 0KP_^!I_^(H_X:7N
M?^A7A_\  T__ !%?/-%'U&A_+^8?6ZW\Q]#?\-+W/_0KP_\ @:?_ (BC_AI>
MY_Z%>'_P-/\ \17SS11]1H?R_F'UNM_,?0W_  TO<_\ 0KP_^!I_^(H_X:7N
M?^A7A_\  T__ !%?/-%'U&A_+^8?6ZW\Q]#?\-+W/_0KP_\ @:?_ (BC_AI>
MY_Z%>'_P-/\ \17SS11]1H?R_F'UNM_,?0W_  TO<_\ 0KP_^!I_^(H_X:7N
M?^A7A_\  T__ !%?/-%'U&A_+^8?6ZW\Q]#?\-+W/_0KP_\ @:?_ (BC_AI>
MY_Z%>'_P-/\ \17SS11]1H?R_F'UNM_,?3.C_M"7&H6>L3GPY%']@M/M0'VP
MG?\ OHX]OW./]9G/M69_PTO<_P#0KP_^!I_^(KQWPC_R"?%O_8)'_I7;US=3
M'!4+OW?S*>*JV6I]#?\ #2]S_P!"O#_X&G_XBC_AI>Y_Z%>'_P #3_\ $5\\
MUM^!])@U[Q?H^E7CRI;WETD,C1$!PK'!P2",_A3>"PZ5W'\R?K=;^8]K_P"&
ME[G_ *%>'_P-/_Q%'_#2]S_T*\/_ (&G_P"(KSN^\"6^HZSI^G>%Y@;N6":>
M[@:\2_%LL9.#YENGS%A_ JEAQUSQ7;X8ZQ'<K:W%WIT%Z]ZUC%;2/)OD=51F
M880@*$D#98@XR,9P#FJ&%ZK\_0UE4Q*=K_U:YZ9_PTO<_P#0KP_^!I_^(H_X
M:7N?^A7A_P# T_\ Q%>5Z'\/=2UW5KBRT:]T^^CAA28W5L99(R'(55PJ%U.>
MNY1C!)P.:F'PWU)(%>ZO].@F\DW,ELS2&6.)9_(=SA-ORMV#9(Z9I_5L+>UO
MS)]OB-[_ )'IW_#2]S_T*\/_ (&G_P"(H_X:7N?^A7A_\#3_ /$5Y9JG@A8?
M%GB'3;75;./3]'<B:^NC(J*-X0*0J%BVXXPJD9!P2.:E\4^"XO#/A..YU&X#
M:U)J$ML(HI28Q&B(VX#R\-D.ISO'#+P3NVI8?"NUEOZC=;$)M-[>G0]._P"&
ME[G_ *%>'_P-/_Q%'_#2]S_T*\/_ (&G_P"(KAO$?@;0['3[>.VO9(-3F2R:
M$37L=R9S-&&?_1XD\V,+G()#9&, Y%9Z_#R2TDU^'6-0@@FTZPAO8<)*HF$C
MHJ@AH]R_>QAE!W$9XR0+#X5_9_,?M<1IKO;MU/2?^&E[G_H5X?\ P-/_ ,11
M_P -+W/_ $*\/_@:?_B*\\\9?"S6O#\-Q>O%&EBDZQ!=[R%%9RBL9#$B-DC^
M'YAD$J,U-9_"V1=2N8=2UO3A;V_VR*66W\UA'/;Q;RC9C!Q@@Y4-P"/O8%+V
M.$Y>:WY] ]IB>;EOV[==OR.]_P"&E[G_ *%>'_P-/_Q%'_#2]S_T*\/_ (&G
M_P"(KQKQ+X3O?#VG:9>7<L,L.H1"6(PI*5 *AL;R@1C@\A6;'?%;-W\,-<M=
M)FU*6:P^PQ*[F42-@H(A*KCY?NN"%4]VX.*IX;"I7:_,GV^(O:_Y'IG_  TO
M<_\ 0KP_^!I_^(H_X:7N?^A7A_\  T__ !%<?H?PSL+V2R-_?M;">YTZ#R(Y
M3([K<1%R0WE !NX!&!M8$GC/.6G@Q5\5^&["ZO8KG3=8G5$N;,L#M\TQN/G0
M88$'L1TQD4EA\*VX\OY]KC=;$*//?3Y'J?\ PTO<_P#0KP_^!I_^(H_X:7N?
M^A7A_P# T_\ Q%>7)\/KV>,R0ZAIT;M&URMK-*XF%L)3&9FPFW:,$D9W8!(6
MD\0?#?7- T>74M3-I%;QAMPWL6W"41[,;?O'.X=BO.>U'U?":*V_J#K8C77;
MT/4O^&E[G_H5X?\ P-/_ ,11_P -+W/_ $*\/_@:?_B*X'P+X,TC6]$TRZU
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M"-^\'"X ) )R3@<<T\/AE)Q<=O7K;_-$*M7:4E+?TZ7_ ,G]QWW_  TO<_\
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MOV?_ /4ZY_O0_P#L]:T/C1Z>0_[_  ^?Y,]<HHHKO/T0**** "BBB@ HHHH
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M +#2_P#I//5/?025EJ:/C,;O".LCULY1_P".FOF;[/7T[XL&[POJP];60?\
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M$JV6A\UUZ^OBSPN9;&2?[!<OYFDP3-=:?YY6WCA*7(&]#C!P..3U7.,UVO\
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M;=NEOR?Z'")X@\%2SQ17MKI[6=O)ICQ"'3@CMMCQ=;F"!G&[&58X../6MO\
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M'->R?">/RX]3]S'_ .S5Q]KI\-K;QP6L,<,$8VI'&H55'H .!7>?#>/RTO\
MW,?_ +-7?E.+5;'QMUO^3-L-1MB.>W<[.BBBON#V0HHHH **** "BBB@ JKI
MG_'J?^NLG_H;5:JIII"V;%B !)*23V^=J +=%<_H/C+0]>OOLFF7<DDQC,L?
MF6TL23Q@X+Q.ZA95!(^9"PY'/(K6U'4+738$FOIT@C>6.%6<_>=V"(H]RQ _
M&BP%JBBB@ HHJ%[E$O(K8K-YDB,ZD0N4 7&<N!M4\C )!/.,X. ":BBB@ HH
MHH **** "BBB@ HHHH **** *M[_ *ZR_P"NW_LC5:JK>_ZZR_Z[?^R-5J@
MHHHH **SM<UFST2WBFOOM1663RHTMK66YD9L$X"1*S'A2<XXQ45UXAT^UU2.
MPF-T+AX?/)6SF:.-/FYDD"%(_N-]\CI1<#6HK)T/Q%IFN10R:;/(XE5V59()
M(G 5@IW*Z@KR1C(&1R,BM:BP!1110!5D_P"0K;_]<9?_ $*.K559/^0K;_\
M7&7_ -"CJU0 4444 %%%% !15?4KVWTVQGO+QREO"A=V"EC@>B@$D^@ ))X'
M-8<WC71HM&&J,=2:TWO&_EZ5=/)"R?>\R,1EX\8SEU QCU% 6.DHK#E\5Z/#
M?M9RW,J7"VWVLJUM* $ZXW;<;\'/EYWX[5N4!<**** "BBB@ JK8?>NO^NQ_
MD*M55L/O77_78_R% %JBBB@ HHKR^ZTO4(UU+3XM/E>TT.*5M/WV_F),9CE
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M':<YKTFJMOZM?D3?;TN%5=4_X\G_ -Y?_0A5JJNJ?\>3_P"\O_H0I#+5%%%
M!1110!^>%S_Q\2_[Y_G452W/_'Q+_OG^=15]2?-!7W+\(/\ DF/AK_KR2OAJ
MON7X0?\ ),?#7_7DE>=F7P+U._+_ (WZ'7T445XYZP455U'4+738HI+V41)+
M-';H2"<R.P51QZD@58\Q-Y3>N\ $KGD \"@!U%&03@$9K'T7Q-H^M&^&FWJ2
MFR<QW 960QD$@GY@.,JPW#C*GG@T ;%%-,B!E4NNYONC/)IC7$0ADE\Q3''G
M>5.<8Z]/2ANVK!:[$M%8GAWQ5HGB*UEN-'U".>.%5:3<K1LBL,JQ5P"%(R02
M,''%;)E0!274!CA<GK]*!76XZN5\<?\ (1\(?]AI?_2>>M>\U[3K.Y@@N)V5
MI]@C98G:-B[A%&\ KDL0,9SWZ<UC^-R#J/@_!!SK*D?^ \]'F/R.@U@;M*O!
MZQ,/TKSC[-[5Z5J(S87 ]8V'Z5QOV>OSOC2M[/$4EY?J'L?::F/]F]J/LWM7
M(?%B"_U;X>>(@8M5T2.R@DE9B\)^V*J-\H*.Y"$[2<A21QW.&^.;FQNO C:(
MU_;6EP;6REN&N896BCMWE4%G*#H=K \@#N5'-?.4J3J*#4OBE9V5[;:Z;[]/
MS$\,D=C]F]JZKP/'Y:WGN4_K7 ?#"2*\\-.;:QT^UMHKJ:&)].@\FVN55L":
M-><*WU/(/)KTOPQ'Y:W'N5_K7I\/S<,WA1?3F_\ 26"H<OO&Y1117ZH,****
M "BBB@ HHHH *S4M5O=&NK61F5)_/B9E." S,,C\ZTJJZ9_QZG_KK)_Z&U)I
M25F--IW1Q/AWPQKZ7N@C73I:6F@V<EK;M93RE[MF01AW!51$ J_=!?D]1CGE
M9/A-J4OPYU7PX4T==U_#>6$3LL@4(REA+,MNA=F 8;FC9N<%FKVJBG+WFV_Z
MUN*/N[?UI8\>T+X8:KIW@&[T:66TFN);FVG>TEN ;.Y6)E+HPCMXB@D ^;*R
M$\%B_.<._P#AOJ[:G8Z<=*TFY22PU)HDD,OV+2FEF@,:PR>63N0;F483)#;=
MF,CWVBGN[O\ JZM_7X;L%[L>5?UK<\5T?X4:W9>%_%VG7.J)=WNK64MK'=2W
M"A+AF+$2S(MNK!^<;C)*<9 .,"K$WPOU6S\3ZW?:$NA0Z=<VD\-M92H3$'EB
MME;?'L*X9H9"QYSN!(;D5[%12_RM]X1]W^O3_(Y+X8>';WPMX7_LW46MBZW,
MTL:VQ!CC1W+!0!'&HQDC"H![5UM%%%Q)6"BBB@84444 %%%% !1110 4444
M5;W_ %UE_P!=O_9&JU56]_UUE_UV_P#9&JU0 4444 <QX[T!M>L[1%TK2-5\
MB4N(-39EC0E2HD7"."RY. 5.<]5ZU0F\(ROXFTZ^:TTR=[>&&-]6E9OMH$8.
M8P"K J^3N(=>&((:NVHH6G]?U_6^@/7^OZ_K8X:S\+ZMI.O6$N@-INFZ.)I!
M=65LB1QB$']VJKY6222['#1X9R<N.*[FBBCI8.MPHHHH JR?\A6W_P"N,O\
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M-95%:>S1'.S5_MJ'_GA<?]\K_C1_;4/_ #PN/^^5_P :RJ*/9H.=FK_;4/\
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MT>739;^XO(;&SCNGLQ+>2+"KR*Q7Y23@@XR/44>S6W]=/\T/G?\ 7]>1V?\
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M@ HHHH **** (6_X^X_]QOYK4U0M_P ?<?\ N-_-:FH0!1110 4444 %%%%
M!1110 4444 %%%% !45OUE_WS_2I:BM^LO\ OG^E S(\4Z"VN1VWEW9M9;=F
MDBD\O?MDVX1L9'1L''?&.*RY/!TL-E#%I>H0P3122E&N+3SD\N1 K+L#K\V
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MSO\ =_7S"^GWG!:OK-K>^(]&LY=0N-&UD[)_L%SJ$<6Q!)SNCC<B9G56 &6
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MBMK.&*WMXE"1Q1($1%'0 #@#VIBZ(FHHHH **** "HK?K+_OG^E2U%;]9?\
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M']C#_GYE_P"^5_PK5HHYGW"R,K^QA_S\R_\ ?*_X57M-)#M<?Z1*-LI7HO/
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MYM9_W!E+02B(!R-I#!@@!#?,2 #/=_$G1(K/2=0A:5])OYI(OM<L$L( 6%Y
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M%B\<TL<=MY6&CWQ+(%FQ+N?YAWQQC-%KXGN=4\+VUTD0L;^XO4L751)FW+2
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M=^7_ !OT.OHHHKQSU@HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M?^^T_P :/M%Q_P ^4O\ WVG^-6J* ,YWN3>Q3?8I-J1NA&].I*GU_P!DU/\
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MY)7PU7W+\(/^28^&O^O)*X<R^!>IVY?\;]#KZQ/%&M2Z+!"\%F;HN6W %_D
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MQ([A<G",HP#D[F4<5D_\+!N)KS1[.STB*2[OIY()5EO"BVY 9HR2(R3O12W
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MM'FTVV8VF!;X0 1 '("@< >W?O4HT321;O;C3+$0/RT8MTVMWY&,=S2=W?\
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M_*/R#E/[OT]J/Z_/_@?<']?E_P $P(_&%I)*85LKPW60J0 Q,TC8)9>'PI4
MY#%?;-):^+8Y]5DL1877FJ[!0I4DHK[6D()&%!V\<MSPO%:LFAZ3*\CRZ78N
M\@P[-;H2XSGGCGGFE;1=*:0R-IEB7+!RQMTR6'0YQU&!S0O,6MC0HHHH&%%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 ?&D_P %_'[32,N@Y!8D?Z9;^O\
MUTJ/_A2OQ _Z '_DY;__ !RBBN_^T:O9?U\SA_L^GW?]?(/^%*_$#_H ?^3E
MO_\ '*^K/AQIMWH_@30].U&+R;RVM4CECW!MK#J,@D'\#116-?%3K)*21M1P
MT*+O$Z.BBBN8Z HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
)HH **** /__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>image00020.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image00020.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  8$!08%! 8&!08'!P8("A *"@D)
M"A0.#PP0%Q08&!<4%A8:'24?&ALC'!86("P@(R8G*2HI&1\M,"TH,"4H*2C_
MVP!# 0<'!PH("A,*"A,H&A8:*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H
M*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"C_P  1" &K OD# 2(  A$! Q$!_\0
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M_I4_WS_RT/K4?VZ[_P"?J?\ [^&H[G_CXE_WS_.HJ^HLCYJ[+/VZ[_Y^I_\
MOX:^T?@:[2?"GP^TC,S&)\ECDG]X]?$M?;'P*_Y)/X>_ZY/_ .C'K@S%?NUZ
MG=E[_>/T.\HHHKQCUPHHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@#\\+G_CXE_WS_.HJEN?^/B7_?/\ZBKZD^:"OMCX%?\
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M'!ZU$J,XRY6M2HU82CS)G445R]WX_P#"]II&G:I<:Q NGZA)Y-O<!69&;T)
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M.X@_='0#O7H%$X.#M+^KA&:G>P4445!04444 %%%% !1110!^>%S_P ?$O\
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M(QP.6R*],^-=VNH3^ =6T[6;>#1ENG4ZG'&EU#!+\NUV!.TX*MUZ8/I7L?\
M8&CE;Q?[)T_%X%6Y'V9/WX7H'X^;';.:<FBZ5'I?]F)IEBNF]/L@MT$77/W,
M8Z^U-XI<RE;9W_\ )4OT!89V:ONFOO;?ZGS[JFDM?1^-K[2_&Z>)M9;2?*NT
MLM,\J-X]R')DC)C9MJL !D]?0BJGQ)U_PK>_ [PQ8:9/9/J,7D;;>(@RP,$(
ME+#JN3G.?O$@\]:^D=+TK3])MS!I5A:6,!.XQVT*Q*3ZX4 51;PGX<=9U;0-
M(99V#S V49$C Y!;Y>3GUHCBHJ2NM$T^BV]$#P[U:W=UU>]O\BUJG_(O7?\
MUZO_ .@&OGCX8?#36O%'@&QNHO'&IZ?IEUYJ-IL2N8PHD96'^M"\X)^[W[U]
M*LB/&8W560C:5(R"/3%0:=86>F6:6FFVMO:6J9V0V\8C1<G)PH  Y)-84ZSI
MJ7+N[?A?_,TG14^5/I?]/\CQCXAV]OX(M/ OAG2IK/3;,SN!K-];1W#VK @E
ME+C:K,6))XQQR *X-O(GU;XGC3M9GUN+^QP3>2N&,S*T>Y@0,;1@@8[=,U]0
MZIIEAJUK]FU2RM;VWW!O*N8ED3(Z'# C-00:#H]O+YL&E:?%+Y'V;>ELBGRO
M^>>0/N_[/2M88FT7S*[=_P 2)8>\ERZ)6_ \*\>W]G?_ +//A?[%=07!MY+*
M"812!O+D6/E&QT8>AIWB 7MG\<-<DF\5V_A9KBQB:UN[JSBF2:(*H* R$!?F
M!Z=2#7MJ^%_#Z:>;%-#TI;(R"4VXM(Q&7'1MN,9]^M6-6T72M81$U?3+&_2,
MY1;JW24+]-P.*?UF*;:6[?XV_P A?5W9)O9)?<W_ )GS7?Z1IUMX7\*16.M?
MV]IMYXG#^8U@UK&,A0Z*C<%<@]..H[5VWCVW ^.E@EM& \WAZY4A1C=\DP _
M05Z_<:-IES%:Q7&FV4L=HP>W22!6$+#H4!'RD>HJ233+"74HM1DLK5]0B0QQ
MW31*944YRH?&0.3QGN:4L3S?^3?BK%1H<O\ Y+^$KGAO@6;P_JG[.4NF:QJH
MMH85?[6UNIFDM<SLR,\: M@D \C!&>>]9V@:QJ&D>+_"=@VL>&O&EC)*EM9F
M&!&N[*/ ^?A<QX')RQX4].M>_:?H>DZ:UPVG:78VC7',Q@MTC,O7[V!SU/7U
MJ/2_#NB:3<O<:7H^FV5PXVM+;6J1LP]"5 -/ZS'GE*V[O8CZM+EC&^W7^OR,
M'XPZ/=Z]\-];L-.1I+MXE>.->K['5MH]20O3UKB=$^-_A33O!%FL[7"ZM:6J
M0MIP@<$R(H7 ;&T+D=2<X[9XKVBLF;PUH4^I#4)]%TR2_#!A<O:QF7(Z'>1G
M/XUC3G%1<)K3<WG"3DIP>IY+\5=4.LZ%X \0ZII\]KH']H1SW]M.N_RU)&TN
M!G*XW=N0V, G%97Q1U#3_$'CZ"?PG<V]XUKH=\VHW-HX=/*,+A59EX/)QC)P
M2*^@;B"*Z@>&YBCFAD&UXY%#*P]"#UJC8Z!H^GV<]I8:3I]M:W *S0PVR(D@
M(P0R@8/!(YJXUXI:+:]OFK:^A+I2;U?:_P G?3U/G/7[.V7]G+P:1!&#)J:L
MY"C+$M,"3]0 /P%=?XTACA^-RK#&B+_PC,XPHQP%D _2O7)- T:338-/DTG3
MWL(&WQ6S6R&*-N>53& >3R!W-1ZWH=IJ$=W.EG9_VI):R6T=V\0\Q592-N_&
MX+D]!55,2I7=M^;_ ,F5E]Q%+#N/*F]E%?\ @+N_O/G?PWKWA6']G+4],N+B
MR75G,H>V8@323%\QN%ZD ;/F' VGIBN@EL9E\9_!VTUF+=<1Z>?,CE7E66,$
M @]P0/Q%>A_#?P%;Z!X3TBQU^RTN]U73S)LN5B$FS=(SC8[*&'WO;FNQN-,L
M+F^M[VXLK66\MLB">2)6DBSUVL1D9]JTJ8F,:C<==6_P:5OO,Z>'E*G:6FEO
MQ3_0\<NHK.7XV^-XM1:6.QD\/[9VA1F=4(CW$!023@GH#7#_ -I3>&--T9-(
M\1>&_&6@1W*BTTFYM5-TK,QY6,J75N3@D]2..U?3<>F6$>I2:C'96JZA(GEO
M=+$HE=1CY2^,D<#C/:JEOX;T.VU$ZA;:+ID-^26-S':QK+D]3N SS6=/$*-D
MULE^%_\ /<TJ8=SO9_U9?Y'SW;+/;^+/B#;ZKXSM?##S7+O<07>G17!NX&W%
M=I<Y/RG[JYZC%>U?"/3X-,^'^E6UEJ<FJV85F@NI+=X"Z%B1A&Y &>/48QQ6
M]J>@:/JL\<^J:3I][-']R2XMDD9/H6!(K14!5 4  #  [5%2OSP4?3MT5O7\
M="X4>6?,WW_'\#P;0_&6@^$/C#X^?Q%?_8UN9(5B/DR2;BJG/W%..HZT[XT>
M*-+\9_#Q+KPQJ#7-A8ZG ;^1;5_W2D-@E7"[@"1QT/%>NWWA'PW?W<EU?>']
M'N;F0Y>::RC=W/J25R:LZ?H.CZ;;3V^G:5I]I;S_ .MB@MDC63C'S #!_&J5
M:"Y96?-&WII83I3;DKKEE?UU/#5T_2]7\50W.K?$A-<FBTV=9(]-T?:WV5HV
M#!G@R!C.=K G.!CFN=_M*;PQINC)I'B+PWXRT".Y46FDW-JINE9F/*QE2ZMR
M<$GJ1QVKZ6TG1-*T?S/[(TRQL/,.7^RVZ1;OKM S4-OX;T.VU$ZA;:+ID-^2
M6-S':QK+D]3N SS5QQ44]5=?+S\O,SEAG);Z_/R\_+;T/'O'EO!:_$35-2\.
M>-K#0/$,EM&EW::O#LAD3:,;9)%*D$ <*&Z'D5V?P)U>36?!!EDTRPT\174D
M*FP@$,%QC'[Q5'')R"?4=NE=GJ^A:1K)C.L:587YC^Y]JMTEV_3<#BKMO!%;
M01P6T4<,,:A4CC4*J@=  . *R=9.GR6U-%1:J<]_Z_KJ9?C+_D4-<_Z\9_\
MT6U>5Z1_R:P__8-G_P#1C5[3-%'/"\4\:212*5='&58'@@@]155-)TU-*_LQ
M-/LUTW:4^R"%1#M/)&S&,>V*SC.T''NT_NO_ )FLH7FI=D_QM_D>!>-[>&V^
M O@*2WACC=;JTD#!1D,R.6/XGDUI^*];CG^*VOV-_KMKX3L[2S3?<PV\2W5^
MI525$S#=QG@#TZ<9KV>XT/2;G3X+"XTNQEL;<J8;>2W1HXRHP-JD8&.V*-0T
M32M1NX+K4-,L;JY@_P!5-/;I(\?.?E8C(Y]*W>(C)MM;N7XV_P C!8=I))[*
M*^YO\[GROHL45Q\.?!T,N)H)/%10H_.5(3(/U_K7K>M1I#^TIX<,2A/,TB0/
MMXW8\W&?R'Y5Z./#>A@*!HNF86?[4!]ECXF_YZ=/O\#YNM6Y-,L)-2BU&2RM
M7U")#''=-$IE13G*A\9 Y/&>YJIXI2=[=_Q5A1PSBK7[?A*Y//;PW"H+B*.4
M(XD4.H;:PY!&>X]:\G^$J[_B#\3EZ;K]!_Z,KURJEGIEA97-S<6=E:V\]TV^
M>6*)4:9O5R!ECR>OK7+&=HRB^JM^*?Z'1./,XM='?\'_ )GS?I6LZ?H_P-\4
M>&=1N8X-=CNY;<63G$KLSK@JO4CKS[5Z</#GA_PYX$T_7?$EAF\TO3;8SCS7
M02R1(-BN@.UV#<+N!P2*[R?0M)GU--2GTNPDU&/&RZ>W1I5QTPY&1^=&MZ+8
M:Y;PP:K!]HAAG2X5"[*N]#E20"-P!['(]JWGB.;NKM7_ "T,HT>5ZZK6R]7?
M4\ALM:UWP?:W-O'%9-JTFG3>)M5DNU=O,=G $*890N%&-W(XZ5['H]\NJ:/9
M7\:-&EU DZHW50R@X/YUG>(O"6B>(IHYM7LO.E2-H=Z3/$6C)!*,48;E) ^5
MLCVK<C18T5(U"HHPJJ, #T%9U*D9QVU_K]+?<53A*,M7I_PWZW?S/G[X?ZOH
M&@^%_'>G>,I[2#6FO+@W<-T0);E2OR[0>7&=V ,XSGOSC>!;:^M=>^$2:D'5
MVBO'C5^HB8L4_#!R/8BOHC4- T;4;R.[U#2=/NKJ/[DT]LCNN/1B,BK%QIEA
M<WUO>W%E:RWEMD03R1*TD6>NUB,C/M6RQ*3O;?\ 1-:?>9RP[DFK][?-IZ_<
M6G&Y2,D9&,CM7@?PM\;:/\.++5?"WC)YM-O[6]DD5S [K,C8P05!/.,Y/&,<
MU[[6=JVA:1K)C.L:587YC^Y]JMTEV_3<#BL*4U&ZDM&;5(.5G'='AGQ-\:)X
M^^$6L7UAIEW;65GJ,*)--@B9=V,C'0C(R.@R.36EXR\3Z1K_ ,2OAI%HVH6U
M[Y,[2R>1('\O<$P&P>#\IXZBO:A96HL?L0MH!9[/+\CRQY>S&-NWICVJA:^&
M=!M#;&UT32X3;.9(#':1KY3'JRX'RDX'(]*UA7A%JRT3NOFK?I<RG1G+=ZM6
M_&__  #S?]GNWAV^,I_*3SFUJ5"^.2!@@9]B2:;\ +=##XUF2.,7+:S,GF%<
MG Y4?0$DUZMI^F6&FB8:=96MH)I#+*((EC\QSU9L#D^YHT_3+#31,-.LK6T$
MTAEE$$2Q^8YZLV!R?<U$ZW,I+NDONM_D5&E;E\FW]]_\SY9\-VZ?\(3K>E^(
M/'EKH,?VR1+_ $NXTJ.>9Y-P^<'/F,<@<C[N/QKO/".G1V_QQTJWFF:_-IX;
MB\NXFA,;L1A0Y5N5.">#R,U[%<>']&N=274+G2-.FOT(*W,ELC2J1TPQ&:L#
M3+ :F=1%E:_V@8_*-UY2^:4_N[\9Q[9K:6*OT_+M;U,_JVN_Y][GRSXHAV>'
M?BA'"FV&'Q#"VT=%'F2C_"O2OBC?VFIZ[\+[O3KJ"[M9-5&V6"0.C89 <$<<
M$$5ZK_8.D>7?)_95ALOFW7:_9DQ<'UDX^8\GKFFIX>T6.*SC31].6.S?S+9!
M:H! V<[D&/E.>XQ26)C>+:V:_P#24OT&\.WS6>]_Q;?ZG@?Q$OKWP=XH\7^'
MM-@D<>+8X9+,)T661MD@^K9;]*][\*Z-#X>\-Z=I-L ([2!8LC^(X^8_B<G\
M:XZ;P9KFM_$JRU_Q+<Z6=*TEI#IMM:*YD;<?E:4L,;AA3P2,@8Q7HU15J)TX
MQ6_7Y:+[D5"#]K*73I\]7][.$^.7_)*?$/\ UQ7_ -&+7!_$V*.?P?\ "N&9
M%>*2[LD=&&0P,:@@U[A?6=MJ%I):W]M#=6T@P\,T8=&'NIX-07.CZ9=16D5S
MIUG-':,K6R20*PA*_=* CY2.V*FC65.WJF.K2=2]NS7WGD?[04,\6L^";I;U
M=,T^&\=7O3;+,EM*0FQV1OE. IZ],&N4U:6+3&\6Z_;>++'QCJB6$<%W -(4
M6Q5I$"R.RDQ.5[#D\>Q%?1U[9VU_:O;7UO#<V[C#Q3('1OJ#P:KV&C:9IUE)
M9Z?IUE:VDF=\$$"HC9ZY4#!S54\1RP46MK]NOR_()T>:?-?M^!\X&XMYO'7P
MV9/%O]NWC3QM)'"B106B'9MC6.,80]00>>!D"NZ^'-W!:?&#XBV4]S!!?7<\
M1MHI' :7"NQVCJV 03CM7IEOX6\/V\<26^A:5$D,HGC5+.-0D@Z.,#AAZ]:L
MOHNEOJJZF^FV3:DHPMV8%,P&,8#XST]ZJ>(C).-M&FOO:?Z&<,/*-G?M^%U^
MI\N^&[=/^$)UO2_$'CRUT&/[9(E_I=QI4<\SR;A\X.?,8Y Y'W<?C7:^'9+'
MPK\7K-O%&H(ULV@0Q:=J-^A@#;54'[Y^1CA^"<C..IY]IN/#^C7.I+J%SI&G
M37Z$%;F2V1I5(Z88C-2ZKI&FZO'''JVGV=\D;;D6Y@64*?4!@<&J>*4MUOOM
MVMV_K8/JW9^F_>_?^MSR'X#W.GWGCWXB7&C;/[/DN8FA*#"D;I>0/0G)%>V5
M2L=)T[3YYY["PM+6:XQYTD,*HTF.FX@9.,G&:NUSU9J<KKLE]RL;TX.*=^K;
M^\****R- HHHH **** "BBB@#\\+G_CXE_WS_.HJEN?^/B7_ 'S_ #J*OJ3Y
MH*^V/@5_R2?P]_UR?_T8]?$]?;'P*_Y)/X>_ZY/_ .C'KS\Q_AKU.[+_ .(_
M0[RO-OBCXQUK3M8TKPOX-MHIO$&I*T@EF *01#/S8/&>"><CY>AR*])KR#XJ
MQ:IX9\?:)XZT_3I=2L;:W:SOH802Z(=QW_3YCST^7!QFO+H*+J)2_IVT_$].
MLVJ;<?ZUU_ S;KQ'\1OAY=6-[XZN-.UK0;B989YK5 KV^>AX1/KR"#C&1D5W
M?B;XD:7H6M/I,6GZQJ]_'$)YH=+M?/,*'H7Y&."/S%>7>,/'#_%^SM?"_@_1
MM1$4UQ&]Y=W**JP(ISGY68>^21TP 2:L_%"V\-Z=XPFGGUGQ'X0UC[.D:ZE#
M"SV]XH ''EG<2  ""5''2NITU+E]I&SUT7RMI]_F<OM.6[IRNM-^]_\ (WO%
M_P 8HH+'PU=>&+.[O;;5+E5DD6W+,JJX#PJN>9CT ]"".H-=AKWQ TW1+/2G
MN;'5I=1U.,26^E06N^\QC)W1YX*]P3V.,X->*ZMJNO7'@[P3K_BXSO;6&OJX
MO)("KO;#:5D90.^UL=SQUSD[GQ2%K-X\\.^*[K4]:L?"]YIWE+JFELT4D!RS
M#=\I8*P8<$9Z^AINA"ZC;J_RND"K3UE?HOSLW_7Y'I^F?$3P_?>&;_6Y)IK.
MWT]C'>0W<12:W<<;&3GYCT &>>.N:I>'?BAHNM:O9Z=)9ZOI<]\N^R;4;7R4
MNAC.8VR0<CITSQWKR/4_"MKK7@/Q#JG@_P#X2G5"UW!---JY5C?I%NRT6 '8
M -GY@#Q@<@BNC\3^([+XF:YX-L/",=U+/8W\=[>2M;O&+)%QE6)&-WTR"0!G
MFE]7A?KOKY:)W_KMW!UYI;KR\]=OZ[WV.PU#XMZ-::[JFCQ:7KU]J.GOMDAL
M[,3%U'WG7#?='&2V.HZUH?\ "S?#/_"%1^)_M<G]GN_DK'Y?[XR_\\]O][\<
M8YSCFO-?#/B[2_"/Q6^(=QKBW$5I+/&!=I;M(D;#=A&*@X+9XSP=IKFK'1-6
MM/#^F>,)=,N_[+B\1OJCV*QYD6W8IB39UXV$=?0].:(X>#4;Z74=?7I_7Y#E
M7FI22ULY:>E[,]S\*?$'2_$6KR:2;35-*U58_.%GJEMY$CI_>49((_'/Y5FZ
M7\6-)U75I-.T[2=>N9X;O[).T=H&CA^;;YCN&PJ9SR>>#Q7,QZK;?$+XP>&M
M4\*B>?2]&@E:ZOS"\:$N"!&-P&3STQT)]*3X-64FH>&OB%:6[".>YU.[A1_0
MLF ?P)J)4HQBY-:VO;YV_(J-24I**>E[7^5_P.BF^,?AN.XE86VL2:5%-]GD
MU:.S+6:OZ%\Y[CMWK9\5^/\ 2O#MU8VGV?4-5O[V/SH+72X//D:/^_C(&WKW
M[&O';'Q/9Z?\';GP%<V%\/%@66S735M79I&:0D2 @8(YSUSD< C!-_QEHNCZ
M)IOA.+Q->:]H&LV6FI;IKM@A>!& YB8H=^1SC '!ZU4J$%*VMKV]=-U_74E5
MYM-];?=JM'\OR['5>*?B;97O@=M5T/4M1TB:'4$L[A3I\<UQ$Y!RCQR,%&?4
M$XQ]:Z'Q-\2-,T+66TE-/UG5]1BA$\\.EVGG&!#T+\C';\Q7A>OZKKNI_"^_
M&J7]QJVCP:O;QZ;J5S 8GN5P^XX/S$?=Y))Y(SQ@==\4X_#EIXTN+RYUCQ%X
M/UF2! -2@A9[:\4 <+Y9W$C !!*CCD53H032:ZO\HOUZ[;_B3[:=K^2_]*:]
M/F>S>$_$>G>*M#@U;1Y3):RY W+M96!P58=B/\\5YCXWU7QWJ'Q4E\-^#-;M
M-/CCT]+PK<PH5^]M/S&-VSR..E=/\%-2U_5?!2W/B9I)9?/=;:>6+RWG@&-K
MLOOSSW&#SU/!^-/!FG^.?CS<Z9JTUW#!'HZ7 :V95;<' Q\RL,?,>U9PA&%9
MQ>ROY]#24Y2HIK=V\NII>#_'NO>'_$VN:#\1K^QNQI]G]N-]:J,(HV_(0JKG
M.X8&T'/KD5U6@_%+2=6UBPTZ73-<TR34 392ZA9^5%<X&?D;)SQC\QZUS>L^
M X/AK\/]?OO D=Y+K<D2J;J4B298MXW;0% &!D\#/&>PKSFUN-!O/&7P]OM(
MO-:U&8WL:W^HZDTCCS25(B#/A<@[ON]CU-:QITZSNEY:::VWL9RJ5*,=7W>N
MO;2_WGH^E_%.^U/Q/XJTV32]4L[6RA=;>>.S#FU9$D9I)]S  MM&U>AQCWK9
MT'XA6.G_  WT?6M:O[W4Y[UVA@ LDCN;N3>P"K"C%0>,=<=.<G%<3:ZC;:-X
M_P#BGI>I.\%[JMN9+-#&Q$JB&5B0<8'![X].M<O)ILS?#+X;:S))J46E6$]P
MMY/IS;9K97E.)%(!(QM//T'>DJ4)*.ED^7\4[_CH5*K.,G;6W-IZ6L>\^&/'
MFE^($U)([?4;&^T]/,N;"_@\FX1<9#;<D8/U],XR*YF'XX>')=-AU!=.U\:>
MTGE377V+,5LV< 2.&QD\'"[C@^O%87P_LO#U]K&NZSH.H^+=8>+3I+9M3U5P
MUO(I .Q2RK(2".F,#!]1G TY5_X9,O/E'WV/3O\ :A4^QIINZ_E_&X_:5)))
M/>_X)'=+\4+F7XK+X>@TC4)M+$"@206V]W9V3;.>>( "?F]ZU-=^*^BZ5J>H
M6<>GZWJ*Z<=M[<V%IYL-L>X=BPQCG/T-<#X8U&V\/?%S0KC5W>"#4_#=I:VK
M^6S"20B,!> <<J>>@XSBLOQT^@Z/XHURYTS7_$W@_7GE,K6K6[/#?OR0T?EG
M!5CW8XYZ=JIT8<RC;H_FT_ZV(5:;BY7UNODFK_U?S/H?1]3M-9TNUU'3I1-9
MW,8EB<#&5/MV/M5RN:^&UWK5_P""-*N?$\1CU:2(M,&0(QY.TE1T)7!(XY/0
M5TM<52/)-Q['93ES04NX4445!84444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 ?GA<_\?$O^^?YU%4MS_Q\2_[Y_G45?4GS05]L? K_ ))/X>_Z
MY/\ ^C'KXGK[8^!7_))_#W_7)_\ T8]>?F/\->IW9?\ Q'Z'>4445XQZX444
M4 %%%% !1110!R7A3P=_8'BOQ-K7V[[1_;4L<GD^3L\G;NXW;CNSN]!TKK:*
M*J4G+?\ JPE%1O;KJ%%%%2,**** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /SPN
M?^/B7_?/\ZBJ6Y_X^)?]\_SJ*OJ3YH*^V/@5_P DG\/?]<G_ /1CU\3U]L?
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M20^9C&=NXC.,C./45>L+VUU&SBN]/N8;JUF7='-!('1QZAAP1]*/,">BBB@
MHJNE]:/?R6*74#7L4:RR6XD!D1&)"L5Z@$@X/L:DN)HK>%I;B1(HD&6=V"JH
M]R: )**KVU]:74]S#:W4$TUJXCGCCD#-$Q (5@/NG!!P>Q%6* "BBJUA?V>H
MQR2:?=V]U''(T+M!('"NIPRD@\$'@CJ* +-%%9NM:]I&A)"^MZK8:<DS;(FO
M+A(0[>B[B,GZ4 :5%58=1LI[QK2"\MI+I(EF:%)5+K&V=KE0<[3@X/0X-6J
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MO#$9Q TJB0Q@X+[<YV@D GIS3K&\MM0LX;NPN(;JUF4/%-"X='4]"K#@CZ4
M3T453O-4T^R#F]OK2W",B-YLRIM9SA <GJQX [GI0!<HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH _/"Y_P"/
MB7_?/\ZBJ6Y_X^)?]\_SJ*OJ3YH*^V/@5_R2?P]_UR?_ -&/7Q/7VQ\"O^23
M^'O^N3_^C'KS\Q_AKU.[+_XC]#O****\8]<**** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@#QCQ/K(T;XZ7DC>)- T%9-"MU,FL1[EE_?R_*G[Z+!_
M$_2LWXX:YJ&E^*;2[M-=E^PK8*Z:;;:A-87$KF3_ %ELP4PW+D8!B;?QCY?F
MS7O-%"T27:_XW_S&WJWWM^%O\CYE\.7K:5J8M=/U'4;6\F\8W@N[.2^E,@A-
MO,\7F1ECC=C.2/F*@Y.T8D\(R:GJ&F>#?M?B'Q$YU3PY>WEVW]JS@R2Q,OEL
M"&RI&[^'&[ W9YS]+44K:67]>[R_\$7VK_U\5_\ @'SQXG\6W]SX%\$"]U:Y
ML;J^T*2\:^:]EMHY9UC3"@0E7EF).53>%Y.58XQDQZKJ1OK3Q#:WMQ)XFO/
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MM;^EOS_S_ \+T'7=8F\5Z:/[2U"3Q++K]Q;ZGI3ROY4&G#S-C^0?E1 HB*R
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MB>OMCX%?\DG\/?\ 7)__ $8]>?F/\->IW9?_ !'Z'>4445XQZX4444 %%%%
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MHFM?83IE\LXOEE>V/ENHE$3!7P2!T)Z=QR,CFMRDXN.C0U)/8****0PHHHH
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M_=_.N1@G(!SCH;NC^-[J[T;PQ%86)O\ 5]6LWNPEW=+$%1 -Q=TBQDE@ %0
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M_?U?\:/[1LO^?RV_[^K_ (T 6J*J_P!HV7_/Y;?]_5_QH_M&R_Y_+;_OZO\
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M)(I$QNCD ##/0\$\?X&K% !1110 4444 %%%% !1110 4444 %%%% !1110
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MBBO'/6"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH *^:/VMII(]8\/>7(Z9AFSM8CNM?2]?,G[77_(9\/?\ 7";^:5V8#^/'
MY_D<V+_@O^NIX-]JN/\ GO+_ -]FC[5<?\]Y?^^S4-==:^!+Q]!L]:O=3TO3
M]-NU!CFNGDY8NZ!,*C'=^[8\ @#DD5[\G&*NSQHIR=D<O]JN/^>\O_?9H^U7
M'_/>7_OLUT@\":P9W@'V<SQZC'ICQJY8K)(,H_ QL;!P0>W2G6G@74;NXM(K
M>ZL'6YU";3DE#OL#1 ,\A.W[F#G/7 /%+VD._P#7],KDGV_K7_)G,_:KC_GO
M+_WV:/M5Q_SWE_[[-:<'AV]E\7+X<+11WYO/L.YR0@DW[<DXSC/M^%:5QX$U
M5[.&ZT-DU^"222)FTN&=VC9-I;<KQJV/F7D CGK1SPT?<.65VCFOM5Q_SWE_
M[[-'VJX_Y[R_]]FIX=(U*;3Y[^'3[R2QMVV37*PL8XV]&;& >1U]:F70-99[
M)%TG4"]\NZT46SYN!C.8^/F&/3-5>)-I%+[5<?\ />7_ +[-;/A6YG-_=9FE
M/^@79Y<_\\'JMXF\/WOAR]@M-354N);>.Y,8#!HPZY"L" 0PZ$=C3_"?_(0N
M_P#KPN__ $G>HFXR@VBXIJ:3,S[5<?\ />7_ +[-688M4G6W:&.]D6XE\B$H
MKD2R<?(OJWS+P.>1ZU0KT7P7XIT?2=,\,0:A:VES+:ZT]U,\XGW6L1\C$B>6
MRAC\C<$-]T<<\U-\JNE<F.KLV<E)IFOQZ>M_)9:HMBS^6MRT4@C+9QM#8QG/
M&*-8TS7]%\K^V;'5=/\ -SY?VJ&2+?CKC<!GJ*[+Q5K.DZIK-QK=EXCDM8I8
M((!IB02B0A-@*-@"/RODWCYB>GRYZ9GQ*\7QZ[JFIVNE06D.D2:G-?+)"LH:
MY9N!(_F,<';V 4<GBLHSFVO=WW\MOZ_JYK*$%S:[;>>__ _K0P;_ $KQ#I]A
M%>ZA8:M:V4V/+N)X9$C?(R,,1@Y'(Q5)/[0>UEND^UM;1,J22C<41FSM!/0$
MX./H:[7QIXSM[W-AI,%I]BN+:PCN[M4E\V8PQ(-C!VV@*P/W5&=HY/?=L_$O
M@Z?Q)J4NH6VD)IZZM";-4TI54VB^=NR%CR<[DR&Y/'8<#G)1NX_UI_G^%Q<D
M7M+I^-F_T_$\G^U7'_/>7_OLT?:KC_GO+_WV:]0&O>$M0@M(KW^S+*0?8I7N
M+?2$#+*"XGR!'M9<>7E2"IZA2<YKZQKOABUUK6;S1X],G:3288[82:>KQ_:Q
M)&'81M$J [0YSL53Z<XH]J[VY1NFOYNWX_Y'F_VJX_Y[R_\ ?9H^U7'_ #WE
M_P"^S7H7Q%?1;?P_ID0T4V>N:A%'?S>4J0+;G:L>PQ["=K;'D #*!Y@//%>;
MUI"7.KV,YQY;:GZ">$O^18TO_KW3^5:U9/A+_D6-+_Z]D_E6M7RSW/?6P444
M4AA1110 4CJKHR.H96&"",@BEJCJ.I160P?GE[(/ZU48N;LD*4E%78VUT?2K
M&UG@M-.L;:VF!$T<4"(D@Q@[@!@\>M5I+[3;.XFFMX8FN9<"22) "^!@;F[X
M[=:Q;R^GNV_>O\O9!P!56NV&#6\V<-3%O:"-"^UF<S)<VT2H\8*D=2RGJ/ZC
M_P"N:\Y^)?C?Q%I.M6\6F:F8K2XM4G55AC/.64\E2>JGO7;5YM\7M.*KIMY&
MP*[9$*]U 8$_AEQ_WU7H82C2C6BI133[ZG/.K4E!ZZG)_$GXI>,]'U32H]-U
MN2%)=-@N''D1,&=LY/*GKCITK)TK]H'QQ9'_ $F>PU#U^T6P7_T65K ^,/\
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MX>_ZY/\ ^C'KXVU]Q)KNI.LHF5KF1A(I!#Y8\@CCGVK[)^!7_))_#W_7)_\
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ML@_=Y)/'3DDU]H_ K_DD_A[_ *Y/_P"C'KXTUHS'6+XW6_SS.YDWJ%.[<<Y
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M;RR!(U+,>@%)&C2.J(,LQP!77:78)90]FE;[S?TK*M65)>9K1HNH_(H66A*
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M5OAOIE_I-M807M]IL45C+IKG3T@A\ZWEP71D\K8,D9RBJ0<XZD4.]G;^M/\
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MF_,TVX*(AD#G).2<$!3D#!QIW6M06,B)J,EK:A(5EN99)PL<.X[5&Y@,[FW
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M=]/<SS0R,T!MT922VU2!'G(_NJ"?<GZU)HVALVGZ/<&]U2SN(K:%985F(1\
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MRQ9O?@"I=[.Q2M=7-":^MX=.:^EDVVJQ^:7VD_+C.<=?PZUE-XMT=8[=VGG
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MEV\MPB2/N.!A2<G)X%:).!D\"@"K]JF_Y\+G_OJ/_P"+H^U3?\^%S_WU'_\
M%U/%-'+O\J1'V-L;:P.UNN#Z'D?G3Z *OVJ;_GPN?^^H_P#XNC[5-_SX7/\
MWU'_ /%U:!!&001ZBB@"K]JF_P"?"Y_[ZC_^+H^U3?\ /A<_]]1__%U:HH J
M_:IO^?"Y_P"^H_\ XNC[5-_SX7/_ 'U'_P#%U:HH J_:IO\ GPN?^^H__BZ/
MM4W_ #X7/_?4?_Q=6J* *OVJ;_GPN?\ OJ/_ .+H^U3?\^%S_P!]1_\ Q=6J
M* *OVJ;_ )\+G_OJ/_XNC[5-_P ^%S_WU'_\75JB@"K]JF_Y\+G_ +ZC_P#B
MZJQ7,O\ :-P?L5P28XQC='D<M_M5J55A_P"0G<_]<H_YO0 ?:IO^?"Y_[ZC_
M /BZ/M4W_/A<_P#?4?\ \75JB@"K]JF_Y\+G_OJ/_P"+H^U3?\^%S_WU'_\
M%T2ZE8Q:A%82WELE],I>.W:51(ZC.2%SDC@]/2HK+6=+OXFDL=2LKF-9!"SP
MSJX$AZ(2#][D<=: )?M4W_/A<_\ ?4?_ ,71]JF_Y\+G_OJ/_P"+J6.Y@E$Q
MCFB<0L4DVN#L8#)#>AP1P?6GJZ-&)%92A&X,#D$>N: *_P!JF_Y\+G_OJ/\
M^+H^U3?\^%S_ -]1_P#Q=5X]?T>2.WDCU;3W2XE\B%EN4(ED_N*<\M[#FKJW
M,#;=LT1W.8UPXY<9RH]Q@\>QH B^U3?\^%S_ -]1_P#Q=5=0N93#'FRN%_?1
MG):/^^./O5J55U+_ %,?_7:+_P!#% !]JF_Y\+G_ +ZC_P#BZ/M4W_/A<_\
M?4?_ ,75JB@"K]JF_P"?"Y_[ZC_^+H^U3?\ /A<_]]1__%TV75-/AU*'3YKZ
MUCOYEWQ6S3*)77GE4SDC@]!V-1-KND(MZS:K8*MD0MT3<(!;DG #\_*<^N*
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M6UM8X;A9[K=$A 8,1MN?FSG@-$_8 J!\OH]5?[0M?^>O_CI_PH_M"U_YZ_\
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MR=C.B_.5SVW$K_P"MVJO]H6O_/7_ ,=/^%']H6O_ #U_\=/^%#=Q)6T#2O\
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M;^O.X'E]Y\.KZXB9))[9XR_F>6LSQ_,TN7.X*<$HD8!QUW?CNKH.H6OP[O\
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M)=AV[)#ANN ^T\C(K9;PQH[7&H3FS_>W\D4ER?,?]XT9RAQGC!';&>^:K_\
M"&:%ME M) )&5B!<RC!#[QM^;Y<-SQBIZIA;1H@E\9VJ1973]1DG02M/ B(7
MMUB(#E_GP>2,;2Q/;-9^G^.8I+5+R[9?LS+=R+Y,).](I0B8)?@D,.,<D]5Q
MSM3>$=%FMXX9+639'YG(N)0[ASEP[!MSACR0Q.:D7PMHJQ>6+!!'LF0)N;:%
ME8,XQG') /MCC%"&RM<>+;:VGT^"\L;VUGO)&B5+CRX]A4@<LSA6SN& A8GL
M.*Z.L4^&-*-M';F&<PI)YQ4W4I\Q\@[I/F_>'('W\]!6U1T%J%%%% PHHHH
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M#?S%5M?,7_1G>(LI!5<,&#*0,$\]:WZ*+:6#K<\^N?AS]HDA>34(&:..%?\
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M>:M:7K7-U%';74=X+2+RQ$TJ1F-6/R[N%(X# ?*..N1>??\ #3_@@_+M^/\
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M\V1G%69_"K?:#-:W9AEF:3SI4!20A@X4@@\E=W&??I0'0ZAV5$9G8*JC)).
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M86YGOKF&VA! ,DT@1<GH,GBN*U3P#)<:<VFVFI".S:)D1YHB\MNQC1 \95E
M8;-P;LV3SGCH=0T>ZDT,:=IMW;6(4A4=;8G;$!@J '&">1N!& 3C!YH?D!;E
MUO2H1,9=3L4$)42[KA!Y>[[N[GC/;/6IK#4++4$=]/N[>Z5&VLT$JN%/H<'@
MUS#^$;V.%H[#5+:U7]XL>VR)V)(X>101(".1@$8*@GJ<,-;PMHUSI%O,M[<V
MMS-(5 :WM3;JB*,*BJ7;"J.  ?7.222?U_7]?\%:W-NBBB@84444 %%%% !1
M110 4444 %%%% 'YX7/_ !\2_P"^?YU%7V@WP7\ ,Q9M!R2<G_3+C_XY2?\
M"E?A_P#] #_R<N/_ (Y7M?VC2[/^OF>1_9]3NOZ^1\85]L? K_DD_A[_ *Y/
M_P"C'JM_PI7X?_\ 0 _\G+C_ ..5VVA:18Z#I-OIFDP?9[&W!6*/>S[022>6
M))Y)ZFN7%XJ%:"C%,Z<+A9T9.4F7Z***\\[@HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
=BB@ HHHH **** "BBB@ HHHH **** "BBB@#_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>image00021.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image00021.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  8$!08%! 8&!08'!P8("A *"@D)
M"A0.#PP0%Q08&!<4%A8:'24?&ALC'!86("P@(R8G*2HI&1\M,"TH,"4H*2C_
MVP!# 0<'!PH("A,*"A,H&A8:*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H
M*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"C_P  1" &? UD# 2(  A$! Q$!_\0
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M_I4_WS_RT/K4?VZ[_P"?J?\ [^&H[G_CXE_WS_.HJ^HLCYJ[+/VZ[_Y^I_\
MOX:]D_97N9YOB%J"S32R+_9<APSDC_6PUXE7M'[*7_)1-1_[!4G_ *.AK#%)
M>QD;X9_O8GU91117SQ[P4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MGS9$'Y9JG%IV8E).]NA?HK@]"^)$6O7VI6>D^&]>GN--E\FZ3-HGEODC&6G
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MR#7=R?#KPQ):FT:QN/L!;?\ 8A?7 M@<YXA#[!SSC;5V_P#!?AZ^.C_:-,B
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** /SPN?^/B7_ 'S_ #J*I;G_ (^)?]\_SJ*O
MJ3YH*]H_92_Y*)J/_8*D_P#1T->+U[1^RE_R434?^P5)_P"CH:Y\5_!D;8;^
M+$^K****^>/?"BN4L['Q>GQ$OKRZU;3W\'/:A+:P6'$Z3?+EBVWI][^(]1\H
MZUU='2X=;!69J/B#1M,OK:RU+5M/L[VZ_P!1;W%RD<DO./E4D%N>.*TZ^:OB
M%<7FC^*OB'-<WL0O[B6QETK2+NPBN4U= J 1@.I=U5@W$94JQ))YX%\5F-*Z
M/I&XFBMH))[B1(H8U+O([!510,DDG@ #O6=9^(]$O=(FU6SUC3;C2X=WFWD5
MTCPQ[1EMS@[1@=<GBN<\9ZM?2>%M>LYO#VHPPG2IRU[YEN;=3Y!)&!+YG7Y?
MN=?;FOG3PU97VFV.F^ K6%WTCQ?9Z?K32#A8HTBW72GW<Q*/HWO2;:<EVM^O
MZ)L$KI/^NGZM'USIFH66JV,5[I=W;WMG*"8Y[>59(WP<'#*2#R"*M5\@?!K6
MD3X>WL/BOQ#JFB-:66= AMKR2U6?+2$O&JL!<2>9\I4[N@&*]-T63Q!XC\;^
M&=.\57^K6$L_A,W=[:6EW+:9N/.5=Y$;*5?G)QCTZ9%5+1NW]:-_?IJNA,7=
M7?\ 6J7ZGML]Q#;F,3S1Q&1Q&F]@N]CT49ZG@\5'IU_9ZG:+=:;=V]Y:L659
MK>02(2"00&!(X((/N*^9X[K^UO#_ ,'-=\5:I>$?;KBWNK^:_D@4!?,"%G5E
M"L=N-W#-C!)JQX'^U:)X%\ :MIVJ:E%-?>)WLIHA=R&W:!YYPR>3GR_X<[MN
M[)Z]*+>\T^]OR_S&]%?RO_Z5?\CZ9KG+GQWX1M;V2SN?%6@PW<<AB>"3485D
M1P<%2I;(.>,5?\,Z_IGB?18-6T.Y^U:?.6$<OELFXJQ5N& /4$=*^=?-\36W
MA/XJS:*EC=:0WB6^AU&U-FTET(&"B66)O,"$JISM9.Q.3TJ7=-I]%?\ %+]2
ME&_WV_/_ "V/IU6#*&4@@C(([TM?-7CCQ#;1:;9Z5X;UZ_LM-M/#"W.EW4FI
M2Q&]< JHB2'8TLWR@$,Y5?\ GGU-;_AN[U'Q9XK\(6NI:WJRVUWX,2^N4M+V
M2W\V<N@\PF-EPV3U'T/&13>E_*_X<W_R+)6R;_K;_P"2/=JK6.H6=_Y_V&[M
M[G[/*T$WDR!_+D7[R-@\,.X/(KYZT#Q+J5]X;^&4OBWQ!J%IX>NEO5U#4!=M
M:F69&80)+<(5900#W&XCG-9OA'5/LVHRP7NL7]CX-N?$^J&\U)+A[8NX5/)6
M6==K1JV6.<KD@<T[>\UZ_@TO^&^7<'HM?ZT?^7Y]CZ@HKYM.MZ[=3:#:6^MZ
MNWAV;QBMEI]\+EUEO+,QL64R9S+&&R YR3CKP#4<5_K&F0-?P^(-;EDL_'?]
MCP)/J$TJ?8R^#$ZLQ$F<_>;+# P11%7=O3\>7_Y)?B)NR?E_]M_\B_P/HRWU
M&RN;ZZLK>\MI;VTVFXMTE5I(=PRN]0<KD<C/6K5>#^(_%L6B^*/BW-XBO]4D
MTG3HM-:UM;>_F@*R/$2$C:-@4W-C=M(SSG-8%KJ6LZ=\*=.N++Q<=:NKW5H7
MUR:'6Y)ETVV<,1#YX\UX$&%#2 %@2>>]).ZOZ?C_ %_6A35G;^MKGTO5;^T+
M/^TO[/\ M=O]O\KS_LWF#S?+SC?LSG;GC.,9KY^GUOQ1%X&\;7.@ZVEUIL,M
MJ+>73[ZXU22S0L/M)CNY8E\W"'=P7*<\CBM[P-+H\OQW=O#NKSZM8?\ ",C;
M<2WKWGS?:>0)7+%O<;C@DCCI3BKNW];7);LF_P"MTCU+6_%?AW0;E+;7-?TG
M3;AT\Q8KR\CA9ER1N 8@XR#S[5IV%[:ZC9Q7>GW,-U:S+NCF@D#HX]0PX(^E
M>1Z]K6E:%^TE;W.N:E8Z;;-X6,:RWDZ0H6-UD*"Q S@'CV-<;IEY/9^*I6N;
MR]T3X:ZIKEY.EY!.]I&Y$2;/WJD&*%Y/,8,"H8CKBI3NEYW_  =K?K^!4E9V
M]/RN?2M%?.EYK&N7'@S4#:^)Y[708?$*Q:;J6H2W*+>V8&6C>[B!D2/=D"8D
M9Q@M7.Z3XOU>\\026>IZA=VGAFWCG%K<W_BJ>VM;B?S.3%J$4.Z=54C:CDGK
MDDC%.^MOZVO^MO45OZ^=OT^X^K:P-5\:>%M(OI++5O$NB6-Y'C?!<W\44BY&
M1E68$9!!_&L#P#J^OP?#?1[O5+:Z\2:C)N!DL56%WCW-L=A<^1GY0H)P,YR
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MP:ENRNNR?WJ__#]BHQN[/NU]W]:=SZ.M-:TJ\N8;:TU.QGN)[<7<445PC-)
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M)("^PD<IO!YX=0,F_P##GQ?XGG^(W]C:S?/?65SX?75XHIOLYF1S( /]2BA
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M3@ :A$2?_'J.2?87/':YIQZ/ID<UU-'IUDLUU&L-PZP*&F11A5<X^90"0 >
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MS\%^%K*VN[>S\-:);V]VH2XBBL(D690<@. N&&>QIG_"<^$O^AHT'_P80_\
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MNLBXM8;.-(ILC!WH!AN..157_A.?"7_0T:#_ .#"'_XJC_A.?"7_ $-&@_\
M@PA_^*I^SEV#GCW+=SX<TVXU+1KUK>-9-(#BS5$55BWIL..,@;>, @>H.!B]
M<6%G<W=K=7-I;S75J6-O-)&&>$L,,48C*Y'!QU%8W_"<^$O^AHT'_P &$/\
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MW&FGL%%%%(84444 ?GA<_P#'Q+_OG^=15+<_\?$O^^?YU%7U)\T%>T?LI?\
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M^'=;T6]33=8D>XCOEB-[<VC1>4BP3R-\BR,&1O*')^88/R]C+KP47+M_P/\
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MGQ+U>2^DNC;Z?YCW4]V0(WQOE@\EA]_H%&1[^HXKU7_AF^P_Z&*[_P# 9?\
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MM+_Z#M[_ -^4I_7J/<7U*KV/F^BOI'_AG?2O^@[??]^DI?\ AGC2O^@Y??\
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M[2R7,L=C"[,\I@EC7_62$;<R\KP !P!SGTO_ (9PTC_H/:A_WZ2C_AG#2/\
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M110 4444 ?GA<_\ 'Q+_ +Y_G6C9Z<^HZ6SV\0$MNWS'. ZG^H/Z'VK.N?\
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M?.O)Y'\N-MR(KLY945AD*I ]JU=>\,:/K\UI+J]DMR]HLJ0[G8!5E0QR @$
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MPC>8\Q0A\ 9*@>M444=$@>K;"BBB@"6V_P!<*N53MO\ 7"KE !1110 4444
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MQMH-S:7]S'=S)'8HDDPFM)HGVOD(RHR!G#$$*5!W'@9-.W*N7^MK?D.[;O\
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MNW;H._\ 7W?Y(R/"VCMHFAP6,UR;RY!>2>Y*;/.E=BSOMR<9)/&3@<5R%O\
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MI+#Q!HVH7-S;V&KZ==3VHS<107*.T(]7 .5_&N,\6>!+[6?%7B'5(7L1'?\
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M!CT-CXSN;C4K4R:4D>BWE[+IUO>"ZW2F:/>"6BV *A,3@$.3]W*C)P=$^_\
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M_K[_ "$]O/\ K^ON\R?2?B-I%[I7VVXAU&W+7=Q:QP+I]S+*_E.REPBQ[L8
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M1@%SY8\P1DY*;L9VYYQTS6?>^%?#U_')'?:#I-S').;EUFLXW#RD8,A!'+$
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MW0#/R=?]H\]>>M5)/!NA2:G%?M9OY\9C;8+B41.T8 C=X@VQW7 PS*2-JX/
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M0NK84444@"BBB@ HHHH EMO]<*N53MO]<*N4 %%%% !1110!^>%S_P ?$O\
MOG^=15+<_P#'Q+_OG^=15]2?-!7M'[*7_)1-1_[!4G_HZ&O%Z]H_92_Y*)J/
M_8*D_P#1T-<^*_@R-L-_%B?5E1W'^I:I*CN/]2U?/'OE*N7U3Q)J5GX[TG0H
M/#M[=:=>0O+-JR$^3;,-V%;Y<9.!U8?>& :ZBBCJ'0*CN&*6\K*<,J$@_A4E
M(ZAT96&588(I23::0UOJ>3^#_%^M^);?P]#>S7.C"33TO#<RP1B75W5?WBQ
MJ4C0'DY&]E8%0JC<=[PCXYO-9ETTZGHT6G6^I:8^IVSQWAG8(AC#!U\M=I_>
M*1@MD=<'BN@N?"NCW.A6.CRVC?8+$1_952:1'AV#"E9 P<$#C(.2"0>":FT_
MP]I>GMIS6EKY9TZT-C:_O&/EPG9E>3S_ *M.3D\=>35-IMV_K?\ 6WW".0_X
M6'>PZ;'J%YH"QVEU8OJ5CY5YYCR0)M+^8OEC8_EN&"J7!P1N'&=&V\<K=:M)
M8VUDLC->QVULXGXGC/F!Y?N\;?)FXYSM'(SQIZ3X/T/2;B6:RLV5I(F@"R3R
M2I%$QRT<2.Q6)"<95 HX'' P[2_".AZ5+ILMA8+$^G0/;6I\QV\N-SEAR3DD
M_P 1R>3SR<FE_P"OZ[+IN_('MI_7]:OKT,+1_'%]?:O917&B10:;>:C=:9#<
MK>EY#)!YOS&/RP A$+<[R0>,8YK8\3:]?Z=JVEZ9I.F07UW?I,ZF>[-O'&(]
MI.XA'/.[L#SCL21=@\.Z5!]C\JUV_9+J6]@_>.=DTN_>W7G/FOP>!G@# Q;G
MTZUN-1M;Z6+==6JND+[B-H?&X8S@YVCKZ4GMH/2]UM_P?\K')^&?&UUJ]UI7
MVS1TL;+5+.6ZMI/M?FR Q[-ZN@0 #YB5(9L@<A2<#+T;XI->V%_J-SX>U&#3
M(;*2_@N%AGQ*BXPK-)#&@=@01L>0<-\PP,]K8^'M+L?[.^RVNS^SHGAM?WC'
MRT?&X<GG.T=<U0T_P/X=L/M(@TX-'<0O;M%--)-&D3G+QQH[%8T)QE4"@X''
M H_K^OP_X(*QR]]XK\06<WBMM8M8[$:=H<=]#!972S#>6FRRR/"/F^11AD*@
MKG!S70P^)=3N]8NX--T:*XTVQN$M;JX>]$<P8HCLR1E-K*H=2274\-@' S-:
M^!= MK74+=;6YE2_M197)N+Z>=WA&[";G<L -[8P1C-2WG@W0KW4S?7-G(\K
M.DDD8N91!*Z8VO)"&\MV&%PS*3\J\\##=NG]:_Y"_K\%^ISGA?XB3ZYKG]G3
M:/\ 9(Y[6:ZM;E)9)5=8V4?>,2Q-D.#F*25??H3TW@._N=5\$:!J%_)YMW=6
M$$TTFT+N=D!)P  .3VJ'1O!.@Z-<03V%K.LL$+6\)EO)IA%$V,QH'<A4^5<*
M, 8X K:TNPMM*TVUT^PC\JTM8EAACW%MJ*, 9))/ [T*UK?UU_X ,M4444@"
MBBB@ HHHH *5>HI*5>HH T**** "BBB@ HHJ&]%PUG.+)XDNBC"%ID+(KXX+
M $$C/4 CZB@#QGQ;9>+KCQQXDN/ ^J2V=O \+ZC')=6\ 9_(4CRPUO(?N!?G
M=@,Y'1>/5O"-Y_:/A71[WSIY_M%G%+YMPJK(^Y <L%^4,<\XX]*\+\<*;_Q)
M?1^-+[X6)JNEJGDMJ]A-"\X*;QC=<9>,9Q_%\P88&.?=/"-Y)J'A71[R>-(I
M;BSAE9$B,2J60' 0DE1ST).*</@?R_7^K=/,)/WE_78M7/\ KC452W/^N-14
M@/+?B%X,UOQQXN\F7[)9Z!8V,D4+WD'VE+B>=2CL(TE1E*)P&;NQP.]8W@WP
M5K]UXLTR_P#&FC0S'3="_L]+B:2*4/<1W#&.55W$ABFUMQ ()/0U[7122LK?
MUU_S8V[_ ->GYV/!/"'PIN+,?#\:GX>M<6\%['K@=HG$F[F%9/F/FKGD#Y@,
M#I79>"_#.KV?P7F\/:G;.FHM!>0+ +I4(1WDV*L@#JOR,N.#CCCC%>DT4Y/F
M33Z_\'_,$[-/L>5^#?#^M6-GKEM-I6I1^'FTN.VMM&U+5%GEDF",'V2AW$<;
M#:HY&.NU:T_%DGBO3/A]I=CX%\/^7J;PQV[1&YB?^S4" '!D=1*R]!S@D9/'
M7T&BB7O7OU_X/^?^5A+W;6_K;_+_ #. \(:??>$_!&FV&B>'M0FN&N]EV-0O
M($G^=B9;IF1I%;DYV@D]JQ?AEX8UW0-:L(8;/5-+T2WM)H[V&_U1;U+F=GRC
MPA3A0/F).R+.[[I->LT4[ZW_ *VM_7_#"MI8\B^(7@&Z\1^,?$5_)I$-[;2^
M&6L[%I7C(^V;W*@*QX89!#$ #UK)_P"$#UO31+/I\,.D-/X/>TO;[[0D>=0R
MIWRL#N9@-W[PYQSS7N=%3;2R\_QO_P#)?@B^;6[_ *V_^1_%G@?P@&GW7Q,L
M9M!TRTL[.T\-?9KK[%<PW$0N#,I.6A=UW-M)R3N8#)%;L>G>,_".D:OI&A>'
MH=;^V:C<W2737,4:/#-N.)"SJPD4D#A6! QD=1Z_13G[ZMZ_B[DQT_#\%8\4
M\!Z)K_A74-!OO[!U/58(O#,.FR&&2")XYUF9V4K/)&=H!P" >,8KM/AYX3GT
MSP3=:9KZIYNHW-S=7%O!*VV(3.6\H.N#P#@D8YSBNWHIMW;;\_Q=_P Q)6V\
MOP5OR,R'0M.AT-]'@MO)TUD:/R(G9 J,3E5(.5')  P .!@54N/".ASZ3;:9
M+8(=/MG,D%N'=4B8YP5 /&W<=N/NG!7&!C>HI#\A ,#%+110 4444 %%%% !
M5^+_ %:_2J%7XO\ 5K]* '4444 9[_>/UI*5_O'ZTE !1110!Q]_X,34_&5_
MJU]<7D=M+96]O$MEJ5S:/N1Y2Q?RF4,/G7&2>_3NJ^#H+7Q!I=SI\-O'8V=A
M=V^V1F>0RS/$V\LV2Q.Q]S$[B6YSDUU]%%M+?UK_ ,..[O?^M#RM? 6MVN@I
MIUJ-'N?M>@V^BWCW,C@6WEJP+Q (?,4^83L/E\J.>>+GCOP3JVKWD4FC2VT;
MFT2T>[ENY$<*I;_6PE)(;E#O)V.JD'.&^;*^D44VVWS>=_S_ ,V+R_KI_DCR
M[4_#NM:KKWC"RM[.RCL-3DM8Y+^X+I*BI$F6B4(1(0=V/F7:PSSTK5OO!EU/
M)K4B-9^9?:Y9:DCL3GRH/L^58[?O?NGP.1\PY&3CO**4?=:?];I_H'D>767@
M36U\6V6I736/E6NK3WWF17LX$L<@E 'V4((8W =<O\S.026Y.8I_ WB(S0Q8
MTR6RANK^1#'J$]I,5N)O,5_,BCWC;EE,2N%?"DMP /5J*5M+#;;=_P"NO^9Y
M=>> ]87PAX8T^S:T?4=)LS:&>/4)[-D)"?,DBHX=3L&8Y(V#<<\<PZY\.-4O
M7L\R65ZK:1#I=T'O;FPB0H6W.(;8JLJ-O/[HE -HPP!./5Z*J[O?Y_G_ )BZ
M67]?U8;&NR-4'10!3J**0)6T04444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 2VW^N%7*IVW^N%7* "BBB@ HHHH _/"Y_X^)?]\_SJ
M*I;G_CXE_P!\_P ZBKZD^:"O:/V4O^2B:C_V"I/_ $=#7B]>T?LI?\E$U'_L
M%2?^CH:Y\5_!D;8;^+$^K*CN/]2U25'<?ZEJ^>/?*5%%% !0>E%!Y%)[: >:
M2?$N\M= BUK4= CAL+JUGGL_+OO,D=XHVD*.OE@(&5'*L"W09"DXK0\2^-]1
MT.'28'T(7&L7R2S&UMY+B>.*)".2\-N[DG>@_P!6%R3\W )ET/X;:'8:,ME>
MI-?L;62TD>6XF";'^_Y<9<K$6[E,$^O-;NO>&M+UY;;^T89M]MN$,MO<RV\J
M!AAE#QLK;2,97.#@9' IO8>ESC_%/CG5SX?U67P_H[PW%IHPU&X:^E\B:T,B
M.4 B*,'=?+8LK%1P!DYP-&_\57EA<:N(+&[U*:STZRN4MHN0[2O(I(5(VD&-
MN6QOX'RKD'=HZIX$\.:G'''<:>T<26OV'R[:XEMT> # B=8V4.HR<!L@9.,9
MJ[?>%]'O_M7VJSWFZAA@D82NIVQ,S1[2#E65F)#+A@<'/ INVMOZW%VO_6W^
M3^\YBP^(4VH:!9WEAIMG=7MSJ/\ 9H@BU#]VCE"P+,8PZ8QAE>-7'/RGC=<'
MC2[>WBM8M)B/B!]0;33:->$0+(L?FEO.\LG9Y>"#Y><D#:.2)M1\!:9<V-G9
MV[W,,,5^+^9VN9I)YW",G,Y?S P!7#;LC: ,8&+[>#]%;1X],^S2BWCG-RLB
MW4HG$Q)S)YX;S-YR06W9()&<<4E_7X?\'_@ ]_Z\_P#@?\$YK6/B-=:?HMM>
MC1!O\^>WO6FGE%M9R0L$.Z:.&3"L3E6947 )8J>*C\=>,K^TT3[7H6%GG\/W
M6IPDSQ/$A3R<-E4<.0)"5VML.,'((9>EF\$Z#+8V=JMK<0):!Q%);7D\$PWG
M+[I4<.VX_,VYCN/)R>:LW/A71;FWB@EL(S!%8R::D89E5;=]H:, '&#L7GJ,
M<$4+^ON?ZV_K>HM*2;_K7_(YJT\8ZDLMS9_8$N-9DU)+&&W>\"VZM]D2=SYH
MA#! "W5&8GT!PL\WC>\:PTG['HT<NJ7NHRZ7);27FR.&6-9"Q\P(Q9/W1P=H
M.#G /RUJCP3H0T^2S%M<>6\Z7)E^VS^>)518U=9M_F*VQ0N0PR,YZG-RT\-Z
M3:0:9#;VFQ--E:>V_>.2LC*ZL[$G+L1(^2V22Q)YYIZ?E^G_  ?\^A"T7]>?
M_ $\(ZT^OZ(E[-:BTG$TUO+"LGF*KQ2M&VUL#<,H2#@<=A6S532].M=+MFM[
M"+RH6EDG*[BV7D<NYY)ZLQ/X\5;I,84444 %%%% !1110 4J]124J]10!H44
M44 %%%% !1145U<0VEK-<W,BQ00H9))&. J@9)/L!0W978)7T1XM\1/#>JZO
MXXO;FZT?QG?VD)B-A+I.KP6L,8\L;L(75MV[=\QY.<= ,^O>'8Y(= TV.9+N
M.1+>-66\F$LZD*,B1P2&?U.3DYKYX^(6O:;J>J:KXB&JW,MA#Y;16MQJ=]I!
M>!HPO[I#& Q61=X*AMPD((&%S[O\/$>/P%X<24.)%TZW#;PP;/EKG.[YL_7G
MUIQ5H->GZ_TPD[R7]=C4N?\ 7&HJEN?]<:BI %%>2_'3QW?^&_[.TOP]JNGZ
M;JTR2WTDMZT80PQ*2(_GXW2-A1CGKTZUJ:3\29-<US2;'0M+@N;>]TB/6'N9
MKSRO*C,A1TVB-LN"#QD G()'6DG=7_KK_D_N!JW]>:7ZK[ST:BO)M!^*FL:R
M/#7D^%K6,^(8KA[+?JIPK0GYO,Q#\JD<@C<>@VCJ-C_A8$EW\'=0\965B(;F
M"UN'6VD?S%62)F3D@ LNY<] <>E.7NIM]!I7:7<]!HKS/P!XCU:>?6K*_NM0
MU#5H+*&]@L+^UM[9V#*<%)824,;L, , R_Q9K=\8:C<VOA&WU74M9'A..%5G
MU!ECCN9$&WF%&8%-VX@ [&SC '-$O=W_ *_KJ*/O6L=?17(?"W5-:U?P3::A
MXCADCNI6D:+S8PDLD&X^6\B+P'*X)  'H!TKE_ASXHU>?4XH?%\NOV>JWT%S
M=VVGWMM:QV[1+)P$V)YP95* B0@G).#0]'9@M5='J]%>3:#\5-8UD>&O)\+6
ML9\0Q7#V6_53A6A/S>9B'Y5(Y!&X]!M'4-TGXOSZU92S:5X=61[339=1ODFO
MQ'Y8222/9&?+/F$F)CDA !C/)Q1+W=_ZM?\ R8TK[?U<];HKS7QKXXU2V^#]
MEXKT.UMH;R\CM)?+GD+"%9F0$ [?F(W8Y ]>V#SWB;XA^)K#Q]'H>GVMJ9FO
MM.MIXI[L&%3-'([)$P@#@$H07;<>!A5R</E?-R];V^>G^9-UR\W2USVNBN%;
MQU=?\)1XGTX:3;BP\/Q1S75W)?B-G#PF0!%9 N<C!+.H YSVKEIOB[J$]CK\
M-MHUO;ZC9Z(VL6LIN)9874'!!+0H"1U^0LK<@-U-3?2_E?\ 7]"DFW;^NG^:
M/8Z*\D'Q2U.UM])L&T!M1UN32HM2NA:FXDC"OD(%,5NYWM@DAE51G&X]:H>,
M_BEK-QX/\3WOAK2IM-;28;<2W%\RI<P32[&*?9V0@[5;!+,.<X!Q5-6=OZWM
M^8H^]:W4]JHKBOB#K^H:8OANPTN2.VN=:OTLFO)$#BW4HS,0#P7.W"@Y&3T-
M<MXC\6:IX;OM1TRUU\ZTLNB7][;W4D<!FM+BW'1O+54*Y)&"F0RX)/2I;M?R
MO^"O^01]ZUNMOQ=CUZBO*K+6]=T6X\!7%YK=SK%OXB*07-O=00(87: R"2(Q
M1H0 000V[@]CS756K^+#XJU3SQ:#0O)(LSY0+^8.02/,!P=V.3SY9XCX+5)<
MK:[7_ 46I)-=;?B=717.>!V\2-IDQ\7+;K>><QC$*C C/S $AB"1G;T'*GEO
MO'HZ3&%7XO\ 5K]*H5?B_P!6OTH =1110!GO]X_6JFJO=QZ7>/ID4<U\L+M;
MQ2-M5Y IV@GL"<5;?[Q^M)2:NK#3L[F#X'N?$%YX8LY_&%C;6&MMN\^WMGW(
MGS';@[FZK@_>-;U%%4W=W)2L<%XQL[[4O$Z):7'VZWMK0/-I=KKDVG7,>6/[
MT"+'F;@-JB1D4%3S\Q(PY?&VI1:9H>G>%(+V]NYOMBRR:HL$TT?V9PCHW^D0
MHY!8?.)&X7)W$DCT76_#VBZ\(1KFD:=J0ASY7VRV2;9G&=NX'&<#IZ4E]X=T
M34--M].O]'TVZT^WV^3:S6J/%%M&!M0C P.!@=*E;6_K^OZN5=7N<UX?\3ZS
MK6L(@33;6RCTFVU&>-?])=WF$ORI*C[-H,8.X!LCIUR*$?CV_?1=)NA'8F>[
M\-7&M2*%;"S1K$5 &[.S,C9'7@<]:]"BM+:*X>>*WA2=T6-I%0!F1<[5)ZX&
MYL#MD^M9]KX9T&T>X>TT32X'N0ZSM%:1J90^-X; ^;=@9SUP,TY:WM_6_P#F
MON"-DU?R_3_@_><->>)_&%O'J \WP_YEOI"ZR&^R3$!3OS!CS1D_+_K<C_KF
M<\=)XVU>>#P;#>VL[6*W,MJDUR,9MH99$61\D$ A6/S'@=>U="^FV+^9OLK9
MO,A^S/F)3NBY_=GCE>3\O3DU/Y,7D>1Y:>3MV>7M&W;C&,=,8[4W_7WO3[K(
ME7T_KHOUNSE[31-,TW53I\6NZGNOK5PUA<ZM--(Z@@&6-G<RH1NQE& Y'&0#
M7.Z!H%D][XP^VZOX@BM]/O###*^O7A%O%]EB<GYI2#@NS98']*[O1/#^C:"L
MHT/2-.TT3$&06=LD._'3.T#.,GKZU/+I=A-'<I+8VKI<R"6=6A4B5QM 9ACY
MB-JX)_NCTI=_3]1KS.4^'FH7NJW%W-K<TZ:I!%%&+4EHT,++N2X\OIND(8G(
MRI4I_"2U[QC>2V>M>$"MQ)!;S:H89L.560-;3;5;U!?;@'OCOBMV\TVTNVD>
M:WA,SP-;&8QJ7$;=5R0>#@''3@<4R32+"?1UTJ[M(+K3Q&L1@N(Q(C*N,!@1
M@]!3O_7]?UJ"ZKO?\OZ^XXO7O$5WI.M>.KNTE^T+I.BV]Q'!(S&))O\ 2&((
M!X) 3.,'&WVJEJWB7Q!I%[J,6=.N=36+2T5MDR09N+J6,_NS*0,+CYA@DC)X
MPH[VRT#1['2Y=,LM)T^VTV;=YEI#;(D3[AALH!@Y'7CFIYM,L)YFEGL;625O
M+W.\*DGRV+1Y)'\+$E?0G(HTNOD-N]_Z[?Y?B<+>^,M9TKPSXDEO(K*\U32]
M0BT^)[>(PQ2F40E'*/+\N#-R#( =OWESQO\ @+6-6U:ROEU^UAMKZSN3 PC:
M(%AL5ANCCFF\MOFQM+DD8;C=@;DFFV,L-Y%+96SQ7N3=(T2E9\J%.\8^;Y0!
MSG@ 4:7IMCI%DEGI5E;6-HA)6"VB6)%R<G"J !DT+S[+]/\ @_?Y"?D>+W_B
M+6="\#>*;R_U*[EL;Z74X[.\,C>987"33(D>_JJ,%78>SC;_ !*!U>H>'[>;
MXA:7:M?Z^MM>:?=7<T4>N7J*9%D@"D!91M $C_*N!STX%=W+I.G3:?-82V%H
M]C,6:6V:%3'(6;<Q9<8.6))SU)S4YM;<W4=R8(C<1HT:2E!O5&()4'J 2JY'
ML/2A:->7^0Y.[=O/\6C@-:NIK7Q:=+74+T:)=SP"\G$[[K2=@=D*R9RJR[8\
MX(VDC'^M!6G]IN?$'CA+>]U*^MM"OS<BUCMKJ2V,YMC&@570AAEFGD^0@LJK
MDE5Q7HK:7I[VMS:O8VK6URS//"85*2LW+%AC#$]R>M17FAZ3?:6NF7NEV-QI
MRXVVDUNCQ#'3"$8X[<4ETO\ U_PW3^F)];?U_P /U.4U#47\-:!>0>']635+
MF+4[>S":A.URUH9I8U*.V[>V ^X;B6YQG&,9MQXT\20>+9=/CL;.XL+"YM;&
M]G(B@$DDJH2ZM)<AD_U@VIY<A8C ;)X[^WT;3+;3H=/MM.LH;"%E>*VC@58H
MV#;@54# (;Y@1WYIL^B:5<:O#JL^F6,NJ0+LBO'MT::->>%<C<!R>A[FFM'K
M_6W_  ?O\@Z6. \4^.M<TWQ/+'IUO97&BVM_:Z?</Y.6624IN!D:9"& D4A4
MBE&,989(6'P!K6LOK$-OJU[#?,XUB0.@ECV>5>(@4J964CDXR,JN%!ZEO0+G
MPWH=UJ3:C<Z-IDVH, K74EJC2D#& 7(SQ@8Y["I;70])M+Z:]M=+L8;R<L99
MX[=%DD+8W;F R<[5SGK@>E)72MZ_E_GK^ VU^7ZGE\GC;Q&WA,WFK+I;#4/#
M=QJ\*6B30- T8C^4N)2S B7.5V%<=3UK8N_%OB"'5M0DC&E_V38ZO9Z88F@D
M,\HG$&6$GF84J9L_=.<8XZUW+:+I;V\<#Z;9-!';M:)&8$*K"V,Q@8P$.U<K
MTX'I4C:98,) UC:D2RI<29A7YY%V[7/'+#8N#U&T>@JKJZ?];W_+03VM_6R_
M4X+4_&VNQ^-[JPL--MWT>QO+:RN))FAC+-*$.X2/<*5.)!M41/O*X!!/'I-9
MT^B:5<:O#JL^F6,NJ0+LBO'MT::->>%<C<!R>A[FM&I6U@>]PHHHH **** "
MBBB@"6V_UPJY5.V_UPJY0 4444 %%%% 'YX7/_'Q+_OG^=15+<_\?$O^^?YU
M%7U)\T%>T?LI?\E$U'_L%2?^CH:\7KVC]E+_ )*)J/\ V"I/_1T-<^*_@R-L
M-_%B?5E1W'^I:I*CN/\ 4M7SQ[Y2KE]4\2:E9^.])T*#P[>W6G7D+RS:LA/D
MVS#=A6^7&3@=6'WA@&NHHHZAT"CZ44C*'4JX#*PP01D$4,#S"SU;7=+O+:X\
M6ZKK.F,UR$DCFL+:?390S;=D<D ,D0^90K3NI)(R&Y N^%_B'?>(EN7M/#5X
ML36CW=C(Z7$<<X&-J.[P*BLX((V-*/O<\#.Y;^!/#]O/"\=K<F&&02Q6;WT[
MVD; Y7;;ES$H4\J N%(!&,"K.A>$=%T*\:ZTNT>*4HT:!IY)%A1FW,D2LQ6)
M2<$J@4<#C@4+:PWO<YG6?B4MJJ-IFE27Z3&WB@93*2\TL;3%"D44C@)$%8D*
MQ^<# Y(O?\)G?RZ1H,UMH$B:CJMV]F+6^DDM1$R)(Q<EHM^PB(D$H"00=H/%
M:]QX0T.?338-9%+?[4;U3#-)%)',23O216#H>2/E(P/E''%3VGAO2;2#3(;>
MTV)ILK3VW[QR5D975G8DY=B)'R6R26)//--6ZB]/Z_K0YO1?'\VJ^*WTV'0K
MTZ=]IFM%OTAN"H>+<&9B81$$W(R@B5CG;E1DXVO$6NWUEJEGI>BZ=!?ZC<0R
MW)6XNC;1I%&5!.\(Y+%G4 ;<=22,<R6OA'1+77&U:"T9;PR/. 9Y#$DKC#R+
M$6\M789!8*&.3D\G,^O^'=-U_P @ZC%/YD&X1RV]S+;2*&&&7?&RMM.!E<X.
M!D<"IZ+\1Z7?8XW6/B?]AM](O(M(*Z9?6T=PUU>SM;QQLQ(\H2"-HA(,'_62
M1J25PQSP_P 0^-=3T#Q1X@\^SBNM)M+&R:UBBD9I7GGEDC7Y5B8_,P ."V @
M(#%B!T5_X(\/WP@66Q:..&!;416UQ+;QO"OW8I$C95D0<X5P1R>.3F;6/".B
M:Q=S7.H6;2RS6PM9-L\B*\:MN7*JP&Y6)*MC<IY!%4_\_NZ?U^8E_E^E_P!3
M L?'6H7FGVRIX>FAUBZO3906]TTUM!)B,RF022PK)L"@C_59W# !'S58D\:7
M1T6PGMM(634[C46TI[1[K:D4R[P3YFTY3*9SMSM.=N?EK3_X0O0_[+-A]FG\
MLW'VLSF\F^T^=C'F>?O\W=M^7.[.WY>G%5]5\$Z=>:3I.EVQDM+&PNQ=[8Y'
M\R0X?)\T,'#EG+>9DMGG.3FD_P#+]+_K_6@=/O\ UM^AFP^-]2N[S^R;#0[:
M3Q!"\XNK>6_,=O$L7EG*S"(E]WG1X&P=3G;CFS#XV>]F\/C3--5XM4LI+^5[
MFX\HVT4;1AQA5;>P\S@# )'7!S5V7P/H$MC;VOV:Y00/(Z317L\=P3)_K-TR
MN)&W<9W,<X&>@QJ6^AZ;;7-C/;6D<+V-LUG;"/*K%"VS*!1QC]VG;C''>CI_
M79_K;_,/Z_K^OD8'AGQ?=:K>Z<E_I*65MJMJ]YITJ77G,\:[3B5=B^6Y5U.
M7'49X&>>7XF7%UI?B,7.FG2[W3].EO4M_M)2[4*.-T4T*XZC#JLL><@MTSVF
MB^$M%T6[>YTZT=)&C:)1)/)*D,9.2D2.Q6)"0,J@4<#C@8JP> _#L,%W ME,
MT%S;O:-%)>32)'"_WHXE9R(E.!Q'M' ]!AZ7&K7U[K_@F9J7CR73O&5MHMSI
MB0VD\D4,=Y=7#0^>SJ#^ZW1^4^"P!7S0YPV$.!FYXZU?6-,U7PQ!HZ6S0WM[
M)%<^=+L)402. /D;^Z6[<JHZ,2-"X\(:+<:N-2EMI?M'F1RLBW4JPR2)C8[P
MAA&[#"X9E)&U>>!B[K>B6&MI:KJ,4C_99A<0M',\3(X!&0R$'HQ!&<$$@YJ7
MK&RW%'3?M^)R'P\\7ZMJ5OH%MK]C$DFH:0-0CO$N S2[/*#F2,(JQDF4$!2P
MQUQTKG=5^*FJSZ1K*Z?H\=I<KI=U?6-V9Y)(R(BH)W& 1.<.&'E/*A(P6 .:
M]-LO#NE67]G_ &:T"_8+1K"V!=F"0'9E.2<_ZM.3D\=>363:_#WPS;0F)+":
M2/[-)9*D]Y/*$@< -$@=SM3"C"K@#'&*J33=UY_K;]!Q:35_(Z33GN)+"W>]
MCBBN6C4RI%(9$5L<@,54D>^!]*LKU%5M/M(K"Q@M+?S3#"@1/-E:5L#IEW)8
M_4DFK*]10[7T)BFDDS0HHHI#"BBB@ K,\4:6=<\-:MI2S" WUI+;"4KNV;T*
M[L9&<9Z9K3HH8TW%W1Y7?^!?&>H:UI>J7OB7P[/=:8DB6OF:$S",OLRP!GX;
MY  1T!/K7IFGI<QV-NE_-'/=K&HFECC\M7?')"Y. 3VR?K5BBG?2Q-BG<_ZX
MU%4MS_KC45(9F6^AZ=;Z]>:U%;D:G=Q)!-,TC-F-,[5 )PHR2> ,D\UF:#X%
M\.Z#?M>:3IYM[AH7M\^?(P$;R&1E"LQ !=B>!QGBNFHH YW3?!7A_3?[$^Q6
M'E?V*LJ6'[Z1O)$OW^K?-G_:SCMBK>D^&](TG0#HEC9(NE,) UM(S2*PD)9P
M=Q)()9N#ZUKT4/7<%IL<YI?@G0-+M-0M[.R<1W\(M[@RW,LKO$%*B,.[%E4
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M_A!$; =R0>, D<[XO\,ZWK&E_P!D?\2O5;5HL1ZAJ1\N[LY_F'VA!'%L=E#
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MEB1<G)PJ@ 9-->?];?\ !^_R#H6Z***0!1110 4J]124J]10!H4444 %%%%
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MU'_L%2?^CH:Y\5_!D;8;^+$^K****^>/?"BBB@ HHHH **** "BBB@ HHHH
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M$A1D98\#/)IVO:[IV@:2^IZM<B"Q0J&E",X^8@#A03U(J.1E\YM;K?\ N/\
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M],NQ%9C@EV.U0S.., =.V EL'7[OZ_R'_P#"8:(6F6*\,S12&)Q%"[X("9Y
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MOYCU% S8HK+N]>TRVE,#7UJUU\V+<3H)#M^]P6'3OGI3Y-<TF*>>&74[))H
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M9@Q4 QX;[JCY]W"CU.>GHH Y?_A#+86ZQ)J6JH1#+!YBS*&VO(), [> "H
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M\6/F/&, =+126FWI]PWKN86D^'CIC7[IJNH3SWA+/-,(6=6R<$$1C@9P%.5
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4* "BBB@ HHHH **** "BBB@#_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>21
<FILENAME>image00022.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image00022.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  8$!08%! 8&!08'!P8("A *"@D)
M"A0.#PP0%Q08&!<4%A8:'24?&ALC'!86("P@(R8G*2HI&1\M,"TH,"4H*2C_
MVP!# 0<'!PH("A,*"A,H&A8:*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H
M*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"C_P  1" &7 T(# 2(  A$! Q$!_\0
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M_I4_WS_RT/K4?VZ[_P"?J?\ [^&H[G_CXE_WS_.HJ^HLCYJ[+/VZ[_Y^I_\
MOX:]]_9-N)IM0\2>=+))B*#&]B<<O7SS7T%^R/\ \A'Q+_UR@_F]<V,7[F7]
M=3HPC_?1/I*BBBO /="BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH _/"Y_X^)?\ ?/\
M.HJEN?\ CXE_WS_.HJ^I/F@KZ"_9'_Y"/B7_ *Y0?S>OGVOH+]D?_D(^)?\
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M%UB5H](U?3K^1!N9+6Y24J/4A2:GLM5TZ_NKJVL;^TN;BU;9<10S*[PMR,.
M<J>#U]#0XM;H%)/5,NT444AA1110 4444 %%4].U2PU/S_[-OK6[\AS'+Y$R
MR>6XZJV#P?8U<H:MN%[A1110 4444 %%5IK^S@O;>SFN[>.[N QA@>0"24+R
MVU<Y..^.E9$WC7PM#*\4WB71(Y48JZ-?Q J1U!&[@TU%O9"<DMV=!15&/6-,
MDTMM3CU&S?354L;M9U,0 ZG?G&/QK-C\;>%9'"1^)M#=V. JW\1)_P#'J:A)
MZ)"<HK5LZ"BJT]_9V]Q;03W5O%-=$B"-Y K2D#)"@G+8'/%6:DH**** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M\"ZGI?CC7/$FD:Y91R:K@/!=:<THC QT*S)D\5<LO!<LWC:#Q1XAU.._O[6
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MVK.=55(--V>GX)HN--PFI+7?[VTSQJQN+N]^ >H7!NG-SX9U=3I]SG+1J"@
M4]<#S#^@[#'T=X9U/^V?#FEZD1M-Y:QSE1V+*#C]:\K^)NAV7AKX7V7@OPW$
M6N=6NXK6$.V9)7+AWD<XY^Z,GH,CH!7J^AV$>D:+8:="<QVEO' I]0J@9_2K
MKSC.#DNLM/N5_O9-*#C-+R_5V7RU-#-&:9FC-<9U#\T9IF:,T /S1FF9HS0
M_-&:9FC- #\T9IF:,T /S1FF9HS0 _-&:9FC- #\T9IN:,T .HIN:,T /S1F
MFYHS0 ZBDS10 M%&:* "BBB@#\\+G_CXE_WS_.HJEN?^/B7_ 'S_ #J*OJ3Y
MH*^@OV1_^0CXE_ZY0?S>OGVOH']DC_D(^)?^N4'\WKEQO\&7]=3HPG\:)])4
M4&F]:\ ]T7--S3]HI-@]Z &%J;NJ3RQ[TGDK[T 1[J3?4GD+ZG\Z/(7U;\Z
M(M]&^I?(3U;\Z3[.GJWYT 1[Z-]2?9T]6_.C[.GJWYT 1[Z-]2?9T]6_.C[.
MGJWYT 1[Z-]2?9T]6_.C[.GJWYT 1[Z-]2?9T]6_.C[.GJWYT 1[Z-]2?9T]
M6_.C[.GJWYT 1[Z-]2?9T]6_.C[.GJWYT 1[Z-]2?9T]6_.C[.GJWYT 1[Z-
M]2?9T]6_.C[.GJWYT 1[Z-]2?9T]6_.C[.GJWYT 1[Z-]2?9T]6_.C[.GJWY
MT 1[Z-]2?9T]6_.C[.GJWYT 1[Z-]2?9T]6_.C[.GJWYT 1[Z-]2?9T]6_.C
M[.GJWYT 1[Z-]2?9T]6_.C[.GJWYT 1[Z-]2?9T]6_.C[.GJWYT 1[Z-]2?9
MT]6_.C[.GJWYT 1[Z-]2?9T]6_.C[.GJWYT 1[Z-]2?9T]6_.C[.GJWYT 1[
MZ-]2?9T]6_.C[.GJWYT 1[Z-]2?9T]6_.C[.GJWYT 1[Z-]2?9T]6_.C[.GJ
MWYT 1[Z-]2?9T]6_.C[.GJWYT 1[Z-]2?9T]6_.C[.GJWYT 1[Z-]2?9T]6_
M.C[.GJWYT 1[Z-]2?9T]6_.C[.GJWYT 1[Z-]2?9T]6_.C[.GJWYT 1[Z-]2
M?9T]6_.C[.GJWYT 1[Z-]2?9T]6_.C[.GJWYT 1[Z-]2?9T]6_.C[.GJWYT
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MY90P '$7?3M_7];^16FO]?U_6IZEI6H6VJZ9:ZA82^=9W42S0R;2N]&&0<$
MC@]Z@FUFQBU":Q,DCW<*0R2110O(565V1&.T'@E&R?X0,G YKQR;P-J-QX-\
M&Z+<^$W2VT^UDBNHK?[#(R7.$42[)F: H_[QB^QY1G@+N;,>F?#_ %JTFTF2
M?P\DM_\ 8M&CGOQ) 7B>UN@TP9BP8YC"$%001&!U %79.5NE_P .XNC_ *ZH
M]W8A5)8X &23VJAINL6>IV]C/8O+-;WUO]J@E$#A&C.W!+$84G<,*<$\X'!Q
MY98^"-17XCWEXVB*;"\DNOMMS>BVE26.16VK'+&4F93N4&*>-T4#Y6^528])
M\%:[%X6T:PL-+&BW=KX<O=-=EFB0"Z=H,.#$Q/SE';<.1U.#4QU5WV_1_P"2
M^\JRO;S/9ZR=:\1Z5HC.NJ77D%+2:^;]V[8ABV^8WR@]-Z\=3G@&O*M8\)2W
M>DK:Z3\.WTC3)+F!KRUAFLS++L23YTMS(;5B&* M*6+#DIE$(JVO@+Q'#X5F
MT]=/?<NDZU9P(T\ P9YXW@3Y-J#*@_=557&, 8II7=G_ %I_F*-FU?K8]T4A
ME!'0C(I:\IO--2_^(%UX<TV6UETB[,&I:W!&VYH)8\81@.%\[$)P>JQR'^+-
M1_%OPEJFM>(K74-)TA[ZYBMTCMY)#;R6\3AV)WAVCFA/S*1+;R;OEY4[5!%K
M;S_J_P!Y*O9WW_K0]4@N$GDG1%E!A?RV+Q,@)P#\I( 88(Y7(SD9R"*FKQOQ
MKIZZ3+J&I>)[>QFT*;Q ES)97=W;Q)?1_84C4 3.L;%9%+;'8?ZO(R0,Y_@C
MP=;^)1I]_>:';3>'R-7>""9DFB7S+B/R< DA@51BI7*C (.-IJ?\OQLG8JVW
M]=_\CV75=7L])AFFU"22&"&WDNI9C$YC2-,;B6 (!YX7.3S@'!INA:S:ZY9F
MZL4O4B#;?]+LIK5CP#D+*BDCGJ!CWXKRK7O ^M:KX,TBPN]-6[NH/"=QI\J3
MRQOB\(MS&,LV"=T;$-G *YSTJS=>";FU-VB>'(;[05UI+HZ-"8%2YMQ91Q+B
M-V6,A91NVN5^YD<[<VTDVK_U>WY:AT3_ *V/7:*\!\9> M6UNU,%IX1DL(8]
M.DCTR."YM)_LDK22-LD,Y;R1_JR/LRY&=OF;47'2^-/ ESK]QXCOI])CN[Y]
M M[?3))GC+)=J9R2A)^1P6CP_'7@]:2U"VMOZZ?Y_@>G6FI6EY/?0VTOF2V,
MH@N%"GY'**^.G/RNIXSUQUJ:UG2ZM8IXA(J2H'42QM&X!&>58!E/L0".]<5X
M0\//I'B/QG*=%BM_[3N$N8KZ,1 3@PHK(<'?N$@D8[AC+D@DDUQ!^&M_=^&[
MH:AHT,VJ0>%;*QT\R21,8;V-9MVQL_(ZDQX?(Z\'K0EI]WZW!*_]>G^?X'N-
M%>9^,?#D][XFFN[[PK_PDT,MC#!9,;B*/^SYE9R[;W8/%NW1GS(@S_)TR%SA
MZI\/K^3PCL72C]KN-<GN]3@M3:R3WEMYTYB&9PT3A=\;A),# /1J7]?B):J_
M];7_ . >T45XEJW@74[KP[X9TNYT2^N["W%T[1M+8W$]J[N/*5DE5;8($+ [
M(W,> L9QDL_Q#X)UB]\ ^#K*]TFYO]0TRR\F6)39W2I+M0 R17!5)%^4C>DB
M.N?E^\<#T3_KN-;V/:J*\1\7>!O$&KW6C27UE=W31:1!;1C3KBU"V-V"?,?S
M+M))4!RF)8BTG[OD$[:T=>\(:M)\3[76;'2GG?[3;L][<&WDB6%54/MD!CN8
M7P&^1?,B;=\P^9L.VJ7G;\=R>E_+^D>KSW"0RP1NLI:9RBE(F< [2?F(!"C
M/+8&<#J0*FKF/&.EWFHZKX9FLX?,CL[Z6:<[@-B&UGC!Y//S.HXSU]*Y7X<>
M!I?#%]X7N(]+BLY$T)[;59(V3=)<[H"HD*G,A&V4!N0!QD9%$=79_P!:/_+\
M2GIM_6IU5]XXT6SU"\LG&K3SV;B.X^R:/>7*1L5#X+QQ,N=K*<9[U='BK0FN
M='MTU2V>?6%+V$:-N:X4(7+*!_#M!^8\=!U(%<W8^$]8D\0^*;O^W]7T:VO;
M]98([-;1UE06\*%SYD,C [E88R/N@X[FU=^$HK"^\')H5BB6NFWA:XDW#>(A
M:SQJ68G<YW.!W/S9]:%LK^7Y:@^MO/\ X!OV/B+2K[5M5TRTO$DO]+*"\@VD
M-%O7<IY'(([C([=:R6^('A_=;B"34KLW%K%>I]BTF[N?W,F=C-Y<3;<[6P&P
M>#Q6!>>$M5&I^)=;TV)(=:%^;C3V=QMNX#;0))"Y!^57:(C)Y5E5L<<T?!?@
MKQ!;RV37&I:EH/E>'].LI/L1M)=\T7F^8C>9')]W<N"N =QY..$M5=^7XIW_
M ,OZ0-)7_KJOZ_IGI.D:O8ZOIBZA83B2U.X%G5HRA4D,KJP#*P((*L 00<BH
M]-U[3=3N4@LK@R2O;K=J#&Z[HF8JK@D 8)4X]1ST(-86N>&'MOAOKNC:*\\]
M[=VUPWFS2#S+B>0,69B  "Q)Z  9X  Q7-ZWH^J>(=136/#\<$FC2:3;HUG+
MA5O=DS,UJYW H-I(((P6PK?*'5C[273_ (#_ %0NE_ZW7Z/_ (-KGJE%>+^%
M? VH0>.'U'5-+OH5>XN)9;AI+!;=K5T81P-L0SOM5D0Q,WE@QY5B%4'8^%UD
M=1O_ +4+B"]T/0?-T[1+B)MZ3(QRT@;HVU!'#N&>4DYYII7^Z_\ 7X?T@>AZ
MA17B-MX*UMOB%#KC:+-;7*ZI<R7-RCVGE2V[I*B%9,M<MP8\H[*B]%3 &+&B
M^ =3\/Z)IK:+HMM#JA\+W%I??OA%Y]X1#Y:R/&P9B,2@.&^4=&&14K6-_P"M
MF_TM\RK>];^M[?\ !/7]0O(-/L+F\O'\NVMXVFE?!.U5&2<#D\#M4EO,EQ!'
M-"VZ.10ZG&,@C(KQ?PAX&U32K'Q?#::1=65KJ>C+;V]O<?88BUP!,"-EMA!D
M.F&8LQ'WFXP%C\%:FUC>?V9X9&CVQM+6&^T[SX5.KO','EYC<K\T8=-\A5G\
MS#@ 9I];>GZW_)?>3T7]=O\ -_<>O7^IVEA<6,%U*4EO93#;J$9M[A&<C@<?
M*C'GT]<5/:SI=6L4\0D5)4#J)8VC< C/*L RGV(!'>O+=)\*:G'?:?/9Z)_9
M&E)K$EW%I?F1#['$;&2(G:C%%WRMG8A(&[<>2V,VU\&W]O8:/'KGA#_A('BT
M.SLK=?M4*?V;<1AO,.]G#1Y)0^9#O;]WTX7+2_3\F-_U]]CVFBN3\=Z _B&'
M0+:6S2ZM8=2CFO(F<%?*$<@.<XW+E@".<@\C&:Y33/ ,FEW.GWFG:-;07UIK
MMQ)%*&0&&P83!8U.<K%\X_=KP"<[<YJ4^_\ 6W^?X,3VO_77_+\4>KU4GU&U
MM]2M+"67;=W2R/#'M)W!,;N<8&-PZ^M>!6'P\\11VVI36^AW-E>WNAWUI=(9
M;-$ENI-C)L=&,LB[@^'GD9^YQDD^A>*?!NH/+H-MX0%MH]M:6EY&[Q(%5&D"
M$+\K*PWL#N=?FQN((8A@WHD_ZZCMK;^NAZ-5:\O[:RDM4NI/+-S*(8B5)!<@
MD G&!G!QG&3@=2!7B]KX&U6;QG;:E)H-[IRK/:R6@M)M/2'3X4"^9"7\MIU!
M82';%\L@D ;82^-J3PV=+\(7EL;&&W\0ZQKA9)%VF64"^::)RPR2$B!?&?E
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MW1E^\&4'(([YZ5D>"/#<^C:3JD=Y'%;W.H3M,XAO[F^*_(J M-.=SMA1R%4
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M4%U_!4]5KPXV?C0 BFI5JNAJ=: )ATHH'044 ?GA<_\ 'Q+_ +Y_G452W/\
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M07>DQZCHD6G0ZMIK:E:/'>F=MBF,,LBF-=I_>J1@MD=<=*$KNW]=?\F#VO\
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MY,[RBO*O$/B;Q',VL75O=1Z0FC:,NL1VT#172WFYI2JRNR?=V0X(B(P7.'8
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M%/5< BG:MX_\9Z2UCY&HO?\ ]I^'H-5F9[.-AIY>>-))(T10S(B.QPY;IDG
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MQ;"^;(&QD9[5W?V-?'/PEUC3CK2Z\MY%<6\&HFS-N)""?+; PKX8#YT 5L9
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M""#[BH-#T:PT*Q:STFW%O:F62?RPS$!G8NV,DX!8DX' SP*=WS<S_K?_ #_
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MH7L*V?V:,JV96!698@S!?F*NH#=.1CURXFBMH))[B1(H8U+O([!510,DDG@
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M:OD^>EC)')_>R4;&<;P:]GHH>JM_7S_KL+JV?-UMIFM1^)H+_P 2KXSN8O\
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MY\9K0E_74WPFE9)GT8]%M_K3]*'HMO\ 6GZ5X![A9HHJ.9RNU5P78X&>GUH
MDHJ'R7/WIY,^V /Y4>0W_/>7\Q_A0!-14/D-_P ]Y?S'^%'D-_SWE_,?X4 3
M45#Y#?\ />7\Q_A1Y#?\]Y?S'^% $U%0^0W_ #WE_,?X4>0W_/>7\Q_A0!-1
M4/D-_P ]Y?S'^%'D-_SWE_,?X4 345#Y#?\ />7\Q_A1Y#?\]Y?S'^% $U%0
M^0W_ #WE_,?X4>0W_/>7\Q_A0!-14/D-_P ]Y?S'^%'D-_SWE_,?X4 345#Y
M#?\ />7\Q_A1Y#?\]Y?S'^% $U%0^0W_ #WE_,?X4>0W_/>7\Q_A0!-14/D-
M_P ]Y?S'^%'D-_SWE_,?X4 345#Y#?\ />7\Q_A1Y#?\]Y?S'^% $U%0^0W_
M #WE_,?X4>0W_/>7\Q_A0!-14/D-_P ]Y?S'^%'D-_SWE_,?X4 345#Y#?\
M/>7\Q_A1Y#?\]Y?S'^% $U%0^0W_ #WE_,?X4>0W_/>7\Q_A0!-14/D-_P ]
MY?S'^%'D-_SWE_,?X4 345#Y#?\ />7\Q_A1Y#?\]Y?S'^% $U%0^0W_ #WE
M_,?X4>0W_/>7\Q_A0!-14/D-_P ]Y?S'^%'D-_SWE_,?X4 345#Y#?\ />7\
MQ_A1Y#?\]Y?S'^% $U%0JS1R*DC;PW"L1@YZX-34 %%%% !1110 45!EYF;8
MY1%)7( R2.O6E\AO^>\OYC_"@":BH?(;_GO+^8_PH\AO^>\OYC_"@":BH?(;
M_GO+^8_PH\AO^>\OYC_"@":BH?(;_GO+^8_PH\AO^>\OYC_"@":BH?(;_GO+
M^8_PH\AO^>\OYC_"@":BH?(;_GO+^8_PH\AO^>\OYC_"@":BH?(;_GO+^8_P
MH\AO^>\OYC_"@":BH?(;_GO+^8_PH\AO^>\OYC_"@":BH?(;_GO+^8_PH\AO
M^>\OYC_"@":BH?(;_GO+^8_PH\AO^>\OYC_"@":BH?(;_GO+^8_PH\AO^>\O
MYC_"@":BH?(;_GO+^8_PH\AO^>\OYC_"@":BH?(;_GO+^8_PH\AO^>\OYC_"
M@":BH?(;_GO+^8_PH\AO^>\OYC_"@":BH?(;_GO+^8_PH\AO^>\OYC_"@":B
MH?(;_GO+^8_PH\AO^>\OYC_"@":BH?(;_GO+^8_PH\AO^>\OYC_"@":BH?(;
M_GO+^8_PH\AO^>\OYC_"@":BH?(;_GO+^8_PH\AO^>\OYC_"@":BH?(;_GO+
M^8_PH\AO^>\OYC_"@":BH?(;_GO+^8_PH\AO^>\OYC_"@":BH?*=>4G?/HP!
M!_2GPOYB9(P02"/0B@!]5+__ )9_4U;JI?\ _+/ZF@"..IUJ".IUH L+T%%"
M]!10!^>%S_Q\2_[Y_G6_X.GCB><7-S;P0HR3 2'YV==P&WD \.V<D#'J<"L"
MY_X^)?\ ?/\ .MKPQ8+=K*\GV?'FQP*)8R_S,'(Z$8X0_I7TT[<CN?.0OS*Q
M0UZ=;C59GC4)$H2.-1()-JJH51N &> .<5[?^R5_R$?$O_7*#^;UXQXJ8-K&
M5"*IM[?:$R!M\E,<'IQCCMZGK7L_[)7_ "$?$O\ UR@_F]<V*_W=_(Z</_O"
M]6?1CT6W^M/TH>BV_P!:?I7A'M%FH9?^/F#_ (%_*IJAE_X^8/\ @7\J )J*
M** "BBB@ HHHH **** .:UOQ=#INIS6%KI>JZK<VT*W%TNGQ(YMXV)VDAF4L
M3M;"(&;C[O(R/XWT.'Q4WA^\NTL[_P B&:(73I$)_-+A4C#$,S_(<KCN*KZM
MX7U$Z]?:KX=UF/2[C4((X+LRV0N<B/=L>/YE"N Y&6#KP/EXYH^(?A]_;&K:
MI?-JA1[V"PA^:W#%?LMP9LY##._., #'7GI1'I?N#ZV_K;_@G1+XJ\/--?Q+
MKVDF6P4O>(+R,M;*.ID&?D [DXH7Q7X>;3VOEU[239+-]F:X%Y'Y8E_YYELX
MW?[/6N U3X4:CJ]]JESJOBN2ZDO+"\T]#):N?*CG92#M\[9E=N/D5 PQGD9H
M\7^"-5L=<3Q!X<C%_=G4TNC;+#%^ZC%G]G8!9)$5R< YWIMST;&"K^[?K^M_
M\AVUT\_R/0KCQ-H5M:V5S<:UID5M?$+:2R7<:I<$]!&2<-^&:L:EJ<&G36,=
MQ@?:YC"K&6- I",^?F8%N%/"ACWQ@$CR_3_A*;WP_P"$H]9N6BN-/TPZ=?6B
M33*D\3D,\>^&6,@Y&"3O4_W3@&NZ\0^%H]5&@I#<FVBTF<RHI0R;QY$D07);
M(QYF<\]/?-.6B=M[_P!?U_3%9O4T=&U_1M<,HT75M/U$PA3)]DN4FV!AE<[2
M<9'(]:YR^^(EG9:G?V\ND:L;*QOHM.N=140>1'-((RHV^;YI'[U!D(>OM4G@
MKP.OAB[LYUOA<?9]%M=(($'E[_)+GS/O'[V_[O;'4U@:K\*?M_BC4M5%YI"?
M;;^&^^T-I&Z_M_+$8V17/FC8#Y7]PXW-3TYO+_@_Y:DZ\OG_ ,#_ #T.Z/B?
M01<7\!UO2Q/IZ&2\C-W'NME'4R#.4'N<5&?%OAP:9)J)\0:0-/CE\A[HWL?E
M))_<+[L!O;.:X74?A(]_:WEG+KB+9&*_CL@MB!+$;MBSF5]_[T#)P $[9R1F
MK/B#X5)JNL3ZE#JTEK<-?1WD:QK+&J 6RP,A,4L;G*J2"&7&<$$9ROZ_'_(I
M[Z>?_ .V\1:]::#X8O\ 7;CS)[&SMFNF^SX9G0#/RY(!R.G-<MI_Q7\/ZA?>
M%+2VCOFF\11/-;YC4"W"!LB;YOE.4<8&[E3Z5K:MX-L[GX=7?A'3&.GV<UD]
ME$Q+3^2K C/S-EL9[FN2TWX/QZ;XC_M:SUN6-EOS>0Q_9@?(4Q3*8TRV /,G
MDDZ8[8[T:<WE_7_#_(3^'3?4[F'QAX9FL[B[A\1:-):6SK%/,M]$4B=CA59M
MV%)/ !ZU%H_C+1-6OKBVM;V'='<+;0NTJ;;MFA68&$ACO&QP>/0]N:X>W^$E
MZ\UW<:OXG:_NKI[!Y97M9#N^RSF4</,^-P."%PH/(7G%;]K\/([3XAW?C"VU
M%TU"YGS(C1ED-N8HT:+&[ .Z-7#@ ]B"*<?/^MO^#_6@/K8Z4^)="$NH1'6M
M,$NG*7O4^UQYM5'4R#/R#W.*+/Q+H5[/:PV6M:9<372LUO'%=QNTP4D,4 /S
M $$''0@UY\OP:LETO7;,ZC,[WL5U#9W$CSN;-+@EI 8S,8GR3G*K'TYR>:Z+
MQ%X&_M34=*O+#4)-+N+18XI[BU:9);B%#D1?)*J8^]]]9,!C@ \TETOY?U\M
M ?EY_P!?/4ZO5+U=.TVYO'AN9U@C,ABMHFEE?'947DD^E9?ACQ-!KPU%/L=Y
MI]WI\PANK6\\O?$2BN.8W=""K \,??%376D7$/AF?2]!U&>QN3$T<%[=,]Z\
M+'^(F1RSD9XW-Z=ABL;P'X3U'PKHD>G?VEI\^9VFN+F.PD26X+*=SNSSOF4M
MABYR,#&WH0=PZ(K^$OBAX>\2:9=:DDR:?ID#K&;J^N[549F)"@A969"<<"0*
M3D8%=)I?B30]7N/(TK6=-OI_*$_EVUTDK>63C?A23MSQGI7%7?PVOM5O8K[7
M?$,=Y?136166/3Q"'BMYS*!(H<AG8D@L-JCLE3:3\-%TZ]M[G^TO.$0U,&,0
M>67^V2B3[VXXVXQG!SUXZ4/17]?RT^_\!Z7T\O\ @_<=EI6OZ/J\TL6DZMI]
M]+",R);7*2LG)'(4G'((^H-<M%\2;22\BB_L/6E@GOIM-M[H_9_+GN(RX**!
M-O&3&P!95'3) YK#^#OAKQ'I.J-<>(K)+2.VT>UTJ$ 1 OY3R'(\N1]PPP&X
M["?[B]*ZKPCX#T?P[<W-\++3[C5Y[NYN3J'V-$G ED9]F_EB &V]>0.@Z4[*
M_P!_Y_Y?TQ='_73_ #_I%33_ (BVUUIS7T^A:U96O]H1Z8KS_9CNG:?R" $F
M8X5^I...1FNDT;6[;5KS5[:V297TR[^QS&0 !G\M),K@G(Q(O7'(/%<Q=_#R
M"\\*/H5W=QSV\FL'5)/-M@R2*;KSS"R%L$$?)D_7':M?P7X2L_";:TFF+;PV
M>H7OVR.VM[<0QVX\J--@"\'F,MG ^]T[DC:VO]?#_P#;?UN2WT_K?_@'2444
M4@"BBB@ HHHH **** "BBB@"&X_UEO\ ]=/_ &4U-4-Q_K+?_KI_[*:FH **
M** "BBB@"&S_ -3_ ,#?_P!"-35#9_ZG_@;_ /H1J:@ HHHH **** "BBB@
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M?^N4'\WKQ+Q%#<V^KS1WL\MQ<;49Y)<[^4! 8'D$ @$=L8KVW]DK_D(^)?\
MKE!_-ZY\5_N[^1TX?_>%ZL^C'HMO]:?I0]%M_K3]*\$]HLU#+_Q\P?\  OY5
M-4,O_'S!_P "_E0!-1110 5R?B"ZU>+7/-MIS%I%K'$TZQS1!W9G.?E:-R>
M.,IGG!/;K*J7&FV-S>0W=Q96TMU!_JII(E9X_P#=8C(_"CJF'2QSWAW4KVXU
M:W^T7WVB*\BN93!L4"W,<JH I !Z,0=Q/(XQTJWK7B.;2=:T^SET>[EM;R=;
M9+U)8M@D96(!4MN_A/.*V+;3[*UN9[FVM+>&XN#F:6.)5:0_[1 R?QKGO'G_
M !\>%O\ L-0_^BY:.B0=3I/-E_Y]W_[Z7_&CS9?^?=_^^E_QJ:B@"'S9?^?=
M_P#OI?\ &CS9?^?=_P#OI?\ &IJ* (?-E_Y]W_[Z7_&CS9?^?=_^^E_QJ:N#
M\17_ ,1(M8N$T#1M"FTU2!#)<7+!V&.20",<YXJHQYG:Y,I<JN=MYLO_ #[O
M_P!]+_C1YLO_ #[O_P!]+_C7B&B^)?C'/XFOK>;0+,Q)GY;F$Q6Z<\;)0<O^
M;?A7?:/>^.9M/U/^W]-TVSF6(&U>QE,C%\\@@AA^/Z&M*E%P5VU]Y$*RF[)/
M[CL?-E_Y]W_[Z7_&CS9?^?=_^^E_QK#VZY;1PF:Y\TM.^51!(0GE'&6"*/OC
M^Z.H&?6I%=Z_]ENX94F^T1649BF$0 ED).6^Z0&Q@%<<$9Q@BL37^OT.EDN'
MCC9V@<*HR?F'^-.\V7_GW?\ [Z7_ !K/LXK^+2[P:G,LLAW%,$,57:."0B \
MY/W1U[UK4 0^;+_S[O\ ]]+_ (T>;+_S[O\ ]]+_ (U7UN34(M+G?1H()[\
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M_7-?YM0!-1110!#<?ZRW_P"NG_LIJ:H;C_66_P#UT_\ 934U !1110 4444
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M'H>;V?PU:&X"K)X=7R[B"YV)H>(UV%_F2,S%5E(8_O#NYY"YI;/X7SVW]O\
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M@"Y14/D-_P ]Y?S'^%'D-_SWE_,?X4 345#Y#?\ />7\Q_A1Y#?\]Y?S'^%
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M-Z\ KW_]DK_D(^)?^N4'\WKEQO\ !E_74Z,)_&B?1CT6W^M/TH>BV_UI^E>
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MZ%1VRKF;Y1_K#V^E3[%_NC\J &?:(?\ GK'_ -]"C[1#_P ]8_\ OH4_8O\
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M=VRR>3MB=5D  #,NX?ED?SI=!]2'2_\ CS'^^_\ Z&:M5GZ8MQ]C&)8OOO\
M\LS_ 'C_ +56MMQ_SUB_[]'_ .*H FHJ';<?\]8O^_1_^*HVW'_/6+_OT?\
MXJ@":BH=MQ_SUB_[]'_XJC;<?\]8O^_1_P#BJ )J*AVW'_/6+_OT?_BJ-MQ_
MSUB_[]'_ .*H FHJ';<?\]8O^_1_^*HVW'_/6+_OT?\ XJ@":H8?^/B?ZK_*
MC;<?\]8O^_1_^*J&)9_/FQ)%G(S^[/I_O4 7**AVW'_/6+_OT?\ XJC;<?\
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M_OT?_BJ )J*AVW'_ #UB_P"_1_\ BJ-MQ_SUB_[]'_XJ@":BH=MQ_P ]8O\
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MW?UH\F/^[^M5*3D[L(Q459$E%1^3'_=_6CR8_P"[^M(9)14?DQ_W?UH\F/\
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M_,@'@C2I#F_DO;]O[US<L3^F*TK7PYHUKCR=,M 1T9H@Q'XGFFZGX@T_2O\
MD)WVG69])[M8S^1KD[[XN^%K>3RH+LWTYZ16D;R$_0[0#^=+VF)J[-M?,OEP
MM'>R^X]"1510J *HZ # %+7G4/C[Q!J9']@_#_6[A6^[)>,+53[Y8$'\ZE\G
MXKZF/DM/#NB(?^>DC32C\BRG\JCZM/[32^8/&4_LIOT1TWBJX:&RA"S6\9:>
M(!9>K'S%QCD=.I]JV(]WEKO*EL#)48!/M7A_C[X=ZW+]EU#QAXX@,[/'"L6Q
M(%*F0!MH# ?*&+$[>@YKK[3X7WS6L+6?C7Q2;8H#$8M7RA7'&W"XQCIBJ="F
ME\?X,CZW._P?BCT.BN!/PV\2'KXXU[_P)'^%)_PK7Q)_T.^O?^! _P *7L8?
MS_@Q_6I?R?BCOZ*X#_A7?BY.(?'6IA.PD"R'\S2?\*]\9?\ 0]W_ /WZ2CV,
M/YU]S_R'];E_(_O1WJ_ZY_\ =']:?7G2>!?&RW4B6WCRZ6554L9;2.0$'/8G
MKQ4W_"#?$+_H?_\ RF1?XTO81_G7X_Y!];?\C_#_ #._HK@/^$'^(8Y7Q^">
MV=,B_P :/^$2^)__ $/%G_X*X?\ XFCV$?YU^/\ D'UM_P C_#_,[^BN _X1
M+XG_ /0\6?\ X+(?_B:!X9^**#:/%>E2@?QO8H"?P"XH]@OYU^/^0?6_[C_#
M_,[^BN!_X1OXI?\ 0SZ/_P" :_\ Q- \/?%2/E?$&A39[26Q7'Y"CZNOYU^/
M^0_K:_D?X?YG?45P7]B?%;_H+>&_^_+_ .%+_8WQ67D:GX88CG:T4@!]C@4?
M5_[R_KY!];7\K_#_ #.\I=-\O^U'VJXDVC<2K $<XP3P>_3\:X/^S_BU_P ]
M?!O_ ),?X5F:)I'Q0B^)&FSZU?6*Z7N)F%K+F!HPO*A#\V?0D=><U4</U<D1
M/%J2LHL]JHHHK,D*AMO^6O\ UT-35#;?\M?^NAH FJI?_P#+/ZFK=5+_ /Y9
M_4T 1QU.M01U.M %A>@HH7H** /SPN?^/B7_ 'S_ #J*I;G_ (^)?]\_SJ*O
MJ3YH*]__ &2O^0CXE_ZY0?S>O *]_P#V2O\ D(^)?^N4'\WKEQO\&7]=3HPG
M\:)]&/1;?ZT_2AZ+;_6GZ5X![I9J&7_CY@_X%_*IJAE_X^8/^!?RH FKS;QE
M?:9>>()H(=2TR*:.!8YWFU:.WP09%V &.3Y@'<'IPX[@$>DUS_B"QUBXN)3I
MDT8CF@$09[IXC;.&)\Q552'/*\$C[N,X8T+=#Z-&^OW1]/7--::-9DA:1!*Z
MEE0L-S 8R0/09'YBF7*W#6KK:RQ1W&,+)+&74'U*AE)_,5EC2ROB2TU'R8FF
M^RR17%PJ[2Q)CVC!)(7Y6(&2!SW/)U)6QHVVH65U<SVUM=V\UQ;G$T4<JLT9
M_P!H Y'XUYK\9[JZ@U#0!!-<1;9C) (QPTP5L?5@=H [[CZUT_AW3;VWU:W^
MT6/V>*SBN8C/O4BX,DJN"H!)Z*2=P')XSUJAX^TV5M?\,7O]IWXC.K0H+0&/
MR1^[D^;[F[/_  *A='_7]=1]T=TF2HW=<<UA^(/"NE:Y\]W;[+GM<0G9(/Q[
M_CFM?R&_Y[R_F/\ "CR&_P">\OYC_"JC.4'S1=B)0C*/+)7."GL/$_AWF$_V
M[IZ]ONW"C]=WZGZ59T;Q+IVJMY<4IAN0<-!,-C@^F._X5VGD-_SWE_,?X5BZ
M]X2TO71F_C<SXPLZ$+(O_ @.?H<BNE5X3TJ+YK_+_AC!T9P_ANZ[/_/_ (<*
MS-->[;4+Y+BY$D<+!%41A>JALY_'%8^H:7XE\+PR3VEQ_;6EQ*7:.0[;A%'7
M'][ ';\%K"\-^/K&^N+Z;RKO]ZZLJPXD/"@<\#!XS6JPTYQ<Z?O+R(^LPB^6
MI[K\STBBN77Q!>SC-CH&M2CL7BV _C@U(LOBVYY@T)8!ZSW2G].#4>QDM[+Y
MHKV\'M=_)G245S\>D>-+@9DN]+M1Z*&8_P B*G3PCKTXS>>)Y%_V8+<+^N1_
M*ER06\U^/^0_:2>T'^'^8SQI<6\/AR]6XN?(,D3)'AL%VQPOOGO[9JYH+K)I
MX:.X$Z%F*D3>=M&>%+Y.2/K7/>,? ,4?AK4;^?5]1NKJSMI9XS,X9,JA;&#R
M,X]:U5\"7VGQJFA^(KR&-!A8KE!*O] /RJK4;:3U]&+FJ]8:>J-RBN=DM?&=
MA]^"RU*,=X)/+<_GC^55V\4-:<:QIFJ6)'5C'O0?\"P/Y4E1D_AL_1_TP]O%
M?%=>J_I'5\BCI6'9>(=(O<>1JD>3_#(P0_DP%:RKO4,LS,IZ$$'-1*$HZ25C
M2,XRUB[DN.<T5D3VY?Q#;@W%R%%NS[5F95)#*!E0<'J>HK3\L_\ /1_T_P *
MDHDHJ/RS_P ]'_3_  H\L_\ /1_T_P * )*1CA20"2!T'>F^43_RTD_3_"CR
MC_ST?\Q0,Q?#]Q>2WU^+Z&:)OD?8[(53.?E7:3^??VZ5NU#%&3O_ 'C#YO\
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MF_V&UG0R,0Q9F<A58A5!8G"CG"C@9/K6UY__ $RE_P"^:;MT)5^I-14/G_\
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M110!#9_ZG_@;_P#H1J+4[^RT^V\W4KB&WMV.PR3L%3)[$G@9]ZEL_P#4_P#
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M9E7[[GK_ +1JU]J@_P">J?G2 FHJ'[5!_P ]4_.C[5!_SU3\Z )J*A^U0?\
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M:C?/_P \4_[^?_6H FHJ'?/_ ,\4_P"_G_UJ-\__ #Q3_OY_]:@":BH=\_\
MSQ3_ +^?_6HWS_\ /%/^_G_UJ )J*AWS_P#/%/\ OY_]:C?/_P \4_[^?_6H
M FHJ'?/_ ,\4_P"_G_UJ-\__ #Q3_OY_]:@":BH=\_\ SQ3_ +^?_6HWS_\
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M^=15+<_\?$O^^?YU%7U)\T%>_P#[)7_(1\2_]<H/YO7@%?0'[)/_ "$/$O\
MUR@_F]<N-_@R_KJ=&$_C1/HQJ+?_ %A^E*U$'^L/TKP#W2>BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MYZ)_WT*/.B_YZ)_WT*Y+R*/)H ZWSHO^>B?]]"CSHO\ GHG_ 'T*Y'R*/(H
MZ[SHO^>B?]]"CSHO^>B?]]"N1\BCR* .N\Z+_GHG_?0H\Z+_ )Z)_P!]"N1\
MBCR* .N\Z+_GHG_?0H\Z+_GHG_?0KD?(H\B@#KO.B_YZ)_WT*/.B_P">B?\
M?0KD?(H\B@#KO.B_YZ)_WT*/.B_YZ)_WT*Y'R*/(H Z[SHO^>B?]]"CSHO\
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M>3[4>3[5?\NCRZ *'D^U'D^U7_+H\N@"AY/M1Y/M5_RZ/+H H>3[4>3[5?\
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MNE1_\*5^('_0 _\ )RW_ /CE%%=_]HU>R_KYG#_9]/N_Z^0?\*5^('_0 _\
M)RW_ /CE>P_LZ^!_$7A"]UR3Q%I_V-+F.)8CY\<FXJ6S]QCCJ.M%%15QM2K%
MP:6I=/!PIR4DV>W8I,445QG6)BC;110 FRDV'THHH 3RSZ4GEGTHHH /+/I1
MY9]*** #RSZ4>6?2BB@ \L^E'EGTHHH /+/I1Y9]*** #RSZ4>6?2BB@ \L^
ME'EGTHHH /+/I1Y9]*** #RSZ4>6?2BB@ \L^E'EGTHHH /+/I1Y9]*** #R
MSZ4>6?2BB@ \L^E'EGTHHH /+/I1Y9]*** #RSZ4>6?2BB@ \L^E'EGTHHH
M/+/I1Y9]*** #RSZ4>6?2BB@ \L^E'EGTHHH /+/I1Y9]*** #RSZ4>6?2BB
M@ \L^E'EGTHHH /+/I1Y9]*** #RSZ4>6?2BB@ \L^E'EGTHHH /+/I1Y9]*
M** #RSZ4>6?2BB@ \L^E'EGTHHH /+/I1Y9]*** #RSZ4>6?2BB@ \L^E'EG
MTHHH /+/I1Y9]*** #RSZ4>6?2BB@ \L^E'EGTHHH /+/I1Y9]*** #RSZ4>
M6?2BB@ \L^E'EGTHHH /+/I1Y9]*** #RSZ4>6?2BB@ \L^E'EGTHHH /+/I
M1Y9]*** #RSZ4>6?2BB@ \L^E'EGTHHH 7RSZ4>6:** %V&EVFBB@!<4N***
, #%+110 4444 ?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>22
<FILENAME>image00023.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image00023.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  8$!08%! 8&!08'!P8("A *"@D)
M"A0.#PP0%Q08&!<4%A8:'24?&ALC'!86("P@(R8G*2HI&1\M,"TH,"4H*2C_
MVP!# 0<'!PH("A,*"A,H&A8:*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H
M*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"C_P  1" &? TX# 2(  A$! Q$!_\0
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M_I4_WS_RT/K4?VZ[_P"?J?\ [^&H[G_CXE_WS_.HJ^HLCYJ[+/VZ[_Y^I_\
MOX:]Q_92N)IO%.M"::20"R! 9B<?.*\%KW7]DS_D:M;_ .O)?_0Q7/BU^YD=
M&%?[V)]/T445\^>Z%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110!^>%S_ ,?$O^^?YU%4
MMS_Q\2_[Y_G45?4GS05[K^R9_P C5K?_ %Y+_P"ABO"J]U_9,_Y&K6_^O)?_
M $,5S8O^#(WPO\:)]/T44R>5((9)93MCC4NQQG  R:^?/>'T5R6E_$/P]JUK
M]ITM]4O;8DKYMMH]Y(F1U&5B(S5W4/&&C:9H,FLZG-=66GQR")GN;&>)@QQC
MY&0/CGKC%6Z<T[-$*I%ZIG045RD_Q \/VUF+RZDU.WLR%/VF?2;N.( ]"7:(
M* <CG/>MF_U[2K#1AJUWJ%M'II176YW@HX;[NTC[V>V,Y[4.$ENAJ<7LS2HK
M!TCQ=HNJZJ^F6MS*FHI'YIM;JVEMI2G]X+(JDCW%/U/Q7HFF:[8:->ZA''JE
M\<06P5F9OK@':#V+8SSZ4N25[6U#GC:]]#;HK'\0>)M(\/M;)JMXL4UTVR"!
M$:664^B1H"S=1T'>I- \0:9K\,TFDW0F\B0Q3(R-')$X_A=& 93]0*.65N:V
M@^97Y;ZFI15'6]7T_0M-EO\ 5[N*TLXOO2R' 'H/<^PYK-TWQAHNHZC#80W$
M\5Y.AEABN[2:V,RCJ4\Q%W^ORYXH49-72!R4=V=!117*6OQ \/7DUU%837]\
MUK*89FL],NKA4<=1N2,C]:2BY;(')1W9U=%-B<2Q)(H8*P# ,I4\^H/(/L:=
M2&%%%% !115/6-2M-'TNYU'4I?)L[9#)+)M+;5'4X )/X"@"Y17)+\1/#K:>
MNH>=J*Z>R[Q=MI5VL.W^]YABVX]\XKI[.Z@O;6*YLYHY[>90\<L;!E=3T((Z
MBJE"4?B1*G&6S)J***DH**** "BF3RI!#)+*=L<:EV.,X &37(V?Q)\-7VGO
M?V4^HW%BF=UQ%I-V\:XZY818&.]4HRELA.2C:[.QHJCHNK6&N:;#J&DW45W9
MS#*2QG(/J/8CN#R*O4FFG9@FFKH***Q_%7B;2/"FG)?Z_=_9+5Y!"K^6\F7(
M) PH)Z T)-NR&W979L45F2Z_I46MVNCO?0C4[E#+%; Y<J 3N([# /)QG%0V
M_B?1[CQ1<^'8;O=K-M$)Y;?RG&U#MYW8VG[R]#WI\LNQ/-'N;-%%%24%%9^O
MZS8>'](N-3U>?[/8VX!DEV,^W) '"@D\D=!4^F7UMJFG6M_8R>;:7,2S1/M*
M[D89!P<$<'O3L[7Z"NKV+-%%8_BKQ-I'A33DO]?N_LEJ\@A5_+>3+D$@84$]
M :$FW9#;LKLV**12&4$=",BEI %%%% !1110 445FV^O:7<:Y/HUO>PRZG;Q
M^;-;H<M&N0/F[ \C@\\TTF]A-I;FE1112&%%8TOB?1XO%$/AR2[QK,T7GQV_
ME/RG/.[&W^$]^U;--IK<2:>B"BBBD,***R?$_B+2_"^EG4==NOLMF'$9D\MG
M^8]!A03^E"3;L@;LKLUJ*9!*D\,<T1W1R*'4XQD$9%/H:MHP3OJ@HHHH **H
M:YK&G:%8->ZO>0VEJIV[Y6QDGH .I/L.:R$\<Z ;RUMI[JYLYKI@D OK&>U$
MK'H%:5%!/T/>J4)2U2)<E'=G3445!J%Y!I]C<WEX_EVUO&TTKX)VJHR3@<G@
M=JDHGHK-\.ZYI_B/2(=4T:X^TV,VX1R[&3=M8J>& /4'M6E3:<79B34E=!11
M12&%%%<Q/XZT&'6[S2!/>SZE9X,\%KIUS<&/(!!)CC(QR*<8N3LD)R45=G3T
M5G:1K-MJQE^RQ7\?EXW?:K">VSG/3S47=T[9QWZUHT--:,$T]4%%%%(84444
M %%%% !16-KWB?1] O=,M-6N_L]QJ4OD6J>4[^8^5&,J"!RR]<=:V:=G:XKJ
M]@HK!\,^+]"\3W%]!H=^MU-9,$N$\MT*$DC^(#/0\C(J;0/$ND^()M0BTB[^
MT/83&WN1Y;IY<@SD?,!GH>1D4W"2W0N>+ZFQ1114E!15/6-2M-'TNYU'4I?)
ML[9#)+)M+;5'4X )/X"C1]2M-8TNVU'39?.L[E!)%)M*[E/0X(!'XBG9VN*Z
MO8N4444AA1110 44C,%4LW  R:R?#'B/2O%&G-?Z%=?:K19&A+^6Z?,,9&&
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M;_2?V@+31X]9U.XTF33&G6TN+R254/S#G<26Y&06R>>O KLOB_\ \DQ\2_\
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MD8W$%"<$_*P(.>179:=X TJRM]=#S7MU>ZU&\5[?W$BM.ZL",#"A5 !X 7'
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MO_":ZH]OYCG5I-0-I:6VT G8B%4< <[2FXY]P:^@XX]L*QN[2D*%+/C+>YP
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M'L;J.*:%)X$D6.;[Z J#AL]QWI5Z"IJZ_K]1T:SF[/\ K]"Y1117,= 4444
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M&?\ H!V'_?H4?\(1X9_Z =A_WZ%=%11[27<.2/8YW_A"/#/_ $ [#_OT*/\
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M_O&IZ "BBB@ HHHH **** "BBJ.O:I#HFAZAJMVLCV]C;R7,BQ@%BJ*6( )
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M.T(.[9P/J:U/^$CT3^VAI']L:;_:Q&19?:D\\C&?]7G=TYZ4 :M%<IXB\?\
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MYH&D%WJE[;K;A%",K00,JW"X7(#.F"<9KV*BFW=W?];?Y(27*K(\5C^%^O\
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M)*R"BBBI&%%%% !1110 5FWG_'\/]T5I5FWG_'\/]T4 6X/NBIQ4$'W14XH
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M1@;@<#(X!JW*[OZ_C_D1;]/P1POC#Q=J'AOQAHUM<P0-H=_M@5HPCW+SL^W
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M^7ZEJBH?](_Z9?K1_I'_ $R_6LS0FHJ'_2/^F7ZT?Z1_TR_6@":BH?\ 2/\
MIE^M'^D?],OUH FHJ'_2/^F7ZT?Z1_TR_6@":BH?](_Z9?K1_I'_ $R_6@":
MBH?](_Z9?K1_I'_3+]: )J*A_P!(_P"F7ZT?Z1_TR_6@":BH?](_Z9?K1_I'
M_3+]: )J*A_TC_IE^M'^D?\ 3+]: )J*A_TC_IE^M'^D?],OUH FHJ'_ $C_
M *9?K1_I'_3+]: )J*A_TC_IE^M'^D?],OUH FHJ'_2/^F7ZT?Z1_P!,OUH
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MP%HJ'-Q_=B_[Z/\ A1FX_NQ?]]'_  H FHJ'-Q_=B_[Z/^%&;C^[%_WT?\*
M)J*AS<?W8O\ OH_X49N/[L7_ 'T?\* ,KP;_ ,@5O^OR\_\ 2F2MNN>\'F?^
MQ6PL6/MEWU8_\_,GM6WFX_NQ?]]'_"@":BH<W']V+_OH_P"%&;C^[%_WT?\
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M FHJ'-Q_=B_[Z/\ A1FX_NQ?]]'_  H FHJ'-Q_=B_[Z/^%&;C^[%_WT?\*
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MC97KZWIBV5[((K6X-W&([ASD!4;.&/!X&>E &M1110!SO@__ %_B'_L*R_\
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M<>&X?%F@G2KEXU@:X@FD$D0E618Y5D*%20"&"[?QZ'I3/B!_R++_ /7U:?\
MI3'7153^%>O^1*^)^G^9RFM>"=.N/#:Z3H,%CHBPW<-]"+>S40B:.17!>)=H
M8$J,C(/N#7,3?"NY,4TD&NVZ7]ZE[%?22::'A=+ID:3RHO,'ED;!@DOWW!C7
MJ5%3_7WZ,M-H\WU#X6PW.AZGIT6K3Q?:+VUO;:7:X:%K>**- Q1U9L^5DE60
MY/!!&:K:I\)HY+#R=$U&/3Y9[&[L+MKB&6]$HN"&DD4R2[U<LN>78<D<]:]1
MHH>N_P#6EOR$M+6Z?\.8UYX>M;_2K*QO)[]5M450]G?3V;,0N.3"ZDCV)(HN
M=!B?2;+3X)[A8K6XAG5[B5[EV\N428+R,6.<8R2<?ABMFBFVV[OU$DDK' 6O
MP_N-*OKB\T+5XH)1=B>SBN[/SXK:/R?*,6U9$) R=I#*5&%Y'71C\%HNG0VI
MNPQ32[C3F8P#!,Q5F<#/ !4X3T(&>*ZZBIM_7RL4G9W1SMUX6A?P;J>@6]U=
M*M];2P&>XGDN60R(5)'F.3@9R$! ';%1^)_"QUM]ZWHMV&EW>FC,.\?O_*^?
M[P^[Y7W>^>HQ73455];_ -=A1]VUNAPE_P""=4GTF:WM=>CM;FYO6O+F6*WF
MB63<BJ5'E3I(O*@C$G3@AJ;<?#UIO#^EZ.-5/V6TTR?3)7:%C),DGE[6#"0%
M6!C7/7.3]WJ.]HI=+?UM;\@6G]?,\\TGP#JFF(MS!K=H^L1W'G)<W%O=7,94
MQF,JRS7;OG!."LBX]""<]1H^@1V/A*TT*:>1XX;=;=I;9FM6( QE2C!D_P"
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MHCYZO_$EZLFN)1*P8)M( '7.<#%0T45HDDK(S;;=V?;GP1_Y)5X<_P"O<_\
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M)_W[_P#KT 345#LG_P">R?\ ?O\ ^O1LG_Y[)_W[_P#KT 345#LG_P">R?\
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M*A\J7_GX?_OE?\*/*E_Y^'_[Y7_"@":BH?*E_P"?A_\ OE?\*/*E_P"?A_\
MOE?\* ,J^_Y'+1_^O.[_ /0X*VZYZ^CD_P"$QT@>>V?L=WSM']Z#VK;\J7_G
MX?\ [Y7_  H FHJ'RI?^?A_^^5_PH\J7_GX?_OE?\* )J*A\J7_GX?\ [Y7_
M  H\J7_GX?\ [Y7_  H FHJ'RI?^?A_^^5_PJ8< 9.?>@ HHHH *S;S_ (_A
M_NBM*LV\_P"/X?[HH MP?=%3BH(/NBIQ0 4444 <:_CIMVH26_A?7[JQL;B6
MWFO(!;,@,9P[*GG>:P&#P$)/8&M/_A,_#(?3XY/$&DQ2ZA%'-:12W:1R3I)]
MPHK$$[NW%<WH]QXAT-=:LH/">H74MQJ-U<6]U]IM4MBLDA*,Y,WF!>><1D]<
M UPVM>"O%MMX-U3PM8V-Y(C6*6T-QIBV,<%\1 JDW33L9MVX%1L PH4;CU"A
MJE?LORU*LN9KS?YZ'KESXLT^U2T>X#)'<W\NGAQ)$RH\:R,S.RN0JXB;K\PX
M# '.-:/4;*5;,QWELXO%W6Q653YXV[LIS\PV\\=N:\^TSPWJL5IH?VFR\O[/
MXDO-1G5Y8SLMY!<[6.&(.?,3@9//L:C^%&G>=J5[>PW4%[H6EF33M#G@8,C0
M,_F2%6'!"_NX01D?N3SR:I+I_6R_7]29=U_6K_17.KUWQ6NFZHVG6.D:GK-[
M% +FXBL/)S!&20I8RR(,L5;"KDG:>.F=.PUJPU#P_#K5I<"339;?[4DQ!7,>
MW=D@X(X['&.]<EX]G\37>KQZ58:)JLGAUX-UW>:9<6R7$S$_ZE#+-&8EQ]YP
M"QSA=I&ZMMK43^$WTBW\/2V]JVG&%+*:X2%%&W8+<O$SE#C^)<@#H<U+ORMK
M?_A_^!;_ (8I6YDGM_PW]?TQFE>+/M5N+K5-'U#0K!D1TN]3GM4C<N0%4;)G
M8,=PP"!Z=>*LVOC+PQ=M:+:>(]&G:\D,5L(KZ)C.XQE4PWS$9' ]17E^L>!I
MM3@M!X>\%_\ ".6L<MN+ZTD-J/MX6Y@?<WE2,K[%24[G.[YB #N:M[Q%X2U*
MY'C&6RL%-QJ.KZ;=6[B1%,D4/V;<V2>-NR7@X/7&<C-Z-_UW7^?X$*[1W&J>
M)] TF]%GJNN:78W9C,P@N;N.)R@R2VUB#M^4\].#Z4GBO7X/#>@RZK<P7%U%
M&\48BM@ID=I)%C4#<RK]YQU(KQKXF:E!:V_CSPL(;#5-6UZ59+8)>VYE5FBC
M5(W@+^<74H"FR-@<J<KR1Z9\4]'O=9\ W.GZ=:S7=T9;5_)@F6)W5)XW?:Y9
M0IVJV#N'/>I^RGWM_P '[BM.:W]?TRQ)XMN+73=2O]6\,:WIMG86DEW))/):
M/O"#<441SN=Q&<9 ''44S2_&JW6I:99ZAH6L:1_::M]CFO#;M',P3?L'DRN5
M;8&8;@!A3SGBN9N-(N[KPUXET[3_  UXNM;J^TJXMXGU?6UNXF=D(50&NY=K
M$D?-M'N15?PWX<U)-?\ #5Q::-XDTIK#<+V?5]8%Y%)$8BK1QQ_:9L,7V'(5
M,!3S_"6M]?+]?^!_DQ/:Z\_TM^O^:.RB\81W&HF&ST;6+K3UNC9MJ<$4;P+*
M&V,-N_S2JOE2XC*C!). 2'67C?1K_5M4L-/DGO'TVW^T3RVT+2QMRP*1E<^8
MX*D$*#@_+][('"6O@:?3I(K*R\-_\3>/4S=1>)_,A B@:X,I7=O\\?(6C,83
M82Q!.UB:[FXL-2B\;:AJMI:QS1G2(X(?,F$:O,LLC;"0&91AE^;:>O>I6ROY
M_E?\QO=V\OS_ ,B;0/%*:IJ;:==Z5J6D7_D"ZC@OQ%NEBSM+*8I''!P""01D
M<4__ (2[1QXR?PN;N(:LMJ+LQF5/NY/RXW;MV!NQC[O-8/AK3K^;QO)K?]C:
MIH\4ML\=XNIWL=T9V+ QK"%EE\M%_>$@% =R_*>JM\6:5K+>+-1O=,TFWU&*
MZT&2RC%TR&W\X.S!)E+!BC;@/E![YP.:'?3Y_D[?I_6@DM_E^:O^IMMXX\.2
M:-JVI:;J]AJL.EVSW5RFG7,<[JJJ6Z!N"=IQDBI;'QEX;O;.ZNH==TOR[-%>
M[S>1YM<]I?F^0YR.>X->77WAGQ5JU[J5Q-I^LLLWAO4--B346T^-8YI/+*)&
M+=N(SM(&]F(P,D=3<\0>&=7US^QG/A2YL1H5HL*B"^MHY9G$D14VQRRE8S%Y
M@$VP,0H*X+8K^OQ?^2T\]PZ?UY?YO_(]9TG4[#6+%+W2;ZUOK-R0D]K,LL;8
M.#AE)!P>*CGUG3+>SN[N?4;**TLW,=S,\ZJD##&0[$X4C(X/J*Y_X<V>L6L&
MK2:W!+%]HN_-A:[CMEO)%\M%+3FV_=,V5(4CG:%SR*Y3XC>"M7UC6[^TL;%;
MWPUJT:7FHP&[^SF2X@4A(@P^9?,(ARP!QY//6D]+6_K^M?GH..NYZ3HFN:3K
MUN]QH>J6.I0(VQY+.X295;&<$J2 <$<>]/U[5(=$T/4-5NUD>WL;>2YD6, L
M512Q !(&<#N17%^![?Q!8ZCJE[J>GZG- ]O!%$=16P%_(ZL^5WVQ$;1*&!&\
M[LE\=>>E\>6%SJO@?Q#I]A'YMW=:?<00Q[@NYVC8*,D@#)(Z\4JEU%N(4[2D
ME(S;/QOON=,CU+P]K6E0:DXBMKFZ-L\;R%2RJ?*F=E) ."0!VSFKUOXRT(^&
M--U[4-0MM*TZ_C1X7U&>.#[PW!22V-V,\ GI5/P[X(TS38].N95U&>^M8AL%
M[JES=I#)LVDHDDC(K8)&0. 2!P:Y6#2/$VD^%_!MI;Z7<>;9:<8+J?319O?V
MTF(_EC:Y;RA&VUMQ&XG:N,=14K)M+O\ YDPU5V>@OXFT&-M.5];TQ6U( V(-
MW&#= XQY7/S]1]W/44Z^\0Z+I^J6^F7^KZ=:ZC<X\BTFN4267)P-J$Y;)! P
M.HKR3P#X7\0^'/M:ZKX6DUD:CF,?:+BTVV^+R>4-+@XVD3*_[M6(96^0?+5O
MQ-X0\0-K?BR*W37+NQUZ1) ;*;3D@V^4D>R=KB-IDV[,YC#\$$#=D4?U_7^8
M^K7]>O\ P#O_ /A.- CU^]T:]U&VL+ZVN([94O)XXOM#O&C@1 ME^)%'3.36
M@?$>B#7!HIUG31K)Z6'VI/M'W=W^KSN^[STZ<UYQJ/A[6X9?&]C'X;;4D\0)
M#;07SW,&T!;6.(O/N(;:K;F&U&8D-\HXS7L?"FOVWAK_ (1&31WEF_MA;\^(
M?/A\IU%P)_.8;_.\[:-F-A&0/FVT):I/R_X/W?C]X/:Y[)1112 **** "BBB
M@#\\+G_CXE_WS_.HJEN?^/B7_?/\ZBKZD^:"O=?V3/\ D:M;_P"O)?\ T,5X
M57NO[)G_ "-6M_\ 7DO_ *&*YL7_  9&^%_C1/I\U#/]VIC4,_W:^?/>$L_]
M6W^\:GJ"S_U;?[QJ>@#QGXP/H=IXL&H:E%>7%Q#81I*J:?9W,4<9:9T.ZXQM
M)\N7[I .T9YVU[)'_JUQTP*\H^()UB[\1M#?W-C8Z2(5:*W_ +4MH7D*S869
MA+ Y(R\8 ! 5L=2PQW'CVRU._P#!.KVNA3W,.JO:N+9K>41R&3:=H#G[N3CG
M(^HHC\(VKSM_70Z&BN ^(MMXGOX=%_X1ZTN3]FOMUS$+PP><@0A26CF0^7D\
M\L>!^[<<5WS;BORD!O4C(HZ7)3N+14.VX_YZQ?\ ?H__ !5&VX_YZQ?]^C_\
M50,FHJ';<?\ /6+_ +]'_P"*HVW'_/6+_OT?_BJ /C;]H7_DL&O_ /;O_P"D
M\=>=5Z)^T%N'Q>U[>06_T?) P/\ CWCKSNOI*'\*/HCYZO\ Q)>K"BBBM3(^
MW/@C_P DJ\.?]>Y_]#:NXK@O@HLY^%GAW9)&%^SG ,9)^^WO7;[;C_GK%_WZ
M/_Q5?-5OXDO5GT5+^''T1-14.VX_YZQ?]^C_ /%4;;C_ )ZQ?]^C_P#%5F:'
MGWQ\_P"1$7_K_MO_ $:M>AVW_'O'_NBO-_CRLP\"KODC(^W6W1"/^6J^]>A6
MRW'V>/\ >Q?='_+,_P#Q5:2_AKU?Z&<?XC^7ZEJBH=MQ_P ]8O\ OT?_ (JC
M;<?\]8O^_1_^*K,T)J_/WQ)_R,6J?]?4O_H9K[\VW'_/6+_OT?\ XJO@+Q'_
M ,C#JF>OVJ7_ -#->GEN\CS<QVB4(W,;AEX8'(.*)',C%FQD^@Q3:*]6RO<\
MR[M8*_1"V_X]XO\ <'\J_.^OT*MEN/L\7[V+[@_Y9GT_WJ\S,_L_/]#TLN^U
M\OU+5%0[;C_GK%_WZ/\ \51MN/\ GK%_WZ/_ ,57E'IDU%0[;C_GK%_WZ/\
M\51MN/\ GK%_WZ/_ ,50!-14.VX_YZQ?]^C_ /%4;;C_ )ZQ?]^C_P#%4 35
MA^.O^1+UW_KRF_\ 0#6MMN/^>L7_ 'Z/_P 56'XX6?\ X0W7-TD1'V*;($9'
M\!_VJNG\:]29_"SY7HHHKZH\(*Z+X<_\CSHG_7TM<[70_#S/_"<:+M(!^TK@
MD9K.K\$O0NG\:/JFBH=MQ_SUB_[]'_XJC;<?\]8O^_1_^*KY8]PFHJ';<?\
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MML$E"*I54[*,AN?;:IJW]?UH*X4444@/SPN?^/B7_?/\ZBJ6Y_X^)?\ ?/\
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M+F_Y[_\ C@KP\P_C'I87^&345#Y<W_/?_P <%'ES?\]__'!7$=)-14/ES?\
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M5XGRV2QV<'GB13S7I+ E<!MI]0*II="4VTKBT5#Y4O\ S\/_ -\K_A1Y4O\
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MSU;^)+U9[M+^''T1-14/E2_\_#_]\K_A1Y4O_/P__?*_X5F:'GWQ\_Y$1?\
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M0M45#Y4O_/P__?*_X4>5+_S\/_WRO^%>:>@345#Y4O\ S\/_ -\K_A1Y4O\
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M8^95 !XXYK3AC2&)(H46.-%"HBC 4#H .PIU% !1110 4444 %%%% !1110
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MP=2X[8SDKGV?Q4T>6PL]2O\ 3]5TS1[R"2>WO[R.(1R^7&9'4*DC2 A5<C*
M':<$Y&3S'9_U_7D>@45SFA>*EU*_BLKW2-4T>ZGA-Q;1WZQ?OT&-Q4QR. 1N
M7*MM;GIP<5_%7BL:-?R0QJKQ6%A+JNH';N=;= 0%09 WNP;!)P C>HH>F_\
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MTA8+D$GYU965N<' 8 ;L#=I=+AUL%%%% !1110 4444 %%%% !1110 4444
M?GA<_P#'Q+_OG^=15+<_\?$O^^?YU%7U)\T%>Z_LF?\ (U:W_P!>2_\ H8KP
MJO=?V3/^1JUO_KR7_P!#%<V+_@R-\+_&B?3YJ&?[M3&H9_NU\^>\)9_ZMO\
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M93WHNKF&SM9;BZE2&WB4O))(VU44=22>@I/J'4Y/PAXA6_L+RX76(=0@9O\
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MO0?$7A"XU*]AT&74Y=<@>6:*VNXE^QW!GFD".9'4%,3@%DW'*-\IR*EN]/\
M$^DZ3H?A.RT?4[CP_::;%#>W^E7%LD]S( %,2&6:,Q+P<N 6.["["-U>KT4O
M+^NMOS'=WN<#ID4=WXTT"+3+$Z?;:%ILL5S;%HR;4RB,16YV%EW;8]Q 8X 0
M_P 0SWU%%-NX6ML%%%%( HHHH **** "BBB@ HHHH **** /SPN?^/B7_?/\
MZBJ6Y_X^)?\ ?/\ .HJ^I/F@KW7]DS_D:M;_ .O)?_0Q7A5>Z_LF?\C5K?\
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M16=]D'I2?9!Z4 :5%9OV0>E'V0>E &E16;]D'I1]D'I0!I45F_9!Z4?9!Z4
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MI*0"EH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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< !1110 4444 %%%% !1110 4444 %%%% '__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>23
<FILENAME>image00024.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image00024.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  8$!08%! 8&!08'!P8("A *"@D)
M"A0.#PP0%Q08&!<4%A8:'24?&ALC'!86("P@(R8G*2HI&1\M,"TH,"4H*2C_
MVP!# 0<'!PH("A,*"A,H&A8:*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H
M*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"C_P  1" '( RP# 2(  A$! Q$!_\0
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M_I4_WS_RT/K4?VZ[_P"?J?\ [^&H[G_CXE_WS_.HJ^HLCYJ[+/VZ[_Y^I_\
MOX:^EOV4)I9O#^NF:1Y"+I "[$X^2OF"OIO]DO\ Y%W7O^OI/_0*Y,<OW+.K
M!/\ ?(]YHHHKPCVPHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MFTK:J/K>^I3YW45[[OTM;3^NY9U7XGZAI=KX.TK2;;0--FU/3(KMKB_+PV4
M*\1J%^Z/EP.<#(%;EYXY\2Z?\+=6\0:CINEQZC:,HMY()Q<6ETA=5WKL?<!R
M>"<]/<#/UCPWXA'A3PQI\_A'1?$5G:Z?%!<V4\PANH)0@#%)BVT+P.G/'XCG
M].^&?B&T^&WC.SAT]+6XUB6%[/1TNQ+]G5) 2#(QVDX[YY"COQ3DJ33VW^_W
MO\OE;S%!U%*.^R_+_/YFG<?$[QGI]QX9FOM!T>2T\11@64$,\@E60A=N]CP
M2X. #P>N173^ O&>NW_C76O"OBNTTZ+4K&%;A)=/+^4Z$+Q\Y)S\XYX[\5C>
M(?!VNW?_  JS[/8[_P"Q6B-_^^C'DX$6>K?-]UONYZ5KZ)X:U:V^.'B#Q!-:
M;=(NK%(89_,0[G BR-H.X?=;J.U*7LFFM/M?@]/ZZBC[71MO[/X[_P!=#I/
MUWXFO+"\?QAIUK872W++ ENP8/#@;6.';G.>XZ=*\S_:@>UCL_"CZC$\MDM^
M6GC0X9XP!N Y')&>X^M>F>!KOQ->6%X_C#3K6PNEN66!+=@P>' VL<.W.<]Q
MTZ5S?Q?\-:MX@O\ PC)I%I]H2PU-+BY/F(GEQ@KD_,1GH>!DUE3:C6BW9;>A
MO43=*25^O]?Y'B^E?\(YKOC_ ,+GX6:#JVGSVUVLMY+/(641AADG+O@8W=QG
M.,'->C_';P#X:A\'^(/$L6F[=:)20W/GRGYFD12=N[;T)[5[37'_ !>T:_\
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M=6\;_==\_*>.< #/'2M+6_'7B4_$^7PIX<L=)N%:R6XAFNF= A(!W.03E>V
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M[O3[I@H63NPRRYY)/# _,1@BNA^&.F^-UOM3U;QS?HANP!#I<+!HX,=^,@<
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M_P!"I_Y4?_M5?.]%'U*A_+^+#ZY6_F_(^B/^&E#_ -"I_P"5'_[51_PTH?\
MH5/_ "H__:J^=Z*/J5#^7\6'URM_-^1]$?\ #2A_Z%3_ ,J/_P!JH_X:4/\
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M C=C R 1G..U:=E8:-XK\.^(YM.TB+2+_281>PF">619H=P5ED\QF^89!!7
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M:'\1_P"RI/"3?V5YO]@274F/M&WS_.)./NG;C/OGVIR=;5)?EYV_0$J-KO\
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MK[7HH_M&IV0?V?3[L^*/^%0^._\ H7I_^_L7_P 51_PJ'QW_ -"]/_W]B_\
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MM0,F3[O'&?E/S<'CBN5TOX=:K;WFEV%S<V#:#IFLS:S#,A?[3,7,A$+IMVJ
M96RP8[@ -HS7$W7P%UB2VOO)U:SCN3?^19R"1_W6D$2*UO\ <X8B5N.1D#GN
M$KM>?]?J_N3[H>EWV_X/^2^]KLSV:^\;Z!8Z7HVHW-[(MKK#(E@1:RLT[,I9
M0$"E@2!P"!Z=:@T;XA^&-9OK6TT_47>:Z,BQ>9:S1*SQ@EX]SH%$B@$E"0P'
M)%0>,?"EQJU_X-?3&MH;;1-22ZD20D$Q+$Z!4P#D_,.#@8[US.G_  XUFV_L
M0_;;&-['7-1U-Y$9V(CN!*$V@J,L/,7(.!P<$T^KM\OP_P W]Q.ME?\ K?\
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MDY545,[MP/*E2""",@@@\UB7'Q#T,:#KVIVAO9VT:W^T7-J]E/!.%*ED.R1
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M%=46_%M<^<D[7*1_;9_)CE8-N=8=_EJ3O;)"C.XYZFF]K+^M%_DPNK?UY_\
M .0T?Q_K4&DVNJ>((M.GM[SP_-KD4%C#)&\7E",F-F9VW[A*.0J[<'KUI9-4
M\8Z=KVJF[ELM0NDTBVFBALK>;RH]T[+(_P!G\QFD9%R?E8-(%"@*:[JU\,:/
M:I8)#9+LL;)M.MU=V<+;MLW(020P/EIRV3QUY-9D/P\\-1+<A;.Y9[A(XVED
MO[AY%6-M\81RY:/:W*[2,=L4W;F37G^MOS7W!TM_73_)_>.\+ZS?:SX7OIFN
M[)]1A:6%9DL9[<(P&5,EM*1)&1D$H6Y&"&PPQYOIOB[6_"_PWTB^DU6TOKDZ
M4NJW*36E[?7$Y<%L,5D;[,F%VB5B4+;L(@7!]@T;1+#1[&2TL8Y!'*[22O-.
M\TLK'@L\CL78X &23@ #H!6/=_#_ ,-W5I!:R6=PEO#:+8>7!?7$*R6Z@A8Y
M CCS5 )QOW=3ZFCK=>7ZW_&P*VS_ *_I'-G6[RX\;VMNDLL,*>)#;,B3R$2Q
M_P!EF7# L1C<0=J@+D XW9)77-<UO2/'?B1H;N":U^PZ;#9VDL4A2*>XN)(5
M=B'Q@-DMA06&T9&W+=G!X6T>"\CNHK0BXCNOMBN97.)O(\C=R?\ GG\N.G?K
MS2ZGX8TC4[RZN;VU:2:ZM193D32('B#%ERJL!N4DE7QN7)P1FAVTM_6G]>@7
MTU\OSO\ D5O"FJW]W)J]AJYM9;_2[D0//:QF..8-$DBL$+.4(#@$%CTSGG Y
MOP-XM\0ZE;Z+<Z[%I?DZSITE[ EG'(K6[1[.&+,V\,'SD!=I&WYLYKM=%T6R
MT6S>VTY)%61S)(\TSSRR.?XGD<EW. !EB> !T %87@7P'I?A+3;:&'S;F[CM
M1:O<22R%2O5O+C9V6(,1N(3&3@G)%)W:=NWXV?ZV!6_$P]$\3>*=8TGPVL,V
MB0:GK-D^J"1[*5X8(%6+]UM\X%G+3+\VX  'Y3U-36O%^N>(/"]W+X=-GII3
MP^-4N#<!W<F59 J12(ZA"OE.?,(;JOR]:[6[\':)=:/IVF/;SQ6FG(([7[/=
MS021(%V;1(CAR"O!!.#@9SBFZUX*T#6K6&VOK BWB@-JL5O/);JT.,>4PC90
MZ?[+9 ]*51<R:C_6_P#P/NN.+2:;_K5?\'T.:L_&6I1Z+=N4MW>TU;3M-1G#
M$O',MKO9OFY?]^^#TX&0><VAXHUM=-UCQ&4TV3P_8_;0;,(ZW0%N77=YNXHQ
M9HS\FQ<!A\Q(P=BX\#>'[C4$O);.8RJ\,FQ;N98B\.WRW,8?8SKL4;B"< #.
M.*F_X0_0_P"UI=1:S9YY"[M')/(\ 9UVNX@+>6KL"06"@G<V3\QS4WS7MY_D
MO^#Z7)A9))^1E?#OQ)JVMR7L&LV\F88XI8[H:3=:?&V\-NB"W&2S(5SN!P0Z
M\#!JO8^*-8_X3"XT_4A:VL!>X2"VET^XC=@@)1TNB3#,64;C&H5E!/4H<])X
M=\-:7X=68:7%.IE"J[W%U+<.54850TC,P49.%!P,G Y-0V'A'1K#5CJ-M;S"
MXWR2(CW4SPQ.Y)=HX68QQL<MDJH/S-ZG)+5Z=@5[:GGOBCQMKMS\/[6>RDM;
M*\U#PK<ZN\Z1N3%*@@XC^<8XE?!))!VGG!!H>$I-9T?QCY6JZM)J4:ZP-.5?
M/O%5$73C/D*]RZMDD??#'.3G[NST.'X=^&88YXUL)FCFM9;(I)>SNJ02;=\2
M!G(C3Y5PJX QQBM1?#.D+J OEM,70N_MP?S'_P!=Y/D;L9Q_J_EQT[XSS3NM
M6O/\]/PT&VK6]?R7ZG%2^(?$<_AK2M<N_P"RVTW4[C3W@AM_.AFMEFN8@$=U
MDQ+\C\D;%R,%65B!/JGC?5(?'4^F6-E+/8V=U;VD\4>DW4[R>:JLT@N4_=1!
M!(A*N"2%;D9%;\7@/PY%-YHL9&(D26-7NIG2 K*LH$2ERL2[T0E4"J=H!!
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MCJ@1YOI?CV?3K_Q,]MKL'BO0;&WMI(=1GGMH(X[B1RK0M/$BQL -K?*K,,X
M8D"K%K\79[S289;30$DU)]>303;M>/%$'9"ZRAWA#[<8X,8/7 /&>_\ %_AR
MT\4Z/_9]]+<P!9H[B*>V8+)%)&X=&7<"O!'0@CVKG+#X8:7:NLDFIZO=2C64
MUUI)Y8R7N539SB,#:1R0 .>F!Q3CVE_6J_2_X=0>VF__  '^MG]YFZW\4I=#
M\2V>DZAI5F2]U;65RUMJ#3O!),!AMJQ8" G'[QHW;!(3&,\V/'_C.>2WVP:<
MLA\7R:.L,4_RRQ(CYC=FBRH!53O +'GY1T/:ZM\+M+U+69[\ZIK-LD^H0ZJ]
MI!+&(3<Q;0LG,9;D* 5W;>X .")XOAOID6JB\2^U+8NKG6TMM\?EI<E65\'9
MOVMNR06."!C R"1Z-_UK'_[8<MG;^M)?\ YT?&-4T"WU2ZT)XDN-/O+B)!=;
MB]S;2^6UN#LYW=0WIGY>*T;KXDW=GJ7B=;W0XH=-\.6\,]_<?;2TI,D'F!(X
MQ'AB#\O+*.ASU JZQ\+(Y[7PIH]B8VT;2=5?59I[J<F=BSNYB5%0*59GP26&
M .C5U<W@C2+BY\427BSW,?B-(X[V&1P$VI'Y8"8 (XYSDG/3%3K9OU_K\;?+
MS#3GL]OZ_1?CY'':_P#$J]L8&LM2TR72]7#6%PD=I>1RA[>XN!%]]X2,@Y#*
M%[_*_.0D/Q U?6?&OA:+3[46?AZ\U._L6E\Q9'NA!$_WE*9B^="5VL20ISCH
M=R7X7:3<P2#4-1U:]NG:U'VR>6,RK';R"2*(80+MW#DXW'/+$X-2V'PUTJQ\
M16.JV]]J86QO+B]M;(R)]GBDG4B7 V;B"6+8+'!Z8!(-*U_O_2WZ_,C6WR_1
MW_&WR.=\=_$'6/"?CG6-EHFH:%I^C07T]N9EA:,M.R,Z'8Q=L8^4D+P>0>N]
MXJ^(#Z/J6I6VGZ0=0CTG3UU/4G-QY)BA;=@1KM/F/A&."57 ^]DXJWXJ^'NE
M>);K6)[^XOHWU33TTV80N@"QI(9 5RIPV3U.1CM3O$G@#3-=OI[J6ZU"T:[M
M18WR6LJJM[ "2(Y,J2.K#<A5L,1G%3KRI==?UM^A;M>_I^G_  3G=1^*5W&?
M%=SIFA6]WI7A^SBO9+F34#$\ZR6_G($01-SV.6'7(STJK??%G4[&+49+CPM"
M%T_3K?5YMNIY_P!&EST_=<R@@_+]WC[_ $KJKKX>Z/<6OBFW$EY%#XB@CMKE
M8W4")(XO*7ROEX^7UW<U#J7PVT?4(=4CFN=05=1TJ'1Y=DB K#$6*LOR??\
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M!4U'[L?^]3H/NTW4?NQ_[U.@^[0!#=_=-7+?_41_[H_E5.[^Z:N6_P#J(_\
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MJL9)][1X5@Y ;/E$K]Y?F'?H9?!EZ--\10P3V_FW6I6VHV.]VQF!+?8LIQD
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MW  ! -HV@Y^8X]%HH6B2733[@>KN_4XK7?"E]?QZXL,MLIOM2L;R+>S#"0-
M7#<=3Y38QGJ,D=M34M%N;KQA8:K&\(MX-.NK1E8G>7E>%E(&,8Q&V>>XX-=#
M12MI;^M5;\AW9Q'A7PG?:1/X1>YEMF&D:&^F3^6S'=(Q@P5RHRO[IN3@\CCT
M@'A'5!XV.I;[+^SQK U0'S6\T@V)MF39LQD,%(.[D$],<]]15\SO?U_%W_,7
M2W];6/+-0^'VJ?9-/EMV@GO;6[U)_*75;K3U:*ZG,H/G0#?N7" H1M.6YX!K
MT+P[IJZ-H&G:;&(U6TMXX (R^T;5 ^7>S-CCC+$^YK1HJ5HK ]7?^M3/M_\
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MTT)75U_7]6 Z2BN>U+Q;I=KI37D=S&^8KB2-9%D4'R<B3=A&90I&#\IYZ G
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M/K^ERWMFLNR&[BM)E2:"?RFD(",7AD=-N6&<,2.<@4U=>[V_X*_5@W=7[_\
M#_H+?>!DNIO$[#4'5=8MV@AC,>Y;/>O[TJ-W.]@K$<<BN?\ $?PLN=;TN33I
MM8L7M&:]V)<Z89Q%]H?>LBJ9@HFC)<"3'1B %Y)U_$WQ1T'P['&]_P":#)+/
M&BM+!#O6%MLDBF61 P#' "DN>RD<U4N/BA96.K3V=S;2W;2W)CLELS&KR1"&
M"3.V213(^9N$C#.1T4]U'WK)?U_7^?F-MIW_ *_K_@&Q;^#3%?1W+7X8K?&]
M*B'&<VGV;;][_@6?P]ZR-*^&?V"UNH?[6\SS].ET_/V;&W?!;Q;_ +_;[/G'
M^UC/&3UOB+74T:.S"V-YJ%W>2^3;VMH$$DC!6<\R,B@!58DLPZ8ZD"L&/Q=>
M:GXG\,VFBV;_ -DZE92W\]U-"I*JNT!,&561@6&3L?D@ ?>*O=^NGX?Y7$O=
M5UTU_'_,TO$&@ZA>?V)+I&HVEG>:7(75[JS:XCD!B:,@JLD9'#9SN[4U/#,Z
M^$=3TK^U)4U'4!-)-J$*&,K-)GYE4-E57@ ;LX4#=GFI9/%,8UY]-@TO5+F*
M&5;>XOH(E>""5D#A6&[S#PR994*C<,D8..<@^)UEJ8NXM*A:*[L[VS@GCNFB
M8B.:?RR<1R,48 -\DFUE.-R]J7Q?/];?\!_B"7*M.@_PG\.?[ O5N5N]/0#4
M?[0^SV&G"TA4FU,!54#M@<[\Y)SGUS4;?#N^AL(+'3]=BAM7AM8KP26/F-+Y
M#[E:,^8/+W#Y6R'X Q@Y)T/^$[2>RCNH]+U6SM)I+<VUU<VR/%=12RJ@9-LN
M5R&!Q)M8!L[&P14T_CW3H["WN4L]1F^T6UI=111QH787,GEQKRX&[=UYP!WI
MZO\ (+6T-7Q-H]SJBV$VG7D=GJ%A<?:+>6: SQ9*,C!T#*2"KMT92#@YZ@\?
MX@^&]]KNHV5YJ6NVEU/ ;:0R7&F!WBDBF\UC;GS (5<80@!F*JN7;'/0^&?&
M=OKVH"T73-2L9&CE=&NUB"L8I!'*HV.QRKD#/W3U4L*COO'NEV7C2#PU<Q7"
M7LX/ER,\2JY$;2<(7$I&%(WA"F[Y=V<BE>UG\_N#>Z*=GX+U/2[R:?1=>CM3
M=LXNS)8B5BAGEE7RB7 1QYSKE@ZG"G:,$&LOP\NH9KR2UUJ)&FD2XC+V1;RY
MX[N6X0G]X-R?O2C+P3C(9>E7+'XB65U8O<?V3J\3M%;36MO(D7F7BW#%8C&!
M(0,E3G>4V]6P.:FT7Q@\GA+6M=UBRFMTTZXNE:W2/]Z(XF/!&X@O@=C@GIQ3
MU3MVU_+\KKT!Z[]?Z_KN5U\"2-;W/VC5!)=75G?6\\JVVU3)=,C%U7<=JKLP
M%))QU;/)23P!OO-7G_M+']H6EQ:[?(_U?FQ01[OO<X\C..,[NV.67WCV=+JQ
M@M="U+[6]Z;6XT^58OM!4V\DJ,A$OEX.P<L_&&! -6A\0=.?[#)#8ZE-:W$%
MM<37"1ILLUG;;%YH+ALE@00@?;C)P.:271>GWA?K\_Z^XU--TN9/$DU].I6*
M"SCL;<DC]YSO=\#.!G:H!YRK=B">0M? 6JZCIU[;ZQJ45O;LVHK:P); O$;B
M5\2.XDPXV-D* I&[DDBM6W^)6DW']OM%9W[P:,DSSS1^3(&,389=J2%D8X.U
M90A8 D9 .([[Q[.EU8P6NA:E]K>]-K<:?*L7V@J;>25&0B7R\'8.6?C# @&B
M^E_ZU_X(6MI_6B*%I\.VTOQ!>:]<R0:N6M[R%K:*Q5+J\CF96$<L\DN'*A=B
MYVJ%XP*;%\.9K[P#8Z7J,MH^H%_M%R=1M!=AG*; "4=&$B)M421NIRN><XK;
M'Q!TY_L,D-CJ4UK<06UQ-<)&FRS6=ML7F@N&R6!!"!]N,G YJU:^,K>XMY[D
MZ;J4-HE\NGI/(L86:0SF E0'+;0XY+ <'C/2BWV?E^/^;#S_ *U7^1-_PCUU
M_P (*V@'6;QKQK-K?^TF=S*'(QOSNW<'_:W8_BSS5#P'X+_X16VUF)9M/QJ4
MXG\JPL!9PPGREC(6,.W!V;NN<D]:AUCXDZ5IES:V[6E]<7%Q/<6Z0Q&%78PN
M$?:KR*9#D\)'N<]EK5\8^)H/#-M:7=UYIMW:4R+'#YCLJ0R2D#YEVGY/1O3
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M%NHK(Q^1(1YTD9D1-VW;DH">N!WP3715\YZ'X8U?7=!\-:EXHT&Z-[K'BO\
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MG ')[TDMK];?G8;>C:Z7_"_YG;:AXXT+3[>QEO);Z-[U7>"V_LVY-RRI]]C
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M< X )/ IVA:U8:[9M<Z9,TD:2-%(LD3Q21..J/&X#(W3A@#@@]#0&QHT444
M%%%5(M2M)=6N=-CES>V\4<\L>T_*CEPASC!R8WZ'MSVH MT4CL$1F8X51DFJ
MVE:A;:MIEIJ&GR^;9W42SPR;2NY&&0<$ C@]Q0!:HHJI?ZC:Z>]HEW+Y;7<X
MMX1M)WR$%@.!QPIY/'% %NBBB@ I&574JX#*PP01D$55TG4;75]-M[_3Y?.M
M)UWQR;2NX?0@$?C4.M:U8Z*MI]ODE#7<PMX$A@DF>1R"V J*3T5B3C  ).*/
M(/,>NCZ8FC_V2FG6:Z5Y9A^Q"!1#L/5=F-N/;&*N0QI#$D4*+'&BA411@*!T
M '84ZB@ HHHH **** *<^EZ?<:E;:A<6-K+?VRLL%R\*M+$&^\%8C*@]\5<J
MIJVHVND:7=ZCJ$ODV=K$TTTFTMM11DG !)X]!5I2&4$=",B@/,6H+^SMM0LY
MK2_MH;JUF79+#/&'1U]&4\$?6IZJ1:E:2ZM<Z;'+F]MXHYY8]I^5'+A#G&#D
MQOT/;GM0'F,;2--:.QC;3[,QV#!K13 N+<@;08QCY" 2.,<5>HHH **J:IJ5
MII5ND]_+Y43S1VZMM+9>1PB#@'JS 9Z#/-6Z "BBB@ HHHH ***K3W]M!?6M
MG+)MN;D.T2;2=P3!;G&!C(ZT 6:*A6X1KN2W"R^9&BN28F"$,2!AR-I/RG(!
M)'&<9&:G]M6)N;NW1Y9)[26*"=(X)'*-(%*]%/&&!+= ,DD8- &C16=INM6.
MID?89)9E+3)O$$@0-%)Y<BEBN 0V0 3S@D9 )K1H **** "BBB@#/M_]:_\
MO&KR]*HV_P#K7_WC5Y>E #J*** /SPN?^/B7_?/\ZZOPO+)::+YJZQJUDKR3
ML(K.?RT)C2,DGD9)W ?A7*7/_'Q+_OG^===X+$D>DWLJ&\E0[T9;6VCG-OPI
M\YE)W8[= .ISD8/TU3X;GSU+6:,#Q1N_X2;5O,8,_P!LFW,!C)WGG&37T/\
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MJ'@73KRQLK-;J^M[>UT^73-L+1_O89%4'<60_,"BL",<]<CBNLHHOK?^NO\
MFQ;;&=:Z/;6UQJDRF1SJ+J\RL1@8C6/"X&1PH_&N7T?X;:?IOEYU35;KRHK.
M"(3-"!'':RF2) $C48!)![D=\\UW-%"T=U_5@Z6.:NO"%M);HMIJ&H6-U'>S
M7T5W;M&9(WE+%U =&0J0Y&&4]CU --E\%V4G@VS\."\U!+:T:%XKE9%\\-%(
M)%8L5P3N49XKIZ*/Z^X+ZW.+F^'MG+;HG]K:NEPPG2[NEDB$MXDQ!D23]WM
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M<Y; R?? S7T=^R7_ ,B[KW_7TG_H%<V,UP_W'3A?]X^\]UD^[5>T_P"/A_\
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MCDDDDXQK:EHNGZG(\E];^:[VTMFQWLN8I-N]>".NU>>HQP:.S]?UL"WU\O\
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MWA=;?UU_RT';2_\ 6Z7ZGM5%>,_&3Q!)IRR*M[-::S!I?VJ!)-:?3XC+\_\
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MLEUV_+[NOH+S_K^OU\SU#2]-M=,BECLUD EE::1I)7E9W;J2SDD]  ,\  #
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MEEO+.3S99&DDDANIH6?<BHRDHP)1E1 4^Z=H)!-7E\.Z4LOF+9JK?:1> !F
M$HB\H-C.,;/EQT]LUY=9^.O$.E:3X51S;:C&;;3O[1G-LV[_ $F0(I+O.N&Q
MG[HF+,"6$8(S>O?&WBJ)+RYC.B"VBAU"Z2-K65G$=I<>5M+>: 6<$?-@!2.C
M9P&XV?+ZK[M1K57_ *U/08/#6E0Z%:Z.L$C:=:M&\,<EQ(Y0HP9/F9BQ (&
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MEKI]O!/I\<MG'?%H=S(+B?RU^=I4"]R BRDD'<$&"1*]DNOZZ_J#W=_ZZ?\
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MRE@8%=PV>7(P:)_N$@EP,$ L"&JK/7^OZL3=?U_74M#P=X8#VSCPYHP:V79
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M]EG5%DMXU,<$14F-Y0SJQ#$-\J!FPK<<58UKQ3?V%UX,C@TYKI-:N/*N7CV
M0KY#R9&YU/5<]&^56'WBH+NW*[W7_!_5"Z>J_!)?I8UK'P[;66@W>E6UQ>1Q
M7,MQ*9DEV2HTTC2,590,89SCZ#.:R9/ =K<V.HQ:EJNJ7]Y>M SWT_D"5/(?
M?$%5(EC(5\M\R'.<-D8 M>'O&-GK=^EM'9WUJMQ$]Q8SW*H$OH58!I(MKL0/
MF0X<*2'! /.'ZMXJ33-52VGTG56L_.AMWU%8T%O')*RJB_,X=LED&Y$906P2
M,-A=5Y_U^8WNRIIO@6TL]1BOY]3U.^O$OO[1:6X,0\R7[.;?D)&JXV$< #D
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M+]F3>/WGF=<9_P!9\_\ O<]>:Q_^%C>#?^AFTG_P)7_&C_A8W@W_ *&;2?\
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MUI_S]0?]_!19A=%BBJ_VZT_Y^H/^_@H^W6G_ #]0?]_!19A=%BBJ_P!NM/\
MGZ@_[^"C[=:?\_4'_?P468718HJO]NM/^?J#_OX*/MUI_P _4'_?P468718H
MJO\ ;K3_ )^H/^_@H^W6G_/U!_W\%%F%T6**K_;K3_GZ@_[^"C[=:?\ /U!_
MW\%%F%T6**K_ &ZT_P"?J#_OX*/MUI_S]0?]_!19A=%BBJ_VZT_Y^H/^_@H^
MW6G_ #]0?]_!19A=%BBJ_P!NM/\ GZ@_[^"I898YEW0R)(N<95LBE8=ROJ/W
M8_\ >IT'W:;J/W8_]ZG0?=H AN_NFKEO_J(_]T?RJG=_=-7+?_41_P"Z/Y4
M/HHHH R+G1?.\66&M>?M^RV<]IY.S.[S7B;=NSQCRL8QSN[8YYG3/AQ9V'C"
M?6472##)<370/]DQ_;?,E!W!KHDL4RS$ *K#(&X@8/3^(/$.G:!'"VI23[IB
MPCBMK66YD8*,L1'$K-M'=L8&1D\BJNH^,M"T[[$;F^)CO(A<1R0P231K$2 )
M9'12L<?(^=RJ]>>#0M=%Z??J-WMK_5C#'@K61X?;1/\ A)@NFP0I!91I9%6V
M(ZE1<-YFZ4;4"$(8@RL^>HQ5\/\ PT_LF>&1;S3X434FU+[/I^F_98%9K1K<
MJB>8VT<ANIY!]<CI)O&F@Q:VVDO=R_;4G2VDVVLS1QRN 41Y0NQ2P9<989)P
M,FC3O&FA:EJXTVSNY7N3++ I-K,L321D[XQ*5"%QM)VALX&<8YH^)>O_  XK
MV_KOH5F\('_A6]MX62_*36UE#;PWPAYCEB"^7,$SU#*K8SVZUFV'PXM]/NM2
MEL-2N+5;G2UTZ#[.@1[5O+6-YE8'[[+%!V&/+]ZWM,\7Z'J4U[':WI'V1&ED
M>:&2&-HU)5I$=U"R("""R$J..>16++\2]';5M$L+&'4)Y-1N_LS!["YA:$&)
MW60JT62K%< \#&]LX1L.[DV^_P"MU_F/;Y?IK^G]7,[2?AK<::NM/!?:'!-J
M=O#!+':Z&$MI?+=R3+$TKF3>)&5OF!(Q@@UT_@GPPOAK1I[$R6S">9YFBL[;
M[+;1;@!MABW-L7C)&XY9F/? ETOQ=HFJ7%Y#:7AW6J-+(\T$D,;1JQ5G1W4+
M(@((+(6 XYY%4_#GC:P\0^(;C3=-BN#'#9QW9FG@EMV8.S* (Y$5MN%R&'!S
MQTI7OIW7X;_H)JVKZ?GM^IGQ^"=2_L,://KZ/I]G'&NF*MB \+12*\+S,7/F
MLIC4?+Y8(+9&2"MBS\&7 U.RU34=42XU*/4FU&X:*V,44A^S-;JB(78H I4\
MLQ)!]>(M'^)&DWFA_P!HWD-_:;KVXLXX%L+F65_)=@7"+%O*[5!8[<*3M)R#
M6CXN\7VGA[P_9:ND4NH6MW<VT$9M$>7<LSJH<>6K$@ Y''S'"@Y84U>_]=?\
M]!N^J]?\F5K#P9]D_L?_ $_?_9VJW>I_ZG'F>?Y_R?>XV^?UYSMZ#/&/JWPP
MAOM/LXS-I5S=6MU>SH=4TI;R#9<RF1E\HNOS*=F'#?PGC#8K8M?'VF-XDU'1
M;U9[:XM;V.SCD$,LD;EXHW0O($V1%BY4*S9)7CKBM2W\4Z1<Z_)HT-S(;]"R
MX-O((F90"R+*5\MG .2JL6'.1P<+XD@<G>[_ *W_ ,V9'_"(7UA-;OX<UB'3
M?]"AL+G=8))NCB+;'A562.)QO?\ @9.1\F!@XVI_"\7MK"DESI%W);7EY<6W
M]IZ0+N)8[E_,=6C,@!</@B0%>!@J<G/7ZWXJTC1+V.UU&XF25U5V,=M+*D*L
MVU6E=%*Q*2" SE1\K<\'#;WQ;HUEK(TNXN9A=>8D3,MK*\,<CXV(\P4QHS97
M"LP)W+Q\PR/7^OZ_K0%IIV_RM^1A:MX#N7L7MM U:#2_M&EKI-TYT]7WQ(&V
M-&J,BQN/,?H"O.-HP*V-5\-O>1^'/)O$BDT>X6;,D&]9E\EXG7 88)5S@Y.#
MC(/2L31?B9I]YI]WJ&HVMU96BWLUG:JMI=33SB(L'<Q"$,H&W)(W!>C%6RM:
M%MX[TV;QA/H6R;:MO;3PWBPRM#,9R^T!PFP#"KAMV&)('*FGN_6W^:_/835M
M^EU^2?Z:B>%O!]QHU]9/=:FEW9Z7;/9:9!';&(Q0L5_UK;V$C!8T4, G0Y!)
MXR_$_P .I=<\2?VH^H6)"W5O=PM=:<9[FU:)D.R"4R 1QL8\E0F268DG/'82
MZ]IL6BW&K27&W3X-X>4QMU1BI 7&6.X$  '=QC.169)XYT"/3X+M[FZ"S7!M
M$A^PS_:/."EO+,&SS VT;L%1D8(X(HN[I]5_G_F#Z^9IWFE?:?$&G:GYVW[)
M#/#Y>S._S"G.<\8V>G.:Q](\(?V=/X=D^W%_['L)['B+;YOF&+Y^IVX\KISU
M]N=3Q#XCTWP]!#+JDLZ^<2(T@M9;B1L#<QV1JS8 &2<8'&3S7)?$'XG0>%)K
M1;739M4CFT^;4FFA68Q^2@7&UHXG4Y+#DE548)(RH,_U^#_2XU=[&6GPCE/V
MXS:M8>?=:9<Z8]W%I96YN%E"?O;B4RDS2 H#GY<Y/ SQTVO^"6U2]U&[BU$0
M3W$-BL):#>L4EK,\R,PW#<I+ %<KP#SSP[1_'-M-HMQ?:Q&EI)#/';-;6J7-
MQ*9'B20((V@20OA\[50X R<8($]QX_\ #D%O!.][,T4L9F+1V<\GD(&*EI]J
M'R &5@3)MP4;/W3BM=%V_P"'_P""*]U?^NG^2*&G>![N+58M2U#6([B[_M4Z
MI(8;3RD)-G]FV*"[%0/O9);TYZUCZ9\*%BO9YM1U&TF$^GW&FSSVU@8;NZ27
M9^\GG,CF24; =V .3P.E=AJGC'0]+U(V-Y=2K, N]H[662*,L,JK2*I17;LI
M(8Y7 .X9T['5+._F:*TF\QUACG.$8#9)G8<D8YVGCJ._44M]5Z?A;\AWU5_Z
MZ_J<O)X4UR]N-+N=7\0VMS/I]VLT:1:;Y41C\J2)P5\TMO993\V_:"JX3KG'
M'PRO9=*_LZ[U^&2V@T6XT2T\NP*-'%+Y85W)E.]U$0SC:#GH.^SK'Q'T.RT3
M6K^U:YO'TRWDN/*6UF3[0$.TF)BF)$#8!=-RKD$D"K\GBZSTWP[I6I^(LV$F
MH,L<<$44\S&5E9A&JF)9"Q"G **2>,9(!:?VE_5[K_,-8M>7Z:_J4]:\%?VG
MJ]Q??;_*\[^SOD\G=C[)<--UW#[^[;[8SSTJCXD\-W]@+_5-$%S>:K-JR:E;
M)#!$PA/V=8&5UDFB#J45NCJ<L,?=K;F\;:#%IMG>K<W$\5WO\F.VLIYYCL.)
M,Q(AD78?E;<HVD@'!.*=_P )KX?^U1P+J <O:+?^8D,C1);E682O(%V(I"-R
MQ'3'4BEK_7R?Z?@"_K\B'P%I>HV7A9XM:^34+NXN+F5<+E/-D9P"%)7(##(#
M,!TW-]X\[>_#.6ZTC0],DU+3I;;3;*&T6:XTE9+F%D #2VLN\&!V ')WX*J1
MT.=?5?B'I5MX6US6+**]N)-*MOM$EI-9W%M*P(.P[7C#;&(/SA2HPQS\IPS1
M_B-I-]K%WIUS'=VDL=U%;1-):S[6,D4<B>8QC"PL3)M".025]3BFK\VGE^&B
M_,3VN_/_ #8:MX(EU+Q?;:Q/>Z>8[>:.6*3^S%%_$J<^4ET'&(F.<J4)(=QG
MD898^![RVUJQF.L0MI5CJ5SJ4%H+,B7=.LV]7E\P@@&9B,(.!@YZUL7_ (ST
M&PLXKJ[O72&5=R$6\K$_O%BQM"D@[W5<$9SVX-+_ ,)CHHU*UL'GN([FX6-E
M$EG,BQF3[B2N4"Q.V.$<JQ) QDBDMK+^OZL#ZW_K^KF)X#^'=KX1U-[BW72/
M*2%K>W-MI,=O<%"P.9Y\EI6  &1L!Y)!."*_B?X=2ZYXD_M1]0L2%NK>[A:Z
MTXSW-JT3(=D$ID CC8QY*A,DLQ).>-S_ (332X--CN[V1OWMU<6L<=G!/=,Q
MB=U8[5CWX&P[CMVJ?XB,$T9/'L$7P]TWQ7): 6UX]LK1K*6\M995CW A<M@-
MNP!SC%">J?;]1N]VGU);+P4+9=(#7WF#3]5N]3(,./,\_P _]W][C'G]><[>
M@SQ#X?\ !E]I6KZ1+)K4<^E:/;RVEC9K9['$;A0OF2;SO90@ (5<CJ,\UJ+X
MST1M'DU+S[H01SBU:)K&<7 F.,1^04\W<00<;<X.>G-*OC+0WDTN.*ZFEEU,
M,;:.*UF=SM8*^Y0I,>UF ;?MVG.[&#@_K\/\A-WU?]:_YE&\\&?:?[5_T_;]
MNUBUU;_4YV>3Y'[O[W.?(^]QC=T..4LO!T]OK<,C:DC:+;7TVI6UDEL5D2>4
M/NWR[\,F99&"[ 02/F(7!(_B3X8EV^3>7DI=#)"L>FW+FX48#&("/,NW/S;-
MVWG=C!J]>^-= LX["6:^9H;Z$7,4L5O+*BPG&)9&52(D^8?.Y4=>>#AQOI;^
MOZM^ V[W3_K^K_B3^$]$DT"RO+5[I+F&2]N+J'$11HUED:0HQW'<0SM\P"\8
MXXR=NN=UOQIH6B:@UCJ-W*ERD23R+':S2B*-B0)'9%(1,J<LQ &.2*GNO%.D
M6FNQ://<R"^D**,6\C1*SYV*\H7RT9L'"LP)XP#D96XGU;]3;HHHH S[?_6O
M_O&KR]*HV_\ K7_WC5Y>E #J*** /SPN?^/B7_?/\ZBJ6Y_X^)?]\_SJ*OJ3
MYH*^F_V2_P#D7=>_Z^D_] KYDKZ;_9+_ .1=U[_KZ3_T"N3'?P6=6"_C(]UD
M^[5>T_X^'_W:L2?=JO:?\?#_ .[7@GMGCW[5\KKX'TN-6(1]0!8#OB-\5\L@
M$D  DG@ 5]1_M8_\B9H__80_]IO7SKX+U.WT7Q9I6I7L;26UK<+*ZH 6 !Z@
M'C(ZCW%>Y@?X.AXN-_C,J:KI&I:0\::MIUY8M*N^-;F!HBZ^HW 9%4*] T=M
M$LM6MAJ'BY;ZUWSS[/L+RP*Y4 %Q-&PWMT)$3XP.3VUK[Q!X.AU:WCL[73I=
M+EUEY[HC3P7%KB(H%+("%W"3*KC@$< \[^U=TK7,?9QU=_ZL>:KI>H-:_:5L
M;HVWEF;S1"VS8&VELXQ@-\N>F>*IUZUK/B'PU<Z-#:WUUINH7$&F2PJ;*P:"
M,2M=JX$:F-0A\O=\P [\\\OO]:\$37T,$_\ 9DEI<W,\1GLM+,)LK-X\)N!0
M%Y5?:VX;CA6&X[L4E6EUCW_KYCE2BGI+^K'D5%>I/J_@^ZT+Q"[FRAN;EY39
M69T]4\D*R>5MD2(MRJG/[Q1DG*G.:O7&M>#)-4:XMY-&M[F:U15WZ9Y]E;,)
M@64)Y",Y:/(!920>-_.0>V>GNL/8JWQ+^F>0 $D  DG@ 5+=VT]G<R6]W#+!
M<1MM>*5"K(?0@\@UZ.M_X0.DR7"RV$=RNFRVL=L;&02F?[4727.UE'[K R7+
M#IFM/6M;\&W\7BNYDOK>XN;ZXFEM4DL,.IW(499/)+X(#<&10.A4YS3]J[VY
M7U_/^F'LE;XET_+^D>1B&4P-.(W,*L$:3:=H8@D GID@'CV-%Q#+;3/#<1/%
M*APR.I5E/N#7H/B#Q9HTKZ\EMI6CWEF^HQFQMOLTEM&(%$P#_N3&2WSK]\D\
M]..-/4=<\(:AI^K%A9K<W%Q*^Z2)MY!V[&CS;LQ"X^Z9HP<'.<Y(JLOY?ZT$
MZ<?YOZU/)ZFM[:>YNH[:WAEEN)&")%&A9V8]  .2?:O2O%&O>&HK65]%_LJX
MO_LIA#C3HRI;SE.X VT2@[-PR4R.1N/!K)D\0VD7Q6NM<2XM9+.2XED646@V
M;60X_=E.O(!^7KDY/6B-235^7O\ A_F$J:B[<W;^OD<8MI<->?95MYC=;S'Y
M(0[]PZC;US[4R>&6WD\N>-XI, [74J<$9!P?4$'\:]*T?5/"D?AG3XM0EL);
MT31RR*;%0Z#>=ZMM@!(P>/WK@@?=7 %1W&I>&+R%KJ>ZLS<1P&+RI+61I)6\
MJ *0=A7"E)!R0?08.:%4E=IK84H))-/<\UHKT_4-<\+7OA[656WTR.]DFN/)
M1;<0%ER/):/9;,0 H''FQY(.X'))\WOK?[)>3VXFAG\IRGFPMN1\'&5/<'M5
M0FY;JPIP4=G<@HHKVWX8_"VR\2^ H=6U>VN8<7LLC21R!&FMDB. N[@9DR,^
MB]N315JQI+FD%.G*H[1/$JZ'X=R/%X^\-O&Q5AJ5N,@^LB@UZ?X\\$^#O!NF
MVLVIZ-XD6:_M_,#1SJT%G*4XB,FSYCN!SD'CGVKR[P!_R/?AS_L)6W_HU:E5
M%4@VMBG3=.:3/5OVL;ZX;Q5H]@97^R)9>>(\_+O9W!./7"BO"P"2  23P *]
MK_:O_P"1[TO_ +!J_P#HV2O%[=@D\;-P P)_.E@TO910\6W[61HZKX=UO1X$
MFU;1]2L87;:LES:O$K'T!8#FLJO9[KQAX/O]1OC+#';VTVN+<W86.9UU*W!;
M9(0^[85)W,N &!X!^[50>)/"$%^7CL]' >_L5F8V0N$>W <3NH:WC"9!3*JB
M\C*^RA6FUK'^M/\ /^M;.5*">DN_X7_R/*+6WFN[B.WM8I)IY6"1QQJ69V/0
M #DFE%O.5F(AD(A_UIVG]WSCYO3GCGO7K>AZSX*TRUTF1+Z W-MJ<%R&^P[)
M((UF8N-ZQ;G&TJ?FD;/HI&*X[PUK^G:5>Z[=7=LEZLQ1H()-RK(1.K<\=E!(
MSQD#((X-1JRDW:),J48KXOZU_P OQ.:N--OK:2..YLKF%Y3MC62)E+G . ".
M>&4_B/6JTB/%(T<BLCJ2K*PP01U!%>F:%J?ANQF0C4[&2\%PTQO[^P>8M&7C
M8JP,;'S2-P##."&PPW E\/B+PM->VZ:A#8R6D<J3%UL561I#/*6+R>669=K(
M2K;@0,;2>*7M9:>Z'LXZZGEU%>K3+H.JS:G=1V%HVDZ?'!>2WEM'A'D4E3 6
M\B +Y@*@*$ RF1DEC7-^ ]1TN/7+^YUS^S((YT)7SH 51BX)\M/L\Z#C(P4'
M'1ASFE4;3TU0I4TK:Z''$$ $@X/0^M)7IUCKNA26>G1->:5%);0/#$]]I?FK
M&OVIG(=1&P+-&R[3\V"'Y4MDEIK_ (1:XLX)[.S3387CD1?L2B4-YTA/F2;&
M9P$,>0=RD#HQXI>U?\O7^OZ_IMTE=KF/,:*]7EU7PBTVJY;2(XYH$420Q%Y'
M8*X.Q6L51<Y4800\C._N/+[RW^S2J@FAFW1I)NB;<!N4-M/N,X([$&JA-R=F
MK$S@HJZ=R"BBBM#,***]1^ OP_M_&VOW,VK!FTG3U5I8U;;YSMG:F>N.&)QS
MP!WJ*E14XN4MD73@ZDE&)Y=17T]\?? WA/2? ,U_8:=;Z=J,,B" VR;?-RP#
M*P'48).3T('/.#X+X=\#^)?$=C)>:)H]U=VJ$J95 "DCJ!DC)^F:SI8B-2'/
MLO,TJT)4Y\F_H<W7K_[+][<0?$8VL4KK;W%I)YL>?E;;@@X]1Z^Y]:\GO;2X
ML;J6UO8);>YB;;)%*A5D/H0>17J'[,W_ "5*#_KUF_D*,39T9>@8>ZJQ]3ZR
MU'[L?^]3H/NTW4?NQ_[U.@^[7SI[Y#=_=-7+?_41_P"Z/Y53N_NFKEO_ *B/
M_='\J 'T444 <SXETS53KFG:UH,=C<W=M!-:/;WL[0(R2&-MPD6-R"#$O&W!
M#'D8%8_B7PQK]_)>&UDTN5]8TI-+U&65I(A!M,G[V&/:^_\ UTGR,R]%^;K7
M?44=+?U_6H[OI_7]6.!N/!=\T&K1136V+K7+'4HBS-Q% +;<&^7[Q\AL <<C
MD<X?IW@^_MAH(DFM3]@UN^U*7:S<QS_:=H7Y?O#STR#@<'D\9[NBG>ZL_P"M
M$OT%TM_77_,\FT'X77-OIU]IE\\4< TR?2[:\&I7=V[))@;_ ")2(H1A%)1
MP)Z%0,'?N-)\5ZG?:%>:E#H<!TR^67[/;W4K[XS#+%(_F&,?-^]!6/9CY3E_
MF^7NJ*5[Z,;=[_/\3R?P]\,+BVL+W3+]HTMO[+GTJWNUU2[NI&23 W^3(1%!
MPJDHFX$XP5 P>I\-Z5X@'BJXU;7X]*A0V$5E''9322DE79B[%D7 .X87G&.I
MZUU]%%]4^W_!_P V)Z[_ -;?Y(\XL?"OB+1YXKS38])N;NVN=16..XNY8HY+
M>ZF$VXD1,5D5E5=H# C)W#H-*_\ "5W%\/=)T+39K>>[TU[*1&G)ACF,$L<A
M!*AB@;81P&QGO7:T4)VM\OP_X(V[N_K^)PE]X0U"Y&M;9;4&^UZRU2/+M\L4
M/V;<I^7[Q\E\=N1R.<4]%\"75AXT-](L,NGQW]QJ,4S:I=LX>8/\HM<B!"#(
MXW_-E?X06)'H]%-.VW]:)?H@;NK/^M_\V<)XV\-:UJNMQW6C_9+9O)2)=034
M+FUGMR')RT<8*72C.5CD*@'<.C$U2\7^$_$FM:^)DN8);&*\M;JV+ZG/;B%(
MGC=HFMHT,<VYD8AW8D;A@#:*](HI+2S[">IY9J'P^U3[)I\MNT$][:W>I/Y2
MZK=:>K174YE!\Z ;]RX0%"-IRW/ --U?PG?:)I]W]@2-XWTBQL;06JS2217E
MM([0D(0Q\HLXRSR?*%Y)!)'JM%'2P[N]_P"M[_F<SK'AMY?!=OH^FR(L]G]G
MEMVF8A'D@=)%#D<X9D )P3R3@FL>S\)ZM-KUEK6H&PANCJYU"YMX)6D2-!9M
M;*J.44NWW6)*KU([#/?44[N[?]?UHA=+'$_$/PM>ZY?:5J&F!9+FR2>$PMJE
MSIP990A+>;;@OD&-?E(P03T(!K,\0?#^\N]&MK#39+*)(/#EWHRAGD"B240[
M"-V]M@\MNK%AQUKTFBDO=V_K?_-C4FFGV//YO".K0:E=ZI8M837B:PNI6L$T
MK)'(GV-;9D=PC%#]]@0K= .YQG^./"OC'Q1ILUK<7.G[+JR>$PV^I7-G':2L
M7^;]VA-R-K(I60HIV$[1NP/4**/Z_"P)VV_KJ<9::7K^CZQ?RV2Z7)I^H3Q7
MEW+(\AFA*Q)'(D<2I^\R(AM8NI!;[K8P9?AII)T[PV_FBX'VF9VC$\;12) O
M[N!2K?,I$2)D'!!)R >*ZZBAZJS_ *_K^MQ+1)(\JN/ .NWGAU](N)-,CCL-
M%N='TZ5)G=K@2A%62;,8\O"Q+E5+Y+$YX ._\1+35)7\)-HMI%=W5KJRRLLV
M\1*HMYP2[JK%!D@;L'!(X/2NVHIW>G]=;CO^OXJQYQ>^%?$K:7:Q0SVS^=/<
MW-_:0:G/8+YLKAU*3Q(9"$^9=N$#[MQQTIWA3P;KNAZ;<QQW]G!?G0+32[>X
MC!E$<\ F'F%64 K^\0\YZ'(]?1:*6R:07?\ 7K<\JM? >NSV7BZ.]>V@DUK2
MEL4#ZM<ZALE7S?F+RHI5#YOW5&!@X'-:?_"(:O<6.I_:6L(KF]UJPU39',[H
MB0BVWKN* DYA?' SE<XR<>A44T[.Z_K6_P"@OZ_"WZ'F4'A6XU7^V)[0R11R
M:U:SVPO8GA(AAN%GEPK#=\TC3X. #\O;!K2U?PKJMUK&H0VS6/\ 8VIW]KJ-
MQ/)*WVB%X?*RB1["K!O(C^8NI7<QP<"N[HH3LDET_P"!_DF-N]WW//;#PIK>
MC&SOM-_LZYU"WGU(&&XGDBB:&ZN?.!WA&(==J<;<'+#(X-6(/"6I+\/-"T.:
M:S-_8W-G/-(A98F\JX25]O&>0IP".N/K7=44EI9]O^'!N[OZ_B<%>>$]5CU.
M_P!5L&L9;P:TNJ6D$TSQQR)]D6V9)&",5.-Y!"MT7U.)/#7A&_TW7M/U.[FM
M"RP:@URD1.%FNKB.;:GRC<J[67<<$\'') [FBA:?E^%@;OO_ %_5V<?X?\,7
MNG#POY\MNW]EV$UK-L9CN9_+P5R.1\AZX[5S=OX#UZQ\.PZ9:2:7*;S0XM$U
M"2::0" )O'FPKL/F<32?(VS.U>>37JE%']?G_F"DUL<'XC\&WVH+XL2TFM@N
MJZ'#IEOYK,"LB>?DOA3A?WJ\C)X/'K2U'P%=W'C274%6&;3[NYM;R9I-4NX?
M*>%4&!;1D12_ZI"&<@@DY#!0*])HIW=^872W]=%^@4444@,^W_UK_P"\:O+T
MJC;_ .M?_>-7EZ4 .HHHH _/"Y_X^)?]\_SJ*I;G_CXE_P!\_P ZBKZD^:"O
MIO\ 9+_Y%W7O^OI/_0*^9*^F_P!DO_D7=>_Z^D_] KDQW\%G5@OXR/=9/NU7
MM/\ CX?_ ':L2?=JO:?\?#_[M>">V>-_M8_\B9H__80_]IO7S9X=TPZSKEEI
MRR>4UU*(@^,[<^V1_.OI/]K'_D3-'_["'_M-Z^:-%U&72-6M=0MTBDEMY!(J
M2@E6([$ @X_&O<P-_8:>9XN-_C:FXO@G5&MW(\@SK(J@+<1-"8RCN9//#^7M
M&P@G.,\9R,56D\':['#<2-8_ZARC()HS(^,9*)NW2*-R_,@*X.<U=7QQ=)&;
M=--TU=.*"(V.)3%Y8##9DR;\$NS9W9SC! XI7\>ZD=SK:V"72[DMKE8V#VL9
M !CC^;;MPN/F#$ GGFM[U>;R_K^NIC:GRKN9WB/PW<Z!;V#7LD+37/F9CAE2
M54V-MQO1F!/J.HQ@TB>%M8:Z^SFVCC<22Q%I;B.-%,8!<EV8*% 9?F)P<C!-
M-\1Z^^MBV4V%E8Q0;RL=J),$NVYB=[L>OOBM.S\>ZO::GI][$(0]G9_8@J-)
M%YJ8P69D=7WGY?F5E^Z/Q:=3EUWU_P" )^SYM-M/^"9T_A75X+>6::"% DGE
MA#=1>9*>.8TW;I%^8?,@88YS4O\ PA^L?;9+4+8&2--[L-1MC&GS;=ID\S:'
MS_ 3N]JT9_B!J,UEJ5LUM"4U!]\^^[O)=W"C!5YRK<*!N8%AV((!%U?BIKBW
MOGK'&$,'D&,7EYDC=N!\WS_-X_N[]O)XYS4\U730=J6NIS5YX?NH+W3+*)6D
MO+Z,,(6784<R,FPY/8KR3C'X5./!VLF:2)8[,ND8E7%_;D3*03F([\2_=;[F
M[!&.O%13^)KV;6;+4BL0N+484'<P<%V8ABS$MG>03G)'OS6SI?Q!N])2XCTO
M2=*LXID$9C@\]!MP00Q$N9,[C_K"^/X<4Y.HEHM0BJ?,KO30SH_!^HW5K;3Z
M<([A9K=9B&ECB.YF<"- S R-B,G:H)]JNP>"G>R,\ES(KM=0VL4"K"97+QB0
MDJ9A@ $8ZY[[:I6OBV>*Q@M+C3M.O8+=%6!;F-V$;*7(? 8!C\YR&!4X&5I!
MXNOQ<PS^3:[XIX[A1L;!9(Q&!][I@#\?RHE[2[M\OO\ \A1]G:-_G]W^9'_P
MB6KB.U=XK2-+@ JTE] @CRF\"0EQY1*\@/M)[9JTW@G5(;5I;A8]XDGA\B":
M*63=%&KDX#\J0P^9<_0Y7,MCXYN;.Z@NHM*TLWJ*%DNL3+-,0FP'S%D#(0/^
M>93/?-+<>/M4FNIKHP6:W<DTLXF <LC21K&V,N0?N*W()R/3BANI?^MQI4[)
MO>_X$"^!/$#730"VM0RIO+M?VXC'SA-N\OMW!B%*YW D<<US4T;PRO'*I21&
M*LIZ@CJ*Z>Z\:WDH*06&G6D!82&&!'VF3S5D9_F<G)**",X & !7-WEP]W>3
MW,@4/-(TC!>@).3BJ@Y_:)GR:\I#1116AF%?>'@^#3Y_A_I%O9.!836$<:%'
M[,@'!/>O@^NP\"_$/7?!MW UA<>?91,3]BN"6B^;[Q4?PL?4>IZY(/)BZ$JT
M5RO5'5A:ZHR?,MSZ9^*FH6]S\+?%D.HE)_LL8B$HCVJ\F5VL.3T<@=N00.E?
M*O@#_D>_#G_82MO_ $:M>B?$3XO:?XM\)W>GQ:%+9WUV(E>3SPR($D,G' +9
M)/7IG\_._ '_ "/?AS_L)6W_ *-6IPU*5.E)25O^&+Q%2-2I%Q=_^'/3?VK_
M /D>]+_[!J_^C9*\6C1I9%C09=B% ]2:]I_:O_Y'O2_^P:O_ *-DKQ>"0PS1
MRK@LC!AGIP:VPEO91N8XN_M96-^Z\&:Y:K.9;>WS"Y1T2]@=R1C=M57)8+GY
MB 0I!!Q@X=-X)UN'4EL)H[&.X8$C=J5L$)#;"N_S-N\-QLSN]JNQ?$/5TTN\
ML"J&&XGEGPMQ<1A#(VYEV)*J,,Y^^K=32Z3\0]5TR\>Y@MK,S%Y75P98V1I)
M-YPR2*<9_A)*D?>!P*$ZNETA-4M;-F1<>'IH=2TFP\U!<7ZJ<2$(L3&1DP23
MC@KUXJW?>$+J.]U%-/FAN[2RF:)W-Q;K,P4@,PB$I)&3U!(]QSBAJ.OW5_JE
MI?RQ0)+;$%%0-MXD:3G))ZL>_2M>Q\?:E9Z3>Z?#;6@BO))))6S*NXN<G*B0
M(V"!AF4L,8SCBJ_>:/U_/3\!?N]5Z?EK^)7U7P=J%I/;I:JUQYN5^;9&4?=(
M-A&XC.(F.0<=L^L?_"&:X(RQM[?_ %:2!/ML&]MZEE55WY9RHSL +8(..1F^
MGQ O_,DDFT_39W8[HRZR?NF)ERRX<9/[YA\V1P.,\T:9\0]7T^.]CB5/+NA'
MN5+BX@VE(Q&"#%*A.5 R&W#(Z"IO6L]%Y%6I77XG&T445N8!1110 4444 %%
M%% !7MG[.?C_ $?PJVI:7KTHM(KMUFBN2"5# 8*MCIVP>G6O$Z*SJTU5BX2-
M*51TY*43Z$^-WQ-77O#,UOX5O#_9HNS97C>6#]H4H&4C<,JN0XSP3M]*]2^!
MT\;?#;1[=+K3KA[>%0PLI=^S=\VUQ_"XSR/4$U\6B600M")'$3L'9 QVLPR
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M (7EX[_Z"<'_ ("1?_$T?\+R\=_]!.#_ ,!(O_B:.7%]T%\+V9M?\,Z>+?\
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M * '_DY;_P#QRC_A2OQ _P"@!_Y.6_\ \<KG?^$Y\6_]#1KW_@PF_P#BJ/\
MA.?%O_0T:]_X,)O_ (JBU?NON?\ F%Z'9_A_D=%_PI7X@?\ 0 _\G+?_ ..4
M?\*5^('_ $ /_)RW_P#CE<[_ ,)SXM_Z&C7O_!A-_P#%4?\ "<^+?^AHU[_P
M83?_ !5%J_=?<_\ ,+T.S_#_ ".B_P"%*_$#_H ?^3EO_P#'*/\ A2OQ _Z
M'_DY;_\ QRN=_P"$Y\6_]#1KW_@PF_\ BJ/^$Y\6_P#0T:]_X,)O_BJ+5^Z^
MY_YA>AV?X?Y'1?\ "E?B!_T /_)RW_\ CE'_  I7X@?] #_R<M__ (Y7._\
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MY_UZ%X6V_P"'_P C3C\!W4RVP%Y86LDKQP!9YG;S)6>1>-L>% $;$Y...I)
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MT'W:;J/W8_\ >IT'W:^=/?(;O[IJY;_ZB/\ W1_*J=W]TU<M_P#41_[H_E0
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M3O$EOK=]X>U"SU.SL?#&I0W%Q9RB:.-Y#$44NN5W$1N=N<X&>XHM=6]?RO\
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M:TWQ!9V>H7<]K>>'KZXEB?79;JZ\^,Q,HG@4!+5QF3,49VD;E(PN*F+YE?\
MK9,I1][E]/S:_0^C9K:WN6@DGABF:%_-A9T#&-L$;E)Z'#$9'8GUJ:O$)=6O
M1X\L[?3M8MA"LE@NEK-KERS75FR(9&6V5'6Y#9F!F9LJ5!)4+D]G\2+RTM]4
MT:+7]6GT?P])'<-+=17SV6ZY 3RHS*C*>5,S!<X8J.#C%-Z*_P#7]?KH3'WK
M>B.PDU2PCU2+39+ZU7498S+':M,HE=!U8)G) ]<5-#=6\\T\4,\4DMNP29$<
M%HV*A@&'8X(.#V(->5^ 6EB\4ZEKOB&2\CU!?#>G3WGG2R(H/^D;RT.[8IP@
M.,?*2V,%FSC7]QXD\.:+K>HZQ#;Z:VM:3>ND]O?/),+L)+/$"#&GELL9D4;6
M;_5J,\"B7NMI]/Z_3[QI7:2ZV_%+\KGN,B)+&T<BJZ,"K*PR"#U!%9]E<Z18
MK#IMC-86ZPN+2*UA=$".$WB)4'0A/FV@?=YZ5Y VH^=I<\7A_P 2ZI?Z?-+I
M,=S=B^=WBN9;H),BR$YC8H1NC! 3(PJYK4@:5/'5C9M<74T%GXH,$ N)WF9$
M&D$XW.23R23D\DDGDFJ4=7_6UO\ /02=XW\K_A?]-3TS4M=TC2[RTM-3U2PL
M[N\;9;0W%PD;SMD#"*2"QR0./44_4-8TS3;JSMM1U&RM+F\?R[:*>=8WG;CY
M4!.6/(X&>HKAOBU?Z2FF:EIO]HZ98:O>6H#Q7,)$^H1#?M@@?()DW$@%1(4+
M_<RPSD_$.\MXI_$\&H@0WVL>'HK?2H).))YP9\PQ_P!Z0/)$2!SRI[5*U_K\
MAVU_KR_S_K6WJ6JZE8Z18R7NK7MM8V<>-\]S*L4:Y.!EF( R2!56Z\2:'::7
M;:G=:SID.FW)58+N2Z18I202 KDX;(!Q@]JYGQSXIT#0+#3KK69[*XU.UNA!
M;1R7:Q(EVT)_UCD[8P$<L2PR%;(!)4'F;"\T+1;K1M4U'6M)N](NH-3\R^MY
M%-I]KFEBD:)&!V\@2!03N.UNY-)NU_ZZ7_'_ "[B6J3[_P!?A_GV/3]5U_1]
M(GM8=6U73[&:[;;;QW-RD33'(&$#$;CDCIZBEEUW2(=:BT>;5+"/5IEWQV37
M""=UP3D1YW$84\@=CZ5XY_:^C:;X;TKPOK%[IFE^(=0T&VMM4NM7N4B%K:[&
M 4+(?GD^9\(!@')<\ -T7BZ_T9;O3M,TC4-.^V0ZA:7$^F"/;?7[*T6R6-\@
MLH0 LX1PRH5W* Q%V]ZWG;\;?U]WF#V^7]??_P $]2HKQ[XW:_\ V;/<I;7T
M]KJ=OIQN;59=:?3XF?+X,,:*3=2@J-T;Y0#:.-QREY=7;ZEK&LQZKJ9DM?$6
MG6EM$MY(MNL,JV@D4Q A&#"5_O X)R,&E!<SLOZU2_4<E;^O*YZ[<7,%LT(N
M)XHC,XBB#N%WN03M7/4X!.!Z&N>E\7^#GUB*TE\0^'VU6&4PQPM>PF9)#\I0
M+NW!CTQU[5YY=7=K/XTT8:CJUW_PD@\22*^F&[=DCME680MY!.U%,8C82!06
M+'DY(J7P%XG2RGGL)?&OA&R3^VKY3I=U%_IAW7<OR[OM*_,V<C]WW'![J'O:
M_P!;+_,)^[?^OYO\CUZ&[MYGN%AN(9&MW\N8*X)B;:&PWH<,#@]B#WJO-K&F
M0:6FISZC9QZ=($9+MYU$3!L!2')P<Y&.><BN&@U[2?#&O^,[?Q!J-KITU[>+
M=VB7$@1KJ,VL*?N@>9#OC9=JY.<#'(SGZ]I$B?!'PQH^IQM'('TBUGC.05/G
MP*P^O6A:I6_N_CO]P65[>IZ>U]:+J"V!NH!?-$9EMS(/,,8(!<+UV@D#/3)I
MNGM8ND\FG&V96F<3- 5(,H.U]Q'\0(P<\Y&#7C&GZW<GQ;#K\D9DOUT:]L(4
M8;3)-#+:Q;.O>X:4 ^XJ>$^(?#=A?>%KF&PAU;7+>-=-\G4'D$TP41W,AD:)
M2I"[93A6Q\QYZ4=-.NWWO]%J+U^?EW_/\SV2UN+>^M([BUFBN;69 R21L'1U
M/<$<$&F06%G;M 8+6WB-O%Y$)2,+Y<?'R+@<+\J\#C@>E<I\.7O+!M5T'5;>
MTL[BTF^TV]O:W#3HMM-DKAV1"0'64?=&, 5SFL:N+?XI1Q?VL]Q.;R")+"#5
M98+B%"@#+]A*F.XBY,C3<%06P<QBG;WDEU_K^OF*_NMOH>KU%:W$-U D]K-'
M-"XRLD;!E;Z$<&O*-&\2/)K7A[1WU>2358_$>HI>6GV@M*L&V[:(2+G(3 C*
M@\8"XZ5A>'M0BM?#\R^'M:O[FY71;^34HOMCNMDZ@&$A,X@;.[;M"[U!8[L;
MA+=M?*Y?+[W+_6[7Z'O-4SJNGBX,!O[03B7R#&9EW>9L\S9C.=VSYL==O/2O
M)O$6G3Z?9^(GM]=\0YL_#ZZM%NU28XN\3?O/O9V_(/W7^J_V.F,_7E76O$=N
MVM7U\EO%XD^SQF/4)K=8_,TI2J*4==NZ0@ #DER!]\@MZ7\O\["CJKO^M+_J
MOQ/<+6Y@O+6*YM)HY[>9!)'+$P9'4C(((X(([BBZN8+.$S7<\4$((4O*X502
M0 ,GU) 'N:^<;;4[RR\+>$[;3=7@M8$T*%K&2XURY@W7^\B5 D:2&Y9&$:_9
MV^Z"5"\\=1\1[NWDU#58M=U:ZM-42^L$TRPCNY%CG@W0EF$&0L@\PRAG*DKM
M'*X%5)6=EW:_&PGIO_7]?F>UT445(&?;_P"M?_>-7EZ51M_]:_\ O&KR]* '
M4444 ?GA<_\ 'Q+_ +Y_G452W/\ Q\2_[Y_G45?4GS05]-_LE_\ (NZ]_P!?
M2?\ H%?,E?3?[)?_ "+NO?\ 7TG_ *!7)COX+.K!?QD>ZR?=JO:?\?#_ .[5
MB3[M5[3_ (^'_P!VO!/;/&_VL?\ D3-'_P"PA_[3>OGGP)+#!XRT>6ZDBC@6
MY0N\K[$ SW;L/>OHO]JVWED\#:;-'&S1PWZF1@,[04< GVSQ^(KY6KW,"KT+
M>IXN-TK7/5],T3PO++=G4ET*W<VZB2"'4/,6WF*OCRG-R-P/[LDCSL,2"% J
M*/1/#+MH; :/$6B)G@FO$<RD1C)9UO N=W0,;?Z'[H\MHK?V4KM\QC[6-DN7
M8[WQE!HWVW3-.TN>-].74)AMM7\UDC?R>@W,?[V 2>F,G%=.OAGP[!JMHVJ6
M6AV=NR2B2(:@TJ,%F"AE8W*?,%'(\PD$GY">%\<JYJFJZAJTZSZK?7=],JA%
MDN9FE8*.@!8DXY/%'LI6BD]KA[2+<FUO;Y'H=KI7A:[N;;3X;6Q>9&5Q+'>2
M,]PQEE'EM\^T)M$>2H! ^;<!5R\LM)L+*6R=K#3&N8(YVABU!FBWM;S E7#L
M63) X+ YQ\W?R>WGEMKB.>VE>&>)@\<D;%61@<@@CD$'O4NH7UWJ5V]UJ-U/
M=W4F-\T\AD=L# RQY/%+V+M;FT8_:JZE;5'8?$'3M L[S2!I36<:2!EO!93"
M4+AA@\3S?PGCYN?0$$5T&GZ+X8DUP&^A\.6]FH<>5'JC3;XMZ[)3FX0*^W=D
M>86](O7R:BJ]F[)<VU_Q)=1-MVWM^'^9Z3I\&CRZ>+3;I5]-;7%U]FMKV_\
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MZ7_V#5_]&R5YMX!L+34_$!MKZTGO$-K<.D,+[':18F9<<')R!@8ZXZ]#Z_\
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M $"[_P#\!W_PH_L+5O\ H%W_ /X#O_A1S+N'*^QFT5I?V%JW_0+O_P#P'?\
MPH_L+5O^@7?_ /@._P#A1S+N'*^QU5KXGM]*\&J--D6/6I?]'!B,BF! /FDX
M(3>PVJ#LR.3N)Z<1;7$UK<Q7%M*\4\3AXY$;#*P.00>QS5W^PM6_Z!=__P"
M[_X4?V%JW_0+O_\ P'?_  J(J,;ER<G8Z;QAX@L=;\.VERGE+JDS@746'+*R
M@[G4MN 5\@X38 >,-C(C^#/_ "5+PW_U]#^1KG?["U;_ *!=_P#^ [_X5W?P
M1\,:U/\ $K1KC^S;N.WM)?.FEDB9$10#U)'4G@"HGRPI22?1EPYI5(NW8^O-
M1^['_O4Z#[M-U#[L?^]3X?NU\Z>^07?W35RW_P!1'_NC^55+H?*:MP?ZB/\
MW1_*@!]%%% $5Q<P6JHUS-%"KL$4R.%#,>@&>Y]*@CU73Y+""^CO[1K*<HL-
MPLRF.0N0JA6S@Y) &.I(Q7/>(<R>.-&CG_X]TT^]FB!Z>>/*4'ZA'DQ[,U>8
M6,3:%\,_!%O#$YTO59]&E38N5M[GSX6<''W5D +9Z;PW=Q3@N9KU2^]M?I^0
MVK*_]?U_P3WRBO*/$FI2Q^,[V)M5NX-?2_LHM*TV.[=5N+-O+\Y_LX8+(/FN
M-SD$H(P01M%9NJ:OK[:'KD%O=7:R^'(5T^YFDGDB$N^==\S2 $@K:JK^8 Q7
MS6(Y%+I?^OZU2]0MK;T_$]IHKQW0Y[S5-%TVU_MEGTVXU\P12Z9K%Q=$P?9W
M9HOMCHCR#>&^8$[>@8%.+&CI=:=J6@7"ZMJ]PS^(+O2F2ZOI94-LB7)5"A.U
MF!C4^8P+\<L1Q32N[?UT_P U^/S3VO\ UU_^1?X'JMK<0W4"3VLT<T+C*R1L
M&5OH1P:H:[H5IKD<27TFH(L9)'V/4+BTSGKN\IUW#V.:\?\ ">H2VVD[?!VI
MWNHZLND7TEW:/<-.EM.N#;CRB2L3%LA0 N]<DAL9$&DZG?W/AJ]2SUT2V,M[
MI,/FV&N7-_+&\EPJ3#[1)&A0LA7,0)V')PNX5,??LO3\78;]W4]TL[:WT^RA
MMK2*.WM;>,1QQH-JQHHP !V  IJ7]F^G#4$NK=K Q>>+D2 Q&/&=^[.-N.<]
M,5G:WH&GZAX;;2[Y+B>QCC *274I,@4<"1MVZ0'N')#?Q9KR?6#J4WP,\/V4
M&CWM[HY\.B6[DM98%PRVX\M'$DB'9GYFVAB=@7!!(HG*RE+M_P '_(<(W:1[
MA&ZR1J\;*Z, RLIR"#W%9]SKVCVNL0:3<ZKI\.J7 W0V<ERBS2#GE4)W$<'H
M.QJMX7U".71-'BG7[)>S6:RK:32)YNU0H8X5B"!N7)!(&X>M<'X@UWPO?>++
MWPQ%J6D:?(U_;W6J3WEVB32SKY9CB@1SEF(2,%@ JCA<L3MN4;3Y/ZW_ *_+
MJ9Q=X<QZ3#K&F3ZO/I4.HV4FJ0())K-)U,T:G&&9,[@.1R1W%1:?K^C:E>7=
MIIVK:?=W5F<7,,%RDCP')&'4'*\@CGTKS'3[JU;5](TP3(NLZ?K^HWFHQ@[9
M(;9UN3YKC.0C"2':W0Y7'3BMI?B'P-KUK+>R:EI%OX:TG2KBUM]/BNU>ZDM"
M$$DDJ*3(BX10J?>.<MAB%$7TOY7_  W]/SUVL6UK;^M_Z?S6YZIIOB70M5MG
MN-,UK3+RW258&EM[N.15D8@*A*DC<20 .IR*NZI8VVJ:;=V%]'YMI=1-!-'N
M*[D8$,,C!&03TKR[3]3T3Q5I/BO7#J6D'S=)\G[%97D4TEI;()&1YFC)Q)EB
M<#A,8!)R3Z=HLEQ+HUA)>@BZ>WC:4$8(<J-WZYJK;W_J]_\ +]!7LTU_5K?Y
M_J6HD6*-(T&$4!5'H!3J**0;:(**** (H;>*&6>2) KSN))#_>8*%!_)0/PJ
M6BB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH S[
M?_6O_O&KR]*HP#]Z_P#O&KR]* '4444 ?GA<_P#'Q+_OG^=15+<_\?$O^^?Y
MU%7U)\T%?3?[)?\ R+NO?]?2?^@5\R5]-_LE_P#(NZ]_U])_Z!7)COX+.K!?
MQD>[..*KQD1S9;@$8S5LBH9(]U>">V.F2*>)HYE22-QAE8 @CW%4?[$T?_H&
M:?\ ^ Z?X5(UL#VIGV4>E--K832>XG]B:/\ ] S3_P#P'3_"C^Q-'_Z!FG_^
M Z?X4OV4>E'V4>E',^X<J["?V)H__0,T_P#\!T_PH_L31_\ H&:?_P" Z?X4
MOV4>E'V4>E',^X<J["?V)H__ $#-/_\  =/\*/[$T?\ Z!FG_P#@.G^%+]E'
MI1]E'I1S/N'*NPG]B:/_ - S3_\ P'3_  H_L31_^@9I_P#X#I_A2_91Z4?9
M1Z4<S[ARKL)_8FC_ /0,T_\ \!T_PH_L31_^@9I__@.G^%+]E'I1]E'I1S/N
M'*NPG]B:/_T#-/\ _ =/\*/[$T?_ *!FG_\ @.G^%+]E'I1]E'I1S/N'*NPG
M]B:/_P! S3__  '3_"C^Q-'_ .@9I_\ X#I_A2_91Z4?91Z4<S[ARKL)_8FC
M_P#0,T__ ,!T_P */[$T?_H&:?\ ^ Z?X4OV4>E'V4>E',^X<J["?V)H_P#T
M#-/_ / =/\*/[$T?_H&:?_X#I_A2_91Z4?91Z4<S[ARKL)_8FC_] S3_ /P'
M3_"IK73M/M)?,M+.T@DQC?'$JG'U J+[*/2C[*/2CF861H;AZC\Z-P]1^=9_
MV4>E'V4>E(9H;AZC\Z-P]1^=9_V4>E'V4>E &AN'J/SHW#U'YUG_ &4>E'V4
M>E &AN'J/SHW#U'YUG_91Z4?91Z4 :&X>H_.C</4?G6?]E'I1]E'I0!H;AZC
M\Z-P]1^=9_V4>E'V4>E &AN'J/SHW#U'YUG_ &4>E'V4>E &AN'J/SHW#U'Y
MUG_91Z4?91Z4 :&X>H_.C</4?G6?]E'I1]E'I0!H;AZC\Z-P]1^=9_V4>E'V
M4>E &AN'J/SHW#U'YUG_ &4>E.6V [4 273"1E53G!R2*EC7"TV.+;4ZB@"M
M<)D5+;R*8U7(! P13V7-5Y(0: +.X>H_.C</4?G5 VH]*3[*/2@">\LK6]DM
M9+E TEM*)H6#%2CX(R"#Z$@CH02#5G</4?G6?]E'I1]E'I0!H;AZC\Z-P]1^
M=9_V4>E'V4>E &AN'J/SHW#U'YUG_91Z4?91Z4 :&X>H_.C</4?G6?\ 91Z4
M?91Z4 :&X>H_.C</4?G6?]E'I1]E'I0!;:"![J.Y95,T:-&C9Z*Q4D?CM7\J
MEW#U'YUG_91Z4?91Z4 :&X>H_.C</4?G6?\ 91Z4?91Z4 3ZC96NI6IMKU!+
M 65RFX@,58, <'D9 R#P>AR*L[AZC\ZS_LH]*/LH]* -#</4?G1N'J/SK/\
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MDD C.<8[U$VMZY-8RNMJUO*L8*C[#,Q?!&7'8<9'EG+=P35S_A!?#G_0._\
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M#G_0._\ (\G_ ,52=?"<JC;;^ZO_ )(=I7N5YM9UI;/:UFZ7;L'4QV<K*D9
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
"_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>24
<FILENAME>image00025.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image00025.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  8$!08%! 8&!08'!P8("A *"@D)
M"A0.#PP0%Q08&!<4%A8:'24?&ALC'!86("P@(R8G*2HI&1\M,"TH,"4H*2C_
MVP!# 0<'!PH("A,*"A,H&A8:*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H
M*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"C_P  1" 'B NH# 2(  A$! Q$!_\0
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M_I4_WS_RT/K4?VZ[_P"?J?\ [^&H[G_CXE_WS_.HJ^HLCYJ[+/VZ[_Y^I_\
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MDM]-ALE<$(Q/S2%OXMI(P"1D\8[]_45W<P6=M+<7<T4%O$I>265PJHHZDD\
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MW52-NX[,#((&[.#C%9]WX5-QJ?A6SEBNKNTT1S<C4+EX@7PI5(MJ8)(.QL[
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MF7P1]3OR_P"-^AU=%%%>.>L%%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110!^>%S_Q\2_[Y_G452W/_'Q+_OG^=15]2?-!7W3\*/\
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M %_B_P#D=.[:0HOF2_KM_GKV2;/I:ZU2RM=1LK"XN8X[R]W_ &>$GYI-@RQ
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M9+R-[^2S"S^;'&LA8P.(R"2!B0C83QRH)(XR!D58KYBTG_D4_$7_ &3BQ_\
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M);:UU3PS?2W-@K7;EKR)T=4:65CYTBDJ25 '..<\]7X(V_V+XA_X5[YGG?\
M"%6OV7RM^_S_ #+CS-N_G=OWX]\8XQ0]%=_U\7_R/XE-:V7?_P"1_P#DOP/I
MZBO%_P!GD^#Q)J0\"?VV86MK<ZA]I#_9ENOFW >9\WG?WL?+C;BO:*J4>5V_
MK^NQ$9<P4445)1^>%S_Q\2_[Y_G452W/_'Q+_OG^=15]2?-!7W3\*/\ DFGA
MG_L'P_\ H(KX6K[I^%'_ "33PS_V#X?_ $$5YV9?!'U._+_C?H=71117CGK!
M117EWQ>^+$'@F*^L-.L[J]UR&S%WN%JTMM;@MM7SV5@5#$$#WQG&:.MAI7/4
M:*X2^^)^B6/BR/0)[?5'D\V*VGOXK0M9VT\@!CBDESPS;EQP1\PR1S4&E?%G
M0M4\8Q>';.SUAI9KJ:SAO6M=MK+)"C-)MD+<[=N#@9R1QCFA:[$WTN>A45Y[
M;_%73KJ\U^WL= \3WAT626"XDM=.,J22QNJ&.,JQW.=P8#C"Y)Q59?C)H)\/
M+J1TSQ MTVH?V9_9)L?].\\+N*^5N_N_-U_7BA:JY35M/ZT/2Z*\U\-?$J>Z
M^&5GXIO]%U/49[BYFA6ST2PDFD*K-(BG83E?E0$EB.?J!6=)\9K:YU7PE#H^
MB:M/9:XEPTDS6IWVS1DH59=V,HP)?GA<$9SP/3^OF%CUNFR*7C95=D)! 9<9
M7W&<C\Z\K'QIT2QT71;C4(-5O);RPCU"ZEL=-.RS@8D"691(_EJ2#P&<\?2M
M'QI\7?#_ (1U46-_:ZM=?Z+%?-/8VPFB2"1R@D9@W"@@9)_O#&2<4VM;?(2?
M7YG5^$_#EKX9T^:VM9KBYDN+B2[N+FY*F6>5SEF;:JKZ     #BMJL;Q/XBM
M/#NGVU[>Q7$EO/=06NZ%0?+,KA%9LD84%AD\GGH:Y(_%[P](=1BM4O9;BSU=
M=%*+&A+SMNPZ_.,Q_*V3D'Y3Q4M_U]W^:!+\?^"_T9Z-17DD?Q9F-WX$MHM(
MOKY/$=HUR]W#9F-4P.,)YC[0#\S_ #MM7!R<\4O"WQMM]8\&7US=V]Q::U9Z
M0^J2/]@8VTJHQ5C"K2*9 K8!&Y1G@-Z-Z7\OTO\ Y M;>?ZGM%%>;>+/B_H?
MA2\AL]5L]8GE:RAOI9;.SWQQ12,5WO\ -\H! SG^\ -QK7^*_C.3P-X+FUNV
MTZ?49!+'$D<:$A=[ ;FQR!V]R5'&<T/3?O;Y[ M?Z^9V5%>2Z7\8H/\ A-KK
M0]9TW4+:.6[M+:T<6;+]G,\*NJW3%L*Y8E0!SP>.,UT.E_$W1-2\8-X?@M]4
M5C-+;0ZA):%;.XGCSYD4<O\ $R[6[8^4X)XIVV_K^MP;MJ=S17'>/OB'I/@F
MXL;?4+74[VYNTDE6'3[8SO'%& 7E<9&$&1D_X&JVM_$JRTOPKH^OQ:%XDU*T
MU*W6[1-.L//>",H'W2D-M3 /][UQD FINK7'9WL=O<1+/!)$Y(612A(ZX(Q6
M5X0\/VOA7PSI^AZ?)/):6,0BC>=@SD9[D #//8"N5U+XL:-;7&D0Z?I?B#6F
MU*SCOQ_96GM<?9X)#A7E .5!YX )X/'3.!I?QPM6TW4KW6/#FO6R0ZU_9%M'
M%9[GF8AMJ[2P)DRA#*.A91SG-/:_];.WYL79_P!:J_Y(]AHKSCPU\7]!U[7K
M32X[#7+)[IV@AN;VR,4#7"KE[??DCS5P01TR, GC.?=?&72](LDDU*TU:_FF
MN;^*)-/T\;MMK)M<%?-;H.=V0"%)(3I0] /5Z9<1+/!)$Y(612A(ZX(Q7G.J
M_%**W\3>"K&PTG4+O3O$=N;H7B0'$494%3UXVY#.3]U<'G/$V@_%WPYJ_P#:
M+B'5;*VM+234([B]LVBCO+9/ORP'JZCCL#R.*4EHT_/\-QINZ:\OQV.K\(>'
M[7PKX9T_0]/DGDM+&(11O.P9R,]R !GGL!6Q7B^O_',6FEZ;>67@SQ:@N[U+
M?%[I;(6C92VZ+#8D8@?*NX="3CC.M<_&'2](\+^&]1U*SU:_FUFQDO8ET^P&
MXK&%+YC\UMG#9^\P 4Y:J;>K?]=24DK17]=#U*BN(\1?$>PT?PUI6N0:-XAU
M>RU& 7,?]EV!F,414-ODY 08(ZGU]#2>%/&Q\1^,KBRLA"^C'1[34[:78RRM
MYS2##9.,84<8!!S19WM_75_HQWTO_6]OU.XHKRB[^,=MI>N^-+?6-#U:'3?#
MIA!N8[?/F;V5>[ <EPRCN@)]JNZQ\7;#1M-L;_4?"_C&"SN$,DLS:2P6S0.4
M#3'=A<XW8&3@C(&0*2U2:ZA;H>E45P.K_%70-,\61Z%)!JDY\V&">_M[;?:6
MLDN/+263/RELKC@]1[U)\+O'DOC=M?\ .T:^TT:;?O:H;B(H)%!QC.?OC!W+
M_#E1S0M=OZV_S0-V_KO_ ,,=U17*^/?&D/@VSAN)]$U_5EDW%AI-B;CR549+
M2'(51]3Z^AKFM?\ C9X8T9K0R6NLW4-S80:F)[6T\Q([>5BH=SN!4 XSD=P!
MD\4+71#LST^BO+?BY\6;?P7!>V6F6=U?:U%9B\#"U:6VMU9MJ&=E(*ACD#WQ
MG&:[?Q'XDM?#MEI]UJ,<Y@N[N&S,D2@K"TIVJSY(PFX@9&3R.*%K^7Z">GY_
MJ;=<GX^\$0>-+>"&YUK7]+CC#*ZZ5?&!9T88*2+@AA^&>3SS5>Z^(5I%X>NM
M7M-%\0:E%!?RZ>(-/LOM$TKQN49U56P$RIY8KTZ<BLBX^,>A)I7A^]M=+U^^
M?6_/6VM+6S#W"O"0)$=-PPPR>F1\I.<46YAZK^NQZ!I&G6VD:59Z=81^7:6D
M*00IG.U%  &?H*=J=FNH:=<V;S7$"SQM&9;>4Q2ID8RKCE6'8BO/'^*D-AX=
M?5)]&U_5U6^N[9AI6E%O)6&0J6D_>LH Q]XL-W)VKR!5\6?%N/1=5\*S65A=
M:IH>M:=/?;;*T>:[;:$*;5W  88EMW3'44-\VKZ_Y7$ER[=/\['4> O =CX-
M?49[?4=7U6_U H;B]U6Z^T3.$!"+NP.!DXX[UUU><:1\3;._UG5+@S0+X8M=
M"M]92Z\MA*%=I-V[D]!&. ,YSUK;\">.].\9&\CM++5=.N[38TEKJ=J;>4QO
MG9(!DY1L'!SVZ"GJ_P"NSM^@M%_7E?\ 4ZRBO+/&7Q:@TSQ5;>'M&LKJXO%U
M2SL+N[DM6:TC\YANC$@88EVG(!XZ]<8JSXH^,6B>'?$]YH=SI6O7,]G-;P7%
MQ:VJO!$9PIC+.7 4'=CGG(. :2]ZS77_ ('^:&]+WZ:GI5%<5J7Q)T73M&\0
MZE<Q7PBT6_\ [-EC2(-)//A,+$H;YL^8H&<=^E7_  'XSL?&EC?7.GVFHV?V
M*Z-G-#?P>3*L@56(*Y)&-X'..0?K0M=5Z_U]Z!Z;ENW\-6<'C*[\2I)<&^NK
M..Q>,L/+"(S,"!C.<L>^/:MNN%TWXGZ)J/BY] M[;5=_FRV\%\]H5M+F>+/F
M0QRDX+C:WH/E/-'A/XG:-XHO9K/3+34A<VMO)/>QS1(ILBCE/*E^;B0E6(49
MX&212NK7Z;_J%M7_ %Y'=45YAX:^-GA?7$DD>WUC2[=;"344GU"T\N.:&/\
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ME7NOQ_R#Z_3[/^OF?:N:,U\5?\+K^('_ $'_ /R3M_\ XW1_PNOX@?\ 0?\
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M\+K^('_0?_\ ).W_ /C=']F5>Z_'_(/K]/L_Z^9]JYHS7Q5_PNOX@?\ 0?\
M_).W_P#C='_"Z_B!_P!!_P#\D[?_ .-T?V95[K\?\@^OT^S_ *^9]JYHS7Q5
M_P +K^('_0?_ /).W_\ C='_  NOX@?]!_\ \D[?_P"-T?V95[K\?\@^OT^S
M_KYGVKFC-?%7_"Z_B!_T'_\ R3M__C='_"Z_B!_T'_\ R3M__C=']F5>Z_'_
M "#Z_3[/^OF?:N:,U\5?\+K^('_0?_\ ).W_ /C='_"Z_B!_T'__ "3M_P#X
MW1_9E7NOQ_R#Z_3[/^OF?:N:,U\5?\+K^('_ $'_ /R3M_\ XW1_PNOX@?\
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MZ#__ ))V_P#\;H_LRKW7X_Y!]?I]G_7S/M7-&:^*O^%U_$#_ *#_ /Y)V_\
M\;H_X77\0/\ H/\ _DG;_P#QNC^S*O=?C_D'U^GV?]?,^U<T9KXJ_P"%U_$#
M_H/_ /DG;_\ QNC_ (77\0/^@_\ ^2=O_P#&Z/[,J]U^/^0?7Z?9_P!?,^U<
MT9KXJ_X77\0/^@__ .2=O_\ &Z/^%U_$#_H/_P#DG;__ !NC^S*O=?C_ )!]
M?I]G_7S/M7-&:^*O^%U_$#_H/_\ DG;_ /QNC_A=?Q _Z#__ ))V_P#\;H_L
MRKW7X_Y!]?I]G_7S/M7-&:^*O^%U_$#_ *#_ /Y)V_\ \;H_X77\0/\ H/\
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MJD6I7.JV:2I=-%++9PM)(@D93#M,;[<@,N"2O) ^9O%12U7D+ZO*^CTW_/\
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M'_\ $T?\,W>'/^@QJ_YQ_P#Q-']H4.X?4JO8^6**^I_^&;O#G_08U?\ ./\
M^)H_X9N\.?\ 08U?\X__ (FC^T*'</J57L?+%%?4_P#PS=X<_P"@QJ_YQ_\
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MC_\ B:/[0H=P^I5>Q\L45]3_ /#-WAS_ *#&K_G'_P#$T?\ #-WAS_H,:O\
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M )Q__$T?VA0[A]2J]CY8HKZG_P"&;O#G_08U?\X__B:/^&;O#G_08U?\X_\
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M\!],B74U37]7 U)=EW\L/[P;P_\ <X^90>,=/2CZ]%O67Y^7_!']4>EH]?\
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M]I1;<'=A6([8[4[_ (3/P_\ ]!*/_OAO\*U3:P)<0JD$2KM;@( .U6/L\/\
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M^I_E4\72H+[_ %D'U/\ *IXNE:%#GZ57M?\ CZG_ -U?ZU8?I5>U_P"/J?\
MW5_K2 M4444 8A\4:8-6_L[_ $[SM_E^;]@N/(W9QM\_9Y><\8W=:VZ\ITUM
M2'QDO;==8U.33K>;+6SN7B^>#?@Y=< %N $88 YSG;ZM1T3![V1S.J>.?#VF
M37L5[>R)+9E5D1+6:0L6.,(%0^80>H3=M[XJK!\2O"=Q!'-!JC2123B!&6UF
M(8D9WCY.8_\ IK]S_:JG??"_1KG5M3U."ZO[*]OY!*TMMY*M&^>6!,9W$Y(_
M>;]H)V[:KVGPET6TLXK:&_U411;8DR\1(M@,?9O]7S'[_?Y/S\T1^'WM]/\
M@A+?W=CO%OK1G=!=0%T.UU$@RI]#Z4[[7;_\]XO^^Q5>V_Y#%]_USB_]GJ]0
M!#]KM_\ GO%_WV*/M=O_ ,]XO^^Q4U% $/VNW_Y[Q?\ ?8H^UV__ #WB_P"^
MQ4U% $/VNW_Y[Q?]]BC[7;_\]XO^^Q4U% $/VNW_ .>\7_?8H^UV_P#SWB_[
M[%"_\?DO_7-/YM4U $/VNW_Y[Q?]]BC[7;_\]XO^^Q4U% $/VNW_ .>\7_?8
MH^UV_P#SWB_[[%344 0_:[?_ )[Q?]]BC[7;_P#/>+_OL5-10!#]KM_^>\7_
M 'V*/M=O_P ]XO\ OL40_P#'Q/\ 5?Y5-0!#]KM_^>\7_?8H^UV__/>+_OL5
M-10!#]KM_P#GO%_WV*/M=O\ \]XO^^Q4U% $/VNW_P">\7_?8H^UV_\ SWB_
M[[%344 0_:[?_GO%_P!]BC[7;_\ />+_ +[%%MUF_P"NA_I4U $/VNW_ .>\
M7_?8H^UV_P#SWB_[[%344 0_:[?_ )[Q?]]BC[7;_P#/>+_OL5-10!#]KM_^
M>\7_ 'V*/M=O_P ]XO\ OL5-3)T:2&1(Y&B=E(610"4..H!XX]Z '(ZNH9&#
M*>A!R*6N:^'=W>7GAIVU&Y-U<PZA?VK3LBH9!%>31*2%  .U!G KI: *47_'
MS/\ [_\ 05<7I5.+_CYG_P!_^@JXO2F M%%%(#\\+G_CXE_WS_.NUTRXTY/"
M4=Q?/=V\D4+PQ?NU*W$@:4@)\P. )OF.,# YR0#Q5S_Q\2_[Y_G74^'[ISI1
MMWUS5XH?*F'V- X@/RL<;A(!@GD_+W[U])55XGS]%VF<C7W3\*/^2:>&?^P?
M#_Z"*^%J^Z?A1_R33PS_ -@^'_T$5QYE\$?4ZLO^-^AU=5+[_4-5NJE]_J&K
MQSUBW575#,-,NS:PK/.(7\N)@"';!PI!(X)XZBK59'B]W3POJIC7<?LS@_/L
MVJ1AFS[#)_"E+8<=T9O@BYU*5K^"]TJ&QM(63[.\=L;<2DC+_(6)X..>]=37
M'_"]9ET&<3VOV9OM!POV809&U><!1GZUV%5+<F.P5YO\9 ;73;;6TSNT6\L[
M\XZE!*4<?3:YS5__ (3QRTH&EC]W,P.;@C,*_P#+0?)R3V RI[/P:U?&.G#6
M-*UK3/+9S>:<T*X&<,=X!_/!JJ4N62;)J1;BT=(I# $$$'D$=Z*Y/X9ZT=7\
M :#>,DKR-:(DC!>KH-C?^/*:Z;S_ /IE+_WS2E'E;BRHRYDFB:BH?/\ ^F4O
M_?-'G_\ 3*7_ +YJ1BWG_'I-_N-_*I%^Z/I56ZGS:S#RI1E#R5]JD6?Y1^ZE
M_P"^: )Z*A\__IE+_P!\T>?_ -,I?^^: )J*A\__ *92_P#?-'G_ /3*7_OF
M@ M_]9<?]=/_ &45-5."?#S_ +J7E\_=_P!D5-Y__3*7_OF@":BH?/\ ^F4O
M_?-'G_\ 3*7_ +YH FJ&ZZ1_]=%H\_\ Z92_]\U#<3Y$?[J4?.IY6@"Y14/G
M_P#3*7_OFCS_ /IE+_WS0!-14/G_ /3*7_OFCS_^F4O_ 'S0!-4-G_Q[)^/\
MZ//_ .F4O_?-0VLV+=1Y<IZ]%]Z +E%0^?\ ],I?^^://_Z92_\ ?- $U%0^
M?_TRE_[YH\__ *92_P#?- !)_P ?4/\ NM_2IJIR3_Z3$?*E^ZW\/TJ;S_\
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MV=?^>DO_ '\- $U%0_9U_P">DO\ W\-'V=?^>DO_ '\- $U%0_9U_P">DO\
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MM'AR!LB4=A[5H53MWES+B'/SG^(>U3>9-_SP_P#'Q6R26Q=B:BH?,F_YX?\
MCXH\R;_GA_X^*8$U%0^9-_SP_P#'Q1YDW_/#_P ?% $U,FEC@A>69TCBC4N[
MN<*H'))/84SS)O\ GA_X^*/,F_YX?^/B@#E?A3<P7GA*6ZLYHI[:;5M5DBEB
M<.DB-J%P0RD<$$'((KL*@LB3 <C!WOD>GS&IZ *47_'S/_O_ -!5Q>E4XO\
MCYG_ -_^@JXO2F M%%%(#\\+G_CXE_WS_.NTT^PTJX\)037WSRI#($>7450(
MV93M2(\G&(S@=?,]ZXNY_P"/B7_?/\Z[+1Y"/#L-B+-6CN;6>9KTPQGR=I?*
MYV$X^49).?F&,<9^DK7Y=#Y^C;GU.(K[I^%'_)-/#/\ V#X?_017PM7W3\*/
M^2:>&?\ L'P_^@BN/,O@CZG5E_QOT.KJI??ZAJMU4OO]0U>.>L6ZR/%MW;V?
MAZ\>\B,L$BB!D$GEY\PA.6_A'S<GL.:UZS_$,\%MHMY-=Q6\T4<9;RKAE5'8
M?=4EN!DX'-3+;4<=T87PQAT^+PRK:0DB6LCAP)9EDD^ZH&X)PIP!QU[GDFNM
MKE?AQJJ:QH!N8["TL3YFUH[4C:6VJ2<#D'G'/IGH1755I+<E;'FHTOQ?ND\V
M2\;_ $HNABN]@![.09"3$.Z\9_YYCK7>L9!JK^6J-^Y7.YL?Q-[&KM55_P"0
MK)_UQ7_T)JGI8?F<-\2#/8>(O!6NE(U^S:E]B<AR1LN$*$GCID+^E=[NN/\
MGE%_W]/_ ,37*?%[3WU'X<:XL'^OMX?M<1'4-$1(,>_R_K72:'?IJNBV&H18
M\N[MXYUQZ,H;^M:RU@GVT_4SCI-KY_H3[KC_ )Y1?]_3_P#$T;KC_GE%_P!_
M3_\ $U-161H5+II_LLV8X@-ASB0GM_NU(K7&T?NHO^_A_P#B:DF3S(9$!QN4
MC-/' H AW7'_ #RB_P"_I_\ B:-UQ_SRB_[^G_XFIJ* (=UQ_P \HO\ OZ?_
M (FC=<?\\HO^_I_^)J:B@"G T^^?$<7W^?WA_NC_ &:FW7'_ #RB_P"_I_\
MB:?&FQI#G.]MWZ ?TI] $.ZX_P">47_?T_\ Q-&ZX_YY1?\ ?T__ !-344 0
M[KC_ )Y1?]_3_P#$U#<-/B/,<0^=>DA_^)JY3)DW[<'&U@WY4 ,W7'_/*+_O
MZ?\ XFC=<?\ /*+_ +^G_P")J:B@"'=<?\\HO^_I_P#B:-UQ_P \HO\ OZ?_
M (FIJ* (=UQ_SRB_[^G_ .)J&T:?[.NV.(CGK(1W_P!VKE,@3RXE4G.* &;K
MC_GE%_W]/_Q-&ZX_YY1?]_3_ /$U-10!#NN/^>47_?T__$T;KC_GE%_W]/\
M\34U% %.1I_M,68XL[6Q^\/M_LU-NN/^>47_ ']/_P 33V3,R/G[H(Q]<?X4
M^@"'=<?\\HO^_I_^)HW7'_/*+_OZ?_B:FHH AW7'_/*+_OZ?_B:BNFG^RS;H
MX@-ASB0GM_NU;J*\_P"/2;_<;^5 $B_='TI:1?NCZ4M %2^_UD'U/\JGBZ5!
M??ZR#ZG^53Q=*8#GZ57M?^/J?_=7^M6'Z57M?^/J?_=7^M("U1110!Y+ISZ\
M?C'*=0O-"@MFN&,=C)=0RW0B-L%S%\OF+N9 Q' P#]3ZU7DT)OH/C[<P)8W\
M=G/$ER95O (9?W!1I#'MY *HF"=V2&Y KUFA?#$<OB?R"BN.UGX@6&E7^H63
MZ=JL]W:-$JQ0Q(#<&3=CR]SJ,#8W+;0=IV[JRK/XN:)=V<-S#8:N8IB'3,48
M)MB,_:3^\XBX/7Y_]BA/F5T)Z:,[BV_Y#%]_USB_]GJ]65;74)UF_P#G^ZD:
MG@]1OJ_]JA_O_H: )J*A^U0_W_T-'VJ'^_\ H: )J*A^U0_W_P!#1]JA_O\
MZ&@":BH?M4/]_P#0U'<:A:V\$DT\P2*-2S,0< "ANVK YO1_M<?Q-\06\NI7
M=Q9KIME<QV\NS9$TLMTK;<*#@"%<9)ZGKQC=U;7-,TE<ZC?00'KM9LL?HHY/
MY5Y3HL-YXD\<ZG*=0O;&WDA6X9D<I(UO(\JPJ/;,3_0#/?GT+2?#7A_3&\R&
MU26?.3-.#(Y/KD]/PQ7%3KUJRO"%EW?YV,HSE+9%3_A+KS4OE\-Z)=7:G@7-
MQ^YB^H)Z_H:/[!\0ZMSK>MFUA/6VTY=GX;SS_.NJ^U0_W_T-'VJ'^_\ H:OZ
MLY_Q9-_@OP_5L?)?XF9&D^$]%TM@]M8QO-U,TW[QR?7)Z'Z8K=J'[5#_ '_T
M-'VJ'^_^AK>%.%-6@K(M14=$345#]JA_O_H:/M4/]_\ 0U8SG/#FA:EI_BK7
M=1N]5@NH=09&,"69C,950J8;><@*,'CD\\=*ZFJ<5S$)YB6X)&.#Z5-]JA_O
M_H: )J*A^U0_W_T-'VJ'^_\ H: )J*A^U0_W_P!#1]JA_O\ Z&@":BH?M4/]
M_P#0T?:H?[_Z&@ MNLW_ %T/]*FJG;W,0,N6ZN3T/M4WVJ'^_P#H: )J*A^U
M0_W_ -#1]JA_O_H: )J*A^U0_P!_]#1]JA_O_H: )J*A^U0_W_T-'VJ'^_\
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MM9BT.=RF<@,=C8(DV\IE=V[ ^49QVKI/!GB&;Q):W5R]G#;P0S&!&2X,OF$
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M^/F?_?\ Z"KB]*IQ?\?,_P#O_P!!5Q>E,!:***0'YX7/_'Q+_OG^=15+<_\
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M_P#K+C_KI_[**FJO;LOF7'S#_6>O^R*GWK_>'YT +12;U_O#\Z-Z_P!X?G0
MM0W72/\ ZZ+4N]?[P_.H+IEQ'\P_UB]Z +%%)O7^\/SHWK_>'YT +12;U_O#
M\Z-Z_P!X?G0 M0V?_'LGX_SJ7>O]X?G4%FR_9T^8=^_O0!8HI-Z_WA^=&]?[
MP_.@!:*3>O\ >'YT;U_O#\Z (I/^/J'_ '6_I4U5Y&7[5#\P^ZW?Z5/O7^\/
MSH 6BDWK_>'YT;U_O#\Z %J*\_X])O\ <;^52;U_O#\ZANV7[+-\P^XW?VH
MF7[H^E+2+]T?2EH J7W^L@^I_E4\72H+[_60?4_RJ>+I3 <_2J]K_P ?4_\
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M7GA^_CFM$O,0NZ0/G#L%.!QSU].:U:S_ !"%.@:D'B$R_9I,QF7R@XVGC?\
MPY]>U3+9E1^)&1\/F1]%DDCM(K57E) CMC '^5><%VW>F<]L=JZ>N1^&>G/I
M>@RV[6DMNHG^1I#@RKL4!MN!MQC;TYVY[UUU:2W(CL<S-X/M[AY&N=1U"5I)
MFE8L8LE6^]&2(\E2 HYY 4 $"MDQH^JR;T5L0KU&?XFJ[55?^0K)_P!<5_\
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M (6_9_\ 0I^,/_!>G_QRO3:*7,NWY_YCY7W_ "/,O^%OV?\ T*?C#_P7I_\
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M8;)&1E/J&4@@_0U;HH SM%T6PT6.2/38#"DA!(,C/C'  W$X4=@, >E:-%%
M%2^_UD'U/\JGBZ5!??ZR#ZG^53Q=*8#GZ57M?^/J?_=7^M6'Z57M?^/J?_=7
M^M("U1110 4444 %%%% %/\ LO3SJHU0V-K_ &D(O(%WY*^=Y><[-^,[<\XS
MBKE%% !1110 4444 %# ,I# $'@@]Z** ,3_ (1+PY_9W]G_ -@:1]@V[?LW
MV*/RL;M^-NW&-WS?7GK6TB+&BHBA44850, #TI:* "BBB@ HHHH R='\2Z%K
M=Q-;Z+K6F:A/ ,RQVEW',T?./F"DD<^M:U>;ZM\+8-48+>7\<L'GW,S0R6H9
M7\Z>27!!;MYF/?;GC.*K>"_A%:>&/'4GB2&_5V:'REAB@:'&456!Q(4*E@TA
M&S.]L[C1'5:Z!+1^[J>B64VFW-Y<RV,EG-= +%.\+*S@*6PK$<\'?@'H=WO5
MVO*#\)//AC>?4+>.]2#[+YBVWF"2((Z['^92R/E&=.AP1G^*H=%^#2VBK;ZC
MJEE?::L_G?8O[,"18,\4SQ[3(PV9BVJN/E4@<XY(ZRL]A/2+:W/66GB2:.%Y
M$660$HA8!F QD@=\9&?K4E>?^&_A^^A:X+F*]@EM/[3N-3VK;B*16DC=-K,,
M^8?WARQ(X10!UKT"@84444 %# ,I# $'@@]Z** ,J;PYH<Z0)/HVFR+ T;Q!
M[5"(VC&$*Y'!4$@$=.U:M%% !1110 4444 %%%% &?I.B:5H[W+Z3IEC8O=/
MYD[6MND1E;GYGV@;CR>3ZUH444 4HO\ CYG_ -_^@JXO2J<7_'S/_O\ ]!5Q
M>E,!:***0'YX7/\ Q\2_[Y_G452W/_'Q+_OG^=15]2?-!7W3\*/^2:>&?^P?
M#_Z"*^%J^Z?A1_R33PS_ -@^'_T$5YV9?!'U._+_ (WZ'5U4OO\ 4-5NJ]RF
M^-EZ9'6O'/6+%%4_MC+]Z%L]\$8I/M__ $Q?\Q18"[15+[?_ -,7_,4?;_\
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MV[_IB_YBBP#K[_60?4_RJ>+I51I#<2H=A55SC)Y-7(Q@4P%?I5>U_P"/J?\
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MUK76O9KZP\AI890)-,1KE!&581K.&!\LLH)!!/4 CC&UX.\/_P#".Z?=1R7
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MG]?UZZ_J5UMZ?U\M/T.ALOB'I<T*7%SNM;=GNT DBF\V0PSI$/+3RLON,B\
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M$=C@<  ].1S_ (.\&:CHNAZ19W4UH\MI>07$AC=BI5+182!E1SN4GZ>_%/\
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MAN2WF*I<L0-X!;"]#M-27+N+MZ7_ #_R/5)9XHGB265$>5MD:LP!=L$X'J<
MG'H#4E>2:I.DO@;P+J-_J-X)D<LMS+=/"[R&TGV[\%<L6"C!'4XQR16/JVM+
MI+^&[>WU6Z&IK#82L=0\02QM*)I09&B@.[[23EPV_"H H7&" EJVO-+[[_Y
M]+>ESW.BO'-0,UII\U\^NZC;M>KJ2W$MSJ$_DHL=T @&TGR%"_*9$ *J2QSB
MK3ZKITVB^'G\0Z[?:1H;6DY2Z_MAXQ-.KJJ?Z4"K2C9N9-W^L7YBK$<"_K\?
M\AV_K^OZL>JW5Q#:6TMQ=2QPV\2&2261@JHH&223P !WI+6Y@NXS):S131AV
MC+1N& 92589'<$$$=B"*^?\ QUJ^HR-XFA?4XO->UG6.WN=4G2XDL_L9.?L
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MVQF7MU#$8(K3H **** "BBB@"O>V<%]'&EU'O6.5)E&2,.C!E/'H0#5BBB@
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MU.E^&9M$TGP?:6TOVMM$C2TDDQY?FQ>28V8+DX.0K8R> >IQ76T55W_7E?\
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M0W%I#K.GQZ7>,/M=G:Z5Y*!1*\A6']Z1$#YA4Y#\ 8P>:]+HI+38'KN>9O\
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M-^Y2,*6. , #CH*R7M-$U6WM]*T3Q9;SW2&6-_\ 38IYF24AV7;@\848 "D
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M^1I6-H1',"[%%9-_(0, HW<%01CI7=44/7<#C];\'3Z@]JT&J&W\FS%HPQ,
M^/XB(YD!_P!UPP_6HK?P(L4REM19H<JK((%R8D8/'&"20%5@.QXR.]=K11UO
M_6M_\V']?E_DBCH]G/86,-K/<BY6&-8T<H5<@<98[CDXQSQSGUXO444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 <Z? _A,D
MD^%]")/))T^+_P")H_X0;PE_T*V@_P#@OA_^)HHKU#S _P"$&\)?]"MH/_@O
MA_\ B:W;2V@L[:*VM(8H+>)0D<42!511T  X HHKGQ.R.C#[LEHHHKC.L***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
IBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>25
<FILENAME>ex1015101.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex1015101.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    /   _^X #D%D
M;V)E &3      ?_; (0 !@0$! 4$!@4%!@D&!08)"P@&!@@+# H*"PH*#! ,
M# P,# P0# X/$ \.#!,3%!03$QP;&QL<'Q\?'Q\?'Q\?'P$'!P<-# T8$! 8
M&A41%1H?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?
M'Q\?'Q\?'Q\?_\  $0@ .@#( P$1  (1 0,1 ?_$ *<  0 #  ,! 0
M       $!08" P<!" $!  ,! 0                (#! $%$  ! P," P4$
M!@@$!P     ! @,$ !$%$@8A,4%1(C(3%&&!,P=QD:%"8B.Q4G*"DC0U%L%#
MTQ6#)$1TE#9&$0 " 0($ @@$! <! 0       0(1 R$Q$@1!46%QH=$B,E(3
M@9'!0O"QX11R@I*B(S-#8@7_V@ , P$  A$#$0 _ /U30"@% * 4 H!0"@%
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MC;>!5YNX)HTG1Q3%9/!;[JAX;#P]:GMK*_V3\D>WH1V]=^R/F99[7VM%P<4
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M^GQR*X_RGH$7X8^'_P +P^ZL$LR^.1W5PD* 4 H!0"@% * 4 H!0"@% * 4
/H#XCPBC.L^T."@% ?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>26
<FILENAME>ex1015102.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex1015102.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    /   _^X #D%D
M;V)E &3      ?_; (0 !@0$! 4$!@4%!@D&!08)"P@&!@@+# H*"PH*#! ,
M# P,# P0# X/$ \.#!,3%!03$QP;&QL<'Q\?'Q\?'Q\?'P$'!P<-# T8$! 8
M&A41%1H?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?
M'Q\?'Q\?'Q\?_\  $0@ /0"6 P$1  (1 0,1 ?_$ )T  0 " P$! 0
M       %!@,$!P$"" $!  ,! 0                (#! $%$  " @$# @0$
M! ,%"0     ! @,$!0 1!B$2,5$B$T%A,A1Q0B,'@:$6P5(S4Q61L6)R@I(D
M1"41  (! @4!! D#!0$        ! A$#(3%!$@0B46%Q,O"!D;'!T4)2$^%B
M(Z'Q@C-#%/_:  P# 0 "$0,1 #\ _5.@&@-&?,5(<I7QGJ>W81I0B+W=D:$
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5,L&@&@&@&@&@&@&@&@&@&@&@/__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>27
<FILENAME>ex1015103.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex1015103.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    9   _^X #D%D
M;V)E &3      ?_; (0  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0(" @(" @(" @(" P,# P,# P,# P$! 0$! 0$" 0$"
M @(! @(# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# P,#_\  $0@ 6@"6 P$1  (1 0,1 ?_$ )$   $#!0$!
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M9P5 QT4'"1B['3 PB _EU6G5Z T!H#0&@- :#'=CLV6'L[""(]6VP ':(CU
M(;  >O0?"5YIUW"\^9'R1C+4O((JT]K6,<UXCRM/&[UM74Z0@LV:5QRX \<Z
MB)(\^LZ2DP H ]74()MD^S4<-1Q;ZC. _*G$-VX,<>[G4(*;@VC#',34#XR@
M:M,GGJ[,4F,^Y92$3AC,$%CIHN8T2I.>HS5=18H@N<3";66?#G(BW9MO[]_]
MQ597&E=2ZA92EYBT'$Z^*=%H1,Z,&G)[,^AT990/%ZB*(E* "!MPU$U;@,&6
M@1!QDC*UMR.X.#@7#=TTBX**,8[CJ0%K'Q!42-!;L=VY!*('V4.IU <0VJEH
MAL?TN!;M&\568EJ1F4GPXF:IKK)F*EX('%=QXJQE03$0ZA,(]OIT'2H1[%JF
M5%JT0:HD*!2I-DBH)E* ; 4J:0$*4H!Z@#07!:-S"4PI@(E[O:;8-MQ =M]N
MH.H>WTZ"H-D"FZBI@4VPAU%$Q1 !#8=A*("&_KV].@P)*#AY=FHPE8MC*,S@
M8#-9%LD^1'<IRCLFY*H #TJ& !#80ZAV].@8%R*PA3J;$M)N!J-8_#B[Q?[Y
MCI1\K%(L7KA4JC.0;N"'(@UBV"0*K*)]75XK=$"^R8PA)I)B(;3A>[DDD;;$
M1U3>UVOBTBI7Q0=M5X9[97"BK.35C51=.70H(M&B*)! H)F!N/='O((X/^#?
M8-_3L&_Y?7JJKH#0&@- :"@B  (B.P!Z1'0<#=;S$5-DBL]/(O7$DLK'PD'
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M5*IILU1A$;#$R2B;8;@BE(+@Z$J94DE%! "B8 ,$]3T[S54: T!H#0&@- :
MT!H#0&@- : T!H.>G+&P@2[OCF$RA %LU;IF7?/#F520*DU;%$#+J&76(78/
M0)@$1 .W0<-'T4+'98_(%Q37+-QK0&4364I)1]6H(6\@\>,9EN@JU0(K9U6C
MP".'( )2;>$3L)U&(5@I>D.T1,([=1A]8AV;[>@.SZ-%>M : T!H#0&@- :
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!V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>28
<FILENAME>ex1015104.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex1015104.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    9   _^X #D%D
M;V)E &3      ?_; (0  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0(" @(" @(" @(" P,# P,# P,# P$! 0$! 0$" 0$"
M @(! @(# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# P,#_\  $0@ 8 &U P$1  (1 0,1 ?_$ +<  0 " 04! 0
M       '" 8! @,%"00* 0$  P$! 0$!            !08'! ,!" (0   &
M @$$  0$! 4# P4   $" P0%!@ '$2$2$P@Q02(446$5"7&!,A:1P4(C%^%2
M)*&Q8I(S4\,E$0 " 00" 0(#!04%! @%!0 ! @, $00%$@8A,1-!(@=183(C
M%'&!0C,5D:%2<A9B@D,DL9*B4V,TE C!T=-5)J.SI"47_]H # ,!  (1 Q$
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M&QLC,G7&Q(WER7-E5069C]@ N2?V5SY>7BX&+)FYTB0X<2EG=V"HJCU+,2
M/M)KZF#]C*L6<G&/&TA'2+5N^8/V2Z;EF]9.TB+M7;5RB8Z+ALX04*<ARB)3
M%$! 1 <_F6*2"5H9E9)D8JRD6((-B"#Y!!\$'TKTBEBGB6:%E>%U#*P((((N
M""/!!'D$>HKZ\\Z]*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3
M%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3
M%*BBSVB>FYA]0=?F,SFVR38;'<GD4L\@JBT>D!0469SF092]Q.S."C=GWJ$;
M>1)=T043%35G<##P\?'7:[4AL?D>$ :SS$?XK>4AO^)_!876,AO*UO8;'.RL
MMM+I05R0 9<ADY1PJ?4+<A7R"MRB>50E7E4I\K0#J2IO];>UNUJFA?K[<86S
MZ1U7>Y%K>[7*6=1E;T+;L.KOY6%2>KF95Y&>CH] [EHQ1:L@42(***8 (#:]
M]EQ[?H6#LVQ\>#(@V>3C+[,:Q@Q>U#, UA=RK.0&<LUO4FJ/US7Y>C^J.SP%
MS,K)P,O3XN2RS2%^$ZSSP,R#PJ"1%4E4"K<7"BKJYF]:Y3%*?#J/RQ2O++V+
M7BO;6J2B#Y_/DT&2UFU?KJ"AW4M K[^W3)R3RI-I64.U.RF'VH:%.)G63^V[
M6TJ1JZ?J&6C4$S'V7IT^;T3/2?#&/_J1L<Y$S2*7_1XT8+M%:Q"SY"V#W'.,
M&-5*.S6_._>$Q?JAKG623*3J:9?Z7%6)A&<_,8F,3GE;GC8K@M&/*3<9'99$
M6.O2*B4N UQ2:CK^J,B1M9I-;A:I ,$^I&</ 1S>+CVX#\3>)JV* C\1'KF4
M[7996XV>1MLYN>;DS/*[?:TC%F/]IK=]1J\32:K&TVO4)@XL"11J/@D:A5']
M@K*\X*D:T$0 !$1X  $1$?D ?$<4]/)JDNK/< ^Y/8C8&KJ707PZFUE69&1G
M=VR3LJ$!/3[6:_1$F%23(449*&^[CY(IG_D%)0\>J!.0 1S1M[T)>N].PNP;
M'*4;K.F95PPI]R-%%R90?F5_*$(5!LP^-ZR+J_U43MW=]GUS5X4JZ#5)^9G2
M76*5[D P&W&2*ZN#)R_AY6XLI->=W51_[L*5IC;GMDK6B+?>V5+U+2HY5]$R
M6T48=[(S&P-OVYTQ5*Y:TTU*KSQ.K(][<C@%RNE15^[9D);NL;:+Z9&9\!(I
M^SQXS/E3, Z8Q(M#BPW%O=:1A^HD/)? 2.Q5RU&[CJ\SZOPX\&>TT/3<K+CC
MP\=&]M\J-6+9.=D68'V1"+8T1 96(D<7=>'JA$14? Q49"1+5)C%0\>SBXUD
M@7M1:,&#=-JT;(EZ]J:#=(I2A^ 9B.1D2Y60^5.Q:>1RS$^I9C<G]Y-?H_&Q
MX<3'CQ<=>,$2*BC[%4  ?N KL<\:]Z8I3%*8I3%*8I3%*8I3%*8I3%*8I6@B
M!0$QA "@ B(B/   =1$1'H  &*5 UA]G]#UJ0D8EYL>&DY:&442FHJJ(R5VD
MH11(I#JEFV%08S;J(\9% ,;[DB7!1Y^&6C#Z7V;-021XK1QL 5,S)!S!].'O
M-'SO\.-[U1\KZD=)Q<B3%&?%/DQ,5D7'63),;"Q*R_ITE]L@$$A^)MY]*S[7
M6T-?;:K_ /=&M[;"W&"*\7CEG\*\(Y!G(M1*#J-D$/I=1LDV[P\C=<B:Q.0[
MBAR&0^SU6QTV4<+:0R090 /%Q8V/H1\"#\"+BI_1]BT79L,[#09<&7B*Y1FC
M<-P=?Q1R ?-'(MQRC<*ZW%P+UGF1]3-,4IBE<:JJ:":BRRA$DDB&4554,!")
MID*)CG.8P@!2E*'(B/P#/Z56=@B EB; #U)K^7=44NY 0"Y)] !50(KV[962
MSZX-5M5WV7T]LF[/]?0V\%OTF+K3F>3CY-W#2<37GCL+5+T>Q.8E5LSG/MD&
M+DYDE$#+HJD4&\3='DP\3,78YF/!V+"B]Q\(W:3@./*\B<HEE0-=H6;W% /(
M @@9=']4<;)V& <+7YDG5]AE_I8L_P"5(C.>7 +$Q$S0N5*I/Q$;'\)(L3</
M*+6ITQ2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*5H8Q2E
M$QA I2@)C&,( 4I0#D1$1Z  !@ DV'K7PD 7/I7DI<??C;5K]MK%ZX>LU$IF
MRZ['0]8K"NTG,D[<5"J;)L3-[8Y1_/R<4[$DU$U&J-/(K%QQ%'2[D1(JY:%
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M1+S"_'B!?S>M4^G&_P!QVGIN%V/=Q1P9N:C2B-.5EB=V,(/+R6]K@6/H2;@
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M'M&DZMC&<E<IDK$TJ\_3("(:-W$G8K-+B@JY)#UFOQZ;B7GI51! YP0;)*'
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MWA\QT/MW4D+8GPIMDNHQ<W5:_(W\,:K]1^S,7C$B!GQX_)QXY@&^:+7Q.ON
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MP:R2:<$7DDF+QA%0_P *QJZL?MY?=5SS/F1'B4>=XU(_71.X18F<)%=JMTC
M51=)L)P6413,8 ,8"B4!'J.9UQ;CSL>%[7^%_LO]M:*9(Q((BR^Z1<"XN0/C
M;UM7U9\K^Z8I6@B  (B/  '(B/P  ^(CBGIZ^E8<>_55M0UMER<LUA*8UK:]
MN?3DVLE&,8ZNMF)Y)>6D'+DY$6;)%@F*QE#F I4_J$>,Z,'$R=EE186%&\F7
M.ZHB*+LS,0%4 >I)( %1LFVP8-4VZR7$6N2$RLS_ "A44%BS?8+"]>1/K:VL
M?N_M[9.YKDH@\UHXES551FDX6;NZMKJM2+6;JFA454$B\N[M)'+.[#1\B8.&
MY&$4Z261. I;]W?C]-=1@=8PE1=@,8S,19Q+D2AHGRV!_P " QX@(O&P,J&Y
MN?S=T$Y7U3[)G=IS@[:9I#!)S#)PAA?W,?!AM8.O-C+ERJ>,M_886! KQ[#7
MG97L78_<;<>MTV;C3^MJ%+^NM,FX10A[;>K [0)#0^LM>O$&ZIF9-F;9L21I
MI9!4"NH-M&(B14CSO1N>@UNFZ=K^M]:VD E[1F3-L9>=N&.+!S+,I/GABH4C
M#?@F$C^"!5&['L]WWS<]F[7JLDQ=3U\::N(1^'R'YJH@4\;E9,A^<G'P^.\<
M8Y!F!])J_1?[OJNI?44ZZC_7.B-=:XB_9!T)2O(*WG@Z1&M(/2CMPJ3E\A8#
M%1F)Q#X?HZ2#5<ADI/@,2S-D,'/V'<!$R[#9Y.0V 3X,2R3L7R /M5;PQ^+<
MF9U/*,5OD>$^X&NZ.K?_ --J,?';8E3:.1XX5]G#MQ)*%K3RA67BD:1MR61E
MK(/3:*_N.T>S._TQ*>#V[MP:MKPZ:WD;*:OT5'GUC7%XUN4I4&$*^L+"9=,T
MDA,FHBX!P @+@2E^_426+"Q--U91_P WKL#GDW'D966PGF5B?)9![:M]A!'P
MN??Z6QR9\N[[:_\ Y;9;1EQK'Y3AX@_3X[(MK*C!7=0/7ER\%K"\YCD)P!SE
M*)A$"]Q@+W" <B <B'(@&9BS*BEG("CU)\ 5K/KX'K0IR'#N(8IR_B4P&#_$
M!$, @@,/*D7'WTJ"?:2S3%+];-]VZOE5-.5K4&PYN)!  %;]0C:K*.FHI]WT
M]X+) (<],L?48\>7M&O3+ .-^LA+ ^A <$@_<;6JG_4+*GPNB;C+Q>7ZB/69
M++Q\-<1.?E]/F_P^1YMY'K68:;K<?3=1:MJ420B<76==TN!CRI\=@,XFN1K%
MN)>T  >Y- !Y^?.<O8LN3/[!GYTU_>GS9Y&O_B>5F/\ >:D^KX,.KZUKM9C
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M*XN7L(X>5KUUHACM8273T?'/BAK>KQ+&57330L6P&T(P>NUUE0;(MVX/#^%
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MJ$2 ZBBKA4QUE#B8X 7JWVZ3)G.#J&ECT,+M[2%V):]@TKW/\R7B&:U@/0
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M^U?6J7.XDB1XKB*A63<R#%,X_P"VB0.F06TW^RVP$4[)'B+^&*)%BB7[+(@
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M41U[K_H4'3-\S&9E"&\9OL$RJE7B]#MNO?3;88VZQ?:W':XV#  D8F-\".0
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MR&LOJ=GBKI6H2UP:BBL5/QK239"ND9NY32=)%5!!TW4X4;.T!,)%4S?40Y1
M>H9QYF)+@Y4F'/;W8V*FWD'["#\018@_$$&I75[+$W&N@VN Q;"R(ED0D%3Q
M<!AR4^5:Q\J?(-P?(K(<YJ[ZK'[@2;]#0]GJL0D=::VS*U'2<45,P%404V_:
M8B@2$F41$/I@H2==/S__  :CENZ.(8NQP[+*%\7!#93C[1 .:C_>D"+^^J']
M29YAU2;68G_G=E+%A1C[\EQ&Y\_X8C(Y^Y2;'TJR3%DVC63..9(D;LV#5NS:
M-TB@5-!LU2(@@BF4.A2)I$  #Y &56:63(F>>8\I78LQ^TDW)_>35W@@BQH$
MQH %@C0*H'P518#]P%J^K/.O6F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2
MF*4Q2F*4Q2F*4Q2L!V=;O[)I4O-I"D,FH+&#KK=81 KZTV60:U^L1_0!$1>S
MLD@G^0&$1Z (Y*:;!78;&/'D\8]RTA_PQH"SG]R@_OJ#['LY-3II\S''+,X\
M(E_Q2N0D:C]KD7^Z]0)LF=E=<TVE^N.H9I9QNJ[5U:&JD[)M#2ZE8B68(-K=
MN6XD1*D@<D0=XH[(144BRDNHFV*8OD,8EMTD.'N-OE=Q[#$J]<QI_<EC7P)'
M;DT.''\0)./ MZ1Q@L?/$&C;K,?KNLP/IOUJ:1NU9F*4BE(Y-#$G%9\Z9N)0
M,I8N@;S--<*"%D*SUJ[6]<U)0ZYK^K(J$BJ^S,F=VX$IY"9E7BZLA.V*9<%*
M47L[8YETN^>KF#N7=+G./4V53>;G,[!MI]QGD?J)GO8"RJH%E1!\$10%4?!0
M*O?7M#K^LZ>#2:Q2,6!+7/EG8DEY'/\ $\C$NY/JQ-9_D34U3%*8I3%*8I3%
M*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*"'("'7KTZ=!_D/
MR'%*Z_N#_;!-<Q$FP\+*+',83].A3G5-R;Y\B(XI7$"@F#R)^95,W]"9%5BK
M%^H?K4Y6$/$/Y!GVOE5X93;O3VQ%:Y.KI$UCM)^]E:3,N'S=E&4_8;U9JM+Z
M[%0YB"#>[O'+J6BE!YX<IO$!$0.V(%F./_7-:LV(I;;8J$2J/+2Q W64>;LT
M8^1P!XC"MZ UG<.7_HWL#:W/8+UC9S,^-(;*F/E/\TF*Q] N0_.>!B1^8TD0
M]8Q5ED /V]QS"/?VF*0>!\9>T/I[@ZGZ]>1ZCE8K1:I_>CS.P/:W3FNP:K.*
MIINMS>]KE))& 686R=3E=<ZEK[TAC$!11TU=666*''*:D.D<.O:(Z#J&AT_1
M-ELW(&?LIH\*$?'V8R)\MQ]@!&-'?X\V'P-9ON\?)WG?]7KBA.HU<3YTK?P_
MJ'O!BI_F53D26/I9#\0:N "9@Y$QQ./(\=O<3H(B(!QY.!XY_P ,SZM(K:<B
M@E[BJJ)\ (B4"D.(\?#^L%1Y_ABE<12N3  @LJ #_P!Q$"B'7CJ H@8/\,5\
MKD!)?YNCA_ B _\ Z0Q2N8A3%#@RAE!YY[C 0!_@ $*4./\ UQ7VN'L7\G/D
M.).X?IX2 O:(] Y A5."_P >>F*5]''XB/\ B8/\QQ2M!* @(<FZAQT,8!Z_
M@(#R XI3M#M[.3<=O;SWF[N...>_GO[N/GSSBE;L4IBE/G_EBE,4IBE/GSR/
MSZ?+KQU_B'&*4Q2F*4Q2MG:81Y$W3KT ./G]/Q$?E\?Q_+%*V^,W<!@54Z<_
M0/:).H<=0[0,(A_'%*U$?&43*JE*4.HF'M(4 Z '(F$0^/YXI6XIBG#DARF#
M\2B4P#_,.0Q2O.'V]]H([6VW=8ZS)5I&Y/(=A'[B5@X"5A#3%@?K2\S0:-5F
ML(]<_J+QV[M[Y*10%%%0W=&"<.U-%=1/3>H=3V>QZUG;[%(3&:>/">1@>,4<
MBM-/.3\%C2)4/Q;WN*W8@'"_J/\ 4/3Z;NNKZCDI)/L4Q9MG'#&1[F1+"1CX
MN*BD@%II)WD!)"H,<NY5%+"Q^A]:W")).[1VL9!/;^T0CY&TQK5T23:T&*9(
M@E7M:5R2(HHS_1JZT,8[T42J%>3"[E<'"J0H=M4WVTQL@KJ]2"NBQB1'<<6E
M-[&>4"_YD@\VN1&/D4V!)OO3^N9F LG8.Q>V_<<]4.2R,7CA"W*8N.S!3[$-
MRH;BIE:\KCDWBR !Q\Q'^/\ TXRNU=ZUQ2G'\?\ $<4IBE,4IBE,4IBE,4IB
ME,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4K3GJ =>O/R$0Z?B(!
MP'\\4J.]MZOJVY]<6S6-T2D5*Y;8XK-Z>(DG,1+,UVCMM)Q<I%230?*UDHB7
M8H.D#"51(542@HFHF)DS=VLV69J,^+9Z]S'F0OR5A\#Z&X/@@@D$'P02#X-1
MNXU&!OM9-J-HGN8,Z\66Y'Q!!!%B&5@&4@W# $>E4<IGL OZB.-AZB]IK>[-
M!5"O3&Q]-;>M,HFJ&TM>Q;9,9NFM42Q39R.SZ:Z*F9Q$D5>*2 2 *Q:+=@FG
M'L;X.H3=QDQMCTV%Y'R\@13XZ*6&'*Y\,Q ^7%?R4D;Y8[>W)(7L6S5.]-TD
M9>H[])'&,/':7%R;\1G0IR(C5&9F;,10JRQK_,<F2-%0\5E#TNTS8:96[5N+
M:*\O*;HWW,%O-F7L0D&3IM9?M6RU9ULV;-4&,1%E@TA.YD2,FC1)>5=+"*94
MDFR2,=WS8ZZ791Z/1L3H=7'^GB-[B5U)][('V>_)=[7( M8VM4W].M-M,'69
M&\W\C2;_ '&1^LF4^D >*-(L1/\ P\:-%0$^6;D[?,QJ['X_E^7\^GX_'*-6
M@UMY'N$.T>W@! _)>!'YAQSW!_A_U4K41  $1^ ?@ B/\@#D1$?P#KBE:&,4
M@=QS%*7D Y,(%#DP@4H<CP'(F'@/SQ2M@+HCW""R0@4>TP@H0>TP_ #=>@XI
M7((].2_5\!#@?CS^8<_+%*!SP'/QX#G^/SQ2M<4IBE. YY^8<AS^0\<_^V*4
MQ2F*4Q2F*5QE2(00$O)0#_24P@3X<=2 /:.*5R"'(<=?Y=!_Q^(8I6G _P#<
M/\/I_'G\/Y8I00Y 0$1Z\]0'@0 ?P$H!QQ\OGBE<*+9) @II@($'GZ1,(AR8
MYU#FX'_4<Z@B8?F.*5L5322+Y  Y>. X2$2B/(\? OQQ2M2I)F[3>10WS[3*
MF, \_(Q3"/.*5RG2*<.WDY.@ARD<R8]?S*(=0Q2JDI>H50<^V\U[;V"=DIZS
M*4:$H]0K#ILV+#4U&+0726F6"_UNEI5P=^\%,P]I40>*B4.X>X+\_?L]>@Q=
M!Q(UAPADO--("><Q8DJK?8JCB+>;\15 C^GNH/?YOJ'F?G;<XR00AAX@10 Q
M3_:<W-["P8@5;;QE%,$A$QB@4I1$QA$Q@+Q_4;GDW< =?QR@U?ZU%,H@ "'0
M.G'/3C_M'\2_EBE;@#@ #\ XZ]?A^>*5KBE,4IBE,4IBE,4IBE,4IBE,4IBE
M,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE<:B*2O'D(4_;SQW!SQSQSQ_'C
M%*X_M&W_ .!/_P"D,5\L*A#>_K1I;V5K,34-RTIG;8.#L+"SQ*)W+V.<L)>/
M$037:R$:X:/D".$#F26*10H*I&$IOEQ8NN=KWW5,B7)T.0T$L\+1/:Q#(WJ"
M#<>#Y!^!\BJ]V+JFB[3'!'NH%E&-.)8SZ%''BX/V,/E8?$&QJ<DD$40X23*F
M' !]/(<@4. YZ]>.?GE=)OY-6$ #P*Y<5]H/7YB'YAQ_F ABE<8I@*A%.XX"
M0# !0.8$S=W'4Y 'M.)>.G/P^6*5Q_;)]ZBG)^Y3MY^LW!>P# '8'/!/ZNO'
?QQ2MPMT1'D4RB/3J(<B/'XC\1Q2N;%*8I3%*8I7_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>29
<FILENAME>ex1015105.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex1015105.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    9   _^X #D%D
M;V)E &3      ?_; (0  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0(" @(" @(" @(" P,# P,# P,# P$! 0$! 0$" 0$"
M @(! @(# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# P,#_\  $0@ ,P"6 P$1  (1 0,1 ?_$ (0  0 !!0$! 0
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A& P& P& P& P& P& P& P& P& P& P& P& P& P&!__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>30
<FILENAME>ex1015107.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex1015107.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    /   _^X #D%D
M;V)E &3      ?_; (0 !@0$! 4$!@4%!@D&!08)"P@&!@@+# H*"PH*#! ,
M# P,# P0# X/$ \.#!,3%!03$QP;&QL<'Q\?'Q\?'Q\?'P$'!P<-# T8$! 8
M&A41%1H?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?
M'Q\?'Q\?'Q\?_\  $0@ *@!D P$1  (1 0,1 ?_$ )0   (# 0$!
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)^'E^&@/= ?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>31
<FILENAME>ex1015106.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex1015106.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    /   _^X #D%D
M;V)E &3      ?_; (0 !@0$! 4$!@4%!@D&!08)"P@&!@@+# H*"PH*#! ,
M# P,# P0# X/$ \.#!,3%!03$QP;&QL<'Q\?'Q\?'Q\?'P$'!P<-# T8$! 8
M&A41%1H?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?
M'Q\?'Q\?'Q\?_\  $0@ &@!: P$1  (1 0,1 ?_$ '@   $% 0$
M      8  @0%!P,( 0$                     $   !0(#! <& @L
M   ! @,$!1$& "$2,3(3!T$B0C,4-!51@6(C-19A4Y&A4I)C5%56%P@8$0$
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;7?W#=WO[.S\7LP#D>Z)O;H;^]L[7XX!V __9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140398303105520">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document and Entity Information - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Mar. 27, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 32.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Entera
Bio Ltd.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001638097<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28,809,922<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Entity Ex Transition Period</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">L3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">Kiryat
Hadassah<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Minrav
Building - Fifth Floor<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Jerusalem<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">9112002<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCountry', window );">Entity Address, Country</a></td>
<td class="text">IL<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">972<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">2-532-7151<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-38556<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">00-0000000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">ENTX<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Ordinary
        shares<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorName', window );">Auditor Name</a></td>
<td class="text">Kesselman
        & Kesselman<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorLocation', window );">Auditor Location</a></td>
<td class="text">Tel-Aviv,
        Israel<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorFirmId', window );">Auditor Firm ID</a></td>
<td class="text">1309<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorFirmId">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>PCAOB issued Audit Firm Identifier</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorFirmId</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:nonemptySequenceNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorLocation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorLocation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCountry">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>ISO 3166-1 alpha-2 country code.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCountry</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:countryCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140398298642816">
<tr>
<th class="tl" colspan="2" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED BALANCE SHEETS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>CURRENT ASSETS:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 12,309<span></span>
</td>
<td class="nump">$ 24,892<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">246<span></span>
</td>
<td class="nump">183<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Other current assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">294<span></span>
</td>
<td class="nump">254<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">TOTAL CURRENT ASSETS</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">12,849<span></span>
</td>
<td class="nump">25,329<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsNoncurrentAbstract', window );"><strong>NON-CURRENT ASSETS:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">139<span></span>
</td>
<td class="nump">156<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">90<span></span>
</td>
<td class="nump">239<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxAssetsNet', window );">Deferred income taxes</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">43<span></span>
</td>
<td class="nump">217<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent', window );">Funds in respect of employee rights upon retirement</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">6<span></span>
</td>
<td class="nump">46<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsNoncurrent', window );">TOTAL NON-CURRENT ASSETS</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">278<span></span>
</td>
<td class="nump">658<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">TOTAL ASSETS</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">13,127<span></span>
</td>
<td class="nump">25,987<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>CURRENT LIABILITIES:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">17<span></span>
</td>
<td class="nump">166<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesAndOtherLiabilities', window );">Accrued expenses and other payables</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,233<span></span>
</td>
<td class="nump">2,801<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Current maturities of operating lease</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">91<span></span>
</td>
<td class="nump">179<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Contract liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">15<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">TOTAL CURRENT LIABILITIES</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,341<span></span>
</td>
<td class="nump">3,161<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrentAbstract', window );"><strong>NON-CURRENT LIABILITIES:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">123<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PostemploymentBenefitsLiabilityNoncurrent', window );">Liability for employee rights upon retirement</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">32<span></span>
</td>
<td class="nump">138<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrent', window );">TOTAL NON-CURRENT LIABILITIES</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">32<span></span>
</td>
<td class="nump">261<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">TOTAL LIABILITIES</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,373<span></span>
</td>
<td class="nump">3,422<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">COMMITMENTS AND CONTINGENCIES</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNumberOfSharesParValueAndOtherDisclosuresAbstract', window );"><strong>SHAREHOLDERS' EQUITY:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Ordinary Shares, NIS 0.0000769 par value: Authorized - as of December 31, 2022 and December 31, 2021, 140,010,000 shares; issued and outstanding as of December 31, 2022, and December 31, 2021 28,809,922 and 28,804,411 shares, respectively</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in capital</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">107,210<span></span>
</td>
<td class="nump">104,950<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">41<span></span>
</td>
<td class="nump">41<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(95,497)<span></span>
</td>
<td class="num">(82,426)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">TOTAL SHAREHOLDERS' EQUITY</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">11,754<span></span>
</td>
<td class="nump">22,565<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">TOTAL LIABILITIES AND SHAREHOLDERS&#8217; EQUITY</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 13,127<span></span>
</td>
<td class="nump">$ 25,987<span></span>
</td>
</tr>
<tr><td colspan="3"></td></tr>
<tr><td colspan="3"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">Represents an amount less than one thousand US dollars.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesAndOtherLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid nor invoiced, and liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesAndOtherLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669686-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130532-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31931-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31917-109318<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset, recognized in statement of financial position, for overfunded defined benefit pension and other postretirement plans.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=123453770&amp;loc=d3e1703-114919<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(10))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=123453770&amp;loc=d3e1731-114919<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6904-107765<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(26))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(24))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PostemploymentBenefitsLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For a classified balance sheet, the carrying amount as of the balance sheet date of the portion of the obligations recognized for the various benefits provided to former or inactive employees, their beneficiaries, and covered dependents after employment but before retirement that is payable after one year (or beyond the operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 712<br> -SubTopic 10<br> -Section 25<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=6410138&amp;loc=d3e79708-111665<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 712<br> -SubTopic 10<br> -Section 25<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=6410138&amp;loc=d3e79691-111665<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PostemploymentBenefitsLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNumberOfSharesParValueAndOtherDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNumberOfSharesParValueAndOtherDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140398302889040">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED BALANCE SHEETS (Parentheticals) - &#8362; / shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Ordinary share, par value</a></td>
<td class="nump">&#8362; 0.0000769<span></span>
</td>
<td class="nump">&#8362; 0.0000769<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Ordinary shares, authorized</a></td>
<td class="nump">140,010,000<span></span>
</td>
<td class="nump">140,010,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Ordinary shares, issued</a></td>
<td class="nump">28,809,922<span></span>
</td>
<td class="nump">28,804,411<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ordinary shares, outstanding</a></td>
<td class="nump">28,809,922<span></span>
</td>
<td class="nump">28,804,411<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140398302864448">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Income Statement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">REVENUES</a></td>
<td class="nump">$ 134<span></span>
</td>
<td class="nump">$ 571<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfRevenue', window );">COST OF REVENUES</a></td>
<td class="nump">101<span></span>
</td>
<td class="nump">373<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GrossProfit', window );">GROSS PROFIT</a></td>
<td class="nump">33<span></span>
</td>
<td class="nump">198<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>OPERATING EXPENSES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">5,848<span></span>
</td>
<td class="nump">6,771<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">7,253<span></span>
</td>
<td class="nump">5,690<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonrecurringIncome', window );">Other income</a></td>
<td class="num">(51)<span></span>
</td>
<td class="num">(46)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">TOTAL OPERATING EXPENSES</a></td>
<td class="nump">13,050<span></span>
</td>
<td class="nump">12,415<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">OPERATING LOSS</a></td>
<td class="nump">13,017<span></span>
</td>
<td class="nump">12,217<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">FINANCIAL EXPENSES (INCOME), net</a></td>
<td class="num">(83)<span></span>
</td>
<td class="nump">29<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">LOSS BEFORE INCOME TAX</a></td>
<td class="nump">12,934<span></span>
</td>
<td class="nump">12,246<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">INCOME TAX EXPENSE (BENEFIT)</a></td>
<td class="nump">137<span></span>
</td>
<td class="num">(59)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">NET LOSS</a></td>
<td class="nump">$ 13,071<span></span>
</td>
<td class="nump">$ 12,187<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">LOSS PER SHARE BASIC</a></td>
<td class="nump">$ 0.45<span></span>
</td>
<td class="nump">$ 0.47<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">LOSS PER SHARE DILUTED</a></td>
<td class="nump">$ 0.45<span></span>
</td>
<td class="nump">$ 0.47<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">WEIGHTED AVERAGE NUMBER OF SHARES OUTSTANDING USED IN COMPUTATION OF BASIC LOSS PER SHARE</a></td>
<td class="nump">28,808,090<span></span>
</td>
<td class="nump">26,133,770<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">WEIGHTED AVERAGE NUMBER OF SHARES OUTSTANDING USED IN COMPUTATION OF DILUTED LOSS PER SHARE</a></td>
<td class="nump">28,808,090<span></span>
</td>
<td class="nump">26,133,770<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate cost of goods produced and sold and services rendered during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GrossProfit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 18: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1,2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GrossProfit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126941158&amp;loc=d3e41242-110953<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonrecurringIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of other income that is infrequent in occurrence or unusual in nature.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=114868883&amp;loc=SL114871943-224233<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonrecurringIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140398298676448">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2"><div>Ordinary shares [Member]</div></th>
<th class="th"><div>Additional paid-in capital [Member]</div></th>
<th class="th"><div>Accumulated other Comprehensive income [Member]</div></th>
<th class="th"><div>Accumulated deficit [Member]</div></th>
<th class="th"><div>Total</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">BALANCE at Dec. 31, 2020</a></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 77,708<span></span>
</td>
<td class="nump">$ 41<span></span>
</td>
<td class="num">$ (70,239)<span></span>
</td>
<td class="nump">$ 7,510<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">BALANCE (in shares) at Dec. 31, 2020</a></td>
<td class="nump">21,057,922<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>CHANGES DURING THE YEAR ENDED</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(12,187)<span></span>
</td>
<td class="num">(12,187)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_entx_ExerciseOfWarrantsValue', window );">Exercise of warrants to ordinary shares</a></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">3,158<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">3,158<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_entx_ExerciseOfWarrantsShares', window );">Exercise of warrants to ordinary shares (in shares)</a></td>
<td class="nump">3,175,050<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices', window );">Issuance of shares due to the ATM program, net of issuance costs</a></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">21,805<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">21,805<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Issuance of shares due to the ATM program, net of issuance costs (in shares)</a></td>
<td class="nump">4,386,728<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of options to ordinary shares</a></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">418<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 418<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of options to ordinary shares (in shares)</a></td>
<td class="nump">177,711<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">177,710<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">1,861<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 1,861<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition', window );">Vested restricted share units</a></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_entx_VestedRestrictedShareUnitsShares', window );">Vested restricted share units (in shares)</a></td>
<td class="nump">7,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">BALANCE (in shares) at Dec. 31, 2021</a></td>
<td class="nump">28,804,411<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">BALANCE at Dec. 31, 2021</a></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">104,950<span></span>
</td>
<td class="nump">41<span></span>
</td>
<td class="num">(82,426)<span></span>
</td>
<td class="nump">22,565<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>CHANGES DURING THE YEAR ENDED</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(13,071)<span></span>
</td>
<td class="num">(13,071)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of options to ordinary shares</a></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">13<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 13<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of options to ordinary shares (in shares)</a></td>
<td class="nump">5,511<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,511<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">2,247<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 2,247<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">BALANCE (in shares) at Dec. 31, 2022</a></td>
<td class="nump">28,809,922<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">BALANCE at Dec. 31, 2022</a></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 107,210<span></span>
</td>
<td class="nump">$ 41<span></span>
</td>
<td class="num">$ (95,497)<span></span>
</td>
<td class="nump">$ 11,754<span></span>
</td>
</tr>
<tr><td colspan="7"></td></tr>
<tr><td colspan="7"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">Represents an amount less than one thousand US dollars.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_entx_ExerciseOfWarrantsShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of warrants exercise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">entx_ExerciseOfWarrantsShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>entx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_entx_ExerciseOfWarrantsValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the exercise of warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">entx_ExerciseOfWarrantsValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>entx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_entx_VestedRestrictedShareUnitsShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares vested restricted share units.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">entx_VestedRestrictedShareUnitsShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>entx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for restricted stock unit under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=126964447&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126964447&amp;loc=d3e11178-113907<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126961718&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140398298614464">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>CASH FLOWS FROM OPERATING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (13,071)<span></span>
</td>
<td class="num">$ (12,187)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments required to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation</a></td>
<td class="nump">64<span></span>
</td>
<td class="nump">53<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Deferred income taxes</a></td>
<td class="nump">174<span></span>
</td>
<td class="num">(217)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share-based compensation</a></td>
<td class="nump">2,247<span></span>
</td>
<td class="nump">1,861<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_entx_FinanceExpensesNet', window );">Finance expenses (income), net</a></td>
<td class="num">(78)<span></span>
</td>
<td class="nump">18<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating asset and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Decrease (increase) in accounts receivable</a></td>
<td class="num">(63)<span></span>
</td>
<td class="nump">72<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherCurrentAssets', window );">Decrease (increase) in other current assets</a></td>
<td class="num">(40)<span></span>
</td>
<td class="nump">7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Increase (decrease) in accounts payable</a></td>
<td class="num">(149)<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities', window );">Increase (decrease) in accrued expenses and other payables</a></td>
<td class="num">(1,568)<span></span>
</td>
<td class="nump">1,471<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability', window );">Decrease in contract liabilities</a></td>
<td class="num">(15)<span></span>
</td>
<td class="num">(143)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(12,499)<span></span>
</td>
<td class="num">(9,063)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>CASH FLOWS FROM INVESTING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_entx_FundsInRespectOfEmployeeRightsUponRetirement', window );">Funds with respect to employee rights upon retirement</a></td>
<td class="num">(55)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchase of property and equipment</a></td>
<td class="num">(47)<span></span>
</td>
<td class="num">(17)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="num">(102)<span></span>
</td>
<td class="num">(17)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>CASH FLOWS FROM FINANCING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of shares through ATM programs, net of issuance costs</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">21,805<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_entx_ProceedsFromOptionsAndWarrantExercises', window );">Exercise of options and warrants into shares</a></td>
<td class="nump">13<span></span>
</td>
<td class="nump">3,576<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">13<span></span>
</td>
<td class="nump">25,381<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">INCREASE (DECREASE) IN CASH, CASH EQUIVALENTS AND RESTRICTED DEPOSITS</a></td>
<td class="num">(12,588)<span></span>
</td>
<td class="nump">16,301<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">CASH, CASH EQUIVALENTS AND RESTRICTED DEPOSITS AT BEGINNING OF THE YEAR</a></td>
<td class="nump">24,964<span></span>
</td>
<td class="nump">8,663<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">CASH, CASH EQUIVALENTS AND RESTRICTED DEPOSITS AT END OF THE YEAR</a></td>
<td class="nump">12,376<span></span>
</td>
<td class="nump">24,964<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_entx_ReconciliationInAmountsOnConsolidatedBalanceSheetsAbstract', window );"><strong>Reconciliation in amounts on consolidated balance sheets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">12,309<span></span>
</td>
<td class="nump">24,892<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalents', window );">Restricted deposits included in other current assets</a></td>
<td class="nump">67<span></span>
</td>
<td class="nump">72<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Total cash and cash equivalents and restricted deposits</a></td>
<td class="nump">12,376<span></span>
</td>
<td class="nump">24,964<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>SUPPLEMENTAL DISCLOSURE OF CASH FLOW TRANSACTIONS:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaidNet', window );">Income taxes paid in cash during the year</a></td>
<td class="nump">165<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract', window );"><strong>SUPPLEMENTARY INFORMATION ON INVESTING AND FINANCING ACTIVITIES NOT INVOLVING CASH FLOWS:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_entx_RightOfUseAssetsObtainedInExchangeForNewOperatingLeaseLiabilities', window );">Operating lease right of use assets obtained in exchange for new operating lease liabilities</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 31<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_entx_FinanceExpensesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of finance expenses, net.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">entx_FinanceExpensesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>entx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_entx_FundsInRespectOfEmployeeRightsUponRetirement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Information about funds in respect of employee rights upon retirement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">entx_FundsInRespectOfEmployeeRightsUponRetirement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>entx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_entx_ProceedsFromOptionsAndWarrantExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from exercise of options and warrants into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">entx_ProceedsFromOptionsAndWarrantExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>entx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_entx_ReconciliationInAmountsOnConsolidatedBalanceSheetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">entx_ReconciliationInAmountsOnConsolidatedBalanceSheetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>entx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_entx_RightOfUseAssetsObtainedInExchangeForNewOperatingLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of right of use assets obtained in exchange for new operating lease liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">entx_RightOfUseAssetsObtainedInExchangeForNewOperatingLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>entx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.1)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4297-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in accrued expenses, and obligations classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 310<br> -Section 45<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126938201&amp;loc=d3e55415-109406<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherCurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherCurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashInvestingAndFinancingItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140398300938640">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>GENERAL<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">DESCRIPTION OF BUSINESS</a></td>
<td class="text">

<div>

<div>

<div>

<div style="line-height:1.25;font-family:Times New Roman, Times, serif"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><strong><span>NOTE
1 - GENERAL</span></strong></span></span></span></span></div>

<div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>

<div>

<table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">
  <tr>
    <td style="vertical-align:top;font-family:Times New Roman, Times, serif;width:47px">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><span>a.</span></span></span></span></span></span></span></div>
        </td>
    <td style="vertical-align:top;font-family:Times New Roman, Times, serif;width:auto">
        <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><span><span><span><span><span><span style="line-height:107%">Entera
        Bio Ltd. (collectively with its subsidiary, the "Company") was incorporated on September 30, 2009 and commenced operation on June 1, 2010.
        On January 8, 2018, the Company incorporated Entera Bio Inc., a wholly owned subsidiary incorporated in Delaware United States. The Company
        is a leader in the development and commercialization of orally delivered large molecule therapeutics for use in areas with significant
        unmet medical need where adoption of injectable therapies is limited due to cost, convenience and compliance challenges for patients.
        The Company&#8217;s most advanced product candidates, EB613 for the treatment of osteoporosis and EB612 for the treatment of hypoparathyroidism,
        are based on its proprietary technology platform and are both in clinical development. Additionally, the Company intends to license its
        oral delivery technology to biopharmaceutical companies for use with their proprietary compounds.</span></span></span></span></span></span></span></span></span></span></span></span></div>
        </td> </tr>
  <tr>
    <td style="vertical-align:top;font-family:Times New Roman, Times, serif;width:47px">&#160;</td>
    <td style="vertical-align:top;font-family:Times New Roman, Times, serif;width:auto">&#160;</td> </tr>
  <tr>
    <td style="vertical-align:top;font-family:Times New Roman, Times, serif;width:47px">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><span>b.</span></span></span></span></span></span></span></div>
        </td>
    <td style="vertical-align:top;font-family:Times New Roman, Times, serif;width:auto">
        <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><span><span style="line-height:107%">The
        Company's ordinary shares, NIS 0.0000769
        par value per share (&#8220;ordinary shares&#8221;), are listed on the Nasdaq Capital Market since July 2018 under the symbol &#8220;ENTX&#8221;.</span></span></span></span></span></span></span></span></div>
        </td> </tr>
  <tr>
    <td style="vertical-align:top;font-family:Times New Roman, Times, serif;width:47px">&#160;</td>
    <td style="vertical-align:top;font-family:Times New Roman, Times, serif;width:auto">&#160;</td> </tr>
  <tr>
    <td style="vertical-align:top;font-family:Times New Roman, Times, serif;width:47px">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><span><span><span>c.</span></span></span></span></span></span></span></span></span></div>
        </td>
    <td style="vertical-align:top;font-family:Times New Roman, Times, serif;width:auto">
        <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><span><span><span><span><span><span style="line-height:107%">On
        December 10, 2018, the Company entered into a research collaboration and license agreement with Amgen (the &#8220;Amgen Agreement&#8221;)
        &#160;for the use of the Company&#8217;s oral delivery platform in the field of inflammatory disease and other serious illnesses. Pursuant
        to the Amgen Agreement, the Company and Amgen have agreed to use the Company&#8217;s proprietary drug delivery platform to develop oral
        formulations for one preclinical large molecule program that Amgen has selected. Amgen is responsible for the clinical development, regulatory
        approval, manufacturing and worldwide commercialization of the programs.<br/><br/>The Company granted Amgen an exclusive, worldwide,
        sublicensable license under certain of its intellectual property relating to its drug delivery technology to develop, manufacture and
        commercialize the applicable products. The Company will retain all intellectual property rights to its drug delivery technology, and Amgen
        will retain all rights to its large molecules and any subsequent improvements, and ownership of certain intellectual property developed
        through the performance of the agreement is to be determined by U.S. patent law.</span></span></span></span></span></span></span></span></span></span></span></span></div>
        </td> </tr>
  <tr>
    <td style="vertical-align:top;font-family:Times New Roman, Times, serif;width:47px">&#160;</td>
    <td style="vertical-align:top;font-family:Times New Roman, Times, serif;width:auto">&#160;</td> </tr>
  <tr>
    <td style="vertical-align:top;font-family:Times New Roman, Times, serif;width:47px">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><span>d.</span></span></span></span></span></span></span></div>
        </td>
    <td style="vertical-align:top;font-family:Times New Roman, Times, serif;width:auto">
        <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><span><span><span><span><span><span style="line-height:115%"><span style="line-height:115%">Because
        </span></span></span></span></span></span></span></span></span>the Company is engaged in research and development activities, it has not
        derived significant income from its activities and has incurred accumulated deficit in the amount of $95.5
        million through December 31, 2022 and negative cash flows from operating activities. The Company's management is of the opinion that its
        available funds as of December 31, 2022 will allow the Company to operate under its current plans into the third quarter of 2024. This
        assumes the use of the Company&#8217;s capital to fund its ongoing operations, including R&amp;D and the completion of the Phase 1 study
        related to the new formulation EB612. This does not include the capital required to fund the Company's proposed Phase 3 study for EB613
        in osteoporosis and comparative study. These factors raise substantial doubt as to the Company's ability to continue as a going concern.
        Management is in the process of evaluating various financing alternatives in the public or private equity markets, debt financing and
        strategic collaborations, as the Company will need to finance future research and development activities, general and administrative expenses
        and working capital through fund raising. However, there is no certainty about the Company's ability to obtain such funding. The financial
        statements do not include any adjustments that may be necessary should the Company be unable to continue as a going concern.<span><span><span><span><span><span><span style="line-height:107%">
        </span></span></span></span></span></span></span></span></span></span></span></div> </td> </tr>
  </table> </div> </div> </div> </div> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI https://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI https://asc.fasb.org/topic&amp;trid=2197479<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140398300308208">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SIGNIFICANT ACCOUNTING POLICIES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">SIGNIFICANT ACCOUNTING POLICIES</a></td>
<td class="text">

<div>

<div>

<div style="line-height:1.25;font-family:Times New Roman, Times, serif;font-weight:bold;text-align:justify"> <div style="font-size:10pt;display:inline">
<div style="font-family:Times New Roman,Times,serif;display:inline"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>NOTE
2 - SIGNIFICANT ACCOUNTING POLICIES</span></span></span></span></div> </div> </div>

<div style="line-height:1.25;text-align:justify">&#160;</div>

<div>

<div>

<table cellpadding="0" cellspacing="0" style="color:#000000;font-family:'Times New Roman',Times,serif;font-size:10pt;text-align:left;width:100%">
  <tr>
    <td style="width:47px;vertical-align:top;font-family:Times New Roman, Times, serif;font-weight:bold;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">a.</span></span></td>
    <td style="width:auto;vertical-align:top">
        <div style="font-weight:bold;text-align:justify"> <div style="font-size:10pt;display:inline"> <div style="font-family:Times New Roman, Times, serif;display:inline;text-align:left"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>Basis
        of presentation of the financial statements</span></span></span></span></span></span></div> </div> </div> </td> </tr>
  </table>

<div style="line-height:1.25;text-align:justify">&#160;</div>

<div style="margin-left:47px;line-height:1.25;text-align:justify"> <div style="font-size:10pt;display:inline"> <div style="font-family:Times New Roman,Times,serif;display:inline">
<div style="display:inline;text-align:left"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><span><span><span><span><span style="line-height:normal">The
consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States
(&#8220;U.S. GAAP&#8221;). Prior to 2021, the Company prepared its financial statements in accordance with International Financial Reporting
Standards (&#8220;IFRS&#8221;), as issued by the International Accounting Standards Board (&#8220;IASB&#8221;), as permitted in the United
States (&#8220;U.S.&#8221;) based on the Company&#8217;s status as a foreign private issuer as defined in the rules promulgated by the
U.S. Securities and Exchange Commission (the &#8220;SEC&#8221;). During 2021, the Company determined that it is no longer qualified as
a foreign private issuer under the SEC rules. As a result, since January 1, 2022, the Company has been required to comply with all of
the disclosure and reporting requirements applicable to U.S. domestic issuers, including preparing its financial statement in accordance
with U.S. GAAP.</span></span></span></span></span></span></span></span></span></span></span></div> </div> </div> </div> </div>
</div>

<div style="line-height:1.25;text-align:justify">&#160;</div>

<div>

<div>

<table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">
  <tr>
    <td style="width:47px;vertical-align:top;font-family:Times New Roman, Times, serif;font-weight:bold;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">b.</span></span></td>
    <td style="width:auto;vertical-align:top">
        <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><strong><span style="line-height:107%">Use
        of estimates in the preparation of financial statements</span></strong></span></span></span></span></span></span></p> </td> </tr>
  </table>

<div style="line-height:1.25;text-align:justify">&#160;</div>

<div style="margin-left:47px;line-height:1.25;font-family:Times New Roman, Times, serif;text-align:justify"> <div style="font-size:10pt;display:inline">
<div style="font-family:Times New Roman,Times,serif;display:inline">

<p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><span style="line-height:normal">The
preparation of the consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions
that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial
statements and the reported amounts of revenues and expenses during the reporting period. Actual results may differ from those estimates.</span></span></span></span></span></span></span></p>
</div> </div> </div> </div>

<p style="margin:0pt">&#160;</p> </div> </div>

<div>

<div>

<div>

<div style="line-height:1.25;text-align:justify">

<table cellpadding="0" cellspacing="0" style="font-family:Times New Roman, Times, serif;font-size:10pt;width:100%;text-align:left;color:rgb(0, 0, 0);border:0px">
  <tr>
    <td style="width:47px;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>c.</strong></span></span></td>
    <td style="width:auto;vertical-align:top">
        <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><strong><span style="line-height:107%">Functional
        currency </span></strong></span></span></span></span></span></span></p> </td> </tr>
  </table> </div>

<p style="margin:0pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">
  <tr>
    <td style="width:47px;text-align:justify">&#160;</td>
    <td style="width:37.25px;vertical-align:top;font-family:Times New Roman, Times, serif;text-align:justify"> <div style="font-size:10pt;display:inline">
        <div style="font-family:Times New Roman,Times,serif;display:inline"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>1)</span></span></span></span></span></span></div>
        </div> </td>
    <td style="width:auto;vertical-align:top">
        <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><span style="line-height:107%">Functional
        and presentation currency</span></span></span></span></span></span></span></p>
        <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt">&#160;</p>
        <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span>Items
        included in the financial statements of the Company are measured using the currency of the primary economic environment in which the entity
        operates (the &#8220;functional currency&#8221;). The U.S. dollar is the currency of the primary economic environment in which the operations
        of the Company are conducted. The consolidated financial statements are presented in U.S. dollars.</span></span></span></span></span></p>
        <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify">&#160;</p>
        <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span>The
        functional currency of the subsidiary is the U.S. dollar.</span></span></span></span></span></p> </td> </tr>
  </table>

<div style="line-height:1.25;text-align:justify">&#160;</div> </div> </div> <div style="font-family:Times New Roman, Times, serif;display:inline;text-align:left">

<table cellpadding="0" cellspacing="0" style="font-family:Times New Roman, Times, serif;font-size:10pt;width:100%;text-align:left;color:rgb(0, 0, 0);border:0px">
  <tr>
    <td style="width:47px;text-align:justify">&#160;</td>
    <td style="width:37.25px;vertical-align:top;font-family:Times New Roman, Times, serif;text-align:justify">
        <div style="font-size:10pt">
        <div style="font-family:Times New Roman, Times, serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><span><span>2)</span></span></span></span></span></span></span></span></div>
        </div> </td>
    <td style="width:auto;vertical-align:top">
        <div style="text-align:justify">
        <div style="font-size:10pt">
        <div style="font-family:Times New Roman, Times, serif;text-align:left"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><span><span>Transactions
        and balances</span></span></span></span></span></span></span></span></div>
        <div style="font-family:Times New Roman, Times, serif">&#160;</div>
        <div style="font-family:Times New Roman, Times, serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span style="line-height:107%">Transactions
        and balances originally denominated in U.S. dollars are presented at their original amounts. Balances in non- U.S. dollar currencies are
        translated into U.S. dollars using historical and current exchange rates for non-monetary and monetary balances, respectively. For non-U.S.
        dollar transactions and other items in the statements of income (indicated below), the following exchange rates are used: (i) for transactions
        &#8211; exchange rates at transaction dates or average exchange rates; and (ii) for other items (derived from non-monetary balance sheet
        items such as depreciation and amortization) &#8211; historical exchange rates. &#160;Currency transaction gains and losses are presented
        in financial income (expenses), as appropriate.</span></span></span></span></span></div> </div> </div> </td> </tr>
  </table> </div> </div>

<p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman,Times,serif">&#160;</p>

<div style="line-height:1.25;font-family:Times New Roman, Times, serif;text-align:justify">

<div/> </div>

<div>

<div>

<div>

<div>

<div>

<div style="line-height:1.25">

<div style="line-height:1.25">

<table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">
  <tr>
    <td style="width:47px;text-align:justify;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>d.</strong></span></span></td>
    <td style="vertical-align:top;text-align:justify">
        <div> <div style="font-size:10pt;display:inline"> <div style="font-family:Times New Roman,Times,serif;display:inline"> <div style="font-weight:bold;display:inline;text-align:left"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><span style="line-height:107%">Principles
        of consolidation</span></span></span></span></span></span></span></div> </div> </div>
        <div style="margin:0pt">&#160;</div> </div>
        <div>
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">
        <div style="line-height:1.25"> <div style="font-size:10pt;display:inline"> <div style="font-family:Times New Roman, Times, serif;display:inline;text-align:left"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><span style="line-height:normal">The
        consolidated financial statements include the accounts of the Company and its subsidiary Entera Bio Inc. All inter-company transactions
        and balances have been eliminated in consolidation.</span></span></span></span></span></span></span></div> </div> </div> </div> </div>
        </td> </tr>
  </table>  </div> </div> </div>

<div style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</div>

<div style="line-height:1.25">

<div style="line-height:1.25">

<div>

<table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">
  <tr>
    <td style="width:47px;text-align:justify;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>e.</strong></span></span></td>
    <td style="vertical-align:top;text-align:justify">
        <div style="font-weight:bold"> <div style="font-size:10pt;display:inline"> <div style="font-family:Times New Roman, Times, serif;display:inline;text-align:left"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><strong><span style="line-height:107%">Cash
        and cash equivalents</span></strong></span></span></span></span></span></span></div> </div>
        <div style="margin:0pt">&#160;</div> </div>
        <div>
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">
        <div style="line-height:1.25">
        <div style="line-height:1.25"> <div style="font-size:10pt;display:inline"> <div style="font-family:Times New Roman, Times, serif;display:inline;text-align:left"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><span style="line-height:normal">The
        Company considers as cash equivalents all short-term, highly liquid investments, which include short-term bank deposits with original
        maturities of three months or less from the date of purchase that are not restricted as to withdrawal or use and are readily convertible
        to known amounts of cash.</span></span></span></span></span></span></span></div> </div> </div> </div> </div> </div> </td> </tr>
  </table>  </div>

<div style="margin-left:70.9pt;line-height:1.25;font-family:Times New Roman, Times, serif;text-align:justify">&#160;</div> </div> </div>

<div>

<div style="line-height:1.25">

<div style="line-height:1.25">

<table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">
  <tr>
    <td style="width:47px;text-align:justify;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>f.</strong></span></span></td>
    <td style="vertical-align:top;text-align:justify">
        <div style="font-weight:bold">
        <div style="font-weight:bold"> <div style="font-size:10pt;display:inline"> <div style="font-family:Times New Roman, Times, serif;display:inline;text-align:left"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong><span style="line-height:107%">Restricted
        cash</span></strong></span></span></div> </div>
        <div style="margin:0pt">&#160;</div> </div> </div>
        <div>
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">
        <div style="line-height:1.25">
        <div style="text-align:left;line-height:1.25">
        <div style="line-height:1.25;text-align:justify"> <div style="font-size:10pt;display:inline"> <div style="font-family:Times New Roman, Times, serif;display:inline;text-align:left"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><span style="line-height:normal;color:black">Restricted
        cash deposited in an interest-bearing saving account which is used as a security for the Company's office rent&#160;and credit card.</span></span></span></span></span></span></span></div>
        </div> </div> </div> </div> </div> </div> </td> </tr>
  </table>

<div style="margin-left:70.9pt;line-height:1.25;font-family:Times New Roman, Times, serif;text-align:justify">&#160;</div>

<div style="line-height:1.25;font-family:Times New Roman, Times, serif;text-align:justify">

<div>

<table cellpadding="0" cellspacing="0" style="border:0px;width:100%">
  <tr>
    <td style="width:47px"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>g.</strong></span></span></td>
    <td>
        <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>Concentrations
        of credit risk</strong></span></span></p> </td> </tr>
  </table>

<p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>

<p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;margin-left:47px"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Financial
instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash and cash equivalents.
The Company maintains cash held in checking accounts and deposits at financial institutions in major Israeli and U.S. banks. Management
believes the Company is not exposed to significant credit risk to its current financial institution, but will continue to monitor regularly
and adjust, if needed, to mitigate risk. The Company has established guidelines regarding diversification of its investments and their
maturities, which are designed to maintain principal and maximize liquidity. To date, the Company has not experienced any losses associated
with this credit risk and continues to believe that this exposure is not significant.</span></span></p> </div>  </div>

<div style="margin-left:70.9pt;line-height:1.25;font-family:Times New Roman, Times, serif;text-align:justify">&#160;</div> </div> </div>
</div>

<div>

<div style="line-height:1.25">

<div>

<div style="line-height:1.25">

<div style="line-height:1.25">

<table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">
  <tr>
    <td style="width:47px;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>h.</strong></span></span></td>
    <td style="vertical-align:top;text-align:justify">
        <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>Fair
        value measurement</strong></span></span></p> </td> </tr>
  </table> </div> </div> </div> </div>

<div>

<p style="margin:0pt">&#160;</p>

<p style="margin-left:47px;margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><span style="line-height:normal">The
</span></span></span></span></span>Company measures fair value and discloses fair value measurements for financial assets and liabilities.
Fair value is based on the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between
market participants at the measurement date. The accounting standard establishes a fair value hierarchy that prioritizes observable and
unobservable inputs used to measure fair value into three broad levels, which are described below:</span></span></p>

<p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>

<p style="margin-left:47px;margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><span style="line-height:normal">Level
</span></span></span></span></span>1: Quoted prices (unadjusted) in active markets that are accessible at the measurement date for assets
or liabilities. The fair value hierarchy gives the highest priority to Level 1 inputs.</span></span></p>

<p style="margin-left:50pt;margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>

<p style="margin-left:47px;margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><span style="color:black">Level
</span></span></span></span></span>2: Observable inputs that are based on inputs not quoted on active markets but corroborated by market
data.</span></span></p>

<p style="margin-left:50pt;margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>

<p style="margin-left:47px;margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><span style="color:black">Level
</span></span></span></span></span>3: Unobservable inputs are used when little or no market data is available. The fair value hierarchy
gives the lowest priority to Level 3 inputs.</span></span></p>

<p style="margin-left:47px;margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p> </div>
</div>

<div/>

<div>

<div style="line-height:1.25">

<div>

<div style="line-height:1.25">

<div style="line-height:1.25">

<table cellpadding="0" cellspacing="0" style="border:0px;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:left;width:100%">
  <tr>
    <td style="width:47px;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>i.</strong></span></span></td>
    <td style="vertical-align:top;text-align:justify">
        <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><strong><span><span>Employee
        severance benefits</span></span></strong></span></span></span></span></p> </td> </tr>
  </table> </div> </div> </div> </div>

<div>

<p style="margin:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>

<p style="margin-top:0pt;margin-left:47px;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span style="line-height:normal">Under
</span>the Israeli Severance Pay Law, 1963, the Company is required to make severance payments upon dismissal of an Israeli employee or
upon termination of employment in certain other circumstances. The severance payment liability to the employees located in Israel (based
upon length of service and the latest monthly salary - one month&#8217;s salary for each year employed) is recorded on the Company&#8217;s
balance sheet under &#8220;Liability for employee rights upon retirement.&#8221; The liability is recorded as if it was payable at each
balance sheet date on an undiscounted basis.</span></span></span></span></p>

<p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>

<p style="margin-top:0pt;margin-left:47px;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span style="line-height:normal">In
</span>accordance with Section 14 of the Israeli Severance Pay Law, 1963, the Company makes regular deposits with certain insurance companies
for accounts controlled by each applicable employee in order to secure the employee&#8217;s retirement benefit obligation. The Company
is fully relieved from any severance pay liability with respect to each such employee after it makes the payments on behalf of the employee.
The liability accrued in respect of these employees and the amounts funded, as of the respective agreement dates, are not reflected in
the Company balance sheet, as the amounts funded are not under the control and management of the Company and the pension or severance
pay risks have been irrevocably transferred to the applicable insurance companies (the &#8220;Contribution Plan&#8221;).</span></span></span></span></p>

<p style="margin-top:0pt;margin-left:50pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>

<p style="margin-top:0pt;margin-left:47px;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span style="line-height:normal">With
regard to the period before December 2013, the liability is funded in part from the purchase of insurance policies or by the establishment
of pension funds with dedicated deposits in the funds. The amounts used to fund these liabilities are included in the balance sheets under
&#8220;Funds in respect of employee rights upon retirement&#8221;. These policies are the Company&#8217;s assets. </span></span></span></span></span></p>

<p style="margin-top:0pt;margin-left:50pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>

<p style="margin-top:0pt;margin-left:47px;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span style="color:black">The
</span>amounts of severance payment expenses were $132&#160;and
$137
for the years ended December 31, 2022&#160;and 2021, respectively.</span></span></span></span><br/>&#160;</p>

<p style="margin-top:0pt;margin-left:47px;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><span style="color:black">The
</span>Company expects to contribute to insurance companies approximately $132
for the year ending December 31, 2023 in connection with its expected severance liabilities for that year.</span></span></span></span></span></span></p>

<p style="margin-top:0pt;margin-left:47px;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p> </div>
</div>

<div/> </div>

<div>

<div>

<div style="line-height:1.25">

<div>

<div style="line-height:1.25">

<div style="line-height:1.25">

<table cellpadding="0" cellspacing="0" style="font-family:Times New Roman, Times, serif;font-size:10pt;width:100%;text-align:left;color:rgb(0, 0, 0);border:0px">
  <tr>
    <td style="width:47px;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>j.</strong></span></span></td>
    <td style="width:auto;vertical-align:top;text-align:justify">
        <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:left"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><strong><span style="line-height:107%">Leases</span></strong></span></span></span></span></span></span></p>
        </td> </tr>
  </table> </div> </div> </div> </div>

<div>

<p style="margin:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>

<p style="margin-top:0pt;margin-left:47px;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The
Company determines if an arrangement is a lease at inception. Balances related to operating leases are included in operating lease right-of-use
(&#8220;ROU&#8221;) assets and current and non-current operating lease liabilities in the consolidated balance sheets.</span></span></p>

<p style="margin:0pt">&#160;</p>

<p style="margin-top:0pt;margin-left:47px;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><span style="line-height:107%">ROU
</span></span></span></span></span>assets represent the Company&#8217;s right to use an underlying asset for the lease term and lease
liabilities represent the Company&#8217;s obligation to make lease payments arising from the lease. Operating lease ROU assets and liabilities
are recognized as of the commencement date based on the present value of lease payments over the lease term. Lease terms will include
options to extend or terminate the lease when it is reasonably certain that the Company will either exercise or not exercise the option
to renew or terminate the lease.</span></span></p>

<p style="margin:0pt">&#160;</p>

<p style="margin-top:0pt;margin-left:47px;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><span style="line-height:107%">The
</span></span></span></span></span>discount rate for the lease is the rate implicit in the lease unless that rate cannot be readily determined.
As the Company&#8217;s leases do not provide an implicit rate, the Company&#8217;s uses its estimated incremental borrowing rate based
on the information available at the commencement date in determining the present value of lease payments. Lease expense for lease payments
is recognized on a straight-line basis over the lease term.</span></span></p>

<p style="margin-top:0pt;margin-left:90px;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>

<p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;margin-left:47px;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Sublease
income is recognized on a straight-line basis over the expected lease term and is included in other income in our consolidated statements
of operations<span style="line-height:107%">.</span></span></span></p> </div> </div>

<p style="margin:0pt">&#160;</p>

<div>

<table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">
  <tr>
    <td style="width:47px;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><strong>k.</strong></span></span></span></span></td>
    <td style="width:auto;vertical-align:top">
        <div style="font-weight:bold;text-align:justify"> <div style="font-size:10pt;display:inline"> <div style="font-family:Times New Roman, Times, serif;display:inline;text-align:left"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><span><span>Property
        and equipment</span></span></span></span></span></span></span></span></div> </div> </div> </td> </tr>
  </table>

<div style="line-height:1.25;text-align:justify">&#160;</div>

<table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">
  <tr>
    <td style="text-align:justify;width:36pt">&#160;</td>
    <td style="vertical-align:top;font-family:Times New Roman, Times, serif;text-align:justify;width:27pt"> <div style="font-size:10pt;display:inline">
        <div style="font-family:Times New Roman,Times,serif;display:inline"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong><span><span><span><span>1)</span></span></span></span></strong></span></span></div>
        </div> </td>
    <td style="vertical-align:top;width:auto">
        <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><span style="line-height:107%">Property
        and equipment are stated at cost, net of accumulated depreciation and amortization.</span></span></span></span></span></span></span></p>
        </td> </tr>
  </table>

<div style="line-height:1.25;text-align:justify">&#160;</div>

<table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">
  <tr>
    <td style="text-align:justify;width:36pt">&#160;</td>
    <td style="vertical-align:top;font-family:Times New Roman, Times, serif;text-align:justify;width:27pt"> <div style="font-size:10pt;display:inline">
        <div style="font-family:Times New Roman,Times,serif;display:inline"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><strong><span><span><span><span>2)</span></span></span></span></strong></span></span></span></span></div>
        </div> </td>
    <td style="vertical-align:top;width:auto">
        <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><span><span><span style="line-height:normal">The
        </span></span></span></span></span>Company&#8217;s property and equipment are depreciated using the straight-line method, which approximates
        the pattern of usage, over the term of the estimated useful life, as follows<span><span><span><span><span style="line-height:normal">:</span></span></span></span></span></span></span></span></span></p>
        </td> </tr>
  </table>

<div>

<div>

<div>

<div>

<div>

<div style="line-height:1.25">&#160;</div>

<div style="margin-left:126pt">

<table border="0" cellpadding="0" cellspacing="0" style="width:70%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left">
  <tr>
    <td style="width:50.94%;vertical-align:top">&#160;</td>
    <td style="width:24.55%;vertical-align:top">&#160;</td>
    <td style="width:24.51%;vertical-align:top;border-bottom:2px solid #000000">
        <div style="line-height:1.25">
        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Years</span></span></div>
        </div> </td> </tr>
  <tr>
    <td style="width:50.94%;vertical-align:bottom">&#160;</td>
    <td style="width:24.55%;vertical-align:bottom">&#160;</td>
    <td style="width:24.51%;vertical-align:bottom">&#160;</td> </tr>
  <tr>
    <td style="width:50.94%;vertical-align:bottom;background-color:rgb(204, 238, 255)">
        <div style="text-align:justify;text-indent:-10.7pt;margin-left:12.6pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Computer
        equipment</span></span></div> </td>
    <td style="width:24.55%;vertical-align:bottom;background-color:rgb(204, 238, 255)">&#160;</td>
    <td style="width:24.51%;vertical-align:bottom;background-color:rgb(204, 238, 255)">
        <div style="text-align:right;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">3-5</span></span></div>
        </td> </tr>
  <tr>
    <td style="width:50.94%;vertical-align:bottom">
        <div style="text-align:justify;text-indent:-10.7pt;margin-left:12.6pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Office
        furniture</span></span></div> </td>
    <td style="width:24.55%;vertical-align:bottom">&#160;</td>
    <td style="width:24.51%;vertical-align:bottom">
        <div style="text-align:right;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">10</span></span></div>
        </td> </tr>
  <tr>
    <td style="width:50.94%;vertical-align:bottom;background-color:rgb(204, 238, 255)">
        <div style="text-align:justify;text-indent:-10.7pt;margin-left:12.6pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Laboratory
        equipment</span></span></div> </td>
    <td style="width:24.55%;vertical-align:bottom;background-color:rgb(204, 238, 255)">&#160;</td>
    <td style="width:24.51%;vertical-align:bottom;background-color:rgb(204, 238, 255)">
        <div style="text-align:right;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">7-10</span></span></div>
        </td> </tr>
  </table> </div> </div> </div>

<div style="margin-left:36pt;line-height:1.25">&#160;</div> </div> </div>  </div>

<div style="margin-left:47px;line-height:1.25;text-align:justify"> <div style="font-size:10pt;display:inline"> <div style="font-family:Times New Roman,Times,serif;display:inline">
<div style="display:inline;text-align:left;margin-bottom:0pt;margin-top:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><span style="line-height:107%">Leasehold
improvements are amortized by the straight-line method over the shorter of (i) the expected lease term and (ii) the estimated useful life
of the improvements.</span></span></span></span></span></span></span></div>

<p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman,Times,serif">&#160;</p> </div> </div> </div> </div>
</div> </div> </div> </div> </div>

<div/>

<div>

<div>

<div>

<div>

<div>

<div style="line-height:1.25;text-align:justify">

<div>

<div style="line-height:1.25">

<div>

<div style="line-height:1.25">

<div style="line-height:1.25">

<table cellpadding="0" cellspacing="0" style="font-family:Times New Roman, Times, serif;font-size:10pt;width:100%;text-align:left;color:rgb(0, 0, 0);border:0px">
  <tr>
    <td style="width:47px;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>l.</strong></span></span></td>
    <td style="vertical-align:top;text-align:justify">
        <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:left"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><strong><span style="line-height:107%">Impairment&#160;of
        long-lived assets</span></strong></span></span></span></span></span></span></p> </td> </tr>
  </table> </div> </div> </div> </div>

<div>

<p style="margin:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>

<p style="margin-top:0pt;margin-left:47px;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><span><span><span style="line-height:normal">The
</span></span></span></span></span>Company tests long-lived assets for impairment whenever events or changes in circumstances indicate
that the carrying amount of an asset may no longer be recoverable. Recoverability of long-lived assets is measured by comparing the carrying
amount of the long-lived asset to the estimated undiscounted future cash flows expected to be generated by the asset. If the sum of the
expected undiscounted cash flow is less than the carrying amount of the asset, the Company recognizes an impairment loss, which is the
excess of the carrying amount over the fair value of the asset, using the expected future discounted cash flows.</span></span></span></span></p>

<p style="margin-top:0pt;margin-left:47px;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>

<p style="margin-top:0pt;margin-left:47px;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span style="line-height:107%">As
of December 31, 2022 and 2021, the Company did not recognize an impairment loss on its long-lived assets.</span></span></span></span></span></p>
</div> </div>

<p style="margin:0pt">&#160;</p>

<div>

<div style="line-height:1.25">

<div>

<div style="line-height:1.25">

<div style="line-height:1.25">

<table cellpadding="0" cellspacing="0" style="font-family:Times New Roman, Times, serif;font-size:10pt;width:100%;text-align:left;color:rgb(0, 0, 0);border:0px">
  <tr>
    <td style="width:47px;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>m.</strong></span></span></td>
    <td style="width:auto;vertical-align:top;text-align:justify">
        <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:left"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><strong><span style="line-height:107%">Share-based
        compensation </span></strong></span></span></span></span></span></span></p> </td> </tr>
  </table> </div> </div> </div> </div>

<div>

<p style="margin:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>

<p style="margin-top:0pt;margin-left:47px;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><span><span><span style="line-height:normal"><span><span>The
</span></span></span></span></span></span></span>Company grants share options and restricted share units (&#8220;RSU&#8221;) (together
&#8220;Share-Based Compensation&#8221;) to its employees, directors and non-employees in consideration for services rendered<span><span><span><span><span style="line-height:normal"><span><span>.</span></span></span></span></span></span></span></span></span></span></span></p>

<p style="margin:0pt">&#160;</p>

<p style="margin-top:0pt;margin-left:47px;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><span style="line-height:normal"><span><span>The
Company accounts for Share-Based Compensation awards classified as equity awards, including share-based option awards and RSUs, using
grant-date fair value. The Company recognize the value of the award as an expense over the requisite service period</span></span></span><span><span><span><span><span><span><span style="line-height:normal">.</span></span></span></span></span></span></span></span></span></span></span></span></span></p>

<p style="margin-top:0pt;margin-left:47px;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>

<p style="margin-top:0pt;margin-left:47px;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><span><span><span><span><span><span><span style="line-height:normal">The
Company applies ASU 2018-07 (Topic 718) that expands the scope of Topic 718 to include Share-Based Compensation transactions for acquiring
goods and services from non-employees. Under the provision of the amendment, the Company measures share-based compensation to non-employees
in the same manner as share-based compensation to employees.</span></span></span></span></span></span></span></span></span></span></span></span></span></p>

<p style="margin-top:0pt;margin-left:90px;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:left">&#160;</p>

<p style="margin-top:0pt;margin-left:47px;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><span style="line-height:107%">The
Company calculates the fair value of stock-based option awards on the date of grant using the Black-Scholes option pricing model. The
option-pricing model requires a number of assumptions, of which the most significant are the expected share price volatility and the expected
option term. The computation of expected volatility is based on the historical volatility of the Company&#8217;s ordinary shares. The
expected option term is calculated using the simplified method, as the Company has concluded that its historical share option exercise
experience does not provide a reasonable basis to estimate expected option terms. The interest rate for periods within the expected term
of an award is based on the U.S. Treasury yield curve in effect at the time of grant. The Company&#8217;s expected dividend rate is zero
because the Company does not currently pay cash dividends on its shares and does not anticipate doing so in the foreseeable future</span></span></span><span><span><span style="line-height:107%">.</span></span></span></span></span></span></span></p>

<p style="margin-top:0pt;margin-left:90px;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:left">&#160;</p>

<p style="margin-top:0pt;margin-left:47px;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><span style="line-height:107%">The
</span>Company elected to recognize compensation costs for awards granted to employees and directors conditioned only on continued service
that have a graded vesting schedule using the accelerated method based on the multiple-option award approach. The Company has elected
to account for forfeitures as they occur<span style="line-height:107%">.</span></span></span></span></span></span></span></p>

<p style="margin-top:0pt;margin-left:47px;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p> </div>
</div>

<div>

<div/>

<div>

<div style="line-height:1.25">

<div>

<div style="line-height:1.25">

<div style="line-height:1.25">

<table cellpadding="0" cellspacing="0" style="font-family:Times New Roman, Times, serif;font-size:10pt;width:100%;text-align:left;color:rgb(0, 0, 0);border:0px">
  <tr>
    <td style="width:47px;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>n.</strong></span></span></td>
    <td style="width:auto;vertical-align:top;text-align:justify">
        <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:left"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><strong><span style="line-height:107%">Research
        and development expenses</span></strong></span></span></span></span></span></span></p> </td> </tr>
  </table> </div> </div> </div> </div>

<div>

<p style="margin:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:left">&#160;</p>

<p style="margin-top:0pt;margin-left:47px;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><span style="line-height:normal">Research
</span></span></span></span></span>and development expenses include costs directly attributable to the conduct of research and development
programs, including the cost of salaries, share-based compensation expenses, payroll taxes and other employee benefits, lab expenses,
consumable equipment and consulting fees. All costs associated with research and developments are expensed as incurred<span><span><span><span><span style="line-height:normal">.</span></span></span></span></span></span></span></p>

<p style="margin:0pt;text-align:left">&#160;</p>

<p style="margin-top:0pt;margin-left:48px;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><span style="line-height:normal">Grants
received from the Israel Innovation Authority (the &#160;&#8220;IIA&#8221;) are recognized when the grant becomes receivable, provided
there is reasonable assurance that the Company will comply with the conditions attached to the grant and there is reasonable assurance
the grant will be received. At the time grants are received, successful development of the related projects is not assured, therefore,
grants are deducted from the research and development expenses as the applicable costs are incurred, and presented in R&amp;D expenses,
net</span></span></span></span></span><span><span><span><span><span style="line-height:107%"><span>.</span></span></span></span></span></span></span></span></p>
</div> </div>  </div>

<div>

<div>

<div style="line-height:1.25">

<div>

<div style="line-height:1.25">

<div style="line-height:1.25">

<table cellpadding="0" cellspacing="0" style="font-family:Times New Roman, Times, serif;font-size:10pt;width:100%;text-align:left;color:rgb(0, 0, 0);border:0px">
  <tr>
    <td style="width:47px;text-align:justify">&#160;</td>
    <td style="width:auto;vertical-align:top;text-align:justify">&#160;</td> </tr>
  <tr>
    <td style="width:47px;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><strong>o.</strong></span></span></span></span></td>
    <td style="width:auto;vertical-align:top;text-align:justify">
        <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:left"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><span><strong><span style="line-height:107%">Revenue
        recognition </span></strong></span></span></span></span></span></span></span></p> </td> </tr>
  </table> </div> </div> </div> </div>

<div>

<p style="margin:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>

<p style="margin-top:0pt;margin-left:47px;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><span><span><span><span><span style="line-height:normal">The
Company recognized revenue from the Amgen Agreement according to ASC 606, "Revenues from Contracts with Customers&#8221;. Prior to the
signing of the Amgen Agreement in 2018, the Company did not have revenue transactions.</span></span></span></span></span></span></span></span></span></span></span></p>

<p style="margin:0pt;text-align:left">&#160;</p>

<p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;margin-left:47px"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>ASC
606 Revenue from Contracts with Customer introduces a five-step model for recognizing revenue from contracts with customers, as follows:</span></span></span></span></p>

<p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;margin-left:47px"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>1.&#160;
Identify the contract with a customer.</span></span></span></span></p>

<p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;margin-left:47px"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>2.&#160;
Identify the performance obligations in the contract.</span></span></span></span></p>

<p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;margin-left:47px"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>3.&#160;
Determine the transaction price.</span></span></span></span></p>

<p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;margin-left:47px"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>4.&#160;
Allocate the transaction price to the performance obligations in the contract.</span></span></span></span></p>

<p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;margin-left:47px"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>5.&#160;
Recognize revenue when (or as) the entity satisfies a performance obligation.</span></span></span></span></p>

<p style="margin:0pt;text-align:left">&#160;</p>

<p style="margin-top:0pt;margin-left:47px;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><span><span><span style="line-height:normal">According
to ASC 606, a performance obligation is a promise to provide a distinct good or service or a series of distinct goods or services. Goods
and services that are not distinct are bundled with other goods or services in the contract until a bundle of goods or services that is
distinct is created. A good or service promised to a customer is distinct if the customer can benefit from the good or service either
on its own or together with other resources that are readily available to the customer and the entity&#8217;s promise to transfer the
good or service to the customer is separately identifiable from other promises in the contract.</span></span></span></span></span></span></span></span></span></p>

<p style="margin:0pt;text-align:left">&#160;</p>

<p style="margin-top:0pt;margin-left:47px;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><span><span><span style="line-height:107%">Options
granted to the customer that do not provide a material right to the customer that it would not receive without entering into the contract
do not give rise to performance obligations.</span></span></span></span></span></span></span></span></span></p>

<p style="margin:0pt">&#160;</p>

<p style="margin-top:0pt;margin-left:47px;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><span><span><span><span><span style="line-height:normal">On
December 10, 2018, the Company entered into the Amgen Agreement for the use of the Company&#8217;s oral delivery platform in the field
of inflammatory diseases and other serious illnesses. As part of the agreement, the Company received non-refundable and non-creditable
initial access payment of $725&#160;from
Amgen in January 2019.</span></span></span></span></span></span></span></span></span></span></span></p>

<p style="margin:0pt">&#160;</p>

<p style="margin-top:0pt;margin-left:47px;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><span><span><span style="line-height:normal">The
Company identified two performance obligations in the agreement: 1) License to use the Company's proprietary drug delivery platform and
2) pre-clinical research and development services (&#8220;pre-clinical R&amp;D services&#8221;). The preclinical R&amp;D services include
discovery, research and design preclinical activities relating to the programs selected by Amgen.</span></span></span></span></span></span></span></span></span></p>

<p style="margin-top:0pt;margin-left:47px;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>

<div/>

<p style="margin-top:0pt;margin-left:47px;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The
Company determined the license to the intellectual property to be a right to use that has significant standalone functionality separately
from the pre-clinical R&amp;D services since the Company is not required to continue to support, develop or maintain the intellectual
property transferred and will not undertake any activities to change the standalone functionality of the intellectual property. Therefore,
the license to the intellectual property is a distinct performance obligation and as such revenue is recognized at the point in time that
control of the license was transferred to Amgen on December 10, 2018.</span></span></p>

<p style="margin-top:0pt;margin-left:47px;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>

<p style="margin-top:0pt;margin-left:47px;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><span><span><span style="line-height:normal">Revenues
attributed to the preclinical R&amp;Ds services are recognized during the period of the pre-clinical R&amp;D services, over time according
to the input model method on a cost-to-cost basis, since the customer benefits from the research and development services as the entity
performs the service.</span></span></span></span></span></span></span></span></span><br/>&#160;</p>

<p style="margin-top:0pt;margin-left:47px;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><span><span><span style="line-height:normal">The
Company evaluated the standalone selling price of the pre-clinical R&amp;D services at $225&#160;and
the right to use the intellectual property at $500.</span></span></span></span></span></span></span></span></span></p>
</div> </div>

<div style="line-height:1.25">

<div>

<div style="line-height:1.25">&#160;</div> </div> </div>

<div>

<p style="margin-top:0pt;margin-left:47px;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><span><span><span style="line-height:normal"><span><span>The
</span></span>transaction price was comprised of fixed consideration and variable consideration (capped research and development reimbursements).
Under ASC 606, the consideration that the Company would be entitled to upon the achievement of contractual milestones, which are contingent
upon the occurrence of future events of development and commercial progress, are a form of variable consideration. Variable consideration
is included in the transaction price if, in the Company&#8217;s judgment, it is highly probable that a significant future reversal of
cumulative revenue under the contract will not occur. Estimates of variable consideration and determination of whether to include estimated
amounts in the transaction price are based largely on an assessment of the Company&#8217;s anticipated performance and all information
(historical, current and forecasted) that is reasonably available. As of December 31, 2022, the Company did not recognize any revenues
from any potential milestone payments<span><span>.</span></span></span></span></span></span></span></span></span></span></span></p>

<p style="margin:0pt;text-align:left">&#160;</p>

<p style="margin-top:0pt;margin-left:47px;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><span style="line-height:107%">An
entity should recognize revenue for a sales-based or usage-based royalty promised in exchange for a license of intellectual property only
when (or as) the later of the following events occurs:</span></span></span></span></span></span></span></p>

<div style="line-height:1.25">

<div style="line-height:1.25">

<div style="line-height:1.25;text-align:left">&#160;</div> </div> </div>

<div style="line-height:1.25">

<div style="line-height:1.25">

<table cellpadding="0" cellspacing="0" style="font-family:Times New Roman, Times, serif;font-size:10pt;width:100%;text-align:left;color:rgb(0, 0, 0);border:0px">
  <tr>
    <td style="width:47px">&#160;</td>
    <td style="width:45px;vertical-align:top;font-family:Times New Roman, Times, serif;text-align:justify">
        <div style="font-size:10pt">
        <div style="font-family:Times New Roman, Times, serif;text-align:left"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>a)</span></span></span></span></div>
        </div> </td>
    <td style="width:auto;vertical-align:top">
        <div>
        <div style="text-align:justify">
        <div style="font-size:10pt">
        <div style="font-family:Times New Roman, Times, serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>The
        subsequent sale or usage occurs; and</span></span></span></span></div> </div> </div> </div> </td> </tr>
  </table>

<table cellpadding="0" cellspacing="0" style="font-family:Times New Roman, Times, serif;font-size:10pt;width:100%;text-align:left;color:rgb(0, 0, 0);border:0px">
  <tr>
    <td style="width:47px;text-align:justify">&#160;</td>
    <td style="width:45px;vertical-align:top;font-family:Times New Roman, Times, serif;text-align:justify">
        <div style="font-size:10pt">
        <div style="font-family:Times New Roman, Times, serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>b)</span></span></span></span></div>
        </div> </td>
    <td style="width:auto;vertical-align:top">
        <div>
        <div style="text-align:justify">
        <div style="font-size:10pt">
        <div style="font-family:Times New Roman, Times, serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>The
        performance obligation to which some or all of the sales based or usage-based royalty has been allocated has been satisfied (or partially
        satisfied).</span></span></span></span></div> </div> </div> </div> </td> </tr>
  </table> </div> </div> </div>

<p style="margin:0pt;text-align:left">&#160;</p>

<p style="margin-top:0pt;margin-left:47px;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><span><span><span style="line-height:normal">As
</span></span></span></span></span>royalties are payable based on future commercial sales, as defined in the agreement, which did not
occur as of the financial statements date, the Company did not recognize any revenues from royalties.&#160;</span></span></span></span></p>

<p style="margin-top:0pt;margin-left:47px;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>

<p style="margin-top:0pt;margin-left:47px;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span style="font-weight:bold"><span><span><span style="font-weight:normal">Revenues
attributed to preclinical R&amp;D services are recognized during the period of the pre-clinical R&amp;D services according to the input
model method on a cost-to-cost basis</span></span></span><span><span><span style="font-weight:normal">.</span></span></span></span></span></span></span></span></span></p>

<p style="margin-top:0pt;margin-left:47px;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>

<p style="margin-top:0pt;margin-left:47px;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span style="line-height:107%">In
2022 and 2021, the Company recorded revenues of $89
and $502,
respectively, related to services provided under the Amgen Agreement.</span></span></span></span></span></p>

<p style="margin-top:0pt;margin-left:47px;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p> </div>


<div/>

<div>

<div style="text-align:justify;line-height:1.25">

<table cellpadding="0" cellspacing="0" style="font-family:Times New Roman, Times, serif;font-size:10pt;width:100%;text-align:left;color:rgb(0, 0, 0);border:0px">
  <tr>
    <td style="width:47px;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><strong>p.</strong></span></span></span></span></td>
    <td style="width:auto;vertical-align:top">
        <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><span><span><strong><span style="line-height:107%">Income
        taxes </span></strong></span></span></span></span></span></span></span></span></p> </td> </tr>
  </table> </div>

<p style="margin:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font-family:Times New Roman, Times, serif;font-size:10pt;width:100%;text-align:left;color:rgb(0, 0, 0);border:0px">
  <tr>
    <td style="width:47px;text-align:justify">&#160;</td>
    <td style="width:40px;vertical-align:top;font-family:Times New Roman, Times, serif;text-align:justify">
        <div style="font-size:10pt">
        <div style="font-family:Times New Roman, Times, serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><span>1)</span></span></span></span></span></span></span></div>
        </div> </td>
    <td style="width:auto;vertical-align:top">
        <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><span style="line-height:normal">Deferred
        taxes</span></span></span></span></span></span></span></p> </td> </tr>
  </table>

<div style="line-height:1.25;text-align:left">&#160;</div>

<div style="margin-left:47px;text-align:justify;line-height:1.25;font-family:Times New Roman, Times, serif">

<div style="font-size:10pt">

<div style="font-family:Times New Roman, Times, serif;margin-left:40px"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><span style="line-height:107%">Deferred&#160;</span></span></span></span></span>income
taxes are computed using the asset and liability method. Under the asset and liability method, deferred income tax assets and liabilities
are determined based on the differences between the financial reporting and tax bases of assets and liabilities and are measured using
the currently enacted tax rates and laws. A valuation allowance is recognized to the extent that it is more likely than not that the deferred
taxes will not be realized in the foreseeable future<span><span><span><span><span style="line-height:107%">.</span></span></span></span></span></span></span></div>
</div> </div>

<p style="margin:0pt;text-align:left">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font-family:Times New Roman, Times, serif;font-size:10pt;width:100%;text-align:left;color:rgb(0, 0, 0);border:0px">
  <tr>
    <td style="width:47px">&#160;</td>
    <td style="width:40px;vertical-align:top;font-family:Times New Roman, Times, serif;text-align:justify">
        <div style="font-size:10pt">
        <div style="font-family:Times New Roman, Times, serif;text-align:left"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><span>2)</span></span></span></span></span></span></span></div>
        </div> </td>
    <td style="width:auto;vertical-align:top">
        <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><span style="line-height:107%">Uncertainty
        in income taxes</span></span></span></span></span></span></span></p> </td> </tr>
  </table>

<div style="line-height:1.25;text-align:left">&#160;</div>

<div style="margin-left:47px;text-align:justify;line-height:1.25;font-family:Times New Roman, Times, serif">

<div style="font-size:10pt">

<div style="font-family:Times New Roman, Times, serif;margin-left:40px"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><span style="line-height:107%">The
Company follows a two-step approach in recognizing and measuring uncertain tax positions. The first step is to evaluate the tax position
for recognition by determining if the available evidence indicates that it is more likely than not that the position will be sustained
based on technical merits. If this threshold is met, the second step is to measure the tax position as the largest amount that has more
than a 50% likelihood of being realized upon ultimate settlement.</span></span></span></span></span></span></span></div> </div> </div>
</div>

<div style="text-align:justify;line-height:1.25;font-family:Times New Roman, Times, serif">

<div style="font-size:10pt">

<div style="font-family:Times New Roman, Times, serif">

<p style="margin:0pt">&#160;</p> </div> </div> </div>

<div>

<div style="line-height:1.25">

<div>

<div style="line-height:1.25">

<div style="line-height:1.25">

<table cellpadding="0" cellspacing="0" style="font-family:Times New Roman, Times, serif;font-size:10pt;width:100%;text-align:left;color:rgb(0, 0, 0);border:0px">
  <tr>
    <td style="width:47px;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><strong>q.</strong></span></span></span></span></td>
    <td style="width:auto;vertical-align:top;text-align:justify">
        <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:left"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><span><span><strong><span style="line-height:107%">Loss
        per share </span></strong></span></span></span></span></span></span></span></span></p> </td> </tr>
  </table> </div> </div> </div> </div>

<div>

<p style="margin:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>

<p style="margin-top:0pt;margin-left:47px;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><span style="line-height:107%">Basic
loss per share is computed on the basis of the net loss, adjusted to recognize the effect of a down-round feature when it is triggered,
for the period, divided by the weighted average number of outstanding ordinary shares during the period.</span></span></span></span></span></span></span></p>

<p style="margin:0pt">&#160;</p>

<p style="margin-top:0pt;margin-left:47px;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><span><span><span><span><span style="line-height:107%">Diluted
</span></span></span></span></span>loss per share is based upon the weighted average number of ordinary shares and of ordinary shares
equivalents outstanding when dilutive. Ordinary share equivalents include outstanding stock options and warrants, which are included under
the treasury stock method when dilutive. The calculation of diluted loss per share does not include options, RSUs and warrants, exercisable
into an aggregate of<span><span><span><span><span style="line-height:107%">&#160;6,255,235
shares and&#160;</span><span style="line-height:107%">6,517,102</span><strong>&#160;</strong></span></span></span></span>shares
for the years ended December&#160;31, 2022&#160;and 2021, respectively, because the effect would have been anti-dilutive.</span></span></span></span></span></span></p>
</div> </div>

<p style="margin:0pt">&#160;</p>

<div>

<div style="line-height:1.25">

<div>

<div style="line-height:1.25">

<div style="line-height:1.25">

<table cellpadding="0" cellspacing="0" style="font-family:Times New Roman, Times, serif;font-size:10pt;width:100%;text-align:left;color:rgb(0, 0, 0);border:0px">
  <tr>
    <td style="width:47px;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong><span><span><span>r.</span></span></span></strong></span></span></td>
    <td style="width:auto;vertical-align:top;text-align:justify">
        <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong><span><span>Legal
        and other contingencies</span></span></strong></span></span></p> </td> </tr>
  </table> </div> </div> </div> </div>

<div>

<p style="margin:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>

<p style="margin-top:0pt;margin-left:47px;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><span style="line-height:107%">Management&#160;</span></span></span></span></span>applies
the guidance in ASC 450-20, &#8220;Loss Contingencies&#8221; when assessing losses resulting from contingencies. If the assessment of
a contingency indicates that it is probable that a material loss has been incurred and the amount of the liability can be estimated, then
the estimated liability is recorded as accrued expenses in the Company&#8217;s consolidated financial statements<span>.</span></span></span></p>

<p style="margin:0pt">&#160;</p>

<p style="margin-top:0pt;margin-left:47px;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Legal
costs incurred in connection with loss contingencies are expensed as incurred<span style="line-height:107%">.</span></span></span></p>

<p style="margin-top:0pt;margin-left:47px;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p> </div>
</div>

<div>

<div/> </div>

<div>

<div style="line-height:1.25">

<div>

<div style="line-height:1.25">

<div style="line-height:1.25">

<table cellpadding="0" cellspacing="0" style="font-family:Times New Roman, Times, serif;font-size:10pt;width:100%;text-align:left;color:rgb(0, 0, 0);border:0px">
  <tr>
    <td style="width:47px;vertical-align:top;font-family:Times New Roman, Times, serif;font-weight:bold;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>s.</span></span></span></span></td>
    <td style="width:auto;vertical-align:top;text-align:justify">
        <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:left"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><span><span><strong><span style="line-height:107%">Newly
        issued and recently adopted accounting pronouncements:</span></strong></span></span></span></span></span></span></span></span></p> </td>
        </tr>
  </table> </div> </div> </div> </div>

<div>

<p style="margin:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>

<p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;margin-left:38pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><em><strong><span><span>Recently
issued accounting pronouncements adopted</span></span></strong></em></span></span></span></span></p>

<p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>

<div style="margin-left:47px">

<table cellpadding="0" cellspacing="0" style="border:0px;width:100%">
  <tr>
    <td style="vertical-align:top;width:20pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>1)</span></span></span></span></td>
    <td style="width:auto">
        <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>In&#160;</span></span><span style="line-height:107%">November
        2021, the FASB issued ASU 2021-10 &#8220;Government Assistance (Topic 832)&#8221;, which requires annual disclosures that increase the
        transparency of transactions involving government grants, including (1) the types of transactions, (2) the accounting for those transactions,
        and (3) the effect of those transactions on an entity&#8217;s financial statements. The amendments in this update are effective for financial
        statements issued for annual periods beginning after December 15, 2021.</span>&#160;<span style="line-height:107%">The adoption of this
        guidance did not have material impact on the Company&#8217;s consolidated financial statements.</span></span></span></span></span></p>
        </td> </tr>
  </table> </div>

<p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>

<div style="margin-left:47px">

<table cellpadding="0" cellspacing="0" style="border:0px;width:100%">
  <tr>
    <td style="vertical-align:top;width:20pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>2)</span></span></span></span></td>
    <td style="width:auto">
        <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>In
        </span></span><span style="line-height:107%">August 2020, the FASB issued ASU 2020-06 &#8220;Debt &#8211; Debt with Conversion and Other
        Options (Subtopic 470-20) and Derivatives and Hedging &#8211; Contracts in Entity&#8217;s Own Equity (Subtopic 815 &#8211; 40).&#8221;
        This guidance simplifies the accounting for certain financial instruments with characteristics of liabilities and equity, including convertible
        instruments and contracts on an entity&#8217;s own equity. The amendments to this guidance are effective for fiscal years beginning after
        December&#160;15, 2021, and interim periods within those fiscal years. The Company early adopted this guidance effective January 1, 2022
        and the impact of the adoption on the Consolidated financial statements was immaterial.</span></span></span></span></span></p> </td> </tr>
  </table> </div>

<p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt">&#160;</p>

<p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;margin-left:38pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><em><strong>Recently
issued accounting pronouncements, not yet adopted</strong></em></span></span></p>

<p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt">&#160;</p>

<div style="margin-left:47px">

<table cellpadding="0" cellspacing="0" style="border:0px;width:100%">
  <tr>
    <td style="vertical-align:top;width:20pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>1)</span></span></span></span></td>
    <td style="width:auto">
        <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>I</span></span></span></span></span><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><span>n
        </span></span><span style="line-height:107%">June 2016, the FASB issued ASU 2016-13 &#8220;Financial Instruments&#8212;Credit Losses&#8212;Measurement
        of Credit Losses on Financial Instruments.&#8221; This guidance replaces the current incurred loss impairment methodology with a methodology
        that reflects expected credit losses and requires consideration of a broader range of reasonable and supportable information to inform
        credit loss estimates. </span></span></span></span></span></span><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="line-height:107%">The
        guidance will be effective for Smaller Reporting Companies (SRCs, as defined by the SEC) for the fiscal year beginning on January 1, 2023,
        including interim periods within that year. The adoption of this guidance will not have material impact on the Company&#8217;s consolidated
        financial statements.</span></span></span></p> </td> </tr>
  </table> </div> </div> </div>  </div> </div> </div> </div> </div> </div> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18726-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI https://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140398300864416">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>OPERATING LEASES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">OPERATING LEASES</a></td>
<td class="text">

<div>

<div>

<div>

<div>

<div>

<div style="font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">NOTE 3 - OPERATING LEASES</span></span></div>

<div style="line-height:1.25;font-weight:bold">&#160;</div>

<table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">
  <tr>
    <td style="width:35.45pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">1)</span></span></td>
    <td style="width:auto;vertical-align:top;text-align:justify">
        <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The Company leases office and research and development
        space under several agreements. The annual lease consideration is a total of $166
        and is linked to the Israeli CPI. The lease agreement expires on June 30, 2023.</span></span></div> </td> </tr>
  </table>

<div style="line-height:1.25">&#160;</div>

<div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">As
of December 31, 2022, the Company provided bank guarantees of approximately $37,
in the aggregate, to secure the fulfillment of its obligations under the lease agreements. </span></span></div>

<div style="line-height:1.25">&#160;</div>

<div>

<table cellpadding="0" cellspacing="0" style="width:100%;font-family:'Times New Roman', Times, serif;font-size:10pt">
  <tr style="vertical-align:top">
    <td style="vertical-align:top;width:35.45pt">
        <div style="text-align:justify;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2)</span></span></div>
        </td>
    <td style="align:left;vertical-align:top;width:auto">
        <div style="text-align:justify;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The
        Company has entered into operating lease agreements for vehicles used by its employees. The lease periods are generally for three years
        and the payments are linked to the Israeli CPI. To secure the terms of the lease agreements, the Company has made certain deposits to
        the leasing company, representing approximately three months of lease payments. The annual lease consideration is a total of $21.</span></span></div>
        </td> </tr>
  </table> </div>

<div style="margin-left:70.4pt;line-height:1.25">&#160;</div>

<div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The
lease cost was as follows:</span></span></div> </div> </div>

<div>

<div>

<div>

<div style="text-align:justify;margin-left:36pt;line-height:1.25">&#160;</div>

<div style="margin-left:45pt">

<table border="0" cellpadding="0" cellspacing="0" style="width:92%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left">
  <tr>
    <td style="vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px" valign="bottom">
        <div style="line-height:1.25">
        <div style="text-align:center;line-height:1.25;font-weight:bold;text-indent:1pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Year
        ended</span></span></div>
        <div style="text-align:center;line-height:1.25;font-weight:bold;text-indent:1pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">December&#160;31,<br/>2022</span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px" valign="bottom">
        <div style="line-height:1.25">
        <div style="text-align:center;line-height:1.25;font-weight:bold;text-indent:1pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Year
        ended</span></span></div>
        <div style="text-align:center;line-height:1.25;font-weight:bold;text-indent:1pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">December&#160;31,<br/>2021</span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td> </tr>
  <tr>
    <td style="vertical-align:bottom;width:76%;padding-bottom:4px;background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Operating
        lease cost</span></span></div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">197</span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">216</span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
        </tr>
  </table> </div> </div> </div>  </div>

<div style="margin-left:36pt">

<p style="margin:0pt">&#160;</p>

<p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Supplemental
cash flow information related to leases was as follows:</span></span></span></span><br/>&#160;</p> </div>

<div style="line-height:1.25">

<div style="margin-left:45pt">

<div>

<div>

<table border="0" cellpadding="0" cellspacing="0" style="width:92%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left">
  <tr>
    <td style="vertical-align:top;padding-bottom:2px" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px" valign="bottom">
        <div style="line-height:1.25">
        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Year
        ended</span></span></div>
        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">December&#160;31,<br/>2022</span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px" valign="bottom">
        <div style="line-height:1.25">
        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Year
        ended</span></span></div>
        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">December&#160;31,<br/>2021</span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td> </tr>
  <tr>
    <td style="vertical-align:top;width:76%;background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:normal"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Operating
        cash flows from operating leases</span></span></div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-weight:normal;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-weight:normal;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:normal"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">197</span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-weight:normal;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-weight:normal;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-weight:normal;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:normal"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">216</span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
        </tr>
  </table> </div> </div>

<p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt">&#160;</p> </div> </div> </div>

<p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;margin-left:47px"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span>Supplemental
balance sheet information related to operating leases was as follows:</span></span></span></span></span></p>

<p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt">&#160;</p>

<div style="text-align:center">

<div style="clear:both;margin-top:00pt;margin-bottom:00pt">

<div style="text-align:center"> <div style="font-size:10pt;display:inline"> <div style="font-family:Times New Roman,Times,serif;display:inline">
<div style="color:#000000;font-weight:normal;font-style:normal;display:inline">

<div>

<div>

<div>

<div style="line-height:1.25">

<div style="line-height:1.25">&#160;</div> </div>

<div style="margin-left:45pt">

<table border="0" cellpadding="0" cellspacing="0" style="width:92%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left">
  <tr>
    <td style="vertical-align:top;padding-bottom:2px" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px" valign="bottom">
        <div style="line-height:1.25">
        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">December&#160;31,<br/>2022</span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px" valign="bottom">
        <div style="line-height:1.25">
        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">December&#160;31,<br/>2021</span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td> </tr>
  <tr>
    <td style="vertical-align:bottom;font-weight:bold;background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="margin-right:36pt;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Operating
        Leases</span></span></div> </td>
    <td colspan="1" style="vertical-align:bottom;font-weight:normal;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align:top;font-weight:normal;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;font-weight:normal;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;font-weight:normal;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align:top;font-weight:normal;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;font-weight:normal;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align:bottom;width:76%" valign="bottom">
        <div style="margin-right:36pt;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:normal"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Operating
        lease right-of-use assets</span></span></div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-weight:normal" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-weight:normal" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%" valign="bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:normal"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">90</span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-weight:normal;white-space:nowrap" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-weight:normal" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-weight:normal" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%" valign="bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:normal"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">239</span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-weight:normal;white-space:nowrap" valign="bottom">&#160;</td> </tr>
  <tr>
    <td style="vertical-align:top;width:76%;font-weight:normal;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-weight:normal;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-weight:normal;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;font-weight:normal;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-weight:normal;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-weight:normal;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-weight:normal;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;font-weight:normal;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-weight:normal;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align:bottom;width:76%" valign="bottom">
        <div style="margin-right:36pt;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:normal"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Current
        lease liabilities</span></span></div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-weight:normal" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-weight:normal" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%" valign="bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:normal"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">91</span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-weight:normal;white-space:nowrap" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-weight:normal" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-weight:normal" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%" valign="bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:normal"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">179</span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-weight:normal;white-space:nowrap" valign="bottom">&#160;</td> </tr>
  <tr>
    <td style="vertical-align:bottom;width:76%;padding-bottom:2px;background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="margin-right:36pt;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:normal"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Non-current
        lease liabilities</span></span></div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;font-weight:normal;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);font-weight:normal;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:normal"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;font-weight:normal;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;font-weight:normal;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);font-weight:normal;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:normal"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">123</span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;font-weight:normal;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align:bottom;width:76%;font-weight:bold" valign="bottom">
        <div style="margin-right:36pt;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Total
        lease liabilities</span></span></div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-weight:normal" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-weight:normal" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%" valign="bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:normal"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">91</span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-weight:normal;white-space:nowrap" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-weight:normal" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-weight:normal" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%" valign="bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:normal"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">302</span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-weight:normal;white-space:nowrap" valign="bottom">&#160;</td> </tr>
  <tr>
    <td style="vertical-align:bottom;width:76%;font-weight:normal;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-weight:normal;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-weight:normal;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;font-weight:normal;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-weight:normal;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-weight:normal;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-weight:normal;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;font-weight:normal;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-weight:normal;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align:top;width:76%" valign="bottom">
        <div style="margin-right:36pt;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:normal"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Weighted-average
        remaining lease term (in years)</span></span></div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-weight:normal" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-weight:normal" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%" valign="bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:normal"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>0.52</span></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-weight:normal;white-space:nowrap" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-weight:normal" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-weight:normal" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%" valign="bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:normal"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">1.53</span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-weight:normal;white-space:nowrap" valign="bottom">&#160;</td> </tr>
  <tr>
    <td style="vertical-align:top;width:76%;background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="margin-right:36pt;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:normal"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Weighted-average
        discount rate</span></span></div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-weight:normal;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-weight:normal;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:normal"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">16</span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:normal"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">%</span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-weight:normal;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-weight:normal;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:normal"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">16</span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:normal"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">%</span></span></div>
        </td> </tr>
  </table> </div> </div> </div>  </div>

<div style="margin-left:96pt;line-height:1.25">&#160;</div>

<p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:left;margin-left:36pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><span>As
of December 31, 2022, the maturity of lease liabilities under our non-cancelable operating leases </span></span></span><span style="line-height:107%">are
$91
to be paid in 2023.</span></span></span></span></span></p> </div> </div> </div> </div> </div> </div> </div> </div> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -URI https://asc.fasb.org/subtopic&amp;trid=77888251<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140398304555680">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">COMMITMENTS AND CONTINGENCIES</a></td>
<td class="text">

<div>

<div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">NOTE
4 - COMMITMENTS</span>&#160;<span style="font-weight:bold">AND CONTINGENCIES</span></span></span></div>

<div style="text-indent:-36pt;margin-left:36pt;line-height:1.25;font-weight:bold">&#160;</div>

<table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">
  <tr>
    <td style="width:35.45pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">a<span style="font-weight:bold">.</span></span></span></td>
    <td style="width:auto;vertical-align:top;text-align:justify">
        <div style="font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Commitment to pay royalties
        to the government of Israel</span></span></div> </td> </tr>
  </table>

<div style="text-indent:-36pt;margin-left:72pt;line-height:1.25">&#160;</div>

<div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The
Company is committed to pay royalties to the IIA on proceeds from sales of products in the research and development of which the Government
participates by way of grants. At the time the grants were received, successful development of the related project was not assumed. In
the case of failure of the project that was partly financed by the IIA, the Company is not obligated to pay any such royalties.</span></span></div>

<div style="line-height:1.25">&#160;</div>

<div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Under
the terms of the Company&#8217;s funding from the IIA, royalties are payable on sales of products developed from IIA funded projects of
3%
during the first three years from commencement of revenues, 4%
during the subsequent three years and 5%
commencing the seventh year up to 100% of the amount of the grant received by the Company (dollar linked) plus annual interest based on
LIBOR. The amount that must be repaid may be increased to three times the amount of the grant received, and the rate of royalties may
be accelerated, if manufacturing of the products developed with the grant money is transferred outside of the State of Israel. In addition,
if the Company undergoes a change of control or otherwise transfers the technology &#8220;know-how&#8221; (as defined under the Research
Law) in or outside of Israel, the amount that must be repaid will be increased up to six times.</span></span></div>

<div style="line-height:1.25">&#160;</div>

<div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The
IIA has not yet declared the alternative benchmark rate to replace LIBOR. However, the Company does not believe it will have significant
impact on the Company&#8217;s financial position or results of operations.</span></span></div>

<div style="line-height:1.25">&#160;</div>

<div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">As
of December 31, 2022, the total royalty amount that would be payable by the Company to the IIA, before the interest and payments as described
above, was approximately $460.
These grants were allocated to research and development.</span></span></div>

<div style="line-height:1.25">&#160;</div>

<div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Following
the signing of the Amgen Agreement, the IIA determined that the Company should pay 5.38%
of each payment received by the Company from Amgen on the license of Intellectual Property up to six times the grant received. As of December
31, 2022, the Company had paid a total amount of $83
to the IIA.</span></span></div>

<div style="text-indent:-36pt;margin-left:36pt;line-height:1.25;font-weight:bold">&#160;</div>

<table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">
  <tr>
    <td style="width:35.45pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">b.</span></span></td>
    <td style="width:auto;vertical-align:top;text-align:justify">
        <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">On June 1, 2010, D.N.A. Biomedical Solutions Ltd.
        ("D.N.A.") and Oramed Ltd., ("Oramed") entered into a joint venture agreement, (the "Joint Venture Agreement") for the establishment of
        Entera Bio Ltd. According to the Joint Venture Agreement each of D.N.A. and Oramed acquired 50%
        of the Company's ordinary shares. D.N.A invested $600
        in the Company, and Oramed and the Company entered into a Patent License Agreement pursuant to which Oramed licensed to the Company one
        of Oramed&#8217;s patents (the &#8220;IPR&amp;D&#8221;).</span></span></div> </td> </tr>
  </table>

<div style="line-height:1.25">&#160;</div>

<div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">On
February 22, 2011, Oramed and the Company entered into a patent transfer agreement, (the "Patent Transfer Agreement") that superseded
the Patent License Agreement, whereby Oramed assigned to the Company all of its rights, title and interest to its patent that Oramed licensed
to the Company in 2010, under certain conditions. Under this agreement, the Company is obligated to pay Oramed royalties equal to 3%
of its net revenues (as defined in the Patent Transfer Agreement).</span></span></div> </div> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI https://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 440<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6491277&amp;loc=d3e6429-115629<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI https://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140398296048304">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SHARE CAPITAL<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>Stockholders' Equity Note [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">SHARE CAPITAL</a></td>
<td class="text">

<div>

<div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>NOTE
5 - SHARE CAPITAL</span></span></span></span></div>

<div style="line-height:1.25">&#160;</div>

<table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">
  <tr>
    <td style="width:35.45pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>1)</span></span></span></span></td>
    <td style="width:auto;vertical-align:top;text-align:justify">
        <div style="font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Rights of
        the Company&#8217;s ordinary shares</span></span></span></span></div> </td> </tr>
  </table>

<div style="margin-left:72pt;line-height:1.25;font-weight:bold">&#160;</div>

<div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Each
ordinary share is entitled to one
vote. The holder of an ordinary shares is also entitled to receive dividends whenever funds are legally available, when
and if declared by the Board of Directors.<br/>&#160;</span></span></span></span></div>

<div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>A
holder of an ordinary share also has the right to receive upon liquidation of the Company, a sum equal to the nominal value of such share,
and if a surplus per share remains, to receive such surplus, subject to the rights conferred on any class of shares which may be issued
in the future. Since its inception, the Company has not declared any dividends.</span></span></span></span></div>

<div style="text-align:justify;margin-left:70.9pt;line-height:1.25">&#160;</div>

<table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">
  <tr>
    <td style="width:35.45pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>2)</span></span></span></span></td>
    <td style="width:auto;vertical-align:top;text-align:justify">
        <div style="font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Changes in
        share capital:</span></span></span></span></div> </td> </tr>
  </table>

<div style="line-height:1.25">&#160;</div>

<table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">
  <tr>
    <td style="width:35.45pt">&#160;</td>
    <td style="width:21.25pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>a.</span></span></span></span></td>
    <td style="width:auto;vertical-align:top">
        <div style="font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>IPO warrants</span></span></span></span></div>
        </td> </tr>
  </table>

<div style="line-height:1.25">&#160;</div>

<div style="text-align:justify;margin-left:56.7pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>In
connection with the Company&#8217;s initial public offering (&#8220;IPO&#8221;) in July 2018, the Company issued 1,400,000
IPO warrants to purchase 700,000
ordinary shares, and these warrants have been listed for trading on the Nasdaq Capital Market since August 12, 2018. The IPO warrants
were immediately exercisable at an initial exercise price of $8.40
per ordinary share for a period of five
years, unless earlier repurchased by the Company under "Fundamental Transactions&#8221; as described in the warrant agreement
or earlier expired as described in the warrant agreement.</span></span></span></span></div>

<div style="text-align:justify;margin-left:56.7pt;line-height:1.25"><br/><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>The
exercise price and number of ordinary shares issuable upon exercise of each warrant are subject to standard adjustments. In addition,
subject to certain exceptions, the exercise price was subject to reduction if, within two
years following the date of original issuance of the warrants, which ended in July 2020, the Company sold or granted any
warrant or option at an effective price per share of less than $8.00
(as adjusted in proportion with any adjustments made from time to time), based on a weighted average, as described in the warrant agreement.
As described in note 5b below, the Company completed a financing round during such two-year period at a price per share lower than the
$8.00, therefore, the exercise price of these warrants adjusted to $5.85
per share.</span></span></span></span></div>

<div style="text-align:justify;margin-left:56.7pt;line-height:1.25">&#160;</div>

<div style="text-align:justify;margin-left:56.7pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>At
the IPO completion date, both of the instruments (warrants and shares) were classified as equity instruments as the warrants are considered
indexed to the entity's own stock based on the provision of ASC 815.<br/>&#160;<br/>In March 2021, 4,500
IPO warrants were exercised into 2,250
ordinary shares for total consideration of $13
at an exercise price of $5.85
per ordinary share.</span></span></span></span></div>

<div style="text-align:justify;margin-left:56.7pt;line-height:1.25">&#160;</div>

<div style="text-align:justify;margin-left:56.7pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>As
of the December 31, 2022 there were 1,395,500
traded warrants to purchase 697,750
ordinary shares outstanding with an exercise price of $5.85.</span></span></span></span></div>

<div style="text-align:justify;margin-left:56.7pt;line-height:1.25">&#160;</div>

<div/>

<div style="text-align:justify;line-height:1.25">

<table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">
  <tr>
    <td style="width:35.45pt">&#160;</td>
    <td style="width:21.25pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>b.</span></span></span></span></td>
    <td style="width:auto;vertical-align:top;text-align:justify">
        <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>In December 2019 and February 2020,
        the Company entered into subscription agreement with a selected group of accredited investors for the private placement of 6,047,706
        ordinary shares for aggregate subscription proceeds to the Company of $14.3
        million at a price of $2.37
        per share. In addition, the Company granted 3,023,871
        warrants, exercisable over a three-year
        period from the date of issuance to purchase up to 3,023,871
        ordinary shares at a per share exercise price of $2.96
        (&#8220;Investors Warrants&#8221;). In addition, the exercise price was subject to reduction if, within one year of the date of original
        issuance of the warrants which ended in December 2020, the Company issued ordinary shares at an effective price per share less than $2.96.<br/>&#160;<br/>Following
        the closing of the offering, the Company issued to a broker-dealer 184,515
        warrants and 92,257
        warrants with per share exercise prices of $2.37
        to $2.96,
        respectively (&#8220;Broker Warrants&#8221;).</span></span></span></span></div> </td> </tr>
  </table> </div>

<div style="text-align:justify;margin-left:56.7pt;line-height:1.25">&#160;</div>

<div style="text-align:justify;margin-left:56.7pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>During
2020, upon issuance of shares through the Company&#8217;s At-the-market equity program at a price per share lower than the exercise price,
the exercise price of the Investors Warrants and the Broker Warrants adjusted to $1.05.
See note 5c.<br/>&#160;<br/>On April 21, 2021, upon satisfaction of the sale price condition pursuant to the subscription agreement,
the Company&#8217;s Board of Directors elected to accelerate the termination date of the Investors Warrants and Broker Warrants. In accordance
with the terms of the applicable agreements, the holders had the opportunity to exercise their warrants until June 23, 2021, following
which any unexercised warrants would terminate.<br/>&#160;</span></span></span></span></div>

<div style="text-align:justify;margin-left:56.7pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Through
June 23, 2021, all warrants holders exercised 3,300,645
warrants into 3,172,800
ordinary shares, either through purchase or a cashless exercise. The total consideration from the exercise of these warrants was $3,145
at an exercise price of $1.05
per share.</span></span></span></span></div>

<div style="line-height:1.25">&#160;</div>

<div style="text-align:justify;margin-left:56.7pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>As
of December 31, 2021, all Investors Warrants and Broker Warrants had been exercised and none remain outstanding.<br/>&#160;</span></span></span></span></div>

<div style="text-align:justify;line-height:1.25">

<table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">
  <tr>
    <td style="width:35.45pt">&#160;</td>
    <td style="width:21.25pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>c.</span></span></span></span></td>
    <td style="width:auto;vertical-align:top;text-align:justify">
        <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>On July 4, 2020, the Company filed
        a primary registration statement on form F-3 and established an at-the-market equity program (the " 2020 ATM Program") that allowed the
        Company to issue up to $13.9
        million of ordinary shares, at the Company&#8217;s discretion. Distributions of the ordinary shares through 2020 ATM Program were made
        pursuant to the terms of an equity distribution agreement dated July 13, 2020, among the Company and Canaccord Genuity LLC (the "Agent").</span></span></span></span></div>
        </td> </tr>
  </table> </div>

<div style="text-align:justify;margin-left:56.7pt;line-height:1.25">&#160;</div>

<div style="text-align:justify;margin-left:56.7pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>In
2020, the Company issued 2,802,731
ordinary shares pursuant to the 2020 ATM Program for net proceeds of $3.2
million at a weighted average price of $1.27
per ordinary share.<br/>&#160;<br/>In 2021, the Company issued an additional 2,546,265
ordinary shares pursuant to the 2020 ATM Program for net proceeds of $9.9
million at a weighted average price of $3.99
per ordinary share.<br/>&#160;</span></span></span></span></div>

<div style="text-align:justify;line-height:1.25">

<table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">
  <tr>
    <td style="width:35.45pt">&#160;</td>
    <td style="width:21.25pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>d.</span></span></span></span></td>
    <td style="width:auto;vertical-align:top;text-align:justify">
        <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>On May 7, 2021, the Company entered
        into a new at-the-market equity program (the "2021 ATM Program") that allowed the Company to issue up to additional five
        million ordinary shares, at the Company's discretion.</span></span></span></span></div> </td> </tr>
  </table> </div>

<div style="line-height:1.25">&#160;</div>

<div>

<div/> </div>

<div style="text-align:justify;margin-left:56.7pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Distributions
of the ordinary shares through the 2021 ATM Program were made pursuant to the terms of an equity distribution agreement dated May 7, 2021
among the Company and B. Riley Securities, Inc.</span></span></span></span></div>

<div style="line-height:1.25">&#160;</div>

<table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">
  <tr>
    <td style="width:35.45pt">&#160;</td>
    <td style="width:21.25pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>e.</span></span></span></span></td>
    <td style="width:auto;vertical-align:top;text-align:justify">
        <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>In June and July 2021, the Company
        issued an aggregate of 1,840,463
        ordinary shares pursuant to the 2021 ATM Program for net proceeds of $12.1
        million at a weighted average price of $6.74
        per ordinary share.</span></span></span></span></div> </td> </tr>
  </table>

<div style="line-height:1.25">&#160;</div>

<table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">
  <tr>
    <td style="width:35.45pt">&#160;</td>
    <td style="width:21.25pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>f.</span></span></span></span></td>
    <td style="width:auto;vertical-align:top;text-align:justify">
        <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>During the year ended December 31,
        2021, several employees and service providers exercised 177,711
        options into 177,711
        ordinary shares for a total consideration of $418
        at a weighted average price of $2.54
        per ordinary share.</span></span></span></span></div> </td> </tr>
  </table>

<div style="line-height:1.25">&#160;</div>

<table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">
  <tr>
    <td style="width:35.45pt">&#160;</td>
    <td style="width:21.25pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>g.</span></span></span></span></td>
    <td style="width:auto;vertical-align:top;text-align:justify">
        <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>During the year ended December 31,
        2022, one employee exercised 5,511
        options into 5,511
        ordinary shares for a total consideration of $13
        at a price of $2.14
        per ordinary share.</span></span></span></span></div> </td> </tr>
  </table> </div> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI https://asc.fasb.org/topic&amp;trid=2208762<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496180-112644<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126731327&amp;loc=SL126733271-114008<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140398305778496">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SHARE-BASED COMPENSATION<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">SHARE-BASED COMPENSATION</a></td>
<td class="text">

<div>

<div>

<div>

<div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">NOTE
6 - SHARE-BASED COMPENSATION</span></span></div>

<div style="line-height:1.25">&#160;</div>

<table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">
  <tr>
    <td style="width:35.45pt;vertical-align:top;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">1)</span></span></td>
    <td style="width:auto;vertical-align:top;text-align:justify">
        <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Share-based compensation plan</span></span></div>
        </td> </tr>
  </table>

<div style="line-height:1.25">&#160;</div>

<div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">On
March 17, 2013, the Company's Board of Directors approved a Share Incentive Plan (the &#8220;2013 Plan&#8221;). Under the 2013 Plan, the
Company reserves specified number of ordinary shares for allocation to stock options (each, an &#8220;Option&#8221;), restricted share
units, restricted share awards and performance-based awards, that had been awarded to employees and non-employees under the 2013 Plan.
Each Option is exercisable for one ordinary share.</span></span></div>

<div style="line-height:1.25">&#160;</div>

<div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Any
Option granted under the 2013 Plan that is not exercised within six years from the date upon which it becomes exercisable will expire.
Since adopting the 2018 Plan (as defined below), the Company has not granted any awards under the 2013 Plan.</span></span></div>

<div style="line-height:1.25">&#160;</div>

<div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">On
July 2, 2018, the Company's Board of Directors and shareholders of the Company approved a new Share Incentive Plan (the &#8220;2018 Plan&#8221;)
and reserved 1,371,398
ordinary shares for allocation to stock options (each, a "2018 Plan Option"), restricted share units, restricted share awards and performance-based
awards, to employees and non-employees for issuance under the 2018 Plan. Each 2018 Plan Option is exercisable for one ordinary share.<br/>&#160;</span></span></div>

<div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Any
2018 Plan Option that is not exercised within 10 years from the date of grant will expire.<br/>&#160;</span></span></div>

<div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The
2018 Plan Options granted to employees are subject to the terms stipulated by section 102(b)(2) of the Israeli Income Tax Ordinance (the
&#8220;Ordinance&#8221;). According to these provisions, the Company will not be allowed to claim as an expense for tax purposes the amounts
credited to the employees as a capital gain benefit in respect of the options granted.</span></span></div>

<div style="line-height:1.25">&#160;</div>

<div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2018
Plan Options granted to related parties or non-employees of the Company are governed by Section 3(i) of the Ordinance or Non-Qualified
Share Options ("NSO"). The Company will be allowed to claim as an expense for tax purposes in the year in which the related parties or
non-employees exercised the options into shares.</span></span></div>

<div style="text-align:justify;margin-left:36pt;line-height:1.25">&#160;</div>

<div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">As
of December 31, 2022, 922,080
ordinary shares remain available for future grants under the 2018 Plan.</span></span></div>

<div style="text-align:justify;margin-left:36pt;line-height:1.25">&#160;</div>

<div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">On
January 2, 2023, the Company&#8217;s Board of Directors approved an increase of 1,440,496
ordinary shares that may be issued under the Company&#8217;s 2018 Plan pursuant of the terms of the 2018 Plan,</span></span></div>

<div style="text-align:center;line-height:1.25">&#160;</div>

<div>

<div/> </div>

<div style="text-align:justify;line-height:1.25">

<table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">
  <tr>
    <td style="width:35.45pt;vertical-align:top;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2)</span></span></td>
    <td style="width:auto;vertical-align:top;text-align:justify">
        <div style="font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">share-based compensation
        grants to employees and directors:</span></span></div> </td> </tr>
  </table>

<p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman,Times,serif">&#160;</p> </div>

<div style="text-align:justify;line-height:1.25">

<table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">
  <tr>
    <td style="width:35.45pt">&#160;</td>
    <td style="width:21.25pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">a)</span></span></td>
    <td style="width:auto;vertical-align:top;text-align:justify">
        <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">On January 4, 2021, options to purchase 1,314,218
        ordinary shares were granted to the Company&#8217;s former Chief Executive Officer, Dr. Spiros Jamas with an exercise price of $1.24
        per share. Prior to the terms of Dr. Jamas&#8217; separation agreement (as described below), the options were to vest over four years
        from the date of grant; 25%
        vest on the first anniversary of the date of grant and the remaining 75%
        of the option to vest in twelve equal quarterly installments following the first anniversary of the grant date.</span> The grant was subject
        to the approval by the Company&#8217;s shareholders, which approved the grant in March 2021. The fair value of the options at the date
        of grant was $1,320.</span></div>
        </td> </tr>
  </table> </div>

<div style="text-align:justify;margin-left:56.7pt;line-height:1.25">&#160;</div>

<div style="text-align:justify;margin-left:56.7pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">On
July 15, 2022, the Company entered into a mutual separation agreement with Dr. Jamas. Pursuant to the separation agreement, Dr. Jamas
received the following benefits: (i)
a one-time lump sum payment of his annual base salary for a period of 13 months, for a total gross amount equal to $412;
and (ii) an extension of the exercise period for the vested portion of the options granted on January 4, 2021, based on the award original
terms, representing an aggregate of 492,832
ordinary shares, through the end of a <span style="-sec-ix-hidden:Fxbrl_20230228114443567">two-year</span> period commencing on July 15,
2022. Effective July 15, 2022, upon termination of the employment agreement with Dr. Jamas, the remaining 821,386
unvested options were forfeited and recognized as a reverse of expense of $457
in general and administrative expenses.</span></span></div>

<div style="line-height:1.25">&#160;</div>

<div style="text-align:justify;line-height:1.25">

<table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">
  <tr>
    <td style="width:35.45pt">&#160;</td>
    <td style="width:21.25pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">b)</span></span></td>
    <td style="width:auto;vertical-align:top;text-align:justify">
        <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">On April 7, 2021, the Company&#8217;s Board of
        Directors approved the following option grants:</span></span></div> </td> </tr>
  </table>

<p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman,Times,serif">&#160;</p> </div>

<div style="line-height:1.25">

<table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">
  <tr>
    <td style="width:59.5pt">&#160;</td>
    <td style="width:18pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">i.</span></span></td>
    <td style="width:auto;vertical-align:top">
        <div style="font-family:'Times New Roman',Times,serif;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Option
        grants to purchase 213,000
        ordinary shares to certain employees and 70,000
        options granted to service providers, with an exercise price of&#8201;$3.61
        per share. The options vest over four
        years from the date of grant; 25%
        vest on the first anniversary of the date of grant and the remaining 75%
        of the option will vest in twelve equal quarterly installments following the first anniversary of the grant date. The fair value of the
        options at the date of grant was $646.</span></span></div>
        </td> </tr>
  </table> </div>

<div style="line-height:1.25">

<p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman,Times,serif">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">
  <tr>
    <td style="width:59.5pt">&#160;</td>
    <td style="width:18pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">ii.</span></span></td>
    <td style="width:auto;vertical-align:top">
        <div style="font-family:'Times New Roman',Times,serif;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Options
        grant to purchase 33,368
        ordinary shares to a non-executive director of the Company, with an exercise price of $3.61.
        The options will vest over three
        years in twelve equal quarterly instalments starting on the vesting commencement date. These options were subject to the
        approval of the shareholders of the Company, which was approved on October 4, 2021. The fair value of the options at the shareholders'
        approval date was $104.</span></span></div>
        </td> </tr>
  </table> </div>

<p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman,Times,serif">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">
  <tr>
    <td style="width:35.45pt">&#160;</td>
    <td style="width:21.25pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">c)</span></span></td>
    <td style="width:auto;vertical-align:top;text-align:justify">
        <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">On April 21, 2021, options to purchase 345,000
        ordinary shares were granted to several executive officers of the Company, with an exercise price of $3.15.
        The options vest over four
        years from the date of grant; 25%
        vest on the first anniversary of the date of grant and the remaining 75%
        of the option will vest in twelve equal quarterly installments following the first anniversary of the grant date. These options were subject
        to the approval of the shareholders of the Company, which was approved on October 4, 2021. The fair value of the options at the shareholders'
        approval date was $1,140.</span></span></div>
        </td> </tr>
  </table>

<div style="text-align:center;line-height:1.25">&#160;</div>

<div>

<div/> </div>

<table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">
  <tr>
    <td style="width:35.45pt">&#160;</td>
    <td style="width:21.25pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">d)</span></span></td>
    <td style="width:auto;vertical-align:top;text-align:justify">
        <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">On August 23, 2021, the Company&#8217;s Board
        of Directors approved the following option grants which were approved by the shareholders of the Company on October 4, 2021.</span></span></div>
        </td> </tr>
  </table>

<p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman,Times,serif">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">
  <tr>
    <td style="width:59.5pt">&#160;</td>
    <td style="width:18pt;vertical-align:top;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">i.</span></span></td>
    <td style="width:auto;vertical-align:top;text-align:justify">
        <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Grants of options to purchase ordinary shares
        with a total fair value 0f $195
        for each of the seven non-executive board members on January 1, 2022. The options will vest over three
        years in twelve equal quarterly instalments starting on January 1, 2022 the vesting commencement date. On January 1, 2022,
        which is considered the awards grant date, the Company granted 752,899
        ordinary shares to non-executive directors with an exercise price of&#8201;$2.815
        per share.</span></span></div> </td> </tr>
  </table>

<div style="line-height:1.25">&#160;</div>

<table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">
  <tr>
    <td style="width:59.5pt">&#160;</td>
    <td style="width:18pt;vertical-align:top;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">ii.</span></span></td>
    <td style="width:auto;vertical-align:top;text-align:justify">
        <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Grants of options to purchase ordinary shares
        with a total fair value 0f $65
        for each of the seven non-executive board members on January 1, 2022. The options will vest over one
        year in four equal quarterly instalments starting on January 1, 2022 the vesting commencement date. On January 1, 2022,
        which is considered the awards grant date, the Company granted 250,964
        ordinary shares to non-executive directors with an exercise price of&#8201;$2.815
        per share.</span></span></div> </td> </tr>
  </table>

<div style="line-height:1.25">&#160;</div>

<div style="text-align:justify;line-height:1.25">

<table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">
  <tr>
    <td style="width:35.45pt">&#160;</td>
    <td style="width:21.25pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">e)</span></span></td>
    <td style="width:auto;vertical-align:top;text-align:justify">
        <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">On March 31, 2022, the Company&#8217;s Board of
        Directors approved the following option grants:</span></span></div> </td> </tr>
  </table>

<p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman,Times,serif">&#160;</p> </div>

<div style="line-height:1.25">

<table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">
  <tr>
    <td style="width:59.5pt">&#160;</td>
    <td style="width:18pt;vertical-align:top;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">i.</span></span></td>
    <td style="width:auto;vertical-align:top">
        <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Options to purchase 80,000
        ordinary shares to an executive officer and a service provider, in each case, with an exercise price of&#8201;$2.86
        per share. The fair value of the options was $147.</span></span></div>
        </td> </tr>
  </table>

<p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman,Times,serif">&#160;</p> </div>

<div style="line-height:1.25">

<table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">
  <tr>
    <td style="width:59.5pt">&#160;</td>
    <td style="width:18pt;vertical-align:top;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">ii.</span></span></td>
    <td style="width:auto;vertical-align:top">
        <div style="text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Options to purchase
        55,000
        ordinary shares to certain executive officers with an exercise price of&#8201;$2.86
        per share. This grant was subject to shareholders' approval, which was obtained at a meeting of the Company&#8217;s shareholders held
        on September 7, 2022. The fair value of the options was $37.</span></span></div>
        <div>&#160;</div>
        <div>
        <div style="text-align:justify;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The
        options vest over four
        years from the date of grant; 25% vest on the first anniversary of the date of grant and the remaining 75% of the option
        will vest in twelve equal quarterly installments following the first anniversary of the grant date.</span></span></div>
        </div> </td> </tr>
  </table> </div>

<p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman,Times,serif">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">
  <tr>
    <td style="width:35.45pt">&#160;</td>
    <td style="width:21.25pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">f)</span></span></td>
    <td style="width:auto;vertical-align:top;text-align:justify">
        <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">On April 28, 2022, the Company&#8217;s Board of
        Directors approved option grants to purchase 220,000
        ordinary shares to employees with an exercise price of&#8201;$2.57
        per share. The
        options vest over four
        years from the date of grant; 25% vest on the first anniversary of the date of grant and the remaining 75% of the option
        will vest in twelve equal quarterly installments following the first anniversary of the grant date. The fair value of
        the options was $364.</span></span></div>
        </td> </tr>
  </table>

<div style="line-height:1.25">&#160;</div>

<table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">
  <tr>
    <td style="width:35.45pt">&#160;</td>
    <td style="width:21.25pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">g)</span></span></td>
    <td style="width:auto;vertical-align:top;text-align:justify">
        <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">On May 11, 2022, the Company&#8217;s Board of
        Directors approved a grant of options to purchase 500,000
        ordinary shares to Ms. Miranda Toledano, who was serving as the Company&#8217;s Chief Financial Officer at the time of the grant. Ms.
        Toledano has since been appointed the Company&#8217;s Chief Executive Officer (as described in Note 6(2)l below). This
        grant was subject to shareholders' approval, which was obtained at a meeting of the Company&#8217;s shareholders held on September 7,
        2022. These options have an exercise price of&#8201;$2.00
        per share and vest over four
        years from the date of grant; 25% vest on the first anniversary of the date of grant and the remaining 75% of the option
        will vest in twelve equal quarterly installments following the first anniversary of the grant date. The fair value of
        the options was $390.</span></span></div>
        </td> </tr>
  </table>

<div style="text-align:center;line-height:1.25">&#160;</div>

<div>

<div/> </div>

<table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">
  <tr>
    <td style="width:35.45pt">&#160;</td>
    <td style="width:21.25pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">h)</span></span></td>
    <td style="width:auto;vertical-align:top;text-align:justify">
        <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">On July 15, 2022, the Company&#8217;s Board of
        Directors appointed Ms. Miranda Toledano as the Company&#8217;s Chief Executive Officer and approved a grant of options to purchase 600,000
        ordinary shares at an exercise price of&#8201;$1.40
        per share, which are in addition to the options described in note 6(2)k above. This
        grant was subject to shareholders' approval, which was obtained at a meeting of the Company&#8217;s shareholders held on September 7,
        2022. The options vest over four
        years from the date of grant; 25% vest on the first anniversary of the date of grant and the remaining 75% of the option
        will vest in twelve equal quarterly installments following the first anniversary of the applicable grant date. The fair
        value of the options was $524.</span></span></div>
        </td> </tr>
  </table>

<div style="line-height:1.25">&#160;</div>

<div style="text-align:justify;margin-left:56.7pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">In
addition, upon the occurrence of a Triggering Event (as defined below) and subject to the approval of the Board of Directors, Ms. Toledano
will be granted additional options to purchases 200,000
ordinary shares. The exercise price will be determined at the time of the Board of Directors&#8217; approval.</span></span></div>

<div style="line-height:1.25">&#160;</div>

<div style="text-align:justify;margin-left:56.7pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">"Triggering
Event" means the earlier of the following events: (i) the execution by the Company of a binding strategic or partnership agreement with
a strategic partner to fund the Company's Phase III FDA Trial; or (b) raising sufficient funding to complete the Company's Phase III FDA
Trial, in each case as such event is approved by the Board of Directors.</span></span></div>

<div style="line-height:1.25">&#160;</div>

<table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">
  <tr>
    <td style="width:35.45pt">&#160;</td>
    <td style="width:21.25pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">i)</span></span></td>
    <td style="width:auto;vertical-align:top;text-align:justify">
        <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">On June 15, 2022, the Company entered into a separation
        agreement with Dr. Phillip Schwartz, the Company&#8217;s former President of R&amp;D, under which Dr. Schwartz agreed to continue to provide
        services to the Company until July 21, 2022 (the &#8220;Separation Date&#8221;). Pursuant to the terms of the separation agreement, which
        were approved by the Company&#8217;s shareholders on September 7, 2022, Dr. Schwartz received a full acceleration of his unvested options,
        as of the Separation Date, to purchase 68,750
        ordinary shares granted in April 2021 that otherwise would have been forfeited. These options, together with 31,250
        already vested options granted in April 2021 and 357,500
        already vested options to purchase ordinary shares granted in 2017, will be exercisable for a period of 10
        years from their respective initial grant dates<span style="font-weight:bold">.</span></span></span></div> </td> </tr>
  </table>

<div style="text-align:justify;margin-left:56.7pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">&#160;<br/>The
acceleration described above was recognized as a "Type III" modification; therefore, on the shareholder approval date, the Company recognized
the incremental costs of unvested options based on the fair value of the options on such date. In addition, the extension of the exercise
period for the vested awards was recognized as a "Type I" modification. The total expense amount was $112
thousand, which was classified as additional share-based compensation costs in the research and development expenses.<br/>&#160;<br/>In
addition, the separation agreement provides for the following payments to Dr. Schwartz, all of which would have otherwise been payable
in accordance with either Israeli law or pursuant to his existing employment agreement: a one-time cash separation payment in an amount
equal to NIS 537,600
(approximately $156)
and additional payments of NIS 737,771
(approximately $214)
in respect of all other ongoing accrued benefits, subject to any mandatory deductions. The foregoing payments were recognized in the research
and development expenses.</span></span></div>

<div style="text-align:justify;margin-left:56.7pt;line-height:1.25">&#160;</div> </div> </div>

<div/>

<div>

<div>

<div style="line-height:1.25">

<div>

<div>

<div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><span>The
fair value of each option granted is estimated at the date of grant using the Black-Scholes option-pricing model, with the following weighted
average assumptions:</span></span></span></span></span></span></span></div> </div> </div>

<p style="margin:0pt">&#160;</p> </div>

<div>

<div>

<div>

<div style="margin-left:54pt">

<table border="0" cellpadding="0" cellspacing="0" style="width:85%">
  <tr>
    <td style="vertical-align:top;padding-bottom:2px" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px" valign="bottom">
        <div style="line-height:1.25">
        <div style="text-align:center;text-indent:0.05pt;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span>2022</span></span></span></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px" valign="bottom">
        <div style="line-height:1.25">
        <div style="text-align:center;text-indent:0.05pt;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span>2021</span></span></span></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td> </tr>
  <tr>
    <td style="vertical-align:top;padding-bottom:4px;background-color:rgb(204, 238, 255);width:70%" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span>Exercise
        price</span></span></span></span></span></div> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:4px;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);width:1%" valign="bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25">&#160;</div> </div> </td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);width:12%" valign="bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span>$1.40-$2.86</span></span></span></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:4px;background-color:rgb(204, 238, 255);white-space:nowrap;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:4px;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);width:1%" valign="bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25">&#160;</div> </div> </td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);width:12%" valign="bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span>$1.24-$3.61</span></span></span></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:4px;background-color:rgb(204, 238, 255);white-space:nowrap;width:1%" valign="bottom">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align:top;padding-bottom:4px;width:70%" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span>Dividend
        yield</span></span></span></span></span></div> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:4px;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;border-bottom:4px double rgb(0, 0, 0);width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;border-bottom:4px double rgb(0, 0, 0);width:12%" valign="bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span>-</span></span></span></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:4px;white-space:nowrap;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:4px;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;border-bottom:4px double rgb(0, 0, 0);width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;border-bottom:4px double rgb(0, 0, 0);width:12%" valign="bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span>-</span></span></span></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:4px;white-space:nowrap;width:1%" valign="bottom">&#160;</td> </tr>
  <tr>
    <td style="vertical-align:top;padding-bottom:4px;background-color:rgb(204, 238, 255);width:70%" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span>Expected
        volatility</span></span></span></span></span></div> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:4px;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);width:12%" valign="bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span>69%-70.2%</span></span></span></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:4px;background-color:rgb(204, 238, 255);white-space:nowrap;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:4px;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);width:12%" valign="bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span>68%-71%</span></span></span></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:4px;background-color:rgb(204, 238, 255);white-space:nowrap;width:1%" valign="bottom">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align:top;padding-bottom:4px;width:70%" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span>Risk-free
        interest rate</span></span></span></span></span></div> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:4px;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;border-bottom:4px double rgb(0, 0, 0);width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;border-bottom:4px double rgb(0, 0, 0);width:12%" valign="bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span>1.35%-3.36%</span></span></span></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:4px;white-space:nowrap;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:4px;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;border-bottom:4px double rgb(0, 0, 0);width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;border-bottom:4px double rgb(0, 0, 0);width:12%" valign="bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span>1.11%-0.94%</span></span></span></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:4px;white-space:nowrap;width:1%" valign="bottom">&#160;</td> </tr>
  <tr>
    <td style="vertical-align:top;padding-bottom:4px;background-color:rgb(204, 238, 255);width:70%" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span>Expected
        life - in years</span></span></span></span></span></div> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:4px;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);width:12%" valign="bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span>5.5-6.5</span></span></span></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:4px;background-color:rgb(204, 238, 255);white-space:nowrap;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:4px;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);width:12%" valign="bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span>6.1-5.8</span></span></span></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:4px;background-color:rgb(204, 238, 255);white-space:nowrap;width:1%" valign="bottom">&#160;</td>
        </tr>
  </table> </div> </div> </div> </div>

<div>

<div style="line-height:1.25">

<div style="margin:0pt">&#160;</div> </div>

<div>

<div style="margin-left:54pt">

<table cellpadding="0" cellspacing="0" style="color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:left;width:92%">
  <tr>
    <td style="vertical-align:top;padding-bottom:2px" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td>
    <td colspan="6" style="vertical-align:top;border-bottom:#000000 solid 2px" valign="bottom">
        <div style="line-height:1.25">
        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span>2022</span></span></span></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td>
    <td colspan="6" style="vertical-align:top;border-bottom:#000000 solid 2px" valign="bottom">
        <div style="line-height:1.25">
        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span>2021</span></span></span></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td> </tr>
  <tr>
    <td style="vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px" valign="bottom">
        <div style="line-height:1.25">
        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span>Number
        of</span></span></span></span></span></div>
        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span>options</span></span></span></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px" valign="bottom">
        <div style="line-height:1.25">
        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span>Weighted</span></span></span></span></span></div>
        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span>average</span></span></span></span></span></div>
        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span>exercise</span></span></span></span></span></div>
        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span>price</span></span></span></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px" valign="bottom">
        <div style="line-height:1.25">
        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span>Number
        of</span></span></span></span></span></div>
        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span>options</span></span></span></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px" valign="bottom">
        <div style="line-height:1.25">
        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span>Weighted</span></span></span></span></span></div>
        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span>average</span></span></span></span></span></div>
        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span>exercise</span></span></span></span></span></div>
        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span>price</span></span></span></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td> </tr>
  <tr>
    <td style="vertical-align:middle;width:52%;background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="text-indent:-1.3pt;margin-left:1.3pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span>Outstanding
        at beginning of the year</span></span></span></span></span></div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span>4,316,859</span></span></span></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span>$</span></span></span></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span>3.63</span></span></span></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span>2,570,109</span></span></span></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span>$</span></span></span></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span>4.85</span></span></span></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align:middle;width:52%" valign="bottom">
        <div style="text-indent:-1.3pt;margin-left:1.3pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span>Granted</span></span></span></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span>2,458,863</span></span></span></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span>2.29</span></span></span></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span>1,975,586</span></span></span></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">
        <div style="line-height:1.25">&#160;</div> </td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span>1.95</span></span></span></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td> </tr>
  <tr>
    <td style="vertical-align:middle;width:52%;background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="text-indent:-1.3pt;margin-left:1.3pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span>Exercised</span></span></span></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span>(5,511</span></span></span></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span>)</span></span></span></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span>2.14</span></span></span></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span>(177,710</span></span></span></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span>)</span></span></span></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span>2.37</span></span></span></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align:middle;width:52%" valign="bottom">
        <div style="text-indent:-1.3pt;margin-left:1.3pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span>Forfeited</span></span></span></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span>(902,009</span></span></span></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span>)</span></span></span></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span>1.41</span></span></span></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span>(16,660</span></span></span></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span>)</span></span></span></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span>2.37</span></span></span></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td> </tr>
  <tr>
    <td style="vertical-align:middle;width:52%;padding-bottom:2px;background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="text-indent:-8.4pt;margin-left:8.4pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span>Expired</span></span></span></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span>(135,115</span></span></span></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span>)</span></span></span></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span>3.80</span></span></span></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span>(34,466</span></span></span></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span>)</span></span></span></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span>4.00</span></span></span></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align:middle;width:52%;padding-bottom:4px" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span>Outstanding
        at end of the year</span></span></span></span></span></div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0)" valign="bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span>5,733,087</span></span></span></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;white-space:nowrap" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0)" valign="bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span>$</span></span></span></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0)" valign="bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span>3.30</span></span></span></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;white-space:nowrap" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0)" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span>4,316,859</span></span></span></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;white-space:nowrap" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0)" valign="bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span>$</span></span></span></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0)" valign="bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span>3.63</span></span></span></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;white-space:nowrap" valign="bottom">&#160;</td> </tr>
  <tr>
    <td style="vertical-align:middle;width:52%;padding-bottom:4px;background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span>Exercisable
        at end of the year</span></span></span></span></span></div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span>3,165,677</span></span></span></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span>$</span></span></span></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span>4.06</span></span></span></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span>2,068,067</span></span></span></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span>$</span></span></span></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span>5.39</span></span></span></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
        </tr>
  </table> </div> </div> </div>  </div> </div>

<p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman,Times,serif">&#160;</p>

<div/>

<div>

<div>

<p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><span><span><span><span><span><span><span><span style="line-height:107%">The
following tables summarizes information concerning outstanding and exercisable options as of December 31, 2022, in terms of ordinary shares:</span></span></span></span></span></span></span></span></span></span></span></span></span></span></p>

<p style="margin:0pt">&#160;</p>

<div>

<div>

<div>

<div style="margin-left:45pt">

<table border="0" cellpadding="0" cellspacing="0" style="color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:left;width:85%">
  <tr>
    <td colspan="18" rowspan="1" style="vertical-align:top;padding-bottom:2px;border-bottom:2px solid black" valign="bottom">
        <div style="line-height:1.25">
        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span>December
        31, 2022</span></span></span></span></span></div> </div> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td> </tr>
  <tr>
    <td colspan="10" style="vertical-align:top;border-bottom:#000000 solid 2px" valign="bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><strong>Options
        outstanding</strong></span></span></span></span></span></div> </div> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;white-space:nowrap;text-align:center" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center" valign="bottom">&#160;</td>
    <td colspan="6" style="vertical-align:top;border-bottom:#000000 solid 2px" valign="bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><strong>Options
        exercisable</strong></span></span></span></span></span></div> </div> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td> </tr>
  <tr>
    <td colspan="2" style="vertical-align:top" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;white-space:nowrap" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align:top" valign="bottom">
        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span>Number
        of</span></span></span></span></span></div> </td>
    <td colspan="1" style="vertical-align:bottom;white-space:nowrap" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align:top" valign="bottom">
        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span>Weighted</span></span></span></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;white-space:nowrap" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align:top" valign="bottom">
        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span>Number
        of</span></span></span></span></span></div> </td>
    <td colspan="1" style="vertical-align:bottom;white-space:nowrap" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align:top" valign="bottom">
        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span>Weighted</span></span></span></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;white-space:nowrap" valign="bottom">&#160;</td> </tr>
  <tr>
    <td colspan="2" style="vertical-align:top" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;white-space:nowrap" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align:top" valign="bottom">
        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span>options</span></span></span></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;white-space:nowrap" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align:top" valign="bottom">
        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span>Average</span></span></span></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;white-space:nowrap" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align:top" valign="bottom">
        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span>options</span></span></span></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;white-space:nowrap" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align:top" valign="bottom">
        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span>Average</span></span></span></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;white-space:nowrap" valign="bottom">&#160;</td> </tr>
  <tr>
    <td colspan="2" style="vertical-align:top" valign="bottom">
        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span>Exercise</span></span></span></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;white-space:nowrap" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align:top" valign="bottom">
        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span>outstanding</span></span></span></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;white-space:nowrap" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align:top" valign="bottom">
        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span>Remaining</span></span></span></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;white-space:nowrap" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align:top" valign="bottom">
        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span>exercisable</span></span></span></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;white-space:nowrap" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align:top" valign="bottom">
        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span>Remaining</span></span></span></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;white-space:nowrap" valign="bottom">&#160;</td> </tr>
  <tr>
    <td colspan="2" style="vertical-align:top" valign="bottom">
        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span>prices
        per</span></span></span></span></span></div> </td>
    <td colspan="1" style="vertical-align:bottom;white-space:nowrap" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align:top" valign="bottom">
        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span>at
        end of</span></span></span></span></span></div> </td>
    <td colspan="1" style="vertical-align:bottom;white-space:nowrap" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align:top" valign="bottom">
        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span>Contractual</span></span></span></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;white-space:nowrap" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align:top" valign="bottom">
        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span>at
        end of</span></span></span></span></span></div> </td>
    <td colspan="1" style="vertical-align:bottom;white-space:nowrap" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align:top" valign="bottom">
        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span>contractual</span></span></span></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;white-space:nowrap" valign="bottom">&#160;</td> </tr>
  <tr>
    <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px" valign="bottom">
        <div style="line-height:1.25">
        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span>share
        (USD)</span></span></span></span></span></div> </div> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px" valign="bottom">
        <div style="line-height:1.25">
        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span>Year</span></span></span></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px" valign="bottom">
        <div style="line-height:1.25">
        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span>Life</span></span></span></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px" valign="bottom">
        <div style="line-height:1.25">
        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span>year</span></span></span></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px" valign="bottom">
        <div style="line-height:1.25">
        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span>Life</span></span></span></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td> </tr>
  <tr style="background-color:rgb(204, 238, 255)">
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span>-</span></span></span></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span>1,560</span></span></span></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span>0.09</span></span></span></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span>1,560</span></span></span></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span>0.09</span></span></span></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
        </tr>
  <tr style="background-color:rgb(255, 255, 255)">
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(255, 255, 255)" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span>1.24</span></span></span></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(255, 255, 255)" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span>492,831</span></span></span></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(255, 255, 255)" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span>1.54</span></span></span></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(255, 255, 255)" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span>492,831</span></span></span></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(255, 255, 255)" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span>1.54</span></span></span></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
        </tr>
  <tr style="background-color:rgb(204, 238, 255)">
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span>1.40</span></span></span></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span>600,000
        </span></span></span></span></span></div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span>9.54</span></span></span></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span>-</span></span></span></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span>-</span></span></span></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
        </tr>
  <tr style="background-color:rgb(255, 255, 255)">
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(255, 255, 255)" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span>2.02</span></span></span></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(255, 255, 255)" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span>500,000</span></span></span></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(255, 255, 255)" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span>9.37</span></span></span></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(255, 255, 255)" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span>-</span></span></span></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(255, 255, 255)" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span>-</span></span></span></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
        </tr>
  <tr style="background-color:rgb(204, 238, 255)">
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span>2.14</span></span></span></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span>400,775</span></span></span></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span>7.26</span></span></span></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span>277,994</span></span></span></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span>7.26</span></span></span></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
        </tr>
  <tr style="background-color:rgb(255, 255, 255)">
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(255, 255, 255)" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span>2.53</span></span></span></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(255, 255, 255)" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span>33,638</span></span></span></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(255, 255, 255)" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span>6.89</span></span></span></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(255, 255, 255)" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><span><span>33,638</span></span></span></span></span></span></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(255, 255, 255)" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span>6.89</span></span></span></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
        </tr>
  <tr style="background-color:rgb(204, 238, 255)">
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span>2.57</span></span></span></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span>205,500</span></span></span></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span>9.33</span></span></span></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span>-</span></span></span></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span>-</span></span></span></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
        </tr>
  <tr style="background-color:rgb(255, 255, 255)">
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(255, 255, 255)" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span>2.815</span></span></span></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(255, 255, 255)" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span>1,003,863</span></span></span></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(255, 255, 255)" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span>9.01</span></span></span></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(255, 255, 255)" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>376,447</span></span></span></span></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(255, 255, 255)" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span>9.01</span></span></span></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
        </tr>
  <tr style="background-color:rgb(204, 238, 255)">
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span>2.86</span></span></span></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span>135,000</span></span></span></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span>9.25</span></span></span></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span>-</span></span></span></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span>-</span></span></span></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
        </tr>
  <tr style="background-color:rgb(255, 255, 255)">
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(255, 255, 255)" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span>3.15</span></span></span></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(255, 255, 255)" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span>345,000</span></span></span></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(255, 255, 255)" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span>8.30</span></span></span></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(255, 255, 255)" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span>123,125</span></span></span></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(255, 255, 255)" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span>8.30</span></span></span></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
        </tr>
  <tr style="background-color:rgb(204, 238, 255)">
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;padding-bottom:2px;background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span>3.61</span></span></span></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;white-space:nowrap;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span>250,868</span></span></span></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;white-space:nowrap;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;padding-bottom:2px;background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span>8.27</span></span></span></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;white-space:nowrap;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span>101,059</span></span></span></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;white-space:nowrap;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;padding-bottom:2px;background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span>8.27</span></span></span></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;white-space:nowrap;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
        </tr>
  <tr style="background-color:rgb(255, 255, 255)">
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;padding-bottom:2px;background-color:rgb(255, 255, 255)" valign="bottom">
        <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span style="line-height:107%">3.68</span></span></span></span></span></p>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;white-space:nowrap;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(255, 255, 255)" valign="bottom">
        <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span style="line-height:107%">294,580</span></span></span></span></span></p>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;white-space:nowrap;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;padding-bottom:2px;background-color:rgb(255, 255, 255)" valign="bottom">
        <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span style="line-height:107%">0.26</span></span></span></span></span></p>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;white-space:nowrap;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(255, 255, 255)" valign="bottom">
        <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span style="line-height:107%">294,580</span></span></span></span></span></p>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;white-space:nowrap;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;padding-bottom:2px;background-color:rgb(255, 255, 255)" valign="bottom">
        <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span style="line-height:107%">0.26</span></span></span></span></span></p>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;white-space:nowrap;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
        </tr>
  <tr style="background-color:rgb(204, 238, 255)">
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;padding-bottom:2px;background-color:rgb(204, 238, 255)" valign="bottom">
        <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span style="line-height:107%">3.97</span></span></span></span></span></p>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;white-space:nowrap;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">
        <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span style="line-height:107%">247,082</span></span></span></span></span></p>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;white-space:nowrap;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;padding-bottom:2px;background-color:rgb(204, 238, 255)" valign="bottom">
        <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span style="line-height:107%">6.05</span></span></span></span></span></p>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;white-space:nowrap;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">
        <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span style="line-height:107%">242,053</span></span></span></span></span></p>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;white-space:nowrap;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;padding-bottom:2px;background-color:rgb(204, 238, 255)" valign="bottom">
        <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span style="line-height:107%">6.05</span></span></span></span></span></p>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;white-space:nowrap;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
        </tr>
  <tr style="background-color:rgb(255, 255, 255)">
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;padding-bottom:2px;background-color:rgb(255, 255, 255)" valign="bottom">
        <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span style="line-height:107%">6.31</span></span></span></span></span></p>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;white-space:nowrap;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid black;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid black;background-color:rgb(255, 255, 255)" valign="bottom">
        <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span style="line-height:107%">1,222,390</span></span></span></span></span></p>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;white-space:nowrap;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;padding-bottom:2px;background-color:rgb(255, 255, 255)" valign="bottom">
        <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span style="line-height:107%">3.08</span></span></span></span></span></p>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;white-space:nowrap;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid black;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid black;background-color:rgb(255, 255, 255)" valign="bottom">
        <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span style="line-height:107%">1,222,390</span></span></span></span></span></p>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;white-space:nowrap;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;padding-bottom:2px;background-color:rgb(255, 255, 255)" valign="bottom">
        <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span style="line-height:107%">3.08</span></span></span></span></span></p>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;white-space:nowrap;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
        </tr>
  <tr style="background-color:rgb(204, 238, 255)">
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;padding-bottom:4px;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;white-space:nowrap;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span>5,733,087</span></span></span></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;white-space:nowrap;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;padding-bottom:4px;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;white-space:nowrap;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span>3,165,677</span></span></span></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;white-space:nowrap;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;padding-bottom:4px;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;white-space:nowrap;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
        </tr>
  </table>  </div> </div> </div>

<div>

<div>

<p style="margin-top:0pt;margin-bottom:0pt"><br/><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><span><span><span><span><span><span><span><span><span style="line-height:107%">The
</span><span style="line-height:107%">aggregate intrinsic value of the total of the outstanding and exercisable options as of December
31, 2022, is $1.</span></span></span></span></span></span></span></span></span></span></span></span></span></span></span></p>
</div> </div> </div>

<div style="line-height:1.25;clear:both">

<p style="margin:0pt">&#160;</p> </div>

<div>

<p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><span><span><span><span><span><span><span><span><span><span><span><span><span>The
</span></span></span></span></span><span style="line-height:107%">following table illustrates the effect of share-based compensation on
the statements of operations:</span></span></span></span></span></span></span></span></span></span></span></span></span></span></span></p>

<p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt">&#160;</p> </div> </div> </div>

<div>

<div style="text-align:center">

<div style="clear:both;margin-top:0pt;margin-bottom:0pt">

<div style="text-align:center"> <div style="font-size:10pt;display:inline"> <div style="font-family:Times New Roman,Times,serif;display:inline">
<div style="color:#000000;font-weight:normal;font-style:normal;display:inline">

<div>

<div>

<div style="margin-left:45pt">

<table border="0" cellpadding="0" cellspacing="0" style="color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:left;width:85%">
  <tr>
    <td style="vertical-align:top;padding-bottom:2px" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px" valign="bottom">
        <div style="line-height:1.25">
        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span>2022</span></span></span></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px" valign="bottom">
        <div style="line-height:1.25">
        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span>2021</span></span></span></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td> </tr>
  <tr>
    <td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="text-align:justify;text-indent:-12.6pt;margin-left:12.6pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span>Cost
        of revenues</span></span></span></span></span></div> </td>
    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span>14</span></span></span></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span>102</span></span></span></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align:bottom;width:76%" valign="bottom">
        <div style="text-align:justify;text-indent:-12.6pt;margin-left:12.6pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span>Research
        and development expenses</span></span></span></span></span></div> </td>
    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span>708</span></span></span></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span>661</span></span></span></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td> </tr>
  <tr>
    <td style="vertical-align:bottom;width:76%;padding-bottom:2px;background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="text-align:justify;text-indent:-12.6pt;margin-left:12.6pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span>General
        and administrative</span></span></span></span></span></div> </td>
    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span>1,525</span></span></span></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span>1,098</span></span></span></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align:bottom;width:76%;padding-bottom:4px" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;padding-bottom:4px" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0)" valign="bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span>2,247</span></span></span></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;white-space:nowrap" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;padding-bottom:4px" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0)" valign="bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span>1,861</span></span></span></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;white-space:nowrap" valign="bottom">&#160;</td> </tr>
  </table> </div> </div> </div> </div> </div> </div> </div> </div> </div> </div>  </div> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI https://asc.fasb.org/topic&amp;trid=2228938<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140398301806048">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAX<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">INCOME TAX</a></td>
<td class="text">

<div>

<div style="line-height:1.25;font-family:Times New Roman, Times, serif"> <div style="font-size:10pt;display:inline"> <div style="font-family:Times New Roman,Times,serif;display:inline"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><span><span><strong>NOTE
7 - <span style="line-height:107%">INCOME TAX</span></strong></span></span></span></span></span></span></span></span>

<div>

<div>

<div style="text-indent:-36pt;margin-left:36pt;line-height:1.25">&#160;</div>

<table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">
  <tr>
    <td style="width:35.45pt;vertical-align:top;font-weight:bold">A.</td>
    <td style="width:auto;vertical-align:top;text-align:justify">
        <div style="font-weight:bold">Corporate tax rate</div> </td> </tr>
  </table>

<div style="line-height:1.25">&#160;</div>

<table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">
  <tr>
    <td style="width:35pt">&#160;</td>
    <td style="vertical-align:top;width:21pt">1)</td>
    <td style="vertical-align:top;text-align:justify;width:auto">
        <div>Ordinary taxable income in Israel is subject to a corporate tax rate of 23%.</div>
        </td> </tr>
  </table>

<div style="line-height:1.25">&#160;</div>

<table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">
  <tr>
    <td style="width:35.45pt">&#160;</td>
    <td style="width:21.25pt;vertical-align:top">2)</td>
    <td style="width:auto;vertical-align:top;text-align:justify">
        <div>The Company&#8217;s subsidiary Entera Bio, Inc. is taxed separately under the U.S. tax laws at a tax rate of 29%
        (Federal and state tax)</div> </td> </tr>
  </table> </div> </div>

<p style="margin:0pt">&#160;</p> </div> </div> </div>

<table cellpadding="0" cellspacing="0" style="color:#000000;font-family:'Times New Roman',Times,serif;font-size:10pt;text-align:left;width:100%">
  <tr>
    <td style="width:47px"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>B.</strong></span></span></td>
    <td style="width:auto;vertical-align:top">
        <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>Losses
        for tax purposes carried forward to future years</strong></span></span></p> </td> </tr>
  <tr>
    <td style="width:47px">&#160;</td>
    <td style="width:auto;vertical-align:top">&#160;</td> </tr>
  <tr>
    <td style="width:47px">&#160;</td>
    <td style="width:auto;vertical-align:top">
        <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The
        balance of carryforward losses as of December 31, 2022&#160;and 2021&#160;are approximately $67.1&#160;million
        and $56.1&#160;million,
        respectively.</span></span></p> </td> </tr>
  <tr>
    <td style="width:47px">&#160;</td>
    <td style="width:auto;vertical-align:top">&#160;</td> </tr>
  <tr>
    <td style="width:47px">&#160;</td>
    <td style="width:auto;vertical-align:top">
        <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Under
        Israeli tax law, tax loss carry forward have no expiration date.</span></span></p> </td> </tr>
  <tr>
    <td style="width:47px">&#160;</td>
    <td style="width:auto;vertical-align:top">&#160;</td> </tr>
  <tr>
    <td style="width:47px"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>C.</strong></span></span></td>
    <td style="width:auto;vertical-align:top">
        <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><span><span><strong><span style="line-height:107%">Tax
        assessments</span></strong></span></span></span></span></span></span></span></span></p> </td> </tr>
  <tr>
    <td style="width:47px">&#160;</td>
    <td style="width:auto;vertical-align:top">&#160;</td> </tr>
  <tr>
    <td style="width:47px">&#160;</td>
    <td style="width:auto;vertical-align:top">
        <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><span><span><span style="line-height:107%">The
        Company and its subsidiary have tax assessments that are considered to be final through tax year 2017.</span></span></span></span></span></span></span></span></span></p>
        </td> </tr>
  <tr>
    <td style="width:47px">&#160;</td>
    <td style="width:auto;vertical-align:top">&#160;</td> </tr>
  <tr>
    <td style="width:47px"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>D.</strong></span></span></td>
    <td style="width:auto;vertical-align:top">
        <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>Loss
        (income) before income taxes is composed of the following</strong></span></span></p> </td> </tr>
  </table>

<div>

<p style="margin:0pt;font-size:10pt">&#160;</p>

<div>

<div>

<div style="margin-left:47px">

<table border="0" cellpadding="0" cellspacing="0" style="color:#000000;float:left;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:left;width:85%">
  <tr>
    <td style="vertical-align:top;padding-bottom:2px" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td>
    <td colspan="6" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);font-weight:bold">
        <div style="line-height:1.25">
        <div style="text-align:center;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Year
        ended December 31</span></span></div> </div> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td> </tr>
  <tr>
    <td style="vertical-align:top;padding-bottom:2px" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0)">
        <div style="line-height:1.25">
        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2022</span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px">&#160;</td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0)">
        <div style="line-height:1.25">
        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2021</span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td> </tr>
  <tr>
    <td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="text-indent:-12.6pt;margin-left:12.6pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Entera
        Bio Ltd.</span></span></div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">12,997</span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">12,362</span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align:bottom;width:76%;padding-bottom:2px" valign="bottom">
        <div style="text-indent:-12.6pt;margin-left:12.6pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Entera
        Bio Inc.</span></span></div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0)" valign="bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(65</span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;white-space:nowrap" valign="bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0)" valign="bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(116</span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;white-space:nowrap" valign="bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
        </div> </td> </tr>
  <tr>
    <td style="vertical-align:bottom;width:76%;padding-bottom:2px;background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="text-indent:-12.6pt;margin-left:12.6pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Total
        loss before taxes</span></span></div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">12,934</span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">12,246</span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
        </tr>
  </table> </div>

<div style="line-height:1.25;clear:both">

<div style="line-height:1.25">&#160;</div> </div> </div> </div> </div>

<div>

<div>

<div style="line-height:1.25;clear:both">

<div style="line-height:1.25">

<div style="line-height:1.25">

<div>

<div>

<div style="line-height:1.25">

<div style="line-height:1.25">

<div style="line-height:1.25">

<div>

<div>

<div>

<div style="line-height:1.25">

<div>

<div style="line-height:1.25">

<div style="line-height:1.25">

<div style="line-height:1.25">

<div style="line-height:1.25;font-weight:bold">

<div style="line-height:1.25">

<div style="line-height:1.25;font-weight:bold">

<table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">
  <tr>
    <td style="width:35.45pt;vertical-align:top;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">E.</span></span></td>
    <td style="width:auto;vertical-align:top;text-align:justify">
        <div style="font-weight:normal">
        <div style="line-height:1.25">
        <div style="line-height:1.25">
        <div style="line-height:1.25">
        <div style="line-height:1.25">
        <div style="line-height:1.25">
        <div style="line-height:1.25">
        <div style="line-height:1.25">
        <div style="line-height:1.25">
        <div style="line-height:1.25">
        <div style="line-height:1.25">
        <div style="line-height:1.25">
        <div style="line-height:1.25">
        <div style="line-height:1.25">
        <div>
        <div style="line-height:1.25">
        <div style="line-height:1.25">
        <div>
        <div>
        <div>
        <div>
        <div style="line-height:1.25;font-weight:bold">
        <div style="line-height:1.25;font-weight:bold">
        <div>
        <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Income tax expense&#160;(benefit):</span></span></div>
        </div> </div> </div> </div> </div> </div> </div> </div> </div> </div> </div> </div> </div> </div> </div> </div> </div> </div> </div> </div>
        </div> </div> </div> </div> </td> </tr>
  </table> </div> </div> </div> </div> </div> </div> </div> </div> </div> </div> </div> </div> </div> </div> </div> </div> </div>

<div style="margin-left:36pt;line-height:1.25">&#160;</div> </div> </div>

<div style="margin-left:36pt">

<table border="0" cellpadding="0" cellspacing="0" style="color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:left;width:85%">
  <tr>
    <td style="vertical-align:top;padding-bottom:2px" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td>
    <td colspan="6" style="vertical-align:bottom;border-bottom:#000000 solid 2px" valign="bottom">
        <div style="line-height:1.25;font-weight:bold">
        <div style="text-align:center;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Year
        ended December 31</span></span></div> </div> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td> </tr>
  <tr>
    <td style="vertical-align:top;padding-bottom:2px" valign="bottom">
        <div style="line-height:1.25">&#160;</div> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0)" valign="bottom">
        <div style="line-height:1.25;font-weight:bold">
        <div style="text-align:center;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2022</span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-weight:bold;white-space:nowrap" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-weight:bold" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0)" valign="bottom">
        <div style="line-height:1.25;font-weight:bold">
        <div style="text-align:center;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2021</span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td> </tr>
  <tr>
    <td rowspan="1" style="vertical-align:top;background-color:rgb(204, 238, 255);height:15px" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Current:</span></span></div>
        </td>
    <td colspan="1" rowspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);height:15px" valign="bottom">&#160;</td>
    <td colspan="2" rowspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);height:15px" valign="bottom">&#160;</td>
    <td colspan="1" rowspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);white-space:nowrap;height:15px" valign="bottom">&#160;</td>
    <td colspan="1" rowspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);height:15px" valign="bottom">&#160;</td>
    <td colspan="2" rowspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);height:15px" valign="bottom">&#160;</td>
    <td colspan="1" rowspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);white-space:nowrap;height:15px" valign="bottom">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align:bottom;width:76%;padding-bottom:2px;height:15px" valign="bottom">
        <div style="text-indent:-12.6pt;margin-left:12.6pt;line-height:1.25;margin-top:0px;margin-bottom:0px"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Subsidiary:</span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;height:15px" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);height:15px" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);height:15px" valign="bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(37</span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:1pt;white-space:nowrap;height:15px" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;height:15px" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);height:15px" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);height:15px" valign="bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">158</span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;white-space:nowrap;height:15px" valign="bottom">&#160;</td> </tr>
  <tr>
    <td style="vertical-align:bottom;width:76%;padding-bottom:2px;background-color:rgb(204, 238, 255);height:15px" valign="bottom">
        <div style="text-indent:-12.6pt;margin-left:12.6pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Total
        current income tax</span></span></div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);height:15px" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);height:15px" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);height:15px" valign="bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(37</span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:1pt;background-color:rgb(204, 238, 255);white-space:nowrap;height:15px" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);height:15px" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);height:15px" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);height:15px" valign="bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">158</span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);white-space:nowrap;height:15px" valign="bottom">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align:bottom;width:76%;height:15px" valign="bottom">
        <div style="text-indent:-12.6pt;margin-left:12.6pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Deferred
        income&#160;taxes</span></span></div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;height:15px" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;height:15px" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;height:15px" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">174</span></span></td>
    <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap;height:15px" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;height:15px" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;height:15px" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;height:15px" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(217</span></span></td>
    <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap;height:15px" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></td>
        </tr>
  <tr>
    <td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255);padding-bottom:2px;height:15px" valign="bottom">
        <div style="text-indent:-12.6pt;margin-left:12.6pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Total
        deferred income taxes</span></span></div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);padding-bottom:2px;height:15px" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);border-bottom:2px solid rgb(0, 0, 0);height:15px" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);border-bottom:2px solid rgb(0, 0, 0);height:15px" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">174</span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);padding-bottom:2px;white-space:nowrap;height:15px" valign="bottom">
        <div style="line-height:1.25">&#160;</div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);padding-bottom:2px;height:15px" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);border-bottom:2px solid rgb(0, 0, 0);height:15px" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);border-bottom:2px solid rgb(0, 0, 0);height:15px" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(217</span></span></td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);padding-bottom:1pt;white-space:nowrap;height:15px" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></td>
        </tr>
  <tr>
    <td style="vertical-align:baseline;width:76%;padding-bottom:4px;height:15px">
        <div style="text-indent:-12.6pt;margin-left:12.6pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Total
        income tax expense (benefit)&#160;</span></span></div> </td>
    <td colspan="1" style="vertical-align:baseline;width:1%;padding-bottom:4px;height:15px">&#160;</td>
    <td colspan="1" style="vertical-align:baseline;width:1%;border-bottom:4px double rgb(0, 0, 0);height:15px">&#160;</td>
    <td colspan="1" style="vertical-align:baseline;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);height:15px">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">137</span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:baseline;width:1%;padding-bottom:4px;white-space:nowrap;height:15px">
        <div style="line-height:1.25">
        <div style="line-height:1.25">&#160;</div> </div> </td>
    <td colspan="1" style="vertical-align:baseline;width:1%;padding-bottom:4px;height:15px">&#160;</td>
    <td colspan="1" style="vertical-align:baseline;width:1%;border-bottom:4px double rgb(0, 0, 0);height:15px">&#160;</td>
    <td colspan="1" style="vertical-align:baseline;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);height:15px">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(59</span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:baseline;width:1%;padding-bottom:1pt;white-space:nowrap;height:15px"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></td>
        </tr>
  </table>

<p style="margin:0pt">&#160;</p>  </div> </div> </div>

<div/>

<table cellpadding="0" cellspacing="0" style="color:rgb(0, 0, 0);font-family:Times New Roman, Times, serif;font-size:10pt;width:100%">
  <tr>
    <td style="width:47px"><span style="font-size:10pt"><span><strong>F.</strong></span></span></td>
    <td style="vertical-align:top;width:auto">
        <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span><span><span><span><span><span><span><strong><span style="line-height:107%">Deferred
        income taxes</span></strong></span></span></span></span></span></span></span></span></p> </td> </tr>
  <tr>
    <td style="width:35px">&#160;</td>
    <td style="vertical-align:top">&#160;</td> </tr>
  </table>

<div>

<div>

<div>

<div style="margin-left:47px">

<div>

<div>

<div>

<table border="0" cellpadding="0" cellspacing="0" style="color:#000000;float:left;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:left;width:85%">
  <tr>
    <td rowspan="1" style="vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td>
    <td colspan="1" rowspan="1" style="vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td>
    <td colspan="6" rowspan="1" style="vertical-align:bottom;border-bottom:#000000 solid 2px" valign="bottom">
        <div style="text-align:center;line-height:1.25;font-weight:bold;text-indent:1pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>December
        31,</span></span></span></span></div> </td>
    <td colspan="1" rowspan="1" style="vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td> </tr>
  <tr>
    <td rowspan="1" style="vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td>
    <td colspan="1" rowspan="1" style="vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td>
    <td colspan="2" rowspan="1" style="vertical-align:bottom;border-bottom:#000000 solid 2px" valign="bottom">
        <div style="text-align:center;line-height:1.25;font-weight:bold;text-indent:4pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>2022</span></span></span></span></div>
        </td>
    <td colspan="1" rowspan="1" style="vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
    <td colspan="1" rowspan="1" style="text-align:center;font-weight:bold;vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td>
    <td colspan="2" rowspan="1" style="vertical-align:bottom;text-align:center;font-weight:bold;border-bottom:#000000 solid 2px" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>2021</span></span></span></span></td>
    <td colspan="1" rowspan="1" style="font-weight:bold;vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
        </tr>
  <tr>
    <td rowspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Deferred
        tax assets:</span></span></span></span></div> </td>
    <td colspan="1" rowspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="2" rowspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" rowspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap" valign="bottom">&#160;</td>
    <td colspan="1" rowspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="2" rowspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" rowspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap" valign="bottom">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align:bottom;width:76%" valign="bottom">
        <div style="text-indent:-35.1pt;margin-left:35.1pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Net
        operating loss carry forward</span></span></span></span></div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>15,428</span></span></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>12,895</span></span></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td> </tr>
  <tr>
    <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:76%" valign="bottom">
        <div style="text-indent:-35.1pt;margin-left:35.1pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Research
        and development</span></span></span></span></div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:9%" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>1,225</span></span></span></span></div>
        </td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:9%" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>1,319</span></span></span></span></div>
        </td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align:bottom;width:76%" valign="bottom">
        <div style="text-indent:-35.1pt;margin-left:35.1pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Share-based
        compensation</span></span></span></span></div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>877</span></span></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>876</span></span></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td> </tr>
  <tr>
    <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:76%" valign="bottom">
        <div style="text-indent:-35.1pt;margin-left:35.1pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Other</span></span></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:9%" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>158</span></span></span></span></div>
        </td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:9%" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>152</span></span></span></span></div>
        </td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align:bottom;width:76%;padding-bottom:2px" valign="bottom">
        <div style="text-indent:-35.1pt;margin-left:35.1pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Net
        deferred tax assets before valuation allowance</span></span></span></span></div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0)" valign="bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>17,688</span></span></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0)" valign="bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>15,242</span></span></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td> </tr>
  <tr>
    <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:76%;padding-bottom:2px" valign="bottom">
        <div style="text-indent:-35.1pt;margin-left:35.1pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Valuation
        allowance</span></span></span></span></div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0)" valign="bottom">&#160;</td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0)" valign="bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>(17,645</span></span></span></span></div>
        </div> </td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;padding-bottom:2px;white-space:nowrap" valign="bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>)</span></span></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0)" valign="bottom">&#160;</td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0)" valign="bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>(15,025</span></span></span></span></div>
        </div> </td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;padding-bottom:2px;white-space:nowrap" valign="bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>)</span></span></span></span></div>
        </div> </td> </tr>
  <tr>
    <td style="vertical-align:bottom;width:76%;padding-bottom:4px" valign="bottom">
        <div style="text-indent:-35.1pt;margin-left:35.1pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Net
        deferred tax assets</span></span></span></span></div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0)" valign="bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>43</span></span></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;white-space:nowrap" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0)" valign="bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>217</span></span></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;white-space:nowrap" valign="bottom">&#160;</td> </tr>
  </table> </div>

<div style="line-height:1.25;clear:both">&#160;</div> </div> </div> </div>

<div style="line-height:1.25;clear:both">

<table cellpadding="0" cellspacing="0" style="font-family:Times New Roman, Times, serif;font-size:10pt;width:100%;color:rgb(0, 0, 0);border-width:0px;border-style:initial;border-color:initial">
  <tr>
    <td style="width:47px">&#160;</td>
    <td style="vertical-align:top;width:auto">
        <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;text-align:justify">The Company has classified the net deferred tax assets as
        long-term. In assessing the likelihood of realizing deferred tax assets, management considers whether it is more likely than not that
        some portion or all of the deferred tax assets will not be realized. The ultimate realization of deferred tax assets is dependent upon
        the generation of future taxable income during the periods in which those temporary differences and carry forward losses become deductible.
        Based on the taxable loss in the Israel, management believes it was more likely than not that the deferred tax assets will not be realized
        in the Israel and believes it was more likely than not that deferred tax assets will be realized for the U.S. subsidiary.</p> </td> </tr>
  </table> </div>

<div>

<p style="margin-top:0px;margin-bottom:0px">&#160;</p>

<table cellpadding="0" cellspacing="0" style="border:0px;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:left;width:100%">
  <tr>
    <td style="width:47px"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><strong>G.</strong></span></span></span></span></td>
    <td style="width:auto;vertical-align:top">
        <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><strong><span style="line-height:107%">Rollforward
        of valuation allowance:</span></strong></span></span></span></span></span></span></p> </td> </tr>
  </table> </div>

<p style="margin:0pt">&#160;</p>

<div style="margin-left:36pt">

<table border="0" cellpadding="0" cellspacing="0" style="color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:left;width:85%">
  <tr style="background-color:rgb(204, 238, 255)">
    <td style="vertical-align:top;background-color:rgb(204, 238, 255);width:89%" valign="bottom">
        <div style="line-height:1.25"> <div style="font-size:10pt;display:inline"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><span style="line-height:107%">Balance
        at January 1, 2021</span></span></span></span></span></span></span></div> </div> </td>
    <td colspan="1" style="vertical-align:bottom;border-bottom:2px solid black;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid black;background-color:rgb(204, 238, 255);width:9%" valign="bottom">
        <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong><span><span><span><span><span style="line-height:107%">12,420</span></span></span></span></span></strong></span></span></p>
        </td>
    <td colspan="1" style="vertical-align:bottom;white-space:nowrap;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
        </tr>
  <tr style="background-color:rgb(255, 255, 255)">
    <td style="vertical-align:top;background-color:rgb(255, 255, 255)" valign="bottom">
        <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><span style="line-height:107%">Additions</span></span></span></span></span></span></span></p>
        </td>
    <td colspan="1" style="vertical-align:bottom;border-bottom:4px double black;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:4px double black;background-color:rgb(255, 255, 255);width:9%" valign="bottom">
        <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><span style="line-height:107%">2,605</span></span></span></span></span></span></span></p>
        </td>
    <td colspan="1" style="vertical-align:bottom;white-space:nowrap;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td> </tr>
  <tr style="background-color:rgb(204, 238, 255)">
    <td style="vertical-align:top;background-color:rgb(204, 238, 255)" valign="bottom">
        <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><span style="line-height:107%">Balance
        at January 1, 2022</span></span></span></span></span></span></span></p> </td>
    <td colspan="1" style="vertical-align:bottom;border-bottom:4px double black;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:4px double black;background-color:rgb(204, 238, 255);width:9%" valign="bottom">
        <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong><span><span><span><span><span style="line-height:107%">15,025</span></span></span></span></span></strong></span></span></p>
        </td>
    <td colspan="1" style="vertical-align:bottom;white-space:nowrap;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td> </tr>
  <tr style="background-color:rgb(255, 255, 255)">
    <td style="vertical-align:top;background-color:rgb(255, 255, 255)" valign="bottom">
        <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><span style="line-height:107%">Additions</span></span></span></span></span></span></span></p>
        </td>
    <td colspan="1" style="vertical-align:bottom;border-bottom:4px double black;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:4px double black;background-color:rgb(255, 255, 255);width:9%" valign="bottom">
        <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><span style="line-height:107%">2,620</span></span></span></span></span></span></span></p>
        </td>
    <td colspan="1" style="vertical-align:bottom;white-space:nowrap;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td> </tr>
  <tr style="background-color:rgb(204, 238, 255)">
    <td style="vertical-align:top;background-color:rgb(204, 238, 255)" valign="bottom">
        <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><span style="line-height:107%">Balance
        at December 31, 2022</span></span></span></span></span></span></span></p> </td>
    <td colspan="1" style="vertical-align:bottom;border-bottom:4px double black;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:4px double black;background-color:rgb(204, 238, 255);width:9%" valign="bottom">
        <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong><span><span><span><span><span style="line-height:107%">17,645</span></span></span></span></span></strong></span></span></p>
        </td>
    <td colspan="1" style="vertical-align:bottom;white-space:nowrap;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td> </tr>
  </table>

<p style="margin:0pt">&#160;</p> </div>

<div/>

<table cellpadding="0" cellspacing="0" style="font-weight:bold;color:rgb(0, 0, 0);font-family:Times New Roman, Times, serif;font-size:10pt;width:100%">
  <tr>
    <td style="vertical-align:top;width:35.45pt"><span style="font-size:10pt"><span>H.</span></span></td>
    <td style="vertical-align:top;text-align:justify;width:auto">
        <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span>Reconciliation of theoretical tax expenses
        to actual expenses</span></span></p> </td> </tr>
  <tr>
    <td style="vertical-align:top;width:35.45pt">&#160;</td>
    <td style="vertical-align:top;text-align:justify;width:auto">&#160;</td> </tr>
  </table>

<p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;margin-left:47px;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The
primary difference between the statutory tax rate of the Company and the effective rate results virtually from the changes in valuation
allowance in respect of carry forward tax losses and research and development expenses due to the uncertainty of the realization of such
tax benefits.</span></span></p>

<p style="margin:0pt">&#160;</p>

<div>

<div>

<div style="line-height:1.25">

<div style="line-height:1.25">

<div style="line-height:1.25">

<div style="line-height:1.25;clear:both">

<div style="line-height:1.25">

<div style="line-height:1.25">

<div>

<div>

<div style="line-height:1.25">

<div style="line-height:1.25">

<div style="line-height:1.25">

<div>

<div>

<div>

<div style="line-height:1.25">

<div>

<div style="line-height:1.25">

<div style="line-height:1.25">

<div style="line-height:1.25">

<div style="line-height:1.25;font-weight:bold">

<div style="line-height:1.25">

<div style="line-height:1.25;font-weight:bold">

<table cellpadding="0" cellspacing="0" style="color:#000000;font-family:'Times New Roman',Times,serif;font-size:10pt;text-align:left;width:100%">
  <tr>
    <td style="width:47px;vertical-align:top;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>I.</span></span></span></span></td>
    <td style="width:auto;vertical-align:top;text-align:justify">
        <div style="font-weight:normal">
        <div style="line-height:1.25">
        <div style="line-height:1.25">
        <div style="line-height:1.25">
        <div style="line-height:1.25">
        <div style="line-height:1.25">
        <div style="line-height:1.25">
        <div style="line-height:1.25">
        <div style="line-height:1.25">
        <div style="line-height:1.25">
        <div style="line-height:1.25">
        <div style="line-height:1.25">
        <div style="line-height:1.25">
        <div style="line-height:1.25">
        <div>
        <div style="line-height:1.25">
        <div style="line-height:1.25">
        <div>
        <div>
        <div>
        <div>
        <div style="line-height:1.25;font-weight:bold">
        <div style="line-height:1.25;font-weight:bold">
        <div>
        <div>
        <div style="line-height:1.25;font-weight:bold">
        <div style="line-height:1.25;font-weight:bold">
        <div style="line-height:1.25;font-weight:bold">
        <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Uncertain
        tax positions</span></span></span></span></div> </div> </div> </div> </div> </div> </div> </div> </div> </div> </div> </div> </div> </div>
        </div> </div> </div> </div> </div> </div> </div> </div> </div> </div> </div> </div> </div> </div> </div> </td> </tr>
  </table> </div> </div> </div> </div> </div> </div> </div> </div> </div> </div> </div> </div> </div> </div> </div> </div> </div> </div>
</div> </div> </div>

<div style="line-height:1.25">&#160;</div> </div>

<div style="margin-left:47px;line-height:1.25;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>As
of December 31, 2022&#160;and 2021, the Company does not have a provision for uncertain tax positions.</span></span></span></span></div>
</div> </div> </div> </div> </div> </div> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32857-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330215-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32705-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6424409&amp;loc=d3e44925-109338<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI https://asc.fasb.org/topic&amp;trid=2144680<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6424122&amp;loc=d3e41874-109331<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140398300894336">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_entx_SupplementaryFinancialStatementInformationAbstract', window );"><strong>Supplementary Financial Statement Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_entx_SupplementaryFinancialStatementInformationTextBlock', window );">SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION</a></td>
<td class="text">

<div>

<div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">NOTE
8 - SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION:</span></span></div>

<div style="line-height:1.25">&#160;</div>

<div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Balance
sheets:</span></span></div>

<div>

<div style="line-height:1.25">&#160;</div>

<table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left;color:#000000;width:100%">
  <tr>
    <td style="vertical-align:top;padding-bottom:2px" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td>
    <td colspan="6" style="vertical-align:top;border-bottom:#000000 solid 2px" valign="bottom">
        <div style="line-height:1.25">
        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">December
        31,</span></span></div> </div> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td> </tr>
  <tr>
    <td style="vertical-align:bottom;padding-bottom:2px" valign="bottom">
        <div style="line-height:1.25;font-weight:bold">&#160;</div> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align:top;border-bottom:2px solid rgb(0, 0, 0)" valign="bottom">
        <div style="line-height:1.25">
        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2022</span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align:top;border-bottom:2px solid rgb(0, 0, 0)" valign="bottom">
        <div style="line-height:1.25">
        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2021</span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td> </tr>
  <tr>
    <td rowspan="1" style="vertical-align:top;width:76%;background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Accrued
        expenses and other payables:</span></span></div> </td>
    <td colspan="1" rowspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" rowspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" rowspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" rowspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
    <td colspan="1" rowspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" rowspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" rowspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" rowspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align:top;width:76%" valign="bottom">
        <div style="text-align:justify;text-indent:14.2pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Employees
        and employees related</span></span></div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">154</span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">147</span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td> </tr>
  <tr>
    <td style="vertical-align:top;width:76%;background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="text-align:justify;text-indent:14.2pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Income
        tax</span></span></div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">134</span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align:top;width:76%" valign="bottom">
        <div style="text-align:justify;text-indent:14.2pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Provision
        for vacation</span></span></div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">146</span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">308</span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td> </tr>
  <tr>
    <td style="vertical-align:top;width:76%;padding-bottom:2px;background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="text-align:justify;line-height:1.25;margin-left:14.2pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Accrued
        expenses</span></span></div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">933</span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2,212</span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align:top;width:76%;padding-bottom:2px" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0)" valign="bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">1,233</span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0)" valign="bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2,801</span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td> </tr>
  </table> </div>  </div> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_entx_SupplementaryFinancialStatementInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">entx_SupplementaryFinancialStatementInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>entx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_entx_SupplementaryFinancialStatementInformationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for supplementary financial statement information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">entx_SupplementaryFinancialStatementInformationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>entx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140398304581616">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUBSEQUENT EVENTS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">SUBSEQUENT EVENTS</a></td>
<td class="text">

<div>

<div>

<div>

<div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">NOTE
9 - SUBSEQUENT EVENT</span></span></div>

<div style="line-height:1.25;font-weight:bold">&#160;</div>

<table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">
  <tr>
    <td style="width:35.45pt;vertical-align:top;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">a.</span></span></td>
    <td style="width:auto;vertical-align:top;text-align:justify">
        <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">On January 2, 2023, 534,246
        options to purchase ordinary shares were granted to six non-executive board members with an exercise price of&#8201;$0.73
        per share. The options will vest over one
        year in four equal quarterly installments starting on January 1, 2023. This grant was approved by the shareholders of
        the Company on October 4, 2021.</span></span></div> </td> </tr>
  </table> </div> </div> </div> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -URI https://asc.fasb.org/topic&amp;trid=2122774<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6842918&amp;loc=SL6314017-165662<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140398301961168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SIGNIFICANT ACCOUNTING POLICIES (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of presentation of the financial statements</a></td>
<td class="text">

<div>

<table cellpadding="0" cellspacing="0" style="color:#000000;font-family:'Times New Roman',Times,serif;font-size:10pt;text-align:left;width:100%">
  <tr>
    <td style="width:47px;vertical-align:top;font-family:Times New Roman, Times, serif;font-weight:bold;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">a.</span></span></td>
    <td style="width:auto;vertical-align:top">
        <div style="font-weight:bold;text-align:justify"> <div style="font-size:10pt;display:inline"> <div style="font-family:Times New Roman, Times, serif;display:inline;text-align:left"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>Basis
        of presentation of the financial statements</span></span></span></span></span></span></div> </div> </div> </td> </tr>
  </table>

<div style="line-height:1.25;text-align:justify">&#160;</div>

<div style="margin-left:47px;line-height:1.25;text-align:justify"> <div style="font-size:10pt;display:inline"> <div style="font-family:Times New Roman,Times,serif;display:inline">
<div style="display:inline;text-align:left"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><span><span><span><span><span style="line-height:normal">The
consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States
(&#8220;U.S. GAAP&#8221;). Prior to 2021, the Company prepared its financial statements in accordance with International Financial Reporting
Standards (&#8220;IFRS&#8221;), as issued by the International Accounting Standards Board (&#8220;IASB&#8221;), as permitted in the United
States (&#8220;U.S.&#8221;) based on the Company&#8217;s status as a foreign private issuer as defined in the rules promulgated by the
U.S. Securities and Exchange Commission (the &#8220;SEC&#8221;). During 2021, the Company determined that it is no longer qualified as
a foreign private issuer under the SEC rules. As a result, since January 1, 2022, the Company has been required to comply with all of
the disclosure and reporting requirements applicable to U.S. domestic issuers, including preparing its financial statement in accordance
with U.S. GAAP.</span></span></span></span></span></span></span></span></span></span></span></div> </div> </div> </div> </div> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of estimates in the preparation of financial statements</a></td>
<td class="text">

<div>

<table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">
  <tr>
    <td style="width:47px;vertical-align:top;font-family:Times New Roman, Times, serif;font-weight:bold;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">b.</span></span></td>
    <td style="width:auto;vertical-align:top">
        <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><strong><span style="line-height:107%">Use
        of estimates in the preparation of financial statements</span></strong></span></span></span></span></span></span></p> </td> </tr>
  </table>

<div style="line-height:1.25;text-align:justify">&#160;</div>

<div style="margin-left:47px;line-height:1.25;font-family:Times New Roman, Times, serif;text-align:justify"> <div style="font-size:10pt;display:inline">
<div style="font-family:Times New Roman,Times,serif;display:inline">

<p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><span style="line-height:normal">The
preparation of the consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions
that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial
statements and the reported amounts of revenues and expenses during the reporting period. Actual results may differ from those estimates.</span></span></span></span></span></span></span></p>
</div> </div> </div> </div> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock', window );">Functional currency</a></td>
<td class="text">

<div>

<div>

<div>

<div style="line-height:1.25;text-align:justify">

<table cellpadding="0" cellspacing="0" style="font-family:Times New Roman, Times, serif;font-size:10pt;width:100%;text-align:left;color:rgb(0, 0, 0);border:0px">
  <tr>
    <td style="width:47px;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>c.</strong></span></span></td>
    <td style="width:auto;vertical-align:top">
        <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><strong><span style="line-height:107%">Functional
        currency </span></strong></span></span></span></span></span></span></p> </td> </tr>
  </table> </div>

<p style="margin:0pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">
  <tr>
    <td style="width:47px;text-align:justify">&#160;</td>
    <td style="width:37.25px;vertical-align:top;font-family:Times New Roman, Times, serif;text-align:justify"> <div style="font-size:10pt;display:inline">
        <div style="font-family:Times New Roman,Times,serif;display:inline"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>1)</span></span></span></span></span></span></div>
        </div> </td>
    <td style="width:auto;vertical-align:top">
        <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><span style="line-height:107%">Functional
        and presentation currency</span></span></span></span></span></span></span></p>
        <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt">&#160;</p>
        <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span>Items
        included in the financial statements of the Company are measured using the currency of the primary economic environment in which the entity
        operates (the &#8220;functional currency&#8221;). The U.S. dollar is the currency of the primary economic environment in which the operations
        of the Company are conducted. The consolidated financial statements are presented in U.S. dollars.</span></span></span></span></span></p>
        <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify">&#160;</p>
        <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span>The
        functional currency of the subsidiary is the U.S. dollar.</span></span></span></span></span></p> </td> </tr>
  </table>

<div style="line-height:1.25;text-align:justify">&#160;</div> </div> </div> <div style="font-family:Times New Roman, Times, serif;display:inline;text-align:left">

<table cellpadding="0" cellspacing="0" style="font-family:Times New Roman, Times, serif;font-size:10pt;width:100%;text-align:left;color:rgb(0, 0, 0);border:0px">
  <tr>
    <td style="width:47px;text-align:justify">&#160;</td>
    <td style="width:37.25px;vertical-align:top;font-family:Times New Roman, Times, serif;text-align:justify">
        <div style="font-size:10pt">
        <div style="font-family:Times New Roman, Times, serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><span><span>2)</span></span></span></span></span></span></span></span></div>
        </div> </td>
    <td style="width:auto;vertical-align:top">
        <div style="text-align:justify">
        <div style="font-size:10pt">
        <div style="font-family:Times New Roman, Times, serif;text-align:left"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><span><span>Transactions
        and balances</span></span></span></span></span></span></span></span></div>
        <div style="font-family:Times New Roman, Times, serif">&#160;</div>
        <div style="font-family:Times New Roman, Times, serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span style="line-height:107%">Transactions
        and balances originally denominated in U.S. dollars are presented at their original amounts. Balances in non- U.S. dollar currencies are
        translated into U.S. dollars using historical and current exchange rates for non-monetary and monetary balances, respectively. For non-U.S.
        dollar transactions and other items in the statements of income (indicated below), the following exchange rates are used: (i) for transactions
        &#8211; exchange rates at transaction dates or average exchange rates; and (ii) for other items (derived from non-monetary balance sheet
        items such as depreciation and amortization) &#8211; historical exchange rates. &#160;Currency transaction gains and losses are presented
        in financial income (expenses), as appropriate.</span></span></span></span></span></div> </div> </div> </td> </tr>
  </table> </div> </div> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Principles of consolidation</a></td>
<td class="text">

<table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">
  <tr>
    <td style="width:47px;text-align:justify;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>d.</strong></span></span></td>
    <td style="vertical-align:top;text-align:justify">
        <div> <div style="font-size:10pt;display:inline"> <div style="font-family:Times New Roman,Times,serif;display:inline"> <div style="font-weight:bold;display:inline;text-align:left"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><span style="line-height:107%">Principles
        of consolidation</span></span></span></span></span></span></span></div> </div> </div>
        <div style="margin:0pt">&#160;</div> </div>
        <div>
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">
        <div style="line-height:1.25"> <div style="font-size:10pt;display:inline"> <div style="font-family:Times New Roman, Times, serif;display:inline;text-align:left"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><span style="line-height:normal">The
        consolidated financial statements include the accounts of the Company and its subsidiary Entera Bio Inc. All inter-company transactions
        and balances have been eliminated in consolidation.</span></span></span></span></span></span></span></div> </div> </div> </div> </div>
        </td> </tr>
  </table> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and cash equivalents</a></td>
<td class="text">

<table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">
  <tr>
    <td style="width:47px;text-align:justify;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>e.</strong></span></span></td>
    <td style="vertical-align:top;text-align:justify">
        <div style="font-weight:bold"> <div style="font-size:10pt;display:inline"> <div style="font-family:Times New Roman, Times, serif;display:inline;text-align:left"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><strong><span style="line-height:107%">Cash
        and cash equivalents</span></strong></span></span></span></span></span></span></div> </div>
        <div style="margin:0pt">&#160;</div> </div>
        <div>
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">
        <div style="line-height:1.25">
        <div style="line-height:1.25"> <div style="font-size:10pt;display:inline"> <div style="font-family:Times New Roman, Times, serif;display:inline;text-align:left"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><span style="line-height:normal">The
        Company considers as cash equivalents all short-term, highly liquid investments, which include short-term bank deposits with original
        maturities of three months or less from the date of purchase that are not restricted as to withdrawal or use and are readily convertible
        to known amounts of cash.</span></span></span></span></span></span></span></div> </div> </div> </div> </div> </div> </td> </tr>
  </table> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy', window );">Restricted cash</a></td>
<td class="text">

<table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">
  <tr>
    <td style="width:47px;text-align:justify;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>f.</strong></span></span></td>
    <td style="vertical-align:top;text-align:justify">
        <div style="font-weight:bold">
        <div style="font-weight:bold"> <div style="font-size:10pt;display:inline"> <div style="font-family:Times New Roman, Times, serif;display:inline;text-align:left"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong><span style="line-height:107%">Restricted
        cash</span></strong></span></span></div> </div>
        <div style="margin:0pt">&#160;</div> </div> </div>
        <div>
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">
        <div style="line-height:1.25">
        <div style="text-align:left;line-height:1.25">
        <div style="line-height:1.25;text-align:justify"> <div style="font-size:10pt;display:inline"> <div style="font-family:Times New Roman, Times, serif;display:inline;text-align:left"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><span style="line-height:normal;color:black">Restricted
        cash deposited in an interest-bearing saving account which is used as a security for the Company's office rent&#160;and credit card.</span></span></span></span></span></span></span></div>
        </div> </div> </div> </div> </div> </div> </td> </tr>
  </table> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentrations of credit risk</a></td>
<td class="text">

<div>

<table cellpadding="0" cellspacing="0" style="border:0px;width:100%">
  <tr>
    <td style="width:47px"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>g.</strong></span></span></td>
    <td>
        <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>Concentrations
        of credit risk</strong></span></span></p> </td> </tr>
  </table>

<p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>

<p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;margin-left:47px"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Financial
instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash and cash equivalents.
The Company maintains cash held in checking accounts and deposits at financial institutions in major Israeli and U.S. banks. Management
believes the Company is not exposed to significant credit risk to its current financial institution, but will continue to monitor regularly
and adjust, if needed, to mitigate risk. The Company has established guidelines regarding diversification of its investments and their
maturities, which are designed to maintain principal and maximize liquidity. To date, the Company has not experienced any losses associated
with this credit risk and continues to believe that this exposure is not significant.</span></span></p> </div> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock', window );">Fair value measurement</a></td>
<td class="text">

<div>

<div style="line-height:1.25">

<div>

<div style="line-height:1.25">

<div style="line-height:1.25">

<table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">
  <tr>
    <td style="width:47px;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>h.</strong></span></span></td>
    <td style="vertical-align:top;text-align:justify">
        <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>Fair
        value measurement</strong></span></span></p> </td> </tr>
  </table> </div> </div> </div> </div>

<div>

<p style="margin:0pt">&#160;</p>

<p style="margin-left:47px;margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><span style="line-height:normal">The
</span></span></span></span></span>Company measures fair value and discloses fair value measurements for financial assets and liabilities.
Fair value is based on the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between
market participants at the measurement date. The accounting standard establishes a fair value hierarchy that prioritizes observable and
unobservable inputs used to measure fair value into three broad levels, which are described below:</span></span></p>

<p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>

<p style="margin-left:47px;margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><span style="line-height:normal">Level
</span></span></span></span></span>1: Quoted prices (unadjusted) in active markets that are accessible at the measurement date for assets
or liabilities. The fair value hierarchy gives the highest priority to Level 1 inputs.</span></span></p>

<p style="margin-left:50pt;margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>

<p style="margin-left:47px;margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><span style="color:black">Level
</span></span></span></span></span>2: Observable inputs that are based on inputs not quoted on active markets but corroborated by market
data.</span></span></p>

<p style="margin-left:50pt;margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>

<p style="margin-left:47px;margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><span style="color:black">Level
</span></span></span></span></span>3: Unobservable inputs are used when little or no market data is available. The fair value hierarchy
gives the lowest priority to Level 3 inputs.</span></span></p>

<p style="margin-left:47px;margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p> </div>
</div> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_entx_EmployeeSeveranceBenefitsPolicyPolicyTextBlock', window );">Employee severance benefits</a></td>
<td class="text">

<div>

<div style="line-height:1.25">

<div>

<div style="line-height:1.25">

<div style="line-height:1.25">

<table cellpadding="0" cellspacing="0" style="border:0px;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:left;width:100%">
  <tr>
    <td style="width:47px;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>i.</strong></span></span></td>
    <td style="vertical-align:top;text-align:justify">
        <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><strong><span><span>Employee
        severance benefits</span></span></strong></span></span></span></span></p> </td> </tr>
  </table> </div> </div> </div> </div>

<div>

<p style="margin:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>

<p style="margin-top:0pt;margin-left:47px;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span style="line-height:normal">Under
</span>the Israeli Severance Pay Law, 1963, the Company is required to make severance payments upon dismissal of an Israeli employee or
upon termination of employment in certain other circumstances. The severance payment liability to the employees located in Israel (based
upon length of service and the latest monthly salary - one month&#8217;s salary for each year employed) is recorded on the Company&#8217;s
balance sheet under &#8220;Liability for employee rights upon retirement.&#8221; The liability is recorded as if it was payable at each
balance sheet date on an undiscounted basis.</span></span></span></span></p>

<p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>

<p style="margin-top:0pt;margin-left:47px;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span style="line-height:normal">In
</span>accordance with Section 14 of the Israeli Severance Pay Law, 1963, the Company makes regular deposits with certain insurance companies
for accounts controlled by each applicable employee in order to secure the employee&#8217;s retirement benefit obligation. The Company
is fully relieved from any severance pay liability with respect to each such employee after it makes the payments on behalf of the employee.
The liability accrued in respect of these employees and the amounts funded, as of the respective agreement dates, are not reflected in
the Company balance sheet, as the amounts funded are not under the control and management of the Company and the pension or severance
pay risks have been irrevocably transferred to the applicable insurance companies (the &#8220;Contribution Plan&#8221;).</span></span></span></span></p>

<p style="margin-top:0pt;margin-left:50pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>

<p style="margin-top:0pt;margin-left:47px;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span style="line-height:normal">With
regard to the period before December 2013, the liability is funded in part from the purchase of insurance policies or by the establishment
of pension funds with dedicated deposits in the funds. The amounts used to fund these liabilities are included in the balance sheets under
&#8220;Funds in respect of employee rights upon retirement&#8221;. These policies are the Company&#8217;s assets. </span></span></span></span></span></p>

<p style="margin-top:0pt;margin-left:50pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>

<p style="margin-top:0pt;margin-left:47px;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span style="color:black">The
</span>amounts of severance payment expenses were $132&#160;and
$137
for the years ended December 31, 2022&#160;and 2021, respectively.</span></span></span></span><br/>&#160;</p>

<p style="margin-top:0pt;margin-left:47px;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><span style="color:black">The
</span>Company expects to contribute to insurance companies approximately $132
for the year ending December 31, 2023 in connection with its expected severance liabilities for that year.</span></span></span></span></span></span></p>

<p style="margin-top:0pt;margin-left:47px;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p> </div>
</div> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Leases</a></td>
<td class="text">

<div>

<div style="line-height:1.25">

<div>

<div style="line-height:1.25">

<div style="line-height:1.25">

<table cellpadding="0" cellspacing="0" style="font-family:Times New Roman, Times, serif;font-size:10pt;width:100%;text-align:left;color:rgb(0, 0, 0);border:0px">
  <tr>
    <td style="width:47px;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>j.</strong></span></span></td>
    <td style="width:auto;vertical-align:top;text-align:justify">
        <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:left"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><strong><span style="line-height:107%">Leases</span></strong></span></span></span></span></span></span></p>
        </td> </tr>
  </table> </div> </div> </div> </div>

<div>

<p style="margin:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>

<p style="margin-top:0pt;margin-left:47px;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The
Company determines if an arrangement is a lease at inception. Balances related to operating leases are included in operating lease right-of-use
(&#8220;ROU&#8221;) assets and current and non-current operating lease liabilities in the consolidated balance sheets.</span></span></p>

<p style="margin:0pt">&#160;</p>

<p style="margin-top:0pt;margin-left:47px;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><span style="line-height:107%">ROU
</span></span></span></span></span>assets represent the Company&#8217;s right to use an underlying asset for the lease term and lease
liabilities represent the Company&#8217;s obligation to make lease payments arising from the lease. Operating lease ROU assets and liabilities
are recognized as of the commencement date based on the present value of lease payments over the lease term. Lease terms will include
options to extend or terminate the lease when it is reasonably certain that the Company will either exercise or not exercise the option
to renew or terminate the lease.</span></span></p>

<p style="margin:0pt">&#160;</p>

<p style="margin-top:0pt;margin-left:47px;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><span style="line-height:107%">The
</span></span></span></span></span>discount rate for the lease is the rate implicit in the lease unless that rate cannot be readily determined.
As the Company&#8217;s leases do not provide an implicit rate, the Company&#8217;s uses its estimated incremental borrowing rate based
on the information available at the commencement date in determining the present value of lease payments. Lease expense for lease payments
is recognized on a straight-line basis over the lease term.</span></span></p>

<p style="margin-top:0pt;margin-left:90px;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>

<p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;margin-left:47px;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Sublease
income is recognized on a straight-line basis over the expected lease term and is included in other income in our consolidated statements
of operations<span style="line-height:107%">.</span></span></span></p> </div> </div> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property and equipment</a></td>
<td class="text">

<div>

<table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">
  <tr>
    <td style="width:47px;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><strong>k.</strong></span></span></span></span></td>
    <td style="width:auto;vertical-align:top">
        <div style="font-weight:bold;text-align:justify"> <div style="font-size:10pt;display:inline"> <div style="font-family:Times New Roman, Times, serif;display:inline;text-align:left"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><span><span>Property
        and equipment</span></span></span></span></span></span></span></span></div> </div> </div> </td> </tr>
  </table>

<div style="line-height:1.25;text-align:justify">&#160;</div>

<table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">
  <tr>
    <td style="text-align:justify;width:36pt">&#160;</td>
    <td style="vertical-align:top;font-family:Times New Roman, Times, serif;text-align:justify;width:27pt"> <div style="font-size:10pt;display:inline">
        <div style="font-family:Times New Roman,Times,serif;display:inline"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong><span><span><span><span>1)</span></span></span></span></strong></span></span></div>
        </div> </td>
    <td style="vertical-align:top;width:auto">
        <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><span style="line-height:107%">Property
        and equipment are stated at cost, net of accumulated depreciation and amortization.</span></span></span></span></span></span></span></p>
        </td> </tr>
  </table>

<div style="line-height:1.25;text-align:justify">&#160;</div>

<table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">
  <tr>
    <td style="text-align:justify;width:36pt">&#160;</td>
    <td style="vertical-align:top;font-family:Times New Roman, Times, serif;text-align:justify;width:27pt"> <div style="font-size:10pt;display:inline">
        <div style="font-family:Times New Roman,Times,serif;display:inline"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><strong><span><span><span><span>2)</span></span></span></span></strong></span></span></span></span></div>
        </div> </td>
    <td style="vertical-align:top;width:auto">
        <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><span><span><span style="line-height:normal">The
        </span></span></span></span></span>Company&#8217;s property and equipment are depreciated using the straight-line method, which approximates
        the pattern of usage, over the term of the estimated useful life, as follows<span><span><span><span><span style="line-height:normal">:</span></span></span></span></span></span></span></span></span></p>
        </td> </tr>
  </table>

<div>

<div>

<div>

<div>

<div>

<div style="line-height:1.25">&#160;</div>

<div style="margin-left:126pt">

<table border="0" cellpadding="0" cellspacing="0" style="width:70%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left">
  <tr>
    <td style="width:50.94%;vertical-align:top">&#160;</td>
    <td style="width:24.55%;vertical-align:top">&#160;</td>
    <td style="width:24.51%;vertical-align:top;border-bottom:2px solid #000000">
        <div style="line-height:1.25">
        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Years</span></span></div>
        </div> </td> </tr>
  <tr>
    <td style="width:50.94%;vertical-align:bottom">&#160;</td>
    <td style="width:24.55%;vertical-align:bottom">&#160;</td>
    <td style="width:24.51%;vertical-align:bottom">&#160;</td> </tr>
  <tr>
    <td style="width:50.94%;vertical-align:bottom;background-color:rgb(204, 238, 255)">
        <div style="text-align:justify;text-indent:-10.7pt;margin-left:12.6pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Computer
        equipment</span></span></div> </td>
    <td style="width:24.55%;vertical-align:bottom;background-color:rgb(204, 238, 255)">&#160;</td>
    <td style="width:24.51%;vertical-align:bottom;background-color:rgb(204, 238, 255)">
        <div style="text-align:right;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">3-5</span></span></div>
        </td> </tr>
  <tr>
    <td style="width:50.94%;vertical-align:bottom">
        <div style="text-align:justify;text-indent:-10.7pt;margin-left:12.6pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Office
        furniture</span></span></div> </td>
    <td style="width:24.55%;vertical-align:bottom">&#160;</td>
    <td style="width:24.51%;vertical-align:bottom">
        <div style="text-align:right;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">10</span></span></div>
        </td> </tr>
  <tr>
    <td style="width:50.94%;vertical-align:bottom;background-color:rgb(204, 238, 255)">
        <div style="text-align:justify;text-indent:-10.7pt;margin-left:12.6pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Laboratory
        equipment</span></span></div> </td>
    <td style="width:24.55%;vertical-align:bottom;background-color:rgb(204, 238, 255)">&#160;</td>
    <td style="width:24.51%;vertical-align:bottom;background-color:rgb(204, 238, 255)">
        <div style="text-align:right;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">7-10</span></span></div>
        </td> </tr>
  </table> </div> </div> </div>

<div style="margin-left:36pt;line-height:1.25">&#160;</div> </div> </div>  </div>

<div style="margin-left:47px;line-height:1.25;text-align:justify"> <div style="font-size:10pt;display:inline"> <div style="font-family:Times New Roman,Times,serif;display:inline">
<div style="display:inline;text-align:left;margin-bottom:0pt;margin-top:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><span style="line-height:107%">Leasehold
improvements are amortized by the straight-line method over the shorter of (i) the expected lease term and (ii) the estimated useful life
of the improvements.</span></span></span></span></span></span></span></div>

<p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman,Times,serif">&#160;</p> </div> </div> </div> </div> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock', window );">Impairment of long-lived assets</a></td>
<td class="text">

<div>

<div style="line-height:1.25">

<div>

<div style="line-height:1.25">

<div style="line-height:1.25">

<table cellpadding="0" cellspacing="0" style="font-family:Times New Roman, Times, serif;font-size:10pt;width:100%;text-align:left;color:rgb(0, 0, 0);border:0px">
  <tr>
    <td style="width:47px;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>l.</strong></span></span></td>
    <td style="vertical-align:top;text-align:justify">
        <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:left"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><strong><span style="line-height:107%">Impairment&#160;of
        long-lived assets</span></strong></span></span></span></span></span></span></p> </td> </tr>
  </table> </div> </div> </div> </div>

<div>

<p style="margin:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>

<p style="margin-top:0pt;margin-left:47px;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><span><span><span style="line-height:normal">The
</span></span></span></span></span>Company tests long-lived assets for impairment whenever events or changes in circumstances indicate
that the carrying amount of an asset may no longer be recoverable. Recoverability of long-lived assets is measured by comparing the carrying
amount of the long-lived asset to the estimated undiscounted future cash flows expected to be generated by the asset. If the sum of the
expected undiscounted cash flow is less than the carrying amount of the asset, the Company recognizes an impairment loss, which is the
excess of the carrying amount over the fair value of the asset, using the expected future discounted cash flows.</span></span></span></span></p>

<p style="margin-top:0pt;margin-left:47px;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>

<p style="margin-top:0pt;margin-left:47px;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span style="line-height:107%">As
of December 31, 2022 and 2021, the Company did not recognize an impairment loss on its long-lived assets.</span></span></span></span></span></p>
</div> </div> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Share-based compensation</a></td>
<td class="text">

<div>

<div style="line-height:1.25">

<div>

<div style="line-height:1.25">

<div style="line-height:1.25">

<table cellpadding="0" cellspacing="0" style="font-family:Times New Roman, Times, serif;font-size:10pt;width:100%;text-align:left;color:rgb(0, 0, 0);border:0px">
  <tr>
    <td style="width:47px;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>m.</strong></span></span></td>
    <td style="width:auto;vertical-align:top;text-align:justify">
        <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:left"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><strong><span style="line-height:107%">Share-based
        compensation </span></strong></span></span></span></span></span></span></p> </td> </tr>
  </table> </div> </div> </div> </div>

<div>

<p style="margin:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>

<p style="margin-top:0pt;margin-left:47px;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><span><span><span style="line-height:normal"><span><span>The
</span></span></span></span></span></span></span>Company grants share options and restricted share units (&#8220;RSU&#8221;) (together
&#8220;Share-Based Compensation&#8221;) to its employees, directors and non-employees in consideration for services rendered<span><span><span><span><span style="line-height:normal"><span><span>.</span></span></span></span></span></span></span></span></span></span></span></p>

<p style="margin:0pt">&#160;</p>

<p style="margin-top:0pt;margin-left:47px;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><span style="line-height:normal"><span><span>The
Company accounts for Share-Based Compensation awards classified as equity awards, including share-based option awards and RSUs, using
grant-date fair value. The Company recognize the value of the award as an expense over the requisite service period</span></span></span><span><span><span><span><span><span><span style="line-height:normal">.</span></span></span></span></span></span></span></span></span></span></span></span></span></p>

<p style="margin-top:0pt;margin-left:47px;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>

<p style="margin-top:0pt;margin-left:47px;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><span><span><span><span><span><span><span style="line-height:normal">The
Company applies ASU 2018-07 (Topic 718) that expands the scope of Topic 718 to include Share-Based Compensation transactions for acquiring
goods and services from non-employees. Under the provision of the amendment, the Company measures share-based compensation to non-employees
in the same manner as share-based compensation to employees.</span></span></span></span></span></span></span></span></span></span></span></span></span></p>

<p style="margin-top:0pt;margin-left:90px;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:left">&#160;</p>

<p style="margin-top:0pt;margin-left:47px;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><span style="line-height:107%">The
Company calculates the fair value of stock-based option awards on the date of grant using the Black-Scholes option pricing model. The
option-pricing model requires a number of assumptions, of which the most significant are the expected share price volatility and the expected
option term. The computation of expected volatility is based on the historical volatility of the Company&#8217;s ordinary shares. The
expected option term is calculated using the simplified method, as the Company has concluded that its historical share option exercise
experience does not provide a reasonable basis to estimate expected option terms. The interest rate for periods within the expected term
of an award is based on the U.S. Treasury yield curve in effect at the time of grant. The Company&#8217;s expected dividend rate is zero
because the Company does not currently pay cash dividends on its shares and does not anticipate doing so in the foreseeable future</span></span></span><span><span><span style="line-height:107%">.</span></span></span></span></span></span></span></p>

<p style="margin-top:0pt;margin-left:90px;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:left">&#160;</p>

<p style="margin-top:0pt;margin-left:47px;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><span style="line-height:107%">The
</span>Company elected to recognize compensation costs for awards granted to employees and directors conditioned only on continued service
that have a graded vesting schedule using the accelerated method based on the multiple-option award approach. The Company has elected
to account for forfeitures as they occur<span style="line-height:107%">.</span></span></span></span></span></span></span></p>

<p style="margin-top:0pt;margin-left:47px;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p> </div>
</div> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and development expenses</a></td>
<td class="text">

<div>

<div style="line-height:1.25">

<div>

<div style="line-height:1.25">

<div style="line-height:1.25">

<table cellpadding="0" cellspacing="0" style="font-family:Times New Roman, Times, serif;font-size:10pt;width:100%;text-align:left;color:rgb(0, 0, 0);border:0px">
  <tr>
    <td style="width:47px;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>n.</strong></span></span></td>
    <td style="width:auto;vertical-align:top;text-align:justify">
        <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:left"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><strong><span style="line-height:107%">Research
        and development expenses</span></strong></span></span></span></span></span></span></p> </td> </tr>
  </table> </div> </div> </div> </div>

<div>

<p style="margin:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:left">&#160;</p>

<p style="margin-top:0pt;margin-left:47px;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><span style="line-height:normal">Research
</span></span></span></span></span>and development expenses include costs directly attributable to the conduct of research and development
programs, including the cost of salaries, share-based compensation expenses, payroll taxes and other employee benefits, lab expenses,
consumable equipment and consulting fees. All costs associated with research and developments are expensed as incurred<span><span><span><span><span style="line-height:normal">.</span></span></span></span></span></span></span></p>

<p style="margin:0pt;text-align:left">&#160;</p>

<p style="margin-top:0pt;margin-left:48px;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><span style="line-height:normal">Grants
received from the Israel Innovation Authority (the &#160;&#8220;IIA&#8221;) are recognized when the grant becomes receivable, provided
there is reasonable assurance that the Company will comply with the conditions attached to the grant and there is reasonable assurance
the grant will be received. At the time grants are received, successful development of the related projects is not assured, therefore,
grants are deducted from the research and development expenses as the applicable costs are incurred, and presented in R&amp;D expenses,
net</span></span></span></span></span><span><span><span><span><span style="line-height:107%"><span>.</span></span></span></span></span></span></span></span></p>
</div> </div> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRecognitionPolicyTextBlock', window );">Revenue recognition</a></td>
<td class="text">

<div>

<div>

<div style="line-height:1.25">

<div>

<div style="line-height:1.25">

<div style="line-height:1.25">

<table cellpadding="0" cellspacing="0" style="font-family:Times New Roman, Times, serif;font-size:10pt;width:100%;text-align:left;color:rgb(0, 0, 0);border:0px">
  <tr>
    <td style="width:47px;text-align:justify">&#160;</td>
    <td style="width:auto;vertical-align:top;text-align:justify">&#160;</td> </tr>
  <tr>
    <td style="width:47px;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><strong>o.</strong></span></span></span></span></td>
    <td style="width:auto;vertical-align:top;text-align:justify">
        <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:left"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><span><strong><span style="line-height:107%">Revenue
        recognition </span></strong></span></span></span></span></span></span></span></p> </td> </tr>
  </table> </div> </div> </div> </div>

<div>

<p style="margin:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>

<p style="margin-top:0pt;margin-left:47px;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><span><span><span><span><span style="line-height:normal">The
Company recognized revenue from the Amgen Agreement according to ASC 606, "Revenues from Contracts with Customers&#8221;. Prior to the
signing of the Amgen Agreement in 2018, the Company did not have revenue transactions.</span></span></span></span></span></span></span></span></span></span></span></p>

<p style="margin:0pt;text-align:left">&#160;</p>

<p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;margin-left:47px"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>ASC
606 Revenue from Contracts with Customer introduces a five-step model for recognizing revenue from contracts with customers, as follows:</span></span></span></span></p>

<p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;margin-left:47px"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>1.&#160;
Identify the contract with a customer.</span></span></span></span></p>

<p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;margin-left:47px"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>2.&#160;
Identify the performance obligations in the contract.</span></span></span></span></p>

<p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;margin-left:47px"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>3.&#160;
Determine the transaction price.</span></span></span></span></p>

<p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;margin-left:47px"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>4.&#160;
Allocate the transaction price to the performance obligations in the contract.</span></span></span></span></p>

<p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;margin-left:47px"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>5.&#160;
Recognize revenue when (or as) the entity satisfies a performance obligation.</span></span></span></span></p>

<p style="margin:0pt;text-align:left">&#160;</p>

<p style="margin-top:0pt;margin-left:47px;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><span><span><span style="line-height:normal">According
to ASC 606, a performance obligation is a promise to provide a distinct good or service or a series of distinct goods or services. Goods
and services that are not distinct are bundled with other goods or services in the contract until a bundle of goods or services that is
distinct is created. A good or service promised to a customer is distinct if the customer can benefit from the good or service either
on its own or together with other resources that are readily available to the customer and the entity&#8217;s promise to transfer the
good or service to the customer is separately identifiable from other promises in the contract.</span></span></span></span></span></span></span></span></span></p>

<p style="margin:0pt;text-align:left">&#160;</p>

<p style="margin-top:0pt;margin-left:47px;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><span><span><span style="line-height:107%">Options
granted to the customer that do not provide a material right to the customer that it would not receive without entering into the contract
do not give rise to performance obligations.</span></span></span></span></span></span></span></span></span></p>

<p style="margin:0pt">&#160;</p>

<p style="margin-top:0pt;margin-left:47px;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><span><span><span><span><span style="line-height:normal">On
December 10, 2018, the Company entered into the Amgen Agreement for the use of the Company&#8217;s oral delivery platform in the field
of inflammatory diseases and other serious illnesses. As part of the agreement, the Company received non-refundable and non-creditable
initial access payment of $725&#160;from
Amgen in January 2019.</span></span></span></span></span></span></span></span></span></span></span></p>

<p style="margin:0pt">&#160;</p>

<p style="margin-top:0pt;margin-left:47px;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><span><span><span style="line-height:normal">The
Company identified two performance obligations in the agreement: 1) License to use the Company's proprietary drug delivery platform and
2) pre-clinical research and development services (&#8220;pre-clinical R&amp;D services&#8221;). The preclinical R&amp;D services include
discovery, research and design preclinical activities relating to the programs selected by Amgen.</span></span></span></span></span></span></span></span></span></p>

<p style="margin-top:0pt;margin-left:47px;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>

<div/>

<p style="margin-top:0pt;margin-left:47px;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The
Company determined the license to the intellectual property to be a right to use that has significant standalone functionality separately
from the pre-clinical R&amp;D services since the Company is not required to continue to support, develop or maintain the intellectual
property transferred and will not undertake any activities to change the standalone functionality of the intellectual property. Therefore,
the license to the intellectual property is a distinct performance obligation and as such revenue is recognized at the point in time that
control of the license was transferred to Amgen on December 10, 2018.</span></span></p>

<p style="margin-top:0pt;margin-left:47px;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>

<p style="margin-top:0pt;margin-left:47px;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><span><span><span style="line-height:normal">Revenues
attributed to the preclinical R&amp;Ds services are recognized during the period of the pre-clinical R&amp;D services, over time according
to the input model method on a cost-to-cost basis, since the customer benefits from the research and development services as the entity
performs the service.</span></span></span></span></span></span></span></span></span><br/>&#160;</p>

<p style="margin-top:0pt;margin-left:47px;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><span><span><span style="line-height:normal">The
Company evaluated the standalone selling price of the pre-clinical R&amp;D services at $225&#160;and
the right to use the intellectual property at $500.</span></span></span></span></span></span></span></span></span></p>
</div> </div>

<div style="line-height:1.25">

<div>

<div style="line-height:1.25">&#160;</div> </div> </div>

<div>

<p style="margin-top:0pt;margin-left:47px;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><span><span><span style="line-height:normal"><span><span>The
</span></span>transaction price was comprised of fixed consideration and variable consideration (capped research and development reimbursements).
Under ASC 606, the consideration that the Company would be entitled to upon the achievement of contractual milestones, which are contingent
upon the occurrence of future events of development and commercial progress, are a form of variable consideration. Variable consideration
is included in the transaction price if, in the Company&#8217;s judgment, it is highly probable that a significant future reversal of
cumulative revenue under the contract will not occur. Estimates of variable consideration and determination of whether to include estimated
amounts in the transaction price are based largely on an assessment of the Company&#8217;s anticipated performance and all information
(historical, current and forecasted) that is reasonably available. As of December 31, 2022, the Company did not recognize any revenues
from any potential milestone payments<span><span>.</span></span></span></span></span></span></span></span></span></span></span></p>

<p style="margin:0pt;text-align:left">&#160;</p>

<p style="margin-top:0pt;margin-left:47px;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><span style="line-height:107%">An
entity should recognize revenue for a sales-based or usage-based royalty promised in exchange for a license of intellectual property only
when (or as) the later of the following events occurs:</span></span></span></span></span></span></span></p>

<div style="line-height:1.25">

<div style="line-height:1.25">

<div style="line-height:1.25;text-align:left">&#160;</div> </div> </div>

<div style="line-height:1.25">

<div style="line-height:1.25">

<table cellpadding="0" cellspacing="0" style="font-family:Times New Roman, Times, serif;font-size:10pt;width:100%;text-align:left;color:rgb(0, 0, 0);border:0px">
  <tr>
    <td style="width:47px">&#160;</td>
    <td style="width:45px;vertical-align:top;font-family:Times New Roman, Times, serif;text-align:justify">
        <div style="font-size:10pt">
        <div style="font-family:Times New Roman, Times, serif;text-align:left"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>a)</span></span></span></span></div>
        </div> </td>
    <td style="width:auto;vertical-align:top">
        <div>
        <div style="text-align:justify">
        <div style="font-size:10pt">
        <div style="font-family:Times New Roman, Times, serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>The
        subsequent sale or usage occurs; and</span></span></span></span></div> </div> </div> </div> </td> </tr>
  </table>

<table cellpadding="0" cellspacing="0" style="font-family:Times New Roman, Times, serif;font-size:10pt;width:100%;text-align:left;color:rgb(0, 0, 0);border:0px">
  <tr>
    <td style="width:47px;text-align:justify">&#160;</td>
    <td style="width:45px;vertical-align:top;font-family:Times New Roman, Times, serif;text-align:justify">
        <div style="font-size:10pt">
        <div style="font-family:Times New Roman, Times, serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>b)</span></span></span></span></div>
        </div> </td>
    <td style="width:auto;vertical-align:top">
        <div>
        <div style="text-align:justify">
        <div style="font-size:10pt">
        <div style="font-family:Times New Roman, Times, serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>The
        performance obligation to which some or all of the sales based or usage-based royalty has been allocated has been satisfied (or partially
        satisfied).</span></span></span></span></div> </div> </div> </div> </td> </tr>
  </table> </div> </div> </div>

<p style="margin:0pt;text-align:left">&#160;</p>

<p style="margin-top:0pt;margin-left:47px;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><span><span><span style="line-height:normal">As
</span></span></span></span></span>royalties are payable based on future commercial sales, as defined in the agreement, which did not
occur as of the financial statements date, the Company did not recognize any revenues from royalties.&#160;</span></span></span></span></p>

<p style="margin-top:0pt;margin-left:47px;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>

<p style="margin-top:0pt;margin-left:47px;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span style="font-weight:bold"><span><span><span style="font-weight:normal">Revenues
attributed to preclinical R&amp;D services are recognized during the period of the pre-clinical R&amp;D services according to the input
model method on a cost-to-cost basis</span></span></span><span><span><span style="font-weight:normal">.</span></span></span></span></span></span></span></span></span></p>

<p style="margin-top:0pt;margin-left:47px;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>

<p style="margin-top:0pt;margin-left:47px;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span style="line-height:107%">In
2022 and 2021, the Company recorded revenues of $89
and $502,
respectively, related to services provided under the Amgen Agreement.</span></span></span></span></span></p>

<p style="margin-top:0pt;margin-left:47px;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p> </div>
<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income taxes</a></td>
<td class="text">

<div>

<div style="text-align:justify;line-height:1.25">

<table cellpadding="0" cellspacing="0" style="font-family:Times New Roman, Times, serif;font-size:10pt;width:100%;text-align:left;color:rgb(0, 0, 0);border:0px">
  <tr>
    <td style="width:47px;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><strong>p.</strong></span></span></span></span></td>
    <td style="width:auto;vertical-align:top">
        <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><span><span><strong><span style="line-height:107%">Income
        taxes </span></strong></span></span></span></span></span></span></span></span></p> </td> </tr>
  </table> </div>

<p style="margin:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font-family:Times New Roman, Times, serif;font-size:10pt;width:100%;text-align:left;color:rgb(0, 0, 0);border:0px">
  <tr>
    <td style="width:47px;text-align:justify">&#160;</td>
    <td style="width:40px;vertical-align:top;font-family:Times New Roman, Times, serif;text-align:justify">
        <div style="font-size:10pt">
        <div style="font-family:Times New Roman, Times, serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><span>1)</span></span></span></span></span></span></span></div>
        </div> </td>
    <td style="width:auto;vertical-align:top">
        <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><span style="line-height:normal">Deferred
        taxes</span></span></span></span></span></span></span></p> </td> </tr>
  </table>

<div style="line-height:1.25;text-align:left">&#160;</div>

<div style="margin-left:47px;text-align:justify;line-height:1.25;font-family:Times New Roman, Times, serif">

<div style="font-size:10pt">

<div style="font-family:Times New Roman, Times, serif;margin-left:40px"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><span style="line-height:107%">Deferred&#160;</span></span></span></span></span>income
taxes are computed using the asset and liability method. Under the asset and liability method, deferred income tax assets and liabilities
are determined based on the differences between the financial reporting and tax bases of assets and liabilities and are measured using
the currently enacted tax rates and laws. A valuation allowance is recognized to the extent that it is more likely than not that the deferred
taxes will not be realized in the foreseeable future<span><span><span><span><span style="line-height:107%">.</span></span></span></span></span></span></span></div>
</div> </div>

<p style="margin:0pt;text-align:left">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font-family:Times New Roman, Times, serif;font-size:10pt;width:100%;text-align:left;color:rgb(0, 0, 0);border:0px">
  <tr>
    <td style="width:47px">&#160;</td>
    <td style="width:40px;vertical-align:top;font-family:Times New Roman, Times, serif;text-align:justify">
        <div style="font-size:10pt">
        <div style="font-family:Times New Roman, Times, serif;text-align:left"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><span>2)</span></span></span></span></span></span></span></div>
        </div> </td>
    <td style="width:auto;vertical-align:top">
        <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><span style="line-height:107%">Uncertainty
        in income taxes</span></span></span></span></span></span></span></p> </td> </tr>
  </table>

<div style="line-height:1.25;text-align:left">&#160;</div>

<div style="margin-left:47px;text-align:justify;line-height:1.25;font-family:Times New Roman, Times, serif">

<div style="font-size:10pt">

<div style="font-family:Times New Roman, Times, serif;margin-left:40px"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><span style="line-height:107%">The
Company follows a two-step approach in recognizing and measuring uncertain tax positions. The first step is to evaluate the tax position
for recognition by determining if the available evidence indicates that it is more likely than not that the position will be sustained
based on technical merits. If this threshold is met, the second step is to measure the tax position as the largest amount that has more
than a 50% likelihood of being realized upon ultimate settlement.</span></span></span></span></span></span></span></div> </div> </div>
</div> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Loss per share</a></td>
<td class="text">

<div>

<div style="line-height:1.25">

<div>

<div style="line-height:1.25">

<div style="line-height:1.25">

<table cellpadding="0" cellspacing="0" style="font-family:Times New Roman, Times, serif;font-size:10pt;width:100%;text-align:left;color:rgb(0, 0, 0);border:0px">
  <tr>
    <td style="width:47px;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><strong>q.</strong></span></span></span></span></td>
    <td style="width:auto;vertical-align:top;text-align:justify">
        <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:left"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><span><span><strong><span style="line-height:107%">Loss
        per share </span></strong></span></span></span></span></span></span></span></span></p> </td> </tr>
  </table> </div> </div> </div> </div>

<div>

<p style="margin:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>

<p style="margin-top:0pt;margin-left:47px;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><span style="line-height:107%">Basic
loss per share is computed on the basis of the net loss, adjusted to recognize the effect of a down-round feature when it is triggered,
for the period, divided by the weighted average number of outstanding ordinary shares during the period.</span></span></span></span></span></span></span></p>

<p style="margin:0pt">&#160;</p>

<p style="margin-top:0pt;margin-left:47px;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><span><span><span><span><span style="line-height:107%">Diluted
</span></span></span></span></span>loss per share is based upon the weighted average number of ordinary shares and of ordinary shares
equivalents outstanding when dilutive. Ordinary share equivalents include outstanding stock options and warrants, which are included under
the treasury stock method when dilutive. The calculation of diluted loss per share does not include options, RSUs and warrants, exercisable
into an aggregate of<span><span><span><span><span style="line-height:107%">&#160;6,255,235
shares and&#160;</span><span style="line-height:107%">6,517,102</span><strong>&#160;</strong></span></span></span></span>shares
for the years ended December&#160;31, 2022&#160;and 2021, respectively, because the effect would have been anti-dilutive.</span></span></span></span></span></span></p>
</div> </div> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesPolicyTextBlock', window );">Legal and other contingencies</a></td>
<td class="text">

<div>

<div style="line-height:1.25">

<div>

<div style="line-height:1.25">

<div style="line-height:1.25">

<table cellpadding="0" cellspacing="0" style="font-family:Times New Roman, Times, serif;font-size:10pt;width:100%;text-align:left;color:rgb(0, 0, 0);border:0px">
  <tr>
    <td style="width:47px;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong><span><span><span>r.</span></span></span></strong></span></span></td>
    <td style="width:auto;vertical-align:top;text-align:justify">
        <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong><span><span>Legal
        and other contingencies</span></span></strong></span></span></p> </td> </tr>
  </table> </div> </div> </div> </div>

<div>

<p style="margin:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>

<p style="margin-top:0pt;margin-left:47px;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><span style="line-height:107%">Management&#160;</span></span></span></span></span>applies
the guidance in ASC 450-20, &#8220;Loss Contingencies&#8221; when assessing losses resulting from contingencies. If the assessment of
a contingency indicates that it is probable that a material loss has been incurred and the amount of the liability can be estimated, then
the estimated liability is recorded as accrued expenses in the Company&#8217;s consolidated financial statements<span>.</span></span></span></p>

<p style="margin:0pt">&#160;</p>

<p style="margin-top:0pt;margin-left:47px;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Legal
costs incurred in connection with loss contingencies are expensed as incurred<span style="line-height:107%">.</span></span></span></p>

<p style="margin-top:0pt;margin-left:47px;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p> </div>
</div> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Newly issued and recently adopted accounting pronouncements</a></td>
<td class="text">

<div>

<div style="line-height:1.25">

<div>

<div style="line-height:1.25">

<div style="line-height:1.25">

<table cellpadding="0" cellspacing="0" style="font-family:Times New Roman, Times, serif;font-size:10pt;width:100%;text-align:left;color:rgb(0, 0, 0);border:0px">
  <tr>
    <td style="width:47px;vertical-align:top;font-family:Times New Roman, Times, serif;font-weight:bold;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>s.</span></span></span></span></td>
    <td style="width:auto;vertical-align:top;text-align:justify">
        <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:left"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><span><span><strong><span style="line-height:107%">Newly
        issued and recently adopted accounting pronouncements:</span></strong></span></span></span></span></span></span></span></span></p> </td>
        </tr>
  </table> </div> </div> </div> </div>

<div>

<p style="margin:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>

<p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;margin-left:38pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><em><strong><span><span>Recently
issued accounting pronouncements adopted</span></span></strong></em></span></span></span></span></p>

<p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>

<div style="margin-left:47px">

<table cellpadding="0" cellspacing="0" style="border:0px;width:100%">
  <tr>
    <td style="vertical-align:top;width:20pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>1)</span></span></span></span></td>
    <td style="width:auto">
        <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>In&#160;</span></span><span style="line-height:107%">November
        2021, the FASB issued ASU 2021-10 &#8220;Government Assistance (Topic 832)&#8221;, which requires annual disclosures that increase the
        transparency of transactions involving government grants, including (1) the types of transactions, (2) the accounting for those transactions,
        and (3) the effect of those transactions on an entity&#8217;s financial statements. The amendments in this update are effective for financial
        statements issued for annual periods beginning after December 15, 2021.</span>&#160;<span style="line-height:107%">The adoption of this
        guidance did not have material impact on the Company&#8217;s consolidated financial statements.</span></span></span></span></span></p>
        </td> </tr>
  </table> </div>

<p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>

<div style="margin-left:47px">

<table cellpadding="0" cellspacing="0" style="border:0px;width:100%">
  <tr>
    <td style="vertical-align:top;width:20pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>2)</span></span></span></span></td>
    <td style="width:auto">
        <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>In
        </span></span><span style="line-height:107%">August 2020, the FASB issued ASU 2020-06 &#8220;Debt &#8211; Debt with Conversion and Other
        Options (Subtopic 470-20) and Derivatives and Hedging &#8211; Contracts in Entity&#8217;s Own Equity (Subtopic 815 &#8211; 40).&#8221;
        This guidance simplifies the accounting for certain financial instruments with characteristics of liabilities and equity, including convertible
        instruments and contracts on an entity&#8217;s own equity. The amendments to this guidance are effective for fiscal years beginning after
        December&#160;15, 2021, and interim periods within those fiscal years. The Company early adopted this guidance effective January 1, 2022
        and the impact of the adoption on the Consolidated financial statements was immaterial.</span></span></span></span></span></p> </td> </tr>
  </table> </div>

<p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt">&#160;</p>

<p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;margin-left:38pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><em><strong>Recently
issued accounting pronouncements, not yet adopted</strong></em></span></span></p>

<p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt">&#160;</p>

<div style="margin-left:47px">

<table cellpadding="0" cellspacing="0" style="border:0px;width:100%">
  <tr>
    <td style="vertical-align:top;width:20pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>1)</span></span></span></span></td>
    <td style="width:auto">
        <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>I</span></span></span></span></span><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><span>n
        </span></span><span style="line-height:107%">June 2016, the FASB issued ASU 2016-13 &#8220;Financial Instruments&#8212;Credit Losses&#8212;Measurement
        of Credit Losses on Financial Instruments.&#8221; This guidance replaces the current incurred loss impairment methodology with a methodology
        that reflects expected credit losses and requires consideration of a broader range of reasonable and supportable information to inform
        credit loss estimates. </span></span></span></span></span></span><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="line-height:107%">The
        guidance will be effective for Smaller Reporting Companies (SRCs, as defined by the SEC) for the fiscal year beginning on January 1, 2023,
        including interim periods within that year. The adoption of this guidance will not have material impact on the Company&#8217;s consolidated
        financial statements.</span></span></span></p> </td> </tr>
  </table> </div> </div> </div> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_entx_EmployeeSeveranceBenefitsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for employee severance benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">entx_EmployeeSeveranceBenefitsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>entx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4273-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Entity's cash and cash equivalents accounting policy with respect to restricted balances. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4273-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for commitments and contingencies, which may include policies for recognizing and measuring loss and gain contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 460<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126907703&amp;loc=d3e12565-110249<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 450<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6491354&amp;loc=d3e6049-115624<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126941378&amp;loc=d3e61044-112788<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18823-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=d3e5614-111684<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -URI https://asc.fasb.org/topic&amp;trid=2175825<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 05<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=109226317&amp;loc=d3e202-110218<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.CC)<br> -URI https://asc.fasb.org/extlink&amp;oid=27011434&amp;loc=d3e125687-122742<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32247-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32847-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32840-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL116659661-227067<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32280-109318<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918666-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99779-112916<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99893-112916<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18823-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18823-107790<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI https://asc.fasb.org/topic&amp;trid=2228938<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2.Q6)<br> -URI https://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140398387352992">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SIGNIFICANT ACCOUNTING POLICIES (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_entx_ScheduleOfEstimatedUsefulLifeTableTextBlock', window );">Schedule of estimated useful life</a></td>
<td class="text">

<div>

<div>

<div>

<div>

<div style="line-height:1.25">&#160;</div>

<div style="margin-left:126pt">

<table border="0" cellpadding="0" cellspacing="0" style="width:70%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left">
  <tr>
    <td style="width:50.94%;vertical-align:top">&#160;</td>
    <td style="width:24.55%;vertical-align:top">&#160;</td>
    <td style="width:24.51%;vertical-align:top;border-bottom:2px solid #000000">
        <div style="line-height:1.25">
        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Years</span></span></div>
        </div> </td> </tr>
  <tr>
    <td style="width:50.94%;vertical-align:bottom">&#160;</td>
    <td style="width:24.55%;vertical-align:bottom">&#160;</td>
    <td style="width:24.51%;vertical-align:bottom">&#160;</td> </tr>
  <tr>
    <td style="width:50.94%;vertical-align:bottom;background-color:rgb(204, 238, 255)">
        <div style="text-align:justify;text-indent:-10.7pt;margin-left:12.6pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Computer
        equipment</span></span></div> </td>
    <td style="width:24.55%;vertical-align:bottom;background-color:rgb(204, 238, 255)">&#160;</td>
    <td style="width:24.51%;vertical-align:bottom;background-color:rgb(204, 238, 255)">
        <div style="text-align:right;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">3-5</span></span></div>
        </td> </tr>
  <tr>
    <td style="width:50.94%;vertical-align:bottom">
        <div style="text-align:justify;text-indent:-10.7pt;margin-left:12.6pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Office
        furniture</span></span></div> </td>
    <td style="width:24.55%;vertical-align:bottom">&#160;</td>
    <td style="width:24.51%;vertical-align:bottom">
        <div style="text-align:right;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">10</span></span></div>
        </td> </tr>
  <tr>
    <td style="width:50.94%;vertical-align:bottom;background-color:rgb(204, 238, 255)">
        <div style="text-align:justify;text-indent:-10.7pt;margin-left:12.6pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Laboratory
        equipment</span></span></div> </td>
    <td style="width:24.55%;vertical-align:bottom;background-color:rgb(204, 238, 255)">&#160;</td>
    <td style="width:24.51%;vertical-align:bottom;background-color:rgb(204, 238, 255)">
        <div style="text-align:right;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">7-10</span></span></div>
        </td> </tr>
  </table> </div> </div> </div>

<div style="margin-left:36pt;line-height:1.25">&#160;</div> </div> </div> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_entx_ScheduleOfEstimatedUsefulLifeTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the estimated useful life used to calculate depreciation of assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">entx_ScheduleOfEstimatedUsefulLifeTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>entx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140398296059072">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>OPERATING LEASES (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCostTableTextBlock', window );">Schedule of lease cost</a></td>
<td class="text">

<div>

<div>

<div style="text-align:justify;margin-left:36pt;line-height:1.25">&#160;</div>

<div style="margin-left:45pt">

<table border="0" cellpadding="0" cellspacing="0" style="width:92%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left">
  <tr>
    <td style="vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px" valign="bottom">
        <div style="line-height:1.25">
        <div style="text-align:center;line-height:1.25;font-weight:bold;text-indent:1pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Year
        ended</span></span></div>
        <div style="text-align:center;line-height:1.25;font-weight:bold;text-indent:1pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">December&#160;31,<br/>2022</span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px" valign="bottom">
        <div style="line-height:1.25">
        <div style="text-align:center;line-height:1.25;font-weight:bold;text-indent:1pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Year
        ended</span></span></div>
        <div style="text-align:center;line-height:1.25;font-weight:bold;text-indent:1pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">December&#160;31,<br/>2021</span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td> </tr>
  <tr>
    <td style="vertical-align:bottom;width:76%;padding-bottom:4px;background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Operating
        lease cost</span></span></div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">197</span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">216</span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
        </tr>
  </table> </div> </div> </div> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_entx_OperatingLeaseSupplementalCashFlowInformationTableTextBlock', window );">Schedule of operating lease cashflow information</a></td>
<td class="text">

<div>

<div>

<table border="0" cellpadding="0" cellspacing="0" style="width:92%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left">
  <tr>
    <td style="vertical-align:top;padding-bottom:2px" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px" valign="bottom">
        <div style="line-height:1.25">
        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Year
        ended</span></span></div>
        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">December&#160;31,<br/>2022</span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px" valign="bottom">
        <div style="line-height:1.25">
        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Year
        ended</span></span></div>
        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">December&#160;31,<br/>2021</span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td> </tr>
  <tr>
    <td style="vertical-align:top;width:76%;background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:normal"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Operating
        cash flows from operating leases</span></span></div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-weight:normal;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-weight:normal;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:normal"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">197</span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-weight:normal;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-weight:normal;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-weight:normal;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:normal"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">216</span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
        </tr>
  </table> </div> </div> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_entx_OperatingLeaseLiabilityAndOperatingLeaseRightOfUseAssetTableTextBlock', window );">Schedule of operating lease liability and operating lease right-of-use asset</a></td>
<td class="text">

<div>

<div>

<div style="line-height:1.25">

<div style="line-height:1.25">&#160;</div> </div>

<div style="margin-left:45pt">

<table border="0" cellpadding="0" cellspacing="0" style="width:92%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left">
  <tr>
    <td style="vertical-align:top;padding-bottom:2px" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px" valign="bottom">
        <div style="line-height:1.25">
        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">December&#160;31,<br/>2022</span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px" valign="bottom">
        <div style="line-height:1.25">
        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">December&#160;31,<br/>2021</span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td> </tr>
  <tr>
    <td style="vertical-align:bottom;font-weight:bold;background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="margin-right:36pt;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Operating
        Leases</span></span></div> </td>
    <td colspan="1" style="vertical-align:bottom;font-weight:normal;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align:top;font-weight:normal;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;font-weight:normal;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;font-weight:normal;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align:top;font-weight:normal;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;font-weight:normal;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align:bottom;width:76%" valign="bottom">
        <div style="margin-right:36pt;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:normal"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Operating
        lease right-of-use assets</span></span></div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-weight:normal" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-weight:normal" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%" valign="bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:normal"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">90</span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-weight:normal;white-space:nowrap" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-weight:normal" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-weight:normal" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%" valign="bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:normal"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">239</span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-weight:normal;white-space:nowrap" valign="bottom">&#160;</td> </tr>
  <tr>
    <td style="vertical-align:top;width:76%;font-weight:normal;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-weight:normal;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-weight:normal;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;font-weight:normal;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-weight:normal;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-weight:normal;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-weight:normal;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;font-weight:normal;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-weight:normal;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align:bottom;width:76%" valign="bottom">
        <div style="margin-right:36pt;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:normal"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Current
        lease liabilities</span></span></div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-weight:normal" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-weight:normal" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%" valign="bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:normal"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">91</span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-weight:normal;white-space:nowrap" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-weight:normal" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-weight:normal" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%" valign="bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:normal"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">179</span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-weight:normal;white-space:nowrap" valign="bottom">&#160;</td> </tr>
  <tr>
    <td style="vertical-align:bottom;width:76%;padding-bottom:2px;background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="margin-right:36pt;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:normal"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Non-current
        lease liabilities</span></span></div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;font-weight:normal;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);font-weight:normal;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:normal"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;font-weight:normal;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;font-weight:normal;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);font-weight:normal;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:normal"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">123</span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;font-weight:normal;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align:bottom;width:76%;font-weight:bold" valign="bottom">
        <div style="margin-right:36pt;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Total
        lease liabilities</span></span></div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-weight:normal" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-weight:normal" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%" valign="bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:normal"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">91</span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-weight:normal;white-space:nowrap" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-weight:normal" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-weight:normal" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%" valign="bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:normal"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">302</span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-weight:normal;white-space:nowrap" valign="bottom">&#160;</td> </tr>
  <tr>
    <td style="vertical-align:bottom;width:76%;font-weight:normal;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-weight:normal;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-weight:normal;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;font-weight:normal;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-weight:normal;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-weight:normal;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-weight:normal;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;font-weight:normal;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-weight:normal;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align:top;width:76%" valign="bottom">
        <div style="margin-right:36pt;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:normal"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Weighted-average
        remaining lease term (in years)</span></span></div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-weight:normal" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-weight:normal" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%" valign="bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:normal"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>0.52</span></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-weight:normal;white-space:nowrap" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-weight:normal" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-weight:normal" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%" valign="bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:normal"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">1.53</span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-weight:normal;white-space:nowrap" valign="bottom">&#160;</td> </tr>
  <tr>
    <td style="vertical-align:top;width:76%;background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="margin-right:36pt;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:normal"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Weighted-average
        discount rate</span></span></div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-weight:normal;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-weight:normal;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:normal"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">16</span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:normal"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">%</span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-weight:normal;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-weight:normal;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:normal"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">16</span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:normal"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">%</span></span></div>
        </td> </tr>
  </table> </div> </div> </div> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_entx_OperatingLeaseLiabilityAndOperatingLeaseRightOfUseAssetTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The tabular disclosure of operating lease liability and operating lease right of use asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">entx_OperatingLeaseLiabilityAndOperatingLeaseRightOfUseAssetTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>entx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_entx_OperatingLeaseSupplementalCashFlowInformationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The tabular disclosure of operating lease supplemental cash flow information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">entx_OperatingLeaseSupplementalCashFlowInformationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>entx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140398301839632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SHARE-BASED COMPENSATION (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of fair value assumptions of option granted using Black-Scholes option-pricing model</a></td>
<td class="text">

<div>

<div>

<div>

<div style="margin-left:54pt">

<table border="0" cellpadding="0" cellspacing="0" style="width:85%">
  <tr>
    <td style="vertical-align:top;padding-bottom:2px" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px" valign="bottom">
        <div style="line-height:1.25">
        <div style="text-align:center;text-indent:0.05pt;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span>2022</span></span></span></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px" valign="bottom">
        <div style="line-height:1.25">
        <div style="text-align:center;text-indent:0.05pt;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span>2021</span></span></span></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td> </tr>
  <tr>
    <td style="vertical-align:top;padding-bottom:4px;background-color:rgb(204, 238, 255);width:70%" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span>Exercise
        price</span></span></span></span></span></div> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:4px;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);width:1%" valign="bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25">&#160;</div> </div> </td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);width:12%" valign="bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span>$1.40-$2.86</span></span></span></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:4px;background-color:rgb(204, 238, 255);white-space:nowrap;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:4px;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);width:1%" valign="bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25">&#160;</div> </div> </td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);width:12%" valign="bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span>$1.24-$3.61</span></span></span></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:4px;background-color:rgb(204, 238, 255);white-space:nowrap;width:1%" valign="bottom">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align:top;padding-bottom:4px;width:70%" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span>Dividend
        yield</span></span></span></span></span></div> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:4px;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;border-bottom:4px double rgb(0, 0, 0);width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;border-bottom:4px double rgb(0, 0, 0);width:12%" valign="bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span>-</span></span></span></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:4px;white-space:nowrap;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:4px;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;border-bottom:4px double rgb(0, 0, 0);width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;border-bottom:4px double rgb(0, 0, 0);width:12%" valign="bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span>-</span></span></span></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:4px;white-space:nowrap;width:1%" valign="bottom">&#160;</td> </tr>
  <tr>
    <td style="vertical-align:top;padding-bottom:4px;background-color:rgb(204, 238, 255);width:70%" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span>Expected
        volatility</span></span></span></span></span></div> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:4px;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);width:12%" valign="bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span>69%-70.2%</span></span></span></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:4px;background-color:rgb(204, 238, 255);white-space:nowrap;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:4px;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);width:12%" valign="bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span>68%-71%</span></span></span></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:4px;background-color:rgb(204, 238, 255);white-space:nowrap;width:1%" valign="bottom">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align:top;padding-bottom:4px;width:70%" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span>Risk-free
        interest rate</span></span></span></span></span></div> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:4px;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;border-bottom:4px double rgb(0, 0, 0);width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;border-bottom:4px double rgb(0, 0, 0);width:12%" valign="bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span>1.35%-3.36%</span></span></span></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:4px;white-space:nowrap;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:4px;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;border-bottom:4px double rgb(0, 0, 0);width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;border-bottom:4px double rgb(0, 0, 0);width:12%" valign="bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span>1.11%-0.94%</span></span></span></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:4px;white-space:nowrap;width:1%" valign="bottom">&#160;</td> </tr>
  <tr>
    <td style="vertical-align:top;padding-bottom:4px;background-color:rgb(204, 238, 255);width:70%" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span>Expected
        life - in years</span></span></span></span></span></div> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:4px;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);width:12%" valign="bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span>5.5-6.5</span></span></span></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:4px;background-color:rgb(204, 238, 255);white-space:nowrap;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:4px;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);width:12%" valign="bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span>6.1-5.8</span></span></span></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:4px;background-color:rgb(204, 238, 255);white-space:nowrap;width:1%" valign="bottom">&#160;</td>
        </tr>
  </table> </div> </div> </div> </div> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Schedule of option activity</a></td>
<td class="text">

<div>

<div style="line-height:1.25">

<div style="margin:0pt">&#160;</div> </div>

<div>

<div style="margin-left:54pt">

<table cellpadding="0" cellspacing="0" style="color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:left;width:92%">
  <tr>
    <td style="vertical-align:top;padding-bottom:2px" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td>
    <td colspan="6" style="vertical-align:top;border-bottom:#000000 solid 2px" valign="bottom">
        <div style="line-height:1.25">
        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span>2022</span></span></span></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td>
    <td colspan="6" style="vertical-align:top;border-bottom:#000000 solid 2px" valign="bottom">
        <div style="line-height:1.25">
        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span>2021</span></span></span></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td> </tr>
  <tr>
    <td style="vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px" valign="bottom">
        <div style="line-height:1.25">
        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span>Number
        of</span></span></span></span></span></div>
        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span>options</span></span></span></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px" valign="bottom">
        <div style="line-height:1.25">
        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span>Weighted</span></span></span></span></span></div>
        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span>average</span></span></span></span></span></div>
        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span>exercise</span></span></span></span></span></div>
        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span>price</span></span></span></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px" valign="bottom">
        <div style="line-height:1.25">
        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span>Number
        of</span></span></span></span></span></div>
        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span>options</span></span></span></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px" valign="bottom">
        <div style="line-height:1.25">
        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span>Weighted</span></span></span></span></span></div>
        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span>average</span></span></span></span></span></div>
        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span>exercise</span></span></span></span></span></div>
        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span>price</span></span></span></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td> </tr>
  <tr>
    <td style="vertical-align:middle;width:52%;background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="text-indent:-1.3pt;margin-left:1.3pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span>Outstanding
        at beginning of the year</span></span></span></span></span></div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span>4,316,859</span></span></span></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span>$</span></span></span></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span>3.63</span></span></span></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span>2,570,109</span></span></span></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span>$</span></span></span></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span>4.85</span></span></span></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align:middle;width:52%" valign="bottom">
        <div style="text-indent:-1.3pt;margin-left:1.3pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span>Granted</span></span></span></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span>2,458,863</span></span></span></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span>2.29</span></span></span></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span>1,975,586</span></span></span></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">
        <div style="line-height:1.25">&#160;</div> </td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span>1.95</span></span></span></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td> </tr>
  <tr>
    <td style="vertical-align:middle;width:52%;background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="text-indent:-1.3pt;margin-left:1.3pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span>Exercised</span></span></span></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span>(5,511</span></span></span></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span>)</span></span></span></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span>2.14</span></span></span></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span>(177,710</span></span></span></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span>)</span></span></span></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span>2.37</span></span></span></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align:middle;width:52%" valign="bottom">
        <div style="text-indent:-1.3pt;margin-left:1.3pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span>Forfeited</span></span></span></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span>(902,009</span></span></span></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span>)</span></span></span></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span>1.41</span></span></span></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span>(16,660</span></span></span></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span>)</span></span></span></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span>2.37</span></span></span></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td> </tr>
  <tr>
    <td style="vertical-align:middle;width:52%;padding-bottom:2px;background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="text-indent:-8.4pt;margin-left:8.4pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span>Expired</span></span></span></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span>(135,115</span></span></span></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span>)</span></span></span></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span>3.80</span></span></span></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span>(34,466</span></span></span></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span>)</span></span></span></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span>4.00</span></span></span></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align:middle;width:52%;padding-bottom:4px" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span>Outstanding
        at end of the year</span></span></span></span></span></div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0)" valign="bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span>5,733,087</span></span></span></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;white-space:nowrap" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0)" valign="bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span>$</span></span></span></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0)" valign="bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span>3.30</span></span></span></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;white-space:nowrap" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0)" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span>4,316,859</span></span></span></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;white-space:nowrap" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0)" valign="bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span>$</span></span></span></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0)" valign="bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span>3.63</span></span></span></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;white-space:nowrap" valign="bottom">&#160;</td> </tr>
  <tr>
    <td style="vertical-align:middle;width:52%;padding-bottom:4px;background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span>Exercisable
        at end of the year</span></span></span></span></span></div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span>3,165,677</span></span></span></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span>$</span></span></span></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span>4.06</span></span></span></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span>2,068,067</span></span></span></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span>$</span></span></span></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span>5.39</span></span></span></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
        </tr>
  </table> </div> </div> </div> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock', window );">Schedule of outstanding and exercisable options of ordinary shares</a></td>
<td class="text">

<table border="0" cellpadding="0" cellspacing="0" style="color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:left;width:85%">
  <tr>
    <td colspan="18" rowspan="1" style="vertical-align:top;padding-bottom:2px;border-bottom:2px solid black" valign="bottom">
        <div style="line-height:1.25">
        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span>December
        31, 2022</span></span></span></span></span></div> </div> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td> </tr>
  <tr>
    <td colspan="10" style="vertical-align:top;border-bottom:#000000 solid 2px" valign="bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><strong>Options
        outstanding</strong></span></span></span></span></span></div> </div> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;white-space:nowrap;text-align:center" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center" valign="bottom">&#160;</td>
    <td colspan="6" style="vertical-align:top;border-bottom:#000000 solid 2px" valign="bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><strong>Options
        exercisable</strong></span></span></span></span></span></div> </div> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td> </tr>
  <tr>
    <td colspan="2" style="vertical-align:top" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;white-space:nowrap" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align:top" valign="bottom">
        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span>Number
        of</span></span></span></span></span></div> </td>
    <td colspan="1" style="vertical-align:bottom;white-space:nowrap" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align:top" valign="bottom">
        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span>Weighted</span></span></span></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;white-space:nowrap" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align:top" valign="bottom">
        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span>Number
        of</span></span></span></span></span></div> </td>
    <td colspan="1" style="vertical-align:bottom;white-space:nowrap" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align:top" valign="bottom">
        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span>Weighted</span></span></span></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;white-space:nowrap" valign="bottom">&#160;</td> </tr>
  <tr>
    <td colspan="2" style="vertical-align:top" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;white-space:nowrap" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align:top" valign="bottom">
        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span>options</span></span></span></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;white-space:nowrap" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align:top" valign="bottom">
        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span>Average</span></span></span></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;white-space:nowrap" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align:top" valign="bottom">
        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span>options</span></span></span></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;white-space:nowrap" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align:top" valign="bottom">
        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span>Average</span></span></span></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;white-space:nowrap" valign="bottom">&#160;</td> </tr>
  <tr>
    <td colspan="2" style="vertical-align:top" valign="bottom">
        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span>Exercise</span></span></span></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;white-space:nowrap" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align:top" valign="bottom">
        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span>outstanding</span></span></span></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;white-space:nowrap" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align:top" valign="bottom">
        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span>Remaining</span></span></span></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;white-space:nowrap" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align:top" valign="bottom">
        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span>exercisable</span></span></span></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;white-space:nowrap" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align:top" valign="bottom">
        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span>Remaining</span></span></span></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;white-space:nowrap" valign="bottom">&#160;</td> </tr>
  <tr>
    <td colspan="2" style="vertical-align:top" valign="bottom">
        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span>prices
        per</span></span></span></span></span></div> </td>
    <td colspan="1" style="vertical-align:bottom;white-space:nowrap" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align:top" valign="bottom">
        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span>at
        end of</span></span></span></span></span></div> </td>
    <td colspan="1" style="vertical-align:bottom;white-space:nowrap" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align:top" valign="bottom">
        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span>Contractual</span></span></span></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;white-space:nowrap" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align:top" valign="bottom">
        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span>at
        end of</span></span></span></span></span></div> </td>
    <td colspan="1" style="vertical-align:bottom;white-space:nowrap" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align:top" valign="bottom">
        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span>contractual</span></span></span></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;white-space:nowrap" valign="bottom">&#160;</td> </tr>
  <tr>
    <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px" valign="bottom">
        <div style="line-height:1.25">
        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span>share
        (USD)</span></span></span></span></span></div> </div> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px" valign="bottom">
        <div style="line-height:1.25">
        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span>Year</span></span></span></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px" valign="bottom">
        <div style="line-height:1.25">
        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span>Life</span></span></span></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px" valign="bottom">
        <div style="line-height:1.25">
        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span>year</span></span></span></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px" valign="bottom">
        <div style="line-height:1.25">
        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span>Life</span></span></span></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td> </tr>
  <tr style="background-color:rgb(204, 238, 255)">
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span>-</span></span></span></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span>1,560</span></span></span></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span>0.09</span></span></span></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span>1,560</span></span></span></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span>0.09</span></span></span></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
        </tr>
  <tr style="background-color:rgb(255, 255, 255)">
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(255, 255, 255)" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span>1.24</span></span></span></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(255, 255, 255)" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span>492,831</span></span></span></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(255, 255, 255)" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span>1.54</span></span></span></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(255, 255, 255)" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span>492,831</span></span></span></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(255, 255, 255)" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span>1.54</span></span></span></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
        </tr>
  <tr style="background-color:rgb(204, 238, 255)">
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span>1.40</span></span></span></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span>600,000
        </span></span></span></span></span></div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span>9.54</span></span></span></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span>-</span></span></span></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span>-</span></span></span></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
        </tr>
  <tr style="background-color:rgb(255, 255, 255)">
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(255, 255, 255)" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span>2.02</span></span></span></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(255, 255, 255)" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span>500,000</span></span></span></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(255, 255, 255)" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span>9.37</span></span></span></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(255, 255, 255)" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span>-</span></span></span></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(255, 255, 255)" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span>-</span></span></span></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
        </tr>
  <tr style="background-color:rgb(204, 238, 255)">
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span>2.14</span></span></span></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span>400,775</span></span></span></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span>7.26</span></span></span></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span>277,994</span></span></span></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span>7.26</span></span></span></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
        </tr>
  <tr style="background-color:rgb(255, 255, 255)">
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(255, 255, 255)" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span>2.53</span></span></span></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(255, 255, 255)" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span>33,638</span></span></span></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(255, 255, 255)" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span>6.89</span></span></span></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(255, 255, 255)" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><span><span>33,638</span></span></span></span></span></span></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(255, 255, 255)" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span>6.89</span></span></span></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
        </tr>
  <tr style="background-color:rgb(204, 238, 255)">
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span>2.57</span></span></span></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span>205,500</span></span></span></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span>9.33</span></span></span></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span>-</span></span></span></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span>-</span></span></span></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
        </tr>
  <tr style="background-color:rgb(255, 255, 255)">
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(255, 255, 255)" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span>2.815</span></span></span></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(255, 255, 255)" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span>1,003,863</span></span></span></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(255, 255, 255)" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span>9.01</span></span></span></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(255, 255, 255)" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>376,447</span></span></span></span></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(255, 255, 255)" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span>9.01</span></span></span></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
        </tr>
  <tr style="background-color:rgb(204, 238, 255)">
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span>2.86</span></span></span></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span>135,000</span></span></span></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span>9.25</span></span></span></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span>-</span></span></span></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span>-</span></span></span></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
        </tr>
  <tr style="background-color:rgb(255, 255, 255)">
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(255, 255, 255)" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span>3.15</span></span></span></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(255, 255, 255)" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span>345,000</span></span></span></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(255, 255, 255)" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span>8.30</span></span></span></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(255, 255, 255)" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span>123,125</span></span></span></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(255, 255, 255)" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span>8.30</span></span></span></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
        </tr>
  <tr style="background-color:rgb(204, 238, 255)">
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;padding-bottom:2px;background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span>3.61</span></span></span></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;white-space:nowrap;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span>250,868</span></span></span></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;white-space:nowrap;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;padding-bottom:2px;background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span>8.27</span></span></span></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;white-space:nowrap;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span>101,059</span></span></span></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;white-space:nowrap;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;padding-bottom:2px;background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span>8.27</span></span></span></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;white-space:nowrap;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
        </tr>
  <tr style="background-color:rgb(255, 255, 255)">
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;padding-bottom:2px;background-color:rgb(255, 255, 255)" valign="bottom">
        <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span style="line-height:107%">3.68</span></span></span></span></span></p>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;white-space:nowrap;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(255, 255, 255)" valign="bottom">
        <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span style="line-height:107%">294,580</span></span></span></span></span></p>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;white-space:nowrap;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;padding-bottom:2px;background-color:rgb(255, 255, 255)" valign="bottom">
        <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span style="line-height:107%">0.26</span></span></span></span></span></p>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;white-space:nowrap;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(255, 255, 255)" valign="bottom">
        <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span style="line-height:107%">294,580</span></span></span></span></span></p>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;white-space:nowrap;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;padding-bottom:2px;background-color:rgb(255, 255, 255)" valign="bottom">
        <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span style="line-height:107%">0.26</span></span></span></span></span></p>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;white-space:nowrap;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
        </tr>
  <tr style="background-color:rgb(204, 238, 255)">
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;padding-bottom:2px;background-color:rgb(204, 238, 255)" valign="bottom">
        <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span style="line-height:107%">3.97</span></span></span></span></span></p>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;white-space:nowrap;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">
        <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span style="line-height:107%">247,082</span></span></span></span></span></p>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;white-space:nowrap;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;padding-bottom:2px;background-color:rgb(204, 238, 255)" valign="bottom">
        <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span style="line-height:107%">6.05</span></span></span></span></span></p>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;white-space:nowrap;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">
        <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span style="line-height:107%">242,053</span></span></span></span></span></p>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;white-space:nowrap;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;padding-bottom:2px;background-color:rgb(204, 238, 255)" valign="bottom">
        <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span style="line-height:107%">6.05</span></span></span></span></span></p>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;white-space:nowrap;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
        </tr>
  <tr style="background-color:rgb(255, 255, 255)">
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;padding-bottom:2px;background-color:rgb(255, 255, 255)" valign="bottom">
        <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span style="line-height:107%">6.31</span></span></span></span></span></p>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;white-space:nowrap;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid black;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid black;background-color:rgb(255, 255, 255)" valign="bottom">
        <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span style="line-height:107%">1,222,390</span></span></span></span></span></p>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;white-space:nowrap;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;padding-bottom:2px;background-color:rgb(255, 255, 255)" valign="bottom">
        <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span style="line-height:107%">3.08</span></span></span></span></span></p>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;white-space:nowrap;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid black;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid black;background-color:rgb(255, 255, 255)" valign="bottom">
        <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span style="line-height:107%">1,222,390</span></span></span></span></span></p>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;white-space:nowrap;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;padding-bottom:2px;background-color:rgb(255, 255, 255)" valign="bottom">
        <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span style="line-height:107%">3.08</span></span></span></span></span></p>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;white-space:nowrap;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
        </tr>
  <tr style="background-color:rgb(204, 238, 255)">
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;padding-bottom:4px;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;white-space:nowrap;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span>5,733,087</span></span></span></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;white-space:nowrap;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;padding-bottom:4px;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;white-space:nowrap;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span>3,165,677</span></span></span></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;white-space:nowrap;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;padding-bottom:4px;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;white-space:nowrap;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
        </tr>
  </table> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Schedule of of share-based compensation on statements of operations</a></td>
<td class="text">

<div>

<div style="text-align:center">

<div style="clear:both;margin-top:0pt;margin-bottom:0pt">

<div style="text-align:center"> <div style="font-size:10pt;display:inline"> <div style="font-family:Times New Roman,Times,serif;display:inline">
<div style="color:#000000;font-weight:normal;font-style:normal;display:inline">

<div>

<div>

<div style="margin-left:45pt">

<table border="0" cellpadding="0" cellspacing="0" style="color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:left;width:85%">
  <tr>
    <td style="vertical-align:top;padding-bottom:2px" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px" valign="bottom">
        <div style="line-height:1.25">
        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span>2022</span></span></span></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px" valign="bottom">
        <div style="line-height:1.25">
        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span>2021</span></span></span></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td> </tr>
  <tr>
    <td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="text-align:justify;text-indent:-12.6pt;margin-left:12.6pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span>Cost
        of revenues</span></span></span></span></span></div> </td>
    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span>14</span></span></span></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span>102</span></span></span></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align:bottom;width:76%" valign="bottom">
        <div style="text-align:justify;text-indent:-12.6pt;margin-left:12.6pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span>Research
        and development expenses</span></span></span></span></span></div> </td>
    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span>708</span></span></span></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span>661</span></span></span></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td> </tr>
  <tr>
    <td style="vertical-align:bottom;width:76%;padding-bottom:2px;background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="text-align:justify;text-indent:-12.6pt;margin-left:12.6pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span>General
        and administrative</span></span></span></span></span></div> </td>
    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span>1,525</span></span></span></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span>1,098</span></span></span></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align:bottom;width:76%;padding-bottom:4px" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;padding-bottom:4px" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0)" valign="bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span>2,247</span></span></span></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;white-space:nowrap" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;padding-bottom:4px" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0)" valign="bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span>1,861</span></span></span></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;white-space:nowrap" valign="bottom">&#160;</td> </tr>
  </table> </div> </div> </div> </div> </div> </div> </div> </div> </div> </div> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of number, weighted-average exercise price or conversion ratio, aggregate intrinsic value, and weighted-average remaining contractual term for outstanding and exercisable options that are fully vested and expected to vest. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140398298648128">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAX (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock', window );">Schedule of loss (income) before income taxes</a></td>
<td class="text">

<div>

<p style="margin:0pt;font-size:10pt">&#160;</p>

<div>

<div>

<div style="margin-left:47px">

<table border="0" cellpadding="0" cellspacing="0" style="color:#000000;float:left;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:left;width:85%">
  <tr>
    <td style="vertical-align:top;padding-bottom:2px" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td>
    <td colspan="6" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);font-weight:bold">
        <div style="line-height:1.25">
        <div style="text-align:center;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Year
        ended December 31</span></span></div> </div> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td> </tr>
  <tr>
    <td style="vertical-align:top;padding-bottom:2px" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0)">
        <div style="line-height:1.25">
        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2022</span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px">&#160;</td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0)">
        <div style="line-height:1.25">
        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2021</span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td> </tr>
  <tr>
    <td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="text-indent:-12.6pt;margin-left:12.6pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Entera
        Bio Ltd.</span></span></div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">12,997</span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">12,362</span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align:bottom;width:76%;padding-bottom:2px" valign="bottom">
        <div style="text-indent:-12.6pt;margin-left:12.6pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Entera
        Bio Inc.</span></span></div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0)" valign="bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(65</span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;white-space:nowrap" valign="bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0)" valign="bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(116</span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;white-space:nowrap" valign="bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
        </div> </td> </tr>
  <tr>
    <td style="vertical-align:bottom;width:76%;padding-bottom:2px;background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="text-indent:-12.6pt;margin-left:12.6pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Total
        loss before taxes</span></span></div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">12,934</span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">12,246</span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
        </tr>
  </table> </div>

<div style="line-height:1.25;clear:both">

<div style="line-height:1.25">&#160;</div> </div> </div> </div> </div> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock', window );">Schedule of tax expenses</a></td>
<td class="text">

<table border="0" cellpadding="0" cellspacing="0" style="color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:left;width:85%">
  <tr>
    <td style="vertical-align:top;padding-bottom:2px" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td>
    <td colspan="6" style="vertical-align:bottom;border-bottom:#000000 solid 2px" valign="bottom">
        <div style="line-height:1.25;font-weight:bold">
        <div style="text-align:center;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Year
        ended December 31</span></span></div> </div> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td> </tr>
  <tr>
    <td style="vertical-align:top;padding-bottom:2px" valign="bottom">
        <div style="line-height:1.25">&#160;</div> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0)" valign="bottom">
        <div style="line-height:1.25;font-weight:bold">
        <div style="text-align:center;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2022</span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-weight:bold;white-space:nowrap" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-weight:bold" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0)" valign="bottom">
        <div style="line-height:1.25;font-weight:bold">
        <div style="text-align:center;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2021</span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td> </tr>
  <tr>
    <td rowspan="1" style="vertical-align:top;background-color:rgb(204, 238, 255);height:15px" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Current:</span></span></div>
        </td>
    <td colspan="1" rowspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);height:15px" valign="bottom">&#160;</td>
    <td colspan="2" rowspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);height:15px" valign="bottom">&#160;</td>
    <td colspan="1" rowspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);white-space:nowrap;height:15px" valign="bottom">&#160;</td>
    <td colspan="1" rowspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);height:15px" valign="bottom">&#160;</td>
    <td colspan="2" rowspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);height:15px" valign="bottom">&#160;</td>
    <td colspan="1" rowspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);white-space:nowrap;height:15px" valign="bottom">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align:bottom;width:76%;padding-bottom:2px;height:15px" valign="bottom">
        <div style="text-indent:-12.6pt;margin-left:12.6pt;line-height:1.25;margin-top:0px;margin-bottom:0px"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Subsidiary:</span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;height:15px" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);height:15px" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);height:15px" valign="bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(37</span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:1pt;white-space:nowrap;height:15px" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;height:15px" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);height:15px" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);height:15px" valign="bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">158</span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;white-space:nowrap;height:15px" valign="bottom">&#160;</td> </tr>
  <tr>
    <td style="vertical-align:bottom;width:76%;padding-bottom:2px;background-color:rgb(204, 238, 255);height:15px" valign="bottom">
        <div style="text-indent:-12.6pt;margin-left:12.6pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Total
        current income tax</span></span></div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);height:15px" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);height:15px" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);height:15px" valign="bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(37</span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:1pt;background-color:rgb(204, 238, 255);white-space:nowrap;height:15px" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);height:15px" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);height:15px" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);height:15px" valign="bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">158</span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);white-space:nowrap;height:15px" valign="bottom">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align:bottom;width:76%;height:15px" valign="bottom">
        <div style="text-indent:-12.6pt;margin-left:12.6pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Deferred
        income&#160;taxes</span></span></div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;height:15px" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;height:15px" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;height:15px" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">174</span></span></td>
    <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap;height:15px" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;height:15px" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;height:15px" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;height:15px" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(217</span></span></td>
    <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap;height:15px" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></td>
        </tr>
  <tr>
    <td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255);padding-bottom:2px;height:15px" valign="bottom">
        <div style="text-indent:-12.6pt;margin-left:12.6pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Total
        deferred income taxes</span></span></div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);padding-bottom:2px;height:15px" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);border-bottom:2px solid rgb(0, 0, 0);height:15px" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);border-bottom:2px solid rgb(0, 0, 0);height:15px" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">174</span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);padding-bottom:2px;white-space:nowrap;height:15px" valign="bottom">
        <div style="line-height:1.25">&#160;</div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);padding-bottom:2px;height:15px" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);border-bottom:2px solid rgb(0, 0, 0);height:15px" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);border-bottom:2px solid rgb(0, 0, 0);height:15px" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(217</span></span></td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);padding-bottom:1pt;white-space:nowrap;height:15px" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></td>
        </tr>
  <tr>
    <td style="vertical-align:baseline;width:76%;padding-bottom:4px;height:15px">
        <div style="text-indent:-12.6pt;margin-left:12.6pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Total
        income tax expense (benefit)&#160;</span></span></div> </td>
    <td colspan="1" style="vertical-align:baseline;width:1%;padding-bottom:4px;height:15px">&#160;</td>
    <td colspan="1" style="vertical-align:baseline;width:1%;border-bottom:4px double rgb(0, 0, 0);height:15px">&#160;</td>
    <td colspan="1" style="vertical-align:baseline;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);height:15px">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">137</span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:baseline;width:1%;padding-bottom:4px;white-space:nowrap;height:15px">
        <div style="line-height:1.25">
        <div style="line-height:1.25">&#160;</div> </div> </td>
    <td colspan="1" style="vertical-align:baseline;width:1%;padding-bottom:4px;height:15px">&#160;</td>
    <td colspan="1" style="vertical-align:baseline;width:1%;border-bottom:4px double rgb(0, 0, 0);height:15px">&#160;</td>
    <td colspan="1" style="vertical-align:baseline;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);height:15px">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(59</span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:baseline;width:1%;padding-bottom:1pt;white-space:nowrap;height:15px"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></td>
        </tr>
  </table>

<p style="margin:0pt">&#160;</p> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Schedule of deferred income taxes</a></td>
<td class="text">

<div style="margin-left:47px">

<div>

<div>

<div>

<table border="0" cellpadding="0" cellspacing="0" style="color:#000000;float:left;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:left;width:85%">
  <tr>
    <td rowspan="1" style="vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td>
    <td colspan="1" rowspan="1" style="vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td>
    <td colspan="6" rowspan="1" style="vertical-align:bottom;border-bottom:#000000 solid 2px" valign="bottom">
        <div style="text-align:center;line-height:1.25;font-weight:bold;text-indent:1pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>December
        31,</span></span></span></span></div> </td>
    <td colspan="1" rowspan="1" style="vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td> </tr>
  <tr>
    <td rowspan="1" style="vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td>
    <td colspan="1" rowspan="1" style="vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td>
    <td colspan="2" rowspan="1" style="vertical-align:bottom;border-bottom:#000000 solid 2px" valign="bottom">
        <div style="text-align:center;line-height:1.25;font-weight:bold;text-indent:4pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>2022</span></span></span></span></div>
        </td>
    <td colspan="1" rowspan="1" style="vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
    <td colspan="1" rowspan="1" style="text-align:center;font-weight:bold;vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td>
    <td colspan="2" rowspan="1" style="vertical-align:bottom;text-align:center;font-weight:bold;border-bottom:#000000 solid 2px" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>2021</span></span></span></span></td>
    <td colspan="1" rowspan="1" style="font-weight:bold;vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
        </tr>
  <tr>
    <td rowspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Deferred
        tax assets:</span></span></span></span></div> </td>
    <td colspan="1" rowspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="2" rowspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" rowspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap" valign="bottom">&#160;</td>
    <td colspan="1" rowspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="2" rowspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" rowspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap" valign="bottom">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align:bottom;width:76%" valign="bottom">
        <div style="text-indent:-35.1pt;margin-left:35.1pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Net
        operating loss carry forward</span></span></span></span></div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>15,428</span></span></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>12,895</span></span></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td> </tr>
  <tr>
    <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:76%" valign="bottom">
        <div style="text-indent:-35.1pt;margin-left:35.1pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Research
        and development</span></span></span></span></div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:9%" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>1,225</span></span></span></span></div>
        </td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:9%" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>1,319</span></span></span></span></div>
        </td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align:bottom;width:76%" valign="bottom">
        <div style="text-indent:-35.1pt;margin-left:35.1pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Share-based
        compensation</span></span></span></span></div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>877</span></span></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>876</span></span></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td> </tr>
  <tr>
    <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:76%" valign="bottom">
        <div style="text-indent:-35.1pt;margin-left:35.1pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Other</span></span></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:9%" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>158</span></span></span></span></div>
        </td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:9%" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>152</span></span></span></span></div>
        </td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align:bottom;width:76%;padding-bottom:2px" valign="bottom">
        <div style="text-indent:-35.1pt;margin-left:35.1pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Net
        deferred tax assets before valuation allowance</span></span></span></span></div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0)" valign="bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>17,688</span></span></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0)" valign="bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>15,242</span></span></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td> </tr>
  <tr>
    <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:76%;padding-bottom:2px" valign="bottom">
        <div style="text-indent:-35.1pt;margin-left:35.1pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Valuation
        allowance</span></span></span></span></div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0)" valign="bottom">&#160;</td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0)" valign="bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>(17,645</span></span></span></span></div>
        </div> </td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;padding-bottom:2px;white-space:nowrap" valign="bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>)</span></span></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0)" valign="bottom">&#160;</td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0)" valign="bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>(15,025</span></span></span></span></div>
        </div> </td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;padding-bottom:2px;white-space:nowrap" valign="bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>)</span></span></span></span></div>
        </div> </td> </tr>
  <tr>
    <td style="vertical-align:bottom;width:76%;padding-bottom:4px" valign="bottom">
        <div style="text-indent:-35.1pt;margin-left:35.1pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Net
        deferred tax assets</span></span></span></span></div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0)" valign="bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>43</span></span></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;white-space:nowrap" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0)" valign="bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>217</span></span></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;white-space:nowrap" valign="bottom">&#160;</td> </tr>
  </table> </div>

<div style="line-height:1.25;clear:both">&#160;</div> </div> </div> </div> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SummaryOfValuationAllowanceTextBlock', window );">Schedule of rollforward of valuation allowance</a></td>
<td class="text">

<div style="margin-left:36pt">

<table border="0" cellpadding="0" cellspacing="0" style="color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:left;width:85%">
  <tr style="background-color:rgb(204, 238, 255)">
    <td style="vertical-align:top;background-color:rgb(204, 238, 255);width:89%" valign="bottom">
        <div style="line-height:1.25"> <div style="font-size:10pt;display:inline"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><span style="line-height:107%">Balance
        at January 1, 2021</span></span></span></span></span></span></span></div> </div> </td>
    <td colspan="1" style="vertical-align:bottom;border-bottom:2px solid black;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid black;background-color:rgb(204, 238, 255);width:9%" valign="bottom">
        <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong><span><span><span><span><span style="line-height:107%">12,420</span></span></span></span></span></strong></span></span></p>
        </td>
    <td colspan="1" style="vertical-align:bottom;white-space:nowrap;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
        </tr>
  <tr style="background-color:rgb(255, 255, 255)">
    <td style="vertical-align:top;background-color:rgb(255, 255, 255)" valign="bottom">
        <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><span style="line-height:107%">Additions</span></span></span></span></span></span></span></p>
        </td>
    <td colspan="1" style="vertical-align:bottom;border-bottom:4px double black;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:4px double black;background-color:rgb(255, 255, 255);width:9%" valign="bottom">
        <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><span style="line-height:107%">2,605</span></span></span></span></span></span></span></p>
        </td>
    <td colspan="1" style="vertical-align:bottom;white-space:nowrap;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td> </tr>
  <tr style="background-color:rgb(204, 238, 255)">
    <td style="vertical-align:top;background-color:rgb(204, 238, 255)" valign="bottom">
        <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><span style="line-height:107%">Balance
        at January 1, 2022</span></span></span></span></span></span></span></p> </td>
    <td colspan="1" style="vertical-align:bottom;border-bottom:4px double black;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:4px double black;background-color:rgb(204, 238, 255);width:9%" valign="bottom">
        <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong><span><span><span><span><span style="line-height:107%">15,025</span></span></span></span></span></strong></span></span></p>
        </td>
    <td colspan="1" style="vertical-align:bottom;white-space:nowrap;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td> </tr>
  <tr style="background-color:rgb(255, 255, 255)">
    <td style="vertical-align:top;background-color:rgb(255, 255, 255)" valign="bottom">
        <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><span style="line-height:107%">Additions</span></span></span></span></span></span></span></p>
        </td>
    <td colspan="1" style="vertical-align:bottom;border-bottom:4px double black;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:4px double black;background-color:rgb(255, 255, 255);width:9%" valign="bottom">
        <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><span style="line-height:107%">2,620</span></span></span></span></span></span></span></p>
        </td>
    <td colspan="1" style="vertical-align:bottom;white-space:nowrap;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td> </tr>
  <tr style="background-color:rgb(204, 238, 255)">
    <td style="vertical-align:top;background-color:rgb(204, 238, 255)" valign="bottom">
        <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><span style="line-height:107%">Balance
        at December 31, 2022</span></span></span></span></span></span></span></p> </td>
    <td colspan="1" style="vertical-align:bottom;border-bottom:4px double black;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:4px double black;background-color:rgb(204, 238, 255);width:9%" valign="bottom">
        <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong><span><span><span><span><span style="line-height:107%">17,645</span></span></span></span></span></strong></span></span></p>
        </td>
    <td colspan="1" style="vertical-align:bottom;white-space:nowrap;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td> </tr>
  </table>

<p style="margin:0pt">&#160;</p> </div> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of income before income tax between domestic and foreign jurisdictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SummaryOfValuationAllowanceTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of valuation allowances to reduce deferred tax assets to net realizable value, including identification of the deferred tax asset more likely than not will not be fully realized and the corresponding amount of the valuation allowance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SummaryOfValuationAllowanceTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140398302852928">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_entx_SupplementaryFinancialStatementInformationAbstract', window );"><strong>Supplementary Financial Statement Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock', window );">Schedule of accounts payable and accrued liabilities</a></td>
<td class="text">

<div>

<div style="line-height:1.25">&#160;</div>

<table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left;color:#000000;width:100%">
  <tr>
    <td style="vertical-align:top;padding-bottom:2px" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td>
    <td colspan="6" style="vertical-align:top;border-bottom:#000000 solid 2px" valign="bottom">
        <div style="line-height:1.25">
        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">December
        31,</span></span></div> </div> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td> </tr>
  <tr>
    <td style="vertical-align:bottom;padding-bottom:2px" valign="bottom">
        <div style="line-height:1.25;font-weight:bold">&#160;</div> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align:top;border-bottom:2px solid rgb(0, 0, 0)" valign="bottom">
        <div style="line-height:1.25">
        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2022</span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align:top;border-bottom:2px solid rgb(0, 0, 0)" valign="bottom">
        <div style="line-height:1.25">
        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2021</span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td> </tr>
  <tr>
    <td rowspan="1" style="vertical-align:top;width:76%;background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Accrued
        expenses and other payables:</span></span></div> </td>
    <td colspan="1" rowspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" rowspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" rowspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" rowspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
    <td colspan="1" rowspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" rowspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" rowspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" rowspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align:top;width:76%" valign="bottom">
        <div style="text-align:justify;text-indent:14.2pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Employees
        and employees related</span></span></div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">154</span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">147</span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td> </tr>
  <tr>
    <td style="vertical-align:top;width:76%;background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="text-align:justify;text-indent:14.2pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Income
        tax</span></span></div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">134</span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align:top;width:76%" valign="bottom">
        <div style="text-align:justify;text-indent:14.2pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Provision
        for vacation</span></span></div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">146</span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">308</span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td> </tr>
  <tr>
    <td style="vertical-align:top;width:76%;padding-bottom:2px;background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="text-align:justify;line-height:1.25;margin-left:14.2pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Accrued
        expenses</span></span></div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">933</span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2,212</span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align:top;width:76%;padding-bottom:2px" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0)" valign="bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">1,233</span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0)" valign="bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2,801</span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td> </tr>
  </table> </div> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_entx_SupplementaryFinancialStatementInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">entx_SupplementaryFinancialStatementInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>entx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140398302685984">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>GENERAL (Detail Textuals)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>&#8362; / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>&#8362; / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_entx_GeneralLineItems', window );"><strong>General [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Ordinary share, par value | &#8362; / shares</a></td>
<td class="nump">&#8362; 0.0000769<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8362; 0.0000769<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (95,497)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (82,426)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_entx_GeneralLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">entx_GeneralLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>entx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140398296169776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SIGNIFICANT ACCOUNTING POLICIES (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computer equipment [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful life</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computer equipment [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful life</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember', window );">Office furniture [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful life</a></td>
<td class="text">10 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=entx_LaboratoryEquipmentMember', window );">Laboratory equipment [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful life</a></td>
<td class="text">7 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=entx_LaboratoryEquipmentMember', window );">Laboratory equipment [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful life</a></td>
<td class="text">10 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=entx_LaboratoryEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=entx_LaboratoryEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140398389011504">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SIGNIFICANT ACCOUNTING POLICIES (Detail Textuals) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jan. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_entx_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SeveranceCosts1', window );">Severance payment expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 132<span></span>
</td>
<td class="nump">$ 137<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_entx_SeveranceExpenses', window );">Severance expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 132<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Number of antidilutive securities excluded from computation of earnings per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,255,235<span></span>
</td>
<td class="nump">6,517,102<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredRevenueRevenueRecognized1', window );">Revenues recorded in revenue recognition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 89<span></span>
</td>
<td class="nump">$ 502<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=entx_AmgenIncMember', window );">From Amgen [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_entx_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_entx_NonRefundableAndNonCreditableInitialTechnologyAccessFeePayment', window );">Non-refundable and non-creditable initial technology access fee payment, including payment for the first year of preclinical services</a></td>
<td class="nump">$ 725<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_entx_AdditionalAmountPaidForServicesToBeRecognized', window );">Additional amount paid for services to be recognized upon commencement of the pre-clinical Research and Development services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 225<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_entx_RightToUseIntellectualProperty', window );">Right to use intellectual property</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_entx_AdditionalAmountPaidForServicesToBeRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the additional amount paid for services to be recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">entx_AdditionalAmountPaidForServicesToBeRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>entx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_entx_NonRefundableAndNonCreditableInitialTechnologyAccessFeePayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the value of non-refundable and non-creditable initial technology access fee payment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">entx_NonRefundableAndNonCreditableInitialTechnologyAccessFeePayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>entx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_entx_RightToUseIntellectualProperty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the value of right to use the intellectual property.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">entx_RightToUseIntellectualProperty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>entx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_entx_SeveranceExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>It represents severance expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">entx_SeveranceExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>entx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_entx_SignificantAccountingPoliciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">entx_SignificantAccountingPoliciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>entx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueRevenueRecognized1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized that was previously reported as deferred or unearned revenue.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenueRevenueRecognized1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SeveranceCosts1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses for special or contractual termination benefits provided to current employees involuntarily terminated under a benefit arrangement associated exit or disposal activities pursuant to an authorized plan. Excludes expenses related to one-time termination benefits, a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SeveranceCosts1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=entx_AmgenIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=entx_AmgenIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140398300946864">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>OPERATING LEASE (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Operating lease cost</a></td>
<td class="nump">$ 197<span></span>
</td>
<td class="nump">$ 216<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140398304558448">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>OPERATING LEASE (Details 1) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Operating cash flows from operating leases</a></td>
<td class="nump">$ 197<span></span>
</td>
<td class="nump">$ 216<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918643-209977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140398296185664">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>OPERATING LEASES (Details 2) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityAbstract', window );"><strong>Operating Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="nump">$ 90<span></span>
</td>
<td class="nump">$ 239<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Current lease liabilities</a></td>
<td class="nump">91<span></span>
</td>
<td class="nump">179<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Non-current lease liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">123<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total lease liabilities</a></td>
<td class="nump">$ 91<span></span>
</td>
<td class="nump">$ 302<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted-average remaining lease term (in years)</a></td>
<td class="text">6 months 7 days<span></span>
</td>
<td class="text">1 year 6 months 10 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Weighted-average discount rate</a></td>
<td class="nump">16.00%<span></span>
</td>
<td class="nump">16.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140398296186464">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>OPERATING LEASES (Detail Textuals) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Maturity of lease liabilities under our non-cancelable operating leases to be paid in 2023</a></td>
<td class="nump">$ 91<span></span>
</td>
<td class="nump">$ 302<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_entx_LeaseArrangementAxis=entx_OperatingLeaseAgreementsForOfficeAndResearchAndDevelopmentSpaceMember', window );">Operating lease agreements for office and research and development space [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentForContingentConsiderationLiabilityOperatingActivities', window );">Annual lease consideration</a></td>
<td class="nump">166<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_entx_BankGuarantees', window );">Value of bank guarantees provided</a></td>
<td class="nump">37<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_entx_LeaseArrangementAxis=entx_OperatingLeaseAgreementsForVehiclesForEmployeesMember', window );">Operating lease agreements for vehicles for employees [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentForContingentConsiderationLiabilityOperatingActivities', window );">Annual lease consideration</a></td>
<td class="nump">$ 21<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_entx_BankGuarantees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the value of bank guarantees.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">entx_BankGuarantees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>entx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeaseDescriptionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeaseDescriptionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentForContingentConsiderationLiabilityOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow, not made soon after acquisition date of business combination, to settle contingent consideration liability exceeding amount recognized at acquisition date. Includes, but is not limited to, measurement period adjustment and less amount paid soon after acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (ee)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3367-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentForContingentConsiderationLiabilityOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_entx_LeaseArrangementAxis=entx_OperatingLeaseAgreementsForOfficeAndResearchAndDevelopmentSpaceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">entx_LeaseArrangementAxis=entx_OperatingLeaseAgreementsForOfficeAndResearchAndDevelopmentSpaceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_entx_LeaseArrangementAxis=entx_OperatingLeaseAgreementsForVehiclesForEmployeesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">entx_LeaseArrangementAxis=entx_OperatingLeaseAgreementsForVehiclesForEmployeesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140398303027952">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES (Detail Textuals)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_entx_AgreementAxis=entx_PatentTransferAgreementMember', window );">Patent Transfer Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_entx_CommitmentsLineItems', window );"><strong>Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_entx_RoyaltyGuaranteesCommitmentsPercentageOfNetRevenues', window );">Percentage of net revenues</a></td>
<td class="nump">3.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=entx_DnaBiomedicalSolutionsLtdMember', window );">D.N.A Biomedical Solutions Ltd [Member] | Joint Venture Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_entx_CommitmentsLineItems', window );"><strong>Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_entx_SaleOfStockAmountOfInvestment', window );">Amount of investment in entity</a></td>
<td class="nump">$ 600<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=entx_DnaBiomedicalSolutionsLtdAndOramedLtdMember', window );">D. N. A Biomedical Solutions Ltd And Oramed Ltd [Member] | Joint Venture Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_entx_CommitmentsLineItems', window );"><strong>Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_entx_SaleOfStockPercentageOfOwnershipOfEntityAcquired', window );">Percentage of ownership of entity acquired</a></td>
<td class="nump">50.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis=us-gaap_GovernmentMember', window );">Government of Israel [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_entx_CommitmentsLineItems', window );"><strong>Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_entx_RoyaltyGuaranteesCommitmentsPercentageSalesOfProductsDevelopedFromProjectsInFirstThreeYearsFromCommencementOfRevenues', window );">Percentage sales of products developed from projects in first three years, from commencement of revenues</a></td>
<td class="nump">3.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_entx_RoyaltyGuaranteesCommitmentsPercentageSalesOfProductsDevelopedFromProjectsSubsequentThreeYears', window );">Percentage sales of products developed from projects subsequent three years</a></td>
<td class="nump">4.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_entx_RoyaltyGuaranteesCommitmentsPercentageSalesOfProductsDevelopedFromProjectsCommencingSeventhYear', window );">Percentage sales of products developed from projects commencing the seventh year up to 100% of amount of grant received</a></td>
<td class="nump">5.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RoyaltyGuaranteesCommitmentsAmount', window );">Total royalty amount payable</a></td>
<td class="nump">$ 460<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_entx_RoyaltyGuaranteesCommitmentsPercentageOfEachPaymentReceivedFromAmgen', window );">Percentage of each payment received from Amgen</a></td>
<td class="nump">5.38%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_entx_PaymentOfRoyaltyGuaranteesCommitments', window );">Royalty amount paid</a></td>
<td class="nump">$ 83<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_entx_CommitmentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">entx_CommitmentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>entx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_entx_PaymentOfRoyaltyGuaranteesCommitments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the amount paid for royalty to IIA.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">entx_PaymentOfRoyaltyGuaranteesCommitments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>entx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_entx_RoyaltyGuaranteesCommitmentsPercentageOfEachPaymentReceivedFromAmgen">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the percentage of each payment received from Amgen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">entx_RoyaltyGuaranteesCommitmentsPercentageOfEachPaymentReceivedFromAmgen</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>entx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_entx_RoyaltyGuaranteesCommitmentsPercentageOfNetRevenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the percentage of net revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">entx_RoyaltyGuaranteesCommitmentsPercentageOfNetRevenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>entx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_entx_RoyaltyGuaranteesCommitmentsPercentageSalesOfProductsDevelopedFromProjectsCommencingSeventhYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the percentage sales of products developed from projects commencing the seventh year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">entx_RoyaltyGuaranteesCommitmentsPercentageSalesOfProductsDevelopedFromProjectsCommencingSeventhYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>entx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_entx_RoyaltyGuaranteesCommitmentsPercentageSalesOfProductsDevelopedFromProjectsInFirstThreeYearsFromCommencementOfRevenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the percentage sales of products developed from projects in first three years, from commencement of revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">entx_RoyaltyGuaranteesCommitmentsPercentageSalesOfProductsDevelopedFromProjectsInFirstThreeYearsFromCommencementOfRevenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>entx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_entx_RoyaltyGuaranteesCommitmentsPercentageSalesOfProductsDevelopedFromProjectsSubsequentThreeYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the percentage sales of products developed from projects subsequent three years.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">entx_RoyaltyGuaranteesCommitmentsPercentageSalesOfProductsDevelopedFromProjectsSubsequentThreeYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>entx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_entx_SaleOfStockAmountOfInvestment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the amount invested in the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">entx_SaleOfStockAmountOfInvestment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>entx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_entx_SaleOfStockPercentageOfOwnershipOfEntityAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the percentage of ownership of entity acquired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">entx_SaleOfStockPercentageOfOwnershipOfEntityAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>entx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RoyaltyGuaranteesCommitmentsAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount the entity has committed to make for future royalty guarantees.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 928<br> -SubTopic 440<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6473578&amp;loc=d3e63223-108013<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RoyaltyGuaranteesCommitmentsAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_entx_AgreementAxis=entx_PatentTransferAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">entx_AgreementAxis=entx_PatentTransferAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=entx_DnaBiomedicalSolutionsLtdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=entx_DnaBiomedicalSolutionsLtdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_entx_AgreementAxis=entx_JointVentureAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">entx_AgreementAxis=entx_JointVentureAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=entx_DnaBiomedicalSolutionsLtdAndOramedLtdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=entx_DnaBiomedicalSolutionsLtdAndOramedLtdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis=us-gaap_GovernmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis=us-gaap_GovernmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140398293682128">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>SHARE CAPITAL (Detail Textuals) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="4">1 Months Ended</th>
<th class="th" colspan="1">2 Months Ended</th>
<th class="th" colspan="4">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 23, 2021</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Feb. 29, 2020</div></th>
<th class="th"><div>Jul. 31, 2018</div></th>
<th class="th"><div>Jul. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>May 07, 2021</div></th>
<th class="th"><div>Jul. 04, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_entx_StockholdersEquityNoteLineItems', window );"><strong>Stockholders Equity Note [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expenses</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,247<span></span>
</td>
<td class="nump">$ 1,861<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Value of shares issued</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of shares through ATM programs, net of issuance costs</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 21,805<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Number of options exercised</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,511<span></span>
</td>
<td class="nump">177,710<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of options to ordinary shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13<span></span>
</td>
<td class="nump">$ 418<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise rice of options exercised</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.14<span></span>
</td>
<td class="nump">$ 2.37<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_entx_EquityProgramAxis=entx_AtmEquityProgram2020Member', window );">ATM Equity Program 2020 [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_entx_StockholdersEquityNoteLineItems', window );"><strong>Stockholders Equity Note [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_entx_AdjustedExercisePriceUnderAtMarketEquityProgram', window );">Adjusted exercise price under At-the-market equity program</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.05<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=entx_BrokerWarrantsType1Member', window );">Broker Warrants Type 1 [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_entx_StockholdersEquityNoteLineItems', window );"><strong>Stockholders Equity Note [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price of warrants issued</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.96<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.96<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=entx_BrokerWarrantsMember', window );">Broker Warrants [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_entx_StockholdersEquityNoteLineItems', window );"><strong>Stockholders Equity Note [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price of warrants issued</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.37<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.37<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=entx_BrokerDealerMember', window );">Broker Dealer [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_entx_StockholdersEquityNoteLineItems', window );"><strong>Stockholders Equity Note [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Number of shares issued</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">184,515<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">184,515<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=entx_BrokerDealerOneMember', window );">Broker-Dealer 1 [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_entx_StockholdersEquityNoteLineItems', window );"><strong>Stockholders Equity Note [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Number of shares issued</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">92,257<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">92,257<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Ordinary shares [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_entx_StockholdersEquityNoteLineItems', window );"><strong>Stockholders Equity Note [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockVotingRights', window );">Voting rights of ordinary share</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">one
vote<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Number of options exercised</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,511<span></span>
</td>
<td class="nump">177,711<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of options to ordinary shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Ordinary shares [Member] | ATM Equity Program 2020 [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_entx_StockholdersEquityNoteLineItems', window );"><strong>Stockholders Equity Note [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Value of shares issued</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13,900<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_entx_SharesIssuedWeightedAveragePricePerShare', window );">Weighted average price of share issued</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.99<span></span>
</td>
<td class="nump">$ 1.27<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_entx_NetProceedsFromIssuanceOfCommonStock', window );">Net proceeds from share issuance</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,900<span></span>
</td>
<td class="nump">$ 3,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Number of shares issued</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,546,265<span></span>
</td>
<td class="nump">2,802,731<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Ordinary shares [Member] | ATM Equity Program 2021 [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_entx_StockholdersEquityNoteLineItems', window );"><strong>Stockholders Equity Note [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_entx_SharesIssuedWeightedAveragePricePerShare', window );">Weighted average price of share issued</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6.74<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_entx_NetProceedsFromIssuanceOfCommonStock', window );">Net proceeds from share issuance</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Number of shares issued</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,840,463<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Ordinary shares [Member] | Several employees and service providers [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_entx_StockholdersEquityNoteLineItems', window );"><strong>Stockholders Equity Note [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Number of options exercised</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,511<span></span>
</td>
<td class="nump">177,711<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod', window );">Number of shares issued on options exercised</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,511<span></span>
</td>
<td class="nump">177,711<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise rice of options exercised</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.14<span></span>
</td>
<td class="nump">$ 2.54<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_entx_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsTotalConsideration', window );">Total Consideration</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13<span></span>
</td>
<td class="nump">$ 418<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">IPO [Member] | Warrant [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_entx_StockholdersEquityNoteLineItems', window );"><strong>Stockholders Equity Note [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_entx_ClassOfWarrantOrRightIssued', window );">Number of warrants issued</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,395,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of ordinary shares called by warrants</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">697,750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price of warrants issued</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.85<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.85<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_entx_ClassOfWarrantOrRightExerciseTerm', window );">Term of warrants issued</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_entx_ClassOfWarrantOrRightThresholdLimitOfPeriodForReductionInExercisePrice', window );">Threshold limit of period for reduction in exercise price</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_entx_ClassOfWarrantOrRightThresholdLimitOfReductionInExercisePrice', window );">Threshold limit of reduction in exercise price</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_entx_ClassOfWarrantOrRightReducedExercisePrice', window );">Reduced exercise price</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.85<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_entx_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsTotalConsideration', window );">Total Consideration</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember', window );">Private Placement [Member] | Accredited investors, including certain board members and their affiliates [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_entx_StockholdersEquityNoteLineItems', window );"><strong>Stockholders Equity Note [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_entx_ClassOfWarrantOrRightIssued', window );">Number of warrants issued</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,023,871<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,023,871<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of ordinary shares called by warrants</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,023,871<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,023,871<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price of warrants issued</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.96<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.96<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_entx_ClassOfWarrantOrRightExerciseTerm', window );">Term of warrants issued</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_entx_NumberOfSharesIssuedUnderPrivatePlacement', window );">Number of shares issued under private placement</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,047,706<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,047,706<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement', window );">Proceeds from private placement</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Price of shares issued under private placement</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.37<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.37<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember', window );">Private Placement [Member] | Warrant [Member] | Chairman of the board and DNA [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_entx_StockholdersEquityNoteLineItems', window );"><strong>Stockholders Equity Note [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_entx_ClassOfWarrantOrRightIssued', window );">Number of warrants issued</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">3,300,645<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price of warrants issued</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 1.05<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Proceeds from exercise of warrants</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 3,145<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember', window );">Private Placement [Member] | Ordinary shares [Member] | Chairman of the board and DNA [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_entx_StockholdersEquityNoteLineItems', window );"><strong>Stockholders Equity Note [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of ordinary shares called by warrants</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">3,172,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr><td colspan="12"></td></tr>
<tr><td colspan="12"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">Represents an amount less than one thousand US dollars.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_entx_AdjustedExercisePriceUnderAtMarketEquityProgram">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjusted Exercise Price under At-the-market equity program.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">entx_AdjustedExercisePriceUnderAtMarketEquityProgram</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>entx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_entx_ClassOfWarrantOrRightExerciseTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the exercise period of warrants or rights.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">entx_ClassOfWarrantOrRightExerciseTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>entx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_entx_ClassOfWarrantOrRightIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the number of warrants or rights issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">entx_ClassOfWarrantOrRightIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>entx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_entx_ClassOfWarrantOrRightReducedExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the reduced exercise price of warrants or rights.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">entx_ClassOfWarrantOrRightReducedExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>entx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_entx_ClassOfWarrantOrRightThresholdLimitOfPeriodForReductionInExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the threshold limit of period for reduction in exercise price of warrants or rights.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">entx_ClassOfWarrantOrRightThresholdLimitOfPeriodForReductionInExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>entx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_entx_ClassOfWarrantOrRightThresholdLimitOfReductionInExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the threshold limit of reduction in exercise price of warrants or rights.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">entx_ClassOfWarrantOrRightThresholdLimitOfReductionInExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>entx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_entx_NetProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the net cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">entx_NetProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>entx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_entx_NumberOfSharesIssuedUnderPrivatePlacement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the number of shares issued under private placement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">entx_NumberOfSharesIssuedUnderPrivatePlacement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>entx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_entx_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsTotalConsideration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the amount of share based compensation arrangements by share based payment award options total consideration.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">entx_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsTotalConsideration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>entx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_entx_SharesIssuedWeightedAveragePricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the weighted average price per share or per unit of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">entx_SharesIssuedWeightedAveragePricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>entx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_entx_StockholdersEquityNoteLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">entx_StockholdersEquityNoteLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>entx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockVotingRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of voting rights of common stock. Includes eligibility to vote and votes per share owned. Include also, if any, unusual voting rights.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockVotingRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfPrivatePlacement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromWarrantExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from holders exercising their stock warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromWarrantExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_entx_EquityProgramAxis=entx_AtmEquityProgram2020Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">entx_EquityProgramAxis=entx_AtmEquityProgram2020Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=entx_BrokerWarrantsType1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=entx_BrokerWarrantsType1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=entx_BrokerWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=entx_BrokerWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=entx_BrokerDealerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=entx_BrokerDealerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=entx_BrokerDealerOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=entx_BrokerDealerOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_entx_EquityProgramAxis=entx_AtmEquityProgram2021Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">entx_EquityProgramAxis=entx_AtmEquityProgram2021Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=entx_SeveralEmployeesAndServiceProvidersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=entx_SeveralEmployeesAndServiceProvidersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=entx_AccreditedInvestorsIncludingCertainBoardMembersAndTheirAffiliatesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=entx_AccreditedInvestorsIncludingCertainBoardMembersAndTheirAffiliatesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=entx_ChairmanOfBoardAndDnaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=entx_ChairmanOfBoardAndDnaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140398298679776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SHARE-BASED COMPENSATION (Details) - $ / shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice', window );">Exercise price</a></td>
<td class="nump">$ 1.4<span></span>
</td>
<td class="nump">$ 1.24<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">69.00%<span></span>
</td>
<td class="nump">68.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">1.35%<span></span>
</td>
<td class="nump">1.11%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected life - in years</a></td>
<td class="text">5 years 6 months<span></span>
</td>
<td class="text">6 years 1 month 6 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice', window );">Exercise price</a></td>
<td class="nump">$ 2.86<span></span>
</td>
<td class="nump">$ 3.61<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">70.20%<span></span>
</td>
<td class="nump">71.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">3.36%<span></span>
</td>
<td class="nump">0.94%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected life - in years</a></td>
<td class="text">6 years 6 months<span></span>
</td>
<td class="text">5 years 9 months 18 days<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Agreed-upon price for the exchange of the underlying asset relating to the share-based payment award.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140398296146160">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SHARE-BASED COMPENSATION (Details 1) - $ / shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Number of options</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding at beginning of the year</a></td>
<td class="nump">4,316,859<span></span>
</td>
<td class="nump">2,570,109<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted</a></td>
<td class="nump">2,458,863<span></span>
</td>
<td class="nump">1,975,586<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercised</a></td>
<td class="num">(5,511)<span></span>
</td>
<td class="num">(177,710)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Forfeited</a></td>
<td class="num">(902,009)<span></span>
</td>
<td class="num">(16,660)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod', window );">Expired</a></td>
<td class="num">(135,115)<span></span>
</td>
<td class="num">(34,466)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding at end of the year</a></td>
<td class="nump">5,733,087<span></span>
</td>
<td class="nump">4,316,859<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Exercisable at end of the year</a></td>
<td class="nump">3,165,677<span></span>
</td>
<td class="nump">2,068,067<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted Average exercise price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding at beginning of the year</a></td>
<td class="nump">$ 3.63<span></span>
</td>
<td class="nump">$ 4.85<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted</a></td>
<td class="nump">2.29<span></span>
</td>
<td class="nump">1.95<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Exercised</a></td>
<td class="nump">2.14<span></span>
</td>
<td class="nump">2.37<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Forfeited</a></td>
<td class="nump">1.41<span></span>
</td>
<td class="nump">2.37<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice', window );">Expired</a></td>
<td class="nump">3.8<span></span>
</td>
<td class="nump">4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding at end of the year</a></td>
<td class="nump">3.3<span></span>
</td>
<td class="nump">3.63<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Exercisable at end of the year</a></td>
<td class="nump">$ 4.06<span></span>
</td>
<td class="nump">$ 5.39<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140398302123696">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SHARE-BASED COMPENSATION (Details 2) - $ / shares<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Exercise Price Per Share</a></td>
<td class="nump">$ 3.3<span></span>
</td>
<td class="nump">$ 3.63<span></span>
</td>
<td class="nump">$ 4.85<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of options outstanding at end of year</a></td>
<td class="nump">5,733,087<span></span>
</td>
<td class="nump">4,316,859<span></span>
</td>
<td class="nump">2,570,109<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Number of options exercisable at end of year</a></td>
<td class="nump">3,165,677<span></span>
</td>
<td class="nump">2,068,067<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=entx_ExercisePricePerShareZeroMember', window );">Exercise Price Per Share - Zero</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Exercise Price Per Share</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of options outstanding at end of year</a></td>
<td class="nump">1,560<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Options outstanding, Weighted Average Remaining contractual Life</a></td>
<td class="text">1 month 2 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Number of options exercisable at end of year</a></td>
<td class="nump">1,560<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Options exercisable, Weighted Average Remaining contractual Life</a></td>
<td class="text">1 month 2 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=entx_ExercisePricePerShareOnePointTwoFourMember', window );">Exercise Price Per Share - 1.24</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Exercise Price Per Share</a></td>
<td class="nump">$ 1.24<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of options outstanding at end of year</a></td>
<td class="nump">492,831<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Options outstanding, Weighted Average Remaining contractual Life</a></td>
<td class="text">1 year 6 months 14 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Number of options exercisable at end of year</a></td>
<td class="nump">492,831<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Options exercisable, Weighted Average Remaining contractual Life</a></td>
<td class="text">1 year 6 months 14 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=entx_ExercisePricePerShareOnePointFourMember', window );">Exercise Price Per Share - 1.4</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Exercise Price Per Share</a></td>
<td class="nump">$ 1.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of options outstanding at end of year</a></td>
<td class="nump">600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Options outstanding, Weighted Average Remaining contractual Life</a></td>
<td class="text">9 years 6 months 14 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Number of options exercisable at end of year</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=entx_ExercisePricePerShareTwoPointZeroTwoMember', window );">Exercise Price Per Share - 2.02</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Exercise Price Per Share</a></td>
<td class="nump">$ 2.02<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of options outstanding at end of year</a></td>
<td class="nump">500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Options outstanding, Weighted Average Remaining contractual Life</a></td>
<td class="text">9 years 4 months 13 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Number of options exercisable at end of year</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=entx_ExercisePricePerShareTwoPointOneFourMember', window );">Exercise Price Per Share - 2.14</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Exercise Price Per Share</a></td>
<td class="nump">$ 2.14<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of options outstanding at end of year</a></td>
<td class="nump">400,775<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Options outstanding, Weighted Average Remaining contractual Life</a></td>
<td class="text">7 years 3 months 3 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Number of options exercisable at end of year</a></td>
<td class="nump">277,994<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Options exercisable, Weighted Average Remaining contractual Life</a></td>
<td class="text">7 years 3 months 3 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=entx_ExercisePricePerShareTwoPointFiveThreeMember', window );">Exercise Price Per Share - 2.53</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Exercise Price Per Share</a></td>
<td class="nump">$ 2.53<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of options outstanding at end of year</a></td>
<td class="nump">33,638<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Options outstanding, Weighted Average Remaining contractual Life</a></td>
<td class="text">6 years 10 months 20 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Number of options exercisable at end of year</a></td>
<td class="nump">33,638<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Options exercisable, Weighted Average Remaining contractual Life</a></td>
<td class="text">6 years 10 months 20 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=entx_ExercisePricePerShareTwoPointFiveSevenMember', window );">Exercise Price Per Share - 2.57</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Exercise Price Per Share</a></td>
<td class="nump">$ 2.57<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of options outstanding at end of year</a></td>
<td class="nump">205,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Options outstanding, Weighted Average Remaining contractual Life</a></td>
<td class="text">9 years 3 months 29 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Number of options exercisable at end of year</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=entx_ExercisePricePerShareTwoPointEightOneFiveMember', window );">Exercise Price Per Share - 2.815</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Exercise Price Per Share</a></td>
<td class="nump">$ 2.815<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of options outstanding at end of year</a></td>
<td class="nump">1,003,863<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Options outstanding, Weighted Average Remaining contractual Life</a></td>
<td class="text">9 years 3 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Number of options exercisable at end of year</a></td>
<td class="nump">376,447<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Options exercisable, Weighted Average Remaining contractual Life</a></td>
<td class="text">9 years 3 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=entx_ExercisePricePerShareTwoPointEightSixMember', window );">Exercise Price Per Share - 2.86</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Exercise Price Per Share</a></td>
<td class="nump">$ 2.86<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of options outstanding at end of year</a></td>
<td class="nump">135,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Options outstanding, Weighted Average Remaining contractual Life</a></td>
<td class="text">9 years 3 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Number of options exercisable at end of year</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=entx_ExercisePricePerShareThreePointOneFiveMember', window );">Exercise Price Per Share - 3.15</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Exercise Price Per Share</a></td>
<td class="nump">$ 3.15<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of options outstanding at end of year</a></td>
<td class="nump">345,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Options outstanding, Weighted Average Remaining contractual Life</a></td>
<td class="text">8 years 3 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Number of options exercisable at end of year</a></td>
<td class="nump">123,125<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Options exercisable, Weighted Average Remaining contractual Life</a></td>
<td class="text">8 years 3 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=entx_ExercisePricePerShareThreePointSixOneMember', window );">Exercise Price Per Share - 3.61</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Exercise Price Per Share</a></td>
<td class="nump">$ 3.61<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of options outstanding at end of year</a></td>
<td class="nump">250,868<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Options outstanding, Weighted Average Remaining contractual Life</a></td>
<td class="text">8 years 3 months 7 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Number of options exercisable at end of year</a></td>
<td class="nump">101,059<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Options exercisable, Weighted Average Remaining contractual Life</a></td>
<td class="text">8 years 3 months 7 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=entx_ExercisePricePerShareThreePointSixEightMember', window );">Exercise Price Per Share - 3.68</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Exercise Price Per Share</a></td>
<td class="nump">$ 3.68<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of options outstanding at end of year</a></td>
<td class="nump">294,580<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Options outstanding, Weighted Average Remaining contractual Life</a></td>
<td class="text">3 months 3 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Number of options exercisable at end of year</a></td>
<td class="nump">294,580<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Options exercisable, Weighted Average Remaining contractual Life</a></td>
<td class="text">3 months 3 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=entx_ExercisePricePerShareThreePointNineSevenMember', window );">Exercise Price Per Share - 3.97</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Exercise Price Per Share</a></td>
<td class="nump">$ 3.97<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of options outstanding at end of year</a></td>
<td class="nump">247,082<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Options outstanding, Weighted Average Remaining contractual Life</a></td>
<td class="text">6 years 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Number of options exercisable at end of year</a></td>
<td class="nump">242,053<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Options exercisable, Weighted Average Remaining contractual Life</a></td>
<td class="text">6 years 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=entx_ExercisePricePerShareSixPointThreeOneMember', window );">Exercise Price Per Share - 6.31</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Exercise Price Per Share</a></td>
<td class="nump">$ 6.31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of options outstanding at end of year</a></td>
<td class="nump">1,222,390<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Options outstanding, Weighted Average Remaining contractual Life</a></td>
<td class="text">3 years 29 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Number of options exercisable at end of year</a></td>
<td class="nump">1,222,390<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Options exercisable, Weighted Average Remaining contractual Life</a></td>
<td class="text">3 years 29 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=entx_ExercisePricePerShareZeroMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=entx_ExercisePricePerShareZeroMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=entx_ExercisePricePerShareOnePointTwoFourMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=entx_ExercisePricePerShareOnePointTwoFourMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=entx_ExercisePricePerShareOnePointFourMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=entx_ExercisePricePerShareOnePointFourMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=entx_ExercisePricePerShareTwoPointZeroTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=entx_ExercisePricePerShareTwoPointZeroTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=entx_ExercisePricePerShareTwoPointOneFourMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=entx_ExercisePricePerShareTwoPointOneFourMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=entx_ExercisePricePerShareTwoPointFiveThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=entx_ExercisePricePerShareTwoPointFiveThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=entx_ExercisePricePerShareTwoPointFiveSevenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=entx_ExercisePricePerShareTwoPointFiveSevenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=entx_ExercisePricePerShareTwoPointEightOneFiveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=entx_ExercisePricePerShareTwoPointEightOneFiveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=entx_ExercisePricePerShareTwoPointEightSixMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=entx_ExercisePricePerShareTwoPointEightSixMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=entx_ExercisePricePerShareThreePointOneFiveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=entx_ExercisePricePerShareThreePointOneFiveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=entx_ExercisePricePerShareThreePointSixOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=entx_ExercisePricePerShareThreePointSixOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=entx_ExercisePricePerShareThreePointSixEightMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=entx_ExercisePricePerShareThreePointSixEightMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=entx_ExercisePricePerShareThreePointNineSevenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=entx_ExercisePricePerShareThreePointNineSevenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=entx_ExercisePricePerShareSixPointThreeOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=entx_ExercisePricePerShareSixPointThreeOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140398293669808">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SHARE-BASED COMPENSATION (Details 3) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation</a></td>
<td class="nump">$ 2,247<span></span>
</td>
<td class="nump">$ 1,861<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember', window );">Cost of revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation</a></td>
<td class="nump">14<span></span>
</td>
<td class="nump">102<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation</a></td>
<td class="nump">708<span></span>
</td>
<td class="nump">661<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation</a></td>
<td class="nump">$ 1,525<span></span>
</td>
<td class="nump">$ 1,098<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140398287812720">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SHARE-BASED COMPENSATION (Detail Textuals)<br> &#8362; / shares in Units, $ / shares in Units, &#8362; in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="6">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="2"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jul. 15, 2022 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>May 11, 2022 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Apr. 07, 2021 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Jan. 04, 2021 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 15, 2022 </div>
<div>ILS (&#8362;) </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 15, 2022 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Apr. 28, 2022 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Aug. 23, 2021 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Apr. 30, 2021 </div>
<div>shares</div>
</th>
<th class="th">
<div>Apr. 21, 2021 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 31, 2022 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>&#8362; / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>&#8362; / shares</div>
</th>
<th class="th">
<div>Jul. 02, 2018 </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription', window );">Description of terms of share-based payment arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The
        options vest over four
        years from the date of grant; 25% vest on the first anniversary of the date of grant and the remaining 75% of the option
        will vest in twelve equal quarterly installments following the first anniversary of the grant date.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of options to purchase ordinary shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,458,863<span></span>
</td>
<td class="nump">1,975,586<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Exercise price of options granted | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.29<span></span>
</td>
<td class="nump">$ 1.95<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vestion period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate intrinsic value of outstanding options | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expenses | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,247<span></span>
</td>
<td class="nump">$ 1,861<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative expenses | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,253<span></span>
</td>
<td class="nump">$ 5,690<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common Stock, Par or Stated Value Per Share | &#8362; / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8362; 0.0000769<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8362; 0.0000769<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=entx_ExecutiveOfficerAndServiceProviderMember', window );">Executive Officer and Service Provider [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Ordinary shares available for future grant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">80,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Exercise price of options granted | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.86<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1', window );">Fair value of options at the date of grant | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 147<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=entx_EmployeesMember', window );">Certain employees [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of options to purchase ordinary shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">213,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Exercise price of options granted | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.61<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vestion period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1', window );">Fair value of options at the date of grant | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 646<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=entx_EmployeesMember', window );">Certain employees [Member] | Vest on the first anniversary of the date of grant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Vesting percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=entx_EmployeesMember', window );">Certain employees [Member] | Vest in twelve equal quarterly installments following the first anniversary of the applicable grant date [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Vesting percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">75.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=entx_ServiceProviderMember', window );">Service Provider [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of options to purchase ordinary shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">70,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Exercise price of options granted | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.61<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.86<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vestion period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1', window );">Fair value of options at the date of grant | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 646<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=entx_ServiceProviderMember', window );">Service Provider [Member] | Vest on the first anniversary of the date of grant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Vesting percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=entx_ServiceProviderMember', window );">Service Provider [Member] | Vest in twelve equal quarterly installments following the first anniversary of the applicable grant date [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Vesting percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">75.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=srt_ExecutiveOfficerMember', window );">Executive Officer [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Ordinary shares available for future grant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">55,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of options to purchase ordinary shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">345,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Exercise price of options granted | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.15<span></span>
</td>
<td class="nump">$ 2.86<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vestion period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1', window );">Fair value of options at the date of grant | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,140<span></span>
</td>
<td class="nump">$ 37<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=srt_ExecutiveOfficerMember', window );">Executive Officer [Member] | Vest on the first anniversary of the date of grant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Vesting percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=srt_ExecutiveOfficerMember', window );">Executive Officer [Member] | Vest in twelve equal quarterly installments following the first anniversary of the applicable grant date [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Vesting percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">75.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=entx_FormerChiefExecutiveOfficerMember', window );">Former CEO [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of options to purchase ordinary shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">492,832<span></span>
</td>
<td class="nump">492,832<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vestion period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years<span></span>
</td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OfficersCompensation', window );">Annual base salary | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 412<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DescriptionOfPostemploymentBenefits', window );">Description of mutual separation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">(i)
a one-time lump sum payment of his annual base salary for a period of 13 months, for a total gross amount equal to $412;
and (ii) an extension of the exercise period for the vested portion of the options granted on January 4, 2021, based on the award original
terms, representing an aggregate of 492,832
ordinary shares, through the end of a two-year period commencing on July 15,
2022.<span></span>
</td>
<td class="text">(i)
a one-time lump sum payment of his annual base salary for a period of 13 months, for a total gross amount equal to $412;
and (ii) an extension of the exercise period for the vested portion of the options granted on January 4, 2021, based on the award original
terms, representing an aggregate of 492,832
ordinary shares, through the end of a two-year period commencing on July 15,
2022.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative expenses | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 457<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares', window );">Number of unvested options forfeited</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">821,386<span></span>
</td>
<td class="nump">821,386<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=entx_NonExecutiveDirectorMember', window );">Non-executive director [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of options to purchase ordinary shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33,368<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Exercise price of options granted | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.61<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vestion period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1', window );">Fair value of options at the date of grant | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 104<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=entx_NonExecutiveDirectorMember', window );">Non-executive director [Member] | Vest over twelve equal quarterly instalments starting on January 1, 2022 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of options to purchase ordinary shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">752,899<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Exercise price of options granted | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.815<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vestion period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1', window );">Fair value of options at the date of grant | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 195<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=entx_NonExecutiveDirectorMember', window );">Non-executive director [Member] | Vest over four equal quarterly instalments starting on January 1, 2022 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of options to purchase ordinary shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">250,964<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Exercise price of options granted | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.815<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vestion period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1', window );">Fair value of options at the date of grant | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 65<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=entx_EmployeeMember', window );">Employee [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription', window );">Description of terms of share-based payment arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The
        options vest over four
        years from the date of grant; 25% vest on the first anniversary of the date of grant and the remaining 75% of the option
        will vest in twelve equal quarterly installments following the first anniversary of the grant date.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of options to purchase ordinary shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">220,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Exercise price of options granted | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.57<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vestion period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1', window );">Fair value of options at the date of grant | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 364<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=srt_ChiefExecutiveOfficerMember', window );">New CEO [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription', window );">Description of terms of share-based payment arrangement</a></td>
<td class="text">This
        grant was subject to shareholders' approval, which was obtained at a meeting of the Company&#8217;s shareholders held on September 7,
        2022. The options vest over four
        years from the date of grant; 25% vest on the first anniversary of the date of grant and the remaining 75% of the option
        will vest in twelve equal quarterly installments following the first anniversary of the applicable grant date.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of options to purchase ordinary shares</a></td>
<td class="nump">600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,314,218<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Exercise price of options granted | $ / shares</a></td>
<td class="nump">$ 1.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.24<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vestion period</a></td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1', window );">Fair value of options at the date of grant | $</a></td>
<td class="nump">$ 524<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,320<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=srt_ChiefExecutiveOfficerMember', window );">New CEO [Member] | Triggering Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of options to purchase ordinary shares</a></td>
<td class="nump">200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=srt_ChiefExecutiveOfficerMember', window );">New CEO [Member] | Vest on the first anniversary of the date of grant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Vesting percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=srt_ChiefExecutiveOfficerMember', window );">New CEO [Member] | Vest in twelve equal quarterly installments following the first anniversary of the applicable grant date [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Vesting percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">75.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=srt_ChiefFinancialOfficerMember', window );">Chief Financial Officer [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription', window );">Description of terms of share-based payment arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">This
        grant was subject to shareholders' approval, which was obtained at a meeting of the Company&#8217;s shareholders held on September 7,
        2022. These options have an exercise price of&#8201;$2.00
        per share and vest over four
        years from the date of grant; 25% vest on the first anniversary of the date of grant and the remaining 75% of the option
        will vest in twelve equal quarterly installments following the first anniversary of the grant date.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of options to purchase ordinary shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Exercise price of options granted | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vestion period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1', window );">Fair value of options at the date of grant | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 390<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=entx_PresidentOfResearchAndDevelopmentMember', window );">President of R&amp;D [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expenses | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 112<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_entx_CashSeparationPayment', window );">Cash separation payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8362; 537,600<span></span>
</td>
<td class="nump">156<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_entx_AdditionalCashSeparationPayment', window );">Additional cash separation payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8362; 737,771<span></span>
</td>
<td class="nump">$ 214<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=entx_PresidentOfResearchAndDevelopmentMember', window );">President of R&amp;D [Member] | 2017 Grant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Ordinary shares available for future grant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">31,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of options to purchase ordinary shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">357,500<span></span>
</td>
<td class="nump">357,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">68,750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vestion period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=entx_ShareIncentivePlan2018Member', window );">2018 Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Number of ordinary shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,371,398<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Ordinary shares available for future grant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">922,080<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized', window );">Number of additional ordinary shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,440,496<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_entx_AdditionalCashSeparationPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents about additional cash separation payment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">entx_AdditionalCashSeparationPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>entx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_entx_CashSeparationPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents about cash separation payment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">entx_CashSeparationPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>entx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DescriptionOfPostemploymentBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of benefits provided to former or inactive employees, their beneficiaries, and covered dependents after employment but before retirement, except for: a) benefits provided through a pension or postretirement benefit plan, b) individual deferred compensation arrangements, c) termination benefits pertaining to exit or disposal activities, and d) stock compensation plans. Benefits may be provided in cash or in kind and may be paid as a result of disability, layoff, death, or other event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 712<br> -SubTopic 10<br> -Section 15<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=6410066&amp;loc=d3e79194-111664<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DescriptionOfPostemploymentBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OfficersCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for salary and wage arising from service rendered by officer. Excludes allocated cost, labor-related nonsalary expense, and direct and overhead labor cost included in cost of good and service sold.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OfficersCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of terms of share-based payment arrangement. Includes, but is not limited to, type of award or grantee and reason for issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of additional shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of vesting of award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of non-vested options forfeited.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=entx_ExecutiveOfficerAndServiceProviderMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=entx_ExecutiveOfficerAndServiceProviderMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=entx_EmployeesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=entx_EmployeesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=entx_ServiceProviderMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=entx_ServiceProviderMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=srt_ExecutiveOfficerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=srt_ExecutiveOfficerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=entx_FormerChiefExecutiveOfficerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=entx_FormerChiefExecutiveOfficerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=entx_NonExecutiveDirectorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=entx_NonExecutiveDirectorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=entx_ShareBasedPaymentArrangementTrancheFiveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=entx_ShareBasedPaymentArrangementTrancheFiveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=entx_ShareBasedPaymentArrangementTrancheSixMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=entx_ShareBasedPaymentArrangementTrancheSixMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=entx_EmployeeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=entx_EmployeeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=srt_ChiefExecutiveOfficerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=srt_ChiefExecutiveOfficerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=entx_TriggeringEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=entx_TriggeringEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=srt_ChiefFinancialOfficerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=srt_ChiefFinancialOfficerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=entx_PresidentOfResearchAndDevelopmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=entx_PresidentOfResearchAndDevelopmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=entx_TwentySeventeenMemberMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=entx_TwentySeventeenMemberMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=entx_ShareIncentivePlan2018Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=entx_ShareIncentivePlan2018Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140398300116608">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAX (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Loss (income) before income taxes</a></td>
<td class="nump">$ 12,934<span></span>
</td>
<td class="nump">$ 12,246<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=entx_EnteraBioLtdMember', window );">Entera Bio Ltd</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Loss (income) before income taxes</a></td>
<td class="nump">12,997<span></span>
</td>
<td class="nump">12,362<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidatedEntitiesAxis=srt_SubsidiariesMember', window );">Entera Bio Inc</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Loss (income) before income taxes</a></td>
<td class="num">$ (65)<span></span>
</td>
<td class="num">$ (116)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126941158&amp;loc=d3e41242-110953<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwardsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwardsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=entx_EnteraBioLtdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=entx_EnteraBioLtdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidatedEntitiesAxis=srt_SubsidiariesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidatedEntitiesAxis=srt_SubsidiariesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140398301906224">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAX (Details 1) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract', window );"><strong>Current:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefit', window );">Total current income tax</a></td>
<td class="num">$ (37)<span></span>
</td>
<td class="nump">$ 158<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract', window );"><strong>Deferred:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit', window );">Deferred income taxes</a></td>
<td class="nump">174<span></span>
</td>
<td class="num">(217)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Total deferred income taxes</a></td>
<td class="nump">174<span></span>
</td>
<td class="num">(217)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Total income tax expense (benefit)</a></td>
<td class="nump">137<span></span>
</td>
<td class="num">(59)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidatedEntitiesAxis=srt_SubsidiariesMember', window );">Subsidiary</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract', window );"><strong>Current:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefit', window );">Total current income tax</a></td>
<td class="num">$ (37)<span></span>
</td>
<td class="nump">$ 158<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred federal, state, and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred national, regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.1)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidatedEntitiesAxis=srt_SubsidiariesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidatedEntitiesAxis=srt_SubsidiariesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140398301851968">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>INCOME TAX (Details 2) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract', window );"><strong>Deferred tax assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating loss carry forward</a></td>
<td class="nump">$ 15,428<span></span>
</td>
<td class="nump">$ 12,895<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment', window );">Research and development</a></td>
<td class="nump">1,225<span></span>
</td>
<td class="nump">1,319<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost', window );">Share-based compensation</a></td>
<td class="nump">877<span></span>
</td>
<td class="nump">876<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOther', window );">Other</a></td>
<td class="nump">158<span></span>
</td>
<td class="nump">152<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Net deferred tax assets before valuation allowance</a></td>
<td class="nump">17,688<span></span>
</td>
<td class="nump">15,242<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">valuation allowance</a></td>
<td class="num">(17,645)<span></span>
</td>
<td class="num">(15,025)<span></span>
</td>
<td class="num">$ (12,420)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Net deferred tax assets</a></td>
<td class="nump">$ 43<span></span>
</td>
<td class="nump">$ 217<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from in-process research and development costs expensed in connection with a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140398304824752">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAX (Details 3) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Opening balance</a></td>
<td class="nump">$ 15,025<span></span>
</td>
<td class="nump">$ 12,420<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount', window );">Additions</a></td>
<td class="nump">2,620<span></span>
</td>
<td class="nump">2,605<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Closing balance</a></td>
<td class="nump">$ 17,645<span></span>
</td>
<td class="nump">$ 15,025<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140398302989840">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAX (Detail Textuals) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Carryforward losses</a></td>
<td class="nump">$ 67.1<span></span>
</td>
<td class="nump">$ 56.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Israeli tax rate [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Income tax rate</a></td>
<td class="nump">23.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember', window );">Foreign Tax Authority [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Income tax rate</a></td>
<td class="nump">29.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwardsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwardsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140398300107088">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract', window );"><strong>Accrued expenses and other payables:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedEmployeeBenefitsCurrent', window );">Employees and employees related</a></td>
<td class="nump">$ 154<span></span>
</td>
<td class="nump">$ 147<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedIncomeTaxesCurrent', window );">Income tax</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">134<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedVacationCurrent', window );">Provision for vacation</a></td>
<td class="nump">146<span></span>
</td>
<td class="nump">308<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="nump">933<span></span>
</td>
<td class="nump">2,212<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesAndOtherLiabilities', window );">Accrued expenses and other payables, total</a></td>
<td class="nump">$ 1,233<span></span>
</td>
<td class="nump">$ 2,801<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedEmployeeBenefitsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations, excluding pension and other postretirement benefits, incurred through that date and payable for perquisites provided to employees pertaining to services received from them. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedEmployeeBenefitsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedIncomeTaxesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all currently due domestic and foreign income tax obligations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(15)(b)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedIncomeTaxesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesAndOtherLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid nor invoiced, and liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesAndOtherLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedVacationCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable for unused vacation time owed to employees based on the entity's vacation benefit given to its employees. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 710<br> -SubTopic 10<br> -Section 25<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=6409733&amp;loc=d3e19396-108361<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedVacationCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140398296071664">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUBSEQUENT EVENTS (Detail Textuals) - shares<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jan. 02, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of options to purchase ordinary shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,458,863<span></span>
</td>
<td class="nump">1,975,586<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of options to ordinary shares (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,511<span></span>
</td>
<td class="nump">177,710<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vestion period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Non Executive Board [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of options to purchase ordinary shares</a></td>
<td class="nump">534,246<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of options to ordinary shares (in shares)</a></td>
<td class="nump">0.73<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vestion period</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=entx_NonExecutiveBoardMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=entx_NonExecutiveBoardMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>zk2329447_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2022"
  xmlns:entx="http://www.enterabio.com/20221231"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2022"
  xmlns:us-gaap="http://fasb.org/us-gaap/2022"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="entx-20221231.xsd" xlink:type="simple"/>
    <context id="C_20220101to20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638097</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638097</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638097</identifier>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_20210101to20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638097</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638097</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_20220101to20221231_srtRangeAxis_srtMinimumMember_usgaapPropertyPlantAndEquipmentByTypeAxis_usgaapComputerEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638097</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_20220101to20221231_srtRangeAxis_srtMaximumMember_usgaapPropertyPlantAndEquipmentByTypeAxis_usgaapComputerEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638097</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_20220101to20221231_srtRangeAxis_srtMinimumMember_usgaapPropertyPlantAndEquipmentByTypeAxis_entxLaboratoryEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638097</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">entx:LaboratoryEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_20220101to20221231_srtRangeAxis_srtMaximumMember_usgaapPropertyPlantAndEquipmentByTypeAxis_entxLaboratoryEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638097</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">entx:LaboratoryEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_20220101to20221231_usgaapPropertyPlantAndEquipmentByTypeAxis_usgaapOfficeEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638097</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_20190101to20190131_usgaapRelatedPartyTransactionsByRelatedPartyAxis_entxAmgenIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638097</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">entx:AmgenIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-01-31</endDate>
        </period>
    </context>
    <context id="C_20191231_usgaapRelatedPartyTransactionsByRelatedPartyAxis_entxAmgenIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638097</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">entx:AmgenIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_20230101to20230102_srtTitleOfIndividualAxis_entxNonExecutiveBoardMember_usgaapSubsequentEventTypeAxis_usgaapSubsequentEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638097</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">entx:NonExecutiveBoardMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-01-02</endDate>
        </period>
    </context>
    <context id="C_20220101to20221231_entxLeaseArrangementAxis_entxOperatingLeaseAgreementsForVehiclesForEmployeesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638097</identifier>
            <segment>
                <xbrldi:explicitMember dimension="entx:LeaseArrangementAxis">entx:OperatingLeaseAgreementsForVehiclesForEmployeesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_20221231_entxLeaseArrangementAxis_entxOperatingLeaseAgreementsForOfficeAndResearchAndDevelopmentSpaceMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638097</identifier>
            <segment>
                <xbrldi:explicitMember dimension="entx:LeaseArrangementAxis">entx:OperatingLeaseAgreementsForOfficeAndResearchAndDevelopmentSpaceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_20220101to20221231_entxLeaseArrangementAxis_entxOperatingLeaseAgreementsForOfficeAndResearchAndDevelopmentSpaceMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638097</identifier>
            <segment>
                <xbrldi:explicitMember dimension="entx:LeaseArrangementAxis">entx:OperatingLeaseAgreementsForOfficeAndResearchAndDevelopmentSpaceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_20220101to20221231_usgaapAccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis_usgaapGovernmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638097</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis">us-gaap:GovernmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_20220101to20221231_entxAgreementAxis_entxJointVentureAgreementMember_usgaapRelatedPartyTransactionsByRelatedPartyAxis_entxDnaBiomedicalSolutionsLtdAndOramedLtdMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638097</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">entx:DnaBiomedicalSolutionsLtdAndOramedLtdMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="entx:AgreementAxis">entx:JointVentureAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_20220101to20221231_entxAgreementAxis_entxPatentTransferAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638097</identifier>
            <segment>
                <xbrldi:explicitMember dimension="entx:AgreementAxis">entx:PatentTransferAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_20221231_usgaapAccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis_usgaapGovernmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638097</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis">us-gaap:GovernmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_20220101to20221231_entxAgreementAxis_entxJointVentureAgreementMember_usgaapRelatedPartyTransactionsByRelatedPartyAxis_entxDnaBiomedicalSolutionsLtdMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638097</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">entx:DnaBiomedicalSolutionsLtdMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="entx:AgreementAxis">entx:JointVentureAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_20220101to20221231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638097</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_20180731_usgaapClassOfWarrantOrRightAxis_usgaapWarrantMember_usgaapSubsidiarySaleOfStockAxis_usgaapIPOMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638097</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-07-31</instant>
        </period>
    </context>
    <context id="C_20180701to20180731_usgaapClassOfWarrantOrRightAxis_usgaapWarrantMember_usgaapSubsidiarySaleOfStockAxis_usgaapIPOMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638097</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-07-01</startDate>
            <endDate>2018-07-31</endDate>
        </period>
    </context>
    <context id="C_20210331_usgaapClassOfWarrantOrRightAxis_usgaapWarrantMember_usgaapSubsidiarySaleOfStockAxis_usgaapIPOMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638097</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="C_20210301to20210331_usgaapClassOfWarrantOrRightAxis_usgaapWarrantMember_usgaapSubsidiarySaleOfStockAxis_usgaapIPOMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638097</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-03-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="C_20191231_usgaapRelatedPartyTransactionsByRelatedPartyAxis_entxAccreditedInvestorsIncludingCertainBoardMembersAndTheirAffiliatesMember_usgaapSubsidiarySaleOfStockAxis_usgaapPrivatePlacementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638097</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">entx:AccreditedInvestorsIncludingCertainBoardMembersAndTheirAffiliatesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_20200229_usgaapRelatedPartyTransactionsByRelatedPartyAxis_entxAccreditedInvestorsIncludingCertainBoardMembersAndTheirAffiliatesMember_usgaapSubsidiarySaleOfStockAxis_usgaapPrivatePlacementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638097</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">entx:AccreditedInvestorsIncludingCertainBoardMembersAndTheirAffiliatesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-02-29</instant>
        </period>
    </context>
    <context id="C_20190101to20191231_usgaapRelatedPartyTransactionsByRelatedPartyAxis_entxAccreditedInvestorsIncludingCertainBoardMembersAndTheirAffiliatesMember_usgaapSubsidiarySaleOfStockAxis_usgaapPrivatePlacementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638097</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">entx:AccreditedInvestorsIncludingCertainBoardMembersAndTheirAffiliatesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="C_20200201to20200229_usgaapRelatedPartyTransactionsByRelatedPartyAxis_entxAccreditedInvestorsIncludingCertainBoardMembersAndTheirAffiliatesMember_usgaapSubsidiarySaleOfStockAxis_usgaapPrivatePlacementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638097</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">entx:AccreditedInvestorsIncludingCertainBoardMembersAndTheirAffiliatesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-02-01</startDate>
            <endDate>2020-02-29</endDate>
        </period>
    </context>
    <context id="C_20191231_usgaapClassOfWarrantOrRightAxis_entxBrokerWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638097</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">entx:BrokerWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_20200229_usgaapClassOfWarrantOrRightAxis_entxBrokerWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638097</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">entx:BrokerWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-02-29</instant>
        </period>
    </context>
    <context id="C_20210623_usgaapClassOfWarrantOrRightAxis_usgaapWarrantMember_usgaapRelatedPartyTransactionsByRelatedPartyAxis_entxChairmanOfBoardAndDnaMember_usgaapSubsidiarySaleOfStockAxis_usgaapPrivatePlacementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638097</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">entx:ChairmanOfBoardAndDnaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-23</instant>
        </period>
    </context>
    <context id="C_20210623_usgaapRelatedPartyTransactionsByRelatedPartyAxis_entxChairmanOfBoardAndDnaMember_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember_usgaapSubsidiarySaleOfStockAxis_usgaapPrivatePlacementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638097</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">entx:ChairmanOfBoardAndDnaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-23</instant>
        </period>
    </context>
    <context id="C_20210601to20210623_usgaapClassOfWarrantOrRightAxis_usgaapWarrantMember_usgaapRelatedPartyTransactionsByRelatedPartyAxis_entxChairmanOfBoardAndDnaMember_usgaapSubsidiarySaleOfStockAxis_usgaapPrivatePlacementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638097</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">entx:ChairmanOfBoardAndDnaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-01</startDate>
            <endDate>2021-06-23</endDate>
        </period>
    </context>
    <context id="C_20200704_entxEquityProgramAxis_entxAtmEquityProgram2020Member_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638097</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="entx:EquityProgramAxis">entx:AtmEquityProgram2020Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-07-04</instant>
        </period>
    </context>
    <context id="C_20201231_entxEquityProgramAxis_entxAtmEquityProgram2020Member_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638097</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="entx:EquityProgramAxis">entx:AtmEquityProgram2020Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_20211231_entxEquityProgramAxis_entxAtmEquityProgram2020Member_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638097</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="entx:EquityProgramAxis">entx:AtmEquityProgram2020Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_20210101to20211231_entxEquityProgramAxis_entxAtmEquityProgram2020Member_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638097</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="entx:EquityProgramAxis">entx:AtmEquityProgram2020Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_20210731_entxEquityProgramAxis_entxAtmEquityProgram2021Member_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638097</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="entx:EquityProgramAxis">entx:AtmEquityProgram2021Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-07-31</instant>
        </period>
    </context>
    <context id="C_20210601to20210731_entxEquityProgramAxis_entxAtmEquityProgram2021Member_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638097</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="entx:EquityProgramAxis">entx:AtmEquityProgram2021Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-01</startDate>
            <endDate>2021-07-31</endDate>
        </period>
    </context>
    <context id="C_20210101to20211231_usgaapRelatedPartyTransactionsByRelatedPartyAxis_entxSeveralEmployeesAndServiceProvidersMember_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638097</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">entx:SeveralEmployeesAndServiceProvidersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_20221231_usgaapClassOfWarrantOrRightAxis_usgaapWarrantMember_usgaapSubsidiarySaleOfStockAxis_usgaapIPOMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638097</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_20201231_entxEquityProgramAxis_entxAtmEquityProgram2020Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638097</identifier>
            <segment>
                <xbrldi:explicitMember dimension="entx:EquityProgramAxis">entx:AtmEquityProgram2020Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_20210507_entxEquityProgramAxis_entxAtmEquityProgram2021Member_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638097</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="entx:EquityProgramAxis">entx:AtmEquityProgram2021Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-05-07</instant>
        </period>
    </context>
    <context id="C_20191231_usgaapClassOfWarrantOrRightAxis_entxBrokerDealerMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638097</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">entx:BrokerDealerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_20200229_usgaapClassOfWarrantOrRightAxis_entxBrokerDealerMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638097</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">entx:BrokerDealerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-02-29</instant>
        </period>
    </context>
    <context id="C_20191231_usgaapClassOfWarrantOrRightAxis_entxBrokerDealerOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638097</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">entx:BrokerDealerOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_20200229_usgaapClassOfWarrantOrRightAxis_entxBrokerDealerOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638097</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">entx:BrokerDealerOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-02-29</instant>
        </period>
    </context>
    <context id="C_20191231_usgaapClassOfWarrantOrRightAxis_entxBrokerWarrantsType1Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638097</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">entx:BrokerWarrantsType1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_20200229_usgaapClassOfWarrantOrRightAxis_entxBrokerWarrantsType1Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638097</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">entx:BrokerWarrantsType1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-02-29</instant>
        </period>
    </context>
    <context id="C_20220101to20221231_usgaapRelatedPartyTransactionsByRelatedPartyAxis_entxSeveralEmployeesAndServiceProvidersMember_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638097</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">entx:SeveralEmployeesAndServiceProvidersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_20200101to20201231_entxEquityProgramAxis_entxAtmEquityProgram2020Member_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638097</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="entx:EquityProgramAxis">entx:AtmEquityProgram2020Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_20230327">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638097</identifier>
        </entity>
        <period>
            <instant>2023-03-27</instant>
        </period>
    </context>
    <context id="C_20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638097</identifier>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="C_20220101to20221231_deiLegalEntityAxis_entxEnteraBioLtdMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638097</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">entx:EnteraBioLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_20210101to20211231_deiLegalEntityAxis_entxEnteraBioLtdMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638097</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">entx:EnteraBioLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_20210101to20211231_srtConsolidatedEntitiesAxis_srtSubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638097</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_20220101to20221231_srtConsolidatedEntitiesAxis_srtSubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638097</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_20220101to20221231_usgaapIncomeTaxAuthorityAxis_usgaapDomesticCountryMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638097</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_20220101to20221231_usgaapIncomeTaxAuthorityAxis_usgaapForeignCountryMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638097</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_20210101to20211231_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638097</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_20210101to20211231_usgaapStatementEquityComponentsAxis_usgaapAccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638097</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_20210101to20211231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638097</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_20210101to20211231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638097</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_20211231_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638097</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_20211231_usgaapStatementEquityComponentsAxis_usgaapAccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638097</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_20211231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638097</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_20211231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638097</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_20220101to20221231_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638097</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_20220101to20221231_usgaapStatementEquityComponentsAxis_usgaapAccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638097</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_20220101to20221231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638097</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_20221231_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638097</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_20221231_usgaapStatementEquityComponentsAxis_usgaapAccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638097</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_20221231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638097</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_20221231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638097</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_20201231_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638097</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_20201231_usgaapStatementEquityComponentsAxis_usgaapAccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638097</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_20201231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638097</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_20201231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638097</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_20220101to20221231_srtRangeAxis_srtMinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638097</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_20221231_srtRangeAxis_srtMaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638097</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_20211231_srtRangeAxis_srtMaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638097</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_20220101to20221231_srtRangeAxis_srtMaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638097</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_20210101to20211231_srtRangeAxis_srtMaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638097</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_20210101to20211231_srtRangeAxis_srtMinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638097</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_20220101to20221231_usgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_entxExercisePricePerShareZeroMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638097</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">entx:ExercisePricePerShareZeroMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_20221231_usgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_entxExercisePricePerShareZeroMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638097</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">entx:ExercisePricePerShareZeroMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_20221231_usgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_entxExercisePricePerShareOnePointTwoFourMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638097</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">entx:ExercisePricePerShareOnePointTwoFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_20220101to20221231_usgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_entxExercisePricePerShareOnePointTwoFourMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638097</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">entx:ExercisePricePerShareOnePointTwoFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_20221231_usgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_entxExercisePricePerShareTwoPointZeroTwoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638097</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">entx:ExercisePricePerShareTwoPointZeroTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_20220101to20221231_usgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_entxExercisePricePerShareTwoPointZeroTwoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638097</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">entx:ExercisePricePerShareTwoPointZeroTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_20221231_usgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_entxExercisePricePerShareTwoPointOneFourMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638097</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">entx:ExercisePricePerShareTwoPointOneFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_20220101to20221231_usgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_entxExercisePricePerShareTwoPointOneFourMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638097</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">entx:ExercisePricePerShareTwoPointOneFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_20221231_usgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_entxExercisePricePerShareTwoPointFiveSevenMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638097</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">entx:ExercisePricePerShareTwoPointFiveSevenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_20220101to20221231_usgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_entxExercisePricePerShareTwoPointFiveSevenMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638097</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">entx:ExercisePricePerShareTwoPointFiveSevenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_20221231_usgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_entxExercisePricePerShareTwoPointEightOneFiveMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638097</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">entx:ExercisePricePerShareTwoPointEightOneFiveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_20220101to20221231_usgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_entxExercisePricePerShareTwoPointEightOneFiveMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638097</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">entx:ExercisePricePerShareTwoPointEightOneFiveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_20221231_usgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_entxExercisePricePerShareTwoPointEightSixMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638097</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">entx:ExercisePricePerShareTwoPointEightSixMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_20220101to20221231_usgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_entxExercisePricePerShareTwoPointEightSixMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638097</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">entx:ExercisePricePerShareTwoPointEightSixMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_20221231_usgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_entxExercisePricePerShareThreePointOneFiveMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638097</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">entx:ExercisePricePerShareThreePointOneFiveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_20220101to20221231_usgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_entxExercisePricePerShareThreePointOneFiveMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638097</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">entx:ExercisePricePerShareThreePointOneFiveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_20221231_usgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_entxExercisePricePerShareThreePointSixOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638097</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">entx:ExercisePricePerShareThreePointSixOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_20220101to20221231_usgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_entxExercisePricePerShareThreePointSixOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638097</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">entx:ExercisePricePerShareThreePointSixOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_20221231_usgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_entxExercisePricePerShareOnePointFourMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638097</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">entx:ExercisePricePerShareOnePointFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_20221231_usgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_entxExercisePricePerShareTwoPointFiveThreeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638097</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">entx:ExercisePricePerShareTwoPointFiveThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_20220101to20221231_usgaapIncomeStatementLocationAxis_usgaapResearchAndDevelopmentExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638097</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_20210101to20211231_usgaapIncomeStatementLocationAxis_usgaapResearchAndDevelopmentExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638097</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_20220101to20221231_usgaapIncomeStatementLocationAxis_usgaapGeneralAndAdministrativeExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638097</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_20210101to20211231_usgaapIncomeStatementLocationAxis_usgaapGeneralAndAdministrativeExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638097</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_20221231_usgaapPlanNameAxis_entxShareIncentivePlan2018Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638097</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">entx:ShareIncentivePlan2018Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_20180702_usgaapPlanNameAxis_entxShareIncentivePlan2018Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638097</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">entx:ShareIncentivePlan2018Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-07-02</instant>
        </period>
    </context>
    <context id="C_20220101to20221231_usgaapPlanNameAxis_entxShareIncentivePlan2018Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638097</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">entx:ShareIncentivePlan2018Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_20210401to20210407_srtTitleOfIndividualAxis_entxEmployeesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638097</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">entx:EmployeesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-04-07</endDate>
        </period>
    </context>
    <context id="C_20210401to20210407_srtTitleOfIndividualAxis_entxNonExecutiveDirectorMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638097</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">entx:NonExecutiveDirectorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-04-07</endDate>
        </period>
    </context>
    <context id="C_20210401to20210421_srtTitleOfIndividualAxis_srtExecutiveOfficerMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638097</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ExecutiveOfficerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-04-21</endDate>
        </period>
    </context>
    <context id="C_20210801to20210823_srtTitleOfIndividualAxis_entxNonExecutiveDirectorMember_usgaapVestingAxis_entxShareBasedPaymentArrangementTrancheSixMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638097</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">entx:NonExecutiveDirectorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">entx:ShareBasedPaymentArrangementTrancheSixMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-08-01</startDate>
            <endDate>2021-08-23</endDate>
        </period>
    </context>
    <context id="C_20210801to20210823_srtTitleOfIndividualAxis_entxNonExecutiveDirectorMember_usgaapVestingAxis_entxShareBasedPaymentArrangementTrancheFiveMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638097</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">entx:NonExecutiveDirectorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">entx:ShareBasedPaymentArrangementTrancheFiveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-08-01</startDate>
            <endDate>2021-08-23</endDate>
        </period>
    </context>
    <context id="C_20210401to20210421_srtTitleOfIndividualAxis_srtExecutiveOfficerMember_usgaapVestingAxis_usgaapShareBasedCompensationAwardTrancheOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638097</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ExecutiveOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-04-21</endDate>
        </period>
    </context>
    <context id="C_20210401to20210421_srtTitleOfIndividualAxis_srtExecutiveOfficerMember_usgaapVestingAxis_usgaapShareBasedCompensationAwardTrancheTwoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638097</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ExecutiveOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-04-21</endDate>
        </period>
    </context>
    <context id="C_20210401to20210407_srtTitleOfIndividualAxis_entxServiceProviderMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638097</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">entx:ServiceProviderMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-04-07</endDate>
        </period>
    </context>
    <context id="C_20210401to20210407_srtTitleOfIndividualAxis_entxEmployeesMember_usgaapVestingAxis_usgaapShareBasedCompensationAwardTrancheTwoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638097</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">entx:EmployeesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-04-07</endDate>
        </period>
    </context>
    <context id="C_20210401to20210407_srtTitleOfIndividualAxis_entxServiceProviderMember_usgaapVestingAxis_usgaapShareBasedCompensationAwardTrancheTwoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638097</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">entx:ServiceProviderMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-04-07</endDate>
        </period>
    </context>
    <context id="C_20210401to20210407_srtTitleOfIndividualAxis_entxEmployeesMember_usgaapVestingAxis_usgaapShareBasedCompensationAwardTrancheOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638097</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">entx:EmployeesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-04-07</endDate>
        </period>
    </context>
    <context id="C_20210401to20210407_srtTitleOfIndividualAxis_entxServiceProviderMember_usgaapVestingAxis_usgaapShareBasedCompensationAwardTrancheOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638097</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">entx:ServiceProviderMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-04-07</endDate>
        </period>
    </context>
    <context id="C_20220101to20221231_usgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_entxExercisePricePerShareTwoPointFiveThreeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638097</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">entx:ExercisePricePerShareTwoPointFiveThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_20220101to20221231_usgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_entxExercisePricePerShareOnePointFourMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638097</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">entx:ExercisePricePerShareOnePointFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_20220101to20221231_usgaapIncomeStatementLocationAxis_usgaapCostOfSalesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638097</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_20210101to20211231_usgaapIncomeStatementLocationAxis_usgaapCostOfSalesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638097</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_20210101to20210104_srtTitleOfIndividualAxis_srtChiefExecutiveOfficerMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638097</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-01-04</endDate>
        </period>
    </context>
    <context id="C_20210101to20210104_srtTitleOfIndividualAxis_srtChiefExecutiveOfficerMember_usgaapVestingAxis_usgaapShareBasedCompensationAwardTrancheOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638097</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-01-04</endDate>
        </period>
    </context>
    <context id="C_20210101to20210104_srtTitleOfIndividualAxis_srtChiefExecutiveOfficerMember_usgaapVestingAxis_usgaapShareBasedCompensationAwardTrancheTwoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638097</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-01-04</endDate>
        </period>
    </context>
    <context id="C_20220601to20220615_srtTitleOfIndividualAxis_entxFormerChiefExecutiveOfficerMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638097</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">entx:FormerChiefExecutiveOfficerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-06-01</startDate>
            <endDate>2022-06-15</endDate>
        </period>
    </context>
    <context id="C_20220331_srtTitleOfIndividualAxis_entxExecutiveOfficerAndServiceProviderMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638097</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">entx:ExecutiveOfficerAndServiceProviderMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="C_20220101to20220331_srtTitleOfIndividualAxis_entxExecutiveOfficerAndServiceProviderMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638097</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">entx:ExecutiveOfficerAndServiceProviderMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="C_20220101to20220331_srtTitleOfIndividualAxis_entxServiceProviderMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638097</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">entx:ServiceProviderMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="C_20220331_srtTitleOfIndividualAxis_srtExecutiveOfficerMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638097</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ExecutiveOfficerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="C_20220101to20220331_srtTitleOfIndividualAxis_srtExecutiveOfficerMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638097</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ExecutiveOfficerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="C_20220101to20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638097</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="C_20220401to20220428_srtTitleOfIndividualAxis_entxEmployeeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638097</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">entx:EmployeeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-04-28</endDate>
        </period>
    </context>
    <context id="C_20220501to20220511_srtTitleOfIndividualAxis_srtChiefFinancialOfficerMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638097</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefFinancialOfficerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-01</startDate>
            <endDate>2022-05-11</endDate>
        </period>
    </context>
    <context id="C_20220701to20220715_srtTitleOfIndividualAxis_srtChiefExecutiveOfficerMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638097</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-07-15</endDate>
        </period>
    </context>
    <context id="C_20220701to20220715_srtTitleOfIndividualAxis_srtChiefExecutiveOfficerMember_usgaapTypeOfArrangementAxis_entxTriggeringEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638097</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">entx:TriggeringEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-07-15</endDate>
        </period>
    </context>
    <context id="C_20210401to20210430_srtTitleOfIndividualAxis_entxPresidentOfResearchAndDevelopmentMember_usgaapAwardTypeAxis_entxTwentySeventeenMemberMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638097</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">entx:PresidentOfResearchAndDevelopmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">entx:TwentySeventeenMemberMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-04-30</endDate>
        </period>
    </context>
    <context id="C_20210430_srtTitleOfIndividualAxis_entxPresidentOfResearchAndDevelopmentMember_usgaapAwardTypeAxis_entxTwentySeventeenMemberMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638097</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">entx:PresidentOfResearchAndDevelopmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">entx:TwentySeventeenMemberMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-30</instant>
        </period>
    </context>
    <context id="C_20220601to20220615_srtTitleOfIndividualAxis_entxPresidentOfResearchAndDevelopmentMember_usgaapAwardTypeAxis_entxTwentySeventeenMemberMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638097</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">entx:PresidentOfResearchAndDevelopmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">entx:TwentySeventeenMemberMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-06-01</startDate>
            <endDate>2022-06-15</endDate>
        </period>
    </context>
    <context id="C_20220601to20220615_srtTitleOfIndividualAxis_entxPresidentOfResearchAndDevelopmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638097</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">entx:PresidentOfResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-06-01</startDate>
            <endDate>2022-06-15</endDate>
        </period>
    </context>
    <context id="C_20220101to20221231_usgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_entxExercisePricePerShareThreePointSixEightMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638097</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">entx:ExercisePricePerShareThreePointSixEightMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_20221231_usgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_entxExercisePricePerShareThreePointSixEightMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638097</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">entx:ExercisePricePerShareThreePointSixEightMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_20220101to20221231_usgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_entxExercisePricePerShareThreePointNineSevenMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638097</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">entx:ExercisePricePerShareThreePointNineSevenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_20221231_usgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_entxExercisePricePerShareThreePointNineSevenMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638097</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">entx:ExercisePricePerShareThreePointNineSevenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_20220101to20221231_usgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_entxExercisePricePerShareSixPointThreeOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638097</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">entx:ExercisePricePerShareSixPointThreeOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_20221231_usgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_entxExercisePricePerShareSixPointThreeOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638097</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">entx:ExercisePricePerShareSixPointThreeOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_20221231_srtRangeAxis_srtMinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638097</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_20211231_srtRangeAxis_srtMinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638097</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <unit id="NIS">
        <measure>iso4217:ILS</measure>
    </unit>
    <unit id="NIS_per_Share">
        <divide>
            <unitNumerator>
                <measure>iso4217:ILS</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="Percent">
        <measure>pure</measure>
    </unit>
    <unit id="USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="USD_per_Share">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <dei:EntityCentralIndexKey
      contextRef="C_20220101to20221231"
      id="Fdei_EntityCentralIndexKey20220219150840900">0001638097</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag
      contextRef="C_20220101to20221231"
      id="Fdei_AmendmentFlag20220219150858854">false</dei:AmendmentFlag>
    <dei:DocumentFiscalPeriodFocus
      contextRef="C_20220101to20221231"
      id="Fdei_DocumentFiscalPeriodFocus20220219151109286">FY</dei:DocumentFiscalPeriodFocus>
    <us-gaap:CommonStockValue
      contextRef="C_20221231"
      id="Fxbrl_20220808213249447"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:CommonStockValue
      contextRef="C_20211231"
      id="Fxbrl_20220808214617486"
      unitRef="USD"
      xsi:nil="true"/>
    <dei:EntityTaxIdentificationNumber
      contextRef="C_20220101to20221231"
      id="Fxbrl_20220429111918108">00-0000000</dei:EntityTaxIdentificationNumber>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition
      contextRef="C_20210101to20211231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"
      id="Fxbrl_20220808213010825_xbrl_20220802040425347_20220801223211777_38"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="C_20201231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"
      id="Fxbrl_20220808214821452"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="C_20210101to20211231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"
      id="Fxbrl_20220808214839417"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_20210101to20211231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"
      id="Fxbrl_20220808214942722"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="C_20211231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"
      id="Fxbrl_20220808220722541"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_20220101to20221231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"
      id="Fxbrl_20220808220938448"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="C_20221231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"
      id="Fxbrl_20220808221051935"
      unitRef="USD"
      xsi:nil="true"/>
    <entx:ExerciseOfWarrantsValue
      contextRef="C_20210101to20211231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"
      id="Fxbrl_20230227104430880"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="C_20220601to20220615_srtTitleOfIndividualAxis_entxFormerChiefExecutiveOfficerMember"
      id="Fxbrl_20230228114443567">P2Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <dei:DocumentType
      contextRef="C_20220101to20221231"
      id="Fxbrl_20220219045605798">10-K</dei:DocumentType>
    <dei:DocumentAnnualReport
      contextRef="C_20220101to20221231"
      id="Fxbrl_20230330095848199">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate
      contextRef="C_20220101to20221231"
      id="Fxbrl_20221031100209631">2022-12-31</dei:DocumentPeriodEndDate>
    <dei:CurrentFiscalYearEndDate
      contextRef="C_20220101to20221231"
      id="Fxbrl_20230228180646841">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalYearFocus
      contextRef="C_20220101to20221231"
      id="Fxbrl_20221031100232614">2022</dei:DocumentFiscalYearFocus>
    <dei:DocumentTransitionReport
      contextRef="C_20220101to20221231"
      id="Fxbrl_20220219045840097">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="C_20220101to20221231"
      id="Fxbrl_20220219045917301">001-38556</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="C_20220101to20221231"
      id="Fxbrl_20230330185621996">Entera Bio Ltd.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="C_20220101to20221231"
      id="Fxbrl_20220307234631165">L3</dei:EntityIncorporationStateCountryCode>
    <dei:EntityAddressAddressLine1
      contextRef="C_20220101to20221231"
      id="Fxbrl_20220219050047075">Kiryat Hadassah</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2
      contextRef="C_20220101to20221231"
      id="Fxbrl_20220219050132138">Minrav Building - Fifth Floor</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown
      contextRef="C_20220101to20221231"
      id="Fxbrl_20220219050215039">Jerusalem</dei:EntityAddressCityOrTown>
    <dei:EntityAddressCountry
      contextRef="C_20220101to20221231"
      id="Fxbrl_20220307234619822">IL</dei:EntityAddressCountry>
    <dei:EntityAddressPostalZipCode
      contextRef="C_20220101to20221231"
      id="Fxbrl_20220219050350418">9112002</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="C_20220101to20221231"
      id="Fxbrl_20220219050426334">972</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="C_20220101to20221231"
      id="Fxbrl_20220219050441325">2-532-7151</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="C_20220101to20221231"
      id="Fxbrl_20220219050502450">Ordinary         shares</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="C_20220101to20221231"
      id="Fxbrl_20220219050516845">ENTX</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="C_20220101to20221231"
      id="Fxbrl_20220219115247109">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityWellKnownSeasonedIssuer
      contextRef="C_20220101to20221231"
      id="Fxbrl_20230330100604736">No</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers
      contextRef="C_20220101to20221231"
      id="Fxbrl_20230330190924391">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus
      contextRef="C_20220101to20221231"
      id="Fxbrl_20230330191005268">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="C_20220101to20221231"
      id="Fxbrl_20230330100012579">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="C_20220101to20221231"
      id="Fxbrl_20230330100029951">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="C_20220101to20221231"
      id="Fxbrl_20230330100052190">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="C_20220101to20221231"
      id="Fxbrl_20230330100105872">true</dei:EntityEmergingGrowthCompany>
    <dei:EntityExTransitionPeriod
      contextRef="C_20220101to20221231"
      id="Fxbrl_20230330100135414">false</dei:EntityExTransitionPeriod>
    <dei:EntityShellCompany
      contextRef="C_20220101to20221231"
      id="Fxbrl_20230330100211917">false</dei:EntityShellCompany>
    <dei:EntityPublicFloat
      contextRef="C_20220630"
      decimals="-5"
      id="Fxbrl_20230330100309896"
      unitRef="USD">32900000</dei:EntityPublicFloat>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="C_20230327"
      decimals="INF"
      id="Fxbrl_20220219151943625"
      unitRef="shares">28809922</dei:EntityCommonStockSharesOutstanding>
    <dei:AuditorFirmId
      contextRef="C_20220101to20221231"
      id="Fxbrl_20230228173924484">1309</dei:AuditorFirmId>
    <dei:AuditorName
      contextRef="C_20220101to20221231"
      id="Fxbrl_20230228173707325">Kesselman &amp; Kesselman</dei:AuditorName>
    <dei:AuditorLocation
      contextRef="C_20220101to20221231"
      id="Fxbrl_20230228173736195">Tel-Aviv, Israel</dei:AuditorLocation>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_20221231"
      decimals="-3"
      id="Fxbrl_20220808213205256_xbrl_20220802012333935_xbrl_20220505162133424_xbrl_20220219060830028_33"
      unitRef="USD">12309000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_20211231"
      decimals="-3"
      id="Fxbrl_20220808213205256_xbrl_20220802012333935_xbrl_20220505162133424_xbrl_20220219060830028_37"
      unitRef="USD">24892000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="C_20221231"
      decimals="-3"
      id="Fxbrl_20220808213205260_xbrl_20220802012333942_xbrl_20220505162133429_xbrl_20220219060830028_43"
      unitRef="USD">246000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="C_20211231"
      decimals="-3"
      id="Fxbrl_20220808213205260_xbrl_20220802012333942_xbrl_20220505162133429_xbrl_20220219060830028_47"
      unitRef="USD">183000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="C_20221231"
      decimals="-3"
      id="Fxbrl_20220808213205265_xbrl_20220802012333948_xbrl_20220505162133433_xbrl_20220219060830028_53"
      unitRef="USD">294000</us-gaap:OtherAssetsCurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="C_20211231"
      decimals="-3"
      id="Fxbrl_20220808213205265_xbrl_20220802012333948_xbrl_20220505162133433_xbrl_20220219060830028_57"
      unitRef="USD">254000</us-gaap:OtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="C_20221231"
      decimals="-3"
      id="Fxbrl_20220808213205268_xbrl_20220802012333953_xbrl_20220505162133436_xbrl_20220219060830028_63"
      unitRef="USD">12849000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="C_20211231"
      decimals="-3"
      id="Fxbrl_20220808213205268_xbrl_20220802012333953_xbrl_20220505162133436_xbrl_20220219060830028_67"
      unitRef="USD">25329000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_20221231"
      decimals="-3"
      id="Fxbrl_20220808213205274_xbrl_20220802012333958_xbrl_20220505162133439_xbrl_20220219060830028_83"
      unitRef="USD">139000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_20211231"
      decimals="-3"
      id="Fxbrl_20220808213205274_xbrl_20220802012333958_xbrl_20220505162133439_xbrl_20220219060830028_87"
      unitRef="USD">156000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="C_20221231"
      decimals="-3"
      id="Fxbrl_20220808213205277_xbrl_20220802012333963_xbrl_20220505162133441_xbrl_20220219060830028_93"
      unitRef="USD">90000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="C_20211231"
      decimals="-3"
      id="Fxbrl_20220808213205277_xbrl_20220802012333963_xbrl_20220505162133441_xbrl_20220219060830028_97"
      unitRef="USD">239000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:DeferredIncomeTaxAssetsNet
      contextRef="C_20221231"
      decimals="-3"
      id="Fxbrl_20220808213205281_xbrl_20220802012333968_xbrl_20220505162133444_xbrl_20220305102200651_xbrl_20220219060830028_93"
      unitRef="USD">43000</us-gaap:DeferredIncomeTaxAssetsNet>
    <us-gaap:DeferredIncomeTaxAssetsNet
      contextRef="C_20211231"
      decimals="-3"
      id="Fxbrl_20220808213205281_xbrl_20220802012333968_xbrl_20220505162133444_xbrl_20220305102200651_xbrl_20220219060830028_97"
      unitRef="USD">217000</us-gaap:DeferredIncomeTaxAssetsNet>
    <us-gaap:DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent
      contextRef="C_20221231"
      decimals="-3"
      id="Fxbrl_20220808213205284_xbrl_20220802012333974_xbrl_20220505162133446_xbrl_20220219060830028_103"
      unitRef="USD">6000</us-gaap:DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent>
    <us-gaap:DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent
      contextRef="C_20211231"
      decimals="-3"
      id="Fxbrl_20220808213205284_xbrl_20220802012333974_xbrl_20220505162133446_xbrl_20220219060830028_107"
      unitRef="USD">46000</us-gaap:DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent>
    <us-gaap:AssetsNoncurrent
      contextRef="C_20221231"
      decimals="-3"
      id="Fxbrl_20220808213205287_xbrl_20220802012333980_xbrl_20220505162133448_xbrl_20220219060830028_113"
      unitRef="USD">278000</us-gaap:AssetsNoncurrent>
    <us-gaap:AssetsNoncurrent
      contextRef="C_20211231"
      decimals="-3"
      id="Fxbrl_20220808213205287_xbrl_20220802012333980_xbrl_20220505162133448_xbrl_20220219060830028_117"
      unitRef="USD">658000</us-gaap:AssetsNoncurrent>
    <us-gaap:Assets
      contextRef="C_20221231"
      decimals="-3"
      id="Fxbrl_20220808213205289_xbrl_20220802012333985_xbrl_20220505162133450_xbrl_20220219060830028_123"
      unitRef="USD">13127000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="C_20211231"
      decimals="-3"
      id="Fxbrl_20220808213205289_xbrl_20220802012333985_xbrl_20220505162133450_xbrl_20220219060830028_127"
      unitRef="USD">25987000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="C_20221231"
      decimals="-3"
      id="Fxbrl_20220808213205292_xbrl_20220802012333989_xbrl_20220505162133452_xbrl_20220219060830028_153"
      unitRef="USD">17000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="C_20211231"
      decimals="-3"
      id="Fxbrl_20220808213205292_xbrl_20220802012333989_xbrl_20220505162133452_xbrl_20220219060830028_157"
      unitRef="USD">166000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesAndOtherLiabilities
      contextRef="C_20221231"
      decimals="-3"
      id="Fxbrl_20220808213205294_xbrl_20220802012333994_xbrl_20220505162133454_xbrl_20220219060830028_163"
      unitRef="USD">1233000</us-gaap:AccruedLiabilitiesAndOtherLiabilities>
    <us-gaap:AccruedLiabilitiesAndOtherLiabilities
      contextRef="C_20211231"
      decimals="-3"
      id="Fxbrl_20220808213205294_xbrl_20220802012333994_xbrl_20220505162133454_xbrl_20220219060830028_167"
      unitRef="USD">2801000</us-gaap:AccruedLiabilitiesAndOtherLiabilities>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="C_20221231"
      decimals="-3"
      id="Fxbrl_20220808213205297_xbrl_20220802012333998_xbrl_20220505162133457_xbrl_20220219060830028_173"
      unitRef="USD">91000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="C_20211231"
      decimals="-3"
      id="Fxbrl_20220808213205297_xbrl_20220802012333998_xbrl_20220505162133457_xbrl_20220219060830028_177"
      unitRef="USD">179000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="C_20221231"
      decimals="-3"
      id="Fxbrl_20220808213205299_xbrl_20220802012334004_xbrl_20220505162133458_xbrl_20220219060830028_183"
      unitRef="USD">0</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="C_20211231"
      decimals="-3"
      id="Fxbrl_20220808213205299_xbrl_20220802012334004_xbrl_20220505162133458_xbrl_20220219060830028_187"
      unitRef="USD">15000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="C_20221231"
      decimals="-3"
      id="Fxbrl_20220808213205301_xbrl_20220802012334009_xbrl_20220505162133460_xbrl_20220219060830028_193"
      unitRef="USD">1341000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="C_20211231"
      decimals="-3"
      id="Fxbrl_20220808213205301_xbrl_20220802012334009_xbrl_20220505162133460_xbrl_20220219060830028_197"
      unitRef="USD">3161000</us-gaap:LiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="C_20221231"
      decimals="-3"
      id="Fxbrl_20220808213205304_xbrl_20220802012334015_xbrl_20220505162133462_xbrl_20220219060830028_213"
      unitRef="USD">0</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="C_20211231"
      decimals="-3"
      id="Fxbrl_20220808213205304_xbrl_20220802012334015_xbrl_20220505162133462_xbrl_20220219060830028_217"
      unitRef="USD">123000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:PostemploymentBenefitsLiabilityNoncurrent
      contextRef="C_20221231"
      decimals="-3"
      id="Fxbrl_20220808213205306_xbrl_20220802012334021_xbrl_20220505162133465_xbrl_20220219060830028_223"
      unitRef="USD">32000</us-gaap:PostemploymentBenefitsLiabilityNoncurrent>
    <us-gaap:PostemploymentBenefitsLiabilityNoncurrent
      contextRef="C_20211231"
      decimals="-3"
      id="Fxbrl_20220808213205306_xbrl_20220802012334021_xbrl_20220505162133465_xbrl_20220219060830028_227"
      unitRef="USD">138000</us-gaap:PostemploymentBenefitsLiabilityNoncurrent>
    <us-gaap:LiabilitiesNoncurrent
      contextRef="C_20221231"
      decimals="-3"
      id="Fxbrl_20220808213205308_xbrl_20220802012334025_xbrl_20220505162133467_xbrl_20220219060830028_233"
      unitRef="USD">32000</us-gaap:LiabilitiesNoncurrent>
    <us-gaap:LiabilitiesNoncurrent
      contextRef="C_20211231"
      decimals="-3"
      id="Fxbrl_20220808213205308_xbrl_20220802012334025_xbrl_20220505162133467_xbrl_20220219060830028_237"
      unitRef="USD">261000</us-gaap:LiabilitiesNoncurrent>
    <us-gaap:Liabilities
      contextRef="C_20221231"
      decimals="-3"
      id="Fxbrl_20220808213205310_xbrl_20220802012334031_xbrl_20220505162133469_xbrl_20220219060830028_243"
      unitRef="USD">1373000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="C_20211231"
      decimals="-3"
      id="Fxbrl_20220808213205310_xbrl_20220802012334031_xbrl_20220505162133469_xbrl_20220219060830028_247"
      unitRef="USD">3422000</us-gaap:Liabilities>
    <us-gaap:CommitmentsAndContingencies
      contextRef="C_20221231"
      id="Fxbrl_20230330102150177"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="C_20211231"
      id="Fxbrl_20230330102202454"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="C_20211231"
      decimals="INF"
      id="Fxbrl_20220809034950441"
      unitRef="NIS_per_Share">0.0000769</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="C_20221231"
      decimals="INF"
      id="Fxbrl_20220808214817829"
      unitRef="NIS_per_Share">0.0000769</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="C_20211231"
      decimals="INF"
      id="Fxbrl_20220809035007189"
      unitRef="shares">140010000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="C_20221231"
      decimals="INF"
      id="Fxbrl_20220808214936276"
      unitRef="shares">140010000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_20221231"
      decimals="INF"
      id="Fxbrl_20220809035046498"
      unitRef="shares">28809922</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_20221231"
      decimals="INF"
      id="Fxbrl_20220808215259598"
      unitRef="shares">28809922</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_20211231"
      decimals="INF"
      id="Fxbrl_20220809035103868"
      unitRef="shares">28804411</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_20211231"
      decimals="INF"
      id="Fxbrl_20220808215224028"
      unitRef="shares">28804411</us-gaap:CommonStockSharesIssued>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="C_20221231"
      decimals="-3"
      id="Fxbrl_20220808213205314_xbrl_20220802012334039_xbrl_20220505162133472_xbrl_20220219060830028_283"
      unitRef="USD">107210000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="C_20211231"
      decimals="-3"
      id="Fxbrl_20220808213205314_xbrl_20220802012334039_xbrl_20220505162133472_xbrl_20220219060830028_287"
      unitRef="USD">104950000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="C_20221231"
      decimals="-3"
      id="Fxbrl_20220808213205316_xbrl_20220802012334043_xbrl_20220505162133474_xbrl_20220219060830028_293"
      unitRef="USD">41000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="C_20211231"
      decimals="-3"
      id="Fxbrl_20220808213205316_xbrl_20220802012334043_xbrl_20220505162133474_xbrl_20220219060830028_297"
      unitRef="USD">41000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="C_20221231"
      decimals="-3"
      id="Fxbrl_20220808213205318_xbrl_20220802012334047_xbrl_20220505162133476_xbrl_20220219060830028_303"
      unitRef="USD">-95497000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="C_20211231"
      decimals="-3"
      id="Fxbrl_20220808213205318_xbrl_20220802012334047_xbrl_20220505162133476_xbrl_20220219060830028_307"
      unitRef="USD">-82426000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="C_20221231"
      decimals="-3"
      id="Fxbrl_20220808213205320_xbrl_20220802012334050_xbrl_20220505162133478_xbrl_20220219060830028_313"
      unitRef="USD">11754000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_20211231"
      decimals="-3"
      id="Fxbrl_20220808213205320_xbrl_20220802012334050_xbrl_20220505162133478_xbrl_20220219060830028_317"
      unitRef="USD">22565000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="C_20221231"
      decimals="-3"
      id="Fxbrl_20220808213205323_xbrl_20220802012334055_xbrl_20220505162133480_xbrl_20220219060830028_323"
      unitRef="USD">13127000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="C_20211231"
      decimals="-3"
      id="Fxbrl_20220808213205323_xbrl_20220802012334055_xbrl_20220505162133480_xbrl_20220219060830028_327"
      unitRef="USD">25987000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:Revenues
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="Fxbrl_20220218235908029_33"
      unitRef="USD">134000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="C_20210101to20211231"
      decimals="-3"
      id="Fxbrl_20220218235908029_37"
      unitRef="USD">571000</us-gaap:Revenues>
    <us-gaap:CostOfRevenue
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="Fxbrl_20220218235908029_43"
      unitRef="USD">101000</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue
      contextRef="C_20210101to20211231"
      decimals="-3"
      id="Fxbrl_20220218235908029_47"
      unitRef="USD">373000</us-gaap:CostOfRevenue>
    <us-gaap:GrossProfit
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="Fxbrl_20220218235908029_53"
      unitRef="USD">33000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="C_20210101to20211231"
      decimals="-3"
      id="Fxbrl_20220218235908029_57"
      unitRef="USD">198000</us-gaap:GrossProfit>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="Fxbrl_20220218235908029_73"
      unitRef="USD">5848000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_20210101to20211231"
      decimals="-3"
      id="Fxbrl_20220218235908029_77"
      unitRef="USD">6771000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="Fxbrl_20220218235908029_83"
      unitRef="USD">7253000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="C_20210101to20211231"
      decimals="-3"
      id="Fxbrl_20220218235908029_87"
      unitRef="USD">5690000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OtherNonrecurringIncome
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="Fxbrl_20220218235908029_93"
      unitRef="USD">51000</us-gaap:OtherNonrecurringIncome>
    <us-gaap:OtherNonrecurringIncome
      contextRef="C_20210101to20211231"
      decimals="-3"
      id="Fxbrl_20220218235908029_97"
      unitRef="USD">46000</us-gaap:OtherNonrecurringIncome>
    <us-gaap:OperatingExpenses
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="Fxbrl_20220218235908029_103"
      unitRef="USD">13050000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="C_20210101to20211231"
      decimals="-3"
      id="Fxbrl_20220218235908029_107"
      unitRef="USD">12415000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="Fxbrl_20220218235908029_113"
      unitRef="USD">-13017000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="C_20210101to20211231"
      decimals="-3"
      id="Fxbrl_20220218235908029_117"
      unitRef="USD">-12217000</us-gaap:OperatingIncomeLoss>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="Fxbrl_20230227103207504"
      unitRef="USD">83000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="C_20210101to20211231"
      decimals="-3"
      id="Fxbrl_20220505170041902"
      unitRef="USD">-29000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="Fxbrl_20220218235908029_143"
      unitRef="USD">-12934000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="C_20210101to20211231"
      decimals="-3"
      id="Fxbrl_20220218235908029_147"
      unitRef="USD">-12246000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="Fxbrl_20220305103516954"
      unitRef="USD">137000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_20210101to20211231"
      decimals="-3"
      id="Fxbrl_20220218235908029_157"
      unitRef="USD">-59000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:NetIncomeLoss
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="Fxbrl_20220218235908029_163"
      unitRef="USD">-13071000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_20210101to20211231"
      decimals="-3"
      id="Fxbrl_20220218235908029_167"
      unitRef="USD">-12187000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareDiluted
      contextRef="C_20220101to20221231"
      decimals="2"
      id="Fxbrl_20220809001710649"
      unitRef="USD_per_Share">0.45</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="C_20220101to20221231"
      decimals="2"
      id="Fxbrl_20220218235908029_183"
      unitRef="USD_per_Share">0.45</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="C_20210101to20211231"
      decimals="2"
      id="Fxbrl_20220809001731689"
      unitRef="USD_per_Share">0.47</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="C_20210101to20211231"
      decimals="2"
      id="Fxbrl_20220218235908029_187"
      unitRef="USD_per_Share">0.47</us-gaap:EarningsPerShareBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="C_20220101to20221231"
      decimals="INF"
      id="Fxbrl_20220809035336353"
      unitRef="shares">28808090</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_20220101to20221231"
      decimals="INF"
      id="Fxbrl_20220218235908029_203"
      unitRef="shares">28808090</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="C_20210101to20211231"
      decimals="INF"
      id="Fxbrl_20220809035344893"
      unitRef="shares">26133770</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_20210101to20211231"
      decimals="INF"
      id="Fxbrl_20220218235908029_207"
      unitRef="shares">26133770</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:SharesOutstanding
      contextRef="C_20201231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"
      decimals="INF"
      id="Fxbrl_20220808214750699_xbrl_20220802040425371_20220801223211790_50"
      unitRef="shares">21057922</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_20201231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fxbrl_20220808214750699_xbrl_20220802040425371_20220801223211790_49"
      unitRef="USD">77708000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_20201231_usgaapStatementEquityComponentsAxis_usgaapAccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="Fxbrl_20220808214750699_xbrl_20220802040425371_20220801223211789_48"
      unitRef="USD">41000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_20201231_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember"
      decimals="-3"
      id="Fxbrl_20220808214750699_xbrl_20220802040425371_20220801223211789_47"
      unitRef="USD">-70239000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_20201231"
      decimals="-3"
      id="Fxbrl_20220808214750699_xbrl_20220802040425371_20220801223211788_46"
      unitRef="USD">7510000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="C_20210101to20211231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"
      decimals="-3"
      id="Fxbrl_20220808213010731_xbrl_20220802040425275_20220801223211740_10"
      unitRef="USD">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_20210101to20211231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fxbrl_20220808213010731_xbrl_20220802040425275_20220801223211740_9"
      unitRef="USD">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_20210101to20211231_usgaapStatementEquityComponentsAxis_usgaapAccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="Fxbrl_20220808213010731_xbrl_20220802040425275_20220801223211739_8"
      unitRef="USD">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_20210101to20211231_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember"
      decimals="-3"
      id="Fxbrl_20220808213010731_xbrl_20220802040425275_20220801223211739_7"
      unitRef="USD">-12187000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_20210101to20211231"
      decimals="-3"
      id="Fxbrl_20220808213010731_xbrl_20220802040425275_20220801223211738_6"
      unitRef="USD">-12187000</us-gaap:NetIncomeLoss>
    <entx:ExerciseOfWarrantsShares
      contextRef="C_20210101to20211231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"
      decimals="INF"
      id="Fxbrl_20230227104420960"
      unitRef="shares">3175050</entx:ExerciseOfWarrantsShares>
    <entx:ExerciseOfWarrantsValue
      contextRef="C_20210101to20211231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fxbrl_20230227104452135"
      unitRef="USD">3158000</entx:ExerciseOfWarrantsValue>
    <entx:ExerciseOfWarrantsValue
      contextRef="C_20210101to20211231_usgaapStatementEquityComponentsAxis_usgaapAccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="Fxbrl_20230227104616769"
      unitRef="USD">0</entx:ExerciseOfWarrantsValue>
    <entx:ExerciseOfWarrantsValue
      contextRef="C_20210101to20211231_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember"
      decimals="-3"
      id="Fxbrl_20230227104624778"
      unitRef="USD">0</entx:ExerciseOfWarrantsValue>
    <entx:ExerciseOfWarrantsValue
      contextRef="C_20210101to20211231"
      decimals="-3"
      id="Fxbrl_20230227104635185"
      unitRef="USD">3158000</entx:ExerciseOfWarrantsValue>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices
      contextRef="C_20210101to20211231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"
      decimals="INF"
      id="Fxbrl_20220808213010746_xbrl_20220802040425293_20220801223211742_15"
      unitRef="shares">4386728</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="C_20210101to20211231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fxbrl_20220808213010746_xbrl_20220802040425293_20220801223211742_14"
      unitRef="USD">21805000</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="C_20210101to20211231_usgaapStatementEquityComponentsAxis_usgaapAccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="Fxbrl_20220808213010746_xbrl_20220802040425293_20220801223211741_13"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="C_20210101to20211231_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember"
      decimals="-3"
      id="Fxbrl_20220808213010746_xbrl_20220802040425293_20220801223211741_12"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="C_20210101to20211231"
      decimals="-3"
      id="Fxbrl_20220808213010746_xbrl_20220802040425293_20220801223211741_11"
      unitRef="USD">21805000</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="C_20210101to20211231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"
      decimals="INF"
      id="Fxbrl_20220808213010768_xbrl_20220802040425307_20220801223211753_21"
      unitRef="shares">177711</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_20210101to20211231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fxbrl_20220808213010768_xbrl_20220802040425307_20220801223211752_20"
      unitRef="USD">418000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_20210101to20211231_usgaapStatementEquityComponentsAxis_usgaapAccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="Fxbrl_20220808213010768_xbrl_20220802040425307_20220801223211752_19"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_20210101to20211231_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember"
      decimals="-3"
      id="Fxbrl_20220808213010768_xbrl_20220802040425307_20220801223211743_18"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_20210101to20211231"
      decimals="-3"
      id="Fxbrl_20220808213010768_xbrl_20220802040425307_20220801223211743_17"
      unitRef="USD">418000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_20210101to20211231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"
      decimals="-3"
      id="Fxbrl_20220808213010808_xbrl_20220802040425336_20220801223211758_33"
      unitRef="USD">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_20210101to20211231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fxbrl_20220808213010808_xbrl_20220802040425336_20220801223211758_32"
      unitRef="USD">1861000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_20210101to20211231_usgaapStatementEquityComponentsAxis_usgaapAccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="Fxbrl_20220808213010808_xbrl_20220802040425336_20220801223211757_31"
      unitRef="USD">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_20210101to20211231_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember"
      decimals="-3"
      id="Fxbrl_20220808213010808_xbrl_20220802040425336_20220801223211757_30"
      unitRef="USD">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_20210101to20211231"
      decimals="-3"
      id="Fxbrl_20220808213010808_xbrl_20220802040425336_20220801223211756_29"
      unitRef="USD">1861000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <entx:VestedRestrictedShareUnitsShares
      contextRef="C_20210101to20211231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"
      decimals="INF"
      id="Fxbrl_20220808213010825_xbrl_20220802040425347_20220801223211778_39"
      unitRef="shares">7000</entx:VestedRestrictedShareUnitsShares>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition
      contextRef="C_20210101to20211231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fxbrl_20220808213010825_xbrl_20220802040425347_20220801223211777_37"
      unitRef="USD">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition
      contextRef="C_20210101to20211231_usgaapStatementEquityComponentsAxis_usgaapAccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="Fxbrl_20220808213010825_xbrl_20220802040425347_20220801223211777_36"
      unitRef="USD">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition
      contextRef="C_20210101to20211231_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember"
      decimals="-3"
      id="Fxbrl_20220808213010825_xbrl_20220802040425347_20220801223211776_35"
      unitRef="USD">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition
      contextRef="C_20210101to20211231"
      decimals="-3"
      id="Fxbrl_20220808213010825_xbrl_20220802040425347_20220801223211776_34"
      unitRef="USD">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition>
    <us-gaap:SharesOutstanding
      contextRef="C_20211231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"
      decimals="INF"
      id="Fxbrl_20220808213010846_xbrl_20220802040425360_20220801223211788_44"
      unitRef="shares">28804411</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_20211231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fxbrl_20220808213010846_xbrl_20220802040425360_20220801223211779_43"
      unitRef="USD">104950000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_20211231_usgaapStatementEquityComponentsAxis_usgaapAccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="Fxbrl_20220808213010846_xbrl_20220802040425360_20220801223211779_42"
      unitRef="USD">41000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_20211231_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember"
      decimals="-3"
      id="Fxbrl_20220808213010846_xbrl_20220802040425360_20220801223211779_41"
      unitRef="USD">-82426000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_20211231"
      decimals="-3"
      id="Fxbrl_20220808213010846_xbrl_20220802040425360_20220801223211778_40"
      unitRef="USD">22565000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="C_20220101to20221231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"
      decimals="-3"
      id="Fxbrl_20220808213010872_xbrl_20220802040425392_20220801223211805_56"
      unitRef="USD">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_20220101to20221231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fxbrl_20220808213010872_xbrl_20220802040425392_20220801223211798_55"
      unitRef="USD">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_20220101to20221231_usgaapStatementEquityComponentsAxis_usgaapAccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="Fxbrl_20220808213010872_xbrl_20220802040425392_20220801223211791_54"
      unitRef="USD">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_20220101to20221231_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember"
      decimals="-3"
      id="Fxbrl_20220808213010872_xbrl_20220802040425392_20220801223211791_53"
      unitRef="USD">-13071000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="Fxbrl_20220808213010872_xbrl_20220802040425392_20220801223211791_52"
      unitRef="USD">-13071000</us-gaap:NetIncomeLoss>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="C_20220101to20221231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"
      decimals="INF"
      id="Fxbrl_20220808213010900_xbrl_20220802045916318_xbrl_20220802040425307_20220801223211753_21"
      unitRef="shares">5511</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_20220101to20221231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fxbrl_20220808213010900_xbrl_20220802045916318_xbrl_20220802040425307_20220801223211752_20"
      unitRef="USD">13000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_20220101to20221231_usgaapStatementEquityComponentsAxis_usgaapAccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="Fxbrl_20220808213010900_xbrl_20220802045916318_xbrl_20220802040425307_20220801223211752_19"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_20220101to20221231_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember"
      decimals="-3"
      id="Fxbrl_20220808213010900_xbrl_20220802045916318_xbrl_20220802040425307_20220801223211743_18"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="Fxbrl_20220808213010900_xbrl_20220802045916318_xbrl_20220802040425307_20220801223211743_17"
      unitRef="USD">13000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_20220101to20221231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"
      decimals="-3"
      id="Fxbrl_20220808213010926_xbrl_20220802040425404_20220801223211821_61"
      unitRef="USD">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_20220101to20221231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fxbrl_20220808213010926_xbrl_20220802040425404_20220801223211820_60"
      unitRef="USD">2247000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_20220101to20221231_usgaapStatementEquityComponentsAxis_usgaapAccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="Fxbrl_20220808213010926_xbrl_20220802040425404_20220801223211820_59"
      unitRef="USD">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_20220101to20221231_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember"
      decimals="-3"
      id="Fxbrl_20220808213010926_xbrl_20220802040425404_20220801223211806_58"
      unitRef="USD">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="Fxbrl_20220808213010926_xbrl_20220802040425404_20220801223211806_57"
      unitRef="USD">2247000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:SharesOutstanding
      contextRef="C_20221231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"
      decimals="INF"
      id="Fxbrl_20220808213010940_xbrl_20220802040425417_20220801223211822_66"
      unitRef="shares">28809922</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_20221231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fxbrl_20220808213010940_xbrl_20220802040425417_20220801223211822_65"
      unitRef="USD">107210000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_20221231_usgaapStatementEquityComponentsAxis_usgaapAccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="Fxbrl_20220808213010940_xbrl_20220802040425417_20220801223211822_64"
      unitRef="USD">41000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_20221231_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember"
      decimals="-3"
      id="Fxbrl_20220808213010940_xbrl_20220802040425417_20220801223211821_63"
      unitRef="USD">-95497000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_20221231"
      decimals="-3"
      id="Fxbrl_20220808213010940_xbrl_20220802040425417_20220801223211821_62"
      unitRef="USD">11754000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="Fxbrl_20220219041121835_33"
      unitRef="USD">-13071000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_20210101to20211231"
      decimals="-3"
      id="Fxbrl_20220219041121835_37"
      unitRef="USD">-12187000</us-gaap:NetIncomeLoss>
    <us-gaap:Depreciation
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="Fxbrl_20220219041121835_63"
      unitRef="USD">64000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="C_20210101to20211231"
      decimals="-3"
      id="Fxbrl_20220219041121835_67"
      unitRef="USD">53000</us-gaap:Depreciation>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="Fxbrl_20220305111909474_xbrl_20220219041121835_63"
      unitRef="USD">174000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="C_20210101to20211231"
      decimals="-3"
      id="Fxbrl_20220305111909474_xbrl_20220219041121835_67"
      unitRef="USD">-217000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:ShareBasedCompensation
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="Fxbrl_20220219041121835_83"
      unitRef="USD">2247000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="C_20210101to20211231"
      decimals="-3"
      id="Fxbrl_20220219041121835_87"
      unitRef="USD">1861000</us-gaap:ShareBasedCompensation>
    <entx:FinanceExpensesNet
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="Fxbrl_20220219041121835_103"
      unitRef="USD">-78000</entx:FinanceExpensesNet>
    <entx:FinanceExpensesNet
      contextRef="C_20210101to20211231"
      decimals="-3"
      id="Fxbrl_20220219041121835_107"
      unitRef="USD">18000</entx:FinanceExpensesNet>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="Fxbrl_20220219041121835_123"
      unitRef="USD">63000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="C_20210101to20211231"
      decimals="-3"
      id="Fxbrl_20220219041121835_127"
      unitRef="USD">-72000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInOtherCurrentAssets
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="Fxbrl_20220219041121835_133"
      unitRef="USD">40000</us-gaap:IncreaseDecreaseInOtherCurrentAssets>
    <us-gaap:IncreaseDecreaseInOtherCurrentAssets
      contextRef="C_20210101to20211231"
      decimals="-3"
      id="Fxbrl_20220219041121835_137"
      unitRef="USD">-7000</us-gaap:IncreaseDecreaseInOtherCurrentAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="Fxbrl_20230227113240554"
      unitRef="USD">-149000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="C_20210101to20211231"
      decimals="-3"
      id="Fxbrl_20220219041121835_147"
      unitRef="USD">2000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="Fxbrl_20220219041121835_153"
      unitRef="USD">-1568000</us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
      contextRef="C_20210101to20211231"
      decimals="-3"
      id="Fxbrl_20220219041121835_157"
      unitRef="USD">1471000</us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="Fxbrl_20220219041121835_163"
      unitRef="USD">-15000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="C_20210101to20211231"
      decimals="-3"
      id="Fxbrl_20220219041121835_167"
      unitRef="USD">-143000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="Fxbrl_20220219041121835_173"
      unitRef="USD">-12499000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="C_20210101to20211231"
      decimals="-3"
      id="Fxbrl_20220305111416980"
      unitRef="USD">-9063000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <entx:FundsInRespectOfEmployeeRightsUponRetirement
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="Fxbrl_20221030215603518_xbrl_20220219041121835_203"
      unitRef="USD">55000</entx:FundsInRespectOfEmployeeRightsUponRetirement>
    <entx:FundsInRespectOfEmployeeRightsUponRetirement
      contextRef="C_20210101to20211231"
      decimals="-3"
      id="Fxbrl_20221030215603518_xbrl_20220219041121835_207"
      unitRef="USD">0</entx:FundsInRespectOfEmployeeRightsUponRetirement>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="Fxbrl_20221030215719839_xbrl_20220219041121835_203"
      unitRef="USD">47000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="C_20210101to20211231"
      decimals="-3"
      id="Fxbrl_20221030215719839_xbrl_20220219041121835_207"
      unitRef="USD">17000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="Fxbrl_20221030215741538"
      unitRef="USD">-102000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="C_20210101to20211231"
      decimals="-3"
      id="Fxbrl_20221030215753542"
      unitRef="USD">-17000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="Fxbrl_20220219041121835_283"
      unitRef="USD">0</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="C_20210101to20211231"
      decimals="-3"
      id="Fxbrl_20220219041121835_287"
      unitRef="USD">21805000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <entx:ProceedsFromOptionsAndWarrantExercises
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="Fxbrl_20220219041121835_293"
      unitRef="USD">13000</entx:ProceedsFromOptionsAndWarrantExercises>
    <entx:ProceedsFromOptionsAndWarrantExercises
      contextRef="C_20210101to20211231"
      decimals="-3"
      id="Fxbrl_20220219041121835_297"
      unitRef="USD">3576000</entx:ProceedsFromOptionsAndWarrantExercises>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="Fxbrl_20220219041121835_303"
      unitRef="USD">13000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="C_20210101to20211231"
      decimals="-3"
      id="Fxbrl_20220219041121835_307"
      unitRef="USD">25381000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="Fxbrl_20220219041121835_313"
      unitRef="USD">-12588000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="C_20210101to20211231"
      decimals="-3"
      id="Fxbrl_20220219041121835_317"
      unitRef="USD">16301000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_20211231"
      decimals="-3"
      id="Fxbrl_20220219041121835_323"
      unitRef="USD">24964000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_20201231"
      decimals="-3"
      id="Fxbrl_20230227113922248"
      unitRef="USD">8663000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_20221231"
      decimals="-3"
      id="Fxbrl_20220809005417307"
      unitRef="USD">12376000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_20211231"
      decimals="-3"
      id="Fxbrl_20220809005506769"
      unitRef="USD">24964000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_20221231"
      decimals="-3"
      id="Fxbrl_20220505171612811"
      unitRef="USD">12309000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_20211231"
      decimals="-3"
      id="Fxbrl_20220505171631694"
      unitRef="USD">24892000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashAndCashEquivalents
      contextRef="C_20221231"
      decimals="-3"
      id="Fxbrl_20220505171702884"
      unitRef="USD">67000</us-gaap:RestrictedCashAndCashEquivalents>
    <us-gaap:RestrictedCashAndCashEquivalents
      contextRef="C_20211231"
      decimals="-3"
      id="Fxbrl_20220505171713125"
      unitRef="USD">72000</us-gaap:RestrictedCashAndCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_20221231"
      decimals="-3"
      id="Fxbrl_20220809005613001"
      unitRef="USD">12376000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_20211231"
      decimals="-3"
      id="Fxbrl_20220809005750289"
      unitRef="USD">24964000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:IncomeTaxesPaidNet
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="Fxbrl_20220505172109460"
      unitRef="USD">165000</us-gaap:IncomeTaxesPaidNet>
    <us-gaap:IncomeTaxesPaidNet
      contextRef="C_20210101to20211231"
      decimals="-3"
      id="Fxbrl_20220505172119135"
      unitRef="USD">2000</us-gaap:IncomeTaxesPaidNet>
    <entx:RightOfUseAssetsObtainedInExchangeForNewOperatingLeaseLiabilities
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="Fxbrl_20221030215529370_xbrl_20220505172109460"
      unitRef="USD">0</entx:RightOfUseAssetsObtainedInExchangeForNewOperatingLeaseLiabilities>
    <entx:RightOfUseAssetsObtainedInExchangeForNewOperatingLeaseLiabilities
      contextRef="C_20210101to20211231"
      decimals="-3"
      id="Fxbrl_20221030215529370_xbrl_20220505172119135"
      unitRef="USD">31000</entx:RightOfUseAssetsObtainedInExchangeForNewOperatingLeaseLiabilities>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock
      contextRef="C_20220101to20221231"
      id="Fxbrl_20220510153034567">

&lt;div&gt;

&lt;div&gt;

&lt;div&gt;

&lt;div style="line-height:1.25;font-family:Times New Roman, Times, serif"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;&lt;span&gt;NOTE
1 - GENERAL&lt;/span&gt;&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;

&lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&#160;&lt;/div&gt;

&lt;div&gt;

&lt;table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align:top;font-family:Times New Roman, Times, serif;width:47px"&gt;
        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;a.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:top;font-family:Times New Roman, Times, serif;width:auto"&gt;
        &lt;div style="text-align:justify;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span style="line-height:107%"&gt;Entera
        Bio Ltd. (collectively with its subsidiary, the "Company") was incorporated on September 30, 2009 and commenced operation on June 1, 2010.
        On January 8, 2018, the Company incorporated Entera Bio Inc., a wholly owned subsidiary incorporated in Delaware United States. The Company
        is a leader in the development and commercialization of orally delivered large molecule therapeutics for use in areas with significant
        unmet medical need where adoption of injectable therapies is limited due to cost, convenience and compliance challenges for patients.
        The Company&#x2019;s most advanced product candidates, EB613 for the treatment of osteoporosis and EB612 for the treatment of hypoparathyroidism,
        are based on its proprietary technology platform and are both in clinical development. Additionally, the Company intends to license its
        oral delivery technology to biopharmaceutical companies for use with their proprietary compounds.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/td&gt; &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align:top;font-family:Times New Roman, Times, serif;width:47px"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:top;font-family:Times New Roman, Times, serif;width:auto"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align:top;font-family:Times New Roman, Times, serif;width:47px"&gt;
        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;b.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:top;font-family:Times New Roman, Times, serif;width:auto"&gt;
        &lt;div style="text-align:justify;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span style="line-height:107%"&gt;The
        Company's ordinary shares, NIS 0.0000769
        par value per share (&#x201c;ordinary shares&#x201d;), are listed on the Nasdaq Capital Market since July 2018 under the symbol &#x201c;ENTX&#x201d;.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/td&gt; &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align:top;font-family:Times New Roman, Times, serif;width:47px"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:top;font-family:Times New Roman, Times, serif;width:auto"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align:top;font-family:Times New Roman, Times, serif;width:47px"&gt;
        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;c.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:top;font-family:Times New Roman, Times, serif;width:auto"&gt;
        &lt;div style="text-align:justify;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span style="line-height:107%"&gt;On
        December 10, 2018, the Company entered into a research collaboration and license agreement with Amgen (the &#x201c;Amgen Agreement&#x201d;)
        &#160;for the use of the Company&#x2019;s oral delivery platform in the field of inflammatory disease and other serious illnesses. Pursuant
        to the Amgen Agreement, the Company and Amgen have agreed to use the Company&#x2019;s proprietary drug delivery platform to develop oral
        formulations for one preclinical large molecule program that Amgen has selected. Amgen is responsible for the clinical development, regulatory
        approval, manufacturing and worldwide commercialization of the programs.&lt;br/&gt;&lt;br/&gt;The Company granted Amgen an exclusive, worldwide,
        sublicensable license under certain of its intellectual property relating to its drug delivery technology to develop, manufacture and
        commercialize the applicable products. The Company will retain all intellectual property rights to its drug delivery technology, and Amgen
        will retain all rights to its large molecules and any subsequent improvements, and ownership of certain intellectual property developed
        through the performance of the agreement is to be determined by U.S. patent law.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/td&gt; &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align:top;font-family:Times New Roman, Times, serif;width:47px"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:top;font-family:Times New Roman, Times, serif;width:auto"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align:top;font-family:Times New Roman, Times, serif;width:47px"&gt;
        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;d.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:top;font-family:Times New Roman, Times, serif;width:auto"&gt;
        &lt;div style="text-align:justify;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span style="line-height:115%"&gt;&lt;span style="line-height:115%"&gt;Because
        &lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;the Company is engaged in research and development activities, it has not
        derived significant income from its activities and has incurred accumulated deficit in the amount of $95.5
        million through December 31, 2022 and negative cash flows from operating activities. The Company's management is of the opinion that its
        available funds as of December 31, 2022 will allow the Company to operate under its current plans into the third quarter of 2024. This
        assumes the use of the Company&#x2019;s capital to fund its ongoing operations, including R&amp;amp;D and the completion of the Phase 1 study
        related to the new formulation EB612. This does not include the capital required to fund the Company's proposed Phase 3 study for EB613
        in osteoporosis and comparative study. These factors raise substantial doubt as to the Company's ability to continue as a going concern.
        Management is in the process of evaluating various financing alternatives in the public or private equity markets, debt financing and
        strategic collaborations, as the Company will need to finance future research and development activities, general and administrative expenses
        and working capital through fund raising. However, there is no certainty about the Company's ability to obtain such funding. The financial
        statements do not include any adjustments that may be necessary should the Company be unable to continue as a going concern.&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span style="line-height:107%"&gt;
        &lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt;
  &lt;/table&gt; &lt;/div&gt; &lt;/div&gt; &lt;/div&gt; &lt;/div&gt; </us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="C_20221231"
      decimals="7"
      id="Fxbrl_20221030152157060"
      unitRef="NIS_per_Share">0.0000769</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="C_20221231"
      decimals="-5"
      id="Fxbrl_20230330101925263"
      unitRef="USD">-95500000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:SignificantAccountingPoliciesTextBlock contextRef="C_20220101to20221231" id="F20230227081832010_0">

&lt;div&gt;

&lt;div&gt;

&lt;div style="line-height:1.25;font-family:Times New Roman, Times, serif;font-weight:bold;text-align:justify"&gt; &lt;div style="font-size:10pt;display:inline"&gt;
&lt;div style="font-family:Times New Roman,Times,serif;display:inline"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;NOTE
2 - SIGNIFICANT ACCOUNTING POLICIES&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt; &lt;/div&gt; &lt;/div&gt;

&lt;div style="line-height:1.25;text-align:justify"&gt;&#160;&lt;/div&gt;

&lt;div&gt;

&lt;div&gt;

&lt;table cellpadding="0" cellspacing="0" style="color:#000000;font-family:'Times New Roman',Times,serif;font-size:10pt;text-align:left;width:100%"&gt;
  &lt;tr&gt;
    &lt;td style="width:47px;vertical-align:top;font-family:Times New Roman, Times, serif;font-weight:bold;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;a.&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width:auto;vertical-align:top"&gt;
        &lt;div style="font-weight:bold;text-align:justify"&gt; &lt;div style="font-size:10pt;display:inline"&gt; &lt;div style="font-family:Times New Roman, Times, serif;display:inline;text-align:left"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;Basis
        of presentation of the financial statements&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt; &lt;/div&gt; &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt;
  &lt;/table&gt;

&lt;div style="line-height:1.25;text-align:justify"&gt;&#160;&lt;/div&gt;

&lt;div style="margin-left:47px;line-height:1.25;text-align:justify"&gt; &lt;div style="font-size:10pt;display:inline"&gt; &lt;div style="font-family:Times New Roman,Times,serif;display:inline"&gt;
&lt;div style="display:inline;text-align:left"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span style="line-height:normal"&gt;The
consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States
(&#x201c;U.S. GAAP&#x201d;). Prior to 2021, the Company prepared its financial statements in accordance with International Financial Reporting
Standards (&#x201c;IFRS&#x201d;), as issued by the International Accounting Standards Board (&#x201c;IASB&#x201d;), as permitted in the United
States (&#x201c;U.S.&#x201d;) based on the Company&#x2019;s status as a foreign private issuer as defined in the rules promulgated by the
U.S. Securities and Exchange Commission (the &#x201c;SEC&#x201d;). During 2021, the Company determined that it is no longer qualified as
a foreign private issuer under the SEC rules. As a result, since January 1, 2022, the Company has been required to comply with all of
the disclosure and reporting requirements applicable to U.S. domestic issuers, including preparing its financial statement in accordance
with U.S. GAAP.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt; &lt;/div&gt; &lt;/div&gt; &lt;/div&gt; &lt;/div&gt;
&lt;/div&gt;

&lt;div style="line-height:1.25;text-align:justify"&gt;&#160;&lt;/div&gt;

&lt;div&gt;

&lt;div&gt;

&lt;table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"&gt;
  &lt;tr&gt;
    &lt;td style="width:47px;vertical-align:top;font-family:Times New Roman, Times, serif;font-weight:bold;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;b.&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width:auto;vertical-align:top"&gt;
        &lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;&lt;span style="line-height:107%"&gt;Use
        of estimates in the preparation of financial statements&lt;/span&gt;&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;/td&gt; &lt;/tr&gt;
  &lt;/table&gt;

&lt;div style="line-height:1.25;text-align:justify"&gt;&#160;&lt;/div&gt;

&lt;div style="margin-left:47px;line-height:1.25;font-family:Times New Roman, Times, serif;text-align:justify"&gt; &lt;div style="font-size:10pt;display:inline"&gt;
&lt;div style="font-family:Times New Roman,Times,serif;display:inline"&gt;

&lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span style="line-height:normal"&gt;The
preparation of the consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions
that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial
statements and the reported amounts of revenues and expenses during the reporting period. Actual results may differ from those estimates.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
&lt;/div&gt; &lt;/div&gt; &lt;/div&gt; &lt;/div&gt;

&lt;p style="margin:0pt"&gt;&#160;&lt;/p&gt; &lt;/div&gt; &lt;/div&gt;

&lt;div&gt;

&lt;div&gt;

&lt;div&gt;

&lt;div style="line-height:1.25;text-align:justify"&gt;

&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman, Times, serif;font-size:10pt;width:100%;text-align:left;color:rgb(0, 0, 0);border:0px"&gt;
  &lt;tr&gt;
    &lt;td style="width:47px;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;c.&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width:auto;vertical-align:top"&gt;
        &lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;&lt;span style="line-height:107%"&gt;Functional
        currency &lt;/span&gt;&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;/td&gt; &lt;/tr&gt;
  &lt;/table&gt; &lt;/div&gt;

&lt;p style="margin:0pt"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"&gt;
  &lt;tr&gt;
    &lt;td style="width:47px;text-align:justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="width:37.25px;vertical-align:top;font-family:Times New Roman, Times, serif;text-align:justify"&gt; &lt;div style="font-size:10pt;display:inline"&gt;
        &lt;div style="font-family:Times New Roman,Times,serif;display:inline"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;1)&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/div&gt; &lt;/td&gt;
    &lt;td style="width:auto;vertical-align:top"&gt;
        &lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span style="line-height:107%"&gt;Functional
        and presentation currency&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
        &lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/p&gt;
        &lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;Items
        included in the financial statements of the Company are measured using the currency of the primary economic environment in which the entity
        operates (the &#x201c;functional currency&#x201d;). The U.S. dollar is the currency of the primary economic environment in which the operations
        of the Company are conducted. The consolidated financial statements are presented in U.S. dollars.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
        &lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify"&gt;&#160;&lt;/p&gt;
        &lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;The
        functional currency of the subsidiary is the U.S. dollar.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;/td&gt; &lt;/tr&gt;
  &lt;/table&gt;

&lt;div style="line-height:1.25;text-align:justify"&gt;&#160;&lt;/div&gt; &lt;/div&gt; &lt;/div&gt; &lt;div style="font-family:Times New Roman, Times, serif;display:inline;text-align:left"&gt;

&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman, Times, serif;font-size:10pt;width:100%;text-align:left;color:rgb(0, 0, 0);border:0px"&gt;
  &lt;tr&gt;
    &lt;td style="width:47px;text-align:justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="width:37.25px;vertical-align:top;font-family:Times New Roman, Times, serif;text-align:justify"&gt;
        &lt;div style="font-size:10pt"&gt;
        &lt;div style="font-family:Times New Roman, Times, serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;2)&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/div&gt; &lt;/td&gt;
    &lt;td style="width:auto;vertical-align:top"&gt;
        &lt;div style="text-align:justify"&gt;
        &lt;div style="font-size:10pt"&gt;
        &lt;div style="font-family:Times New Roman, Times, serif;text-align:left"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;Transactions
        and balances&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;div style="font-family:Times New Roman, Times, serif"&gt;&#160;&lt;/div&gt;
        &lt;div style="font-family:Times New Roman, Times, serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span style="line-height:107%"&gt;Transactions
        and balances originally denominated in U.S. dollars are presented at their original amounts. Balances in non- U.S. dollar currencies are
        translated into U.S. dollars using historical and current exchange rates for non-monetary and monetary balances, respectively. For non-U.S.
        dollar transactions and other items in the statements of income (indicated below), the following exchange rates are used: (i) for transactions
        &#x2013; exchange rates at transaction dates or average exchange rates; and (ii) for other items (derived from non-monetary balance sheet
        items such as depreciation and amortization) &#x2013; historical exchange rates. &#160;Currency transaction gains and losses are presented
        in financial income (expenses), as appropriate.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt; &lt;/div&gt; &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt;
  &lt;/table&gt; &lt;/div&gt; &lt;/div&gt;

&lt;p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman,Times,serif"&gt;&#160;&lt;/p&gt;

&lt;div style="line-height:1.25;font-family:Times New Roman, Times, serif;text-align:justify"&gt;

&lt;div/&gt; &lt;/div&gt;

&lt;div&gt;

&lt;div&gt;

&lt;div&gt;

&lt;div&gt;

&lt;div&gt;

&lt;div style="line-height:1.25"&gt;

&lt;div style="line-height:1.25"&gt;

&lt;table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"&gt;
  &lt;tr&gt;
    &lt;td style="width:47px;text-align:justify;vertical-align:top"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;d.&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="vertical-align:top;text-align:justify"&gt;
        &lt;div&gt; &lt;div style="font-size:10pt;display:inline"&gt; &lt;div style="font-family:Times New Roman,Times,serif;display:inline"&gt; &lt;div style="font-weight:bold;display:inline;text-align:left"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span style="line-height:107%"&gt;Principles
        of consolidation&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt; &lt;/div&gt; &lt;/div&gt;
        &lt;div style="margin:0pt"&gt;&#160;&lt;/div&gt; &lt;/div&gt;
        &lt;div&gt;
        &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;
        &lt;div style="line-height:1.25"&gt; &lt;div style="font-size:10pt;display:inline"&gt; &lt;div style="font-family:Times New Roman, Times, serif;display:inline;text-align:left"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span style="line-height:normal"&gt;The
        consolidated financial statements include the accounts of the Company and its subsidiary Entera Bio Inc. All inter-company transactions
        and balances have been eliminated in consolidation.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt; &lt;/div&gt; &lt;/div&gt; &lt;/div&gt; &lt;/div&gt;
        &lt;/td&gt; &lt;/tr&gt;
  &lt;/table&gt;  &lt;/div&gt; &lt;/div&gt; &lt;/div&gt;

&lt;div style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&#160;&lt;/div&gt;

&lt;div style="line-height:1.25"&gt;

&lt;div style="line-height:1.25"&gt;

&lt;div&gt;

&lt;table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"&gt;
  &lt;tr&gt;
    &lt;td style="width:47px;text-align:justify;vertical-align:top"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;e.&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="vertical-align:top;text-align:justify"&gt;
        &lt;div style="font-weight:bold"&gt; &lt;div style="font-size:10pt;display:inline"&gt; &lt;div style="font-family:Times New Roman, Times, serif;display:inline;text-align:left"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;&lt;span style="line-height:107%"&gt;Cash
        and cash equivalents&lt;/span&gt;&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt; &lt;/div&gt;
        &lt;div style="margin:0pt"&gt;&#160;&lt;/div&gt; &lt;/div&gt;
        &lt;div&gt;
        &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;
        &lt;div style="line-height:1.25"&gt;
        &lt;div style="line-height:1.25"&gt; &lt;div style="font-size:10pt;display:inline"&gt; &lt;div style="font-family:Times New Roman, Times, serif;display:inline;text-align:left"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span style="line-height:normal"&gt;The
        Company considers as cash equivalents all short-term, highly liquid investments, which include short-term bank deposits with original
        maturities of three months or less from the date of purchase that are not restricted as to withdrawal or use and are readily convertible
        to known amounts of cash.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt; &lt;/div&gt; &lt;/div&gt; &lt;/div&gt; &lt;/div&gt; &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt;
  &lt;/table&gt;  &lt;/div&gt;

&lt;div style="margin-left:70.9pt;line-height:1.25;font-family:Times New Roman, Times, serif;text-align:justify"&gt;&#160;&lt;/div&gt; &lt;/div&gt; &lt;/div&gt;

&lt;div&gt;

&lt;div style="line-height:1.25"&gt;

&lt;div style="line-height:1.25"&gt;

&lt;table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"&gt;
  &lt;tr&gt;
    &lt;td style="width:47px;text-align:justify;vertical-align:top"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;f.&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="vertical-align:top;text-align:justify"&gt;
        &lt;div style="font-weight:bold"&gt;
        &lt;div style="font-weight:bold"&gt; &lt;div style="font-size:10pt;display:inline"&gt; &lt;div style="font-family:Times New Roman, Times, serif;display:inline;text-align:left"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;&lt;span style="line-height:107%"&gt;Restricted
        cash&lt;/span&gt;&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt; &lt;/div&gt;
        &lt;div style="margin:0pt"&gt;&#160;&lt;/div&gt; &lt;/div&gt; &lt;/div&gt;
        &lt;div&gt;
        &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;
        &lt;div style="line-height:1.25"&gt;
        &lt;div style="text-align:left;line-height:1.25"&gt;
        &lt;div style="line-height:1.25;text-align:justify"&gt; &lt;div style="font-size:10pt;display:inline"&gt; &lt;div style="font-family:Times New Roman, Times, serif;display:inline;text-align:left"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span style="line-height:normal;color:black"&gt;Restricted
        cash deposited in an interest-bearing saving account which is used as a security for the Company's office rent&#160;and credit card.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/div&gt; &lt;/div&gt; &lt;/div&gt; &lt;/div&gt; &lt;/div&gt; &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt;
  &lt;/table&gt;

&lt;div style="margin-left:70.9pt;line-height:1.25;font-family:Times New Roman, Times, serif;text-align:justify"&gt;&#160;&lt;/div&gt;

&lt;div style="line-height:1.25;font-family:Times New Roman, Times, serif;text-align:justify"&gt;

&lt;div&gt;

&lt;table cellpadding="0" cellspacing="0" style="border:0px;width:100%"&gt;
  &lt;tr&gt;
    &lt;td style="width:47px"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;g.&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;
        &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;Concentrations
        of credit risk&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;/td&gt; &lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&#160;&lt;/p&gt;

&lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;margin-left:47px"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Financial
instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash and cash equivalents.
The Company maintains cash held in checking accounts and deposits at financial institutions in major Israeli and U.S. banks. Management
believes the Company is not exposed to significant credit risk to its current financial institution, but will continue to monitor regularly
and adjust, if needed, to mitigate risk. The Company has established guidelines regarding diversification of its investments and their
maturities, which are designed to maintain principal and maximize liquidity. To date, the Company has not experienced any losses associated
with this credit risk and continues to believe that this exposure is not significant.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;/div&gt;  &lt;/div&gt;

&lt;div style="margin-left:70.9pt;line-height:1.25;font-family:Times New Roman, Times, serif;text-align:justify"&gt;&#160;&lt;/div&gt; &lt;/div&gt; &lt;/div&gt;
&lt;/div&gt;

&lt;div&gt;

&lt;div style="line-height:1.25"&gt;

&lt;div&gt;

&lt;div style="line-height:1.25"&gt;

&lt;div style="line-height:1.25"&gt;

&lt;table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"&gt;
  &lt;tr&gt;
    &lt;td style="width:47px;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;h.&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="vertical-align:top;text-align:justify"&gt;
        &lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;Fair
        value measurement&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;/td&gt; &lt;/tr&gt;
  &lt;/table&gt; &lt;/div&gt; &lt;/div&gt; &lt;/div&gt; &lt;/div&gt;

&lt;div&gt;

&lt;p style="margin:0pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin-left:47px;margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span style="line-height:normal"&gt;The
&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;Company measures fair value and discloses fair value measurements for financial assets and liabilities.
Fair value is based on the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between
market participants at the measurement date. The accounting standard establishes a fair value hierarchy that prioritizes observable and
unobservable inputs used to measure fair value into three broad levels, which are described below:&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&#160;&lt;/p&gt;

&lt;p style="margin-left:47px;margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span style="line-height:normal"&gt;Level
&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;1: Quoted prices (unadjusted) in active markets that are accessible at the measurement date for assets
or liabilities. The fair value hierarchy gives the highest priority to Level 1 inputs.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin-left:50pt;margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&#160;&lt;/p&gt;

&lt;p style="margin-left:47px;margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span style="color:black"&gt;Level
&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;2: Observable inputs that are based on inputs not quoted on active markets but corroborated by market
data.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin-left:50pt;margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&#160;&lt;/p&gt;

&lt;p style="margin-left:47px;margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span style="color:black"&gt;Level
&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;3: Unobservable inputs are used when little or no market data is available. The fair value hierarchy
gives the lowest priority to Level 3 inputs.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin-left:47px;margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&#160;&lt;/p&gt; &lt;/div&gt;
&lt;/div&gt;

&lt;div/&gt;

&lt;div&gt;

&lt;div style="line-height:1.25"&gt;

&lt;div&gt;

&lt;div style="line-height:1.25"&gt;

&lt;div style="line-height:1.25"&gt;

&lt;table cellpadding="0" cellspacing="0" style="border:0px;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:left;width:100%"&gt;
  &lt;tr&gt;
    &lt;td style="width:47px;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;i.&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="vertical-align:top;text-align:justify"&gt;
        &lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;&lt;span&gt;&lt;span&gt;Employee
        severance benefits&lt;/span&gt;&lt;/span&gt;&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;/td&gt; &lt;/tr&gt;
  &lt;/table&gt; &lt;/div&gt; &lt;/div&gt; &lt;/div&gt; &lt;/div&gt;

&lt;div&gt;

&lt;p style="margin:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&#160;&lt;/p&gt;

&lt;p style="margin-top:0pt;margin-left:47px;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span style="line-height:normal"&gt;Under
&lt;/span&gt;the Israeli Severance Pay Law, 1963, the Company is required to make severance payments upon dismissal of an Israeli employee or
upon termination of employment in certain other circumstances. The severance payment liability to the employees located in Israel (based
upon length of service and the latest monthly salary - one month&#x2019;s salary for each year employed) is recorded on the Company&#x2019;s
balance sheet under &#x201c;Liability for employee rights upon retirement.&#x201d; The liability is recorded as if it was payable at each
balance sheet date on an undiscounted basis.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&#160;&lt;/p&gt;

&lt;p style="margin-top:0pt;margin-left:47px;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span style="line-height:normal"&gt;In
&lt;/span&gt;accordance with Section 14 of the Israeli Severance Pay Law, 1963, the Company makes regular deposits with certain insurance companies
for accounts controlled by each applicable employee in order to secure the employee&#x2019;s retirement benefit obligation. The Company
is fully relieved from any severance pay liability with respect to each such employee after it makes the payments on behalf of the employee.
The liability accrued in respect of these employees and the amounts funded, as of the respective agreement dates, are not reflected in
the Company balance sheet, as the amounts funded are not under the control and management of the Company and the pension or severance
pay risks have been irrevocably transferred to the applicable insurance companies (the &#x201c;Contribution Plan&#x201d;).&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin-top:0pt;margin-left:50pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&#160;&lt;/p&gt;

&lt;p style="margin-top:0pt;margin-left:47px;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span style="line-height:normal"&gt;With
regard to the period before December 2013, the liability is funded in part from the purchase of insurance policies or by the establishment
of pension funds with dedicated deposits in the funds. The amounts used to fund these liabilities are included in the balance sheets under
&#x201c;Funds in respect of employee rights upon retirement&#x201d;. These policies are the Company&#x2019;s assets. &lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin-top:0pt;margin-left:50pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&#160;&lt;/p&gt;

&lt;p style="margin-top:0pt;margin-left:47px;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span style="color:black"&gt;The
&lt;/span&gt;amounts of severance payment expenses were $132&#160;and
$137
for the years ended December 31, 2022&#160;and 2021, respectively.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;br/&gt;&#160;&lt;/p&gt;

&lt;p style="margin-top:0pt;margin-left:47px;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span style="color:black"&gt;The
&lt;/span&gt;Company expects to contribute to insurance companies approximately $132
for the year ending December 31, 2023 in connection with its expected severance liabilities for that year.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin-top:0pt;margin-left:47px;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&#160;&lt;/p&gt; &lt;/div&gt;
&lt;/div&gt;

&lt;div/&gt; &lt;/div&gt;

&lt;div&gt;

&lt;div&gt;

&lt;div style="line-height:1.25"&gt;

&lt;div&gt;

&lt;div style="line-height:1.25"&gt;

&lt;div style="line-height:1.25"&gt;

&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman, Times, serif;font-size:10pt;width:100%;text-align:left;color:rgb(0, 0, 0);border:0px"&gt;
  &lt;tr&gt;
    &lt;td style="width:47px;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;j.&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width:auto;vertical-align:top;text-align:justify"&gt;
        &lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:left"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;&lt;span style="line-height:107%"&gt;Leases&lt;/span&gt;&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt; &lt;/tr&gt;
  &lt;/table&gt; &lt;/div&gt; &lt;/div&gt; &lt;/div&gt; &lt;/div&gt;

&lt;div&gt;

&lt;p style="margin:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&#160;&lt;/p&gt;

&lt;p style="margin-top:0pt;margin-left:47px;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;The
Company determines if an arrangement is a lease at inception. Balances related to operating leases are included in operating lease right-of-use
(&#x201c;ROU&#x201d;) assets and current and non-current operating lease liabilities in the consolidated balance sheets.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin:0pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin-top:0pt;margin-left:47px;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span style="line-height:107%"&gt;ROU
&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;assets represent the Company&#x2019;s right to use an underlying asset for the lease term and lease
liabilities represent the Company&#x2019;s obligation to make lease payments arising from the lease. Operating lease ROU assets and liabilities
are recognized as of the commencement date based on the present value of lease payments over the lease term. Lease terms will include
options to extend or terminate the lease when it is reasonably certain that the Company will either exercise or not exercise the option
to renew or terminate the lease.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin:0pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin-top:0pt;margin-left:47px;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span style="line-height:107%"&gt;The
&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;discount rate for the lease is the rate implicit in the lease unless that rate cannot be readily determined.
As the Company&#x2019;s leases do not provide an implicit rate, the Company&#x2019;s uses its estimated incremental borrowing rate based
on the information available at the commencement date in determining the present value of lease payments. Lease expense for lease payments
is recognized on a straight-line basis over the lease term.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin-top:0pt;margin-left:90px;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&#160;&lt;/p&gt;

&lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;margin-left:47px;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Sublease
income is recognized on a straight-line basis over the expected lease term and is included in other income in our consolidated statements
of operations&lt;span style="line-height:107%"&gt;.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;/div&gt; &lt;/div&gt;

&lt;p style="margin:0pt"&gt;&#160;&lt;/p&gt;

&lt;div&gt;

&lt;table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"&gt;
  &lt;tr&gt;
    &lt;td style="width:47px;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;k.&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width:auto;vertical-align:top"&gt;
        &lt;div style="font-weight:bold;text-align:justify"&gt; &lt;div style="font-size:10pt;display:inline"&gt; &lt;div style="font-family:Times New Roman, Times, serif;display:inline;text-align:left"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;Property
        and equipment&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt; &lt;/div&gt; &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt;
  &lt;/table&gt;

&lt;div style="line-height:1.25;text-align:justify"&gt;&#160;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"&gt;
  &lt;tr&gt;
    &lt;td style="text-align:justify;width:36pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:top;font-family:Times New Roman, Times, serif;text-align:justify;width:27pt"&gt; &lt;div style="font-size:10pt;display:inline"&gt;
        &lt;div style="font-family:Times New Roman,Times,serif;display:inline"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;1)&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/div&gt; &lt;/td&gt;
    &lt;td style="vertical-align:top;width:auto"&gt;
        &lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span style="line-height:107%"&gt;Property
        and equipment are stated at cost, net of accumulated depreciation and amortization.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt; &lt;/tr&gt;
  &lt;/table&gt;

&lt;div style="line-height:1.25;text-align:justify"&gt;&#160;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"&gt;
  &lt;tr&gt;
    &lt;td style="text-align:justify;width:36pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:top;font-family:Times New Roman, Times, serif;text-align:justify;width:27pt"&gt; &lt;div style="font-size:10pt;display:inline"&gt;
        &lt;div style="font-family:Times New Roman,Times,serif;display:inline"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;2)&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/div&gt; &lt;/td&gt;
    &lt;td style="vertical-align:top;width:auto"&gt;
        &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span style="line-height:normal"&gt;The
        &lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;Company&#x2019;s property and equipment are depreciated using the straight-line method, which approximates
        the pattern of usage, over the term of the estimated useful life, as follows&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span style="line-height:normal"&gt;:&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt; &lt;/tr&gt;
  &lt;/table&gt;

&lt;div&gt;

&lt;div&gt;

&lt;div&gt;

&lt;div&gt;

&lt;div&gt;

&lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;

&lt;div style="margin-left:126pt"&gt;

&lt;table border="0" cellpadding="0" cellspacing="0" style="width:70%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left"&gt;
  &lt;tr&gt;
    &lt;td style="width:50.94%;vertical-align:top"&gt;&#160;&lt;/td&gt;
    &lt;td style="width:24.55%;vertical-align:top"&gt;&#160;&lt;/td&gt;
    &lt;td style="width:24.51%;vertical-align:top;border-bottom:2px solid #000000"&gt;
        &lt;div style="line-height:1.25"&gt;
        &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Years&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="width:50.94%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="width:24.55%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="width:24.51%;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="width:50.94%;vertical-align:bottom;background-color:rgb(204, 238, 255)"&gt;
        &lt;div style="text-align:justify;text-indent:-10.7pt;margin-left:12.6pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Computer
        equipment&lt;/span&gt;&lt;/span&gt;&lt;/div&gt; &lt;/td&gt;
    &lt;td style="width:24.55%;vertical-align:bottom;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt;
    &lt;td style="width:24.51%;vertical-align:bottom;background-color:rgb(204, 238, 255)"&gt;
        &lt;div style="text-align:right;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;3-5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/td&gt; &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="width:50.94%;vertical-align:bottom"&gt;
        &lt;div style="text-align:justify;text-indent:-10.7pt;margin-left:12.6pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Office
        furniture&lt;/span&gt;&lt;/span&gt;&lt;/div&gt; &lt;/td&gt;
    &lt;td style="width:24.55%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="width:24.51%;vertical-align:bottom"&gt;
        &lt;div style="text-align:right;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;10&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/td&gt; &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="width:50.94%;vertical-align:bottom;background-color:rgb(204, 238, 255)"&gt;
        &lt;div style="text-align:justify;text-indent:-10.7pt;margin-left:12.6pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Laboratory
        equipment&lt;/span&gt;&lt;/span&gt;&lt;/div&gt; &lt;/td&gt;
    &lt;td style="width:24.55%;vertical-align:bottom;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt;
    &lt;td style="width:24.51%;vertical-align:bottom;background-color:rgb(204, 238, 255)"&gt;
        &lt;div style="text-align:right;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;7-10&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/td&gt; &lt;/tr&gt;
  &lt;/table&gt; &lt;/div&gt; &lt;/div&gt; &lt;/div&gt;

&lt;div style="margin-left:36pt;line-height:1.25"&gt;&#160;&lt;/div&gt; &lt;/div&gt; &lt;/div&gt;  &lt;/div&gt;

&lt;div style="margin-left:47px;line-height:1.25;text-align:justify"&gt; &lt;div style="font-size:10pt;display:inline"&gt; &lt;div style="font-family:Times New Roman,Times,serif;display:inline"&gt;
&lt;div style="display:inline;text-align:left;margin-bottom:0pt;margin-top:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span style="line-height:107%"&gt;Leasehold
improvements are amortized by the straight-line method over the shorter of (i) the expected lease term and (ii) the estimated useful life
of the improvements.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;

&lt;p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman,Times,serif"&gt;&#160;&lt;/p&gt; &lt;/div&gt; &lt;/div&gt; &lt;/div&gt; &lt;/div&gt;
&lt;/div&gt; &lt;/div&gt; &lt;/div&gt; &lt;/div&gt; &lt;/div&gt;

&lt;div/&gt;

&lt;div&gt;

&lt;div&gt;

&lt;div&gt;

&lt;div&gt;

&lt;div&gt;

&lt;div style="line-height:1.25;text-align:justify"&gt;

&lt;div&gt;

&lt;div style="line-height:1.25"&gt;

&lt;div&gt;

&lt;div style="line-height:1.25"&gt;

&lt;div style="line-height:1.25"&gt;

&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman, Times, serif;font-size:10pt;width:100%;text-align:left;color:rgb(0, 0, 0);border:0px"&gt;
  &lt;tr&gt;
    &lt;td style="width:47px;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;l.&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="vertical-align:top;text-align:justify"&gt;
        &lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:left"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;&lt;span style="line-height:107%"&gt;Impairment&#160;of
        long-lived assets&lt;/span&gt;&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;/td&gt; &lt;/tr&gt;
  &lt;/table&gt; &lt;/div&gt; &lt;/div&gt; &lt;/div&gt; &lt;/div&gt;

&lt;div&gt;

&lt;p style="margin:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&#160;&lt;/p&gt;

&lt;p style="margin-top:0pt;margin-left:47px;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span style="line-height:normal"&gt;The
&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;Company tests long-lived assets for impairment whenever events or changes in circumstances indicate
that the carrying amount of an asset may no longer be recoverable. Recoverability of long-lived assets is measured by comparing the carrying
amount of the long-lived asset to the estimated undiscounted future cash flows expected to be generated by the asset. If the sum of the
expected undiscounted cash flow is less than the carrying amount of the asset, the Company recognizes an impairment loss, which is the
excess of the carrying amount over the fair value of the asset, using the expected future discounted cash flows.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin-top:0pt;margin-left:47px;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&#160;&lt;/p&gt;

&lt;p style="margin-top:0pt;margin-left:47px;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span style="line-height:107%"&gt;As
of December 31, 2022 and 2021, the Company did not recognize an impairment loss on its long-lived assets.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
&lt;/div&gt; &lt;/div&gt;

&lt;p style="margin:0pt"&gt;&#160;&lt;/p&gt;

&lt;div&gt;

&lt;div style="line-height:1.25"&gt;

&lt;div&gt;

&lt;div style="line-height:1.25"&gt;

&lt;div style="line-height:1.25"&gt;

&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman, Times, serif;font-size:10pt;width:100%;text-align:left;color:rgb(0, 0, 0);border:0px"&gt;
  &lt;tr&gt;
    &lt;td style="width:47px;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;m.&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width:auto;vertical-align:top;text-align:justify"&gt;
        &lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:left"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;&lt;span style="line-height:107%"&gt;Share-based
        compensation &lt;/span&gt;&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;/td&gt; &lt;/tr&gt;
  &lt;/table&gt; &lt;/div&gt; &lt;/div&gt; &lt;/div&gt; &lt;/div&gt;

&lt;div&gt;

&lt;p style="margin:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&#160;&lt;/p&gt;

&lt;p style="margin-top:0pt;margin-left:47px;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span style="line-height:normal"&gt;&lt;span&gt;&lt;span&gt;The
&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;Company grants share options and restricted share units (&#x201c;RSU&#x201d;) (together
&#x201c;Share-Based Compensation&#x201d;) to its employees, directors and non-employees in consideration for services rendered&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span style="line-height:normal"&gt;&lt;span&gt;&lt;span&gt;.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin:0pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin-top:0pt;margin-left:47px;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span style="line-height:normal"&gt;&lt;span&gt;&lt;span&gt;The
Company accounts for Share-Based Compensation awards classified as equity awards, including share-based option awards and RSUs, using
grant-date fair value. The Company recognize the value of the award as an expense over the requisite service period&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span style="line-height:normal"&gt;.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin-top:0pt;margin-left:47px;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&#160;&lt;/p&gt;

&lt;p style="margin-top:0pt;margin-left:47px;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span style="line-height:normal"&gt;The
Company applies ASU 2018-07 (Topic 718) that expands the scope of Topic 718 to include Share-Based Compensation transactions for acquiring
goods and services from non-employees. Under the provision of the amendment, the Company measures share-based compensation to non-employees
in the same manner as share-based compensation to employees.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin-top:0pt;margin-left:90px;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:left"&gt;&#160;&lt;/p&gt;

&lt;p style="margin-top:0pt;margin-left:47px;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span style="line-height:107%"&gt;The
Company calculates the fair value of stock-based option awards on the date of grant using the Black-Scholes option pricing model. The
option-pricing model requires a number of assumptions, of which the most significant are the expected share price volatility and the expected
option term. The computation of expected volatility is based on the historical volatility of the Company&#x2019;s ordinary shares. The
expected option term is calculated using the simplified method, as the Company has concluded that its historical share option exercise
experience does not provide a reasonable basis to estimate expected option terms. The interest rate for periods within the expected term
of an award is based on the U.S. Treasury yield curve in effect at the time of grant. The Company&#x2019;s expected dividend rate is zero
because the Company does not currently pay cash dividends on its shares and does not anticipate doing so in the foreseeable future&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span&gt;&lt;span&gt;&lt;span style="line-height:107%"&gt;.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin-top:0pt;margin-left:90px;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:left"&gt;&#160;&lt;/p&gt;

&lt;p style="margin-top:0pt;margin-left:47px;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span style="line-height:107%"&gt;The
&lt;/span&gt;Company elected to recognize compensation costs for awards granted to employees and directors conditioned only on continued service
that have a graded vesting schedule using the accelerated method based on the multiple-option award approach. The Company has elected
to account for forfeitures as they occur&lt;span style="line-height:107%"&gt;.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin-top:0pt;margin-left:47px;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&#160;&lt;/p&gt; &lt;/div&gt;
&lt;/div&gt;

&lt;div&gt;

&lt;div/&gt;

&lt;div&gt;

&lt;div style="line-height:1.25"&gt;

&lt;div&gt;

&lt;div style="line-height:1.25"&gt;

&lt;div style="line-height:1.25"&gt;

&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman, Times, serif;font-size:10pt;width:100%;text-align:left;color:rgb(0, 0, 0);border:0px"&gt;
  &lt;tr&gt;
    &lt;td style="width:47px;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;n.&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width:auto;vertical-align:top;text-align:justify"&gt;
        &lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:left"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;&lt;span style="line-height:107%"&gt;Research
        and development expenses&lt;/span&gt;&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;/td&gt; &lt;/tr&gt;
  &lt;/table&gt; &lt;/div&gt; &lt;/div&gt; &lt;/div&gt; &lt;/div&gt;

&lt;div&gt;

&lt;p style="margin:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:left"&gt;&#160;&lt;/p&gt;

&lt;p style="margin-top:0pt;margin-left:47px;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span style="line-height:normal"&gt;Research
&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;and development expenses include costs directly attributable to the conduct of research and development
programs, including the cost of salaries, share-based compensation expenses, payroll taxes and other employee benefits, lab expenses,
consumable equipment and consulting fees. All costs associated with research and developments are expensed as incurred&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span style="line-height:normal"&gt;.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin:0pt;text-align:left"&gt;&#160;&lt;/p&gt;

&lt;p style="margin-top:0pt;margin-left:48px;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span style="line-height:normal"&gt;Grants
received from the Israel Innovation Authority (the &#160;&#x201c;IIA&#x201d;) are recognized when the grant becomes receivable, provided
there is reasonable assurance that the Company will comply with the conditions attached to the grant and there is reasonable assurance
the grant will be received. At the time grants are received, successful development of the related projects is not assured, therefore,
grants are deducted from the research and development expenses as the applicable costs are incurred, and presented in R&amp;amp;D expenses,
net&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span style="line-height:107%"&gt;&lt;span&gt;.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
&lt;/div&gt; &lt;/div&gt;  &lt;/div&gt;

&lt;div&gt;

&lt;div&gt;

&lt;div style="line-height:1.25"&gt;

&lt;div&gt;

&lt;div style="line-height:1.25"&gt;

&lt;div style="line-height:1.25"&gt;

&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman, Times, serif;font-size:10pt;width:100%;text-align:left;color:rgb(0, 0, 0);border:0px"&gt;
  &lt;tr&gt;
    &lt;td style="width:47px;text-align:justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="width:auto;vertical-align:top;text-align:justify"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="width:47px;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;o.&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width:auto;vertical-align:top;text-align:justify"&gt;
        &lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:left"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;&lt;span style="line-height:107%"&gt;Revenue
        recognition &lt;/span&gt;&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;/td&gt; &lt;/tr&gt;
  &lt;/table&gt; &lt;/div&gt; &lt;/div&gt; &lt;/div&gt; &lt;/div&gt;

&lt;div&gt;

&lt;p style="margin:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&#160;&lt;/p&gt;

&lt;p style="margin-top:0pt;margin-left:47px;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span style="line-height:normal"&gt;The
Company recognized revenue from the Amgen Agreement according to ASC 606, "Revenues from Contracts with Customers&#x201d;. Prior to the
signing of the Amgen Agreement in 2018, the Company did not have revenue transactions.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin:0pt;text-align:left"&gt;&#160;&lt;/p&gt;

&lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;margin-left:47px"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;ASC
606 Revenue from Contracts with Customer introduces a five-step model for recognizing revenue from contracts with customers, as follows:&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;margin-left:47px"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;1.&#160;
Identify the contract with a customer.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;margin-left:47px"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;2.&#160;
Identify the performance obligations in the contract.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;margin-left:47px"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;3.&#160;
Determine the transaction price.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;margin-left:47px"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;4.&#160;
Allocate the transaction price to the performance obligations in the contract.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;margin-left:47px"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;5.&#160;
Recognize revenue when (or as) the entity satisfies a performance obligation.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin:0pt;text-align:left"&gt;&#160;&lt;/p&gt;

&lt;p style="margin-top:0pt;margin-left:47px;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span style="line-height:normal"&gt;According
to ASC 606, a performance obligation is a promise to provide a distinct good or service or a series of distinct goods or services. Goods
and services that are not distinct are bundled with other goods or services in the contract until a bundle of goods or services that is
distinct is created. A good or service promised to a customer is distinct if the customer can benefit from the good or service either
on its own or together with other resources that are readily available to the customer and the entity&#x2019;s promise to transfer the
good or service to the customer is separately identifiable from other promises in the contract.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin:0pt;text-align:left"&gt;&#160;&lt;/p&gt;

&lt;p style="margin-top:0pt;margin-left:47px;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span style="line-height:107%"&gt;Options
granted to the customer that do not provide a material right to the customer that it would not receive without entering into the contract
do not give rise to performance obligations.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin:0pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin-top:0pt;margin-left:47px;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span style="line-height:normal"&gt;On
December 10, 2018, the Company entered into the Amgen Agreement for the use of the Company&#x2019;s oral delivery platform in the field
of inflammatory diseases and other serious illnesses. As part of the agreement, the Company received non-refundable and non-creditable
initial access payment of $725&#160;from
Amgen in January 2019.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin:0pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin-top:0pt;margin-left:47px;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span style="line-height:normal"&gt;The
Company identified two performance obligations in the agreement: 1) License to use the Company's proprietary drug delivery platform and
2) pre-clinical research and development services (&#x201c;pre-clinical R&amp;amp;D services&#x201d;). The preclinical R&amp;amp;D services include
discovery, research and design preclinical activities relating to the programs selected by Amgen.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin-top:0pt;margin-left:47px;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&#160;&lt;/p&gt;

&lt;div/&gt;

&lt;p style="margin-top:0pt;margin-left:47px;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;The
Company determined the license to the intellectual property to be a right to use that has significant standalone functionality separately
from the pre-clinical R&amp;amp;D services since the Company is not required to continue to support, develop or maintain the intellectual
property transferred and will not undertake any activities to change the standalone functionality of the intellectual property. Therefore,
the license to the intellectual property is a distinct performance obligation and as such revenue is recognized at the point in time that
control of the license was transferred to Amgen on December 10, 2018.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin-top:0pt;margin-left:47px;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&#160;&lt;/p&gt;

&lt;p style="margin-top:0pt;margin-left:47px;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span style="line-height:normal"&gt;Revenues
attributed to the preclinical R&amp;amp;Ds services are recognized during the period of the pre-clinical R&amp;amp;D services, over time according
to the input model method on a cost-to-cost basis, since the customer benefits from the research and development services as the entity
performs the service.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;br/&gt;&#160;&lt;/p&gt;

&lt;p style="margin-top:0pt;margin-left:47px;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span style="line-height:normal"&gt;The
Company evaluated the standalone selling price of the pre-clinical R&amp;amp;D services at $225&#160;and
the right to use the intellectual property at $500.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
&lt;/div&gt; &lt;/div&gt;

&lt;div style="line-height:1.25"&gt;

&lt;div&gt;

&lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt; &lt;/div&gt; &lt;/div&gt;

&lt;div&gt;

&lt;p style="margin-top:0pt;margin-left:47px;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span style="line-height:normal"&gt;&lt;span&gt;&lt;span&gt;The
&lt;/span&gt;&lt;/span&gt;transaction price was comprised of fixed consideration and variable consideration (capped research and development reimbursements).
Under ASC 606, the consideration that the Company would be entitled to upon the achievement of contractual milestones, which are contingent
upon the occurrence of future events of development and commercial progress, are a form of variable consideration. Variable consideration
is included in the transaction price if, in the Company&#x2019;s judgment, it is highly probable that a significant future reversal of
cumulative revenue under the contract will not occur. Estimates of variable consideration and determination of whether to include estimated
amounts in the transaction price are based largely on an assessment of the Company&#x2019;s anticipated performance and all information
(historical, current and forecasted) that is reasonably available. As of December 31, 2022, the Company did not recognize any revenues
from any potential milestone payments&lt;span&gt;&lt;span&gt;.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin:0pt;text-align:left"&gt;&#160;&lt;/p&gt;

&lt;p style="margin-top:0pt;margin-left:47px;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span style="line-height:107%"&gt;An
entity should recognize revenue for a sales-based or usage-based royalty promised in exchange for a license of intellectual property only
when (or as) the later of the following events occurs:&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;div style="line-height:1.25"&gt;

&lt;div style="line-height:1.25"&gt;

&lt;div style="line-height:1.25;text-align:left"&gt;&#160;&lt;/div&gt; &lt;/div&gt; &lt;/div&gt;

&lt;div style="line-height:1.25"&gt;

&lt;div style="line-height:1.25"&gt;

&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman, Times, serif;font-size:10pt;width:100%;text-align:left;color:rgb(0, 0, 0);border:0px"&gt;
  &lt;tr&gt;
    &lt;td style="width:47px"&gt;&#160;&lt;/td&gt;
    &lt;td style="width:45px;vertical-align:top;font-family:Times New Roman, Times, serif;text-align:justify"&gt;
        &lt;div style="font-size:10pt"&gt;
        &lt;div style="font-family:Times New Roman, Times, serif;text-align:left"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;a)&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/div&gt; &lt;/td&gt;
    &lt;td style="width:auto;vertical-align:top"&gt;
        &lt;div&gt;
        &lt;div style="text-align:justify"&gt;
        &lt;div style="font-size:10pt"&gt;
        &lt;div style="font-family:Times New Roman, Times, serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;The
        subsequent sale or usage occurs; and&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt; &lt;/div&gt; &lt;/div&gt; &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt;
  &lt;/table&gt;

&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman, Times, serif;font-size:10pt;width:100%;text-align:left;color:rgb(0, 0, 0);border:0px"&gt;
  &lt;tr&gt;
    &lt;td style="width:47px;text-align:justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="width:45px;vertical-align:top;font-family:Times New Roman, Times, serif;text-align:justify"&gt;
        &lt;div style="font-size:10pt"&gt;
        &lt;div style="font-family:Times New Roman, Times, serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;b)&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/div&gt; &lt;/td&gt;
    &lt;td style="width:auto;vertical-align:top"&gt;
        &lt;div&gt;
        &lt;div style="text-align:justify"&gt;
        &lt;div style="font-size:10pt"&gt;
        &lt;div style="font-family:Times New Roman, Times, serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;The
        performance obligation to which some or all of the sales based or usage-based royalty has been allocated has been satisfied (or partially
        satisfied).&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt; &lt;/div&gt; &lt;/div&gt; &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt;
  &lt;/table&gt; &lt;/div&gt; &lt;/div&gt; &lt;/div&gt;

&lt;p style="margin:0pt;text-align:left"&gt;&#160;&lt;/p&gt;

&lt;p style="margin-top:0pt;margin-left:47px;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span style="line-height:normal"&gt;As
&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;royalties are payable based on future commercial sales, as defined in the agreement, which did not
occur as of the financial statements date, the Company did not recognize any revenues from royalties.&#160;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin-top:0pt;margin-left:47px;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&#160;&lt;/p&gt;

&lt;p style="margin-top:0pt;margin-left:47px;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span style="font-weight:bold"&gt;&lt;span&gt;&lt;span&gt;&lt;span style="font-weight:normal"&gt;Revenues
attributed to preclinical R&amp;amp;D services are recognized during the period of the pre-clinical R&amp;amp;D services according to the input
model method on a cost-to-cost basis&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span&gt;&lt;span&gt;&lt;span style="font-weight:normal"&gt;.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin-top:0pt;margin-left:47px;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&#160;&lt;/p&gt;

&lt;p style="margin-top:0pt;margin-left:47px;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span style="line-height:107%"&gt;In
2022 and 2021, the Company recorded revenues of $89
and $502,
respectively, related to services provided under the Amgen Agreement.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin-top:0pt;margin-left:47px;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&#160;&lt;/p&gt; &lt;/div&gt;


&lt;div/&gt;

&lt;div&gt;

&lt;div style="text-align:justify;line-height:1.25"&gt;

&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman, Times, serif;font-size:10pt;width:100%;text-align:left;color:rgb(0, 0, 0);border:0px"&gt;
  &lt;tr&gt;
    &lt;td style="width:47px;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;p.&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width:auto;vertical-align:top"&gt;
        &lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;&lt;span style="line-height:107%"&gt;Income
        taxes &lt;/span&gt;&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;/td&gt; &lt;/tr&gt;
  &lt;/table&gt; &lt;/div&gt;

&lt;p style="margin:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman, Times, serif;font-size:10pt;width:100%;text-align:left;color:rgb(0, 0, 0);border:0px"&gt;
  &lt;tr&gt;
    &lt;td style="width:47px;text-align:justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="width:40px;vertical-align:top;font-family:Times New Roman, Times, serif;text-align:justify"&gt;
        &lt;div style="font-size:10pt"&gt;
        &lt;div style="font-family:Times New Roman, Times, serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;1)&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/div&gt; &lt;/td&gt;
    &lt;td style="width:auto;vertical-align:top"&gt;
        &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span style="line-height:normal"&gt;Deferred
        taxes&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;/td&gt; &lt;/tr&gt;
  &lt;/table&gt;

&lt;div style="line-height:1.25;text-align:left"&gt;&#160;&lt;/div&gt;

&lt;div style="margin-left:47px;text-align:justify;line-height:1.25;font-family:Times New Roman, Times, serif"&gt;

&lt;div style="font-size:10pt"&gt;

&lt;div style="font-family:Times New Roman, Times, serif;margin-left:40px"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span style="line-height:107%"&gt;Deferred&#160;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;income
taxes are computed using the asset and liability method. Under the asset and liability method, deferred income tax assets and liabilities
are determined based on the differences between the financial reporting and tax bases of assets and liabilities and are measured using
the currently enacted tax rates and laws. A valuation allowance is recognized to the extent that it is more likely than not that the deferred
taxes will not be realized in the foreseeable future&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span style="line-height:107%"&gt;.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
&lt;/div&gt; &lt;/div&gt;

&lt;p style="margin:0pt;text-align:left"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman, Times, serif;font-size:10pt;width:100%;text-align:left;color:rgb(0, 0, 0);border:0px"&gt;
  &lt;tr&gt;
    &lt;td style="width:47px"&gt;&#160;&lt;/td&gt;
    &lt;td style="width:40px;vertical-align:top;font-family:Times New Roman, Times, serif;text-align:justify"&gt;
        &lt;div style="font-size:10pt"&gt;
        &lt;div style="font-family:Times New Roman, Times, serif;text-align:left"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;2)&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/div&gt; &lt;/td&gt;
    &lt;td style="width:auto;vertical-align:top"&gt;
        &lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span style="line-height:107%"&gt;Uncertainty
        in income taxes&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;/td&gt; &lt;/tr&gt;
  &lt;/table&gt;

&lt;div style="line-height:1.25;text-align:left"&gt;&#160;&lt;/div&gt;

&lt;div style="margin-left:47px;text-align:justify;line-height:1.25;font-family:Times New Roman, Times, serif"&gt;

&lt;div style="font-size:10pt"&gt;

&lt;div style="font-family:Times New Roman, Times, serif;margin-left:40px"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span style="line-height:107%"&gt;The
Company follows a two-step approach in recognizing and measuring uncertain tax positions. The first step is to evaluate the tax position
for recognition by determining if the available evidence indicates that it is more likely than not that the position will be sustained
based on technical merits. If this threshold is met, the second step is to measure the tax position as the largest amount that has more
than a 50% likelihood of being realized upon ultimate settlement.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt; &lt;/div&gt; &lt;/div&gt;
&lt;/div&gt;

&lt;div style="text-align:justify;line-height:1.25;font-family:Times New Roman, Times, serif"&gt;

&lt;div style="font-size:10pt"&gt;

&lt;div style="font-family:Times New Roman, Times, serif"&gt;

&lt;p style="margin:0pt"&gt;&#160;&lt;/p&gt; &lt;/div&gt; &lt;/div&gt; &lt;/div&gt;

&lt;div&gt;

&lt;div style="line-height:1.25"&gt;

&lt;div&gt;

&lt;div style="line-height:1.25"&gt;

&lt;div style="line-height:1.25"&gt;

&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman, Times, serif;font-size:10pt;width:100%;text-align:left;color:rgb(0, 0, 0);border:0px"&gt;
  &lt;tr&gt;
    &lt;td style="width:47px;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;q.&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width:auto;vertical-align:top;text-align:justify"&gt;
        &lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:left"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;&lt;span style="line-height:107%"&gt;Loss
        per share &lt;/span&gt;&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;/td&gt; &lt;/tr&gt;
  &lt;/table&gt; &lt;/div&gt; &lt;/div&gt; &lt;/div&gt; &lt;/div&gt;

&lt;div&gt;

&lt;p style="margin:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&#160;&lt;/p&gt;

&lt;p style="margin-top:0pt;margin-left:47px;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span style="line-height:107%"&gt;Basic
loss per share is computed on the basis of the net loss, adjusted to recognize the effect of a down-round feature when it is triggered,
for the period, divided by the weighted average number of outstanding ordinary shares during the period.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin:0pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin-top:0pt;margin-left:47px;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span style="line-height:107%"&gt;Diluted
&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;loss per share is based upon the weighted average number of ordinary shares and of ordinary shares
equivalents outstanding when dilutive. Ordinary share equivalents include outstanding stock options and warrants, which are included under
the treasury stock method when dilutive. The calculation of diluted loss per share does not include options, RSUs and warrants, exercisable
into an aggregate of&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span style="line-height:107%"&gt;&#160;6,255,235
shares and&#160;&lt;/span&gt;&lt;span style="line-height:107%"&gt;6,517,102&lt;/span&gt;&lt;strong&gt;&#160;&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;shares
for the years ended December&#160;31, 2022&#160;and 2021, respectively, because the effect would have been anti-dilutive.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
&lt;/div&gt; &lt;/div&gt;

&lt;p style="margin:0pt"&gt;&#160;&lt;/p&gt;

&lt;div&gt;

&lt;div style="line-height:1.25"&gt;

&lt;div&gt;

&lt;div style="line-height:1.25"&gt;

&lt;div style="line-height:1.25"&gt;

&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman, Times, serif;font-size:10pt;width:100%;text-align:left;color:rgb(0, 0, 0);border:0px"&gt;
  &lt;tr&gt;
    &lt;td style="width:47px;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;r.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width:auto;vertical-align:top;text-align:justify"&gt;
        &lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;&lt;span&gt;&lt;span&gt;Legal
        and other contingencies&lt;/span&gt;&lt;/span&gt;&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;/td&gt; &lt;/tr&gt;
  &lt;/table&gt; &lt;/div&gt; &lt;/div&gt; &lt;/div&gt; &lt;/div&gt;

&lt;div&gt;

&lt;p style="margin:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&#160;&lt;/p&gt;

&lt;p style="margin-top:0pt;margin-left:47px;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span style="line-height:107%"&gt;Management&#160;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;applies
the guidance in ASC 450-20, &#x201c;Loss Contingencies&#x201d; when assessing losses resulting from contingencies. If the assessment of
a contingency indicates that it is probable that a material loss has been incurred and the amount of the liability can be estimated, then
the estimated liability is recorded as accrued expenses in the Company&#x2019;s consolidated financial statements&lt;span&gt;.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin:0pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin-top:0pt;margin-left:47px;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Legal
costs incurred in connection with loss contingencies are expensed as incurred&lt;span style="line-height:107%"&gt;.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin-top:0pt;margin-left:47px;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&#160;&lt;/p&gt; &lt;/div&gt;
&lt;/div&gt;

&lt;div&gt;

&lt;div/&gt; &lt;/div&gt;

&lt;div&gt;

&lt;div style="line-height:1.25"&gt;

&lt;div&gt;

&lt;div style="line-height:1.25"&gt;

&lt;div style="line-height:1.25"&gt;

&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman, Times, serif;font-size:10pt;width:100%;text-align:left;color:rgb(0, 0, 0);border:0px"&gt;
  &lt;tr&gt;
    &lt;td style="width:47px;vertical-align:top;font-family:Times New Roman, Times, serif;font-weight:bold;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;s.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width:auto;vertical-align:top;text-align:justify"&gt;
        &lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:left"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;&lt;span style="line-height:107%"&gt;Newly
        issued and recently adopted accounting pronouncements:&lt;/span&gt;&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;
        &lt;/tr&gt;
  &lt;/table&gt; &lt;/div&gt; &lt;/div&gt; &lt;/div&gt; &lt;/div&gt;

&lt;div&gt;

&lt;p style="margin:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&#160;&lt;/p&gt;

&lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;margin-left:38pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;em&gt;&lt;strong&gt;&lt;span&gt;&lt;span&gt;Recently
issued accounting pronouncements adopted&lt;/span&gt;&lt;/span&gt;&lt;/strong&gt;&lt;/em&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&#160;&lt;/p&gt;

&lt;div style="margin-left:47px"&gt;

&lt;table cellpadding="0" cellspacing="0" style="border:0px;width:100%"&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align:top;width:20pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;1)&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width:auto"&gt;
        &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;In&#160;&lt;/span&gt;&lt;/span&gt;&lt;span style="line-height:107%"&gt;November
        2021, the FASB issued ASU 2021-10 &#x201c;Government Assistance (Topic 832)&#x201d;, which requires annual disclosures that increase the
        transparency of transactions involving government grants, including (1) the types of transactions, (2) the accounting for those transactions,
        and (3) the effect of those transactions on an entity&#x2019;s financial statements. The amendments in this update are effective for financial
        statements issued for annual periods beginning after December 15, 2021.&lt;/span&gt;&#160;&lt;span style="line-height:107%"&gt;The adoption of this
        guidance did not have material impact on the Company&#x2019;s consolidated financial statements.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt; &lt;/tr&gt;
  &lt;/table&gt; &lt;/div&gt;

&lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&#160;&lt;/p&gt;

&lt;div style="margin-left:47px"&gt;

&lt;table cellpadding="0" cellspacing="0" style="border:0px;width:100%"&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align:top;width:20pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;2)&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width:auto"&gt;
        &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;In
        &lt;/span&gt;&lt;/span&gt;&lt;span style="line-height:107%"&gt;August 2020, the FASB issued ASU 2020-06 &#x201c;Debt &#x2013; Debt with Conversion and Other
        Options (Subtopic 470-20) and Derivatives and Hedging &#x2013; Contracts in Entity&#x2019;s Own Equity (Subtopic 815 &#x2013; 40).&#x201d;
        This guidance simplifies the accounting for certain financial instruments with characteristics of liabilities and equity, including convertible
        instruments and contracts on an entity&#x2019;s own equity. The amendments to this guidance are effective for fiscal years beginning after
        December&#160;15, 2021, and interim periods within those fiscal years. The Company early adopted this guidance effective January 1, 2022
        and the impact of the adoption on the Consolidated financial statements was immaterial.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;/td&gt; &lt;/tr&gt;
  &lt;/table&gt; &lt;/div&gt;

&lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;margin-left:38pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;em&gt;&lt;strong&gt;Recently
issued accounting pronouncements, not yet adopted&lt;/strong&gt;&lt;/em&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/p&gt;

&lt;div style="margin-left:47px"&gt;

&lt;table cellpadding="0" cellspacing="0" style="border:0px;width:100%"&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align:top;width:20pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;1)&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width:auto"&gt;
        &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;I&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;n
        &lt;/span&gt;&lt;/span&gt;&lt;span style="line-height:107%"&gt;June 2016, the FASB issued ASU 2016-13 &#x201c;Financial Instruments&#x2014;Credit Losses&#x2014;Measurement
        of Credit Losses on Financial Instruments.&#x201d; This guidance replaces the current incurred loss impairment methodology with a methodology
        that reflects expected credit losses and requires consideration of a broader range of reasonable and supportable information to inform
        credit loss estimates. &lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="line-height:107%"&gt;The
        guidance will be effective for Smaller Reporting Companies (SRCs, as defined by the SEC) for the fiscal year beginning on January 1, 2023,
        including interim periods within that year. The adoption of this guidance will not have material impact on the Company&#x2019;s consolidated
        financial statements.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;/td&gt; &lt;/tr&gt;
  &lt;/table&gt; &lt;/div&gt; &lt;/div&gt; &lt;/div&gt;  &lt;/div&gt; &lt;/div&gt; &lt;/div&gt; &lt;/div&gt; &lt;/div&gt; &lt;/div&gt; </us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock contextRef="C_20220101to20221231" id="F20230227081832012_1">

&lt;div&gt;

&lt;table cellpadding="0" cellspacing="0" style="color:#000000;font-family:'Times New Roman',Times,serif;font-size:10pt;text-align:left;width:100%"&gt;
  &lt;tr&gt;
    &lt;td style="width:47px;vertical-align:top;font-family:Times New Roman, Times, serif;font-weight:bold;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;a.&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width:auto;vertical-align:top"&gt;
        &lt;div style="font-weight:bold;text-align:justify"&gt; &lt;div style="font-size:10pt;display:inline"&gt; &lt;div style="font-family:Times New Roman, Times, serif;display:inline;text-align:left"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;Basis
        of presentation of the financial statements&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt; &lt;/div&gt; &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt;
  &lt;/table&gt;

&lt;div style="line-height:1.25;text-align:justify"&gt;&#160;&lt;/div&gt;

&lt;div style="margin-left:47px;line-height:1.25;text-align:justify"&gt; &lt;div style="font-size:10pt;display:inline"&gt; &lt;div style="font-family:Times New Roman,Times,serif;display:inline"&gt;
&lt;div style="display:inline;text-align:left"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span style="line-height:normal"&gt;The
consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States
(&#x201c;U.S. GAAP&#x201d;). Prior to 2021, the Company prepared its financial statements in accordance with International Financial Reporting
Standards (&#x201c;IFRS&#x201d;), as issued by the International Accounting Standards Board (&#x201c;IASB&#x201d;), as permitted in the United
States (&#x201c;U.S.&#x201d;) based on the Company&#x2019;s status as a foreign private issuer as defined in the rules promulgated by the
U.S. Securities and Exchange Commission (the &#x201c;SEC&#x201d;). During 2021, the Company determined that it is no longer qualified as
a foreign private issuer under the SEC rules. As a result, since January 1, 2022, the Company has been required to comply with all of
the disclosure and reporting requirements applicable to U.S. domestic issuers, including preparing its financial statement in accordance
with U.S. GAAP.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt; &lt;/div&gt; &lt;/div&gt; &lt;/div&gt; &lt;/div&gt; </us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:UseOfEstimates contextRef="C_20220101to20221231" id="F20230227081832012_2">

&lt;div&gt;

&lt;table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"&gt;
  &lt;tr&gt;
    &lt;td style="width:47px;vertical-align:top;font-family:Times New Roman, Times, serif;font-weight:bold;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;b.&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width:auto;vertical-align:top"&gt;
        &lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;&lt;span style="line-height:107%"&gt;Use
        of estimates in the preparation of financial statements&lt;/span&gt;&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;/td&gt; &lt;/tr&gt;
  &lt;/table&gt;

&lt;div style="line-height:1.25;text-align:justify"&gt;&#160;&lt;/div&gt;

&lt;div style="margin-left:47px;line-height:1.25;font-family:Times New Roman, Times, serif;text-align:justify"&gt; &lt;div style="font-size:10pt;display:inline"&gt;
&lt;div style="font-family:Times New Roman,Times,serif;display:inline"&gt;

&lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span style="line-height:normal"&gt;The
preparation of the consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions
that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial
statements and the reported amounts of revenues and expenses during the reporting period. Actual results may differ from those estimates.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
&lt;/div&gt; &lt;/div&gt; &lt;/div&gt; &lt;/div&gt; </us-gaap:UseOfEstimates>
    <us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock contextRef="C_20220101to20221231" id="F20230227081832013_3">

&lt;div&gt;

&lt;div&gt;

&lt;div&gt;

&lt;div style="line-height:1.25;text-align:justify"&gt;

&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman, Times, serif;font-size:10pt;width:100%;text-align:left;color:rgb(0, 0, 0);border:0px"&gt;
  &lt;tr&gt;
    &lt;td style="width:47px;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;c.&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width:auto;vertical-align:top"&gt;
        &lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;&lt;span style="line-height:107%"&gt;Functional
        currency &lt;/span&gt;&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;/td&gt; &lt;/tr&gt;
  &lt;/table&gt; &lt;/div&gt;

&lt;p style="margin:0pt"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"&gt;
  &lt;tr&gt;
    &lt;td style="width:47px;text-align:justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="width:37.25px;vertical-align:top;font-family:Times New Roman, Times, serif;text-align:justify"&gt; &lt;div style="font-size:10pt;display:inline"&gt;
        &lt;div style="font-family:Times New Roman,Times,serif;display:inline"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;1)&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/div&gt; &lt;/td&gt;
    &lt;td style="width:auto;vertical-align:top"&gt;
        &lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span style="line-height:107%"&gt;Functional
        and presentation currency&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
        &lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/p&gt;
        &lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;Items
        included in the financial statements of the Company are measured using the currency of the primary economic environment in which the entity
        operates (the &#x201c;functional currency&#x201d;). The U.S. dollar is the currency of the primary economic environment in which the operations
        of the Company are conducted. The consolidated financial statements are presented in U.S. dollars.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
        &lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify"&gt;&#160;&lt;/p&gt;
        &lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;The
        functional currency of the subsidiary is the U.S. dollar.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;/td&gt; &lt;/tr&gt;
  &lt;/table&gt;

&lt;div style="line-height:1.25;text-align:justify"&gt;&#160;&lt;/div&gt; &lt;/div&gt; &lt;/div&gt; &lt;div style="font-family:Times New Roman, Times, serif;display:inline;text-align:left"&gt;

&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman, Times, serif;font-size:10pt;width:100%;text-align:left;color:rgb(0, 0, 0);border:0px"&gt;
  &lt;tr&gt;
    &lt;td style="width:47px;text-align:justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="width:37.25px;vertical-align:top;font-family:Times New Roman, Times, serif;text-align:justify"&gt;
        &lt;div style="font-size:10pt"&gt;
        &lt;div style="font-family:Times New Roman, Times, serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;2)&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/div&gt; &lt;/td&gt;
    &lt;td style="width:auto;vertical-align:top"&gt;
        &lt;div style="text-align:justify"&gt;
        &lt;div style="font-size:10pt"&gt;
        &lt;div style="font-family:Times New Roman, Times, serif;text-align:left"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;Transactions
        and balances&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;div style="font-family:Times New Roman, Times, serif"&gt;&#160;&lt;/div&gt;
        &lt;div style="font-family:Times New Roman, Times, serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span style="line-height:107%"&gt;Transactions
        and balances originally denominated in U.S. dollars are presented at their original amounts. Balances in non- U.S. dollar currencies are
        translated into U.S. dollars using historical and current exchange rates for non-monetary and monetary balances, respectively. For non-U.S.
        dollar transactions and other items in the statements of income (indicated below), the following exchange rates are used: (i) for transactions
        &#x2013; exchange rates at transaction dates or average exchange rates; and (ii) for other items (derived from non-monetary balance sheet
        items such as depreciation and amortization) &#x2013; historical exchange rates. &#160;Currency transaction gains and losses are presented
        in financial income (expenses), as appropriate.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt; &lt;/div&gt; &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt;
  &lt;/table&gt; &lt;/div&gt; &lt;/div&gt; </us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock>
    <us-gaap:ConsolidationPolicyTextBlock contextRef="C_20220101to20221231" id="F20230227081832013_4">

&lt;table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"&gt;
  &lt;tr&gt;
    &lt;td style="width:47px;text-align:justify;vertical-align:top"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;d.&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="vertical-align:top;text-align:justify"&gt;
        &lt;div&gt; &lt;div style="font-size:10pt;display:inline"&gt; &lt;div style="font-family:Times New Roman,Times,serif;display:inline"&gt; &lt;div style="font-weight:bold;display:inline;text-align:left"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span style="line-height:107%"&gt;Principles
        of consolidation&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt; &lt;/div&gt; &lt;/div&gt;
        &lt;div style="margin:0pt"&gt;&#160;&lt;/div&gt; &lt;/div&gt;
        &lt;div&gt;
        &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;
        &lt;div style="line-height:1.25"&gt; &lt;div style="font-size:10pt;display:inline"&gt; &lt;div style="font-family:Times New Roman, Times, serif;display:inline;text-align:left"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span style="line-height:normal"&gt;The
        consolidated financial statements include the accounts of the Company and its subsidiary Entera Bio Inc. All inter-company transactions
        and balances have been eliminated in consolidation.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt; &lt;/div&gt; &lt;/div&gt; &lt;/div&gt; &lt;/div&gt;
        &lt;/td&gt; &lt;/tr&gt;
  &lt;/table&gt; </us-gaap:ConsolidationPolicyTextBlock>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock contextRef="C_20220101to20221231" id="F20230227081832013_5">

&lt;table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"&gt;
  &lt;tr&gt;
    &lt;td style="width:47px;text-align:justify;vertical-align:top"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;e.&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="vertical-align:top;text-align:justify"&gt;
        &lt;div style="font-weight:bold"&gt; &lt;div style="font-size:10pt;display:inline"&gt; &lt;div style="font-family:Times New Roman, Times, serif;display:inline;text-align:left"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;&lt;span style="line-height:107%"&gt;Cash
        and cash equivalents&lt;/span&gt;&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt; &lt;/div&gt;
        &lt;div style="margin:0pt"&gt;&#160;&lt;/div&gt; &lt;/div&gt;
        &lt;div&gt;
        &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;
        &lt;div style="line-height:1.25"&gt;
        &lt;div style="line-height:1.25"&gt; &lt;div style="font-size:10pt;display:inline"&gt; &lt;div style="font-family:Times New Roman, Times, serif;display:inline;text-align:left"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span style="line-height:normal"&gt;The
        Company considers as cash equivalents all short-term, highly liquid investments, which include short-term bank deposits with original
        maturities of three months or less from the date of purchase that are not restricted as to withdrawal or use and are readily convertible
        to known amounts of cash.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt; &lt;/div&gt; &lt;/div&gt; &lt;/div&gt; &lt;/div&gt; &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt;
  &lt;/table&gt; </us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy contextRef="C_20220101to20221231" id="F20230227081832014_6">

&lt;table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"&gt;
  &lt;tr&gt;
    &lt;td style="width:47px;text-align:justify;vertical-align:top"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;f.&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="vertical-align:top;text-align:justify"&gt;
        &lt;div style="font-weight:bold"&gt;
        &lt;div style="font-weight:bold"&gt; &lt;div style="font-size:10pt;display:inline"&gt; &lt;div style="font-family:Times New Roman, Times, serif;display:inline;text-align:left"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;&lt;span style="line-height:107%"&gt;Restricted
        cash&lt;/span&gt;&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt; &lt;/div&gt;
        &lt;div style="margin:0pt"&gt;&#160;&lt;/div&gt; &lt;/div&gt; &lt;/div&gt;
        &lt;div&gt;
        &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;
        &lt;div style="line-height:1.25"&gt;
        &lt;div style="text-align:left;line-height:1.25"&gt;
        &lt;div style="line-height:1.25;text-align:justify"&gt; &lt;div style="font-size:10pt;display:inline"&gt; &lt;div style="font-family:Times New Roman, Times, serif;display:inline;text-align:left"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span style="line-height:normal;color:black"&gt;Restricted
        cash deposited in an interest-bearing saving account which is used as a security for the Company's office rent&#160;and credit card.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/div&gt; &lt;/div&gt; &lt;/div&gt; &lt;/div&gt; &lt;/div&gt; &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt;
  &lt;/table&gt; </us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy>
    <us-gaap:ConcentrationRiskCreditRisk
      contextRef="C_20220101to20221231"
      id="Fxbrl_20230330110451620">

&lt;div&gt;

&lt;table cellpadding="0" cellspacing="0" style="border:0px;width:100%"&gt;
  &lt;tr&gt;
    &lt;td style="width:47px"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;g.&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;
        &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;Concentrations
        of credit risk&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;/td&gt; &lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&#160;&lt;/p&gt;

&lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;margin-left:47px"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Financial
instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash and cash equivalents.
The Company maintains cash held in checking accounts and deposits at financial institutions in major Israeli and U.S. banks. Management
believes the Company is not exposed to significant credit risk to its current financial institution, but will continue to monitor regularly
and adjust, if needed, to mitigate risk. The Company has established guidelines regarding diversification of its investments and their
maturities, which are designed to maintain principal and maximize liquidity. To date, the Company has not experienced any losses associated
with this credit risk and continues to believe that this exposure is not significant.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;/div&gt; </us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:FairValueMeasurementPolicyPolicyTextBlock contextRef="C_20220101to20221231" id="F20230227081832014_7">

&lt;div&gt;

&lt;div style="line-height:1.25"&gt;

&lt;div&gt;

&lt;div style="line-height:1.25"&gt;

&lt;div style="line-height:1.25"&gt;

&lt;table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"&gt;
  &lt;tr&gt;
    &lt;td style="width:47px;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;h.&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="vertical-align:top;text-align:justify"&gt;
        &lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;Fair
        value measurement&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;/td&gt; &lt;/tr&gt;
  &lt;/table&gt; &lt;/div&gt; &lt;/div&gt; &lt;/div&gt; &lt;/div&gt;

&lt;div&gt;

&lt;p style="margin:0pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin-left:47px;margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span style="line-height:normal"&gt;The
&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;Company measures fair value and discloses fair value measurements for financial assets and liabilities.
Fair value is based on the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between
market participants at the measurement date. The accounting standard establishes a fair value hierarchy that prioritizes observable and
unobservable inputs used to measure fair value into three broad levels, which are described below:&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&#160;&lt;/p&gt;

&lt;p style="margin-left:47px;margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span style="line-height:normal"&gt;Level
&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;1: Quoted prices (unadjusted) in active markets that are accessible at the measurement date for assets
or liabilities. The fair value hierarchy gives the highest priority to Level 1 inputs.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin-left:50pt;margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&#160;&lt;/p&gt;

&lt;p style="margin-left:47px;margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span style="color:black"&gt;Level
&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;2: Observable inputs that are based on inputs not quoted on active markets but corroborated by market
data.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin-left:50pt;margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&#160;&lt;/p&gt;

&lt;p style="margin-left:47px;margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span style="color:black"&gt;Level
&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;3: Unobservable inputs are used when little or no market data is available. The fair value hierarchy
gives the lowest priority to Level 3 inputs.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin-left:47px;margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&#160;&lt;/p&gt; &lt;/div&gt;
&lt;/div&gt; </us-gaap:FairValueMeasurementPolicyPolicyTextBlock>
    <entx:EmployeeSeveranceBenefitsPolicyPolicyTextBlock
      contextRef="C_20220101to20221231"
      id="F20230227081832050_33">

&lt;div&gt;

&lt;div style="line-height:1.25"&gt;

&lt;div&gt;

&lt;div style="line-height:1.25"&gt;

&lt;div style="line-height:1.25"&gt;

&lt;table cellpadding="0" cellspacing="0" style="border:0px;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:left;width:100%"&gt;
  &lt;tr&gt;
    &lt;td style="width:47px;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;i.&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="vertical-align:top;text-align:justify"&gt;
        &lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;&lt;span&gt;&lt;span&gt;Employee
        severance benefits&lt;/span&gt;&lt;/span&gt;&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;/td&gt; &lt;/tr&gt;
  &lt;/table&gt; &lt;/div&gt; &lt;/div&gt; &lt;/div&gt; &lt;/div&gt;

&lt;div&gt;

&lt;p style="margin:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&#160;&lt;/p&gt;

&lt;p style="margin-top:0pt;margin-left:47px;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span style="line-height:normal"&gt;Under
&lt;/span&gt;the Israeli Severance Pay Law, 1963, the Company is required to make severance payments upon dismissal of an Israeli employee or
upon termination of employment in certain other circumstances. The severance payment liability to the employees located in Israel (based
upon length of service and the latest monthly salary - one month&#x2019;s salary for each year employed) is recorded on the Company&#x2019;s
balance sheet under &#x201c;Liability for employee rights upon retirement.&#x201d; The liability is recorded as if it was payable at each
balance sheet date on an undiscounted basis.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&#160;&lt;/p&gt;

&lt;p style="margin-top:0pt;margin-left:47px;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span style="line-height:normal"&gt;In
&lt;/span&gt;accordance with Section 14 of the Israeli Severance Pay Law, 1963, the Company makes regular deposits with certain insurance companies
for accounts controlled by each applicable employee in order to secure the employee&#x2019;s retirement benefit obligation. The Company
is fully relieved from any severance pay liability with respect to each such employee after it makes the payments on behalf of the employee.
The liability accrued in respect of these employees and the amounts funded, as of the respective agreement dates, are not reflected in
the Company balance sheet, as the amounts funded are not under the control and management of the Company and the pension or severance
pay risks have been irrevocably transferred to the applicable insurance companies (the &#x201c;Contribution Plan&#x201d;).&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin-top:0pt;margin-left:50pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&#160;&lt;/p&gt;

&lt;p style="margin-top:0pt;margin-left:47px;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span style="line-height:normal"&gt;With
regard to the period before December 2013, the liability is funded in part from the purchase of insurance policies or by the establishment
of pension funds with dedicated deposits in the funds. The amounts used to fund these liabilities are included in the balance sheets under
&#x201c;Funds in respect of employee rights upon retirement&#x201d;. These policies are the Company&#x2019;s assets. &lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin-top:0pt;margin-left:50pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&#160;&lt;/p&gt;

&lt;p style="margin-top:0pt;margin-left:47px;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span style="color:black"&gt;The
&lt;/span&gt;amounts of severance payment expenses were $132&#160;and
$137
for the years ended December 31, 2022&#160;and 2021, respectively.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;br/&gt;&#160;&lt;/p&gt;

&lt;p style="margin-top:0pt;margin-left:47px;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span style="color:black"&gt;The
&lt;/span&gt;Company expects to contribute to insurance companies approximately $132
for the year ending December 31, 2023 in connection with its expected severance liabilities for that year.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin-top:0pt;margin-left:47px;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&#160;&lt;/p&gt; &lt;/div&gt;
&lt;/div&gt; </entx:EmployeeSeveranceBenefitsPolicyPolicyTextBlock>
    <us-gaap:SeveranceCosts1
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="F20230227081832049_28"
      unitRef="USD">132000</us-gaap:SeveranceCosts1>
    <us-gaap:SeveranceCosts1
      contextRef="C_20210101to20211231"
      decimals="-3"
      id="F20230227081832049_29"
      unitRef="USD">137000</us-gaap:SeveranceCosts1>
    <entx:SeveranceExpenses
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="F20230227081832049_30"
      unitRef="USD">132000</entx:SeveranceExpenses>
    <us-gaap:LesseeLeasesPolicyTextBlock contextRef="C_20220101to20221231" id="F20230227081832014_8">

&lt;div&gt;

&lt;div style="line-height:1.25"&gt;

&lt;div&gt;

&lt;div style="line-height:1.25"&gt;

&lt;div style="line-height:1.25"&gt;

&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman, Times, serif;font-size:10pt;width:100%;text-align:left;color:rgb(0, 0, 0);border:0px"&gt;
  &lt;tr&gt;
    &lt;td style="width:47px;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;j.&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width:auto;vertical-align:top;text-align:justify"&gt;
        &lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:left"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;&lt;span style="line-height:107%"&gt;Leases&lt;/span&gt;&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt; &lt;/tr&gt;
  &lt;/table&gt; &lt;/div&gt; &lt;/div&gt; &lt;/div&gt; &lt;/div&gt;

&lt;div&gt;

&lt;p style="margin:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&#160;&lt;/p&gt;

&lt;p style="margin-top:0pt;margin-left:47px;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;The
Company determines if an arrangement is a lease at inception. Balances related to operating leases are included in operating lease right-of-use
(&#x201c;ROU&#x201d;) assets and current and non-current operating lease liabilities in the consolidated balance sheets.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin:0pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin-top:0pt;margin-left:47px;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span style="line-height:107%"&gt;ROU
&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;assets represent the Company&#x2019;s right to use an underlying asset for the lease term and lease
liabilities represent the Company&#x2019;s obligation to make lease payments arising from the lease. Operating lease ROU assets and liabilities
are recognized as of the commencement date based on the present value of lease payments over the lease term. Lease terms will include
options to extend or terminate the lease when it is reasonably certain that the Company will either exercise or not exercise the option
to renew or terminate the lease.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin:0pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin-top:0pt;margin-left:47px;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span style="line-height:107%"&gt;The
&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;discount rate for the lease is the rate implicit in the lease unless that rate cannot be readily determined.
As the Company&#x2019;s leases do not provide an implicit rate, the Company&#x2019;s uses its estimated incremental borrowing rate based
on the information available at the commencement date in determining the present value of lease payments. Lease expense for lease payments
is recognized on a straight-line basis over the lease term.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin-top:0pt;margin-left:90px;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&#160;&lt;/p&gt;

&lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;margin-left:47px;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Sublease
income is recognized on a straight-line basis over the expected lease term and is included in other income in our consolidated statements
of operations&lt;span style="line-height:107%"&gt;.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;/div&gt; &lt;/div&gt; </us-gaap:LesseeLeasesPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock contextRef="C_20220101to20221231" id="F20230227081832031_9">

&lt;div&gt;

&lt;table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"&gt;
  &lt;tr&gt;
    &lt;td style="width:47px;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;k.&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width:auto;vertical-align:top"&gt;
        &lt;div style="font-weight:bold;text-align:justify"&gt; &lt;div style="font-size:10pt;display:inline"&gt; &lt;div style="font-family:Times New Roman, Times, serif;display:inline;text-align:left"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;Property
        and equipment&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt; &lt;/div&gt; &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt;
  &lt;/table&gt;

&lt;div style="line-height:1.25;text-align:justify"&gt;&#160;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"&gt;
  &lt;tr&gt;
    &lt;td style="text-align:justify;width:36pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:top;font-family:Times New Roman, Times, serif;text-align:justify;width:27pt"&gt; &lt;div style="font-size:10pt;display:inline"&gt;
        &lt;div style="font-family:Times New Roman,Times,serif;display:inline"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;1)&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/div&gt; &lt;/td&gt;
    &lt;td style="vertical-align:top;width:auto"&gt;
        &lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span style="line-height:107%"&gt;Property
        and equipment are stated at cost, net of accumulated depreciation and amortization.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt; &lt;/tr&gt;
  &lt;/table&gt;

&lt;div style="line-height:1.25;text-align:justify"&gt;&#160;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"&gt;
  &lt;tr&gt;
    &lt;td style="text-align:justify;width:36pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:top;font-family:Times New Roman, Times, serif;text-align:justify;width:27pt"&gt; &lt;div style="font-size:10pt;display:inline"&gt;
        &lt;div style="font-family:Times New Roman,Times,serif;display:inline"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;2)&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/div&gt; &lt;/td&gt;
    &lt;td style="vertical-align:top;width:auto"&gt;
        &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span style="line-height:normal"&gt;The
        &lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;Company&#x2019;s property and equipment are depreciated using the straight-line method, which approximates
        the pattern of usage, over the term of the estimated useful life, as follows&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span style="line-height:normal"&gt;:&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt; &lt;/tr&gt;
  &lt;/table&gt;

&lt;div&gt;

&lt;div&gt;

&lt;div&gt;

&lt;div&gt;

&lt;div&gt;

&lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;

&lt;div style="margin-left:126pt"&gt;

&lt;table border="0" cellpadding="0" cellspacing="0" style="width:70%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left"&gt;
  &lt;tr&gt;
    &lt;td style="width:50.94%;vertical-align:top"&gt;&#160;&lt;/td&gt;
    &lt;td style="width:24.55%;vertical-align:top"&gt;&#160;&lt;/td&gt;
    &lt;td style="width:24.51%;vertical-align:top;border-bottom:2px solid #000000"&gt;
        &lt;div style="line-height:1.25"&gt;
        &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Years&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="width:50.94%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="width:24.55%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="width:24.51%;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="width:50.94%;vertical-align:bottom;background-color:rgb(204, 238, 255)"&gt;
        &lt;div style="text-align:justify;text-indent:-10.7pt;margin-left:12.6pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Computer
        equipment&lt;/span&gt;&lt;/span&gt;&lt;/div&gt; &lt;/td&gt;
    &lt;td style="width:24.55%;vertical-align:bottom;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt;
    &lt;td style="width:24.51%;vertical-align:bottom;background-color:rgb(204, 238, 255)"&gt;
        &lt;div style="text-align:right;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;3-5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/td&gt; &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="width:50.94%;vertical-align:bottom"&gt;
        &lt;div style="text-align:justify;text-indent:-10.7pt;margin-left:12.6pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Office
        furniture&lt;/span&gt;&lt;/span&gt;&lt;/div&gt; &lt;/td&gt;
    &lt;td style="width:24.55%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="width:24.51%;vertical-align:bottom"&gt;
        &lt;div style="text-align:right;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;10&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/td&gt; &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="width:50.94%;vertical-align:bottom;background-color:rgb(204, 238, 255)"&gt;
        &lt;div style="text-align:justify;text-indent:-10.7pt;margin-left:12.6pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Laboratory
        equipment&lt;/span&gt;&lt;/span&gt;&lt;/div&gt; &lt;/td&gt;
    &lt;td style="width:24.55%;vertical-align:bottom;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt;
    &lt;td style="width:24.51%;vertical-align:bottom;background-color:rgb(204, 238, 255)"&gt;
        &lt;div style="text-align:right;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;7-10&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/td&gt; &lt;/tr&gt;
  &lt;/table&gt; &lt;/div&gt; &lt;/div&gt; &lt;/div&gt;

&lt;div style="margin-left:36pt;line-height:1.25"&gt;&#160;&lt;/div&gt; &lt;/div&gt; &lt;/div&gt;  &lt;/div&gt;

&lt;div style="margin-left:47px;line-height:1.25;text-align:justify"&gt; &lt;div style="font-size:10pt;display:inline"&gt; &lt;div style="font-family:Times New Roman,Times,serif;display:inline"&gt;
&lt;div style="display:inline;text-align:left;margin-bottom:0pt;margin-top:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span style="line-height:107%"&gt;Leasehold
improvements are amortized by the straight-line method over the shorter of (i) the expected lease term and (ii) the estimated useful life
of the improvements.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;

&lt;p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman,Times,serif"&gt;&#160;&lt;/p&gt; &lt;/div&gt; &lt;/div&gt; &lt;/div&gt; &lt;/div&gt; </us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <entx:ScheduleOfEstimatedUsefulLifeTableTextBlock
      contextRef="C_20220101to20221231"
      id="F20230227081832031_10">

&lt;div&gt;

&lt;div&gt;

&lt;div&gt;

&lt;div&gt;

&lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;

&lt;div style="margin-left:126pt"&gt;

&lt;table border="0" cellpadding="0" cellspacing="0" style="width:70%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left"&gt;
  &lt;tr&gt;
    &lt;td style="width:50.94%;vertical-align:top"&gt;&#160;&lt;/td&gt;
    &lt;td style="width:24.55%;vertical-align:top"&gt;&#160;&lt;/td&gt;
    &lt;td style="width:24.51%;vertical-align:top;border-bottom:2px solid #000000"&gt;
        &lt;div style="line-height:1.25"&gt;
        &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Years&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="width:50.94%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="width:24.55%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="width:24.51%;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="width:50.94%;vertical-align:bottom;background-color:rgb(204, 238, 255)"&gt;
        &lt;div style="text-align:justify;text-indent:-10.7pt;margin-left:12.6pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Computer
        equipment&lt;/span&gt;&lt;/span&gt;&lt;/div&gt; &lt;/td&gt;
    &lt;td style="width:24.55%;vertical-align:bottom;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt;
    &lt;td style="width:24.51%;vertical-align:bottom;background-color:rgb(204, 238, 255)"&gt;
        &lt;div style="text-align:right;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;3-5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/td&gt; &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="width:50.94%;vertical-align:bottom"&gt;
        &lt;div style="text-align:justify;text-indent:-10.7pt;margin-left:12.6pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Office
        furniture&lt;/span&gt;&lt;/span&gt;&lt;/div&gt; &lt;/td&gt;
    &lt;td style="width:24.55%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="width:24.51%;vertical-align:bottom"&gt;
        &lt;div style="text-align:right;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;10&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/td&gt; &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="width:50.94%;vertical-align:bottom;background-color:rgb(204, 238, 255)"&gt;
        &lt;div style="text-align:justify;text-indent:-10.7pt;margin-left:12.6pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Laboratory
        equipment&lt;/span&gt;&lt;/span&gt;&lt;/div&gt; &lt;/td&gt;
    &lt;td style="width:24.55%;vertical-align:bottom;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt;
    &lt;td style="width:24.51%;vertical-align:bottom;background-color:rgb(204, 238, 255)"&gt;
        &lt;div style="text-align:right;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;7-10&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/td&gt; &lt;/tr&gt;
  &lt;/table&gt; &lt;/div&gt; &lt;/div&gt; &lt;/div&gt;

&lt;div style="margin-left:36pt;line-height:1.25"&gt;&#160;&lt;/div&gt; &lt;/div&gt; &lt;/div&gt; </entx:ScheduleOfEstimatedUsefulLifeTableTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="C_20220101to20221231_srtRangeAxis_srtMinimumMember_usgaapPropertyPlantAndEquipmentByTypeAxis_usgaapComputerEquipmentMember"
      id="F20230227081832033_17">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="C_20220101to20221231_srtRangeAxis_srtMaximumMember_usgaapPropertyPlantAndEquipmentByTypeAxis_usgaapComputerEquipmentMember"
      id="F20230227081832034_18">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="C_20220101to20221231_usgaapPropertyPlantAndEquipmentByTypeAxis_usgaapOfficeEquipmentMember"
      id="F20230227081832047_21">P10Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="C_20220101to20221231_srtRangeAxis_srtMinimumMember_usgaapPropertyPlantAndEquipmentByTypeAxis_entxLaboratoryEquipmentMember"
      id="F20230227081832034_19">P7Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="C_20220101to20221231_srtRangeAxis_srtMaximumMember_usgaapPropertyPlantAndEquipmentByTypeAxis_entxLaboratoryEquipmentMember"
      id="F20230227081832034_20">P10Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock
      contextRef="C_20220101to20221231"
      id="F20230227081832032_11">

&lt;div&gt;

&lt;div style="line-height:1.25"&gt;

&lt;div&gt;

&lt;div style="line-height:1.25"&gt;

&lt;div style="line-height:1.25"&gt;

&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman, Times, serif;font-size:10pt;width:100%;text-align:left;color:rgb(0, 0, 0);border:0px"&gt;
  &lt;tr&gt;
    &lt;td style="width:47px;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;l.&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="vertical-align:top;text-align:justify"&gt;
        &lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:left"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;&lt;span style="line-height:107%"&gt;Impairment&#160;of
        long-lived assets&lt;/span&gt;&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;/td&gt; &lt;/tr&gt;
  &lt;/table&gt; &lt;/div&gt; &lt;/div&gt; &lt;/div&gt; &lt;/div&gt;

&lt;div&gt;

&lt;p style="margin:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&#160;&lt;/p&gt;

&lt;p style="margin-top:0pt;margin-left:47px;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span style="line-height:normal"&gt;The
&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;Company tests long-lived assets for impairment whenever events or changes in circumstances indicate
that the carrying amount of an asset may no longer be recoverable. Recoverability of long-lived assets is measured by comparing the carrying
amount of the long-lived asset to the estimated undiscounted future cash flows expected to be generated by the asset. If the sum of the
expected undiscounted cash flow is less than the carrying amount of the asset, the Company recognizes an impairment loss, which is the
excess of the carrying amount over the fair value of the asset, using the expected future discounted cash flows.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin-top:0pt;margin-left:47px;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&#160;&lt;/p&gt;

&lt;p style="margin-top:0pt;margin-left:47px;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span style="line-height:107%"&gt;As
of December 31, 2022 and 2021, the Company did not recognize an impairment loss on its long-lived assets.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
&lt;/div&gt; &lt;/div&gt; </us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy
      contextRef="C_20220101to20221231"
      id="F20230227081832032_12">

&lt;div&gt;

&lt;div style="line-height:1.25"&gt;

&lt;div&gt;

&lt;div style="line-height:1.25"&gt;

&lt;div style="line-height:1.25"&gt;

&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman, Times, serif;font-size:10pt;width:100%;text-align:left;color:rgb(0, 0, 0);border:0px"&gt;
  &lt;tr&gt;
    &lt;td style="width:47px;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;m.&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width:auto;vertical-align:top;text-align:justify"&gt;
        &lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:left"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;&lt;span style="line-height:107%"&gt;Share-based
        compensation &lt;/span&gt;&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;/td&gt; &lt;/tr&gt;
  &lt;/table&gt; &lt;/div&gt; &lt;/div&gt; &lt;/div&gt; &lt;/div&gt;

&lt;div&gt;

&lt;p style="margin:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&#160;&lt;/p&gt;

&lt;p style="margin-top:0pt;margin-left:47px;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span style="line-height:normal"&gt;&lt;span&gt;&lt;span&gt;The
&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;Company grants share options and restricted share units (&#x201c;RSU&#x201d;) (together
&#x201c;Share-Based Compensation&#x201d;) to its employees, directors and non-employees in consideration for services rendered&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span style="line-height:normal"&gt;&lt;span&gt;&lt;span&gt;.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin:0pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin-top:0pt;margin-left:47px;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span style="line-height:normal"&gt;&lt;span&gt;&lt;span&gt;The
Company accounts for Share-Based Compensation awards classified as equity awards, including share-based option awards and RSUs, using
grant-date fair value. The Company recognize the value of the award as an expense over the requisite service period&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span style="line-height:normal"&gt;.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin-top:0pt;margin-left:47px;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&#160;&lt;/p&gt;

&lt;p style="margin-top:0pt;margin-left:47px;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span style="line-height:normal"&gt;The
Company applies ASU 2018-07 (Topic 718) that expands the scope of Topic 718 to include Share-Based Compensation transactions for acquiring
goods and services from non-employees. Under the provision of the amendment, the Company measures share-based compensation to non-employees
in the same manner as share-based compensation to employees.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin-top:0pt;margin-left:90px;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:left"&gt;&#160;&lt;/p&gt;

&lt;p style="margin-top:0pt;margin-left:47px;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span style="line-height:107%"&gt;The
Company calculates the fair value of stock-based option awards on the date of grant using the Black-Scholes option pricing model. The
option-pricing model requires a number of assumptions, of which the most significant are the expected share price volatility and the expected
option term. The computation of expected volatility is based on the historical volatility of the Company&#x2019;s ordinary shares. The
expected option term is calculated using the simplified method, as the Company has concluded that its historical share option exercise
experience does not provide a reasonable basis to estimate expected option terms. The interest rate for periods within the expected term
of an award is based on the U.S. Treasury yield curve in effect at the time of grant. The Company&#x2019;s expected dividend rate is zero
because the Company does not currently pay cash dividends on its shares and does not anticipate doing so in the foreseeable future&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span&gt;&lt;span&gt;&lt;span style="line-height:107%"&gt;.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin-top:0pt;margin-left:90px;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:left"&gt;&#160;&lt;/p&gt;

&lt;p style="margin-top:0pt;margin-left:47px;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span style="line-height:107%"&gt;The
&lt;/span&gt;Company elected to recognize compensation costs for awards granted to employees and directors conditioned only on continued service
that have a graded vesting schedule using the accelerated method based on the multiple-option award approach. The Company has elected
to account for forfeitures as they occur&lt;span style="line-height:107%"&gt;.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin-top:0pt;margin-left:47px;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&#160;&lt;/p&gt; &lt;/div&gt;
&lt;/div&gt; </us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:ResearchAndDevelopmentExpensePolicy
      contextRef="C_20220101to20221231"
      id="F20230227081832032_13">

&lt;div&gt;

&lt;div style="line-height:1.25"&gt;

&lt;div&gt;

&lt;div style="line-height:1.25"&gt;

&lt;div style="line-height:1.25"&gt;

&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman, Times, serif;font-size:10pt;width:100%;text-align:left;color:rgb(0, 0, 0);border:0px"&gt;
  &lt;tr&gt;
    &lt;td style="width:47px;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;n.&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width:auto;vertical-align:top;text-align:justify"&gt;
        &lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:left"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;&lt;span style="line-height:107%"&gt;Research
        and development expenses&lt;/span&gt;&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;/td&gt; &lt;/tr&gt;
  &lt;/table&gt; &lt;/div&gt; &lt;/div&gt; &lt;/div&gt; &lt;/div&gt;

&lt;div&gt;

&lt;p style="margin:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:left"&gt;&#160;&lt;/p&gt;

&lt;p style="margin-top:0pt;margin-left:47px;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span style="line-height:normal"&gt;Research
&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;and development expenses include costs directly attributable to the conduct of research and development
programs, including the cost of salaries, share-based compensation expenses, payroll taxes and other employee benefits, lab expenses,
consumable equipment and consulting fees. All costs associated with research and developments are expensed as incurred&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span style="line-height:normal"&gt;.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin:0pt;text-align:left"&gt;&#160;&lt;/p&gt;

&lt;p style="margin-top:0pt;margin-left:48px;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span style="line-height:normal"&gt;Grants
received from the Israel Innovation Authority (the &#160;&#x201c;IIA&#x201d;) are recognized when the grant becomes receivable, provided
there is reasonable assurance that the Company will comply with the conditions attached to the grant and there is reasonable assurance
the grant will be received. At the time grants are received, successful development of the related projects is not assured, therefore,
grants are deducted from the research and development expenses as the applicable costs are incurred, and presented in R&amp;amp;D expenses,
net&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span style="line-height:107%"&gt;&lt;span&gt;.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
&lt;/div&gt; &lt;/div&gt; </us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:RevenueRecognitionPolicyTextBlock
      contextRef="C_20220101to20221231"
      id="F20230227081832033_14">

&lt;div&gt;

&lt;div&gt;

&lt;div style="line-height:1.25"&gt;

&lt;div&gt;

&lt;div style="line-height:1.25"&gt;

&lt;div style="line-height:1.25"&gt;

&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman, Times, serif;font-size:10pt;width:100%;text-align:left;color:rgb(0, 0, 0);border:0px"&gt;
  &lt;tr&gt;
    &lt;td style="width:47px;text-align:justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="width:auto;vertical-align:top;text-align:justify"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="width:47px;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;o.&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width:auto;vertical-align:top;text-align:justify"&gt;
        &lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:left"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;&lt;span style="line-height:107%"&gt;Revenue
        recognition &lt;/span&gt;&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;/td&gt; &lt;/tr&gt;
  &lt;/table&gt; &lt;/div&gt; &lt;/div&gt; &lt;/div&gt; &lt;/div&gt;

&lt;div&gt;

&lt;p style="margin:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&#160;&lt;/p&gt;

&lt;p style="margin-top:0pt;margin-left:47px;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span style="line-height:normal"&gt;The
Company recognized revenue from the Amgen Agreement according to ASC 606, "Revenues from Contracts with Customers&#x201d;. Prior to the
signing of the Amgen Agreement in 2018, the Company did not have revenue transactions.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin:0pt;text-align:left"&gt;&#160;&lt;/p&gt;

&lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;margin-left:47px"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;ASC
606 Revenue from Contracts with Customer introduces a five-step model for recognizing revenue from contracts with customers, as follows:&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;margin-left:47px"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;1.&#160;
Identify the contract with a customer.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;margin-left:47px"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;2.&#160;
Identify the performance obligations in the contract.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;margin-left:47px"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;3.&#160;
Determine the transaction price.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;margin-left:47px"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;4.&#160;
Allocate the transaction price to the performance obligations in the contract.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;margin-left:47px"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;5.&#160;
Recognize revenue when (or as) the entity satisfies a performance obligation.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin:0pt;text-align:left"&gt;&#160;&lt;/p&gt;

&lt;p style="margin-top:0pt;margin-left:47px;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span style="line-height:normal"&gt;According
to ASC 606, a performance obligation is a promise to provide a distinct good or service or a series of distinct goods or services. Goods
and services that are not distinct are bundled with other goods or services in the contract until a bundle of goods or services that is
distinct is created. A good or service promised to a customer is distinct if the customer can benefit from the good or service either
on its own or together with other resources that are readily available to the customer and the entity&#x2019;s promise to transfer the
good or service to the customer is separately identifiable from other promises in the contract.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin:0pt;text-align:left"&gt;&#160;&lt;/p&gt;

&lt;p style="margin-top:0pt;margin-left:47px;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span style="line-height:107%"&gt;Options
granted to the customer that do not provide a material right to the customer that it would not receive without entering into the contract
do not give rise to performance obligations.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin:0pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin-top:0pt;margin-left:47px;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span style="line-height:normal"&gt;On
December 10, 2018, the Company entered into the Amgen Agreement for the use of the Company&#x2019;s oral delivery platform in the field
of inflammatory diseases and other serious illnesses. As part of the agreement, the Company received non-refundable and non-creditable
initial access payment of $725&#160;from
Amgen in January 2019.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin:0pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin-top:0pt;margin-left:47px;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span style="line-height:normal"&gt;The
Company identified two performance obligations in the agreement: 1) License to use the Company's proprietary drug delivery platform and
2) pre-clinical research and development services (&#x201c;pre-clinical R&amp;amp;D services&#x201d;). The preclinical R&amp;amp;D services include
discovery, research and design preclinical activities relating to the programs selected by Amgen.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin-top:0pt;margin-left:47px;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&#160;&lt;/p&gt;

&lt;div/&gt;

&lt;p style="margin-top:0pt;margin-left:47px;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;The
Company determined the license to the intellectual property to be a right to use that has significant standalone functionality separately
from the pre-clinical R&amp;amp;D services since the Company is not required to continue to support, develop or maintain the intellectual
property transferred and will not undertake any activities to change the standalone functionality of the intellectual property. Therefore,
the license to the intellectual property is a distinct performance obligation and as such revenue is recognized at the point in time that
control of the license was transferred to Amgen on December 10, 2018.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin-top:0pt;margin-left:47px;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&#160;&lt;/p&gt;

&lt;p style="margin-top:0pt;margin-left:47px;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span style="line-height:normal"&gt;Revenues
attributed to the preclinical R&amp;amp;Ds services are recognized during the period of the pre-clinical R&amp;amp;D services, over time according
to the input model method on a cost-to-cost basis, since the customer benefits from the research and development services as the entity
performs the service.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;br/&gt;&#160;&lt;/p&gt;

&lt;p style="margin-top:0pt;margin-left:47px;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span style="line-height:normal"&gt;The
Company evaluated the standalone selling price of the pre-clinical R&amp;amp;D services at $225&#160;and
the right to use the intellectual property at $500.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
&lt;/div&gt; &lt;/div&gt;

&lt;div style="line-height:1.25"&gt;

&lt;div&gt;

&lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt; &lt;/div&gt; &lt;/div&gt;

&lt;div&gt;

&lt;p style="margin-top:0pt;margin-left:47px;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span style="line-height:normal"&gt;&lt;span&gt;&lt;span&gt;The
&lt;/span&gt;&lt;/span&gt;transaction price was comprised of fixed consideration and variable consideration (capped research and development reimbursements).
Under ASC 606, the consideration that the Company would be entitled to upon the achievement of contractual milestones, which are contingent
upon the occurrence of future events of development and commercial progress, are a form of variable consideration. Variable consideration
is included in the transaction price if, in the Company&#x2019;s judgment, it is highly probable that a significant future reversal of
cumulative revenue under the contract will not occur. Estimates of variable consideration and determination of whether to include estimated
amounts in the transaction price are based largely on an assessment of the Company&#x2019;s anticipated performance and all information
(historical, current and forecasted) that is reasonably available. As of December 31, 2022, the Company did not recognize any revenues
from any potential milestone payments&lt;span&gt;&lt;span&gt;.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin:0pt;text-align:left"&gt;&#160;&lt;/p&gt;

&lt;p style="margin-top:0pt;margin-left:47px;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span style="line-height:107%"&gt;An
entity should recognize revenue for a sales-based or usage-based royalty promised in exchange for a license of intellectual property only
when (or as) the later of the following events occurs:&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;div style="line-height:1.25"&gt;

&lt;div style="line-height:1.25"&gt;

&lt;div style="line-height:1.25;text-align:left"&gt;&#160;&lt;/div&gt; &lt;/div&gt; &lt;/div&gt;

&lt;div style="line-height:1.25"&gt;

&lt;div style="line-height:1.25"&gt;

&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman, Times, serif;font-size:10pt;width:100%;text-align:left;color:rgb(0, 0, 0);border:0px"&gt;
  &lt;tr&gt;
    &lt;td style="width:47px"&gt;&#160;&lt;/td&gt;
    &lt;td style="width:45px;vertical-align:top;font-family:Times New Roman, Times, serif;text-align:justify"&gt;
        &lt;div style="font-size:10pt"&gt;
        &lt;div style="font-family:Times New Roman, Times, serif;text-align:left"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;a)&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/div&gt; &lt;/td&gt;
    &lt;td style="width:auto;vertical-align:top"&gt;
        &lt;div&gt;
        &lt;div style="text-align:justify"&gt;
        &lt;div style="font-size:10pt"&gt;
        &lt;div style="font-family:Times New Roman, Times, serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;The
        subsequent sale or usage occurs; and&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt; &lt;/div&gt; &lt;/div&gt; &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt;
  &lt;/table&gt;

&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman, Times, serif;font-size:10pt;width:100%;text-align:left;color:rgb(0, 0, 0);border:0px"&gt;
  &lt;tr&gt;
    &lt;td style="width:47px;text-align:justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="width:45px;vertical-align:top;font-family:Times New Roman, Times, serif;text-align:justify"&gt;
        &lt;div style="font-size:10pt"&gt;
        &lt;div style="font-family:Times New Roman, Times, serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;b)&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/div&gt; &lt;/td&gt;
    &lt;td style="width:auto;vertical-align:top"&gt;
        &lt;div&gt;
        &lt;div style="text-align:justify"&gt;
        &lt;div style="font-size:10pt"&gt;
        &lt;div style="font-family:Times New Roman, Times, serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;The
        performance obligation to which some or all of the sales based or usage-based royalty has been allocated has been satisfied (or partially
        satisfied).&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt; &lt;/div&gt; &lt;/div&gt; &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt;
  &lt;/table&gt; &lt;/div&gt; &lt;/div&gt; &lt;/div&gt;

&lt;p style="margin:0pt;text-align:left"&gt;&#160;&lt;/p&gt;

&lt;p style="margin-top:0pt;margin-left:47px;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span style="line-height:normal"&gt;As
&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;royalties are payable based on future commercial sales, as defined in the agreement, which did not
occur as of the financial statements date, the Company did not recognize any revenues from royalties.&#160;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin-top:0pt;margin-left:47px;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&#160;&lt;/p&gt;

&lt;p style="margin-top:0pt;margin-left:47px;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span style="font-weight:bold"&gt;&lt;span&gt;&lt;span&gt;&lt;span style="font-weight:normal"&gt;Revenues
attributed to preclinical R&amp;amp;D services are recognized during the period of the pre-clinical R&amp;amp;D services according to the input
model method on a cost-to-cost basis&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span&gt;&lt;span&gt;&lt;span style="font-weight:normal"&gt;.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin-top:0pt;margin-left:47px;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&#160;&lt;/p&gt;

&lt;p style="margin-top:0pt;margin-left:47px;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span style="line-height:107%"&gt;In
2022 and 2021, the Company recorded revenues of $89
and $502,
respectively, related to services provided under the Amgen Agreement.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin-top:0pt;margin-left:47px;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&#160;&lt;/p&gt; &lt;/div&gt;
</us-gaap:RevenueRecognitionPolicyTextBlock>
    <entx:NonRefundableAndNonCreditableInitialTechnologyAccessFeePayment
      contextRef="C_20190101to20190131_usgaapRelatedPartyTransactionsByRelatedPartyAxis_entxAmgenIncMember"
      decimals="-3"
      id="F20230227081832047_22"
      unitRef="USD">725000</entx:NonRefundableAndNonCreditableInitialTechnologyAccessFeePayment>
    <entx:AdditionalAmountPaidForServicesToBeRecognized
      contextRef="C_20191231_usgaapRelatedPartyTransactionsByRelatedPartyAxis_entxAmgenIncMember"
      decimals="-3"
      id="F20230227081832048_23"
      unitRef="USD">225000</entx:AdditionalAmountPaidForServicesToBeRecognized>
    <entx:RightToUseIntellectualProperty
      contextRef="C_20191231_usgaapRelatedPartyTransactionsByRelatedPartyAxis_entxAmgenIncMember"
      decimals="-3"
      id="F20230227081832048_24"
      unitRef="USD">500000</entx:RightToUseIntellectualProperty>
    <us-gaap:DeferredRevenueRevenueRecognized1
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="Fxbrl_20230228150010939"
      unitRef="USD">89000</us-gaap:DeferredRevenueRevenueRecognized1>
    <us-gaap:DeferredRevenueRevenueRecognized1
      contextRef="C_20210101to20211231"
      decimals="-3"
      id="Fxbrl_20230228150015534"
      unitRef="USD">502000</us-gaap:DeferredRevenueRevenueRecognized1>
    <us-gaap:IncomeTaxPolicyTextBlock
      contextRef="C_20220101to20221231"
      id="F20230227081832033_15">

&lt;div&gt;

&lt;div style="text-align:justify;line-height:1.25"&gt;

&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman, Times, serif;font-size:10pt;width:100%;text-align:left;color:rgb(0, 0, 0);border:0px"&gt;
  &lt;tr&gt;
    &lt;td style="width:47px;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;p.&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width:auto;vertical-align:top"&gt;
        &lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;&lt;span style="line-height:107%"&gt;Income
        taxes &lt;/span&gt;&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;/td&gt; &lt;/tr&gt;
  &lt;/table&gt; &lt;/div&gt;

&lt;p style="margin:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman, Times, serif;font-size:10pt;width:100%;text-align:left;color:rgb(0, 0, 0);border:0px"&gt;
  &lt;tr&gt;
    &lt;td style="width:47px;text-align:justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="width:40px;vertical-align:top;font-family:Times New Roman, Times, serif;text-align:justify"&gt;
        &lt;div style="font-size:10pt"&gt;
        &lt;div style="font-family:Times New Roman, Times, serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;1)&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/div&gt; &lt;/td&gt;
    &lt;td style="width:auto;vertical-align:top"&gt;
        &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span style="line-height:normal"&gt;Deferred
        taxes&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;/td&gt; &lt;/tr&gt;
  &lt;/table&gt;

&lt;div style="line-height:1.25;text-align:left"&gt;&#160;&lt;/div&gt;

&lt;div style="margin-left:47px;text-align:justify;line-height:1.25;font-family:Times New Roman, Times, serif"&gt;

&lt;div style="font-size:10pt"&gt;

&lt;div style="font-family:Times New Roman, Times, serif;margin-left:40px"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span style="line-height:107%"&gt;Deferred&#160;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;income
taxes are computed using the asset and liability method. Under the asset and liability method, deferred income tax assets and liabilities
are determined based on the differences between the financial reporting and tax bases of assets and liabilities and are measured using
the currently enacted tax rates and laws. A valuation allowance is recognized to the extent that it is more likely than not that the deferred
taxes will not be realized in the foreseeable future&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span style="line-height:107%"&gt;.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
&lt;/div&gt; &lt;/div&gt;

&lt;p style="margin:0pt;text-align:left"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman, Times, serif;font-size:10pt;width:100%;text-align:left;color:rgb(0, 0, 0);border:0px"&gt;
  &lt;tr&gt;
    &lt;td style="width:47px"&gt;&#160;&lt;/td&gt;
    &lt;td style="width:40px;vertical-align:top;font-family:Times New Roman, Times, serif;text-align:justify"&gt;
        &lt;div style="font-size:10pt"&gt;
        &lt;div style="font-family:Times New Roman, Times, serif;text-align:left"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;2)&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/div&gt; &lt;/td&gt;
    &lt;td style="width:auto;vertical-align:top"&gt;
        &lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span style="line-height:107%"&gt;Uncertainty
        in income taxes&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;/td&gt; &lt;/tr&gt;
  &lt;/table&gt;

&lt;div style="line-height:1.25;text-align:left"&gt;&#160;&lt;/div&gt;

&lt;div style="margin-left:47px;text-align:justify;line-height:1.25;font-family:Times New Roman, Times, serif"&gt;

&lt;div style="font-size:10pt"&gt;

&lt;div style="font-family:Times New Roman, Times, serif;margin-left:40px"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span style="line-height:107%"&gt;The
Company follows a two-step approach in recognizing and measuring uncertain tax positions. The first step is to evaluate the tax position
for recognition by determining if the available evidence indicates that it is more likely than not that the position will be sustained
based on technical merits. If this threshold is met, the second step is to measure the tax position as the largest amount that has more
than a 50% likelihood of being realized upon ultimate settlement.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt; &lt;/div&gt; &lt;/div&gt;
&lt;/div&gt; </us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:EarningsPerSharePolicyTextBlock
      contextRef="C_20220101to20221231"
      id="F20230227081832033_16">

&lt;div&gt;

&lt;div style="line-height:1.25"&gt;

&lt;div&gt;

&lt;div style="line-height:1.25"&gt;

&lt;div style="line-height:1.25"&gt;

&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman, Times, serif;font-size:10pt;width:100%;text-align:left;color:rgb(0, 0, 0);border:0px"&gt;
  &lt;tr&gt;
    &lt;td style="width:47px;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;q.&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width:auto;vertical-align:top;text-align:justify"&gt;
        &lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:left"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;&lt;span style="line-height:107%"&gt;Loss
        per share &lt;/span&gt;&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;/td&gt; &lt;/tr&gt;
  &lt;/table&gt; &lt;/div&gt; &lt;/div&gt; &lt;/div&gt; &lt;/div&gt;

&lt;div&gt;

&lt;p style="margin:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&#160;&lt;/p&gt;

&lt;p style="margin-top:0pt;margin-left:47px;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span style="line-height:107%"&gt;Basic
loss per share is computed on the basis of the net loss, adjusted to recognize the effect of a down-round feature when it is triggered,
for the period, divided by the weighted average number of outstanding ordinary shares during the period.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin:0pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin-top:0pt;margin-left:47px;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span style="line-height:107%"&gt;Diluted
&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;loss per share is based upon the weighted average number of ordinary shares and of ordinary shares
equivalents outstanding when dilutive. Ordinary share equivalents include outstanding stock options and warrants, which are included under
the treasury stock method when dilutive. The calculation of diluted loss per share does not include options, RSUs and warrants, exercisable
into an aggregate of&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span style="line-height:107%"&gt;&#160;6,255,235
shares and&#160;&lt;/span&gt;&lt;span style="line-height:107%"&gt;6,517,102&lt;/span&gt;&lt;strong&gt;&#160;&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;shares
for the years ended December&#160;31, 2022&#160;and 2021, respectively, because the effect would have been anti-dilutive.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
&lt;/div&gt; &lt;/div&gt; </us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_20220101to20221231"
      decimals="INF"
      id="Fxbrl_20230227154246022"
      unitRef="shares">6255235</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_20210101to20211231"
      decimals="INF"
      id="F20230227081832048_26"
      unitRef="shares">6517102</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:CommitmentsAndContingenciesPolicyTextBlock
      contextRef="C_20220101to20221231"
      id="F20230227081832050_31">

&lt;div&gt;

&lt;div style="line-height:1.25"&gt;

&lt;div&gt;

&lt;div style="line-height:1.25"&gt;

&lt;div style="line-height:1.25"&gt;

&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman, Times, serif;font-size:10pt;width:100%;text-align:left;color:rgb(0, 0, 0);border:0px"&gt;
  &lt;tr&gt;
    &lt;td style="width:47px;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;r.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width:auto;vertical-align:top;text-align:justify"&gt;
        &lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;&lt;span&gt;&lt;span&gt;Legal
        and other contingencies&lt;/span&gt;&lt;/span&gt;&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;/td&gt; &lt;/tr&gt;
  &lt;/table&gt; &lt;/div&gt; &lt;/div&gt; &lt;/div&gt; &lt;/div&gt;

&lt;div&gt;

&lt;p style="margin:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&#160;&lt;/p&gt;

&lt;p style="margin-top:0pt;margin-left:47px;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span style="line-height:107%"&gt;Management&#160;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;applies
the guidance in ASC 450-20, &#x201c;Loss Contingencies&#x201d; when assessing losses resulting from contingencies. If the assessment of
a contingency indicates that it is probable that a material loss has been incurred and the amount of the liability can be estimated, then
the estimated liability is recorded as accrued expenses in the Company&#x2019;s consolidated financial statements&lt;span&gt;.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin:0pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin-top:0pt;margin-left:47px;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Legal
costs incurred in connection with loss contingencies are expensed as incurred&lt;span style="line-height:107%"&gt;.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin-top:0pt;margin-left:47px;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&#160;&lt;/p&gt; &lt;/div&gt;
&lt;/div&gt; </us-gaap:CommitmentsAndContingenciesPolicyTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="C_20220101to20221231"
      id="F20230227081832049_27">

&lt;div&gt;

&lt;div style="line-height:1.25"&gt;

&lt;div&gt;

&lt;div style="line-height:1.25"&gt;

&lt;div style="line-height:1.25"&gt;

&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman, Times, serif;font-size:10pt;width:100%;text-align:left;color:rgb(0, 0, 0);border:0px"&gt;
  &lt;tr&gt;
    &lt;td style="width:47px;vertical-align:top;font-family:Times New Roman, Times, serif;font-weight:bold;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;s.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width:auto;vertical-align:top;text-align:justify"&gt;
        &lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:left"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;&lt;span style="line-height:107%"&gt;Newly
        issued and recently adopted accounting pronouncements:&lt;/span&gt;&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;
        &lt;/tr&gt;
  &lt;/table&gt; &lt;/div&gt; &lt;/div&gt; &lt;/div&gt; &lt;/div&gt;

&lt;div&gt;

&lt;p style="margin:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&#160;&lt;/p&gt;

&lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;margin-left:38pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;em&gt;&lt;strong&gt;&lt;span&gt;&lt;span&gt;Recently
issued accounting pronouncements adopted&lt;/span&gt;&lt;/span&gt;&lt;/strong&gt;&lt;/em&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&#160;&lt;/p&gt;

&lt;div style="margin-left:47px"&gt;

&lt;table cellpadding="0" cellspacing="0" style="border:0px;width:100%"&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align:top;width:20pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;1)&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width:auto"&gt;
        &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;In&#160;&lt;/span&gt;&lt;/span&gt;&lt;span style="line-height:107%"&gt;November
        2021, the FASB issued ASU 2021-10 &#x201c;Government Assistance (Topic 832)&#x201d;, which requires annual disclosures that increase the
        transparency of transactions involving government grants, including (1) the types of transactions, (2) the accounting for those transactions,
        and (3) the effect of those transactions on an entity&#x2019;s financial statements. The amendments in this update are effective for financial
        statements issued for annual periods beginning after December 15, 2021.&lt;/span&gt;&#160;&lt;span style="line-height:107%"&gt;The adoption of this
        guidance did not have material impact on the Company&#x2019;s consolidated financial statements.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt; &lt;/tr&gt;
  &lt;/table&gt; &lt;/div&gt;

&lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&#160;&lt;/p&gt;

&lt;div style="margin-left:47px"&gt;

&lt;table cellpadding="0" cellspacing="0" style="border:0px;width:100%"&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align:top;width:20pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;2)&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width:auto"&gt;
        &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;In
        &lt;/span&gt;&lt;/span&gt;&lt;span style="line-height:107%"&gt;August 2020, the FASB issued ASU 2020-06 &#x201c;Debt &#x2013; Debt with Conversion and Other
        Options (Subtopic 470-20) and Derivatives and Hedging &#x2013; Contracts in Entity&#x2019;s Own Equity (Subtopic 815 &#x2013; 40).&#x201d;
        This guidance simplifies the accounting for certain financial instruments with characteristics of liabilities and equity, including convertible
        instruments and contracts on an entity&#x2019;s own equity. The amendments to this guidance are effective for fiscal years beginning after
        December&#160;15, 2021, and interim periods within those fiscal years. The Company early adopted this guidance effective January 1, 2022
        and the impact of the adoption on the Consolidated financial statements was immaterial.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;/td&gt; &lt;/tr&gt;
  &lt;/table&gt; &lt;/div&gt;

&lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;margin-left:38pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;em&gt;&lt;strong&gt;Recently
issued accounting pronouncements, not yet adopted&lt;/strong&gt;&lt;/em&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/p&gt;

&lt;div style="margin-left:47px"&gt;

&lt;table cellpadding="0" cellspacing="0" style="border:0px;width:100%"&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align:top;width:20pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;1)&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width:auto"&gt;
        &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;I&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;n
        &lt;/span&gt;&lt;/span&gt;&lt;span style="line-height:107%"&gt;June 2016, the FASB issued ASU 2016-13 &#x201c;Financial Instruments&#x2014;Credit Losses&#x2014;Measurement
        of Credit Losses on Financial Instruments.&#x201d; This guidance replaces the current incurred loss impairment methodology with a methodology
        that reflects expected credit losses and requires consideration of a broader range of reasonable and supportable information to inform
        credit loss estimates. &lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="line-height:107%"&gt;The
        guidance will be effective for Smaller Reporting Companies (SRCs, as defined by the SEC) for the fiscal year beginning on January 1, 2023,
        including interim periods within that year. The adoption of this guidance will not have material impact on the Company&#x2019;s consolidated
        financial statements.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;/td&gt; &lt;/tr&gt;
  &lt;/table&gt; &lt;/div&gt; &lt;/div&gt; &lt;/div&gt; </us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:LesseeOperatingLeasesTextBlock contextRef="C_20220101to20221231" id="F20230227081114746_0">

&lt;div&gt;

&lt;div&gt;

&lt;div&gt;

&lt;div&gt;

&lt;div&gt;

&lt;div style="font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;NOTE 3 - OPERATING LEASES&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;

&lt;div style="line-height:1.25;font-weight:bold"&gt;&#160;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"&gt;
  &lt;tr&gt;
    &lt;td style="width:35.45pt;vertical-align:top"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;1)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width:auto;vertical-align:top;text-align:justify"&gt;
        &lt;div&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;The Company leases office and research and development
        space under several agreements. The annual lease consideration is a total of $166
        and is linked to the Israeli CPI. The lease agreement expires on June 30, 2023.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt;
  &lt;/table&gt;

&lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;

&lt;div style="text-align:justify;margin-left:36pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;As
of December 31, 2022, the Company provided bank guarantees of approximately $37,
in the aggregate, to secure the fulfillment of its obligations under the lease agreements. &lt;/span&gt;&lt;/span&gt;&lt;/div&gt;

&lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;

&lt;div&gt;

&lt;table cellpadding="0" cellspacing="0" style="width:100%;font-family:'Times New Roman', Times, serif;font-size:10pt"&gt;
  &lt;tr style="vertical-align:top"&gt;
    &lt;td style="vertical-align:top;width:35.45pt"&gt;
        &lt;div style="text-align:justify;line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2)&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/td&gt;
    &lt;td style="align:left;vertical-align:top;width:auto"&gt;
        &lt;div style="text-align:justify;line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;The
        Company has entered into operating lease agreements for vehicles used by its employees. The lease periods are generally for three years
        and the payments are linked to the Israeli CPI. To secure the terms of the lease agreements, the Company has made certain deposits to
        the leasing company, representing approximately three months of lease payments. The annual lease consideration is a total of $21.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/td&gt; &lt;/tr&gt;
  &lt;/table&gt; &lt;/div&gt;

&lt;div style="margin-left:70.4pt;line-height:1.25"&gt;&#160;&lt;/div&gt;

&lt;div style="text-align:justify;margin-left:36pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;The
lease cost was as follows:&lt;/span&gt;&lt;/span&gt;&lt;/div&gt; &lt;/div&gt; &lt;/div&gt;

&lt;div&gt;

&lt;div&gt;

&lt;div&gt;

&lt;div style="text-align:justify;margin-left:36pt;line-height:1.25"&gt;&#160;&lt;/div&gt;

&lt;div style="margin-left:45pt"&gt;

&lt;table border="0" cellpadding="0" cellspacing="0" style="width:92%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left"&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align:bottom;padding-bottom:2px" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px" valign="bottom"&gt;
        &lt;div style="line-height:1.25"&gt;
        &lt;div style="text-align:center;line-height:1.25;font-weight:bold;text-indent:1pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Year
        ended&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;div style="text-align:center;line-height:1.25;font-weight:bold;text-indent:1pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;December&#160;31,&lt;br/&gt;2022&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/div&gt; &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px" valign="bottom"&gt;
        &lt;div style="line-height:1.25"&gt;
        &lt;div style="text-align:center;line-height:1.25;font-weight:bold;text-indent:1pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Year
        ended&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;div style="text-align:center;line-height:1.25;font-weight:bold;text-indent:1pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;December&#160;31,&lt;br/&gt;2021&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/div&gt; &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align:bottom;width:76%;padding-bottom:4px;background-color:rgb(204, 238, 255)" valign="bottom"&gt;
        &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Operating
        lease cost&lt;/span&gt;&lt;/span&gt;&lt;/div&gt; &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom"&gt;
        &lt;div style="line-height:1.25"&gt;
        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;197&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/div&gt; &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom"&gt;
        &lt;div style="line-height:1.25"&gt;
        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;216&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/div&gt; &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
        &lt;/tr&gt;
  &lt;/table&gt; &lt;/div&gt; &lt;/div&gt; &lt;/div&gt;  &lt;/div&gt;

&lt;div style="margin-left:36pt"&gt;

&lt;p style="margin:0pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;Supplemental
cash flow information related to leases was as follows:&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;br/&gt;&#160;&lt;/p&gt; &lt;/div&gt;

&lt;div style="line-height:1.25"&gt;

&lt;div style="margin-left:45pt"&gt;

&lt;div&gt;

&lt;div&gt;

&lt;table border="0" cellpadding="0" cellspacing="0" style="width:92%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left"&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align:top;padding-bottom:2px" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px" valign="bottom"&gt;
        &lt;div style="line-height:1.25"&gt;
        &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Year
        ended&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;December&#160;31,&lt;br/&gt;2022&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/div&gt; &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px" valign="bottom"&gt;
        &lt;div style="line-height:1.25"&gt;
        &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Year
        ended&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;December&#160;31,&lt;br/&gt;2021&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/div&gt; &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align:top;width:76%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;
        &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:normal"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Operating
        cash flows from operating leases&lt;/span&gt;&lt;/span&gt;&lt;/div&gt; &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;font-weight:normal;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;font-weight:normal;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;
        &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:normal"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;197&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;font-weight:normal;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;font-weight:normal;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;font-weight:normal;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;
        &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:normal"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;216&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
        &lt;/tr&gt;
  &lt;/table&gt; &lt;/div&gt; &lt;/div&gt;

&lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/p&gt; &lt;/div&gt; &lt;/div&gt; &lt;/div&gt;

&lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;margin-left:47px"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;Supplemental
balance sheet information related to operating leases was as follows:&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/p&gt;

&lt;div style="text-align:center"&gt;

&lt;div style="clear:both;margin-top:00pt;margin-bottom:00pt"&gt;

&lt;div style="text-align:center"&gt; &lt;div style="font-size:10pt;display:inline"&gt; &lt;div style="font-family:Times New Roman,Times,serif;display:inline"&gt;
&lt;div style="color:#000000;font-weight:normal;font-style:normal;display:inline"&gt;

&lt;div&gt;

&lt;div&gt;

&lt;div&gt;

&lt;div style="line-height:1.25"&gt;

&lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt; &lt;/div&gt;

&lt;div style="margin-left:45pt"&gt;

&lt;table border="0" cellpadding="0" cellspacing="0" style="width:92%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left"&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align:top;padding-bottom:2px" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px" valign="bottom"&gt;
        &lt;div style="line-height:1.25"&gt;
        &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;December&#160;31,&lt;br/&gt;2022&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/div&gt; &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px" valign="bottom"&gt;
        &lt;div style="line-height:1.25"&gt;
        &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;December&#160;31,&lt;br/&gt;2021&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/div&gt; &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align:bottom;font-weight:bold;background-color:rgb(204, 238, 255)" valign="bottom"&gt;
        &lt;div style="margin-right:36pt;line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Operating
        Leases&lt;/span&gt;&lt;/span&gt;&lt;/div&gt; &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;font-weight:normal;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align:top;font-weight:normal;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;font-weight:normal;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;font-weight:normal;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align:top;font-weight:normal;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;font-weight:normal;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
        &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align:bottom;width:76%" valign="bottom"&gt;
        &lt;div style="margin-right:36pt;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:normal"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Operating
        lease right-of-use assets&lt;/span&gt;&lt;/span&gt;&lt;/div&gt; &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;font-weight:normal" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;font-weight:normal" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%" valign="bottom"&gt;
        &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:normal"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;90&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;font-weight:normal;white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;font-weight:normal" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;font-weight:normal" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%" valign="bottom"&gt;
        &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:normal"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;239&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;font-weight:normal;white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align:top;width:76%;font-weight:normal;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;font-weight:normal;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;font-weight:normal;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;font-weight:normal;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;font-weight:normal;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;font-weight:normal;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;font-weight:normal;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;font-weight:normal;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;font-weight:normal;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
        &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align:bottom;width:76%" valign="bottom"&gt;
        &lt;div style="margin-right:36pt;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:normal"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Current
        lease liabilities&lt;/span&gt;&lt;/span&gt;&lt;/div&gt; &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;font-weight:normal" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;font-weight:normal" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%" valign="bottom"&gt;
        &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:normal"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;91&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;font-weight:normal;white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;font-weight:normal" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;font-weight:normal" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%" valign="bottom"&gt;
        &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:normal"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;179&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;font-weight:normal;white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align:bottom;width:76%;padding-bottom:2px;background-color:rgb(204, 238, 255)" valign="bottom"&gt;
        &lt;div style="margin-right:36pt;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:normal"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Non-current
        lease liabilities&lt;/span&gt;&lt;/span&gt;&lt;/div&gt; &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;font-weight:normal;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);font-weight:normal;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom"&gt;
        &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:normal"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;font-weight:normal;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;font-weight:normal;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);font-weight:normal;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom"&gt;
        &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:normal"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;123&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;font-weight:normal;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
        &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align:bottom;width:76%;font-weight:bold" valign="bottom"&gt;
        &lt;div style="margin-right:36pt;line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Total
        lease liabilities&lt;/span&gt;&lt;/span&gt;&lt;/div&gt; &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;font-weight:normal" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;font-weight:normal" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%" valign="bottom"&gt;
        &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:normal"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;91&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;font-weight:normal;white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;font-weight:normal" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;font-weight:normal" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%" valign="bottom"&gt;
        &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:normal"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;302&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;font-weight:normal;white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align:bottom;width:76%;font-weight:normal;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;font-weight:normal;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;font-weight:normal;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;font-weight:normal;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;font-weight:normal;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;font-weight:normal;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;font-weight:normal;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;font-weight:normal;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;font-weight:normal;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
        &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align:top;width:76%" valign="bottom"&gt;
        &lt;div style="margin-right:36pt;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:normal"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Weighted-average
        remaining lease term (in years)&lt;/span&gt;&lt;/span&gt;&lt;/div&gt; &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;font-weight:normal" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;font-weight:normal" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%" valign="bottom"&gt;
        &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:normal"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;0.52&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;font-weight:normal;white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;font-weight:normal" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;font-weight:normal" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%" valign="bottom"&gt;
        &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:normal"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;1.53&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;font-weight:normal;white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align:top;width:76%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;
        &lt;div style="margin-right:36pt;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:normal"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Weighted-average
        discount rate&lt;/span&gt;&lt;/span&gt;&lt;/div&gt; &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;font-weight:normal;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;font-weight:normal;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;
        &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:normal"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;16&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom"&gt;
        &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:normal"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;%&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;font-weight:normal;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;font-weight:normal;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;
        &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:normal"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;16&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom"&gt;
        &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:normal"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;%&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/td&gt; &lt;/tr&gt;
  &lt;/table&gt; &lt;/div&gt; &lt;/div&gt; &lt;/div&gt;  &lt;/div&gt;

&lt;div style="margin-left:96pt;line-height:1.25"&gt;&#160;&lt;/div&gt;

&lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:left;margin-left:36pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;As
of December 31, 2022, the maturity of lease liabilities under our non-cancelable operating leases &lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="line-height:107%"&gt;are
$91
to be paid in 2023.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;/div&gt; &lt;/div&gt; &lt;/div&gt; &lt;/div&gt; &lt;/div&gt; &lt;/div&gt; &lt;/div&gt; &lt;/div&gt; </us-gaap:LesseeOperatingLeasesTextBlock>
    <us-gaap:PaymentForContingentConsiderationLiabilityOperatingActivities
      contextRef="C_20220101to20221231_entxLeaseArrangementAxis_entxOperatingLeaseAgreementsForOfficeAndResearchAndDevelopmentSpaceMember"
      decimals="-3"
      id="F20230227081114758_22"
      unitRef="USD">166000</us-gaap:PaymentForContingentConsiderationLiabilityOperatingActivities>
    <entx:BankGuarantees
      contextRef="C_20221231_entxLeaseArrangementAxis_entxOperatingLeaseAgreementsForOfficeAndResearchAndDevelopmentSpaceMember"
      decimals="-3"
      id="F20230227081114758_21"
      unitRef="USD">37000</entx:BankGuarantees>
    <us-gaap:PaymentForContingentConsiderationLiabilityOperatingActivities
      contextRef="C_20220101to20221231_entxLeaseArrangementAxis_entxOperatingLeaseAgreementsForVehiclesForEmployeesMember"
      decimals="-3"
      id="F20230227081114758_20"
      unitRef="USD">21000</us-gaap:PaymentForContingentConsiderationLiabilityOperatingActivities>
    <us-gaap:LeaseCostTableTextBlock
      contextRef="C_20220101to20221231"
      id="F20230227081114760_27">

&lt;div&gt;

&lt;div&gt;

&lt;div style="text-align:justify;margin-left:36pt;line-height:1.25"&gt;&#160;&lt;/div&gt;

&lt;div style="margin-left:45pt"&gt;

&lt;table border="0" cellpadding="0" cellspacing="0" style="width:92%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left"&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align:bottom;padding-bottom:2px" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px" valign="bottom"&gt;
        &lt;div style="line-height:1.25"&gt;
        &lt;div style="text-align:center;line-height:1.25;font-weight:bold;text-indent:1pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Year
        ended&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;div style="text-align:center;line-height:1.25;font-weight:bold;text-indent:1pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;December&#160;31,&lt;br/&gt;2022&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/div&gt; &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px" valign="bottom"&gt;
        &lt;div style="line-height:1.25"&gt;
        &lt;div style="text-align:center;line-height:1.25;font-weight:bold;text-indent:1pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Year
        ended&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;div style="text-align:center;line-height:1.25;font-weight:bold;text-indent:1pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;December&#160;31,&lt;br/&gt;2021&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/div&gt; &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align:bottom;width:76%;padding-bottom:4px;background-color:rgb(204, 238, 255)" valign="bottom"&gt;
        &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Operating
        lease cost&lt;/span&gt;&lt;/span&gt;&lt;/div&gt; &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom"&gt;
        &lt;div style="line-height:1.25"&gt;
        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;197&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/div&gt; &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom"&gt;
        &lt;div style="line-height:1.25"&gt;
        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;216&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/div&gt; &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
        &lt;/tr&gt;
  &lt;/table&gt; &lt;/div&gt; &lt;/div&gt; &lt;/div&gt; </us-gaap:LeaseCostTableTextBlock>
    <us-gaap:OperatingLeaseCost
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="F20230227081114758_23"
      unitRef="USD">197000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="C_20210101to20211231"
      decimals="-3"
      id="F20230227081114758_24"
      unitRef="USD">216000</us-gaap:OperatingLeaseCost>
    <entx:OperatingLeaseSupplementalCashFlowInformationTableTextBlock
      contextRef="C_20220101to20221231"
      id="F20230227081114760_28">

&lt;div&gt;

&lt;div&gt;

&lt;table border="0" cellpadding="0" cellspacing="0" style="width:92%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left"&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align:top;padding-bottom:2px" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px" valign="bottom"&gt;
        &lt;div style="line-height:1.25"&gt;
        &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Year
        ended&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;December&#160;31,&lt;br/&gt;2022&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/div&gt; &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px" valign="bottom"&gt;
        &lt;div style="line-height:1.25"&gt;
        &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Year
        ended&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;December&#160;31,&lt;br/&gt;2021&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/div&gt; &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align:top;width:76%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;
        &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:normal"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Operating
        cash flows from operating leases&lt;/span&gt;&lt;/span&gt;&lt;/div&gt; &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;font-weight:normal;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;font-weight:normal;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;
        &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:normal"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;197&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;font-weight:normal;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;font-weight:normal;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;font-weight:normal;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;
        &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:normal"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;216&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
        &lt;/tr&gt;
  &lt;/table&gt; &lt;/div&gt; &lt;/div&gt; </entx:OperatingLeaseSupplementalCashFlowInformationTableTextBlock>
    <us-gaap:OperatingLeasePayments
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="F20230227081114759_25"
      unitRef="USD">197000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments
      contextRef="C_20210101to20211231"
      decimals="-3"
      id="F20230227081114760_26"
      unitRef="USD">216000</us-gaap:OperatingLeasePayments>
    <entx:OperatingLeaseLiabilityAndOperatingLeaseRightOfUseAssetTableTextBlock contextRef="C_20220101to20221231" id="F20230227081114748_1">

&lt;div&gt;

&lt;div&gt;

&lt;div style="line-height:1.25"&gt;

&lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt; &lt;/div&gt;

&lt;div style="margin-left:45pt"&gt;

&lt;table border="0" cellpadding="0" cellspacing="0" style="width:92%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left"&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align:top;padding-bottom:2px" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px" valign="bottom"&gt;
        &lt;div style="line-height:1.25"&gt;
        &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;December&#160;31,&lt;br/&gt;2022&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/div&gt; &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px" valign="bottom"&gt;
        &lt;div style="line-height:1.25"&gt;
        &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;December&#160;31,&lt;br/&gt;2021&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/div&gt; &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align:bottom;font-weight:bold;background-color:rgb(204, 238, 255)" valign="bottom"&gt;
        &lt;div style="margin-right:36pt;line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Operating
        Leases&lt;/span&gt;&lt;/span&gt;&lt;/div&gt; &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;font-weight:normal;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align:top;font-weight:normal;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;font-weight:normal;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;font-weight:normal;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align:top;font-weight:normal;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;font-weight:normal;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
        &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align:bottom;width:76%" valign="bottom"&gt;
        &lt;div style="margin-right:36pt;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:normal"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Operating
        lease right-of-use assets&lt;/span&gt;&lt;/span&gt;&lt;/div&gt; &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;font-weight:normal" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;font-weight:normal" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%" valign="bottom"&gt;
        &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:normal"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;90&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;font-weight:normal;white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;font-weight:normal" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;font-weight:normal" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%" valign="bottom"&gt;
        &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:normal"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;239&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;font-weight:normal;white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align:top;width:76%;font-weight:normal;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;font-weight:normal;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;font-weight:normal;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;font-weight:normal;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;font-weight:normal;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;font-weight:normal;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;font-weight:normal;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;font-weight:normal;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;font-weight:normal;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
        &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align:bottom;width:76%" valign="bottom"&gt;
        &lt;div style="margin-right:36pt;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:normal"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Current
        lease liabilities&lt;/span&gt;&lt;/span&gt;&lt;/div&gt; &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;font-weight:normal" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;font-weight:normal" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%" valign="bottom"&gt;
        &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:normal"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;91&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;font-weight:normal;white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;font-weight:normal" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;font-weight:normal" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%" valign="bottom"&gt;
        &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:normal"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;179&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;font-weight:normal;white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align:bottom;width:76%;padding-bottom:2px;background-color:rgb(204, 238, 255)" valign="bottom"&gt;
        &lt;div style="margin-right:36pt;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:normal"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Non-current
        lease liabilities&lt;/span&gt;&lt;/span&gt;&lt;/div&gt; &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;font-weight:normal;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);font-weight:normal;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom"&gt;
        &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:normal"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;font-weight:normal;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;font-weight:normal;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);font-weight:normal;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom"&gt;
        &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:normal"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;123&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;font-weight:normal;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
        &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align:bottom;width:76%;font-weight:bold" valign="bottom"&gt;
        &lt;div style="margin-right:36pt;line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Total
        lease liabilities&lt;/span&gt;&lt;/span&gt;&lt;/div&gt; &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;font-weight:normal" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;font-weight:normal" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%" valign="bottom"&gt;
        &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:normal"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;91&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;font-weight:normal;white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;font-weight:normal" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;font-weight:normal" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%" valign="bottom"&gt;
        &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:normal"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;302&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;font-weight:normal;white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align:bottom;width:76%;font-weight:normal;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;font-weight:normal;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;font-weight:normal;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;font-weight:normal;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;font-weight:normal;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;font-weight:normal;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;font-weight:normal;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;font-weight:normal;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;font-weight:normal;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
        &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align:top;width:76%" valign="bottom"&gt;
        &lt;div style="margin-right:36pt;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:normal"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Weighted-average
        remaining lease term (in years)&lt;/span&gt;&lt;/span&gt;&lt;/div&gt; &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;font-weight:normal" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;font-weight:normal" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%" valign="bottom"&gt;
        &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:normal"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;0.52&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;font-weight:normal;white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;font-weight:normal" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;font-weight:normal" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%" valign="bottom"&gt;
        &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:normal"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;1.53&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;font-weight:normal;white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align:top;width:76%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;
        &lt;div style="margin-right:36pt;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:normal"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Weighted-average
        discount rate&lt;/span&gt;&lt;/span&gt;&lt;/div&gt; &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;font-weight:normal;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;font-weight:normal;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;
        &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:normal"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;16&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom"&gt;
        &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:normal"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;%&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;font-weight:normal;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;font-weight:normal;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;
        &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:normal"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;16&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom"&gt;
        &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:normal"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;%&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/td&gt; &lt;/tr&gt;
  &lt;/table&gt; &lt;/div&gt; &lt;/div&gt; &lt;/div&gt; </entx:OperatingLeaseLiabilityAndOperatingLeaseRightOfUseAssetTableTextBlock>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="C_20221231"
      decimals="-3"
      id="F20230227081114748_3"
      unitRef="USD">90000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="C_20211231"
      decimals="-3"
      id="F20230227081114749_4"
      unitRef="USD">239000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="C_20221231"
      decimals="-3"
      id="F20230227081114749_5"
      unitRef="USD">91000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="C_20211231"
      decimals="-3"
      id="F20230227081114749_6"
      unitRef="USD">179000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="C_20221231"
      decimals="-3"
      id="F20230227081114749_7"
      unitRef="USD">0</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="C_20211231"
      decimals="-3"
      id="F20230227081114749_8"
      unitRef="USD">123000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiability
      contextRef="C_20221231"
      decimals="-3"
      id="F20230227081114749_9"
      unitRef="USD">91000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseLiability
      contextRef="C_20211231"
      decimals="-3"
      id="F20230227081114750_10"
      unitRef="USD">302000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1 contextRef="C_20221231" id="F20230227081114750_11">P0Y6M7D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1 contextRef="C_20211231" id="F20230227081114750_12">P1Y6M10D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="C_20221231"
      decimals="2"
      id="F20230227081114750_13"
      unitRef="Percent">0.16</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="C_20211231"
      decimals="2"
      id="F20230227081114750_14"
      unitRef="Percent">0.16</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseLiability
      contextRef="C_20221231"
      decimals="-3"
      id="Fxbrl_20230227144319586"
      unitRef="USD">91000</us-gaap:OperatingLeaseLiability>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="C_20220101to20221231" id="F20230227081114771_0">

&lt;div&gt;

&lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-weight:bold"&gt;NOTE
4 - COMMITMENTS&lt;/span&gt;&#160;&lt;span style="font-weight:bold"&gt;AND CONTINGENCIES&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;

&lt;div style="text-indent:-36pt;margin-left:36pt;line-height:1.25;font-weight:bold"&gt;&#160;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"&gt;
  &lt;tr&gt;
    &lt;td style="width:35.45pt;vertical-align:top"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;a&lt;span style="font-weight:bold"&gt;.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width:auto;vertical-align:top;text-align:justify"&gt;
        &lt;div style="font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Commitment to pay royalties
        to the government of Israel&lt;/span&gt;&lt;/span&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt;
  &lt;/table&gt;

&lt;div style="text-indent:-36pt;margin-left:72pt;line-height:1.25"&gt;&#160;&lt;/div&gt;

&lt;div style="text-align:justify;margin-left:36pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;The
Company is committed to pay royalties to the IIA on proceeds from sales of products in the research and development of which the Government
participates by way of grants. At the time the grants were received, successful development of the related project was not assumed. In
the case of failure of the project that was partly financed by the IIA, the Company is not obligated to pay any such royalties.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;

&lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;

&lt;div style="text-align:justify;margin-left:36pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Under
the terms of the Company&#x2019;s funding from the IIA, royalties are payable on sales of products developed from IIA funded projects of
3%
during the first three years from commencement of revenues, 4%
during the subsequent three years and 5%
commencing the seventh year up to 100% of the amount of the grant received by the Company (dollar linked) plus annual interest based on
LIBOR. The amount that must be repaid may be increased to three times the amount of the grant received, and the rate of royalties may
be accelerated, if manufacturing of the products developed with the grant money is transferred outside of the State of Israel. In addition,
if the Company undergoes a change of control or otherwise transfers the technology &#x201c;know-how&#x201d; (as defined under the Research
Law) in or outside of Israel, the amount that must be repaid will be increased up to six times.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;

&lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;

&lt;div style="text-align:justify;margin-left:36pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;The
IIA has not yet declared the alternative benchmark rate to replace LIBOR. However, the Company does not believe it will have significant
impact on the Company&#x2019;s financial position or results of operations.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;

&lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;

&lt;div style="text-align:justify;margin-left:36pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;As
of December 31, 2022, the total royalty amount that would be payable by the Company to the IIA, before the interest and payments as described
above, was approximately $460.
These grants were allocated to research and development.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;

&lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;

&lt;div style="text-align:justify;margin-left:36pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Following
the signing of the Amgen Agreement, the IIA determined that the Company should pay 5.38%
of each payment received by the Company from Amgen on the license of Intellectual Property up to six times the grant received. As of December
31, 2022, the Company had paid a total amount of $83
to the IIA.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;

&lt;div style="text-indent:-36pt;margin-left:36pt;line-height:1.25;font-weight:bold"&gt;&#160;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"&gt;
  &lt;tr&gt;
    &lt;td style="width:35.45pt;vertical-align:top"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;b.&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width:auto;vertical-align:top;text-align:justify"&gt;
        &lt;div&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;On June 1, 2010, D.N.A. Biomedical Solutions Ltd.
        ("D.N.A.") and Oramed Ltd., ("Oramed") entered into a joint venture agreement, (the "Joint Venture Agreement") for the establishment of
        Entera Bio Ltd. According to the Joint Venture Agreement each of D.N.A. and Oramed acquired 50%
        of the Company's ordinary shares. D.N.A invested $600
        in the Company, and Oramed and the Company entered into a Patent License Agreement pursuant to which Oramed licensed to the Company one
        of Oramed&#x2019;s patents (the &#x201c;IPR&amp;amp;D&#x201d;).&lt;/span&gt;&lt;/span&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt;
  &lt;/table&gt;

&lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;

&lt;div style="text-align:justify;margin-left:36pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;On
February 22, 2011, Oramed and the Company entered into a patent transfer agreement, (the "Patent Transfer Agreement") that superseded
the Patent License Agreement, whereby Oramed assigned to the Company all of its rights, title and interest to its patent that Oramed licensed
to the Company in 2010, under certain conditions. Under this agreement, the Company is obligated to pay Oramed royalties equal to 3%
of its net revenues (as defined in the Patent Transfer Agreement).&lt;/span&gt;&lt;/span&gt;&lt;/div&gt; &lt;/div&gt; </us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <entx:RoyaltyGuaranteesCommitmentsPercentageSalesOfProductsDevelopedFromProjectsInFirstThreeYearsFromCommencementOfRevenues
      contextRef="C_20220101to20221231_usgaapAccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis_usgaapGovernmentMember"
      decimals="2"
      id="F20230227081114771_1"
      unitRef="Percent">0.03</entx:RoyaltyGuaranteesCommitmentsPercentageSalesOfProductsDevelopedFromProjectsInFirstThreeYearsFromCommencementOfRevenues>
    <entx:RoyaltyGuaranteesCommitmentsPercentageSalesOfProductsDevelopedFromProjectsSubsequentThreeYears
      contextRef="C_20220101to20221231_usgaapAccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis_usgaapGovernmentMember"
      decimals="2"
      id="F20230227081114772_2"
      unitRef="Percent">0.04</entx:RoyaltyGuaranteesCommitmentsPercentageSalesOfProductsDevelopedFromProjectsSubsequentThreeYears>
    <entx:RoyaltyGuaranteesCommitmentsPercentageSalesOfProductsDevelopedFromProjectsCommencingSeventhYear
      contextRef="C_20220101to20221231_usgaapAccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis_usgaapGovernmentMember"
      decimals="2"
      id="F20230227081114772_3"
      unitRef="Percent">0.05</entx:RoyaltyGuaranteesCommitmentsPercentageSalesOfProductsDevelopedFromProjectsCommencingSeventhYear>
    <us-gaap:RoyaltyGuaranteesCommitmentsAmount
      contextRef="C_20221231_usgaapAccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis_usgaapGovernmentMember"
      decimals="-3"
      id="F20230227081114772_7"
      unitRef="USD">460000</us-gaap:RoyaltyGuaranteesCommitmentsAmount>
    <entx:RoyaltyGuaranteesCommitmentsPercentageOfEachPaymentReceivedFromAmgen
      contextRef="C_20220101to20221231_usgaapAccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis_usgaapGovernmentMember"
      decimals="4"
      id="F20230227081114772_4"
      unitRef="Percent">0.0538</entx:RoyaltyGuaranteesCommitmentsPercentageOfEachPaymentReceivedFromAmgen>
    <entx:PaymentOfRoyaltyGuaranteesCommitments
      contextRef="C_20220101to20221231_usgaapAccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis_usgaapGovernmentMember"
      decimals="-3"
      id="F20230227081114772_8"
      unitRef="USD">83000</entx:PaymentOfRoyaltyGuaranteesCommitments>
    <entx:SaleOfStockPercentageOfOwnershipOfEntityAcquired
      contextRef="C_20220101to20221231_entxAgreementAxis_entxJointVentureAgreementMember_usgaapRelatedPartyTransactionsByRelatedPartyAxis_entxDnaBiomedicalSolutionsLtdAndOramedLtdMember"
      decimals="2"
      id="F20230227081114772_5"
      unitRef="Percent">0.50</entx:SaleOfStockPercentageOfOwnershipOfEntityAcquired>
    <entx:SaleOfStockAmountOfInvestment
      contextRef="C_20220101to20221231_entxAgreementAxis_entxJointVentureAgreementMember_usgaapRelatedPartyTransactionsByRelatedPartyAxis_entxDnaBiomedicalSolutionsLtdMember"
      decimals="-3"
      id="F20230227081114772_9"
      unitRef="USD">600000</entx:SaleOfStockAmountOfInvestment>
    <entx:RoyaltyGuaranteesCommitmentsPercentageOfNetRevenues
      contextRef="C_20220101to20221231_entxAgreementAxis_entxPatentTransferAgreementMember"
      decimals="2"
      id="F20230227081114772_6"
      unitRef="Percent">0.03</entx:RoyaltyGuaranteesCommitmentsPercentageOfNetRevenues>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock
      contextRef="C_20220101to20221231"
      id="Fxbrl_20230330110216722">

&lt;div&gt;

&lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;NOTE
5 - SHARE CAPITAL&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;

&lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"&gt;
  &lt;tr&gt;
    &lt;td style="width:35.45pt;vertical-align:top"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;1)&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width:auto;vertical-align:top;text-align:justify"&gt;
        &lt;div style="font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;Rights of
        the Company&#x2019;s ordinary shares&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt;
  &lt;/table&gt;

&lt;div style="margin-left:72pt;line-height:1.25;font-weight:bold"&gt;&#160;&lt;/div&gt;

&lt;div style="text-align:justify;margin-left:36pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;Each
ordinary share is entitled to one
vote. The holder of an ordinary shares is also entitled to receive dividends whenever funds are legally available, when
and if declared by the Board of Directors.&lt;br/&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;

&lt;div style="text-align:justify;margin-left:36pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;A
holder of an ordinary share also has the right to receive upon liquidation of the Company, a sum equal to the nominal value of such share,
and if a surplus per share remains, to receive such surplus, subject to the rights conferred on any class of shares which may be issued
in the future. Since its inception, the Company has not declared any dividends.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;

&lt;div style="text-align:justify;margin-left:70.9pt;line-height:1.25"&gt;&#160;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"&gt;
  &lt;tr&gt;
    &lt;td style="width:35.45pt;vertical-align:top"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;2)&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width:auto;vertical-align:top;text-align:justify"&gt;
        &lt;div style="font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;Changes in
        share capital:&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt;
  &lt;/table&gt;

&lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"&gt;
  &lt;tr&gt;
    &lt;td style="width:35.45pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width:21.25pt;vertical-align:top"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;a.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width:auto;vertical-align:top"&gt;
        &lt;div style="font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;IPO warrants&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/td&gt; &lt;/tr&gt;
  &lt;/table&gt;

&lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;

&lt;div style="text-align:justify;margin-left:56.7pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;In
connection with the Company&#x2019;s initial public offering (&#x201c;IPO&#x201d;) in July 2018, the Company issued 1,400,000
IPO warrants to purchase 700,000
ordinary shares, and these warrants have been listed for trading on the Nasdaq Capital Market since August 12, 2018. The IPO warrants
were immediately exercisable at an initial exercise price of $8.40
per ordinary share for a period of five
years, unless earlier repurchased by the Company under "Fundamental Transactions&#x201d; as described in the warrant agreement
or earlier expired as described in the warrant agreement.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;

&lt;div style="text-align:justify;margin-left:56.7pt;line-height:1.25"&gt;&lt;br/&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;The
exercise price and number of ordinary shares issuable upon exercise of each warrant are subject to standard adjustments. In addition,
subject to certain exceptions, the exercise price was subject to reduction if, within two
years following the date of original issuance of the warrants, which ended in July 2020, the Company sold or granted any
warrant or option at an effective price per share of less than $8.00
(as adjusted in proportion with any adjustments made from time to time), based on a weighted average, as described in the warrant agreement.
As described in note 5b below, the Company completed a financing round during such two-year period at a price per share lower than the
$8.00, therefore, the exercise price of these warrants adjusted to $5.85
per share.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;

&lt;div style="text-align:justify;margin-left:56.7pt;line-height:1.25"&gt;&#160;&lt;/div&gt;

&lt;div style="text-align:justify;margin-left:56.7pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;At
the IPO completion date, both of the instruments (warrants and shares) were classified as equity instruments as the warrants are considered
indexed to the entity's own stock based on the provision of ASC 815.&lt;br/&gt;&#160;&lt;br/&gt;In March 2021, 4,500
IPO warrants were exercised into 2,250
ordinary shares for total consideration of $13
at an exercise price of $5.85
per ordinary share.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;

&lt;div style="text-align:justify;margin-left:56.7pt;line-height:1.25"&gt;&#160;&lt;/div&gt;

&lt;div style="text-align:justify;margin-left:56.7pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;As
of the December 31, 2022 there were 1,395,500
traded warrants to purchase 697,750
ordinary shares outstanding with an exercise price of $5.85.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;

&lt;div style="text-align:justify;margin-left:56.7pt;line-height:1.25"&gt;&#160;&lt;/div&gt;

&lt;div/&gt;

&lt;div style="text-align:justify;line-height:1.25"&gt;

&lt;table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"&gt;
  &lt;tr&gt;
    &lt;td style="width:35.45pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width:21.25pt;vertical-align:top"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;b.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width:auto;vertical-align:top;text-align:justify"&gt;
        &lt;div&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;In December 2019 and February 2020,
        the Company entered into subscription agreement with a selected group of accredited investors for the private placement of 6,047,706
        ordinary shares for aggregate subscription proceeds to the Company of $14.3
        million at a price of $2.37
        per share. In addition, the Company granted 3,023,871
        warrants, exercisable over a three-year
        period from the date of issuance to purchase up to 3,023,871
        ordinary shares at a per share exercise price of $2.96
        (&#x201c;Investors Warrants&#x201d;). In addition, the exercise price was subject to reduction if, within one year of the date of original
        issuance of the warrants which ended in December 2020, the Company issued ordinary shares at an effective price per share less than $2.96.&lt;br/&gt;&#160;&lt;br/&gt;Following
        the closing of the offering, the Company issued to a broker-dealer 184,515
        warrants and 92,257
        warrants with per share exercise prices of $2.37
        to $2.96,
        respectively (&#x201c;Broker Warrants&#x201d;).&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt;
  &lt;/table&gt; &lt;/div&gt;

&lt;div style="text-align:justify;margin-left:56.7pt;line-height:1.25"&gt;&#160;&lt;/div&gt;

&lt;div style="text-align:justify;margin-left:56.7pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;During
2020, upon issuance of shares through the Company&#x2019;s At-the-market equity program at a price per share lower than the exercise price,
the exercise price of the Investors Warrants and the Broker Warrants adjusted to $1.05.
See note 5c.&lt;br/&gt;&#160;&lt;br/&gt;On April 21, 2021, upon satisfaction of the sale price condition pursuant to the subscription agreement,
the Company&#x2019;s Board of Directors elected to accelerate the termination date of the Investors Warrants and Broker Warrants. In accordance
with the terms of the applicable agreements, the holders had the opportunity to exercise their warrants until June 23, 2021, following
which any unexercised warrants would terminate.&lt;br/&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;

&lt;div style="text-align:justify;margin-left:56.7pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;Through
June 23, 2021, all warrants holders exercised 3,300,645
warrants into 3,172,800
ordinary shares, either through purchase or a cashless exercise. The total consideration from the exercise of these warrants was $3,145
at an exercise price of $1.05
per share.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;

&lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;

&lt;div style="text-align:justify;margin-left:56.7pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;As
of December 31, 2021, all Investors Warrants and Broker Warrants had been exercised and none remain outstanding.&lt;br/&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;

&lt;div style="text-align:justify;line-height:1.25"&gt;

&lt;table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"&gt;
  &lt;tr&gt;
    &lt;td style="width:35.45pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width:21.25pt;vertical-align:top"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;c.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width:auto;vertical-align:top;text-align:justify"&gt;
        &lt;div&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;On July 4, 2020, the Company filed
        a primary registration statement on form F-3 and established an at-the-market equity program (the " 2020 ATM Program") that allowed the
        Company to issue up to $13.9
        million of ordinary shares, at the Company&#x2019;s discretion. Distributions of the ordinary shares through 2020 ATM Program were made
        pursuant to the terms of an equity distribution agreement dated July 13, 2020, among the Company and Canaccord Genuity LLC (the "Agent").&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/td&gt; &lt;/tr&gt;
  &lt;/table&gt; &lt;/div&gt;

&lt;div style="text-align:justify;margin-left:56.7pt;line-height:1.25"&gt;&#160;&lt;/div&gt;

&lt;div style="text-align:justify;margin-left:56.7pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;In
2020, the Company issued 2,802,731
ordinary shares pursuant to the 2020 ATM Program for net proceeds of $3.2
million at a weighted average price of $1.27
per ordinary share.&lt;br/&gt;&#160;&lt;br/&gt;In 2021, the Company issued an additional 2,546,265
ordinary shares pursuant to the 2020 ATM Program for net proceeds of $9.9
million at a weighted average price of $3.99
per ordinary share.&lt;br/&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;

&lt;div style="text-align:justify;line-height:1.25"&gt;

&lt;table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"&gt;
  &lt;tr&gt;
    &lt;td style="width:35.45pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width:21.25pt;vertical-align:top"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;d.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width:auto;vertical-align:top;text-align:justify"&gt;
        &lt;div&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;On May 7, 2021, the Company entered
        into a new at-the-market equity program (the "2021 ATM Program") that allowed the Company to issue up to additional five
        million ordinary shares, at the Company's discretion.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt;
  &lt;/table&gt; &lt;/div&gt;

&lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;

&lt;div&gt;

&lt;div/&gt; &lt;/div&gt;

&lt;div style="text-align:justify;margin-left:56.7pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;Distributions
of the ordinary shares through the 2021 ATM Program were made pursuant to the terms of an equity distribution agreement dated May 7, 2021
among the Company and B. Riley Securities, Inc.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;

&lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"&gt;
  &lt;tr&gt;
    &lt;td style="width:35.45pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width:21.25pt;vertical-align:top"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;e.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width:auto;vertical-align:top;text-align:justify"&gt;
        &lt;div&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;In June and July 2021, the Company
        issued an aggregate of 1,840,463
        ordinary shares pursuant to the 2021 ATM Program for net proceeds of $12.1
        million at a weighted average price of $6.74
        per ordinary share.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt;
  &lt;/table&gt;

&lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"&gt;
  &lt;tr&gt;
    &lt;td style="width:35.45pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width:21.25pt;vertical-align:top"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;f.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width:auto;vertical-align:top;text-align:justify"&gt;
        &lt;div&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;During the year ended December 31,
        2021, several employees and service providers exercised 177,711
        options into 177,711
        ordinary shares for a total consideration of $418
        at a weighted average price of $2.54
        per ordinary share.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt;
  &lt;/table&gt;

&lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"&gt;
  &lt;tr&gt;
    &lt;td style="width:35.45pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width:21.25pt;vertical-align:top"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;g.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width:auto;vertical-align:top;text-align:justify"&gt;
        &lt;div&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;During the year ended December 31,
        2022, one employee exercised 5,511
        options into 5,511
        ordinary shares for a total consideration of $13
        at a price of $2.14
        per ordinary share.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt;
  &lt;/table&gt; &lt;/div&gt; </us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:CommonStockVotingRights
      contextRef="C_20220101to20221231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"
      id="F20230227081114811_0">one
vote</us-gaap:CommonStockVotingRights>
    <entx:ClassOfWarrantOrRightIssued
      contextRef="C_20180731_usgaapClassOfWarrantOrRightAxis_usgaapWarrantMember_usgaapSubsidiarySaleOfStockAxis_usgaapIPOMember"
      decimals="INF"
      id="F20230227081114812_1"
      unitRef="shares">1400000</entx:ClassOfWarrantOrRightIssued>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="C_20180731_usgaapClassOfWarrantOrRightAxis_usgaapWarrantMember_usgaapSubsidiarySaleOfStockAxis_usgaapIPOMember"
      decimals="INF"
      id="F20230227081114812_2"
      unitRef="shares">700000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="C_20180731_usgaapClassOfWarrantOrRightAxis_usgaapWarrantMember_usgaapSubsidiarySaleOfStockAxis_usgaapIPOMember"
      decimals="2"
      id="F20230227081114812_3"
      unitRef="USD_per_Share">8.4</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <entx:ClassOfWarrantOrRightExerciseTerm
      contextRef="C_20180701to20180731_usgaapClassOfWarrantOrRightAxis_usgaapWarrantMember_usgaapSubsidiarySaleOfStockAxis_usgaapIPOMember"
      id="F20230227081114813_4">P5Y</entx:ClassOfWarrantOrRightExerciseTerm>
    <entx:ClassOfWarrantOrRightThresholdLimitOfPeriodForReductionInExercisePrice
      contextRef="C_20180701to20180731_usgaapClassOfWarrantOrRightAxis_usgaapWarrantMember_usgaapSubsidiarySaleOfStockAxis_usgaapIPOMember"
      id="F20230227081114813_5">P2Y</entx:ClassOfWarrantOrRightThresholdLimitOfPeriodForReductionInExercisePrice>
    <entx:ClassOfWarrantOrRightThresholdLimitOfReductionInExercisePrice
      contextRef="C_20180701to20180731_usgaapClassOfWarrantOrRightAxis_usgaapWarrantMember_usgaapSubsidiarySaleOfStockAxis_usgaapIPOMember"
      decimals="2"
      id="F20230227081114813_6"
      unitRef="USD_per_Share">8</entx:ClassOfWarrantOrRightThresholdLimitOfReductionInExercisePrice>
    <entx:ClassOfWarrantOrRightReducedExercisePrice
      contextRef="C_20180701to20180731_usgaapClassOfWarrantOrRightAxis_usgaapWarrantMember_usgaapSubsidiarySaleOfStockAxis_usgaapIPOMember"
      decimals="2"
      id="F20230227081114813_7"
      unitRef="USD_per_Share">5.85</entx:ClassOfWarrantOrRightReducedExercisePrice>
    <entx:ClassOfWarrantOrRightIssued
      contextRef="C_20210331_usgaapClassOfWarrantOrRightAxis_usgaapWarrantMember_usgaapSubsidiarySaleOfStockAxis_usgaapIPOMember"
      decimals="INF"
      id="F20230227081114814_8"
      unitRef="shares">4500</entx:ClassOfWarrantOrRightIssued>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="C_20210331_usgaapClassOfWarrantOrRightAxis_usgaapWarrantMember_usgaapSubsidiarySaleOfStockAxis_usgaapIPOMember"
      decimals="INF"
      id="F20230227081114814_9"
      unitRef="shares">2250</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <entx:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsTotalConsideration
      contextRef="C_20210301to20210331_usgaapClassOfWarrantOrRightAxis_usgaapWarrantMember_usgaapSubsidiarySaleOfStockAxis_usgaapIPOMember"
      decimals="-3"
      id="F20230227081114814_10"
      unitRef="USD">13000</entx:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsTotalConsideration>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="C_20210331_usgaapClassOfWarrantOrRightAxis_usgaapWarrantMember_usgaapSubsidiarySaleOfStockAxis_usgaapIPOMember"
      decimals="2"
      id="F20230227081114815_11"
      unitRef="USD_per_Share">5.85</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <entx:ClassOfWarrantOrRightIssued
      contextRef="C_20221231_usgaapClassOfWarrantOrRightAxis_usgaapWarrantMember_usgaapSubsidiarySaleOfStockAxis_usgaapIPOMember"
      decimals="INF"
      id="F20230227081114832_56"
      unitRef="shares">1395500</entx:ClassOfWarrantOrRightIssued>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="C_20221231_usgaapClassOfWarrantOrRightAxis_usgaapWarrantMember_usgaapSubsidiarySaleOfStockAxis_usgaapIPOMember"
      decimals="INF"
      id="F20230227081114833_57"
      unitRef="shares">697750</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="C_20221231_usgaapClassOfWarrantOrRightAxis_usgaapWarrantMember_usgaapSubsidiarySaleOfStockAxis_usgaapIPOMember"
      decimals="2"
      id="F20230227081114833_58"
      unitRef="USD_per_Share">5.85</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <entx:NumberOfSharesIssuedUnderPrivatePlacement
      contextRef="C_20200229_usgaapRelatedPartyTransactionsByRelatedPartyAxis_entxAccreditedInvestorsIncludingCertainBoardMembersAndTheirAffiliatesMember_usgaapSubsidiarySaleOfStockAxis_usgaapPrivatePlacementMember"
      decimals="INF"
      id="Fxbrl_20230228132916187"
      unitRef="shares">6047706</entx:NumberOfSharesIssuedUnderPrivatePlacement>
    <entx:NumberOfSharesIssuedUnderPrivatePlacement
      contextRef="C_20191231_usgaapRelatedPartyTransactionsByRelatedPartyAxis_entxAccreditedInvestorsIncludingCertainBoardMembersAndTheirAffiliatesMember_usgaapSubsidiarySaleOfStockAxis_usgaapPrivatePlacementMember"
      decimals="INF"
      id="F20230227081114820_12"
      unitRef="shares">6047706</entx:NumberOfSharesIssuedUnderPrivatePlacement>
    <us-gaap:ProceedsFromIssuanceOfPrivatePlacement
      contextRef="C_20200201to20200229_usgaapRelatedPartyTransactionsByRelatedPartyAxis_entxAccreditedInvestorsIncludingCertainBoardMembersAndTheirAffiliatesMember_usgaapSubsidiarySaleOfStockAxis_usgaapPrivatePlacementMember"
      decimals="-5"
      id="Fxbrl_20230228133001926"
      unitRef="USD">14300000</us-gaap:ProceedsFromIssuanceOfPrivatePlacement>
    <us-gaap:ProceedsFromIssuanceOfPrivatePlacement
      contextRef="C_20190101to20191231_usgaapRelatedPartyTransactionsByRelatedPartyAxis_entxAccreditedInvestorsIncludingCertainBoardMembersAndTheirAffiliatesMember_usgaapSubsidiarySaleOfStockAxis_usgaapPrivatePlacementMember"
      decimals="-5"
      id="F20230227081114820_13"
      unitRef="USD">14300000</us-gaap:ProceedsFromIssuanceOfPrivatePlacement>
    <us-gaap:SharePrice
      contextRef="C_20200229_usgaapRelatedPartyTransactionsByRelatedPartyAxis_entxAccreditedInvestorsIncludingCertainBoardMembersAndTheirAffiliatesMember_usgaapSubsidiarySaleOfStockAxis_usgaapPrivatePlacementMember"
      decimals="2"
      id="Fxbrl_20230228132938100"
      unitRef="USD_per_Share">2.37</us-gaap:SharePrice>
    <us-gaap:SharePrice
      contextRef="C_20191231_usgaapRelatedPartyTransactionsByRelatedPartyAxis_entxAccreditedInvestorsIncludingCertainBoardMembersAndTheirAffiliatesMember_usgaapSubsidiarySaleOfStockAxis_usgaapPrivatePlacementMember"
      decimals="2"
      id="F20230227081114820_14"
      unitRef="USD_per_Share">2.37</us-gaap:SharePrice>
    <entx:ClassOfWarrantOrRightIssued
      contextRef="C_20200229_usgaapRelatedPartyTransactionsByRelatedPartyAxis_entxAccreditedInvestorsIncludingCertainBoardMembersAndTheirAffiliatesMember_usgaapSubsidiarySaleOfStockAxis_usgaapPrivatePlacementMember"
      decimals="INF"
      id="Fxbrl_20230228132950878"
      unitRef="shares">3023871</entx:ClassOfWarrantOrRightIssued>
    <entx:ClassOfWarrantOrRightIssued
      contextRef="C_20191231_usgaapRelatedPartyTransactionsByRelatedPartyAxis_entxAccreditedInvestorsIncludingCertainBoardMembersAndTheirAffiliatesMember_usgaapSubsidiarySaleOfStockAxis_usgaapPrivatePlacementMember"
      decimals="INF"
      id="F20230227081114821_15"
      unitRef="shares">3023871</entx:ClassOfWarrantOrRightIssued>
    <entx:ClassOfWarrantOrRightExerciseTerm
      contextRef="C_20200201to20200229_usgaapRelatedPartyTransactionsByRelatedPartyAxis_entxAccreditedInvestorsIncludingCertainBoardMembersAndTheirAffiliatesMember_usgaapSubsidiarySaleOfStockAxis_usgaapPrivatePlacementMember"
      id="Fxbrl_20230228133032196">P3Y</entx:ClassOfWarrantOrRightExerciseTerm>
    <entx:ClassOfWarrantOrRightExerciseTerm
      contextRef="C_20190101to20191231_usgaapRelatedPartyTransactionsByRelatedPartyAxis_entxAccreditedInvestorsIncludingCertainBoardMembersAndTheirAffiliatesMember_usgaapSubsidiarySaleOfStockAxis_usgaapPrivatePlacementMember"
      id="F20230227081114821_16">P3Y</entx:ClassOfWarrantOrRightExerciseTerm>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="C_20200229_usgaapRelatedPartyTransactionsByRelatedPartyAxis_entxAccreditedInvestorsIncludingCertainBoardMembersAndTheirAffiliatesMember_usgaapSubsidiarySaleOfStockAxis_usgaapPrivatePlacementMember"
      decimals="INF"
      id="Fxbrl_20230228133118411"
      unitRef="shares">3023871</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="C_20191231_usgaapRelatedPartyTransactionsByRelatedPartyAxis_entxAccreditedInvestorsIncludingCertainBoardMembersAndTheirAffiliatesMember_usgaapSubsidiarySaleOfStockAxis_usgaapPrivatePlacementMember"
      decimals="INF"
      id="F20230227081114821_17"
      unitRef="shares">3023871</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="C_20200229_usgaapRelatedPartyTransactionsByRelatedPartyAxis_entxAccreditedInvestorsIncludingCertainBoardMembersAndTheirAffiliatesMember_usgaapSubsidiarySaleOfStockAxis_usgaapPrivatePlacementMember"
      decimals="2"
      id="Fxbrl_20230228133128455"
      unitRef="USD_per_Share">2.96</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="C_20191231_usgaapRelatedPartyTransactionsByRelatedPartyAxis_entxAccreditedInvestorsIncludingCertainBoardMembersAndTheirAffiliatesMember_usgaapSubsidiarySaleOfStockAxis_usgaapPrivatePlacementMember"
      decimals="2"
      id="F20230227081114821_18"
      unitRef="USD_per_Share">2.96</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="C_20200229_usgaapRelatedPartyTransactionsByRelatedPartyAxis_entxAccreditedInvestorsIncludingCertainBoardMembersAndTheirAffiliatesMember_usgaapSubsidiarySaleOfStockAxis_usgaapPrivatePlacementMember"
      decimals="2"
      id="Fxbrl_20230228133138472"
      unitRef="USD_per_Share">2.96</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="C_20191231_usgaapRelatedPartyTransactionsByRelatedPartyAxis_entxAccreditedInvestorsIncludingCertainBoardMembersAndTheirAffiliatesMember_usgaapSubsidiarySaleOfStockAxis_usgaapPrivatePlacementMember"
      decimals="2"
      id="Fxbrl_20230228100113652"
      unitRef="USD_per_Share">2.96</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:SharesIssued
      contextRef="C_20200229_usgaapClassOfWarrantOrRightAxis_entxBrokerDealerMember"
      decimals="INF"
      id="Fxbrl_20230228133157525"
      unitRef="shares">184515</us-gaap:SharesIssued>
    <us-gaap:SharesIssued
      contextRef="C_20191231_usgaapClassOfWarrantOrRightAxis_entxBrokerDealerMember"
      decimals="INF"
      id="Fxbrl_20230228101446660"
      unitRef="shares">184515</us-gaap:SharesIssued>
    <us-gaap:SharesIssued
      contextRef="C_20200229_usgaapClassOfWarrantOrRightAxis_entxBrokerDealerOneMember"
      decimals="INF"
      id="Fxbrl_20230228133202830"
      unitRef="shares">92257</us-gaap:SharesIssued>
    <us-gaap:SharesIssued
      contextRef="C_20191231_usgaapClassOfWarrantOrRightAxis_entxBrokerDealerOneMember"
      decimals="INF"
      id="Fxbrl_20230228101451219"
      unitRef="shares">92257</us-gaap:SharesIssued>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="C_20200229_usgaapClassOfWarrantOrRightAxis_entxBrokerWarrantsMember"
      decimals="2"
      id="Fxbrl_20230228133226908"
      unitRef="USD_per_Share">2.37</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="C_20191231_usgaapClassOfWarrantOrRightAxis_entxBrokerWarrantsMember"
      decimals="2"
      id="F20230227081114825_26"
      unitRef="USD_per_Share">2.37</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="C_20200229_usgaapClassOfWarrantOrRightAxis_entxBrokerWarrantsType1Member"
      decimals="2"
      id="Fxbrl_20230228133248658"
      unitRef="USD_per_Share">2.96</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="C_20191231_usgaapClassOfWarrantOrRightAxis_entxBrokerWarrantsType1Member"
      decimals="2"
      id="Fxbrl_20230228101543156"
      unitRef="USD_per_Share">2.96</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <entx:AdjustedExercisePriceUnderAtMarketEquityProgram
      contextRef="C_20201231_entxEquityProgramAxis_entxAtmEquityProgram2020Member"
      decimals="2"
      id="F20230227081114834_62"
      unitRef="USD_per_Share">1.05</entx:AdjustedExercisePriceUnderAtMarketEquityProgram>
    <entx:ClassOfWarrantOrRightIssued
      contextRef="C_20210623_usgaapClassOfWarrantOrRightAxis_usgaapWarrantMember_usgaapRelatedPartyTransactionsByRelatedPartyAxis_entxChairmanOfBoardAndDnaMember_usgaapSubsidiarySaleOfStockAxis_usgaapPrivatePlacementMember"
      decimals="INF"
      id="F20230227081114826_32"
      unitRef="shares">3300645</entx:ClassOfWarrantOrRightIssued>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="C_20210623_usgaapRelatedPartyTransactionsByRelatedPartyAxis_entxChairmanOfBoardAndDnaMember_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember_usgaapSubsidiarySaleOfStockAxis_usgaapPrivatePlacementMember"
      decimals="INF"
      id="F20230227081114826_33"
      unitRef="shares">3172800</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="C_20210601to20210623_usgaapClassOfWarrantOrRightAxis_usgaapWarrantMember_usgaapRelatedPartyTransactionsByRelatedPartyAxis_entxChairmanOfBoardAndDnaMember_usgaapSubsidiarySaleOfStockAxis_usgaapPrivatePlacementMember"
      decimals="-3"
      id="F20230227081114827_34"
      unitRef="USD">3145000</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="C_20210623_usgaapClassOfWarrantOrRightAxis_usgaapWarrantMember_usgaapRelatedPartyTransactionsByRelatedPartyAxis_entxChairmanOfBoardAndDnaMember_usgaapSubsidiarySaleOfStockAxis_usgaapPrivatePlacementMember"
      decimals="2"
      id="F20230227081114827_35"
      unitRef="USD_per_Share">1.05</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:CommonStockValue
      contextRef="C_20200704_entxEquityProgramAxis_entxAtmEquityProgram2020Member_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"
      decimals="-5"
      id="F20230227081114830_42"
      unitRef="USD">13900000</us-gaap:CommonStockValue>
    <us-gaap:SharesIssued
      contextRef="C_20201231_entxEquityProgramAxis_entxAtmEquityProgram2020Member_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"
      decimals="INF"
      id="F20230227081114830_43"
      unitRef="shares">2802731</us-gaap:SharesIssued>
    <entx:NetProceedsFromIssuanceOfCommonStock
      contextRef="C_20200101to20201231_entxEquityProgramAxis_entxAtmEquityProgram2020Member_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"
      decimals="-5"
      id="Fxbrl_20230228102503264"
      unitRef="USD">3200000</entx:NetProceedsFromIssuanceOfCommonStock>
    <entx:SharesIssuedWeightedAveragePricePerShare
      contextRef="C_20201231_entxEquityProgramAxis_entxAtmEquityProgram2020Member_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"
      decimals="2"
      id="F20230227081114831_46"
      unitRef="USD_per_Share">1.27</entx:SharesIssuedWeightedAveragePricePerShare>
    <us-gaap:SharesIssued
      contextRef="C_20211231_entxEquityProgramAxis_entxAtmEquityProgram2020Member_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"
      decimals="INF"
      id="F20230227081114831_47"
      unitRef="shares">2546265</us-gaap:SharesIssued>
    <entx:NetProceedsFromIssuanceOfCommonStock
      contextRef="C_20210101to20211231_entxEquityProgramAxis_entxAtmEquityProgram2020Member_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"
      decimals="-5"
      id="F20230227081114831_48"
      unitRef="USD">9900000</entx:NetProceedsFromIssuanceOfCommonStock>
    <entx:SharesIssuedWeightedAveragePricePerShare
      contextRef="C_20211231_entxEquityProgramAxis_entxAtmEquityProgram2020Member_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"
      decimals="2"
      id="F20230227081114831_49"
      unitRef="USD_per_Share">3.99</entx:SharesIssuedWeightedAveragePricePerShare>
    <us-gaap:SharesIssued
      contextRef="C_20210507_entxEquityProgramAxis_entxAtmEquityProgram2021Member_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"
      decimals="-6"
      id="F20230227081114834_63"
      unitRef="shares">5000000</us-gaap:SharesIssued>
    <us-gaap:SharesIssued
      contextRef="C_20210731_entxEquityProgramAxis_entxAtmEquityProgram2021Member_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"
      decimals="INF"
      id="F20230227081114831_50"
      unitRef="shares">1840463</us-gaap:SharesIssued>
    <entx:NetProceedsFromIssuanceOfCommonStock
      contextRef="C_20210601to20210731_entxEquityProgramAxis_entxAtmEquityProgram2021Member_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"
      decimals="-5"
      id="F20230227081114832_52"
      unitRef="USD">12100000</entx:NetProceedsFromIssuanceOfCommonStock>
    <entx:SharesIssuedWeightedAveragePricePerShare
      contextRef="C_20210731_entxEquityProgramAxis_entxAtmEquityProgram2021Member_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"
      decimals="2"
      id="F20230227081114831_51"
      unitRef="USD_per_Share">6.74</entx:SharesIssuedWeightedAveragePricePerShare>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="C_20210101to20211231_usgaapRelatedPartyTransactionsByRelatedPartyAxis_entxSeveralEmployeesAndServiceProvidersMember_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"
      decimals="INF"
      id="F20230227081114832_53"
      unitRef="shares">177711</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod
      contextRef="C_20210101to20211231_usgaapRelatedPartyTransactionsByRelatedPartyAxis_entxSeveralEmployeesAndServiceProvidersMember_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"
      decimals="INF"
      id="F20230227081114832_54"
      unitRef="shares">177711</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod>
    <entx:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsTotalConsideration
      contextRef="C_20210101to20211231_usgaapRelatedPartyTransactionsByRelatedPartyAxis_entxSeveralEmployeesAndServiceProvidersMember_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"
      decimals="-3"
      id="Fxbrl_20230228102140874"
      unitRef="USD">418000</entx:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsTotalConsideration>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="C_20210101to20211231_usgaapRelatedPartyTransactionsByRelatedPartyAxis_entxSeveralEmployeesAndServiceProvidersMember_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"
      decimals="2"
      id="F20230227081114832_55"
      unitRef="USD_per_Share">2.54</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="C_20220101to20221231_usgaapRelatedPartyTransactionsByRelatedPartyAxis_entxSeveralEmployeesAndServiceProvidersMember_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"
      decimals="INF"
      id="Fxbrl_20230228102310848"
      unitRef="shares">5511</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod
      contextRef="C_20220101to20221231_usgaapRelatedPartyTransactionsByRelatedPartyAxis_entxSeveralEmployeesAndServiceProvidersMember_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"
      decimals="INF"
      id="Fxbrl_20230228102316321"
      unitRef="shares">5511</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod>
    <entx:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsTotalConsideration
      contextRef="C_20220101to20221231_usgaapRelatedPartyTransactionsByRelatedPartyAxis_entxSeveralEmployeesAndServiceProvidersMember_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"
      decimals="-3"
      id="Fxbrl_20230228102335627"
      unitRef="USD">13000</entx:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsTotalConsideration>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="C_20220101to20221231_usgaapRelatedPartyTransactionsByRelatedPartyAxis_entxSeveralEmployeesAndServiceProvidersMember_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"
      decimals="2"
      id="Fxbrl_20230228102249646"
      unitRef="USD_per_Share">2.14</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="C_20220101to20221231"
      id="F20230227081114939_166">

&lt;div&gt;

&lt;div&gt;

&lt;div&gt;

&lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;NOTE
6 - SHARE-BASED COMPENSATION&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;

&lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"&gt;
  &lt;tr&gt;
    &lt;td style="width:35.45pt;vertical-align:top;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;1)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width:auto;vertical-align:top;text-align:justify"&gt;
        &lt;div&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Share-based compensation plan&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/td&gt; &lt;/tr&gt;
  &lt;/table&gt;

&lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;

&lt;div style="text-align:justify;margin-left:36pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;On
March 17, 2013, the Company's Board of Directors approved a Share Incentive Plan (the &#x201c;2013 Plan&#x201d;). Under the 2013 Plan, the
Company reserves specified number of ordinary shares for allocation to stock options (each, an &#x201c;Option&#x201d;), restricted share
units, restricted share awards and performance-based awards, that had been awarded to employees and non-employees under the 2013 Plan.
Each Option is exercisable for one ordinary share.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;

&lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;

&lt;div style="text-align:justify;margin-left:36pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Any
Option granted under the 2013 Plan that is not exercised within six years from the date upon which it becomes exercisable will expire.
Since adopting the 2018 Plan (as defined below), the Company has not granted any awards under the 2013 Plan.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;

&lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;

&lt;div style="text-align:justify;margin-left:36pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;On
July 2, 2018, the Company's Board of Directors and shareholders of the Company approved a new Share Incentive Plan (the &#x201c;2018 Plan&#x201d;)
and reserved 1,371,398
ordinary shares for allocation to stock options (each, a "2018 Plan Option"), restricted share units, restricted share awards and performance-based
awards, to employees and non-employees for issuance under the 2018 Plan. Each 2018 Plan Option is exercisable for one ordinary share.&lt;br/&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;

&lt;div style="text-align:justify;margin-left:36pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Any
2018 Plan Option that is not exercised within 10 years from the date of grant will expire.&lt;br/&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;

&lt;div style="text-align:justify;margin-left:36pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;The
2018 Plan Options granted to employees are subject to the terms stipulated by section 102(b)(2) of the Israeli Income Tax Ordinance (the
&#x201c;Ordinance&#x201d;). According to these provisions, the Company will not be allowed to claim as an expense for tax purposes the amounts
credited to the employees as a capital gain benefit in respect of the options granted.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;

&lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;

&lt;div style="text-align:justify;margin-left:36pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2018
Plan Options granted to related parties or non-employees of the Company are governed by Section 3(i) of the Ordinance or Non-Qualified
Share Options ("NSO"). The Company will be allowed to claim as an expense for tax purposes in the year in which the related parties or
non-employees exercised the options into shares.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;

&lt;div style="text-align:justify;margin-left:36pt;line-height:1.25"&gt;&#160;&lt;/div&gt;

&lt;div style="text-align:justify;margin-left:36pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;As
of December 31, 2022, 922,080
ordinary shares remain available for future grants under the 2018 Plan.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;

&lt;div style="text-align:justify;margin-left:36pt;line-height:1.25"&gt;&#160;&lt;/div&gt;

&lt;div style="text-align:justify;margin-left:36pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;On
January 2, 2023, the Company&#x2019;s Board of Directors approved an increase of 1,440,496
ordinary shares that may be issued under the Company&#x2019;s 2018 Plan pursuant of the terms of the 2018 Plan,&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;

&lt;div style="text-align:center;line-height:1.25"&gt;&#160;&lt;/div&gt;

&lt;div&gt;

&lt;div/&gt; &lt;/div&gt;

&lt;div style="text-align:justify;line-height:1.25"&gt;

&lt;table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"&gt;
  &lt;tr&gt;
    &lt;td style="width:35.45pt;vertical-align:top;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width:auto;vertical-align:top;text-align:justify"&gt;
        &lt;div style="font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;share-based compensation
        grants to employees and directors:&lt;/span&gt;&lt;/span&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman,Times,serif"&gt;&#160;&lt;/p&gt; &lt;/div&gt;

&lt;div style="text-align:justify;line-height:1.25"&gt;

&lt;table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"&gt;
  &lt;tr&gt;
    &lt;td style="width:35.45pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width:21.25pt;vertical-align:top"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;a)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width:auto;vertical-align:top;text-align:justify"&gt;
        &lt;div&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;On January 4, 2021, options to purchase 1,314,218
        ordinary shares were granted to the Company&#x2019;s former Chief Executive Officer, Dr. Spiros Jamas with an exercise price of $1.24
        per share. Prior to the terms of Dr. Jamas&#x2019; separation agreement (as described below), the options were to vest over four years
        from the date of grant; 25%
        vest on the first anniversary of the date of grant and the remaining 75%
        of the option to vest in twelve equal quarterly installments following the first anniversary of the grant date.&lt;/span&gt; The grant was subject
        to the approval by the Company&#x2019;s shareholders, which approved the grant in March 2021. The fair value of the options at the date
        of grant was $1,320.&lt;/span&gt;&lt;/div&gt;
        &lt;/td&gt; &lt;/tr&gt;
  &lt;/table&gt; &lt;/div&gt;

&lt;div style="text-align:justify;margin-left:56.7pt;line-height:1.25"&gt;&#160;&lt;/div&gt;

&lt;div style="text-align:justify;margin-left:56.7pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;On
July 15, 2022, the Company entered into a mutual separation agreement with Dr. Jamas. Pursuant to the separation agreement, Dr. Jamas
received the following benefits: (i)
a one-time lump sum payment of his annual base salary for a period of 13 months, for a total gross amount equal to $412;
and (ii) an extension of the exercise period for the vested portion of the options granted on January 4, 2021, based on the award original
terms, representing an aggregate of 492,832
ordinary shares, through the end of a &lt;span style="-sec-ix-hidden:Fxbrl_20230228114443567"&gt;two-year&lt;/span&gt; period commencing on July 15,
2022. Effective July 15, 2022, upon termination of the employment agreement with Dr. Jamas, the remaining 821,386
unvested options were forfeited and recognized as a reverse of expense of $457
in general and administrative expenses.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;

&lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;

&lt;div style="text-align:justify;line-height:1.25"&gt;

&lt;table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"&gt;
  &lt;tr&gt;
    &lt;td style="width:35.45pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width:21.25pt;vertical-align:top"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;b)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width:auto;vertical-align:top;text-align:justify"&gt;
        &lt;div&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;On April 7, 2021, the Company&#x2019;s Board of
        Directors approved the following option grants:&lt;/span&gt;&lt;/span&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman,Times,serif"&gt;&#160;&lt;/p&gt; &lt;/div&gt;

&lt;div style="line-height:1.25"&gt;

&lt;table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"&gt;
  &lt;tr&gt;
    &lt;td style="width:59.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width:18pt;vertical-align:top"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;i.&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width:auto;vertical-align:top"&gt;
        &lt;div style="font-family:'Times New Roman',Times,serif;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Option
        grants to purchase 213,000
        ordinary shares to certain employees and 70,000
        options granted to service providers, with an exercise price of&#x2009;$3.61
        per share. The options vest over four
        years from the date of grant; 25%
        vest on the first anniversary of the date of grant and the remaining 75%
        of the option will vest in twelve equal quarterly installments following the first anniversary of the grant date. The fair value of the
        options at the date of grant was $646.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/td&gt; &lt;/tr&gt;
  &lt;/table&gt; &lt;/div&gt;

&lt;div style="line-height:1.25"&gt;

&lt;p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman,Times,serif"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"&gt;
  &lt;tr&gt;
    &lt;td style="width:59.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width:18pt;vertical-align:top"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;ii.&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width:auto;vertical-align:top"&gt;
        &lt;div style="font-family:'Times New Roman',Times,serif;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Options
        grant to purchase 33,368
        ordinary shares to a non-executive director of the Company, with an exercise price of $3.61.
        The options will vest over three
        years in twelve equal quarterly instalments starting on the vesting commencement date. These options were subject to the
        approval of the shareholders of the Company, which was approved on October 4, 2021. The fair value of the options at the shareholders'
        approval date was $104.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/td&gt; &lt;/tr&gt;
  &lt;/table&gt; &lt;/div&gt;

&lt;p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman,Times,serif"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"&gt;
  &lt;tr&gt;
    &lt;td style="width:35.45pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width:21.25pt;vertical-align:top"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;c)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width:auto;vertical-align:top;text-align:justify"&gt;
        &lt;div&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;On April 21, 2021, options to purchase 345,000
        ordinary shares were granted to several executive officers of the Company, with an exercise price of $3.15.
        The options vest over four
        years from the date of grant; 25%
        vest on the first anniversary of the date of grant and the remaining 75%
        of the option will vest in twelve equal quarterly installments following the first anniversary of the grant date. These options were subject
        to the approval of the shareholders of the Company, which was approved on October 4, 2021. The fair value of the options at the shareholders'
        approval date was $1,140.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/td&gt; &lt;/tr&gt;
  &lt;/table&gt;

&lt;div style="text-align:center;line-height:1.25"&gt;&#160;&lt;/div&gt;

&lt;div&gt;

&lt;div/&gt; &lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"&gt;
  &lt;tr&gt;
    &lt;td style="width:35.45pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width:21.25pt;vertical-align:top"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;d)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width:auto;vertical-align:top;text-align:justify"&gt;
        &lt;div&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;On August 23, 2021, the Company&#x2019;s Board
        of Directors approved the following option grants which were approved by the shareholders of the Company on October 4, 2021.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/td&gt; &lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman,Times,serif"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"&gt;
  &lt;tr&gt;
    &lt;td style="width:59.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width:18pt;vertical-align:top;font-family:'Times New Roman',Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;i.&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width:auto;vertical-align:top;text-align:justify"&gt;
        &lt;div&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Grants of options to purchase ordinary shares
        with a total fair value 0f $195
        for each of the seven non-executive board members on January 1, 2022. The options will vest over three
        years in twelve equal quarterly instalments starting on January 1, 2022 the vesting commencement date. On January 1, 2022,
        which is considered the awards grant date, the Company granted 752,899
        ordinary shares to non-executive directors with an exercise price of&#x2009;$2.815
        per share.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt;
  &lt;/table&gt;

&lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"&gt;
  &lt;tr&gt;
    &lt;td style="width:59.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width:18pt;vertical-align:top;font-family:'Times New Roman',Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;ii.&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width:auto;vertical-align:top;text-align:justify"&gt;
        &lt;div&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Grants of options to purchase ordinary shares
        with a total fair value 0f $65
        for each of the seven non-executive board members on January 1, 2022. The options will vest over one
        year in four equal quarterly instalments starting on January 1, 2022 the vesting commencement date. On January 1, 2022,
        which is considered the awards grant date, the Company granted 250,964
        ordinary shares to non-executive directors with an exercise price of&#x2009;$2.815
        per share.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt;
  &lt;/table&gt;

&lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;

&lt;div style="text-align:justify;line-height:1.25"&gt;

&lt;table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"&gt;
  &lt;tr&gt;
    &lt;td style="width:35.45pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width:21.25pt;vertical-align:top"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;e)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width:auto;vertical-align:top;text-align:justify"&gt;
        &lt;div&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;On March 31, 2022, the Company&#x2019;s Board of
        Directors approved the following option grants:&lt;/span&gt;&lt;/span&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman,Times,serif"&gt;&#160;&lt;/p&gt; &lt;/div&gt;

&lt;div style="line-height:1.25"&gt;

&lt;table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"&gt;
  &lt;tr&gt;
    &lt;td style="width:59.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width:18pt;vertical-align:top;font-family:'Times New Roman',Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;i.&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width:auto;vertical-align:top"&gt;
        &lt;div&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Options to purchase 80,000
        ordinary shares to an executive officer and a service provider, in each case, with an exercise price of&#x2009;$2.86
        per share. The fair value of the options was $147.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/td&gt; &lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman,Times,serif"&gt;&#160;&lt;/p&gt; &lt;/div&gt;

&lt;div style="line-height:1.25"&gt;

&lt;table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"&gt;
  &lt;tr&gt;
    &lt;td style="width:59.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width:18pt;vertical-align:top;font-family:'Times New Roman',Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;ii.&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width:auto;vertical-align:top"&gt;
        &lt;div style="text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Options to purchase
        55,000
        ordinary shares to certain executive officers with an exercise price of&#x2009;$2.86
        per share. This grant was subject to shareholders' approval, which was obtained at a meeting of the Company&#x2019;s shareholders held
        on September 7, 2022. The fair value of the options was $37.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;div&gt;&#160;&lt;/div&gt;
        &lt;div&gt;
        &lt;div style="text-align:justify;line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;The
        options vest over four
        years from the date of grant; 25% vest on the first anniversary of the date of grant and the remaining 75% of the option
        will vest in twelve equal quarterly installments following the first anniversary of the grant date.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt;
  &lt;/table&gt; &lt;/div&gt;

&lt;p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman,Times,serif"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"&gt;
  &lt;tr&gt;
    &lt;td style="width:35.45pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width:21.25pt;vertical-align:top"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;f)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width:auto;vertical-align:top;text-align:justify"&gt;
        &lt;div&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;On April 28, 2022, the Company&#x2019;s Board of
        Directors approved option grants to purchase 220,000
        ordinary shares to employees with an exercise price of&#x2009;$2.57
        per share. The
        options vest over four
        years from the date of grant; 25% vest on the first anniversary of the date of grant and the remaining 75% of the option
        will vest in twelve equal quarterly installments following the first anniversary of the grant date. The fair value of
        the options was $364.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/td&gt; &lt;/tr&gt;
  &lt;/table&gt;

&lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"&gt;
  &lt;tr&gt;
    &lt;td style="width:35.45pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width:21.25pt;vertical-align:top"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;g)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width:auto;vertical-align:top;text-align:justify"&gt;
        &lt;div&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;On May 11, 2022, the Company&#x2019;s Board of
        Directors approved a grant of options to purchase 500,000
        ordinary shares to Ms. Miranda Toledano, who was serving as the Company&#x2019;s Chief Financial Officer at the time of the grant. Ms.
        Toledano has since been appointed the Company&#x2019;s Chief Executive Officer (as described in Note 6(2)l below). This
        grant was subject to shareholders' approval, which was obtained at a meeting of the Company&#x2019;s shareholders held on September 7,
        2022. These options have an exercise price of&#x2009;$2.00
        per share and vest over four
        years from the date of grant; 25% vest on the first anniversary of the date of grant and the remaining 75% of the option
        will vest in twelve equal quarterly installments following the first anniversary of the grant date. The fair value of
        the options was $390.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/td&gt; &lt;/tr&gt;
  &lt;/table&gt;

&lt;div style="text-align:center;line-height:1.25"&gt;&#160;&lt;/div&gt;

&lt;div&gt;

&lt;div/&gt; &lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"&gt;
  &lt;tr&gt;
    &lt;td style="width:35.45pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width:21.25pt;vertical-align:top"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;h)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width:auto;vertical-align:top;text-align:justify"&gt;
        &lt;div&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;On July 15, 2022, the Company&#x2019;s Board of
        Directors appointed Ms. Miranda Toledano as the Company&#x2019;s Chief Executive Officer and approved a grant of options to purchase 600,000
        ordinary shares at an exercise price of&#x2009;$1.40
        per share, which are in addition to the options described in note 6(2)k above. This
        grant was subject to shareholders' approval, which was obtained at a meeting of the Company&#x2019;s shareholders held on September 7,
        2022. The options vest over four
        years from the date of grant; 25% vest on the first anniversary of the date of grant and the remaining 75% of the option
        will vest in twelve equal quarterly installments following the first anniversary of the applicable grant date. The fair
        value of the options was $524.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/td&gt; &lt;/tr&gt;
  &lt;/table&gt;

&lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;

&lt;div style="text-align:justify;margin-left:56.7pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;In
addition, upon the occurrence of a Triggering Event (as defined below) and subject to the approval of the Board of Directors, Ms. Toledano
will be granted additional options to purchases 200,000
ordinary shares. The exercise price will be determined at the time of the Board of Directors&#x2019; approval.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;

&lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;

&lt;div style="text-align:justify;margin-left:56.7pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;"Triggering
Event" means the earlier of the following events: (i) the execution by the Company of a binding strategic or partnership agreement with
a strategic partner to fund the Company's Phase III FDA Trial; or (b) raising sufficient funding to complete the Company's Phase III FDA
Trial, in each case as such event is approved by the Board of Directors.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;

&lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"&gt;
  &lt;tr&gt;
    &lt;td style="width:35.45pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width:21.25pt;vertical-align:top"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;i)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width:auto;vertical-align:top;text-align:justify"&gt;
        &lt;div&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;On June 15, 2022, the Company entered into a separation
        agreement with Dr. Phillip Schwartz, the Company&#x2019;s former President of R&amp;amp;D, under which Dr. Schwartz agreed to continue to provide
        services to the Company until July 21, 2022 (the &#x201c;Separation Date&#x201d;). Pursuant to the terms of the separation agreement, which
        were approved by the Company&#x2019;s shareholders on September 7, 2022, Dr. Schwartz received a full acceleration of his unvested options,
        as of the Separation Date, to purchase 68,750
        ordinary shares granted in April 2021 that otherwise would have been forfeited. These options, together with 31,250
        already vested options granted in April 2021 and 357,500
        already vested options to purchase ordinary shares granted in 2017, will be exercisable for a period of 10
        years from their respective initial grant dates&lt;span style="font-weight:bold"&gt;.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt;
  &lt;/table&gt;

&lt;div style="text-align:justify;margin-left:56.7pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&#160;&lt;br/&gt;The
acceleration described above was recognized as a "Type III" modification; therefore, on the shareholder approval date, the Company recognized
the incremental costs of unvested options based on the fair value of the options on such date. In addition, the extension of the exercise
period for the vested awards was recognized as a "Type I" modification. The total expense amount was $112
thousand, which was classified as additional share-based compensation costs in the research and development expenses.&lt;br/&gt;&#160;&lt;br/&gt;In
addition, the separation agreement provides for the following payments to Dr. Schwartz, all of which would have otherwise been payable
in accordance with either Israeli law or pursuant to his existing employment agreement: a one-time cash separation payment in an amount
equal to NIS 537,600
(approximately $156)
and additional payments of NIS 737,771
(approximately $214)
in respect of all other ongoing accrued benefits, subject to any mandatory deductions. The foregoing payments were recognized in the research
and development expenses.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;

&lt;div style="text-align:justify;margin-left:56.7pt;line-height:1.25"&gt;&#160;&lt;/div&gt; &lt;/div&gt; &lt;/div&gt;

&lt;div/&gt;

&lt;div&gt;

&lt;div&gt;

&lt;div style="line-height:1.25"&gt;

&lt;div&gt;

&lt;div&gt;

&lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;The
fair value of each option granted is estimated at the date of grant using the Black-Scholes option-pricing model, with the following weighted
average assumptions:&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt; &lt;/div&gt; &lt;/div&gt;

&lt;p style="margin:0pt"&gt;&#160;&lt;/p&gt; &lt;/div&gt;

&lt;div&gt;

&lt;div&gt;

&lt;div&gt;

&lt;div style="margin-left:54pt"&gt;

&lt;table border="0" cellpadding="0" cellspacing="0" style="width:85%"&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align:top;padding-bottom:2px" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px" valign="bottom"&gt;
        &lt;div style="line-height:1.25"&gt;
        &lt;div style="text-align:center;text-indent:0.05pt;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;2022&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/div&gt; &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px" valign="bottom"&gt;
        &lt;div style="line-height:1.25"&gt;
        &lt;div style="text-align:center;text-indent:0.05pt;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;2021&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/div&gt; &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align:top;padding-bottom:4px;background-color:rgb(204, 238, 255);width:70%" valign="bottom"&gt;
        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;Exercise
        price&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt; &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:4px;background-color:rgb(204, 238, 255);width:1%" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);width:1%" valign="bottom"&gt;
        &lt;div style="line-height:1.25"&gt;
        &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt; &lt;/div&gt; &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);width:12%" valign="bottom"&gt;
        &lt;div style="line-height:1.25"&gt;
        &lt;div style="line-height:1.25;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;$1.40-$2.86&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/div&gt; &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:4px;background-color:rgb(204, 238, 255);white-space:nowrap;width:1%" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:4px;background-color:rgb(204, 238, 255);width:1%" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);width:1%" valign="bottom"&gt;
        &lt;div style="line-height:1.25"&gt;
        &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt; &lt;/div&gt; &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);width:12%" valign="bottom"&gt;
        &lt;div style="line-height:1.25"&gt;
        &lt;div style="line-height:1.25;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;$1.24-$3.61&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/div&gt; &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:4px;background-color:rgb(204, 238, 255);white-space:nowrap;width:1%" valign="bottom"&gt;&#160;&lt;/td&gt;
        &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align:top;padding-bottom:4px;width:70%" valign="bottom"&gt;
        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;Dividend
        yield&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt; &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:4px;width:1%" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;border-bottom:4px double rgb(0, 0, 0);width:1%" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;border-bottom:4px double rgb(0, 0, 0);width:12%" valign="bottom"&gt;
        &lt;div style="line-height:1.25"&gt;
        &lt;div style="line-height:1.25;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/div&gt; &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:4px;white-space:nowrap;width:1%" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:4px;width:1%" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;border-bottom:4px double rgb(0, 0, 0);width:1%" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;border-bottom:4px double rgb(0, 0, 0);width:12%" valign="bottom"&gt;
        &lt;div style="line-height:1.25"&gt;
        &lt;div style="line-height:1.25;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/div&gt; &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:4px;white-space:nowrap;width:1%" valign="bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align:top;padding-bottom:4px;background-color:rgb(204, 238, 255);width:70%" valign="bottom"&gt;
        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;Expected
        volatility&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt; &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:4px;background-color:rgb(204, 238, 255);width:1%" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);width:1%" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);width:12%" valign="bottom"&gt;
        &lt;div style="line-height:1.25"&gt;
        &lt;div style="line-height:1.25;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;69%-70.2%&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/div&gt; &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:4px;background-color:rgb(204, 238, 255);white-space:nowrap;width:1%" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:4px;background-color:rgb(204, 238, 255);width:1%" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);width:1%" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);width:12%" valign="bottom"&gt;
        &lt;div style="line-height:1.25"&gt;
        &lt;div style="line-height:1.25;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;68%-71%&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/div&gt; &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:4px;background-color:rgb(204, 238, 255);white-space:nowrap;width:1%" valign="bottom"&gt;&#160;&lt;/td&gt;
        &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align:top;padding-bottom:4px;width:70%" valign="bottom"&gt;
        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;Risk-free
        interest rate&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt; &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:4px;width:1%" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;border-bottom:4px double rgb(0, 0, 0);width:1%" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;border-bottom:4px double rgb(0, 0, 0);width:12%" valign="bottom"&gt;
        &lt;div style="line-height:1.25"&gt;
        &lt;div style="line-height:1.25;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;1.35%-3.36%&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/div&gt; &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:4px;white-space:nowrap;width:1%" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:4px;width:1%" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;border-bottom:4px double rgb(0, 0, 0);width:1%" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;border-bottom:4px double rgb(0, 0, 0);width:12%" valign="bottom"&gt;
        &lt;div style="line-height:1.25"&gt;
        &lt;div style="line-height:1.25;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;1.11%-0.94%&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/div&gt; &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:4px;white-space:nowrap;width:1%" valign="bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align:top;padding-bottom:4px;background-color:rgb(204, 238, 255);width:70%" valign="bottom"&gt;
        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;Expected
        life - in years&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt; &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:4px;background-color:rgb(204, 238, 255);width:1%" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);width:1%" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);width:12%" valign="bottom"&gt;
        &lt;div style="line-height:1.25"&gt;
        &lt;div style="line-height:1.25;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;5.5-6.5&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/div&gt; &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:4px;background-color:rgb(204, 238, 255);white-space:nowrap;width:1%" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:4px;background-color:rgb(204, 238, 255);width:1%" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);width:1%" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);width:12%" valign="bottom"&gt;
        &lt;div style="line-height:1.25"&gt;
        &lt;div style="line-height:1.25;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;6.1-5.8&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/div&gt; &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:4px;background-color:rgb(204, 238, 255);white-space:nowrap;width:1%" valign="bottom"&gt;&#160;&lt;/td&gt;
        &lt;/tr&gt;
  &lt;/table&gt; &lt;/div&gt; &lt;/div&gt; &lt;/div&gt; &lt;/div&gt;

&lt;div&gt;

&lt;div style="line-height:1.25"&gt;

&lt;div style="margin:0pt"&gt;&#160;&lt;/div&gt; &lt;/div&gt;

&lt;div&gt;

&lt;div style="margin-left:54pt"&gt;

&lt;table cellpadding="0" cellspacing="0" style="color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:left;width:92%"&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align:top;padding-bottom:2px" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="vertical-align:top;border-bottom:#000000 solid 2px" valign="bottom"&gt;
        &lt;div style="line-height:1.25"&gt;
        &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;2022&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/div&gt; &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="vertical-align:top;border-bottom:#000000 solid 2px" valign="bottom"&gt;
        &lt;div style="line-height:1.25"&gt;
        &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;2021&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/div&gt; &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align:bottom;padding-bottom:2px" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px" valign="bottom"&gt;
        &lt;div style="line-height:1.25"&gt;
        &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;Number
        of&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;options&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/div&gt; &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px" valign="bottom"&gt;
        &lt;div style="line-height:1.25"&gt;
        &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;Weighted&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;average&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;exercise&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;price&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/div&gt; &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px" valign="bottom"&gt;
        &lt;div style="line-height:1.25"&gt;
        &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;Number
        of&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;options&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/div&gt; &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px" valign="bottom"&gt;
        &lt;div style="line-height:1.25"&gt;
        &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;Weighted&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;average&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;exercise&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;price&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/div&gt; &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align:middle;width:52%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;
        &lt;div style="text-indent:-1.3pt;margin-left:1.3pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;Outstanding
        at beginning of the year&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt; &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;
        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;4,316,859&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;
        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;
        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;3.63&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;
        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;2,570,109&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;
        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;
        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;4.85&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
        &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align:middle;width:52%" valign="bottom"&gt;
        &lt;div style="text-indent:-1.3pt;margin-left:1.3pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;Granted&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%" valign="bottom"&gt;
        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;2,458,863&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%" valign="bottom"&gt;
        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;2.29&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%" valign="bottom"&gt;
        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;1,975,586&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom"&gt;
        &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%" valign="bottom"&gt;
        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;1.95&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align:middle;width:52%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;
        &lt;div style="text-indent:-1.3pt;margin-left:1.3pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;Exercised&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;
        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;(5,511&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom"&gt;
        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;
        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;2.14&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;
        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;(177,710&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom"&gt;
        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;
        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;2.37&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
        &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align:middle;width:52%" valign="bottom"&gt;
        &lt;div style="text-indent:-1.3pt;margin-left:1.3pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;Forfeited&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%" valign="bottom"&gt;
        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;(902,009&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom"&gt;
        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%" valign="bottom"&gt;
        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;1.41&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%" valign="bottom"&gt;
        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;(16,660&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom"&gt;
        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%" valign="bottom"&gt;
        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;2.37&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align:middle;width:52%;padding-bottom:2px;background-color:rgb(204, 238, 255)" valign="bottom"&gt;
        &lt;div style="text-indent:-8.4pt;margin-left:8.4pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;Expired&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom"&gt;
        &lt;div style="line-height:1.25"&gt;
        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;(135,115&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/div&gt; &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom"&gt;
        &lt;div style="line-height:1.25"&gt;
        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/div&gt; &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom"&gt;
        &lt;div style="line-height:1.25"&gt;
        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;3.80&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/div&gt; &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom"&gt;
        &lt;div style="line-height:1.25"&gt;
        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;(34,466&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/div&gt; &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom"&gt;
        &lt;div style="line-height:1.25"&gt;
        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/div&gt; &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom"&gt;
        &lt;div style="line-height:1.25"&gt;
        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;4.00&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/div&gt; &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
        &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align:middle;width:52%;padding-bottom:4px" valign="bottom"&gt;
        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;Outstanding
        at end of the year&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt; &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0)" valign="bottom"&gt;
        &lt;div style="line-height:1.25"&gt;
        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;5,733,087&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/div&gt; &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0)" valign="bottom"&gt;
        &lt;div style="line-height:1.25"&gt;
        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/div&gt; &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0)" valign="bottom"&gt;
        &lt;div style="line-height:1.25"&gt;
        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;3.30&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/div&gt; &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0)" valign="bottom"&gt;
        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;4,316,859&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0)" valign="bottom"&gt;
        &lt;div style="line-height:1.25"&gt;
        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/div&gt; &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0)" valign="bottom"&gt;
        &lt;div style="line-height:1.25"&gt;
        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;3.63&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/div&gt; &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align:middle;width:52%;padding-bottom:4px;background-color:rgb(204, 238, 255)" valign="bottom"&gt;
        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;Exercisable
        at end of the year&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt; &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom"&gt;
        &lt;div style="line-height:1.25"&gt;
        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;3,165,677&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/div&gt; &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom"&gt;
        &lt;div style="line-height:1.25"&gt;
        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/div&gt; &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom"&gt;
        &lt;div style="line-height:1.25"&gt;
        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;4.06&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/div&gt; &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom"&gt;
        &lt;div style="line-height:1.25"&gt;
        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;2,068,067&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/div&gt; &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom"&gt;
        &lt;div style="line-height:1.25"&gt;
        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/div&gt; &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom"&gt;
        &lt;div style="line-height:1.25"&gt;
        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;5.39&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/div&gt; &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
        &lt;/tr&gt;
  &lt;/table&gt; &lt;/div&gt; &lt;/div&gt; &lt;/div&gt;  &lt;/div&gt; &lt;/div&gt;

&lt;p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman,Times,serif"&gt;&#160;&lt;/p&gt;

&lt;div/&gt;

&lt;div&gt;

&lt;div&gt;

&lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span style="line-height:107%"&gt;The
following tables summarizes information concerning outstanding and exercisable options as of December 31, 2022, in terms of ordinary shares:&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin:0pt"&gt;&#160;&lt;/p&gt;

&lt;div&gt;

&lt;div&gt;

&lt;div&gt;

&lt;div style="margin-left:45pt"&gt;

&lt;table border="0" cellpadding="0" cellspacing="0" style="color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:left;width:85%"&gt;
  &lt;tr&gt;
    &lt;td colspan="18" rowspan="1" style="vertical-align:top;padding-bottom:2px;border-bottom:2px solid black" valign="bottom"&gt;
        &lt;div style="line-height:1.25"&gt;
        &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;December
        31, 2022&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt; &lt;/div&gt; &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td colspan="10" style="vertical-align:top;border-bottom:#000000 solid 2px" valign="bottom"&gt;
        &lt;div style="line-height:1.25"&gt;
        &lt;div style="line-height:1.25;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;Options
        outstanding&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt; &lt;/div&gt; &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;white-space:nowrap;text-align:center" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="vertical-align:top;border-bottom:#000000 solid 2px" valign="bottom"&gt;
        &lt;div style="line-height:1.25"&gt;
        &lt;div style="line-height:1.25;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;Options
        exercisable&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt; &lt;/div&gt; &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td colspan="2" style="vertical-align:top" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align:top" valign="bottom"&gt;
        &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;Number
        of&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt; &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align:top" valign="bottom"&gt;
        &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;Weighted&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align:top" valign="bottom"&gt;
        &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;Number
        of&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt; &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align:top" valign="bottom"&gt;
        &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;Weighted&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td colspan="2" style="vertical-align:top" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align:top" valign="bottom"&gt;
        &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;options&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align:top" valign="bottom"&gt;
        &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;Average&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align:top" valign="bottom"&gt;
        &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;options&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align:top" valign="bottom"&gt;
        &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;Average&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td colspan="2" style="vertical-align:top" valign="bottom"&gt;
        &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;Exercise&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align:top" valign="bottom"&gt;
        &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;outstanding&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align:top" valign="bottom"&gt;
        &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;Remaining&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align:top" valign="bottom"&gt;
        &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;exercisable&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align:top" valign="bottom"&gt;
        &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;Remaining&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td colspan="2" style="vertical-align:top" valign="bottom"&gt;
        &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;prices
        per&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt; &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align:top" valign="bottom"&gt;
        &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;at
        end of&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt; &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align:top" valign="bottom"&gt;
        &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;Contractual&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align:top" valign="bottom"&gt;
        &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;at
        end of&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt; &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align:top" valign="bottom"&gt;
        &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;contractual&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px" valign="bottom"&gt;
        &lt;div style="line-height:1.25"&gt;
        &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;share
        (USD)&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt; &lt;/div&gt; &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px" valign="bottom"&gt;
        &lt;div style="line-height:1.25"&gt;
        &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;Year&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/div&gt; &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px" valign="bottom"&gt;
        &lt;div style="line-height:1.25"&gt;
        &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;Life&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/div&gt; &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px" valign="bottom"&gt;
        &lt;div style="line-height:1.25"&gt;
        &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;year&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/div&gt; &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px" valign="bottom"&gt;
        &lt;div style="line-height:1.25"&gt;
        &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;Life&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/div&gt; &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color:rgb(204, 238, 255)"&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;
        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;
        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;1,560&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;
        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;0.09&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;
        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;1,560&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;
        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;0.09&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
        &lt;/tr&gt;
  &lt;tr style="background-color:rgb(255, 255, 255)"&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;
        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;1.24&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;
        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;492,831&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;
        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;1.54&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;
        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;492,831&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;
        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;1.54&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
        &lt;/tr&gt;
  &lt;tr style="background-color:rgb(204, 238, 255)"&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;
        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;1.40&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;
        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;600,000
        &lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt; &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;
        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;9.54&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;
        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;
        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
        &lt;/tr&gt;
  &lt;tr style="background-color:rgb(255, 255, 255)"&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;
        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;2.02&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;
        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;500,000&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;
        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;9.37&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;
        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;
        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
        &lt;/tr&gt;
  &lt;tr style="background-color:rgb(204, 238, 255)"&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;
        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;2.14&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;
        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;400,775&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;
        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;7.26&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;
        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;277,994&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;
        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;7.26&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
        &lt;/tr&gt;
  &lt;tr style="background-color:rgb(255, 255, 255)"&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;
        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;2.53&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;
        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;33,638&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;
        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;6.89&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;
        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;33,638&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;
        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;6.89&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
        &lt;/tr&gt;
  &lt;tr style="background-color:rgb(204, 238, 255)"&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;
        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;2.57&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;
        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;205,500&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;
        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;9.33&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;
        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;
        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
        &lt;/tr&gt;
  &lt;tr style="background-color:rgb(255, 255, 255)"&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;
        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;2.815&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;
        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;1,003,863&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;
        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;9.01&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;
        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;376,447&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;
        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;9.01&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
        &lt;/tr&gt;
  &lt;tr style="background-color:rgb(204, 238, 255)"&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;
        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;2.86&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;
        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;135,000&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;
        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;9.25&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;
        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;
        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
        &lt;/tr&gt;
  &lt;tr style="background-color:rgb(255, 255, 255)"&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;
        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;3.15&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;
        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;345,000&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;
        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;8.30&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;
        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;123,125&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;
        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;8.30&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
        &lt;/tr&gt;
  &lt;tr style="background-color:rgb(204, 238, 255)"&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;padding-bottom:2px;background-color:rgb(204, 238, 255)" valign="bottom"&gt;
        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;3.61&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;white-space:nowrap;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;
        &lt;div style="line-height:1.25"&gt;
        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;250,868&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/div&gt; &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;white-space:nowrap;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;padding-bottom:2px;background-color:rgb(204, 238, 255)" valign="bottom"&gt;
        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;8.27&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;white-space:nowrap;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;
        &lt;div style="line-height:1.25"&gt;
        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;101,059&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/div&gt; &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;white-space:nowrap;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;padding-bottom:2px;background-color:rgb(204, 238, 255)" valign="bottom"&gt;
        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;8.27&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;white-space:nowrap;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
        &lt;/tr&gt;
  &lt;tr style="background-color:rgb(255, 255, 255)"&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;padding-bottom:2px;background-color:rgb(255, 255, 255)" valign="bottom"&gt;
        &lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span style="line-height:107%"&gt;3.68&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;white-space:nowrap;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;
        &lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span style="line-height:107%"&gt;294,580&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;white-space:nowrap;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;padding-bottom:2px;background-color:rgb(255, 255, 255)" valign="bottom"&gt;
        &lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span style="line-height:107%"&gt;0.26&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;white-space:nowrap;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;
        &lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span style="line-height:107%"&gt;294,580&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;white-space:nowrap;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;padding-bottom:2px;background-color:rgb(255, 255, 255)" valign="bottom"&gt;
        &lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span style="line-height:107%"&gt;0.26&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;white-space:nowrap;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
        &lt;/tr&gt;
  &lt;tr style="background-color:rgb(204, 238, 255)"&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;padding-bottom:2px;background-color:rgb(204, 238, 255)" valign="bottom"&gt;
        &lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span style="line-height:107%"&gt;3.97&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;white-space:nowrap;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;
        &lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span style="line-height:107%"&gt;247,082&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;white-space:nowrap;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;padding-bottom:2px;background-color:rgb(204, 238, 255)" valign="bottom"&gt;
        &lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span style="line-height:107%"&gt;6.05&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;white-space:nowrap;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;
        &lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span style="line-height:107%"&gt;242,053&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;white-space:nowrap;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;padding-bottom:2px;background-color:rgb(204, 238, 255)" valign="bottom"&gt;
        &lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span style="line-height:107%"&gt;6.05&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;white-space:nowrap;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
        &lt;/tr&gt;
  &lt;tr style="background-color:rgb(255, 255, 255)"&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;padding-bottom:2px;background-color:rgb(255, 255, 255)" valign="bottom"&gt;
        &lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span style="line-height:107%"&gt;6.31&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;white-space:nowrap;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid black;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid black;background-color:rgb(255, 255, 255)" valign="bottom"&gt;
        &lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span style="line-height:107%"&gt;1,222,390&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;white-space:nowrap;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;padding-bottom:2px;background-color:rgb(255, 255, 255)" valign="bottom"&gt;
        &lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span style="line-height:107%"&gt;3.08&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;white-space:nowrap;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid black;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid black;background-color:rgb(255, 255, 255)" valign="bottom"&gt;
        &lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span style="line-height:107%"&gt;1,222,390&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;white-space:nowrap;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;padding-bottom:2px;background-color:rgb(255, 255, 255)" valign="bottom"&gt;
        &lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span style="line-height:107%"&gt;3.08&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;white-space:nowrap;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
        &lt;/tr&gt;
  &lt;tr style="background-color:rgb(204, 238, 255)"&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;padding-bottom:4px;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;white-space:nowrap;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom"&gt;
        &lt;div style="line-height:1.25"&gt;
        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;5,733,087&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/div&gt; &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;white-space:nowrap;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;padding-bottom:4px;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;white-space:nowrap;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom"&gt;
        &lt;div style="line-height:1.25"&gt;
        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;3,165,677&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/div&gt; &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;white-space:nowrap;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;padding-bottom:4px;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;white-space:nowrap;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
        &lt;/tr&gt;
  &lt;/table&gt;  &lt;/div&gt; &lt;/div&gt; &lt;/div&gt;

&lt;div&gt;

&lt;div&gt;

&lt;p style="margin-top:0pt;margin-bottom:0pt"&gt;&lt;br/&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span style="line-height:107%"&gt;The
&lt;/span&gt;&lt;span style="line-height:107%"&gt;aggregate intrinsic value of the total of the outstanding and exercisable options as of December
31, 2022, is $1.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
&lt;/div&gt; &lt;/div&gt; &lt;/div&gt;

&lt;div style="line-height:1.25;clear:both"&gt;

&lt;p style="margin:0pt"&gt;&#160;&lt;/p&gt; &lt;/div&gt;

&lt;div&gt;

&lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;The
&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="line-height:107%"&gt;following table illustrates the effect of share-based compensation on
the statements of operations:&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/p&gt; &lt;/div&gt; &lt;/div&gt; &lt;/div&gt;

&lt;div&gt;

&lt;div style="text-align:center"&gt;

&lt;div style="clear:both;margin-top:0pt;margin-bottom:0pt"&gt;

&lt;div style="text-align:center"&gt; &lt;div style="font-size:10pt;display:inline"&gt; &lt;div style="font-family:Times New Roman,Times,serif;display:inline"&gt;
&lt;div style="color:#000000;font-weight:normal;font-style:normal;display:inline"&gt;

&lt;div&gt;

&lt;div&gt;

&lt;div style="margin-left:45pt"&gt;

&lt;table border="0" cellpadding="0" cellspacing="0" style="color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:left;width:85%"&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align:top;padding-bottom:2px" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px" valign="bottom"&gt;
        &lt;div style="line-height:1.25"&gt;
        &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;2022&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/div&gt; &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px" valign="bottom"&gt;
        &lt;div style="line-height:1.25"&gt;
        &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;2021&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/div&gt; &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;
        &lt;div style="text-align:justify;text-indent:-12.6pt;margin-left:12.6pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;Cost
        of revenues&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt; &lt;/td&gt;
    &lt;td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;
        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;14&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;
        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;102&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
        &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align:bottom;width:76%" valign="bottom"&gt;
        &lt;div style="text-align:justify;text-indent:-12.6pt;margin-left:12.6pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;Research
        and development expenses&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt; &lt;/td&gt;
    &lt;td colspan="1" style="text-align:right;vertical-align:bottom;width:1%" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%" valign="bottom"&gt;
        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;708&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align:right;vertical-align:bottom;width:1%" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%" valign="bottom"&gt;
        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;661&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align:bottom;width:76%;padding-bottom:2px;background-color:rgb(204, 238, 255)" valign="bottom"&gt;
        &lt;div style="text-align:justify;text-indent:-12.6pt;margin-left:12.6pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;General
        and administrative&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt; &lt;/td&gt;
    &lt;td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom"&gt;
        &lt;div style="line-height:1.25"&gt;
        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;1,525&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/div&gt; &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom"&gt;
        &lt;div style="line-height:1.25"&gt;
        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;1,098&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/div&gt; &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
        &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align:bottom;width:76%;padding-bottom:4px" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;padding-bottom:4px" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0)" valign="bottom"&gt;
        &lt;div style="line-height:1.25"&gt;
        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;2,247&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/div&gt; &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;padding-bottom:4px" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0)" valign="bottom"&gt;
        &lt;div style="line-height:1.25"&gt;
        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;1,861&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/div&gt; &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;/table&gt; &lt;/div&gt; &lt;/div&gt; &lt;/div&gt; &lt;/div&gt; &lt;/div&gt; &lt;/div&gt; &lt;/div&gt; &lt;/div&gt; &lt;/div&gt; &lt;/div&gt;  &lt;/div&gt; </us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="C_20180702_usgaapPlanNameAxis_entxShareIncentivePlan2018Member"
      decimals="INF"
      id="F20230227081114909_108"
      unitRef="shares">1371398</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="C_20221231_usgaapPlanNameAxis_entxShareIncentivePlan2018Member"
      decimals="INF"
      id="F20230227081114909_107"
      unitRef="shares">922080</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
      contextRef="C_20220101to20221231_usgaapPlanNameAxis_entxShareIncentivePlan2018Member"
      decimals="INF"
      id="F20230227081114910_109"
      unitRef="shares">1440496</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="C_20210101to20210104_srtTitleOfIndividualAxis_srtChiefExecutiveOfficerMember"
      decimals="INF"
      id="Fxbrl_20230228105542355"
      unitRef="shares">1314218</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="C_20210101to20210104_srtTitleOfIndividualAxis_srtChiefExecutiveOfficerMember"
      decimals="2"
      id="Fxbrl_20230228105553803"
      unitRef="USD_per_Share">1.24</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="C_20210101to20210104_srtTitleOfIndividualAxis_srtChiefExecutiveOfficerMember_usgaapVestingAxis_usgaapShareBasedCompensationAwardTrancheOneMember"
      decimals="2"
      id="Fxbrl_20230228105603802"
      unitRef="Percent">0.25</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="C_20210101to20210104_srtTitleOfIndividualAxis_srtChiefExecutiveOfficerMember_usgaapVestingAxis_usgaapShareBasedCompensationAwardTrancheTwoMember"
      decimals="2"
      id="Fxbrl_20230228105614228"
      unitRef="Percent">0.75</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
      contextRef="C_20210101to20210104_srtTitleOfIndividualAxis_srtChiefExecutiveOfficerMember"
      decimals="-3"
      id="Fxbrl_20230228105624538"
      unitRef="USD">1320000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
    <us-gaap:DescriptionOfPostemploymentBenefits
      contextRef="C_20220601to20220615_srtTitleOfIndividualAxis_entxFormerChiefExecutiveOfficerMember"
      id="Fxbrl_20230228114535533">(i)
a one-time lump sum payment of his annual base salary for a period of 13 months, for a total gross amount equal to $412;
and (ii) an extension of the exercise period for the vested portion of the options granted on January 4, 2021, based on the award original
terms, representing an aggregate of 492,832
ordinary shares, through the end of a two-year period commencing on July 15,
2022.</us-gaap:DescriptionOfPostemploymentBenefits>
    <us-gaap:OfficersCompensation
      contextRef="C_20220601to20220615_srtTitleOfIndividualAxis_entxFormerChiefExecutiveOfficerMember"
      decimals="-3"
      id="Fxbrl_20230228114513250"
      unitRef="USD">412000</us-gaap:OfficersCompensation>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="C_20220601to20220615_srtTitleOfIndividualAxis_entxFormerChiefExecutiveOfficerMember"
      decimals="INF"
      id="Fxbrl_20230228114504037"
      unitRef="shares">492832</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares
      contextRef="C_20220601to20220615_srtTitleOfIndividualAxis_entxFormerChiefExecutiveOfficerMember"
      decimals="INF"
      id="Fxbrl_20230228114427110"
      unitRef="shares">821386</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="C_20220601to20220615_srtTitleOfIndividualAxis_entxFormerChiefExecutiveOfficerMember"
      decimals="-3"
      id="Fxbrl_20230228114415665"
      unitRef="USD">457000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="C_20210401to20210407_srtTitleOfIndividualAxis_entxEmployeesMember"
      decimals="INF"
      id="F20230227081114919_126"
      unitRef="shares">213000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="C_20210401to20210407_srtTitleOfIndividualAxis_entxServiceProviderMember"
      decimals="INF"
      id="F20230227081114927_142"
      unitRef="shares">70000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="C_20210401to20210407_srtTitleOfIndividualAxis_entxServiceProviderMember"
      decimals="2"
      id="F20230227081114950_186"
      unitRef="USD_per_Share">3.61</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="C_20210401to20210407_srtTitleOfIndividualAxis_entxEmployeesMember"
      decimals="2"
      id="F20230227081114928_143"
      unitRef="USD_per_Share">3.61</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="C_20210401to20210407_srtTitleOfIndividualAxis_entxServiceProviderMember"
      id="Fxbrl_s_20230330125251734">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="C_20210401to20210407_srtTitleOfIndividualAxis_entxEmployeesMember"
      id="Fxbrl_20230330125251734">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="C_20210401to20210407_srtTitleOfIndividualAxis_entxServiceProviderMember_usgaapVestingAxis_usgaapShareBasedCompensationAwardTrancheOneMember"
      decimals="2"
      id="F20230227081114952_190"
      unitRef="Percent">0.25</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="C_20210401to20210407_srtTitleOfIndividualAxis_entxEmployeesMember_usgaapVestingAxis_usgaapShareBasedCompensationAwardTrancheOneMember"
      decimals="2"
      id="F20230227081114930_147"
      unitRef="Percent">0.25</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="C_20210401to20210407_srtTitleOfIndividualAxis_entxServiceProviderMember_usgaapVestingAxis_usgaapShareBasedCompensationAwardTrancheTwoMember"
      decimals="2"
      id="F20230227081114951_188"
      unitRef="Percent">0.75</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="C_20210401to20210407_srtTitleOfIndividualAxis_entxEmployeesMember_usgaapVestingAxis_usgaapShareBasedCompensationAwardTrancheTwoMember"
      decimals="2"
      id="F20230227081114929_145"
      unitRef="Percent">0.75</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
      contextRef="C_20210401to20210407_srtTitleOfIndividualAxis_entxServiceProviderMember"
      decimals="-3"
      id="F20230227081114952_189"
      unitRef="USD">646000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
      contextRef="C_20210401to20210407_srtTitleOfIndividualAxis_entxEmployeesMember"
      decimals="-3"
      id="F20230227081114929_146"
      unitRef="USD">646000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="C_20210401to20210407_srtTitleOfIndividualAxis_entxNonExecutiveDirectorMember"
      decimals="INF"
      id="F20230227081114920_127"
      unitRef="shares">33368</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="C_20210401to20210407_srtTitleOfIndividualAxis_entxNonExecutiveDirectorMember"
      decimals="2"
      id="F20230227081114922_131"
      unitRef="USD_per_Share">3.61</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="C_20210401to20210407_srtTitleOfIndividualAxis_entxNonExecutiveDirectorMember"
      id="Fxbrl_20230330125307484">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
      contextRef="C_20210401to20210407_srtTitleOfIndividualAxis_entxNonExecutiveDirectorMember"
      decimals="-3"
      id="F20230227081114927_140"
      unitRef="USD">104000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="C_20210401to20210421_srtTitleOfIndividualAxis_srtExecutiveOfficerMember"
      decimals="INF"
      id="F20230227081114920_128"
      unitRef="shares">345000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="C_20210401to20210421_srtTitleOfIndividualAxis_srtExecutiveOfficerMember"
      decimals="2"
      id="F20230227081114922_132"
      unitRef="USD_per_Share">3.15</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="C_20210401to20210421_srtTitleOfIndividualAxis_srtExecutiveOfficerMember"
      id="Fxbrl_20230330125322325">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="C_20210401to20210421_srtTitleOfIndividualAxis_srtExecutiveOfficerMember_usgaapVestingAxis_usgaapShareBasedCompensationAwardTrancheOneMember"
      decimals="2"
      id="F20230227081114924_136"
      unitRef="Percent">0.25</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="C_20210401to20210421_srtTitleOfIndividualAxis_srtExecutiveOfficerMember_usgaapVestingAxis_usgaapShareBasedCompensationAwardTrancheTwoMember"
      decimals="2"
      id="F20230227081114924_137"
      unitRef="Percent">0.75</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
      contextRef="C_20210401to20210421_srtTitleOfIndividualAxis_srtExecutiveOfficerMember"
      decimals="-3"
      id="F20230227081114927_141"
      unitRef="USD">1140000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
      contextRef="C_20210801to20210823_srtTitleOfIndividualAxis_entxNonExecutiveDirectorMember_usgaapVestingAxis_entxShareBasedPaymentArrangementTrancheFiveMember"
      decimals="-3"
      id="F20230227081114936_158"
      unitRef="USD">195000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="C_20210801to20210823_srtTitleOfIndividualAxis_entxNonExecutiveDirectorMember_usgaapVestingAxis_entxShareBasedPaymentArrangementTrancheFiveMember"
      id="Fxbrl_20230330125332741">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="C_20210801to20210823_srtTitleOfIndividualAxis_entxNonExecutiveDirectorMember_usgaapVestingAxis_entxShareBasedPaymentArrangementTrancheFiveMember"
      decimals="INF"
      id="F20230227081114935_157"
      unitRef="shares">752899</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="C_20210801to20210823_srtTitleOfIndividualAxis_entxNonExecutiveDirectorMember_usgaapVestingAxis_entxShareBasedPaymentArrangementTrancheFiveMember"
      decimals="3"
      id="F20230227081114922_133"
      unitRef="USD_per_Share">2.815</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
      contextRef="C_20210801to20210823_srtTitleOfIndividualAxis_entxNonExecutiveDirectorMember_usgaapVestingAxis_entxShareBasedPaymentArrangementTrancheSixMember"
      decimals="-3"
      id="F20230227081114936_160"
      unitRef="USD">65000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="C_20210801to20210823_srtTitleOfIndividualAxis_entxNonExecutiveDirectorMember_usgaapVestingAxis_entxShareBasedPaymentArrangementTrancheSixMember"
      id="Fxbrl_20230330125342141">P1Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="C_20210801to20210823_srtTitleOfIndividualAxis_entxNonExecutiveDirectorMember_usgaapVestingAxis_entxShareBasedPaymentArrangementTrancheSixMember"
      decimals="INF"
      id="F20230227081114921_129"
      unitRef="shares">250964</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="C_20210801to20210823_srtTitleOfIndividualAxis_entxNonExecutiveDirectorMember_usgaapVestingAxis_entxShareBasedPaymentArrangementTrancheSixMember"
      decimals="3"
      id="F20230227081114923_134"
      unitRef="USD_per_Share">2.815</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="C_20220331_srtTitleOfIndividualAxis_entxExecutiveOfficerAndServiceProviderMember"
      decimals="INF"
      id="Fxbrl_20230228114600349"
      unitRef="shares">80000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="C_20220101to20220331_srtTitleOfIndividualAxis_entxServiceProviderMember"
      decimals="2"
      id="Fxbrl_s_20221030170139370"
      unitRef="USD_per_Share">2.86</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="C_20220101to20220331_srtTitleOfIndividualAxis_entxExecutiveOfficerAndServiceProviderMember"
      decimals="2"
      id="Fxbrl_20230228114906381"
      unitRef="USD_per_Share">2.86</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
      contextRef="C_20220101to20220331_srtTitleOfIndividualAxis_entxExecutiveOfficerAndServiceProviderMember"
      decimals="-3"
      id="Fxbrl_20230228115152783"
      unitRef="USD">147000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="C_20220331_srtTitleOfIndividualAxis_srtExecutiveOfficerMember"
      decimals="INF"
      id="Fxbrl_20230228115200286"
      unitRef="shares">55000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="C_20220101to20220331_srtTitleOfIndividualAxis_entxServiceProviderMember"
      decimals="2"
      id="Fxbrl_s_20221030172710053"
      unitRef="USD_per_Share">2.86</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="C_20220101to20220331_srtTitleOfIndividualAxis_srtExecutiveOfficerMember"
      decimals="2"
      id="Fxbrl_20230228115207754"
      unitRef="USD_per_Share">2.86</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
      contextRef="C_20220101to20220331_srtTitleOfIndividualAxis_srtExecutiveOfficerMember"
      decimals="-3"
      id="Fxbrl_20230228115213430"
      unitRef="USD">37000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription
      contextRef="C_20220101to20220331"
      id="Fxbrl_20230228115233528">The
        options vest over four
        years from the date of grant; 25% vest on the first anniversary of the date of grant and the remaining 75% of the option
        will vest in twelve equal quarterly installments following the first anniversary of the grant date.</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="C_20220101to20220331"
      id="Fxbrl_20230228115221470">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="C_20220401to20220428_srtTitleOfIndividualAxis_entxEmployeeMember"
      decimals="INF"
      id="Fxbrl_20230228115246112"
      unitRef="shares">220000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="C_20220401to20220428_srtTitleOfIndividualAxis_entxEmployeeMember"
      decimals="2"
      id="Fxbrl_20230228115252271"
      unitRef="USD_per_Share">2.57</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription
      contextRef="C_20220401to20220428_srtTitleOfIndividualAxis_entxEmployeeMember"
      id="Fxbrl_20230228115314000">The
        options vest over four
        years from the date of grant; 25% vest on the first anniversary of the date of grant and the remaining 75% of the option
        will vest in twelve equal quarterly installments following the first anniversary of the grant date.</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="C_20220401to20220428_srtTitleOfIndividualAxis_entxEmployeeMember"
      id="Fxbrl_20230228115303854">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
      contextRef="C_20220401to20220428_srtTitleOfIndividualAxis_entxEmployeeMember"
      decimals="-3"
      id="Fxbrl_20230228115321149"
      unitRef="USD">364000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="C_20220501to20220511_srtTitleOfIndividualAxis_srtChiefFinancialOfficerMember"
      decimals="INF"
      id="Fxbrl_20230228115329584"
      unitRef="shares">500000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription
      contextRef="C_20220501to20220511_srtTitleOfIndividualAxis_srtChiefFinancialOfficerMember"
      id="Fxbrl_20230228115512200">This
        grant was subject to shareholders' approval, which was obtained at a meeting of the Company&#x2019;s shareholders held on September 7,
        2022. These options have an exercise price of&#x2009;$2.00
        per share and vest over four
        years from the date of grant; 25% vest on the first anniversary of the date of grant and the remaining 75% of the option
        will vest in twelve equal quarterly installments following the first anniversary of the grant date.</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="C_20220501to20220511_srtTitleOfIndividualAxis_srtChiefFinancialOfficerMember"
      decimals="2"
      id="Fxbrl_20230228115349904"
      unitRef="USD_per_Share">2</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="C_20220501to20220511_srtTitleOfIndividualAxis_srtChiefFinancialOfficerMember"
      id="Fxbrl_20230228115401506">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
      contextRef="C_20220501to20220511_srtTitleOfIndividualAxis_srtChiefFinancialOfficerMember"
      decimals="-3"
      id="Fxbrl_20230228115412102"
      unitRef="USD">390000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="C_20220701to20220715_srtTitleOfIndividualAxis_srtChiefExecutiveOfficerMember"
      decimals="INF"
      id="Fxbrl_20230228115520463"
      unitRef="shares">600000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="C_20220701to20220715_srtTitleOfIndividualAxis_srtChiefExecutiveOfficerMember"
      decimals="2"
      id="Fxbrl_20230228115538118"
      unitRef="USD_per_Share">1.4</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription
      contextRef="C_20220701to20220715_srtTitleOfIndividualAxis_srtChiefExecutiveOfficerMember"
      id="Fxbrl_20230228115602861">This
        grant was subject to shareholders' approval, which was obtained at a meeting of the Company&#x2019;s shareholders held on September 7,
        2022. The options vest over four
        years from the date of grant; 25% vest on the first anniversary of the date of grant and the remaining 75% of the option
        will vest in twelve equal quarterly installments following the first anniversary of the applicable grant date.</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="C_20220701to20220715_srtTitleOfIndividualAxis_srtChiefExecutiveOfficerMember"
      id="Fxbrl_20230228115550920">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
      contextRef="C_20220701to20220715_srtTitleOfIndividualAxis_srtChiefExecutiveOfficerMember"
      decimals="-3"
      id="Fxbrl_20230228115608325"
      unitRef="USD">524000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="C_20220701to20220715_srtTitleOfIndividualAxis_srtChiefExecutiveOfficerMember_usgaapTypeOfArrangementAxis_entxTriggeringEventMember"
      decimals="INF"
      id="Fxbrl_20230228115624800"
      unitRef="shares">200000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="C_20210401to20210430_srtTitleOfIndividualAxis_entxPresidentOfResearchAndDevelopmentMember_usgaapAwardTypeAxis_entxTwentySeventeenMemberMember"
      decimals="INF"
      id="Fxbrl_20230228115646297"
      unitRef="shares">68750</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="C_20210430_srtTitleOfIndividualAxis_entxPresidentOfResearchAndDevelopmentMember_usgaapAwardTypeAxis_entxTwentySeventeenMemberMember"
      decimals="INF"
      id="Fxbrl_20230228115655873"
      unitRef="shares">31250</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="C_20220601to20220615_srtTitleOfIndividualAxis_entxPresidentOfResearchAndDevelopmentMember_usgaapAwardTypeAxis_entxTwentySeventeenMemberMember"
      decimals="INF"
      id="Fxbrl_20230228115701279"
      unitRef="shares">357500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="C_20220601to20220615_srtTitleOfIndividualAxis_entxPresidentOfResearchAndDevelopmentMember_usgaapAwardTypeAxis_entxTwentySeventeenMemberMember"
      id="Fxbrl_20230228115706687">P10Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_20220601to20220615_srtTitleOfIndividualAxis_entxPresidentOfResearchAndDevelopmentMember"
      decimals="-3"
      id="Fxbrl_20230228115714373"
      unitRef="USD">112000</us-gaap:AllocatedShareBasedCompensationExpense>
    <entx:CashSeparationPayment
      contextRef="C_20220601to20220615_srtTitleOfIndividualAxis_entxPresidentOfResearchAndDevelopmentMember"
      decimals="-3"
      id="Fxbrl_20230228130502260"
      unitRef="NIS">537600000</entx:CashSeparationPayment>
    <entx:CashSeparationPayment
      contextRef="C_20220601to20220615_srtTitleOfIndividualAxis_entxPresidentOfResearchAndDevelopmentMember"
      decimals="-3"
      id="Fxbrl_20230228130507093"
      unitRef="USD">156000</entx:CashSeparationPayment>
    <entx:AdditionalCashSeparationPayment
      contextRef="C_20220601to20220615_srtTitleOfIndividualAxis_entxPresidentOfResearchAndDevelopmentMember"
      decimals="-3"
      id="Fxbrl_20230228130514055"
      unitRef="NIS">737771000</entx:AdditionalCashSeparationPayment>
    <entx:AdditionalCashSeparationPayment
      contextRef="C_20220601to20220615_srtTitleOfIndividualAxis_entxPresidentOfResearchAndDevelopmentMember"
      decimals="-3"
      id="Fxbrl_20230228130518598"
      unitRef="USD">214000</entx:AdditionalCashSeparationPayment>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock contextRef="C_20220101to20221231" id="F20230227081114851_0">

&lt;div&gt;

&lt;div&gt;

&lt;div&gt;

&lt;div style="margin-left:54pt"&gt;

&lt;table border="0" cellpadding="0" cellspacing="0" style="width:85%"&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align:top;padding-bottom:2px" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px" valign="bottom"&gt;
        &lt;div style="line-height:1.25"&gt;
        &lt;div style="text-align:center;text-indent:0.05pt;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;2022&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/div&gt; &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px" valign="bottom"&gt;
        &lt;div style="line-height:1.25"&gt;
        &lt;div style="text-align:center;text-indent:0.05pt;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;2021&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/div&gt; &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align:top;padding-bottom:4px;background-color:rgb(204, 238, 255);width:70%" valign="bottom"&gt;
        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;Exercise
        price&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt; &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:4px;background-color:rgb(204, 238, 255);width:1%" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);width:1%" valign="bottom"&gt;
        &lt;div style="line-height:1.25"&gt;
        &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt; &lt;/div&gt; &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);width:12%" valign="bottom"&gt;
        &lt;div style="line-height:1.25"&gt;
        &lt;div style="line-height:1.25;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;$1.40-$2.86&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/div&gt; &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:4px;background-color:rgb(204, 238, 255);white-space:nowrap;width:1%" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:4px;background-color:rgb(204, 238, 255);width:1%" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);width:1%" valign="bottom"&gt;
        &lt;div style="line-height:1.25"&gt;
        &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt; &lt;/div&gt; &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);width:12%" valign="bottom"&gt;
        &lt;div style="line-height:1.25"&gt;
        &lt;div style="line-height:1.25;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;$1.24-$3.61&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/div&gt; &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:4px;background-color:rgb(204, 238, 255);white-space:nowrap;width:1%" valign="bottom"&gt;&#160;&lt;/td&gt;
        &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align:top;padding-bottom:4px;width:70%" valign="bottom"&gt;
        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;Dividend
        yield&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt; &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:4px;width:1%" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;border-bottom:4px double rgb(0, 0, 0);width:1%" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;border-bottom:4px double rgb(0, 0, 0);width:12%" valign="bottom"&gt;
        &lt;div style="line-height:1.25"&gt;
        &lt;div style="line-height:1.25;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/div&gt; &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:4px;white-space:nowrap;width:1%" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:4px;width:1%" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;border-bottom:4px double rgb(0, 0, 0);width:1%" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;border-bottom:4px double rgb(0, 0, 0);width:12%" valign="bottom"&gt;
        &lt;div style="line-height:1.25"&gt;
        &lt;div style="line-height:1.25;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/div&gt; &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:4px;white-space:nowrap;width:1%" valign="bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align:top;padding-bottom:4px;background-color:rgb(204, 238, 255);width:70%" valign="bottom"&gt;
        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;Expected
        volatility&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt; &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:4px;background-color:rgb(204, 238, 255);width:1%" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);width:1%" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);width:12%" valign="bottom"&gt;
        &lt;div style="line-height:1.25"&gt;
        &lt;div style="line-height:1.25;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;69%-70.2%&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/div&gt; &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:4px;background-color:rgb(204, 238, 255);white-space:nowrap;width:1%" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:4px;background-color:rgb(204, 238, 255);width:1%" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);width:1%" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);width:12%" valign="bottom"&gt;
        &lt;div style="line-height:1.25"&gt;
        &lt;div style="line-height:1.25;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;68%-71%&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/div&gt; &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:4px;background-color:rgb(204, 238, 255);white-space:nowrap;width:1%" valign="bottom"&gt;&#160;&lt;/td&gt;
        &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align:top;padding-bottom:4px;width:70%" valign="bottom"&gt;
        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;Risk-free
        interest rate&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt; &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:4px;width:1%" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;border-bottom:4px double rgb(0, 0, 0);width:1%" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;border-bottom:4px double rgb(0, 0, 0);width:12%" valign="bottom"&gt;
        &lt;div style="line-height:1.25"&gt;
        &lt;div style="line-height:1.25;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;1.35%-3.36%&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/div&gt; &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:4px;white-space:nowrap;width:1%" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:4px;width:1%" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;border-bottom:4px double rgb(0, 0, 0);width:1%" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;border-bottom:4px double rgb(0, 0, 0);width:12%" valign="bottom"&gt;
        &lt;div style="line-height:1.25"&gt;
        &lt;div style="line-height:1.25;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;1.11%-0.94%&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/div&gt; &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:4px;white-space:nowrap;width:1%" valign="bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align:top;padding-bottom:4px;background-color:rgb(204, 238, 255);width:70%" valign="bottom"&gt;
        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;Expected
        life - in years&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt; &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:4px;background-color:rgb(204, 238, 255);width:1%" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);width:1%" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);width:12%" valign="bottom"&gt;
        &lt;div style="line-height:1.25"&gt;
        &lt;div style="line-height:1.25;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;5.5-6.5&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/div&gt; &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:4px;background-color:rgb(204, 238, 255);white-space:nowrap;width:1%" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:4px;background-color:rgb(204, 238, 255);width:1%" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);width:1%" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);width:12%" valign="bottom"&gt;
        &lt;div style="line-height:1.25"&gt;
        &lt;div style="line-height:1.25;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;6.1-5.8&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/div&gt; &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:4px;background-color:rgb(204, 238, 255);white-space:nowrap;width:1%" valign="bottom"&gt;&#160;&lt;/td&gt;
        &lt;/tr&gt;
  &lt;/table&gt; &lt;/div&gt; &lt;/div&gt; &lt;/div&gt; &lt;/div&gt; </us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
      contextRef="C_20221231_srtRangeAxis_srtMinimumMember"
      decimals="2"
      id="Fxbrl_20230330184810532"
      unitRef="USD_per_Share">1.4</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
      contextRef="C_20221231_srtRangeAxis_srtMaximumMember"
      decimals="2"
      id="F20230227081114857_8"
      unitRef="USD_per_Share">2.86</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
      contextRef="C_20211231_srtRangeAxis_srtMinimumMember"
      decimals="2"
      id="Fxbrl_20230330184828074"
      unitRef="USD_per_Share">1.24</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
      contextRef="C_20211231_srtRangeAxis_srtMaximumMember"
      decimals="2"
      id="F20230227081114858_10"
      unitRef="USD_per_Share">3.61</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="C_20220101to20221231"
      decimals="2"
      id="F20230227081114853_4"
      unitRef="Percent">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="C_20210101to20211231"
      decimals="2"
      id="F20230227081114856_5"
      unitRef="Percent">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="C_20220101to20221231_srtRangeAxis_srtMinimumMember"
      decimals="2"
      id="F20230227081114858_11"
      unitRef="Percent">0.69</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="C_20220101to20221231_srtRangeAxis_srtMaximumMember"
      decimals="3"
      id="F20230227081114860_13"
      unitRef="Percent">0.702</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="C_20210101to20211231_srtRangeAxis_srtMinimumMember"
      decimals="2"
      id="F20230227081114862_18"
      unitRef="Percent">0.68</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="C_20210101to20211231_srtRangeAxis_srtMaximumMember"
      decimals="2"
      id="F20230227081114860_14"
      unitRef="Percent">0.71</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="C_20220101to20221231_srtRangeAxis_srtMinimumMember"
      decimals="4"
      id="F20230227081114859_12"
      unitRef="Percent">0.0135</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="C_20220101to20221231_srtRangeAxis_srtMaximumMember"
      decimals="4"
      id="F20230227081114861_15"
      unitRef="Percent">0.0336</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="C_20210101to20211231_srtRangeAxis_srtMinimumMember"
      decimals="4"
      id="F20230227081114863_19"
      unitRef="Percent">0.0111</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="C_20210101to20211231_srtRangeAxis_srtMaximumMember"
      decimals="4"
      id="F20230227081114861_16"
      unitRef="Percent">0.0094</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_20220101to20221231_srtRangeAxis_srtMinimumMember"
      id="F20230227081114856_6">P5Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_20220101to20221231_srtRangeAxis_srtMaximumMember"
      id="F20230227081114942_170">P6Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_20210101to20211231_srtRangeAxis_srtMinimumMember"
      id="F20230227081114865_20">P6Y1M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_20210101to20211231_srtRangeAxis_srtMaximumMember"
      id="F20230227081114862_17">P5Y9M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="C_20220101to20221231" id="F20230227081114852_1">

&lt;div&gt;

&lt;div style="line-height:1.25"&gt;

&lt;div style="margin:0pt"&gt;&#160;&lt;/div&gt; &lt;/div&gt;

&lt;div&gt;

&lt;div style="margin-left:54pt"&gt;

&lt;table cellpadding="0" cellspacing="0" style="color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:left;width:92%"&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align:top;padding-bottom:2px" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="vertical-align:top;border-bottom:#000000 solid 2px" valign="bottom"&gt;
        &lt;div style="line-height:1.25"&gt;
        &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;2022&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/div&gt; &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="vertical-align:top;border-bottom:#000000 solid 2px" valign="bottom"&gt;
        &lt;div style="line-height:1.25"&gt;
        &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;2021&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/div&gt; &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align:bottom;padding-bottom:2px" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px" valign="bottom"&gt;
        &lt;div style="line-height:1.25"&gt;
        &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;Number
        of&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;options&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/div&gt; &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px" valign="bottom"&gt;
        &lt;div style="line-height:1.25"&gt;
        &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;Weighted&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;average&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;exercise&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;price&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/div&gt; &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px" valign="bottom"&gt;
        &lt;div style="line-height:1.25"&gt;
        &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;Number
        of&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;options&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/div&gt; &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px" valign="bottom"&gt;
        &lt;div style="line-height:1.25"&gt;
        &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;Weighted&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;average&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;exercise&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;price&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/div&gt; &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align:middle;width:52%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;
        &lt;div style="text-indent:-1.3pt;margin-left:1.3pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;Outstanding
        at beginning of the year&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt; &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;
        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;4,316,859&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;
        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;
        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;3.63&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;
        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;2,570,109&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;
        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;
        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;4.85&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
        &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align:middle;width:52%" valign="bottom"&gt;
        &lt;div style="text-indent:-1.3pt;margin-left:1.3pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;Granted&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%" valign="bottom"&gt;
        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;2,458,863&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%" valign="bottom"&gt;
        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;2.29&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%" valign="bottom"&gt;
        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;1,975,586&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom"&gt;
        &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%" valign="bottom"&gt;
        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;1.95&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align:middle;width:52%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;
        &lt;div style="text-indent:-1.3pt;margin-left:1.3pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;Exercised&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;
        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;(5,511&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom"&gt;
        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;
        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;2.14&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;
        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;(177,710&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom"&gt;
        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;
        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;2.37&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
        &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align:middle;width:52%" valign="bottom"&gt;
        &lt;div style="text-indent:-1.3pt;margin-left:1.3pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;Forfeited&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%" valign="bottom"&gt;
        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;(902,009&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom"&gt;
        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%" valign="bottom"&gt;
        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;1.41&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%" valign="bottom"&gt;
        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;(16,660&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom"&gt;
        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%" valign="bottom"&gt;
        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;2.37&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align:middle;width:52%;padding-bottom:2px;background-color:rgb(204, 238, 255)" valign="bottom"&gt;
        &lt;div style="text-indent:-8.4pt;margin-left:8.4pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;Expired&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom"&gt;
        &lt;div style="line-height:1.25"&gt;
        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;(135,115&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/div&gt; &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom"&gt;
        &lt;div style="line-height:1.25"&gt;
        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/div&gt; &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom"&gt;
        &lt;div style="line-height:1.25"&gt;
        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;3.80&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/div&gt; &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom"&gt;
        &lt;div style="line-height:1.25"&gt;
        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;(34,466&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/div&gt; &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom"&gt;
        &lt;div style="line-height:1.25"&gt;
        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/div&gt; &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom"&gt;
        &lt;div style="line-height:1.25"&gt;
        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;4.00&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/div&gt; &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
        &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align:middle;width:52%;padding-bottom:4px" valign="bottom"&gt;
        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;Outstanding
        at end of the year&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt; &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0)" valign="bottom"&gt;
        &lt;div style="line-height:1.25"&gt;
        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;5,733,087&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/div&gt; &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0)" valign="bottom"&gt;
        &lt;div style="line-height:1.25"&gt;
        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/div&gt; &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0)" valign="bottom"&gt;
        &lt;div style="line-height:1.25"&gt;
        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;3.30&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/div&gt; &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0)" valign="bottom"&gt;
        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;4,316,859&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0)" valign="bottom"&gt;
        &lt;div style="line-height:1.25"&gt;
        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/div&gt; &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0)" valign="bottom"&gt;
        &lt;div style="line-height:1.25"&gt;
        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;3.63&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/div&gt; &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align:middle;width:52%;padding-bottom:4px;background-color:rgb(204, 238, 255)" valign="bottom"&gt;
        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;Exercisable
        at end of the year&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt; &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom"&gt;
        &lt;div style="line-height:1.25"&gt;
        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;3,165,677&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/div&gt; &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom"&gt;
        &lt;div style="line-height:1.25"&gt;
        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/div&gt; &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom"&gt;
        &lt;div style="line-height:1.25"&gt;
        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;4.06&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/div&gt; &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom"&gt;
        &lt;div style="line-height:1.25"&gt;
        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;2,068,067&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/div&gt; &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom"&gt;
        &lt;div style="line-height:1.25"&gt;
        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/div&gt; &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom"&gt;
        &lt;div style="line-height:1.25"&gt;
        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;5.39&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/div&gt; &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
        &lt;/tr&gt;
  &lt;/table&gt; &lt;/div&gt; &lt;/div&gt; &lt;/div&gt; </us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="C_20211231"
      decimals="INF"
      id="F20230227081114865_21"
      unitRef="shares">4316859</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="C_20211231"
      decimals="2"
      id="F20230227081114866_22"
      unitRef="USD_per_Share">3.63</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="C_20201231"
      decimals="INF"
      id="F20230227081114866_23"
      unitRef="shares">2570109</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="C_20201231"
      decimals="2"
      id="F20230227081114867_24"
      unitRef="USD_per_Share">4.85</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="C_20220101to20221231"
      decimals="INF"
      id="F20230227081114868_26"
      unitRef="shares">2458863</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="C_20220101to20221231"
      decimals="2"
      id="F20230227081114868_27"
      unitRef="USD_per_Share">2.29</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="C_20210101to20211231"
      decimals="INF"
      id="F20230227081114868_28"
      unitRef="shares">1975586</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="C_20210101to20211231"
      decimals="2"
      id="F20230227081114869_29"
      unitRef="USD_per_Share">1.95</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="C_20220101to20221231"
      decimals="INF"
      id="F20230227081114869_30"
      unitRef="shares">5511</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="C_20220101to20221231"
      decimals="2"
      id="F20230227081114867_25"
      unitRef="USD_per_Share">2.14</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="C_20210101to20211231"
      decimals="INF"
      id="F20230227081114870_31"
      unitRef="shares">177710</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="C_20210101to20211231"
      decimals="2"
      id="F20230227081114870_32"
      unitRef="USD_per_Share">2.37</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="C_20220101to20221231"
      decimals="INF"
      id="F20230227081114871_33"
      unitRef="shares">902009</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="C_20220101to20221231"
      decimals="2"
      id="F20230227081114871_34"
      unitRef="USD_per_Share">1.41</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="C_20210101to20211231"
      decimals="INF"
      id="F20230227081114873_35"
      unitRef="shares">16660</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="C_20210101to20211231"
      decimals="2"
      id="F20230227081114873_36"
      unitRef="USD_per_Share">2.37</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
      contextRef="C_20220101to20221231"
      decimals="INF"
      id="F20230227081114874_37"
      unitRef="shares">135115</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="C_20220101to20221231"
      decimals="2"
      id="F20230227081114874_38"
      unitRef="USD_per_Share">3.8</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
      contextRef="C_20210101to20211231"
      decimals="INF"
      id="F20230227081114874_39"
      unitRef="shares">34466</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="C_20210101to20211231"
      decimals="2"
      id="F20230227081114875_40"
      unitRef="USD_per_Share">4</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="C_20221231"
      decimals="INF"
      id="F20230227081114875_41"
      unitRef="shares">5733087</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="C_20221231"
      decimals="2"
      id="F20230227081114876_42"
      unitRef="USD_per_Share">3.3</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="C_20211231"
      decimals="INF"
      id="F20230227081114876_43"
      unitRef="shares">4316859</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="C_20211231"
      decimals="2"
      id="F20230227081114877_44"
      unitRef="USD_per_Share">3.63</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="C_20221231"
      decimals="INF"
      id="F20230227081114877_45"
      unitRef="shares">3165677</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="C_20221231"
      decimals="2"
      id="F20230227081114877_46"
      unitRef="USD_per_Share">4.06</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="C_20211231"
      decimals="INF"
      id="F20230227081114878_47"
      unitRef="shares">2068067</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="C_20211231"
      decimals="2"
      id="F20230227081114878_48"
      unitRef="USD_per_Share">5.39</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock
      contextRef="C_20220101to20221231"
      id="Fxbrl_20230228131212864">

&lt;table border="0" cellpadding="0" cellspacing="0" style="color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:left;width:85%"&gt;
  &lt;tr&gt;
    &lt;td colspan="18" rowspan="1" style="vertical-align:top;padding-bottom:2px;border-bottom:2px solid black" valign="bottom"&gt;
        &lt;div style="line-height:1.25"&gt;
        &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;December
        31, 2022&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt; &lt;/div&gt; &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td colspan="10" style="vertical-align:top;border-bottom:#000000 solid 2px" valign="bottom"&gt;
        &lt;div style="line-height:1.25"&gt;
        &lt;div style="line-height:1.25;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;Options
        outstanding&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt; &lt;/div&gt; &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;white-space:nowrap;text-align:center" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="vertical-align:top;border-bottom:#000000 solid 2px" valign="bottom"&gt;
        &lt;div style="line-height:1.25"&gt;
        &lt;div style="line-height:1.25;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;Options
        exercisable&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt; &lt;/div&gt; &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td colspan="2" style="vertical-align:top" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align:top" valign="bottom"&gt;
        &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;Number
        of&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt; &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align:top" valign="bottom"&gt;
        &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;Weighted&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align:top" valign="bottom"&gt;
        &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;Number
        of&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt; &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align:top" valign="bottom"&gt;
        &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;Weighted&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td colspan="2" style="vertical-align:top" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align:top" valign="bottom"&gt;
        &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;options&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align:top" valign="bottom"&gt;
        &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;Average&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align:top" valign="bottom"&gt;
        &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;options&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align:top" valign="bottom"&gt;
        &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;Average&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td colspan="2" style="vertical-align:top" valign="bottom"&gt;
        &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;Exercise&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align:top" valign="bottom"&gt;
        &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;outstanding&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align:top" valign="bottom"&gt;
        &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;Remaining&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align:top" valign="bottom"&gt;
        &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;exercisable&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align:top" valign="bottom"&gt;
        &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;Remaining&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td colspan="2" style="vertical-align:top" valign="bottom"&gt;
        &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;prices
        per&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt; &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align:top" valign="bottom"&gt;
        &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;at
        end of&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt; &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align:top" valign="bottom"&gt;
        &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;Contractual&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align:top" valign="bottom"&gt;
        &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;at
        end of&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt; &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align:top" valign="bottom"&gt;
        &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;contractual&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px" valign="bottom"&gt;
        &lt;div style="line-height:1.25"&gt;
        &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;share
        (USD)&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt; &lt;/div&gt; &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px" valign="bottom"&gt;
        &lt;div style="line-height:1.25"&gt;
        &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;Year&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/div&gt; &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px" valign="bottom"&gt;
        &lt;div style="line-height:1.25"&gt;
        &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;Life&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/div&gt; &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px" valign="bottom"&gt;
        &lt;div style="line-height:1.25"&gt;
        &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;year&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/div&gt; &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px" valign="bottom"&gt;
        &lt;div style="line-height:1.25"&gt;
        &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;Life&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/div&gt; &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color:rgb(204, 238, 255)"&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;
        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;
        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;1,560&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;
        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;0.09&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;
        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;1,560&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;
        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;0.09&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
        &lt;/tr&gt;
  &lt;tr style="background-color:rgb(255, 255, 255)"&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;
        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;1.24&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;
        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;492,831&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;
        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;1.54&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;
        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;492,831&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;
        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;1.54&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
        &lt;/tr&gt;
  &lt;tr style="background-color:rgb(204, 238, 255)"&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;
        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;1.40&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;
        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;600,000
        &lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt; &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;
        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;9.54&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;
        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;
        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
        &lt;/tr&gt;
  &lt;tr style="background-color:rgb(255, 255, 255)"&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;
        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;2.02&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;
        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;500,000&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;
        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;9.37&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;
        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;
        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
        &lt;/tr&gt;
  &lt;tr style="background-color:rgb(204, 238, 255)"&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;
        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;2.14&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;
        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;400,775&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;
        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;7.26&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;
        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;277,994&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;
        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;7.26&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
        &lt;/tr&gt;
  &lt;tr style="background-color:rgb(255, 255, 255)"&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;
        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;2.53&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;
        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;33,638&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;
        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;6.89&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;
        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;33,638&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;
        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;6.89&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
        &lt;/tr&gt;
  &lt;tr style="background-color:rgb(204, 238, 255)"&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;
        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;2.57&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;
        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;205,500&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;
        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;9.33&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;
        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;
        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
        &lt;/tr&gt;
  &lt;tr style="background-color:rgb(255, 255, 255)"&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;
        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;2.815&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;
        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;1,003,863&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;
        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;9.01&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;
        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;376,447&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;
        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;9.01&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
        &lt;/tr&gt;
  &lt;tr style="background-color:rgb(204, 238, 255)"&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;
        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;2.86&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;
        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;135,000&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;
        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;9.25&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;
        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;
        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
        &lt;/tr&gt;
  &lt;tr style="background-color:rgb(255, 255, 255)"&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;
        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;3.15&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;
        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;345,000&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;
        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;8.30&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;
        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;123,125&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;
        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;8.30&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
        &lt;/tr&gt;
  &lt;tr style="background-color:rgb(204, 238, 255)"&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;padding-bottom:2px;background-color:rgb(204, 238, 255)" valign="bottom"&gt;
        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;3.61&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;white-space:nowrap;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;
        &lt;div style="line-height:1.25"&gt;
        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;250,868&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/div&gt; &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;white-space:nowrap;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;padding-bottom:2px;background-color:rgb(204, 238, 255)" valign="bottom"&gt;
        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;8.27&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;white-space:nowrap;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;
        &lt;div style="line-height:1.25"&gt;
        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;101,059&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/div&gt; &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;white-space:nowrap;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;padding-bottom:2px;background-color:rgb(204, 238, 255)" valign="bottom"&gt;
        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;8.27&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;white-space:nowrap;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
        &lt;/tr&gt;
  &lt;tr style="background-color:rgb(255, 255, 255)"&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;padding-bottom:2px;background-color:rgb(255, 255, 255)" valign="bottom"&gt;
        &lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span style="line-height:107%"&gt;3.68&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;white-space:nowrap;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;
        &lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span style="line-height:107%"&gt;294,580&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;white-space:nowrap;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;padding-bottom:2px;background-color:rgb(255, 255, 255)" valign="bottom"&gt;
        &lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span style="line-height:107%"&gt;0.26&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;white-space:nowrap;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;
        &lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span style="line-height:107%"&gt;294,580&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;white-space:nowrap;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;padding-bottom:2px;background-color:rgb(255, 255, 255)" valign="bottom"&gt;
        &lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span style="line-height:107%"&gt;0.26&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;white-space:nowrap;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
        &lt;/tr&gt;
  &lt;tr style="background-color:rgb(204, 238, 255)"&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;padding-bottom:2px;background-color:rgb(204, 238, 255)" valign="bottom"&gt;
        &lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span style="line-height:107%"&gt;3.97&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;white-space:nowrap;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;
        &lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span style="line-height:107%"&gt;247,082&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;white-space:nowrap;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;padding-bottom:2px;background-color:rgb(204, 238, 255)" valign="bottom"&gt;
        &lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span style="line-height:107%"&gt;6.05&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;white-space:nowrap;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;
        &lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span style="line-height:107%"&gt;242,053&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;white-space:nowrap;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;padding-bottom:2px;background-color:rgb(204, 238, 255)" valign="bottom"&gt;
        &lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span style="line-height:107%"&gt;6.05&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;white-space:nowrap;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
        &lt;/tr&gt;
  &lt;tr style="background-color:rgb(255, 255, 255)"&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;padding-bottom:2px;background-color:rgb(255, 255, 255)" valign="bottom"&gt;
        &lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span style="line-height:107%"&gt;6.31&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;white-space:nowrap;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid black;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid black;background-color:rgb(255, 255, 255)" valign="bottom"&gt;
        &lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span style="line-height:107%"&gt;1,222,390&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;white-space:nowrap;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;padding-bottom:2px;background-color:rgb(255, 255, 255)" valign="bottom"&gt;
        &lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span style="line-height:107%"&gt;3.08&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;white-space:nowrap;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid black;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid black;background-color:rgb(255, 255, 255)" valign="bottom"&gt;
        &lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span style="line-height:107%"&gt;1,222,390&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;white-space:nowrap;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;padding-bottom:2px;background-color:rgb(255, 255, 255)" valign="bottom"&gt;
        &lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span style="line-height:107%"&gt;3.08&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;white-space:nowrap;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
        &lt;/tr&gt;
  &lt;tr style="background-color:rgb(204, 238, 255)"&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;padding-bottom:4px;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;white-space:nowrap;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom"&gt;
        &lt;div style="line-height:1.25"&gt;
        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;5,733,087&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/div&gt; &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;white-space:nowrap;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;padding-bottom:4px;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;white-space:nowrap;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom"&gt;
        &lt;div style="line-height:1.25"&gt;
        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;3,165,677&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/div&gt; &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;white-space:nowrap;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;padding-bottom:4px;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;white-space:nowrap;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
        &lt;/tr&gt;
  &lt;/table&gt; </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="C_20221231_usgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_entxExercisePricePerShareZeroMember"
      decimals="0"
      id="F20230227081114937_162"
      unitRef="USD_per_Share">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="C_20221231_usgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_entxExercisePricePerShareZeroMember"
      decimals="INF"
      id="F20230227081114898_86"
      unitRef="shares">1560</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="C_20220101to20221231_usgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_entxExercisePricePerShareZeroMember"
      id="F20230227081114879_49">P0Y1M2D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="C_20221231_usgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_entxExercisePricePerShareZeroMember"
      decimals="INF"
      id="F20230227081114880_50"
      unitRef="shares">1560</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="C_20220101to20221231_usgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_entxExercisePricePerShareZeroMember"
      id="F20230227081114881_51">P0Y1M2D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="C_20221231_usgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_entxExercisePricePerShareOnePointTwoFourMember"
      decimals="2"
      id="F20230227081114899_87"
      unitRef="USD_per_Share">1.24</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="C_20221231_usgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_entxExercisePricePerShareOnePointTwoFourMember"
      decimals="INF"
      id="F20230227081114881_52"
      unitRef="shares">492831</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="C_20220101to20221231_usgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_entxExercisePricePerShareOnePointTwoFourMember"
      id="F20230227081114882_53">P1Y6M14D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="C_20221231_usgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_entxExercisePricePerShareOnePointTwoFourMember"
      decimals="INF"
      id="F20230227081114882_54"
      unitRef="shares">492831</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="C_20220101to20221231_usgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_entxExercisePricePerShareOnePointTwoFourMember"
      id="F20230227081114883_55">P1Y6M14D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="C_20221231_usgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_entxExercisePricePerShareOnePointFourMember"
      decimals="2"
      id="F20230227081114942_171"
      unitRef="USD_per_Share">1.4</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="C_20221231_usgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_entxExercisePricePerShareOnePointFourMember"
      decimals="INF"
      id="F20230227081114899_88"
      unitRef="shares">600000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="C_20220101to20221231_usgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_entxExercisePricePerShareOnePointFourMember"
      id="F20230227081114939_165">P9Y6M14D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="C_20221231_usgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_entxExercisePricePerShareOnePointFourMember"
      decimals="INF"
      id="F20230227081114940_168"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="C_20221231_usgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_entxExercisePricePerShareTwoPointZeroTwoMember"
      decimals="2"
      id="F20230227081114900_89"
      unitRef="USD_per_Share">2.02</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="C_20221231_usgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_entxExercisePricePerShareTwoPointZeroTwoMember"
      decimals="INF"
      id="F20230227081114883_56"
      unitRef="shares">500000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="C_20220101to20221231_usgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_entxExercisePricePerShareTwoPointZeroTwoMember"
      id="F20230227081114883_57">P9Y4M13D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="C_20221231_usgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_entxExercisePricePerShareTwoPointZeroTwoMember"
      decimals="INF"
      id="F20230227081114884_58"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="C_20221231_usgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_entxExercisePricePerShareTwoPointOneFourMember"
      decimals="2"
      id="F20230227081114900_90"
      unitRef="USD_per_Share">2.14</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="C_20221231_usgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_entxExercisePricePerShareTwoPointOneFourMember"
      decimals="INF"
      id="F20230227081114885_60"
      unitRef="shares">400775</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="C_20220101to20221231_usgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_entxExercisePricePerShareTwoPointOneFourMember"
      id="F20230227081114885_61">P7Y3M3D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="C_20221231_usgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_entxExercisePricePerShareTwoPointOneFourMember"
      decimals="INF"
      id="F20230227081114886_62"
      unitRef="shares">277994</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="C_20220101to20221231_usgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_entxExercisePricePerShareTwoPointOneFourMember"
      id="F20230227081114886_63">P7Y3M3D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="C_20221231_usgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_entxExercisePricePerShareTwoPointFiveThreeMember"
      decimals="2"
      id="F20230227081114938_163"
      unitRef="USD_per_Share">2.53</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="C_20221231_usgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_entxExercisePricePerShareTwoPointFiveThreeMember"
      decimals="INF"
      id="F20230227081114900_91"
      unitRef="shares">33638</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="C_20220101to20221231_usgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_entxExercisePricePerShareTwoPointFiveThreeMember"
      id="F20230227081114938_164">P6Y10M20D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="C_20221231_usgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_entxExercisePricePerShareTwoPointFiveThreeMember"
      decimals="INF"
      id="F20230227081114941_169"
      unitRef="shares">33638</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="C_20220101to20221231_usgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_entxExercisePricePerShareTwoPointFiveThreeMember"
      id="Fxbrl_20230228123058155">P6Y10M20D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="C_20221231_usgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_entxExercisePricePerShareTwoPointFiveSevenMember"
      decimals="2"
      id="F20230227081114901_92"
      unitRef="USD_per_Share">2.57</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="C_20221231_usgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_entxExercisePricePerShareTwoPointFiveSevenMember"
      decimals="INF"
      id="F20230227081114887_64"
      unitRef="shares">205500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="C_20220101to20221231_usgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_entxExercisePricePerShareTwoPointFiveSevenMember"
      id="F20230227081114888_65">P9Y3M29D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="C_20221231_usgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_entxExercisePricePerShareTwoPointFiveSevenMember"
      decimals="INF"
      id="F20230227081114888_66"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="C_20221231_usgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_entxExercisePricePerShareTwoPointEightOneFiveMember"
      decimals="3"
      id="F20230227081114901_93"
      unitRef="USD_per_Share">2.815</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="C_20221231_usgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_entxExercisePricePerShareTwoPointEightOneFiveMember"
      decimals="INF"
      id="F20230227081114889_68"
      unitRef="shares">1003863</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="C_20220101to20221231_usgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_entxExercisePricePerShareTwoPointEightOneFiveMember"
      id="F20230227081114890_69">P9Y3D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="C_20221231_usgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_entxExercisePricePerShareTwoPointEightOneFiveMember"
      decimals="INF"
      id="F20230227081114890_70"
      unitRef="shares">376447</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="C_20220101to20221231_usgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_entxExercisePricePerShareTwoPointEightOneFiveMember"
      id="F20230227081114891_71">P9Y3D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="C_20221231_usgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_entxExercisePricePerShareTwoPointEightSixMember"
      decimals="2"
      id="F20230227081114902_94"
      unitRef="USD_per_Share">2.86</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="C_20221231_usgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_entxExercisePricePerShareTwoPointEightSixMember"
      decimals="INF"
      id="F20230227081114891_72"
      unitRef="shares">135000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="C_20220101to20221231_usgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_entxExercisePricePerShareTwoPointEightSixMember"
      id="F20230227081114891_73">P9Y3M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="C_20221231_usgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_entxExercisePricePerShareTwoPointEightSixMember"
      decimals="INF"
      id="F20230227081114892_74"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="C_20221231_usgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_entxExercisePricePerShareThreePointOneFiveMember"
      decimals="2"
      id="F20230227081114903_95"
      unitRef="USD_per_Share">3.15</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="C_20221231_usgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_entxExercisePricePerShareThreePointOneFiveMember"
      decimals="INF"
      id="F20230227081114893_76"
      unitRef="shares">345000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="C_20220101to20221231_usgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_entxExercisePricePerShareThreePointOneFiveMember"
      id="F20230227081114893_77">P8Y3M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="C_20221231_usgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_entxExercisePricePerShareThreePointOneFiveMember"
      decimals="INF"
      id="F20230227081114894_78"
      unitRef="shares">123125</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="C_20220101to20221231_usgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_entxExercisePricePerShareThreePointOneFiveMember"
      id="F20230227081114894_79">P8Y3M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="C_20221231_usgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_entxExercisePricePerShareThreePointSixOneMember"
      decimals="2"
      id="F20230227081114904_96"
      unitRef="USD_per_Share">3.61</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="C_20221231_usgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_entxExercisePricePerShareThreePointSixOneMember"
      decimals="INF"
      id="F20230227081114896_80"
      unitRef="shares">250868</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="C_20220101to20221231_usgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_entxExercisePricePerShareThreePointSixOneMember"
      id="F20230227081114896_81">P8Y3M7D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="C_20221231_usgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_entxExercisePricePerShareThreePointSixOneMember"
      decimals="INF"
      id="F20230227081114897_82"
      unitRef="shares">101059</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="C_20220101to20221231_usgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_entxExercisePricePerShareThreePointSixOneMember"
      id="F20230227081114897_83">P8Y3M7D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="C_20221231_usgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_entxExercisePricePerShareThreePointSixEightMember"
      decimals="2"
      id="Fxbrl_20230228121220208_20230227081114904_96"
      unitRef="USD_per_Share">3.68</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="C_20221231_usgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_entxExercisePricePerShareThreePointSixEightMember"
      decimals="INF"
      id="Fxbrl_20230228121220208_20230227081114896_80"
      unitRef="shares">294580</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="C_20220101to20221231_usgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_entxExercisePricePerShareThreePointSixEightMember"
      id="Fxbrl_20230228121220208_20230227081114896_81">P0Y3M3D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="C_20221231_usgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_entxExercisePricePerShareThreePointSixEightMember"
      decimals="INF"
      id="Fxbrl_20230228121220208_20230227081114897_82"
      unitRef="shares">294580</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="C_20220101to20221231_usgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_entxExercisePricePerShareThreePointSixEightMember"
      id="Fxbrl_20230228121220208_20230227081114897_83">P0Y3M3D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="C_20221231_usgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_entxExercisePricePerShareThreePointNineSevenMember"
      decimals="2"
      id="Fxbrl_20230228121257544_xbrl_20230228121220208_20230227081114904_96"
      unitRef="USD_per_Share">3.97</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="C_20221231_usgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_entxExercisePricePerShareThreePointNineSevenMember"
      decimals="INF"
      id="Fxbrl_20230228121257544_xbrl_20230228121220208_20230227081114896_80"
      unitRef="shares">247082</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="C_20220101to20221231_usgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_entxExercisePricePerShareThreePointNineSevenMember"
      id="Fxbrl_20230228121257544_xbrl_20230228121220208_20230227081114896_81">P6Y18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="C_20221231_usgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_entxExercisePricePerShareThreePointNineSevenMember"
      decimals="INF"
      id="Fxbrl_20230228121257544_xbrl_20230228121220208_20230227081114897_82"
      unitRef="shares">242053</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="C_20220101to20221231_usgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_entxExercisePricePerShareThreePointNineSevenMember"
      id="Fxbrl_20230228121257544_xbrl_20230228121220208_20230227081114897_83">P6Y18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="C_20221231_usgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_entxExercisePricePerShareSixPointThreeOneMember"
      decimals="2"
      id="Fxbrl_20230228121259249_xbrl_20230228121220208_20230227081114904_96"
      unitRef="USD_per_Share">6.31</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="C_20221231_usgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_entxExercisePricePerShareSixPointThreeOneMember"
      decimals="INF"
      id="Fxbrl_20230228121259249_xbrl_20230228121220208_20230227081114896_80"
      unitRef="shares">1222390</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="C_20220101to20221231_usgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_entxExercisePricePerShareSixPointThreeOneMember"
      id="Fxbrl_20230228121259249_xbrl_20230228121220208_20230227081114896_81">P3Y29D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="C_20221231_usgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_entxExercisePricePerShareSixPointThreeOneMember"
      decimals="INF"
      id="Fxbrl_20230228121259249_xbrl_20230228121220208_20230227081114897_82"
      unitRef="shares">1222390</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="C_20220101to20221231_usgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_entxExercisePricePerShareSixPointThreeOneMember"
      id="Fxbrl_20230228121259249_xbrl_20230228121220208_20230227081114897_83">P3Y29D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="C_20221231"
      decimals="INF"
      id="F20230227081114897_84"
      unitRef="shares">5733087</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="C_20221231"
      decimals="INF"
      id="F20230227081114898_85"
      unitRef="shares">3165677</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="C_20221231"
      decimals="-3"
      id="F20230227081114907_103"
      unitRef="USD">1000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock contextRef="C_20220101to20221231" id="F20230227081114852_2">

&lt;div&gt;

&lt;div style="text-align:center"&gt;

&lt;div style="clear:both;margin-top:0pt;margin-bottom:0pt"&gt;

&lt;div style="text-align:center"&gt; &lt;div style="font-size:10pt;display:inline"&gt; &lt;div style="font-family:Times New Roman,Times,serif;display:inline"&gt;
&lt;div style="color:#000000;font-weight:normal;font-style:normal;display:inline"&gt;

&lt;div&gt;

&lt;div&gt;

&lt;div style="margin-left:45pt"&gt;

&lt;table border="0" cellpadding="0" cellspacing="0" style="color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:left;width:85%"&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align:top;padding-bottom:2px" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px" valign="bottom"&gt;
        &lt;div style="line-height:1.25"&gt;
        &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;2022&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/div&gt; &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px" valign="bottom"&gt;
        &lt;div style="line-height:1.25"&gt;
        &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;2021&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/div&gt; &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;
        &lt;div style="text-align:justify;text-indent:-12.6pt;margin-left:12.6pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;Cost
        of revenues&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt; &lt;/td&gt;
    &lt;td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;
        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;14&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;
        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;102&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
        &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align:bottom;width:76%" valign="bottom"&gt;
        &lt;div style="text-align:justify;text-indent:-12.6pt;margin-left:12.6pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;Research
        and development expenses&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt; &lt;/td&gt;
    &lt;td colspan="1" style="text-align:right;vertical-align:bottom;width:1%" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%" valign="bottom"&gt;
        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;708&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align:right;vertical-align:bottom;width:1%" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%" valign="bottom"&gt;
        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;661&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align:bottom;width:76%;padding-bottom:2px;background-color:rgb(204, 238, 255)" valign="bottom"&gt;
        &lt;div style="text-align:justify;text-indent:-12.6pt;margin-left:12.6pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;General
        and administrative&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt; &lt;/td&gt;
    &lt;td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom"&gt;
        &lt;div style="line-height:1.25"&gt;
        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;1,525&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/div&gt; &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom"&gt;
        &lt;div style="line-height:1.25"&gt;
        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;1,098&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/div&gt; &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
        &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align:bottom;width:76%;padding-bottom:4px" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;padding-bottom:4px" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0)" valign="bottom"&gt;
        &lt;div style="line-height:1.25"&gt;
        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;2,247&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/div&gt; &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;padding-bottom:4px" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0)" valign="bottom"&gt;
        &lt;div style="line-height:1.25"&gt;
        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;1,861&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/div&gt; &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;/table&gt; &lt;/div&gt; &lt;/div&gt; &lt;/div&gt; &lt;/div&gt; &lt;/div&gt; &lt;/div&gt; &lt;/div&gt; &lt;/div&gt; &lt;/div&gt; &lt;/div&gt; </us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_20220101to20221231_usgaapIncomeStatementLocationAxis_usgaapCostOfSalesMember"
      decimals="-3"
      id="F20230227081114943_172"
      unitRef="USD">14000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_20210101to20211231_usgaapIncomeStatementLocationAxis_usgaapCostOfSalesMember"
      decimals="-3"
      id="F20230227081114943_173"
      unitRef="USD">102000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_20220101to20221231_usgaapIncomeStatementLocationAxis_usgaapResearchAndDevelopmentExpenseMember"
      decimals="-3"
      id="F20230227081114904_97"
      unitRef="USD">708000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_20210101to20211231_usgaapIncomeStatementLocationAxis_usgaapResearchAndDevelopmentExpenseMember"
      decimals="-3"
      id="F20230227081114905_98"
      unitRef="USD">661000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_20220101to20221231_usgaapIncomeStatementLocationAxis_usgaapGeneralAndAdministrativeExpenseMember"
      decimals="-3"
      id="F20230227081114905_99"
      unitRef="USD">1525000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_20210101to20211231_usgaapIncomeStatementLocationAxis_usgaapGeneralAndAdministrativeExpenseMember"
      decimals="-3"
      id="F20230227081114906_100"
      unitRef="USD">1098000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="F20230227081114906_101"
      unitRef="USD">2247000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_20210101to20211231"
      decimals="-3"
      id="F20230227081114907_102"
      unitRef="USD">1861000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="C_20220101to20221231"
      id="F20230227081114972_14">

&lt;div&gt;

&lt;div style="line-height:1.25;font-family:Times New Roman, Times, serif"&gt; &lt;div style="font-size:10pt;display:inline"&gt; &lt;div style="font-family:Times New Roman,Times,serif;display:inline"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;NOTE
7 - &lt;span style="line-height:107%"&gt;INCOME TAX&lt;/span&gt;&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;

&lt;div&gt;

&lt;div&gt;

&lt;div style="text-indent:-36pt;margin-left:36pt;line-height:1.25"&gt;&#160;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"&gt;
  &lt;tr&gt;
    &lt;td style="width:35.45pt;vertical-align:top;font-weight:bold"&gt;A.&lt;/td&gt;
    &lt;td style="width:auto;vertical-align:top;text-align:justify"&gt;
        &lt;div style="font-weight:bold"&gt;Corporate tax rate&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt;
  &lt;/table&gt;

&lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"&gt;
  &lt;tr&gt;
    &lt;td style="width:35pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:top;width:21pt"&gt;1)&lt;/td&gt;
    &lt;td style="vertical-align:top;text-align:justify;width:auto"&gt;
        &lt;div&gt;Ordinary taxable income in Israel is subject to a corporate tax rate of 23%.&lt;/div&gt;
        &lt;/td&gt; &lt;/tr&gt;
  &lt;/table&gt;

&lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"&gt;
  &lt;tr&gt;
    &lt;td style="width:35.45pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width:21.25pt;vertical-align:top"&gt;2)&lt;/td&gt;
    &lt;td style="width:auto;vertical-align:top;text-align:justify"&gt;
        &lt;div&gt;The Company&#x2019;s subsidiary Entera Bio, Inc. is taxed separately under the U.S. tax laws at a tax rate of 29%
        (Federal and state tax)&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt;
  &lt;/table&gt; &lt;/div&gt; &lt;/div&gt;

&lt;p style="margin:0pt"&gt;&#160;&lt;/p&gt; &lt;/div&gt; &lt;/div&gt; &lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" style="color:#000000;font-family:'Times New Roman',Times,serif;font-size:10pt;text-align:left;width:100%"&gt;
  &lt;tr&gt;
    &lt;td style="width:47px"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;B.&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width:auto;vertical-align:top"&gt;
        &lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;Losses
        for tax purposes carried forward to future years&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;/td&gt; &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="width:47px"&gt;&#160;&lt;/td&gt;
    &lt;td style="width:auto;vertical-align:top"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="width:47px"&gt;&#160;&lt;/td&gt;
    &lt;td style="width:auto;vertical-align:top"&gt;
        &lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;The
        balance of carryforward losses as of December 31, 2022&#160;and 2021&#160;are approximately $67.1&#160;million
        and $56.1&#160;million,
        respectively.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;/td&gt; &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="width:47px"&gt;&#160;&lt;/td&gt;
    &lt;td style="width:auto;vertical-align:top"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="width:47px"&gt;&#160;&lt;/td&gt;
    &lt;td style="width:auto;vertical-align:top"&gt;
        &lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Under
        Israeli tax law, tax loss carry forward have no expiration date.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;/td&gt; &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="width:47px"&gt;&#160;&lt;/td&gt;
    &lt;td style="width:auto;vertical-align:top"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="width:47px"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;C.&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width:auto;vertical-align:top"&gt;
        &lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;&lt;span style="line-height:107%"&gt;Tax
        assessments&lt;/span&gt;&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;/td&gt; &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="width:47px"&gt;&#160;&lt;/td&gt;
    &lt;td style="width:auto;vertical-align:top"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="width:47px"&gt;&#160;&lt;/td&gt;
    &lt;td style="width:auto;vertical-align:top"&gt;
        &lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span style="line-height:107%"&gt;The
        Company and its subsidiary have tax assessments that are considered to be final through tax year 2017.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt; &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="width:47px"&gt;&#160;&lt;/td&gt;
    &lt;td style="width:auto;vertical-align:top"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="width:47px"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;D.&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width:auto;vertical-align:top"&gt;
        &lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;Loss
        (income) before income taxes is composed of the following&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;/td&gt; &lt;/tr&gt;
  &lt;/table&gt;

&lt;div&gt;

&lt;p style="margin:0pt;font-size:10pt"&gt;&#160;&lt;/p&gt;

&lt;div&gt;

&lt;div&gt;

&lt;div style="margin-left:47px"&gt;

&lt;table border="0" cellpadding="0" cellspacing="0" style="color:#000000;float:left;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:left;width:85%"&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align:top;padding-bottom:2px" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);font-weight:bold"&gt;
        &lt;div style="line-height:1.25"&gt;
        &lt;div style="text-align:center;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Year
        ended December 31&lt;/span&gt;&lt;/span&gt;&lt;/div&gt; &lt;/div&gt; &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align:top;padding-bottom:2px" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0)"&gt;
        &lt;div style="line-height:1.25"&gt;
        &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2022&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/div&gt; &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;white-space:nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0)"&gt;
        &lt;div style="line-height:1.25"&gt;
        &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2021&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/div&gt; &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;
        &lt;div style="text-indent:-12.6pt;margin-left:12.6pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Entera
        Bio Ltd.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt; &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;
        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;12,997&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;
        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;12,362&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
        &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align:bottom;width:76%;padding-bottom:2px" valign="bottom"&gt;
        &lt;div style="text-indent:-12.6pt;margin-left:12.6pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Entera
        Bio Inc.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt; &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0)" valign="bottom"&gt;
        &lt;div style="line-height:1.25"&gt;
        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;(65&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/div&gt; &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;white-space:nowrap" valign="bottom"&gt;
        &lt;div style="line-height:1.25"&gt;
        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/div&gt; &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0)" valign="bottom"&gt;
        &lt;div style="line-height:1.25"&gt;
        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;(116&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/div&gt; &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;white-space:nowrap" valign="bottom"&gt;
        &lt;div style="line-height:1.25"&gt;
        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align:bottom;width:76%;padding-bottom:2px;background-color:rgb(204, 238, 255)" valign="bottom"&gt;
        &lt;div style="text-indent:-12.6pt;margin-left:12.6pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Total
        loss before taxes&lt;/span&gt;&lt;/span&gt;&lt;/div&gt; &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom"&gt;
        &lt;div style="line-height:1.25"&gt;
        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;12,934&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/div&gt; &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom"&gt;
        &lt;div style="line-height:1.25"&gt;
        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;12,246&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/div&gt; &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
        &lt;/tr&gt;
  &lt;/table&gt; &lt;/div&gt;

&lt;div style="line-height:1.25;clear:both"&gt;

&lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt; &lt;/div&gt; &lt;/div&gt; &lt;/div&gt; &lt;/div&gt;

&lt;div&gt;

&lt;div&gt;

&lt;div style="line-height:1.25;clear:both"&gt;

&lt;div style="line-height:1.25"&gt;

&lt;div style="line-height:1.25"&gt;

&lt;div&gt;

&lt;div&gt;

&lt;div style="line-height:1.25"&gt;

&lt;div style="line-height:1.25"&gt;

&lt;div style="line-height:1.25"&gt;

&lt;div&gt;

&lt;div&gt;

&lt;div&gt;

&lt;div style="line-height:1.25"&gt;

&lt;div&gt;

&lt;div style="line-height:1.25"&gt;

&lt;div style="line-height:1.25"&gt;

&lt;div style="line-height:1.25"&gt;

&lt;div style="line-height:1.25;font-weight:bold"&gt;

&lt;div style="line-height:1.25"&gt;

&lt;div style="line-height:1.25;font-weight:bold"&gt;

&lt;table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"&gt;
  &lt;tr&gt;
    &lt;td style="width:35.45pt;vertical-align:top;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;E.&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width:auto;vertical-align:top;text-align:justify"&gt;
        &lt;div style="font-weight:normal"&gt;
        &lt;div style="line-height:1.25"&gt;
        &lt;div style="line-height:1.25"&gt;
        &lt;div style="line-height:1.25"&gt;
        &lt;div style="line-height:1.25"&gt;
        &lt;div style="line-height:1.25"&gt;
        &lt;div style="line-height:1.25"&gt;
        &lt;div style="line-height:1.25"&gt;
        &lt;div style="line-height:1.25"&gt;
        &lt;div style="line-height:1.25"&gt;
        &lt;div style="line-height:1.25"&gt;
        &lt;div style="line-height:1.25"&gt;
        &lt;div style="line-height:1.25"&gt;
        &lt;div style="line-height:1.25"&gt;
        &lt;div&gt;
        &lt;div style="line-height:1.25"&gt;
        &lt;div style="line-height:1.25"&gt;
        &lt;div&gt;
        &lt;div&gt;
        &lt;div&gt;
        &lt;div&gt;
        &lt;div style="line-height:1.25;font-weight:bold"&gt;
        &lt;div style="line-height:1.25;font-weight:bold"&gt;
        &lt;div&gt;
        &lt;div&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Income tax expense&#160;(benefit):&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/div&gt; &lt;/div&gt; &lt;/div&gt; &lt;/div&gt; &lt;/div&gt; &lt;/div&gt; &lt;/div&gt; &lt;/div&gt; &lt;/div&gt; &lt;/div&gt; &lt;/div&gt; &lt;/div&gt; &lt;/div&gt; &lt;/div&gt; &lt;/div&gt; &lt;/div&gt; &lt;/div&gt; &lt;/div&gt; &lt;/div&gt; &lt;/div&gt;
        &lt;/div&gt; &lt;/div&gt; &lt;/div&gt; &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt;
  &lt;/table&gt; &lt;/div&gt; &lt;/div&gt; &lt;/div&gt; &lt;/div&gt; &lt;/div&gt; &lt;/div&gt; &lt;/div&gt; &lt;/div&gt; &lt;/div&gt; &lt;/div&gt; &lt;/div&gt; &lt;/div&gt; &lt;/div&gt; &lt;/div&gt; &lt;/div&gt; &lt;/div&gt; &lt;/div&gt;

&lt;div style="margin-left:36pt;line-height:1.25"&gt;&#160;&lt;/div&gt; &lt;/div&gt; &lt;/div&gt;

&lt;div style="margin-left:36pt"&gt;

&lt;table border="0" cellpadding="0" cellspacing="0" style="color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:left;width:85%"&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align:top;padding-bottom:2px" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="vertical-align:bottom;border-bottom:#000000 solid 2px" valign="bottom"&gt;
        &lt;div style="line-height:1.25;font-weight:bold"&gt;
        &lt;div style="text-align:center;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Year
        ended December 31&lt;/span&gt;&lt;/span&gt;&lt;/div&gt; &lt;/div&gt; &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align:top;padding-bottom:2px" valign="bottom"&gt;
        &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0)" valign="bottom"&gt;
        &lt;div style="line-height:1.25;font-weight:bold"&gt;
        &lt;div style="text-align:center;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2022&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/div&gt; &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-weight:bold;white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-weight:bold" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0)" valign="bottom"&gt;
        &lt;div style="line-height:1.25;font-weight:bold"&gt;
        &lt;div style="text-align:center;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2021&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/div&gt; &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td rowspan="1" style="vertical-align:top;background-color:rgb(204, 238, 255);height:15px" valign="bottom"&gt;
        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Current:&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/td&gt;
    &lt;td colspan="1" rowspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);height:15px" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" rowspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);height:15px" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" rowspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);white-space:nowrap;height:15px" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" rowspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);height:15px" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" rowspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);height:15px" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" rowspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);white-space:nowrap;height:15px" valign="bottom"&gt;&#160;&lt;/td&gt;
        &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align:bottom;width:76%;padding-bottom:2px;height:15px" valign="bottom"&gt;
        &lt;div style="text-indent:-12.6pt;margin-left:12.6pt;line-height:1.25;margin-top:0px;margin-bottom:0px"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Subsidiary:&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;height:15px" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);height:15px" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);height:15px" valign="bottom"&gt;
        &lt;div style="line-height:1.25"&gt;
        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;(37&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/div&gt; &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:1pt;white-space:nowrap;height:15px" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;height:15px" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);height:15px" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);height:15px" valign="bottom"&gt;
        &lt;div style="line-height:1.25"&gt;
        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;158&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/div&gt; &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;white-space:nowrap;height:15px" valign="bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align:bottom;width:76%;padding-bottom:2px;background-color:rgb(204, 238, 255);height:15px" valign="bottom"&gt;
        &lt;div style="text-indent:-12.6pt;margin-left:12.6pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Total
        current income tax&lt;/span&gt;&lt;/span&gt;&lt;/div&gt; &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);height:15px" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);height:15px" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);height:15px" valign="bottom"&gt;
        &lt;div style="line-height:1.25"&gt;
        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;(37&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/div&gt; &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:1pt;background-color:rgb(204, 238, 255);white-space:nowrap;height:15px" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);height:15px" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);height:15px" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);height:15px" valign="bottom"&gt;
        &lt;div style="line-height:1.25"&gt;
        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;158&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/div&gt; &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);white-space:nowrap;height:15px" valign="bottom"&gt;&#160;&lt;/td&gt;
        &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align:bottom;width:76%;height:15px" valign="bottom"&gt;
        &lt;div style="text-indent:-12.6pt;margin-left:12.6pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Deferred
        income&#160;taxes&lt;/span&gt;&lt;/span&gt;&lt;/div&gt; &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;height:15px" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;height:15px" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;height:15px" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;174&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap;height:15px" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;height:15px" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;height:15px" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;height:15px" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;(217&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap;height:15px" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
        &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255);padding-bottom:2px;height:15px" valign="bottom"&gt;
        &lt;div style="text-indent:-12.6pt;margin-left:12.6pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Total
        deferred income taxes&lt;/span&gt;&lt;/span&gt;&lt;/div&gt; &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);padding-bottom:2px;height:15px" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);border-bottom:2px solid rgb(0, 0, 0);height:15px" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);border-bottom:2px solid rgb(0, 0, 0);height:15px" valign="bottom"&gt;
        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;174&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);padding-bottom:2px;white-space:nowrap;height:15px" valign="bottom"&gt;
        &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);padding-bottom:2px;height:15px" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);border-bottom:2px solid rgb(0, 0, 0);height:15px" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);border-bottom:2px solid rgb(0, 0, 0);height:15px" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;(217&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);padding-bottom:1pt;white-space:nowrap;height:15px" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
        &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align:baseline;width:76%;padding-bottom:4px;height:15px"&gt;
        &lt;div style="text-indent:-12.6pt;margin-left:12.6pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Total
        income tax expense (benefit)&#160;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt; &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:baseline;width:1%;padding-bottom:4px;height:15px"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:baseline;width:1%;border-bottom:4px double rgb(0, 0, 0);height:15px"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:baseline;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);height:15px"&gt;
        &lt;div style="line-height:1.25"&gt;
        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;137&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/div&gt; &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:baseline;width:1%;padding-bottom:4px;white-space:nowrap;height:15px"&gt;
        &lt;div style="line-height:1.25"&gt;
        &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt; &lt;/div&gt; &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:baseline;width:1%;padding-bottom:4px;height:15px"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:baseline;width:1%;border-bottom:4px double rgb(0, 0, 0);height:15px"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:baseline;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);height:15px"&gt;
        &lt;div style="line-height:1.25"&gt;
        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;(59&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/div&gt; &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:baseline;width:1%;padding-bottom:1pt;white-space:nowrap;height:15px"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
        &lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="margin:0pt"&gt;&#160;&lt;/p&gt;  &lt;/div&gt; &lt;/div&gt; &lt;/div&gt;

&lt;div/&gt;

&lt;table cellpadding="0" cellspacing="0" style="color:rgb(0, 0, 0);font-family:Times New Roman, Times, serif;font-size:10pt;width:100%"&gt;
  &lt;tr&gt;
    &lt;td style="width:47px"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;strong&gt;F.&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="vertical-align:top;width:auto"&gt;
        &lt;p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;&lt;span style="line-height:107%"&gt;Deferred
        income taxes&lt;/span&gt;&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;/td&gt; &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="width:35px"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:top"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;/table&gt;

&lt;div&gt;

&lt;div&gt;

&lt;div&gt;

&lt;div style="margin-left:47px"&gt;

&lt;div&gt;

&lt;div&gt;

&lt;div&gt;

&lt;table border="0" cellpadding="0" cellspacing="0" style="color:#000000;float:left;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:left;width:85%"&gt;
  &lt;tr&gt;
    &lt;td rowspan="1" style="vertical-align:bottom;padding-bottom:2px" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" rowspan="1" style="vertical-align:bottom;padding-bottom:2px" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" rowspan="1" style="vertical-align:bottom;border-bottom:#000000 solid 2px" valign="bottom"&gt;
        &lt;div style="text-align:center;line-height:1.25;font-weight:bold;text-indent:1pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;December
        31,&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt; &lt;/td&gt;
    &lt;td colspan="1" rowspan="1" style="vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td rowspan="1" style="vertical-align:bottom;padding-bottom:2px" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" rowspan="1" style="vertical-align:bottom;padding-bottom:2px" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" rowspan="1" style="vertical-align:bottom;border-bottom:#000000 solid 2px" valign="bottom"&gt;
        &lt;div style="text-align:center;line-height:1.25;font-weight:bold;text-indent:4pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;2022&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/td&gt;
    &lt;td colspan="1" rowspan="1" style="vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" rowspan="1" style="text-align:center;font-weight:bold;vertical-align:bottom;padding-bottom:2px" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" rowspan="1" style="vertical-align:bottom;text-align:center;font-weight:bold;border-bottom:#000000 solid 2px" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;2021&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="1" rowspan="1" style="font-weight:bold;vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
        &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td rowspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255)" valign="bottom"&gt;
        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;Deferred
        tax assets:&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt; &lt;/td&gt;
    &lt;td colspan="1" rowspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" rowspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" rowspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" rowspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" rowspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" rowspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
        &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align:bottom;width:76%" valign="bottom"&gt;
        &lt;div style="text-indent:-35.1pt;margin-left:35.1pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;Net
        operating loss carry forward&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt; &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%" valign="bottom"&gt;
        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;15,428&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%" valign="bottom"&gt;
        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;12,895&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:76%" valign="bottom"&gt;
        &lt;div style="text-indent:-35.1pt;margin-left:35.1pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;Research
        and development&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt; &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:9%" valign="bottom"&gt;
        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;1,225&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/td&gt;
    &lt;td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:9%" valign="bottom"&gt;
        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;1,319&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/td&gt;
    &lt;td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
        &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align:bottom;width:76%" valign="bottom"&gt;
        &lt;div style="text-indent:-35.1pt;margin-left:35.1pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;Share-based
        compensation&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt; &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%" valign="bottom"&gt;
        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;877&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%" valign="bottom"&gt;
        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;876&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:76%" valign="bottom"&gt;
        &lt;div style="text-indent:-35.1pt;margin-left:35.1pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;Other&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:9%" valign="bottom"&gt;
        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;158&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/td&gt;
    &lt;td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:9%" valign="bottom"&gt;
        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;152&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/td&gt;
    &lt;td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
        &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align:bottom;width:76%;padding-bottom:2px" valign="bottom"&gt;
        &lt;div style="text-indent:-35.1pt;margin-left:35.1pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;Net
        deferred tax assets before valuation allowance&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt; &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0)" valign="bottom"&gt;
        &lt;div style="line-height:1.25"&gt;
        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;17,688&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/div&gt; &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0)" valign="bottom"&gt;
        &lt;div style="line-height:1.25"&gt;
        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;15,242&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/div&gt; &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:76%;padding-bottom:2px" valign="bottom"&gt;
        &lt;div style="text-indent:-35.1pt;margin-left:35.1pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;Valuation
        allowance&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt; &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0)" valign="bottom"&gt;
        &lt;div style="line-height:1.25"&gt;
        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;(17,645&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/div&gt; &lt;/td&gt;
    &lt;td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;padding-bottom:2px;white-space:nowrap" valign="bottom"&gt;
        &lt;div style="line-height:1.25"&gt;
        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/div&gt; &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0)" valign="bottom"&gt;
        &lt;div style="line-height:1.25"&gt;
        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;(15,025&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/div&gt; &lt;/td&gt;
    &lt;td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;padding-bottom:2px;white-space:nowrap" valign="bottom"&gt;
        &lt;div style="line-height:1.25"&gt;
        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align:bottom;width:76%;padding-bottom:4px" valign="bottom"&gt;
        &lt;div style="text-indent:-35.1pt;margin-left:35.1pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;Net
        deferred tax assets&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt; &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0)" valign="bottom"&gt;
        &lt;div style="line-height:1.25"&gt;
        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;43&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/div&gt; &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0)" valign="bottom"&gt;
        &lt;div style="line-height:1.25"&gt;
        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;217&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/div&gt; &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;/table&gt; &lt;/div&gt;

&lt;div style="line-height:1.25;clear:both"&gt;&#160;&lt;/div&gt; &lt;/div&gt; &lt;/div&gt; &lt;/div&gt;

&lt;div style="line-height:1.25;clear:both"&gt;

&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman, Times, serif;font-size:10pt;width:100%;color:rgb(0, 0, 0);border-width:0px;border-style:initial;border-color:initial"&gt;
  &lt;tr&gt;
    &lt;td style="width:47px"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:top;width:auto"&gt;
        &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;text-align:justify"&gt;The Company has classified the net deferred tax assets as
        long-term. In assessing the likelihood of realizing deferred tax assets, management considers whether it is more likely than not that
        some portion or all of the deferred tax assets will not be realized. The ultimate realization of deferred tax assets is dependent upon
        the generation of future taxable income during the periods in which those temporary differences and carry forward losses become deductible.
        Based on the taxable loss in the Israel, management believes it was more likely than not that the deferred tax assets will not be realized
        in the Israel and believes it was more likely than not that deferred tax assets will be realized for the U.S. subsidiary.&lt;/p&gt; &lt;/td&gt; &lt;/tr&gt;
  &lt;/table&gt; &lt;/div&gt;

&lt;div&gt;

&lt;p style="margin-top:0px;margin-bottom:0px"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="border:0px;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:left;width:100%"&gt;
  &lt;tr&gt;
    &lt;td style="width:47px"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;G.&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width:auto;vertical-align:top"&gt;
        &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;&lt;span style="line-height:107%"&gt;Rollforward
        of valuation allowance:&lt;/span&gt;&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;/td&gt; &lt;/tr&gt;
  &lt;/table&gt; &lt;/div&gt;

&lt;p style="margin:0pt"&gt;&#160;&lt;/p&gt;

&lt;div style="margin-left:36pt"&gt;

&lt;table border="0" cellpadding="0" cellspacing="0" style="color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:left;width:85%"&gt;
  &lt;tr style="background-color:rgb(204, 238, 255)"&gt;
    &lt;td style="vertical-align:top;background-color:rgb(204, 238, 255);width:89%" valign="bottom"&gt;
        &lt;div style="line-height:1.25"&gt; &lt;div style="font-size:10pt;display:inline"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span style="line-height:107%"&gt;Balance
        at January 1, 2021&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt; &lt;/div&gt; &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;border-bottom:2px solid black;background-color:rgb(204, 238, 255);width:1%" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align:bottom;border-bottom:2px solid black;background-color:rgb(204, 238, 255);width:9%" valign="bottom"&gt;
        &lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:right"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span style="line-height:107%"&gt;12,420&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;white-space:nowrap;background-color:rgb(204, 238, 255);width:1%" valign="bottom"&gt;&#160;&lt;/td&gt;
        &lt;/tr&gt;
  &lt;tr style="background-color:rgb(255, 255, 255)"&gt;
    &lt;td style="vertical-align:top;background-color:rgb(255, 255, 255)" valign="bottom"&gt;
        &lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span style="line-height:107%"&gt;Additions&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;border-bottom:4px double black;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align:bottom;border-bottom:4px double black;background-color:rgb(255, 255, 255);width:9%" valign="bottom"&gt;
        &lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:right"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span style="line-height:107%"&gt;2,605&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;white-space:nowrap;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color:rgb(204, 238, 255)"&gt;
    &lt;td style="vertical-align:top;background-color:rgb(204, 238, 255)" valign="bottom"&gt;
        &lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span style="line-height:107%"&gt;Balance
        at January 1, 2022&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;border-bottom:4px double black;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align:bottom;border-bottom:4px double black;background-color:rgb(204, 238, 255);width:9%" valign="bottom"&gt;
        &lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:right"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span style="line-height:107%"&gt;15,025&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;white-space:nowrap;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color:rgb(255, 255, 255)"&gt;
    &lt;td style="vertical-align:top;background-color:rgb(255, 255, 255)" valign="bottom"&gt;
        &lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span style="line-height:107%"&gt;Additions&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;border-bottom:4px double black;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align:bottom;border-bottom:4px double black;background-color:rgb(255, 255, 255);width:9%" valign="bottom"&gt;
        &lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:right"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span style="line-height:107%"&gt;2,620&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;white-space:nowrap;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color:rgb(204, 238, 255)"&gt;
    &lt;td style="vertical-align:top;background-color:rgb(204, 238, 255)" valign="bottom"&gt;
        &lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span style="line-height:107%"&gt;Balance
        at December 31, 2022&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;border-bottom:4px double black;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align:bottom;border-bottom:4px double black;background-color:rgb(204, 238, 255);width:9%" valign="bottom"&gt;
        &lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:right"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span style="line-height:107%"&gt;17,645&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;white-space:nowrap;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="margin:0pt"&gt;&#160;&lt;/p&gt; &lt;/div&gt;

&lt;div/&gt;

&lt;table cellpadding="0" cellspacing="0" style="font-weight:bold;color:rgb(0, 0, 0);font-family:Times New Roman, Times, serif;font-size:10pt;width:100%"&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align:top;width:35.45pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;H.&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="vertical-align:top;text-align:justify;width:auto"&gt;
        &lt;p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;Reconciliation of theoretical tax expenses
        to actual expenses&lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;/td&gt; &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align:top;width:35.45pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:top;text-align:justify;width:auto"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;margin-left:47px;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;The
primary difference between the statutory tax rate of the Company and the effective rate results virtually from the changes in valuation
allowance in respect of carry forward tax losses and research and development expenses due to the uncertainty of the realization of such
tax benefits.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin:0pt"&gt;&#160;&lt;/p&gt;

&lt;div&gt;

&lt;div&gt;

&lt;div style="line-height:1.25"&gt;

&lt;div style="line-height:1.25"&gt;

&lt;div style="line-height:1.25"&gt;

&lt;div style="line-height:1.25;clear:both"&gt;

&lt;div style="line-height:1.25"&gt;

&lt;div style="line-height:1.25"&gt;

&lt;div&gt;

&lt;div&gt;

&lt;div style="line-height:1.25"&gt;

&lt;div style="line-height:1.25"&gt;

&lt;div style="line-height:1.25"&gt;

&lt;div&gt;

&lt;div&gt;

&lt;div&gt;

&lt;div style="line-height:1.25"&gt;

&lt;div&gt;

&lt;div style="line-height:1.25"&gt;

&lt;div style="line-height:1.25"&gt;

&lt;div style="line-height:1.25"&gt;

&lt;div style="line-height:1.25;font-weight:bold"&gt;

&lt;div style="line-height:1.25"&gt;

&lt;div style="line-height:1.25;font-weight:bold"&gt;

&lt;table cellpadding="0" cellspacing="0" style="color:#000000;font-family:'Times New Roman',Times,serif;font-size:10pt;text-align:left;width:100%"&gt;
  &lt;tr&gt;
    &lt;td style="width:47px;vertical-align:top;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;I.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width:auto;vertical-align:top;text-align:justify"&gt;
        &lt;div style="font-weight:normal"&gt;
        &lt;div style="line-height:1.25"&gt;
        &lt;div style="line-height:1.25"&gt;
        &lt;div style="line-height:1.25"&gt;
        &lt;div style="line-height:1.25"&gt;
        &lt;div style="line-height:1.25"&gt;
        &lt;div style="line-height:1.25"&gt;
        &lt;div style="line-height:1.25"&gt;
        &lt;div style="line-height:1.25"&gt;
        &lt;div style="line-height:1.25"&gt;
        &lt;div style="line-height:1.25"&gt;
        &lt;div style="line-height:1.25"&gt;
        &lt;div style="line-height:1.25"&gt;
        &lt;div style="line-height:1.25"&gt;
        &lt;div&gt;
        &lt;div style="line-height:1.25"&gt;
        &lt;div style="line-height:1.25"&gt;
        &lt;div&gt;
        &lt;div&gt;
        &lt;div&gt;
        &lt;div&gt;
        &lt;div style="line-height:1.25;font-weight:bold"&gt;
        &lt;div style="line-height:1.25;font-weight:bold"&gt;
        &lt;div&gt;
        &lt;div&gt;
        &lt;div style="line-height:1.25;font-weight:bold"&gt;
        &lt;div style="line-height:1.25;font-weight:bold"&gt;
        &lt;div style="line-height:1.25;font-weight:bold"&gt;
        &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;Uncertain
        tax positions&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt; &lt;/div&gt; &lt;/div&gt; &lt;/div&gt; &lt;/div&gt; &lt;/div&gt; &lt;/div&gt; &lt;/div&gt; &lt;/div&gt; &lt;/div&gt; &lt;/div&gt; &lt;/div&gt; &lt;/div&gt; &lt;/div&gt;
        &lt;/div&gt; &lt;/div&gt; &lt;/div&gt; &lt;/div&gt; &lt;/div&gt; &lt;/div&gt; &lt;/div&gt; &lt;/div&gt; &lt;/div&gt; &lt;/div&gt; &lt;/div&gt; &lt;/div&gt; &lt;/div&gt; &lt;/div&gt; &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt;
  &lt;/table&gt; &lt;/div&gt; &lt;/div&gt; &lt;/div&gt; &lt;/div&gt; &lt;/div&gt; &lt;/div&gt; &lt;/div&gt; &lt;/div&gt; &lt;/div&gt; &lt;/div&gt; &lt;/div&gt; &lt;/div&gt; &lt;/div&gt; &lt;/div&gt; &lt;/div&gt; &lt;/div&gt; &lt;/div&gt; &lt;/div&gt;
&lt;/div&gt; &lt;/div&gt; &lt;/div&gt;

&lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt; &lt;/div&gt;

&lt;div style="margin-left:47px;line-height:1.25;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;As
of December 31, 2022&#160;and 2021, the Company does not have a provision for uncertain tax positions.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
&lt;/div&gt; &lt;/div&gt; &lt;/div&gt; &lt;/div&gt; &lt;/div&gt; &lt;/div&gt; </us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="C_20220101to20221231_usgaapIncomeTaxAuthorityAxis_usgaapDomesticCountryMember"
      decimals="2"
      id="Fxbrl_20230330104022412"
      unitRef="Percent">0.23</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="C_20220101to20221231_usgaapIncomeTaxAuthorityAxis_usgaapForeignCountryMember"
      decimals="2"
      id="Fxbrl_20230330104030550"
      unitRef="Percent">0.29</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:OperatingLossCarryforwards
      contextRef="C_20221231"
      decimals="-5"
      id="F20230227081114972_17"
      unitRef="USD">67100000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="C_20211231"
      decimals="-5"
      id="F20230227081114972_18"
      unitRef="USD">56100000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock
      contextRef="C_20220101to20221231"
      id="Fxbrl_20230228130917561">

&lt;div&gt;

&lt;p style="margin:0pt;font-size:10pt"&gt;&#160;&lt;/p&gt;

&lt;div&gt;

&lt;div&gt;

&lt;div style="margin-left:47px"&gt;

&lt;table border="0" cellpadding="0" cellspacing="0" style="color:#000000;float:left;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:left;width:85%"&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align:top;padding-bottom:2px" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);font-weight:bold"&gt;
        &lt;div style="line-height:1.25"&gt;
        &lt;div style="text-align:center;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Year
        ended December 31&lt;/span&gt;&lt;/span&gt;&lt;/div&gt; &lt;/div&gt; &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align:top;padding-bottom:2px" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0)"&gt;
        &lt;div style="line-height:1.25"&gt;
        &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2022&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/div&gt; &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;white-space:nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0)"&gt;
        &lt;div style="line-height:1.25"&gt;
        &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2021&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/div&gt; &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;
        &lt;div style="text-indent:-12.6pt;margin-left:12.6pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Entera
        Bio Ltd.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt; &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;
        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;12,997&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;
        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;12,362&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
        &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align:bottom;width:76%;padding-bottom:2px" valign="bottom"&gt;
        &lt;div style="text-indent:-12.6pt;margin-left:12.6pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Entera
        Bio Inc.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt; &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0)" valign="bottom"&gt;
        &lt;div style="line-height:1.25"&gt;
        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;(65&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/div&gt; &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;white-space:nowrap" valign="bottom"&gt;
        &lt;div style="line-height:1.25"&gt;
        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/div&gt; &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0)" valign="bottom"&gt;
        &lt;div style="line-height:1.25"&gt;
        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;(116&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/div&gt; &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;white-space:nowrap" valign="bottom"&gt;
        &lt;div style="line-height:1.25"&gt;
        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align:bottom;width:76%;padding-bottom:2px;background-color:rgb(204, 238, 255)" valign="bottom"&gt;
        &lt;div style="text-indent:-12.6pt;margin-left:12.6pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Total
        loss before taxes&lt;/span&gt;&lt;/span&gt;&lt;/div&gt; &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom"&gt;
        &lt;div style="line-height:1.25"&gt;
        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;12,934&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/div&gt; &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom"&gt;
        &lt;div style="line-height:1.25"&gt;
        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;12,246&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/div&gt; &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
        &lt;/tr&gt;
  &lt;/table&gt; &lt;/div&gt;

&lt;div style="line-height:1.25;clear:both"&gt;

&lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt; &lt;/div&gt; &lt;/div&gt; &lt;/div&gt; &lt;/div&gt; </us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="C_20220101to20221231_deiLegalEntityAxis_entxEnteraBioLtdMember"
      decimals="-3"
      id="F20230227081114972_19"
      unitRef="USD">-12997000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="C_20210101to20211231_deiLegalEntityAxis_entxEnteraBioLtdMember"
      decimals="-3"
      id="F20230227081114973_20"
      unitRef="USD">-12362000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="C_20220101to20221231_srtConsolidatedEntitiesAxis_srtSubsidiariesMember"
      decimals="-3"
      id="Fxbrl_20220305152625682_20230227081114972_19"
      unitRef="USD">65000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="C_20210101to20211231_srtConsolidatedEntitiesAxis_srtSubsidiariesMember"
      decimals="-3"
      id="Fxbrl_20220305152625682_20230227081114973_20"
      unitRef="USD">116000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="Fxbrl_20220305152701116_xbrl_20220305152625682_20230227081114972_19"
      unitRef="USD">-12934000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="C_20210101to20211231"
      decimals="-3"
      id="Fxbrl_20220305152701116_xbrl_20220305152625682_20230227081114973_20"
      unitRef="USD">-12246000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock
      contextRef="C_20220101to20221231"
      id="F20230227081114976_41">

&lt;table border="0" cellpadding="0" cellspacing="0" style="color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:left;width:85%"&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align:top;padding-bottom:2px" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="vertical-align:bottom;border-bottom:#000000 solid 2px" valign="bottom"&gt;
        &lt;div style="line-height:1.25;font-weight:bold"&gt;
        &lt;div style="text-align:center;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Year
        ended December 31&lt;/span&gt;&lt;/span&gt;&lt;/div&gt; &lt;/div&gt; &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align:top;padding-bottom:2px" valign="bottom"&gt;
        &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0)" valign="bottom"&gt;
        &lt;div style="line-height:1.25;font-weight:bold"&gt;
        &lt;div style="text-align:center;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2022&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/div&gt; &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-weight:bold;white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-weight:bold" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0)" valign="bottom"&gt;
        &lt;div style="line-height:1.25;font-weight:bold"&gt;
        &lt;div style="text-align:center;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2021&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/div&gt; &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td rowspan="1" style="vertical-align:top;background-color:rgb(204, 238, 255);height:15px" valign="bottom"&gt;
        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Current:&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/td&gt;
    &lt;td colspan="1" rowspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);height:15px" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" rowspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);height:15px" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" rowspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);white-space:nowrap;height:15px" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" rowspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);height:15px" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" rowspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);height:15px" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" rowspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);white-space:nowrap;height:15px" valign="bottom"&gt;&#160;&lt;/td&gt;
        &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align:bottom;width:76%;padding-bottom:2px;height:15px" valign="bottom"&gt;
        &lt;div style="text-indent:-12.6pt;margin-left:12.6pt;line-height:1.25;margin-top:0px;margin-bottom:0px"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Subsidiary:&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;height:15px" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);height:15px" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);height:15px" valign="bottom"&gt;
        &lt;div style="line-height:1.25"&gt;
        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;(37&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/div&gt; &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:1pt;white-space:nowrap;height:15px" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;height:15px" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);height:15px" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);height:15px" valign="bottom"&gt;
        &lt;div style="line-height:1.25"&gt;
        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;158&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/div&gt; &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;white-space:nowrap;height:15px" valign="bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align:bottom;width:76%;padding-bottom:2px;background-color:rgb(204, 238, 255);height:15px" valign="bottom"&gt;
        &lt;div style="text-indent:-12.6pt;margin-left:12.6pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Total
        current income tax&lt;/span&gt;&lt;/span&gt;&lt;/div&gt; &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);height:15px" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);height:15px" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);height:15px" valign="bottom"&gt;
        &lt;div style="line-height:1.25"&gt;
        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;(37&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/div&gt; &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:1pt;background-color:rgb(204, 238, 255);white-space:nowrap;height:15px" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);height:15px" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);height:15px" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);height:15px" valign="bottom"&gt;
        &lt;div style="line-height:1.25"&gt;
        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;158&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/div&gt; &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);white-space:nowrap;height:15px" valign="bottom"&gt;&#160;&lt;/td&gt;
        &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align:bottom;width:76%;height:15px" valign="bottom"&gt;
        &lt;div style="text-indent:-12.6pt;margin-left:12.6pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Deferred
        income&#160;taxes&lt;/span&gt;&lt;/span&gt;&lt;/div&gt; &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;height:15px" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;height:15px" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;height:15px" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;174&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap;height:15px" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;height:15px" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;height:15px" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;height:15px" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;(217&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap;height:15px" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
        &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255);padding-bottom:2px;height:15px" valign="bottom"&gt;
        &lt;div style="text-indent:-12.6pt;margin-left:12.6pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Total
        deferred income taxes&lt;/span&gt;&lt;/span&gt;&lt;/div&gt; &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);padding-bottom:2px;height:15px" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);border-bottom:2px solid rgb(0, 0, 0);height:15px" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);border-bottom:2px solid rgb(0, 0, 0);height:15px" valign="bottom"&gt;
        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;174&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);padding-bottom:2px;white-space:nowrap;height:15px" valign="bottom"&gt;
        &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);padding-bottom:2px;height:15px" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);border-bottom:2px solid rgb(0, 0, 0);height:15px" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);border-bottom:2px solid rgb(0, 0, 0);height:15px" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;(217&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);padding-bottom:1pt;white-space:nowrap;height:15px" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
        &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align:baseline;width:76%;padding-bottom:4px;height:15px"&gt;
        &lt;div style="text-indent:-12.6pt;margin-left:12.6pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Total
        income tax expense (benefit)&#160;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt; &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:baseline;width:1%;padding-bottom:4px;height:15px"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:baseline;width:1%;border-bottom:4px double rgb(0, 0, 0);height:15px"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:baseline;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);height:15px"&gt;
        &lt;div style="line-height:1.25"&gt;
        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;137&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/div&gt; &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:baseline;width:1%;padding-bottom:4px;white-space:nowrap;height:15px"&gt;
        &lt;div style="line-height:1.25"&gt;
        &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt; &lt;/div&gt; &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:baseline;width:1%;padding-bottom:4px;height:15px"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:baseline;width:1%;border-bottom:4px double rgb(0, 0, 0);height:15px"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:baseline;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);height:15px"&gt;
        &lt;div style="line-height:1.25"&gt;
        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;(59&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/div&gt; &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:baseline;width:1%;padding-bottom:1pt;white-space:nowrap;height:15px"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
        &lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="margin:0pt"&gt;&#160;&lt;/p&gt; </us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="C_20220101to20221231_srtConsolidatedEntitiesAxis_srtSubsidiariesMember"
      decimals="-3"
      id="Fxbrl_20230228134937123"
      unitRef="USD">-37000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="C_20210101to20211231_srtConsolidatedEntitiesAxis_srtSubsidiariesMember"
      decimals="-3"
      id="F20230227081114975_26"
      unitRef="USD">158000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="Fxbrl_20230228134908782"
      unitRef="USD">-37000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="C_20210101to20211231"
      decimals="-3"
      id="Fxbrl_20220305155620306_20230227081114975_26"
      unitRef="USD">158000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalStateAndLocalTaxExpenseBenefit
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="Fxbrl_20230228142546107_xbrl_20220305155912894_xbrl_20220305155728354_xbrl_20220305155620306_20230227081114975_25"
      unitRef="USD">174000</us-gaap:DeferredFederalStateAndLocalTaxExpenseBenefit>
    <us-gaap:DeferredFederalStateAndLocalTaxExpenseBenefit
      contextRef="C_20210101to20211231"
      decimals="-3"
      id="Fxbrl_20230228142546107_xbrl_20220305155912894_xbrl_20220305155728354_xbrl_20220305155620306_20230227081114975_26"
      unitRef="USD">-217000</us-gaap:DeferredFederalStateAndLocalTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="Fxbrl_20230228142548077_xbrl_20220305155912894_xbrl_20220305155728354_xbrl_20220305155620306_20230227081114975_25"
      unitRef="USD">174000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="C_20210101to20211231"
      decimals="-3"
      id="Fxbrl_20230228142548077_xbrl_20220305155912894_xbrl_20220305155728354_xbrl_20220305155620306_20230227081114975_26"
      unitRef="USD">-217000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="Fxbrl_20230228143853981_xbrl_20230228142548077_xbrl_20220305155912894_xbrl_20220305155728354_xbrl_20220305155620306_20230227081114975_25"
      unitRef="USD">137000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_20210101to20211231"
      decimals="-3"
      id="Fxbrl_20230228143853981_xbrl_20230228142548077_xbrl_20220305155912894_xbrl_20220305155728354_xbrl_20220305155620306_20230227081114975_26"
      unitRef="USD">-59000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock
      contextRef="C_20220101to20221231"
      id="F20230227081114972_15">

&lt;div style="margin-left:47px"&gt;

&lt;div&gt;

&lt;div&gt;

&lt;div&gt;

&lt;table border="0" cellpadding="0" cellspacing="0" style="color:#000000;float:left;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:left;width:85%"&gt;
  &lt;tr&gt;
    &lt;td rowspan="1" style="vertical-align:bottom;padding-bottom:2px" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" rowspan="1" style="vertical-align:bottom;padding-bottom:2px" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" rowspan="1" style="vertical-align:bottom;border-bottom:#000000 solid 2px" valign="bottom"&gt;
        &lt;div style="text-align:center;line-height:1.25;font-weight:bold;text-indent:1pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;December
        31,&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt; &lt;/td&gt;
    &lt;td colspan="1" rowspan="1" style="vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td rowspan="1" style="vertical-align:bottom;padding-bottom:2px" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" rowspan="1" style="vertical-align:bottom;padding-bottom:2px" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" rowspan="1" style="vertical-align:bottom;border-bottom:#000000 solid 2px" valign="bottom"&gt;
        &lt;div style="text-align:center;line-height:1.25;font-weight:bold;text-indent:4pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;2022&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/td&gt;
    &lt;td colspan="1" rowspan="1" style="vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" rowspan="1" style="text-align:center;font-weight:bold;vertical-align:bottom;padding-bottom:2px" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" rowspan="1" style="vertical-align:bottom;text-align:center;font-weight:bold;border-bottom:#000000 solid 2px" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;2021&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="1" rowspan="1" style="font-weight:bold;vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
        &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td rowspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255)" valign="bottom"&gt;
        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;Deferred
        tax assets:&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt; &lt;/td&gt;
    &lt;td colspan="1" rowspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" rowspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" rowspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" rowspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" rowspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" rowspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
        &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align:bottom;width:76%" valign="bottom"&gt;
        &lt;div style="text-indent:-35.1pt;margin-left:35.1pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;Net
        operating loss carry forward&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt; &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%" valign="bottom"&gt;
        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;15,428&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%" valign="bottom"&gt;
        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;12,895&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:76%" valign="bottom"&gt;
        &lt;div style="text-indent:-35.1pt;margin-left:35.1pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;Research
        and development&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt; &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:9%" valign="bottom"&gt;
        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;1,225&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/td&gt;
    &lt;td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:9%" valign="bottom"&gt;
        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;1,319&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/td&gt;
    &lt;td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
        &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align:bottom;width:76%" valign="bottom"&gt;
        &lt;div style="text-indent:-35.1pt;margin-left:35.1pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;Share-based
        compensation&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt; &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%" valign="bottom"&gt;
        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;877&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%" valign="bottom"&gt;
        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;876&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:76%" valign="bottom"&gt;
        &lt;div style="text-indent:-35.1pt;margin-left:35.1pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;Other&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:9%" valign="bottom"&gt;
        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;158&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/td&gt;
    &lt;td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:9%" valign="bottom"&gt;
        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;152&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/td&gt;
    &lt;td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
        &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align:bottom;width:76%;padding-bottom:2px" valign="bottom"&gt;
        &lt;div style="text-indent:-35.1pt;margin-left:35.1pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;Net
        deferred tax assets before valuation allowance&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt; &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0)" valign="bottom"&gt;
        &lt;div style="line-height:1.25"&gt;
        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;17,688&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/div&gt; &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0)" valign="bottom"&gt;
        &lt;div style="line-height:1.25"&gt;
        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;15,242&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/div&gt; &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:76%;padding-bottom:2px" valign="bottom"&gt;
        &lt;div style="text-indent:-35.1pt;margin-left:35.1pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;Valuation
        allowance&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt; &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0)" valign="bottom"&gt;
        &lt;div style="line-height:1.25"&gt;
        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;(17,645&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/div&gt; &lt;/td&gt;
    &lt;td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;padding-bottom:2px;white-space:nowrap" valign="bottom"&gt;
        &lt;div style="line-height:1.25"&gt;
        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/div&gt; &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0)" valign="bottom"&gt;
        &lt;div style="line-height:1.25"&gt;
        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;(15,025&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/div&gt; &lt;/td&gt;
    &lt;td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;padding-bottom:2px;white-space:nowrap" valign="bottom"&gt;
        &lt;div style="line-height:1.25"&gt;
        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align:bottom;width:76%;padding-bottom:4px" valign="bottom"&gt;
        &lt;div style="text-indent:-35.1pt;margin-left:35.1pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;Net
        deferred tax assets&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt; &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0)" valign="bottom"&gt;
        &lt;div style="line-height:1.25"&gt;
        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;43&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/div&gt; &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0)" valign="bottom"&gt;
        &lt;div style="line-height:1.25"&gt;
        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;217&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/div&gt; &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;/table&gt; &lt;/div&gt;

&lt;div style="line-height:1.25;clear:both"&gt;&#160;&lt;/div&gt; &lt;/div&gt; &lt;/div&gt; &lt;/div&gt; </us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="C_20221231"
      decimals="-3"
      id="F20230227081114970_2"
      unitRef="USD">15428000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="C_20211231"
      decimals="-3"
      id="F20230227081114970_3"
      unitRef="USD">12895000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment
      contextRef="C_20221231"
      decimals="-3"
      id="F20230227081114970_4"
      unitRef="USD">1225000</us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment>
    <us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment
      contextRef="C_20211231"
      decimals="-3"
      id="F20230227081114970_5"
      unitRef="USD">1319000</us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="C_20221231"
      decimals="-3"
      id="Fxbrl_20220305162048791_20230227081114970_6"
      unitRef="USD">877000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="C_20211231"
      decimals="-3"
      id="Fxbrl_20220305162048791_20230227081114971_7"
      unitRef="USD">876000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="C_20221231"
      decimals="-3"
      id="F20230227081114970_6"
      unitRef="USD">158000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="C_20211231"
      decimals="-3"
      id="F20230227081114971_7"
      unitRef="USD">152000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="C_20221231"
      decimals="-3"
      id="Fxbrl_20220305162112863_20230227081114970_6"
      unitRef="USD">17688000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="C_20211231"
      decimals="-3"
      id="Fxbrl_20220305162112863_20230227081114971_7"
      unitRef="USD">15242000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="C_20221231"
      decimals="-3"
      id="Fxbrl_20220305162203888_xbrl_20220305162112863_20230227081114970_6"
      unitRef="USD">17645000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="C_20211231"
      decimals="-3"
      id="Fxbrl_20220305162203888_xbrl_20220305162112863_20230227081114971_7"
      unitRef="USD">15025000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="C_20221231"
      decimals="-3"
      id="F20230227081114971_8"
      unitRef="USD">43000</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="C_20211231"
      decimals="-3"
      id="F20230227081114975_39"
      unitRef="USD">217000</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:SummaryOfValuationAllowanceTextBlock
      contextRef="C_20220101to20221231"
      id="F20230227081114972_16">

&lt;div style="margin-left:36pt"&gt;

&lt;table border="0" cellpadding="0" cellspacing="0" style="color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:left;width:85%"&gt;
  &lt;tr style="background-color:rgb(204, 238, 255)"&gt;
    &lt;td style="vertical-align:top;background-color:rgb(204, 238, 255);width:89%" valign="bottom"&gt;
        &lt;div style="line-height:1.25"&gt; &lt;div style="font-size:10pt;display:inline"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span style="line-height:107%"&gt;Balance
        at January 1, 2021&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt; &lt;/div&gt; &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;border-bottom:2px solid black;background-color:rgb(204, 238, 255);width:1%" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align:bottom;border-bottom:2px solid black;background-color:rgb(204, 238, 255);width:9%" valign="bottom"&gt;
        &lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:right"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span style="line-height:107%"&gt;12,420&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;white-space:nowrap;background-color:rgb(204, 238, 255);width:1%" valign="bottom"&gt;&#160;&lt;/td&gt;
        &lt;/tr&gt;
  &lt;tr style="background-color:rgb(255, 255, 255)"&gt;
    &lt;td style="vertical-align:top;background-color:rgb(255, 255, 255)" valign="bottom"&gt;
        &lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span style="line-height:107%"&gt;Additions&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;border-bottom:4px double black;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align:bottom;border-bottom:4px double black;background-color:rgb(255, 255, 255);width:9%" valign="bottom"&gt;
        &lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:right"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span style="line-height:107%"&gt;2,605&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;white-space:nowrap;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color:rgb(204, 238, 255)"&gt;
    &lt;td style="vertical-align:top;background-color:rgb(204, 238, 255)" valign="bottom"&gt;
        &lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span style="line-height:107%"&gt;Balance
        at January 1, 2022&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;border-bottom:4px double black;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align:bottom;border-bottom:4px double black;background-color:rgb(204, 238, 255);width:9%" valign="bottom"&gt;
        &lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:right"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span style="line-height:107%"&gt;15,025&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;white-space:nowrap;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color:rgb(255, 255, 255)"&gt;
    &lt;td style="vertical-align:top;background-color:rgb(255, 255, 255)" valign="bottom"&gt;
        &lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span style="line-height:107%"&gt;Additions&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;border-bottom:4px double black;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align:bottom;border-bottom:4px double black;background-color:rgb(255, 255, 255);width:9%" valign="bottom"&gt;
        &lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:right"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span style="line-height:107%"&gt;2,620&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;white-space:nowrap;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color:rgb(204, 238, 255)"&gt;
    &lt;td style="vertical-align:top;background-color:rgb(204, 238, 255)" valign="bottom"&gt;
        &lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span style="line-height:107%"&gt;Balance
        at December 31, 2022&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;border-bottom:4px double black;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align:bottom;border-bottom:4px double black;background-color:rgb(204, 238, 255);width:9%" valign="bottom"&gt;
        &lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:right"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span style="line-height:107%"&gt;17,645&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
        &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;white-space:nowrap;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="margin:0pt"&gt;&#160;&lt;/p&gt; &lt;/div&gt; </us-gaap:SummaryOfValuationAllowanceTextBlock>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="C_20201231"
      decimals="-3"
      id="F20230227081114971_9"
      unitRef="USD">12420000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="C_20210101to20211231"
      decimals="-3"
      id="F20230227081114971_12"
      unitRef="USD">2605000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="C_20211231"
      decimals="-3"
      id="F20230227081114971_10"
      unitRef="USD">15025000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="F20230227081114971_13"
      unitRef="USD">2620000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="C_20221231"
      decimals="-3"
      id="F20230227081114971_11"
      unitRef="USD">17645000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <entx:SupplementaryFinancialStatementInformationTextBlock
      contextRef="C_20220101to20221231"
      id="Fxbrl_20230330094603682">

&lt;div&gt;

&lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;NOTE
8 - SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION:&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;

&lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;

&lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Balance
sheets:&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;

&lt;div&gt;

&lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left;color:#000000;width:100%"&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align:top;padding-bottom:2px" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="vertical-align:top;border-bottom:#000000 solid 2px" valign="bottom"&gt;
        &lt;div style="line-height:1.25"&gt;
        &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;December
        31,&lt;/span&gt;&lt;/span&gt;&lt;/div&gt; &lt;/div&gt; &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align:bottom;padding-bottom:2px" valign="bottom"&gt;
        &lt;div style="line-height:1.25;font-weight:bold"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align:top;border-bottom:2px solid rgb(0, 0, 0)" valign="bottom"&gt;
        &lt;div style="line-height:1.25"&gt;
        &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2022&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/div&gt; &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align:top;border-bottom:2px solid rgb(0, 0, 0)" valign="bottom"&gt;
        &lt;div style="line-height:1.25"&gt;
        &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2021&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/div&gt; &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td rowspan="1" style="vertical-align:top;width:76%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;
        &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Accrued
        expenses and other payables:&lt;/span&gt;&lt;/span&gt;&lt;/div&gt; &lt;/td&gt;
    &lt;td colspan="1" rowspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" rowspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" rowspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" rowspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" rowspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" rowspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" rowspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" rowspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
        &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align:top;width:76%" valign="bottom"&gt;
        &lt;div style="text-align:justify;text-indent:14.2pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Employees
        and employees related&lt;/span&gt;&lt;/span&gt;&lt;/div&gt; &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%" valign="bottom"&gt;
        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;154&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%" valign="bottom"&gt;
        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;147&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align:top;width:76%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;
        &lt;div style="text-align:justify;text-indent:14.2pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Income
        tax&lt;/span&gt;&lt;/span&gt;&lt;/div&gt; &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;
        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;
        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;134&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
        &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align:top;width:76%" valign="bottom"&gt;
        &lt;div style="text-align:justify;text-indent:14.2pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Provision
        for vacation&lt;/span&gt;&lt;/span&gt;&lt;/div&gt; &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%" valign="bottom"&gt;
        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;146&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%" valign="bottom"&gt;
        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;308&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align:top;width:76%;padding-bottom:2px;background-color:rgb(204, 238, 255)" valign="bottom"&gt;
        &lt;div style="text-align:justify;line-height:1.25;margin-left:14.2pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Accrued
        expenses&lt;/span&gt;&lt;/span&gt;&lt;/div&gt; &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom"&gt;
        &lt;div style="line-height:1.25"&gt;
        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;933&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/div&gt; &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom"&gt;
        &lt;div style="line-height:1.25"&gt;
        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2,212&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/div&gt; &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
        &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align:top;width:76%;padding-bottom:2px" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0)" valign="bottom"&gt;
        &lt;div style="line-height:1.25"&gt;
        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;1,233&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/div&gt; &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0)" valign="bottom"&gt;
        &lt;div style="line-height:1.25"&gt;
        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2,801&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/div&gt; &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;/table&gt; &lt;/div&gt;  &lt;/div&gt; </entx:SupplementaryFinancialStatementInformationTextBlock>
    <us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock
      contextRef="C_20220101to20221231"
      id="Fxbrl_20220808200946504">

&lt;div&gt;

&lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left;color:#000000;width:100%"&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align:top;padding-bottom:2px" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="vertical-align:top;border-bottom:#000000 solid 2px" valign="bottom"&gt;
        &lt;div style="line-height:1.25"&gt;
        &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;December
        31,&lt;/span&gt;&lt;/span&gt;&lt;/div&gt; &lt;/div&gt; &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align:bottom;padding-bottom:2px" valign="bottom"&gt;
        &lt;div style="line-height:1.25;font-weight:bold"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align:top;border-bottom:2px solid rgb(0, 0, 0)" valign="bottom"&gt;
        &lt;div style="line-height:1.25"&gt;
        &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2022&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/div&gt; &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align:top;border-bottom:2px solid rgb(0, 0, 0)" valign="bottom"&gt;
        &lt;div style="line-height:1.25"&gt;
        &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2021&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/div&gt; &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td rowspan="1" style="vertical-align:top;width:76%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;
        &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Accrued
        expenses and other payables:&lt;/span&gt;&lt;/span&gt;&lt;/div&gt; &lt;/td&gt;
    &lt;td colspan="1" rowspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" rowspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" rowspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" rowspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" rowspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" rowspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" rowspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" rowspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
        &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align:top;width:76%" valign="bottom"&gt;
        &lt;div style="text-align:justify;text-indent:14.2pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Employees
        and employees related&lt;/span&gt;&lt;/span&gt;&lt;/div&gt; &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%" valign="bottom"&gt;
        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;154&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%" valign="bottom"&gt;
        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;147&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align:top;width:76%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;
        &lt;div style="text-align:justify;text-indent:14.2pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Income
        tax&lt;/span&gt;&lt;/span&gt;&lt;/div&gt; &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;
        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;
        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;134&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
        &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align:top;width:76%" valign="bottom"&gt;
        &lt;div style="text-align:justify;text-indent:14.2pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Provision
        for vacation&lt;/span&gt;&lt;/span&gt;&lt;/div&gt; &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%" valign="bottom"&gt;
        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;146&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%" valign="bottom"&gt;
        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;308&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align:top;width:76%;padding-bottom:2px;background-color:rgb(204, 238, 255)" valign="bottom"&gt;
        &lt;div style="text-align:justify;line-height:1.25;margin-left:14.2pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Accrued
        expenses&lt;/span&gt;&lt;/span&gt;&lt;/div&gt; &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom"&gt;
        &lt;div style="line-height:1.25"&gt;
        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;933&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/div&gt; &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom"&gt;
        &lt;div style="line-height:1.25"&gt;
        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2,212&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/div&gt; &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
        &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align:top;width:76%;padding-bottom:2px" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0)" valign="bottom"&gt;
        &lt;div style="line-height:1.25"&gt;
        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;1,233&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/div&gt; &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0)" valign="bottom"&gt;
        &lt;div style="line-height:1.25"&gt;
        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2,801&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/div&gt; &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;/table&gt; &lt;/div&gt; </us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock>
    <us-gaap:AccruedEmployeeBenefitsCurrent
      contextRef="C_20221231"
      decimals="-3"
      id="Fxbrl_20220808200953075_xbrl_20220510112546992"
      unitRef="USD">154000</us-gaap:AccruedEmployeeBenefitsCurrent>
    <us-gaap:AccruedEmployeeBenefitsCurrent
      contextRef="C_20211231"
      decimals="-3"
      id="Fxbrl_20220808200953075_xbrl_20220510112707928"
      unitRef="USD">147000</us-gaap:AccruedEmployeeBenefitsCurrent>
    <us-gaap:AccruedIncomeTaxesCurrent
      contextRef="C_20221231"
      decimals="-3"
      id="Fxbrl_20220808200953077_xbrl_20220510112605192"
      unitRef="USD">0</us-gaap:AccruedIncomeTaxesCurrent>
    <us-gaap:AccruedIncomeTaxesCurrent
      contextRef="C_20211231"
      decimals="-3"
      id="Fxbrl_20220808200953077_xbrl_20220510112721383"
      unitRef="USD">134000</us-gaap:AccruedIncomeTaxesCurrent>
    <us-gaap:AccruedVacationCurrent
      contextRef="C_20221231"
      decimals="-3"
      id="Fxbrl_20220808200953079_xbrl_20220510112621448"
      unitRef="USD">146000</us-gaap:AccruedVacationCurrent>
    <us-gaap:AccruedVacationCurrent
      contextRef="C_20211231"
      decimals="-3"
      id="Fxbrl_20220808200953079_xbrl_20220510112732615"
      unitRef="USD">308000</us-gaap:AccruedVacationCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="C_20221231"
      decimals="-3"
      id="Fxbrl_20220808200953081_xbrl_20220510112644305"
      unitRef="USD">933000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="C_20211231"
      decimals="-3"
      id="Fxbrl_20220808200953081_xbrl_20220510112742136"
      unitRef="USD">2212000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesAndOtherLiabilities
      contextRef="C_20221231"
      decimals="-3"
      id="Fxbrl_20220808200953083_xbrl_20220510112657784"
      unitRef="USD">1233000</us-gaap:AccruedLiabilitiesAndOtherLiabilities>
    <us-gaap:AccruedLiabilitiesAndOtherLiabilities
      contextRef="C_20211231"
      decimals="-3"
      id="Fxbrl_20220808200953083_xbrl_20220510112751072"
      unitRef="USD">2801000</us-gaap:AccruedLiabilitiesAndOtherLiabilities>
    <us-gaap:SubsequentEventsTextBlock
      contextRef="C_20220101to20221231"
      id="Fxbrl_20230228133032277">

&lt;div&gt;

&lt;div&gt;

&lt;div&gt;

&lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;NOTE
9 - SUBSEQUENT EVENT&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;

&lt;div style="line-height:1.25;font-weight:bold"&gt;&#160;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"&gt;
  &lt;tr&gt;
    &lt;td style="width:35.45pt;vertical-align:top;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;a.&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width:auto;vertical-align:top;text-align:justify"&gt;
        &lt;div&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;On January 2, 2023, 534,246
        options to purchase ordinary shares were granted to six non-executive board members with an exercise price of&#x2009;$0.73
        per share. The options will vest over one
        year in four equal quarterly installments starting on January 1, 2023. This grant was approved by the shareholders of
        the Company on October 4, 2021.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt;
  &lt;/table&gt; &lt;/div&gt; &lt;/div&gt; &lt;/div&gt; </us-gaap:SubsequentEventsTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="C_20230101to20230102_srtTitleOfIndividualAxis_entxNonExecutiveBoardMember_usgaapSubsequentEventTypeAxis_usgaapSubsequentEventMember"
      decimals="INF"
      id="Fxbrl_20230228135953818"
      unitRef="shares">534246</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="C_20230101to20230102_srtTitleOfIndividualAxis_entxNonExecutiveBoardMember_usgaapSubsequentEventTypeAxis_usgaapSubsequentEventMember"
      decimals="INF"
      id="Fxbrl_20230228140034596"
      unitRef="shares">0.73</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="C_20230101to20230102_srtTitleOfIndividualAxis_entxNonExecutiveBoardMember_usgaapSubsequentEventTypeAxis_usgaapSubsequentEventMember"
      id="Fxbrl_20230330124225419">P1Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <link:footnoteLink
      xlink:role="http://www.xbrl.org/2003/role/link"
      xlink:type="extended">
        <link:loc
          xlink:href="#Fxbrl_20220808213249447"
          xlink:label="Fxbrl_20220808213249447"
          xlink:type="locator"/>
        <link:footnote id="FN20220808221358290" xlink:label="FN20220808221358290" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Represents an amount less than one thousand US dollars.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fxbrl_20220808213249447"
          xlink:to="FN20220808221358290"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fxbrl_20220808214617486"
          xlink:label="Fxbrl_20220808214617486"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fxbrl_20220808214617486"
          xlink:to="FN20220808221358290"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fxbrl_20220808213010825_xbrl_20220802040425347_20220801223211777_38"
          xlink:label="Fxbrl_20220808213010825_xbrl_20220802040425347_20220801223211777_38"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fxbrl_20220808213010825_xbrl_20220802040425347_20220801223211777_38"
          xlink:to="FN20220808221358290"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fxbrl_20220808214821452"
          xlink:label="Fxbrl_20220808214821452"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fxbrl_20220808214821452"
          xlink:to="FN20220808221358290"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fxbrl_20220808214839417"
          xlink:label="Fxbrl_20220808214839417"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fxbrl_20220808214839417"
          xlink:to="FN20220808221358290"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fxbrl_20220808214942722"
          xlink:label="Fxbrl_20220808214942722"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fxbrl_20220808214942722"
          xlink:to="FN20220808221358290"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fxbrl_20220808220722541"
          xlink:label="Fxbrl_20220808220722541"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fxbrl_20220808220722541"
          xlink:to="FN20220808221358290"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fxbrl_20220808220938448"
          xlink:label="Fxbrl_20220808220938448"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fxbrl_20220808220938448"
          xlink:to="FN20220808221358290"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fxbrl_20220808221051935"
          xlink:label="Fxbrl_20220808221051935"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fxbrl_20220808221051935"
          xlink:to="FN20220808221358290"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fxbrl_20230227104430880"
          xlink:label="Fxbrl_20230227104430880"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fxbrl_20230227104430880"
          xlink:to="FN20220808221358290"
          xlink:type="arc"/>
    </link:footnoteLink>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>75
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M:[VA>T#ISI94IW!19UAO8?,#8_.#5C;_#YHD_:^9BI.JQ1&A+%J$KH7(&\8
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MJ:$E7['85W?BZ8IG#C43>POA1^E?])3).C6TB",E@DP9$ 1>N/O/GK.)V%/
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ML/'%"\^F-T+Q)BV:E"=YLBF,#F -7#G-&43<BNV "V;$5C+*,HD>K$:,1)_
M=J>,4A=J-3L5, M2PW96V\&T0*.&>,*D70:GBY%FMU.U"0HNP^Y1!<;UN'\Y
MOA[/QR-SML-63OS>=/=>U@Z=+B@2VSDR9_ ->ZFB;ZR3']86Q2#3JMK8!4-B
M.T4".AE#YN#/T#)%/$KSLDAI/<-K3B0FRJ1:*C%09L?!%9@+RL16ANH-LGH#
MVIM8>LH#U)!-Q&'.-J)NZPD:ES'K,KA=E:$+UL-VVAN(4$EHYI#OL0?/3T$;
M$>ID5F80@PAN5N K^ [;">^P4MJ+3R-(G<0P=;6)U*4H;E4L/BFXCCA'%TQO
MY1%BI<WO;E?>R=JAXP6#$CN#EFN2-W82T6FPO),,(A#$%0NTUT3:J?(ZP_6"
M5D+^",<3G1HI*4/793"MH$]2T"<YACXK=I@1JDZ4.E0#F5:&04&EQ-X7[J"^
M!<_0\M%V.4L;I*A+*OI64O >L?/>8'IS,Y[?P"S.4'\R1(/I9#Z>_#Z:#*K0
M6NV9XPL9 _7G#1WZ7+ I:5F3T^RJ?S>ZFEX/1W>S7]#HC_OQ_&]S9K*R\G=G
MIG>R=NAUP<?$SL=3N?1")E_0;,W ?AU-QC/DG#KPTVYUH8Z0:,O\F)^A?JS6
M0GK_0<%Q GU40MM#ON#! Y0;K]_!T@JD_!3^8M>I.QA^'0=%Z4"?D1=%2?&2
MUBRQBA1<) FRPG+=;!J13KWC=.O=;.STUJV[&&?CU%^;%F_+_1?# ER^,4'_
MX'^-F^ '&G'SAO]Y0X=+7]0UQ%[7])=++_E0S7Q89F]Y @W>@FT\Q7RCPX;2
MQ6D3K!&32<[M-IV*G%24.<1>YD"U&P>QSQ1_+7*A7X8Y62=?[+<\ZY^-T/5J
M1JMX[#*'GRF+>H?:>_M]R$N^\A:>D32IWK6?=)MNM]Q%F.0ZQ"45C00MRA-J
M+T]VA&1*@$:XAM(#MYOE;X(&,4*:K8IREQ8U"CVFG=]CSY2A]L%_^M AN/W9
MY@+1OPH;>FF#F*67IDFM<OBD* FHO22 +'/'TP!/NDT6(A8DC2>4BU&$U!H>
MB)##Q>ZX MW/T%+X/I/1J2D5-/8.3P(N']-#J BEO>SN,WO^-#_HNDS/@\K/
M*3T;4&I\X\*;W8%-,<3N9.V&R4<OC #\"H9S3MO Z7)W6+6[46*3'M\\"*5$
MD%ZN.5MRF0C ^Y40ZO4F&2 _,NS]#U!+ P04    " !$@']6%1C0,IP"   P
M!P  &    'AL+W=O<FMS:&5E=',O<VAE970S+GAM;*U574_;,!3]*U:0T"9!
M\]E0((U4VB*0&*THVQZF/;C);6/AQ)GMM,"OG^V$J-W"5*3E(?&U[SD^Q[&O
MHRWC3R(#D.@YIX486IF4Y85MBR2#'(L>*Z%0(RO&<RQ5R->V*#G@U(!R:GN.
M$]HY)H451Z9OSN.(59*2 N8<B2K/,7^Y LJV0\NUWCH>R#J3NL..HQ*O80'R
M:SGG*K);EI3D4 C""L1A-;1&[L4XU/DFX1N!K=AI(^UDR=B3#F[3H>5H04 A
MD9H!J\\&QD"I)E(R?C6<5CNE!NZVW]BOC7?E98D%C!G]3E*9#:V!A5)8X8K*
M![:]@<9/7_,EC KS1MLZMZ^2DTI(EC=@I2 G1?W%S\TZ[ #<X!V UP"\0P%^
M _"-T5J9L37!$L<19UO$=;9BTPVS-@:MW)!"_\6%Y&J4*)R,Q[/[Q>SN=C)Z
MG$[0U>AN=#^>HL7-=/JX0)_FF$,A,Y DP51\1J?H^&C@A]XELI'(U*"(;*E$
M:"H[:2:\JB?TWIEP DD/^>X)\AS/ZX"/#X>[^W!;66_]>ZU_S_#Y[_ M)):@
M=J5$;(6N28&+A&"*YDP0L\U^C)9"<K79?G99K;F#;FY] "]$B1,86NJ$"> ;
ML.+C(S=T+KN,_R>RO67PVV7P_\4>SWBJO/.7^K>>H!)SM,&T@B[7-=7 4.DJ
ML8G/>N$YG#K]R-[L.CH@<4]MT*H-/J!6G"!<R8QQ\@IIE]Z:+-R1X0:.XSKJ
M^4/P(9E[BONMXO['%!,AJFZU_;\T>(.!<WZN3\N>V.[$('#=;JUAJS7\F%95
M_(7$A>I==PD.#Q7<G=@AV-ZI9_HN^8+YFA0"45@IJ-,[4]9Y79_K0++2E+@E
MDZI@FF:FKC3@.D&-KQB3;X&NFNTE&?\&4$L#!!0    ( $2 ?U9/HIXOE 0
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MNN7B@22'O.%\2PAM7_/;/?:W.&4&]/LN2<CY@0U0_<]B\C]02P,$%     @
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M9]:<=F&ROB>[PVJ[FXRNB[-23S3+:%1<K@CV29(#V._/E&9O-WD#^R.#XW\
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MR8>8[_3EY1./8Q[JQRVC'A/* 'Y?<QZ_?U OR.Z_^_\!4$L#!!0    ( $2
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MOV$T9Z5J"7?2'3-H78 ]S;%F'+H'*9",)!CYL^!%&1HVH18TG#S7Q AP:FI
M$#CT46:+?RH?PA^<7W^C>//L^.2I/OQJ-U6AGTZ?'4FPQ.(YN636J +&1!3$
M08QO/*3?*\%1/DRRS@NJV;$0K/6B\92Z(9D,;A_>Z%NLOY(&5BXI'^;0BY)T
M8ZQ(/F:[T8$4(ZKL>!<5,G.L2,7$1DK8#\U/*!RE3'E=L ,1J0VG2S0CJ2V^
M[U007VD/:0SK1U(+NZAS3+PNX!LHHLM4X*N"!JPM,)U0(;\<CWX9JJ2Y;GHV
M1"EPAH+HA)Z'FM4:#G$$:4,LC0Z$Q<+;0S$MF!6($NJ789RGACU-J'"1DXPH
M,RZ8+(+8,.H]))6 9-0XC8[1W1*@I22:*?0G$W=)R*%MXDFE14<'?^-[ N)2
MN3BP#4\IVY'PY?L*+J53Q.-W,S],6U1.R! XJTMK!'>R0L-ZJ)60.]MP-5^"
M*&F8]\=Z%P<>B85LDJLC;%]B[8+FO%;'^321/'+N]>Z>M#D/^MJR_=SINXJ2
M+:"*&X[+1DKFOIP-V@95';FN>!QQ7V088)-Z&=)7T7^8UB*[*O+>F7$,"*+Q
M6 :IXB:_D]0OK!*#@)RR)'YA'HBI*.GH2,SLE&T$L)8*0H:%O.@I&GN?F*F&
M\W@$\D*J(B4A>RMP(=2)AA&9?D],.Z#YP@Q%,.[6<5*IKYK&WHB>G_=0(\[>
MTS+TU=7Y@.BX[!!QU>W*"+WB!" E:NMHV8N(GP2]*:E=U'I<%O6'+%M2 )_P
M#-+U:>;0=?)0$+F3U"N[+B]6)N8G0H&WZ_T;J6$L[S W.D@FT^>)NO 8%QCF
M 1,J#<+U.P(<J=B]B0<L#9:I!N%"RL:;<P),E-'13E2R/(3#E?7A9%I_>GK?
M^09#3QIKA TC9">%)'<P=$ $OG[Y:[[>O'@3UYDH I.9LJ13W+51_G0C%+D7
MX\O0X!GH/5\OH0?GR]9(VB&].?93%E'[4C\Y>3+1!U]"8X@G7MJ&+R_X9.Z2
MKXT@N8]I4FQX4^>5G3P6]*+>WA&\$3+8#=*XU!B(3H-\1L0I$*>_I"SMH8P<
M6&MQ5AR>%M"(8]>9C8]<"ZZ B(RD 9JL6(Q7+ *O[+&E;.Z>ZRF0:DF5K,5=
MT':>Y;NN<5JF9ULCX4CYJA-9DD7:O,QC 2E=*-.GF7H3$D;1]:0RS5$RTX\S
M=0Z**+/>/20I"?S<KF>D7@$B!L&P[S@DE.6.DE:8)MCB%IP8[]DAXZL%K& J
M5;!]XR4-IG9^Y9CX(9:5"(6PETX3P*/R0P"B1!<]^(KN:)Q+!D*'WM,K-<*&
MHXING$LOYGU3UN0YN7S,V>2]);<%J.D610UZ9#)'LGMS)+H[%7>34E/.+;OS
M>_QY:;#['#2+)@T+^+YW^ T *Y2*!M/?7M=4Q)/R48\*T6S#2\.L)ES#+2%Y
M'@DKU+/SF[RJPVV!$0D1MK&JQ."='"TKZT) N-HF;GLY<.NDSV^P;24654G0
M)0:%4K_Z#KW^Y+OT[,R'4!379\Y*NX6?"">U5%KE^LGN21#QK>WKF&12_&'I
MV;XC[HU<CVC"9$^2\ILM:7@;M'VWF8+\1L5\=WHRV>%!>:?0L=SE=T.5OW=F
M/]#-*5I2 @R<MD&()&J&ICMPF^)JX*+.UVNN-9 .^A)4[$J2+=H>AU#7C:'J
M*E]LX>IBR+ "56,>(O"A+ KA%S8DD"!4HK@>2Z^065741N";6XX6OPOA_9>G
MLS/6"242 /7A#@VD]O=Q7A44B33B=J_\@P0BV0@ 1_H#]+21<]O"FW]C/8<#
MELYEV?;+'6(%5VIV1%'_N*C!3R'7*G;#B>@\0O%N-"V A3!J?/> "D[[1H94
MFYQ10=G^W62;"">WEX8U^*:KU/T81WGTX'-I6!AU9OE>K-25^!S&<A_=H:)2
M8A1EY]./FN;339.-+[=)S9V2FF"+?6C(4?*4II:.[[#5MN'RLK^XP $KNA U
MU+D?$J2_A+6C43.^<36T6%R_H2LSDW!ZY-1B[V*;.34PYYUARVV)4A O[<.E
M[(ZN'DE]*8J>]I46MM3M]K <"FV[1,IG$F#N3Y\#A^@8>O;$<;D=)0WZ "/&
MA5Z?1&R03C$H9"A/QZG81=HZD!Z(NB4DG8B)\ 1;.+:[YQRS@!,1[KNNK>9]
MXO5W&(0;CGPK<4IN0_F25[RO\X#B3'SIC)C*4P@D<MT@-@@8#256*GM38G#<
MV6/Z5Q+V2:* ,>R$)M!/9"$#4RZ)QLH?FB_!R9BQ@1JJ+DF[8:Q=,.S:7X\M
MS$^)@D[ZEQF<,CD\IG9LP/OTC*:=G9QDOLQZWJ@ .U<<;]M[.'4A4#"OC0OE
M,&K#Y\M0;6OM75YW=P.DHOI#N DBLX.V<9S;199MX#WN(6)*)]MX#V^X77,C
M]W$*Y'GNN<JEND_W,N ^^(#RVD0J_3B^'Z/F,G:/?=%M ZZM.6IO$"%U-!@6
M@'Y0 /'B:.[3AW)X%5!]R0Q2V.9^O8KOCRB>JSWV]6"P^7\QK7'.&NU)_8P]
MZ4Q?->J!;@%1UY9#YLPIQ2_/_LY) ]1Q-E'I;:U)VI6+!(9"2G+)=PN-96J#
MO)![4ZK+?T"*TR,@//%L_DUXU-P5^@8%:"F(P'RK)O2U9&1JN#Y%!?< -)+U
M\B6DG&_*C/)>[I]S48Z>^K !+:JY22O8\RMCOY;*M[2:KR)Z_R!I9S)!)=DU
M:^I\B/8,A#T"C(F#X?);0:<H/>*0('%>M*86=EU])]2/UPW'Q%B!"IO& I&#
MC\P)5JBA &F*E2@2?&=%C<@K(H'O*N(HJ2_&&QD/1AW=ORQ37GWA_QZKP:G6
M>;ND8JGTKP=(0K0K)CK79R?_(6Q4*RMZ/C=2>T"8)EO@#G1?^]JL,UU7>TWY
M/5,?K'/D":0VR9]-%(H;5_$E)Y'2+8QU5]\X%8E3^8BF3/Q]#]'9<3_(UV*I
MEHMDZ!8@W%(/?F%RKFNRUY-S@<DOEY1P3%1(+,2$)[Z@&CN*M_SA$@5\?QEP
MZ!8@0^+(PM6B<9']OF_(])NJ)N[4D\GL[&PR.SU32:GVR>1L^G0R/9FIEIKO
M2W^K6#*2>)N:NOAJN(H#=R!#I207RG'^<EOCO^SB5)BE/5J'O9DOSS'8B=,S
MY3+UT=S":?JO+N3&?2&EY[RT]S\VL8TE"^1.Z'.JP?#8.'_?T+ 8^8^K1G^D
M9BJDJP;/]N[\^B)\_"%MN=GT>'H22L;O":?('>-S1]>I.-+XGMVST]F1SR7"
MO9RA[=,T%!>':^O!;ANJ94ADEZNT],%+N#"<]NVJYL;6?$MM.1 AU=:T_WDX
ME1#;W6W\G;UDD8D^G,G/B8A$(^DB^F@H*\3AZ=&6JM\?R=&CV2Y=[+J.&2ZN
M^(:ASQ3IFMV&FVZL(KP3I?E$U\X[^OYX&(&(6$._96Z65<..,U\0PAB [AEW
MO:>>@M(W<:SX-D57LO@D1Y756,^@_C=QO_M+G#^]A<H1"8'TO%_"DQ =)WN5
M[>3XY$E0MC=FWL7;N/P@95N^%>E"WO")ZU*^8J,/K_MYQ]KX^.G)\>SDB,>\
M,?PY377CS?\?IER2E,+B0V$8)_)V?)"?;O%*NNW#XL^F9W'RXY.C\,T28BM.
M,THS-O+<+IT+ 71\)2]<@)1Z,CP6R +U]$D-J_/H;I._4M+=I1:0WAI-5PQW
MTH31G4I+93U9\)ZJ,GA*F=NEK(X"YQW=1=E6175/%:6+P;W#:GV_8TA6EBXX
MOIA@Z#IB=(UCP@:BMKZ&4J'*&/39@XMH#4&__^Q6->66U3J8!R6//^E_)VQ<
M=XBMJ2/6C?IGCV0)F>B3?88Q?7(\/0V&,7S3=S6<+Q_B[,6EW$+\P!<5_;M?
MD_N#8'HTA+C>N5[0:3W6Z=9LZKPPZ4<IW1#+..XEUV4$7]O:+L,G9NDK^0JJ
M-8N:NVJQ5>MO4H;+EAP-?1P)M\%C_S[7<\!5 LY\.TZ^4QK:@X3-I,;"SU4C
M7X[[I$@>5;)?\C$29[B1[X 9QRI_O4:R@[WCMY5>0\DZ#Z^_7$HC*'R%Z#'.
M]=O+HUA@370\L1G;;"GOZ40-%K[7:/*.%]KMY?68EW_'S:N=;G[7]\6/DH_!
M@:B7_,D[+0;[D._"X]OX5?VY?$P^#)=/\G\%<*8KV+598.I)]O3L0(H#X0&N
MF3\MG]NNLVO^<V5(-6@ ?E]8VX4'VB#^?PV\_E]02P,$%     @ 1(!_5F:2
M;EUY!   P0H  !@   !X;"]W;W)K<VAE971S+W-H965T.2YX;6RM5MENXS84
M?>=7$&I:=(#8VK),4MN DTG;%#-)D*0=%$4?:.E*(D*1&I**X[_O)64Y=AP;
M+= 76USNX3EW(T=SI9],!6#I2RVD&0>5M<UY&)JL@IJ9H6I XDJA=,TL#G49
MFD8#R[U1+<(DBD["FG$93$9^[DY/1JJU@DNXT]2T=<WTX@*$FH^#..@G[GE9
M63<13D8-*^$![._-G<91N$+)>0W2<"6IAF(<3./SBR.WWV_X@\/<K'U3IV2F
MU),;7.?C('*$0$!F'0+#OV>X!"$<$-+XML0,5D<ZP_7O'OUGKQVUS)B!2R6^
M\MQ6X^!C0',H6"OLO9K_"DL]QPXO4\+X7SKO]L:X.6N-5?72&!G47';_[&7I
MAS6#C]$.@V1ID'C>W4&>Y2=FV62DU9QJMQO1W(>7ZJV1')<N* ]6XRI'.SNY
MO;NZGSY>W_Q"/U]-'ZX>1J%%5+<69DN$BPXAV8$0)_2+DK8R]$KFD&\"A$AG
MQ2GI.5TD>Q$_03:D:7Q(DRA)]N"E*XVIQTMWX'T&#)NA?TUGQFI,@[_?$]E!
M'+T/X4KCW#0L@W& N6] /T,P^>&[^"3Z:0_!HQ7!HWWH_RH(^Q%N;A^O:$H'
M]"T4B3^0QPKHI:H;)A=4=+Y01<$SH$SFU,EA.JO\((=GK-,&J\X2KY>V&%0L
M8IS73%!6:@"W:H;4P3(I6YSVJ#136*NXF_EZXX8R:I7%9570@_CDA+@3<!K)
M/T&.:]0BQ+71# 2GEW?7'68'MCJ)PDO#M>,LZ6^M!)I&/C/2(9T:@M"8+E#/
MD&2?,H<>MU?<:/6,K'(L7OE$RY9I)BUX'U#6X.H+Q^(&L: 'Z>DAX=);LQ+/
M+W'^T/$TD+4:_$+1BH(+X9DA K<(-!.\]*+-TEUV6X89DL2'@O3$*F8H+H!&
M;ESB*=AIG>]DN65+L?O29ZAX)I!X:YR:A3\;ZD:H!<I9]QWB<)6C_Y%S"=)%
M#N4Y#%LA)%U@P(V/AB/:L$5WB-N^+S8;?D#>M??A>UHW(^"$UBS'! %M\9[
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M']6MQ=N@LY++4F@GC696S$]ZD]&7LWV2#P)_2K%T&\^,,ID9\T@OT_RD-Z2
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MG4X89K:R)A,B=VQN3<D<5Y" 57S.ZPP-E#I(4XFYS8K0T%P\@6JJ-H)E(;%
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ME7A%I'\C:;0W:.4:Q9:FRI4*ZZQ.I+:H8VBO"\EX/.X9NH&/'2EX7?ER4(O
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MO&>]/^0J!/$?Z^R1!P3AZ?= .+=171<9"-3X;5>##L1SJ%#? _-I#^8,1[!
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M+K?;0IGYR=&Q#I8L]U8.(9P?"D!#<A:<9W8=T1 =^S\A.KY'=*PENL[,82W
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MZN*/FM\1?;Q[]X[_='V%D179)0H_FY_S4BA-H];(2 JEHP2[QX_;DQEX[Y1
M1@+[,R%.I  7Y *<@^ZOZ!QZ'28YEI9S^7U;6;OM*#:PAW6WAO"#V^[3-4QX
MJ[\/,[S=Y[P##,&$SI#OQQ_$9GMY[=B-7T-=M.%I19E0F&WX G=O:MIQM+-"
M9F>)>F]O%<15T)";PT#-O+Y[3N=^M[UV#8'=G;O8WX?K;2X/;\J1TFQP,>TD
MQP[-MYR^\>TNGP"H0(:)-)69M"K8';PZMQMG-HD=)EJ%]\QT^D5NZDSBPQK7
MT(-JIS5>X'/:JR] 9OF 6?]0U% @J$FB/A%BNY2*SGOT^B@<<27Q-8.6T'<"
M&%-D> #YD?<U/S(T<E\83QSHF(^]>&)=JBL4BO3$:;EJ_S!2;\_3VRMFT.G8
M@R[84T =JA3M@39%07,S!^Y/E<V"5_\D'AZ#TL"*="AD<'NHUDUA>I.)]/,8
MX  <KJV@,3(N/K I%C*S"R%]-GR@L\QXH@LW%%;($;K>&%^]H#*.?WQV8TF<
M$8DSZE_&9DF"3A*,S2;?M<)<RQ?L4>$ZP1C^N?F*KH 1OA09X"M3U2-+9L_'
M$\\-GK-D"I_\Y^RCTI_'2UQM540G4&211IGOAO'S<>B&R7/X[/O/QYX[BY[O
MI&9J*?D80V;.$L1N/$[<F"6N/X[=:<>$#W0@E.WZ./8G:SQOC.^7JB>\<5M7
MT#H04S.!QZQ6*L\[G11M!D=.Z"?.-)ZQ9PR\%K+ B2>>XWMX(W*GL5E.!>,"
M)XJGSA0?<8,9\YW9)'9B\+GOSN(V)@MV!G=]GYW#8W[$SOS)Q)D +O$ZG+"?
MFHQC9S,O@$(]@V\@@#X\F3A)TCYX0P??X#$_C!W?C^%^Z$X]=A9&3I0D<!GA
M5&;/2+O;W9H7.Y,P=+SIA,P+O4-[;W;I-"0@=/PD=I+)A-SA)> &#QC(2_!&
M[(8SDSZ[O@P%:?MC _5W.F%E?L. R02U 'IZ$X2=XD05W;1N=V#,L9?#\U/8
M+C8,OT<<+UCS/&N>;[=J.V.V]SKC[C#68FOH5H._*P.[@^LV/;O#?6S:X-Z
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MGMB56&Z7:/\LC,JVB0.LW$K*J@IT#BF=KHY5[7'%;0P *A"]2^C[/;^2PAD
MW6'YO3+D%)6:&YUYR1@E6TC/K/OO!Q(MUP>(]LRR/N#4AX::W:8>LOR;(=NF
MB-Z1M+V3VQ+&C<.ESCTV.7S3MK;$O"87]1YBL6'2^:76\Y^PNU>%XJ>6/7MR
MZFW!E&A$0SSUIQ+!<:"Z5_X>2'1L8^-;/H)=!_#^QM4HDV;A+X!T\BAS5]V2
MVM7VCGE:7:W6XM4%]8,P"X544CF'ZB"8CCO<5)>^ZL7IPE^T9MKAVN8?E[@G
M2T,"^#[7VC4OY*"]>9_\"U!+ P04    " !$@']60*$=_KD"  #Y!0  &0
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MH_GT^=5LAA-HQ'\6^L$E?TO<RL*8;_APD[\ZFB!&NM19C2 4_'.OKW59(B3
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M[,$B\_4!ME6F_Q]"?M8B/QM<\^UF6YI'L$%.HR.)WM]"5WI9])O@'T KQB(
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M' #?E\;4X0$7B+]Z]?I_ 5!+ P04    " !$@']6F)YJ F8"   6!0  &0
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M @GB :S@PSNW[WQJ(7A4$SQJ0P\6^LU%10J8QS@U9''(I6IBV8K3S/('$('
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MQR",@=Z/.5?;B0E0-_C@#U!+ P04    " !$@']66"MP>(P%   -#0  &0
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M7:1"46FWAVD/)KF U3A.;:<4:1]^3@()DXI96?.2V([OY__9YYS=67'Q*)<
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MBNH-!0%*)81IA"(:PFLBS9@&6@,1TB"H50IJ_4\@D)>#@6#D'SF=[5)]N\9
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MLU "6USE<L7JS]#J&6B^F.7"?%'=Q Y4QK@2DA4M6-D%H<V*G]I[. "XPQ,
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M@\L]6"W6#W\F?]5WQ-X <_C$ *L>8+4'V$\,&-8#ANT!HR<&C.H!HV,'V/4
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M!*6IR6Z:2L-7.NG2$.TMH9J#:BZJ>:CFHUJ :B&J1:@6HYJ@-#7#30=JJ.]
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M$X$B6"E(E1QJ&7C:)J8#R;:FTUHRJ?HV\[I1K35P+:"^KQB3IX$VD#?K@_\
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MF#*0SS>4BI>!FJ!N<V?_ 5!+ P04    " !$@']6/')?"G4+  "\@@  &0
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M*C5L-;",HX:9@X='X9[]DY1SJ-3P5[@ .DP-.B8&2 -5:O1/M9*NU51JV&H
M)*:F%>5(J7>@I!;4C=6D:A&5&C836(BQ$P^4&"4'S4C5(BHU;#Y0%5,CCLY
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M:/ME GX$P(\X("$4.*+7(]*,$*E:1*6&[00N$J?." G2C!"I6D2EALUO+#A
MEQ&JI1P7!>^JP^.+G12*J-2P00!%PFQ.2'1S0HYM\Z"]GL1,W0YMUTS0C0"Z
M$<=/"@U4">%[9] F)1XJ->PP$(\PFPL2W5P0]SW7[2P50DHJ5&K8-" 5<?Q<
MT$"5>W1+4MBA4L,+NP#L> >D@ *OST"UHFYT)E6+J-2PFT!!WJE30!YI"HA4
M+:)2P^8#%GET*2"O+P54=G>\'A$I!5&I87N @CRS*2"OFP)RN.@^YZINAK9I
M)EC' ];QCI\#&JBR_;5&[W5+BC14:MAC0!K/;.K'ZZ9^.GV2E'"HU+!?C<78
MWK=D01&R^;C_VPRUHG;4("4?*C7L)I"/YY\Z9).F@4C5(BHU;#Y D:>&(JV0
M'71"]J:[XRN=%'^HU+ ]@#^>[NH&FB&[N[H!=_M"-BG14*GAY1F!:/S]5C>@
M#-D#50;M3(03[*1'M92NUU1JV&O@'5^=@CDT=-?R:$S)N,/:5[6Z&=JFF> 4
M'SC%5W.*B2\U!JK4ZJ"DT$.EAKT&Z/'?G?KA8Z]O">I+M:)NN"95BZC4L)M
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MX4(*RT4S_"H$S]&04ARM0([/T?1%W$"Y*PA$8QS[' ?^7W#/T3 D:V']Z[N
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M/I)O(]7@[V&2A]4MIBL_8BB I8 T+MNB8:#)6R69<!*K=O^)</%X4$-/O.^
M2@.QOR2$[R;R@.S%./@'4$L#!!0    ( $2 ?U9&1F+B?20  *2Z @ 9
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M4U%-0S4=U0Q4,U'-0C4;U1Q4<U'-0S4?U0)4"U$M0K68TMH!7E?T%'%%;W_
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M)*>RG,9R.LL9+&>RG,5R-LLY+.>RG,=R/LL%+!>R7,1R,<9U,GW<R'3QQ?/
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MSX(P!OK]A'.UFA@'58<<_@902P,$%     @ 1(!_5AB\QR+  @  KP<  !D
M  !X;"]W;W)K<VAE971S+W-H965T-#$N>&ULK95K;]HP%(;_BI554RMUS17H
M6(B40JLBM10!W;2/)CF0J$Z<V>;2?S_;22-*4M1)^T)LY[ROGW."C_T=92\\
M 1!HGY&<#XQ$B*)OFCQ*(,/\BA:0RS<KRC(LY)2M35XPP+$69<1T+*MK9CC-
MC<#7:U,6^'0C2)K#E"&^R3+,7F^ T-W L(VWA5FZ3H1:, ._P&N8@W@NIDS.
MS-HE3C/(>4ISQ& U,$*[/^RI>!WP,X4=/Q@CE<F2TA<U&<<#PU) 0" 2R@'+
MQQ:&0(@RDAA_*D^CWE()#\=O[G<Z=YG+$G,84O(KC44R,*X-%,,*;XB8T=T]
M5/ETE%]$"=>_:%?%6@:*-ES0K!)+@BS-RR?>5W4X$-C>!P*G$CB?%;B5P-6)
MEF0ZK1$6./ 9W2&FHJ6;&NC::+7,)LW55YP+)M^F4B>"^?-T^G#[>#M9A+/?
MZ&X\"2?#<?B YHMPH9?1>'+W-'L,%^.G"3H?@< IX1?H&WJ>C]#YV04Z0VF.
M%@G=<)S'W#>%I%+>9E01W)0$S@<$(XBND&M?(L=RG!;Y\/-R^[W<E+6H"^+4
M!7&TG_N!7QA%; ,Q@KT\*!PXDEDA*A)@J,"O>$F ]]N2+%V]=E=U%ON\P!$,
M#'G8.+ M&,'7+W;7^M&6\G\R>U< MRZ >\H]N,T*0E^ARASJ&0."!<1MN9>&
M/6VHVL8VL#N>;VX/4VJ)\7IUS#M2KR;U3I*.\XAF@ 3>MT&5VN[!AM814C/"
M=KUVI$Z-U#F)-&5TF^H.)QLLVN((JV;5AM=I;NYUCP";,:YUW0[8K0&[)P&/
M_]YM:-W&MM]=]PBM&>,XMM/.UJO9>O_$UG+T+I&@ I,VZE[S#^8TL)M!SK5E
M'V&;!^U4766/F*W3G","*RFSKGKRN[#R>B@G@A:ZPRZID/U:#Q-YHP)3 ?+]
MBE+Q-E%-N[ZC@[]02P,$%     @ 1(!_5F%^_5VM P  F!(  !D   !X;"]W
M;W)K<VAE971S+W-H965T-#(N>&ULO9A=CYLX%(;_BL5*JU;:'3X"26::1&H"
MJ^UJ9S3;=&8OJEXX<)*@ J:V2:92?WQMP]"0$&^CNGL#&/P^]GD/V-B3/:$?
MV1: HZ<\*]C4VG)>WM@VB[>08W9%2BC$DS6A.>:B2#<V*RG@1(GRS/8<9VCG
M."VLV43=NZ>S":EXEA9P3Q&K\AS3SW/(R'YJN=;SC;?I9LOE#7LV*?$&EL ?
MRGLJ2G9+2=(<"I:2 E%83ZW7[DWD*H&J\9C"GAU<(QG*BI"/LO FF5J.[!%D
M$'.)P.*T@P5DF22)?GQJH%;;IA0>7C_3_U#!BV!6F,&"9/^F"=].K;&%$ECC
M*N-OR?Y/: (*)"\F&5-'M*_K!B,+Q17C)&_$H@=Y6M1G_-08<2!P_3,"KQ%X
MQX+@C&#0" ;'@N$9@=\(_._M4M (5.AV';LR+L0<SR:4[!&5M05-7BCWE5KX
ME1;R15ER*IZF0L=GRX?Y,OKG(;I[AZ)'<5RB%R%PG&;H'3SQ"F?L)?H=L2VF
MP"8V%RU*G1TW]$5-]\[0!^B6%'S+4%0DD/3H0[W>]30 6X3:QNL]QSOWM,2_
M<'&%'.\WY#G>H"\@O?P6TRLT<)7<ZXM'+P\AULJC[Y>[&C,&;?('BC<XE_QJ
MQ>!3!05'T4X>W_\M:J W''+VH:=[\QKG]^/DF';#2AS#U!*#%@.Z VOVZR_N
MT'G5Y[1)6&@2%AF"=7+BMSGQ=?39796O@"*R1J240RE#G*"RHO%6#(>(T"0M
MQ(!^_HN<:_&7YL@D+*QA0P63$]ANYOG!>#P4W^'NT/[3>N[U* C&P[9>Q]F@
M=3;0.AL] 8U3:6+'VR-+T8NT:"Y?]MFK;>-2>TW"PN#$MB!PW2-O3RNYH]'(
M=?JM';;6#K76/@)3TWX)-"5]X_Q<J[_4-GUG?/09,.W[-D*3O8@,P3J&CUK#
M1]H83T?N6Y#CQ@?T!=V)1(AW/:[D+QB:$TR3]G%?:K0M79H:D[#0)"PR!.ND
M:]RF:VQVHAV;S(E)6&@2%AF"=7)RW>;D^N=.M->GX^W ]_QA=\1=:'MQJ?LF
M89$A6,=]U_FV\'#^A^FX:<3U#M+@7(V.?BD6^KY<F@6CM,@4K9N'@P6@^X-S
M]W\ 7#7?]BX.M<*+73=)BTS1:M?M@Q5X#G2CMCX8BDE5\'IQVMYMMU=>JTV%
MH_NAW'91*_MOF'K/1BP]-ZGX1C)8"Z1XQ\6O'*VW0>H")Z5:YZ\(YR17EUO
M"5!903Q?$\*?"[*!=C-J]A502P,$%     @ 1(!_5E;>X EO P  UA8   T
M  !X;"]S='EL97,N>&ULW5A=;]HP%/TK4;I.K30UA*PI60%I0ZHT:9LJM0][
MJPQQP)+C9([IH(_[.?M9^R7SC?,%]46L#QLLJ,3V\3GW^/J&)!T6:LWIW8)2
MY:Q2+HJ1NU J?^=YQ6Q!4U)<9#D5&DDRF1*ENW+N%;FD)"Z E'*OW^N%7DJ8
M<,=#L4QO4E4XLVPIU,B-FB''G#[&(]</W[J.D9MD,1VY#V>OORTS=?W*,>>3
M-R<GO8O>P_GU-G)60>>N9Q6^W$,8E<5$0[OHKQ\_-_V:HR/?SCC;F((%NMHK
M+;OR@DH/-J7+Z:=:R!!/,5IDH>DH+1,Z"/FJ9R5WJ!C1WR\/.Q.!BO?WVLT=
MNU@*>U6ACX=))MIZ#UPSH".3E#J/A(_<">%L*AFP$I(ROC;#?1B893R3CM(7
MFK;BPTCQ9&#?]. :K'12)C)9QC81S/>TFKX%U#TPR#AO#/9=,S >YD0I*L6-
M[I23R\%GD%.U[]>Y=CB79.WW+]V64)YTD&DF8RJ;,+Y;#XV'G"9@1[+Y LXJ
MRST E<I2W8@9F6>"E!YJ1M70LC/*^1W\0'U--K1726=/RSH335,;JII&QG1
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M["H)@BBR(X#9'00!AL#5B".8 _" (4%0W@>W[D=>?9_RVO]DCW\#4$L#!!0
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MS3B"]8=FE< KVE8Q(;]8NOT"8G953,@OEF:_'"2>>MB;PPUYQM+LF:\ D=E
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MDN,>) <?HP1!(2I'02I'82I'@2I'H2I'P2I'X2I' 2M'(:M (:M (:M (:M
M(:M (:M (:M (:M (:M (:M (:M$(:M$(:M$(:M$(:M$(:M$(:M$(:M$(:M$
M(:M$(6N"0M8$A:S)?Y+U7>O57_]+:->X5F5S]&?=#YOY)U!+ 0(4 Q0    (
M $2 ?U8'04UB@0   +$    0              "  0    !D;V-0<F]P<R]A
M<' N>&UL4$L! A0#%     @ 1(!_5E8C78ON    *P(  !$
M ( !KP   &1O8U!R;W!S+V-O<F4N>&UL4$L! A0#%     @ 1(!_5IE<G",0
M!@  G"<  !,              ( !S $  'AL+W1H96UE+W1H96UE,2YX;6Q0
M2P$"% ,4    " !$@']6;[WRLY8'    ,@  &               @($-"
M>&PO=V]R:W-H965T<R]S:&5E=#$N>&UL4$L! A0#%     @ 1(!_5OV][S"T
M!@  /AP  !@              ("!V0\  'AL+W=O<FMS:&5E=',O<VAE970R
M+GAM;%!+ 0(4 Q0    ( $2 ?U85&- RG (  # '   8              "
M@<,6  !X;"]W;W)K<VAE971S+W-H965T,RYX;6Q02P$"% ,4    " !$@']6
M3Z*>+Y0$  "_$   &               @(&5&0  >&PO=V]R:W-H965T<R]S
M:&5E=#0N>&UL4$L! A0#%     @ 1(!_5J3'=$:O!@  /B@  !@
M     ("!7QX  'AL+W=O<FMS:&5E=',O<VAE970U+GAM;%!+ 0(4 Q0    (
M $2 ?U;S&*UY>@<   L?   8              " @40E  !X;"]W;W)K<VAE
M971S+W-H965T-BYX;6Q02P$"% ,4    " !$@']6#N#.L7T%  "W"P  &
M            @('T+   >&PO=V]R:W-H965T<R]S:&5E=#<N>&UL4$L! A0#
M%     @ 1(!_5OALG-)!%P  =T   !@              ("!IS(  'AL+W=O
M<FMS:&5E=',O<VAE970X+GAM;%!+ 0(4 Q0    ( $2 ?U9FDFY=>00  ,$*
M   8              " @1Y*  !X;"]W;W)K<VAE971S+W-H965T.2YX;6Q0
M2P$"% ,4    " !$@']6_Y1%+U$'   7$0  &0              @('-3@
M>&PO=V]R:W-H965T<R]S:&5E=#$P+GAM;%!+ 0(4 Q0    ( $2 ?U;%1IB$
MI0D  .\9   9              " @556  !X;"]W;W)K<VAE971S+W-H965T
M,3$N>&UL4$L! A0#%     @ 1(!_5CO7]SWU#P  'C8  !D
M ("!,6   'AL+W=O<FMS:&5E=',O<VAE970Q,BYX;6Q02P$"% ,4    " !$
M@']6$T5B+*H&  "%#P  &0              @(%=<   >&PO=V]R:W-H965T
M<R]S:&5E=#$S+GAM;%!+ 0(4 Q0    ( $2 ?U9 H1W^N0(  /D%   9
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M970Q."YX;6Q02P$"% ,4    " !$@']66"MP>(P%   -#0  &0
M    @('[FP  >&PO=V]R:W-H965T<R]S:&5E=#$Y+GAM;%!+ 0(4 Q0    (
M $2 ?U9P1*Q_VP,  ,P)   9              " @;ZA  !X;"]W;W)K<VAE
M971S+W-H965T,C N>&UL4$L! A0#%     @ 1(!_5J>W[U;# @  P04  !D
M             ("!T*4  'AL+W=O<FMS:&5E=',O<VAE970R,2YX;6Q02P$"
M% ,4    " !$@']6%6WGT)L"  "/"   &0              @('*J   >&PO
M=V]R:W-H965T<R]S:&5E=#(R+GAM;%!+ 0(4 Q0    ( $2 ?U:6:$JF% ,
M *H-   9              " @9RK  !X;"]W;W)K<VAE971S+W-H965T,C,N
M>&UL4$L! A0#%     @ 1(!_5HJP1;FF!   E10  !D              ("!
MYZX  'AL+W=O<FMS:&5E=',O<VAE970R-"YX;6Q02P$"% ,4    " !$@']6
M2%V&!5<"  "1!0  &0              @('$LP  >&PO=V]R:W-H965T<R]S
M:&5E=#(U+GAM;%!+ 0(4 Q0    ( $2 ?U;&D.I]9 (  *D%   9
M      " @5*V  !X;"]W;W)K<VAE971S+W-H965T,C8N>&UL4$L! A0#%
M  @ 1(!_5C%E:G3? @  D @  !D              ("![;@  'AL+W=O<FMS
M:&5E=',O<VAE970R-RYX;6Q02P$"% ,4    " !$@']6"N;TDWX#  "F#
M&0              @($#O   >&PO=V]R:W-H965T<R]S:&5E=#(X+GAM;%!+
M 0(4 Q0    ( $2 ?U::-L9V, 0   </   9              " @;B_  !X
M;"]W;W)K<VAE971S+W-H965T,CDN>&UL4$L! A0#%     @ 1(!_5E,UQIOQ
M$0  ? H! !D              ("!'\0  'AL+W=O<FMS:&5E=',O<VAE970S
M,"YX;6Q02P$"% ,4    " !$@']6$ *@GM0#  "X#P  &0
M@(%'U@  >&PO=V]R:W-H965T<R]S:&5E=#,Q+GAM;%!+ 0(4 Q0    ( $2
M?U:L>3;.Y ,  /(.   9              " @5+:  !X;"]W;W)K<VAE971S
M+W-H965T,S(N>&UL4$L! A0#%     @ 1(!_5CQR7PIU"P  O((  !D
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M=#,W+GAM;%!+ 0(4 Q0    ( $2 ?U:O$8@%) ,  (P+   9
M  " @;X8 0!X;"]W;W)K<VAE971S+W-H965T,S@N>&UL4$L! A0#%     @
M1(!_5F3K/K:6 @  T 8  !D              ("!&1P! 'AL+W=O<FMS:&5E
M=',O<VAE970S.2YX;6Q02P$"% ,4    " !$@']6%(-WA_X"   M"P  &0
M            @('F'@$ >&PO=V]R:W-H965T<R]S:&5E=#0P+GAM;%!+ 0(4
M Q0    ( $2 ?U88O,<BP (  *\'   9              " @1LB 0!X;"]W
M;W)K<VAE971S+W-H965T-#$N>&UL4$L! A0#%     @ 1(!_5F%^_5VM P
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M2P$"% ,4    " !$@']6OLLS09D!  !U&0  &@              @ %1,0$
M>&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'-02P$"% ,4    " !$@']6(]5N
M#:@!  "X&0  $P              @ $B,P$ 6T-O;G1E;G1?5'EP97-=+GAM
7;%!+!08     ,@ R )4-  #[- $    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.23.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>155</ContextCount>
  <ElementCount>245</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>true</FootnotesReported>
  <SegmentCount>69</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>6</UnitCount>
  <MyReports>
    <Report instance="zk2329447.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0001 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.enterabio.com/role/DocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="zk2329447.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>0002 - Statement - CONSOLIDATED BALANCE SHEETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.enterabio.com/role/CONSOLIDATEDBALANCESHEETS</Role>
      <ShortName>CONSOLIDATED BALANCE SHEETS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="zk2329447.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>0003 - Statement - CONSOLIDATED BALANCE SHEETS (Parentheticals)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.enterabio.com/role/CONSOLIDATEDBALANCESHEETSParentheticals</Role>
      <ShortName>CONSOLIDATED BALANCE SHEETS (Parentheticals)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="zk2329447.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>0004 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.enterabio.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF OPERATIONS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="zk2329447.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>0005 - Statement - CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.enterabio.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="zk2329447.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>0006 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.enterabio.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF CASH FLOWS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="zk2329447.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>0007 - Disclosure - GENERAL</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.enterabio.com/role/GENERAL</Role>
      <ShortName>GENERAL</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="zk2329447.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>0008 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.enterabio.com/role/SIGNIFICANTACCOUNTINGPOLICIES</Role>
      <ShortName>SIGNIFICANT ACCOUNTING POLICIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="zk2329447.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>0009 - Disclosure - OPERATING LEASES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.enterabio.com/role/OPERATINGLEASES</Role>
      <ShortName>OPERATING LEASES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="zk2329447.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>0010 - Disclosure - COMMITMENTS AND CONTINGENCIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.enterabio.com/role/COMMITMENTS</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="zk2329447.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>0011 - Disclosure - SHARE CAPITAL</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.enterabio.com/role/SHARECAPITAL</Role>
      <ShortName>SHARE CAPITAL</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="zk2329447.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>0012 - Disclosure - SHARE-BASED COMPENSATION</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.enterabio.com/role/SHAREBASEDCOMPENSATION</Role>
      <ShortName>SHARE-BASED COMPENSATION</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="zk2329447.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>0013 - Disclosure - INCOME TAX</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.enterabio.com/role/INCOMETAX</Role>
      <ShortName>INCOME TAX</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="zk2329447.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>0014 - Disclosure - SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.enterabio.com/role/SUPPLEMENTARYFINANCIALSTATEMENTINFORMATION</Role>
      <ShortName>SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="zk2329447.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>0015 - Disclosure - SUBSEQUENT EVENTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.enterabio.com/role/SUBSEQUENTEVENT</Role>
      <ShortName>SUBSEQUENT EVENTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="zk2329447.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>0016 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.enterabio.com/role/SIGNIFICANTACCOUNTINGPOLICIESPolicies</Role>
      <ShortName>SIGNIFICANT ACCOUNTING POLICIES (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="zk2329447.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>0017 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.enterabio.com/role/SIGNIFICANTACCOUNTINGPOLICIESTables</Role>
      <ShortName>SIGNIFICANT ACCOUNTING POLICIES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.enterabio.com/role/SIGNIFICANTACCOUNTINGPOLICIES</ParentRole>
      <Position>17</Position>
    </Report>
    <Report instance="zk2329447.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>0018 - Disclosure - OPERATING LEASES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.enterabio.com/role/OPERATINGLEASESTables</Role>
      <ShortName>OPERATING LEASES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.enterabio.com/role/OPERATINGLEASES</ParentRole>
      <Position>18</Position>
    </Report>
    <Report instance="zk2329447.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>0019 - Disclosure - SHARE-BASED COMPENSATION (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.enterabio.com/role/SHAREBASEDCOMPENSATIONTables</Role>
      <ShortName>SHARE-BASED COMPENSATION (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.enterabio.com/role/SHAREBASEDCOMPENSATION</ParentRole>
      <Position>19</Position>
    </Report>
    <Report instance="zk2329447.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>0020 - Disclosure - INCOME TAX (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.enterabio.com/role/INCOMETAXTables</Role>
      <ShortName>INCOME TAX (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.enterabio.com/role/INCOMETAX</ParentRole>
      <Position>20</Position>
    </Report>
    <Report instance="zk2329447.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>0021 - Disclosure - SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.enterabio.com/role/SUPPLEMENTARYFINANCIALSTATEMENTINFORMATIONTable</Role>
      <ShortName>SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.enterabio.com/role/SUPPLEMENTARYFINANCIALSTATEMENTINFORMATION</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="zk2329447.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>0022 - Disclosure - GENERAL (Detail Textuals)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.enterabio.com/role/GENERALDetailTextuals</Role>
      <ShortName>GENERAL (Detail Textuals)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.enterabio.com/role/GENERAL</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="zk2329447.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>0023 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.enterabio.com/role/SIGNIFICANTACCOUNTINGPOLICIESDetails</Role>
      <ShortName>SIGNIFICANT ACCOUNTING POLICIES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.enterabio.com/role/SIGNIFICANTACCOUNTINGPOLICIESTables</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="zk2329447.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>0024 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Detail Textuals)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.enterabio.com/role/SIGNIFICANTACCOUNTINGPOLICIESDetailTextuals</Role>
      <ShortName>SIGNIFICANT ACCOUNTING POLICIES (Detail Textuals)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.enterabio.com/role/SIGNIFICANTACCOUNTINGPOLICIESTables</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="zk2329447.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>0025 - Disclosure - OPERATING LEASE (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.enterabio.com/role/OperatingLeaseDetails</Role>
      <ShortName>OPERATING LEASE (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.enterabio.com/role/OPERATINGLEASESTables</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="zk2329447.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>0026 - Disclosure - OPERATING LEASE (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.enterabio.com/role/OperatingLeaseDetails1</Role>
      <ShortName>OPERATING LEASE (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.enterabio.com/role/OPERATINGLEASESTables</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="zk2329447.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>0027 - Disclosure - OPERATING LEASES (Details 2)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.enterabio.com/role/OPERATINGLEASESDetails</Role>
      <ShortName>OPERATING LEASES (Details 2)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.enterabio.com/role/OPERATINGLEASESTables</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="zk2329447.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>0028 - Disclosure - OPERATING LEASES (Detail Textuals)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.enterabio.com/role/OPERATINGLEASESDetailTextuals</Role>
      <ShortName>OPERATING LEASES (Detail Textuals)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.enterabio.com/role/OPERATINGLEASESTables</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="zk2329447.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>0029 - Disclosure - COMMITMENTS AND CONTINGENCIES (Detail Textuals)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.enterabio.com/role/COMMITMENTSDetailTextuals</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES (Detail Textuals)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.enterabio.com/role/COMMITMENTS</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="zk2329447.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>0030 - Disclosure - SHARE CAPITAL (Detail Textuals)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.enterabio.com/role/SHARECAPITALDetailTextuals</Role>
      <ShortName>SHARE CAPITAL (Detail Textuals)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.enterabio.com/role/SHARECAPITAL</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="zk2329447.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>0031 - Disclosure - SHARE-BASED COMPENSATION (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.enterabio.com/role/SHAREBASEDCOMPENSATIONDetails</Role>
      <ShortName>SHARE-BASED COMPENSATION (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.enterabio.com/role/SHAREBASEDCOMPENSATIONTables</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="zk2329447.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>0032 - Disclosure - SHARE-BASED COMPENSATION (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.enterabio.com/role/SHAREBASEDCOMPENSATIONDetails1</Role>
      <ShortName>SHARE-BASED COMPENSATION (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.enterabio.com/role/SHAREBASEDCOMPENSATIONTables</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="zk2329447.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>0033 - Disclosure - SHARE-BASED COMPENSATION (Details 2)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.enterabio.com/role/SHAREBASEDCOMPENSATIONDetails2</Role>
      <ShortName>SHARE-BASED COMPENSATION (Details 2)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.enterabio.com/role/SHAREBASEDCOMPENSATIONTables</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="zk2329447.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>0034 - Disclosure - SHARE-BASED COMPENSATION (Details 3)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.enterabio.com/role/SHAREBASEDCOMPENSATIONDetails3</Role>
      <ShortName>SHARE-BASED COMPENSATION (Details 3)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.enterabio.com/role/SHAREBASEDCOMPENSATIONTables</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="zk2329447.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>0035 - Disclosure - SHARE-BASED COMPENSATION (Detail Textuals)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.enterabio.com/role/SHAREBASEDCOMPENSATIONDetailTextuals</Role>
      <ShortName>SHARE-BASED COMPENSATION (Detail Textuals)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.enterabio.com/role/SHAREBASEDCOMPENSATIONTables</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="zk2329447.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>0036 - Disclosure - INCOME TAX (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.enterabio.com/role/INCOMETAXDetails1</Role>
      <ShortName>INCOME TAX (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.enterabio.com/role/INCOMETAXTables</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="zk2329447.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>0037 - Disclosure - INCOME TAX (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.enterabio.com/role/INCOMETAXDetails3</Role>
      <ShortName>INCOME TAX (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.enterabio.com/role/INCOMETAXTables</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="zk2329447.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>0038 - Disclosure - INCOME TAX (Details 2)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.enterabio.com/role/INCOMETAXDetails</Role>
      <ShortName>INCOME TAX (Details 2)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.enterabio.com/role/INCOMETAXTables</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="zk2329447.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>0039 - Disclosure - INCOME TAX (Details 3)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.enterabio.com/role/INCOMETAXDetails2</Role>
      <ShortName>INCOME TAX (Details 3)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.enterabio.com/role/INCOMETAXTables</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="zk2329447.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>0040 - Disclosure - INCOME TAX (Detail Textuals)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.enterabio.com/role/INCOMETAXDetailTextuals</Role>
      <ShortName>INCOME TAX (Detail Textuals)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.enterabio.com/role/INCOMETAXTables</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="zk2329447.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>0041 - Disclosure - SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.enterabio.com/role/SUPPLEMENTARYFINANCIALSTATEMENTINFORMATIONDetails</Role>
      <ShortName>SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.enterabio.com/role/SUPPLEMENTARYFINANCIALSTATEMENTINFORMATIONTable</ParentRole>
      <Position>41</Position>
    </Report>
    <Report instance="zk2329447.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>0042 - Disclosure - SUBSEQUENT EVENTS (Detail Textuals)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.enterabio.com/role/SUBSEQUENTEVENTSNarrative</Role>
      <ShortName>SUBSEQUENT EVENTS (Detail Textuals)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.enterabio.com/role/SUBSEQUENTEVENT</ParentRole>
      <Position>42</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <Logs>
    <Log type="Warning">[ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 1 fact(s) appearing in ix:hidden were eligible for transformation: us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 -  zk2329447.htm 27</Log>
  </Logs>
  <InputFiles>
    <File doctype="10-K" original="zk2329447.htm">zk2329447.htm</File>
    <File>entx-20221231.xsd</File>
    <File>entx-20221231_cal.xml</File>
    <File>entx-20221231_def.xml</File>
    <File>entx-20221231_lab.xml</File>
    <File>entx-20221231_pre.xml</File>
    <File>exhibit_10-14.htm</File>
    <File>exhibit_10-15.htm</File>
    <File>exhibit_21-1.htm</File>
    <File>exhibit_23-1.htm</File>
    <File>exhibit_31-1.htm</File>
    <File>exhibit_31-2.htm</File>
    <File>exhibit_32-1.htm</File>
    <File>exhibit_32-2.htm</File>
  </InputFiles>
  <SupplementalFiles>
    <File>image00015.jpg</File>
    <File>image00016.jpg</File>
    <File>image00017.jpg</File>
    <File>image00018.jpg</File>
    <File>image00020.jpg</File>
    <File>image00021.jpg</File>
    <File>image00022.jpg</File>
    <File>image00023.jpg</File>
    <File>image00024.jpg</File>
    <File>image00025.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="553">http://fasb.org/us-gaap/2022</BaseTaxonomy>
    <BaseTaxonomy items="37">http://xbrl.sec.gov/dei/2022</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>81
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "zk2329447.htm": {
   "axisCustom": 3,
   "axisStandard": 18,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2022": 553,
    "http://xbrl.sec.gov/dei/2022": 37
   },
   "contextCount": 155,
   "dts": {
    "calculationLink": {
     "local": [
      "entx-20221231_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "entx-20221231_def.xml"
     ]
    },
    "inline": {
     "local": [
      "zk2329447.htm"
     ]
    },
    "labelLink": {
     "local": [
      "entx-20221231_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "entx-20221231_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "entx-20221231.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd",
      "https://xbrl.sec.gov/country/2022/country-2022.xsd",
      "https://xbrl.sec.gov/currency/2022/currency-2022.xsd",
      "https://xbrl.sec.gov/dei/2022/dei-2022.xsd",
      "https://xbrl.sec.gov/exch/2022/exch-2022.xsd",
      "https://xbrl.sec.gov/naics/2022/naics-2022.xsd",
      "https://xbrl.sec.gov/sic/2022/sic-2022.xsd",
      "https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd"
     ]
    }
   },
   "elementCount": 461,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2022": 10,
    "http://www.enterabio.com/20221231": 1,
    "http://xbrl.sec.gov/dei/2022": 4,
    "total": 15
   },
   "keyCustom": 37,
   "keyStandard": 208,
   "memberCustom": 45,
   "memberStandard": 24,
   "nsprefix": "entx",
   "nsuri": "http://www.enterabio.com/20221231",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2329447.htm",
      "contextRef": "C_20220630",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "dei:EntityPublicFloat",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0001 - Document - Document and Entity Information",
     "menuCat": "Cover",
     "order": "1",
     "role": "http://www.enterabio.com/role/DocumentAndEntityInformation",
     "shortName": "Document and Entity Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2329447.htm",
      "contextRef": "C_20220630",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "dei:EntityPublicFloat",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2329447.htm",
      "contextRef": "C_20220101to20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0010 - Disclosure - COMMITMENTS AND CONTINGENCIES",
     "menuCat": "Notes",
     "order": "10",
     "role": "http://www.enterabio.com/role/COMMITMENTS",
     "shortName": "COMMITMENTS AND CONTINGENCIES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2329447.htm",
      "contextRef": "C_20220101to20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2329447.htm",
      "contextRef": "C_20220101to20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0011 - Disclosure - SHARE CAPITAL",
     "menuCat": "Notes",
     "order": "11",
     "role": "http://www.enterabio.com/role/SHARECAPITAL",
     "shortName": "SHARE CAPITAL",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2329447.htm",
      "contextRef": "C_20220101to20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2329447.htm",
      "contextRef": "C_20220101to20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0012 - Disclosure - SHARE-BASED COMPENSATION",
     "menuCat": "Notes",
     "order": "12",
     "role": "http://www.enterabio.com/role/SHAREBASEDCOMPENSATION",
     "shortName": "SHARE-BASED COMPENSATION",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2329447.htm",
      "contextRef": "C_20220101to20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2329447.htm",
      "contextRef": "C_20220101to20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0013 - Disclosure - INCOME TAX",
     "menuCat": "Notes",
     "order": "13",
     "role": "http://www.enterabio.com/role/INCOMETAX",
     "shortName": "INCOME TAX",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2329447.htm",
      "contextRef": "C_20220101to20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2329447.htm",
      "contextRef": "C_20220101to20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "entx:SupplementaryFinancialStatementInformationTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0014 - Disclosure - SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION",
     "menuCat": "Notes",
     "order": "14",
     "role": "http://www.enterabio.com/role/SUPPLEMENTARYFINANCIALSTATEMENTINFORMATION",
     "shortName": "SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2329447.htm",
      "contextRef": "C_20220101to20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "entx:SupplementaryFinancialStatementInformationTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2329447.htm",
      "contextRef": "C_20220101to20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0015 - Disclosure - SUBSEQUENT EVENTS",
     "menuCat": "Notes",
     "order": "15",
     "role": "http://www.enterabio.com/role/SUBSEQUENTEVENT",
     "shortName": "SUBSEQUENT EVENTS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2329447.htm",
      "contextRef": "C_20220101to20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2329447.htm",
      "contextRef": "C_20220101to20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0016 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Policies)",
     "menuCat": "Policies",
     "order": "16",
     "role": "http://www.enterabio.com/role/SIGNIFICANTACCOUNTINGPOLICIESPolicies",
     "shortName": "SIGNIFICANT ACCOUNTING POLICIES (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2329447.htm",
      "contextRef": "C_20220101to20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2329447.htm",
      "contextRef": "C_20220101to20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "entx:ScheduleOfEstimatedUsefulLifeTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0017 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Tables)",
     "menuCat": "Tables",
     "order": "17",
     "role": "http://www.enterabio.com/role/SIGNIFICANTACCOUNTINGPOLICIESTables",
     "shortName": "SIGNIFICANT ACCOUNTING POLICIES (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2329447.htm",
      "contextRef": "C_20220101to20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "entx:ScheduleOfEstimatedUsefulLifeTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2329447.htm",
      "contextRef": "C_20220101to20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0018 - Disclosure - OPERATING LEASES (Tables)",
     "menuCat": "Tables",
     "order": "18",
     "role": "http://www.enterabio.com/role/OPERATINGLEASESTables",
     "shortName": "OPERATING LEASES (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2329447.htm",
      "contextRef": "C_20220101to20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2329447.htm",
      "contextRef": "C_20220101to20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0019 - Disclosure - SHARE-BASED COMPENSATION (Tables)",
     "menuCat": "Tables",
     "order": "19",
     "role": "http://www.enterabio.com/role/SHAREBASEDCOMPENSATIONTables",
     "shortName": "SHARE-BASED COMPENSATION (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2329447.htm",
      "contextRef": "C_20220101to20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2329447.htm",
      "contextRef": "C_20221231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0002 - Statement - CONSOLIDATED BALANCE SHEETS",
     "menuCat": "Statements",
     "order": "2",
     "role": "http://www.enterabio.com/role/CONSOLIDATEDBALANCESHEETS",
     "shortName": "CONSOLIDATED BALANCE SHEETS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2329447.htm",
      "contextRef": "C_20221231",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:AccountsReceivableNetCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2329447.htm",
      "contextRef": "C_20220101to20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0020 - Disclosure - INCOME TAX (Tables)",
     "menuCat": "Tables",
     "order": "20",
     "role": "http://www.enterabio.com/role/INCOMETAXTables",
     "shortName": "INCOME TAX (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2329447.htm",
      "contextRef": "C_20220101to20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "entx:SupplementaryFinancialStatementInformationTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2329447.htm",
      "contextRef": "C_20220101to20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0021 - Disclosure - SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION (Tables)",
     "menuCat": "Tables",
     "order": "21",
     "role": "http://www.enterabio.com/role/SUPPLEMENTARYFINANCIALSTATEMENTINFORMATIONTable",
     "shortName": "SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "entx:SupplementaryFinancialStatementInformationTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2329447.htm",
      "contextRef": "C_20220101to20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:CommonStockParOrStatedValuePerShare",
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2329447.htm",
      "contextRef": "C_20221231",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unitRef": "NIS_per_Share",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0022 - Disclosure - GENERAL (Detail Textuals)",
     "menuCat": "Details",
     "order": "22",
     "role": "http://www.enterabio.com/role/GENERALDetailTextuals",
     "shortName": "GENERAL (Detail Textuals)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "div",
       "entx:ScheduleOfEstimatedUsefulLifeTableTextBlock",
       "div",
       "div",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2329447.htm",
      "contextRef": "C_20220101to20221231_srtRangeAxis_srtMinimumMember_usgaapPropertyPlantAndEquipmentByTypeAxis_usgaapComputerEquipmentMember",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0023 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Details)",
     "menuCat": "Details",
     "order": "23",
     "role": "http://www.enterabio.com/role/SIGNIFICANTACCOUNTINGPOLICIESDetails",
     "shortName": "SIGNIFICANT ACCOUNTING POLICIES (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "div",
       "entx:ScheduleOfEstimatedUsefulLifeTableTextBlock",
       "div",
       "div",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2329447.htm",
      "contextRef": "C_20220101to20221231_srtRangeAxis_srtMinimumMember_usgaapPropertyPlantAndEquipmentByTypeAxis_usgaapComputerEquipmentMember",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "span",
       "span",
       "p",
       "div",
       "div",
       "entx:EmployeeSeveranceBenefitsPolicyPolicyTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2329447.htm",
      "contextRef": "C_20220101to20221231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:SeveranceCosts1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0024 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Detail Textuals)",
     "menuCat": "Details",
     "order": "24",
     "role": "http://www.enterabio.com/role/SIGNIFICANTACCOUNTINGPOLICIESDetailTextuals",
     "shortName": "SIGNIFICANT ACCOUNTING POLICIES (Detail Textuals)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "span",
       "span",
       "p",
       "div",
       "div",
       "entx:EmployeeSeveranceBenefitsPolicyPolicyTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2329447.htm",
      "contextRef": "C_20220101to20221231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:SeveranceCosts1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "us-gaap:LeaseCostTableTextBlock",
       "div",
       "div",
       "div",
       "div",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2329447.htm",
      "contextRef": "C_20220101to20221231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeaseCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0025 - Disclosure - OPERATING LEASE (Details)",
     "menuCat": "Details",
     "order": "25",
     "role": "http://www.enterabio.com/role/OperatingLeaseDetails",
     "shortName": "OPERATING LEASE (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "us-gaap:LeaseCostTableTextBlock",
       "div",
       "div",
       "div",
       "div",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2329447.htm",
      "contextRef": "C_20220101to20221231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeaseCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "entx:OperatingLeaseSupplementalCashFlowInformationTableTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2329447.htm",
      "contextRef": "C_20220101to20221231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeasePayments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0026 - Disclosure - OPERATING LEASE (Details 1)",
     "menuCat": "Details",
     "order": "26",
     "role": "http://www.enterabio.com/role/OperatingLeaseDetails1",
     "shortName": "OPERATING LEASE (Details 1)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "entx:OperatingLeaseSupplementalCashFlowInformationTableTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2329447.htm",
      "contextRef": "C_20220101to20221231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeasePayments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2329447.htm",
      "contextRef": "C_20221231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeaseRightOfUseAsset",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0027 - Disclosure - OPERATING LEASES (Details 2)",
     "menuCat": "Details",
     "order": "27",
     "role": "http://www.enterabio.com/role/OPERATINGLEASESDetails",
     "shortName": "OPERATING LEASES (Details 2)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "entx:OperatingLeaseLiabilityAndOperatingLeaseRightOfUseAssetTableTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2329447.htm",
      "contextRef": "C_20221231",
      "decimals": null,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "entx:OperatingLeaseLiabilityAndOperatingLeaseRightOfUseAssetTableTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2329447.htm",
      "contextRef": "C_20221231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeaseLiability",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0028 - Disclosure - OPERATING LEASES (Detail Textuals)",
     "menuCat": "Details",
     "order": "28",
     "role": "http://www.enterabio.com/role/OPERATINGLEASESDetailTextuals",
     "shortName": "OPERATING LEASES (Detail Textuals)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "div",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2329447.htm",
      "contextRef": "C_20220101to20221231_entxLeaseArrangementAxis_entxOperatingLeaseAgreementsForOfficeAndResearchAndDevelopmentSpaceMember",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:PaymentForContingentConsiderationLiabilityOperatingActivities",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "div",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2329447.htm",
      "contextRef": "C_20220101to20221231_entxAgreementAxis_entxPatentTransferAgreementMember",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "entx:RoyaltyGuaranteesCommitmentsPercentageOfNetRevenues",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Percent",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0029 - Disclosure - COMMITMENTS AND CONTINGENCIES (Detail Textuals)",
     "menuCat": "Details",
     "order": "29",
     "role": "http://www.enterabio.com/role/COMMITMENTSDetailTextuals",
     "shortName": "COMMITMENTS AND CONTINGENCIES (Detail Textuals)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "div",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2329447.htm",
      "contextRef": "C_20220101to20221231_entxAgreementAxis_entxPatentTransferAgreementMember",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "entx:RoyaltyGuaranteesCommitmentsPercentageOfNetRevenues",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Percent",
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:CommonStockParOrStatedValuePerShare",
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2329447.htm",
      "contextRef": "C_20221231",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unitRef": "NIS_per_Share",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0003 - Statement - CONSOLIDATED BALANCE SHEETS (Parentheticals)",
     "menuCat": "Statements",
     "order": "3",
     "role": "http://www.enterabio.com/role/CONSOLIDATEDBALANCESHEETSParentheticals",
     "shortName": "CONSOLIDATED BALANCE SHEETS (Parentheticals)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:CommonStockSharesAuthorized",
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2329447.htm",
      "contextRef": "C_20221231",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:CommonStockSharesAuthorized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "span",
       "span",
       "span",
       "div",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2329447.htm",
      "contextRef": "C_20220101to20221231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0030 - Disclosure - SHARE CAPITAL (Detail Textuals)",
     "menuCat": "Details",
     "order": "30",
     "role": "http://www.enterabio.com/role/SHARECAPITALDetailTextuals",
     "shortName": "SHARE CAPITAL (Detail Textuals)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "span",
       "span",
       "div",
       "div",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2329447.htm",
      "contextRef": "C_20201231_entxEquityProgramAxis_entxAtmEquityProgram2020Member",
      "decimals": "2",
      "lang": null,
      "name": "entx:AdjustedExercisePriceUnderAtMarketEquityProgram",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD_per_Share",
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "span",
       "span",
       "span",
       "div",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "div",
       "div",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2329447.htm",
      "contextRef": "C_20220101to20221231",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Percent",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0031 - Disclosure - SHARE-BASED COMPENSATION (Details)",
     "menuCat": "Details",
     "order": "31",
     "role": "http://www.enterabio.com/role/SHAREBASEDCOMPENSATIONDetails",
     "shortName": "SHARE-BASED COMPENSATION (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "span",
       "span",
       "span",
       "div",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "div",
       "div",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2329447.htm",
      "contextRef": "C_20220101to20221231",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Percent",
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "span",
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "div",
       "div",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2329447.htm",
      "contextRef": "C_20211231",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0032 - Disclosure - SHARE-BASED COMPENSATION (Details 1)",
     "menuCat": "Details",
     "order": "32",
     "role": "http://www.enterabio.com/role/SHAREBASEDCOMPENSATIONDetails1",
     "shortName": "SHARE-BASED COMPENSATION (Details 1)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "span",
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "div",
       "div",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2329447.htm",
      "contextRef": "C_20220101to20221231",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "span",
       "span",
       "span",
       "div",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "div",
       "div",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2329447.htm",
      "contextRef": "C_20221231",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
      "reportCount": 1,
      "unitRef": "USD_per_Share",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0033 - Disclosure - SHARE-BASED COMPENSATION (Details 2)",
     "menuCat": "Details",
     "order": "33",
     "role": "http://www.enterabio.com/role/SHAREBASEDCOMPENSATIONDetails2",
     "shortName": "SHARE-BASED COMPENSATION (Details 2)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "span",
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2329447.htm",
      "contextRef": "C_20221231_usgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_entxExercisePricePerShareZeroMember",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD_per_Share",
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "span",
       "span",
       "span",
       "div",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2329447.htm",
      "contextRef": "C_20220101to20221231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0034 - Disclosure - SHARE-BASED COMPENSATION (Details 3)",
     "menuCat": "Details",
     "order": "34",
     "role": "http://www.enterabio.com/role/SHAREBASEDCOMPENSATIONDetails3",
     "shortName": "SHARE-BASED COMPENSATION (Details 3)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "span",
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2329447.htm",
      "contextRef": "C_20220101to20221231_usgaapIncomeStatementLocationAxis_usgaapCostOfSalesMember",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2329447.htm",
      "contextRef": "C_20220101to20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0035 - Disclosure - SHARE-BASED COMPENSATION (Detail Textuals)",
     "menuCat": "Details",
     "order": "35",
     "role": "http://www.enterabio.com/role/SHAREBASEDCOMPENSATIONDetailTextuals",
     "shortName": "SHARE-BASED COMPENSATION (Detail Textuals)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2329447.htm",
      "contextRef": "C_20220101to20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2329447.htm",
      "contextRef": "C_20220101to20221231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0036 - Disclosure - INCOME TAX (Details)",
     "menuCat": "Details",
     "order": "36",
     "role": "http://www.enterabio.com/role/INCOMETAXDetails1",
     "shortName": "INCOME TAX (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2329447.htm",
      "contextRef": "C_20220101to20221231_deiLegalEntityAxis_entxEnteraBioLtdMember",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "div",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "div",
       "div",
       "div",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2329447.htm",
      "contextRef": "C_20220101to20221231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CurrentIncomeTaxExpenseBenefit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0037 - Disclosure - INCOME TAX (Details 1)",
     "menuCat": "Details",
     "order": "37",
     "role": "http://www.enterabio.com/role/INCOMETAXDetails3",
     "shortName": "INCOME TAX (Details 1)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "div",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "div",
       "div",
       "div",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2329447.htm",
      "contextRef": "C_20220101to20221231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CurrentIncomeTaxExpenseBenefit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "div",
       "div",
       "div",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2329447.htm",
      "contextRef": "C_20221231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0038 - Disclosure - INCOME TAX (Details 2)",
     "menuCat": "Details",
     "order": "38",
     "role": "http://www.enterabio.com/role/INCOMETAXDetails",
     "shortName": "INCOME TAX (Details 2)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "div",
       "div",
       "div",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2329447.htm",
      "contextRef": "C_20221231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "span",
       "span",
       "div",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "div",
       "div",
       "div",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2329447.htm",
      "contextRef": "C_20211231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:DeferredTaxAssetsValuationAllowance",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0039 - Disclosure - INCOME TAX (Details 3)",
     "menuCat": "Details",
     "order": "39",
     "role": "http://www.enterabio.com/role/INCOMETAXDetails2",
     "shortName": "INCOME TAX (Details 3)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "span",
       "span",
       "span",
       "span",
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:SummaryOfValuationAllowanceTextBlock",
       "div",
       "div",
       "div",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2329447.htm",
      "contextRef": "C_20220101to20221231",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2329447.htm",
      "contextRef": "C_20220101to20221231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0004 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS",
     "menuCat": "Statements",
     "order": "4",
     "role": "http://www.enterabio.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS",
     "shortName": "CONSOLIDATED STATEMENTS OF OPERATIONS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2329447.htm",
      "contextRef": "C_20220101to20221231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2329447.htm",
      "contextRef": "C_20221231",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0040 - Disclosure - INCOME TAX (Detail Textuals)",
     "menuCat": "Details",
     "order": "40",
     "role": "http://www.enterabio.com/role/INCOMETAXDetailTextuals",
     "shortName": "INCOME TAX (Detail Textuals)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2329447.htm",
      "contextRef": "C_20221231",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
       "div",
       "entx:SupplementaryFinancialStatementInformationTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2329447.htm",
      "contextRef": "C_20221231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AccruedEmployeeBenefitsCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0041 - Disclosure - SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION (Details)",
     "menuCat": "Details",
     "order": "41",
     "role": "http://www.enterabio.com/role/SUPPLEMENTARYFINANCIALSTATEMENTINFORMATIONDetails",
     "shortName": "SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
       "div",
       "entx:SupplementaryFinancialStatementInformationTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2329447.htm",
      "contextRef": "C_20221231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AccruedEmployeeBenefitsCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "span",
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "div",
       "div",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2329447.htm",
      "contextRef": "C_20220101to20221231",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0042 - Disclosure - SUBSEQUENT EVENTS (Detail Textuals)",
     "menuCat": "Details",
     "order": "42",
     "role": "http://www.enterabio.com/role/SUBSEQUENTEVENTSNarrative",
     "shortName": "SUBSEQUENT EVENTS (Detail Textuals)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "us-gaap:SubsequentEventsTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2329447.htm",
      "contextRef": "C_20230101to20230102_srtTitleOfIndividualAxis_entxNonExecutiveBoardMember_usgaapSubsequentEventTypeAxis_usgaapSubsequentEventMember",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2329447.htm",
      "contextRef": "C_20201231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockholdersEquity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0005 - Statement - CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY",
     "menuCat": "Statements",
     "order": "5",
     "role": "http://www.enterabio.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY",
     "shortName": "CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2329447.htm",
      "contextRef": "C_20201231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockholdersEquity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2329447.htm",
      "contextRef": "C_20220101to20221231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0006 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "menuCat": "Statements",
     "order": "6",
     "role": "http://www.enterabio.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
     "shortName": "CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2329447.htm",
      "contextRef": "C_20220101to20221231",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:Depreciation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2329447.htm",
      "contextRef": "C_20220101to20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0007 - Disclosure - GENERAL",
     "menuCat": "Notes",
     "order": "7",
     "role": "http://www.enterabio.com/role/GENERAL",
     "shortName": "GENERAL",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2329447.htm",
      "contextRef": "C_20220101to20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2329447.htm",
      "contextRef": "C_20220101to20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0008 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES",
     "menuCat": "Notes",
     "order": "8",
     "role": "http://www.enterabio.com/role/SIGNIFICANTACCOUNTINGPOLICIES",
     "shortName": "SIGNIFICANT ACCOUNTING POLICIES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2329447.htm",
      "contextRef": "C_20220101to20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2329447.htm",
      "contextRef": "C_20220101to20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0009 - Disclosure - OPERATING LEASES",
     "menuCat": "Notes",
     "order": "9",
     "role": "http://www.enterabio.com/role/OPERATINGLEASES",
     "shortName": "OPERATING LEASES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2329447.htm",
      "contextRef": "C_20220101to20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 69,
   "tag": {
    "dei_AmendmentDescription": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of changes contained within amended document.",
        "label": "Amendment Description"
       }
      }
     },
     "localname": "AmendmentDescription",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.enterabio.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.enterabio.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AuditorFirmId": {
     "auth_ref": [
      "r403",
      "r405",
      "r406"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "PCAOB issued Audit Firm Identifier",
        "label": "Auditor Firm ID"
       }
      }
     },
     "localname": "AuditorFirmId",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.enterabio.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "nonemptySequenceNumberItemType"
    },
    "dei_AuditorLocation": {
     "auth_ref": [
      "r403",
      "r405",
      "r406"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Location"
       }
      }
     },
     "localname": "AuditorLocation",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.enterabio.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "internationalNameItemType"
    },
    "dei_AuditorName": {
     "auth_ref": [
      "r403",
      "r405",
      "r406"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Name"
       }
      }
     },
     "localname": "AuditorName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.enterabio.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "internationalNameItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.enterabio.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]",
        "terseLabel": "CURRENT ASSETS"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.enterabio.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentAnnualReport": {
     "auth_ref": [
      "r403",
      "r405",
      "r406"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an annual report.",
        "label": "Document Annual Report"
       }
      }
     },
     "localname": "DocumentAnnualReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.enterabio.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.enterabio.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.enterabio.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.enterabio.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r404"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.enterabio.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r407"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.enterabio.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.enterabio.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.enterabio.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.enterabio.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine3": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 3 such as an Office Park",
        "label": "Entity Address, Address Line Three"
       }
      }
     },
     "localname": "EntityAddressAddressLine3",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.enterabio.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.enterabio.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCountry": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ISO 3166-1 alpha-2 country code.",
        "label": "Entity Address, Country"
       }
      }
     },
     "localname": "EntityAddressCountry",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.enterabio.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "countryCodeItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.enterabio.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.enterabio.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r401"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.enterabio.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.enterabio.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.enterabio.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains.",
        "label": "Entity [Domain]"
       }
      }
     },
     "localname": "EntityDomain",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.enterabio.com/role/INCOMETAXDetails1"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r401"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.enterabio.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityExTransitionPeriod": {
     "auth_ref": [
      "r410"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.",
        "label": "Entity Ex Transition Period"
       }
      }
     },
     "localname": "EntityExTransitionPeriod",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.enterabio.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.enterabio.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r401"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.enterabio.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.enterabio.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r408"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.enterabio.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityPublicFloat": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.",
        "label": "Entity Public Float"
       }
      }
     },
     "localname": "EntityPublicFloat",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.enterabio.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r401"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.enterabio.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r401"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.enterabio.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r401"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.enterabio.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r401"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.enterabio.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_EntityVoluntaryFilers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.",
        "label": "Entity Voluntary Filers"
       }
      }
     },
     "localname": "EntityVoluntaryFilers",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.enterabio.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "auth_ref": [
      "r409"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.",
        "label": "Entity Well-known Seasoned Issuer"
       }
      }
     },
     "localname": "EntityWellKnownSeasonedIssuer",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.enterabio.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_LegalEntityAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The set of legal entities associated with a report.",
        "label": "Legal Entity [Axis]"
       }
      }
     },
     "localname": "LegalEntityAxis",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.enterabio.com/role/INCOMETAXDetails1"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.enterabio.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r400"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.enterabio.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r402"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.enterabio.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.enterabio.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "entx_AccreditedInvestorsIncludingCertainBoardMembersAndTheirAffiliatesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information regarding accredited investors, including certain board members and their affiliates.",
        "label": "Accredited Investors, Including Certain Board Members And Their Affiliates [Member]",
        "verboseLabel": "Accredited investors, including certain board members and their affiliates [Member]"
       }
      }
     },
     "localname": "AccreditedInvestorsIncludingCertainBoardMembersAndTheirAffiliatesMember",
     "nsuri": "http://www.enterabio.com/20221231",
     "presentation": [
      "http://www.enterabio.com/role/SHARECAPITALDetailTextuals"
     ],
     "xbrltype": "domainItemType"
    },
    "entx_AdditionalAmountPaidForServicesToBeRecognized": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the additional amount paid for services to be recognized.",
        "label": "Additional Amount Paid For Services To Be Recognized",
        "verboseLabel": "Additional amount paid for services to be recognized upon commencement of the pre-clinical Research and Development services"
       }
      }
     },
     "localname": "AdditionalAmountPaidForServicesToBeRecognized",
     "nsuri": "http://www.enterabio.com/20221231",
     "presentation": [
      "http://www.enterabio.com/role/SIGNIFICANTACCOUNTINGPOLICIESDetailTextuals"
     ],
     "xbrltype": "monetaryItemType"
    },
    "entx_AdditionalCashSeparationPayment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents about additional cash separation payment.",
        "label": "Additional Cash Separation Payment",
        "terseLabel": "Additional cash separation payment"
       }
      }
     },
     "localname": "AdditionalCashSeparationPayment",
     "nsuri": "http://www.enterabio.com/20221231",
     "presentation": [
      "http://www.enterabio.com/role/SHAREBASEDCOMPENSATIONDetailTextuals"
     ],
     "xbrltype": "monetaryItemType"
    },
    "entx_AdjustedExercisePriceUnderAtMarketEquityProgram": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Adjusted Exercise Price under At-the-market equity program.",
        "label": "Adjusted Exercise Price Under At Market Equity Program",
        "terseLabel": "Adjusted exercise price under At-the-market equity program"
       }
      }
     },
     "localname": "AdjustedExercisePriceUnderAtMarketEquityProgram",
     "nsuri": "http://www.enterabio.com/20221231",
     "presentation": [
      "http://www.enterabio.com/role/SHARECAPITALDetailTextuals"
     ],
     "xbrltype": "perShareItemType"
    },
    "entx_AgreementAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by the type of agreements.",
        "label": "Agreement [Axis]"
       }
      }
     },
     "localname": "AgreementAxis",
     "nsuri": "http://www.enterabio.com/20221231",
     "presentation": [
      "http://www.enterabio.com/role/COMMITMENTSDetailTextuals"
     ],
     "xbrltype": "stringItemType"
    },
    "entx_AgreementDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the agreement",
        "label": "Agreement [Domain]"
       }
      }
     },
     "localname": "AgreementDomain",
     "nsuri": "http://www.enterabio.com/20221231",
     "presentation": [
      "http://www.enterabio.com/role/COMMITMENTSDetailTextuals"
     ],
     "xbrltype": "domainItemType"
    },
    "entx_AmendmentToBusinessDevelopmentServicesAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amendment to business development services agreement.",
        "label": "Amendment To Business Development Services Agreement [Member]",
        "terseLabel": "Amendment to business development services agreement [Member]"
       }
      }
     },
     "localname": "AmendmentToBusinessDevelopmentServicesAgreementMember",
     "nsuri": "http://www.enterabio.com/20221231",
     "presentation": [
      "http://www.enterabio.com/role/SHAREBASEDCOMPENSATIONDetailTextuals"
     ],
     "xbrltype": "domainItemType"
    },
    "entx_AmgenIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents one of the related party.",
        "label": "Amgen Inc [Member]",
        "terseLabel": "From Amgen [Member]",
        "verboseLabel": "Amgen Inc [Member]"
       }
      }
     },
     "localname": "AmgenIncMember",
     "nsuri": "http://www.enterabio.com/20221231",
     "presentation": [
      "http://www.enterabio.com/role/SIGNIFICANTACCOUNTINGPOLICIESDetailTextuals"
     ],
     "xbrltype": "domainItemType"
    },
    "entx_AtmEquityProgram2020Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information related to at-the-market equity program for 2020.",
        "label": "Atm Equity Program 2020 [Member]",
        "verboseLabel": "ATM Equity Program 2020 [Member]"
       }
      }
     },
     "localname": "AtmEquityProgram2020Member",
     "nsuri": "http://www.enterabio.com/20221231",
     "presentation": [
      "http://www.enterabio.com/role/SHARECAPITALDetailTextuals"
     ],
     "xbrltype": "domainItemType"
    },
    "entx_AtmEquityProgram2021Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information related to at-the-market equity program for 2021.",
        "label": "Atm Equity Program 2021 [Member]",
        "verboseLabel": "ATM Equity Program 2021 [Member]"
       }
      }
     },
     "localname": "AtmEquityProgram2021Member",
     "nsuri": "http://www.enterabio.com/20221231",
     "presentation": [
      "http://www.enterabio.com/role/SHARECAPITALDetailTextuals"
     ],
     "xbrltype": "domainItemType"
    },
    "entx_BankGuarantees": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the value of bank guarantees.",
        "label": "Bank Guarantees",
        "verboseLabel": "Value of bank guarantees provided"
       }
      }
     },
     "localname": "BankGuarantees",
     "nsuri": "http://www.enterabio.com/20221231",
     "presentation": [
      "http://www.enterabio.com/role/OPERATINGLEASESDetailTextuals"
     ],
     "xbrltype": "monetaryItemType"
    },
    "entx_BrokerDealerMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stand for broker-dealer.",
        "label": "Broker Dealer [Member]"
       }
      }
     },
     "localname": "BrokerDealerMember",
     "nsuri": "http://www.enterabio.com/20221231",
     "presentation": [
      "http://www.enterabio.com/role/SHARECAPITALDetailTextuals"
     ],
     "xbrltype": "domainItemType"
    },
    "entx_BrokerDealerOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stand for broker-dealer one.",
        "label": "Broker Dealer One [Member]",
        "verboseLabel": "Broker-Dealer 1 [Member]"
       }
      }
     },
     "localname": "BrokerDealerOneMember",
     "nsuri": "http://www.enterabio.com/20221231",
     "presentation": [
      "http://www.enterabio.com/role/SHARECAPITALDetailTextuals"
     ],
     "xbrltype": "domainItemType"
    },
    "entx_BrokerWarrantsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the type of warrants as broker warrants.",
        "label": "Broker Warrants [Member]",
        "verboseLabel": "Broker Warrants [Member]"
       }
      }
     },
     "localname": "BrokerWarrantsMember",
     "nsuri": "http://www.enterabio.com/20221231",
     "presentation": [
      "http://www.enterabio.com/role/SHARECAPITALDetailTextuals"
     ],
     "xbrltype": "domainItemType"
    },
    "entx_BrokerWarrantsType1Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the type of warrant as Broker Warrants Type 1.",
        "label": "Broker Warrants Type 1 [Member]",
        "verboseLabel": "Broker Warrants Type 1 [Member]"
       }
      }
     },
     "localname": "BrokerWarrantsType1Member",
     "nsuri": "http://www.enterabio.com/20221231",
     "presentation": [
      "http://www.enterabio.com/role/SHARECAPITALDetailTextuals"
     ],
     "xbrltype": "domainItemType"
    },
    "entx_BrokerWarrantsType2Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the type of warrants as Broker Warrants Type 2.",
        "label": "Broker Warrants Type 2 [Member]",
        "verboseLabel": "Broker Warrants Type 2 [Member]"
       }
      }
     },
     "localname": "BrokerWarrantsType2Member",
     "nsuri": "http://www.enterabio.com/20221231",
     "presentation": [
      "http://www.enterabio.com/role/SHARECAPITALDetailTextuals"
     ],
     "xbrltype": "domainItemType"
    },
    "entx_CashFeesInPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the cash fees in percentage.",
        "label": "Cash Fees In Percentage",
        "verboseLabel": "Cash fees in percentage of total proceeds paid by subscribers invested through the Broker"
       }
      }
     },
     "localname": "CashFeesInPercentage",
     "nsuri": "http://www.enterabio.com/20221231",
     "presentation": [
      "http://www.enterabio.com/role/SHARECAPITALDetailTextuals"
     ],
     "xbrltype": "percentItemType"
    },
    "entx_CashSeparationPayment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents about cash separation payment.",
        "label": "Cash Separation Payment",
        "terseLabel": "Cash separation payment"
       }
      }
     },
     "localname": "CashSeparationPayment",
     "nsuri": "http://www.enterabio.com/20221231",
     "presentation": [
      "http://www.enterabio.com/role/SHAREBASEDCOMPENSATIONDetailTextuals"
     ],
     "xbrltype": "monetaryItemType"
    },
    "entx_ChairmanOfBoardAndDnaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information regarding two related parties.",
        "label": "Chairman Of Board And Dna [Member]",
        "verboseLabel": "Chairman of the board and DNA [Member]"
       }
      }
     },
     "localname": "ChairmanOfBoardAndDnaMember",
     "nsuri": "http://www.enterabio.com/20221231",
     "presentation": [
      "http://www.enterabio.com/role/SHARECAPITALDetailTextuals"
     ],
     "xbrltype": "domainItemType"
    },
    "entx_ClassOfWarrantOrRightExerciseTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the exercise period of warrants or rights.",
        "label": "Class Of Warrant Or Right, Exercise Term",
        "verboseLabel": "Term of warrants issued"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightExerciseTerm",
     "nsuri": "http://www.enterabio.com/20221231",
     "presentation": [
      "http://www.enterabio.com/role/SHARECAPITALDetailTextuals"
     ],
     "xbrltype": "durationItemType"
    },
    "entx_ClassOfWarrantOrRightIssued": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the number of warrants or rights issued.",
        "label": "Class Of Warrant Or Right, Issued",
        "verboseLabel": "Number of warrants issued"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightIssued",
     "nsuri": "http://www.enterabio.com/20221231",
     "presentation": [
      "http://www.enterabio.com/role/GENERALDetailTextuals",
      "http://www.enterabio.com/role/SHARECAPITALDetailTextuals"
     ],
     "xbrltype": "sharesItemType"
    },
    "entx_ClassOfWarrantOrRightPercentageOfIpoPricePerUnit": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the percentage of IPO price per unit of warrants or rights.",
        "label": "Class Of Warrant Or Right, Percentage Of Ipo Price Per Unit",
        "verboseLabel": "Percentage of IPO price per unit"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightPercentageOfIpoPricePerUnit",
     "nsuri": "http://www.enterabio.com/20221231",
     "presentation": [
      "http://www.enterabio.com/role/SHARECAPITALDetailTextuals"
     ],
     "xbrltype": "percentItemType"
    },
    "entx_ClassOfWarrantOrRightReducedExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the reduced exercise price of warrants or rights.",
        "label": "Class Of Warrant Or Right, Reduced Exercise Price",
        "verboseLabel": "Reduced exercise price"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightReducedExercisePrice",
     "nsuri": "http://www.enterabio.com/20221231",
     "presentation": [
      "http://www.enterabio.com/role/SHARECAPITALDetailTextuals"
     ],
     "xbrltype": "perShareItemType"
    },
    "entx_ClassOfWarrantOrRightThresholdConsecutiveTradingDays": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the threshold period of specified consecutive trading days.",
        "label": "Class Of Warrant Or Right, Threshold Consecutive Trading Days",
        "verboseLabel": "Threshold consecutive trading days"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightThresholdConsecutiveTradingDays",
     "nsuri": "http://www.enterabio.com/20221231",
     "presentation": [
      "http://www.enterabio.com/role/SHARECAPITALDetailTextuals"
     ],
     "xbrltype": "durationItemType"
    },
    "entx_ClassOfWarrantOrRightThresholdLimitOfLastReportedSalePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the threshold limit of last reported sale price of warrants or rights.",
        "label": "Class Of Warrant Or Right, Threshold Limit Of Last Reported Sale Price",
        "verboseLabel": "Threshold limit of last reported sale price"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightThresholdLimitOfLastReportedSalePrice",
     "nsuri": "http://www.enterabio.com/20221231",
     "presentation": [
      "http://www.enterabio.com/role/SHARECAPITALDetailTextuals"
     ],
     "xbrltype": "perShareItemType"
    },
    "entx_ClassOfWarrantOrRightThresholdLimitOfPeriodForReductionInExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the threshold limit of period for reduction in exercise price of warrants or rights.",
        "label": "Class Of Warrant Or Right, Threshold Limit Of Period For Reduction In Exercise Price",
        "verboseLabel": "Threshold limit of period for reduction in exercise price"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightThresholdLimitOfPeriodForReductionInExercisePrice",
     "nsuri": "http://www.enterabio.com/20221231",
     "presentation": [
      "http://www.enterabio.com/role/SHARECAPITALDetailTextuals"
     ],
     "xbrltype": "durationItemType"
    },
    "entx_ClassOfWarrantOrRightThresholdLimitOfReductionInExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the threshold limit of reduction in exercise price of warrants or rights.",
        "label": "Class Of Warrant Or Right, Threshold Limit Of Reduction In Exercise Price",
        "verboseLabel": "Threshold limit of reduction in exercise price"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightThresholdLimitOfReductionInExercisePrice",
     "nsuri": "http://www.enterabio.com/20221231",
     "presentation": [
      "http://www.enterabio.com/role/SHARECAPITALDetailTextuals"
     ],
     "xbrltype": "perShareItemType"
    },
    "entx_CommitmentsAndContingenciesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information and financial data about the commitments.",
        "label": "Commitments And Contingencies [Table]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesTable",
     "nsuri": "http://www.enterabio.com/20221231",
     "presentation": [
      "http://www.enterabio.com/role/COMMITMENTSDetailTextuals"
     ],
     "xbrltype": "stringItemType"
    },
    "entx_CommitmentsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Commitments [Line Items]"
       }
      }
     },
     "localname": "CommitmentsLineItems",
     "nsuri": "http://www.enterabio.com/20221231",
     "presentation": [
      "http://www.enterabio.com/role/COMMITMENTSDetailTextuals"
     ],
     "xbrltype": "stringItemType"
    },
    "entx_ConsultantMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information of consultant.",
        "label": "Consultant [Member]",
        "terseLabel": "Consultant [Member]"
       }
      }
     },
     "localname": "ConsultantMember",
     "nsuri": "http://www.enterabio.com/20221231",
     "presentation": [
      "http://www.enterabio.com/role/SHAREBASEDCOMPENSATIONDetailTextuals"
     ],
     "xbrltype": "domainItemType"
    },
    "entx_DnaBiomedicalSolutionsLtdAndOramedLtdMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information regarding both of the related parties combined.",
        "label": "Dna Biomedical Solutions Ltd And Oramed Ltd [Member]",
        "verboseLabel": "D. N. A Biomedical Solutions Ltd And Oramed Ltd [Member]"
       }
      }
     },
     "localname": "DnaBiomedicalSolutionsLtdAndOramedLtdMember",
     "nsuri": "http://www.enterabio.com/20221231",
     "presentation": [
      "http://www.enterabio.com/role/COMMITMENTSDetailTextuals"
     ],
     "xbrltype": "domainItemType"
    },
    "entx_DnaBiomedicalSolutionsLtdMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information regarding one of the related parties.",
        "label": "Dna Biomedical Solutions Ltd [Member]",
        "verboseLabel": "D.N.A Biomedical Solutions Ltd [Member]"
       }
      }
     },
     "localname": "DnaBiomedicalSolutionsLtdMember",
     "nsuri": "http://www.enterabio.com/20221231",
     "presentation": [
      "http://www.enterabio.com/role/COMMITMENTSDetailTextuals",
      "http://www.enterabio.com/role/SHARECAPITALDetailTextuals"
     ],
     "xbrltype": "domainItemType"
    },
    "entx_EffectOfDownRoundTriggerAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "It represents effect of down round trigger amount.",
        "label": "Effect Of Down Round Trigger Amount",
        "verboseLabel": "Effect of down round trigger amount"
       }
      }
     },
     "localname": "EffectOfDownRoundTriggerAmount",
     "nsuri": "http://www.enterabio.com/20221231",
     "presentation": [
      "http://www.enterabio.com/role/SHARECAPITALDetailTextuals"
     ],
     "xbrltype": "monetaryItemType"
    },
    "entx_EmployeeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Employee [Member]",
        "label": "Employee [Member]",
        "terseLabel": "Employee [Member]"
       }
      }
     },
     "localname": "EmployeeMember",
     "nsuri": "http://www.enterabio.com/20221231",
     "presentation": [
      "http://www.enterabio.com/role/SHAREBASEDCOMPENSATIONDetailTextuals"
     ],
     "xbrltype": "domainItemType"
    },
    "entx_EmployeeSeveranceBenefitsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for employee severance benefits.",
        "label": "Employee Severance Benefits Policy [Policy Text Block]",
        "verboseLabel": "Employee severance benefits"
       }
      }
     },
     "localname": "EmployeeSeveranceBenefitsPolicyPolicyTextBlock",
     "nsuri": "http://www.enterabio.com/20221231",
     "presentation": [
      "http://www.enterabio.com/role/SIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "entx_EmployeesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information of employees.",
        "label": "Employees [Member]",
        "terseLabel": "Certain employees [Member]"
       }
      }
     },
     "localname": "EmployeesMember",
     "nsuri": "http://www.enterabio.com/20221231",
     "presentation": [
      "http://www.enterabio.com/role/SHAREBASEDCOMPENSATIONDetailTextuals"
     ],
     "xbrltype": "domainItemType"
    },
    "entx_EnteraBioLtdMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for Entera Bio Ltd.",
        "label": "Entera Bio Ltd [Member]",
        "verboseLabel": "Entera Bio Ltd"
       }
      }
     },
     "localname": "EnteraBioLtdMember",
     "nsuri": "http://www.enterabio.com/20221231",
     "presentation": [
      "http://www.enterabio.com/role/INCOMETAXDetails1"
     ],
     "xbrltype": "domainItemType"
    },
    "entx_EquityProgramAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by equity program.",
        "label": "Equity Program [Axis]"
       }
      }
     },
     "localname": "EquityProgramAxis",
     "nsuri": "http://www.enterabio.com/20221231",
     "presentation": [
      "http://www.enterabio.com/role/SHARECAPITALDetailTextuals"
     ],
     "xbrltype": "stringItemType"
    },
    "entx_EquityProgramDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the equity program.",
        "label": "Equity Program [Domain]"
       }
      }
     },
     "localname": "EquityProgramDomain",
     "nsuri": "http://www.enterabio.com/20221231",
     "presentation": [
      "http://www.enterabio.com/role/SHARECAPITALDetailTextuals"
     ],
     "xbrltype": "domainItemType"
    },
    "entx_ExecutiveOfficerAndServiceProviderMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents about executive officer and service provider.",
        "label": "Executive Officer And Service Provider [Member]",
        "terseLabel": "Executive Officer and Service Provider [Member]"
       }
      }
     },
     "localname": "ExecutiveOfficerAndServiceProviderMember",
     "nsuri": "http://www.enterabio.com/20221231",
     "presentation": [
      "http://www.enterabio.com/role/SHAREBASEDCOMPENSATIONDetailTextuals"
     ],
     "xbrltype": "domainItemType"
    },
    "entx_ExerciseOfWarrantsShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of warrants exercise.",
        "label": "Exercise Of Warrants Shares",
        "terseLabel": "Exercise of warrants to ordinary shares (in shares)"
       }
      }
     },
     "localname": "ExerciseOfWarrantsShares",
     "nsuri": "http://www.enterabio.com/20221231",
     "presentation": [
      "http://www.enterabio.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY"
     ],
     "xbrltype": "sharesItemType"
    },
    "entx_ExerciseOfWarrantsValue": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the exercise of warrants.",
        "label": "Exercise Of Warrants Value",
        "terseLabel": "Exercise of warrants to ordinary shares"
       }
      }
     },
     "localname": "ExerciseOfWarrantsValue",
     "nsuri": "http://www.enterabio.com/20221231",
     "presentation": [
      "http://www.enterabio.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "entx_ExercisePricePerShareOnePointFourMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member is stand for 1.4.",
        "label": "Exercise Price Per Share One Point Four [Member]",
        "verboseLabel": "Exercise Price Per Share - 1.4"
       }
      }
     },
     "localname": "ExercisePricePerShareOnePointFourMember",
     "nsuri": "http://www.enterabio.com/20221231",
     "presentation": [
      "http://www.enterabio.com/role/SHAREBASEDCOMPENSATIONDetails2"
     ],
     "xbrltype": "domainItemType"
    },
    "entx_ExercisePricePerShareOnePointTwoFourMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise price per share 1.24.",
        "label": "Exercise Price Per Share One Point Two Four [Member]",
        "terseLabel": "Exercise Price Per Share - 1.24"
       }
      }
     },
     "localname": "ExercisePricePerShareOnePointTwoFourMember",
     "nsuri": "http://www.enterabio.com/20221231",
     "presentation": [
      "http://www.enterabio.com/role/SHAREBASEDCOMPENSATIONDetails2"
     ],
     "xbrltype": "domainItemType"
    },
    "entx_ExercisePricePerShareOnePointZeroSixMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise Price Per Share 1.06.",
        "label": "Exercise Price Per Share One Point Zero Six [Member]",
        "terseLabel": "Exercise Price Per Share - 1.06"
       }
      }
     },
     "localname": "ExercisePricePerShareOnePointZeroSixMember",
     "nsuri": "http://www.enterabio.com/20221231",
     "presentation": [
      "http://www.enterabio.com/role/SHAREBASEDCOMPENSATIONDetails2"
     ],
     "xbrltype": "domainItemType"
    },
    "entx_ExercisePricePerShareSixPointThreeOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise Price Per Share 6.31.",
        "label": "Exercise Price Per Share Six Point Three One [Member]",
        "terseLabel": "Exercise Price Per Share - 6.31"
       }
      }
     },
     "localname": "ExercisePricePerShareSixPointThreeOneMember",
     "nsuri": "http://www.enterabio.com/20221231",
     "presentation": [
      "http://www.enterabio.com/role/SHAREBASEDCOMPENSATIONDetails2"
     ],
     "xbrltype": "domainItemType"
    },
    "entx_ExercisePricePerShareThreePointNineSevenMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise Price Per Share 3.97.",
        "label": "Exercise Price Per Share Three Point Nine Seven [Member]",
        "terseLabel": "Exercise Price Per Share - 3.97"
       }
      }
     },
     "localname": "ExercisePricePerShareThreePointNineSevenMember",
     "nsuri": "http://www.enterabio.com/20221231",
     "presentation": [
      "http://www.enterabio.com/role/SHAREBASEDCOMPENSATIONDetails2"
     ],
     "xbrltype": "domainItemType"
    },
    "entx_ExercisePricePerShareThreePointOneFiveMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise Price Per Share 3.15.",
        "label": "Exercise Price Per Share Three Point One Five [Member]",
        "terseLabel": "Exercise Price Per Share - 3.15"
       }
      }
     },
     "localname": "ExercisePricePerShareThreePointOneFiveMember",
     "nsuri": "http://www.enterabio.com/20221231",
     "presentation": [
      "http://www.enterabio.com/role/SHAREBASEDCOMPENSATIONDetails2"
     ],
     "xbrltype": "domainItemType"
    },
    "entx_ExercisePricePerShareThreePointSixEightMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise Price Per Share 3.68.",
        "label": "Exercise Price Per Share Three Point Six Eight [Member]",
        "terseLabel": "Exercise Price Per Share - 3.68"
       }
      }
     },
     "localname": "ExercisePricePerShareThreePointSixEightMember",
     "nsuri": "http://www.enterabio.com/20221231",
     "presentation": [
      "http://www.enterabio.com/role/SHAREBASEDCOMPENSATIONDetails2"
     ],
     "xbrltype": "domainItemType"
    },
    "entx_ExercisePricePerShareThreePointSixOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise Price Per Share 3.61.",
        "label": "Exercise Price Per Share Three Point Six One [Member]",
        "terseLabel": "Exercise Price Per Share - 3.61"
       }
      }
     },
     "localname": "ExercisePricePerShareThreePointSixOneMember",
     "nsuri": "http://www.enterabio.com/20221231",
     "presentation": [
      "http://www.enterabio.com/role/SHAREBASEDCOMPENSATIONDetails2"
     ],
     "xbrltype": "domainItemType"
    },
    "entx_ExercisePricePerShareTwoPointEightOneFiveMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member is stand for exercise price per 2.815",
        "label": "Exercise Price Per Share Two Point Eight One Five [Member]",
        "verboseLabel": "Exercise Price Per Share - 2.815"
       }
      }
     },
     "localname": "ExercisePricePerShareTwoPointEightOneFiveMember",
     "nsuri": "http://www.enterabio.com/20221231",
     "presentation": [
      "http://www.enterabio.com/role/SHAREBASEDCOMPENSATIONDetails2"
     ],
     "xbrltype": "domainItemType"
    },
    "entx_ExercisePricePerShareTwoPointEightSixMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member is stand for exercise price per 2.86.",
        "label": "Exercise Price Per Share Two Point Eight Six [Member]",
        "verboseLabel": "Exercise Price Per Share - 2.86"
       }
      }
     },
     "localname": "ExercisePricePerShareTwoPointEightSixMember",
     "nsuri": "http://www.enterabio.com/20221231",
     "presentation": [
      "http://www.enterabio.com/role/SHAREBASEDCOMPENSATIONDetails2"
     ],
     "xbrltype": "domainItemType"
    },
    "entx_ExercisePricePerShareTwoPointFiveSevenMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member is stand for exercise price per 2.57.",
        "label": "Exercise Price Per Share Two Point Five Seven [Member]",
        "verboseLabel": "Exercise Price Per Share - 2.57"
       }
      }
     },
     "localname": "ExercisePricePerShareTwoPointFiveSevenMember",
     "nsuri": "http://www.enterabio.com/20221231",
     "presentation": [
      "http://www.enterabio.com/role/SHAREBASEDCOMPENSATIONDetails2"
     ],
     "xbrltype": "domainItemType"
    },
    "entx_ExercisePricePerShareTwoPointFiveThreeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise Price Per Share 2.53.",
        "label": "Exercise Price Per Share Two Point Five Three [Member]",
        "terseLabel": "Exercise Price Per Share - 2.53"
       }
      }
     },
     "localname": "ExercisePricePerShareTwoPointFiveThreeMember",
     "nsuri": "http://www.enterabio.com/20221231",
     "presentation": [
      "http://www.enterabio.com/role/SHAREBASEDCOMPENSATIONDetails2"
     ],
     "xbrltype": "domainItemType"
    },
    "entx_ExercisePricePerShareTwoPointOneFourMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise Price Per Share 2.14.",
        "label": "Exercise Price Per Share Two Point One Four [Member]",
        "terseLabel": "Exercise Price Per Share - 2.14"
       }
      }
     },
     "localname": "ExercisePricePerShareTwoPointOneFourMember",
     "nsuri": "http://www.enterabio.com/20221231",
     "presentation": [
      "http://www.enterabio.com/role/SHAREBASEDCOMPENSATIONDetails2"
     ],
     "xbrltype": "domainItemType"
    },
    "entx_ExercisePricePerShareTwoPointZeroTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member is stand for 2.02.",
        "label": "Exercise Price Per Share Two Point Zero Two [Member]",
        "verboseLabel": "Exercise Price Per Share - 2.02"
       }
      }
     },
     "localname": "ExercisePricePerShareTwoPointZeroTwoMember",
     "nsuri": "http://www.enterabio.com/20221231",
     "presentation": [
      "http://www.enterabio.com/role/SHAREBASEDCOMPENSATIONDetails2"
     ],
     "xbrltype": "domainItemType"
    },
    "entx_ExercisePricePerShareZeroMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "No exercise price per share.",
        "label": "Exercise Price Per Share Zero [Member]",
        "terseLabel": "Exercise Price Per Share - Zero"
       }
      }
     },
     "localname": "ExercisePricePerShareZeroMember",
     "nsuri": "http://www.enterabio.com/20221231",
     "presentation": [
      "http://www.enterabio.com/role/SHAREBASEDCOMPENSATIONDetails2"
     ],
     "xbrltype": "domainItemType"
    },
    "entx_FinanceExpensesNet": {
     "auth_ref": [],
     "calculation": {
      "http://www.enterabio.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 0.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of finance expenses, net.",
        "label": "Finance Expenses, Net",
        "terseLabel": "Finance expenses (income), net"
       }
      }
     },
     "localname": "FinanceExpensesNet",
     "nsuri": "http://www.enterabio.com/20221231",
     "presentation": [
      "http://www.enterabio.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "entx_FormerChiefExecutiveOfficerMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Former Chief Executive Officer.",
        "label": "Former Chief Executive Officer [Member]",
        "terseLabel": "Former CEO [Member]"
       }
      }
     },
     "localname": "FormerChiefExecutiveOfficerMember",
     "nsuri": "http://www.enterabio.com/20221231",
     "presentation": [
      "http://www.enterabio.com/role/SHAREBASEDCOMPENSATIONDetailTextuals"
     ],
     "xbrltype": "domainItemType"
    },
    "entx_FundsInRespectOfEmployeeRightsUponRetirement": {
     "auth_ref": [],
     "calculation": {
      "http://www.enterabio.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information about funds in respect of employee rights upon retirement.",
        "label": "Funds In Respect Of Employee Rights Upon Retirement",
        "negatedLabel": "Funds with respect to employee rights upon retirement",
        "terseLabel": "Funds in respect of employee rights upon retirement"
       }
      }
     },
     "localname": "FundsInRespectOfEmployeeRightsUponRetirement",
     "nsuri": "http://www.enterabio.com/20221231",
     "presentation": [
      "http://www.enterabio.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "entx_GeneralLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "General [Line Items]"
       }
      }
     },
     "localname": "GeneralLineItems",
     "nsuri": "http://www.enterabio.com/20221231",
     "presentation": [
      "http://www.enterabio.com/role/GENERALDetailTextuals"
     ],
     "xbrltype": "stringItemType"
    },
    "entx_GeneralTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about general information of the entity.",
        "label": "General [Table]"
       }
      }
     },
     "localname": "GeneralTable",
     "nsuri": "http://www.enterabio.com/20221231",
     "presentation": [
      "http://www.enterabio.com/role/GENERALDetailTextuals"
     ],
     "xbrltype": "stringItemType"
    },
    "entx_InvestorRelationsServicesAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Investor relations services agreement.",
        "label": "Investor Relations Services Agreement [Member]",
        "terseLabel": "Investor relations services agreement [Member]"
       }
      }
     },
     "localname": "InvestorRelationsServicesAgreementMember",
     "nsuri": "http://www.enterabio.com/20221231",
     "presentation": [
      "http://www.enterabio.com/role/SHAREBASEDCOMPENSATIONDetailTextuals"
     ],
     "xbrltype": "domainItemType"
    },
    "entx_IssuanceOfOrdinarySharesAndWarrantsDueToPrivatePlacementNetOfIssuanceCosts": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of issuance of ordinary shares and warrants due to a private placement net of issuance costs.",
        "label": "Issuance Of Ordinary Shares And Warrants Due To Private Placement Net Of Issuance Costs",
        "verboseLabel": "Issuance of ordinary shares and warrants due to a private placement net of issuance costs"
       }
      }
     },
     "localname": "IssuanceOfOrdinarySharesAndWarrantsDueToPrivatePlacementNetOfIssuanceCosts",
     "nsuri": "http://www.enterabio.com/20221231",
     "presentation": [
      "http://www.enterabio.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "entx_IssuanceOfOrdinarySharesAndWarrantsDueToPrivatePlacementNetOfIssuanceCostsShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of ordinary shares and warrants issued due to a private placement net of issuance costs.",
        "label": "Issuance Of Ordinary Shares And Warrants Due To Private Placement Net Of Issuance Costs Shares",
        "terseLabel": "Issuance of ordinary shares and warrants due to a private placement net of issuance costs (in shares)"
       }
      }
     },
     "localname": "IssuanceOfOrdinarySharesAndWarrantsDueToPrivatePlacementNetOfIssuanceCostsShares",
     "nsuri": "http://www.enterabio.com/20221231",
     "presentation": [
      "http://www.enterabio.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY"
     ],
     "xbrltype": "sharesItemType"
    },
    "entx_JointVentureAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information regarding the joint venture agreement.",
        "label": "Joint Venture Agreement [Member]",
        "verboseLabel": "Joint Venture Agreement [Member]"
       }
      }
     },
     "localname": "JointVentureAgreementMember",
     "nsuri": "http://www.enterabio.com/20221231",
     "presentation": [
      "http://www.enterabio.com/role/COMMITMENTSDetailTextuals"
     ],
     "xbrltype": "domainItemType"
    },
    "entx_LaboratoryEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tangible personal property used in laboratory.",
        "label": "Laboratory Equipment [Member]",
        "verboseLabel": "Laboratory equipment [Member]"
       }
      }
     },
     "localname": "LaboratoryEquipmentMember",
     "nsuri": "http://www.enterabio.com/20221231",
     "presentation": [
      "http://www.enterabio.com/role/SIGNIFICANTACCOUNTINGPOLICIESDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "entx_LeaseArrangementAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information of lease arrangement.",
        "label": "Lease Arrangement [Axis]"
       }
      }
     },
     "localname": "LeaseArrangementAxis",
     "nsuri": "http://www.enterabio.com/20221231",
     "presentation": [
      "http://www.enterabio.com/role/OPERATINGLEASESDetailTextuals"
     ],
     "xbrltype": "stringItemType"
    },
    "entx_LeaseArrangementDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the lease arrangement.",
        "label": "Lease Arrangement [Domain]"
       }
      }
     },
     "localname": "LeaseArrangementDomain",
     "nsuri": "http://www.enterabio.com/20221231",
     "presentation": [
      "http://www.enterabio.com/role/OPERATINGLEASESDetailTextuals"
     ],
     "xbrltype": "domainItemType"
    },
    "entx_NetProceedsFromIssuanceOfCommonStock": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the net cash inflow from the additional capital contribution to the entity.",
        "label": "Net Proceeds From Issuance Of Common Stock",
        "verboseLabel": "Net proceeds from share issuance"
       }
      }
     },
     "localname": "NetProceedsFromIssuanceOfCommonStock",
     "nsuri": "http://www.enterabio.com/20221231",
     "presentation": [
      "http://www.enterabio.com/role/GENERALDetailTextuals",
      "http://www.enterabio.com/role/SHARECAPITALDetailTextuals"
     ],
     "xbrltype": "monetaryItemType"
    },
    "entx_NonExecutiveBoardMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member is stand for Non Executive Board.",
        "label": "Non Executive Board [Member]"
       }
      }
     },
     "localname": "NonExecutiveBoardMember",
     "nsuri": "http://www.enterabio.com/20221231",
     "presentation": [
      "http://www.enterabio.com/role/SUBSEQUENTEVENTSNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "entx_NonExecutiveDirectorMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Non-executive director.",
        "label": "Non Executive Director [Member]",
        "terseLabel": "Non-executive director [Member]"
       }
      }
     },
     "localname": "NonExecutiveDirectorMember",
     "nsuri": "http://www.enterabio.com/20221231",
     "presentation": [
      "http://www.enterabio.com/role/SHAREBASEDCOMPENSATIONDetailTextuals"
     ],
     "xbrltype": "domainItemType"
    },
    "entx_NonRefundableAndNonCreditableInitialTechnologyAccessFeePayment": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the value of non-refundable and non-creditable initial technology access fee payment.",
        "label": "Non Refundable And Non Creditable Initial Technology Access Fee Payment",
        "terseLabel": "Non-refundable and non-creditable initial technology access fee payment",
        "verboseLabel": "Non-refundable and non-creditable initial technology access fee payment, including payment for the first year of preclinical services"
       }
      }
     },
     "localname": "NonRefundableAndNonCreditableInitialTechnologyAccessFeePayment",
     "nsuri": "http://www.enterabio.com/20221231",
     "presentation": [
      "http://www.enterabio.com/role/SIGNIFICANTACCOUNTINGPOLICIESDetailTextuals"
     ],
     "xbrltype": "monetaryItemType"
    },
    "entx_NumberOfNonExecutiveBoardMembers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the number of non executive board members.",
        "label": "Number Of Non Executive Board Members",
        "verboseLabel": "Number of non executive board members"
       }
      }
     },
     "localname": "NumberOfNonExecutiveBoardMembers",
     "nsuri": "http://www.enterabio.com/20221231",
     "presentation": [
      "http://www.enterabio.com/role/SUBSEQUENTEVENTSNarrative"
     ],
     "xbrltype": "integerItemType"
    },
    "entx_NumberOfSharesIssuedUnderPrivatePlacement": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the number of shares issued under private placement.",
        "label": "Number Of Shares Issued Under Private Placement",
        "verboseLabel": "Number of shares issued under private placement"
       }
      }
     },
     "localname": "NumberOfSharesIssuedUnderPrivatePlacement",
     "nsuri": "http://www.enterabio.com/20221231",
     "presentation": [
      "http://www.enterabio.com/role/SHARECAPITALDetailTextuals"
     ],
     "xbrltype": "sharesItemType"
    },
    "entx_OperatingLeaseAgreementsForOfficeAndResearchAndDevelopmentSpaceMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the operating lease agreements for office and research and development space.",
        "label": "Operating Lease Agreements For Office And Research And Development Space [Member]",
        "verboseLabel": "Operating lease agreements for office and research and development space [Member]"
       }
      }
     },
     "localname": "OperatingLeaseAgreementsForOfficeAndResearchAndDevelopmentSpaceMember",
     "nsuri": "http://www.enterabio.com/20221231",
     "presentation": [
      "http://www.enterabio.com/role/OPERATINGLEASESDetailTextuals"
     ],
     "xbrltype": "domainItemType"
    },
    "entx_OperatingLeaseAgreementsForVehiclesForEmployeesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the operating lease agreements for vehicles for employees.",
        "label": "Operating Lease Agreements For Vehicles For Employees [Member]",
        "verboseLabel": "Operating lease agreements for vehicles for employees [Member]"
       }
      }
     },
     "localname": "OperatingLeaseAgreementsForVehiclesForEmployeesMember",
     "nsuri": "http://www.enterabio.com/20221231",
     "presentation": [
      "http://www.enterabio.com/role/OPERATINGLEASESDetailTextuals"
     ],
     "xbrltype": "domainItemType"
    },
    "entx_OperatingLeaseLiabilityAndOperatingLeaseRightOfUseAssetTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The tabular disclosure of operating lease liability and operating lease right of use asset.",
        "label": "Operating Lease Liability And Operating Lease Right Of Use Asset [Table Text Block]",
        "verboseLabel": "Schedule of operating lease liability and operating lease right-of-use asset"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityAndOperatingLeaseRightOfUseAssetTableTextBlock",
     "nsuri": "http://www.enterabio.com/20221231",
     "presentation": [
      "http://www.enterabio.com/role/OPERATINGLEASESTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "entx_OperatingLeaseSupplementalCashFlowInformationTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The tabular disclosure of operating lease supplemental cash flow information.",
        "label": "Operating Lease Supplemental Cash Flow Information [Table Text Block]",
        "terseLabel": "Schedule of operating lease cashflow information"
       }
      }
     },
     "localname": "OperatingLeaseSupplementalCashFlowInformationTableTextBlock",
     "nsuri": "http://www.enterabio.com/20221231",
     "presentation": [
      "http://www.enterabio.com/role/OPERATINGLEASESTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "entx_PatentTransferAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information regarding the patent transfer agreement.",
        "label": "Patent Transfer Agreement [Member]",
        "verboseLabel": "Patent Transfer Agreement [Member]"
       }
      }
     },
     "localname": "PatentTransferAgreementMember",
     "nsuri": "http://www.enterabio.com/20221231",
     "presentation": [
      "http://www.enterabio.com/role/COMMITMENTSDetailTextuals"
     ],
     "xbrltype": "domainItemType"
    },
    "entx_PaymentOfRoyaltyGuaranteesCommitments": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the amount paid for royalty to IIA.",
        "label": "Payment Of Royalty Guarantees Commitments",
        "verboseLabel": "Royalty amount paid"
       }
      }
     },
     "localname": "PaymentOfRoyaltyGuaranteesCommitments",
     "nsuri": "http://www.enterabio.com/20221231",
     "presentation": [
      "http://www.enterabio.com/role/COMMITMENTSDetailTextuals"
     ],
     "xbrltype": "monetaryItemType"
    },
    "entx_PlacementAgencyAgreementWithGpNumenkariIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information regarding Placement Agency Agreement With Gp Numenkari Inc.",
        "label": "Placement Agency Agreement With Gp Numenkari Inc [Member]",
        "verboseLabel": "Placement Agency agreement with GP Numenkari Inc [Member]"
       }
      }
     },
     "localname": "PlacementAgencyAgreementWithGpNumenkariIncMember",
     "nsuri": "http://www.enterabio.com/20221231",
     "presentation": [
      "http://www.enterabio.com/role/SHARECAPITALDetailTextuals"
     ],
     "xbrltype": "domainItemType"
    },
    "entx_PresidentOfResearchAndDevelopmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "President Of Research And Development [Member]",
        "label": "President Of Research And Development [Member]",
        "terseLabel": "President of R&amp;D [Member]"
       }
      }
     },
     "localname": "PresidentOfResearchAndDevelopmentMember",
     "nsuri": "http://www.enterabio.com/20221231",
     "presentation": [
      "http://www.enterabio.com/role/SHAREBASEDCOMPENSATIONDetailTextuals"
     ],
     "xbrltype": "domainItemType"
    },
    "entx_ProceedsFromOptionsAndWarrantExercises": {
     "auth_ref": [],
     "calculation": {
      "http://www.enterabio.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from exercise of options and warrants into shares.",
        "label": "Proceeds From Options And Warrant Exercises",
        "terseLabel": "Exercise of options and warrants into shares"
       }
      }
     },
     "localname": "ProceedsFromOptionsAndWarrantExercises",
     "nsuri": "http://www.enterabio.com/20221231",
     "presentation": [
      "http://www.enterabio.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "entx_ReconciliationInAmountsOnConsolidatedBalanceSheetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Reconciliation In Amounts On Consolidated Balance Sheets [Abstract]",
        "terseLabel": "Reconciliation in amounts on consolidated balance sheets:"
       }
      }
     },
     "localname": "ReconciliationInAmountsOnConsolidatedBalanceSheetsAbstract",
     "nsuri": "http://www.enterabio.com/20221231",
     "presentation": [
      "http://www.enterabio.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "entx_ReversalOfExpensesUponForfeitureOfOptions": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reversal of expenses upon forfeiture of options.",
        "label": "Reversal Of Expenses Upon Forfeiture Of Options",
        "terseLabel": "Reversal of expenses upon forfeiture of options"
       }
      }
     },
     "localname": "ReversalOfExpensesUponForfeitureOfOptions",
     "nsuri": "http://www.enterabio.com/20221231",
     "presentation": [
      "http://www.enterabio.com/role/SHAREBASEDCOMPENSATIONDetailTextuals"
     ],
     "xbrltype": "monetaryItemType"
    },
    "entx_RightOfUseAssetsObtainedInExchangeForNewOperatingLeaseLiabilities": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of right of use assets obtained in exchange for new operating lease liabilities.",
        "label": "Right Of Use Assets Obtained In Exchange For New Operating Lease Liabilities",
        "terseLabel": "Operating lease right of use assets obtained in exchange for new operating lease liabilities"
       }
      }
     },
     "localname": "RightOfUseAssetsObtainedInExchangeForNewOperatingLeaseLiabilities",
     "nsuri": "http://www.enterabio.com/20221231",
     "presentation": [
      "http://www.enterabio.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "entx_RightToUseIntellectualProperty": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the value of right to use the intellectual property.",
        "label": "Right To Use Intellectual Property",
        "verboseLabel": "Right to use intellectual property"
       }
      }
     },
     "localname": "RightToUseIntellectualProperty",
     "nsuri": "http://www.enterabio.com/20221231",
     "presentation": [
      "http://www.enterabio.com/role/SIGNIFICANTACCOUNTINGPOLICIESDetailTextuals"
     ],
     "xbrltype": "monetaryItemType"
    },
    "entx_RoyaltyGuaranteesCommitmentsPercentageOfEachPaymentReceivedFromAmgen": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the percentage of each payment received from Amgen.",
        "label": "Royalty Guarantees Commitments Percentage Of Each Payment Received From Amgen",
        "verboseLabel": "Percentage of each payment received from Amgen"
       }
      }
     },
     "localname": "RoyaltyGuaranteesCommitmentsPercentageOfEachPaymentReceivedFromAmgen",
     "nsuri": "http://www.enterabio.com/20221231",
     "presentation": [
      "http://www.enterabio.com/role/COMMITMENTSDetailTextuals"
     ],
     "xbrltype": "percentItemType"
    },
    "entx_RoyaltyGuaranteesCommitmentsPercentageOfNetRevenues": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the percentage of net revenues.",
        "label": "Royalty Guarantees Commitments Percentage Of Net Revenues",
        "verboseLabel": "Percentage of net revenues"
       }
      }
     },
     "localname": "RoyaltyGuaranteesCommitmentsPercentageOfNetRevenues",
     "nsuri": "http://www.enterabio.com/20221231",
     "presentation": [
      "http://www.enterabio.com/role/COMMITMENTSDetailTextuals"
     ],
     "xbrltype": "percentItemType"
    },
    "entx_RoyaltyGuaranteesCommitmentsPercentageSalesOfProductsDevelopedFromProjectsCommencingSeventhYear": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the percentage sales of products developed from projects commencing the seventh year.",
        "label": "Royalty Guarantees Commitments Percentage Sales Of Products Developed From Projects Commencing Seventh Year",
        "verboseLabel": "Percentage sales of products developed from projects commencing the seventh year up to 100% of amount of grant received"
       }
      }
     },
     "localname": "RoyaltyGuaranteesCommitmentsPercentageSalesOfProductsDevelopedFromProjectsCommencingSeventhYear",
     "nsuri": "http://www.enterabio.com/20221231",
     "presentation": [
      "http://www.enterabio.com/role/COMMITMENTSDetailTextuals"
     ],
     "xbrltype": "percentItemType"
    },
    "entx_RoyaltyGuaranteesCommitmentsPercentageSalesOfProductsDevelopedFromProjectsInFirstThreeYearsFromCommencementOfRevenues": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the percentage sales of products developed from projects in first three years, from commencement of revenues.",
        "label": "Royalty Guarantees Commitments Percentage Sales Of Products Developed From Projects In First Three Years, From Commencement Of Revenues",
        "verboseLabel": "Percentage sales of products developed from projects in first three years, from commencement of revenues"
       }
      }
     },
     "localname": "RoyaltyGuaranteesCommitmentsPercentageSalesOfProductsDevelopedFromProjectsInFirstThreeYearsFromCommencementOfRevenues",
     "nsuri": "http://www.enterabio.com/20221231",
     "presentation": [
      "http://www.enterabio.com/role/COMMITMENTSDetailTextuals"
     ],
     "xbrltype": "percentItemType"
    },
    "entx_RoyaltyGuaranteesCommitmentsPercentageSalesOfProductsDevelopedFromProjectsSubsequentThreeYears": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the percentage sales of products developed from projects subsequent three years.",
        "label": "Royalty Guarantees Commitments Percentage Sales Of Products Developed From Projects Subsequent Three Years",
        "verboseLabel": "Percentage sales of products developed from projects subsequent three years"
       }
      }
     },
     "localname": "RoyaltyGuaranteesCommitmentsPercentageSalesOfProductsDevelopedFromProjectsSubsequentThreeYears",
     "nsuri": "http://www.enterabio.com/20221231",
     "presentation": [
      "http://www.enterabio.com/role/COMMITMENTSDetailTextuals"
     ],
     "xbrltype": "percentItemType"
    },
    "entx_SaleOfStockAmountOfInvestment": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the amount invested in the entity.",
        "label": "Sale Of Stock, Amount Of Investment",
        "verboseLabel": "Amount of investment in entity"
       }
      }
     },
     "localname": "SaleOfStockAmountOfInvestment",
     "nsuri": "http://www.enterabio.com/20221231",
     "presentation": [
      "http://www.enterabio.com/role/COMMITMENTSDetailTextuals"
     ],
     "xbrltype": "monetaryItemType"
    },
    "entx_SaleOfStockPercentageOfOwnershipOfEntityAcquired": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the percentage of ownership of entity acquired.",
        "label": "Sale Of Stock, Percentage Of Ownership Of Entity Acquired",
        "verboseLabel": "Percentage of ownership of entity acquired"
       }
      }
     },
     "localname": "SaleOfStockPercentageOfOwnershipOfEntityAcquired",
     "nsuri": "http://www.enterabio.com/20221231",
     "presentation": [
      "http://www.enterabio.com/role/COMMITMENTSDetailTextuals"
     ],
     "xbrltype": "percentItemType"
    },
    "entx_ScheduleOfEstimatedUsefulLifeTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the estimated useful life used to calculate depreciation of assets.",
        "label": "Schedule Of Estimated Useful Life [Table Text Block]",
        "verboseLabel": "Schedule of estimated useful life"
       }
      }
     },
     "localname": "ScheduleOfEstimatedUsefulLifeTableTextBlock",
     "nsuri": "http://www.enterabio.com/20221231",
     "presentation": [
      "http://www.enterabio.com/role/SIGNIFICANTACCOUNTINGPOLICIESTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "entx_ServiceProviderMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information of service provider.",
        "label": "Service Provider [Member]",
        "terseLabel": "Service Provider [Member]"
       }
      }
     },
     "localname": "ServiceProviderMember",
     "nsuri": "http://www.enterabio.com/20221231",
     "presentation": [
      "http://www.enterabio.com/role/SHAREBASEDCOMPENSATIONDetailTextuals"
     ],
     "xbrltype": "domainItemType"
    },
    "entx_SeveralEmployeesAndServiceProvidersMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information regarding two related parties.",
        "label": "Several Employees And Service Providers [Member]",
        "verboseLabel": "Several employees and service providers [Member]"
       }
      }
     },
     "localname": "SeveralEmployeesAndServiceProvidersMember",
     "nsuri": "http://www.enterabio.com/20221231",
     "presentation": [
      "http://www.enterabio.com/role/SHARECAPITALDetailTextuals"
     ],
     "xbrltype": "domainItemType"
    },
    "entx_SeveranceExpenses": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "It represents severance expenses.",
        "label": "Severance Expenses",
        "verboseLabel": "Severance expenses"
       }
      }
     },
     "localname": "SeveranceExpenses",
     "nsuri": "http://www.enterabio.com/20221231",
     "presentation": [
      "http://www.enterabio.com/role/SIGNIFICANTACCOUNTINGPOLICIESDetailTextuals"
     ],
     "xbrltype": "monetaryItemType"
    },
    "entx_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsTotalConsideration": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the amount of share based compensation arrangements by share based payment award options total consideration.",
        "label": "Share Based Compensation Arrangements By Share Based Payment Award Options Total Consideration",
        "verboseLabel": "Total Consideration"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsTotalConsideration",
     "nsuri": "http://www.enterabio.com/20221231",
     "presentation": [
      "http://www.enterabio.com/role/SHARECAPITALDetailTextuals"
     ],
     "xbrltype": "monetaryItemType"
    },
    "entx_ShareBasedPaymentArrangementTrancheFiveMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fifth portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period.",
        "label": "Share Based Payment Arrangement Tranche Five [Member]",
        "terseLabel": "Vest over twelve equal quarterly instalments starting on January 1, 2022 [Member]"
       }
      }
     },
     "localname": "ShareBasedPaymentArrangementTrancheFiveMember",
     "nsuri": "http://www.enterabio.com/20221231",
     "presentation": [
      "http://www.enterabio.com/role/SHAREBASEDCOMPENSATIONDetailTextuals"
     ],
     "xbrltype": "domainItemType"
    },
    "entx_ShareBasedPaymentArrangementTrancheFourMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Forth portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period.",
        "label": "Share Based Payment Arrangement Tranche Four [Member]",
        "terseLabel": "Vest in three equal installments until January 8, 2021 [Member]"
       }
      }
     },
     "localname": "ShareBasedPaymentArrangementTrancheFourMember",
     "nsuri": "http://www.enterabio.com/20221231",
     "presentation": [
      "http://www.enterabio.com/role/SHAREBASEDCOMPENSATIONDetailTextuals"
     ],
     "xbrltype": "domainItemType"
    },
    "entx_ShareBasedPaymentArrangementTrancheSixMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sixth portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period.",
        "label": "Share Based Payment Arrangement Tranche Six [Member]",
        "terseLabel": "Vest over four equal quarterly instalments starting on January 1, 2022 [Member]"
       }
      }
     },
     "localname": "ShareBasedPaymentArrangementTrancheSixMember",
     "nsuri": "http://www.enterabio.com/20221231",
     "presentation": [
      "http://www.enterabio.com/role/SHAREBASEDCOMPENSATIONDetailTextuals"
     ],
     "xbrltype": "domainItemType"
    },
    "entx_ShareIncentivePlan2013Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share Incentive Plan 2013.",
        "label": "Share Incentive Plan 2013 [Member]",
        "terseLabel": "2013 Plan [Member]"
       }
      }
     },
     "localname": "ShareIncentivePlan2013Member",
     "nsuri": "http://www.enterabio.com/20221231",
     "presentation": [
      "http://www.enterabio.com/role/SHAREBASEDCOMPENSATIONDetailTextuals"
     ],
     "xbrltype": "domainItemType"
    },
    "entx_ShareIncentivePlan2018Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share Incentive Plan 2018.",
        "label": "Share Incentive Plan 2018 [Member]",
        "terseLabel": "2018 Plan [Member]"
       }
      }
     },
     "localname": "ShareIncentivePlan2018Member",
     "nsuri": "http://www.enterabio.com/20221231",
     "presentation": [
      "http://www.enterabio.com/role/SHAREBASEDCOMPENSATIONDetailTextuals"
     ],
     "xbrltype": "domainItemType"
    },
    "entx_SharesGrantedInPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the percentage of he number of shares issued to subscribers invested through the Broker.",
        "label": "Shares Granted In Percentage",
        "verboseLabel": "Shares granted in percentage"
       }
      }
     },
     "localname": "SharesGrantedInPercentage",
     "nsuri": "http://www.enterabio.com/20221231",
     "presentation": [
      "http://www.enterabio.com/role/SHARECAPITALDetailTextuals"
     ],
     "xbrltype": "percentItemType"
    },
    "entx_SharesIssuedWeightedAveragePricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the weighted average price per share or per unit of equity securities issued.",
        "label": "Shares Issued Weighted Average Price Per Share",
        "verboseLabel": "Weighted average price of share issued"
       }
      }
     },
     "localname": "SharesIssuedWeightedAveragePricePerShare",
     "nsuri": "http://www.enterabio.com/20221231",
     "presentation": [
      "http://www.enterabio.com/role/SHARECAPITALDetailTextuals"
     ],
     "xbrltype": "perShareItemType"
    },
    "entx_SignificantAccountingPoliciesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Significant Accounting Policies [Line Items]"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesLineItems",
     "nsuri": "http://www.enterabio.com/20221231",
     "presentation": [
      "http://www.enterabio.com/role/SIGNIFICANTACCOUNTINGPOLICIESDetailTextuals"
     ],
     "xbrltype": "stringItemType"
    },
    "entx_SignificantAccountingPoliciesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This table may contain information related to significant accounting policies.",
        "label": "Significant Accounting Policies [Table]"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesTable",
     "nsuri": "http://www.enterabio.com/20221231",
     "presentation": [
      "http://www.enterabio.com/role/SIGNIFICANTACCOUNTINGPOLICIESDetailTextuals"
     ],
     "xbrltype": "stringItemType"
    },
    "entx_StockholdersEquityNoteLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Stockholders Equity Note [Line Items]"
       }
      }
     },
     "localname": "StockholdersEquityNoteLineItems",
     "nsuri": "http://www.enterabio.com/20221231",
     "presentation": [
      "http://www.enterabio.com/role/SHARECAPITALDetailTextuals"
     ],
     "xbrltype": "stringItemType"
    },
    "entx_StockholdersEquityNoteTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of information regarding the share capital of the entity.",
        "label": "Stockholders Equity Note [Table]"
       }
      }
     },
     "localname": "StockholdersEquityNoteTable",
     "nsuri": "http://www.enterabio.com/20221231",
     "presentation": [
      "http://www.enterabio.com/role/SHARECAPITALDetailTextuals"
     ],
     "xbrltype": "stringItemType"
    },
    "entx_SupplementaryFinancialStatementInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplementary Financial Statement Information [Abstract]"
       }
      }
     },
     "localname": "SupplementaryFinancialStatementInformationAbstract",
     "nsuri": "http://www.enterabio.com/20221231",
     "xbrltype": "stringItemType"
    },
    "entx_SupplementaryFinancialStatementInformationTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for supplementary financial statement information.",
        "label": "Supplementary Financial Statement Information [Text Block]",
        "terseLabel": "SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION"
       }
      }
     },
     "localname": "SupplementaryFinancialStatementInformationTextBlock",
     "nsuri": "http://www.enterabio.com/20221231",
     "presentation": [
      "http://www.enterabio.com/role/SUPPLEMENTARYFINANCIALSTATEMENTINFORMATION"
     ],
     "xbrltype": "textBlockItemType"
    },
    "entx_TransactionCosts": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "It represents transaction costs.",
        "label": "Transaction Costs",
        "verboseLabel": "Transaction costs"
       }
      }
     },
     "localname": "TransactionCosts",
     "nsuri": "http://www.enterabio.com/20221231",
     "presentation": [
      "http://www.enterabio.com/role/SHARECAPITALDetailTextuals"
     ],
     "xbrltype": "monetaryItemType"
    },
    "entx_TriggeringEventMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information of triggering event.",
        "label": "Triggering Event [Member]",
        "verboseLabel": "Triggering event [Member]"
       }
      }
     },
     "localname": "TriggeringEventMember",
     "nsuri": "http://www.enterabio.com/20221231",
     "presentation": [
      "http://www.enterabio.com/role/SHAREBASEDCOMPENSATIONDetailTextuals"
     ],
     "xbrltype": "domainItemType"
    },
    "entx_TwentySeventeenMemberMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Twenty Seventeen Member [Member]",
        "label": "Twenty Seventeen Member [Member]",
        "terseLabel": "2017 Grant [Member]"
       }
      }
     },
     "localname": "TwentySeventeenMemberMember",
     "nsuri": "http://www.enterabio.com/20221231",
     "presentation": [
      "http://www.enterabio.com/role/SHAREBASEDCOMPENSATIONDetailTextuals"
     ],
     "xbrltype": "domainItemType"
    },
    "entx_TwentyTwentyOneGrantMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Twenty Twenty One Grant [Member]",
        "label": "Twenty Twenty One Grant [Member]",
        "terseLabel": "2021 Grant [Member]"
       }
      }
     },
     "localname": "TwentyTwentyOneGrantMember",
     "nsuri": "http://www.enterabio.com/20221231",
     "presentation": [
      "http://www.enterabio.com/role/SHAREBASEDCOMPENSATIONDetailTextuals"
     ],
     "xbrltype": "domainItemType"
    },
    "entx_VestedRestrictedShareUnitsShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares vested restricted share units.",
        "label": "Vested Restricted Share Units Shares",
        "terseLabel": "Vested restricted share units (in shares)"
       }
      }
     },
     "localname": "VestedRestrictedShareUnitsShares",
     "nsuri": "http://www.enterabio.com/20221231",
     "presentation": [
      "http://www.enterabio.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY"
     ],
     "xbrltype": "sharesItemType"
    },
    "entx_WarrantToPurchaseOrdinaryShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "It represents warrant to purchase ordinary share",
        "label": "Warrant To Purchase Ordinary Share",
        "verboseLabel": "Warrant to purchase ordinary share"
       }
      }
     },
     "localname": "WarrantToPurchaseOrdinaryShare",
     "nsuri": "http://www.enterabio.com/20221231",
     "presentation": [
      "http://www.enterabio.com/role/GENERALDetailTextuals"
     ],
     "xbrltype": "perShareItemType"
    },
    "srt_ChiefExecutiveOfficerMember": {
     "auth_ref": [
      "r428"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Chief Executive Officer [Member]",
        "terseLabel": "Chief Executive Officer [Member]",
        "verboseLabel": "New CEO [Member]"
       }
      }
     },
     "localname": "ChiefExecutiveOfficerMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.enterabio.com/role/SHAREBASEDCOMPENSATIONDetailTextuals"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ChiefFinancialOfficerMember": {
     "auth_ref": [
      "r428"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Chief Financial Officer [Member]"
       }
      }
     },
     "localname": "ChiefFinancialOfficerMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.enterabio.com/role/SHAREBASEDCOMPENSATIONDetailTextuals"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ConsolidatedEntitiesAxis": {
     "auth_ref": [
      "r149",
      "r313",
      "r314",
      "r315",
      "r316",
      "r343",
      "r381",
      "r434",
      "r437",
      "r438"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidated Entities [Axis]"
       }
      }
     },
     "localname": "ConsolidatedEntitiesAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.enterabio.com/role/INCOMETAXDetails1",
      "http://www.enterabio.com/role/INCOMETAXDetails3"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ConsolidatedEntitiesDomain": {
     "auth_ref": [
      "r149",
      "r313",
      "r314",
      "r315",
      "r316",
      "r343",
      "r381",
      "r434",
      "r437",
      "r438"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidated Entities [Domain]"
       }
      }
     },
     "localname": "ConsolidatedEntitiesDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.enterabio.com/role/INCOMETAXDetails1",
      "http://www.enterabio.com/role/INCOMETAXDetails3"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_DirectorMember": {
     "auth_ref": [
      "r428"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Director [Member]",
        "terseLabel": "Director [Member]"
       }
      }
     },
     "localname": "DirectorMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.enterabio.com/role/SHAREBASEDCOMPENSATIONDetailTextuals"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ExecutiveOfficerMember": {
     "auth_ref": [
      "r428"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Executive Officer [Member]",
        "terseLabel": "Executive Officer [Member]",
        "verboseLabel": "Executive officers [Member]"
       }
      }
     },
     "localname": "ExecutiveOfficerMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.enterabio.com/role/SHAREBASEDCOMPENSATIONDetailTextuals"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r204",
      "r205",
      "r206",
      "r207",
      "r241",
      "r348",
      "r370",
      "r382",
      "r383",
      "r392",
      "r394",
      "r399",
      "r439",
      "r485",
      "r486",
      "r487",
      "r488",
      "r489",
      "r490"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]",
        "verboseLabel": "Maximum [Member]"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.enterabio.com/role/SHAREBASEDCOMPENSATIONDetails",
      "http://www.enterabio.com/role/SIGNIFICANTACCOUNTINGPOLICIESDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r204",
      "r205",
      "r206",
      "r207",
      "r241",
      "r348",
      "r370",
      "r382",
      "r383",
      "r392",
      "r394",
      "r399",
      "r439",
      "r485",
      "r486",
      "r487",
      "r488",
      "r489",
      "r490"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]",
        "verboseLabel": "Minimum [Member]"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.enterabio.com/role/SHAREBASEDCOMPENSATIONDetails",
      "http://www.enterabio.com/role/SIGNIFICANTACCOUNTINGPOLICIESDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r204",
      "r205",
      "r206",
      "r207",
      "r239",
      "r241",
      "r271",
      "r272",
      "r273",
      "r347",
      "r348",
      "r370",
      "r382",
      "r383",
      "r392",
      "r394",
      "r399",
      "r432",
      "r439",
      "r486",
      "r487",
      "r488",
      "r489",
      "r490"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.enterabio.com/role/SHAREBASEDCOMPENSATIONDetails",
      "http://www.enterabio.com/role/SIGNIFICANTACCOUNTINGPOLICIESDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r204",
      "r205",
      "r206",
      "r207",
      "r239",
      "r241",
      "r271",
      "r272",
      "r273",
      "r347",
      "r348",
      "r370",
      "r382",
      "r383",
      "r392",
      "r394",
      "r399",
      "r432",
      "r439",
      "r486",
      "r487",
      "r488",
      "r489",
      "r490"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.enterabio.com/role/SHAREBASEDCOMPENSATIONDetails",
      "http://www.enterabio.com/role/SIGNIFICANTACCOUNTINGPOLICIESDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_SubsidiariesMember": {
     "auth_ref": [
      "r443",
      "r479",
      "r480",
      "r482"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsidiaries [Member]",
        "terseLabel": "Subsidiary",
        "verboseLabel": "Entera Bio Inc"
       }
      }
     },
     "localname": "SubsidiariesMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.enterabio.com/role/INCOMETAXDetails1",
      "http://www.enterabio.com/role/INCOMETAXDetails3"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_TitleOfIndividualAxis": {
     "auth_ref": [
      "r428",
      "r481"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of Individual [Axis]"
       }
      }
     },
     "localname": "TitleOfIndividualAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.enterabio.com/role/SHAREBASEDCOMPENSATIONDetailTextuals",
      "http://www.enterabio.com/role/SUBSEQUENTEVENTSNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_TitleOfIndividualWithRelationshipToEntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of Individual [Domain]"
       }
      }
     },
     "localname": "TitleOfIndividualWithRelationshipToEntityDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.enterabio.com/role/SHAREBASEDCOMPENSATIONDetailTextuals",
      "http://www.enterabio.com/role/SUBSEQUENTEVENTSNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis": {
     "auth_ref": [
      "r20"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by legal entity of counterparty. A counterparty is the other party that participates in a financial transaction.",
        "label": "Legal Entity of Counterparty, Type [Axis]"
       }
      }
     },
     "localname": "AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.enterabio.com/role/COMMITMENTSDetailTextuals"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts Payable and Accrued Liabilities, Current [Abstract]",
        "terseLabel": "Accounts payable - other:",
        "verboseLabel": "Accrued expenses and other payables:"
       }
      }
     },
     "localname": "AccountsPayableAndAccruedLiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.enterabio.com/role/SUPPLEMENTARYFINANCIALSTATEMENTINFORMATIONDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r14",
      "r398"
     ],
     "calculation": {
      "http://www.enterabio.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 0.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.enterabio.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "auth_ref": [
      "r196",
      "r197"
     ],
     "calculation": {
      "http://www.enterabio.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 10.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.",
        "label": "Accounts Receivable, after Allowance for Credit Loss, Current",
        "terseLabel": "Accounts receivable"
       }
      }
     },
     "localname": "AccountsReceivableNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.enterabio.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccretionExpenseIncludingAssetRetirementObligations": {
     "auth_ref": [
      "r431"
     ],
     "calculation": {
      "http://www.enterabio.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 50.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accretion expense, which includes, but is not limited to, accretion expense from asset retirement obligations, environmental remediation obligations, and other contingencies."
       }
      }
     },
     "localname": "AccretionExpenseIncludingAssetRetirementObligations",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedEmployeeBenefitsCurrent": {
     "auth_ref": [
      "r16"
     ],
     "calculation": {
      "http://www.enterabio.com/role/SUPPLEMENTARYFINANCIALSTATEMENTINFORMATIONDetails": {
       "order": 0.0,
       "parentTag": "us-gaap_AccruedLiabilitiesAndOtherLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations, excluding pension and other postretirement benefits, incurred through that date and payable for perquisites provided to employees pertaining to services received from them. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Employees and employees related",
        "terseLabel": "Employees and employees related"
       }
      }
     },
     "localname": "AccruedEmployeeBenefitsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.enterabio.com/role/SUPPLEMENTARYFINANCIALSTATEMENTINFORMATIONDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedIncomeTaxesCurrent": {
     "auth_ref": [
      "r4",
      "r103",
      "r111"
     ],
     "calculation": {
      "http://www.enterabio.com/role/SUPPLEMENTARYFINANCIALSTATEMENTINFORMATIONDetails": {
       "order": 30.0,
       "parentTag": "us-gaap_AccruedLiabilitiesAndOtherLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all currently due domestic and foreign income tax obligations.",
        "label": "Income tax",
        "terseLabel": "Income tax"
       }
      }
     },
     "localname": "AccruedIncomeTaxesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.enterabio.com/role/SUPPLEMENTARYFINANCIALSTATEMENTINFORMATIONDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesAndOtherLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://www.enterabio.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 10.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      },
      "http://www.enterabio.com/role/SUPPLEMENTARYFINANCIALSTATEMENTINFORMATIONDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses incurred but not yet paid nor invoiced, and liabilities classified as other.",
        "label": "Accrued Liabilities and Other Liabilities",
        "terseLabel": "Accrued expenses and other payables",
        "totalLabel": "Accrued expenses and other payables, total",
        "verboseLabel": "Accrued expenses and other payables"
       }
      }
     },
     "localname": "AccruedLiabilitiesAndOtherLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.enterabio.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.enterabio.com/role/SUPPLEMENTARYFINANCIALSTATEMENTINFORMATIONDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedVacationCurrent": {
     "auth_ref": [
      "r16",
      "r64"
     ],
     "calculation": {
      "http://www.enterabio.com/role/SUPPLEMENTARYFINANCIALSTATEMENTINFORMATIONDetails": {
       "order": 10.0,
       "parentTag": "us-gaap_AccruedLiabilitiesAndOtherLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for unused vacation time owed to employees based on the entity's vacation benefit given to its employees. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Vacation, Current",
        "terseLabel": "Provision for vacation"
       }
      }
     },
     "localname": "AccruedVacationCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.enterabio.com/role/SUPPLEMENTARYFINANCIALSTATEMENTINFORMATIONDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r22",
      "r23",
      "r24",
      "r131",
      "r367",
      "r375",
      "r376"
     ],
     "calculation": {
      "http://www.enterabio.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 0.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "verboseLabel": "Accumulated other comprehensive income"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.enterabio.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r21",
      "r24",
      "r91",
      "r340",
      "r371",
      "r372",
      "r414",
      "r415",
      "r416",
      "r424",
      "r425",
      "r426"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "Accumulated Other Comprehensive Income (Loss) [Member]",
        "verboseLabel": "Accumulated other Comprehensive income [Member]"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.enterabio.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdditionalPaidInCapitalCommonStock": {
     "auth_ref": [
      "r9"
     ],
     "calculation": {
      "http://www.enterabio.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 20.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.",
        "label": "Additional Paid in Capital, Common Stock",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.enterabio.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r279",
      "r280",
      "r281",
      "r424",
      "r425",
      "r426",
      "r474"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]",
        "verboseLabel": "Additional paid-in capital [Member]"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.enterabio.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalOther": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of other increase (decrease) in additional paid in capital (APIC).",
        "label": "Adjustments to Additional Paid in Capital, Other",
        "verboseLabel": "Amount transferred from Other Reserves to Additional paid in Capital"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalOther",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.enterabio.com/role/SHARECAPITALDetailTextuals"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for restricted stock unit under share-based payment arrangement.",
        "label": "APIC, Share-based Payment Arrangement, Restricted Stock Unit, Increase for Cost Recognition",
        "terseLabel": "Vested restricted share units"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.enterabio.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [
      "r78",
      "r79",
      "r243"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.",
        "label": "APIC, Share-based Payment Arrangement, Increase for Cost Recognition",
        "verboseLabel": "Share-based compensation"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.enterabio.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "verboseLabel": "Adjustments required to reconcile net loss to net cash used in operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.enterabio.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r275"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Share-based Payment Arrangement, Expense",
        "terseLabel": "Share-based compensation",
        "verboseLabel": "Stock-based compensation expenses"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.enterabio.com/role/SHAREBASEDCOMPENSATIONDetailTextuals",
      "http://www.enterabio.com/role/SHAREBASEDCOMPENSATIONDetails3",
      "http://www.enterabio.com/role/SHARECAPITALDetailTextuals"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r171"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "verboseLabel": "Number of antidilutive securities excluded from computation of earnings per share"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.enterabio.com/role/SIGNIFICANTACCOUNTINGPOLICIESDetailTextuals"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]"
       }
      }
     },
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.enterabio.com/role/SHAREBASEDCOMPENSATIONDetailTextuals"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r102",
      "r110",
      "r127",
      "r145",
      "r184",
      "r187",
      "r191",
      "r198",
      "r208",
      "r209",
      "r210",
      "r211",
      "r212",
      "r213",
      "r214",
      "r215",
      "r216",
      "r313",
      "r315",
      "r321",
      "r398",
      "r435",
      "r436",
      "r483"
     ],
     "calculation": {
      "http://www.enterabio.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "TOTAL ASSETS"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.enterabio.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "ASSETS"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.enterabio.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r124",
      "r133",
      "r145",
      "r198",
      "r208",
      "r209",
      "r210",
      "r211",
      "r212",
      "r213",
      "r214",
      "r215",
      "r216",
      "r313",
      "r315",
      "r321",
      "r398",
      "r435",
      "r436",
      "r483"
     ],
     "calculation": {
      "http://www.enterabio.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 0.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "TOTAL CURRENT ASSETS"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.enterabio.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "CURRENT ASSETS:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.enterabio.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsNoncurrent": {
     "auth_ref": [
      "r145",
      "r198",
      "r208",
      "r209",
      "r210",
      "r211",
      "r212",
      "r213",
      "r214",
      "r215",
      "r216",
      "r313",
      "r315",
      "r321",
      "r435",
      "r436",
      "r483"
     ],
     "calculation": {
      "http://www.enterabio.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 10.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer.",
        "label": "Assets, Noncurrent",
        "totalLabel": "TOTAL NON-CURRENT ASSETS"
       }
      }
     },
     "localname": "AssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.enterabio.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsNoncurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "NON-CURRENT ASSETS:"
       }
      }
     },
     "localname": "AssetsNoncurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.enterabio.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r246",
      "r247",
      "r248",
      "r250",
      "r251",
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r265",
      "r266",
      "r267",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.enterabio.com/role/SHAREBASEDCOMPENSATIONDetailTextuals"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "verboseLabel": "Basis of presentation of the financial statements"
       }
      }
     },
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.enterabio.com/role/SIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r41",
      "r126",
      "r385"
     ],
     "calculation": {
      "http://www.enterabio.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 0.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://www.enterabio.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 0.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash and cash equivalents",
        "verboseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.enterabio.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.enterabio.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "auth_ref": [
      "r42"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.",
        "label": "Cash and Cash Equivalents, Policy [Policy Text Block]",
        "verboseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.enterabio.com/role/SIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy": {
     "auth_ref": [
      "r42",
      "r100"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Entity's cash and cash equivalents accounting policy with respect to restricted balances. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.",
        "label": "Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]",
        "verboseLabel": "Restricted cash"
       }
      }
     },
     "localname": "CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.enterabio.com/role/SIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r36",
      "r41",
      "r44"
     ],
     "calculation": {
      "http://www.enterabio.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents",
        "periodEndLabel": "CASH, CASH EQUIVALENTS AND RESTRICTED DEPOSITS AT END OF THE YEAR",
        "periodStartLabel": "CASH, CASH EQUIVALENTS AND RESTRICTED DEPOSITS AT BEGINNING OF THE YEAR",
        "totalLabel": "Total cash and cash equivalents and restricted deposits"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.enterabio.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r36",
      "r98"
     ],
     "calculation": {
      "http://www.enterabio.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "INCREASE (DECREASE) IN CASH, CASH EQUIVALENTS AND RESTRICTED DEPOSITS"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.enterabio.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ClassOfStockDomain": {
     "auth_ref": [
      "r128",
      "r129",
      "r130",
      "r145",
      "r165",
      "r166",
      "r168",
      "r170",
      "r174",
      "r175",
      "r198",
      "r208",
      "r210",
      "r211",
      "r212",
      "r215",
      "r216",
      "r217",
      "r218",
      "r220",
      "r224",
      "r230",
      "r321",
      "r384",
      "r411",
      "r421",
      "r427"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock.",
        "label": "Class of Stock [Domain]"
       }
      }
     },
     "localname": "ClassOfStockDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.enterabio.com/role/SHARECAPITALDetailTextuals"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfWarrantOrRightAxis": {
     "auth_ref": [
      "r62",
      "r66"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of warrant or right issued.",
        "label": "Class of Warrant or Right [Axis]"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.enterabio.com/role/SHARECAPITALDetailTextuals"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfWarrantOrRightDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months.",
        "label": "Class of Warrant or Right [Domain]"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.enterabio.com/role/SHARECAPITALDetailTextuals"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "auth_ref": [
      "r231"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding.",
        "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights",
        "verboseLabel": "Exercise price of warrants issued"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.enterabio.com/role/SHARECAPITALDetailTextuals"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": {
     "auth_ref": [
      "r231"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.",
        "label": "Class of Warrant or Right, Number of Securities Called by Warrants or Rights",
        "verboseLabel": "Number of ordinary shares called by warrants"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.enterabio.com/role/GENERALDetailTextuals",
      "http://www.enterabio.com/role/SHARECAPITALDetailTextuals"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r18",
      "r105",
      "r116"
     ],
     "calculation": {
      "http://www.enterabio.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 10.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments and Contingencies",
        "terseLabel": "COMMITMENTS AND CONTINGENCIES"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.enterabio.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r57",
      "r202",
      "r203",
      "r377",
      "r433"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "verboseLabel": "COMMITMENTS AND CONTINGENCIES"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.enterabio.com/role/COMMITMENTS"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommitmentsAndContingenciesPolicyTextBlock": {
     "auth_ref": [
      "r58",
      "r378"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for commitments and contingencies, which may include policies for recognizing and measuring loss and gain contingencies.",
        "label": "Commitments and Contingencies, Policy [Policy Text Block]",
        "verboseLabel": "Legal and other contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.enterabio.com/role/SIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r424",
      "r425",
      "r474"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Ordinary shares [Member]"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.enterabio.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY",
      "http://www.enterabio.com/role/GENERALDetailTextuals",
      "http://www.enterabio.com/role/SHARECAPITALDetailTextuals"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r8"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Ordinary share, par value"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.enterabio.com/role/CONSOLIDATEDBALANCESHEETSParentheticals",
      "http://www.enterabio.com/role/GENERALDetailTextuals",
      "http://www.enterabio.com/role/SHAREBASEDCOMPENSATIONDetailTextuals"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r8"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Ordinary shares, authorized"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.enterabio.com/role/CONSOLIDATEDBALANCESHEETSParentheticals"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r8"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "terseLabel": "Ordinary shares, issued"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.enterabio.com/role/CONSOLIDATEDBALANCESHEETSParentheticals"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r8",
      "r59"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding",
        "terseLabel": "Ordinary shares, outstanding"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.enterabio.com/role/CONSOLIDATEDBALANCESHEETSParentheticals"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r8",
      "r398"
     ],
     "calculation": {
      "http://www.enterabio.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 30.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "periodEndLabel": "Common Stock, Value, Issued, Ending Balance",
        "periodStartLabel": "Common Stock, Value, Issued, Beginning Balance",
        "terseLabel": "Ordinary Shares, NIS 0.0000769 par value: Authorized - as of December 31, 2022 and December 31, 2021, 140,010,000 shares; issued and outstanding as of December 31, 2022, and December 31, 2021 28,809,922 and 28,804,411 shares, respectively",
        "totalLabel": "Common Stock, Value, Issued, Total",
        "verboseLabel": "Value of shares issued"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.enterabio.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.enterabio.com/role/SHARECAPITALDetailTextuals"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommonStockVotingRights": {
     "auth_ref": [
      "r60"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of voting rights of common stock. Includes eligibility to vote and votes per share owned. Include also, if any, unusual voting rights.",
        "label": "Common Stock, Voting Rights",
        "verboseLabel": "Voting rights of ordinary share"
       }
      }
     },
     "localname": "CommonStockVotingRights",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.enterabio.com/role/SHARECAPITALDetailTextuals"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ComputerEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems.",
        "label": "Computer Equipment [Member]",
        "verboseLabel": "Computer equipment [Member]"
       }
      }
     },
     "localname": "ComputerEquipmentMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.enterabio.com/role/SIGNIFICANTACCOUNTINGPOLICIESDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "auth_ref": [
      "r108",
      "r178"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for credit risk.",
        "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]",
        "verboseLabel": "Concentrations of credit risk"
       }
      }
     },
     "localname": "ConcentrationRiskCreditRisk",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.enterabio.com/role/SIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConsolidationPolicyTextBlock": {
     "auth_ref": [
      "r90",
      "r386"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.",
        "label": "Consolidation, Policy [Policy Text Block]",
        "verboseLabel": "Principles of consolidation"
       }
      }
     },
     "localname": "ConsolidationPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.enterabio.com/role/SIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityCurrent": {
     "auth_ref": [
      "r233",
      "r234",
      "r235"
     ],
     "calculation": {
      "http://www.enterabio.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 20.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.",
        "label": "Contract with Customer, Liability, Current",
        "terseLabel": "Contract liabilities",
        "totalLabel": "Other Liabilities, Current, Total"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.enterabio.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostOfRevenue": {
     "auth_ref": [
      "r29",
      "r145",
      "r198",
      "r208",
      "r209",
      "r210",
      "r211",
      "r212",
      "r213",
      "r214",
      "r215",
      "r216",
      "r321",
      "r435"
     ],
     "calculation": {
      "http://www.enterabio.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS": {
       "order": 10.0,
       "parentTag": "us-gaap_GrossProfit",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate cost of goods produced and sold and services rendered during the reporting period.",
        "label": "Cost of Revenue",
        "terseLabel": "COST OF REVENUES"
       }
      }
     },
     "localname": "CostOfRevenue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.enterabio.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostOfSalesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing cost of sales.",
        "label": "Cost of Sales [Member]",
        "terseLabel": "Cost of revenues"
       }
      }
     },
     "localname": "CostOfSalesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.enterabio.com/role/SHAREBASEDCOMPENSATIONDetails3"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Federal, State and Local, Tax Expense (Benefit) [Abstract]",
        "verboseLabel": "Current:"
       }
      }
     },
     "localname": "CurrentFederalStateAndLocalTaxExpenseBenefitAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.enterabio.com/role/INCOMETAXDetails3"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CurrentIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r89",
      "r298",
      "r306",
      "r423"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.",
        "label": "Current Income Tax Expense (Benefit)",
        "verboseLabel": "Total current income tax"
       }
      }
     },
     "localname": "CurrentIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.enterabio.com/role/INCOMETAXDetails3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit": {
     "auth_ref": [
      "r470"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred federal, state, and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred national, regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.",
        "label": "Deferred Federal, State and Local, Tax Expense (Benefit)",
        "negatedLabel": "Losses and benefits for tax purposes for the year, for which deferred taxes were recorded",
        "verboseLabel": "Deferred income taxes"
       }
      }
     },
     "localname": "DeferredFederalStateAndLocalTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.enterabio.com/role/INCOMETAXDetails3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Federal, State and Local, Tax Expense (Benefit) [Abstract]",
        "verboseLabel": "Deferred:"
       }
      }
     },
     "localname": "DeferredFederalStateAndLocalTaxExpenseBenefitAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.enterabio.com/role/INCOMETAXDetails3"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredIncomeTaxAssetsNet": {
     "auth_ref": [
      "r286",
      "r287"
     ],
     "calculation": {
      "http://www.enterabio.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 30.0,
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting.",
        "label": "Deferred Income Tax Assets, Net",
        "terseLabel": "Deferred income taxes"
       }
      }
     },
     "localname": "DeferredIncomeTaxAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.enterabio.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r39",
      "r89",
      "r299",
      "r305",
      "r306",
      "r423"
     ],
     "calculation": {
      "http://www.enterabio.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Deferred Income Tax Expense (Benefit)",
        "negatedLabel": "Total deferred income tax",
        "terseLabel": "Deferred income taxes",
        "verboseLabel": "Total deferred income taxes"
       }
      }
     },
     "localname": "DeferredIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.enterabio.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.enterabio.com/role/INCOMETAXDetails3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredRevenueRevenueRecognized1": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue recognized that was previously reported as deferred or unearned revenue.",
        "label": "Deferred Revenue, Revenue Recognized",
        "terseLabel": "Revenues recorded in revenue recognition"
       }
      }
     },
     "localname": "DeferredRevenueRevenueRecognized1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.enterabio.com/role/SIGNIFICANTACCOUNTINGPOLICIESDetailTextuals"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsGross": {
     "auth_ref": [
      "r293"
     ],
     "calculation": {
      "http://www.enterabio.com/role/INCOMETAXDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "Deferred Tax Assets, Gross",
        "totalLabel": "Net deferred tax assets before valuation allowance"
       }
      }
     },
     "localname": "DeferredTaxAssetsGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.enterabio.com/role/INCOMETAXDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment": {
     "auth_ref": [
      "r87",
      "r472"
     ],
     "calculation": {
      "http://www.enterabio.com/role/INCOMETAXDetails": {
       "order": 20.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from in-process research and development costs expensed in connection with a business combination.",
        "label": "Deferred Tax Assets, in Process Research and Development",
        "verboseLabel": "Research and development"
       }
      }
     },
     "localname": "DeferredTaxAssetsInProcessResearchAndDevelopment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.enterabio.com/role/INCOMETAXDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsNet": {
     "auth_ref": [
      "r471"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "Deferred Tax Assets, Net of Valuation Allowance",
        "terseLabel": "Net deferred tax assets",
        "totalLabel": "Net deferred tax assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.enterabio.com/role/INCOMETAXDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Net of Valuation Allowance [Abstract]",
        "verboseLabel": "Deferred tax assets:"
       }
      }
     },
     "localname": "DeferredTaxAssetsNetOfValuationAllowanceAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.enterabio.com/role/INCOMETAXDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": {
     "auth_ref": [
      "r87",
      "r472"
     ],
     "calculation": {
      "http://www.enterabio.com/role/INCOMETAXDetails": {
       "order": 30.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.",
        "label": "Deferred Tax Assets, Operating Loss Carryforwards",
        "verboseLabel": "Net operating loss carry forward"
       }
      }
     },
     "localname": "DeferredTaxAssetsOperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.enterabio.com/role/INCOMETAXDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsOther": {
     "auth_ref": [
      "r87",
      "r472"
     ],
     "calculation": {
      "http://www.enterabio.com/role/INCOMETAXDetails": {
       "order": 0.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.",
        "label": "Deferred Tax Assets, Other",
        "verboseLabel": "Other"
       }
      }
     },
     "localname": "DeferredTaxAssetsOther",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.enterabio.com/role/INCOMETAXDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost": {
     "auth_ref": [
      "r87",
      "r472"
     ],
     "calculation": {
      "http://www.enterabio.com/role/INCOMETAXDetails": {
       "order": 10.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost",
        "verboseLabel": "Share-based compensation"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.enterabio.com/role/INCOMETAXDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r294"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.",
        "label": "Deferred Tax Assets, Valuation Allowance",
        "negatedLabel": "Less - valuation allowance",
        "negatedTerseLabel": "valuation allowance",
        "periodEndLabel": "Closing balance",
        "periodStartLabel": "Opening balance",
        "terseLabel": "valuation allowance",
        "verboseLabel": "Less - valuation allowance"
       }
      }
     },
     "localname": "DeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.enterabio.com/role/INCOMETAXDetails",
      "http://www.enterabio.com/role/INCOMETAXDetails2"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent": {
     "auth_ref": [
      "r101",
      "r109",
      "r236",
      "r237",
      "r238",
      "r393"
     ],
     "calculation": {
      "http://www.enterabio.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 0.0,
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset, recognized in statement of financial position, for overfunded defined benefit pension and other postretirement plans.",
        "label": "Assets for Plan Benefits, Defined Benefit Plan",
        "terseLabel": "Funds in respect of employee rights upon retirement"
       }
      }
     },
     "localname": "DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.enterabio.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Depreciation": {
     "auth_ref": [
      "r39",
      "r53"
     ],
     "calculation": {
      "http://www.enterabio.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 30.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.",
        "label": "Depreciation",
        "verboseLabel": "Depreciation"
       }
      }
     },
     "localname": "Depreciation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.enterabio.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativesPolicyTextBlock": {
     "auth_ref": [
      "r93",
      "r94",
      "r95",
      "r96",
      "r97",
      "r148"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for its derivative instruments and hedging activities.",
        "label": "Derivatives, Policy [Policy Text Block]",
        "verboseLabel": "Derivatives"
       }
      }
     },
     "localname": "DerivativesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.enterabio.com/role/SIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DescriptionOfPostemploymentBenefits": {
     "auth_ref": [
      "r65"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of benefits provided to former or inactive employees, their beneficiaries, and covered dependents after employment but before retirement, except for: a) benefits provided through a pension or postretirement benefit plan, b) individual deferred compensation arrangements, c) termination benefits pertaining to exit or disposal activities, and d) stock compensation plans. Benefits may be provided in cash or in kind and may be paid as a result of disability, layoff, death, or other event.",
        "label": "Description of Postemployment Benefits",
        "terseLabel": "Description of mutual separation"
       }
      }
     },
     "localname": "DescriptionOfPostemploymentBenefits",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.enterabio.com/role/SHAREBASEDCOMPENSATIONDetailTextuals"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r245",
      "r276",
      "r277",
      "r278",
      "r283",
      "r395"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement [Text Block]",
        "terseLabel": "SHARE-BASED COMPENSATION"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.enterabio.com/role/SHAREBASEDCOMPENSATION"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Payment Arrangement [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DomesticCountryMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax department of the government that is entitled to levy and collect income taxes from the entity in its country of domicile.",
        "label": "Domestic Tax Authority [Member]",
        "verboseLabel": "Israeli tax rate [Member]"
       }
      }
     },
     "localname": "DomesticCountryMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.enterabio.com/role/INCOMETAXDetailTextuals"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r141",
      "r155",
      "r156",
      "r157",
      "r158",
      "r159",
      "r163",
      "r165",
      "r168",
      "r169",
      "r170",
      "r172",
      "r319",
      "r320",
      "r364",
      "r368",
      "r389"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic and Diluted",
        "terseLabel": "LOSS PER SHARE BASIC"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.enterabio.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareDiluted": {
     "auth_ref": [
      "r141",
      "r155",
      "r156",
      "r157",
      "r158",
      "r159",
      "r165",
      "r168",
      "r169",
      "r170",
      "r172",
      "r319",
      "r320",
      "r364",
      "r368",
      "r389"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Diluted",
        "verboseLabel": "LOSS PER SHARE DILUTED"
       }
      }
     },
     "localname": "EarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.enterabio.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "auth_ref": [
      "r46",
      "r47"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.",
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "verboseLabel": "Loss per share"
       }
      }
     },
     "localname": "EarningsPerSharePolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.enterabio.com/role/SIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": {
     "auth_ref": [
      "r146",
      "r289",
      "r307"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss).",
        "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent",
        "terseLabel": "Statutory tax rate of Entera Bio Ltd.",
        "verboseLabel": "Income tax rate"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.enterabio.com/role/INCOMETAXDetailTextuals"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.enterabio.com/role/SHAREBASEDCOMPENSATIONDetails3"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r59",
      "r122",
      "r137",
      "r138",
      "r139",
      "r150",
      "r151",
      "r152",
      "r154",
      "r160",
      "r162",
      "r173",
      "r199",
      "r232",
      "r279",
      "r280",
      "r281",
      "r301",
      "r302",
      "r318",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r340",
      "r371",
      "r372",
      "r373"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.enterabio.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY",
      "http://www.enterabio.com/role/GENERALDetailTextuals",
      "http://www.enterabio.com/role/SHARECAPITALDetailTextuals"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.",
        "label": "Fair Value Measurement, Policy [Policy Text Block]",
        "verboseLabel": "Fair value measurement"
       }
      }
     },
     "localname": "FairValueMeasurementPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.enterabio.com/role/SIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ForeignCountryMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax departments of governments entitled to levy and collect income taxes from the entity outside the entity's country of domicile.",
        "label": "Foreign Tax Authority [Member]",
        "verboseLabel": "U.S. tax rate [Member]"
       }
      }
     },
     "localname": "ForeignCountryMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.enterabio.com/role/INCOMETAXDetailTextuals"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock": {
     "auth_ref": [
      "r329"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.",
        "label": "Foreign Currency Transactions and Translations Policy [Policy Text Block]",
        "verboseLabel": "Functional currency"
       }
      }
     },
     "localname": "ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.enterabio.com/role/SIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r30"
     ],
     "calculation": {
      "http://www.enterabio.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS": {
       "order": 10.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "General and Administrative Expense",
        "terseLabel": "General and administrative expenses",
        "verboseLabel": "General and administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.enterabio.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS",
      "http://www.enterabio.com/role/SHAREBASEDCOMPENSATIONDetailTextuals"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "auth_ref": [
      "r27"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing general and administrative expense.",
        "label": "General and Administrative Expense [Member]",
        "terseLabel": "General and administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.enterabio.com/role/SHAREBASEDCOMPENSATIONDetails3"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GovernmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Organization that is the governing authority of a community.",
        "label": "Government [Member]",
        "verboseLabel": "Government of Israel [Member]"
       }
      }
     },
     "localname": "GovernmentMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.enterabio.com/role/COMMITMENTSDetailTextuals"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GrossProfit": {
     "auth_ref": [
      "r28",
      "r145",
      "r184",
      "r186",
      "r190",
      "r192",
      "r198",
      "r208",
      "r209",
      "r210",
      "r211",
      "r212",
      "r213",
      "r214",
      "r215",
      "r216",
      "r321",
      "r391",
      "r435"
     ],
     "calculation": {
      "http://www.enterabio.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS": {
       "order": 0.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.",
        "label": "Gross Profit",
        "totalLabel": "GROSS PROFIT"
       }
      }
     },
     "localname": "GrossProfit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.enterabio.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IPOMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "First sale of stock by a private company to the public.",
        "label": "IPO [Member]",
        "verboseLabel": "IPO [Member]"
       }
      }
     },
     "localname": "IPOMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.enterabio.com/role/GENERALDetailTextuals",
      "http://www.enterabio.com/role/SHARECAPITALDetailTextuals"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ImpairmentOfIntangibleAssetsFinitelived": {
     "auth_ref": [
      "r420",
      "r430"
     ],
     "calculation": {
      "http://www.enterabio.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 60.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of a finite-lived intangible asset to fair value."
       }
      }
     },
     "localname": "ImpairmentOfIntangibleAssetsFinitelived",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": {
     "auth_ref": [
      "r52",
      "r56"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.",
        "label": "Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]",
        "verboseLabel": "Impairment of long-lived assets"
       }
      }
     },
     "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.enterabio.com/role/SIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "auth_ref": [
      "r25",
      "r99",
      "r106",
      "r118",
      "r184",
      "r186",
      "r190",
      "r192",
      "r365",
      "r391"
     ],
     "calculation": {
      "http://www.enterabio.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS": {
       "order": 0.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "negatedLabel": "Loss (income) before income taxes",
        "negatedTerseLabel": "Loss before income taxes",
        "negatedTotalLabel": "LOSS BEFORE INCOME TAX",
        "positiveLabel": "Net loss for the year",
        "positiveVerboseLabel": "Loss before income taxes",
        "terseLabel": "Comprehensive loss",
        "totalLabel": "LOSS BEFORE INCOME TAX",
        "verboseLabel": "Loss (income) before income taxes"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.enterabio.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS",
      "http://www.enterabio.com/role/INCOMETAXDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r200",
      "r201"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.enterabio.com/role/SHAREBASEDCOMPENSATIONDetails3"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [
      "r201"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.enterabio.com/role/SHAREBASEDCOMPENSATIONDetails3"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxAuthorityAxis": {
     "auth_ref": [
      "r82"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by tax jurisdiction.",
        "label": "Income Tax Authority [Axis]"
       }
      }
     },
     "localname": "IncomeTaxAuthorityAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.enterabio.com/role/INCOMETAXDetailTextuals"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxAuthorityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes.",
        "label": "Income Tax Authority [Domain]"
       }
      }
     },
     "localname": "IncomeTaxAuthorityDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.enterabio.com/role/INCOMETAXDetailTextuals"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]",
        "terseLabel": "Rollforward of valuation allowance:"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r146",
      "r290",
      "r291",
      "r297",
      "r303",
      "r308",
      "r310",
      "r311",
      "r312"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "Income Tax Disclosure [Text Block]",
        "verboseLabel": "INCOME TAX"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.enterabio.com/role/INCOMETAX"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r147",
      "r161",
      "r162",
      "r183",
      "r288",
      "r304",
      "r309",
      "r369"
     ],
     "calculation": {
      "http://www.enterabio.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS": {
       "order": 10.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income Tax Expense (Benefit)",
        "negatedLabel": "TAXES ON INCOME",
        "positiveTerseLabel": "Actual income tax (benefit) expense",
        "terseLabel": "INCOME TAX EXPENSE (BENEFIT)",
        "totalLabel": "Actual income tax (benefit) expense",
        "verboseLabel": "Total income tax expense (benefit)"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.enterabio.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS",
      "http://www.enterabio.com/role/INCOMETAXDetails3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "auth_ref": [
      "r136",
      "r284",
      "r285",
      "r291",
      "r292",
      "r296",
      "r300"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.",
        "label": "Income Tax, Policy [Policy Text Block]",
        "verboseLabel": "Income taxes"
       }
      }
     },
     "localname": "IncomeTaxPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.enterabio.com/role/SIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxesPaidNet": {
     "auth_ref": [
      "r43"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.",
        "label": "Income Taxes Paid, Net",
        "terseLabel": "Income taxes paid in cash during the year"
       }
      }
     },
     "localname": "IncomeTaxesPaidNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.enterabio.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "auth_ref": [
      "r38"
     ],
     "calculation": {
      "http://www.enterabio.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 20.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.",
        "label": "Increase (Decrease) in Accounts Payable",
        "verboseLabel": "Increase (decrease) in accounts payable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.enterabio.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "auth_ref": [
      "r38"
     ],
     "calculation": {
      "http://www.enterabio.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 110.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.",
        "label": "Increase (Decrease) in Accounts Receivable",
        "negatedLabel": "Decrease (increase) in accounts receivable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.enterabio.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities": {
     "auth_ref": [
      "r419"
     ],
     "calculation": {
      "http://www.enterabio.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 120.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in accrued expenses, and obligations classified as other.",
        "label": "Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities",
        "totalLabel": "Increase (Decrease) in Accounts Payable and Accrued Liabilities, Total",
        "verboseLabel": "Increase (decrease) in accrued expenses and other payables"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.enterabio.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInContractWithCustomerLiability": {
     "auth_ref": [
      "r349",
      "r419"
     ],
     "calculation": {
      "http://www.enterabio.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 130.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.",
        "label": "Increase (Decrease) in Contract with Customer, Liability",
        "terseLabel": "Decrease in contract liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInContractWithCustomerLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.enterabio.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Changes in operating asset and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.enterabio.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingLeaseLiability": {
     "auth_ref": [
      "r419",
      "r476"
     ],
     "calculation": {
      "http://www.enterabio.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 80.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in obligation for operating lease."
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherCurrentAssets": {
     "auth_ref": [
      "r419"
     ],
     "calculation": {
      "http://www.enterabio.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 100.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in current assets classified as other.",
        "label": "Increase (Decrease) in Other Current Assets",
        "negatedLabel": "Decrease (increase) in other current assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherCurrentAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.enterabio.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "terseLabel": "CHANGES DURING THE YEAR ENDED"
       }
      }
     },
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.enterabio.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LeaseCostTableTextBlock": {
     "auth_ref": [
      "r477"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.",
        "label": "Lease, Cost [Table Text Block]",
        "terseLabel": "Schedule of lease cost"
       }
      }
     },
     "localname": "LeaseCostTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.enterabio.com/role/OPERATINGLEASESTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LeasesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases [Abstract]"
       }
      }
     },
     "localname": "LeasesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_LegalEntityTypeOfCounterpartyDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Nature of the other party participating in a financial transaction.",
        "label": "Legal Entity Type of Counterparty [Domain]"
       }
      }
     },
     "localname": "LegalEntityTypeOfCounterpartyDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.enterabio.com/role/COMMITMENTSDetailTextuals"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LesseeLeaseDescriptionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Lessee, Lease, Description [Line Items]"
       }
      }
     },
     "localname": "LesseeLeaseDescriptionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.enterabio.com/role/OPERATINGLEASESDetailTextuals"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeaseDescriptionTable": {
     "auth_ref": [
      "r334"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about lessee's leases.",
        "label": "Lessee, Lease, Description [Table]"
       }
      }
     },
     "localname": "LesseeLeaseDescriptionTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.enterabio.com/role/OPERATINGLEASESDetailTextuals"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "auth_ref": [
      "r333"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee.",
        "label": "Lessee, Leases [Policy Text Block]",
        "verboseLabel": "Leases"
       }
      }
     },
     "localname": "LesseeLeasesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.enterabio.com/role/SIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "auth_ref": [
      "r478"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.",
        "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]",
        "verboseLabel": "Schedule of maturities of undiscounted lease liabilities"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.enterabio.com/role/OPERATINGLEASESTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeasesTextBlock": {
     "auth_ref": [
      "r339"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.",
        "label": "Lessee, Operating Leases [Text Block]",
        "verboseLabel": "OPERATING LEASES"
       }
      }
     },
     "localname": "LesseeOperatingLeasesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.enterabio.com/role/OPERATINGLEASES"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r15",
      "r145",
      "r198",
      "r208",
      "r209",
      "r210",
      "r211",
      "r212",
      "r213",
      "r214",
      "r215",
      "r216",
      "r314",
      "r315",
      "r316",
      "r321",
      "r390",
      "r435",
      "r483",
      "r484"
     ],
     "calculation": {
      "http://www.enterabio.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 0.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "TOTAL LIABILITIES"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.enterabio.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities [Abstract]",
        "terseLabel": "LIABILITIES"
       }
      }
     },
     "localname": "LiabilitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.enterabio.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r13",
      "r104",
      "r114",
      "r398",
      "r422",
      "r429",
      "r475"
     ],
     "calculation": {
      "http://www.enterabio.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "TOTAL LIABILITIES AND SHAREHOLDERS\u2019 EQUITY"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.enterabio.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "Liabilities and shareholders' equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.enterabio.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r17",
      "r125",
      "r145",
      "r198",
      "r208",
      "r209",
      "r210",
      "r211",
      "r212",
      "r213",
      "r214",
      "r215",
      "r216",
      "r314",
      "r315",
      "r316",
      "r321",
      "r398",
      "r435",
      "r483",
      "r484"
     ],
     "calculation": {
      "http://www.enterabio.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 0.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "TOTAL CURRENT LIABILITIES"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.enterabio.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "CURRENT LIABILITIES:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.enterabio.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesNoncurrent": {
     "auth_ref": [
      "r1",
      "r2",
      "r3",
      "r5",
      "r6",
      "r145",
      "r198",
      "r208",
      "r209",
      "r210",
      "r211",
      "r212",
      "r213",
      "r214",
      "r215",
      "r216",
      "r314",
      "r315",
      "r316",
      "r321",
      "r435",
      "r483",
      "r484"
     ],
     "calculation": {
      "http://www.enterabio.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 10.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation due after one year or beyond the normal operating cycle, if longer.",
        "label": "Liabilities, Noncurrent",
        "totalLabel": "TOTAL NON-CURRENT LIABILITIES"
       }
      }
     },
     "localname": "LiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.enterabio.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesNoncurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Noncurrent [Abstract]",
        "terseLabel": "NON-CURRENT LIABILITIES:"
       }
      }
     },
     "localname": "LiabilitiesNoncurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.enterabio.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r142"
     ],
     "calculation": {
      "http://www.enterabio.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 20.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash provided by financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.enterabio.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "terseLabel": "CASH FLOWS FROM FINANCING ACTIVITIES:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.enterabio.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r142"
     ],
     "calculation": {
      "http://www.enterabio.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 0.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash used in investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.enterabio.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "terseLabel": "CASH FLOWS FROM INVESTING ACTIVITIES:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.enterabio.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r36",
      "r37",
      "r40"
     ],
     "calculation": {
      "http://www.enterabio.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 10.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash used in operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.enterabio.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "CASH FLOWS FROM OPERATING ACTIVITIES:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.enterabio.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r26",
      "r40",
      "r107",
      "r117",
      "r123",
      "r134",
      "r135",
      "r139",
      "r145",
      "r153",
      "r155",
      "r156",
      "r157",
      "r158",
      "r161",
      "r162",
      "r167",
      "r184",
      "r186",
      "r190",
      "r192",
      "r198",
      "r208",
      "r209",
      "r210",
      "r211",
      "r212",
      "r213",
      "r214",
      "r215",
      "r216",
      "r320",
      "r321",
      "r391",
      "r435"
     ],
     "calculation": {
      "http://www.enterabio.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 90.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.enterabio.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "negatedTotalLabel": "NET LOSS",
        "positiveLabel": "Net loss",
        "terseLabel": "Net loss",
        "totalLabel": "Net Income (Loss) Attributable to Parent, Total"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.enterabio.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.enterabio.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY",
      "http://www.enterabio.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "verboseLabel": "Newly issued and recently adopted accounting pronouncements"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.enterabio.com/role/SIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NoncashInvestingAndFinancingItemsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Noncash Investing and Financing Items [Abstract]",
        "verboseLabel": "SUPPLEMENTARY INFORMATION ON INVESTING AND FINANCING ACTIVITIES NOT INVOLVING CASH FLOWS:"
       }
      }
     },
     "localname": "NoncashInvestingAndFinancingItemsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.enterabio.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "auth_ref": [
      "r31"
     ],
     "calculation": {
      "http://www.enterabio.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS": {
       "order": 10.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).",
        "label": "Nonoperating Income (Expense)",
        "negatedLabel": "FINANCIAL EXPENSES (INCOME), net",
        "negatedTerseLabel": "FINANCIAL EXPENSES (INCOME), net",
        "terseLabel": "FINANCE EXPENSES (INCOME), net"
       }
      }
     },
     "localname": "NonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.enterabio.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OfficeEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tangible personal property used in an office setting. Examples include, but are not limited to, computers, copiers and fax machine.",
        "label": "Office Equipment [Member]",
        "verboseLabel": "Office furniture [Member]"
       }
      }
     },
     "localname": "OfficeEquipmentMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.enterabio.com/role/SIGNIFICANTACCOUNTINGPOLICIESDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OfficersCompensation": {
     "auth_ref": [
      "r417"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for salary and wage arising from service rendered by officer. Excludes allocated cost, labor-related nonsalary expense, and direct and overhead labor cost included in cost of good and service sold.",
        "label": "Salary and Wage, Officer, Excluding Cost of Good and Service Sold",
        "terseLabel": "Annual base salary"
       }
      }
     },
     "localname": "OfficersCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.enterabio.com/role/SHAREBASEDCOMPENSATIONDetailTextuals"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://www.enterabio.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS": {
       "order": 10.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.",
        "label": "Operating Expenses",
        "negatedTotalLabel": "TOTAL OPERATING EXPENSES",
        "totalLabel": "TOTAL OPERATING EXPENSES"
       }
      }
     },
     "localname": "OperatingExpenses",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.enterabio.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses [Abstract]",
        "terseLabel": "OPERATING EXPENSES:"
       }
      }
     },
     "localname": "OperatingExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.enterabio.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r184",
      "r186",
      "r190",
      "r192",
      "r391"
     ],
     "calculation": {
      "http://www.enterabio.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS": {
       "order": 0.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "negatedTotalLabel": "OPERATING LOSS",
        "totalLabel": "OPERATING LOSS"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.enterabio.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseCost": {
     "auth_ref": [
      "r335",
      "r397"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.",
        "label": "Operating Lease, Cost",
        "terseLabel": "Operating lease cost",
        "verboseLabel": "Annual lease consideration"
       }
      }
     },
     "localname": "OperatingLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.enterabio.com/role/OperatingLeaseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiability": {
     "auth_ref": [
      "r331"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.",
        "label": "Operating Lease, Liability",
        "terseLabel": "Maturity of lease liabilities under our non-cancelable operating leases to be paid in 2023",
        "verboseLabel": "Total lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.enterabio.com/role/OPERATINGLEASESDetailTextuals",
      "http://www.enterabio.com/role/OPERATINGLEASESDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Liability [Abstract]",
        "verboseLabel": "Operating Leases"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.enterabio.com/role/OPERATINGLEASESDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r331"
     ],
     "calculation": {
      "http://www.enterabio.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 30.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating Lease, Liability, Current",
        "terseLabel": "Current lease liabilities",
        "verboseLabel": "Current maturities of operating lease"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.enterabio.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.enterabio.com/role/OPERATINGLEASESDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r331"
     ],
     "calculation": {
      "http://www.enterabio.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 10.0,
       "parentTag": "us-gaap_LiabilitiesNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating Lease, Liability, Noncurrent",
        "terseLabel": "Non-current lease liabilities",
        "verboseLabel": "Operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.enterabio.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.enterabio.com/role/OPERATINGLEASESDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasePayments": {
     "auth_ref": [
      "r332",
      "r336"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.",
        "label": "Operating Lease, Payments",
        "terseLabel": "Operating leases cost for rental space and vehicles",
        "verboseLabel": "Operating cash flows from operating leases"
       }
      }
     },
     "localname": "OperatingLeasePayments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.enterabio.com/role/OperatingLeaseDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r330"
     ],
     "calculation": {
      "http://www.enterabio.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 20.0,
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease, Right-of-Use Asset",
        "verboseLabel": "Operating lease right-of-use assets"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.enterabio.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.enterabio.com/role/OPERATINGLEASESDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "auth_ref": [
      "r338",
      "r397"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average discount rate for operating lease calculated at point in time.",
        "label": "Operating Lease, Weighted Average Discount Rate, Percent",
        "verboseLabel": "Weighted-average discount rate"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.enterabio.com/role/OPERATINGLEASESDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "auth_ref": [
      "r337",
      "r397"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "verboseLabel": "Weighted-average remaining lease term (in years)"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.enterabio.com/role/OPERATINGLEASESDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_OperatingLossCarryforwards": {
     "auth_ref": [
      "r85"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.",
        "label": "Operating Loss Carryforwards",
        "verboseLabel": "Carryforward losses"
       }
      }
     },
     "localname": "OperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.enterabio.com/role/INCOMETAXDetailTextuals"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLossCarryforwardsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Operating Loss Carryforwards [Line Items]"
       }
      }
     },
     "localname": "OperatingLossCarryforwardsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.enterabio.com/role/INCOMETAXDetailTextuals",
      "http://www.enterabio.com/role/INCOMETAXDetails1",
      "http://www.enterabio.com/role/INCOMETAXDetails3"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingLossCarryforwardsTable": {
     "auth_ref": [
      "r86"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting pertinent information, such as tax authority, amounts, and expiration dates, of net operating loss carryforwards, including an assessment of the likelihood of utilization.",
        "label": "Operating Loss Carryforwards [Table]"
       }
      }
     },
     "localname": "OperatingLossCarryforwardsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.enterabio.com/role/INCOMETAXDetailTextuals",
      "http://www.enterabio.com/role/INCOMETAXDetails1",
      "http://www.enterabio.com/role/INCOMETAXDetails3"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": {
     "auth_ref": [
      "r0",
      "r92"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.",
        "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]",
        "terseLabel": "DESCRIPTION OF BUSINESS",
        "verboseLabel": "GENERAL"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.enterabio.com/role/GENERAL"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r16"
     ],
     "calculation": {
      "http://www.enterabio.com/role/SUPPLEMENTARYFINANCIALSTATEMENTINFORMATIONDetails": {
       "order": 20.0,
       "parentTag": "us-gaap_AccruedLiabilitiesAndOtherLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Accrued Liabilities, Current",
        "terseLabel": "Accrued expenses"
       }
      }
     },
     "localname": "OtherAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.enterabio.com/role/SUPPLEMENTARYFINANCIALSTATEMENTINFORMATIONDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsCurrent": {
     "auth_ref": [
      "r132",
      "r398"
     ],
     "calculation": {
      "http://www.enterabio.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 20.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current assets classified as other.",
        "label": "Other Assets, Current",
        "terseLabel": "Other current assets"
       }
      }
     },
     "localname": "OtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.enterabio.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNonrecurringIncome": {
     "auth_ref": [
      "r32"
     ],
     "calculation": {
      "http://www.enterabio.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS": {
       "order": 20.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of other income that is infrequent in occurrence or unusual in nature.",
        "label": "Other Nonrecurring Income",
        "negatedLabel": "Other income",
        "verboseLabel": "Other income"
       }
      }
     },
     "localname": "OtherNonrecurringIncome",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.enterabio.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentForContingentConsiderationLiabilityOperatingActivities": {
     "auth_ref": [
      "r35"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow, not made soon after acquisition date of business combination, to settle contingent consideration liability exceeding amount recognized at acquisition date. Includes, but is not limited to, measurement period adjustment and less amount paid soon after acquisition date.",
        "label": "Payment for Contingent Consideration Liability, Operating Activities",
        "verboseLabel": "Annual lease consideration"
       }
      }
     },
     "localname": "PaymentForContingentConsiderationLiabilityOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.enterabio.com/role/OPERATINGLEASESDetailTextuals"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r33"
     ],
     "calculation": {
      "http://www.enterabio.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 0.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Purchase of property and equipment"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.enterabio.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PlanNameAxis": {
     "auth_ref": [
      "r444",
      "r445",
      "r446",
      "r447",
      "r448",
      "r449",
      "r450",
      "r451",
      "r452",
      "r453",
      "r454",
      "r455",
      "r456",
      "r457",
      "r458",
      "r459",
      "r460",
      "r461",
      "r462",
      "r463",
      "r464",
      "r465",
      "r466",
      "r467",
      "r468",
      "r469"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by plan name for share-based payment arrangement.",
        "label": "Plan Name [Axis]"
       }
      }
     },
     "localname": "PlanNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.enterabio.com/role/SHAREBASEDCOMPENSATIONDetailTextuals"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PlanNameDomain": {
     "auth_ref": [
      "r444",
      "r445",
      "r446",
      "r447",
      "r448",
      "r449",
      "r450",
      "r451",
      "r452",
      "r453",
      "r454",
      "r455",
      "r456",
      "r457",
      "r458",
      "r459",
      "r460",
      "r461",
      "r462",
      "r463",
      "r464",
      "r465",
      "r466",
      "r467",
      "r468",
      "r469"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement.",
        "label": "Plan Name [Domain]"
       }
      }
     },
     "localname": "PlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.enterabio.com/role/SHAREBASEDCOMPENSATIONDetailTextuals"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PostemploymentBenefitsLiabilityNoncurrent": {
     "auth_ref": [
      "r441",
      "r442"
     ],
     "calculation": {
      "http://www.enterabio.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 0.0,
       "parentTag": "us-gaap_LiabilitiesNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For a classified balance sheet, the carrying amount as of the balance sheet date of the portion of the obligations recognized for the various benefits provided to former or inactive employees, their beneficiaries, and covered dependents after employment but before retirement that is payable after one year (or beyond the operating cycle if longer).",
        "label": "Postemployment Benefits Liability, Noncurrent",
        "terseLabel": "Liability for employee rights upon retirement"
       }
      }
     },
     "localname": "PostemploymentBenefitsLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.enterabio.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrivatePlacementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A private placement is a direct offering of securities to a limited number of sophisticated investors such as insurance companies, pension funds, mezzanine funds, stock funds and trusts.",
        "label": "Private Placement [Member]",
        "verboseLabel": "Private Placement [Member]"
       }
      }
     },
     "localname": "PrivatePlacementMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.enterabio.com/role/SHARECAPITALDetailTextuals"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "auth_ref": [
      "r34"
     ],
     "calculation": {
      "http://www.enterabio.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 0.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the additional capital contribution to the entity.",
        "label": "Proceeds from Issuance of Common Stock",
        "verboseLabel": "Proceeds from issuance of shares through ATM programs, net of issuance costs"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.enterabio.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.enterabio.com/role/SHARECAPITALDetailTextuals"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfPrivatePlacement": {
     "auth_ref": [
      "r34"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement.",
        "label": "Proceeds from Issuance of Private Placement",
        "verboseLabel": "Proceeds from private placement"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfPrivatePlacement",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.enterabio.com/role/SHARECAPITALDetailTextuals"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromWarrantExercises": {
     "auth_ref": [
      "r418"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the amount received from holders exercising their stock warrants.",
        "label": "Proceeds from Warrant Exercises",
        "verboseLabel": "Proceeds from exercise of warrants"
       }
      }
     },
     "localname": "ProceedsFromWarrantExercises",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.enterabio.com/role/SHARECAPITALDetailTextuals"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProfessionalFees": {
     "auth_ref": [
      "r119",
      "r120"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A fee charged for services from professionals such as doctors, lawyers and accountants. The term is often expanded to include other professions, for example, pharmacists charging to maintain a medicinal profile of a client or customer.",
        "label": "Professional Fees",
        "terseLabel": "Monthly fee"
       }
      }
     },
     "localname": "ProfessionalFees",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.enterabio.com/role/SHAREBASEDCOMPENSATIONDetailTextuals"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "auth_ref": [
      "r55"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.",
        "label": "Long-Lived Tangible Asset [Axis]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.enterabio.com/role/SIGNIFICANTACCOUNTINGPOLICIESDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Property, Plant and Equipment [Line Items]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.enterabio.com/role/SIGNIFICANTACCOUNTINGPOLICIESDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r55",
      "r115",
      "r366",
      "r398"
     ],
     "calculation": {
      "http://www.enterabio.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 10.0,
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "terseLabel": "Property and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.enterabio.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "auth_ref": [
      "r55",
      "r379",
      "r380"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property, Plant and Equipment, Policy [Policy Text Block]",
        "verboseLabel": "Property and equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.enterabio.com/role/SIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "auth_ref": [
      "r54"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.",
        "label": "Long-Lived Tangible Asset [Domain]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.enterabio.com/role/SIGNIFICANTACCOUNTINGPOLICIESDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.",
        "label": "Property, Plant and Equipment, Useful Life",
        "verboseLabel": "Estimated useful life"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.enterabio.com/role/SIGNIFICANTACCOUNTINGPOLICIESDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_RelatedPartyDomain": {
     "auth_ref": [
      "r240",
      "r341",
      "r342"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party [Domain]"
       }
      }
     },
     "localname": "RelatedPartyDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.enterabio.com/role/COMMITMENTSDetailTextuals",
      "http://www.enterabio.com/role/SHARECAPITALDetailTextuals",
      "http://www.enterabio.com/role/SIGNIFICANTACCOUNTINGPOLICIESDetailTextuals"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "auth_ref": [
      "r240",
      "r341",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r482"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party [Axis]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.enterabio.com/role/COMMITMENTSDetailTextuals",
      "http://www.enterabio.com/role/SHARECAPITALDetailTextuals",
      "http://www.enterabio.com/role/SIGNIFICANTACCOUNTINGPOLICIESDetailTextuals"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r80",
      "r121",
      "r491"
     ],
     "calculation": {
      "http://www.enterabio.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS": {
       "order": 0.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and Development Expense",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.enterabio.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research and Development Expense [Member]",
        "terseLabel": "Research and development expenses"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.enterabio.com/role/SHAREBASEDCOMPENSATIONDetails3"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "auth_ref": [
      "r80"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.",
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "verboseLabel": "Research and development expenses"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.enterabio.com/role/SIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RestrictedCashAndCashEquivalents": {
     "auth_ref": [
      "r41",
      "r44",
      "r100",
      "r112",
      "r126"
     ],
     "calculation": {
      "http://www.enterabio.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 10.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Restricted Cash and Cash Equivalents",
        "terseLabel": "Restricted deposits included in other current assets"
       }
      }
     },
     "localname": "RestrictedCashAndCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.enterabio.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.",
        "label": "Restricted Stock Units (RSUs) [Member]",
        "terseLabel": "Restricted Stock Units (RSUs)"
       }
      }
     },
     "localname": "RestrictedStockUnitsRSUMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.enterabio.com/role/SHAREBASEDCOMPENSATIONDetailTextuals"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r10",
      "r61",
      "r113",
      "r374",
      "r376",
      "r398"
     ],
     "calculation": {
      "http://www.enterabio.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 10.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "terseLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.enterabio.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.enterabio.com/role/GENERALDetailTextuals"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r122",
      "r150",
      "r151",
      "r152",
      "r154",
      "r160",
      "r162",
      "r199",
      "r279",
      "r280",
      "r281",
      "r301",
      "r302",
      "r318",
      "r371",
      "r373"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Accumulated Deficit [Member]",
        "verboseLabel": "Accumulated deficit [Member]"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.enterabio.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueRecognitionPolicyTextBlock": {
     "auth_ref": [
      "r387",
      "r388"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.",
        "label": "Revenue [Policy Text Block]",
        "verboseLabel": "Revenue recognition"
       }
      }
     },
     "localname": "RevenueRecognitionPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.enterabio.com/role/SIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Revenues": {
     "auth_ref": [
      "r140",
      "r145",
      "r181",
      "r182",
      "r185",
      "r188",
      "r189",
      "r193",
      "r194",
      "r195",
      "r198",
      "r208",
      "r209",
      "r210",
      "r211",
      "r212",
      "r213",
      "r214",
      "r215",
      "r216",
      "r321",
      "r365",
      "r435"
     ],
     "calculation": {
      "http://www.enterabio.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS": {
       "order": 0.0,
       "parentTag": "us-gaap_GrossProfit",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).",
        "label": "Revenues",
        "positiveLabel": "REVENUES",
        "verboseLabel": "Revenues"
       }
      }
     },
     "localname": "Revenues",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.enterabio.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RoyaltyGuaranteesCommitmentsAmount": {
     "auth_ref": [
      "r351"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount the entity has committed to make for future royalty guarantees.",
        "label": "Royalty Guarantees, Commitments, Amount",
        "verboseLabel": "Total royalty amount payable"
       }
      }
     },
     "localname": "RoyaltyGuaranteesCommitmentsAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.enterabio.com/role/COMMITMENTSDetailTextuals"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.",
        "label": "Sale of Stock [Domain]"
       }
      }
     },
     "localname": "SaleOfStockNameOfTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.enterabio.com/role/GENERALDetailTextuals",
      "http://www.enterabio.com/role/SHARECAPITALDetailTextuals"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses.",
        "label": "Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]",
        "verboseLabel": "Schedule of accounts payable and accrued liabilities"
       }
      }
     },
     "localname": "ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.enterabio.com/role/SUPPLEMENTARYFINANCIALSTATEMENTINFORMATIONTable"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock": {
     "auth_ref": [
      "r88"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.",
        "label": "Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]",
        "verboseLabel": "Schedule of tax expenses"
       }
      }
     },
     "localname": "ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.enterabio.com/role/INCOMETAXTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "auth_ref": [
      "r84"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.",
        "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]",
        "verboseLabel": "Schedule of deferred income taxes"
       }
      }
     },
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.enterabio.com/role/INCOMETAXTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "auth_ref": [
      "r81"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.",
        "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]",
        "verboseLabel": "Schedule of rconciliation of statutory tax rate"
       }
      }
     },
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.enterabio.com/role/INCOMETAXTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": {
     "auth_ref": [
      "r75",
      "r77"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements.",
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.enterabio.com/role/SHAREBASEDCOMPENSATIONDetails3"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "auth_ref": [
      "r75"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.",
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]",
        "terseLabel": "Schedule of of share-based compensation on statements of operations"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.enterabio.com/role/SHAREBASEDCOMPENSATIONTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock": {
     "auth_ref": [
      "r423"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of income before income tax between domestic and foreign jurisdictions.",
        "label": "Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]",
        "verboseLabel": "Schedule of loss (income) before income taxes"
       }
      }
     },
     "localname": "ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.enterabio.com/role/INCOMETAXTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "auth_ref": [
      "r55"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table]"
       }
      }
     },
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.enterabio.com/role/SIGNIFICANTACCOUNTINGPOLICIESDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r242",
      "r244",
      "r246",
      "r247",
      "r248",
      "r250",
      "r251",
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r265",
      "r266",
      "r267",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.enterabio.com/role/SHAREBASEDCOMPENSATIONDetailTextuals",
      "http://www.enterabio.com/role/SHAREBASEDCOMPENSATIONDetails",
      "http://www.enterabio.com/role/SHAREBASEDCOMPENSATIONDetails2"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "auth_ref": [
      "r68",
      "r69",
      "r70"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.",
        "label": "Share-based Payment Arrangement, Option, Activity [Table Text Block]",
        "terseLabel": "Schedule of option activity"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.enterabio.com/role/SHAREBASEDCOMPENSATIONTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "auth_ref": [
      "r73"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
        "label": "Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "terseLabel": "Schedule of fair value assumptions of option granted using Black-Scholes option-pricing model"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.enterabio.com/role/SHAREBASEDCOMPENSATIONTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SeriesAPreferredStockMember": {
     "auth_ref": [
      "r412",
      "r413",
      "r440"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Series A preferred stock.",
        "label": "Series A Preferred Stock [Member]",
        "verboseLabel": "Series A Preferred Stock [Member]"
       }
      }
     },
     "localname": "SeriesAPreferredStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.enterabio.com/role/SHARECAPITALDetailTextuals"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SeriesBPreferredStockMember": {
     "auth_ref": [
      "r412",
      "r413",
      "r440"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Series B preferred stock.",
        "label": "Series B Preferred Stock [Member]",
        "verboseLabel": "Series B Preferred Stock [Member]"
       }
      }
     },
     "localname": "SeriesBPreferredStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.enterabio.com/role/SHARECAPITALDetailTextuals"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SeveranceCosts1": {
     "auth_ref": [
      "r39"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses for special or contractual termination benefits provided to current employees involuntarily terminated under a benefit arrangement associated exit or disposal activities pursuant to an authorized plan. Excludes expenses related to one-time termination benefits, a discontinued operation or an asset retirement obligation.",
        "label": "Severance Costs",
        "verboseLabel": "Severance payment expenses"
       }
      }
     },
     "localname": "SeveranceCosts1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.enterabio.com/role/SIGNIFICANTACCOUNTINGPOLICIESDetailTextuals"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r38"
     ],
     "calculation": {
      "http://www.enterabio.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 70.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Noncash Expense",
        "verboseLabel": "Share-based compensation"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.enterabio.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "auth_ref": [
      "r395"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period",
        "terseLabel": "Vestion period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.enterabio.com/role/SHAREBASEDCOMPENSATIONDetailTextuals",
      "http://www.enterabio.com/role/SUBSEQUENTEVENTSNarrative"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription": {
     "auth_ref": [
      "r66",
      "r67"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of terms of share-based payment arrangement. Includes, but is not limited to, type of award or grantee and reason for issuance.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Description",
        "terseLabel": "Description of terms of share-based payment arrangement"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.enterabio.com/role/SHAREBASEDCOMPENSATIONDetailTextuals"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "auth_ref": [
      "r261"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "terseLabel": "Restricted Share Units granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.enterabio.com/role/SHAREBASEDCOMPENSATIONDetailTextuals"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "auth_ref": [
      "r262"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period",
        "terseLabel": "Restricted Share Units vested"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.enterabio.com/role/SHAREBASEDCOMPENSATIONDetailTextuals"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue": {
     "auth_ref": [
      "r265"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of share-based awards for which the grantee gained the right by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value",
        "terseLabel": "Fair value of the RSU at the grant date"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.enterabio.com/role/SHAREBASEDCOMPENSATIONDetailTextuals"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agreed-upon price for the exchange of the underlying asset relating to the share-based payment award.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Exercise Price",
        "terseLabel": "Exercise price"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.enterabio.com/role/SHAREBASEDCOMPENSATIONDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "auth_ref": [
      "r272"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "terseLabel": "Dividend yield"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.enterabio.com/role/SHAREBASEDCOMPENSATIONDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "auth_ref": [
      "r271"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate",
        "terseLabel": "Expected volatility"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.enterabio.com/role/SHAREBASEDCOMPENSATIONDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "auth_ref": [
      "r273"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
        "terseLabel": "Risk-free interest rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.enterabio.com/role/SHAREBASEDCOMPENSATIONDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.enterabio.com/role/SHAREBASEDCOMPENSATIONDetailTextuals",
      "http://www.enterabio.com/role/SHAREBASEDCOMPENSATIONDetails",
      "http://www.enterabio.com/role/SHAREBASEDCOMPENSATIONDetails2"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of additional shares authorized for issuance under share-based payment arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized",
        "terseLabel": "Number of additional ordinary shares authorized"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.enterabio.com/role/SHAREBASEDCOMPENSATIONDetailTextuals"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": {
     "auth_ref": [
      "r396"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares authorized for issuance under share-based payment arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized",
        "terseLabel": "Number of ordinary shares authorized"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.enterabio.com/role/SHAREBASEDCOMPENSATIONDetailTextuals"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "auth_ref": [
      "r76"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant",
        "terseLabel": "Ordinary shares available for future grant"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.enterabio.com/role/SHAREBASEDCOMPENSATIONDetailTextuals"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "auth_ref": [
      "r252"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number",
        "terseLabel": "Exercisable at end of the year",
        "verboseLabel": "Number of options exercisable at end of year"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.enterabio.com/role/SHAREBASEDCOMPENSATIONDetails1",
      "http://www.enterabio.com/role/SHAREBASEDCOMPENSATIONDetails2"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r252"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "terseLabel": "Exercisable at end of the year"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.enterabio.com/role/SHAREBASEDCOMPENSATIONDetails1"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod": {
     "auth_ref": [
      "r257"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period",
        "negatedLabel": "Expired",
        "terseLabel": "Expired"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.enterabio.com/role/SHAREBASEDCOMPENSATIONDetails1"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "auth_ref": [
      "r256"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period",
        "negatedLabel": "Forfeited",
        "terseLabel": "Forfeited"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.enterabio.com/role/SHAREBASEDCOMPENSATIONDetails1"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [
      "r254"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross",
        "terseLabel": "Granted",
        "verboseLabel": "Number of options to purchase ordinary shares"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.enterabio.com/role/SHAREBASEDCOMPENSATIONDetailTextuals",
      "http://www.enterabio.com/role/SHAREBASEDCOMPENSATIONDetails1",
      "http://www.enterabio.com/role/SUBSEQUENTEVENTSNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "auth_ref": [
      "r76"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value",
        "terseLabel": "Aggregate intrinsic value of outstanding options"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.enterabio.com/role/SHAREBASEDCOMPENSATIONDetailTextuals"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r250",
      "r251"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number",
        "periodEndLabel": "Outstanding at end of the year",
        "periodStartLabel": "Outstanding at beginning of the year",
        "terseLabel": "Number of options outstanding at end of year"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.enterabio.com/role/SHAREBASEDCOMPENSATIONDetails1",
      "http://www.enterabio.com/role/SHAREBASEDCOMPENSATIONDetails2"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]",
        "terseLabel": "Number of options"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.enterabio.com/role/SHAREBASEDCOMPENSATIONDetails1"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r250",
      "r251"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Outstanding at end of the year",
        "periodStartLabel": "Outstanding at beginning of the year",
        "terseLabel": "Exercise Price Per Share"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.enterabio.com/role/SHAREBASEDCOMPENSATIONDetails1",
      "http://www.enterabio.com/role/SHAREBASEDCOMPENSATIONDetails2"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]",
        "terseLabel": "Weighted Average exercise price"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.enterabio.com/role/SHAREBASEDCOMPENSATIONDetails1"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock": {
     "auth_ref": [
      "r70"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of number, weighted-average exercise price or conversion ratio, aggregate intrinsic value, and weighted-average remaining contractual term for outstanding and exercisable options that are fully vested and expected to vest. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding and Exercisable [Table Text Block]",
        "terseLabel": "Schedule of outstanding and exercisable options of ordinary shares"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.enterabio.com/role/SHAREBASEDCOMPENSATIONTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod": {
     "auth_ref": [
      "r76"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued under share-based payment arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Shares Issued in Period",
        "verboseLabel": "Number of shares issued on options exercised"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.enterabio.com/role/SHARECAPITALDetailTextuals"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r246",
      "r247",
      "r248",
      "r250",
      "r251",
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r265",
      "r266",
      "r267",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Award Type [Domain]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.enterabio.com/role/SHAREBASEDCOMPENSATIONDetailTextuals"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r255"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "terseLabel": "Exercised",
        "verboseLabel": "Weighted average exercise rice of options exercised"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.enterabio.com/role/SHAREBASEDCOMPENSATIONDetails1",
      "http://www.enterabio.com/role/SHARECAPITALDetailTextuals"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r257"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price",
        "terseLabel": "Expired"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.enterabio.com/role/SHAREBASEDCOMPENSATIONDetails1"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r256"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price",
        "terseLabel": "Forfeited"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.enterabio.com/role/SHAREBASEDCOMPENSATIONDetails1"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r254"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "terseLabel": "Granted",
        "verboseLabel": "Exercise price of options granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.enterabio.com/role/SHAREBASEDCOMPENSATIONDetailTextuals",
      "http://www.enterabio.com/role/SHAREBASEDCOMPENSATIONDetails1"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationAwardTrancheOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "First portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period.",
        "label": "Share-based Payment Arrangement, Tranche One [Member]",
        "terseLabel": "Vest on the first anniversary of the date of grant [Member]"
       }
      }
     },
     "localname": "ShareBasedCompensationAwardTrancheOneMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.enterabio.com/role/SHAREBASEDCOMPENSATIONDetailTextuals"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationAwardTrancheThreeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Third portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period.",
        "label": "Share-based Payment Arrangement, Tranche Three [Member]",
        "terseLabel": "Shares vested on the signing date [Member]"
       }
      }
     },
     "localname": "ShareBasedCompensationAwardTrancheThreeMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.enterabio.com/role/SHAREBASEDCOMPENSATIONDetailTextuals"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationAwardTrancheTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Second portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period.",
        "label": "Share-based Payment Arrangement, Tranche Two [Member]",
        "terseLabel": "Vest in twelve equal quarterly installments following the first anniversary of the applicable grant date [Member]"
       }
      }
     },
     "localname": "ShareBasedCompensationAwardTrancheTwoMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.enterabio.com/role/SHAREBASEDCOMPENSATIONDetailTextuals"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "auth_ref": [
      "r249",
      "r268",
      "r269",
      "r270",
      "r271",
      "r274",
      "r282",
      "r283"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.",
        "label": "Share-based Payment Arrangement [Policy Text Block]",
        "verboseLabel": "Share-based compensation"
       }
      }
     },
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.enterabio.com/role/SIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis": {
     "auth_ref": [
      "r72"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by range of option prices pertaining to options granted.",
        "label": "Exercise Price Range [Axis]"
       }
      }
     },
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.enterabio.com/role/SHAREBASEDCOMPENSATIONDetails2"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain": {
     "auth_ref": [
      "r74"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Supplementary information on outstanding and exercisable share awards as of the balance sheet date which stratifies outstanding options by ranges of exercise prices.",
        "label": "Exercise Price Range [Domain]"
       }
      }
     },
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.enterabio.com/role/SHAREBASEDCOMPENSATIONDetails2"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SharePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Price of a single share of a number of saleable stocks of a company.",
        "label": "Share Price",
        "verboseLabel": "Price of shares issued under private placement"
       }
      }
     },
     "localname": "SharePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.enterabio.com/role/GENERALDetailTextuals",
      "http://www.enterabio.com/role/SHARECAPITALDetailTextuals"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage": {
     "auth_ref": [
      "r444"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of vesting of award under share-based payment arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage",
        "terseLabel": "Vesting percentage"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.enterabio.com/role/SHAREBASEDCOMPENSATIONDetailTextuals"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "auth_ref": [
      "r270"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term",
        "terseLabel": "Expected life - in years"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.enterabio.com/role/SHAREBASEDCOMPENSATIONDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "auth_ref": [
      "r76"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value",
        "terseLabel": "Aggregate intrinsic value of exercisable options"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.enterabio.com/role/SHAREBASEDCOMPENSATIONDetailTextuals"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r76"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term",
        "verboseLabel": "Options exercisable, Weighted Average Remaining contractual Life"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.enterabio.com/role/SHAREBASEDCOMPENSATIONDetails2"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of non-vested options forfeited.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested Options Forfeited, Number of Shares",
        "periodEndLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested, Number of Shares, Ending Balance",
        "periodStartLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested, Number of Shares, Beginning Balance",
        "verboseLabel": "Number of unvested options forfeited"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.enterabio.com/role/SHAREBASEDCOMPENSATIONDetailTextuals"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r71"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "verboseLabel": "Options outstanding, Weighted Average Remaining contractual Life"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.enterabio.com/role/SHAREBASEDCOMPENSATIONDetails2"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1": {
     "auth_ref": [
      "r265"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value",
        "terseLabel": "Fair value of options at the date of grant"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.enterabio.com/role/SHAREBASEDCOMPENSATIONDetailTextuals"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharesIssued": {
     "auth_ref": [
      "r59"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.",
        "label": "Shares, Issued",
        "verboseLabel": "Number of shares issued"
       }
      }
     },
     "localname": "SharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.enterabio.com/role/GENERALDetailTextuals",
      "http://www.enterabio.com/role/SHARECAPITALDetailTextuals"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.",
        "label": "Shares, Outstanding",
        "periodEndLabel": "BALANCE (in shares)",
        "periodStartLabel": "BALANCE (in shares)"
       }
      }
     },
     "localname": "SharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.enterabio.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r45",
      "r143"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.",
        "label": "Significant Accounting Policies [Text Block]",
        "verboseLabel": "SIGNIFICANT ACCOUNTING POLICIES"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.enterabio.com/role/SIGNIFICANTACCOUNTINGPOLICIES"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StatementClassOfStockAxis": {
     "auth_ref": [
      "r128",
      "r129",
      "r130",
      "r145",
      "r165",
      "r166",
      "r168",
      "r170",
      "r174",
      "r175",
      "r198",
      "r208",
      "r210",
      "r211",
      "r212",
      "r215",
      "r216",
      "r217",
      "r218",
      "r220",
      "r224",
      "r230",
      "r321",
      "r384",
      "r411",
      "r421",
      "r427"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by the different classes of stock of the entity.",
        "label": "Class of Stock [Axis]"
       }
      }
     },
     "localname": "StatementClassOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.enterabio.com/role/SHARECAPITALDetailTextuals"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r19",
      "r59",
      "r122",
      "r137",
      "r138",
      "r139",
      "r150",
      "r151",
      "r152",
      "r154",
      "r160",
      "r162",
      "r173",
      "r199",
      "r232",
      "r279",
      "r280",
      "r281",
      "r301",
      "r302",
      "r318",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r340",
      "r371",
      "r372",
      "r373"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.enterabio.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY",
      "http://www.enterabio.com/role/GENERALDetailTextuals",
      "http://www.enterabio.com/role/SHARECAPITALDetailTextuals"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.enterabio.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r150",
      "r151",
      "r152",
      "r173",
      "r350"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.enterabio.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesIssuedForServices": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.",
        "label": "Stock Issued During Period, Shares, Issued for Services",
        "verboseLabel": "Issuance of shares due to the ATM program, net of issuance costs (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesIssuedForServices",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.enterabio.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r7",
      "r8",
      "r59",
      "r61",
      "r255"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period",
        "negatedLabel": "Exercised",
        "terseLabel": "Exercise of options to ordinary shares (in shares)",
        "verboseLabel": "Number of options exercised"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.enterabio.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY",
      "http://www.enterabio.com/role/SHAREBASEDCOMPENSATIONDetails1",
      "http://www.enterabio.com/role/SHARECAPITALDetailTextuals",
      "http://www.enterabio.com/role/SUBSEQUENTEVENTSNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueIssuedForServices": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.",
        "label": "Stock Issued During Period, Value, Issued for Services",
        "verboseLabel": "Issuance of shares due to the ATM program, net of issuance costs"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueIssuedForServices",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.enterabio.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "auth_ref": [
      "r19",
      "r59",
      "r61"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued as a result of the exercise of stock options.",
        "label": "Stock Issued During Period, Value, Stock Options Exercised",
        "verboseLabel": "Exercise of options to ordinary shares"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.enterabio.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY",
      "http://www.enterabio.com/role/SHARECAPITALDetailTextuals"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r8",
      "r11",
      "r12",
      "r51",
      "r398",
      "r422",
      "r429",
      "r475"
     ],
     "calculation": {
      "http://www.enterabio.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 20.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "periodEndLabel": "BALANCE",
        "periodStartLabel": "BALANCE",
        "totalLabel": "TOTAL SHAREHOLDERS' EQUITY"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.enterabio.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.enterabio.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityNoteAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Note [Abstract]"
       }
      }
     },
     "localname": "StockholdersEquityNoteAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "auth_ref": [
      "r63",
      "r144",
      "r218",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r227",
      "r228",
      "r229",
      "r232",
      "r317"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.",
        "label": "Stockholders' Equity Note Disclosure [Text Block]",
        "verboseLabel": "SHARE CAPITAL"
       }
      }
     },
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.enterabio.com/role/SHARECAPITAL"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StockholdersEquityNumberOfSharesParValueAndOtherDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity, Number of Shares, Par Value and Other Disclosures [Abstract]",
        "terseLabel": "SHAREHOLDERS' EQUITY:"
       }
      }
     },
     "localname": "StockholdersEquityNumberOfSharesParValueAndOtherDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.enterabio.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.",
        "label": "Subsequent Event [Line Items]"
       }
      }
     },
     "localname": "SubsequentEventLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.enterabio.com/role/SUBSEQUENTEVENTSNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventMember": {
     "auth_ref": [
      "r328",
      "r345"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event [Member]",
        "terseLabel": "Subsequent Event [Member]"
       }
      }
     },
     "localname": "SubsequentEventMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.enterabio.com/role/SUBSEQUENTEVENTSNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventTable": {
     "auth_ref": [
      "r328",
      "r345"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued.",
        "label": "Subsequent Event [Table]"
       }
      }
     },
     "localname": "SubsequentEventTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.enterabio.com/role/SUBSEQUENTEVENTSNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "auth_ref": [
      "r328",
      "r345"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Axis]"
       }
      }
     },
     "localname": "SubsequentEventTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.enterabio.com/role/SUBSEQUENTEVENTSNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "auth_ref": [
      "r328",
      "r345"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Domain]"
       }
      }
     },
     "localname": "SubsequentEventTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.enterabio.com/role/SUBSEQUENTEVENTSNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Abstract]"
       }
      }
     },
     "localname": "SubsequentEventsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "auth_ref": [
      "r344",
      "r346"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.",
        "label": "Subsequent Events [Text Block]",
        "verboseLabel": "SUBSEQUENT EVENTS"
       }
      }
     },
     "localname": "SubsequentEventsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.enterabio.com/role/SUBSEQUENTEVENT"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of sale of the entity's stock.",
        "label": "Sale of Stock [Axis]"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.enterabio.com/role/GENERALDetailTextuals",
      "http://www.enterabio.com/role/SHARECAPITALDetailTextuals"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SummaryOfValuationAllowanceTextBlock": {
     "auth_ref": [
      "r83"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of valuation allowances to reduce deferred tax assets to net realizable value, including identification of the deferred tax asset more likely than not will not be fully realized and the corresponding amount of the valuation allowance.",
        "label": "Summary of Valuation Allowance [Table Text Block]",
        "verboseLabel": "Schedule of rollforward of valuation allowance"
       }
      }
     },
     "localname": "SummaryOfValuationAllowanceTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.enterabio.com/role/INCOMETAXTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental Cash Flow Information [Abstract]",
        "terseLabel": "SUPPLEMENTAL DISCLOSURE OF CASH FLOW TRANSACTIONS:"
       }
      }
     },
     "localname": "SupplementalCashFlowInformationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.enterabio.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TypeOfArrangementAxis": {
     "auth_ref": [
      "r473"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]"
       }
      }
     },
     "localname": "TypeOfArrangementAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.enterabio.com/role/SHAREBASEDCOMPENSATIONDetailTextuals"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r48",
      "r49",
      "r50",
      "r176",
      "r177",
      "r179",
      "r180"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "verboseLabel": "Use of estimates in the preparation of financial statements"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.enterabio.com/role/SIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount": {
     "auth_ref": [
      "r295"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.",
        "label": "Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount",
        "terseLabel": "Net change in valuation allowance",
        "verboseLabel": "Additions"
       }
      }
     },
     "localname": "ValuationAllowanceDeferredTaxAssetChangeInAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.enterabio.com/role/INCOMETAXDetails2"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_VestingAxis": {
     "auth_ref": [
      "r444",
      "r445",
      "r446",
      "r447",
      "r448",
      "r449",
      "r450",
      "r451",
      "r452",
      "r453",
      "r454",
      "r455",
      "r456",
      "r457",
      "r458",
      "r459",
      "r460",
      "r461",
      "r462",
      "r463",
      "r464",
      "r465",
      "r466",
      "r467",
      "r468",
      "r469"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by vesting schedule of award under share-based payment arrangement.",
        "label": "Vesting [Axis]"
       }
      }
     },
     "localname": "VestingAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.enterabio.com/role/SHAREBASEDCOMPENSATIONDetailTextuals"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_VestingDomain": {
     "auth_ref": [
      "r444",
      "r445",
      "r446",
      "r447",
      "r448",
      "r449",
      "r450",
      "r451",
      "r452",
      "r453",
      "r454",
      "r455",
      "r456",
      "r457",
      "r458",
      "r459",
      "r460",
      "r461",
      "r462",
      "r463",
      "r464",
      "r465",
      "r466",
      "r467",
      "r468",
      "r469"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Vesting schedule of award under share-based payment arrangement.",
        "label": "Vesting [Domain]"
       }
      }
     },
     "localname": "VestingDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.enterabio.com/role/SHAREBASEDCOMPENSATIONDetailTextuals"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WarrantMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount.",
        "label": "Warrant [Member]",
        "verboseLabel": "Warrant [Member]"
       }
      }
     },
     "localname": "WarrantMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.enterabio.com/role/SHARECAPITALDetailTextuals"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r164",
      "r170"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "terseLabel": "WEIGHTED AVERAGE NUMBER OF SHARES OUTSTANDING USED IN COMPUTATION OF DILUTED LOSS PER SHARE"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.enterabio.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r163",
      "r170"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted Average Number of Shares Outstanding, Basic and Diluted",
        "terseLabel": "WEIGHTED AVERAGE NUMBER OF SHARES OUTSTANDING USED IN COMPUTATION OF BASIC LOSS PER SHARE"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.enterabio.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 6
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "205",
   "URI": "https://asc.fasb.org/topic&trid=2122149",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 201.5-02(24))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(1)(a))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(10))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(15)(1))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(15))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126941378&loc=d3e61044-112788",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(10))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(15)(b)(1))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(2))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(8))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "220",
   "Subparagraph": "(k)",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=124433917&loc=SL114874205-224268",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07.2(a),(b),(c),(d))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=120401555&loc=SL114874292-224272",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "https://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(18))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(8))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(9))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL116659661-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(1))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18726-107790",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(n))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-04(a))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1448-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1505-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1252-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1278-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1337-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e3842-109258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4428-111522",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4531-111522",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 201.5-02(25))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.3,4)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e637-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496180-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e681-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21475-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126919976&loc=SL49130531-203044",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126919976&loc=SL49130532-203044",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130549-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123453770&loc=d3e1703-114919",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123453770&loc=d3e1731-114919",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669686-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(n)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=SL116886442-113899",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4534-113899",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4549-113899",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(10))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(4))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(v)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(l)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.1,2)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.D.2.Q6)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "https://asc.fasb.org/topic&trid=2228938",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e32247-109318",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e32280-109318",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e31917-109318",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e31931-109318",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.2)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32840-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32847-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 201.5-02(26))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.1)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.2)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.4)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.C)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "https://asc.fasb.org/topic&trid=2144680",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=SL126733271-114008",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(4)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=114868883&loc=SL114871943-224233",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "830",
   "URI": "https://asc.fasb.org/topic&trid=2175825",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918666-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918673-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(1)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(3)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(4)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/subtopic&trid=77888251",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124437977&loc=d3e55792-112764",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "855",
   "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "855",
   "URI": "https://asc.fasb.org/topic&trid=2122774",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "https://asc.fasb.org/extlink&oid=126937589&loc=SL119991595-234733",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "912",
   "URI": "https://asc.fasb.org/extlink&oid=126938201&loc=d3e55415-109406",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(ee)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3367-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "440",
   "Topic": "928",
   "URI": "https://asc.fasb.org/extlink&oid=6473578&loc=d3e63223-108013",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61929-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61929-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62059-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62059-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62395-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62395-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62479-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62479-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=SL6807758-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=SL6807758-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(1)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61872-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(2)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61872-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(9))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(ii)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "440",
   "Subparagraph": "(a)",
   "Topic": "954",
   "URI": "https://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "450",
   "Topic": "954",
   "URI": "https://asc.fasb.org/extlink&oid=6491354&loc=d3e6049-115624",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Subparagraph": "(d)",
   "Topic": "958",
   "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99779-112916",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99893-112916",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 4))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(c)",
   "Topic": "976",
   "URI": "https://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "978",
   "URI": "https://asc.fasb.org/extlink&oid=126945304&loc=d3e27327-108691",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r384": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "1402",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e4984-109258",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117819544-158441",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(20))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r400": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r401": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r402": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r403": {
   "Name": "Form 10-K",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "310",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r404": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "308",
   "Subsection": "a",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r405": {
   "Name": "Form 20-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "220",
   "Subsection": "f",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r406": {
   "Name": "Form 40-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "240",
   "Subsection": "f",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r407": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r408": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r409": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "405",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3044-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r410": {
   "Name": "Securities Act",
   "Number": "7A",
   "Publisher": "SEC",
   "Section": "B",
   "Subsection": "2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054",
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(4))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4273-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(d))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "55",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e2626-109256",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r428": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4647-111522",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4297-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r430": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16373-109275",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r431": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "410",
   "URI": "https://asc.fasb.org/extlink&oid=6392676&loc=d3e7480-110848",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r432": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "410",
   "URI": "https://asc.fasb.org/extlink&oid=6393242&loc=d3e13237-110859",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r433": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "https://asc.fasb.org/topic&trid=2127136",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r434": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r435": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r436": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r437": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r438": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r439": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r440": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r441": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "10",
   "Topic": "712",
   "URI": "https://asc.fasb.org/extlink&oid=6410138&loc=d3e79691-111665",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r442": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "10",
   "Topic": "712",
   "URI": "https://asc.fasb.org/extlink&oid=6410138&loc=d3e79708-111665",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r443": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(n)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r444": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r445": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r446": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r447": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r448": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r449": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "https://asc.fasb.org/topic&trid=2122369",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r450": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r451": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r452": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r453": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r454": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r455": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r456": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r457": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r458": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r459": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r460": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r461": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r462": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r463": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r464": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r465": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r466": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r467": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r468": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r469": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(v)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r470": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r471": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r472": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32621-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r473": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "808",
   "URI": "https://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r474": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r475": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r476": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(1)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r477": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r478": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918701-209980",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r479": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r480": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r481": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39599-107864",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r482": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r483": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r484": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r485": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r486": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r487": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r488": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r489": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r490": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r491": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "730",
   "Topic": "912",
   "URI": "https://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226317&loc=d3e202-110218",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.CC)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=27011434&loc=d3e125687-122742",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "https://asc.fasb.org/topic&trid=2144648",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "460",
   "URI": "https://asc.fasb.org/extlink&oid=126907703&loc=d3e12565-110249",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(23))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21475-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "50",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=6784392&loc=d3e188667-122775",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "https://asc.fasb.org/topic&trid=2208762",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "10",
   "Topic": "710",
   "URI": "https://asc.fasb.org/extlink&oid=6409733&loc=d3e19396-108361",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "15",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "712",
   "URI": "https://asc.fasb.org/extlink&oid=6410066&loc=d3e79194-111664",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5047-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.F)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11149-113907",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11178-113907",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "https://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32632-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=d3e5614-111684",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c),(3)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "810",
   "URI": "https://asc.fasb.org/topic&trid=2197479",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5579240-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5579245-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=d3e41620-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=d3e41638-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=d3e41675-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "940",
   "URI": "https://asc.fasb.org/extlink&oid=126941158&loc=d3e41242-110953",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  }
 },
 "version": "2.2"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>82
<FILENAME>0001178913-23-001272-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001178913-23-001272-xbrl.zip
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M;]!X5=J9AGRM4UJ=4*DI8_O45N3-:L9FH<HC*B(X&((SF /.WO;/U2I6DK5
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M-^%]WW1JR3<ZBV 6,7>-.,ZET,MH54?X(K',,S3[T./N&F_0K_\'4$L#!!0
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MPA['@XU(A0[65;%W&Y$-'>X@(O<_*"&ZK3(.1F!E7_X/4$L#!!0    ( $2
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M!J-1J2SA^1$"/W1+T_I86PTA[Y##?[&GWE/@+3S7"6++=<,DB)%B/@Y]S_5
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M0,E@BT!O^V8G;[Q79SG(Z'NOSB)>G247<LH)A\85::'A9%-C>'7V0YAE<H!
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MY\!#A[./[I><P98;>R]I'A7CX*@UKBT9]$+Y++=.\.TA<;#&"^BNY'(K6W<
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ML[<P_ ;@MK0==NU>L"\C:@=5+_@<3M"11=39(E(3G52>0 ;,%H>:=W6RL>\
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MJ)'YU)@/I/6I/*]QL,'(>4V5T<L4"KA/9#+[::<"+X'1 L?WTBU.U+;:T4Y
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MN*K+KGY4S^Z>$_*K5KLNRVNKNG=VXH:")B&)TQ2I!BG;FD]_,P&^)($@2($
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M:[#[==!JBL]^[A7E=>QMT-R,HFCCAH]D'=,ZX8F*SLX_&(''Q<*CIUOX6=*
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MG9*SCR9\SSCR8@K#D:VZ,!N=N;Y&)R2M.?MHPAN-(Y@@P)P_>"$PCW$S\]*
M6E1E]M&$-WK8/(>!=QO&KAQCI=SLHPDO]$@6 :Z>1*ED14Q4=/;1A*=Y6I(P
M5#&1U8*SCR:\RM/*#</+30(!=R+W?3LE9Q]-^)BI^S;V0;N#><!7516,8TV=
MV4<3?N:7. 0+XE)N".7RW"L[^VC"P_P*^O4?$<Q;GHB;Q!'QQTFR:9!H39W9
M]_WZGCNR<,,L G\+ZF2Y5VKV?;\^!Y?WPX<E2$&JBOO%9M_WZTV>B+>A((+S
MB^=ID(9U%G"_V.S[?KU&WM_-F[=THP61&&=1T=GW_?H."/)PMO&T73W'80VN
MG3*S[UMZ"[!#;ZS/\PM^$N.?\">SD>=1X@<I#*7HA210+8%@)-Q@3U>$IA#$
M7\8N];\05)YD%/G3)0GH:#X/P@#BE(3_0@!99_.S[ULZH!-GV]*CG3C;ENZP
MCJWOLUF2&XY6&#P_N(%_&],G0E\"CR33^)(\$B]>1,'?B6C.U;Z1V?<M_>1P
MD/_0TF$."'E+K]J(_,I-ED]D[?+)UX.[78GG/2K59C^T=*Z&T;7TL8;1M72Q
MM>C^MDG *-V\$>H%"7F@H$5?(Y_04?K%I;^1].;W#<X,:;R@[JH>;:MF9C]H
M\L>6T&ORKY;0:_*7"TH(V[\7!_F'A68_:/)='7K6Y'OR1FO7=$7%9C]J\A\=
M>]?D _*39.!BLL6$:_)"PGB-/\S]3]%Y0S34I;'9CYK\Q0"8:/(M V"BR0^M
M%B2"@+@)8K74[$=-7J13WYI\0*>^-5GP3GUKLN'I:L<K08D/#3AJ:\Q^U&3=
M=6+Z29/-UXI)DR<X[.&\-:;S'),FFZX5DR;KK!63'CM[Z4:_?=ZXN(U"2&WP
MM%MJ]I,>.]NM;SUVMEO?>NQL=5U'_OT/2\Y^TF-OC\.@Q[Y>TO@W0J^)&Q+:
M@.&@Y.R3'GMZ' 8]]K/:\B0BZC"*PK-/>JRF#B1Z;*4.))HL)&O\5Y>B%6@:
M*X*RLT^:K.71.#19SJ-Q:+*B.VWC$>,&9UI;8?9)DTW5B$BGA=6"Z&>=]K;:
MP45;1!<Y(IW65P\BG598#R(]UAB7G&\A AKC*3H/?N0N1/N_M65G/^NQQ<?C
MT&.+C\>AQQ9CVR%)DGRI=S+/E4"&1EQC]K,>NZP7DQ[+K!>3'MO<:O='O.=S
M_D&/4=8"18\UU@)%CQF^6KH!7;G19,ZF0*/(OXY<N2&65 %8FFRQ;EB:3+-N
M6)HL=>@F23%X)_0Q6"S3?%!/":W=16NL"! U&?$^(6JRZ7U"U&3B13VQ XZU
M1R<D50"6)BNO&5;;^]"F8&FR_J(^RK!I,A^O8[:=#3_[&@7UCJ%E.T! D\^P
M1T"3=[%'0),?$G7\2/R-MW<BHA5R40, N4<?U1?D'GU67Y![]&%3J)(LX]"_
MBJ.$>!N\C9.=%+YVM_6S@PYM 9$>/9U9(CWZ1J-$VM[Y[D3D+E@%Z61^YR;9
M?5/B/[EAA^&AU"*0ZM$7VR/5HW^V1ZI'G[T/(<]50YF1Q?GR..INJ5NW#F1[
M]._#(]MC9# \LCW&%/MP>N$HH68B]K!$S40T8HF:IO@D7D%'N*:(UV\@AL!,
M$23R I),W6?AY3RE>K/SMK?]S0/4%$.4'=T%$1FG9%4?P0G* A!-?O]X()I\
M-42BFS!UFP[?[I<# )K\9W< FGQ:=P!Z_,PU\2AQ$S*.\C^G[MLCF6\B7Y+>
M4;4JP-3C,WJ'J<?^]PY3CRV_CMS+(%X1/_#<\"D.-^@XDKL4=QTFU(5?P-_E
M"MFBB=EYVSOU0X&MQ^X;AZW'2]3VV1%J 4^/[^@-GA[/TAL\/7[G9CXG'H2-
MU_%K]!B#C9G28+$@E%^;K4,GKP7@]/BDGL#I\40]@=/C?VY6ZS#>DH83HKNE
MH',]7J5;YYJNCW?L7(^%SYM](B^$XI,IER0B\R!-'N(P\+;\OU/REEY"J[\U
M@5-K!<#KL?.6P.OQ I; Z_$1>;<-YX;WBD'WFGQ U^XU6?FNW6NRXRSC'#C;
M1I]\6!) :++7QX'09+>/ J'I^O;.S2[9U?6#@@!!DQ4_!H(F6UQM67Z175 4
M8&BRJL?"T&0?W[)MRLE\'G@0+$5^=M&:I2OVFRXIJ=8'P)HLJCG FFRP.<":
MK/;!"62>9ED"4%@> &FRX/H :;+FV@!INJ1]V,$O;KBI78ZO*0YP-%EY77 T
M67Q=<#19_NK>T0.A3!<F$7F(@RB]C3?-]D"E.L#5YB',P-7F'\S U>8=ZON;
MOL9'(MYI 4#K]1"&0.OU(H9 Z_4TPB[_F]#X*7@[ O1."[-S35?<#8/6Z[,,
M@=;KV7:ZQ!66B-LKB!H[JG5=(P"]1R_8-_0>/6+?T'OTCJ"7W(1!5=*8^Z!%
M$P"[1R_9)^P>_62?L'OTE*POUNM]$'%%[8"\MA4 WZ/'[!V\IF0%EL#WZ$'+
M;D%/T:@=!7VG#0#>HQ?M%WB//K1?X#UZT+)3L&\W> #S*.2[C0#T'CUHW]![
M]*)]0^_1D^[TVLV3BIL V$8\J7[81GRH;M@7FK)*B/M\C5F/3"N/L(BUS0#\
M/OVG ?A]>E$#\/OTI=5^NRT B)L V'UZTAYA]^E%>X3=IP?-^D2E[!R=B]L
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M3*5=(*C)4P^7H"9//ER"FCQ]!<ADS:[CEV,CSP&E1*.^-H#5Y=6-@-7ETXV
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M.'7?LJE=]E2!RN&1#LT!:^.^?Q"LC<<&'&;Q]L$NL&9^-16!B?%XH#<FIF.
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MHRP%4>793\8S*/?/R&Z4W@<C.S$S2U:):T8*!SYJ:@!V.[%J@>0N.QO4<"9
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M9L!Y&<!G/ )IA\]X!N8[5$S,V,520*MLB]74 .RFHP"=V$W[=X9$):O7;D%
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M,LA["-&7XF*!K"(P&4*DI8>)\:A*:>.ZN@?]R7@.Y"X8C4<FE1U\A27)P]*
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M^24.H1E\R<;&P-[M'85Z,O.J4Q+JR<RF1+0>@^2W6TK(.$H)A0#:I$A%?:-
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MN':8/,1AX&U;DY6VAJ2'$8D:)CV,R)"OJ9=I>;]&/J'LV75.@(&^W.Z>5,(
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M%I6VJRCJUH(.;E,(<B!4<\\,*U](=WF(U;YZPZ*;( 8U.J9+&F\6RU&ZRA)
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MF]);ON^3B01"!J\J$GSFHQ!)G/5@+?#O+!*1<[IJY#D<O9>D")G&C3?"I"-
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MVS&_D$#<OP4P:'9K-2@0MV6KU'_%5FM?-;3V99%KH&YYO_-;ME/PN^%K\C4
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MS:^\1\]E@2N.FSU_(&4V6(41\L3>2PDHA7^5\XT"^Y/'_/-:H-#AAI_5?HZ
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M]^#K&^6P"I4F8;Q8B(V>OKY1#JK*HA3,7H4B$][_]0Z29[]1#JD: 0H09!*
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M@@3\JAYS=3)H\:/% 8R^.AF2.(#!6".#%E>^'<=EG[B,[D2.PJ*O7+-HS]$
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MR^X?^1&JY6;C.7RR$;AY]D+Y;*-;I2,!L@8:*T"K&7.$P*!JK( ^0F 8-E6
MUOMVKFUF+UIR1, H#0D@1B&$ !BQ00%R"(!4AJ  G2CZ;/LIXP" D1PH3R>&
M"ON!41TJ3\Y^8'P'RF/'3W$11(;S,F"KT N2ZS MNUD@CZ&I/'9\]>,#J8"9
M/'E\(!$PDB<9G^OO80,BR 1,59",TC9*/3LP47$.*/4,PD %R8C]ORP*[[T?
M!4H@W>, %20CMHU23T5,5)P#2CUA,5!!*F+%:G>0C0)\$E5OFD#NR6%:2,6M
M!NL U@-K.1.L Q@0J(56#'L_LH%A%S%6RX<*Y,,<HH-6_$(X!Q B2,=9X!Q
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MYQ.H>DJ 2J-8<_Y]PR#? P\3X%AS_OW(,-\?,VDXM37GW^?<I]]B]E?*!2K
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M JA+$_%[L5 *I*%7ER;B]])V]5BL+DW-[^KQ5%T:K6_\SO_WE.5]8\4.=8D
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MQ!'O+)FA,^=0"G'$FTU&Z. <P4;BJ.B\@!7#ULJW@\S*ZS 2_RB&L]K3 W_
M:8&'*\,=+08CUQ&M@<I01Y)#Q!Q/!B$'I6$_M7*H-=6P5T-/:N50_1MYC[9X
M'*N3Z>4/.!VN1@K5]QHL&K(!2J'62^Q$WB%[E&S%J3C;'_SP22S4%@V4@])P
MC'YQU)HR0:?A&/WBF'7GQ?9V&[%M_J9<OL=UPWO=!3=50(,)1I\L9JVI;5O;
MWWS."^#$K%HY7#QYVK+EIODDKR_R^(@)<%R]2+VRG[($6>5:*IR^]4C-Y^"3
MB[KEM8X6SO5ZK.JS]@I,7(Y4C=G/A7L6)YYS*1XOBIZ*$_%P?E>U &:] @A@
MXJ,4P*P#WH^&>:RL[$@F@LW?+9,/?);S 3C;JJD*Q'IJO\HJWLUR.":0_Z@%
M""( .8Y: #'2V@9=B4=UQ;4O.$TJ)$*H'DH4<.)32(10772F.W!:TSY10G73
M105RBSY1S+J2+T'PZ65Y1E&\#R$.O 6.YV<K +/Z1:(T":.G1F&.'.0/IU"/
M6><G\0[(.$ZA_NQC!V0SIU"/N \SE[-^QHIT.<IM3+%R[903S^*4:?:2BR37
MM6DYG.GUU)_";'%_I>)*/;<[##BMRQ\5^0/.!ZL6P$3P@T^3P\CU CMZXASU
M(4CCU/:E9ZO9.9P2UD@>$=^U[44R)]LG9HN)H9CQJ1^&_0/.%FNNY"R0OH,S
MRIHK0>S)K[W 2]@-[VO=19#8P=;[YK-LW^7BZ9/]7V$DG_F0SQ6]@U/.#E&#
M6:^PF961M_:>Y9W).S@I[5!5F*C#B'G;H+DV\ [.5:LL3\]^D%PIRV.VL=P>
MN5[!VWUD\X'9$>.Q>-5 _M.7PW-GH^<=G.!VO%("-3G&$R '&J\4,28^LD"0
M5V[@S-WSKB26V>,>67XBCN,%>4^?*&+]]J,"R4^?*.FZ ME.GRCB+*7'M**;
MA3/UFBF@&XTE0I#5F"G C,SPD45!+1/H.SB1;Z<L9LUT[0;92*<LIK_%!<15
M%(HKO._@A+KU8IA>;E@+,HEZ,43?+O8'/F$2];R,KKSX$,:VO]S<A,%6DNR,
M6G=H 9PL=Y0^Q-H:B1^D":/T8=:_7+X35WZN^>\NY5M?J1=L\]M G+Y=L VG
M>N4R'XL;"R9RF41L"XJ<?J'/O[+E$S,6L5A$/\@[IOPL9C1-ZDV0[TSYV9<:
MFW#BXBD_B\@\I_4FR.:F_"SBO8AIO0G2R2D_BW@/8UIO@B1WRL\BWON8UIL@
M_Y[RLXCW3*;U)C@_F/2S+]6;\+1DPL^^I^Q-7B)[4F851MD&?A)YW])$G+9>
MAZ CX?G--%\DS=E'^O"(R<^H+Y)FZB-]>,249]07R?#S^_1;[+F>'7DL2[W"
M^Z2O[^#$Z ;29-H8@,UP"J&4)A/[ #9#0J^41H])F4U6+&F5QV'>P:G0(1'T
MZ"M-NLF/966G*^!4YSHQ>FB*LQ-PFG.](#HB<<T\>XP[><JKIH?.=21(82@K
MI(=+*60HX*AN(M5:?0^E48N11=-#+M1BZ"--PZS:G@2<'%PK1ZMVZGAZ^  @
M1Z%^6+RR/5=D07P'Y_]6E*90%W7;>P;Y1FD*?F^E>WX'9_4FF*,<1M$SHI/*
M20ZCZ!_,Z>0@AU'T#^9T<H[#*/K'\98(^MZ "D7_^-T205^3YR9USA+ F;A!
M&0J]5!='_WA-[MR#N+;4N-]TN;.#+5L$)KFOWL'9MD^@G4(='^.;?NXP7ONY
MQTT_+1FOG<*H>8QO^LG.>.T4QN*F];=AX#(W=1)QCR4?K69[L6#]SRP9V#LX
M-?E8E?1Z%@,O]/.N@2KI]2&2K[#](7^(D(/NIVEZ#?1JNHNQG\3I-9Q!/<*Y
MR@TUX/;I$;-C=L6R_R^"F>.(*UY\XO\D4W:]@].8]POC1F@O,AW!ZQ'&C4N]
M<>)JA>-$*7.+9[<]%G.X.LXV1B/EVH5\H.-F8S22C />W3#O,0]R'>/JER=9
MQPU\.@+5+T^M_EKQQ8-.O@U1O=[1B&8=;3I.-[5Z'^87';,Z3O=YQXN.C1VG
MFQ2'$>>%Q&[>%R_97:9QPDE65!C[]/4=G!-]J"I2K:0/]0 >IU=%J@V4T7AI
M'[S$]JL-8#@I^@ MI&I8@W4 MP.UT*I7T=44J2GEB@]'.8"]*>1IU:4*WP"N
MII G57_W2>C\N0M]ET5QEE3J+O3]Z^S-,0YU &W3JR)5JWVH!Q VO2K4NDZ8
M[S,G26U_%86\-TG*_#%P&G>-%&8-KI:EZ3 Y*@O1L!1.OEX50HR/&Q&_(@6>
MS/E>VT*$4ZA#(HC^AE& M (2P:Z+*L_=.S@U>:LDJN>WMC\/$M[CK?G'1*;T
M5!S@/]A1=>P2SCMN(HZ-[I.=<(O$C"J[VK!E@<-G4?4H ZF F0)4A)R.L)ML
M-"O?[K@ITV&^@[.3]XF20Y4]:_$.SDVN$Z.!IIO^ LY3KA,CBP8<UW5BJ'VV
M,*M:91'VE9-OWO!3<92\/2K!&<W'J$.ORZ'H-<QBN#JJ=5^\!W*5\BX'3H]N
MK(-J+3=Q:AB+H8[SJ$\-H3'4@;@&:VKC;,-IRUUV*_,?S(ZNO4>!74-VCM![
M!O%]RSN=]7?F/[)/G,?M.#F"TY*/UGF>?NBA5"-TGD$_(&)W_3WD\'LXF+FJ
M,ZC]"G4/5S-71;6N'P+7B^4NM'BHW>%%9WOQKZ_OX9SGXQ12K7>-!\:Q.%#A
M&<; .%('*B3&"&KK$^_A3.D]DL3BNH%I$(>C\:Y??1/_/9P9G<C9D*:U,%6B
M<6*C?GBB6%A]#^<@5Q6GX>N:]3 O410GXOO [6ZF<2@PV>B3)5(K:EQP<O%>
M6<+U584@G%K<6 ?A^JOAA,F J0X:]9F?4N"(X#&_6YI&'56VPV-[MS0IO]<B
MRF1X;TN1JH<:%I/!ORU%HUYJS^R^AU.-JP5HU$8#@0DCJ E0JX-:2)D0 H4@
MM3JI$,%9L/6"B'5TRY)+.]ZMHO#1<YE[\?00B\? KKW #AP^=9J)-RSS"0"<
MEGJ %L3:&X059 ,#M)Q%O=;"%^0+([2=13W7L(-\8X0V>O6^"!Y9G+1C'.0G
M [30JV<U5I"_#-!R%O5:BVF0[(S0=A;U7,,.TJ01VNC5>[FTV8AQD% -T$*O
MGI58X=R] [2<1;U6,0WG]!VA[2SJN89]*!_3:<.M]RI),8>EHURU@KBUU;!8
M1Y1J!0GY6$=S:@41=^_:%NO(2JT@8@:>ML4ZJE$KB)CY[I9]SR^DBRSV41CP
MOSHR=W.L?M'\/9R@=[ NU/8[&+>&1PS4A=D+\&)\7*AX7>"6<S9YO+T:7.!D
MO^9*,&MX %*80A@KP:W3L!C7LUZE>(3X/9P:&!;"K3,0"<P)0"&B=0)S!5 (
M<Q36(($Y!"B$.#HO-QO/86)W\E![=/@]G#58+8#8/B $(,]0"R"VB\R@*+X,
M]R(>LCQY[^%DP<KRZ#70L1_D!LKRF/XO6F7>'CE+A9,#=PMC>EYA.3AN=PL3
M\SDX+G<+(_;]'6,JS@0GWX6%*$5/#0DX'L-"%**I/M.$4]JJBE.HAX;U\ BL
M*$[.]_#HJRA.H367.0*X\?#(VRU-(6[JML.C;K<TA:BIV0[G:U64)A,S5?JM
M]W!&5DB$3/344?2/PRT1,G%41]$_%K=$Z$54-1[#Z5'[1.E%6 U5_P@-B-*+
MN/(\*ISWM$>27DU5F/J'<[4DY7HR'.4[DO3ZB?JI3SB5:+\PO0BL(X.S@_8+
MTXO#!K*AO*$F3"8:B[N^'(XA@2@ER,1=#8,A?2@ER$18#8,A:2@ER,32G;?=
M)<O-0\QD!DT.Q9 IM 7)1%87D2%-: N2B;.68?5'7LK-$#BMYF!=5&M2C=N0
M6QCH(E/?7Y@PEKFS1_[3+;O*+[;?V0E;L<C)!C)#\F&@BTQ]F^"&$W\.UD6U
MON^82-!8_'+-HOUKCMN0N!CHHEK?:MR&#,= %XGZ#N/XTHZBITV6Q)AS!S@?
MJ4:*1!TJL!CPH(X4R7JY*1-NOH?SD)J(DZRI+/GF>S@+:9\H)JIH:P?YT'T9
M!G'H>Z[\QRQP5Q&+>=<N_[G<Y&>E;/^>_R0[$5>MB,'Y2D_S@7/UD.K%^?=P
M.M23?^ME^0UF::?^%F8O>G*_P:E<3_XMS)FX>+^B^\A0N6X*IW3MD<1L0WV8
M8#ZGE\2,;VF9?&"DP@&SMFYI]/IHV0ZSM&YI;+\K@PAF9( (=@TH4<#L"Q#!
MKHO;,(B86 XO#Y5P%#"/ D2PZT*) B8X@ C)NH#I!B""/?JUSBA]_0"G %66
MQXZEKOWZ,;M='CN*NO;KQ^=V><3XR?=2KL.H?/\C$8S0<Z6)XLV,? ]/=<WX
M YQ\\SC%B!%YK$= 6G"<8L08+_;;N.6K*'08<^-K7NA^%T:)6!3,;E9E6W(?
MX,R?0]3@U[\A6I!]#%%#H&[7X<SY*_4B5CRIMO+M(.'3P?+>"0<+DI0!6@C4
MK!%6D,H,T()9K]R86WO/9C\\$:8@I6F4PZR;W([\7:T/<.[15DE,F\,X8?N#
M'\J N& !VWA)K#KT\@%.-6JNY$R0@M3'7 EFNXF\1[&[Z=O9[>_\MMT'..,H
M((%96Q &F)JH)5#KH1HS%W&<VEQ*O,"WWX?9@Z8<#LPT>H51:Z<?&<PJ>H7)
MU5D[MC@\F$>8:2!7>PJ,,'\PTT"D'K_84<1IS?P'BQQ/W&3\ "<WU<H1J;,N
M'CBUJ58.MWXV+([YC-'V\X<[Q6;I/8L>/8?%Q4FL#W!64T,-N'5FAA&F&V8:
MB-3C-9.QJ&$9K;)$ZB:W6\,L6F5Q_:V>J%W(!WZSJ1*<.M1$'+=6U.;=E*=H
M/L"Y0@VD*6*[97RLA;.!:N7HXM%Q!UB.8LMJ9\WZ &?R--9!L=XZ..$LGL8Z
M*-:GZ.B*)1HX::>).,5:?(C9)O5OO TG%G!:3A-Q\NAT1*-7'#$R_Y[:4<(B
M_ZD\F+0(-F&TEQLHU<FD\@#A!SBKYU!5B'5ZQWP^.717W."GLOF!1$51FHCM
M:SZ'BKDOQ4DSR;;@?* Z,7IHRDH!J8A>D!ZB(EV.F/S6?AQ_\9)=781C!NG*
ML:K/VBL@T3E6-6+O>[17X'RDQZI&/$,!F%Z;=\')27MEZ;6!ZG3^!S@U::\L
M05P73_7?9 ,4G+)T@!:"6%6'N#_ 64V'J#D;M$8$JD\-:F\<,RZRXRS]BCTR
M/Y0\O5P:A7.BZ@51ZT^/2,.N=()4ZZC8F(53IYJ(4ZVO$IV&"?6+4ZV[;+7F
MZP<X\ZJ).-6Z*]%IB$N_.&[=)9'G\%Y</*$B]G_X_\1:QJ/M9T?WX/2MO;*X
MM=:'2\-8>F0IU5?CF"6<WE4K1Z*>Y+&,A\!+XKO[AZ)/A'.]Z@4)(]*Q#8T@
M:LPE-I]GN7,[$DD.XIGCI/M44K\KMO$<C\]PX,2P!M*HM66 34,[>J4)U5L9
M@AJBH90@5#\%!CBG+""!6@^/+$B96)HI3E>(99G+-$["/8NJ90(XSZRI"M2:
MTII8FU#"B6B-=9P'3@W#,-2!'[5WS FW?"CB\_I/GL^'J##@4XYD%[K- O]D
M+D>LX1^#M>'7\3#L&JHR6!NI>N]LVL.I</N%2=5J%YF&QO0)X]<9GP' V6_+
M,O@U(.S4<)"\# E_PLEIRS*8.RKAD^TG3Q]36QRZ94P\O;/WLEG=;"]2T'$$
M,*GHE\:,%1-L,)/HET:,KWO;9\N-G.:)*UK+C6*+',Y4:R"-6&_WSHZYJ; P
M?R@R7ME/(HW7+'"["5=D@J]:!PSGMCU*[_GZ V051^G%C/W2;O%.&.= W/+E
M)KOAO[9_Y"NC^;6WCCM YG&,6A+1,<8;(%LY1BV)V+AB&Q9%S.7&9AF">%3K
MF@E(>\:J)!$30[T DJJQ*DG$PGRS82+! ROC5R36%4P\<+C9\AQBVQ5PYMZC
M])*(BE'^ %G@47IIQ(>\+,U8?F7I?F='[,*.F5M_B'+F<^$\65\UT5ZQR M=
M\?!4GFKT YP">)H/THBHTP"JA1M,7B?[Z OUI $A/O5'2;3JK!.Z8)LPJCHD
M/KT1CY,[XFUR_G-OV^WH# CS.-4DXFNL5PQX\SC5)&(%ODB3=^H&1+E'!XG:
M-SM+68 VX,1#%)+P -"WB4OGVRSM[L5352;/0303N<0+KQAPY&,_0MA3\J?Q
M+$UV823Z_X? 99%<2EH>Y*(VCWZ.KKB_OXKX>'(G8.?N@W,E3_QERCZM0,1Y
M)KJG=@<,9U<^@?9S]XT!Y1ZMG<3XI.XLZM9_MOTTZV7B.-UG/^OXR8!4G^1+
MQ.+I*)\9T.>3? DSSCB'YSWK*LJ7=J3EQ4$9.'NU3@PS K1H8!ZK$4.OFPL
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M0?Z?_R;MN^$*_]?_P__!_R\RGO^O_Q]02P,$%     @ 1(!_5@*0154H0
MAWP$ !4   !E;G1X+3(P,C(Q,C,Q7W!R92YX;6SM75MWV[:6?I]?D<D\IZEO
M;7-6SYDER[*C&5G2D>2T9UZX: JR>4J1+D@Z=G_] "1%D2*N) A*D%Z2V '
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MHY?VHA 56M)*<3+4ISVTEX>HT"'V*@^K6Z%XQ$&Z?<6VB(E*A"+4"-O12.5
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MU24I/M%D[!Z$.'$U25-[<TEV*FK;ELBX"?!1(TI(VEH1*>4MW7N"(/E&>!O
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M+X+-#IH6_;JZ1*K^Y/Y^N,#I<9H3;O";96Z4:-MHJ>8ZD8.T'>SD]((PAD!
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M 1!WJ&&4OW)]!X.PE3)*]*_I1PP'A [#, ;+FQAB(VU"3!H\6H@6S2-%ERQ
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MM3+/0&, "[:G=?X+#N "43756;D0K14S0S.K=A<0M=*F!625!,L8E))>JKL
M<KE*\S/2CX5,>9:+9&5,1_OA>E+VTXOSIOG0I(D[GD7CT3P82;#_YI.1& [G
M(AB/)OXLB$8S[U&:W+(T60D8 U:1E1/S,ORWD,?K%/T(N"8IFL2; $^$(3CD
MY)Z<)M6"J!1,Q"6S,+!(E#!'E[)"2P\NP0<DV>%=T^IEW,AS/?CW'WX'VL,-
M?/OATY'RX >P4/4<&I).NVJP,O(X!P89./9>1+FS7%=@E*1G;*&CV(SS-,U/
MRV=WXTF[ASS4]G^=YG]>K%\>U0X"S%E+8D0$#B\P$=R#2[FIYTV5/DQ(L#]S
M1N-#8MG^^>^V IO^K86Z3>>DP94R:NNBUV\_H!RC]0*[=)&$"Z7 DBQ,UY$<
M$.NA69HFRZ0BPF(Z2D%NXG*#GETAV05)FC!AR3(LDH!0#N=<JL;M4\C4*\9P
MB*[M"3S!Q_W'GV:>!U2V?FGO+WWJ/M\?D+QPRC!?29(.J[PDX>#(;RMXPQ*(
MO*Q(N5WAI0YMM<G+JAS:VID5L%SQ&IAJX$2P(L>PZ:E2N[ST@>1UJX?"2;C3
MYR#'ON*8[!7@:IX=.E^:_B_*-P9DP+'(\@JF!]M4)B>2(1W>._R"MJNQUW&1
M+WDL\CW@NZ2(2!R 09+;"ZZ)I31&(!&&*$A2.Z58,F0%S )/246AYZ:7X:&Q
MG7?C;&=;B&&^A,T,:1<ZP%^;VE_SQ;S];X"";;+7( DHQ22SA#X01PU";M6D
MZG+[Q<V=3'TTA9+TK![[,\*6\"Q8.*(Z$KHAZV*/"=&'*XM\?;QPYCVOQ&1:
MKF%!$/T$XCQO"A&8ZUE2R11XXN\@;\ZY 4@3[/)R#52;5^A05PG3; 2>0EC9
M;@PQ1P-.;=G'2A["-D2)P#< D5>MBZPM2_$JL"HE>!5)YG3\'9!()0@B>M^"
M#?P\59P5R#0':JCR 7ZW$"<H)L!RAZD40,[D0PSLA_'6=%XRDPG-%D<8@!A
MFZH223:@-8:=7!4)?%"<,=A&DJ@ GI -KP+>GE:.)_/0>'ET)5[^LHD9C",,
MJ\/ O<W'N?&RFLPZ:'$H$Y[:)1:]Z!\;WQKHX%2]OW-D7[44-8_(#GM8M*G5
M=2C6I736R"JPZ;#+IT5254!3H!S0MP.>&0V=2)R5FH[S^G$/;<_]*^WY^[S"
M50/[($,_LBT*1) C-]FL;GQ\>#>,V[)RW[0])'+1P=?;I DHB9\Y3Y+]#O
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M#&Z3)]$,401)T+?.L=".9)W)CM_6"$-'1X$R$"D7V7>@BE(DT2;VI3)$U1
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M!=(=N>OQ4P5U^495KXRKTB]V,KG;#)Q&;I1"Q#:,@%QDSE5TM+\/&1Q7Q?8
MK]V38<LG$88JHE"$;<\=B3'7/=,U'( G&\'8''8/QLI"CM<:RWY-:1=\8*T3
MT "!E68Y-[4%(OTN,;\8_957'--%K3VAK%K,H\W#3 UXSVJE*7XV/J+-%Q9S
M *7]D^#SA';V+3Y?YR-;E.GQFE"F+6/F-5L9[%07]KW3\BT%1SV> T==)Q!U
MX27U@FK/LSSK(SO'CM=_CA7BA\S=!$N0A%XQ[;83J].8GAJEO5J]#:) M[A*
MD:B THQK*G=/9,SP38=#HD-=][_G%/9T\=74@@ZM%?C;Z5>@CZU@B\ODH0(
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M':I^APL_=]=6.24ZK-=Z0W_K0)KZ91%7$1(,D;0PL;8FF,R4W*;6A;FY _%
M:9AY3.=!O?P GW-.\PE8MA33F:D[3XC-J%LJ#\'+!:9]!&FB&P-H3+292F]A
M^<+20Q2Z,?UD@E9(0]B1G"G=/D*1KER9&79GLLZY_L&E,1T$G$M9(@F7AR:$
MMT+8K$/7?.!V'Z3@2ZI11\T ,NL69%C@I,PF6,UO\T__.3"VPP[&IO?M#C"V
M-QV,;3'?5[_S?*U5<UUUNHXKD\E:Q-H:UM_EGVIP-E%$$"[UFJW5,LFJZ.9
M%E,IDWK,1)_+SBE%>DZNPS*N)TWK;T-RM&C@-0S%/_ T $1D*K^Q42AIE535
MW*D(CLVQFS5+IP(3%QG!3-!J]C*/'"5V@9?-4^$X><FQPFVLE=Z$T?%8J'&0
MI=<BQCQ(G4CAN;Q8>[-*2;V*2*W4LJF9C 6 C'+/:@4<K<ZX>S?HGC[>W=2"
MZ1\<&A6+'?'8C"0X>K7_:J?_YOB5GROE;\ C.%P[ ;6 @%IUPE(F)VB2&>/%
MEO$BMB?[L"J!J1L#*"P]Q; &[6QGJRC56 =B7=*&7:.5',':9JVL46*'>>Y\
MXR(WH G@D=CO^-;2)*^"^!E_,;Y^WGMZFFET'6;?);?"AI>G_5KH+& LR4I\
MUE\(G7)N<_&-X]IY7=W2;L)40"ZEH(YG;#M<!_6'!AJ;Y!J0G6AY"J)E^=RP
M><5MW#8'["IW?2G!^:?@7U_/+\X__=8HO:=S%)% 56A5&%<)@#.9VT:^U)4H
M.-8W4F.;!$R)S2*NN_(JAYOGXR]#+(6!E86GHY3\5GDYX)K&7!L0'MUKZ=R
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MFZ-RQG.[ V )P=PF=8]N(W47.T$^B&(-D-<7[P_V7AZ^!-7^$<C7S2.4]XT
M_,--9B//AQ46 :HDUP)1[\<QS::+3SOY*%&N?Q*X((#*H?X_,Y=@(=A;HVM*
MYWM[:%#BK?0F1^6YC:8T4]U:9?[JOIM_0AOPNHJ.VW#Y:IQC;8]=2MS<&;W3
M8EXS@];\90\VO%NX"8--&WN[GW+#!NG[23=N#><X:N]8*^^.<']?HR+AN_+\
MYM9WK+(U_!\BJ\K)[A,<X]6JLY7O8Z%6NRH?,MO$L*$5KSF3>[6+S;KCTKKK
M0MC0QBI^A9OF0U8]^*I>60<N:O; 51@9++K6Q=ILTI15NQH+#7U4-&E+<SX(
M46K8J$-:5-_RML!1<RC.06^N&I&YV/R<#MMST:+U";1#-A]F#HC2,9-8%B+:
MNQ5&M T>:DEEE2C1=9ZPEL$>BHWO+MTL5-0L.B%& ])20#U![<0MG?.%J^A;
MZ.B;/2H>U:WOS/4E!*>SN%57LOO'<)IA-*&<]XSB- .IW5?'<78TU4I3#.8T
M:^A@.A\$SFG&85&=MP5T/C)M:K:&O]A9^TZU.&Y;\)EJY46L%E*^Y[77Z'R]
MCZ0YQ0-U)=AXY_)]N9)O %YVKMS.E?M$7+FK$U6K.NV?$HRH@^!V$-P.@MM!
M<#L([E.&X'8G7P>@[<1W8]DZ &U'*$\ 0/O\O)@W E WS[7YX#5!GXMK<Y-Q
M(TMQR$*1FS:L36!B(D[WD<4JM6WR6IJN+U8$$ C"0!_,MQKZL-U< EZ=4S>2
MQ8U YV!$6I$AVUQSI'94>#>X'69H-#!P6A4#15 )]86O0I^F,[L)G9DG!&G"
MT(_](\1^[+=5-=J4\X"]P5],!SS$5##"([[F"&)4 3P,6(<1&6Y;RC:BQ<#S
M6$-@" &C>TD53N@P)Y@(![ORM^OV!I(&_M,+LE/6W.^I/>UCI6V>%FKH1$;K
M^WY+V^TZ9W+4G0B>*5UJZ 'M]-]%4B) H-]#>O;YQI890_78<,_F]T!ZYC2Q
MWT83II+.J]U]TRW+8>T*46"A(\RZL#YO-WZ_EQ4J_/]Z]2Y<<;]("3U>C*J.
MWN%^[\WK/:I\YS+3SUB?ZQM=93D)P3BA5TL/)"OU["U@M,$(G?W^^6-P0-3_
M#T?"E?ET;V\>"HRA_[IWN,]CF #7TTB]T=A2?E_X3O,]2_(BO914"M12@S-Z
MQOKHZ^L3.H5["Q&;8S7,J"P9C @&](H&Q*V0&^^W*RTBQ-1([.0Z+N-")#(M
M<SBR[%#X@K&&+]4&9T]L6D^['LX](F=\:O/>7E RB%&W8@_IJ,0.ZS :"VQ<
MW8GOD5TGPEP1=C!/A/7W=ON=#)M'3-^J;K;MC1)/DP2AOO\4W)&1U^)W,=WI
MOSGJ>X+"7(*_5AIWBTRJ"<G^<7!E;J7VHZT/_0"_V*?R*'2#<N1!FH 4(6SF
M5,8@[[;Z^]LLS'+=+1+%&P)685X@2 N5E" MW Z2EA:T2D_B!UC>&X*I=%JI
MO4DY'H#\@\=2WU9_*C J1F5ZR\!&!2_ C(Z5[F+.7&5O4736#+:4]4=L%WVH
MLKP(0-!&BN04OUF77_7OX4&+C-IQ!HUW!EMJB'C4[4[$W8.(.VP3<:>PI]S_
MM\FSK9;8%E,N T"O@].J?3HH$F<_1FJ 5EG!_<^W?1AQF3 H>':T^2E*1^T=
M44DD\5$[KMXW<8WE4%!F0I4ZX;D[4=Q1%R4=JO*Z*,-ZJRR($+ ARF*49E04
M.Y,3D&MPOT";B@UDO;>85$)X\72X%N:;->G9#M2O92QW/!<?^B6)$7YZ\?O9
MKQ<O%B6%@WF>2,?9Z8+L',<K/;<1<*FB?G.(Q[HMVQV8S2G>_XK?PQMGAM%>
MF3#:ZM+R5D9(!^V$M"JZ\4*U]TXFJUWSP?M?/O_QY?33?W,SMS7F6%IW=SZ&
M8V0G%).<WM_ +JVC/S.W+#N-Q#CX+5-1+*]7Z2FE)I !P3[6Y:F<$YUZU46G
M-CHZM8X,9F";/[[\_OF_S\Y6S+?+@(;NJ%FWX8)7!!VR"5:M.G430,!BXLY(
MCA=WPQS<&?5PV^D]+$9C_FB=WM7-@=_49M?@K?#N&_?HE\]S.NSJ)QV#:KC1
M#4M?=T+_>0E]K:NS4MY0KA;"%_PAK@T9OZ$ ]/ZJ%2UWD)LW?S@UVR$6"X L
MUJ&4;G1ADQFI_U7 %PFH;WQ&/RAV,]O3-,S2L5_VHAGS=Z(X^!VZ1EP,P)I7
M_TEK.L9[2,RSF(^Q[1ANQ0L\2$F2\T*.7?X-@GY%/IF<P*%FG6E>(.>.B6P=
ME=V"RK20WFPZFW$Z<#"W(?/OB5X>[/R\^SEQ,;(GQ*V #R[FX8W%&RR'>3 #
MN37T 4>QW^_U7Z\(]6 &<@?P@X=[>-/;WUL&]V#&<1?XP^J1#_>F:SX+*;ND
MC&W%>3W(67X:Q_Y1/BN&Z>B:2*EKBFSZ8W'#G$]3=_#*<@Q$^!W$=)E$.[J9
M\'2D"GE/53B.YS8W.UZPZ,;!\IET]52B>?G5]\<YB]EM^L1[6Z'9V2EY _W2
MDK2O:WM^VOT4C%QHSC]?!V^#;Q,%^@48J&.1M\UU[I1HSQ>@F4>Z0&Z$:O4K
M,UOT68%V/V"!O76 !5K]I8?-H/#>FM $"ZUAW3W\QCZGW<,)QDT:7=,?HV(<
MPQ__'U!+ P04    " !$@']6262Q^ 0#  !D"P  $    &5X:&EB:71?,C$M
M,2YH=&W%5DUSVC 0O7>F_V'K3)M+;+"=$#"&F01(ZC8#&8<<FIML":RIL!A9
M!,BOK_S!=YK0A&ETL7<E[=NWDI_7C>2(-3]_ G C@G#VIMXEE8PTW5+^+)Q?
M=!UN:$CBA&"0W($'_2=<,QX@EJ_(1IN'DQ&))82"(*E63A(:#^%2<(0%Q4,"
MMWYO0!D!RS9LPS3.3+NZMK_%QW-!AY$$LU8[ QVLLF6O;]?U/-]2D; ;<#R'
M8!ARQD5#.QID0X-$SAEI: ,>2WV 1I3-'3CNTQ%)H$NFX/,1BH]/(/.<0$($
M'=0A6YW0)^* 61[+.D@RDSIB=!@[P,A >3(<!X[*V:AK>3:8/B[J% G(-C0T
M52M)Q#*5@ M,U-:8QZ0.N:4'7$H^4G#C&22<40P!0^'OY;SD8P=.MR<CDI8H
M2W*V2BFGKK:J-4/!)S'6MZ?6^>3IU6&$Q)#&>DK/ 321?.D2.4KFTQ;\5E1S
M8T%O/72VL4"C,59 #NAF-:WH!EKN8C0F^I*289T5!S$M7 %G6.&[DV9G%M&
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MPGB&H7N@C9<(/3+=3;<QIE"31DV9"\T*J6L<9Y*KDD4#E8F2##A6:[*#R."
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MA7Z>A$B)P]0+J!,FE$*<1+X3.5&80O:M8/,;.<0Z*7!3AQT%0L^<FYH36"8
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M*D\;NP'9CC>C?M6^,>6#]7O9/U!+ P04    " !$@']6L[UGU?$$   P%
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MYC=TY#BEV\VX.E#T?5EHH,EZKGE6><M_4Y"?P8[7P/(E>UPDZK.Y.^ICT=K
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M/[1RH(FMY8D7.(IM,'3F%%5L=5*"!OQ HN)_,[WEG_ W*A<$^=GIB_TWI"+
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MOK Y<OACBH$4Z:">,S:E["<__CV#$*1E S8:&/Z;FD]'UJ=_8%HF@Z+S;HE
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MU0+N2_GS[HJ&XVTUU*WZF^1S!H6E*>[/]PXV(97@.4<D+BI(V?1OP/+GO$S
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M5+_(JJ.$E%>F]V-//P0==(+.%C46_Z$!61E$[*'!3\A29+^BR/]]%0H2N.&
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M$+O?%6HZ3'I-$/274NNLZD!Z;2W9E:D@Y0Q\KV3E/&3N%]]0%LQ2K7^DS(^
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M1HQX_TDSIC6T)E1EWBQ>RV0+@E+,\ .M;L&6;I5\U0S]KEGXJV8]X4;02Y1
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M+R$R8#_P223JHH-;&W[16]*KLBZX%:)C6ZQGX72T:.!#* (5 G[;[\_1D_E
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M?>@V=>4P<P^!!=51+$=X-TH7!5'O\XZE=S;\"*KOLD&LA1!;*'6?H*I\1-"
MO]/08(+D=LB-_#2Z+&<:(?PA)?RF#B%YV7U];/M1&J.@/8OFK2%?!Y4KG)CK
MZ!F^'*TI3:?@_G$T4H$Y) %BX<=,JBIS,\X_^-ZR)&N/^-UH>6G)=]#%$K6=
MEXEW&7G.#R#=!:6AX'X52"?3PYK2SX(R,> $ F4AL;?BD4[U"^(A)'>:GJ4,
MB<P9#A5!1/7@I>FZYB-IE;K#NMS#3U],^]F/+C_V8-@R\!>7YDJ-'8R 0 ^"
MBZXSGG]&+6-GHX$B.[9EZ]63"C10L#KG4@5]UP0^",RRN'4R,M$RVFACP??8
M/8+E\7SL904U'1 #.Y%(]X-H9]5MU@"U4>W!M7T=)0@A[K.\=XH0#9 %-:,I
MY_&8;W4'@_X=JBY(CV4U1[*.=K<);CP^N-L"KM9RN5'*T_=!#6!*'WK790I!
MI _1K*P9##?G3K'(+KS?WCIZ:"?*2QMX,>RSEM9'H5Z>U?<=!4'[](4-+1L\
M@F=J(X^I*6Y=XR!\LS\BNK^I48V'F78*,X/]9X\=;4G+@SE&=01#G@X?7+6W
MMJ6F72V9"\3=.-/215W>&EWMSA,*AYQG[J1VVI;X[5*DN)I-(E[TEZC@0IVE
M/^<[<C$IE)765G2_Y30\%+DI:Y.44&4;B[G%/?3[A_%?T86>_%E>_F]V+N7?
M_!:LH(]G?*V&[^C^9#<$L_@8NEJO3:,!%B,5S"!#PL_)(:N?CHG_L-E 16*V
M:^4*O% 4'1BAW:ZZGXX>_6V4CS>3UCD?/^G'_9PU 50TWN[,J?KQ G0VH)@)
M:\!RO'X#Q_FS(AI0*D%\+$G8X-L!'R=H=4A1]Z08.W^*9-N]L2O>K;$M\=D_
M9+_3:5"KLG^FCQ(\4AURTYI[1H#/T#:RX^P$2\>#=<C:H/F'97A0A"#\_?-K
MU2T7K/E&G$=O@5Z2D952> M<RF4JTKDE%/%%Z VCN7;XS3>\>),,M./FE5K>
M LI\C^ 38N7QIF%3[;8.NV)M-_@X^'E9:K6>=)>G27!9K]HZPP:19,E0A&YI
MKT-5SJJ8V[K%[(,2<;W6PO9%/<J6NY2$/I%?#I:U!*TI];^,#W<6C*;E#8;;
M.AX<<9J:^3F2^SUBE[_H?6G:'[>TU-H_UGYI^\MR,)LJ\Z6&F?E1\F7;A=?J
M T:L5J(V=YHAPU#^'TM*R[TL%][>=#'ALA?KV!4(,+)GXF5I4P]SSRI/.0Y\
MML_K<>-HNUK/ULW2EC!;Y2)$M";I#;(P3(@7+B"&?&%,LZTW__3(N1$,\S_;
M-1SJ$TBZ#6EOXZ9ZY"##_> SK6=>]H-Q+(,LTV^97]]1_-4H_VZ,NY_ID?,E
MX_)H"BH3!K-E-54I>B;BX=D6@]U)68Q[%8-QMV[#IA/$S=" Q)[UV248BK&V
M+"T?#:S?F)!C'<BB9X8UBD.[46Y+DT>80/=,AGZKFX[_ZX%B8=1%$!JX9J"K
M*G<0:LUP$LVTF/C2 .^%TC0]S<C*26XE!-Q\);.!ZNT[SI=$^&&H_4V8&<RZ
M*Z]7MS1'L>1CJO6#.',DG$6E&%&^*#<\.;J;XZ IZ_M;]B'./]R_R5W4W'YS
M:(44Y/K/G5'Z2A?4_H-IDO]3B1@]_+\ 4$L#!!0    ( $2 ?U;LCQ)>1>$
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MM[1V]_3V]0\,#OV>F)R:GIG]-S>/6%O?V-S:WMG=0YV<GIU?7**OKO^C"P>
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M)_Z="PKWMM)5N[R;@%6*7KM(,1Q6%:36[H=SS\#\#XM^=3Y&E^>;J"("^+M
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M.7EWR%]B/96\903#1&.DD.OJXYZI,[PMTQ+Q((DYVJUR#[MDGC-+ *ONIY,
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MQE'Z>@UT2)XBO".=Y7GL$/^,]B:ZYS<A>"_6_R2_(5X\^.V>C0TFQ8G9%U<
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MQZRY&EI[$]3FG%]R(B(>W(RZ#>"3D\F![UELX8QJ_ZMQY(X2$<R)7UM#4/A
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M];KP.4[I6%1:X(;^J5-[L(I9_$($_9O@UK*0RX 1+8_E5^^ZV!,NX[0FX[]
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M/ZNM[5/;OR/O_PD?E]= A(>"(G1]ZTYMNF2<JT[Y> DN9F6^KZ+KQ; A1'5
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M06#1B)MINHMW,(:98:Z13 1!P@XUMD.O6HYNAME969.Z @QA#4YY!@;Z.1=
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M;QCB#5[T >&>E[ [!XS#"1-6,9T4[N1KHU"T]Y66+2;X)94/E35*C2+(0I9
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M0;F='BYN"+]-L9?7H X<MG0MFW@]X0@Z#A,[F95G[4%''(_%R,1HTG653:^
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MV!](L)DL2E'4'5WE,1I-';V\^$5&<&\Y<)$(Q]@$MA&?PP0.'/#E8E1IZ2@
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M(<5U5>.8!7XOR$B]FKMD&F5;75-[0\5,GK-B-5"*+,1T?I[:(1P=Q+@:>JT
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MRR%OZ=Z%NP@F9FAC7?11E3P0Y\M,%1=[9*/*TE_S-$)EG(@FY*X^M\]2; N
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M2=C,,>>//&%=*,<#&;,;K.;43$MV!(<EG+>>13[>S7W140_0S#Q/*+=!8U&
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M>6]F6!B=FN%W0%'B+-X\J:.LA$<0N+/\$)=B(GP&S?):GBPQ)L<B\[G::_>
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MB)/)B-W2I3SC2!17BSY]3 L1^,2#L]^"^6931Q5T^C*:;)X450.MD,#CM'=
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M7/8>RM^D4>\6GM[ -LLO C/S6(VS' 0J*C7/]/-*VFO\1L3ANI\^I$YIQ@,
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MB/?Y*.[#6(>Q&C]HA%"=[WL>EX0S(#S)CR8?/K*W:X39JB\R"A'=X>FIRNG
MNR[IZ))+2D<KV]*X)V'/<TON=_O[P\PX&'U[8$WS('8G6K"#[<UKMD:N_#76
MKCY@<AU][]M'A^$!'ZO,QOB!T7UW?T7\;_GVQ\-OP?GI \#*;;>%(37:[F'
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M/KL^,_B+<6I7UQ[5.!]7FZ4(DI6\FX2PZ;H.Y\G3GT<!@1@V]!MC_X@[^U?
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M656G;5.9ANY0/:IG?XESPVU\L0=M0C/*YT#MS]KZMFU+9%FHMVD6F1--:Z;
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MI/$E@\8;W]*CN''>3#X'-W_MQ5[ R0-'\RTPE*2TV<&XFU%()5-/:I(G@PF
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M4AP#DPA2]8:)Y9_UX_O6%74\[^IB%^BE!L))BE1P92VK@[@7I/<^I,_;R(F
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MJ<*[J4WZQA8>U<'TD@EFF*@6[A&R2%3S>>-%HMWG9J[EMVGJV(NMR3I4SPL
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M$[=3LTOQ+NZ!,0V-LE;M0XE6?&3"V2RR;,9D1K%6;($:NF 7J>$9LQ+&-)]
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M[JXP0* XT"R[O/45I01=(Y)"&<!<'<&KWI+-E>IY-F_,S+X:$#MDE&GA%<V
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MOWPX#!_.F=#2&7S4Z#1.*:W9*RVKS29/^K)S=K+F6]W:')IT$5*DWP)'UV
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M5@!5),-3ZVK*3"J#A./-/OZ3423C#"D:2-&11 --GE#D,\C>.U=YU =K7#2
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MV5D']I0%W^W[*5*^L";K2M,>#N[N[P(MSS22#X\I+\]^:GE0"%W=X+HX_.D
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M@1,I\CZVWR7 !=L]!VL:$098^20(9B]0GV F"S^?^A#_VTC&?A>M-*4YHV#
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M31P,7+J70837+9WWR+TCNWTNE"L_L1C0T_ JIT4MR="&!3>V+R9D$[7?CGL
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M52749+0Z)Z-F>%LGT->=W!"YS.@-D%Q.;6'%;;([[A2\'$[TB6S1/X F7^!
M4<%/M!6)8.THV!;(M\[YV=E 1A:>3[S W) :P-XN]O)_ZI YRXH4T\KPU@PM
M)IZ&8]?],#L9.QGW4JV)R7;F<MEE5V1',]_-IM81Z ^-  ],6$DZ&OB2N'MY
M2(D&2&1.GB<?W:A' PV&:&"!#3ZNCX+90G=!<*$=6@)'HF9@LWVH<D 3U1F)
M\G&!GW;K(Z4@XRJP'PJGJ)^HY6,.&C"!G5W6H0%X\J7E@J?\XB5[R\R=T(?P
MJF'Q'UT$L=C#-5FD/&HW&:3"]YY'%M-BQMVCO^<R^VL?:1=LBN?X,VA@E@>V
M3_Z]8S'Y6MO+RM#\#4,*+V^ON-=HP*ZCUBRFUK114UP@#+^7S7'?.<BX.D17
M&T7QX63^%,)M^QA;X%TM)Q.ATYD?W8]R9TFO>T[POQ;Q#1[LZ!??633$SUY-
M843P@8@!KXVQBO9M'V&UZJ:N6AW,O#+ O-#VZ>L[3K>>TI&$M]Y9MSNX!S.1
M Z=TD=F+%2X44^A6-G3MM@?HQ.]HX)L:[ ]C07ZQ!U!KEDG@D2RV8Y9X0L9@
MV@BP0.:5U]@\-DWJREWI8\F+#V_Q<CO,BD<E9IX56Z;>L+]?7$:X)#O>1)AV
M'E>>+[MO$7E?01FE1.5$_?+G#T NHVY?8NW"=C_#$0'0WQRIANI$ X<7;F@
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M#'+HY\-^&Y,W:'B03!;/-[U3NUM7K(7TJVC7#RLSQ0:R']E9*E 561B\DN3
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MPI+T*TMMAJ4CCVR^<-9)C+>M_F=9M76P['N!>Y(K H5'@('?,04Q+>DYJ$9
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M22>%_U:+/"=OR]DKJ?11NA(DG61+[K;7.5S0KNH8,5>EV*;F=YR./<#AK'R
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M5WG;)'\G5?I>H@9@5.&=,Z:#-##GTE35#RYZFO1/2.F _&^CI+@K?WJY2==
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M["KAO?73NSHXOC2\_WAR- 3TQ]$.,,@;:VAY.5).M1/=<?S]=^FI1<+&FG:
M(FYBE7.1<QGL:>RGZ@0@MN9@B2K9'Y$>];>,Z\!5^;EWAK56"@\ /6[.,U?%
M+66&L6)G]-<^O$OKG]N.K0XM]<$3Z*KTM]IZP-FDX6D8<'FG24413 M^ $#'
M,W'S9(^.;<[;0EPM<S4NM(%[DPW"A^2.:9.,+Y=FIX/\-C\4S8G0MR1G7U.8
ME+H)J <=YLY,^'BJI-Z?L+:FVL3%ZVG=RU0D?T@9V(34H1R.S 8)&_J^$EG;
M73(E7F>.OQ?!WDI![ZDW-2#JHN0I^S]@,JWG-)FN3=AKX=R_MEW&@]*>GPV6
M\Q[D+GR1V8^+M?&;%=Q[-OESO2AL9"=V)I%/P4- +FXFG=WNH]VN'\_S+TG^
M7D%ODG)JW+WO=3.]XRQ*.C,<2!<$XO9[$KC.DOJJY/@'5NX<Q9KC;Q:G/NM2
M%=:JJ*OOIRSJ^;)>EK&UJ*YYR4Q5VA%SP5@SE=_N5DWZ3WNHC0GI66?E-CC@
M7P+)3O-W.L\QU/?!'"57[EO=**,'0*EAYQF6_*?;^U=^ O-7N/\EDYPQ4'\W
MMBVX<"$VQFRTM6BUIU07@B9J4\9S\@7ZA_@+69.&.09?!/SWF92R.)*;W6K+
M@HW:&_Z_I/0._O^IN?2G/P (_!X &7-I#P#R/T&)VPTA:Y^#KP*5^>"SDQQ%
M"J>QVLJ()(35L(V[AP]75Q@F ;(GU&,LTM%>>@?%K"LU14H^:@3/1^AK2QR0
MB;/@8)NQ=,HMZ'>4TGD5\+S)A>W!)<TKJA*1M:FV'P6N)4$I]<S#A]V,'6+/
MQ$5LVM[:V+G'WY7C(W,%I8ZQ''3K4*QQW9_B;GJTU3TH_?3;EL@0N21<W%_0
M.WW9%2R^L1Y*O1K$H(3Z3LL!/:@O>TPJ&9%Q+W\B'+Z.HM*44'U9R?V81JM/
MUVMP;U1ZO7([+S&LR,>;Z-FWSGM4/;EQI"5)6=RC>@H#)XF3?N8LP-/%E>DE
M#EB?DZV22*7XQC1/8,]$M_.EZG;7ZF^HV"+>R.*)]&&I),GJ^Y>]A;DGG"0M
M)M$O$[@Y]/'<Q5>A,SA_.*HP<JOW.0$EW78B,\-5D)<;N8:KR0,R+,35M++\
M0:TJ!D[F.UZWN B(^9Q5;E:WL0L\S8D2=9?,:-=$:(6LQ_]4^$I36#[Y\^-^
M8HD/5>J*HGR(@#=BTFY19[XJDFP_T?Q]JEZGG;YI'$IZ.''Y*YLM$4<IB74F
M-ID^/S!<QU7VNA6/33ED"@&D O'.8%V76ZQ2]-ON[T'EA:/T8%>C)Y10H) C
M]K>4NSUWSUS@<S=]5H3$S-%]AF=UQ?NJ]V"P*^P?8W\",A3CZ)=7RF3#?,OG
M/J86;!;9SSOM2G8:GQ?!Q*)Y# 8U^/3(*ZK\V106VI#SE7$%_ I8@X/K^P[W
MN%-5-<\W);^4)D:QID0K?]<9YL*U2*:G4,RGMS31P#4T,>_U9F]-_!W](0Z4
MY*CP-;2&4"BN/REI5XVD'0A?7:Q>K7,K6)+.S2Q&C((EQRQN)!3TOFN_&^0]
M9:'85P_P,Y 6CGOC6]+X@F.J.-6'M4T?NOA8!M^@F1A*J50*4/Y.OR4R&T]@
M5/F/54N[!I]8K(L7[:_6;,R8PD6?P%SVC&$;B75:Z$[-.><K?%U:!KJ<XY:Z
M:T$5A!7MF(=G+G_UU)^3.]Q#_YH]9*:4A(LOQ#K5;S8SGIYMK0GQQ9Z\;NPJ
M=#B9I!F7R[V;@:OM#6^R6"8HVXREB5K%U?GWL\8A>@;XR!=$(KEF5U)PO_V@
MQ*.67Z^[9S.=0Y6*<M9/C;WMN%.]<2C<\<K%:;"EP+UB*D>_X%E>],=JGBR*
MS[MI$N#/1'"XC@K%%WTEV)%2.B?8L G$J#3J8D"ZSNTF8[I[<[Z-O(XTT,36
MEB@5Z&^+6:2'".;A+Z"+>$1N=$G_T;^W5AJ^^7[*%>',R+^^EGTSN[Y$VI@R
MY5U8'I KSMH 712V% X?2GUW8G=%B<M:BQTJZ&'JPZV6\JAHSOW^0IE P3S#
MW%X@NYR./P:P"]A3K#FOK49&6Q0X: X_S?%4:D8V:!\B*2L4PF68/XU\E2W"
M':/V!!NWF&6YN#AXVGUU>D;@Y>4,4] 727JL3"+=M2RJCNOWJ+!&)6 N%%-L
MG\FKJ/EE:-Y*;6 @MKG[,??<!MYX;CZ4LP48]E2M+0+C)3G(IZ^?:5IEP6:5
MH QJHRBE)S\K[ECQ="KI+T0/EI8T)VC0J>;#$R4EHZU/7\U#4A.29A)@^77L
M0/[Y^K:F*2_NZ+%**P^J#U!QWBI6Z7_XB'#48A=XR--7[((UABA)_..)62\O
MJ>,K'('V,/E$&E_SYBX;PHSX@]7Y#UN'3Z<WBY!'O<E'"$OE!!KF)CS\&WW>
M&Z6ETKPE48V335A[S=R?^XYC1)8 WRV#6^62R!V\F #J@6$VE$LE5;XV@0RI
MU.K,>00+Q,1,K5XN" >\Z4-KQC [-639E)!GO^1,- @:NM:6LTY9]#N'=ZO5
MBI(7:2TJS1Z703F40&7Y %QP4O";I"7XC$O!L_I9D[\-N!]TQ:=<$,XR0^^K
M@XC>[#%]N8)#*$92%>(#'C."2E2*!E) >8&:"&0J4=3!;7L/^@Y3*EDTS'"@
MP=8\N$4UK:5D1U1Z*]74H!\'MX#1/E?,"!P-<Q]1'BD%+R.R7].32F#:[?*)
M0-*[0YR63T:?]N%'$H<'XVQ!5#>B#M0]39(U4Q"D3>*MG3B,2W<Q)QPZ]Z"U
M$X&+0 GR6K<DW['3L&9Z_TG[7((TU;:6YN>9F.9$:]%C='(,CZ^I@A@,*4"Q
MF)W&3F_@)$\PKZ_(M$1$Q):$-E,D:$J52+]+%[W4%A,E^B"$%==#@2>GFM4U
MGN5 @=KYD"M/>%)%*^@NAGN-))99E R)5]DOR[<C[,!.-C5Z?U=%57WY6PDS
M-/"UP.>' OK^'Q Z=&4%^F8:51KR $ (>]>*Z2?TJ9#3ZUO+BGYK^M-^-VQ]
M.NT_YR!/9K(H%<_U957O:KK&;>.8WZFRP0:F5V_S<:!/JVU2-QS+_[A?+N9K
MV2U]BS_2MFY&>#JV[[C7&>7[I(O.UILY,<40 ^375%?WS+Q0X4*F9W9L8>??
M I/>-YI?I?_@PT^QX4=A%$EMT"<'K)1&5.]^8BEM^S0%K92[=B(N=K68VA)9
ML:JQ]VU^13@WC05:!"]H(2P47<=B#&;7_+*]FU;IT)O*O V&VH;#R4+&;ER@
M]$8:?IL!9W=W\-3D4MYJ!J(U*WY_N-60IS2#W>?Y3[!V/C'G$@"GC'V#/94I
MU..-(R<A:G&KX0YW3R=B^UT ,05H021Y_P+#Q.5YRD1:K#'RZZ>;RE_2'.XS
M;.7@G)G,V/QE\'I?MY+)8RA<#J#KNNT)JU@8V.HLB-\[?0"( LWWW$X4R<1"
MV7DB,;-SM, .,?W]>Y\M7/,\09?M0A9[]B2-!\!G:K^4YNGU-"ZY(<N[L^JP
MAO6 92'FONX0!/BGZVP,X/?'/.S!TMTFL>BR'XECNG>Y1$#>)]BTA$6M5*9]
M_?9,SQ*S:*OC2>T%[7_HB?'_I!N;PKIP*1;,IQ?]K<QJ_8U"W<DO!D(%55C^
MD58VNPG2YT')LXKV<6N'RX7!KCUHPA#0L+!^*2N'!P 9'Z;AF>"RH9KEI;3G
M8X3 0'F=8C(_6O89<:\,-H_&)X/""66'6A&(-SCM!?ZIV.?V."NFBC!79</C
M$%*Y^$5HAYE :VX&E<!1[.9;<=&2:M[L.N5-D8KL?5V=!L\&97Q?;.[F-88_
M* [:0;650\0>M8%!FKN&F_M&+K8][D&K'#]0W/0X00TT_ND-RJR8=S%-V7U2
M01/Y.9J1AQ1TR3#?AX>-_:B%D,/8Y2[( +<&V>\82&""]C)O5-QD$=#A;4I/
M=V 82ODU<#W7J:N#T15>CH29]#LVM111QY'KL#1$*22OX%E%WHPB;)#B8Q[J
M3N,<7UT^.![L_X9+$1*BJU-.3!2?NIWT=AA [ #\W2'!U=-8_0W#&@1$W'OO
M6R4PLX98/S-<6OT%5_,B< 1^G&X+G.W:YY.:F!W]NBBO,78D*#?N9\BBY<V'
MC73T"]0+4;#211NPE&*'S'RCN))5YA$ADD2C_:-L$3<,=3>O2.K#NX"?(B2N
MH[M80\8 V/""\)*N<X'S'(:&=):("V^H^,'G(9=<I>PR'*QV0WZI<URDY,^(
M$]-?1B->'X$VSN6P\=;$AK3'3=#6ICPCP:LMJNUD3031N?C.IR=Q8(>-)2YC
M&=I/(62_]+TM69@C1B)0&A( VRSP2FMTYBC:.&LL0M0@O>?3CQ'EUW2N=PL2
M*'!VN-:X@9T\-7;B"\(F?T.+9E%K1:$A'/TL<KW&"#WM?GMF=]^M5P6170D5
MF-Q-"1;"1_E-**)0H-^RP$@I#6^?SXI5[E@,EKUED$6+_=2\R:(B%M?CMKKN
M,')B(T&Q3]]] ."N?K^-PPYZ93!5FU-5FJ&U;*=#DY %^7==/!\6CHI8SU.L
MG\5^#)2\#-W%4&E&'-D0,Y.H]69M50]?FI-(.CW<M7!MP4*I#Q#:<I<V3N%G
MD-3A %QT0:Y50/JF6BFP[?K>8[G/9Y& _B]NG)"A5]L*GKPXF'S_I3*("SLU
MFE>)N..]PDM:SZB0ES+9MUWTL[WP8!=GURI+&+F+\&L:BV<,M,%XG:H;\>4B
M[?+<K@QY5DENCTVP':V:?0/'*BC-$&GOZEJ9#CW</8H [H2<&) -I<XI .[4
MDTLP(26[:;(':L*K&F_L YKU'\-38QP:*K#[1#K#B*4#GFIOM4%8&!/-C^!X
MID>14<*"FQ<_= BS?2?BMH/([YQVC66Q5LZJOT9G*X-5KZZ4%#7?G5/Q0-AG
M.W)FVNA6[PP@J+/6 ,RLTIR5W1Q+N[O?W/=6R+#]GR]]_HKNK9%W9\ ?+85Q
M&K^9IT!D[-#-*K8^OUDX\NBPQT_&SDD(3'ABW23]H7^J9L>TW)?%L@J?)93;
M9U9[ ;;B)+PFI9.*F3H8Z-Z>B=]:JY8<&W7"X*\K+$).76ERWQTVSU2^I@1U
M>]2I&!!=QA"[FI?63")#W+6^H2KO*KVZ!R17\<XK8Z<6T[ ;DWJ@YD!1(:/,
MB&J1B2Y;O3^S8CD#EY35KP0#.%^%)2-]R^CBSSN/S](7U^(%_*QOH+FW^K_B
MHXM!#P!'T$TD<4=S_][M7B)4YC+X>(C_+JBOBOLC54GJ-^;>Q>UE0[MFGNJ,
M5S9XXR_"_NA0&R6Z%AF(TS6&H:L_N'43O_";^C,Y+J%V[?6V>X38V[6K(KJB
MT^/=X?6L95X:(*==*=_R2Q%]2=-%=*HZ3;!$D=B"Z=9F5=54\LW$2/A0@/RJ
MPJ_5 (9X?W&->_&_!%+Q7OXM]7U;_@-@PNE?!!)2'0\KO7J]=I&I ,)CJF.Y
M$UR>NV_1#3HJ#F0*&L=^ +#S/@"N-B@-W"[BS(;_7&>;+YS==.ZM,_Z/ P$2
M1V[RTU*21\M*D^=?@KZ9HZ^7K$UF+@XRYCV*PKJQOQ?$##7R>14.L\;9KUHH
MF$XX[V\7Q&R\D?U__Y+U?ZPZD1HB>]0X$/7F$X7$U@A1PP/@\.LHI2:>A-=1
M8;<.3)N[+- 4D&1M-Y<]QUMV2^U.LX,J$#/E.5X[9UR5IW(L2ATA]=A;98_6
M4HJ1=/ 90(O3WXM7G1Z5]CKVNZ;BC^']437%FKHJ*T 81G\5#O_[[%JL 8+6
MJ;))@9,6#X#?.XRK>;$Q*_9W)GEG97YD5PR4>CRF$U)1+DW=9+0*M%E*UT?Y
M0<5RY\#^7<>@*_W<UUOW;"^6CT_)'@#4\E3FIN7KKZW#S2,Z7@^.):(9_[VO
MP4AR"\J[QGD K(\ ;T&46N>HG 1_UK>!]#Z(H!'V!\"K?V76Z(Y_MN]VE7P*
M_7<IVP7Q<(UZ,MO/;I$O>,4? -$:]ZK=#X#>2;*_,>,IP0-@,#WHJH6C<"]I
M/VR!9;E-Q$4D+_)CI5/R@I1HHN++=8:J)X\$Q7<Y_EZVZ\%FY,/"?P!02P,$
M%     @ 1(!_5G00FBF$_@  Q14!  X   !I;6%G93 P,#$X+FIP9]2X=U23
M0?CO&41 44'I':0(2I?>!:0+"-(C("(UA- )74% NH#T)KT&I(30D0XB-9!(
MJ*%W"#7TY7?OW=V[Y^[>O5O.GK/SGOEKYKSS?.=YYIG/,S?_;A8 CS55-50!
M! 0$@ ^W'^!F&J ,(+Y+1$QTEYB8B)B$A/@>Z6-2TOOW2:G(R!\^IJ6BHZ.E
MHJ%A8.9B96#D8**A8>-CXWC&_?S%<WI6?B%^'B$NGN<\__$3 A(2$M)[I)2D
MI)0\##0,//^7V\UOP)-[!,5W]@@)V %WGA 0/B&XZ0:P @ $1 3_J0'^2R.X
M0WAK+\F]^Z0/;B? 'P/N$! 2WKE+2$1T]^[M:,#M..#N$R**I\**Q)1Z5B3L
MKE0OO\3GWN-0JNZ@UA_;YQ3YZ!9\GY2&EHZ>@>L9-\_S%Z)BXA*24M+*KU54
MU=0U--\9&!H9FYB:67^RL;6S=W!T]_#T\H;Z^(9\#0T+_Q81F9#X(RDY)34M
M/2^_H+"HN*2TK*:V#EZ/:&ALZNSJ[NGMZQ_X,XZ<F$2A_TUAL(M+RRNK:^L;
MF[B#PZ/CDU/\V?E_Z"( $!+\S^U_5]>36UUW[MXEO$OR'[H([GC_QX0G=XF>
M"A-3*.J16+E2LK_\<H]**3ZWNN,^AXC^/O5'MS%2&DY1+!?N/Z3])V7_8\*"
M_V\I^U^$_:^Z,("'A 2WSB-\ E  '#!F;+77:5TG*<PK'(R>3P0Y-]\ <DIO
M 'O8DMV@I47+TY'#DO)-OKCT9KZKIKWKP.(;0'M8VRQ>=?L&\/!2?+@G=>HI
M9V:BY4/T3/L]A>54/.BZ):'ELF_!HCC0$M>N7)47R=LG]R$OD@?P_Z-.>-BY
M=BW/=0/POP%(1Q8VW@#B(H+F%8;SJDKE[7EW+;^R'KSQ%[L!6&A8/C+^KX5O
M#_Y7PI=;0$NL>%7/N$?_KL)W+*=I@VSFUYP.?/2:&77V6I&Q2<N] F!5F>R*
M@KS,[/XM^TKC7A:!&\!7=^ ^*N=$L.X&X#1[E?+WT,M'3MX)+--TU ^+T;48
M.RK_]G-2#/C@>1%]K$S&CYB<3!>Z8)_\!"-M_I[A2K2U9F1AF2/&*]ZY=A-Q
MDBPDC.%L3/NH'_"RF[07IQNU(QIW=QZ:J"-^#H,WD>@1_9[B_DM+\-MJ?G1<
M#V(URRQ&_7L]B*J.^1T069><S>@W7<ZSF^._52/%:ON/D,DY<74=L'&F772I
M7)W1P\(Y#E<$%T[;CU P#F; #7XT2-)]N'-T+ 5CIB^V;2__%VKVR%QAR[TA
MKSS(WO0&8'?5ON-U [":6@W('[(4A)PB[.A.2^JRK+513WT\8E2'KSEE3'?L
M3)5RE S2A_^VV<RTJM@H+FJ3+>E?CR!0'@.0#MZ33TTQA?V;XB&92.=+W9^F
M Z[,JXV%'5S-=]-LFF,>OO$EOKNO0R:BFW1"9C.#SJM]AB..(2YDR1&'%?<%
M/1,'ROVY;RDGE#8PXLRKDZCM?+_XEY[%BWD&L<8]P<7Q0%9'LQ\TWA1 T1-D
M<^6*Y)H3)V$TDUVKU_4#?$PN-*7KY#QQIJNH)?$J";;WS,!*@N1C@NIV\+T^
MRU=0F(U2@?5?5)AC'>/*F^WUBBUM=XV6VNS=$8/J;-1LY)"H\;T->F9E(4F2
M+;UI:*)R4W7VR;0ITK8&L0KZMAN?'W>U2D*(JVBTM-;YY#AFX"P6\W):RUQS
M3:\V2L?&"%C*;?@M[*) 2K*COT]VM:;"7X-K/GKWR+"^[D)4O-PE1:/D]8&\
MU_X'5NFXC#T6<I:Z"2!E@IJ:BDNV##ZQ$ _I0C,DI_''POE;!A[6HTY+Z"4H
M7G83]^DL-@4H=S/(IW$^<4R'A48C2^R7&AO5IZZ_?.-.#QPVTIF^ 5B62/7(
M6)[_F\@KW60HRBDZ8\5(H.JS_;XM'JZ:7/;*4;OYR'>6(*)DI>MC/##7W_F3
ME9^DSJG]DERNW%Z2C96>*$'4,(_!58Q_M<(GP/IKNHW!FU-GIA^^2TN,QCYR
MS7DB"ZK 6YR//^+H.(]M9QI+\0%K+;*3B6=5(^0NWD4S%?Y!4";HK?HQSU(O
M!K+BESQ+YTVB1NZ-6!6.>-6[.;Z<S7E&R_W=I)N6 \G>&OYV8EMT\NNF1'U]
ML,-=/?H5D\N^_VQA92$]LB9AYIO1U[T_)_QCIK06W*/\#"O.\"$!XGI7ID6M
MAHGN/DFC@3.-CH5SAMPJ:/&%_-8KX#TG" QNVFWAYRBL1*TC-!9V P"B=ZL4
MLI2^9FBPSXRW#J='#D_"9[G5[-'&DWQ\#]LW>R8[5=HW&J*1Q\QV;Y#\^EOZ
M$TX5.P6] Y7<)F.UR+O?'_$*SSI9Y#54,>.OD5T65"'FR'P$"ES4J.4I9 X(
M]_(A(R2,]LCU#P"SQHGIDEMV/4J"AR98R.>*]1MT4=&Q?:;=.YXU*M4N+YS?
MGS_DFHCT@B 6M[WJ#'E;C75JD:JYWD$.1%](.U=-D]B?MFW,Z BY"6^E:P/?
M IDI#O5B7F\0-<^\*/\@:<C?L58IC0*+E8*,/]W:<P,@QR,O++'E4,0VB\ZT
MZ6[@X)KS#<"X.>9"S;S5M==Q)-3?RJX"^JRK.ST>,0ZN-*A]$/6E1E;X/>U3
M-8BBF>:/)3]85EO0.+N8-:_HJ?&9P[6=KLJ[\6-S!2.$R(8Q*F64L&X _/+/
MSW,;#6JRC"K[\\*)>HQM>?'<>^6_\<"9@MA4R>4[ZJOY22>\:1!WS<A!G'RA
M>X$]+>)$VA^3]/?)7NPXT]Z/M9^_N8_$EE_Z.Z,7)SXBE_&0LL++/Q8RMNF*
MO"6;2F?T'"']1^7%JI[R%"\,8Q2^G;[@Y>[T+43!L5MR2C< [0S-IBPMN<RS
M>1JZ:*:R[! Y$C-SM6[?9VE>]4W)U453,_6D7:X>\8TC;YZS332("5@4/B]F
M<0Z#41O= -[6("N&YG*](2#'AK_(/R4A<O(?754S2DP=D\O=BRR <T!A-BW(
MB_ZO<2[JA7:@V,T3?CW3Y#:VL<ICDE]UDW5G>XE/88N-JO&NZ!=DCC+ME.LT
M;N_5?"H=7#2<.YZ9.B\I4[)\^2)+&1(]]N?DE[O :BMUFL0W47LQGJ,S.%A>
MYDRX9FKWK>;9QM=A'3]7,P]1U$*Z'Q'U8O&2?*-K0!!9_/Z%_L1"76/"5#$\
M;5G_C^OP/W42.LD1W_GQ0%[E$BBC!3JHAAO1/J8S")/V$:]!%.VT>#-5NA5'
M3F(W>0[%<M.K2 0,CN4$(A>N:?Q5$+BY^"#HB>54S93ZW5]U<[:/*Q?.,"VL
M&0C'A9T;@+U*0]UD)?O^V/./95L9NS:/V!1O 'SXBZD];:NR1DF@(:3/*N!C
MSHNLHZ#</2KCJ.+>Z:W[/X.H\+0F8W533$^;OS<3<4_EO[\FD>]M3<! *V&+
MV;,H=9M7ZYMN].K]'/NEI:H>D\N1H?8&7E&<>2WYW3ET@4.PV8ULJOWA_$53
MOM3; &K^ZOIKFS0_,20^ ; 4C;3!3Q8K!.LT6Q<-\D](N$[-_-.6^+%?&S*\
M4\RQ(KE@1U(HB=W4>)9\<NE%6:4MGC%]-'.<SBMAB*[+8OXHW5MJ9;4:78RI
MI."?U^ZV+6B8/)H&BWD^B%$:YB4&1*7=YN&0T5UNZJ3LU<S^UO\<W,;_;7";
MH;O3F>=^.O%[9KWT6U 7Q\URJ-_;.@A)]Z^\]2JOQ2J,NG/V4C%*!X'3[BT'
M.Q"U14ZS"SN^_7O*YVVE2?;1&A'J[".?%(7-B?1N6O9]WZ6(_(EH:P9^Z+-$
M"/S\K#'UN2<,>]'>>C;9^W6Y,@72'6'TU3QC#^_L6TB=50YJTHD=JZPJ,S&A
M#YJ,*O\:%81TI2_>E!Y.*S(K1!663)E.:\0DOM>ISK<KNL_&,/RW&18U8416
MO;A#J;G_%W.$"6W!?+)F!_K0*#[=+E'L$CX:LE+&D<V=CW092[\VHG5U'*]X
M%S;Y-&*'+I3+*S&-R7F%-F>X3'2-/UZ@P+I9IHE7P0@MFL74*P;6[^T>.)6?
M=(F'G#MSB%ZT6FK7QD[N'C^0I-@(!M;5OHA(/;J?>$BY_L+I3Y/ F('H+$AK
MTB:;7T2_IB6!,$)_SN-[;P#=<\F-N5PX[EFX=PGC W.[-]EXBD<MWNKC=Z0O
M?Z[&&L-#TKS%[/,:(1$6?+< Q=M9"U+X>.&=PJZV?-9FX<UDYX6\+-$8**G\
M.9L(R9T8LQ!D[1V\X,VPQ:E]@8-IWZ0K,EIHOB^C1(9%N&]U#!/\%MLT"X_P
MD!.WQTYX9HF/.U"]5+O-![6$HY_5G]5EW>]$ ],ZZ[AKQ4HJE;L5'M<QDW2G
MVT8%^-QY;W%GC^-O*7,3$1_]OVR)#P"9M<-FN\7GSK)@GUQ&+;V[-(/2,[!+
M"&\B(@1P-N$_#\7UM>K6)E5!-JAW./PLS^U45&R[JM8/'6.*E,LV#AS5U4$J
MC<HOEBK?25V]D*FB6#>*\4"8H=((S6I@OQ-VQ822+W(/ O7][&"ZO-O&+V\-
M4NO)>>S!^NA9@C/D:>JF6]XKZR2O,Z??]*:UGS\S[5:6H189FZ&5_#:Q]EQO
M<8.,Q,;O^MEB[\G7S7"FB)C=U^&?>JG)DU?P\_]E&JZBO<K=+IKP#+HS938[
M8"/7FS>FYL[BK=3W@4Q(L7]KPKC.2 >.'>(%MB"=X5J6\@'2$/G)ECY+?OP:
MZ2LY$A+VEB:1MR4%YRQ9)HT=/9ZRW,!]YVHLA!5*IFW=TQ3^C29 VY!B79Z=
MK5)]EL-S!*&93YQ8CH_KF7^<KB[+(1L_*^M-7G76!J[C<%&-2/GZ-G_/!<HR
M>210C=T1,6U#0L1X(=)+VBDC\"#AE,% J=]L+"&5*I^@B=CY4%FMTAAEL['<
MQI;?Q&_WZ)T\9N%ANZEKLL9O7,T$ HXOT<766=B*/5;!SNO6$3HX/'OW!M#)
M0@VY)?]6L[E>XSC#YG2M<D7B4P)KG2<S1)N*%PU+SB )Y>AI?U%\E3WB[?L.
MHADKEED:R7]G7VD,+*B8'A+TDC#SSM]N:?@<-7JA)MQ@#+P2.R#;[$IOWU+'
M3.7$L7(B^^X#W@<+\GMDU#NOH>YT_"IXEZXPGD([QQL@3GM-&'U:A!-V!;7?
M +B"!G'/)!U4-4YN ,M@R%;N<LXCCRQIRRA?EX9?=2ZR8B!/N@1JR=1[[="7
M\K>PEP%SQ.MVI:NVXC(6GZ#JMD#8^Q'6P&]=9;L6ZB3MA-EYK2Q;V-/0W:JZ
M\H&C A!,0'*Q[KLVFW"%'0\9XVK?A2E,6Z(KW2BM8M,,EE25%%1*+:%_%CMG
M.Y=)^05/\.[=XX+IF%VDI5_[LJ35"EU)LW/.3,4-@')5FP92!WW0T>25S_&(
MJ.7-_DRY\+^W5!]@B<A5][/T$]X,!4*\L@E.;"ZUNJ>\,GE\QB&Y)M6@DU:!
MO1+ 31B?()(M,O(.M*#[<!KJ%4 J]^S9N-V/OR<',OT2F39?/JK+>G$PE^R/
M?+X4QJ;N)JJ,[2S0JENG-CIHY6X6-'(['&VHO'_MR V"77O7K[S+Y]&04Q@T
M.KH8R?"<E5;W9\0&>,TID#FXOK?L=8)YX#4:>DUV$[RY!O2%5%T3I#^0'@7=
MQP=IH=I$_)42#9 PR-Q,SW+A7ZM)+4%NDNC+_.Q)3'&GX)V\-Z58O%IZQ^#]
MPID"IAA8\_.C]\9:A7AWS?'C&#7#:OA!U3%%T::E\/3?:62P.NMG:D]A/8>#
M^:JEP;7EO]BP!/C.21 9Y-",]27>K@M3%2%+#3,?]J=]G'"@6^\HW3S(O--2
M&'Y9U_O8CF[;S4T:C0RD /[8;TM G+I8S/)7?-1*9?5W%Q\[+/_PB:5Q+[U[
MHHT>*O,.E6'4-@HK;/,^9(Z2-'9>^<Y<H>L?DKY-K51B"."A SPD,#6N+%/A
MNK(':T9]S<S)6?5'+S#S+E)?X-,N*:L<FKPRQ:)"DWE_$*7KO/Q]IMLK?LHL
M_>X2O""ZWQ?6PE6P::SVMF'"_U7-W& P8>WG C+\[TV? >[8I+TVUOV3-.QZ
MY=+83MMPBO$C3Z%#^M/^?X/^W4L_%UPUJFYW!D=H4E\%.@FQEIZ9OL8A/X7D
M^Q?8K;N]2'XQ;F3FL)5+_@@Z:&Y^)=:XDD-_!)/0C.ID>".>C/$.W1/SN!Y3
M?ZQ,&3 JL?,;\'E*:B=[$MC#0!SO@$M4'/>7LP.#R8J+9Q3+S# _U?\2D3W@
M6?!=(^0D/=&&J"./9\6!CRS&>9NE H_T'X:L!\0UK-:T<"\$D4$U5H+(-]YB
MM'@P!\X.3'':PQJ$TY*+>=3C,85^6X=-]6VAPU%NIV#DBET .='H6ANZ:!_=
M)=/]HSZQ[ TFS#@,\6WW38YR,FOPA5%<MT8EK.WIY>M$W9EG+"R*20M?G[&M
M79_Q6ZPY8 ,81KK1V6SUU08H@:4GVB[,$9Z,T.FL_-TJ-J]<?^'\JF\"Q^W5
MSR<J%RY$#VIK[W,LK?#HS+C(&+9H@F4\O(_]+B-,O"JK)H$#W$&'\G[XQ%RH
M_LB"=YC8(P',,+^J)5L!+O30[N/7/TRQ0!*I$27 4B&-M$[5H@(E]+@@I%-D
M@+E+S>7\!I"Q.JU$>-<^#:I"*G]*\F7'XO?\/=E[@](YY*_N_J6O%OT93!;X
MKGF%9?"+F3P[WAVK\&23-ZAB?73&O(1PB$*:AO!+,^C1#$!JA+H8E5N&!EY6
M010$.<3"DC/L4X;1!X>'LI!>!H-\[%I7%J_1A),G=+BR?G7Q3Y#X<W8^ Q[_
MA]A RT[$-3N4AA,7F"81DKM?EV)4_U<W'&(D9NH>OWJO84#V4V9 QY!O92&6
MGUP?,;ZS>X3_R_"^7"S3M5;U5\W5^)WXWT>R!A9\^W;A+6:_XAYOQ%O0!4TV
MVJKI;32J2YX,\RI4;*;OSL]93K:B6A(NLH9Y%^2NRHN_>12,<HP>\_(6@OZ!
M=QE,&%1)?A"E<L_V3G*ZR(=,QBF;RM/OK\9C8V2VI1]%&WE-(Y*4-&R/;3D3
M HO@Y=DMDQI2:N>70R4=R#A>69+?OB27G.V$_N^*RG;3X _2GMX *B.J4PXY
M6&-$.J6G\#E+K,0J B<AKZHOP">JA.9WJ.QPAI!N-*PHD36D1<R/-<1#%_[&
M1@06W_Q\M;^;6&:9F\E]HZ_5_09 =,GH<VN%82L*O% _Z0DJ:DB>NT/_X4U6
M=;#D0JV'Y+*Q/HQ1,S#Y&-Z^<!G_M53!2VXO2&O^FF0HTS+XR)(<I$#?QB;X
MC=]I=RVB(YBW\&$NF7\O*;3_3&I39.^]1-A,5-5]X'1CHB8"YS3VK]HI3E"8
M1:YQ9"+]6(X;^Y4!$=,"\EQBIGA^M+656EB=5$CPC?'T0S[$HOR[:[;T8C-J
M7RW\C;2LLE8,^]C*886^A,?C-L79SZI+\3D94F4FWY KS6WQ1].'-X#@-R6:
M^4E)\)0ESU,6*^P5KPJ.MCLH0KE7J,.5O_%UU X;)5$;Z@RIX$WH,"/MXH<R
M/UB7KOHFRXO-(0+:GT>[_-/@HSW_6S/S.CX9_*>:@JK][F57-,%G$I;FQ;CP
M:UJ<]J+Y5M-K"0EU\0CE%B>U#SWW9O&K^2AY)KR626TUO'UT)_T!]91S=7+4
MQ^/>M\&J;B[N ]RE%?D6+]!M$;P>8V)!F[.>HEGT\B"@T?P<$H%M:Q65=VR(
MGH9R]Z"B/(G^/H9&SG!,Y_4QLLX%_XGJ#/GR6?+W4J%O _(IJDT*VO6FD3YL
M[Y4)<-HEVFZ_<J6-#B^+F04*1#%YH?7[1*M51$M"E^X^):T ]"XAZ4>D8%HQ
M=WJ[#"?\U8HV<NS1RW#AH+XN[FRJ.]4'7I6:);.1C8O6 A<*O<*6N4)=?P1O
MP6,\L_T9E":N9&3Q@I7D4JJ%(B!?MSU>3#@Z<'5>1FTT6&U2)8!\$<JPU,4
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M1\QS4T.W_I$61D:VML/XYU5.C[DWQQU'1LZGC4\]I#$'[4^"!KJA[ZX[$F\
MSWDG>5\L=6%L1K[!Q*9@",?Z:E&AD54A3$QF3"/&-SNO\;FVDG% SF*Z=%G/
ML&QYTR5#4.X@_N(=_HL-#*BVT$JN,R&*^D9?V.A24>,L1?BRF*YCW1>=C,_H
M8OC*L!9Y#!9'=LX)(YUM'02-%FTDQ%]]JB%Y6/226(U$@6?!>.RX#W0#>-C"
MNOA(#\YL_#H,V"?E0Z'!/A=@P@'0;80]-WH[/H_.;E]6<10(\ O2TCV43<><
M:N#4(JYI.]P_@EM$N H6F>4WE44#W2#:H3E[GPU?C7PDENKQP%Q5?L&.D%PJ
MQOV6(!"S,4<GC_8'C36+=Z__?.ZLII.V%*>*NF3%7D%40S0GCLH=ZBY<[@H3
M3:T0]/4;$T&/V+.P.??7+>A^)0\J(ZW@B-150WIW;DA::L*L[KN929V63UE5
M:)WS><O!XV=9]*H:S1YGID#E+EGS_%N*P'-C8ZR[1C%=E6'U":C=&7)YT^$'
MP6I\BK,=P_=ZB<!0;D7D\4A4FVP&$,DOZ/S!Q+]AEX/LVW;FPI/H%34Y%5^!
ME/V1#HQ131,L+ 1,O5E_!![^$[-9HF'(40_H<\0@_:4*'=*'"\M-,&?&YQ'O
M/ 53=U;!&QV<Y+])&S\:%MKN[AVTM@]>$SQX>#6Q4]CFU=8>=TFYJOL0[V>(
MXPZ&ES>.!"]26&B<#*D9^UBW(G[\N@$DIW8^7&*.U5$S.X=T:KEETXX;7>\^
MF"Z$1VNX$^[%VF+D/9T>AJ#E#DW24[H$21Q]D8YH#'4=8OC:NMJ.=&>FAA >
ML??=W3RXQ)#T)Q$A@.#S"UZT(7O"=9UHH4JGCN[(H;SQ?F7BR<7($XT;P .)
MZR?\3?#.J[@=>>.T_JM5V>4M9/'^<7DV:Z.)/..E[IAU^KR^EA+7-?IKM43H
M=#F%COIT+[D[NO1XJSVD[6YS4_KJDM*\Z/"X^KQ3IDW$@"1Y+!QA=PM,IE#;
MM:Z3]/=O-R38SD;S&U[:,=6NN<J2N6/JDI^1,35M-WL@S,_I^\BYY,$2D*H<
M[:8<R5F+]U )+>305V?C'GG&R$FOAP3R2KL**@KOX3;0)2USVO>X^BRZ;B\4
MRE5PE ZTJ35R%^I[P$\ADR7U29L6\H\@J2\1X2PU>Q@P>3&U80C/"0^D057!
M'PQI:1U6BA&I- ;5:;9]> ->$")D-"Z2-HKO[11YAP@:WMHU?HKEQ X&SB?E
MS.<.^ -Q5:%V>+O;M ;;2$%(T"SR_$1D/?MX^0&KT7MO6/>-+QJ\?S*W.HV]
M_@*!,L@4(+%J#Z7>_7()Z/FTH7"_Y4G!?(^?S<]. 7:9[X.B-:%RL>B/(GN1
MNZ"$@M(#-Z7SYDV/=U\G?A2#J=NK&O9O %_D.<=D)7(=,=S?Q!YH"QK73]@Z
MC!_H/4F445T  HYZI7%[ICDT+8;8&P"5OUQ+T,->)4684FT__R4\K1^2R;HX
M+)(X\B96Q7<D4IX%;]PC$;SW?@S;T$1(;.,=\<^#,?(Q$#>DX7Y;),U O9CO
M'Z4::T8:IGV(2!=N\?AH$*S;R"VW96B1(UW.N>>Y4=C>'ZY9S%=:;CJ/:S_;
M]?&.S(WK8:42@\G_&7Q5GZ)3';?C&UO-:"X49R\5^4S>+'1VH,]_+9-%L-.,
MZOHIWAN+WQ$#L^[4F\&[,!OIF67LK71*!MPX]VSAL1$.L2/:;_*L4&"W6859
M<FV^HKL?'2DGWV #64;P=];KN^1,!KK[TYV">8,%;5'WD<M9E?[Y')<)0H ?
M,C5I )<"<D>7[EXA#8OS)[*RA<^.KI/:BV^3ED_QY^(P9N.><^+J/!.\%C!#
MQ\&YBD_ U2E^R1Z<\4?5.-"-W!W9SMGD,7</60>"!74%,J&.'O@E@0) &HW"
M[V62N8!_51_BCWAC2>2VUBT?0@6[VFCAC8C1HQ+^O,9%I^3O_7+TF0EJW-%+
MB:9>K ]DJ:TJGA4[_ 06+BJD?NW?CIS+?4!-M]/'7-I'222S!58@S\Z!%H8E
MAM:UM<>TP*>KEVLZB":+>VMEA?]0V"3)=I. R$4>BHS&F7D.Q10FQ^_;5.Q\
M0("B&FQ2>^B4>>-I3*LG+K)!F!L EG3_>M8UL*.WWKTD\%QWWO,& %K9#-Q]
M;K-O^X5/FE/?Q%:..JF")(M[5[U7(6IU7?[$08V2"G7N=OVD6K]K8'XD ^>M
ME@(-TASS5\&Q+K[%10N]UW+68[]0O]L!@;=YC,S^QGB39;(<I_@WD94ODI/B
M[3J,,/+Y3.(46D37M7R()YPV&6X5KT,%.Q2$E@ ?"/HJ\?FW<1AZ^0Z:XKL;
M_VAH_%'>VSW&)_^$E20"I4J.X\+E*5!\VV#(D8QM<(\7L,(F[U^KZP^V^,Q,
MI@.-34?K_PU3O?#X= 8# X/\=.;#SH]&]ZO(37_BW7%F0\OPMN#Q=5E!JA?5
M>T1?XA^[A "LF0&+]9X/>&7D!!<ZJNL1(2--P0[1PJ&'G+RW&S89*\6=S3OE
MT4Z(AV@B)MF01R4?$!.C:MZDM3YN/'<)?F4*WCTB%-/2Q3M@^:7XC$8T#E!_
MMG;JEW9$F!/]\[T%1V8MR-1N:Y7\H:$JW0[3^&,'MRG@3J# .E;V>9&#Q5,\
M;.D&@'\#AD$$=M(XZL-PRO=V&L^^2^B(,_]VS6XY7,U^V[Z?'56D;A%PW]\,
M56^3^AVU1D\:("6[5BIV%!3I3XB-HS;O\ZQR>#S[OO>_@*CF8_43J=+=2WKL
M5CG_BV'SEUSP\573[<6(=+&(OJ>_"NRR?8;])I#=O>+.5Z(;Q98YFWWOR)];
MS$+P1T>6>;(I/0S/TO(N[>$UX^G3KVI:1P5H?#X\>.AZ61.S]I,.4RP_"_IA
M+@VYZX 10[5CV\E OD2M?^!M\(*9U$KF00K8*@>QOR]U'V'V\1%X+4S4;_ZQ
M(FQVBJ\I4TBL1G/XWY/Z[=(W.VR[SOFM5O_\^?8-PWZE9Q5]<4[Y=OV1DJ.&
MU_<KGX$U@LFK6)<JWQET=K5SNGUZ>:>(?J -""F>27%>W[2:Y'LVP=(I,VW;
M'G.WRI'KW8OGO71%;B0<F=Y5TE<%-X#EI#GKZT"V&\!HCZ=1(&TL^3?I\(AJ
M"MD3!_L[(C2)=RF&LHG%2P"^%+ZXXD5MPC<X@1_GS@CP20:WC5?<WT\#)!Q)
M;-?P(1(Z'8H=V^O#W%+-EU';:.RUW7=S?VE\S&()S$G6;K%5VIS\KX9-Y+@0
M\^=UR0@%_5>R"VB)149[?S6)[@?3#P3)-Y)]0;+&M!)C\,GERDA#+Y]P)\7Z
M!3 AD[7DTH8-@0'!Z$/294_!L+;'$\>-8J K4@QHPR?^7SU:<O,M<\'%DEB=
MJ_16<=[1#8"#M=Q4H$I[OG(6(:O0Z>N9G;NH&_J@S!0SJ^9>/,/9:9^$>IMM
M_VJ*#OR3AW[CB[E1K=AD52\YJW;1+K"A17SHOLZ]#Q'!<GV.1UKS88%/6L=%
M=UYNJ9DZU1W,VZ@VI CO2EDU>RW>W]:@K@5A8<_0W>^V?IGM3-I]!@XHI*]Y
M6-,Q:DQ?<F3:19:E?ANJ;V_%UZ/72D7W#X)O;WOO??BM@:M#Y)WG63> KAV:
M:]36;]\W2JY\#!6'6D3KJ<(R%DKW^#,O6Z()8B>G\3)=Z1;MN)"^-8M?\';H
MZQ=Y]EUER9:I)7)XNELXHB[N8B7&@+3*@>LTI;Y5J[S.;I%3PZ\_;9/("4G"
MAOX[SX$J;_13Q)J*_Q,; =0>3B:NHX?1-P %//>@&7-AZTBH_T.!'6PZ%TX&
MD_B"F$7#?B Z<5*#SP6ZC$:=U.]C@#T0$)5+!\776)Z)%WFQ ( +X*A2[YH1
MJG$I=Q5VKB2>=A+BP2[R1_U'-,VC9I>E6#+>(B0?^&A(&M/;J_ "A1&+Y#FE
MP90)$>O*O1"F7C)TF#]2&<O;&&C?\CY_.42E][Y874^%"O!?.L$9]K;<9J6X
M ;0%9:GHS]P ^KK;]W+6](PG<D2I3P4[R<^>R3/< *HXJ\+*_^N'<0LOFWW!
M=^V"^/E<-#K%'XH30&"'1)3E629RD;8M;30'NB\YV$LM*LQ- .2<BZVJ+4$G
MD?"P<P5BC#EW&D2^EDG_F?H,K(.>*?:13X-'H='S4SF&G3(W4.T+**,!+A$?
M2R\6Q(H' I$?8C4JG>HV<A.\WX83*747AV%\(S?]^7&6:CB^[UD*;] TDU_#
M0 -@I>EI)_UNC6>+!+]'Z#=?^"F$LU#MMTB<QX86!B0?;B?TK0;D&9]I'@C]
M58-HKLH_T@H [Q,5C>7/EW)Z0YQSO6F^BX"7&H<E844;$]%%R:B#N:MH*X;O
M/S[.[9SZ 1OA=K@0Q8;&NOGBK?ISS^7.!P$Z?NS)-=62=/YK">3.?9(]ECCC
M[EG&+DQA;]:)MO&[)GC<4+.Y]/0P36GTJI(ZP#IGS5(&=(JQ*,?R/]OUV_%[
MA^/S_H;Y@89QJ'QL_L8C\O6MSDR C$>5;@UZ.Y 9?^L)P<5^V]AY$\_&ZM17
MXUSCG^>;[]X1.20887:/Y=7 YC(GMC5YP]N'VN,SA2F3=X#:?A:GEPD';46Q
M"%R,6J2L#.2G0WI8?L%<-[+_!%6D44F,8F375_7Z==8JGM/77H\+".V+6=NO
MZ?)H^BH>C,N*?PV\KQ>].QQH-8VK>HIN48& ER#A\KR3'LU9).H78MVJSY]R
M_SDSX2$-D93YPD08ZVK6=%WK@"6/TX:!LOVEC7(+OK$UFK"H.$@\QX@':YSY
M^D6FZ46M:"H,G18='3\W3  C+MO=X5-H1P6J(ZU',I8MZ6A]^SK@F+4+C2C7
M,F=T\<@?W#P)IA"!S\B7CRIQ/$U.K\\IQ+QX^7[.C ZU%>AUQB'EOS3J644R
MZ3QT>\KW(FC!5+_2CM<+#E:U8QO=7+JJ3ZJ,\5L%%HX*C^H&^-@;D_@$V!K3
M92PX#SJ3N*"R,;\O/'<T1K_JZV^.'XWS7]N\0";ZMU(&UH,%!YAUOUZS;62S
M3V9HB4O7)Y;Z6/A[80JKOA_T72TO!RN,6)NV,[6HE4$M.ZHMUQ$?QY?G5"C5
MK=7.R+:CA3C@KNWD.RV",/RI=NL8/(=QZ]3H25WPYO6K$]3TCQ#&%$.GS*/W
M:^N/G .1+UBQ,Z1=;)N/0\[$!.WH4%_U9V&L)2\2DI[7G^@:KLLL5G7[@5@?
M80:PK!0."8ZZ/E3.]<@NF=1A;_]V"6:I'LM67!V#0K?"8^ F9NB/0[I7)D+7
M'J7W;6E L='F46MJ<N_X3_]9:"7E$G=7%2G>LK->^O8,7"7OSW?0)^Y0M/]Q
MCP_[*$,VR1VYLUW9)H#',!OKM$\X9:A$_0WN4-:-&6/NO\]4NK:_[FO82S5C
M+'C:[!5!YDF5(V%_NCNB>,OT/?RLQB@GCRF/'9!6^I66:5N^PW*?FW!./(()
M=]GG;AKX$)_B4^7_&E4'C&'4"_LSBZ)[#W0E>+N2CJT]<,;<N0$D6@0L9)EM
MCO2:48=_]C>N &&<:LHL'!"HD2A>U^B5Z14Z^HO/;H U2=@.L3TLD.=2??]J
M8@A4NE5"%&;MI'%12N9M34@0SKV!BM#[ZE/1-ACH5S7ZU,Q-*^W8,F:X'A(=
MR!B[:$2#Z4XW>!>0K6TF\Q+E>!UZF+V$\)W$!76#&3LQ82D.?H^ND)MZ=<E#
M-H]3Y:7)&#GK7]&15#D>,+)23FW< $B<_8G<K?QE36B 8DBCR:D"V^_Q;&P?
M8MW14DQWA'0FSLU[XVZYZ:LT^.R1.\B:4]_].[WU.CE"MS,\//REN<"UX]!L
MD+GR]$A26_U%UGCMQ0V <+R%<JF9G&;.T<CK1#H[RZ]X6P2X*73O$T%M2)WP
MT5YL'@POV%//(@AO;1K/:P*"@,GP0UM#PZ04^D]=3%4<B9$'5;'&QM</<)\L
MN,;9^:^JBP<+WZA"$^E5;P!^10JS8IN6CRYE9047LK@U><I%A<)RF%<@:3<
M?36LR?#CD\ QSVETU?$JF'X$XR>!/-C S^_RX/,763)^;JEIQ.F@Q (TV"FU
MB%,<UNIX?&F7K6\ E7*.2:<]58_,H!!--'"GQL21EGCJC4OP:,/%],1WZ W
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MOR0BK:JH:T(CFG+6KMX?Q;@OQH7717BH0.IG>RI>V]8ECY.+"C$3S^S.:
MY'*NQBW42T,B/0CC$Z]Z3&A8[D>U'+L2Q17-ST>2 TNXD57>GA;NW'E[>1Z\
MKG6YZMBL4TM:KNM?Q2@A?1D618[J(6\+&D#@V)S0;\)KKE\YXR^XE-*;S OV
MUK>?P/0VC_!!5+ZS5'KON>W_JX?$_U[_?^61<4R%>BG[U__92IWXJ-_>+!RX
MT-CB\JV$H7R3OPCQ<\WILK(_/]W&[?A>WN]@QIE/4AE*U?^PZ$^BRDB8#:72
MTW_[/RCD_W#9 2!4IA^?YKVXAW ^W%9)F9+-!'>\:P[<#=Q[X[UEQB(Z+J8-
M40'QTP+!--Y.&B[)6\+V^XIO[],-*\Z0J?)Z11:+[P1^+2GT\Q2ZI,26Z][#
M.XZH(@=;C!96U2[&A:5L%?2#"+X ?^B]+EB>*6Q0??%<58;H_Z'A_]]YY;_I
MAGX7T^;2XUHPI=4'0'M<F\/RO:C$+\FR9.KEU%F+CRAU<62)XFD5TP\RGM>G
M1-<*N"@RE=YU(U'6-MN\()Q6?LT4':OB5L^BL+_S5Z)F9M,(XV&$$)EV;FN(
M?"*8T,$9_W+FIW5TICO>6'-]S$S4*XJAINA?4L/;5PM,7E6,R$ :4+WOHPG]
M]QONCB&*B3KPI-DI_4T?SH15??^6SUH\3!2OUIA7$+#VROFD-FO-#<L A85K
M[S.6K!)HO@9R-UY0$/P4(5ZTLUO0',H>*]=AF.$>UD791<3;Q\E$*(;^=J2E
MSF?;A/+X9]7V%,R9L$'M?'^=@_-RJG\C'1>VSU*^:/YZ$\-A[C"8KV7M4 @[
MTK9'=D$>[()K.E<4?(39ZM[<C_Y QH"H"PKS+0KUOO?+G.-M36,UD+<.13<3
MD*7=-<030\%I:MC2"6 7$G_>T?MBNPJBT.5Y;?%Z"W3KGR#O1<_S^6Y=<@>&
M*U2XV+:^XPFJW='/2E:/B>).T0:SL<_P*T[7@5Y5;[Y+Q?PYR_?_IAV3*>8Q
ME5L9!HVJR>3FF_=Y\>AL?,IOL]WJ)=!6ZSGDA&MG./M JL$SBPW.=5D8K6JP
MJ@3TPO71530KA 5R(<:<^-A37M<'T'2>3.LV1)H^F-5U*7R#M!5>B6;N44M+
MWNM1F><_OP%8[L_ODR):G=.#.N2>7D*PKT-7@BC7010O9*0FV$G+;@ >B<V?
M_5B.VZE*19_S"=2\WJ0WUU$F' V9,0Z#UBZLEOJ5;QRLST_IF3KX?I(."!.P
MJ<^F(3C]R_PDI9R'YP^VPRE)+D#IH@MMS$I6M+_M'=_E\RS5265"^%[\^[Y:
MW[P%GA%)NCY'MW%^&/J2%<\*S:](" A:"+)D+SSMSB$U<Z0Q:I_V]>_$KJAE
M\S9$B[>9[5J+[!%(ERU5FKC.P:!1?19,^Y<,KS&QI8[5FT@^<>>:4E-OZ[5'
MF4Z 8*#DLC<;*P]*_@DTPPA'$UH9-B;:W$H\CD'U8GH7:NJ'+E('N&J)9$LM
M9]N$5$4.C8&0_0M]I-6^ 8/3KT%0@:ZGJT>*!-25$QN&GV(CJ/=)P'JID@_V
M]XC#3J]9]X/(\FX @GW7)$NCNTLXE@C!D_"4BHVJJ\S[K=,>X=O_ME;=#ZQ)
M*J7?P6Z]^GX#(1W35E6L58Q)IISI<XNA4E$U$0D)_;V5V -=S=EW!T9UH1D\
MYPJ9:@-B/$I6);166O-G^!(I(IQBF4*=B!-TS&MF5EL%^^884BSV@?@@31H4
MZE#V<7^%)OLT7^0G%5)R _V?+E*;//7I09;HLQ-6\Z"J+<N-=)IK_OV5GFX7
M(#Y$/=G'5GRL-Z6Z5C:?/AHPQ?=2WJ)EXN2:?4S 4R9+?-H$:3L!_B*"Z?.(
MX7OER?=YQ767=Z2OR^],K+@E65N,)NBQ0*GX4'<4].ES$!V1B^8O(X[/4AUB
M4>#]Z5YM&?-Y1Z.7FX\WC.N_O\%$'_#.:G_F/OAKQ<[H?5E"+KE2V_T?9P%H
M>8C<988CCEO;^77?P7&0<(&U6$;=QPZ40\]^Q_?X,8I +E()&F>GT7#[:4=Q
MX[>Z<K"5NM'?>TPU:B]J>@>Z>!^[W-LEU]P/BI GF*SK^'A-@^ O,9TV,5G7
M<G#>98<6"HK6B@_%E][]4.L>,M>\$Z3<L%_5P;M#^2K2KQE_= */[J#4X$0.
M'-1EO.),&![6==:6V*]':!>N_=-#:<C7WP!"KGRS5-JC+B7<'3P]P8O,+$"0
MH7%#NLR_M*=&Z^8A5HK;VF]1@4_QQAIUX\[.8LWT_,=:7\ .?"+Y!3&9E W,
MS<:R]2Z2S.HD(VMXR"*B:;P*7#3.%U0+9D,2Q63-_(HJMQ_X:+:@TB;.7Q=J
M*-EQUN8TWG%+VV9>B?D!84M:31,[$#'&C:&A[8XWR'+.E_<9)+QY8OJ=-:XY
M4!$.7NU5>,]33RIG5#LJ)__BG"6E -^L.O&I_JOE5(>/Q_MI3.LR.=^?"F/?
M>[.(YQA?IMB%QZ^2;X$SFQFYRQ5\FXW&P<41D2WZ<ZJ5%;0^1!K#2M__':VV
MU':UDT".LAR';";>-(FZF<R^[''YMB%6YU@FA-K]F_$CFRLNW"JV8!8ESP#R
MQOAG&PZGT.1[PMYOGHJLQ,F_C[+_O#U(]-=T6#BLUR]AS.$*? ,@V3UD\IP_
M'[L!_+X81G=9/K[D7>0%TM?M.'=Y'C8!%?D[.<>3/I)Q<'M!AX4SGWQ_ 6&$
MCFCN^]/8Z;MSS6YO0$!V5/$5R&8ARQ_JFT+WZ3D_B^Q9^!5>BJ#S4++\KCQC
MV]AQ\ Y_H9#YH$(&%5&;:J1ZL+K&TV3%E1H:!3] SBN<^!?O<GQ^E_&?_8 0
MC02_XIC9$ WAZ (HP)K0/4'C:.'$K6:Z'7MKZ?DN#P*-6 3> +XV=WV>"4?7
M_? S$'2+\:/Y\';:I'WHX//\<^YV*MW%&\ CX%2'M\(W#RB,6YE/1&Y;,X'M
MJ18O30?@^TN9[[SAX=BAJYS@2PF'>TAGSQ@) X:>97?U#:+MY<: <2?;A887
M/>0S3&3_2+"LW[@AU+.SYAMW+H#P!)YN"'>*(YK2N7'ZP.[*Y!5C^6.-!^EF
M<_.H^7+DRJI1#KKJ#'1X()>BC1(=TM=*/1I2'<;MY QF@==,'VJO=VA@ F+4
MO*L<:%QG-7S*_@'['-A[7,9G\NZ9_S)\GWB0V/"!I9$%'K'03EH? L.'G2LZ
M5<^UMHC'=^3,FG61YCWMIY-IZ?H2WU\EAV/MO %0;AGYQOY/M+QG5%/A]^\9
ME*)217H1! 0$ H(4Z=)+I'="4WH-O4,HTCL(" A(EQJI05JD-Q&IT81>I1-Z
M"6'XW77G/W?NK#6SIKW8Z[S(R<DYS]GG^7X_>S\G^>[!LJ+Y?C5S3L<!Q[\T
M%G2RZ.9X(NETOE'6+/JQET\67$'!H=G7'UJ05Q.XBCJ3'90!+D6TLGQ;U @5
MK+Z+I$$^[H!RCP9?H@07.:P[]:8Z+(LL0M)?53D>6LSMZ3>FG]%\DN1V_Z1B
M!7:^?Y31C6_#A*2U72+U7%QV@R\W!CA FL4_0=*MN3+O9QHJ?U*&O7K0"]C]
M<D+_8\P+)W@!_FKN+W.TH+;'&I2DN:G7D3O[PC[;*EFQ.8F:G?]:+H45;Z*^
M8*VILP.QA(.&J>AW00]E!?I.YU_UM=%4"_66[9C:[M:8\8#-!]F9/\V'E9[,
MO=I*VY'WSU" [I'F_OJT^/>O6&M;XDT><_"O4,V8.MZ?.-HMAJR*E=%.9[W)
M;/7H0:5(Q7J;:(>$I2Q?'6&/X? CO(_WO](/.,%B9*AWKF02@NXOH,PMZW(X
M4QR?]VV?[>$W$*8M/&]1GI^):$JW22?VU-#/;+*</;N1N04\4S''(D WJ)L%
M^Q+_[,%0QL.-&)^J;8G:RN:63Z;#:R-U"QZ V&_D"]UW%,[TF<S) >NZ;,*6
MI8_ACYWH9<EC)[Z(59R'>S'/D<[9E_O7<<K&7,W$]$+(_'U[KWE,3O+5>2L-
M-ORM.Y)?T$\WQOZIKC_ZVZ4K]& \,&)U.:N6)3Q8VKIB$:Q0MW45-U-7JG9O
MT,<=/<I\0/4YXM+0 ;V?3(0/%#F]!0"ALD/4)W<,)"TKT+599NX?H]SX#=[9
M/G/RCZ^.\%UKUCJ-N/+D7T,NHG5\S)\G.J87)6_:C[N&ZQSU+E\2YP17MZ)'
M/R3&,1)]8+](H>Y6.ES5:6@^/!%] I9P.(,?*\*]LF4AK==)'^-HW^]GI%:]
M82<V1A82'I3^1FJU=#1&[N9*%Q0Z#&D=<*AA=R(Y=<),Z/4^BWGJGW!9"EQ
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M$)ANFE>?TIJQ:9TZ.<\IH;CYV&/!Q)K:ZB?8F#]$])/H-6$G+AZTLH'KN 7
MS/LA?ME71[> 5P/%&*-86+!<Q;AC#?Q/,\N3T0J4";&#K_3G!SUV?$8>ER6>
M#]CI-Z7Q5K7H=[)">6=W=YN]&Q&-N9/,[(K&[&G-<IQ3[%U+-MQ"HVU"1;Z4
M?2<PV^+8+<C.?UK3_4G;Z .<*Z[E\NFSFHM1<*)36U/;R9FI6=M:KG+!UY9Z
M<$]]'3++<3WN4*QD[[44)GKH7E=XK=/"J\9#I2S8ZU;'TYV\7JX1D]J:!%=@
MBS"1T.[F>]\EAO- [N2L(_@R9,9R@W+VSI\,W )*L.0T&+),KU6!^"M,C,)O
MGVIIAAYF<2/CC[%%!68COZK7AN@C/G6OD[L<]P,9?TC<"U:;\L[7TY@2$?DM
M)='@1*OW=V!@>T7E42WG$N@=F^?W8< IS+?XHQ&P]@9RU9ZT$W0+ (?&#X[E
M!C,,P(K\ \7:IW[EKUI2,LN#9.O%"JS42/X*7>:I7[HK"ZY'1B*3@UB2%F0[
M#]?[SDPU=G-#YLL+D,NYQM:TBNGX'G'//@X9.?)1\>.MAZT%45/MUHZTW +"
MLO\]W/&[<89>$,7XY_4O\"9+>VZ,&XGN58R6;Z6"Y9R):\Z/=AVCC2F-*,.;
MF!+=50(7F"Z**A?]BPYDFV@TJ!S]VO+'/C>^V7.H=R5FQ(\S%1?JY9E4=0^X
M'W]>Q1VXN'D!.YX)Z5&?160OXYRQX[E=%/XI?:(,FI%65["<VN$J*3\+IFOA
M@/B9!+7G?9\L18RSYIB^*;0"*D0\QU?LVH4#-?80L31GRS6P4W-+4/0L)PWH
M$7/64M1"A1>K57]AF"?>YK\ ;37&$II'/RIY^K5D/GB2M]9HD/<$:B9\!4'M
MF>?@DXK/Q&CA4_-#[+]\>=_N&GC](L03EH;<>-\"I.4<#F[<_'V;,;)]ZE?X
M@78-_$U_7&KUS&: -+\)6O.\W%2R7=B?ZO&K/2!>BGY-O9W+V5@CUB-^&A*"
MDE:79(Q+G*TE21YJ_^G)WX/)XJ;^)O1=YK.1C]*3\Q+N.O@EOG<ZI*S+?M2"
M 3-;6^%@RI_SQ3\+-/IGHS%:O[6M.6/OB5D;O:H.L51:M>0+J.#+OXQQ/VHC
M5QWYL"8KLA1;@>W24SM B.A'ML2:7)^:M[62E&4S"KRIV]U^P15<X2>N5*"%
M&2@8FKW"45-[XW.7E3\NX<OCL5+F9=NY8C$437H<+0V='V'V#.8*KX_K[&2L
M:W:[2UT"U/4#;)@^K\(.NTK@VA?5=1HKH-[G97V_$^RR")U5BU+6W*,>:GU2
MIW5'_;")%A?9]=8!ZH% %1?H(_B*2!ND#2MPN8ACNNQ50TQW4!>A_LPY1RJV
MMDX@6A(7;</W15R5[;B&+DMN-A8_4NMLO(OY":!N7('0^ ^L+();FV?0*KD]
MS*(#DL; 9?>KS($I5DY%ZV;%RDPFS+17H6]Q_LPMH.[@Q/>2D^$68"EP][Q-
MK(A:L&/T_',E';!*P+%V_R^.[LIGJ>02=,O'_'"*L#W=&EK\E](@?8F*?N)_
M:S-LD09Q_%,6N2(MC\MWP,3&HZ,(WJ,<J8IN-_=5-\&T_8_Z?U'(6T#,%!9!
M(RUP$W +R+U..^;,7MGSZKW2C"O:,AISK%("YFHY2J56MN4>*=T9MO*H4H?N
M3Y56&("RD):14]O>M?]47X7&-%E])=393%4XJ"]B205BC>>/>=J#V7"C2J04
M)_*8MWP[H;%3=7P#/ =C*(^/;B#GBX=2)!?G%N9<.@QB<=;( E>9&?8ND(.Z
MZ;;?$SYG$ELJ7@"CA_+<:)/-YY6V6ED3S!-CK+KJ:72'ZU-9SH'UI2@2/U[7
M#56 0;?VSU:2ATP1&H&95"#]O<T[/-Z_!?!W,S- KG"(\>\K,G@81'RPR2J=
MZU/?IBF.AS4VZ#K#WG>JJQP5)F8!.=L 5H:U+Y@[X?A0+$NYL,/9\_S;=/,?
M(!O87_<PCH&;UNWGR 8=VLOF&UTOOV9H7G&<T_[=/,YR-+4?TNU0<XJ^PMX"
MR 93L,]Q?R9$O@9+BGY!YH86?I'S"R!/#^OW>]48_(%T\YE9?M]:JO*K^,TF
M6#S##>Z[EU_IV-FUUF[>GNI6"H=N!RG-!-/;^CX84UZ.9[D:&?DS?Y$34BH0
M&#V.0:S[0-XDYUV&TF!/K\<_^<"HG;,9/C*T9*X\P*H+F_-((K_'<XN:S,VK
M/O-LER\R7CTV)I(5D,RC'P1!5O>\P8YI.Q*'DTT)[0G#P-/!H!>VK?'<O_L?
M"P9D7?_]V_U([#$+X(G%L<$I+[<(4&)[X)0D"RXH+/3E?5E:.+X-A0K15_%B
MS:VCR_\DX84[N/INB\0*KHD^E9GA$TZ)T?//,XB?WLXZ9T@ND>R+?9YD/<_T
M0/1FQ28%+]23XAK)SM)/3C7?6Q[;S$Y8#1RK2A#/79 5YR\CI7\<P+?',,CV
MS!US1,X7>,-LZTR:])DFZRL[/$(D7ICHF8$R !NE8> S'II] QV5=[ETN681
M<"H0G/5>C.UZGC[8YS>AY 7U<!J9,KX/62N.9>\?Z$\R0;F0_O61?P/,AAE?
MI,"<3"'=Q'ECFB(M2 $^MN;TUQZLH+B(@6[?C':".#JN"GJ86G'Q<&_:)=12
MZ.#@N&1C)^6)DR^F/&H9_4E*J_1/Z_<INX))>D/OIB8A*9V]MR]-@C/)$*\Y
MDJZCG7T'5_A+WKVKM.!O"P95*)7+ ?M/*'KJ_UJ,LEH"S?59E0SGNL^%"$:?
M?#9JT]$\=^U"K$..+HMU&]3N)ES)6X#%V\LIT$7:"MIY,V]OU60*K9VAW*AX
M9'>M,84N387G,0G>RTO1#GL7-PH@=0LVP PT+O/2G;2>5AH9?YOL0HN@\X*@
M>P_%S>M+%#BQU!Q5^#_8^260\ D%Y'_LA73H^F]GE1N_6P"0_+-(2.B!SLSL
MM0X\?KWV5,%#R 3,E<<1Z/K-C_Z^UWW/"_KWA"\%,W06@I5F]X/%5Y5"3*7E
M?VYE8=##5*ES'UO;TDH>17-;_YIHY[WN>;3JZ\F[)<'M*&)_XVA_CB.AGBDT
MP/FI_$J[*-O=;)EP;98,\>I!!8_ZN(9XN-XOZ79TLLEDM\I3KRE0)<.S4F-L
M>&6VCD0]D9MJ&IW7=M3IO<EW# JL)M%B@J=+S_P.R!>J;(2,IA);47A%GOJH
M>%".XZ=^=T]_(:\S\A+?.EKW@<Q2Q(OYQ;PQV>-KY&4<4#RX%F?IA[T_(,-X
M<0LP1."F.S#\)1P2 E'O"M &WX-L;@&@-LH6.A>MMK2JSZST0F2DWI:,'3I?
M_8-Z?9_\:_MH&GP\GGY$E526I/.I%,(C+*_0_>@"&$&;NW-WGQ[^:PL-YT^P
MMUUWG'HE-1%GUO1SD,]\U,US?O1)6O?0"EQ"-[ 4 9/=^;9:@CA=O_&3XEWA
M2O Q>,J2W&.<;9B@"FI.WQYXQF,^-\S< :R/O'01&^G7/QM0'=-R7-&B*J1\
MWN8?#TXPQ+R>7%8#LMXS?A_SLVU._GZS>JON ZO +)A;<?XIXK03>1E0! 9!
MP>#CZ<LRK Z[DVC7<_\,&]Z0ZIB6:.ZS@.,$2:/,EM7U1$E:3_]?GH2\X!X9
M00PD3DJ++-QYY=F::!&WJ_QCB.<&BM?;'M6#+T\\1C-[A-E?A?VFTDU*;\0U
M3V$[!H'F=PY5]M@\A>VB?R7?N5<L]&G#I$AVTM^'K98\-&WMEVE4 \D1XJH<
M6?&B*I?A=-3D ^.QM O,N<Y GC,-F7VDEMARKNK[_V:T:E)';'B;L@R(PP+<
MQ9\.*O&:FUPF.>P'3U_5P<OFM@OXO[?E@O-J3:4IS96L&TFM7:F"RHX*M.N_
MO')[8QY_^.I[M.9GAL+89@25OZ./1JBYI$FD0D=G2[1XK2GO<$*;_+)1H.K
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M1F;K*DBJ]'/7.W0XPJKO0'=J$;(_5CHL5W;R&7\P4$\CGY@N;!<HDH9(]#L
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MM^6GHCZM,=6?S!?36\>]!O;UO]6L"),3H.:/F[L^>T,=3A.^[D46Z%CH7R&
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MRB/Z>#$XPJ&9#><Z)7\+-P-]'OR&ZRU5@B6K8.(;[RUF,$_Y[AOYJWK2U4"
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MJF-.GJ)^0MTY)GV9]Z.X<P#TAZ-4]SU*-]K5:SJ^L><!N=W6H<X54-&R<,]
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M0/U:=-'QVG@(N)0"2VIXCP&QM+Z&\G61B!*O[75&! CMX<NFP9YZ)H8?L[A
M\?',EK$\?EUA>YV$Z6"92P(9VNP[&F(U:C+Z. :%EA.RT2NB75(/,2H>1\N'
M$-3S^:S&GYM-'SST0BF2M#@V ONX!>ZZ/KB.+SNU[$UW0$_M^@R\3P/F8NF
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MW^=S@C,FBM/F'\^^U"H- +EU:3?IDSX?/;,EW2C0?=:[R-OW?"B-*BA+I>2
MGB[3Q"W'[D6+SC,(:!"]0=ZGT;*@#RP91O*E/@QS6[HJ\?6FHCB.]WVN$\+3
M)O0-5F9)Y5J2.C&YC.(#+$06I3S[/NJ $,SU+#'O.FM><6RS=4)N W?7$:/1
M^I4$O/>W;\MLDZ2,&Q9XG++R&:<&71EQ$YE>@*^)1TWEP+.F)9M$C(-MZYL
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M@$V,8^IDLQGHG*0,\S#GVY26*0H0@;1>.R'Y:VJ^VY1/23&[. KE_QHAF$Z
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M+!9@H)WH[AOP^]GJN'""&'"G:=A4?![$<UFZ'GVC(-1$$7UD[2#MN:*H?PI
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M24Q!?,[O,#M7D47QN:W%1L:QC-5XGY]FC_'UGT$S:J@6Z@NE2\.K(MQIWSB
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M==BJ&;8RKL^0)7>[OX-(+\I7XFFV?Q4@"B>/I\PR#KG>5V:"ZGX)A_=46J$
M1@Z=[T1Y%=&BZ^$)&=LC?B-D/"1F58@59-]RQ77]FM.9C/7IUH&M\5?(U"6]
MXNR9$]4R7K,X7X$ MGK+&.4W:DOPWU'EFYBPE-J/0.R!DGT:F[# N75&8O$9
M*7$_'\\56$T82[7 C0.V0PEM>R3M;U&;'_<\"ERVUO=^+>VG"E=5]_X&*$"P
M/WP]B&)E$4'9^>1:O[&ZJ6T\O\5^NS4=)FYC.(6+P6IN%"VNNTR9DF899P4M
MW5>\G>H1J:\G\<X\[W 9L5KY[';UO8"GA>7M45+H5LQ39ED1P9$ 207=K(6
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MW\3[Y2"\A()G-X3>+V!,TJR,/C,Y;\$MVCB.ACJX<KF).#W4 !\?=94IR:^
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M)&4YFA_ZTDHXODF($.3(CC@-,Q^)$'MARQ71\EKKO(D0^=HU1WMF%J'(/$7
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M]4:_YR62M-Y#/T5?6OT-K3C*#MT[<#3*:(&<@T.@C_;W)^A.S-G; TRP8#_
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MRGJT^*E,U8JX$&$D3ICP9=CR0OO0^?9S5.(Y=V=GBF7O%?X?592F_YBWX?5
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M;MV3^O?NRBT^+*2K6&Q3R3B/"82"$SX.OP(37FPG$PUB,# 2CO$-<K]7:<=
M-J7?8QW!A,+YK69,Z7D:NV.4";Y+S476ZYS@+?5.UE]IT7U",3U3#!AG6E(M
MU5IY!N=9WP?3QX6/8X?%[E-HH%9^'P,!NQX*/LBO;E1<VN$)3_ #@G"HD">=
M.36?%8RWD*[_ORUH_M='06^I7=]8<&GAUO&$+$JJG5\9.=JK[X'.-S7@ZSTD
MDI1;U\H528(J::P7FI#>RAA93;@[!)DP 3"=$51,=-G4\/U*YIUUVONH]_/?
M5-P7Y%SLJUOI )5_6_11G3@NOB2P%TQ*,1)=%ER0OHT,*ML9]:8; F J<\<K
MS&E^LG<B[[9!Q/FC).J>A3&IIY3XT%]4(I >Q))EA1+IHZX&,&(-BV_H(((Q
M^%V#?VY]49="B3D3&JLZHLN3QC4FC?2)#"JG#OJ:=S2_+&.-/OX^<*GX'7IF
M':Q*JLD4M=V)]!X-M'505WBW"X/W9/:)L$6#)8]4W*UYS&H)*T10GOBRU$%
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M)!0SE.FFUQQ95R\%'PN%Y4\8+]@$:F?>Z,A097<G5O2/54JJ<@18SX-\0Z+
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M#*4QEL1&R-?0:ZDE[_O!*-=^\@)3#FC[9Z15I\;-2UO%V<V^]SH?SK(B@2+
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M= ]ZXQ4DT)TWN^*.SKPC8Q"I,.BM=OA=-FL%3I-6D+ON_()!8'=C$'&B'9-
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MM=IAVGVWO,VQ5>G;,9F8Q$+'%>'4;H33\S1[CL^^E%2#A'U:M.%,4*($R/Y
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M?<S,2+H5++4O0,U+M#XYK9%56]%=Z.3QC4Q$9-8A3CHOS,I!1/EE^U!>E:>
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M<7,I[Y=:[.GK0E@="+^%71AL<B7TL;WI)&08YV2/8L_@&&KR.G 1E?B#\L)
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M4-?S)>PG%!_PG[8(_SXRN<#]TQC4$=(5!)"XYTH*SL@^'HZ_EM'^^_- <3>
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MT-C4U=W3V]<_,#@T.34],SLWO["X =W<VM[9W=L_.#N_N+RZOKF]N_\7+A0
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MGS2+QC1XGS+2(O/B!2N<+9KH%4K'B=*I;B;ZN,O2VL*486M+;;1W@\04/\&
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M$A70C;M^SKX+Q+X-1AQVTV)OG:F'"HBJXQJ_W"RRQO%E:HQW=3O7-/C1.>%
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MUF?B[S>USA0Z5![V(V_<!84T1][T&8VDDK!07Z32-]8BFI" 6''N/20 +>O
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MWG1NYG!/Z?4;N]H7V&KYY=/5.+W?ER$SW1:HJZT!F_G1^<5PCIGRRU![^^_
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MV3N&,IUG_48E;<$=-V"=^XQC>+6UNU1:?.3GLK(7:*R,F86,#Z:.[^?N+Y&
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ME[9B2K?#5LC4PNRZ$L?P^B][[;](JX32OSA#:.-_8>TMP]K:NJ[A4(&V6*%
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MI\VFN$ #HS*/X_O#)A3S1=V?;#?,P@!/4E2A&JVGXS>CBA]3ZTYA-U]7B73
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M*J5F%FRS9-?CK2SBDX![QM&I#;8+OR(K*;IRUKJX_]W8)BG)'F*48Z!\E$#
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M@"9DJ,!^*/UZW/FL_6DF\_3 +> 8UC._YIE^#AKR'+)&+$;C\X'(QE&R$[>
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M.?+>>2B?WO?L)RU(W5^>%/.+2\T5^,?-+NH@L7 6K35O 7?]#S;"?*1\#^F
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M/]CQZ<X-%!N4*$(RB7A[BXIU>J5%Q)%T_MR QBJ\W_H9VU_X'TSD)O?+*SG
MA3"+YAI0DEM\GIG\+W/:8-+#3S/*<E00-/QR3RFM2>-=N1D.\.9D>4J?QNNB
M!$8YKM#/9,"DV?B^80LJ'.$ML$M'2E-AM8/;)31TBCUU%/3QVTOLF/AJ^R<
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M,M* >CPB#3)[2C#7O/">?LH3 ,^'1SQ-1Q._5UM!.3P[A<WK\T<HS_ @?2*
MP)UGY>5<->VUFX?3FB^?[@PLS6#G_(SS5\5Y#ZRI04?[0^U@I2P+EJ>6-% @
MS/)82#D6^#C4F/8>+/ JE3 !FYKT*%WXU7LHLY-9XTIICC!9?S]]:QTU5.R
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MR0>WUZ<]70]I]\\>PO.> %U*I7+1\@\\D"B14*11OXJ9G5@-XU\R =D  %(
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MT3CLW<Z<D+M/4<8&WS]/Y6_*GVN=_)0/O1RPVAW@ ;[RN \;2[6V/Q*YJ0X
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M&IV(>#43&7P%NQQGS2D!U>6'S<^IZ599Z]\6(ZL'G Y2P[#%[5_8DL E[D7
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M=" /,L@CG,'*M*\=KFBLIV1-84X'J_T$"%=@:_S@ E6IY,_^%H67N:"T>!#
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ME.Z^[V*LM/H$P+"+S/'T4"4G";=W8Q.LLZT\$J@6B"#]1M8?8-B/_DI1"S\
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M%91Z<93-_A_DO7547$NW+]H$@@0GN <:"1K<-4$:@CN-)$B0IG'7!!*":X
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M7.+D\'C/>]D]M"NU_I/%=71*_3K^5QR\A%E/[D[1YHQVKR:) H2H+>?C=6Q
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M^.G#WY&[KOY:R^6/?4>W<#\*4]2OE9CJPP5,<62R<JI>^O@ ]21=&[$TT*(
MUU2W.8W.A:(\C+)K'92</:4"SZ$YMPK)U,7A;FR=P-#(J*-@PD8<+HHOL=5>
MRV8'M9GZ$!O;A@A-J=EW9 0P%_'742@4.!]I(V0HVM&"4I**[6J)79=J5YWI
M\,5-BVQU;Q[7M)H3@?)M4-6CCKE0^1O%OV\J=K#U@+X0$)?W&KF6>NA<%12.
M9$/8\WX=SQF5)KGYF;M;Q2GVA>2S.+U_M85'[J7&1O1"'S7E#,&-MZUK.OL
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MVJRPQ-\WR_*O6E/]:X\6"DT[SNC/&R^T)CDX4"DS+J<59@&7G3UI"A4M03]
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MT$K[C=K9IBPLE @:A))?9Z=5?+?)<6*09.O*C.LA+P6U$?@G^^LGQ6%Q[%(
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MQMS,_6=K*/S9J66[E [W+,[&V(TW2):$)5_Q^A9P0B-RY"L_95P'D,-=67P
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MQ!?8^6M'^KV]1)8%#-*@79I.EEQ3&(KK.=H(QMJZ*$CLO"KBKRB==$>-PW@
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M+ 7B>OD7A[OY]?3>A1NEDX7ZOF\;XHBD+F2D=],R1@:7A)FZS7M 45W-8_V
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MD?E;_>5L.WLTO29EO<[82A+.&4D4:I4TT'J&4*"##[YN[J!U4/@>FN!VP/4
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M/'F2$#651V>"1V[!"QPP"]!LP%^(_D8_/8/7QH!= VWX[*&*O#0  *+K/C^
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MP[\:$&+DXP0R>P0N44JU:RV-BDJ]J)5E--H"CF4[17T@#N<@18!(6_K%QV1
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M,+_ )'W]$<O<]1F+T%=LLC>)^;4].*PO->'D%FZ3N!1LPNOLI_] ^S=D_W/
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M36!]N;B@7X[K!@W.C??1OQ/9SMO!+VG579M8;^8>TH!7]*)3TZ#T*Q]-?L3
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M%-K,WBY<*S!_)_D3$V5XECDF(OC 9.+CKI8Z9\+RMZ?<T45Q*0/'<H#DRWK
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M"C%-G'D,&:\?Y!*!M^!Q_5/QT&.1X>-+<7ZUJN15(]_I'V&V!,]"8;3?DM$
M%PYF\QOL%5V7D$? &L.D@D]J]9J)^F%O)_74L8?J81N>J\<1K:JEJTQE6SRW
M ;M.(S;Q3RE6=P;4 =>DB5.B8,]H&  A.7*MTM(U(SPJR*'_?7&%1Q4"$%)P
MT6$S^QZ[SR*YNWTWB#8I=]@\=R53$77*2.E#VT?3,1?+?IFR,JU0]!I(-5W#
M_V9A)3A@\%Q@2N4#70E[1$-NV]:SQ@;/$VR'J0 -R-QGC]+LAVFG"7\7X%:D
MN<Z'.RM,J1]F*)T*YRQ V/.;3$)H\:[SH)N?V>BM4N6$2\(HNE-=:OH(MW)Z
MMY3*300Z5[=T(Z:+9 */PXZT9?&J@R0XS*8^_'?<^*U!J=27A; YGYZM\W/)
MN)?S4RUFX0R8:;V4JY3-\:I1XV__Y"SI)(FJ31D??RE+*/_]#?@=<PME0%&!
M9/:?C"!WAGSG![QW\-1;%9_\?(DWRDG3<+[8'+?Y-T-F>T2Q7WZMW55HUY%[
MP']V<J,:I\;#WV.6/R?07'5!,;:EAHS9;00+?H2U(^U!KTP^MH#0T$_ND^5N
M>X#-7C@Z+EVF8O^=FYS3IH#GN^_(LZ*UZ%NR'H?$[<S"OA7\[(2[V>ERI;8"
MUQTCQ0@VF!VE'0PBEW?=ORXC%R_S/X.W;QR(JMN?9I7V2I9E"@P!ZKUO:%<1
MO*@+/B,H$C::=\M18HK;9&TR'':.8&!<<6)*UFP3HZ@U+5UHR&S+71[.CEDU
M5FN2,D+YZ2.MB['[#?*Q')%F-&VA[)D?Y"1\Y4WKM";ZARVA!6M;SRYB>-M
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MFG0GZM@%#_Y637Z&..->L?2JP )5AC*3I%;,DR>3-0\1O-;3<>G%@C,:.H\
M*WU]PO&T7(H&6@&4VSCYC@%Q(52?*"VCF051V/XQ=SF".W])SB552Y%%7Q='
M1-/*]/6"%=;,0_Z8D4^^_8H*'K!9GMW!,FV8[6QA644LQB1Y.)KC2.?0X3W3
M?"$Q?%SY;L& S<S(RTR^U0[:6,O..#FN/T WN(/\:HSF;OQ!ZEE02M^>;0LU
MSI^?T[^F3*N=/<[$_@H2_M"2HS"4^08%Q[4G&'SA7I@5R[S@4S/F/72SEYC_
M$"\3-<U;T.? CEZ;EOCY@\>!:+5\'^4V?XK%BO^ST<6UN EOU"&T$<:>#7C_
M9P[J-UNBX+DR'B)1;S$7UXEQY:-K7#"+X6Y]ZHR6(*F:8WJOAGBS [W9=W,F
MP/E9,Z[KS'0UI(4J%V@77RIMWGGXR[L^;<-:2X[,FX1P2:\9.WA5FFHD>6#L
M@PRM<*M@.Y(&G@ZJ^=O<QX=G:]+0"/;*#T5>J/71\_2&H[($8@.X YEK3I1#
M['[;"F#9B=7?Q4A:-0F2)JLP) +>QP][<KQZ_I69%J<[QGQ&00;%-7D:@5.X
M'T!GKZB>M)DKP&IQY<7!"!T,MQ1-%U3?\S3.?X;[W%6;[L0C%+>^J59 5K0G
MT=(@N;^*M4P6OY-V'N5L0/]P-_Y#7' 4252_9,6?[0LC#&L?]LG4U^[Y??2R
M?XI\(RUTS,R2$EFK=!(2)+Z\$*)TXKHX&4G)@N3M[-1[:I%P%OX=[MDD.:T?
M%0#?WL;B,4ER&BHYC,LI@HRF*XZI+AMCLLDG^D)S3R[JMPQXF-7Q8[H%AV($
M5H,I\2F<:$/Z:2>UV@C&[6OAIN!J,79WJOW:&9XAMF1Z5OJ6F)Z%X,CKR-7W
M.]S 28WFUIZ)7KP(,:8"N^NKU*; -F#S1Z\5,%RUH<Y<NW?U1Y9K5FGFW0NH
M0+B)1*I]X<(O^#QPX%75[0RA_/VZT\[P0<^/,-4 4]<X5STW=;VOZ(I9(M-;
M=Q-G7D-C=K !QM%)-B[EA95Z'A1Z6A)4BCA7A.BJ/7U7!:\-R1C1IY)O V))
MAS(,93:M<=WH&9@-:LE!0#?5Y[(YJZU,*BU1>Z/PH>PW3@0M?5^]S[ L5C+]
M1E&N=KB$BO@X,:W3B?<7;<#QE#W8"FUKNEJ80P[O")N)([%0-]_G!_6A4DRJ
M4AR9_[UQ_52)'+EGK$A]R"#JLKOOD]"3$,15$9X3V2[@<<2V/O>R<<-BN[9Y
M49*W/!P0U1$^DK7X7MS.,HH-@VT)Y>1<K^SMTKG/@G^9 <AZX:%TY*_9XE4\
M[\C]MW)!,TJWXOC@6IH#-SA]31*%SM'K(UZ<R2K%5\,*5@J:(<6B&4(F"=UN
M;YM$F%'3&D\$PX_X[ED%:K.%#H9CT2H-QU[MF0\D\])'4G@+?ZU:\!;F-[Z1
MEA+UV!W/*]'K+:6H9H'4I :BHP&((\7<=UR$('OO%H,2!<,NTMIFMN:.[C4W
MM,\#3GMWU\ZN) VY-^7:5PXW*#-GZDX"PNW*ZRO0,R#[G\X#'1BX?I5SG;$Q
MMM1YD*-/25/6JS")7JCKV3^ M-Y?+G1,B]'G[0O"#?8$XAG.@9"R4 >&]_V0
M5IZ2=@<MQI331A46&?T_;J(XSZ?E^?[^4F,+LS%/]\S6U0\4%$LB\?AGD#40
ML(-NHR8%-_8Y,GX$=+[)]4YWS1(GO[AO=#Q4%$VF/ -SK&>[&,3AH<:@!$5Y
M+..U\-H74^SP;2ND;RS)!^\YLN@.I9X;LM]3=5&&63 Z-?1.]6G*O%12%?=$
MPDIKZ/!P=@4> 69G$(^'N".['4FO;?.)VVPS]VV)KYG4SX\ [3W^@IVOWV:4
M*!7ISBE03?YVZ5[X--CFRJI8]Y+88#A*^8_PP)$K3 :UF2<\_*)CM?^"ICK^
MH&@%Z!;N:T'P_F78Z(HL"DYF, J&&+R6ZD67%!3,+B LE\64P58SQG V>(/*
MR1 SV@= 27("H ;IN:GY.W#21T^VH#OZ17]U9(A6-M"X5S..=Q$193W^DJC/
ML[G08#*8Y#Q/Q1'Y2]<:3 =7BLP/]Y7OV; Q6(S3S5H 6S(U$]H^O&(G3KVL
M?D#9.WI2ZGO;_/XK*CB& T0#!3(DG3U)4TN+;['O9RWD!\M*@$GE9.9/'&1R
MJA9(I8>U,FGJ_3.;AG&-5TBIL?_-AW9C)^D8KO:.M5KK_((0R/ (J33\ HC%
MSG?S2Z? (TD+;)6N8-!4T[_13&EL_G2''?0O1MAS'^?02&ZB/X_+VD.<@-M8
MF[V*20HORA"4&PFN?:*3:D[_Z8+O8M C@ WY&S*E^ BXM;KD0Z%T%YDD^*_U
MA%WW3L3!+]:8XLMMXDNF$>S_M]("->7&VV+MZ2F?BKF6Z.QYCG@<.S+^ A+3
MTMIKG%4(CYE=\F\;4='#-V\25_BGCEHD[:PVC(Y2#>N!T>\]^F+[)VB9Q"5,
MQB"^_EHYJC70UOJ:AF9HU-&^Y^R*][.6>5F@:3*X75AH5TYS$ZE%=2UA#X.>
ME")DJF/K0&'%OPO#^U+%>].(=H^9YG[UATG6 N+WSZOV^\2<[[[6=.2#ITUJ
MFBMK*GNC<7_5\"Q7+PXTZ%2+D/TRV3QD;0Q&(Z-_VS:4]VT..G:)J-AA@B"-
M0F&BU/RGZ9U7OCG/;*OW2.NONO3@ILB!_K-IZ7=L9X+:)F=%VZAH9TJ:-RD/
M@6T2$T<7P1:G!FT0FZMF/D+(Q>DZ0.JXL_T5.('NX*MQ=8+KX47<8,3P ?&7
M?U[Y[ZST $]$+4*R%*NTU!MX_@C@'6UCN(FZ_G3J&7IQ/:T<DF<8'>)<Y*U&
M-9%7'(=S5DIW-$2=$;?PC'50C'[-WU?VQG$EVH#G#OX)[E@XF;[_I2F-78W*
M@?*7I<*;-/I%L) YPSH@ZNX)@:V3Y+,,!54']US(J+]1KV5I6,(JU#.:)-Q#
M>@,$8*\+T]9T#GO"0S>GUI,Z1UXLR"?U$XSE/*LG_V+UXM6E_K-W<]!XA-6O
MNOC$HB?E<)43_G/*TJHF-BS;T&M"@?ZCZG!$7!\N\+=".UU;N,<762OCDGR&
MY$!T!G6&<89$D1:'W)3)#2YQ3/$>=22,YMS("58QA,A9\J*)%/.OV+W#B\GI
M"J!_O913V&5^Y;,;C"6@Q#"8]*&)CT AE/:DT> ODU!) /\I-(:/AL K1#ZD
MN]^^S(%MT<$A#QILD/R!GL]4@R HP +-.]"*PM-\IG9@'?1"IJ@^AS/R@@^F
MZP>NMY=ZPYPL]%?;P],JQGWDJW21[IB_JP7Z8DLJN./S"4/@ /[7%+:?FZXA
M,9<][.N%EY573[>$P"K2UE)?+R)SU^*_S97G0_9>VT,.(>T9HU&L'].=HFOY
M'%N>)S, R#)I$H)=-;Q\>T40DL_,3\,@Y08+>X+TII75@7UV]^?4)S]I=X-U
M_Q;U.@=^N-I[!\TWFCZ,M/:#@-:I?+_,O*F?;-$?R-^]N\H>*II?F!>)L(C[
MW/RIDD&Y9#?P$S&VO&@ECKO3S7$O[TW;%D&)C=9Y7QE_IA[#63+;=#NB_(VB
M5NJ6R@^EK8C[! SB(]@<"6C.:/818 >]!Z5L/V0,4SNF9CK.9AZ.D??R:MF
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M6^V11I%K/GA!=8\ ?!M#\?&*\K6)6B6-;E*'T[&"9GU% G<Z^5\V4H%.7$M
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MNC?JAPA!,_\7!KOQKXJ=BUM,PN>U%M:=8QKF,(< *GIW;Z-(P/X5-\V/ *.
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M!]SC0546QASF^88C'_[D<LQ75=J%:.:(NO#VID)#0QEC1E&HNHKDW0 )&S3
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M%O.J3\*K,-'U'64</M V&QK8SD7U6%D%+B--H3_6,[\K*/S<77GS^R\PFM/
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MAT].^WERPLUD=)_=JH]79^5[0M&-/63B^^JC8\T-JVUK5I498P+&L@1E'[E
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M:"-D$]8[HGKO/$I$S2ZRPG'\-VA_1_;_#%C@_R=D_P'LG[@0 &)LK'OC85,
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ML4 HQ[1H1];L'+3=/%W=N2T\'S^YP1/;A]%Q*V*+:AN1&0@[4.FF5_G&E7(
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MIM'#TD9M:,"#CTA)9,:*@#,^APV'?LL\=CEMM_UPX^/<-@R A&3U:O;P!3R
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MLE;Y/%$L1QP39L@"JO/% G9]"[Z!9";?'H @UR9V%*D*U>)5Y28&T,%"[<N
MEUIL)P L@<5:S,TOR(PV$UP'5CPADV\'T)ZMPMFO=+/Z5B(?OQ0WRYP524VL
M#^C\UO2SPD%P-E!(^P6O1R<SV?CYTJ-/WI/STVINN=(RA(^YE?DB#G'59*4I
M#'G.%C2@Y0)U4.(<Y>P@;1]>[X+R92_B#.&F*5_0:F$U@S:=Q:Q)O\-^]M%R
MS',<:MQU[KU$:06&2JGCL2;>Y0MHN=TBF=&Q1?I&30%8^(7F9,/+4U9 20*K
MNT0ODN<,302S(K>T-U/.*MR^G"ZFWIZE#==24;9)8/(@T\'7W[4KCX3QV6$
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M_+ZZX&(P7KH>3@-+Z@\:K-6\]%RHR]'QTH5+XARY=+G53Q78YP#%O1.SN!*
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M8"/07  ' <NS]7#;8#3GMAS;M*]"ONE=,5:VS;S% H^*XR[=CTJQ_01<ACC
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M(;(GN#%..(TP'F#!CCF7\Q5*YI?YNZ:(WD]4G"'LL[IK:%0.6=\<ZQ)OEN$
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M=LW)TPGZ@X=A^S_W,-@B ,^X19^8%V=FX+87R)$G?F^ZP[$X);Y,9>!X3\1
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M7CONF/LS<AJBG+XKB+J16_5NX[*00.>7OS7,=R,:3YR/ZXX*Q2!LD1$*IQ"
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M5-ZNL.%VYBUKALD%!5YJ;J5MM*3+:LMT?+5CXG<RF:E_X4O\C.5B'RP'ST0
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M<_K]UQ/5B<+F5JU*NDO7+\.O?KX;P5V(=WDD_0O/2/OWG1,"[<[83R")I44
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MV8J(NWE7K)C7\+.B!343(:SF9K']0MB>-';^K:OV5RH'-V7.UFYI^6VA5@.
M4')=L_@JJ\R&:X\V,RH?:619[I)V?0Q^/[Z8R>(\0T03W<K*>8\]ESO?G8O^
M]A5NZ?BB13K#&'?*N&GA7K)NQ'SX$'5#4R0#(Z<LR !G^<OII/^.]%J+]V/L
MGYR[=2]T=,7)NHE#YQ $7YJ0!]F!Z6Z;0JJ,]"JIX)6ES?HH)KH5CYRV7KQ1
M+8:'M;&:699*Q K[-I'RI]R^.?*" :ADKN?[\2.G#,#BSHU3\:R+A+8Z]$.2
M@8M*.I]7J>;KM,(YH2"17>\!KX-[ -HAL[REC_XDB_3:0I@NGW+;=#-'R4ZM
M,V&L;C\M5$OTV-]._,G(MAU)STMR)_QA]IXBIP+S!/? @&)S*K#%LF'R\4*U
MPPNY6[0XYGB0[U=KP$<%@;6&E(AGAWN=>G23U?< ;-?&F=U;F?JZD',OD/6:
MJ1&-RL.F1$L\R>%JCQA5&-_JL#0/XE\Z6F80VHGD3MN6#/49U WEMP9,X[U4
M8)-.HCE[@A?XIS"ZDG/HG<^*3]Q3\-[H6=T>W&P_\^2S"VE(X*C$#%OU>2,O
MJ* =WP9I@,P0NPDV47BMO,:9A1+W2<HI,>+,\DY;I7QR(_WD;,&G6H&UFI4%
M-(@4$S_Z=:4 A9%?C!W21TY7YILWF1TZ,-CI<\(7]9Y/R35CZ#/Z-TO_Y[H+
ML!,H87C/TX\LKX0TD@^M67@8FT'Y%K4)%<,D$T _*LZ/I,V#+!'ET21?/B9N
M@=TO"[29K^'JL)Y+9RC"QO2EO#R1L4A.,9]U5\O)UK]&VN5G[]+."1.2?1XJ
M24Z.A(%B9(=@6)^;)"DY?3!3Z@.+:S/W>XP5FN*@Z\X'<V0544W#'ZXLY=M2
M>J"6/G/@W"C\VE&*M5V7BB62N7*.8AKCQ$'QNU5J?#1[6%YA77>R6B6$9<K&
M<9A^62ET[U7L (=C'PBVLM].K]P>RKLBJNBQC9Q,<78-EU_.._\6N[QY703/
M77!=[XPU ]?FY.Y>D!8+ZE8MZ>2F.9 ?%A9J?[/& -O%,FE3D;A:7XSL[E*X
MR$+WQ_6.^&*V9D5RKEO?I$9Z^.OI>JUF$%C,-L9W@;TK!_D"S[%Y::>T%2(,
MDQ58,B58%X)')AY>&+S@E'SOT$5),GT^NF\JBM]004J0V9&)N6>VF=050\#;
MRY)CR.'V2:Z<X]&CE5KF&YC^-:OP)4[&;.)U&U3$5'IJGR<,OV7"IL2F>#$Z
M#CQ4V3/'SV],2T[))'">Q@D9.3STDAA@EN7C6!PZ+<S&XHC>E\</CWR<7^JS
M.IQ>8?FPA+X.I<(K\V@XH'2]5KN?:%"<5:#V;I)7)0"8]MVAK_3]&I]?C9>A
M=EMU187V,K;%>,Y6UH.F6X'8-52:9UBBQJ?H02P/>N-&M11DM6_@-=<_^?<:
M=@3I&[+W9H[LON\F"'Y!7Z"4%?J<I%J1BI?]R5:2\NS.0R7H[=@YMMJ!D8<'
MF1N;D<8/%E7\"@#>0UNA&!U]WP/8*\/\W<3&](R"8>2%=GQ))>T'/L B476O
MBB?5,L1/F@_[/9VV<TXV T:*5GQP=RZ>7->Y:'EUX?;6LVV;S3'V4V/%"I[(
MY$QI![^OSOX2OB!&=M0P"9QJ%BDQ5[20?U;;T,@[2M:G4ED S756?LE/^V!!
MH&@&SCD6%<B]Y*$XQ5I=(@CG=M572N<7/5[$CYU;"C_&V%&!":U$<,E%R3?$
M.Y$<E1B0H1X6.#A']U>9,\9*]97X2;Q<P4-[V*#!'?747)3H&)33FFBW-6_>
M@UEP-FYR>3%A(); VV##*+&@;4<6 J[O55*N!+'= [;>\:B;?FL+J29>D%>?
M.>L&22$;8"]^6$(.=].!W4DNC2K)MY[@A.7M)MP8P\ORM';Y^*&L] UO$W12
ML?/EM6EQ7PB&0A4 5_I=HN2W6KNMA'&:I)&&5&;UU0LV8?V;V&PXO#&<;8?3
MP<8VT9XU-ET0W!-D2V^6T"6>P28*][?19,^K-_QMOL3LIY4"S>.LA[9>P'!?
M+L5(GM_Y?+VIN7-'L"T$?;J2YT8_OUTBO52J+6^MK8^<5X:ZKMV^:39;>8MI
M?!4C^6YCQO>$,IBG/3/-5(ZT?^?C1?:MY-(2O$RH]4A$T$'/+O_*0SM0GVRN
M=[5V*JX+ [N::-3AX1CA#'_8:'T@N*0A<,J$EF^ ?]B#ZI'E!804\>Y+R%%L
MIMQ^M!D-]KSRS%.R93C]:G/:?)!EPOLD6A1435>H, A_O'1UMW+1L/]%29SZ
M?WV7U_],P$XRPA]_![N66Y!^44\DPIV3B"TTOW#AD"0Q3\/9"P<Q#"8>1N.,
MISO/5DK"2^PFD9JSUC!FV& 28\N+<W,[SPC,2NX!-:S?W1X-!R1]+A< LA,#
M< DJILI[[=876!'@OEVPI31 9$BP"%Q?:^GVUIZ$-^V;P&T#_S9PES&J@[=,
MR$<7)S!T1?39@FLZG(((_F1/-N["\F"6 [,3+=4775E+(/K:31C:ZWM;1Z[N
MN1 *RWYX#GP6F4@G%/:7?CMD!*+])_=W%J@7=AX&OZ.",WT2Y;W[[K-1;GD/
MN#BZ!V2?S*:I9WJ/:0=U'WBXH;:-0U_^0&!-U[V1O1U&GT>BP=<(GM.56(1X
M(C6<HHM7P'L ;5%GQOFASQEOZ5H]NU^8P)7FZE*L!-'^-J!'^O;@2+?U?PKB
M.6VS)CN=(2Y[97?V=DI%Z'\<KBJ@/WALU4R",CP]$8_TB<\>?.$>(%'B3E$'
M\^B%_RSCNX)6/48JO08"#V:6<*.N+5K/?ZH-VOWB8AY$2U30H5_.V^RVP!;]
MGZ94:V*)NUI_7?4J;OJRT64\G[[N0I_9J;8;DK*V/WK%5]B?("Q:9Z%I&1C!
M ,:&W=VLH<*+O69?@ YD@7K$Y/ZAM Y 0BNC&ZSW9F5J Y?"@TT:S/_*Q(SK
M$4RL)>SP\;6)EQBDC(OK5DQL[*SRJ 9Z)ZOREPV@_L7=Z*^;1Q'E/UV;#EHO
MN\8[7[Z!IMP#7O*4_+%/:'CS:]X#5K%G^:2?4!FD4$M('E-=%.[ +*>28"S7
M>J&,987"U*5AJZ.P*$&&.R]6AYHQF/ HC(&4;>+!K<Q*3/)(63O[ZYV_\;#_
M:<B(_]$.7!LN_J?.]O_VFD!;B#Z4E>IF/V.F.;-%8>W%%U?;ZRBRQP*N*L#9
MQ=D$]8;$>P#FEEM]VQK^UCT@NJ3LSC[Q.D>GT,&G3VT6WB +FRA5-W+QF7WK
MT!(SYXD8GV/\UN$MB!'CC<PY*70T\-5(BUC"0-[^\"";3XA(M[OU_W1:UZ2@
MDRA)3!CG7XDDBH)W_K7L!8&V7/W_U3?,OVFDU3]K6RHUWX1INZ:\S^AYXAII
MQG)6E2\=^$D7]_W^//@$_3*.YGT=&E83 'M"CY'Z.&([S%.V1,N<-"T5NJ0G
M6ZRCW4TW$8_;,Q$""'8S>8T4#WG/6A]*6'MZ#V!&C("&%L.ER]N&$ M,H2;+
M.<\]YF#K9SCC1R&=I9L&Q9Q"?NC "A3U</.;]F16 F'-TN6Y*_'T*\U=9?U^
M$^L.&=2Z%-L<C2W6_8:/6P#B0YZDX\FNA!OR.O/\/:Y7>;I@/0JQ WMB^*3@
M+I]V+0/)U\ PIBR[OK4X9_5SV%/WZYUR[5-9.%G?S</0X]'/-T,NPUEMH<*R
MA>)K0(KHJHI;JXB+>M()3HT?]K18!\S"V7@Y"D/?+<1(]Y)KVL)@DA20 O,\
M2#NMH62DE_O6<#."1U8[VW7LN21A^J=MQ%0A(Y7*)JC!&[T%#W9E7-3A;:O-
MH[9-3;65$;3-]8%+E.(A6NKH)',!JBB7M)_0["W<KT\5IVA:*B<7N@2G^T[*
M8+3.84XYK!NM.DIA<QVHM59,W>42@VP_-&(2Z()%HTZ<U_?!>HG O2?FM?<
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M?0L04!HE3\V=0) >GN?B=38*W7-G%LP]/$=/KN)>MDZP:'<]7?*QUNQE7E(
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M""P+PC#7[$UMQD4K<2O]>I+[_4$2T/7R4X="XT/W#'@;P<'F/:#].MV:_2K
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M44LI&\+[,5@K:W8$VHAY'?:5W.ML6Y@JWA\P8!?CEWVD7!/?5H9@1,%ZA_>
MV?,/OP03?W(@_]]8Z0HIE/&W [TT\U:\>&S;YFMX4H]=3.CI3BL)2\+,\3W
M(BUAI Q)I'7CU6:]$]"'Z7#SJSMVZ_G/*<7J)MTW#N'ZR!)'3JS3W56C',Y1
MQM]4ZNC&?2-D\=IVVX6A77443%T0[+KZIJ;8S9+<0(\DZ[<V%CB3M,^X8A7X
M-[:12T7V'/1:O;@D&YM#"=*EWMOWC)9S[&-^6/%8N6-.0. PYWN V:U:$@ *
MG\#O=92!KVFLF]@K@O0AU@QIWZ6W*\=+]=D[[8KRAK>O$H6%5A_O@^QJ4)I"
M8C+-ABRMWW \XX@=.H@Z=^M 10-2Q\0YJ!^#]=/TI+:D3-L"&3NOA6J)^ZG3
M7WV,Y>_;F1T'*P1[+W]?WL7 Y[J+V7S)DGLZ _(78_Y@[VY8L4Y??@!SO22*
M>85:\[E_\_I4YXWKA#BIF\GK;\5&59]$#]&P\EJ?#ZBK>[4]E(FHUKT'X"M8
MKC3$J<M)[+V/U.P>!5,8UC!F'['Z)M(Z];Y7MVEFL?9\V_@U?8'2DP]%UK)5
ME:- MX!^M4;>'22B?;OHX. */5*<L#:NT& UKJL/X.OF'*$P"LEH/.GKI:;D
M\DU5EUXM>R)7H%>:QE-!]&*A>'*P+:(XW_ # ,ZI']G#N_=6+;5HO^V*AJ%D
M&:Q_C!4B2D4"E +?S!6_9#'2:N2"7WI?:QJC+I<+8U7%HENI)+0BF=5@8H8X
M<3Q;H*NG^<#!:Z#<UL2XFY]WVR2U&>3]M#L="!^>JB%HG8U[$SJ"DC!MI-'7
M1,LK:X-2&?BH2;$(9WM+QW07SM 4N'NA/A,0L"_HU=)=&OV6A<W$R6'S@'FK
M@@7I4SCV$_!@UCV HU]W;YI"/B[+PCE1_=(E.:UD\^ ',WGN<-R 3FQ!%'>$
MO\A#C%UI[D%]+'3A]_3EE5H2NDL+_=5/AMDV'Q%JNGCNOI BDZ1QNY9WYZ'-
MI_T0$RORW$S+B@H/IL!_=7T/>/8,\6+=U<$CM,Z$;*XNH^[&]=S^5%7R1\FK
M-&-FZ-#8P EAK).'I>N,QKH9&]X*1N:IH5?#:B(0F!KI2DTY5VJPO'H<"%%D
M!VEMF3]SB2]6^12LV5R#6EF0</W2*E^1T[(Y,\SGJUNZ@\WQZ:W0N^<7N2T<
M"]S26!QN[WI-IIF&:=K1T&@O2B<[$_!V&H5Q=:5B(>2##DQ8&/3VFG./Y;I6
MG(D)<L2)EH=P.!70+;!M+/-**] N1)JW5'V+^[^&)R@:G[YPCINUH09XQ/ET
MPBF;*QK*4Y2G/C3=HB95UFFPOD,VGV_(8+N-.IPE_D%^WM<K+8ZYI*8_^]*]
MJ?R/ TRI:1>$&&1Q/))H]Z9U49LC=GG8M>=N80W4:7B[ L5?WVS?R<\J_#C1
MFP'QY)>V.B@Y.&+]*!6X)?:1Q!RK0_DV?FIC!0D#^,D"9-A!)$MW=YABKP=W
M>YO0.PC0[M\*PNFJ8^+P0Z/%XQAV45&,3[;,VWVL:GJGT=L\QKI]W'O!HBR-
MA?FHFSQL\+D.@8U#-,;YMH@EZ64'N#3;B6CJ/$R:KKZ2-YK82HO'GX4DY#TS
M43]R>+CA,L_<N*3>AQU#*JF)TI)SH6%)Y>; K<,U_A5*\89 [@C,:-Y$>VU.
M7GF[25__-,2P)MSQ]_'MMR/?$FQA<2,W'!XK_%J5.$8P"PE=](K:;CE'/_,3
M_]XRID5CS)3^^QE6VH2U/O#+CQ5F,UCE)G3OBO5I<3@YHCQG1F)R=+5W79(C
M<]RPAY>Z['X(ASE@F9,248/8-FJ-K%+7\Y#1A/"5-BC^*==?1Y6-V/J53R.S
MS-\#C$B+OY;)__;+=:/XR_&+)K"ZC&Y^\["I9'?&04]DI(0ZP2D9U)=M>ACN
MD=YP1DPP/BZNDKU9A!<:V4NTKH EN_:8\,K$5+LB;SYG%DQ7TQ([/=;X32&9
M3YTZVA6-LB9M/0,-XF-JQM!998EW#S"VH+(RFSFW9DOEMDZ*..+[;LP>3>X;
MON(?NE<S^O2G($J,9.F>N]Y7J-]XR>:B;2)RP8/@8=GO>V")%I0X,ZV2P!PL
M4,5&5;UTO#9).Y,\#A/>P9V%ZFVZZ<H] ,WBQ/.5O_Y4\3DR5HP>$4C&@R^)
MU@Z)&;]._*V)QJ)GSA4R"T:WSG&&_[D<I]B#'A#JM\EJRR;9'FG<:R[IC6A^
M,5Y-G0TC(Z<-]=PW+C8\7<=OA#D5K%7D2.M928! VUU. 9+,W5W("!7OH>NW
M,/O<:QVF0Y-'60P-M "A6%0A^@9O_8QK/Y!0.JO3*OL3_2O@Z^,A;_);U)X@
ME/:R@*Z'9 F$T.Y@V]M39BGBZ]"OJ)72/2X\PU1=O <@XQQS%UM-;'I,\8;Q
MB=[1Q>_^XD(Z<;<QT2\CI/L-TWLGK:T/2O10&^H#"=,5F)X  SA%,< -N[88
M/[8!8Y=J.TX$5:-XBP/%)UTZ:$XZUM1.U-8ZZ?.4U=(.>G<NMQD_VX6TEL1&
M[@'??WBR'Q^69,GF\1:8@+I$R2;/+H>"Y]+I4]QAQ>[6[].#Q+3RUA0P=NO<
M?;K9*^>8=2WM>FJQ*)#E:J=QL>*@JYV&SB(>6RT2F?4-?O/?B9YV/TGJ4D*S
M;5KT<RYU3T6R%<%&]([_I[WKC&IJ[=*A2!,$,:%)DQ:0]E$5J8JAB$@5A%"4
M7@R]"Z(TI1>E"!($00@0D!H@0)0.4@5!$D)"EPY2I&?@N^NN>^>;N6N^]:V9
M6?-C?CQ_WG>M<\Y:9Y]W/WN?_>PMX3BVXP\,P9NF$S%$;N5I'NJ]B*5)D2C@
MF$3ISH(F50],@;<S)?GU;VKV%F^VIS2\;EUEL5,GB0@GV(7DHA_B'J.O\#UR
MBPO/>_-,)>AF?D5I3%#,,047OOJD$@U1QP[41,(2Q?:TI^)#6RXN>KB8]/DR
MX,,T?052;ML/SR6NM='P^PA<>H:.:=;N_ZD)F3DG;R6VT5'EX5EX<S=6(>/X
M._PAW"*^']#S>* T?!)5K<?DA/W9B^5&%B[IT)X7J:K7CK#;9JA^R\UH+I=S
MNG<96E93XGS@;<'\,1;].J)'0YK5DWWI1E",=V/U2<W5@]I R9;#\\?6+:J,
MQ' UF/SP7??:YH+YULK[4@W)3";2[M[@OGI]CPFX#&ZQ&1"N]:U<TJ?D4]X^
MAVBNMS/PE:R=#S3RO-1C8EKJ7+]R(->%W&GE2[HCJ]MX3;-AF-SY[&9(Z2]M
MSLHU15.72VG=Q(>^)1MXG)YR&Y.%NL#H"K/34*OL7;6';!=N\H8/V# P5Y<=
M3ESVQ^P0=I1PM[[ZCB6VW'A:D#O@SA/9JC@1^]),TOPZ-TT;K\I4G0H),$G9
M(=7G'A#%<&^LG4/U9?4QW[(AI"JS9[Z'/5=[FID-;Q&84/&6K><C_D@M;AK-
M(5*+FW]" L!GQT]MJG ?KCG51-UFQ50W4OYHT'YD;HPWT"$&NR9XR/49[DRN
MD#P";".RZ'8*$T2Z$&[;),"EQ1OW7DPIBO,8U6T<?\@"7D,=W&^OU//F);NK
M99\IP[SA1611_(BFP5N50R0EEY$8*?SD L4'"!<A7I:F^LNE0MRIAZVPP+'$
M91D)QT'<_%@L<;83:K;/F$@ IH$0"!!79XX[!S30(O_'P^\4_VL"HM\;'?P=
M,4N3BFAGWFP=""_V$W/A!G]22"=?0=XST>]FT._0??FB^](/TFQ6>H/2;+1M
MU[3E;$[]8O'NKCYTPD*/^:)<*U7R>"S+IT^<<, *-05XY-OI=JZ:/@! ]HFB
M!OC;L?WV+R3V2O\Y#?ES"4K^:P.(@],??PO-S!>B9549,S2:2A<S'V6IF.+<
M4GADV/KQ;8[L7,I.%"8Q"=CIRR4!9>+V"4Z"^IO=EZE,#:5I^,-HU@VEZ/(K
M !>TE8N"W"ZO (WE_4U^G<G<]$#MU3U_R-R># GBJTT]L-V>=)9W2S=O]5-T
ME<2WFR(H//IOV 4-4HZ86%6=QNNW28"DT?)"YPDJ$D"G7BL ##AJ\Z?^^6$1
M+CA8\\ ^2V>T^LOWO,2^Y-6R]\D&TAK3QF_I2TY?266(,(5Y#.3A$KN6/3]O
M>!)$JC!:*($UF<6,3#CRF0,%.Z]_A^:"&K,!1-W9'Q:0(E?0)E/J)7O/QN.S
MY3WV>S>8-&B6& "Z$%"..W+15)P--;)B+]V_.Q11IT&X2FXE%?Y%V$0P*(YS
M^QT#G7#1FE ,EA9<E\P7)2?Q4_&<L;ZT-O@98/WT\@_,0^,:I1!B\84!B1KH
M!^.@7M8A+28T3,UC@L6-&D$TZ95IOU$1=CM)%&@3=X&-D\ES@GN$3!#879#
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M@\K&0[]D;^\BRX%+LD,6%A#.E"I^%A6;*F+<&G[ 8LP7HKA^?";13?([09,
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MUZ5@):N;N]A\[-A;X'I\:.>3\WO''Y+3;W:):9$ =U$[I[XEE>=(Q/HESS:
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MW:9PI+F0[A4[,KW@3\#>UY)7OPQIS[Q-P@ VS&$=>SL*IX0; P(+M>6X&$!
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M1S>M41CE]+YQ_G?2R%.L=Q<E9A-]6>Z7I KP]>,9K18B>ZRVYID?4K0,471
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MIQ6=M_L[@+UAG!52#=0H"OQB"I9_U6Z!_ZOICW_,M:%!6];K)K[)8QA2K."
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M(#2HN![5""7QMRN-#8[RX[Q](95J,@8T2?X)0C/5HO_#6]K>Z3GWVV:""$S
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MT<R$*S]A[+_D]; W\@=@S@,=C]4V5G0'*?H#<&GCNGX%4J]P$^VG<AO$? N
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MK(5G0P/4T)--2+...0NC\UV38OG)EI_'ZKF'#^;F#V(NOMUAT:=<^$ __K7
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M.W-2,B?:(V3UNV@JAZ<<TBSBL?J/R;D:&\WG6&&X_-K5MLS(TVDG6,KQC7'
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M";W GU2*X/9IM*J1KV&3@RC>+U<>YR:0-%?K45N))J<>D;EM"7;"FK<I)6=
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M<$[>2TK*HOJ+.OCC7:;.,I'7Z%A7-OW4Q:$L5FC$V8QO$%<KX8((GX"%383
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ML' E:C;+*,E>>=V3I=;+I: 2BR5+ICY5>>D-V_LG=PHIDM+NP[DA9X]+4L^
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M3*6-,.*1!4-MU4?=SX"P9@KHQ7XC9*I'B-/T 4DW;J&3L8C)MKIZ+?/Q*T+
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M0=$L_B-#XOJC[:Q]D:\U90T*GO2O*Z,?BPD.YE72)-*XLFBLKOEA,FI!/ST
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M'AGYYMT6\1TG9=&M]8#R:4F(7,-ZDQ-O7@DD(RS#MMJ5\3I4'EO1*DJSQI1
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M/"W>/#%>"KG43N6C8FM#3*^+;?W7["5";9UZ_G5GZ(*V%#K13 :+<>"?3,N
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M)V9:P@MU.PT,XS^M_"/'\6P!JNVXJ@/F'4[KC,'8VX1N@7P[21L!ZB\ S1?
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MA-4@)@0[=.['V3]CK=_0-#Q^F5OQ3/$U4(Z5R$\<PR$&*7\8"29'Q;V4^@/
M8;V[&H',I>P$"\Y6/B)9,D?5-:3.'ICXN@=EN\9"1+BKVXY)+.2Q]*X8TC?[
MP-]"2,""US6JH'UL%8VW=\*#A@P'F%E:,FI;+@M7;:8M4AZYT_#EN=,_ !'R
MY8'#WW"):_/UEB-R1UU%;^!]P_?$!TQO<?(1RI1?3\_XB4,I'AS?&VX#K+ZH
M%+OL'1-6DHG^F[!)_%]BITETFO^H:BK]CWUQW@%N.?-"!6045H$<YM- _HLG
M;: AU25.V[II/J 1V;&A+8?)MOW>;RXO?AP'ZIR(M,)]'W?@9V:J8)34*!JE
MA2TAJT5WB2W3=^%LW,IUV]9(E+-FFR<!\Y)80%P)2\*V'XX.-2=,W+08V$&3
MT8"V+-%UU^-?$$PSQ=Z6KC1=Y3GO<L06N23T:.GWNK1!R4O[S<?OM E?T24+
MO5SV1AX3DBI'XH[0[<4SD]M/X0?.$<W&6-^G#YTZ(H2KQ;J9X_&S\7TJ6T;X
M)L_VY1P3"L7>\AZ3I]14D998>HSA^V]7NE)'Q;:J^*P</=WS=YTZ !YM3HV<
MY8PQG14E4$N,)WQ3]3B#L1("!A>I*J^SWB).6F''NQY]WW?%&E+F@:T0&U8A
MS"7;1I[/6T-MTV>DV<KH D[UIRT+8R=3%R$EE38^"[<J/G![J> 66IZ2?D&!
M:ON-\#5U/PH63.R$M.]_P3YVHVB<V_%VUQ6Y@%';%VYC18?+Y_@&J3U)V!()
M78W$:$W1J&QBM]BID[:"6_$/]3]>LW &J$O:F7.EF7,7'!L9*:PW?[\4[?D#
MZ/*JV/'PS=70)1!!@G9/YHTU/$(V%)P3G*"V?J_D6LR4:0C2/W$ L(004W/G
M#RIV?_VDZ>CL49>_[%(]>;EL78(/5?R*R<]J:79OX1X:JYKM2!M6"XMC0;#.
M^/F!BG;]CU:$D E(A9<SL$_;*AGP>Y>03A/[9T=\J']LU.OVYME[?H*#TH;:
MEN8/GLXUP$7.'M>? _(ITA_2!OJ\<[&?$\5Y ;$TW)%J<*]UB)N-"^2AD-IP
M]%2+'[K(JXK/U)"6S(1Y!&B0H)Y+^P,P&%<'YR..CR+/QXA4N'=<AXM,ORT%
M9#C3EL5S'Z5DA,,EM%V%7"5%":(^>H()#'?%9L_P$DY5HZ_>R@A*0TWS(S[W
MT] VO"Z1$_;//FWC.0F)9JYOU>#1J$_:IR#WGKO267*QMTW)LU.=R.N))E8:
M@D9M29C$:L68<<Z)$!'/U\?V><9I<)^]:XZQ,]QH$MBG-T+AK0:[7;U.;<Q.
M:+0K!X_=PZ\,'<4GZ%[$K/P@>M6F/B(V:W_($G.P)F0ZPMU-DL8N8N#^7"@N
M0AO0#_ PE-+J)A!^<VPZ&^<B$WFYKAXD"/_+&]X1%@BKD$@:=CH)ONM;PU*3
MF5X2.;&9R4U?NQ8YOY/=2L^KRB<85;P_9._X9<# %2>S+;G3+T5/-5./M]!.
MSEK!9]QWK0A^WF/!/_\^U7E%N@7!P?%%_@E';;M+]ZV5QN\Y\VNBBU>9+F'G
M/'@,M6P5-:50G(S")I@R"@\K&GWT==[W 7GO^%Q)T9#N6T4'J*,!!7&WZ-8W
M=V=V*&5@X:K>,\AB_T<ES-3!P74)VMSR$['9,=7$!^8:5;L 0Z;,RVN0/#M,
MF(<72BJ-KHPV2JB.%J85$AWN@OT+/"OPNVO)#LJUW3:KBQSE8K&,T'>-MU[L
MV&<2^"GT^A@OU?'@#P 4TL$&)#:?NRA%^*P$86UQKHM=:?NY2$?5M^6BQK(?
MK;^V.E?H?=YVD/:W<--L/]8,"Q(1TK#^7:U(UY[JXL'[;)"8I$:261F'&3^9
MK).2U0JK]EYT7?)>I7R^L]C!OH%X!X;,GB,QA?C.NK'WO'NJ2-L_-HQ%&&#1
M_O8D_C)S9EI[)V6LP!"E8.7G<PEE2W1H@."0=U&I9)%O\14X2V"[L&6;ME=U
M7+2$S%SP.]+CC\,OK$I-C8?G@+QOOX.:H.PPYB))?(4N"AI29YYL@' BM^$]
M1[Y*E5HYL#QKD"H[LC'E&^%0?<Y[X&9YVLIW;4U-+0Z9HS OE+LY[M[M=C19
MU6;DX=E ;:U-.@YF8KA$1PPE]"V&FZ6OI,D!>:#<.BC'JKLY-Q_BD(\:M'_'
M-%5?<@C,8B1ILRRQFL]NY$INK5KO!:9?3$.D%T:7W6RG5A\CBI5*<MAYLD!#
M0\*6? D;IX.8)@>J<4V")1Q,VB4K_KB!<D3WDBY%\X;S\V-V+M8V D&)EP$^
M"BQ'*3Y]N[U439R:2]BT^!Y(@Z2B.7@=6PVL4WM/R.$JH1A5>="ZRUN0[>?A
MI*OL;;>IBYLRL ?N""'A#015TE#*U;8'.5]YY\WI@&):ZUP+M"BUWP<*/6MR
MKA!.*[9#7"QJ:814+1<O.NR9H4T<W4LUFQ:X6%M,'8KL2>H:T0PD6O_JJ%K=
MXL?UKF;A?MH)F+Y\\60<XIF5( /28/5!YQ=<VK5-]@OLKQZ"Q3-MOGQ&>MI8
M%HQYDG]=='K( B[N^M['RN524G'6H?Y\TZ1+SYA*XJY=8.!]2UC6DN1TO8;8
MLIH4+9?L].U'5TK3+MY8O4'\.\.R8QQ&8H $]C<MC=N%OT%<3'SAQN6&:"J0
MZMO.W',3T(*):(^/')A$RT_DT/8T'C2?,VBU66WFL3"NJ[12B0LTDU4#'BKU
M^!#X4 <UA+!+@KRW#7UN'#6W!G&%&[=+J\"@Z^Q,_2^6?)5U+1KZ?E7OH70J
M>B"0)]@=(R+[VZ*:-5(L7-'ZH),L-U=VNJI5Z46A0XT6$0%[WUK?A)T2..-P
MPSI:[7.,^6<(FSDNENM-5WU5^>U?JP%03X[=SB[#M_R=2XN0C@T[3^[-G-1$
M?'!;8E?777_[LN1S2OQV&[%UI'\^ 7^<M&O(8&MLIH"+4.AV<WY69EZJ8<%2
MK'Z94X NG%LL(>R[_#91/4C"WKO?+.C5SB0HZY)\=]E.'*UG27]+-S1D2$!A
MH+/OC;%YSQ#-$4T.(,0V=.ZM87^MCD'+69ZNX8^&<5WAZHZ@?@DSK-67QO,A
M?TWZ,5FZT.?!Y2\(_YU_'!Q''^GYJ2'#Z?[,_6GSY]<UL$5K(Q^_V!ZH#Q9V
MZJZC.A'N[UGJ)Z-Q+M9RM<YO(NVM4S;.\#^FLWV&L4+5)$?]JA3['[EFZU!F
MAV,*3Z<4V5-3W*0* ISY"A)">W@[&L8+H*Z$[]#;Q:[B \V6:/S6(7('0@\1
M51 =NZ?.;,2LP:H#79N%T5C;1YYK,%C[T*'!?3OCI@_B GXO:<OPQ-YMY\H;
M\F1ZT'-@<L@M2&8*&L45DS,<5W?:8@AA30E7*_S_^!WT%:^/%QU\,B/3[&R
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M9T]C)08YZLXO/%U4PS-6J[VJ;(TB6,;-4L/8VGLS+:.P9DK3:YS2."W2$GW
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MU^X)BW+#M*#G:3Q^@?!;XR>:7QIDQ7%/'23;L/UI2$FV*.;G+F#_Y9 8QU5
MGO>I8[EL"'RW!Q5B/J<[?NP3B;$@<;P53SWO+;_\/DZ0[^#:/'V3)L99.ONB
M_"!_)S$^H=BH1DB-ABM,E8?%.9E>2G C<3O5H*1 *-;^UA('W6'V-2OW*":N
M>/)FIXR[8JW %>N%J+G)\6P$O!58];O9MF@\G%D<EC)LA4VUT$AKAU%<"-:1
MQ[?/MW\#I*:,W><TV.29HCPON[RUB:AE 1DBNP8!#8JTW(66="R4M)S[/[A1
MI&AJG@FB^@(B=P(LAA. L&"E^,-X0@E</XSJ';V#0,EO2"TOT:*$HD[1Z7+9
M[E['V"G5RB;3 09A+-9P/^S,F;Q09@0B$F4*64UD\W&@9([ 'W8?=EN$JLGN
M\6L=PZ/J4,OS2,)4A\9R!N91B5,]!->*%\$9D>*(TX3*9U(&I<EE(PW3\P7V
MF129@A\"7#EOOWQ22^AP]QWST'%\03<A*ON2YT!%9<KYR%([95'+$:H:2^.*
M%CT .+O8JN?\BE\2*)FG&.(71)A0U!_@7\A713Z#F5JZ2U<-PZ;]D!DFP[):
M-[&LID5DOU<HDPN>C^/LX;T/[!4[X @;E=;?)$7+"OIJ?_OQ4MA\1RIH>)95
MM" 5Q%+?1-D9GW*:B_W&DS[M27]$H*R'#]U,WX>"(2]Z;PVV;*>]=#[7'NO
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MG7$^.% G7DIE1 8.> 4#LP6/3[K  ;4! >SS"1Y/.RES1'" U@4<T#:F#Z2
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M1DC8IBX,0[?D3)-2GPF2]OHHZN'AE'SP1AS!H2P=YHZT0@I]KP4"AB>*4ZP
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M7J:D6%BH&]0-5T]>]W'7]G,PQ&=Z<),FMX%)+*]U^:>"'EAG1:UL6Z!I&H?
M3CRL,61!HL-$&%?7>/>50.9,N'PLD,5'[B>"&=#1C&PS/($AB4S<EI#(9!2
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M:( %"KQ^@@/2X( H)3@ 8V]]Y?[5KN@-S![&K0GY]\B86WU]P>?5I%/<HA+
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M1'V0;9ZV*V?F\E(XYM/6\<A>F.R-^28.KR9.1%$Q]@"#[Q1"P-<;/<!_P</
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M\F31N=K[UZTR3,NU>)/+DKA$'J/AU9FUE"Z2ZOB*"DK3I^7#JWJGP9"KM(:
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MTU=:)N2[Q+N0*/<1"+!,D( FD&KNTD8UXK"!Q\VM)K$^2(:I;80;C@VIY3L
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M3_T,&&RI $.FP'LXY]3_H6,HZ@F%O]*@7ZJ%=Z.D_Z.362.\"9=M>(CTM4:
METF^=$%83HJR]))1HA]YM(,JN(H3?(=@]<<_9*XK<U4*%66:D29,VQAQ9FR
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M4#8B3#4/PG*$7^X:-[I#:LM_)/X?]MAC/?I<S3^8:4/T(,P634'[6'W?M'+
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M;^:]?^9D?3=_W+/NRC[W^_:W][EW!?T/O0IX\4%111& @8$!,'_\ - + 'D
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M"YJ3V_QSQCR[!:\&&VVI>P!*ZNNM+!L8+:<#T?4E=9>NC-$"E_4ZG[L:GY5
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MX1;?83U6KMGSBO!_(B+FR@>Z)8ZJBG@<92)$X&[#E7 IICV?6*AS4558743
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M>=YV3,Z*1$F:Z07KGL)#'>J-?JZW33F8'9E^9%=&&2Q%;@EMAB=@:T=;;4C
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MMXT78U.'FA3YZ_6@.%5RB>5(?8- *5GP"I!HYYHID^W$V+#C2=36NR%%KUC
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M9)JJZX?JQ8,0]I5L*/?A$O]^..<T3<LR+9Z'>H9P2/C )S0W3"Q7VEJ2;KY
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M>Y^4'@UNP891,QO:*)EI\O&5OMGYG6#U.X.5MPKL I!XSL?*Z_P/!6OM)=T
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M%&^4A:$7FL56XY<'?.5H^HD^D[Q<$QOB=T)3)3:.S):@@R^I7\S+>['/BZI
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MCVV]=Q(IF'V(LGW^VZ5/^WA0%^F;&]U3_>JER99A>0UC44\,P  #X-%0E"5
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MP"X$7Z'>OG?9/W7%*-83M7\Y8E.:0ZM^3%@2(J^9W-M0':M&D2H/>=\CQA*
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MN(<-8#(,H(<<AA!RMVFC:F9JC%^=VMR49_,U,KH_-\%P+(&XGE;34K$0][F
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M/MO?[\SWLN@2)G R[NWJR!$QD0;9E4>Y/47S#6MR;&_>3:0I+23A-[G!)"=
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M ?0T=GGUN5"V&  X6$]Z:_W4HC@[C%(M+DJ&H/#@5H+H8CT%_]!N1R%?T[-
M$DTV 4@[P:ZG[$PG]$7ED,X"?UP1KX,B9?]>=>87#,#)A*4H\NCKS +\4Y<
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MREY"U&VL#QPMS3<OS!22YXJ$]%-!4TSHU8/V$Z>$S32('R]"MJM !V%%;2<
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MREB9^G.BTO-HHDHM2(#<?_ /2Q39.+\Y)61?XRA1VQ[V2#U]S+;8 O,[>0$
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M;G%U$0+UDCXVAB>]G.&,]%>7+EU[1MA;PQ55+C,&ASQ(]'IIB/6-U:6\+QE
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M<\GBD)^H2G>Z*M;7^JY\+-]%@6V'5-3E^"=K+6),M4$Q)7_V_-6_R@,= ^\
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MC;[=9X^U^^G'_HDSHH^Q@KL/!C).K7<Q7B 7A//'8@M"V7=<JRS_@0?Y5WC
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MQR/_^Q95NBIP81\;=)*K 50\F.+H$<!J,D OS-BQ>SK.FJX[:R@HK;PV2JX
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MFHC]M2PZ@HS]O2M: 6%SE"GI!7]+0.<K?-VZ_36P_^Y8OME8GRST*TEJ .A
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MF<;4M>A7Z!R$(J*B$C80M)^'0-IG'2 S5LP ,/Y#3BX8Z9F@W.) ^+,P?;8
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MW.97 SGX*W^7[-1CO<>6L!G*#)BU)K]_6O-/PA:GF=S[ 'E7\"/89K2:>[3
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MY2)R7_W?[XS^3P \&O\74$L#!!0    ( $2 ?U:Q^[?7:]\# $_<(  -
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M>W^* ZM1'R4?WMWSZ^8&/,6XPO7BD6]/#H(P$.](?'O?#_!M(N*QXD?/=45
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MD>&\12A)[YE([_4<,ZW_2<]JDUAITZV%33=]E+,L7(O2#GM%=MCZD%%I.ZV
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M!! &[3P0@9?$\*# [M,YARJ0L^PX!J6-7RG"$+V>H-@<:G/X<G,#;_4P9A<
MV>&>1J%OA2"4#6I,+2E"=-,TUZZWC8JN:SOJVO#<ZL5W7TR0]*RM1L?ZO79=
M.ZI9N\T=+/_:1@Y+IRGS?[J^YP"#ID3?\ZQHR '>$;S=QLN 42@1PJ7IVF/7
M2^3(:F\N' @;%Z>G<K \#ZV]FRGR3%),*0!I39ZAA7F9"#1$U9:<E<+WR:.W
MGD\G<O"5$T:14-@K%#2,(CR,"W%_;[UP'/L3M;U%KWU[6WR/J$#U05L1@OKA
MQ4S76)&$L6W$2_I@!.6)$](9$(@-?Q)[M+&PD>A*WXIJ%]NIDLY2_50QONH(
M^(V.B_7K34K0@D?HXOB0BN.CV#SGB4"!WB)]ZC%(-6D2+I\;-=OU6J-^7&T
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M4I1O. V8;O%1E77R[[&73"KIB*Z$3R<==(@U %(6D?454\RBF++-&-3$NI3
M;W2,R \QL &>6SRO-RGM2%+:60]2@N'^SY6 G\!1^M]R9^<MU:[<V=WUV-E=
M%!)3F:)H9HVI7RTQ_*',"4O' QQ_JM/RCL+ Y?QFO!CH9.QS8N#%2' KM5(:
MS-X$()9=%1G;78?(F!SP?V%JGH=)Q[>"-AZ^\-5GPTY/AW/8#<>)1#NT,+#V
M;%2QM_<J N%[_\14[+[W_3!P!F$DB61O#6BD:/"IP+A.\U"1<*['HY%/GS'9
M!&$BGH\P]E\%8>P7$L;^>A#&U."/J#@%ZPZ('$!VV/U(2 +Y XMC#KD4P*:$
M\T!]Q%0^O"$EK%3L/!L%-1JOA(0.BVEH'310X?"/N%B%10J% ]UG#1.]&D+X
M7$P(:W**,SU\[N][%G#.)%B?)0G<MX9'Q21PM!X4,#7Z5 U@V,.."$3L-(S@
MA4&F\;.L@[F,Q"U6Q9T%\4A6S*0SOZ]@>;6)IXPTO\5(\UF>(V3@^0U&GAO-
M^JN0T8UZH8QNU-=#34\/_]C#ZL0P@CORS7-EG/E()=U;OV!=(!KY8@ER^;40
M3*.88-8EJVYJ^"F5'!EUJ,]GW#5?@7$'.]Y0R3J-=<C6D0-6/9ZLB[L Q,'
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MP$-I9,:3'U\<?W3X^\W9Q?GAU7];US>'P',GYS?6U<DOAU?'9^>_6*<75W_
MG]4O%Q>_X6=]S?7CB^AGC%O!7DP/'"%^O-@Z#((QJ($KC8"8"H,M:B8CX4LR
MUVGP$D1@ 4]07]4+HSL[<JM^&'XC-,X4)"WM%R'/B6 ]AXBKI3"T&/X0$63
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M&ZO4<17_8?*0SA$FPL1"<%(,.7=IA!XM" $RCI.:T:0(3!AUE7PRH53I$![
M4504]GV@^3+\_J:($R.KD? ]RBXA;PE\'O*=T OBF")IR*(C=%*\0<9/BA$U
MUT,_GI0O?)B@UF8].TOG/O"PO S>KQ6)X9[KHA_MTI\>'UH](5R,.1(A]<=
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M;:WS^L\W>)YV5+Q<3>LFXCPOU01HZ[^:0 ?-QO:#)!F>][K5L%=5C_TJN%:
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M:#)D%IEF.0DQS)8RYV>\F44DQPA:TM8 "K+D4!O;B.T_&XY1QR3X'92%3N\
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M-!*J"P,PLI3$S6_LP%S$MYCP-^_U!AAJ4PW( (IF0#15E\-PC]CEX#LX3F2
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M3'$QM)U];*#I4#W!55K%?<D5F\NVPAF0U*,6/_IT.#T,<,VCYY3T=64PMH_
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MK*#47XR7I.H4.0\CD2\A7)<W*2=('<(?YJM9?J W6D8D:'JMGBN/Y^%!HIU
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M3 &'5'KCS!BK/@V:H^1_-ML-FCETJ%@'(V'"]*'P ER,W+VN 9Y/D7;X\@H
MOL[Q14W1(L8QIQ.JK\/T@%/4ZU4^E%!-Q9Q.+J/HS:JM:"+U17&AF,JW\"'2
M= \/TG5F[?4$:K]<9JO$Z#(.IXDUX?684)[T'=Y_A_\&8SO8!^FW?@D+CP@M
MQF6U5A><&X\J\\CD?;G>Y(,0D.Q&_PY+S9K;DBIMI<J:72YNH;"6AE=&#6D)
M8#2J6DF7\BZAHWP=I-$Z^T^:'NT+"^;,TB0539(<#1($^X-U%$@3ZITY<A'
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MEP/?:/QBQ47ZS$9HMR=D_J=GI]/,2;S7<Y^EK(9[E)%-Q::P=!-L[!'A"VG
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MR"Y>G(3DDG9VL\NF$8)&*3*4_I@"MU%W%YAU7P#FA-&"#JDET-ZY 4HB##9
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MX+0<1"=CM0+F*&0_68A2.X]1, BLE[!(\_&[G+;'KGMQ4I&VA-@JTWX[U>H
MDXA4Q@"E1&9V*942O\KA2.FV5 @%XMN[AQXG3'9<3FT1HC&%>29!HT6]D#N5
MA%#G>6*7G;+A"4)>$-[959 0Y;% JE>[VBO$\O8('5A+^F9).$1Y29N;B5+(
MBBJWI,T'QDWX?*8R>@?R>++'U> ;4'A!M(1:.QB'HP=[J^GAKH1Z 7]9:%]I
MQD9,+MQT5]VP"X5U3O[0?Q#:A?2,CD\>OOBA:CJRM)>%8AA?)!&\\X-PPER/
MVFF O1J)4: RC6EJ2!I> 0KTY.F4N7$>F9<"VAJ2'])I;$,6W-=<3/_4CFV<
MM#+1XS =)>_RDT>/OD.CC]-G+Q4IA1][)#DC!#E:L!TOH)10H0/96VC40PAC
M*%1T^'NO](<+Q!5!P90K;;'8@)$6P4 #2W;:'T$]-KRVD+X^(S8OXH79&]%G
MMOP@C1')RVEF%?2Q!QOI8Q?"F3C7LA1AF9'O<1OY=@NECO"#13P#V&H:^Y^I
MFA&8![25[#O\.[^HV::);5 8YM5E_7DFE]MVOI3BB&JEF2R]G>6)0,9N)%K"
MBW/=D.Z<\VK%+@OW0+";@6#?W /!/M))"%IB"A,C0DA3HY 1KUWRIEH96?BA
M22$+\ZZ,1<M/+,F[46?1<_3/?97"9]<^E;F);C .CVEX'%H_,)#(Q^-T72^U
MMXO?Q+TL<Q&42X"+;<RSL$IG": *PW4T?4/UNEW],^B)<G-=EG;!ZN^3HQF[
M+@X'@)N9K-' R9OPH]X9B<DW?_SXK-(>%=U ESL<N#=",8Z-G'VP%&-CUKB0
MA)05,(T_)4<[E+2&WINC2R3S?)"U(BR4/ Y!Y!672Z[9>>',Y\-L:)"4 $NV
M9R>QM9P-S7^&>Q(H1/9VW92,4AA?S$O&.EFIB%!<%3!S,,WD!T;+X8N792C]
M #RX0O];+J42(\9Y4L8'_*F:CIFJ& GCC8F A6S/AQU3A0Q9R!@7S;:],<S=
M;[LTD([<N,^BQ&/CDM<^?B(O-4XA?V&L41V>53;P4F>7%UI$6D07-E19:VO@
MD>>4M/ (V@@O80H.<( SX]?F0MGEW.((A7GLM$B@3S#VRB)%DZK1?A5H^<Y]
MX)QEPL^J=,:R=>^5AI+-!2QMF;&22L4+_R#1BCGY0*C!H5^SL72D=23+<M"+
M=QA@Z,/BHU;SJJ2DS8-UB]J.&7A%4C70T+L7+']FRGKSFJ$:_)-@]G]")6'@
MIG\AK7_O.$-[8E3@Z $@)2%.JBY+*NJU%V?,Q+OPI(@\C-QKGE%I,PHQ\@'3
MOAY&B?5(FZ2--$:R+S-F>XU^!*PX19&<E[M&]3W=0)7RB[I"$0HL&XQV;A84
M\HI!8WGPDG0Q7^CZ8@Q]V7"HE ]^34*K-;9VYH8>M#G-@<$]>YQ/AJY$KGO3
MZ=F%9<2Z^*Q$L>7+.LV"9K\1_?CX2U.EN5++,+21]%@T:^S;]A:YI['1.0&O
MYA,S^OZ&9:=8RHL0>XA&C\>WLO%(T/7E/YXGGN#$*SP'ZT5(H-I^N$VPIE,^
M_KK>8V(:UNE>^BG+C&K_=2U32D*2^(JUB=A(\#*3>A$^7;II?&]V=68?\T:$
MZ<*,N3046YLTVY[*3E6<E^9&',KVI_LG/82NI%Q0322WH%+T+):#=$*6 BH3
M7H78T55*J^IR9LE\8Z7-Y$L# >_.3M^^MOYCP8W7$-3 AN!"WU&Q:Z2DP#IS
MR"#88"S",/X<C_B/Z^Q4[SUYO=VP(3#$,=RI"G>?)Z58L=3F-^D@=0L' !BS
M0A)EN!2SZ++7VU4)8@7>WZNBW=U08@O8E9HVVQK==O"U7TE_=G.K&D@LMEJ2
M.AVMF89H"XLAVTR#0I'IL#]5"#_G+(6ANZD 46#<9+4MBZR/"$GX?RE-*A?-
M@U#&\D6]1A_6.3HX4K:D0KZ !@VIXR=_@ X871=%*-OWRF>A584>XK;JN,AB
MF;],C*-A['5:P2D?9NF5-QOR[/8) 6(H'0-"S;/O&'T\VS Y[/T L?/7L*20
M7/ W34/?M/NHZD:^EVF*RXQJQ((+H1E8^',1R,2O$HFQV']ZK>&BB$6\O3:K
M:/[Z40F53JWBX*OY6Z,CHC*V(U>JO7P&KY*J>"<A>#-"T5!)IE6&L.LO>**T
MUQC,&,L#N),Q$VW&Y=5HR((N44!+M^NY&?Y['G+3..!LT6'51&9%@JG<13G2
M8:;$M!C.IS>J@X+F;7OEHI]1EUHZY,66 9^TGZ08[]CV?AM?_XJ9H="U^^3"
M:Q!?O")WO-(VPJGKD 9J]"CG,Y#2Q!?OIF8;@'W 6WT$2E^@U+QQ&C^MSJ+Q
M''61085@N0.=YD,0,=H<HO0='B8;2J&A1.A?FM$*1W@7E.F+=_L4^3!4'S-E
MO!SE[%)4G^<AU"R#<RF0'$39PF(ZY;KA3.^#[A\)NG]['W3?GS17?9BLG.B(
MC!PHTT/O-#K&36?(0!?8RN$!4LE+*(9B'$ ,$6>(&  %B6%/;UC&(6RJ;@&N
MEVJY<ZXK&AK0-^:K66SNO@+W+UWU$@-U@4P3)!CLA5:KU-758.&.=_7?,X67
MTW'L*>,(+C%)YT_<V>67P(!AHSI%\Z;$1L6*^KY$\[.4K1!642P.LZ8P@"2S
M'ZU2IZIQ69=\C0A%DU0S"+B%3?;DK4RU1T/>73%K:,DX%!O.L[=**@\5E7_+
M8H862TE90_&'+D'*W_>")'!)5\F];'Z6LJGJJE".Y]^:D'"83$A'##J?1L_8
MA<\RMVD\"=EU+TN?I2S=H.?&=)>HKH$CJ6F$DUR'35Z=.%I,86"=!>H+HSP&
MUZ(-:4P8@Y\S+\F'7^*:3BR"7M+IF XG%@P%L+U(SUA[K R<D,9D-:?W OYY
M"G@R^9/!K_YV'0@7+>KX4?'/A0W]]FCOC$I??^XW2;,A28013ZG:N23C$'S>
MC(![O>F+]KT5KJ(QAL)[V?PL93-Q0A5;KJ4T\>)PMVLH*+/<5B2U9NT)Q<FU
MGI-0K*@D6!NY _^:]# ZT]U+R><H)6,%<1]55KNP]^8-",+&\S^!5X%306"2
MN:Q2!#$4)_X+N6+^)/A(" 6<B6=_IP'L^'XAX52#)P8F4K2WB]0\#$[G9,YN
M&@,4PM+ IGHEF<%@!P6Z>7VF<LRG[FAN/8'2X4,UJS9")(JHB&:RC,W3=[L_
M"72SC%$3;RE#QM6V5K"19:F4I3?Q_V4B2OYQGT<WIVQ^>YDQJ?9&Q$B:3KJ_
M1D97?WQ^)?=II@LZ&[N-0[JFQL:LR /%Q=AKR>662ELKPPNUNTQ'SQ_M._ "
M>_!I\['+'K$GD/_)<T3/;!9O<;48F?N=GIXW,7-N:9(@G"/M4C50'(FLGYW*
MMGJ1 5OQUC=ZV[92UI_/MYL\1R-(3J,^>?3H\1=/'GWQXIDC6.B9^0>^^N+)
MM_2!X\GIMNVX1H_/X-Y'^!\.#])W<9*+E39#)C]HUVW*58]A1F+D^^?M8-TP
MV8E54?MEL&3V\NSD'A[TPU3'$T.],B &8YFF05A@R1CP$]A*L)GE^-WCW4\*
MM5C8E%UR2PT%B@IMR'8&,E:T'DF@G6QXAO#L64"5]8STQV@_4"1R)+^03?)M
M(S,L:RPZG_#8]GQZ>)!'TK)6Y)*D9RUW87,=I"\F\X;<:$Y"-]PL#*7T''+F
MSIFIM7E?-W%M,WJ$X#VYO(Q*4A#"R!B4XM/#LJ/CR8\R"*X&F@XCCQP.-/@3
M=)O#PL'N8MM,2I>KM-B X"4K8^43Y]RO&L%J,'%*\,OWASE%G)&91=;]CBE/
MZLG?Z<I@Y,G3QURL]N2)0%;Z"B(DT1^\>/=P\H_F>/+5TZ]I<QY_R8T3A%@*
M9TNUS*UT#$1280T.X6^W2^/T[QU]*#;0+N"7>4=MR7&GH1\>W&;LU[CU.N\=
MD6YGB]ETVB97ZE%,POB@D1TR5"1OAZMW>#"J'+EJ?#JY-(BH%'_Q*]BL;<MR
M'[*S!#I#&N$%0;)K>^_.H3[[0?5PN*PQY9[L 368 1,8?R6*-*K;/Y$- \!0
M:IE<H'_>\P95?$[IL YW(]W<JJOO]M ,Y2F)4U&MM$DQQR>T!5+'70172ZDN
M'[_<N,-?)1 <D641I!7([2\+3JF1^T=CFKE9&"15S>S[3.U?VH4]"8*0EZ"O
MM;%(.;FJ"C1:KR^6=B;0*FHZ$8ISQ;GT#_G+<)N>X4C<!\,^5QF1O>]*86'S
MLFFQ],A4(A^-Q8?UBBO68#<GY1Q<9=%&%1ILF07F0M=9+3O=/R$+L89W:%Q[
MPMHF+^1OG[=-P?TLTW4<+;J.1PDP*+K!%=(86%"VQI P%EJ^E]K/5&JY;TE3
M5_^4^@A59BZ5B-E[Q](^P&^ VPZ&%[?2@E>SN6X0G;@7D<]31,Z,TM9X,^<E
MZ0_@V,;%9+_+=!_%_VRE@&U:Q2'&"'O?J_8@3Q")I%;VP--2P(<Y6#1%&7PS
M:Z87T]H,E1>G1#P*4)<L45\FLFG2JJF&&TS_OP*#]&AL<P_@_6[+2C.H?2A,
MR@M/^F$O0[2_D]TOY\:)1@XD2@512YX,F?_@N Y;S32D["H"W\5VLP7UP*RY
MJ*O<[N:_S\O1KPKKDPN7__X>%?X15/AW]ZCP6Z<?@N"=FH#=>>W)N/B7X)3U
MD(ZZ(E9'M2^C@V@>6.^NZ(GS?>$R9U=-3F]6EOM,*_R'./G(_.O8><4QB;X6
M4F'A>$(AB%'(H/9#&)TDT@V=<B' K[@(^8QRNW9O;2&,US$:9J_+><;7'-!F
MT\,#7P#</Q8U5KVGY3Y\Z;)C)877-R[H\>3,/#:.:)=+Y:07DLP:&;G(,QNF
MJ\LB'N'"FWOAO)8Q5WO'M-S[19.9H[G?'/+*\"2L->=NG8_8RI2F)DE<+DF;
M7EU9-B<*B5>Q!2)GAIALN%BI)CU3EJWU7V ;9'[$*U6L=^GIV??\SVSH(EG@
MC^%EMR]-C>C4GR+9DY$BD<#@(?P,TB0!Y(1@H#9,:H@-<.QI8U;7SR__]W1R
M\O+YV92K+VG=2!3G57%> K-=ER2K\U)A-:CBKSHH71X226.U6FWK,N1>]!?S
M7;>P'APR^*L*9'#*PJ\9]X^?,:B.9JV7;I+&L8(9'):=K<F>!9E:*-GU&*@Z
M ^OX,)D5#$8N0-]4FRWJ:S)B-]E;=.R<QCHR0 *L_*QR_KY$[\_OA(HPMNR\
M'-%MX/7VG 8LI"5EMW&*A!?O/GG:_"0OP?TT5U?B*]IC^JDJ=1:,9YZ\8[GZ
M&=4!KWSS3^V"0>'DLY]?G;+/=E4Z6578XY0&U.I?'DIG:ISI=2TY97PW&23%
M6C"/%X+QX%"Z<'@ =BCFUP+A1KH=--O$8ZPZ!?N6RM"Z)EW(9<,K5'OB%@)\
M/5X7OB0CV6M<<L-K=T " >9B#E$K/E.8QMX4DCG>M@'*H*6GX88+I9^I6PRG
MD-D5IWNG4FT&P+5ED64&?@[2=O*99XW(1_19<Y3&<#S11JC>)0'.G/_]0?<P
M:ZRM9; 9#C5D&QFDN*P6-*4=F9G'AP>^"YP-?O+XD6F?.9FNTK635!G(]/6"
M+_#K:Z44V&]%D8IBRH#STHP)IX^7FOMN"Y-@PZS!AP=:CLXI(V;7#K7R,3:K
M;:U)E3#L0 &W;75QP:([6S:S]V3*-^ND?U+7<_>+\V&H["W+#X*5\DI#I?2X
M*C,"CPB+&B,R&  7!+P48 TJW2!EJ/O\9!'1(/7&^]<7?5<!?@[,N1Y^1-/K
M7P',$-V;<K&0>/Z ,.8N3$M?EL62.?6D&1*0S;,M:/C\J_P-_WJX/;)+(K^I
MR)0#59:#;4[XN71$'G_YX+N'>53B&:(2WSSAJ,2C+Z=.AUX@:D(&(8"RS((T
M#*UX+W((L_0[4%-&'R,C8SDX L<3J&A)X"'IJ=>+P[4??Z5_.\>Y 03&SK>X
M"/XZ9H%@;O1VX[VSM9MP?)]KDW&+< 'V"R5D<UI\;7VCYP-:8-U6  PV!IY!
MHXFP0B'VQ/1 RF.8&9]&.0\PC9OWIR())VE]WR#G(A7\IR=OIA'3[DNNJ@&&
MC[$L3/L'EPF=37N(_2  Q$!B)X1T($3CWQ:==E2>FQ*$:,W%MG+0 &^ CD!C
M(97P4ZEGPGZ#U]?QEV_V:S2QKZ?>R+*&Q8%6%J.$5BP"K,M"RZ.O17Y(R:H*
MES/JT"\[SYH26Q9D?E[RCLBN%Z&; HYSE5'?W>2]PK\JH!PZI6WD(@8F\*5?
MW,A58ROUGGO$2,1*\,N?W&)[9JOQJ5".+^E2HR45\RFVS)FR>$2LWH.@Y+ZY
M4<D)2GCD U\]^H8_\#6?CSCS/:5;8G,-3<%@)[[KRH<WAD1H+$GD(KY\X.DH
MS5>B9#% 85M>VJV9,3 ZN8PU1!F0<H+RT=](0\E MI,S5N1Q<(EM2&G\+&21
M$:\^2)&6Y-\FJOU):B,UM!<?LM_%9N:CQ]\?'CQX_%#N_:I[?W1.WN6"3NEY
ML30;KU_W@](U5H,/GCS4 \W$!LM=\J#2)6FW#UQ KWH3'MHKH^6R-11,W\A*
M2[9)X-$/GC[,2T"WRP6]A(/0JW(CLZ4/,Z&3>KL/OI1OV-SX[9EAH),D=YF^
M#,([;7ZAM5.Q,V-*8NQU3)G-"P>\\W6E^5]*@EWMMT5A!,W!(!1*3Z<<MV5A
M-7LK\=5V9G"X_3PW--,+/4D"5] 52Y?%ON=QIV<&P85JL?@T1;F+I:9W7U[&
M1E=[HRW'T<=>B@,"'GWP[>52:][8>N/\=3$C.;FH1!IY@8ZCTF#6X'$6&JRC
M1.40J%!PV]3[OL$DHE'ACJIALGLX8O0H" 5D/ "P@/D"%#,ERY0B^56:7DA[
MS Y<,Q?81VI]R(_Z@JM<1G9-S/J4_;K1V$(K'H7MDJ/+W%W,%B< QK$EUQ(>
ME00Q.4;@ +?2GY_\(MU'(R71B!=H#R<S>!9ON;O-NG5,ZA&=A6\_XBR,4$5F
M2A9\I<-N0;DNA6YY@-9X=1F=O5#?L"SHM,P9T4:?.ZEK<AU?LC3T@++?/NW5
M"CR<"&$JD]V98B>U.]\J8Y/*M#2YQ#3*KBR=W2O8%P^5UJU/7KM/0XD95X:-
MS<P71 &$(+4<C>:)] <5("TOM)YUGRJ0$ZEJU!$T]2Y--07MOP@GF=P(#0;U
MJGI^Y_1@2U=,#I.:0R7ZK)%*=#:+)1J0J& #R;G=9**>Z0:2M.%2Z+R793$?
M5_-JXVB9P1?.JW>?C+TQ&?OTT7TR]M95E-[F*M?LXF/0-4[7W!US<N\[M&;R
M)N,C<&)7<#+J&9<3)3KB?=[!P%"!MQT>I^?ZO.@J)<!HRZ.<NF^O/6.1@E<G
MX!#?!4"%#X,[DF;U21\W%\7/CN:]OL'TAM3LI)BV]KO@L$1#*P;O14GU/9R,
M3&D>%[S)U\\ZT-)N,-95C9F*^6<D$M95%D#:NY6<*Q3OB^EMH0-I<C5?H73;
M;BZ[6(^Q[RDSZ74MQC>D0F-7NJTWK^I G&!L;FMG<]?.>:&=X$CPQS9@)*?
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ME*AC;=3<4OPJ^8"LXW#<6MQ(O;W=H'F4I" $Q9#1\:Q*FM<\]!M.XT4/(9$
M7LW0.M8D(,4-O8TNYZL6BC_1AY-=7PEM@)C>FB8.32A-]3>+PX.(;HB!K +-
M1^\8_;.G4Z;=^EV6%]319N"P1:D)*06EI)PC<F"5P4/,0)+TE(3C-A;.T+A$
MT//[68DG#\CC-.W[$PCK-0N4\5!K<-FC\$>Q4'-O)X&C"!7,[5-'7ZB.?YBQ
M93Q^9';<8J1%<>C$5-P00'YNC4^ O!H\Q.P#:V+J&+9:U=F8>K6_O9*;4#EL
M9YJ,0]K<NW%LU+P0=;P_K:M)W[&X:8)-69NH 70*[9+.S?$M'&VE3 I%EG3:
M=R=HY-%2R0/-#A[?//N;VL.^33;#<'U3P]HPC/$G):/>$[)=]<'\@X7WN2_1
M*U/-WP695A*_%/4:&XIZV-V:8 _.Y8P,/1IF8<WR-.=*>B@>RFM1B7@^P[#J
M].00_T_*&7VS&SK:V@AA$]4TDGIE7: #X*AX#UK$IYY:)@5#8=&U"XL<6[-,
MAIU9AN\]/+ CD:8N*>HT;QAPHZVA\\[0-W1RUY;UB?@T:G9<!R(OZC5])!+D
MY3@W/177KG7'85H'#&ND<W>?1.FF.^%?E7),'%#P6_?;;TH"4.=3C:2-2LT#
M.6-WSTB(,@:./CD=:XR+EOV6TY>G&LNG#[5"C ^I@ -@O=53BVG0=FOKX*J^
M:=L.#\Q[%(1&68LOE)IVCR@4N_6]WP\+%-T8YO1_\BA[Z);QG*/*=,=M)&MS
MIQ+4RTPCS^$&B%PV2F!#ZQQ 3=XX;T0E'1Z\H\WG<I22?K&?&VF*?!;HL3C9
M6-JY2L>R%Y@Q5 K? ^6:]Y7;D?-(UL7L/7?^-J..(4F'!YAI,@[PR2@DPAP5
M/6VNQ;S!F#B6O<IN+K%<NWV(+\Z;J\T+G)3U3S3S5J%1J4FA##/Q019BU0ON
M-O2 ?%"<GW/DG<_VP[RVX'GJXI;F1L.X;CY^<J9[7[@W,B/]41/7CAN<XW/S
M)J7>2G(NG5WH3MWSYJ&Y(^^4(9&D2"/,VUY>VD+':^)Z&F5,=[!%]J%:;7$.
MF).LK(.Q$=KF22.XGN0)+:@9JKU053]<:0EC$.S^/+5F3-$Z2]<9T*JM7*]\
MFL:MI<YJ-\) 1]N4<*5$NGZKMG]@V?2Y+)?"\M2:M9F<*@<;V$'4.Z-HJ\[@
MD?#8=!0TUHHQEZG[J%'/ 2TVTG]TJ#)V0WE#3D>O\ MK196DOJ\(II-^H](:
M:#V:*9U !E2P<PW=Z&W'Y/-9WU)SRM5%M6<YM]:^ Y0JA:2*Q6.Y0VU'9FE4
M=RF_CQU77C^XTT=#JK]^.7IHXACJC&X%?B'=6O_:T,)M;ZGIB[#\T6&S-PQO
M</B:6/.;'$X!2-W@<?[VSDA'MPSAF3-*^A;;@Z.,]5 @J77V8H1Q5$@W.-B*
M.PX;,M:%M-\D5-6K6*NPM0J. :S=I$#Y$,ZH-2XX.WW6*6R*?\RZ=++NZD(G
M4[Y_9];0T.-WM#KWN<F/Y"8?W^<F?X<]G-%%&C9VWQ'^F=34#V7)D275LW?M
M@5V77C-ZJU!-B"]?EP%9;O"]C?6E]";VW,Y9[.^P,'D;5[$H D5JZ!$);;)J
M7(<)&_!89<X?H-GZDS+4 [0:#_@U[MHH%G>ZQ_]5*J&=-#@O5D@[7Q97"K+/
M"7%?O'-KE[MNTM9Q'4)_7I(HD*1K(BX"/V!>#Z%-HYN.AIH7T(3&1\&#B7WN
M LQ0#6:%SMQQH!O;EPDO$J*\?+U%'8AQ5NK*4STY?=E)L+)'E''!79OR[ZZM
M7Y.56["E^2YY:IV!/?5<6J\ I)FOF,Z$K+=M.XQZ^-$[/(C3TLBH'NHD(*G\
MBLM[:JGZX)A877K*O9'B$,%'^ALWQY-_,%E\;P"81+:<VH*-NZA!IJ(8M",Y
MYX@>'>R+(Y1Z30<S#)V8U SU98=MW:S5X$+9+9EE;+E)3 F,]<%)6%0<T60P
M,BU&L50W60\/&27B]3&2U#I]WGS,QI>"/Y790$!S@7<)N7"RW!->&$%Y'K'A
ML^)XTRA%>];6+?9E>MR@_)\E"T^4(R>=8SDKZ-^7?B1Q!9!UOV9J5P2"XY27
MC01(@];/V+4_M>)^%0_>G2>W!RHCA+;1OG,:.X0[AUML*I-B%+2^9=U)G;87
MX4^]\N7&>*CFA?Q9W+RC=VUK[QKM?#S>5'JTK9A3&&-,BI9!$I2GYWU)] WH
M$,5UE#+0GFV@?H9Y*.Q/ZLI)MU,)/PEW+8<! CQ(:/$0YGNKN*2209* 4F[&
MIFRL#(G1H.60XR9Y1;W11TWLT9/T&<DB\8OYD+&:E=(4*\+EB[1)K>N[,GL@
M+>+2*B:T>ZND1$&S4+32]WO#Y;^<DV_A/?OFYH=\!(E%+B <IVL,NO>*_'IC
M%!H=:B9PWJOGNIZ(2"@"59OM=KVQ!(6P[9NR15=D%IAMS<F*6;6&4I\U%@A8
MTD^H2*1K26\M>7"W/?^UG/7K3SA%[JT'EJ1@E]+(/@4\9Z+Y4RY(XGF;B0*L
M8-5>%RT2E,MRLP'?0K>E;:DM@-(3T:ZL_@F2HD5*/%;UK^!@N"KUE;C<K.IR
M1LI8^ZFT['W'"^8OH"#=XY> A1CDGT!5QG$DQV!4:8;<'BD][F%QI' 0*;Q@
MNP96AQ4,<38V!4N*.>C4H&:$:1JFQ34*7Y$YTS(+C<];H^4OU+S0#J]::*1-
M'8QM3\4OHDI4)65W9.A(4:U@@@5.[IRJ72'WYSL-P88DP$AI3&9H5*&HK.J8
M\I@^O-B2SZ! 4:GA))MUJ^2A;;E8HO[2(.7]2LO9$HS+85,&6-,]6,0A&(\W
M*.FMWZ1O4+ILB@4;VAEQ!R*G@T.-[)^>T;#_D#93(H<'?^FSFCB(M?,)3?UE
MUQ;EG1>4(LH32KD'=.2<+^#RS2Z-<:K9_!X(>MM):<FPU8,=7CFBC:?1*R6&
M ?*G.BZ/Q3]['C[V<].M*ZYO/IH\?_WSP]08 LBM$8[[CDN8R<N=&\#3S:GC
MR0F#/_N]3-GJDIQ*UO]4A/]E&B%]Y8U48?W0L'YY\/+-#P\G7["-[JG"%T+&
MF&@U'KQ\\>QALJMVB5(@.=2ZF,9L[JLFBUU-7@E/#([=SU(*^>#E*UH,@)2\
MLC6%4W_:DII)56@#4G]:0ZG(/9/+N,N:@,380!R&UN;K"-X$O?>@3ZD]> $-
M]:MOOGQT]/B[;Q\Q1-MKDG2VU4IB3/3?O#/*K08P5<1>)HZI>;=4/<4270%A
M\T#(B[U0DYCQPQ>:.O.F0$%"N_$&%J[5V33M;:6*N;4W<C@F?HEB63'OF8#$
M#4 /)8#'FMWV2Y/&YR7I[&34_EPN2?.]K^Z>4XQ$_XN7VD"$15$F3@+]SS+>
M-U,+]5O^C!%UYV5 B O+!YF/-:=\^/S2P6B9/FR>0?#&-LJ2BI:(#H:H@1EE
MN?FQ!G.%2LC8RQ1A\ZM66\[)W&[IOF#W#' C ]NG0C/S(4BSD(%;E:A/:*1^
M>D$BNDG( I\?ABG=E-4$5B\CZD!WZ4T92U<_(4X(5@7GE&&A^]W,?89\,R[2
M^>>IRX(7\TM+<U9![1NK@\-;A7K""\S$H$!+7X$91(OFHMC(0ZU)4K-M4YU:
MEA^D(=PG<SZ2S'ERG\RY=1$$-(%<!3,6\E^*Z[N-V>LUA)?K'<#&Z?IRU]&!
M+VI3>E4[/V(ML"-=L&.3?[WD4\X:<\70> 02Y/QPK!?M%3F*82Z.NC!..0,$
M@+L"KM_L:@O>A-5W3DY:)'C$WM9[9C L6,HTWV9%_Q)5[+YZXRT+@N>S:$D[
MB8XXY^K41&AX&99F2?NBP0._KP$I'<"SIT:6) Z85.**41/?6L[AL6EOPTVI
M;]O[,O,Q)2+C6.W[?B]_:;)S[)5N]0E=[$?_6<W>LZJ!L&PW.'.7U3D*%O99
M<=SVQ>PN3IB0NTPG"&AA$GH^#K3,#?Q,A\<#:;+>I.%HS3A?>I(A9;+.-E"@
MH?*%_BRE10T"&9S_X&Y18DO2&UNQ!@O-"DRE]1-F25^ONDO-HQ0XJJB]T!!%
M^GLV)CHXJVXBM4!7%8=&V[):G=/]"^E,S@ H>0KF<I2?JKECHR<7#GB1%"TI
MD96@-VAX.CYR!V9DY]+WN:I2@-4P'AA);P-*PY8E%"6&#)E\'0$W?H!^!H^P
M4#HM;P4 J,_FCTXFC<QF15I0UYZ_H;"N>5-*.2,H0&COD%'36D:6'G(C+]R>
MN5D>(RT(,/70FU=5LT2YE(U'ZH'P'O,C&-$LGZNX04,5X?9CVVRT8+!>PU=O
M-TY-2"HC:]A"#A7+_D*SDPL-N!T'M4!IM&TYS>2@]!_QZ6<20SJ9;>Y[BWSV
MBK:_I9I9[#3N[>&SJ45V$XA;/G%]21NP+,^Y-)C/^.3_;*O)IEAI+)V_R&#)
M;A/RI%U0:VV":/-#57^C@*7LI'H/VFE6;#LM=I:^3EVI\/TF.P%))4PMV@E1
M%N6?C*<1R<]&M2JDB:]^,!4<<!;KJN'ZX7DY:TT_@F(*-DI 2$@9X$YS\GL'
M>G^,/MMCI![!2W;4D; ];5KKOBW(DAD:E=JO3H0AX?%WWWT-J?[YY>D)D];;
MH;.P-2QSG*]E58148OFAG&TW"I%FQ'+0Y@ADF(6^RRQR T[KS1CDNR?=.:M
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MI7"N9*L-.5#-+8? Q$LJ1[K[QL&?K1Y.&M;YP\<L!90Q]^T$08P*^A[J0Y\
M'?Z<JQQ26[S4OD?!7_J,-)S7##U%$.>EX.7I_3\I!%>-I9$'_YWG-2O_"DV"
M_^U__E!R\-D#48R\F'MO@BZDH 4ZV[;-=<TD&UG@BA'MR::3"G.0/I,R/.>J
M,;>!IF.-?TBKKC "+AU;;%DI3<XY(@XV#T;&2@Q]9@VP0B)_=LD,EUSNZ=V
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M9VOC^MCW^8:3Z9!=],NT%D)@.Z<Y\Y*.G#]3H.,'*?]"F%QHCP#[3' W75;
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M_>62_#.V]?I'OC=!V[F"W9?K#L1-]>J77_[7+Y6O5SLX0NY8S,Q0_-<['2P
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M#@]00LS&\W'50@X0^R+P"H5[!QG**B#L\!)";64R$WQM0BWKSJ,FY)*U=KL
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MZ,<G-/QU,D0H?],-NG%,\^W2DDD72JHIBF\D5.>BR<L7-3>C8U$F"X[+,,5
M8_/PI/!94>%FT@2GH&"U$3931'<%F-O/?_Q9\Q\M%\@!'&TURQE-FB 6G9)$
MB++0N80Q 8[A*NO>0)$>I<^FS4;UZ8]J-W=:SBJL-C9MLUU_/]']7HI4<DF%
M!JQJX7.0>&12.F>4F13EI-%F%TH-VWW/&DUI,QO/>@WE3WCZ)7V"F57DM-;&
M)4!\-^RH22N:U^V2RVC+&BK.2R)*EFL=4G#[Q>RE\EY*Y8GPXN^<"!&M^;-O
M_OSPL8#1PW\]*JRI+IAU>%:$H*/_W/[;C[51?C.IK@2KN*W6\.70.T6SFM:D
M_)W*@Y*-QLE(XMPB]X)W+P7O^SDW */ U+\KF'#N:J%T8WLK^NLNY#385R%=
MN=J/!G473#):?V0RZ8C([)+KV*WGYI(;JZ RQ)&"%>%6VY^<4)Z&7]+T>>]Y
MC%#&'D@/T5A@=[^*T] Q9!TEP&,RW.C.[8&+,D1JMGYS/=/Z\]E($OEZOR:&
M@(BB2=4TC=<KPVSL[]G]N6?"0[Q<XC"C,DXTR:P(F<Y>R_!$Y3-U%T!C-^5N
MS*(^ECOV2OC^"H>+E&W6V4 BW&"$\)E9K<P(<QOQK;]1F+X5]@^$R?)]8_P<
M:,:T'O<(&\ CC]CU<T9E,JIJL8[AVF-G==>H?XO68R3UDHX=&H2];-]+V3::
MVK'I0+2Z,EJHNJYEN/#30+WM7$GLX^C!$ED!,ZM73K2-7=B/LG08+BM\LWM9
M[E,<MSCZ /CEZYC7Q%3*I**-LGS92!YLQ-'1@5!]%NB]F-]+,?\NM<V/$9U"
M^X& 83CX5$4M9D#WYW\OSU\GL3OEE,C;>EEXK3VF5,]BF[C%9<Y$IT5686\P
M;IZ]HOCM" HJJ)C?'A.&<7:SR_,Q*^C),FS"-6BP5U("02"<\-,T:H!9 QI=
MLL1**AA&QWXP9_T?9QD3<<Y>PGX3$@9S8^Y.G$=<Q(&#Z'285RNA**U0="<R
M;%T1GK\1H"FPO%MIAE&Y"N[_A7E><.RKZ?D*S%_;O:#<2T%YDR;.SG?")#QH
MP=)7ER1P6V@9_[Q9&(?ZK7XDE?R=!LIK_\(UE8K_>P&[EP+V?]E^(1I$$2C@
M ZY/M9? >'\XR4#$*(9Y$G()?#7UB5W%V<(EQBW(>!DE;E/UU*4QR_+HW,X-
MUH!T<7H^_TR*94/0(M+[&E_=R^!]E$$%D&\+#J5)%,9QNC+&DIG/I:Q*S^O9
M+!S,L[);CT=NQ^]?%GX?T.DO?N/0Z?>,-^LP":/4H6P @"6([,M&:&+O'A:7
M 4='E_Y.L!WRX[YGW,X(7.?.*2+S'<#06%TC9KZ4P81A66/H)5_N3U\C6>X?
M'SX^?CA9ANT@Y_U*1JY@U_[X\-'QH]Z_/.04P#%602,5!.9E.MTL-R)D,\XE
MH@?VQZ\^/_[<?L^Q>'*^P2\\BJ(W:4TH@/5K?M :4>WI:;U"KXP6!9*W65>6
M2"&'^8XA=44?/3'XMOZZ2\I= \4H5QD=>X/W>_GF.SQI:>,5L F8+KU9"6&L
MD/E+EVM?T&VVL&X$[\+(X>S>5YU*B!RYNV]Q$V4@YD9&<;.E*('I)W_#T%7)
M/FD>7*=;78TO-,UH!I0SXMO1SAMV6T9.IXR]'^+-GF7\A ,A,XU!+#$&Y5F/
MFLS^>?091[EWG.H(#\>2(+%W./M1+0DXM*D1<..O7_WO<GGQ]=.1ZBN>_I*8
M[X>3EW^?8$3L=M(F[2M;?I6=+GK*(4>ZP%E3Q?8K=N:SFZ*W6IDO:LN-,P#D
MT8\G%_5EL]8YN61D59D%D+U;5^'3;0.$FKU *=Q":<FZ)I'R;YNPCTU0:%]\
M]C6&AM@T6X'UHQIQ37()^\6#(8%1=19\I919LKE:^J7Z/_*V\NCX,CJKA8(P
M-E67\%W]U/'AP8D?)B1:01L%LODUZ+Y@9FP$+G?:;-;O )>3)C[10V6<>V7$
MH)R^..A@B84BR..%(9K' %<RZD6BCJB1.!)&&F#  @KCT?FH1N;J$NX?KE#;
M@$);]:5FCI$RE'>,S8 )?!VV.?P3)A(M 7*9ET A3LCZ?E6Y:<GRSL>3;ZII
MN5&F=X@XJ/-1>U8$=GC29J6,#FN.QRV5",&://MP'Y7,F&>,5^6:VAXRHIN5
M42E ZT'B9.3MS,8DKT%D0=)[H3(V^OCAT^TLC+J X)OS2EH?Z[FO)J9G @5?
M:7.DI<FRT80]&MI&!6=%XRQ'$RV7/$18G]-4FK7.(I)YJ;B[/#ME>O96R]&!
MHQU%0*H[07XVSQKT)UIN=T/#4HMN__25>E[FL[:R7B":T@4U':G= 7U @IJB
M_@%$DXI]&9$$T1(V!7<'@D 8=.6H$W<N[;*SDCQ'R:(70FF/AC;MS=$O"YN%
M2L\\.[BBKRN$X(+C X-!W%01QG"+M+PU+[CET0D,GI9>8=IG[SV=DTF&GD1_
M"!L3(^MF^E83$T9$ GE:)QX<L<'R_(\Q%G@'O'70+;=4VH.+>%OH]:T0US31
M[V!#WHD X?W$%]^8?2+-"D2MPQ87SE[=\)9]0YD[]K_"IH<K!_S0[5#N-ZU&
M,S5U:\WU>!IGKINJ*H-*A(VZL9O5@B0=7_L%(Z3'QKL>KNLN!Y=8:(07/W'6
M1]"J?WSX\/A!"IKV/O7/\*GODT/=]QV# FNKR4?@.S((_/5]QQ<WZDA:.UY8
M9Z@GPTJW@,"\3=5587K*&U)Z\7;+T#CIUZ["I=C(1 G9R4&5\K(49'O\K7!
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M5C6")HKMD-;\.-+QF(F75/>H65S2LJ!Y8D0P!9'*.AUO;'\4RHH(0.]V4>N
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M2@P1?$UH'R:B*31[UF]:P%>EQ_)1[S5=DR4!W+[+\DH3R4Q2##8HOI6B=+5
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MZC_^/13U?TXVOD\HX30"PI=NHMGB;KL*TKD6BL[):=VP3;\B:8)S,T(,>[+
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M)4.E./Y^1[<T>=A^MUF-%"L,[X.,)]\K'M3Z',W_N5F=(XZHNXTT8PU>)%[
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M@/C,"0#QG!"&K5:52WB6T83'&-%["D?6!KQ$QMB04M<0Z?;*BR-U1,VG7!@
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M2#C8\"@U%IO9GHMDTVT1P>ZO7-,?86LE 6?79KS$RS G-N\AXEEAAY33*6%
M(IZ#']LLS"^30E@_BRT^H\O?I1L%BM,0+W$@2W(QZYEK&:\E@2@$&S1<)4@D
M>KZDYA@F5TW[MM_D!O&W!?/#0ED:Q#>-63\MV[8F)"9VG8MGOBLA/SP3[Q3K
M^03C>)U5M5,D4&.0Z0+[*_)EFY4BH5@;QP^%@$9OKA$4W6FNZE4U):.<,6*
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MJDRJ]DRE7$^L3MXHE]*'2T#&@)J/DC'W%2"[7MV..2 -QB;ES<[ZF2,GI>-
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M!5;Z ;J;U1.DHX)$H#IRC$M-S(5I1ME?$4X]]Y%>;>-PY(A . NX[V;7:KP
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M2E@:'E&%]20PL[37D_&$W3Z$ +9!F_[Y8A=>!MOX&ZI==F$5/__LB[)0]X;
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MR^U::VC%-<N>F(I"30PH_$^Y4,,%37JYJ(]52(F!\BF<5.0XR.7+.WW:U<S
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MHO!WA)D\V)7DUC37VS-6LY@(]L\^(LS)\_7V$A(8,;<= QDI+!HY#^>#J6.
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MU^#:M)#2+OE[AMN@,3%M;$,;;]+9%LR >KCIC211+%K;57(NM[AAF?Q1&]J
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M48=A=&::69S7F;CG-*Z'&- TUP*4+,1$*KL/$RK=;4K'Z*Y.21D[;]+O[Q_
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M=<UZ1HJVTX&?GKB1?X@VQML[ F.K,Q$2$;<_UU-U1A1F,6HF"_^>E-\CM>S
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MV%@NA"F3#&4G7/2^:I0#6^C?OJ9L0*_1 %DQWPX-H,0\I67Q59Q/!KJ\M3U
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M;&Z*+ 30T2IRXE_KI?H#+' I=Z+"3+K!,,:)1>%6BB*\3*DNW-HC7]^D6-'
M\04J>9 [TZXA8K+,,N&\!6=Q$21_TK])D1+?(H@*)"B2.;Z0Q  [EGL4=\A#
M @7BO&*N&C1@5(GK76 Z'!6<=N!E/1C[&CN.\6XSJ.Z!2<5:4-*&V)2 1%%M
M]K!/L_"$@AU'7/JJNR**?,:M$*W@25([0-#+4@V@J=61!2%ZHV#%A>Z%W+E1
M2D5H!E:N#FV0O%%Q1BR88JOKG=] !R_2"*Q5FF7+0"*^)%I/*= S%:%2.V@5
M21&03^4^74W0>S&,$"0O1339GM3^ZKU!X9:ET4CLGZ)^'_S<(T1K9O55*@)>
M?CY/@)2X*KH^LP?6O +D)2KVE$^95L5E\@FN1&&+E4ZJ KKU70!<"QN7#"8K
M-*$>?*"RHK&]T+Y99;+V<70H4=;M'"7L9)=7O ::5<:!%79G42)LYUAO164/
M=D%9)5B2>.W]K3W"I"17E>(9%!['&DH0'70#2#D1-4IFA;!,%IMPQQ+<&' N
MN;L?K)2,#MQOP1#,[%=(4 C7(6H[GFT4L&F@10\=QY$RWG\-_@I@L%DT8O2C
MW\*_0&CCX&I];9Y'?0Q!^Z;)ZQ88.3TB>-7?&8\8"!PIG%/2Y<@8*P8+6#>Q
MJAY5G<YZ3C+&]35K9VRM7%*4:EV\L]LL"MBTYCW4S*AZ4/J\\7YQ*:N\5K(3
MUJ%D=@&XH4B5DU*,5.&&BK3I1U-$&P4+G#$-2XU+6+.=&A1;3QD_98,4]6-?
M748V4(&4#AE5@?674D+"0Q$%SE%G1\;*# I@9E+4U.*OYK),!$_61Q:_I:)]
MTFE-WV.3"LN<LY3NXD%,@%U2-4_G /<BL0P-):B.L%&X&/F!X(JW6I[MJRC,
M87'Q3+G\;G01<2\_B1*8[%1JE5L7D!QD:]W'>?6-#AR].I+:)[Q.8YPTG(4<
M,;_0Q_@SS W'?'2-?$LP-+2:"U8J2J!1R5FJ2ID@$J&%7]>R5"F5XV@JM2?+
MS1XE</VD>:$T.Z^&.8$&YQ8.1C8>J0IV$%-D<M9JD7J-Y12LKY6TFH*3UT7?
ML&B):::12G%=+%NUXMW*0TWK3E:;/?I^U+=8BM$W*#W2L!(YJM_:,!L_\W(<
M4%!7I2"L-[E5STEX(TD P15D=YDG8 A8#/YKR5I0Q]Z(K)$'B6*IZ(=$--A!
MO+E*A]K-I0!2@()-N/]VY_,M*DR&V)&XN.2<.'0G72E63:;.(Z+VM*@K["IL
M^"7%^?X()>LMT7QU_'3V15F0>LX4BM)WMZ('[[D-426\>U6F85DD6/O]8.GE
M,( MON4[>8KTUN*]EP9O 8E-XL2DZ\>!!&-6(?HEEM)E$:E?A X="X@(NB<]
MAI$F&A)#"1OE6L]9LD.YC) 55Q\T]66H^UJT;==:7Q-Z@"&Q#&DGRE@CU&L0
M$PB&N>0L4#58X4OXRU]*]]I!&ET'Z&*!6$NNL^T5A\/6%G6^?J6-K@Z(HW06
M3UPU8(F)18B@,L&J]RR^-3A"%%G&+60@6/89B:K -XU&S(A70MM!!7$M+0O.
M]@7U^J!BR?HZ5BRHM]A[1MN:<RN T%F,[ZEHF_;A*?FEK2:_]%#PF"H0CB@X
M%ETWD\N-0_"+'#L98_L&T\Z?E XNWX,VW$KZZK;-SBJGIV_ ='TU^5Y ["-8
MST$7@IH>UVAL=1BZ@QBA-/\0E>VCLG[-6H40:_5ZX.6%?"7],99ZJ#+/6PO(
M-V,,<4R)<;YI:YO@<QG!#_6.><]KKFF)!(8*;J3;,@&2)J&1N5!I T=P80B5
M *(%^8O12/%UK$L=KB!RQ\]"$ H\J-2.NHD#SD*KS!AT;) KE*8XWAB/R"XO
M+00'"NT88Z4MEN)K47\#WK+CW7!EIOC V@][#YZP'@MX_@;P9K/=H6_]<PQ+
M"W_;LAT.?#RY2+Z"X<)B.E#>A&JNK+7,0F:WH:=D4C4WF#E%JHNL[B %%WFH
MN"X=L'H3M4@=0;:XP,KG2U-&R#/Q!M0HC0SM(FU^;M-))1A$OZR<7D[J&5M'
M6U 3>8U*9I?O6 +4,E;%WEK)?CC7(G&863B(WR/<>@I1P[P0CIQLG7C<TPZV
M72!%@-1]=,4S*SLMCXJDPZGBI;(D**[*B>AER^^(LZ<#JX.WG_#I<N.S>%06
M2*8L6HGLTF+78CFM7$15"#8\2&KIN3AWYE7'SSX?GR&IK7WRW#*_]35-PU>V
M"2E1*WZ4+>4608&^%DD<3+!6G6+U;%]1Y;&!".J$!G:H0-D+N(_09QW$94^4
MM)+.BBNK<:!TN K%]=)<!WZM937/&2>$4,CJ#ZY#:FU!:ALL]U.\-KC8 5)(
M(I>($X^#X4HD[EKGH*SU+L7!I Q-,Y*4=T?UHIF C[S#=\X >P%N)R!'$[#F
MZQ.HMY2:LN^0#[QKRB>8OL;_I..$?$+A-C +SY>"2>FLKRG+@-H9X:Q0+($:
M27)&$2+@!Z-)*%B&0;Y['W6O"D!*% N*'R13+:@4MY00N1$C=$["JDPI=@GY
MOK/=F4-%:V^_O57VUJ^O'?.79'.GBJ(R/Z21DG^V,21^A' 29*.YG6NX]>@B
M#!#@@TX18E:U_:H(TBS4[#!X5#\C/ 7=5F?W)^4$.RM",&L8$*(K44[2Q:U7
M<WA)R6UV6GL_T?F 46T^;%0[K7T<E:L))/<X;5BT,,KGQW(:M?U4E/4M&K*3
MO=G:_<E1VZ9MU3Y8O'4X]'Z((:7$47?"K/$$*)HO?OEBPO5\2!3NAL;(M#JA
M@HLL#?JV2B^5NW]-L)Y]?8WR3WG-?>8$/^S&=G6C6?=863.I1'!),2F+. \K
MAH/&^]"J17/!FPO.#;AJ )')O);$+S6(TQO!R!680/:%X$]P4:E2!I\;<CBN
M*6&A\@5]%?8O&84HPP]U]<@H#M#,_""SUGK969;9C,X)5@0I8?P]<Y64%6[]
M"F#Z'CT\'3G"J:E<.9*.4;AY%*K,JXB5&-PK:<\>UV -(RU#PO%C8;+Y8]R_
ME'Y'43D&<Z ^6^PK )6L$)H:4Z.(%>2*_=:]:A1])^&TY)K0O?X53P) $^G>
M\;!OM?/0E.H3T"W%/B-ME#0Q#B&,U;TVF7_6+O.D.'.1&]+W27XB)1XX5:^U
ME%%1/,!<137 B+-W7FIP4;.(L>#\2M/3<OSYPN*.&@9_<,^5W.B&!LRJ7Q'?
M6L6MY:M&;/"<6M.G7,WD^5N%#G?,$_6.DF"9GZFA=;[K&?&F+(C!WA_6'I->
M2GTK=ZR68^S2;/1(+$P\.6ZD^K5=B44]L-;+%?,R<9R^/2IHY)K1B ^N6!EY
M1=9A(156/3M!V@HEO<"_GJPI+$4!TG5)%9*JUEN5II7J7.S5RR5!-QCG7 YV
MA=V\ 3_54)9AQ@*V\C+DP@AMT=:J+N99U1D\TY2#NTDG >U:,I;@@B='(\W&
M!)]RD5%9,:<@>1 E&5$-:64QX#P?50':4]";I)GC[$$Q?3T>)!P:308_B&P6
M'ET"KT8S<+XXP%BT(+:9'_FJT+:0%+/5(*1_37WW%YQ\5+RAF$[4&2/N[&''
M<H-(N(:T/)R4RZD>DH4([ K)90T1N2K+M8 AFA>;_$I,N>*!#Y.U#,+LB7,"
MU[N @2KZ%.+SIND:L[??1VY&3?FEWJJI=1F+%W4[JYQ<8I12M7U*P%Q2J'*F
M$:+@+Q_0+?RPT996<W.%6$7\!SW#1>:='1U2!]T_Q["WG5V$V6WO^=P>B$^0
MUM@C5B%6<<TA5D9X'PV3NFJ K;'9S=F^K00W6#DQZ4RM(6!%U%5M^R3D\RH,
MJ%*AJ&I5>BRX8?)%#.A$W*ZAE86RA.?4C3]J$FR[28(]Q#S^XG1!EI4JBO@!
M5J3'H42@+HF8,N+D"9X>Q==D,]]0K"4.L%A2$$\QR([E!^:&#2;T'A6*G1A!
M 3(%3VCC-$KOS)+-8W-7B75,BR30)GCR,1^5Y583$F4CR+9'A<%44?!/ACE2
M341@SPU>$);,Y;BP]N,JT!.,.V"WAIGZ$\M-T>8F IM8UK3=;Z3XC-1DV-=6
M=X+V!B\LW!^-0U/<CH0YUAJ*&XB22Z!45'FHBS:DIVM[?Z.]O[_O$]&+Z1B0
M]BX5JBO]3/,32$\LIY>X]#TE9T$T+#69<1>ZKK3G35-W/1HA;&G$6#2182<U
MBR_=D/1=M%PB(NX6$G(K:T:UF'SSH/U$%X 464IC;_5:DJ?2#3L&R_+:(M92
M@3[PHS0SB=T&Y!RY@67+ZRHM,7SX)2W/Q6H(' EE 8UC6;]2STJ4YV.,_;!2
M*%2K@(95"Q)NNKY@BJLX))-5J.=[),&9:E?/=4A"9V(-(9Q]P<**@7J%+=W?
MUM@ :B <7M*E2H?\4BM,Z\S-;B;/758XQZNC5<5?A&IG;=# 0.Q[ZAGAUBA=
M7.>\CA,,O@6SP[;?,)@T0M]=*0'G3C'\@ZJ0@O'[>WH5RMMC;8G6CJX?2P)F
MG7BW!07+[+#ET#2O<$E>T$- BT"RMM5!#U''!VS;$%:"^(EY] VN"]#J5[FU
M"&KDDS<*+@SX-T&M*[D'>')C13_N E(HPA%+O_JR"4)HJQ86]/M(V)QAF%'A
M:FDYI0Z%(']$ZY ;^="&7AZ&?TK!)4A5$.58IDV=]LN]GIS-5@NGR([U2N6&
M$]24<CM7"&B:T2B$%W)SJ(3!I$ROW**J2]OI\$CK!!8)IF%N'QL<1X%5X+=.
MN9WPD:$:P05TGD[Z0-?BP0-*-XH]1;R(]2M!R:1PR?U%5,\; \0A8EVA K-:
M*PK98"&479K4FURIWTMH6NIZ5\7%YLW$="B7,7S4)X)14A&F/-%!IY#K]$_!
M1M(_X#K%2W&CN,8B!B=*5SDG8QA%.K;KMAWZZD"39QIRF^(F)7PO2\/:9#LV
M*(C#\,W07T)SZ]!=B\JW;QKLW"E(8JQ"3*K>K))S,T8.YTU4-::;PBP#F:E?
M\C;F-\'($5E!4;66'M8DU_ [J)]!,PFYZY7DQTE9A=]&$6&8DGSB/W'3:JY1
MY52L(J$B(BQLLE9#+4&NJ&QRW5^S_/(O9:4K7@-/ T>[_4UAS"D8RG>#1%Y>
M$K@VI[P9:(2I:BT%H;6GI%\1.B=B5@M,8W "%[X*CZ_VS7&"#0,-L)Y2]>4>
M=>08>**.;@L#IHP!6P$Y2 VC&7DC6'"!'*?:/6$\4M4]'V6Z_5_0N2\XC"/@
MFH2WE'K")B7@Q0-I'[%_C/<R,1@6"H2B]!2T9\-A-!XR3!_:K$'$"EQPFV6\
MM:\K4282\Y7U K!_*.AD$TGF9?"<.K=16>U*,%<R.?1O2H4Q,(Y4'J ]&EWH
M3L/<-0>8PWE" ,[N3$5'E\H7N4I2U)FEA>]ZJ]*REBU,MY/6KJN2&2I''Z?-
MRC+P-0A_^:"5%]B.0=@5^OJE^=VOG;836,0V^U;@=7([HFH7W)(-#K!;<,N<
M$N%K$8&J_9(]F98BW^SIP>6!.I>J9+EB%=]TF2+'=$!%^5QR"YX9;%0ZQ/5B
MH#R/R<BS'G5"DDEKS4?*=-2_V!ZCC?RAAL&<$>0N5_!)&$$B0P4B]0)C_<91
M>L,CL1YF>1@N'R5Z")?D@""=-QDN[&&KVT$N!)(0]QR8Z#B;W(+]HO$GJHYK
MH"0'UUWBOISZ494WLJSEWS' XE\57]-7IB!W/]@1'=XC%]7&M:[9!=6.<XFE
MO(S/XWP)KH'U-40<$@,R*JARETD=Z ZB/5!-I)(HH?0H 7%PU:WU0*92SVQ<
M&8N)BKPF_EB9GP9UAANHRA7EI?TG@TA$&GX-8IQ1<0C+G?--L?@NZ?.4]U8-
MSQJ$D^ 8<C&*3FT$>.EIZJT\CW3HGE25CEA0$&%H(>+6W6FTPJR$' D4\?"T
MZ2D1RYQ0]_3/-68J; 0LJ-0P,SFK75-M'T=\4FQ2&2CK4W(-FG2(LG*LE!#-
MA=]#)MZ$6\125JMX*SLER+J>O*Z3E;6FU=/4,]$P M#-BU+40^?<Y=^'\@(I
M%!*?B-'^564:N;XZ>;7T='7&;>_DQ1E4$XTVA0&Q+/>$[1@VW4WX&[=7]RJ
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MMMCMAH<@HW>)?,\&P3</JY<00@N^"7GZD9!8U$L2B8]!9!L$US 8Q3TT?BP
MHOI6JX!BE^>(.TB0ZA_U0FAT 3[?OZ)WXWU@L7W4$<Z ^09W+^HI=_!FQ,L^
M''"#M>D D)E.X5RFCN !%FJ @0O8P-/P%5=%:3KK:WH^O@.OP&I*U@#!"U6L
M<YPK3@8#[(F5B\CN9,--JJB4#$\00.6!?!+T U&LU]=NI$U%<8XA4VIV&2!R
M>M]WZ\%OTBSNWT3]$-S,]#:(BUO"52>RX7B<P_4 1QGT_G4JU%F@0D8A)[0)
M;N]B@X? .50>#3OA&.!'TX@':NKS]1JX$R*KC;PQ\C7&F+)6. 4&'P#A)"1
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M(DJXRTV'$V.06R3&E"2Y"B>02:A&D\.<8B%J/[:XKO&!M!^$IZU\U\#,BA]
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M3IF  0B#C#"?:OP,+&U6;^)SAQ=J&-J6BF1!R70TT41DK*CT\!-=CDY<\OK
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M$.>_57-(SA$C*BW0.3$:]X;04[C7.N655,FI H:>Z!RH^P5KFBG%)>T?+EV
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MYR&BS3;??YN-:=7L\O>[R][+9H^_]SW^Z7EL\:+MB9E-AZ>Q$Z8*^=:]'_P
M 7KQRZOC1 <;P(4-OV$<C/FJ#0VP!4CVQ-:JLXP+MD>K"?'L\N)59W/+]SK=
M/?B?[>W7VG??[OPTA\0IU,]'$CE[KPGA<O(D5>CAI]GF.Y=NQM#T3..=;:6G
M3F&.#9CKWDO&PR5,HV;39&;[\\RLW=U:UI%<V+8]SGW?G((?]Q1L[R[->VE.
M07,*5O04O-KJ[CZ[8S#S[.8R/9L3LU %]+R.P>[W? H<_W[!+M"]G)M#:7[+
M5L_)>9P#N/*7T6.[')M/'BI>23.JD;;'D+;N;K>1ME62MD<P&Q[;(.CL/GD*
M\[E;O(VXS6%_KI+&6@W+LJ;;[/#PZ.C#ASD&>*+A255%]ING/R"KY ?*DMX[
M![48CV_**&I6=ZZ!+=9=6^22+2 WO0AIFIZL7M@AG3')>(^$ZW>QRXT::=1(
M(V"-@#V)@-'HEAP==% B&+WA/JP83V_5/;W;\UW'=+;]O:V]%?*1GEP[-_+V
MJ/*VX^\NKT"@D;<?7MY>[7>>9PBHN7F?9<"QO;0:P&<<<+Q?->]L)NT,0# K
M=+16RQMLZKWN>^YW_<[VTNZ9INZQ.0<K>@ZV_9W]S>8<-.?@!S\';7][I[D/
M?O!S\+U6]7:^XZ+>Y=3TS@6Y,9O?<R+@CX@7ME(.SD/[S&<_MV[C-TK*IN_A
M_WL]O?M[E2ZPA\UC49&,[=4)TSX,H6:U@FG-@7BN!V)KISD0S8%H#H2Y(9KS
MT)R'QW-U5D+(V]^/%?3]Y'A,^3D"]Z[4V?T.PA9-^.Z7=M??;#^_*$<3OVL.
MPH(/0L?O- >A.0@__$'8VVS2FC_X*?A>TSG/3[VOA,MS+X26:51&*^3+-/7(
MCQ(TVVO*D1O!7$'![.ROD%RNCN72"-NC:,%VNX&!>:Z2^0R[,KI[JY.[?:YM
M&=7TP]9<Z0>AJ42Z/6/[7C@TE2MQKFKG^:0.[!V),*2>[Z?CBSC\?L(]2YGN
MPA(%S\U[GG",5\?B:LY?<_[FJ$%9FMORN.?O69J@S5%MCNKL5^7^TFSPYJK\
M4<[?DNO.5NY0O>IVEQ9(694+\*E:=.X8YFQE:Y_#8O4*UAZJXA:N&[Z;6W<)
M-6HK!*7T/"_+1M2?A:AW_/;>T@(MC:@WHOYDHKZWMSH 4HV</XJ</Z'/\KU4
MDCVZDS')Q_BY"& AX<_K:U.>\/>+S/L9?XK/*7_?7N\_QGD1#6XGDXK3;]YX
M40$_Z-42C0NI<?V[:E'@60+O/S1#I$P,U<55Z-V&099[8=(/^][[L!<.+\+,
MZ[;!+]SL= B.#?[0]F["+/1>MKM;/K*RX\<OMW?;^!=_?2T+\U'80["V^+;E
M?8 G.S_VZ47#X(\TBXI;9#I+QYEF.^-'!T6111=CVB>O2.%?ZR&.?0^>?OI?
MP7#T]KWOY6%V'?7@&:,LO8Y@"NMK\-N#X668>.#PACQ%_OO!91:&A)*,CTP)
M=^'3^8$7J,_SEG<.W^Z'O2P,<B3M5F-T%FOR6N5P9(:C()-AX ]&600_I9^-
M0OASW[L)<+01N)Y1?.OUQS3;093 WOU%!.&X/L55E/7E9UFXT8.-Q'.C)J[G
MW?)^AP%'?3AAA7=)$'H%K&5RJU=W?8V' "\A>@'LOHH2&5UI85H/DT31$>].
MOWSX$ER&[V 5_SR _]&ZHA?#A.C47[WUQ/<NTI%RO>43=?+QPQ<3G_YYC(OO
M/+[*I0#'&358_6_U[YR3F2!/>^P>8?X,+OGNWW_&Y_TRP\3UTT?PR<8%?K01
M#&!,;[P@O@EN\Q>@9*XR]2VY"401;F(XD)>#-"!_X"R?4IF;FZ TU>9TZ&N"
M=[Y)_U\M%#K_TPM0=&HF2]%WBN?0)7-?DN(KDRS.=J9%[6V2IM/'&T_3R^YN
M%S]<7YOA06W2.?0P<_:5RN/GY4$,'\.X\)M9& ?XN:ZX %W42Y,$E2QHB)NH
MN*)7EO4!GG96A M1?[W[K5G 6L=5<>JY??.TB4/T49?VP[P'ZP,_""[2Z_"!
MRNF.&Y]41)TN0*FM$^X2 /]["X#_2&.5LJ)@:V(Q%_<4S/]Y!'J[M><-HS@&
M88+KV[JX2+)WS+_.\M!V27! 8%ZV6YOZ$>Z-YTI]H'^VOH:_VVSMZ-^I0R"7
M%0XQ#M4-B1;$ERM\7<>#!\+=B",]>K?3[J+DGH6C@@?)!@C!RKI#W&SMZU?!
M+^Q[%I8$K9FHP/-H#0-?.HH#.(=]>7G7TW=S:10^FL"P77SH S!\@SA&XV>0
MAX5W 0N!KW7&T[7' \>]B."8@"TQ#/#B#F+6#7#"^V/6 W@^<[""BBQ,+F&-
M$KS=;;V09I=!HNP*GB0,A?^*(V7!I/$BQ5![]RV94J,4S^E(9I@7XSX.%T:"
MW^Q4OYF$-_BXX3CF1W_YE_E1S3P[]CQ#V-7T-N3]!4&F)_B6P%CK'W@IG(LB
M&H*TC();$G_9%GP][/87L!M!_25\S_ JS*XY[C3^[W_OV=C&!RZV\9&#;;RD
MJW &K.5YE,ENJPLR*MK$U23;K=U[:!)'7-J61JC7),IE")+UM9*D;=F2EJ3)
M1B_(K[S\"@:X<4&7D2UUWF46)")J_2B#RS;-^,R%W\+>F!8(SB]<M/)Q5;2W
MZ&[6'I$KM%Z]S!Y>1>$ )$&]XH1?T0)9Z4<X+E0<Y$/!:N,25%^[[6JR=!#F
M.?T0K),PG#181]^\I\-R G_,Q[ ,O9"U2TM=7G(TEN@>FZ:K(UUX>JR:KCZK
MIJLEG1DS&.[[HK:OF>TA[^4>&8O.\5A?>]G9)[MR4&DOF_GQ<&1.4)0F-ZAY
M$5_OK-/UZ0$1"+_UKH+D$I0IN8W]:#  $4O0GX9_!1$L KR(QAE^2*;I)7R
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MAB=_#_DIH(DC<"9AX0(.CE$4C?U%\$,S%3MEG_ "HSZ8HX@DES$,PT(%D?X
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M#'F>]B(Z3:I@:7W-#BM+;D-"SS DV*<^3I,'S^'\0I2,<P73U<_*I(?1!7"
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MS,]'K*U!GC);(/>[XGQZ4=8;#Y&4D?@1#[BE!H8%]WD.:XHD>?UH@.<L!Y%
MVF XE[A7IBE6#WD8]$-U?1ON2-BM*H,TDX6B\/#3F699'6!W)6A3G('Y5A^A
MXCUT-AN%(X?_,FJ')0X@)<P;Z>M)4N^T0VW(]&'$O:F(I5D$POYR.;U_OXIB
ME@MK\9W#H?5 A@9;AM<C&G+],.^!><00!9^1HK4CNI31!F:D1YV/"M:6.-EC
MJ\&T9M1PX+/0V)H]I>@0P2-'1 27Y)LI8!6!(XASG]E5P]F4#Z\,B3[*._V8
MD!2(U)GA95Q"22TL<G9KY,5<CK(1?,+5Q45;XNP=GD(A]L8!F&,B=.$Y"$3_
MD@;-EHM[#N"AMTJ'\3G#E<,S%(&=7Z#9<O$'0CY<ATSH#"9W^,T\$T[. $XA
MDXKRC-2]BCS/=2H1&5K)9D!29NKAY>_#/Q>X+=K7B!(4%=0.L,IB4CVU(7O*
M:A@$MI?"+N">+?<$XS4'ZSRB"R2M,P[IX!"<".XG[E2HS!3D4<='T[_TX6RA
M#X-]VLC#RU:>-GX(!N0JI,L _\7^NBA:Q"F!88#P#K 3G\ 0M(5-9*V*55>-
MJ3HD91F&K$S@WDY[^@XF6PWM,F:6Q[N[%SI:7684\1UXUWCX8J0[FQ;'/D5*
MG,E<QA +F7#.T+S3_PJ&H[?O+>0=:LIMH<8B4";4D",U<O8X658R(RM\KL'K
M"T,/#VAG\RUKTXTS:I0GE_C,C&Q]K<9(VZ@10GI8^ZUZ]9.Q>2\($N0!L16"
M,7I'@8=#"\9HJ:?T& &EVEU%,@Y_WJ,3$/13,D<G8BU1Y(&91E4HQ ?!!@G"
M.XH5N B@07YJ>4C@?N<S]9LC&=DE!D?(M'.13/ F*&[QQL9S!4H_N FR/L),
M16DF'. H#1$Y;L+2G:+%!1+JJRMEKL'LS3T8,A6)D9F0._C*!O-7PBI,OEX[
M0@KJ6+3,O."T-Y>9$X&REMVK775?O/-H&++#!W]@TY)1*= D1VPD5'YU6#KX
MG3)NC)@%!:@Y+29P]T6%4(T/@B@3/FL9O]9&PGW=)TT>?H-W))>A/MT\.?F-
M&DV4*]7T%SH@N3#/HW=1'S? G03S";Y +-N(CT=N%WK#&5Y*J5A!FJ.<5D9O
MXTRA")YI@84^XA3=.5"PF^!* KUY+8*@-XJQW7C.2'<O[.6,DA;E%H>OUQ^C
M<,@_(7VWPN#2%AM?>?C2GF#"@1$_#!LJ[VG0/+L_&#3/'.$.91.S8^,<[?0N
MA8Y':O;; :P=Y=:\BV%>&V<]<( P(##2-A5Y#BE8>.IXZ*@&J>1D-";E<043
MB&]ME\"*$OCBYI'?\RIX+2ZZ'!CP3V#P&"%WI@>_>G51^BJE(T15D<*'[_3X
M.UF4_[DQ  L5W@5?"S&A  L(7^B_-@^ W4"SL"\K\BI\/6&%*^J7?4RTEO K
MI#27ZZ#7\I0K""7>#=="OE-01$<V>$@-'E)E",^)D=PPD(O3T/"0_\BB^YP8
MJKV&B/Q'V.:&B/SYZ)R5Y":O79V&KOQ^Q*^'F,, XUCE_QO4BZ9G;[;IM+>>
M:=->(]"-0-<*]/*HDY]+&^I\=\EIF(/WV;N2,K;K,$Z))J'A=EYY;N?=S=5A
MO7LRE=W(R\SRLK/SY#Y<_?H]1X+O7[D*DS.B_6&41'F!-4[7X>JT[S?LQ=\3
M>W';W^YL/P=C9R4"<LVQ^&&.Q>;^TNR@'YW3N\&G:3IJ[W-(.WYG:W=EC,^F
M4;P1ZP7=/7LKY%,]9;/X7 27Y9:#'C=!'.?Y..P[;7M9FJ38&T'UE$NM5#J4
M%M=,C2[BT3F==O;H5,] ;YSG-7U$3JEZ;0_6/?N(EEG 5;M_QS!\;U<Z0:/^
M/U[@![L'+W[Y^__9V#A(>E=IMK'QBY1)MCP>A?N?];6Z3[W_QI[6J BX% \<
M;?@@5G]_;UH"N>?&^Q1D?X:%=QKE?\XQ2?HP2K#/XHW7W<&JTX=S!<+6JQK#
M/L,-#(,X#C/IA^32VR$L2/1PEM'OO\9V[P>KL9VV]5H"\(1Y'Z(P[K_Q?CYF
M[;%Q#OOAP8DK/[WZ!V<G!L$PBF_?_*U4R?@WGRL9J9#Q;L;SZ9SHI$,L>9%R
M 4LF<<5=@=RT[S!K]M/)=N7IE0',,=VZ8U_Z@RDA=4I&2R6E,ZVT6S3*1R'Z
M*WQ#YY0ECP3/FB,5D[)\*?&:[#?R(\ ++)D2L/"S&#UF\>34LOZW%/_YT:>]
M_\72Y<OH&VO^%TKQ>U6D #TW]8R:12K7U3J[@^\SP]XS6 .6MBC;9<Y2[&\]
MREHL=)(?CC\??#X\/OAH!G5V?@ S/_I\?N8=?'[OG7W]\N4C_?W@]-_>^X/S
M@\D+,=WPFWZ 9K8D[CR C[UNL!Q'IP?K:^^.3[R/Y^]KA6-5QWYX\OGLY.,Q
M;.71^_4U+0'6QC^GV1R<K:^=?/#>'QT>?7IW=*K;+F>9P_.4O?.#=Q^/:-*P
MD^>S[M<,<^7+AJV6:JM"YY[WCC7VN6\=V_6>>O7L;[>V:U7NVY+G.F,N;H;K
MW+E3*X;$Y*MAJ[55>U&^=4,/.@3N51>B.O8'&R<U%L)CRS*:UO72:\42IN9P
MI^S_8VSV<I;G[X%WE86#?[SXO^R;E\V?TZ,O)Z?G9G:@$XX_OS_Z<@3_\_G<
M.SWZ]?@,+JJC]]Z7K^\^'A]Z!X>')U\_GQ]__M7[<'SZZ>\_!S4CDUDI#\E[
M]>7PX.2==_S>^YRVO+]'W^"?$O"W8(P],LT^?+O(XO\%K=L%Q;O7WNWN=[:V
M]K9>>$DPA(?VP^C- ?;4I]F'*!L>]U\08AR(ZRG.[1!_V=EL;[:+%/_4[G3;
M+WYI=S?W__ZS\ZY?7I=%9;+$S'OPK,-#(;M'V<[]S?+(Y\C+?+="[MHC:@YU
M=LF;N6WP.?9[]I*1>^Z$>)YXO;UI;[?VM^$&?-A]\Z@:Y]W!1]B H[/?CH[.
MS\J*Y]")-ZK9O@MB0A\XNPI#C*@&M2=UE0]HVSZ-E:/:R 7(Q<D7\'S.C^'0
MSB849PYDP8D&:WJ.XE'Q*AY??S\SZ?CMX/3HMY./[X].SX[^^^OQ^;_O(R2'
MA+]!.&%G%N;8W[PC L-XCI+3;21GBN0<'IS]=B]A07S #X@/^!SE8JN1BRER
M\?GD_*ARU6#V,S?3DRRH+2[>!YT$-?+R'"5D>T8)D8CK0A,8=P-/S)=96=90
M*+)4,Y9'V)N]_5DB;YSBHPR?LV+541;5!%<ET\B)QKH)3DP]XN94!O%&I2"M
M()RL/68<G:Q/]6UO*PE(*_^H<H/>Q)3:J*2+)B[(G2)0FTP;\1NNNI/E;)JP
M%-4LHIV(J@_%/(8.M']E'P[)9YL8*0:]M[=];W__M>.SJQ#.W_,B2Y-+?J+\
M+T]C?0VNT..D'XY"JE+P3F%2>4'8_U\8_LTJF<'P324&(X^N#\W(?ZZZ\VW\
MMW*H>&954)&$.67M7J]<_N:_</;2^3*+Q07"56%-+:'%UF^+;)U:L!HA>9<&
M&<' O7?P_&RK'/_U",](X+V+4N]CT:]DPVK_L\3M^6$D0C8P<O;P9!0EX'##
M26>4VGK#R-V<:.K!?@[;9ZEQ59'UW'9TEC.NZ2P4<"TS3G -V"WJ[0G'?Y:'
MVY6%]]4BDY]^P1'#];5<0H:+?@$HIP=,GO7:^MJ=BDW&-=,#"=,6_-9\?)%'
M_2C(;N\[Y5<$S"DPR(>\U8)C_!I1/G'B$X=1 2FV5Z7V%Z3VIZUD[2\9W6?2
MVOMW3772$C( NJ)OF#KV.A&>]ZTN\*J!G/?7UWHF6F4CY/^-GRWXK24F QLX
MFI )$X%H^_F>JV+!1]IKDZ"?[+V"K\8,.ADC8/T@S#+&80T8%E'$Z'XK.>G+
M]77(2D8)X1P!&%.^GGP:R&)'8 !R0<&8#10Z"L*TC&]]XD*)8T\Q3BF$^)R'
M5,?W,Y!P YTZ==JFC48=NON*()S5]37GL,Y_<J:/TCZN$[_D,S@H2YHB8KA[
M6*#UYAYPB0E$7G"?)^'1 WF\\^RA'(!X(?H]GE@&9ZZCOK$XVC1'CC  ?$WH
M B;#BJ3B@#+706N"[ER0;;500^<'-K=<PWFR.)W!]5T$Q+^UOO8^'5\4W@%U
M"5AJ05.('#"Y':I;9G(;A\SX\6N*<@6?]<(LF2 *42,C*R8CL[G=1,=AF^#3
MR23(A+] ;@ZA\A+V*P:@#ASA8BJDGB-.EZF\!\6)L/IUPQ#AVJ,MX+7[=2U#
MM0/RG1=>!6BU$CL4PNQC5R"^#G'L%==>25WC+\CD@8,AFA>^A6#R]#5B(0*3
M)#(\@5D0Y2'9QG*XJ-6ND X<M)L#<Y;NG/RG*I,/LT-DX660:3LI-\0YV&!%
M_"8.6Y.L&</J3]_"?FI3"A)%I8'SETD.49P4VP^O"/$*C LB223;(LH-:4]Q
M.UL\Y1GYY<_MQ->&528?_G=!'N5@;8"=(;&7NY3[8J,LC99?KI;/0\QV/%YT
M99[@0KVWHUC=F&(DCRXTD8"EWO^6.QR!)T3 Y'P_(@*6\!LZ3\0A(GZ;(G$M
M6STK&W*J7R5-MJP)H/))-OM,;_F=^10#Q:%C.1*#*!OB/21IEO4U\C2(3)6_
MJZY<*_%R<@UW%%T<')%_Y3@:KZ5$]S4#1F6A:0]EKI7(2O#<U)"@R1O)3"C3
M@I);@]2@@[!/H%0Y7OY\:\?!C6;"\X+1"$9//039.-:$/$@<S4:!B-R9^3T1
MIBJZG4,DA<US"E6K9]*T&N?I^U&9OS/G);(U"\<>'S81CCQ\;HICPHDA4DOB
MVWK ?!3',A^"\ZLTMQ\L9UQH<6]"H0=#?FWF\.-3B<M+W&,7 CF@B6?1NV 6
M=C:P;<+"Q]V%61XS <8 M1N1V,#BZ(@=Z@WU%5_/HS\FZL\PR\ 2@_\WR& Q
M)AC3D9:)6:T\<O&4JA;.;EOMHCOG8YLY; V,&?8G3"[AAJ5_E!U"SC?9(9A.
M1.($4TJ8[A2$,V9J+K,2NL7?)F-CJE0Y2#=AY0:0K8=WN82K^,Y9W^==@(00
M+[F$ST;C;(0"B51S;!605U6U#)BH-+H.$[0<*G;'/#.F@P9_Q*CM3:BMD21E
M@OCT+FO;^M]'2E __472;H^^/=^;I+VY^].+NG,WTY><PWF"1(MR(#3PB1RZ
MR0G1B0FM^0<PRM)>V$?\$&+Q0U;R/-<T7/E$[:7.QZ,/<+J6GO7*O/\8:F_4
M*?K;MV\X <J1E98@$E,ILFF+"HH6O.6=H8:POFSP<+X%B+":7/I4(A%X!5*C
M7: 3[WLAL:'U0A,XXEM5".<)U]K"BI$TP(^[>^P[RLFC>)I99TWMK0L4JJD5
M8A<F*K[(, Q72>V-L^IC_.\FC&/X[_I:Z1UXE6!JSR:@7\$3MH"7U5M+Q-KL
MT,!;AH*0'!+UN+8)2>SICK=RLW,%(-W;4UCX['IJ*C65 E5,3 >C/'RC_B#_
MP!6M4RK?MS9WX;J3YNXWFW#V-K&FE?^KBEG;V_ D9"X$>?K'BW)9_/<6LVRW
MMV>X0JTO_9S_/$M#[^[F;K>S7=/0^QD^F*6=]U]P_84Q3,0L_G_]W^[>6T__
M0[G9=SYAFZ-/_$ZQ^8%$I8,/120Z8H W,W7+?@.\YE[%>=::U'W=+/Y]%__
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M]AHM.<FJ*I05"1>@H)B,%!,?4+@-Q>18: L"<]"M.L4(AVW2:&5W[NKHD R
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MAP^CR^.C\0/\2WLK2K??I ">\D5B 4ME%'E\Q/Z5V#\??IR-SSS)#W++5P@
M=\GKA"P<5OY,J](7Q.)_@>!14N*(^:E&26K!TB]4.Y,F1->YUO>W$V!Q^#<J
M>][?"3L5?W648I=(/72XF/6VQ&P#AGR2X"/+K,$6;PCN_H;S-6^(VG1\@[A=
MMX'G+ZLYEY7H0AR'G:6&FA1<D4Q..]/:/T%V!Q 3>%FD[4:*6W G^Z>X674'
MA< M@<!9$!A]#(6:ZWOQN0GT*0]]$IE<A=!GFSE,.>-CSLB7N]NX:'H\K/7O
M..KU$)/C[D=_C&Y^)+>C+[?H1M2KU;!>K27W6^WN ",C@\?XU--[\I,8;G*[
M_:;<E!TSYQ#EYLEC5:TFJPVN"SHKG<X2Z@%2Z4SVZ2R_X&&W]XZK-F-J0:[9
M4V'5_U3NG+4"Q[=7S#E(J.4L:[+-^"%8R>TW:97V()*H*IIVL6?N%9_;=V':
MSNV4\["R5(5FZ2Q,Y# )8LJ=F!*&7JTFIB+T@6W&8>Z=F(IW!KPCS>"W^]MQ
M:-K=W?WMMZN'O36Q*I7990"G8@RQ,(AKPC2[,0WD-\NT[3O+G"9W=2A _VB7
MSC&WHYN*.2\$90O*7D79,75H-647H0S)@_XAD_;._I)#58%X+MK-;\%R1O]W
M-[H9C\9BQELBOZK*?+$*[=6[/8-*AV8S\)AB@K/$)HHUF06 8HZG"K:];BZP
MAD"T"=ZW/E5;5:F7$*QEV#8TU,L Q4:O"RQH*<DLZC;ZG4JJ3]4R@P[IW>^4
M_!)BN)N17Q&VRWFC)T*[10P'*DUE^(T8Q H/!D*-05'GFJ'9CJ7@:#QAC&13
MA&O"2>)3?3@. ",91@Z^7%'>:[2ZI3LYA>7W#A ^[N3;&.$+R8IJG \.:S)/
MAE2G [6\Z5R$ ,HBA_*(KGXE)'@<;%>_=>VH(YPS/M2'XOF-:5ADXEH6H"$;
M_U&6M;^YK5'YWGPUP)F]];X7C$TPMF(86TPES,[8BE %.Q7JB2\86](FBYS_
M[1JK^E%N/[@M<O]KE*Y<$Q-?CL]CNET0-.J-9V[4EU=3V&AN,7"W*HT2!0T*
M&MR6!N-*508:+"2EKM7HR!7JXW[@3K=*ZR,):7;7M^/2M!!AP@H3MA!N&Q^^
MXW/;8"1O.3I/,-\-E1^Y0EVB*Y:I(]B#8 ]EL8=T96PE>RA '0NQAU:C]2[8
M X.[[@ZC?;1A_W9U,[RYN J[D#S'D?3AZN;B]OOH8T/BJ&(0,2-<6+(YA ?:
MP$![<K/=:O:ZS<XRY[PQ#3/*/,O-C.IOGA:U5U.V!N@@QGD+/E*$$H:C?7K-
M9D<>-%N[L)%"U;#6H%[\I"YE7Y7V@UU'&FY\'7V[O1])3*&2'H;_)RK#BN6'
M!UR:(L<[= 4FYC?+G%_ 6S7#!<KG-JAIV%\)\"K"KGM07HD]>G4L!:2&9BC6
MVY5#YC;P2^2+EJGKE&,ZQ")V2?TV(C;K0+0)%73\'N@XYC,JEXX+]SUMD695
M53KFT-7<PU2.ZL.TG& MH.YX3B7IP]?1S>C;U4.B02@,0&$ ;LA1VV  -MM=
M^7S0C?F1?"[)[;ZOQ"#E=1"3VQ7RO(NL)$&"Y:1ZR_$>7]GIL%"-I%LS-TP-
M,&-O"=V=]YUD=3,*]7DO+;UJZTTOA-WC+%_5='%Z95T2*'(%N0;L82.Y<1[S
M:MT09[^I55OT6MDGX>U1RQ.L0;"& EE#3*5<QQJ*=FW)_8H8=X6R!@9WK@V:
MJMF$I0+-741KU?=Z!L(R*BSL?C>ZE\:_#^]'TM?A^.I"&MY<2I=7US\>1I?"
M8A)J4>W4HGYST&S*/;EYWADLJT0CQ3( ]>P[8HUGBD4N-=UUB+JIW?2X(-8C
M?8"O)C7#:E)KC=M[(\4NWAMO>15?%5N;E+V&YEDGJ9KQX/4]P?,$SZLJSVO+
MY_T=>-Y*@[!<GA<S9K/RO$+7 #POR:0]>)XG;-Q#MZ\JM%?O]@RJ;^-6U:#]
MQ^CJM]_!7CT=_C&Z'_X62JNZ^?']*]BWM]^8B3N6;G\\C!_ Q,7N3S_&HTOI
MZD:ZN/U^]^-A^'!U>X-7QLQ@&CT,[&1A%0L-L98:8KO;;I^WXY,C_T%!(^H0
M=EQY)C?N_(E8MU.N*%)]R;YU'=M1#$31C2Q-F]X=5K*N;K[EJ"JVXEVV4I83
M6\?F9O,VBVGU&_UFO]%,;*M]\)JCX(6"%U:5%W8Z_7@SZ=UY8;H%6CPOC)G-
MN_+"?!?3.F_([7:CUWN7O#!J1?_548 >OP0K80L\/EI%+9_#)/#K$@W\&B4"
M[_U9GKN/KAH/,W)\I$PFYAPN>X-#D S3@:<!6DEPGP:8^&PINK10+$<RIY(S
M\X<7T)_>^H*/TM_E&HJKPI$ABJ -8[/?:.ZQ A\?'TTU0S$F&KP/2,(A.+;*
M/EO&P0@JKMO1\/XGGW+L(=R@<LS%IV9@7W'<; )N1@_F\ZJCD-A92/0PPI("
MS;63V*LG.E$L)(_9YQ 4<A(8"7>''C\A6$Q5/$(QVOQ+D_X7,3,-9$$ZWRN\
MF']R\F70VN!$%\ O3Y\LHOQYJDQA29\4_45YLP&,F>5=P\4L8R=X0+%MI+(7
MO^$LI]G\Y3-'$\QQCJXBQGKX%R?27SF0(5 7F;!F+9XD\HS%$L8F_K,6"9;1
M=0G0K;#70Z^D+< 3@+UVI!0<RP<!$W\ZE@D,+,O+(HRBV?OEY,OHYF%T/SP^
M^GIU*UT_A(+N]*$Q7%WUSR+M;%;CB R8N/;T=CRN,#2J9B]TY>V39N!NG'Q)
MUQ!A@SZOO'K[+[=>WEH -UCL>@A#<BSV(H98J!*B7^KWV^O+T?UX]+\_KA[^
M^4CEI_8Z-"8S$]EQFIS<F2@XST@AC8O;F_'M]=7E\&%T>7PT?H!_OP/"C]'1
M=O'[\.:WT1A=<./0 GZ5V!(V0?RX6%WL?,YKI+'C+5V*_O/AQ]GX#,PM75<L
M^_A(,T!S,5T;]&QX,GF=$&!05'FF8PT7Q.)_@2*B?,S(>M>R9:I<2DP\T2#7
MA.@Z5W;]OU%_]?Y../6X?AG=G]7<?4GC6))T@30\D>COH+/C'YNZOQ/*AC*K
MR"5X-/8,WOF)9)DOV4#-U,8RN_FQRFU0/&DFB:#"]0$NKNE?M[S90+!J9B]O
M)MP7VUNX:S!O]?;&,2]A0\LEE?(!;JT&N((8'M'>#^04:@?P&K3)#MVVGM=8
MR'45JNSD1:O<WA<*<'4PH^(;5;N3K30;V/O>%:"D1CWA0MO/![QU*%>BAI]#
M8#"3&"O1Q\="9P'LYG1S_T0=U\WL%H9YFFV[1-UAW4+?J)"^(?C!+G0QG)NN
MX=B"&&H+<![T40[6\RWZC9C6LZ;$_:_]C3U><6K*;I=^&<)!8HZ&HF\MW_)?
M4?XQO949!0M%4T\U8T5&0H':04UV;]T>3I2%YH20:-=]$PRU_@RU9@K'VH8
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M\X96GFE@V<WP5;/Y-?#AW#3&CCGY\SO!^-NN!6ARH]GM-0:M5DE#=VI+.QL
M+J LD _5ENF$[SJUR>14>SV=::I*C$\QYH/_[[9.OOQ/1JU.T*( O+(4*S2'
MU9I#O"LGE>\ST/.)93-E( ?5(0A2WBF:>F5<L&!33(W8?GA5K]?H-?M"D1"
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M*7UG47&15Q7*%5#6('NZ%,ZQ0M#&!G"%7QQMBIBQ$-5G1>UFO]],*$05]"L
MKPF5OPN5H0O6<G>-RO"'HKNDVN'9)!VBFU126G/^4S(.Y3 (J;:LH[: "YZW
MFN>=R^>]\T'Y/&^?L=V:L[WW8)#4 \J]F4W92+O5Z?7ZI9-V?K'2=70L*%<
M7EGZ?A?*0[LK]W,RF(2A(^H:JQ ,39J^'H!S9=NN8DQH2(UY\R75)1A4 RU6
M&CY\EQ:6^6PI\X9D$ >OTKP[)J8='^PDBB%K!;C(.]DLL[ASGIAV,FC'"B):
MCW(WL4C^BDX'O'0MT"7OX/6FRH)V[/-OIC4FUD]M4O$H7J?1[I\W>JU#:.Q6
M%=8@H!2IQCMVB&T/.G*OSAUBJX+E O"]4ZS0+];H%YV,^@4U6(M5+XH/^;7D
M1K_9%=J& +Q:@ L.5Q2'DQ_E=H4XG"C>K C%U<-6J0>4[]*B*H15M:K#JLH+
M6 J^) "O*?<2NM<:AB87S-"$5;@+G?!UO(<*QLHU@@V7(9H+1+B558A5CXR*
M5)F]RY9ZMP^GLN6\G]@^O-E;EBU=D#9990N+C-(O;QFA>;2G5CHZ*N/0*UG,
MBSF(I-AZ0%F%BL=*QT8'G5:O):9G"L"K KC0,(K2,%KPR2;6:_$*1O'QT8Y\
M"*E8@E,<%.""Q17'XN3D <'[8W$B0%H1JJN'P5(/*-^E694[N^JT'^7DD<![
M8U<B2%IUJA> [YV#"1UL#5-+'BV<+U,3YJ$H*ZUAE)3&;DZ?%,!Q0)[Y @P!
M!=&N-G%1D7.S=W%2W9P;,3ZSCNFN]8!2).6FJV?P2Z)ZUCZ/N<CZC^U8_<!0
M_9=K.V@:V@]FBE.>"BXJMRY"8NN>@"UI \WQ##>FU]V3B?ELT*?DWWA(3.2L
M,'\0@.^=UQV0.E$,^XO5)-2*_14?,Y4;_?-#2-(2K.6@ !<\L2B>V'MLQU)/
MZ\4319"U(D1:#U.R'E *@S<O[A9+>ZL5=Q,QV:HS"0'XWAF>T/!6\4#X))87
MMW\>**S5BI>Z+A1 "^/9ZQC=6KR*ZM>4N.X?Q ;K0[+@'TN;X*^T0HYB>+Y%
MK\4<RGZR<)Y,2R56:"F2;>H:;".\N=F0\'\?Z[NZF#PK:[E%)R+503BVNHG"
ML1-+6.KU']O1R3B,EN]]4J92\ <2<@T&B?8:S6;2$-'5\E!PI%S6<D"L])#Y
MYL$SR?!=:RJ -V26O<=VG[\@M698\)CWLQ:AP0D-;N\:'#"E6,IY9O?&U[A[
MPU?\4"NCBM]:ET>U8_R[.7X%XS[ M0C&+1AW%1CW^4$Q[NHF(@@F+BS\RBQ%
M6/C5X\7GC^W8:+8Z\^*JI$T(QGN :Q':L]">J\"Q8\.N*L>Q!<.M6^E^V5D?
MA>:4E7R>(K&OZHE] IW*,(2K0@<U17J!X6(M@OD+YB_6(DA#D$:MUE(/.J@I
MT@L,%VL1S%\P?U$IE4NE% 7QA7WP9.IJ(8[OK\/KX<W%* !I^"!=CBY&W[^.
M[J6V#$MHMF11(54L>XO$;SJ+5TDUW2>=2$\Z+*D2(::<N%\!"SVDX%+RK-OV
M>7,YN-3O/W9BP256_G3K.K:C&$AB2>&?/=<_M?J-/AQH9XLY@X+IU#U%:ALH
M#XHUOG<^F+WPJ=7LM5K=CIQ]]*%@#P>X%J%?"?UJ'_I5;_#8B?5AIEK0# PQ
M8ME,9<I!P2JA82@<\* KBLX%0Q4,53#4/3+46&?G8AAJD44^"2.*!%\5=JRP
M8]\5>_Q0#'^,=7DNA#_F5WBSS PEFQ[DZ<F7?JO1:9WOES.>=1>Y: ';LI@:
MX/%'(:J$VBS4YBJKS?W'3JP]=G:QD(N*VVHUNN==H>:*$9V5:.5Z0QQ)-^U\
MN[96*2'F?0!>I?RJ/8H,,9*SCDFR]8!23"A9H8+U6HDJV*"UI(+UF]W';JP+
M$@@AYDJ\!DF4H'VU_"KKEIB?>3@L1P"^=\9T0+(_=U[5&_0?N[$N0<7QJHHU
MPGQG5"0 %WSK4/B6_-B-I3,7R+>JVP?RG5%4/0RI>D#Y'LV][)'8C7A1+/6O
M.%Y41CA6;C>:O7<PA:W*H=3:;:;0\=ZSCE<08XVE &[(6 5?K!D>9>&+A9=_
MUZ#6>R^AU-$KL2::321S*ID+Q'U;<DS)M%3-4*PW-B.S/H'6.F0 '4Z*3Y$Y
M/'MT6@R:S65YUAW(YVTY>9IS,];WM]M^;"5G<E[9MDO42]<"/9^UZF45V_3+
M6T9_'DFJI065MJGB[C:Z6Q1POS/".]Q<]GHQL=IRK/!=ZZJE!^U^I]//7BTM
M:%$ 7EF*%6K'%FH'VML9U8X_%-TEQ6L=)90VMX42(@"O%N""\97.^.1!Q1B?
MB"]7A!CK8=W4 \IW:8.5Q<4Z[4>Y7RTN5I4)?8)E"< KR]B$QK8=K^N5P.N$
MB5GE^M:*S;&K<IR6AHE.GW D).!3,!.RSFVY"TWBV?O\UW)3E/8^_S6G_),J
MU^$*VLIE+0?$% Z9 QPZN6?6=5N)G5K@QW*9<$M^/(^E?60>]_P4'_>\9K0S
M58P/K?)8,-D#7(M0QH0RMG?NW'P\CT7':\6=BP^FMQJM3D^P;+$6P;(%RZX$
MR^[&XOKU8MG530,07%MX,RJS%.'-J!SS;9X_=F/I"+5BOE7)7A"<]@#7(O1C
MH1]7@47'LBCVSZ*%*T),27^?4]);=4['J$-FH)B>(:9GH(CLQ/(/J8B4EQ,-
M^ZW6XWFL=7.6*>G[KJ^G4]('C0'RE ,6@F*ZG)@N)Z;+[5+W+S>[\J#=%5/2
MW_5:A'XE]*M]Z5>Q=O.9II-5+_M!;O8:P$Z%OB76(ABJ8*C[8ZBQ/OC%,%0Q
M);TFO$C8L77EF.^</69N(;T!?Y0?SV.]^0OACV6TY1]T&YW!GL-<8DKZ[BVL
MA:@2:K-0F_>I-H-8B$T6R"X6\O$?R(U>MR/4W-2<A;\Z"N V_'Y\M#Z>SU?P
MZ](2?DWJD^!MZ@;/_8V8UK.F>%L1X/6@H(X.]*XO_X- TET!+)F:IF.8#F'X
M?Q/RZ;>[_=:@>2*]SO5/NF(\_^V$&*<_QB=?[@G8:#9J*A+ H,SA@!Q))[8M
M.3/X )08^,5T;<50I1]CX":ZKECV&45*[W4QC(P@9G!PX?^*.J^-WQ5BQ!/8
M!E#("@_ Q--+'F8D&71E@LTY%.,-:%+"O89CL@@>E0:P/EN*+BT4R\%I"V!R
M>SM/?WH[$WR4_G[74%P5:!<9A:&"Q<Y^HREY:,\G S?5#,68: "#[:F_B!GY
MXD+"^6QZYKS!BF,N/L$1>OU6.(=K>AS./^/L#.\DT^LG.E$LY*^SSR%(Y"10
MG&Q/W /.,I[]ER;]+Y(@9: (T_D>XL7\$S!&VCLBPT)Y)J=/%E'^/%6FL,Q/
MBOZBO-D VBS(5F,:#Y,S>)BQ[:9J$'[#95&S^<MGCF$HWJ(KBXDI_L6)]%<.
M^++ C0 ?R(U%)NQ;BV^)S&ZQ'9;L@.?_SW8LTW@N LU&-P^C^V'R<KY>W4K7
M#Y=QIL*A68M)VW^9OHO;BZO4Q$*4UQ?#\>^/E*MKKT-C,C.1JM.X]\Z[?G%[
M,[Z]OKH</HPNDS=A_ #??8?3&4NWWR2$3OIV??N/\;;$G.=&%N-<^G$V/DM>
M!U=[0.CZVI"=8L.7O1%9A>&67U(-6YH07>>6P=].@!?BWZCF>W_SE04,]L1+
M*MX^4;AXI_>F;SA/>P/P]B7+FTL-7M20^*[=S.JL2%1T%O,_0=@&$!)0'E7I
MDDRH:U-JRRGYRWF;J''#<^791M+>#PE#6QL5&54129F^KZ$1 E<49#JG9=87
MZ479$$4%^E0:?1(96X709S,.1^57?J[A\!F<RMVS03>P>UB74_[9?D06JK(!
MX%2GE;[=WWZ7;N_ $'FXNOE-&EX\7/UQ]7 U&G_*M0*G@$##6IHM/[:1X94E
ML$.QUUON]>:\@^G]O?-?MN,0G;/6$H-H-\_D) 91"#^X(4X I6[:^4ZG]0(@
M>1]\4<^-!2:]V&*E&LNO2P1IR8-F1Y9;<K_=?6S'\CO>SXCP%2&Y2AUHEJ'>
M%:(207W9J2_646 =]<D^]<D%4%^K(?<WSY 2U%>(25%SU2'4&R. UL*V%Q91
M<>Z]10"[)YI.)(,X5+G 3_'WB6+/)!<#K9HAF0MB*0[&>!$=?VJ.1NS2+8_"
MF-H^WQUO/),9F"2FNP]E_2#/1>!$:3C!.7B))EWSK+-/KGR).4T3+76>C5 K
MJZE6;J)5QG/VPZ=>4D^I\\V3,TO0(ZN)@@*U,Z-VS&!:@]H%V$M?NF7-J-L6
MM2MHCNQ=[$V)9863-35J94N.\DKR=6H*S3$7S;&Z#*G=[,HR,*5!I]=YW$ $
M,PQDWIT'Y77TBLT@R5=BD*GFE#5>LU>66!;V7"7>?3A4N<ZQFHDL$]2'3<FR
M4 ]L2R[+_9H[?1Z<B[;.^DYHA&T :V&S;(5=M&^[J!\OTT<,^+K<=KK2#:6%
M_2_P?!V>QP?99\7S(CP!<J-_7LELA8HZ ]@[,"ZH3=\^5TA>?J/EFJ%"4\+4
M0%OZP!P%'QL8F12. F&2;)OK(3=]&0T(__J)HQRW-^P;4I(/(# V>GUA:U0E
M&4LP@[HS@\UX06]S7E"( E-;%E#)4'Y:\48QM1HSQ7@FH>2J:+*4;1-'PM8D
MNJ8\:7H!>5,'; [MN !ADM;V#*ID+JVTC<H+G4XL O9U ">:1/2CC\ARL V/
MBSV2+#(AVD^LB1=FDM",MC:36C%7YA5'-P\3KXPAQ[E['^7*RFHJ*_5#F$R5
M)D[!&$HWF5HQU^^6?*'0 &YO\Q%B%6$0E32HJJ3HF-BX7YJXE@6P,OM*E,-6
M/[RTF?81KX>-<QDVP8'AP9"B04G:1V?S>3FB-J]"!/.^"7$S.LP@[3/18;'2
MOHKT*)P9Z3CH(5%(QJLDR9FQ4-Z$)T,8+!OI$FU@8SU9;K<ZS6XW-E<JW5JY
M8[A6>J^-SJ"NMLKAJ1R"-]2=-VRDWG0V<&:DLX<B(L+"?[%#SXW^67M9N>F?
M]2NDW%@N48/<-HP.,Z\&5W>$/Z/Z9M1F_HQNMF@*XL5UD"<P--B8RELOG2#T
M7>EJ2J-[7E:6RCM70@3![ETQZ&93#':CUV)2X3O5;-RWDSLDH=OP@7M(XE$0
MT!P0@_!(P[EDN:H*.^US 191I)DW0,,;>2,(S8:$__M8,;,I7XAW8:&UT8WB
M1?IQ7GO!,?\?FC.[<&W8"&)YS#5QPF&AJE!W[P,/]^;*J;*V)5B?8'W[1M(-
M65\&-7-3UE=L:]K.YIEW@O>5ROMRFAQ4\[:WD8[Y:QO9%JU$[U5*5$L"O"/N
MWDMJZG\!N'AGF3\UE:A?WW[8V//&]Q<,?8PL7:=M-3J#S0.1Q<\0>C=\6W :
MP6DV;;/5D<\'_6:N7*90]7'0:&Y1NB&83.'*H66^K-G.'++2UC*!]5"4DRI1
M.SC*;A>?[P;E6J9;N[.K"ASO&(<8ERQWHEQ]9DY>W?PQ&A<Z<_*  ]ZB@\%[
M/8.M_'"'/X_J&ZPMU"SE17-FDD7L!9DX.'>*S!>Z^4:(1 _5EMP%V#X6<32+
MX PK40@@DGVS6\DRF,DMN7O>;'?E?EHSZM9R0SA$T"OCGN'D[73$,?*>(N0/
MP,=['QU+*CCL;AYPKD@V<!G6;OT(4!!_\0E]&6F_ER?MY^ [FVJO1#W]#[',
MDR^G=:7ZW0VL0PU+WKG69!9)ZS.GTL+"F*3S1@L!<#+G(G=51T0*WFND@//!
MGCSHMP<9=" OB'"GO-&AL0_F<$*'Q=YQ++W3%<,9&NK(0]2RNBYL7N4M @<B
M.BEX3F5Y3BSY;2>>4T@UA> Y%0Q6%I?'6U>U,CW;33-^$KOD;#>1-RWRI@N2
M*!VYV^YGS'>Y\E!_CUEUS<WK^$6Z= T56\'R!,LKB.5UV]U.*U>65VR%R/Y5
M9L'Q"LP!+"6_KXQ\I[WD5)61+[6G?+I#>4>MSJR"G27KE-KV[>IF>'-19&J;
M"#.7DTU:L2SDRIZ+P(G*![WK[8H$DV1"2#C%;VJ9<TFS;1=GZV&\V\99P;;D
MS&#[GV?2\.$[AL"?+65NT_&N>(U__<2T17__ VNOU8K/2??0YAL@RQ4_^]OI
MA3F?F\;8,2=_%N.ZVT>ZC4CJ?E>H'H]R;H'JA;28E1O]9EF9I:5FT;_+&.#H
ME5@3;2FUS%S@F;(6LR^*92G85%\S'),+81$*K)0^+/SBF[+7031Y/\Q;;QGN
M#PWU'PSS/0HI:TZ0O/]2]XI9OH)#" Y1.H?HY<,ABE#!VHUN[_P=,(EM72$'
ME_\?3]1:\!"N]/0F334#C '1FDRDY!;+$]OQ=/^4A()O'D:6G4-5!>5IOXJ1
M(,SW2)@Q;]%.A%F(VZC;:/<W'S%0%>*L:EN&R@7-KVXN[D?#\2@ _L/EB'WT
M4;JZD3"HWJ _I='__KCZ8W@]NGD82\.;2^E^-'ZXO[IX&%U*EZ.[V_'5PU@$
MU:L70*UN[N,25Y1CZ@JR1/P_%@3!L@@=-F\[EC9QB(I?@$T7_2!TY1W 8*KQ
M3ML3W44N,WJ=S!3CF=PK#AE-IV124H5CI!EKMU_6L"4Q%;+2-"_X3>E*F!Q3
MPO;.;@HI;CQOM)MES8IZ3SZFRJER5%4+(,^JLTG#!^GKZ+>KFQO,D+S])CW\
M/I+^.1K>"Y^4,'USY[JM?)6\)"::GPW<:0S..[6U@065"BK-2*5M(-2>++<'
MK5:K$ZN\S9M"F[E1:+]Q7K=.\SEG/77*R7HZ)&5G!%^5I.9L=CI%,UF 1E)-
M]TDGM<E]V!WD0V37K6:_.6@VNQVYEQ!+R)M=YQCM:S7:>\Z$R$R1>U.Z!,\0
M/*- GM%MGO?.!\((JQS/8'"+FGU1_UW'_11G5LV:_?U89_<$),)$TS4%F74
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MVP6Q% ?6% "K8Z]-B:(!SD-SX0^6H"V93XX"0%'/&>$].%'CEPQXN.D]B3]
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MD;;\=0BU_5W,>;#01'?>8)$Z2Q2%H\"KH@<5-5OX[H373C$M ">\<(84L&$
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MC?C*ISKZ@7J6WHAU?ARG\=&<)<(K>(-'GU5ZO<_Q(IX&P$G+"]'C5YSJ(R.
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M83I(#&$<]U(R[# 3J$]=RF$PZG3GT1#0R$L?GE&&9L7RC:<LV10DO.UU";9
MIZ&!2/JG9;XINO,6I&QB1]97;MVSNST3F.8-)6E!V&KR^"B6VHR:B.41"RMU
M08758X%(YNM*7U9A3!X>YXRS/:/8EZX_" \X7K2^<KC3!:),\#9O%1!,\DN'
M=GJ91%=<M5T[F8(9@K+&,<SPSU^3AY8;N_J7=R9EH_:V\85O--5N/1!M]\DF
M_W:I<T31B<\U.=OZC*)Z_;FD^=O3_?@'P "V["908YY0.&H^"1ZP!QZ0$ET
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M<U=8$M?O1'U&+N2]!>.#F$Q#6=\HRC%O7^ C$"#.6^CA?;GKW]QI?CSC$B>
MYP'YI\^";. VNC:E R/C[-ZKAPGXC&: AN@R;DH7/YDI"!\L PY^0B7)<G4K
MH3"&A<^$[IBCT00UWZ0)/9H-V_&6GB@O3%@]>W),2M!BU_ JD^0$]C3D645+
MS#\ *9IHY(F"!@4/QVQ8VMR7(+@;S.5HD\CC&7C^K#C%"IEJ43 #$/^N@'2R
MWB2>VA25L;2]*A<2/.KKRQI/:*P1$G0"E#;W9$Y6F;&1J"@PVZ/(P$4R;RS'
MQ N9==E-N0;5(=ZP^-VWZ598<:7MF9#HPF[;5J)O&I+)R2.WK2+Q=]<@.%3X
M/$V-D,]/Y;:G1GSS&?)5(/*H7&M]OK"(JCG2-4WYX9]]9[67<SJZSH,/.'_D
M6F3]B0_V-( EP6^1A:Y,N-CW9IOY62$T!01EC&91^Y&EKYNZ^?S&Q+X2_BAD
MF:+1:I$ICI^R:<8([5HQ89#R1";FM.26;W18'*TP>;),!;MZ6'2^%7SDCU9C
MD3L^0YO^'9K7QH;)X9\!/*$7^\E'() W\'06A/0K;<<$4]&K[HUJ,>.YHNNP
M4_=^UQ&F9J#F]6%\?Q&=/,#K;L:CBX^2EU8=4E1":A!L9E0#:3?">IJGQJ6J
M0(I#G\@5LR5#>&E1NQC  5";6,*;YUU&\X)6.;8WNK7\1ILB$RE[)E)'9"*)
M3"21B20RD58S%Y&)E,K[RI)RZW)G9+G3ZYP_-I=39ZX)Z*/D=D&U3^/Y&B,M
M=IZ),ILD"2_G>11B<"%CD=K2J71[!VR'9D)=CX;CT3B+Z$KN@1(!.=;Z:.OT
MG5^7UO'KC@D\GLQ;E[#3[IYUNO# I*9;!1Q(W"V0>RX-I<3\(0\[-77"FQQ.
M-3Y+.VTR?"@L!^?O#1FW<10YZ.[^4#0O\L>"=/3Q2Y:B1AL\F0Z=7YXR+V>)
M!73[C_&2Y#LV/ON;:?FE.,Y%^$W77J6*SR>&:(!1]_9Z%O$(CWNEC&5H47L6
M7S9\U6SZ193U^.-M;(#FEN[ET%#O^4["KY?!/HYQ][Y3YW0NPWKD\_.$:N>P
MUQDV'!C GT$OR2O;4HBN21=W5^RTV#'Y9XCF/S7QT9I$!TF[R6S)F%T6M,';
MO/W:ZG9K"9V<(I[<<Z#T^!,+H!:<+[A^$+P_^>A),?X$.UG!L#WA[4.QA]DK
M]6#H;]D1WB\61GS[]!6>^YO_V"3TK1/2MGM) Z;\ 8N\WT&##9>:>.W+IJX^
MU72=U\A)&@:8_,FA=FCHU!(^)_B-LF6Z)B'H%M(Q).*V%Y2^_$OWBI_$Y4^J
MZYQ+R[2&GILV4HNO94/%?6.ZC ?:EWMT)LGCD':1NC4QMWVM]B7BA?38$Q:#
M4LN+U@T"59D>*XC1"G4P_B0S;8+#=EV;N1^1ULA\H9MOA-AAH>%Y$-$( @F,
MRH#^QIV4\$@62(U'01=,>+/[5DFG" / 3HQ^^Z-EP*,,F;8P5%3B1\)50CL?
M8HPY[/5FSV&A;7HGMI]8H!+$(G91YLW6-(>SF+& .=L#OIBB5)^8^5-5U></
MCC;PZ\A#EARE1DN.28U$C62C!*F4V&:O>=9)5#%JH;10)N!AH.W0I '%]AJL
M?DI1XY+2O+-8Z.?-A.H6BAT7\/('W/)";//=MCUSL]^N[U)G4I\Y>7V!GUD!
M&+1^^9S@T-[.;(X5062-GC.'S6<.M>>_:2U>3[ 9/5R!7FS\+*43.:P L>9O
M)_))T6]HK7D#][;S%_!-E6B,24I\7;),3W*6KI']*6[6E)(?#113 ZXH*%GA
MGR!B XAIHZ4U7+$&BXIUBF+^=602ZUA^8)3F@K6?7V::0TZIUP,XX8NE+ 2I
M"%*ISJ+2246N.*F$-+/LDHL)T][Y+\L = " 6,04RS];S4Y#:K7[\*/;_;@M
MKN_9KO/5[@#:0,%+]\MM<:[<79'?_N[&''UPHCP,X^BJZ:)"%BWQ+1_"$&.P
M$%TXR(-"0=Z-09=BA62U;]O+MD/4Q$0C8J/6H3LXTP=QQV2A/'1'6BM!-Q'<
M0'"#4KE!9RMND-X7=Q=_4SRT=GC<@,&]2S[E*N\).E^R33LIK5RQX'3XL;M8
ML.$WM&F?8L^DJ6Z^1!*>+:(KO%\_C\"O\=!%_J'J?4(WO$T;M\2]7%F]??U(
M;#)*H.'U7\#JO\&"KH*U%^0./ 37'(:@:NV7PP54W]-P$)X%X703=%!%%#IP
M.C@LCUJ0\X#NM$KXSA**/,IRI_FJFLWZ="_E2,2:P^>CZB<4M>S3K*X&."ML
MZ/>$I)E,YL$C2(65)C-/%\F0^;$W)]I>L+9,[UDUZ*IBX @RSTSF:'7'ADQE
M)O.J>,=V]?GNUP>V:C!4*<TXTCMREMQ(A77^**6O1-2=]J3HK/O1C! GS:6V
MK+AMY%RK5+>5A,K)C(7A":_*5AJ.3L#EXK9@V:IF+W3E[9-F(%M-NG;]*<<>
MLK2@C6N^$QZX0?9BI_\HKW!G^JFT0T.-?G./0-U.?]AD:-NDA#S';5IQA[,<
M,[CK#RS947A4Z^M)$LY(@4+"C[=)9EPL^S!'*XH+"6JF)6?45R\_[CI_MUTY
M=O-*6JZ&Z5Y9CXLXH3V<4-1^WB*7=Q]L:(^A!I:Y2U=Q:DY/<;PUSO]T2HLQ
ME.A8+,UI^+X<@F"VKLF;7;)/TWH&Y.(,'#0KX/+?JSN_QJ\2%,4H:O"X)O=T
M/47EZ%YO#^I'4KND'U1#:ZI8A*QBX*0'[*H!GP@(UQL<@5_"N-I,L%^P!NC+
MIE5HDHDPJ80"F%D!7)-)Y0<#.=H5:U/%V]U47@&L-IX+DMH#2:W)6LI 4OD9
M57+OX(VJ9>&?%(RJ:%RH+,2],8W3R9[TAH33J)AJ&XT5 X \3API4JX&S%E+
MK5,6(9),X]PZUL<MA5L##4WRUX&FVBM13_]#+//DRVG9G#HWTMQC5P;!3P0_
MJ10_Z>?!3W)4 %OM=\96=O8>Q5.U#B5EZ,%TPN/&A>=(F+G;,[I!1D8G7$:U
M0G!!2V734K?Y*,<ZGF<GIOQT!0"J?M24HZRO@.T@P!%!4A&$%_BU?_S:V(R*
M)#<=LC?]'_0-1#U5<!3<<VCZC$7FBF8$0V9P?(OT03/84)C$^3W"O'IW*B$[
M_?5UNJ@7RJOU0@\5APP3[SW\HU\^ /;)Z=972!4\M<GDD^I:B*8G7YIGW=9R
M[?_*L=$5T@:KC=V"D JPK=:14&R.9@XD)*\A(?FLVUY'0I6CG8JT4CLLE4#5
M[ G.N98 Y8AHJ%8!G5X$K1*8Y)K*JB4F><F1^AYP^HY8DVQ!<?]*[IPZ;86]
M4ZVU8W_KVGRIKKCS2R5[V F^)?A6P+?6U*]MQ;>6'>J";]4+=[+PK0('0 PR
M3M\LH8/=4ANIV)#0DCK:A7^NGBX/9.1:FO,6C!H.92?P>>>F:TD&)K1B7SR=
M]NR*];]+=E>$EQ,YH&;OEY,OB@5J>_*(XM<G2W_TN(_<Z;3E0;>?-<V[[/CW
M\9%C2D\XI%G#V=>XN^W8U.#$?U+Z+6;[9U6OR!7S3]8W]DMN(;BVK5_X&7+*
M0W9 \)4TD^6GO^J-N_^!3&EV,QWHJG^2V-@"9.3IDT64/T^5*>SA)T5_4=YL
M6-7,\J[AB8%,VC07KY]CQT8'/>$W7"(UF[]\YI2&N6#1!<>$%?_B1/HK!W)O
M+--K#YDVL2</()(Q,PF*4G'5L4SC^<OHYF%T/SP^^GIU*UT_7)ZQ9F(WMP^C
ML?1P*SW\/I(N;F_&M]=7E\.'T:7T[>IF>'-Q-;R6Q@_PP7>X?PSXQAZV"6YF
MZ N:(&%3A/(&9[W<AC'[D>[[P%*82WB3/.;QX<?9^.SX2#5U7;%LE!#.S'1M
MQ5!A->1U0A:.9,] &DKPD00RC?^5Y>362-@Y*M_V_V?O2Y_;1JY]OZM*_P/*
MR=S8512#A:M]WU31DNQ1RI;T),W<W/>%!9%-$1D(8 #0LO+7OW.ZL2\D  ($
M2/548DE<@$;WV9??"7^XS ,D\FBE9%^:6,DW@RO/,2:UW*^%,%J'TC11$G1N
M/C]K#D6\GACS<U@*V!K$F(%IA(Z-;MIKJU(\UBR3OSZS,?*M"%@B2IW3DYYP
M!B+G^_>K!T^XX(&ZF[WY I/K"Y16#U?77R]!2%W>%]"+X:'&9S0D';>D\^ ]
M)CP !CB;$V5VLYNU$4TVI(?C'D%4YV8'_]DEE'X7\7(_)5,!M9"$NN5(LZS:
MB/\<>0!U[9@IJP]OR[_6MJ,M7K/<W^0JZNCQ]SD=T;U7ZJM@F:^JCDY0L"IX
M!UVF)Q.>QZ"?!:?IRK94HF?G&9)^;S%:'\KYG-MTU>WN[7;NJ:?Z?0D.'FPM
M?/=5T&R0C[C++H1Z9).]O;VZF@C@ ZXL<T;(W)V28X.;9N->P\OS]<QQ52@1
M+&*#)3Q;4KTY)S^(;JZ\<WE9:O &?NJK?UZG)RL5*5%;J0Y<\?%5 &,;/_QD
MJ2#CN\+$H=]PX"'84=/7A1=BX<UF1/M!YL#RZ]F,V/9BK<=ORA;%4.)AL?\B
M,X<BPQNF@^A[H'[F7>'* (<1/CA#;QN^M% U'?2(]WWO>\Y295_&->NOPD(S
MT/^>X[+=K6(N?&B#\3[F(YR\&MID? ^6O QV.\'&^7300=#<[QBR8!N,Q4"V
MMZWN+OW77T:R-/P$E 4.$,8O*(7Y^QD0)!I@L'LLVF&DT*![]+#/]!)(N7C-
MX.3QX[!).>*J8'M$\>'OZ#)>OZY5)$!"[) EX@9'P7&\QS7=+&[=%5UX"_H"
MZ[EUUW!E?-$LVWE86H3@X#0;W\2K@1E#1Q[<+.[@>\::Y)C=,UW;:!=-9C2F
M:U^;P$7?3-5 Z^@+)4_8T3O*)[AO]N?7;^1)U2_!;G)>;Q;G^"UB(3V_/KRN
MR.2G9KN7#'CT.XU2518,3O9B_0*6^-K"H\=37^#NP&^P/:QFC)WF++1#>.J6
MNT<=(==YRE.YIO.\7S_:Y-]K^$)PI$=Y<+TM!V?[&Q$Y/=0$.8](J>F(7.Z"
MA=XCU3A+/*2C/*-^VAG-_,=GY\3V@!Z/L%ZA4D*[V!/+S$/U_J+ZUM>TGJ;S
M%-Q[YD$+H$?^)/,/PDI?XX$;:U4'BP >G@ K/X)6G8/$/CWY=O7YYJXK/ 1W
MH2KU>8V?0CU-X[7/H"'A+\V8681^E5HB2% .53/;%MFA)$<5/RA=*BM\'0+7
M/CV!BZM@+^@8JL:/:PMXW5@O8,<8-0=Z/ZY87C1G&;KELVD0JN8=^-->$,O"
M)UT[MC;WK8=[QUT%LTO1VA#0U<'3Z9R>:!%ER.+[3R:J.V&V5,&YQ:\BI5JF
M+IB68,*GK1<-*VO=>[(=<<AL:8 G\_0JH$:5Q4]_&N;+V=)\H7]*GX3W*CX)
M&"VP1I9&P._=N18;G([Z\@'M.+Q)\ ALU9WPKJ<=VHNFZ]%38Y1E:S_9L1VS
MA4.M:C0WEJYE^4H<9%I@#<(H$<@/&%YU@#YAEXS9$A;Z)Z-/V"380UV=$<'E
MC]_,%R X*VI+SI$F\-J/1-?@;4%SV*8O5?C#ADW0%N#1H4FMP3? 7#6-=#.+
M22[@T)5I4RK$$P=.7>O40/(R2:9QU&>V.0GG8)>P*S=>(W3_8J[U.<LM,5,T
M)A(#MZD#GP)AS?P67QK2@*([M$V@'&G/+.V1S$]/U$=0"QTVN&H%PN<GR'2'
M@*.1GI%+ZL\$CL<F%3JA#Y65F6M$]Y7/ ?8&22SJ[ND),*8=]1E573=GGB^6
MY:T>,]U_H?/0*# ]-090< 0J;_+\1 QA\@3:%C>BXX< Y@1]-ZH[*!N$2=Y>
M4IY SS8GH?9*&'HWBTMUMG3G'=ZYNAZM/+KF@[3F>MNLN:XR2C/HX+ ([(4G
M1S+-,^HXL2-UE8&NP7)8D.,*'D?7P3Q&8PTL99#Z(.IB6CO%O.H*$ZHF/,EY
M>A(5G=[-E^J<Y=]55YH&-EM>>3:*D(E[]. >;Z"7EM)!><DV2OK+M+K!9<Q<
MHHK'[AN)W3\F#J>.J'PMTTL,X1]K@PB4L26Q(UQTK[N3KO!9,Y_)')<HW)OZ
MFAJ)PC=GW@V6]/X=^^R[#U2KWEC P'/ZF0Z\Q_Z$]VB"F&!Q#M"R*OS+A%\$
M]$LQ[JH&^N<]TOF[?]"W_W#?]M437 =XA[("F%9 C9J]=.-#P8(N\4XJ+IVN
M0D#&MVB@T>6BC(LS$8N"CCU[Z&G4V;_7&JX^IQSK1^081BQN%O>..?LSK-UN
M7@SPY9;:"A0=E343]RXY1!I>UU\XE4CX"GTP][G\=YEH<B76'8N,WU)AANXD
M>PZ0>>%W_ M>&&I  3X!P*[BF$RZ-?![U1&-I&'W2W"XT5#RWT QX=&JUBM+
MV-M==GI 9C^ 0N#$\JJ><=:1,;/Y9G%%K_B<4?;?LO.I4!\-Q.2!!.>A17S.
M3H1IW*",9Q_$), M/ XPW3?70 G8<+6V[+7*TH LA>1>T+5EYAX?>Q<V#1(A
M$/9QW_]=T1O93+*XH9*KV[O_^HLR^G3AQDH^I*K5O.G# _4,;HS3DR_DT5HC
M^Z U!U0,"B#?\;%=]6-221'NGN^#]X&P$*<>A;T&"Q2.$SUA_$8608"#O(0[
M@ZGKK<Q&)R9)!^#JX?%K<-:TC0#,"Q"K.JOI\?UQ^!)^PEL_KB1&7[ZYY:?U
M#%<KLBC:#+2V"J^!%&!1/9 ZO[OQ-<T.[T0L-YC("[HW#L*5Y-]HG,.[.:76
MH)1?=4V< AFG=%G&3LL[W9@TJS=WY)ZQ01P_*12)=;HR*9, ,YF=5_4V4-4[
MX%6]O*J75_7RJEY>U=ORJMYH^TN!RMG4XM^@OTA1P.X496DPE!.X%=0%6YHZ
M"&K[$MQCQ!!VR'Y+?_<SQCQ,.*SPMR^<"?>_3>Y -DUNKQXFWXJKP1R>"0_J
MY3\7:0O#'GP1;OAAZ1Q,.Q):2TLOQP(PVVDTKU>]M00W3\BZC7YW>),QQ04>
M360/T54D!G5=YR%?<$/K!/R3WCIA&E2 _F%BVP0[T-P)$UK'@OX2D[MX[J9!
M$\E!!B1T#]?S^Y5&8WZ8"/P2=:18'1"3Y>BGJT:<=O#!P2TT(T_OIJ$$.$EM
M3D"U8SC P'H)6NS)RD1US-CHKX+Z0]5H>RP-&ABG)]3U7P2U&6["[+.I6G,:
MZ]7@^HYIV:Y)Z!%044';2N("@W?#=K.MQ@H66CJ%RPKO]QI.6] U./NYRHI&
M%K%0GV"OGX.(!;YGF,]P QV[ZM<TYTB+GNG=.OY9X/<L6C@66&0,1! #-L$"
MV'?91['B^Y'59)O!<K&<W?"*L Q:90W';--LI4M1+(#H59C9]AK#.VZ 8+'&
M0&Q7N->,&:$A!?QE1>NT8IE-5HGC4Q&MS_'H<4N?<0EJ&8K=<;Z6 ZZ\\W.#
M_):4]SDM)42*#A;$6 U,8,U1]8_5*>HCIM,,9)O(1V5\YF9(6MTB>PJ3=&OH
M]^KV1GA1+5K(E4>^;@$ZJ35CTQ]TATVH=^QB @5H$)8B\$N5XQ:Z9F@.+?]<
M/^I@/YH+4)F8#G_O)\-NO#08QE#^L09#"DS"43Q_@<HS3V)B),FQ9IISU,HW
MB_]A!WIC44OTBEXP:8Y*(W'H&Z&IWPP9H.X;D20J-FAH<PT,G7 :-_@./&\B
M3<',A7!JXNKZRS:4HTY/%#MB:GXT3+\TV[.V9DOL-LNY?XE 2.I&@&D-CP%/
M2&8((:,1^QS,8#+__.I^SG8_F&+U'\PV#S,W.>8^^'T L,W^WM-JZ4="T):E
M!0&T@,12:4&(6R1WK=IS]=_".=.,PG?5^I,X@DW-PLGZ"0O?)98>'3$G)GRZ
MIR>TSE1[QC0\*]\E/XDUTVRJ\U2L /99T'T'6PVT&<E;&H<$D0 K3#VR2_?Z
MMWAY_TV?"E)@71LA@]_O+Z9@_$_O\=S\U*!8)#,XZO;22 )=BIB;@P>NHJ^A
MF=3ER^-.*[&*U8V;C8"YZ1O+O.I];G$*.N\+[(=-C'>_+L"K.CVA35IQWQQ3
MVSH!SPG>U#6"[0&>Q$H4F;(D^+LO\%/%\ "0=;A4Q>L^"9>Z>RE9EV>"%#GR
ML']/\G-%BZQR?;-ZKRM;C=/(0,W*G+:4Q,0#BC.#BGC:II$(EMAK*F*HI^Y_
MU:L5]G?,(F'GV7;@JAC\4.>X";0V(-ZB%/JX5^O LBEXOLPJB*T46QA"WX)3
M7+O2;-&AA@E<(A_?];?S';9=VAC8^*8]:\[-XI:R]A?3NO-N>V5$!.$A,*?S
M8F;P)GS-K>"G.S]WN\M,2WNBP19*!\;,[S_S%%/'#7X0VA$=&':R&#7L;-A)
M[ BB5=\LN $ZS:4>[ VCY^XJ,@+&XXQV-;&##T(X%+W.QF 2?"R?5E-B]2NY
M3KOMAURMDDNU>[#8A;$O.]B59:Y,*W ":#%4P-["LSHG;I<]A54PZ<\/';]3
M$_3CBXL:*KAHWIV<8OCT9!+[G&$"@?8?L6_-?(F2V@Q^ZH3>Q6M+ ZJF-1."
MVUA,HW[ #&>T6]75VDA["8*#J].2*Y4N[?3DK[A;]'X6;<-*%52,1\(&HK^1
ML"UYR7:XG6PIF9+YT9-HOSM*]B S.XP>TQ[U] &Z\!.'U3ZB0^$R!Y(=RGC@
M3M-9>D)=,VS'6C-V?A_0+O -LP8^L&XW&O[6%AJSH@A-W$2^ZT;[@RO@ET"K
M:W,L[L30^!PXQB^MI(D86F;]@@\*%!7(#+=C^H=FN]F!R?VY,)+ZT4P*_1W,
MB^^T[PZ1AG,!.(RD7JP;J% ,099$Y2"<VUZGOSU^0(_6$V1N!6[./4P,+*T\
MCG P6RUWY)3>@D04@04(: .;QQA^_BN??NB%1ENR;@*\\&?D&U2$!%PE_/($
MM^*):E'[\VOP&;?M;0+'/[]A-C>=87P>7DWZ.;A9W"9.9(=IW6D-;ZZU63)<
MTD\9(E51O*2IS:U13T<9@"OLC0J;H0B@[DL@"3#3DTGK/&2JR--^#@<H4\>%
MBS7:+'BECC+N9^@YC,0BS$K94+FB3/L)%(3J==RA;/5@/.P,<VDY1'S!4!#Z
M7*[36%;<XAF,ZA*W3>Q\7>*V8=%*!XR0GS-]/0\RHKQW98?>E2'O7>&]*[QW
MA?>N;!8NO'<E4_;M%9$^M8O38[/<A+*I (UAM@N)S@WA/1HVF@&&?&C?/);<
MM+RT]IN0&L]M-60P*B_,J\5-3"+!U%]K6G^Y6>#RRJ(TIH(IP _ O&)JIT@4
M.0!!8V>6YN84?= 'YH( [2! %7P6C9$5+5N?S>"[&LMT(0*':=D^" SX*3\P
M'4K1%#V@X*W3K$:2(H^E@32*IG%\!Y$Z2,SKIFW]M^PNM]Y-4KP4$2X[+H?A
M,?$?\,I[OBL#F1N8[YQEWVFW O-2$+3J =C8FBP6FH[U1G8A=R?^+)5XG7F<
M1#D\E7K7_9;&(:_P[>WWH"/VP,\7TZ8L9B*UI(6YU2=@0$2DB+*EC_T?!UK)
M"@C$N$L1X83DQ*RX6_>RB.%WY18M()!S'NYR(]O'PV?A>/D@$B_O5\1MB8K!
MLOLOC;W^L"/BN_+[+_6ZR8S%!L8#+:M[!33;(FL)-:6,)#'1V4<E9D9%P7&Q
MR*YAN+R\DABINVF+CXL+=MUBN:L,B[!#4!D2J3J,*!JO%"T?C_3%T7"76H'C
MX9C:C#=I*N4HS,SLZ#@>ABFSPTH'=K,S&B;'UFY@DZ"*,]Q-@("SH$4VXVFX
M-I@B2^,<Z<7-5>S'9'MM*K_-49R,3+#S?AZ3+;6QG!GG=] :SG@Y<Q)?+:09
ML-C3'P?E53K[!<[AY###K<[EC4C2J)>S'F2G)/'!,\A>]$C]V?K#YZS]JYMX
M=( Y*W[6(6]E0(+UY%&OWZ^K-N!X&&Y?K@[P7UV5&D?$=95X1>-"T3F_%]N/
M<7M;[B,4)]VE$DU8IL'&M'EUY?%NHA"R<T9;4;RK*)03B'<6N2WC:;)E4R?1
MMC:BA)!11KUAOH9I+F1J$#+1\Q!%25(&_;K.@XN9XF(FI2,C-!4HG+)#5,70
M=" /*B*5K2D,^*-E_DDL6!"LW<IICO>'?3EA$X2S0%NX,+L,$ _Y,UW1!5U0
M?89MC.:E7F\P&*0':C,?*D+*>WXH<(DZ?2E9HI@C(I$]X#-^TO#K2"FX*25/
M^L8@>SSLOB1+B<Z:6@Z[JN<:8_=+H3AMH.\Q-9_E"MCY?0%9'HS%VNJ$BY*-
M=\W&3/'^-)DAK4-'-KT91?,#F6VX"7KJC0;UU9V7I2<<$28U97I)_1ZHU]:1
M56U[DL_\"94E@=Q<,:]#?_5]+K;8I,-5'B%/>/-]4A>TF__TA#F%%*$D[%"Z
MGJ"SM,SU4SIJV<0Y@Y?/GAD8D]O*O++,)TM]S@,($%-4'=9HG0H'("2];G_\
M38PXBL,%*+WI(%KX-'$O$>% 6ODT<1CV%$/<O64/FR:<_,$LD4\&CH[S''D#
MOU('_TE=,:7+Y?3DGA 7!F*6XGO<&,($ME\79-8X)[D$@FVQ]L+=2O=D;%B4
M>U;^N)W(A"AO$'VRIM ]\3A=):%_!:_H$#T:?TZX.V0;9Z"J?E/^%H*)$0L+
MV=#Q<TCXIR<^1!]>U_8'L*]6NC9C:&'>XEV8'1?YGL[6I [9"H$^\ CIX&&?
MFAWT4P.3;6TXL+UTHI^L>'N\"%P^%L)A8$Y!7WE@\='QKMZSDWJAD9N24 ],
M]IR>Q+8)IT@%Z''N_@>;E,NV&TP5>2?P@H&L[-#S5C L<KY4-6!RXV9!>6-B
MS"\,M0UY#$44.X->6MNR?T"YL1#P3/)AZ.T(AA <7?7'4 :1O=DCE(9R9Y0/
MO)%HV#_MVP1^II?"]\U4>\D ZEQ.9$",:3@-?OXX#(D6 _W!4'DN[2T/ITJB
M."Q<2.G2A*?+,VC"!V8X-L8N#_L M)'*VCLA/^!QU99N/,K3J\4$W W_Z2@<
M(!<H(@X2X1H8^>Q':O91[-K _J"8D)C%8R,3PGW\U=MIO&ELGTUCLR-L&KMQ
M82=[G93\\$+3$7/,6P_UZ)_1)+#(DV8[KCZW/:L'0<=0%@E?SA3*!_X,<,H7
M@KHI8L"&TM)%").'[X+G7+O#:%7TC<B<(0EZ"_+6B2-CT59WB\[RN?WBM)?,
M@89&\N"(E-2XXU#LE7+M=S$2JVF,4+KC''T022C;#L9STGSUN09^/87$ZX*[
M#A2A/;HSZ+T$9:RTP#,>X\?,0'D0!S-4;AB+(O@^.9H?C'CFH7N&FA7G=(8O
MI6M)\0A;A1U]BLXC!A(]5PT6 !"^$H->\]NW<Y<8)T]T&G(N#>GS+ \X9@]#
MR*Q R<NP"0=Q6ZZR=!RN(F8MAX,W$N7.4$G6!R91@N(\DN K["+$0<Q^RV#.
M=* H]T5%'D11UJ^)D]ZC%MJ"5)'IC2]K_#S*"T^E*Z><1Z1W+ [16Q2F29KV
MHO7K8>K^'_?B$W9MZA;=$LOU#-I'^96X+G(R,YD.B9>&:,JL^11IHP9U>JJ>
M3_; T23JHK?('JGI$R@G>_J]04<>I+F,-<J>E.T>52%Y)%_R-'X:Y27/.-5J
MJUKRC*N2/&W8Z5TE#QC*:7N^3?)PE_[07/KY<;KTW]578=A)T8 NU$NHBMR@
M9:(&7#:'>XX7W.*=9SGE135N;SHH:NU+8E\<%I,\4BT:-U7,#Y(->2!W(L-_
M\CCGFSWSOT5\\LH+9'+B6&X$M.0XEL5Q+$<<QY+C6'(<2XYCN5FX<!S+3-G'
M<2R+X%@F "PKCE_77=P:3D7X\P"R<A%N[$)*ST?LG(8(V>*G)^E)B,]=X4[3
MR:L0E#1UA"MC6[ZQI(7&7<E:B&Y;)<4ANI)7!BM212+UIA-&/<IH/[(;7/51
M"[/0/I/QIW[1-C2)CF-K@;-7;-+&J"=V>H.TB3K>/N8(LTH5A5GE:5^N)LP:
M%- U?"H[9,?E;EK&+>Z 5Q1O[4N5Q5M;L.6[QEO!3NAM@:0K/ 0I*[3!-69;
M-.;B"#4FZZNB@IK"># 8CG"58; >IDQM@GRN"^1YI9NOA+A3(XGU@W9/X0#'
M$BT.*-N3\5/D7R9DV#K99&8F?.B;[CP[K_@V7?%&<VJE:F?OV4-?>L\\,>;W
M[(EOO0=N7ED/AYVAM$DGL,G+!9H<\%32H4PW31_,&CX85AI7!CM+?F ;#RP-
M8[O8,,EXF8S4$T?#7E*9[V&<Y $>:_EVA)XTVG"PE5AEP)SIL">[G*7?>.)Q
M:,R\VS* ^F"/>??6\3XW"=^<2?C$34*Y0T'@/'-PF]T7UT>*)(YZ"=2-2BP_
MV1=%\N&(HC*&1+_3W]'N2Y[*0)$3$+=U6W[\P.JS^Q2E/Y"'#=A]!WFH%4\?
MCYA]A2!OX9_>>-!+0/ T;N<=ZK'N;N=)>[/S(A/Z(A#GV[.BO'RI?/G2F)<O
M\?(E7K[$RY=X^5++RY>$2+E/ZAR;:-1LK(RGTB!A3EUH-D(5KRV6._8-*M=J
M.3=MQTZ84_8#T.5G/3W''+./W@D$K(T5,INU)@$[;?@E*[H346./ICZO)<J!
M@NCT9. 5;)U]GMR#$#J_^7Y[>7T_>;BZN7[CY3UIP9N]G(R48-%#B3)1#CI[
M1!8"A@FX#.?M&J7ZU&N%>E$&^RH&O#%.3[ZKUFPI2+3T#E$ HET2*2B#Z@J3
MK9@^$.C&8@4>2"6<@' +^\E:8%Q(4KPD?368_D !(MT*'??-#H.K\$K]+()9
M75@U8IQJ"PUN95 LLQ3(!1:BT$$8LA/%R<SH@OFQI_=$G2T[6&[E+HGYH=YZ
M.G@W!X0VYD/H)4]/T&VSDV\(*KJQMJ= J;<&3^[2%7NSP_I\?+P;^BI#9(SF
MK4%;G 6OK)-[ LK\$E8NL.4*FAV9GX9/C='/+2Y?[:A$^R/5"=;0N9OAC55,
MV3:V_[!;ANF$0L+NU!!;^TECRW9L.!>%[61@DIH#)P="@D0W_$73=7AA!5R
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M]RL-]@:.\UEUYVT7&(&5.,J^,A+3L4UW:4"(GF7Y+M.*CK@:_/=MK0$L 2G
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MG@47KERX[F Q@VPMWO:P/>F6$*YMBDTIW5%%CG7KA7!%LH"+)BZ:&K'[JAN
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M8X82CL L;NI7SXBNNQZJ_S=L_\S[.]NGV,X7<>,G9-+@$;C6_*C_R[N4\I[
MT1Z]$RSSQ?TCR^L&?D_ME<MH^WS45=S#:L,^VTW*B#?V:.KS/4DCC[F#=7M<
M7J1$:*=X2,KA5%0(%BQ!W$0=45)P2=DE!WF71L5\G\MGT->BB9@*=\5.L-J0
M;BCF4^V-'%+VK.) ?\HR=K[G@%-A 2H,620MI<+=A)*\@1HJ3UO5G:<K>KEB
M#W]H6I7ECT,"=5&$</D1'\ 1>^FL4ODC?L('<,*<B8_^B-O/Q-R*>+O4Z8;A
MVDN<_(!W.V"W%(8?\+$>,.?@(S_@UG-PQ?;#H9V/5V78W@/B'+BCB(W$JODA
M'^4AWY%G53/X$1_Q$4>C_?R0C_*0#X"/W[C!M,)VC% 2;D7V@17"N7"?9ZPZ
MH20KQ87A1WQD1WP.7\4.I[6JMU?4\D/F?,R/>.,1SPZ!CW<RF?9=]]3>LZ;U
MT\&BW_]^?Y%_L$SS]4Z5W+1*[N>4Y?W[OT40_RKK<^8D=<0D]4U;E(O3<)+B
M))5.4H5P23E)<9(Z7BD5L:B]F^6!JREE[?N01JV"13MX*.8<H#MC93B5!FT;
M@S)=V[B,]%705^W)VEF:V%\Z_]T 47/OF+,_V<UO==6P/[]&;G2'ZY[\U.PI
M+/1GY*U;^#)>\?\1R_Q.&.I:$<P?,8KYL]!^DOG9?^!B[WX]:\4HAY3>I49A
MR][6O=^X?!F-1]-1Y9"MN2?%M4:0E(%IE#K]047SF[@(.>![OP$1$L$XB,,"
MCJ>]]#'JC]LER&-A \6O$ AEL!Z(]2QOAS5H6MJ$I,F9368?YVL+7=IWOXI=
M<1P'U>-RY*W=^PW(D8VFR$B<]HL/#:]J(D?3PH&;(D?"QER$-&:*C*1I/WWL
M]0ZF2#9"<98I(G%3I+URQ%U=SN!IOT\O7%_P-'J#AL7!EL6T41QL#FZ,IZ/*
MIT <8.STQB"WIF8X#R_F%W-ME0FC;H-.AY/O'98!4BOG-<GU7.(TZ,. !5)G
MMJ9]/LPVV5)JUO98[HP4B<N35O TER?-.33RM*_PV&HQT9/IVTC=?N^@?)NC
M96LN4AHT44"F5(Y(W>HP*S=1CIVGN3QISD11IOWT.>H\YLI-E!W#K[QVM>62
M86/M:D^>2L/T?,S;C+_6%WSM\>QO.WB>RYMFTSV5#Z@]B.!K96[-0!0[HBB&
M14)9L<*ER6'?^PU(DPU^S5@93Z5!Y8[-T<5><WDUXT/S:HZ6J;E := =$D&B
M5&Z?'$3DM:Q]PKOUVL?&7(34(T+.CHJ<B\7Y>)EE6ZDRCV(3Q>DHO0/L;87Y
M'EY,JNVPT!I^KR/2)W=%^;#TX-'F_;C$:;"&09GVWU;7^C;94B;8UV?!/BY/
M6L'37)XT6L.0WB?"0WV9HF=#M$\9'E2T[VC9FHN4!DV4WK3_MH)]%9@H!QSO
M.UI&YD+D+<;[>%W?VXQ"YXSWC2L':CG@>-^-0>JJ[).[TH&U51]M[HE+G :-
MZ?YT4*?$::\QG25;2O4LB6)G..QS>=(*GN;RI+EX'XB3RG&BCB[>%Q,]F?&^
M85<>'%2\[VC9FHN4!DV4P;1ZG/Z#B/=5::+(PV%G/.8N3SMXFLN3YDP4$">5
M([\<35LU-U%XN>51)@5RC00:3:4,V? VXZ]?M!_D86D14D\$MJ\<ECERM-E
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M:.3])3QMW#81M\T<',N],<^U%))F]]I/*LNH5*L)[&G054J"/;5&_+VEDI?
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MZXT%^Z=:KWA8K .7"F%4DE>VI1(=V][M]>._L W7,045Y'#\?+&!8@NJL**
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M3<0_=.%,??#$(EZ@'^S8.MM($<?2L#](#L?T(0)9^.<S76V0O'.CJ!-C[D:
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MFH $2,0B;CP*P6DZYT@?+GG8:9&("EMJ.SUY>U=M2=.X;/_,H= KYX."?)!
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MZCLC;\>>>J[9*UU]!7L,O[=GOMO(;Y]5':DNE+%VA'^HQAK5N 2;LQ4U;E,
M;"<_(RM;\*C#>18XU.(%Q/*>5K:%VO8[H($Z_3519DCR%Z?0G&&R[7YYK@R)
M6"4R2T\6"WKJFQ7:JHJNF^2DG(IYR5V=E4^@]_OT#KL+].B%FF6L-DGX"2AV
MI+PM.8L,*VEW@LL,'VX2EUL.LTKY769%;TV URFXI03&7%)0QV7Y.7C73^3*
MF- A*/L9??:KW!F(13/>M7%5;C&>GY,*".UZK' NM N8Y5M0P#<ZO?N2XKN"
MT=:\HK<FQ?=AADOB450JM=4.KTJ <ZN;6]W<ZFZYO*Y53B<0;2NPNNN87@Y6
M=^DH"K>ZN=6]J]7MC8W":5'<[N9V=UOM;NDHFJL.W>XN-NQ]8W$:'^^>X(Z4
M#'2.\>[#$A([^H./=^?CW3/IDX]WY^/=^7CW&L:[A]5FC789\JB @]B#2>M"
MF?GIF5J^@H'GB7&+*>7A%52=;ZBSS*S_5OK=7C_G9/'?NGE*)%-NE2P-;V0R
M^AT!NIAINN;72CM+8EJ$+I?6]A*&T1LJ/W=, 2S?-;SOO9>C%+'<"12LW]^R
MJ04,W/I,C/@L\M0F@1J$P\.2G)ZL+.TY6LXN/!+GA1!6"6X[J@,[!1_ D[>P
M%-\MY/<Z%E IX-\$O@_>SP_"/F41>ZT[MO!#LY P]%=A89G/]),S&F*CFN9'
M@";CE[SBZ_#M%5P-[Q6MJ\=5N+7U>&/+'081GQWDTZ$P7Q,D3[SO&BYN.:IF
M.*_>0\3:"NPUSB/">SRZB-,)9LXG$;.'R6_J$:O_$\FFGXINV-2#[K2 MAQ*
M7//5>=%"*CF[&OIO,<GRMQJ;'E*:"%*>KN8(ZU5"$FQ7\AO[(%*E?'H==C((
M4'WG*?_<,7QNOY<O]&<A057)%]NVGGU\L68I^+MG0H5L?["65J:=IQ!@4_-R
M!3]2NK_K_[&IO:JA'Z#E4U_=9E*D])AOZK:BJCE!DGOR7<)$.0%/%(SW1!*3
M/0]Z!EAKU8EX+7,3KHVMJTL5/!956%GF#\U&-P [5'U/(4K=6TR [+TOT+%?
M?^PI8BRG=O=YB%V*J"BB..X-1&4P\BN8P;WZ^?%^O5KIM"<9G,<OF@&.FZ;J
M]^ MTA>O#)8V@UVKH->OC+%; \UA$.WT9"2<"?>_W]Y^H_'LR=W_IH6YA:OK
M+S=WWR</5S?7']/II @WYGO^_*9YW3OEUQC82T(<.W4'-E*>+([$D4QIKR\F
M!K?>SY9DOM;)S6(RF]$0\JWZBH)W8LSA%:"=^3=-?=1T8%MB/^ [^Z#"E#,K
M#:F1/,2-X<VXAQ5UW,H&/^M'(]_]#H.L.]#*H$@9A[L=;B-C 2SFO.;S]J34
M?MC/TX3!*D$EUM&^VA &=WE4[1SG$;."FJ+KS JE)%WO!V2T+<2=5IZ68?TW
M1=2<8%I&,(GV_I813)84M,R7+4L(,F2(4;IK)6SC)K9KO05+\O,XZ,:9%(5J
MQ6R]+*LR^Q"W[V8"I+ 6>.R#6\<&V,3#V:!JA/C!G5U;UO&&:8BIF%)E#T5'
M[48K'<+ TU*O*^\+9/KR>:6;KR1<(8+BFW@O"Q;158?,BPKP7.?(QX!7&F?=
M#/3O1FGZBCCLAX#^^Y(H27*_-QB/$\ 'KHKW:,0;[7V^MBR2WG!589=L;VNI
M?MPRW._D[A;1)Z?[LG0_%(=C.8%H7ICN*^P.[VT'4VZ6[G?0CU4Z/2W2H5<4
MD3:29JU%7=8[ JA]]Z[8#CT($35,B*@!_,Q4S8ST'M2?I ZMO-!^DOG9?XAE
MOOOU;-]B:6]^8FOIG_->T[PWE"5EE$ F*,)[%5H&RMXM8NYF5T6$MU[-2K!2
M+%[YH<YHX07WKH_(RQ@G5;@L]7I97L8?+@WLQ:ON#5KN7;2(+CF]EZ7WH2(/
MI'YI>J].9RKBJ.7TOHLW7=60V-S:,Y%H#->8,G6ZWU1C/6[VOH?O5C!8MV4N
M0FTKKKIGHDG!.9*2AD*OIX@)P7F#N?1DL>0^#(:QLGW68J4%&CLR88,3&+F8
MX&)B3V)BV),E)3'$I["8J!**'$3.&Q 4N\4M]E"DO6%7&A4\[1(J1RXPE*1=
MT1\.1XG>C*2LF!AS*D5"+]4;C^C(;3(P&C4>.'^^7?X<PH]A5HZO,']6J=='
MHG2P_+FIV3?:SKD-^[)\3TKDQ\;^35D>28HB*K(\'";G,S[:Y-]K,.,N?\ _
M=I4M<NULW1S3ULW/]Y?_]W?LT;S\ _XMTYRYY83VVOD7PM3<V 2X%6G%1=AJ
M#&Q%S86;MBND2ATKOS'\L34R[3Q7.L)&P>WR91\$]TA*I'#N$5V1#H?&9G5B
MV S/V+(0-0N;JS^_!A^Y55_QI0F"8]VL:)?Z5_B@8U\9MW2"]5?+M-/DN>)S
M-/XF3VW+>= <[*F],F"?M/E:U2<_-7N*[=[7IG'YD\S6"._UV81;?:?]A=.U
MC2N."9*'UQ6AWTQ]EWTSI$@HF*0=UB!7UU^VJ)"^TNO(*6FGX*Q-MA<(_;5:
M6[,E[)4 1H)FX"FQ6PHOQ"+"$^X6#JTV!5O[*<#5SHCWJ,(C/JOP3)>,PZP=
M!!H3X'UKIL$%5R!Q$0_MO_X":ECZ]-<<A]X31:77'R>'Y3H@>*]L&U3S!1U"
MSDZ/'K1-WW1/]]*]^?S8SE3L#I-6>W"@/NXH&PSOG2\=,/Z#V(Y@@CS8CF8@
MR3U9[O>DQ"3-TEQ'__D#5N ?FM3"HPEM_9E-9A_G:^L%^,$FQKM?32-49_A*
M5"MAR6@(B[&V!+BPJ@OPC^402W^%UVU'U77<"QO$)KP,FX C[:-CO!0\,\UF
MO$:GR*LK!-P MGM\93"#N+5+4"W(9^8B5/88PNR Z][,'!,A/GIL:F]"990!
M9=D.PI&%[N=]JCZ@<G$O(]]#5RB'/CZJ'F%<V#_$>.RT1K"]PM]_C2&Z[(;^
M6,(VW VY=M!G-)?'@\VT\U",7CU<?A]/-2#0)^WGQ)@M382T3H%YKJC\&6X7
MK'J<RNBY06 S8'0;]TK.?YM<?[V\#Y9T=2U,KB^$BZO[R=>[2P:8+OS/U<-O
MPN3\_.;WZX<)OG!S[?UY=?V5?B% H(&OGG^[N?_][C)SQ])Q;BO#HJG'?P,=
ME4H#=6.RM(G[)HVQW^1(^>_F^N'NYEN( 9&9;N]NSB\O@(/NFV*A_3S]90A\
M&>'3-'NFF_;:0H/+<"Q39TWWMY8Y(V NIA?&[/;@.<J!:GGTF[5U>@*OJLRT
M[S#7#FW-%=JP,VWE0T*CV7N^U,A"\$URX6:Q ,?/HMO#WO,1T+SW.@*XG )A
M6TQB"-D&L6WWVJ<G\V#?9^%]7_G[+KR'2R$TM0 &TK, AO2<+&";YFB7WZUU
M^(2DJ&=2_SWY0+\J]>?N7V#CP#KQYI<_&>RV,)DY+G3VTUI7F1<%]WI>ZT^X
MTM,3C 43^D6X&EUG ED/-FRIP7I>$$%[@7<P\:/T/CY5"1=PO:Y '2:TW>D3
M$/]MQ.,ST2MG&V8S)#[$GL<I G0=*IP,6T'*E3OT:'+L'G7S_;VO2HLTSK[?
M??+%\(,T_&2?GMR1E6DYN-E7Z$D80(\N+S/W."!3]DE0=D?,U 'QV^L5L5Q\
MQUUX6K,I,CVPC(8V!%;;@^,/&D"SE^CYXI>?$6 >_@]_GYZH<W29'<2T=\]C
M%CX/7,C"OXWEG0FE^BP>7T1X'/[RV"/$X"Q&XOK- 7FD+R)E ?B@*N,A&U=B
MPV&R&!G%R9Q3X'S;-*@EI=K ?A2X'T2*BC&V)Q=;7W<S2A1NW[_-Z4EP'V]X
MP I>4BU?Z 9+LCU$29OM]D_W"59K:V7:;(B .IN!@TA70.7X$PA8BXX<@'?(
M"L6ORG "\98K2X-+KV!'NZ<G5_EWA,DED)6F#@J"),0,BJNJH!X/+WDPV#:;
M(_A<2N"^%GF ="\//AUJ5F'E(="RX154K!"#4CEPB$60YAG5"6$XYA!CS@E<
M0$?:7^-(#IW-ZEBH&H;N0&_K=,(&B" 'V-=F$5=&UBK.4D3=ZD/?)K8QEI_%
M/\-DO,%,YL3-B7NC&J$T':;)$(R,15S21Z%N"P9!#8619M1-8!UK3IH^B>K9
MD$[907MPCN <L5>. +HGVLJA$CK6M3+7'&J#('L\@\T)'@#-SB2(&YYY:5KN
MQ"//!Q4"HYE*?Y;UA/?F&MS3,2WF@=*<#= _,,^'3_A!S@"< ?;$ %'/ J0[
MYC8CG<_@'#AP.2![,'O(S)/\:\,C>2K'_[W6F$$#WB&M" @;.?AY:OFX9A4(
M?7WN#0AX!K*W4'NP2 +ZV%E:)3M86G'<L"E/^V)-3D] X6I4@V*X""2'KH'R
M97*ED^'NIOE5S^HKG</@GBD]$GJ PK-FA_94N )I!K*!'1X0R[^(9QS@L1FO
MH= 2'F0TV :+7:Q11J*1H)ES)BKM]2->Q3.Q+<W^TSMY-Y2$JWLD",D C^0[
M\_"*2LEG$9IE=WH"WV+K@PU <J1FS!+M\">+L$^#1PY.L2^.*3%[_B1\)>1.
MXIUQ(V"U:+SG"EMMP2:0I:Z2BDW01AI+1'.8 T[K"\J&;Y"Y;7M#-#:=;D]/
MT@@W(S0J/'KQSIFE49$1A(A8-"<>FCO#%YXL&B;^8JG/Y,6T_A3>RZ*D?/#J
M(\[-9^ NAQ!*[?<8@3*Q2DBXL9Y4(ZS/\=,/($/G+T! ]&LV#7N]/[^YO_GP
MYLB(1I]AT]SP,Z, 1E QR\>// >,&PN@%9!J6.,2#,2,DLKIB4<K1Q.+/F=2
M$".,34:>]T)1#ZCOF%7PB%-2#=-3 O3Q,Z5(*IU04C,Q0&,!X<UIY1\E/5VU
M'?@&%MA[]5;LP_3&GC&"3BJE,C*G*H>YQZ[]]'IZHFM_HD4$^BWQC4ZQE3:2
M?&_6TM]35O]S8UG]S\>9U;]Y^.WR+EQ3XT]BXB4QG"MS<N5Y8UQY?IQ<&12F
M!:NZN_PZN;O (C9@T<NKK]?"/WZ_N[J_N#I';KT7'GZ;/ BW=[1/!_CX_O:2
MO;$W![L=C+SC0Z17)TO)\F0I7WUR?07)D6_E*#L>5U%HO/\Z8ZPJ]F@V^+>R
M4%#183LH\VXG=P]75U?[$WIXP],3N.7^O !/MDOB_AXSDZS9 22>/KF.[!'L
M\1MG:EZEJ\!_0)X))F*O_%#!,X"?0#TJS2-X[R;FMD=:9>E'DC2^H/^Q[\XQ
M54=C$V?.4IO]B:&6CYJA.9IW]= GV,*RWF57]]Y-;B55HI+H"5)&(+O\RT^A
MQ"E<7-V!CKZYN^^<GES^\_+\]X>K/RZ%FR]?KLXO[^YI>>WYS=WMS=WDX5+X
M>O/'Y1T6KE_6'@#),QJUKFC!Z0EVFODAQB"I1F>B^!%,OPXRJ'B<8["9_J[9
MPL0PUG[XQ"N<TBQ:D.;%F9Z0\OR:#9;,T\PG2UTM-8Q/T* W<;"4RED*CT0W
M7ZIU(9@&];T'WYM06NI-L$O(X^Y0_B4U3U<>QG O5G7D6S%F_4CK'W%=8&,"
M!6XPEC9E"8?=X:CDWC0Z]B_OUDR>RN[,0.[VCYIJ;EU)LFU_-J-7;>&Q%.5U
M?GYY^>7+SMOHJC('/CO;4TN%)\V#E;O)I]3FB3)LMV&[MI<C9%%LX3/8K!!V
M)XIF07<V&^W?-0L4JQHL\!]=X<'4R5PU3-^"7Z^R+I!X6B1G/(/(LX5TG0T6
MGHYNM_"^_P%NL%[YF]VT)*]E^Q'7H7%!7%.:3".AWO;T[/6%:Q_N2]JF0%^V
M77]=J$:(_?Y756?FC[.OJ@4&K5:?G"VU4?MD'"41#RO+.#53R3Z8*U'^40\_
MM9]7K&ZPPM\TT"2Z\!46YOQGPY8<N +IO1$%<K,B:+1C&5"=-%Z?A;Y7XI]8
MSG)M"?>J =I5W8,]WBJF&,KU*8?=R6$?W/*=S/%!6JX/]N^T7IO&F3>5-%B\
M9X96YKCNX$I6)+7K=EH/5TY^Q8ZG4%/)-XT\$@L^)H0]V=*.ZWO)]5O?G-"M
MS)6M($)3AWYUA41'.%^J&B68.'C;9Z^9:+M >4.&^)WY!.[^/[I@BELSHJXK
MXK-^Q7S6,G8:5.;@MLU4\1DI6%:(HR@CW<\T['D"VT68S']HMFF]!FT!W/"/
M[N==N#7LN_IJF=6I,N&]_$;56;_& %-+?8@<C!G&BZV;(]M5TQDW&[]WA1O;
ML<P?E?*:\%XY;K6&N,=O5JU-UG/-V;\BRQ_/;H:U[HD:TF"7NJ[9E?"40)E*
M@?_W:E=BK4^8]!*XQ6\I85)OHK%=[/2_IJ$Z:L0FU&=J91SE:BED*N'8G;#^
MT:;G<]EZUHKVXPM?L5.2P7%AUO[:?-:,XB9@1I=*KAUH8[LU\ *"ZLT)@M)@
M5W4*!LW]Y7D$?)1NGVK/U7\+%@4ZM,B_UW 4#*%)7:UT(!LL+G5,89T.KM&:
MQP?/,/'%U#E!=/'?W7[PC8Y$NQ]8V>6!8[9?NY^TM]O1%I ;)4NRZWCH_BX/
MO3%BU?WO1TOX^X9*MA('WX*RSTWEGD<CY?,62"8+(RDJ-ESE!X/O"X%L_,TN
M0FE9^"\4!>'\\J8CV!JRV#_6"(- L3:$6X32026RQ$J[U<K4#(=AGMGL*]_M
M8+WIB_210-CM/Z_A+H@>X]\] WJ&0;;]1E2:"0F$P;V#/YY>W=5^5U\9+DAT
M*;AG%)=!%NEX'MH?<GZFDQ]$%W2X*-#;4EMU/'!"N*]FX$PD']'M?\!6Q9L1
MXOQ]IJZ0-Q!<Q_J3.!1 S@)&G2'$$7W81\UTR&P)6X#64,IB@KU1W>%87G-+
M,MLCO,=+4FPR\1-]F_XN??K 'AI/1P(/B<&."M_]RVV5(.ZF?2&/%IN]YIXR
M^:&9:UM_A0-EA!A:+SN?1-V,>W"G)VF@0:&:3%S7P]W5USO$5[;4%0'BF]GX
M&<$TT.^#HUR8L[6->!PSX$5:<& [ZA/N*O;IT&=1X9D>S?DKQ8,"LNH("\M\
M!G7X!%PLX'Z<GB#>I$X1MD*H90@'1$D1:"Z\ N$],Z ^"N??;__Y 0_R'VN#
ML!E)PL1ABPXV!*G)5E_H'OO+G",]F2M*-/"<2%BG)PP)]N%.%,?">\-\$<X?
M_GD&?S 0:J )>#I*P_!8;B\3XG,%8$VJ\%=)&@H@5'2JY):PP\(WV%K#1J B
M'^23$4#L4>%A(B=Z>I+!HQYKP4_=6<ZPS^DJ8('/JO$G78LC?/_V!Q"C,OH$
M^]@5WM,;6FP.U>>N<*?IY%7X\ODN^,P'Q+I'Q!<;]PKQNPA%R?>8!&U5Y]6#
M3#&>X"RN;F^ )B8/WVU&/0M3U\V7,[!U/X#X0;V$(%;(T'_M 5FPC4%#^>D)
M<>Y +B"2&>D*EZJE:P116JC,PL="B@SOP>E)L D_<!K=RB*VYIG>>+XA48 !
MBA5NTYWY"OOT*MPN5?!N NJYN[T#ZJ'$*(MB#X4E3OZ,B0 $!]=M,\S\=&I
M&G D_/$/$ P&;*M7?^/?[>+R[CNCH^O+?WZ]_!:\<_W/K]\^Q 4/: $4.)^[
MDRX^V^7,-,!X N*GZWU8+QS[].1W0T/:QB.A!&4(WS]/\..,LYG1=6F *(2-
M,LB:2DYV!7R"Z__]'>0D&&@@>I8FXN$$4KZPQ7*TC?>R>!R-]P=B3[%R]VB9
MN^#N>50=!\AX21,D,(B$B#U$IVP@I\5N$+WJE6VI1#][9'!J6?>@?.1J'FD,
MUX9#>%J&;YIR(]^\D?J!>3.C=UB$F#8$PAR8+-W3DWL7$)2IB-"R[XF!#\CF
M9%@H_&]?SMT'81J0$*H5T NE-UVM'W6JGA'87_N!DIAI:(W LO%&=+N!/E"-
MXRS#8"44_"L SEKIJF'040XF,S8PTA&&,_0G&>#=?!@NNA8ZZ<!=R_-:=UP'
MD:)TN:MQ9UO\?B]\G4QN.\+5E[M[-JWG?'+S&92"@WK>FMNI.QX(<!QW8[#-
MF<C_[\P5DJ"V/-.$@8ZYV*QVZ %C1X+;#B20>K_3DY#L]B)"[O=HB[)G1L=P
MB /A'=PV]!$F]JEQKNODB79*?X]>83(#XQAT!/ 6;"R=^)"Q'<(YAB<7&I#.
M+=OY"5NDRC0I(YL: /O:*G.P6BFC76#3-Y,N>,QSRQ)8"9L\9MY3/Z%'?1SF
MQ;$)1#C<)7*UL*D><A\N0L:M*Z6H3)) )L&S^L](.?S9M"CF-AA0Q AD4HS9
MGUU[!@PN^ 2"2^+T%S!79FM=M="+0G^@*WPFS@L"!0;FO4@_&G)<\,$BJZ S
M4M$F5O57V^_V=Z6BZ6T51EI<P0L/_)LZ5\'P$3YKIO ;' 4U1K\Y\RZR,Q,G
MB 5HJ8AQ.0MFJE+$4#CF_\_>ES6WC25KOC."_P%1W7U+BH!4HG:7[[T1*ENN
M<DUY&<M]>WI>)B#R4$09!-A8)*M__>1V-@"D*%L+1:&CHVQ+ ,Z6F2>7+S-/
M+H$JJ=6P[26S\?GD[/3GX+?79Y]94_OP^57 AB/PT6\*>:?$$@?#;&N<L5!B
ME3>?HL;JSU?7.,#-Q';&ES#?2]34A_0MW/JK'&V[-$BQ'2M(=)FX"%#8]1FH
MP%LH[M45+.-/U"TCZ?D$[_=[V-2B0HV>I3B<#;5WCE,M9(TH3<=8N'@HG5PJ
MK3B2K/<.@PJO(XEA&8:/D^W7VU9A_ T.$1C,43M%S86+B35(M,547A51HJ;:
MEH 7\821&C.Q/LHK(.DL3[ Q%]A9V&Y'$Q86A1!E/L+JCG1587>#R76>Q3 M
MV.PLY5L21A[&U=1QL(/1A/-^MTV*,TW\%R#/MW!!N=,V,HZW$M[X91N6LGTV
M7&:U0<MBGYFP]--+;M+/:LD((NS.L-\$F53H!& RU!_T!=/>3IM<HC+4XL*9
MD6TW) <!>81&L&/Y-7%:,4,YR&UE_LQRZ="$A\XVIB8WXQLP,JY4T93L:)6#
MG#!6<DA,'%H%L-\;O#A^@7+Z';T'ZSFJ43^5.46[O3G*;')=Q'#?IXUV6U.L
MXBO>H7F>BS=9$4VCKW<2W05J/-I_R0'=?F\#Z#H=Y1A,ADW,1L!IFZ#AI4I/
MB3C8> FG64&%S8MA'I]C4>BB5-DLR[,"Q2:P<BFUS7_C'<%.=HH:-UQFR25+
MK7D+)2\[G8(9+@,* ,)47^ 3L@?!QP1DZ.N@9>(_!9=P04]AB-=[>!V<ZS@$
MA23+8C.DL<=Q#HL8Y=7%3_KYYL-T'^+3?S^#Q<2%J4%C226>XGW);8C,'8X4
MAST-]==@25J1Q+4CT=#&N'[ HLB&^)W@?]#=\=&X.] G*ON$C?"8DFHDQWX)
MZG[DDQ7.'=TYO,TH 0L[))P]U=S!!]&1VJ172W0_Z8V?P<;W>Z]9* -= 054
M)?=0XYKP'LE.Z2[&SHL^D5")H'24 0&E2BY>N=O8KX/%HOA"PR,J'"_WGQGU
MH./MQTM >7[;N@"2DM=@4;QY?<([8#K)PX:10A*,(]!M0%B(WP?>^4=TG:(?
M&P]DX;7P6I5P694@*%VAQJJWWD][MA_S; P606;F9?9<3P&]6%5Y@7?C)VP)
M#U/)LE'P>S9)"Z"DY@10M/^25VEQ%=-^X+]_1R/PVB@?%Z ;48%_4))X\]QZ
MUO1)/ :8TBE(XFOV[J'M>"I'Q!Y@_.D[!9R1)7$QI7U$SR]YW&0Y[]_^AM\&
MU7"BBE%4VQ5/X7B'^@:9=J1YP%L@W$$IF,8HSEGBTG1JM_E)"3=\&3W.+;P:
MN6P+4TZ>2S1.@W1-3M>=F''O@%QMEM@R02&)]IR \$_(Y&';7PVCJ1+%2+ V
M%+U@Z^S%=N"/U.)[#N:[GC^KRTB<W$81>LN*$-5#0^LHV'C_S[-3F@P;.Y]/
M_^=D$VVFBR0[CW2$C6P/[TN%,<O\6Q^,OPN0S-Q(#*X/%,Q:WHMY!"NI0)"A
MH8)H(W-'#7$+BC9L!$MDW&*\YP/TC+)&7N&NP'4'.ZA-F78<B9FM]H3;4#S*
M/]Q5"284'"GSD4\MD3W\!R@LZ:>OH;$S7\<72"^P& S$^%ZD"74UY7T8H4T*
MP@JO+NS- X8]S!?NFBVI1)^@GQ&>QDM^3$UA$I1NU#*&9#NN3IN@1!)41)\N
MJR@0@1M$'#5$L?L)1B9[+WC%$=#@(SN_"K*/Q=_G1$M \YGJ:!YUD"!].1Z-
M$K4EL5.G^X]56[2>_4;"*#L<1MEY$=9H68Q\6P(0O7")](?Y!2X=T 2 ZO[8
M_K@M>DSM%K?*CVU[TO2CU,(Y.(_YD5#S])X\O:\CLS;6CHI7OV<&#[W8R@?K
M[AS7-F!/]F3PXL6Q_&@G]#TXXK/U53M_@),1J(LQ11VI 11L&MR;0"*P ]O.
MMC5L$QU1Y7UW G]FSS5AD.J)<T,W!F[.G%.QRA9YT=W3@2>PH"=Z,.SY.I49
M2U@3DC3<U390*<TW@>WAL6&6SUK4.?TKK=)&P=!X+ME7 EMB79>$N!/3] 3=
M,\"OQ#5-E[E0>+LD?0.6)\BT/T"I@8W/4'P"T__Q2A_R8"#!POV0Y _HNGD!
MXE*)D-6/"2T,=ODLY^QK@V3KUX#1D-"G?$8^MBCX-9I.H^ LOH#_TKHG69JQ
M[T2[F/L]X\MPM"7"9*0I5M&$D]H./IA+"_W#ZE*Z^S:OHG]5(+UHZTN)1@?&
MRH!CXU9 %5@:I,FY_D.2X>B@ITN2%/^:P6Y]_=HATV;P8Z\@:CA#Z[71;_)^
MS?E@%\@T@<Q!%\A\:#]9/?7Y'J(*"Q10ZXXZ!'E-G%6/()"?.)XB)HSO*^.X
MWR7I]3LH;^BVWP\%7\/.8L[CUI]"A:3-[^?&(032)#+)=!+#N>$XS@]V!\&&
M^JHA-=0UCMK8+9S\IC^S^?[#\SR+ZM("/3JLR+C15FTH4^.CR HZ^,@I#HQ]
M\LY.9*>]!0G RWOE)/\<@;7K 9DD2BU;3!8 JAJU2Y &B\+6G2_F>%@)^.'I
M,+[SZ/W'LYJI4+#F$'C'@W&HG6/ZFC/+/:<,,R+/6-=P(SP'I,*E\X<A=UNJ
MXS-P/S 8)FRH*V>3&*_563)$V^7D[/7)__XY./OMXZ^;/OJM97/@)BQ0#3:!
M5.IH:=42QN=':3:.MTZHQ6;!YA$,\/Z?%AFT*PO$K1 VDC7%D8$WHO4Q9GWO
M^-"^L.N3)7F Z"K<<A09<A7F[ (F)PL^]48ACLHD#D[1NH+?<Y#WFARB'_6+
M18WX30#ZC%PHO\0"UL/YO0%+!X9-1C4/BOEYZ*H')C3MQ8'LF^R8C8HB&D[
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MC.?7IMA1>HK5:NM;-71+#WJKI2>_9R<QZX)%8<%W6(%XGKC$?%#!=KTMU33
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MHPP?Y"A>Y]MV1A\G<9+$L^!L.+F*\O+?P<;^JKO%EC)X[O*DND#E$W%/W5)
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M6\SDW1GL.Z T#:%-HH(M9(,R0^$TRV&:C"<?\ K-3^$'",7"GTODTZVQBO^
M6P)L 2.4*"H?:G%":D;HC\AE9T'^)-?ZFZ1V3("%*96-=0F9*ADC$D\S0'SO
M^=HU K/Z $>+CCU1J19@! *[-_-#JP.],^YQ@-AL@ GT=-GZ:2 *!J!L';]H
M P.8,Z[CXV^& _1[]XP'"):" X"ZX>,!-"AX7+E71W.UWP ,"!;@ CS0P/T
M YK3;\<&H"!I P=X[VNK8._@J!4FR4XE_"IP]%X['C(4>C4.[5T*-PR.! _0
M[[4  @ZWL="KS:J4 &P&.V)\<8IIZEKL''+:B5@@?L#@]5(8!\: ]GN+4W=J
MB >]MGF0AKWMP4&+'U%4SQK&V=UXRSJ63VJ1&:.F@P;D'UI+6DH1?PTV#DV
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MA[>/X.VCHT'C[=W!_O;.9D#N3W;&H=O=^ BS]"(C(]A $8Q]4VO#,46#L,Q
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MNDO8 B)DF6,TE/+Z\$15T_: SUJ"$<*_M34Z+@QN0Z9C/!+  5)5PYCG1@T
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MI#2N2<<+1J%'>M0)7(^>M)1C4@+'I%G5JE65Y;]KLM@O;E9G%%L'^97E46=
M,;)SY]IL0!WWI*U\ >4+3"=,MIN:7E7'%&^)3LLGR_1*$0:%\@5*X@O(X_:K
M"OGA!Y[[<*)7E2M0 E= KS>U1K.H0)/R!90OH'R!G,TOX*6N;5O^B5Y,N01E
M6Y78!ZCJ6K,P,:U\@'VDT_+)L&+41@'4>3AV]Q?J4/('I:;[</J->EBQ^40O
MIDQ#V4VLO3.]&[K6:*DP_*[I8K\8NK2F=\GJV]RZ>+'JV7.=$[V8P@&'?H'P
MX,K:Z#5#JZU;ET#=;MTKXCR$HC9KJ@)USW9%.'=L.RDLP,L,+"U#@.UIOF%[
M&G*B5V4W'/_]B:XNZ)9!R!M:_:RI-6M%7*I1=G=YA6VKH//+ SB;7- .,%<K
MI'WLI?2/XZ-+[(G$2Y/K<R'P)IH;5QIGO\QMNCF?'OELEC-@3O#Q5&\ES9AP
M[H_\@ZV@+U\UZ:FMMIN5>FWEO>Z -'E%[61)\TIK\XK:<7^O452?U82O1/<T
M=TCB2LZS'=8JA,\PKST8#> 9:PQN\7<:4,^W2+U&>D%%2Y9SQVS2>; >-+*D
M]5<.X[#D])<KO%I.^ON,C?Z2);FB*6'/'+%!"-)-KWW[T"%#RQ:-+N?4"$XZ
MIO:ZY_C^KZ$#[]5Y1T6=>.R>>KROG!6DB#?JOOA,]+9XLC([>+(HF&4>_1I5
MG?0JP#*^29]ASL_V S:XZX6@?TFK6L76=@ !#3O9>=: OE'BS17K>@O$.UL^
M],(Q*QGJO78?&+89(GJ+TZ6QG(([X3ULF-1T\7 E-4FRKFBV>40,#N45=5R0
ML[W 8RS0R#GU \]":Z!'+2<@EZ%I47)Y7JW#PXO+LA\T#>?RM,M)P^="C:?$
M'9#5B?6>G&E&+=O"%H,5)Q9\K==X'E?F@1![2-O/O*6S[#\<N(2:?X66E^F_
M^D9%8J[*0(=#3BAWJOHG)"I#KVK-1GLQ61FM&MY#562U!EGE*M)QD&15U]KU
MC.N1$%6]T=:,1DL1U1I$E:M4P.$0%5=]M;JF5[,R**:G6D/7SAI9@E/T]#(]
MY;JP>T#T)*Z^*E)9@U1RW4P\(%)!T=-H:JTYY)+81[6V5JLV%#VM$\;-=4/H
MP A*GR]_E!^W"8(ZX(.!A035-, XRA*4,(Q>TG6/U/.H$RPAI8@R%Y-FLB)%
MHSEH]( /#Y9IT49KB=!K-Y11MBX]'7 \?TDL=+D.-1J8QZGH:1UZ>HNQ]7J]
MK=7U,^(6KT3G$)ZNM=IMS3"JJ63#U6EQ09+.:ADYILVHARE,HXC^ (TB[43^
M+5*6)!J6)/280,G,*P2-V;=D5RK']<;4EODR^+7\!&^Y9Y*[EB3[3.@].^U[
MC/X\I4/8Q4=J/])G'V8>>=$S?: 5YIT*#JA.GCYE0/>Q/GDB^$TJ84<BPL#G
MT[DZ<RY/R"0>\B%&]SZE4"W$@>@,UF-FZ%F!A=9A)PQ&K@<3#LC0]<B%[X?4
M,9G@(-(%'@B>R;D[GC#'I\@<Y,:FCA]AJ.\!""*:?1EWNP+(W8@='PU=VW8?
M42:(9+")YSY8 WC)!-E(+8=8SA IDN]2G!A_8:8X8([.C#5Q!@U</V$F%RIN
MZ!$FP&2FP31!,$DP/HXL<Y1Z\OC(CU% 0(00.HT%2V)A;ANUS23Z;2L?;FD2
M7(KYEN3#+;C0)%A<2CS@6>*[MC4@>%&BJA'\;^WKMY^6;SA%6MOINX<LEZS\
MG ;LWO6>-YD0*XD@!<Y5\XR-%V;8)+XRFBQ#\=O!RW6(PF'*8$DQ-@B'/N.\
M#&P=3D FL"?FF9;/\$$W#/P +(^4O:N1V][O\%.:+,(PX4G9_GQ!L,^P.?G;
M1B]<9 ET"[G\BBO6P?R_^?AL<$IASV"L):N-Z7_B6>8+7% ^BH_8-EEEJ?GW
M[XI_WR;_+M=J'AN#K8S\2A^H97,S$FW681B$'HM-5VGY+K:,3]B3:8><\:=&
M']I@6(/"!'L<L!".'7)"W[\G>Z=.UKA@62@AI"W\-:&R8>988[OB!MJ.!![=
M[ W1HJ7;&\=67V&K1-@R=XFM3=9+V:OKH=U%VC5E@DXPS"7N5$@]^\SO13!O
MKE&Z+DH**%CQHNV5&T5%%<8HW(!54%50W0E4"[1NEP>G]U6]OK)X0^G-"[7_
M+>Z_@ )OS?K:!3W21[96 $.81171K24+PB,/5?;M;5;6TK6&WM*,IK'7%;8.
MGPAW2 )_WPKJR\$.C<K9XIODBA.4."Z8_D[WFOC6+W18"I.H5;Q)I"K5;1)G
M=<W0ZUK+**(CW#8E\_;&+9^946;Z-"K5NB)-);!B@F@;AE8MI-'!/A2V?X62
MW]61C>,&6SNV479X>1AUO^UP17R*^!3Q*>)[>\2WDPC$1DY-#]FBWI!T4%Z-
MPL'^C;OW.'@#GMR=&U";*&?L;9HD#>VL5M.JK;F-:HI1X<J65N?:A\1"M4IM
MS:BCXH0W)\*G"QCLC&9?%2S?NC^JJLXLK3J3R:J94N'EJCI3HOY6V5)4D87?
M$ 24A[L7WENR!O]\=W'7O=)K?UI ;O?64\<Q1RZ2G<3OYJD/YTN6K=<65X3*
M#PP:!NZK@;'179YW;^\Z%]?)DFZ[EYV[BQ_7O>\7-SW2N?XB/NE^(7>WG>M>
MYYQ_J?%OOES<=L_O?MR2B^LOW9LN_+@^[ZY?.*NTW>V^,-_TK#YVPNDSVWT4
MY7^<9Q)XU/&I*>J/N:89>AZ_&VWA9>I?J1-BP3%1A0A^8F4!? L? ZEJ/V,U
MHXGKL\'T0($KBP\Q*Q@QCS?/P6I.^.XC]DH]/II0+WCF UJ.>#A7V:$]JC&T
MN9Y[343L7*,H\]S<BGH%$ PV;C":F>I:BQ>'@F/.XCYE*7Y6O!14>8O0,2BQ
MP ?Z>G!M/-1F3R9C VR&YY%'R[;E!TB=R8ILYL,82>L*7@OP[[HA2C3'Y21=
MAV&77[0ML%(!$KBL.Q+]*>D];N@4\, -A=$#WE?O&93T*7-$Z2U\P:9^0()'
MEY_2VRQ(MZT:8@,SF[_C?\)5O.S_9]W\^>)-L8MBEPX9R%;7&E;+$6VN@9!Y
M=VM-9H @88]=+\4KO%=JXY>(XM-5=7RL44E,.L$\U1F6T) !416,194[K/01
M@K(07;-CAK'&V.:2!HR(+9 135AW!-Q&J%QVLB*L8N>(#\D87O4LF!T-,H_Y
MP=8J9N;0\ME4WNU84Q?.@(T="Q#+DX".CSKW'F-CAH*2UQB,>YYO2!OO@?'S
M(_1@G\AJ(-RC^HM(O %Y9$ FST@S'"K/A%$LF3CD51,'4^W?W:C7.Q@W2,S#
MT(;A N"7 )4 $._8"@*1.Y40.U:7L>ECA71,DU>2O;>?M>,CF)=3,'=->=D9
M&)4S#_4&\7(DD@B=P='<16I@1<%8,'LT.*^%$]"?S,$US^P1.>[X*&%[L,+H
MX %KZ&A<(]DN:"H8=$#'H-3@%]/U87[XACUA#AGS!00YYT;#<&#ZX7"(7(VL
M"(8BUK2D6+HRM+FJ'%E\%#0+I;EX? 1_NV/+][GQ""OA@X+P /T#1B) H,]&
MU![.R!%>K$<6T30MSPS'"$%3EM9E#P@P4$9A_W]ET4Q\%^ ]YKL!,2&,57S8
MM@!Y5*X&-#3*,AP>WUB(C;GRY& E1X?G!E(;L#4DM\RF2.LWW(J_2]G^AR,V
M>/76A(LOZ2-0,:_.+$D?QN1ZO_I)R :I)_EG:#@"X0_8$)8ZB$AI:K3W2,Z4
M6WM(S #=\01=J@'8>L!]PC\3.A&A'FDQ,3>J6P^TK)!?0ANB<P:JT9.X2>F_
MI,#L3\=]Y.)@9(TE&VJBZ)7C,(Y!(6)P;O9D ;BQ1)X7^WG'1RE'+^)'N85*
M6>KRWH0>E@L#NT$*A2F\:+..<001,H5F(>"DG\O-GZEO1USL1>B+;1 RQEZP
M?4;ZGAO")N'7(;>I<(1."#()%\,U">.(X<$]1-B H>@"\*"<YUXUEY+I=6+#
M;H=TG^"SN&IYBC=W(Z]V@D'4C+'&1\;H(OPI>?00L@Z9N" WG[6(+[FN$(PU
M!P\)Z/WDF6FX'Q_Q].DEP-<R;W$[5DH4T'' ^;/S4BER/Q%KB%;X(ZP3V35
M3,>+&LB2K[.S'Q]-3?_91=,B&I+3BNV[T0(PKC/@\/#=,9M6IYJPYB5AQR.@
MX.%#P-S1*!720Z*DZ8T>'^&3?(-]EJ286\-%&Y%(Z2.[1'S#ZV(+)!X0&7>.
MCX2$D")FCKR0P #Q#1^0>^8 !&P )<(4::Z/94V9C_0+E#EF+."MIZ5D%D@'
M217;21%Q^<)<3 T.*L:'X5#@F]@48< 2LD!%E7AK4R/39$R-KRI9(Z[OP0U8
MU'5;S/.VS*:T;01V/Z+Y'-[U7-M&2/<2SCH@T^EW]#R$3IMR@[3%\M&/6,!,
M02<E=[2,OEWPX"+-"UY7%+YFSCWX-&C"YYETX;=QI();7-8#RY;IQW5RA].7
MYA( Z &L!#]67)'Y)X* ED?NT$'!1W\(>X)KK_'$=I_Y@JD_UQ(1[[+X.<ZS
M\.$SC_1+Y33UEI8PZO%1I(9X'#,2\)+39[72"8_!3.]S^:*U6$7'EX_BX=YK
MB3CAKL67*:\;OTN!W*^0BV&L;18III#+3:SSRGCX%@2CS3"Z"D*,_J_+;S7)
MS:7'!MH",\M%:!T?R0#30H&<UN2<KKR4((:_0>[Q:K7"6I!R&7R"OH_A N%X
MPBM@['OL'O;.!N^1VL#XM&$BA],3#Q5PBX/'G/FT/(H<KSHMZV&H:)$@MS,;
MXX*8WH,2\+,6C-@U #;: @;Z1'P/(](RTLWQ@Z_*S8DBTQ%$(B]@FJN'G(-@
M ,L=1!%$.? (_&@1TD[K#!;; 9&)S(>([18 -P^EH&DB!2JGVCY8%<AK)AN$
MZ**AK?2<GJ1".E/T@D#!7WUB8 S3$TM;M,/$40,MF=:/:>EP?)2>0 ;VL?!X
MZ*'WY"-3.BYQA?F>EEE\'0EL&M5?YJZ$DS]B)%KN%)J1H!(2$&=L*'DE@GPZ
MGL*Z)J7&-#7QN*T[[G.#+#J;B#< BS*I;88H\&!5DC P0E2 6C_<')!,C:$2
MYX"L8X=M(\P-RF; A=:AAK2%"2ZBO*[[DT=9'RQX04H.*P:"Z'K X[Y1J+9"
M/E,\MW>G&Q#)Z#B/8D\]CV(.G A>@CT5PDTH!515VOS@.A&, =NBLK\"^N1B
MR2,Z[?5%/K7X%G6E/[WX*#(>=3:29@H8\?SPT@LC-Q]T*1=-(JHLP-#KGL>F
MA"TC6LF \- U]0?T+]!;\1*X"0F+YU!!/3QWN4EGIY3- M)3!@63'00R) @6
M:**M\6"+_P[ [#A."+KMEDU<CYMX,W'#)<O^2+ZAYAR02XN!>X:4 @3CD"OZ
M[*&(E]]>5<@/']34@T9Z#-OZ=$%A"9C] ?8-C MOV"8%!>. D?23]ZOBNBO:
M>1:-*2W(];]("N%C3D#=>](NAJ=&UD2&3CA-.:YS*FB%L>0,@D.=ZW.<(HKQ
M1U%-H3.'H+G$JJ<#_LFB!AB;1T*PV0,VX ,(1CN0>[*\*>+2I*G(U;>(.S@
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M 2P.QH2QL!]Z?@/!R+CX19W&&55U'%?HD6\]2>^I*NE0-K3=I:WT64TO[MV
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M@Z6%GF/YH[U<WG1%4G+N.D,+,XTLS 4*/$8#3A;W6)9.W#0)7(+,RZO,RQ,
M>111F7J=C#'5"'Z!Q\96P-]V!C*5U!=YK\Q^3F65)K5O>1',)W.$A'9\=.Z.
MQY:/"G$!N\]<XUP*PP6'"QLY49B2MRN?*40W4Q=K[H5G6LV&N#6<7V?(F[U]
MUQY$I&,-_OGNXJY[I3?_M #9]]93QS%'+MXUEN N0'_ ?*G<X^9B>9X?&#0,
MW%<#8Z.[_/KC-KU+T':D]_O55>?VCTVJKV7WSU<T'*9/'#</D&L7% R=3&Q
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M,C,Q7V-A;"YX;6Q02P$"% ,4    " !$@']6""+<\N8E  !P7P( %0
M        @ $#'@  96YT>"TR,#(R,3(S,5]D968N>&UL4$L! A0#%     @
M1(!_5OD]=[6NU   8/<+ !4              ( !'$0  &5N='@M,C R,C$R
M,S%?;&%B+GAM;%!+ 0(4 Q0    ( $2 ?U8"D$55*$   (=\!  5
M      "  ?T8 0!E;G1X+3(P,C(Q,C,Q7W!R92YX;6Q02P$"% ,4    " !$
M@']6KW!'UG4J   6$ $ $0              @ %860$ 97AH:6)I=%\Q,"TQ
M-"YH=&U02P$"% ,4    " !$@']6:-3#O Y%  "!,P( $0
M@ '\@P$ 97AH:6)I=%\Q,"TQ-2YH=&U02P$"% ,4    " !$@']6262Q^ 0#
M  !D"P  $               @ $YR0$ 97AH:6)I=%\R,2TQ+FAT;5!+ 0(4
M Q0    ( $2 ?U;,&/XRS0,   ,-   0              "  6O, 0!E>&AI
M8FET7S(S+3$N:'1M4$L! A0#%     @ 1(!_5G >OJ6,"0  O#,  !
M         ( !9M ! &5X:&EB:71?,S$M,2YH=&U02P$"% ,4    " !$@']6
MI"@2VZ$)  "]-   $               @ $@V@$ 97AH:6)I=%\S,2TR+FAT
M;5!+ 0(4 Q0    ( $2 ?U;&^M-USP0  #@3   0              "  >_C
M 0!E>&AI8FET7S,R+3$N:'1M4$L! A0#%     @ 1(!_5K.]9]7Q!   ,!0
M !               ( ![.@! &5X:&EB:71?,S(M,BYH=&U02P$"% ,4
M" !$@']6"_' 'P)G  #YG@  #@              @ $+[@$ :6UA9V4P,# Q
M-2YJ<&=02P$"% ,4    " !$@']6[(\27D7A  "]ZP  #@
M@ $Y50( :6UA9V4P,# Q-BYJ<&=02P$"% ,4    " !$@']6G,Q:YPS?  #[
M^@  #@              @ &J-@, :6UA9V4P,# Q-RYJ<&=02P$"% ,4
M" !$@']6=!":*83^  #%%0$ #@              @ 'B%00 :6UA9V4P,# Q
M."YJ<&=02P$"% ,4    " !$@']6.C4A\ [?  #-]   #@
M@ &2% 4 :6UA9V4P,# R,"YJ<&=02P$"% ,4    " !$@']6P0-9284F 0!/
M/ $ #@              @ ',\P4 :6UA9V4P,# R,2YJ<&=02P$"% ,4
M" !$@']6J)1Y(AO5  #C^@  #@              @ %]&@< :6UA9V4P,# R
M,BYJ<&=02P$"% ,4    " !$@']6^%4.Y*77  "U_   #@
M@ '$[P< :6UA9V4P,# R,RYJ<&=02P$"% ,4    " !$@']6U1V32(^$ 0 ,
MJ0$ #@              @ &5QP@ :6UA9V4P,# R-"YJ<&=02P$"% ,4
M" !$@']60XHFZ<$0 0![- $ #@              @ %03 H :6UA9V4P,# R
M-2YJ<&=02P$"% ,4    " !$@']6L?NWUVO? P!/W"  #0
I@ $]70L >FLR,S(Y-#0W+FAT;5!+!08     &  8 - %  #3/ \    !

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
